PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Sakala, C; Newburn, M				Sakala, Carol; Newburn, Mary			Meeting needs of childbearing women and newborn infants through strengthened midwifery	LANCET			English	Editorial Material							HEALTH		[Sakala, Carol] Natl Partnership Women & Families, Childbirth Connect Programs, Washington, DC 20009 USA; [Newburn, Mary] NCT, London W3 6NH, England		Sakala, C (corresponding author), Natl Partnership Women & Families, Childbirth Connect Programs, Washington, DC 20009 USA.	csakala@nationalpartnership.org						Bell AF, 2014, J MIDWIFERY WOM HEAL, V59, P35, DOI 10.1111/jmwh.12101; Buckley S., 2014, HORMONAL PHYSL CHILD; Care Quality Commission, NAT FIND 2013 SURV W; Collado MC, 2012, GUT MICROBES, V3, P352, DOI 10.4161/gmic.21215; Csaba G, 2011, CLIN EPIGENETICS, V2, P187, DOI 10.1007/s13148-011-0024-8; Dahlen HG, 2013, MED HYPOTHESES, V80, P656, DOI 10.1016/j.mehy.2013.01.017; Declercq ER, 2013, LISTENING MOTHERS IL; Gluckman PD, 2007, AM J HUM BIOL, V19, P1, DOI 10.1002/ajhb.20590; Halfon N, 2014, MATERN CHILD HLTH J, V18, P344, DOI 10.1007/s10995-013-1346-2; International Confederation of Midwives, 2010, ESS COMP BAS MIDW PR; Kriebel D, 2001, AM J PUBLIC HEALTH, V91, P1351, DOI 10.2105/AJPH.91.9.1351; Olza-Fernandez I, 2014, FRONT NEUROENDOCRIN, V35, P459, DOI 10.1016/j.yfrne.2014.03.007; Renfrew MJ, 2014, LANCET; UNFPA, 2014, STAT WORLDS MIDW 201	14	26	26	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 20	2014	384	9948					E39	E40		10.1016/S0140-6736(14)60856-4	http://dx.doi.org/10.1016/S0140-6736(14)60856-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AQ2PU	24965817				2023-01-03	WOS:000342630600001
J	Zhang, P; Xi, M; Zhao, L; Li, QQ; He, LR; Liu, SL; Shen, JX; Liu, MZ				Zhang, Peng; Xi, Mian; Zhao, Lei; Li, Qiao-Qiao; He, Liru; Liu, Shiliang; Shen, Jingxian; Liu, Meng-Zhong			Unilateral Cervical Nodal Metastasis Is an Independent Prognostic Factor for Esophageal Squamous Cell Carcinoma Patients Undergoing Chemoradiotherapy: A Retrospective Study	PLOS ONE			English	Article							TUMOR LENGTH; CANCER; SURVIVAL; PATTERN	Purpose: To determine the prognostic significance of unilateral cervical lymph nodal metastasis (CLNM) in patients with inoperable thoracic esophageal squamous cell carcinoma (SCC) and to identify significant prognostic factors in these patients. Patients and methods: This retrospective study involved 395 patients with inoperable esophageal SCC treated with concurrent chemoradiotherapy. The patients were classified into three groups according to their cervical lymph node status: group A, no evidence of CLNM; group B, unilateral CLNM; group C, other distant metastases. Overall survival (OS) and progression-free survival (PFS) were calculated. Significant prognostic factors were identified using univariate and multivariate analyses. Results: The 3-year OS rates in groups A, B and C were 46.7%, 33.5% and 8.3%, respectively (p<0.001, log-rank test). The corresponding PFS rates were 40.7%, 26.4% and 4.7% (p<0.001, log-rank test). Group B had a similar prognosis to that of group A and better 3-year OS (p = 0.009) and PFS (p = 0.006) rates than those of group C. Multivariate analysis demonstrated that T stage, chemotherapy regimen and cervical lymph node involvement were independent prognostic factors affecting OS and PFS. Conclusions: Compared to other distant metastases, unilateral CLNM is associated with longer OS in esophageal SCC and should be regarded as a regional disease. Sex, T stage, concurrent chemotherapy modality and cervical lymph node involvement are independent predictors of survival in esophageal SCC.	[Zhang, Peng; Xi, Mian; Zhao, Lei; Li, Qiao-Qiao; He, Liru; Liu, Shiliang; Shen, Jingxian; Liu, Meng-Zhong] Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China; [Zhang, Peng; Xi, Mian; Zhao, Lei; Li, Qiao-Qiao; He, Liru; Liu, Shiliang; Shen, Jingxian; Liu, Meng-Zhong] Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Zhang, Peng; Xi, Mian; Zhao, Lei; Li, Qiao-Qiao; He, Liru; Liu, Shiliang; Liu, Meng-Zhong] Sun Yat Sen Univ, Ctr Canc, Dept Radiat Oncol, Guangzhou 510275, Guangdong, Peoples R China; [Shen, Jingxian] Sun Yat Sen Univ, Ctr Canc, Imaging Diag & Intervent Ctr, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University	Liu, MZ (corresponding author), Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China.	liumengzhong@126.com			Natural Science Foundation of China [81272487]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the Natural Science Foundation of China (No. 81272487). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2010, CHIN J RAD ONCOL, V19, P179, DOI DOI 10.3760/CMA.J.ISSN.1004-4221.2010.03.001; Chen JQ, 2009, EUR J CARDIO-THORAC, V36, P480, DOI 10.1016/j.ejcts.2009.03.056; Chen LQ, 2008, CHIN J CLIN THORAC C, V15, P52; Christie NA, 1999, J THORAC CARDIOV SUR, V118, P900, DOI 10.1016/S0022-5223(99)70060-7; Eloubeidi MA, 2002, CANCER-AM CANCER SOC, V95, P1434, DOI 10.1002/cncr.10868; Heo M, 2013, INT J STAT MED RES, V2, P104; Huang W, 2010, RADIOTHER ONCOL, V95, P229, DOI 10.1016/j.radonc.2010.01.006; Isono K, 2004, ESOPHAGUS, V1, P61; Kato H, 2000, J SURG ONCOL, V74, P282, DOI 10.1002/1096-9098(200008)74:4<282::AID-JSO8>3.0.CO;2-R; Kim K, 2001, ANN THORAC SURG, V71, P290, DOI 10.1016/S0003-4975(00)02221-9; Li HC, 2007, EUR SURG RES, V39, P1, DOI 10.1159/000096925; Li QQ, 2010, DIS ESOPHAGUS, V23, P253, DOI 10.1111/j.1442-2050.2009.01003.x; Li WF, 2013, INT J RADIAT ONCOL, V86, P249, DOI 10.1016/j.ijrobp.2012.09.003; Liu H, 2011, RADIOTHER ONCOL, V99, P181, DOI 10.1016/j.radonc.2011.05.011; Micheli A, 1998, EUR J CANCER, V34, P2271, DOI 10.1016/S0959-8049(98)00324-4; Minsky BD, 2002, J CLIN ONCOL, V20, P1167, DOI 10.1200/JCO.20.5.1167; Nomura M, 2012, INT J RADIAT ONCOL, V82, P946, DOI 10.1016/j.ijrobp.2010.12.045; Prenzel KL, 2010, ANN THORAC SURG, V90, P1662, DOI 10.1016/j.athoracsur.2010.07.008; Rice TW, 2010, ANN SURG ONCOL, V17, P1721, DOI 10.1245/s10434-010-1024-1; Rice TW, 1998, ANN THORAC SURG, V65, P787, DOI 10.1016/S0003-4975(97)01387-8; Shimada H, 2007, HEPATO-GASTROENTEROL, V54, P100; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Tong DKH, 2008, J GASTROINTEST SURG, V12, P1638, DOI 10.1007/s11605-008-0654-0; van Hagen P, 2012, NEW ENGL J MED, V366, P2074, DOI 10.1056/NEJMoa1112088; Yendamuri S, 2009, CANCER-AM CANCER SOC, V115, P508, DOI 10.1002/cncr.24062	25	3	5	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 30	2014	9	6							e101332	10.1371/journal.pone.0101332	http://dx.doi.org/10.1371/journal.pone.0101332			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK5ZO	24979040	Green Submitted, gold, Green Published			2023-01-03	WOS:000338506400119
J	Brojatsch, J; Lima, H; Kar, AK; Jacobson, LS; Muehlbauer, SM; Chandran, K; Diaz-Griffero, F				Brojatsch, Juergen; Lima, Heriberto, Jr.; Kar, Alak K.; Jacobson, Lee S.; Muehlbauer, Stefan M.; Chandran, Kartik; Diaz-Griffero, Felipe			A Proteolytic Cascade Controls Lysosome Rupture and Necrotic Cell Death Mediated by Lysosome-Destabilizing Adjuvants	PLOS ONE			English	Article							DIPEPTIDYL PEPTIDASE-I; LEUCINE METHYL-ESTER; CYTOTOXIC LYMPHOCYTES; PROTEASOME INHIBITORS; CATHEPSIN-B; URIC-ACID; NECROSIS; INFLAMMASOME; ACTIVATE; DISRUPTION	Recent studies have linked necrotic cell death and proteolysis of inflammatory proteins to the adaptive immune response mediated by the lysosome-destabilizing adjuvants, alum and Leu-Leu-OMe (LLOMe). However, the mechanism by which lysosome-destabilizing agents trigger necrosis and proteolysis of inflammatory proteins is poorly understood. The proteasome is a cellular complex that has been shown to regulate both necrotic cell death and proteolysis of inflammatory proteins. We found that the peptide aldehyde proteasome inhibitors, MG115 and MG132, block lysosome rupture, degradation of inflammatory proteins and necrotic cell death mediated by the lysosome-destabilizing peptide LLOMe. However, non-aldehyde proteasome inhibitors failed to prevent LLOMe-induced cell death suggesting that aldehyde proteasome inhibitors triggered a pleotropic effect. We have previously shown that cathepsin C controls lysosome rupture, necrotic cell death and the adaptive immune response mediated by LLOMe. Using recombinant cathepsin C, we found that aldehyde proteasome inhibitors directly block cathepsin C, which presumably prevents LLOMe toxicity. The cathepsin B inhibitor CA-074-Me also blocks lysosome rupture and necrotic cell death mediated by a wide range of necrosis inducers, including LLOMe. Using cathepsin-deficient cells and recombinant cathepsins, we demonstrate that the cathepsins B and C are not required for the CA-074-Me block of necrotic cell death. Taken together, our findings demonstrate that lysosome-destabilizing adjuvants trigger an early proteolytic cascade, involving cathepsin C and a CA-074-Me-dependent protease. Identification of these early events leading to lysosome rupture will be crucial in our understanding of processes controlling necrotic cell death and immune responses mediated by lysosome-destabilizing adjuvants.	[Brojatsch, Juergen; Lima, Heriberto, Jr.; Kar, Alak K.; Jacobson, Lee S.; Muehlbauer, Stefan M.; Chandran, Kartik; Diaz-Griffero, Felipe] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine	Brojatsch, J (corresponding author), Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA.	jurgen.brojatsch@einstein.yu.edu		brojatsch, jurgen/0000-0002-7424-365X	National Institutes of Health [1R56AI092497-01A1, 5R01AI088027-02, R01 AI087390]; Martin Turkish Foundation; M-O'Connor-Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI087390, R01AI088027, R56AI092497] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Martin Turkish Foundation; M-O'Connor-Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	HL, LSJ, SMM, and JB were funded by the National Institutes of Health grants 1R56AI092497-01A1 (to HL, LSJ, SMM, and JB), 5R01AI088027-02 (to KC), and R01 AI087390 (to AK and FD-G), and by the Martin Turkish Foundation and the M-O'Connor-Foundation. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alileche A, 2006, CELL CYCLE, V5, P100, DOI 10.4161/cc.5.1.2283; Basu S, 2000, CELL STRESS CHAPERON, V5, P373; Brennan MA, 2000, MOL MICROBIOL, V38, P31, DOI 10.1046/j.1365-2958.2000.02103.x; Brojatsch Jurgen, 2014, Front Biosci (Elite Ed), V6, P139; Christofferson DE, 2010, CURR OPIN CELL BIOL, V22, P263, DOI 10.1016/j.ceb.2009.12.003; Diaz-Griffero F, 2002, J VIROL, V76, P12866, DOI 10.1128/JVI.76.24.12866-12876.2002; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Festjens N, 2006, BBA-BIOENERGETICS, V1757, P1371, DOI 10.1016/j.bbabio.2006.06.014; Fink SL, 2006, CELL MICROBIOL, V8, P1812, DOI 10.1111/j.1462-5822.2006.00751.x; Franchi L, 2009, NAT IMMUNOL, V10, P241, DOI 10.1038/ni.1703; Guicciardi ME, 2013, CELL CYCLE, V12, P1995, DOI 10.4161/cc.25317; Guicciardi ME, 2004, ONCOGENE, V23, P2881, DOI 10.1038/sj.onc.1207512; Halangk W, 2000, J CLIN INVEST, V106, P773, DOI 10.1172/JCI9411; Hentze H, 2003, CELL DEATH DIFFER, V10, P956, DOI 10.1038/sj.cdd.4401264; Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631; Iyer SS, 2009, P NATL ACAD SCI USA, V106, P20388, DOI 10.1073/pnas.0908698106; Jacobson LS, 2013, J BIOL CHEM, V288, P7481, DOI 10.1074/jbc.M112.400655; Keller M, 2008, CELL, V132, P818, DOI 10.1016/j.cell.2007.12.040; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; Kono H, 2008, NAT REV IMMUNOL, V8, P279, DOI 10.1038/nri2215; Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087; Kroemer G, 2005, CELL DEATH DIFFER, V12, P1463, DOI 10.1038/sj.cdd.4401724; Li HF, 2009, J IMMUNOL, V183, P1528, DOI 10.4049/jimmunol.0901080; Lima H, 2013, CELL CYCLE, V12, P1868, DOI 10.4161/cc.24903; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Marichal T, 2011, NAT MED, V17, P996, DOI 10.1038/nm.2403; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Muehlbauer SM, 2007, CELL CYCLE, V6, P758, DOI 10.4161/cc.6.6.3991; Muehlbauer SM, 2010, AM J PATHOL, V177, P735, DOI 10.2353/ajpath.2010.090828; Newman Z, 2009, INFECT IMMUN, P1; Newman ZL, 2009, INFECT IMMUN, V77, P4327, DOI 10.1128/IAI.00730-09; Nour AM, 2009, INFECT IMMUN, V77, P1262, DOI 10.1128/IAI.01032-08; Orlowski RZ, 1999, CELL DEATH DIFFER, V6, P303, DOI 10.1038/sj.cdd.4400505; Petrilli V, 2007, CURR OPIN IMMUNOL, V19, P615, DOI 10.1016/j.coi.2007.09.002; Reinheckel T, 2013, CELL CYCLE, V12, P1994, DOI 10.4161/cc.25316; Roth W, 2000, FASEB J, V14, P2075, DOI 10.1096/fj.99-0970com; Rovere-Querini P, 2004, EMBO REP, V5, P825, DOI 10.1038/sj.embor.7400205; Squires RC, 2007, J BIOL CHEM, V282, P34260, DOI 10.1074/jbc.M705687200; THIELE DL, 1990, J EXP MED, V172, P183, DOI 10.1084/jem.172.1.183; THIELE DL, 1990, P NATL ACAD SCI USA, V87, P83, DOI 10.1073/pnas.87.1.83; Ting JPY, 2008, NAT REV IMMUNOL, V8, P372, DOI 10.1038/nri2296; Turk BE, 2007, BIOCHEM J, V402, P405, DOI 10.1042/BJ20061891; Vanden Berghe T, 2010, CELL DEATH DIFFER, V17, P922, DOI 10.1038/cdd.2009.184; Wang F, 2011, MOL BIOCHEM PARASIT, V175, P10, DOI 10.1016/j.molbiopara.2010.08.004	44	23	25	2	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2014	9	6							e95032	10.1371/journal.pone.0095032	http://dx.doi.org/10.1371/journal.pone.0095032			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI5ML	24893007	Green Published, Green Submitted, gold			2023-01-03	WOS:000336911400003
J	Kerac, M; Bunn, J; Chagaluka, G; Bahwere, P; Tomkins, A; Collins, S; Seal, A				Kerac, Marko; Bunn, James; Chagaluka, George; Bahwere, Paluku; Tomkins, Andrew; Collins, Steve; Seal, Andrew			Follow-Up of Post-Discharge Growth and Mortality after Treatment for Severe Acute Malnutrition (FuSAM Study): A Prospective Cohort Study	PLOS ONE			English	Article							NUTRITION REHABILITATION; MALNOURISHED CHILDREN; HIV PREVALENCE; EFFICACY; MALAWI; MANAGEMENT; SURVIVAL; OUTCOMES; TIME	Background: Management of Severe Acute Malnutrition (SAM) plays a vital role in achieving global child survival targets. Effective treatment programmes are available but little is known about longer term outcomes following programme discharge. Methods: From July 2006 to March 2007, 1024 children (median age 21.5 months, IQR 15-32) contributed 1187 admission episodes to an inpatient-based SAM treatment centre in Blantyre, Malawi. Long term outcomes, were determined in a longitudinal cohort study, a year or more after initial programme discharge. We found information on 88%(899/1024). Results: In total, 42%(427/1024) children died during or after treatment. 25%(105/427) of deaths occurred after normal programme discharge, >90 days after admission. Mortality was greatest among HIV seropositive children: 62%(274/445). Other risk factors included age,12 months; severity of malnutrition at admission; and disability. In survivors, weight-for-height and weight-for-age improved but height-for-age remained low, mean -22.97 z-scores (SD 1.3). Conclusions: Although SAM mortality in this setting was unacceptably high, our findings offer important lessons for future programming, policy and research. First is the need for improved programme evaluation: most routine reporting systems would have missed late deaths and underestimated total mortality due to SAM. Second, a more holistic view of SAM is needed: while treatment will always focus on nutritional interventions, it is vital to also identify and manage underlying clinical conditions such as HIV and disability. Finally early identification and treatment of SAM should be emphasised: our results suggest that this could improve longer term as well as short term outcomes. As international policy and programming becomes increasingly focused on stunting and post-malnutrition chronic disease outcomes, SAM should not be forgotten. Proactive prevention and treatment services are essential, not only to reduce mortality in the short term but also because they have potential to impact on longer term morbidity, growth and development of survivors.	[Kerac, Marko; Bahwere, Paluku; Collins, Steve] Valid Int, Oxford, England; [Kerac, Marko; Bunn, James; Chagaluka, George] Coll Med, Dept Paediat & Child Hlth, Blantyre, Malawi; [Kerac, Marko; Tomkins, Andrew; Seal, Andrew] UCL, Inst Global Hlth, London, England; [Kerac, Marko] UCL, Leonard Cheshire Disabil & Inclus Dev Ctr, London, England; [Bunn, James] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; [Bahwere, Paluku] Univ Libre Brussels, Ctr Res Epidemiol Biostat & Clin Res, Brussels, Belgium	University of Malawi; University of London; University College London; University of London; University College London; Liverpool School of Tropical Medicine; University of Liverpool; Universite Libre de Bruxelles	Kerac, M (corresponding author), Valid Int, Oxford, England.	marko.kerac@gmail.com	Seal, Andrew/C-8550-2014; Kerac, Marko/GQR-1136-2022	Seal, Andrew/0000-0003-3656-4054; Kerac, Marko/0000-0002-3745-7317	UNICEF Malawi; NIHR; National Institute for Health Research [ACF-2008-18-010, CL-2012-18-005] Funding Source: researchfish	UNICEF Malawi; NIHR(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR))	UNICEF Malawi funded this study. Valid International provided support in the form of salaries for authors MK (from end 2005 to Jan 2008 only - the 'baseline' period of this study) PB, and SC but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. MK gratefully acknowledges NIHR for funding his current UCL Academic Clinical Lecturer post.	[Anonymous], 2009, WHO CHILD GROWTH STA; Bahwere P., 2012, Journal of Public Health and Epidemiology, V4, P215; Bahwere P, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-106; Black RE, 2013, LANCET, V382, P427, DOI 10.1016/S0140-6736(13)60937-X; Collins S, 2003, LANCET, V362, P249, DOI 10.1016/S0140-6736(03)13926-8; Collins S, 2001, LANCET, V358, P498, DOI 10.1016/S0140-6736(01)05630-6; Collins S, 2007, ARCH DIS CHILD, V92, P453, DOI 10.1136/adc.2006.098327; Collins S, 2006, FOOD NUTR BULL, V27, pS49, DOI 10.1177/15648265060273S304; de Onis M, 2009, ARCH PEDIATRIE, V16, P47, DOI 10.1016/j.arcped.2008.10.010; de Onis Mercedes, 2004, Food Nutr Bull, V25, pS27; Dulloo AG, 2008, BEST PRACT RES CL EN, V22, P155, DOI 10.1016/j.beem.2007.08.001; Fergusson P, 2009, INT HEALTH, V1, P10, DOI 10.1016/j.inhe.2009.03.001; Fergusson P, 2009, T ROY SOC TROP MED H, V103, P541, DOI 10.1016/j.trstmh.2008.10.029; Gillespie SHL, 2003, IFPRI REPORT; *GOV MAL, 2007, INT GUID MAN AC MALN; Grobler-Tanner C, 2004, 8 FANTA; Groce NE, 2013, LANCET GLOB HEALTH, V1, pE180, DOI 10.1016/S2214-109X(13)70056-1; HENNART P, 1987, J TROP PEDIATRICS, V33, P10, DOI 10.1093/tropej/33.1.10; Kerac M, 2011, THESIS UCL; Kerac M, 2009, LANCET, V374, P136, DOI 10.1016/S0140-6736(09)60884-9; PECOUL B, 1992, ANN TROP PAEDIATR, V12, P47, DOI 10.1080/02724936.1992.11747546; PERRA A, 1995, EUR J CLIN NUTR, V49, P353; Pocock SJ, 2002, LANCET, V359, P1686, DOI 10.1016/S0140-6736(02)08594-X; Sadler K, 2008, J TROP PEDIATRICS, V54, P364, DOI 10.1093/tropej/fmn029; SPHERE, 2011, SPHER PROJ HUM CHART; Stettler N, 2010, CURR OPIN CLIN NUTR, V13, P294, DOI 10.1097/MCO.0b013e328337d7b9; Thurstans S, 2008, BMC PEDIATR, V8, DOI 10.1186/1471-2431-8-22; UNICEF, 2013, UNICEF GLOB PARTN CH; VANROOSMALENWIEBENGA MW, 1987, J TROP PEDIATRICS, V33, P24, DOI 10.1093/tropej/33.1.24; Victora CG, 2010, PEDIATRICS, V125, pE473, DOI 10.1542/peds.2009-1519; *WHO WFP UNSCN UNI, 2007, COMM BAS MAN SEV AC; World Health Organization, 2006, WHO CAS DEF HIV SURV	32	108	109	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2014	9	6							e96030	10.1371/journal.pone.0096030	http://dx.doi.org/10.1371/journal.pone.0096030			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI5ML	24892281	Green Accepted, Green Published, gold			2023-01-03	WOS:000336911400005
J	Paul, SM; Reddy, K				Paul, Steven M.; Reddy, Kiran			Young blood rejuvenates old brains	NATURE MEDICINE			English	Editorial Material							DECLINE	Age-related cognitive decline occurs in many mammals, including humans, resulting from a decline in hippocampal function, and it is associated with reduced synaptic plasticity in hippocampal circuits. In this issue of Nature Medicine, a new study shows that cognitive impairment observed in aged mice is largely reversible following exposure to the blood of young mice.	[Paul, Steven M.] Weill Cornell Med Coll, Brain & Mind Res Inst, Appel Alzheimers Dis Res Inst, New York, NY 10021 USA; [Paul, Steven M.; Reddy, Kiran] Third Rock Ventures, Boston, MA USA	Cornell University	Paul, SM (corresponding author), Weill Cornell Med Coll, Brain & Mind Res Inst, Appel Alzheimers Dis Res Inst, New York, NY 10021 USA.	smpaulmd@med.cornell.edu	Paul, Steve/ABE-5400-2020					Bertoni-Freddari C, 2003, ANN NY ACAD SCI, V1010, P635, DOI 10.1196/annals.1299.116; Holtzman DM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002369; Katsimpardi L, 2014, SCIENCE, V344, P630, DOI 10.1126/science.1251141; Kida S, 2002, NAT NEUROSCI, V5, P348, DOI 10.1038/nn819; Loffredo FS, 2013, CELL, V153, P828, DOI 10.1016/j.cell.2013.04.015; Morrison JH, 2012, NAT REV NEUROSCI, V13, P240, DOI 10.1038/nrn3200; Ruckh JM, 2012, CELL STEM CELL, V10, P96, DOI 10.1016/j.stem.2011.11.019; Salpeter SJ, 2013, DIABETES, V62, P2843, DOI 10.2337/db13-0160; Sinha M, 2014, SCIENCE, V344, P649, DOI 10.1126/science.1251152; Small SA, 2002, ANN NEUROL, V51, P290, DOI 10.1002/ana.10105; Villeda SA, 2014, NAT MED, V20, P659, DOI 10.1038/nm.3569; Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357	12	6	6	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2014	20	6					582	583		10.1038/nm.3597	http://dx.doi.org/10.1038/nm.3597			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	AI7LB	24901563				2023-01-03	WOS:000337071000014
J	Volkow, ND; Frieden, TR; Hyde, PS; Cha, SS				Volkow, Nora D.; Frieden, Thomas R.; Hyde, Pamela S.; Cha, Stephen S.			Medication-Assisted Therapies - Tackling the Opioid-Overdose Epidemic	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DEATHS		[Volkow, Nora D.] NIDA, NIH, Bethesda, MD 20892 USA; [Hyde, Pamela S.] Subst Abuse & Mental Hlth Serv Adm, Rockville, MD USA; [Cha, Stephen S.] Ctr Medicare Serv, Ctr Medicaid & CHIP Serv, Baltimore, MD USA; [Cha, Stephen S.] Ctr Medicaid Serv, Ctr Medicaid & CHIP Serv, Baltimore, MD USA; [Frieden, Thomas R.] Ctr Dis Control & Prevent, Atlanta, GA USA	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); Centers for Medicare & Medicaid Services; Centers for Medicare & Medicaid Services; Centers for Disease Control & Prevention - USA	Volkow, ND (corresponding author), NIDA, NIH, Bethesda, MD 20892 USA.			Frieden, Thomas/0000-0002-4759-2256	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000550] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Centers for Disease Control and Prevention (CDC), 2013, ADDR PRESCR DRUG AB; Clark RE, 2013, JAMA INTERN MED, V173, P1571, DOI 10.1001/jamainternmed.2013.9059; Jones CM, 2013, JAMA-J AM MED ASSOC, V309, P657, DOI 10.1001/jama.2013.272; Knudsen HK, 2011, J ADDICT MED, V5, P21, DOI 10.1097/ADM.0b013e3181d41ddb; Schwartz RP, 2013, AM J PUBLIC HEALTH, V103, P917, DOI 10.2105/AJPH.2012.301049	5	670	671	0	40	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 29	2014	370	22					2063	2066		10.1056/NEJMp1402780	http://dx.doi.org/10.1056/NEJMp1402780			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AH9BM	24758595	Bronze			2023-01-03	WOS:000336434000003
J	Lemmens, RJM; Timmermans, AAA; Janssen-Potten, YJM; Pulles, SANTD; Geers, RPJ; Bakx, WGM; Smeets, RJEM; Seelen, HAM				Lemmens, Ryanne J. M.; Timmermans, Annick A. A.; Janssen-Potten, Yvonne J. M.; Pulles, Sanne A. N. T. D.; Geers, Richard P. J.; Bakx, Wilbert G. M.; Smeets, Rob J. E. M.; Seelen, Henk A. M.			Accelerometry Measuring the Outcome of Robot-Supported Upper Limb Training in Chronic Stroke: A Randomized Controlled Trial	PLOS ONE			English	Article							ASSISTED THERAPY; ARM ACTIVITY; ACTIVITY LEVEL; RECOVERY; REHABILITATION; INDIVIDUALS; PERFORMANCE; EXERCISE; GRAVITY; IMPACT	Purpose: This study aims to assess the extent to which accelerometers can be used to determine the effect of robot-supported task-oriented arm-hand training, relative to task-oriented arm-hand training alone, on the actual amount of arm-hand use of chronic stroke patients in their home situation. Methods: This single-blind randomized controlled trial included 16 chronic stroke patients, randomly allocated using blocked randomization (n = 2) to receive task-oriented robot-supported arm-hand training or task-oriented (unsupported) arm-hand training. Training lasted 8 weeks, 4 times/ week, 2 Chi 30 min/ day using the (T-) TOAT ((Technology-supported)-Task-Oriented-Arm-Training) method. The actual amount of arm-hand use, was assessed at baseline, after 8 weeks training and 6 months after training cessation. Duration of use and intensity of use of the affected arm-hand during unimanual and bimanual activities were calculated. Results: Duration and intensity of use of the affected arm-hand did not change significantly during and after training, with or without robot-support (i.e. duration of use of unimanual use of the affected arm-hand: median difference of -0.17% in the robot-group and -0.08% in the control group between baseline and after training cessation; intensity of the affected arm-hand: median difference of 3.95% in the robot-group and 3.32% in the control group between baseline and after training cessation). No significant between-group differences were found. Conclusions: Accelerometer data did not show significant changes in actual amount of arm-hand use after task-oriented training, with or without robot-support. Next to the amount of use, discrimination between activities performed and information about quality of use of the affected arm-hand are essential to determine actual arm-hand performance.	[Lemmens, Ryanne J. M.; Timmermans, Annick A. A.; Janssen-Potten, Yvonne J. M.; Smeets, Rob J. E. M.; Seelen, Henk A. M.] Maastricht Univ, Dept Rehabil Med, Res Sch CAPHRI, Maastricht, Netherlands; [Lemmens, Ryanne J. M.; Timmermans, Annick A. A.; Janssen-Potten, Yvonne J. M.; Pulles, Sanne A. N. T. D.; Geers, Richard P. J.; Bakx, Wilbert G. M.; Smeets, Rob J. E. M.; Seelen, Henk A. M.] Adelante, Ctr Expertise Rehabil & Audiol, Hoensbroek, Netherlands; [Timmermans, Annick A. A.] Hasselt Univ, BIOMED Biomed Res Inst, Diepenbeek, Belgium; [Bakx, Wilbert G. M.] Adelante Rehabil Ctr, Hoensbroek, Netherlands; [Seelen, Henk A. M.] Maastricht Univ, Med Ctr, Dept Rehabil Med, Maastricht, Netherlands	Maastricht University; Hasselt University; Maastricht University	Lemmens, RJM (corresponding author), Maastricht Univ, Dept Rehabil Med, Res Sch CAPHRI, Maastricht, Netherlands.	ryanne.lemmens@maastrichtuniversity.nl	Pulles, Alexandra/AAD-9251-2021; Smeets, Rob JEM/D-1522-2011; Pulles, Alexandra/AAB-6275-2019	Smeets, Rob JEM/0000-0002-9503-366X; Pulles, Alexandra/0000-0002-0130-428X; Timmermans, Annick/0000-0002-5461-947X	Philips Research, The Netherlands; Technical University Eindhoven, The Netherlands; Adelante Centre of Expertise in Rehabilitation and Audiology (formerly Rehabilitation Foundation Limburg), The Netherlands	Philips Research, The Netherlands(Netherlands Government); Technical University Eindhoven, The Netherlands; Adelante Centre of Expertise in Rehabilitation and Audiology (formerly Rehabilitation Foundation Limburg), The Netherlands(Netherlands Government)	This study was funded by 3 parties, i.e. Philips Research, The Netherlands; Technical University Eindhoven, The Netherlands; and Adelante Centre of Expertise in Rehabilitation and Audiology (formerly Rehabilitation Foundation Limburg), The Netherlands. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altun K, 2010, PATTERN RECOGN, V43, P3605, DOI 10.1016/j.patcog.2010.04.019; Barman J, 2011, IEEE ENG MED BIO, P5219, DOI 10.1109/IEMBS.2011.6091291; Broeks JG, 1999, DISABIL REHABIL, V21, P357; Cambridge-Neurotechnology-Ltd, 2008, ACT US MAN; Conroy SS, 2011, ARCH PHYS MED REHAB, V92, P1754, DOI 10.1016/j.apmr.2011.06.016; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; De Bleser R., 1991, LOGOPEDIE FONIATRIE, V63, P207; Ferber S, 2001, J CLIN EXP NEUROPSYC, V23, P599, DOI 10.1076/jcen.23.5.599.1243; Fortune E, 2011, IEEE ENG MED BIO, P3059, DOI 10.1109/IEMBS.2011.6090836; GAUTHIER L, 1989, INT J CLIN NEUROPSYC, V11, P49; Hesse S, 2007, WHAT DOES CLIN EXPEC; Housman SJ, 2009, NEUROREHAB NEURAL RE, V23, P505, DOI 10.1177/1545968308331148; Hsieh YW, 2011, NEUROREHAB NEURAL RE, V25, P503, DOI 10.1177/1545968310394871; Hubbard IJ, 2009, OCCUP THER INT, V16, P175, DOI 10.1002/oti.275; Kahn LE, 2006, J NEUROENG REHABIL, V3, DOI 10.1186/1743-0003-3-12; Kwakkel G, 2013, INT J STROKE, V8, P25, DOI 10.1111/j.1747-4949.2012.00967.x; Kwakkel G, 2008, NEUROREHAB NEURAL RE, V22, P111, DOI 10.1177/1545968307305457; Lang CE, 2013, J HAND THER, V26, P104, DOI 10.1016/j.jht.2012.06.005; Lang CE, 2012, J HAND THER, V26, P115; Lemmens RJM, 2013, RELIABILITY REGISTRA; Lemmens RJM, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-21; Liao WW, 2012, CLIN REHABIL, V26, P111, DOI 10.1177/0269215511416383; Linde Van der RQ, 2002, HAPTICMASTER NEW HIG, P1; Lo AC, 2010, NEW ENGL J MED, V362, P1772, DOI 10.1056/NEJMoa0911341; Magill RA, 2007, MOTOR LEARNING CONTR, P2; Mehrholz J, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006676.pub2; Mehrholz J, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006876.pub3, 10.1002/14651858.CD006876.pub4]; Michielsen ME, 2012, ARCH PHYS MED REHAB, V93, P1975, DOI 10.1016/j.apmr.2012.03.016; Nichols-Larsen DS, 2005, STROKE, V36, P1480, DOI 10.1161/01.STR.0000170706.13595.4f; Page SJ, 2004, ARCH PHYS MED REHAB, V85, P1377, DOI 10.1016/j.apmr.2003.12.031; Peter O, 2011, INT J REHABIL RES, V34, P196, DOI 10.1097/MRR.0b013e328346e8ad; Prange GB, 2006, J REHABIL RES DEV, V43, P171, DOI 10.1682/JRRD.2005.04.0076; Rohrer B, 2002, J NEUROSCI, V22, P8297; Schmidt RA, 1999, CONDITIONS PRACTICE, P321; Schmidt RA, 1999, MOTOR CONTROL LEAR A, P432; Timmermans Annick A. A., 2009, 2009 IEEE International Conference on Rehabilitation Robotics: Reaching Users & the Community (ICORR), P98, DOI 10.1109/ICORR.2009.5209558; Timmermans AAA, 2014, J NEUROENGINEERING R, V11; Timmermans AAA, 2011, IEEE ENG MED BIO, P3507, DOI 10.1109/IEMBS.2011.6090947; Timmermans AAA, 2010, NEUROREHAB NEURAL RE, V24, P858, DOI 10.1177/1545968310368963; Timmermans AAA, 2010, IEEE T NEUR SYS REH, V18, P284, DOI 10.1109/TNSRE.2010.2047608; Uswatte G, 2005, ARCH PHYS MED REHAB, V86, P1498, DOI 10.1016/j.apmr.2005.01.010; Uswatte G, 2005, REHABIL PSYCHOL, V50, P34, DOI 10.1037/0090-5550.50.1.34; Uswatte G, 2006, NEUROREHABILITATION, V21, P147; van der Pas SC, 2011, ARCH PHYS MED REHAB, V92, P1437, DOI 10.1016/j.apmr.2011.02.021; van Heugten C M, 2004, Tijdschr Gerontol Geriatr, V35, P196; Van Peppen RPS, 2004, CLIN REHABIL, V18, P833, DOI 10.1191/0269215504cr843oa; WMA-Declaration-of-Helsinki, 2008, WMA DECL HELS ETH PR; Wolfe CDA, 2000, BRIT MED BULL, V56, P275, DOI 10.1258/0007142001903120; World Health Organisation, 2001, ICF INT CLASFUNCT; Wu CY, 2000, ARCH PHYS MED REHAB, V81, P95, DOI 10.1053/apmr.2000.0810095	50	27	27	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2014	9	5							e96414	10.1371/journal.pone.0096414	http://dx.doi.org/10.1371/journal.pone.0096414			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AH8EY	24823925	Green Published, Green Submitted, gold			2023-01-03	WOS:000336369200019
J	Forrest, GF; Hutchinson, K; Lorenz, DJ; Buehner, JJ; VanHiel, LR; Sisto, SA; Basso, DM				Forrest, Gail F.; Hutchinson, Karen; Lorenz, Douglas J.; Buehner, Jeffrey J.; VanHiel, Leslie R.; Sisto, Sue Ann; Basso, D. Michele			Are the 10 Meter and 6 Minute Walk Tests Redundant in Patients with Spinal Cord Injury?	PLOS ONE			English	Article							OUTCOME MEASURES; AMBULATION; CAPACITY; VALIDITY; DISTANCE; ABILITY; SPEED; GAIT	Objective: To evaluate the relationship and redundancy between gait speeds measured by the 10 Meter Walk Test (10MWT) and 6 Minute Walk Test (6MWT) after motor incomplete spinal cord injury (iSCI). To identify gait speed thresholds supporting functional ambulation as measured with the Spinal Cord Injury Functional Ambulation Inventory (SCI-FAI). Design: Prospective observational cohort. Setting: Seven outpatient rehabilitation centers from the Christopher and Dana Reeve Foundation NeuroRecovery Network (NRN). Participants: 249 NRN patients with American Spinal Injury Association Impairment Scale (AIS) level C (n = 20), D (n = 179) and (n = 50) iSCI not AIS evaluated, from February 2008 through April 2011. Interventions: Locomotor training using body weight support and walking on a treadmill, overground and home/community practice. Main Outcome Measure(s): 10MWT and 6MWT collected at enrollment, approximately every 20 sessions, and upon discharge. Results: The 10MWT and 6MWT speeds were highly correlated and the 10MWT speeds were generally faster. However, the predicted 6MWT gait speed from the 10MWT, revealed increasing error with increased gait speed. Regression lines remained significantly different from lines of agreement, when the group was divided into fast (>= 0.44 m/s) and slow walkers (< 0.44 m/s). Significant differences between 6MWT and 10MWT gait speeds were observed across SCI-FAI walking mobility categories (Wilcoxon sign rank test p<.001), and mean speed thresholds for limited community ambulation differed for each measure. The smallest real difference for the 6MWT and 10MWT, as well as the minimally clinically important difference (MCID) values, were also distinct for the two tests. Conclusions: While the speeds were correlated between the 6MWT and 10MWT, redundancy in the tests using predictive modeling was not observed. Different speed thresholds and separate MCIDs were defined for community ambulation for each test.	[Forrest, Gail F.] Kessler Fdn Res Ctr, Human Performance & Engn Lab, W Orange, NJ 07052 USA; [Forrest, Gail F.] Rutgers State Univ, Dept Phys Med & Rehabil, Newark, NJ 07102 USA; [Hutchinson, Karen] Boston Univ, Dept Phys Therapy & Athlet Training, Boston, MA 02215 USA; [Lorenz, Douglas J.] Univ Louisville, Sch Publ Hlth & Informat Sci, Dept Bioinformat & Biostat, Louisville, KY 40292 USA; [Lorenz, Douglas J.] Univ Louisville, Kentucky Spinal Cord Res Ctr, Louisville, KY 40292 USA; [Buehner, Jeffrey J.] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA; [VanHiel, Leslie R.] Shepherd Ctr, Hulse Spinal Cord Injury Lab, Atlanta, GA USA; [VanHiel, Leslie R.] Shepherd Ctr, Crawford Res Inst, Atlanta, GA USA; [Sisto, Sue Ann] SUNY Stony Brook, Sch Hlth Technol & Management, Rehabil Res & Movement Performance Lab, Stony Brook, NY 11794 USA; [Basso, D. Michele] Ohio State Univ, Sch Allied Med Profess, Ctr Brain & Spinal Cord Repair, Columbus, OH 43210 USA	Kessler Institute for Rehabilitation; Rutgers State University Newark; Rutgers State University New Brunswick; Boston University; University of Louisville; University of Louisville; University System of Ohio; Ohio State University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University System of Ohio; Ohio State University	Forrest, GF (corresponding author), Kessler Fdn Res Ctr, Human Performance & Engn Lab, W Orange, NJ 07052 USA.	gforrest@kesslerfoundation.org			Christopher and Dana Reeve Foundation [NRN-2008]	Christopher and Dana Reeve Foundation	Funding for this work is from the Christopher and Dana Reeve Foundation; NRN-2008. THESE FUNDERS AIDED IN PAYMENT OF TREATMENT SESSIONS/STAFF. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barbeau H, 2007, NEUROREHAB NEURAL RE, V21, P302, DOI 10.1177/1545968306298937; Beckerman H, 2001, QUAL LIFE RES, V10, P571, DOI 10.1023/A:1013138911638; Behmran AL, 2000, PHYS THER, V80, P688, DOI 10.1093/ptj/80.7.688; Behrman AL, 2005, PHYS THER, V85, P1356, DOI 10.1093/ptj/85.12.1356; Brooks D, 2003, AM J RESP CRIT CARE, V167, P1287, DOI 10.1164/ajrccm.167.9.950; Buehner JJ, 2012, ARCH PHYS MED REHAB, V93, P1530, DOI 10.1016/j.apmr.2012.02.035; DeVivo MJ, 2012, SPINAL CORD, V50, P365, DOI 10.1038/sc.2011.178; Ditunno JF, 2005, J REHABIL RES DEV, V42, P35, DOI 10.1682/JRRD.2004.08.0098; DIXON R E, 1969, Journal of Physiology (Cambridge), V202, p68P; Dobkin BH, 2006, NEUROLOGY, V66, P584, DOI 10.1212/01.wnl.0000198502.88147.dd; Field-Fote EC, 2001, J REHABIL MED, V33, P177, DOI 10.1080/165019701750300645; Forrest GF, 2012, ARCH PHYS MED REHAB, V93, P1553, DOI 10.1016/j.apmr.2011.08.051; Harkema SJ, 2012, ARCH PHYS MED REHAB, V93, P1508, DOI 10.1016/j.apmr.2011.01.024; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.2307/2336325; Jackson AB, 2008, J SPINAL CORD MED, V31, P487, DOI 10.1080/10790268.2008.11753644; Kim CM, 2004, SPINAL CORD, V42, P156, DOI 10.1038/sj.sc.3101569; Lam T, 2008, SPINAL CORD, V46, P246, DOI 10.1038/sj.sc.3102134; Lemay JF, 2010, SPINAL CORD, V48, P245, DOI 10.1038/sc.2009.119; Lorenz DJ, 2011, STAT MED, V30, P3181, DOI 10.1002/sim.4368; Musselman KE, 2007, PHYS THER REV, V12, P287, DOI 10.1179/108331907X223128; Musselman KE, 2007, J REHABIL MED, V39, P567, DOI 10.2340/16501977-0090; Pinheiro J. C, 2000, MIXED EFFECTS MODELS; R Development Core Team, 2011, LANG ENV STAT COMP V; Steffen TM, 2002, PHYS THER, V82, P128, DOI 10.1093/ptj/82.2.128; Tilson JK, 2010, PHYS THER, V90, P196, DOI 10.2522/ptj.20090079; Tyson S, 2009, CLIN REHABIL, V23, P1018, DOI 10.1177/0269215509339004; van Hedel HJ, 2005, ARCH PHYS MED REHAB, V86, P190, DOI 10.1016/j.apmr.2004.02.010; van Hedel HJ, 2009, NEUROREHAB NEURAL RE; van Hedel HJA, 2005, SPINAL CORD, V43, P593, DOI 10.1038/sj.sc.3101768; van Hedel HJA, 2007, NEUROREHAB NEURAL RE, V21, P295, DOI 10.1177/1545968306297861; van Hedel HJA, 2009, NEUROREHAB NEURAL RE, V23, P117, DOI 10.1177/1545968308320640; Wirz M, 2010, SPINAL CORD, V48, P407, DOI 10.1038/sc.2009.149; YOUDEN W. J., 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3	33	45	45	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2014	9	5							e94108	10.1371/journal.pone.0094108	http://dx.doi.org/10.1371/journal.pone.0094108			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG6EE	24788068	gold, Green Published, Green Submitted			2023-01-03	WOS:000335510600010
J	Clemens, B; Jung, S; Mingoia, G; Weyer, D; Domahs, F; Willmes, K				Clemens, Benjamin; Jung, Stefanie; Mingoia, Gianluca; Weyer, David; Domahs, Frank; Willmes, Klaus			Influence of Anodal Transcranial Direct Current Stimulation (tDCS) over the Right Angular Gyrus on Brain Activity during Rest	PLOS ONE			English	Article							DEFAULT-MODE NETWORK; HUMAN MOTOR CORTEX; INDEPENDENT COMPONENT ANALYSIS; STATE FUNCTIONAL CONNECTIVITY; DORSOLATERAL PREFRONTAL CORTEX; MAGNETIC STIMULATION; DC-STIMULATION; STRUCTURAL CONNECTIVITY; HEALTHY-INDIVIDUALS; PARKINSONS-DISEASE	Although numerous studies examined resting-state networks (RSN) in the human brain, so far little is known about how activity within RSN might be modulated by non-invasive brain stimulation applied over parietal cortex. Investigating changes in RSN in response to parietal cortex stimulation might tell us more about how non-invasive techniques such as transcranial direct current stimulation (tDCS) modulate intrinsic brain activity, and further elaborate our understanding of how the resting brain responds to external stimulation. Here we examined how activity within the canonical RSN changed in response to anodal tDCS applied over the right angular gyrus (AG). We hypothesized that changes in resting-state activity can be induced by a single tDCS session and detected with functional magnetic resonance imaging (fMRI). Significant differences between two fMRI sessions (pre-tDCS and post-tDCS) were found in several RSN, including the cerebellar, medial visual, sensorimotor, right frontoparietal, and executive control RSN as well as the default mode and the task positive network. The present results revealed decreased and increased RSN activity following tDCS. Decreased RSN activity following tDCS was found in bilateral primary and secondary visual areas, and in the right putamen. Increased RSN activity following tDCS was widely distributed across the brain, covering thalamic, frontal, parietal and occipital regions. From these exploratory results we conclude that a single session of anodal tDCS over the right AG is sufficient to induce large-scale changes in resting-state activity. These changes were localized in sensory and cognitive areas, covering regions close to and distant from the stimulation site.	[Clemens, Benjamin] Rhein Westfal TH Aachen, Sch Med, Dept Psychiat Psychotherapy & Psychosomat, Aachen, Germany; [Clemens, Benjamin; Mingoia, Gianluca; Weyer, David; Willmes, Klaus] Rhein Westfal TH Aachen, Sch Med, Interdisciplinary Ctr Clin Res, Brain Imaging Facil, Aachen, Germany; [Clemens, Benjamin; Willmes, Klaus] Rhein Westfal TH Aachen, Sch Med, Sect Neuropsychol, Neurol Clin, Aachen, Germany; [Jung, Stefanie] Univ Tubingen, Dept Psychol, Tubingen, Germany; [Jung, Stefanie] IWM KMRC, Knowledge Media Res Ctr, Tubingen, Germany; [Domahs, Frank] Univ Marburg, Dept German Linguist, Marburg, Germany	RWTH Aachen University; RWTH Aachen University; RWTH Aachen University; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Leibniz Institut fur Wissensmedien; Philipps University Marburg	Clemens, B (corresponding author), Rhein Westfal TH Aachen, Sch Med, Dept Psychiat Psychotherapy & Psychosomat, Aachen, Germany.	bclemens@ukaachen.de	Clemens, Benjamin/AAW-7273-2021; Willmes, Klaus F/A-1268-2014	Willmes, Klaus F/0000-0002-9012-0553	START program of the Faculty of Medicine, RWTH Aachen University, Aachen, Germany	START program of the Faculty of Medicine, RWTH Aachen University, Aachen, Germany	This research was supported by the START program of the Faculty of Medicine, RWTH Aachen University, Aachen, Germany (http://www.medizin.rwth-aachen.de/go/id/tfy). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Accornero N, 2007, EXP BRAIN RES, V178, P261, DOI 10.1007/s00221-006-0733-y; Amadi U, 2014, NEUROIMAGE, V88, P155, DOI 10.1016/j.neuroimage.2013.11.037; Andrews SC, 2011, BRAIN STIMUL, V4, P84, DOI 10.1016/j.brs.2010.06.004; Antal A, 2007, EUR J NEUROSCI, V26, P2687, DOI 10.1111/j.1460-9568.2007.05896.x; Antal A, 2012, RESTOR NEUROL NEUROS, V30, P255, DOI 10.3233/RNN-2012-110208; Antal A, 2011, NEUROIMAGE, V55, P590, DOI 10.1016/j.neuroimage.2010.11.085; Arrington CM, 2000, J COGNITIVE NEUROSCI, V12, P106, DOI 10.1162/089892900563975; Banich MT, 2000, COGNITIVE BRAIN RES, V10, P1, DOI 10.1016/S0926-6410(00)00015-X; Beauchamp MS, 2001, NEUROIMAGE, V14, P310, DOI 10.1006/nimg.2001.0788; Beckmann CF, 2005, NEUROIMAGE, V25, P294, DOI 10.1016/j.neuroimage.2004.10.043; Beckmann CF, 2004, IEEE T MED IMAGING, V23, P137, DOI 10.1109/TMI.2003.822821; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; Benninger DH, 2010, J NEUROL NEUROSUR PS, V81, P1105, DOI 10.1136/jnnp.2009.202556; Binder JR, 2009, CEREB CORTEX, V19, P2767, DOI 10.1093/cercor/bhp055; Birn RM, 2012, NEUROIMAGE, V62, P864, DOI 10.1016/j.neuroimage.2012.01.016; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Biswal BB, 2010, P NATL ACAD SCI USA, V107, P4734, DOI 10.1073/pnas.0911855107; Brunelin J, 2012, AM J PSYCHIAT, V169, P719, DOI 10.1176/appi.ajp.2012.11071091; Brunoni AR, 2013, JAMA PSYCHIAT, V70, P383, DOI 10.1001/2013.jamapsychiatry.32; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Cattaneo Z, 2011, NEUROSCIENCE, V183, P64, DOI 10.1016/j.neuroscience.2011.03.058; Cecere R, 2013, J NEUROSCI, V33, P6469, DOI 10.1523/JNEUROSCI.3431-12.2013; Chambers CD, 2004, NAT NEUROSCI, V7, P217, DOI 10.1038/nn1203; Clemens B, 2015, CEREB CORTEX, V25, P1771, DOI 10.1093/cercor/bht366; Clemens B, 2013, NEUROPSYCHOLOGIA, V51, P1279, DOI 10.1016/j.neuropsychologia.2013.03.023; Clemens B, 2013, RESTOR NEUROL NEUROS, V31, P311, DOI 10.3233/RNN-120266; Clemens B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025453; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Corbetta M, 2008, NEURON, V58, P306, DOI 10.1016/j.neuron.2008.04.017; Cordes D, 2000, AM J NEURORADIOL, V21, P1636; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; De Luca M, 2005, EXP BRAIN RES, V167, P587, DOI 10.1007/s00221-005-0059-1; Dehaene S, 2004, CURR OPIN NEUROBIOL, V14, P218, DOI 10.1016/j.conb.2004.03.008; Di Martino A, 2008, CEREB CORTEX, V18, P2735, DOI 10.1093/cercor/bhn041; Downar J, 2000, NAT NEUROSCI, V3, P277, DOI 10.1038/72991; Filippi M, 2013, HUM BRAIN MAPP, V34, P1330, DOI 10.1002/hbm.21514; Fiori V, 2011, J COGNITIVE NEUROSCI, V23, P2309, DOI 10.1162/jocn.2010.21579; Floel A, 2008, J COGNITIVE NEUROSCI, V20, P1415, DOI 10.1162/jocn.2008.20098; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Fox MD, 2006, P NATL ACAD SCI USA, V103, P10046, DOI 10.1073/pnas.0604187103; Fox MD, 2012, NEUROIMAGE, V62, P2232, DOI 10.1016/j.neuroimage.2012.03.035; Fregni F, 2006, BIPOLAR DISORD, V8, P203, DOI 10.1111/j.1399-5618.2006.00291.x; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Fregni F, 2007, NAT CLIN PRACT NEURO, V3, P383, DOI 10.1038/ncpneuro0530; Fregni F, 2006, MOVEMENT DISORD, V21, P1693, DOI 10.1002/mds.21012; Frey S, 2008, J NEUROSCI, V28, P11435, DOI 10.1523/JNEUROSCI.2388-08.2008; Garavan H, 2006, BRAIN RES, V1105, P130, DOI 10.1016/j.brainres.2006.03.029; Gerardin E, 2004, NEUROREPORT, V15, P2327, DOI 10.1097/00001756-200410250-00005; Greicius MD, 2004, P NATL ACAD SCI USA, V101, P4637, DOI 10.1073/pnas.0308627101; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Greicius MD, 2008, HUM BRAIN MAPP, V29, P839, DOI 10.1002/hbm.20537; Greicius MD, 2007, BIOL PSYCHIAT, V62, P429, DOI 10.1016/j.biopsych.2006.09.020; Herwig U, 2003, BRAIN TOPOGR, V16, P95, DOI 10.1023/B:BRAT.0000006333.93597.9d; Holland R, 2011, CURR BIOL, V21, P1403, DOI 10.1016/j.cub.2011.07.021; Homan P, 2011, AM J PSYCHIAT, V168, P853, DOI 10.1176/appi.ajp.2011.11030496; Horwitz B, 1998, P NATL ACAD SCI USA, V95, P8939, DOI 10.1073/pnas.95.15.8939; Iyer MB, 2005, NEUROLOGY, V64, P872, DOI 10.1212/01.WNL.0000152986.07469.E9; Jacobson L, 2012, EXP BRAIN RES, V216, P1, DOI 10.1007/s00221-011-2891-9; Jamadar S, 2013, BRAIN IMAGING BEHAV, V7, P15, DOI 10.1007/s11682-012-9168-1; Kasahara K, 2013, NEUROSCI LETT, V545, P86, DOI 10.1016/j.neulet.2013.04.022; Keeser D, 2011, J NEUROSCI, V31, P15284, DOI 10.1523/JNEUROSCI.0542-11.2011; KEMP JM, 1971, PHILOS T R SOC B, V262, P441, DOI 10.1098/rstb.1971.0106; Kiviniemi V, 2004, MAGN RESON IMAGING, V22, P197, DOI 10.1016/j.mri.2003.09.007; Koyama MS, 2010, CEREB CORTEX, V20, P2549, DOI 10.1093/cercor/bhq005; Kuo MF, 2008, NEUROPSYCHOLOGIA, V46, P2122, DOI 10.1016/j.neuropsychologia.2008.02.023; Lang N, 2005, EUR J NEUROSCI, V22, P495, DOI 10.1111/j.1460-9568.2005.04233.x; Liebetanz D, 2002, BRAIN, V125, P2238, DOI 10.1093/brain/awf238; Lindenberg R, 2013, J NEUROSCI, V33, P9176, DOI 10.1523/JNEUROSCI.0055-13.2013; Loo CK, 2012, BRIT J PSYCHIAT, V200, P52, DOI 10.1192/bjp.bp.111.097634; Maeoka H, 2012, NEUROSCI LETT, V512, P12, DOI 10.1016/j.neulet.2012.01.037; Makris N, 2009, CEREB CORTEX, V19, P777, DOI 10.1093/cercor/bhn124; Marangolo P, 2011, BEHAV BRAIN RES, V225, P498, DOI 10.1016/j.bbr.2011.08.008; McKeown MJ, 1998, P NATL ACAD SCI USA, V95, P803, DOI 10.1073/pnas.95.3.803; Meinzer M, 2012, J NEUROSCI, V32, P1859, DOI 10.1523/JNEUROSCI.4812-11.2012; Merzagora AC, 2010, NEUROIMAGE, V49, P2304, DOI 10.1016/j.neuroimage.2009.10.044; Mingoia G, 2013, PSYCHIAT RES-NEUROIM, V214, P80, DOI 10.1016/j.pscychresns.2013.05.013; Mingoia G, 2012, SCHIZOPHR RES, V138, P143, DOI 10.1016/j.schres.2012.01.036; Miniussi C, 2008, BRAIN STIMUL, V1, P326, DOI 10.1016/j.brs.2008.07.002; Miranda PC, 2006, CLIN NEUROPHYSIOL, V117, P1623, DOI 10.1016/j.clinph.2006.04.009; Miranda PC, 2009, CLIN NEUROPHYSIOL, V120, P1183, DOI 10.1016/j.clinph.2009.03.023; Moliadze V, 2010, CLIN NEUROPHYSIOL, V121, P2165, DOI 10.1016/j.clinph.2010.04.033; Monchi O, 2006, ANN NEUROL, V59, P257, DOI 10.1002/ana.20742; Nitsche MA, 2007, J NEUROPHYSIOL, V97, P3109, DOI 10.1152/jn.01312.2006; Nitsche MA, 2004, NEUROPSYCHOPHARMACOL, V29, P1573, DOI 10.1038/sj.npp.1300517; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2003, J PHYSIOL-LONDON, V553, P293, DOI 10.1113/jphysiol.2003.049916; Nitsche MA, 2011, RESTOR NEUROL NEUROS, V29, P463, DOI 10.3233/RNN-2011-0618; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Oostendorp TF, 2008, IEEE ENG MED BIO, P4226, DOI 10.1109/IEMBS.2008.4650142; Park CH, 2013, NEUROSCI LETT, V539, P7, DOI 10.1016/j.neulet.2013.01.047; Pena-Gomez C, 2012, BRAIN STIMUL, V5, P252, DOI 10.1016/j.brs.2011.08.006; Polania R, 2012, HUM BRAIN MAPP, V33, P2499, DOI 10.1002/hbm.21380; Polania R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030971; Polania R, 2011, HUM BRAIN MAPP, V32, P1236, DOI 10.1002/hbm.21104; Polania R, 2011, NEUROIMAGE, V54, P2287, DOI 10.1016/j.neuroimage.2010.09.085; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Ralchle ME, 2007, NEUROIMAGE, V37, P1083, DOI 10.1016/j.neuroimage.2007.02.041; Rorden C, 2000, BEHAV NEUROL, V12, P191, DOI 10.1155/2000/421719; Rosazza C, 2011, NEUROL SCI, V32, P773, DOI 10.1007/s10072-011-0636-y; Rubia K, 2006, HUM BRAIN MAPP, V27, P973, DOI 10.1002/hbm.20237; Sadleir RJ, 2010, NEUROIMAGE, V51, P1310, DOI 10.1016/j.neuroimage.2010.03.052; Satterthwaite TD, 2012, NEUROIMAGE, V60, P623, DOI 10.1016/j.neuroimage.2011.12.063; Schlaug G, 2008, EXPERT REV MED DEVIC, V5, P759, DOI 10.1586/17434440.5.6.759; Schutter DJLG, 2004, SYNTHESE, V141, P155, DOI 10.1023/B:SYNT.0000042951.25087.16; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Seghier ML, 2013, NEUROSCIENTIST, V19, P43, DOI 10.1177/1073858412440596; Sehm B, 2012, J NEUROPHYSIOL, V108, P3253, DOI 10.1152/jn.00606.2012; Shafi MM, 2012, EUR J NEUROSCI, V35, P805, DOI 10.1111/j.1460-9568.2012.08035.x; Sheline YI, 2010, J NEUROSCI, V30, P17035, DOI 10.1523/JNEUROSCI.3987-10.2010; Shulman GL, 1997, J COGNITIVE NEUROSCI, V9, P648, DOI 10.1162/jocn.1997.9.5.648; Shulman GL, 2009, J NEUROSCI, V29, P4392, DOI 10.1523/JNEUROSCI.5609-08.2009; Silvanto J, 2008, TRENDS COGN SCI, V12, P447, DOI 10.1016/j.tics.2008.09.004; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Stagg CJ, 2011, NEUROSCIENTIST, V17, P37, DOI 10.1177/1073858410386614; Stagg CJ, 2009, J NEUROSCI, V29, P5202, DOI 10.1523/JNEUROSCI.4432-08.2009; Stefan K, 2004, J NEUROPHYSIOL, V92, P66, DOI 10.1152/jn.00383.2003; Stevens WD, 2010, CEREB CORTEX, V20, P1997, DOI 10.1093/cercor/bhp270; Sturm W, 2004, NEUROPSYCHOLOGIA, V42, P563, DOI 10.1016/j.neuropsychologia.2003.11.004; Suh HS, 2010, IEEE ENG MED BIO, P2053, DOI 10.1109/IEMBS.2010.5626502; Supekar K, 2010, NEUROIMAGE, V52, P290, DOI 10.1016/j.neuroimage.2010.04.009; Teo Florence, 2011, Front Psychiatry, V2, P45, DOI 10.3389/fpsyt.2011.00045; Uddin LQ, 2010, CEREB CORTEX, V20, P2636, DOI 10.1093/cercor/bhq011; Uddin LQ, 2009, HUM BRAIN MAPP, V30, P625, DOI 10.1002/hbm.20531; Van Dijk KRA, 2012, NEUROIMAGE, V59, P431, DOI 10.1016/j.neuroimage.2011.07.044; Vanderhasselt MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062219; Wagner T, 2007, NEUROIMAGE, V35, P1113, DOI 10.1016/j.neuroimage.2007.01.027; Wong D L, 1988, Pediatr Nurs, V14, P9; Zheng X, 2011, NEUROIMAGE, V58, P26, DOI 10.1016/j.neuroimage.2011.06.018	132	22	22	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2014	9	4							e95984	10.1371/journal.pone.0095984	http://dx.doi.org/10.1371/journal.pone.0095984			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG3EI	24760013	Green Published, gold, Green Submitted			2023-01-03	WOS:000335298200122
J	Olivo-Marston, SE; Hursting, SD; Perkins, SN; Schetter, A; Khan, M; Croce, C; Harris, CC; Lavigne, J				Olivo-Marston, Susan E.; Hursting, Stephen D.; Perkins, Susan N.; Schetter, Aaron; Khan, Mohammed; Croce, Carlo; Harris, Curtis C.; Lavigne, Jackie			Effects of Calorie Restriction and Diet-Induced Obesity on Murine Colon Carcinogenesis, Growth and Inflammatory Factors, and MicroRNA Expression	PLOS ONE			English	Article							ABERRANT CRYPT FOCI; MALE F344 RATS; COLORECTAL-CANCER; FACTOR-I; PLASMA ADIPONECTIN; PHYSICAL-ACTIVITY; BINDING PROTEIN-3; ENERGY-BALANCE; OB/OB MICE; RISK	Obesity is an established colon cancer risk factor, while preventing or reversing obesity via a calorie restriction (CR) diet regimen decreases colon cancer risk. Unfortunately, the biological mechanisms underlying these associations are poorly understood, hampering development of mechanism-based approaches for preventing obesity-related colon cancer. We tested the hypotheses that diet-induced obesity (DIO) would increase (and CR would decrease) colon tumorigenesis in the mouse azoxymethane (AOM) model. In addition, we established that changes in inflammatory cytokines, growth factors, and microRNAs are associated with these energy balance-colon cancer links, and thus represent mechanism-based targets for colon cancer prevention. Mice were injected with AOM once a week for 5 weeks and randomized to: 1) control diet; 2) 30% CR diet; or 3) DIO diet. Mice were euthanized at week 5 (n = 12/group), 10 (n = 12/group), and 20 (n = 20/group) after the last AOM injection. Colon tumors were counted, and cytokines, insulin-like growth factor 1 (IGF-1), IGF binding protein 3 (IGFBP-3), adipokines, proliferation, apoptosis, and expression of microRNAs (miRs) were measured. The DIO diet regimen induced an obese phenotype (similar to 36% body fat), while CR induced a lean phenotype (similar to 14% body fat); controls were intermediate (similar to 26% body fat). Relative to controls, DIO increased (and CR decreased) the number of colon tumors (p = 0.01), cytokines (p<0.001), IGF-1 (p = 0.01), and proliferation (p<0.001). DIO decreased (and CR increased) IGFBP-3 and apoptosis (p<0.001). miRs including mir-425, mir-196, mir-155, mir-150, mir-351, mir-16, let-7, mir34, and mir-138 were differentially expressed between the dietary groups. We conclude that the enhancing effects of DIO and suppressive effects of CR on colon carcinogenesis are associated with alterations in several biological pathways, including inflammation, IGF-1, and microRNAs.	[Olivo-Marston, Susan E.; Schetter, Aaron; Khan, Mohammed; Harris, Curtis C.] NCI, Human Carcinogenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Olivo-Marston, Susan E.] Ohio State Univ, Div Epidemio, Coll Publ Hlth, Columbus, OH 43210 USA; [Hursting, Stephen D.] Univ Texas Austin, Dept Nutr Sci, Austin, TX 78712 USA; [Hursting, Stephen D.] Univ Texas MD Anderson Canc Ctr, Dept Mol Carcinogenesis, Smithville, TX USA; [Perkins, Susan N.] NCI, Ctr Canc Training, NIH, Bethesda, MD 20892 USA; [Croce, Carlo] Ohio State Univ, Coll Med, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Lavigne, Jackie] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Ohio; Ohio State University; University of Texas System; University of Texas Austin; University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Ohio; Ohio State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Olivo-Marston, SE (corresponding author), NCI, Human Carcinogenesis Lab, Ctr Canc Res, NIH, Bldg 37, Bethesda, MD 20892 USA.	solivo-marston@cph.osu.edu	Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647	NATIONAL CANCER INSTITUTE [ZIABC011492, P30CA016058] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA016058] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abolhassani M, 2008, CANCER RES, V68, P9423, DOI 10.1158/0008-5472.CAN-08-1017; ALBANES D, 1987, Nutrition and Cancer, V9, P199; Barb D, 2006, EXPERT OPIN INV DRUG, V15, P917, DOI 10.1517/13543784.15.8.917; Bobe G, 2008, NUTR CANCER, V60, P373, DOI 10.1080/01635580701775142; Ealey KN, 2008, MOL CARCINOGEN, V47, P667, DOI 10.1002/mc.20419; Farquharson A, MOL BIOL REPORTS, P1; Fenton JI, 2009, DIABETES OBES METAB, V11, P343, DOI 10.1111/j.1463-1326.2008.00974.x; Fenton JI, 2005, CANCER EPIDEM BIOMAR, V14, P1646, DOI 10.1158/1055-9965.EPI-04-0916; GIOVANELLA BC, 1982, JNCI-J NATL CANCER I, V68, P249; Giovannucci E, 2000, CANCER EPIDEM BIOMAR, V9, P345; GIOVANNUCCI E, 1995, ANN INTERN MED, V122, P327, DOI 10.7326/0003-4819-122-5-199503010-00002; Giovannucci E, 1996, CANCER CAUSE CONTROL, V7, P253, DOI 10.1007/BF00051301; Giovannucci E, 2001, J NUTR, V131, p3109S, DOI 10.1093/jn/131.11.3109S; Giovannucci E, 2000, GROWTH HORM IGF RES, V10, pS30, DOI 10.1016/S1096-6374(00)90014-5; Hardwick JCH, 2001, GASTROENTEROLOGY, V121, P79, DOI 10.1053/gast.2001.25490; Huang XF, 2009, GUT, V58, P1169; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; Hursting SD, 2007, CURR CANCER DRUG TAR, V7, P484; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; KLURFELD DM, 1987, CANCER RES, V47, P2759; KOENUMA M, 1989, JPN J CANCER RES, V80, P51, DOI 10.1111/j.1349-7006.1989.tb02244.x; KUMAR SP, 1990, CANCER RES, V50, P5761; Lashinger LM, CANC PREVENTION RES, V4, P11051; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Liu Z, J NUTR BIOCH; MACRAE FA, 1993, PREV MED, V22, P750, DOI 10.1006/pmed.1993.1069; Mai V, 2003, CANCER RES, V63, P1752; Mentor-Marcel RA, 2009, CANCER PREV RES, V2, P60, DOI 10.1158/1940-6207.CAPR-08-0086; Moore T, 2008, CANC PREVENTION RES, V76; Olivo SE, 2005, CARCINOGENESIS, V26, P1563, DOI 10.1093/carcin/bgi118; Olivo-Marston SE, 2009, MOL CARCINOGEN, V48, P1071, DOI 10.1002/mc.20577; Otake S, 2005, CLIN CANCER RES, V11, P3642, DOI 10.1158/1078-0432.CCR-04-1868; Otake S, 2010, WORLD J GASTROENTERO, V16, P1252, DOI 10.3748/wjg.v16.i10.1252; Padidar S, 2011, J CELL PHYSIOL, V226, P2123, DOI 10.1002/jcp.22546; Palmqvist R, 2002, GUT, V50, P642, DOI 10.1136/gut.50.5.642; Raju J, 2003, CANCER RES, V63, P6595; REDDY BS, 1987, CANCER RES, V47, P1226; Rondini EA, 2011, MOL CARCINOGEN, V50, P370, DOI 10.1002/mc.20720; Ruhl CE, 2007, AM J CLIN NUTR, V85, P1121; Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425; Schimanski CC, 2009, WORLD J GASTROENTERO, V15, P2089, DOI 10.3748/wjg.15.2089; Slattery ML, 1997, CANCER RES, V57, P75; Takagi T, 2010, J GASTROEN HEPATOL, V25, pS129, DOI 10.1111/j.1440-1746.2009.06216.x; TANNENBAUM A, 1947, ANN NY ACAD SCI, V49, P5, DOI 10.1111/j.1749-6632.1947.tb30929.x; Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Watanabe A, 2011, LEUKEMIA, V25, P1324, DOI 10.1038/leu.2011.81; Weber RV, 2000, DIGEST DIS SCI, V45, P890, DOI 10.1023/A:1005560621722; Wei EK, 2005, JNCI-J NATL CANCER I, V97, P1688, DOI 10.1093/jnci/dji376; Wheatley KE, 2008, NUTR CANCER, V60, P61, DOI 10.1080/01635580701510150; Yakar S, 2006, ENDOCRINOLOGY, V147, P5826, DOI 10.1210/en.2006-0311; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Zeng H, 2011, CLIN EXPT PHARM PHYS	53	73	77	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 14	2014	9	4							e94765	10.1371/journal.pone.0094765	http://dx.doi.org/10.1371/journal.pone.0094765			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI6GP	24732966	Green Published, gold, Green Submitted			2023-01-03	WOS:000336970400096
J	Liu, J; Zhang, GL; Huang, GQ; Li, L; Li, CP; Wang, M; Liang, XY; Xie, D; Yang, CM; Li, Y; Sun, XR; Zhang, HS; Wan, BS; Zhang, WH; Yu, H; Zhang, RY; Yu, YN; Wang, Z; Wang, YY				Liu, Jun; Zhang, Guo-Liang; Huang, Gui-Qin; Li, Li; Li, Chun-Ping; Wang, Mei; Liang, Xiao-Yan; Xie, Di; Yang, Chang-Ming; Li, Yan; Sun, Xiu-Rong; Zhang, Hong-Sen; Wan, Bai-Song; Zhang, Wei-Hua; Yu, Hao; Zhang, Ru-Yang; Yu, Ya-Nan; Wang, Zhong; Wang, Yong-Yan			Therapeutic Effect of Jinzhen Oral Liquid for Hand Foot and Mouth Disease: A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Trial	PLOS ONE			English	Article							ENTEROVIRUS 71; CLINICAL-FEATURES; PULMONARY-EDEMA; BAICALIN; EPIDEMIC; MANAGEMENT	Background: No specific antiviral agent against hand foot and mouth disease (HFMD) is available for clinical practice today. Objective: To evaluate the efficacy and safety of Jinzhen oral solution in treating uncomplicated HFMD. Methods: In this randomized, double-blind, placebo-controlled trial, 399 children aged 1 to 7 years with laboratory confirmed HFMD were randomized to receive Jinzhen oral liquid or placebo 3 times daily for 7 days with a 3-day follow-up. The primary outcomes were time to the first disappearance of oral ulcers and vesicles on hand or foot and time to the first normalization of temperature (fever clearance). Results: There were 199 children enrolling into the Jinzhen group including 79 with fever and 200 into the placebo group including 93 with fever. Jinzhen reduced the time to the first disappearance of oral ulcers and vesicles on hand or foot to 4.9 days (95% CI, 4.6 to 5.2 days), compared with 5.7 days (95% CI, 5.4 to 6.0 days) in the placebo group (P = 0.0036). The median time of fever clearance was shorter in the 79 children who received Jinzhen (43.41 hrs, 95% CI, 37.05 to 49.76) than that in the 93 children who received placebo (54.92 hrs, 95% CI, 48.16 to 61.68) (P = 0.0161). Moreover, Jinzhen reduced the risk of symptoms by 28.5% compared with placebo (HR, 0.7150, 95% CI, 0.5719 to 0.8940, P = 0.0032). More importantly, treatment failure rate was significantly lower in the Jinzhen group (8.04%) compared with that in the placebo group (15.00%) (P = 0.0434). The incidence of serious adverse events did not differ significantly between the two groups (9 in Jinzhen group vs. 18 in placebo, P = 0.075). Conclusions: Children with HFMD may benefit from Jinzhen oral liquid treatment as compared with placebo.	[Liu, Jun; Yu, Ya-Nan; Wang, Zhong; Wang, Yong-Yan] China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing, Peoples R China; [Zhang, Guo-Liang] Anhui Univ Tradit Chinese Med, Affiliated Hosp 1, Dept Infect Dis, Hefei, Anhui, Peoples R China; [Huang, Gui-Qin; Sun, Xiu-Rong; Zhang, Hong-Sen] Infect Dis Hosp Cangzhou City, Dept Infect Dis, Cangzhou, Hebei, Peoples R China; [Li, Li; Wang, Mei; Liang, Xiao-Yan; Xie, Di; Yang, Chang-Ming; Li, Yan] Fifth Peoples Hosp Guiyang City, Dept Infect Dis, Guiyang, Guizhou, Peoples R China; [Wan, Bai-Song; Zhang, Wei-Hua] Infect Dis Hosp Tangshan City, Dept Infect Dis, Tangshan, Hebei, Peoples R China; [Yu, Hao; Zhang, Ru-Yang] Nanjing Med Univ, Dept Epidemiol & Biostat, Nanjing, Jiangsu, Peoples R China	China Academy of Chinese Medical Sciences; Institute of Basic Research In Clinical Medicine, CACMS; Anhui University of Chinese Medicine; Nanjing Medical University	Wang, Z (corresponding author), China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing, Peoples R China.	zhonw@vip.sina.com; wangyongyan2010@sina.cn	liang, xiaoyan/GYJ-5006-2022; zhang, weihua/GXV-1334-2022; Yu, Yan/GYV-4514-2022; Wang, Zhong/AAY-7574-2020		Traditional Chinese Medicine (TCM) Research Project of TCM Preventing and Curing Infectious Diseases of State Administration of TCM of People's Republic of China [200907001-5]	Traditional Chinese Medicine (TCM) Research Project of TCM Preventing and Curing Infectious Diseases of State Administration of TCM of People's Republic of China	This work was supported by the Traditional Chinese Medicine (TCM) Research Project of TCM Preventing and Curing Infectious Diseases of State Administration of TCM of People's Republic of China [200907001-5](http://www.satcm.gov.cn/). However, the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bendig J W, 1996, Commun Dis Rep CDR Rev, V6, pR81; Chan KP, 2003, EMERG INFECT DIS, V9, P78; Chang LY, 1999, LANCET, V354, P1682, DOI 10.1016/S0140-6736(99)04434-7; China's National Health and Family Planning Commission Office for Disease Control and Prevention National Patriotic Public Health Campaign Office), 2011, OV NAT EP NOT DIS JA; Fujimoto T, 2002, MICROBIOL IMMUNOL, V46, P621, DOI 10.1111/j.1348-0421.2002.tb02743.x; Gao SY, 2009, CHINA MED HERALD, V6, P244; Ho MT, 1999, NEW ENGL J MED, V341, P929, DOI 10.1056/NEJM199909233411301; Hsieh Chia-Jung, 2007, Clin Mol Allergy, V5, P5, DOI 10.1186/1476-7961-5-5; Kim DS, 2010, PLANTA MED, V76, P678, DOI 10.1055/s-0029-1240649; Li MH, 2009, BRIT J PHARMACOL, V157, P244, DOI 10.1111/j.1476-5381.2009.00139.x; Liu L, 2009, INT IMMUNOPHARMACOL, V9, P1568, DOI 10.1016/j.intimp.2009.09.013; Lu J, 2011, J ETHNOPHARMACOL, V134, P911, DOI 10.1016/j.jep.2011.01.049; [陆权 LU Quan], 2010, [中国实用儿科杂志, Chinese Journal of Practical Pediatrics], V25, P383; Ma E, 2010, JPN J INFECT DIS, V63, P422; Ministry of Health of P.R.C, DIAGN TREATM GUID HF; Ooi MH, 2010, LANCET NEUROL, V9, P1097, DOI 10.1016/S1474-4422(10)70209-X; Pharmacopoeia Commission of the People's Republic of China, 2010, PHARMACOPOEIA PEOPLE, VI, P829; Solomon T, 2010, LANCET INFECT DIS, V10, P778, DOI 10.1016/S1473-3099(10)70194-8; Sun LM, 2011, JPN J INFECT DIS, V64, P13; Tan LQ, 2011, CHINESE FOREIGN WOME, V19, P300; THOMAS I, 1993, CUTIS, V52, P265; Toida M, 2003, J CLIN LASER MED SUR, V21, P363, DOI 10.1089/104454703322650176; Tsai CC, 2006, NEUROPHARMACOLOGY, V51, P709, DOI 10.1016/j.neuropharm.2006.05.010; Tu XK, 2009, NEUROCHEM RES, V34, P1626, DOI 10.1007/s11064-009-9953-4; Wang SM, 2005, PEDIATR PULM, V39, P219, DOI 10.1002/ppul.20157; Wang Z, 2011, J CLIN PHARMACOL, V51, P1132, DOI 10.1177/0091270010382913; Woo KJ, 2006, IMMUNOBIOLOGY, V211, P359, DOI 10.1016/j.imbio.2006.02.002; Xu G, 2010, BIOL PHARM BULL, V33, P238, DOI 10.1248/bpb.33.238; Yoon SB, 2009, J ETHNOPHARMACOL, V125, P286, DOI 10.1016/j.jep.2009.06.027; Zhang G. L., 2010, CLIN J TRADITIONAL C, V22, P574	30	5	8	2	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 10	2014	9	4							e94466	10.1371/journal.pone.0094466	http://dx.doi.org/10.1371/journal.pone.0094466			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI5LS	24722423	Green Submitted, gold, Green Published			2023-01-03	WOS:000336909100074
J	Saslow, LR; Kim, S; Daubenmier, JJ; Moskowitz, JT; Phinney, SD; Goldman, V; Murphy, EJ; Cox, RM; Moran, P; Hecht, FM				Saslow, Laura R.; Kim, Sarah; Daubenmier, Jennifer J.; Moskowitz, Judith T.; Phinney, Stephen D.; Goldman, Veronica; Murphy, Elizabeth J.; Cox, Rachel M.; Moran, Patricia; Hecht, Fredrick M.			A Randomized Pilot Trial of a Moderate Carbohydrate Diet Compared to a Very Low Carbohydrate Diet in Overweight or Obese Individuals with Type 2 Diabetes Mellitus or Prediabetes	PLOS ONE			English	Article							BLOOD-GLUCOSE; FATTY-ACIDS; WEIGHT-LOSS; QUESTIONNAIRE; INSULIN; ENERGY	We compared the effects of two diets on glycated hemoglobin (HbA1c) and other health-related outcomes in overweight or obese adults with type 2 diabetes or prediabetes (HbA1c>6%). We randomized participants to either a medium carbohydrate, low fat, calorie-restricted, carbohydrate counting diet (MCCR) consistent with guidelines from the American Diabetes Association (n = 18) or a very low carbohydrate, high fat, non calorie-restricted diet whose goal was to induce nutritional ketosis (LCK, n = 16). We excluded participants receiving insulin; 74% were taking oral diabetes medications. Groups met for 13 sessions over 3 months and were taught diet information and psychological skills to promote behavior change and maintenance. At 3 months, mean HbA1c level was unchanged from baseline in the MCCR diet group, while it decreased 0.6% in the LCK group; there was a significant between group difference in HbA1c change favoring the LCK group (-0.6%, 95% CI, -1.1% to -0.03%, p = 0.04). Forty-four percent of the LCK group discontinued one or more diabetes medications, compared to 11% of the MCCR group (p = 0.03); 31% discontinued sulfonylureas in the LCK group, compared to 5% in the MCCR group (p = 0.05). The LCK group lost 5.5 kg vs. 2.6 kg lost in MCCR group (p = 0.09). Our results suggest that a very low carbohydrate diet coupled with skills to promote behavior change may improve glycemic control in type 2 diabetes while allowing decreases in diabetes medications.	[Saslow, Laura R.; Kim, Sarah; Daubenmier, Jennifer J.; Moskowitz, Judith T.; Goldman, Veronica; Murphy, Elizabeth J.; Moran, Patricia; Hecht, Fredrick M.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Phinney, Stephen D.] UC Davis Sch Med Emeritus, Davis, CA USA; [Cox, Rachel M.] Childrens Hosp & Res Ctr, Oakland, CA USA	University of California System; University of California San Francisco	Saslow, LR (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.	SaslowL@ocim.ucsf.edu		Saslow, Laura/0000-0003-3991-3205; phinney, stephen/0000-0002-3322-3978	William K. Bowes, Jr. Foundation; NIH from the National Center for Complementary and Alternative Medicine (NCCAM) [T32AT003997]; NIH from the National Institute of Mental Health [K24 MH093225]; NIH from NCCAM [K24 AT007827]; National Center for Complementary & Integrative Health [T32AT003997, K24AT007827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K24MH093225] Funding Source: NIH RePORTER	William K. Bowes, Jr. Foundation; NIH from the National Center for Complementary and Alternative Medicine (NCCAM); NIH from the National Institute of Mental Health; NIH from NCCAM; National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	The research was supported by a grant from the William K. Bowes, Jr. Foundation. Laura Saslow was supported by NIH grant T32AT003997 from the National Center for Complementary and Alternative Medicine (NCCAM). Judith Moskowitz was supported by NIH grant K24 MH093225 from the National Institute of Mental Health. Frederick Hecht was supported by NIH grant K24 AT007827 from NCCAM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Accurso A, 2008, NUTR METAB, V5, DOI 10.1186/1743-7075-5-9; Amer Diabet Assoc, 2013, DIABETES CARE, V36, P1033, DOI 10.2337/dc12-2625; Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS11, DOI 10.2337/dc13-S011; Association AD, 2011, AM DIAB ASS COMPL GU; Association AD, 2009, ALL CARB COUNT; BARTONE PT, 1989, J NERV MENT DIS, V177, P317, DOI 10.1097/00005053-198906000-00001; Boden G, 2005, ANN INTERN MED, V142, P403, DOI 10.7326/0003-4819-142-6-200503150-00006; BURNS TW, 1963, J LAB CLIN MED, V62, P646; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cohen J., 2013, STAT POWER ANAL BEHA; Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB; Daubenmier J, 2011, J OBES, V2011, DOI 10.1155/2011/651936; Daubenmier JJ, 2005, PSYCHOL WOMEN QUART, V29, P207, DOI 10.1111/j.1471-6402.2005.00183.x; Fonseca VA, 2009, DIABETES CARE, V32, P1, DOI [10.2337/dc09-9033, 10.2337/dc09-S301]; Gannon MC, 2006, NUTR METABOLISM, V3, DOI 10.1186/1743-7075-3-16; Inzucchi SE, 2012, DIABETOLOGIA, V55, P1577, DOI 10.1007/s00125-012-2534-0; McClain AD, 2013, DIABETES OBESITY; MERTZ W, 1991, AM J CLIN NUTR, V54, P291, DOI 10.1093/ajcn/54.2.291; Moskowitz JT, 2003, PSYCHOSOM MED, V65, P620, DOI 10.1097/01.PSY.0000073873.74829.23; Moskowitz JT, 2011, J HLTH PSYCHOL; Polonsky WH, 2005, DIABETES CARE, V28, P626, DOI 10.2337/diacare.28.3.626; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Santos F, 2012, OBESITY REV; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; STUNKARD AJ, 1985, J PSYCHOSOM RES, V29, P71, DOI 10.1016/0022-3999(85)90010-8; Subar AF, 2012, J ACAD NUTR DIET, V112, P1134, DOI 10.1016/j.jand.2012.04.016; Sumithran P, 2008, OBES RES CLIN PRACT, V2, P1, DOI 10.1016/j.orcp.2007.11.003; TAYLOR LA, 1988, J BEHAV MED, V11, P279, DOI 10.1007/BF00844433; Trumbo P, 2002, J AM DIET ASSOC, V102, P1621, DOI 10.1016/S0002-8223(02)90346-9; VANSTRIEN T, 1986, INT J EAT DISORDER, V5, P295, DOI 10.1002/1098-108X(198602)5:2<295::AID-EAT2260050209>3.0.CO;2-T; Wallace TM, 2004, DIABETES CARE, V27, P1487, DOI 10.2337/diacare.27.6.1487; Westman EC, 2008, NUTR METAB, V5, DOI [10.1186/1743-7075-5-10, 10.1186/1743-7075-5-36]; White MA, 2002, OBES RES, V10, P107, DOI 10.1038/oby.2002.17	33	106	108	2	50	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2014	9	4							e91027	10.1371/journal.pone.0091027	http://dx.doi.org/10.1371/journal.pone.0091027			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AE9PC	24717684	Green Published, Green Submitted, gold			2023-01-03	WOS:000334339000009
J	Yu, XH; Ge, NJ; Guo, X; Shen, SQ; Liang, J; Huang, XJ; Wan, SG; Xing, JL; Huang, QC; Yang, YF				Yu, Xiaohe; Ge, Naijian; Guo, Xu; Shen, Shuqun; Liang, Jun; Huang, Xiaojun; Wan, Shaogui; Xing, Jingliang; Huang, Qichao; Yang, Yefa			Genetic Variants in the EPCAM Gene Is Associated with the Prognosis of Transarterial Chemoembolization Treated Hepatocellular Carcinoma with Portal Vein Tumor Thrombus	PLOS ONE			English	Article							CELL ADHESION MOLECULE; CANCER; EXPRESSION; CD326	The epithelial cell adhesion molecule (EPCAM) is involved in the tumorigenesis and progression of many malignancies, including hepatocellular carcinoma (HCC). Single nucleotide polymorphisms (SNPs) of EPCAM have been reported to be with the risk and prognosis of several malignancies. However, the association of SNPs in EPCAM gene with the prognosis of HCC patients has never been investigated. In this study, two functional SNPs (rs1126497 and rs1421) in the EPCAM gene were selected and genotyped in a cohort of 448 unresectable Chinese HCC patients treated by TACE. The association of the two SNPs with the overall survival (OS) of patients was assessed by univariate and multivariate Cox proportional hazards model and Kaplan-Meier curve. Our data showed that there was no significant association between either SNP and OS of patients. However, in the stratified analysis, the variant-containing genotypes (WV+VV) of SNP rs1126497 exhibited a significant association with poorer OS in HCC patients who had portal vein tumor thrombus (PVTT) in multivariate analysis of Cox proportional hazard model (hazard ratio, 1.71; 95% confidence interval, 1.16-2.53, P = 0.007), and in Kaplan-Meier curve analysis (P = 0.023), comparing to those carrying wild-type genotype. Our results suggest that SNP rs1126497 in the EPCAM gene may serve as an independent prognosis biomarker for unresectable HCC patient with PVTT, which warranted further validating investigation.	[Yu, Xiaohe; Ge, Naijian; Shen, Shuqun; Liang, Jun; Yang, Yefa] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Radioact Intervent, Shanghai, Peoples R China; [Guo, Xu] Cell Engn Res Ctr, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China; [Guo, Xu] Dept Cell Biol, Xian, Shaanxi, Peoples R China; [Huang, Xiaojun; Xing, Jingliang; Huang, Qichao] Fourth Mil Med Univ, Expt Teaching Ctr Basic Med, Xian 710032, Shaanxi, Peoples R China; [Wan, Shaogui] Henan Univ, Pharmaceut Coll, Kaifeng, Henan, Peoples R China	Naval Medical University; Henan University	Huang, QC (corresponding author), Fourth Mil Med Univ, Expt Teaching Ctr Basic Med, Xian 710032, Shaanxi, Peoples R China.	huangqichao1@163.com; yangyefa66@163.com	Huang, Qichao/K-5706-2018		National Natural Science Foundation of China [81272522]; New Century Excellent Talents in University [81171966]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET))	This work was supported by grants 81272522 from the National Natural Science Foundation of China and grants 81171966 from New Century Excellent Talents in University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bae JS, 2012, INT J ONCOL, V41, P2150, DOI 10.3892/ijo.2012.1631; Baeuerle PA, 2007, BRIT J CANCER, V96, P417, DOI 10.1038/sj.bjc.6603494; Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199; Chamary JV, 2006, NAT REV GENET, V7, P98, DOI 10.1038/nrg1770; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI 10.1016/j.ejca.2011.12.021; Fouse SD, 2013, CANCER CELL, V23, P711, DOI 10.1016/j.ccr.2013.05.016; Gutzmer R, 2004, J IMMUNOL, V173, P1023, DOI 10.4049/jimmunol.173.2.1023; Hu M, 2012, MOL BIOL REP, V39, P7303, DOI 10.1007/s11033-012-1560-9; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Jia LZ, 2012, ACTA MED OKAYAMA, V66, P131; Jiang L, 2011, BREAST CANCER RES TR, V126, P487, DOI 10.1007/s10549-010-1094-6; Llovet JM, 2003, HEPATOLOGY, V37, P429, DOI 10.1053/jhep.2003.50047; Llovet JM, 2002, LANCET, V359, P1734, DOI 10.1016/S0140-6736(02)08649-X; Luo J, 2011, ANN SURG ONCOL, V18, P413, DOI 10.1245/s10434-010-1321-8; Munz M, 2009, CANCER RES, V69, P5627, DOI 10.1158/0008-5472.CAN-09-0654; Osta WA, 2004, CANCER RES, V64, P5818, DOI 10.1158/0008-5472.CAN-04-0754; Pak MG, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-53; Patriarca C, 2012, CANCER TREAT REV, V38, P68, DOI 10.1016/j.ctrv.2011.04.002; Shastry BS, 2009, METHODS MOL BIOL, V578, P3, DOI 10.1007/978-1-60327-411-1_1; Shi G, 2013, METHODS; Song DS, 2013, WORLD J GASTROENTERO, V19, P4679, DOI 10.3748/wjg.v19.i29.4679; Sun YF, 2013, HEPATOLOGY, V57, P1458, DOI 10.1002/hep.26151; Trzpis M, 2007, AM J PATHOL, V171, P386, DOI 10.2353/ajpath.2007.070152; Winter MJ, 2003, EXP CELL RES, V285, P50, DOI 10.1016/S0014-4827(02)00045-9; Wu L, 2010, CANCER BIOTHER RADIO, V25, P657, DOI 10.1089/cbr.2010.0801; Xue TC, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-60; Yamashita T, 2009, GASTROENTEROLOGY, V136, P1012, DOI 10.1053/j.gastro.2008.12.004; Yang Y, 2014, CANCER SCI, V105, P89, DOI 10.1111/cas.12318	29	9	10	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2014	9	4							e93416	10.1371/journal.pone.0093416	http://dx.doi.org/10.1371/journal.pone.0093416			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE9PC	24718422	Green Published, gold, Green Submitted			2023-01-03	WOS:000334339000031
J	Spiotto, MT; Weichselbaum, RR				Spiotto, Michael T.; Weichselbaum, Ralph R.			Comparison of 3D Confromal Radiotherapy and Intensity Modulated Radiotherapy with or without Simultaneous Integrated Boost during Concurrent Chemoradiation for Locally Advanced Head and Neck Cancers	PLOS ONE			English	Article							SQUAMOUS-CELL CARCINOMAS; RADIATION-THERAPY; ACCELERATED RADIOTHERAPY; STANDARD FRACTIONATION; IMRT; CHEMOTHERAPY; SIB	Objective: Radiotherapy techniques have evolved from 3D conformal radiotherapy (3D-CRT) to intensity modulated radiotherapy (IMRT) where boost fields are delivered either sequentially (IMRTseq) or with a simultaneous integrated boost (IMRT+ SIB). Our goal was to compare the outcomes of patients treated with IMRT+ SIB to traditional standards. Methods: We analyzed the efficacy and toxicity of patients treated with concurrent chemoradiation using 3D-CRT, IMRTseq or IMRT+ SIB. Between 1993 and 2012, 379 patients with non-metastatic Stage III-IV head and neck squamous cell cancer were treated with concurrent chemoradiation using 3D-CRT (n = 125), IMRTseq (n = 120) and IMRT+ SIB (n = 134). Results: Patients treated with any technique had similar rates of 2y local control, 2y regional control, 2y progression free survival and 2y overall survival. Patients treated with IMRT+ SIB had lower rates acute toxicity according to Grade 3 or greater mucositis (3D-CRT: 44.0% vs. IMRTseq: 36.7% vs. IMRT+ SIB: 22.4%; P<.0001), dermatitis (3D-CRT: 44.0% vs. IMRTseq: 20.0% vs. IMRT+ SIB: 7.5%; P<.0001) and feeding tube placement during radiotherapy (3D-CRT: 80.0% vs. IMRTseq: 50.8% vs. IMRT+ SIB: 44.0%; P<.0001) as well as late toxicity as measured by feeding tube use (P<.0001) and tracheostomy use (P<.0001). On multivariate analysis, IMRT+ SIB predicted for less mucositis, dermatitis and feeding tube use compared to 3D-CRT and for less dermatitis compared to IMRTseq. Conclusions: Compared to 3D-CRT and IMRTseq, IMRT+ SIB provided similar outcomes and potentially less toxicity indicating it is a feasible technique for chemoradiation in locally advanced head and neck cancer.	[Spiotto, Michael T.; Weichselbaum, Ralph R.] Univ Chicago, Med Ctr, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; [Spiotto, Michael T.; Weichselbaum, Ralph R.] Univ Chicago, Dept Radiat Oncol, Hosp & Hlth Sci Syst, Chicago, IL 60637 USA	University of Chicago; University of Chicago Medical Center; University of Chicago	Spiotto, MT (corresponding author), Univ Chicago, Med Ctr, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA.	mspiotto@radonc.uchicago.edu	Spiotto, Michael/AAC-8331-2021		Burroughs Wellcome Career Award for Medical Scientists; Fanconi Anemia Research Fund; NATIONAL CANCER INSTITUTE [R25CA132822] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000430] Funding Source: NIH RePORTER	Burroughs Wellcome Career Award for Medical Scientists(Burroughs Wellcome Fund); Fanconi Anemia Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	M.T.S. was supported by a grant from the Burroughs Wellcome Career Award for Medical Scientists and the Fanconi Anemia Research Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ang K, 2010, INT J RADIAT ONCOL, V77, P1, DOI 10.1016/j.ijrobp.2010.01.019; Brizel DM, 1998, NEW ENGL J MED, V338, P1798, DOI 10.1056/NEJM199806183382503; Chao KSC, 2003, INT J RADIAT ONCOL, V55, P312, DOI 10.1016/S0360-3016(02)03940-8; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cozzi L, 2004, INT J RADIAT ONCOL, V58, P617, DOI 10.1016/j.ijrobp.2003.09.059; Eisbruch A, 2010, INT J RADIAT ONCOL, V76, P1333, DOI 10.1016/j.ijrobp.2009.04.011; Franceschini D, 2013, LARYNGOSCOPE, V123, pE97, DOI 10.1002/lary.24257; Fu KK, 2000, INT J RADIAT ONCOL, V48, P7, DOI 10.1016/S0360-3016(00)00663-5; Karnofsky DA, 1949, CLIN EVALUATION CHEM; Lauve A, 2004, INT J RADIAT ONCOL, V60, P374, DOI 10.1016/j.ijrobp.2004.03.010; Leclerc M, 2013, RADIOTHER ONCOL, V106, P333, DOI 10.1016/j.radonc.2013.03.002; Lee NY, 2007, INT J RADIAT ONCOL, V69, P459, DOI 10.1016/j.ijrobp.2007.03.013; Lee SW, 2006, INT J RADIAT ONCOL, V65, P152, DOI 10.1016/j.ijrobp.2005.10.040; Mohan R, 2000, INT J RADIAT ONCOL, V46, P619, DOI 10.1016/S0360-3016(99)00438-1; Montejo ME, 2011, INT J RADIAT ONCOL, V81, pE845, DOI 10.1016/j.ijrobp.2010.10.021; Nutting CM, 2011, LANCET ONCOL, V12, P127, DOI 10.1016/S1470-2045(10)70290-4; Orlandi E, 2010, CRIT REV ONCOL HEMAT, V73, P111, DOI 10.1016/j.critrevonc.2009.03.003; Overgaard J, 2003, LANCET, V362, P933, DOI 10.1016/S0140-6736(03)14361-9; Palazzi M, 2006, TUMORI J, V92, P503, DOI 10.1177/030089160609200607; Schwartz M, 2007, OTOLARYNG HEAD NECK, V136, P549, DOI 10.1016/j.otohns.2006.10.044; Studer G, 2006, RADIAT ONCOL, V1, DOI 10.1186/1748-717X-1-7; Xia P, 2000, INT J RADIAT ONCOL, V48, P329, DOI 10.1016/S0360-3016(00)00585-X	22	37	41	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 8	2014	9	4							e94456	10.1371/journal.pone.0094456	http://dx.doi.org/10.1371/journal.pone.0094456			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE7FA	24714187	Green Published, Green Submitted, gold			2023-01-03	WOS:000334160900134
J	McAllister, DA; Ahmed, FS; Austin, JHM; Henschke, CI; Keller, BM; Lemeshow, A; Reeves, AP; Mesia-Vela, S; Pearson, GDN; Shiau, MC; Schwartz, JE; Yankelevitz, DF; Barr, RG				McAllister, David A.; Ahmed, Firas S.; Austin, John H. M.; Henschke, Claudia I.; Keller, Brad M.; Lemeshow, Adina; Reeves, Anthony P.; Mesia-Vela, Sonia; Pearson, G. D. N.; Shiau, Maria C.; Schwartz, Joseph E.; Yankelevitz, David F.; Barr, R. Graham			Emphysema Predicts Hospitalisation and Incident Airflow Obstruction among Older Smokers: A Prospective Cohort Study	PLOS ONE			English	Article							COMPUTED-TOMOGRAPHY; LUNG-CANCER; PULMONARY-EMPHYSEMA; COPD; CT; PREVALENCE; TRIAL; DIAGNOSIS; MORTALITY; DISEASE	Background: Emphysema on CT is common in older smokers. We hypothesised that emphysema on CT predicts acute episodes of care for chronic lower respiratory disease among older smokers. Materials and Methods: Participants in a lung cancer screening study age >= 60 years were recruited into a prospective cohort study in 2001-02. Two radiologists independently visually assessed the severity of emphysema as absent, mild, moderate or severe. Percent emphysema was defined as the proportion of voxels <= -910 Hounsfield Units. Participants completed a median of 5 visits over a median of 6 years of follow-up. The primary outcome was hospitalization, emergency room or urgent office visit for chronic lower respiratory disease. Spirometry was performed following ATS/ERS guidelines. Airflow obstruction was defined as FEV1/FVC ratio <0.70 and FEV <80% predicted. Results: Of 521 participants, 4% had moderate or severe emphysema, which was associated with acute episodes of care (rate ratio 1.89; 95% CI: 1.01- 3.52) adjusting for age, sex and race/ ethnicity, as was percent emphysema, with similar associations for hospitalisation. Emphysema on visual assessment also predicted incident airflow obstruction ( HR 5.14; 95% CI 2.19- 21.1). Conclusion: Visually assessed emphysema and percent emphysema on CT predicted acute episodes of care for chronic lower respiratory disease, with the former predicting incident airflow obstruction among older smokers.	[McAllister, David A.] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland; [McAllister, David A.; Ahmed, Firas S.; Lemeshow, Adina; Mesia-Vela, Sonia; Schwartz, Joseph E.; Barr, R. Graham] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10027 USA; [Austin, John H. M.; Pearson, G. D. N.] Columbia Univ Coll Phys & Surg, Dept Radiol, New York, NY 10032 USA; [Henschke, Claudia I.; Yankelevitz, David F.] Mt Sinai Med Ctr, Dept Radiol, New York, NY 10029 USA; [Keller, Brad M.] Univ Penn, Dept Biomed Engn, Philadelphia, PA 19104 USA; [Reeves, Anthony P.] Cornell Univ, Coll Engn, Sch Elect & Comp Engn, Ithaca, NY USA; [Shiau, Maria C.] NYU, Langone Med Ctr, Dept Radiol, New York, NY USA; [Barr, R. Graham] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA	University of Edinburgh; Columbia University; Columbia University; Icahn School of Medicine at Mount Sinai; University of Pennsylvania; Cornell University; New York University; NYU Langone Medical Center; Columbia University	Barr, RG (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10027 USA.	rgb9@columbia.edu	Shiau, Maria/GQH-8481-2022	Schwartz, Joseph/0000-0002-8944-3566; McAllister, David/0000-0003-3550-1764	National Institutes of Health [R01-HL075476, R01-HL077612, R01-HL093081, RR024156, ES09089]; City of New York Department of Health and Mental Hygiene; Starr Foundation; Empire Blue Cross and Blue Shield; New York Community Trust; New York State Office of Science, Technology, and Academic Research; Rogers Family Fund; Weill Medical College of Cornell University; Cornell University; AMDeC Foundation; Chest Heart and Stroke Scotland [ResFell07/A109] Funding Source: researchfish; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024156] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077612, R01HL075476, R01HL093081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH013043] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); City of New York Department of Health and Mental Hygiene; Starr Foundation; Empire Blue Cross and Blue Shield; New York Community Trust; New York State Office of Science, Technology, and Academic Research; Rogers Family Fund; Weill Medical College of Cornell University(General Electric); Cornell University; AMDeC Foundation; Chest Heart and Stroke Scotland; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	Collection of spirometric and percent emphysema measures, longitudinal components from the third visit onwards, and analysis and interpretation of the data were supported via grants R01-HL075476, R01-HL077612, R01-HL093081, RR024156, and ES09089 from the National Institutes of Health. The baseline and second visits were funded by the City of New York Department of Health and Mental Hygiene; the Starr Foundation; Empire Blue Cross and Blue Shield; the New York Community Trust; New York State Office of Science, Technology, and Academic Research; the Rogers Family Fund; Weill Medical College of Cornell University; Cornell University; and AMDeC Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aaron SD, 2008, STAT CONS COPD EX TR; Aberle DR, 2011, NEW ENGL J MED, V365, P395, DOI 10.1056/NEJMoa1102873; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 2010, NATL VITAL STAT REPO; Barr RG, 2008, RESP CARE, V53, P433; BERGIN C, 1986, AM REV RESPIR DIS, V133, P541; Burge S, 2003, EUR RESPIR J, V21, p46S, DOI 10.1183/09031936.03.00078002; Camiciottoli G, 2009, EUR RADIOL, V19, P58, DOI 10.1007/s00330-008-1131-6; Cazzola M, 2008, EUR RESPIR J, V31, P416, DOI 10.1183/09031936.00099306; Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304; COXSON HO, 1995, J APPL PHYSIOL, V79, P1525, DOI 10.1152/jappl.1995.79.5.1525; de Torres JP, 2007, CHEST, V132, P1932, DOI 10.1378/chest.07-1490; Gatsonis CA, 2011, RADIOLOGY, V258, P243, DOI 10.1148/radiol.10091808; Gelb AF, 1996, CHEST, V109, P353, DOI 10.1378/chest.109.2.353; Gevenois PA, 1996, RADIOLOGY, V199, P825, DOI 10.1148/radiology.199.3.8638012; Gietema HA, 2011, ACAD RADIOL, V18, P661, DOI 10.1016/j.acra.2011.01.011; Hall WB, 2009, ARCH INTERN MED, V169, P1961, DOI 10.1001/archinternmed.2009.360; Han MLK, 2011, RADIOLOGY, V261, P274, DOI 10.1148/radiol.11110173; Haruna A, 2010, CHEST, V138, P635, DOI 10.1378/chest.09-2836; Henschke CI, 2006, RADIOLOGY, V239, P586, DOI 10.1148/radiol.2392050261; Hoesein FAAM, 2011, THORAX, V66, P782, DOI 10.1136/thx.2010.145995; HRUBAN RH, 1987, AM REV RESPIR DIS, V136, P935, DOI 10.1164/ajrccm/136.4.935; Hurst JR, 2010, NEW ENGL J MED, V363, P1128, DOI 10.1056/NEJMoa0909883; Jithoo A, 2013, EUR RESPIR J, V41, P548, DOI 10.1183/09031936.00132011; Johannessen A, 2013, AM J RESP CRIT CARE, V187, P602, DOI 10.1164/rccm.201209-1722OC; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; MULLER NL, 1988, CHEST, V94, P782, DOI 10.1378/chest.94.4.782; Omori H, 2006, RESPIROLOGY, V11, P205, DOI 10.1111/j.1440-1843.2006.00827.x; Onuma Y, 2006, J AM COLL CARDIOL, V48, P402, DOI 10.1016/j.jacc.2006.04.071; Tashkin DP, 2008, NEW ENGL J MED, V359, P1543, DOI 10.1056/NEJMoa0805800; Vestbo J, 2011, NEW ENGL J MED, V365, P1184, DOI 10.1056/NEJMoa1105482; Wise Robert A, 2008, Proc Am Thorac Soc, V5, P385, DOI 10.1513/pats.200709-153ET; World Health Organisation, 2008, WHO BURD CHRON OBSTR; Zulueta JJ, 2011, CHEST	34	22	22	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 3	2014	9	4							e93221	10.1371/journal.pone.0093221	http://dx.doi.org/10.1371/journal.pone.0093221			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE6LR	24699215	Green Published, Green Accepted, gold			2023-01-03	WOS:000334105000047
J	Lim, SH; Wu, LX; Kiew, LV; Chung, LY; Burgess, K; Lee, HB				Lim, Siang Hui; Wu, Liangxing; Kiew, Lik Voon; Chung, Lip Yong; Burgess, Kevin; Lee, Hong Boon			Rosamines Targeting the Cancer Oxidative Phosphorylation Pathway	PLOS ONE			English	Article							DELOCALIZED LIPOPHILIC CATIONS; RAT-LIVER MITOCHONDRIA; CARDIAC TOXICITY; CARCINOMA-CELLS; INHIBITORS; DOXORUBICIN; RESISTANCE; ACIDOSIS; SCREEN; GROWTH	Reprogramming of energy metabolism is pivotal to cancer, so mitochondria are potential targets for anticancer therapy. A prior study has demonstrated the anti-proliferative activity of a new class of mitochondria-targeting rosamines. This present study describes in vitro cytotoxicity of second-generation rosamine analogs, their mode of action, and their in vivo efficacies in a tumor allografted mouse model. Here, we showed that these compounds exhibited potent cytotoxicity (average IC50<0.5 mu M), inhibited Complex II and ATP synthase activities of the mitochondrial oxidative phosphorylation pathway and induced loss of mitochondrial transmembrane potential. A NCI-60 cell lines screen further indicated that rosamine analogs 4 and 5 exhibited potent antiproliferative effects with Log(10)GI(50) = -7 (GI(50) = 0.1 mu M) and were more effective against a colorectal cancer sub-panel than other cell lines. Preliminary in vivo studies on 4T1 murine breast cancer-bearing female BALB/c mice indicated that treatment with analog 5 in a single dosing of 5 mg/kg or a schedule dosing of 3 mg/kg once every 2 days for 6 times (q2dx6) exhibited only minimal induction of tumor growth delay. Our results suggest that rosamine analogs may be further developed as mitochondrial targeting agents. Without a doubt proper strategies need to be devised to enhance tumor uptake of rosamines, i.e. by integration to carrier molecules for better therapeutic outcome.	[Lim, Siang Hui; Lee, Hong Boon] Canc Res Initiat Fdn CARIF, Drug Discovery Lab, Subang Jaya, Selangor, Malaysia; [Lim, Siang Hui; Chung, Lip Yong] Univ Malaya, Dept Pharm, Kuala Lumpur, Malaysia; [Wu, Liangxing; Burgess, Kevin] Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; [Kiew, Lik Voon] Univ Malaya, Fac Med, Dept Pharmacol, Kuala Lumpur 50603, Malaysia	Universiti Malaya; Texas A&M University System; Texas A&M University College Station; Universiti Malaya	Lee, HB (corresponding author), Canc Res Initiat Fdn CARIF, Drug Discovery Lab, Subang Jaya, Selangor, Malaysia.	hongboon.lee@carif.com.my	KIEW, LIK VOON/B-8789-2010; CHUNG, LIP YONG/B-7764-2010; Lim, Siang Hui/H-2804-2014; Burgess, Kevin/B-5372-2015	KIEW, LIK VOON/0000-0002-6855-9631; CHUNG, LIP YONG/0000-0002-3596-768X; Burgess, Kevin/0000-0001-6597-1842; , LEE/0000-0002-0768-2222	Cancer Research Initiatives Foundation; Malaysia Ministry of Higher Education's HIR-MOHE [UM.C/625/1/HIR/MOHE/MED/17, UM.C/625/1/HIR/MOHE/MED/33]; Universiti Malaya [PS204/2010B]; National Institutes of Health [GM087981]; Robert A. Welch Foundation [A-1121]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM087981] Funding Source: NIH RePORTER	Cancer Research Initiatives Foundation; Malaysia Ministry of Higher Education's HIR-MOHE; Universiti Malaya(Universiti Malaya); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Robert A. Welch Foundation(The Welch Foundation); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grants from Cancer Research Initiatives Foundation, Malaysia Ministry of Higher Education's HIR-MOHE grants (UM.C/625/1/HIR/MOHE/MED/17 and UM.C/625/1/HIR/MOHE/MED/33), Universiti Malaya Post Graduate Research Grant (PS204/2010B), and by grants to KB from The National Institutes of Health (GM087981) and The Robert A. Welch Foundation (A-1121). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aiken MJ, 2009, CLIN NUCL MED, V34, P762, DOI 10.1097/RLU.0b013e3181b7d76f; Alcala AM, 2012, CLIN CANCER RES, V18, P33, DOI 10.1158/1078-0432.CCR-11-0997; Ayoola A, 2012, CANCER INVEST, V30, P433, DOI 10.3109/07357907.2012.666691; Biasutto L, 2010, MITOCHONDRION, V10, P670, DOI 10.1016/j.mito.2010.06.004; BOYD MR, 1995, DRUG DEVELOP RES, V34, P91, DOI 10.1002/ddr.430340203; Don AS, 2004, TRENDS MOL MED, V10, P372, DOI 10.1016/j.molmed.2004.06.005; Frezza C, 2007, NAT PROTOC, V2, P287, DOI 10.1038/nprot.2006.478; Gerebtzoff G, 2004, CHEMBIOCHEM, V5, P676, DOI 10.1002/cbic.200400017; Hollingshead MG, 2008, JNCI-J NATL CANCER I, V100, DOI 10.1093/jnci/djn351; HUANG DP, 1980, INT J CANCER, V26, P127, DOI 10.1002/ijc.2910260202; Jin W, 2010, CARCINOGENESIS, V31, P1939, DOI 10.1093/carcin/bgq180; Kesterson JP, 2010, CHEMOTHERAPY, V56, P108, DOI 10.1159/000312644; Kowaltowski AJ, 1999, J BIOENERG BIOMEMBR, V31, P581, DOI 10.1023/A:1005421112345; Kraut JA, 2012, NAT REV NEPHROL, V8, P589, DOI 10.1038/nrneph.2012.186; Kurtoglu M, 2009, MOL NUTR FOOD RES, V53, P68, DOI 10.1002/mnfr.200700457; LAMPIDIS TJ, 1985, BIOMED PHARMACOTHER, V39, P220; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Lim SH, 2009, ANTI-CANCER DRUG, V20, P461, DOI 10.1097/CAD.0b013e32832b7bee; McBride HM, 2006, CURR BIOL, V16, pR551, DOI 10.1016/j.cub.2006.06.054; Modica-Napolitano JS, 2001, ADV DRUG DELIVER REV, V49, P63, DOI 10.1016/S0169-409X(01)00125-9; MODICANAPOLITANO JS, 1984, BIOCHEM BIOPH RES CO, V118, P717, DOI 10.1016/0006-291X(84)91453-0; MORENO SNJ, 1988, J BIOL CHEM, V263, P12493; Nadanaciva S, 2007, TOXICOL IN VITRO, V21, P902, DOI 10.1016/j.tiv.2007.01.011; Nahta R, 2007, ONCOGENE, V26, P3637, DOI 10.1038/sj.onc.1210379; Plowman J, 1997, ANTICANCER DRUG DEV, P101; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Renda F, 2013, EUR REV MED PHARMACO, V17, P45; Shoemaker RH, 2006, NAT REV CANCER, V6, P813, DOI 10.1038/nrc1951; Toogood PL, 2008, CURR OPIN CHEM BIOL, V12, P457, DOI 10.1016/j.cbpa.2008.06.002; Wang F, 2010, MOL ASPECTS MED, V31, P75, DOI 10.1016/j.mam.2009.12.003; Workman P, 2010, BRIT J CANCER, V102, P1555, DOI 10.1038/sj.bjc.6605642; Wu LX, 2008, J ORG CHEM, V73, P8711, DOI 10.1021/jo800902j	32	13	19	2	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2014	9	3							e82934	10.1371/journal.pone.0082934	http://dx.doi.org/10.1371/journal.pone.0082934			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC9HN	24622277	Green Published, Green Submitted, gold			2023-01-03	WOS:000332845300002
J	Rasgon, NL; Geist, CL; Kenna, HA; Wroolie, TE; Williams, KE; Silverman, DHS				Rasgon, Natalie L.; Geist, Cheri L.; Kenna, Heather A.; Wroolie, Tonita E.; Williams, Katherine E.; Silverman, Daniel H. S.			Prospective Randomized Trial to Assess Effects of Continuing Hormone Therapy on Cerebral Function in Postmenopausal Women at Risk for Dementia	PLOS ONE			English	Article							MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION-TOMOGRAPHY; ALZHEIMERS-DISEASE RELATION; HEALTH INITIATIVE MEMORY; BRAIN METABOLIC-CHANGE; OLDER-ADULTS; REPLACEMENT THERAPY; GLUCOSE-METABOLISM; ESTROGEN THERAPY; ELDERLY-PEOPLE	The objective of this study was to examine the effects of estrogen-based hormone therapy (HT) on regional cerebral metabolism in postmenopausal women (mean age = 58, SD = 5) at risk for development of dementia. The prospective clinical trial design included pre- and post-intervention neuroimaging of women randomized to continue (HT+) or discontinue (HT-) therapy following an average of 10 years of use. The primary outcome measure was change in brain metabolism during the subsequent two years, as assessed with fluorodeoxyglucose-18 positron emission tomography (FDG-PET). Longitudinal FDG-PET data were available for 45 study completers. Results showed that women randomized to continue HT experienced relative preservation of frontal and parietal cortical metabolism, compared with women randomized to discontinue HT. Women who discontinued 17-beta estradiol (17 beta E)-based HT, as well as women who continued conjugated equine estrogen (CEE)-based HT, exhibited significant decline in metabolism of the precuneus/posterior cingulate cortical (PCC) area. Significant decline in PCC metabolism was additionally seen in women taking concurrent progestins (with either 17 beta E or CEE). Together, these findings suggest that among postmenopausal subjects at risk for developing dementia, regional cerebral cortical metabolism is relatively preserved for at least two years in women randomized to continue HT, compared with women randomized to discontinue HT. In addition, continuing unopposed 17 beta E therapy is associated specifically with preservation of metabolism in PCC, known to undergo the most significant decline in the earliest stages of Alzheimer's disease.	[Rasgon, Natalie L.; Kenna, Heather A.; Wroolie, Tonita E.; Williams, Katherine E.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford Ctr Neurosci Womens Hlth, Stanford, CA 94305 USA; [Geist, Cheri L.; Silverman, Daniel H. S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Ahmanson Translat Imaging Div,Sch Med, Los Angeles, CA 90095 USA	Stanford University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Rasgon, NL (corresponding author), Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford Ctr Neurosci Womens Hlth, Stanford, CA 94305 USA.	nrasgon@stanford.edu	Rasgon, Natalie/ABH-9813-2020		National Institute on Aging [R01 AG22008]; National Center for Research Resources, National Institutes of Health [M01 RR00070]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG022008] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Center for Research Resources, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was funded by a grant from the National Institute on Aging (R01 AG22008 to N. Rasgon) and supported in part by grant M01 RR00070 from the National Center for Research Resources, National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barnes DE, 2012, ARCH GEN PSYCHIAT, V69, P493, DOI 10.1001/archgenpsychiatry.2011.1481; Bassett SS, 2006, BRAIN, V129, P1229, DOI 10.1093/brain/awl089; Boccardi M, 2006, MENOPAUSE, V13, P584, DOI 10.1097/01.gme.0000196811.88505.10; Bondi MW, 2005, NEUROLOGY, V64, P501, DOI 10.1212/01.WNL.0000150885.00929.7E; Bookheimer SY, 2000, NEW ENGL J MED, V343, P450, DOI 10.1056/NEJM200008173430701; Brann DW, 2007, STEROIDS, V72, P381, DOI 10.1016/j.steroids.2007.02.003; Coker LH, 2010, J STEROID BIOCHEM, V118, P304, DOI 10.1016/j.jsbmb.2009.11.007; Drzezga A, 2003, EUR J NUCL MED MOL I, V30, P1104, DOI 10.1007/s00259-003-1194-1; DUARA R, 1986, NEUROLOGY, V36, P879, DOI 10.1212/WNL.36.7.879; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Frick KM, 2012, BEHAV NEUROSCI, V126, P29, DOI 10.1037/a0026660; Friston KJ, 2005, NEUROIMAGE, V24, P244, DOI 10.1016/j.neuroimage.2004.08.055; Genon S, 2012, NEUROBIOL AGING; Gleason CE, 2005, ANN NY ACAD SCI, V1052, P93, DOI 10.1196/annals.1347.007; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Han SD, 2007, NEUROBIOL AGING, V28, P238, DOI 10.1016/j.neurobiolaging.2005.12.013; Harman SM, 2005, ANN NY ACAD SCI, V1052, P43, DOI 10.1196/annals.1347.004; Henderson VW, 2011, WOMENS HEALTH, V7, P81, DOI 10.2217/WHE.10.87; Henderson VW, 2006, NEUROSCIENCE, V138, P1031, DOI 10.1016/j.neuroscience.2005.06.017; HOM J, 1994, J CLIN EXP NEUROPSYC, V16, P568, DOI 10.1080/01688639408402668; Houston WS, 2005, J INT NEUROPSYCH SOC, V11, P863, DOI 10.1017/S1355617705051015; Hu Ling, 2006, Chinese Medical Sciences Journal, V21, P214; Jacobson MW, 2005, NEUROPSYCHOLOGY, V19, P822, DOI 10.1037/0894-4105.19.6.822; Jacobson MW, 2005, J CLIN EXP NEUROPSYC, V27, P240, DOI 10.1080/13803390490515441; Jarvik LF, 2005, J GERIATR PSYCH NEUR, V18, P187, DOI 10.1177/0891988705281862; Johnson SC, 2006, J NEUROSCI, V26, P6069, DOI 10.1523/JNEUROSCI.0959-06.2006; Kantarci K, 2000, NEUROLOGY, V55, P210, DOI 10.1212/WNL.55.2.210; Kordower JH, 2001, ANN NEUROL, V49, P202, DOI 10.1002/1531-8249(20010201)49:2<202::AID-ANA40>3.3.CO;2-V; LARUE A, 1995, J CLIN EXP NEUROPSYC, V17, P65, DOI 10.1080/13803399508406582; LARUE A, 1992, J CLIN EXP NEUROPSYC, V14, P533, DOI 10.1080/01688639208402842; Lehtovirta M, 1996, J NEUROL NEUROSUR PS, V60, P644, DOI 10.1136/jnnp.60.6.644; Lehtovirta M, 1996, NEUROLOGY, V46, P413, DOI 10.1212/WNL.46.2.413; Lord C, 2008, NEUROBIOL AGING, V29, P95, DOI 10.1016/j.neurobiolaging.2006.09.001; Maeshima H, 2012, J AFFECT DISORDERS, V143, P84, DOI 10.1016/j.jad.2012.05.033; Maki PM, 2000, NEUROBIOL AGING, V21, P373, DOI 10.1016/S0197-4580(00)00123-8; MAZZIOTTA JC, 1992, SEMIN NUCL MED, V22, P233, DOI 10.1016/S0001-2998(05)80118-7; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Meguro K, 1999, BRAIN, V122, P1519, DOI 10.1093/brain/122.8.1519; Mielke R, 1996, ACTA NEUROPATHOL, V91, P174, DOI 10.1007/s004010050410; Minoshima S, 1997, ANN NEUROL, V42, P85, DOI 10.1002/ana.410420114; NEWMAN SK, 1994, J NEUROL NEUROSUR PS, V57, P967, DOI 10.1136/jnnp.57.8.967; Olazaran J., 2013, INT J ALZHEIMERS DIS, V2013; Pardo JV, 2007, NEUROIMAGE, V35, P1231, DOI 10.1016/j.neuroimage.2006.12.044; Phelps ME., 1986, POSITRON EMISSION TO; Polkowski K, 2000, Acta Pol Pharm, V57, P135; Rasgon N, 2008, REGIONAL CEREBRAL ME; Rasgon NL, 2005, NEUROBIOL AGING, V26, P229, DOI 10.1016/j.neurobiolaging.2004.03.003; Rasgon NL, 2001, PSYCHIAT RES-NEUROIM, V107, P11, DOI 10.1016/S0925-4927(01)00084-1; Raz N, 2004, NEUROREPORT, V15, P2531, DOI 10.1097/00001756-200411150-00020; Robertson D, 2009, CLIMACTERIC, V12, P301, DOI 10.1080/13697130902730742; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Silverman D., 2009, PET EVALUATION ALZHE; Silverman DHS, 2008, SEMIN NUCL MED, V38, P251, DOI 10.1053/j.semnuclmed.2008.02.006; Silverman DHS, 2007, BREAST CANCER RES TR, V103, P303, DOI 10.1007/s10549-006-9380-z; Silverman Daniel H.S., 1999, Clin Positron Imaging, V2, P119, DOI 10.1016/S1095-0397(99)00020-5; Silverman DHS, 2011, PSYCHONEUROENDOCRINO, V36, P502, DOI 10.1016/j.psyneuen.2010.08.002; SMALL GW, 1993, ARCH NEUROL-CHICAGO, V50, P209, DOI 10.1001/archneur.1993.00540020085022; Small GW, 2000, P NATL ACAD SCI USA, V97, P6037, DOI 10.1073/pnas.090106797; SMALL GW, 1995, AM J PSYCHIAT, V152, P1757; SMALL GW, 1995, JAMA-J AM MED ASSOC, V273, P942, DOI 10.1001/jama.273.12.942; Smith CD, 1999, NEUROLOGY, V53, P1391, DOI 10.1212/WNL.53.7.1391; Smith CD, 2002, NEUROLOGY, V58, P1197, DOI 10.1212/WNL.58.8.1197; Smith YR, 2006, J CLIN ENDOCR METAB, V91, P4476, DOI 10.1210/jc.2006-0907; Suzuki S, 2006, ENDOCRINE, V29, P209, DOI 10.1385/ENDO:29:2:209; Vincent A, 2000, MAYO CLIN PROC, V75, P1174, DOI 10.4065/75.11.1174; Wishart HA, 2006, AM J PSYCHIAT, V163, P1603, DOI 10.1176/appi.ajp.163.9.1603; Wolf H, 2003, ACTA NEUROL SCAND, V107, P52, DOI 10.1034/j.1600-0404.107.s179.10.x; Wroolie TE, 2011, AM J GERIAT PSYCHIAT, V19, P792, DOI 10.1097/JGP.0b013e3181ff678a	69	45	45	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2014	9	3							e89095	10.1371/journal.pone.0089095	http://dx.doi.org/10.1371/journal.pone.0089095			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC9HN	24622517	Green Submitted, Green Published, gold			2023-01-03	WOS:000332845300006
J	Kong, FF; Ying, HM; Du, CR; Huang, S; Zhou, JJ; Hu, CS				Kong, Fang-fang; Ying, Hongmei; Du, Cheng-run; Huang, Shuang; Zhou, Jun-jun; Hu, Chao-su			Effectiveness and Toxicities of Intensity-Modulated Radiation Therapy for Patients with T4 Nasopharyngeal Carcinoma	PLOS ONE			English	Article							CLINICAL-OUTCOMES; PHASE-II; RADIOTHERAPY; CISPLATIN; EXPERIENCE; DOCETAXEL; PATTERNS; FAILURE; PLANS	Objective: To evaluate the effectiveness and toxicities in T4 nasopharyngeal carcinoma (NPC) using intensity-modulated radiotherapy (IMRT) combined with chemotherapy. Methods: This is a retrospective analysis of 81 patients treated with intensity-modulated radiotherapy (IMRT). All the primary tumors were attributed to T4 stage according to the AJCC2010 staging system. And the distribution of disease by N stage was N0 in 13.6%, N1 in 30.9%, N2 in 37%, and N3 in 18.5%. Cisplatin-based chemotherapy was offered to all patients. Radiotherapy-related toxicities were graded according to the Acute and the Late Radiation Morbidity Scoring Criteria of the Radiation Therapy Oncology Group (RTOG) scoring criteria. Chemotherapy-related toxicities were graded by National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0. Prognostic factors were assessed by univariate analysis. Results: With a median follow-up of 37 months, 12 patients experienced local regional failure and total distant metastasis occurred in 18 patients, representing the major mode of failure. Ten patients died. Among them, 70% died of distant metastasis. The 3-year actuarial rates of local failure-free survival (LFFS), regional failure-free survival (RFFS), distant failure-free survival (DFFS), overall survival (OS), and progression-free survival (PFS) were 83.8%, 97.4%, 81.3%, 90%, and 69.7%, respectively. Acute and late toxicities were mild or moderate. Conclusions: IMRT provides excellent local-regional control for T4 NPC. Distant metastasis remains the major cause of treatment failure. Further explorations of the sequence and regimen of systemic therapy are needed in the future.	[Kong, Fang-fang; Ying, Hongmei; Du, Cheng-run; Huang, Shuang; Zhou, Jun-jun; Hu, Chao-su] Fudan Univ, Dept Radiat Oncol, Shanghai Canc Ctr, Shanghai 200433, Peoples R China; [Kong, Fang-fang; Ying, Hongmei; Du, Cheng-run; Huang, Shuang; Zhou, Jun-jun; Hu, Chao-su] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200433, Peoples R China	Fudan University; Fudan University	Ying, HM (corresponding author), Fudan Univ, Dept Radiat Oncol, Shanghai Canc Ctr, Shanghai 200433, Peoples R China.	yinghongmei2013@163.com		Hu, Chaosu/0000-0002-6503-0951; Hu, Chaosu/0000-0001-7697-5224				Anne W, 1998, INT J RADIAT ONCOL, V40, P35; Cao CN, 2013, ORAL ONCOL, V49, P175, DOI 10.1016/j.oraloncology.2012.08.013; Cheng JCH, 2001, INT J CANCER, V96, P126, DOI 10.1002/ijc.1004; Du CR, 2013, INT J CLIN ONCOL, V18, P464, DOI 10.1007/s10147-012-0403-y; Hui EP, 2009, J CLIN ONCOL, V27, P242, DOI 10.1200/JCO.2008.18.1545; Hunt MA, 2001, INT J RADIAT ONCOL, V49, P623, DOI 10.1016/S0360-3016(00)01389-4; Kam MKM, 2003, INT J RADIAT ONCOL, V56, P145, DOI 10.1016/S0360-3016(03)00075-0; Kwong DLW, 2004, CANCER, V101, P1584, DOI 10.1002/cncr.20552; Lee AWM, 2004, CLIN ONCOL-UK, V16, P269, DOI 10.1016/j.clon.2004.01.008; Lee AWM, 2002, INT J RADIAT ONCOL, V53, P75, DOI 10.1016/S0360-3016(02)02711-6; Lu HM, 2008, CANCER TREAT REV, V34, P27, DOI 10.1016/j.ctrv.2007.08.004; Ma BBY, 2012, ANN ONCOL, V23, P1287, DOI 10.1093/annonc/mdr401; Ng WT, 2011, INT J RADIAT ONCOL, V79, P420, DOI 10.1016/j.ijrobp.2009.11.024; Sanguineti G, 1997, INT J RADIAT ONCOL, V37, P985, DOI 10.1016/S0360-3016(97)00104-1; Su SF, 2012, INT J RADIAT ONCOL, V82, P327, DOI 10.1016/j.ijrobp.2010.09.011; Teo P, 1996, INT J RADIAT ONCOL, V36, P291, DOI 10.1016/S0360-3016(96)00323-9; Xia P, 2000, INT J RADIAT ONCOL, V48, P329, DOI 10.1016/S0360-3016(00)00585-X; Xiao WW, 2011, CANCER-AM CANCER SOC, V117, P1874, DOI 10.1002/cncr.25754; Xu TT, 2012, MED ONCOL, V29, P272, DOI 10.1007/s12032-010-9803-x; Yi JL, 2006, INT J RADIAT ONCOL, V65, P161, DOI 10.1016/j.ijrobp.2005.12.003	20	14	18	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2014	9	3							e91362	10.1371/journal.pone.0091362	http://dx.doi.org/10.1371/journal.pone.0091362			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC4IY	24608637	Green Published, Green Submitted, gold			2023-01-03	WOS:000332485800130
J	Humair, JP; Garin, N; Gerstel, E; Carballo, S; Carballo, D; Keller, PF; Guessous, I				Humair, Jean-Paul; Garin, Nicolas; Gerstel, Eric; Carballo, Sebastian; Carballo, David; Keller, Pierre-Frederic; Guessous, Idris			Acute Respiratory and Cardiovascular Admissions after a Public Smoking Ban in Geneva, Switzerland	PLOS ONE			English	Article							SECONDHAND SMOKE; FREE LEGISLATION; PASSIVE SMOKING; RISK-FACTORS; STROKE; ASSOCIATION; HOSPITALIZATIONS; IMPLEMENTATION; METAANALYSIS; DISEASE	Background: Many countries have introduced legislations for public smoking bans to reduce the harmful effects of exposure to tobacco smoke. Smoking bans cause significant reductions in admissions for acute coronary syndromes but their impact on respiratory diseases is unclear. In Geneva, Switzerland, two popular votes led to a stepwise implementation of a state smoking ban in public places, with a temporary suspension. This study evaluated the effect of this smoking ban on hospitalisations for acute respiratory and cardiovascular diseases. Methods: This before and after intervention study was conducted at the University Hospitals of Geneva, Switzerland, across 4 periods with different smoking legislations. It included 5,345 patients with a first hospitalisation for acute coronary syndrome, ischemic stroke, acute exacerbation of chronic obstructive pulmonary disease, pneumonia and acute asthma. The main outcomes were the incidence rate ratios (IRR) of admissions for each diagnosis after the final ban compared to the pre-ban period and adjusted for age, gender, season, influenza epidemic and secular trend. Results: Hospitalisations for acute exacerbation of chronic obstructive pulmonary disease significantly decreased over the 4 periods and were lowest after the final ban (IRR = 0.54 [95%CI: 0.42-0.68]). We observed a trend in reduced admissions for acute coronary syndromes (IRR = 0.90 [95%CI: 0.80-1.00]). Admissions for ischemic stroke, asthma and pneumonia did not significantly change. Conclusions: A legislative smoking ban was followed by a strong decrease in hospitalisations for acute exacerbation of chronic obstructive pulmonary disease and a trend for reduced admissions for acute coronary syndrome. Smoking bans are likely to be very beneficial for patients with chronic obstructive pulmonary disease.	[Humair, Jean-Paul] Univ Hosp Geneva, Div Primary Care Med, Geneva, Switzerland; [Garin, Nicolas; Gerstel, Eric; Carballo, Sebastian] Univ Hosp Geneva, Div Gen Internal Med, Geneva, Switzerland; [Garin, Nicolas] Chablais Reg Hosp, Div Internal Med, Monthey, Switzerland; [Gerstel, Eric] Clin La Colline, Div Ambulatory Care & Emergency Med, Geneva, Switzerland; [Carballo, David; Keller, Pierre-Frederic] Univ Hosp Geneva, Div Cardiol, Geneva, Switzerland; [Guessous, Idris] Univ Hosp Geneva, Div Primary Care Med, Unit Populat Epidemiol, Geneva, Switzerland; [Guessous, Idris] Univ Lausanne Hosp, Community Prevent Unit, Lausanne, Switzerland	University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Humair, JP (corresponding author), Univ Hosp Geneva, Div Primary Care Med, Geneva, Switzerland.	Jean-Paul.Humair@hcuge.ch		Gerstel, Eric/0000-0003-0754-1873	Department of Regional Affairs, Economics & Health of the Canton of Geneva	Department of Regional Affairs, Economics & Health of the Canton of Geneva	This study was funded by the Department of Regional Affairs, Economics & Health of the Canton of Geneva. The funder had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	[Anonymous], 2011, LAW SMOK BAN PUBL PL; Barnoya J, 2005, CIRCULATION, V111, P2684, DOI 10.1161/CIRCULATIONAHA.104.492215; Bonetti PO, 2011, SWISS MED WKLY, V141, DOI 10.4414/smw.2011.13206; Callinan JE, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005992.pub2; Durham AD, 2011, SWISS MED WKLY, V141, DOI 10.4414/smw.2011.13317; Easton JD, 2009, STROKE, V40, P2276, DOI 10.1161/STROKEAHA.108.192218; Eisner Mark D, 2009, Int J Chron Obstruct Pulmon Dis, V4, P169; Etat de Geneve, 2011, CANTONAL STAT RESIDE; Garcia-Aymerich J, 2003, THORAX, V58, P100, DOI 10.1136/thorax.58.2.100; Glymour MM, 2008, AM J PREV MED, V35, P245, DOI 10.1016/j.amepre.2008.05.024; Goodman P, 2007, AM J RESP CRIT CARE, V175, P840, DOI 10.1164/rccm.200608-1085OC; He J, 1999, NEW ENGL J MED, V340, P920, DOI 10.1056/NEJM199903253401204; He Y, 2008, CIRCULATION, V118, P1535, DOI 10.1161/CIRCULATIONAHA.108.784801; Herman PM, 2011, AM J PUBLIC HEALTH, V101, P491, DOI 10.2105/AJPH.2009.179572; Kent BD, 2012, CHEST, V142, P673, DOI 10.1378/chest.11-2757; Li Y, 2011, AM J EMERG MED, V29, P768, DOI 10.1016/j.ajem.2010.02.027; Loeb M, 2009, J AM GERIATR SOC, V57, P1036, DOI 10.1111/j.1532-5415.2009.02259.x; Lucker LM, 2011, SWISS MED WKLY, V141, DOI 10.4414/smw.2011.13177; Mackay D, 2010, NEW ENGL J MED, V363, P1139, DOI 10.1056/NEJMoa1002861; Menzies D, 2006, JAMA-J AM MED ASSOC, V296, P1742, DOI 10.1001/jama.296.14.1742; Naiman A, 2010, CAN MED ASSOC J, V182, P761, DOI 10.1503/cmaj.091130; [National Centre of Influenza Central Laboratory of Virology University Hospitals of Geneva], 2007, INFL SURV SWITZ SENT; [National Influenza Reference Centre Laboratory of Virology University Hospitals of Geneva], 2009, INFL SURV SWITZ SENT; [National Influenza Reference Centre Laboratory of Virology University Hospitals of Geneva], 2010, SEAS INFL A H1N1 200; [National Influenza Reference Centre Laboratory of Virology University Hospitals of Geneva], 2008, INFL SURV SWITZ SENT; Oono IP, 2011, J PUBLIC HEALTH-UK, V33, P496, DOI 10.1093/pubmed/fdr025; Rayens MK, 2008, J ALLERGY CLIN IMMUN, V122, P537, DOI 10.1016/j.jaci.2008.06.029; Sapey E, 2006, THORAX, V61, P250, DOI 10.1136/thx.2005.041822; Schanzer DL, 2013, INFLUENZA OTHER RESP, V7, P799, DOI 10.1111/irv.12011; Sims M, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2161; Swiss Federal Statistical Office, 2010, HOSP STAT YEAR 2000; Tan CE, 2012, CIRCULATION, V126, P2177, DOI 10.1161/CIRCULATIONAHA.112.121301; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; U.S. Department of Health and Human Services, 2006, HLTH CONS INV EXP TO; World Health Organization, 1992, INT STAT CLASS DIS H	35	21	24	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2014	9	3							e90417	10.1371/journal.pone.0090417	http://dx.doi.org/10.1371/journal.pone.0090417			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC4GP	24599156	Green Published, Green Submitted, gold			2023-01-03	WOS:000332479400073
J	New, K; Konstantopoulos, A; Arulkumaran, S; Day-Stirk, F				New, Karen; Konstantopoulos, Andreas; Arulkumaran, Sabaratnam; Day-Stirk, Frances			Every Newborn: the professional organisations' perspective	LANCET			English	Editorial Material									[New, Karen] Council Int Neonatal Nurses, Boston, MA 02131 USA; [Konstantopoulos, Andreas] Int Pediat Assoc, Elk Grove Village, IL USA; [Arulkumaran, Sabaratnam] Int Federat Gynecol & Obstet, London, England; [Day-Stirk, Frances] Int Confederat Midw, The Hague, Netherlands		New, K (corresponding author), Council Int Neonatal Nurses, Boston, MA 02131 USA.	karennew@coinnurses.org	New, Karen/E-7548-2011	New, Karen/0000-0002-6196-2452				Bhutta ZA, 2014, LANCET; Darmstadt GL, 2014, LANCET; Dickson KE, 2014, LANCET; Lawn JE, 2014, LANCET; Mason E, 2014, LANCET; Save the Children, 2013, SURV 1 DAY STAT WORL; Wall SN, 2009, INT J GYNECOL OBSTET, V107, pS47, DOI 10.1016/j.ijgo.2009.07.013; WHO, 2014, EV NEWB ACT PLAN END; World Health Organization (WHO), 2004, MAK PREGN SAF CRIT R	9	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 12	2014	384	9938					E25	E26		10.1016/S0140-6736(14)60692-9	http://dx.doi.org/10.1016/S0140-6736(14)60692-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AL1YC	24853602				2023-01-03	WOS:000338921500003
J	Montastier, E; Dejean, S; Le Gall, C; Saris, WHM; Langin, D; Viguerie, N				Montastier, Emilie; Dejean, Sebastien; Le Gall, Caroline; Saris, Wim H. M.; Langin, Dominique; Viguerie, Nathalie			Adipose Tissue CIDEA Is Associated, Independently of Weight Variation, to Change in Insulin Resistance during a Longitudinal Weight Control Dietary Program in Obese Individuals	PLOS ONE			English	Article							HOMEOSTASIS MODEL ASSESSMENT; IMPAIRED GLUCOSE-TOLERANCE; GENE-EXPRESSION; LIPID DROPLETS; ENERGY RESTRICTION; MAINTENANCE; SENSITIVITY; HUMANS; STABILIZATION; TRANSCRIPTOME	Aim: Weight loss reduces risk factors associated with obesity. However, long-term metabolic improvement remains a challenge. We investigated quantitative gene expression of subcutaneous adipose tissue in obese individuals and its relationship with low calorie diet and long term weight maintenance induced changes in insulin resistance. Research Design: Three hundred eleven overweight and obese individuals followed a dietary protocol consisting of an 8-week low calorie diet followed by a 6-month ad libitum weight-maintenance diet. Individuals were clustered according to insulin resistance trajectories assessed using homeostasis model assessment of insulin resistance (HOMA-IR) index. Adipose tissue mRNA levels of 267 genes selected for regulation according to obesity, metabolic status and response to dieting was assessed using high throughput RT-qPCR. A combination of discriminant analyses was used to identify genes with regulation according to insulin resistance trajectories. Partial correlation was used to control for change in body mass index. Results: Three different HOMA-IR profile groups were determined. HOMA-IR improved during low calorie diet in the 3 groups. At the end of the 6-month follow-up, groups A and B had reduced HOMA-IR by 50%. In group C, HOMA-IR had returned to baseline values. Genes were differentially expressed in the adipose tissue of individuals according to groups but a single gene, CIDEA, was common to all phases of the dietary intervention. Changes in adipose tissue CIDEA mRNA levels paralleled variations in insulin sensitivity independently of change in body mass index. Overall, CIDEA was up-regulated in adipose tissue of individuals with successful long term insulin resistance relapse and not in adipose tissue of unsuccessful individuals. Conclusion: The concomitant change in adipose tissue CIDEA mRNA levels and insulin sensitivity suggests a beneficial role of adipose tissue CIDEA in long term glucose homeostasis, independently of weight variation.	[Montastier, Emilie; Langin, Dominique; Viguerie, Nathalie] Inst Natl Sante & Rech Med INSERM, Inst Metab & Cardiovasc Dis I2MC, Obes Res Lab, UMR1048, Toulouse, France; [Montastier, Emilie; Langin, Dominique; Viguerie, Nathalie] Univ Toulouse 3, Univ Toulouse, UMR1048, F-31062 Toulouse, France; [Montastier, Emilie; Langin, Dominique] Toulouse Univ Hosp, Dept Clin Biochem, Toulouse, France; [Dejean, Sebastien; Le Gall, Caroline] Toulouse Univ, Inst Math, CNRS, UMR 5219, Toulouse, France; [Saris, Wim H. M.] Maastricht Univ, Med Ctr, Dept Human Biol, NUTRIM Sch Nutr Toxicol & Metab, Maastricht, Netherlands	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Mathematical Sciences (INSMI); Universite de Toulouse; Universite Toulouse 1 Capitole; Universite Toulouse III - Paul Sabatier; Universite de Toulouse - Jean Jaures; Institut National des Sciences Appliquees de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Maastricht University; Maastricht University Medical Centre (MUMC)	Viguerie, N (corresponding author), Inst Natl Sante & Rech Med INSERM, Inst Metab & Cardiovasc Dis I2MC, Obes Res Lab, UMR1048, Toulouse, France.	nathalie.viguerie@inserm.fr	; Viguerie, Nathalie/M-2422-2017	Montastier, Emilie/0000-0002-7303-3837; Langin, Dominique/0000-0002-2669-7825; Viguerie, Nathalie/0000-0002-1730-9915	European Communities [EMIF-MET, FP7-115372, DiOGenes, FP6-513946, HEALTH-F2-2008-2011 00]; Fondation pour la Recherche Medicale; Agence Nationale de la Recherche (LIPOB and OBELIP); Region Midi-Pyrenees	European Communities(European Commission); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Agence Nationale de la Recherche (LIPOB and OBELIP)(French National Research Agency (ANR)); Region Midi-Pyrenees(Region Provence-Alpes-Cote d'AzurRegion Occitanie)	The study was supported by funding from the European Communities (EMIF-MET, FP7-115372, DiOGenes, FP6-513946, HEALTH-F2-2008-2011 00), Fondation pour la Recherche Medicale, Agence Nationale de la Recherche (LIPOB and OBELIP) and Region Midi-Pyrenees. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdul-Ghani MA, 2006, DIABETES, V55, P1430, DOI 10.2337/db05-1200; Alligier M, 2013, J CLIN ENDOCR METAB, V98, P802, DOI 10.1210/jc.2012-3289; Antuna-Puente B, 2011, DIABETES METAB, V37, P179, DOI 10.1016/j.diabet.2011.01.002; BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936; Bonora E, 2000, DIABETES CARE, V23, P57, DOI 10.2337/diacare.23.1.57; Brasaemle DL, 2007, J LIPID RES, V48, P2547, DOI 10.1194/jlr.R700014-JLR200; Capel F, 2008, J CLIN ENDOCR METAB, V93, P4315, DOI 10.1210/jc.2008-0814; Capel F, 2009, DIABETES, V58, P1558, DOI 10.2337/db09-0033; Chalmers J, 1999, J HYPERTENS, V17, P151; Christianson JL, 2010, J LIPID RES, V51, P3455, DOI 10.1194/jlr.M009498; Dahlman I, 2005, AM J CLIN NUTR, V81, P1275; de la Fuente A, 2004, BIOINFORMATICS, V20, P3565, DOI 10.1093/bioinformatics/bth445; Girousse A, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001485; Gong JY, 2009, CURR OPIN LIPIDOL, V20, P121, DOI 10.1097/MOL.0b013e328328d0bb; Greenberg AS, 2011, J CLIN INVEST, V121, P2102, DOI 10.1172/JCI46069; Gummesson A, 2007, J CLIN ENDOCR METAB, V92, P4759, DOI 10.1210/jc.2007-1136; Johansson LE, 2012, AM J CLIN NUTR, V96, P196, DOI 10.3945/ajcn.111.020578; Keller MP, 2010, ANNU REV NUTR, V30, P341, DOI 10.1146/annurev.nutr.012809.104747; Klimcakova E, 2011, DIABETOLOGIA, V54, P876, DOI 10.1007/s00125-010-2014-3; Lappalainen T, 2013, NATURE, V501, P506, DOI 10.1038/nature12531; Larsen TM, 2010, OBES REV, V11, P76, DOI 10.1111/j.1467-789X.2009.00603.x; Larsen TM, 2010, NEW ENGL J MED, V363, P2102, DOI 10.1056/NEJMoa1007137; Laurencikiene J, 2008, CANCER RES, V68, P9247, DOI 10.1158/0008-5472.CAN-08-1343; Lin SC, 2004, TRENDS MOL MED, V10, P434, DOI 10.1016/j.molmed.2004.07.005; Marquez-Quinones A, 2010, AM J CLIN NUTR, V92, P975, DOI 10.3945/ajcn.2010.29808; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Mutch DM, 2011, AM J CLIN NUTR, V94, P1399, DOI 10.3945/ajcn.110.006858; Nordstrom EA, 2005, DIABETES, V54, P1726, DOI 10.2337/diabetes.54.6.1726; Puri V, 2008, P NATL ACAD SCI USA, V105, P7833, DOI 10.1073/pnas.0802063105; Sun K, 2011, J CLIN INVEST, V121, P2094, DOI 10.1172/JCI45887; Tuomilehto Jaakko, 2001, New England Journal of Medicine, V344, P1343, DOI 10.1056/NEJM200105033441801; Viguerie N, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002959; Wing RR, 2011, DIABETES CARE, V34, P1481, DOI 10.2337/dc10-2415; Yonezawa T, 2011, MOL BIOSYST, V7, P91, DOI 10.1039/c0mb00099j; Zhou ZH, 2003, NAT GENET, V35, P49, DOI 10.1038/ng1225	35	8	9	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 1	2014	9	7							e98707	10.1371/journal.pone.0098707	http://dx.doi.org/10.1371/journal.pone.0098707			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM1UX	24983748	gold, Green Published, Green Submitted			2023-01-03	WOS:000339635000007
J	Fujimaki, T; Saiki, S; Tashiro, E; Yamada, D; Kitagawa, M; Hattori, N; Imoto, M				Fujimaki, Takahiro; Saiki, Shinji; Tashiro, Etsu; Yamada, Daisuke; Kitagawa, Mitsuhiro; Hattori, Nobutaka; Imoto, Masaya			Identification of Licopyranocoumarin and Glycyrurol from Herbal Medicines as Neuroprotective Compounds for Parkinson's Disease	PLOS ONE			English	Article							COMPLEX-I DEFICIENCY; SUBSTANTIA-NIGRA; DOPAMINERGIC-NEURONS; MITOCHONDRIAL DYSFUNCTION; ANTIOXIDANT ACTIVITY; OXIDATIVE STRESS; PARS COMPACTA; SH-SY5Y CELLS; MOUSE MODEL; MPTP MODEL	In the course of screening for the anti-Parkinsonian drugs from a library of traditional herbal medicines, we found that the extracts of choi-joki-to and daio-kanzo-to protected cells from MPP+-induced cell death. Because choi-joki-to and daio-kanzo-to commonly contain the genus Glycyrrhiza, we isolated licopyranocoumarin (LPC) and glycyrurol (GCR) as potent neuroprotective principals from Glycyrrhiza. LPC and GCR markedly blocked MPP+-induced neuronal PC12D cell death and disappearance of mitochondrial membrane potential, which were mediated by JNK. LPC and GCR inhibited MPP+-induced JNK activation through the suppression of reactive oxygen species (ROS) generation, thereby inhibiting MPP+-induced neuronal PC12D cell death. These results indicated that LPC and GCR derived from choi-joki-to and daio-kanzo-to would be promising drug leads for PD treatment in the future.	[Fujimaki, Takahiro; Tashiro, Etsu; Kitagawa, Mitsuhiro; Imoto, Masaya] Keio Univ, Fac Sci & Technol, Dept Biosci & Informat, Yokohama, Kanagawa 223, Japan; [Saiki, Shinji; Yamada, Daisuke; Hattori, Nobutaka] Juntendo Univ, Sch Med, Dept Neurol, Bunkyo Ku, Tokyo 113, Japan	Keio University; Juntendo University	Hattori, N (corresponding author), Juntendo Univ, Sch Med, Dept Neurol, Bunkyo Ku, Tokyo 113, Japan.	nhattori@juntendo.ac.jp; imoto@bio.keio.ac.jp	Saiki, Shinji/ABC-8214-2021; Hattori, Nobutaka/ACR-0069-2022	Saiki, Shinji/0000-0002-9732-8488; Tashiro, Etsu/0000-0003-4533-623X	Health Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare of Japan; Grants-in-Aid for Scientific Research [23102006, 26350974] Funding Source: KAKEN	Health Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by Health Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare of Japan. The extract powder of 128 traditional herbal (kampo) medicines (The Kampo, TJ-1 similar to 3, TJ-5 similar to 12, TJ-14 similar to 41, TJ-43, TJ-45 similar to 48, TJ-50 similar to 93, TJ-95 similar to 128, TJ-133 similar to 138) and powder of Glycyrrhiza were kindly donated from Tsumura Corporation (Tokyo, Japan). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alam ZI, 1997, J NEUROCHEM, V69, P1196, DOI 10.1046/j.1471-4159.1997.69031196.x; Asl MN, 2008, PHYTOTHER RES, V22, P709, DOI 10.1002/ptr.2362; Bae N, 2011, J ETHNOPHARMACOL, V134, P313, DOI 10.1016/j.jep.2010.12.016; Beal MF, 2001, NAT REV NEUROSCI, V2, P325, DOI 10.1038/35072550; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; BINDOFF LA, 1989, LANCET, V2, P49, DOI 10.1016/S0140-6736(89)90291-2; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; Cao BY, 2010, J ETHNOPHARMACOL, V131, P122, DOI 10.1016/j.jep.2010.06.009; Chung V, 2006, MOVEMENT DISORD, V21, P1709, DOI 10.1002/mds.21008; COHEN G, 1984, EUR J PHARMACOL, V106, P209, DOI 10.1016/0014-2999(84)90700-3; DAVIS GC, 1979, PSYCHIAT RES, V1, P249, DOI 10.1016/0165-1781(79)90006-4; Dawson TM, 2002, NAT NEUROSCI, V5, P1058, DOI 10.1038/nn941; DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x; Doo AR, 2010, J ETHNOPHARMACOL, V131, P433, DOI 10.1016/j.jep.2010.07.008; Eberhardt O, 2003, TOXICOL LETT, V139, P135, DOI 10.1016/S0378-4274(02)00428-9; Esteves ARF, 2008, MITOCHONDRION, V8, P219, DOI 10.1016/j.mito.2008.03.004; Fernandez-Puntero B, 2001, BIOL PHARM BULL, V24, P777, DOI 10.1248/bpb.24.777; Floor E, 1998, J NEUROCHEM, V70, P268; Hanawa N, 2008, J BIOL CHEM, V283, P13565, DOI 10.1074/jbc.M708916200; Hasegawa A, 2002, JPN J PHARMACOL, V89, P164, DOI 10.1254/jjp.89.164; Hashimoto R., 2012, EVID-BASED COMPL ALT, V2012, DOI DOI 10.1155/2012/693717; HATANO T, 1989, CHEM PHARM BULL, V37, P3005, DOI 10.1248/cpb.37.3005; HEIKKILA RE, 1984, SCIENCE, V224, P1451, DOI 10.1126/science.6610213; HEIKKILA RE, 1984, NATURE, V311, P467, DOI 10.1038/311467a0; Hunot S, 2004, P NATL ACAD SCI USA, V101, P665, DOI 10.1073/pnas.0307453101; Iizuka A, 2000, J Atheroscler Thromb, V6, P49; Infanger DW, 2006, ANTIOXID REDOX SIGN, V8, P1583, DOI 10.1089/ars.2006.8.1583; Jin H, 2013, BIOCH BIOPHYSICA ACT; Kasai A, 2008, BIOL PHARM BULL, V31, P838, DOI 10.1248/bpb.31.838; KATOHSEMBA R, 1987, J NEUROSCI RES, V17, P36, DOI 10.1002/jnr.490170106; Kawatani M, 2003, EXP CELL RES, V286, P57, DOI 10.1016/S0014-4827(03)00098-3; Kim SY, 2007, NEUROSCI LETT, V413, P132, DOI 10.1016/j.neulet.2006.11.074; Klintworth H, 2007, TOXICOL SCI, V97, P149, DOI 10.1093/toxsci/kfm029; Kobayashi K, 2002, BIOL PHARM BULL, V25, P1108, DOI 10.1248/bpb.25.1108; Kong XC, 2011, BRAIN RES, V1383, P99, DOI 10.1016/j.brainres.2011.01.093; Kumazawa S, 2002, J AGR FOOD CHEM, V50, P373, DOI 10.1021/jf010938r; Li XF, 2011, BRAIN RES, V1382, P9, DOI 10.1016/j.brainres.2011.01.015; Lin X, 2009, FEBS J, V276, P2022, DOI 10.1111/j.1742-4658.2009.06938.x; Manyam B V, 1999, Adv Neurol, V80, P565; Martinez TN, 2012, ANTIOXID REDOX SIGN, V16, P920, DOI 10.1089/ars.2011.4033; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Newhouse K, 2004, TOXICOL SCI, V79, P137, DOI 10.1093/toxsci/kfh089; Ng TB, 2000, LIFE SCI, V66, P709, DOI 10.1016/S0024-3205(99)00642-6; Nishimura K, 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1093/ecam/nen082; Oi H, 2002, P NATL ACAD SCI USA, V99, P3042, DOI 10.1073/pnas.052709499; Park SW, 2011, NEUROSCI RES, V69, P283, DOI 10.1016/j.neures.2011.01.004; Park SW, 2004, NEUROSCI LETT, V363, P243, DOI 10.1016/j.neulet.2004.03.072; Parker WD, 2008, BRAIN RES, V1189, P215, DOI 10.1016/j.brainres.2007.10.061; Parker WD, 1998, AM J HUM GENET, V62, P758, DOI 10.1086/301812; Saporito MS, 1999, J PHARMACOL EXP THER, V288, P421; Sawada M, 2006, J NEURAL TRANSM-SUPP, P373; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; Seaton TA, 1997, BRAIN RES, V777, P110; Smigrodzki R, 2004, NEUROBIOL AGING, V25, P1273, DOI 10.1016/j.neurobiolaging.2004.02.020; Song JX, 2012, J ETHNOPHARMACOL, V139, P698, DOI 10.1016/j.jep.2011.12.030; Swerdlow RH, 1999, BIOCHEM BIOPH RES CO, V261, P701, DOI 10.1006/bbrc.1999.1095; Tao WW, 2012, FITOTERAPIA, V83, P422, DOI 10.1016/j.fitote.2011.12.010; Tatton WG, 2003, ANN NEUROL, V53, pS61, DOI 10.1002/ana.10489; Testa CM, 2005, MOL BRAIN RES, V134, P109, DOI 10.1016/j.molbrainres.2004.11.007; Trimmer PA, 2004, J NEUROCHEM, V88, P800, DOI 10.1046/j.1471-4159.2003.02168.x; Tsukamoto S, 2005, BIOL PHARM BULL, V28, P2000, DOI 10.1248/bpb.28.2000; Vladimirov Iu A, 1991, Biull Eksp Biol Med, V112, P472; Voss T, 2008, CURR NEUROL NEUROSCI, V8, P304, DOI 10.1007/s11910-008-0047-5; Xia XG, 2001, P NATL ACAD SCI USA, V98, P10433, DOI 10.1073/pnas.181182298; Yang LC, 2009, J NEUROCHEM, V109, P1427, DOI 10.1111/j.1471-4159.2009.06074.x; Yao S, 2006, J CHROMATOGR A, V1115, P64, DOI 10.1016/j.chroma.2006.02.071; Yurekli VA, 2013, CELL MOL NEUROBIOL, V33, P205, DOI 10.1007/s10571-012-9886-3; Zhou JJ, 2013, BRAIN RES, V1508, P53, DOI 10.1016/j.brainres.2013.02.049	68	16	17	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 24	2014	9	6							e100395	10.1371/journal.pone.0100395	http://dx.doi.org/10.1371/journal.pone.0100395			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK7UT	24960051	Green Submitted, gold, Green Published			2023-01-03	WOS:000338633900044
J	Remer, LA				Remer, Lorraine A.			ATMOSPHERIC SCIENCE Just add aerosols	SCIENCE			English	Editorial Material									Univ Maryland Baltimore Cty, Joint Ctr Earth Syst Technol, Baltimore, MD 21228 USA	University System of Maryland; University of Maryland Baltimore County	Remer, LA (corresponding author), Univ Maryland Baltimore Cty, Joint Ctr Earth Syst Technol, 5523 Res Pk Dr, Baltimore, MD 21228 USA.	remer@umbc.edu						Chin M, 2014, ATMOS CHEM PHYS, V14, P3657, DOI 10.5194/acp-14-3657-2014; Koren I, 2008, SCIENCE, V321, P946, DOI 10.1126/science.1159185; Koren I, 2014, SCIENCE, V344, P1143, DOI 10.1126/science.1252595; Rosenfeld D, 2014, SCIENCE, V343, P379, DOI 10.1126/science.1247490; Yuan T, 2011, ATMOS CHEM PHYS, V11, P7119, DOI 10.5194/acp-11-7119-2011	5	0	0	1	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 6	2014	344	6188					1089	1089		10.1126/science.1255398	http://dx.doi.org/10.1126/science.1255398			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AI3UU	24904141				2023-01-03	WOS:000336791200022
J	Feltner, C; Jones, CD; Cene, CW; Zheng, ZJ; Sueta, CA; Coker-Schwimmer, EJL; Arvanitis, M; Lohr, KN; Middleton, JC; Jonas, DE				Feltner, Cynthia; Jones, Christine D.; Cene, Crystal W.; Zheng, Zhi-Jie; Sueta, Carla A.; Coker-Schwimmer, Emmanuel J. L.; Arvanitis, Marina; Lohr, Kathleen N.; Middleton, Jennifer C.; Jonas, Daniel E.			Transitional Care Interventions to Prevent Readmissions for Persons With Heart Failure A Systematic Review and Meta-analysis	ANNALS OF INTERNAL MEDICINE			English	Review							RANDOMIZED CONTROLLED-TRIAL; HOME-BASED INTERVENTION; ACUTE MYOCARDIAL-INFARCTION; DISEASE MANAGEMENT PROGRAM; MULTIDISCIPLINARY CARE; SELF-CARE; ELDERLY-PATIENTS; HIGH-RISK; HOSPITAL DISCHARGE; CLINICAL-OUTCOMES	Background: Nearly 25% of patients hospitalized with heart failure (HF) are readmitted within 30 days. Purpose: To assess the efficacy, comparative effectiveness, and harms of transitional care interventions to reduce readmission and mortality rates for adults hospitalized with HF. Data Sources: MEDLINE, Cochrane Library, CINAHL, ClinicalTrials.gov, and World Health Organization International Clinical Trials Registry Platform (1 January 1990 to late October 2013). Study Selection: Two reviewers independently selected randomized, controlled trials published in English reporting a readmission or mortality rate within 6 months of an index hospitalization. Data Extraction: One reviewer extracted data, and another checked accuracy. Two reviewers assessed risk of bias and graded strength of evidence (SOE). Data Synthesis: Forty-seven trials were included. Most enrolled adults with moderate to severe HF and a mean age of 70 years. Few trials reported 30-day readmission rates. At 30 days, a high-intensity home-visiting program reduced all-cause readmission and the composite end point (all-cause readmission or death; low SOE). Over 3 to 6 months, home-visiting programs and multidisciplinary heart failure (MDS-HF) clinic interventions reduced all-cause readmission (high SOE). Home-visiting programs reduced HF-specific readmission and the composite end point (moderate SOE). Structured telephone support (STS) interventions reduced HF-specific readmission (high SOE) but not all-cause readmissions (moderate SOE). Home-visiting programs, MDS-HF clinics, and STS interventions produced a mortality benefit. Neither telemonitoring nor primarily educational interventions reduced readmission or mortality rates. Limitations: Few trials reported 30-day readmission rates. Usual care was heterogeneous and sometimes not adequately described. Conclusion: Home-visiting programs and MDS-HF clinics reduced all-cause readmission and mortality; STS reduced HF-specific readmission and mortality. These interventions should receive the greatest consideration by systems or providers seeking to implement transitional care interventions for persons with HF.	Univ N Carolina, Chapel Hill, NC 27599 USA; Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC USA; Univ Colorado, Aurora, CO USA; [Lohr, Kathleen N.] RTI Int, Res Triangle Pk, NC 27709 USA; [Zheng, Zhi-Jie] RTI Int, Rockville, MD 20852 USA	University of North Carolina; University of North Carolina Chapel Hill; University of Colorado System; University of Colorado Anschutz Medical Campus; Research Triangle Institute; Research Triangle Institute	Feltner, C (corresponding author), Univ N Carolina, Dept Med, 5034 Old Clin Bldg,CB 7110, Chapel Hill, NC 27599 USA.	cindy_feltner@med.unc.edu	Sueta, Carla/AAH-8100-2021	Lohr, Kathleen/0000-0002-3825-0713; Arvanitis, Marina/0000-0002-2186-5164	AHRQ [HHSA290201200008I]; U.S. Department of Health and Human Services [HHSA29032003T]	AHRQ(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); U.S. Department of Health and Human Services	In part by AHRQ (grant HHSA290201200008I) and the U.S. Department of Health and Human Services (contract HHSA29032003T).	Alberta NM, 2007, PATIENT EDUC COUNS, V69, P129, DOI 10.1016/j.pec.2007.08.007; Allen LA, 2012, CIRC-HEART FAIL, V5, P672, DOI 10.1161/CIRCHEARTFAILURE.112.967356; Angermann CE, 2012, CIRC-HEART FAIL, V5, P25, DOI 10.1161/CIRCHEARTFAILURE.111.962969; Barth V, 2001, HOME HLTH CARE MAN P, V13, P436; Benatar D, 2003, ARCH INTERN MED, V163, P347, DOI 10.1001/archinte.163.3.347; Bernheim SM, 2010, CIRC-CARDIOVASC QUAL, V3, P459, DOI 10.1161/CIRCOUTCOMES.110.957613; Bueno H, 2010, JAMA-J AM MED ASSOC, V303, P2141, DOI 10.1001/jama.2010.748; Centers for Medicaid and Medicare Services, 2013, READM RED PROGR; Centers for Medicare & Medicaid Services Office of Information Services, 2006, MED RANK ALL SHORT S; Coleman EA, 2003, J AM GERIATR SOC, V51, P556, DOI 10.1046/j.1532-5415.2003.51186.x; Dar O, 2009, EUR J HEART FAIL, V11, P319, DOI 10.1093/eurjhf/hfn050; Davis KK, 2012, EUR J HEART FAIL, V14, P1041, DOI 10.1093/eurjhf/hfs096; Dendale P, 2012, EUR J HEART FAIL, V14, P333, DOI 10.1093/eurjhf/hfr144; Dharmarajan K, 2013, JAMA-J AM MED ASSOC, V309, P355, DOI 10.1001/jama.2012.216476; Domingues FB, 2011, ARQ BRAS CARDIOL, V96, P233, DOI 10.1590/S0066-782X2011005000014; Ducharme A, 2005, CAN MED ASSOC J, V173, P40, DOI 10.1503/cmaj.1041137; Duffy JR, 2010, J NURS CARE QUAL, V25, P56, DOI 10.1097/NCQ.0b013e3181ad0fbd; Dunagan WC, 2005, J CARD FAIL, V11, P358, DOI 10.1016/j.cardfail.2004.12.004; Ekman I, 1998, EUR HEART J, V19, P1254, DOI 10.1053/euhj.1998.1095; Feltner C, 2014, TRANSITIONA IN PRESS; Goldberg LR, 2003, AM HEART J, V146, P705, DOI 10.1016/S0002-8703(03)00393-4; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Holland R, 2007, BRIT MED J, V334, P1098, DOI 10.1136/bmj.39164.568183.AE; Inglis SC, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007228.pub2; Irabrgui BAE, 2007, REV ESP CARDIOL, V60, P914, DOI 10.1157/13109644; Jaarsma T, 1999, EUR HEART J, V20, P673, DOI 10.1053/euhj.1998.1341; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Jerant AF, 2001, MED CARE, V39, P1234, DOI 10.1097/00005650-200111000-00010; Jerant Anthony F, 2003, Home Health Care Serv Q, V22, P1, DOI 10.1300/J027v22n01_01; Kasper EK, 2002, J AM COLL CARDIOL, V39, P471, DOI 10.1016/S0735-1097(01)01761-2; Kimmelstiel C, 2004, CIRCULATION, V110, P1450, DOI 10.1161/01.CIR.0000141562.22216.00; Kociol RD, 2012, CIRC-HEART FAIL, V5, P680, DOI 10.1161/CIRCHEARTFAILURE.112.967406; Koelling TM, 2005, CIRCULATION, V111, P179, DOI 10.1161/01.CIR.0000151811.53450.B8; Kwok T, 2008, J CLIN NURS, V17, P109, DOI 10.1111/j.1365-2702.2007.01978.x; Laramee AS, 2003, ARCH INTERN MED, V163, P809, DOI 10.1001/archinte.163.7.809; Ledwidge M, 2003, EUR J HEART FAIL, V5, P381, DOI 10.1016/S1388-9842(02)00235-0; Linne Agneta Bjorck, 2006, BMC Cardiovasc Disord, V6, P30, DOI 10.1186/1471-2261-6-30; Liu MH, 2012, INT HEART J, V53, P11, DOI 10.1536/ihj.53.11; Lopez Cabezas C, 2006, Farm Hosp, V30, P328; McDonald K, 2002, J CARD FAIL, V8, P142, DOI 10.1054/jcaf.2002.124340; McDonald K, 2001, EUR J HEART FAIL, V3, P209, DOI 10.1016/S1388-9842(00)00134-3; Naylor MD, 2011, HEALTH AFFAIR, V30, P746, DOI 10.1377/hlthaff.2011.0041; Naylor MD, 2004, J AM GERIATR SOC, V52, P675, DOI 10.1111/j.1532-5415.2004.52202.x; Nucifora G, 2006, J CARDIOVASC MED, V7, P614, DOI 10.2459/01.JCM.0000237910.34000.58; Oddone E Z, 1999, Eff Clin Pract, V2, P201; Owens DK, 2010, J CLIN EPIDEMIOL, V63, P513, DOI 10.1016/j.jclinepi.2009.03.009; Pandor A, 2013, HEART, V99, P1717, DOI 10.1136/heartjnl-2013-303811; Pekmezaris R, 2012, TELEMED E-HEALTH, V18, P101, DOI 10.1089/tmj.2011.0095; Pugh LC., 2001, MEDSURG NURS, V10, P71; Rainville EC, 1999, AM J HEALTH-SYST PH, V56, P1339, DOI 10.1093/ajhp/56.13.1339; Raman G, 2008, NONPHARMACOLOGIC INT; RICH MW, 1993, J GEN INTERN MED, V8, P585, DOI 10.1007/BF02599709; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Riegel B, 2006, J CARD FAIL, V12, P211, DOI 10.1016/j.cardfail.2006.01.005; Riegel B, 2002, ARCH INTERN MED, V162, P705, DOI 10.1001/archinte.162.6.705; Riegel Barbara, 2004, J Cardiovasc Nurs, V19, P174; Schu nemann HJ, 2011, COCHRANE HDB SYSTEMA; Schwarz Karen A, 2008, Prog Cardiovasc Nurs, V23, P18, DOI 10.1111/j.1751-7117.2008.tb00527.x; Sethares KA, 2004, HEART LUNG, V33, P249, DOI 10.1016/j.hrtlng.2004.03.005; Stauffer BD, 2011, ARCH INTERN MED, V171, P1238, DOI 10.1001/archinternmed.2011.274; Stewart S, 1999, LANCET, V354, P1077, DOI 10.1016/S0140-6736(99)03428-5; Stewart S, 1998, ARCH INTERN MED, V158, P1067, DOI 10.1001/archinte.158.10.1067; Stromberg A, 2003, EUR HEART J, V24, P1014, DOI 10.1016/S0195-668X(03)00112-X; Sutton AJ, 2002, STAT MED, V21, P1539; Takeda A, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002752.pub3; Thompson DR, 2005, EUR J HEART FAIL, V7, P377, DOI 10.1016/j.ejheart.2004.10.008; Triller DM, 2007, AM J HEALTH-SYST PH, V64, P2244, DOI 10.2146/ajhp050492; Tsuyuki RT, 2004, J CARD FAIL, V10, P473, DOI 10.1016/j.cardfail.2004.02.005; Viswanathan M AM, 2012, METHODS GUIDE EFFECT; Wakefield BJ, 2008, TELEMED J E-HEALTH, V14, P753, DOI 10.1089/tmj.2007.0131; Wakefield BJ, 2009, J TELEMED TELECARE, V15, P46, DOI 10.1258/jtt.2008.080701; Woodend AK, 2008, HEART LUNG, V37, P36, DOI 10.1016/j.hrtlng.2007.04.004	72	428	442	7	122	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 3	2014	160	11					774	+		10.7326/M14-0083	http://dx.doi.org/10.7326/M14-0083			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AJ0MT	24862840	Green Submitted			2023-01-03	WOS:000337348700004
J	Tallis, R				Tallis, Ray			Assisted dying is not the same as euthanasia	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												raymond@rtallis.wanadoo.co.uk						Hartropp P., 2014, BMJ; YouGov, 2013, YOU GOV DIGN DYING S	2	2	2	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 28	2014	348								g3532	10.1136/bmj.g3532	http://dx.doi.org/10.1136/bmj.g3532			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AI3EH	24871316				2023-01-03	WOS:000336742000009
J	Chaiyachati, KH; Gordon, K; Long, T; Levin, W; Khan, A; Meyer, E; Justice, A; Brienza, R				Chaiyachati, Krisda H.; Gordon, Kirsha; Long, Theodore; Levin, Woody; Khan, Ali; Meyer, Emily; Justice, Amy; Brienza, Rebecca			Continuity in a VA Patient-Centered Medical Home Reduces Emergency Department Visits	PLOS ONE			English	Article							CONTROLLED-TRIAL; HEALTH SYSTEM; PRIMARY-CARE; VETERANS; LESSONS; DISEASE	Background: One major goal of the Patient-Centered Medical Home (PCMH) is to improve continuity of care between patients and providers and reduce the utilization of non-primary care services like the emergency department (ED). Objective: To characterize continuity under the Veterans Health Administration's PCMH model - the Patient Aligned Care Team (PACT), at one large Veterans Affair's (VA's) primary care clinic, determine the characteristics associated with high levels of continuity, and assess the association between continuity and ED visits. Design: Retrospective, observational cohort study of patients at the West Haven VA (WHVA) Primary Care Clinic from March 2011 to February 2012. Patients: The 13,495 patients with established care at the Clinic, having at least one visit, one year before March 2011. Main Measures: Our exposure variable was continuity of care -a patient seeing their assigned primary care provider (PCP) at each clinic visit. The outcome of interest was having an ED visit. Results: The patients encompassed 42,969 total clinic visits, and 3185 (24%) of them had 15,458 ED visits. In a multivariable logistic regression analysis, patients with continuity of care - at least one visit with their assigned PCP - had lower ED utilization compared to individuals without continuity (adjusted odds ratio [AOR] 0.54; 95% CI: 0.41, 0.71), controlling for frequency of primary care visits, comorbidities, insurance, distance from the ED, and having a trainee PCP assigned. Likewise, the adjusted rate of ED visits was 544/1000 person-year (PY) for patients with continuity vs. 784/1000 PY for patients without continuity (p = 0.001). Compared to patients with low continuity (<33% of visits), individuals with medium (33-50%) and high (>50%) continuity were less likely to utilize the ED. Conclusions: Strong continuity of care is associated with decreased ED utilization in a PCMH model and improving continuity may help reduce the utilization of non-primary care services.	[Chaiyachati, Krisda H.; Long, Theodore; Khan, Ali; Meyer, Emily; Justice, Amy; Brienza, Rebecca] VA Connecticut Healthcare Syst, Ctr Excellence Primary Care Educ, West Haven, CT 06516 USA; [Chaiyachati, Krisda H.; Long, Theodore; Khan, Ali; Justice, Amy; Brienza, Rebecca] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; [Gordon, Kirsha; Levin, Woody; Justice, Amy; Brienza, Rebecca] VA Connecticut Healthcare Syst, West Haven, CT USA; [Long, Theodore] Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT USA; [Levin, Woody] Evergreen Design, Guilford, CT USA; [Khan, Ali] Iora Hlth, Collect Primary Care, Brooklyn, NY USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University	Chaiyachati, KH (corresponding author), VA Connecticut Healthcare Syst, Ctr Excellence Primary Care Educ, West Haven, CT 06516 USA.	Krisda.Chaiyachati@yale.edu		Chaiyachati, Krisda/0000-0003-3326-6641	Office of Academic Affiliations; VA Connecticut Health System Center of Excellence in Primary Care Education; Evergreen Design; Iora Health; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000142] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [U01AA020790] Funding Source: NIH RePORTER	Office of Academic Affiliations(US Department of Veterans Affairs); VA Connecticut Health System Center of Excellence in Primary Care Education; Evergreen Design; Iora Health; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	This publication was supported by the Office of Academic Affiliations and the VA Connecticut Health System Center of Excellence in Primary Care Education. Neither funding source had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation or review of the manuscript. The Office of Academic Affiliation did approve the manuscript for publication, but no modifications were made to the manuscript. Evergreen Design provided support in the form of a salary for author WL, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Iora Health provided support in the form of a salary for author AK, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	[Anonymous], 2007, JOINT PRINC PAT CTR; BICE TW, 1977, MED CARE, V15, P347, DOI 10.1097/00005650-197704000-00010; Bodenheimer T, 2006, NEW ENGL J MED, V355, P861, DOI 10.1056/NEJMp068155; Burge F, 2003, MED CARE, V41, P992, DOI 10.1097/00005650-200308000-00012; Chang A, 2012, J GEN INTERN MED; Dewan NA, 2011, COPD, V8, P153, DOI 10.3109/15412555.2011.560129; Dewing S, 2012, AIDS BEHAV, V16, P1286, DOI 10.1007/s10461-011-0059-z; Duncan LG, 2012, J PAIN SYMPTOM MANAG, V43, P161, DOI 10.1016/j.jpainsymman.2011.04.007; Fields D, 2010, HEALTH AFFAIR, V29, P819, DOI 10.1377/hlthaff.2010.0009; Flores-Mateo G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035903; Gill JM, 2000, ARCH FAM MED, V9, P333, DOI 10.1001/archfami.9.4.333; Grafstein E, 2013, ACAD EMERG MED, V20, P63, DOI 10.1111/acem.12063; Grumbach K., 2010, OUTCOMES IMPLEMENTIN; Harbrecht MG, 2012, HEALTH AFFAIR, V31, P2010, DOI 10.1377/hlthaff.2012.0359; Henschen BL, 2013, J GEN INTERN MED; Hochman ME, 2013, JAMA INTERN MED; Ionescu-Ittu R, 2007, CAN MED ASSOC J, V177, P1362, DOI 10.1503/cmaj.061615; Ishani A, 2011, DIABETES CARE, V34, P1689, DOI 10.2337/dc10-2121; Justice AC, 2006, MED CARE, V44, pS52, DOI 10.1097/01.mlr.0000228003.08925.8c; Kuehn BM, 2012, JAMA-J AM MED ASSOC, V307, P442, DOI 10.1001/jama.2012.47; Lee TA, 2007, J GEN INTERN MED, V22, P403, DOI 10.1007/s11606-007-0277-2; MAGILL MK, 1987, J FAM PRACTICE, V24, P165; Markova T, 2012, J AM BOARD FAM MED, V25, P224, DOI 10.3122/jabfm.2012.02.110181; McCusker J, 2012, CAN MED ASSOC J, V184, pE307, DOI 10.1503/cmaj.111069; Nutting PA, 2011, HEALTH AFFAIR, V30, P439, DOI 10.1377/hlthaff.2010.0159; Parekh AK, 2010, JAMA-J AM MED ASSOC, V303, P1303, DOI 10.1001/jama.2010.381; Reid RJ, 2009, AM J MANAG CARE, V15, pE71; Rice KL, 2010, AM J RESP CRIT CARE, V182, P890, DOI 10.1164/rccm.200910-1579OC; Roby DH, 2010, MED CARE RES REV, V67, P412, DOI 10.1177/1077558710368682; Rosland AM, 2013, AM J MANAG CARE, V19, pE263; Sia C, 2004, PEDIATRICS, V113, P1473; Sidorov JE, 2008, HEALTH AFFAIR, V27, P1231, DOI 10.1377/hlthaff.27.5.1231; Westover AN, 2007, ARCH GEN PSYCHIAT, V64, P495, DOI 10.1001/archpsyc.64.4.495; Wharam JF, 2013, HEALTH AFFAIR, V32, P1398, DOI 10.1377/hlthaff.2012.1426	34	28	28	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2014	9	5							e96356	10.1371/journal.pone.0096356	http://dx.doi.org/10.1371/journal.pone.0096356			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AI5NG	24867300	Green Submitted, gold, Green Published			2023-01-03	WOS:000336914100004
J	Harrold, TC; Randall, DA; Falster, MO; Lujic, S; Jorm, LR				Harrold, Timothy C.; Randall, Deborah A.; Falster, Michael O.; Lujic, Sanja; Jorm, Louisa R.			The Contribution of Geography to Disparities in Preventable Hospitalisations between Indigenous and Non-Indigenous Australians	PLOS ONE			English	Article							CARE-SENSITIVE CONDITIONS; MULTILEVEL ANALYSIS; RACIAL DISPARITIES; NEW-ZEALAND; HEALTH	Objectives: To quantify the independent roles of geography and Indigenous status in explaining disparities in Potentially Preventable Hospital (PPH) admissions between Indigenous and non-Indigenous Australians. Design, setting and participants: Analysis of linked hospital admission data for New South Wales (NSW), Australia, for the period July 1 2003 to June 30 2008. Main outcome measures: Age-standardised admission rates, and rate ratios adjusted for age, sex and Statistical Local Area (SLA) of residence using multilevel models. Results: PPH diagnoses accounted for 987,604 admissions in NSW over the study period, of which 3.7% were for Indigenous people. The age-standardised PPH admission rate was 76.5 and 27.3 per 1,000 for Indigenous and non-Indigenous people respectively. PPH admission rates in Indigenous people were 2.16 times higher than in non-Indigenous people of the same age group and sex who lived in the same SLA. The largest disparities in PPH admission rates were seen for diabetes complications, chronic obstructive pulmonary disease and rheumatic heart disease. Both rates of PPH admission in Indigenous people, and the disparity in rates between Indigenous than non-Indigenous people, varied significantly by SLA, with greater disparities seen in regional and remote areas than in major cities. Conclusions: Higher rates of PPH admission among Indigenous people are not simply a function of their greater likelihood of living in rural and remote areas. The very considerable geographic variation in the disparity in rates of PPH admission between Indigenous and non-Indigenous people indicates that there is potential to reduce unwarranted variation by characterising outlying areas which contribute the most to this disparity.	[Harrold, Timothy C.; Randall, Deborah A.; Falster, Michael O.; Lujic, Sanja; Jorm, Louisa R.] Univ Western Sydney, Ctr Hlth Res, Sydney, NSW, Australia	Western Sydney University	Harrold, TC (corresponding author), Univ Western Sydney, Ctr Hlth Res, Sydney, NSW, Australia.	tharr@doh.health.nsw.gov.au	Dalla Zuanna, Teresa/G-3133-2015; Falster, Michael/X-7118-2019; Jorm, Louisa/AAN-6874-2020	Falster, Michael/0000-0001-6444-7272; Jorm, Louisa/0000-0003-0390-661X; Lujic, Sanja/0000-0002-9555-0261; Randall, Deborah/0000-0002-5075-0227	National Health and Medical Research Council [573313]	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by National Health and Medical Research Council grant number 573313. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Australian Bureau of Statistics, 2008, REG POP GROWTH; Australian bureau of Statistics, 2012, 2006 CDATA ONL; Australian Bureau of Statistics, 2012, YB AUSTR 2012; Australian Bureau of Statistics, 2008, EXP EST AB TORR STRA; Australian Bureau of Statistics, 2010, HLTH WELF AUSTR AB T; Australian Institute of Health and Welfare, 2010, IND ID HOSP SEP DAT; Australian Institute of Health and Welfare, 2004, RUR REG REM HLTH GUI; Australian Institute of Health and Welfare, 2011, AUSTR HOSP STAT 2009; Australian Institute of Health Welfare, 2012, NATL HEALTHCARE AGRE; Bentley Jason P, 2012, N S W Public Health Bull, V23, P17, DOI 10.1071/NB11034; Biddle N., 2013, CAEPR INDIGENOUS POP; Brown A, 2009, HEART LUNG CIRC, V18, P96, DOI 10.1016/j.hlc.2009.01.005; Canadian Institute for Health Information, 2013, CAN I HLTH INF FACT; Council of Australian Governments, 2008, INT AGR IGA FED FIN; Craig P, 2012, J EPIDEMIOL COMMUN H, V66, P1182, DOI 10.1136/jech-2011-200375; Department of Health Victoria, 2012, VICT AMB CAR SENS CO; Gaskin DJ, 2000, MED CARE RES REV, V57, P85, DOI 10.1177/107755800773743619; Health Department of, 2010, HLTH LIF PROGR FRAM; Jackson G, 2001, AUST NZ J PUBL HEAL, V25, P212, DOI 10.1111/j.1467-842X.2001.tb00565.x; Katterl R, 2012, PHC RIS POLICY ISSUE; Laditka JN, 2006, ETHNIC HEALTH, V11, P247, DOI 10.1080/13557850600565640; Li SQ, 2009, MED J AUSTRALIA, V190, P532, DOI 10.5694/j.1326-5377.2009.tb02551.x; McDermott R, 2004, QUAL SAF HEALTH CARE, V13, P295, DOI 10.1136/qhc.13.4.295; Merlo J, 2005, J EPIDEMIOL COMMUN H, V59, P443, DOI 10.1136/jech.2004.023473; National Centre for Classification in Health, 2006, INT STAT CLASS DIS H; National Statistics Service, 2013, STAT INT INV COMM DA; NSW Health, 2012, NSW HLTH STAT HOSP P; O'Neil SS, 2010, AM J PREV MED, V38, P381, DOI 10.1016/j.amepre.2009.12.026; Office of Economic and Statistical Research (OESR), 2010, SYNTH EST RES POP IN; Pellekaan SMV, 2005, POSTGRAD MED J, V81, P618, DOI 10.1136/pgmj.2004.031377; Probst JC, 2004, AM J PUBLIC HEALTH, V94, P1695, DOI 10.2105/AJPH.94.10.1695; Queensland Health, 2012, HLTH QUEENSL REP CHI; Randall DA, 2013, AUST NZ J PUBL HEAL, V37, P442, DOI 10.1111/1753-6405.12114; Rasbash J., 2012, MLWIN VERSION 2 25; Richardson K, 2009, SOC SCI MED, V69, P1252, DOI 10.1016/j.socscimed.2009.07.036; SAS Institute, 2010, SAS VERS 9 3; Scribner RA, 2009, SOC SCI MED, V69, P1584, DOI 10.1016/j.socscimed.2009.08.010; Sentell TL, 2013, PREV CHRONIC DIS, V10, DOI 10.5888/pcd10.120340; Steering Committee for the Review of Government Service Provision (SCRGSP), 2010, NAT AGR PERF INF 200; Subramanian SV, 2005, AM J PUBLIC HEALTH, V95, P260, DOI 10.2105/AJPH.2003.034132; Tobias M, 2006, AUST NZ J PUBL HEAL, V30, P457, DOI 10.1111/j.1467-842X.2006.tb00464.x	41	11	11	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2014	9	5							e97892	10.1371/journal.pone.0097892	http://dx.doi.org/10.1371/journal.pone.0097892			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AI4ML	24859265	Green Submitted, Green Published, gold			2023-01-03	WOS:000336839400030
J	Ueno, N; Hasebe, T; Kaneko, A; Yamamoto, M; Fujiya, M; Kohgo, Y; Kono, T; Wang, CZ; Yuan, CS; Bissonnette, M; Chang, EB; Musch, MW				Ueno, Nobuhiro; Hasebe, Takumu; Kaneko, Atsushi; Yamamoto, Masahiro; Fujiya, Mikihiro; Kohgo, Yutaka; Kono, Toru; Wang, Chong-Zhi; Yuan, Chun-Su; Bissonnette, Marc; Chang, Eugene B.; Musch, Mark W.			TU-100 (Daikenchuto) and Ginger Ameliorate Anti-CD3 Antibody Induced T Cell-Mediated Murine Enteritis: Microbe-Independent Effects Involving Akt and NF-kappa B Suppression	PLOS ONE			English	Article							TRADITIONAL JAPANESE MEDICINE; TUMOR-NECROSIS-FACTOR; MONOCLONAL-ANTIBODY; BETA-GLUCOSIDASE; HERBAL MEDICINE; COLONIC TRANSIT; COMPOUND K; ACTIVATION; EXPRESSION; 6-SHOGAOL	The Japanese traditional medicine daikenchuto (TU-100) has anti-inflammatory activities, but the mechanisms remain incompletely understood. TU-100 includes ginger, ginseng, and Japanese pepper, each component possessing bioactive properties. The effects of TU-100 and individual components were investigated in a model of intestinal T lymphocyte activation using anti-CD3 antibody. To determine contribution of intestinal bacteria, specific pathogen free (SPF) and germ free (GF) mice were used. TU-100 or its components were delivered by diet or by gavage. Anti-CD3 antibody increased jejunal accumulation of fluid, increased TNF alpha, and induced intestinal epithelial apoptosis in both SPF and GF mice, which was blocked by either TU-100 or ginger, but not by ginseng or Japanese pepper. TU-100 and ginger also blocked anti-CD3-stimulated Akt and NF-kappa B activation. A co-culture system of colonic Caco2BBE and Jurkat-1 cells was used to examine Tlymphocyte/epithelial cells interactions. Jurkat-1 cells were stimulated with anti-CD3 to produce TNF alpha that activates epithelial cell NF-kappa B. TU-100 and ginger blocked anti-CD3 antibody activation of Akt in Jurkat cells, decreasing their TNF alpha production. Additionally, TU-100 and ginger alone blocked direct TNF alpha stimulation of Caco2BBE cells and decreased activation of caspase-3 and polyADP ribose. The present studies demonstrate a new anti-inflammatory action of TU-100 that is microbe-independent and due to its ginger component.	[Ueno, Nobuhiro; Hasebe, Takumu; Bissonnette, Marc; Chang, Eugene B.; Musch, Mark W.] Univ Chicago, Dept Med, Knapp Ctr Biomed Discovery, Chicago, IL 60637 USA; [Ueno, Nobuhiro; Hasebe, Takumu; Fujiya, Mikihiro; Kohgo, Yutaka] Asahikawa Med Univ, Dept Med, Div Gastroenterol & Hematol Oncol, Asahikawa, Hokkaido, Japan; [Kaneko, Atsushi; Yamamoto, Masahiro] Tsumura & Co, Tsumura Res Labs, Ami, Ibaraki, Japan; [Kono, Toru] Sapporo Higashi Tokushukai Hosp, Ctr Clin & Biomed Res, Sapporo, Hokkaido, Japan; [Kono, Toru] Asahikawa Med Univ, Div Gastroenterol & Gen Surg, Dept Surg, Asahikawa, Hokkaido, Japan; [Wang, Chong-Zhi; Yuan, Chun-Su] Univ Chicago, Dept Anesthesia & Crit Care, Tang Ctr Herbal Med Res, Chicago, IL 60637 USA	University of Chicago; Asahikawa Medical College; Tsumura & Company; Asahikawa Medical College; University of Chicago	Musch, MW (corresponding author), Univ Chicago, Dept Med, Knapp Ctr Biomed Discovery, 5841 S Maryland Ave, Chicago, IL 60637 USA.	mmusch@medicine.bsd.uchicago.edu	Wang, Chong-Zhi/B-8337-2014; Kohgo, Yutaka/AAN-4863-2020	Wang, Chong-Zhi/0000-0002-0950-2109; Hasebe, Takumu/0000-0002-4333-4428	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [P30 DK42086, DK47722, DK097268, NCCAM AT004418, AT005362]; National Institutes of Health [CA036745]; Samuel Freedman Research Laboratories for Gastrointestinal Cancer Research; University of Chicago Comprehensive Cancer Center; Tsumura Corporation; NATIONAL CANCER INSTITUTE [R01CA036745, R37CA036745, R01CA164124] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000430] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [P01AT004418, K01AT005362] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047722, P30DK042086, R37DK047722, R01DK097268] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Samuel Freedman Research Laboratories for Gastrointestinal Cancer Research; University of Chicago Comprehensive Cancer Center; Tsumura Corporation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): P30 DK42086 (EBC), DK47722 (EBC), DK097268 (EBC), NCCAM AT004418 (CSY) and AT005362 (CSY); the National Institutes of Health: CA036745 (MB); the Samuel Freedman Research Laboratories for Gastrointestinal Cancer Research; and the University of Chicago Comprehensive Cancer Center. The funders had no role in study design, data collection, data analysis, or decision to publish. This work was also supported by grants from the Tsumura Corporation. This funder provided support in the form of salaries for authors AK and MY but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the "author contributions" section.	ABRAMOWICZ D, 1989, TRANSPLANTATION, V47, P606, DOI 10.1097/00007890-198904000-00008; Calixto JB, 2005, PHARMACOL THERAPEUT, V106, P179, DOI 10.1016/j.pharmthera.2004.11.008; CHARPENTIER B, 1992, TRANSPLANTATION, V54, P997, DOI 10.1097/00007890-199212000-00011; Chikakiyo M, 2012, SURG TODAY, V42, P60, DOI 10.1007/s00595-011-0014-7; Clayburgh DR, 2005, J CLIN INVEST, V115, P2702, DOI 10.1172/JCI24970; Dougherty U, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-111; Dugasani S, 2010, J ETHNOPHARMACOL, V127, P515, DOI 10.1016/j.jep.2009.10.004; Endo M, 2014, J GASTROENTEROL, V49, P1026, DOI 10.1007/s00535-013-0854-6; Horiuchi A, 2010, GASTROENTEROL RES, V3, P151, DOI 10.4021/gr219w; Huang HC, 2011, BIOSCI BIOTECH BIOCH, V75, P1067, DOI 10.1271/bbb.100851; Hung JY, 2009, J AGR FOOD CHEM, V57, P9809, DOI 10.1021/jf902315e; Iturrino J, 2013, ALIMENT PHARM THER, V37, P776, DOI 10.1111/apt.12264; Iwabu J, 2010, DRUG METAB DISPOS, V38, P2040, DOI 10.1124/dmd.110.033589; Iwasa T, 2012, DIGEST DIS SCI, V57, P2571, DOI 10.1007/s10620-012-2218-0; Jin XL, 2001, DIGEST DIS SCI, V46, P1171, DOI 10.1023/A:1010690624187; Jin Y, 2008, CARCINOGENESIS, V29, P2351, DOI 10.1093/carcin/bgn211; Kaneko A, 2013, GASTROENT RES PRACT, V2013, DOI 10.1155/2013/384057; Kim MK, 2005, J MICROBIOL, V43, P456; Kim SO, 2005, ONCOGENE, V24, P2558, DOI 10.1038/sj.onc.1208446; Kono T, 2008, J SURG RES, V150, P78, DOI 10.1016/j.jss.2008.02.057; Kono T, 2013, AM J PHYSIOL-GASTR L, V304, pG428, DOI 10.1152/ajpgi.00356.2012; Kono T, 2011, J GASTROENTEROL, V46, P1187, DOI 10.1007/s00535-011-0438-2; Kono T, 2010, J CROHNS COLITIS, V4, P161, DOI 10.1016/j.crohns.2009.09.006; Kono T, 2009, SURGERY, V146, P837, DOI 10.1016/j.surg.2009.06.012; Li XH, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/146142; Lucas PC, 2004, J CELL SCI, V117, P31, DOI 10.1242/jcs.00904; Manabe N, 2010, AM J PHYSIOL-GASTR L, V298, pG970, DOI 10.1152/ajpgi.00043.2010; Masuda Y, 2004, BIOFACTORS, V21, P293, DOI 10.1002/biof.552210157; Miura N, 2005, INT IMMUNOL, V17, P513, DOI 10.1093/intimm/dxh231; Munekage M, 2011, DRUG METAB DISPOS, V39, P1784, DOI 10.1124/dmd.111.040097; Murata P, 2002, LIFE SCI, V70, P2061, DOI 10.1016/S0024-3205(01)01552-1; Musch MW, 2002, J CLIN INVEST, V110, P1739, DOI 10.1172/JCI200215695; Pan MH, 2008, MOL NUTR FOOD RES, V52, P1467, DOI 10.1002/mnfr.200700515; PETERSON MD, 1992, J CELL SCI, V102, P581; Quan LH, 2012, J AGR FOOD CHEM, V60, P3776, DOI 10.1021/jf300186a; Radojevic N, 1999, AM J PHYSIOL-REG I, V276, pR715, DOI 10.1152/ajpregu.1999.276.3.R715; Riera CE, 2009, BRIT J PHARMACOL, V157, P1398, DOI 10.1111/j.1476-5381.2009.00307.x; Tang YM, 2010, AM J PATHOL, V176, P158, DOI 10.2353/ajpath.2010.090548; Wang CC, 2003, IN VIVO, V17, P641; Wang CZ, 2012, INT J ONCOL, DOI [10.3892/ijo.2012.1399, DOI 10.3892/IJ0.2012.1399]; Wang L, 2011, J BIOTECHNOL, V156, P125, DOI 10.1016/j.jbiotec.2011.07.024; Wang XJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028232; Weng CJ, 2012, MOL NUTR FOOD RES, V56, P1304, DOI 10.1002/mnfr.201200173; Wu H, 2010, MOL NUTR FOOD RES, V54, P1296, DOI 10.1002/mnfr.200900409; Yasanoya H, 2011, EVIDENCE BASED COMP, DOI org/10.1155/2011/264286.; Zhang ZY, 2013, INT J MOL SCI, V14, P2980, DOI 10.3390/ijms14022980	46	14	14	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2014	9	5							e97456	10.1371/journal.pone.0097456	http://dx.doi.org/10.1371/journal.pone.0097456			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI4ML	24857966	gold, Green Published, Green Submitted			2023-01-03	WOS:000336839400017
J	Lopez-Cortes, LF; Viciana, P; Giron-Gonzalez, JA; Romero-Palacios, A; Marquez-Solero, M; Martinez-Perez, MA; Lopez-Ruz, MA; de la Torre-Lima, J; Tellez-Perez, F; Delgado-Fernandez, M; Garcia-Lazaro, M; Lozano, F; Mohamed-Balghata, MO				Lopez-Cortes, Luis F.; Viciana, Pompeyo; Giron-Gonzalez, Jose A.; Romero-Palacios, Alberto; Marquez-Solero, Manuel; Martinez-Perez, Maria A.; Lopez-Ruz, Miguel A.; de la Torre-Lima, Javier; Tellez-Perez, Francisco; Delgado-Fernandez, Marcial; Garcia-Lazaro, Milagros; Lozano, Fernando; Mohamed-Balghata, Mohamed O.		Soc Andaluza Enfermedades Infeccio	Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population	PLOS ONE			English	Article							DOUBLE-BLIND; EXPERIENCED PATIENTS; PHARMACOKINETICS; RESISTANCE; EFAVIRENZ; TMC125; SAFETY; NAIVE; INDIVIDUALS; TRIALS	Etravirine (ETV) is recommended in combination with a boosted protease inhibitor plus an optimized background regimen for salvage therapy, but there is limited experience with its use in combination with two nucleos(t)ide reverse-transcriptase inhibitors (NRTIs). This multicenter study aimed to assess the efficacy of this combination in two scenarios: group A) subjects without virologic failure on or no experience with non-nucleoside reverse-transcriptase inhibitors (NNRTIs) switched due to adverse events and group B) subjects switched after a virologic failure on an efavirenz-or nevirapine-based regimen. The primary endpoint was efficacy at 52 weeks analysed by intention-to-treat. Virologic failure was defined as the inability to suppress plasma HIV-RNA to <50 copies/mL after 24 weeks on treatment, or a confirmed viral load >200 copies/mL in patients who had previously achieved a viral suppression or had an undetectable viral load at inclusion. Two hundred eighty seven patients were included. Treatment efficacy rates in group A and B were 88.0% (CI95, 83.9-92.1%) and 77.4% (CI95, 65.0-89.7%), respectively; the rates reached 97.2% (CI95, 95.1-99.3%) and 90.5% (CI95, 81.7-99.3), by on-treatment analysis. The once-a-day ETV treatment was as effective as the twice daily dosing regimen. Grade 1-2 adverse events were observed motivating a treatment switch in 4.2% of the subjects. In conclusion, ETV (once-or twice daily) plus two analogs is a suitable, well-tolerated combination both as a switching strategy and after failure with first generation NNRTIs, ensuring full drug activity.	[Lopez-Cortes, Luis F.; Viciana, Pompeyo] Univ Seville, CSIC, Hosp Univ Virgen del Rocio, Inst Biomed Sevilla IBiS, Seville, Spain; [Giron-Gonzalez, Jose A.] Hosp Univ Puerta del Mar, Cadiz, Spain; [Romero-Palacios, Alberto] Hosp Univ Puerto Real, Cadiz, Spain; [Marquez-Solero, Manuel] Hosp Univ Virgen de la Victoria, Malaga, Spain; [Martinez-Perez, Maria A.] Hosp Univ San Cecilio, Granada, Spain; [Lopez-Ruz, Miguel A.] Hosp Univ Virgen de las Nieves, Granada, Spain; [de la Torre-Lima, Javier] Hosp Costa del Sol, Malaga, Spain; [Tellez-Perez, Francisco] Hosp La Linea, Cadiz, Spain; [Delgado-Fernandez, Marcial] Hosp Univ Carlos Haya, Malaga, Spain; [Garcia-Lazaro, Milagros] Hosp Univ Reina Sofia, Cordoba, Spain; [Lozano, Fernando] Hosp Univ Valme, Seville, Spain; [Mohamed-Balghata, Mohamed O.] Complejo Hospitalario Jaen, Jaen, Spain; [Lopez-Cortes, Luis F.] Hosp Univ Virgen del Rocio, Seville, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital; Universidad de Cadiz; Hospital Universitario Puerta del Mar; Universidad de Cadiz; Hospital Universitario Puerto Real; Hospital Virgen de la Victoria; Universidad de Malaga; Hospital Universitario San Cecilio; Hospital Universitario Virgen de las Nieves; Hospital Carlos Haya; Hospital Universitario Reina Sofia - Cordoba; Hospital Valme; Virgen del Rocio University Hospital	Lopez-Cortes, LF (corresponding author), Univ Seville, CSIC, Hosp Univ Virgen del Rocio, Inst Biomed Sevilla IBiS, Seville, Spain.	lflopez@us.es	Girón-González, José-Antonio/AAG-4199-2020; Girón-González, José-Antonio/H-3990-2014; IBIS, VIH/O-8856-2015; De La Torre-Lima, Javier/B-9904-2019; Lopez.Cortes, Luis Fernando/W-8323-2019	Girón-González, José-Antonio/0000-0002-7482-5828; Girón-González, José-Antonio/0000-0002-7482-5828; De La Torre-Lima, Javier/0000-0003-4718-0320; Lopez.Cortes, Luis Fernando/0000-0002-3804-3458; Romero Palacios, Alberto/0000-0003-1345-4901; Marquez, Manuel/0000-0002-7901-6966; Tellez, Francisco/0000-0002-9997-6761	Abbott Laboratories (Spain); Bristol-Myers Squibb; Gilead Sciences; Glaxo Smithkline; Roche Pharma S.A.; ViiV Healthcare	Abbott Laboratories (Spain); Bristol-Myers Squibb(Bristol-Myers Squibb); Gilead Sciences(Gilead Sciences); Glaxo Smithkline(GlaxoSmithKline); Roche Pharma S.A.; ViiV Healthcare	The authors have read the journal's policy and have the following conflicts: The authors have not conflicts of interest related to this manuscript. However, Luis F. Lopez-Cortes, Pompeyo Viciana, Jose A. Giron-Gonzalez, Manuel Marquez-Solero, Javier de la Torre-Lima, Marcial Delgado-Fernandez, and Fernando Lozano have received honoraria for speaking at symposia organized on behalf of Abbott laboratories (Spain), Bristol-Myers Squibb, Glaxo Smithkline, Gilead Sciences, Janssen-Cilag Espana, Merck Sharp & Dohme Espana, Roche Pharma SA, and ViiV Healthcare. Also, they have received unrestricted funds for research from Abbott Laboratories (Spain), Bristol-Myers Squibb, Bristol-Myers Squibb, Gilead Sciences, Glaxo Smithkline, Roche Pharma S.A., and ViiV Healthcare.	Andries K, 2004, ANTIMICROB AGENTS CH, V48, P4680, DOI 10.1128/AAC.48.12.4680-4686.2004; Boffito M, 2009, JAIDS-J ACQ IMM DEF, V52, P222, DOI 10.1097/QAI.0b013e3181b061d0; Casado JL, 2013, HIV CLIN TRIALS, V14, P1, DOI 10.1410/hct1401-1; Croxtall JD, 2012, DRUGS, V72, P847, DOI 10.2165/11209110-000000000-00000; DeJesus E, 2010, ANTIVIR THER, V15, P711, DOI 10.3851/IMP1562; Estebanez M, 2013, AIDS, V27, P141, DOI 10.1097/QAD.0b013e328358fcc2; European Medicines Agency, 2011, INT PROD INF; Gazzard BG, 2003, AIDS, V17, pF49, DOI 10.1097/00002030-200312050-00001; Gazzard B, 2011, AIDS, V25, P2249, DOI 10.1097/QAD.0b013e32834c4c06; Gruzdev B, 2003, AIDS, V17, P2487, DOI 10.1097/00002030-200311210-00011; Gutierrez-Valencia A, 2012, J ANTIMICROB CHEMOTH, V67, P681, DOI 10.1093/jac/dkr534; Kakuda TN, 2011, CLIN PHARMACOKINET, V50, P25, DOI 10.2165/11534740-000000000-00000; Katlama C, 2010, ANTIVIR THER, V15, P1045, DOI 10.3851/IMP1662; Katlama C, 2009, AIDS, V23, P2289, DOI 10.1097/QAD.0b013e3283316a5e; Panel on Antiretroviral Guidelines for Adults and Adolescents, 2013, GUIDELINES USE ANTIR; Ruxrungtham K, 2008, HIV MED, V9, P883, DOI 10.1111/j.1468-1293.2008.00644.x; Scholler-Gyure M, 2009, CLIN PHARMACOKINET, V48, P561, DOI 10.2165/10895940-000000000-00000; U. S. Food and Drug Administration, 2011, INT FULL PRESCR INF; van Heeswijk RPG, 2013, ANTIVIR THER, V18, P553, DOI 10.3851/IMP2527; Vingerhoets J, 2010, AIDS, V24, P503, DOI 10.1097/QAD.0b013e32833677ac; Waters L, 2011, AIDS, V25, P65, DOI 10.1097/QAD.0b013e328341685b	21	4	4	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2014	9	5							e97262	10.1371/journal.pone.0097262	http://dx.doi.org/10.1371/journal.pone.0097262			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM1NZ	24836963	gold, Green Published, Green Submitted			2023-01-03	WOS:000339614800035
J	Marshall, MR; Walker, RC; Polkinghorne, KR; Lynn, KL				Marshall, Mark R.; Walker, Rachael C.; Polkinghorne, Kevan R.; Lynn, Kelvin L.			Survival on Home Dialysis in New Zealand	PLOS ONE			English	Article							STAGE RENAL-DISEASE; PERITONEAL-DIALYSIS; ESRD PATIENTS; COMPARING MORTALITY; PATIENT SURVIVAL; RISK-FACTORS; HEMODIALYSIS; MODALITY; OUTCOMES; STATES	Background: New Zealand (NZ) has a high prevalence of both peritoneal dialysis (PD) and home haemodialysis (HD) relative to other countries, and probably less selection bias. We aimed to determine if home dialysis associates with better survival than facility HD by simultaneous comparisons of the three modalities. Methods: We analysed survival by time-varying dialysis modality in New Zealanders over a 15-year period to 31-Dec-2011, adjusting for patient co-morbidity by Cox proportional hazards multivariate regression. Results: We modelled 6,419 patients with 3,254 deaths over 20,042 patient-years of follow-up. Patients treated with PD and facility HD are similar; those on home HD are younger and healthier. Compared to facility HD, home dialysis (as a unified category) associates with an overall 13% lower mortality risk. Home HD associates with a 52% lower mortality risk. PD associates with a 20% lower mortality risk in the early period (< 3 years) that is offset by a 33% greater mortality risk in the late period (> 3 years), with no overall net effect. There was effect modification and less observable benefit associated with PD in those with diabetes mellitus, co-morbidity, and in NZ Maori and Pacific People. There was no effect modification by age or by era. Conclusion: Our study supports the culture of home dialysis in NZ, and suggests that the extent and duration of survival benefit associated with early PD may be greater than appreciated. We are planning further analyses to exclude residual confounding from unmeasured co-morbidity and other sociodemographic factors using database linkage to NZ government datasets. Finally, our results suggest further research into the practice of PD in NZ Maori and Pacific People, as well as definitive study to determine the best timing for switching from PD in the late phase.	[Marshall, Mark R.] Univ Auckland, Fac Med & Hlth Sci, Auckland 1, New Zealand; [Marshall, Mark R.] Counties Manukau Dist Hlth Board, Dept Renal Med, Auckland, New Zealand; [Marshall, Mark R.; Polkinghorne, Kevan R.] Royal Adelaide Hosp, Australia & New Zealand Dialysis & Transplant Reg, Adelaide, SA 5000, Australia; [Walker, Rachael C.] Hawkes Bay Dist Hlth Board, Renal Dept, Hastings, New Zealand; [Walker, Rachael C.] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW 2006, Australia; [Polkinghorne, Kevan R.] Monash Med Ctr, Dept Nephrol, Clayton, Vic 3168, Australia; [Polkinghorne, Kevan R.] Monash Univ, Dept Med, Clayton, Vic, Australia; [Polkinghorne, Kevan R.] Monash Univ, Dept Epidemiol & Prevent Med, Clayton, Vic, Australia; [Lynn, Kelvin L.] Kidney Hlth New Zealand, Christchurch, New Zealand	University of Auckland; Royal Adelaide Hospital; University of Sydney; Monash University; Monash University; Monash University	Marshall, MR (corresponding author), Univ Auckland, Fac Med & Hlth Sci, Auckland 1, New Zealand.	mrmarshall@middlemore.co.nz	Marshall, Mark/Y-6745-2018; Marshall, Mark Roger/K-5751-2019	Marshall, Mark/0000-0003-0499-4527; Marshall, Mark Roger/0000-0003-0499-4527; Polkinghorne, Kevan/0000-0002-9851-002X; Walker, Rachael/0000-0001-5163-4351	Royal Australasian College of Physicians Foundation	Royal Australasian College of Physicians Foundation	The Royal Australasian College of Physicians Foundation funded this study through a Jacquot Research Establishment Award to M. M. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbott KC, 2004, KIDNEY INT, V65, P597, DOI 10.1111/j.1523-1755.2004.00385.x; Blagg CR, 2005, NEPHROLOGY, V10, P206, DOI 10.1111/j.1440-1797.2005.00383.x; Boissinot L, 2013, PERITON DIALYSIS INT, V33, P391, DOI 10.3747/pdi.2011.00134; Chan CT, 2009, ADV CHRONIC KIDNEY D, V16, P158, DOI 10.1053/j.ackd.2009.02.010; CHRISTENSEN AJ, 1990, HEALTH PSYCHOL, V9, P225, DOI 10.1037/0278-6133.9.2.225; CHRISTENSEN AJ, 1992, J BEHAV MED, V15, P313, DOI 10.1007/BF00844725; Churchill DN, 1997, J AM SOC NEPHROL, V8, P965; Collins AJ, 1999, AM J KIDNEY DIS, V34, P1065, DOI 10.1016/S0272-6386(99)70012-0; Dale PL, 2008, CURR MED RES OPIN, V24, P193, DOI 10.1185/030079908X253410; Ganesh SK, 2003, J AM SOC NEPHROL, V14, P415, DOI 10.1097/01.ASN.0000043140.23422.4F; Golper TA, 2011, PERITON DIALYSIS INT, V31, P12, DOI 10.3747/pdi.2010.00143; GRANT AC, 1992, PERITON DIALYSIS INT, V12, P365; Heaf JG, 2002, NEPHROL DIAL TRANSPL, V17, P112, DOI 10.1093/ndt/17.1.112; Inrig JK, 2006, CLIN J AM SOC NEPHRO, V1, P774, DOI 10.2215/CJN.00580705; Jaar BG, 2005, ANN INTERN MED, V143, P174, DOI 10.7326/0003-4819-143-3-200508020-00003; Kraus Michael, 2007, Hemodial Int, V11, P468, DOI 10.1111/j.1542-4758.2007.00229.x; Lameire N, 2000, PERITON DIALYSIS INT, V20, pS134; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Lynn KL, 2005, NEPHROLOGY, V10, P231, DOI 10.1111/j.1440-1797.2005.00399.x; Mailloux L U, 1996, Adv Ren Replace Ther, V3, P112; MAILLOUX LU, 1994, CLIN NEPHROL, V42, P127; MAILLOUX LU, 1988, AM J MED, V84, P855, DOI 10.1016/0002-9343(88)90063-0; Marshall MR, 2011, AM J KIDNEY DIS, V58, P782, DOI 10.1053/j.ajkd.2011.04.027; McDonald SP, 2009, J AM SOC NEPHROL, V20, P155, DOI 10.1681/ASN.2007111188; McGregor D, 2000, NEW ZEAL MED J, V113, P27; McGregor DO, 2001, BLOOD PURIFICAT, V19, P293, DOI 10.1159/000046957; Mowatt G, 2003, Health Technol Assess, V7, P1; Mowatt G, 2004, INT J TECHNOL ASSESS, V20, P258, DOI 10.1017/S0266462304001060; National Institutes of Health NIoDaDaKD, 2012, US REN DAT SYST USRD; Nitsch D, 2011, NEPHROL DIAL TRANSPL, V26, P1670, DOI 10.1093/ndt/gfq561; Polaschek N, 2007, J REN CARE, V33, P20, DOI 10.1111/j.1755-6686.2007.tb00032.x; PROWANT B, 1983, AM J KIDNEY DIS, V3, P27, DOI 10.1016/S0272-6386(83)80006-7; Rodriguez RA, 2012, CLIN J AM SOC NEPHRO, V7, P1055, DOI 10.2215/CJN.05410512; RUBIN J, 1989, AM J MED SCI, V297, P80, DOI 10.1097/00000441-198902000-00004; RUBIN J, 1983, KIDNEY INT, V23, P51, DOI 10.1038/ki.1983.10; Rubin J, 1985, ASAIO J, V8, P22; Sanabria M, 2008, KIDNEY INT, V73, pS165, DOI 10.1038/sj.ki.5002619; Saner E, 2005, NEPHROL DIAL TRANSPL, V20, P604, DOI 10.1093/ndt/gfh674; Schaubel DE, 1998, PERITON DIALYSIS INT, V18, P478; Snyder JJ, 2003, KIDNEY INT, V64, P1838, DOI 10.1046/j.1523-1755.2003.00287.x; Snyder WL, 1977, ABSTR HOSP MAN STUD, V14, P18102; Stack AG, 2004, KIDNEY INT, V65, P2398, DOI 10.1111/j.1523-1755.2004.00654.x; Stack AG, 2003, KIDNEY INT, V64, P1071, DOI 10.1046/j.1523-1755.2003.00165.x; Termorshuizen F, 2003, J AM SOC NEPHROL, V14, P2851, DOI 10.1097/01.ASN.0000091585.45723.9E; Thodis ED, 2011, J NEPHROL, V24, P398, DOI 10.5301/JN.2011.8374; Tonelli M, 2007, KIDNEY INT, V72, P1023, DOI 10.1038/sj.ki.5002443; Van Biesen W, 2000, J AM SOC NEPHROL, V11, P116, DOI 10.1681/ASN.V111116; Vonesh EF, 2006, KIDNEY INT, V70, pS3, DOI 10.1038/sj.ki.5001910; Vonesh EF, 2004, KIDNEY INT, V66, P2389, DOI 10.1111/j.1523-1755.2004.66028.x; Vonesh EF, 1999, J AM SOC NEPHROL, V10, P354; Vonesh EF, 2000, KIDNEY INT, V57, pS19, DOI 10.1046/j.1523-1755.2000.07405.x; WELLER JM, 1982, KIDNEY INT, V21, P78, DOI 10.1038/ki.1982.11; WILLIAMS GW, 1983, KIDNEY INT, V24, P691, DOI 10.1038/ki.1983.212; Winkelmayer WC, 2002, J AM SOC NEPHROL, V13, P2353, DOI 10.1097/01.ASN.0000025785.41314.76; Woods JD, 1996, KIDNEY INT, V49, P1464, DOI 10.1038/ki.1996.206; Wyld M, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001307; Xu R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050766	57	33	33	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2014	9	5							e96847	10.1371/journal.pone.0096847	http://dx.doi.org/10.1371/journal.pone.0096847			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG9HB	24806458	Green Submitted, gold, Green Published			2023-01-03	WOS:000335728900106
J	Wang, JY; Wu, PK; Chen, PCH; Yen, CC; Hung, GY; Chen, CF; Hung, SC; Tsai, SF; Liu, CL; Chen, TH; Chen, WM				Wang, Jir-You; Wu, Po-Kuei; Chen, Paul Chih-Hsueh; Yen, Chuen-Chuan; Hung, Giun-Yi; Chen, Cheng-Fong; Hung, Shih-Chieh; Tsai, Shih-Fen; Liu, Chien-Lin; Chen, Tain-Hsiung; Chen, Wei-Ming			Manipulation Therapy Prior to Diagnosis Induced Primary Osteosarcoma Metastasis-From Clinical to Basic Research	PLOS ONE			English	Article							ALTERNATIVE MEDICINE; CELL-PROLIFERATION; MASSAGE THERAPY; MOUSE EPIDERMIS; TUMOR-GROWTH; PROMOTE; COMPLEMENTARY	Osteosarcoma (OS) patients who suffer manipulation therapy (MT) prior to diagnosis resulted in poor prognosis with increasing metastasis or recurrence rate. The aim of the study is to establish an in vivo model to identify the effects of MT on OS. The enrolled 235 OS patients were followed up in this study. In vivo nude mice model with tibia injection of GFP-labeled human OS cells were randomly allocated into MT(+) that with repeated massage on tumor site twice a week and no treatment as MT(2) group. The five-year survival, metastasis and recurrence rates were recorded in clinical subjects. X-ray plainfilm, micro-PET/CT scan, histopathology, serum metalloproteinase 2 (MMP2), metalloproteinase 9 (MMP9) level and human kinase domain insert receptor (KDR) pattern were assayed in mice model. The results showed that patient with MT decreased 5-year survival and higher recurrence or metastasis rate. Compatible with clinical findings, the decreased body weight (30.5 +/- 60.65 g) and an increased tumor volume (8.3 +/- 61.18 mm(3)) in MT(+) mice were observed. The increasing signal intensity over lymph node region of hind limb by micro-PET/CT and the tumor cells were detected in lung and bilateral lymph nodes only in MT(+) group. MMP2 (2.14 +/- 9.8 ng/ml) and MMP9 (25.5 +/- 1.81 ng/ml) were higher in MT(+) group than in MT(2) group (165 +/- 7.8 ng/ml and 16.9 +/- 1.40 ng/ml, individually) as well as KDR expression. Taking clinical observations and in vivo evidence together, MT treatment leads to poor prognosis of primary osteosarcoma; physicians should pay more attention on patients who seek MT before diagnosis.	[Wang, Jir-You; Wu, Po-Kuei; Chen, Cheng-Fong; Hung, Shih-Chieh; Liu, Chien-Lin; Chen, Tain-Hsiung; Chen, Wei-Ming] Taipei Vet Gen Hosp, Dept Orthopaed, Taipei, Taiwan; [Wang, Jir-You; Wu, Po-Kuei; Chen, Paul Chih-Hsueh; Yen, Chuen-Chuan; Hung, Giun-Yi; Chen, Cheng-Fong; Hung, Shih-Chieh; Tsai, Shih-Fen; Liu, Chien-Lin; Chen, Tain-Hsiung; Chen, Wei-Ming] Taipei Vet Gen Hosp, Dept Orthopaed, Therapeut & Res Ctr Musculoskeletal Tumor, Taipei, Taiwan; [Wang, Jir-You; Hung, Shih-Chieh] Natl Yang Ming Univ, Sch Med, Inst Tradit Med, Taipei 112, Taiwan; [Wu, Po-Kuei; Chen, Cheng-Fong; Hung, Shih-Chieh; Liu, Chien-Lin; Chen, Tain-Hsiung; Chen, Wei-Ming] Natl Yang Ming Univ, Dept Surg, Taipei 112, Taiwan; [Wu, Po-Kuei; Chen, Cheng-Fong; Hung, Shih-Chieh; Liu, Chien-Lin; Chen, Tain-Hsiung; Chen, Wei-Ming] Natl Yang Ming Univ, Sch Med, Inst Clin, Taipei 112, Taiwan; [Chen, Paul Chih-Hsueh] Taipei Vet Gen Hosp, Dept Pathol & Lab Med, Taipei, Taiwan; [Yen, Chuen-Chuan] Taipei Vet Gen Hosp, Dept Med, Div Hematol & Oncol, Taipei, Taiwan; [Hung, Giun-Yi] Taipei Vet Gen Hosp, Dept Pediat, Taipei, Taiwan; [Hung, Shih-Chieh] Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan; [Hung, Shih-Chieh] Natl Yang Ming Univ, Dept Pharmacol, Taipei 112, Taiwan; [Tsai, Shih-Fen] Natl Hlth Res Inst, Div Mol & Genom Med, Zhunan, Miaoli, Taiwan	Taipei Veterans General Hospital; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; Taipei Veterans General Hospital; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Health Research Institutes - Taiwan	Chen, WM (corresponding author), Taipei Vet Gen Hosp, Dept Orthopaed, Taipei, Taiwan.	wmchen@vghtpe.gov.tw	Hung, Giun-Yi/J-4158-2014; Tsai, Shih-Feng/E-3997-2010		Taipei Veterans General Hospital [V100C-108]	Taipei Veterans General Hospital(Taipei Veterans General Hospital)	This work is supported by a grant of Taipei Veterans General Hospital (V100C-108). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ando Kosei, 2012, Sarcoma, V2012, P523432, DOI 10.1155/2012/523432; BERTSCH S, 1976, CELL TISSUE KINET, V9, P445, DOI 10.1111/j.1365-2184.1976.tb01295.x; Bjornland K, 2005, J SURG RES, V127, P151, DOI 10.1016/j.jss.2004.12.016; Broadhead Matthew L., 2011, Sarcoma, V2011, P959248, DOI 10.1155/2011/959248; Calenda Elaine, 2006, Curr Pain Headache Rep, V10, P270, DOI 10.1007/s11916-006-0031-1; Cassileth BR, 2004, J PAIN SYMPTOM MANAG, V28, P244, DOI 10.1016/j.jpainsymman.2003.12.016; Chandwani KD, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/979213; Cleton-Jansen AM, 2009, BRIT J CANCER, V101, P2064, DOI 10.1038/sj.bjc.6605482; Collinge William, 2012, Semin Oncol Nurs, V28, P45, DOI 10.1016/j.soncn.2011.11.005; Diaz NM, 2004, AM J SURG PATHOL, V28, P1641, DOI 10.1097/00000478-200412000-00014; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Ferrari C, 2004, ACTA ORTHOP SCAND, V75, P487, DOI 10.1080/00016470410001295-1; Han J, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-37; Hodgson NA, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/456897; Jane SW, 2009, J PAIN SYMPTOM MANAG, V37, P754, DOI 10.1016/j.jpainsymman.2008.04.021; Keir ST, 2011, SUPPORT CARE CANCER, V19, P711, DOI 10.1007/s00520-010-1032-5; Khanna C, 2001, CANCER RES, V61, P3750; Knox LC, 1922, ANN SURG, V75, P129, DOI 10.1097/00000658-192202000-00001; Li IH, 2010, NEUROIMAGE, V49, P1259, DOI 10.1016/j.neuroimage.2009.07.072; Liu F, 2002, HEPATOLOGY, V35, P1314, DOI 10.1053/jhep.2002.33467; Luo XJ, 2008, LAB INVEST, V88, P1264, DOI 10.1038/labinvest.2008.98; Ma KH, 2009, NEUROIMAGE, V45, P687, DOI 10.1016/j.neuroimage.2008.12.060; MARKS F, 1979, CANCER RES, V39, P4183; Mialou V, 2005, CANCER-AM CANCER SOC, V104, P1100, DOI 10.1002/cncr.21263; Park SY, 2012, J KOREAN SURG SOC, V82, P356, DOI 10.4174/jkss.2012.82.6.356; Sergi C, 2008, EXP GERONTOL, V43, P1039, DOI 10.1016/j.exger.2008.09.009; Sherman Karen J, 2005, BMC Complement Altern Med, V5, P13, DOI 10.1186/1472-6882-5-13; Snoeks TJA, 2011, BONE, V49, P1264, DOI 10.1016/j.bone.2011.09.037; Su Y, 2011, ONCOGENE, V30, P3907, DOI 10.1038/onc.2011.97; SWEETNAM R, 1982, BRIT J HOSP MED, V28, P112; Teng ZZ, 2012, ATHEROSCLEROSIS, V223, P321, DOI 10.1016/j.atherosclerosis.2012.06.015; Thurber GM, 2010, J SURG ONCOL, V102, P758, DOI 10.1002/jso.21735; Tindle HA, 2005, ALTERN THER HEALTH M, V11, P42; Tomlinson RE, 2013, BONE, V52, P212, DOI 10.1016/j.bone.2012.09.035; Turner RR, 2005, AM J SURG PATHOL, V29, P1254, DOI 10.1097/01.pas.0000173022.95099.ca; Wanchai A, 2012, NURS HEALTH SCI, V14, P339, DOI 10.1111/j.1442-2018.2012.00730.x; Witt F, 2013, TISSUE ENG A; Wu PK, 2010, J BONE JOINT SURG BR, V92B, P1580, DOI 10.1302/0301-620X.92B11.24706; Xu WT, 2009, CANCER LETT, V281, P32, DOI 10.1016/j.canlet.2009.02.022; Yu ST, 2010, CANCER RES, V70, P2585, DOI 10.1158/0008-5472.CAN-09-3841	40	12	12	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2014	9	5							e96571	10.1371/journal.pone.0096571	http://dx.doi.org/10.1371/journal.pone.0096571			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG9HB	24804772	Green Published, Green Submitted, gold			2023-01-03	WOS:000335728900072
J	Palladino, C; Briz, V; Bellon, JM; Climent, FJ; de Ory, SJ; Mellado, MJ; Navarro, ML; Ramos, JT; Taveira, N; de Jose, MI; Munoz-Fernandez, MA				Palladino, Claudia; Briz, Veronica; Maria Bellon, Jose; Climent, Francisco J.; de Ory, Santiago J.; Jose Mellado, Maria; Luisa Navarro, Maria; Ramos, Jose T.; Taveira, Nuno; Isabel de Jose, Maria; Angeles Munoz-Fernandez, Maria		CoRISpeS-Madrid Cohort Working Grp	Determinants of Highly Active Antiretroviral Therapy Duration in HIV-1-Infected Children and Adolescents in Madrid, Spain, from 1996 to 2012	PLOS ONE			English	Article							HIV-INFECTED CHILDREN; UNITED-KINGDOM; MORTALITY; REGIMEN; DURABILITY; NEVIRAPINE; LOPINAVIR; ADHERENCE; SURVIVAL; INFANTS	Objectives: To investigate the duration of sequential HAART regimens and predictors of first-line regimen discontinuation among HIV-1 vertically infected children and adolescents. Design: Multicentre survey of antiretroviral-naive patients enrolled in the HIV-Paediatric Cohor,t CoRISpeS-Madrid Cohort, Spain. Methods: Patients with a follow-up of >= 1 month spent on HAART, with available baseline CD4 count and HIV-viral load (VL) were included. Time spent on sequential HAART regimens was estimated and multivariable regression was used to identify predictors of time to first-line regimen discontinuation. Results: 104 patients were followed for a median 8 years after starting HAART among 1996-2012; baseline %CD4 was 21.5 (12.3-34.0)and viral load was 5.1 (4.6-5.6) log(10) copies/mL. Patients received a mean of 1.9 regimens. Median time on first-line HAART (n = 104) was 64.5 months; second HAART (n = 56) 69.8 months; and third HAART (n = 21) 66.5 months. Eleven (11%) patients were lost to follow-up while on first-line HAART and 54% discontinued (cumulative incidence of 16% and 38% by 1 and 3-year, respectively). The main predictor of first-line regimen discontinuation was suboptimal adherence to antiretrovirals (AHR: 2.60; 95% CI: 1.44-4.70). Conclusions: Adherence to therapy was the main determinant of the duration of the first-line HAART regimen in children. It is important to identify patients at high risk for non-adherence, such as very young children and adolescents, in provide special care and support to those patients.	[Palladino, Claudia; Taveira, Nuno] Univ Lisbon, Fac Pharm, Inst Invest Med iMed ULisboa, P-1699 Lisbon, Portugal; [Briz, Veronica; de Ory, Santiago J.; Angeles Munoz-Fernandez, Maria] Hosp Gen Univ Gregorio Maranon, Madrid, Spain; [Briz, Veronica; de Ory, Santiago J.; Angeles Munoz-Fernandez, Maria] Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain; [Briz, Veronica; de Ory, Santiago J.; Angeles Munoz-Fernandez, Maria] CIBER BBN, Networking Res Ctr Bioengn Biomat & Nanomed, Madrid, Spain; [Maria Bellon, Jose] Hosp Gen Univ Gregorio Maranon, Fdn Invest Biomed, Unidad Invest, Madrid, Spain; [Climent, Francisco J.; Isabel de Jose, Maria] Hosp Univ La Paz, Serv Infecciosas Infantil, Madrid, Spain; [Jose Mellado, Maria] Hosp Univ Carlos III, Serv Pediat, Madrid, Spain; [Luisa Navarro, Maria] Hosp Gen Univ Gregorio Maranon, Serv Pediat, Madrid, Spain; [Ramos, Jose T.] Hosp Univ Getafe, Serv Pediat, Madrid, Spain; [Taveira, Nuno] Inst Hlth Sci Egas Moniz, Ctr Interdisciplinary Invest Egas Moniz, Caparica, Portugal	Universidade de Lisboa; General University Gregorio Maranon Hospital; CIBER - Centro de Investigacion Biomedica en Red; CIBERBBN; General University Gregorio Maranon Hospital; Hospital Universitario La Paz; Hospital Carlos III; General University Gregorio Maranon Hospital; Hospital Universitario de Getafe; Instituto Superior de Ciencias da Saude Egas Moniz	de Jose, MI (corresponding author), Hosp Univ La Paz, Serv Infecciosas Infantil, Madrid, Spain.	maribeldejose@hotmail.com; mmunoz.hgugm@gmail.com	iMed.ULisboa, EEPHIV/B-4222-2014; Cano, Jose Maria Bellon/G-3061-2012; Bellon-Cano, José María/G-6120-2016; Briz, Veronica VB/T-4183-2017; Palladino, Claudia/E-2523-2014; Taveira, Nuno C/A-6252-2014	Cano, Jose Maria Bellon/0000-0002-8492-1565; Bellon-Cano, José María/0000-0002-8492-1565; Briz, Veronica VB/0000-0003-2297-5098; Palladino, Claudia/0000-0002-8148-0928; Taveira, Nuno C/0000-0003-0176-5585; Mellado Pena, Maria Jose/0000-0003-2251-9666; Munoz-Fernandez/0000-0002-0813-4500	Fondo de Investigacion de Sanidad en Espana (FIS) [PI11-00888, PS09/02029, PI13/02016]; Red Espanola de Investigacion en SIDA (RIS) [RETIC RD06/0006/0035 RD12-0017-0037, RD06/0006/0021, RD12/0017/0029, RD09/0076/00103]; "Fundacion para la Investigacion y la Prevencion del Sida en Espana" (FIPSE); Comunidad de Madrid [S-2010/BMD-2351, S-2010/BMD-2332]; PENTA; Fundacion Eugenio Rodriguez Pascual; Fundacao para a Ciencia e Tecnologia (FCT), Portugal [PTDC/SAU-FAR/115290/2009, PTDC/SAU-EPI/122400/2010]; Portuguese Fundacao para a Ciencia e Tecnologia (FCT) [SFRH/BPD/77448/2011]; Spanish Fondo de Investigacion Sanitaria (Sara Borrell) [CD09/00433]; Fundação para a Ciência e a Tecnologia [PTDC/SAU-EPI/122400/2010, PTDC/SAU-FAR/115290/2009] Funding Source: FCT	Fondo de Investigacion de Sanidad en Espana (FIS); Red Espanola de Investigacion en SIDA (RIS); "Fundacion para la Investigacion y la Prevencion del Sida en Espana" (FIPSE); Comunidad de Madrid(Comunidad de Madrid); PENTA; Fundacion Eugenio Rodriguez Pascual; Fundacao para a Ciencia e Tecnologia (FCT), Portugal(Portuguese Foundation for Science and Technology); Portuguese Fundacao para a Ciencia e Tecnologia (FCT)(Portuguese Foundation for Science and Technology); Spanish Fondo de Investigacion Sanitaria (Sara Borrell); Fundação para a Ciência e a Tecnologia	This work was supported by grants provided by the Fondo de Investigacion de Sanidad en Espana (FIS) [grant numbers PI11-00888, PS09/02029, and PI13/02016], Red Espanola de Investigacion en SIDA (RIS) [grant numbers RETIC RD06/0006/0035 RD12-0017-0037; RD06/0006/0021, RD12/0017/0029 and RD09/0076/00103], "Fundacion para la Investigacion y la Prevencion del Sida en Espana" (FIPSE), Comunidad de Madrid [grant numbers, S-2010/BMD-2351, S-2010/BMD-2332], PENTA and Fundacion Eugenio Rodriguez Pascual and grants PTDC/SAU-FAR/115290/2009 and PTDC/SAU-EPI/122400/2010 from Fundacao para a Ciencia e Tecnologia (FCT) (http://www.fct.pt), Portugal. Claudia Palladino is supported by the Portuguese Fundacao para a Ciencia e Tecnologia (FCT) (SFRH/BPD/77448/2011). Veronica Briz is supported by the Spanish Fondo de Investigacion Sanitaria (Sara Borrell CD09/00433. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abgrall S, 2012, AIDS; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], 1994, Morbidity and Mortality Weekly Report, V43, P1; Chen RY, 2003, CLIN INFECT DIS, V37, P714, DOI 10.1086/377271; Climent FJ, 2008, AIDS 2008 17 INT AID; de Martino M, 2000, JAMA-J AM MED ASSOC, V284, P190, DOI 10.1001/jama.284.2.190; Donegan K, 2013, PEDIATR INFECT DIS J, V32, P45, DOI 10.1097/INF.0b013e31827842c9; European Centre for Disease Prevention and Control/WHO Regional Office for Europe, 2012, HIV AIDS SURV EUR 20; European Medicines Agency, 2011, EMA336112011; Gafni RI, 2006, PEDIATRICS, V118, pE711, DOI 10.1542/peds.2005-2525; Garcia-Merino I, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-27; Gortmaker SL, 2001, NEW ENGL J MED, V345, P1522, DOI 10.1056/NEJMoa011157; Granados JMS, 2003, PEDIATR INFECT DIS J, V22, P863, DOI 10.1097/01.inf.0000091282.70253.5f; de Jose MI, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-2; Judd A, 2007, CLIN INFECT DIS, V45, P918, DOI 10.1086/521167; Judd A, 2011, AIDS, V25, P2279, DOI 10.1097/QAD.0b013e32834d614c; Kim JY, 2009, PHARMACOEPIDEM DR S, V18, P589, DOI 10.1002/pds.1755; La Rovere, 2004, AIDS, V18, P1443, DOI 10.1097/01.aids.0000131334.38172.01; McConnell MS, 2005, JAIDS-J ACQ IMM DEF, V38, P488, DOI 10.1097/01.qai.0000134744.72079.cc; Menson EN, 2006, BMJ-BRIT MED J, V332, P1183, DOI 10.1136/bmj.332.7551.1183; Ministerio de Sanidad Politica Social e Igualdad, 2012, VIG EP VIH SIDA ESP; O'Brien ME, 2003, JAIDS-J ACQ IMM DEF, V34, P407, DOI 10.1097/00126334-200312010-00008; Palella FJ, 2002, AIDS, V16, P1617, DOI 10.1097/00002030-200208160-00007; Palladino C, 2009, AIDS RES HUM RETROV, V25, P1091, DOI 10.1089/aid.2009.0070; Palumbo P, 2010, NEW ENGL J MED, V363, P1510, DOI 10.1056/NEJMoa1000931; Panel de expertos del Colaborativo Espanol para la Infeccion VIH Pediatrica (CEVIHP) Sociedad Espanola de Infectologia Pediatrica (SEIP) de la Asociacion Espanola de Pediatria (AEP) y Secretaria del Plan nacional del Sida, 2012, DOC CONS CEVIHP SEIP; Patel K, 2008, CLIN INFECT DIS, V46, P507, DOI 10.1086/526524; Persaud D, 2007, J INFECT DIS, V195, P1402, DOI 10.1086/513871; Purdy JB, 2008, J ASSOC NURSE AIDS C, V19, P158, DOI 10.1016/j.jana.2007.08.003; Puthanakit T, 2007, CLIN INFECT DIS, V44, P599, DOI 10.1086/510489; Reddi Anand, 2007, BMC Pediatr, V7, P13, DOI 10.1186/1471-2431-7-13; Resino S, 2006, CLIN INFECT DIS, V43, P243, DOI 10.1086/505213; Ribeiro FA, 2012, BRAZ J INFECT DIS, V16, P27, DOI 10.1590/S1413-86702012000100005; Ruhinda EN, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-170; Van Dyke RB, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.4.e61; Violari A, 2012, NEW ENGL J MED, V366, P2380, DOI 10.1056/NEJMoa1113249	37	7	7	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2014	9	5							e96307	10.1371/journal.pone.0096307	http://dx.doi.org/10.1371/journal.pone.0096307			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG6EE	24788034	gold, Green Published			2023-01-03	WOS:000335510600092
J	Xu, X; Yonkers, KA; Ruger, JP				Xu, Xiao; Yonkers, Kimberly A.; Ruger, Jennifer P.			Costs of a Motivational Enhancement Therapy Coupled with Cognitive Behavioral Therapy versus Brief Advice for Pregnant Substance Users	PLOS ONE			English	Article							ABUSE TREATMENT; HIV PREVENTION; BIRTH-WEIGHT; WOMEN; ALCOHOL; ADDICTION; DRINKING; DRUGS; ERA	Objectives: To determine and compare costs of a nurse-administered behavioral intervention for pregnant substance users that integrated motivational enhancement therapy with cognitive behavioral therapy (MET-CBT) to brief advice (BA) administered by an obstetrical provider. Both interventions were provided concurrent with prenatal care. Methods: We conducted a micro-costing study that prospectively collected detailed resource utilization and unit cost data for each of the two intervention arms (MET-CBT and BA) within the context of a randomized controlled trial. A three-step approach for identifying, measuring and valuing resource utilization was used. All cost estimates were inflation adjusted to 2011 U.S. dollars. Results: A total of 82 participants received the MET-CBT intervention and 86 participants received BA. From the societal perspective, the total cost (including participants' time cost) of the MET-CBT intervention was $120,483 or $1,469 per participant. In contrast, the total cost of the BA intervention was $27,199 or $316 per participant. Personnel costs (nurse therapists and obstetric providers) for delivering the intervention sessions and supervising the program composed the largest share of the MET-CBT intervention costs. Program set up costs, especially intervention material design and training costs, also contributed substantially to the overall cost. Conclusions: Implementation of an MET-CBT program to promote drug abstinence in pregnant women is associated with modest costs. Future cost effectiveness and cost benefit analyses integrating costs with outcomes and benefits data will enable a more comprehensive understanding of the intervention in improving the care of substance abusing pregnant women.	[Xu, Xiao; Yonkers, Kimberly A.] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA; [Yonkers, Kimberly A.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA; [Ruger, Jennifer P.] Yale Univ, Dept Hlth Policy & Management, New Haven, CT USA; [Ruger, Jennifer P.] Yale Univ, Sch Med, Dept Publ Hlth, New Haven, CT 06510 USA	Yale University; Yale University; Yale University; Yale University	Xu, X (corresponding author), Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA.	xiao.xu@yale.edu			National Institutes of Health (National Institute on Drug Abuse) [R01DA025555, R01DA019135]; Patrick and Catherine Weldon Donaghue Medical Research Foundation; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA019135, R01DA025555, R01DA027194, R21DA029914] Funding Source: NIH RePORTER	National Institutes of Health (National Institute on Drug Abuse)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); Patrick and Catherine Weldon Donaghue Medical Research Foundation; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This research was supported by grants from the National Institutes of Health (National Institute on Drug Abuse grants R01DA025555 and R01DA019135). JPR was also supported by the Patrick and Catherine Weldon Donaghue Medical Research Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], NSDUH SER H; Barnett PG, 2009, MED CARE, V47, pS82, DOI 10.1097/MLR.0b013e31819e1f3f; Behnke M, 2013, PEDIATRICS, V131, pE1009, DOI 10.1542/peds.2012-3931; Burstyn I, 2010, CAN J PUBLIC HEALTH, V101, P149, DOI 10.1007/BF03404362; Chang G, 1999, J STUD ALCOHOL, V60, P306, DOI 10.15288/jsa.1999.60.306; Cowell AJ, 2012, J STUD ALCOHOL DRUGS, V73, P226, DOI 10.15288/jsad.2012.73.226; Daley M, 2005, SUBST USE MISUSE, V40, P375, DOI 10.1081/JA-200030798; Daley M, 2000, J SUBST ABUSE TREAT, V19, P445, DOI 10.1016/S0740-5472(00)00138-0; Daley M, 2001, J PSYCHOACTIVE DRUGS, V33, P57, DOI 10.1080/02791072.2001.10400469; DeAntonio DA, 2010, MON LABOR REV, V133, P41; Dunlap LJ, 2010, MED CARE, V48, P306, DOI 10.1097/MLR.0b013e3181ca3d40; French Michael T, 2002, Subst Abus, V23, P31, DOI 10.1023/A:1013630710518; Frick KD, 2009, MED CARE, V47, pS76, DOI 10.1097/MLR.0b013e31819bc064; Gorsky RD, 1996, PUBLIC HEALTH REP, V111, P115; Grivell R, 2009, BEST PRACT RES CL OB, V23, P795, DOI 10.1016/j.bpobgyn.2009.06.004; Heerey Adrienne, 2002, Expert Rev Pharmacoecon Outcomes Res, V2, P29, DOI 10.1586/14737167.2.1.29; Internal Review Service, 2006, IRS ANN 2007 STAND M; Internal Review Service, 2008, IRS ANN 2009 STAND M; Internal Review Service, 2007, IRS ANN 2008 STAND M; Internal Review Service, 2009, IRS ANN 2010 STAND M; Internal Review Service IRS, INT REV SERV IRS ANN; Jansson LM, 1996, J SUBST ABUSE TREAT, V13, P321, DOI 10.1016/S0740-5472(96)00070-0; Kilmer B, 2011, J STUD ALCOHOL DRUGS, V72, P823, DOI 10.15288/jsad.2011.72.823; Neighbors CJ, 2010, J STUD ALCOHOL DRUGS, V71, P384, DOI 10.15288/jsad.2010.71.384; Office of National Drug Control Policy, 2004, EC COSTS DRUG AB US; PHIBBS CS, 1991, JAMA-J AM MED ASSOC, V266, P1521, DOI 10.1001/jama.266.11.1521; Rayburn WF, 2007, CLIN PERINATOL, V34, P559, DOI 10.1016/j.clp.2007.09.001; Rodriguez EM, 1996, AIDS, V10, P273, DOI 10.1097/00002030-199603000-00006; Ruger JP, 2012, HEALTH SERV RES, V47, P865, DOI 10.1111/j.1475-6773.2011.01335.x; Ruger JP, 2012, ADDICT BEHAV, V37, P1, DOI 10.1016/j.addbeh.2011.07.042; Ruger JP, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-46; Ruger JP, 2010, PUBLIC HEALTH REP, V125, P83, DOI 10.1177/00333549101250S111; Russell M, 1996, AM J PUBLIC HEALTH, V86, P1435, DOI 10.2105/AJPH.86.10.1435; Schulte J, 2007, PEDIATRICS, V119, pE900, DOI 10.1542/peds.2006-1123; Svikis DS, 1997, DRUG ALCOHOL DEPEN, V45, P105, DOI 10.1016/S0376-8716(97)01352-5; Taillac Cosette, 2007, Perm J, V11, P5; Tan SS, 2009, EUR J HEALTH ECON, V10, P39, DOI 10.1007/s10198-008-0101-x; U.S. Bureau of Labor Statistics, OV BLS WAG DAT AR OC; U. S. Bureau of Labor Statistics, 2012, CONS PRIC IND; U.S. Census Bureau Center for Economic Studies, 2006, Q WORKF IND 2006 201; Van Dyke RB, 2011, LIFE SCI, V88, P922, DOI 10.1016/j.lfs.2011.03.006; Weinstein MC., 1996, COST EFFECTIVENESS H; Yonkers KA, 2012, GEN HOSP PSYCHIAT, V34, P439, DOI 10.1016/j.genhosppsych.2012.06.002; Yonkers KA, 2010, OBSTET GYNECOL, V116, P827, DOI 10.1097/AOG.0b013e3181ed8290; Yonkers KA, 2009, ARCH WOMEN MENT HLTH, V12, P221, DOI 10.1007/s00737-009-0069-2	45	5	5	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2014	9	4							e95264	10.1371/journal.pone.0095264	http://dx.doi.org/10.1371/journal.pone.0095264			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AG3EI	24760017	Green Published, gold			2023-01-03	WOS:000335298200043
J	Melaku, YA; Zeleke, EG				Melaku, Yohannes Adama; Zeleke, Ejigu Gebeye			Contraceptive Utilization and Associated Factors among HIV Positive Women on Chronic Follow Up Care in Tigray Region, Northern Ethiopia: A Cross Sectional Study	PLOS ONE			English	Article							TRANSMISSION; MEN	Background: In sub-Sahara Africa, more than 60% of all new HIV infections are occurring in women, infants and young children. Maternal to child transmission is responsible for 90% of childhood HIV infection. Preventing unwanted pregnancy among HIV positive women is imperative to reduce maternal and infant morbidity and mortality. Methods: A cross-sectional survey was conducted among 964 HIV positive women in selected 12 health centers of Tigray region. In this paper, analysis was restricted only for 847 women who were sexually active and non-pregnant. In each health center the number of study participants was allocated proportionally to the load of HIV positive women in chronic care clinics. The data were entered into EpiData version 3.1, and cleaned and analyzed using Stata version 11.1. Descriptive summary of data and logistic regression were used to identify possible predictors using odds ratio with 95% confidence interval and P-value of 0.05. Findings: Three hundred ninety four (46.5%) of all HIV positive women had intension to have more children. Three hundred seventy five (44.3%) were using contraceptive methods at time of survey. Injectable (70.7%) and male condom (47.6%) were most commonly used type of contraceptives. In the multivariable analysis, women who were urban dwellers (AOR = 2.55; 95% CI: 1.27, 5.02), completed primary education (AOR = 2.27; 95% CI: 1.12, 2.86) and those openly discussed about contraceptive methods with their husbands or sexual partners (AOR = 6.3; 95% CI: 3.42, 11.76) were more likely to use contraceptive. Women who have one or more living children were also more likely to use contraceptive compared with women with no child. Conclusion: Less than half of women used contraceptive methods. The use of condoms could impact unintended pregnancies and reduced risks of vertical and sexual transmission. Efforts to increase contraceptive utilization focusing on the barrier methods should be strengthen in HIV/AIDS chronic care units.	[Melaku, Yohannes Adama] Mekelle Univ, Coll Hlth Sci, Dept Publ Hlth, Mekelle, Ethiopia; [Zeleke, Ejigu Gebeye] Univ Gondar, Inst Publ Hlth, Dept Epidemiol & Biostat, Gondar, Ethiopia	Mekelle University; University of Gondar	Melaku, YA (corresponding author), Mekelle Univ, Coll Hlth Sci, Dept Publ Hlth, Mekelle, Ethiopia.	adamayohannes@gmail.com	Melaku, Yohannes Adama/S-2451-2019	Melaku, Yohannes Adama/0000-0002-3051-7313	United States Agency for International Development (USAID) through Management Sciences for Health (MSH) [AID-663-A-11-00006]	United States Agency for International Development (USAID) through Management Sciences for Health (MSH)(United States Agency for International Development (USAID))	This study is made possible by the generous support of the United States Agency for International Development (USAID) through Management Sciences for Health (MSH) under cooperative agreement No. AID-663-A-11-00006. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2011, FACT SHEET GLOB AIDS; Berhane Y, 2013, ISRN AIDS, V10; Beyeza-Kashesya J, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-144; Beyeza-Kashesya J, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-247; Carpenter LM, 1999, AIDS, V13, P1083, DOI 10.1097/00002030-199906180-00012; Central Statistical Agency,, 2012, ETH DEM HLTH SURV 20; Central Statistical Agency [Ethiopia], 2007, ETH CENS REP 2007; Chen JL, 2001, FAM PLANN PERSPECT, V33, P144, DOI 10.2307/2673717; Crede S, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-197; Dube ALN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051861; Ethiopia HIV/AIDS Prevention & Control Office (HAPCO) and Global HIV/AIDS Monitoring and Evaluation Team (GAMET), 2012, HIV AIDS ETH EP SYNT; Ethiopian Health and Nutrition Research Institute (EHNRI), 2011, ROUND REP 2009 ANT C; Harries J, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-282; Hladik W, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007691; Kaida A, 2008, AIDS CARE, V20, P21, DOI 10.1080/09540120701426540; Kaida A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013868; King R, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-530; Kipp W, 2011, REPROD HEALTH, V8, DOI 10.1186/1742-4755-8-27; Kirshenbaum SB, 2004, PERSPECT SEX REPRO H, V36, P106, DOI 10.1111/j.1931-2393.2004.tb00198.x; Loutfy MR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007925; Mmbaga EJ, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-86; Nakayiwa S, 2006, AIDS BEHAV, V10, pS95, DOI 10.1007/s10461-006-9126-2; Nattabi B, 2011, CONFLICT HLTH, V5; Obare F, 2012, BMC WOMENS HEALTH, V12, DOI 10.1186/1472-6874-12-34; Oraka CO, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-S1-P78; Pagano M., 2000, PRINCIPLES BIOSTATIS, V2nd; Paiva V, 2003, REPROD HEALTH MATTER, V11, P91, DOI 10.1016/S0968-8080(03)02293-6; Stuart GS, 2009, CONTRACEPTION, V80, P412, DOI 10.1016/j.contraception.2009.03.014; The United Nations' Division for the Advancement of Women, 1979, CONV EL ALL FORMS DI; Tigray Regional Health Bureau, 2012, TIGR HLTH PROF 2010; UN, 2007, WORLD CONTR US; UNAIDS, 2011, AIDS EP UPD UN NAT J; USAID Tigray Health Bureau, 2012, TIGR REG STAT SYNTH, P3; Van Ness PH, 2007, 10531 SUGI 31, P1; Wanyenze RK, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-35; Wanyenze RK, 2013, BMC PUBLIC HLTH, V13; Warren EC, 2013, BMC PREGNANCY CHILDB, V13; WHO, 2003, WHO M 20 22 MARCH 20; Wilcher R, 2009, AIDS, V23, pS1, DOI 10.1097/01.aids.0000363772.45635.35	39	27	27	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2014	9	4							e94682	10.1371/journal.pone.0094682	http://dx.doi.org/10.1371/journal.pone.0094682			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG3IK	24743241	Green Submitted, gold, Green Published			2023-01-03	WOS:000335309100040
J	Patterson, KG; Pittaro, JLD; Bastedo, PS; Hess, DA; Haeryfar, SMM; McCormick, JK				Patterson, Kelcey G.; Pittaro, Jennifer L. Dixon; Bastedo, Peter S.; Hess, David A.; Haeryfar, S. M. Mansour; McCormick, John K.			Control of Established Colon Cancer Xenografts Using a Novel Humanized Single Chain Antibody-Streptococcal Superantigen Fusion Protein Targeting the 5T4 Oncofetal Antigen	PLOS ONE			English	Article							TOXIC-SHOCK-SYNDROME; PYROGENIC EXOTOXIN-C; STAPHYLOCOCCAL-ENTEROTOXIN-A; RECEPTOR BETA-CHAIN; CRYSTAL-STRUCTURE; PHASE-I; NAPTUMOMAB ESTAFENATOX; T-CELLS; 3-DIMENSIONAL STRUCTURE; BACTERIAL SUPERANTIGEN	Superantigens (SAgs) are microbial toxins that cross-link T cell receptors with major histocompatibility class II (MHC-II) molecules leading to the activation of large numbers of T cells. Herein, we describe the development and preclinical testing of a novel tumor-targeted SAg (TTS) therapeutic built using the streptococcal pyrogenic exotoxin C (SpeC) SAg and targeting cancer cells expressing the 5T4 tumor-associated antigen (TAA). To inhibit potentially harmful widespread immune cell activation, a SpeC mutation within the high-affinity MHC-II binding interface was generated (SpeC(D203A)) that demonstrated a pronounced reduction in mitogenic activity, yet this mutant could still induce immune cell-mediated cancer cell death in vitro. To target 5T4(+) cancer cells, we engineered a humanized single chain variable fragment (scFv) antibody to recognize 5T4 (scFv5T4). Specific targeting of scFv5T4 was verified. SpeC(D203A) fused to scFv5T4 maintained the ability to activate and induce immune cell-mediated cytotoxicity of colorectal cancer cells. Using a xenograft model of established human colon cancer, we demonstrated that the SpeC-based TTS was able to control the growth and spread of large tumors in vivo. This required both TAA targeting by scFv5T4 and functional SAg activity. These studies lay the foundation for the development of streptococcal SAgs as 'next-generation' TTSs for cancer immunotherapy.	[Patterson, Kelcey G.; Pittaro, Jennifer L. Dixon; Bastedo, Peter S.; Haeryfar, S. M. Mansour; McCormick, John K.] Univ Western Ontario, Dept Microbiol & Immunol, London, ON, Canada; [Haeryfar, S. M. Mansour; McCormick, John K.] Univ Western Ontario, Ctr Human Immunol, London, ON, Canada; [Hess, David A.] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada; [Hess, David A.] Robarts Res Inst, Vasc Biol Res Grp, London, ON N6A 5C1, Canada; [Haeryfar, S. M. Mansour; McCormick, John K.] Lawson Hlth Res Inst, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	McCormick, JK (corresponding author), Univ Western Ontario, Dept Microbiol & Immunol, London, ON, Canada.	john.mccormick@uwo.ca	Hess, David A/M-2828-2013; McCormick, John/E-4232-2015	McCormick, John/0000-0003-3742-7289	Canadian Institutes of Health Research (CIHR) [MOP-64176]; CIHR	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); CIHR(Canadian Institutes of Health Research (CIHR))	This work was supported by Canadian Institutes of Health Research (CIHR) operating grant to JKM (MOP-64176). SMMH holds a Canada Research Chair in Viral Immunity and Pathogenesis and JKM was the recipient of a New Investigator Award from the CIHR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABRAHMSEN L, 1995, EMBO J, V14, P2978, DOI 10.1002/j.1460-2075.1995.tb07300.x; Alpaugh RK, 1998, CLIN CANCER RES, V4, P1903; Ami K, 2002, CLIN EXP IMMUNOL, V128, P453, DOI 10.1046/j.1365-2249.2002.01854.x; Andersen PS, 2002, BIOCHEMISTRY-US, V41, P5177, DOI 10.1021/bi0200209; Arden Bernhard, 1995, Immunogenetics, V42, P455; Arstila TP, 1999, SCIENCE, V286, P958, DOI 10.1126/science.286.5441.958; Basma H, 1999, INFECT IMMUN, V67, P1871; Borghaei H, 2009, J CLIN ONCOL, V27, P4116, DOI 10.1200/JCO.2008.20.2515; Brouillard JNP, 2007, J MOL BIOL, V367, P925, DOI 10.1016/j.jmb.2007.01.024; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Carreno BM, 2009, CLIN CANCER RES, V15, P3277, DOI 10.1158/1078-0432.CCR-08-2502; CHEN TR, 1987, CANCER GENET CYTOGEN, V27, P125, DOI 10.1016/0165-4608(87)90267-6; Cheng JD, 2004, J CLIN ONCOL, V22, P602, DOI 10.1200/JCO.2004.12.034; Dinges MM, 2000, CLIN MICROBIOL REV, V13, P16, DOI 10.1128/CMR.13.1.16-34.2000; DOHLSTEN M, 1994, P NATL ACAD SCI USA, V91, P8945, DOI 10.1073/pnas.91.19.8945; DOHLSTEN M, 1990, IMMUNOLOGY, V71, P96; Eisen T, 2014, CURR ONCOL REP, V16, DOI 10.1007/s11912-013-0370-0; Erlandsson E, 2003, J MOL BIOL, V333, P893, DOI 10.1016/j.jmb.2003.09.009; Fields BA, 1996, NATURE, V384, P188, DOI 10.1038/384188a0; Fleischer B, 1996, INFECT IMMUN, V64, P987, DOI 10.1128/IAI.64.3.987-994.1996; Forsberg G, 2001, BRIT J CANCER, V85, P129, DOI 10.1054/bjoc.2001.1891; Forsberg G, 2010, J IMMUNOTHER, V33, P492, DOI 10.1097/CJI.0b013e3181d75820; Giantonio BJ, 1997, J CLIN ONCOL, V15, P1994, DOI 10.1200/JCO.1997.15.5.1994; Hayworth JL, 2012, IMMUNOL CELL BIOL, V90, P699, DOI 10.1038/icb.2011.90; Hedlund G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079082; HERRMANN T, 1992, EUR J IMMUNOL, V22, P1935, DOI 10.1002/eji.1830220739; HOLE N, 1988, BRIT J CANCER, V57, P239, DOI 10.1038/bjc.1988.53; Holtfreter S, 2006, J INFECT DIS, V193, P1275, DOI 10.1086/503048; Holtfreter S, 2004, INFECT IMMUN, V72, P4061, DOI 10.1128/IAI.72.7.4061-4071.2004; Hu DL, 2007, CELL MICROBIOL, V9, P2267, DOI 10.1111/j.1462-5822.2007.00957.x; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Ishikawa F, 2005, BLOOD, V106, P1565, DOI 10.1182/blood-2005-02-0516; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kalos M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002842; Kapust RB, 2001, PROTEIN ENG, V14, P993, DOI 10.1093/protein/14.12.993; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Kasper KJ, 2008, J IMMUNOL, V181, P3384, DOI 10.4049/jimmunol.181.5.3384; KAWABE Y, 1990, J EXP MED, V172, P1065, DOI 10.1084/jem.172.4.1065; KIM JS, 1994, SCIENCE, V266, P1870, DOI 10.1126/science.7997880; Kochenderfer JN, 2012, BLOOD, V119, P2709, DOI 10.1182/blood-2011-10-384388; Kochenderfer JN, 2010, BLOOD, V116, P4099, DOI 10.1182/blood-2010-04-281931; Li HM, 1998, IMMUNITY, V9, P807, DOI 10.1016/S1074-7613(00)80646-9; Li PL, 1997, J EXP MED, V186, P375, DOI 10.1084/jem.186.3.375; Li YL, 2001, IMMUNITY, V14, P93, DOI 10.1016/S1074-7613(01)00092-9; McCormick JK, 2000, J IMMUNOL, V165, P2306, DOI 10.4049/jimmunol.165.4.2306; McCormick JK, 2001, ANNU REV MICROBIOL, V55, P77, DOI 10.1146/annurev.micro.55.1.77; Morita CT, 2001, IMMUNITY, V14, P331, DOI 10.1016/S1074-7613(01)00113-3; Nielsen SE, 2000, J IMMUNOTHER, V23, P146, DOI 10.1097/00002371-200001000-00017; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Petersson K, 2001, EMBO J, V20, P3306, DOI 10.1093/emboj/20.13.3306; Porter DL, 2011, NEW ENGL J MED, V365, P725, DOI 10.1056/NEJMoa1103849; Rahman AKMNU, 2006, J IMMUNOL, V177, P8595, DOI 10.4049/jimmunol.177.12.8595; Rahman AKMNU, 2011, J BIOL CHEM, V286, P4871, DOI 10.1074/jbc.M110.189068; Rosendahl A, 1998, INT J CANCER, V76, P274, DOI 10.1002/(SICI)1097-0215(19980413)76:2<274::AID-IJC16>3.0.CO;2-C; Roussel A, 1997, NAT STRUCT BIOL, V4, P635, DOI 10.1038/nsb0897-635; Sambrook J., 2001, MOL CLONING LAB MANU, V3; Schlievert PM, 2000, INFECT IMMUN, V68, P3630, DOI 10.1128/IAI.68.6.3630-3634.2000; Shaw DM, 2007, BRIT J CANCER, V96, P567, DOI 10.1038/sj.bjc.6603567; Shaw DM, 2000, BBA-GEN SUBJECTS, V1524, P238, DOI 10.1016/S0304-4165(00)00165-3; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; SOUTHALL PJ, 1990, BRIT J CANCER, V61, P89, DOI 10.1038/bjc.1990.20; STARZYNSKA T, 1994, BRIT J CANCER, V69, P899, DOI 10.1038/bjc.1994.173; Sundberg EJ, 2002, STRUCTURE, V10, P687, DOI 10.1016/S0969-2126(02)00759-1; SUNDSTEDT A, 1995, J IMMUNOL, V154, P6306; Sundstedt A, 2008, INT IMMUNOPHARMACOL, V8, P442, DOI 10.1016/j.intimp.2007.11.006; Sundstedt A, 2012, J IMMUNOTHER, V35, P344, DOI 10.1097/CJI.0b013e318253ec25; Swann PG, 2008, CURR OPIN IMMUNOL, V20, P493, DOI 10.1016/j.coi.2008.05.013; Terman DS, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00038; Tripp TJ, 2003, INFECT IMMUN, V71, P1548, DOI 10.1128/IAI.71.3.1548-1550.2003; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; Vesely MD, 2013, ANN NY ACAD SCI, V1284, P1, DOI 10.1111/nyas.12105; WEI S, 1994, IMMUNOGENETICS, V40, P27, DOI 10.1007/BF00163961; Xu SX, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00052	74	6	6	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2014	9	4							e95200	10.1371/journal.pone.0095200	http://dx.doi.org/10.1371/journal.pone.0095200			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI5PW	24736661	gold, Green Published, Green Submitted			2023-01-03	WOS:000336922600154
J	Liao, JC; Ho, CH; Liang, FW; Wang, JJ; Lin, KC; Chio, CC; Kuo, JR				Liao, Jen-Chieh; Ho, Chung-Han; Liang, Fu-Wen; Wang, Jhi-Joung; Lin, Kao-Chang; Chio, Chung-Ching; Kuo, Jinn-Rung			One-Year Mortality Associations in Hemodialysis Patients after Traumatic Brain Injury-An Eight-Year Population-Based Study	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; STAGE RENAL-DISEASE; LONG-TERM SURVIVAL; REPLACEMENT THERAPY; PROLONGED STAY; RESOURCE USE; IMPACT; DIALYSIS; OUTCOMES; RISK	Purpose: This study aimed to investigate the one-year mortality associations in hemodialysis patients who underwent neurosurgical intervention after traumatic brain injury (TBI) using a nationwide database in Taiwan. Materials and Methods: An age-and gender-matched longitudinal cohort study of 4416 subjects, 1104 TBI patients with end-stage renal disease (ESRD) and 3312 TBI patients without ESRD, was conducted using the National Health Insurance Research Database in Taiwan between January 2000 and December 2007. The demographic characteristics, length of stay (LOS), length of ICU stay, length of ventilation (LOV), and tracheostomy were collected and analyzed. The co-morbidities of hypertension (HTN), diabetes mellitus (DM), myocardial infarction (MI), stroke, and heart failure (HF) were also evaluated. Results: TBI patients with ESRD presented a shorter LOS, a longer length of ICU stay and LOV, and a higher percentage of comorbidities compared with those without ESRD. TBI patients with ESRD displayed a stable trend of one-year mortality rate, 75.82% to 76.79%, from 2000-2007. For TBI patients with ESRD, the median survival time was 0.86 months, and preexisting stroke was a significant risk factor of mortality (HR: 1.29, 95% C.I.: 1.08-1.55). Pre-existing DM (HR: 1.35, 95% C.I.: 1.12-1.63) and MI (HR: 1.61, 95% C.I.: 1.07-2.42) effect on the mortality in ESRD patients who underwent TBI surgical intervention in the younger (age < 65) and older (age >= 65) population, respectively. In addition, the length of ICU stay and tracheostomy may provide important information to predict the mortality risk. Conclusions: This is the first report indicating an increased risk of one-year mortality among TBI patients with a pre-existing ERSD insult. Comorbidities were more common in TBI patients with ESRD. Physicians should pay more attention to TBI patients with ESRD based on the status of age, comorbidities, length of ICU stay, and tracheostomy to improve their survival.	[Liao, Jen-Chieh; Chio, Chung-Ching; Kuo, Jinn-Rung] Chi Mei Med Ctr, Dept Neurosurg, Tainan, Taiwan; [Ho, Chung-Han; Wang, Jhi-Joung; Lin, Kao-Chang; Kuo, Jinn-Rung] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan; [Liang, Fu-Wen] Natl Cheng Kung Univ, Coll Med, Inst Publ Hlth, Tainan 70101, Taiwan; [Lin, Kao-Chang; Kuo, Jinn-Rung] Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan; [Ho, Chung-Han] Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm, Tainan, Taiwan	Chi Mei Hospital; Chi Mei Hospital; National Cheng Kung University; Southern Taiwan University of Science & Technology; Chia Nan University of Pharmacy & Science	Kuo, JR (corresponding author), Chi Mei Med Ctr, Dept Neurosurg, Tainan, Taiwan.	kuojinnrung@gmail.com		Ho, Chung-Han/0000-0001-5925-8477; Liang, Fu-Wen/0000-0002-3396-037X				Arabi Y, 2002, INT J QUAL HEALTH C, V14, P403, DOI 10.1093/intqhc/14.5.403; Bagshaw SM, 2006, AM J KIDNEY DIS, V48, P402, DOI 10.1053/j.ajkd.2006.06.002; Bell M, 2008, CRIT CARE MED, V36, P2773, DOI 10.1097/CCM.0b013e318187815a; Chae JW, 2011, NEPHRON CLIN PRACT, V117, pC379, DOI 10.1159/000321525; Chan M, 2013, CRIT CARE RES PRACT, V2013, DOI 10.1155/2013/715807; Chapman RJ, 2009, CRIT CARE, V13, DOI 10.1186/cc7867; Chen YC, 2011, SCIENTOMETRICS, V86, P365, DOI 10.1007/s11192-010-0289-2; Chien CC, 2012, AM J HYPERTENS, V25, P900, DOI 10.1038/ajh.2012.60; Chiu WT, 1997, NEUROL RES, V19, P261, DOI 10.1080/01616412.1997.11740811; Collins Allan J, 2012, Am J Kidney Dis, V59, pe1, DOI 10.1053/j.ajkd.2011.11.015; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Davenport A, 2001, AM J KIDNEY DIS, V37, P457, DOI 10.1053/ajkd.2001.22068; Dhanani J, 2013, J THORAC CARDIOV SUR, V146, P90, DOI 10.1016/j.jtcvs.2012.06.037; Freeman BD, 2005, CRIT CARE MED, V33, P2513, DOI 10.1097/01.CCM.0000186369.91799.44; Gale SC, 2007, AM SURGEON, V73, P454; Gogbashian A, 2004, EUR J CARDIO-THORAC, V25, P695, DOI 10.1016/j.ejcts.2004.02.022; Hamilton MA, 2011, ANESTH ANALG, V112, P1392, DOI 10.1213/ANE.0b013e3181eeaae5; Heyland DK, 1998, CHEST, V114, P192, DOI 10.1378/chest.114.1.192; Higgins TL, 2003, CRIT CARE MED, V31, P45, DOI 10.1097/00003246-200301000-00007; Hoffmann F, 2011, NEPHROL DIAL TRANSPL, V26, P1634, DOI 10.1093/ndt/gfq609; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; HWANG SJ, 2000, ACTA NEPHROL, V14, P139; Insurance BoNH, 2002, NAT HLTH INS ANN STA; Iseki K, 2000, NEPHROL DIAL TRANSPL, V15, P1808, DOI 10.1093/ndt/15.11.1808; Iseki K, 1996, KIDNEY INT, V50, P1672, DOI 10.1038/ki.1996.484; Kawamura M, 1998, AM J KIDNEY DIS, V31, P991, DOI 10.1053/ajkd.1998.v31.pm9631844; Kuo HW, 2007, AM J KIDNEY DIS, V49, P46, DOI 10.1053/j.ajkd.2006.10.007; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Laupland KB, 2006, CHEST, V129, P954, DOI 10.1378/chest.129.4.954; Liu C.Y., 2006, J HEALTH MANAG, V4, P1; Lok CE, 2004, NEPHROL DIAL TRANSPL, V19, P3098, DOI 10.1093/ndt/gfh540; McIntyre A, 2013, BRAIN INJURY, V27, P31, DOI 10.3109/02699052.2012.700086; Miller RS, 2000, J TRAUMA, V48, P229, DOI 10.1097/00005373-200002000-00006; Murakami M, 2004, NEUROL MED-CHIR, V44, P225, DOI 10.2176/nmc.44.225; PLUMMER AL, 1989, CHEST, V96, P178, DOI 10.1378/chest.96.1.178; Prevention CfDCa, 2010, GET STATS TRAUM BRAI; Rhodes A, 2011, INTENS CARE MED, V37, P1466, DOI 10.1007/s00134-011-2299-9; Rothen HU, 2007, INTENS CARE MED, V33, P1329, DOI 10.1007/s00134-007-0690-3; Rumbak MJ, 2004, CRIT CARE MED, V32, P1689, DOI 10.1097/01.CCM.0000134835.05161.B6; Schirmer-Mikalsen K, 2013, ACTA ANAESTH SCAND, V57, P46, DOI 10.1111/j.1399-6576.2012.02785.x; Sood MM, 2011, NEPHROL DIAL TRANSPL, V26, P2965, DOI 10.1093/ndt/gfq835; Strijack B, 2009, J AM SOC NEPHROL, V20, P2441, DOI 10.1681/ASN.2009040366; *SYST USRD, 2005, USRDS 2005 ANN DAT R; System URD, 1998, USRDS 1998 ANN DAT R; System USRD, 2019, ANN DAT REP; Taylor MD, 2002, J TRAUMA, V53, P407, DOI 10.1097/00005373-200209000-00001; Thompson HJ, 2010, ANN SURG, V252, P370, DOI 10.1097/SLA.0b013e3181df03d6; TOMITA J, 1995, AM J KIDNEY DIS, V25, P405, DOI 10.1016/0272-6386(95)90101-9; Wang HK, 2012, INJURY, V43, P1432, DOI 10.1016/j.injury.2011.03.059; Weissman C, 2000, INTENS CARE MED, V26, P1319, DOI 10.1007/s001340000612; Weissman C, 1997, CRIT CARE MED, V25, P1594, DOI 10.1097/00003246-199709000-00031; Yang WC, 2008, NEPHROL DIAL TRANSPL, V23, P3977, DOI 10.1093/ndt/gfn406	52	6	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 8	2014	9	4							e93956	10.1371/journal.pone.0093956	http://dx.doi.org/10.1371/journal.pone.0093956			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AE7FA	24714730	Green Published, Green Submitted, gold			2023-01-03	WOS:000334160900066
J	Ndumbi, P; Falutz, J; Pai, NP; Tsoukas, CM				Ndumbi, Patricia; Falutz, Julian; Pai, Nitika Pant; Tsoukas, Christos M.			Delay in cART Initiation Results in Persistent Immune Dysregulation and Poor Recovery of T-Cell Phenotype Despite a Decade of Successful HIV Suppression	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; C-REACTIVE PROTEIN; ANTIRETROVIRAL THERAPY; LYMPHOCYTE SUBSETS; INFECTED PATIENTS; CONTROLLED-TRIAL; CYTOMEGALOVIRUS; HOMEOSTASIS; COUNT; AIDS	Background: Successful combination antiretroviral therapy (cART) increases levels of CD4+ T-cells, however this increase may not accurately reflect long-term immune recovery since T-cell dysregulation and loss of T-cell homeostasis often persist. We therefore assessed the impact of a decade of effective cART on immune regulation, T-cell homeostasis, and overall T-cell phenotype. Methods: We conducted a retrospective study of 288 HIV+ cART-naive patients initiating therapy. We identified 86 individuals who received cART for at least a decade, of which 44 consistently maintained undetectable plasma HIV-RNA levels throughout therapy. At baseline, participants were classified into three groups according to pre-treatment CD4+ T-cell counts: Group I (CD4 < 200 cells/mm(3)); Group II (CD4: 200-350 cells/mm(3)); Group III (CD4 > 350 cells/mm(3)). Outcomes of interest were: (1) CD4+ T-cell count restoration (CD4 > 532 cells/mm(3)); (2) normalization of CD4: CD8 T-cell ratio (1.2-3.3); (3) maintenance of CD3+ T-cell homeostasis (CD3: 65%-85% of peripheral lymphocytes); (4) normalization of the complete T Cell phenotype (TCP). Results: Despite a decade of sustained successful cART, complete T-cell phenotype normalization only occurred in 16% of patients, most of whom had initiated therapy at high CD4+ T-cell counts (> 350 cells/mm(3)). The TCP parameter that was the least restored among patients was the CD4: CD8 T-cell ratio. Conclusions: Failure to normalize the complete T-cell phenotype was most apparent in patients who initiated cART with a CD4+ T-cell count < 200 cells/mm(3). The impact of this impaired T-cell phenotype on life-long immune function and potential comorbidities remains to be elucidated.	[Ndumbi, Patricia; Falutz, Julian; Tsoukas, Christos M.] McGill Univ, Ctr Hlth, Immune Deficiency Treatment Ctr, Montreal, PQ, Canada; [Pai, Nitika Pant] McGill Univ, Ctr Hlth, Div Clin Epidemiol, Montreal, PQ, Canada	McGill University; McGill University	Ndumbi, P (corresponding author), McGill Univ, Ctr Hlth, Immune Deficiency Treatment Ctr, Montreal, PQ, Canada.	patricia.ndumbi@mail.mcgill.ca; chris.tsoukas@muhc.mcgill.ca		Pant Pai, Nitika/0000-0002-4672-0500	Canadian Institutes of Health Research (CIHR) [200303HHP-118726-HSR-CFAC-26137]; McGill University Health Center (MUHC)	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); McGill University Health Center (MUHC)	This work was supported by research funding from the Canadian Institutes of Health Research (CIHR) grant 200303HHP-118726-HSR-CFAC-26137. Paticia Ndumbi was also supported by the McGill University Health Center (MUHC) graduate fellowship award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADLEMAN LM, 1993, J ACQ IMMUN DEF SYND, V6, P144; Althoff KN, 2010, AIDS, V24, P2467, DOI 10.1097/QAD.0b013e32833e6d14; Baker JV, 2008, JAIDS-J ACQ IMM DEF, V48, P541, DOI 10.1097/QAI.0b013e31817bebb3; Bower JE, 2003, JNCI-J NATL CANCER I, V95, P1165, DOI 10.1093/jnci/djg0019; Cameron DW, 1998, LANCET, V351, P543, DOI 10.1016/S0140-6736(97)04161-5; Carmichael K F, 2006, Afr J Med Med Sci, V35, P53; Chattopadhyay PK, 2006, AIDS RES HUM RETROV, V22, P501, DOI 10.1089/aid.2006.22.501; EDELMAN AS, 1989, FASEB J, V3, P22, DOI 10.1096/fasebj.3.1.2562947; FAHEY JL, 1984, AM J MED, V76, P95, DOI 10.1016/0002-9343(84)90756-3; FERGUSON FG, 1995, J GERONTOL A-BIOL, V50, pB378, DOI 10.1093/gerona/50A.6.B378; Gange SJ, 1998, P NATL ACAD SCI USA, V95, P10848, DOI 10.1073/pnas.95.18.10848; Goodrum F, 2012, CELL MICROBIOL, V14, P644, DOI 10.1111/j.1462-5822.2012.01774.x; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; Hirsch M, 1999, J INFECT DIS, V180, P659, DOI 10.1086/314948; Hogg RS, 2001, JAMA-J AM MED ASSOC, V286, P2568, DOI 10.1001/jama.286.20.2568; Jain V, 2013, J INFECT DIS, V208, P1202, DOI 10.1093/infdis/jit311; Keller M, 2009, AIDS, V23, P731, DOI 10.1097/QAD.0b013e328326f77f; Kelley CF, 2009, CLIN INFECT DIS, V48, P787, DOI 10.1086/597093; Khoruts A, 2005, IMMUNOL LETT, V98, P23, DOI 10.1016/j.imlet.2004.10.022; LABALETTE M, 1994, CLIN EXP IMMUNOL, V95, P465; Leung V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077665; Lo J, 2010, AIDS, V24, P243, DOI 10.1097/QAD.0b013e328333ea9e; MALONE JL, 1990, J ACQ IMMUN DEF SYND, V3, P144; Malphettes M, 2009, CLIN INFECT DIS, V49, P1329, DOI 10.1086/606059; Margolick J B, 1997, Semin Immunol, V9, P381, DOI 10.1006/smim.1997.0096; MARGOLICK JB, 1995, NAT MED, V1, P674, DOI 10.1038/nm0795-674; Margolick JB, 1993, JAIDS J ACQUIRED IMM, V6; Moore RD, 2007, CLIN INFECT DIS, V44, P441, DOI 10.1086/510746; Muhlestein JB, 2000, CIRCULATION, V102, P1917, DOI 10.1161/01.CIR.102.16.1917; Naeger DM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008886; Ndumbi P, 2013, AIDS; Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208; Shete A, 2010, INDIAN J MED RES, V132, P667; Staras SAS, 2006, CLIN INFECT DIS, V43, P1143, DOI 10.1086/508173; Stockinger B, 2004, CURR OPIN IMMUNOL, V16, P775, DOI 10.1016/j.coi.2004.09.003; Strindhall J, 2012, AGE DORDR; Torti C, 2012, CLIN MICROBIOL INFEC, V18, P449, DOI 10.1111/j.1469-0691.2011.03650.x; Vila LM, 2006, ARTHRIT RHEUM-ARTHR, V55, P799, DOI 10.1002/art.22224; Wikby A, 1998, MECH AGEING DEV, V102, P187, DOI 10.1016/S0047-6374(97)00151-6; Wikby A, 2008, BIOGERONTOLOGY, V9, P299, DOI 10.1007/s10522-008-9138-6; Zhu JH, 1999, J AM COLL CARDIOL, V34, P1738, DOI 10.1016/S0735-1097(99)00410-6; ZOLLAPAZNER S, 1987, P NATL ACAD SCI USA, V84, P5404, DOI 10.1073/pnas.84.15.5404	42	12	14	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 7	2014	9	4							e94018	10.1371/journal.pone.0094018	http://dx.doi.org/10.1371/journal.pone.0094018			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE7EP	24710051	Green Submitted, gold, Green Published			2023-01-03	WOS:000334159800087
J	Stadelmann, K; Latshang, TD; Nussbaumer-Ochsner, Y; Tarokh, L; Ulrich, S; Kohler, M; Bloch, KE; Achermann, P				Stadelmann, Katrin; Latshang, Tsogyal D.; Nussbaumer-Ochsner, Yvonne; Tarokh, Leila; Ulrich, Silvia; Kohler, Malcolm; Bloch, Konrad E.; Achermann, Peter			Impact of Acetazolamide and CPAP on Cortical Activity in Obstructive Sleep Apnea Patients	PLOS ONE			English	Article							POSITIVE AIRWAY PRESSURE; SLOW-WAVE ACTIVITY; DAYTIME SLEEPINESS; SPECTRAL-ANALYSIS; BENZODIAZEPINE HYPNOTICS; DOUBLE-BLIND; EEG; ALTITUDE; ARCHITECTURE; MECHANISMS	Study Objectives: 1) To investigate the impact of acetazolamide, a drug commonly prescribed for altitude sickness, on cortical oscillations in patients with obstructive sleep apnea syndrome (OSAS). 2) To examine alterations in the sleep EEG after short- term discontinuation of continuous positive airway pressure (CPAP) therapy. Design: Data from two double- blind, placebo- controlled randomized cross- over design studies were analyzed. Setting: Polysomnographic recordings in sleep laboratory at 490 m and at moderate altitudes in the Swiss Alps: 1630 or 1860 m and 2590 m. Patients: Study 1: 39 OSAS patients. Study 2: 41 OSAS patients. Interventions: Study 1: OSAS patients withdrawn from treatment with CPAP. Study 2: OSAS patients treated with autoCPAP. Treatment with acetazolamide (500-750 mg) or placebo at moderate altitudes. Measurements and Results: An evening dose of 500 mg acetazolamide reduced slow-wave activity (SWA; approximately 10%) and increased spindle activity (approximately 10%) during non-REM sleep. In addition, alpha activity during wake after lights out was increased. An evening dose of 250 mg did not affect these cortical oscillations. Discontinuation of CPAP therapy revealed a reduction in SWA (5-10%) and increase in beta activity (approximately 25%). \Conclusions: The higher evening dose of 500 mg acetazolamide showed the `` spectral fingerprint'' of Benzodiazepines, while 250 mg acetazolamide had no impact on cortical oscillations. However, both doses had beneficial effects on oxygen saturation and sleep quality.	[Stadelmann, Katrin; Tarokh, Leila; Achermann, Peter] Univ Zurich, Inst Pharmacol & Toxicol, Zurich, Switzerland; [Stadelmann, Katrin; Kohler, Malcolm; Bloch, Konrad E.; Achermann, Peter] Univ Zurich, Zurich Ctr Integrat Human Physiol, Zurich, Switzerland; [Latshang, Tsogyal D.; Nussbaumer-Ochsner, Yvonne; Ulrich, Silvia; Kohler, Malcolm; Bloch, Konrad E.] Univ Bern, Univ Hosp Child & Adolescent Psychiat & Psychothe, Bern, Switzerland	University of Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); University of Bern; University Hospital of Bern	Achermann, P (corresponding author), Univ Zurich, Inst Pharmacol & Toxicol, Zurich, Switzerland.	acherman@pharma.uzh.ch	Achermann, Peter/N-1215-2014	Achermann, Peter/0000-0002-0208-3511; Tarokh, Leila/0000-0003-4014-428X; Ulrich, Silvia/0000-0002-5250-5022	University of Zurich Research Priority Program (URPP Integrative Human Physiology); Swiss National Science Foundation; Lung League Zurich; Center for Clinical Research, University of Zurich; Center for Clinical Research, University Hospital	University of Zurich Research Priority Program (URPP Integrative Human Physiology); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Lung League Zurich; Center for Clinical Research, University of Zurich; Center for Clinical Research, University Hospital	This study was supported by a research grant from the University of Zurich Research Priority Program (URPP Integrative Human Physiology), the Swiss National Science Foundation, the Lung League Zurich and the Center for Clinical Research, University of Zurich and University Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AESCHBACH D, 1994, PSYCHOPHARMACOLOGY, V114, P209, DOI 10.1007/BF02244838; Banks S, 2007, J CLIN SLEEP MED, V3, P519; Borbely A A, 1982, Hum Neurobiol, V1, P195; BORBELY AA, 1983, EUR J PHARMACOL, V89, P157, DOI 10.1016/0014-2999(83)90622-2; BORBELY AA, 1985, HUM NEUROBIOL, V4, P189; BRUNNER DP, 1991, PSYCHOPHARMACOLOGY, V104, P1, DOI 10.1007/BF02244546; Caruana-Montaldo B, 2000, CHEST, V117, P205, DOI 10.1378/chest.117.1.205; Dijk DJ, 2010, SLEEP, V33, P211, DOI 10.1093/sleep/33.2.211; Dingli K, 2002, EUR RESPIR J, V20, P1246, DOI 10.1183/09031936.02.00288202; Engleman HM, 1997, THORAX, V52, P114, DOI 10.1136/thx.52.2.114; ENGLEMAN HM, 1993, THORAX, V48, P911, DOI 10.1136/thx.48.9.911; Fietze I, 1997, J SLEEP RES, V6, P128, DOI 10.1046/j.1365-2869.1997.00029.x; Fischer R, 2004, EUR RESPIR J, V23, P47, DOI 10.1183/09031936.03.00113102; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; Gottselig JM, 2002, BRAIN, V125, P373, DOI 10.1093/brain/awf021; Guilleminault C, 2001, EUR RESPIR J, V17, P838, DOI 10.1183/09031936.01.17508380; Heinzer R, 2001, CHEST, V119, P1807, DOI 10.1378/chest.119.6.1807; Himanen SL, 2003, SLEEP MED, V4, P229, DOI 10.1016/S1389-9457(02)00239-3; Ho ML, 2011, NEUROL INT, V3, P60, DOI 10.4081/ni.2011.e15; Hoshikawa M, 2007, J APPL PHYSIOL, V103, P2005, DOI 10.1152/japplphysiol.00315.2007; Jackson E. K., 2006, GOODMAN GILMANS PHAR, P297; Javaheri S, 2006, AM J RESP CRIT CARE, V173, P234, DOI 10.1164/rccm.200507-1035OC; Johnson PL, 2010, J SLEEP RES, V19, P148, DOI 10.1111/j.1365-2869.2009.00745.x; Latshang TD, 2013, SLEEP IN PRESS; Latshang TD, 2012, JAMA-J AM MED ASSOC, V308, P2390, DOI 10.1001/jama.2012.94847; Leaf DE, 2007, J APPL PHYSIOL, V102, P1313, DOI 10.1152/japplphysiol.01572.2005; McArdle N, 2001, AM J RESP CRIT CARE, V164, P1459, DOI 10.1164/ajrccm.164.8.2008146; Morisson F, 2001, CHEST, V119, P45, DOI 10.1378/chest.119.1.45; Morisson F, 1998, EUR RESPIR J, V11, P1135, DOI 10.1183/09031936.98.11051135; Nussbaumer-Ochsner Y, 2012, SLEEP, V35, P419, DOI 10.5665/sleep.1708; Nussbaumer-Ochsner Y, 2012, CHEST, V141, P131, DOI 10.1378/chest.11-0375; Nussbaumer-Ochsner Y, 2010, THORAX, V65, P429, DOI 10.1136/thx.2009.125849; Ondze B, 2003, CLIN NEUROPHYSIOL, V114, P867, DOI 10.1016/S1388-2457(02)00389-9; Punjabi Naresh M, 2008, Proc Am Thorac Soc, V5, P136, DOI 10.1513/pats.200709-155MG; Rechtschaffen A., 1968, MANUAL STANDARDIZED; Ritchie ND, 2012, J TRAVEL MED, V19, P298, DOI 10.1111/j.1708-8305.2012.00629.x; Stadelmann K, 2014, J SLEEP RES IN PRESS; Stadelmann K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076945; Staley Kevin J., 2002, Epilepsy Curr, V2, P35, DOI 10.1046/j.1535-7597.2002.00018.x; STALEY KJ, 1995, SCIENCE, V269, P977, DOI 10.1126/science.7638623; Treiman DM, 2001, EPILEPSIA, V42, P8, DOI 10.1046/j.1528-1157.2001.042suppl.3008.x; West JB, 2007, HIGH ALTITUDE MED PH, P251	42	5	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 7	2014	9	4							e93931	10.1371/journal.pone.0093931	http://dx.doi.org/10.1371/journal.pone.0093931			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE7EP	24710341	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000334159800074
J	Neubauer, S; Redwood, C				Neubauer, Stefan; Redwood, Charles			New Mechanisms and Concepts for Cardiac-Resynchronization Therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HEART		[Neubauer, Stefan; Redwood, Charles] Univ Oxford, Div Cardiovasc Med, Radcliffe Dept Med, Oxford, England	University of Oxford	Neubauer, S (corresponding author), Univ Oxford, Div Cardiovasc Med, Radcliffe Dept Med, Oxford, England.			Neubauer, Stefan/0000-0001-9017-5645				Go AS, 2013, CIRCULATION, V127, pE6, DOI 10.1161/CIR.0b013e31828124ad; Holzmeister J, 2011, LANCET, V378, P722, DOI 10.1016/S0140-6736(11)61228-2; Kirk JA, 2013, J CLIN INVEST; Marston SB, 2008, J MOL CELL CARDIOL, V45, P603, DOI 10.1016/j.yjmcc.2008.07.004; Sugden PH, 2008, BRIT J PHARMACOL, V153, pS137, DOI 10.1038/sj.bjp.0707659	5	11	12	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 20	2014	370	12					1164	1166		10.1056/NEJMcibr1315508	http://dx.doi.org/10.1056/NEJMcibr1315508			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AD2HA	24645952				2023-01-03	WOS:000333054000016
J	Buchel, C; Geuter, S; Sprenger, C; Eippert, F				Buechel, Christian; Geuter, Stephan; Sprenger, Christian; Eippert, Falk			Placebo Analgesia: A Predictive Coding Perspective	NEURON			English	Review							MIDBRAIN PERIAQUEDUCTAL GRAY; ROSTRAL VENTROMEDIAL MEDULLA; PREFRONTAL CORTICAL PROJECTIONS; SYNDROME IBS PATIENTS; NUCLEUS RAPHE MAGNUS; SPINAL-CORD; BRAIN ACTIVITY; AFFERENT CONNECTIONS; EFFERENT PROJECTIONS; NEURAL SUBSTRATE	This Perspective reviews recent findings in placebo hypoalgesia and provides a conceptual account of how expectations and experience can lead to placebo hypoalgesia. In particular, we put forward the idea that the ascending and the descending pain system resembles a recurrent system that allows for the implementation of predictive coding-meaning that the brain is not passively waiting for nociceptive stimuli to impinge on it but is actively making inferences based on prior experience and expectations. The Bayesian formulation within the predictive coding framework can directly account for differences in the magnitude but also the precision of expectations that are known to influence the strength of placebo hypoalgesia. We discuss how modulatory neurotransmitters such as opioids might be related to the characterization of expectations with an emphasis on the precision of these expectations. Finally, we develop experimental strategies that are suited to test this framework at the behavioral and neuronal level.	[Buechel, Christian; Geuter, Stephan; Sprenger, Christian] Univ Med Ctr Hamburg Eppendorf, Dept Syst Neurosci, D-20246 Hamburg, Germany; [Buechel, Christian] Stanford Univ, Dept Psychol, Stanford, CA 94305 USA; [Eippert, Falk] Univ Oxford, Ctr Funct Magnet Resonance Imaging Brain FMRIB, Oxford OX3 9DU, England	University of Hamburg; University Medical Center Hamburg-Eppendorf; Stanford University; University of Oxford	Buchel, C (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Syst Neurosci, D-20246 Hamburg, Germany.	buechel@uke.de	Eippert, Falk/M-6188-2013	Eippert, Falk/0000-0002-3986-1719; GEUTER, STEPHAN/0000-0002-4935-5692	DFG [SFB 936, FOR 1328]; ERC [ERC-2010-AdG_20100407]; Marie Curie Fellowship [273805]	DFG(German Research Foundation (DFG)); ERC(European Research Council (ERC)European Commission); Marie Curie Fellowship(European Commission)	We would like to thank Selim Onat, Andreas Kleinschmidt, and Karl Friston for helpful comments and discussions. C. B and S. G. are supported by the DFG, SFB 936, project A06, C. B. and C. S. are supported by the ERC, ERC-2010-AdG_20100407 and by the DFG Research group FOR 1328, and F. E. is supported by a Marie Curie Fellowship (grant agreement number 273805, "Pain modulation'').	ABOLS IA, 1981, J COMP NEUROL, V201, P285, DOI 10.1002/cne.902010211; Adams Rick A, 2013, Front Psychiatry, V4, P47, DOI 10.3389/fpsyt.2013.00047; AGGLETON JP, 1980, BRAIN RES, V190, P347, DOI 10.1016/0006-8993(80)90279-6; Aicher SA, 2012, J CHEM NEUROANAT, V43, P103, DOI 10.1016/j.jchemneu.2011.11.002; AIMONE LD, 1988, J NEUROSCI, V8, P2652; Amanzio M, 2013, HUM BRAIN MAPP, V34, P738, DOI 10.1002/hbm.21471; Apkarian AV, 2005, EUR J PAIN, V9, P463, DOI 10.1016/j.ejpain.2004.11.001; Atlas LY, 2012, NEUROSCI LETT, V520, P140, DOI 10.1016/j.neulet.2012.03.039; Atlas LY, 2012, J NEUROSCI, V32, P8053, DOI 10.1523/JNEUROSCI.0383-12.2012; Atlas LY, 2010, J NEUROSCI, V30, P12964, DOI 10.1523/JNEUROSCI.0057-10.2010; Bantick SJ, 2002, BRAIN, V125, P310, DOI 10.1093/brain/awf022; BASBAUM AI, 1984, ANNU REV NEUROSCI, V7, P309, DOI 10.1146/annurev.ne.07.030184.001521; BASBAUM AI, 1979, J COMP NEUROL, V187, P513, DOI 10.1002/cne.901870304; BASBAUM AI, 1978, J COMP NEUROL, V178, P209, DOI 10.1002/cne.901780203; BASBAUM AI, 1976, ANAT REC, V184, P354; Baumgartner U, 2006, NEUROIMAGE, V30, P692, DOI 10.1016/j.neuroimage.2005.10.033; Bee L, 2009, SYNAPTIC PLASTICITY IN PAIN, P307, DOI 10.1007/978-1-4419-0226-9_14; BEITZ AJ, 1982, NEUROSCIENCE, V7, P133, DOI 10.1016/0306-4522(82)90157-9; BEITZ AJ, 1982, J NEUROSCI, V2, P829; Benedetti F, 2006, PAIN, V121, P133, DOI 10.1016/j.pain.2005.12.016; Benedetti F, 1999, J NEUROSCI, V19, P3639; Benedetti F, 1996, PAIN, V64, P535, DOI 10.1016/0304-3959(95)00179-4; Benedetti F, 2006, J NEUROSCI, V26, P12014, DOI 10.1523/JNEUROSCI.2947-06.2006; Benedetti F, 2013, PHYSIOL REV, V93, P1207, DOI 10.1152/physrev.00043.2012; Benedetti F, 2011, NAT MED, V17, P1228, DOI 10.1038/nm.2435; Bingel U, 2006, PAIN, V120, P8, DOI 10.1016/j.pain.2005.08.027; Bingel U, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001244; BOLLES RC, 1982, ANNU REV PSYCHOL, V33, P87, DOI 10.1146/annurev.ps.33.020182.000511; Borsook D, 2013, PROG NEUROBIOL, V104, P93, DOI 10.1016/j.pneurobio.2013.02.003; Brodersen KH, 2012, NEUROIMAGE, V63, P1162, DOI 10.1016/j.neuroimage.2012.08.035; Brown CA, 2008, PAIN, V135, P240, DOI 10.1016/j.pain.2007.05.022; Brown EC, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00147; CAMERON AA, 1995, J COMP NEUROL, V351, P568, DOI 10.1002/cne.903510407; Carlino E, 2011, CURR OPIN ANESTHESIO, V24, P540, DOI 10.1097/ACO.0b013e328349d0c2; CARLTON SM, 1985, J COMP NEUROL, V241, P382, DOI 10.1002/cne.902410310; Carmichael ST, 1995, J COMP NEUROL, V363, P615, DOI 10.1002/cne.903630408; Chib VS, 2009, J NEUROSCI, V29, P12315, DOI 10.1523/JNEUROSCI.2575-09.2009; CICALA GA, 1990, PSYCHOL SCI, V1, P312, DOI 10.1111/j.1467-9280.1990.tb00224.x; Clark A, 2013, BEHAV BRAIN SCI, V36, P181, DOI 10.1017/S0140525X12000477; CLARK WC, 1969, J ABNORM PSYCHOL, V74, P363, DOI 10.1037/h0027509; Colloca L, 2005, NAT REV NEUROSCI, V6, P545, DOI 10.1038/nrn1705; Colloca L, 2008, PAIN, V139, P306, DOI 10.1016/j.pain.2008.04.021; Colloca L, 2006, PAIN, V124, P126, DOI 10.1016/j.pain.2006.04.005; Colloca L, 2010, PAIN, V151, P430, DOI 10.1016/j.pain.2010.08.007; Corlett PR, 2009, PSYCHOPHARMACOLOGY, V206, P515, DOI 10.1007/s00213-009-1561-0; Coste CP, 2011, CEREB CORTEX, V21, P2612, DOI 10.1093/cercor/bhr050; Craggs JG, 2007, NEUROIMAGE, V38, P720, DOI 10.1016/j.neuroimage.2007.07.057; CRAIG AD, 1995, J COMP NEUROL, V361, P225, DOI 10.1002/cne.903610204; Crombez G, 2011, PAIN, V152, P1449, DOI 10.1016/j.pain.2011.02.028; Dogrul A, 2009, BRAIN RES, V1280, P52, DOI 10.1016/j.brainres.2009.05.001; Dolan, 2013, WALL MELZACKS TXB PA, P248; Dostrovsky JO, 2013, WALL MELZACKS TXB PA, P182; Edwards MJ, 2012, BRAIN, V135, P3495, DOI 10.1093/brain/aws129; Efron B, 2009, J AM STAT ASSOC, V104, P1015, DOI 10.1198/jasa.2009.tm08523; Egner T, 2010, J NEUROSCI, V30, P16601, DOI 10.1523/JNEUROSCI.2770-10.2010; Eippert F, 2008, J NEUROSCI, V28, P5465, DOI 10.1523/JNEUROSCI.5336-07.2008; Eippert F, 2013, PLACEBO AND PAIN: FROM BENCH TO BEDSIDE, P53, DOI 10.1016/B978-0-12-397928-5.00007-6; Eippert F, 2009, SCIENCE, V326, P404, DOI 10.1126/science.1180142; Eippert F, 2009, NEURON, V63, P533, DOI 10.1016/j.neuron.2009.07.014; Ellingsen DM, 2013, P NATL ACAD SCI USA, V110, P17993, DOI 10.1073/pnas.1305050110; Enck P, 2013, NAT REV DRUG DISCOV, V12, P191, DOI 10.1038/nrd3923; FANSELOW MS, 1986, ANN NY ACAD SCI, V467, P40, DOI 10.1111/j.1749-6632.1986.tb14617.x; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Fields H, 2004, NAT REV NEUROSCI, V5, P565, DOI 10.1038/nrn1431; FIELDS HL, 1983, J NEUROSCI, V3, P2545; Flaten MA, 2011, PHILOS T R SOC B, V366, P1818, DOI 10.1098/rstb.2010.0407; Floyd NS, 2001, J COMP NEUROL, V432, P307, DOI 10.1002/cne.1105; Friston KJ, 2010, NAT REV NEUROSCI, V11, P127, DOI 10.1038/nrn2787; FRISTON KJ, 1994, NEUROSCIENCE, V59, P229, DOI 10.1016/0306-4522(94)90592-4; Gao KM, 2000, J NEUROPHYSIOL, V84, P1719, DOI 10.1152/jn.2000.84.4.1719; Geuter S, 2013, J NEUROSCI, V33, P13784, DOI 10.1523/JNEUROSCI.2191-13.2013; Geuter S, 2013, NEUROIMAGE, V67, P227, DOI 10.1016/j.neuroimage.2012.11.029; Harrison LM, 2006, NEURAL NETWORKS, V19, P535, DOI 10.1016/j.neunet.2005.11.002; Heinricher MM, 2009, BRAIN RES REV, V60, P214, DOI 10.1016/j.brainresrev.2008.12.009; Heinricher M.M., 2013, WALL MELZACKS TXB PA, P129; HEINRICHER MM, 1994, NEUROSCIENCE, V63, P279, DOI 10.1016/0306-4522(94)90022-1; Heinricher MM, 2001, PAIN, V92, P129, DOI 10.1016/S0304-3959(00)00480-2; HEINRICHER MM, 1987, J NEUROSCI, V7, P271; HERRERO MT, 1991, BRAIN RES, V543, P201, DOI 10.1016/0006-8993(91)90029-U; Hesselmann G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009926; Hohwy J, 2008, COGNITION, V108, P687, DOI 10.1016/j.cognition.2008.05.010; HOPKINS DA, 1978, EXP BRAIN RES, V32, P529; Huang YP, 2011, WIRES COGN SCI, V2, P580, DOI 10.1002/wcs.142; Iglesias S, 2013, NEURON, V80, P519, DOI 10.1016/j.neuron.2013.09.009; Jasmin L, 2004, J COMP NEUROL, V468, P425, DOI 10.1002/cne.10978; Jehee JFM, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000373; Jensen KB, 2012, P NATL ACAD SCI USA, V109, P15959, DOI 10.1073/pnas.1202056109; Johansen JP, 2010, NAT NEUROSCI, V13, P979, DOI 10.1038/nn.2594; Kaptchuk T.J., 2010, PLOS ONE, V22, P5, DOI DOI 10.1371/J0URNAL.P0NE.0015591; Kato G, 2006, J NEUROSCI, V26, P1787, DOI 10.1523/JNEUROSCI.4856-05.2006; Keltner JR, 2006, J NEUROSCI, V26, P4437, DOI 10.1523/JNEUROSCI.4463-05.2006; Kessner S, 2013, JAMA-J AM MED ASSOC, V310, P1733, DOI 10.1001/jama.2013.277446; Kessner S, 2013, JAMA INTERN MED, V173, P1468, DOI 10.1001/jamainternmed.2013.6705; Kleinschmidt A, 1998, P ROY SOC B-BIOL SCI, V265, P2427, DOI 10.1098/rspb.1998.0594; Knill DC, 2004, TRENDS NEUROSCI, V27, P712, DOI 10.1016/j.tins.2004.10.007; Knutson B, 2000, NEUROIMAGE, V12, P20, DOI 10.1006/nimg.2000.0593; Kong J, 2006, J NEUROSCI, V26, P381, DOI 10.1523/JNEUROSCI.3556-05.2006; Kong J, 2007, REV NEUROSCIENCE, V18, P173; Koster-Hale J, 2013, NEURON, V79, P836, DOI 10.1016/j.neuron.2013.08.020; Koyama T, 2005, P NATL ACAD SCI USA, V102, P12950, DOI 10.1073/pnas.0408576102; Krahe C, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00386; KRETTEK JE, 1977, J COMP NEUROL, V172, P687, DOI 10.1002/cne.901720408; Krummenacher P, 2010, PAIN, V148, P368, DOI 10.1016/j.pain.2009.09.033; Leknes S, 2013, PAIN, V154, P402, DOI 10.1016/j.pain.2012.11.018; LEVINE JD, 1978, LANCET, V2, P654, DOI 10.1016/S0140-6736(78)92762-9; LEWIS ME, 1981, SCIENCE, V211, P1166, DOI 10.1126/science.6258227; LIBERMAN R, 1964, J PSYCHIAT RES, V2, P233, DOI 10.1016/0022-3956(64)90010-X; Lima D, 2008, SCI PAIN, V5, P477; Lorenz J, 2003, BRAIN, V126, P1079, DOI 10.1093/brain/awg102; Lorenz R, 2005, BRAIN BEHAV IMMUN, V19, P283, DOI 10.1016/j.bbi.2005.03.010; Lu HC, 2010, PAIN, V148, P75, DOI 10.1016/j.pain.2009.10.012; Lui F, 2010, PAIN, V151, P816, DOI 10.1016/j.pain.2010.09.021; LUNDH LG, 1987, SCAND J PSYCHOL, V28, P128, DOI 10.1111/j.1467-9450.1987.tb00747.x; MANTYH PW, 1983, J NEUROPHYSIOL, V49, P582, DOI 10.1152/jn.1983.49.3.582; MANTYH PW, 1983, J NEUROPHYSIOL, V49, P567, DOI 10.1152/jn.1983.49.3.567; MANTYH PW, 1982, J COMP NEUROL, V211, P50, DOI 10.1002/cne.902110106; Marshall TM, 2012, PAIN, V153, P86, DOI 10.1016/j.pain.2011.09.021; Mason P, 2012, CURR OPIN NEUROBIOL, V22, P640, DOI 10.1016/j.conb.2012.03.008; Matre D, 2006, J NEUROSCI, V26, P559, DOI 10.1523/JNEUROSCI.4218-05.2006; Mazzola L, 2012, NEUROIMAGE, V60, P409, DOI 10.1016/j.neuroimage.2011.12.072; McDonald AJ, 1996, NEUROSCIENCE, V71, P55, DOI 10.1016/0306-4522(95)00417-3; McNally GP, 2011, TRENDS NEUROSCI, V34, P283, DOI 10.1016/j.tins.2011.03.005; McNally GP, 2004, J NEUROSCI, V24, P6912, DOI 10.1523/JNEUROSCI.1828-04.2004; McNally GP, 2004, BEHAV NEUROSCI, V118, P111, DOI 10.1037/0735-7044.118.1.111; Meissner K, 2011, J NEUROSCI, V31, P16117, DOI 10.1523/JNEUROSCI.4099-11.2011; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; MESULAM MM, 1983, J COMP NEUROL, V214, P170, DOI 10.1002/cne.902140206; Millan MJ, 2002, PROG NEUROBIOL, V66, P355, DOI 10.1016/S0301-0082(02)00009-6; Morgan MM, 2008, PAIN, V140, P376, DOI 10.1016/j.pain.2008.09.009; Morley S, 2008, BRIT J ANAESTH, V101, P25, DOI 10.1093/bja/aen123; Morris JS, 2001, NEUROIMAGE, V13, P1044, DOI 10.1006/nimg.2000.0721; Morton DL, 2009, PAIN, V146, P194, DOI 10.1016/j.pain.2009.07.026; MUFSON EJ, 1981, NEUROSCIENCE, V6, P1231, DOI 10.1016/0306-4522(81)90184-6; MUSIL SY, 1988, J COMP NEUROL, V272, P219, DOI 10.1002/cne.902720206; Nakamura Y, 2012, PAIN, V153, P227, DOI 10.1016/j.pain.2011.10.024; O'Reilly JX, 2012, EUR J NEUROSCI, V35, P1169, DOI 10.1111/j.1460-9568.2012.08010.x; Oken BS, 2008, BRAIN, V131, P2812, DOI 10.1093/brain/awn116; Ongur D, 1998, J COMP NEUROL, V401, P480; Ossipov MH, 2010, J CLIN INVEST, V120, P3779, DOI 10.1172/JCI43766; Pecina M, 2013, MOL PSYCHIATR, V18, P135, DOI 10.1038/mp.2012.16; Pedersen NP, 2011, J NEUROPHYSIOL, V106, P731, DOI 10.1152/jn.01062.2010; Petrovic P, 2002, SCIENCE, V295, P1737, DOI 10.1126/science.1067176; Ploghaus A, 2000, P NATL ACAD SCI USA, V97, P9281, DOI 10.1073/pnas.160266497; Ploner M, 2010, P NATL ACAD SCI USA, V107, P355, DOI 10.1073/pnas.0906186106; Pollo A, 2001, PAIN, V93, P77, DOI 10.1016/S0304-3959(01)00296-2; PRICE DD, 1984, J PERS, V52, P389, DOI 10.1111/j.1467-6494.1984.tb00359.x; Price DD, 1999, PAIN, V83, P147, DOI 10.1016/S0304-3959(99)00081-0; Price DD, 2008, ANNU REV PSYCHOL, V59, P565, DOI 10.1146/annurev.psych.59.113006.095941; Rao RPN, 1999, NAT NEUROSCI, V2, P79, DOI 10.1038/4580; Ren K., 2009, SCI PAIN, P723; Rescorta RA, 1972, CLASSICAL CONDITION, P64; Ritter A, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00530; RIZVI TA, 1991, J COMP NEUROL, V303, P121, DOI 10.1002/cne.903030111; ROOM P, 1985, J COMP NEUROL, V242, P40, DOI 10.1002/cne.902420104; RUSSCHEN FT, 1982, J COMP NEUROL, V206, P159, DOI 10.1002/cne.902060206; SAKAI K, 1990, BRAIN RES BULL, V24, P437, DOI 10.1016/0361-9230(90)90098-K; Schenk LA, 2014, PAIN, V155, P150, DOI 10.1016/j.pain.2013.09.024; Schmack K, 2013, J NEUROSCI, V33, P13701, DOI 10.1523/JNEUROSCI.1778-13.2013; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; Schweinhardt P, 2009, J NEUROSCI, V29, P4882, DOI 10.1523/JNEUROSCI.5634-08.2009; Scott DJ, 2008, ARCH GEN PSYCHIAT, V65, P220, DOI 10.1001/archgenpsychiatry.2007.34; Scott DJ, 2007, NEURON, V55, P325, DOI 10.1016/j.neuron.2007.06.028; Sethi AK, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2011.00395; SRINIVASAN MV, 1982, PROC R SOC SER B-BIO, V216, P427, DOI 10.1098/rspb.1982.0085; Stein N, 2012, PAIN, V153, P2210, DOI 10.1016/j.pain.2012.07.010; Sterzer P, 2008, CURR BIOL, V18, pR697, DOI 10.1016/j.cub.2008.06.021; Stewart-Williams S, 2004, PSYCHOL BULL, V130, P324, DOI 10.1037/0033-2909.130.2.324; Sugiyo S, 2005, J COMP NEUROL, V493, P510, DOI 10.1002/cne.20797; Summerfield C, 2006, SCIENCE, V314, P1311, DOI 10.1126/science.1132028; Tamae A, 2005, J PHYSIOL-LONDON, V568, P243, DOI 10.1113/jphysiol.2005.091843; Todorovic A, 2011, J NEUROSCI, V31, P9118, DOI 10.1523/JNEUROSCI.1425-11.2011; Tracey I, 2002, J NEUROSCI, V22, P2748, DOI 10.1523/JNEUROSCI.22-07-02748.2002; Tracey I, 2007, NEURON, V55, P377, DOI 10.1016/j.neuron.2007.07.012; Tracey I, 2010, NAT MED, V16, P1277, DOI 10.1038/nm.2229; Valet M, 2004, PAIN, V109, P399, DOI 10.1016/j.pain.2004.02.033; Vase L, 2005, PAIN, V115, P338, DOI 10.1016/j.pain.2005.03.014; Vase L, 2003, PAIN, V105, P17, DOI 10.1016/S0304-3959(03)00073-3; Vase L, 2002, PAIN, V99, P443, DOI 10.1016/S0304-3959(02)00205-1; Vase L, 2009, PAIN, V145, P36, DOI 10.1016/j.pain.2009.04.008; Verne GN, 2003, PAIN, V105, P223, DOI 10.1016/S0304-3959(03)00210-0; VOLZ HP, 1990, ANAT EMBRYOL, V181, P177; Waber RL, 2008, JAMA-J AM MED ASSOC, V299, P1016, DOI 10.1001/jama.299.9.1016; Wager T.D., 2013, PLACEBO ANALGESIA, P362; Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065; Wager TD, 2007, P NATL ACAD SCI USA, V104, P11056, DOI 10.1073/pnas.0702413104; Wager TD, 2013, NEW ENGL J MED, V368, P1388, DOI 10.1056/NEJMoa1204471; Watson A, 2007, NEUROREPORT, V18, P771, DOI 10.1097/WNR.0b013e3280c1e2a8; Watson A, 2009, PAIN, V145, P24, DOI 10.1016/j.pain.2009.04.003; Whalley B, 2008, J PSYCHOSOM RES, V64, P537, DOI 10.1016/j.jpsychores.2007.11.007; Woolf CJ, 2011, PAIN, V152, pS2, DOI 10.1016/j.pain.2010.09.030; Yelle MD, 2009, J NEUROSCI, V29, P10264, DOI 10.1523/JNEUROSCI.4648-08.2009; Yoshida W, 2013, J NEUROSCI, V33, P5638, DOI 10.1523/JNEUROSCI.4984-12.2013; Zubieta JK, 2005, J NEUROSCI, V25, P7754, DOI 10.1523/JNEUROSCI.0439-05.2005; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	194	239	240	0	63	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	MAR 19	2014	81	6					1223	1239		10.1016/j.neuron.2014.02.042	http://dx.doi.org/10.1016/j.neuron.2014.02.042			17	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AD5XH	24656247	Green Published, Bronze			2023-01-03	WOS:000333326000004
J	Hoberman, A; Greenfield, SP; Mattoo, TK; Keren, R; Mathews, R; Pohl, HG; Kropp, BP; Skoog, SJ; Nelson, CP; Moxey-Mims, M; Chesney, RW; Carpenter, MA				Hoberman, Alejandro; Greenfield, Saul P.; Mattoo, Tej K.; Keren, Ron; Mathews, Ranjiv; Pohl, Hans G.; Kropp, Bradley P.; Skoog, Steven J.; Nelson, Caleb P.; Moxey-Mims, Marva; Chesney, Russell W.; Carpenter, Myra A.		RIVUR Trial Investigators	Antimicrobial Prophylaxis for Children with Vesicoureteral Reflux	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							URINARY-TRACT-INFECTION; ANTIBIOTIC-PROPHYLAXIS; TRIAL; PYELONEPHRITIS; MULTICENTER	Background Children with febrile urinary tract infection commonly have vesicoureteral reflux. Because trial results have been limited and inconsistent, the use of antimicrobial prophylaxis to prevent recurrences in children with reflux remains controversial. Methods In this 2-year, multisite, randomized, placebo-controlled trial involving 607 children with vesicoureteral reflux that was diagnosed after a first or second febrile or symptomatic urinary tract infection, we evaluated the efficacy of trimethoprimsulfamethoxazole prophylaxis in preventing recurrences (primary outcome). Secondary outcomes were renal scarring, treatment failure (a composite of recurrences and scarring), and antimicrobial resistance. Results Recurrent urinary tract infection developed in 39 of 302 children who received prophylaxis as compared with 72 of 305 children who received placebo (relative risk, 0.55; 95% confidence interval [CI], 0.38 to 0.78). Prophylaxis reduced the risk of recurrences by 50% (hazard ratio, 0.50; 95% CI, 0.34 to 0.74) and was particularly effective in children whose index infection was febrile (hazard ratio, 0.41; 95% CI, 0.26 to 0.64) and in those with baseline bladder and bowel dysfunction (hazard ratio, 0.21; 95% CI, 0.08 to 0.58). The occurrence of renal scarring did not differ significantly between the prophylaxis and placebo groups (11.9% and 10.2%, respectively). Among 87 children with a first recurrence caused by Escherichia coli, the proportion of isolates that were resistant to trimethoprim-sulfamethoxazole was 63% in the prophylaxis group and 19% in the placebo group. Conclusions Among children with vesicoureteral reflux after urinary tract infection, antimicrobial prophylaxis was associated with a substantially reduced risk of recurrence but not of renal scarring.	[Hoberman, Alejandro] Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Pittsburgh, PA 15213 USA; [Greenfield, Saul P.] Women & Childrens Hosp Buffalo, Buffalo, NY USA; [Mattoo, Tej K.] Wayne State Univ, Sch Med, Detroit, MI USA; [Hoberman, Alejandro; Keren, Ron] Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; [Mathews, Ranjiv] Johns Hopkins Sch Med, Baltimore, MD USA; [Pohl, Hans G.] Childrens Natl Med Ctr, Washington, DC 20010 USA; [Kropp, Bradley P.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA; [Skoog, Steven J.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Nelson, Caleb P.] Boston Childrens Hosp, Boston, MA USA; [Moxey-Mims, Marva] NIDDK, Bethesda, MD 20892 USA; [Chesney, Russell W.] Le Bonheur Childrens Hosp, Memphis, TN USA; [Carpenter, Myra A.] Univ N Carolina, Chapel Hill, NC USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Women & Children's Hospital of Buffalo; Wayne State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Johns Hopkins University; Johns Hopkins Medicine; Children's National Health System; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oregon Health & Science University; Harvard University; Boston Children's Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of North Carolina; University of North Carolina Chapel Hill	Hoberman, A (corresponding author), Childrens Hosp Pittsburgh, 3414 Fifth Ave,CHOB 3rd Fl,Rm 321, Pittsburgh, PA 15213 USA.	hoberman@chp.edu	Montini, Giovanni/AAC-6612-2022; Mattoo, Tej K/CFB-5385-2022	Montini, Giovanni/0000-0002-7350-4475; Pohl, Hans/0000-0001-9679-0948; Moxey-Mims, Marva/0000-0001-8542-9313	National Institute of Diabetes and Digestive and Kidney Diseases; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000003, UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK074063, U01DK074082, U01DK074059, U01DK074062, K23DK088943, U01DK074053, U01DK074064] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; RIVUR ClinicalTrials.gov number, NCT00405704.	[Anonymous], 1987, Br Med J (Clin Res Ed), V295, P237; Benninga M, 2005, J PEDIATR GASTR NUTR, V40, P273, DOI 10.1097/01.MPG.0000158071.24327.88; Brandstrom P, 2010, J UROLOGY, V184, P286, DOI 10.1016/j.juro.2010.01.061; Brandstrom P, 2010, J UROLOGY, V184, P292, DOI 10.1016/j.juro.2010.01.060; Carpenter MA, 2013, PEDIATRICS, V132, pE34, DOI 10.1542/peds.2012-2301; Chesney Russell W, 2008, Pediatrics, V122 Suppl 5, pS233, DOI 10.1542/peds.2008-1285c; Clinical and Laboratory Standards Institute, 2012, PERF STAND ANT SUSC; Craig JC, 2010, NEW ENGL J MED, V362, P1250; Farhat W, 2000, J UROLOGY, V164, P1011, DOI 10.1016/S0022-5347(05)67239-4; Garin EH, 2006, PEDIATRICS, V117, P626, DOI 10.1542/peds.2005-1362; Greenfield SP, 2012, J UROLOGY, V188, P1608, DOI 10.1016/j.juro.2012.06.032; Hoberman A, 2003, NEW ENGL J MED, V348, P195, DOI 10.1056/NEJMoa021698; Hoberman A, 2009, NEW ENGL J MED, V361, P1804, DOI 10.1056/NEJMe0907623; Keren R, 2008, PEDIATRICS, V122, P1409, DOI 10.1542/peds.2008-1285d; LEVITT SB, 1981, PEDIATRICS, V67, P392; Montini G, 2008, PEDIATRICS, V122, P1064, DOI 10.1542/peds.2007-3770; Pennesi M, 2008, PEDIATRICS, V121, pE1489, DOI 10.1542/peds.2007-2652; Roberts KB, 2011, PEDIATRICS, V128, P595, DOI 10.1542/peds.2011-1330; Roussey-Kesler G, 2008, J UROLOGY, V179, P674, DOI 10.1016/j.juro.2007.09.090; Smellie JM, 2001, LANCET, V357, P1329, DOI 10.1016/S0140-6736(00)04520-7; WEISS R, 1992, J UROLOGY, V148, P1667, DOI 10.1016/S0022-5347(17)36998-7; Ziessman HA, 2009, J UROLOGY, V182, P272, DOI 10.1016/j.juro.2009.02.144	22	280	291	2	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 19	2014	370	25					2367	2376		10.1056/NEJMoa1401811	http://dx.doi.org/10.1056/NEJMoa1401811			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AJ0OA	24795142	Green Accepted, Green Published, Bronze			2023-01-03	WOS:000337353000005
J	Zhang, LD; Hu, P; Chen, X; Bie, P				Zhang, Leida; Hu, Peng; Chen, Xi; Bie, Ping			Transarterial Chemoembolization (TACE) plus Sorafenib Versus TACE for Intermediate or Advanced Stage Hepatocellular Carcinoma: A Meta-Analysis	PLOS ONE			English	Article							RANDOMIZED-TRIALS; NATIONWIDE SURVEY; CLINICAL-TRIALS; SURVIVAL; IMPROVES; ANGIOGENESIS; COMBINATION; JAPANESE; GROWTH; BIAS	Background: Sorafenib is used in patients with intermediate or advanced stage hepatocellular carcinoma (HCC) before or after of transarterial chemoembolization (TACE). However, the survival outcomes of TACE combined with sorafenib versus TACE alone remain controversial. Thus, we conducted a meta-analysis to evaluate the efficacy and safety of the combination therapy of TACE plus sorafenib in patients with intermediate or advanced stage of HCC. Methods: Pubmed and Embase databases were systematically reviewed for studies published up to November 2013, that compared TACE alone or in combination with sorafenib. Pooled hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated for overall survival (OS), time to progression (TTP), objective response rate (ORR), and progression free survival (PFS) using random-effects or fixed-effects model, depending on the heterogeneity between the included studies. Results: Six studies published from 2011 to 2013, with a total of 1254 patients, were included in this meta-analysis. The pooled results showed that TACE combined with sorafenib significantly improved OS (HR = 0.65; 95% CI: 0.47-0.89, P = 0.007), TTP (HR = 0.68; 95% CI: 0.52-0.87, P = 0.003), ORR (HR = 1.06; 95% CI: 1.01-1.12, P = 0.021), but did not affect PFS (HR = 0.84; 95% CI: 0.62-1.14, P = 0.267). The incidence of grade III/IV adverse reaction was higher in the TACE plus sorafenib group than in the TACE group. Conclusions: The meta-analysis confirmed that the combination therapy of TACE plus sorafenib in patients with intermediate or advanced stage of HCC, can improve the OS, TTP, and ORR. This combination therapy was also associated with a significantly increased risk of adverse reactions.	[Zhang, Leida; Hu, Peng; Chen, Xi; Bie, Ping] Third Mil Med Univ, Southwest Hosp, Dept Hepatobiliary Surg, Chongqin, Peoples R China	Army Medical University	Bie, P (corresponding author), Third Mil Med Univ, Southwest Hosp, Dept Hepatobiliary Surg, Chongqin, Peoples R China.	pengboyfei@msn.com						Arii S, 2000, HEPATOLOGY, V32, P1224, DOI 10.1053/jhep.2000.20456; Bai W, 2013, J DIGEST DIS, V14, P181, DOI 10.1111/1751-2980.12038; Bayer, 2013, PHAS 2 RAND DOUBL BL; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Bruix J, 2004, GASTROENTEROLOGY, V127, pS179, DOI 10.1053/j.gastro.2004.09.032; Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199; Cabrera R, 2011, ALIMENT PHARM THER, V34, P205, DOI 10.1111/j.1365-2036.2011.04697.x; Chang YS, 2007, CANCER CHEMOTH PHARM, V59, P561, DOI 10.1007/s00280-006-0393-4; Chao Y, 2010, 2010 ASCO GASTR CANC; Choi GH, 2013, RADIOLOGY, V269, P602, DOI 10.1148/radiol.13130150; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Farrell GC, 2010, J GASTROEN HEPATOL, V25, P657, DOI 10.1111/j.1440-1746.2009.06167.x; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Ikai I, 2004, CANCER-AM CANCER SOC, V101, P796, DOI 10.1002/cncr.20426; Kudo M, 2011, EUR J CANCER, V47, P2117, DOI 10.1016/j.ejca.2011.05.007; Kunz R, 1998, BRIT MED J, V317, P1185, DOI 10.1136/bmj.317.7167.1185; Lencioni R, 2010, J CLIN ONCOL, V28; Llovet JM, 2003, HEPATOLOGY, V37, P429, DOI 10.1053/jhep.2003.50047; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; MANTEL N, 1959, J NATL CANCER I, V22, P719; Mathonnet M, 2006, WORLD J GASTROENTERO, V12, P3782, DOI 10.3748/wjg.v12.i23.3782; Muhammad A, 2013, WORLD J HEPATOL, V5, P364, DOI 10.4254/wjh.v5.i7.364; Park J., 2010, P 4 ANN C INT LIV CA, P26; Qu XD, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-263; Sansonno D, 2012, ONCOLOGIST, V17, P359, DOI 10.1634/theoncologist.2011-0313; Sergio A, 2008, AM J GASTROENTEROL, V103, P914, DOI 10.1111/j.1572-0241.2007.01712.x; Shea B., 2013, NEWCASTLE OTTAWA SCA; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Yuen MF, 2009, J GASTROEN HEPATOL, V24, P346, DOI 10.1111/j.1440-1746.2009.05784.x; Zhang T, 2010, ANTI-CANCER DRUG, V21, P326, DOI 10.1097/CAD.0b013e3283350e26; Zhang X, 2012, HEPATOB PANCREAT DIS, V11, P458, DOI 10.1016/S1499-3872(12)60209-4	34	80	84	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 19	2014	9	6							e100305	10.1371/journal.pone.0100305	http://dx.doi.org/10.1371/journal.pone.0100305			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AN6QP	24945380	Green Published, gold, Green Submitted			2023-01-03	WOS:000340721500058
J	Wang, B; Yang, Q; Bai, WW; Xing, YF; Lu, XT; Sun, YY; Zhao, YX				Wang, Bo; Yang, Qing; Bai, Wen-wu; Xing, Yi-fan; Lu, Xiao-ting; Sun, Yuan-yuan; Zhao, Yu-xia			Tongxinluo Protects against Pressure Overload-Induced Heart Failure in Mice Involving VEGF/Akt/eNOS Pathway Activation	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; ISCHEMIA-REPERFUSION INJURY; CARDIOMYOCYTE-SPECIFIC OVEREXPRESSION; INDUCED CARDIAC-HYPERTROPHY; MYOCARDIAL-INFARCTION; CELL MOBILIZATION; OXIDATIVE STRESS; KNOCKOUT MICE; FAILING HEART	Background: It has been demonstrated that Tongxinluo (TXL), a traditional Chinese medicine compound, improves ischemic heart disease in animal models via vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (eNOS). The present study aimed to investigate whether TXL protects against pressure overload-induced heart failure in mice and explore the possible mechanism of action. Methods and Results: Transverse aortic constriction (TAC) surgery was performed in mice to induce heart failure. Cardiac function was evaluated by echocardiography. Myocardial pathology was detected using hematoxylin and eosin or Masson trichrome staining. We investigated cardiomyocyte ultrastructure using transmission electron microscopy. Angiogenesis and oxidative stress levels were determined using CD31 and 8-hydroxydeoxyguanosine immunostaining and malondialdehyde assay, respectively. Fetal gene expression was measured using real-time PCR. Protein expression of VEGF, phosphorylated (p)-VEGF receptor 2 (VEGFR2), p-phosphatidylinositol 3-kinase (PI3K), p-Akt, p-eNOS, heme oxygenase-1 (HO-1), and NADPH oxidase 4 (Nox4) were measured with western blotting. Twelve-week low-and high-dose TXL treatment following TAC improved cardiac systolic and diastolic function and ameliorated left ventricular hypertrophy, fibrosis, and myocardial ultrastructure derangement. Importantly, TXL increased myocardial capillary density significantly and attenuated oxidative stress injury in failing hearts. Moreover, TXL upregulated cardiac nitrite content and the protein expression of VEGF, p-VEGFR2, p-PI3K, p-Akt, p-eNOS, and HO-1, but decreased Nox4 expression in mouse heart following TAC. Conclusion: Our findings indicate that TXL protects against pressure overload-induced heart failure in mice. Activation of the VEGF/Akt/eNOS signaling pathway might be involved in TXL improvement of the failing heart.	[Wang, Bo; Xing, Yi-fan; Zhao, Yu-xia] Shandong Univ, Qilu Hosp, Dept Tradit Chinese Med, Jinan 250100, Peoples R China; [Yang, Qing] Shandong Univ, Inst Pathogen Biol, Jinan 250100, Peoples R China; [Bai, Wen-wu; Lu, Xiao-ting; Sun, Yuan-yuan] Shandong Univ, Qilu Hosp, Key Lab Cardiovasc Remodeling & Funct Res, Jinan 250100, Peoples R China	Shandong University; Shandong University; Shandong University	Zhao, YX (corresponding author), Shandong Univ, Qilu Hosp, Dept Tradit Chinese Med, Jinan 250100, Peoples R China.	yu_xia_zhao@163.com			National 973 Basic Research Program of China [2012CB518603]; National Natural Science Foundation of China [81100103, 30873325, 81173251]; Natural Science Foundation of Shandong Province [ZR2011HQ020]	National 973 Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province)	This work was supported by grants from the National 973 Basic Research Program of China (2012CB518603), the National Natural Science Foundation of China (81100103, 30873325, and 81173251), and the Natural Science Foundation of Shandong Province (ZR2011HQ020). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anisimov A, 2013, CIRCULATION, V127, P424, DOI 10.1161/CIRCULATIONAHA.112.127472; Bai Wen-Wu, 2013, EVID-BASED COMPL ALT, V2013, DOI DOI 10.1155/2013/813247; Bugger H, 2010, CARDIOVASC RES, V85, P376, DOI 10.1093/cvr/cvp344; Chaanine AH, 2011, EUR J HEART FAIL, V13, P825, DOI 10.1093/eurjhf/hfr080; *CHIN PHARM COMM, 2005, PHARM PEOPL REP CHIN, V1; Di Napoli P, 2005, CARDIOVASC RES, V66, P462, DOI 10.1016/j.cardiores.2005.02.008; Elrod JW, 2006, ARTERIOSCL THROM VAS, V26, P1517, DOI 10.1161/01.ATV.0000224324.52466.e6; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Hafstad AD, 2013, BASIC RES CARDIOL, V108, DOI 10.1007/s00395-013-0359-8; Higashikuni Y, 2012, ARTERIOSCL THROM VAS, V32, P654, DOI 10.1161/ATVBAHA.111.240341; Janssens S, 2004, CIRC RES, V94, P1256, DOI 10.1161/01.RES.0000126497.38281.23; Khoo NKH, 2010, FREE RADICAL BIO MED, V48, P230, DOI 10.1016/j.freeradbiomed.2009.10.046; Kitamura T, 2008, NAT CELL BIOL, V10, P329, DOI 10.1038/ncb1695; Kuroda J, 2010, P NATL ACAD SCI USA, V107, P15565, DOI 10.1073/pnas.1002178107; Landmesser U, 2004, CIRCULATION, V110, P1933, DOI 10.1161/01.CIR.0000143232.67642.7A; Li XD, 2010, AM J PHYSIOL-HEART C, V299, pH1255, DOI 10.1152/ajpheart.00459.2010; Liang JQ, 2011, J ETHNOPHARMACOL, V133, P517, DOI 10.1016/j.jep.2010.10.031; Liao YL, 2004, CIRCULATION, V110, P692, DOI 10.1161/01.CIR.0000137831.08683.E1; Liu YH, 2002, HYPERTENSION, V39, P375, DOI 10.1161/hy02t2.102796; Matsushima S, 2013, CIRC RES, V112, P651, DOI 10.1161/CIRCRESAHA.112.279760; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; Nako H, 2012, HYPERTENS RES, V35, P194, DOI 10.1038/hr.2011.175; Patel VB, 2013, CIRC RES, V112, P1542, DOI 10.1161/CIRCRESAHA.111.300299; PEARLMAN JD, 1995, NAT MED, V1, P1085, DOI 10.1038/nm1095-1085; Ruetten H, 2005, CARDIOVASC RES, V66, P444, DOI 10.1016/j.cardiores.2005.01.021; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; Sano M, 2007, NATURE, V446, P444, DOI 10.1038/nature05602; Scherrer-Crosbie M, 2001, CIRCULATION, V104, P1286, DOI 10.1161/hc3601.094298; Serpi R, 2011, CARDIOVASC RES, V89, P204, DOI 10.1093/cvr/cvq267; Shiojima I, 2005, J CLIN INVEST, V115, P2108, DOI 10.1172/JCI24682; Shiojima I, 2012, AM J PATHOL, V181, P1969, DOI 10.1016/j.ajpath.2012.08.020; Shyu KG, 2005, J BIOMED SCI, V12, P409, DOI 10.1007/s11373-005-3008-x; Souders CA, 2012, AM J PATHOL, V181, P1226, DOI 10.1016/j.ajpath.2012.06.015; Sumimoto H, 2008, FEBS J, V275, P3249, DOI 10.1111/j.1742-4658.2008.06488.x; Tang JM, 2011, CARDIOVASC RES, V91, P402, DOI 10.1093/cvr/cvr053; Verma SK, 2012, CIRCULATION, V126, P418, DOI 10.1161/CIRCULATIONAHA.112.112185; Wang GW, 2010, CIRCULATION, V121, P1912, DOI 10.1161/CIRCULATIONAHA.109.905471; Xu XH, 2011, J CARDIOTHORAC SURG, V6, DOI 10.1186/1749-8090-6-54; Zhang L, 2009, AM J PHYSIOL-HEART C, V297, pH2004, DOI 10.1152/ajpheart.00208.2009	39	34	40	1	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2014	9	6							e98047	10.1371/journal.pone.0098047	http://dx.doi.org/10.1371/journal.pone.0098047			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI6CB	24887083	gold, Green Published			2023-01-03	WOS:000336956300035
J	Kurtyka, CA; Chen, L; Cress, WD				Kurtyka, Courtney A.; Chen, Lu; Cress, W. Douglas			E2F Inhibition Synergizes with Paclitaxel in Lung Cancer Cell Lines	PLOS ONE			English	Article							RETINOBLASTOMA PROTEIN; S-PHASE; TRANSCRIPTIONAL REPRESSION; RB/E2F PATHWAY; RB PROTEIN; PD 0332991; CYCLE; PROLIFERATION; INACTIVATION; EXPRESSION	The CDK/Rb/E2F pathway is commonly disrupted in lung cancer, and thus, it is predicted that blocking the E2F pathway would have therapeutic potential. To test this hypothesis, we have examined the activity of HLM006474 (a small molecule pan-E2F inhibitor) in lung cancer cell lines as a single agent and in combination with other compounds. HLM006474 reduces the viability of both SCLC and NSCLC lines with a biological IC50 that varies between 15 and 75 mu M, but with no significant difference between the groups. Combination of HLM006474 with cisplatin and gemcitabine demonstrate little synergy; however, HLM006474 synergizes with paclitaxel. Surprisingly, we discovered that brief treatment of cells with HLM006474 led to an increase of E2F3 protein levels (due to de-repression of these promoter sites). Since paclitaxel sensitivity has been shown to correlate with E2F3 levels, we hypothesized that HLM006474 synergy with paclitaxel may be mediated by transient induction of E2F3. To test this, H1299 cells were depleted of E2F3a and E2F3b with siRNA and treated with paclitaxel. Assays of proliferation showed that both siRNAs significantly reduced paclitaxel sensitivity, as expected. Taken together, these results suggest that HLM006474 may have efficacy in lung cancer and may be useful in combination with taxanes.	[Kurtyka, Courtney A.; Chen, Lu; Cress, W. Douglas] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Biol & Evolut, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Cress, WD (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Biol & Evolut, Tampa, FL 33612 USA.	douglas.cress@moffitt.org			National Cancer Institute [CA119997]; Bankhead Coley Cancer Research Program of the Florida Department of Health [FDH 08BB-05]; Moffitt Cancer Center; NATIONAL CANCER INSTITUTE [P50CA119997, P30CA076292] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Bankhead Coley Cancer Research Program of the Florida Department of Health; Moffitt Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a grant from the National Cancer Institute (CA119997), the Bankhead Coley Cancer Research Program of the Florida Department of Health (FDH 08BB-05) and the Moffitt Cancer Center. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ACS, 2010, CANC FACTS FIG 2010, P1; Adams MR, 2000, MOL CELL BIOL, V20, P3633, DOI 10.1128/MCB.20.10.3633-3639.2000; Beasley MB, 2003, HUM PATHOL, V34, P136, DOI 10.1053/hupa.2003.8; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Chen L, 2012, J BIOL CHEM, V287, P40106, DOI 10.1074/jbc.M112.380865; Chong JL, 2009, NATURE, V462, P930, DOI 10.1038/nature08677; Chong JL, 2009, MOL CELL BIOL, V29, P414, DOI 10.1128/MCB.01161-08; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Conklin JF, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2254; Cooper CS, 2006, LUNG CANCER, V54, P155, DOI 10.1016/j.lungcan.2006.07.005; Corsino P, 2009, J BIOL CHEM, V284, P29945, DOI 10.1074/jbc.M109.055251; Danielian PS, 2008, ONCOGENE, V27, P6561, DOI 10.1038/onc.2008.253; Dickson MA, 2013, J CLIN ONCOL, V31, P2024, DOI 10.1200/JCO.2012.46.5476; Flaherty KT, 2012, CLIN CANCER RES, V18, P568, DOI 10.1158/1078-0432.CCR-11-0509; Guha M, 2013, NAT BIOTECHNOL, V31, P187, DOI 10.1038/nbt0313-187a; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; He LL, 2008, J BIOL CHEM, V283, P31012, DOI 10.1074/jbc.M803547200; He S, 2000, MOL CELL BIOL, V20, P363, DOI 10.1128/MCB.20.1.363-371.2000; He YW, 2000, ONCOGENE, V19, P3422, DOI 10.1038/sj.onc.1203682; Hu QH, 2006, NUCLEIC ACIDS RES, V34, P6272, DOI 10.1093/nar/gkl801; Humbert PO, 2000, GENE DEV, V14, P690; Hurst CD, 2008, ONCOGENE, V27, P2716, DOI 10.1038/sj.onc.1210934; KELLEY MJ, 1995, JNCI-J NATL CANCER I, V87, P756, DOI 10.1093/jnci/87.10.756; Kong LJ, 2007, ONCOGENE, V26, P321, DOI 10.1038/sj.onc.1209817; Lang SE, 2001, J BIOL CHEM, V276, P32627, DOI 10.1074/jbc.M102067200; Leonard JP, 2012, BLOOD, V119, P4597, DOI 10.1182/blood-2011-10-388298; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Ma YH, 2008, CANCER RES, V68, P6292, DOI 10.1158/0008-5472.CAN-08-0121; Ma YH, 2010, J BIOL CHEM, V285, P9813, DOI 10.1074/jbc.M109.091496; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Matsumura N, 2009, MOL CANCER RES, V7, P210, DOI 10.1158/1541-7786.MCR-08-0255; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Porlan E, 2013, NAT NEUROSCI, V16, P1567, DOI 10.1038/nn.3545; Sangwan M, 2012, ONCOGENE, V31, P5019, DOI 10.1038/onc.2011.654; Schwartz GK, 2011, BRIT J CANCER, V104, P1862, DOI 10.1038/bjc.2011.177; SHAPIRO GI, 1995, CANCER RES, V55, P6200; SHAPIRO GI, 1995, CANCER RES, V55, P505; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIMIZU E, 1994, ONCOGENE, V9, P2441; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Tordai A, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2088; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; XU HJ, 1991, CANCER RES, V51, P2735; Zheng YB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070371; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459	52	32	32	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2014	9	5							e96357	10.1371/journal.pone.0096357	http://dx.doi.org/10.1371/journal.pone.0096357			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI3UI	24831239	gold, Green Published, Green Submitted			2023-01-03	WOS:000336789500017
J	Yang, ZK; Han, QF; Zhu, TY; Ren, YP; Chen, JH; Zhao, HP; Chen, MH; Dong, J; Wang, Y; Hao, CM; Zhang, R; Zhang, XH; Wang, M; Tian, N; Wang, HY				Yang, Zhi-Kai; Han, Qing-Feng; Zhu, Tong-Ying; Ren, Ye-Ping; Chen, Jiang-Hua; Zhao, Hui-Ping; Chen, Meng-Hua; Dong, Jie; Wang, Yue; Hao, Chuan-Ming; Zhang, Rui; Zhang, Xiao-Hui; Wang, Mei; Tian, Na; Wang, Hai-Yan			The Associations between the Family Education and Mortality of Patients on Peritoneal Dialysis	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; SOCIAL SUPPORT; HEMODIALYSIS-PATIENTS; TECHNIQUE FAILURE; OUTCOMES; CAREGIVERS; IMPACT; SURVIVAL; EPISODE; UPDATE	Aims: To investigate whether education level of family members predicts all-cause and cardiovascular death and initial-episode peritonitis in patients on peritoneal dialysis (PD). Methods: A total of 2264 patients on chronic PD were collected from seven centers affiliated with the Socioeconomic Status on the Outcome of Peritoneal Dialysis (SSOP) Study. All demographic, socioeconomic and laboratory data of patients and the education level of all family members were recorded at baseline. Multivariate Cox regression was used to calculate the hazard ratio (HR) of all-cause and cardiovascular mortality, and initial-episode peritonitis with adjustments for recognized traditional factors. Results: There were no significant differences in baseline characteristics between patients with (n = 1752) and without (n = 512) complete education information. According to the highest education level of patients' family, included 1752 patients were divided into four groups, i.e. elementary or lower (15%), middle (27%), high (24%) and more than high school (34%). The family highest education (using elementary school or lower group as reference, hazard ratio and 95% confidence interval of middle school group, high school group and more than high school group was 0.68[0.48-0.96], 0.64[0.45-0.91], 0.66[0.48-0.91], respectively) rather than their average education level or patients' or spouse's education was significantly associated with the higher mortality. Neither patients' nor family education level did correlate to the risk for cardiovascular death or initial-episode peritonitis. Conclusions: Family members' education level was found to be a novel predictor of PD outcome. Family, as the main source of health care providers, should be paid more attention in our practice.	[Yang, Zhi-Kai; Dong, Jie; Wang, Hai-Yan] Peking Univ, Key Lab Renal Dis, Minist Educ, Inst Nephrol,Dept Med,Renal Div,Hosp 1,Minist Hlt, Beijing 100871, Peoples R China; [Han, Qing-Feng; Wang, Yue] Peking Univ, Hosp 3, Dept Nephrol, Beijing 100871, Peoples R China; [Zhu, Tong-Ying; Hao, Chuan-Ming] Fudan Univ, Huashan Hosp, Dept Nephrol, Shanghai 200433, Peoples R China; [Ren, Ye-Ping; Zhang, Rui] Harbin Med Univ, Affiliated Hosp 2, Dept Nephrol, Harbin, Heilongjiang, Peoples R China; [Chen, Jiang-Hua; Zhang, Xiao-Hui] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Kidney Dis Ctr, Hangzhou 310003, Zhejiang, Peoples R China; [Zhao, Hui-Ping; Wang, Mei] Peking Univ, Peoples Hosp, Dept Nephrol, Beijing 100871, Peoples R China; [Chen, Meng-Hua; Tian, Na] Ningxia Med Univ, Gen Hosp, Dept Nephrol, Ningxia, Peoples R China	Peking University; Peking University; Fudan University; Harbin Medical University; Zhejiang University; Peking University; Ningxia Medical University	Dong, J (corresponding author), Peking Univ, Key Lab Renal Dis, Minist Educ, Inst Nephrol,Dept Med,Renal Div,Hosp 1,Minist Hlt, Beijing 100871, Peoples R China.	dongjie@medmail.com.cn	Dong, Jie/AFM-0048-2022; tian, na/GVR-9226-2022		New Century Excellent Talents from Education Department, China; Baxer Clinical Research Award from Baxter Corp, China; ISN Research Award from ISN GO RP Committee	New Century Excellent Talents from Education Department, China; Baxer Clinical Research Award from Baxter Corp, China; ISN Research Award from ISN GO RP Committee	This study is in part supported by New Century Excellent Talents from Education Department, China, Baxer Clinical Research Award from Baxter Corp, China and ISN Research Award from ISN GO R&P Committee. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afolalu B, 2009, PERITON DIALYSIS INT, V29, P292; Beanlands Heather, 2005, Nephrol Nurs J, V32, P621; Cohen SD, 2007, ADV CHRONIC KIDNEY D, V14, P335, DOI 10.1053/j.ackd.2007.04.007; FARIAS MG, 1994, KIDNEY INT, V46, P1392, DOI 10.1038/ki.1994.410; Griva K, 2013, PERITON DIALYSIS INT, V33, P280, DOI 10.3747/pdi.2011.00308; Horsburgh M E, 1998, ANNA J, V25, P219; Horsburgh ME, 1998, NEPHROL NURS J, V25, P229; Jain AK, 2012, J AM SOC NEPHROL, V23, P533, DOI 10.1681/ASN.2011060607; Khan CM, 2013, HEALTH PSYCHOL, V32, P739, DOI 10.1037/a0028609; Kimmel PL, 2000, J AM SOC NEPHROL, V11, P1518, DOI 10.1681/ASN.V1181518; Li PKT, 2010, PERITON DIALYSIS INT, V30, P393, DOI 10.3747/pdi.2010.00049; Martin LC, 2011, CLIN J AM SOC NEPHRO, V6, P1944, DOI 10.2215/CJN.11431210; Mehrotra R, 2012, PERITON DIALYSIS INT, V32, P322, DOI 10.3747/pdi.2011.00084; Molloy GJ, 2008, HEALTH PSYCHOL, V27, P286, DOI 10.1037/0278-6133.27.2.286; Mujais S, 2006, KIDNEY INT, V70, pS21, DOI 10.1038/sj.ki.5001912; Oliver MJ, 2010, NEPHROL DIAL TRANSPL, V25, P2737, DOI 10.1093/ndt/gfq085; Patel SS, 2005, SEMIN DIALYSIS, V18, P98, DOI 10.1111/j.1525-139X.2005.18203.x; Plantinga LC, 2010, CLIN J AM SOC NEPHRO, V5, P1480, DOI 10.2215/CJN.01240210; Schaubel DE, 2001, KIDNEY INT, V60, P1517, DOI 10.1046/j.1523-1755.2001.00969.x; Schipper K, 2011, NEPHROL DIAL TRANSPL, V26, P3189, DOI 10.1093/ndt/gfq833; Sezer S, 2013, CLIN NEPHROL, V80, P342, DOI 10.5414/CN107742; Smith SC, 2004, CIRCULATION, V109, P3112, DOI 10.1161/01.CIR.0000133427.35111.67; Stephens MAP, 2013, HEALTH PSYCHOL, V32, P1029, DOI 10.1037/a0030018; Stephens MAP, 2009, HEALTH PSYCHOL, V28, P48, DOI 10.1037/a0012385; Szeto CC, 2008, PERITON DIALYSIS INT, V28, P252; Thong MSY, 2007, NEPHROL DIAL TRANSPL, V22, P845, DOI 10.1093/ndt/gfl700; Tonelli M, 2007, KIDNEY INT, V72, P1023, DOI 10.1038/sj.ki.5002443; Tong A, 2008, NEPHROL DIAL TRANSPL, V23, P3960, DOI 10.1093/ndt/gfn415; Tsai TC, 2006, KIDNEY INT, V70, P1983, DOI 10.1038/sj.ki.5001811; Untas A, 2011, CLIN J AM SOC NEPHRO, V6, P142, DOI 10.2215/CJN.02340310; Xu R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050766; Xu R, 2012, PERITON DIALYSIS INT, V32, P94, DOI 10.3747/pdi.2010.00213; Ye XQ, 2008, J PSYCHOSOM RES, V65, P157, DOI 10.1016/j.jpsychores.2008.04.007	33	26	27	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 5	2014	9	5							e95894	10.1371/journal.pone.0095894	http://dx.doi.org/10.1371/journal.pone.0095894			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI1ZV	24797080	Green Published, Green Submitted, gold			2023-01-03	WOS:000336656000028
J	Nagler, M; Bachmann, LM; Schmid, P; Muller, PR; Wuillemin, WA				Nagler, Michael; Bachmann, Lucas M.; Schmid, Pirmin; Mueller, Pascale Raddatz; Wuillemin, Walter A.			Patient Self-Management of Oral Anticoagulation with Vitamin K Antagonists in Everyday Practice: Efficacy and Safety in a Nationwide Long-Term Prospective Cohort Study	PLOS ONE			English	Article							ATRIAL-FIBRILLATION; WARFARIN; TRIAL; THERAPY; CARE; METAANALYSIS; PREVENTION; GUIDELINES; INTENSITY; ACCURACY	Patient self-management (PSM) of oral anticoagulation is under discussion, because evidence from real-life settings is missing. Using data from a nationwide, prospective cohort study in Switzerland, we assessed overall long-term efficacy and safety of PSM and examined subgroups. Data of 1140 patients (5818.9 patient-years) were analysed and no patient were lost to follow-up. Median follow-up was 4.3 years (range 0.2-12.8 years). Median age at the time of training was 54.2 years (range 18.2-85.2) and 34.6% were women. All-cause mortality was 1.4 per 100 patient-years (95% CI 1.1-1.7) with a higher rate in patients with atrial fibrillation (2.5; 1.6-3.7; p<0.001), patients >50 years of age (2.0; 1.6-2.6; p<0.001), and men (1.6; 1.2-2.1; p = 0.036). The rate of thromboembolic events was 0.4 (0.2-0.6) and independent from indications, sex and age. Major bleeding were observed in 1.1 (0.9-1.5) per 100 patient-years. Efficacy was comparable to standard care and new oral anticoagulants in a network meta-analysis. PSM of properly trained patients is effective and safe in a long-term real-life setting and robust across clinical subgroups. Adoption in various clinical settings, including those with limited access to medical care or rural areas is warranted.	[Nagler, Michael; Schmid, Pirmin; Mueller, Pascale Raddatz; Wuillemin, Walter A.] Luzemer Kantonsspital, Div Haematol, CH-6000 Luzern, Switzerland; [Nagler, Michael; Schmid, Pirmin; Mueller, Pascale Raddatz; Wuillemin, Walter A.] Luzemer Kantonsspital, Cent Haematol Lab, CH-6000 Luzern, Switzerland; [Nagler, Michael] Inselspital Univ Hosp, Dept Haematol, Bern, Switzerland; [Nagler, Michael] Inselspital Univ Hosp, Cent Haematol Lab, Bern, Switzerland; [Bachmann, Lucas M.] Medignition Inc, Zug, Switzerland; [Wuillemin, Walter A.] Univ Bern, Bern, Switzerland	Lucerne Cantonal Hospital; Lucerne Cantonal Hospital; University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; University of Bern	Wuillemin, WA (corresponding author), Luzemer Kantonsspital, Div Haematol, CH-6000 Luzern, Switzerland.	walter.wuillemin@luks.ch	Nagler, Michael/H-6715-2019	Nagler, Michael/0000-0003-4319-2367; Schmid, Pirmin/0000-0002-1171-7643; , Lucas/0000-0002-9868-154X	charitable foundation Coagulation Care; Research Fund Haematology Luzerner Kantonsspital	charitable foundation Coagulation Care; Research Fund Haematology Luzerner Kantonsspital	The study was funded by the charitable foundation Coagulation Care, and Research Fund Haematology Luzerner Kantonsspital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adam SS, 2012, ANN INTERN MED, V157, P796, DOI 10.7326/0003-4819-157-10-201211200-00532; Ageno W, 2012, CHEST, V141, pE44S, DOI 10.1378/chest.11-2292; Agnelli G, 2013, NEW ENGL J MED, V368, P699, DOI 10.1056/NEJMoa1207541; Anaya P, 2011, ANN INTERN MED, V154, DOI 10.7326/0003-4819-154-7-201104050-00009; Ansell J, 2005, INT J CARDIOL, V99, P37, DOI 10.1016/j.ijcard.2003.11.008; Baczek VL, 2012, BMC FAM PRACT, V13, DOI 10.1186/1471-2296-13-5; Bauersachs R, 2010, NEW ENGL J MED, V363, P2499, DOI 10.1056/NEJMoa1007903; Biss TT, 2011, J THROMB HAEMOST, V9, P1090, DOI 10.1111/j.1538-7836.2011.04248.x; Bloomfield HE, 2011, ANN INTERN MED, V154, DOI 10.7326/0003-4819-154-7-201104050-00005; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469; Christensen TD, 2012, J THROMB HAEMOST, V10, P251, DOI 10.1111/j.1538-7836.2011.04568.x; Christensen TD, 2007, INT J CARDIOL, V118, P54, DOI 10.1016/j.ijcard.2006.06.018; Douketis James D, 2006, Evid Based Cardiovasc Med, V10, P124, DOI 10.1016/j.ebcm.2006.04.021; Effing T, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002990.pub2; Fitzmaurice DA, 2005, BRIT MED J, V331, P1057, DOI 10.1136/bmj.38618.580903.AE; Fitzmaurice DA, 2005, BRIT J HAEMATOL, V131, P156, DOI 10.1111/j.1365-2141.2005.05739.x; Fitzmaurice DA, 2001, BRIT MED J, V323, P985, DOI 10.1136/bmj.323.7319.985; Fritschi J, 2007, SWISS MED WKLY, V137, P252; Garcia-Alamino JM, 2010, COCHRANE DB SYST REV; Gardiner C, 2006, BRIT J HAEMATOL, V132, P598, DOI 10.1111/j.1365-2141.2005.05899.x; Hamad MAS, 2009, EUR J CARDIO-THORAC, V35, P265, DOI 10.1016/j.ejcts.2008.10.020; Heneghan C, 2012, LANCET, V379, P322, DOI 10.1016/S0140-6736(11)61294-4; Hobbs FDR, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d3653; Kearon C, 1999, NEW ENGL J MED, V340, P901, DOI 10.1056/NEJM199903253401201; Kessels A, 2013, OA EPIDEMIOLOGY, V1, P7, DOI DOI 10.13172/2053-079X-1-1-690; Kyrle PA, 2012, LANCET, V379, P292, DOI 10.1016/S0140-6736(11)61748-0; Levi M, 2008, BLOOD, V111, P4471, DOI 10.1182/blood-2007-11-123711; Li Wan Po A, 2012, LANCET, V379, P1789; Lip GYH, 2007, INT J CLIN PRACT, V61, P9, DOI 10.1111/j.1742-1241.2006.01151.x; Mair H, 2012, INTERACT CARDIOV TH, V14, P253, DOI 10.1093/icvts/ivr088; Murray E, 2004, BRIT MED J, V328, P437, DOI 10.1136/bmj.328.7437.437; Nagler M, 2013, J THROMB HAEMOST, V11, P197, DOI 10.1111/jth.12050; Ogilvie IM, 2010, AM J MED, V123, P638, DOI 10.1016/j.amjmed.2009.11.025; Palareti G, 2006, NEW ENGL J MED, V355, P1780, DOI 10.1056/NEJMoa054444; Pisters R, 2009, SEMIN THROMB HEMOST, V35, P554, DOI 10.1055/s-0029-1241048; Po ALW, 2012, LANCET, V379, P1788, DOI 10.1016/S0140-6736(12)60757-0; Ridker PM, 2003, NEW ENGL J MED, V348, P1425, DOI 10.1056/NEJMoa035029; ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236; Sawicki PT, 1999, JAMA-J AM MED ASSOC, V281, P145, DOI 10.1001/jama.281.2.145; Sawicki PT, 2003, J INTERN MED, V254, P515, DOI 10.1046/j.1365-2796.2003.01215.x; Schulman S, 2012, BLOOD, V119, P3016, DOI 10.1182/blood-2011-10-378950; Schulman S, 2009, NEW ENGL J MED, V361, P2342, DOI 10.1056/NEJMoa0906598; Sidhu P, 2001, ANN THORAC SURG, V72, P1523, DOI 10.1016/S0003-4975(01)03049-1; Siebenhofer A, 2011, ANN INTERN MED, V155, P336, DOI 10.7326/0003-4819-155-5-201109060-00018; Siebenhofer A, 2008, THROMB HAEMOSTASIS, V100, P1089, DOI 10.1160/TH08-06-0361; Uhlig K, 2013, ANN INTERN MED, V159, P185, DOI 10.7326/0003-4819-159-3-201308060-00008; van Walraven C, 2006, CHEST, V129, P1155, DOI 10.1378/chest.129.5.1155	47	20	23	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2014	9	4							e95761	10.1371/journal.pone.0095761	http://dx.doi.org/10.1371/journal.pone.0095761			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG2DP	24748062	Green Published, gold			2023-01-03	WOS:000335226500142
J	Cai, J; Feng, J; Xie, SL; Wang, FP; Xu, QF				Cai, Jin; Feng, Jia; Xie, Shulian; Wang, Feipeng; Xu, Qiufeng			Laminaria japonica Extract, an Inhibitor of Clavibater michiganense Subsp Sepedonicum	PLOS ONE			English	Article							BACTERIAL RING ROT; ANTIMICROBIAL ACTIVITY; CHEMICAL-COMPOSITION; VOLATILE COMPONENTS; ESSENTIAL OIL; ANTIFUNGAL ACTIVITY; PYRUVATE-KINASE; CELL-MEMBRANE; CAUSAL AGENT; IN-VITRO	Bacterial ring rot of potato is one of the most serious potato plant and tuber diseases. Laminaria japonica extract was investigated for its antimicrobial activity against Clavibater michiganense subsp. sepedonicum (Spieckermann & Kotthoff) Davis et al., the causative agent of bacterial ring rot of potato. The results showed that the optimum extraction conditions of antimicrobial substances from L. japonica were an extraction temperature of 80 degrees C, an extraction time of 12 h, and a solid to liquid ratio of 1: 25. Active compounds of L. japonica were isolated by solvent partition, thin layer chromatography (TLC) and column chromatography. All nineteen fractionations had antimicrobial activities against C. michiganense subsp. sepedonicum, while Fractionation three (Fr. 3) had the highest (P<0.05) antimicrobial activity. Chemical composition analysis identified a total of 26 components in Fr. 3. The main constituents of Fr. 3 were alkanes (80.97%), esters (5.24%), acids (4.87%) and alcohols (2.21%). Antimicrobial activity of Fr. 3 against C. michiganense subsp. sepedonicum could be attributed to its ability to damage the cell wall and cell membrane, induce the production of reactive oxygen species (ROS), increase cytosolic Ca2+ concentration, inhibit the glycolytic pathway (EMP) and tricarboxylic acid (TCA) cycle, inhibit protein and nucleic acid synthesis, and disrupt the normal cycle of DNA replication. These findings indicate that L. japonica extracts have potential for inhibiting C. michiganense subsp. sepedonicum.	[Cai, Jin; Feng, Jia; Xie, Shulian; Wang, Feipeng; Xu, Qiufeng] Shanxi Univ, Sch Life Sci, Taiyuan, Peoples R China	Shanxi University	Xie, SL (corresponding author), Shanxi Univ, Sch Life Sci, Taiyuan, Peoples R China.	xiesl@sxu.edu.cn						Abdel-Monaim MF, 2011, CROP PROT, V30, P185, DOI 10.1016/j.cropro.2010.09.016; Ahuja I, 2012, TRENDS PLANT SCI, V17, P73, DOI 10.1016/j.tplants.2011.11.002; Alteri CJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000448; Anastasiou D, 2011, SCIENCE, V334, P1278, DOI 10.1126/science.1211485; Antony J., 2006, Sensor Review, V26, P227, DOI 10.1108/02602280610675519; Asano T, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003581; Avila JG, 1999, J ETHNOPHARMACOL, V66, P75, DOI 10.1016/S0378-8741(98)00203-7; Bagheri-Gavkosh S, 2009, MYCOPATHOLOGIA, V168, P249, DOI 10.1007/s11046-009-9220-x; BAKKEN LR, 1987, MICROBIAL ECOL, V13, P103, DOI 10.1007/BF02011247; Barros L, 2007, EUR FOOD RES TECHNOL, V225, P151, DOI 10.1007/s00217-006-0394-x; Bernardo-Gil MG, 2009, J SUPERCRIT FLUID, V49, P32, DOI 10.1016/j.supflu.2008.12.004; Boussaada O, 2009, J ESSENT OIL RES, V21, P179, DOI 10.1080/10412905.2009.9700142; BOWLER C, 1992, ANNU REV PLANT PHYS, V43, P83, DOI 10.1146/annurev.pp.43.060192.000503; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brady N. C., 1984, NATURE PROPERTIES SO, P528; Cardoso RA, 2010, GENET MOL RES, V9, P231, DOI 10.4238/vol9-1gmr688; Castro MS, 2005, PROTEIN PEPTIDE LETT, V12, P13; Chen CZS, 2002, BIOMATERIALS, V23, P3359, DOI 10.1016/S0142-9612(02)00036-4; Chen JC, 2007, CURR BIOL, V17, pR203, DOI 10.1016/j.cub.2007.01.031; Chen Y, 1994, FOOD FERMENT IND, V3, P26; Chen YJ, 2012, J SCI FOOD AGR, V92, P1937, DOI 10.1002/jsfa.5565; CHENG KJ, 1970, J BACTERIOL, V104, P748, DOI 10.1128/JB.104.2.748-753.1970; Cheng XL, 2013, RSC ADV, V3, P2296, DOI 10.1039/c2ra23131j; Choi YS, 2012, MEAT SCI, V91, P1, DOI 10.1016/j.meatsci.2011.11.011; Devi KP, 2010, J ETHNOPHARMACOL, V130, P107, DOI 10.1016/j.jep.2010.04.025; Dhankhar Sandeep, 2012, Recent Pat Antiinfect Drug Discov, V7, P242; Diez C, 2008, J CHROMATOGR A, V1180, P10, DOI 10.1016/j.chroma.2007.12.036; Efthimiadou EK, 2008, BIOORG MED CHEM LETT, V18, P4033, DOI 10.1016/j.bmcl.2008.05.115; Efthimiadou EK, 2010, J INORG BIOCHEM, V104, P455, DOI 10.1016/j.jinorgbio.2009.12.019; Foreman J, 2003, NATURE, V422, P442, DOI 10.1038/nature01485; FRIEDLANDER ML, 1984, J CLIN PATHOL, V37, P961, DOI 10.1136/jcp.37.9.961; [耿飞 GENG Fei], 2011, [食品科学, Food Science], V32, P88; Go H, 2010, TOXICOL IN VITRO, V24, P1546, DOI 10.1016/j.tiv.2010.06.018; Gulec C, 2007, ASIAN J CHEM, V19, P4069; Haines LR, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000373; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HALLIWELL B, 1994, NUTR REV, V52, P253; Han GY, 2002, J INORG BIOCHEM, V91, P230, DOI 10.1016/S0162-0134(02)00369-0; HARA S, 1995, J BIOL CHEM, V270, P29923, DOI 10.1074/jbc.270.50.29923; Holley RA, 2005, FOOD MICROBIOL, V22, P273, DOI 10.1016/j.fm.2004.08.006; Huang CB, 2010, ARCH ORAL BIOL, V55, P555, DOI 10.1016/j.archoralbio.2010.05.009; Ibrahim HR, 1996, J AGR FOOD CHEM, V44, P3799, DOI 10.1021/jf960133x; Imura Y, 2007, BBA-BIOMEMBRANES, V1768, P2578, DOI 10.1016/j.bbamem.2007.06.013; Ippolito A, 2000, CROP PROT, V19, P715, DOI 10.1016/S0261-2194(00)00095-8; Jia XY, 2010, CHROMATOGRAPHIA, V71, P839, DOI 10.1365/s10337-010-1547-4; Karabay-Yavasoglu NU, 2007, PHYTOTHER RES, V21, P153, DOI 10.1002/ptr.2045; Khan MSA, 2011, PHYTOMEDICINE, V19, P48, DOI 10.1016/j.phymed.2011.07.005; Kilickap E, 2010, INT J ADV MANUF TECH, V49, P911, DOI 10.1007/s00170-009-2469-x; Knight SC, 1997, ANNU REV PHYTOPATHOL, V35, P349, DOI 10.1146/annurev.phyto.35.1.349; Kohanski MA, 2007, CELL, V130, P797, DOI 10.1016/j.cell.2007.06.049; Kumar A, 2009, AFR J PHARM PHARMACO, V3, P560; Kumar RS, 2008, J INORG BIOCHEM, V102, P234, DOI 10.1016/j.jinorgbio.2007.08.005; LEPECQ JB, 1967, J MOL BIOL, V27, P87, DOI 10.1016/0022-2836(67)90353-1; Li LR, 2013, APPL MICROBIOL BIOT, V97, P1711, DOI 10.1007/s00253-012-4352-1; Li N, 2005, FOOD CHEM TOXICOL, V43, P421, DOI 10.1016/j.fct.2004.12.001; Li QQ, 2010, EUR J PHARMACOL, V626, P146, DOI 10.1016/j.ejphar.2009.09.044; Lieberthal W, 1998, AM J PHYSIOL-RENAL, V274, pF315, DOI 10.1152/ajprenal.1998.274.2.F315; Liu RM, 2002, FOOD FERM IND, V29, P61; Liu X, 2009, EUR FOOD RES TECHNOL, V229, P247, DOI 10.1007/s00217-009-1057-5; Lu X, 2012, APPL MICROBIOL BIOT, V95, P939, DOI 10.1007/s00253-011-3793-2; Lupea AX, 2003, REV CHIM-BUCHAREST, V54, P923; Mattevi A, 1996, FEBS LETT, V389, P15, DOI 10.1016/0014-5793(96)00462-0; Michielin EMZ, 2009, BIORESOURCE TECHNOL, V100, P6615, DOI 10.1016/j.biortech.2009.07.061; Mori IC, 2004, PLANT PHYSIOL, V135, P702, DOI 10.1104/pp.104.042069; MUIRHEAD KA, 1985, BIO-TECHNOL, V3, P337, DOI 10.1038/nbt0485-337; Munger J, 2006, PLOS PATHOG, V2, P1165, DOI 10.1371/journal.ppat.0020132; Muthukumar A, 2010, CROP PROT, V29, P1483, DOI 10.1016/j.cropro.2010.08.009; Navarro C, 2011, NATURE, V478, P119, DOI 10.1038/nature10431; Nishida M, 2006, J CHROMATOGR B, V842, P106, DOI 10.1016/j.jchromb.2006.07.039; Ozdemir G, 2006, PHARM BIOL, V44, P183, DOI 10.1080/13880200600685949; Palic R, 2002, FLAVOUR FRAG J, V17, P323, DOI 10.1002/ffj.1084; Passos XS, 2003, PHARM BIOL, V41, P319, DOI 10.1076/phbi.41.5.319.15936; Peng ZF, 2012, CARBOHYD POLYM, V89, P1022, DOI 10.1016/j.carbpol.2012.03.043; POLITOFF AL, 1969, J GEN PHYSIOL, V53, P498, DOI 10.1085/jgp.53.4.498; Qiu YE, 2004, XINJIANG AGR SCI, P88; Rafiqi M, 2012, CURR OPIN PLANT BIOL, V15, P477, DOI 10.1016/j.pbi.2012.05.003; Rigden DJ, 1999, J MOL BIOL, V291, P615, DOI 10.1006/jmbi.1999.2918; Rizwan K, 2012, INT J MOL SCI, V13, P6440, DOI 10.3390/ijms13056440; Schepers E, 2009, J IMMUNOL METHODS, V348, P74, DOI 10.1016/j.jim.2009.07.002; SECOR GA, 1987, AM POTATO J, V64, P699; Shen HM, 1996, FREE RADICAL BIO MED, V21, P139, DOI 10.1016/0891-5849(96)00019-6; SIKKEMA J, 1995, MICROBIOL REV, V59, P201, DOI 10.1128/MMBR.59.2.201-222.1995; Sinek K, 2012, ASIAN J CHEM, V24, P1931; Smania A. Jr., 1999, International Journal of Medicinal Mushrooms, V1, P325; Song Feng-ping, 2009, Chinese Journal of Pesticide Science, V11, P213; Sukatar A, 2006, ANN MICROBIOL, V56, P275, DOI 10.1007/BF03175018; Sun L, 2003, J CHROMATOGR A, V1014, P165, DOI 10.1016/S0021-9673(03)00574-0; Talibi I, 2012, CROP PROT, V35, P41, DOI 10.1016/j.cropro.2011.12.016; Tarushi A, 2009, J INORG BIOCHEM, V103, P898, DOI 10.1016/j.jinorgbio.2009.03.007; Tseng CK, 2001, J APPL PHYCOL, V13, P375, DOI 10.1023/A:1017972812576; Ultee A, 2002, APPL ENVIRON MICROB, V68, P1561, DOI 10.1128/AEM.68.4.1561-1568.2002; Valiei M, 2011, J MED PLANTS RES, V5, P6972, DOI 10.5897/JMPR11.963; van Beckhoven JRCM, 2002, J APPL MICROBIOL, V93, P840, DOI 10.1046/j.1365-2672.2002.01765.x; van der Wolf JM, 2005, J PHYTOPATHOL, V153, P358, DOI 10.1111/j.1439-0434.2005.00985.x; Wang C, 2013, LIFE SCI, V92, P1004, DOI 10.1016/j.lfs.2013.03.016; Wang GuanLin, 2005, Scientia Agricultura Sinica, V38, P2321; Wang HK, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0029452, 10.1371/journal.pone.0038619, 10.1371/journal.pone.0041330]; Wang J, 2013, INT J FOOD MICROBIOL, V161, P151, DOI 10.1016/j.ijfoodmicro.2012.11.025; Wang QA, 2010, ARCH MICROBIOL, V192, P893, DOI 10.1007/s00203-010-0617-1; Wu PG, 2010, BIOMATERIALS, V31, P7526, DOI 10.1016/j.biomaterials.2010.06.032; Xiong JH, 2007, FOOD MACH, V23, P78; Yang DM, 2010, J CHIN I FOOD SCI TE, V10, P47; Yang WW, 2013, ENVIRON TOXICOL PHAR, V35, P320, DOI 10.1016/j.etap.2013.01.006; Yao XL, 2012, FOOD CHEM, V132, P1883, DOI 10.1016/j.foodchem.2011.12.021; Yayli N, 2006, TURK J CHEM, V30, P71; Yun Bao-Yi, 2012, Yao Xue Xue Bao, V47, P1587; ZENG CK, 1984, HYDROBIOLOGIA, V116, P152; [郑怡 Zheng Yi], 2004, [海洋科学, Marine Sciences], V28, P42; Zhou W, 2010, CHROMATOGRAPHIA, V72, P719, DOI 10.1365/s10337-010-1747-y; Zito P, 2011, NAT PROD RES, V25, P1339, DOI 10.1080/14786419.2010.535157; 陈云, 2010, [山西农业科学, Journal of Shanxi Agricultural Sciences], V38, P140	111	5	5	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 8	2014	9	4							e94329	10.1371/journal.pone.0094329	http://dx.doi.org/10.1371/journal.pone.0094329			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE7FA	24714388	Green Submitted, Green Published, gold			2023-01-03	WOS:000334160900117
J	Price, R; MacLennan, G; Glen, J				Price, Richard; MacLennan, Graeme; Glen, John		SuDDICU Collaboration	Selective digestive or oropharyngeal decontamination and topical oropharyngeal chlorhexidine for prevention of death in general intensive care: systematic review and network meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							VENTILATOR-ASSOCIATED PNEUMONIA; CRITICALLY-ILL PATIENTS; PLAQUE ANTISEPTIC DECONTAMINATION; RESPIRATORY-TRACT INFECTIONS; DOUBLE-BLIND; ORAL DECONTAMINATION; NOSOCOMIAL INFECTIONS; CONTROLLED-TRIAL; ANTIBIOTIC-PROPHYLAXIS; BACTERIAL-COLONIZATION	Objectives To determine the effect on mortality of selective digestive decontamination, selective oropharyngeal decontamination, and topical oropharyngeal chlorhexidine in adult patients in general intensive care units and to compare these interventions with each other in a network meta-analysis. Design Systematic review, conventional meta-analysis, and network meta-analysis. Medline, Embase, and CENTRAL were searched to December 2012. Previous meta-analyses, conference abstracts, and key journals were also searched. We used pairwise meta-analyses to estimate direct evidence from intervention-control trials and a network meta-analysis within a Bayesian framework to combine direct and indirect evidence. Inclusion criteria Prospective randomised controlled trials that recruited adult patients in general intensive care units and studied selective digestive decontamination, selective oropharyngeal decontamination, or oropharyngeal chlorhexidine compared with standard care or placebo. Results Selective digestive decontamination had a favourable effect on mortality, with a direct evidence odds ratio of 0.73 (95% confidence interval 0.64 to 0.84). The direct evidence odds ratio for selective oropharyngeal decontamination was 0.85 (0.74 to 0.97). Chlorhexidine was associated with increased mortality (odds ratio 1.25, 1.05 to 1.50). When each intervention was compared with the other, both selective digestive decontamination and selective oropharyngeal decontamination were superior to chlorhexidine. The difference between selective digestive decontamination and selective oropharyngeal decontamination was uncertain. Conclusion Selective digestive decontamination has a favourable effect on mortality in adult patients in general intensive care units. In these patients, the effect of selective oropharyngeal decontamination is less certain. Both selective digestive decontamination and selective oropharyngeal decontamination are superior to chlorhexidine, and there is a possibility that chlorhexidine is associated with increased mortality.	[Price, Richard] Royal Alexandra Hosp, Intens Care Unit, Paisley PA2 9PN, Renfrew, Scotland; [MacLennan, Graeme] Univ Aberdeen, Hlth Serv Res Unit, Aberdeen AB25 2ZD, Scotland; [Glen, John] Glan Clwyd Gen Hosp, Intens Care Unit, Bodelwyddan LL18 5UJ, Wales	University of Aberdeen	Price, R (corresponding author), Royal Alexandra Hosp, Intens Care Unit, Paisley PA2 9PN, Renfrew, Scotland.	rjp@doctors.org.uk		MacLennan, Graeme/0000-0002-1039-5646	Chief Scientist Office [HSRU1] Funding Source: Medline	Chief Scientist Office		AERDTS SJA, 1991, CHEST, V100, P783, DOI 10.1378/chest.100.3.783; Bastin AJ, 2009, ANAESTHESIA, V64, P46, DOI 10.1111/j.1365-2044.2008.05676.x; Bekaert M, 2011, AM J RESP CRIT CARE, V184, P1133, DOI 10.1164/rccm.201105-0867OC; Bellissimo-Rodrigues F, 2009, INFECT CONT HOSP EP, V30, P952, DOI 10.1086/605722; Bergmans DCJJ, 2001, AM J RESP CRIT CARE, V164, P382, DOI 10.1164/ajrccm.164.3.2005003; Berry AM, 2011, INT J NURS STUD, V48, P681, DOI 10.1016/j.ijnurstu.2010.11.004; BLAIR P, 1991, SURGERY, V110, P303; BOLAND JP, 1991, 17 C CHEM; BONTEN MJM, 1994, AM J RESP CRIT CARE, V150, P1332, DOI 10.1164/ajrccm.150.5.7952561; Bonten MJM, 2003, INTENS CARE MED, V29, P672, DOI 10.1007/s00134-003-1714-2; Cabov T, 2010, WIEN KLIN WOCHENSCHR, V122, P397, DOI 10.1007/s00508-010-1397-y; Carvajal C, 2010, MED CLIN-BARCELONA, V135, P491, DOI 10.1016/j.medcli.2010.02.039; Chan EY, 2007, BMJ-BRIT MED J, V334, P889, DOI 10.1136/bmj.39136.528160.BE; Chlebicki MN, 2007, CRIT CARE MED, V35, P595, DOI 10.1097/01.CCM.0000253395.70708.AC; COCKERILL FR, 1992, ANN INTERN MED, V117, P545, DOI 10.7326/0003-4819-117-7-545; Cuthbertson BH, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-117; de Jonge E, 2003, LANCET, V362, P1011, DOI 10.1016/S0140-6736(03)14409-1; de Jonge E, 2003, LANCET, V362, P2119, DOI 10.1016/S0140-6736(03)15122-7; de Smet AMGA, 2009, NEW ENGL J MED, V360, P20, DOI 10.1056/NEJMoa0800394; de Smet AMGA, 2012, CURR OPIN INFECT DIS, V25, P211, DOI 10.1097/QCO.0b013e3283507f8c; Dias S, 2011, 2 NICE DSU; Fourrier F, 2000, INTENS CARE MED, V26, P1239, DOI 10.1007/s001340000585; Fourrier F, 2005, CRIT CARE MED, V33, P1728, DOI 10.1097/01.CCM.0000171537.03493.B0; Garcia MS, 1998, AM J RESP CRIT CARE, V158, P908, DOI 10.1164/ajrccm.158.3.9712079; GarrousteOrgeas M, 1997, AM J RESP CRIT CARE, V156, P1647, DOI 10.1164/ajrccm.156.5.96-04076; HUMPHREYS H, 1992, INTENS CARE MED, V18, P459, DOI 10.1007/BF01708581; Institute for Healthcare Improvement, 2012, GUID PREV VENTILATOR; Jacobs S., 1992, CLIN INTENSIVE CARE, V3, P52; JOHANSON WG, 1972, ANN INTERN MED, V77, P701, DOI 10.7326/0003-4819-77-5-701; Koeman M, 2006, AM J RESP CRIT CARE, V173, P1348, DOI 10.1164/rccm.200505-820OC; Kola A, 2007, J HOSP INFECT, V66, P207, DOI 10.1016/j.jhin.2007.03.025; Kollef MH, 2003, CHEST, V123, p464S, DOI 10.1378/chest.123.5_suppl.464S; Krueger WA, 2002, AM J RESP CRIT CARE, V166, P1029, DOI 10.1164/rccm.2105141; Labeau SO, 2011, LANCET INFECT DIS, V11, P845, DOI 10.1016/S1473-3099(11)70127-X; Liberati A, 2009, COCHRANE DB SYST REV, V4, P22, DOI 10.1002/14651858.CD000022.pub2; Lunn DJ, 2000, STAT COMPUT, V10, P325, DOI 10.1023/A:1008929526011; Macnaughton P., 2004, INTENSIVE CARE MED, V30; Munro CL, 2009, AM J CRIT CARE, V18, P428, DOI 10.4037/ajcc2009792; National Institute for Health and Clinical Excellence, TECHN PAT SAF SOL VE; Oostdijk EAN, 2012, INTENS CARE MED, V38, P533, DOI 10.1007/s00134-012-2488-1; Palomar M., 1997, CLIN INTENSIVE CARE, V8, P228, DOI [10.3109/tcic.8.5.228.235, DOI 10.3109/TCIC.8.5.228.235]; Panchabhai TS, 2009, CHEST, V135, P1150, DOI 10.1378/chest.08-1321; Pileggi C, 2011, CRIT CARE, V15, DOI 10.1186/cc10285; Pineda LA, 2006, CRIT CARE, V10, DOI 10.1186/cc4837; Pugh RJ, 2010, CRIT CARE S1, V14, P85; PUGIN J, 1991, JAMA-J AM MED ASSOC, V265, P2704, DOI 10.1001/jama.265.20.2704; Rello J, 2010, INTENS CARE MED, V36, P773, DOI 10.1007/s00134-010-1841-5; Rios F, 2005, P AM THORACIC SOC, pA820; ROCHA LA, 1992, INTENS CARE MED, V18, P398, DOI 10.1007/BF01694341; Scannapieco FA, 2009, CRIT CARE, V13, DOI 10.1186/cc7967; Schultz MJ, 2011, CRIT CARE, V15, DOI 10.1186/cc9963; Silvestri L, 2008, ANAESTH INTENS CARE, V36, P324, DOI 10.1177/0310057X0803600304; Silvestri L, 2007, J HOSP INFECT, V65, P187, DOI 10.1016/j.jhin.2006.10.014; Silvestri L, 2009, J CRIT CARE, V24, DOI 10.1016/j.jcrc.2008.11.005; Silvestri L, 2010, CRIT CARE MED, V38, P1370, DOI 10.1097/CCM.0b013e3181d9db8c; Stoutenbeek CP, 2007, INTENS CARE MED, V33, P261, DOI 10.1007/s00134-006-0455-4; Tad-Y D, 2007, CHEST, V132, p498a; Tantipong H, 2008, INFECT CONT HOSP EP, V29, P131, DOI 10.1086/526438; ULRICH C, 1989, INTENS CARE MED, V15, P424, DOI 10.1007/BF00255597; van Saene HKF, 2003, INTENS CARE MED, V29, P677, DOI 10.1007/s00134-003-1722-2; van Till JWO, 2007, CRIT CARE, V11, DOI 10.1186/cc6191; VANSAENE HF, 1992, CRIT CARE MED, V20, P691, DOI 10.1097/00003246-199205000-00024; Verbrugh HA, 2003, LANCET, V362, P2117, DOI 10.1016/S0140-6736(03)15117-3; Verwaest C, 1997, CRIT CARE MED, V25, P63, DOI 10.1097/00003246-199701000-00014; Walden AP, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6697; WINTER R, 1992, J ANTIMICROB CHEMOTH, V30, P73, DOI 10.1093/jac/30.1.73	66	139	141	1	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 31	2014	348								g2197	10.1136/bmj.g2197	http://dx.doi.org/10.1136/bmj.g2197			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AE4TK	24687313	hybrid, Green Published			2023-01-03	WOS:000333976100002
J	Acosta, SA; Tajiri, N; Shinozuka, K; Ishikawa, H; Sanberg, PR; Sanchez-Ramos, J; Song, SJ; Kaneko, Y; Borlongan, CV				Acosta, Sandra A.; Tajiri, Naoki; Shinozuka, Kazutaka; Ishikawa, Hiroto; Sanberg, Paul R.; Sanchez-Ramos, Juan; Song, Shijie; Kaneko, Yuji; Borlongan, Cesar V.			Combination Therapy of Human Umbilical Cord Blood Cells and Granulocyte Colony Stimulating Factor Reduces Histopathological and Motor Impairments in an Experimental Model of Chronic Traumatic Brain Injury	PLOS ONE			English	Article							MARROW STROMAL CELLS; CEREBRAL-ARTERY OCCLUSION; ENDOTHELIAL GROWTH-FACTOR; MESENCHYMAL STEM-CELLS; FACTOR G-CSF; FUNCTIONAL RECOVERY; NEUROTROPHIC FACTORS; COLLAGEN SCAFFOLDS; MILD HYPOTHERMIA; PROGENITOR CELLS	Traumatic brain injury (TBI) is associated with neuro-inflammation, debilitating sensory-motor deficits, and learning and memory impairments. Cell-based therapies are currently being investigated in treating neurotrauma due to their ability to secrete neurotrophic factors and anti-inflammatory cytokines that can regulate the hostile milieu associated with chronic neuroinflammation found in TBI. In tandem, the stimulation and mobilization of endogenous stem/progenitor cells from the bone marrow through granulocyte colony stimulating factor (G-CSF) poses as an attractive therapeutic intervention for chronic TBI. Here, we tested the potential of a combined therapy of human umbilical cord blood cells (hUCB) and G-CSF at the acute stage of TBI to counteract the progressive secondary effects of chronic TBI using the controlled cortical impact model. Four different groups of adult Sprague Dawley rats were treated with saline alone, G-CSF+saline, hUCB+saline or hUCB+G-CSF, 7-days post CCI moderate TBI. Eight weeks after TBI, brains were harvested to analyze hippocampal cell loss, neuroinflammatory response, and neurogenesis by using immunohistochemical techniques. Results revealed that the rats exposed to TBI treated with saline exhibited widespread neuroinflammation, impaired endogenous neurogenesis in DG and SVZ, and severe hippocampal cell loss. hUCB monotherapy suppressed neuroinflammation, nearly normalized the neurogenesis, and reduced hippocampal cell loss compared to saline alone. G-CSF monotherapy produced partial and short-lived benefits characterized by low levels of neuroinflammation in striatum, DG, SVZ, and corpus callosum and fornix, a modest neurogenesis, and a moderate reduction of hippocampal cells loss. On the other hand, combined therapy of hUCB+G-CSF displayed synergistic effects that robustly dampened neuroinflammation, while enhancing endogenous neurogenesis and reducing hippocampal cell loss. Vigorous and long-lasting recovery of motor function accompanied the combined therapy, which was either moderately or short-lived in the monotherapy conditions. These results suggest that combined treatment rather than monotherapy appears optimal for abrogating histophalogical and motor impairments in chronic TBI.	[Acosta, Sandra A.; Tajiri, Naoki; Shinozuka, Kazutaka; Ishikawa, Hiroto; Sanberg, Paul R.; Kaneko, Yuji; Borlongan, Cesar V.] Univ S Florida, Coll Med, Dept Neurosurg & Brain Repair, Ctr Excellence Aging & Brain Repair, Tampa, FL 33620 USA; [Sanberg, Paul R.] Univ S Florida, Off Res & Innovat, Tampa, FL USA; [Sanchez-Ramos, Juan; Song, Shijie] James Haley Vet Affairs Med Ctr, Tampa, FL USA; [Sanchez-Ramos, Juan; Song, Shijie] Univ S Florida, Dept Neurol, Tampa, FL 33620 USA; [Sanchez-Ramos, Juan; Song, Shijie] Univ S Florida, Dept Mol Pharmacol & Physiol, Tampa, FL USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Borlongan, CV (corresponding author), Univ S Florida, Coll Med, Dept Neurosurg & Brain Repair, Ctr Excellence Aging & Brain Repair, Tampa, FL 33620 USA.	cborlong@health.usf.edu	Sanchez-Ramos, Juan/O-7870-2014; Borlongan, Cesar/I-5696-2012; Tajiri, Naoki/K-1230-2012; Sanchez-Ramos, Juan/A-1188-2009	Borlongan, Cesar/0000-0002-2966-9782; Tajiri, Naoki/0000-0003-2189-662X; Sanberg, Paul/0000-0001-9130-4592; Sanchez-Ramos, Juan/0000-0002-3391-7857; Shinozuka, Kazutaka/0000-0002-6435-4460; Ishikawa, Hiroto/0000-0003-0760-7203	Department of Defense [W81XWH-11-1-0634]; University of South Florida Signature Interdisciplinary Program in Neuroscience funds; University of South Florida; Veterans Administration Reintegration Funds; University of South Florida Neuroscience Collaborative Program; National Institutes of Health [1R01NS071956-01A1]; James and Esther King Biomedical Research Foundation [1KG01-33966]; SanBio Inc.; KMPHC; NeuralStem Inc.; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS071956] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001407] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); University of South Florida Signature Interdisciplinary Program in Neuroscience funds; University of South Florida; Veterans Administration Reintegration Funds; University of South Florida Neuroscience Collaborative Program; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); James and Esther King Biomedical Research Foundation; SanBio Inc.; KMPHC; NeuralStem Inc.; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Veterans Affairs(US Department of Veterans Affairs)	Financial support for this study was provided by the Department of Defense W81XWH-11-1-0634, the University of South Florida Signature Interdisciplinary Program in Neuroscience funds, the University of South Florida and Veterans Administration Reintegration Funds, and the University of South Florida Neuroscience Collaborative Program. CVB and PRS serve as consultant and founder, respectively, of Saneron CCEL Therapeutics, Inc. CVB is funded by the National Institutes of Health 1R01NS071956-01A1, James and Esther King Biomedical Research Foundation 1KG01-33966, SanBio Inc., KMPHC and NeuralStem Inc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Azouvi P, 2009, PROG BRAIN RES, V177, P89, DOI 10.1016/S0079-6123(09)17708-7; Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Bakhtiary Mehrdad, 2010, Iranian Biomedical Journal, V14, P142; Bath PMW, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005207.pub4; Bigler ED, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00395; Borlongan CV, 2011, LEUKEMIA, V25, P1674, DOI 10.1038/leu.2011.167; Borlongan CV, 2004, STROKE, V35, P2385, DOI 10.1161/01.STR.0000141680.49960.d7; BORLONGAN CV, 1995, J NEUROSCI, V15, P5372; Campbell K, 2013, BRAIN RES, V1502, P47, DOI 10.1016/j.brainres.2013.01.038; Coelho Carl A., 2007, Seminars in Speech and Language, V28, P122, DOI 10.1055/s-2007-970570; Cox CS, 2011, NEUROSURGERY, V68, P588, DOI 10.1227/NEU.0b013e318207734c; Cui LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064684; Dasari VR, 2008, NEUROBIOL DIS, V32, P486, DOI 10.1016/j.nbd.2008.09.005; England TJ, 2012, STROKE, V43, P405, DOI 10.1161/STROKEAHA.111.636449; Ettenhofer ML, 2009, J CLIN EXP NEUROPSYC, V31, P363, DOI 10.1080/13803390802175270; Fabrizio KS, 2010, NURS CLIN N AM, V45, P569, DOI 10.1016/j.cnur.2010.06.003; Farbota KDM, 2012, J INT NEUROPSYCH SOC, V18, P1006, DOI 10.1017/S1355617712000835; Faul M, 2010, TRAUMATIC BRAIN INJU, DOI DOI 10.15620/CDC.5571; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Glover LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033646; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; Guan J, 2013, BIOMATERIALS, V34, P5937, DOI 10.1016/j.biomaterials.2013.04.047; Guo XH, 2012, INT J NEUROSCI, V122, P723, DOI 10.3109/00207454.2012.716109; Hartung T, 1998, Curr Opin Hematol, V5, P221, DOI 10.1097/00062752-199805000-00013; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Huang XT, 2013, J NEUROTRAUM, V30, P2080, DOI 10.1089/neu.2013.2996; Imamura K, 2005, ACTA NEUROPATHOL, V109, P141, DOI 10.1007/s00401-004-0919-y; Imamura K, 2003, ACTA NEUROPATHOL, V106, P518, DOI 10.1007/s00401-003-0766-2; Iskander A, 2013, STEM CELL TRANSL MED, V2, P703, DOI 10.5966/sctm.2013-0066; Joo YD, 2011, CYTOKINE, V54, P36, DOI 10.1016/j.cyto.2010.12.020; Jung KH, 2006, BRAIN RES, V1073, P190, DOI 10.1016/j.brainres.2005.12.037; Khatibi NH, 2011, ACTA NEUROCHIR SUPPL, V111, P265, DOI 10.1007/978-3-7091-0693-8_44; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Lewis FD, 2013, J SPEC OPER MED, V13, P56; Liu CY, 2008, NEUROSURGERY, V63, pN12, DOI 10.1227/01.NEU.0000339457.01711.3B; Lopes FRP, 2013, NEUROSCIENCE, V230, P184, DOI 10.1016/j.neuroscience.2012.10.025; Loving CL, 2013, BIOLOGICALS, V41, P368, DOI 10.1016/j.biologicals.2013.07.001; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Lyman GH, 2013, ANN ONCOL, V24, P2475, DOI 10.1093/annonc/mdt226; Maegele M, 2008, MINIM INVASIV THER, V17, P119, DOI 10.1080/13645700801970087; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2013, J NEUROSURG, V118, P381, DOI 10.3171/2012.11.JNS12753; Massengale M, 2005, J EXP MED, V201, P1579, DOI 10.1084/jem.20050030; Maurer MH, 2008, CURR MED CHEM, V15, P1407, DOI 10.2174/092986708784567671; Minnerup Jens, 2009, Exp Transl Stroke Med, V1, P2, DOI 10.1186/2040-7378-1-2; Morita Y, 2007, NEUROSCI RES, V58, P356, DOI 10.1016/j.neures.2007.04.006; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; Ozen LJ, 2012, ARCH CLIN NEUROPSYCH, V27, P85, DOI 10.1093/arclin/acr087; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Popa-Wagner A, 2010, STROKE, V41, P1027, DOI 10.1161/STROKEAHA.109.575621; Prakash A, 2013, PHARMACOL BIOCHEM BE, V110, P46, DOI 10.1016/j.pbb.2013.05.015; Sakowitz OW, 2006, ACTA NEUROCHIR SUPPL, V96, P139; Sanberg PR, 2012, PROG BRAIN RES, V201, P99, DOI 10.1016/B978-0-444-59544-7.00006-8; Sanchez-Ramos J, 2009, NEUROSCIENCE, V163, P55, DOI 10.1016/j.neuroscience.2009.05.071; Sasaki A, 2008, BRAIN RES, V1214, P159, DOI 10.1016/j.brainres.2008.02.084; Schneider A, 2005, J CLIN INVEST, V115, P2083, DOI 10.1172/JCI23559; Shahaduzzaman M, 2013, AGE, V35, P2071, DOI 10.1007/s11357-012-9496-5; Sheibani N, 2004, CRIT CARE MED, V32, P2274, DOI 10.1097/01.CCM.0000145998.11686.ED; Shyu WC, 2004, CIRCULATION, V110, P1847, DOI 10.1161/01.CIR.0000142616.07367.66; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Stachura DL, 2013, BLOOD; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Tajiri N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043779; Takahashi K, 2008, BRAIN RES, V1234, P172, DOI 10.1016/j.brainres.2008.07.086; Toth ZE, 2008, BLOOD, V111, P5544, DOI 10.1182/blood-2007-10-119073; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Tsuji T, 1999, GROWTH FACTORS, V16, P225, DOI 10.3109/08977199909002132; Tu Y, 2012, J NEUROTRAUM, V29, P2393, DOI 10.1089/neu.2012.2374; Walker PA, 2012, SURGERY, V152, P790, DOI 10.1016/j.surg.2012.06.006; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Willing AE, 2003, CELL TRANSPLANT, V12, P449, DOI 10.3727/000000003108746885; Wong D, 2013, BRAIN INJURY, V27, P1377, DOI 10.3109/02699052.2013.823662; Yang DY, 2010, NEUROL RES, V32, P1041, DOI 10.1179/016164110X12807570510013; Yang M, 2010, CELL TRANSPLANT, V19, P1073, DOI 10.3727/096368910X503415; Yang YN, 2013, PEDIATR NEONATOL, V54, P380, DOI 10.1016/j.pedneo.2013.04.011; Yasuda Y, 2007, BRAIN RES, V1138, P196, DOI 10.1016/j.brainres.2006.12.054; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zhang C, 2006, NEUROSCIENCE, V141, P687, DOI 10.1016/j.neuroscience.2006.04.054; Zhao Li R, 2013, Recent Pat CNS Drug Discov, V8, P2; Zhao LR, 2007, EXP NEUROL, V204, P569, DOI 10.1016/j.expneurol.2006.12.001	83	72	74	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2014	9	3							e90953	10.1371/journal.pone.0090953	http://dx.doi.org/10.1371/journal.pone.0090953			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC9HN	24621603	gold, Green Published, Green Submitted			2023-01-03	WOS:000332845300037
J	Iminjan, M; Amat, N; Li, XH; Upur, H; Ahmat, D; He, B				Iminjan, Mubarak; Amat, Nurmuhammat; Li, Xiao-Hui; Upur, Halmurat; Ahmat, Dilnur; He, Bin			Investigation into the Toxicity of Traditional Uyghur Medicine Quercus Infectoria Galls Water Extract	PLOS ONE			English	Article							CAM	Objective: Quercus infectoria galls (QIG) is being widely used in Traditional Uyghur Medicine. To gather preclinical safety information for the aqueous extract of QIG, a toxicity study was performed. Methods: Subject animals were randomized, and devided into exposure and control groups. In the acute toxicity phase, three different doses-5, 7.5, and 10 g/kg, respectively-were administered via enema to imprinting control region (ICR) mice. An experiment using the maximum tolerance dose (MTD) i.e.10 g/kg was also performed. Data were gathered for 14 days, and study parameters were clinical signs, body weight, general behavior, adverse effects and mortality. At the day 14, major organs of the subjects were examined histologically. Chronic toxicity was also evaluated in Wistar rats for over 180 consecutive days. The rats were divided into three groups with different doses of 0.2 g/kg, 0.8 g/kg, and 2 g/kg, QIG. Furthermore, observations were carried out in rabbits to investigate if there were signs of irritation. Results: In comparison to control group, acute, chronic toxicity and mortality were not significantly increased in exposure group. Conclusion: Study result suggests that the aqueous extract of QIG is unlikely to have significant toxicity and that clinical trials may proceed safely.	[Iminjan, Mubarak] Cent S Univ, XiangYa Hosp, Changsha, Hunan, Peoples R China; [Iminjan, Mubarak] Xinjiang Med Univ, Inst Pharmaceut Sci, Urumqi, Xinjiang, Peoples R China; [Amat, Nurmuhammat; Upur, Halmurat] Xinjiang Med Univ, Tradit Uyghur Med Inst, Urumqi, Xinjiang, Peoples R China; [Li, Xiao-Hui] Cent S Univ, Dept Pharm, Changsha, Hunan, Peoples R China; [Ahmat, Dilnur] Xinjiang Uyghur Autonomous Reg Petr Hosp, Dept Pharm, Urumqi, Peoples R China; [He, Bin] Xinjiang Uyghur Autonomous Reg Peoples Hosp, Dept Pharm, Urumqi, Xinjiang, Peoples R China	Central South University; Xinjiang Medical University; Xinjiang Medical University; Central South University	Amat, N (corresponding author), Xinjiang Med Univ, Tradit Uyghur Med Inst, Urumqi, Xinjiang, Peoples R China.	nur818@hotmail.com; halmurat@263.net			National Science and technology support program sub project of China [2006BA106A17-09]	National Science and technology support program sub project of China	This study was supported with funding from the National Science and technology support program sub project of China (2006BA106A17-09). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BROCK WJ, 1995, FOOD CHEM TOXICOL, V33, P483, DOI 10.1016/0278-6915(95)00008-P; Chopra R.N., 1956, CSIR, V208, P255; Cooper EL, 2004, EVID-BASED COMPL ALT, V1, P215, DOI 10.1093/ecam/neh032; Cooper EL, 2005, EVID-BASED COMPL ALT, V2, P125, DOI 10.1093/ecam/neh094; DAR MS, 1979, PLANTA MED, V35, P156, DOI 10.1055/s-0028-1097197; DAR MS, 1976, J PHARM SCI, V65, P1791, DOI 10.1002/jps.2600651224; Everest A, 2005, J ETHNOBIOL ETHNOMED, V1, DOI 10.1186/1746-4269-1-6; [勾晓玉 GOU Xiao-Yu], 2009, [第四军医大学学报, Journal of the Fourth Military Medical University], V30, P501; Hamid H, 2005, PHARM BIOL, V43, P317, DOI 10.1080/13880200590951711; He J, 2009, WORLD J GASTROENTERO, V15, P3441; Huang JJ, 2010, WORLD J GASTROENTERO, V16, P350; Hwang JK, 2000, PLANTA MED, V66, P273, DOI 10.1055/s-2000-8569; IKRAM M, 1977, PLANTA MED, V31, P286, DOI 10.1055/s-0028-1097531; Kaur G, 2004, J ETHNOPHARMACOL, V90, P285, DOI 10.1016/j.jep.2003.10.009; Kaur G, 2008, CHEM-BIOL INTERACT, V171, P272, DOI 10.1016/j.cbi.2007.10.002; Mabeku LBK, 2007, J ETHNOPHARMACOL, V111, P598, DOI 10.1016/j.jep.2007.01.010; Mubarak I, 2012, CHINA J HOSP PHARM, V32, P1397; Mubarak I, 2011, SCI TECHNOLOGY REV, V29, P29; Nassirhadjy M, 2007, XINJIANG YIKE DA XUE, V29, P935; National Pharmacopoeia Committee, 2005, PHARM PEOPL REP CH 1; Olson H, 2000, REGUL TOXICOL PHARM, V32, P56, DOI 10.1006/rtph.2000.1399; ONDERDONK AB, 1985, DIGEST DIS SCI, V30, pS40, DOI 10.1007/BF01296973; Qin Y, 2009, J ETHNOPHARMACOL, V126, P543, DOI 10.1016/j.jep.2009.08.047; Tsao JCI, 2005, EVID-BASED COMPL ALT, V2, P149, DOI 10.1093/ecam/neh092; TWAIJ HAA, 1983, J ETHNOPHARMACOL, V9, P299, DOI 10.1016/0378-8741(83)90037-5; Wang J.Y., 2007, SHIZHEN GUOYI GUOYAO, V18, P2570; Wu HL, 2005, XINJIANG YIKEDA XUEB, V28, P35; Yamunarani K., 2005, Acta Phytopathologica et Entomologica Hungarica, V40, P43, DOI 10.1556/APhyt.40.2005.1-2.6; Yuan R., 2005, STUDY CHEM CONSTITUE; Zhu M, 2002, PHYTOTHER RES, V16, P276, DOI 10.1002/ptr.839	30	15	15	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2014	9	3							e90756	10.1371/journal.pone.0090756	http://dx.doi.org/10.1371/journal.pone.0090756			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC4IY	24608135	Green Published, Green Submitted, gold			2023-01-03	WOS:000332485800048
J	Gillick, MR				Gillick, Muriel R.			When Frail Elderly Adults Get Sick: Alternatives to Hospitalization	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CARE; PROGRAM		[Gillick, Muriel R.] Harvard Univ, Sch Med, Harvard Pilgrim Hlth Care Inst, Boston, MA 02215 USA	Harvard Pilgrim Health Care; Harvard University; Harvard Medical School	Gillick, MR (corresponding author), Harvard Univ, Sch Med, Harvard Pilgrim Hlth Care Inst, Dept Populat Med, 133 Brookline Ave,6th Floor, Boston, MA 02215 USA.	muriel_gillick@hphc.org						Alexcih L, 2010, INDIVIDUALS LIVING C; Centers for Medicare & Medicaid Services, CHRONIC CONDITIONS M; Clegg A, 2013, LANCET, V381, P752, DOI 10.1016/S0140-6736(12)62167-9; CREDITOR MC, 1993, ANN INTERN MED, V118, P219, DOI 10.7326/0003-4819-118-3-199302010-00011; D'Souza S, 2013, BMJ-BRIT MED J, V346; Fox MT, 2012, J AM GERIATR SOC, V60, P2237, DOI 10.1111/jgs.12028; Fried TR, 2011, ARCH INTERN MED, V171, P1854, DOI 10.1001/archinternmed.2011.424; Fromme EK, 2012, JAMA-J AM MED ASSOC, V307, P34, DOI 10.1001/jama.2011.1956; Leff B, 2005, ANN INTERN MED, V143, P798, DOI 10.7326/0003-4819-143-11-200512060-00008; Meret-Hanke LA, 2011, GERONTOLOGIST, V51, P774, DOI 10.1093/geront/gnr040	10	5	7	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 4	2014	160	3					201	202		10.7326/M13-1793	http://dx.doi.org/10.7326/M13-1793			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AA2VE	24658696				2023-01-03	WOS:000330951500008
J	Smith, IJ; Godinez, GL; Singh, BK; McCaughey, KM; Alcantara, RR; Gururaja, T; Ho, MS; Nguyen, HN; Friera, AM; White, KA; McLaughlin, JR; Hansen, D; Romero, JM; Baltgalvis, KA; Claypool, MD; Li, W; Lang, W; Yam, GC; Gelman, MS; Ding, RX; Yung, SL; Creger, DP; Chen, Y; Singh, R; Smuder, AJ; Wiggs, MP; Kwon, OS; Sollanek, KJ; Powers, SK; Masuda, ES; Taylor, VC; Payan, DG; Kinoshita, T; Kinsella, TM				Smith, Ira J.; Godinez, Guillermo L.; Singh, Baljit K.; McCaughey, Kelly M.; Alcantara, Raniel R.; Gururaja, Tarikere; Ho, Melissa S.; Nguyen, Henry N.; Friera, Annabelle M.; White, Kathy A.; McLaughlin, John R.; Hansen, Derek; Romero, Jason M.; Baltgalvis, Kristen A.; Claypool, Mark D.; Li, Wei; Lang, Wayne; Yam, George C.; Gelman, Marina S.; Ding, Rongxian; Yung, Stephanie L.; Creger, Daniel P.; Chen, Yan; Singh, Rajinder; Smuder, Ashley J.; Wiggs, Michael P.; Kwon, Oh-Sung; Sollanek, Kurt J.; Powers, Scott K.; Masuda, Esteban S.; Taylor, Vanessa C.; Payan, Donald G.; Kinoshita, Taisei; Kinsella, Todd M.			Inhibition of Janus kinase signaling during controlled mechanical ventilation prevents ventilation-induced diaphragm dysfunction	FASEB JOURNAL			English	Article						muscle wasting; mitochondria; oxidative stress; STAT3	INTENSIVE-CARE-UNIT; SERINE PHOSPHORYLATION; MITOCHONDRIAL STAT3; OXIDATIVE STRESS; MUSCLE ATROPHY; DEGRADATION; ACTIVATION; WEAKNESS; P38	Controlled mechanical ventilation (CMV) is associated with the development of diaphragm atrophy and contractile dysfunction, and respiratory muscle weakness is thought to contribute significantly to delayed weaning of patients. Therefore, therapeutic strategies for preventing these processes may have clinical benefit. The aim of the current study was to investigate the role of the Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) signaling pathway in CMV-mediated diaphragm wasting and weakness in rats. CMV-induced diaphragm atrophy and contractile dysfunction coincided with marked increases in STAT3 phosphorylation on both tyrosine 705 (Tyr705) and serine 727 (Ser727). STAT3 activation was accompanied by its translocation into mitochondria within diaphragm muscle and mitochondrial dysfunction. Inhibition of JAK signaling during CMV prevented phosphorylation of both target sites on STAT3, eliminated the accumulation of phosphorylated STAT3 within the mitochondria, and reversed the pathologic alterations in mitochondrial function, reduced oxidative stress in the diaphragm, and maintained normal diaphragm contractility. In addition, JAK inhibition during CMV blunted the activation of key proteolytic pathways in the diaphragm, as well as diaphragm atrophy. These findings implicate JAK/STAT3 signaling in the development of diaphragm muscle atrophy and dysfunction during CMV and suggest that the delayed extubation times associated with CMV can be prevented by inhibition of Janus kinase signaling.	[Smith, Ira J.; Godinez, Guillermo L.; Singh, Baljit K.; McCaughey, Kelly M.; Alcantara, Raniel R.; Gururaja, Tarikere; Ho, Melissa S.; Nguyen, Henry N.; Friera, Annabelle M.; White, Kathy A.; McLaughlin, John R.; Hansen, Derek; Romero, Jason M.; Baltgalvis, Kristen A.; Claypool, Mark D.; Li, Wei; Lang, Wayne; Yam, George C.; Gelman, Marina S.; Ding, Rongxian; Yung, Stephanie L.; Creger, Daniel P.; Chen, Yan; Singh, Rajinder; Masuda, Esteban S.; Taylor, Vanessa C.; Payan, Donald G.; Kinoshita, Taisei; Kinsella, Todd M.] Rigel Pharmaceut Inc, San Francisco, CA 94080 USA; [Smuder, Ashley J.; Wiggs, Michael P.; Kwon, Oh-Sung; Sollanek, Kurt J.; Powers, Scott K.] Univ Florida, Dept Appl Physiol & Kinesiol, Gainesville, FL USA	State University System of Florida; University of Florida	Kinsella, TM (corresponding author), Rigel Pharmaceut Inc, 1180 Vet Blvd, San Francisco, CA 94080 USA.	tkinsella@rigel.com	Kwon, Oh Sung/AAL-4116-2021	Masuda, Esteban/0000-0002-3175-2868; Chen, Yan/0000-0002-5690-5381	Rigel Pharmaceuticals; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD043730] Funding Source: NIH RePORTER	Rigel Pharmaceuticals; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	The authors thank Joseph B. Shrager and H. Tang (Stanford University, Stanford, CA, USA) for useful insights, and Vadim Markovtsov (Rigel Pharmaceuticals) for helpful discussions and reading of the manuscript. I.J.S., G. L. G., B. K. S., K. M. M., R. R. A., T. G., M. S. H., H.N.N., A. M. F., K. A. W., J.R.M., D. H., J.M.R., K. A. B., M. D. C., W. Li, W. Lang, G.C.Y., M. S. G., R. D., S.L.Y., D. P. C., Y.C., R. S., E. S. M., V. C. T., D. G. P., T. K., and T. M. K. are employees and/or stockholders of Rigel Pharmaceuticals, Inc. Experiments conducted at the University of Florida were supported by funding from Rigel Pharmaceuticals (to S.K.P.).	Betters JL, 2004, AM J RESP CRIT CARE, V170, P1179, DOI 10.1164/rccm.200407-939OC; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Dasta JF, 2005, CRIT CARE MED, V33, P1266, DOI 10.1097/01.CCM.0000164543.14619.00; De Jonghe B, 2007, CRIT CARE MED, V35, P2007, DOI 10.1097/01.ccm.0000281450.01881.d8; Deuse T, 2012, TRANSPLANTATION, V94, P695, DOI 10.1097/TP.0b013e3182660496; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Esteban A, 2000, AM J RESP CRIT CARE, V161, P1450, DOI 10.1164/ajrccm.161.5.9902018; Gough DJ, 2009, SCIENCE, V324, P1713, DOI 10.1126/science.1171721; Hermans G, 2010, CRIT CARE, V14, DOI 10.1186/cc9094; Jaber S, 2011, AM J RESP CRIT CARE, V183, P364, DOI 10.1164/rccm.201004-0670OC; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Kavazis AN, 2009, FREE RADICAL BIO MED, V46, P842, DOI 10.1016/j.freeradbiomed.2009.01.002; Kim J, 2009, KOREAN J PHYSIOL PHA, V13, P491, DOI 10.4196/kjpp.2009.13.6.491; Kurdi M, 2009, AM J PHYSIOL-HEART C, V297, pH1545, DOI 10.1152/ajpheart.00032.2009; Levine S, 2008, NEW ENGL J MED, V358, P1327, DOI 10.1056/NEJMoa070447; Lokireddy S, 2011, MOL ENDOCRINOL, V25, P1936, DOI 10.1210/me.2011-1124; Maes K, 2007, AM J RESP CRIT CARE, V175, P1134, DOI 10.1164/rccm.200609-1342OC; McClung JM, 2007, J PHYSIOL-LONDON, V585, P203, DOI 10.1113/jphysiol.2007.141119; McClung JM, 2007, AM J RESP CRIT CARE, V175, P150, DOI 10.1164/rccm.200601-142OC; Meyer DM, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-41; Moresi V, 2010, CELL, V143, P35, DOI 10.1016/j.cell.2010.09.004; Ochala J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020558; Polge C, 2011, FASEB J, V25, P3790, DOI 10.1096/fj.11-180968; Powers SK, 2011, CRIT CARE MED, V39, P1749, DOI 10.1097/CCM.0b013e3182190b62; Reid MB, 2011, J PHYSIOL-LONDON, V589, P2171, DOI 10.1113/jphysiol.2010.203356; Shulga N, 2012, J CELL SCI, V125, P2995, DOI 10.1242/jcs.103093; Smuder AJ, 2010, FREE RADICAL BIO MED, V49, P1152, DOI 10.1016/j.freeradbiomed.2010.06.025; Song B, 2013, REGUL PEPTIDES, V185, P44, DOI 10.1016/j.regpep.2013.06.007; Szczepanek K, 2011, J BIOL CHEM, V286, P29610, DOI 10.1074/jbc.M111.226209; Tammineni P, 2013, J BIOL CHEM, V288, P4723, DOI 10.1074/jbc.M112.378984; Tang HB, 2011, FASEB J, V25, P2921, DOI 10.1096/fj.11-183798; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Vassilakopoulos T, 2004, AM J RESP CRIT CARE, V169, P336, DOI 10.1164/rccm.200304-489CP; Wegrzyn J, 2009, SCIENCE, V323, P793, DOI 10.1126/science.1164551; Whidden MA, 2010, J APPL PHYSIOL, V108, P1376, DOI 10.1152/japplphysiol.00098.2010; White JP, 2011, AM J PHYSIOL-REG I, V300, pR201, DOI 10.1152/ajpregu.00300.2010; Wunsch H, 2010, CRIT CARE MED, V38, P1947, DOI 10.1097/CCM.0b013e3181ef4460; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; Zhang QF, 2013, J BIOL CHEM, V288, P31280, DOI 10.1074/jbc.M113.505057; Zhou LH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021680	42	37	40	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					2790	2803		10.1096/fj.13-244210	http://dx.doi.org/10.1096/fj.13-244210			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24671708	Green Published, hybrid			2023-01-03	WOS:000337949400006
J	Cook, D; Rocker, G				Cook, Deborah; Rocker, Graeme			Dying with Dignity in the Intensive Care Unit	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							OF-LIFE CARE; SURROGATE DECISION-MAKERS; FAMILY-MEMBERS; MECHANICAL VENTILATION; PALLIATIVE CARE; RANDOMIZED-TRIAL; END; ICU; SUPPORT; RECOMMENDATIONS	THE TRADITIONAL GOALS OF INTENSIVE CARE ARE TO REDUCE THE -morbidity and mortality associated with critical illness, maintain organ function, and restore health. Despite technological advances, death in the intensive care unit (ICU) remains commonplace. Death rates vary widely within and among countries and are influenced by many factors.(1) Comparative international data are lacking, but an estimated one in five deaths in the United States occurs in a critical care bed.(2) In this review, we address the concept of dignity for patients dying in the ICU. When the organ dysfunction of critical illness defies treatment, when the goals of care can no longer be met, or when life support is likely to result in outcomes that are incongruent with patients' values, ICU clinicians must ensure that patients die with dignity. The definition of "dying with dignity" recognizes the intrinsic, unconditional quality of human worth but also external qualities of physical comfort, autonomy, meaningfulness, preparedness, and interpersonal connection.(3) Respect should be fostered by being mindful of the "ABCDs" of dignity-conserving care (attitudes, behaviors, compassion, and dialogue)(4) (Table 1). Preserving the dignity of patients, avoiding harm, and preventing or resolving conflict are conditions of the privilege and responsibility of caring for patients at the end of life. In our discussion of principles, evidence, and practices, we assume that there are no extant conflicts between the ICU team and the patient's family. Given the scope of this review, readers are referred elsewhere for guidance on conflict prevention and resolution in the ICU.(5,6) The concept of dying with dignity in the ICU implies that although clinicians may forgo some treatments, care can be enhanced as death approaches. Fundamental to maintaining dignity is the need to understand a patient's unique perspectives on what gives life meaning in a setting replete with depersonalizing devices. The goal is caring for patients in a manner that is consistent with their values at a time of incomparable vulnerability, when they rarely can speak for themselves. 7 For example, patients who value meaningful relationships may decline life-prolonging measures when such relationships are no longer possible. Conversely, patients for whom physical autonomy is not crucial may accept technological dependence if it confers a reasonable chance of an acceptable, albeit impaired, outcome. 8 At issue is what each patient would be willing to undergo for a given probability of survival and anticipated quality of life.	[Cook, Deborah] McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; [Cook, Deborah] McMaster Univ, Dept Clin Epidemiol, Hamilton, ON L8N 3Z5, Canada; [Cook, Deborah] McMaster Univ, Dept Biostat, Hamilton, ON L8N 3Z5, Canada; [Rocker, Graeme] Dalhousie Univ, Dept Med, Halifax, NS, Canada	McMaster University; McMaster University; McMaster University; Dalhousie University	Cook, D (corresponding author), McMaster Univ, Hlth Sci Ctr, Rm 2C11,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	debcook@mcmaster.ca						Adhikari NKJ, 2010, LANCET, V376, P1339, DOI 10.1016/S0140-6736(10)60446-1; Angus DC, 2004, CRIT CARE MED, V32, P638, DOI 10.1097/01.CCM.0000114816.62331.08; Azoulay E, 2005, AM J RESP CRIT CARE, V171, P987, DOI 10.1164/rccm.200409-1295OC; Back Anthony L, 2003, Ann Intern Med, V138, P439; Bowman K, 2010, END LIFE CARE INTENS; Brush DR, 2012, AM J RESP CRIT CARE, V186, P633, DOI 10.1164/rccm.201202-0354OC; Bulow HH, 2008, INTENS CARE MED, V34, P423, DOI 10.1007/s00134-007-0973-8; Carlet J, 2004, INTENS CARE MED, V30, P770, DOI 10.1007/s00134-004-2241-5; Char SJL, 2010, AM J RESP CRIT CARE, V182, P905, DOI 10.1164/rccm.201002-0262OC; Charles C, 1999, BRIT MED J, V319, P780, DOI 10.1136/bmj.319.7212.780; Chochinov H, 2007, BRIT MED J, V335, P184, DOI 10.1136/bmj.39244.650926.47; Choong K, 2010, CLIN INVEST MED, V33, pE240; Clarke EB, 2003, CRIT CARE MED, V31, P2255, DOI 10.1097/01.CCM.0000084849.96385.85; Cook D, 2003, NEW ENGL J MED, V349, P1123, DOI 10.1056/NEJMoa030083; Cook DJ, 1999, CAN MED ASSOC J, V161, P1109; Cox CE, 2009, CRIT CARE MED, V37, P2888, DOI 10.1097/CCM.0b013e3181ab86ed; Curtis JR, 2007, CRIT CARE MED, V35, P932, DOI 10.1097/01.CCM.0000256725.73993.74; Curtis JR, 2011, AM J RESP CRIT CARE, V183, P348, DOI 10.1164/rccm.201006-1004OC; Davidson JE, 2007, CRIT CARE MED, V35, P605, DOI 10.1097/01.CCM.0000254067.14607.EB; Drazen JM, 2003, NEW ENGL J MED, V349, P1109, DOI 10.1056/NEJMp038146; Heyland DK, 2002, CRIT CARE MED, V30, P1413, DOI 10.1097/00003246-200207000-00002; Heyland DK, 2003, INTENS CARE MED, V29, P75, DOI 10.1007/s00134-002-1569-y; Heyland DK, 2006, CAN MED ASSOC J, V174, P627, DOI 10.1503/cmaj.050626; Hough CL, 2005, J CRIT CARE, V20, P20, DOI 10.1016/j.jcrc.2004.09.006; Kompanje EJO, 2008, INTENS CARE MED, V34, P1593, DOI 10.1007/s00134-008-1172-y; Lanken PN, 2008, AM J RESP CRIT CARE, V177, P912, DOI 10.1164/rccm.200605-587ST; Lautrette A, 2007, NEW ENGL J MED, V356, P469, DOI 10.1056/NEJMoa063446; Lilly CM, 2007, NEW ENGL J MED, V356, P513, DOI 10.1056/NEJMe068253; Majesko A, 2012, CRIT CARE MED, V40, P2281, DOI 10.1097/CCM.0b013e3182533317; Maugans TA, 1996, ARCH FAM MED, V5, P11, DOI 10.1001/archfami.5.1.11; McDonagh JR, 2004, CRIT CARE MED, V32, P1484, DOI 10.1097/01.CCM.0000127262.16690.65; Nelson JE, 2006, QUAL SAF HEALTH CARE, V15, P264, DOI 10.1136/qshc.2005.017707; Nelson JE, 2006, CRIT CARE MED, V34, P2547, DOI 10.1097/01.CCM.0000239233.63425.1D; Pochard F, 2005, J CRIT CARE, V20, P90, DOI 10.1016/j.jcrc.2004.11.004; Prendergast TJ, 2010, END LIFE CARE ICU AD, P202; Proulx Kathryn, 2004, Am J Hosp Palliat Care, V21, P116, DOI 10.1177/104990910402100209; Scheunemann LP, 2012, AM J RESP CRIT CARE, V186, P480, DOI 10.1164/rccm.201204-0710CP; Schneiderman LJ, 2003, JAMA-J AM MED ASSOC, V290, P1166, DOI 10.1001/jama.290.9.1166; Simpson C, 2004, BIOETHICS, V18, P428, DOI 10.1111/j.1467-8519.2004.00408.x; Sinuff T, 2009, CRIT CARE MED, V37, P154, DOI 10.1097/CCM.0b013e318192fb7c; Sprung CL, 2003, JAMA-J AM MED ASSOC, V290, P790, DOI 10.1001/jama.290.6.790; Sulmasy DP, 2009, CHEST, V135, P1634, DOI 10.1378/chest.08-2241; Truog RD, 2008, CRIT CARE MED, V36, P953, DOI 10.1097/CCM.0B013E3181659096; Vincent JL, 1999, CRIT CARE MED, V27, P1626, DOI 10.1097/00003246-199908000-00042; Wall RJ, 2007, CHEST, V132, P1425, DOI 10.1378/chest.07-0419; White DB, 2007, ARCH INTERN MED, V167, P461, DOI 10.1001/archinte.167.5.461; White DB, 2009, AM J RESP CRIT CARE, V180, P320, DOI 10.1164/rccm.200811-1776OC; who, WHO DEF PALL CAR; Zier LS, 2012, ANN INTERN MED, V156, P360, DOI 10.7326/0003-4819-156-5-201203060-00008; [No title captured]	50	154	168	1	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 26	2014	370	26					2506	2514		10.1056/NEJMra1208795	http://dx.doi.org/10.1056/NEJMra1208795			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AJ6KY	24963569				2023-01-03	WOS:000337804400008
J	Liu, ZY; Wei, WJ; Bai, LJ; Dai, RW; You, YB; Chen, SJ; Tian, J				Liu, Zhenyu; Wei, Wenjuan; Bai, Lijun; Dai, Ruwei; You, Youbo; Chen, Shangjie; Tian, Jie			Exploring the Patterns of Acupuncture on Mild Cognitive Impairment Patients Using Regional Homogeneity	PLOS ONE			English	Article							FMRI CONNECTIVITY ANALYSIS; HUMAN BRAIN; ALZHEIMERS-DISEASE; FUNCTIONAL CONNECTIVITY; NETWORK; STIMULATION; DEFAULT; MODULATION	Purpose: To investigate the different responses to acupuncture in MCI patients and age-matched healthy subjects reflected by the Regional Homogeneity (ReHo) indices. Methods: The experiment was performed at the acupoint KI3 in 12 MCI patients and 12 healthy controls, respectively. A novel non-repeated event-related (NRER) fMRI design paradigm was applied to separately detect neural activities related to different stages of acupuncture (pre-acupuncture resting state, needling manipulation and post-acupuncture resting state). ReHo values were calculated for MCI patients and healthy controls in pre-and post-acupuncture resting state. Then, a two-way ANCOVA with repeated measures with post-hoc two sample t-tests was performed to explore the different responses to acupuncture in the two groups. Results: The ANCOVA revealed a significant main effect of group, but no significant main effect of acupuncture and interactions between group and acupuncture. During the pre-acupuncture resting state, ReHo values increased in the precentral gyrus (PCG), superior frontal gyrus (SFG), and insula (INS) and decreased mainly in middle temporal gyrus (MTG), parahippocampal (PHIP) and cingulate cortex in MCI patients compared with healthy controls. Furthermore, we found that the regions including precuneus (PCUN), and cingulate cortex showed increased ReHo values for MCI patients following acupuncture. For healthy controls, the medial frontal gyrus, PCG, anterior cingulate cortex (ACC) and INS showed enhanced ReHo values following acupuncture. During the post-acupuncture resting state, MCI patients showed increased ReHo values mainly in the MTG, superior parietal lobule (SPL), middle frontal gyrus (MFG), supramarginal (SMG), and PCG, and decreased ReHo values mainly in the frontal regions, PHIP, and posterior cingulated cortex (PCC) compared to healthy controls. Conclusion: Though we found some ReHo changes between MCI patients and healthy controls, the two-way ANCOVA results showed no significant effects after multiple corrections. Further study is needed to reveal the real acupuncture effects on MCI patients.	[Liu, Zhenyu; Wei, Wenjuan; Bai, Lijun; Dai, Ruwei; You, Youbo; Tian, Jie] Chinese Acad Sci, Inst Automat, Key Lab Mol Imaging & Funct Imaging, Beijing, Peoples R China; [Chen, Shangjie] Southern Med Univ, Baoan Hosp, Dept Acupuncture & Massage, Shenzhen, Peoples R China; [Tian, Jie] Xidian Univ, Sch Life Sci & Technol, Life Sci Res Ctr, Xian, Shaanxi, Peoples R China	Chinese Academy of Sciences; Institute of Automation, CAS; Southern Medical University - China; Xidian University	Bai, LJ (corresponding author), Chinese Acad Sci, Inst Automat, Key Lab Mol Imaging & Funct Imaging, Beijing, Peoples R China.	bailj4152615@gmail.com; tian@ieee.org	Liu, Zhenyu/G-8444-2018; tian, jie/M-6336-2013; Tian, Jie/H-1190-2011; Bai, Lijun/C-5119-2015	Liu, Zhenyu/0000-0001-7559-8519; Tian, Jie/0000-0003-0498-0432; Bai, Lijun/0000-0001-8790-5424	National Basic Research Program of China (973 Program) [2011CB707700]; National Natural Science Foundation of China [81227901, 61231004, 30970771, 81000640, 81171314, 30970769, 81071217]; Fundamental Research Funds for the Central Universities [2011JBM226]; NIH [R01HD046526, R01HD060595]; Beijing Nova program [Z111101054511116]; Beijing Natural Science Foundation [4122082]; Fellowship for Young International Scientists of the Chinese Academy of Sciences [2010Y2GA03]; Chinese Academy of Sciences Visiting Professorship for Senior International Scientists [2012T1G0036, 2010T2G36, 2012T1G0039]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD046526, R01HD060595] Funding Source: NIH RePORTER	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Beijing Nova program(Beijing Municipal Science & Technology Commission); Beijing Natural Science Foundation(Beijing Natural Science Foundation); Fellowship for Young International Scientists of the Chinese Academy of Sciences; Chinese Academy of Sciences Visiting Professorship for Senior International Scientists; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This paper is supported by the National Basic Research Program of China (973 Program) under grant 2011CB707700 (http://www.973.gov.cn/Default_3. aspx), the National Natural Science Foundation of China under grant no. 81227901, 61231004, 30970771, 81000640, 81171314, 30970769, 81071217 (http://www. nsfc.gov.cn/Portal0/default152.htm), the Fundamental Research Funds for the Central Universities (2011JBM226) and NIH (R01HD046526 & R01HD060595), the Beijing Nova program (grant number Z111101054511116), and Beijing Natural Science Foundation (grant number 4122082), the Fellowship for Young International Scientists of the Chinese Academy of Sciences under grant no. 2010Y2GA03, the Chinese Academy of Sciences Visiting Professorship for Senior International Scientists under grant no. 2012T1G0036, 2010T2G36, 2012T1G0039. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ashburner J, 1999, HUM BRAIN MAPP, V7, P254, DOI 10.1002/(SICI)1097-0193(1999)7:4<254::AID-HBM4>3.0.CO;2-G; Bai F, 2008, NEUROSCI LETT, V438, P111, DOI 10.1016/j.neulet.2008.04.021; Bai LJ, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-73; Bai LJ, 2010, J MAGN RESON IMAGING, V31, P71, DOI 10.1002/jmri.22006; Bai LJ, 2009, CURR MED IMAGING REV, V5, P167, DOI 10.2174/157340509789000589; Bai LJ, 2009, HUM BRAIN MAPP, V30, P3445, DOI 10.1002/hbm.20769; Bai LJ, 2009, PROG NAT SCI-MATER, V19, P827, DOI 10.1016/j.pnsc.2008.09.009; Bai LJ, 2009, BRAIN RES, V1279, P37, DOI 10.1016/j.brainres.2009.04.056; Beijing Shanghai and Nanjing College of Traditional Chinese Medicine. Acupuncture Institute of the Academy of Traditional Chinese Medicine, 1980, ESS CHIN AC; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Dhond RP, 2008, PAIN, V136, P407, DOI 10.1016/j.pain.2008.01.011; Enck P, 2010, AUTON NEUROSCI-BASIC, V157, P68, DOI 10.1016/j.autneu.2010.03.005; Fang JL, 2009, HUM BRAIN MAPP, V30, P1196, DOI 10.1002/hbm.20583; Feng YY, 2012, MAGN RESON IMAGING, V30, P672, DOI 10.1016/j.mri.2012.01.003; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; Goddard G, 2005, J PAIN, V6, P237, DOI 10.1016/j.jpain.2004.12.009; Grady CL, 2001, BRAIN, V124, P739, DOI 10.1093/brain/124.4.739; Grundman M, 2004, ARCH NEUROL-CHICAGO, V61, P59, DOI 10.1001/archneur.61.1.59; He Y, 2007, NEUROIMAGE, V35, P488, DOI 10.1016/j.neuroimage.2006.11.042; Horwitz B, 1995, NEUROREPORT, V6, P2287, DOI 10.1097/00001756-199511270-00005; Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037; Hui KKS, 2000, HUM BRAIN MAPP, V9, P13, DOI 10.1002/(SICI)1097-0193(2000)9:1<13::AID-HBM2>3.0.CO;2-F; Ikonomovic MD, 2003, J ALZHEIMERS DIS, V5, P39, DOI 10.3233/JAD-2003-5106; Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010; Kendall M.G., 1990, RANK CORRELATION MET, V5th; Kiviniemi V, 2008, HUM BRAIN MAPP, V29, P810, DOI 10.1002/hbm.20582; Kong J, 2007, J ALTERN COMPLEM MED, V13, P1059, DOI 10.1089/acm.2007.0524; Liu HH, 2006, NEUROREPORT, V17, P19, DOI 10.1097/01.wnr.0000195666.22714.35; Luijpen MW, 2004, NEUROREHAB NEURAL RE, V18, P166, DOI 10.1177/0888439004268785; Mayer DJ, 2000, ANNU REV MED, V51, P49, DOI 10.1146/annurev.med.51.1.49; Molsberger AF, 2010, PAIN, V151, P146, DOI 10.1016/j.pain.2010.06.036; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Napadow V, 2005, HUM BRAIN MAPP, V24, P193, DOI 10.1002/hbm.20081; NIH, 1998, JAMA; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Paakki JJ, 2010, BRAIN RES, V1321, P169, DOI 10.1016/j.brainres.2009.12.081; Petersen RC, 2001, ARCH NEUROL-CHICAGO, V58, P1985, DOI 10.1001/archneur.58.12.1985; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Qi ZG, 2010, NEUROIMAGE, V50, P48, DOI 10.1016/j.neuroimage.2009.12.025; Qin W, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-55; Song XW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025031; Wu T, 2009, HUM BRAIN MAPP, V30, P1502, DOI 10.1002/hbm.20622; Yoo SS, 2004, NEUROIMAGE, V22, P932, DOI 10.1016/j.neuroimage.2004.02.017; Yu DH, 2012, NMR BIOMED, V25, P806, DOI 10.1002/nbm.1796; Yu JC, 2006, NEUROL RES, V28, P97, DOI 10.1179/016164106X91951; Yuan YG, 2008, J AFFECT DISORDERS, V111, P145, DOI 10.1016/j.jad.2008.02.016; Zang YF, 2004, NEUROIMAGE, V22, P394, DOI 10.1016/j.neuroimage.2003.12.030; Zhang ZQ, 2012, NEUROIMAGE, V59, P1429, DOI 10.1016/j.neuroimage.2011.08.049; Zhong CG, 2012, J MAGN RESON IMAGING, V35, P572, DOI 10.1002/jmri.22887; Zhou YL, 2008, ACUPUNCTURE ELECTRO, V33, P9, DOI 10.3727/036012908803861186; Zhu L, 1954, NEW ACUPUNCTURE XIN; Zuo XN, 2013, NEUROIMAGE, V65, P374, DOI 10.1016/j.neuroimage.2012.10.017	52	10	16	4	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 26	2014	9	6							e99335	10.1371/journal.pone.0099335	http://dx.doi.org/10.1371/journal.pone.0099335			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK2WP	24968124	Green Submitted, Green Published, gold			2023-01-03	WOS:000338280800010
J	Lund, CA; Moller, AM; Wetterslev, J; Lundstrom, LH				Lund, Caterina A.; Moller, Ann M.; Wetterslev, Jorn; Lundstrom, Lars H.			Organizational Factors and Long-Term Mortality after Hip Fracture Surgery. A Cohort Study of 6143 Consecutive Patients Undergoing Hip Fracture Surgery	PLOS ONE			English	Article							RISK-FACTORS; FEMORAL FRACTURES; SURGICAL FIXATION; ELDERLY-PATIENTS; DELAY; MORBIDITY; TIME; OPERATION; STAY; ASSOCIATION	Objective: In hospital and health care organizational factors may be changed to reduce postoperative mortality. The aim of this study is to evaluate a possible association between mortality and 'length of hospital stay', 'priority of surgery', 'time of surgery', or 'surgical delay' in hip fracture surgery. Design: Observational cohort study. Setting: Prospectively and consecutively reported data from the Danish Anaesthesia Database were linked to The Danish National Registry of Patients and The Civil Registration System. Records on vital status, admittance, discharges, codes of diagnosis, anaesthetic and surgical procedures were retrieved. Participants: 6143 patients aged more than 65 years undergoing hip fracture surgery. Main Outcome Measures: All-cause mortality. Results: The one year mortality was 30% (28-31%, 95% Confidence interval (CI)). In a multivariate model 'length of hospital stay' less than 10 days and more than 20 days are associated with mortality with hazard ratios of 1.34 (1.20-1.53 CI, p<0.001) and 1.27 (1.06-1.51 CI, p<0.001), respectively. 'Priority of surgery' categorized as 'non-scheduled' is associated with mortality with a hazard ratio of 1.31 (1.13-1.50 CI, p<0.001). Surgical delay and time of surgery are not significantly associated with mortality. Conclusion: Non-scheduled surgery and length of hospital stay were associated with increased mortality. Confounding by indication may bias observational studies evaluating early and late discharge as well as priority; therefore cluster randomized clinical trials comparing different clinical set ups may be warranted evaluating health care organizational factors.	[Lund, Caterina A.; Moller, Ann M.] Herlev Univ Hosp, Dept Anaesthesia & Intens Care, DK-2730 Herlev, Denmark; [Wetterslev, Jorn; Lundstrom, Lars H.] Copenhagen Univ Hosp, Rigshosp, Ctr Clin Intervent Res, Copenhagen Trial Unit, Copenhagen, Denmark; [Lundstrom, Lars H.] Hillerod Univ Hosp, Nordsjaellands Hosp, Dept Anaesthesia, Hillerod, Denmark	University of Copenhagen; Herlev & Gentofte Hospital; Rigshospitalet; University of Copenhagen; University of Copenhagen	Moller, AM (corresponding author), Herlev Univ Hosp, Dept Anaesthesia & Intens Care, DK-2730 Herlev, Denmark.	ann.moeller@regionh.dk	Wetterslev, Jørn/ABF-1251-2020; Moller, Ann Merete/AAO-6020-2021	Wetterslev, Jørn/0000-0001-7778-1771; Lundstrom, Lars/0000-0002-2179-1433				Bergeron E, 2006, J TRAUMA, V60, P753, DOI 10.1097/01.ta.0000214649.53190.2a; Bjorgul K, 2010, J ARTHROPLASTY, V25, P134, DOI 10.1016/j.arth.2010.04.010; Bosma E, 2010, J BONE JOINT SURG BR, V92B, P110, DOI 10.1302/0301-620X.92B1.22671; Bottle A, 2006, BMJ-BRIT MED J, V332, P947, DOI 10.1136/bmj.38790.468519.55; BREDAHL C, 1992, INJURY, V23, P83, DOI 10.1016/0020-1383(92)90037-S; Campbell MK, 2004, BMJ-BRIT MED J, V328, P702, DOI 10.1136/bmj.328.7441.702; Clague JE, 2002, INJURY, V33, P1, DOI 10.1016/S0020-1383(01)00142-5; Deeks J J, 2003, Health Technol Assess, V7, piii; Dorotka R, 2003, J BONE JOINT SURG BR, V85B, P1107, DOI 10.1302/0301-620X.85B8.14282; Egerod I, 2010, DAN MED BULL, V57; EISKJAER S, 1991, CLIN ORTHOP RELAT R, P295; Franzo A, 2005, EUR J EPIDEMIOL, V20, P985, DOI 10.1007/s10654-005-4280-9; Gdalevich M, 2004, ARCH ORTHOP TRAUM SU, V124, P334, DOI 10.1007/s00402-004-0662-9; Grimes JP, 2002, AM J MED, V112, P702, DOI 10.1016/S0002-9343(02)01119-1; Hahn Seokyung, 2005, BMC Med Res Methodol, V5, P10, DOI 10.1186/1471-2288-5-10; Holt G, 2008, J BONE JOINT SURG BR, V90B, P1357, DOI 10.1302/0301-620X.90B10.21328; Holvik K, 2010, J AGING HEALTH, V22, P1114, DOI 10.1177/0898264310378040; Kehlet H, 2003, LANCET, V362, P1921, DOI 10.1016/S0140-6736(03)14966-5; Kehlet H, 2002, AM J SURG, V183, P630, DOI 10.1016/S0002-9610(02)00866-8; KENZORA JE, 1984, CLIN ORTHOP RELAT R, P45; KEYS A, 1972, J CHRON DIS, V25, P329, DOI 10.1016/0021-9681(72)90027-6; Lefaivre KA, 2009, J BONE JOINT SURG BR, V91B, P922, DOI 10.1302/0301-620X.91B7.22446; Leung F, 2010, OSTEOPOROSIS INT, V21, pS529, DOI 10.1007/s00198-010-1391-2; Majumdar SR, 2006, MED CARE, V44, P552, DOI 10.1097/01.mlr.0000215812.13720.2e; Moran CG, 2005, J BONE JOINT SURG AM, V87A, P483, DOI 10.2106/JBJS.D.01796; Orosz GM, 2004, JAMA-J AM MED ASSOC, V291, P1738, DOI 10.1001/jama.291.14.1738; OWENS WD, 1978, ANESTHESIOLOGY, V49, P239, DOI 10.1097/00000542-197810000-00003; PARKER MJ, 1992, J BONE JOINT SURG BR, V74, P203, DOI 10.1302/0301-620X.74B2.1544952; Radcliff TA, 2008, J BONE JOINT SURG AM, V90A, P34, DOI 10.2106/JBJS.G.00065; Rae HC, 2007, ANZ J SURG, V77, P889, DOI 10.1111/j.1445-2197.2007.04267.x; ROGERS FB, 1995, J TRAUMA, V39, P261, DOI 10.1097/00005373-199508000-00012; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147; Schafer JL, 1999, STAT METHODS MED RES, V8, P3, DOI 10.1191/096228099671525676; Siegmeth AW, 2005, J BONE JOINT SURG BR, V87B, P1123, DOI 10.1302/0301-620X.87B8; Simunovic N, 2010, CAN MED ASSOC J, V182, P1609, DOI 10.1503/cmaj.092220; Sund R, 2005, QUAL SAF HEALTH CARE, V14, P371, DOI 10.1136/qshc.2004.012831; Vidal EIO, 2009, OSTEOPOROSIS INT, V20, P723, DOI 10.1007/s00198-008-0757-1; von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI [10.1016/j.jclinepi.2007.11.008, 10.2471/BLT.07.045120]; Weller I, 2005, J BONE JOINT SURG BR, V87B, P361, DOI 10.1302/0301-620X.87B3.15300; Zuckerman JD, 1996, NEW ENGL J MED, V334, P1519, DOI 10.1056/NEJM199606063342307	41	42	45	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2014	9	6							e99308	10.1371/journal.pone.0099308	http://dx.doi.org/10.1371/journal.pone.0099308			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK2VQ	24926876	Green Published, Green Submitted, gold			2023-01-03	WOS:000338278100034
J	Piek, E; Kollen, BJ; van der Meer, K; Penninx, BWJH; Nolen, WA				Piek, Ellen; Kollen, Boudewijn J.; van der Meer, Klaas; Penninx, Brenda W. J. H.; Nolen, Willem A.			Maintenance Use of Antidepressants in Dutch General Practice: Non-Guideline Concordant	PLOS ONE			English	Article							MAJOR DEPRESSIVE DISORDER; MENTAL-HEALTH-CARE; 5-YEAR FOLLOW-UP; RELIABILITY; INVENTORY; ANXIETY; NETHERLANDS; RECALL	Background: There is hardly evidence on maintenance treatment with antidepressants in primary care. Nevertheless, depression guidelines recommend maintenance treatment i.e. treatment to prevent recurrences, in patients with high risk of recurrence, and many patients use maintenance treatment with antidepressants. This study explores the characteristics of patients on maintenance treatment with antidepressants in general practice, and compares these characteristics with guideline recommendations for maintenance treatment. Methods: We used data (baseline, two-year and four-year follow-up) of primary care respondents with remitted depressive disorder (>= 6 months) from the Netherlands Study of Depression and Anxiety (n = 776). Maintenance treatment was defined as the use of an antidepressant for >= 12 months. Multilevel logistic regression was used to describe the association between sociodemographic, clinical and care characteristics and use of maintenance treatment with antidepressants. Results: Older patients, patients with a lower education, those using benzodiazepines or receiving psychological/psychiatric care and patients with a concurrent history of a dysthymic or anxiety disorder more often received maintenance treatment with antidepressants. Limitations: Measurements were not made at the start of an episode, but at predetermined points in time. Diagnoses were based on interview (CIDI) data and could therefore in some cases have been different from the GP diagnosis. Conclusions: Since patients with chronic or recurrent depression do not use maintenance treatment with antidepressants more often, characteristics of patients on maintenance treatment do not fully correspond with guideline recommendations. However, patients on maintenance treatment appear to be those with more severe disorder and/or more comorbidity.	[Piek, Ellen; Kollen, Boudewijn J.; van der Meer, Klaas] Univ Groningen, Univ Med Ctr Groningen, Dept Gen Practice, Groningen, Netherlands; [Penninx, Brenda W. J. H.; Nolen, Willem A.] Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat, Groningen, Netherlands; [Penninx, Brenda W. J. H.] Leiden Univ, Dept Psychiat, Med Ctr, Leiden, Netherlands; [Penninx, Brenda W. J. H.] Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Dept Psychiat, Amsterdam, Netherlands	University of Groningen; University of Groningen; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Vrije Universiteit Amsterdam	Piek, E (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Gen Practice, Groningen, Netherlands.	e.piek@umcg.nl	Penninx, Brenda WJH/S-7627-2017	Penninx, Brenda WJH/0000-0001-7779-9672	Geestkracht program of the Netherlands Organisation for Health Research and Development (Zon-Mw) [10-000-1002]; VU University Medical Center; GGZ inGeest; Arkin; Leiden University Medical Center; GGZ Rivierduinen; University Medical Center Groningen; Lentis; GGZ Friesland; GGZ Drenthe; Scientific Institute for Quality of Healthcare (IQ healthcare); Netherlands Institute for Health Services Research (NIVEL); Netherlands Institute of Mental Health and Addiction (Trimbos Institute)	Geestkracht program of the Netherlands Organisation for Health Research and Development (Zon-Mw)(Netherlands Organization for Health Research and Development); VU University Medical Center; GGZ inGeest; Arkin; Leiden University Medical Center; GGZ Rivierduinen; University Medical Center Groningen; Lentis; GGZ Friesland; GGZ Drenthe; Scientific Institute for Quality of Healthcare (IQ healthcare); Netherlands Institute for Health Services Research (NIVEL); Netherlands Institute of Mental Health and Addiction (Trimbos Institute)	The infrastructure for the NESDA study (www.nesda.nl) is funded through the Geestkracht program of the Netherlands Organisation for Health Research and Development (Zon-Mw, grant number 10-000-1002) and is supported by participating universities and mental health care organizations (VU University Medical Center, GGZ inGeest, Arkin, Leiden University Medical Center, GGZ Rivierduinen, University Medical Center Groningen, Lentis, GGZ Friesland, GGZ Drenthe, Scientific Institute for Quality of Healthcare (IQ healthcare), Netherlands Institute for Health Services Research (NIVEL) and Netherlands Institute of Mental Health and Addiction (Trimbos Institute). There was no additional funding for this study. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Andrews G, 1999, PSYCHOL MED, V29, P787, DOI 10.1017/S0033291799008648; Bauer M, 2007, WORLD J BIOL PSYCHIA, V8, P67, DOI 10.1080/15622970701227829; BECK AT, 1979, J CONSULT CLIN PSYCH, V47, P343, DOI 10.1037/0022-006X.47.2.343; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Burton C, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X625166; Denicoff KD, 1997, J PSYCHIAT RES, V31, P593, DOI 10.1016/S0022-3956(96)00027-1; Holma IAK, 2008, BRIT J PSYCHIAT, V193, P163, DOI 10.1192/bjp.bp.107.045708; Honig A, 2001, PATIENT EDUC COUNS, V43, P43, DOI 10.1016/S0738-3991(00)00144-0; Institute for Clinical Systems Improvement, 2009, ICSI HLTH CAR GUID M; Kaymaz N, 2008, J CLIN PSYCHIAT, V69, P1423, DOI 10.4088/JCP.v69n0910; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Korner A, 2008, PSYCHOTHER PSYCH MED, V58, P238, DOI 10.1055/s-2007-986199; Meadows G, 2000, SOC PSYCH PSYCH EPID, V35, P427, DOI 10.1007/s001270050260; Meeuwissen JAC, 2009, MULTIDISCIPLINAIRE R; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; National Collaborating Centre for Mental Health, 2009, DEPR TREATM MAN DEPR; National Institute for Clinical Excellence, 2009, DEPR AD TREATM MAN D; Patten S B, 2000, Chronic Dis Can, V21, P68; Penninx BWJH, 2008, INT J METH PSYCH RES, V17, P121, DOI 10.1002/mpr.256; Piek E, 2011, BMC FAM PRACT, V12, DOI 10.1186/1471-2296-12-41; Piek E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014784; Piek E, 2010, EUR J GEN PRACT, V16, P106, DOI 10.3109/13814781003692463; RUSH AJ, 1986, PSYCHIAT RES, V18, P65; Saucier G, 1998, J PERS ASSESS, V70, P263, DOI 10.1207/s15327752jpa7002_6; Sunderland M, 2010, SOC PSYCH PSYCH EPID, V46, P775; Susser E, 2000, SCHIZOPHR RES, V42, P67, DOI 10.1016/S0920-9964(99)00088-2; Tacchini G, 1994, Minerva Psichiatr, V35, P63; ten Doesschate MC, 2009, J CLIN PSYCHIAT, V70, P63, DOI 10.4088/JCP.08m04119; TERLUIN B, 2004, HUISARTS WET, V47, P26; Twisk J, 2006, APPL MULTILEVEL ANAL, DOI [10.1017/CBO9780511610806, DOI 10.1017/CBO9780511610806]; Van der Veen WJ, 2009, INT J METH PSYCH RES, V18, P229, DOI 10.1002/mpr.297; Van Weel-Baumgarten EM., 2012, HUISARTS WET, V55, P252; VANMARWIJK HWJ, 2003, HUISARTS WET, V46, P614; Wells JE, 2004, PSYCHOL MED, V34, P1001, DOI 10.1017/S0033291703001843; Wilson I, 2003, FAM PRACT, V20, P685, DOI 10.1093/fampra/cmg611; WITTCHEN HU, 1991, BRIT J PSYCHIAT, V159, P645, DOI 10.1192/bjp.159.5.645	36	14	14	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2014	9	5							e97463	10.1371/journal.pone.0097463	http://dx.doi.org/10.1371/journal.pone.0097463			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI4ML	24858011	gold, Green Submitted, Green Published			2023-01-03	WOS:000336839400018
J	Prathapan, A; Vineetha, VP; Raghu, KG				Prathapan, Ayyappan; Vineetha, Vadavanath Prabhakaran; Raghu, Kozhiparambil Gopalan			Protective Effect of Boerhaavia diffusa L. against Mitochondrial Dysfunction in Angiotensin II Induced Hypertrophy in H9c2 Cardiomyoblast Cells	PLOS ONE			English	Article							PERMEABILITY TRANSITION PORE; RESPIRATORY-CHAIN COMPLEXES; CARDIAC-HYPERTROPHY; HEART-FAILURE; OXIDATIVE STRESS; ARSENIC TRIOXIDE; THERAPEUTIC TARGET; BOERHAVIA-DIFFUSA; GROWTH-FACTOR; RAT	Mitochondrial dysfunction plays a critical role in the development of cardiac hypertrophy and heart failure. So mitochondria are emerging as one of the important druggable targets in the management of cardiac hypertrophy and other associated complications. In the present study, effects of ethanolic extract of Boerhaavia diffusa (BDE), a green leafy vegetable against mitochondrial dysfunction in angiotensin II (Ang II) induced hypertrophy in H9c2 cardiomyoblasts was evaluated. H9c2 cells challenged with Ang II exhibited pathological hypertrophic responses and mitochondrial dysfunction which was evident from increment in cell volume (49.09 +/- 1.13%), protein content (55.17 +/- 1.19%), LDH leakage (58.74 +/- 1.87%), increased intracellular ROS production (26.25 +/- 0.91%), mitochondrial superoxide generation (65.06 +/- 2.27%), alteration in mitochondrial transmembrane potential (Delta Psi m), opening of mitochondrial permeability transition pore (mPTP) and mitochondrial swelling. In addition, activities of mitochondrial respiratory chain complexes (I-IV), aconitase, NADPH oxidase, thioredoxin reductase, oxygen consumption rate and calcium homeostasis were evaluated. Treatment with BDE significantly prevented the generation of intracellular ROS and mitochondrial superoxide radicals and protected the mitochondria by preventing dissipation of DYm, opening of mPTP, mitochondrial swelling and enhanced the activities of respiratory chain complexes and oxygen consumption rate in H9c2 cells. Activities of aconitase and thioredoxin reductase which was lowered (33.77 +/- 0.68% & 45.81 +/- 0.71% respectively) due to hypertrophy, were increased in BDE treated cells (P <= 0.05). Moreover, BDE also reduced the intracellular calcium overload in Ang II treated cells. Overall results revealed the protective effects of B. diffusa against mitochondrial dysfunction in hypertrophy in H9c2 cells and the present findings may shed new light on the therapeutic potential of B. diffusa in addition to its nutraceutical potentials.	[Prathapan, Ayyappan; Vineetha, Vadavanath Prabhakaran; Raghu, Kozhiparambil Gopalan] CSIR Natl Inst Interdisciplinary Sci & Technol NI, Agroproc & Nat Prod Div, Thiruvananthapuram, Kerala, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - National Institute Interdisciplinary Science & Technology (NIIST)	Raghu, KG (corresponding author), CSIR Natl Inst Interdisciplinary Sci & Technol NI, Agroproc & Nat Prod Div, Thiruvananthapuram, Kerala, India.	raghukgopal2009@gmail.com	Raghu, K G/AAT-8042-2021	Ayappan, Prathapan/0000-0002-5508-2360	Council of Scientific and Industrial Research (CSIR)	Council of Scientific and Industrial Research (CSIR)(Council of Scientific & Industrial Research (CSIR) - India)	First author thank Council of Scientific and Industrial Research (CSIR) for Senior Research Fellowship.	Abel ED, 2011, CARDIOVASC RES, V90, P234, DOI 10.1093/cvr/cvr015; Agrawal M, 2010, INT J PHARM SCI RES, V1, P1, DOI 10.13040/IJPSR.0975-8232.1(5).1-21; Ahsan MK, 2009, ANTIOXID REDOX SIGN, V11, P2741, DOI [10.1089/ars.2009.2683, 10.1089/ARS.2009.2683]; Aviello G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019628; Bayeva M, 2013, J AM COLL CARDIOL, V61, P599, DOI 10.1016/j.jacc.2012.08.1021; Bayeva M, 2010, CURR HYPERTENS REP, V12, P426, DOI 10.1007/s11906-010-0149-8; Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, pC817, DOI 10.1152/ajpcell.00139.2004; Calderon-Montano JM, 2011, MINI-REV MED CHEM, V11, P298, DOI 10.2174/138955711795305335; Cassis L, 2002, AM J PHYSIOL-REG I, V282, pR445, DOI 10.1152/ajpregu.00261.2001; Chaminda T, 2001, PHYTOTHER RES, V15, P519, DOI 10.1002/ptr.994; Chan SHH, 2009, HYPERTENSION, V53, P217, DOI 10.1161/HYPERTENSIONAHA.108.116905; Correa F, 2013, FREE RADICAL BIO MED, V61, P119, DOI 10.1016/j.freeradbiomed.2013.03.017; Dai DF, 2011, CIRC RES, V108, P837, DOI 10.1161/CIRCRESAHA.110.232306; Doughan AK, 2008, CIRC RES, V102, P488, DOI 10.1161/CIRCRESAHA.107.162800; Ferreres F, 2005, PHYTOCHEM ANALYSIS, V16, P451, DOI 10.1002/pca.869; Hajjar RJ, 2006, CIRC RES, V98, P169, DOI 10.1161/01.RES.0000204557.09610.01; Javadov S, 2007, CELL PHYSIOL BIOCHEM, V20, P1, DOI 10.1159/000103747; Javadov S, 2006, J PHARMACOL EXP THER, V317, P1036, DOI 10.1124/jpet.105.100107; Javadov S, 2009, J PHARMACOL EXP THER, V330, P670, DOI 10.1124/jpet.109.153213; Ji KQ, 2008, ANN THORAC CARDIOVAS, V14, P210; Kaur M, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep192; Kim HS, 2010, YONSEI MED J, V51, P187, DOI 10.3349/ymj.2010.51.2.187; Kristal BS, 1996, J BIOL CHEM, V271, P6033, DOI 10.1074/jbc.271.11.6033; LAMI N, 1991, CHEM PHARM BULL, V39, P1551, DOI 10.1248/cpb.39.1551; Larson AJ, 2012, ADV NUTR, V3, P39, DOI 10.3945/an.111.001271; Lin CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038706; Lin CS, 2003, RES VET SCI, V74, P219, DOI 10.1016/S0034-5288(02)00189-3; Liobikas J, 2011, J NAT PROD, V74, P1640, DOI 10.1021/np200060p; Liu CJ, 2008, MOL CELL BIOCHEM, V313, P167, DOI 10.1007/s11010-008-9754-0; Manu KA, 2009, IMMUNOPHARM IMMUNOT, V31, P377, DOI 10.1080/08923970802702036; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Mukhopadhyay P, 2007, BIOCHEM BIOPH RES CO, V358, P203, DOI 10.1016/j.bbrc.2007.04.106; Murdoch CE, 2006, CARDIOVASC RES, V71, P208, DOI 10.1016/j.cardiores.2006.03.016; Osterholt M, 2013, HEART FAIL REV, V18, P645, DOI 10.1007/s10741-012-9346-7; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Pandey KB, 2009, OXID MED CELL LONGEV, V2, P270, DOI 10.4161/oxim.2.5.9498; Pandey R, 2005, INT IMMUNOPHARMACOL, V5, P541, DOI 10.1016/j.intimp.2004.11.001; Pari L, 2004, J MED FOOD, V7, P472, DOI 10.1089/jmf.2004.7.472; Paul MK, 2008, TOXICOL APPL PHARM, V226, P140, DOI 10.1016/j.taap.2007.09.020; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; Prathapan A, 2013, BRIT J NUTR, V110, P1201, DOI 10.1017/S0007114513000561; Prathapan A, 2011, J FOOD BIOCHEM, V35, P1548, DOI 10.1111/j.1745-4514.2010.00477.x; Qin FZ, 2006, FREE RADICAL BIO MED, V40, P236, DOI 10.1016/j.freeradbiomed.2005.08.010; Rafieian-kopaei M, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/680856; Raghu KG, 2009, J TRACE ELEM MED BIO, V23, P61, DOI 10.1016/j.jtemb.2008.10.001; Rimbaud S, 2009, PHARMACOL REP, V61, P131, DOI 10.1016/S1734-1140(09)70015-5; Ritchie RH, 2006, CLIN EXP PHARMACOL P, V33, P159, DOI 10.1111/j.1440-1681.2006.04342.x; Riya MP, 2014, J SCI FOOD AGR, V94, P943, DOI 10.1002/jsfa.6340; Rocha M, 2014, MED RES REV, V34, P160, DOI 10.1002/med.21285; Rooban BN, 2010, BIOL TRACE ELEM RES, V138, P282, DOI 10.1007/s12011-010-8633-1; Rosca MG, 2010, CARDIOVASC RES, V88, P40, DOI 10.1093/cvr/cvq240; Seddon M, 2007, HEART, V93, P903, DOI 10.1136/hrt.2005.068270; Shukla SK, 2010, NAT PROD RES, V24, P873, DOI 10.1080/14786410903417378; Sreeja S, 2009, J ETHNOPHARMACOL, V126, P221, DOI 10.1016/j.jep.2009.08.041; Sudheesh NP, 2013, INT J CARDIOL, V165, P117, DOI 10.1016/j.ijcard.2011.07.103; Sudheesh NP, 2009, BIOGERONTOLOGY, V10, P627, DOI 10.1007/s10522-008-9208-9; Takemoto M, 2001, J CLIN INVEST, V108, P1429, DOI 10.1172/JCI200113350; Takimoto E, 2007, HYPERTENSION, V49, P241, DOI 10.1161/01.HYP.0000254415.31362.a7; Vineetha VP, 2013, CARDIOVASC TOXICOL, V13, P123, DOI 10.1007/s12012-012-9191-x; Vineetha VP, 2014, FOOD FUNCT, V5, P502, DOI 10.1039/c3fo60470e; Wallace TC, 2011, ADV NUTR, V2, P1, DOI 10.3945/an.110.000042; Wang GW, 2010, CIRCULATION, V121, P1912, DOI 10.1161/CIRCULATIONAHA.109.905471; Will Y, 2006, NAT PROTOC, V1, P1; Yan L, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0070658, 10.1371/journal.pone.0072548]	64	61	73	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2014	9	4							e96220	10.1371/journal.pone.0096220	http://dx.doi.org/10.1371/journal.pone.0096220			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AL1WP	24788441	Green Submitted, Green Published, gold			2023-01-03	WOS:000338917300033
J	Henriksen, DP; Brabrand, M; Lassen, AT				Henriksen, Daniel Pilsgaard; Brabrand, Mikkel; Lassen, Annmarie Touborg			Prognosis and Risk Factors for Deterioration in Patients Admitted to a Medical Emergency Department	PLOS ONE			English	Article							IN-HOSPITAL MORTALITY; VITAL SIGNS; ADMISSION; CARE; ASSOCIATION; COHORT; SCORE; WARD	Objective: Patients that initially appear stable on arrival to the hospital often have less intensive monitoring of their vital signs, possibly leading to excess mortality. The aim was to describe risk factors for deterioration in vital signs and the related prognosis among patients with normal vital signs at arrival to a medical emergency department (MED). Design and setting: Single-centre, retrospective cohort study of all patients admitted to the MED from September 2010-August 2011. Subjects: Patients were included when their vital signs (systolic blood pressure, pulse rate, respiratory rate, Glasgow Coma Scale, oxygen saturation and temperature) were within the normal range at arrival. Deterioration was defined as a deviation from the defined normal range 2-24 hours after arrival. Results: 4292 of the 6257 (68.6%) admitted to the MED had a full set of vital signs at first presentation, 1440/4292 (33.6%) had all normal vital signs and were included in study, 44.0% were male, median age 64 years (5th/95th percentile: 21-90 years) and 446/1440 (31.0%) deteriorated within 24 hours. Independent risk factors for deterioration included age 65-84 years odds ratio (OR): 1.79 (95% confidence interval [CI]: 1.27-2.52), 85+ years OR 1.67 (95% CI: 1.10-2.55), Do-not-attempt-to-resuscitate order OR 3.76 (95% CI: 1.37-10.31) and admission from the open general ED OR 1.35 (95% CI: 1.07-1.71). Thirty-day mortality was 7.9% (95% CI: 5.5-10.7%) among deteriorating patients and 1.9% (95% CI: 1.2-3.0%) among the non-deteriorating, hazard ratio 4.11 (95% CI: 2.38-7.10). Conclusions: Among acutely admitted medical patients who arrive with normal vital signs, 31.0% showed signs of deterioration within 24 hours. Risk factors included old age, Do-not-attempt-to-resuscitate order, admission from the open general ED. Thirty-day mortality among patients with deterioration was four times higher than among non-deteriorating patients. Further research is needed to determine whether intensified monitoring of vital signs can help to prevent deterioration or mortality among medical emergency patients.	[Henriksen, Daniel Pilsgaard; Lassen, Annmarie Touborg] Odense Univ Hosp, Dept Emergency Med, DK-5000 Odense, Denmark; [Brabrand, Mikkel] Sydvestjysk Sygehus, Dept Med, Esbjerg, Denmark	University of Southern Denmark; Odense University Hospital	Henriksen, DP (corresponding author), Odense Univ Hosp, Dept Emergency Med, DK-5000 Odense, Denmark.	dphenriksen@health.sdu.dk	Lassen, Annmarie/AAA-5816-2019; Brabrand, Mikkel/F-7276-2011	Brabrand, Mikkel/0000-0002-3340-8251; Henriksen, Daniel Pilsgaard/0000-0003-1303-6195; Lassen, Annmarie/0000-0003-4942-6152	University of Southern Denmark; Research Foundation of Odense University Hospital; philanthropically private fund TrygFonden given; philanthropically private fund	University of Southern Denmark; Research Foundation of Odense University Hospital; philanthropically private fund TrygFonden given; philanthropically private fund	DPH was supported by: University of Southern Denmark, The Research Foundation of Odense University Hospital, as well as an unrestricted grant from the philanthropically private fund TrygFonden given to the University of Southern Denmark. ATL was supported by an unrestricted grant from the philanthropically private fund TrygFonden given to University of Southern Denmark, and is employed as a consultant at the Department of Emergency Medicine, Odense University Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Armstrong B, 2008, EMERG MED J, V25, P799, DOI 10.1136/emj.2007.052951; Barfod C, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-29; Barfod C, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-28; Bleyer AJ, 2011, RESUSCITATION, V82, P1387, DOI 10.1016/j.resuscitation.2011.06.033; Buist M, 2004, RESUSCITATION, V62, P137, DOI 10.1016/j.resuscitation.2004.03.005; Centre for Clinical Practice at NICE (UK), 2007, NICE CLIN GUIDEL, V50, P1; Farley H, 2010, ACAD EMERG MED, V17, P718, DOI 10.1111/j.1553-2712.2010.00796.x; Fuhrmann L, 2008, RESUSCITATION, V77, P325, DOI 10.1016/j.resuscitation.2008.01.009; Gjerstorff ML, 2011, SCAND J PUBLIC HEALT, V39, P42, DOI 10.1177/1403494810393562; Goldhill DR, 1999, ANAESTHESIA, V54, P853; Guttmann A, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2983; Hallas J, 2001, PHARMACOEPIDEM DR S, V10, P619, DOI 10.1002/pds.638; Hands C, 2013, BMJ QUAL SAF, V22, P719, DOI 10.1136/bmjqs-2013-001954; Hogan H, 2012, BMJ QUAL SAF, V21, P737, DOI 10.1136/bmjqs-2011-001159; Jones D, 2013, RESUSCITATION, V84, P1029, DOI 10.1016/j.resuscitation.2013.01.013; Kellett J, 2011, EUR J INTERN MED, V22, P375, DOI 10.1016/j.ejim.2011.03.005; Kennedy M, 2010, ACAD EMERG MED, V17, P1080, DOI 10.1111/j.1553-2712.2010.00872.x; Lighthall GK, 2009, RESUSCITATION, V80, P1264, DOI 10.1016/j.resuscitation.2009.08.012; Lynge E, 2011, SCAND J PUBLIC HEALT, V39, P30, DOI 10.1177/1403494811401482; Pedersen CB, 2011, SCAND J PUBLIC HEALT, V39, P22, DOI 10.1177/1403494810387965; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Schmidt Morten, 2010, Clin Epidemiol, V2, P195, DOI 10.2147/CLEP.S12171; Scott I, 2009, INT J QUAL HEALTH C, V21, P397, DOI 10.1093/intqhc/mzp045; Simchen E, 2007, CRIT CARE MED, V35, P449, DOI 10.1097/01.CCM.0000253407.89594.15; Subbe CP, 2001, QJM-MON J ASSOC PHYS, V94, P521, DOI 10.1093/qjmed/94.10.521; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Wuerz R, 2001, ACAD EMERG MED, V8, P61	27	29	29	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2014	9	4							e94649	10.1371/journal.pone.0094649	http://dx.doi.org/10.1371/journal.pone.0094649			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE9PC	24718637	gold, Green Published, Green Submitted			2023-01-03	WOS:000334339000136
J	Wildeman, C; Emanuel, N				Wildeman, Christopher; Emanuel, Natalia			Cumulative Risks of Foster Care Placement by Age 18 for US Children, 2000-2011	PLOS ONE			English	Article							HEALTH-STATUS; PROTECTION	Foster care placement is among the most tragic events a child can experience because it more often than not implies that a child has experienced or is at very high risk of experiencing abuse or neglect serious enough to warrant state intervention. Yet it is unclear how many children will experience foster care placement at some point between birth and age 18. Using synthetic cohort life tables and data from the Adoption and Foster Care Analysis and Reporting System (AFCARS), we estimated how many U. S. children were placed in foster care between birth and age 18, finding support for three conclusions. First, up to 5.91% of all U. S. children were ever placed in foster care between their birth and age 18. Second, Native American (up to 15.44%) and Black (up to 11.53%) children were at far higher risk of placement. Foster care is thus quite common in the U. S., especially for historically disadvantaged racial/ethnic groups. Third, differences in foster care placement were minimal between the sexes, indicating that the high risks of foster care placement are shared almost equally by boys and girls.	[Wildeman, Christopher] Yale Univ, Dept Sociol, New Haven, CT 06520 USA; [Emanuel, Natalia] Yale Univ, Dept Econ, New Haven, CT 06520 USA	Yale University; Yale University	Wildeman, C (corresponding author), Yale Univ, Dept Sociol, New Haven, CT 06520 USA.	christopher.wildeman@yale.edu			Children's Bureau; Administration on Children, Youth and Families; Administration for Children and Families; United States Department of Health and Human Services	Children's Bureau; Administration on Children, Youth and Families; Administration for Children and Families(United States Department of Health & Human Services); United States Department of Health and Human Services	Funding for the project was provided by the Children's Bureau, Administration on Children, Youth and Families, Administration for Children and Families, United States Department of Health and Human Services. All analyses and interpretations presented here are solely those of the authors, and the collector of the data, the funder, the Archive, Cornell University and their agents or employees bear no responsibility for the analyses or interpretations presented here. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2010, AD FOST CAR AN REP S; [Anonymous], 2008, AD FOST CAR AN REP S; [Anonymous], 1926, REP PUBLIC HLTH MED; [Anonymous], 2007, AD FOST CAR AN REP S; [Anonymous], 2009, AD FOST CAR AN REP S; [Anonymous], 2006, AD FOST CAR AN REP S; CHERNOFF R, 1994, PEDIATRICS, V93, P594; Clausen J.M., 1998, J CHILD FAM STUD, V7, P283, DOI [DOI 10.1023/A:1022989411119, 10.1023/A:1022989411119]; Doyle JJ, 2008, J POLIT ECON, V116, P746, DOI 10.1086/590216; Doyle JJ, 2007, AM ECON REV, V97, P1583, DOI 10.1257/aer.97.5.1583; Gilbert R, 2009, LANCET, V373, P68, DOI 10.1016/S0140-6736(08)61706-7; HALFON N, 1995, ARCH PEDIAT ADOL MED, V149, P386, DOI 10.1001/archpedi.1995.02170160040006; Harman JS, 2000, ARCH PEDIAT ADOL MED, V154, P1114, DOI 10.1001/archpedi.154.11.1114; Jee S, 2010, CHILD YOUTH SERV REV, V32, P685, DOI 10.1016/j.childyouth.2010.01.004; Magruder J, 2008, CHILD WELFARE, V87, P169; National Data Archive on Child Abuse and Neglect, 2002, AD FOST CAR AN REP S; National Data Archive on Child Abuse and Neglect, 2004, AD FOST CAR AN REP S; National Data Archive on Child Abuse and Neglect, 2003, AD FOST CAR AN REP S; National Data Archive on Child Abuse and Neglect, 2005, AD FOST CAR AN REP S; National Data Archive on Child Abuse and Neglect, 2012, AD FOST CAR AN REP S; National Data Archive on Child Abuse and Neglect, 2011, AD FOST CAR AN REP S; PAN-AFRICAN PARLIAMENT, 2012, 21 ORDINARY SESSION; Preston S. H., 2001, DEMOGRAPHY MEASURING; Putnam-Hornstein E, 2011, CHILD MALTREATMENT, V16, P163, DOI 10.1177/1077559511411179; StataCorp, 2019, STATA STAT SOFTWARE; U.S. Department of Health and Human Services Administration for Children and Families Administration on Children Youth and Families Children's Bureau, 2012, FED REP SYST AD FOST; U.S. Department of Health and Human Services Centers for Disease Control and Prevention National Center for Health Statistics CDC WONDER Online Database, 2011, BRIDG RAC POP EST 19	27	100	100	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2014	9	3							e92785	10.1371/journal.pone.0092785	http://dx.doi.org/10.1371/journal.pone.0092785			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AE0SR	24671254	Green Submitted, Green Published, gold			2023-01-03	WOS:000333677000074
J	Kim, JS; Zee, DS				Kim, Ji-Soo; Zee, David S.			Benign Paroxysmal Positional Vertigo	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RANDOMIZED CLINICAL-TRIAL; SEMONT MANEUVER; SELF-TREATMENT; NYSTAGMUS; VARIANT; CANALOLITHIASIS; EFFICACY	A 58-year-old woman seeks care from her primary physician after the occurrence of sudden vertigo and imbalance with nausea and vomiting, which began that morning when she got out of bed. The vertigo lasted less than a minute but recurred when she lay back down in bed, rolled over in bed, or got up again. She reports no tinnitus or hearing loss. How should this patient be evaluated and treated?	[Kim, Ji-Soo] Seoul Natl Univ, Bundang Hosp, Dept Neurol, Coll Med, Songnam, South Korea; [Zee, David S.] Johns Hopkins Univ Hosp, Dept Neurol, Sch Med, Baltimore, MD 21287 USA; [Zee, David S.] Johns Hopkins Univ Hosp, Dept Otolaryngol Head & Neck Surg, Sch Med, Baltimore, MD 21287 USA; [Zee, David S.] Johns Hopkins Univ Hosp, Dept Neurosci, Sch Med, Baltimore, MD 21287 USA; [Zee, David S.] Johns Hopkins Univ Hosp, Dept Ophthalmol, Sch Med, Baltimore, MD 21287 USA	Seoul National University (SNU); Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Zee, DS (corresponding author), Johns Hopkins Univ Hosp, Dept Neurol, 600 N Wolfe St, Baltimore, MD 21287 USA.	dzee@jhu.edu	Kim, Ji-Soo/D-8744-2012	Kim, Ji-Soo/0000-0002-1508-2024				Appiani GC, 2005, OTOL NEUROTOL, V26, P257, DOI 10.1097/00129492-200503000-00022; Asprella Libonati G, 2005, Acta Otorhinolaryngol Ital, V25, P277; Balatsouras DG, 2012, OTOLARYNG HEAD NECK, V146, P98, DOI 10.1177/0194599811425158; BALOH RW, 1993, NEUROLOGY, V43, P2542, DOI 10.1212/WNL.43.12.2542; BALOH RW, 1995, NEUROLOGY, V45, P1297, DOI 10.1212/WNL.45.7.1297; BALOH RW, 1987, NEUROLOGY, V37, P371, DOI 10.1212/WNL.37.3.371; Bertholon P, 2002, J NEUROL NEUROSUR PS, V72, P366, DOI 10.1136/jnnp.72.3.366; Bhattacharyya N, 2008, OTOLARYNG HEAD NECK, V139, pS47, DOI 10.1016/j.otohns.2008.08.022; Cambi J, 2013, J NEUROL, V260, P1489, DOI 10.1007/s00415-012-6815-9; Casani AP, 2002, LARYNGOSCOPE, V112, P172, DOI 10.1097/00005537-200201000-00030; Choung YH, 2006, LARYNGOSCOPE, V116, P1776, DOI 10.1097/01.mlg.0000231291.44818.be; Devaiah AK, 2010, OTOLARYNG HEAD NECK, V142, P155, DOI 10.1016/j.otohns.2009.09.013; DIX MR, 1952, P ROY SOC MED, V45, P341, DOI 10.1177/003591575204500604; EPLEY JM, 1992, OTOLARYNG HEAD NECK, V107, P399, DOI 10.1177/019459989210700310; Faldon ME, 2008, AUDIOL NEURO-OTOL, V13, P345, DOI 10.1159/000136153; Fife TD, 2008, NEUROLOGY, V70, P2067, DOI 10.1212/01.wnl.0000313378.77444.ac; Furman JM, 1999, NEW ENGL J MED, V341, P1590, DOI 10.1056/NEJM199911183412107; Gordon CR, 2004, ACTA NEUROL SCAND, V110, P166, DOI 10.1111/j.1600-0404.2004.00296.x; Gufoni M, 1998, Acta Otorhinolaryngol Ital, V18, P363; Han BI, 2006, NEUROLOGY, V66, P706, DOI 10.1212/01.wnl.0000201184.69134.23; Helminski JO, 2010, PHYS THER, V90, P663, DOI 10.2522/ptj.20090071; Herdman SJ, 1996, ARCH OTOLARYNGOL, V122, P281; Hilton M, 2004, COCHRANE DB SYST REV, V2; Hunt WT, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008675.pub2; Imai T, 2005, NEUROLOGY, V64, P920, DOI 10.1212/01.WNL.0000152890.00170.DA; Jeong SH, 2009, NEUROLOGY, V72, P1069, DOI 10.1212/01.wnl.0000345016.33983.e0; Jeong SH, 2013, J NEUROL, V260, P832, DOI 10.1007/s00415-012-6712-2; Kattah JC, 2009, STROKE, V40, P3504, DOI 10.1161/STROKEAHA.109.551234; Kerber KA, 2013, OTOLARYNG HEAD NECK, V148, P425, DOI 10.1177/0194599812471633; Kim JS, 2012, NEUROLOGY, V78, P159, DOI 10.1212/WNL.0b013e31823fcd26; Kim JS, 2012, NEUROLOGY, V79, P700, DOI 10.1212/WNL.0b013e3182648b8b; Korres S, 2011, OTOL NEUROTOL, V32, P1302, DOI 10.1097/MAO.0b013e31822f0bc5; Lee SH, 2007, J NEUROL SCI, V256, P75, DOI 10.1016/j.jns.2007.02.026; LEMPERT T, 1994, NEUROLOGY, V44, P2213, DOI 10.1212/WNL.44.11.2213-a; Lopez-Escamez JA, 2005, EUR ARCH OTO-RHINO-L, V262, P507, DOI 10.1007/s00405-004-0841-x; Mandala M, 2012, J NEUROL, V259, P882, DOI 10.1007/s00415-011-6272-x; MCCLURE JA, 1985, J OTOLARYNGOL, V14, P30; Nunez RA, 2000, OTOLARYNG HEAD NECK, V122, P647, DOI 10.1016/S0194-5998(00)70190-2; Nuti D, 1996, J VESTIBUL RES-EQUIL, V6, P173, DOI 10.1016/0957-4271(95)02040-3; Nuti D., 2013, OXFORD TXB VERTIGO I, P217; Nuti D, 2009, ANN NY ACAD SCI, V1164, P316, DOI 10.1111/j.1749-6632.2008.03720.x; Oh HJ, 2007, NEUROLOGY, V68, P1219, DOI 10.1212/01.wnl.0000259037.76469.e4; Oh SY, 2009, J NEUROL, V256, P1330, DOI 10.1007/s00415-009-5122-6; Radtke A, 2004, NEUROLOGY, V63, P150, DOI 10.1212/01.WNL.0000130250.62842.C9; Semont A, 1988, Adv Otorhinolaryngol, V42, P290; Soto-Varela A, 2011, OTOL NEUROTOL, V32, P1008, DOI 10.1097/MAO.0b013e3182267f02; Steddin S, 1996, ANN NEUROL, V40, P918; Tanimoto H, 2005, NEUROLOGY, V65, P1299, DOI 10.1212/01.wnl.0000180518.34672.3d; Vannucchi P, 1997, J VESTIBUL RES-EQUIL, V7, P1; von Brevern M, 2007, J NEUROL NEUROSUR PS, V78, P710, DOI 10.1136/jnnp.2006.100420	50	214	242	0	44	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 20	2014	370	12					1138	1147		10.1056/NEJMcp1309481	http://dx.doi.org/10.1056/NEJMcp1309481			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AD2HA	24645946				2023-01-03	WOS:000333054000010
J	Chokshi, DA				Chokshi, Dave A.			Improving Health Care for Veterans - A Watershed Moment for the VA	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TRANSFORMATION; SYSTEM		[Chokshi, Dave A.] NYU, Dept Populat Hlth, Langone Med Ctr, New York, NY 10012 USA; [Chokshi, Dave A.] NYU, Dept Med, Langone Med Ctr, New York, NY 10016 USA	New York University; NYU Langone Medical Center; New York University; NYU Langone Medical Center	Chokshi, DA (corresponding author), NYU, Dept Populat Hlth, Langone Med Ctr, New York, NY 10012 USA.			Chokshi, Dave/0000-0001-7467-4591				Department of Veterans Affairs Office of Public and Intergovernmental Affairs, 2014, IND 2013 SURV SHOWS; Government Accountability Office, 2012, GAO13130; Jha AK, 2003, NEW ENGL J MED, V348, P2218, DOI 10.1056/NEJMsa021899; Kizer KW, 2012, J GEN INTERN MED, V27, P395, DOI 10.1007/s11606-011-1981-5; Kizer KW, 2009, ANNU REV PUBL HEALTH, V30, P313, DOI 10.1146/annurev.publhealth.29.020907.090940; Trivedi AN, 2011, MED CARE, V49, P76, DOI 10.1097/MLR.0b013e3181f53575	6	28	28	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 24	2014	371	4					297	299		10.1056/NEJMp1406868	http://dx.doi.org/10.1056/NEJMp1406868			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AL7TY	24896820	Bronze			2023-01-03	WOS:000339339800005
J	Wright, J				Wright, Jessica			NANOTECHNOLOGY Deliver on a promise	NATURE			English	Editorial Material																		Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956; Hrkach J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003651; Verma S, 2012, NEW ENGL J MED, V367, P1783, DOI 10.1056/NEJMoa1209124	3	27	27	0	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	2014	509	7502					S58	S59		10.1038/509S58a	http://dx.doi.org/10.1038/509S58a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AH9JC	24870822				2023-01-03	WOS:000336457100005
J	Orentlicher, D; Pope, TM; Rich, BA				Orentlicher, David; Pope, Thaddeus Mason; Rich, Ben A.			The Changing Legal Climate for Physician Aid in Dying	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Orentlicher, David] Indiana Univ, Hall Ctr Law & Hlth, Robert H McKinney Sch Law, Indianapolis, IN 46202 USA; [Pope, Thaddeus Mason] Hamline Univ, Sch Law, Hlth Law Inst, St Paul, MN USA; [Rich, Ben A.] Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Mitchell Hamline School of Law; University of California System; University of California Davis	Orentlicher, D (corresponding author), Indiana Univ, Hall Ctr Law & Hlth, Robert H McKinney Sch Law, 530 W New York St, Indianapolis, IN 46202 USA.	dorentli@iu.edu	Pope, Thaddeus/K-9452-2019	Pope, Thaddeus/0000-0002-7163-505X				American Public Health Association, POL STAT DAT; CANTOR NL, 1977, RUTGERS LAW REV, V30, P243; Ganzini L, 2009, J PAIN SYMPTOM MANAG, V38, P807, DOI 10.1016/j.jpainsymman.2009.04.026; GELFAND G, 1987, WISC LAW REV, P737; Hall M. A., 2013, HLTH CARE LAW ETHICS; Orentlicher D, 1996, NEW ENGL J MED, V335, P663, DOI 10.1056/NEJM199608293350912	6	12	12	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	2014	311	19					1961	1962		10.1001/jama.2014.4117	http://dx.doi.org/10.1001/jama.2014.4117			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AH4UA	24733479	Green Published			2023-01-03	WOS:000336122800011
J	Rowe, BH				Rowe, Brian H.			Review: Prehospital noninvasive ventilation for severe respiratory distress reduces hospital mortality	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Alberta, Edmonton, AB, Canada	University of Alberta	Rowe, BH (corresponding author), Univ Alberta, Edmonton, AB, Canada.							Hess DR, 2009, RESP CARE, V54, P1306; Lim WJ, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004360.pub4; Picot J, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004104.PUB3; Vital FMR, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005351.pub2	4	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 20	2014	160	10							JC2	10.7326/0003-4819-160-10-201405200-02002	http://dx.doi.org/10.7326/0003-4819-160-10-201405200-02002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AJ0MJ	24842436				2023-01-03	WOS:000337347100001
J	Almagrami, AA; Alshawsh, MA; Saif-Ali, R; Shwter, A; Salem, SD; Abdulla, MA				Almagrami, Amel A.; Alshawsh, Mohammed A.; Saif-Ali, Riyadh; Shwter, Abdrabuh; Salem, Sameer D.; Abdulla, Mahmood A.			Evaluation of Chemopreventive Effects of Acanthus ilicifolius against Azoxymethane-Induced Aberrant Crypt Foci in the Rat Colon	PLOS ONE			English	Article							CELL-PROLIFERATION; COLORECTAL-CANCER; OXIDATIVE STRESS; IN-VIVO; APOPTOSIS; ANTIOXIDANT; INDUCTION; CARCINOGENESIS; BAX; PATHOGENESIS	Background: Acanthus ilicifolius, a mangrove medicinal plant, is traditionally used to treat a variety of diseases. The aim of this research is to assess the chemoprotective outcomes of A. ilicifolius ethanolic extract against azoxymethane (AOM) induced colonic aberrant crypt foci (ACF) in rats. Methodology/Principal Findings: In our study, rats were arranged in to five groups. Rats in the normal control group were given subcutaneous injections of normal saline once weekly for 2 weeks. The AOM control, reference and treatment groups were given subcutaneous injection of AOM, 15 mg/kg body weight, once weekly for 2 weeks each. The reference group was treated with 35 mg/kg 5-Fluorouracil via intraperitoneal injection once weekly for 8 weeks, and the treatment groups were administered by gavage with 250 and 500 mg/kg A. ilicifolius extract daily for 8 weeks. Both normal and AOM control groups received the vehicle; 10% Tween-20 only. Rats treated with 250 mg/kg and 500 mg/kg of A. ilicifolius extracts showed a decrease in the mean number of ACF by 65% and 53%, respectively. Those fed with A. ilicifolius showed significantly decreased multiplicity of ACF formations when compared with the results from the AOM control group. The 250 mg/kg A. ilicifolius treatment group showed significant decreases in lipid peroxidation MDA levels when compared with the AOM control group. In immunohistochemistry staining, the proliferating nuclear cell antigen (PCNA)-positive cells were significantly higher in the AOM control group than in the A. ilicifolius-treated groups. RT-PCR showed that A. ilicifolius caused a change in the regulation of apoptosis-related genes expression. Conclusion/Significance: The results of the current study show that AOM-treated rats receiving oral exposure to A. ilicifolius demonstrated a significant decrease in the number of ACF in the colon when compared to AOM-treated rats receiving vehicle only. A ilicifolius may be an effective herbal approach for the prevention of AOM-induced ACF in the rat colon.	[Almagrami, Amel A.; Shwter, Abdrabuh; Abdulla, Mahmood A.] Univ Malaya, Fac Med, Dept Biomed Sci, Kuala Lumpur, Malaysia; [Alshawsh, Mohammed A.] Univ Malaya, Fac Med, Dept Pharmacol, Kuala Lumpur 50603, Malaysia; [Saif-Ali, Riyadh; Salem, Sameer D.] Fac Med, Dept Biochem, Sanaa, Yemen	Universiti Malaya; Universiti Malaya	Almagrami, AA (corresponding author), Univ Malaya, Fac Med, Dept Biomed Sci, Kuala Lumpur, Malaysia.	amel_almagrami@yahoo.com; ammeen@um.edu.my	Alshawsh, Mohammed Abdullah/B-2887-2010	Alshawsh, Mohammed Abdullah/0000-0001-8342-5183; Saif-Ali, Riyadh/0000-0002-0246-3856	University of Malaya [PV042/2011A]; High Impact Research Grant from the Ministry of Higher Education Malaysia [UM-MOHE UM.C/625/1/HIR/MOHE/SC/09]	University of Malaya(Universiti Malaya); High Impact Research Grant from the Ministry of Higher Education Malaysia	This research is supported by University of Malaya grants; PV042/2011A, and High Impact Research Grant UM-MOHE UM.C/625/1/HIR/MOHE/SC/09 from the Ministry of Higher Education Malaysia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Numair KS, 2011, EXP BIOL MED, V236, P1005, DOI 10.1258/ebm.2011.011010; AOAC, 1995, OFF METH AN ASS AN C; Babu BH, 2002, J ETHNOPHARMACOL, V79, P27, DOI 10.1016/S0378-8741(01)00347-6; Babu BH, 2001, FITOTERAPIA, V72, P272, DOI 10.1016/S0367-326X(00)00300-2; Bejar LM, 2012, GAC SANIT, V26, P69, DOI 10.1016/j.gaceta.2011.04.016; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; BIRD RP, 1987, CANCER LETT, V37, P147, DOI 10.1016/0304-3835(87)90157-1; Bird RP, 2000, TOXICOL LETT, V112, P395, DOI 10.1016/S0378-4274(99)00261-1; BIRD RP, 1995, CANCER LETT, V93, P55, DOI 10.1016/0304-3835(95)03788-X; Boonstra J, 2004, GENE, V337, P1, DOI 10.1016/j.gene.2004.04.032; Bousserouel S, 2011, PATHOL INT, V61, P80, DOI 10.1111/j.1440-1827.2010.02621.x; Bousserouel S, 2010, ONCOL REP, V23, P511, DOI 10.3892/or_00000663; Cheng L, 2003, WORLD J GASTROENTERO, V9, P2642; Corpet DE, 2002, NUTR CANCER, V43, P1, DOI 10.1207/S15327914NC431_1; Di Carlo G, 1999, LIFE SCI, V65, P337, DOI 10.1016/S0024-3205(99)00120-4; DIPPLE A, 1995, CARCINOGENESIS, V16, P437, DOI 10.1093/carcin/16.3.437; Dobrovolskaia MA, 2005, CURR CANCER DRUG TAR, V5, P325, DOI 10.2174/1568009054629645; DOWD LE, 1959, ANAL CHEM, V31, P1184, DOI 10.1021/ac60151a033; Eastwood GL, 1995, J CLIN GASTROENTEROL, V21, pS1; Gupta SC, 2010, CANCER METAST REV, V29, P405, DOI 10.1007/s10555-010-9235-2; Hirose Y, 1996, JPN J CANCER RES, V87, P575, DOI 10.1111/j.1349-7006.1996.tb00262.x; JACOBS LR, 1986, CANCER RES, V46, P1727; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kanchanapoom T, 2001, PHYTOCHEMISTRY, V56, P369, DOI 10.1016/S0031-9422(00)00362-9; Kapiszewska M, 2006, VEGETABLE MEAT CONSU; Kim ND, 2006, CURR CANCER DRUG TAR, V6, P681; Kohno H, 2006, INT J CANCER, V118, P2936, DOI 10.1002/ijc.21719; Kundu T, 2005, CANCER LETT, V230, P111, DOI 10.1016/j.canlet.2004.12.035; Lee WR, 2002, BIOCHEM PHARMACOL, V63, P225, DOI 10.1016/S0006-2952(01)00876-0; LIPKIN M, 1983, CANCER RES, V43, P1899; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Natarajan V, 2003, Indian J Med Microbiol, V21, P98; OECD, 2001, GUID 423 AC OR TOX A; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OSAWA T, 1990, BASIC LIFE SCI, V52, P139; Patel BB, 2009, AM J PHYSIOL-GASTR L, V296, pG955, DOI 10.1152/ajpgi.90726.2008; PONDER BAJ, 1986, J NATL CANCER I, V77, P967; Raju J, 2004, CANCER EPIDEM BIOMAR, V13, P1392; RAO CV, 1993, CARCINOGENESIS, V14, P2219, DOI 10.1093/carcin/14.11.2219; RAO CV, 1993, CANCER RES, V53, P4182; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Rodriguez-Ramiro I, 2011, MOL NUTR FOOD RES, V55, P1895, DOI 10.1002/mnfr.201100363; ROJA G, 1994, PHYTOCHEMISTRY, V36, P65, DOI 10.1016/S0031-9422(00)97013-4; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Shahidi F, 2010, PHYTOCHEM REV, V9, P147, DOI 10.1007/s11101-009-9142-8; Singh Amrita, 2001, Indian Journal of Experimental Biology, V39, P263; Siu IM, 1999, CANCER RES, V59, P63; Srimuangwong K, 2012, WORLD J GASTROENTERO, V18, P6951, DOI 10.3748/wjg.v18.i47.6951; Takayama T, 1998, NEW ENGL J MED, V339, P1277, DOI 10.1056/NEJM199810293391803; Tanaka T, 1997, CARCINOGENESIS, V18, P957, DOI 10.1093/carcin/18.5.957; Waly MI, 2012, ASIAN PAC J CANCER P, V13, P4051, DOI 10.7314/APJCP.2012.13.8.4051; Woestmann Ralf, 2008, Senckenbergiana Maritima, V38, P31; Wu J, 2003, PHARMAZIE, V58, P363; Wu WS, 2006, CANCER METAST REV, V25, P695, DOI 10.1007/s10555-006-9037-8; Yang HL, 2006, CANCER LETT, V231, P215, DOI 10.1016/j.canlet.2005.02.004; Yusoff HM, 2012, ASIAN PAC J CANCER P, V13, P3983, DOI 10.7314/APJCP.2012.13.8.3983; ZHAN QM, 1994, ONCOGENE, V9, P3743	57	18	18	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2014	9	5							e96004	10.1371/journal.pone.0096004	http://dx.doi.org/10.1371/journal.pone.0096004			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI1ZC	24819728	Green Published, gold			2023-01-03	WOS:000336653300010
J	Cully, M				Cully, Megan			PUBLIC HEALTH The politics of antibiotics	NATURE			English	Editorial Material														Cully, Megan/0000-0003-4726-134X				Aarestrup FM, 2010, AM J VET RES, V71, P726, DOI 10.2460/ajvr.71.7.726; European Medicines Agency, 2013, SAL VET ANT AG 25 EU; Hollis A, 2013, NEW ENGL J MED, V369, P2474, DOI 10.1056/NEJMp1311479; Zhu YG, 2013, P NATL ACAD SCI USA, V110, P3435, DOI 10.1073/pnas.1222743110	4	75	77	2	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 1	2014	509	7498					S16	S17		10.1038/509S16a	http://dx.doi.org/10.1038/509S16a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG1TM	24784425	Bronze			2023-01-03	WOS:000335199100009
J	Pereira, PMR; Silva, S; Cavaleiro, JAS; Ribeiro, CAF; Tome, JPC; Fernandes, R				Pereira, Patricia M. R.; Silva, Sandrina; Cavaleiro, Jose A. S.; Ribeiro, Carlos A. F.; Tome, Joao P. C.; Fernandes, Rosa			Galactodendritic Phthalocyanine Targets Carbohydrate-Binding Proteins Enhancing Photodynamic Therapy	PLOS ONE			English	Article							PHOTOPHYSICAL PROPERTIES; SUPEROXIDE-DISMUTASE; CONJUGATED CHLORINS; CELL RECOGNITION; EXPRESSION; PHOTOSENSITIZERS; DENDRIMERS; EFFICIENCY; PORPHYRIN; DELIVERY	Photosensitizers (PSs) are of crucial importance in the effectiveness of photodynamic therapy (PDT) for cancer. Due to their high reactive oxygen species production and strong absorption in the wavelength range between 650 and 850 nm, where tissue light penetration is rather high, phthalocyanines (Pcs) have been studied as PSs of excellence. In this work, we report the evaluation of a phthalocyanine surrounded by a carbohydrate shell of sixteen galactose units distributed in a dendritic manner (PcGal(16)) as a new and efficient third generation PSs for PDT against two bladder cancer cell lines, HT-1376 and UM-UC-3. Here, we define the role of galacto-dendritic units in promoting the uptake of a Pc through interaction with GLUT1 and galectin-1. The photoactivation of PcGal(16) induces cell death by generating oxidative stress. Although PDT with PcGal(16) induces an increase on the activity of antioxidant enzymes immediately after PDT, bladder cancer cells are unable to recover from the PDT-induced damage effects for at least 72 h after treatment. PcGal(16) co-localization with galectin-1 and GLUT1 and/or generation of oxidative stress after PcGal(16) photoactivation induces changes in the levels of these proteins. Knockdown of galectin-1 and GLUT1, via small interfering RNA (siRNA), in bladder cancer cells decreases intracellular uptake and phototoxicity of PcGal(16). The results reported herein show PcGal(16) as a promising therapeutic agent for the treatment of bladder cancer, which is the fifth most common type of cancer with the highest rate of recurrence of any cancer.	[Pereira, Patricia M. R.; Silva, Sandrina; Cavaleiro, Jose A. S.; Tome, Joao P. C.] Univ Aveiro, QOPNA, P-3800 Aveiro, Portugal; [Pereira, Patricia M. R.; Silva, Sandrina; Cavaleiro, Jose A. S.; Tome, Joao P. C.] Univ Aveiro, Dept Chem, P-3800 Aveiro, Portugal; [Pereira, Patricia M. R.; Ribeiro, Carlos A. F.] Univ Coimbra, Fac Med, Inst Biomed Imaging & Life Sci, Lab Pharmacol & Expt Therapeut, Coimbra, Portugal; [Tome, Joao P. C.] Univ Ghent, Dept Organ Chem, B-9000 Ghent, Belgium; [Fernandes, Rosa] Ctr Invest Environm Genet & Oncobiol, Coimbra, Portugal; [Fernandes, Rosa] Univ Coimbra, Fac Med, IBILI, Ctr Ophthalmol & Vis Sci, Coimbra, Portugal	Universidade de Aveiro; Universidade de Aveiro; Universidade de Coimbra; Ghent University; Universidade de Coimbra; Universidade de Coimbra	Tome, JPC (corresponding author), Univ Aveiro, QOPNA, P-3800 Aveiro, Portugal.	jtome@ua.pt; rcfernandes@fmed.uc.pt	Tome, Joao P. C./K-6782-2014; Fernandes, Rosa/P-1102-2014	Tome, Joao P. C./0000-0001-6057-4936; Fernandes, Rosa/0000-0001-7828-2296; Silva, Sandrina/0000-0001-7728-8485; Cavaleiro, Jose/0000-0001-5495-5126; Pereira, Patricia/0000-0002-4772-9339	FCT- Fundacao para a Ciencia e a Tecnologia, Portugal [PTDC/CTM/101538/2008]; FCT; Fundo Europeu de Desenvolvimento Regional (FEDER) [Pest-C/SAU/UI3282/2011, Pest-C/SAU/UI3282/2013, PEst-C/QUI/UI0062/2013]	FCT- Fundacao para a Ciencia e a Tecnologia, Portugal(Portuguese Foundation for Science and Technology); FCT(Portuguese Foundation for Science and TechnologyEuropean Commission); Fundo Europeu de Desenvolvimento Regional (FEDER)(European Commission)	The synthesis of the photosensitizer was supported by the grant PTDC/CTM/101538/2008 (FCT- Fundacao para a Ciencia e a Tecnologia, Portugal). Thanks are due to FCT and Fundo Europeu de Desenvolvimento Regional (FEDER) for funding IBILI (Pest-C/SAU/UI3282/2011 and Pest-C/SAU/UI3282/2013) and QOPNA (PEst-C/QUI/UI0062/2013) research units. Thanks are due to ACIMAGO (ref. 12/12). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allison RR, 2010, PHOTODIAGN PHOTODYN, V7, P61, DOI 10.1016/j.pdpdt.2010.02.001; Almeida RD, 2004, BBA-REV CANCER, V1704, P59, DOI 10.1016/j.bbcan.2004.05.003; [Anonymous], TETRAHEDRON IN PRESS; [Anonymous], CURR ORG SY IN PRESS; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; Ballardini R, 2003, EUR J ORG CHEM, V2003, P288; Ballut S, 2009, CHEM COMMUN, P224, DOI 10.1039/b816128c; Bancirova M, 2011, LUMINESCENCE, V26, P685, DOI 10.1002/bio.1296; BARNETT JEG, 1975, BIOCHEM J, V145, P417, DOI 10.1042/bj1450417a; Bogoeva VP, 2010, PROTEOMICS, V10, P1946, DOI 10.1002/pmic.200900581; Buytaert E, 2007, BBA-REV CANCER, V1776, P86, DOI 10.1016/j.bbcan.2007.07.001; Carruthers A, 2009, AM J PHYSIOL-ENDOC M, V297, pE836, DOI 10.1152/ajpendo.00496.2009; Chan JYW, 1999, LIFE SCI, V65, P63, DOI 10.1016/S0024-3205(99)00219-2; CHIARIOTTI L, 1992, ONCOGENE, V7, P2507; Choi CF, 2008, ORG BIOMOL CHEM, V6, P2173, DOI 10.1039/b802212g; Cindolo L, 1999, INT J CANCER, V84, P39, DOI 10.1002/(SICI)1097-0215(19990219)84:1<39::AID-IJC8>3.3.CO;2-5; Daly R, 2012, CHEM-EUR J, V18, P14671, DOI 10.1002/chem.201202064; David A, 2010, ISR J CHEM, V50, P204, DOI 10.1002/ijch.201000021; Ernst B, 2009, NAT REV DRUG DISCOV, V8, P661, DOI 10.1038/nrd2852; Fernandes R, 2004, MOL VIS, V10, P618; Fernandes R, 2011, AM J PHYSIOL-CELL PH, V300, pC927, DOI 10.1152/ajpcell.00140.2010; Fujimoto K, 2000, J AM CHEM SOC, V122, P3558, DOI 10.1021/ja993993d; Gary-Bobo M, 2013, CURR MED CHEM, V20, P1946, DOI 10.2174/0929867311320150002; Gillies ER, 2005, DRUG DISCOV TODAY, V10, P35, DOI 10.1016/S1359-6446(04)03276-3; Hirohara S, 2005, J PHOTOCH PHOTOBIO B, V78, P7, DOI 10.1016/j.jphotobiol.2004.09.003; Iqbal Z, 2009, TETRAHEDRON LETT, V50, P873, DOI 10.1016/j.tetlet.2008.12.015; Klajnert B, 2012, CURR MED CHEM, V19, P4903; Laville I, 2006, J MED CHEM, V49, P2558, DOI 10.1021/jm0580151; Lee PPS, 2005, TETRAHEDRON LETT, V46, P1551, DOI 10.1016/j.tetlet.2004.12.137; Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527; LOTAN R, 1988, ANN NY ACAD SCI, V551, P385, DOI 10.1111/j.1749-6632.1988.tb22372.x; Lourenco LMO, 2009, RAPID COMMUN MASS SP, V23, P3478, DOI 10.1002/rcm.4262; Noguchi Y, 2000, CANCER LETT, V154, P175, DOI 10.1016/S0304-3835(00)00392-X; Pandey SK, 2007, MOL PHARMACEUT, V4, P448, DOI 10.1021/mp060135x; Park YK, 2008, B KOREAN CHEM SOC, V29, P130; Pereira PMR, 2014, ORG BIOMOL CHEM, V12, P1804, DOI 10.1039/c3ob42082e; Plaetzer K, 2009, LASER MED SCI, V24, P259, DOI 10.1007/s10103-008-0539-1; Ribeiro AO, 2006, TETRAHEDRON LETT, V47, P9177, DOI 10.1016/j.tetlet.2006.10.155; Saczko J, 2007, FOLIA HISTOCHEM CYTO, V45, P93; Sattler UGA, 2009, INT J RADIAT BIOL, V85, P963, DOI 10.3109/09553000903258889; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; SIES H, 1993, EUR J BIOCHEM, V215, P213, DOI 10.1111/j.1432-1033.1993.tb18025.x; Silva AMG, 2005, SYNLETT, P857, DOI 10.1055/s-2005-863736; Silva JN, 2008, PHOTOCH PHOTOBIO SCI, V7, P834, DOI 10.1039/b800348c; Silva S, 2012, CHEM COMMUN, V48, P3608, DOI 10.1039/c2cc17561d; Singh S, 2010, BIOCONJUGATE CHEM, V21, P2136, DOI 10.1021/bc100356z; Soares ARM, 2012, CHEM RES TOXICOL, V25, P940, DOI 10.1021/tx300035a; Soares ARM, 2009, CARBOHYD RES, V344, P507, DOI 10.1016/j.carres.2008.12.009; Townsend DM, 2003, ONCOGENE, V22, P7369, DOI 10.1038/sj.onc.1206940; Vedachalam S, 2011, MEDCHEMCOMM, V2, P371, DOI 10.1039/c0md00175a; Wang ZJ, 2012, J PHOTOCH PHOTOBIO B, V115, P16, DOI 10.1016/j.jphotobiol.2012.06.005; Weydert CJ, 2010, NAT PROTOC, V5, P51, DOI 10.1038/nprot.2009.197; Wolinsky JB, 2008, ADV DRUG DELIVER REV, V60, P1037, DOI 10.1016/j.addr.2008.02.012; Younes M, 1996, CANCER RES, V56, P1164; Zheng G, 2001, J ORG CHEM, V66, P8709, DOI 10.1021/jo0105080	55	47	47	3	77	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 24	2014	9	4							e95529	10.1371/journal.pone.0095529	http://dx.doi.org/10.1371/journal.pone.0095529			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG6CB	24763311	Green Published, gold, Green Submitted			2023-01-03	WOS:000335505000024
J	Mogasale, V; Desai, SN; Mogasale, VV; Park, JK; Ochiai, RL; Wierzba, TF				Mogasale, Vittal; Desai, Sachin N.; Mogasale, Vijayalaxmi V.; Park, Jin Kyung; Ochiai, R. Leon; Wierzba, Thomas F.			Case Fatality Rate and Length of Hospital Stay among Patients with Typhoid Intestinal Perforation in Developing Countries: A Systematic Literature Review	PLOS ONE			English	Review							ILEAL PERFORATION; SURGICAL EXPERIENCE; PROGNOSTIC-FACTORS; CHILDREN; MANAGEMENT; MORBIDITY; MORTALITY; SCOURGE	Background: Typhoid fever remains a major health problem in the developing world. Intestinal perforation is a lethal complication and continues to occur in impoverished areas despite advances in preventive and therapeutic strategies. Objectives: To estimate the case fatality rate (CFR) and length of hospital stay among patients with typhoid intestinal perforation in developing countries. Data Sources: Peer-reviewed publications listed in PubMed and Google Scholar. Study Eligibility: The publications containing data on CFR or length of hospitalization for typhoid fever from low, lower middle and upper middle income countries based on World Bank classification. Limits are English language, human research and publication date from 1st January 1991 to 31st December 2011. Participants: Subjects with reported typhoid intestinal perforation. Interventions: None, standard practice as reported in the publication. Study Appraisal and Synthesis Methods: Systematic literature review followed by meta-analysis after regional classification on primary data. Descriptive methods were applied on secondary data. Results: From 42 published reports, a total of 4,626 hospitalized typhoid intestinal perforation cases and 706 deaths were recorded (CFR = 15.4%; 95% CI; 13.0%-17.8%) with a significant regional differences. The overall mean length of hospitalization for intestinal perforation from 23 studies was 18.4 days (N = 2,542; 95% CI; 15.6-21.1). Limitations: Most typhoid intestinal perforation studies featured in this review were from a limited number of countries. Conclusions: The CFR estimated in this review is a substantial reduction from the 39.6% reported from a literature review for years 1960 to 1990. Aggressive resuscitation, appropriate antimicrobial coverage, and prompt surgical intervention may have contributed to decrease mortality. Implications: The quantification of intestinal perforation outcomes and its regional disparities as presented here is valuable in prioritizing and targeting typhoid-preventive interventions to the most affected areas.	[Mogasale, Vittal] Int Vaccine Inst, Dev & Delivery Unit, Access Dept, Policy & Econ Res Ctr, Seoul, South Korea; [Desai, Sachin N.] Int Vaccine Inst, Dev & Delivery Unit, Clin Dev & Regulatory Dept, Seoul, South Korea; [Mogasale, Vijayalaxmi V.] Int Vaccine Inst, Dept Epidemiol, Dev & Delivery Unit, Seoul, South Korea; [Park, Jin Kyung] Int Vaccine Inst, Biostat & Data Management Dept, Dev & Delivery Unit, Seoul, South Korea; [Ochiai, R. Leon] Int Vaccine Inst, Seoul, South Korea; [Wierzba, Thomas F.] Int Vaccine Inst, Dev & Delivery Unit, Seoul, South Korea	International Vaccine Institute; International Vaccine Institute; International Vaccine Institute; International Vaccine Institute; International Vaccine Institute; International Vaccine Institute	Mogasale, V (corresponding author), Int Vaccine Inst, Dev & Delivery Unit, Access Dept, Policy & Econ Res Ctr, Seoul, South Korea.	vmogasale@ivi.int	Mogasale, Vittal/HCH-7125-2022; Mogasale, Vittal/C-7853-2011	Mogasale, Vittal/0000-0003-0596-8072; Mogasale, Vijayalaxmi V/0000-0002-9564-8760	Bill and Melinda Gates Foundation	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation)	This work is supported by the Bill and Melinda Gates Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abantanga FA, 2009, ANN AFR MED, V8, P236, DOI 10.4103/1596-3519.59578; Adesunkanmi ARK, 1997, J ROY COLL SURG EDIN, V42, P395; Agbakwuru E A, 2003, West Afr J Med, V22, P22; Ahmed Hafiz Naweed, 2006, JPMA Journal of the Pakistan Medical Association, V56, P230; AKGUN Y, 1995, BRIT J SURG, V82, P1512, DOI 10.1002/bjs.1800821120; Ameh EA, 1999, ANN TROP PAEDIATR, V19, P267, DOI 10.1080/02724939992356; Ansari AG, 2009, GOMAL J MED SCI, V7, P27; Atamanalp SS, 2007, WORLD J SURG, V31, P1883, DOI 10.1007/s00268-007-9141-0; Athie CG, 1998, SURGERY, V123, P632, DOI 10.1067/msy.1998.87453; Aziz Muzaffar, 2005, J Coll Physicians Surg Pak, V15, P704; Beniwal U. S., 2003, Indian Journal of Surgery, V65, P172; BHUTTA ZA, 1991, REV INFECT DIS, V13, P832; Bhutta ZA, 1996, ARCH DIS CHILD, V75, P214, DOI 10.1136/adc.75.3.214; Bhutta ZA, 2006, BMJ-BRIT MED J, V333, P78, DOI 10.1136/bmj.333.7558.78; Chanh NQ, 2004, CLIN INFECT DIS, V39, P61, DOI 10.1086/421555; Chatterjee H, 2001, Trop Gastroenterol, V22, P155; Clegg-Lamptey JNA, 2007, TROP DOCT, V37, P231, DOI 10.1258/004947507782332784; Crump JA, 2004, B WORLD HEALTH ORGAN, V82, P346; Edino S T, 2004, Niger J Med, V13, P345; Edino ST, 2007, J NATL MED ASSOC, V99, P1042; Ekenze SO, 2008, NIGER J CLIN PRACT, V11, P58; Glass GV, 1976, EDUC RESEARCHER, V5, P3, DOI [10.2307/1174772ISSN0536-1036, DOI 10.3102/0013189X005010003, 10.2307/1174772]; GUPTA V, 1994, POSTGRAD MED J, V70, P19, DOI 10.1136/pgmj.70.819.19; Hulley SB, 2007, DESIGNING CLIN RES; Irabor D. O., 2003, Nigerian Journal of Surgical Research, V5, P92; Karmacharya B, 2006, Kathmandu Univ Med J (KUMJ), V4, P22; Khan A, 2000, J SURG PAKISTAN, V5, P37; Khan TM, 1997, JPMI, V11, P175; Kouame J, 2004, ACTA CHIR BELG, V104, P445, DOI 10.1080/00015458.2004.11679590; KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441; Malik MA, 2006, WORLD J MED SCI, V1, P112; Meier DE, 1998, WORLD J SURG, V22, P319, DOI 10.1007/s002689900388; Mirza SH, 1996, J MED MICROBIOL, V44, P317, DOI 10.1099/00222615-44-5-317; MOCK CN, 1992, ANN SURG, V215, P244, DOI 10.1097/00000658-199203000-00008; Na'aya HU, 2004, ANN AF MED, V3, P69; Nasir AA, 2011, PEDIAT SURG INT; Ndububa D A, 1992, Trop Gastroenterol, V13, P56; Nuhu Ali, 2010, Afr J Paediatr Surg, V7, P9, DOI 10.4103/0189-6725.59351; Oheneh-Yeboah M, 2007, West Afr J Med, V26, P32; Onen A, 2002, PEDIATR SURG INT, V18, P696, DOI 10.1007/s00383-002-0794-3; Osifo Osarumwense David, 2010, Afr J Paediatr Surg, V7, P96, DOI 10.4103/0189-6725.62857; Osime O. C., 2007, Journal of Medicine and Biomedical Research, V6, P13; Otegbayo J A, 2002, Trop Gastroenterol, V23, P9; Parry CM, 2002, NEW ENGL J MED, V347, P1770, DOI 10.1056/NEJMra020201; Rahman GA, 2001, PEDIATR SURG INT, V17, P628, DOI 10.1007/s003830100008; RICHENS J, 1991, TROP DOCT, V21, P149, DOI 10.1177/004947559102100405; Saxe JM, 2005, AM J SURG, V189, P342, DOI 10.1016/j.amjsurg.2004.11.032; Shukla VK, 2004, DIGEST DIS SCI, V49, P161, DOI 10.1023/B:DDAS.0000011620.56077.97; Singh K P, 1991, J Indian Med Assoc, V89, P255; Spearman C, 1904, AM J PSYCHOL, V15, P72, DOI 10.2307/1412159; Sterne JAC, 2004, STATA J, V4, P127, DOI 10.1177/1536867X0400400204; Sumer A, 2010, WORLD J GASTROENTERO, V16, P4164, DOI 10.3748/wjg.v16.i33.4164; Sutton AJAK, 2000, METHODS METAANALYSIS; Tade A O, 2008, Niger J Med, V17, P387; Talwar S, 1997, Trop Gastroenterol, V18, P78; Talwar S, 1997, AUST NZ J SURG, V67, P351, DOI 10.1111/j.1445-2197.1997.tb01990.x; Uba AF, 2007, PEDIATR SURG INT, V23, P33, DOI 10.1007/s00383-006-1796-3; Ugwu B T, 2005, West Afr J Med, V24, P1; Ukwenya AY, 2011, ANN AFR MED, V10, P259, DOI 10.4103/1596-3519.87040; VANBASTEN JP, 1994, TROP GEOGR MED, V46, P336; Worku B., 2000, Ethiopian Journal of Health Development, V14, P311; World Health Organization, 2003, BACKGR DOC DIAGN TRE; WorldBank, 2011, COUNTR LEND GROUPS I	63	36	38	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2014	9	4							e93784	10.1371/journal.pone.0093784	http://dx.doi.org/10.1371/journal.pone.0093784			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG3IK	24743649	Green Submitted, Green Published, gold			2023-01-03	WOS:000335309100019
J	Oladimeji, O; Isaakidis, P; Obasanya, OJ; Eltayeb, O; Khogali, M; Van den Bergh, R; Kumar, AMV; Hinderaker, SG; Abdurrahman, ST; Lawson, L; Cuevas, LE				Oladimeji, Olanrewaju; Isaakidis, Petros; Obasanya, Olusegun J.; Eltayeb, Osman; Khogali, Mohammed; Van den Bergh, Rafael; Kumar, Ajay M. V.; Hinderaker, Sven Gudmund; Abdurrahman, Saddiq T.; Lawson, Lovett; Cuevas, Luis E.			Intensive-Phase Treatment Outcomes among Hospitalized Multidrug-Resistant Tuberculosis Patients: Results from a Nationwide Cohort in Nigeria	PLOS ONE			English	Article							COMMUNITY-BASED TREATMENT; SOUTH-AFRICA; METAANALYSIS; CULTURE; THERAPY; LIMA; PERU	Background: Nigeria is faced with a high burden of Human Immunodeficiency Virus (HIV) infection and multidrug-resistant tuberculosis (MDR-TB). Treatment outcomes among MDR-TB patients registered across the globe have been poor, partly due to high loss-to-follow-up. To address this challenge, MDR-TB patients in Nigeria are hospitalized during the intensive-phase(IP) of treatment (first 6-8 months) and are provided with a package of care including standardized MDR-TB treatment regimen, antiretroviral therapy (ART) and cotrimoxazole prophylaxis (CPT) for HIV-infected patients, nutritional and psychosocial support. In this study, we report the end-IP treatment outcomes among them. Methods: In this retrospective cohort study, we reviewed the patient records of all bacteriologically-confirmed MDR-TB patients admitted for treatment between July 2010 and October 2012. Results: Of 162 patients, 105(65%) were male, median age was 34 years and 28(17%) were HIV-infected; all 28 received ART and CPT. Overall, 138(85%) were alive and culture negative at the end of IP, 24(15%) died and there was no loss-to-follow-up. Mortality was related to low CD4-counts at baseline among HIV-positive patients. The median increase in body mass index among those documented to be underweight was 2.6 kg/m(2) (p<0.01) and CD4-counts improved by a median of 52 cells/microL among the HIV-infected patients (p<0.01). Conclusions: End-IP treatment outcomes were exceptional compared to previously published data from international cohorts, thus confirming the usefulness of a hospitalized model of care. However, less than five percent of all estimated 3600 MDR-TB patients in Nigeria were initiated on treatment during the study period. Given the expected scale-up of MDR-TB care, the hospitalized model is challenging to sustain and the national TB programme is contemplating to move to ambulatory care. Hence, we recommend using both ambulatory and hospitalized approaches, with the latter being reserved for selected high-risk groups.	[Oladimeji, Olanrewaju; Lawson, Lovett] Zankli Med Ctr, Abuja, Nigeria; [Oladimeji, Olanrewaju; Cuevas, Luis E.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; [Isaakidis, Petros; Khogali, Mohammed; Van den Bergh, Rafael] MSF, Operat Res Unit, Luxembourg, Luxembourg; [Obasanya, Olusegun J.] Fed Minist Hlth, Natl TB & Leprosy Control Unit, Abuja, Nigeria; [Eltayeb, Osman] Damien Fdn Belgium, Nigeria Project, Ibadan, Nigeria; [Kumar, Ajay M. V.] Int Union TB & Lung Dis Union, South East Asia Reg Off, New Delhi, India; [Hinderaker, Sven Gudmund] Univ Bergen, Ctr Int Hlth, Bergen, Norway; [Abdurrahman, Saddiq T.] Fed Capital Terr, TB & Leprosy Control Program, Abuja, Nigeria	Liverpool School of Tropical Medicine; University of Liverpool; Doctors Without Borders; University of Bergen	Oladimeji, O (corresponding author), Zankli Med Ctr, Abuja, Nigeria.	droladfb@gmail.com	Oladimeji, Olanrewaju/AAE-9633-2019; Cuevas, Luis E/I-3697-2015	Oladimeji, Olanrewaju/0000-0002-5356-901X; Cuevas, Luis E/0000-0002-6581-0587; Lawson, Lovett/0000-0001-9019-7537; Isaakidis, Petros/0000-0002-7881-1554; Madhugiri Venkatachalaiah, Ajay Kumar/0000-0003-1011-8531; Van den Bergh, Rafael/0000-0001-6277-8713	Medecins Sans Frontieres Luxembourg, Brussels Operational Centre, Luxembourg; Bloomberg Philanthropies; Department for International Development (DFID), UK; European and Developing Countries Clinical Trial Partnership (EDCTP)	Medecins Sans Frontieres Luxembourg, Brussels Operational Centre, Luxembourg; Bloomberg Philanthropies; Department for International Development (DFID), UK; European and Developing Countries Clinical Trial Partnership (EDCTP)	Funding for the course was provided by Medecins Sans Frontieres Luxembourg, Brussels Operational Centre, Luxembourg, the Bloomberg Philanthropies, and the Department for International Development (DFID), UK. Dr Olanrewaju Oladimeji is a research fellow based in Abuja Nigeria, jointly appointed by Zankli Medical Services, Nigeria and the Liverpool School of Tropical Medicine, United Kingdom and funded by a Strategic Award grant from the European and Developing Countries Clinical Trial Partnership (EDCTP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahuja SD, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001300; Andrews JR, 2007, J INFECT DIS, V196, pS482, DOI 10.1086/521121; [Anonymous], 2009, MAN MDR TB FIELD GUI; Brust J, 2010, PLOS ONE, V6; Chadha SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026659; Federal Ministry of Health Nigeria Department of Public Health, 2010, NAT TUB LEPR CONTR P, V5th; Federal Ministry of Health Nigeria (FMOH), 2012, NATL DRUG RES TB PRE; Hafkin J, 2013, INT J TUBERC LUNG D, V17, P348, DOI 10.5588/ijtld.12.0100; Harries AD, 2004, INT J TUBERC LUNG D, V8, P204; Heller T, 2010, INT J TUBERC LUNG D, V14, P420; Isaakidis P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068869; Isaakidis P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028066; James C, 2011, CULTURE CONVERSION H; Jenkins HE, 2013, INT J TUBERC LUNG D, V17, P373, DOI 10.5588/ijtld.12.0464; Johnston JC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006914; Khann S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059903; Kilale AM, 2013, PUBLIC HEALTH ACTION, V3, P156, DOI 10.5588/pha.12.0103; Mitnick C, 2003, NEW ENGL J MED, V348, P119, DOI 10.1056/NEJMoa022928; Orenstein EW, 2009, LANCET INFECT DIS, V9, P153, DOI 10.1016/S1473-3099(09)70041-6; Qi W, 2011, INT J TUBERC LUNG D, V15, P137; Raguenaud ME, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-54; Shin S, 2004, SOC SCI MED, V59, P1529, DOI 10.1016/j.socscimed.2004.01.027; Tupasi TE, 2006, PLOS MED, V3, P1587, DOI 10.1371/journal.pmed.0030352; World Health Organization, 2011, GUID PROGR MAN DRUG; World Health Organization, 2012, MULT EXT DRUG RES TB; World Health Organization (WHO), 2013, MULT EXT DRUG RES	26	24	24	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 10	2014	9	4							e94393	10.1371/journal.pone.0094393	http://dx.doi.org/10.1371/journal.pone.0094393			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI5LS	24722139	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000336909100065
J	Maconochie, IK; Bingham, R				Maconochie, Ian K.; Bingham, Robert			ABC of Resuscitation, 6th Edition Paediatric Resuscitation	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							LIFE-SUPPORT		[Maconochie, Ian K.] St Marys Hosp London, London, England; Great Ormond St Childrens Hosp London, London, England	Imperial College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Maconochie, IK (corresponding author), St Marys Hosp London, London, England.			Maconochie, Ian/0000-0001-6319-8550				Biarent D, 2010, RESUSCITATION, V81, P1364, DOI 10.1016/j.resuscitation.2010.08.012; de Caen AR, 2010, RESUSCITATION, V81, pE213, DOI 10.1016/j.resuscitation.2010.08.028	2	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 8	2014	348								g1732					12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AE9SD	24714205				2023-01-03	WOS:000334348500011
J	Yatkin, E; Polari, L; Laajala, TD; Smeds, A; Eckerman, C; Holmbom, B; Saarinen, NM; Aittokallio, T; Makela, SI				Yatkin, Emrah; Polari, Lauri; Laajala, Teemu D.; Smeds, Annika; Eckerman, Christer; Holmbom, Bjarne; Saarinen, Niina M.; Aittokallio, Tero; Makela, Sari I.			Novel Lignan and Stilbenoid Mixture Shows Anticarcinogenic Efficacy in Preclinical PC-3M-luc2 Prostate Cancer Model	PLOS ONE			English	Article							CELLS IN-VITRO; RESVERATROL; APOPTOSIS; GROWTH; TRAIL; CHEMOPREVENTION; MECHANISMS; PLANT; ADENOCARCINOMA; PROLIFERATION	Prostate cancer is the most common cancer of men in the Western world, and novel approaches for prostate cancer risk reduction are needed. Plant-derived phenolic compounds attenuate prostate cancer growth in preclinical models by several mechanisms, which is in line with epidemiological findings suggesting that consumption of plant-based diets is associated with low risk of prostate cancer. The objective of this study was to assess the effects of a novel lignan-stilbenoid mixture in PC-3M-luc2 human prostate cancer cells in vitro and in orthotopic xenografts. Lignan and stilbenoid -rich extract was obtained from Scots pine (Pinus sylvestris) knots. Pine knot extract as well as stilbenoids (methyl pinosylvin and pinosylvin), and lignans (matairesinol and nortrachelogenin) present in pine knot extract showed antiproliferative and proapoptotic efficacy at >= 40 mu M concentration in vitro. Furthermore, pine knot extract derived stilbenoids enhanced tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induced apoptosis already at >= 10 mu M concentrations. In orthotopic PC-3M-luc2 xenograft bearing immunocompromized mice, three-week peroral exposure to pine knot extract (52 mg of lignans and stilbenoids per kg of body weight) was well tolerated and showed anti-tumorigenic efficacy, demonstrated by multivariate analysis combining essential markers of tumor growth (i.e. tumor volume, vascularization, and cell proliferation). Methyl pinosylvin, pinosylvin, matairesinol, nortrachelogenin, as well as resveratrol, a metabolite of pinosylvin, were detected in serum at total concentration of 7-73 mu M, confirming the bioavailability of pine knot extract derived lignans and stilbenoids. In summary, our data indicates that pine knot extract is a novel and cost-effective source of resveratrol, methyl pinosylvin and other bioactive lignans and stilbenoids. Pine knot extract shows anticarcinogenic efficacy in preclinical prostate cancer model, and our in vitro data suggests that compounds derived from the extract may have potential as novel chemosensitizers to TRAIL. These findings promote further research on health-related applications of wood biochemicals.	[Yatkin, Emrah; Polari, Lauri; Saarinen, Niina M.; Makela, Sari I.] Univ Turku, Turku, Finland; [Yatkin, Emrah; Polari, Lauri; Saarinen, Niina M.; Makela, Sari I.] Univ Turku, Inst Biomed, TCDM, Turku, Finland; [Laajala, Teemu D.; Aittokallio, Tero] Univ Turku, Dept Math & Stat, Turku, Finland; [Smeds, Annika; Eckerman, Christer; Holmbom, Bjarne] Abo Akad Univ, Proc Chem Ctr, Lab Wood & Paper Chem, Turku, Finland; [Aittokallio, Tero] Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland	University of Turku; University of Turku; University of Turku; Abo Akademi University; University of Helsinki	Makela, SI (corresponding author), Univ Turku, Turku, Finland.	sarmak@utu.fi	Aittokallio, Tero/B-6583-2009	Aittokallio, Tero/0000-0002-0886-9769; Laajala, Teemu Daniel/0000-0002-7016-7354; Saarinen, Niina/0000-0003-3531-378X; Yatkin, Emrah/0000-0002-2597-6638; Makela, Sari/0000-0002-8698-4076; Polari, Lauri/0000-0002-0052-6489	FIBIC Finnish Bioeconomy Cluster; BioRefine program of Finnish Funding Agency for Technology and Innovation; Academy of Finland	FIBIC Finnish Bioeconomy Cluster; BioRefine program of Finnish Funding Agency for Technology and Innovation; Academy of Finland(Academy of Finland)	This project was supported by the FIBIC Finnish Bioeconomy Cluster, the BioRefine program of Finnish Funding Agency for Technology and Innovation, and Academy of Finland. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adlercreutz H, 2007, CRIT REV CL LAB SCI, V44, P483, DOI 10.1080/10408360701612942; Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060; Bylund A, 2005, EXP BIOL MED, V230, P217; Bylund A, 2000, PROSTATE, V42, P304, DOI 10.1002/(SICI)1097-0045(20000301)42:4<304::AID-PROS8>3.0.CO;2-Z; De Maesschalck R, 2000, CHEMOMETR INTELL LAB, V50, P1, DOI 10.1016/S0169-7439(99)00047-7; Deeb DD, 2005, J EXP THER ONCOL, V5, P81; Fulda S, 2004, CANCER RES, V64, P337, DOI 10.1158/0008-5472.CAN-03-1656; Ganapathy S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015627; Gonzalvez F, 2010, ONCOGENE, V29, P4752, DOI 10.1038/onc.2010.221; Harper CE, 2007, CARCINOGENESIS, V28, P1946, DOI 10.1093/carcin/bgm144; Holmbom Bjarne, 2003, Phytochemistry Reviews, V2, P331, DOI 10.1023/B:PHYT.0000045493.95074.a8; Horvath Z, 2007, ANTICANCER RES, V27, P3459; Hutz JE, 2013, J BIOMOL SCREEN, V18, P367, DOI 10.1177/1087057112469257; Karna P, 2011, CARCINOGENESIS, V32, P1872, DOI 10.1093/carcin/bgr215; Kwon GT, 2012, J NUTR BIOCHEM, V23, P228, DOI 10.1016/j.jnutbio.2010.11.019; Laajala TD, 2012, CLIN CANCER RES, V18, P4385, DOI 10.1158/1078-0432.CCR-11-3215; Landstrom M, 1998, PROSTATE, V36, P151, DOI 10.1002/(SICI)1097-0045(19980801)36:3&lt;151::AID-PROS2&gt;3.0.CO;2-K; Li GL, 2012, SCI WORLD J, DOI 10.1100/2012/874053; Lieberman R, 2001, UROLOGY, V58, P835, DOI 10.1016/S0090-4295(01)01416-9; Lin X, 2001, ANTICANCER RES, V21, P3995; Lin X, 2002, UROLOGY, V60, P919, DOI 10.1016/S0090-4295(02)01863-0; Mahalanobis P., 1936, P NATL I SCI INDIA, P49; McCann MJ, 2008, MOL NUTR FOOD RES, V52, P567, DOI 10.1002/mnfr.200700052; Park EJ, 2013, FOOD CHEM TOXICOL, V55, P424, DOI 10.1016/j.fct.2013.01.007; Peuhu E, 2010, ONCOGENE, V29, P898, DOI 10.1038/onc.2009.386; Peuhu E, 2013, BIOCHEM PHARMACOL, V86, P571, DOI 10.1016/j.bcp.2013.05.026; Roupe K, 2005, J PHARMACEUT BIOMED, V38, P148, DOI 10.1016/j.jpba.2004.12.015; Scalbert A, 2000, J NUTR, V130, p2073S, DOI 10.1093/jn/130.8.2073S; Scott E, 2012, MOL NUTR FOOD RES, V56, P7, DOI 10.1002/mnfr.201100400; Shankar S, 2007, MOL CELL BIOCHEM, V304, P273, DOI 10.1007/s11010-007-9510-x; Smeds AI, 2005, J CHROMATOGR B, V816, P87, DOI 10.1016/j.jchromb.2004.11.017; Smeds AI, 2004, J CHROMATOGR B, V813, P303, DOI 10.1016/j.jchromb.2004.10.033; Smeds AI, 2007, J AGR FOOD CHEM, V55, P1337, DOI 10.1021/jf0629134; Smeds AI, 2006, J PHARMACEUT BIOMED, V41, P898, DOI 10.1016/j.jpba.2005.12.036; Smeds AI, 2012, HOLZFORSCHUNG, V66, P283, DOI [10.1515/HF.2011.151, 10.1515/hf.2011.151]; Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189; Szliszka E, 2011, INT J ONCOL, V39, P771, DOI 10.3892/ijo.2011.1116; Trottier G, 2010, NAT REV UROL, V7, P21, DOI 10.1038/nrurol.2009.234; Vang O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019881; Venkateswaran V, 2010, NAT REV UROL, V7, P442, DOI 10.1038/nrurol.2010.102; Wang TTY, 2008, CARCINOGENESIS, V29, P2001, DOI 10.1093/carcin/bgn131; Wang TTY, 2010, MOL NUTR FOOD RES, V54, P335, DOI 10.1002/mnfr.200900143; Wiezorek J, 2010, CLIN CANCER RES, V16, P1701, DOI 10.1158/1078-0432.CCR-09-1692; Willfor S, 2003, HOLZFORSCHUNG, V57, P359, DOI 10.1515/HF.2003.054; Xu Q, 2012, NUTR RES, V32, P648, DOI 10.1016/j.nutres.2012.07.002	45	22	25	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 3	2014	9	4							e93764	10.1371/journal.pone.0093764	http://dx.doi.org/10.1371/journal.pone.0093764			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE6LR	24699425	Green Published, gold, Green Submitted			2023-01-03	WOS:000334105000103
J	Fischer, NO; Weilhammer, DR; Dunkle, A; Thomas, C; Hwang, M; Corzett, M; Lychak, C; Mayer, W; Urbin, S; Collette, N; Chang, JC; Loots, GG; Rasley, A; Blanchette, CD				Fischer, Nicholas O.; Weilhammer, Dina R.; Dunkle, Alexis; Thomas, Cynthia; Hwang, Mona; Corzett, Michele; Lychak, Cheri; Mayer, Wasima; Urbin, Salustra; Collette, Nicole; Chang, Jiun Chiun; Loots, Gabriela G.; Rasley, Amy; Blanchette, Craig D.			Evaluation of Nanolipoprotein Particles (NLPs) as an In Vivo Delivery Platform	PLOS ONE			English	Article							HIGH-DENSITY-LIPOPROTEINS; GOLD NANOPARTICLES; DRUG-DELIVERY; FUNCTIONALIZED NANOPARTICLES; CHOLESTEROL EFFLUX; MEMBRANE-PROTEINS; TARGETED DELIVERY; AMPHOTERICIN-B; TOXICITY; APOLIPOPROTEIN	Nanoparticles hold great promise for the delivery of therapeutics, yet limitations remain with regards to the use of these nanosystems for efficient long-lasting targeted delivery of therapeutics, including imparting functionality to the platform, in vivo stability, drug entrapment efficiency and toxicity. To begin to address these limitations, we evaluated the functionality, stability, cytotoxicity, toxicity, immunogenicity and in vivo biodistribution of nanolipoprotein particles (NLPs), which are mimetics of naturally occurring high-density lipoproteins (HDLs). We found that a wide range of molecules could be reliably conjugated to the NLP, including proteins, single-stranded DNA, and small molecules. The NLP was also found to be relatively stable in complex biological fluids and displayed no cytotoxicity in vitro at doses as high as 320 mu g/ml. In addition, we observed that in vivo administration of the NLP daily for 14 consecutive days did not induce significant weight loss or result in lesions on excised organs. Furthermore, the NLPs did not display overt immunogenicity with respect to antibody generation. Finally, the biodistribution of the NLP in vivo was found to be highly dependent on the route of administration, where intranasal administration resulted in prolonged retention in the lung tissue. Although only a select number of NLP compositions were evaluated, the findings of this study suggest that the NLP platform holds promise for use as both a targeted and non-targeted in vivo delivery vehicle for a range of therapeutics.	[Fischer, Nicholas O.; Weilhammer, Dina R.; Dunkle, Alexis; Thomas, Cynthia; Hwang, Mona; Corzett, Michele; Lychak, Cheri; Mayer, Wasima; Urbin, Salustra; Collette, Nicole; Loots, Gabriela G.; Rasley, Amy; Blanchette, Craig D.] Lawrence Livermore Natl Lab, Biosci & Biotechnol Div, Livermore, CA 94550 USA; [Chang, Jiun Chiun; Loots, Gabriela G.] Univ Calif Merced, Sch Nat Sci, Merced, CA USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; University of California Merced	Rasley, A (corresponding author), Lawrence Livermore Natl Lab, Biosci & Biotechnol Div, Livermore, CA 94550 USA.	rasley2@llnl.gov; blanchette2@llnl.gov	Loots, Gabriela G/AGA-4868-2022; Fischer, Nicholas/AAE-2409-2019	Loots, Gabriela G/0000-0001-9546-5561; Fischer, Nicholas/0000-0001-7575-4390; Weilhammer, Dina/0000-0002-7618-4702; Rasley, Amy/0000-0002-4767-6628; Collette, Nicole/0000-0002-9068-8712	LLNL LDRD [09-LW-077, 11-LW-015, 11-ERD-016]	LLNL LDRD	LLNL LDRD 09-LW-077; LLNL LDRD 11-LW-015; LLNL LDRD 11-ERD-016. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ackermann L, 2008, ORG LETT, V10, P3081, DOI 10.1021/ol801078r; Azarmi S, 2008, ADV DRUG DELIVER REV, V60, P863, DOI 10.1016/j.addr.2007.11.006; Baylon JL, 2013, J AM CHEM SOC, V135, P8542, DOI 10.1021/ja4003525; Bhatt RL, 2003, J MED CHEM, V46, P190, DOI 10.1021/jm020022r; Bhattacharya P, 2010, J VIROL, V84, P361, DOI 10.1128/JVI.01355-09; Blanchette CD, 2008, J LIPID RES, V49, P1420, DOI 10.1194/jlr.M700586-JLR200; Blanchette CD, 2010, BIOCONJUGATE CHEM, V21, P1321, DOI 10.1021/bc100129s; Blanchette CD, 2009, BBA-BIOMEMBRANES, V1788, P724, DOI 10.1016/j.bbamem.2008.11.019; Cappuccio JA, 2008, MOL CELL PROTEOMICS, V7, P2246, DOI 10.1074/mcp.M800191-MCP200; Cappuccio Jenny A., 2009, V498, P273, DOI 10.1007/978-1-59745-196-3_18; CHAPMAN MJ, 1980, J LIPID RES, V21, P789; Chen HT, 2004, J AM CHEM SOC, V126, P10044, DOI 10.1021/ja048548j; Cho KJ, 2008, CLIN CANCER RES, V14, P1310, DOI 10.1158/1078-0432.CCR-07-1441; Chromy BA, 2007, J AM CHEM SOC, V129, P14348, DOI 10.1021/ja074753y; Corbierre MK, 2004, LANGMUIR, V20, P2867, DOI 10.1021/la0355702; Courrier HM, 2002, CRIT REV THER DRUG, V19, P425, DOI 10.1615/CritRevTherDrugCarrierSyst.v19.i45.40; Cuenca AG, 2006, CANCER-AM CANCER SOC, V107, P459, DOI 10.1002/cncr.22035; Ding Y, 2012, BIOMATERIALS, V33, P8893, DOI 10.1016/j.biomaterials.2012.08.057; Fischer NO, 2013, J AM CHEM SOC, V135, P2044, DOI 10.1021/ja3063293; Fischer NO, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011643; Fischer NO, 2010, BIOCONJUGATE CHEM, V21, P1018, DOI 10.1021/bc100083d; Fischer NO, 2009, BIOCONJUGATE CHEM, V20, P460, DOI 10.1021/bc8003155; Fotakis G, 2006, TOXICOL LETT, V160, P171, DOI 10.1016/j.toxlet.2005.07.001; Frias JC, 2006, NANO LETT, V6, P2220, DOI 10.1021/nl061498r; Gaidukov Leonid, 2009, BMC Clin Pharmacol, V9, P18, DOI 10.1186/1472-6904-9-18; Gao TJ, 2011, PROTEIN SCI, V20, P437, DOI 10.1002/pro.577; Goodman CM, 2004, BIOCONJUGATE CHEM, V15, P897, DOI 10.1021/bc049951i; GREF R, 1994, SCIENCE, V263, P1600, DOI 10.1126/science.8128245; Hoang A, 2012, EUR HEART J, V33, P657, DOI 10.1093/eurheartj/ehr103; Irngartinger M, 2004, EUR J PHARM BIOPHARM, V58, P7, DOI 10.1016/j.ejpb.2004.03.016; Jia H, 2009, NANOMEDICINE-UK, V4, P951, DOI [10.2217/nnm.09.81, 10.2217/NNM.09.81]; Justesen BH, 2013, ANAL CHEM, V85, P3497, DOI 10.1021/ac4000915; Karver MR, 2012, ANGEW CHEM INT EDIT, V51, P920, DOI 10.1002/anie.201104389; Kim TY, 2004, CLIN CANCER RES, V10, P3708, DOI 10.1158/1078-0432.CCR-03-0655; Lattuada M, 2007, LANGMUIR, V23, P2158, DOI 10.1021/la062092x; Lynch I, 2007, ADV COLLOID INTERFAC, V134-35, P167, DOI 10.1016/j.cis.2007.04.021; Ma CIJ, 2012, BIOCHEM CELL BIOL, V90, P636, DOI [10.1139/O2012-015, 10.1139/o2012-015]; Malik N, 1999, ANTI-CANCER DRUG, V10, P767, DOI 10.1097/00001813-199909000-00010; Manchester M, 2006, ADV DRUG DELIVER REV, V58, P1505, DOI 10.1016/j.addr.2006.09.014; Mareeva T, 2010, J IMMUNOL METHODS, V353, P78, DOI 10.1016/j.jim.2009.11.010; Markman M, 2006, EXPERT OPIN PHARMACO, V7, P1469, DOI 10.1517/14656566.7.11.1469; Miyazaki M, 2013, BBA-BIOMEMBRANES, V1828, P1340, DOI 10.1016/j.bbamem.2013.01.012; Murphy CJ, 2008, ACCOUNTS CHEM RES, V41, P1721, DOI 10.1021/ar800035u; NESTLER JE, 1985, ENDOCRINOLOGY, V117, P502, DOI 10.1210/endo-117-2-502; Nguyen CA, 2003, INT J PHARMACEUT, V254, P69, DOI 10.1016/S0378-5173(02)00685-3; NIVEN RW, 1995, CRIT REV THER DRUG, V12, P151, DOI 10.1615/CritRevTherDrugCarrierSyst.v12.i2-3.20; Ochsenbein AF, 2000, IMMUNOL TODAY, V21, P624, DOI 10.1016/S0167-5699(00)01754-0; Rensen PCN, 2001, ADV DRUG DELIVER REV, V47, P251, DOI 10.1016/S0169-409X(01)00109-0; Rollett A, 2012, INT J PHARMACEUT, V427, P460, DOI 10.1016/j.ijpharm.2012.02.028; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; Salvati A, 2013, NAT NANOTECHNOL, V8, P137, DOI [10.1038/nnano.2012.237, 10.1038/NNANO.2012.237]; Simon M, 2012, BIOCONJUGATE CHEM, V23, P279, DOI 10.1021/bc200591x; Toledo JD, 2012, J CELL BIOCHEM, V113, P1208, DOI 10.1002/jcb.23453; Trang P, 2008, Oncogene, V27 Suppl 2, pS52, DOI 10.1038/onc.2009.353; Tufteland M, 2008, J PHARM SCI-US, V97, P4425, DOI 10.1002/jps.21325; Wadsater M, 2012, J BIOL CHEM, V287, P34596, DOI 10.1074/jbc.M112.400085; Weilhammer DR, 2013, BIOMATERIALS, V34, P10305, DOI 10.1016/j.biomaterials.2013.09.038; Wu W, 2005, ANGEW CHEM INT EDIT, V44, P6358, DOI 10.1002/anie.200501613; Yuan Y, 2013, J DRUG TARGET, V21, P367, DOI 10.3109/1061186X.2012.757769; Zhang P, 2012, J AM CHEM SOC; Ziv O, 2008, J BIOMED MATER RES A, V85A, P1011, DOI 10.1002/jbm.a.31518	61	39	43	1	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 27	2014	9	3							e93342	10.1371/journal.pone.0093342	http://dx.doi.org/10.1371/journal.pone.0093342			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE0SW	24675794	Green Submitted, gold, Green Published			2023-01-03	WOS:000333677500110
J	Brown, JR; Sox, HC; Goodman, DC				Brown, Jeremiah R.; Sox, Harold C.; Goodman, David C.			Financial Incentives to Improve Quality Skating to the Puck or Avoiding the Penalty Box?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CARE		[Brown, Jeremiah R.; Sox, Harold C.; Goodman, David C.] Geisel Sch Med Dartmouth, Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH USA	Dartmouth College	Brown, JR (corresponding author), Dartmouth Hitchcock Med Ctr, Dartmouth Inst Hlth Policy & Clin Practice, Geisel Sch Med Dartmouth, One Med Ctr Dr,HB 7505, Lebanon, NH 03756 USA.	jbrown@dartmouth.edu	Goodman, David/AAG-7497-2020		AHRQ HHS [K01 HS018443] Funding Source: Medline; NHLBI NIH HHS [R01 HL119664] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brock J, 2013, JAMA-J AM MED ASSOC, V309, P381, DOI 10.1001/jama.2012.216607; Calikoglu S, 2012, HEALTH AFFAIR, V31, P2649, DOI 10.1377/hlthaff.2012.0357; Lyu H, 2013, JAMA SURG, V148, P362, DOI 10.1001/2013.jamasurg.270; The Medicare Payment Advisory Commission, C MED HLTH CAR DEL S	4	20	20	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 12	2014	311	10					1009	1010		10.1001/jama.2014.421	http://dx.doi.org/10.1001/jama.2014.421			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AC5QO	24618957	Green Accepted			2023-01-03	WOS:000332575800013
J	Gil-Humanes, J; Piston, F; Altamirano-Fortoul, R; Real, A; Comino, I; Sousa, C; Rosell, CM; Barro, F				Gil-Humanes, Javier; Piston, Fernando; Altamirano-Fortoul, Rossana; Real, Ana; Comino, Isabel; Sousa, Carolina; Rosell, Cristina M.; Barro, Francisco			Reduced-Gliadin Wheat Bread: An Alternative to the Gluten-Free Diet for Consumers Suffering Gluten-Related Pathologies	PLOS ONE			English	Article							CELIAC-DISEASE; OPAQUE-2 CORN; NUTRITIONAL-VALUE; ALPHA-GLIADIN; EPITOPES; MALIGNANCY; MODEL; INTEGRATION; PREVALENCE; EXPRESSION	Wheat flour cannot be tolerated by those who suffer allergies to gluten. Human pathologies associated with grain proteins have increased worldwide in recent years, and the only effective treatment available is a lifelong gluten-free diet, which is complicated to follow and detrimental to gut health. This manuscript describes the development of wheat bread potentially suitable for celiac patients and other gluten-intolerant individuals. We have made bread using wheat flour with very low content of the specific gluten proteins (near gliadin-free) that are the causal agents for pathologies such as celiac disease. Loaves were compared with normal wheat breads and rice bread. Organoleptic, nutritional, and immunotoxic properties were studied. The reduced-gliadin breads showed baking and sensory properties, and overall acceptance, similar to those of normal flour, but with up to 97% lower gliadin content. Moreover, the low-gliadin flour has improved nutritional properties since its lysine content is significantly higher than that of normal flour. Conservative estimates indicate that celiac patients could safely consume 67 grams of bread per day that is made with low-gliadin flour. However, additional studies, such as feeding trials with gluten-intolerant patients, are still needed in order to determine whether or not the product can be consumed by the general celiac population, as well as the actual tolerated amount that can be safely ingested. The results presented here offer a major opportunity to improve the quality of life for millions of sufferers of gluten intolerance throughout the world.	[Gil-Humanes, Javier; Piston, Fernando; Barro, Francisco] CSIC, Inst Agr Sostenible, Cordoba, Spain; [Altamirano-Fortoul, Rossana; Rosell, Cristina M.] CSIC, Inst Agroquim & Tecnol Alimentos, E-46010 Valencia, Spain; [Real, Ana; Comino, Isabel; Sousa, Carolina] Univ Seville, Fac Farm, Dept Microbiol & Parasitol, Seville, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Agricultura Sostenible (IAS); Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Agroquimica y Tecnologia de los Alimentos (IATA); University of Sevilla	Gil-Humanes, J (corresponding author), CSIC, Inst Agr Sostenible, Cordoba, Spain.	javigil@ias.csic.es; fbarro@ias.csic.es	Barro, Francisco/J-3254-2014; Barro, Francisco/E-8572-2017; Gil-Humanes, Javier/AAU-4381-2020; Piston, Fernando/AAD-6975-2020; Rosell, Cristina M/F-4888-2010	Barro, Francisco/0000-0002-7652-229X; Rosell, Cristina M/0000-0001-7197-5874; Altamirano-Fortoul, Rossana/0000-0002-5323-8931; Sousa Martin, Carolina/0000-0002-9235-9496; Gil Humanes, Javier/0000-0002-7283-6945	Spanish Ministry of Economy and Competitiveness [AGL2010-19643-C02-02]; European Regional Development Fund (FEDER); Junta de Andalucia [P09AGR-4783]; Generalitat Valenciana [Prometeo 2012/064]	Spanish Ministry of Economy and Competitiveness(Spanish Government); European Regional Development Fund (FEDER)(European Commission); Junta de Andalucia(Junta de Andalucia); Generalitat Valenciana(Center for Forestry Research & Experimentation (CIEF)European Commission)	The Spanish Ministry of Economy and Competitiveness (Project AGL2010-19643-C02-02), the European Regional Development Fund (FEDER), and Junta de Andalucia (Project P09AGR-4783) supported this work. Authors also acknowledge the financial support of Generalitat Valenciana (Project Prometeo 2012/064). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	*AACCI, 2000, APPR METH AN; Abadie V, 2011, ANNU REV IMMUNOL, V29, P493, DOI 10.1146/annurev-immunol-040210-092915; Altenbach Susan B, 2011, GM Crops, V2, P66, DOI 10.4161/gmcr.2.1.15884; Arentz-Hansen H, 2000, J EXP MED, V191, P603, DOI 10.1084/jem.191.4.603; Arentz-Hansen H, 2002, GASTROENTEROLOGY, V123, P803, DOI 10.1053/gast.2002.35381; Bethune MT, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040034; Catassi C, 2007, AM J CLIN NUTR, V85, P160, DOI 10.1093/ajcn/85.1.160; CICLITIRA PJ, 1980, CLIN SCI, V59, pP25; Comino I, 2011, GUT, V60, P915, DOI 10.1136/gut.2010.225268; Corrao G, 2001, LANCET, V358, P356, DOI 10.1016/S0140-6736(01)05554-4; Perez LC, 2012, EUR J INTERN MED, V23, P9, DOI 10.1016/j.ejim.2011.08.030; CROMWELL GL, 1967, J ANIM SCI, V26, P1325, DOI 10.2527/jas1967.2661325x; De Palma G, 2009, BRIT J NUTR, V102, P1154, DOI 10.1017/S0007114509371767; Demirkesen I, 2010, J FOOD ENG, V96, P295, DOI 10.1016/j.jfoodeng.2009.08.004; DREWS JE, 1969, J NUTR, V97, P537, DOI 10.1093/jn/97.4.537; Fido RJ, 1997, J CEREAL SCI, V26, P271, DOI 10.1006/jcrs.1997.0138; FRISONI M, 1995, GUT, V36, P375, DOI 10.1136/gut.36.3.375; Frizzi A, 2008, PLANT BIOTECHNOL J, V6, P13, DOI 10.1111/j.1467-7652.2007.00290.x; Gevers H. O., 1992, Quality protein maize., P49; Ghosh S, 2004, ECOL FOOD NUTR, V43, P107, DOI 10.1080/03670240490280267; Gil-Humanes J, 2008, J CEREAL SCI, V48, P565, DOI 10.1016/j.jcs.2008.03.005; Gil-Humanes J, 2011, J EXP BOT, V62, P4203, DOI 10.1093/jxb/err119; Gil-Humanes J, 2010, P NATL ACAD SCI USA, V107, P17023, DOI 10.1073/pnas.1007773107; Glover DV, 1992, QUALITY PROTEIN MAIZ, P49; GUPTA HO, 1979, J AGR FOOD CHEM, V27, P390, DOI 10.1021/jf60222a046; Hager AS, 2012, EUR FOOD RES TECHNOL, V235, P333, DOI 10.1007/s00217-012-1763-2; HOLMES GKT, 1989, GUT, V30, P333, DOI 10.1136/gut.30.3.333; Hournard NM, 2007, PLANT BIOTECHNOL J, V5, P605, DOI 10.1111/j.1467-7652.2007.00265.x; ICC, 1994, 1161 ICC INT ASS CER; Ihaka R., 1996, J COMPUT GRAPH STAT, V5, P299, DOI [DOI 10.1080/10618600.1996.10474713, 10.2307/1390807]; Ivarsson A, 2000, ACTA PAEDIATR, V89, P165, DOI 10.1080/080352500750028771; Kagnoff MF, 2007, J CLIN INVEST, V117, P41, DOI 10.1172/JCI30253; Kasarda D.D., 1989, WHEAT UNIQUE, P277; Kasarda DD, 2013, J AGR FOOD CHEM, V61, P1155, DOI 10.1021/jf305122s; KIES C, 1972, J NUTR, V102, P757, DOI 10.1093/jn/102.6.757; KLEIN RG, 1971, J ANIM SCI, V32, P256; Kupper C, 2005, GASTROENTEROLOGY, V128, pS121, DOI 10.1053/j.gastro.2005.02.024; LEONARD JN, 1983, BRIT MED J, V286, P16, DOI 10.1136/bmj.286.6358.16; LOGAN RFA, 1989, GASTROENTEROLOGY, V97, P265, DOI 10.1016/0016-5085(89)90060-7; Ludvigsson JF, 2013, AM J GASTROENTEROL, V108, P818, DOI 10.1038/ajg.2013.60; Marco C, 2008, EUR FOOD RES TECHNOL, V227, P1205, DOI 10.1007/s00217-008-0838-6; Mariani P, 1998, J PEDIATR GASTR NUTR, V27, P519, DOI 10.1097/00005176-199811000-00004; Segura MEM, 2011, PLANT FOOD HUM NUTR, V66, P224, DOI 10.1007/s11130-011-0244-2; MCCARTHY CF, 1991, EUR J GASTROEN HEPAT, V3, P125; MERTZ ET, 1964, SCIENCE, V145, P279, DOI 10.1126/science.145.3629.279; Moron B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002294; Moron B, 2008, AM J CLIN NUTR, V87, P405, DOI 10.1093/ajcn/87.2.405; Murray JA, 2004, AM J CLIN NUTR, V79, P669; Pellegrineschi A, 2002, GENOME, V45, P421, DOI 10.1139/G01-154; Piston F, 2013, BMC PLANT BIOL, V13, DOI 10.1186/1471-2229-13-136; Rojas JA, 2000, EUR FOOD RES TECHNOL, V212, P57, DOI 10.1007/s002170000209; Rosell CM, 2012, WOODHEAD PUBL FOOD S, P687; Sapone A, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-23; Sciarini LS, 2012, J FOOD ENG, V111, P590, DOI 10.1016/j.jfoodeng.2012.03.011; Shewry PR, 2007, J CEREAL SCI, V46, P239, DOI 10.1016/j.jcs.2007.06.006; Shewry PR, 2003, ADV GENET, V49, P111, DOI 10.1016/S0065-2660(03)01003-4; Silvester JA, 2007, CAN J GASTROENTEROL, V21, P557, DOI 10.1155/2007/342685; Sollid LM, 2011, J INTERN MED, V269, P604, DOI 10.1111/j.1365-2796.2011.02376.x; Sollid LM, 2000, ANNU REV IMMUNOL, V18, P53, DOI 10.1146/annurev.immunol.18.1.53; Sollid LM, 2002, NAT REV IMMUNOL, V2, P647, DOI 10.1038/nri885; Spaenij-Dekking L, 2005, GASTROENTEROLOGY, V129, P797, DOI 10.1053/j.gastro.2005.06.017; Trier JS, 1998, GASTROENTEROLOGY, V115, P211, DOI 10.1016/S0016-5085(98)70383-X; Tye-Din JA, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001012; Vader W, 2002, GASTROENTEROLOGY, V122, P1729, DOI 10.1053/gast.2002.33606; van den Broeck HC, 2010, THEOR APPL GENET, V121, P1527, DOI 10.1007/s00122-010-1408-4; van den Broeck HC, 2009, BMC PLANT BIOL, V9, DOI 10.1186/1471-2229-9-41; van Herpen TWJM, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-1; Ventura A, 1999, GASTROENTEROLOGY, V117, P297, DOI 10.1053/gast.1999.0029900297; Wen SS, 2012, P NATL ACAD SCI USA, V109, P20543, DOI 10.1073/pnas.1217927109; Wenefrida Ida, 2009, Recent Pat DNA Gene Seq, V3, P219; WHO, 2003, E79832 WHO; Wu XR, 2007, PLANT J, V50, P627, DOI 10.1111/j.1365-313X.2007.03076.x; YOUNG VR, 1971, J NUTR, V101, P1475, DOI 10.1093/jn/101.11.1475; Zuidmeer L, 2008, J ALLERGY CLIN IMMUN, V121, P1210, DOI 10.1016/j.jaci.2008.02.019	74	56	58	2	54	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2014	9	3							e90898	10.1371/journal.pone.0090898	http://dx.doi.org/10.1371/journal.pone.0090898			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC9HN	24621595	gold, Green Published			2023-01-03	WOS:000332845300035
J	Alford, JE; Gumbs, J; Anderson, EC				Alford, Justine E.; Gumbs, Jade; Anderson, Emma C.			A New Role for Clathrin Adaptor Proteins 1 and 3 in Lipoplex Trafficking	PLOS ONE			English	Article							INTRACELLULAR TRAFFICKING; HIV-1 GAG; GENE DELIVERY; PLASMID DNA; TRANSFECTION; COMPLEX; CELLS	Intracellular protein trafficking through secretory and endocytic pathways depends on the function of adaptor proteins that bind motifs on cargo proteins. The adaptor proteins then recruit coat proteins such as clathrin, enabling the formation of a transport vesicle. While studying the role of the clathrin adaptor proteins, AP-1, AP-2 and AP-3 in viral protein trafficking, we discovered that AP-1 and AP-3 potentially have a role in successful transfection of mammalian cells with DNA-liposome complexes (lipoplexes). We showed that AP-1, -2 and -3 are not required for lipoplexes to enter cells, but that lipoplexes and/or released DNA are unable to reach the nucleus in the absence of AP-1 or AP-3, leading to minimal exogenous gene expression. In contrast, gene expression from liposome-delivered mRNA, which does not require nuclear entry, was not impaired by the absence of AP-1 or AP-3. Despite the use of lipoplexes to mediate gene delivery being so widely used in cell biology and, more recently, gene therapy, the mechanism by which lipoplexes or DNA reach the nucleus is poorly characterised. This work sheds light on the components involved in this process, and demonstrates a novel role for AP-1 and AP-3 in trafficking lipoplexes.	[Alford, Justine E.; Gumbs, Jade; Anderson, Emma C.] Univ Warwick, Sch Life Sci, Coventry CV4 7AL, W Midlands, England	University of Warwick	Anderson, EC (corresponding author), Univ Warwick, Sch Life Sci, Coventry CV4 7AL, W Midlands, England.	e.c.anderson@warwick.ac.uk			UK Medical Research Council [G0701220]; Medical Research Council [G0701220] Funding Source: researchfish; MRC [G0701220] Funding Source: UKRI	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the UK Medical Research Council (grant number G0701220 to ECA and a PhD studentship to JEA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Azevedo C, 2009, P NATL ACAD SCI USA, V106, P21161, DOI 10.1073/pnas.0909176106; Batonick M, 2005, VIROLOGY, V342, P190, DOI 10.1016/j.virol.2005.08.001; Camus G, 2007, MOL BIOL CELL, V18, P3193, DOI 10.1091/mbc.E06-12-1147; Cardarelli F, 2012, MOL PHARMACEUT, V9, P334, DOI 10.1021/mp200374e; Dong XH, 2005, CELL, V120, P663, DOI 10.1016/j.cell.2004.12.023; DOWTY ME, 1995, P NATL ACAD SCI USA, V92, P4572, DOI 10.1073/pnas.92.10.4572; Duzgunes N, 2012, METHOD ENZYMOL, V509, P355, DOI 10.1016/B978-0-12-391858-1.00018-6; El Ouahabi A, 1999, J HISTOCHEM CYTOCHEM, V47, P1159; Elouahabi A, 2005, MOL THER, V11, P336, DOI 10.1016/j.ymthe.2004.12.006; Farina F, 2013, NUCLEIC ACIDS RES, V41, P4926, DOI 10.1093/nar/gkt204; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Hirst J, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001170; Hoekstra D, 2007, BIOCHEM SOC T, V35, P68, DOI 10.1042/BST0350068; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Kyere SK, 2012, VIRUS RES, V169, P411, DOI 10.1016/j.virusres.2012.06.007; Lechardeur D, 1999, GENE THER, V6, P482, DOI 10.1038/sj.gt.3300867; Mesika A, 2005, HUM GENE THER, V16, P200, DOI 10.1089/hum.2005.16.200; Miller AM, 2009, ADV DRUG DELIVER REV, V61, P603, DOI 10.1016/j.addr.2009.02.008; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; Rehman ZU, 2013, ACS NANO, V7, P3767, DOI 10.1021/nn3049494; Robinson MS, 2004, TRENDS CELL BIOL, V14, P167, DOI 10.1016/j.tcb.2004.02.002; Schmidt MR, 2009, P NATL ACAD SCI USA, V106, P15344, DOI 10.1073/pnas.0904268106; Vaughan EE, 2006, MOL THER, V13, P422, DOI 10.1016/j.ymthe.2005.10.004	23	4	4	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 11	2014	9	3							e91429	10.1371/journal.pone.0091429	http://dx.doi.org/10.1371/journal.pone.0091429			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC9GM	24618578	Green Published, Green Submitted, gold			2023-01-03	WOS:000332842400092
J	Aye, Y; Li, M; Long, MJC; Weiss, RS				Aye, Y.; Li, M.; Long, M. J. C.; Weiss, R. S.			Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies	ONCOGENE			English	Review							CELL LUNG-CANCER; SMALL-SUBUNIT P53R2; DNA-DAMAGE RESPONSE; CHRONIC LYMPHOCYTIC-LEUKEMIA; ONCOGENE-INDUCED SENESCENCE; IN-VITRO; ESCHERICHIA-COLI; MAMMALIAN-CELLS; DEOXYCYTIDINE KINASE; MITOCHONDRIAL-DNA	Accurate DNA replication and repair is essential for proper development, growth and tumor-free survival in all multicellular organisms. A key requirement for the maintenance of genomic integrity is the availability of adequate and balanced pools of deoxyribonucleoside triphosphates (dNTPs), the building blocks of DNA. Notably, dNTP pool alterations lead to genomic instability and have been linked to multiple human diseases, including mitochondrial disorders, susceptibility to viral infection and cancer. In this review, we discuss how a key regulator of dNTP biosynthesis in mammals, the enzyme ribonucleotide reductase (RNR), impacts cancer susceptibility and serves as a target for anti-cancer therapies. Because RNR-regulated dNTP production can influence DNA replication fidelity while also supporting genome-protecting DNA repair, RNR has complex and stage-specific roles in carcinogenesis. Nevertheless, cancer cells are dependent on RNR for de novo dNTP biosynthesis. Therefore, elevated RNR expression is a characteristic of many cancers, and an array of mechanistically distinct RNR inhibitors serve as effective agents for cancer treatment. The dNTP metabolism machinery, including RNR, has been exploited for therapeutic benefit for decades and remains an important target for cancer drug development.	[Aye, Y.] Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY USA; [Aye, Y.] Weill Cornell Med Coll, Dept Biochem, New York, NY USA; [Li, M.; Weiss, R. S.] Cornell Univ, Dept Biomed Sci, Ithaca, NY USA; [Long, M. J. C.] Brandeis Univ, Grad Program Biochem, Waltham, MA USA	Cornell University; Cornell University; Cornell University; Brandeis University	Aye, Y (corresponding author), 224 Baker Lab Chem & Chem Biol, Ithaca, NY 14853 USA.	ya222@cornell.edu; rsw26@cornell.edu		Long, marcus/0000-0002-0343-9671	ACCEL program; NSF [SBE-0547373]; President's Council of Cornell Women; Milstein sesquicentennial junior faculty fellowship; HHMI; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [DP2GM114850] Funding Source: NIH RePORTER	ACCEL program; NSF(National Science Foundation (NSF)); President's Council of Cornell Women; Milstein sesquicentennial junior faculty fellowship; HHMI(Howard Hughes Medical Institute); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Professors Rick Cerione and Jennifer Surtees for helpful discussion and comments on the manuscript. YA acknowledges a faculty development grant from the ACCEL program supported by NSF (SBE-0547373), an Affinito-Stewart grant from the President's Council of Cornell Women and a Milstein sesquicentennial junior faculty fellowship. MJCL acknowledges an HHMI international student predoctoral fellowship.	Ahluwalia D, 2013, P NATL ACAD SCI USA, V110, P18596, DOI 10.1073/pnas.1310849110; Aird KM, 2014, CELL CYCLE, V13, P199, DOI 10.4161/cc.26953; Aird KM, 2013, CELL REP, V3, P1252, DOI 10.1016/j.celrep.2013.03.004; AKERBLOM L, 1981, P NATL ACAD SCI-BIOL, V78, P2159, DOI 10.1073/pnas.78.4.2159; Akita H, 2009, ONCOGENE, V28, P2903, DOI 10.1038/onc.2009.158; Alvarez-Salas LM, 2008, CURR TOP MED CHEM, V8, P1379, DOI 10.2174/156802608786141133; Anderson DD, 2012, J BIOL CHEM, V287, P7051, DOI 10.1074/jbc.M111.333120; Anglana M, 2003, CELL, V114, P385, DOI 10.1016/S0092-8674(03)00569-5; Avolio TM, 2007, ANTI-CANCER DRUG, V18, P377, DOI 10.1097/CAD.0b013e328013c04f; AVRAMIS VI, 1983, BIOCHEM BIOPH RES CO, V113, P35, DOI 10.1016/0006-291X(83)90428-X; Aye Y, 2012, J BIOL CHEM, V287, P35768, DOI 10.1074/jbc.M112.396911; Aye Y, 2012, CHEM BIOL, V19, P799, DOI 10.1016/j.chembiol.2012.05.015; Aye Y, 2011, P NATL ACAD SCI USA, V108, P9815, DOI 10.1073/pnas.1013274108; BEBENEK K, 1992, J BIOL CHEM, V267, P3589; Bepler G, 2004, J CLIN ONCOL, V22, P1878, DOI 10.1200/JCO.2004.12.002; Bepler G, 2008, J THORAC ONCOL, V3, P1112, DOI 10.1097/JTO.0b013e3181874936; Bepler G, 2006, J CLIN ONCOL, V24, P4731, DOI 10.1200/JCO.2006.06.1101; Bergman AM, 2005, CANCER RES, V65, P9510, DOI 10.1158/0008-5472.CAN-05-0989; Bester AC, 2011, CELL, V145, P435, DOI 10.1016/j.cell.2011.03.044; Bonate PL, 2006, NAT REV DRUG DISCOV, V5, P855, DOI 10.1038/nrd2055; Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040; Burkhalter MD, 2009, DNA REPAIR, V8, P1258, DOI 10.1016/j.dnarep.2009.07.009; Burrell RA, 2013, NATURE, V494, P492, DOI 10.1038/nature11935; CARAS IW, 1988, MOL CELL BIOL, V8, P2698, DOI 10.1128/MCB.8.7.2698; Ceppi P, 2006, ANN ONCOL, V17, P1818, DOI 10.1093/annonc/mdl300; Chabes A, 2000, J BIOL CHEM, V275, P17747, DOI 10.1074/jbc.M000799200; Chabes A, 2003, CELL, V112, P391, DOI 10.1016/S0092-8674(03)00075-8; Chabes AL, 2004, J BIOL CHEM, V279, P10796, DOI 10.1074/jbc.M312482200; Chabes AL, 2003, P NATL ACAD SCI USA, V100, P3925, DOI 10.1073/pnas.0330774100; Chandra D, 2006, CELL, V125, P1333, DOI 10.1016/j.cell.2006.05.026; Chang LF, 2008, P NATL ACAD SCI USA, V105, P18519, DOI 10.1073/pnas.0803313105; Chaston TB, 2003, CLIN CANCER RES, V9, P402; Chimploy K, 2013, J BIOL CHEM, V288, P13145, DOI 10.1074/jbc.M113.461111; COHEN A, 1978, P NATL ACAD SCI USA, V75, P472, DOI 10.1073/pnas.75.1.472; CORY JG, 1994, BIOCHEM PHARMACOL, V48, P335, DOI 10.1016/0006-2952(94)90105-8; Cotruvo JA, 2011, ANNU REV BIOCHEM, V80, P733, DOI 10.1146/annurev-biochem-061408-095817; Courbet S, 2008, NATURE, V455, P557, DOI 10.1038/nature07233; D'Angiolella V, 2012, CELL, V149, P1023, DOI 10.1016/j.cell.2012.03.043; Davidson JD, 2004, CANCER RES, V64, P3761, DOI 10.1158/0008-5472.CAN-03-3363; Dong XP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092320; Duxbury MS, 2004, ONCOGENE, V23, P1539, DOI 10.1038/sj.onc.1207272; Duxbury MS, 2004, SURGERY, V136, P261, DOI 10.1016/j.surg.2004.04.029; ELFORD HL, 1970, J BIOL CHEM, V245, P5228; ELLEDGE SJ, 1993, BIOESSAYS, V15, P333, DOI 10.1002/bies.950150507; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; ENGSTROM Y, 1988, EMBO J, V7, P1615, DOI 10.1002/j.1460-2075.1988.tb02987.x; ENGSTROM Y, 1984, EMBO J, V3, P863, DOI 10.1002/j.1460-2075.1984.tb01897.x; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; Faderl S, 2005, BLOOD, V105, P940, DOI 10.1182/blood-2004-05-1933; Fairman JW, 2011, NAT STRUCT MOL BIOL, V18, P316, DOI 10.1038/nsmb.2007; Fan HZ, 1998, CANCER RES, V58, P1650; Fan HZ, 1996, P NATL ACAD SCI USA, V93, P14036, DOI 10.1073/pnas.93.24.14036; Fan HZ, 1997, P NATL ACAD SCI USA, V94, P13181, DOI 10.1073/pnas.94.24.13181; FEIG DI, 1994, CANCER RES, V54, pS1890; Ferracin M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-123; Ferrandina G, 2010, CANCER CHEMOTH PHARM, V65, P679, DOI 10.1007/s00280-009-1073-y; FERSHT AR, 1979, P NATL ACAD SCI USA, V76, P4946, DOI 10.1073/pnas.76.10.4946; Filatov D, 1996, J BIOL CHEM, V271, P23698, DOI 10.1074/jbc.271.39.23698; Finch RA, 2000, BIOCHEM PHARMACOL, V59, P983, DOI 10.1016/S0006-2952(99)00419-0; Fisher SB, 2013, CANCER-AM CANCER SOC, V119, P445, DOI 10.1002/cncr.27619; Fu Y, 2013, BIOCHEMISTRY-US, V52, P7050, DOI 10.1021/bi400781z; Gautam A, 2003, ONCOGENE, V22, P2135, DOI 10.1038/sj.onc.1206232; Gautam A, 2006, CANCER RES, V66, P6497, DOI 10.1158/0008-5472.CAN-05-4462; Ge XQ, 2007, GENE DEV, V21, P3331, DOI 10.1101/gad.457807; Gon S, 2011, P NATL ACAD SCI USA, V108, P19311, DOI 10.1073/pnas.1113664108; Gong WY, 2012, LUNG CANCER, V75, P374, DOI 10.1016/j.lungcan.2011.08.003; Gonzalez H, 1998, HEMATOL CELL THER, V40, P113; GRASLUND A, 1982, J BIOL CHEM, V257, P5711; Guittet O, 2001, J BIOL CHEM, V276, P40647, DOI 10.1074/jbc.M106088200; Guittet O, 2008, NITRIC OXIDE-BIOL CH, V19, P84, DOI 10.1016/j.niox.2008.04.011; Hakansson P, 2006, J BIOL CHEM, V281, P7834, DOI 10.1074/jbc.M512894200; HEHLMANN R, 1993, BLOOD, V82, P398, DOI 10.1182/blood.V82.2.398.bloodjournal822398; Hofer A, 2012, CRIT REV BIOCHEM MOL, V47, P50, DOI 10.3109/10409238.2011.630372; Hu CM, 2012, CANCER CELL, V22, P36, DOI 10.1016/j.ccr.2012.04.038; HURTA RAR, 1992, J BIOL CHEM, V267, P7066; Itoi T, 2007, J GASTROENTEROL, V42, P389, DOI 10.1007/s00535-007-2017-0; Johansson E, 1998, J BIOL CHEM, V273, P29816, DOI 10.1074/jbc.273.45.29816; Jordheim LP, 2011, LANCET ONCOL, V12, P693, DOI 10.1016/S1470-2045(10)70244-8; Jordheim LP, 2005, MOL CANCER THER, V4, P1268, DOI 10.1158/1535-7163.MCT-05-0121; Jorgensen CLT, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-541; Kashlan OB, 2003, BIOCHEMISTRY-US, V42, P1696, DOI 10.1021/bi020634d; Kimura T, 2003, NAT GENET, V34, P440, DOI 10.1038/ng1212; King KM, 2006, MOL PHARMACOL, V69, P346, DOI 10.1124/mol.105.015768; Kollberg G, 2009, NEUROMUSCULAR DISORD, V19, P147, DOI 10.1016/j.nmd.2008.11.014; KUNZ BA, 1991, ANNU REV GENET, V25, P339, DOI 10.1146/annurev.ge.25.120191.002011; Lee Y, 2003, CANCER RES, V63, P2802; LEVIN VA, 1992, SEMIN ONCOL, V19, P34; Lin ZP, 2004, J BIOL CHEM, V279, P27030, DOI 10.1074/jbc.M402056200; Lindemalm S, 2004, CANCER LETT, V210, P171, DOI 10.1016/j.canlet.2004.03.007; Lis ET, 2008, DNA REPAIR, V7, P801, DOI 10.1016/j.dnarep.2008.02.007; Liu XY, 2006, CLIN CANCER RES, V12, P6337, DOI 10.1158/1078-0432.CCR-06-0799; Liu XY, 2013, CLIN SCI, V124, P567, DOI 10.1042/CS20120240; Liu XY, 2011, CANCER RES, V71, P3202, DOI 10.1158/0008-5472.CAN-11-0054; Lu AG, 2012, WORLD J GASTROENTERO, V18, P4704, DOI 10.3748/wjg.v18.i34.4704; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746; Manegold C, 2000, INVEST NEW DRUG, V18, P29, DOI 10.1023/A:1006327729228; Mannava S, 2012, AGING-US, V4, P917, DOI 10.18632/aging.100512; Mannava S, 2013, AM J PATHOL, V182, P142, DOI 10.1016/j.ajpath.2012.09.011; Mansson E, 2003, BIOCHEM PHARMACOL, V65, P237, DOI 10.1016/S0006-2952(02)01484-3; Martin KR, 2002, HUM EXP TOXICOL, V21, P71, DOI 10.1191/0960327102ht213oa; Mathews CK, 2006, FASEB J, V20, P1300, DOI 10.1096/fj.06-5730rev; Matsushita S, 2012, J DERMATOL SCI, V68, P19, DOI 10.1016/j.jdermsci.2012.07.005; MCCLARTY GA, 1987, BIOCHEMISTRY-US, V26, P8004, DOI 10.1021/bi00398a068; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; Meyer Y, 2009, ANNU REV GENET, V43, P335, DOI 10.1146/annurev-genet-102108-134201; Minnihan EC, 2013, ACCOUNTS CHEM RES, V46, P2524, DOI 10.1021/ar4000407; Morikawa T, 2010, HISTOPATHOLOGY, V57, P885, DOI 10.1111/j.1365-2559.2010.03725.x; Morikawa T, 2010, HUM PATHOL, V41, P1742, DOI 10.1016/j.humpath.2010.06.001; Moss J, 2010, GENE DEV, V24, P2705, DOI 10.1101/gad.1970810; Nakahira S, 2007, INT J CANCER, V120, P1355, DOI 10.1002/ijc.22390; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; Niida H, 2010, GENE DEV, V24, P333, DOI 10.1101/gad.1863810; Nocentini G, 1996, CRIT REV ONCOL HEMAT, V22, P89, DOI 10.1016/1040-8428(95)00187-5; Nordlund N, 2006, ANNU REV BIOCHEM, V75, P681, DOI 10.1146/annurev.biochem.75.103004.142443; Nutting CM, 2009, ANN ONCOL, V20, P1275, DOI 10.1093/annonc/mdn775; NYHOLM S, 1993, BIOCHEMISTRY-US, V32, P11569, DOI 10.1021/bi00094a013; Oh YK, 2009, ADV DRUG DELIVER REV, V61, P850, DOI 10.1016/j.addr.2009.04.018; Ohtaka K, 2008, ONCOL REP, V20, P279, DOI 10.3892/or_00000004; Okumura H, 2006, CLIN CANCER RES, V12, P3740, DOI 10.1158/1078-0432.CCR-05-2416; Okumura H, 2005, BRIT J CANCER, V92, P284, DOI 10.1038/sj.bjc.6602322; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; Pfisterer J, 2005, INT J GYNECOL CANCER, V15, P36, DOI 10.1111/j.1525-1438.2005.15355.x; PLUNKETT W, 1987, CANCER RES, V47, P3005; Pontarin G, 2007, J BIOL CHEM, V282, P16820, DOI 10.1074/jbc.M701310200; Pontarin G, 2012, P NATL ACAD SCI USA, V109, P13302, DOI 10.1073/pnas.1211289109; Pontarin G, 2008, P NATL ACAD SCI USA, V105, P17801, DOI 10.1073/pnas.0808198105; Popovic-Bijelic A, 2011, J INORG BIOCHEM, V105, P1422, DOI 10.1016/j.jinorgbio.2011.07.003; Rahman MA, 2012, J CONTROL RELEASE, V159, P384, DOI 10.1016/j.jconrel.2012.01.045; Rampazzo C, 2010, MUTAT RES-GEN TOX EN, V703, P2, DOI 10.1016/j.mrgentox.2010.06.002; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; REICHARD P, 1961, J BIOL CHEM, V236, P1150; Reischl D, 2009, NANOMED-NANOTECHNOL, V5, P8, DOI 10.1016/j.nano.2008.06.001; Reubold TF, 2012, CELL SIGNAL, V24, P1420, DOI 10.1016/j.cellsig.2012.03.007; Reynolds C, 2009, J CLIN ONCOL, V27, P5808, DOI 10.1200/JCO.2009.21.9766; Rodriguez J, 2011, EUR J CANCER, V47, P839, DOI 10.1016/j.ejca.2010.11.032; Rofougaran R, 2006, J BIOL CHEM, V281, P27705, DOI 10.1074/jbc.M605573200; Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751; Sabouri N, 2008, NUCLEIC ACIDS RES, V36, P5660, DOI 10.1093/nar/gkn555; SAHLIN M, 1989, BIOCHEMISTRY-US, V28, P2618, DOI 10.1021/bi00432a039; Sandler A, 1999, Oncologist, V4, P241; Saven A, 1998, BLOOD, V92, P1918, DOI 10.1182/blood.V92.6.1918; Shaibani A, 2009, ARCH NEUROL-CHICAGO, V66, P1028, DOI 10.1001/archneurol.2009.139; Shao J, 2006, CURR CANCER DRUG TAR, V6, P409, DOI 10.2174/156800906777723949; Sigal DS, 2010, BLOOD, V116, P2884, DOI 10.1182/blood-2010-02-246140; Sigmond J, 2010, ANTI-CANCER DRUG, V21, P591, DOI 10.1097/CAD.0b013e32833a3543; Simon G, 2007, J CLIN ONCOL, V25, P2741, DOI 10.1200/JCO.2006.08.2099; Spasokoukotskaja T, 1998, ADV EXP MED BIOL, V431, P641; Spasokoukotskaja T, 1999, EUR J CANCER, V35, P1862, DOI 10.1016/S0959-8049(99)00223-3; Sterkers Y, 1998, BLOOD, V91, P616, DOI 10.1182/blood.V91.2.616.616_616_622; Stover PJ, 2012, CANCER CELL, V22, P3, DOI 10.1016/j.ccr.2012.06.010; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Stubbe JA, 1995, CHEM BIOL, V2, P793, DOI 10.1016/1074-5521(95)90084-5; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tang H, 2013, CLIN CANCER RES, V19, P1577, DOI 10.1158/1078-0432.CCR-12-2321; Temperini C, 2006, BIOORG MED CHEM LETT, V16, P4316, DOI 10.1016/j.bmcl.2006.05.068; Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; ULLMAN B, 1980, J BIOL CHEM, V255, P8308; Uramoto H, 2006, ANTICANCER RES, V26, P983; Walker S, 2009, HEALTH TECHNOL ASSES, V13, P35, DOI 10.3310/hta13suppl1/06; Wang J, 2007, P NATL ACAD SCI USA, V104, P14324, DOI 10.1073/pnas.0706803104; Wang LM, 2012, CHINESE MED J-PEKING, V125, P2151, DOI 10.3760/cma.j.issn.0366-6999.2012.12.013; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; WEINBERG G, 1981, P NATL ACAD SCI-BIOL, V78, P2447, DOI 10.1073/pnas.78.4.2447; Wheeler LJ, 2005, DNA REPAIR, V4, P1450, DOI 10.1016/j.dnarep.2005.09.003; Wonganan P, 2012, CANCER BIOL THER, V13, P908, DOI 10.4161/cbt.20843; WRIGHT JA, 1987, SOMAT CELL MOLEC GEN, V13, P155, DOI 10.1007/BF01534695; Xu X, 2008, CANCER RES, V68, P2652, DOI 10.1158/0008-5472.CAN-07-5873; Xue LJ, 2007, CANCER RES, V67, P16, DOI 10.1158/0008-5472.CAN-06-3200; Yamaguchi T, 2001, CANCER RES, V61, P8256; Yanamoto S, 2005, CANCER LETT, V223, P67, DOI 10.1016/j.canlet.2004.10.019; Yanamoto S, 2003, CANCER LETT, V190, P233, DOI 10.1016/S0304-3835(02)00588-8; Yanamoto S, 2009, ORAL ONCOL, V45, P521, DOI 10.1016/j.oraloncology.2008.07.005; Yokomakura N, 2007, ONCOL REP, V18, P561; Zhang KQ, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-11; Zhang YW, 2009, J BIOL CHEM, V284, P18085, DOI 10.1074/jbc.M109.003020; Zheng Z, 2007, NEW ENGL J MED, V356, P800, DOI 10.1056/NEJMoa065411; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhu LJ, 2009, BIOCHEM PHARMACOL, V78, P1178, DOI 10.1016/j.bcp.2009.06.103	181	228	234	3	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2015	34	16					2011	2021		10.1038/onc.2014.155	http://dx.doi.org/10.1038/onc.2014.155			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG3IL	24909171				2023-01-03	WOS:000353173400001
J	Gelber, AC				Gelber, Allan C.			Osteoarthritis	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							EVIDENCE-BASED RECOMMENDATIONS; EULAR-STANDING-COMMITTEE; KNEE OSTEOARTHRITIS; OLDER-ADULTS; TASK-FORCE; OARSI RECOMMENDATIONS; HIP OSTEOARTHRITIS; PHYSICAL-THERAPY; SUBSEQUENT KNEE; MENISCAL TEAR											ALTMAN R, 1991, ARTHRITIS RHEUM, V34, P505, DOI 10.1002/art.1780340502; ALTMAN R, 1990, ARTHRITIS RHEUM, V33, P1601, DOI 10.1002/art.1780331101; Altman R, 1986, ARTHRITIS RHEUM, V29; BAKER DG, 1993, NEW ENGL J MED, V329, P1013, DOI 10.1056/NEJM199309303291407; Belamy N, 2006, COCHRANE DB SYST REV; Bellamy N, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005321.pub2; Catella-Lawson F, 2001, NEW ENGL J MED, V345, P1809, DOI 10.1056/NEJMoa003199; Clegg DO, 2006, NEW ENGL J MED, V354, P795, DOI 10.1056/NEJMoa052771; Deyle GD, 2000, ANN INTERN MED, V132, P173, DOI 10.7326/0003-4819-132-3-200002010-00002; Englund M, 2003, ARTHRITIS RHEUM-US, V48, P2178, DOI 10.1002/art.11088; Ettinger WH, 1997, JAMA-J AM MED ASSOC, V277, P25, DOI 10.1001/jama.277.1.25; Felson DT, 2007, ARTHRIT RHEUM-ARTHR, V57, P6, DOI 10.1002/art.22464; FELSON DT, 1988, ANN INTERN MED, V109, P18, DOI 10.7326/0003-4819-109-1-18; Felson DT, 2001, ANN INTERN MED, V134, P541, DOI 10.7326/0003-4819-134-7-200104030-00007; FELSON DT, 1992, ANN INTERN MED, V116, P535, DOI 10.7326/0003-4819-116-7-535; Felson DT, 2006, NEW ENGL J MED, V354, P841, DOI 10.1056/NEJMcp051726; Felson DT, 1998, ARTHRITIS RHEUM, V41, P1343, DOI 10.1002/1529-0131(199808)41:8<1343::AID-ART3>3.0.CO;2-9; Felson DT, 2003, ANN INTERN MED, V139, P330, DOI 10.7326/0003-4819-139-5_Part_1-200309020-00008; Felson DT, 2000, ANN INTERN MED, V133, P635, DOI 10.7326/0003-4819-133-8-200010170-00016; Felson DT, 2000, ANN INTERN MED, V133, P72637; Gelber AC, 1999, AM J MED, V107, P542, DOI 10.1016/S0002-9343(99)00292-2; Gelber AC, 2000, ANN INTERN MED, V133, P321, DOI 10.7326/0003-4819-133-5-200009050-00007; Gossec L, 2011, OSTEOARTHR CARTILAGE, V19, P147, DOI 10.1016/j.joca.2010.10.025; Hochberg MC, 2012, ARTHRIT CARE RES, V64, P465, DOI 10.1002/acr.21596; Jordan KM, 2003, ANN RHEUM DIS, V62, P1145, DOI 10.1136/ard.2003.011742; Katz JN, 2013, NEW ENGL J MED, V368, P1675, DOI 10.1056/NEJMoa1301408; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; Kirkley A, 2008, NEW ENGL J MED, V359, P1097, DOI 10.1056/NEJMoa0708333; Lane NE, 2007, NEW ENGL J MED, V357, P1413, DOI 10.1056/NEJMcp071112; Lin FY, 2004, BMJ-BRIT MED J, V329, P324, DOI 10.1136/bmj.38159.639028.7C; Manheimer E, 2007, ANN INTERN MED, V146, P868, DOI 10.7326/0003-4819-146-12-200706190-00008; McAlindon TE, 2014, OSTEOARTHR CARTILAGE, V22, P363, DOI 10.1016/j.joca.2014.01.003; McGettigan P, 2006, JAMA-J AM MED ASSOC, V296, P1633, DOI 10.1001/jama.296.13.jrv60011; Messier SP, 2004, ARTHRITIS RHEUM-US, V50, P1501, DOI 10.1002/art.20256; Messier SP, 2013, JAMA-J AM MED ASSOC, V310, P1263, DOI 10.1001/jama.2013.277669; Moseley JB, 2002, NEW ENGL J MED, V347, P81, DOI 10.1056/NEJMoa013259; Parkes MJ, 2013, JAMA-J AM MED ASSOC, V310, P72320; Pincus T, 2001, ARTHRITIS RHEUM-US, V44, P1587, DOI 10.1002/1529-0131(200107)44:7<1587::AID-ART282>3.0.CO;2-X; Punzi L, 2004, BEST PRACT RES CL RH, V18, P739, DOI 10.1016/j.berh.2004.05.010; Reichenbach S, 2007, ANN INTERN MED, V146, P580, DOI 10.7326/0003-4819-146-8-200704170-00009; Roddy E, 2005, RHEUMATOLOGY, V44, P67, DOI 10.1093/rheumatology/keh399; Sharma L, 2001, JAMA-J AM MED ASSOC, V286, P188, DOI 10.1001/jama.286.2.188; Siverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247; Slemenda C, 1998, ARTHRITIS RHEUM, V41, P1951, DOI 10.1002/1529-0131(199811)41:11<1951::AID-ART9>3.0.CO;2-9; Slemenda C, 1997, ANN INTERN MED, V127, P97, DOI 10.7326/0003-4819-127-2-199707150-00001; SPIEGEL BMR, 2006, AM J MED, V119, pNIL56, DOI [DOI 10.1016/j.amjmed.2005.11.020, DOI 10.1016/J.AMJMED.2005.11.020]; Superic Cabuslay E, 1996, ARTHRIT CARE RES, V9, P292; Uthman OA, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5555; Wolfe MM, 1999, NEW ENGL J MED, V340, P1888, DOI 10.1056/NEJM199906173402407; Yazigi F, 2013, BMC MUSCULOSKEL DIS, V14, P320; Zhang W, 2008, OSTEOARTHR CARTILAGE, V16, P137, DOI 10.1016/j.joca.2007.12.013; Zhang W, 2007, OSTEOARTHR CARTILAGE, V15, P981, DOI 10.1016/j.joca.2007.06.014; Zhang W, 2007, ANN RHEUM DIS, V66, P377, DOI 10.1136/ard.2006.062091; Zhang W, 2005, ANN RHEUM DIS, V64, P669, DOI 10.1136/ard.2004.028886; Zhang YQ, 2001, ARTHRITIS RHEUM, V44, P2065, DOI 10.1002/1529-0131(200109)44:9<2065::AID-ART356>3.0.CO;2-Z	55	18	18	3	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	2014	161	1					1	16	ITC1	10.7326/0003-4819-161-1-201407010-01001	http://dx.doi.org/10.7326/0003-4819-161-1-201407010-01001			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CW3QX	24979462				2023-01-03	WOS:000364907900001
J	Ude, CC; Sulaiman, SB; Ng, MH; Chen, HC; Ahmad, J; Yahaya, NM; Saim, AB; Idrus, RBH				Ude, Chinedu C.; Sulaiman, Shamsul B.; Ng Min-Hwei; Chen Hui-Cheng; Ahmad, Johan; Yahaya, Norhamdan M.; Saim, Aminuddin B.; Idrus, Ruszymah B. H.			Cartilage Regeneration by Chondrogenic Induced Adult Stem Cells in Osteoarthritic Sheep Model	PLOS ONE			English	Article							DEGENERATIVE JOINT DISEASE; BONE-MARROW; ADIPOSE-TISSUE; IN-VITRO; DIFFERENTIATION; THERAPIES; MEDICINE; REPAIR; YIELD	Objectives: In this study, Adipose stem cells (ADSC) and bone marrow stem cells (BMSC), multipotent adult cells with the potentials for cartilage regenerations were induced to chondrogenic lineage and used for cartilage regenerations in surgically induced osteoarthritis in sheep model. Methods: Osteoarthritis was induced at the right knee of sheep by complete resection of the anterior cruciate ligament and medial meniscus following a 3-weeks exercise regimen. Stem cells from experimental sheep were culture expanded and induced to chondrogenic lineage. Test sheep received a single dose of 2610 7 autologous PKH26-labelled, chondrogenically induced ADSCs or BMSCs as 5 mls injection, while controls received 5 mls culture medium. Results: The proliferation rate of ADSCs 34.4 +/- 1.6 hr was significantly higher than that of the BMSCs 48.8 +/- 5.3 hr (P = 0.008). Chondrogenic induced BMSCs had significantly higher expressions of chondrogenic specific genes (Collagen II, SOX9 and Aggrecan) compared to chondrogenic ADSCs (P = 0.031, 0.010 and 0.013). Grossly, the treated knee joints showed regenerated de novo cartilages within 6 weeks post-treatment. On the International Cartilage Repair Society grade scores, chondrogenically induced ADSCs and BMSCs groups had significantly lower scores than controls (P = 0.0001 and 0.0001). Fluorescence of the tracking dye (PKH26) in the injected cells showed that they had populated the damaged area of cartilage. Histological staining revealed loosely packed matrixes of de novo cartilages and immunostaining demonstrated the presence of cartilage specific proteins, Collagen II and SOX9. Conclusion: Autologous chondrogenically induced ADSCs and BMSCs could be promising cell sources for cartilage regeneration in osteoarthritis.	[Ude, Chinedu C.; Sulaiman, Shamsul B.; Ng Min-Hwei; Idrus, Ruszymah B. H.] Univ Kebangsaan Malaysia, Med Ctr, Tissue Engn Ctr, Cheras, Selangor, Malaysia; [Chen Hui-Cheng] Univ Putra Malaysia, Fac Vet Med, Dept Clin Vet, Serdang 43400, Selangor, Malaysia; [Ahmad, Johan; Yahaya, Norhamdan M.] Univ Kebangsaan Malaysia, Med Ctr, Dept Orthoped & Traumatol, Cheras, Selangor, Malaysia; [Saim, Aminuddin B.] Ampang Putri Specialist Hosp, ENT Consultant Clin, Ampang, Selangor, Malaysia; [Ude, Chinedu C.; Idrus, Ruszymah B. H.] Univ Kebangsaan Malaysia, Fac Med, Dept Physiol, Kuala Lumpur, Selangor, Malaysia	Universiti Kebangsaan Malaysia; Universiti Putra Malaysia; Universiti Kebangsaan Malaysia; Universiti Kebangsaan Malaysia	Idrus, RBH (corresponding author), Univ Kebangsaan Malaysia, Med Ctr, Tissue Engn Ctr, Cheras, Selangor, Malaysia.	ruszyidrus@gmail.com	Sulaiman, Shamsul/AFW-2819-2022; Ng, Angela Min Hwei/ABC-6726-2020	Sulaiman, Shamsul/0000-0003-2148-6575; Ng, Angela Min Hwei/0000-0002-5791-639X; Chen, Hui Cheng/0000-0003-3717-0831; Saim, Aminuddin Bin/0000-0002-8090-0855	Malaysian Ministry of Education [UKM-AP-2011-26, DPP-2013-084]; Universiti Kebangsaan Malaysia Medical Center (Tissue Engineering Center Chemical) [50-67-01-001]	Malaysian Ministry of Education; Universiti Kebangsaan Malaysia Medical Center (Tissue Engineering Center Chemical)	This study was supported by grants from the Malaysian Ministry of Education (UKM-AP-2011-26), (DPP-2013-084) and the grant from the Universiti Kebangsaan Malaysia Medical Center (Tissue Engineering Center Chemical grant: 50-67-01-001). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AICHROTH PM, 1991, INT ORTHOP, V15, P351; Al Faqeh H, 2012, EXP GERONTOL, V47, P458, DOI 10.1016/j.exger.2012.03.018; Alfaqeh H, 2008, Med J Malaysia, V63 Suppl A, P37; Alfaqeh HH, 2011, SAUDI MED J, V32, P640; Aubin PP, 2007, CLIN ORTHOP REL S391, pS318; Aust L, 2004, CYTOTHERAPY, V6, P7, DOI 10.1080/14653240310004539; Brian OD, 2010, TISSUE ENG A, V16; Centeno CJ, 2008, PAIN PHYSICIAN, V11, P343; Chen K, 2013, INT J ORAL MAX SURG, V42, P240, DOI 10.1016/j.ijom.2012.05.030; Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003; Dragoo JL, 2007, TISSUE ENG, V13, P1615, DOI 10.1089/ten.2006.0249; Estes BT, 2010, NAT PROTOC, V5, P1294, DOI 10.1038/nprot.2010.81; Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826; Guilak F, 2010, CLIN ORTHOP RELAT R, V468, P2530, DOI 10.1007/s11999-010-1410-9; Hamid AA, 2012, CLINICS, V67, P99, DOI 10.6061/clinics/2012(02)03; Hennig T, 2007, J CELL PHYSIOL, V211, P682, DOI 10.1002/jcp.20977; HORAN PK, 1989, NATURE, V340, P167, DOI 10.1038/340167a0; Hunziker EB, 2002, OSTEOARTHR CARTILAGE, V10, P432, DOI 10.1053/joca.2002.0801; Im GI, 2005, OSTEOARTHR CARTILAGE, V13, P845, DOI 10.1016/j.joca.2005.05.005; Izadpanah R, 2006, J CELL BIOCHEM, V99, P1285, DOI 10.1002/jcb.20904; Kim HJ, 2009, J ORTHOP RES, V27, P612, DOI 10.1002/jor.20766; Maumus M, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt55; Mehlhorn AT, 2006, TISSUE ENG, V12, P2853, DOI 10.1089/ten.2006.12.2853; Mifune Y, 2013, OSTEOARTHR CARTILAGE, V21, P175, DOI 10.1016/j.joca.2012.09.018; Munirah S, 2005, TISSUE ENG REGEN MED, V2, P347; Murphy CL, 2001, TISSUE ENG, V7, P791, DOI 10.1089/107632701753337735; Murphy JM, 2003, ARTHRITIS RHEUM-US, V48, P3464, DOI 10.1002/art.11365; Oedayrajsingh-Varma MJ, 2006, CYTOTHERAPY, V8, P166, DOI 10.1080/14653240600621125; Pak Jaewoo, 2011, J Med Case Rep, V5, P296, DOI 10.1186/1752-1947-5-296; Puetzer JL, 2010, TISSUE ENG PART B-RE, V16, P435, DOI [10.1089/ten.teb.2009.0705, 10.1089/ten.TEB.2009.0705]; Ratajczak MZ, 2012, LEUKEMIA, V26, P1166, DOI 10.1038/leu.2011.389; Rider DA, 2008, STEM CELLS, V26, P1598, DOI 10.1634/stemcells.2007-0480; Saw KY, 2010, J ARTHRO, V11, DOI 10.1016/; Sha'ban M, 2011, TISSUE ENG REGEN MED, V8, P32; Sigma, 1993, RESEARCH, V53, P2360; Tew SR, 2000, ARTHRITIS RHEUM-US, V43, P215, DOI 10.1002/1529-0131(200001)43:1<215::AID-ANR26>3.0.CO;2-X; Ude CC, 2012, TISSUE CELL, V44, P156, DOI 10.1016/j.tice.2012.02.001; Wickham MQ, 2003, CLIN ORTHOP RELAT R, P196, DOI 10.1097/01.blo.0000072467.53786.ca	38	75	77	2	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 9	2014	9	6							e98770	10.1371/journal.pone.0098770	http://dx.doi.org/10.1371/journal.pone.0098770			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI8LF	24911365	Green Published, Green Submitted, Green Accepted, gold			2023-01-03	WOS:000337165600014
J	Mahadevan, D; Morales, C; Cooke, LS; Manziello, A; Mount, DW; Persky, DO; Fisher, RI; Miller, TP; Qi, WQ				Mahadevan, Daruka; Morales, Carla; Cooke, Laurence S.; Manziello, Ann; Mount, David W.; Persky, Daniel O.; Fisher, Richard I.; Miller, Thomas P.; Qi, Wenqing			Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Potentially Curative in Mice with Aggressive DLBCL Co-Overexpressing MYC and BCL2	PLOS ONE			English	Article							B-CELL LYMPHOMA; PLUS CYCLOPHOSPHAMIDE; AURORA; PROLIFERATION; DOXORUBICIN; EXPRESSION; INHIBITOR; SURVIVAL; THERAPY; MLN8237	Pearson correlation coefficient for expression analysis of the Lymphoma/Leukemia Molecular Profiling Project (LLMPP) demonstrated Aurora A and B are highly correlated with MYC in DLBCL and mantle cell lymphoma (MCL), while both Auroras correlate with BCL2 only in DLBCL. Auroras are up-regulated by MYC dysregulation with associated aneuploidy and resistance to microtubule targeted agents such as vincristine. Myc and Bcl2 are differentially expressed in U-2932, TMD-8, OCI-Ly10 and Granta-519, but only U-2932 cells over-express mutated p53. Alisertib [MLN8237 or M], a highly selective small molecule inhibitor of Aurora A kinase, was synergistic with vincristine [VCR] and rituximab [R] for inhibition of cell proliferation, abrogation of cell cycle checkpoints and enhanced apoptosis versus single agent or doublet therapy. A DLBCL (U-2932) mouse model showed tumor growth inhibition (TGI) of similar to 10-20% (p = 0.001) for M, VCR and M-VCR respectively, while R alone showed similar to 50% TGI (p = 0.001). M-R and VCR-R led to tumor regression [TR], but relapsed 10 days after discontinuing therapy. In contrast, M-VCR-R demonstrated TR with no relapse >40 days after stopping therapy with a Kaplan-Meier survival of 100%. Genes that are modulated by M-VCR-R (CENP-C, Auroras) play a role in centromere-kinetochore function in an attempt to maintain mitosis in the presence of synthetic lethality. Together, our data suggest that the interaction between alisertib plus VCR plus rituximab is synergistic and synthetic lethal in Myc and Bcl-2 co-expressing DLBCL. Alisertib plus vincristine plus rituximab [M-VCR-R] may represent a new strategy for DLBCL therapy.	[Mahadevan, Daruka; Morales, Carla; Cooke, Laurence S.; Qi, Wenqing] Univ Tennessee, Ctr Hlth Sci, Dept Med, Memphis, TN 38163 USA; [Manziello, Ann; Mount, David W.; Persky, Daniel O.; Miller, Thomas P.] Univ Arizona, Dept Med, Ctr Canc, Tucson, AZ USA; [Fisher, Richard I.] Fox Chase Canc Ctr Temple Hlth, Dept Med, Philadelphia, PA USA	University of Tennessee System; University of Tennessee Health Science Center; University of Arizona	Mahadevan, D (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Med, Memphis, TN 38163 USA.	dmahadevan@westclinic.com; wqi@uthsc.edu			Lymphoma SPORE [1 P5O CA B080501A1]	Lymphoma SPORE	This work was supported by Lymphoma SPORE (1 P5O CA B080501A1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aukema SM, 2011, BLOOD, V117, P2319, DOI 10.1182/blood-2010-09-297879; Barrans S, 2010, J CLIN ONCOL, V28, P3360, DOI 10.1200/JCO.2009.26.3947; Cuccuini W, 2012, BLOOD, V119, P4619, DOI 10.1182/blood-2012-01-406033; den Hollander J, 2010, BLOOD, V116, P1498, DOI 10.1182/blood-2009-11-251074; Dunleavy K, 2011, ANN ONCOL, V22, P106; Friedberg JW, 2014, J CLIN ONCOL, V32, P44, DOI 10.1200/JCO.2012.46.8793; Friedberg JW, 2012, J CLIN ONCOL, V30, P3439, DOI 10.1200/JCO.2012.43.5800; Green TM, 2012, J CLIN ONCOL, V30, P3460, DOI 10.1200/JCO.2011.41.4342; Johnson NA, 2012, J CLIN ONCOL, V30, P3452, DOI 10.1200/JCO.2011.41.0985; Mahadevan D, 2012, CLIN CANCER RES, V18, P2210, DOI 10.1158/1078-0432.CCR-11-2413; Mead GM, 2008, BLOOD, V112, P2248, DOI 10.1182/blood-2008-03-145128; Pfreundschuh M, 2012, J CLIN ONCOL, V30, P3433, DOI 10.1200/JCO.2012.44.4729; Qi WQ, 2013, LEUKEMIA RES, V37, P434, DOI 10.1016/j.leukres.2012.10.017; Qi WQ, 2011, BIOCHEM PHARMACOL, V81, P881, DOI 10.1016/j.bcp.2011.01.017; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Rosenwald A, 2003, CANCER CELL, V3, P185, DOI 10.1016/S1535-6108(03)00028-X; Sasaki N, 2011, EXP HEMATOL, V39, P817, DOI 10.1016/j.exphem.2011.05.002; Savage KJ, 2009, BLOOD, V114, P3533, DOI 10.1182/blood-2009-05-220095	18	27	28	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2014	9	6							e95184	10.1371/journal.pone.0095184	http://dx.doi.org/10.1371/journal.pone.0095184			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI5ML	24893165	gold, Green Submitted, Green Published			2023-01-03	WOS:000336911400004
J	Rong, Y; Walston, S; Welliver, MX; Chakravarti, A; Quick, AM				Rong, Yi; Walston, Steve; Welliver, Meng Xu; Chakravarti, Arnab; Quick, Allison M.			Improving Intra-Fractional Target Position Accuracy Using a 3D Surface Surrogate for Left Breast Irradiation Using the Respiratory-Gated Deep-Inspiration Breath-Hold Technique	PLOS ONE			English	Article							MAMMARY LYMPH-NODES; DOSIMETRIC IMPACT; CANCER PATIENTS; IMAGING-SYSTEM; HEART-DISEASE; ORGAN MOTION; RADIOTHERAPY; RADIATION; MORTALITY; REDUCTION	Purpose: To evaluate the use of 3D optical surface imaging as a surrogate for respiratory gated deep-inspiration breath-hold (DIBH) for left breast irradiation. Material and Methods: Patients with left-sided breast cancer treated with lumpectomy or mastectomy were selected as candidates for DIBH treatment for their external beam radiation therapy. Treatment plans were created on both free breathing (FB) and DIBH computed tomography (CT) simulation scans to determine dosimetric benefits from DIBH. The Real-time Position Management (RPM) system was used to acquire patient's breathing trace during DIBH CT acquisition and treatment delivery. The reference 3D surface models from FB and DIBH CT scans were generated and transferred to the "AlignRT" system for patient positioning and real-time treatment monitoring. MV Cine images were acquired during treatment for each beam as quality assurance for intra-fractional position verification. The chest wall excursions measured on these images were used to define the actual target position during treatment, and to investigate the accuracy and reproducibility of RPM and AlignRT. Results: Reduction in heart dose can be achieved using DIBH for left breast/chest wall radiation. RPM was shown to have inferior correlation with the actual target position, as determined by the MV Cine imaging. Therefore, RPM alone may not be an adequate surrogate in defining the breath-hold level. Alternatively, the AlignRT surface imaging demonstrated a superior correlation with the actual target positioning during DIBH. Both the vertical and magnitude real-time deltas (RTDs) reported by AlignRT can be used as the gating parameter, with a recommended threshold of +/- 3 mm and 5 mm, respectively. Conclusion: The RPM system alone may not be sufficient for the required level of accuracy in left-sided breast/CW DIBH treatments. The 3D surface imaging can be used to ensure patient setup and monitor inter-and intra-fractional motions. Furthermore, the target position accuracy during DIBH treatment can be improved by AlignRT as a superior surrogate, in addition to the RPM system.	[Rong, Yi; Walston, Steve; Welliver, Meng Xu; Chakravarti, Arnab; Quick, Allison M.] Ohio State Univ, James Canc Hosp, Wexner Med Ctr, Dept Radiat Oncol, Columbus, OH 43210 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Rong, Y (corresponding author), Ohio State Univ, James Canc Hosp, Wexner Med Ctr, Dept Radiat Oncol, Columbus, OH 43210 USA.	yi.rong@osumc.edu	Quick, Allison/AAH-8533-2020; Quick, Allison/AAH-7715-2020	Quick, Allison/0000-0002-2260-6586; 	NIH/NCI/CTEP [1R01CA169368]; NIH/NCI [1RC2CA148190, 1U10CA180850-01]; OSU-CCC Funds; NATIONAL CANCER INSTITUTE [U10CA180850, R01CA169368, RC2CA148190, P30CA016058] Funding Source: NIH RePORTER	NIH/NCI/CTEP; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OSU-CCC Funds; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Dr. Arnab Chakravarti was supported by NIH/NCI/CTEP 1R01CA169368; NIH/NCI 1RC2CA148190; NIH/NCI 1U10CA180850-01; and OSU-CCC Funds. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe O, 2005, LANCET, V366, P2087; Alderliesten T, 2013, INT J RADIAT ONCOL, V85, P536, DOI 10.1016/j.ijrobp.2012.04.004; Arthur DW, 2000, INT J RADIAT ONCOL, V48, P139, DOI 10.1016/S0360-3016(00)00633-7; Betgen A, 2013, RADIOTHER ONCOL, V106, P225, DOI 10.1016/j.radonc.2012.12.016; Bouillon K, 2011, J AM COLL CARDIOL, V57, P445, DOI 10.1016/j.jacc.2010.08.638; Cervino LI, 2009, PHYS MED BIOL, V54, P6853, DOI 10.1088/0031-9155/54/22/007; Darby SC, 2013, NEW ENGL J MED, V368, P987, DOI 10.1056/NEJMoa1209825; Djajaputra D, 2005, MED PHYS, V32, P65, DOI 10.1118/1.1828251; Early Breast Canc Trialists Collab, 2011, LANCET, V378, P1707, DOI 10.1016/S0140-6736(11)61629-2; Fisher B, 2002, NEW ENGL J MED, V347, P1233, DOI 10.1056/NEJMoa022152; Furuya T, 2013, J RADIAT RES, V54, P157, DOI 10.1093/jrr/rrs064; Gierga DP, 2012, INT J RADIAT ONCOL, V84, pE663, DOI 10.1016/j.ijrobp.2012.07.2379; Gutt R, 2008, CLIN BREAST CANCER, V8, P443, DOI 10.3816/CBC.2008.n.054; Hjelstuen MHB, 2012, ACTA ONCOL, V51, P333, DOI 10.3109/0284186X.2011.618510; Korreman SS, 2005, RADIOTHER ONCOL, V76, P311, DOI 10.1016/j.radonc.2005.07.009; Lu HM, 2000, INT J RADIAT ONCOL, V47, P895, DOI 10.1016/S0360-3016(00)00512-5; Mageras GS, 2004, SEMIN RADIAT ONCOL, V14, P65, DOI 10.1053/j.semradonc.2003.10.009; McGale P, 2011, RADIOTHER ONCOL, V100, P167, DOI 10.1016/j.radonc.2011.06.016; Meeks SL, 2005, SEMIN RADIAT ONCOL, V15, P192, DOI 10.1016/j.semradonc.2005.01.004; Mege A, 2011, CANCER RADIOTHER, V15, P495, DOI 10.1016/j.canrad.2011.06.003; Nemoto K, 2009, JPN J RADIOL, V27, P259, DOI 10.1007/s11604-009-0336-1; Peng JL, 2010, MED PHYS, V37, P5421, DOI 10.1118/1.3483783; Pepin EW, 2011, MED PHYS, V38, P1912, DOI 10.1118/1.3556588; Qi XS, 2010, INT J RADIAT ONCOL, V78, P609, DOI 10.1016/j.ijrobp.2009.11.053; Remouchamps VM, 2003, INT J RADIAT ONCOL, V55, P392, DOI 10.1016/S0360-3016(02)04143-3; Remouchamps VM, 2003, INT J RADIAT ONCOL, V56, P704, DOI 10.1016/S0360-3016(03)00010-5; RUTQVIST LE, 1990, BRIT J CANCER, V61, P866, DOI 10.1038/bjc.1990.193; Schoffel PJ, 2007, PHYS MED BIOL, V52, P3949, DOI 10.1088/0031-9155/52/13/019; Sixel KE, 2001, INT J RADIAT ONCOL, V49, P199, DOI 10.1016/S0360-3016(00)01455-3; Stranzl H, 2009, STRAHLENTHER ONKOL, V185, P155, DOI 10.1007/s00066-009-1939-2; Tang X, 2013, CLIN EXPERI IN PRESS; Vikstrom J, 2011, ACTA ONCOL, V50, P42, DOI 10.3109/0284186X.2010.512923; Wagner TH, 2007, MED DOSIM, V32, P111, DOI 10.1016/j.meddos.2007.01.008; Yue NJ, 2007, MED PHYS, V34, P2789, DOI 10.1118/1.2739815	34	36	40	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2014	9	5							e97933	10.1371/journal.pone.0097933	http://dx.doi.org/10.1371/journal.pone.0097933			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK3KS	24853144	Green Submitted, Green Published, gold			2023-01-03	WOS:000338323200035
J	Chen, T; Cai, MX; Li, YY; He, ZX; Shi, XC; Song, W; Wang, YH; Xi, Y; Kang, YM; Tian, ZJ				Chen, Ting; Cai, Meng-Xin; Li, You-You; He, Zhi-Xiong; Shi, Xiu-Chao; Song, Wei; Wang, You-Hua; Xi, Yue; Kang, Yu-Ming; Tian, Zhen-Jun			Aerobic Exercise Inhibits Sympathetic Nerve Sprouting and Restores beta-Adrenergic Receptor Balance in Rats with Myocardial Infarction	PLOS ONE			English	Article							NITRIC-OXIDE SYNTHASE; ALTERED CONTRACTILE RESPONSE; ISCHEMIA-REPERFUSION INJURY; VENTRICULAR-FIBRILLATION; HEART-FAILURE; UP-REGULATION; SUDDEN-DEATH; IN-VIVO; STIMULATION; BETA(3)-ADRENOCEPTOR	Background: Cardiac sympathetic nerve sprouting and the dysregulation of beta-adrenergic receptor (beta-AR) play a critical role in the deterioration of cardiac function after myocardial infarction (MI). Growing evidence indicates that exercise provides protection against MI. The aims of this study were to investigate whether aerobic exercise following MI could inhibit sympathetic nerve sprouting and restore the balance of beta 3-AR/beta 1-AR. Methods: Male Sprague-Dawley rats were divided into three groups: sham-operated control group (SC), MI group (MI), and MI with aerobic exercise group (ME). The rats in ME group were assigned to 8 weeks of exercise protocol (16 m/min, 50 min/d, 5 d/wk). The expression of nerve growth factor (NGF), the sympathetic nerve marker-tyrosine hydroxylase (TH), the nerve sprouting marker-growth associated protein 43 (GAP43), and beta 1- and beta 2-AR expression in the peri-infarct area of the left ventricle (LV) were measured by Western blot and immunohistochemistry, while beta 3-AR expression was determined by Western blot and immunofluorescence. Endothelial nitric oxide synthase (NOS2), phospho-NOS2 (p-NOS2), and neuronal nitric oxide synthase (NOS1) were measured by Western blot. Results: MI increased LV end-diastolic pressure (LVEDP), and decreased LV systolic pressure (LVSP). Compared with the MI group, aerobic exercise significantly decreased LVEDP and increased LVSP. The protein expression of TH, GAP43 and NGF was significantly increased after MI, which was normalized by exercise. Compared with the SC group, the ratios of beta 2-AR/beta 1-AR and beta 3-AR/beta 1-AR were elevated in the MI group, and the protein expression of beta 3-AR and NOS1 increased after MI. Compared with the MI group, the ratios of beta 2-AR/beta 1-AR and beta 3-AR/beta 1-AR were normalized in the ME group, while the protein expression of beta 3-AR and NOS1 significantly increased, and NOS2 was activated by exercise. Conclusions: Aerobic exercise inhibits cardiac sympathetic nerve sprouting, restores beta 3-AR/beta 1-AR balance and increases beta 3-AR expression through the activation of NOS2 and NOS1 after myocardial infarction.	[Chen, Ting; Cai, Meng-Xin; He, Zhi-Xiong; Shi, Xiu-Chao; Song, Wei; Wang, You-Hua; Xi, Yue; Tian, Zhen-Jun] Shaanxi Normal Univ, Inst Sports & Exercise Biol, Xian, Shaanxi, Peoples R China; [Chen, Ting] Tibet Univ Nationalities, Dept Sports & Exercise, Xian Yang, Shaanxi, Peoples R China; [Li, You-You] Fourth Mil Med Univ, Dept Physiol, Xian 710032, Shaanxi, Peoples R China; [Li, You-You] Fourth Mil Med Univ, Dept Cardiol, Xian 710032, Shaanxi, Peoples R China; [Kang, Yu-Ming] Xi An Jiao Tong Univ, Cardiovasc Res Ctr, Sch Med, Dept Physiol & Pathophysiol, Xian 710049, Shaanxi, Peoples R China	Shaanxi Normal University; Xizang Minzu University; Air Force Military Medical University; Air Force Military Medical University; Xi'an Jiaotong University	Tian, ZJ (corresponding author), Shaanxi Normal Univ, Inst Sports & Exercise Biol, Xian, Shaanxi, Peoples R China.	tianzhenjun1965@yahoo.cn			National Natural Science Foundation of China [81360297, 31040045, 81100174, 31171141]; National Basic Research Program of China [2012CB517805]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China(National Basic Research Program of China)	This work was supported by National Natural Science Foundation of China (Grant No. 81360297, 31040045, 81100174 and 31171141) and National Basic Research Program of China (No. 2012CB517805). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ajijola OA, 2012, J AM COLL CARDIOL, V59, P962, DOI 10.1016/j.jacc.2011.11.031; Amour J, 2007, ANESTHESIOLOGY, V107, P452, DOI 10.1097/01.anes.0000278909.40408.24; [Anonymous], 2002, AM J PHYSL REGUL INT, VIII, P283; Aragon JP, 2011, J AM COLL CARDIOL, V58, P2683, DOI 10.1016/j.jacc.2011.09.033; Nguyen BL, 2012, CARDIOVASC PATHOL, V21, P143, DOI 10.1016/j.carpath.2011.08.001; Billman GE, 1997, CIRCULATION, V96, P1914, DOI 10.1161/01.CIR.96.6.1914; Billman GE, 2006, AM J PHYSIOL-HEART C, V290, pH2590, DOI 10.1152/ajpheart.01220.2005; Billman GE, 2009, AM J PHYSIOL-HEART C, V297, pH1171, DOI 10.1152/ajpheart.00534.2009; Bostrom P, 2010, CELL, V143, P1072, DOI 10.1016/j.cell.2010.11.036; Calvert JW, 2011, CIRC RES, V108, P1448, DOI 10.1161/CIRCRESAHA.111.241117; Cao JM, 2000, CIRCULATION, V101, P1960, DOI 10.1161/01.CIR.101.16.1960; Cheng HJ, 2001, CIRC RES, V89, P599, DOI 10.1161/hh1901.098042; de Waard MC, 2007, CIRC RES, V100, P1079, DOI 10.1161/01.RES.0000262655.16373.37; de Waard MC, 2010, J MOL CELL CARDIOL, V48, P1041, DOI 10.1016/j.yjmcc.2010.02.005; French JP, 2008, FASEB J, V22, P2862, DOI 10.1096/fj.07-102541; Giallauria F, 2013, EUR J NUCL MED MOL I, V40, P315, DOI 10.1007/s00259-012-2302-x; Heusch G, 2011, J AM COLL CARDIOL, V58, P2692, DOI 10.1016/j.jacc.2011.09.034; HOCHMAN JS, 1982, CIRCULATION, V65, P1446, DOI 10.1161/01.CIR.65.7.1446; Holycross BJ, 2007, AM J PHYSIOL-HEART C, V293, pH2702, DOI 10.1152/ajpheart.00763.2007; Houle MS, 2001, J APPL PHYSIOL, V91, P1627, DOI 10.1152/jappl.2001.91.4.1627; Kimura K, 2012, CIRC RES, V110, P325, DOI 10.1161/CIRCRESAHA.111.257253; Kraljevic J, 2013, CARDIOVASC RES, V99, P55, DOI 10.1093/cvr/cvt080; Kulandavelu S, 2012, J AM COLL CARDIOL, V59, P1988, DOI 10.1016/j.jacc.2012.01.058; Leosco D, 2008, CARDIOVASC RES, V78, P385, DOI 10.1093/cvr/cvm109; Lu J, 2012, J MOL NEUROSCI, V48, P448, DOI 10.1007/s12031-012-9720-x; Mann N, 2012, CIRCULATION, V126, P2625, DOI 10.1161/CIRCULATIONAHA.111.060376; Marshall KD, 2013, J APPL PHYSIOL, V114, P131, DOI 10.1152/japplphysiol.01059.2012; Martinez DG, 2011, HYPERTENSION, V58, P1049, DOI 10.1161/HYPERTENSIONAHA.111.176644; Moens AL, 2009, J MOL CELL CARDIOL, V47, P576, DOI 10.1016/j.yjmcc.2009.06.005; Moniotte S, 2001, CIRCULATION, V103, P1649, DOI 10.1161/01.CIR.103.12.1649; Niu XL, 2012, J AM COLL CARDIOL, V59, P1979, DOI 10.1016/j.jacc.2011.12.046; Ren CY, 2008, AUTON NEUROSCI-BASIC, V144, P22, DOI 10.1016/j.autneu.2008.08.004; Ribeiro F, 2012, REV PORT CARDIOL, V31, P135, DOI 10.1016/j.repc.2011.12.009; Roof SR, 2013, BASIC RES CARDIOL, V108, DOI 10.1007/s00395-013-0332-6; Sasano T, 2008, J AM COLL CARDIOL, V51, P2266, DOI 10.1016/j.jacc.2008.02.062; Saygili E, 2010, J MOL CELL CARDIOL, V49, P79, DOI 10.1016/j.yjmcc.2010.01.019; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; Ursino MG, 2009, PHARMACOL RES, V59, P221, DOI 10.1016/j.phrs.2009.01.002; Veras-Silva AS, 1997, AM J PHYSIOL-HEART C, V273, pH2627, DOI 10.1152/ajpheart.1997.273.6.H2627; Waring C.D., 2012, EUR HEART J; Watts VL, 2013, J MOL CELL CARDIOL, V62, P8, DOI 10.1016/j.yjmcc.2013.04.025; Xu XH, 2008, J MOL CELL CARDIOL, V44, P114, DOI 10.1016/j.yjmcc.2007.10.004; Zhou SM, 2004, CIRC RES, V95, P76, DOI 10.1161/01.RES.0000133678.22968.e3	43	14	20	3	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2014	9	5							e97810	10.1371/journal.pone.0097810	http://dx.doi.org/10.1371/journal.pone.0097810			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AN9SK	24842290	gold, Green Published, Green Submitted			2023-01-03	WOS:000340948600078
J	Vivodtzev, I; Rivard, B; Gagnon, P; Mainguy, V; Dube, A; Belanger, M; Jean, B; Maltais, F				Vivodtzev, Isabelle; Rivard, Benoit; Gagnon, Philippe; Mainguy, Vincent; Dube, Annie; Belanger, Marthe; Jean, Brigitte; Maltais, Francois			Tolerance and Physiological Correlates of Neuromuscular Electrical Stimulation in COPD: A Pilot Study	PLOS ONE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; MUSCLE STRENGTH; QUADRICEPS; EXERCISE; CONTRACTIONS; VOLUNTARY; RESPONSES; ENDURANCE; CAPACITY; FATIGUE	Rationale: Neuromuscular electrical stimulation (NMES) of the lower limbs is an emerging training strategy in patients with COPD. The efficacy of this technique is related to the intensity of the stimulation that is applied during the training sessions. However, little is known about tolerance to stimulation current intensity and physiological factors that could determine it. Our goal was to find potential physiological predictors of the tolerance to increasing NMES stimulation intensity in patients with mild to severe COPD. Methods: 20 patients with COPD (FEV1 = 54+/-14% pred.) completed 2 supervised NMES sessions followed by 5 self-directed sessions at home and one final supervised session. NMES was applied simultaneously to both quadriceps for 45 minutes, at a stimulation frequency of 50 Hz. Spirometry, body composition, muscle function and aerobic capacity were assessed at baseline. Cardiorespiratory responses, leg discomfort, muscle fatigue and markers of systemic inflammation were assessed during or after the last NMES session. Tolerance to NMES was quantified as the increase in current intensity from the initial to the final NMES session (Delta Int). Results: Mean Delta Int was 12+/-10 mA. FEV1, fat-free-mass, quadriceps strength, aerobic capacity and leg discomfort during the last NMES session positively correlated with Delta Int (r = 0.42 to 0.64, all p <= 0.06) while post/pre NMES IL-6 ratio negatively correlated with Delta Int (r = -0.57, p = 0.001). FEV1, leg discomfort during last NMES session and post/pre IL-6 ratio to NMES were independent factors of variance in Delta Int (r(2) = 0.72, p = 0.001). Conclusion: Lower tolerance to NMES was associated with increasing airflow obstruction, low tolerance to leg discomfort during NMES and the magnitude of the IL-6 response after NMES.	[Vivodtzev, Isabelle; Gagnon, Philippe; Mainguy, Vincent; Dube, Annie; Belanger, Marthe; Jean, Brigitte; Maltais, Francois] Univ Laval, Inst Univ Cardiol & Pneumol Quebec, Ctr Rech, Quebec City, PQ, Canada; [Vivodtzev, Isabelle] Univ Grenoble Alpes, Hypoxia Resp & Cardiovasc Physiopathol HP2, Grenoble, France; [Vivodtzev, Isabelle] INSERM, Hypoxia Resp & Cardiovasc Physiopathol HP2, Grenoble, France; [Vivodtzev, Isabelle] Ctr Hosp Grenoble, Grenoble, France; [Rivard, Benoit] CHA Hop Enfant Jesus, Dept Physiotherapie, Quebec City, PQ, Canada	Laval University; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Laval University	Vivodtzev, I (corresponding author), Univ Laval, Inst Univ Cardiol & Pneumol Quebec, Ctr Rech, Quebec City, PQ, Canada.	IVivodtzev@chu-grenoble.fr	Vivodtzev, Isabelle/M-7368-2014	Vivodtzev, Isabelle/0000-0002-5201-8603	CIHR [MOP-84091]	CIHR(Canadian Institutes of Health Research (CIHR))	The sutdy was supported by CIHR grant MOP-84091. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdellaoui A, 2011, EUR RESPIR J, V38, P781, DOI 10.1183/09031936.00167110; Allaire J, 2004, THORAX, V59, P673, DOI 10.1136/thx.2003.020636; Botter A, 2011, EUR J APPL PHYSIOL, V111, P2461, DOI 10.1007/s00421-011-2093-y; Bourjeily-Habr G, 2002, THORAX, V57, P1045, DOI 10.1136/thorax.57.12.1045; Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304; Debigare R, 2003, CHEST, V124, P83, DOI 10.1378/chest.124.1.83; DELITTO A, 1992, PHYS THER, V72, P410, DOI 10.1093/ptj/72.6.410; Gagnon P, 2009, J APPL PHYSIOL, V107, P832, DOI 10.1152/japplphysiol.91546.2008; Giavedoni S, 2012, RESP MED, V106, P1429, DOI 10.1016/j.rmed.2012.05.005; Gleeson M, 2000, IMMUNOL CELL BIOL, V78, P554, DOI 10.1046/j.1440-1711.2000.00953.x; HAMILTON AL, 1995, AM J RESP CRIT CARE, V152, P2021, DOI 10.1164/ajrccm.152.6.8520771; HEYMSFIELD SB, 1994, JPEN-PARENTER ENTER, V18, P91, DOI 10.1177/014860719401800291; Jonsdottir IH, 2000, J PHYSIOL-LONDON, V528, P157, DOI 10.1111/j.1469-7793.2000.00157.x; Maffiuletti NA, 2010, EUR J APPL PHYSIOL, V110, P223, DOI 10.1007/s00421-010-1502-y; McCarthy JJ, 2010, CURR OPIN CLIN NUTR, V13, P230, DOI 10.1097/MCO.0b013e32833781b5; Neder JA, 2002, THORAX, V57, P333, DOI 10.1136/thorax.57.4.333; Pepin V, 2005, AM J RESP CRIT CARE, V172, P1517, DOI 10.1164/rccm.200507-1037OC; Petrofsky J, 2008, EUR J APPL PHYSIOL, V103, P265, DOI 10.1007/s00421-008-0700-3; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Ratkevicius A, 1998, EUR J APPL PHYSIOL O, V77, P462, DOI 10.1007/s004210050361; Revill SM, 1999, THORAX, V54, P213, DOI 10.1136/thx.54.3.213; Sillen MJH, 2008, RESP MED, V102, P786, DOI 10.1016/j.rmed.2008.01.013; Sillen MJH, 2009, CHEST, V136, P44, DOI 10.1378/chest.08-2481; Theurel J, 2007, RESP PHYSIOL NEUROBI, V157, P341, DOI 10.1016/j.resp.2006.12.002; Van Helvoort HAC, 2006, MED SCI SPORT EXER, V38, P1543, DOI 10.1249/01.mss.0000228331.13123.53; Vivodtzev I, 2008, J CARDIOPULM REHABIL, V28, P79, DOI 10.1097/01.HCR.0000314201.02053.a3; Vivodtzev I, 2006, CHEST, V129, P1540, DOI 10.1378/chest.129.6.1540; Vivodtzev I, 2012, CHEST, V141, P716, DOI 10.1378/chest.11-0839; Vivodtzev I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017007; Zanotti E, 2003, CHEST, V124, P292, DOI 10.1378/chest.124.1.292	30	16	17	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2014	9	5							e94850	10.1371/journal.pone.0094850	http://dx.doi.org/10.1371/journal.pone.0094850			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI4LX	24817528	gold, Green Submitted, Green Published			2023-01-03	WOS:000336838000009
J	de Iongh, A				de Iongh, Anya			Patients need support to self manage their long term conditions	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												anya.deiongh@cantab.net						Health Foundation, 2014, CLOS DOORS; NHS Confederation, 2012, INV EM PSYCH WELLB P; NHS England, DOM 2 ENH QUAL LIF P; The Health Foundation, 2013, SUST SPREAD SELF MAN	4	2	2	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 28	2014	348								g2973	10.1136/bmj.g2973	http://dx.doi.org/10.1136/bmj.g2973			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AG5PN	24778324	Green Published, Bronze			2023-01-03	WOS:000335471000011
J	Liu, SH; Li, YJ; Wu, HH; Lee, CC; Lin, CY; Weng, CH; Chen, YC; Chang, MY; Hsu, HH; Fang, JT; Hung, CC; Yang, CW; Tian, YC				Liu, Shou-Hsuan; Li, Yi-Jung; Wu, Hsin-Hsu; Lee, Cheng-Chia; Lin, Chan-Yu; Weng, Cheng-Hao; Chen, Yung-Chang; Chang, Ming-Yang; Hsu, Hsiang-Hao; Fang, Ji-Tseng; Hung, Cheng-Chieh; Yang, Chih-Wei; Tian, Ya-Chung			High-Sensitivity C-Reactive Protein Predicts Mortality and Technique Failure in Peritoneal Dialysis Patients	PLOS ONE			English	Article							RESIDUAL RENAL-FUNCTION; SOLUTE TRANSPORT RATE; SERUM-ALBUMIN; HEMODIALYSIS-PATIENTS; CARDIOVASCULAR-DISEASE; CHRONIC INFLAMMATION; ALL-CAUSE; MEMBRANE-TRANSPORT; SURVIVAL; OUTCOMES	Introduction: An elevated level of serum C-reactive protein (CRP) is widely considered an indicator of an underlying inflammatory disease and a long-term prognostic predictor for dialysis patients. This cross-sectional cohort study was designed to assess the correlation between the level of high-sensitivity CRP (HS-CRP) and the outcome of peritoneal dialysis (PD) patients. Methods: A total of 402 patients were stratified into 3 tertiles (lower, middle, upper) according to serum HS-CRP level and and followed up from October 2009 to September 2011. During follow-up, cardiovascular events, infection episodes, technique failure, and mortality rate were recorded. Results: During the 24-month follow-up, 119 of 402 patients (29.6%) dropped out from PD, including 28 patients (7.0%) who died, 81 patients (20.1%) who switched to hemodialysis, and 10 patients (2.5%) who underwent kidney transplantation. The results of Kaplan-Meier analysis and log-rank test demonstrated a significant difference in the cumulative patient survival rate across the 3 tertiles (the lowest rate in upper tertile). On multivariate Cox regression analysis, only higher HS-CRP level, older age, the presence of diabetes mellitus (DM), lower serum albumin level, and the occurrence of cardiovascular events during follow-up were identified as independent predictors of mortality. Every 1 mg/L increase in HS-CRP level was independently predictive of a 1.4% increase in mortality. Multivariate Cox regression analysis also showed that higher HS-CRP level, the presence of DM, lower hemoglobin level, lower serum albumin level, higher dialysate/plasma creatinine ratio, and the occurrence of infective episodes and cardiovascular events during follow-up were independent predictors of technique failure. Conclusions: The present study shows the importance of HS-CRP in the prediction of 2-year mortality and technique survival in PD patients independent of age, diabetes, hypoalbuminemia, and the occurrence of cardiovascular events.	[Liu, Shou-Hsuan; Li, Yi-Jung; Wu, Hsin-Hsu; Lee, Cheng-Chia; Lin, Chan-Yu; Weng, Cheng-Hao; Chen, Yung-Chang; Chang, Ming-Yang; Hsu, Hsiang-Hao; Fang, Ji-Tseng; Hung, Cheng-Chieh; Yang, Chih-Wei; Tian, Ya-Chung] Chang Gung Univ, Kidney Res Ctr, Dept Nephrol, Lin Kou Chang Gung Mem Hosp, Tao Yuan, Taiwan; [Liu, Shou-Hsuan; Li, Yi-Jung; Wu, Hsin-Hsu; Lee, Cheng-Chia; Lin, Chan-Yu; Weng, Cheng-Hao; Chen, Yung-Chang; Chang, Ming-Yang; Hsu, Hsiang-Hao; Fang, Ji-Tseng; Hung, Cheng-Chieh; Yang, Chih-Wei; Tian, Ya-Chung] Chang Gung Univ, Dept Med, Tao Yuan, Taiwan; [Li, Yi-Jung; Wu, Hsin-Hsu; Weng, Cheng-Hao] Chang Gung Univ, Grad Inst Clin Med Sci, Tao Yuan, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; Chang Gung University	Tian, YC (corresponding author), Chang Gung Univ, Kidney Res Ctr, Dept Nephrol, Lin Kou Chang Gung Mem Hosp, Tao Yuan, Taiwan.	dryctian@adm.cgmh.org.tw	Chang, Ming-Yang/AGH-5397-2022	Chang, Ming-Yang/0000-0001-8899-0376; Lee, Cheng-Chia/0000-0002-6973-5908; Wu, Hsin Hsu/0000-0002-0028-7836				Ates K, 2005, PERITON DIALYSIS INT, V25, P256; Avram Morrell M, 2005, Adv Perit Dial, V21, P154; Bargman JM, 2001, J AM SOC NEPHROL, V12, P2158, DOI 10.1681/ASN.V12102158; Brimble KS, 2006, J AM SOC NEPHROL, V17, P2591, DOI 10.1681/ASN.2006030194; Calle MC, 2012, DIABETES METAB; Chen HY, 2010, QJM-INT J MED, V103, P837, DOI 10.1093/qjmed/hcq036; Cho JH, 2010, NEPHROL DIAL TRANSPL, V25, P1964, DOI 10.1093/ndt/gfp767; Choi HY, 2010, NEPHROL DIAL TRANSPL, V25, P1266, DOI 10.1093/ndt/gfp598; Chung SH, 2003, NEPHROL DIAL TRANSPL, V18, P590, DOI 10.1093/ndt/18.3.590; Chung SH, 2001, NEPHROL DIAL TRANSPL, V16, P2240, DOI 10.1093/ndt/16.11.2240; Churchill DN, 1998, J AM SOC NEPHROL, V9, P1285; Corrado E, 2007, G ITAL CARDIOL, V8, P327, DOI 10.1714/681.7922; Don BR, 2000, J NEPHROL, V13, P249; Ducloux D, 2002, KIDNEY INT, V62, P1417, DOI 10.1111/j.1523-1755.2002.kid562.x; Filiopoulos Vasilis, 2009, Inflammation & Allergy Drug Targets, V8, P369; Filiopoulos V, 2009, INT J ARTIF ORGANS, V32, P872, DOI 10.1177/039139880903201206; Fine A, 2002, KIDNEY INT, V61, P615, DOI 10.1046/j.1523-1755.2002.00145.x; Herzig KA, 2001, J AM SOC NEPHROL, V12, P814, DOI 10.1681/ASN.V124814; Honda H, 2006, AM J KIDNEY DIS, V47, P139, DOI 10.1053/j.ajkd.2005.09.014; Johnson David W, 2007, Hemodial Int, V11, P1, DOI 10.1111/j.1542-4758.2007.00146.x; Jones CH, 1997, NEPHROL DIAL TRANSPL, V12, P554, DOI 10.1093/ndt/12.3.554; Kang SH, 2012, RENAL FAILURE, V34, P149, DOI 10.3109/0886022X.2011.646808; Kaul K, 2010, CURR DIABETES REV, V6, P294, DOI 10.2174/157339910793360851; Kavanagh D, 2004, NEPHROL DIAL TRANSPL, V19, P2584, DOI 10.1093/ndt/gfh386; Kaysen GA, 2000, KIDNEY INT, V58, P346, DOI 10.1046/j.1523-1755.2000.00172.x; Kaysen GA, 2009, CLIN J AM SOC NEPHRO, V4, pS56, DOI 10.2215/CJN.03090509; Krediet RT, 2010, NAT REV NEPHROL, V6, P451, DOI 10.1038/nrneph.2010.68; Lacson E, 2004, SEMIN DIALYSIS, V17, P438, DOI 10.1111/j.0894-0959.2004.17604.x; Li PKT, 2005, PERITON DIALYSIS INT, V25, pS80; Liao CT, 2009, NEPHROL DIAL TRANSPL, V24, P2909, DOI 10.1093/ndt/gfp056; Meuwese CL, 2011, NAT REV NEPHROL, V7, P166, DOI 10.1038/nrneph.2011.2; Mujais S, 2006, KIDNEY INT, V70, pS21, DOI 10.1038/sj.ki.5001912; Noh H, 1998, PERITON DIALYSIS INT, V18, P387; Nolan CR, 2005, J AM SOC NEPHROL, V16, pS120, DOI 10.1681/ASN.2005060662; Oh KH, 2008, NEPHROL DIAL TRANSPL, V23, P2356, DOI 10.1093/ndt/gfm921; OWEN WF, 1993, NEW ENGL J MED, V329, P1001, DOI 10.1056/NEJM199309303291404; Panichi V, 2000, BLOOD PURIFICAT, V18, P183, DOI 10.1159/000014417; Pecoits-Filho R, 2004, PERITON DIALYSIS INT, V24, P327; Perez-Flores Isabel, 2007, Adv Perit Dial, V23, P140; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Rumpsfeld M, 2006, J AM SOC NEPHROL, V17, P271, DOI 10.1681/ASN.2005050566; Stenvinkel P, 2005, BLOOD PURIFICAT, V23, P72, DOI 10.1159/000082014; Stenvinkel P, 2005, KIDNEY INT, V67, P1216, DOI 10.1111/j.1523-1755.2005.00200.x; Torzewski J, 1998, ARTERIOSCL THROM VAS, V18, P1386, DOI 10.1161/01.ATV.18.9.1386; VOLANAKIS JE, 1981, J IMMUNOL, V126, P1820; Wang AYM, 2009, NEPHROL DIAL TRANSPL, V24, P3826, DOI 10.1093/ndt/gfp325; Wang AYM, 2003, J AM SOC NEPHROL, V14, P1871, DOI 10.1097/01.ASN.0000070071.57901.B3; Wang T, 1999, PERITON DIALYSIS INT, V19, P17; Wanner C, 2002, NEPHROL DIAL TRANSPL, V17, P29, DOI 10.1093/ndt/17.suppl_8.29; Wanner C, 2009, SEMIN DIALYSIS, V22, P438, DOI 10.1111/j.1525-139X.2009.00596.x; Westhuyzen J, 2005, ANN CLIN LAB SCI, V35, P46; Windgassen EB, 2011, POSTGRAD MED, V123, P114, DOI 10.3810/pgm.2011.01.2252; Yeun JY, 2000, AM J KIDNEY DIS, V35, P469, DOI 10.1016/S0272-6386(00)70200-9; Yeun JY, 1997, AM J KIDNEY DIS, V30, P923, DOI 10.1016/S0272-6386(97)90105-0; Zalunardo NY, 2007, KIDNEY INT, V71, P687, DOI 10.1038/sj.ki.5002127	55	24	27	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2014	9	3							e93063	10.1371/journal.pone.0093063	http://dx.doi.org/10.1371/journal.pone.0093063			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE0SD	24667814	gold, Green Published, Green Submitted			2023-01-03	WOS:000333675600134
J	Bartels, DJP; van Laarhoven, AIM; Haverkamp, EA; Wilder-Smith, OH; Donders, ART; van Middendorp, H; van de Kerkhof, PCM; Evers, AWM				Bartels, Danielle J. P.; van Laarhoven, Antoinette I. M.; Haverkamp, Elise A.; Wilder-Smith, Oliver H.; Donders, A. Rogier T.; van Middendorp, Henriet; van de Kerkhof, Peter C. M.; Evers, Andrea W. M.			Role of Conditioning and Verbal Suggestion in Placebo and Nocebo Effects on Itch	PLOS ONE			English	Article							INDIVIDUAL-DIFFERENCES; MOTION SICKNESS; DAILY STRESSORS; ANALGESIA; PAIN; EXPECTATIONS; PERSONALITY; VALIDATION; EXPECTANCY; PSORIASIS	Placebo and nocebo effects are known to play a key role in treatment effects in a wide variety of conditions. These effects have frequently been investigated with regard to pain and also in other physical sensations, but have hardly been investigated with regard to itch. In addition, neither in pain nor in any other physical sensation, the single and combined contribution of the expectancy mechanisms of conditioning and verbal suggestion have ever been investigated in both placebo and nocebo effects within one design. For the first time, the role of verbal suggestion and conditioning in placebo and nocebo effects on itch was experimentally investigated. Expectations about itch stimuli were induced in healthy subjects by verbal suggestion, conditioning, or a combination of both procedures, and compared with a control group without expectation induction. Itch was induced electrically by means of quantitative sensory testing. Significant placebo and nocebo effects were induced in the group in which combined procedures of conditioning and verbal suggestion were applied in comparison with the control group. The conditioning and verbal suggestion procedures applied individually did not induce significant placebo and nocebo effects when compared with the control group. The results of this study extend existing evidence on different physical sensations, like pain, by showing that also for itch, the combination of conditioning and verbal suggestion is most promising in inducing both placebo and nocebo effects. More research on placebo and nocebo effects at a perceptive and neurobiological level is warranted to further elucidate the common and specific mechanisms underlying placebo and nocebo effects on itch and other physical sensations.	[Bartels, Danielle J. P.; van Laarhoven, Antoinette I. M.; van Middendorp, Henriet; Evers, Andrea W. M.] Leiden Univ, Inst Psychol, Unit Hlth Med & Neuropsychol, Leiden, Netherlands; [Bartels, Danielle J. P.; van Laarhoven, Antoinette I. M.; Haverkamp, Elise A.; van Middendorp, Henriet; Evers, Andrea W. M.] Radboud Univ Nijmegen, Dept Med Psychol, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Wilder-Smith, Oliver H.] Radboud Univ Nijmegen, Med Ctr, Dept Anesthesiol Pain & Palliat Med, NL-6525 ED Nijmegen, Netherlands; [Donders, A. Rogier T.] Radboud Univ Nijmegen, Med Ctr, Dept Hlth Evidence, NL-6525 ED Nijmegen, Netherlands; [van de Kerkhof, Peter C. M.] Radboud Univ Nijmegen, Dept Dermatol, Med Ctr, NL-6525 ED Nijmegen, Netherlands	Leiden University; Leiden University - Excl LUMC; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	Bartels, DJP (corresponding author), Leiden Univ, Inst Psychol, Unit Hlth Med & Neuropsychol, Leiden, Netherlands.	D.Bartels@fsw.leidenuniv.nl	Evers, Andrea/GWV-9705-2022; van Middendorp, Henriet/B-8300-2013; Evers, Andrea/U-8983-2019; Wilder-Smith, Oliver H.G./E-7541-2012; van de Kerkhof, P.C.M./H-8059-2014; Evers, A.W.M./L-4299-2015; Donders, A.R.T./L-4277-2015	Evers, Andrea/0000-0002-0090-5091; Wilder-Smith, Oliver H.G./0000-0003-4390-2381; Donders, A.R.T./0000-0002-0484-1419; van Laarhoven, Antoinette/0000-0001-6932-9283; van Middendorp, Henriet/0000-0003-4575-0895	Netherlands Organization for Scientific Research (NOW)	Netherlands Organization for Scientific Research (NOW)(Netherlands Organization for Scientific Research (NWO))	This work is financed by the Netherlands Organization for Scientific Research (NOW, http://www.nwo.nl/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amanzio M, 1999, J NEUROSCI, V19, P484, DOI 10.1523/JNEUROSCI.19-01-00484.1999; Atlas LY, 2012, NEUROSCI LETT, V520, P140, DOI 10.1016/j.neulet.2012.03.039; Benedetti F, 2011, PATIENT EDUC COUNS, V84, P413, DOI 10.1016/j.pec.2011.04.034; Benedetti F, 2011, NEUROPSYCHOPHARMACOL, V36, P339, DOI 10.1038/npp.2010.81; Benedetti F, 2008, ANNU REV PHARMACOL, V48, P33, DOI 10.1146/annurev.pharmtox.48.113006.094711; Brouwer D, 2008, PSYCHOL ASSESSMENT, V20, P310, DOI 10.1037/1040-3590.20.3.310; Colloca L, 2008, PAIN, V136, P211, DOI 10.1016/j.pain.2008.02.006; Colloca L, 2006, PAIN, V124, P126, DOI 10.1016/j.pain.2006.04.005; Colloca L, 2013, PAIN, V154, P511, DOI 10.1016/j.pain.2013.02.002; Colloca L, 2011, PSYCHOSOM MED, V73, P598, DOI 10.1097/PSY.0b013e3182294a50; Colloca L, 2010, PAIN, V151, P430, DOI 10.1016/j.pain.2010.08.007; Enck P, 2013, NAT REV DRUG DISCOV, V12, P191, DOI 10.1038/nrd3923; Evers AWM, 2010, BRIT J DERMATOL, V163, P986, DOI 10.1111/j.1365-2133.2010.09984.x; Eysenck HJ, 1975, EPQ EYSENCK PERSONAL; Geers AL, 2005, J PSYCHOSOM RES, V58, P121, DOI 10.1016/j.jpsychores.2004.08.011; Geers AL, 2007, J PSYCHOSOM RES, V62, P563, DOI 10.1016/j.jpsychores.2006.12.005; Holle H, 2012, P NATL ACAD SCI USA, V109, P19816, DOI 10.1073/pnas.1216160109; Horing B, 2013, PSYCHOSOM MED, V75, P497, DOI 10.1097/PSY.0b013e3182915ee7; Ikoma A, 2005, PAIN, V113, P148, DOI 10.1016/j.pain.2004.10.003; Jensen KB, 2012, P NATL ACAD SCI USA, V109, P15959, DOI 10.1073/pnas.1202056109; Klinger R, 2007, PAIN, V128, P31, DOI 10.1016/j.pain.2006.08.025; Klosterhalfen S, 2000, PSYCHOSOM MED, V62, P671, DOI 10.1097/00006842-200009000-00011; Lee HF, 2012, PAIN, V153, P1301, DOI 10.1016/j.pain.2012.03.018; Martin-Pichora Andrea L, 2011, J Pain Res, V4, P67, DOI 10.2147/JPR.S15966; MEYER TJ, 1990, BEHAV RES THER, V28, P487, DOI 10.1016/0005-7967(90)90135-6; Mitchell LA, 2004, J PAIN, V5, P233, DOI 10.1016/j.jpain.2004.03.004; Morton DL, 2009, PAIN, V146, P194, DOI 10.1016/j.pain.2009.07.026; Musial F, 2007, WORLD J GASTROENTERO, V13, P3425, DOI 10.3748/wjg.v13.i25.3425; Niemeier V., 2000, DERMATOL PSYCHOSOM, V1, P15, DOI [10.1159/000057993, DOI 10.1159/000057993]; Papoiu A D P, 2011, Br J Dermatol, V164, P1299, DOI 10.1111/j.1365-2133.2011.10318.x; Pecina M, 2013, NEUROPSYCHOPHARMACOL, V38, P639, DOI 10.1038/npp.2012.227; Pollo A, 2008, EUR J NEUROSCI, V28, P379, DOI 10.1111/j.1460-9568.2008.06344.x; Price DD, 2008, ANNU REV PSYCHOL, V59, P565, DOI 10.1146/annurev.psych.59.113006.095941; SCHEIER MF, 1994, J PERS SOC PSYCHOL, V67, P1063, DOI 10.1037/0022-3514.67.6.1063; Schneider G, 2006, CLIN EXP DERMATOL, V31, P762, DOI 10.1111/j.1365-2230.2006.02211.x; Scholz O, 1994, Z KLIN PSYCHOL-FORSC, V23, P127; SNYDER CR, 1991, J PERS SOC PSYCHOL, V60, P570, DOI 10.1037/0022-3514.60.4.570; van Laarhoven AIM, 2012, BRIT J DERMATOL, V167, P262, DOI 10.1111/j.1365-2133.2012.10933.x; van Laarhoven AIM, 2011, PAIN, V152, P1486, DOI 10.1016/j.pain.2011.01.043; Verhoeven EWM, 2009, BRIT J DERMATOL, V161, P295, DOI 10.1111/j.1365-2133.2009.09194.x; Verhoeven EWM, 2008, ACTA DERM-VENEREOL, V88, P211, DOI 10.2340/00015555-0452; Verhoeven EWM, 2009, J INVEST DERMATOL, V129, P2075, DOI 10.1038/jid.2008.460; Vlaeyen JWS, 2000, PAIN, V85, P317, DOI 10.1016/S0304-3959(99)00242-0; VOUDOURIS NJ, 1990, PAIN, V43, P121, DOI 10.1016/0304-3959(90)90057-K; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	45	86	87	2	172	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2014	9	3							e91727	10.1371/journal.pone.0091727	http://dx.doi.org/10.1371/journal.pone.0091727			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AD6ER	24646924	gold, Green Submitted, Green Published			2023-01-03	WOS:000333348500049
J	Bartoszewski, R; Hering, A; Marszall, M; Hajduk, JS; Bartoszewska, S; Kapoor, N; Kochan, K; Ochocka, R				Bartoszewski, Rafal; Hering, Anna; Marszall, Marcin; Hajduk, Justyna Stefanowicz; Bartoszewska, Sylwia; Kapoor, Niren; Kochan, Kinga; Ochocka, Renata			Mangiferin Has an Additive Effect on the Apoptotic Properties of Hesperidin in Cyclopia sp. Tea Extracts	PLOS ONE			English	Article							NF-KAPPA-B; BREAST-CANCER CELLS; TIME PCR DATA; REAL-TIME; XCELLIGENCE SYSTEM; PROTEIN TRADD; RECEPTOR 1; ACTIVATION; PATHWAYS; GENE	A variety of biological pro-health activities have been reported for mangiferin and hesperidin, two major phenolic compounds of Honeybush (Cyclopia sp.) tea extracts. Given their increasing popularity, there is a need for understanding the mechanisms underlying the biological effects of these compounds. In this study, we used real-time cytotoxicity cellular analysis of the Cyclopia sp. extracts on HeLa cells and found that the higher hesperidin content in non-fermented "green" extracts correlated with their higher cytotoxicity compared to the fermented extracts. We also found that mangiferin had a modulatory effect on the apoptotic effects of hesperidin. Quantitative PCR analysis of hesperidin-induced changes in apoptotic gene expression profile indicated that two death receptor pathway members, TRADD and TRAMP, were up regulated. The results of this study suggest that hesperidin mediates apoptosis in HeLa cells through extrinsic pathway for programmed cell death.	[Bartoszewski, Rafal; Hering, Anna; Hajduk, Justyna Stefanowicz; Kochan, Kinga; Ochocka, Renata] Med Univ Gdansk, Dept Biol & Pharmaceut Bot, Gdansk, Poland; [Bartoszewska, Sylwia] Med Univ Gdansk, Dept Inorgan Chem, Gdansk, Poland; [Kapoor, Niren] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA; [Marszall, Marcin] Med Univ Gdansk, Dept Toxicol, Gdansk, Poland	Fahrenheit Universities; Medical University Gdansk; Fahrenheit Universities; Medical University Gdansk; University of Alabama System; University of Alabama Birmingham; Fahrenheit Universities; Medical University Gdansk	Bartoszewski, R (corresponding author), Med Univ Gdansk, Dept Biol & Pharmaceut Bot, Gdansk, Poland.	rafalbar@gumed.edu.pl	Bartoszewska, Sylwia/L-3922-2019; Bartoszewski, Rafal A/D-6311-2011	Bartoszewska, Sylwia/0000-0001-8063-1272; Bartoszewski, Rafal A/0000-0002-2864-6757; hering, anna/0000-0003-1060-5380	National Science Center KBN Programme [66991/B/P01/2011/40]	National Science Center KBN Programme	This work has been supported by National Science Center KBN Programme under contract 66991/B/P01/2011/40 (to RO). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ang E, 2011, J CELL BIOCHEM, V112, P89, DOI 10.1002/jcb.22800; Bartoszewski R, 2011, METHOD ENZYMOL, V491, P3, DOI 10.1016/B978-0-12-385928-0.00001-8; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; Caraux G, 2005, BIOINFORMATICS, V21, P1280, DOI 10.1093/bioinformatics/bti141; Crnkovic-Mertens I, 2003, ONCOGENE, V22, P8330, DOI 10.1038/sj.onc.1206973; Das J, 2012, TOXICOL APPL PHARM, V260, P35, DOI 10.1016/j.taap.2012.01.015; du Plessis-Stoman D, 2011, AFR J TRADIT COMPLEM, V8, P177; Erskine CL, 2012, JOVE-J VIS EXP, DOI 10.3791/3683; Garg A, 2001, PHYTOTHER RES, V15, P655, DOI 10.1002/ptr.1074; Ghorbani A, 2012, EUR J NUTR, V51, P39, DOI 10.1007/s00394-011-0187-2; Ghosh M, 2012, FREE RADICAL RES, V46, P116, DOI 10.3109/10715762.2011.644240; Golke A, 2012, POL J VET SCI, V15, P151, DOI 10.2478/v10181-011-0126-4; Gong X, 2013, J NUTR BIOCHEM, V24, P1173, DOI 10.1016/j.jnutbio.2012.09.003; Guan N, 2013, MOL BIOSYST, V9, P1035, DOI 10.1039/c3mb25421f; Guha S, 1996, CHEMOTHERAPY, V42, P443, DOI 10.1159/000239478; Hellevik T, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-59; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Joubert E, 2012, S AFR J BOT, V82, P113, DOI 10.1016/j.sajb.2012.07.019; Joubert E, 2003, EUR FOOD RES TECHNOL, V216, P270, DOI 10.1007/s00217-002-0644-5; Jurmeister S, 2012, MOL CELL BIOL, V32, P633, DOI 10.1128/MCB.06212-11; Kamara BI, 2003, J AGR FOOD CHEM, V51, P3874, DOI 10.1021/jf0210730; KO FN, 1991, EUR J PHARMACOL, V192, P133; Kokotkiewicz A, 2012, Z NATURFORSCH C, V67, P65, DOI 10.5560/ZNC.2012.67c0065; Larionov A, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-62; Leatherbarrow RJ, 2009, GRAFIT VERSION 7 7 0; Lee CJ, 2010, PHYTOTHER RES, V24, pS15, DOI 10.1002/ptr.2856; Lee KH, 2010, TOXICOL LETT, V194, P42, DOI 10.1016/j.toxlet.2010.01.021; Li HZ, 2013, TOXICOL APPL PHARM, V272, P180, DOI 10.1016/j.taap.2013.05.011; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Menkovic N, 2010, PHYTOTHER RES, V24, P1693, DOI 10.1002/ptr.3225; Muruganandan S, 2005, J ETHNOPHARMACOL, V97, P497, DOI 10.1016/j.jep.2004.12.010; Nandakumar N, 2011, BIOMED PREV NUTR, V1, P207; Nazari M, 2011, EUR J PHARMACOL, V650, P526, DOI 10.1016/j.ejphar.2010.10.053; Ondrey F, 2009, CLIN CANCER RES, V15, P2, DOI 10.1158/1078-0432.CCR-08-0326; Pal PB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056894; Park HJ, 2008, PHYTOMEDICINE, V15, P147, DOI 10.1016/j.phymed.2007.07.061; Pobezinskaya YL, 2011, J IMMUNOL, V186, P5212, DOI 10.4049/jimmunol.1002374; Rajendran Peramaiyan, 2013, Int J Biomed Sci, V9, P68; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Scrace S, 2013, METHODS MOL BIOL, V1046, P295, DOI 10.1007/978-1-62703-538-5_17; Shoji K, 2011, ARCH PHARM RES, V34, P469, DOI 10.1007/s12272-011-0316-8; TENG CM, 1989, BIOCHEM PHARMACOL, V38, P3791, DOI 10.1016/0006-2952(89)90587-X; Vanden Heuvel JP, 1999, TOXICOL SCI, V47, P1, DOI 10.1093/toxsci/47.1.1; Wang H, 2007, ACTA PHARMACOL SIN, V28, P1968, DOI 10.1111/j.1745-7254.2007.00724.x; Wang YJ, 2000, MOL CELL BIOL, V20, P4505, DOI 10.1128/MCB.20.13.4505-4512.2000; Xia J, 2006, J PHARMACEUT BIOMED, V41, P1401, DOI 10.1016/j.jpba.2006.02.030; ZHENG MS, 1990, CHINESE MED J-PEKING, V103, P160	48	38	38	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2014	9	3							e92128	10.1371/journal.pone.0092128	http://dx.doi.org/10.1371/journal.pone.0092128			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC9MJ	24633329	Green Published, gold, Green Submitted			2023-01-03	WOS:000332858400145
J	Senn, N; Rarau, P; Salib, M; Manong, D; Siba, P; Rogerson, S; Mueller, I; Genton, B				Senn, Nicolas; Rarau, Patricia; Salib, Mary; Manong, Doris; Siba, Peter; Rogerson, Stephen; Mueller, Ivo; Genton, Blaise			Use of Antibiotics within the IMCI Guidelines in Outpatient Settings in Papua New Guinean Children: An Observational and Effectiveness Study	PLOS ONE			English	Article							C-REACTIVE PROTEIN; CHILDHOOD ILLNESS IMCI; INTEGRATED MANAGEMENT; HOSPITALIZED CHILDREN; FEBRILE ILLNESSES; SEVERE PNEUMONIA; MALARIA; BACTERIAL; INFECTION; DIAGNOSIS	Introduction: There is a need to investigate the effectiveness and appropriateness of antibiotics prescription within the Integrated Management of Childhood Illness (IMCI) strategy in the context of routine outpatient clinics. Methods: Making use of a passive case detection system established for a malaria prevention trial in outpatient clinics in Papua New Guinea, the appropriateness and effectiveness of the use of antibiotics within the IMCI was assessed in 1605 young children. Main outcomes were prescription of antibiotics and re-attendances within 14 days for mild pneumonia, mild diarrhoea and uncomplicated malaria whether they were managed with or without antibiotics (proxy of effectiveness). Appropriateness was assessed for both mild and severe cases, while effectiveness was assessed only for mild diseases. Results: A total of 6975 illness episodes out of 8944 fulfilled inclusion criteria (no previous attendance <14 days+full medical records). Clinical incidence rates (episodes/child/year; 95% CI) were 0.85 (0.81-0.90) for pneumonia, 0.62 (0.58-0.66) for malaria and 0.72 (0.65-0.93) for diarrhoea. Fifty three percent of 6975 sick children were treated with antibiotics, 11% were not treated with antibiotics when they should have been and in 29% antibiotics were prescribed when they should not have been. Re-attendance rates within 14 days following clinical diagnosis of mild pneumonia were 9% (126/1401) when managed with antibiotics compared to 8% (56/701) when managed without (adjusted Hazard Ratio (aHR) = 1.00 (0.57-1.76), p = 0.98). Rates for mild diarrhoea were 8% (73/874) and 9% (79/866) respectively (aHR = 0.8 (0.42-1.57), p = 0.53). Conclusion: Non-adherence to IMCI recommendations for prescription of antibiotics is common in routine settings in Papua New Guinea. Although recommended, the use of antibiotics in young children with mild pneumonia as defined by IMCI criteria did not impact on their outcome. Better tools and new strategies for the identification of bacterial infections that require antibiotics are urgently needed.	[Senn, Nicolas; Rarau, Patricia; Salib, Mary; Manong, Doris; Siba, Peter; Mueller, Ivo] PNG Inst Med Res, Vector Born Unit, Madang, MAD, Papua N Guinea; [Senn, Nicolas; Genton, Blaise] Swiss Trop & Publ Hlth Inst, Hlth Intervent Unit, Basel, BS, Switzerland; [Senn, Nicolas; Genton, Blaise] Univ Basel, Basel, BS, Switzerland; [Senn, Nicolas; Rogerson, Stephen] Univ Melbourne, Dept Med, Melbourne, Vic, Australia; [Mueller, Ivo] Walter & Eliza Hall Inst Med Res, Dept Infect & Immun, Melbourne, Vic 3050, Australia; [Mueller, Ivo] Ctr Recerca Salut Int Barcelona CRESIB, Barcelona, Spain	PNG Institute Of Medical Research; University of Basel; Swiss Tropical & Public Health Institute; University of Basel; University of Melbourne; Walter & Eliza Hall Institute; ISGlobal; CRESIB	Senn, N (corresponding author), PNG Inst Med Res, Vector Born Unit, Madang, MAD, Papua N Guinea.	nicolas.senn@gmail.com		Rarau, Patricia/0000-0003-0795-4686; Rogerson, Stephen/0000-0003-4287-1982	Leenaards Foundation (Lausanne, Switzerland)	Leenaards Foundation (Lausanne, Switzerland)	Nicolas Senn is supported by an academic "bridge-releve" scholarship provided by the Leenaards Foundation (Lausanne, Switzerland). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Animut A, 2009, JPN J INFECT DIS, V62, P107; Bassat Q, 2011, AM J TROP MED HYG, V85, P626, DOI 10.4269/ajtmh.2011.11-0223; Bisoffi Z, 2011, MALARIA J, V10, P1475; Bryce J, 2005, LANCET, V365, P1147, DOI 10.1016/S0140-6736(05)71877-8; Carrol ED, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006621; Deressa W, 2007, T ROY SOC TROP MED H, V101, P939, DOI 10.1016/j.trstmh.2007.04.018; Diez-Padrisa N, 2012, TROP MED INT HEALTH, V17, P1100, DOI 10.1111/j.1365-3156.2012.03035.x; Duke T, 2002, B WORLD HEALTH ORGAN, V80, P16; El Arifeen S, 2004, LANCET, V364, P1595, DOI 10.1016/S0140-6736(04)17312-1; Factor SH, 2001, B WORLD HEALTH ORGAN, V79, P1096; Falk G, 2009, FAM PRACT, V26, P10, DOI 10.1093/fampra/cmn095; Feikin DR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016085; Flood RG, 2008, PEDIATR INFECT DIS J, V27, P95, DOI 10.1097/INF.0b013e318157aced; Gwer S, 2007, AM J TROP MED HYG, V77, P6, DOI 10.4269/ajtmh.2007.77.6; Hament JM, 1999, FEMS IMMUNOL MED MIC, V26, P189, DOI 10.1111/j.1574-695X.1999.tb01389.x; Hazir T, 2011, CLIN INFECT DIS, V52, P293, DOI 10.1093/cid/ciq142; Horwood C, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-62; Horwood C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005937; Kallander K, 2004, ACTA TROP, V90, P211, DOI 10.1016/j.actatropica.2003.11.013; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Manning L, 2011, ANTIMICROB AGENTS CH, V55, P4454, DOI 10.1128/AAC.00526-11; ODEMPSEY TJD, 1993, T ROY SOC TROP MED H, V87, P662, DOI 10.1016/0035-9203(93)90279-Y; Paediatric Society of Papua New Guinea, 2005, STAND TREATM COMM IL; Reyburn H, 2004, BMJ-BRIT MED J, V329, P1212, DOI 10.1136/bmj.38251.658229.55; Roca A, 2006, TROP MED INT HEALTH, V11, P373, DOI 10.1111/j.1365-3156.2006.01566.x; Schellenberg JA, 2004, HEALTH POLICY PLANN, V19, P1, DOI 10.1093/heapol/czh001; Schmidt HJ, 2010, RESPIROLOGY, V15, P733, DOI 10.1111/j.1440-1843.2010.01745.x; Schuetz P, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007498.pub2; Schuetz P, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-107; Senn N, 2011, CLIN INFECT DIS, V23, P23; Senn N, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001195; Shah D, 1999, Indian Pediatr, V36, P767; SHANN F, 1984, LANCET, V2, P537; VELEMA JP, 1991, INT J EPIDEMIOL, V20, P474, DOI 10.1093/ije/20.2.474; WHO, 2012, WORLD MALARIA REPORT 2012, P1; WHO, 2005, COUNTR HLTH INF PROF; WHO, 2007, INT MAN CHILDH ILLN	37	22	22	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 13	2014	9	3							e90990	10.1371/journal.pone.0090990	http://dx.doi.org/10.1371/journal.pone.0090990			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC9JS	24626194	Green Accepted, Green Published, gold			2023-01-03	WOS:000332851300048
J	Grieb, B; Engler, G; Sharott, A; von Nicolai, C; Streichert, T; Papageorgiou, I; Schulte, A; Westphal, M; Lamszus, K; Engel, AK; Moll, CKE; Hamel, W				Grieb, Benjamin; Engler, Gerhard; Sharott, Andrew; von Nicolai, Constantin; Streichert, Thomas; Papageorgiou, Ismini; Schulte, Alexander; Westphal, Manfred; Lamszus, Katrin; Engel, Andreas K.; Moll, Christian K. E.; Hamel, Wolfgang			High-Frequency Stimulation of the Subthalamic Nucleus Counteracts Cortical Expression of Major Histocompatibility Complex Genes in a Rat Model of Parkinson's Disease	PLOS ONE			English	Article							DEEP-BRAIN-STIMULATION; CLASS-II INDUCIBILITY; SUBSTANTIA-NIGRA; 6-HYDROXYDOPAMINE LESION; DOPAMINERGIC-NEURONS; BETA-OSCILLATIONS; CEREBRAL-CORTEX; MESSENGER-RNA; BASAL GANGLIA; MOTOR CORTEX	High-frequency stimulation of the subthalamic nucleus (STN-HFS) is widely used as therapeutic intervention in patients suffering from advanced Parkinson's disease. STN-HFS exerts a powerful modulatory effect on cortical motor control by orthodromic modulation of basal ganglia outflow and via antidromic activation of corticofugal fibers. However, STN-HFS-induced changes of the sensorimotor cortex are hitherto unexplored. To address this question at a genomic level, we performed mRNA expression analyses using Affymetrix microarray gene chips and real-time RT-PCR in sensorimotor cortex of parkinsonian and control rats following STN-HFS. Experimental parkinsonism was induced in Brown Norway rats by bilateral nigral injections of 6-hydroxydopamine and was assessed histologically, behaviorally, and electrophysiologically. We applied prolonged (23h) unilateral STN-HFS in awake and freely moving animals, with the non-stimulated hemisphere serving as an internal control for gene expression analyses. Gene enrichment analysis revealed strongest regulation in major histocompatibility complex (MHC) related genes. STN-HFS led to a cortical downregulation of several MHC class II (RT1-Da, Db1, Ba, and Cd74) and MHC class I (RT1CE) encoding genes. The same set of genes showed increased expression levels in a comparison addressing the effect of 6-hydroxydopamine lesioning. Hence, our data suggest the possible association of altered microglial activity and synaptic transmission by STN-HFS within the sensorimotor cortex of 6-hydroxydopamine treated rats.	[Grieb, Benjamin; Engler, Gerhard; Sharott, Andrew; von Nicolai, Constantin; Engel, Andreas K.; Moll, Christian K. E.] Univ Med Ctr Hamburg Eppendorf, Dept Neurophysiol & Pathophysiol, Hamburg, Germany; [Streichert, Thomas] Univ Med Ctr Hamburg Eppendorf, Dept Clin Chem, Hamburg, Germany; [Papageorgiou, Ismini] Heidelberg Univ, Inst Physiol & Pathophysiol, Div Gen Neurophysiol, Heidelberg, Germany; [Schulte, Alexander; Westphal, Manfred; Lamszus, Katrin; Hamel, Wolfgang] Univ Med Ctr Hamburg Eppendorf, Dept Neurosurg, Hamburg, Germany; [Grieb, Benjamin] Heidelberg Univ, Ctr Psychosocial Med, Dept Gen Psychiat, Heidelberg, Germany; [von Nicolai, Constantin] Univ Tubingen, Ctr Integrat Neurosci, Tubingen, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ruprecht Karls University Heidelberg; Eberhard Karls University of Tubingen	Grieb, B (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Neurophysiol & Pathophysiol, Hamburg, Germany.	benjamin.grieb@med.uni-heidelberg.de	Engel, Andreas K./AAH-6384-2019; Engel, Andreas K/C-7781-2012; Papageorgiou, Ismini/AAI-7329-2020; /H-8186-2012	Engel, Andreas K./0000-0003-4899-8466; Engel, Andreas K/0000-0003-4899-8466; Papageorgiou, Ismini/0000-0001-5810-0483; Sharott, Andrew/0000-0002-1594-3349	University Medical Center Hamburg-Eppendorf	University Medical Center Hamburg-Eppendorf	The study received intramural funding from the University Medical Center Hamburg-Eppendorf. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AGNEW WF, 1986, EXP NEUROL, V92, P162, DOI 10.1016/0014-4886(86)90132-9; AKIYAMA H, 1989, BRAIN RES, V489, P247, DOI 10.1016/0006-8993(89)90857-3; Alberts JL, 2008, EXP NEUROL, V214, P1, DOI 10.1016/j.expneurol.2008.07.019; ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; Alla JA, 2009, BIOCHEM BIOPH RES CO, V387, P186, DOI 10.1016/j.bbrc.2009.07.011; Ashby P, 2001, CLIN NEUROPHYSIOL, V112, P431, DOI 10.1016/S1388-2457(00)00532-0; Baker KB, 2002, MOVEMENT DISORD, V17, P969, DOI 10.1002/mds.10206; Bar-Gad I, 2003, PROG NEUROBIOL, V71, P439, DOI 10.1016/j.pneurobio.2003.12.001; BENABID AL, 1994, STEREOT FUNCT NEUROS, V62, P76, DOI 10.1159/000098600; Brazhnik E, 2012, J NEUROSCI, V32, P7869, DOI 10.1523/JNEUROSCI.0943-12.2012; Cassidy M, 2002, BRAIN, V125, P1235, DOI 10.1093/brain/awf135; Chung SJ, 2006, EUR NEUROL, V56, P127, DOI 10.1159/000095704; Cirelli C, 2004, NEURON, V41, P35, DOI 10.1016/S0896-6273(03)00814-6; Corriveau RA, 1998, NEURON, V21, P505, DOI 10.1016/S0896-6273(00)80562-0; Darbaky Y, 2003, EUR J NEUROSCI, V18, P951, DOI 10.1046/j.1460-9568.2003.02803.x; Dejean C, 2009, CEREB CORTEX, V19, P1055, DOI 10.1093/cercor/bhn149; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Deuschl G, 2006, NEW ENGL J MED, V355, P896, DOI 10.1056/NEJMoa060281; Drai D, 2000, J NEUROSCI METH, V96, P119, DOI 10.1016/S0165-0270(99)00194-6; Dymecki J, 1996, FOLIA NEUROPATHOL, V34, P102; Ferro MM, 2005, J NEUROSCI METH, V148, P78, DOI 10.1016/j.jneumeth.2005.04.005; Fox CM, 2001, BRAIN RES, V896, P56, DOI 10.1016/S0006-8993(00)03270-4; Gimsa U, 2006, J NEUROSCI METH, V150, P212, DOI 10.1016/j.jneumeth.2005.06.013; Gradinaru V, 2009, SCIENCE, V324, P354, DOI 10.1126/science.1167093; Grieb B, 2013, FRONT SYST NEUROSCI, V7, DOI 10.3389/fnsys.2013.00095; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Hammond C, 2007, TRENDS NEUROSCI, V30, P357, DOI 10.1016/j.tins.2007.05.004; Harnack D, 2004, J NEUROSCI METH, V138, P207, DOI 10.1016/j.jneumeth.2004.04.019; Harnack D, 2008, EXP NEUROL, V210, P257, DOI 10.1016/j.expneurol.2007.10.002; Havik B, 2007, NEUROSCIENCE, V148, P925, DOI 10.1016/j.neuroscience.2007.07.024; Healy-Stoffel M, 2012, J NEUROSCI METH, V210, P187, DOI 10.1016/j.jneumeth.2012.07.013; Henning J, 2007, EUR J NEUROSCI, V25, P239, DOI 10.1111/j.1460-9568.2006.05264.x; HIRSCH E, 1988, NATURE, V334, P345, DOI 10.1038/334345a0; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huh GS, 2000, SCIENCE, V290, P2155, DOI 10.1126/science.290.5499.2155; Hummon AB, 2007, BIOTECHNIQUES, V42, P467, DOI 10.2144/000112401; Imamura K, 2003, ACTA NEUROPATHOL, V106, P518, DOI 10.1007/s00401-003-0766-2; Kadar E, 2011, BRAIN RES, V1391, P1, DOI 10.1016/j.brainres.2011.03.059; Kemmel V, 2010, PHYSIOL GENOMICS, V41, P146, DOI 10.1152/physiolgenomics.00208.2009; KITAI ST, 1981, BRAIN RES, V214, P411, DOI 10.1016/0006-8993(81)91204-X; Krack P, 2002, MOVEMENT DISORD, V17, pS188, DOI 10.1002/mds.10163; Kuriakose R, 2010, CEREB CORTEX, V20, P1926, DOI 10.1093/cercor/bhp269; Levy R, 2002, J NEUROSCI, V22, P2855, DOI 10.1523/JNEUROSCI.22-07-02855.2002; Li S, 2007, J NEUROPHYSIOL, V98, P3525, DOI 10.1152/jn.00808.2007; Liu F, 2011, CURR NEUROPHARMACOL, V9, P260, DOI 10.2174/157015911795017155; MacKinnon CD, 2005, EUR J NEUROSCI, V21, P1394, DOI 10.1111/j.1460-9568.2005.03952.x; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; McRitchie DA, 1997, EXP NEUROL, V144, P202, DOI 10.1006/exnr.1997.6418; Monakow K H, 1978, Exp Brain Res, V33, P395; Nambu A, 2005, J NEUROL, V252, P1, DOI 10.1007/s00415-005-4002-y; Neumann H, 1998, P NATL ACAD SCI USA, V95, P5779, DOI 10.1073/pnas.95.10.5779; Neumann H, 1996, EUR J NEUROSCI, V8, P2582, DOI 10.1111/j.1460-9568.1996.tb01552.x; Neumann H, 2001, GLIA, V36, P191, DOI 10.1002/glia.1108; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Paxinos G., 2005, RAT BRAIN STEREOTAXI; PENNYPACKER KR, 1995, TRENDS PHARMACOL SCI, V16, P317, DOI 10.1016/S0165-6147(00)89061-6; Raz A, 2010, ANESTH ANALG, V111, P1285, DOI 10.1213/ANE.0b013e3181f565f2; SAKAI K, 1994, BRAIN RES, V633, P144, DOI 10.1016/0006-8993(94)91533-4; Sarro SM, 2010, LEUKEMIA RES, V34, P1670, DOI 10.1016/j.leukres.2010.06.031; Schulte A, 2011, GLIA, V59, P590, DOI 10.1002/glia.21127; Schulte T, 2006, NEUROSCIENCE, V138, P1377, DOI 10.1016/j.neuroscience.2005.12.034; Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098; Schwarting RKW, 1996, PROG NEUROBIOL, V50, P275, DOI 10.1016/S0301-0082(96)00040-8; Sharott A, 2005, EUR J NEUROSCI, V21, P1413, DOI 10.1111/j.1460-9568.2005.03973.x; Shebl FM, 2010, CANCER EPIDEM BIOMAR, V19, P978, DOI 10.1158/1055-9965.EPI-10-0064; Shen KZ, 2003, SYNAPSE, V50, P314, DOI 10.1002/syn.10274; Spieles-Engemann AL, 2011, J PARKINSON DIS, V1, P123, DOI 10.3233/JPD-2011-11008; Strackx E, 2008, EXP NEUROL, V211, P413, DOI 10.1016/j.expneurol.2008.02.006; Tan SJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021328; Temel Y, 2004, NEUROSCI LETT, V367, P92, DOI 10.1016/j.neulet.2004.05.087; Temel Y, 2005, EXP NEUROL, V193, P43, DOI 10.1016/j.expneurol.2004.12.025; Temperli P, 2003, NEUROLOGY, V60, P78, DOI 10.1212/WNL.60.1.78; Thobois S, 2010, BRAIN, V133, P1111, DOI 10.1093/brain/awq032; Tian Q, 2004, MOL CELL PROTEOMICS, V3, P960, DOI 10.1074/mcp.M400055-MCP200; UHL GR, 1985, NEUROLOGY, V35, P1215, DOI 10.1212/WNL.35.8.1215; Vogel C, 2012, NAT REV GENET, V13, P227, DOI 10.1038/nrg3185; Walker HC, 2012, MOVEMENT DISORD, V27, P1404, DOI 10.1002/mds.25137; Walker HC, 2009, NEUROSURGERY, V65, P302, DOI 10.1227/01.NEU.0000349764.34211.74; Walker QD, 2012, NEUROPHARMACOLOGY, V62, P2267, DOI 10.1016/j.neuropharm.2012.01.029; West MJ, 2002, PROG BRAIN RES, V135, P43; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; WONG GHW, 1984, NATURE, V310, P688, DOI 10.1038/310688a0; Zaidel A, 2010, BRAIN, V133, P2007, DOI 10.1093/brain/awq144	85	5	5	2	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2014	9	3							e91663	10.1371/journal.pone.0091663	http://dx.doi.org/10.1371/journal.pone.0091663			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC9HN	24621597	gold, Green Published, Green Submitted			2023-01-03	WOS:000332845300114
J	Forkpah, C; Dixon, LR; Fahrbach, SE; Rueppell, O				Forkpah, Cordelia; Dixon, Luke R.; Fahrbach, Susan E.; Rueppell, Olav			Xenobiotic Effects on Intestinal Stem Cell Proliferation in Adult Honey Bee (Apis mellifera L) Workers	PLOS ONE			English	Article							COLONY COLLAPSE DISORDER; PESTICIDE-RESIDUES; HYMENOPTERA; EXPOSURE; MIDGUT; TOXICITY; MICROSPORIDIA; SENSITIVITY; MICROFLORA; ACARICIDES	The causes of the current global decline in honey bee health are unknown. One major group of hypotheses invokes the pesticides and other xenobiotics to which this important pollinator species is often exposed. Most studies have focused on mortality or behavioral deficiencies in exposed honey bees while neglecting other biological functions and target organs. The midgut epithelium of honey bees presents an important interface between the insect and its environment. It is maintained by proliferation of intestinal stem cells throughout the adult life of honey bees. We used caged honey bees to test multiple xenobiotics for effects on the replicative activity of the intestinal stem cells under laboratory conditions. Most of the tested compounds did not alter the replicative activity of intestinal stem cells. However, colchicine, methoxyfenozide, tetracycline, and a combination of coumaphos and tau-fluvalinate significantly affected proliferation rate. All substances except methoxyfenozide decreased proliferation rate. Thus, the results indicate that some xenobiotics frequently used in apiculture and known to accumulate in honey bee hives may have hitherto unknown physiological effects. The nutritional status and the susceptibility to pathogens of honey bees could be compromised by the impacts of xenobiotics on the maintenance of the midgut epithelium. This study contributes to a growing body of evidence that more comprehensive testing of xenobiotics may be required before novel or existing compounds can be considered safe for honey bees and other non-target species.	[Forkpah, Cordelia; Dixon, Luke R.; Rueppell, Olav] Univ N Carolina, Dept Biol, Greensboro, NC 27412 USA; [Fahrbach, Susan E.] Wake Forest Univ, Dept Biol, Winston Salem, NC 27109 USA	University of North Carolina; University of North Carolina Greensboro; Wake Forest University	Rueppell, O (corresponding author), Univ N Carolina, Dept Biol, Greensboro, NC 27412 USA.	olav_rueppell@uncg.edu	Rueppell, Olav/G-2679-2010	Rueppell, Olav/0000-0001-5370-4229	North Carolina Biotechnology Center; USDA National Institute of Food and Agriculture [2010-65104-20533]; Division Of Integrative Organismal Systems [1256878] Funding Source: National Science Foundation	North Carolina Biotechnology Center; USDA National Institute of Food and Agriculture(United States Department of Agriculture (USDA)); Division Of Integrative Organismal Systems(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO))	This project was supported by the North Carolina Biotechnology Center and the Agriculture and Food Research Initiative Competitive Grant no. 2010-65104-20533 from the USDA National Institute of Food and Agriculture. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alaux C, 2010, BIOL LETTERS, V6, P562, DOI 10.1098/rsbl.2009.0986; Bendahou N, 1999, ECOTOX ENVIRON SAFE, V44, P147, DOI 10.1006/eesa.1999.1812; Berry JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076536; Blacquiere T, 2012, ECOTOXICOLOGY, V21, P973, DOI 10.1007/s10646-012-0863-x; Boncristiani H, 2012, J INSECT PHYSIOL, V58, P613, DOI 10.1016/j.jinsphys.2011.12.011; Bryden J, 2013, ECOL LETT, V16, P1463, DOI 10.1111/ele.12188; Buchon N, 2009, GENE DEV, V23, P2333, DOI 10.1101/gad.1827009; Carlson GR, 2001, PEST MANAG SCI, V57, P115, DOI 10.1002/1526-4998(200102)57:2<115::AID-PS245>3.0.CO;2-A; Chauzat MP, 2006, J ECON ENTOMOL, V99, P253, DOI 10.1603/0022-0493-99.2.253; Chopra I, 2001, MICROBIOL MOL BIOL R, V65, P232, DOI 10.1128/MMBR.65.2.232-260.2001; Cox-Foster DL, 2007, SCIENCE, V318, P283, DOI 10.1126/science.1146498; Decourtye A, 2013, NATURE, V497, P188, DOI 10.1038/497188a; Desneux N, 2007, ANNU REV ENTOMOL, V52, P81, DOI 10.1146/annurev.ento.52.110405.091440; Ellis JD, 2010, J APICULT RES, V49, P134, DOI 10.3896/IBRA.1.49.1.30; Fernandes KM, 2010, SOCIOBIOLOGY, V56, P489; FEYEREISEN R, 1976, GEN COMP ENDOCR, V29, P319, DOI 10.1016/0016-6480(76)90044-7; Gallai N, 2009, ECOL ECON, V68, P810, DOI 10.1016/j.ecolecon.2008.06.014; Genersch E, 2010, APIDOLOGIE, V41, P332, DOI 10.1051/apido/2010014; Gill RJ, 2012, NATURE, V491, P105, DOI 10.1038/nature11585; Gilliam M, 1997, FEMS MICROBIOL LETT, V155, P1; Gregorc A, 2011, PESTIC BIOCHEM PHYS, V99, P200, DOI 10.1016/j.pestbp.2010.12.005; Hakim RS, 2010, ANNU REV ENTOMOL, V55, P593, DOI 10.1146/annurev-ento-112408-085450; Han P, 2012, ECOTOXICOLOGY, V21, P2214, DOI 10.1007/s10646-012-0976-2; Hawthorne DJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026796; Henry M, 2012, SCIENCE, V336, P348, DOI 10.1126/science.1215039; Heylen K, 2011, APIDOLOGIE, V42, P103, DOI 10.1051/apido/2010043; Higes M, 2013, ENV MICROBIOL REP, V5, P17, DOI 10.1111/1758-2229.12024; James RR, 2012, J INVERTEBR PATHOL, V109, P175, DOI 10.1016/j.jip.2011.12.005; Johnson RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054092; Johnson RM, 2010, APIDOLOGIE, V41, P312, DOI 10.1051/apido/2010018; Johnson RM, 2009, P NATL ACAD SCI USA, V106, P14790, DOI 10.1073/pnas.0906970106; Johnson RM, 2009, J ECON ENTOMOL, V102, P474, DOI 10.1603/029.102.0202; Kakmand F. A., 2008, J DOHUK U, V11, P144; Krupke CH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029268; Mao WF, 2011, P NATL ACAD SCI USA, V108, P12657, DOI 10.1073/pnas.1109535108; Martel AC, 2006, FOOD ADDIT CONTAM A, V23, P265, DOI 10.1080/02652030500469048; Martinson VG, 2012, APPL ENVIRON MICROB, V78, P2830, DOI 10.1128/AEM.07810-11; Mattila HR, 2006, J ECON ENTOMOL, V99, P604, DOI 10.1603/0022-0493-99.3.604; Morse RA, 2000, BEE CULT, V128, P1, DOI DOI 10.3896/IBRA.1.49.1.01; Mullin CA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009754; Nazzi F, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002735; Neumann P, 2010, J APICULT RES, V49, P1, DOI 10.3896/IBRA.1.49.1.01; Ninov N, 2009, PLOS BIOL, V7, P892, DOI 10.1371/journal.pbio.1000079; Ohlstein B, 2006, NATURE, V439, P470, DOI 10.1038/nature04333; Palmer MJ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2648; Pettis JS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070182; Pettis JS, 2012, NATURWISSENSCHAFTEN, V99, P153, DOI 10.1007/s00114-011-0881-1; Rada V, 1997, APIDOLOGIE, V28, P357, DOI 10.1051/apido:19970603; Rharrabe K, 2009, PESTIC BIOCHEM PHYS, V93, P112, DOI 10.1016/j.pestbp.2008.12.002; Rinderer TE, 2012, J APICULT RES, V51, P218, DOI 10.3896/IBRA.1.51.2.13; Smagghe G, 2005, ANN NY ACAD SCI, V1040, P472, DOI 10.1196/annals.1327.094; SMIRLE MJ, 1984, J ECON ENTOMOL, V77, P63, DOI 10.1093/jee/77.1.63; Snodgrass R.E., 1956, ANATOMY HONEY BEE; Sullivan JT, 2005, J INVERTEBR PATHOL, V90, P32, DOI 10.1016/j.jip.2005.04.005; Thompson HM, 2005, FOOD ADDIT CONTAM, V22, P573, DOI 10.1080/02652030500089986; Vachon V, 2012, J INVERTEBR PATHOL, V111, P1, DOI 10.1016/j.jip.2012.05.001; vanEngelsdorp D, 2010, J ECON ENTOMOL, V103, P1517, DOI 10.1603/EC09429; vanEngelsdorp D, 2010, J INVERTEBR PATHOL, V103, pS80, DOI 10.1016/j.jip.2009.06.011; vanEngelsdorp D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006481; WAHL O, 1983, OECOLOGIA, V59, P106, DOI 10.1007/BF00388082; Ward KN, 2008, EXP GERONTOL, V43, P530, DOI 10.1016/j.exger.2008.03.012; Willard LE, 2011, APIDOLOGIE, V42, P508, DOI 10.1007/s13592-011-0006-z; Williams GR, 2013, J APICULT RES, V52, DOI 10.3896/IBRA.1.52.1.04; Williamson SM, 2013, J EXP BIOL, V216, P1799, DOI 10.1242/jeb.083931; Wu JY, 2012, J INVERTEBR PATHOL, V109, P326, DOI 10.1016/j.jip.2012.01.005; Wu JY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014720; Yang EC, 2008, J ECON ENTOMOL, V101, P1743, DOI 10.1603/0022-0493-101.6.1743; Yang EC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049472	68	21	22	1	52	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2014	9	3							e91180	10.1371/journal.pone.0091180	http://dx.doi.org/10.1371/journal.pone.0091180			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC4IY	24608542	Green Published, gold, Green Submitted			2023-01-03	WOS:000332485800111
J	Noble, AJ; McCrone, P; Seed, PT; Goldstein, LH; Ridsdale, L				Noble, Adam J.; McCrone, Paul; Seed, Paul T.; Goldstein, Laura H.; Ridsdale, Leone			Clinical- and Cost-Effectiveness of a Nurse Led Self-Management Intervention to Reduce Emergency Visits by People with Epilepsy	PLOS ONE			English	Article							QUALITY-OF-LIFE; CARE; QUESTIONNAIRE; DEPARTMENTS; POPULATION; DEPRESSION; KNOWLEDGE; SERVICES; ANXIETY; EUROPE	People with chronic epilepsy (PWE) often make costly, and clinically unnecessary emergency department (ED) visits. Some do it frequently. No studies have examined interventions to reduce them. An intervention delivered by an epilepsy nurse specialist (ENS) might reduce visits. The rationale is it may optimize patients' self-management skills and knowledge of appropriate ED use. We examined such an intervention's clinical-and cost-effectiveness. Eighty-five adults with epilepsy were recruited from three London EDs with similar catchment populations. Forty-one PWE recruited from two EDs received treatment-as-usual (TAU) and formed the comparison group. The remaining 44 PWE were recruited from the ED of a hospital that had implemented a new ENS service for PWE attending ED. These participants formed the intervention group. They were offered 2 one-to-one sessions with an ENS, plus TAU. Participants completed questionnaires on health service use and psychosocial well-being at baseline, 6- and 12-month follow-up. Covariates were identified and adjustments made. Sixty-nine (81%) participants were retained at follow-up. No significant effect of the intervention on ED visits at 12 months or on other outcomes was found. However, due to less time as inpatients, the average service cost for intervention participants over follow-up was less than for TAU participants' (adjusted difference 558 pound, 95% CI, -2409 pound, 648) pound. Covariates most predictive of subsequent ED visits were patients' baseline feelings of stigmatization due to epilepsy and low confidence in managing epilepsy. The intervention did not lead to a reduction in ED use, but did not cost more, partly because those receiving the intervention had shorter hospital admissions. Our findings on long-term ED predictors clarifies what causes ED use, and suggests that future interventions might focus more on patients' perceptions of stigma and on their confidence in managing epilepsy. If addressed, ED visits might be reduced and efficiency-savings generated.	[Noble, Adam J.] Univ Liverpool, Inst Psychol Hlth & Soc, Dept Psychol Sci, Liverpool L69 3BX, Merseyside, England; [Noble, Adam J.; Ridsdale, Leone] Kings Coll London, Inst Psychiat, Dept Clin Neurosci, London WC2R 2LS, England; [McCrone, Paul] Kings Coll London, Inst Psychiat, London WC2R 2LS, England; [Seed, Paul T.] Kings Coll London, Div Womens Hlth, London WC2R 2LS, England; [Goldstein, Laura H.] Kings Coll London, Inst Psychiat, Dept Psychol, London WC2R 2LS, England	University of Liverpool; University of London; King's College London; University of London; King's College London; University of London; King's College London; University of London; King's College London	Noble, AJ (corresponding author), Univ Liverpool, Inst Psychol Hlth & Soc, Dept Psychol Sci, Liverpool L69 3BX, Merseyside, England.	adam.noble@liv.ac.uk	; Seed, Paul T/C-4435-2008; Goldstein, Laura/E-7817-2010	McCrone, Paul/0000-0001-7001-4502; Seed, Paul T/0000-0001-7904-7933; Noble, Adam/0000-0002-8070-4352; Goldstein, Laura/0000-0001-9387-3035; Ridsdale, Leone/0000-0002-2234-2859	National Institute for Health Research (NIHR) Health Services and Delivery Research (HSR) programme [08/1808/247]; NIHR Dementia Biomedical Research Unit at South London and Maudsley NHS Foundation Trust; NIHR Dementia Biomedical Research Unit at King's College London; National Institute for Health Research [08/1815/234] Funding Source: researchfish	National Institute for Health Research (NIHR) Health Services and Delivery Research (HSR) programme(National Institute for Health Research (NIHR)); NIHR Dementia Biomedical Research Unit at South London and Maudsley NHS Foundation Trust; NIHR Dementia Biomedical Research Unit at King's College London; National Institute for Health Research(National Institute for Health Research (NIHR))	The project was supported by funding from the National Institute for Health Research (NIHR) Health Services and Delivery Research (HS&R) programme (08/1808/247) and the NIHR Dementia Biomedical Research Unit at South London and Maudsley NHS Foundation Trust and King's College London. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The views and opinions expressed are those of the authors and do not necessarily reflect those of the HS&DR programme, NIHR, NHS or the Department of Health.	Amiel S, 2002, BRIT MED J, V325, P746, DOI 10.1136/bmj.325.7367.746; Babyak MA, 2004, PSYCHOSOM MED, V66, P411, DOI 10.1097/01.psy.0000127692.23278.a9; BAKER GA, 1993, EPILEPSY RES, V16, P65, DOI 10.1016/0920-1211(93)90041-5; Baker GA, 1998, SEIZURE-EUR J EPILEP, V7, P201, DOI 10.1016/S1059-1311(98)80036-8; Bautista RED, 2008, EPILEPSY RES, V79, P120, DOI 10.1016/j.eplepsyres.2008.01.003; Beecham J, 1992, MEASURING MENTAL HLT, P163; Bradley P., 2009, COCHRANE DB SYST REV, V2008; Casado V, 2011, NEUROLOGIA, V26, P233, DOI 10.1016/j.nrl.2010.07.033; Cramer JA, 1996, EPILEPSIA, V37, P577, DOI 10.1111/j.1528-1157.1996.tb00612.x; Curtis L., 2010, UNIT COSTS HLTH SOCI; Department of Health, 2012, CAS STUD 2 EM ADM EP; Department of Health, 2010, NHS REF COSTS 2009 1; DiIorio C, 1996, NURS RES, V45, P211, DOI 10.1097/00006199-199607000-00004; Dolan P, 1995, SOCIAL TARIFF EUROQO; Elhai JD, 2008, PSYCHIAT RES, V160, P129, DOI 10.1016/j.psychres.2007.07.003; Faught E, 2008, NEUROLOGY, V71, P1572, DOI 10.1212/01.wnl.0000319693.10338.b9; Forsgren L, 2005, EUR J NEUROL, V12, P245, DOI 10.1111/j.1468-1331.2004.00992.x; Fraser RT, 2011, EPILEPSY BEHAV, V20, P291, DOI 10.1016/j.yebeh.2010.10.010; HART YM, 1995, EPILEPSY RES, V21, P51, DOI 10.1016/0920-1211(95)00008-X; Helde G, 2005, EPILEPSY BEHAV, V7, P451, DOI 10.1016/j.yebeh.2005.06.008; Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V286, P821, DOI 10.1001/jama.286.7.821; Jacoby A, 1998, EPILEPSIA, V39, P776, DOI 10.1111/j.1528-1157.1998.tb01164.x; JARVIE S, 1993, SEIZURE, V2, P179, DOI 10.1016/S1059-1311(05)80125-6; Kitson A, 2000, SERVICES PATIENTS EP; Mills N, 1999, SEIZURE-EUR J EPILEP, V8, P1; National Institute for Health and Care Excellence, 2012, MEAS EFF COST EFF QA; National Society for Epilepsy, 2012, DIAL 999; Ndiapi Njankouo, 2011, INT SCI C HARDWOOD P; NHS Right Care, 2010, NHS ATL VAR HEALTHC; Noble AJ, 2013, J NEUROL, V260, P1022, DOI 10.1007/s00415-012-6749-2; Noble AJ, 2012, EPILEPSIA, V53, P1820, DOI 10.1111/j.1528-1167.2012.03586.x; Olesen J, 2012, EUR J NEUROL, V19, P155, DOI 10.1111/j.1468-1331.2011.03590.x; Parmar MK, 1995, SURVIVAL ANAL PRACTI, P193; Pearson M, 2012, NATL AUDIT SEIZURE M; Public Health England, 2010, PROF LOC HLTH; Pugliatti M, 2007, EPILEPSIA, V48, P2224; Ramaratnam S, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002029.pub3; Ridsdale L, 2000, EPILEPSIA, V41, P1014, DOI 10.1111/j.1528-1157.2000.tb00287.x; Ridsdale L, 1999, BRIT J GEN PRACT, V49, P285; Ridsdale L, 1997, BRIT MED J, V314, P120, DOI 10.1136/bmj.314.7074.120; Ridsdale L, 2012, EPILEPSY BEHAV, V25, P529, DOI 10.1016/j.yebeh.2012.09.034; Royl G, 2010, NERVENARZT, V81, P1226, DOI 10.1007/s00115-010-3020-x; Tan JH, 2005, SEIZURE-EUR J EPILEP, V14, P464, DOI 10.1016/j.seizure.2005.07.010; Tapp S, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003000.pub2; Tatum WO, 2008, EPILEPSY RES, V82, P156, DOI 10.1016/j.eplepsyres.2008.07.017; Taylor J, 2011, EPILEPSY BEHAV, V21, P255, DOI 10.1016/j.yebeh.2011.04.002; Thapar A, 2009, EPILEPSY BEHAV, V14, P134, DOI 10.1016/j.yebeh.2008.09.004; The Health and Social Care Information Centre, 2010, DIS PREV QUAL O UTC; The Health and Social Care Information Centre, 2011, INP STAT 2010 11 PRI; WAGNER AK, 1995, QUAL LIFE RES, V4, P115, DOI 10.1007/BF01833606; Warren E, 1998, EVALUATION NURSE SPE; WILBY J, 2005, HLTH TECHNOLOGY ASSE, V9; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	54	28	29	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 6	2014	9	3							e90789	10.1371/journal.pone.0090789	http://dx.doi.org/10.1371/journal.pone.0090789			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AC4ID	24603669	Green Published, gold			2023-01-03	WOS:000332483600086
J	Wang, ZQ; Liang, PP; Zhao, ZL; Han, Y; Song, HQ; Xu, JY; Lu, J; Li, KC				Wang, Zhiqun; Liang, Peipeng; Zhao, Zhilian; Han, Ying; Song, Haiqing; Xu, Jianyang; Lu, Jie; Li, Kuncheng			Acupuncture Modulates Resting State Hippocampal Functional Connectivity in Alzheimer Disease	PLOS ONE			English	Article							MILD COGNITIVE IMPAIRMENT; APOLIPOPROTEIN-E GENOTYPE; BRAIN NETWORKS; DEFAULT-MODE; EARLY-DIAGNOSIS; FMRI; MRI; ASYMMETRY; CORTEX; DEMENTIA	Our objective is to clarify the effects of acupuncture on hippocampal connectivity in patients with Alzheimer disease (AD) using functional magnetic resonance imaging (fMRI). Twenty-eight right-handed subjects (14 AD patients and 14 healthy elders) participated in this study. Clinical and neuropsychological examinations were performed on all subjects. MRI was performed using a SIEMENS verio 3-Tesla scanner. The fMRI study used a single block experimental design. We first acquired baseline resting state data during the initial 3 minutes and then performed acupuncture stimulation on the Tai chong and He gu acupoints for 3 minutes. Last, we acquired fMRI data for another 10 minutes after the needle was withdrawn. The preprocessing and data analysis were performed using statistical parametric mapping (SPM5) software. Two-sample t-tests were performed using data from the two groups in different states. We found that during the resting state, several frontal and temporal regions showed decreased hippocampal connectivity in AD patients relative to control subjects. During the resting state following acupuncture, AD patients showed increased connectivity in most of these hippocampus related regions compared to the first resting state. In conclusion, we investigated the effect of acupuncture on AD patients by combing fMRI and traditional acupuncture. Our fMRI study confirmed that acupuncture at Tai chong and He gu can enhance the hippocampal connectivity in AD patients.	[Wang, Zhiqun; Liang, Peipeng; Zhao, Zhilian; Lu, Jie; Li, Kuncheng] Capital Med Univ, Dept Radiol, Xuanwu Hosp, Beijing, Peoples R China; [Han, Ying; Song, Haiqing] Capital Med Univ, Dept Neurol, Xuanwu Hosp, Beijing, Peoples R China; [Xu, Jianyang] Chinese Peoples Armed Police Forces, Gen Hosp, Beijing, Peoples R China; [Li, Kuncheng] Minist Educ, Key Lab Neurodegenerat Dis, Beijing, Peoples R China; [Liang, Peipeng; Li, Kuncheng] Beijing Key Lab Magnet Resonance Imaging & Brain, Beijing, Peoples R China	Capital Medical University; Capital Medical University	Lu, J (corresponding author), Capital Med Univ, Dept Radiol, Xuanwu Hosp, Beijing, Peoples R China.	lujie@xwh.ccmu.edu.cn; likuncheng@xwh.ccmu.edu.cn	Han, Ying/H-7111-2017; Lu, Jie/GNW-3367-2022		Scientific Research Foundation for the Returned Overseas Chinese Scholars; Natural Science Foundation of China [81000606, 81370037, 61105118, 81141018, 81030028, 81225012]; China Postdoctoral Science Foundation [201003142];  [Z101107052210002];  [Z111107067311036]	Scientific Research Foundation for the Returned Overseas Chinese Scholars(Scientific Research Foundation for the Returned Overseas Chinese Scholars); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); ; 	This work was supported by the Project Sponsored by the Scientific Research Foundation for the Returned Overseas Chinese Scholars, the Natural Science Foundation of China (Grant No. 81000606, 81370037, 61105118, 81141018, 81030028, and 81225012), China Postdoctoral Science Foundation funded project (No. 201003142), and Key Work of Special Project supported by the city government (Z101107052210002 and Z111107067311036). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen G, 2007, ARCH NEUROL-CHICAGO, V64, P1482, DOI 10.1001/archneur.64.10.1482; American Psychiatric Association (Washington), 1994, DSM 4, V4th; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Backman L, 1999, NEUROLOGY, V52, P1861, DOI 10.1212/WNL.52.9.1861; Bai F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029288; Bai F, 2009, BIOL PSYCHIAT, V65, P951, DOI 10.1016/j.biopsych.2008.10.017; Bai LJ, 2009, BRAIN RES, V1279, P37, DOI 10.1016/j.brainres.2009.04.056; Bigler ED, 2002, J INT NEUROPSYCH SOC, V8, P925, DOI 10.1017/S1355617702870072; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; BRAAK H, 1995, NEUROBIOL AGING, V16, P271, DOI 10.1016/0197-4580(95)00021-6; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Buckner RL, 2005, J NEUROSCI, V25, P7709, DOI 10.1523/JNEUROSCI.2177-05.2005; Chetelat G, 2003, NEUROIMAGE, V18, P525, DOI 10.1016/S1053-8119(02)00026-5; Desikan RS, 2009, BRAIN; Dhond RP, 2008, PAIN, V136, P407, DOI 10.1016/j.pain.2008.01.011; Fang JL, 2009, HUM BRAIN MAPP, V30, P1196, DOI 10.1002/hbm.20583; Feng YY, 2012, MAGN RESON IMAGING, V30, P672, DOI 10.1016/j.mri.2012.01.003; Feng YY, 2011, MAGN RESON IMAGING, V29, P958, DOI 10.1016/j.mri.2011.04.009; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Geroldi C, 2000, J NEUROL NEUROSUR PS, V68, P93, DOI 10.1136/jnnp.68.1.93; Goveas JS, 2011, J MAGN RESON IMAGING, V34, P764, DOI 10.1002/jmri.22662; Grady CL, 2003, J NEUROSCI, V23, P986, DOI 10.1523/jneurosci.23-03-00986.2003; Greicius MD, 2004, P NATL ACAD SCI USA, V101, P4637, DOI 10.1073/pnas.0308627101; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Li SJ, 2002, RADIOLOGY, V225, P253, DOI 10.1148/radiol.2251011301; Liang PP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022153; Liu ZY, 2012, PSYCHIAT RES-NEUROIM, V202, P118, DOI 10.1016/j.pscychresns.2012.03.002; Lowe MJ, 1998, NEUROIMAGE, V7, P119, DOI 10.1006/nimg.1997.0315; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Pedraza O, 2004, J INT NEUROPSYCH SOC, V10, P664, DOI 10.1017/S1355617704105080; Pennanen C, 2004, NEUROBIOL AGING, V25, P303, DOI 10.1016/S0197-4580(03)00084-8; Petrella JR, 2003, RADIOLOGY, V226, P315, DOI 10.1148/radiol.2262011600; Qin W, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-55; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Szabo CA, 2001, AM J NEURORADIOL, V22, P1342; Tregellas JR, 2007, SCHIZOPHR RES, V92, P262, DOI 10.1016/j.schres.2006.12.033; Wang L, 2006, NEUROIMAGE, V31, P496, DOI 10.1016/j.neuroimage.2005.12.033; Wang ZQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042730; Wang ZQ, 2011, J NEUROL SCI, V309, P79, DOI 10.1016/j.jns.2011.07.017; Wang ZQ, 2009, ACTA RADIOL, V50, P312, DOI 10.1080/02841850802709219; Zhou YL, 2008, ACUPUNCTURE ELECTRO, V33, P9, DOI 10.3727/036012908803861186	43	130	138	1	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 6	2014	9	3							e91160	10.1371/journal.pone.0091160	http://dx.doi.org/10.1371/journal.pone.0091160			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC4ID	24603951	Green Submitted, Green Published, gold			2023-01-03	WOS:000332483600137
J	Chi, H; Hsu, CH; Chang, JH; Chiu, NC; Hung, HY; Kao, HA; Weng, LC; Huang, FY; Chiu, YY; Chang, LY; Huang, LM				Chi, Hsin; Hsu, Chyong-Hsin; Chang, Jui-Hsing; Chiu, Nan-Chang; Hung, Han-Yang; Kao, Hsin-An; Weng, Li-Chuan; Huang, Fu-Yuan; Chiu, Yu-Ying; Chang, Luan-Yin; Huang, Li-Min			A Novel Six Consecutive Monthly Doses of Palivizumab Prophylaxis Protocol for the Prevention of Respiratory Syncytial Virus Infection in High-Risk Preterm Infants in Taiwan	PLOS ONE			English	Article							MONOCLONAL-ANTIBODY; PREMATURE-INFANTS; CHILDREN; HOSPITALIZATIONS; REHOSPITALIZATION; COST; PHARMACOKINETICS; EPIDEMIOLOGY; DISEASE; SAFETY	Background: Respiratory syncytial virus (RSV) circulates year round in Taiwan. A novel six consecutive monthly doses of palivizumab for RSV prevention protocol has been approved for high risk preterm infants since December 2010. This study aimed to determine the clinical effectiveness and safety of this novel protocol for the prevention of RSV infection. Methods: From April 2011 to March 2013, we enrolled infants born at <= 28 weeks gestation and infants born at <= 35 weeks gestation with chronic lung disease (CLD) who received palivizumab prophylaxis as study group and followed up for 12 months. Historic control, those who were born and followed up between July 2000 and June 2008, were retrieved for propensity score matching. Primary endpoint was RSV-related hospitalization, and secondary endpoints included the length of hospital stay and intensive care unit (ICU) care. Results: We enrolled 127 infants (108 infants born at <= 28 weeks and 19 infants born at 29-35 weeks with CLD). They completed 6-dose palivizumab as scheduled. Among the study group, the RSV-related hospitalizations were 2 (1.6%) within 6 months and 5 (3.9%) within 12 months after discharge. We matched 127 infants in the control group with 127 infants in the study group by propensity score matching. The reduction of RSV-related hospitalization rates were 86% (10.2% vs 1.6%, p = 0.002) within 6 months after discharge and 78% (15.7% vs 3.9%, p = 0.004) within 12 months after discharge. Compared to the control group, the rate of ICU care significantly decreased from 7.1% to 0.8% (p = 0.024) within 6 months after discharge and from 7.9% to 0.8% (p = 0.014) within 12 months after discharge. Adverse events were recorded in 6.4% injections. Conclusions: Six monthly intramuscular administration of palivizumab is effective for prevention of RSV hospitalization in regions with no single seasonal peak of RSV infection such as Taiwan.	[Chi, Hsin; Hsu, Chyong-Hsin; Chang, Jui-Hsing; Chiu, Nan-Chang; Hung, Han-Yang; Kao, Hsin-An; Huang, Fu-Yuan] Mackay Mem Hosp, Dept Pediat, Taipei, Taiwan; [Chi, Hsin; Chang, Luan-Yin; Huang, Li-Min] Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan; [Chi, Hsin; Chiu, Nan-Chang] Mackay Jr Coll Med Nursing & Management, Dept Nursing, Taipei, Taiwan; [Chi, Hsin] Mackay Med Coll, Dept Med, New Taipei City, Taiwan; [Weng, Li-Chuan] Mackay Mem Hosp, Dept Med Res, Tamsui, Taiwan; [Chiu, Yu-Ying] Mackay Mem Hosp, Dept Clin Virol Lab Med, Tamsui, Taiwan; [Chang, Luan-Yin; Huang, Li-Min] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Dept Pediat, Taipei 10764, Taiwan	Mackay Memorial Hospital; National Taiwan University; Mackay Junior College of Medicine, Nursing & Management; Mackay Medical College; Mackay Memorial Hospital; Mackay Memorial Hospital; National Taiwan University; National Taiwan University Hospital	Huang, LM (corresponding author), Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan.	lmhuang@ntu.edu.tw		CHANG, LUAN-YIN/0000-0003-2632-1956; HUANG, LI-MIN/0000-0002-9291-260X	Mackay Memorial Hospital, Taipei, Taiwan [MMH 9944, MMH 10038]; Taiwan Foundation of Prematurity	Mackay Memorial Hospital, Taipei, Taiwan; Taiwan Foundation of Prematurity	This study was supported by grants MMH 9944 and MMH 10038 from Mackay Memorial Hospital, Taipei, Taiwan and grants from the Taiwan Foundation of Prematurity. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abramson JS, 2003, PEDIATRICS, V112, P1442; Austin PC, 2008, PHARMACOEPIDEM DR S, V17, P1218, DOI 10.1002/pds.1674; Bocchini JA, 2009, PEDIATRICS, V124, P1216, DOI [10.1542/peds.2009-1806, 10.1542/peds.2009-2345]; Bont L, 2011, PEDIATR INFECT DIS J, V30, P785, DOI 10.1097/INF.0b013e31821fef9e; Boyce TG, 2000, J PEDIATR-US, V137, P865, DOI 10.1067/mpd.2000.110531; Carbonell-Estrany X, 2000, PEDIATR INFECT DIS J, V19, P592, DOI 10.1097/00006454-200007000-00002; Chan PWK, 2002, PEDIATR PULM, V34, P47, DOI 10.1002/ppul.10095; Chew FT, 1998, EPIDEMIOL INFECT, V121, P121, DOI 10.1017/S0950268898008905; Chi H, 2011, J FORMOS MED ASSOC, V110, P388, DOI 10.1016/S0929-6646(11)60057-0; Cilla G, 2006, EPIDEMIOL INFECT, V134, P506, DOI 10.1017/S0950268805005571; ElHassan NO, 2006, ARCH PEDIAT ADOL MED, V160, P1070, DOI 10.1001/archpedi.160.10.1070; Frogel M, 2008, J PERINATOL, V28, P511, DOI 10.1038/jp.2008.28; Fryzek JP, 2011, ADV THER, V28, P195, DOI 10.1007/s12325-010-0106-6; Grimaldi M, 2007, PEDIATR PULM, V42, P189, DOI 10.1002/ppul.20503; Groothius JR, 2001, PEDIATR INFECT DIS J, V20, P628, DOI 10.1097/00006454-200106000-00018; Hall CB, 2009, NEW ENGL J MED, V360, P588, DOI 10.1056/NEJMoa0804877; Hall CB, 2010, MANDELL DOUGLAS BENN, P2207; Halsey NA, 1998, PEDIATRICS, V102, P1211, DOI 10.1542/peds.102.5.1211; Joffe S, 1999, PEDIATRICS, V104, P894, DOI 10.1542/peds.104.4.894; Johnson S, 1997, J INFECT DIS, V176, P1215, DOI 10.1086/514115; Lee Jian-Te, 2007, Journal of Microbiology Immunology and Infection, V40, P293; Loscertales MP, 2002, PEDIATR INFECT DIS J, V21, P148, DOI 10.1097/00006454-200202000-00013; Meissner HC, 2004, PEDIATRICS, V114, P1082, DOI 10.1542/peds.2004-1300; Mitchell I, 2011, PEDIATR INFECT DIS J, V30, P651, DOI 10.1097/INF.0b013e31821146f7; Mullooly JP, 2007, VACCINE, V25, P846, DOI 10.1016/j.vaccine.2006.09.041; Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531; Pedraz C, 2003, PEDIATR INFECT DIS J, V22, P823, DOI 10.1097/01.inf.0000086403.50417.7c; Robbie GJ, 2012, ANTIMICROB AGENTS CH, V56, P4927, DOI 10.1128/AAC.06446-11; Romero JR, 2003, PEDIATR INFECT DIS J, V22, pS46, DOI 10.1097/00006454-200302001-00007; Rossi GA, 2007, EUR J PEDIATR, V166, P1267, DOI 10.1007/s00431-007-0418-y; Saez-Llorens X, 2004, PEDIATR INFECT DIS J, V23, P707, DOI 10.1097/01.inf.0000133165.85909.08; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; Simoes EAF, 1999, LANCET, V354, P847, DOI 10.1016/S0140-6736(99)80040-3; Singleton R, 2003, PEDIATR INFECT DIS J, V22, P540, DOI 10.1097/00006454-200306000-00010; Sommer Constanze, 2011, Open Microbiol J, V5, P144, DOI 10.2174/1874285801105010144; Stensballe LG, 2003, PEDIATR INFECT DIS J, V22, pS21, DOI 10.1097/00006454-200302001-00004; Tsai HP, 2001, J CLIN MICROBIOL, V39, P111, DOI 10.1128/JCM.39.1.111-118.2001; Underwood MA, 2007, J PERINATOL, V27, P614, DOI 10.1038/sj.jp.7211801; Wegner S, 2004, PEDIATRICS, V114, P1612, DOI 10.1542/peds.2004-0959; Yusuf S, 2007, EPIDEMIOL INFECT, V135, P1077, DOI 10.1017/S095026880600776X	40	14	14	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2014	9	6							e100981	10.1371/journal.pone.0100981	http://dx.doi.org/10.1371/journal.pone.0100981			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK6BK	24971565	Green Published, Green Submitted, gold			2023-01-03	WOS:000338512200079
J	Hoag, H				Hoag, Hannah			DRUG DELIVERY Brain food	NATURE			English	Editorial Material							NEUROGENESIS; GENERATION											Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003; Caicco MJ, 2013, J CONTROL RELEASE, V166, P197, DOI 10.1016/j.jconrel.2013.01.002; Gupta D, 2006, BIOMATERIALS, V27, P2370, DOI 10.1016/j.biomaterials.2005.11.015; Jin KL, 2006, P NATL ACAD SCI USA, V103, P13198, DOI 10.1073/pnas.0603512103; Kolb B, 2007, J CEREBR BLOOD F MET, V27, P983, DOI 10.1038/sj.jcbfm.9600402; Nakaguchi K, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/915160; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Wang Y, 2013, CURR TOP NUTRACEUT R, V11, P1	8	3	3	0	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 26	2014	510	7506					S6	S7		10.1038/510S6a	http://dx.doi.org/10.1038/510S6a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AJ6LK	24964026	Bronze			2023-01-03	WOS:000337806300005
J	Peng, HS; Liao, MB; Zhang, MY; Xie, Y; Xu, L; Zhang, YJ; Zheng, XFS; Wang, HY; Chen, YF				Peng, Hai-Shan; Liao, Ming-Bin; Zhang, Mei-Yin; Xie, Yin; Xu, Li; Zhang, Yao-Jun; Zheng, X. F. Steven; Wang, Hui-Yun; Chen, Yi-Fei			Synergistic Inhibitory Effect of Hyperbaric Oxygen Combined with Sorafenib on Hepatoma Cells	PLOS ONE			English	Article							ADVANCED HEPATOCELLULAR-CARCINOMA; CANCER-CELLS; IN-VITRO; THERAPY; APOPTOSIS; PATHWAYS; SURVIVAL; HYPOXIA; CHEMOTHERAPY; MOBILIZATION	Objectives: Hypoxia is a common phenomenon in solid tumors, associated with chemotherapy and radiotherapy resistance, recurrence and metastasis. Hyperbaric oxygen (HBO) therapy can increase tissue oxygen pressure and content to prevent the resistance, recurrence and metastasis of cancer. Presently, Sorafenib is a first-line drug, targeted for hepatocellular carcinoma (HCC) but effective in only a small portion of patients and can induce hypoxia. The purpose of this study is to investigate the effect of HBO in combination with sorafenib on hepatoma cells. Methods: Hepatoma cell lines (BEL-7402 and SK-Hep1) were treated with HBO at 2 atmosphere absolute pressure for 80 min per day or combined with sorafenib or cisplatin. At different time points, cells were tested for cell growth, colony formation, apoptosis, cell cycle and migration. Finally, miRNA from the hepatoma cells was detected by microRNA array and validated by qRT-PCR. Results: Although HBO, sorafenib or cisplatin alone could inhibit growth of hepatoma cells, HBO combined with sorafenib or cisplatin resulted in much greater synergistic growth inhibition (cell proliferation and colony formation) in hepatoma cells. Similarly, the synergistic effect of HBO and sorafenib on induction of apoptosis was also observed in hepatoma cells. HBO induced G1 arrest in SK-Hep1 not in BEL-7402 cells, but enhanced cell cycle arrest induced by sorafenib in BEL-7402 treated cells. However, HBO had no obvious effect on the migration of hepatoma cells, and microRNA array analysis showed that hepatoma cells with HBO treatment had significantly different microRNA expression profiles from those with blank control. Conclusions: We show for the first time that HBO combined with sorafenib results in synergistic growth inhibition and apoptosis in hepatoma cells, suggesting a potential application of HBO combined with sorafenib in HCC patients. Additionally, we also show that HBO significantly altered microRNA expression in hepatoma cells.	[Peng, Hai-Shan; Zhang, Mei-Yin; Xie, Yin; Wang, Hui-Yun] State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Peng, Hai-Shan; Zhang, Mei-Yin; Xie, Yin; Wang, Hui-Yun] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, Guangzhou 510275, Guangdong, Peoples R China; [Liao, Ming-Bin; Chen, Yi-Fei] Guangzhou Med Univ, Guangzhou Peoples Hosp 1, Hyperbar Oxygen Therapy Ctr, Guangzhou, Guangdong, Peoples R China; [Xu, Li; Zhang, Yao-Jun] Sun Yat Sen Univ, Ctr Canc, Dept Hepatobiliary Oncol, Guangzhou 510275, Guangdong, Peoples R China; [Zheng, X. F. Steven] Rutgers State Univ, Rutgers Canc Inst New Jersey, New Brunswick, NJ 08903 USA	State Key Lab Oncology South China; Sun Yat Sen University; Guangzhou Medical University; Sun Yat Sen University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Wang, HY (corresponding author), State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China.	wanghyun@mail.sysu.edu.cn; xwcyfmm2001@aliyun.com	YANG, YANG/U-3889-2017; Chen, Yi/HIR-2608-2022; Zhang, Yaojun/U-2965-2019	Zhang, Yaojun/0000-0002-9752-4729	Guangdong Natural Science Foundation [S2012010008627]; State Key Laboratory of Oncology in South China	Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province); State Key Laboratory of Oncology in South China	The project is supported by Guangdong Natural Science Foundation (grant No: S2012010008627 for YFC) and partially supported by Research Fund of State Key Laboratory of Oncology in South China (to HYW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADAMS JF, 1963, BMJ-BRIT MED J, P314, DOI 10.1136/bmj.1.5326.314; Agnello F, 2013, WORLD J HEPATOL, V5, P417, DOI 10.4254/wjh.v5.i8.417; Chai H, 2010, INT J CLIN EXP PATHO, V3, P408; Chang AY, 2013, ANTI-CANCER DRUG, V24, P251, DOI 10.1097/CAD.0b013e32835ba289; Chen YC, 2007, LEUKEMIA RES, V31, P805, DOI 10.1016/j.leukres.2006.09.016; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Danesh-Sani SA, 2012, J CRANIOFAC SURG, V23, pE483, DOI 10.1097/SCS.0b013e3182668777; Daruwalla J, 2007, J DRUG TARGET, V15, P487, DOI 10.1080/10611860701499839; Di Costanzo GG, 2012, DIGEST LIVER DIS, V44, P788, DOI 10.1016/j.dld.2012.04.001; Di Marco V, 2013, ANN ONCOL, V24, pii30, DOI 10.1093/annonc/mdt055; Durmaz E, 1999, Br J Nurs, V8, P1067; Edwards ML, 2010, J VET EMERG CRIT CAR, V20, P289, DOI 10.1111/j.1476-4431.2010.00535_1.x; FELDMEIER JJ, 1994, UNDERSEA HYPERBAR M, V21, P467; Galmiche A, 2013, CANC LETT; Gedaly R, 2010, ANTICANCER RES, V30, P4951; Gill AL, 2004, QJM-INT J MED, V97, P385, DOI 10.1093/qjmed/hch074; Hsu CH, 2010, J HEPATOL, V53, P126, DOI 10.1016/j.jhep.2010.01.035; Hsu Chiun, 2009, Expert Rev Clin Pharmacol, V2, P129, DOI 10.1586/17512433.2.2.129; Huang SB, 2010, MOL CANCER THER, V9, P742, DOI 10.1158/1535-7163.MCT-09-1004; Kalns JE, 1999, IN VITRO CELL DEV-AN, V35, P98; Kane RC, 2009, ONCOLOGIST, V14, P95, DOI 10.1634/theoncologist.2008-0185; Lee CH, 2012, UNDERSEA HYPERBAR M, V39, P1089; Liang YJ, 2013, HEPATOLOGY, V57, P1847, DOI 10.1002/hep.26224; Liu LP, 2012, CLIN CANCER RES, V18, P5662, DOI 10.1158/1078-0432.CCR-12-0552; Liu WW, 2013, TARGET ONCOL, V8, P79, DOI 10.1007/s11523-013-0259-8; Moen I, 2012, TARGET ONCOL, V7, P233, DOI 10.1007/s11523-012-0233-x; Mori S, 2009, ONCOGENE, V28, P2796, DOI 10.1038/onc.2009.139; Nakada T, 2012, UROL INT, V89, P208, DOI 10.1159/000338910; Nakano M, 2013, ONCOLOGY-BASEL, V84, P108, DOI 10.1159/000342650; Ohguri T, 2009, INT J HYPERTHER, V25, P160, DOI 10.1080/02656730802610357; Ranieri G, 2012, CURR MED CHEM, V19, P938, DOI 10.2174/092986712799320736; Thom SR, 2006, AM J PHYSIOL-HEART C, V290, pH1378, DOI 10.1152/ajpheart.00888.2005; Thom SR, 2011, WOUND REPAIR REGEN, V19, P149, DOI 10.1111/j.1524-475X.2010.00660.x; Wei RR, 2013, CLIN CANCER RES, V19, P4780, DOI 10.1158/1078-0432.CCR-12-2728; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Xu Li, 2009, Zhonghua Zhongliu Zazhi, V31, P58, DOI 10.3760/cma.j.issn.0253-3766.2009.01.015; Yeh YT, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/290575; Yu CR, 2006, MOL CANCER THER, V5, P2378, DOI 10.1158/1535-7163.MCT-06-0235; Zavaglia C, 2013, EUR J GASTROEN HEPAT, V25, P180, DOI 10.1097/MEG.0b013e328359e550; Zhai B, 2013, WORLD J HEPATOL, V5, P345, DOI 10.4254/wjh.v5.i7.345; Zhang T, 2010, ANTI-CANCER DRUG, V21, P326, DOI 10.1097/CAD.0b013e3283350e26	41	15	15	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 23	2014	9	6							e100814	10.1371/journal.pone.0100814	http://dx.doi.org/10.1371/journal.pone.0100814			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AL1WV	24956259	Green Published, gold, Green Submitted			2023-01-03	WOS:000338917900097
J	Newman, S; Cheng, T; Ghahate, DM; Bobelu, J; Sandy, P; Faber, T; Shah, VO				Newman, Sara; Cheng, Terri; Ghahate, Donica M.; Bobelu, Jeanette; Sandy, Phillip; Faber, Thomas; Shah, Vallabh O.			Assessing Knowledge and Attitudes of Diabetes in Zuni Indians Using a Culture-Centered Approach	PLOS ONE			English	Article							AFRICAN-AMERICANS; HEALTH; CARE; PERCEPTIONS; BARRIERS; DISEASE; ADULTS	Introduction: The Zuni Pueblo, in collaboration with the University of New Mexico, have formed the Zuni Health Initiative (ZHI) engaged in community-based participatory research to plan and implement educational interventions to reduce health disparities. We conducted the first phase of ZHI study and identified barriers to healthcare. We concluded that the burden presented by these barriers ultimately translates into a lack of patient activation and engagement in their health care including for diabetes, effectively hindering adoption of healthy behaviors. Methods: Community health representatives (CHRs) led 10 one-hour focus group sessions to elicit information on diabetes knowledge and self-management strategies at which a total of 84 people participated. Audiotapes were translated and transcribed by bilingual ZHI staff. We reduced the text to thematic categories, constructed a coding dictionary and inserted the text into NVivo 9 program. Results: The focus groups revealed that despite extensive personal or family experiences with diabetes or complications, participants identified knowledge gaps in the disease progression and disease management. However, we gained insight into how many Zunis conceptualize the etiology of diabetes, risk factors associated with diabetes, sources of knowledge and self-management practices. Conclusion: We concluded that many of the Zuni diabetics experience significant impacts on their life when they were diagnosed with diabetes and suffered the plight of stigmatization. We further concluded that developing Zuni culture specific diabetes care should focus on family involvement with continued education.	[Newman, Sara] Univ Colorado, Denver, CO 80202 USA; [Cheng, Terri; Ghahate, Donica M.; Bobelu, Jeanette; Sandy, Phillip; Shah, Vallabh O.] Univ New Mexico, Hlth Sci Ctr, Sch Med, Albuquerque, NM 87131 USA; [Faber, Thomas] Indian Hlth Serv Comprehens Ctr Zuni Pueblo, Zuni, NM USA	University of Colorado System; University of Colorado Denver; University of New Mexico; University of New Mexico's Health Sciences Center	Shah, VO (corresponding author), Univ New Mexico, Hlth Sci Ctr, Sch Med, Albuquerque, NM 87131 USA.	vshah@salud.unm.edu			National Center for research Resources [5P20RR016480-12]; National Institute of General Medical Sciences from NIH [8P20GM103451-12]; National Center for Research Resources; National Center for Advancing Translational Sciences of the National Institutes of Health [8UL1TR000041]; University of New Mexico Clinical and Translational Science Center; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000041] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103451] Funding Source: NIH RePORTER	National Center for research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institute of General Medical Sciences from NIH; National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Translational Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); University of New Mexico Clinical and Translational Science Center; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This project was supported in full from the grants funded by the National Center for research Resources (5P20RR016480-12) and the National Institute of General Medical Sciences (8P20GM103451-12) from NIH. The authors would also like to acknowledge partial support from the pilot project grant funding from the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number 8UL1TR000041, The University of New Mexico Clinical and Translational Science Center. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Maskari F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052857; Amer Diabet Assoc, 2013, DIABETES CARE, V36, P1033, DOI 10.2337/dc12-2625; American Diabetes Association, 2007, Diabetes Care, V30 Suppl 1, pS4; Anderson RM, 2000, DIABETES EDUCATOR, V26, P280, DOI 10.1177/014572170002600208; Bradshaw BG, 2007, DIABETES EDUCATOR, V33, P650, DOI 10.1177/0145721707303809; Burt R. S., 2005, BROKERAGE CLOSURE IN; Downing-Matibag TM, 2009, QUAL HEALTH RES, V19, P1196, DOI 10.1177/1049732309344206; Dutta MJ, 2007, COMMUN THEORY, V17, P204; Fukunaga LL, 2011, PREV CHRONIC DIS, V8; Lautenschlager L, 2006, J NUTR EDUC BEHAV, V38, P307, DOI 10.1016/j.jneb.2006.04.004; Lukunaga LL, 2011, PREVENTING CHRONIC D, V8; Melkus GD, 2004, APPL NURS RES, V17, P10, DOI 10.1016/j.apnr.2003.10.009; Morgan D. L., 1997, FOCUS GROUPS QUALITA, V16; Norris SL, 2006, DIABETIC MED, V23, P544, DOI 10.1111/j.1464-5491.2006.01845.x; ONEIL JD, 1986, HUM ORGAN, V45, P119, DOI 10.17730/humo.45.2.q34m761r857km8lh; Sarkisian CA, 2005, ETHNIC DIS, V15, P283; Scavini M, 2003, DIABETES CARE, V26, P55, DOI 10.2337/diacare.26.1.55; Shah VO, 2014, CTS-CLIN TRANSL SCI, V7, P6, DOI 10.1111/cts.12127; Shah VN, 2009, INT J DIABETES DEV C, V29, P118, DOI 10.4103/0973-3930.54288; Shah VO, 2003, J AM SOC NEPHROL, V14, P1320, DOI 10.1097/01.ASN.0000059920.00228.A0; Stidley CA, 2003, J AM SOC NEPHROL, V14, pS139, DOI 10.1097/01.ASN.0000070151.95421.87; Thomas D.R., 2003, GEN INDUCTIVE APPROA; Tripp-Reimer T., 2001, DIABETES SPECTR, V14, P13, DOI 10.2337/diaspect.14.1.13; U.S. Department of Health and Human Services, 2007, OB AM IND AL NAT	24	12	12	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 11	2014	9	6							e99614	10.1371/journal.pone.0099614	http://dx.doi.org/10.1371/journal.pone.0099614			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AK7TQ	24919064	Green Submitted, Green Published, gold			2023-01-03	WOS:000338631000099
J	Turc, G; Aguettaz, P; Ponchelle-Dequatre, N; Henon, H; Naggara, O; Leclerc, X; Cordonnier, C; Leys, D; Mas, JL; Oppenheim, C				Turc, Guillaume; Aguettaz, Pierre; Ponchelle-Dequatre, Nelly; Henon, Hilde; Naggara, Olivier; Leclerc, Xavier; Cordonnier, Charlotte; Leys, Didier; Mas, Jean-Louis; Oppenheim, Catherine			External Validation of the MRI-DRAGON Score: Early Prediction of Stroke Outcome after Intravenous Thrombolysis	PLOS ONE			English	Article							ACUTE ISCHEMIC-STROKE; IV THROMBOLYSIS; REGRESSION; EVENTS; IMPACT	Background and Purpose: The aim of our study was to validate in an independent cohort the MRI-DRAGON score, an adaptation of the (CT-) DRAGON score to predict 3-month outcome in acute ischemic stroke patients undergoing MRI before intravenous thrombolysis (IV-tPA). Methods: We reviewed consecutive (2009-2013) anterior circulation stroke patients treated within 4.5 hours by IV-tPA in the Lille stroke unit (France), where MRI is the first-line pretherapeutic work-up. We assessed the discrimination and calibration of the MRI-DRAGON score to predict poor 3-month outcome, defined as modified Rankin Score >2, using c-statistic and the Hosmer-Lemeshow test, respectively. Results: We included 230 patients (mean +/- SD age 70.4 +/- 16.0 years, median [IQR] baseline NIHSS 8 [5-14]; poor outcome in 78(34%) patients). The c-statistic was 0.81 (95%CI 0.75-0.87), and the Hosmer-Lemeshow test was not significant (p = 0.54). Conclusions: The MRI-DRAGON score showed good prognostic performance in the external validation cohort. It could therefore be used to inform the patient's relatives about long-term prognosis and help to identify poor responders to IV-tPA alone, who may be candidates for additional therapeutic strategies, if they are otherwise eligible for such procedures based on the institutional criteria.	[Turc, Guillaume; Mas, Jean-Louis] Hop St Anne, Dept Neurol, F-75674 Paris, France; [Turc, Guillaume; Naggara, Olivier; Mas, Jean-Louis; Oppenheim, Catherine] Univ Paris 05, Sorbonne Paris Cite, INSERM UMR S894, Paris, France; [Naggara, Olivier; Oppenheim, Catherine] Hop St Anne, Dept Radiol, F-75674 Paris, France; [Ponchelle-Dequatre, Nelly; Henon, Hilde; Cordonnier, Charlotte; Leys, Didier] Lille Univ Hosp, Dept Neurol, Lille, France; [Aguettaz, Pierre; Ponchelle-Dequatre, Nelly; Henon, Hilde; Leclerc, Xavier; Cordonnier, Charlotte; Leys, Didier] Univ Lille Nord France, UDSL, EA 1046, Lille, France; [Aguettaz, Pierre; Leclerc, Xavier] Lille Univ Hosp, Dept Radiol, Lille, France	GHU PARIS Psychiatrie Neurosciences; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; GHU PARIS Psychiatrie Neurosciences; UDICE-French Research Universities; Universite Paris Cite; Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; CHU Lille	Turc, G (corresponding author), Hop St Anne, Dept Neurol, F-75674 Paris, France.	g.turc@ch-sainte-anne.fr	Cordonnier, Charlotte/O-3258-2017; LEYS, Didier/G-2955-2016; Oppenheim, Catherine/N-1635-2018; Naggara, Olivier/R-3939-2017	Cordonnier, Charlotte/0000-0002-5697-6892; LEYS, Didier/0000-0003-4408-4392; Turc, Guillaume/0000-0001-5059-4095; Oppenheim, Catherine/0000-0003-3410-0862; Naggara, Olivier/0000-0002-9544-379X				Aries MJH, 2009, J NEUROL SCI, V285, P114, DOI 10.1016/j.jns.2009.06.010; Barber PA, 2005, J NEUROL NEUROSUR PS, V76, P1528, DOI 10.1136/jnnp.2004.059261; de Margerie-Mellon C, 2013, STROKE, V44, P3565, DOI 10.1161/STROKEAHA.113.003047; Giralt-Steinhauer E, 2013, CEREBROVASC DIS, V36, P110, DOI 10.1159/000352061; Moons KGM, 2012, HEART, V98, P691, DOI 10.1136/heartjnl-2011-301247; Nezu T, 2010, NEUROLOGY, V75, P555, DOI 10.1212/WNL.0b013e3181eccf78; Ovesen C, 2013, J CLIN NEUROSCI, V20, P1635, DOI 10.1016/j.jocn.2013.04.023; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Rha JH, 2007, STROKE, V38, P967, DOI 10.1161/01.STR.0000258112.14918.24; Strbian D, 2012, NEUROLOGY, V78, P427, DOI 10.1212/WNL.0b013e318245d2a9; Strbian D, 2013, STROKE, V44, P2718, DOI 10.1161/STROKEAHA.113.002033; Tei H, 2011, J NEUROL, V258, P559, DOI 10.1007/s00415-010-5787-x; Tei H, 2010, J NEUROL, V257, P767, DOI 10.1007/s00415-009-5406-x; Turc G, 2013, STROKE, V44, P1323, DOI 10.1161/STROKEAHA.111.000127; Vittinghoff E, 2007, AM J EPIDEMIOL, V165, P710, DOI 10.1093/aje/kwk052; Wahlgren N, 2008, LANCET, V372, P1303, DOI 10.1016/S0140-6736(08)61339-2	16	9	9	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2014	9	6							e99164	10.1371/journal.pone.0099164	http://dx.doi.org/10.1371/journal.pone.0099164			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK4YO	24896827	gold, Green Published, Green Submitted			2023-01-03	WOS:000338430700122
J	Aoki, Y; Yoshida, K; Nishizawa, D; Kasai, S; Ichinohe, T; Ikeda, K; Fukuda, K				Aoki, Yoshinori; Yoshida, Kaori; Nishizawa, Daisuke; Kasai, Shinya; Ichinohe, Tatsuya; Ikeda, Kazutaka; Fukuda, Ken-ichi			Factors that Affect Intravenous Patient-Controlled Analgesia for Postoperative Pain Following Orthognathic Surgery for Mandibular Prognathism	PLOS ONE			English	Article							ASSOCIATION; GENE	The predictors of postoperative pain and analgesic consumption were previously found to include preoperative pain, anxiety, age, type of surgery, and genotype, but remaining unclear was whether intraoperative factors could predict postoperative pain. In the present study, we investigated the time-course of fentanyl consumption using intravenous patient-controlled analgesia records from patients who underwent orthognathic surgery for mandibular prognathism and analyzed the influence of anesthesia methods and surgical methods together with sex on the time course. A significant difference in the time course of fentanyl administration was found (P<0.001). No significant difference in the time course of fentanyl administration was found between males and females (P = 0.653), with no interaction between time course and sex (P = 0.567). No significant difference in the time course of fentanyl administration was found among anesthesia methods, such as fentanyl induction followed by fentanyl maintenance, fentanyl induction followed by remifentanil maintenance, and remifentanil induction followed by remifentanil maintenance (P = 0.512), but an interaction between time course and anesthesia method was observed (P = 0.004). A significant difference in the time course of fentanyl administration was found between surgical methods, such as bilateral mandibular sagittal split ramus osteotomy (BSSRO) and BSSRO combined with Le Fort I osteotomy (bimaxillary; P = 0.008), with no interaction between time course and surgical method (P = 0.535). Total postoperative 24 h consumption associated with the bimaxillary procedure was significantly higher than with BSSRO (P = 0.008). The present results indicate that administration patterns and total 24 h consumption were different among the three groups of anesthesia methods and between the two groups of surgical methods, respectively. Although more research on patient-controlled analgesia patterns and consumption is necessary, the present study will contribute to adequately relieving individual patients from postoperative pain.	[Aoki, Yoshinori; Yoshida, Kaori; Nishizawa, Daisuke; Kasai, Shinya; Ikeda, Kazutaka] Tokyo Metropolitan Inst Med Sci, Addict Subst Project, Tokyo 113, Japan; [Aoki, Yoshinori; Yoshida, Kaori; Ichinohe, Tatsuya; Fukuda, Ken-ichi] Tokyo Dent Coll, Dept Dent Anesthesiol, Tokyo, Japan	Tokyo Metropolitan Institute of Medical Science; Tokyo Dental College	Ikeda, K (corresponding author), Tokyo Metropolitan Inst Med Sci, Addict Subst Project, Tokyo 113, Japan.	ikeda-kz@igakuken.or.jp		Ichinohe, Tatsuya/0000-0001-5793-3379	Ministry of Health, Labour and Welfare (MHLW) of Japan [H21-3jigan-ippan-011, H22-Iyaku-015, H25-Iyaku-020]; JSPS KAKENHI [20602020, 20390162, 23390377, 24790544, 24659549, 26293347]; MEXT KAKENHI [25116532]; Smoking Research Foundation; Naito Foundation; Astellas Foundation for Research on Metabolic Disorders; Grants-in-Aid for Scientific Research [25116532] Funding Source: KAKEN	Ministry of Health, Labour and Welfare (MHLW) of Japan(Ministry of Health, Labour and Welfare, Japan); JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); MEXT KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Smoking Research Foundation; Naito Foundation(Naito Memorial Foundation); Astellas Foundation for Research on Metabolic Disorders; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by grants from the Ministry of Health, Labour and Welfare (MHLW) of Japan (H21-3jigan-ippan-011, H22-Iyaku-015, and H25-Iyaku-020), JSPS KAKENHI grant no. 20602020, 20390162, 23390377, 24790544, 24659549, and 26293347, MEXT KAKENHI grant no. 25116532, the Smoking Research Foundation, the Naito Foundation, and the Astellas Foundation for Research on Metabolic Disorders. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aoki Y, 2013, NEUROSCI LETT, V542, P1, DOI 10.1016/j.neulet.2013.02.039; BELL WH, 1975, J ORAL SURG, V33, P412; Burkle H, 1996, ANESTH ANALG, V83, P646, DOI 10.1097/00000539-199609000-00038; Chegini Soudeh, 2012, Anesth Prog, V59, P69, DOI 10.2344/11-10.1; de Santana-Santos T, 2013, MED ORAL PATOL ORAL, V18, pE65, DOI 10.4317/medoral.18039; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Fukuda K, 2009, PAIN, V147, P194, DOI 10.1016/j.pain.2009.09.004; Haerle F, 1997, ATLAS CRANIOMAXILLOF, p[90, 100]; Ip HYV, 2009, ANESTHESIOLOGY, V111, P657, DOI 10.1097/ALN.0b013e3181aae87a; Kehlet H, 2001, BRIT J ANAESTH, V87, P62, DOI 10.1093/bja/87.1.62; Nagatsuka C, 2000, Anesth Prog, V47, P119; Nishizawa D, 2014, MOL PSYCHIATR, V19, P55, DOI 10.1038/mp.2012.164; Nishizawa D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007060; OBWEGESER H, 1965, SSO Schweiz Monatsschr Zahnheilkd, V75, P365; TRAUNER R, 1957, Oral Surg Oral Med Oral Pathol, V10, P677, DOI 10.1016/S0030-4220(57)80063-2; United Nations, 2011, REP INT NARC CONTR B, P59; Warltier DC, 2000, ANESTHESIOLOGY, V92, P253, DOI 10.1097/00000542-200001000-00038; Wassmund M, 1935, LEHRBUCH PRAKTISCHEN, VI, P282; Weiser TG, 2008, LANCET, V372, P139, DOI 10.1016/S0140-6736(08)60878-8	19	7	9	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2014	9	6							e98548	10.1371/journal.pone.0098548	http://dx.doi.org/10.1371/journal.pone.0098548			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI5ML	24893040	gold, Green Published, Green Submitted			2023-01-03	WOS:000336911400063
J	Pearcey, GEP; Power, KE; Button, DC				Pearcey, Gregory E. P.; Power, Kevin E.; Button, Duane C.			Differences in Supraspinal and Spinal Excitability during Various Force Outputs of the Biceps Brachii in Chronic- and Non-Resistance Trained Individuals	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; CROSS-SECTIONAL AREA; MOTONEURONS IN-VIVO; MOTOR UNIT BEHAVIOR; LOWER-LIMB MUSCLES; VOLUNTARY CONTRACTIONS; NEURAL ADAPTATIONS; CORTICOSPINAL STIMULATION; FATIGUING CONTRACTION; SYSTEMATIC VARIATIONS	Motor evoked potentials (MEP) and cervicomedullary evoked potentials (CMEP) may help determine the corticospinal adaptations underlying chronic resistance training-induced increases in voluntary force production. The purpose of the study was to determine the effect of chronic resistance training on corticospinal excitability (CE) of the biceps brachii during elbow flexion contractions at various intensities and the CNS site (i.e. supraspinal or spinal) predominantly responsible for any training-induced differences in CE. Fifteen male subjects were divided into two groups: 1) chronic resistance-trained (RT), (n = 8) and 2) non-RT, (n = 7). Each group performed four sets of,5 s elbow flexion contractions of the dominant arm at 10 target forces (from 10%-100% MVC). During each contraction, subjects received 1) transcranial magnetic stimulation, 2) transmastoid electrical stimulation and 3) brachial plexus electrical stimulation, to determine MEP, CMEP and compound muscle action potential (M-max) amplitudes, respectively, of the biceps brachii. All MEP and CMEP amplitudes were normalized to M-max. MEP amplitudes were similar in both groups up to 50% MVC, however, beyond 50% MVC, MEP amplitudes were lower in the chronic RT group (p<0.05). CMEP amplitudes recorded from 10-100% MVC were similar for both groups. The ratio of MEP amplitude/absolute force and CMEP amplitude/absolute force were reduced (p<0.012) at all contraction intensities from 10-100% MVC in the chronic-RT compared to the non-RT group. In conclusion, chronic resistance training alters supraspinal and spinal excitability. However, adaptations in the spinal cord (i.e. motoneurone) seem to have a greater influence on the altered CE.	[Pearcey, Gregory E. P.; Power, Kevin E.; Button, Duane C.] Mem Univ Newfoundland, Sch Human Kinet & Recreat, St John, NF, Canada; [Button, Duane C.] Mem Univ Newfoundland, Fac Med, St John, NF, Canada	Memorial University Newfoundland; Memorial University Newfoundland	Button, DC (corresponding author), Mem Univ Newfoundland, Sch Human Kinet & Recreat, St John, NF, Canada.	dbutton@mun.ca	Behm, David George/I-6509-2019	Behm, David George/0000-0002-9406-6056; Power, Kevin/0000-0001-5958-0271; Pearcey, Gregory/0000-0002-6751-4351	Memorial University start-up grant [208604]	Memorial University start-up grant	This research was supported by a Memorial University start-up grant 208604. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aagaard P, 2002, J APPL PHYSIOL, V92, P2309, DOI 10.1152/japplphysiol.01185.2001; Beaumont E, 2003, MUSCLE NERVE, V27, P228, DOI 10.1002/mus.10308; Beaumont E, 2002, J PHYSIOL-LONDON, V540, P129, DOI 10.1113/jphysiol.2001.013084; Beck S, 2007, BRAIN RES, V1179, P51, DOI 10.1016/j.brainres.2007.08.048; Button DC, 2006, J PHYSIOL-LONDON, V573, P663, DOI 10.1113/jphysiol.2006.107292; CAROLAN B, 1992, J APPL PHYSIOL, V73, P911, DOI 10.1152/jappl.1992.73.3.911; CARP JS, 1994, J NEUROPHYSIOL, V72, P431, DOI 10.1152/jn.1994.72.1.431; Carroll TJ, 2011, ACTA PHYSIOL, V202, P119, DOI 10.1111/j.1748-1716.2011.02271.x; Carroll TJ, 2009, ACTA PHYSIOL, V197, P161, DOI 10.1111/j.1748-1716.2009.01992.x; Carroll TJ, 2002, J PHYSIOL-LONDON, V544, P641, DOI 10.1113/jphysiol.2002.024463; Carroll TJ, 2001, SPORTS MED, V31, P829, DOI 10.2165/00007256-200131120-00001; Davidson AW, 2010, MUSCLE NERVE, V42, P514, DOI 10.1002/mus.21717; DE LUCA CJ, 1982, J PHYSIOL-LONDON, V329, P113, DOI 10.1113/jphysiol.1982.sp014293; De Luca CJ, 1996, J NEUROPHYSIOL, V76, P1503, DOI 10.1152/jn.1996.76.3.1503; Del Balso C, 2007, J APPL PHYSIOL, V103, P402, DOI 10.1152/japplphysiol.00477.2006; del Olmo MF, 2006, EUR J APPL PHYSIOL, V96, P722, DOI 10.1007/s00421-006-0153-5; Di Lazzaro V, 1998, J PHYSIOL-LONDON, V508, P625; Dragert K, 2013, EXP BRAIN RES, V225, P93, DOI 10.1007/s00221-012-3351-x; Enoka RM, 1997, J BIOMECH, V30, P447, DOI 10.1016/S0021-9290(96)00170-4; Falvo MJ, 2010, EUR J APPL PHYSIOL, V109, P923, DOI 10.1007/s00421-010-1432-8; Folland JP, 2007, SPORTS MED, V37, P145, DOI 10.2165/00007256-200737020-00004; Gandevia SC, 1999, J PHYSIOL-LONDON, V521, P749, DOI 10.1111/j.1469-7793.1999.00749.x; Gardiner P, 2006, J APPL PHYSIOL, V101, P1228, DOI 10.1152/japplphysiol.00482.2006; GARFINKEL S, 1992, MED SCI SPORT EXER, V24, P1220; Gelli F, 2007, EUR J NEUROSCI, V25, P3469, DOI 10.1111/j.1460-9568.2007.05590.x; Goodwill AM, 2012, MUSCLE NERVE, V46, P384, DOI 10.1002/mus.23316; Griffin L, 2007, J ELECTROMYOGR KINES, V17, P446, DOI 10.1016/j.jelekin.2006.05.001; HAKKINEN K, 1983, MED SCI SPORT EXER, V15, P455; Heckman CJ, 2003, EXERC SPORT SCI REV, V31, P96, DOI 10.1097/00003677-200304000-00008; Heckman CJ, 2008, NEUROSCIENTIST; Jensen JL, 2005, J APPL PHYSIOL, V99, P1558, DOI 10.1152/japplphysiol.01408.2004; Jones KE, 1997, J NEUROPHYSIOL, V77, P405, DOI 10.1152/jn.1997.77.1.405; Khan SI, 2012, J PHYSIOL-LONDON, V590, P4957, DOI 10.1113/jphysiol.2012.235697; Kidgell DJ, 2010, J STRENGTH COND RES, V24, P3123, DOI 10.1519/JSC.0b013e3181f56794; Kidgell DJ, 2010, HUM MOVEMENT SCI, V29, P631, DOI 10.1016/j.humov.2010.01.004; Lee RH, 1998, J NEUROPHYSIOL, V80, P572, DOI 10.1152/jn.1998.80.2.572; Lee RH, 1998, J NEUROPHYSIOL, V80, P583, DOI 10.1152/jn.1998.80.2.583; Levenez M, 2008, J NEUROPHYSIOL, V99, P554, DOI 10.1152/jn.00963.2007; MacDonell CW, 2012, J NEUROPHYSIOL, V107, P265, DOI 10.1152/jn.00122.2011; Martin PG, 2008, J PHYSIOL-LONDON, V586, P1277, DOI 10.1113/jphysiol.2007.140426; Martin PG, 2006, J NEUROPHYSIOL, V95, P3512, DOI 10.1152/jn.01230.2005; Martin PG, 2009, J NEUROPHYSIOL, V102, P606, DOI 10.1152/jn.91348.2008; Matthews PBC, 1999, J PHYSIOL-LONDON, V518, P867, DOI 10.1111/j.1469-7793.1999.0867p.x; MAZZOCCHIO R, 1994, J PHYSIOL-LONDON, V474, P261, DOI 10.1113/jphysiol.1994.sp020018; McNeil CJ, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00152; McNeil CJ, 2011, J PHYSIOL-LONDON, V589, P3533, DOI 10.1113/jphysiol.2011.207191; Narici MV, 1996, ACTA PHYSIOL SCAND, V157, P175, DOI 10.1046/j.1365-201X.1996.483230000.x; OLIVIER E, 1995, J PHYSIOL-LONDON, V485, P257, DOI 10.1113/jphysiol.1995.sp020728; Oya T, 2008, J APPL PHYSIOL, V105, P1527, DOI 10.1152/japplphysiol.90586.2008; Pearcey GEP, 2013, APPL PHYSIOL NUTR ME, V38, P1069; Rossi A, 2012, J NEUROPHYSIOL, V108, P2473, DOI 10.1152/jn.00477.2012; Rossi S, 2011, CLIN NEUROPHYSIOL, V122, P1686, DOI 10.1016/j.clinph.2010.12.037; Tallent J, 2013, J ELECTROMYOGR KINES, V23, P1075, DOI 10.1016/j.jelekin.2013.04.014; Taylor JL, 2006, J ELECTROMYOGR KINES, V16, P215, DOI 10.1016/j.jelekin.2005.07.001; Taylor JL, 2002, J PHYSIOL-LONDON, V541, P949, DOI 10.1113/jphysiol.2002.016782; Tillin NA, 2011, MUSCLE NERVE, V43, P375, DOI 10.1002/mus.21885; Ugawa Y, 1995, ELECTROMYOGR MOTOR C, V97, P451, DOI 10.1016/0924-980X(95)00214-6; UGAWA Y, 1991, ANN NEUROL, V29, P418, DOI 10.1002/ana.410290413; Van Cutsem M, 1998, J PHYSIOL-LONDON, V513, P295, DOI 10.1111/j.1469-7793.1998.295by.x; Vila-Cha C, 2010, J APPL PHYSIOL, V109, P1455, DOI 10.1152/japplphysiol.01213.2009; Weier AT, 2012, ACTA PHYSIOL, V206, P109, DOI 10.1111/j.1748-1716.2012.02454.x	61	34	34	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2014	9	5							e98468	10.1371/journal.pone.0098468	http://dx.doi.org/10.1371/journal.pone.0098468			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI3UR	24875495	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000336790800042
J	Liu, YS; Zhang, X; Liu, Y; Jin, XX; Fan, C; Ye, HQ; Ou, ME; Lv, LW; Wu, G; Zhou, YS				Liu, Yunsong; Zhang, Xiao; Liu, Yang; Jin, Xiaoxiao; Fan, Cong; Ye, Hongqiang; Ou, Meng'en; Lv, Longwei; Wu, Gang; Zhou, Yongsheng			Bi-Functionalization of a Calcium Phosphate-Coated Titanium Surface with Slow-Release Simvastatin and Metronidazole to Provide Antibacterial Activities and Pro-Osteodifferentiation Capabilities	PLOS ONE			English	Article							MESENCHYMAL STEM-CELL; IN-VITRO; CLOSTRIDIUM-DIFFICILE; BONE; DIFFERENTIATION; RESISTANCE; IMPLANTS; ADHESION; REGENERATION; MECHANISM	Coating the surface of titanium implants or other bone graft substitute materials with calcium phosphate (Ca-P) crystals is an effective way to enhance the osteoconduction of the implants. Ca-P coating alone cannot confer pro-osteodifferentiation and antibacterial capabilities on implants; however, it can serve as a carrier for biological agents which could improve the performance of implants and bone substitutes. Here, we constructed a novel, bi-functional Ca-P coating with combined pro-osteodifferentiation and antibacterial capabilities. Different concentrations of metronidazole (MNZ) and simvastatin (SIM) were integrated into biomimetic Ca-P coatings on the surface of titanium disks. The biological effects of this bi-functional biomimetic coating on human bone marrow mesenchymal stem cells (hBMMSCs), human adipose derived stromal cells (hASCs), and Porphyromonas gingivalis were assessed in vitro. We observed that Ca-P coatings loaded with both SIM and MNZ display favorable release kinetics without affecting cell proliferation or attachment. In the inhibition zone test, we found that the bi-functional coating showed lasting antibacterial effects when incubated with Porphyromonas gingivalis for 2 and 4 days. Moreover, the osteodifferentiation of hBMMSCs and hASCs were increased when cultured on this bi-functional coating for 7 and 14 days. Both drugs were loaded onto the Ca-P coating at specific concentrations (10 25 M SIM; 10 22 M MNZ) to achieve optimal release kinetics. Considering the safety, stability and low cost of SIM and MNZ, this novel bifunctional Ca-P coating technique represents a promising method to improve the performance of metal implants or other bone substitute materials, and can theoretically be easily translated to clinical applications.	[Liu, Yunsong; Zhang, Xiao; Jin, Xiaoxiao; Fan, Cong; Ye, Hongqiang; Ou, Meng'en; Lv, Longwei; Zhou, Yongsheng] Peking Univ, Sch & Hosp Stomatol, Dept Prosthodont, Beijing 100871, Peoples R China; [Liu, Yunsong; Zhou, Yongsheng] Natl Engn Lab Digital & Mat Technol Stomatol, Beijing, Peoples R China; [Liu, Yang] Peking Univ, Sch & Hosp Stomatol, Dept Orthodont, Beijing 100871, Peoples R China; [Wu, Gang] Vrije Univ Amsterdam, Res Inst MOVE, Acad Ctr Dentristry Amsterdam ACTA, Dept Oral Implantol & Prosthet Dent, Amsterdam, Netherlands; [Zhou, Yongsheng] Peking Univ, Sch & Hosp Stomatol, Cent Lab, Beijing 100871, Peoples R China	Peking University; Peking University; Academic Center for Dentistry Amsterdam; Vrije Universiteit Amsterdam; Peking University	Zhou, YS (corresponding author), Peking Univ, Sch & Hosp Stomatol, Dept Prosthodont, Beijing 100871, Peoples R China.	kqzhouysh@hsc.pku.edu.cn	Lv, Longwei/ABA-5055-2020; wu, gang/C-5072-2012	wu, gang/0000-0001-8941-2500	National Natural Science Foundation of China [30901693, 81170937]; Program for New Century Excellent Talents in University from Ministry of Education [BMU20110274]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for New Century Excellent Talents in University from Ministry of Education(Program for New Century Excellent Talents in University (NCET))	This study was supported by grants from the National Natural Science Foundation of China (No. 30901693, No. 81170937), http://www.nsfc.gov.cn/Portal0/default152.htm. This study was also supported by the Program for New Century Excellent Talents in University from Ministry of Education (BMU20110274), http://www.moe.edu.cn/publicfiles/business/htmlfiles/moe/A16/index.html. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akiyama K, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt131; Boyanova L, 2004, ANAEROBE, V10, P261, DOI 10.1016/j.anaerobe.2004.06.001; Endres M, 2003, TISSUE ENG, V9, P689, DOI 10.1089/107632703768247386; Gaines S T, 1988, J Bone Joint Surg Am, V70, P1430; Goodman SB, 2013, BIOMATERIALS, V34, P3174, DOI 10.1016/j.biomaterials.2013.01.074; GRISTINA AG, 1987, SCIENCE, V237, P1588, DOI 10.1126/science.3629258; He J, 2012, J BIOMED MATER RES A, V100A, P1706, DOI 10.1002/jbm.a.34121; Herberg S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058207; Hickok NJ, 2012, ADV DRUG DELIVER REV, V64, P1165, DOI 10.1016/j.addr.2012.03.015; Huang Z, 2013, BIOMATERIALS, V34, P3303, DOI 10.1016/j.biomaterials.2013.01.054; Kang JM, 2012, ACTA BIOMATER, V8, P1759, DOI 10.1016/j.actbio.2012.01.005; Kunishima H, 2013, J INFECT CHEMOTHER, V19, P360, DOI 10.1007/s10156-013-0553-5; LeGeros RZ, 2002, CLIN ORTHOP RELAT R, P81; Leitsch D, 2009, MOL MICROBIOL, V72, P518, DOI 10.1111/j.1365-2958.2009.06675.x; Liu Y, 2007, J DENT RES, V86, P84, DOI 10.1177/154405910708600114; Liu Y, 2011, NAT MED, V17, P1594, DOI 10.1038/nm.2542; Liu YL, 2010, J R SOC INTERFACE, V7, pS631, DOI 10.1098/rsif.2010.0115.focus; Liu YS, 2008, BIOMATERIALS, V29, P3338, DOI 10.1016/j.biomaterials.2008.04.037; Liu YS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056002; MANKIN HJ, 1983, CLIN ORTHOP RELAT R, P69; Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946; Nolan R, 2014, CLIN ORAL IMPLAN RES, V25, P252, DOI 10.1111/clr.12124; Pauly S, 2009, BONE, V45, P505, DOI 10.1016/j.bone.2009.05.010; Pelaez T, 2008, J CLIN MICROBIOL, V46, P3028, DOI 10.1128/JCM.00524-08; Peter B, 2005, BONE, V36, P52, DOI 10.1016/j.bone.2004.10.004; Saran N, 2011, CLIN ORTHOP RELAT R, V469, P1470, DOI 10.1007/s11999-010-1573-4; Sun LM, 2002, J BIOMED MATER RES, V62, P228, DOI 10.1002/jbm.10315; Tavakoli N, 2007, J PHARMACEUT BIOMED, V43, P325, DOI 10.1016/j.jpba.2006.06.002; Uzzan B, 2007, BONE, V40, P1581, DOI 10.1016/j.bone.2007.02.019; van der Wouden EJ, 2001, SCAND J GASTROENTERO, V36, P10, DOI 10.1080/003655201753265055; Wu G, 2010, TISSUE ENG PART C-ME, V16, P1255, DOI [10.1089/ten.tec.2009.0588, 10.1089/ten.TEC.2009.0588]; Wu G, 2010, BIOMATERIALS, V31, P7485, DOI 10.1016/j.biomaterials.2010.06.037; Yang F, 2011, ORAL SURG ORAL MED O, V111, P551, DOI 10.1016/j.tripleo.2010.06.018; Yang XF, 2009, DENT MATER, V25, P473, DOI 10.1016/j.dental.2008.09.007; Yardimci C, 2010, J CHROMATOGR SCI, V48, P95, DOI 10.1093/chromsci/48.2.95; Zhang WX, 2008, J BIOL CHEM, V283, P4723, DOI 10.1074/jbc.M704147200; Zhou W, 2010, BIOMATERIALS, V31, P3212, DOI 10.1016/j.biomaterials.2010.01.036; Zhou YS, 2010, BIOMATERIALS, V31, P5325, DOI 10.1016/j.biomaterials.2010.03.037	38	21	21	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2014	9	5							e97741	10.1371/journal.pone.0097741	http://dx.doi.org/10.1371/journal.pone.0097741			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM0UW	24844416	Green Published, Green Submitted, gold			2023-01-03	WOS:000339563400054
J	Wang, F; Dai, WQ; Wang, YG; Shen, M; Chen, K; Cheng, P; Zhang, Y; Wang, CF; Li, JJ; Zheng, YY; Lu, J; Yang, J; Zhu, R; Zhang, HW; Zhou, YQ; Xu, L; Guo, CY				Wang, Fan; Dai, Weiqi; Wang, Yugang; Shen, Miao; Chen, Kan; Cheng, Ping; Zhang, Yan; Wang, Chengfen; Li, Jingjing; Zheng, Yuanyuan; Lu, Jie; Yang, Jing; Zhu, Rong; Zhang, Huawei; Zhou, Yingqun; Xu, Ling; Guo, Chuanyong			The Synergistic In Vitro and In Vivo Antitumor Effect of Combination Therapy with Salinomycin and 5-Fluorouracil against Hepatocellular Carcinoma	PLOS ONE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CANCER STEM-CELLS; BREAST-CANCER; CATENIN; RESISTANCE; ACTIVATION; GROWTH; LINES; CHEMORESISTANCE; CHEMOTHERAPY	Hepatocellular carcinoma (HCC) is one of the few cancers in which a continuous increase in incidence has been observed over several years. Drug resistance is a major problem in the treatment of HCC. In the present study, we used salinomycin (Sal) and 5-fluorouracil (5-FU) combination therapy on HCC cell lines Huh7, LM3 and SMMC-7721 and nude mice subcutaneously tumor model to study whether Sal could increase the sensitivity of hepatoma cells to the traditional chemotherapeutic agent such as 5-FU. The combination of Sal and 5-FU resulted in a synergistic antitumor effect against liver tumors both in vitro and in vivo. Sal reversed the 5-FU-induced increase in CD133(+) EPCAM(+) cells, epithelial-mesenchymal transition and activation of the Wnt/beta-catenin signaling pathway. The combination of Sal and 5-FU may provide us with a new approach to reverse drug resistant for the treatment of patients with HCC.	[Wang, Fan; Dai, Weiqi; Shen, Miao; Chen, Kan; Cheng, Ping; Zhang, Yan; Wang, Chengfen; Li, Jingjing; Zheng, Yuanyuan; Lu, Jie; Yang, Jing; Zhou, Yingqun; Guo, Chuanyong] Tongji Univ Med, Shanghai Peoples Hosp 10, Dept Gastroenterol, Shanghai, Peoples R China; [Wang, Yugang; Xu, Ling] Jiaotong Univ Med, Shanghai Tongren Hosp, Dept Gastroenterol, Shanghai, Peoples R China; [Zhu, Rong] Nanjing Med Univ, Clin Med Shanghai Peoples Hosp 10, Dept Gastroenterol, Shanghai, Peoples R China; [Zhang, Huawei] Suzhou Univ, Hosp 1, Dept Gastroenterol, Suzhou 215006, Peoples R China	Tongji University; Shanghai Jiao Tong University; Nanjing Medical University; Soochow University - China	Xu, L (corresponding author), Jiaotong Univ Med, Shanghai Tongren Hosp, Dept Gastroenterol, Shanghai, Peoples R China.	xuling606@sina.com; guochuanyong@hotmail.com		Guo, Chuanyong/0000-0002-6527-4673	National Nature Science Foundation of China [81302788]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC))	This research was funded by National Nature Science Foundation of China (No. 81302788). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chen Y, 2012, INT J BIOL SCI, V8, P992, DOI 10.7150/ijbs.4454; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Collura A, 2013, CELL MOL LIFE SCI, V70, P729, DOI 10.1007/s00018-012-1160-9; Dang HE, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-396; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Dylla SJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002428; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Haraguchi N, 2010, J CLIN INVEST, V120, P3326, DOI 10.1172/JCI42550; He L, 2013, PANCREATOLOGY, V13, P72, DOI 10.1016/j.pan.2012.11.314; Huntly BJP, 2005, NATURE, V435, P1169, DOI 10.1038/4351169a; Ikeda M, 2008, JPN J CLIN ONCOL, V38, P675, DOI 10.1093/jjco/hyn087; Jin J, 2002, WORLD J GASTROENTERO, V8, P1029, DOI 10.3748/wjg.v8.i6.1029; Kelland LR, 2004, EUR J CANCER, V40, P827, DOI 10.1016/j.ejca.2003.11.028; Kusunoki S, 2013, GYNECOL ONCOL, V129, P598, DOI 10.1016/j.ygyno.2013.03.005; Lan X, 2013, INT J MOL MED, V31, P315, DOI 10.3892/ijmm.2012.1208; Li XF, 2013, CANCER LETT, V336, P379, DOI 10.1016/j.canlet.2013.03.027; Lin DY, 1997, J GASTROEN HEPATOL, V12, pS319, DOI 10.1111/j.1440-1746.1997.tb00516.x; Macdonald JS, 2001, NEW ENGL J MED, V345, P725, DOI 10.1056/NEJMoa010187; Macdonald JS, 2001, SEMIN ONCOL, V28, P30, DOI 10.1053/sonc.2001.20750; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martin M, 2005, NEW ENGL J MED, V352, P2302, DOI 10.1056/NEJMoa043681; Miyake M, 2012, ONCOL LETT, V3, P1195, DOI 10.3892/ol.2012.662; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Na DC, 2011, EXP MOL PATHOL, V90, P66, DOI 10.1016/j.yexmp.2010.10.003; Noda T, 2009, BRIT J CANCER, V100, P1647, DOI 10.1038/sj.bjc.6605064; Santisteban M, 2009, CANCER RES, V69, P2887, DOI 10.1158/0008-5472.CAN-08-3343; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sun YF, 2013, HEPATOLOGY, V57, P1458, DOI 10.1002/hep.26151; Tanahashi T, 2013, INT J ONCOL, V42, P556, DOI 10.3892/ijo.2012.1726; Tang QL, 2011, CANCER LETT, V311, P113, DOI 10.1016/j.canlet.2011.07.016; Terpstra W, 1996, BLOOD, V88, P1944, DOI 10.1182/blood.V88.6.1944.bloodjournal8861944; Uchibori K, 2012, INT J ONCOL, V40, P1005, DOI 10.3892/ijo.2011.1300; Voskoglou-Nomikos T, 2003, CLIN CANCER RES, V9, P4227; Wagner RT, 2010, STEM CELLS, V28, P1794, DOI 10.1002/stem.502; Wang F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050638; Workman P, 2010, BRIT J CANCER, V102, P1555, DOI 10.1038/sj.bjc.6605642; Yang LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036; Yang W, 2008, CANCER RES, V68, P4287, DOI 10.1158/0008-5472.CAN-07-6691; Yoo BK, 2009, P NATL ACAD SCI USA, V106, P12938, DOI 10.1073/pnas.0901451106; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zhang WJ, 2012, BIOCHEM BIOPH RES CO, V417, P679, DOI 10.1016/j.bbrc.2011.11.142; Zhang Y, 2012, CANCER LETT, V322, P70, DOI 10.1016/j.canlet.2012.02.010	42	48	50	1	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2014	9	5							e97414	10.1371/journal.pone.0097414	http://dx.doi.org/10.1371/journal.pone.0097414			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI4LX	24816638	Green Published, gold, Green Submitted			2023-01-03	WOS:000336838000134
J	Kazatchkine, M				Kazatchkine, Michel			PERSONAL VIEW Russia's ban on methadone for drug users in Crimea will worsen the HIV/AIDS epidemic and risk public health	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									UN Secretary Gen Special Envoy HIV AIDS Eastern E, Int AIDS Soc, CH-1202 Geneva, Switzerland		Kazatchkine, M (corresponding author), UN Secretary Gen Special Envoy HIV AIDS Eastern E, Int AIDS Soc, Ave France 23, CH-1202 Geneva, Switzerland.							Andrey Rylkov Foundation for Health and Social Justice, 2011, ACT IR TEPL WHO REC; Andrey Rylkov Foundation for Health and Social Justice, 2012, IV AN COMPL UN SPEC; [Anonymous], 2004, 2004 REP GLOB AIDS E; [Anonymous], 2014, 24 WORLD        0420; Degenhardt L, 2010, LANCET, V376, P285, DOI 10.1016/S0140-6736(10)60742-8; Drug Reporter, 2014, DRUG REPORTER   0402; European Centre for Disease Prevention and Control/World Health Organization Regional Office for Europe, 2013, HIV AIDS SURV EUR 20; Federal Service of the Russian Federation for Narcotics Control, 2014, ORG ANT ACT CRIM FED; Federal Service of the Russian Federation for Narcotics Control, 2014, DECR SIGN EST REG AN; Russian Federation, FED LAW DRUGS PSYCH; Stebenkova Lyudmila, 2014, MEMBERS MOSCOW CITY; Subata E., 2013, OPIOID SUBSTITUTION; Ukrainian Center for Socially Dangerous Disease Control of the Ministry of Health, INF QUANT QUAL CHAR; UNAIDS, 2010, REP GLOB AIDS EP 201; World Health Organization, 2012, WHO UNODC UNAIDS TEC; World Health Organization, 2009, GUID PSYCH ASS PHARM	16	20	21	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 8	2014	348								g3118	10.1136/bmj.g3118	http://dx.doi.org/10.1136/bmj.g3118			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AH0OM	24812004	Bronze			2023-01-03	WOS:000335819700013
J	Milenkovic, D; Vanden Berghe, W; Boby, C; Leroux, C; Declerck, K; Szic, KSV; Heyninck, K; Laukens, K; Bizet, M; Defrance, M; Dedeurwaerder, S; Calonne, E; Fuks, F; Haegeman, G; Haenen, GRMM; Bast, A; Weseler, AR				Milenkovic, Dragan; Vanden Berghe, Wim; Boby, Celine; Leroux, Christine; Declerck, Ken; Szic, Katarzyna Szarc Vel; Heyninck, Karen; Laukens, Kris; Bizet, Martin; Defrance, Matthieu; Dedeurwaerder, Sarah; Calonne, Emilie; Fuks, Francois; Haegeman, Guy; Haenen, Guido R. M. M.; Bast, Aalt; Weseler, Antje R.			Dietary Flavanols Modulate the Transcription of Genes Associated with Cardiovascular Pathology without Changes in Their DNA Methylation State	PLOS ONE			English	Article							BLOOD MONONUCLEAR-CELLS; EXPRESSION PROFILES; LEUKOCYTE ADHESION; SMOKING; POLYPHENOLS; CANCER; SUPPLEMENTATION; EPIGENETICS; EPIGENOME; PATTERNS	Background: In a recent intervention study, the daily supplementation with 200 mg monomeric and oligomeric flavanols (MOF) from grape seeds for 8 weeks revealed a vascular health benefit in male smokers. The objective of the present study was to determine the impact of MOF consumption on the gene expression profile of leukocytes and to assess changes in DNA methylation. Methodology/Principal Findings: Gene expression profiles were determined using whole genome microarrays (Agilent) and DNA methylation was assessed using HumanMethylation450 BeadChips (Illumina). MOF significantly modulated the expression of 864 genes. The majority of the affected genes are involved in chemotaxis, cell adhesion, cell infiltration or cytoskeleton organisation, suggesting lower immune cell adhesion to endothelial cells. This was corroborated by in vitro experiments showing that MOF exposure of monocytes attenuates their adhesion to TNF-alpha-stimulated endothelial cells. Nuclear factor kappa B (NF-kappa B) reporter gene assays confirmed that MOF decrease the activity of NF-kB. Strong inter-individual variability in the leukocytes' DNA methylation was observed. As a consequence, on group level, changes due to MOF supplementation could not be found. Conclusion: Our study revealed that an 8 week daily supplementation with 200 mg MOF modulates the expression of genes associated with cardiovascular disease pathways without major changes of their DNA methylation state. However, strong inter-individual variation in leukocyte DNA methylation may obscure the subtle epigenetic response to dietary flavanols. Despite the lack of significant changes in DNA methylation, the modulation of gene expression appears to contribute to the observed vascular health effect of MOF in humans.	[Milenkovic, Dragan] INRA, UNH, CRNH Auvergne, UMR 1019, Clermont Ferrand, France; [Milenkovic, Dragan] Univ Clermont Ferrand 2, Univ Auvergne, Unite Nutr Humaine, Clermont Ferrand, France; [Vanden Berghe, Wim; Heyninck, Karen; Haegeman, Guy] Univ Ghent, Lab Eukaryot Gene Express & Signal Transduct LEGE, B-9000 Ghent, Belgium; [Vanden Berghe, Wim; Declerck, Ken; Szic, Katarzyna Szarc Vel] Univ Antwerp, Dept Biomed Sci, PPES, Antwerp, Belgium; [Boby, Celine; Leroux, Christine] INRA, Herbivores UMR1213, F-63122 St Genes Champanelle, France; [Laukens, Kris] Univ Antwerp, Dept Math & Comp Sci, B-2020 Antwerp, Belgium; [Laukens, Kris] Univ Antwerp, Univ Antwerp Hosp, Biomed Informat Res Ctr Antwerp Biomina, Edegem, Belgium; [Bizet, Martin; Defrance, Matthieu; Dedeurwaerder, Sarah; Calonne, Emilie; Fuks, Francois] Free Univ Brussels, Lab Canc Epigenet, Brussels, Belgium; [Haenen, Guido R. M. M.; Bast, Aalt; Weseler, Antje R.] Maastricht Univ, Dept Toxicol, Maastricht, Netherlands	INRAE; Universite Clermont Auvergne (UCA); Ghent University; University of Antwerp; INRAE; VetAgro Sup; University of Antwerp; University of Antwerp; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Maastricht University	Weseler, AR (corresponding author), INRA, UNH, CRNH Auvergne, UMR 1019, Clermont Ferrand, France.	a.weseler@maastrichtuniversity.nl	Berghe, Wim Vanden/S-6425-2018; Bast, Aalt/I-7809-2013; Vanden Berghe, Wim/HGE-4696-2022; Laukens, Kris/V-1121-2018	Berghe, Wim Vanden/0000-0003-0161-7355; Laukens, Kris/0000-0002-8217-2564; Defrance, Matthieu/0000-0002-3090-3142; Leroux, Christine/0000-0001-6835-3978; Bast, Aalt/0000-0002-5383-2789; Declerck, Ken/0000-0001-8104-8054; Haenen, Guido/0000-0001-6986-290X; BOBY, Celine/0000-0002-4420-7033; Milenkovic, Dragan/0000-0001-6353-0912	International Nutrition Company (INC) BV, Loosdrecht, The Netherlands; European Union [226588]; University of Antwerp, Belgium	International Nutrition Company (INC) BV, Loosdrecht, The Netherlands(Netherlands Government); European Union(European Commission); University of Antwerp, Belgium	The study was financially supported by International Nutrition Company (INC) BV, Loosdrecht, The Netherlands, the European Union (grant 226588, entitled Flaviola) within the Seventh Framework Programme and by the University of Antwerp, Belgium. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adalsteinsson BT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046705; Auclair Sylvain, 2009, Atherosclerosis, V204, pe21, DOI 10.1016/j.atherosclerosis.2008.12.007; Bell JT, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-405; Bellavia A, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000212; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Boomgaarden I, 2010, BRIT J NUTR, V104, P336, DOI 10.1017/S0007114510000711; Boque N, 2013, MOL NUTR FOOD RES, V57, P1473, DOI 10.1002/mnfr.201200686; Breitling LP, 2011, AM J HUM GENET, V88, P450, DOI 10.1016/j.ajhg.2011.03.003; Chanet A, 2013, BRIT J NUTR, V110, P587, DOI 10.1017/S0007114512005454; Chanet A, 2012, J NUTR BIOCHEM, V23, P469, DOI 10.1016/j.jnutbio.2011.02.001; Chao CL, 2011, EUR J NUTR, V50, P401, DOI 10.1007/s00394-010-0151-6; Coban D, 2012, MOL NUTR FOOD RES, V56, P1270, DOI 10.1002/mnfr.201100818; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Crescenti A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065744; de Boer VCJ, 2006, CELL MOL LIFE SCI, V63, P2847, DOI 10.1007/s00018-006-6316-z; Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511; Dedeurwaerder S, 2013, BRIEF BIOIN IN PRESS; Del Rio D, 2013, ANTIOXID REDOX SIGN, V18, P1818, DOI 10.1089/ars.2012.4581; Dogan MV, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-151; Ehrlich S, 2012, CAN J PSYCHIAT, V57, P168, DOI 10.1177/070674371205700306; Elliott HR, 2014, CLIN EPIGENETICS, V6, DOI 10.1186/1868-7083-6-4; Faulk C, 2011, EPIGENETICS-US, V6, P791, DOI 10.4161/epi.6.7.16209; Feringa HHH, 2011, J AM DIET ASSOC, V111, P1173, DOI 10.1016/j.jada.2011.05.015; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Friso S, 2013, CANCER EPIDEM BIOMAR, V22, P348, DOI 10.1158/1055-9965.EPI-12-0859; Gao Y, 2012, WORLD J GASTRO ONCOL, V4, P193, DOI 10.4251/wjgo.v4.i8.193; Gibbs JR, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000952; Gluckman PD, 2009, NAT REV ENDOCRINOL, V5, P401, DOI 10.1038/nrendo.2009.102; Heiss C, 2010, EUR HEART J, V31, P2583, DOI 10.1093/eurheartj/ehq332; Howard TD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026791; Jacoby M, 2012, EPIGENETICS-US, V7, P1421, DOI 10.4161/epi.22845; Joubert BR, 2012, ENVIRON HEALTH PERSP, V120, P1425, DOI 10.1289/ehp.1205412; Kaul D, 2004, PHYTOTHER RES, V18, P177, DOI 10.1002/ptr.1411; Leiro J, 2005, INT IMMUNOPHARMACOL, V5, P393, DOI 10.1016/j.intimp.2004.10.006; Libby P, 2006, AM J CLIN NUTR, V83, p456S; Man SM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003197; Milenkovic D, 2013, FREE RADICAL BIO MED, V64, P40, DOI 10.1016/j.freeradbiomed.2013.05.046; Milenkovic D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026669; Moser M, 2009, NAT MED, V15, P300, DOI 10.1038/nm.1921; Mundy GR, 2007, NUTR REV, V65, pS147, DOI [10.1111/j.1753-4887.2007.tb00353.x, 10.1301/nr.2007.dec.S147-S151]; Nola S, 2008, HUM MOL GENET, V17, P3552, DOI 10.1093/hmg/ddn248; Ordovas JM, 2010, NAT REV CARDIOL, V7, P510, DOI 10.1038/nrcardio.2010.104; Overman A, 2011, INT J OBES LOND, V34, P800; Paur I, 2008, FOOD CHEM TOXICOL, V46, P1288, DOI 10.1016/j.fct.2007.09.103; Price EM, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-4; Ray P, 2012, BIOCHEM J, V442, P433, DOI 10.1042/BJ20111341; Reinius LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041361; Schroeter H, 2010, MOL ASPECTS MED, V31, P546, DOI 10.1016/j.mam.2010.09.008; Scoccianti C, 2011, EPIGENETICS-US, V6, P1114, DOI 10.4161/epi.6.9.16515; Shanmugam MK, 2012, SUBCELL BIOCH, V61, P627; Shenker NS, 2013, HUM MOL GENET, V22, P843, DOI 10.1093/hmg/dds488; Simoons M L, 1998, Ned Tijdschr Geneeskd, V142, P2096; Sulistyoningrum DC, 2012, EPIGENETICS-US, V7, P514, DOI 10.4161/epi.19836; Symonds ME, 2009, NAT REV ENDOCRINOL, V5, P604, DOI 10.1038/nrendo.2009.195; Tome-Carneiro J, 2013, PHARMACOL RES, V72, P69, DOI 10.1016/j.phrs.2013.03.011; Tonna S, 2010, NAT REV NEPHROL, V6, P332, DOI 10.1038/nrneph.2010.55; Udali S, 2013, MOL ASPECTS MED, V34, P883, DOI 10.1016/j.mam.2012.08.001; van den Berg R, 2001, ENVIRON TOXICOL PHAR, V9, P147, DOI 10.1016/S1382-6689(00)00070-3; van der Velpen V, 2013, J NUTR, V143, P774, DOI 10.3945/jn.113.174037; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Vanden Berghe W, 2012, PHARMACOL RES, V65, P565, DOI 10.1016/j.phrs.2012.03.007; Vanhees K, 2011, FASEB J, V25, P797, DOI 10.1096/fj.10-172155; Von Hundelshausen P, 2009, MICROCIRCULATION, V16, P84, DOI 10.1080/10739680802564787; Wan ES, 2012, HUM MOL GENET, V21, P3073, DOI 10.1093/hmg/dds135; Weber C, 2004, ARTERIOSCL THROM VAS, V24, P1997, DOI 10.1161/01.ATV.0000142812.03840.6f; Weseler AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028460; Zeilinger S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063812; Zhang DD, 2010, AM J HUM GENET, V86, P411, DOI 10.1016/j.ajhg.2010.02.005	68	38	39	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 24	2014	9	4							e95527	10.1371/journal.pone.0095527	http://dx.doi.org/10.1371/journal.pone.0095527			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG6CB	24763279	Green Published, gold			2023-01-03	WOS:000335505000022
J	Koffman, J; Ho, YK; Davies, J; Gao, W; Higginson, IJ				Koffman, Jonathan; Ho, Yuen King; Davies, Joanna; Gao, Wei; Higginson, Irene J.			Does Ethnicity Affect Where People with Cancer Die ? A Population-Based 10 Year Study	PLOS ONE			English	Article							SPECIALIST PALLIATIVE CARE; HEALTH-CARE; UNITED-STATES; DEATH; PLACE; HOSPICE; LIFE; END; INEQUALITIES; MINORITY	Background: Ageing is a growing issue for people from UK black, Asian and minority ethnic (BAME) groups. The health experiences of these groups are recognised as a 'tracer' to measure success in end of life patient-preferred outcomes that includes place of death (PoD). Aim: To examine patterns in PoD among BAME groups who died of cancer. Material and Methods: Mortality data for 93,375 cancer deaths of those aged >= 65 years in London from 2001-2010 were obtained from the UK Office for National Statistics (ONS). Decedent's country of birth was used as a proxy for ethnicity. Linear regression examined trends in place of death across the eight ethnic groups and Poisson regression examined the association between country of birth and place of death. Results: 76% decedents were born in the UK, followed by Ireland (5.9%), Europe(5.4%) and Caribbean(4.3%). Most deaths(52.5%) occurred in hospital, followed by home(18.7%). During the study period, deaths in hospital declined with an increase in home deaths; trend for time analysis for those born in UK(0.50%/yr[0.36-0.64%] p < 0.001), Europe (1.00%/yr[0.64-1.30%] p < 0.001), Asia(1.09%/yr[0.94-1.20%] p < 0.001) and Caribbean(1.03%/yr[0.72-1.30%] p < 0.001). However, time consistent gaps across the geographical groups remained. Following adjustment hospital deaths were more likely for those born in Asia(Proportion ratio(PR) 1.12[95% CI1.08-1.15] p < 0.001) and Africa(PR 1.11[95% CI1.07-1.16] p < 0.001). Hospice deaths were less likely for those born in Asia(PR 0.73 [0.68-0.80] p < 0.001), Africa (PR 0.83[95% CI0.74-0.93] p < 0.001), and 'other' geographical regions (PR0.90[95% 0.82-0.98] p < 0.001). Home deaths were less likely for those born in the Caribbean(PR0.91[95% CI 0.85-0.98] p < 0.001). Conclusions: Location of death varies by country of birth. BAME groups are more likely to die in a hospital and less likely to die at home or in a hospice. Further investigation is needed to determine whether these differences result from patient-centred preferences, or other environment or service-related factors. This knowledge will enable strategies to be developed to improve access to relevant palliative care and related services, where necessary.	[Koffman, Jonathan; Ho, Yuen King; Davies, Joanna; Gao, Wei; Higginson, Irene J.] Kings Coll London, Cicely Saunders Inst, Dept Palliat Care Policy & Rehabil, London WC2R 2LS, England	University of London; King's College London	Koffman, J (corresponding author), Kings Coll London, Cicely Saunders Inst, Dept Palliat Care Policy & Rehabil, London WC2R 2LS, England.	jonathan.koffman@kcl.ac.uk	Gao, Wei/G-8653-2011; Higginson, Irene Julie/C-7309-2012	Gao, Wei/0000-0001-8298-3415; Higginson, Irene Julie/0000-0002-3687-1313; Koffman, Jonathan/0000-0001-8513-5681	National Institute for Health Research Health Services and Delivery Research (NIHR HS DR) [09/2000/58]; National Institute for Health Research [09/2000/58] Funding Source: researchfish	National Institute for Health Research Health Services and Delivery Research (NIHR HS DR); National Institute for Health Research(National Institute for Health Research (NIHR))	The GUIDE Care project was funded by the National Institute for Health Research Health Services and Delivery Research (NIHR HS& DR) programme (Project number 09/2000/58). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Affairs UNDoEaS, 2006, WORLD MIGR STOCK 200; Ahmad WIU, 2007, SOCIOL HEALTH ILL, V29, P795, DOI 10.1111/j.1467-9566.2007.01051.x; Ahmed N, 2004, PALLIATIVE MED, V18, P525, DOI 10.1191/0269216304pm921oa; Arora S., 2001, RACISM MED AGENDA CH, P141; Aspinall PJ, 1999, J PUBLIC HEALTH MED, V21, P125, DOI 10.1093/pubmed/21.2.125; Barratt H, 2001, BRIT MED J, V323, P240; Bhopal RS, 2012, J PUBLIC HEALTH-UK, V34, P167, DOI 10.1093/pubmed/fds004; Bruera E, 2003, J PAIN SYMPTOM MANAG, V26, P637, DOI 10.1016/S0885-3924(03)00204-5; Calazani N, 2013, PALLIATIVE END LIFE; Centre NI, 2009, GOOD IS HES ETHN COD; Cohen LL, 2008, J PALLIAT MED, V11, P763, DOI 10.1089/jpm.2007.0216; Connor SR, 2008, PALLIATIVE MED, V22, P205, DOI 10.1177/0269216308089305; Coupland VH, 2011, PALLIATIVE MED, V25, P314, DOI 10.1177/0269216310395986; Decker SL, 2007, EUR J PUBLIC HEALTH, V17, P285, DOI 10.1093/eurpub/ckl243; Enguidanos S, 2005, J AM GERIATR SOC, V53, P1411, DOI 10.1111/j.1532-5415.2005.53410.x; Europe WROf, 2010, HLTH SYST CAN ADDR H; Fischbacher CM, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-142; Flory J, 2004, HEALTH AFFAIR, V23, P194, DOI 10.1377/hlthaff.23.3.194; Gao W, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001410; Gastrell Julie, 2004, Health Stat Q, P7; Goddard M, 2001, SOC SCI MED, V53, P1149, DOI 10.1016/S0277-9536(00)00415-9; Gomes B, 2006, BMJ-BRIT MED J, V332, P515, DOI 10.1136/bmj.38740.614954.55; Gomes B, 2012, ANN ONCOL, V23, P2006, DOI 10.1093/annonc/mdr602; Gomes B, 2013, BMC PALLIAT CARE, V12, DOI 10.1186/1472-684X-12-7; Haas JS, 2007, J GEN INTERN MED, V22, P396, DOI 10.1007/s11606-006-0034-y; Health Do, 2008, END LIF CAR STRAT PR; Health SAf, 2013, HACKNEY COMPASSIONAT; Higginson IJ, 2005, CLIN GERIATR MED, V21, P45, DOI 10.1016/j.cger.2004.08.003; Hopp FP, 2000, J AM GERIATR SOC, V48, P658, DOI 10.1111/j.1532-5415.2000.tb04724.x; Hospices Ht, 2012, EXCELLENCE HOSPICE C; Iwashyna TJ, 2002, J AM GERIATR SOC, V50, P1113, DOI 10.1046/j.1532-5415.2002.50269.x; Jack RH, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-281; Karim K, 2000, PALLIATIVE MED, V14, P471, DOI 10.1191/026921600701536390; Karlsen S, 2010, ETHNIC HEALTH, V15, P549, DOI 10.1080/13557858.2010.497204; Kirkup J., 2012, TELEGRAPH; Koffman J, 2000, J PUBLIC HEALTH MED, V22, P245, DOI 10.1093/pubmed/22.2.245; Koffman J, 2001, PALLIATIVE MED, V15, P337, DOI 10.1191/026921601678320322; Koffman J, 2008, OXFORD TXB PALLIATIV, P141; Koffman J, 2011, PSYCHO-ONCOLOGY, DOI [10.1002/pon.1912: 4-400, DOI 10.1002/PON.1912:4-400]; Koffman J., 2006, EUR J PALLIAT CARE, V11, P18; Koffman J, 2007, PALLIATIVE MED, V21, P145, DOI 10.1177/0269216306074639; Koffman Jonathan, 2004, J Palliat Med, V7, P628, DOI 10.1089/jpm.2004.7.628; Lock A, 2005, BMC PALLIAT CARE, V4, DOI [10.1186/1472-1684X-1184-1186, DOI 10.1186/1472-1684X-1184-1186]; Lorant V, 2011, EUR J PUBLIC HEALTH, V21, P235, DOI 10.1093/eurpub/ckq061; Marmot M, 2005, LANCET, V365, P1099, DOI 10.1016/S0140-6736(05)74234-3; Martins T, 2013, BMC FAM PRACT, V14, DOI 10.1186/1471-2296-14-197; Mathers CD, 2005, B WORLD HEALTH ORGAN, V83, P171; McLennan D., 2011, ENGLISH INDICES DEPR; R Mathur, 2013, J PUBLIC HLTH, V36, P19; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Simpson L., 2007, H OFFICIAL STAT, V23, P185; Sleeman KE, 2013, PALLIATIVE MED, V27, P840, DOI 10.1177/0269216313490436; Smaje C, 1997, DEATH GENDER ETHNICI, P142; Statistics OfN, 2012, ETHN NAT ID ENGL WAL; Statistics OfN, 2013, 2011 CENS AN COMP RU; Statistics OfN, 2012, 2011 CENS KEY STAT E; Stronks K, 2009, ETHN HLTH, V14, P1; Teno JM, 2013, JAMA-J AM MED ASSOC, V309, P470, DOI 10.1001/jama.2012.207624; United Nations General Assembly, 1949, UN DECL HUM RIGHTS, V3381; Velikova G, 2004, BRIT J CANCER, V90, P1926, DOI 10.1038/sj.bjc.6601795; Wei G, 2013, PLOS MED, V10; Wood DJ, 2004, PALLIATIVE MED, V18, P543, DOI 10.1191/0269216304pm892oa; Worth A, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b183	63	25	25	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 21	2014	9	4							e95052	10.1371/journal.pone.0095052	http://dx.doi.org/10.1371/journal.pone.0095052			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AG2DX	24751724	Green Published, Green Submitted, gold			2023-01-03	WOS:000335227400028
J	Nguyen, HL; Ha, DA; Phan, DT; Nguyen, QN; Nguyen, VL; Nguyen, NH; Nguyen, H; Goldberg, RJ				Nguyen, Hoa L.; Duc Anh Ha; Dat Tuan Phan; Quang Ngoc Nguyen; Viet Lan Nguyen; Nguyen Hanh Nguyen; Ha Nguyen; Goldberg, Robert J.			Sex Differences in Clinical Characteristics, Hospital Management Practices, and In-Hospital Outcomes in Patients Hospitalized in a Vietnamese Hospital with a First Acute Myocardial Infarction	PLOS ONE			English	Article							ACUTE-CORONARY-SYNDROME; GENDER-DIFFERENCES; EARLY MORTALITY; HEART-DISEASE; ST ELEVATION; WOMEN; REGISTRY; MEN; SURVIVAL; TRENDS	Background: Cardiovascular disease is one of the leading causes of morbidity and mortality in Vietnam. We conducted a pilot study of Hanoi residents hospitalized with acute myocardial infarction (AMI) at the Vietnam National Heart Institute in Hanoi. The objectives of this observational study were to examine sex differences in clinical characteristics, hospital management, in-hospital clinical complications, and mortality in patients hospitalized with an initial AMI. Methods: The study population consisted of 302 Hanoi residents hospitalized with a first AMI at the largest tertiary care medical center in Hanoi in 2010. Results: The average age of study patients was 66 years and one third were women. Women were older (70 vs. 64 years) and were more likely than men to have had hyperlipidemia previously diagnosed (10% vs. 2%). During hospitalization, women were less likely to have undergone percutaneous coronary intervention (PCI) compared with men (57% vs. 74%), and women were more likely to have developed heart failure compared with men (19% vs. 10%). Women experienced higher in-hospital case-fatality rates (CFRs) than men (13% vs. 4%) and these differences were attenuated after adjustment for age and history of hyperlipidemia (OR: 2.64; 95% CI: 1.01, 6.89), and receipt of PCI during hospitalization (OR: 2.09; 95% CI: 0.77, 5.09). Conclusions: Our pilot data suggest that among patients hospitalized with a first AMI in Hanoi, women experienced higher in-hospital CFRs than men. Full-scale surveillance of all Hanoi residents hospitalized with AMI at all Hanoi medical centers is needed to confirm these findings. More targeted and timely educational and treatment approaches for women appear warranted.	[Nguyen, Hoa L.; Nguyen Hanh Nguyen; Ha Nguyen] Inst Populat Hlth & Dev, Hanoi, Vietnam; [Nguyen, Hoa L.] Univ Oxford, Clin Res Unit, Ho Chi Minh City, Vietnam; [Duc Anh Ha] Minist Hlth, Hanoi, Vietnam; [Dat Tuan Phan; Quang Ngoc Nguyen; Viet Lan Nguyen] Viet Nam Natl Heart Inst, Hanoi, Vietnam; [Goldberg, Robert J.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA	University of Oxford; University of Massachusetts System; University of Massachusetts Worcester	Nguyen, HL (corresponding author), Inst Populat Hlth & Dev, Hanoi, Vietnam.	hoanguyen@phad.org	Nguyen, Hoa/AAA-5685-2020	Nguyen, Hoa/0000-0002-4998-8510	Global Health Office, University of Massachusetts Medical School, Worcester, MA, USA	Global Health Office, University of Massachusetts Medical School, Worcester, MA, USA	This study was funded by the Global Health Office, University of Massachusetts Medical School, Worcester, MA, USA. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2007, HLTH STAT YB 2006; [Anonymous], 2001, HLTH STAT YB 2000; Bowker TJ, 2000, EUR HEART J, V21, P1458, DOI 10.1053/euhj.2000.2237; Butala NM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025904; DEMIROVIC J, 1995, AM J CARDIOL, V75, P1096, DOI 10.1016/S0002-9149(99)80737-1; Dey S, 2009, HEART, V95, P20, DOI 10.1136/hrt.2007.138537; Ebrahim S, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001377; El-Menyar A, 2009, AM J CARDIOL, V104, P1018, DOI 10.1016/j.amjcard.2009.06.003; Goldberg RJ, 2009, AM J CARDIOL, V103, P598, DOI 10.1016/j.amjcard.2008.10.038; Heer T, 2002, AM J CARDIOL, V89, P511, DOI 10.1016/S0002-9149(01)02289-5; Hoang Van Minh, 2006, Prev Chronic Dis, V3, pA89; Jamison DT, 2006, DIS CONTROL PRIORITI; Jiang SL, 2006, AM J CARDIOL, V98, P1000, DOI 10.1016/j.amjcard.2006.05.015; MacIntyre K, 2001, J AM COLL CARDIOL, V38, P729, DOI 10.1016/S0735-1097(01)01465-6; Marrugat J, 1998, JAMA-J AM MED ASSOC, V280, P1405, DOI 10.1001/jama.280.16.1405; McManus DD, 2011, AM J MED, V124, P40, DOI 10.1016/j.amjmed.2010.07.023; Ministry of Health, 2010, HLTH STAT YB 2009; Nguyen HL, 2010, CIRC-CARDIOVASC QUAL, V3, P82, DOI 10.1161/CIRCOUTCOMES.109.884361; Pagidipati NJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062061; Radovanovic D, 2007, HEART, V93, P1369, DOI 10.1136/hrt.2006.106781; Rogers WJ, 2008, AM HEART J, V156, P1026, DOI 10.1016/j.ahj.2008.07.030; Rosengren A, 2001, EUR HEART J, V22, P314, DOI 10.1053/euhj.2000.2368; Song XT, 2007, CHINESE MED J-PEKING, V120, P1063, DOI 10.1097/00029330-200706020-00007; Srichaiveth Boonchu, 2007, Journal of the Medical Association of Thailand, V90, P65; Tunstall-Pedoe H, 1999, LANCET, V353, P1547, DOI 10.1016/S0140-6736(99)04021-0; Vaccarino V, 1999, NEW ENGL J MED, V341, P217, DOI 10.1056/NEJM199907223410401; Wang XL, 2013, J INT MED RES, V41, P231, DOI 10.1177/0300060512474567; Wenger N, 2008, CLIN PHARMACOL THER, V83, P37, DOI 10.1038/sj.clpt.6100447	28	8	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 21	2014	9	4							e95631	10.1371/journal.pone.0095631	http://dx.doi.org/10.1371/journal.pone.0095631			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG2DX	24752383	Green Published, Green Submitted, gold			2023-01-03	WOS:000335227400093
J	Lacasse, Y				Lacasse, Yves			Review: Exercise programs after pulmonary rehabilitation preserve short-term exercise capacity in COPD	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							DISEASE		Univ Laval, Hop Laval, Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada	Laval University	Lacasse, Y (corresponding author), Univ Laval, Hop Laval, Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada.							Keating A, 2011, CHRON RESP DIS, V8, P89, DOI 10.1177/1479972310393756; Lacasse Y, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003793.pub2; Maltais F, 2008, ANN INTERN MED, V149, P869, DOI 10.7326/0003-4819-149-12-200812160-00006	3	0	0	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 16	2014	160	8							JC4	10.7326/0003-4819-160-8-201404150-02004	http://dx.doi.org/10.7326/0003-4819-160-8-201404150-02004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CW3QU	24733221				2023-01-03	WOS:000364907600003
J	Yamanishi, R; Yoshigai, E; Okuyama, T; Mori, M; Murase, H; Machida, T; Okumura, T; Nishizawa, M				Yamanishi, Ryota; Yoshigai, Emi; Okuyama, Tetsuya; Mori, Masatoshi; Murase, Hiromitsu; Machida, Toru; Okumura, Tadayoshi; Nishizawa, Mikio			The Anti-Inflammatory Effects of Flavanol-Rich Lychee Fruit Extract in Rat Hepatocytes	PLOS ONE			English	Article							NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; HEXOSE CORRELATED COMPOUND; MESSENGER-RNA; GENE-EXPRESSION; INDUCTION; POLYPHENOL; BINDING; INOS; DNA	Flavanol (flavan-3-ol)- rich lychee fruit extract (FRLFE) is a mixture of oligomerized polyphenols primarily derived from lychee fruit and is rich in flavanol monomers, dimers, and trimers. Supplementation with this functional food has been shown to suppress inflammation and tissue damage caused by high-intensity exercise training. However, it is unclear whether FRLFE has in vitro anti-inflammatory effects, such as suppressing the production of the proinflammatory cytokine tumor necrosis factor a (TNF-alpha) and the proinflammatory mediator nitric oxide (NO), which is synthesized by inducible nitric oxide synthase (iNOS). Here, we analyzed the effects of FRLFE and its constituents on the expression of inflammatory genes in interleukin 1 beta (IL- 1 beta)- treated rat hepatocytes. FRLFE decreased the mRNA and protein expression of the iNOS gene, leading to the suppression of IL- 1 beta- induced NO production. FRLFE also decreased the levels of the iNOS antisense transcript, which stabilizes iNOS mRNA. By contrast, unprocessed lychee fruit extract, which is rich in flavanol polymers, and flavanol monomers had little effect on NO production. When a construct harboring the iNOS promoter fused to the firefly luciferase gene was used, FRLFE decreased the luciferase activity in the presence of IL- 1 beta, suggesting that FRLFE suppresses the promoter activity of the iNOS gene at the transcriptional level. Electrophoretic mobility shift assays indicated that FRLFE reduced the nuclear transport of a key regulator, nuclear factor kappa B (NF-kappa B). Furthermore, FRLFE inhibited the phosphorylation of NF-kappa B inhibitor alpha(I kappa B-alpha). FRLFE also reduced the mRNA levels of NF-kappa B target genes encoding cytokines and chemokines, such as TNF-alpha. Therefore, FRLFE inhibited NF-kappa B activation and nuclear translocation to suppress the expression of these inflammatory genes. Our results suggest that flavanols may be responsible for the anti-inflammatory and hepatoprotective effects of FRLFE and may be used to treat inflammatory diseases.	[Yamanishi, Ryota; Yoshigai, Emi; Mori, Masatoshi; Murase, Hiromitsu; Machida, Toru; Nishizawa, Mikio] Ritsumeikan Univ, Coll Life Sci, Dept Biomed Sci, Kusatsu, Shiga, Japan; [Okuyama, Tetsuya] Ritsumeikan Univ, Grad Sch Sci & Engn, Kusatsu, Shiga, Japan; [Okumura, Tadayoshi] Ritsumeikan Univ, Res Org Sci & Technol, Kusatsu, Shiga, Japan; [Okumura, Tadayoshi] Kansai Med Univ, Dept Surg, Hirakata, Osaka, Japan	Ritsumeikan University; Ritsumeikan University; Ritsumeikan University; Kansai Medical University	Nishizawa, M (corresponding author), Ritsumeikan Univ, Coll Life Sci, Dept Biomed Sci, Kusatsu, Shiga, Japan.	nishizaw@sk.ritsumei.ac.jp	Nishizawa, Mikio/M-4544-2014	Nishizawa, Mikio/0000-0002-1117-2807	Amino Up Chemical Co., Ltd. (Sapporo, Japan); Amino Up Chemical Co., Ltd.; Ritsumeikan Global Innovation Research Organization (R-GIRO) of Ritsumeikan University	Amino Up Chemical Co., Ltd. (Sapporo, Japan); Amino Up Chemical Co., Ltd.; Ritsumeikan Global Innovation Research Organization (R-GIRO) of Ritsumeikan University	1) T. Okumura and M. Nishizawa received research grants from Amino Up Chemical Co., Ltd. (Sapporo, Japan). 2) E. Yoshigai, T. Okuyama, T. Okumura, and M. Nishizawa received travel grants from Amino Up Chemical Co., Ltd. 3) E. Yoshigai, T. Okumura, and M. Nishizawa received research funding from the Ritsumeikan Global Innovation Research Organization (R-GIRO) of Ritsumeikan University. 4) R. Yamanishi, M. Mori, H. Murase, and T. Machida performed this study as graduate students of the Graduate School of Science and Engineering, Ritsumeikan University and did not receive the above-mentioned research grants. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], ANAL BIOCH, V126, P131; Aruoma OI, 2006, BIOFACTORS, V27, P245, DOI 10.1002/biof.5520270121; Brat P, 2006, J NUTR, V136, P2368, DOI 10.1093/jn/136.9.2368; Cheadle C, 2003, J MOL DIAGN, V5, P73, DOI 10.1016/S1525-1578(10)60455-2; Colasanti M, 2000, TRENDS PHARMACOL SCI, V21, P249, DOI 10.1016/S0165-6147(00)01499-1; Faghihi MA, 2009, NAT REV MOL CELL BIO, V10, P637, DOI 10.1038/nrm2738; Fujii H, 2007, FOOD CHEM TOXICOL, V45, P378, DOI 10.1016/j.fct.2006.08.026; Fujji H, 2006, BIOSCI BIOTECH BIOCH, V70, P2104, DOI 10.1271/bbb.60053; Gurib-Fakim Ameenah, 2006, Molecular Aspects of Medicine, V27, P1, DOI 10.1016/j.mam.2005.07.008; Hackman Robert M., 2008, Phytochemistry Reviews, V7, P195, DOI 10.1007/s11101-007-9070-4; Kalgaonkar S, 2010, PHYTOTHER RES, V24, P1223, DOI 10.1002/ptr.3137; KANEMAKI T, 1993, PROSTAGLANDINS, V45, P459, DOI 10.1016/0090-6980(93)90122-N; Kimura T, 2013, CELL MOL LIFE SCI, V70, P1451, DOI 10.1007/s00018-012-1216-x; Kitadate K, 2014, REGUL TOXICOL PHARM, V68, P140, DOI 10.1016/j.yrtph.2013.12.001; Kitade H, 1996, HEPATOLOGY, V23, P797, DOI 10.1002/hep.510230421; Kuzuhara T, 2006, J BIOL CHEM, V281, P17446, DOI 10.1074/jbc.M601196200; Lawrence T, 2010, INT J BIOCHEM CELL B, V42, P519, DOI 10.1016/j.biocel.2009.12.016; Lin YL, 1999, EUR J PHARMACOL, V367, P379, DOI 10.1016/S0014-2999(98)00953-4; Mackenzie GG, 2004, FASEB J, V18, P167, DOI 10.1096/fj.03-0402fje; Mahmoudi S, 2009, MOL CELL, V33, P462, DOI 10.1016/j.molcel.2009.01.028; Mao T, 2000, J NUTR, V130, p2093S, DOI 10.1093/jn/130.8.2093S; Matsui K, 2011, EUR SURG RES, V47, P274, DOI 10.1159/000333833; Matsui K, 2008, HEPATOLOGY, V47, P686, DOI 10.1002/hep.22036; Matsui K, 2007, JPEN-PARENTER ENTER, V31, P373, DOI 10.1177/0148607107031005373; Matsuura T, 2012, HEPATOL RES, V42, P76, DOI 10.1111/j.1872-034X.2011.00891.x; Miura T, 2010, BIOTECHNOLOGY IN FUNCTIONAL FOODS AND NUTRACEUTICALS, P91, DOI 10.1201/9781420087123-c6; Modarresi F, 2012, NAT BIOTECHNOL, V30, P453, DOI 10.1038/nbt.2158; Nafisi S, 2009, J PHOTOCH PHOTOBIO B, V94, P1, DOI 10.1016/j.jphotobiol.2008.08.001; Nakanishi H, 2004, J HEPATOL, V41, P730, DOI 10.1016/j.jhep.2004.07.007; Nishizawa M, 2000, GENES CELLS, V5, P111, DOI 10.1046/j.1365-2443.2000.00310.x; Nishizawa M, 2012, FRONT BIOSCI-LANDMRK, V17, P938, DOI 10.2741/3965; Nishizawa M, 2011, PHYTOTHER RES, V25, P1486, DOI 10.1002/ptr.3430; Nonaka G., 2004, International Patent Application, Patent No. [WO2004103988(A1), 2004103988, WO/2004/103988 A1]; Ogasawara J, 2009, PHYTOTHER RES, V23, P1626, DOI 10.1002/ptr.2846; Sakitani K, 1997, HEPATOLOGY, V25, P416; Serra A, 2013, EUR J NUTR, V52, P1029, DOI 10.1007/s00394-012-0409-2; Shimizu K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085520; Shoji T, 2006, J AGR FOOD CHEM, V54, P884, DOI 10.1021/jf052260b; SINGLETON V. L., 1965, AMER J ENOL VITICULT, V16, P144; Suganuma M, 1998, CARCINOGENESIS, V19, P1771, DOI 10.1093/carcin/19.10.1771; Takimoto Y, 2013, NITRIC OXIDE-BIOL CH, V28, P47, DOI 10.1016/j.niox.2012.10.003; Tanaka T., 2007, JPN J FOOD CHEM, V14, P134; Uehata T, 2013, BBA-GENE REGUL MECH, V1829, P708, DOI 10.1016/j.bbagrm.2013.03.001; Ververidis Filippos, 2007, Biotechnology Journal, V2, P1214, DOI 10.1002/biot.200700084; Werner A, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-31; Yamada M, 2007, NITRIC OXIDE-BIOL CH, V17, P98, DOI 10.1016/j.niox.2007.06.003; Yamashita Y, 2013, BIOSCI BIOTECH BIOCH, V77, P888, DOI 10.1271/bbb.130095; Yoshigai E., 2012, HOAJ BIOL, V1, P10, DOI 10.7243/2050-0874-1-10.; Yoshigai E., 2012, HOAJ BIOL, V1, P10, DOI DOI 10.7243/2050-0874-1-10; Yoshigai E, 2014, HEPATOL RES, V44, P571, DOI 10.1111/hepr.12157; Yoshigai E, 2013, BIOCHEM BIOPH RES CO, V439, P54, DOI 10.1016/j.bbrc.2013.08.029; Yoshigai E, 2013, NITRIC OXIDE-BIOL CH, V30, P9, DOI 10.1016/j.niox.2013.01.001	52	32	33	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2014	9	4							e93818	10.1371/journal.pone.0093818	http://dx.doi.org/10.1371/journal.pone.0093818			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE6MJ	24705335	Green Published, Green Submitted, gold			2023-01-03	WOS:000334107500071
J	Mayneris-Perxachs, J; Sala-Vila, A; Chisaguano, M; Castellote, AI; Estruch, R; Covas, MI; Fito, M; Salas-Salvado, J; Martinez-Gonzalez, MA; Lamuela-Raventos, R; Ros, E; Lopez-Sabater, MC				Mayneris-Perxachs, Jordi; Sala-Vila, Aleix; Chisaguano, Maribel; Castellote, Ana I.; Estruch, Ramon; Isabel Covas, Maria; Fito, Montserrat; Salas-Salvado, Jordi; Martinez-Gonzalez, Miguel A.; Lamuela-Raventos, Rosa; Ros, Emilio; Carmen Lopez-Sabater, M.		PREDIMED Study Investigators	Effects of 1-Year Intervention with a Mediterranean Diet on Plasma Fatty Acid Composition and Metabolic Syndrome in a Population at High Cardiovascular Risk	PLOS ONE			English	Article							ESTIMATED DESATURASE ACTIVITIES; INSULIN SENSITIVITY; WEIGHT-LOSS; OBESITY; BLOOD; NUTS; MEN; PATTERNS; DISEASE; PROFILE	Background & Aims: Metabolic syndrome (MetS) has become an important public concern due to its increasing prevalence. An altered fatty acid composition has been associated with MetS, but the Mediterranean diet has been shown to have a protective effect. The aim of the present study was to analyze the influence of a Mediterranean dietary pattern, as assessed by the biomarkers of food supplied, on the plasma fatty acid composition and its relation with MetS after 1 year of intervention. Methods: A total of 424 subjects were randomly selected from the PREDIMED randomized dietary trial after completing a 1-year intervention program. Participants aged 55 to 80 years and at high risk of cardiovascular disease were randomly assigned to three dietary interventions: Mediterranean diet supplemented with virgin olive oil or nuts, or a low-fat diet. Results: After 1 year of intervention participants in the virgin olive oil group showed significantly increased plasma concentrations of palmitic and oleic acids, but reduced proportions of margaric, stearic, and linoleic acids. In turn, subjects in the nut group showed significantly increased levels of palmitic, linoleic, and a-linolenic acids, but reduced proportions of myristic, margaric, palmitoleic, and dihommo-c-linoleic acids. Increases in the biomarkers of foods supplied to the Mediterranean diet groups, i.e., oleic and a-linolenic acids, were beneficially associated with the incidence, reversion and prevalence of MetS. No weight changes were observed among participants. Conclusions: The nut and olive oil diets induced a fatty acid composition that has been shown to be beneficial in the face of MetS. Therefore, a Mediterranean diet rich in fats of vegetable origin may be a useful tool for the management of MetS without the need for concerns over weight gain due to its high fat content.	[Mayneris-Perxachs, Jordi; Chisaguano, Maribel; Castellote, Ana I.; Lamuela-Raventos, Rosa; Carmen Lopez-Sabater, M.] Univ Barcelona, Dept Nutr & Food Sci XARTA INSA, Fac Pharm, Barcelona, Spain; [Sala-Vila, Aleix; Ros, Emilio] Hosp Clin Barcelona, Biomed Res Inst August Pi & Sunyer IDIBAPS, Lipid Clin, Endocrinol & Nutr Serv, Barcelona, Spain; [Estruch, Ramon] Hosp Clin Barcelona, Dept Internal Med, Barcelona, Spain; [Isabel Covas, Maria; Fito, Montserrat] Municipal Inst Med Res, Cardiovasc Epidemiol Unit, Barcelona, Spain; [Salas-Salvado, Jordi] Univ Rovira & Virgili, Fac Med, IISPV, Human Nutr Unit, E-43201 Reus, Spain; [Martinez-Gonzalez, Miguel A.] Univ Navarra, Sch Med, Dept Prevent Med & Publ Hlth, E-31080 Pamplona, Spain; [Sala-Vila, Aleix; Chisaguano, Maribel; Castellote, Ana I.; Estruch, Ramon; Isabel Covas, Maria; Fito, Montserrat; Salas-Salvado, Jordi; Martinez-Gonzalez, Miguel A.; Lamuela-Raventos, Rosa; Ros, Emilio; Carmen Lopez-Sabater, M.] Physiopathol Obes & Nutr CIBEROBN, Madrid, Spain	University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; Universitat Rovira i Virgili; Institut d'Investigacio Sanitaria Pere Virgili (IISPV); University of Navarra; CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN	Lopez-Sabater, MC (corresponding author), Univ Barcelona, Dept Nutr & Food Sci XARTA INSA, Fac Pharm, Barcelona, Spain.	mclopez@ub.edu	Martinez-Gonzalez, Miguel A./AAE-7669-2019; Mayneris-Perxachs, Jordi/B-2589-2018; Sanchez-Villegas, Almudena/T-6733-2019; Algorta, Jaime/CAF-7793-2022; Guasch-Ferre, Marta/H-6680-2019; Estruch, Ramon/AAZ-3723-2020; Salas-Salvado, Jordi/C-7229-2017; Casas, Rosa/ABD-1915-2020; IBIS, ATENCION PRIMARIA/I-3524-2016; Fito, Montserrat/C-1822-2012; Lapetra, Jose/F-2552-2015; Mayneris-Perxachs, Jordi/AAG-7724-2020; Toledo, Estefania/H-6211-2014; ZAZPE, ITZIAR/B-1970-2017; Lamuela-Raventos, Rosa M/F-3986-2016	Mayneris-Perxachs, Jordi/0000-0003-3788-3815; Sanchez-Villegas, Almudena/0000-0001-7733-9238; Algorta, Jaime/0000-0002-7042-5675; Guasch-Ferre, Marta/0000-0001-8525-1404; Salas-Salvado, Jordi/0000-0003-2700-7459; Casas, Rosa/0000-0002-0211-9166; Fito, Montserrat/0000-0002-1817-483X; Mayneris-Perxachs, Jordi/0000-0003-3788-3815; Basora, Josep/0000-0003-0278-1149; Ros, Emilio/0000-0002-2573-1294; Martinez-Gonzalez, Miguel A./0000-0002-3917-9808; Diaz-Lopez, Andres/0000-0002-7500-5629; Toledo, Estefania/0000-0002-6263-4434; ZAZPE, ITZIAR/0000-0002-8787-2981; Lamuela-Raventos, Rosa M/0000-0002-1287-4560; Fernandez-Ballart, Joan D./0000-0002-1320-6484	Ministerio de Ciencia e Innovacion [AGL2008-04124, AGL2009-09730]	Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government)	This research was supported by national grants from the "Ministerio de Ciencia e Innovacion" (AGL2008-04124 and AGL2009-09730). CIBEROBN, CIBERESP and RETIC Alimentacion Saludable are initiative from the ISCIII, Government of Spain. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abete I, 2010, NUTR REV, V68, P214, DOI 10.1111/j.1753-4887.2010.00280.x; Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644; Baxter AJ, 2006, ASIA PAC J CLIN NUTR, V15, P134; Bondia-Pons I, 2007, EUR J CLIN NUTR, V61, P1345, DOI 10.1038/sj.ejcn.1602662; Bondia-Pons I, 2004, J CHROMATOGR B, V809, P339, DOI 10.1016/j.jchromb.2004.07.002; Brynes AE, 2000, AM J CLIN NUTR, V72, P1111; Buckland G, 2008, OBES REV, V9, P582, DOI 10.1111/j.1467-789X.2008.00503.x; Cicerale S, 2009, CRIT REV FOOD SCI, V49, P218, DOI 10.1080/10408390701856223; Colette C, 2003, INT J OBESITY, V27, P648, DOI 10.1038/sj.ijo.0802299; Corpeleijn E, 2006, DIABETOLOGIA, V49, P2392, DOI 10.1007/s00125-006-0383-4; Desroches S, 2007, APPL PHYSIOL NUTR ME, V32, P23, DOI [10.1139/H06-095, 10.1139/h06-095]; Erkkila A, 2008, PROG LIPID RES, V47, P172, DOI 10.1016/j.plipres.2008.01.004; Esposito K, 2010, METAB SYNDR RELAT D, V8, P197, DOI 10.1089/met.2009.0095; Estruch R, 2013, NEW ENGL J MED, V368, P1279, DOI 10.1056/NEJMoa1200303; Ford ES, 2008, DIABETES CARE, V31, P1898, DOI 10.2337/dc08-0423; Gami AS, 2007, J AM COLL CARDIOL, V49, P403, DOI 10.1016/j.jacc.2006.09.032; Grundy SM, 2008, ARTERIOSCL THROM VAS, V28, P629, DOI 10.1161/ATVBAHA.107.151092; Grundy SM, 2005, CIRCULATION, V112, P2735, DOI 10.1161/CIRCULATIONAHA.105.169404; Hodson L, 2008, PROG LIPID RES, V47, P348, DOI 10.1016/j.plipres.2008.03.003; Jones PJH, 2008, METABOLISM, V57, P1198, DOI 10.1016/j.metabol.2008.04.012; Lopez-Miranda J, 2010, NUTR METAB CARDIOVAS, V20, P284, DOI 10.1016/j.numecd.2009.12.007; Martinez-Gonzalez M.A., 2010, INT J EPIDEMIOL, V41, P377, DOI DOI 10.1093/ije/dyq250; Mattes RD, 2010, ASIA PAC J CLIN NUTR, V19, P137; Perez-Lopez FR, 2009, MATURITAS, V64, P67, DOI 10.1016/j.maturitas.2009.07.013; Raatz SK, 2001, J NUTR, V131, P231; Riccardi G, 2004, CLIN NUTR, V23, P447, DOI 10.1016/j.clnu.2004.02.006; Richard C, 2011, NUTR METAB CARDIOVAS, V21, P628, DOI 10.1016/j.numecd.2010.01.012; Riserus U, 2009, PROG LIPID RES, V48, P44, DOI 10.1016/j.plipres.2008.10.002; Sabate J, 2010, ASIA PAC J CLIN NUTR, V19, P131; Sabate J, 2009, AM J CLIN NUTR, V89, pS1643, DOI 10.3945/ajcn.2009.26736Q; Schwartz GJ, 2008, CELL METAB, V8, P281, DOI 10.1016/j.cmet.2008.08.005; Simonsen NR, 1998, AM J CLIN NUTR, V68, P134, DOI 10.1093/ajcn/68.1.134; Vessby B, 2002, ANN NY ACAD SCI, V967, P183; Vessby B, 2001, DIABETOLOGIA, V44, P312, DOI 10.1007/s001250051620; Warensjo E, 2006, NUTR METAB CARDIOVAS, V16, P128, DOI 10.1016/j.numecd.2005.06.001; Warensjo E, 2008, NUTR METAB CARDIOVAS, V18, P683, DOI 10.1016/j.numecd.2007.11.002; Warensjo E, 2006, AM J CLIN NUTR, V84, P442	37	48	50	0	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2014	9	3							e85202	10.1371/journal.pone.0085202	http://dx.doi.org/10.1371/journal.pone.0085202			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AD6FV	24651160	Green Published, Green Submitted, gold			2023-01-03	WOS:000333352800002
J	Woodhouse, C; Camelo, JL; Wehby, GL				Woodhouse, Cristina; Lopez Camelo, Jorge; Wehby, George L.			A Comparative Analysis of Prenatal Care and Fetal Growth in Eight South American Countries	PLOS ONE			English	Article							BIRTH-WEIGHT; RACIAL DISPARITIES; INFANT HEALTH; OUTCOMES; IMPACT; BRAZIL	There has been little work that comprehensively compared the relationship between prenatal care and infant health across multiple countries using similar data sources and analytical models. Such comparative analyses are useful for understanding the background of differences in infant health between populations. We evaluated the association between prenatal care visits and fetal growth measured by birth weight (BW) in grams or low birth weight (<2500 grams; LBW) adjusted for gestational age in eight South American countries using similarly collected data across countries and the same analytical models. OLS and logistic regressions were estimated adjusting for a large set of relevant infant, maternal, and household characteristics and birth year and hospital fixed effects. Birth data were acquired from 140 hospitals that are part of the Latin American Collaborative Study of Congenital Malformations (ECLAMC) network. The analytical sample included 56,014 liveborn infants (similar to 69% of total sample) with complete data born without congenital anomalies in the years 1996-2011 in Brazil, Argentina, Chile, Venezuela, Ecuador, Colombia, Bolivia, and Uruguay. Prenatal care visits were significantly (at p<.05) and positively associated with BW and negatively associated with LBW for all countries. The OLS coefficients ranged from 9 grams per visit in Bolivia to 36 grams in Uruguay. The association with LBW was strongest for Chile (OR = 0.87 per visit) and lowest for Argentina and Venezuela (OR = 0.95). The association decreased in the recent decade compared to earlier years. Our findings suggest that estimates of association between prenatal care and fetal growth are population-specific and may not be generalizable to other populations. Furthermore, as one of the indicators for a country's healthcare system for maternal and child health, prenatal care is a highly variable indicator between countries in South America.	[Woodhouse, Cristina] Univ Iowa, Coll Med, Iowa City, IA USA; [Lopez Camelo, Jorge] Consejo Nacl Invest Cient & Tecn, CEMIC, RA-1033 Buenos Aires, DF, Argentina; [Wehby, George L.] Univ Iowa, Iowa City, IA 52242 USA; [Wehby, George L.] Univ Iowa, Coll Publ Hlth, Dept Hlth Management & Policy, Natl Bur Econ Res, Iowa City, IA USA	University of Iowa; Centro de Educacion Medica e Investigaciones Clinicas (CEMIC); Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Iowa; National Bureau of Economic Research; University of Iowa	Wehby, GL (corresponding author), Univ Iowa, Iowa City, IA 52242 USA.	george-wehby@uiowa.edu		Lopez-Camelo, Jorge S./0000-0002-3146-5447	National Institutes of Health (NIH)/Fogarty International [R03 TW0081180]; FOGARTY INTERNATIONAL CENTER [R03TW008110] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/Fogarty International; FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	This work was supported by grant R03 TW0081180 from the National Institutes of Health (NIH)/Fogarty International. The NIH/Fogarty International had no role in the study design, data collection and analysis, or manuscript writing and submission. No additional funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional funding was received.	Abrevaya J., 2001, EMPIR ECON, V26, P247, DOI DOI 10.1007/S001810000052; Castilla EE, 2004, COMMUNITY GENET, V7, P76, DOI 10.1159/000080776; Cox RG, 2011, MATERN CHILD HLTH J, V15, P931, DOI 10.1007/s10995-009-0542-6; Padilho PD, 2009, NUTR HOSP, V24, P207; DONALDSON PJ, 1984, MED CARE, V22, P177, DOI 10.1097/00005650-198402000-00009; Ferri CP, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-209; Jewell RT, 2007, APPL ECON, V39, P415, DOI 10.1080/00036840500439028; Jewell RT, 2006, HEALTH ECON, V15, P1245, DOI 10.1002/hec.1121; Lau C, 2011, OBSTET GYNECOL, V117, P978, DOI 10.1097/AOG.0b013e318212140e; Liu XX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037336; Martin Joyce A, 2011, Natl Vital Stat Rep, V60, P1; Nyarko KA, 2013, AM J PUBLIC HEALTH, V103, P1675, DOI 10.2105/AJPH.2012.301021; Nyarko KA, 2013, J PEDIATR-US, V162, P42, DOI 10.1016/j.jpeds.2012.06.040; Reichman NE, 2009, HEALTH ECON, V18, P761, DOI 10.1002/hec.1402; Serruya Suzanne Jacob, 2004, Cad. Saúde Pública, V20, P1281, DOI 10.1590/S0102-311X2004000500022; VanderWeele TJ, 2009, J CLIN EPIDEMIOL, V62, P438, DOI 10.1016/j.jclinepi.2008.08.001; Varvarigou AA, 2010, J PEDIATR ENDOCR MET, V23, P215, DOI 10.1515/JPEM.2010.23.3.215; Wardlaw TM, 2004, LOW BIRTHW COUNTR RE; WBG, 2012, WORLD DATABANK; Wehby GL, 2014, HEALTH ECON, V23, P69, DOI 10.1002/hec.2901; Wehby GL, 2010, ECON HUM BIOL, V8, P197, DOI 10.1016/j.ehb.2010.04.002; Wehby GL, 2009, HEALTH ECON, V18, P1307, DOI 10.1002/hec.1431; Wehby GL, 2009, ECON HUM BIOL, V7, P84, DOI 10.1016/j.ehb.2008.10.001; Wehby GL, 2009, HEALTH POLICY PLANN, V24, P175, DOI 10.1093/heapol/czp005; Wooldridge J.M., 2002, ECONOMETRIC ANAL CRO; World Health Organization, 2012, WORLD HLTH STAT 2012; World Health Organization, 2012, MAT NEWB CHILD AD HL; You D., 2012, LEVELS TRENDS CHILD; Zhang L, 2011, MATERN CHILD HLTH J, V15, P910, DOI 10.1007/s10995-009-0516-8	29	13	14	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 13	2014	9	3							e91292	10.1371/journal.pone.0091292	http://dx.doi.org/10.1371/journal.pone.0091292			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AC9JS	24625630	Green Submitted, gold, Green Published			2023-01-03	WOS:000332851300071
J	Daughtridge, GW; Archibald, T; Conway, PH				Daughtridge, Giffin W.; Archibald, Traci; Conway, Patrick H.			Quality Improvement of Care Transitions and the Trend of Composite Hospital Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Daughtridge, Giffin W.] Univ Penn, Philadelphia, PA 19104 USA; [Archibald, Traci; Conway, Patrick H.] Ctr Medicare & Medicaid Serv, Baltimore, MD 21244 USA; [Conway, Patrick H.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA	University of Pennsylvania; Centers for Medicare & Medicaid Services; Cincinnati Children's Hospital Medical Center	Conway, PH (corresponding author), Ctr Medicare & Medicaid Serv, Mailstop S3-02-01,7500 Secur Blvd, Baltimore, MD 21244 USA.	patrick.conway@cms.hhs.gov						Baier RR, 2013, AM J MANAG CARE, V19, P450; Baugh CW, 2013, NEW ENGL J MED, V369, P302, DOI 10.1056/NEJMp1304493; Brock J, 2013, JAMA-J AM MED ASSOC, V309, P381, DOI 10.1001/jama.2012.216607; Centers for Medicare & Medicaid Services (CMS), 2013, QUALITY IMPROVEMENT; Feng ZL, 2012, HEALTH AFFAIR, V31, P1251, DOI 10.1377/hlthaff.2012.0129	5	14	14	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 12	2014	311	10					1013	1014		10.1001/jama.2014.509	http://dx.doi.org/10.1001/jama.2014.509			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AC5QO	24618959				2023-01-03	WOS:000332575800015
J	McAllister, L; Anderson, J; Werth, K; Cho, I; Copeland, K; Bouveret, NL; Plant, D; Mendelman, PM; Cobb, DK				McAllister, Linda; Anderson, Jonathan; Werth, Kristen; Cho, Iksung; Copeland, Karen; Bouveret, Nancy Le Cam; Plant, David; Mendelman, Paul M.; Cobb, David K.			Needle-free jet injection for administration of influenza vaccine: a randomised non-inferiority trial	LANCET			English	Article							IMMUNOGENICITY; SAFETY; PREVALENCE; SYRINGE; ADULTS; YOUNG; FEAR	Background Administration of vaccines by needle-free technology such as jet injection might off er an alternative to needles and syringes that avoids the issue of needle phobia and the risk of needle-stick injury. We aimed to assess the immunogenicity and safety of trivalent influenza vaccine given by needle-free jet injector compared with needle and syringe. Methods For this randomised, comparator-controlled trial, we randomly assigned (1:1) healthy adults (aged 18-64 years) who attended one of four employee health clinics in the University of Colorado health system, with stratification by site, to receive one dose of the trivalent inactivated influenza vaccine Afluria given either intramuscularly with a needle-free jet injector (Stratis; PharmaJet, Golden, CO, USA) or with needle and syringe. Randomisation was done with a computer-generated randomisation schedule with a block size of 100. Because of the nature of the study, masking of participants was not possible. Immunogenicity was assessed by measurement of the hemagglutination inhibition antibody titres in serum for the three viral strains included in the vaccine. We included six coprimary endpoints: three strain-specific geometric mean titre ratios and the absolute differences in three strain-specific seroconversion rates. The immune response of the jet injector group was regarded as non-inferior to that of the needle and syringe group if both the upper bound of each of the three 95% CIs for the strain-specific geometric mean titre ratios was 1.5 or less, and the upper bound of the three 95% CIs for the strain-specific seroconversion rate differences was less than 10 percentage points. We used t test for group comparison. This study is registered with ClinicalTrials.gov, number NCT01688921. Findings During the 2012-13 influenza season of the northern hemisphere, we allocated 1250 participants to receive vaccination by needle-free jet injector (n=627) or needle and syringe (n=623). In the intention-to-treat immunogenicity population, all participants with two serum samples were included (575 in the jet injector group and 574 in the needle and syringe group). The immune response to Afluria when given by needle-free jet injector met the criteria for non-inferiority for all six coprimary endpoints. The jet injector group met the geometric mean titre criterion for non-inferiority for the A/H1N1, A/H3N2, and B strains (upper bound of the 95% CI for the geometric mean titre ratios were 1.10 for A/H1N1, 1.17 for A/H3N2, and 1.04 for B strains). The jet injector group met the seroconversion rate criterion for non-inferiority for the A/H1N1, A/H3N2, and B strains (upper bound of the 95% CI of the seroconversion rate differences were 6.0% for A/H1N1, 7.0% for A/H3N2, and 5.7% for B strains). We recorded serious adverse events in three participants, none of which were study related. Interpretation The immune response to influenza vaccine given with the jet injector device was non-inferior to the immune response to influenza vaccine given with needle and syringe. The device had a clinically acceptable safety profile, but was associated with a higher frequency of local injection site reactions than was the use of needle and syringe. The Stratis needle-free jet injector device could be used as an alternative method of administration of Afluria trivalent influenza vaccine.	[McAllister, Linda; Werth, Kristen; Cho, Iksung] PharmaJet, Golden, CO 80401 USA; [Anderson, Jonathan; Bouveret, Nancy Le Cam; Plant, David] BioCSL, Parkville, Vic, Australia; [Copeland, Karen] Boulder Stat, Boulder, CO USA; [Cobb, David K.] Med Ctr Rockies, Loveland, CO USA		McAllister, L (corresponding author), PharmaJet, Golden, CO 80401 USA.	linda.mcallister@pharmajet.com		Anderson, Jonathan/0000-0002-7316-428X	Biomedical Advanced Research and Development Authority (BARDA); PATH; bioCSL; PharmaJet	Biomedical Advanced Research and Development Authority (BARDA); PATH; bioCSL; PharmaJet	Funding Biomedical Advanced Research and Development Authority (BARDA), PATH, bioCSL, and PharmaJet.	American Nurses Association, 2002, AM NURS ASS NEEDL PR; Atkinson William L, 2002, MMWR Recomm Rep, V51, P1; Beyer WEP, 2004, VIRUS RES, V103, P125, DOI 10.1016/j.virusres.2004.02.024; Beyer WEP, 1996, VACCINE, V14, P1331, DOI 10.1016/S0264-410X(96)00058-8; BioCSL, 2013, AFL INFL VACC STN BL; CANTER J, 1990, ARCH INTERN MED, V150, P1923, DOI 10.1001/archinte.150.9.1923; Committee for Proprietary MedicinalProducts, 1997, CPMPBWP21496; duChatelet IP, 1997, VACCINE, V15, P449, DOI 10.1016/S0264-410X(96)00173-9; FDA, 2011, FDA UPD COMM US JET; FDA, 2007, GUID IND CLIN DAT NE; Giudice EL, 2006, ADV DRUG DELIVER REV, V58, P68, DOI 10.1016/j.addr.2005.12.003; Kroger Andrew T., 2011, Morbidity and Mortality Weekly Report, V60, P3; HINGSON RA, 1963, MIL MED, V128, P525, DOI 10.1093/milmed/128.6.525; Jackson LA, 2001, VACCINE, V19, P4703, DOI 10.1016/S0264-410X(01)00225-0; Kennedy ED, 2013, INFLUENZA VACCINATIO; Kieninger D, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-343; Konietschke F, 2010, CRC BIOSTATISTICS SE; Levine MM, 2003, NAT MED, V9, P99, DOI 10.1038/nm0103-99; Lloyd J., 2000, TECHNOLOGIES VACCINE; Mazurek Gerald H., 2010, Morbidity and Mortality Weekly Report, V59, P1; Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I; Nir Y, 2003, AM J TROP MED HYG, V68, P341, DOI 10.4269/ajtmh.2003.68.341; Pruss-Ustun A, 2005, AM J IND MED, V48, P482, DOI 10.1002/ajim.20230; Sasaki S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002975; Simon JK, 2011, VACCINE, V29, P9544, DOI 10.1016/j.vaccine.2011.09.097; STEINGLASS R, 1995, B WORLD HEALTH ORGAN, V73, P57; Taddio A, 2012, VACCINE, V30, P4807, DOI 10.1016/j.vaccine.2012.05.011; Weniger B.G., 2012, VACCINES, P1200; Weniger BG, 2006, NEEDLE FREE INJECTIO; Wright S, 2009, AUST FAM PHYSICIAN, V38, P172	30	48	49	0	39	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 23	2014	384	9944					674	681		10.1016/S0140-6736(14)60524-9	http://dx.doi.org/10.1016/S0140-6736(14)60524-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AO5CJ	24881803				2023-01-03	WOS:000341359100025
J	Blasi, F; Cesana, G; Conti, S; Chiodini, V; Aliberti, S; Fornari, C; Mantovani, LG				Blasi, Francesco; Cesana, Giancarlo; Conti, Sara; Chiodini, Virginio; Aliberti, Stefano; Fornari, Carla; Mantovani, Lorenzo Giovanni			The Clinical and Economic Impact of Exacerbations of Chronic Obstructive Pulmonary Disease: A Cohort of Hospitalized Patients	PLOS ONE			English	Article							COPD EXACERBATIONS; MORTALITY; SPIROMETRY; OUTCOMES; COSTS	Background: Chronic Obstructive Pulmonary Disease (COPD) is a common disease with significant health and economic consequences. This study assesses the burden of COPD in the general population, and the influence of exacerbations (E-COPD) on disease progression and costs. Methods: This is a secondary data analysis of healthcare administrative databases of the region of Lombardy, in northern Italy. The study included >= 40 year-old patients hospitalized for a severe E-COPD (index event) during 2006. Patients were classified in relation to the number and type of E-COPD experienced in a three-year pre-index period. Subjects were followed up until December 31st, 2009, collecting data on healthcare resource use and vital status. Results: 15857 patients were enrolled -9911 males, mean age: 76 years (SD 10). Over a mean follow-up time of 2.4 years (1.36), 81% of patients had at least one E-COPD with an annual rate of 3.2 exacerbations per person-year and an all-cause mortality of 47%. A history of exacerbation influenced the occurrence of new E-COPD and mortality after discharge for an E-COPD. On average, the healthcare system spent 6725(sic) per year per person (95% CI 6590-6863). Occurrence and type of exacerbations drove the direct healthcare cost. Less than one quarter of patients presented claims for pulmonary function tests. Conclusions: COPD imposes a substantial burden on healthcare systems, mainly attributable to the type and occurrence of E-COPD, or in other words, to the exacerbator phenotypes. A more tailored approach to the management of COPD patients is required.	[Blasi, Francesco] Univ Milan, Osped Maggiore Policlin, IRCCS Fdn Ca Granda, Dept Pathophysiol & Transplantat, Milan, Italy; [Cesana, Giancarlo; Conti, Sara; Chiodini, Virginio; Fornari, Carla; Mantovani, Lorenzo Giovanni] Univ Milano Bicocca, CESP, Res Ctr Publ Hlth, Dept Stat & Quantitat Methods, Monza, Italy; [Aliberti, Stefano] Univ Milano Bicocca, AO San Gerardo, Dept Hlth Sci, Resp Unit, Monza, Italy; [Mantovani, Lorenzo Giovanni] Univ Napoli Federico II, Naples, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of Milano-Bicocca; University of Milano-Bicocca; University of Naples Federico II	Fornari, C (corresponding author), Univ Milano Bicocca, CESP, Res Ctr Publ Hlth, Dept Stat & Quantitat Methods, Monza, Italy.	carla.fornari@unimib.it	BLASI, FRANCESCO B/O-5885-2017; Aliberti, Stefano/AAL-8032-2021; Aliberti, Stefano/K-9115-2016; Mantovani, Lorenzo Giovanni/AAC-4263-2021; Conti, Sara/J-4891-2019	BLASI, FRANCESCO B/0000-0002-2285-9970; Aliberti, Stefano/0000-0002-0090-4531; Aliberti, Stefano/0000-0002-0090-4531; Conti, Sara/0000-0002-5774-3740; Fornari, Carla/0000-0002-9609-9556; Mantovani, Lorenzo Giovanni/0000-0003-3866-8199	Nycomed-Takeda SpA	Nycomed-Takeda SpA	Nycomed-Takeda SpA funded this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Moreover, this does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.	Abramson MJ, 2010, MED J AUSTRALIA, V193, P104, DOI 10.5694/j.1326-5377.2010.tb03817.x; Almagro P, 2002, CHEST, V2002, P5; [Anonymous], 2008, WORLD HLTH STAT 2008; Bang H, 2000, BIOMETRIKA, V87, P329, DOI 10.1093/biomet/87.2.329; Bertella E, 2013, MULTIDISCIP RESP MED, V8, DOI 10.1186/2049-6958-8-24; Calverley PMA, 2009, LANCET, V374, P685, DOI 10.1016/S0140-6736(09)61255-1; Cazzola M, 2008, EUR RESPIR J, V31, P416, DOI 10.1183/09031936.00099306; Celli B, 2009, AM J RESP CRIT CARE, V180, P948, DOI 10.1164/rccm.200906-0876OC; Celli BR, 2004, EUROPEAN RESP J, V23, P942; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Dal Negro Roberto, 2008, Int J Chron Obstruct Pulmon Dis, V3, P1; Dalal Anand A, 2010, Int J Chron Obstruct Pulmon Dis, V5, P341, DOI 10.2147/COPD.S13771; Donaldson GC, 2010, CHEST, V137, P1091, DOI 10.1378/chest.09-2029; Groenewegen KH, 2003, CHEST, V124, P459, DOI 10.1378/chest.124.2.459; Hurst JR, 2010, NEW ENGL J MED, V363, P1128, DOI 10.1056/NEJMoa0909883; Johnson AK, 2008, CHRONIC OBSTRUCTIVE, P15; Lokke A, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004069; Mapel DW, 2012, PHARMACOECONOMICS, V30, P869, DOI 10.2165/11633330-000000000-00000; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Monteagudo M, 2011, ARCH BRONCONEUMOL, V47, P226, DOI 10.1016/j.arbres.2010.10.009; Pasquale MK, 2012, INT J CHRONIC OBSTR, V7, P757, DOI 10.2147/COPD.S36997; Patel IS, 2002, THORAX, V57, P759, DOI 10.1136/thorax.57.9.759; Press W, 2007, GLOBAL SURVEILLANCE; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Rodriguez-Roisin R, 2006, THORAX, V61, P535, DOI 10.1136/thx.2005.041863; Seemungal Terence A R, 2009, Int J Chron Obstruct Pulmon Dis, V4, P203; Simoens S, 2007, INT J CLIN PRACT, V61, P200, DOI 10.1111/j.1742-1241.2006.01240.x; Soler-Cataluna JJ, 2005, THORAX, V60, P925, DOI 10.1136/thx.2005.040527; Suissa S, 2012, THORAX, V67, P957, DOI 10.1136/thoraxjnl-2011-201518; Toy EL, 2010, COPD, V7, P214, DOI 10.3109/15412555.2010.481697; Yu Andrew P, 2011, J Med Econ, V14, P315, DOI 10.3111/13696998.2011.576295	31	72	72	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2014	9	6							e101228	10.1371/journal.pone.0101228	http://dx.doi.org/10.1371/journal.pone.0101228			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK6BK	24971791	Green Published, Green Submitted, gold			2023-01-03	WOS:000338512200106
J	Feng, ST; Li, JG; Luo, YJ; Yin, TH; Cai, HS; Wang, Y; Dong, Z; Shuai, XT; Li, ZP				Feng, Shi-Ting; Li, Jingguo; Luo, Yanji; Yin, Tinghui; Cai, Huasong; Wang, Yong; Dong, Zhi; Shuai, Xintao; Li, Zi-Ping			pH-Sensitive Nanomicelles for Controlled and Efficient Drug Delivery to Human Colorectal Carcinoma LoVo Cells	PLOS ONE			English	Article							PHARMACEUTICAL NANOCARRIERS; COPOLYMER MICELLES; POLYMERIC MICELLES; IRON-OXIDE; CANCER; TUMOR; NANOPARTICLES; PACLITAXEL; SYSTEMS; RELEASE	Background: The triblock copolymers PEG-P(Asp-DIP)-P(Lys-Ca) (PEALCa) of polyethylene glycol (PEG), poly(N-(N', N'-diisopropylaminoethyl) aspartamide) (P(Asp-DIP)), and poly (lysine-cholic acid) (P(Lys-Ca)) were synthesized as a pH-sensitive drug delivery system. In neutral aqueous environment such as physiological environment, PEALCa can self-assemble into stable vesicles with a size around 50-60 nm, avoid uptake by the reticuloendothelial system (RES), and encase the drug in the core. However, the PEALCa micelles disassemble and release drug rapidly in acidic environment that resembles lysosomal compartments. Methodology/Principal Findings: The anticancer drug Paclitaxel (PTX) and hydrophilic superparamagnetic iron oxide (SPIO) were encapsulated inside the core of the PEALCa micelles and used for potential cancer therapy. Drug release study revealed that PTX in the micelles was released faster at pH 5.0 than at pH 7.4. Cell culture studies showed that the PTX-SPIO-PEALCa micelle was effectively internalized by human colon carcinoma cell line (LoVo cells), and PTX could be embedded inside lysosomal compartments. Moreover, the human colorectal carcinoma (CRC) LoVo cells delivery effect was verified in vivo by magnetic resonance imaging (MRI) and histology analysis. Consequently effective suppression of CRC LoVo cell growth was evaluated. Conclusions/Significance: These results indicated that the PTX-SPION-loaded pH-sensitive micelles were a promising MRI-visible drug release system for colorectal cancer therapy.	[Feng, Shi-Ting; Luo, Yanji; Cai, Huasong; Dong, Zhi; Li, Zi-Ping] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Radiol, Guangzhou 510275, Guangdong, Peoples R China; [Li, Jingguo; Wang, Yong; Shuai, Xintao] Sun Yat Sen Univ, Sch Chem & Chem Engn, Minist Educ, PCFM Lab, Guangzhou 510275, Guangdong, Peoples R China; [Yin, Tinghui] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Med Ultrason, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Li, ZP (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Radiol, Guangzhou 510275, Guangdong, Peoples R China.	liziping163@163.com	Shuai, Xintao/C-5819-2008; Li, Jingguo/E-7523-2015; 庭辉, 尹/I-5114-2014	Shuai, Xintao/0000-0003-4271-0310; Yin, Tinghui/0000-0003-4201-3953; Wang, Yong/0000-0002-8349-7555	National Natural Science Foundation of China [81000626]; Zhujiang Scientific and Technological New Star Foundation [2012J2200084]; Fundamental Research Funds for the Central Universities [10ykpy11]; Natural Science Foundation of Guangdong Province [S2013010016004]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Zhujiang Scientific and Technological New Star Foundation; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province)	This work was supported by: 1. National Natural Science Foundation of China (81000626); 2. Zhujiang Scientific and Technological New Star Foundation (2012J2200084); 3. Fundamental Research Funds for the Central Universities (10ykpy11); 4. Natural Science Foundation of Guangdong Province (S2013010016004). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alvarez-Lorenzo C, 2008, MINI-REV MED CHEM, V8, P1065, DOI 10.2174/138955708785909952; Byrne JD, 2008, ADV DRUG DELIVER REV, V60, P1615, DOI 10.1016/j.addr.2008.08.005; Chang GT, 2010, MACROMOL BIOSCI, V10, P1248, DOI 10.1002/mabi.201000117; Chen YT, 2012, INT J NANOMED, V7, P359, DOI 10.2147/IJN.S24083; Chen YB, 2007, CHINESE MED J-PEKING, V120, P703, DOI 10.1097/00029330-200704020-00017; Dai J, 2011, ANGEW CHEM INT EDIT, V50, P9404, DOI 10.1002/anie.201103806; Foersch S, 2012, DIGEST DIS, V30, P469, DOI 10.1159/000341692; Gao GH, 2010, SMALL, V6, P1201, DOI 10.1002/smll.200902317; Hawkins MJ, 2008, ADV DRUG DELIVER REV, V60, P876, DOI 10.1016/j.addr.2007.08.044; Hu YQ, 2007, POLYMER, V48, P3437, DOI 10.1016/j.polymer.2007.04.011; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Ju CY, 2013, J PHARM SCI-US, V102, P2707, DOI 10.1002/jps.23649; Khemtong C, 2009, CANCER RES, V69, P1651, DOI 10.1158/0008-5472.CAN-08-3231; Klaikherd A, 2009, J AM CHEM SOC, V131, P4830, DOI 10.1021/ja809475a; Lee ES, 2003, J CONTROL RELEASE, V90, P363, DOI 10.1016/S0168-3659(03)00205-0; Lee ES, 2008, J CONTROL RELEASE, V132, P164, DOI 10.1016/j.jconrel.2008.05.003; Lee JH, 2007, NAT MED, V13, P95, DOI [10.1038/nm1467, 10.20659/jfp.13.1_95]; Liao CD, 2011, EUR J RADIOL, V80, P699, DOI 10.1016/j.ejrad.2010.08.005; Liu J, 2010, CARBOHYD POLYM, V82, P432, DOI 10.1016/j.carbpol.2010.04.084; Luo JT, 2009, BIOMACROMOLECULES, V10, P900, DOI 10.1021/bm801423p; Lutz JF, 2006, BIOMACROMOLECULES, V7, P3132, DOI 10.1021/bm0607527; Lynn DM, 2001, J AM CHEM SOC, V123, P8155, DOI 10.1021/ja016288p; Mei L, 2009, J PHARM SCI-US, V98, P2040, DOI 10.1002/jps.21581; Mi Y, 2011, BIOMATERIALS, V32, P4058, DOI 10.1016/j.biomaterials.2011.02.022; Mo R, 2011, BIOMATERIALS, V32, P4609, DOI 10.1016/j.biomaterials.2011.03.005; Nasongkla N, 2006, NANO LETT, V6, P2427, DOI 10.1021/nl061412u; Otsuka H, 2003, ADV DRUG DELIVER REV, V55, P403, DOI 10.1016/S0169-409X(02)00226-0; Panchagnula R, 1998, INT J PHARMACEUT, V172, P1, DOI 10.1016/S0378-5173(98)00188-4; Ranganathan R, 2012, INT J NANOMED, V7, P1043, DOI 10.2147/IJN.S25182; Savic R, 2003, SCIENCE, V300, P615, DOI 10.1126/science.1078192; Sawant RM, 2006, BIOCONJUGATE CHEM, V17, P943, DOI 10.1021/bc060080h; Torchilin V, 2009, EUR J PHARM BIOPHARM, V71, P431, DOI 10.1016/j.ejpb.2008.09.026; Wang WW, 2012, ADV MATER, V24, P115, DOI 10.1002/adma.201104066; Wu H, 2013, BIOMATERIALS, V34, P1213, DOI 10.1016/j.biomaterials.2012.08.072; Yang R, 2009, INT J PHARMACEUT, V371, P142, DOI 10.1016/j.ijpharm.2008.12.007; Yang XQ, 2010, BIOCONJUGATE CHEM, V21, P496, DOI 10.1021/bc900422j; Yin HQ, 2008, J CONTROL RELEASE, V126, P130, DOI 10.1016/j.jconrel.2007.11.014	37	41	41	0	69	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2014	9	6							e100732	10.1371/journal.pone.0100732	http://dx.doi.org/10.1371/journal.pone.0100732			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK8WO	24964012	Green Published, Green Submitted, gold			2023-01-03	WOS:000338709500077
J	Lopez-Guimera, G; Dashti, HS; Smith, CE; Sanchez-Carracedo, D; Ordovas, JM; Garaulet, M				Lopez-Guimera, Gemma; Dashti, Hassan S.; Smith, Caren E.; Sanchez-Carracedo, David; Ordovas, Jose M.; Garaulet, Marta			CLOCK 3111 T/C SNP Interacts with Emotional Eating Behavior for Weight-Loss in a Mediterranean Population	PLOS ONE			English	Article							FOOD-INTAKE; METABOLIC SYNDROME; LOSS MAINTENANCE; LIFE-STYLE; OBESITY; OVERWEIGHT; GENE; STRESS; PREDICTORS; WOMEN	Objective: The goals of this research was (1) to analyze the role of emotional eating behavior on weight-loss progression during a 30-week weight-loss program in 1,272 individuals from a large Mediterranean population and (2) to test for interaction between CLOCK 3111 T/C SNP and emotional eating behavior on the effectiveness of the weight-loss program. Design and Methods: A total of 1,272 overweight and obese participants (BMI: 31 +/- 5 kg/m(2)), aged 20 to 65 years, attending outpatient weight-loss clinics were recruited for this analysis. Emotional eating behavior was assessed by the Emotional Eating Questionnaire (EEQ), a questionnaire validated for overweight and obese Spanish subjects. Anthropometric measures, dietary intake and weight-loss progression were assessed and analyzed throughout the 30-week program. Multivariate analysis and linear regression models were performed to test for gene-environment interaction. Results: Weight-loss progression during the 30-week program differed significantly according to the degree of emotional eating behavior. Participants classified as 'very emotional eaters' experienced more irregular (P = 0.007) weight-loss, with a lower rate of weight decline (-0.002 vs. -0.003, P<0.05) in comparison with less emotional eaters. The percentage of weight-loss was also significantly higher in 'non-emotional eaters' (P = 0.009). Additionally, we identified a significant gene-environment interaction associated with weight-loss at the CLOCK 3111 T/C locus (P = 0.017). By dichotomizing the emotional eating behavior score, linear regression analysis indicated that minor C allele carriers with a high emotional score (> = 11), lost significantly less weight than those C carriers with a low emotional score (<11) (P = 0.005). Conclusions: Emotional eating behavior associates with weight-loss pattern, progression and total weight-loss. Additionally, CLOCK 3111 T/C SNP interacts with emotional eating behavior to modulate total weight loss. These results suggest that the assessment of this locus and emotional eating behavior could improve the development of effective, long-tern weight-management interventions.	[Lopez-Guimera, Gemma; Sanchez-Carracedo, David] Univ Autonoma Barcelona, Dept Clin & Hlth Psychol, E-08193 Barcelona, Spain; [Dashti, Hassan S.; Smith, Caren E.; Ordovas, Jose M.] Tufts Univ, Nutr & Genom Lab, Jean Mayer US Dept Agr, Human Nutr Res Ctr Aging, Boston, MA 02111 USA; [Garaulet, Marta] Univ Murcia, Dept Physiol, Murcia, Spain; [Ordovas, Jose M.] CNIC, Dept Epidemiol, Madrid, Spain; [Ordovas, Jose M.] Inst Madrileno Estudios Avanzados Alimentac IMDEA, Madrid, Spain	Autonomous University of Barcelona; Tufts University; United States Department of Agriculture (USDA); University of Murcia; Centro Nacional de Investigaciones Cardiovasculares (CNIC)	Garaulet, M (corresponding author), Univ Murcia, Dept Physiol, Murcia, Spain.	garaulet@um.es	Greiver, Michelle/N-8764-2015; Sánchez-Carracedo, David/A-4505-2009; Garaulet, Marta/K-6625-2014; Ordovas, Jose/B-8727-2013	Greiver, Michelle/0000-0001-8957-0285; Sánchez-Carracedo, David/0000-0002-3945-6940; Garaulet, Marta/0000-0002-4066-3509; Dashti, Hassan/0000-0002-1650-679X; Ordovas, Jose/0000-0002-7581-5680	NHLBI NIH HHS [HL-54776, K08 HL112845, R01 HL054776] Funding Source: Medline; NIDDK NIH HHS [DK075030, R01 DK075030] Funding Source: Medline; NIMHD NIH HHS [L60 MD003562] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054776, K08HL112845] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bacon L, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-9; Bandin C, 2013, INT J OBESITY, V37, P1044, DOI 10.1038/ijo.2012.180; Bandin C, 2014, INT J OBESITY, V38, P1083, DOI 10.1038/ijo.2013.211; Barte JCM, 2010, OBES REV, V11, P899, DOI 10.1111/j.1467-789X.2010.00740.x; Benedetti F, 2003, AM J MED GENET B, V123B, P23, DOI 10.1002/ajmg.b.20038; BLAIR AJ, 1990, APPETITE, V15, P151, DOI 10.1016/0195-6663(90)90047-C; Bond DS, 2009, INT J OBESITY, V33, P173, DOI 10.1038/ijo.2008.256; Boyle AP, 2012, GENOME RES, V22, P1790, DOI 10.1101/gr.137323.112; Bray GA, 2009, LANCET, V374, P1677, DOI 10.1016/S0140-6736(09)61457-4; Bryant EJ, 2008, OBES REV, V9, P409, DOI 10.1111/j.1467-789X.2007.00426.x; Carter FA, 2012, APPETITE, V58, P1063, DOI 10.1016/j.appet.2012.01.016; Corbalan-Tutau M.D., 2009, REV ESP OBES, V7, P144; Corbalan MD, 2009, NUTRITION, V25, P861, DOI 10.1016/j.nut.2009.02.013; Elfhag K, 2005, OBES REV, V6, P67, DOI 10.1111/j.1467-789X.2005.00170.x; Evers C, 2010, PERS SOC PSYCHOL B, V36, P792, DOI 10.1177/0146167210371383; Garaulet M, 2013, INT J OBESITY, V37, P604, DOI 10.1038/ijo.2012.229; Garaulet M, 2012, INT J OBESITY, V36, P1436, DOI 10.1038/ijo.2011.270; Garaulet M, 2012, NUTR HOSP, V27, P645, DOI [10.1590/S0212-16112012000200043, 10.3305/nh.2012.27.2.5659]; Garaulet M, 2010, INT J OBESITY, V34, P516, DOI 10.1038/ijo.2009.255; Garaulet M, 1999, J HUM NUTR DIET, V12, P219, DOI 10.1046/j.1365-277x.1999.00163.x; Garaulet M, 2010, J AM DIET ASSOC, V110, P917, DOI 10.1016/j.jada.2010.03.017; Garaulet M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017435; Garaulet M, 2010, ADV DRUG DELIVER REV, V62, P967, DOI 10.1016/j.addr.2010.05.005; Garaulet M, 2010, EUR J HUM GENET, V18, P364, DOI 10.1038/ejhg.2009.176; Garaulet M, 2009, AM J CLIN NUTR, V90, P1466, DOI 10.3945/ajcn.2009.27536; Geliebter Allan, 2003, Eat Behav, V3, P341, DOI 10.1016/S1471-0153(02)00100-9; Gibson EL, 2006, PHYSIOL BEHAV, V89, P53, DOI 10.1016/j.physbeh.2006.01.024; GOLDSTEIN DJ, 1992, INT J OBESITY, V16, P397; Hainer V, 2008, DIABETES CARE, V31, pS269, DOI 10.2337/dc08-s265; Hays NP, 2008, OBESITY, V16, P52, DOI 10.1038/oby.2007.12; Jansen A, 2008, APPETITE, V51, P556, DOI 10.1016/j.appet.2008.04.009; KARLSSON J, 1994, APPETITE, V23, P15, DOI 10.1006/appe.1994.1031; Kissling C, 2008, AM J MED GENET B, V147B, P333, DOI 10.1002/ajmg.b.30602; Konttinen H, 2010, APPETITE, V54, P473, DOI 10.1016/j.appet.2010.01.014; Kripke Daniel F, 2009, J Circadian Rhythms, V7, P2, DOI 10.1186/1740-3391-7-2; LAVERY MA, 1993, J AM DIET ASSOC, V93, P1017, DOI 10.1016/0002-8223(93)92041-U; Leblanc V, 2012, CLIN NUTR, V31, P481, DOI 10.1016/j.clnu.2011.12.013; Macht M, 2003, PHYSIOL BEHAV, V80, P367, DOI 10.1016/j.physbeh.2003.08.012; Macht M, 2008, APPETITE, V50, P1, DOI 10.1016/j.appet.2007.07.002; Mann T, 2007, AM PSYCHOL, V62, P220, DOI 10.1037/0003-066X.62.3.220; Milagro FI, 2012, CHRONOBIOL INT, V29, P1180, DOI 10.3109/07420528.2012.719967; Nguyen-Michel ST, 2007, APPETITE, V49, P494, DOI 10.1016/j.appet.2007.03.005; Oliver G, 2000, PSYCHOSOM MED, V62, P853, DOI 10.1097/00006842-200011000-00016; Royal JD, 2010, PERS INDIV DIFFER, V49, P565, DOI 10.1016/j.paid.2010.04.022; Scott EM, 2008, INT J OBESITY, V32, P658, DOI 10.1038/sj.ijo.0803778; Serra-Majem L, 2001, PUBLIC HEALTH NUTR, V4, P1409, DOI 10.1079/PHN2001229; Serretti A, 2003, AM J MED GENET B, V121B, P35, DOI 10.1002/ajmg.b.20053; Sherwood NE, 1999, INT J OBESITY, V23, P485, DOI 10.1038/sj.ijo.0800846; Teixeira Pedro J, 2004, Int J Behav Nutr Phys Act, V1, P12; Teixeira PJ, 2010, OBESITY, V18, P725, DOI 10.1038/oby.2009.281; Teixeira PJ, 2005, OBES REV, V6, P43, DOI 10.1111/j.1467-789X.2005.00166.x; Teixeira PJ, 2002, J BEHAV MED, V25, P499, DOI 10.1023/A:1020687832448; Torres SJ, 2007, NUTRITION, V23, P887, DOI 10.1016/j.nut.2007.08.008; Tuomilehto Jaakko, 2001, New England Journal of Medicine, V344, P1343, DOI 10.1056/NEJM200105033441801; Von Schantz M, 2008, J GENET, V87, P513, DOI 10.1007/s12041-008-0074-7; Wallis DJ, 2009, APPETITE, V52, P355, DOI 10.1016/j.appet.2008.11.007; Wallis DJ, 2004, APPETITE, V43, P39, DOI 10.1016/j.appet.2004.02.001; Wing RR, 2005, AM J CLIN NUTR, V82, p222S, DOI 10.1093/ajcn/82.1.222S	58	28	28	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2014	9	6							e99152	10.1371/journal.pone.0099152	http://dx.doi.org/10.1371/journal.pone.0099152			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AP1YS	24905098	Green Published, gold, Green Submitted			2023-01-03	WOS:000341869000106
J	Simmonds, B; Fox, K; Davis, M; Ku, PW; Gray, S; Hillsdon, M; Sharp, D; Stathi, A; Thompson, J; Coulson, J; Trayers, T				Simmonds, Bethany; Fox, Kenneth; Davis, Mark; Ku, Po-Wen; Gray, Selena; Hillsdon, Melvyn; Sharp, Debbie; Stathi, Afroditi; Thompson, Janice; Coulson, Joanna; Trayers, Tanya			Objectively Assessed Physical Activity and Subsequent Health Service Use of UK Adults Aged 70 and Over: A Four to Five Year Follow Up Study	PLOS ONE			English	Article							LIFE-STYLE INTERVENTIONS; OLDER-ADULTS; CARE UTILIZATION; INDEPENDENCE; ELDERS; ASSOCIATION; DISABILITY; MORTALITY; MOBILITY; PEOPLE	Objectives: To examine the associations between volume and intensity of older peoples' physical activity, with their subsequent health service usage over the following four to five years. Study Design: A prospective cohort design using baseline participant characteristics, objectively assessed physical activity and lower limb function provided by Project OPAL (Older People and Active Living). OPAL-PLUS provided data on numbers of primary care consultations, prescriptions, unplanned hospital admissions, and secondary care referrals, extracted from medical records for up to five years following the baseline OPAL data collection. Participants and Data Collection: OPAL participants were a diverse sample of 240 older adults with a mean age of 78 years. They were recruited from 12 General Practitioner surgeries from low, middle, and high areas of deprivation in a city in the West of England. Primary care consultations, secondary care referrals, unplanned hospital admissions, number of prescriptions and new disease diagnoses were assessed for 213 (104 females) of the original 240 OPAL participants who had either consented to participate in OPAL-PLUS or already died during the follow-up period. Results: In regression modelling, adjusted for socio-economic variables, existing disease, weight status, minutes of moderate-to-vigorous physical activity (MVPA) per day predicted subsequent numbers of prescriptions. Steps taken per day and MVPA also predicted unplanned hospital admissions, although the strength of the effect was reduced when further adjustment was made for lower limb function. Conclusions: Community-based programs are needed which are successful in engaging older adults in their late 70s and 80s in more walking, MVPA and activity that helps them avoid loss of physical function. There is a potential for cost savings to health services through reduced reliance on prescriptions and fewer unplanned hospital admissions.	[Simmonds, Bethany; Fox, Kenneth; Davis, Mark; Coulson, Joanna] Univ Bristol, Sch Policy Studies, Ctr Exercise Nutr & Hlth Sci, Bristol, Avon, England; [Ku, Po-Wen] Natl Changhua Univ Educ, Grad Inst Sports & Hlth, Changua, Taiwan; [Gray, Selena] Univ W England, Dept Hlth & Appl Social Sci, Bristol BS16 1QY, Avon, England; [Hillsdon, Melvyn] Univ Exeter, Exeter, Devon, England; [Sharp, Debbie; Trayers, Tanya] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England; [Stathi, Afroditi] Univ Bath, Dept Hlth, Bath BA2 7AY, Avon, England; [Fox, Kenneth; Thompson, Janice] Univ Birmingham, Sch Sport & Exercise Sci, Birmingham, W Midlands, England	University of Bristol; National Changhua University of Education; University of West England; University of Exeter; University of Bristol; University of Bath; University of Birmingham	Simmonds, B (corresponding author), Bristol Royal Infirm & Gen Hosp, Univ Hosp Bristol, Dept Rheumatol, Bristol, Avon, England.	bethany.simmonds@bristol.ac.uk	Ku, Po-Wen/S-7723-2019; STATHI, AFRODITI/AAM-4377-2020	STATHI, AFRODITI/0000-0003-2162-777X; Simmonds, Bethany Adela Joanna/0000-0003-2463-7623; Ku, Po-Wen/0000-0001-9724-018X; sharp, deborah/0000-0003-3071-9860; Thompson, Janice/0000-0002-7312-3226; Fox, Kenneth/0000-0003-2216-4287	Dunhill Medical Trust [R200/0511]; Avon Primary Care Research Collaborative; South West General Practitioners Trust; National Prevention Research Initiative - British Heart Foundation [G0501312]; Cancer Research UK; Department of Health; Diabetes UK; Economic and Social Research Council; Medical Research Council; Research and Development Office for the Northern Ireland Health and Social Services; Chief Scientist Office; Scottish Executive Health Department; Welsh Assembly Government; World Cancer Research Fund; MRC [MR/K00414X/1, G0501312] Funding Source: UKRI; Medical Research Council [MR/K00414X/1, G0501312] Funding Source: researchfish; The Dunhill Medical Trust [R200/0511] Funding Source: researchfish	Dunhill Medical Trust(Dunhill Medical Trust); Avon Primary Care Research Collaborative; South West General Practitioners Trust; National Prevention Research Initiative - British Heart Foundation; Cancer Research UK(Cancer Research UK); Department of Health; Diabetes UK(Diabetes UK); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Research and Development Office for the Northern Ireland Health and Social Services; Chief Scientist Office; Scottish Executive Health Department; Welsh Assembly Government; World Cancer Research Fund(World Cancer Research Fund International (WCRF)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); The Dunhill Medical Trust(Dunhill Medical Trust)	This follow-up work (OPAL-PLUS) was supported by The Dunhill Medical Trust grant number R200/0511 with additional support from the Avon Primary Care Research Collaborative and the South West General Practitioners Trust. Project OPAL provided the baseline data and was funded by Phase 1 of the National Prevention Research Initiative (http://www.npri.org.uk; grant No. G0501312) that was supported by the British Heart Foundation, Cancer Research UK, Department of Health, Diabetes UK, Economic and Social Research Council, Medical Research Council, Research and Development Office for the Northern Ireland Health and Social Services, Chief Scientist Office, Scottish Executive Health Department, Welsh Assembly Government, and World Cancer Research Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams SA, 2005, AM J EPIDEMIOL, V161, P389, DOI 10.1093/aje/kwi054; [Anonymous], 2010, WHO GLOB STAT REP NO; Bonnefoy M, 2001, J AM GERIATR SOC, V49, P28, DOI 10.1046/j.1532-5415.2001.49006.x; Breeze E, 2005, INT J EPIDEMIOL, V34, P276, DOI 10.1093/ije/dyh328; Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475; Craig R, 2009, HLTH SURVEY ENGLAND; Davis MG, 2011, INT J BEHAV NUTR PHY, V8, DOI 10.1186/1479-5868-8-116; Davis MG, 2011, MED SCI SPORT EXER, V43, P647, DOI 10.1249/MSS.0b013e3181f36196; Department of Health, 2011, START ACT STAY ACT R; Fox KR, 2011, HEALTH PLACE, V17, P633, DOI 10.1016/j.healthplace.2011.01.002; Gine-Garriga M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066392; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; HAAN M, 1987, AM J EPIDEMIOL, V125, P989, DOI 10.1093/oxfordjournals.aje.a114637; House of Lords Select Committee on Public Service and Demographic Change, 2013, READ AG REP; Ip EH, 2013, J GERONTOL A-BIOL, V68, P426, DOI 10.1093/gerona/gls186; Lai JKC, 2013, J BONE MINER RES, V28, P2222, DOI 10.1002/jbmr.1963; MACINTYRE S, 1993, J SOC POLICY, V22, P213, DOI 10.1017/S0047279400019310; Marsh AP, 2011, J GERONTOL A-BIOL, V66, P1376, DOI 10.1093/gerona/glr158; Martin MY, 2006, J AGING PHYS ACTIV, V14, P392, DOI 10.1123/japa.14.4.392; Meltzer D, 2012, HLTH CARE QUALITY AC; Morina N, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-39; Nemet GF, 2000, SOC SCI MED, V50, P1197, DOI 10.1016/S0277-9536(99)00365-2; NICE, 2013, PHYS ACT BRIEF ADV A, V44, P44; Office for National Statistics, 2007, IND DEPR 2007 SUP OU; Perkins AJ, 2001, PREV MED, V32, P492, DOI 10.1006/pmed.2001.0832; Petrella RJ, 1999, PREV MED, V29, P571, DOI 10.1006/pmed.1999.0573; Prior MK, 2012, SOC WORK HEALTH CARE, V51, P345, DOI 10.1080/00981389.2011.644103; Rejeski WJ, 2013, CLIN INTERV AGING, V8, P1119, DOI 10.2147/CIA.S49737; Rejeski WJ, 2009, J GERONTOL A-BIOL, V64, P462, DOI 10.1093/gerona/gln041; Roberts RO, 1996, J CLIN EPIDEMIOL, V49, P989, DOI 10.1016/0895-4356(96)00143-6; Sari N, 2011, MATURITAS, V70, P285, DOI 10.1016/j.maturitas.2011.08.004; Sari N, 2010, CAN J PUBLIC HEALTH, V101, P385, DOI 10.1007/BF03404858; Cabrera MAS, 2012, CAN J AGING, V31, P357, DOI 10.1017/S0714980812000244; Smee D. J., 2012, CURRENT GERONTOLOGY; Tooth LR, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-179; US Department of Health and Human Services, 2008, PHYS ACT GUID AM; Wang FF, 2005, OBES RES, V13, P1450, DOI 10.1038/oby.2005.175; Wolff JL, 2002, ARCH INTERN MED, V162, P2269, DOI 10.1001/archinte.162.20.2269	38	26	36	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2014	9	5							e97676	10.1371/journal.pone.0097676	http://dx.doi.org/10.1371/journal.pone.0097676			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AI5NG	24866573	Green Published, gold			2023-01-03	WOS:000336914100019
J	Gjelsvik, B; Heyerdahl, F; Lunn, D; Hawton, K				Gjelsvik, Bergljot; Heyerdahl, Fridtjof; Lunn, Daniel; Hawton, Keith			Change in Access to Prescribed Medication following an Episode of Deliberate Self-Poisoning: A Multilevel Approach	PLOS ONE			English	Article							HARM; POLYPHARMACY; DEATH; TIME	Objective: Patients with a history of deliberate self-poisoning (DSP) are prescribed a greater amount of medication than the general public. DSP is the most robust risk factor for repeat episodes of DSP and subsequent death by suicide, and one might therefore expect that access to prescribed medication would be reduced following an episode of DSP. However, it is unclear whether access to prescribed medication changes after an episode of DSP. The objectives of this study were to investigate changes in 1) overall, psychotropic, non-psychotropic and the psychotropic subgroup antidepressant prescribed medication availability in DSP patients following an episode of DSP, 2) prescribing of the medication ingested in the episode, and 3) potential effects of gender, age and repeater status on such change. Methods: The design was longitudinal. We included 171 patients admitted for DSP between January 2006 and March 2007. Data on patients' prescriptions prior to admission were retrieved from The Norwegian Prescription Database. The outcome measure was the difference between medication load in the year following compared to the year prior to the DSP episode. Results: There was a significant increase in total medication load following DSP, including both psychotropic and non-psychotropic medication. Antidepressant medication load remained stable. There was a tendency for access to drugs ingested in the episode to increase following the episode, albeit not significantly. Medication load increased with age across all medication groups irrespective of time period and gender. Conclusions: The findings show that physicians do not curb prescribing to patients who have recently deliberately self-poisoned. Moreover, they highlight the need for cautious and judicious prescribing for these patients, in combination with psychological and social interventions.	[Gjelsvik, Bergljot] Univ Oslo, Dept Psychol, Oslo, Norway; [Heyerdahl, Fridtjof] Oslo Univ Hosp, Dept Acute Med, Oslo, Norway; [Lunn, Daniel] Univ Oxford, Dept Stat, Oxford OX1 3TG, England; [Hawton, Keith] Univ Oxford, Ctr Suicide Res, Dept Psychiat, Oxford, England	University of Oslo; University of Oslo; University of Oxford; University of Oxford	Gjelsvik, B (corresponding author), Univ Oslo, Dept Psychol, Oslo, Norway.	bergljot.gjelsvik@psykologi.uio.no			Ministry of Education and Research; Ministry of Health and Care in Norway; National Institute for Health Research [NF-SI-0508-10053] Funding Source: researchfish	Ministry of Education and Research; Ministry of Health and Care in Norway; National Institute for Health Research(National Institute for Health Research (NIHR))	This study was funded jointly by the Ministry of Education and Research and The Ministry of Health and Care in Norway. Professor Keith Hawton is a UK National Institute for Health Research senior investigator. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bergen H, 2012, LANCET, V380, P1568, DOI 10.1016/S0140-6736(12)61141-6; Bjornaas MA, 2009, CLIN TOXICOL, V47, P116, DOI 10.1080/15563650701771981; de Leo D, 1999, INT J PSYCHIAT MED, V29, P149, DOI 10.2190/E87K-FG03-CHEE-UJD3; Deisenhammer EA, 2009, J CLIN PSYCHIAT, V70, P19, DOI 10.4088/JCP.07m03904; Furlanetto LM, 2005, J AFFECT DISORDERS, V86, P87, DOI 10.1016/j.jad.2004.12.011; Gjelsvik B, 2013, J CLIN PSYCHIAT, V74, P630, DOI 10.4088/JCP.12l08298; Gjelsvik Bergljot, 2012, J Clin Psychiatry, V73, pe548, DOI 10.4088/JCP.11m07209; Gvion Y, 2011, ARCH SUICIDE RES, V15, P93, DOI 10.1080/13811118.2011.565265; Hawton K, 2006, PSYCHOL MED, V36, P397, DOI 10.1017/S0033291705006914; Hawton K, 2003, PSYCHOL MED, V33, P987, DOI 10.1017/S0033291703007943; HAWTON K, 2005, PREVENTION TREATMENT, P279; Hoiseth G, 2007, INT J LEGAL MED, V121, P403, DOI 10.1007/s00414-006-0139-1; Hovstadius B, 2012, CLIN GERIATR MED, V28, P159, DOI 10.1016/j.cger.2012.01.001; International language for drug utilization research, 2013, INT LANGUAGE DRUG UT; Kjosavik SR, 2009, PHARMACOEPIDEM DR S, V18, P572, DOI 10.1002/pds.1756; National Institute for Health and Clinical Excellence, 2011, SELF HARM LONG TERM; Neutel CI, 2012, PHARMACOEPIDEM DR S, V21, P172; Neutel CI, 2012, PHARMACOEPIDEM DR S, V21, P199, DOI 10.1002/pds.2214; Prescott K, 2009, BRIT J CLIN PHARMACO, V68, P260, DOI 10.1111/j.1365-2125.2009.03458.x; Tang NKY, 2006, PSYCHOL MED, V36, P575, DOI 10.1017/S0033291705006859	20	14	14	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2014	9	5							e98086	10.1371/journal.pone.0098086	http://dx.doi.org/10.1371/journal.pone.0098086			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AK3KS	24854351	Green Published, gold			2023-01-03	WOS:000338323200043
J	Manyando, C; Njunju, EM; Mwakazanga, D; Chongwe, G; Mkandawire, R; Champo, D; Mulenga, M; De Crop, M; Claeys, Y; Ravinetto, RM; van Overmeir, C; D' Alessandro, U; Van Geertruyden, JP				Manyando, Christine; Njunju, Eric M.; Mwakazanga, David; Chongwe, Gershom; Mkandawire, Rhoda; Champo, Davies; Mulenga, Modest; De Crop, Maaike; Claeys, Yves; Ravinetto, Raffaella M.; van Overmeir, Chantal; D' Alessandro, Umberto; Van Geertruyden, Jean-Pierre			Safety of Daily Co-Trimoxazole in Pregnancy in an Area of Changing Malaria Epidemiology: A Phase 3b Randomized Controlled Clinical Trial	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTION; TRIMETHOPRIM-SULFAMETHOXAZOLE; SULFADOXINE-PYRIMETHAMINE; PLACENTAL MALARIA; PRETERM DELIVERY; BIRTH-WEIGHT; MATERNAL HIV; WOMEN; PREVENTION	Introduction: Antibiotic therapy during pregnancy may be beneficial and impacts positively on the reduction of adverse pregnancy outcomes. No studies have been done so far on the effects of daily Co-trimoxazole (CTX) prophylaxis on birth outcomes. A phase 3b randomized trial was conducted to establish that daily (TX in pregnancy is not inferior to SP intermittent preventive treatment (PT) in reducing placental malaria; preventing peripheral parasitaemia; preventing perinatal mortality and also improving birth weight. To establish its safety on the offspring by measuring the gestational age and birth weight at delivery, and compare the safety and efficacy profile of CTX to that of SP Methods: Pregnant women (HIV infected and uninfected) attending antenatal clinic were randomized to receive either daily CTX or sulfadoxine-pyrimethamine as per routine IPT. Safety was assessed using standard and pregnancy specific measurements. Women were followed up monthly until delivery and then with their offspring up to six weeks after delivery. Results: Data from 346 pregnant women (CTX = 190; SP = 156) and 311 newborns (CTX = 166 and SP = 145) showed that preterm deliveries (CTX 3.6%; SP 3.0%); still births (CTX 3.0%; SP 2.1%), neonatal deaths (CTX 0%; SP 1.4%), and spontaneous abortions (CTX 0.6%; SP 0%) were similar between study arms. The low birth weight rates were 9% for CTX and 13% for SP. There were no birth defects reported. Both drug exposure groups had full term deliveries with similar birth weights (mean of 3.1 Kg). The incidence and severity of AEs in the two groups were comparable. Conclusion: Exposure to daily CTX in pregnancy may not be associated with particular safety risks in terms of birth outcomes such as preterm deliveries, still births, neonatal deaths and spontaneous abortions compared to SP. However, more data are required on CTX use in pregnant women both among HIV infected and un-infected individuals.	[Manyando, Christine; Njunju, Eric M.; Mwakazanga, David; Chongwe, Gershom; Champo, Davies; Mulenga, Modest] Trop Dis Res Ctr, Ndola, Zambia; [Mkandawire, Rhoda] Choma Dist Hlth Management Team, Choma, Zambia; [De Crop, Maaike; Claeys, Yves; Ravinetto, Raffaella M.; van Overmeir, Chantal; D' Alessandro, Umberto] Inst Trop Med, B-2000 Antwerp, Belgium; [D' Alessandro, Umberto] MRC, Fajara, Gambia; [Manyando, Christine; Njunju, Eric M.; Van Geertruyden, Jean-Pierre] Univ Antwerp, Int Hlth Unit, B-2020 Antwerp, Belgium; [Ravinetto, Raffaella M.] Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Leuven, Belgium	Institute of Tropical Medicine (ITM); University of London; London School of Hygiene & Tropical Medicine; University of Antwerp; KU Leuven	Manyando, C (corresponding author), Trop Dis Res Ctr, Ndola, Zambia.	cmanyando@yahoo.com	Van geertruyden, Jean-Pierre/S-3254-2019; Van geertruyden, Jean-Pierre/K-6425-2014; D'Alessandro, Umberto/D-3457-2015; Chongwe, Gershom/V-8783-2017	Van geertruyden, Jean-Pierre/0000-0001-5006-6364; Van geertruyden, Jean-Pierre/0000-0001-5006-6364; D'Alessandro, Umberto/0000-0001-6341-5009; Chongwe, Gershom/0000-0003-3303-308X	Belgian Development Cooperation	Belgian Development Cooperation	The study was funded under a program for institutional capacity strengthening, funded by the Belgian Development Cooperation and coordinated by the Institute of Tropical Medicine in Antwerp. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALLEN S, 1991, J INFECT DIS, V164, P67, DOI 10.1093/infdis/164.1.67; ALTMAN DG, 1995, BRIT MED J, V311, P485, DOI 10.1136/bmj.311.7003.485; Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1; [Anonymous], 2007, ASS SAF ART COMP PRE; [Anonymous], ROLL BACK MAL PARTN; [Anonymous], 2012, INT PREV TREATM MAL; [Anonymous], ASS SAF ART COMP PRE; Ayisi JG, 2003, AIDS, V17, P585, DOI 10.1097/00002030-200303070-00014; BLOLAND PB, 1995, AIDS, V9, P721, DOI 10.1097/00002030-199507000-00009; Brentlinger PE, 2006, LANCET INFECT DIS, V6, P100, DOI 10.1016/S1473-3099(06)70383-8; Chizema-Kawesha E, 2010, AM J TROP MED HYG, V83, P480, DOI 10.4269/ajtmh.2010.10-0035; Cot M, 2003, BRIT MED BULL, V67, P137, DOI 10.1093/bmb/ldg003; Czeizel AE, 2001, REPROD TOXICOL, V15, P637, DOI 10.1016/S0890-6238(01)00178-2; Desai M, 2007, LANCET INFECT DIS, V7, P93, DOI 10.1016/S1473-3099(07)70021-X; DUBOWITZ LM, 1970, J PEDIATR-US, V77, P1, DOI 10.1016/S0022-3476(70)80038-5; Hauth JC, 1995, NEW ENGL J MED, V333, P1732, DOI 10.1056/NEJM199512283332603; Hernandez-Diaz S, 2000, NEW ENGL J MED, V343, P1608, DOI 10.1056/NEJM200011303432204; Juarez-Vazquez J, 2002, BJOG-INT J OBSTET GY, V109, P1009, DOI 10.1016/S1470-0328(02)01378-2; Manyando C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056916; Manyando C, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-249; Marti-Carvajal A, 2004, ARCH LATINOAM NUTR, V54, P45; Masaninga F, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-341; Mermin J, 2004, LANCET, V364, P1428, DOI 10.1016/S0140-6736(04)17225-5; Meshnick SR, 2006, J INFECT DIS, V194, P273, DOI 10.1086/505087; Nosten F, 1999, LANCET, V354, P546, DOI 10.1016/S0140-6736(98)09247-2; Omar SA, 2001, T ROY SOC TROP MED H, V95, P657, DOI 10.1016/S0035-9203(01)90107-5; Parise ME, 1998, AM J TROP MED HYG, V59, P813, DOI 10.4269/ajtmh.1998.59.813; Peters PJ, 2007, DRUG SAFETY, V30, P481, DOI 10.2165/00002018-200730060-00003; Shulman CE, 2003, T ROY SOC TROP MED H, V97, P30, DOI 10.1016/S0035-9203(03)90012-5; Siega-Riz AM, 2004, AM J OBSTET GYNECOL, V191, P1851, DOI 10.1016/j.ajog.2004.07.076; Steketee RW, 1996, AM J TROP MED HYG, V55, P33, DOI 10.4269/ajtmh.1996.55.33; Steketee RW, 1996, AM J TROP MED HYG, V55, P42, DOI 10.4269/ajtmh.1996.55.42; Ter Kuile FO, 2004, AM J TROP MED HYG, V71, P41, DOI 10.4269/ajtmh.2004.71.41; Thera MA, 2005, J INFECT DIS, V192, P1823, DOI 10.1086/498249; Ticconi C, 2003, JAIDS-J ACQ IMM DEF, V34, P289, DOI 10.1097/00126334-200311010-00005; van Eijk AM, 2002, T ROY SOC TROP MED H, V96, P586, DOI 10.1016/S0035-9203(02)90319-6; Van Geertruyden JP, 2004, AM J TROP MED HYG, V71, P35, DOI 10.4269/ajtmh.2004.71.35; Verhoeff FH, 1999, TROP MED INT HEALTH, V4, P5, DOI 10.1046/j.1365-3156.1999.00349.x; Verhoeff FH, 1998, ANN TROP MED PARASIT, V92, P141, DOI 10.1080/00034989859979; Walter J, 2006, J INFECT DIS, V194, P1510, DOI 10.1086/508996; Whitty CJM, 2005, BJOG-INT J OBSTET GY, V112, P1189, DOI 10.1111/j.1471-0528.2005.00714.x; WHO, 2012, WORLD MALARIA REPORT 2012, P1; WHO, 2010, WORLD MALARIA REPORT 2010, P1; World Health Organization (WHO), 2006, GUID COTR PROPH HIV	44	13	13	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2014	9	5							e96017	10.1371/journal.pone.0096017	http://dx.doi.org/10.1371/journal.pone.0096017			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI3UI	24830749	gold, Green Published, Green Submitted			2023-01-03	WOS:000336789500012
J	Hu, H; Duan, ZH; Long, XR; Hertzanu, Y; Shi, HB; Liu, S; Yang, ZQ				Hu, Hao; Duan, Zhenhua; Long, Xiaoran; Hertzanu, Yancu; Shi, Haibin; Liu, Sheng; Yang, Zhengqiang			Sorafenib Combined with Transarterial Chemoembolization versus Transarterial Chemoembolization Alone for Advanced-Stage Hepatocellular Carcinoma: A Propensity Score Matching Study	PLOS ONE			English	Article							MAIN PORTAL-VEIN; PHASE-II; PROGNOSIS; EFFICACY; SAFETY	Aims: The purpose of the present study was to compare the efficacies of transarterial chemoembolization (TACE) combined with sorafenib versus TACE monotherapy for treating patients with advanced hepatocellular carcinoma (HCC). Methods: We enrolled 321 patients and selected 280 with advanced HCC (Barcelona Clinic Liver Cancer stage C) who underwent TACE therapy between February 2009 and February 2013. TACE alone (monotherapy group) was administered to 198 patients (70.7%), and the remaining 82 (29.3%) underwent repeat combined TACE and sorafenib therapy (combined group). To minimize selection bias, these latter 82 patients were matched using propensity-score matching at a 1:2 ratio with 164 patients who received TACE monotherapy. The primary endpoints were overall survival (OS) and related subgroup analysis. The secondary endpoints were time to progression (TTP) and treatment-related adverse events. Results: Of the respective patients in the combined and monotherapy groups, 64.6% and 49.2% had vascular invasion, 87.8% and 91.1% had extrahepatic metastasis, and 54.3% and 47.1% had both. In the propensity-score-matched cohort, the OS survival of the combined group was significantly higher compared with the monotherapy group (7.0 months vs. 4.9 months, respectively, P = 0.003). The TTP was significantly longer in the combined group (2.6 months vs. 1.9 months, respectively, P = 0.001). Subgroup analysis showed that the outcomes of patients with advanced HCC without main portal vein invasion who were treated with combined therapy were significantly better compared with those who received monotherapy (P<0.05). Univariate and subsequent multivariate analyses revealed that the addition of sorafenib was an independent predictor of favorable OS and TTP (adjusted hazard ratios, 0.63 and 0.62, respectively; P<0.05 for both). Conclusion: Sorafenib plus TACE was more effective than TACE monotherapy for treating patients with advanced HCC without main portal vein invasion. Future trials with larger samples are required to validate these preliminary findings.	[Hu, Hao; Shi, Haibin; Liu, Sheng; Yang, Zhengqiang] Nanjing Med Univ, Affiliated Hosp 1, Dept Intervent Radiol, Nanjing, Jiangsu, Peoples R China; [Duan, Zhenhua] Chengdu Ctr Dis Control & Prevent, Chengdu, Peoples R China; [Long, Xiaoran] Anhui Med Univ, Sch Pharm, Hefei, Peoples R China; [Hertzanu, Yancu] Ben Gurion Univ Negev, Fac Hlth Sci, IL-84105 Beer Sheva, Israel	Nanjing Medical University; Anhui Medical University; Ben Gurion University	Yang, ZQ (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Intervent Radiol, Nanjing, Jiangsu, Peoples R China.	olivialong@sina.cn						Bai W, 2013, J DIGEST DIS; Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Chung GE, 2011, RADIOLOGY, V258, P627, DOI 10.1148/radiol.10101058; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI 10.1016/j.ejca.2011.12.021; Georgiades CS, 2005, J VASC INTERV RADIOL, V16, P1653, DOI 10.1097/01.RVI.0000182185.47500.7A; Kim JE, 2012, ONCOLOGY-BASEL, V82, P119, DOI 10.1159/000336082; Kim KM, 2009, J GASTROEN HEPATOL, V24, P806, DOI 10.1111/j.1440-1746.2008.05728.x; Kim Sung Eun, 2011, Korean J Hepatol, V17, P113, DOI 10.3350/kjhep.2011.17.2.113; Kudo M, 2011, EUR J CANCER, V47, P2117, DOI 10.1016/j.ejca.2011.05.007; Kurth T, 2006, AM J EPIDEMIOL, V163, P262, DOI 10.1093/aje/kwj047; Lee HS, 1997, CANCER-AM CANCER SOC, V79, P2087, DOI 10.1002/(SICI)1097-0142(19970601)79:11<2087::AID-CNCR5>3.0.CO;2-M; Lee S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077240; Leuven E., 2003, PSMATCH2 STATA MODUL; Liao MH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068453; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Luo J, 2011, ANN SURG ONCOL, V18, P413, DOI 10.1245/s10434-010-1321-8; Muhammad A, 2013, WORLD J HEPATOL, V5, P364, DOI 10.4254/wjh.v5.i7.364; Okusaka T, 1997, HEPATO-GASTROENTEROL, V44, P251; Park JW, 2012, J HEPATOL, V56, P1336, DOI 10.1016/j.jhep.2012.01.006; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Pawlik TM, 2011, J CLIN ONCOL, V29, P3960, DOI 10.1200/JCO.2011.37.1021; Pinter M, 2012, RADIOLOGY, V263, P590, DOI 10.1148/radiol.12111550; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Takayasu K, 2006, GASTROENTEROLOGY, V131, P461, DOI 10.1053/j.gastro.2006.05.021; Takayasu K, 2010, AM J ROENTGENOL, V194, P830, DOI 10.2214/AJR.09.3308; Uka K, 2007, WORLD J GASTROENTERO, V13, P414, DOI 10.3748/wjg.v13.i3.414	28	47	52	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2014	9	5							e96620	10.1371/journal.pone.0096620	http://dx.doi.org/10.1371/journal.pone.0096620			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI4LX	24817002	Green Published, gold, Green Submitted			2023-01-03	WOS:000336838000047
J	Liang, JM; Luan, YX; Lu, B; Zhang, HB; Luo, YN; Ge, PF				Liang, Jianmin; Luan, Yongxin; Lu, Bin; Zhang, Hongbo; Luo, Yi-nan; Ge, Pengfei			Protection of Ischemic Postconditioning against Neuronal Apoptosis Induced by Transient Focal Ischemia Is Associated with Attenuation of NF-kappa B/p65 Activation	PLOS ONE			English	Article							NF-KAPPA-B; CEREBRAL ISCHEMIA/REPERFUSION INJURY; SIGNALING PATHWAY CONTRIBUTES; TRAUMATIC BRAIN-INJURY; CELL-DEATH; REPERFUSION INJURY; STATUS EPILEPTICUS; INFARCT SIZE; RATS; INHIBITION	Background and Purpose: Accumulating evidences have demonstrated that nuclear factor kappa B/p65 plays a protective role in the protection of ischemic preconditioning and detrimental role in lethal ischemia-induced programmed cell death including apoptosis and autophagic death. However, its role in the protection of ischemic postconditioning is still unclear. Methods: Rat MCAO model was used to produce transient focal ischemia. The procedure of ischemic postconditioning consisted of three cycles of 30 seconds reperfusion/reocclusion of MCA. The volume of cerebral infarction was measured by TTC staining and neuronal apoptosis was detected by TUNEL staining. Western blotting was used to analyze the changes in protein levels of Caspase-3, NF-kappa B/p65, phosphor-NF-kappa B/p65, IkB alpha, phosphor-IkB alpha, Noxa, Bim and Bax between rats treated with and without ischemic postconditioning. Laser scanning confocal microscopy was used to examine the distribution of NF-kappa B/p65 and Noxa. Results: Ischemic postconditioning made transient focal ischemia-induced infarct volume decrease obviously from 38.6% +/- 65.8% to 23.5% +/- 64.3%, and apoptosis rate reduce significantly from 46.5% +/- 66.2 to 29.6% +/- 65.3% at reperfusion 24 h following 2 h focal cerebral ischemia. Western blotting analysis showed that ischemic postconditioning suppressed markedly the reduction of NF-kappa B/p65 in cytoplasm, but elevated its content in nucleus either at reperfusion 6 h or 24 h. Moreover, the decrease of IkBa and the increase of phosphorylated IkB alpha and phosphorylated NF-kappa B/p65 at indicated reperfusion time were reversed by ischemic postconditioning. Correspondingly, proapoptotic proteins Caspase-3, cleaved Caspase-3, Noxa, Bim and Bax were all mitigated significantly by ischemic postconditioning. Confocal microscopy revealed that ischemic postconditioning not only attenuated ischemia-induced translocation of NF-kappa B/p65 from neuronal cytoplasm to nucleus, but also inhibited the abnormal expression of proapoptotic protein Noxa within neurons. Conclusions: We demonstrated in this study that the protection of ischemic postconditioning on neuronal apoptosis caused by transient focal ischemia is associated with attenuation of the activation of NF-kappa B/p65 in neurons.	[Liang, Jianmin; Zhang, Hongbo] Jilin Univ, Hosp 1, Dept Pediat, Changchun 130023, Peoples R China; [Luan, Yongxin; Lu, Bin; Luo, Yi-nan; Ge, Pengfei] Jilin Univ, Hosp 1, Dept Neurosurg, Changchun 130023, Peoples R China; [Liang, Jianmin; Luo, Yi-nan; Ge, Pengfei] Jilin Univ, Hosp 1, Neurosci Res Ctr, Changchun 130023, Peoples R China	Jilin University; Jilin University; Jilin University	Ge, PF (corresponding author), Jilin Univ, Hosp 1, Dept Neurosurg, Changchun 130023, Peoples R China.	pengfeige@gmail.com			National Nature and Science Foundation [30973110, 81171234]; Science and Technology Department of Jilin Province [20080139]	National Nature and Science Foundation(National Natural Science Foundation of China (NSFC)); Science and Technology Department of Jilin Province	This work was supported by National Nature and Science Foundation (30973110) and (81171234), the Outstanding Youth Grant (20080139) from the Science and Technology Department of Jilin Province. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albers GW, 2002, NEW ENGL J MED, V347, P1713, DOI 10.1056/NEJMsb020987; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Blondeau N, 2001, J NEUROSCI, V21, P4668, DOI 10.1523/JNEUROSCI.21-13-04668.2001; Chu WH, 2013, J TRAUMA ACUTE CARE, V74, P1446, DOI 10.1097/TA.0b013e31829246ad; Chuang YC, 2010, J NEUROSCI RES, V88, P1898, DOI 10.1002/jnr.22369; Clemens JA, 1997, MOL BRAIN RES, V48, P187, DOI 10.1016/S0169-328X(97)00092-2; Danielisova V, 2006, CELL MOL NEUROBIOL, V26, P1181, DOI 10.1007/s10571-006-9034-z; Darling CE, 2005, AM J PHYSIOL-HEART C, V289, pH1618, DOI 10.1152/ajpheart.00055.2005; Ding ZM, 2012, INT J MOL SCI, V13, P6089, DOI 10.3390/ijms13056089; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Engel T, 2011, J CEREBR BLOOD F MET, V31, P1196, DOI 10.1038/jcbfm.2011.26; Feng XD, 2013, MOL MED REP, V7, P1516, DOI 10.3892/mmr.2013.1392; Fischer Uwe M, 2006, Interact Cardiovasc Thorac Surg, V5, P531, DOI 10.1510/icvts.2006.130765; Gao XW, 2008, J NEUROCHEM, V105, P943, DOI 10.1111/j.1471-4159.2008.05218.x; Guo JY, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-79; Han HS, 2003, J CEREBR BLOOD F MET, V23, P589, DOI 10.1097/01.WCB.0000059566.39780.8D; Hu J, 2005, MOL CARCINOGEN, V44, P274, DOI 10.1002/mc.20142; Hu J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050764; Inta I, 2006, J NEUROSCI, V26, P12896, DOI 10.1523/JNEUROSCI.3670-06.2006; Ishihara Y, 2012, J PHARMACOL SCI, V119, P251, DOI 10.1254/jphs.12079FP; Jang ER, 2011, NEUROCHEM INT, V58, P52, DOI 10.1016/j.neuint.2010.10.012; Kim EJ, 2010, TRANSL STROKE RES, V1, P40, DOI 10.1007/s12975-009-0006-8; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Kin H, 2008, SHOCK, V29, P761, DOI 10.1097/SHK.0b013e31815cfd5a; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Kong YH, 2013, NEUROCHEM RES, V38, P815, DOI 10.1007/s11064-013-0984-5; Li L, 2013, INFLAMM RES, V62, P387, DOI 10.1007/s00011-013-0590-7; Li WL, 2013, NEUROSCIENCE, V244, P16, DOI 10.1016/j.neuroscience.2013.03.045; Li ZY, 2012, J INT MED RES, V40, P954, DOI 10.1177/147323001204000314; Liang JM, 2013, J INT MED RES, V41, P618, DOI 10.1177/0300060513476587; Liang JM, 2012, INT J MED SCI, V9, P923, DOI 10.7150/ijms.4878; Liu KX, 2009, INTENS CARE MED, V35, P933, DOI 10.1007/s00134-009-1428-1; Loukogeorgakis SP, 2006, CIRCULATION, V113, P1015, DOI 10.1161/CIRCULATIONAHA.105.590398; Nakai M, 2000, J NEUROCHEM, V74, P647, DOI 10.1046/j.1471-4159.2000.740647.x; Pignataro Giuseppe, 2011, Int J Physiol Pathophysiol Pharmacol, V3, P1; Pizzi M, 2009, FEBS J, V276, P27, DOI 10.1111/j.1742-4658.2008.06767.x; Qian YS, 2012, NEUROCHEM INT, V60, P759, DOI 10.1016/j.neuint.2012.03.011; Ren CC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003851; Ryu HJ, 2011, NEUROSCIENCE, V187, P93, DOI 10.1016/j.neuroscience.2011.04.048; Sasaki CY, 2005, J BIOL CHEM, V280, P34538, DOI 10.1074/jbc.M504943200; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Shen WH, 2003, ACTA PHARMACOL SIN, V24, P1125; Song YS, 2010, J CEREBR BLOOD F MET, V30, P1265, DOI 10.1038/jcbfm.2010.6; Wang JY, 2008, STROKE, V39, P983, DOI 10.1161/STROKEAHA.107.499079; Wang Y, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/124614; Xing BZ, 2008, STROKE, V39, P2362, DOI 10.1161/STROKEAHA.107.507939; Xiong J, 2011, INFLAMM RES, V60, P547, DOI 10.1007/s00011-010-0303-4; Xu L, 2002, BIOCHEM BIOPH RES CO, V299, P14, DOI 10.1016/S0006-291X(02)02573-1; Xu M, 2012, BRAIN RES, V1454, P48, DOI 10.1016/j.brainres.2012.03.020; Yin LL, 2012, INT J NEUROSCI, V122, P748, DOI 10.3109/00207454.2012.721827; You WC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060290; Yuan YJ, 2011, BRAIN RES, V1367, P85, DOI 10.1016/j.brainres.2010.10.017; Zeng M, 2013, BIOCHEM BIOPH RES CO, V436, P180, DOI 10.1016/j.bbrc.2013.05.070; Zhang W, 2005, J CEREBR BLOOD F MET, V25, P30, DOI 10.1038/sj.jcbfm.9600004; Zhao H, 2006, J CEREBR BLOOD F MET, V26, P1114, DOI 10.1038/sj.jcbfm.9600348; Zhou XL, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-251	57	30	31	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 6	2014	9	5							e96734	10.1371/journal.pone.0096734	http://dx.doi.org/10.1371/journal.pone.0096734			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AJ9KS	24800741	gold, Green Published, Green Submitted			2023-01-03	WOS:000338029800116
J	Pal, SK; Ruel, N; Villegas, S; Chang, M; DeWalt, K; Wilson, TG; Vogelzang, NJ; Yuh, BE				Pal, Sumanta K.; Ruel, Nora; Villegas, Sergio; Chang, Mark; DeWalt, Kara; Wilson, Timothy G.; Vogelzang, Nicholas J.; Yuh, Bertram E.			CKD-EPI and Cockcroft-Gault Equations Identify Similar Candidates for Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer	PLOS ONE			English	Article							CISPLATIN-BASED CHEMOTHERAPY; GLOMERULAR-FILTRATION-RATE; UROTHELIAL CARCINOMA; SERUM CREATININE; THERAPY; UNFIT	Clinical guidelines suggest neoadjuvant cisplatin-based chemotherapy prior to cystectomy in the setting of muscle-invasive bladder cancer (MIBC). A creatinine clearance (CrCl) >60 mL/min is frequently used to characterize cisplatin-eligible patients, and use of the CKD-EPI equation to estimate CrCl has been advocated. From a prospectively maintained institutional database, patients with MIBC who received cystectomy were identified and clinicopathologic information was ascertained. CrCl prior to surgery was computed using three equations: (1) Cockcroft-Gault (CG), (2) CKD-EPI, and (3) MDRD. The primary objective was to determine if the CG and CKD-EPI equations identified a different proportion of patients who were cisplatin-eligible, based on an estimated CrCl of >60 mL/min. Cisplatin-eligibility was also assessed in subsets based on age, CCI score and race. Actuarial rates of neoadjuvant cisplatin-based chemotherapy use were also reported. Of 126 patients, 70% and 71% of patients were found to be cisplatin-eligible by the CKD-EPI and CG equations, respectively (P = 0.9). The MDRD did not result in significantly different characterization of cisplatin-eligibility as compared to the CKD-EPI and CG equations. In the subset of patients age >80, the CKD-EPI equation identified a much smaller proportion of cisplatin-eligible patients (25%) as compared to the CG equation (50%) or the MDRD equation (63%). Only 34 patients (27%) received neoadjuvant cisplatin-based chemotherapy. Of the 92 patients who did not receive neoadjuvant chemotherapy, 64% had a CrCl >60 mL/min by CG. In contrast to previous reports, the CKD-EPI equation does not appear to characterize a broader span of patients as cisplatin-eligible. Older patients (age >80) may less frequently be characterized as cisplatin-eligible by CKD-EPI. The discordance between actual rates of neoadjuvant chemotherapy use and rates of cisplatin eligibility suggest that other factors (e. g., patient and physician preference) may guide clinical decision-making.	[Pal, Sumanta K.; Villegas, Sergio; Chang, Mark; DeWalt, Kara] City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, Duarte, CA 91010 USA; [Ruel, Nora] City Hope Comprehens Canc Ctr, Dept Informat Sci, Div Biostat, Duarte, CA USA; [Wilson, Timothy G.; Yuh, Bertram E.] City Hope Comprehens Canc Ctr, Dept Surg, Div Urol, Duarte, CA USA; [Vogelzang, Nicholas J.] US Oncol Res, Ctr Comprehens Canc, Las Vegas, NV USA	City of Hope; City of Hope; City of Hope; US Oncology Network	Pal, SK (corresponding author), City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, Duarte, CA 91010 USA.	spal@coh.org		Ruel, Nora/0000-0002-4591-3618	NIH [K12 2K12CA001727-16A1]; NATIONAL CANCER INSTITUTE [K12CA001727, P30CA033572] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH K12 2K12CA001727-16A1 (SKP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2005, EUR UROL, V48, P202; [Anonymous], 2005, EUR UROL, V48, pdiscussion; [Anonymous], 2013, NCCN CLIN PRACT GUID; Bellmunt J, 2000, J CLIN ONCOL, V18, P3247, DOI 10.1200/JCO.2000.18.18.3247; Fedeli U, 2011, J UROLOGY, V185, P72, DOI 10.1016/j.juro.2010.09.015; Galsky MD, 2011, J CLIN ONCOL, V29, P2432, DOI 10.1200/JCO.2011.34.8433; Galsky MD, 2011, LANCET ONCOL, V12, P211, DOI 10.1016/S1470-2045(10)70275-8; GOLDBERG TH, 1987, ARCH INTERN MED, V147, P1430, DOI 10.1001/archinte.147.8.1430; Griffiths G, 2011, J CLIN ONCOL, V29, P2171, DOI 10.1200/JCO.2010.32.3139; Grossman HB, 2003, NEW ENGL J MED, V349, P859, DOI 10.1056/NEJMoa022148; Inker LA, 2012, NEW ENGL J MED, V367, P20, DOI 10.1056/NEJMoa1114248; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; OSTROW S, 1980, CANCER, V46, P1715, DOI 10.1002/1097-0142(19801015)46:8<1715::AID-CNCR2820460802>3.0.CO;2-H; Pal SK, 2013, J NATL COMPR CANC NE, V11, P793, DOI 10.6004/jnccn.2013.0101; Pal SK, 2012, CLIN GENITOURIN CANC, V10, P246, DOI 10.1016/j.clgc.2012.08.004; Qu AQ, 2013, ASCO M, V31, P4530; Raj GV, 2011, CANCER-AM CANCER SOC, V117, P276, DOI 10.1002/cncr.25429; ROSSOF AH, 1979, CANCER TREAT REP, V63, P1557; Siefker-Radtke AO, 2012, CANCER; Sternberg CN, 2013, EUR UROL, V63, P58, DOI 10.1016/j.eururo.2012.08.010; Tsao CK, 2012, CLIN GENITOURIN CANC, V10, P15, DOI 10.1016/j.clgc.2011.10.004; Yuh BE, 2012, J UROL	23	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 10	2014	9	4							e94471	10.1371/journal.pone.0094471	http://dx.doi.org/10.1371/journal.pone.0094471			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI5LS	24722472	gold, Green Submitted, Green Published			2023-01-03	WOS:000336909100075
J	Liu, L; Chen, H; Wang, MM; Zhao, Y; Cai, GH; Qi, XS; Han, GH				Liu, Lei; Chen, Hui; Wang, Mengmeng; Zhao, Yan; Cai, Guohong; Qi, Xingshun; Han, Guohong			Combination Therapy of Sorafenib and TACE for Unresectable HCC: A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							CONCURRENT TRANSARTERIAL CHEMOEMBOLIZATION; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; DRUG-ELUTING BEADS; HEPATOCELLULAR-CARCINOMA; PHASE-III; CANCER; MULTICENTER; MANAGEMENT; EFFICACY	Background and Aim: A large number of studies have tried to combine sorafenib with TACE for patients with unresectable hepatocellular carcinoma (HCC) and the results were controversial. We conducted this systematic review and meta-analysis to evaluate the safety and efficacy of combination therapy of sorafenib and TACE in the management of unresectable HCC. Methods: MEDLINE, PsycINFO, Scopus, EMBASE, and the Cochrane Library were searched from January 1990 to October 2013 and these databases were searched for appropriate studies combining TACE and sorafenib in treatment of HCC. Two authors independently reviewed the databases and extracted the data and disagreements were resolved by discussion. Effective value and safety were analyzed. Effective value included disease control rate (DCR), time to progression (TTP) and overall survival (OS). Results: 17 studies were included in the study. In the 10 noncomparative studies, DCR ranged from 18.4 to 91.2%. Median TTP ranged from 7.1 to 9.0 months, and median OS ranged from 12 to 27 months. In the 7 comparative studies, the hazard ratio (HR) for TTP was found to be 0.76 (95% CI 0.66-0.89; P<0.001) with low heterogeneity among studies (P = 0.243; I-2 = 25.5%). However, the HR for OS was found to be 0.81 (95% CI 0.65-1.01; P = 0.061) with low heterogeneity among studies (P = 0.259; I-2 = 25.4%). The common toxicities included fatigue, diarrhea, nausea, hand foot skin reaction (HFSR), hematological events, hepatotoxicity, alopecia, hepatotoxicity, hypertension and rash/desquamation. AEs are generally manageable with dose reductions. Conclusions: Combination therapy may bring benefits for unresectable HCC patients in terms of TTP but not OS. Further well-designed randomized controlled studies are needed to confirm the efficacy of combination therapy.	[Liu, Lei; Chen, Hui; Qi, Xingshun; Han, Guohong] Fourth Mil Med Univ, Xijing Hosp, Xijing Hosp Digest Dis, Dept Digest Intervent Radiol, Xian 710032, Shaanxi, Peoples R China; [Zhao, Yan] Xi An Jiao Tong Univ, Affiliated Hosp 1, Coll Med, Dept Gastroenterol, Xian 710049, Shaanxi, Peoples R China; [Cai, Guohong] Fourth Mil Med Univ, KK Leung Brain Res Ctr, Dept Anat Histol & Embryol, Xian 710032, Shaanxi, Peoples R China; [Wang, Mengmeng] Fourth Mil Med Univ, Sch Mil Prevent Med, Dept Hlth Serv, Xian 710032, Shaanxi, Peoples R China	Air Force Military Medical University; Xi'an Jiaotong University; Air Force Military Medical University; Air Force Military Medical University	Han, GH (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Xijing Hosp Digest Dis, Dept Digest Intervent Radiol, Xian 710032, Shaanxi, Peoples R China.	guohhan@126.com	Qi, Xingshun/M-7063-2013	Qi, Xingshun/0000-0002-9448-6739; Liu, Lei/0000-0002-3570-2219				Bai W, 2013, J DIGEST DIS, V14, P181, DOI 10.1111/1751-2980.12038; Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep.20933; Bruix J, 2001, J HEPATOL, V35, P421, DOI 10.1016/S0168-8278(01)00130-1; Cabrera R, 2011, ALIMENT PHARM THER, V34, P205, DOI 10.1111/j.1365-2036.2011.04697.x; Choi GH, 2013, RADIOLOGY, V269, P602, DOI 10.1148/radiol.13130150; Chung YH, 2013, INT J CANCER, V132, P2448, DOI 10.1002/ijc.27925; Dufour JF, 2010, ONCOLOGIST, V15, P1198, DOI 10.1634/theoncologist.2010-0180; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; Erhardt A, 2009, HEPATOLOGY S1080A, V50, pA1675; Faloppi L, 2011, CANCER TREAT REV, V37, P169, DOI 10.1016/j.ctrv.2010.08.001; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Forner A, 2010, SEMIN LIVER DIS, V30, P61, DOI 10.1055/s-0030-1247133; Higgins J., 2009, COCHRANE HDB SYSTEMA; Hoffmann K, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-349; Huang YH, 2013, CHINESE MED J-PEKING, V126, P385, DOI 10.3760/cma.j.issn.0366-6999.20113067; Kudo M, 2011, EUR J CANCER, V47, P2117, DOI 10.1016/j.ejca.2011.05.007; Lee JH, 2011, 46 ANN M EUR ASS STU; Lencioni R, 2012, J CLIN ONCOGENE, V30; Li X, 2004, WORLD J GASTROENTERO, V10, P2878; Martin RC II, 2010, ASCO GASTR CANC S JA; Martin R, 2012, HEPATO-GASTROENTEROL, V59, P255, DOI 10.5754/hge10240; Muhammad A, 2013, WORLD J HEPATOL, V5, P364, DOI 10.4254/wjh.v5.i7.364; Park JW, 2013, LIVER INT, V33, P327, DOI 10.1111/liv.12083; Park JW, 2012, J HEPATOL, V56, P1336, DOI 10.1016/j.jhep.2012.01.006; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pawlik TM, 2011, J CLIN ONCOL, V29, P3960, DOI 10.1200/JCO.2011.37.1021; Qu XD, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-263; Raoul JL, 2011, CANCER TREAT REV, V37, P212, DOI 10.1016/j.ctrv.2010.07.006; Sansonno D, 2012, ONCOLOGIST, V17, P359, DOI 10.1634/theoncologist.2011-0313; Sieghart W, 2012, EUR RADIOL, V22, P1214, DOI 10.1007/s00330-011-2368-z; Weintraub JL, 2013, J VASC INTERV RADIOL, V24, P1123, DOI 10.1016/j.jvir.2013.01.494; Wilhelm SM, 2008, MOL CANCER THER, V7, P3129, DOI 10.1158/1535-7163.MCT-08-0013; Zhao Y, 2013, ANN ONCOL, V24, P1786, DOI 10.1093/annonc/mdt072	33	76	83	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2014	9	3							e91124	10.1371/journal.pone.0091124	http://dx.doi.org/10.1371/journal.pone.0091124			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AD6FV	24651044	Green Submitted, gold, Green Published			2023-01-03	WOS:000333352800031
J	Renfrew, MJ; McFadden, A; Bastos, MH; Campbell, J; Channon, AA; Cheung, NF; Silva, DRAD; Downe, S; Kennedy, HP; Malata, A; McCormick, F; Wick, L; Declercq, E				Renfrew, Mary J.; McFadden, Alison; Bastos, Maria Helena; Campbell, James; Channon, Andrew Amos; Cheung, Ngai Fen; Audebert Delage Silva, Deborah Rachel; Downe, Soo; Kennedy, Holly Powell; Malata, Address; McCormick, Felicia; Wick, Laura; Declercq, Eugene			Midwifery and quality care: findings from a new evidence-informed framework for maternal and newborn care	LANCET			English	Article							CESAREAN-SECTION RATES; LOW-RISK WOMEN; CANADIAN MIDWIFERY; COST-EFFECTIVENESS; BIRTH ATTENDANTS; LOW-INCOME; HEALTH; DELIVERY; MORTALITY; COUNTRIES	In this first paper in a series of four papers on midwifery, we aimed to examine, comprehensively and systematically, the contribution midwifery can make to the quality of care of women and infants globally, and the role of midwives and others in providing midwifery care. Drawing on international definitions and current practice, we mapped the scope of midwifery. We then developed a framework for quality maternal and newborn care using a mixed-methods approach including synthesis of findings from systematic reviews of women's views and experiences, effective practices, and maternal and newborn care providers. The framework differentiates between what care is provided and how and by whom it is provided, and describes the care and services that childbearing women and newborn infants need in all settings. We identified more than 50 short-term, medium-term, and long-term outcomes that could be improved by care within the scope of midwifery; reduced maternal and neonatal mortality and morbidity, reduced stillbirth and preterm birth, decreased number of unnecessary interventions, and improved psychosocial and public health outcomes. Midwifery was associated with more efficient use of resources and improved outcomes when provided by midwives who were educated, trained, licensed, and regulated. Our findings support a system-level shift from maternal and newborn care focused on identification and treatment of pathology for the minority to skilled care for all. This change includes preventive and supportive care that works to strengthen women's capabilities in the context of respectful relationships, is tailored to their needs, focuses on promotion of normal reproductive processes, and in which first-line management of complications and accessible emergency treatment are provided when needed. Midwifery is pivotal to this approach, which requires effective interdisciplinary teamwork and integration across facility and community settings. Future planning for maternal and newborn care systems can benefit from using the quality framework in planning workforce development and resource allocation.	[Renfrew, Mary J.; McFadden, Alison] Univ Dundee, Coll Med Dent & Nursing, Sch Nursing & Midwifery, Mother & Infant Res Unit, Dundee DD1 4HJ, Scotland; [Bastos, Maria Helena] Pan Amer Hlth Org, Brasilia, DF, Brazil; [Campbell, James] Inst Cooperac Social Integrare, Barcelona, Spain; [Channon, Andrew Amos] Univ Southampton, Fac Social & Human Sci, Div Social Stat & Demog, Southampton, Hants, England; [Cheung, Ngai Fen] Maternal & Child Hlth Assoc China, Midwifery Expert Comm, Beijing, Peoples R China; [Audebert Delage Silva, Deborah Rachel] Parto Principio Mulheres Rede Pela Maternidade At, Sao Caetano do Sul, Brazil; [Downe, Soo] Univ Cent Lancashire, Sch Hlth, Preston PR1 2HE, Lancs, England; [Kennedy, Holly Powell] Yale Univ, Sch Nursing, New Haven, CT 06536 USA; [Malata, Address] Univ Malawi, Kamuzu Coll Nursing, Lilongwe, Malawi; [McCormick, Felicia] Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England; [Wick, Laura] Birzeit Univ, Inst Community & Publ Hlth, Birzeit, Israel; [Declercq, Eugene] Boston Univ, Sch Publ Hlth, Community Hlth Sci, Boston, MD USA	University of Dundee; Pan American Health Organization; University of Southampton; University of Central Lancashire; Yale University; University of Malawi; University of York - UK; Birzeit University; Boston University	Renfrew, MJ (corresponding author), Univ Dundee, Coll Med Dent & Nursing, Sch Nursing & Midwifery, Mother & Infant Res Unit, Dundee DD1 4HJ, Scotland.	m.renfrew@dundee.ac.uk	Bastos, Maria Helena/AAS-3664-2020	Bastos, Maria Helena/0000-0002-1001-1083; Channon, Andrew/0000-0003-4855-0418; Renfrew, Mary/0000-0003-2905-403X; Cheung, Ngai Fen/0000-0002-2246-3925; McFadden, Alison/0000-0002-5164-2025	Bill and Melinda Gates Foundation [OPP1042500]; University of York; University of Dundee	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); University of York(European Commission); University of Dundee	The work on this paper was supported partly through a grant from the Bill and Melinda Gates Foundation to the University of York and the University of Dundee (grant number OPP1042500), and additional support from the University of York and the University of Dundee. The funding organisations had no role in the undertaking of the analysis and synthesis of the findings of this report. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of their employers or the Bill and Melinda Gates Foundation. Thomson Prentice was the technical editor for the Lancet Series on Midwifery. Project support was provided by Natalie Muir, and administrative support by Jenny Brown and Tracy Sparey. Julie Glanville from the York Health Economics Consortium led the literature searches, and the Midwives Information and Resource Service (MIDIRS) supported the search work. Mari Tikkanen and her colleagues from M4ID produced figure 2. Marcos Dias contributed to the analysis and classification of the systematic reviews. Linda Orr and Jenna Breckenridge contributed to the review of meta-syntheses. We thank the close readers and colleagues who made helpful contributions: Olaya Astudillo, Agneta Bridges, Mariam Claeson, Bernadette Daelmans, Frances Day-Stirk, Declan Devane, France Donnay, Elizabeth Duff, Frances Ganges, Atf Gherissi, Wendy Graham, Metin Gulmezoglu, Kathy Herschderfer, Elizabeth Mason, Blerta Maliqi, Matthews Mathai, Zoe Mullan, Frances McConville, Jennifer McNeil, Mary Newburn, Hermen Ormel, Kerreen Reiger, Severin Ritter von Xylander, Arul Sabaratnam, Kerri Schuiling, Kate Somers, Kate Teela, Joyce Thompson, and Cathy Warwick. All co-authors of the Lancet Series on Midwifery contributed to the concepts and commented on drafts of this paper. Members of the Lancet Series on Midwifery Helicopter Group made important additional contributions: Vincent Fauveau, Nester Moyo, Susan Murray, and Veronica Walford. Other members of the Lancet Series on Midwifery Executive Group made important contributions throughout the writing of this paper: Luc de Bernis, Helga Fogstad, Caroline S E Homer, Zoe Matthews, and Petra ten Hoope-Bender.	Aasheim V, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006672.pub2; Adam T, 2005, BMJ-BRIT MED J, V331, P1107, DOI 10.1136/bmj.331.7525.1107; Adegoke A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040220; Alderdice F, 2013, MIDWIFERY, V29, P389, DOI 10.1016/j.midw.2012.05.010; Alfirevic Z, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006066.pub2; Althabe F, 2006, BIRTH-ISS PERINAT C, V33, P270, DOI 10.1111/j.1523-536X.2006.00118.x; [Anonymous], COCHRANE DATABASE SY, DOI DOI 10.1002/14651858.CD003755.PUB2; [Anonymous], 2006, QUAL CAR PROC MAK ST; [Anonymous], 2016, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003519.PUB3; [Anonymous], 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000225; [Anonymous], 2005, COCHRANE DATABASE SY; Australian Health Ministers Conference, 2011, AUSTR HLTH MIN C NAT; Basevi V, 2001, COCHRANE DB SYST REV, V4; Beck CT, 2004, NURS RES, V53, P216, DOI 10.1097/00006199-200407000-00004; BECKMANN MM, 2006, COCHRANE DB SYST REV, V1; Begley CM, 2011, COCHRANE DB SYST REV, V11; Behague DP, 2002, BMJ-BRIT MED J, V324, P942, DOI 10.1136/bmj.324.7343.942; Belizan JM, 1999, BMJ-BRIT MED J, V319, P1397, DOI 10.1136/bmj.319.7222.1397; Black RE, 2013, LANCET, V382, P427, DOI 10.1016/S0140-6736(13)60937-X; Bourgeault IL, 2000, SOCIOL HEALTH ILL, V22, P172, DOI 10.1111/1467-9566.00198; [Brasil Ministerio da Saude Ministerio da Saude], 2012, SAUD BRAS 2011 AN SI; Brocklehurst P., 2002, COCHRANE DB SYST REV; Brocklehurst P, 2000, COCHRANE DB SYST REV, V4; Brocklehurst P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000262.pub4; Buppasiri P, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007079.pub2; Carroli G, 2009, COCHRANE DB SYST REV, V01, DOI [10.1002/14651858.CD000081.pub2, DOI 10.1002/14651858.CD000081.PUB2]; Cheung NF, 2009, EVIDENCE BASED MIDWI, V7, P101; Cheung Ngai, 2011, PROMOTING NORMAL BIR, P190; Cheung NF, 2009, MIDWIFERY, V25, P744, DOI 10.1016/j.midw.2008.01.009; Chou D, 2013, COCHRANE DB SYST REV, V1; Cluett ER, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000111.pub3; Conde-Agudelo A, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002771.pub2; Conrad P, 2010, SOC SCI MED, V70, P1943, DOI 10.1016/j.socscimed.2010.02.019; COTTER A, 2001, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001808, DOI 10.1002/14651858.CD001808]; Cousens S, 2011, LANCET, V377, P1319, DOI 10.1016/S0140-6736(10)62310-0; Crowther C, 2000, COCHRANE DB SYST REV, V2; Crowther CA, 2013, COCHRANE DB SYST REV, V2; Crowther CA, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000110.pub2; Dare MR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005302.pub2; Das J, 2012, HEALTH AFFAIR, V31, P2774, DOI 10.1377/hlthaff.2011.1356; Das J, 2012, SOC SCI MED, V75, P1660, DOI 10.1016/j.socscimed.2012.06.018; De-Regil LM, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007950.pub2; DeJong J, 2012, PUBLIC HEALTH IN THE ARABWORLD, P249; DEMICHELI V, 2005, COCHRANE DB SYST REV, V4, P2959, DOI DOI 10.1002/14651858.CD2959.PDBC; Dennett Sue, 2002, Health Serv J, V112, P24; Dennis CL, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006309; Deussen AR, 2011, COCHRANE DB SYST REV, V5; Dixon-Woods Mary, 2006, BMC Med Res Methodol, V6, P35, DOI 10.1186/1471-2288-6-35; Dixon-Woods Mary, 2005, J Health Serv Res Policy, V10, P45, DOI 10.1258/1355819052801804; Dodd J, 2004, COCHRANE DB SYST REV, V4; dos Santos ML, 2010, REV TEMPUS ACTAS SAU, V4, P17; Dowswell T, 2010, COCHRANE DB SYST REV, V8; Dowswell T, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000934.pub2; Duley L, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004659.pub2; Duley L, 2010, COCHRANE DB SYST REV, V10, DOI DOI 10.1002/14651858.CD000128.PUB2; Duley L, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000025.pub2; Duley L, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000127.pub2; Dyson L, 2005, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD001688.PUB2; Engel C., 2003, NZ COLL MIDWIVES J, V21, P12; Entwistle V, 2012, J HEALTH SERV RES PO, V17, P70, DOI 10.1258/jhsrp.2011.011029; Feng XL, 2012, B WORLD HEALTH ORGAN, V90, P30, DOI 10.2471/BLT.11.090399; Finlayson K, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001373; French L.M., 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001067.PUB2; Garner P, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000169.pub2; Gibbons L, 2010, 30 WHO; Gibbons L, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2012.02.026; Gogia S, 2010, B WORLD HEALTH ORGAN, V88, P658, DOI 10.2471/BLT.09.069369; Graham WJ, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001368; Graham WJ, 2012, LANCET, V379, pE5, DOI 10.1016/S0140-6736(10)62267-2; Green JM, 2012, BIRTH-ISS PERINAT C, V39, P291, DOI 10.1111/birt.12003; Gulmezoglu AM, 2011, COCHRANE DB SYST REV, V5, DOI DOI 10.1002/14651858.CD000220.PUB2; Haider BA, 2012, COCHRANE DB SYST REV, V11; Harvey SA, 2007, B WORLD HEALTH ORGAN, V85, P783, DOI 10.2471/BLT.06.038455; Hassan-Bitar S, 2011, MIDWIFERY, V27, P154, DOI 10.1016/j.midw.2009.05.007; Hedayati H, 2003, COCHRANE DB SYST REV, V3; Hodnett E, 2012, COCHRANE DB SYST REV, V10; Hodnett ED, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000012.pub4; Hodnett ED, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000198.pub2; Hofmeyr GJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001059.pub3; Hofmeyr GJ, 2002, COCHRANE DB SYST REV, V1; Hofmeyr GJ, 2012, COCHRANE DB SYST REV, V10, DOI DOI 10.1002/14651858.CD.(000083.PUB2); Homer CSE, 2009, MIDWIFERY, V25, P673, DOI 10.1016/j.midw.2007.11.003; Homer CSE, 2014, LANCET; Hopewell S, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000010.pub3; Hunter S, 2007, COCHRANE DB SYST REV, V4; Hutton EK, 2009, BIRTH-ISS PERINAT C, V36, P180, DOI 10.1111/j.1523-536X.2009.00322.x; International Confederation of Midwives, 2013, ESS COMP BAS MIDW PR; International Confederation of Midwives (ICM), 2017, DEF MIDW INT CONF; International ICF, 2012, MEAS DHS STATCOMPILE; International Institute for Population Sciences (IIPS) Macro International Inc, 2006, IND DEM HLTH SURV 20; International Labour Office, 2012, INT STAND CLASS OCC, VI; Jaafar SH, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007202.pub3; Jewell D. J., 2001, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001142, DOI 10.1002/14651858.CD001142]; Jin M., 2009, JILIN MED J, V3, P198; Johanson R, 2002, BRIT MED J, V324, P892, DOI 10.1136/bmj.324.7342.892; Kavanagh J, 2005, COCHRANE DB SYST REV, V3; Kettle C, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000947.pub3; Khan-Neelofur D, 1998, PAEDIATR PERINAT EP, V12, P7, DOI 10.1046/j.1365-3016.12.s2.6.x; Klomp T, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009351.pub2; Koblinsky M, 2006, LANCET, V368, P1377, DOI 10.1016/S0140-6736(06)69382-3; Koblinsky M, 2012, J HEALTH POPUL NUTR, V30, P124, DOI 10.3329/jhpn.v30i2.11294; Kramer MS, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003517.pub2; Lassi ZS, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007754.pub3; Lauzon L, 2001, COCHRANE DB SYST REV, V3; Lawrence A, 2009, COCHRANE DB SYST REV, V2; Lewin S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004015.pub3; Liabsuetrakul T, 2007, COCHRANE DB SYST REV, V2; Lopez LM, 2012, COCHRANE DB SYST REV, V15; Loudon I., 1992, DEATH CHILDBIRTH INT; Lu X., 2012, CHINA CAESAREAN SECT; Lumley J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001055.pub3; Malott AM, 2009, J OBSTET GYNAECOL CA, V31, P974, DOI 10.1016/S1701-2163(16)34328-6; Mander R, 2010, J CLIN NURS, V19, P517, DOI 10.1111/j.1365-2702.2009.02849.x; Marmot M, 2012, LANCET, V380, P1011, DOI 10.1016/S0140-6736(12)61228-8; Mason Frances, 2013, SUPERFOOD BABIES OVE; Mavalankar D, 2011, MIDWIFERY, V27, P700, DOI 10.1016/j.midw.2010.05.010; Mills J., 2001, COCHRANE DB SYST REV, V1; Mori R., 2012, COCHRANE DB SYST REV, V7, DOI DOI 10.1002/14651858.CD000230.PUB4:; Mori R., 2012, COCHRANE DB SYST REV, V3; Murray S, 1996, MIDWIVES SAFER MOTHE, P89; Nardin JM, 2011, COCHRANE DB SYST REV, V5; National Department of Health, 2009, MIN TASKF MAT HLTH P; Oliveira-Menegozzo JM, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005944.pub2; Ota E, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000032.pub2; Pang R., 2012, CHINE J NURS ED, V7, P293; Partnership for Maternal Newborn and Child Health, 2011, GLOB REV KEY INT REL; Pathmanathan I., 2003, INT BANK RECONSTRUCT; Pena-Rosas JP, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004736.pub4; Pena-Rosas JP, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009997; Pennick VE, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001139.pub2; Perkins BB, 2003, MED DELIVERY BUSINES; Petticrew M, 2003, J EPIDEMIOL COMMUN H, V57, P527, DOI 10.1136/jech.57.7.527; Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat, 2013, WORLD POP PROSP 2012; Renfrew MJ, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001141.pub4; Requejo J, 2012, COUNTDOWN 2015 MATER; Reveiz L, 2013, COCHRANE DB SYST REV, V7; Royal College of Obstetricians and Gynaecologists Royal College of Midwives Royal College of Anaesthetists Royal College of Paediatrics and Child Health, 2007, MIN STAND ORG DEL CA; Rumbold A, 2011, COCHRANE DB SYST REV, V1; Ryan P, 2013, MIDWIFERY, V29, P368, DOI 10.1016/j.midw.2012.02.005; Sandall J, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004667.pub5, 10.1002/14651858.CD004667.pub3]; Sandall J, 2010, J MIDWIFERY WOM HEAL, V55, P255, DOI 10.1016/j.jmwh.2010.02.002; Save the Children, 2013, STAT WORLDS MOTH; Seneviratne HR, 2000, INT J GYNECOL OBSTET, V70, P113, DOI 10.1016/S0020-7292(00)00223-X; Shaban I, 2012, MIDWIFERY, V28, P106, DOI 10.1016/j.midw.2010.11.012; Shah A, 2009, INT J GYNECOL OBSTET, V107, P191, DOI 10.1016/j.ijgo.2009.08.013; Sharma B, 2013, MIDWIFERY, V29, P628, DOI 10.1016/j.midw.2012.05.008; Shepperd S, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000086; Sibley LM, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005460; Siegfried N, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003510.pub3; Singh S, 2009, ADDING IT COSTS BENE; Siriwachirachai T, 2010, COCHRANE DB SYST REV, V12; Smaill F, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000490.pub2; Smith CA, 2011, COCHRANE DB SYST REV, V7; Smith CA, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009290.pub2; Smith CA, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009514; Smyth RM, 2013, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD14006167.PUB14651854.; Soltani H, 2011, COCHRANE DB SYST REV, V9; Soltani H, 2010, COCHRANE DB SYST REV, V8; Souza ASR, 2010, FEMINA, V38, P506; Souza JP, 2013, LANCET, V381, P1747, DOI 10.1016/S0140-6736(13)60686-8; Steer PJ, 2009, LANCET, V374, P675, DOI 10.1016/S0140-6736(09)61544-0; Storeng KT, 2008, SOC SCI MED, V66, P545, DOI 10.1016/j.socscimed.2007.10.001; Sturt AS, 2010, COCHRANE DB SYST REV, V3; Su LL, 2012, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD005457.PUB3; Sufang G, 2007, B WORLD HEALTH ORGAN, V85, P755, DOI 10.2471/BLT.06.035808; Suwannachat B, 2012, COCHRANE DB SYST REV, V8; Swadpanich U, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006178.pub2; The Cochrane Collaboration Pregnancy and Childbirth Group, 2014, REV PUBL COCHR LIB; Thorpe KE, 2009, J CLIN EPIDEMIOL, V62, P464, DOI [10.1503/cmaj.090523, 10.1016/j.jclinepi.2008.12.011]; Treweek S, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-37; Tuncalp O, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000494.pub4; UNFPA, 2011, STAT WORLDS MIDW 201; UNFPA, 2007, MAT MORT UPD 2006 EX; UNFPA International Confederation of Midwives WHO, 2010, GLOB CALL ACT STRENG; UNICEF, 2012, STAT WORLDS CHILDR 2; UNICEF, 2017, LEVELS TRENDS CHILD; UNICEF, 2010, 2009 COV EV SURV ALL; UNICEF WHO, 2013, EV NEWB ACT PLAN END; United Nations Secretary General, 2010, GLOB STRAT WOM CHILD; United Nations (UN), 2013, MILL DEV GOALS REP 2; Van Lerberghe W, 2014, LANCET; van Teijlingen E, 2009, SOCIOL RES ONLINE, V14; Vazquez JC, 2011, COCHRANE DB SYST REV, V1; Villar J, 2007, BRIT MED J, V335, P1025, DOI 10.1136/bmj.39363.706956.55; Villar J, 2006, LANCET, V367, P1819, DOI 10.1016/S0140-6736(06)68704-7; WHO, 2013, WORLD MALARIA REPORT 2013, P1; WHO, 2008, MON BUILD BLOCKS HLT; WHO, 2014, TRENDS MAT MORT 1990; WHO, 2002, STRAT DIR STRENGTH N; Wilson A, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d7102; World Health Organization, 2005, WORLD HLTH REPORT 20; World Health Organization (WHO), 2004, MAK PREGN SAF CRIT R; 杨雪峰, 2002, [中国实用妇科与产科杂志, Chineses Journal of Practical Gynecology and Obstetrics], V18, P45	193	577	589	8	125	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 20	2014	384	9948					1129	1145		10.1016/S0140-6736(14)60789-3	http://dx.doi.org/10.1016/S0140-6736(14)60789-3			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AQ2PU	24965816				2023-01-03	WOS:000342630600034
J	Mok, TSK; Loong, HH				Mok, Tony S. K.; Loong, Herbert H.			A REVELation in non-small-cell lung cancer treatment?	LANCET			English	Editorial Material							ENDOTHELIAL GROWTH-FACTOR; PHASE-III; BEVACIZUMAB; CHEMOTHERAPY; TRIAL; COMBINATION; CARBOPLATIN; MUTATIONS; DOCETAXEL		[Mok, Tony S. K.; Loong, Herbert H.] Chinese Univ Hong Kong, Dept Clin Oncol, Fac Med, State Key Lab Oncol South China, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; State Key Lab Oncology South China	Mok, TSK (corresponding author), Chinese Univ Hong Kong, Dept Clin Oncol, Fac Med, State Key Lab Oncol South China, Hong Kong, Hong Kong, Peoples R China.	tony@clo.cuhk.edu.hk	Mok, Tony Shu Kam/B-2310-2019; Loong, Herbert/J-5413-2017	Mok, Tony Shu Kam/0000-0002-8251-0551; Loong, Herbert/0000-0002-6607-1106				Dowlati A, 2008, CLIN CANCER RES, V14, P1407, DOI 10.1158/1078-0432.CCR-07-1154; Garon EB, 2014, LANCET; Jubb AM, 2006, J CLIN ONCOL, V24, P217, DOI 10.1200/JCO.2005.01.5388; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Miles DW, 2013, BRIT J CANCER, V108, P1052, DOI 10.1038/bjc.2013.69; Mok T, 2014, J THORAC ONCOL, V9, P848, DOI 10.1097/JTO.0000000000000160; Reck M, 2014, LANCET ONCOL, V15, P143, DOI 10.1016/S1470-2045(13)70586-2; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Sequist LV, 2013, J CLIN ONCOL, V31, P3327, DOI 10.1200/JCO.2012.44.2806; Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Van Cutsem E, 2012, J CLIN ONCOL, V30, P2119, DOI 10.1200/JCO.2011.39.9824	12	4	5	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 23	2014	384	9944					640	642		10.1016/S0140-6736(14)60895-3	http://dx.doi.org/10.1016/S0140-6736(14)60895-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AO5CJ	24933331				2023-01-03	WOS:000341359100007
J	Sklansky, M; Nadkarni, N; Ramirez-Avila, L				Sklansky, Mark; Nadkarni, Nikhil; Ramirez-Avila, Lynn			Banning the Handshake From the Health Care Setting	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							TRANSMISSION		[Sklansky, Mark] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Div Pediat Cardiol,Mattel Childrens Hosp, Los Angeles, CA 90095 USA; [Nadkarni, Nikhil] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Ramirez-Avila, Lynn] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Div Infect Dis,Mattel Childrens Hosp, Los Angeles, CA 90095 USA; [Ramirez-Avila, Lynn] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Sklansky, M (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, 200 Med Plaza,Ste 330, Los Angeles, CA 90095 USA.	msklansky@mednet.ucla.edu						Boyce JM, 2002, INFECT CONT HOSP EP, V23, pS3, DOI 10.1086/503164; Doring G, 1996, PEDIATR PULM, V21, P90, DOI 10.1002/(SICI)1099-0496(199602)21:2<90::AID-PPUL5>3.0.CO;2-T; Erasmus V, 2010, INFECT CONT HOSP EP, V31, P283, DOI 10.1086/650451; Ghareeb PA, 2013, J HOSP INFECT, V85, P321, DOI 10.1016/j.jhin.2013.08.010; HAMBURGER M, 1947, AM J MED, V2, P23, DOI 10.1016/0002-9343(47)90003-X; Jabbar U, 2010, INFECT CONT HOSP EP, V31, P565, DOI 10.1086/652772; KINGERY F A, 1964, JAMA, V189, P850	7	18	18	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	2014	311	24					2477	2478		10.1001/jama.2014.4675	http://dx.doi.org/10.1001/jama.2014.4675			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AJ5VE	24833502				2023-01-03	WOS:000337757000016
J	Lancaster, T				Lancaster, Tim			In pregnant smokers, the nicotine patch did not increase abstinence or birthweight more than placebo	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford, England	University of Oxford	Lancaster, T (corresponding author), Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford, England.			Lancaster, Timothy Ross/0000-0002-0580-1099					0	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 17	2014	160	12							JC11	10.7326/0003-4819-160-12-201406170-02011	http://dx.doi.org/10.7326/0003-4819-160-12-201406170-02011			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AJ0VR	24935505				2023-01-03	WOS:000337374900011
J	Sarkar, G; Curran, GL; Sarkaria, JN; Lowe, VJ; Jenkins, RB				Sarkar, Gobinda; Curran, Geoffry L.; Sarkaria, Jann N.; Lowe, Val J.; Jenkins, Robert B.			Peptide Carrier-Mediated Non-Covalent Delivery of Unmodified Cisplatin, Methotrexate and Other Agents via Intravenous Route to the Brain	PLOS ONE			English	Article							CONVECTION-ENHANCED DELIVERY; CANCER RESISTANCE PROTEIN; INCREASING DRUG-DELIVERY; BLOOD-BRAIN; IN-VIVO; BARRIER DISRUPTION; THERAPEUTIC ENZYME; TROJAN HORSE; ULTRASOUND; RECEPTOR	Background: Rapid pre-clinical evaluation of chemotherapeutic agents against brain cancers and other neurological disorders remains largely unattained due to the presence of the blood-brain barrier (BBB), which limits transport of most therapeutic compounds to the brain. A synthetic peptide carrier, K16ApoE, was previously developed that enabled transport of target proteins to the brain by mimicking a ligand-receptor system. The peptide carrier was found to generate transient BBB permeability, which was utilized for non-covalent delivery of cisplatin, methotrexate and other compounds to the brain. Approach: Brain delivery of the chemotherapeutics and other agents was achieved either by injecting the carrier peptide and the drugs separately or as a mixture, to the femoral vein. A modification of the method comprised injection of K16ApoE pre-mixed with cetuximab, followed by injection of a 'small-molecule' drug. Principal findings: Seven-of-seven different small molecules were successfully delivered to the brain via K16ApoE. Depending on the method, brain uptake with K16ApoE was 0.72-1.1% for cisplatin and 0.58-0.92% for methotrexate (34-50-fold and 54-92 fold greater for cisplatin and methotrexate, respectively, with K16ApoE than without). Visually intense brain-uptake of Evans Blue, Light Green SF and Crocein scarlet was also achieved. Direct intracranial injection of EB show locally restricted distribution of the dye in the brain, whereas K16ApoE-mediated intravenous injection of EB resulted in the distribution of the dye throughout the brain. Experiments with insulin suggest that ligand-receptor signaling intrinsic to the BBB provides a natural means for passive transport of some molecules across the BBB. Significance: The results suggest that the carrier peptide can non-covalently transport various chemotherapeutic agents to the brain. Thus, the method offers an avenue for pre-clinical evaluation of various small and large therapeutic molecules against brain tumors and other neurological disorders.	[Sarkar, Gobinda; Jenkins, Robert B.] Mayo Clin & Mayo Fdn, Dept Expt Pathol, Rochester, MN 55905 USA; [Curran, Geoffry L.] Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55905 USA; [Sarkaria, Jann N.] Mayo Clin & Mayo Fdn, Dept Radiat Oncol, Rochester, MN 55905 USA; [Lowe, Val J.] Mayo Clin & Mayo Fdn, Dept Nucl Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Sarkar, G (corresponding author), Mayo Clin & Mayo Fdn, Dept Expt Pathol, 200 1st St SW, Rochester, MN 55905 USA.	sarkar.gobinda@mayo.edu; rjenkins@mayo.edu			Mayo Clinic; Bernie and Edith Waterman Foundation; Ting Tsung and Wei Fong Chao Family Foundation	Mayo Clinic; Bernie and Edith Waterman Foundation; Ting Tsung and Wei Fong Chao Family Foundation	This work has been funded by the Mayo Clinic and by Bernie and Edith Waterman and the Ting Tsung and Wei Fong Chao Family Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agarwal S, 2010, J PHARMACOL EXP THER, V334, P147, DOI 10.1124/jpet.110.167601; Allard E, 2009, BIOMATERIALS, V30, P2302, DOI 10.1016/j.biomaterials.2009.01.003; Angelov L, 2009, J CLIN ONCOL, V27, P3503, DOI 10.1200/JCO.2008.19.3789; Banks WA, 1999, J NEUROVIROL, V5, P538, DOI 10.3109/13550289909021284; Banks WA, 2012, PHARMACOL THERAPEUT, V136, P82, DOI 10.1016/j.pharmthera.2012.07.006; Bartus RT, 1996, EXP NEUROL, V142, P14, DOI 10.1006/exnr.1996.0175; Bellavance MA, 2008, AAPS J, V10, P166, DOI 10.1208/s12248-008-9018-7; Blanchette M, 2011, METHODS MOL BIOL, V686, P447, DOI 10.1007/978-1-60761-938-3_23; Boado RJ, 2010, J PHARMACOL EXP THER, V333, P961, DOI 10.1124/jpet.109.165092; Carlson SK, 2006, MOL IMAGING BIOL, V8, P324, DOI 10.1007/s11307-006-0058-z; Carman AJ, 2011, J NEUROSCI, V31, P13272, DOI 10.1523/JNEUROSCI.3337-11.2011; Choi JJ, 2010, IEEE T BIO-MED ENG, V57, P145, DOI 10.1109/TBME.2009.2034533; Cosolo W.C., 1989, AM J PHYSIOL, V256, P443; Cote J, 2010, NEUROPEPTIDES, V44, P177, DOI 10.1016/j.npep.2009.12.009; CROWLE AJ, 1977, J IMMUNOL METHODS, V17, P379, DOI 10.1016/0022-1759(77)90122-3; Deeken JF, 2007, CLIN CANCER RES, V13, P1663, DOI 10.1158/1078-0432.CCR-06-2854; Deng CX, 2010, THER DELIV, V1, P819, DOI 10.4155/TDE.10.66; Dhanikula RS, 2008, MOL PHARM, V5, P105, DOI 10.1021/mp700086j; Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005; GREIG NH, 1990, CANCER CHEMOTH PHARM, V25, P320, DOI 10.1007/BF00686230; Groothuis DR, 2000, NEURO-ONCOLOGY, V2, P45, DOI 10.1093/neuonc/2.1.45; Hdeib A, 2011, EXPERT OPIN BIOL TH, V11, P799, DOI 10.1517/14712598.2011.579097; Hynynen K, 2006, J NEUROSURG, V105, P445, DOI 10.3171/jns.2006.105.3.445; JEFFERIES WA, 1984, NATURE, V312, P162, DOI 10.1038/312162a0; Karkan D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002469; Kioi M, 2006, TECHNOL CANCER RES T, V5, P239, DOI 10.1177/153303460600500307; Kudawara I, 2013, J CHEMOTHERAPY, V25, P41, DOI 10.1179/1973947812Y.0000000055; Lagas JS, 2010, MOL CANCER THER, V9, P319, DOI 10.1158/1535-7163.MCT-09-0663; Lee JH, 2011, CANCER BIOL THER, V11, P108, DOI 10.4161/cbt.11.1.14526; Lillehei KO, 1996, NEUROSURGERY, V39, P1191, DOI 10.1097/00006123-199612000-00023; Marquet F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022598; Meng Y, 2014, MOL THER, V22, P547, DOI 10.1038/mt.2013.267; Mesiwala AH, 2002, ULTRASOUND MED BIOL, V28, P389, DOI 10.1016/S0301-5629(01)00521-X; Minami T, 1998, TOXICOLOGY, V130, P107, DOI 10.1016/S0300-483X(98)00103-6; Mittal A, 2009, J HAZARD MATER, V163, P568, DOI 10.1016/j.jhazmat.2008.07.005; Mouzon A, 2013, CHEMOTHERAPY, V59, P85, DOI 10.1159/000351133; Sands MS, 2014, MOL THER, V22, P483, DOI 10.1038/mt.2014.12; Sarkar G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028881; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Sheikov N, 2004, ULTRASOUND MED BIOL, V30, P979, DOI 10.1016/j.ultrasmedbio.2004.04.010; Siegal T, 2002, CLIN PHARMACOKINET, V41, P171, DOI 10.2165/00003088-200241030-00002; Siegal T, 2013, NEURO-ONCOLOGY, V15, P656, DOI 10.1093/neuonc/not016; Spencer BJ, 2007, P NATL ACAD SCI USA, V104, P7594, DOI 10.1073/pnas.0702170104; Steeg PS, 2011, NAT REV CANCER, V11, P352, DOI 10.1038/nrc3053; Stopa B, 2006, INT J BIOL MACROMOL, V40, P1, DOI 10.1016/j.ijbiomac.2006.05.002; Wang DR, 2013, P NATL ACAD SCI USA, V110, P2999, DOI 10.1073/pnas.1222742110; Waterhouse Rikki N, 2003, Mol Imaging Biol, V5, P376, DOI 10.1016/j.mibio.2003.09.014; Zhou JB, 2013, P NATL ACAD SCI USA, V110, P11751, DOI 10.1073/pnas.1304504110; Zlokovic BV, 2000, ENDOCRINOLOGY, V141, P1434, DOI 10.1210/en.141.4.1434	49	20	21	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2014	9	5							e97655	10.1371/journal.pone.0097655	http://dx.doi.org/10.1371/journal.pone.0097655			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI3AL	24847943	gold, Green Published, Green Submitted			2023-01-03	WOS:000336730600047
J	Brosseau, L; Rahman, P; Poitras, S; Toupin-April, K; Paterson, G; Smith, C; King, J; Casimiro, L; De Angelis, G; Loew, L; Cavallo, S; Mc Ewan, J				Brosseau, Lucie; Rahman, Prinon; Poitras, Stephane; Toupin-April, Karine; Paterson, Gail; Smith, Christine; King, Judy; Casimiro, Lynn; De Angelis, Gino; Loew, Laurianne; Cavallo, Sabrina; Mc Ewan, Jessica			A Systematic Critical Appraisal of Non-Pharmacological Management of Rheumatoid Arthritis with Appraisal of Guidelines for Research and Evaluation II	PLOS ONE			English	Article							CLINICAL-PRACTICE GUIDELINES; BRITISH HEALTH-PROFESSIONALS; AGREE II; QUALITY; VALIDITY; SOCIETY; DISEASE; TRIALS	Clinical practice guidelines (CPGs) have been developed to summarize evidence about the management of rheumatoid arthritis (RA) and facilitate the uptake of evidence-based knowledge by consumers, health professionals, health administrators and policy makers. The objectives of this review was to assess the quality of CPGS on non-pharmacological management of RA with a standardized and validated instrument - the Appraisal of Guidelines for Research and Evaluation (AGREE II) tool and summarize the key recommendations from these CPGs. Scientific literature databases from 2001 to 2013 were systematically searched and a total of 13 CPGs for RA was identified. Only a minority of AGREE II domains were effectively addressed by the CPGS. Scope and purpose was effectively addressed in 10 out of 13 CPGs, stakeholder involvement in 11 CPGs, rigor of development in 6 CPGs, clarity/presentation in 9 CPGs, editorial independence in 1 CPGs, and applicability in none of the CPGs. The overall quality of the included CPGs according to the 7-point AGREE II scoring system was 4.8 +/- 1.04. Patient education/self-management, aerobic, dynamic and stretching exercises were the commonly recommended for the non-pharmacological management of RA by the high-quality CPGs. The general clinical management recommendations tended to be similar among high-quality CPGs. Non-pharmacological management interventions were superficially addressed in more than half of the selected CPGs. CPGs creators should use the AGREE II criteria when developing guidelines. Innovative and effective methods of CPGs implementation to users are needed to ultimately enhance the quality of life of arthritic individuals. In addition, it was difficult to establish between strongly recommended, recommended and weakly recommended, as there is no consensus between the strength of the recommendations between the appraised CPGs.	[Brosseau, Lucie; Poitras, Stephane; Smith, Christine; King, Judy; Casimiro, Lynn; De Angelis, Gino; Loew, Laurianne] Univ Ottawa, Fac Hlth Sci, Sch Rehabil Sci, Ottawa, ON, Canada; [Rahman, Prinon] Dalhousie Univ, Dept Epidemiol & Community Hlth, Halifax, NS, Canada; [Toupin-April, Karine] Inst Populat Hlth, Ctr Global Hlth, Ottawa, ON, Canada; [Casimiro, Lynn] Montfort Hosp, Dept Acad Affairs, Ottawa, ON, Canada; [Paterson, Gail] Arthrit Soc, Ottawa, ON, Canada; [Mc Ewan, Jessica] Univ Ottawa Lib, Ottawa, ON, Canada; [Cavallo, Sabrina] Univ Montreal, Ecole Sante Publ, Montreal, PQ, Canada	University of Ottawa; Dalhousie University; University of Ottawa; University of Ottawa; University of Ottawa; Universite de Montreal	Brosseau, L (corresponding author), Univ Ottawa, Fac Hlth Sci, Sch Rehabil Sci, Ottawa, ON, Canada.	Lucie.Brosseau@uottawa.ca	Cavallo, Sabrina/AAX-8970-2020; King, Judy/L-1070-2018; Cavallo, Sabrina/AAN-9872-2021	King, Judy/0000-0003-4530-9987; Loew, Laurianne/0000-0002-7059-8859; De Angelis, Gino/0000-0003-2099-9870; Poitras, Stephane/0000-0002-8049-958X	Canadian Institutes of Health Research's (CIHR) Community Outreach Program for Non-Governmental Organizations; CIHR Institute of Musculoskeletal Health and Arthritis Community Outreach Grant [ICS-123828]	Canadian Institutes of Health Research's (CIHR) Community Outreach Program for Non-Governmental Organizations(Canadian Institutes of Health Research (CIHR)); CIHR Institute of Musculoskeletal Health and Arthritis Community Outreach Grant(Canadian Institutes of Health Research (CIHR))	The authors are thankful for the financial support of the Canadian Institutes of Health Research's (CIHR) Community Outreach Program for Non-Governmental Organizations. This project was funded by the CIHR Institute of Musculoskeletal Health and Arthritis Community Outreach Grant: #ICS-123828. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akobeng AK, 2005, ARCH DIS CHILD, V90, P837, DOI 10.1136/adc.2005.071761; [Anonymous], 2011, MAN EARL RHEUM ARTHR; Brooks D, 2005, PHYSIOTHER CAN, V57, P123; Brosseau L, 2004, PHYS THER, V84, P934; Brosseau L, 2004, PHYS THER, V84, P1016; Brosseau L, 2011, HLTH ED J, V71, P397, DOI DOI 10.1177/0017896911419346]; Brosseau Lucie, 2004, Physiotherapy Theory and Practice, V20, P91, DOI 10.1080/09593980490453057; Brosseau L, 2012, HEALTH EDUC J, V71, P255, DOI 10.1177/0017896910387317; Brouwers MC, 2010, CAN MED ASSOC J, V182, pE472, DOI 10.1503/cmaj.091716; Brouwers MC, 2010, CAN MED ASSOC J, V182, P1045, DOI 10.1503/cmaj.091714; Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207; Combe B, 2007, ANN RHEUM DIS, V66, P34, DOI 10.1136/ard.2005.044354; Davis DA, 1997, CAN MED ASSOC J, V157, P408; Forestier R, 2009, JOINT BONE SPINE, V76, P691, DOI 10.1016/j.jbspin.2009.01.017; Gossec L, 2006, JOINT BONE SPINE, V73, P396, DOI 10.1016/j.jbspin.2006.01.008; Grossman JH, 1990, CLIN PRACTICE GUIDEL, V38; Hurdowar A, 2007, J EVAL CLIN PRACT, V13, P657, DOI 10.1111/j.1365-2753.2007.00708.x; Hurkmans EJ, 2011, ACTA REUMATOL PORT, V36, P146; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jawaheer D, 2006, ARTHRITIS RHEUM-US, V54, P3087, DOI 10.1002/art.22120; Kwoh CK, 2002, ARTHRITIS RHEUM-US, V46, P328; Luqmani R, 2006, RHEUMATOLOGY, V45, P1167, DOI 10.1093/rheumatology/kel215a; Luqmani R, 2009, RHEUMATOLOGY, V48, P436, DOI 10.1093/rheumatology/ken450a; Macedo LG, 2010, J CLIN EPIDEMIOL, V63, P920, DOI 10.1016/j.jclinepi.2009.10.005; Maetzel A, 2004, ANN RHEUM DIS, V63, P395, DOI 10.1136/ard.2003.006031; McGraw KO, 1996, PSYCHOL METHODS, V1, P30, DOI 10.1037/1082-989X.1.1.30; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Myasoedova Elena, 2010, Curr Rheumatol Rep, V12, P379, DOI 10.1007/s11926-010-0117-y; Olivo SA, 2008, PHYS THER, V88, P156, DOI 10.2522/ptj.20070147; Pencharz JN, 2002, ARTHRITIS RES, V4, P36, DOI 10.1186/ar381; Poitras S, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2339; Regnaux JP, 2012, COCHRANE DATABASE SY, V2012; Royal Australian College of General Practitioners, 2009, CLIN GUID DIAGN MAN; Sackett DL, 2007, CLIN ORTHOP RELAT R, P3, DOI 10.1097/BLO.06013e31802fba1e; Shea BJ, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-10; Shekelle PG, 2001, JAMA-J AM MED ASSOC, V286, P1461, DOI 10.1001/jama.286.12.1461; Simons WR, 2012, J OCCUP ENVIRON MED, V54, P48, DOI 10.1097/JOM.0b013e31823c13e7; Straus SE, 2013, KNOWLEDGE TRANSLATION IN HEALTH CARE: MOVING FROM EVIDENCE TO PRACTICE, 2ND EDITION, P1, DOI 10.1002/9781118413555; Symmons DPM, 2002, BEST PRACT RES CL RH, V16, P707, DOI 10.1053/berh.2002.0257; The National Institute for Health and Clinical Excellence (NICE), 2009, RHEUM ARTHR NAT CLIN; Toupin KA, 2013, ADDRESSING UNMET NEE, P122; Ward MM, 2009, NAT REV RHEUMATOL, V5, P302, DOI 10.1038/nrrheum.2009.90	42	36	37	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2014	9	5							e95369	10.1371/journal.pone.0095369	http://dx.doi.org/10.1371/journal.pone.0095369			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AN9SK	24840205	gold, Green Submitted, Green Published			2023-01-03	WOS:000340948600006
J	Wille, S; Schumacher, P; Paas, J; Tenholte, D; Eminaga, O; Muller, U; Muthen, N; Mehner, J; Cornely, O; Engelmann, U				Wille, Sebastian; Schumacher, Pauline; Paas, Jenny; Tenholte, Dirk; Eminaga, Okyaz; Mueller, Ute; Muthen, Noemi; Mehner, Jan; Cornely, Oliver; Engelmann, Udo			Catheterless Long-Term Ambulatory Urodynamic Measurement Using a Novel Three-Device System	PLOS ONE			English	Article							DETRUSOR OVERACTIVITY; BLADDER; PRESSURE; BIOCOMPATIBILITY; SYMPTOMS	Aims: Long-term urodynamics are required because bladder-emptying disorders are often not clearly revealed by conventional urodynamics. Patients with severe clinical overactive bladder symptoms, for instance, often show normal results. This may be due to the short evaluation time and psychological factors that complicate conventional urodynamics. This study aimed to develop an ambulatory three-component urodynamic measurement system that is easy to operate, registers urodynamic parameters for several days, and has no negative impact on the patient. Methods: We developed an intravesical capsule combined with a hand-held device to register voiding desire and micturition, and an alarm pad device that detects urine loss. Recently, the intravesical capsule and its proven function were detailed in the literature. Here, we present detailed in vitro results using a female bladder model. The flexible capsule was C-shaped to minimize the risk of expulsion from the bladder during micturition. Results of biocompatibility evaluation of the intravesical capsule, which is called Wille Capsule (WiCa) are described. Results: The WiCa with an oval nose and a maximum outer diameter of 5.5 mm was easily inserted through a 25-French cystoscope. Removing the WiCa by grasping the nose using the female model with bladder was easily conducted. Expulsion of the WiCa during voiding was avoided through a novel C-shaped device design. Based on in vitro cytotoxicity studies, the capsule is a promising and safe device. Conclusion: Our novel system is an innovative minimally-invasive tool for accurate long-term urodynamic measurement, and does not require inserting a transurethral catheter.	[Wille, Sebastian; Paas, Jenny; Eminaga, Okyaz; Engelmann, Udo] Univ Cologne, Dept Urol, D-50931 Cologne, Germany; [Schumacher, Pauline; Muthen, Noemi; Cornely, Oliver] ZKS Koln Zentrum Klin Studien, Cologne, Germany; [Tenholte, Dirk; Mehner, Jan] Tech Univ Chemnitz, Fac Elect Engn & Informat Technol, Chemnitz, Germany; [Mueller, Ute] BMP Lab Med Mat Prufung GmbH, Aachen, Germany; [Cornely, Oliver] Univ Cologne, Fac Med, Cologne Excellence Cluster Cellular Stress Respon, D-50931 Cologne, Germany	University of Cologne; University of Cologne; Technische Universitat Chemnitz; University of Cologne	Wille, S (corresponding author), Univ Cologne, Dept Urol, D-50931 Cologne, Germany.	sebastian.wille@uk-koeln.de	Cornely, Oliver A./J-5095-2013; Eminaga, Okyaz/ABH-7208-2020	Cornely, Oliver A./0000-0001-9599-3137; /0000-0003-0861-3138	German Federal Ministry of Research and Education (BMBF) [01KN1106]; Center for Clinical Trial Cologne (ZKS Koln)	German Federal Ministry of Research and Education (BMBF)(Federal Ministry of Education & Research (BMBF)); Center for Clinical Trial Cologne (ZKS Koln)	SW, PS, JP, NM, and OAC are supported by the German Federal Ministry of Research and Education (BMBF grant 01KN1106). The project was supported by the Center for Clinical Trial Cologne (ZKS Koln). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrams P, 2003, UROLOGY, V62, P28, DOI 10.1016/j.urology.2003.09.050; Belanger MC, 2000, ARTIF ORGANS, V24, P879, DOI 10.1046/j.1525-1594.2000.06504.x; BMP GmbH, 2012, INV REP B0343 12 CYT, P1; BMP GmbH, 2013, INV REP B0133 13 CYT, P1; Braden M, 1995, Eur J Prosthodont Restor Dent, V3, P163; Clasbrummel B, 2005, CHIR GASTROENTEROL, V21, P38, DOI 10.1159/000089346; Digesu GA, 2003, NEUROUROL URODYNAM, V22, P105, DOI 10.1002/nau.10099; Hashim H, 2006, J UROLOGY, V175, P191, DOI 10.1016/S0022-5347(05)00067-4; Jourand P, 2010, SENSOR ACTUAT A-PHYS, V162, P160, DOI 10.1016/j.sna.2010.01.035; Pizzoferrato Arturo, 1994, Clinical Materials, V15, P173, DOI 10.1016/0267-6605(94)90081-7; Radley SC, 2001, J UROLOGY, V166, P2253, DOI 10.1016/S0022-5347(05)65545-0; Schnakenberg U, 2002, Biomed Tech (Berl), V47 Suppl 1 Pt 1, P191, DOI 10.1515/bmte.2002.47.s1a.191; Vijayananthan A, 2008, BIOMED IMAGING INTER, V4, P5; Wang CC, 2008, IEEE T BIOMED CIRC S, V2, P44, DOI 10.1109/TBCAS.2008.921601; Wille S, 2013, EUR UROL, V63, P966, DOI 10.1016/j.eururo.2013.01.029	15	9	10	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2014	9	5							e96280	10.1371/journal.pone.0096280	http://dx.doi.org/10.1371/journal.pone.0096280			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AN9SK	24840482	gold, Green Published, Green Submitted			2023-01-03	WOS:000340948600007
J	Riccobono, F; Schobesberger, S; Scott, CE; Dommen, J; Ortega, IK; Rondo, L; Almeida, J; Amorim, A; Bianchi, F; Breitenlechner, M; David, A; Downard, A; Dunne, EM; Duplissy, J; Ehrhart, S; Flagan, RC; Franchin, A; Hansel, A; Junninen, H; Kajos, M; Keskinen, H; Kupc, A; Kurten, A; Kvashin, AN; Laaksonen, A; Lehtipalo, K; Makhmutov, V; Mathot, S; Nieminen, T; Onnela, A; Petaja, T; Praplan, AP; Santos, FD; Schallhart, S; Seinfeld, JH; Sipila, M; Spracklen, DV; Stozhkov, Y; Stratmann, F; Tome, A; Tsagkogeorgas, G; Vaattovaara, P; Viisanen, Y; Vrtala, A; Wagner, PE; Weingartner, E; Wex, H; Wimmer, D; Carslaw, KS; Curtius, J; Donahue, NM; Kirkby, J; Kulmala, M; Worsnop, DR; Baltensperger, U				Riccobono, Francesco; Schobesberger, Siegfried; Scott, Catherine E.; Dommen, Josef; Ortega, Ismael K.; Rondo, Linda; Almeida, Joao; Amorim, Antonio; Bianchi, Federico; Breitenlechner, Martin; David, Andre; Downard, Andrew; Dunne, Eimear M.; Duplissy, Jonathan; Ehrhart, Sebastian; Flagan, Richard C.; Franchin, Alessandro; Hansel, Armin; Junninen, Heikki; Kajos, Maija; Keskinen, Helmi; Kupc, Agnieszka; Kuerten, Andreas; Kvashin, Alexander N.; Laaksonen, Ari; Lehtipalo, Katrianne; Makhmutov, Vladimir; Mathot, Serge; Nieminen, Tuomo; Onnela, Antti; Petaja, Tuukka; Praplan, Arnaud P.; Santos, Filipe D.; Schallhart, Simon; Seinfeld, John H.; Sipila, Mikko; Spracklen, Dominick V.; Stozhkov, Yuri; Stratmann, Frank; Tome, Antonio; Tsagkogeorgas, Georgios; Vaattovaara, Petri; Viisanen, Yrjo; Vrtala, Aron; Wagner, Paul E.; Weingartner, Ernest; Wex, Heike; Wimmer, Daniela; Carslaw, Kenneth S.; Curtius, Joachim; Donahue, Neil M.; Kirkby, Jasper; Kulmala, Markku; Worsnop, Douglas R.; Baltensperger, Urs			Oxidation Products of Biogenic Emissions Contribute to Nucleation of Atmospheric Particles	SCIENCE			English	Article							SULFURIC-ACID; AEROSOL MICROPHYSICS; ORGANIC-COMPOUNDS; GROWTH-RATES; GLOBAL-MODEL; H2SO4; SIZE; NANOPARTICLES; UNCERTAINTY; MAGNITUDE	Atmospheric new-particle formation affects climate and is one of the least understood atmospheric aerosol processes. The complexity and variability of the atmosphere has hindered elucidation of the fundamental mechanism of new-particle formation from gaseous precursors. We show, in experiments performed with the CLOUD (Cosmics Leaving Outdoor Droplets) chamber at CERN, that sulfuric acid and oxidized organic vapors at atmospheric concentrations reproduce particle nucleation rates observed in the lower atmosphere. The experiments reveal a nucleation mechanism involving the formation of clusters containing sulfuric acid and oxidized organic molecules from the very first step. Inclusion of this mechanism in a global aerosol model yields a photochemically and biologically driven seasonal cycle of particle concentrations in the continental boundary layer, in good agreement with observations.	[Riccobono, Francesco; Dommen, Josef; Bianchi, Federico; Praplan, Arnaud P.; Weingartner, Ernest; Baltensperger, Urs] Paul Scherrer Inst, Lab Atmospher Chem, Villigen, Switzerland; [Schobesberger, Siegfried; Ortega, Ismael K.; Duplissy, Jonathan; Franchin, Alessandro; Junninen, Heikki; Kajos, Maija; Lehtipalo, Katrianne; Nieminen, Tuomo; Petaja, Tuukka; Schallhart, Simon; Sipila, Mikko; Kulmala, Markku; Worsnop, Douglas R.] Univ Helsinki, Dept Phys, Helsinki, Finland; [Scott, Catherine E.; Dunne, Eimear M.; Spracklen, Dominick V.; Carslaw, Kenneth S.] Univ Leeds, Sch Earth & Environm, Leeds, W Yorkshire, England; [Rondo, Linda; Almeida, Joao; Ehrhart, Sebastian; Kuerten, Andreas; Wimmer, Daniela; Curtius, Joachim; Kirkby, Jasper] Goethe Univ Frankfurt, Inst Atmospher & Environm Sci, D-60054 Frankfurt, Germany; [Amorim, Antonio; Santos, Filipe D.; Tome, Antonio] Univ Lisbon, Lab Syst Instrumentat & Modeling Sci & Technol Sp, P-1699 Lisbon, Portugal; [Amorim, Antonio; Santos, Filipe D.; Tome, Antonio] Univ Beira Interior, Lisbon, Portugal; [Breitenlechner, Martin; Hansel, Armin] Ionicon Analyt GmbH, Innsbruck, Austria; [Breitenlechner, Martin; Hansel, Armin] Univ Innsbruck, Inst Ion & Appl Phys, A-6020 Innsbruck, Austria; [David, Andre; Mathot, Serge; Onnela, Antti; Kirkby, Jasper] CERN European Org Nucl Res, Geneva, Switzerland; [Downard, Andrew; Flagan, Richard C.; Seinfeld, John H.] CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; [Keskinen, Helmi; Laaksonen, Ari; Vaattovaara, Petri] Univ Eastern Finland, Kuopio, Finland; [Kupc, Agnieszka; Vrtala, Aron; Wagner, Paul E.] Univ Vienna, Fac Phys, Vienna, Austria; [Kvashin, Alexander N.; Makhmutov, Vladimir; Stozhkov, Yuri] PN Lebedev Phys Inst, Solar & Cosm Ray Res Lab, Moscow 117924, Russia; [Duplissy, Jonathan; Nieminen, Tuomo; Sipila, Mikko; Kulmala, Markku] Univ Helsinki, Helsinki Inst Phys, Helsinki, Finland; [Stratmann, Frank; Tsagkogeorgas, Georgios; Wex, Heike] Leibniz Inst Tropospher Res, Leipzig, Germany; [Viisanen, Yrjo] Finnish Meteorol Inst, FIN-00101 Helsinki, Finland; [Donahue, Neil M.] Carnegie Mellon Univ, Ctr Atmospher Particle Studies, Pittsburgh, PA 15213 USA; [Worsnop, Douglas R.] Aerodyne Res Inc, Billerica, MA 01821 USA	Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; University of Helsinki; University of Leeds; Goethe University Frankfurt; Universidade de Lisboa; Universidade da Beira Interior; University of Innsbruck; European Organization for Nuclear Research (CERN); California Institute of Technology; University of Eastern Finland; University of Vienna; Russian Academy of Sciences; Russian Academy of Science Lebedev Physical Institute; Helsinki Institute of Physics; University of Helsinki; Leibniz Institut fur Tropospharenforschung (TROPOS); Finnish Meteorological Institute; Carnegie Mellon University; Aerodyne Research	Baltensperger, U (corresponding author), Paul Scherrer Inst, Lab Atmospher Chem, Villigen, Switzerland.	urs.baltensperger@psi.ch	Franchin, Alessandro/GVR-8219-2022; Kürten, Andreas/O-3851-2019; Tome, Antonio R/A-5681-2013; Santos, Filipe/M-7709-2013; Carslaw, Ken S/C-8514-2009; Kirkby, Jasper/A-4973-2012; Nieminen, Tuomo/AAB-8686-2020; Weingartner, Ernest/B-6793-2009; Schobesberger, Siegfried/L-4454-2014; Amorim, Antonio/C-8460-2013; Franchin, Alessandro/AAH-3069-2019; Tinoco Mendes, Andre David/D-4314-2011; Spracklen, Dominick V/B-4890-2014; Yuri, Stozhkov/ABG-7096-2021; Sipilä, Mikko/G-3024-2010; Laaksonen, Ari/B-5094-2011; Makhmutov, Vladimir/N-2086-2015; Scott, Catherine E/K-8758-2013; Petäjä, Tuukka/A-8009-2008; Donahue, Neil M/A-2329-2008; Stozhkov, Yuri/M-7433-2015; Bianchi, Federico/G-8428-2012; Breitenlechner, Martin/AAA-3402-2021; Spracklen, Dominick/AAA-6257-2019; Duplissy, Jonathan/A-1723-2010; Kulmala, Markku T/I-7671-2016; Curtius, Joachim/A-2681-2011; Nieminen, Tuomo J/D-1618-2011; Worsnop, Douglas R/D-2817-2009; Praplan, Arnaud P./F-8357-2011; Viisanen, Yrjö/CAG-3818-2022; Wex, Heike/X-5882-2018; Hansel, Armin/F-3915-2010; Dunne, Eimear M/H-1567-2014; Junninen, Heikki/C-2157-2014; Ortega Colomer, Ismael Kenneth/A-7930-2008	Kürten, Andreas/0000-0002-8955-4450; Tome, Antonio R/0000-0001-9144-7120; Santos, Filipe/0000-0001-7316-1479; Carslaw, Ken S/0000-0002-6800-154X; Kirkby, Jasper/0000-0003-2341-9069; Nieminen, Tuomo/0000-0002-2713-715X; Weingartner, Ernest/0000-0002-2427-4634; Schobesberger, Siegfried/0000-0002-5777-4897; Amorim, Antonio/0000-0003-0638-2321; Tinoco Mendes, Andre David/0000-0001-5854-7699; Sipilä, Mikko/0000-0002-8594-7003; Laaksonen, Ari/0000-0002-1657-2383; Makhmutov, Vladimir/0000-0002-2242-1055; Scott, Catherine E/0000-0002-0187-969X; Petäjä, Tuukka/0000-0002-1881-9044; Donahue, Neil M/0000-0003-3054-2364; Stozhkov, Yuri/0000-0003-1917-0328; Bianchi, Federico/0000-0003-2996-3604; Duplissy, Jonathan/0000-0001-8819-0264; Kulmala, Markku T/0000-0003-3464-7825; Curtius, Joachim/0000-0003-3153-4630; Worsnop, Douglas R/0000-0002-8928-8017; Praplan, Arnaud P./0000-0002-9944-3084; Viisanen, Yrjö/0000-0002-9660-3281; Wex, Heike/0000-0003-2129-9323; Hansel, Armin/0000-0002-1062-2394; Dunne, Eimear M/0000-0001-7085-8473; Breitenlechner, Martin/0000-0002-2382-6660; Ehrhart, Sebastian/0000-0002-6517-5341; Junninen, Heikki/0000-0001-7178-9430; Keskinen, Helmi/0000-0003-3614-0542; Ortega Colomer, Ismael Kenneth/0000-0002-9299-2013; Kupc/Straus, Agnieszka/0000-0002-7996-2506; Dommen, Josef/0000-0002-0006-0009; Lehtipalo, Katrianne/0000-0002-1660-2706	CERN; European Commission Seventh Framework Programme (Marie Curie Initial Training Network "CLOUD-ITN") [215072]; European Research Council [227463]; Academy of Finland via the Centre of Excellence program [1118615, 1133872]; German Federal Ministry of Education and Research [01LK0902A]; Swiss National Science Foundation [206621_125025, 206620_130527]; Austrian Science Fund [P19546, L593]; Portuguese Foundation for Science and Technology [CERN/FP/116387/2010]; Russian Foundation for Basic Research [N08-02-91006-CERN]; Davidow Foundation; Royal Society Wolfson Award; NSF [AGS1136479, CHE1012293]; Direct For Mathematical & Physical Scien [1012293] Funding Source: National Science Foundation; Div Atmospheric & Geospace Sciences [1136479] Funding Source: National Science Foundation; Austrian Science Fund (FWF) [L 593] Funding Source: researchfish; Natural Environment Research Council [NE/G015015/1] Funding Source: researchfish	CERN; European Commission Seventh Framework Programme (Marie Curie Initial Training Network "CLOUD-ITN"); European Research Council(European Research Council (ERC)European Commission); Academy of Finland via the Centre of Excellence program; German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Austrian Science Fund(Austrian Science Fund (FWF)); Portuguese Foundation for Science and Technology(Portuguese Foundation for Science and Technology); Russian Foundation for Basic Research(Russian Foundation for Basic Research (RFBR)); Davidow Foundation; Royal Society Wolfson Award(Royal Society of London); NSF(National Science Foundation (NSF)); Direct For Mathematical & Physical Scien(National Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS)); Div Atmospheric & Geospace Sciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	We thank CERN for supporting CLOUD with important technical and financial resources and providing a particle beam from the CERN PS; J.-L. Agostini, P. Carrie, L.-P. De Menezes, F. Josa, I. Krasin, R. Kristic, O. S. Maksumov, S. V. Mizin, R. Sitals, A. Wasem, and M. Wilhelmsson for their important contributions to the experiment; and C. Kuang and V.-M. Kerminen for providing the observational data sets used in Fig. 1A and the authors that contributed to them. This research was funded by the European Commission Seventh Framework Programme (Marie Curie Initial Training Network "CLOUD-ITN," grant no. 215072), the European Research Council Advanced Grant "ATMNUCLE" (no. 227463), the Academy of Finland via the Centre of Excellence program (project no. 1118615) and grant no. 1133872, the German Federal Ministry of Education and Research (project no. 01LK0902A), the Swiss National Science Foundation (project no. 206621_125025 and 206620_130527), the Austrian Science Fund (project no. P19546 and L593), the Portuguese Foundation for Science and Technology (project no. CERN/FP/116387/2010), the Russian Foundation for Basic Research (grant N08-02-91006-CERN), the Davidow Foundation, the Royal Society Wolfson Award, and the NSF (grants AGS1136479 and CHE1012293). The data reported in this paper are available online as .txt files in the supplementary materials).	Almeida J, 2013, NATURE, V502, P359, DOI 10.1038/nature12663; Ball SM, 1999, J GEOPHYS RES-ATMOS, V104, P23709, DOI 10.1029/1999JD900411; Carslaw KS, 2013, FARADAY DISCUSS, V165, P495, DOI 10.1039/c3fd00043e; Chen M, 2012, P NATL ACAD SCI USA, V109, P18713, DOI 10.1073/pnas.1210285109; Ehn M, 2010, ATMOS CHEM PHYS, V10, P8513, DOI 10.5194/acp-10-8513-2010; Ehrhart S, 2013, ATMOS CHEM PHYS, V13, P11465, DOI 10.5194/acp-13-11465-2013; Eisele FL, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2005JD006568; GUENTHER A, 1995, J GEOPHYS RES-ATMOS, V100, P8873, DOI 10.1029/94JD02950; Hakola H, 2012, ATMOS CHEM PHYS, V12, P11665, DOI 10.5194/acp-12-11665-2012; Kirkby J, 2011, NATURE, V476, P429, DOI 10.1038/nature10343; Kuang C, 2008, J GEOPHYS RES-ATMOS, V113, DOI 10.1029/2007JD009253; Kulmala M, 2004, J AEROSOL SCI, V35, P143, DOI 10.1016/j.jaerosci.2003.10.003; Kulmala M, 2013, SCIENCE, V339, P943, DOI 10.1126/science.1227385; Kurten T, 2008, ATMOS CHEM PHYS, V8, P4095, DOI 10.5194/acp-8-4095-2008; Laaksonen A, 2008, ATMOS CHEM PHYS, V8, P7255, DOI 10.5194/acp-8-7255-2008; Lee LA, 2013, ATMOS CHEM PHYS, V13, P8879, DOI 10.5194/acp-13-8879-2013; Mann GW, 2010, GEOSCI MODEL DEV, V3, P519, DOI 10.5194/gmd-3-519-2010; Merikanto J, 2009, ATMOS CHEM PHYS, V9, P8601, DOI 10.5194/acp-9-8601-2009; Metzger A, 2010, P NATL ACAD SCI USA, V107, P6646, DOI 10.1073/pnas.0911330107; Nadykto AB, 2007, CHEM PHYS LETT, V435, P14, DOI 10.1016/j.cplett.2006.12.050; OXTOBY DW, 1994, J CHEM PHYS, V100, P7665, DOI 10.1063/1.466859; Paasonen P, 2010, ATMOS CHEM PHYS, V10, P11223, DOI 10.5194/acp-10-11223-2010; Riccobono F, 2012, ATMOS CHEM PHYS, V12, P9427, DOI 10.5194/acp-12-9427-2012; Riipinen I, 2007, ATMOS CHEM PHYS, V7, P1899, DOI 10.5194/acp-7-1899-2007; Schobesberger S, 2013, P NATL ACAD SCI USA, V110, P17223, DOI 10.1073/pnas.1306973110; Sihto SL, 2006, ATMOS CHEM PHYS, V6, P4079, DOI 10.5194/acp-6-4079-2006; Sipila M, 2010, SCIENCE, V327, P1243, DOI 10.1126/science.1180315; Solomon S., 2007, PHYS SCI BASIS WORKI; Sorokin A, 2007, ATMOS ENVIRON, V41, P3740, DOI 10.1016/j.atmosenv.2007.01.017; Spracklen DV, 2010, ATMOS CHEM PHYS, V10, P4775, DOI 10.5194/acp-10-4775-2010; Spracklen DV, 2005, ATMOS CHEM PHYS, V5, P2227, DOI 10.5194/acp-5-2227-2005; Weber RJ, 1996, CHEM ENG COMMUN, V151, P53, DOI 10.1080/00986449608936541; Weber RJ, 1997, J GEOPHYS RES-ATMOS, V102, P4375, DOI 10.1029/96JD03656; Weber RJ, 1998, J GEOPHYS RES-ATMOS, V103, P16385, DOI 10.1029/97JD02465; Young LH, 2008, ATMOS CHEM PHYS, V8, P4997, DOI 10.5194/acp-8-4997-2008; Yu F, 2009, ATMOS CHEM PHYS, V9, P7691, DOI 10.5194/acp-9-7691-2009; Zhang RY, 2012, CHEM REV, V112, P1957, DOI 10.1021/cr2001756; Zhang RY, 2009, P NATL ACAD SCI USA, V106, P17650, DOI 10.1073/pnas.0910125106; Zhang RY, 2004, SCIENCE, V304, P1487, DOI 10.1126/science.1095139	39	357	361	21	578	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 16	2014	344	6185					717	721		10.1126/science.1243527	http://dx.doi.org/10.1126/science.1243527			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AH1WQ	24833386	Green Accepted, Green Submitted			2023-01-03	WOS:000335912900033
J	Ebinger, M; Winter, B; Wendt, M; Weber, JE; Waldschmidt, C; Rozanski, M; Kunz, A; Koch, P; Kellner, PA; Gierhake, D; Villringer, K; Fiebach, JB; Grittner, U; Hartmann, A; Mackert, BM; Endres, M; Audebert, HJ				Ebinger, Martin; Winter, Benjamin; Wendt, Matthias; Weber, Joachim E.; Waldschmidt, Carolin; Rozanski, Michal; Kunz, Alexander; Koch, Peter; Kellner, Philipp A.; Gierhake, Daniel; Villringer, Kersten; Fiebach, Jochen B.; Grittner, Ulrike; Hartmann, Andreas; Mackert, Bruno-Marcel; Endres, Matthias; Audebert, Heinrich J.		STEMO Consortium	Effect of the Use of Ambulance-Based Thrombolysis on Time to Thrombolysis in Acute Ischemic Stroke A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; PHANTOM-S; ALTEPLASE; CARE; MANAGEMENT; THERAPY; UNIT	IMPORTANCE Time to thrombolysis is crucial for outcome in acute ischemic stroke. OBJECTIVE To determine if starting thrombolysis in a specialized ambulance reduces delays. DESIGN, SETTING, AND PARTICIPANTS In the Prehospital Acute Neurological Treatment and Optimization of Medical care in Stroke Study (PHANTOM-S), conducted in Berlin, Germany, we randomly assigned weeks with and without availability of the Stroke Emergency Mobile (STEMO) from May 1, 2011, to January 31, 2013. Berlin has an established stroke care infrastructure with 14 stroke units. We included 6182 adult patients (STEMO weeks: 44.3% male, mean [SD] age, 73.9 [15.0] y; control weeks: 45.2% male, mean [SD] age, 74.3 [14.9] y) for whom a stroke dispatch was activated. INTERVENTIONS The intervention comprised an ambulance (STEMO) equipped with a CT scanner, point-of-care laboratory, and telemedicine connection; a stroke identification algorithm at dispatcher level; and a prehospital stroke team. Thrombolysis was started before transport to hospital if ischemic stroke was confirmed and contraindications excluded. MAIN OUTCOMES AND MEASURES Primary outcome was alarm-to-thrombolysis time. Secondary outcomes included thrombolysis rate, secondary intracerebral hemorrhage after thrombolysis, and 7-day mortality. RESULTS Time reduction was assessed in all patients with a stroke dispatch from the entire catchment area in STEMO weeks (3213 patients) vs control weeks (2969 patients) and in patients in whom STEMO was available and deployed (1804 patients) vs control weeks (2969 patients). Compared with thrombolysis during control weeks, there was a reduction of 15 minutes (95% CI, 11-19) in alarm-to-treatment times in the catchment area during STEMO weeks (76.3 min; 95% CI, 73.2-79.3 vs 61.4 min; 95% CI, 58.7-64.0; P < .001). Among patients for whom STEMO was deployed, mean alarm-to-treatment time (51.8 min; 95% CI, 49.0-54.6) was shorter by 25 minutes (95% CI, 20-29; P < .001) than during control weeks. Thrombolysis rates in ischemic stroke were 29% (310/1070) during STEMO weeks and 33% (200/614) after STEMO deployment vs 21% (220/1041) during control weeks (differences, 8%; 95% CI, 4%-12%; P < .001, and 12%, 95% CI, 7%-16%; P < .001, respectively). STEMO deployment incurred no increased risk for intracerebral hemorrhage (STEMO deployment: 7/200; conventional care: 22/323; adjusted odds ratio [OR], 0.42, 95% CI, 0.18-1.03; P = .06) or 7-day mortality (9/199 vs 15/323; adjusted OR, 0.76; 95% CI, 0.31-1.82; P = .53). CONCLUSIONS AND RELEVANCE Compared with usual care, the use of ambulance-based thrombolysis resulted in decreased time to treatment without an increase in adverse events. Further studies are needed to assess the effects on clinical outcomes.	[Ebinger, Martin; Winter, Benjamin; Wendt, Matthias; Weber, Joachim E.; Waldschmidt, Carolin; Rozanski, Michal; Kunz, Alexander; Koch, Peter; Endres, Matthias; Audebert, Heinrich J.] Charite, Dept Neurol, D-10117 Berlin, Germany; [Ebinger, Martin; Winter, Benjamin; Rozanski, Michal; Kunz, Alexander; Gierhake, Daniel; Villringer, Kersten; Fiebach, Jochen B.; Grittner, Ulrike; Endres, Matthias; Audebert, Heinrich J.] Charite, Ctr Stroke Res Berlin CSB, D-10117 Berlin, Germany; [Kellner, Philipp A.] Vivantes Klinikum Friedrichshain, Rettungsstelle, Berlin, Germany; [Grittner, Ulrike] Charite, Dept Biostat & Clin Epidemiol, D-10117 Berlin, Germany; [Hartmann, Andreas] Rhon Klinikum Klinikum Frankfurt Oder, Frankfurt, Oder, Germany; [Mackert, Bruno-Marcel] Vivantes Auguste Viktoria Klinikum, Berlin, Germany; [Endres, Matthias] Charite, ExcellenceCluster NeuroCure, D-10117 Berlin, Germany; [Endres, Matthias] German Ctr Neurodegenerat Dis DZNE, Berlin, Germany; [Endres, Matthias] German Ctr Cardiovasc Res DZHK, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); German Centre for Cardiovascular Research	Ebinger, M (corresponding author), Charite, Klin & Hsch Ambulanz Neurol, Charitepl 1, D-10117 Berlin, Germany.	martin.ebinger@charite.de	Weber, Joachim/AAL-2799-2020; Grittner, Ulrike/I-2026-2019	Weber, Joachim/0000-0002-1666-6021; Grittner, Ulrike/0000-0003-2595-0224; Fiebach, Jochen B./0000-0002-7936-6958; Audebert, Heinrich J./0000-0002-4785-0366; Endres, Matthias/0000-0001-6520-3720	Zukunftsfonds Berlin; Technology Foundation Berlin; EU; European Regional Development Fund (ERDF)	Zukunftsfonds Berlin; Technology Foundation Berlin; EU(European Commission); European Regional Development Fund (ERDF)(European Commission)	PHANTOM-S was funded by the Zukunftsfonds Berlin and the Technology Foundation Berlin with EU co-financing by the European Regional Development Fund (ERDF).	Audebert HJ, 2013, NEUROLOGY, V81, P501, DOI 10.1212/WNL.0b013e31829e0fdd; Ebinger M, 2012, INT J STROKE, V7, P348, DOI 10.1111/j.1747-4949.2011.00756.x; Fassbender K, 2013, LANCET NEUROL, V12, P585, DOI 10.1016/S1474-4422(13)70100-5; Fonarow GC, 2011, CIRCULATION, V123, P750, DOI 10.1161/CIRCULATIONAHA.110.974675; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; Kohrmann M, 2011, INT J STROKE, V6, P493, DOI 10.1111/j.1747-4949.2011.00585.x; Koennecke HC, 2011, NEUROLOGY, V77, P965, DOI 10.1212/WNL.0b013e31822dc795; Koennecke HC, 2012, BERLINER SCHLAGANFAL; Krebes S, 2012, STROKE, V43, P776, DOI 10.1161/STROKEAHA.111.634980; Lansberg MG, 2009, STROKE, V40, P2079, DOI 10.1161/STROKEAHA.108.540708; Lees KR, 2010, LANCET, V375, P1695, DOI 10.1016/S0140-6736(10)60491-6; Meretoja A, 2012, NEUROLOGY, V79, P306, DOI 10.1212/WNL.0b013e31825d6011; Murray CJL, 2013, NEW ENGL J MED, V369, P448, DOI 10.1056/NEJMra1201534; National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, 1995, NEW ENGL J MED, V333, P1581, DOI [10.1056/NEJM199512143332401, DOI 10.1056/NEJM199512143332401]; Sandercock P, 2012, LANCET, V379, P2352, DOI 10.1016/S0140-6736(12)60768-5; Saver JL, 2013, JAMA-J AM MED ASSOC, V309, P2480, DOI 10.1001/jama.2013.6959; Schwamm LH, 2013, NEUROLOGY, V80, P130, DOI 10.1212/WNL.0b013e31827d44ca; Wahlgren N, 2008, LANCET, V372, P1303, DOI 10.1016/S0140-6736(08)61339-2; Wahlgren N, 2007, LANCET, V369, P275, DOI 10.1016/S0140-6736(07)60149-4; Walter S, 2012, LANCET NEUROL, V11, P397, DOI 10.1016/S1474-4422(12)70057-1; Wardlaw JM, 2012, LANCET, V379, P2364, DOI 10.1016/S0140-6736(12)60738-7; Weber JE, 2013, NEUROLOGY, V80, P163, DOI 10.1212/WNL.0b013e31827b90e5	23	288	307	1	43	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	2014	311	16					1622	1631		10.1001/jama.2014.2850	http://dx.doi.org/10.1001/jama.2014.2850			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AF4OU	24756512	Bronze			2023-01-03	WOS:000334693900022
J	Stamp, R; Schembri, A; Fenlon, J; Rentelis, R; Woll, B; Cormier, K				Stamp, Rose; Schembri, Adam; Fenlon, Jordan; Rentelis, Ramas; Woll, Bencie; Cormier, Kearsy			Lexical Variation and Change in British Sign Language	PLOS ONE			English	Article							HAND	This paper presents results from a corpus-based study investigating lexical variation in BSL. An earlier study investigating variation in BSL numeral signs found that younger signers were using a decreasing variety of regionally distinct variants, suggesting that levelling may be taking place. Here, we report findings from a larger investigation looking at regional lexical variants for colours, countries, numbers and UK placenames elicited as part of the BSL Corpus Project. Age, school location and language background were significant predictors of lexical variation, with younger signers using a more levelled variety. This change appears to be happening faster in particular sub- groups of the deaf community (e.g., signers from hearing families). Also, we find that for the names of some UK cities, signers from outside the region use a different sign than those who live in the region.	[Stamp, Rose; Fenlon, Jordan; Rentelis, Ramas; Woll, Bencie; Cormier, Kearsy] UCL, Deafness Cognit & Language Res Ctr DCAL, London, England; [Schembri, Adam] La Trobe Univ, Linguist Program, Melbourne, Vic, Australia; [Schembri, Adam] La Trobe Univ, Ctr Res Language Div, Melbourne, Vic, Australia	University of London; University College London; La Trobe University; La Trobe University	Stamp, R (corresponding author), UCL, Deafness Cognit & Language Res Ctr DCAL, London, England.	rose_stamp@hotmail.com	Cormier, Kearsy/C-2327-2009; Woll, Bencie/C-2040-2008; Schembri, Adam Charles/ABE-6139-2020	Woll, Bencie/0000-0002-3300-4775; Schembri, Adam Charles/0000-0002-8814-5911; Fenlon, Jordan/0000-0003-1127-2637; Stamp, Rose/0000-0002-1993-559X	Economic and Social Research Council (ESRC) [RES-062-23-0825]; Economic and Social Research Council of Great Britain [RES-620-28-6001, RES-620-28-0002]; ESRC [RES-620-28-6001, ES/I03479X/1, ES/F017251/1] Funding Source: UKRI; Economic and Social Research Council [ES/F017251/1, RES-620-28-6001, ES/I03479X/1] Funding Source: researchfish	Economic and Social Research Council (ESRC)(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Economic and Social Research Council of Great Britain(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))	The data for this study were collected as part of the British Sign Language Corpus Project, supported by the Economic and Social Research Council (ESRC) (Grant RES-062-23-0825 and postgraduate award, Stamp, 2013). Additional work was supported by the Economic and Social Research Council of Great Britain grants RES-620-28-6001 and RES-620-28-0002: Deafness Cognition and Language Research Centre. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ARMSTRONG NIGEL, 2001, SOCIAL STYLISTIC VAR; Ash Sharon, 2002, HDB LANGUAGE VARIATI, P402; Baayen RH, 2008, J MEM LANG, V59, P390, DOI 10.1016/j.jml.2007.12.005; Bayard D., 1989, REO J LINGUISTIC SOC, V32, P17; Bayley R, 2002, HDB LANGUAGE VARIATI, P312; Bonvillian RJ, 1993, PSYCHOL PERSPECTIVES, P229; Brien David, 1992, DICT BRIT SIGN LANGU; Chambers J. K., 2004, LEGACIES COLONIAL EN, P224; CHAMBERS JACK K., 2000, ENGL WORLD-WIDE, V21, P1; Chambers JK, 1999, VARIATION LINGUISTIC, V8, P117; Cheshire J., 2002, HDB LANGUAGE VARIATI; Coates J., 2001, J SOCIOLING, V5, P507, DOI [10.1111/1467-9481.00162, DOI 10.1111/1467-9481.00162]; Cormier K, 2011, P C LANG DOC LING TH; Cormier K, 2012, P 5 WORKSH REPR PROC, P7; Cormier K, 2008, SIGN LANG LINGUIST, V11, P3, DOI 10.1075/sl&l.11.1.03cor; Crasborn O., 2008, P LREC 2008 6 INT C; Eckert P., 1997, HDB SOCIOLINGUISTICS, DOI DOI 10.1002/9781405166256.CH9; Elton F, 2008, BRIT SIGN LANGUAGE L; Elton F, 2010, CHANGING WAY WE SIGN; Fenlon J, 2013, LANG COMMUN, V33, P69, DOI 10.1016/j.langcom.2012.09.001; Foran C, 1995, CONTACT VOICE IRISH, V23; Francis W. N., 1983, DIALECTOLOGY INTRO; Giles Howard., 1997, SOCIOLINGUISTICS REA, P232, DOI DOI 10.1007/978-1-349-25582-5_19; Hiddinga A, 2011, LANG SOC, V40, P483, DOI 10.1017/S0047404511000480; Hoyer K, 2007, SOCIOLINGUIST DEAF, V13, P195; Jackson Peter, 1990, BRITAINS DEAF HERITA; Jaeger TF, 2008, J MEM LANG, V59, P434, DOI 10.1016/j.jml.2007.11.007; Johnson DE, 2009, LANG LINGUIST COMPAS, V3, P359, DOI 10.1111/j.1749-818x.2008.00108.x; Johnston T., 2003, THEORETICAL ISSUES S, P47; Johnston T., 2007, AUSTR SIGN LANGUAGE; Johnston T, 2010, INT J CORPUS LINGUIS, V15, P106, DOI 10.1075/ijcl.15.1.05joh; Karchmer M. A., 2004, SIGN LANG STUD, V4, P138, DOI DOI 10.1353/SLS.2004.0005; Katseff S, 2004, THEOR ISS SIGN LANG; Kyle J, 1993, LANGUAGE SIGN DEV DE; Kyle Jim, 1988, SIGN LANGUAGE STUDY, DOI Cambridge; Labov W., 1972, SOCIOLINGUISTIC PATT; Ladd P, 2003, UNDERSTANDING; Lane H., 1992, MASK BENEVOLENCE DIS; LeMaster Barbara, 1991, SIGN LANGUAGE STUDIE, V73, P361, DOI DOI 10.1353/SLS.1991.0034; Lodge R. Anthony, 2004, SOCIOLINGUISTIC HIST; Lucas C., 2001, SOCIOLINGUISTIC VARI; Marschark M., 2018, RAISING ED DEAF CHIL; Matthews PA, 1996, IRISH DEAF COMMUNITY; McKee R, 2011, SIGN LANG STUD, V11, P485, DOI 10.1353/sls.2011.0012; Mickelburgh R, 2004, TELEGRAPH; Nagy N, 2011, J SOCIOLING, V15, P366, DOI 10.1111/j.1467-9841.2011.00488.x; Office for National Statistics UK, 2011, 2011 CENS QUICK STAT; Quinn G, 2010, SIGN LANG STUD, V10, P476, DOI 10.1353/sls.0.0056; Rand David., 1991, GOLDVARB 2 1 VARIABL; Sankoff David, 1988, LINGUISTICS CAMBRIDG, P140, DOI DOI 10.1017/CBO9780511620577.009; Schembri A, 2008, C CONSTR EXPL SIGN L; Schembri A, 2011, BRIT SIGN LANGUAGE C; Schembri A., 2010, LANGUAGE DOCUMENTATI, VVII, P105; Schembri A, 2009, BRIT SIGN LANGUAGE B; Schembri A, 2013, LANG DOC CONSERV, V7, P136; Schembri A, 2009, LANG VAR CHANGE, V21, P193, DOI 10.1017/S0954394509990081; Schembri Adam., 2010, SIGN LANGUAGES, P476, DOI [10.1017/CBO9780511712203.022, DOI 10.1017/CBO9780511712203.022]; Schembri Adam, 1999, SIGN LANGUAGE LINGUI, V2, P115, DOI [DOI 10.1075/SLL.2.2.03JOH, 10.1075/sll.2.2.03joh]; Stamp R, J SOCIOLINGUISTICS; Sutton-Spence R., 1999, LINGUISTICS BRIT SIG; Sutton-Spence R., 1990, LANG VAR CHANGE, V2, P313, DOI [10.1017/S0954394500000399, DOI 10.1017/S0954394500000399]; Sutton-Spence R., 1994, THESIS U BRISTOL; Tagliamonte SA, 2007, LANG VAR CHANGE, V19, P199, DOI 10.1017/S095439450707007X; The Sun Newspaper, 2004, SUN             0322, P8; The Warnock Report, 1978, REP COMM ENQ ED HAND; The World Federation of the Deaf, 2003, COUNTR NAM SIGN BOOK; Trudgill P., 1986, DIALECTS CONTACT; Uus K, 2006, PEDIATRICS, V117, pE887, DOI 10.1542/peds.2005-1064; Valli C., 2005, LINGUISTICS AM SIGN; Watt D., 2002, J SOCIOLING, V6, P44, DOI [DOI 10.1111/1467-9481.00176, 10.1111/1467-9481.00176]; Weinreich U., 1968, EMPIRICAL FDN THEORY; Williams Ann, 1999, URBAN VOICES ACCENT, P141; Woll B., 1987, SIGN SCH, P12; Woll B., 1991, VARIATION RECENT CHA; Woll B, 1994, PERSPECTIVES SIGN LA, V2, P293; Woll B., 2001, SOCIOLINGUISTICS SIG, P8, DOI DOI 10.1017/CBO9780511612824.004; Woll Bencie., 1990, CURRENT TRENDS EUROP, P61	77	36	36	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2014	9	4							e94053	10.1371/journal.pone.0094053	http://dx.doi.org/10.1371/journal.pone.0094053			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AG3EI	24759673	Green Submitted, Green Published, gold			2023-01-03	WOS:000335298200009
J	Christie, MP; Simerska, P; Jen, FEC; Hussein, WM; Rawi, MFM; Hartley-Tassell, LE; Day, CJ; Jennings, MP; Toth, I				Christie, Michelle P.; Simerska, Pavla; Jen, Freda E. -C.; Hussein, Waleed M.; Rawi, Mohamad F. M.; Hartley-Tassell, Lauren E.; Day, Christopher J.; Jennings, Michael P.; Toth, Istvan			A Drug Delivery Strategy: Binding Enkephalin to Asialoglycoprotein Receptor by Enzymatic Galactosylation	PLOS ONE			English	Article							IN-VITRO EVALUATION; GUINEA-PIG ILEUM; ANALGESIC ACTIVITY; GLUCOSE-UPTAKE; GLYCOSYLATION; PEPTIDES; AMINOPEPTIDASE; ABSORPTION; BARRIER; ALPHA	Glycosylation of biopharmaceuticals can mediate cell specific delivery by targeting carbohydrate receptors. Additionally, glycosylation can improve the physico-chemical (drug-like) properties of peptide based drug candidates. The main purpose of this study was to examine if glycosylation of the peptide enkephalin could facilitate its binding to the carbohydrate receptor, asialoglycoprotein. Firstly, we described the one-pot enzymatic galactosylation of lactose modified enkephalin in the presence of uridine-5'-diphosphogalactose 4-epimerase and lipopolysaccharyl alpha-1,4-galactosyltransferase. Stability experiments using human plasma and Caco-2 cell homogenates showed that glycosylation considerably improved the stability of enkephalin (at least 60% remained stable after a 2 hr incubation at 37 degrees C). In vitro permeability experiments using Caco-2 cells revealed that the permeability of mono-and trisaccharide conjugated enkephalins was 14 and 28 times higher, respectively, than that of enkephalin alone (Papp 3.1x10(-8) cm/s). By the methods of surface plasmon resonance and molecular modeling, we demonstrated that the enzymatic glycosylation of enkephalin enabled binding the asialoglycoprotein receptor. The addition of a trisaccharide moiety to enkephalin improved the binding of enkephalin to the asialoglycoprotein receptor two fold (K-D=91 mu M). The docking scores from molecular modeling showed that the binding modes and affinities of the glycosylated enkephalin derivatives to the asialoglycoprotein receptor complemented the results from the surface plasmon resonance experiments.	[Christie, Michelle P.; Simerska, Pavla; Hussein, Waleed M.; Rawi, Mohamad F. M.; Toth, Istvan] Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld, Australia; [Jen, Freda E. -C.; Hartley-Tassell, Lauren E.; Day, Christopher J.; Jennings, Michael P.] Griffith Univ, Inst Glyc, Southport, Qld 4215, Australia; [Toth, Istvan] Univ Queensland, Sch Pharm, Pharm Australia Ctr Excellence, Woolloongabba, Qld, Australia	University of Queensland; Griffith University; University of Queensland	Toth, I (corresponding author), Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld, Australia.	i.toth@uq.edu.au	Day, Christopher/Z-3305-2019; Toth, Istvan/C-1965-2013; Hussein, Waleed/AAK-7916-2021; Jennings, Michael P/G-4822-2013	Toth, Istvan/0000-0002-4572-397X; Hussein, Waleed/0000-0001-5392-1880; Jennings, Michael P/0000-0002-1027-4684; Day, Christopher/0000-0001-7953-4408; Christie, Michelle/0000-0002-7001-3400	Australian Research Council [DP1092829]; Australian Postdoctoral Fellowship [DP1092829]; NHMRC [565526, DP103130141];  [DP110100212]	Australian Research Council(Australian Research Council); Australian Postdoctoral Fellowship; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); 	This work was supported by an Australian Research Council Discovery Project Grant (DP1092829). P. S. was supported by an Australian Postdoctoral Fellowship (DP1092829), M.P.J. was supported by a (NHMRC program grant 565526 and DP103130141) and I. T. was supported by a Professorial Research Fellowship (DP110100212), http://www.arc.gov.au, http://www.nhmrc.gov.au. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALBERT R, 1993, LIFE SCI, V53, P517, DOI 10.1016/0024-3205(93)90703-6; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; Bergeon JA, 2008, BIOPOLYMERS, V90, P633, DOI 10.1002/bip.21003; Christie MP, 2013, CHEMPLUSCHEM, V78, P793, DOI 10.1002/cplu.201300115; COHEN ML, 1983, J PHARMACOL EXP THER, V224, P379; Cros CD, 2011, BIOORGAN MED CHEM, V19, P1528, DOI 10.1016/j.bmc.2010.12.042; Dangoor D, 2008, J PEPT SCI, V14, P321, DOI 10.1002/psc.932; Di L, 2005, INT J PHARMACEUT, V297, P110, DOI 10.1016/j.ijpharm.2005.03.022; Drozdowski LA, 2006, WORLD J GASTROENTERO, V12, P1657, DOI 10.3748/wjg.v12.i11.1657; DuMont AL, 2013, P NATL ACAD SCI USA, V110, P10794, DOI 10.1073/pnas.1305121110; Egleton RD, 2001, J PHARMACOL EXP THER, V299, P967; Egleton Richard D, 2005, NeuroRx, V2, P44, DOI 10.1007/BF03206641; Ehrenkranz JRL, 2005, DIABETES-METAB RES, V21, P31, DOI 10.1002/dmrr.532; ELLING L, 1993, GLYCOBIOLOGY, V3, P349, DOI 10.1093/glycob/3.4.349; Engel A, 2003, PHARM RES-DORDR, V20, P51, DOI 10.1023/A:1022294624256; Fang JW, 1998, J AM CHEM SOC, V120, P6635, DOI 10.1021/ja9808898; GEARY LE, 1982, J PHARMACOL EXP THER, V221, P104; Gentilucci L, 2006, CURR MED CHEM, V13, P2449, DOI 10.2174/092986706777935041; Goodwin D, 2012, CURR MED CHEM, V19, P4451, DOI 10.2174/092986712803251548; Gunther C, 2001, FASEB J, V15, P1646, DOI 10.1096/fj.00-0645fje; HANSEN DW, 1992, J MED CHEM, V35, P684, DOI 10.1021/jm00082a008; Harvey HA, 2001, MOL MICROBIOL, V42, P659, DOI 10.1046/j.1365-2958.2001.02666.x; Harvey HA, 2000, MOL MICROBIOL, V36, P1059, DOI 10.1046/j.1365-2958.2000.01938.x; Hokke CH, 1996, GLYCOCONJUGATE J, V13, P687, DOI 10.1007/BF00731458; Johnston K, 2005, FEBS LETT, V579, P1653, DOI 10.1016/j.febslet.2004.12.099; Johnstone Ken D., 2005, Current Drug Delivery, V2, P215, DOI 10.2174/1567201054367977; Kellam B, 1998, INT J PHARM, V161, P55, DOI 10.1016/S0378-5173(97)00328-1; Koda Y, 2008, BIOORGAN MED CHEM, V16, P6286, DOI 10.1016/j.bmc.2008.04.020; Lomino JV, 2013, BIOORGAN MED CHEM, V21, P2262, DOI 10.1016/j.bmc.2013.02.007; Meier M, 2000, J MOL BIOL, V300, P857, DOI 10.1006/jmbi.2000.3853; Michael S, 2000, EUR J PHARM SCI, V10, P133, DOI 10.1016/S0928-0987(99)00093-7; MolDock Scores, 2011, MOL VIRT DOCK US MAN; Moradi SV, 2013, BIOORGAN MED CHEM, V21, P4259, DOI 10.1016/j.bmc.2013.04.068; Morimoto K, 2003, MOL THER, V7, P254, DOI 10.1016/S1525-0016(02)00053-9; Negri L, 1998, BRIT J PHARMACOL, V124, P1516, DOI 10.1038/sj.bjp.0701971; Nomoto M, 1998, J PHARM SCI, V87, P326, DOI 10.1021/js970269p; PACIFICO F, 1995, BIOCHEM BIOPH RES CO, V210, P138, DOI 10.1006/bbrc.1995.1638; POLT R, 1992, J AM CHEM SOC, V114, P10249, DOI 10.1021/ja00052a022; POLT R, 1994, P NATL ACAD SCI USA, V91, P7114, DOI 10.1073/pnas.91.15.7114; RASMUSSEN GJ, 1991, INT J PHARM, V76, P113, DOI 10.1016/0378-5173(91)90349-S; Sambuy Y, 2005, CELL BIOL TOXICOL, V21, P1, DOI 10.1007/s10565-005-0085-6; Simerska P, 2013, J MOL CATAL B-ENZYM, V97, P196, DOI 10.1016/j.molcatb.2013.08.018; Simerska P, 2011, MED RES REV, V31, P520, DOI 10.1002/med.20191; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; Susaki H, 1999, BIOL PHARM BULL, V22, P1094; Suzuki K, 1999, J PHARMACOL EXP THER, V288, P888; Thomsen R, 2006, J MED CHEM, V49, P3315, DOI 10.1021/jm051197e; Varamini P, 2012, J MED CHEM, V55, P5859, DOI 10.1021/jm300418d; Wang J, 2006, J DRUG TARGET, V14, P127, DOI 10.1080/10611860600648221; Wong AK, 2002, EUR J PHARM SCI, V16, P113, DOI 10.1016/S0928-0987(02)00078-7; Yang JM, 2004, PROTEINS, V55, P288, DOI 10.1002/prot.20035; Zelensky AN, 2005, FEBS J, V272, P6179, DOI 10.1111/j.1742-4658.2005.05031.x; Zheng Y, 2012, SURGERY, V151, P13, DOI 10.1016/j.surg.2011.07.010	53	13	13	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2014	9	4							e95024	10.1371/journal.pone.0095024	http://dx.doi.org/10.1371/journal.pone.0095024			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI5PW	24736570	Green Published, gold			2023-01-03	WOS:000336922600128
J	Fujie, S; Sato, K; Miyamoto-Mikami, E; Hasegawa, N; Fujita, S; Sanada, K; Hamaoka, T; Iemitsu, M				Fujie, Shumpei; Sato, Koji; Miyamoto-Mikami, Eri; Hasegawa, Natsuki; Fujita, Satoshi; Sanada, Kiyoshi; Hamaoka, Takafumi; Iemitsu, Motoyuki			Reduction of Arterial Stiffness by Exercise Training Is Associated with Increasing Plasma Apelin Level in Middle-Aged and Older Adults	PLOS ONE			English	Article							NITRIC-OXIDE; HYPERTENSIVE PATIENTS; CARDIOVASCULAR RISK; PHYSICAL-ACTIVITY; BLOOD-PRESSURE; APJ; ATHEROSCLEROSIS; RECEPTOR; DISEASE; EXPRESSION	Aging-induced deterioration of arterial stiffness is decreased by regular exercise, and increased nitric oxide (NO) production participates in this effect. Apelin regulates endothelial NO synthase in endothelial cells, promoting NO production. However, the effect of aerobic exercise training on circulating apelin levels in healthy middle-aged and older adults remains unknown. Accordingly, this study aimed to clarify the effects of regular aerobic exercise on apelin concentrations in middle-aged and older adults. Thirty-four healthy middle-aged and older subjects (67.0 +/- 1.3 years) were randomly divided into two groups: exercise intervention and sedentary controls. Subjects in the training group completed 8-week of aerobic exercise training (60-70% peak oxygen uptake [VO2peak] for 45 min, 3 days/week). Before and after the intervention, we evaluated plasma apelin and nitrite/nitrate (NOx) concentrations, VO2peak, and arterial stiffness index. In the training group, VO2peak was significantly increased, and carotid beta-stiffness was significantly decreased, after the intervention (P<0.05). Moreover, plasma apelin and NOx levels were significantly increased in the training group after the intervention (P<0.05). Additionally, there was a correlation between the training effects of plasma apelin levels and carotid beta-stiffness (r = -0.508, P = 0.032) and plasma NOx levels (r = 0.494, P = 0.037). By contrast, none of these parameters changed significantly in the control group. These results suggest that the increased in plasma apelin levels may be associated with exercise training-induced alternation of arterial stiffness in middle-aged and older adults.	[Fujie, Shumpei; Sato, Koji; Miyamoto-Mikami, Eri; Hasegawa, Natsuki; Fujita, Satoshi; Sanada, Kiyoshi; Hamaoka, Takafumi; Iemitsu, Motoyuki] Ritsumeikan Univ, Fac Sport & Hlth Sci, Shiga, Japan	Ritsumeikan University	Iemitsu, M (corresponding author), Ritsumeikan Univ, Fac Sport & Hlth Sci, Shiga, Japan.	iemitsu@fc.ritsumei.ac.jp	MIYAMOTO-MIKAMI, ERI/AAT-3245-2020	Miyamoto-Mikami, Eri/0000-0002-4864-8581; Sanada, Kiyoshi/0000-0003-3703-4098	Ministry of Education, Culture, Sports, Science and Technology of Japan [23680071, 25560378]; Grants-in-Aid for Scientific Research [25560378] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (#23680071 and #25560378, M. Iemitsu). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersen Charlotte U, 2011, Pulm Circ, V1, P334, DOI 10.4103/2045-8932.87299; ARNETT DK, 1994, AM J EPIDEMIOL, V140, P669, DOI 10.1093/oxfordjournals.aje.a117315; Blacher J, 1999, HYPERTENSION, V33, P1111, DOI 10.1161/01.HYP.33.5.1111; Goetze JP, 2006, REGUL PEPTIDES, V133, P134, DOI 10.1016/j.regpep.2005.09.032; Hambrecht R, 2003, CIRCULATION, V107, P3152, DOI 10.1161/01.CIR.0000074229.93804.5C; HIRAI T, 1989, CIRCULATION, V80, P78, DOI 10.1161/01.CIR.80.1.78; Ishida J, 2004, J BIOL CHEM, V279, P26274, DOI 10.1074/jbc.M404149200; Jia Yue Xia, 2007, Peptides, V28, P2023, DOI 10.1016/j.peptides.2007.07.016; Kadoglou NPE, 2013, DIABETIC MED, V30, pE41, DOI 10.1111/dme.12055; Kadoglou NPE, 2012, EUR J INTERN MED, V23, P137, DOI 10.1016/j.ejim.2011.10.020; Kawano H, 2006, J HYPERTENS, V24, P1753, DOI 10.1097/01.hjh.0000242399.60838.14; Kleinz MJ, 2005, REGUL PEPTIDES, V126, P233, DOI 10.1016/j.regpep.2004.10.019; Kleinz MJ, 2005, PHARMACOL THERAPEUT, V107, P198, DOI 10.1016/j.pharmthera.2005.04.001; Laurent S, 2001, HYPERTENSION, V37, P1236, DOI 10.1161/01.HYP.37.5.1236; Lee DK, 2005, ENDOCRINOLOGY, V146, P231, DOI 10.1210/en.2004-0359; Maeda S, 2004, HYPERTENS RES, V27, P947, DOI 10.1291/hypres.27.947; MOHIADDIN RH, 1989, BRIT HEART J, V62, P90; Napoli C, 2001, NITRIC OXIDE-BIOL CH, V5, P88, DOI 10.1006/niox.2001.0337; Przewlocka-Kosmala M, 2011, J HYPERTENS, V29, P971, DOI 10.1097/HJH.0b013e328344da76; ROWE JW, 1987, AM J CARDIOL, V60, pG68, DOI 10.1016/0002-9149(87)90594-7; Tanabe T, 2003, ACTA PHYSIOL SCAND, V178, P3, DOI 10.1046/j.1365-201X.2003.01100.x; Tanaka H, 1998, ARTERIOSCL THROM VAS, V18, P127, DOI 10.1161/01.ATV.18.1.127; Tanaka H, 2000, CIRCULATION, V102, P1270, DOI 10.1161/01.CIR.102.11.1270; Tanaka H, 2001, J AM COLL CARDIOL, V37, P153, DOI 10.1016/S0735-1097(00)01054-8; Tatemoto K, 2001, REGUL PEPTIDES, V99, P87, DOI 10.1016/S0167-0115(01)00236-1; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; VAITKEVICIUS PV, 1993, CIRCULATION, V88, P1456, DOI 10.1161/01.CIR.88.4.1456; Zhang J, 2006, LIFE SCI, V79, P1153, DOI 10.1016/j.lfs.2006.03.040	28	47	48	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2014	9	4							e93545	10.1371/journal.pone.0093545	http://dx.doi.org/10.1371/journal.pone.0093545			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE6KM	24691252	Green Published, gold, Green Submitted			2023-01-03	WOS:000334101100101
J	Flis, S; Gnyszka, A; Flis, K				Flis, Sylwia; Gnyszka, Agnieszka; Flis, Krzysztof			DNA Methyltransferase Inhibitors Improve the Effect of Chemotherapeutic Agents in SW48 and HT-29 Colorectal Cancer Cells	PLOS ONE			English	Article							EPIGENETIC THERAPY; METHYLATION INHIBITOR; COLON-CANCER; ZEBULARINE; DECITABINE; DAMAGE; DRUG; 5-AZA-2'-DEOXYCYTIDINE; DEMETHYLATION; AZACITIDINE	DNA methylation is an epigenetic phenomenon known to play an important role in the development and progression of human cancer. Enzyme responsible for this process is DNA methyltransferase 1 (DNMT1) that maintains an altered methylation pattern by copying it from parent to daughter DNA strands after replication. Aberrant methylation of the promoter regions of genes critical for normal cellular functions is potentially reversible. Therefore, inactivation of DNMT1 seems to be a valuable target for the development of cancer therapies. Currently, the most popular DNMT inhibitors (DNMTi) are cytidine analogues like 5-azacytidine, 5-aza-2'-deoxycytidine (decitabine) and pyrimidin-2-one ribonucleoside (zebularine). In colorectal cancer, epigenetic modifications play an essential role at each step of carcinogenesis. Therefore, we have addressed the hypothesis that DNA methyltransferase inhibitors may potentiate inhibitory effects of classical chemotherapeutic agents, such as oxaliplatin and 5-fluorouracil (5-FU), commonly used in colorectal cancer therapy. Here, our report shows that DNMTi can have positive interactions with standard chemotherapeutics in colorectal cancer treatment. Using pharmacological models for the drug-drug interaction analysis, we have revealed that the combination of decitabine with 5-FU or oxaliplatin shows the most attractive interaction (synergism), whereas the effect of zebularine in combinations with chemotherapeutics is moderate and may be depended on genetic/epigenetic background of a cell line or secondary drug used in combination. Our results suggest that DNMTi administered in combination with standard chemotherapeutics might improve the treatment of patients with colorectal cancers.	[Flis, Sylwia; Gnyszka, Agnieszka] Natl Med Inst, Dept Pharmacol, Warsaw, Poland; [Flis, Krzysztof] Polish Acad Sci, Inst Biochem & Biophys, Dept Genet, Warsaw, Poland	National Medicines Institute Lekow (NIL); Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences	Flis, S (corresponding author), Natl Med Inst, Dept Pharmacol, Warsaw, Poland.	sylwia.flis@yahoo.pl	Flis, Sylwia/N-6795-2013; FLIS, Krzysztof/K-6559-2012	Flis, Sylwia/0000-0002-6071-9952	National Science Center of Poland [N405 139139]	National Science Center of Poland(National Science Centre, Poland)	This study was supported by grant no. N405 139139 from the National Science Center of Poland (http://www.ncn.gov.pl/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Appleton K, 2007, J CLIN ONCOL, V25, P4603, DOI 10.1200/JCO.2007.10.8688; Bardhan Kankana, 2013, Cancers (Basel), V5, P676, DOI 10.3390/cancers5020676; Ben-Kasus T, 2005, BIOCHEM PHARMACOL, V70, P121, DOI 10.1016/j.bcp.2005.04.010; Blinman P, 2010, EUR J CANCER, V46, P1800, DOI 10.1016/j.ejca.2009.12.032; Chau I, 2006, ANN ONCOL, V17, P1347, DOI 10.1093/annonc/mdl029; Cheng JC, 2004, MOL CELL BIOL, V24, P1270, DOI 10.1128/MCB.24.3.1270-1278.2004; Cheng JC, 2004, CANCER CELL, V6, P151, DOI 10.1016/j.ccr.2004.06.023; CHOU TC, 1983, TRENDS PHARMACOL SCI, V4, P450, DOI 10.1016/0165-6147(83)90490-X; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Cowan LA, 2010, EPIGENOMICS-UK, V2, P71, DOI 10.2217/EPI.09.44; Crea F, 2009, MOL CANCER THER, V8, P1964, DOI 10.1158/1535-7163.MCT-09-0027; Deng G, 2002, BRIT J CANCER, V86, P574, DOI 10.1038/sj.bjc.6600148; Esteller M, 2001, CANCER RES, V61, P2816; Flis S, 2009, CANCER CELL INT, V9, DOI 10.1186/1475-2867-9-10; Flotho C, 2009, LEUKEMIA, V23, P1019, DOI 10.1038/leu.2008.397; Gessner PK, 1995, TOXICOLOGY, V105, P161, DOI 10.1016/0300-483X(95)03210-7; Gnyszka A, 2013, ANTICANCER RES, V33, P2989; Goffin J, 2002, ANN ONCOL, V13, P1699, DOI 10.1093/annonc/mdf314; Hellebrekers DMEI, 2007, BBA-REV CANCER, V1775, P76, DOI 10.1016/j.bbcan.2006.07.003; Holleran JL, 2005, CLIN CANCER RES, V11, P3862, DOI 10.1158/1078-0432.CCR-04-2406; Issa JP, 2000, ANN NY ACAD SCI, V910, P140; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; LEE T, 1974, CANCER RES, V34, P2482; Lemaire M, 2005, ANTI-CANCER DRUG, V16, P301, DOI 10.1097/00001813-200503000-00009; Lind GE, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-28; Mahyar-Roemer M, 2001, INT J CANCER, V94, P615, DOI 10.1002/ijc.1516; Marquez VE, 2005, ANN NY ACAD SCI, V1058, P246, DOI 10.1196/annals.1359.037; Mossman D, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-366; National Cancer Institute website, CANC DRUG INF FDA AP; Nowsheen S., 2012, Experimental Oncology, V34, P243; Palii SS, 2008, MOL CELL BIOL, V28, P752, DOI 10.1128/MCB.01799-07; Pogribny IP, 2013, CANCER LETT, V334, P39, DOI 10.1016/j.canlet.2012.09.010; Riches LC, 2008, MUTAGENESIS, V23, P331, DOI 10.1093/mutage/gen039; Roos WP, 2013, CANCER LETT, V332, P237, DOI 10.1016/j.canlet.2012.01.007; Skladanowski A, 2009, CHEM REV, V109, P2951, DOI 10.1021/cr900026u; Toledo LI, 2011, MOL ONCOL, V5, P368, DOI 10.1016/j.molonc.2011.07.002; Yoo CB, 2004, BIOCHEM SOC T, V32, P910, DOI 10.1042/BST0320910; Yoo CB, 2008, CANCER PREV RES, V1, P233, DOI 10.1158/1940-6207.CAPR-07-0008	39	34	36	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 27	2014	9	3							e92305	10.1371/journal.pone.0092305	http://dx.doi.org/10.1371/journal.pone.0092305			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE0SW	24676085	gold, Green Submitted, Green Published			2023-01-03	WOS:000333677500019
J	Ubbink, DT; Tump, E; Koenders, JA; Kleiterp, S; Goslings, JC; Brolmann, FE				Ubbink, Dirk T.; Tump, Evelien; Koenders, Josje A.; Kleiterp, Sieta; Goslings, J. Carel; Brolmann, Fleur E.			Which Reasons Do Doctors, Nurses, and Patients Have for Hospital Discharge? A Mixed-Methods Study	PLOS ONE			English	Article							QUALITATIVE RESEARCH; HEALTH-CARE; CRITERIA; DELAYS	Background: The decision to discharge a patient from a hospital is a complex process governed by many medical and non-medical factors, while the actual reasons for discharge frequently remain ill-defined. Aim: To define relevant discharge criteria as perceived by doctors, nurses and patients for the development of a standard hospital discharge policy, we collected actual reasons and most pivotal medical and organisational criteria for discharge among all stakeholders. Setting: A tertiary referral university teaching hospital. Methods: We conducted a mixed methods analysis, using patient questionnaires, interviews and a focus group with caregivers, and observations during the daily rounds of doctors, nurses and patients during their hospital stay. Fourteen wards of the Surgery, Paediatrics and Neurology departments contributed. Results: We observed 426 patients during their hospital stay. Forty doctors and nurses were interviewed, and 7 senior nurses attended a focus group. The most commonly used discharge criteria were clinical factors, organisational discharge issues and patient-related factors. A total of 269 patients returned their questionnaires. About one third of the adult patients and nearly half of the children (or their parents) felt their personal situation and assistance needed at home was insufficiently taken into account before discharge. Patients were least satisfied with the information given about what they were allowed to do or should avoid after discharge and their involvement in the planning of their discharge. Thus, besides obvious medical reasons for discharge, several non-medical reasons were signalled by all stakeholders as important issues to be improved. Conclusions: A set of discharge criteria could be defined that is useful for a more uniform hospital discharge policy that may help reduce unnecessary length of stay and improve patient satisfaction.	[Ubbink, Dirk T.; Koenders, Josje A.] Univ Amsterdam, Acad Med Ctr, Dept Qual Assurance & Proc Innovat, NL-1105 AZ Amsterdam, Netherlands; [Ubbink, Dirk T.] Univ Amsterdam, Acad Med Ctr, Dept Surg, NL-1105 AZ Amsterdam, Netherlands; [Tump, Evelien] Univ Amsterdam, Acad Med Ctr, Dept Paediat, NL-1105 AZ Amsterdam, Netherlands; [Kleiterp, Sieta] Univ Amsterdam, Acad Med Ctr, Dept Obstet & Gynaecol, NL-1105 AZ Amsterdam, Netherlands; [Goslings, J. Carel] Univ Amsterdam, Acad Med Ctr, Dept Trauma Surg, NL-1105 AZ Amsterdam, Netherlands; [Brolmann, Fleur E.] St Lucas Andreas Hosp, Dept Plast Reconstruct & Hand Surg, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Sint Lucas Andreas Hospital	Ubbink, DT (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Qual Assurance & Proc Innovat, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	d.ubbink@amc.nl	Ubbink, Dirk/AAF-1266-2021	Ubbink, Dirk/0000-0001-9398-8879	hospital's internal committee	hospital's internal committee	This study was funded by an unrestricted grant from the hospital's internal committee for quality improvement projects to perform this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], JCI ACC STAND HOSP; de Vries EN, 2009, QUAL SAF HEALTH CARE, V18, P121, DOI 10.1136/qshc.2008.027524; Delnoij DMJ, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-88; Fiore JF, 2012, COLORECTAL DIS, V14, P270, DOI 10.1111/j.1463-1318.2010.02477.x; Fiore JF, 2012, DIS COLON RECTUM, V55, P416, DOI 10.1097/DCR.0b013e318244a8f2; Fox MT, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-70; Holland DE, 2011, PROF CASE MANAG, V16, P240, DOI 10.1097/NCM.0b013e31822361d8; Hwabejire JO, 2013, JAMA SURG, V148, P956, DOI 10.1001/jamasurg.2013.2148; Kehlet H, 2008, ANN SURG, V248, P189, DOI 10.1097/SLA.0b013e31817f2c1a; Kleefstra SM, 2010, QUAL SAF HEALTH CARE, V19, DOI 10.1136/qshc.2008.030825; Mays N, 2000, BMJ-BRIT MED J, V320, P50, DOI 10.1136/bmj.320.7226.50; Middleton Sandy, 2004, Aust Health Rev, V28, P255; Moons P, 2005, ONTSLAGMANAGEMENT BE; NSW Health, 2001, SHAR RESP PAT CAR HO; Ou LX, 2011, AUST HEALTH REV, V35, P357, DOI 10.1071/AH09843; Ou LX, 2009, AUST HEALTH REV, V33, P513, DOI 10.1071/AH090513; Phillips CO, 2004, JAMA-J AM MED ASSOC, V291, P1358, DOI 10.1001/jama.291.11.1358; Pieper B, 2007, J WOUND OSTOMY CONT, V34, P245, DOI 10.1097/01.WON.0000270817.06942.00; Pieper B, 2006, J WOUND OSTOMY CONT, V33, P281, DOI 10.1097/00152192-200605000-00009; Saklad M., 1941, ANESTHESIOLOGY, V2, P281, DOI [10.1097/00000542-194105000-00004, DOI 10.1097/00000542-194105000-00004]; SELKER HP, 1989, MED CARE, V27, P112, DOI 10.1097/00005650-198902000-00003; Shepperd S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000313.pub4; Srivastava R, 2009, J HOSP MED, V4, P481, DOI 10.1002/jhm.490; Stikvoort-Lodewijks MJ, 2008, ZORGEN POSTOPERATIEV; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Ubbink DT, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-000891; Weiss ME, 2014, HEALTH SERV RES, V49, P304, DOI 10.1111/1475-6773.12092; Wong ELY, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-242; Zander K, 2010, PROF CASE MANAG, V15, P188, DOI 10.1097/NCM.0b013e3181e26a80	29	13	13	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 13	2014	9	3							e91333	10.1371/journal.pone.0091333	http://dx.doi.org/10.1371/journal.pone.0091333			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC9JS	24625666	gold, Green Published, Green Submitted			2023-01-03	WOS:000332851300072
J	Michaleff, ZA; Maher, CG; Lin, CWC; Rebbeck, T; Jull, G; Latimer, J; Connelly, L; Sterling, M				Michaleff, Zoe A.; Maher, Chris G.; Lin, Chung-Wei Christine; Rebbeck, Trudy; Jull, Gwendolen; Latimer, Jane; Connelly, Luke; Sterling, Michele			Comprehensive physiotherapy exercise programme or advice for chronic whiplash (PROMISE): a pragmatic randomised controlled trial	LANCET			English	Article							THERAPEUTIC INTERVENTIONS; DISORDER WAD; CLINICAL-TRIAL; PAIN; DISABILITY; SCALE; NECK; RESPONSIVENESS; VALIDATION; EDUCATION	Background Evidence suggests that brief physiotherapy programmes are as effective for acute whiplash-associated disorders as more comprehensive programmes; however, whether this also holds true for chronic whiplash-associated disorders is unknown. We aimed to estimate the effectiveness of a comprehensive exercise programme delivered by physiotherapists compared with advice in people with a chronic whiplash-associated disorder. Methods PROMISE is a two group, pragmatic randomised controlled trial in patients with chronic (>3 months and <5 years) grade 1 or 2 whiplash-associated disorder. Participants were randomly assigned by a computer-generated randomisation schedule to receive either the comprehensive exercise programme (20 sessions) or advice (one session and telephone support). Sealed opaque envelopes were used to conceal allocation. The primary outcome was pain intensity measured on a 0-10 scale. Outcomes were measured at baseline, 14 weeks, 6 months, and 12 months by a masked assessor. Analysis was by intention to treat, and treatment effects were calculated with linear mixed models. The trial is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12609000825257. Findings 172 participants were allocated to either the comprehensive exercise programme (n=86) or advice group (n=86); 157 (91%) were followed up at 14 weeks, 145 (84%) at 6 months, and 150 (87%) at 12 months. A comprehensive exercise programme was not more effective than advice alone for pain reduction in the participants. At 14 weeks the treatment effect on a 0-10 pain scale was 0. 0 (95% CI -0.7 to 0.7), at 6 months 0.2 (-0.5 to 1.0), and at 12 months -0.1 (-0.8 to 0.6). CNS hyperexcitability and symptoms of post-traumatic stress did not modify the eff ect of treatment. We recorded no serious adverse events. Interpretation We have shown that simple advice is equally as effective as a more intense and comprehensive physiotherapy exercise programme. The need to identify effective and affordable strategies to prevent and treat acute through to chronic whiplash associated disorders is an important health priority. Future avenues of research might include improving understanding of the mechanisms responsible for persistent pain and disability, investigating the effectiveness and timing of drugs, and study of content and delivery of education and advice. Funding The National Health and Medical Research Council of Australia, Motor Accidents Authority of New South Wales, and Motor Accident Insurance Commission of Queensland.	[Michaleff, Zoe A.; Maher, Chris G.; Lin, Chung-Wei Christine; Latimer, Jane] George Inst Global Hlth, Sydney, NSW, Australia; [Michaleff, Zoe A.; Maher, Chris G.; Lin, Chung-Wei Christine; Latimer, Jane] Sydney Med Sch, Sydney, NSW, Australia; [Rebbeck, Trudy] Univ Sydney, Fac Hlth Sci, Sydney, NSW 2050, Australia; [Connelly, Luke; Sterling, Michele] Univ Queensland, Ctr Natl Res Disabil & Rehabil Med, Brisbane, Qld, Australia; [Jull, Gwendolen] Univ Queensland, Sch Hlth & Rehabil Sci, Div Physiotherapy, Brisbane, Qld, Australia; [Connelly, Luke] Univ Queensland, Hlth Sch Econ, Australian Ctr Econ Res, Brisbane, Qld, Australia; [Connelly, Luke] Univ Queensland, UQ Ctr Clin Res, Brisbane, Qld, Australia	George Institute for Global Health; University of Sydney; University of Sydney; University of Sydney; University of Queensland; University of Queensland; University of Queensland; University of Queensland	Michaleff, ZA (corresponding author), Univ Sydney, George Inst Global Hlth, Sydney, NSW 2050, Australia.	zmichaleff@georgeinstitute.org.au	Lin, Chung-Wei Christine/S-8840-2019; Rebbeck, Trudy/AAF-6300-2021; Jull, Gwendolen/F-4233-2010; Sterling, Michele/F-1679-2010; Maher, Christopher/AAC-6267-2019	Lin, Chung-Wei Christine/0000-0001-6192-7238; Rebbeck, Trudy/0000-0002-4453-4739; Jull, Gwendolen/0000-0003-2670-1318; Sterling, Michele/0000-0003-1772-2248; Maher, Christopher/0000-0002-1628-7857; Michaleff, Zoe/0000-0002-0360-4956; Sterling, Michele/0000-0001-8242-2685; Connelly, Luke/0000-0002-1734-4809	National Health and Medical Research Council - the Motor Accidents Authority of New South Wales; Motor Accidents Insurance Commission Queensland; Australian Research Council; National Health and Medical Research Council; Motor Accidents Authority of New South Wales	National Health and Medical Research Council - the Motor Accidents Authority of New South Wales; Motor Accidents Insurance Commission Queensland; Australian Research Council(Australian Research Council); National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Motor Accidents Authority of New South Wales	This investigator-initiated trial was funded by the National Health and Medical Research Council with supplementary funding from the Motor Accidents Authority of New South Wales and the Motor Accidents Insurance Commission Queensland. CGM and JL's research fellowships are funded by the Australian Research Council. C-WCL, TR, MS's research fellowships are funded by the National Health and Medical Research Council. Assistance with recruitment was provided by the Motor Accidents Authority of New South Wales, the Motor Accidents Insurance Commission Queensland, QBE Insurance, Allianz Insurance, Dr Clive Sun Consultant in Rehabilitation Medicine and Pain Medicine, and the Sydney Specialist Physiotherapy Centre. We thank the treating physiotherapy centres in New South Wales: Bay Active Physio, Dora Street Physiotherapy, Macarthur Physiotherapy and Sports Injury Centre, North Ryde Physiotherapy, Park Central Physiotherapy, Penrith Physiotherapy Sports Centre, Spine Care Centre, Special Spinal Rehab, Sydney Specialist Physiotherapy Centre, Sydney Spine Physio, and Queensland: Axis Physiotherapy, Bracken Ridge Physio, Brisbane City Physiotherapy, Carina Central Physiotherapy, Indooroopilly Physiotherapy, Milton Physiotherapy, Performance Rehab, Physiotherapy Sports and Rehab Clinic, Physiomatic.	American College of Sports Medicine, 2010, ACSMS GUIDELINES EXE; Australian Bureau of Statistics, 1995, NAT HLTH SURV SF 36; Bennett MI, 2005, J PAIN, V6, P149, DOI 10.1016/j.jpain.2004.11.007; Blincoe L, 2000, EC IMPACT MOTOR VEHI; Boudreau S, 2007, PAIN, V132, P169, DOI 10.1016/j.pain.2007.07.019; Gross A, 2012, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD005106.PUB4; Hole D E, 1995, Man Ther, V1, P36, DOI 10.1054/math.1995.0248; Jull G, 2007, PAIN, V129, P28, DOI 10.1016/j.pain.2006.09.030; Jull G., WHIPLASH INJURY RECO; Jull G, 2013, PAIN, V154, P1798, DOI 10.1016/j.pain.2013.05.041; Jull GA, 2011, SPINE, V36, pS173, DOI 10.1097/BRS.0b013e31823883e6; Kamper SJ, 2008, PAIN, V138, P617, DOI 10.1016/j.pain.2008.02.019; Kamper SJ, 2011, CLIN J PAIN, V27, P495, DOI 10.1097/AJP.0b013e31820e1185; Kamper SJ, 2009, J MAN MANIP THER, V17, P163, DOI 10.1179/jmt.2009.17.3.163; Lamb SE, 2013, LANCET, V381, P546, DOI 10.1016/S0140-6736(12)61304-X; Lord SM, 1996, NEW ENGL J MED, V335, P1721, DOI 10.1056/NEJM199612053352302; Maxwell S, 2013, MANUAL THER, V18, P172, DOI 10.1016/j.math.2012.07.004; McCarthy S, 2008, OCCUP MED-OXFORD, V58, P379, DOI 10.1093/occmed/kqn062; Meeus M, 2012, PAIN PHYSICIAN, V15, P351; Michaleff ZA, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471-2474-10-149; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; Nicholas M., 2004, MUSCULOSKELETAL PHYS, V2nd; Pengel LHM, 2004, SPINE, V29, P879, DOI 10.1097/00007632-200404150-00011; Rushton A, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000265; Scholten-Peeters GGM, 2006, SPINE, V31, P723, DOI 10.1097/01.brs.0000206381.15224.0f; Soderlund Anne, 2001, Physiotherapy Theory and Practice, V17, P229; Stewart MJ, 2007, PAIN, V128, P59, DOI 10.1016/j.pain.2006.08.030; Sun X, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c117; Teasell RW, 2010, PAIN RES MANAG, V15, P313, DOI 10.1155/2010/487279; Teasell RW, 2010, PAIN RES MANAG, V15, P305, DOI 10.1155/2010/108685; Teasell RW, 2010, PAIN RES MANAG, V15, P323, DOI 10.1155/2010/914358; Teasell RW, 2010, PAIN RES MANAG, V15, P295, DOI 10.1155/2010/640164; TRACsa: trauma and injury recovery, 2008, TRACSA TRAUMA INJURY; Verhagen AP, 2007, COCHRANE DB SYST REV, V4; VERNON H, 1991, J MANIP PHYSIOL THER, V14, P409; Walton DM, 2013, CLIN J PAIN, V29, P499, DOI 10.1097/AJP.0b013e318269569c; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Westaway MD, 1998, J ORTHOP SPORT PHYS, V27, P331, DOI 10.2519/jospt.1998.27.5.331; Willis C, 2004, PAIN, V110, P681, DOI 10.1016/j.pain.2004.05.008	39	105	108	1	30	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 12	2014	384	9938					133	141		10.1016/S0140-6736(14)60457-8	http://dx.doi.org/10.1016/S0140-6736(14)60457-8			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AL1YC	24703832				2023-01-03	WOS:000338921500032
J	Samarasekera, U; Horton, R				Samarasekera, Udani; Horton, Richard			The world we want for every newborn child	LANCET			English	Editorial Material									[Samarasekera, Udani; Horton, Richard] The Lancet, London NW1 7BY, England		Samarasekera, U (corresponding author), The Lancet, London NW1 7BY, England.							Bhutta ZA, 2014, LANCET; Darmstadt GL, 2014, LANCET; Dickson KE, 2014, LANCET; Jamison DT, 2013, LANCET, V382, P1898, DOI 10.1016/S0140-6736(13)62105-4; Lawn JE, 2014, LANCET; Mason E, 2014, LANCET; WHO, 2014, EV NEWB ACT PLAN END; You D, 2013, LEVELS TRENDS CHILD	8	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 12	2014	384	9938					107	109		10.1016/S0140-6736(14)60837-0	http://dx.doi.org/10.1016/S0140-6736(14)60837-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AL1YC	24853598				2023-01-03	WOS:000338921500009
J	Brar, SS; Aharonian, V; Mansukhani, P; Moore, N; Shen, AYJ; Jorgensen, M; Dua, A; Short, L; Kane, K				Brar, Somjot S.; Aharonian, Vicken; Mansukhani, Prakash; Moore, Naing; Shen, Albert Y-J; Jorgensen, Michael; Dua, Aman; Short, Lindsay; Kane, Kevin			Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial	LANCET			English	Article							PERCUTANEOUS CORONARY INTERVENTION; INDUCED NEPHROPATHY; SODIUM-BICARBONATE; MEDIA; ANGIOGRAPHY; PREDICTION; HYDRATION; RESPONSIVENESS; FAILURE; VOLUME	Background The administration of intravenous fluid remains the cornerstone treatment for the prevention of contrast-induced acute kidney injury. However, no well-defined protocols exist to guide fluid administration in this treatment. We aimed to establish the efficacy of a new fluid protocol to prevent contrast-induced acute kidney injury. Methods In this randomised, parallel-group, comparator-controlled, single-blind phase 3 trial, we assessed the efficacy of a new fluid protocol based on the left ventricular end-diastolic pressure for the prevention of contrast-induced acute kidney injury in patients undergoing cardiac catheterisation. The primary outcome was the occurrence of contrast-induced acute kidney injury, which was defined as a greater than 25% or greater than 0.5 mg/dL increase in serum creatinine concentration. Between Oct 10, 2010, and July 17, 2012, 396 patients aged 18 years or older undergoing cardiac catheterisation with an estimated glomerular filtration rate of 60 mL/min per 1.73 m(2) or less and one or more of several risk factors (diabetes mellitus, history of congestive heart failure, hypertension, or age older than 75 years) were randomly allocated in a 1:1 ratio to left ventricular end-diastolic pressure-guided volume expansion (n=196) or the control group (n=200) who received a standard fluid administration protocol. Four computer-generated concealed randomisation schedules, each with permuted block sizes of 4, were used for randomisation, and participants were allocated to the next sequential randomisation number by sealed opaque envelopes. Patients and laboratory personnel were masked to treatment assignment, but the physicians who did the procedures were not masked. Both groups received intravenous 0.9% sodium chloride at 3 mL/kg for 1 h before cardiac catheterisation. Analyses were by intention to treat. Adverse events were assessed at 30 days and 6 months and all such events were classified by staff who were masked to treatment assignment. This trial is registered with ClinicalTrials.gov, number NCT01218828. Findings Contrast-induced acute kidney injury occurred less frequently in patients in the left ventricular end-diastolic pressure-guided group (6.7% [12/178]) than in the control group (16.3% [28/172]; relative risk 0.41, 95% CI 0.22-0.79; p=0.005). Hydration treatment was terminated prematurely because of shortness of breath in three patients in each group. Interpretation Left ventricular end-diastolic pressure-guided fluid administration seems to be safe and effective in preventing contrast-induced acute kidney injury in patients undergoing cardiac catheterisation.	[Brar, Somjot S.; Shen, Albert Y-J; Jorgensen, Michael; Dua, Aman] Kaiser Permanente, Dept Cardiol, Los Angeles, CA 90027 USA; [Brar, Somjot S.; Aharonian, Vicken; Mansukhani, Prakash; Moore, Naing; Short, Lindsay; Kane, Kevin] Kaiser Permanente, Reg Cardiac Cath Lab, Los Angeles, CA 90027 USA; [Brar, Somjot S.] Kaiser Permanente, Dept Res & Evaluat, Pasadena, CA USA	Kaiser Permanente; Kaiser Permanente; Kaiser Permanente	Brar, SS (corresponding author), Kaiser Permanente, Cardiac Cath Lab, 4867 Sunset Blvd,Room 3755, Los Angeles, CA 90027 USA.	sbrar@cvri.org			Kaiser Permanente Southern California regional research committee grant	Kaiser Permanente Southern California regional research committee grant	Funding Kaiser Permanente Southern California regional research committee grant.	Bader BD, 2004, CLIN NEPHROL, V62, P1, DOI 10.5414/cnp62001; Bartholomew BA, 2004, AM J CARDIOL, V93, P1515, DOI 10.1016/j.amjcard.2004.03.008; Brar SS, 2008, JAMA-J AM MED ASSOC, V300, P1038, DOI 10.1001/jama.300.9.1038; Brar SS, 2009, CLIN J AM SOC NEPHRO, V4, P1584, DOI 10.2215/CJN.03120509; Briguori C, 2007, CIRCULATION, V115, P1211, DOI 10.1161/CIRCULATIONAHA.106.687152; Charron C, 2006, CURR OPIN CRIT CARE, V12, P249, DOI 10.1097/01.ccx.0000224870.24324.cc; Chertow GM, 2005, J AM SOC NEPHROL, V16, P3365, DOI 10.1681/ASN.2004090740; Drazner MH, 2008, CIRC-HEART FAIL, V1, P170, DOI 10.1161/CIRCHEARTFAILURE.108.769778; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; GATTINONI L, 1995, NEW ENGL J MED, V333, P1025, DOI 10.1056/NEJM199510193331601; Gurm HS, 2013, J AM COLL CARDIOL, V61, P2242, DOI 10.1016/j.jacc.2013.03.026; Heyman SN, 2010, INVEST RADIOL, V45, P188, DOI 10.1097/RLI.0b013e3181d2eed8; Hofer CK, 2005, CHEST, V128, P848, DOI 10.1378/chest.128.2.848; James MT, 2011, CIRCULATION, V123, P409, DOI 10.1161/CIRCULATIONAHA.110.970160; James MT, 2010, KIDNEY INT, V78, P803, DOI 10.1038/ki.2010.258; Marenzi G, 2006, NEW ENGL J MED, V354, P2773, DOI 10.1056/NEJMoa054209; Marenzi G, 2012, JACC-CARDIOVASC INTE, V5, P90, DOI 10.1016/j.jcin.2011.08.017; Mehran R, 2004, J AM COLL CARDIOL, V44, P1393, DOI 10.1016/j.jacc.2004.06.068; Merten GJ, 2004, JAMA-J AM MED ASSOC, V291, P2328, DOI 10.1001/jama.291.19.2328; Michard F, 2002, CHEST, V121, P2000, DOI 10.1378/chest.121.6.2000; Mueller C, 2002, ARCH INTERN MED, V162, P329, DOI 10.1001/archinte.162.3.329; Navaneethan SD, 2009, AM J KIDNEY DIS, V53, P617, DOI 10.1053/j.ajkd.2008.08.033; Parikh CR, 2008, ARCH INTERN MED, V168, P987, DOI 10.1001/archinte.168.9.987; Rihal CS, 2002, CIRCULATION, V105, P2259, DOI 10.1161/01.CIR.0000016043.87291.33; Seeliger E, 2012, EUR HEART J, V33, P2007, DOI 10.1093/eurheartj/ehr494; Seeliger E, 2010, RADIOLOGY, V256, P406, DOI 10.1148/radiol.10091485; Seeliger E, 2009, AM J PHYSIOL-RENAL, V296, pF1334, DOI 10.1152/ajprenal.90476.2008; Solomon RJ, 2007, CIRCULATION, V115, P3189, DOI 10.1161/CIRCULATIONAHA.106.671644; Stone GW, 2003, JAMA-J AM MED ASSOC, V290, P2284, DOI 10.1001/jama.290.17.2284; Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), 2010, Eur Heart J, V31, P2501, DOI 10.1093/eurheartj/ehq277; Thygesen K, 2012, CIRCULATION, V126, P2020, DOI 10.1161/CIR.0b013e31826e1058; Vroon DH, 1990, CLIN METHODS HIST PH; Weisbord SD, 2008, ARCH INTERN MED, V168, P1325, DOI 10.1001/archinte.168.12.1325; Weisbord SD, 2008, CLIN J AM SOC NEPHRO, V3, P273, DOI 10.2215/CJN.02580607	34	226	234	2	22	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 24	2014	383	9931					1814	1823		10.1016/S0140-6736(14)60689-9	http://dx.doi.org/10.1016/S0140-6736(14)60689-9			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AH6US	24856027				2023-01-03	WOS:000336267800028
J	Kris, MG; Johnson, BE; Berry, LD; Kwiatkowski, DJ; Iafrate, AJ; Wistuba, II; Varella-Garcia, M; Franklin, WA; Aronson, SL; Su, PF; Shyr, Y; Camidge, DR; Sequist, LV; Glisson, BS; Khuri, FR; Garon, EB; Pao, W; Rudin, C; Schiller, J; Haura, EB; Socinski, M; Shirai, K; Chen, HD; Giaccone, G; Ladanyi, M; Kugler, K; Minna, JD; Bunn, PA				Kris, Mark G.; Johnson, Bruce E.; Berry, Lynne D.; Kwiatkowski, David J.; Iafrate, A. John; Wistuba, Ignacio I.; Varella-Garcia, Marileila; Franklin, Wilbur A.; Aronson, Samuel L.; Su, Pei-Fang; Shyr, Yu; Camidge, D. Ross; Sequist, Lecia V.; Glisson, Bonnie S.; Khuri, Fadlo R.; Garon, Edward B.; Pao, William; Rudin, Charles; Schiller, Joan; Haura, Eric B.; Socinski, Mark; Shirai, Keisuke; Chen, Heidi; Giaccone, Giuseppe; Ladanyi, Marc; Kugler, Kelly; Minna, John D.; Bunn, Paul A.			Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROTEIN EXPRESSION; MUTATIONS; GENE; EGFR; GEFITINIB; ADENOCARCINOMA; IDENTIFICATION; MULTICENTER; SENSITIVITY; PREVALENCE	IMPORTANCE Targeting oncogenic drivers (genomic alterations critical to cancer development and maintenance) has transformed the care of patients with lung adenocarcinomas. The Lung Cancer Mutation Consortium was formed to perform multiplexed assays testing adenocarcinomas of the lung for drivers in 10 genes to enable clinicians to select targeted treatments and enroll patients into clinical trials. OBJECTIVES To determine the frequency of oncogenic drivers in patients with lung adenocarcinomas and to use the data to select treatments targeting the identified driver(s) and measure survival. DESIGN, SETTING, AND PARTICIPANTS From 2009 through 2012, 14 sites in the United States enrolled patients with metastatic lung adenocarcinomas and a performance status of 0 through 2 and tested their tumors for 10 drivers. Information was collected on patients, therapies, and survival. INTERVENTIONS Tumors were tested for 10 oncogenic drivers, and results were used to select matched targeted therapies. MAIN OUTCOMES AND MEASURES Determination of the frequency of oncogenic drivers, the proportion of patients treated with genotype-directed therapy, and survival. RESULTS From 2009 through 2012, tumors from 1007 patients were tested for at least 1 gene and 733 for 10 genes (patients with full genotyping). An oncogenic driver was found in 466 of 733 patients (64%). Among these 733 tumors, 182 tumors (25%) had the KRAS driver; sensitizing EGFR, 122 (17%); ALK rearrangements, 57 (8%); other EGFR, 29 (4%); 2 or more genes, 24 (3%); ERBB2 (formerly HER2), 19 (3%); BRAF, 16 (2%); PIK3CA, 6 (<1%); MET amplification, 5 (<1%); NRAS, 5 (<1%); MEK1, 1 (<1%); AKT1, 0. Results were used to select a targeted therapy or trial in 275 of 1007 patients (28%). The median survival was 3.5 years (interquartile range [IQR], 1.96-7.70) for the 260 patients with an oncogenic driver and genotype-directed therapy compared with 2.4 years (IQR, 0.88-6.20) for the 318 patients with any oncogenic driver(s) who did not receive genotype-directed therapy (propensity score-adjusted hazard ratio, 0.69 [95% CI, 0.53-0.9], P = .006). CONCLUSIONS AND RELEVANCE Actionable drivers were detected in 64% of lung adenocarcinomas. Multiplexed testing aided physicians in selecting therapies. Although individuals with drivers receiving a matched targeted agent lived longer, randomized trials are required to determine if targeting therapy based on oncogenic drivers improves survival.	[Kris, Mark G.; Ladanyi, Marc] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA; [Johnson, Bruce E.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Berry, Lynne D.; Su, Pei-Fang; Shyr, Yu; Pao, William; Chen, Heidi] Vanderbilt Ingram Canc Ctr, Nashville, TN USA; [Kwiatkowski, David J.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Iafrate, A. John; Sequist, Lecia V.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Wistuba, Ignacio I.; Glisson, Bonnie S.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Varella-Garcia, Marileila; Franklin, Wilbur A.; Camidge, D. Ross; Kugler, Kelly; Bunn, Paul A.] Univ Colorado, Canc Ctr Denver, Aurora, CO USA; [Aronson, Samuel L.] Partners HealthCare Ctr Personalized Genet Med, Boston, MA USA; [Khuri, Fadlo R.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA; [Garon, Edward B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Rudin, Charles] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA; [Schiller, Joan; Minna, John D.] Univ Texas Southwestern, Med Ctr, Dallas, TX USA; [Haura, Eric B.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; [Socinski, Mark] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA; [Shirai, Keisuke] Med Univ S Carolina, Charleston, SC USA; [Giaccone, Giuseppe] NCI, Bethesda, MD 20892 USA; [Giaccone, Giuseppe] Georgetown Univ, Sch Med, Washington, DC USA	Memorial Sloan Kettering Cancer Center; Harvard University; Dana-Farber Cancer Institute; Vanderbilt University; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; University of Texas System; UTMD Anderson Cancer Center; University of Colorado System; University of Colorado Anschutz Medical Campus; Partners Healthcare System; Emory University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Johns Hopkins University; Johns Hopkins Medicine; University of Texas System; University of Texas Southwestern Medical Center Dallas; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Medical University of South Carolina; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Georgetown University	Kris, MG (corresponding author), Mem Sloan Kettering Canc Ctr, 300 E 66th St, New York, NY 10065 USA.	krism@mskcc.org	Camidge, David Ross/AAG-9144-2019; Rudin, Charles/R-2530-2019; Ladanyi, Marc/AAG-8585-2019; Khuri, Fadlo R./AAU-4942-2020; Giaccone, Giuseppe/E-8297-2017	Rudin, Charles/0000-0001-5204-3465; Khuri, Fadlo R./0000-0002-8638-7618; Giaccone, Giuseppe/0000-0002-5023-7562; Kris, Mark/0000-0002-7317-5341	National Institutes of Health, National Cancer Institute [HSS NIH NCI 1RC2CA148394-010]; NATIONAL CANCER INSTITUTE [K23CA149079, P01CA129243, RC2CA148394, P30CA016672, P50CA058187, P30CA008748, P30CA046934] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000124] Funding Source: NIH RePORTER	National Institutes of Health, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This study was entirely supported by a grant from the National Institutes of Health, National Cancer Institute (HSS NIH NCI 1RC2CA148394-010).	Arcila ME, 2013, MOL CANCER THER, V12, P220, DOI 10.1158/1535-7163.MCT-12-0620; Arcila ME, 2012, CLIN CANCER RES, V18, P4910, DOI 10.1158/1078-0432.CCR-12-0912; Aronson SJ, 2011, HUM MUTAT, V32, P532, DOI 10.1002/humu.21470; Atherly AJ, 2012, BRIT J CANCER, V106, P1100, DOI 10.1038/bjc.2012.60; Barletta JA, 2009, J CELL MOL MED, V13, P1977, DOI 10.1111/j.1582-4934.2008.00594.x; Bergethon K, 2012, J CLIN ONCOL, V30, P863, DOI 10.1200/JCO.2011.35.6345; Camidge DR, 2012, LANCET ONCOL, V13, P1011, DOI 10.1016/S1470-2045(12)70344-3; Cappuzzo F, 2010, LANCET ONCOL, V11, P521, DOI 10.1016/S1470-2045(10)70112-1; Cardarella S, 2012, J THORAC ONCOL, V7, P1767, DOI 10.1097/JTO.0b013e3182745bcb; Chaft JE, 2012, MOL CANCER THER, V11, P485, DOI 10.1158/1535-7163.MCT-11-0692; D'Angelo SP, 2012, J THORAC ONCOL, V7, P1815, DOI 10.1097/JTO.0b013e31826bb7b2; Dias-Santagata D, 2010, EMBO MOL MED, V2, P146, DOI 10.1002/emmm.201000070; Dogan S, 2012, CLIN CANCER RES, V18, P6169, DOI 10.1158/1078-0432.CCR-11-3265; Dziadziuszko R, 2012, J THORAC ONCOL, V7, P340, DOI 10.1097/JTO.0b013e318240ca0d; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hammerman PS, 2011, CANCER DISCOV, V1, P78, DOI 10.1158/2159-8274.CD-11-0005; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Keedy VL, 2011, J CLIN ONCOL, V29, P2121, DOI 10.1200/JCO.2010.31.8923; Kohno T, 2012, NAT MED, V18, P375, DOI 10.1038/nm.2644; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Lipson D, 2012, NAT MED, V18, P382, DOI 10.1038/nm.2673; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; National Comprehensive Cancer Network, NCCN CLIN PRACT GUID; Ohashi K, 2013, CLIN CANCER RES, V19, P2584, DOI 10.1158/1078-0432.CCR-12-3173; Oxnard GR, 2013, J THORAC ONCOL, V8, P179, DOI 10.1097/JTO.0b013e3182779d18; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Paik PK, 2011, J CLIN ONCOL, V29, P2046, DOI 10.1200/JCO.2010.33.1280; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Pao W, 2011, LANCET ONCOL, V12, P175, DOI 10.1016/S1470-2045(10)70087-5; Pao W, 2009, CLIN CANCER RES, V15, P5317, DOI 10.1158/1078-0432.CCR-09-0913; Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396; Rami-Porta R, 2007, J THORAC ONCOL, V2, P593, DOI 10.1097/JTO.0b013e31807a2f81; Seidel D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006802; Sequist LV, 2011, ANN ONCOL, V22, P2616, DOI 10.1093/annonc/mdr489; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Su ZL, 2011, J MOL DIAGN, V13, P74, DOI 10.1016/j.jmoldx.2010.11.010; Thatcher N, 2005, LANCET, V366, P1527, DOI 10.1016/S0140-6736(05)67625-8; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358	41	1094	1149	4	86	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	2014	311	19					1998	2006		10.1001/jama.2014.3741	http://dx.doi.org/10.1001/jama.2014.3741			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AH4UA	24846037	Green Accepted, Bronze			2023-01-03	WOS:000336122800022
J	Bossers, WJR; Scherder, EJA; Boersma, F; Hortobagyi, T; van der Woude, LHV; van Heuvelen, MJG				Bossers, Willem J. R.; Scherder, Erik J. A.; Boersma, Froukje; Hortobagyi, Tibor; van der Woude, Lucas H. V.; van Heuvelen, Marieke J. G.			Feasibility of a Combined Aerobic and Strength Training Program and Its Effects on Cognitive and Physical Function in Institutionalized Dementia Patients. A Pilot Study	PLOS ONE			English	Article							NURSING-HOME RESIDENTS; OLDER-ADULTS; ALZHEIMERS-DISEASE; PERFORMANCE-MEASURES; EXERCISE PROGRAM; BODY STRENGTH; PEOPLE; IMPAIRMENT; MOBILITY; BALANCE	Objectives: We examined the feasibility of a combined aerobic and strength training program in institutionalized dementia patients and studied the effects on cognitive and physical function. Methods: Thirty-three patients with dementia, recruited from one nursing home, participated in this non-randomized pilot study (25 women; age = 85.2 +/- 4.9 years; Mini Mental State Examination = 16.8 +/- 4.0). In phase 1 of the study, seventeen patients in the Exercise group (EG) received a combined aerobic and strength training program for six weeks, five times per week, 30 minutes per session, in an individually supervised format and successfully concluded the pre and posttests. In phase 2 of the study, sixteen patients in the Social group (SG) received social visits at the same frequency, duration, and format and successfully concluded the pre and posttests. Results: Indices of feasibility showed that the recruitment and adherence rate, respectively were 46.2% and 86.3%. All EG patients completed the exercise program according to protocol without adverse events. After the six-week program, no significant differences on cognitive function tests were found between the EG and SG. There was a moderate effect size in favor for the EG for the Visual Memory Span Forward; a visual attention test. There were significant differences between groups in favor for the EG with moderate to large effects for the physical tests Walking Speed (p=.003), Six-Minute Walk Test (p=.031), and isometric quadriceps strength (p=.012). Conclusions: The present pilot study showed that it is feasible to conduct a combined aerobic and strength training program in institutionalized patients with dementia. The selective cognitive visual attention improvements and more robust changes in motor function in favor of EG vs. SG could serve as a basis for large randomized clinical trials.	[Bossers, Willem J. R.; Scherder, Erik J. A.; Hortobagyi, Tibor; van der Woude, Lucas H. V.; van Heuvelen, Marieke J. G.] Univ Groningen, Univ Med Ctr Groningen, Ctr Human Movement Sci, Groningen, Netherlands; [Scherder, Erik J. A.] Vrije Univ Amsterdam, Dept Clin Neuropsychol, Amsterdam, Netherlands; [Boersma, Froukje] Univ Groningen, Univ Med Ctr Groningen, Dept Gen Practice, Groningen, Netherlands; [van der Woude, Lucas H. V.] Univ Groningen, Univ Med Ctr Groningen, Ctr Rehabil, Groningen, Netherlands	University of Groningen; Vrije Universiteit Amsterdam; University of Groningen; University of Groningen	Bossers, WJR (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Ctr Human Movement Sci, Groningen, Netherlands.	w.j.r.bossers@umcg.nl	van der Woude, Lucas H/E-7986-2018	van der Woude, Lucas H/0000-0002-8472-334X				Bassuk SS, 1999, ANN INTERN MED, V131, P165, DOI 10.7326/0003-4819-131-3-199908030-00002; Blankevoort CG, 2013, PHYS THER, V93, P69, DOI 10.2522/ptj.20110164; Blankevoort CG, 2010, DEMENT GERIATR COGN, V30, P392, DOI 10.1159/000321357; Bossers WJR, 2012, DEMENT GER COGN D EX, V2, P589, DOI 10.1159/000345038; Broadbent NJ, 2004, P NATL ACAD SCI USA, V101, P14515, DOI 10.1073/pnas.0406344101; Brown AD, 2010, NEUROBIOL AGING, V31, P2047, DOI 10.1016/j.neurobiolaging.2008.11.002; Brucki SMD, 2004, BRAZ J MED BIOL RES, V37, P1771, DOI 10.1590/S0100-879X2004001200002; Chandler JM, 1998, ARCH PHYS MED REHAB, V79, P24, DOI 10.1016/S0003-9993(98)90202-7; Cohen J., 2013, STAT POWER ANAL BEHA; Colcombe S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.t01-1-01430; Enright Paul L, 2003, Respir Care, V48, P783; Erickson KI, 2011, P NATL ACAD SCI USA, V108, P3017, DOI 10.1073/pnas.1015950108; Etnier JL, 2006, BRAIN RES REV, V52, P119, DOI 10.1016/j.brainresrev.2006.01.002; Fiser WM, 2010, J GERONTOL A-BIOL, V65, P1332, DOI 10.1093/gerona/glq137; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Forbes D, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006489.pub3; Frandin K, 1995, SCAND J REHABIL MED, V27, P231; GURALNIK JM, 1994, AGING-CLIN EXP RES, V6, P410, DOI 10.1007/BF03324272; Hammes J, 1973, STROOP KLEUR WOORD T; Heyn P, 2004, ARCH PHYS MED REHAB, V85, P1694, DOI 10.1016/j.apmr.2004.03.019; HINRICHSEN GA, 1994, GERONTOLOGIST, V34, P95, DOI 10.1093/geront/34.1.95; Huang T, 2014, SCAND J MED SCI SPOR, V24, P1, DOI 10.1111/sms.12069; Jarnlo Gun-Britt, 2003, Physiotherapy Theory and Practice, V19, P35, DOI 10.1080/09593980307969; Jones CJ, 1999, RES Q EXERCISE SPORT, V70, P113, DOI 10.1080/02701367.1999.10608028; Krist L, 2013, CLIN INTERV AGING, V8, P443, DOI 10.2147/CIA.S42136; LaRoche DP, 2011, GAIT POSTURE, V33, P668, DOI 10.1016/j.gaitpost.2011.02.022; Lindeboom J, 1989, AMSTERDAM DEMENTIA S; Liu-Ambrose T, 2009, BRIT J SPORT MED, V43, P25, DOI 10.1136/bjsm.2008.055616; Luppa M, 2010, AGE AGEING, V39, P31, DOI 10.1093/ageing/afp202; Luteijn F, 1983, HANDLEIDING GRONINGE; Mangione KK, 2010, J AM GERIATR SOC, V58, P1911, DOI 10.1111/j.1532-5415.2010.03076.x; Nation DA, 2011, MED HYPOTHESES, V76, P847, DOI 10.1016/j.mehy.2011.02.034; Nelson ME, 2007, MED SCI SPORT EXER, V39, P1435, DOI [10.1249/mss.0b013e3180616aa2, 10.1161/CIRCULATIONAHA.107.185650]; ORY MG, 1993, J AM GERIATR SOC, V41, P283, DOI 10.1111/j.1532-5415.1993.tb06707.x; Perri R, 2014, J ALZHEIMERS DIS, V39, P669, DOI 10.3233/JAD-131337; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Raji CA, 2009, NEUROLOGY, V73, P1899, DOI 10.1212/WNL.0b013e3181c3f293; Rhodes RE, 1999, SPORTS MED, V28, P397, DOI 10.2165/00007256-199928060-00003; Rogers SD, 2008, J AGING PHYS ACTIV, V16, P61, DOI 10.1123/japa.16.1.61; Rosen VM, 1997, J EXP PSYCHOL GEN, V126, P211, DOI 10.1037/0096-3445.126.3.211; ROSSITERFORNOFF JE, 1995, J GERONTOL A-BIOL, V50, pM291, DOI 10.1093/gerona/50A.6.M291; Schafer JH, 2005, J AM GERIATR SOC, V53, P381, DOI 10.1111/j.1532-5415.2005.53153.x; Schutzer KA, 2004, PREV MED, V39, P1056, DOI 10.1016/j.ypmed.2004.04.003; Steinberg M, 2009, INT J GERIATR PSYCH, V24, P680, DOI 10.1002/gps.2175; Tak ECPM, 2012, J AGING PHYS ACTIV, V20, P32, DOI 10.1123/japa.20.1.32; Tappen RM, 1997, J GERONTOL A-BIOL, V52, pM52, DOI 10.1093/gerona/52A.1.M52; Thomas VS, 2003, J GERONTOL A-BIOL, V58, P746; Verkerke GJ, 2003, MED BIOL ENG COMPUT, V41, P283, DOI 10.1007/BF02348432; Volkers KM, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-38; Vreugdenhil A, 2012, SCAND J CARING SCI, V26, P12, DOI 10.1111/j.1471-6712.2011.00895.x; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wiesmann M, 2013, J CEREBR BLOOD F MET, V33, P1696, DOI 10.1038/jcbfm.2013.159; Wilson B, 1987, RIVERMEAD BEHAV MEMO; Yaguez L, 2011, INT J GERIATR PSYCH, V26, P173, DOI 10.1002/gps.2510	54	36	36	0	45	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2014	9	5							e97577	10.1371/journal.pone.0097577	http://dx.doi.org/10.1371/journal.pone.0097577			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AM0UW	24844772	Green Published, gold, Green Submitted			2023-01-03	WOS:000339563400036
J	Lemyze, M; Taufour, P; Duhamel, A; Temime, J; Nigeon, O; Vangrunderbeeck, N; Barrailler, S; Gasan, G; Pepy, F; Thevenin, D; Mallat, J				Lemyze, Malcolm; Taufour, Pauline; Duhamel, Alain; Temime, Johanna; Nigeon, Olivier; Vangrunderbeeck, Nicolas; Barrailler, Stephanie; Gasan, Gaelle; Pepy, Florent; Thevenin, Didier; Mallat, Jihad			Determinants of Noninvasive Ventilation Success or Failure in Morbidly Obese Patients in Acute Respiratory Failure	PLOS ONE			English	Article							POSITIVE-PRESSURE VENTILATION; EXPIRATORY FLOW LIMITATION; HYPOVENTILATION SYNDROME; MECHANICAL VENTILATION; TASK-FORCE; MANAGEMENT; PREVALENCE; GUIDELINES; DISORDERS; SEVERITY	Purpose: Acute respiratory failure (ARF) is a common life-threatening complication in morbidly obese patients with obesity hypoventilation syndrome (OHS). We aimed to identify the determinants of noninvasive ventilation (NIV) success or failure for this indication. Methods: We prospectively included 76 consecutive patients with BMI>40 kg/m(2) diagnosed with OHS and treated by NIV for ARF in a 15-bed ICU of a tertiary hospital. Results: NIV failed to reverse ARF in only 13 patients. Factors associated with NIV failure included pneumonia (n = 12/13, 92% vs n = 9/63, 14%; p<0.0001), high SOFA (10 vs 5; p<0.0001) and SAPS2 score (63 vs 39; p<0.0001) at admission. These patients often experienced poor outcome despite early resort to endotracheal intubation (in-hospital mortality, 92.3% vs 17.5%; p<0.001). The only factor significantly associated with successful response to NIV was idiopathic decompensation of OHS (n = 30, 48% vs n = 0, 0%; p = 0.001). In the NIV success group (n = 63), 33 patients (53%) experienced a delayed response to NIV (with persistent hypercapnic acidosis during the first 6 hours). Conclusions: Multiple organ failure and pneumonia were the main factors associated with NIV failure and death in morbidly obese patients in hypoxemic ARF. On the opposite, NIV was constantly successful and could be safely pushed further in case of severe hypercapnic acute respiratory decompensation of OHS.	[Lemyze, Malcolm; Taufour, Pauline; Temime, Johanna; Barrailler, Stephanie; Gasan, Gaelle; Pepy, Florent; Thevenin, Didier; Mallat, Jihad] Schaffner Hosp, Dept Resp & Crit Care Med, Lens, France; [Duhamel, Alain] CHRU Lille, Lille Univ Hosp, Dept Biostat, Lille, France; [Nigeon, Olivier; Vangrunderbeeck, Nicolas] Schaffner Hosp, Resp Step Down Unit, Lens, France	Universite de Lille - ISITE; CHU Lille	Lemyze, M (corresponding author), Schaffner Hosp, Dept Resp & Crit Care Med, Lens, France.	malcolmlemyze@yahoo.fr	Duhamel, Alain/A-4899-2013					[Anonymous], 1960, BMJ-BRIT MED J, V2, P1665; [Anonymous], 1998, WHONUTNCD981; Antonelli M, 2001, INTENS CARE MED, V27, P1718, DOI 10.1007/s00134-001-1114-4; BaHammam A, 2005, RESP MED, V99, P718, DOI 10.1016/j.rmed.2004.10.021; Baydur A, 2004, CHEST, V125, P98, DOI 10.1378/chest.125.1.98; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; Carrillo A, 2012, AM J RESP CRIT CARE, V186, P1279, DOI 10.1164/rccm.201206-1101OC; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; de Llano LAP, 2005, CHEST, V128, P587, DOI 10.1378/chest.128.2.587; Duarte AG, 2007, CRIT CARE MED, V35, P732, DOI 10.1097/01.CCM.0000256842.39767.41; El-Solh A, 2001, CHEST, V120, P1989, DOI 10.1378/chest.120.6.1989; Esteban A, 2004, NEW ENGL J MED, V350, P2452, DOI 10.1056/NEJMoa032736; Ferreira FL, 2001, JAMA-J AM MED ASSOC, V286, P1754, DOI 10.1001/jama.286.14.1754; Ferretti A, 2001, CHEST, V119, P1401, DOI 10.1378/chest.119.5.1401; Finucane MM, 2011, LANCET, V377, P557, DOI 10.1016/S0140-6736(10)62037-5; Futier E, 2011, ANESTHESIOLOGY, V114, P1354, DOI 10.1097/ALN.0b013e31821811ba; Hart N, 2014, THORAX, V69, P83, DOI 10.1136/thoraxjnl-2013-204298; KELLY BJ, 1993, CHEST, V104, P1818, DOI 10.1378/chest.104.6.1818; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Lemyze M, 2013, CRIT CARE MED, V41, P481, DOI 10.1097/CCM.0b013e31826ab4af; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159; Marik PE, 2012, OBES REV, V13, P902, DOI 10.1111/j.1467-789X.2012.01014.x; Marik PE, 2013, J INTENSIVE CARE MED, V28, P124, DOI 10.1177/0885066612444261; Martino JL, 2011, CHEST, V140, P1198, DOI 10.1378/chest.10-3023; Masa JF, 2001, CHEST, V119, P1102, DOI 10.1378/chest.119.4.1102; Mokhlesi B, 2010, RESP CARE, V55, P1347; Moretti M, 2000, THORAX, V55, P819, DOI 10.1136/thorax.55.10.819; Nava S, 2009, LANCET, V374, P250, DOI 10.1016/S0140-6736(09)60496-7; Nowbar S, 2004, AM J MED, V116, P1, DOI 10.1016/j.amjmed.2003.08.022; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Pelosi P, 1997, J APPL PHYSIOL, V82, P811, DOI 10.1152/jappl.1997.82.3.811; Piper AJ, 2011, AM J RESP CRIT CARE, V183, P292, DOI 10.1164/rccm.201008-1280CI; Priou P, 2010, CHEST, V138, P84, DOI 10.1378/chest.09-2472; Raurich JM, 2010, RESP CARE, V55, P1442; Steier J, 2009, THORAX, V64, P719, DOI 10.1136/thx.2008.109728; Torbicki A, 2008, EUR HEART J, V29, P2276, DOI 10.1093/eurheartj/ehn310; Yamane T, 2008, AM J RESP CRIT CARE, V178, P295, DOI 10.1164/rccm.200801-113OC; Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016/j.jacc.2013.05.019; ZWILLICH CW, 1975, AM J MED, V59, P343, DOI 10.1016/0002-9343(75)90392-7	41	35	35	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2014	9	5							e97563	10.1371/journal.pone.0097563	http://dx.doi.org/10.1371/journal.pone.0097563			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI1ZC	24819141	Green Published, gold, Green Submitted			2023-01-03	WOS:000336653300123
J	Cai, CY; Chen, YC; Zhong, SP; Ji, B; Wang, JZ; Bai, XT; Shi, GG				Cai, Congyi; Chen, Yicun; Zhong, Shuping; Ji, Bin; Wang, Jinzhi; Bai, Xueting; Shi, Ganggang			Anti-Inflammatory Activity of N-Butanol Extract from Ipomoea stolonifera In Vivo and In Vitro	PLOS ONE			English	Article							ADJUVANT-INDUCED ARTHRITIS; COASTAL MEDICINAL-PLANTS; OIL EAR TEST; NATURAL-PRODUCTS; RAT; EDEMA; ACID; INFLAMMATION; ANTIOXIDANT; DIVERSITY	Ipomoea stolonifera (I. stolonifera) has been used for the treatment of inflammatory diseases including rheumatism and rheumatoid arthritis in Chinese traditional medicine. However, the anti-inflammatory activity of I. stolonifera has not been elucidated. For this reason, the anti-inflammatory activity of n-butanol extract of I. stolonifera (BE-IS) was evaluated in vivo by using acute models (croton oil-induced mouse ear edema, carrageenan-induced rat paw edema, and carrageenan-induced rat pleurisy) and chronic models (cotton pellet-induced rat granuloma, and complete Freund's adjuvant (CFA)induced rat arthritis). Results indicated that oral administration of BE-IS significantly attenuated croton oil-induced ear edema, decreased carrageenan-induced paw edema, reduced carrageenan-induced exudates and cellular migration, inhibited cotton pellet-induced granuloma formation and improved CFA-induced arthritis. Preliminary mechanism studies demonstrated that BE-IS decreased the levels of myeloperoxidase (MPO) and malondialdehyde (MDA), increased the activity of anti-oxidant enzyme superoxide dismutase (SOD) in vivo, and reduced the production of nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1 beta and IL-6 in lipopolysaccharide-activated RAW264.7 macrophages in vitro. Results obtained in vivo and in vitro demonstrate that BE-IS has considerable anti-inflammatory potential, which provided experimental evidences for the traditional application of Ipomoea stolonifera in inflammatory diseases.	[Cai, Congyi; Chen, Yicun; Ji, Bin; Bai, Xueting; Shi, Ganggang] Shantou Univ, Coll Med, Dept Pharmacol, Shantou, Peoples R China; [Cai, Congyi] Shantou Univ, Coll Med, Affiliated Hosp 2, Dept Pharm, Shantou, Peoples R China; [Zhong, Shuping] Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; [Wang, Jinzhi] Shantou Univ, Coll Med, Dept Chem, Shantou, Peoples R China; [Shi, Ganggang] Shantou Univ, Coll Med, Affiliated Hosp 1, Dept Cardiovasc Dis, Shantou, Peoples R China	Shantou University; Shantou University; University of Southern California; Shantou University; Shantou University	Shi, GG (corresponding author), Shantou Univ, Coll Med, Dept Pharmacol, Shantou, Peoples R China.	ggshi@stu.edu.cn			National Natural Science Foundation of China [30973922]; Guangdong Natural Science Foundation [9351503102000001]; central government special funds the development of local colleges and universities; Administration of Traditional Chinese Medicine of Guangdong Province, China [2010408]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province); central government special funds the development of local colleges and universities; Administration of Traditional Chinese Medicine of Guangdong Province, China	This study was undertaken and supported within a grant from the National Natural Science Foundation of China (No. 30973922), the teamwork projects funded by the Guangdong Natural Science Foundation (No. 9351503102000001), the central government special funds supporting the development of local colleges and universities, and Administration of Traditional Chinese Medicine of Guangdong Province, China (No. 2010408). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad SF, 2006, PHARMACOL RES, V53, P233, DOI 10.1016/j.phrs.2005.11.005; [Anonymous], 2002, OECD GUID DOC ACUT O; Antonisamy P, 2011, J PHARM PHARMACOL, V63, P1070, DOI 10.1111/j.2042-7158.2011.01300.x; Barbour SE, 1998, MOL IMMUNOL, V35, P977, DOI 10.1016/S0161-5890(98)00070-4; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Cabrini DA, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq026; Costantino V, 2004, CURR MED CHEM, V11, P1671, DOI 10.2174/0929867043364973; de Souza MM, 2000, J ETHNOPHARMACOL, V69, P85, DOI 10.1016/S0378-8741(99)00142-7; DEYOUNG LM, 1989, AGENTS ACTIONS, V26, P335; Eddouks M, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/142087; Glauser MP, 1996, DRUGS, V52, P9, DOI 10.2165/00003495-199600522-00004; Hou Y, 2010, CURR MED CHEM, V17, P1191, DOI 10.2174/092986710790827834; Huang MH, 2011, J ETHNOPHARMACOL, V135, P545, DOI 10.1016/j.jep.2011.03.057; IALENTI A, 1993, BRIT J PHARMACOL, V110, P701, DOI 10.1111/j.1476-5381.1993.tb13868.x; Inbaneson Samuel Jacob, 2012, Asian Pacific Journal of Tropical Biomedicine, V2, P364, DOI 10.1016/S2221-1691(12)60057-4; Kang M, 2010, J ETHNOPHARMACOL, V131, P485, DOI 10.1016/j.jep.2010.07.025; Kim HW, 2003, CARCINOGENESIS, V24, P235, DOI 10.1093/carcin/24.2.235; Krogh R, 1999, PHARMAZIE, V54, P464; Mannel DN, 2000, CHEM IMMUNOL, V74, P141; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Matallana G, 2005, AM J BOT, V92, P1513, DOI 10.3732/ajb.92.9.1513; MATSUDA R, 1992, FOLIA PHARMACOL JPN, V99, P363, DOI 10.1254/fpj.99.363; Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201; MIKAMI T, 1983, EUR J PHARMACOL, V95, P1, DOI 10.1016/0014-2999(83)90261-3; MOLLOY RG, 1993, BRIT J SURG, V80, P289, DOI 10.1002/bjs.1800800308; Mondol MAM, 2013, MAR DRUGS, V11, P2846, DOI 10.3390/md11082846; Morteza-Semnani K, 2004, FITOTERAPIA, V75, P123, DOI 10.1016/j.fitote.2003.12.007; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAGATOMI H, 1984, ARZNEIMITTELFORSCH, V34-1, P599; Nasri R, 2013, CURR PROTEIN PEPT SC, V14, P199; Odum W E, 1977, Science, V197, P1071, DOI 10.1126/science.197.4308.1071-a; OECD Guidelines, 2000, OECD ENV HLTH SAF PU, V19; Park HH, 2013, INT IMMUNOPHARMACOL, V15, P296, DOI 10.1016/j.intimp.2012.12.005; PONGPRAYOON U, 1991, PLANTA MED, V57, P515, DOI 10.1055/s-2006-960196; Qiu H, 1995, GUIHAIA, V15, P7; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; Rasool M, 2007, FUND CLIN PHARMACOL, V21, P157, DOI 10.1111/j.1472-8206.2006.00461.x; Ravikumar S, 2005, J ENVIRON BIOL, V26, P383; Roth SH, 2012, DRUGS, V72, P873, DOI 10.2165/11633740-000000000-00000; SELYE H, 1953, JAMA-J AM MED ASSOC, V152, P1207, DOI 10.1001/jama.1953.63690130001006; Simon RA, 2003, CLIN REV ALLERG IMMU, V24, P189, DOI 10.1385/CRIAI:24:2:189; TUBARO A, 1986, AGENTS ACTIONS, V19, P371, DOI 10.1007/BF01971259; TUBARO A, 1986, AGENTS ACTIONS, V17, P347, DOI 10.1007/BF01982641; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; VINEGAR R, 1982, FED PROC, V41, P2588; WEST MA, 1995, J TRAUMA, V39, P404; Williams A, 2010, ENVIRON MANAGE, V46, P738, DOI 10.1007/s00267-010-9558-3; WINTER CA, 1957, J AM PHARM ASSOC, V46, P515, DOI 10.1002/jps.3030460902; WINTER CA, 1962, P SOC EXP BIOL MED, V111, P544	51	33	35	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 21	2014	9	4							e95931	10.1371/journal.pone.0095931	http://dx.doi.org/10.1371/journal.pone.0095931			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG2DX	24752203	Green Published, Green Submitted, gold			2023-01-03	WOS:000335227400145
J	Romo-Vaquero, M; Selma, MV; Larrosa, M; Obiol, M; Garcia-Villalba, R; Gonzalez-Barrio, R; Issaly, N; Flanagan, J; Roller, M; Tomas-Barberan, FA; Garcia-Conesa, MT				Romo-Vaquero, Maria; Selma, Maria-Victoria; Larrosa, Mar; Obiol, Maria; Garcia-Villalba, Rocio; Gonzalez-Barrio, Rocio; Issaly, Nicolas; Flanagan, John; Roller, Marc; Tomas-Barberan, Francisco A.; Garcia-Conesa, Maria-Teresa			A Rosemary Extract Rich in Carnosic Acid Selectively Modulates Caecum Microbiota and Inhibits beta-Glucosidase Activity, Altering Fiber and Short Chain Fatty Acids Fecal Excretion in Lean and Obese Female Rats	PLOS ONE			English	Article							GUT MICROBIOTA; IN-VITRO; DIET; INFLAMMATION; PREBIOTICS; MICE; POPULATIONS; POLYPHENOLS; METABOLISM; INULIN	Background: Carnosic acid (CA) and rosemary extracts (RE) show body-weight, energy metabolism and inflammation regulatory properties in animal models but the mechanisms are not yet understood. Gut microbiota plays an important role in the host metabolism and inflammatory status and is modulated by the diet. The aim of this research was to investigate whether a RE enriched in CA affected caecum microbiota composition and activity in a rat model of genetic obesity. Methods and Principal Findings: A RE (40% CA) was administered with the diet (0.5% w/w) to lean (fa/+) and obese (fa/fa) female Zucker rats for 64 days. Changes in the microbiota composition and beta-glucosidase activity in the caecum and in the levels of macronutrients and short chain fatty acids (SCFA) in feces were examined. The RE increased the Blautia coccoides and Bacteroides/Prevotella groups and reduced the Lactobacillus/Leuconostoc/Pediococccus group in both types of animals. Clostridium leptum was significantly decreased and Bifidobacterium increased only in the lean rats. beta-Glucosidase activity was significantly reduced and fecal fiber excretion increased in the two genotypes. The RE also increased the main SCFA excreted in the feces of the obese rats but decreased them in the lean rats reflecting important differences in the uptake and metabolism of these molecules between the two genotypes. Conclusions: Our results indicate that the consumption of a RE enriched in CA modifies microbiota composition and decreases beta-glucosidase activity in the caecum of female Zucker rats while it increases fiber fecal elimination. These results may contribute to explain the body weight gain reducing effects of the RE. The mutated leptin receptor of the obese animals significantly affects the microbiota composition, the SCFA fecal excretion and the host response to the RE intake.	[Romo-Vaquero, Maria; Selma, Maria-Victoria; Larrosa, Mar; Obiol, Maria; Garcia-Villalba, Rocio; Tomas-Barberan, Francisco A.; Garcia-Conesa, Maria-Teresa] CSIC, CEBAS, Dept Food Sci & Technol, Res Grp Qual Safety & Bioact Plant Foods, Murcia, Spain; [Garcia-Villalba, Rocio] Univ Murcia, Fac Vet Sci, Dept Human Nutr & Food Sci, Murcia, Spain; [Issaly, Nicolas] Naturex SL, Valencia, Spain; [Flanagan, John; Roller, Marc] Naturex SA, Avignon, France	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Edafologia y Biologia Aplicada del Segura (CEBAS); University of Murcia	Garcia-Conesa, MT (corresponding author), CSIC, CEBAS, Dept Food Sci & Technol, Res Grp Qual Safety & Bioact Plant Foods, Murcia, Spain.	mtconesa@cebas.csic.es	Gonzalez-Barrio, Rocío/F-2180-2018; Selma, Maria Victoria/N-3997-2014; LARROSA, MAR/H-6012-2012; Villalba, Rocio Garcia/G-7217-2015; Tomás-Barberán, Francisco/D-6686-2011; García-Conesa, María-Teresa/N-4032-2014; Vaquero, María Romo/G-6883-2015	Gonzalez-Barrio, Rocío/0000-0002-6648-5229; Selma, Maria Victoria/0000-0002-6780-974X; LARROSA, MAR/0000-0002-8863-4686; Tomás-Barberán, Francisco/0000-0002-0790-1739; García-Conesa, María-Teresa/0000-0002-4125-853X; Vaquero, María Romo/0000-0002-0084-6060; Garcia Villalba, Rocio/0000-0003-1883-1673	Spanish Centre for the Development of Industrial Technology (CDTI) as part of the project SENIFOOD [CEN-20091006]; Project Consolider Ingenio [CSD2007-00063]; Seneca Foundation of the Region of Murcia, Spain [GERM 06 04486, 05556/PI/04]	Spanish Centre for the Development of Industrial Technology (CDTI) as part of the project SENIFOOD; Project Consolider Ingenio(Spanish Government); Seneca Foundation of the Region of Murcia, Spain	This project was financed by the Spanish Centre for the Development of Industrial Technology (CDTI) as part of the project SENIFOOD, which belongs to the CENIT subvention program (Ref: CEN-20091006). This work was also supported by the Project Consolider Ingenio 2010, CSD2007-00063 (Fun-C-Food) and by the Seneca Foundation of the Region of Murcia, Spain (Group of Excellence GERM 06 04486 and 05556/PI/04). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AOAC, 1999, OFF METH ASS OFF AGR; Bailey D. T., 1999, US Patent, Patent No. [5,859,293, 5859293, 5.859.293]; Blaut Michael, 2012, Handb Exp Pharmacol, P251, DOI 10.1007/978-3-642-24716-3_11; Cani PD, 2007, DIABETOLOGIA, V50, P2374, DOI 10.1007/s00125-007-0791-0; Cardona F, 2013, J NUTR BIOCHEM, V24, P1415, DOI 10.1016/j.jnutbio.2013.05.001; Conterno L, 2011, GENES NUTR, V6, P241, DOI 10.1007/s12263-011-0230-1; Dabek M, 2008, FEMS MICROBIOL ECOL, V66, P487, DOI 10.1111/j.1574-6941.2008.00520.x; den Besten G, 2013, AM J PHYSL GASTROINT; den Besten G, 2013, J LIPID RES, V54, P2325, DOI 10.1194/jlr.R036012; El Kaoutari A, 2013, NAT REV MICROBIOL, V11, P497, DOI 10.1038/nrmicro3050; Everard A, 2013, BEST PRACT RES CL GA, V27, P73, DOI 10.1016/j.bpg.2013.03.007; Everard A, 2011, DIABETES, V60, P2775, DOI 10.2337/db11-0227; FAO, 2008, FATS FATT AC HUM NUT, P1; FAVIER ML, 1995, METABOLISM, V44, P200, DOI 10.1016/0026-0495(95)90265-1; Franks AH, 1998, APPL ENVIRON MICROB, V64, P3336; Furet JP, 2009, FEMS MICROBIOL ECOL, V68, P351, DOI 10.1111/j.1574-6941.2009.00671.x; Garcia-Villalba R, 2012, J SEP SCI, V35, P1906, DOI 10.1002/jssc.201101121; Cano PG, 2013, OBESITY, V21, P2310, DOI 10.1002/oby.20330; Geurts L, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00149; Gibson GR, 1996, P NUTR SOC, V55, P899, DOI 10.1079/PNS19960087; GREENWOOD MRC, 1993, ANN NY ACAD SCI, V676, P253; Grootaert C, 2011, BENEF MICROBES, V2, P305, DOI 10.3920/BM2011.0020; Guglielmetti S, 2013, J AGR FOOD CHEM, V61, P8134, DOI 10.1021/jf402495k; Jordan MJ, 2012, J AGR FOOD CHEM, V60, P9603, DOI 10.1021/jf302881t; Kovatcheva-Datchary P, 2013, BEST PRACT RES CL GA, V27, P59, DOI 10.1016/j.bpg.2013.03.017; Larrosa M, 2010, J NUTR BIOCHEM, V21, P717, DOI 10.1016/j.jnutbio.2009.04.012; Larrosa M, 2009, J AGR FOOD CHEM, V57, P2211, DOI 10.1021/jf803638d; Lecerf JM, 2012, BRIT J NUTR, V108, P1847, DOI 10.1017/S0007114511007252; Lee H, 2013, PEDIATR GASTROENTERO, V16, P143, DOI 10.5223/pghn.2013.16.3.143; Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102; Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a; Manz W, 1996, MICROBIOL-SGM, V142, P1097, DOI 10.1099/13500872-142-5-1097; Molan AL, 2010, PHYTOTHER RES, V24, P1614, DOI 10.1002/ptr.3145; Murphy EF, 2013, GUT, V62, P220, DOI 10.1136/gutjnl-2011-300705; Neyrinck AM, 2013, BRIT J NUTR, V109, P802, DOI 10.1017/S0007114512002206; Possemiers S, 2006, J NUTR, V136, P1862, DOI 10.1093/jn/136.7.1862; Puhl NJ, 2012, ANAEROBE, V18, P67, DOI 10.1016/j.anaerobe.2011.12.007; Reikvam DH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017996; Roberfroid M, 2010, BRIT J NUTR, V104, pS1, DOI 10.1017/S0007114510003363; Vaquero MR, 2013, MOL NUTR FOOD RES, V57, P1834, DOI 10.1002/mnfr.201300052; Romo-Vaquero M, 2013, MOL NUTR FOOD RES, DOI [10.1002/mnfr.2013005241, DOI 10.1002/MNFR.2013005241]; Romo-Vaquero M, 2012, PLOS ONE, V7; Selma MV, 2009, J AGR FOOD CHEM, V57, P6485, DOI 10.1021/jf902107d; Slavin J, 2013, NUTRIENTS, V5, P1417, DOI 10.3390/nu5041417; Tagliabue A, 2013, NUTR METAB CARDIOVAS, V23, P160, DOI 10.1016/j.numecd.2012.09.002; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Vinolo MAR, 2011, J NUTR BIOCHEM, V22, P849, DOI 10.1016/j.jnutbio.2010.07.009; Waldram A, 2009, J PROTEOME RES, V8, P2361, DOI 10.1021/pr8009885; Wang Y, 2010, NUTRITION, V26, P305, DOI 10.1016/j.nut.2009.04.014; Wichmann A, 2013, CELL HOST MICROBE, V14, P582, DOI 10.1016/j.chom.2013.09.012; Wright SM, 2012, ABDOM IMAGING, V37, P730, DOI 10.1007/s00261-012-9862-x; Xiong YM, 2004, P NATL ACAD SCI USA, V101, P1045, DOI 10.1073/pnas.2637002100; Zdunczyk Z, 2006, NUTRITION, V22, P898, DOI 10.1016/j.nut.2006.05.010	53	44	46	0	49	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 14	2014	9	4							e94687	10.1371/journal.pone.0094687	http://dx.doi.org/10.1371/journal.pone.0094687			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI6GP	24733124	Green Published, Green Submitted, gold			2023-01-03	WOS:000336970400073
J	Shkumatov, A; Baek, K; Kong, H				Shkumatov, Artem; Baek, Kwanghyun; Kong, Hyunjoon			Matrix Rigidity-Modulated Cardiovascular Organoid Formation from Embryoid Bodies	PLOS ONE			English	Article							STEM-CELLS; SELF-ORGANIZATION; AXIS FORMATION; IN-VITRO; DIFFERENTIATION; CARDIOMYOCYTES; MUSCLE; REGENERATION; PROGENITORS; EFFICIENCY	Stem cell clusters, such as embryoid bodies (EBs) derived from embryonic stem cells, are extensively studied for creation of multicellular clusters and complex functional tissues. It is common to control phenotypes of ES cells with varying molecular compounds; however, there is still a need to improve the controllability of cell differentiation, and thus, the quality of created tissue. This study demonstrates a simple but effective strategy to promote formation of vascularized cardiac muscle-like tissue in EBs and form contracting cardiovascular organoids by modulating the stiffness of a cell adherent hydrogel. Using collagen-conjugated polyacrylamide hydrogels with controlled elastic moduli, we discovered that cellular organization in a form of vascularized cardiac muscle sheet was maximal on the gel with the stiffness similar to cardiac muscle. We envisage that the results of this study will greatly contribute to better understanding of emergent behavior of stem cells in developmental and regeneration process and will also expedite translation of EB studies to drug-screening device assembly and clinical treatments.	[Shkumatov, Artem] Univ Illinois, Dept Pathobiol, Coll Vet Med, Urbana, IL 61801 USA; [Baek, Kwanghyun] Univ Illinois, Dept Mat Sci & Engn, Urbana, IL 61801 USA; [Kong, Hyunjoon] Univ Illinois, Dept Chem & Biomol Engn, Dept Pathobiol, Inst Genom Biol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Kong, H (corresponding author), Univ Illinois, Dept Chem & Biomol Engn, Dept Pathobiol, Inst Genom Biol, Urbana, IL 61801 USA.	hjkong06@illinois.edu			National Science Foundation [CAREER: DMR-0847253, CBET-0939511]	National Science Foundation(National Science Foundation (NSF))	This work was supported by National Science Foundation (CAREER: DMR-0847253 and STC-EBICS Grant CBET-0939511). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Carpenedo RL, 2007, STEM CELLS, V25, P2224, DOI 10.1634/stemcells.2006-0523; Condorelli G, 2001, P NATL ACAD SCI USA, V98, P10733, DOI 10.1073/pnas.191217898; Dang SM, 2002, BIOTECHNOL BIOENG, V78, P442, DOI 10.1002/bit.10220; Darabi R, 2008, NAT MED, V14, P134, DOI 10.1038/nm1705; Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995; Discher DE, 2009, SCIENCE, V324, P1673, DOI 10.1126/science.1171643; Engler AJ, 2008, J CELL SCI, V121, P3794, DOI 10.1242/jcs.029678; Fuchs C, 2012, CELLS TISSUES ORGANS, V195, P377, DOI 10.1159/000328712; Galvez BG, 2008, CELL DEATH DIFFER, V15, P1417, DOI 10.1038/cdd.2008.75; HSU YC, 1972, NATURE, V239, P200, DOI 10.1038/239200a0; Jacot JG, 2010, J BIOMECH, V43, P93, DOI 10.1016/j.jbiomech.2009.09.014; Kong HJ, 2003, BIOMATERIALS, V24, P4023, DOI 10.1016/S0142-9612(03)00295-3; Kong HJ, 2006, P NATL ACAD SCI USA, V103, P18534, DOI 10.1073/pnas.0605960103; Liang Y, 2011, BIOMATERIALS, V32, P9308, DOI 10.1016/j.biomaterials.2011.08.045; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; Mummery C, 2003, CIRCULATION, V107, P2733, DOI 10.1161/01.CIR.0000068356.38592.68; Murphy CL, 2002, TISSUE ENG, V8, P551, DOI 10.1089/107632702760240472; Nieto A, 2007, CELL BIOL INT, V31, P269, DOI 10.1016/j.cellbi.2006.11.006; Rust WL, 2006, STEM CELLS DEV, V15, P889, DOI 10.1089/scd.2006.15.889; ten Berge D, 2008, CELL STEM CELL, V3, P508, DOI 10.1016/j.stem.2008.09.013; TUCKWELL DS, 1993, CRIT REV ONCOL HEMAT, V15, P149, DOI 10.1016/1040-8428(93)90053-7; Walsh S, 2010, CARDIOVASC RES, V86, P365, DOI 10.1093/cvr/cvq005; Wobus AM, 1997, J MOL CELL CARDIOL, V29, P1525, DOI 10.1006/jmcc.1997.0433; WOBUS AM, 1995, TOXICOL IN VITRO, V9, P477, DOI 10.1016/0887-2333(95)00023-2; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568	25	43	46	3	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 14	2014	9	4							e94764	10.1371/journal.pone.0094764	http://dx.doi.org/10.1371/journal.pone.0094764			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI6GP	24732893	Green Submitted, gold, Green Published			2023-01-03	WOS:000336970400095
J	Moss, H; O'Neill, D				Moss, Hilary; O'Neill, Desmond			Aesthetic deprivation in clinical settings	LANCET			English	Editorial Material									[O'Neill, Desmond] Tallaght Hosp, Trinity Ctr Hlth Sci, Ctr Ageing Neurosci & Humanities, Dublin 24, Ireland; [Moss, Hilary] Tallaght Hosp, Natl Ctr Arts & Hlth, Dublin 24, Ireland	Trinity College Dublin; Trinity College Dublin	O'Neill, D (corresponding author), Tallaght Hosp, Trinity Ctr Hlth Sci, Ctr Ageing Neurosci & Humanities, Dublin 24, Ireland.	doneill@tcd.ie	MOSS, HILARY/I-2921-2016; MOSS, HILARY/S-7810-2017; O'Neill, Desmond/D-1486-2013	MOSS, HILARY/0000-0003-4813-2910; MOSS, HILARY/0000-0003-4813-2910; O'Neill, Desmond/0000-0002-5542-9897				Cuypers K, 2012, J EPIDEMIOL COMMUN H, V66, P698, DOI 10.1136/jech.2010.113571; Eco U., 2011, IRAN MED J; Moss H, 2014, J ADV NURS, V70, P121, DOI 10.1111/jan.12175; Saito Yuriko, 2007, EVERYDAY AESTHETICS; Sarkamo T, 2008, BRAIN, V131, P866, DOI 10.1093/brain/awn013; Wikstrom Britt-Maj, 2002, Clin Nurs Res, V11, P22, DOI 10.1177/1054773802011001003	6	25	25	2	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 22	2014	383	9922					1032	1033		10.1016/S0140-6736(14)60507-9	http://dx.doi.org/10.1016/S0140-6736(14)60507-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AD8MV	24665475				2023-01-03	WOS:000333521200013
J	Grimaldi-Bensouda, L; Begaud, B; Rossignol, M; Avouac, B; Lert, F; Rouillon, F; Benichou, J; Massol, J; Duru, G; Magnier, AM; Abenhaim, L; Guillemot, D				Grimaldi-Bensouda, Lamiae; Begaud, Bernard; Rossignol, Michel; Avouac, Bernard; Lert, France; Rouillon, Frederic; Benichou, Jacques; Massol, Jacques; Duru, Gerard; Magnier, Anne-Marie; Abenhaim, Lucien; Guillemot, Didier			Management of Upper Respiratory Tract Infections by Different Medical Practices, Including Homeopathy, and Consumption of Antibiotics in Primary Care: The EPI3 Cohort Study in France 2007-2008	PLOS ONE			English	Article							CONSULTATION RATES	Background: Prescribing of antibiotics for upper respiratory tract infections (URTI) varies substantially in primary care. Objectives: To describe and compare antibiotic and antipyretic/anti-inflammatory drugs use, URTI symptoms' resolution and occurrence of potentially-associated infections in patients seeking care from general practitioners (GPs) who exclusively prescribe conventional medications (GP-CM), regularly prescribe homeopathy within a mixed practice (GP-Mx), or are certified homeopathic GPs (GP-Ho). Method: The EPI3 survey was a nationwide population-based study of a representative sample of 825 GPs and their patients in France (2007-2008). GP recruitment was stratified by self-declared homeopathic prescribing preferences. Adults and children with confirmed URTI were asked to participate in a standardized telephone interview at inclusion, one-, three- and twelve-month follow up. Study outcomes included medication consumption, URTI symptoms' resolution and potentially-associated infections (sinusitis or otitis media/externa) as reported by patients. Analyses included calibration to account for non-respondents and groups were compared using multivate analyses adjusting for baseline differences with a propensity score. Results: 518 adults and children with URTI (79.3% rhinopharyngitis) were included (36.9% response rate comparable between groups). As opposed to GP-CM patients, patients in the GP-Ho group showed significantly lower consumption of antibiotics (Odds ratio (OR) = 0.43, 95% confidence interval (CI): 0.27-0.68) and antipyretic/anti-inflammatory drugs (OR = 0.54, 95% CI: 0.38-0.76) with similar evolution in related symptoms (OR = 1.16, 95% CI: 0.64-2.10). An excess of potentially-associated infections (OR = 1.70, 95% CI: 0.90-3.20) was observed in the GP-Ho group (not statistically significant). No difference was found between GP-CM and GP-Mx patients. Conclusion: Patients who chose to consult GPs certified in homeopathy used less antibiotics and antipyretic/antiinflammatory drugs for URTI than those seen by GPs prescribing conventional medications. No difference was observed in patients consulting GPs within mixed-practice. A non-statistically significant excess was estimated through modelling for associated infections in the GP-Ho group and needs to be further studied.	[Grimaldi-Bensouda, Lamiae; Avouac, Bernard] LA SER, Paris, France; [Grimaldi-Bensouda, Lamiae] Inst Pasteur, Pharmacoepidemiol & Infect Dis Res Grp, Paris, France; [Begaud, Bernard] Univ Bordeaux Segalen, INSERM, U657, Bordeaux, France; [Rossignol, Michel] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada; [Rossignol, Michel] LA SER Ctr Risk Res, Montreal, PQ, Canada; [Lert, France] INSERM, Ctr Epidemiol & Populat Hlth, U1018, Villejuif, France; [Rouillon, Frederic] Univ Paris 05, St Anne Hosp, Paris, France; [Benichou, Jacques] Univ Bordeaux 2, Dept Pharmacol, INSERM, Tondu Hosp Case 41,U657, F-33076 Bordeaux, France; [Benichou, Jacques] Univ Hosp Rouen, Dept Biostat, Rouen, France; [Massol, Jacques] Univ Franche Comte, Fac Med, F-25030 Besancon, France; [Duru, Gerard] Cyklad Grp, Rillieux La Pape, France; [Magnier, Anne-Marie] Univ Paris 06, Fac Med, Paris, France; [Abenhaim, Lucien] Univ London London Sch Hyg & Trop Med, Dept Epidemiol, London WC1E 7HT, England; [Abenhaim, Lucien] LA SER Europe Ltd, London, England; [Guillemot, Didier] Inst Pasteur, Paris, France; [Guillemot, Didier] Univ Paris Ile France Ouest, Fac Med, Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; McGill University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; GHU PARIS Psychiatrie Neurosciences; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; CHU de Rouen; Universite de Franche-Comte; CHU Besancon; UDICE-French Research Universities; Sorbonne Universite; University of London; London School of Hygiene & Tropical Medicine; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Grimaldi-Bensouda, L (corresponding author), LA SER, Paris, France.	Lamiae.grimaldi@la-ser.com	Guillemot, Didier/AAN-3051-2020	Guillemot, Didier/0000-0002-8497-1765; Grimaldi-Bensouda, Lamiae/0000-0003-1952-5467	Laboratoires Boiron, France	Laboratoires Boiron, France	This study was funded by Laboratoires Boiron, France. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altunc U, 2007, MAYO CLIN PROC, V82, P69; Ashworth M, 2005, BRIT J GEN PRACT, V55, P603; Chahwakilian P, 2011, J ANTIMICROB CHEMOTH, V66, P2872, DOI 10.1093/jac/dkr387; Costelloe Ceire, 2010, BMJ, V340, pc2096, DOI 10.1136/bmj.c2096; Davey Peter, 2010, Expert Rev Clin Pharmacol, V3, P667, DOI 10.1586/ecp.10.46; de Sande-Bruinsma NV, 2008, EMERG INFECT DIS, V14, P1722, DOI 10.3201/eid1411.070467; DEVILLE JC, 1992, J AM STAT ASSOC, V87, P376, DOI 10.2307/2290268; Dommergues MA, 2012, SCAND J INFECT DIS, V44, P495, DOI 10.3109/00365548.2012.669840; Ferech M, 2006, J ANTIMICROB CHEMOTH, V58, P423, DOI 10.1093/jac/dkl183; Filipetto Frank A, 2008, Patient Prefer Adherence, V2, P35; Grimaldi-Bensouda L, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000215; Grimaldi-Bensouda L, 2012, PHARMACOEPIDEM DR S, V21, P753, DOI 10.1002/pds.3194; Haidvogl Max, 2007, BMC Complement Altern Med, V7, P7, DOI 10.1186/1472-6882-7-7; Huttner B, 2010, LANCET INFECT DIS, V10, P17, DOI 10.1016/S1473-3099(09)70305-6; Jain Asha, 2003, Homeopathy, V92, P71, DOI 10.1016/S1475-4916(03)00004-3; Kirkby R, 2010, HOMEOPATHY, V99, P69, DOI 10.1016/j.homp.2009.09.001; Kooreman P, 2012, EUR J HEALTH ECON, V13, P769, DOI 10.1007/s10198-011-0330-2; Labarthe G., 2004, DREES ETUDES RESULTA, V315, P1; Lamiae GB, 2010, PHARMACOEPIDEM DR S, V19, P591, DOI 10.1002/pds.1952; Pulcini C, 2013, EUR J PUBLIC HEALTH, V23, P262, DOI 10.1093/eurpub/cks100; Rossi E, 2009, HOMEOPATHY, V98, P2, DOI 10.1016/j.homp.2008.11.005; Smith SM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001831.pub4; Trichard M, 2005, Homeopathy, V94, P3, DOI 10.1016/j.homp.2004.11.021; Vincent S, 2013, J ALTERN COMPLEM MED, V19, P146, DOI 10.1089/acm.2011.0706; Welschen I, 2004, FAM PRACT, V21, P234, DOI 10.1093/fampra/cmh303; Williams-Piehota PA, 2011, ALTERN THER HEALTH M, V17, P22; World Health Organization, 1977, STAT CLASS DIS CAUS	27	32	33	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2014	9	3							e89990	10.1371/journal.pone.0089990	http://dx.doi.org/10.1371/journal.pone.0089990			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AD6ER	24646513	Green Published, gold, Green Submitted			2023-01-03	WOS:000333348500011
J	Du, CYQ; Choi, RCY; Dong, TTX; Lau, DTW; Tsim, KWK				Du, Crystal Y. Q.; Choi, Roy C. Y.; Dong, Tina T. X.; Lau, David T. W.; Tsim, Karl W. K.			Yu Ping Feng San, an Ancient Chinese Herbal Decoction, Regulates the Expression of Inducible Nitric Oxide Synthase and Cyclooxygenase-2 and the Activity of Intestinal Alkaline Phosphatase in Cultures	PLOS ONE			English	Article							KAPPA-B ACTIVATION; DANGGUI BUXUE TANG; URSOLIC ACID; RADIX ASTRAGALI; MUCOSAL DEFENSE; MACROPHAGES; MEDICINE; ALPHA; MODEL; COX-2	Yu Ping Feng San (YPFS), a Chinese herbal decoction comprising Astragali Radix (AR; Huangqi), Atractylodis Macrocephalae Rhizoma (AMR; Baizhu), and Saposhnikoviae Radix (SR; Fangfeng), has been used clinically to treat inflammatory bowel diseases (IBD). Previously, we demonstrated a dual role of YPFS in regulating cytokine release in cultured macrophages. In this study, we elucidated the anti-inflammatory effect of YPFS that is mediated through modulating the expression of three key enzymes involved in IBD: inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and intestinal alkaline phosphatase (IALP). In a lipopolysaccharide (LPS)-induced chronic-inflammation model of cultured murine macrophages, YPFS treatment suppressed the activation of iNOS and COX-2 expression in a dose-dependent manner. Conversely, application of YPFS in cultured small intestinal enterocytes markedly induced the expression of IALP in a time-dependent manner, which might strengthen the intestinal detoxification system. A duality of YPFS in modulating the expression of iNOS and COX-2 was determined here. The expression of iNOS and COX-2 in macrophages was induced by YPFS, and this activation was partially blocked by the NF-kappa B-specific inhibitor BAY 11-7082, indicating a role of NF-kappa B signaling. These YPFS-induced changes in gene regulation strongly suggest that the anti-inflammatory effects of YPFS are mediated through the regulation of inflammatory enzymes.	[Tsim, Karl W. K.] Hong Kong Univ Sci & Technol, Div Life Sci, Hong Kong, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Ctr Chinese Med, Hong Kong, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology	Tsim, KWK (corresponding author), Hong Kong Univ Sci & Technol, Div Life Sci, Hong Kong, Hong Kong, Peoples R China.	botsim@ust.hk	Du, Crystal Yingqing/AAH-5824-2020	Du, Crystal Yingqing/0000-0003-1353-4477; Lau, Tai Wai David/0000-0002-3443-1808; Tsim, Karl/0000-0003-4808-1674	Hong Kong Research Grants Council [T13-607/12R]; GRF [662911, 663012, 662713, N_HKUST629/13]; Hong Kong Jockey Club Charities Trust and Foundation of The Awareness of Nature [TAON12SC01]; ITC [GHP/059/12SZ]	Hong Kong Research Grants Council(Hong Kong Research Grants Council); GRF; Hong Kong Jockey Club Charities Trust and Foundation of The Awareness of Nature; ITC	This research was supported by Hong Kong Research Grants Council Theme-based Research Scheme (T13-607/12R), GRF (662911, 663012, 662713, N_HKUST629/13), The Hong Kong Jockey Club Charities Trust and Foundation of The Awareness of Nature (TAON12SC01) and ITC (GHP/059/12SZ) to Karl Tsim. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bi CWC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051670; Chen X, 2000, J Tradit Chin Med, V20, P302; Chiu SC, 2009, PHYTOTHER RES, V23, P363, DOI 10.1002/ptr.2633; Choi KW, 2003, ANN INTERN MED, V139, P715, DOI 10.7326/0003-4819-139-9-200311040-00005; Du CYQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078622; Fang SP, 2005, BIOL PHARM BULL, V28, P829, DOI 10.1248/bpb.28.829; Gilroy DW, 1998, INFLAMMATION, V22, P509, DOI 10.1023/A:1022350111213; Goldberg RF, 2008, P NATL ACAD SCI USA, V105, P3551, DOI 10.1073/pnas.0712140105; Hoo RLC, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-67; Ikeda Y, 2007, J IMMUNOL, V178, P4854, DOI 10.4049/jimmunol.178.8.4854; Kankuri E, 1999, INFLAMMATION, V23, P141, DOI 10.1023/A:1020241028723; Khan S, 2011, J CELL BIOCHEM, V112, P2179, DOI 10.1002/jcb.23137; Lanas A, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2465; Lee JC, 2007, PHYTOMEDICINE, V14, P390, DOI 10.1016/j.phymed.2006.09.012; Li CQ, 2007, PHYTOTHER RES, V21, P347, DOI 10.1002/ptr.2040; LICHTENBERGER LM, 1983, SCIENCE, V219, P1327, DOI 10.1126/science.6828859; Liu Q, 2013, J ETHNOPHARMACOL, V150, P521, DOI 10.1016/j.jep.2013.08.056; Makino T, 2005, BIOL PHARM BULL, V28, P110, DOI 10.1248/bpb.28.110; Makino T, 2004, BIOL PHARM BULL, V27, P554, DOI 10.1248/bpb.27.554; McCafferty DM, 1997, GASTROENTEROLOGY, V112, P1022, DOI 10.1053/gast.1997.v112.pm9041266; MILLER TA, 1983, AM J PHYSIOL, V245, pG601, DOI 10.1152/ajpgi.1983.245.5.G601; Mizuno H, 1997, GASTROENTEROLOGY, V112, P387, DOI 10.1053/gast.1997.v112.pm9024292; Molnar K, 2012, WORLD J GASTROENTERO, V18, P3254, DOI 10.3748/wjg.v18.i25.3254; Morin MJ, 2001, AM J PHYSIOL-GASTR L, V281, pG552, DOI 10.1152/ajpgi.2001.281.2.G552; NAJID A, 1992, FEBS LETT, V299, P213, DOI 10.1016/0014-5793(92)80117-Y; Newberry RD, 1999, NAT MED, V5, P900, DOI 10.1038/11341; Poon PMK, 2006, AM J CHINESE MED, V34, P13, DOI 10.1142/S0192415X0600359X; Sakamoto C, 1998, J GASTROENTEROL, V33, P618, DOI 10.1007/s005350050147; Shishodia S, 2003, CANCER RES, V63, P4375; Suh N, 1998, CANCER RES, V58, P717; Tuin A, 2009, GUT, V58, P379, DOI 10.1136/gut.2007.128868; Wallace JL, 1997, GASTROENTEROLOGY, V112, P1000, DOI 10.1053/gast.1997.v112.pm9041264; WALLACE JL, 1995, ALIMENT PHARM THERAP, V9, P227; Wallace JL, 2000, GASTROENTEROLOGY, V119, P512, DOI 10.1053/gast.2000.9304; Wang CC, 1999, CANCER LETT, V145, P151, DOI 10.1016/S0304-3835(99)00248-7; Willoughby DA, 2000, LANCET, V355, P646, DOI 10.1016/S0140-6736(99)12031-2; You HJ, 2001, FEBS LETT, V509, P156, DOI 10.1016/S0014-5793(01)03161-1; Zheng KYZ, 2010, J ETHNOPHARMACOL, V132, P259, DOI 10.1016/j.jep.2010.08.029; Zheng YZ, 2010, PLANTA MED, V76, P439, DOI 10.1055/s-0029-1186222; Zhu KY, 2010, J SEP SCI, V33, P3666, DOI 10.1002/jssc.201000498	40	15	16	1	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 26	2014	9	6							e100382	10.1371/journal.pone.0100382	http://dx.doi.org/10.1371/journal.pone.0100382			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK2WP	24967898	Green Submitted, Green Published, gold			2023-01-03	WOS:000338280800038
J	Liu, YB; Pan, JY; Jin, KK; Liu, CL; Wang, J; Chen, L; Chen, L; Yuan, JD				Liu, Yangbo; Pan, Jingye; Jin, Keke; Liu, Cailong; Wang, Jing; Chen, Li; Chen, Lei; Yuan, Jiandong			Analysis of 30 Patients with Acupuncture-Induced Primary Inoculation Tuberculosis	PLOS ONE			English	Article							CUTANEOUS TUBERCULOSIS	Primary inoculation tuberculosis is a skin condition that develops at the site of inoculation of Mycobacterium tuberculosis in tuberculosis-free individuals. This report describes the diagnosis, treatment and >1 year follow-up of 30 patients presenting with acupuncture-induced primary inoculation tuberculosis. Our data provide a deeper insight into this rare route of infection of tuberculosis. We also review effective treatment options.	[Liu, Yangbo; Liu, Cailong; Wang, Jing; Chen, Lei; Yuan, Jiandong] Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou, Zhejiang, Peoples R China; [Pan, Jingye] Wenzhou Med Univ, Affiliated Hosp 1, Intens Care Unit, Wenzhou, Zhejiang, Peoples R China; [Jin, Keke] Wenzhou Med Univ, Wenzhou, Zhejiang, Peoples R China; [Chen, Li] Univ Melbourne, Melbourne, Vic, Australia	Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical University; University of Melbourne	Yuan, JD (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou, Zhejiang, Peoples R China.	chenlei@wzhospital.cn; liuybwz@me.com		yangbo, liu/0000-0002-1180-4974; CHEN, LI/0000-0002-6717-5708				American Thoracic Society C and Infectious Diseases Society of America, 2003, MMWR RECOMMENDATIONS; [Anonymous], 2011, GLOB TUB CONTR 2011; BLOCH AB, 1989, CLIN CHEST MED, V10, P297; Centers for Disease Control and Prevention, MANT TB SKINT FAC GU; Jardin OD, 2010, ENFERM INFEC MICR CL, V28, P596, DOI 10.1016/j.eimc.2009.08.003; GOETTE DK, 1978, ARCH DERMATOL, V114, P567, DOI 10.1001/archderm.114.4.567; HAIM S, 1978, CUTIS, V21, P643; Ho C. K., 2006, Hong Kong Medical Journal, V12, P272; Lee JJ, 2003, INT J TUBERC LUNG D, V7, P569; Lu Hong-qing, 2012, Zhongguo Zhen Jiu, V32, P570; Luca Simona, 2013, Maedica (Bucur), V8, P53; Otu J, 2008, J INFECT DEV COUNTR, V2, P200; Rook G, 2000, ANN NY ACAD SCI, V917, P913; Rook GAW, 1997, PSYCHONEUROENDOCRINO, V22, pS109, DOI 10.1016/S0306-4530(97)00014-0; Saitoh H, 2000, Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi, V11, P19; Tappeiner G, 2008, FITZPATRICKS DERMATO; Tigoulet F, 2003, Bull Soc Pathol Exot, V96, P362; Walker LA, 2002, COMPLEMENT THER MED, V10, P8, DOI 10.1054/ctim.2002.0522; Wong Hoong-Wai, 2005, Australas J Dermatol, V46, P84, DOI 10.1111/j.1440-0960.2005.00147.x; Zhao Xiu-Ping, 2009, Zhongguo Zhen Jiu, V29, P10	20	3	5	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 24	2014	9	6							e100377	10.1371/journal.pone.0100377	http://dx.doi.org/10.1371/journal.pone.0100377			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK7UT	24959854	Green Submitted, Green Published, gold			2023-01-03	WOS:000338633900041
J	Martens, L; Goode, G; Wold, JFH; Beck, L; Martin, G; Perings, C; Stolt, P; Baggerman, L				Martens, Leon; Goode, Grahame; Wold, Johan F. H.; Beck, Lionel; Martin, Georgina; Perings, Christian; Stolt, Pelle; Baggerman, Lucas			Structured Syncope Care Pathways Based on Lean Six Sigma Methodology Optimises Resource Use with Shorter Time to Diagnosis and Increased Diagnostic Yield	PLOS ONE			English	Article							PATIENT SATISFACTION; EMERGENCY-DEPARTMENT; MANAGEMENT	Aim: To conduct a pilot study on the potential to optimise care pathways in syncope/Transient Loss of Consciousness management by using Lean Six Sigma methodology while maintaining compliance with ESC and/or NICE guidelines. Methods: Five hospitals in four European countries took part. The Lean Six Sigma methodology consisted of 3 phases: 1) Assessment phase, in which baseline performance was mapped in each centre, processes were evaluated and a new operational model was developed with an improvement plan that included best practices and change management; 2) Improvement phase, in which optimisation pathways and standardised best practice tools and forms were developed and implemented. Staff were trained on new processes and change-management support provided; 3) Sustaining phase, which included support, refinement of tools and metrics. The impact of the implementation of new pathways was evaluated on number of tests performed, diagnostic yield, time to diagnosis and compliance with guidelines. One hospital with focus on geriatric populations was analysed separately from the other four. Results: With the new pathways, there was a 59% reduction in the average time to diagnosis (p = 0.048) and a 75% increase in diagnostic yield (p = 0.007). There was a marked reduction in repetitions of diagnostic tests and improved prioritisation of indicated tests. Conclusions: Applying a structured Lean Six Sigma based methodology to pathways for syncope management has the potential to improve time to diagnosis and diagnostic yield.	[Martens, Leon; Baggerman, Lucas] Medtron Hosp Solut, Heerlen, Netherlands; [Goode, Grahame] Blackpool Victoria Hosp, Blackpool, England; [Wold, Johan F. H.] Med Ctr Alkmaar, Alkmaar, Netherlands; [Beck, Lionel] Ctr Hosp Univ Caremeau, Nimes, France; [Martin, Georgina] Northern Gen Royal Hallamshire Hosp, Sheffield, S Yorkshire, England; [Perings, Christian] St Marien Hosp, Lunen, Germany; [Stolt, Pelle] MagliaRotta, Basel, Switzerland	Medical Center Of Alkmaar; Universite de Montpellier; CHU de Nimes; St. Marien Hospital	Stolt, P (corresponding author), MagliaRotta, Basel, Switzerland.	pelle.stolt@magliarotta.com		Stolt, Pelle/0000-0001-6270-3332				Baron-Esquivias G, 2010, EUROPACE, V12, P869, DOI 10.1093/europace/euq018; Brignole M, 2006, EUROPACE, V8, P644, DOI 10.1093/europace/eul071; Brignole M, 2010, EUROPACE, V12, P109, DOI 10.1093/europace/eup370; Camacho Fabian, 2006, N C Med J, V67, P409; CAMPBELL JL, 1994, FAM PRACT, V11, P438, DOI 10.1093/fampra/11.4.438; De Bleser Leentje, 2006, J Nurs Manag, V14, P553, DOI 10.1111/j.1365-2934.2006.00702.x; Disertori M, 2003, EUROPACE, V5, P283, DOI 10.1016/S1099-5129(03)00049-7; Edvardsson NG, 2012, ECE 2012 MUN GERM P; Edvardsson N, 2011, EUROPACE, V13, P262, DOI 10.1093/europace/euq418; Farwell DJ, 2004, HEART, V90, P52, DOI 10.1136/heart.90.1.52; Guldner S, 2012, DTSCH ARZTEBL INT, V109, P58, DOI 10.3238/arztebl.2012.0058; Kong MC, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-62; McCarthy F, 2010, IRISH J MED SCI, V179, P551, DOI 10.1007/s11845-010-0497-z; Moya A, 2009, EUR HEART J, V30, P2631, DOI 10.1093/eurheartj/ehp298; NICE, CG 109 TRANS LOSS CO; Niedzwiecki D, 2012, UCLA HLTH SYSTEM; Sanders NA, 2013, PACE, V36, P152, DOI 10.1111/pace.12033; Shen WK, 2004, CIRCULATION, V110, P3636, DOI 10.1161/01.CIR.0000149236.92822.07; Shirazi SAA, 2013, INT J CARE PATHW, V16, P160; Soteriades ES, 2002, NEW ENGL J MED, V347, P878, DOI 10.1056/NEJMoa012407; Womack J.P., 1990, MACHINE CHANGED WORL	21	17	18	0	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2014	9	6							e100208	10.1371/journal.pone.0100208	http://dx.doi.org/10.1371/journal.pone.0100208			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK2VQ	24927475	Green Submitted, Green Published, gold			2023-01-03	WOS:000338278100119
J	Ni, XJ; Liu, SN; Lu, FC; Shi, XG; Guo, XF				Ni, Xiaojia; Liu, Shaonan; Lu, Fuchang; Shi, Xiaogeng; Guo, Xinfeng			Efficacy and Safety of Tai Chi for Parkinson's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials	PLOS ONE			English	Review							QUALITY-OF-LIFE; CHALLENGES INHERENT; RISK-FACTORS; EXERCISE; INTERVENTION; FALLS	Background and Objective: In Parkinson's disease (PD), wearing off and side effects of long-term medication and complications pose challenges for neurologists. Although Tai Chi is beneficial for many illnesses, its efficacy for PD remains uncertain. The purpose of this review was to evaluate the efficacy and safety of Tai Chi for PD. Methods: Randomized controlled trials (RCTs) of Tai Chi for PD were electronically searched by the end of December 2013 and identified by two independent reviewers. The tool from the Cochrane Handbook 5.1 was used to assess the risk of bias. A standard meta-analysis was performed using RevMan 5.2 software. Results: Ten trials with PD of mild-to-moderate severity were included in the review, and nine trials (n = 409) were included in the meta-analysis. The risk of bias was generally high in the blinding of participants and personnel. Improvements in the Unified Parkinson's Disease Rating Scale Part III (mean difference (MD) -4.34, 95% confidence interval (CI) -6.67 - -2.01), Berg Balance Scale (MD: 4.25, 95% CI: 2.83-5.66), functional reach test (MD: 3.89, 95% CI: 1.73-6.04), Timed Up and Go test (MD: -0.75, 95% CI: -1.30 - -0.21), stride length (standardized MD: 0.56, 95% CI: 0.03-1.09), health-related quality of life (standardized MD: -1.10, 95% CI: -1.81- -0.39) and reduction of falls were greater after interventions with Tai Chi plus medication. Satisfaction and safety were high. Intervention with Tai Chi alone was more effective for only a few balance and mobility outcomes. Conclusions: Tai Chi performed with medication resulted in promising gains in mobility and balance, and it was safe and popular among PD patients at an early stage of the disease. This provides a new evidence for PD management. More RCTs with larger sample size that carefully address blinding and prudently select outcomes are needed.	[Ni, Xiaojia] Guangdong Prov Hosp Chinese Med, Res & Dev Dept New Drugs, Guangzhou, Guangdong, Peoples R China; [Ni, Xiaojia; Lu, Fuchang] Guangzhou Univ Chinese Med, Coll Clin Med 2, Guangzhou, Guangdong, Peoples R China; [Liu, Shaonan; Guo, Xinfeng] Guangdong Prov Hosp Chinese Med, Key Unit Methodol Clin Res, Guangzhou, Guangdong, Peoples R China; [Shi, Xiaogeng] Guangdong Prov Hosp Chinese Med, Dept Neurol, Guangzhou, Guangdong, Peoples R China	Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine	Guo, XF (corresponding author), Guangdong Prov Hosp Chinese Med, Key Unit Methodol Clin Res, Guangzhou, Guangdong, Peoples R China.	drguoxinfeng@163.com	Ni, Xiaojia/C-1378-2014; Northcote, Matthew/B-8209-2019; Guo, Xinfeng/AAG-6818-2019; Northcote, Matthew/L-1135-2019; Liu, Shaonan/K-4946-2019; GUO, Xinfeng/AAM-6850-2021	Ni, Xiaojia/0000-0001-6624-5244; Guo, Xinfeng/0000-0003-2699-9740; Liu, Shaonan/0000-0003-4618-5779; Liu, Shaonan/0000-0001-7981-7977	Joint Special Project of Guangdong Provincial Department of Science and Technology-Guangdong Provincial Academy of Chinese Medical Sciences: Construction and Application of Evidence-Based Knowledge Management System for Traditional Chinese Medicine, China [2012A032500009]	Joint Special Project of Guangdong Provincial Department of Science and Technology-Guangdong Provincial Academy of Chinese Medical Sciences: Construction and Application of Evidence-Based Knowledge Management System for Traditional Chinese Medicine, China	This study was supported by Joint Special Project of Guangdong Provincial Department of Science and Technology-Guangdong Provincial Academy of Chinese Medical Sciences: Construction and Application of Evidence-Based Knowledge Management System for Traditional Chinese Medicine (No. 2012A032500009), China. http://pro.gdstc.gov.cn/stms/main.jsp The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amano S, 2013, PARKINSONISM RELAT D, V19, P955, DOI 10.1016/j.parkreldis.2013.06.007; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; Antonini A, 2009, EXPERT REV NEUROTHER, V9, P859, DOI 10.1586/ERN.09.48; Caminiti G, 2011, REHABIL RES PRACT, V2011, DOI 10.1155/2011/761958; Chang Jason Y, 2011, Medsurg Nurs, V20, P63; Choi Hye-Jung, 2013, ISRN Neurol, V2013, P548240, DOI 10.1155/2013/548240; Ding M, 2012, AM J PHYS MED REHAB, V91, P1091, DOI 10.1097/PHM.0b013e31826edd21; Gladfelter BA, 2011, EFFECT TAI CHI EXERC; Goetz CG, 2003, MOVEMENT DISORD, V18, P738, DOI 10.1002/mds.10473; Hackney ME, 2008, GAIT POSTURE, V28, P456, DOI 10.1016/j.gaitpost.2008.02.005; Hackney ME, 2009, PARKINSONISM RELAT D, V15, P644, DOI 10.1016/j.parkreldis.2009.03.003; Hall AM, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471-2474-10-55; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Higginson IJ, 2010, PLOS ONE, V7; Irwin MR, 2008, SLEEP, V31, P1001; Kenny RAM, 2011, J AM GERIATR SOC, V59, P148, DOI 10.1111/j.1532-5415.2010.03234.x; Kerr GK, 2010, NEUROLOGY, V75, P116, DOI 10.1212/WNL.0b013e3181e7b688; Lan C, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/502131; Lee MS, 2008, PARKINSONISM RELAT D, V14, P589, DOI 10.1016/j.parkreldis.2008.02.003; Li FZ, 2008, AM J PUBLIC HEALTH, V98, P1195, DOI 10.2105/AJPH.2007.120402; Li FZ, 2014, MOVEMENT DISORD, V29, P539, DOI 10.1002/mds.25787; Li FZ, 2012, NEW ENGL J MED, V366, P511, DOI 10.1056/NEJMoa1107911; Li JX, 2011, MOTION CONTROL EFFEC; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; National Center for Complementary and Alternative Medicine, 2006, TAI CHI HLTH PURP; National Collaborating Centre for Chronic Conditions (UK), 2006, PARK DIS NAT CLIN GU; Nocera Joe R, 2013, J Yoga Phys Ther, V3, DOI 10.4172/2157-7595.1000137; Okun MS, 2010, EXPERT REV NEUROTHER, V10, P1847, DOI 10.1586/ERN.10.156; Ossig C, 2013, J NEURAL TRANSM, V120, P523, DOI 10.1007/s00702-013-1008-y; OXMAN AD, 1993, ANN NY ACAD SCI, V703, P125, DOI 10.1111/j.1749-6632.1993.tb26342.x; Pahwa R, 2009, CURR MED RES OPIN, V25, P841, DOI [10.1185/03007990902779319, 10.1185/03007990902779319 ]; Pedrosa DJ, 2013, NEUROPSYCH DIS TREAT, V9, P321, DOI [10.2147/NDT.S32302, 10.2147/NDT.532302]; Rudzinska M, 2013, NEUROL NEUROCHIR POL, V47, P431, DOI 10.5114/ninp.2013.38223; Schrag A, 2006, MOVEMENT DISORD, V21, P1200, DOI 10.1002/mds.20914; Shulman LM, 2010, ARCH NEUROL-CHICAGO, V67, P64, DOI 10.1001/archneurol.2009.295; Soh SE, 2012, PHYSIOTHER CAN, V64, P338, DOI 10.3138/ptc.2011-26; Tang JL, 2010, FUNDAMENTALS EVIDENC; Tanner CM, 2014, MOV DISORD; Toh SFM, 2013, HONG KONG J OCCUP TH, V23, P69, DOI 10.1016/j.hkjot.2013.11.001; Tomlinson CL, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5004; Wang Chenchen, 2010, BMC Complement Altern Med, V10, P23, DOI 10.1186/1472-6882-10-23; Wang CC, 2011, RHEUM DIS CLIN N AM, V37, P19, DOI 10.1016/j.rdc.2010.11.002; Wang CC, 2010, NEW ENGL J MED, V363, P743, DOI 10.1056/NEJMoa0912611; Wang J, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/215254; Wayne PM, 2008, J ALTERN COMPLEM MED, V14, P191, DOI 10.1089/acm.2007.7170B; Wayne PM, 2008, J ALTERN COMPLEM MED, V14, P95, DOI 10.1089/acm.2007.7170A; Wayne PM, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-7; WHO, 2006, NEUR DIS PUBL HLTH C; Wood L, 2008, BMJ-BRIT MED J, V336, P601, DOI 10.1136/bmj.39465.451748.AD; Yeh GY, 2010, RESP CARE, V55, P1475; Zhang ZX, 2005, LANCET, V365, P595, DOI 10.1016/S0140-6736(05)70801-1; [朱毅 Zhu Yi], 2011, [中国康复理论与实践, Chinese Journal of Rehabilitation Theory and Practice], V17, P355	53	66	69	0	51	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2014	9	6							e99377	10.1371/journal.pone.0099377	http://dx.doi.org/10.1371/journal.pone.0099377			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK2VQ	24927169	Green Published, gold, Green Submitted			2023-01-03	WOS:000338278100037
J	Watts, G				Watts, Geoff			Richard John Cremer Obituary	LANCET			English	Biographical-Item																			0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 24	2014	383	9931					1800	1800		10.1016/S0140-6736(14)60871-0	http://dx.doi.org/10.1016/S0140-6736(14)60871-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AH6US	24868571				2023-01-03	WOS:000336267800014
J	Reddy, PBJ; Sehrawat, S; Suryawanshi, A; Rajasagi, NK; Khatri, M; Rouse, BT				Reddy, Pradeep B. J.; Sehrawat, Sharvan; Suryawanshi, Amol; Rajasagi, Naveen K.; Khatri, Madhu; Rouse, Barry T.			An Approach to Control Relapse of Inflammatory Lesions after Discontinuation of Primary Therapy	PLOS ONE			English	Article							SIMPLEX-VIRUS TYPE-1; REGULATORY T-CELLS; MULTIPLE-SCLEROSIS; SPHINGOSINE 1-PHOSPHATE; IMMUNOPATHOLOGY; FINGOLIMOD; FTY720; T(H)17; DIFFERENTIATION; STABILIZATION	Long-term treatment with the fungal metabolite drug FTY720 (Fingolimod) was shown to be highly effective in controlling viral immunopathological lesions. However, in this report we show that the anti-inflammatory effect of FTY720 in herpes simplex virus-1 (HSV-1) induced ocular inflammation is lost upon the discontinuation of treatment and lesions rapidly recurred. The lesions that developed after FTY720 treatment withdrawal involved mainly Th17 cells rather than Th1 cells explained in part by differential expression of surface CD103, an integrin that permits migration of effector cells to inflammatory sites. The expression of IL-6, a proinflammatory cytokine involved in the generation of Th17 cells, was found to be increased in FTY treated mice as compared to controls and this effect could be abrogated upon administration of neutralizing antibody to IL-6. Furthermore, IL-17RKO mice failed to show the recurrence of stromal keratitis (SK) lesions upon FTY720 withdrawal. These results indicate that approaches such as neutralization of proinflammatory cytokines might be considered along with FTY720 treatment if interruption of drug therapy becomes necessary.	[Reddy, Pradeep B. J.; Sehrawat, Sharvan; Suryawanshi, Amol; Rajasagi, Naveen K.; Khatri, Madhu; Rouse, Barry T.] Univ Tennessee, Coll Vet Med, Dept Pathobiol, Knoxville, TN 37901 USA	University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture	Rouse, BT (corresponding author), Univ Tennessee, Coll Vet Med, Dept Pathobiol, Knoxville, TN 37901 USA.	btr@utk.edu	Suryawanshi, Amol/J-3787-2019	Suryawanshi, Amol/0000-0001-5031-5818	National Institute of Allergy and Infectious Diseases [AI 063365]; National Eye Institute [EY 005093]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI063365] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by National Institute of Allergy and Infectious Diseases Grant AI 063365 and National Eye Institute Grant EY 005093 to BTR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bettelli E, 2008, NATURE, V453, P1051, DOI 10.1038/nature07036; Brinkmann V, 2010, NAT REV DRUG DISCOV, V9, P883, DOI 10.1038/nrd3248; Cohen JA, 2010, NEW ENGL J MED, V362, P402, DOI 10.1056/NEJMoa0907839; Fujimoto M, 2008, ARTHRITIS RHEUM-US, V58, P3710, DOI 10.1002/art.24126; Garris CS, 2013, NAT IMMUNOL, V14, P1166, DOI 10.1038/ni.2730; Halford WP, 1996, J IMMUNOL, V157, P3542; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Hayashi K, 2006, J GEN VIROL, V87, P2161, DOI 10.1099/vir.0.81772-0; HENDRICKS RL, 1992, J IMMUNOL, V149, P3023; Ingwersen J, 2012, CLIN IMMUNOL, V142, P15, DOI [10.1016/j.clim.2011.05.005, 10.1016/j.clim.2011.10.008]; Kanangat S, 1996, VIROLOGY, V219, P295, DOI 10.1006/viro.1996.0250; Kebir H, 2007, NAT MED, V13, P1173, DOI 10.1038/nm1651; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432; Liu GW, 2010, NAT IMMUNOL, V11, P1047, DOI 10.1038/ni.1939; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; NIEMIALTOWSKI MG, 1992, J IMMUNOL, V149, P3035; NIEMIALTOWSKI MG, 1992, J IMMUNOL, V148, P1864; Penaranda C, 2010, DIABETES, V59, P1461, DOI 10.2337/db09-1129; Rajasagi NK, 2011, J IMMUNOL, V186, P1735, DOI 10.4049/jimmunol.1003456; Reddy PBJ, 2012, J VIROL, V86, P10606, DOI 10.1128/JVI.01391-12; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; Rouse BT, 2010, NAT REV IMMUNOL, V10, P514, DOI 10.1038/nri2802; Rowe AM, 2013, PROG RETIN EYE RES, V32, P88, DOI 10.1016/j.preteyeres.2012.08.002; Sehrawat S, 2008, J VIROL, V82, P6838, DOI 10.1128/JVI.00697-08; Sehrawat S, 2008, J IMMUNOL, V180, P7636, DOI 10.4049/jimmunol.180.11.7636; Suryawanshi A, 2011, J IMMUNOL, V187, P1919, DOI 10.4049/jimmunol.1100736; Tzartos JS, 2008, AM J PATHOL, V172, P146, DOI 10.2353/ajpath.2008.070690; van Loosdregt J, 2013, IMMUNITY, V39, P259, DOI 10.1016/j.immuni.2013.05.018; Veiga-Parga T, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002427; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Yoshida Y, 2011, BIOL PHARM BULL, V34, P933, DOI 10.1248/bpb.34.933; Zhao ZS, 1998, SCIENCE, V279, P1344, DOI 10.1126/science.279.5355.1344	34	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2014	9	5							e98051	10.1371/journal.pone.0098051	http://dx.doi.org/10.1371/journal.pone.0098051			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM0UW	24846129	Green Submitted, Green Published, gold			2023-01-03	WOS:000339563400085
J	Hillman, NH; Gisslen, T; Polglase, GR; Kallapur, SG; Jobe, AH				Hillman, Noah H.; Gisslen, Tate; Polglase, Graeme R.; Kallapur, Suhas G.; Jobe, Alan H.			Ventilation-Induced Increases in EGFR Ligand mRNA Are Not Altered by Intra-Amniotic LPS or Ureaplasma in Preterm Lambs	PLOS ONE			English	Article							ANGIOTENSIN-CONVERTING ENZYME; EPIDERMAL-GROWTH-FACTOR; RESPIRATORY-DISTRESS-SYNDROME; FETAL SHEEP; BRONCHOALVEOLAR LAVAGE; FACTOR-ALPHA; LUNG; GENE; AMPHIREGULIN; PULMONARY	Chorioamnionitis and mechanical ventilation are associated with bronchopulmonary dysplasia (BPD) in preterm infants. Mechanical ventilation at birth activates both inflammatory and acute phase responses. These responses can be partially modulated by previous exposure to intra-amniotic (IA) LPS or Ureaplasma parvum (UP). Epidermal growth factor receptor (EGFR) ligands participate in lung development, and angiotensin converting enzyme (ACE) 1 and ACE2 contribute to lung inflammation. We asked whether brief mechanical ventilation at birth altered EGFR and ACE pathways and if antenatal exposure to IA LPS or UP could modulate these effects. Ewes were exposed to IA injections of UP, LPS or saline multiple days prior to preterm delivery at 85% gestation. Lambs were either immediately euthanized or mechanically ventilated for 2 to 3 hr. IA UP and LPS cause modest changes in the EGFR ligands amphiregulin (AREG), epiregulin (EREG), heparin binding epidermal growth factor (HB-EGF), and betacellulin (BTC) mRNA expression. Mechanical ventilation greatly increased mRNA expression of AREG, EREG, and HB-EGF, with no additional increases resulting from IA LPS or UP. With ventilation AREG and EREG mRNA localized to cells in terminal airspace. EGFR mRNA also increased with mechanical ventilation. IA UP and LPS decreased ACE1 mRNA and increased ACE2 mRNA, resulting in a 4 fold change in the ACE1/ACE2 ratio. Mechanical ventilation with large tidal volumes increased both ACE1 and ACE2 expression. The alterations seen in ACE with IA exposures and EGFR pathways with mechanical ventilation may contribute to the development of BPD in preterm infants.	[Hillman, Noah H.; Gisslen, Tate] St Louis Univ, Div Neonatol, St Louis, MO 63103 USA; [Hillman, Noah H.; Kallapur, Suhas G.; Jobe, Alan H.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Pulm Biol, Cincinnati, OH USA; [Polglase, Graeme R.; Kallapur, Suhas G.; Jobe, Alan H.] Univ Western Australia, Sch Women & Infants Hlth, Perth, WA 6009, Australia; [Polglase, Graeme R.] Monash Univ, Monash Inst Med Res, Ritchie Ctr, Melbourne, Vic 3004, Australia	Saint Louis University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of Western Australia; Monash University	Hillman, NH (corresponding author), St Louis Univ, Div Neonatol, St Louis, MO 63103 USA.	Hillman@slu.edu		Polglase, Graeme/0000-0002-8906-614X	National Institute of Health [R01-HD072842, K08-HL097085, R01-HD12714, R01-HD57869]; Women's and Infants' Research Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD072842, R01HD057869] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD012714] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL097085] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Women's and Infants' Research Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by grants from the National Institute of Health R01-HD072842 (AHJ), K08-HL097085 (NHH), R01-HD12714 (AHJ), R01-HD57869 (SGK), and the Women's and Infants' Research Foundation. TG is at University of Minnesota. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Been JV, 2010, J PEDIATR-US, V156, P10, DOI 10.1016/j.jpeds.2009.07.044; Been JV, 2010, PEDIATR RES, V67, P83, DOI 10.1203/PDR.0b013e3181c13276; Blanchet S, 2004, AM J RESP CELL MOL, V30, P421, DOI 10.1165/rcmb.2003-0281RC; CATTERTON WZ, 1979, PEDIATR RES, V13, P104, DOI 10.1203/00006450-197902000-00004; Collins JJP, 2010, AM J PHYSIOL-LUNG C, V299, pL852, DOI 10.1152/ajplung.00183.2010; Dolinay T, 2006, PHYSIOL GENOMICS, V26, P68, DOI 10.1152/physiolgenomics.00110.2005; Finer NN, 2010, NEW ENGL J MED, V362, P1970, DOI 10.1056/NEJMoa0911783; Fischer HS, 2013, PEDIATRICS, V132, pE1351, DOI 10.1542/peds.2013-1880; Fukumoto J, 2010, AM J PHYSIOL-LUNG C, V298, pL131, DOI 10.1152/ajplung.90576.2008; Gisslen T, 2013, INNATE IMMUN; Hardie WD, 2008, AM J PHYSIOL-LUNG C, V294, pL1217, DOI 10.1152/ajplung.00020.2008; Hillman NH, 2007, AM J RESP CRIT CARE, V176, P575, DOI 10.1164/rccm.200701-051OC; Hillman NH, 2012, PEDIATR RES, V72, P593, DOI 10.1038/pr.2012.135; Hillman NH, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-151; IDELL S, 1987, CHEST, V91, P52, DOI 10.1378/chest.91.1.52; Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712; Ince DA, 2010, GENET TEST MOL BIOMA, V14, P643, DOI 10.1089/gtmb.2010.0072; Jobe AH, 2000, AM J OBSTET GYNECOL, V182, P401, DOI 10.1016/S0002-9378(00)70231-6; Jobe AJ, 1999, PEDIATR RES, V46, P641, DOI 10.1203/00006450-199912000-00001; Kallapur SG, 2007, J IMMUNOL, V179, P8491, DOI 10.4049/jimmunol.179.12.8491; Kallapur SG, 2011, J IMMUNOL, V187, P2688, DOI 10.4049/jimmunol.1100779; Kramer BW, 2007, AM J PHYSIOL-LUNG C, V293, pL345, DOI 10.1152/ajplung.00003.2007; Lasaitiene D, 2004, CLIN PHYSIOL FUNCT I, V24, P65, DOI 10.1046/j.1475-0961.2003.00530.x; Lin CW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053817; Manzo ND, 2012, AM J RESP CELL MOL, V47, P349, DOI 10.1165/rcmb.2011-0257OC; Marchetti A, 2005, J CLIN ONCOL, V23, P857, DOI 10.1200/JCO.2005.08.043; Matsuda A, 2012, BMC MED GENET, V13, DOI 10.1186/1471-2350-13-76; Miettinen PJ, 1997, DEV BIOL, V186, P224, DOI 10.1006/dbio.1997.8593; Morley CJ, 2008, NEW ENGL J MED, V358, P700, DOI 10.1056/NEJMoa072788; Moss TJM, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.06.065; Nogueira-Silva C, 2012, MOL MED, V18, P231, DOI 10.2119/molmed.2011.00210; Ortiz LA, 2002, AM J PHYSIOL-LUNG C, V282, pL1209, DOI 10.1152/ajplung.00144.2001; Polglase GR, 2010, PEDIATR RES, V67, P630, DOI 10.1203/PDR.0b013e3181dbbd18; RAABERG L, 1995, PEDIATR RES, V37, P175, DOI 10.1203/00006450-199502000-00009; Rey-Parra GJ, 2012, J MOL MED, V90, P637, DOI 10.1007/s00109-012-0859-2; Satar M, 2012, J MATERN-FETAL NEO M, V25, P1712, DOI 10.3109/14767058.2012.663017; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Tschumperlin DJ, 2004, NATURE, V429, P83, DOI 10.1038/nature02543; Van Marter LJ, 2002, J PEDIATR-US, V140, P171, DOI 10.1067/mpd.2002.121381; Wang F, 2009, CYTOKINE, V48, P246, DOI 10.1016/j.cyto.2009.08.001; Wang YL, 2009, J PHYSIOL-LONDON, V587, P1739, DOI 10.1113/jphysiol.2008.163899; Wosten-van Asperen RM, 2011, J PATHOL, V225, P618, DOI 10.1002/path.2987; Yerrapureddy A, 2010, CELL PHYSIOL BIOCHEM, V25, P113, DOI 10.1159/000272056; Zhou Y, 2012, J BIOL CHEM, V287, P41991, DOI 10.1074/jbc.M112.356824	45	7	7	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2014	9	4							e96087	10.1371/journal.pone.0096087	http://dx.doi.org/10.1371/journal.pone.0096087			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AL1WP	24788984	Green Published, Green Submitted, gold			2023-01-03	WOS:000338917300025
J	Hira, SK; Mishra, AK; Ray, B; Manna, PP				Hira, Sumit Kumar; Mishra, Avnish Kumar; Ray, Biswajit; Manna, Partha Pratim			Targeted Delivery of Doxorubicin-Loaded Poly (epsilon-caprolactone)-b-Poly (N-vinylpyrrolidone) Micelles Enhances Antitumor Effect in Lymphoma	PLOS ONE			English	Article							DRUG-DELIVERY; INTRACELLULAR RELEASE; BLOCK-COPOLYMERS; CELLS; POLYMERIZATION; NANOPARTICLES; COMBINATION; APOPTOSIS; TISSUE	Background: The present study was motivated by the need to design a safe nano-carrier for the delivery of doxorubicin which could be tolerant to normal cells. PCL63-b-PNVP90 was loaded with doxorubicin (6 mg/ml), and with 49.8% drug loading efficiency; it offers a unique platform providing selective immune responses against lymphoma. Methods: In this study, we have used micelles of amphiphilic PCL63-b-PNVP90 block copolymer as nano-carrier for controlled release of doxorubicin (DOX). DOX is physically entrapped and stabilized in the hydrophobic cores of the micelles and biological roles of these micelles were evaluated in lymphoma. Results: DOX loaded PCL63-b-PNVP90 block copolymer micelles (DOX-PCL63-b-PNVP90) shows enhanced growth inhibition and cytotoxicity against human (K-562, JE6.1 and Raji) and mice lymphoma cells (Dalton's lymphoma, DL). DOX-PCL63-b-PNVP90 demonstrates higher levels of tumoricidal effect against DOX-resistant tumor cells compared to free DOX. DOX-PCL63- b-PNVP90 demonstrated effective drug loading and a pH-responsive drug release character besides exhibiting sustained drug release performance in in-vitro and intracellular drug release experiments. Conclusion: Unlike free DOX, DOX-PCL63-b-PNVP90 does not show cytotoxicity against normal cells. DOX-PCL63-b-PNVP90 prolonged the survival of tumor (DL) bearing mice by enhancing the apoptosis of the tumor cells in targeted organs like liver and spleen.	[Hira, Sumit Kumar; Manna, Partha Pratim] Banaras Hindu Univ, Dept Zool, Fac Sci, Immunobiol Lab, Varanasi 221005, Uttar Pradesh, India; [Mishra, Avnish Kumar; Ray, Biswajit] Banaras Hindu Univ, Dept Chem, Fac Sci, Varanasi 221005, Uttar Pradesh, India	Banaras Hindu University (BHU); Banaras Hindu University (BHU)	Ray, B (corresponding author), Banaras Hindu Univ, Dept Chem, Fac Sci, Varanasi 221005, Uttar Pradesh, India.	biswajitray2003@yahoo.co.in; pp_manna@yahoo.com	HIRA, SUMIT KUMAR/J-9271-2014; Ray, Biswajit/I-9968-2018	HIRA, SUMIT KUMAR/0000-0001-6113-4721; Manna, Partha Pratim/0000-0003-2939-0818	Department of Biotechnology (DBT), New Delhi, India [BT/PR11490/BRB/10/675/2008]; Department of Science and Technology, Government of India [SR/S1/PC-25/2006]; CSIR, New Delhi, India	Department of Biotechnology (DBT), New Delhi, India(Department of Biotechnology (DBT) India); Department of Science and Technology, Government of India(Department of Science & Technology (India)); CSIR, New Delhi, India(Council of Scientific & Industrial Research (CSIR) - India)	Present work is supported by a grant from Department of Biotechnology (DBT), New Delhi, India, No. BT/PR11490/BRB/10/675/2008(PPM). BR gratefully acknowledges the financial support from the Department of Science and Technology, Government of India, through grant no. SR/S1/PC-25/2006. SKH and AKM are recipients of junior & senior research fellowship from CSIR, New Delhi, India. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833; Chaudhuri P, 2009, ACS NANO, V3, P2505, DOI 10.1021/nn900318y; Chung TW, 2004, POLYMER, V45, P1591, DOI 10.1016/j.polymer.2003.12.074; Dash TK, 2012, MOL PHARMACEUT, V9, P2365, DOI 10.1021/mp3001952; Dash TK, 2012, J CONTROL RELEASE, V158, P15, DOI 10.1016/j.jconrel.2011.09.064; Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Gamen S, 2000, EXP CELL RES, V258, P223, DOI 10.1006/excr.2000.4924; Gao Y, 2011, ACS NANO, V5, P9788, DOI 10.1021/nn2033105; GOLDIE H, 1951, CANCER RES, V11, P73; Jeon HJ, 2009, J POLYM SCI POL CHEM, V47, P3078, DOI 10.1002/pola.23396; Kam NWS, 2006, ANGEW CHEM INT EDIT, V45, P577, DOI 10.1002/anie.200503389; KLEIN E, 1954, CANCER RES, V14, P139; Leiva A, 2007, J COLLOID INTERF SCI, V310, P136, DOI 10.1016/j.jcis.2007.01.013; Lele BS, 2002, MACROMOLECULES, V35, P6714, DOI 10.1021/ma020433h; Li Y, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/5/055106; Lorenzo E, 2002, J BIOL CHEM, V277, P10883, DOI 10.1074/jbc.M107442200; Matsumura Y, 2004, BRIT J CANCER, V91, P1775, DOI 10.1038/sj.bjc.6602204; Mishra AK, 2011, MACROMOLECULES, V44, P2465, DOI 10.1021/ma102453h; Patel VK, 2010, POLYM BULL, V65, P97, DOI 10.1007/s00289-009-0185-1; Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387; Reddy LH, 2007, J CONTROL RELEASE, V124, P20, DOI 10.1016/j.jconrel.2007.08.018; Rihova B, 2003, J CONTROL RELEASE, V91, P1, DOI 10.1016/S0168-3659(03)00235-9; Sun HL, 2010, BIOMACROMOLECULES, V11, P848, DOI 10.1021/bm1001069; Takemura G, 2007, PROG CARDIOVASC DIS, V49, P330, DOI 10.1016/j.pcad.2006.10.002; Tolcher AW, 1999, J CLIN ONCOL, V17, P478, DOI 10.1200/JCO.1999.17.2.478; Torchilin V, 2011, ADV DRUG DELIVER REV, V63, P131, DOI 10.1016/j.addr.2010.03.011; Wang YC, 2011, BIOCONJUGATE CHEM, V22, P1939, DOI 10.1021/bc200139n; Weiss B, 2007, BIOCONJUGATE CHEM, V18, P1087, DOI 10.1021/bc060342f; Xu G, 2002, CLIN CANCER RES, V8, P2605	30	55	56	0	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 8	2014	9	4							e94309	10.1371/journal.pone.0094309	http://dx.doi.org/10.1371/journal.pone.0094309			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE7FA	24714166	Green Published, Green Submitted, gold			2023-01-03	WOS:000334160900114
J	Moloney, TM; Witney, AG				Moloney, Tonya M.; Witney, Alice G.			Pressure Pain Thresholds Increase after Preconditioning 1 Hz Repetitive Transcranial Magnetic Stimulation with Transcranial Direct Current Stimulation	PLOS ONE			English	Article							HUMAN MOTOR CORTEX; NEUROPATHIC PAIN; HOMEOSTATIC METAPLASTICITY; INTRACORTICAL INHIBITION; ELECTRICAL-STIMULATION; WRITERS CRAMP; FIBROMYALGIA; TDCS; EXCITABILITY; MODULATION	Background: The primary motor cortex (M1) is an effective target of non-invasive cortical stimulation (NICS) for pain threshold modulation. It has been suggested that the initial level of cortical excitability of M1 plays a key role in the plastic effects of NICS. Objective: Here we investigate whether transcranial direct current stimulation (tDCS) primed 1 Hz repetitive transcranial magnetic stimulation (rTMS) modulates experimental pressure pain thresholds and if this is related to observed alterations in cortical excitability. Method: 15 healthy, male participants received 10 min 1 mA anodal, cathodal and sham tDCS to the left M1 before 15 min 1 Hz rTMS in separate sessions over a period of 3 weeks. Motor cortical excitability was recorded at baseline, post-tDCS priming and post-rTMS through recording motor evoked potentials (MEPs) from right FDI muscle. Pressure pain thresholds were determined by quantitative sensory testing (QST) through a computerized algometer, on the palmar thenar of the right hand pre- and post-stimulation. Results: Cathodal tDCS-primed 1 Hz-rTMS was found to reverse the expected suppressive effect of 1 Hz rTMS on cortical excitability; leading to an overall increase in activity (p < 0.001) with a parallel increase in pressure pain thresholds (p < 0.01). In contrast, anodal tDCS-primed 1 Hz-rTMS resulted in a corresponding decrease in cortical excitability (p < 0.05), with no significant effect on pressure pain. Conclusion: This study demonstrates that priming the M1 before stimulation of 1 Hz-rTMS modulates experimental pressure pain thresholds in a safe and controlled manner, producing a form of analgesia.	[Moloney, Tonya M.] Trinity Coll Dublin, Trinity Coll Inst Neurosci, Dept Physiol, Dublin, Ireland; Trinity Coll Dublin, Trinity Ctr BioEngn, Dublin, Ireland	Trinity College Dublin; Trinity College Dublin	Moloney, TM (corresponding author), Trinity Coll Dublin, Trinity Coll Inst Neurosci, Dept Physiol, Dublin, Ireland.	molonet@tcd.ie	Witney, Alice G./AAH-3107-2021	Witney, Alice G./0000-0002-3726-8479	Department of Physiology, Trinity College, Dublin	Department of Physiology, Trinity College, Dublin	This study was supported by the Department of Physiology, Trinity College, Dublin [http://www.tcd.ie/Graduate_Studies/prospectivestudents/awards/studentships/]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antal A, 2008, CEREB CORTEX, V18, P2701, DOI 10.1093/cercor/bhn032; Antal A, 2010, J PAIN SYMPTOM MANAG, V39, P890, DOI 10.1016/j.jpainsymman.2009.09.023; Bachmann CG, 2010, CLIN NEUROPHYSIOL, V121, P2083, DOI 10.1016/j.clinph.2010.05.005; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; Borckardt JJ, 2011, CLIN J PAIN, V27, P486, DOI 10.1097/AJP.0b013e31820d2733; Borckardt JJ, 2006, J ECT, V22, P259, DOI 10.1097/01.yct.0000244248.40662.9a; Carli G, 2002, PAIN, V100, P259, DOI 10.1016/S0304-3959(02)00297-X; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Cosentino G, 2012, EUR J NEUROSCI, V35, P119, DOI 10.1111/j.1460-9568.2011.07939.x; Di Lazzaro V, 1999, EXP BRAIN RES, V124, P525, DOI 10.1007/s002210050649; FISCHER AA, 1987, PAIN, V30, P115, DOI 10.1016/0304-3959(87)90089-3; Fregni F, 2007, LANCET NEUROL, V6, P188, DOI 10.1016/S1474-4422(07)70032-7; Garcia-Larrea L, 1999, PAIN, V83, P259, DOI 10.1016/S0304-3959(99)00114-1; Garcia-Larrea L, 2007, NEUROIMAGE, V37, pS71, DOI 10.1016/j.neuroimage.2007.05.062; Harstall C, 2003, PAIN CLIN UPDATES, V11, P1, DOI DOI 10.1016/S1070-7212(03)00004-6; Harte SE, 2013, MED BIOL ENG COMPUT, P1, DOI DOI 10.1002/MMA.2899; Lang N, 2004, BIOL PSYCHIAT, V56, P634, DOI 10.1016/j.biopsych.2004.07.017; Lefaucheur JP, 2006, NEUROLOGY, V67, P1568, DOI 10.1212/01.wnl.0000242731.10074.3c; Lucas JM, 2011, PAIN, V152, P1398, DOI 10.1016/j.pain.2011.02.025; Marlow NM, 2013, PAIN PRACT, V13, P131, DOI 10.1111/j.1533-2500.2012.00562.x; Mogil JS, 2012, NAT REV NEUROSCI, V13, P859, DOI 10.1038/nrn3360; Moloney TM, 2013, NEUROSCI LETT, V534, P289, DOI 10.1016/j.neulet.2012.11.049; Mylius V, 2012, PAIN, V153, P1350, DOI 10.1016/j.pain.2012.04.009; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2005, J PHYSIOL-LONDON, V568, P291, DOI 10.1113/jphysiol.2005.092429; O'Connell NE, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008208.pub2; Peyron R, 2007, NEUROIMAGE, V34, P310, DOI 10.1016/j.neuroimage.2006.08.037; Pleger B, 2004, NEUROSCI LETT, V356, P87, DOI 10.1016/j.neulet.2003.11.037; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Ruohonen J, 2012, CLIN NEUROPHYSIOL, V123, P2006, DOI 10.1016/j.clinph.2012.02.082; Schepers RJ, 2010, NEUROSCI BIOBEHAV R, V34, P177, DOI 10.1016/j.neubiorev.2009.10.003; Siebner HR, 1999, NEUROSCI LETT, V262, P133, DOI 10.1016/S0304-3940(99)00056-7; Siebner HR, 1999, NEUROLOGY, V52, P529, DOI 10.1212/WNL.52.3.529; Siebner HR, 2004, J NEUROSCI, V24, P3379, DOI 10.1523/JNEUROSCI.5316-03.2004; Summers J, 2004, NEUROSCI LETT, V368, P197, DOI 10.1016/j.neulet.2004.07.008; Tamura Y, 2004, PAIN, V107, P107, DOI 10.1016/j.pain.2003.10.011; Treede RD, 2002, PAIN, V98, P235, DOI 10.1016/S0304-3959(02)00203-8; Turrigiano GG, 2004, NAT REV NEUROSCI, V5, P97, DOI 10.1038/nrn1327; Turrigiano G, 2011, ANNU REV NEUROSCI, V34, P89, DOI 10.1146/annurev-neuro-060909-153238; Valle Angela, 2009, J Pain Manag, V2, P353; Villamar MF, 2013, J PAIN, V14, P371, DOI 10.1016/j.jpain.2012.12.007; Wiethoff S, 2014, BRAIN STIMUL, V7, P468, DOI 10.1016/j.brs.2014.02.003; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; Zaghi Soroush, 2009, J Pain Manag, V2, P339; Ziemann U, 2008, BRAIN STIMUL, V1, P60, DOI 10.1016/j.brs.2007.08.003	45	8	10	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2014	9	3							e92540	10.1371/journal.pone.0092540	http://dx.doi.org/10.1371/journal.pone.0092540			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AD6GL	24658333	gold, Green Submitted, Green Published			2023-01-03	WOS:000333355300096
J	Wunsch, H; Christiansen, CF; Johansen, MB; Olsen, M; Ali, N; Angus, DC; Sorensen, HT				Wunsch, Hannah; Christiansen, Christian F.; Johansen, Martin B.; Olsen, Morten; Ali, Naeem; Angus, Derek C.; Sorensen, Henrik Toft			Psychiatric Diagnoses and Psychoactive Medication Use Among Nonsurgical Critically Ill Patients Receiving Mechanical Ventilation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-DISTRESS-SYNDROME; NATIONAL-COMORBIDITY-SURVEY; CARE-UNIT SURVIVORS; LONG-TERM OUTCOMES; CRITICAL ILLNESS; INTENSIVE-CARE; SEVERE SEPSIS; PROSPECTIVE COHORT; OLDER AMERICANS; DEPRESSION	IMPORTANCE The relationship between critical illness and psychiatric illness is unclear. OBJECTIVE To assess psychiatric diagnoses and medication prescriptions before and after critical illness. DESIGN, SETTING, AND PARTICIPANTS Population-based cohort study in Denmark of critically ill patients in 2006-2008 with follow-up through 2009, and 2 matched comparison cohorts from hospitalized patients and from the general population. EXPOSURES Critical illness defined as intensive care unit admission with mechanical ventilation. MAIN OUTCOMES AND MEASURES Adjusted prevalence ratios (PRs) of psychiatrist-diagnosed psychiatric illnesses and prescriptions for psychoactive medications in the 5 years before critical illness. For patients with no psychiatric history, quarterly cumulative incidence (risk) and adjusted hazard ratios (HRs) for diagnoses and medications in the following year, using Cox regression. RESULTS Among 24 179 critically ill patients, 6.2% had 1 or more psychiatric diagnoses in the prior 5 years vs 5.4% for hospitalized patients (adjusted PR, 1.31; 95% CI, 1.22-1.42; P<.001) and 2.4% for the general population (adjusted PR, 2.57; 95% CI, 2.41-2.73; P<.001). Five-year preadmission psychoactive prescription rates were similar to hospitalized patients: 48.7% vs 48.8% (adjusted PR, 0.97; 95% CI, 0.95-0.99; P<.001) but were higher than the general population (33.2%; adjusted PR, 1.40; 95% CI, 1.38-1.42; P<.001). Among the 9912 critical illness survivors with no psychiatric history, the absolute risk of new psychiatric diagnoses was low but higher than hospitalized patients: 0.5% vs 0.2% over the first 3 months (adjusted HR, 3.42; 95% CI, 1.96-5.99; P<.001), and the general population cohort (0.02%; adjusted HR, 21.77; 95% CI, 9.23-51.36; P<.001). Risk of new psychoactive medication prescriptions was also increased in the first 3 months: 12.7% vs 5.0% for the hospital cohort (adjusted HR, 2.45; 95% CI, 2.19-2.74; P<.001) and 0.7% for the general population (adjusted HR, 21.09; 95% CI, 17.92-24.82; P<.001). These differences had largely resolved by 9 to 12 months after discharge. CONCLUSIONS AND RELEVANCE Prior psychiatric diagnoses are more common in critically ill patients than in hospital and general population cohorts. Among survivors of critical illness, new psychiatric diagnoses and psychoactive medication use is increased in the months after discharge. Our data suggest both a possible role of psychiatric disease in predisposing patients to critical illness and an increased but transient risk of new psychiatric diagnoses and treatment after critical illness.	[Wunsch, Hannah] Columbia Univ, Coll Phys & Surg, New York, NY USA; [Wunsch, Hannah] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA; [Christiansen, Christian F.; Johansen, Martin B.; Olsen, Morten; Sorensen, Henrik Toft] Aarhus Univ Hosp, Dept Clin Epidemiol, DK-8200 Aarhus N, Denmark; [Christiansen, Christian F.] Aarhus Univ Hosp, Dept Anesthesiol & Intens Care, DK-8200 Aarhus N, Denmark; [Ali, Naeem] Ohio State Univ, Coll Med, Dept Internal Med, Columbus, OH 43210 USA; [Angus, Derek C.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA	Columbia University; Columbia University; Aarhus University; Aarhus University; University System of Ohio; Ohio State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Christiansen, CF (corresponding author), Aarhus Univ Hosp, Dept Clin Epidemiol, Olof Palmes Alle 43-45, DK-8200 Aarhus N, Denmark.	cc@dce.au.dk	Johansen, Martin Nygård/L-6845-2014; Christiansen, Christian/ABE-9423-2021; Angus, Derek C/E-9671-2012; Sorensen, Henrik Toft/Z-6181-2019; Christiansen, Christian Fynbo/B-5870-2014	Johansen, Martin Nygård/0000-0001-9790-0985; Christiansen, Christian/0000-0002-0727-953X; Sorensen, Henrik Toft/0000-0003-4299-7040; Christiansen, Christian Fynbo/0000-0002-0727-953X; ALI, NORA'AINI/0000-0003-1391-2757				Abrams TE, 2010, ARCH SURG-CHICAGO, V145, P947, DOI 10.1001/archsurg.2010.190; Blichert-Hansen Linea, 2013, Clin Epidemiol, V5, P9, DOI 10.2147/CLEP.S37763; Christensen Steffen, 2011, Clin Epidemiol, V3, P203, DOI 10.2147/CLEP.S20247; Christiansen CF, 2011, ACTA ANAESTH SCAND, V55, P962, DOI 10.1111/j.1399-6576.2011.02480.x; Davydow DS, 2008, GEN HOSP PSYCHIAT, V30, P421, DOI 10.1016/j.genhosppsych.2008.05.006; Davydow DS, 2013, AM J GERIAT PSYCHIAT, V21, P887, DOI 10.1016/j.jagp.2013.01.017; Davydow DS, 2009, INTENS CARE MED, V35, P796, DOI 10.1007/s00134-009-1396-5; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Fogelberg DJ, 2012, ARCH PHYS MED REHAB, V93, P1313, DOI 10.1016/j.apmr.2012.04.031; FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819; Friese RS, 2008, CRIT CARE MED, V36, P697, DOI 10.1097/CCM.0B013E3181643F29; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Iwashyna TJ, 2012, J AM GERIATR SOC, V60, P1070, DOI 10.1111/j.1532-5415.2012.03989.x; Iwashyna TJ, 2012, AM J RESP CRIT CARE, V185, P835, DOI 10.1164/rccm.201109-1660OC; Iwashyna TJ, 2010, JAMA-J AM MED ASSOC, V304, P1787, DOI 10.1001/jama.2010.1553; KESSLER RC, 1993, J AFFECT DISORDERS, V29, P85, DOI 10.1016/0165-0327(93)90026-G; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Kildemoes HW, 2011, SCAND J PUBLIC HEALT, V39, P38, DOI 10.1177/1403494810394717; Martin JL, 2012, AM J GERIAT PSYCHIAT, V20, P477, DOI 10.1097/JGP.0b013e31824877c1; MCMICHAEL AJ, 1976, J OCCUP ENVIRON MED, V18, P165, DOI 10.1097/00043764-197603000-00009; Mikkelsen ME, 2012, AM J RESP CRIT CARE, V185, P1307, DOI 10.1164/rccm.201111-2025OC; Munk-Olsen T, 2011, NEW ENGL J MED, V364, P332, DOI 10.1056/NEJMoa0905882; MunkJorgensen P, 1997, DAN MED BULL, V44, P82; Needham DM, 2012, CRIT CARE MED, V40, P502, DOI 10.1097/CCM.0b013e318232da75; Nelson JE, 2004, CRIT CARE MED, V32, P1527, DOI 10.1097/01.CCM.0000129485.08835.5A; Olsen M, 2011, CARDIOL YOUNG, V21, P197, DOI 10.1017/S1047951110001769; Parikh SV, 1997, CAN J PSYCHIAT, V42, P929, DOI 10.1177/070674379704200903; Pedersen CB, 2006, DAN MED BULL, V53, P441; Puthucheary ZA, 2013, JAMA-J AM MED ASSOC, V310, P1591, DOI 10.1001/jama.2013.278481; Rosted E, 2013, GERIATR NURS, V34, P477, DOI 10.1016/j.gerinurse.2013.08.001; Shah FA, 2013, AM J RESP CRIT CARE, V188, P586, DOI 10.1164/rccm.201212-2154OC; Stuart M, 2001, GERONTOLOGIST, V41, P474, DOI 10.1093/geront/41.4.474; Thygesen SK, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-83; VERHAAK PFM, 1993, BRIT J GEN PRACT, V43, P203; Weinert CR, 2001, CHEST, V119, P547, DOI 10.1378/chest.119.2.547; Weinert C, 2006, PSYCHOSOMATICS, V47, P399, DOI 10.1176/appi.psy.47.5.399; Wunsch H, 2010, CRIT CARE, V14, DOI 10.1186/cc8863; Wunsch H, 2010, JAMA-J AM MED ASSOC, V303, P849, DOI 10.1001/jama.2010.216; Zisberg A, 2012, DRUG AGING, V29, P565, DOI 10.2165/11632350-000000000-00000	39	86	88	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 19	2014	311	11					1133	1142		10.1001/jama.2014.2137	http://dx.doi.org/10.1001/jama.2014.2137			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AD1RC	24643603				2023-01-03	WOS:000333010100018
J	Karampampa, K; Andersson, T; Drefahl, S; Ahlbom, A; Modig, K				Karampampa, Korinna; Andersson, Tomas; Drefahl, Sven; Ahlbom, Anders; Modig, Karin			Does Improved Survival Lead to a More Fragile Population: Time Trends in Second and Third Hospital Admissions among Men and Women above the Age of 60 in Sweden	PLOS ONE			English	Article							MORTALITY; EUROPE; DISEASES; HEALTH; OLD	Background:Life expectancy and time to first hospitalization have been prolonged, indicating that people live longer without needing hospital care. Life expectancy increased partially due to improved survival from severe diseases, which, however, could lead to a more fragile population. If so, time to a subsequent hospitalization could decrease. Alternatively, the overall trend of improved health could continue after the first hospitalization, prolonging also the time to subsequent hospitalizations. This study analyzes trends in subsequent hospitalizations among Swedish men and women above the age of 60, relating them to first hospitalization. It also looks at trends in the proportion of never hospitalized. Methods: Individuals were followed in national registers for hospital admissions and deaths between 1972 and 2010. The proportion of never hospitalized individuals at given ages and time points, and the annual change in the risks of first and subsequent hospitalizations, were calculated. Findings: An increase in the proportion of never hospitalized was seen over time. The risks of first as well as subsequent hospitalizations were reduced by almost 10% per decade for both men and women. Improvements were observed mainly for individuals below the ages of 90 and up to the year 2000. Conclusions: The reduction in annual risk of both first and subsequent hospitalizations up to 90 years of age speaks in favor of a postponement of the overall morbidity among the elderly and provides no support for the hypothesis that the population becomes more fragile due to increased survival from severe diseases.	[Karampampa, Korinna; Andersson, Tomas; Drefahl, Sven; Ahlbom, Anders; Modig, Karin] Karolinska Inst, Inst Environm Med, Epidemiol Unit, S-10401 Stockholm, Sweden; [Andersson, Tomas] Stockholm Cty Council, Ctr Occupat & Environm Med, Stockholm, Sweden; [Drefahl, Sven] Stockholm Univ, Dept Sociol, Demog Unit, S-10691 Stockholm, Sweden	Karolinska Institutet; Stockholm County Council; Stockholm University	Karampampa, K (corresponding author), Karolinska Inst, Inst Environm Med, Epidemiol Unit, S-10401 Stockholm, Sweden.	korinna.karampampa@ki.se	Modig, Karin/H-1542-2014	Drefahl, Sven/0000-0003-4533-7558; Modig, Karin/0000-0002-5151-4867	Swedish Research Council for Health; Working Life and Social Research (Forskningsradet for halsa, arbetsliv och valfard, FAS) [2011-0843]; Swedish Society of Medicine (Svenska Lakaresallskapet)	Swedish Research Council for Health; Working Life and Social Research (Forskningsradet for halsa, arbetsliv och valfard, FAS); Swedish Society of Medicine (Svenska Lakaresallskapet)	Funding was received from the Swedish Research Council for Health, Working Life and Social Research (Forskningsradet for halsa, arbetsliv och valfard, FAS) grant number: 2011-0843), and the Swedish Society of Medicine (Svenska Lakaresallskapet). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2013, CAUS DEATH REG; Bosetti C, 2013, ANN ONCOLOGY OFFICIA; Bronnum-Hansen H, 2009, AGE AGEING, V38, P47, DOI 10.1093/ageing/afn239; Cooper R, 2000, CIRCULATION, V102, P3137; Drefahl S, 2012, J INTERN MED, V272, P100, DOI 10.1111/j.1365-2796.2012.02518.x; Herberts P., 2011, ANN REPORT; Holosko MJ, 2009, SOC WORK PUBLIC HLTH, V24, P210, DOI 10.1080/19371910802595299; Karampampa K, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003447; Karim-Kos HE, 2008, EUR J CANCER, V44, P1345, DOI 10.1016/j.ejca.2007.12.015; Kesteloot H, 2006, EUR HEART J, V27, P107, DOI 10.1093/eurheartj/ehi511; Larsson K, 2006, SCAND J PUBLIC HEALT, V34, P185, DOI 10.1080/14034950600677253; Levi F, 2009, EUR J CARDIOV PREV R, V16, P333, DOI 10.1097/HJR.0b013e328325d67d; Modig K, 2013, INT J EPIDEMIOLOGY; Modig K, 2013, INT J EPIDEMIOL, V42, P914, DOI 10.1093/ije/dyt035; Modig K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064928; National Board of Health and Welfare [Socialstyrelsen], 2011, INP DIS SWED 1987 20; National Board of Health and Welfare [Socialstyrelsen], 2013, PAT REG; Qiu CX, 2013, NEUROLOGY, V80, P1888, DOI 10.1212/WNL.0b013e318292a2f9; Rasmussen Lene Juel, 2011, Mech Ageing Dev, V132, P522, DOI 10.1016/j.mad.2011.07.004; Socialstyrelsen [National Board of Health and Welfare], 2012, PAT 2010 DRG PERSP; Statistics Sweden, 2013, LONG INT DAT HLTH IN; Statistics Sweden [Statistika Centralbyran], 2013, TOT POP REG; Vaupel JW, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000128	23	10	10	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 9	2014	9	6							e99034	10.1371/journal.pone.0099034	http://dx.doi.org/10.1371/journal.pone.0099034			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI8LF	24911650	gold, Green Published, Green Submitted			2023-01-03	WOS:000337165600036
J	Cheah, KY; Howarth, GS; Bindon, KA; Kennedy, JA; Bastian, SEP				Cheah, Ker Y.; Howarth, Gordon S.; Bindon, Keren A.; Kennedy, James A.; Bastian, Susan E. P.			Low Molecular Weight Procyanidins from Grape Seeds Enhance the Impact of 5-Fluorouracil Chemotherapy on Caco-2 Human Colon Cancer Cells	PLOS ONE			English	Article							GROWTH-FACTOR; PROANTHOCYANIDINS; ANTIOXIDANT; APOPTOSIS; ANGIOGENESIS; POLYPHENOLS; EXPRESSION; FRACTIONS; PATHWAYS; RECEPTOR	Objective: Grape seed procyanidins (PC) are flavan-3-ol oligomers and polymers known for their biological activity in the gut. Grape seed extract (GSE) have been reported to reduce intestinal injury in a rat model of mucositis. We sought to investigate effects of purified PC fractions differing in mean degree of polymerization (mDP) combined with 5-Fluorouracil (5-FU) chemotherapy on the viability of colon cancer cells (Caco-2). Design: SixPC fractions (F1-F6) were isolated from Cabernet Sauvignon seeds at two ripeness stages: pre-veraison unripe (immature) and ripe (mature), utilizing step gradient, low-pressure chromatography on a Sephadex LH-20 resin. Fractions were tested on Caco-2 cells, alone and in combination with 5-FU. Eluted fractions were characterized by phloroglucinolysis and gel permeation chromatography. Cell viability was determined by the 3-(4,5-Dimethylthiazol-2yl)-2,5-diphenyl-tetrazolium bromide) (MTT) assay. Results: All isolated fractions significantly reduced Caco-2 cell viability compared to the control (P<0.05), but F2 and F3 (mDP 2-6) were the most active fractions (immature F2 = 32% mDP 2.4, F3 = 35% mDP 5.8 and mature F2 = 13% mDP 3.6 and F3 = 17% mDP 5.9; percentage of viable cells remaining) on Caco-2 cells. When combined with 5-FU, immature fractions F1-F3 enhanced the cell toxicity effects of 5-FU by 27-73% (P<0.05). Mature seed PC fractions (F1-F4) significantly enhanced the toxicity of 5-FU by 60-83% against Caco-2 cells (P<0.05). Moreover, some fractions alone were more potent at decreasing viability in Caco-2 cells (P<0.05; immature fractions = 65-68% and mature fractions = 83-87%) compared to 5-FU alone (37%). Conclusions: PCs of mDP 2-6 (immature F1-F3 and mature F1 and F4) not only enhanced the impact of 5-FU in killing Caco-2 cells, but also surpassed standard 5-FU chemotherapy as an anti-cancer agent. The bioactivity of PC is therefore attributed primarily to lower molecular weight PCs.	[Cheah, Ker Y.; Bastian, Susan E. P.] Sch Agr Food & Wine, Wine Sci & Business Grp, Glen Osmond, SA, Australia; [Cheah, Ker Y.; Howarth, Gordon S.] Children Youth & Womens Hlth Serv, Ctr Paediat & Adolescent Gastroenterol, Adelaide, SA, Australia; [Howarth, Gordon S.] Univ Adelaide, Sch Anim & Vet Sci, Adelaide, SA 5005, Australia; [Bindon, Keren A.; Kennedy, James A.] Australian Wine Res Inst, Adelaide, SA, Australia; [Kennedy, James A.] Calif State Univ Fresno, Dept Viticulture & Enol, Fresno, CA 93740 USA	University of Adelaide; Australian Wine Research Institute; California State University System; California State University Fresno	Bastian, SEP (corresponding author), Sch Agr Food & Wine, Wine Sci & Business Grp, Waite Campus,PMB 1, Glen Osmond, SA, Australia.	sue.bastian@adelaide.edu.au	Howarth, Gordon/AAM-8699-2020; Kennedy, James A/A-1636-2012	Howarth, Gordon/0000-0001-6979-6084; Kennedy, James A/0000-0002-5453-8469; Bastian, Susan/0000-0002-8790-2044	South Australian Health and Medical Research Institute Cancer Council	South Australian Health and Medical Research Institute Cancer Council	Professor Gordon Howarth is supported by a South Australian Health and Medical Research Institute Cancer Council Senior Research Fellowship. The current study was performed under the collaboration between Wine Science and Business Group, The University of Adelaide and Australian Wine Research Institute (AWRI). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Actis-Goretta L, 2008, J NUTR BIOCHEM, V19, P797, DOI 10.1016/j.jnutbio.2007.10.004; Benzie IFF, 1999, J AGR FOOD CHEM, V47, P633, DOI 10.1021/jf9807768; Bindon KA, 2011, J AGR FOOD CHEM, V59, P2696, DOI 10.1021/jf1047207; Bindon KA, 2010, J AGR FOOD CHEM, V58, P2520, DOI 10.1021/jf9037453; Cheah KY, 2013, DIGEST DIS SCI, V58, P970, DOI 10.1007/s10620-012-2464-1; Cheah KY, 2009, CANCER BIOL THER, V8, P382, DOI 10.4161/cbt.8.4.7453; Cheah KY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085184; Choi KC, 2011, BIOCHEM J, V433, P235, DOI 10.1042/BJ20100980; Choy YY, 2013, J AGR FOOD CHEM, V61, P121, DOI 10.1021/jf301939e; Deprez S, 2001, ANTIOXID REDOX SIGN, V3, P957, DOI 10.1089/152308601317203503; Dinicola S, 2012, INT J MOL SCI, V13, P651, DOI 10.3390/ijms13010651; Dinicola S, 2010, BRIT J NUTR, V104, P824, DOI 10.1017/S0007114510001522; Du Y, 2007, J AGR FOOD CHEM, V55, P1695, DOI 10.1021/jf063071b; Engelbrecht AM, 2007, CANCER LETT, V258, P144, DOI 10.1016/j.canlet.2007.08.020; Faria A, 2006, J AGR FOOD CHEM, V54, P2392, DOI 10.1021/jf0526487; Huang SS, 2012, INT J MOL MED, V30, P1410, DOI 10.3892/ijmm.2012.1147; Huang SS, 2012, NUTR RES, V32, P530, DOI 10.1016/j.nutres.2012.05.012; Huynh-Delerme C, 2005, TOXICOL IN VITRO, V19, P439, DOI 10.1016/j.tiv.2004.08.003; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Kaur M, 2008, NUTR CANCER, V60, P2, DOI 10.1080/01635580802381295; Keefe DM, 2008, EXPERT OPIN EMERG DR, V13, P511, DOI [10.1517/14728214.13.3.511, 10.1517/14728214.13.3.511 ]; Kennedy JA, 2003, J CHROMATOGR A, V995, P99, DOI 10.1016/S0021-9673(03)00420-5; Kern M, 2005, MOL NUTR FOOD RES, V49, P317, DOI 10.1002/mnfr.200400086; Lizarraga D, 2007, FEBS J, V274, P4802, DOI 10.1111/j.1742-4658.2007.06010.x; Nomoto H, 2004, NUTR CANCER, V49, P81, DOI 10.1207/s15327914nc4901_11; Park SY, 2011, J MED FOOD, V14, P9, DOI 10.1089/jmf.2010.1264; Pierini R, 2008, MOL NUTR FOOD RES, V52, P1399, DOI 10.1002/mnfr.200700513; Poncet-Legrand C, 2003, LANGMUIR, V19, P10563, DOI 10.1021/la034927z; RiceEvans CA, 1996, FREE RADICAL BIO MED, V20, P933, DOI 10.1016/0891-5849(95)02227-9; Scalbert A, 2002, BIOMED PHARMACOTHER, V56, P276, DOI 10.1016/S0753-3322(02)00205-6; Spencer JPE, 2001, BIOCHEM BIOPH RES CO, V285, P588, DOI 10.1006/bbrc.2001.5211; Torres JL, 2002, J AGR FOOD CHEM, V50, P7548, DOI 10.1021/jf025868i; Ugartondo V, 2007, CHEM RES TOXICOL, V20, P1543, DOI 10.1021/tx700253y; Van Cutsem EJD, 2005, ANN ONCOL, V16, P16, DOI 10.1093/annonc/mdi808; Wang YH, 2011, INT IMMUNOPHARMACOL, V11, P1620, DOI 10.1016/j.intimp.2011.05.024	35	37	37	0	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2014	9	6							e98921	10.1371/journal.pone.0098921	http://dx.doi.org/10.1371/journal.pone.0098921			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AP1YS	24905821	Green Published, gold, Green Submitted			2023-01-03	WOS:000341869000079
J	Kim, HG; Lee, JS; Choi, MK; Han, JM; Son, CG				Kim, Hyeong-Geug; Lee, Jin-Seok; Choi, Min-Kyung; Han, Jong-Min; Son, Chang-Gue			Ethanolic Extract of Astragali Radix and Salviae Radix Prohibits Oxidative Brain Injury by Psycho-Emotional Stress in Whisker Removal Rat Model	PLOS ONE			English	Article							KAPPA-B; INFLAMMATION; DISORDERS; MYELOPHIL; RESPONSES; MICE; DEPRESSION; DISEASE; DAMAGE; CELLS	Myelophil, an ethanolic extract of Astragali Radix and Salviae Radix, has been clinically used to treat chronic fatigue and stress related disorders in South Korea. In this study, we investigated the protective effects of Myelophil on a whisker removal-induced psycho-emotional stress model. SD rats were subjected to whisker removal after oral administration of Myelophil or ascorbic acid for consecutive 4 days. Whisker removal considerably increased total reactive oxygen species in serum levels as well as cerebral cortex and hippocampal regions in brain tissues. Lipidperoxidation levels were also increased in the cerebral cortex, hippocampus regions, and brain tissue injuries as shown in histopathology and immunohistochemistry. However, Myelophil significantly ameliorated these alterations, and depletion of glutathione contents in both cerebral cortex and hippocampus regions respectively. Serum levels of corticosterone and adrenaline were notably altered after whisker removal stress, whereas these abnormalities were significantly normalized by pre-treatment with Myelophil. The NF-kappa B was notably activated in both cerebral cortex and hippocampus after whisker removal stress, while it was efficiently blocked by pre-treatment with Myelophil. Myelophil also significantly normalizes alterations of tumor necrosis factor-alpha, interleukin (IL)-1 beta, IL-6 and interferon-gamma in both gene expressions and protein levels. These results suggest that Myelophil has protective effects on brain damages in psycho-emotional stress, and the underlying mechanisms involve regulation of inflammatory proteins, especially NF-kappa B modulation.	[Kim, Hyeong-Geug; Lee, Jin-Seok; Choi, Min-Kyung; Han, Jong-Min; Son, Chang-Gue] Daejeon Univ, Oriental Med Coll, Daejeon Oriental Hosp, Liver & Immunol Res Ctr, Taejon, South Korea	Daejeon University	Son, CG (corresponding author), Daejeon Univ, Oriental Med Coll, Daejeon Oriental Hosp, Liver & Immunol Res Ctr, Taejon, South Korea.	ckson@dju.ac.kr	son, chang gue/ABC-2215-2021		Oriental Medicine R&D Project, Ministry of Health Welfare [B100045]; KM-Based Herbal Drug Research Group of Korea Institute of Oriental Medicine, Rep. of Korea [K13101]	Oriental Medicine R&D Project, Ministry of Health Welfare; KM-Based Herbal Drug Research Group of Korea Institute of Oriental Medicine, Rep. of Korea	This study was supported by a grant (B100045) from the Oriental Medicine R&D Project, Ministry of Health & Welfare, and a grant (K13101) from KM-Based Herbal Drug Research Group of Korea Institute of Oriental Medicine, Rep. of Korea. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ashcraft KA, 2008, BRAIN BEHAV IMMUN, V22, P1231, DOI 10.1016/j.bbi.2008.06.008; Braun S, 2000, NEUROSCI LETT, V295, P101, DOI 10.1016/S0304-3940(00)01603-7; Busciglio J, 1998, ANN NY ACAD SCI, V851, P429, DOI 10.1111/j.1749-6632.1998.tb09021.x; Chen T, 2011, BRAIN RES BULL, V84, P163, DOI 10.1016/j.brainresbull.2010.11.015; Cho JH, 2009, COMPLEMENT THER MED, V17, P141, DOI 10.1016/j.ctim.2008.11.003; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Colaianna M, 2013, ANTIOXID REDOX SIGN, V18, P1385, DOI 10.1089/ars.2012.4569; Dimitrijevic M, 2012, IMMUNOL RES, V52, P64, DOI 10.1007/s12026-012-8275-9; Dinkel K, 2002, J NEUROVIROL, V8, P513, DOI 10.1080/13550280290100914; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; Hayashi I, 2007, MUTAT RES-GEN TOX EN, V631, P55, DOI 10.1016/j.mrgentox.2007.04.006; HERBERT V, 1994, STEM CELLS, V12, P289, DOI 10.1002/stem.5530120305; Hu J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050764; Ishiwata H, 2005, NEUROSCIENCE, V133, P893, DOI 10.1016/j.neuroscience.2005.03.048; Jaremka LM, 2013, DEPRESS ANXIETY, V30, P288, DOI 10.1002/da.22078; KAMAL AAM, 1989, ENVIRON RES, V49, P173, DOI 10.1016/S0013-9351(89)80062-3; Kambayashi Y, 2009, J CLIN BIOCHEM NUTR, V44, P46, DOI 10.3164/jcbn.08-162; Kim HG, 2013, J ETHNOPHARMACOL, V148, P505, DOI 10.1016/j.jep.2013.04.046; Koolhaas JM, 2011, NEUROSCI BIOBEHAV R, V35, P1291, DOI 10.1016/j.neubiorev.2011.02.003; Laflamme N, 1999, J NEUROSCI, V19, P10923, DOI 10.1523/JNEUROSCI.19-24-10923.1999; Lederbogen F, 2012, NERVENARZT, V83, P1448, DOI 10.1007/s00115-012-3666-7; Lee JS, 2012, PROG NEURO-PSYCHOPH, V39, P339, DOI 10.1016/j.pnpbp.2012.07.006; Oka T, 2013, BIOPSYCHOSOC MED, V7, DOI 10.1186/1751-0759-7-7; Rahman MM, 2008, J AGR FOOD CHEM, V56, P7545, DOI 10.1021/jf800930s; Rinwa P, 2013, ARCH PHARM RES, DOI 10.1007/s12272-013-0205-4; Sato H, 2010, J CLIN BIOCHEM NUTR, V47, P224, DOI 10.3164/jcbn.10-58; Sinha R, 2003, PSYCHOPHARMACOLOGY, V170, P62, DOI 10.1007/s00213-003-1525-8; Talwar SK, 2002, NATURE, V417, P37, DOI 10.1038/417037a; Traeger L, 2013, ONCOL NURS FORUM, V40, pE327, DOI 10.1188/13.ONF.E327-E336; Videbech P, 2001, UGESKRIFT LAEGER, V163, P6568; Wang L, 2007, EVID-BASED COMPL ALT, V4, P195, DOI 10.1093/ecam/nel080; WHEELER CR, 1990, ANAL BIOCHEM, V184, P193, DOI 10.1016/0003-2697(90)90668-Y; Wong DL, 2008, ANN NY ACAD SCI, V1148, P249, DOI 10.1196/annals.1410.048; Zhang WJ, 2003, THROMB HAEMOSTASIS, V90, P904, DOI 10.1160/TH03-03-0136	36	11	12	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2014	9	5							e98329	10.1371/journal.pone.0098329	http://dx.doi.org/10.1371/journal.pone.0098329			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI4TS	24870587	Green Submitted, Green Published, gold			2023-01-03	WOS:000336858300036
J	Kraitsy, K; Uecal, M; Grossauer, S; Bruckmann, L; Pfleger, F; Ropele, S; Fazekas, F; Gruenbacher, G; Patz, S; Absenger, M; Porubsky, C; Smolle-Juettner, F; Tezer, I; Molcanyi, M; Fasching, U; Schaefer, U				Kraitsy, Klaus; Uecal, Muammer; Grossauer, Stefan; Bruckmann, Lukas; Pfleger, Florentina; Ropele, Stefan; Fazekas, Franz; Gruenbacher, Gerda; Patz, Silke; Absenger, Markus; Porubsky, Christian; Smolle-Juettner, Freyja; Tezer, Irem; Molcanyi, Marek; Fasching, Ulrike; Schaefer, Ute			Repetitive Long-Term Hyperbaric Oxygen Treatment (HBOT) Administered after Experimental Traumatic Brain Injury in Rats Induces Significant Remyelination and a Recovery of Sensorimotor Function	PLOS ONE			English	Article							MYELIN BASIC-PROTEIN; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; SOMATOSENSORY-EVOKED POTENTIALS; ISCHEMIA-REPERFUSION INJURY; FLUID-PERCUSSION INJURY; MITOCHONDRIAL-FUNCTION; CEREBRAL-ISCHEMIA; HEAD-INJURY; THERAPY; MODEL	Cells in the central nervous system rely almost exclusively on aerobic metabolism. Oxygen deprivation, such as injury-associated ischemia, results in detrimental apoptotic and necrotic cell loss. There is evidence that repetitive hyperbaric oxygen therapy (HBOT) improves outcomes in traumatic brain-injured patients. However, there are no experimental studies investigating the mechanism of repetitive long-term HBOT treatment-associated protective effects. We have therefore analysed the effect of long-term repetitive HBOT treatment on brain trauma-associated cerebral modulations using the lateral fluid percussion model for rats. Trauma-associated neurological impairment regressed significantly in the group of HBO-treated animals within three weeks post trauma. Evaluation of somatosensory-evoked potentials indicated a possible remyelination of neurons in the injured hemisphere following HBOT. This presumption was confirmed by a pronounced increase in myelin basic protein isoforms, PLP expression as well as an increase in myelin following three weeks of repetitive HBO treatment. Our results indicate that protective long-term HBOT effects following brain injury is mediated by a pronounced remyelination in the ipsilateral injured cortex as substantiated by the associated recovery of sensorimotor function.	[Kraitsy, Klaus; Uecal, Muammer; Pfleger, Florentina; Gruenbacher, Gerda; Patz, Silke; Fasching, Ulrike; Schaefer, Ute] Med Univ Graz, Res Unit Expt Neurotraumatol, Graz, Austria; [Grossauer, Stefan; Bruckmann, Lukas] Med Univ Graz, Dept Neurosurg, Graz, Austria; [Ropele, Stefan; Fazekas, Franz] Med Univ Graz, Clin Div Gen Neurol, Graz, Austria; [Absenger, Markus] Med Univ Graz, Med Res Ctr, Core Facil Microscopy, Graz, Austria; [Porubsky, Christian; Smolle-Juettner, Freyja; Tezer, Irem] Med Univ Graz, Dept Surg, Div Thorac & Hyperbar Surg, Graz, Austria; [Molcanyi, Marek] Univ Cologne, Dept Neurosurg, D-50931 Cologne, Germany; [Molcanyi, Marek] Univ Cologne, Inst Neurophysiol, D-50931 Cologne, Germany	Medical University of Graz; Medical University of Graz; Medical University of Graz; Medical University of Graz; Medical University of Graz; University of Cologne; University of Cologne	Schaefer, U (corresponding author), Med Univ Graz, Res Unit Expt Neurotraumatol, Graz, Austria.	ute.schaefer@medunigraz.at						Adamides AA, 2009, ACTA NEUROCHIR, V151, P1399, DOI 10.1007/s00701-009-0398-y; Amantini A, 2008, EUR J ANAESTH, V25, P196, DOI 10.1017/S0265021507003183; Ames A, 2000, BRAIN RES REV, V34, P42, DOI 10.1016/S0165-0173(00)00038-2; Asou Hiroaki, 1995, Keio Journal of Medicine, V44, P47; Barrett KF, 2004, UNDERSEA HYPERBAR M, V31, P395; Bentz K, 2010, CELL PHYSIOL BIOCHEM, V26, P821, DOI 10.1159/000323991; Beynon C, 2012, J NEUROTRAUM, V29, P2109, DOI 10.1089/neu.2012.2365; Brkic P, 2012, BRAIN INJ; Butt AM, 1997, J NEUROSCI RES, V48, P588; Calvert JW, 2002, BRAIN RES, V951, P1, DOI 10.1016/S0006-8993(02)03094-9; Campbell J.N., 2011, J NEUROTRAUMA; Capello E, 1997, ANN NEUROL, V41, P797, DOI 10.1002/ana.410410616; Chang CF, 2000, EXP NEUROL, V166, P298, DOI 10.1006/exnr.2000.7506; Chang JJJ, 2009, CRIT CARE MED, V37, P283, DOI 10.1097/CCM.0b013e318192fbd7; CONTRERAS FL, 1988, J NEUROSURG, V68, P137, DOI 10.3171/jns.1988.68.1.0137; Crawford AH, 2013, J COMP PATHOL, V149, P242, DOI 10.1016/j.jcpa.2013.05.004; Cummins FJ, 2010, J CARDIOVASC TRANSL, V3, P683, DOI 10.1007/s12265-010-9221-7; Daugherty WP, 2004, J NEUROSURG, V101, P499, DOI 10.3171/jns.2004.101.3.0499; DeBruin LS, 2006, BIOCHEM CELL BIOL, V84, P993, DOI 10.1139/O06-180; Dell'Acqua ML, 2012, NEUROPATH APPL NEURO, V38, P454, DOI 10.1111/j.1365-2990.2011.01228.x; DEROSBO NK, 1991, DEV NEUROSCI-BASEL, V13, P34; Eovaldi B, 2010, NEUROPSYCH DIS TREAT, V6, P785, DOI 10.2147/NDT.S16071; Franklin RJM, 2008, NAT REV NEUROSCI, V9, P839, DOI 10.1038/nrn2480; Freund P, 2012, J NEUROL NEUROSUR PS, V83, P629, DOI 10.1136/jnnp-2011-301875; Furlonger A J, 2000, Crit Care Resusc, V2, P246; Gambi D, 1996, ITAL J NEUROL SCI, V17, P23, DOI 10.1007/BF01995706; Golden Z, 2006, DISABIL REHABIL, V28, P1379, DOI 10.1080/09638280600638364; Golden ZL, 2002, INT J NEUROSCI, V112, P119, DOI 10.1080/00207450212027; Grin'kina NM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053775; Harauz G, 2013, J NEUROCHEM, V125, P334, DOI 10.1111/jnc.12195; Harch PG, 2007, BRAIN RES, V1174, P120, DOI 10.1016/j.brainres.2007.06.105; Hardy P, 2007, J NEUROL SCI, V253, P94, DOI 10.1016/j.jns.2006.12.005; HOMAN RW, 1987, ELECTROEN CLIN NEURO, V66, P376, DOI 10.1016/0013-4694(87)90206-9; Huchzermeyer C, 2013, J CEREBR BLOOD F MET, V33, P263, DOI 10.1038/jcbfm.2012.165; Hyder F, 2006, J CEREBR BLOOD F MET, V26, P865, DOI 10.1038/sj.jcbfm.9600263; IULIANO BA, 1994, J NEUROL SCI, V123, P186, DOI 10.1016/0022-510X(94)90222-4; Kann O, 2007, AM J PHYSIOL-CELL PH, V292, pC641, DOI 10.1152/ajpcell.00222.2006; Kao HK, 2009, PULM PHARMACOL THER, V22, P473, DOI 10.1016/j.pupt.2009.04.006; KEREN O, 1991, Brain Injury, V5, P233, DOI 10.3109/02699059109008094; Koch JD, 2008, J CEREBR BLOOD F MET, V28, P1294, DOI 10.1038/jcbfm.2008.15; Lee LC, 2012, AM J PHYS MED REHAB, V91, P528, DOI 10.1097/PHM.0b013e31824ad556; Li JS, 2009, NEUROSCIENCE, V159, P1309, DOI 10.1016/j.neuroscience.2009.01.011; Li JS, 2008, BRAIN RES, V1210, P223, DOI 10.1016/j.brainres.2008.03.007; Liu ZJ, 2008, ANTIOXID REDOX SIGN, V10, P1869, DOI 10.1089/ars.2008.2121; Maegele M, 2008, MINIM INVASIV THER, V17, P119, DOI 10.1080/13645700801970087; Martini RP, 2009, J NEUROSURG, V111, P644, DOI 10.3171/2009.2.JNS08998; Mattiasson GJ, 2000, J NEUROSCI METH, V95, P75, DOI 10.1016/S0165-0270(99)00162-4; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; Michalski D, 2009, BRAIN RES, V1303, P161, DOI 10.1016/j.brainres.2009.09.038; Miljkovic-Lolic M, 2003, BRAIN RES, V971, P90, DOI 10.1016/S0006-8993(03)02364-3; MINK RB, 1995, STROKE, V26, P2307, DOI 10.1161/01.STR.26.12.2307; Molcanyi M, 2007, J NEUROTRAUM, V24, P625, DOI 10.1089/neu.2006.0180; MONDELLI M, 1989, ITAL J NEUROL SCI, V10, P433, DOI 10.1007/BF02334949; Morelli A, 2011, CELL BIOCHEM BIOPHYS, V61, P179, DOI 10.1007/s12013-011-9174-8; Murtie JC, 2005, NEUROBIOL DIS, V19, P171, DOI 10.1016/j.nbd.2004.12.006; NEUBAUER RA, 1992, CLIN NUCL MED, V17, P477, DOI 10.1097/00003072-199206000-00010; NEUBAUER RA, 1993, J NEUROSURG, V78, P687; NEUBAUER RA, 1994, SOUTHERN MED J, V87, P933, DOI 10.1097/00007611-199409000-00015; Niklas A, 2004, J NEUROL SCI, V219, P77, DOI 10.1016/j.jns.2003.12.013; Ohguri T, 2007, INT J RADIAT ONCOL, V67, P248, DOI 10.1016/j.ijrobp.2006.08.009; Ostrowski RP, 2006, STROKE, V37, P1314, DOI 10.1161/01.STR.0000217310.88450.c3; Ostrowski RP, 2005, J CEREBR BLOOD F MET, V25, P554, DOI 10.1038/sj.jcbfm.9600048; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Palzur E, 2008, BRAIN RES, V1221, P126, DOI 10.1016/j.brainres.2008.04.078; Prakash A, 2012, J PEDIATR NEUROSCI, V7, P4, DOI 10.4103/1817-1745.97610; Puri V, 2005, MUSCLE NERVE, V32, P230, DOI 10.1002/mus.20316; Raible DJ, 2012, J NEUROTRAUM, V29, P2548, DOI 10.1089/neu.2012.2483; Ren HJ, 2001, CHINESE MED J-PEKING, V114, P387; Riess P, 2007, J NEUROTRAUM, V24, P216, DOI 10.1089/neu.2006.0141; ROBERTSON A, 1993, ACTA NEUROPATHOL, V86, P163, DOI 10.1007/BF00334883; ROCKSWOLD GL, 1992, J NEUROSURG, V76, P929, DOI 10.3171/jns.1992.76.6.0929; Rockswold SB, 2007, NEUROL RES, V29, P162, DOI 10.1179/016164107X181798; Rockswold SB, 2010, J NEUROSURG, V112, P1080, DOI 10.3171/2009.7.JNS09363; Rogatsky GG, 2005, BRAIN RES, V1047, P131, DOI 10.1016/j.brainres.2005.02.049; SHIBASAKI H, 1982, ANN NEUROL, V12, P355, DOI 10.1002/ana.410120407; Sleigh JW, 1999, J NEUROSURG, V91, P577, DOI 10.3171/jns.1999.91.4.0577; Smith G, 2012, BALLET REV, V40, P18; Soustiel JF, 2008, NEUROPATH APPL NEURO, V34, P412, DOI 10.1111/j.1365-2990.2007.00906.x; STANLEY GP, 1991, BRAIN, V114, P1827, DOI 10.1093/brain/114.4.1827; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Sullivan GM, 2013, J NEUROPATH EXP NEUR, V72, P1106, DOI 10.1097/NEN.0000000000000009; Thompson JK, 2003, SCIENCE, V299, P1070, DOI 10.1126/science.1079220; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; Vlodavsky E, 2005, ACTA NEUROPATHOL, V110, P120, DOI 10.1007/s00401-004-0946-8; Wang GH, 2010, J NEUROTRAUM, V27, P1733, DOI 10.1089/neu.2009.1175; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Yi JH, 2007, BRAIN RES, V1154, P200, DOI 10.1016/j.brainres.2007.04.011; Zhang K, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00005; Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687	89	21	23	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2014	9	5							e97750	10.1371/journal.pone.0097750	http://dx.doi.org/10.1371/journal.pone.0097750			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI3AL	24848795	Green Published, Green Submitted, gold			2023-01-03	WOS:000336730600054
J	Moll, J; Weingartner, JH; Bado, P; Basilio, R; Sato, JR; Melo, BR; Bramati, IE; de Oliveira-Souza, R; Zahn, R				Moll, Jorge; Weingartner, Julie H.; Bado, Patricia; Basilio, Rodrigo; Sato, Joao R.; Melo, Bruno R.; Bramati, Ivanei E.; de Oliveira-Souza, Ricardo; Zahn, Roland			Voluntary Enhancement of Neural Signatures of Affiliative Emotion Using fMRI Neurofeedback	PLOS ONE			English	Article							HUMAN BRAIN ACTIVITY; REAL-TIME FMRI; FUNCTIONAL MRI; INDIVIDUAL-DIFFERENCES; NATURAL IMAGES; ACTIVATION; SELF; CLASSIFICATION; COOPERATION; OXYTOCIN	In Ridley Scott's film "Blade Runner", empathy-detection devices are employed to measure affiliative emotions. Despite recent neurocomputational advances, it is unknown whether brain signatures of affiliative emotions, such as tenderness/affection, can be decoded and voluntarily modulated. Here, we employed multivariate voxel pattern analysis and real-time fMRI to address this question. We found that participants were able to use visual feedback based on decoded fMRI patterns as a neurofeedback signal to increase brain activation characteristic of tenderness/affection relative to pride, an equally complex control emotion. Such improvement was not observed in a control group performing the same fMRI task without neurofeedback. Furthermore, the neurofeedback-driven enhancement of tenderness/affection-related distributed patterns was associated with local fMRI responses in the septohypothalamic area and frontopolar cortex, regions previously implicated in affiliative emotion. This demonstrates that humans can voluntarily enhance brain signatures of tenderness/affection, unlocking new possibilities for promoting prosocial emotions and countering antisocial behavior.	[Moll, Jorge; Weingartner, Julie H.; Bado, Patricia; Basilio, Rodrigo; Sato, Joao R.; Melo, Bruno R.; Bramati, Ivanei E.; de Oliveira-Souza, Ricardo; Zahn, Roland] DOr Inst Res & Educ IDOR, Cognit & Behav Neurosci Unit, Rio De Janeiro, Brazil; [Moll, Jorge; Weingartner, Julie H.; Bado, Patricia; Basilio, Rodrigo; Sato, Joao R.; Melo, Bruno R.; Bramati, Ivanei E.; de Oliveira-Souza, Ricardo; Zahn, Roland] DOr Inst Res & Educ IDOR, Neuroinformat Workgrp, Rio De Janeiro, Brazil; [Bado, Patricia] Univ Fed Rio de Janeiro, ICB, Rio De Janeiro, Brazil; [Sato, Joao R.] Univ Fed ABC, Ctr Math Computat & Cognit, Santo Andre, Brazil; [de Oliveira-Souza, Ricardo] Fed Univ State Rio de Janeiro, Gaffree & Guinle Univ Hosp, Rio De Janeiro, Brazil; [Zahn, Roland] Kings Coll London, Inst Psychiat, Ctr Affect Disorders, London WC2R 2LS, England	IDOR - Instituto D'Or de Ensino e Pesquisa; IDOR - Instituto D'Or de Ensino e Pesquisa; Universidade Federal do Rio de Janeiro; Universidade Federal do ABC (UFABC); University of London; King's College London	Moll, J (corresponding author), DOr Inst Res & Educ IDOR, Cognit & Behav Neurosci Unit, Rio De Janeiro, Brazil.	jorge.moll@idor.org	Moll, Jorge/AAF-8388-2021; Zahn, Roland/O-8944-2019; BADO, PATRICIA/AAF-6217-2021; Zahn, Roland/C-4665-2008	Moll, Jorge/0000-0002-4297-591X; Zahn, Roland/0000-0002-8447-1453; BADO, PATRICIA/0000-0001-8543-2547; Zahn, Roland/0000-0002-8447-1453; Sato, Joao Ricardo/0000-0002-7503-9781	FAPERJ Sediadas grant; INNT grant; CAPES; CNPq; IDOR; MRC [G0902304]; FAPESP, Brazil [2013/10498-6]; Medical Research Council [G0902304] Funding Source: researchfish	FAPERJ Sediadas grant(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); INNT grant; CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); IDOR; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); FAPESP, Brazil(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This research was supported by FAPERJ Sediadas and INNT grants, CAPES, CNPq and by intramural grants from IDOR; R.Z. was supported by an MRC clinician scientist award (G0902304). J.R.S. was supported by FAPESP (grant number 2013/10498-6), Brazil. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allman J, 2002, NEUROSCIENTIST, V8, P335, DOI 10.1177/107385840200800409; Andari E, 2010, P NATL ACAD SCI USA, V107, P4389, DOI 10.1073/pnas.0910249107; Avenanti A, 2010, CURR BIOL, V20, P1018, DOI 10.1016/j.cub.2010.03.071; Bartels A, 2004, NEUROIMAGE, V21, P1155, DOI 10.1016/j.neuroimage.2003.11.003; BISHOP MP, 1963, SCIENCE, V140, P394, DOI 10.1126/science.140.3565.394; Bodurka J, 2007, NEUROIMAGE, V34, P542, DOI 10.1016/j.neuroimage.2006.09.039; Chu C, 2012, NEUROIMAGE, V60, P59, DOI 10.1016/j.neuroimage.2011.11.066; Coricelli G, 2005, NAT NEUROSCI, V8, P1255, DOI 10.1038/nn1514; COX RW, 1995, MAGNET RESON MED, V33, P230, DOI 10.1002/mrm.1910330213; De Oliveira-Souza R, 2008, CRIM JUSTICE BEHAV, V35, P427, DOI 10.1177/0093854807310853; Decety J, 2004, NEUROIMAGE, V23, P744, DOI 10.1016/j.neuroimage.2004.05.025; Decety Jean, 2004, Behav Cogn Neurosci Rev, V3, P71, DOI 10.1177/1534582304267187; deCharms RC, 2005, P NATL ACAD SCI USA, V102, P18626, DOI 10.1073/pnas.0505210102; Depue RA, 2005, BEHAV BRAIN SCI, V28, P313; Eslinger PJ, 1998, EUR NEUROL, V39, P193, DOI 10.1159/000007933; Fan Y, 2011, NEUROSCI BIOBEHAV R, V35, P903, DOI 10.1016/j.neubiorev.2010.10.009; Fehr E, 2004, TRENDS COGN SCI, V8, P185, DOI 10.1016/j.tics.2004.02.007; FRISTON KJ, 1995, NEUROIMAGE, V2, P157, DOI 10.1006/nimg.1995.1018; GORMAN DG, 1992, ARCH NEUROL-CHICAGO, V49, P308, DOI 10.1001/archneur.1992.00530270128029; Green AE, 2006, BRAIN RES, V1096, P125, DOI 10.1016/j.brainres.2006.04.024; Green S, 2012, ARCH GEN PSYCHIAT, V69, P1014, DOI 10.1001/archgenpsychiatry.2012.135; Harmelech T, 2013, J NEUROSCI, V33, P9488, DOI 10.1523/JNEUROSCI.5911-12.2013; Hein G, 2010, NEURON, V68, P149, DOI 10.1016/j.neuron.2010.09.003; Hsu M, 2008, SCIENCE, V320, P1092, DOI 10.1126/science.1153651; Hyman SE, 2007, AM J BIOETHICS, V7, P8, DOI 10.1080/15265160601063969; Hyman SE, 2011, NEURON, V69, P595, DOI 10.1016/j.neuron.2011.02.012; Insel TR, 2001, NAT REV NEUROSCI, V2, P129, DOI 10.1038/35053579; IRVIN RW, 1990, PHYSIOL BEHAV, V48, P693, DOI 10.1016/0031-9384(90)90213-N; Kay KN, 2008, NATURE, V452, P352, DOI 10.1038/nature06713; Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701; Krueger F, 2007, P NATL ACAD SCI USA, V104, P20084, DOI 10.1073/pnas.0710103104; LaConte SM, 2007, HUM BRAIN MAPP, V28, P1033, DOI 10.1002/hbm.20326; MILLER NE, 1978, ANNU REV PSYCHOL, V29, P373, DOI 10.1146/annurev.ps.29.020178.002105; Mitchell TM, 2008, SCIENCE, V320, P1191, DOI 10.1126/science.1152876; Moll J, 2005, NAT REV NEUROSCI, V6, P799, DOI 10.1038/nrn1768; Moll J, 2006, P NATL ACAD SCI USA, V103, P15623, DOI 10.1073/pnas.0604475103; Moll J, 2012, J NEUROSCI, V32, P12499, DOI 10.1523/JNEUROSCI.6508-11.2012; Moll J, 2011, NEUROIMAGE, V54, P1735, DOI 10.1016/j.neuroimage.2010.08.026; Morey RA, 2012, NEUROIMAGE, V60, P683, DOI 10.1016/j.neuroimage.2011.12.069; Morrone-Strupinsky JV, 2007, PERS INDIV DIFFER, V42, P1267, DOI 10.1016/j.paid.2006.10.005; Mourao-Miranda J, 2005, NEUROIMAGE, V28, P980, DOI 10.1016/j.neuroimage.2005.06.070; Naselaris T, 2009, NEURON, V63, P902, DOI 10.1016/j.neuron.2009.09.006; Nelson EE, 1998, NEUROSCI BIOBEHAV R, V22, P437, DOI 10.1016/S0149-7634(97)00052-3; Panksepp J, 2011, SCIENCE, V334, P1358, DOI 10.1126/science.1216480; Papageorgiou TD, 2013, P NATL ACAD SCI USA, V110, P13630, DOI 10.1073/pnas.1210738110; Phan KL, 2004, NEUROREPORT, V15, P527, DOI 10.1097/00001756-200403010-00029; Posse S, 2003, NEUROIMAGE, V18, P760, DOI 10.1016/S1053-8119(03)00004-1; Rilling JK, 2002, NEURON, V35, P395, DOI 10.1016/S0896-6273(02)00755-9; Ruiz S, 2013, HUM BRAIN MAPP, V34, P200, DOI 10.1002/hbm.21427; Sato JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081658; Sato JR, 2008, NEUROIMAGE, V42, P1473, DOI 10.1016/j.neuroimage.2008.06.024; Scheinost D, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.24; Schweizer S, 2013, J NEUROSCI, V33, P5301, DOI 10.1523/JNEUROSCI.2593-12.2013; Sitaram R, 2011, NEUROIMAGE, V56, P753, DOI 10.1016/j.neuroimage.2010.08.007; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Takahashi H, 2004, NEUROIMAGE, V23, P967, DOI 10.1016/j.neuroimage.2004.07.054; Takahashi H, 2008, CEREB CORTEX, V18, P898, DOI 10.1093/cercor/bhm120; Vapnik V., 1998, NATURE STATISTI810; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Weiskopf N, 2003, NEUROIMAGE, V19, P577, DOI 10.1016/S1053-8119(03)00145-9; WORSLEY KJ, 1995, NEUROIMAGE, V2, P173, DOI 10.1006/nimg.1995.1023; Zaborszky L, 2008, NEUROIMAGE, V42, P1127, DOI 10.1016/j.neuroimage.2008.05.055; Zahn R, 2009, NEUROSCI LETT, V457, P107, DOI 10.1016/j.neulet.2009.03.090; Zahn R, 2009, CEREB CORTEX, V19, P276, DOI 10.1093/cercor/bhn080; Zarahn E, 1997, NEUROIMAGE, V457, P107; Zotev V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024522	66	31	32	2	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2014	9	5							e97343	10.1371/journal.pone.0097343	http://dx.doi.org/10.1371/journal.pone.0097343			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI3AL	24847819	Green Published, Green Submitted, gold			2023-01-03	WOS:000336730600025
J	Schutte, HJ; Jansen, S; Schafroth, MU; Goslings, JC; van der Velde, N; de Rooij, SEJA				Schutte, Hermien Janneke; Jansen, Sofie; Schafroth, Matthias U.; Goslings, J. Carel; van der Velde, Nathalie; de Rooij, Sophia E. J. A.			SSRIs Increase Risk of Blood Transfusion in Patients Admitted for Hip Surgery	PLOS ONE			English	Article							SEROTONIN REUPTAKE INHIBITORS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ANTIDEPRESSANTS; ASSOCIATION; MORTALITY	Background: Recent studies have shown that an increased bleeding tendency can be caused by Selective Serotonin Reuptake Inhibitors (SSRI) use. We aimed to investigate the occurrence and risk of blood transfusion in SSRI users compared to non-SSRI users in a cohort of patients admitted for hip-surgery. Methods: We conducted a retrospective cohort study of patients who underwent planned or emergency hip surgery from 1996 to 2011 in the Academic Medical Center in Amsterdam. Primary outcome measure was risk of blood transfusion. Secondary outcome measures were pre- and postoperative hemoglobin level. Multivariate logistic regression was used to adjust for potential confounders. Results: One-hundred and fourteen SSRI users were compared to 1773 non-SSRI users. Risk of blood transfusion during admission was increased for SSRI users in multivariate analyses (OR 1.7 [95% CI 1.1-2.5]). Also, pre-operative hemoglobin levels were lower in SSRI users (7.8 +/- 1.0 mmol/L) compared to non-SSRI users (8.0 +/- 1.0 mmol/L) (p=0.042)), as were postoperative hemoglobin levels (6.2 +/- 1.0 mmol/L vs. 6.4 +/- 1.0 mmol/L respectively) (p=0.017)). Conclusions: SSRI users undergoing hip surgery have an increased risk for blood transfusion during admission, potentially explained by a lower hemoglobin level before surgery. SSRI use should be considered as a potential risk indicator for increased blood loss in patients admitted for hip surgery. These results need to be confirmed in a prospective study.	[Schutte, Hermien Janneke; Jansen, Sofie; van der Velde, Nathalie; de Rooij, Sophia E. J. A.] Univ Amsterdam, Acad Med Ctr, Dept Med, Geriatr Med Sect, NL-1105 AZ Amsterdam, Netherlands; [Schafroth, Matthias U.] Univ Amsterdam, Acad Med Ctr, Dept Orthoped Surg, NL-1105 AZ Amsterdam, Netherlands; [Goslings, J. Carel] Univ Amsterdam, Acad Med Ctr, Trauma Unit, Dept Surg, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	de Rooij, SEJA (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Med, Geriatr Med Sect, NL-1105 AZ Amsterdam, Netherlands.	s.e.derooij@amc.uva.nl		van der Velde, Nathalie/0000-0002-6477-6209				Andrade C, 2010, J CLIN PSYCHIAT, V71, P1565, DOI 10.4088/JCP.09r05786blu; Auerbach AD, 2013, JAMA INTERN MED, V173, P1075, DOI 10.1001/jamainternmed.2013.714; Carvajal A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019819; Centraal Begeleidings Orgaan, 2011, BLOOD TRANSF GUID; Centraal Begeleidings Orgaan, 2004, BLOOD TRANSF GUID; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cobain TJ, 2007, TRANSFUSION MED, V17, P1, DOI 10.1111/j.1365-3148.2006.00709.x; College van zorgverzekeringen, 2012, AANT GEBR 2007 2011; COOK EH, 1994, J NEUROCHEM, V63, P465; de Abajo FJ, 2008, ARCH GEN PSYCHIAT, V65, P795, DOI 10.1001/archpsyc.65.7.795; Gardarsdottir H, 2007, J AFFECT DISORDERS, V98, P109, DOI 10.1016/j.jad.2006.07.003; Jansen S, 2012, EUROPEAN GERIATRIC M, V3, pS2; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Morel-Kopp MC, 2009, J THROMB HAEMOST, V7, P573, DOI 10.1111/j.1538-7836.2009.03278.x; Movig KLL, 2003, ARCH INTERN MED, V163, P2354, DOI 10.1001/archinte.163.19.2354; NARANJO CA, 1995, DRUG AGING, V7, P184, DOI 10.2165/00002512-199507030-00004; OWENS WD, 1978, ANESTHESIOLOGY, V49, P239, DOI 10.1097/00000542-197810000-00003; Radovanovic I, 2012, ACTA ORTHOP BELG, V78, P187; Rogers MAM, 2007, J WOMENS HEALTH, V16, P1412, DOI 10.1089/jwh.2007.0397; Rothman JK, 2008, MODERN EPIDEMIOLOGY, V3rd; Shander A, 2009, SURG INFECT, V10, P277, DOI 10.1089/sur.2007.055; Takeuchi K, 2011, J PHARMACOL EXP THER, V338, P850, DOI 10.1124/jpet.111.183293; Targownik LE, 2009, AM J GASTROENTEROL, V104, P1475, DOI 10.1038/ajg.2009.128; van Haelst IMM, 2010, ANESTHESIOLOGY, V112, P631, DOI 10.1097/ALN.0b013e3181cf8fdf; Vidal X, 2008, DRUG SAFETY, V31, P159, DOI 10.2165/00002018-200831020-00005; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; Wu WC, 2012, ANN SURG, V255, P708, DOI 10.1097/SLA.0b013e31824a55b9; Ziegelstein RC, 2009, INTERN MED J, V39, P38, DOI 10.1111/j.1445-5994.2008.01794.x	28	15	17	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2014	9	5							e95906	10.1371/journal.pone.0095906	http://dx.doi.org/10.1371/journal.pone.0095906			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI3AL	24848000	Green Published, gold, Green Submitted			2023-01-03	WOS:000336730600008
J	Qin, Y; Fu, MY; Takahashi, M; Iwanami, A; Kuga, D; Rao, RG; Sudhakar, D; Huang, T; Kiyohara, M; Torres, K; Dillard, C; Inagaki, A; Kasahara, N; Goodglick, L; Braun, J; Mischel, PS; Gordon, LK; Wadehra, M				Qin, Yu; Fu, Maoyong; Takahashi, Masamichi; Iwanami, Akio; Kuga, Daisuke; Rao, Rajiv G.; Sudhakar, Deepthi; Huang, Tiffany; Kiyohara, Meagan; Torres, Kathleen; Dillard, Christen; Inagaki, Akihito; Kasahara, Noriyuki; Goodglick, Lee; Braun, Jonathan; Mischel, Paul S.; Gordon, Lynn K.; Wadehra, Madhuri			Epithelial Membrane Protein-2 ( EMP2) Activates Src Protein and Is a Novel Therapeutic Target for Glioblastoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						Cell Invasion; Glioblastoma; Immunotherapy; Tetraspanins; Tumor Marker; EMP2	ALPHA-V-BETA-3 INTEGRIN; MOLECULAR DETERMINANTS; IN-VITRO; CANCER; EXPRESSION; GROWTH; CELLS; ANTIBODY; ANGIOGENESIS; VITRONECTIN	Background: EMP2 is a tetraspan protein linked with aggressive disease. Results: EMP2 correlates with activated Src in patients with GBM. Using intracranial mouse models, EMP2 promotes tumor cell invasiveness. Antibodies to EMP2 reduce GBM tumor load. Conclusion: EMP2 is a novel therapeutic target in GBM. Significance: The clinical outcome for patients with GBM remains poor, and thus new targeted therapies are needed. Despite recent advances in molecular classification, surgery, radiotherapy, and targeted therapies, the clinical outcome of patients with malignant brain tumors remains extremely poor. In this study, we have identified the tetraspan protein epithelial membrane protein-2 (EMP2) as a potential target for glioblastoma (GBM) killing. EMP2 had low or undetectable expression in normal brain but was highly expressed in GBM as 95% of patients showed some expression of the protein. In GBM cells, EMP2 enhanced tumor growth in vivo in part by up-regulating v3 integrin surface expression, activating focal adhesion kinase and Src kinases, and promoting cell migration and invasion. Consistent with these findings, EMP2 expression significantly correlated with activated Src kinase in patient samples and promoted tumor cell invasion using intracranial mouse models. As a proof of principle to determine whether EMP2 could serve as a target for therapy, cells were treated using specific anti-EMP2 antibody reagents. These reagents were effective in killing GBM cells in vitro and in reducing tumor load in subcutaneous mouse models. These results support the role of EMP2 in the pathogenesis of GBM and suggest that anti-EMP2 treatment may be a novel therapeutic treatment.	[Qin, Yu; Gordon, Lynn K.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA; [Fu, Maoyong; Iwanami, Akio; Kuga, Daisuke; Rao, Rajiv G.; Sudhakar, Deepthi; Huang, Tiffany; Kiyohara, Meagan; Torres, Kathleen; Dillard, Christen; Goodglick, Lee; Braun, Jonathan; Wadehra, Madhuri] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; [Goodglick, Lee; Braun, Jonathan; Wadehra, Madhuri] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; [Takahashi, Masamichi; Inagaki, Akihito; Kasahara, Noriyuki] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; [Mischel, Paul S.] Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; [Mischel, Paul S.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego	Wadehra, M (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Box 951732,675 Charles Young Dr South, Los Angeles, CA 90095 USA.	mwadehra@mednet.ucla.edu	Takahashi, Masamichi/GRJ-2866-2022	Kasahara, Noriyuki/0000-0002-6069-9082; Braun, Jonathan/0000-0003-1646-2974; Takahashi, Masamichi/0000-0001-8792-1993; Dillard, Christen/0000-0002-7218-9960	National Institutes of Health from NCI Early Detection Research Network [CA-86366, R01 CA163971, CA 143931CDU/UCLA, P30 CA016042]; CFAR [5P30 AI028697]; Stein Oppenheimer seed grant; NATIONAL CANCER INSTITUTE [P30CA016042, U24CA086366, R01CA163971, U54CA143931] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000124] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028697] Funding Source: NIH RePORTER	National Institutes of Health from NCI Early Detection Research Network(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CFAR; Stein Oppenheimer seed grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported, in whole or in part, by National Institutes of Health Grants CA-86366 from NCI Early Detection Research Network (to L. G.), R01 CA163971 (to M. W.), CA 143931CDU/UCLA Cancer Center Partnership U54 (to M. W.), Grant P30 CA016042 to Jonsson Comprehensive Cancer Center, and Grant 5P30 AI028697 from CFAR. This work was also supported by a Stein Oppenheimer seed grant (to L. G.).	Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Acconcia F, 2006, ENDOCRINOLOGY, V147, P1203, DOI 10.1210/en.2005-1293; Agus DB, 1999, CANCER RES, V59, P4761; Beckman RA, 2007, CANCER-AM CANCER SOC, V109, P170, DOI 10.1002/cncr.22402; Buonerba C, 2011, CRIT REV ONCOL HEMAT, V80, P54, DOI 10.1016/j.critrevonc.2010.09.001; Chang MW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037935; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; Cronin M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030940; D'Abaco GM, 2007, J CLIN NEUROSCI, V14, P1041, DOI 10.1016/j.jocn.2007.06.019; de Groot J, 2009, J NEURO-ONCOL, V95, P151, DOI 10.1007/s11060-009-9916-2; Fan QW, 2013, CANCER CELL, V24, P438, DOI 10.1016/j.ccr.2013.09.004; Frank RT, 2011, BBA-REV CANCER, V1816, P191, DOI 10.1016/j.bbcan.2011.07.002; Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452; Fu M, 2014, MOL CANCER THER, V13, P902, DOI 10.1158/1535-7163.MCT-13-0199; Fu MY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019945; Fu MY, 2010, CLIN CANCER RES, V16, P3954, DOI 10.1158/1078-0432.CCR-10-0368; Fukai J, 2008, CANCER SCI, V99, P2062, DOI 10.1111/j.1349-7006.2008.00945.x; Giese A, 1996, INT J CANCER, V67, P275, DOI 10.1002/(SICI)1097-0215(19960717)67:2<275::AID-IJC20>3.0.CO;2-9; GLADSON CL, 1991, J CLIN INVEST, V88, P1924, DOI 10.1172/JCI115516; Gordon LK, 2013, ONCOGENE, V32, P5369, DOI 10.1038/onc.2012.622; Habeeb O, 2010, CANCER-AM CANCER SOC, V116, P4718, DOI 10.1002/cncr.25259; Hehlgans S, 2007, BBA-REV CANCER, V1775, P163, DOI 10.1016/j.bbcan.2006.09.001; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Huang TT, 2013, CANCER GENE THER, V20, P544, DOI 10.1038/cgt.2013.51; JIAO Y, 2012, PLOS ONE, V7, DOI DOI 10.1371/JOURNAL.PONE.0041591; Kanamori M, 2006, J BIOL CHEM, V281, P37256, DOI 10.1074/jbc.M605344200; Kawaguchi T, 2006, CANCER RES, V66, P11331, DOI 10.1158/0008-5472.CAN-06-1540; Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596; Kerr JS, 2000, EXPERT OPIN INV DRUG, V9, P1271, DOI 10.1517/13543784.9.6.1271; Kim K, 2008, MOL CANCER RES, V6, P426, DOI 10.1158/1541-7786.MCR-07-0313; Lorger M., 2012, INTEGRIN SIGNALING A, P311; McEarchern JA, 2007, BLOOD, V109, P1185, DOI 10.1182/blood-2006-07-034017; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Morales SA, 2009, INVEST OPHTH VIS SCI, V50, P462, DOI 10.1167/iovs.07-1598; Petras Miklos, 2009, Magy Onkol, V53, P253, DOI 10.1556/MOnkol.53.2009.3.3; Rolle CE, 2010, NEUROSURG CLIN N AM, V21, P201, DOI 10.1016/j.nec.2009.08.002; Rooprai HK, 1999, INT J DEV NEUROSCI, V17, P613, DOI 10.1016/S0736-5748(99)00051-9; Shimazaki K, 2008, CLIN CANCER RES, V14, P7367, DOI 10.1158/1078-0432.CCR-08-1016; Teodorczyk M, 2010, J CELL PHYSIOL, V222, P1, DOI 10.1002/jcp.21901; Wadehra M, 2006, DEV BIOL, V292, P430, DOI 10.1016/j.ydbio.2006.01.015; Wadehra M, 2005, DEV BIOL, V287, P336, DOI 10.1016/j.ydbio.2005.09.003; Wadehra M, 2003, EXP MOL PATHOL, V74, P106, DOI 10.1016/S0014-4800(03)00009-1; Wadehra M, 2002, J BIOL CHEM, V277, P41094, DOI 10.1074/jbc.M206868200; Wadehra M, 2006, CANCER-AM CANCER SOC, V107, P90, DOI 10.1002/cncr.21957; Wang MY, 2006, CANCER RES, V66, P7864, DOI 10.1158/0008-5472.CAN-04-4392; Wang SD, 2012, ONCOGENE, V31, P5132, DOI 10.1038/onc.2012.16; Wang WJ, 2005, J NEUROSURG, V103, P1058, DOI 10.3171/jns.2005.103.6.1058; Wang YL, 2004, ONCOGENE, V23, P1283, DOI 10.1038/sj.onc.1207244; Wick W, 2011, NEURO-ONCOLOGY, V13, P566, DOI 10.1093/neuonc/nor039; Zagzag D, 2006, LAB INVEST, V86, P1221, DOI 10.1038/labinvest.3700482	51	20	23	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2014	289	20					13974	13985		10.1074/jbc.M113.543728	http://dx.doi.org/10.1074/jbc.M113.543728			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	AH2XF	24644285	hybrid, Green Published			2023-01-03	WOS:000335984600028
J	Atkinson, P; French, J; Nice, CA				Atkinson, Paul; French, James; Nice, C. Andrew			THERAPEUTICS Procedural sedation and analgesia for adults in the emergency department	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PROPOFOL; KETAMINE; ASSOCIATION; RELOCATION; MIDAZOLAM; THEATER; SAFETY		[Atkinson, Paul; French, James] Dalhousie Univ, St John Reg Hosp, Dept Emergency Med, St John, NB E2L 4L4, Canada; [Atkinson, Paul] Mem Univ Newfoundland, Discipline Emergency Med, St John Reg Hosp, St John, NB, Canada; [Nice, C. Andrew] Dalhousie Univ, St John Reg Hosp, Dept Anesthesia Pain Management & Perioperat Med, St John, NB E2L 4L4, Canada; [Nice, C. Andrew] Mem Univ Newfoundland, St John Reg Hosp, Discipline Anesthesia, St John, NB, Canada	Dalhousie University; Memorial University Newfoundland; Dalhousie University; Memorial University Newfoundland	Atkinson, P (corresponding author), Dalhousie Univ, St John Reg Hosp, Dept Emergency Med, St John, NB E2L 4L4, Canada.	Paul.atkinson@dal.ca						Andolfatto G, 2012, ANN EMERG MED, V59, P504, DOI 10.1016/j.annemergmed.2012.01.017; Baker Stephanie N, 2011, J Pharm Pract, V24, P189, DOI 10.1177/0897190011400554; Boyle A, 2011, EMERG MED J, V28, P383, DOI 10.1136/emj.2010.092965; Campbell Sam G, 2006, CJEM, V8, P85; Dawson N, 2014, EMERG MED J, V31, P207, DOI 10.1136/emermed-2012-202147; Deitch K, 2010, ANN EMERG MED, V55, P258, DOI 10.1016/j.annemergmed.2009.07.030; Frank RL, 2013, UPTODATE; Gagg J, 2009, EMERG MED J, V26, P39, DOI 10.1136/emj.2008.057737; Godwin SA, 2005, ANN EMERG MED, V45, P177, DOI 10.1016/j.annemergmed.2004.11.002; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Hohl CM, 2008, ACAD EMERG MED, V15, P1, DOI 10.1111/j.1553-2712.2007.00022.x; Hohl CM, 2008, ACAD EMERG MED, V15, P32, DOI 10.1111/j.1553-2712.2007.00023.x; Mathieu N, 2009, EMERG MED J, V26, P37, DOI 10.1136/emj.2008.057729; Mellin-Olsen J, 2010, EUR J ANAESTH, V27, P592, DOI 10.1097/EJA.0b013e32833b1adf; Messenger DW, 2008, ACAD EMERG MED, V15, P877, DOI 10.1111/j.1553-2712.2008.00219.x; Miner JR, 2007, ANN EMERG MED, V49, P15, DOI 10.1016/j.annemergmed.2006.06.042; Miner JR, 2003, ACAD EMERG MED, V10, P638, DOI 10.1111/j.1553-2712.2003.tb00048.x; Neily J, 2010, JAMA-J AM MED ASSOC, V304, P1693, DOI 10.1001/jama.2010.1506; Newton A, 2008, EMERG MED J, V25, P498, DOI 10.1136/emj.2007.053421; O'Connor RE, 2011, ANN EMERG MED, V58, P365, DOI 10.1016/j.annemergmed.2011.06.020; O'Sullivan I, 2003, EMERG MED J, V20, P214, DOI 10.1136/emj.20.3.214; Reves JG, 2010, MILLERS ANESTHESIA; Shiga T, 2005, ANESTHESIOLOGY, V103, P429, DOI 10.1097/00000542-200508000-00027; Sivilotti MLA, 2010, CAN J EMERG MED, V12, P397; Stoelting RK., 2006, PHARM PHYSL ANESTHET, V4; The Royal College of Anaesthetists & The College of Emergency Medicine, 2012, SAF SED AD EM DEP; Tobias JD, 2011, SAUDI J ANAESTH, V5, P395, DOI 10.4103/1658-354X.87270; WHO, 2006, 36 ECDD 2006 4 3 CRI	28	8	8	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 8	2014	348								g2965	10.1136/bmj.g2965	http://dx.doi.org/10.1136/bmj.g2965			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AH0OM	24812113				2023-01-03	WOS:000335819700005
J	Moyer, VA				Moyer, Virginia A.		US Preventive Serv Task Force	Primary Care Behavioral Interventions to Reduce Illicit Drug and Nonmedical Pharmaceutical Use in Children and Adolescents: US Preventive Services Task Force Recommendation Statement	ANNALS OF INTERNAL MEDICINE			English	Article							MOTHER-DAUGHTER PROGRAM; SUBSTANCE USE; OUTCOMES; GIRLS; COMPUTER; TRIAL	Description: Update of the 2008 U. S. Preventive Services Task Force (USPSTF) recommendation on screening for illicit drug use. Methods: The USPSTF reviewed the evidence on interventions to help adolescents who have never used drugs to remain abstinent and interventions to help adolescents who are using drugs but do not meet criteria for a substance use disorder to reduce or stop their use. Population: This recommendation applies to children and adolescents younger than age 18 years who have not been diagnosed with a substance use disorder. Recommendation: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of primary care-based behavioral interventions to prevent or reduce illicit drug or nonmedical pharmaceutical use in children and adolescents. (I statement)	[Moyer, Virginia A.; US Preventive Serv Task Force] US Prevent Serv Task ForceM, Rockville, MD 20850 USA		Moyer, VA (corresponding author), US Prevent Serv Task ForceM, Rockville, MD 20850 USA.		Phillips, William R./V-1065-2017	Phillips, William R./0000-0003-2802-4349				Fang L, 2013, PSYCHOL ADDICT BEHAV, V27, P788, DOI 10.1037/a0030925; Fang L, 2010, J ADOLESCENT HEALTH, V47, P529, DOI 10.1016/j.jadohealth.2010.03.011; Harris SK, 2012, PEDIATRICS, V129, P1072, DOI 10.1542/peds.2011-1624; Johnston L.D., 2013, MONITORING FUTURE NA; Patnode CD, 2014, AHRQ PUBLICATION, V106; Schinke SP, 2009, PREV MED, V49, P429, DOI 10.1016/j.ypmed.2009.08.001; Schinke SP, 2009, ADDICT BEHAV, V34, P1060, DOI 10.1016/j.addbeh.2009.06.007; Substance Abuse and Mental Health Services Administration, 2013, NSDUH SER H, VH-46; Substance Abuse and Mental Health Services Administration, NSDUH SER, VSMA, P13; US Preventive Services Task Force, 2008, SCREEN ILL DRUG US; Walton MA, 2013, DRUG ALCOHOL DEPEN, V132, P646, DOI 10.1016/j.drugalcdep.2013.04.020; Williams JF, 2011, PEDIATRICS, V128, pE1330, DOI 10.1542/peds.2011-1754	12	18	18	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 6	2014	160	9					634	U208		10.7326/M14-0334	http://dx.doi.org/10.7326/M14-0334			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AI0GO	24615535				2023-01-03	WOS:000336524400005
J	Gaudry, KS; Cummings, DE				Gaudry, Kate S.; Cummings, Daniel E.			Patent office backlog adds billions to national drug expenditure	NATURE BIOTECHNOLOGY			English	Editorial Material									[Gaudry, Kate S.] Kilpatrick Townsend & Stockton LLP, Washington, DC 20005 USA; [Cummings, Daniel E.] Creighton Univ, Sch Law, Omaha, NE 68178 USA	Creighton University	Gaudry, KS (corresponding author), Kilpatrick Townsend & Stockton LLP, Washington, DC 20005 USA.	kgaudry@kilpatricktownsend.com						Alazraki M., 2011, DAILYFINANCE    0227; Centers for Medicare & Medicaid Services, 2013, NAT HLTH EXP; Dicken J.E., 2012, DRUG PRICING RES SAV; Gaudry K. S., 2014, LOOK RESULTS USPTOS; Gaudry KS, 2011, NAT BIOTECHNOL, V29, P876, DOI 10.1038/nbt.1993; Hemphill CS, 2012, J HEALTH ECON, V31, P327, DOI 10.1016/j.jhealeco.2012.01.004; Hemphill CS, 2011, J EMPIR LEGAL STUD, V8, P613, DOI 10.1111/j.1740-1461.2011.01235.x; Morgan S., 2010, COMMONWEALTH FUND PU, V89, P1408; Office of the Inspector General, 2006, GEN DRUG UT STAT MED; US Department of Health and Human Services, 2013, 1227 ADA HHS; US Patent and Trademark Office, 2012, US DEP COMM MAN PAT; US Patent and Trademark Office, 2013, PRES BUDG SUBM FISC; US Patent and Trademark Office, 2012, PERF ACC REP FISC YE	13	2	3	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2014	32	5					436	439		10.1038/nbt.2894	http://dx.doi.org/10.1038/nbt.2894			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	AH3PH	24811513				2023-01-03	WOS:000336036100015
J	Hassan, MK; Watari, H; Salah-eldin, AE; Sultan, AS; Mohamed, Z; Fujioka, Y; Ohba, Y; Sakuragi, N				Hassan, Mohamed K.; Watari, Hidemichi; Salah-eldin, Alaa-eldin; Sultan, Ahmed S.; Mohamed, Zainab; Fujioka, Yoichiro; Ohba, Yusuke; Sakuragi, Noriaki			Histone Deacetylase Inhibitors Sensitize Lung Cancer Cells to Hyperthermia: Involvement of Ku70/SirT-1 in Thermo-Protection	PLOS ONE			English	Article							DOUBLE-STRAND BREAKS; BAX; APOPTOSIS; KU70; ACETYLATION; BCL-2; SURVIVAL; STRESS; CYCLE; MYC	This study describes the sensitization mechanism to thermal stress by histone deacetylase inhibitors (HDACIs) in lung cancer cells and shows that Ku70, based on its acetylation status, mediates the protection of lung cancer from hyperthermia (42.5 degrees C, 1-6 hrs). Ku70 regulates apoptosis by sequestering pro-apoptotic Bax. However, its role in thermal stress is not fully understood. The findings showed that, pre-treating lung cancer cells with HDACIs, nicotinamide (NM) or Trichostatin A (TsA) or both significantly enhanced hyperthermia-induced Bax-dependent apoptosis in PC-10 cells. We found that hyperthermia induces SirT-1, Sirtuin, upregulation but not HDAC6 or SirT-3, therefore transfection with dominant negative SirT-1 (Y/H) also eliminated the protection and resulted in more cell death by hyperthermia, in H1299 cells through Bax activation. Hyperthermia alone primed lung cancer cells to apoptosis without prominent death. After hyperthermia Bax was upregulated, Bcl-2 was downregulated, the Bax/Bcl-2 ratio was inversed and Bax/Bcl-2 heterodimer was dissociated. Although hyperthermia did not affect total Ku70 expression level, it stimulated Ku70 deacetylation, which in turn could bind more Bax in the PC-10 cells. These findings suggest an escape mechanism from hyperthermia-induced Bax activation. To verify the role of Ku70 in this protection mechanism, Ku70 was silenced by siRNA. Ku70 silencing significantly sensitized the lung cancer cells to hyperthermia. The Ku70 KD cells underwent cytotoxic G1 arrest and caspase-dependant apoptosis when compared to scrambled transfectants which showed only G2/M cytostatic arrest in the cell lines investigated, suggesting an additional cell cycle-dependent, novel, role of Ku70 in protection from hyperthermia. Taken together, our data show a Ku70-dependent protection mechanism from hyperthermia. Targeting Ku70 and/or its acetylation during hyperthermia may represent a promising therapeutic approach for lung cancer.	[Hassan, Mohamed K.; Watari, Hidemichi; Mohamed, Zainab; Sakuragi, Noriaki] Hokkaido Univ, Grad Sch Med, Dept Obstet & Gynecol, Sapporo, Hokkaido, Japan; [Hassan, Mohamed K.] Port Said Univ, Dept Zool, Biotechnol Program, Fac Sci, Port Said, Egypt; [Salah-eldin, Alaa-eldin] Aswan Univ, Aswan Fac Sci, Dept Zool, Aswan, Egypt; [Sultan, Ahmed S.] Georgetown Univ, Med Ctr, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA; [Fujioka, Yoichiro; Ohba, Yusuke] Hokkaido Univ, Grad Sch Med, Dept Cell Physiol, Sapporo, Hokkaido, Japan	Hokkaido University; Egyptian Knowledge Bank (EKB); Port Said University; Egyptian Knowledge Bank (EKB); Aswan University; Georgetown University; Hokkaido University	Hassan, MK (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Obstet & Gynecol, Sapporo, Hokkaido, Japan.	mohamedkamel24@yahoo.com; watarih@med.hokudai.ac.jp	Hassan, Mohamed/K-6076-2019; Fujioka, Yoichiro/AAF-3313-2019	Fujioka, Yoichiro/0000-0002-5760-9357; Sultan, Ahmad/0000-0001-5776-1837	Ministry of Education, Culture, Sports, Science and Technology of Japan [C 22591844, 20659255]; Grants-in-Aid for Scientific Research [25670184, 26293041] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported in part by a grant-in-aid HW for Scientific Research (C 22591844 and 20659255) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ayene IS, 2005, MOL CANCER THER, V4, P529, DOI 10.1158/1535-7163.MCT-04-0130; Calderwood SK, 2002, INT J HYPERTHER, V18, P597, DOI 10.1080/0265673021000019666; Chen CS, 2007, CANCER RES, V67, P5318, DOI 10.1158/0008-5472.CAN-06-3996; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chowdhury I, 2006, CELL MOL BIOL LETT, V11, P506, DOI 10.2478/s11658-006-0041-3; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; DEWEY WC, 1990, RADIAT RES, V122, P268, DOI 10.2307/3577755; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; HIGASHIKUBO R, 1989, RADIAT RES, V119, P246, DOI 10.2307/3577617; Inoue S, 1997, LUNG CANCER, V17, P85, DOI 10.1016/S0169-5002(97)00652-1; Jose G, 2007, BIOCHEM SOC T, V35, P797; Kampinga HH, 2005, CANCER RES, V65, P10632, DOI 10.1158/0008-5472.CAN-05-0006; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Korsmeyer SJ, 2007, CELL DEATH DIFFER, V11, P66; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Li WX, 1996, RADIAT RES, V145, P324, DOI 10.2307/3578988; Li Y, 2007, CELL DEATH DIFFER, V14, P2058, DOI 10.1038/sj.cdd.4402219; Lim chang-Su, 2006, MED HYPO, V67, P341; Mazumder S, 2007, MOL CELL BIOL, V27, P3511, DOI 10.1128/MCB.01448-06; Monteiro JP, 2011, PROTEIN PEPTIDE LETT, V18, P167; Moroi J, 1996, INT J HYPERTHER, V12, P345, DOI 10.3109/02656739609022523; Mosser DD, 2004, ONCOGENE, V23, P2907, DOI 10.1038/sj.onc.1207529; Nijhuis EHA, 2008, INT J HYPERTHER, V24, P357, DOI 10.1080/02656730801944914; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pagliari LJ, 2005, P NATL ACAD SCI USA, V102, P17975, DOI 10.1073/pnas.0506712102; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Reed JC, 2006, CELL DEATH DIFFER, V13, P1378, DOI 10.1038/sj.cdd.4401975; Rossi A, 2006, CANCER RES, V66, P7678, DOI 10.1158/0008-5472.CAN-05-4282; StClair EG, 1997, J BIOL CHEM, V272, P29347; Subramanian C, 2005, P NATL ACAD SCI USA, V102, P4842, DOI 10.1073/pnas.0408351102; Takahashi A, 2004, CANCER RES, V64, P8839, DOI 10.1158/0008-5472.CAN-04-1876; Takahashi I, 2002, SURGERY, V131, pS78, DOI 10.1067/msy.2002.119308; van der Zee J, 2002, ANN ONCOL, V13, P1173, DOI 10.1093/annonc/mdf280; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Weterings E, 2004, DNA REPAIR, V3, P1425, DOI 10.1016/j.dnarep.2004.06.003; Wust P, 2002, LANCET ONCOL, V3, P487, DOI 10.1016/S1470-2045(02)00818-5; Yamaguchi H, 2001, ONCOGENE, V20, P7779, DOI 10.1038/sj.onc.1204984; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Zhao HJ, CLIN CANC RES, V6, P1073; Zolzer F, 2001, RADIAT RES, V155, P50, DOI 10.1667/0033-7587(2001)155[0050:GPDAIA]2.0.CO;2	42	9	9	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 11	2014	9	4							e94213	10.1371/journal.pone.0094213	http://dx.doi.org/10.1371/journal.pone.0094213			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI3CI	24728004	Green Submitted, Green Published, gold			2023-01-03	WOS:000336736200046
J	Yang, CY; Li, F; Du, BW; Chen, B; Wang, F; Wang, MK				Yang, Chunyan; Li, Fu; Du, Baowen; Chen, Bin; Wang, Fei; Wang, Mingkui			Isolation and Characterization of New Phenolic Compounds with Estrogen Biosynthesis-Inhibiting and Antioxidation Activities from Broussonetia papyrifera Leaves	PLOS ONE			English	Article							AROMATASE INHIBITORS; LIQUID-CHROMATOGRAPHY; CELL-LINE; IDENTIFICATION; ALPHA; CONSTITUENTS; GLYCOSIDES; EXTRACT	Broussonetia papyrifera leaves (BPL) as a traditional Chinese medicine are also used in livestock feed for stimulating reproduction, adipose tissue and muscle development; however, the mechanism of their action is still unknown. Through estrogen biosynthesis-guided fractionation in human ovarian granulosa-like KGN cells, five new phenolic glycosides, broussoside A-E(1-5), along with fifteen known dietary phenolic compounds, were isolated from the n-butanol extract of BPL, and their structures were elucidated on the basis of NMR spectra analysis and chemical evidence. New compounds 3, 4, 5 and the known compounds 9 and 10 were found to potently inhibit estrogen biosynthesis in KGN cells. In addition, compounds 9, 17, 18, and 20 showed strong antioxidant activity against ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6sulfonic acid) diammonium salt) and DPPH (1, 1'-diphenyl-2-picryl-hydrazyl radical) assays. These findings suggest that BPL may improve meat quality through the regulation of estrogen biosynthesis. Furthermore, they may be useful for the discovery of potential aromatase modulators from natural products. Finally, they could be considered as a new source for natural antioxidants.	[Yang, Chunyan; Li, Fu; Du, Baowen; Chen, Bin; Wang, Fei; Wang, Mingkui] Chinese Acad Sci, Key Lab Mt Ecol Restorat & Bioresource Utilizat &, Chengdu, Peoples R China; [Yang, Chunyan; Li, Fu; Du, Baowen; Chen, Bin; Wang, Fei; Wang, Mingkui] Chinese Acad Sci, Chengdu Inst Biol, Key Lab Sichuan Prov, Chengdu, Peoples R China; [Yang, Chunyan] Univ Chinese Acad Sci, Beijing, Peoples R China	Chinese Academy of Sciences; Chinese Academy of Sciences; Chengdu Institute of Biology, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Wang, F (corresponding author), Chinese Acad Sci, Key Lab Mt Ecol Restorat & Bioresource Utilizat &, Chengdu, Peoples R China.	wangfei@cib.ac.cn; wangmk@cib.ac.cn		Wang, Fei/0000-0002-2513-502X	National New Drug Innovation 441 Major Project of 442 China [2011ZX09307-002-02]; National Natural Science Foundation of China 443 [20932007, 21372214]	National New Drug Innovation 441 Major Project of 442 China; National Natural Science Foundation of China 443	This work was supported by the National New Drug Innovation 441 Major Project of 442 China (2011ZX09307-002-02) and National Natural Science Foundation of China 443 (Grants 20932007 and 21372214). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alu'datt MH, 2013, FOOD CHEM, V139, P93, DOI 10.1016/j.foodchem.2012.12.061; Bao L, 2010, NAT PROD RES DEV, V22, P939; [鲍玲 Bao Ling], 2010, [天然产物研究与开发, Natural Product R & D], V22, P934; Bhattacharya P, 2013, REV BRAS FARMACOGN, V23, P342, DOI 10.1590/S0102-695X2013005000020; BHAUMIK PK, 1987, PHYTOCHEMISTRY, V26, P3090, DOI 10.1016/S0031-9422(00)84606-3; Bonfield K, 2012, BIOORGAN MED CHEM, V20, P2603, DOI 10.1016/j.bmc.2012.02.042; Cooke PS, 2004, EXP BIOL MED, V229, P1127, DOI 10.1177/153537020422901107; Dawidowicz AL, 2013, EUR FOOD RES TECHNOL, V236, P1099, DOI 10.1007/s00217-013-1982-1; Du QZ, 2012, FOOD CHEM, V131, P1181, DOI 10.1016/j.foodchem.2011.09.095; Gao DF, 2011, FOOD CHEM, V124, P432, DOI 10.1016/j.foodchem.2010.06.048; Gerothanassis IP, 1998, J AGR FOOD CHEM, V46, P4185, DOI 10.1021/jf9804591; GOLLAPUDI SR, 1989, PHYTOCHEMISTRY, V28, P3556, DOI 10.1016/0031-9422(89)80394-2; KIM SY, 1994, J AM OIL CHEM SOC, V71, P633, DOI 10.1007/BF02540592; Kisiel W, 2000, FITOTERAPIA, V71, P269, DOI 10.1016/S0367-326X(99)00158-6; Krafczyk N, 2008, J AGR FOOD CHEM, V56, P3368, DOI 10.1021/jf703701n; Lee D, 2001, J NAT PROD, V64, P1286, DOI 10.1021/np010288l; Lee JH, 2013, FOOD CHEM, V136, P843, DOI 10.1016/j.foodchem.2012.08.057; Liu YB, 2012, J FUNCT FOODS, V4, P116, DOI 10.1016/j.jff.2011.08.006; Lu DF, 2012, J AGR FOOD CHEM, V60, P8411, DOI 10.1021/jf3022817; McInnes KJ, 2008, BREAST CANCER RES TR, V112, P429, DOI 10.1007/s10549-007-9883-2; Minglu X, 2011, J HENAN I SCI TECHNO, P51; Mun'im A, 2003, BIOSCI BIOTECH BIOCH, V67, P410, DOI 10.1271/bbb.67.410; Nair VD, 2013, IND CROP PROD, V45, P406, DOI 10.1016/j.indcrop.2013.01.008; Nishi Y, 2001, ENDOCRINOLOGY, V142, P437, DOI 10.1210/en.142.1.437; Ouyang MA, 2007, J AGR FOOD CHEM, V55, P6460, DOI 10.1021/jf0709808; Pineda B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053902; Reyes JM, 2012, SMALL RUMINANT RES, V106, P178, DOI 10.1016/j.smallrumres.2012.03.017; Ryu HW, 2010, J AGR FOOD CHEM, V58, P202, DOI 10.1021/jf903068k; Sarkar A, 2012, J MOL MODEL, V18, P2621, DOI 10.1007/s00894-011-1274-2; Sashidhara KV, 2013, EUR J MED CHEM, V60, P497, DOI 10.1016/j.ejmech.2012.12.019; Shi J, 2010, MOLECULES, V15, P3556, DOI 10.3390/molecules15053556; Shibano M, 2008, J NAT MED-TOKYO, V62, P349, DOI 10.1007/s11418-008-0244-1; Shoeb M, 2007, J NAT MED, V61, P164, DOI 10.1007/s11418-006-0117-4; Stauffer F, 2012, BIOORG MED CHEM LETT, V22, P1860, DOI 10.1016/j.bmcl.2012.01.076; Suvannang N, 2011, MOLECULES, V16, P3597, DOI 10.3390/molecules16053597; Tang WW, 2012, FITOTERAPIA, V83, P513, DOI 10.1016/j.fitote.2011.12.016; Tarola AM, 2013, FOOD ANAL METHOD, V6, P227, DOI 10.1007/s12161-012-9431-5; ter Veld MGR, 2006, J AGR FOOD CHEM, V54, P4407, DOI 10.1021/jf052864f; Xiong Y, 2009, CHINA FOREST SCI TEC, V23, P42; Xu ML, 2010, FOOD SCI BIOTECHNOL, V19, P677, DOI 10.1007/s10068-010-0095-x; Yang CY, 2013, NAT PROD RES, V27, P2055, DOI 10.1080/14786419.2013.811660; Yang CY, 2012, J SEP SCI, V35, P977, DOI 10.1002/jssc.201101104; Yang LJ, 2013, J ETHNOPHARMACOL, V145, P715, DOI 10.1016/j.jep.2012.11.031; Yang YH, 2012, AQUACULTURE, V350, P1, DOI 10.1016/j.aquaculture.2012.04.031; Yao Y, 2011, INT J MOL SCI, V12, P6445, DOI 10.3390/ijms12106445; Yi B, 2011, MOLECULES, V16, P10157, DOI 10.3390/molecules161210157; Zheng ZP, 2008, FOOD CHEM, V106, P529, DOI 10.1016/j.foodchem.2007.06.037; Zhu LF, 2012, J AGR FOOD CHEM, V60, P12170, DOI 10.1021/jf302726t	48	9	12	1	57	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 8	2014	9	4							e94198	10.1371/journal.pone.0094198	http://dx.doi.org/10.1371/journal.pone.0094198			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE7FA	24714659	Green Published, Green Submitted, gold			2023-01-03	WOS:000334160900104
J	Valles, AS; Aveldano, MI; Furland, NE				Valles, Ana S.; Aveldano, Marta I.; Furland, Natalia E.			Altered Lipid Homeostasis in Sertoli Cells Stressed by Mild Hyperthermia	PLOS ONE			English	Article							APOPTOTIC SPERMATOGENIC CELLS; POLYENOIC FATTY-ACIDS; LONG-CHAIN; IN-VITRO; MITOCHONDRIAL DYSFUNCTION; PHAGOCYTIC FUNCTION; DROPLET FORMATION; MEMBRANE BARRIER; HEAT-STRESS; RAT TESTIS	Spermatogenesis is known to be vulnerable to temperature. Exposures of rat testis to moderate hyperthermia result in loss of germ cells with survival of Sertoli cells (SC). Because SC provide structural and metabolic support to germ cells, our aim was to test the hypothesis that these exposures affect SC functions, thus contributing to germ cell damage. In vivo, regularly repeated exposures (one of 15 min per day, once a day during 5 days) of rat testes to 43 degrees C led to accumulation of neutral lipids. This SC-specific lipid function took 1-2 weeks after the last of these exposures to be maximal. In cultured SC, similar daily exposures for 15 min to 43 degrees C resulted in significant increase in triacylglycerol levels and accumulation of lipid droplets. After incubations with [H-3] arachidonate, the labeling of cardiolipin decreased more than that of other lipid classes. Another specifically mitochondrial lipid metabolic function, fatty acid oxidation, also declined. These lipid changes suggested that temperature affects SC mitochondrial physiology, which was confirmed by significantly increased degrees of membrane depolarization and ROS production. This concurred with reduced expression of two SC-specific proteins, transferrin, and Wilms' Tumor 1 protein, markers of SC secretion and differentiation functions, respectively, and with an intense SC cytoskeletal perturbation, evident by loss of microtubule network (alpha-tubulin) and microfilament (f-actin) organization. Albeit temporary and potentially reversible, hyperthermia-induced SC structural and metabolic alterations may be long-lasting and/or extensive enough to respond for the decreased survival of the germ cells they normally foster.	[Furland, Natalia E.] Consejo Nacl Invest Cient & Tecn, Inst Invest Bioquim Bahi Blanca, Bahia Blanca, Buenos Aires, Argentina; Univ Nacl Sur, RA-8000 Bahia Blanca, Buenos Aires, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of the South	Furland, NE (corresponding author), Consejo Nacl Invest Cient & Tecn, Inst Invest Bioquim Bahi Blanca, Bahia Blanca, Buenos Aires, Argentina.	nfurland@criba.edu.ar	Vallés, Ana Sofía/GVU-5374-2022		Consejo Nacional de Investigaciones Cientificas y Tecnicas; Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCYT); Universidad Nacional del Sur, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCYT)(ANPCyT); Universidad Nacional del Sur, Argentina	This work was supported by grants from Consejo Nacional de Investigaciones Cientificas y Tecnicas, Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCYT), and Universidad Nacional del Sur, Argentina. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adamczyk A, 2006, NEUROCHEM INT, V49, P407, DOI 10.1016/j.neuint.2006.01.025; Appaix F, 2003, EXP PHYSIOL, V88, P175, DOI 10.1113/eph8802511; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boren J, 2012, CELL DEATH DIFFER, V19, P1561, DOI 10.1038/cdd.2012.34; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Butler A, 2002, AM J PATHOL, V161, P1061, DOI 10.1016/S0002-9440(10)64267-8; CHEMES H, 1986, ENDOCRINOLOGY, V119, P1673, DOI 10.1210/endo-119-4-1673; Chen M, 2008, ENDOCRINOLOGY, V149, P4871, DOI 10.1210/en.2007-1093; Chicco AJ, 2007, AM J PHYSIOL-CELL PH, V292, pC33, DOI 10.1152/ajpcell.00243.2006; Connerth M, 2012, SCIENCE, V338, P815, DOI 10.1126/science.1225625; Furland NE, 2007, BIOL REPROD, V77, P181, DOI 10.1095/biolreprod.106.056556; Furland NE, 2011, LIPIDS, V46, P443, DOI 10.1007/s11745-011-3527-3; Gao F, 2006, P NATL ACAD SCI USA, V103, P11987, DOI 10.1073/pnas.0600994103; Guitton N, 1999, INT J RADIAT BIOL, V75, P327, DOI 10.1080/095530099140500; Hikim APS, 1999, REV REPROD, V4, P38; Hikim APS, 2003, ENDOCRINOLOGY, V144, P3167, DOI 10.1210/en.2003-0175; Horvath SE, 2013, PROG LIPID RES, V52, P590, DOI 10.1016/j.plipres.2013.07.002; Houtkooper RH, 2008, CELL MOL LIFE SCI, V65, P2493, DOI 10.1007/s00018-008-8030-5; Kanter M, 2013, TOXICOL IND HEALTH, V29, P99, DOI 10.1177/0748233711425082; KERR JB, 1974, J REPROD FERTIL, V36, P439; Kiebish MA, 2013, J LIPID RES, V54, P1312, DOI 10.1194/jlr.M034728; Kiebish MA, 2012, J BIOL CHEM, V287, P25086, DOI 10.1074/jbc.M112.340521; Linden D, 2004, J LIPID RES, V45, P1279, DOI 10.1194/jlr.M400010-JLR200; Liu MX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045694; Lue YH, 1999, ENDOCRINOLOGY, V140, P1709, DOI 10.1210/en.140.4.1709; Lue YH, 2000, ENDOCRINOLOGY, V141, P1414, DOI 10.1210/en.141.4.1414; Maguire SM, 1997, J MOL ENDOCRINOL, V19, P67, DOI 10.1677/jme.0.0190067; MATHER JP, 1980, BIOL REPROD, V23, P243, DOI 10.1095/biolreprod23.1.243; Moore CR, 1924, SCIENCE, V59, P41, DOI 10.1126/science.59.1515.41; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nakanishi Y, 2004, BIOL PHARM BULL, V27, P13, DOI 10.1248/bpb.27.13; Nauciene Z, 2012, MEDICINA-LITHUANIA, V48, P249, DOI 10.3390/medicina48050036; Oresti GM, 2013, REPRODUCTION, V146, P471, DOI 10.1530/REP-13-0199; Oresti GM, 2010, J LIPID RES, V51, P2909, DOI 10.1194/jlr.M006429; Oresti GM, 2010, J LIPID RES, V51, P2600, DOI 10.1194/jlr.M006395; Paradies G, 2010, FREE RADICAL BIO MED, V48, P1286, DOI 10.1016/j.freeradbiomed.2010.02.020; PINEAU C, 1991, CELL TISSUE RES, V264, P589, DOI 10.1007/BF00319048; POORTHUIS BJHM, 1976, J LIPID RES, V17, P433; Ritzen E.M, 1989, TESTIS, P269; Rockett JC, 2001, BIOL REPROD, V65, P229, DOI 10.1095/biolreprod65.1.229; RUSSELL LD, 1977, ANAT RECORD, V187, P347, DOI 10.1002/ar.1091870307; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Scharnhorst V, 2001, GENE, V273, P141, DOI 10.1016/S0378-1119(01)00593-5; Setchell BP, 1998, J REPROD FERTIL, V114, P179, DOI 10.1530/jrf.0.1140179; Sharpe RM, 2003, REPRODUCTION, V125, P769, DOI 10.1530/rep.0.1250769; SKINNER MK, 1980, J BIOL CHEM, V255, P9523; Tatsuta T, 2014, TRENDS CELL BIOL, V24, P44, DOI 10.1016/j.tcb.2013.07.011; Vance D. E., 1991, BIOCH LIPIDS LIPOPRO; Wang HZ, 2006, REPRODUCTION, V132, P485, DOI 10.1530/rep.1.01213; Xiong WP, 2009, REPRODUCTION, V137, P469, DOI 10.1530/REP-08-0343; Yamamoto CM, 2000, BIOL REPROD, V63, P1683, DOI 10.1095/biolreprod63.6.1683; Yin HY, 2012, FREE RADICAL RES, V46, P959, DOI 10.3109/10715762.2012.676642; Zukiene R, 2010, INT J HYPERTHER, V26, P56, DOI 10.3109/02656730903262140	53	22	22	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2014	9	4							e91127	10.1371/journal.pone.0091127	http://dx.doi.org/10.1371/journal.pone.0091127			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE6KM	24690895	Green Published, Green Submitted, gold			2023-01-03	WOS:000334101100013
J	Khan, U; Nicell, JA				Khan, Usman; Nicell, Jim A.			Contraceptive Options and Their Associated Estrogenic Environmental Loads: Relationships and Trade-Offs	PLOS ONE			English	Article							UNITED-STATES; UNINTENDED PREGNANCY; ENDOCRINE DISRUPTION; AQUATIC ENVIRONMENT; COST-EFFECTIVENESS; STEROID ESTROGENS; URINARY-EXCRETION; DRINKING-WATER; WILD FISH; ETHINYLESTRADIOL	This work explores the relationships between a user's choice of a given contraceptive option and the load of steroidal estrogens that can be associated with that choice. Family planning data for the USA served as a basis for the analysis. The results showed that collectively the use of contraception in the USA conservatively averts the release of approximately 4.8 tonnes of estradiol equivalents to the environment. 35% of the estrogenic load released over the course of all experienced pregnancies events and 34% the estrogenic load represented by all resultant legacies are a result of contraception failure and the non-use of contraception. A scenario analysis conducted to explore the impacts of discontinuing the use of ethinylestradiol-based oral contraceptives revealed that this would not only result in a 1.7-fold increase in the estrogenic loading of the users, but the users would also be expected to experience undesired family planning outcomes at a rate that is 3.3 times higher. Additional scenario analyses in which ethinylestradiol-based oral contraceptive users were modeled as having switched entirely to the use of male condoms, diaphragms or copper IUDs suggested that whether a higher or lower estrogenic load can be associated with the switching population depends on the typical failure rates of the options adopted following discontinuation. And, finally, it was estimated that, in the USA, at most 13% of the annual estrogenic load can be averted by fully meeting the contraceptive needs of the population. Therefore, while the issue of estrogen impacts on the environment cannot be addressed solely by meeting the population's contraceptive needs, a significant fraction of the estrogenic mass released to environment can be averted by improving the level with which their contraceptive needs are met.	[Khan, Usman; Nicell, Jim A.] McGill Univ, Dept Civil Engn & Appl Mech, Montreal, PQ H3A 2K6, Canada	McGill University	Nicell, JA (corresponding author), McGill Univ, Dept Civil Engn & Appl Mech, Montreal, PQ H3A 2K6, Canada.	jim.nicell@mcgill.ca		Nicell, Jim/0000-0003-0119-2967	Natural Sciences and Engineering Research Council of Canada	Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR)	This work was funded by the Natural Sciences and Engineering Research Council of Canada (see www.nserc.ca). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aerni HR, 2004, ANAL BIOANAL CHEM, V378, P688, DOI 10.1007/s00216-003-2276-4; Anderson PD, 2012, ENVIRON TOXICOL CHEM, V31, P1407, DOI 10.1002/etc.1824; [Anonymous], 2010, MED LETT DRUGS THER, V52, P71; [Anonymous], 2012, FACTS UN PREGN US; [Anonymous], 2012, NATURE, V491, P496; Atkinson SK, 2011, ARCH ENVIRON CON TOX, V60, P1, DOI 10.1007/s00244-010-9515-4; Barber LB, 2011, SCI TOTAL ENVIRON, V409, P4720, DOI 10.1016/j.scitotenv.2011.06.039; BERG FD, 1992, ARCH GYNECOL OBSTET, V251, P17, DOI 10.1007/BF02718274; Caldwell DJ, 2012, ENVIRON TOXICOL CHEM, V31, P1396, DOI 10.1002/etc.1825; Caldwell DJ, 2010, ENVIRON HEALTH PERSP, V118, P338, DOI 10.1289/ehp.0900654; DeQuattro ZA, 2012, ENVIRON TOXICOL CHEM, V31, P851, DOI 10.1002/etc.1754; Desbrow C, 1998, ENVIRON SCI TECHNOL, V32, P1549, DOI 10.1021/es9707973; Desforges JPW, 2010, ENVIRON POLLUT, V158, P3279, DOI 10.1016/j.envpol.2010.07.017; EMA, 2012, IOA ASS REP; Finer LB, 2006, PERSPECT SEX REPRO H, V38, P90, DOI 10.1363/3809006; Finer LB, 2012, FERTIL STERIL, V98, P893, DOI 10.1016/j.fertnstert.2012.06.027; Gilbert N, 2012, NATURE, V491, P503, DOI 10.1038/491503a; Goldhaber M K, 1991, Epidemiology, V2, P33; Hogan MC, 2010, LANCET, V375, P1609, DOI 10.1016/S0140-6736(10)60518-1; Institute for Health Metrics and Evaluation, 2010, INF CHILD MORT EST C; Jobling S, 1998, ENVIRON SCI TECHNOL, V32, P2498, DOI 10.1021/es9710870; Johnson AC, 2004, ENVIRON SCI TECHNOL, V38, P3649, DOI 10.1021/es035342u; Johnson AC, 2013, ENVIRON SCI TECHNOL, V47, P12297, DOI 10.1021/es4030035; Johnson AC, 2011, ENVIRON SCI TECHNOL, V45, P1028, DOI 10.1021/es103358t; JOHNSON DW, 1979, CLIN CHIM ACTA, V94, P207, DOI 10.1016/0009-8981(79)90015-9; Jurgens MD, 2002, ENVIRON TOXICOL CHEM, V21, P480, DOI 10.1002/etc.5620210302; Kase R, 2011, WASTE WATER EVALUATI; Kidd KA, 2007, P NATL ACAD SCI USA, V104, P8897, DOI 10.1073/pnas.0609568104; Kiley JW, 2011, INT J WOMENS HEALTH, V3, P281, DOI 10.2147/IJWH.S22645; Kostich M, 2010, SETAC N AM 2010 ANN; McKie R, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e4029; Mosher William D, 2010, Vital Health Stat 23, P1; Owen R, 2012, NATURE, V485, P441, DOI 10.1038/485441a; Owens R., 2013, LATE LESSONS EARLY W, p[279, 292]; Paulos PM, 2011, THESIS U N TEXAS; Rajaratnam JK, 2010, LANCET, V375, P1988, DOI 10.1016/S0140-6736(10)60703-9; Rosenberg MJ, 1998, AM J OBSTET GYNECOL, V179, P577, DOI 10.1016/S0002-9378(98)70047-X; Runnalls TJ, 2013, ENVIRON SCI TECHNOL, V47, P2077, DOI 10.1021/es3048834; Runnalls TJ, 2010, HUM ECOL RISK ASSESS, V16, P1318, DOI 10.1080/10807039.2010.526503; Sinclair CJ, 2006, ENVIRON SCI TECHNOL, V40, P7283, DOI 10.1021/es0603507; Sumpter JP, 2008, J ENVIRON MONITOR, V10, P1476, DOI 10.1039/b815741n; Tanna RN, 2013, ENVIRON TOXICOL CHEM, V32, P1981, DOI 10.1002/etc.2262; Tetreault GR, 2011, AQUAT TOXICOL, V104, P278, DOI 10.1016/j.aquatox.2011.05.008; Thorpe KL, 2001, ENVIRON SCI TECHNOL, V35, P2476, DOI 10.1021/es001767u; TIKKANEN MJ, 1973, J STEROID BIOCHEM, V4, P57, DOI 10.1016/0022-4731(73)90080-0; Trudeau VL, 2011, FRONT EXP ENDOCRINOL, DOI DOI 10.3389/FEND0.2011.00083/FULL.ACCESSED; Trussell J, 2008, EUR J CONTRACEP REPR, V13, P219, DOI 10.1080/13625180802359263; Trussell J, 2007, CONTRACEPTION, V75, P168, DOI 10.1016/j.contraception.2006.11.009; Trussell J, 2013, CONTRACEPTION, V87, P154, DOI 10.1016/j.contraception.2012.07.016; Trussell J, 2012, CONTRACEPTION, V85, P218, DOI 10.1016/j.contraception.2011.06.011; Trussell J, 2011, CONTRACEPTION, V83, P397, DOI 10.1016/j.contraception.2011.01.021; Trussell J, 2009, CONTRACEPTION, V79, P5, DOI 10.1016/j.contraception.2008.08.003; Vajda AM, 2008, ENVIRON SCI TECHNOL, V42, P3407, DOI 10.1021/es0720661; Vajda AM, 2011, AQUAT TOXICOL, V103, P213, DOI 10.1016/j.aquatox.2011.02.007; Ventura Stephanie J, 2012, Natl Vital Stat Rep, V60, P1; Whidbey CM, 2012, WATER RES, V46, P5287, DOI 10.1016/j.watres.2012.07.016; Williams RJ, 2009, ENVIRON TOXICOL CHEM, V28, P220, DOI 10.1897/08-047.1; Wise A, 2011, ENVIRON SCI TECHNOL, V45, P51, DOI 10.1021/es1014482; Worstall Tim, 2012, FORBES; Yamamoto T. O., 1969, P117; YAMAMOTO TO, 1965, GEN COMP ENDOCR, V5, P527, DOI 10.1016/0016-6480(65)90041-9; Zeilinger J, 2009, ENVIRON TOXICOL CHEM, V28, P2663, DOI 10.1897/08-485.1	62	9	9	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2014	9	3							e92630	10.1371/journal.pone.0092630	http://dx.doi.org/10.1371/journal.pone.0092630			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE0SR	24670973	gold, Green Published, Green Submitted			2023-01-03	WOS:000333677000059
J	Tang, NKY; Sanborn, AN				Tang, Nicole K. Y.; Sanborn, Adam N.			Better Quality Sleep Promotes Daytime Physical Activity in Patients with Chronic Pain? A Multilevel Analysis of the Within-Person Relationship	PLOS ONE			English	Article							ELECTRONIC DIARY ASSESSMENT; LOW-BACK-PAIN; FEAR-AVOIDANCE; INDIVIDUAL-DIFFERENCES; MUSCULOSKELETAL PAIN; MOOD DISTURBANCE; INSOMNIA; CONSEQUENCES; VALIDATION; ACTIGRAPHY	Background: Promoting physical activity is key to the management of chronic pain, but little is understood about the factors facilitating an individual's engagement in physical activity on a day-to-day basis. This study examined the within-person effect of sleep on next day physical activity in patients with chronic pain and insomnia. Methods: 119 chronic pain patients monitored their sleep and physical activity for a week in their usual sleeping and living environment. Physical activity was measured using actigraphy to provide a mean activity score each hour. Sleep was estimated with actigraphy and an electronic diary, providing an objective and subjective index of sleep efficiency (A-SE, SE) and a sleep quality rating (SQ). The individual and relative roles of these sleep parameters, as well as morning ratings of pain and mood, in predicting subsequent physical activity were examined in multilevel models that took into account variations in relationships at the 'Day' and 'Participant' levels. Results: Of the 5 plausible predictors SQ was the only significant within-person predictor of subsequent physical activity, such that nights of higher sleep quality were followed by days of more physical activity, from noon to 11 pm. The temporal association was not explained by potential confounders such as morning pain, mood or effects of the circadian rhythm. Conclusions: In the absence of interventions, chronic pain patients spontaneously engaged in more physical activity following a better night of sleep. Improving nighttime sleep may well be a novel avenue for promoting daytime physical activity in patients with chronic pain.	[Tang, Nicole K. Y.; Sanborn, Adam N.] Univ Warwick, Dept Psychol, Coventry CV4 7AL, W Midlands, England	University of Warwick	Sanborn, AN (corresponding author), Univ Warwick, Dept Psychol, Coventry CV4 7AL, W Midlands, England.	n.tang@warwick.ac.uk	Sanborn, Adam/G-3715-2010; Tang, Nicole KY/B-9998-2009	Sanborn, Adam/0000-0003-0442-4372; Tang, Nicole KY/0000-0001-7836-9965	National Institute for Health Research, UK [PDA/02/06/085]	National Institute for Health Research, UK(National Institute for Health Research (NIHR))	The study was funded by a personal award to NT from the National Institute for Health Research, UK (PDA/02/06/085). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aaron LA, 2005, J PAIN, V6, P107, DOI 10.1016/j.jpain.2004.11.003; AFFLECK G, 1991, HEALTH PSYCHOL, V10, P419, DOI 10.1037/0278-6133.10.6.419; AFFLECK G, 1994, J PERS SOC PSYCHOL, V66, P329, DOI 10.1037/0022-3514.66.2.329; Affleck G, 1999, J CONSULT CLIN PSYCH, V67, P746, DOI 10.1037/0022-006X.67.5.746; AKERSTEDT T, 1994, PERCEPT MOTOR SKILL, V79, P287, DOI 10.2466/pms.1994.79.1.287; Asmundson GJG, 1999, CLIN PSYCHOL REV, V19, P97, DOI 10.1016/S0272-7358(98)00034-8; Asmundson GJG, 1998, J ANXIETY DISORD, V12, P57, DOI 10.1016/S0887-6185(97)00049-2; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Bolger N, 2003, ANNU REV PSYCHOL, V54, P579, DOI 10.1146/annurev.psych.54.101601.145030; Booth JN, 2012, OBESITY, V20, P278, DOI 10.1038/oby.2011.306; Carney CE, 2012, SLEEP, V35, P287, DOI 10.5665/sleep.1642; Dam TTL, 2008, J AM GERIATR SOC, V56, P1665, DOI 10.1111/j.1532-5415.2008.01846.x; Eccleston C, 1999, PSYCHOL BULL, V125, P356, DOI 10.1037/0033-2909.125.3.356; Edinger J.D., 2006, DUKE STRUCTURED INTE; Edinger JD, 2004, SLEEP, V27, P1567, DOI 10.1093/sleep/27.8.1567; Goldman SE, 2007, SLEEP, V30, P1317, DOI 10.1093/sleep/30.10.1317; Haack M, 2005, PAIN, V119, P56, DOI 10.1016/j.pain.2005.09.011; Hallal PC, 2012, LANCET, V380, P247, DOI 10.1016/S0140-6736(12)60646-1; Harris S, 2003, PAIN, V105, P363, DOI 10.1016/S0304-3959(03)00251-3; Harvey AG, 2008, SLEEP, V31, P383, DOI 10.1093/sleep/31.3.383; HASENBRING M, 1994, SPINE, V19, P2759, DOI 10.1097/00007632-199412150-00004; Hasenbring MI, 2010, CLIN J PAIN, V26, P747, DOI 10.1097/AJP.0b013e3181e104f2; HAYTHORNTHWAITE JA, 1991, J PAIN SYMPTOM MANAG, V6, P65, DOI 10.1016/0885-3924(91)90520-E; Helmus M, 2012, EUR J PAIN, V16, P1158, DOI 10.1002/j.1532-2149.2011.00109.x; Huijnen IPJ, 2011, EUR J PAIN, V15, P748, DOI 10.1016/j.ejpain.2010.11.015; Huijnen IPJ, 2010, PAIN, V150, P161, DOI 10.1016/j.pain.2010.04.021; Keklund G, 1997, J SLEEP RES, V6, P217, DOI 10.1111/j.1365-2869.1997.00217.x; Lentz MJ, 1999, J RHEUMATOL, V26, P1586; Leonhardt C, 2009, GMS PSYCHOSOCIAL MED, V6; LETHEM J, 1983, BEHAV RES THER, V21, P401, DOI 10.1016/0005-7967(83)90009-8; Lichstein KL, 2006, SLEEP, V29, P232; MOLDOFSKY H, 1976, PSYCHOSOM MED, V38, P35, DOI 10.1097/00006842-197601000-00006; Morgenthaler T, 2007, SLEEP, V30, P519, DOI 10.1093/sleep/30.4.519; Morin CM, 1998, CLIN J PAIN, V14, P311, DOI 10.1097/00002508-199812000-00007; National Institute for Clinical Excellence, 2013, PH44 PHYS ACT BRIEF; National Institute for Clinical Excellence, 2012, PH41 WALK CYCL GUID; National Institute for Clinical Excellence, 2006, PH2 4 COMM US METH I; Peters ML, 2000, PAIN, V84, P181, DOI 10.1016/S0304-3959(99)00206-7; PHILIPS HC, 1987, BEHAV RES THER, V25, P273, DOI 10.1016/0005-7967(87)90005-2; Pilsworth SN, 2001, SLEEP, V24, pA106; Pincus T, 2001, PSYCHOL BULL, V127, P599, DOI 10.1037//0033-2909.127.5.599; Roehrs T, 2006, SLEEP, V29, P145, DOI 10.1093/sleep/29.2.145; Smith MT, 2007, SLEEP, V30, P494, DOI 10.1093/sleep/30.4.494; Smith MT, 2009, CURR PAIN HEADACHE R, V13, P447, DOI 10.1007/s11916-009-0073-2; Stone AA, 2003, CONTROL CLIN TRIALS, V24, P182, DOI 10.1016/S0197-2456(02)00320-3; Tang NKY, 2007, J SLEEP RES, V16, P85, DOI 10.1111/j.1365-2869.2007.00571.x; Tang NKY, 2012, SLEEP, V35, P675, DOI 10.5665/sleep.1830; The IASP Taxonomy Working Group, 2013, CLASS CHRON PAIN DES; Van Damme S, 2010, NEUROSCI BIOBEHAV R, V34, P204, DOI 10.1016/j.neubiorev.2009.01.005; Vendrig AA, 1997, PAIN, V73, P71, DOI 10.1016/S0304-3959(97)00075-4; Verbunt J, 2004, UNDERSTANDING TREATI, P139; VLAEYEN JWS, 1995, PAIN, V62, P363, DOI 10.1016/0304-3959(94)00279-N; Vlaeyen JWS, 2000, PAIN, V85, P317, DOI 10.1016/S0304-3959(99)00242-0; WADDELL G, 1993, PAIN, V52, P157, DOI 10.1016/0304-3959(93)90127-B; WHO, 2010, SCREENING DONATED BLOOD FOR TRANSFUSION: TRANSMISSIBLE INFECTIONS, P1	55	50	51	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2014	9	3							e92158	10.1371/journal.pone.0092158	http://dx.doi.org/10.1371/journal.pone.0092158			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AE0SD	24667276	gold, Green Published, Green Submitted			2023-01-03	WOS:000333675600023
J	Morris, T; Sumners, DP; Green, DA				Morris, Theresa; Sumners, David Paul; Green, David Andrew			Inspiratory High Frequency Airway Oscillation Attenuates Resistive Loaded Dyspnea and Modulates Respiratory Function in Young Healthy Individuals	PLOS ONE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; CHEST-WALL VIBRATION; MUSCLE-SPINDLE ENDINGS; HIGH-INTENSITY; LUNG-FUNCTION; INTERCOSTAL MUSCLES; EXERCISE TOLERANCE; SOCIETY STATEMENT; UPTAKE KINETICS; MOTOR CONTROL	Direct chest-wall percussion can reduce breathlessness in Chronic Obstructive Pulmonary Disease and respiratory function may be improved, in health and disease, by respiratory muscle training (RMT). We tested whether high-frequency airway oscillation (HFAO), a novel form of airflow oscillation generation can modulate induced dyspnoea and respiratory strength and/or patterns following 5 weeks of HFAO training (n = 20) compared to a SHAM-RMT (conventional flow-resistive RMT) device (n = 15) in healthy volunteers (13 males; aged 20-36 yrs). HFAO causes oscillations with peak-to-peak amplitude of 1 cm H2O, whereas the SHAM-RMT device was identical but created no pressure oscillation. Respiratory function, dyspnoea and ventilation during 3 minutes of spontaneous resting ventilation, 1 minute of maximal voluntary hyperventilation and 1 minute breathing against a moderate inspiratory resistance, were compared PRE and POST 5-weeks of training (2630 breaths at 70% peak flow, 5 days a week). Training significantly reduced NRS dyspnoea scores during resistive loaded ventilation, both in the HFAO (p = 0.003) and SHAM-RMT (p = 0.005) groups. Maximum inspiratory static pressure (cm H2O) was significantly increased by HFAO training (vs. PRE; p<0.001). Maximum inspiratory dynamic pressure was increased by training in both the HFAO (vs. PRE; p<0.001) and SHAM-RMT (vs. PRE; p = 0.021) groups. Peak inspiratory flow rate (L. s(-1)) achieved during the maximum inspiratory dynamic pressure manoeuvre increased significantly POST (vs. PRE; p = 0.001) in the HFAO group only. HFAO reduced inspiratory resistive loading-induced dyspnoea and augments static and dynamic maximal respiratory manoeuvre performance in excess of flow-resistive IMT (SHAM-RMT) in healthy individuals without the respiratory discomfort associated with RMT.	[Morris, Theresa; Green, David Andrew] Kings Coll London, Ctr Human & Aerosp Physiol Sci, London, England; [Sumners, David Paul] London S Bank Univ, London, England	University of London; King's College London; London South Bank University	Green, DA (corresponding author), Kings Coll London, Ctr Human & Aerosp Physiol Sci, London, England.	David.a.green@kcl.ac.uk			Guys & St Thomas Charity [R090766]	Guys & St Thomas Charity	The work has been facilitated by a Guys & St Thomas Charity (http://www.gsttcharity.org.uk/) grant (R090766). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ambrosino N, 2008, RESP MED, V102, pS17, DOI 10.1016/S0954-6111(08)70004-0; Bailey CD, 2010, BMC PULM MED, V10, DOI 10.1186/1471-2466-10-63; Bailey SJ, 2010, J APPL PHYSIOL, V109, P457, DOI 10.1152/japplphysiol.00077.2010; Beckerman M, 2005, CHEST, V128, P3177, DOI 10.1378/chest.128.5.3177; BOLSER DC, 1988, J APPL PHYSIOL, V64, P2458, DOI 10.1152/jappl.1988.64.6.2458; BOLSER DC, 1987, J APPL PHYSIOL, V62, P1046, DOI 10.1152/jappl.1987.62.3.1046; Bongianni F, 1996, BRAIN RES BULL, V39, P267, DOI 10.1016/0361-9230(95)02139-6; BONGIOVANNI LG, 1990, J PHYSIOL-LONDON, V423, P1; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Braido F, 2011, CURR MED RES OPIN, V27, P981, DOI 10.1185/03007995.2011.563285; BRESLIN EH, 1990, CHEST, V98, P298, DOI 10.1378/chest.98.2.298; Brown PI, 2008, EUR J APPL PHYSIOL, V104, P111, DOI 10.1007/s00421-008-0794-7; BURKE D, 1976, J PHYSIOL-LONDON, V261, P673, DOI 10.1113/jphysiol.1976.sp011580; Butler JE, 2001, J PHYSIOL-LONDON, V534, P583, DOI 10.1111/j.1469-7793.2001.00583.x; Calverley PMA, 2006, EUR RESPIR REV, V15, P72, DOI 10.1183/09059180.00010004; COON RL, 1993, J APPL PHYSIOL, V74, P811, DOI 10.1152/jappl.1993.74.2.811; Cristiano LM, 1997, AM J RESP CRIT CARE, V155, P1552, DOI 10.1164/ajrccm.155.5.9154856; Decramer M, 2009, J APPL PHYSIOL, V107, P971, DOI 10.1152/japplphysiol.91459.2008; Delecluse C, 2003, MED SCI SPORT EXER, V35, P1033, DOI 10.1249/01.MSS.0000069752.96438.B0; DETROYER A, 1994, AM J RESP CRIT CARE, V150, P41, DOI 10.1164/ajrccm.150.1.8025770; Diba C, 2011, RESP MED, V105, P1345, DOI 10.1016/j.rmed.2011.03.013; Downey AE, 2007, RESP PHYSIOL NEUROBI, V156, P137, DOI 10.1016/j.resp.2006.08.006; Edwards AM, 2004, EUR J APPL PHYSIOL, V93, P139, DOI 10.1007/s00421-004-1188-0; ELDRIDGE FL, 1992, RESP PHYSIOL, V90, P31, DOI 10.1016/0034-5687(92)90132-G; ELMANSHAWI A, 1986, J APPL PHYSIOL, V61, P896, DOI 10.1152/jappl.1986.61.3.896; Enright S, 2004, CHEST, V126, P405, DOI 10.1378/chest.126.2.405; Enright SJ, 2006, PHYS THER, V86, P345, DOI 10.1093/ptj/86.3.345; Evans KC, 2010, BIOL PSYCHOL, V84, P13, DOI 10.1016/j.biopsycho.2010.02.005; FLUME PA, 1994, RESP PHYSIOL, V95, P53, DOI 10.1016/0034-5687(94)90047-7; Fujie T, 2002, RESP PHYSIOL NEUROBI, V130, P305, DOI 10.1016/S0034-5687(02)00014-2; Gandevia SC, 1996, AM J RESP CRIT CARE, V153, P622, DOI 10.1164/ajrccm.153.2.8564108; GANDEVIA SC, 1987, TRENDS NEUROSCI, V10, P81, DOI 10.1016/0166-2236(87)90030-0; GANDEVIA SC, 1989, RESP PHYSIOL, V77, P203, DOI 10.1016/0034-5687(89)90007-8; Geddes EL, 2008, RESP MED, V102, P1715, DOI 10.1016/j.rmed.2008.07.005; Gerodimos V, 2010, J SCI MED SPORT, V13, P438, DOI 10.1016/j.jsams.2009.09.001; Gift A G, 1989, Rehabil Nurs, V14, P323; Gift A G, 1998, Am J Crit Care, V7, P200; Gosselink R, 2000, ARCH PHYS MED REHAB, V81, P747, DOI 10.1053/apmr.2000.5616; Gosselink R, 2011, EUR RESPIR J, V37, P416, DOI 10.1183/09031936.00031810; Griffin L, 2001, J PHYSIOL-LONDON, V535, P929, DOI 10.1111/j.1469-7793.2001.00929.x; Grimby G, 2012, RELATIVE CONTRIBUTIO, P159; Guenette JA, 2007, J SCI MED SPORT, V10, P341, DOI 10.1016/j.jsams.2007.02.003; GUYATT GH, 1987, J CHRON DIS, V40, P1129, DOI 10.1016/0021-9681(87)90080-4; HOMMA I, 1978, RESP PHYSIOL, V35, P335, DOI 10.1016/0034-5687(78)90007-5; How SC, 2007, RESP PHYSIOL NEUROBI, V157, P270, DOI 10.1016/j.resp.2007.01.008; Huang CH, 2009, APPL PSYCHOPHYS BIOF, V34, P17, DOI 10.1007/s10484-008-9073-y; HUFSCHMIDT HJ, 1958, PFLUG ARCH GES PHYS, V267, P508, DOI 10.1007/BF00361737; Jolley CJ, 2009, EUR RESPIR J, V33, P289, DOI 10.1183/09031936.00093408; Kaminsky DA, 2012, RESP CARE, V57, P85, DOI 10.4187/respcare.01411; Kellerman BA, 2000, MED SCI SPORT EXER, V32, P1859, DOI 10.1097/00005768-200011000-00007; KILLIAN KJ, 1984, J APPL PHYSIOL, V57, P686, DOI 10.1152/jappl.1984.57.3.686; Koppers RJH, 2006, RESP MED, V100, P714, DOI 10.1016/j.rmed.2005.07.013; Lamb TW, 2012, NATURE VIBRATION HYP, P404; Leduc D, 2003, J PHYSL; Lee LY, 2009, RESP PHYSIOL NEUROBI, V167, P26, DOI 10.1016/j.resp.2008.05.006; Mahler Donald A, 2005, COPD, V2, P99; Mahut B, 2011, RESPIROLOGY, V16, P666, DOI 10.1111/j.1440-1843.2011.01953.x; MAN GCW, 1990, J APPL PHYSIOL, V68, P714, DOI 10.1152/jappl.1990.68.2.714; MANNING HL, 1992, RESP PHYSIOL, V90, P19, DOI 10.1016/0034-5687(92)90131-F; Marks GB, 1996, THORAX, V51, P793, DOI 10.1136/thx.51.8.793; MARSDEN CD, 1969, BRAIN, V92, P647, DOI 10.1093/brain/92.3.647; McConnell AK, 2004, INT J SPORTS MED, V25, P284, DOI 10.1055/s-2004-815827; McConnell AK, 2004, SPORTS MED, V34, P117, DOI 10.2165/00007256-200434020-00005; McConnell AK, 2010, MED SCI SPORT EXER, V42, P1696, DOI 10.1249/MSS.0b013e3181d435cf; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Mitchell GS, 2003, J APPL PHYSIOL, V94, P358, DOI 10.1152/japplphysiol.00523.2002; Moosavi SH, 2004, J APPL PHYSIOL, V97, P2098, DOI 10.1152/japplphysiol.00056.2004; Moosavi SH, 2000, RESP PHYSIOL, V122, P45, DOI 10.1016/S0034-5687(00)00135-3; NADEL JA, 1961, J APPL PHYSIOL, V16, P717, DOI 10.1152/jappl.1961.16.4.717; Nakayama H, 1998, INTERNAL MED, V37, P831, DOI 10.2169/internalmedicine.37.831; Nici L, 2006, AM J RESP CRIT CARE, V173, P1390, DOI 10.1164/rccm.200508-1211ST; Nield MA, 1999, ARCH PHYS MED REHAB, V80, P100, DOI 10.1016/S0003-9993(99)90315-5; Nishino T, 2000, AM J RESP CRIT CARE, V161, P1963, DOI 10.1164/ajrccm.161.6.9910009; Nishino T, 2009, J PAIN SYMPTOM MANAG, V37, P212, DOI 10.1016/j.jpainsymman.2008.02.017; O'Donnell DE, 2009, RESP PHYSIOL NEUROBI, V167, P116, DOI 10.1016/j.resp.2009.01.010; O'Donnell DE, 2008, J APPL PHYSIOL, V105, P753, DOI 10.1152/japplphysiol.90336.2008b; OKROY JA, 1993, RESPIRATION, V60, P279; Oxberry SG, 2012, AM HEART J, V164, P229, DOI 10.1016/j.ahj.2012.05.003; Parshall MB, 2012, AM J RESP CRIT CARE, V185, P435, DOI 10.1164/rccm.201111-2042ST; Ramirez-Sarmiento A, 2002, AM J RESP CRIT CARE, V166, P1491, DOI 10.1164/rccm.200202-075OC; REDLINE S, 1991, J APPL PHYSIOL, V70, P240, DOI 10.1152/jappl.1991.70.1.240; REID WD, 1995, PHYS THER, V75, P996, DOI 10.1093/ptj/75.11.996; Ries Andrew L, 2005, COPD, V2, P105; Ries AL, 2007, CHEST, V131, p4S, DOI 10.1378/chest.06-2418; Romer LM, 2003, MED SCI SPORT EXER, V35, P237, DOI 10.1249/01.MSS.0000048642.58419.1E; Romer LM, 2002, INT J SPORTS MED, V23, P353, DOI 10.1055/s-2002-33143; SIBUYA M, 1994, AM J RESP CRIT CARE, V149, P1235, DOI 10.1164/ajrccm.149.5.8173764; SIMON PM, 1989, AM REV RESPIR DIS, V140, P1021, DOI 10.1164/ajrccm/140.4.1021; Sloan Jeff A, 2005, COPD, V2, P57; SMITH JC, 1986, J APPL PHYSIOL, V60, P928, DOI 10.1152/jappl.1986.60.3.928; Sonetti DA, 2001, RESP PHYSIOL, V127, P185, DOI 10.1016/S0034-5687(01)00250-X; Sumners DP, 2008, RESP PHYSIOL NEUROBI, V160, P350, DOI 10.1016/j.resp.2007.10.005; Sumners DP, 2009, EUROPEAN J APPL; Turner LA, 2012, J APPL PHYSIOL, V112, P127, DOI 10.1152/japplphysiol.00954.2011; Turner LA, 2011, MED SCI SPORT EXER, V43, P2031, DOI 10.1249/MSS.0b013e31821f4090; Undem BJ, 2009, RESP PHYSIOL NEUROBI, V167, P36, DOI 10.1016/j.resp.2008.11.012; Verges S, 2009, RESP PHYSIOL NEUROBI, V169, P282, DOI 10.1016/j.resp.2009.09.005; Volianitis S, 2001, MED SCI SPORT EXER, V33, P803; Wang QX, 2010, RESP CARE, V55, P1449; Weiner P, 2004, EUR RESPIR J, V23, P61, DOI 10.1183/09031936.03.00059503; Weiner P, 2003, CHEST J, V124; Widdicombe J, 2009, RESP PHYSIOL NEUROBI, V167, P2, DOI 10.1016/j.resp.2008.09.012; Wilcock IM, 2009, J STRENGTH COND RES, V23, P593, DOI 10.1519/JSC.0b013e318196b81f; Witt JD, 2007, J PHYSIOL-LONDON, V584, P1019, DOI 10.1113/jphysiol.2007.140855; Wouters EFM, 2002, THORAX, V57, P1067, DOI 10.1136/thorax.57.12.1067	105	3	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2014	9	3							e91291	10.1371/journal.pone.0091291	http://dx.doi.org/10.1371/journal.pone.0091291			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AD6FV	24651392	Green Submitted, Green Published, gold			2023-01-03	WOS:000333352800037
J	Garon, EB; Ciuleanu, TE; Arrieta, O; Prabhash, K; Syrigos, KN; Goksel, T; Park, K; Gorbunova, V; Kowalyszyn, RD; Pikiel, J; Czyzewicz, G; Orlov, SV; Lewanski, CR; Thomas, M; Bidoli, P; Dakhil, S; Gans, S; Kim, JH; Grigorescu, A; Karaseva, N; Reck, M; Cappuzzo, F; Alexandris, E; Sashegyi, A; Yurasov, S; Perol, M				Garon, Edward B.; Ciuleanu, Tudor-Eliade; Arrieta, Oscar; Prabhash, Kumar; Syrigos, Konstantinos N.; Goksel, Tuncay; Park, Keunchil; Gorbunova, Vera; Dario Kowalyszyn, Ruben; Pikiel, Joanna; Czyzewicz, Grzegorz; Orlov, Sergey V.; Lewanski, Conrad R.; Thomas, Michael; Bidoli, Paolo; Dakhil, Shaker; Gans, Steven; Kim, Joo-Hang; Grigorescu, Alexandru; Karaseva, Nina; Reck, Martin; Cappuzzo, Federico; Alexandris, Ekaterine; Sashegyi, Andreas; Yurasov, Sergey; Perol, Maurice			Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial	LANCET			English	Article							III TRIAL; BEVACIZUMAB; CARBOPLATIN; PACLITAXEL; CHEMOTHERAPY; SURVIVAL; ANGIOGENESIS; ERLOTINIB; LIFE	Background Ramucirumab is a human IgG1 monoclonal antibody that targets the extracellular domain of VEGFR-2. We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC) after platinum-based therapy. Methods In this multicentre, double-blind, randomised phase 3 trial (REVEL), we enrolled patients with squamous or non-squamous NSCLC who had progressed during or after a first-line platinum-based chemotherapy regimen. Patients were randomly allocated (1:1) with a centralised, interactive voice-response system (stratified by sex, region, performance status, and previous maintenance therapy [yes vs no]) to receive docetaxel 75 mg/m(2) and either ramucirumab (10 mg/kg) or placebo on day 1 of a 21 day cycle until disease progression, unacceptable toxicity, withdrawal, or death. The primary endpoint was overall survival in all patients allocated to treatment. We assessed adverse events according to treatment received. This study is registered with ClinicalTrials.gov, number NCT01168973. Findings Between Dec 3, 2010, and Jan 24, 2013, we screened 1825 patients, of whom 1253 patients were randomly allocated to treatment. Median overall survival was 10.5 months (IQR 5.1-21.2) for 628 patients allocated ramucirumab plus docetaxel and 9.1 months (4.2-18.0) for 625 patients who received placebo plus docetaxel (hazard ratio 0.86, 95% CI 0.75-0.98; p=0.023). Median progression-free survival was 4.5 months (IQR 2.3-8.3) for the ramucirumab group compared with 3.0 months (1.4-6.9) for the control group (0.76, 0.68-0.86; p<0.0001). We noted treatment-emergent adverse events in 613 (98%) of 627 patients in the ramucirumab safety population and 594 (95%) of 618 patients in the control safety population. The most common grade 3 or worse adverse events were neutropenia (306 patients [49%] in the ramucirumab group vs 246 [40%] in the control group), febrile neutropenia (100 [16%] vs 62 [10%]), fatigue (88 [14%] vs 65 [10%]), leucopenia (86 [14%] vs 77 [12%]), and hypertension (35 [6%] vs 13 [2%]). The numbers of deaths from adverse events (31 [5%] vs 35 [6%]) and grade 3 or worse pulmonary haemorrhage (eight [1%] vs eight [1%]) did not differ between groups. Toxicities were manageable with appropriate dose reductions and supportive care. Interpretation Ramucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC.	[Garon, Edward B.] Univ Calif Los Angeles, David Geffen Sch Med, Translat Res Oncol US Network, Los Angeles, CA 90095 USA; [Ciuleanu, Tudor-Eliade] Inst Oncol Ion Chiricuta, Cluj Napoca, Romania; [Ciuleanu, Tudor-Eliade] Univ Med & Pharm Iuliu Hatieganu, Cluj Napoca, Romania; [Arrieta, Oscar] Inst Nacl Cancerol INCAN, Mexico City, DF, Mexico; [Prabhash, Kumar] Tata Mem Hosp, Bombay, Maharashtra, India; [Syrigos, Konstantinos N.] Sotiria Gen Hosp, Athens Sch Med, Oncol Unit GPP, Athens, Greece; [Goksel, Tuncay] Ege Univ, Sch Med, Izmir, Turkey; [Park, Keunchil] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul, South Korea; [Gorbunova, Vera] NN Blokhin Canc Res Ctr, Dept Chemotherapy, Moscow, Russia; [Dario Kowalyszyn, Ruben] Clin Viedma, Ctr Invest Clin, Viedma, Argentina; [Pikiel, Joanna] Wojewodzkie Ctr Onkol, Gdansk, Poland; [Czyzewicz, Grzegorz] John Paul 2 Hosp, Dept Chemotherapy, Krakow, Poland; [Orlov, Sergey V.] Pavlov State Med Univ, St Petersburg, Russia; [Lewanski, Conrad R.] Charing Cross Hosp, London, England; [Thomas, Michael] Univ Klinikum Heidelberg, Thoraxklin, Translat Lung Res Ctr Heidelberg TLRC H, German Ctr Lung Res DZL, Heidelberg, Germany; [Bidoli, Paolo] San Gerardo Hosp, Monza, Italy; [Dakhil, Shaker] Canc Ctr Kansas, Wichita, KS USA; [Gans, Steven] St Jansdal Hosp, Herderwijk, Netherlands; [Kim, Joo-Hang] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Seoul, South Korea; [Grigorescu, Alexandru] Inst Oncol, Dept Med Oncol, Bucharest, Romania; [Karaseva, Nina] City Clin Oncol Dispensary, St Petersburg, Russia; [Reck, Martin] German Ctr Lung Res DZL, LungenClin Grosshansdorf, Grosshansdorf, Germany; [Cappuzzo, Federico] Ist Toscano Tumori, Livorno, Italy; [Alexandris, Ekaterine; Yurasov, Sergey] Eli Lilly, ImClone Syst, Bridgewater, NJ USA; [Sashegyi, Andreas] Eli Lilly & Co, Indianapolis, IN 46285 USA; [Perol, Maurice] Leon Berard Canc Ctr, Lyon, France	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Oncology Institute Prof. Dr. Ion Chiricuta; Iuliu Hatieganu University of Medicine & Pharmacy; Instituto Nacional de Cancerologia (INCAN); Tata Memorial Centre (TMC); Tata Memorial Hospital; Athens Medical School; National & Kapodistrian University of Athens; Ege University; Sungkyunkwan University (SKKU); Samsung Medical Center; N.N. Blokhin Russian Cancer Research Center; Pavlov First Saint Petersburg State Medical University; Imperial College London; Ruprecht Karls University Heidelberg; San Gerardo Hospital; Cancer Center of Kansas; Yonsei University; Yonsei University Health System; Institute of Oncology "Prof. Dr. Al Trestioreanu"; Grosshansdorf Hospital; ISPRO Istituto per lo studio, la prevenzione e la rete oncologica; Eli Lilly; Eli Lilly; UNICANCER; Centre Leon Berard	Garon, EB (corresponding author), Translat Oncol Res Lab, 2825 Santa Monica Blvd,Suite 200, Santa Monica, CA 90404 USA.	egaron@mednet.ucla.edu	Cappuzzo, federico/R-2827-2016; GRIGORESCU, Alexandru Calin/M-7751-2018; Arrieta, Oscar/ABH-6022-2020; Reck, Martin/ABF-5721-2020; Park, Keunchil/ABD-7072-2021; Park, Keunchil/ABD-5852-2021; Orlov, Sergey/AAC-8379-2022; Syrigos, Kostas/AAE-8045-2019; Ciuleanu, Tudor-Eliade/ABH-8452-2020	Cappuzzo, federico/0000-0002-6295-6767; Reck, Martin/0000-0002-5348-4462; Park, Keunchil/0000-0002-4846-7449; Orlov, Sergey/0000-0001-6080-8042; Arrieta, Oscar/0000-0002-1164-3779; Ciuleanu, Tudor Eliade/0000-0003-0958-5597	Eli Lilly	Eli Lilly(Eli Lilly)	Funding Eli Lilly.	Booth CM, 2012, J CLIN ONCOL, V30, P1030, DOI 10.1200/JCO.2011.38.7571; Crino L, 2014, EUR RESPIR REV, V23, P79, DOI 10.1183/09059180.00008913; Di Maio M, 2010, EUR J CANCER, V46, P735, DOI 10.1016/j.ejca.2009.12.013; Fossella FV, 2000, J CLIN ONCOL, V18, P2354, DOI 10.1200/JCO.2000.18.12.2354; Fuchs CS, 2014, LANCET, V383, P31, DOI 10.1016/S0140-6736(13)61719-5; Garassino MC, 2013, LANCET ONCOL, V14, P981, DOI 10.1016/S1470-2045(13)70310-3; Garon EB, 2012, CLIN LUNG CANCER, V13, P505, DOI 10.1016/j.cllc.2012.06.007; Gerber DE, 2013, J CLIN ONCOL, V31, P1009, DOI 10.1200/JCO.2012.43.7459; Hainsworth JD, 2011, J THORAC ONCOL, V6, P109, DOI 10.1097/JTO.0b013e3181f94ad4; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanna N, 2004, J CLIN ONCOL, V22, P1589, DOI 10.1200/JCO.2004.08.163; HOLLEN PJ, 1993, EUR J CANCER, V29A, pS51, DOI 10.1016/S0959-8049(05)80262-X; Hotta K, 2007, J THORAC ONCOL, V2, P402, DOI 10.1097/01.JTO.0000268673.95119.c7; Johnson DH, 2004, J CLIN ONCOL, V22, P2184, DOI 10.1200/JCO.2004.11.022; Kim ES, 2008, LANCET, V372, P1809, DOI 10.1016/S0140-6736(08)61758-4; Leighl NB, 2012, CURR ONCOL, V19, pS52, DOI 10.3747/co.19.1114; Li TH, 2013, J CLIN ONCOL, V31, P1039, DOI 10.1200/JCO.2012.45.3753; Mackey J, 2013, SAN ANT BREAST CANC; Ramalingam SS, 2008, J CLIN ONCOL, V26, P60, DOI 10.1200/JCO.2007.13.1144; Reck M, 2010, ANN ONCOL, V21, P1804, DOI 10.1093/annonc/mdq020; Reck M, 2014, LANCET ONCOL, V15, P143, DOI 10.1016/S1470-2045(13)70586-2; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Sandler AB, 2009, J CLIN ONCOL, V27, P1405, DOI 10.1200/JCO.2008.16.2412; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Shepherd FA, 2000, J CLIN ONCOL, V18, P2095, DOI 10.1200/JCO.2000.18.10.2095; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; Smith NR, 2010, CLIN CANCER RES, V16, P3548, DOI 10.1158/1078-0432.CCR-09-2797; Spratlin JL, 2010, J CLIN ONCOL, V28, P780, DOI 10.1200/JCO.2009.23.7537; Stinchcombe Thomas E, 2009, Proc Am Thorac Soc, V6, P233, DOI 10.1513/pats.200809-110LC; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; *US DEP HHS, COMM TERM CRIT ADV E; Wilke H, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.3_suppl.lba7; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	34	805	842	4	75	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 23	2014	384	9944					665	673		10.1016/S0140-6736(14)60845-X	http://dx.doi.org/10.1016/S0140-6736(14)60845-X			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AO5CJ	24933332				2023-01-03	WOS:000341359100024
J	Mayer-Barber, KD; Andrade, BB; Oland, SD; Amaral, EP; Barber, DL; Gonzales, J; Derrick, SC; Shi, RR; Kumar, NP; Wei, W; Yuan, X; Zhang, GL; Cai, Y; Babu, S; Catalfamo, M; Salazar, AM; Via, LE; Barry, CE; Sher, A				Mayer-Barber, Katrin D.; Andrade, Bruno B.; Oland, Sandra D.; Amaral, Eduardo P.; Barber, Daniel L.; Gonzales, Jacqueline; Derrick, Steven C.; Shi, Ruiru; Kumar, Nathella Pavan; Wei, Wang; Yuan, Xing; Zhang, Guolong; Cai, Ying; Babu, Subash; Catalfamo, Marta; Salazar, Andres M.; Via, Laura E.; Barry, Clifton E., III; Sher, Alan			Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk	NATURE			English	Article							NECROSIS-FACTOR-ALPHA; MYCOBACTERIUM-TUBERCULOSIS; INDUCTION; SUSCEPTIBILITY; INFLAMMATION; INFECTION; IMMUNITY; INNATE	Tuberculosis remains second only to HIV/AIDS as the leading cause of mortality worldwide due to a single infectious agent(1). Despite chemotherapy, the global tuberculosis epidemic has intensified because of HIV co-infection, the lack of an effective vaccine and the emergence of multi-drug-resistant bacteria(2-5). Alternative host-directed strategies could be exploited to improve treatment efficacy and outcome, contain drug-resistant strains and reduce disease severity and mortality(6). The innate inflammatory response elicited by Mycobacterium tuberculosis (Mtb) represents a logical host target(7). Here we demonstrate that interleukin-1 (IL-1) confers host resistance through the induction of eicosanoids that limit excessive type I interferon (IFN) production and foster bacterial containment. We further show that, in infected mice and patients, reduced IL-1 responses and/or excessive type I IFN induction are linked to an eicosanoid imbalance associated with disease exacerbation. Host-directed immunotherapy with clinically approved drugs that augment prostaglandin E2 levels in these settings prevented acute mortality of Mtb-infected mice. Thus, IL-1 and type I IFNs represent two major counter-regulatory classes of inflammatory cytokines that control the outcome of Mtb infection and are functionally linked via eicosanoids. Our findings establish proof of concept for host-directed treatment strategies that manipulate the host eicosanoid network and represent feasible alternatives to conventional chemotherapy.	[Mayer-Barber, Katrin D.; Andrade, Bruno B.; Oland, Sandra D.; Amaral, Eduardo P.; Sher, Alan] NIAID, Immunobiol Sect, LPD, NIH, Bethesda, MD 20892 USA; [Amaral, Eduardo P.] Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, BR-05508900 Sao Paulo, Brazil; [Barber, Daniel L.] NIAID, Lymphocyte Biol Unit T, LPD, NIH, Bethesda, MD 20892 USA; [Gonzales, Jacqueline; Via, Laura E.; Barry, Clifton E., III] NIAID, TB Res Sect, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA; [Derrick, Steven C.] US FDA, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; [Shi, Ruiru; Wei, Wang; Yuan, Xing] Henan Chest Hosp, Zhengzhou 450003, Peoples R China; [Kumar, Nathella Pavan; Babu, Subash] Int Ctr Excellence Res, NIH, Madras 600031, Tamil Nadu, India; [Kumar, Nathella Pavan] NIRT, Madras 600031, Tamil Nadu, India; [Zhang, Guolong] SinoUS Int Res Ctr TB, Zhengzhou 450003, Peoples R China; [Zhang, Guolong] Henan Publ Hlth Ctr, Zhengzhou 450003, Peoples R China; [Babu, Subash] NIAID, Helminth Immunol Sect, LPD, NIH, Bethesda, MD 20892 USA; [Catalfamo, Marta] NIAID, Clin & Mol Retrovirol Sect, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA; [Salazar, Andres M.] Oncovir Inc, Washington, DC 20008 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Universidade de Sao Paulo; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); US Food & Drug Administration (FDA); Indian Council of Medical Research (ICMR); ICMR - National Institute for Research in Tuberculosis (NIRT); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Mayer-Barber, KD (corresponding author), NIAID, Immunobiol Sect, LPD, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	mayerk@niaid.nih.gov	Barry, Clifton E/ABE-7992-2020; Via, Laura/AAD-3917-2021; Kumar, Nathella Pavan/AAU-2328-2021; Andrade, Bruno/J-9111-2012; Babu, Subash/GXG-4746-2022; Zhang, Guolong/HCI-5587-2022; Barry, III, Clifton/H-3839-2012; Amaral, Eduardo EP/M-2456-2014; Andrade, Bruno/AAI-2248-2020	Barry, Clifton E/0000-0002-2927-270X; Via, Laura/0000-0001-6074-9521; Andrade, Bruno/0000-0001-6833-3811; Barry, III, Clifton/0000-0002-2927-270X; Amaral, Eduardo EP/0000-0001-5465-8113; 	NIAID Intramural Research program; Concept Acceleration Program-Award from DMID, NIAID; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001081, ZIAAI001171, ZIAAI001044, ZIAAI001065, ZIAAI000783, ZIAAI000734] Funding Source: NIH RePORTER	NIAID Intramural Research program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Concept Acceleration Program-Award from DMID, NIAID; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the NIAID Intramural Research program and a Concept Acceleration Program-Award (K.D.M.-B., B.B.A. and A.S.) from DMID, NIAID. We are grateful to K. Elkins, S. Morris, M. Belcher as well as the NIAID ABSL3 support staff for facilitating our animal studies. We thank R. Chen, L. Goldfeder and Q. Gao for sharing their clinical trial expertise and research facilities, respectively. We also thank K. Kauffman, R. Thompson, S. Hieny, P. Dayal, D. Surman, L. Meng, Z. Li, L. Lifa, Q. Shen and Z. Huang for technical assistance, H. Boshoff for help with direct anti-mycobacterial activity assays and M. S. Jawahar, V. V. Banurekha and R. Sridhar for recruitment and clinical evaluation of patients in Chennai, India. We are grateful to F. Andrade Neto, H. Remold, K. Arora, J. Aliberti, M. Moayeri, P. Murphy, A. O'Garra, R. Germain and C. Serhan for discussion or critical reading of the manuscript. Finally, we thank the patients, volunteer participants, and clinical staff of the Tuberculosis department of Henan Chest Hospital in Zhengzhou, China and the Department of Clinical Research (NIRT) and Department of Thoracic Medicine (Government Stanley Medical Hospital) in Chennai, India for their participation in our clinical studies.	Andrade BB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062618; Antonelli LRV, 2010, J CLIN INVEST, V120, P1674, DOI 10.1172/JCI40817; Bafica A, 2005, J CLIN INVEST, V115, P1601, DOI 10.1172/JCI23949; Barry CE, 2009, NAT REV MICROBIOL, V7, P845, DOI 10.1038/nrmicro2236; Berry MPR, 2010, NATURE, V466, P973, DOI 10.1038/nature09247; Bishai W, 2013, NAT MED, V19, P410, DOI 10.1038/nm.3153; Chen MJ, 2008, J EXP MED, V205, P2791, DOI 10.1084/jem.20080767; Divangahi M, 2009, NAT IMMUNOL, V10, P899, DOI 10.1038/ni.1758; Gandhi NR, 2010, LANCET, V375, P1830, DOI 10.1016/S0140-6736(10)60410-2; Humason G. L., 1979, ANIMAL TISSUE TECHNI, P355; Kaufmann SHE, 2013, CURR OPIN IMMUNOL, V25, P441, DOI 10.1016/j.coi.2013.05.005; Kirtikara K, 1998, J EXP MED, V187, P517, DOI 10.1084/jem.187.4.517; Kuo HP, 2000, AM J RESP CRIT CARE, V161, P192, DOI 10.1164/ajrccm.161.1.9902113; Law K, 1996, AM J RESP CRIT CARE, V153, P799, DOI 10.1164/ajrccm.153.2.8564135; Lawn SD, 2011, LANCET, V378, P57, DOI 10.1016/S0140-6736(10)62173-3; Maertzdorf J, 2011, GENES IMMUN, V12, P15, DOI 10.1038/gene.2010.51; Manca C, 2001, P NATL ACAD SCI USA, V98, P5752, DOI 10.1073/pnas.091096998; Mayer-Barber KD, 2011, IMMUNITY, V35, P1023, DOI 10.1016/j.immuni.2011.12.002; Mayer-Barber KD, 2010, J IMMUNOL, V184, P3326, DOI 10.4049/jimmunol.0904189; Nathan C, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003081; O'Garra A, 2013, ANNU REV IMMUNOL, V31, P475, DOI 10.1146/annurev-immunol-032712-095939; Ottenhoff THM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045839; Rayamajhi M, 2010, VIRULENCE, V1, P418, DOI 10.4161/viru.1.5.12787; Redford PS, 2014, J INFECT DIS, V209, P270, DOI 10.1093/infdis/jit424; Rousu J, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003018; Russell DG, 2010, SCIENCE, V328, P852, DOI 10.1126/science.1184784; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Stanley SA, 2007, J IMMUNOL, V178, P3143, DOI 10.4049/jimmunol.178.5.3143; Tobin DM, 2012, CELL, V148, P434, DOI 10.1016/j.cell.2011.12.023; Tobin DM, 2010, CELL, V140, P717, DOI 10.1016/j.cell.2010.02.013; Tsao T.C.Y., 1999, Tubercle and Lung Disease, V79, P279, DOI 10.1054/tuld.1999.0215; Wang C H, 2001, Respirology, V6, P79	32	481	496	2	154	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 3	2014	511	7507					99	U491		10.1038/nature13489	http://dx.doi.org/10.1038/nature13489			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK1TN	24990750	Green Accepted, Green Published			2023-01-03	WOS:000338199400044
J	Turer, AT; Lewis, GD; O'Sullivan, JF; Elmariah, S; Mega, JL; Addo, TA; Sabatine, MS; de Lemos, JA; Gerszten, RE				Turer, Aslan T.; Lewis, Gregory D.; O'Sullivan, John F.; Elmariah, Sammy; Mega, Jessica L.; Addo, Tayo A.; Sabatine, Marc S.; de Lemos, James A.; Gerszten, Robert E.			Increases in Myocardial Workload Induced by Rapid Atrial Pacing Trigger Alterations in Global Metabolism	PLOS ONE			English	Article							BILE-ACIDS; ISCHEMIA; ADENOSINE; HUMANS; BLOOD; FAT	Objective: To determine whether increases in cardiac work lead to alterations in the plasma metabolome and whether such changes arise from the heart or peripheral organs. Background: There is growing evidence that the heart influences systemic metabolism through endocrine effects and affecting pathways involved in energy homeostasis. Methods: Nineteen patients referred for cardiac catheterization were enrolled. Peripheral and selective coronary sinus (CS) blood sampling was performed at serial timepoints following the initiation of pacing, and metabolite profiling was performed by liquid chromatography-mass spectrometry (LC-MS). Results: Pacing-stress resulted in a 225% increase in the median rate? pressure product from baseline. Increased myocardial work induced significant changes in the peripheral concentration of 43 of 125 metabolites assayed, including large changes in purine [ adenosine (+99%, p = 0.006), ADP (+42%, p = 0.01), AMP (+79%, p = 0.004), GDP (+69%, p = 0.003), GMP (+58%, p = 0.01), IMP (+50%, p = 0.03), xanthine (+61%, p = 0.0006)], and several bile acid metabolites. The CS changes in metabolites qualitatively mirrored those in the peripheral blood in both timing and magnitude, suggesting the heart was not the major source of the metabolite release. Conclusions: Isolated increases in myocardial work can induce changes in the plasma metabolome, but these changes do not appear to be directly cardiac in origin. A number of these dynamic metabolites have known signaling functions. Our study provides additional evidence to a growing body of literature on metabolic 'cross-talk' between the heart and other organs.	[Turer, Aslan T.; de Lemos, James A.] Univ Texas SW Med Ctr Dallas, Dept Med, Div Cardiol, Dallas, TX 75390 USA; [Lewis, Gregory D.; O'Sullivan, John F.; Elmariah, Sammy; Addo, Tayo A.; Gerszten, Robert E.] Massachusetts Gen Hosp, Dept Internal Med, Div Cardiol, Boston, MA 02114 USA; [Mega, Jessica L.; Sabatine, Marc S.] Brigham & Womens Hosp, Boston, MA 02115 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital	Turer, AT (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Med, Div Cardiol, Dallas, TX 75390 USA.	aslan.turer@utsouthwestern.edu	Elmariah, Sammy/AAG-8752-2021; de Lemos, James/ABD-6669-2021; Sabatine, Marc/AAJ-6751-2020	Sabatine, Marc/0000-0002-0691-3359; Elmariah, Sammy/0000-0002-8013-8733; O'Sullivan, John/0000-0001-8016-5128	Abbott Laboratories; Ortho-Clinical Diagnostics; Roche Diagnostics; Singulex; National Institutes of Health [K23 HL 091106, R01HL098280, R01DK081572, HHSN268201000033C]; American Heart Association Established Investigator Award; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL091106, R01HL098280] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK081572] Funding Source: NIH RePORTER	Abbott Laboratories(Abbott Laboratories); Ortho-Clinical Diagnostics; Roche Diagnostics; Singulex; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association Established Investigator Award(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Dr. Sabatine: Abbott Laboratories, Ortho-Clinical Diagnostics, Roche Diagnostics, Singulex; Dr. de Lemos: Abbott Diagnostics, Roche Diagnostics; Dr Lewis: National Institutes of Health Grant: #K23 HL 091106; Dr Gerszten: National Institutes of Health Grants #R01HL098280 and #R01DK081572, National Institutes of Health contract #HHSN268201000033C, and American Heart Association Established Investigator Award; the other authors have no relevant disclosures. No companies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bodi V, 2012, J AM COLL CARDIOL, V59, P1629, DOI 10.1016/j.jacc.2011.09.083; Bostrom P, 2012, NATURE, V481, P463, DOI 10.1038/nature10777; Boudina S, 2007, CIRCULATION, V115, P3213, DOI 10.1161/CIRCULATIONAHA.106.679597; Brunner MP, 2011, CIRC-CARDIOVASC GENE, V4, P695, DOI 10.1161/CIRCGENETICS.111.960575; Cao RS, 2010, J LIPID RES, V51, P2234, DOI 10.1194/jlr.M004929; ELY SW, 1992, CIRCULATION, V85, P893, DOI 10.1161/01.CIR.85.3.893; Grueter CE, 2012, CELL, V149, P671, DOI 10.1016/j.cell.2012.03.029; Hylemon PB, 2009, J LIPID RES, V50, P1509, DOI 10.1194/jlr.R900007-JLR200; Lewis GD, 2008, J CLIN INVEST, V118, P3503, DOI 10.1172/JCI35111; Lewis GD, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001006; MARKHAM RV, 1983, AM J CARDIOL, V51, P1589, DOI 10.1016/0002-9149(83)90192-3; Paganelli F, 2000, EUR J CLIN INVEST, V30, P105; Rhee EP, 2013, J AM SOC NEPHROL, V24, P1330, DOI 10.1681/ASN.2012101006; Sabatine MS, 2005, CIRCULATION, V112, P3868, DOI 10.1161/CIRCULATIONAHA.105.569137; Turer AT, 2011, J AM COLL CARDIOL, V57, P2398, DOI 10.1016/j.jacc.2010.11.066; Turer AT, 2009, CIRCULATION, V119, P1736, DOI 10.1161/CIRCULATIONAHA.108.816116; Wang TJ, 2012, NEW ENGL J MED, V367, P377, DOI 10.1056/NEJMcibr1204796	17	6	6	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 16	2014	9	6							e99058	10.1371/journal.pone.0099058	http://dx.doi.org/10.1371/journal.pone.0099058			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AJ5PV	24932507	Green Published, gold, Green Submitted			2023-01-03	WOS:000337738600020
J	Chirinos, JA; Gurubhagavatula, I; Teff, K; Rader, DJ; Wadden, TA; Townsend, R; Foster, GD; Maislin, G; Saif, H; Broderick, P; Chittams, J; Hanlon, AL; Pack, AI				Chirinos, Julio A.; Gurubhagavatula, Indira; Teff, Karen; Rader, Daniel J.; Wadden, Thomas A.; Townsend, Raymond; Foster, Gary D.; Maislin, Greg; Saif, Hassam; Broderick, Preston; Chittams, Jesse; Hanlon, Alexandra L.; Pack, Allan I.			CPAP, Weight Loss, or Both for Obstructive Sleep Apnea	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITIVE AIRWAY PRESSURE; C-REACTIVE PROTEIN; CARDIOVASCULAR-DISEASE; INSULIN SENSITIVITY; LOW-CARBOHYDRATE; BLOOD-PRESSURE; RISK-FACTORS; ASSOCIATION; OBESITY; DIET	BACKGROUND Obesity and obstructive sleep apnea tend to coexist and are associated with inflammation, insulin resistance, dyslipidemia, and high blood pressure, but their causal relation to these abnormalities is unclear. METHODS We randomly assigned 181 patients with obesity, moderate-to-severe obstructive sleep apnea, and serum levels of C-reactive protein (CRP) greater than 1.0 mg per liter to receive treatment with continuous positive airway pressure (CPAP), a weight-loss intervention, or CPAP plus a weight-loss intervention for 24 weeks. We assessed the incremental effect of the combined interventions over each one alone on the CRP level (the primary end point), insulin sensitivity, lipid levels, and blood pressure. RESULTS Among the 146 participants for whom there were follow-up data, those assigned to weight loss only and those assigned to the combined interventions had reductions in CRP levels, insulin resistance, and serum triglyceride levels. None of these changes were observed in the group receiving CPAP alone. Blood pressure was reduced in all three groups. No significant incremental effect on CRP levels was found for the combined interventions as compared with either weight loss or CPAP alone. Reductions in insulin resistance and serum triglyceride levels were greater in the combined-intervention group than in the group receiving CPAP only, but there were no significant differences in these values between the combined-intervention group and the weight-loss group. In per-protocol analyses, which included 90 participants who met prespecified criteria for adherence, the combined interventions resulted in a larger reduction in systolic blood pressure and mean arterial pressure than did either CPAP or weight loss alone. CONCLUSIONS In adults with obesity and obstructive sleep apnea, CPAP combined with a weight-loss intervention did not reduce CRP levels more than either intervention alone. In secondary analyses, weight loss provided an incremental reduction in insulin resistance and serum triglyceride levels when combined with CPAP. In addition, adherence to a regimen of weight loss and CPAP may result in incremental reductions in blood pressure as compared with either intervention alone.	[Chirinos, Julio A.; Gurubhagavatula, Indira] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA; [Chirinos, Julio A.; Gurubhagavatula, Indira; Rader, Daniel J.; Wadden, Thomas A.; Townsend, Raymond; Maislin, Greg; Saif, Hassam; Broderick, Preston; Pack, Allan I.] Univ Penn, Perelman Sch Med, Hosp Univ Penn, Philadelphia, PA 19104 USA; [Teff, Karen] Monell Chem Senses Ctr, Philadelphia, PA USA; [Foster, Gary D.] Temple Univ, Sch Med, Philadelphia, PA 19122 USA; [Chittams, Jesse; Hanlon, Alexandra L.] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; University of Pennsylvania; Pennsylvania Medicine; Monell Chemical Senses Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania	Chirinos, JA (corresponding author), Univ Penn, Div Cardiol, Rm 8B111,Univ & Woodland Aves, Philadelphia, PA 19104 USA.	julio.chirinos@uphs.upenn.edu	Maislin, Greg/S-5322-2019; Hanlon, Alexandra L/J-9585-2013	Pack, Allan/0000-0002-2879-0484	National Heart, Lung, and Blood Institute [HL-R01080076, P01 HL094307]; Novo Nordisk; Nutrisystem; Orexigen; Boehringer Ingelheim; Weight Watchers; ConAgra Foods; Tate and Lyle; UnitedHealth Group; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080076, P01HL094307] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Novo Nordisk(Novo Nordisk); Nutrisystem; Orexigen; Boehringer Ingelheim(Boehringer Ingelheim); Weight Watchers; ConAgra Foods; Tate and Lyle; UnitedHealth Group; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by grants from the National Heart, Lung, and Blood Institute (HL-R01080076, to Dr. Chirinos; and P01 HL094307, to Dr. Pack).; Dr. Wadden reports receiving fees for serving on advisory boards for Novo Nordisk, Nutrisystem, and Orexigen, consulting fees from Boehringer Ingelheim, and grant support from Weight Watchers, Novo Nordisk, and Nutrisystem. Dr. Foster reports receiving fees for serving on advisory boards for ConAgra Foods, Tate and Lyle, and UnitedHealth Group and reports being an employee of Weight Watchers. No other potential conflict of interest relevant to this article was reported.	Akashiba T, 2005, INTERNAL MED, V44, P899, DOI 10.2169/internalmedicine.44.899; Barbe F, 2010, AM J RESP CRIT CARE, V181, P718, DOI 10.1164/rccm.200901-0050OC; Bazzano LA, 2007, HYPERTENSION, V50, P417, DOI 10.1161/HYPERTENSIONAHA.106.085175; Bergman RN, 2007, DIABETES, V56, P1489, DOI 10.2337/db07-9903; BERGMAN RN, 1987, J CLIN INVEST, V79, P790, DOI 10.1172/JCI112886; Brown DL, 2011, J CLIN SLEEP MED, V7, P103; Colish J, 2012, CHEST, V141, P674, DOI 10.1378/chest.11-0615; Coughlin SR, 2007, EUR RESPIR J, V29, P720, DOI 10.1183/09031936.00043306; Craig SE, 2012, THORAX, V67, P1090, DOI 10.1136/thoraxjnl-2012-202178; Dorkova Z, 2008, CHEST, V134, P686, DOI 10.1378/chest.08-0556; Fox CS, 2007, CIRCULATION, V116, P39, DOI 10.1161/CIRCULATIONAHA.106.675355; GRUNSTEIN R, 1993, INT J OBESITY, V17, P533; Haentjens P, 2007, ARCH INTERN MED, V167, P757, DOI 10.1001/archinte.167.8.757; Harsch IA, 2004, AM J RESP CRIT CARE, V169, P156, DOI 10.1164/rccm.200302-206OC; Horvath K, 2008, ARCH INTERN MED, V168, P571, DOI 10.1001/archinte.168.6.571; Ip MSM, 2002, AM J RESP CRIT CARE, V165, P670, DOI 10.1164/ajrccm.165.5.2103001; Ishida K, 2009, CHEST, V136, P125, DOI 10.1378/chest.08-1431; Malhotra A, 2002, LANCET, V360, P237, DOI 10.1016/S0140-6736(02)09464-3; McNicholas WT, 2007, EUR RESPIR J, V29, P614; McNicholas WT, 2007, EUR RESPIR J, V29, P156, DOI 10.1183/09031936.00027406; Nicklas BJ, 2004, AM J CLIN NUTR, V79, P544; Nieto FJ, 2000, JAMA-J AM MED ASSOC, V283, P1829, DOI 10.1001/jama.283.14.1829; Nieto FJ, 2002, JAMA-J AM MED ASSOC, V288, P1985; Pack AI, 2009, PROG CARDIOVASC DIS, V51, P434, DOI 10.1016/j.pcad.2009.01.002; Patruno V, 2007, CHEST, V131, P1393, DOI 10.1378/chest.06-2192; Peppard PE, 2000, JAMA-J AM MED ASSOC, V284, P3015, DOI 10.1001/jama.284.23.3015; Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901; Rodway GW, 2010, SLEEP, V33, P260, DOI 10.1093/sleep/33.2.260; Samaha FF, 2003, NEW ENGL J MED, V348, P2074, DOI 10.1056/NEJMoa022637; Seshadri P, 2006, AM J MED, V119, P191, DOI 10.1016/j.amjmed.2005.12.008; Seshadri P, 2004, AM J MED, V117, P398, DOI 10.1016/j.amjmed.2004.04.009; Shamsuzzaman ASM, 2002, CIRCULATION, V105, P2462, DOI 10.1161/01.CIR.0000018948.95175.03; Shamsuzzaman ASM, 2003, JAMA-J AM MED ASSOC, V290, P1906, DOI 10.1001/jama.290.14.1906; Sharma SK, 2008, SLEEP MED, V9, P149, DOI 10.1016/j.sleep.2007.02.004; Shinohara E, 1997, J INTERN MED, V241, P11, DOI 10.1046/j.1365-2796.1997.63889000.x; Singer JD, 1998, J EDUC BEHAV STAT, V23, P323; Tasali Esra, 2008, Proc Am Thorac Soc, V5, P207, DOI 10.1513/pats.200708-139MG; Wadden TA, 2012, CIRCULATION, V125, P1157, DOI 10.1161/CIRCULATIONAHA.111.039453; Wadden TA, 2011, NEW ENGL J MED, V365, P1969, DOI 10.1056/NEJMoa1109220; Yang D, 2013, SLEEP BREATH, V17, P33, DOI 10.1007/s11325-012-0680-8; Yokoe T, 2003, CIRCULATION, V107, P1129, DOI 10.1161/01.CIR.0000052627.99976.18; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	42	295	299	2	53	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 12	2014	370	24					2265	2275		10.1056/NEJMoa1306187	http://dx.doi.org/10.1056/NEJMoa1306187			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AI7BB	24918371	Green Published, Green Accepted			2023-01-03	WOS:000337033700006
J	Noah, TL; Zhang, HT; Zhou, HB; Glista-Baker, E; Muller, L; Bauer, RN; Meyer, M; Murphy, PC; Jones, S; Letang, B; Robinette, C; Jaspers, I				Noah, Terry L.; Zhang, Hongtao; Zhou, Haibo; Glista-Baker, Ellen; Mueller, Loretta; Bauer, Rebecca N.; Meyer, Megan; Murphy, Paula C.; Jones, Shannon; Letang, Blanche; Robinette, Carole; Jaspers, Ilona			Effect of Broccoli Sprouts on Nasal Response to Live Attenuated Influenza Virus in Smokers: A Randomized, Double-Blind Study	PLOS ONE			English	Article							EPITHELIAL-CELLS; CANCER CHEMOPREVENTION; CIGARETTE-SMOKING; RISK-FACTORS; H1N1 2009; SULFORAPHANE; INFECTION; EXPOSURE; EXPRESSION; NRF2	Background: Smokers have increased susceptibility and altered innate host defense responses to influenza virus infection. Broccoli sprouts are a source of the Nrf2 activating agentsulforaphane, and short term ingestion of broccoli sprout homogenates (BSH) has been shown to reduce nasal inflammatory responses to oxidant pollutants. Objectives: Assess the effects of BSH on nasal cytokines, virus replication, and Nrf2-dependent enzyme expression in smokers and nonsmokers. Methods: We conducted a randomized, double-blind, placebo-controlled trial comparing the effects of BSH on serially sampled nasal lavage fluid (NLF) cytokines, viral sequence quantity, and Nrf2-dependent enzyme expression in NLF cells and biopsied epithelium. Healthy young adult smokers and nonsmokers ingested BSH or placebo (alfalfa sprout homogenate) for 4 days, designated Days -1, 0, 1, 2. On Day 0 they received standard vaccine dose of live attenuated influenza virus (LAIV) intranasally. Nasal lavage fluids and nasal biopsies were collected serially to assess response to LAIV. Results: In area under curve analyses, post-LAIV IL-6 responses (P =0.03) and influenza sequences (P =0.01) were significantly reduced in NLF from BSH-treated smokers, whileNAD(P) H: quinoneoxidoreductasein NLF cells was significantly increased. In nonsmokers, a similar trend for reduction in virus quantity with BSH did not reach statistical significance. Conclusions: In smokers, short term ingestion of broccoli sprout homogenates appears to significantly reduce some virus-induced markers of inflammation, as well as reducing virus quantity. Nutritional antioxidant interventions have promise as a safe, low-cost strategy for reducing influenza risk among smokers and other at risk populations.	[Noah, Terry L.; Glista-Baker, Ellen; Jones, Shannon; Robinette, Carole; Jaspers, Ilona] Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC 27599 USA; [Noah, Terry L.; Murphy, Paula C.; Jaspers, Ilona] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA; [Zhang, Hongtao; Zhou, Haibo] Univ N Carolina, Dept Biostat, Chapel Hill, NC USA; [Bauer, Rebecca N.] Univ N Carolina, Curriculum Toxicol, Chapel Hill, NC USA; [Meyer, Megan] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA; [Letang, Blanche] Univ N Carolina, Biol & Biomed Sci Program, Chapel Hill, NC USA; [Mueller, Loretta] Univ Childrens Hosp Basel, Basel, Switzerland	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Basel	Noah, TL (corresponding author), Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC 27599 USA.	terry_noah@med.unc.edu	Jaspers, Ilona/AAZ-5035-2020; ZHOU, Haibo/M-7373-2017		NIEHS NIH HHS [R01 ES013611, T32 ES007126, P30 ES010126] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES013611, T32ES007126, P30ES010126] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Biswal Shyam, 2012, Proc Am Thorac Soc, V9, P47, DOI 10.1513/pats.201201-009MS; Cantin AM, 2012, CURR MOL MED, V12, P836; Cheung KL, 2010, AAPS J, V12, P87, DOI 10.1208/s12248-009-9162-8; Cho HY, 2009, AM J RESP CRIT CARE, V179, P138, DOI 10.1164/rccm.200804-535OC; Cohen HA, 2004, ARCH PEDIAT ADOL MED, V158, P217, DOI 10.1001/archpedi.158.3.217; Dinkova-Kostova AT, 2007, CANCER EPIDEM BIOMAR, V16, P847, DOI 10.1158/1055-9965.EPI-06-0934; Guerrero-Beltran CE, 2012, EXP TOXICOL PATHOL, V64, P503, DOI 10.1016/j.etp.2010.11.005; Gerhauser C, 2013, CURR OPIN CLIN NUTR, V16, P405, DOI 10.1097/MCO.0b013e328362014e; Harvey CJ, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002042; Heber D, 2014, FOOD FUNCT, V5, P35, DOI 10.1039/c3fo60277j; Huttunen R, 2011, J INTERN MED, V269, P258, DOI 10.1111/j.1365-2796.2010.02332.x; Ison MG, 2011, CURR OPIN VIROL, V1, P563, DOI 10.1016/j.coviro.2011.09.002; Jaspers I, 1999, J BIOL CHEM, V274, P31025, DOI 10.1074/jbc.274.43.31025; Jaspers I, 2010, AM J RESP CELL MOL, V43, P368, DOI 10.1165/rcmb.2009-0254OC; KARK JD, 1981, AM J PUBLIC HEALTH, V71, P530, DOI 10.2105/AJPH.71.5.530; KARK JD, 1982, NEW ENGL J MED, V307, P1042, DOI 10.1056/NEJM198210213071702; Kensler TW, 2010, CARCINOGENESIS, V31, P90, DOI 10.1093/carcin/bgp231; Kesic MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035108; Kesic MJ, 2011, FREE RADICAL BIO MED, V51, P444, DOI 10.1016/j.freeradbiomed.2011.04.027; LEBIUSH M, 1982, MIL MED, V147, P43, DOI 10.1093/milmed/147.1.43; Lenzi L, 2012, J BRAS PNEUMOL, V38, P57, DOI 10.1590/S1806-37132012000100009; Li CKF, 2013, CURR OPIN IMMUNOL, V25, P470, DOI 10.1016/j.coi.2013.07.005; Macchia I, 1999, INT J IMMUNOPHARMACO, V21, P185, DOI 10.1016/S0192-0561(98)00080-0; Matsumoto K, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-15; Nantz MP, 2013, NUTR J, V12, DOI 10.1186/1475-2891-12-161; Negishi H, 2013, J NUTR, V143, P1794, DOI 10.3945/jn.113.179036; Noah TL, 2012, AM J RESP CRIT CARE, V185, P179, DOI 10.1164/rccm.201103-0465OC; Noah TL, 2011, ENVIRON HEALTH PERSP, V119, P78, DOI 10.1289/ehp.1002258; Rager JE, 2013, AM J PHYSIOL-LUNG C, V305, pL432, DOI 10.1152/ajplung.00116.2013; Riedl MA, 2009, CLIN IMMUNOL, V130, P244, DOI 10.1016/j.clim.2008.10.007; Ritz SA, 2007, AM J PHYSIOL-LUNG C, V292, pL33, DOI 10.1152/ajplung.00170.2006; Shapiro TA, 2006, NUTR CANCER, V55, P53, DOI 10.1207/s15327914nc5501_7; Urashima M, 2010, AM J CLIN NUTR, V91, P1255, DOI 10.3945/ajcn.2009.29094; Ward KA, 2011, EMERG INFECT DIS, V17, P1409, DOI 10.3201/eid1708.100842; Wilson KM, 2013, J PEDIATR-US, V162, P16, DOI 10.1016/j.jpeds.2012.06.043; Wong CM, 2013, INFLUENZA OTHER RESP, V7, P531, DOI 10.1111/j.1750-2659.2012.00411.x; Woolson RFC., 2002, STAT METHODS ANAL BI, Ved 2; Yageta Y, 2013, AM J RESP CELL MOL B	38	28	34	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 9	2014	9	6							e98671	10.1371/journal.pone.0098671	http://dx.doi.org/10.1371/journal.pone.0098671			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI8LF	24910991	Green Published, Green Submitted, gold			2023-01-03	WOS:000337165600009
J	William, L				William, Leeroy			PERSONAL VIEW Non-palliative care staff need to deliver generalist end of life care	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PATHWAYS		[William, Leeroy] Monash Hlth, Monash Med Ctr, Melbourne, Vic, Australia; [William, Leeroy] Eastern Hlth, Box Hill Hosp, Melbourne, Vic, Australia; [William, Leeroy] Monash Univ, Melbourne, Vic 3004, Australia	Monash University; Box Hill Hospital; Monash University	William, L (corresponding author), Monash Hlth, Monash Med Ctr, Melbourne, Vic, Australia.	leeroy.william@monashhealth.org.au	Ram, Prem/K-4511-2012; William, Leeroy/D-7029-2017; William, Leeroy/AAY-4041-2021; William, Leeroy/Q-4186-2019	William, Leeroy/0000-0002-8661-2221; 				Boyd K, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e7718; Campbell H, 1998, BMJ-BRIT MED J, V316, P133; Chinthapalli K, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4669; Department of Health, 2013, MOR CAS LESS PATHW R; Egan T, 2009, HEALTH, V13, P107, DOI 10.1177/1363459308097363; Heyland DK, 2006, CAN MED ASSOC J, V174, P627, DOI 10.1503/cmaj.050626; Janssen AL, 2010, PATIENT EDUC COUNS, V81, P251, DOI 10.1016/j.pec.2010.02.009; MacLeod RD, 2001, SOC SCI MED, V52, P1719, DOI 10.1016/S0277-9536(00)00289-6; Peabody FW, 1927, J AMER MED ASSOC, V88, P0877, DOI 10.1001/jama.1927.02680380001001; Roach MS, 1984, PERSPECTIVES CARING, V1; Rotter T, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006632.pub2; Sleeman KE, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4779	12	3	3	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 20	2014	348								g3426	10.1136/bmj.g3426	http://dx.doi.org/10.1136/bmj.g3426			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AH8ZW	24846881				2023-01-03	WOS:000336429100011
J	Andrew, EVW; Pell, C; Angwin, A; Auwun, A; Daniels, J; Mueller, I; Phuanukoonnon, S; Pool, R				Andrew, Erin V. W.; Pell, Christopher; Angwin, Angeline; Auwun, Alma; Daniels, Job; Mueller, Ivo; Phuanukoonnon, Suparat; Pool, Robert			Factors Affecting Attendance at and Timing of Formal Antenatal Care: Results from a Qualitative Study in Madang, Papua New Guinea	PLOS ONE			English	Article							PREGNANT-WOMEN; SULFADOXINE-PYRIMETHAMINE; MATERNAL MORTALITY; RURAL MALAWI; SOUTH-AFRICA; MALARIA; HEALTH; PERCEPTIONS; SERVICES; PERSPECTIVES	Background: Appropriate antenatal care (ANC) is key for the health of mother and child. However, in Papua New Guinea (PNG), only a third of women receive any ANC during pregnancy. Drawing on qualitative research, this paper explores the influences on ANC attendance and timing of first visit in the Madang region of Papua New Guinea. Methods: Data were collected in three sites utilizing several qualitative methods: free-listing and sorting of terms and definitions, focus group discussions, in-depth interviews, observation in health care facilities and case studies of pregnant women. Respondents included pregnant women, their relatives, biomedical and traditional health providers, opinion leaders and community members. Results: Although generally reported to be important, respondents' understanding of the procedures involved in ANC was limited. Factors influencing attendance fell into three main categories: accessibility, attitudes to ANC, and interpersonal issues. Although women saw accessibility (distance and cost) as a barrier, those who lived close to health facilities and could easily afford ANC also demonstrated poor attendance. Attitudes were shaped by previous experiences of ANC, such as waiting times, quality of care, and perceptions of preventative care and medical interventions during pregnancy. Interpersonal factors included relationships with healthcare providers, pregnancy disclosure, and family conflict. A desire to avoid repeat clinic visits, ideas about the strength of the fetus and parity were particularly relevant to the timing of first ANC visit. Conclusions: This long-term in-depth study (the first of its kind in Madang, PNG) shows how socio-cultural and economic factors influence ANC attendance. These factors must be addressed to encourage timely ANC visits: interventions could focus on ANC delivery in health facilities, for example, by addressing healthcare staff's attitudes towards pregnant women.	[Andrew, Erin V. W.; Pell, Christopher; Mueller, Ivo; Pool, Robert] Univ Barcelona, Hosp Clin, Barcelona Ctr Int Hlth Res CRESIB, Barcelona, Spain; [Pell, Christopher; Pool, Robert] Univ Amsterdam, Ctr Social Sci & Global Hlth, Amsterdam, Netherlands; [Angwin, Angeline; Auwun, Alma; Daniels, Job; Mueller, Ivo; Phuanukoonnon, Suparat] Papua New Guinea Inst Med Res, Madang, Papua N Guinea; [Mueller, Ivo] Royal Melbourne Hosp, Walter & Eliza Hall Inst, Infect & Immun Div, Parkville, Vic 3050, Australia	ISGlobal; CRESIB; University of Barcelona; Hospital Clinic de Barcelona; University of Amsterdam; PNG Institute Of Medical Research; Royal Melbourne Hospital; Walter & Eliza Hall Institute	Andrew, EVW (corresponding author), Univ Barcelona, Hosp Clin, Barcelona Ctr Int Hlth Res CRESIB, Barcelona, Spain.	erinvwandrew@gmail.com		Pell, Christopher/0000-0001-9405-5851	Malaria in Pregnancy (MiP) Consortium - Bill and Melinda Gates Foundation [OPP46099]	Malaria in Pregnancy (MiP) Consortium - Bill and Melinda Gates Foundation	This research was supported and endorsed by the Malaria in Pregnancy (MiP) Consortium, which is funded by a grant from the Bill and Melinda Gates Foundation (www.gatesfoundation.org), Grant OPP46099. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrahams N, 2001, J MIDWIFERY WOM HEAL, V46, P240, DOI 10.1016/S1526-9523(01)00138-6; Adetunji JA, 1996, SOC SCI MED, V43, P1561, DOI 10.1016/S0277-9536(96)00052-4; Ager A, 2005, HEALTH POLICY PLANN, V20, P176, DOI 10.1093/heapol/czi021; [Anonymous], 2008, WORLDWIDE PREVALENCE; Atuyambe L, 2008, COPING RESPONSES PRE; Atuyambe L, 2009, J ADOLESCENCE, V32, P781, DOI 10.1016/j.adolescence.2008.10.012; Bloom SS, 1999, HEALTH POLICY PLANN, V14, P38, DOI 10.1093/heapol/14.1.38; BMJ Evidence Centre, 2011, BEST PRACT ROUT ANT; BRABIN BJ, 1990, ANN TROP MED PARASIT, V84, P1; Campbell J., 2011, STATE WORLDS MIDWIFE; Carroli G, 2001, PAEDIATR PERINAT EP, V15, P1; Chapman RR, 2006, MED ANTHROPOL Q, V20, P487, DOI 10.1525/maq.2006.20.4.487; Chapman Rachel R, 2004, Med Anthropol, V23, P229, DOI 10.1080/01459740490487107; Chapman RR, 2003, SOC SCI MED, V57, P355, DOI 10.1016/S0277-9536(02)00363-5; Choudhury N, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-15; Davis-Floyd Robbie E., 1997, CHILDBIRTH AUTHORITA, P55; Davy C, 2009, PRIMARY HLTH CARE KN; Davy CP, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-268; Dowswell T, 2010, COCHRANE DATABASE SY, P10; Duke T, 1999, LANCET, V354, P1291, DOI 10.1016/S0140-6736(99)00335-9; Finlayson K, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001373; Garner P., 1990, Health Policy and Planning, V5, P49, DOI 10.1093/heapol/5.1.49; Government of Papua New Guinea, 2010, NAT HLTH PLAN 2011 2; Griffiths P, 2001, J BIOSOC SCI, V33, P339, DOI 10.1017/S002193200100339X; Grossmann-Kendall F, 2001, REPROD HEALTH MATTER, V9, P90, DOI 10.1016/S0968-8080(01)90095-3; Hill Z, 2007, PUBLIC HEALTH NUTR, V10, P827, DOI 10.1017/S1368980007382554; Hinton R, 2010, WOMEN STUD INT FORUM, V33, P180, DOI 10.1016/j.wsif.2009.12.006; Kabakian-Khasholian T, 2000, SOC SCI MED, V51, P103, DOI 10.1016/S0277-9536(99)00443-8; Karel HS, 1999, PACIFIC HLTH DIALOG, V6, P326; Kinney MV, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000294; Klufio C, 1993, POPULATION FAMILY HL; Kyomuhendo GB, 2003, REPROD HEALTH MATTER, V11, P16, DOI 10.1016/S0968-8080(03)02176-1; Larsen Gail L., 2004, Papua New Guinea Medical Journal, V47, P202; Launiala A, 2007, T ROY SOC TROP MED H, V101, P980, DOI 10.1016/j.trstmh.2007.04.005; Launiala A, 2006, ACTA TROP, V98, P111, DOI 10.1016/j.actatropica.2005.12.008; MARSHALL LB, 1985, SOC SCI MED, V21, P341, DOI 10.1016/0277-9536(85)90111-X; Mathole T, 2004, MIDWIFERY, V20, P122, DOI 10.1016/j.midw.2003.10.003; Matsuoka S, 2010, HEALTH POLICY, V95, P255, DOI 10.1016/j.healthpol.2009.12.011; Mbonye AK, 2006, HEALTH POLICY, V77, P279, DOI 10.1016/j.healthpol.2005.07.020; Menendez C, 2007, LANCET INFECT DIS, V7, P126, DOI 10.1016/S1473-3099(07)70024-5; Mrisho M, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-10; Mubyazi GM, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-54; Mueller Ivo, 2008, Papua New Guinea Medical Journal, V51, P12; Mumtaz Z, 2007, SOCIOL HEALTH ILL, V29, P1, DOI 10.1111/j.1467-9566.2007.00519.x; Myer L, 2003, J MIDWIFERY WOM HEAL, V48, P268, DOI 10.1016/S1526-9523(02)00421-X; Ndyomugyenyi R, 1998, HEALTH POLICY PLANN, V13, P94, DOI 10.1093/heapol/13.1.94; Pell C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022452; Regmi K., 2009, BR J MIDWIFERY, V17, P382, DOI [10.12968/bjom.2009.17.6.42608, DOI 10.12968/BJOM.2009.17.6.42608, DOI 10.12968/BJ0M.2009.17.6.42608]; Ribera JM, 2007, PLOS MED, V4, P631, DOI 10.1371/journal.pmed.0040092; Rogerson SJ, 2000, T ROY SOC TROP MED H, V94, P549, DOI 10.1016/S0035-9203(00)90083-X; Ronsmans C, 2006, LANCET, V368, P1189, DOI 10.1016/S0140-6736(06)69380-X; Sanga K, 2010, AUST NZ J OBSTET GYN, V50, P21, DOI 10.1111/j.1479-828X.2009.01116.x; SHARP PT, 1982, PAPUA NEW GUINEA MED, V25, P108; Simkhada B, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-34; Stokes E, 2008, BJOG-INT J OBSTET GY, V115, P1641, DOI 10.1111/j.1471-0528.2008.01950.x; Strauss A., 1997, GROUNDED THEORY PRAC; Tautz S, 2000, SOC SCI MED, V50, P689, DOI 10.1016/S0277-9536(99)00321-4; Tinoco-Ojanguren R, 2008, SOC SCI MED, V66, P1057, DOI 10.1016/j.socscimed.2007.11.006; Tolhurst R, 2008, MIDWIFERY, V24, P83, DOI 10.1016/j.midw.2006.09.003; Villar J, 2001, LANCET, V357, P1551, DOI 10.1016/S0140-6736(00)04722-X; Waiswa Peter, 2008, BMC Pregnancy Childbirth, V8, P21, DOI 10.1186/1471-2393-8-21; Wardlow H, 2004, SIGNS J WOMEN CULTUR, V29; World Bank, 2011, REPR HLTH GLANC PAP; World Health Organization, 2010, COUNTR COOP STRAT PN; World Health Organization, 2002, ANT CAR RAND TRIAL M	65	39	40	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2014	9	5							e93025	10.1371/journal.pone.0093025	http://dx.doi.org/10.1371/journal.pone.0093025			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AN9SK	24842484	Green Published, gold			2023-01-03	WOS:000340948600002
J	Ciuffreda, MC; Tolva, V; Casana, R; Gnecchi, M; Vanoli, E; Spazzolini, C; Roughan, J; Calvillo, L				Ciuffreda, Maria Chiara; Tolva, Valerio; Casana, Renato; Gnecchi, Massimiliano; Vanoli, Emilio; Spazzolini, Carla; Roughan, John; Calvillo, Laura			Rat Experimental Model of Myocardial Ischemia/Reperfusion Injury: An Ethical Approach to Set up the Analgesic Management of Acute Post-Surgical Pain	PLOS ONE			English	Article							INFARCT SIZE; TRAMADOL; RESPONSES; CARPROFEN; ISCHEMIA	Rationale: During the past 30 years, myocardial ischemia/reperfusion injury in rodents became one of the most commonly used model in cardiovascular research. Appropriate pain-prevention appears critical since it may influence the outcome and the results obtained with this model. However, there are no proper guidelines for pain management in rats undergoing thoracic surgery. Accordingly, we evaluated three analgesic regimens in cardiac ischemia/reperfusion injury. This study was strongly focused on 3R's ethic principles, in particular the principle of Reduction. Methods: Rats undergoing surgery were treated with pre-surgical tramadol (45 mg/kg intra-peritoneal), or carprofen (5 mg/kg sub-cutaneous), or with pre-surgical administration of carprofen followed by 2 post-surgery tramadol injections (multi-modal group). We assessed behavioral signs of pain and made a subjective evaluation of stress and suffering one and two hours after surgery. Results: Multi-modal treatment significantly reduced the number of signs of pain compared to carprofen alone at both the first hour (61 +/- 42 vs 123 +/- 47; p < 0.05) and the second hour (43 +/- 21 vs 74 +/- 24; p < 0.05) post-surgery. Tramadol alone appeared as effective as multi-modal treatment during the first hour, but signs of pain significantly increased one hour later (from 66 +/- 72 to 151 +/- 86, p < 0.05). Carprofen alone was more effective at the second hour post-surgery when signs of pain reduced to 74 +/- 24 from 113 +/- 40 in the first hour (p < 0.05). Stress behaviors during the second hour were observed in only 20% of rats in the multi-modal group compared to 75% and 86% in the carprofen and tramadol groups, respectively (p < 0.05). Conclusions: Multi-modal treatment with carprofen and tramadol was more effective in preventing pain during the second hour after surgery compared with both tramadol or carprofen. Our results suggest that the combination of carprofen and tramadol represent the best therapy to prevent animal pain after myocardial ischemia/reperfusion. We obtained our results accordingly with the ethical principle of Reduction.	[Ciuffreda, Maria Chiara; Gnecchi, Massimiliano] Fdn IRCCS, Policlin San Matteo, IRCCS Inst Treatment & Res, Dept Cardiothorac & Vasc Sci,Coronary Care Unit, I-27100 Pavia, Italy; [Ciuffreda, Maria Chiara; Gnecchi, Massimiliano] Fdn IRCCS, Policlin San Matteo, IRCCS Inst Treatment & Res, Lab Clin & Expt Cardiol, I-27100 Pavia, Italy; [Ciuffreda, Maria Chiara; Gnecchi, Massimiliano] Fdn IRCCS Policlin San Matteo, Lab Expt Cardiol Cell & Mol Therapy, I-27100 Pavia, Italy; [Tolva, Valerio; Casana, Renato] IRCCS Ist Auxol Italiano, Dept Surg, Milan, Italy; [Gnecchi, Massimiliano] Univ Pavia, Dept Mol Med, Unit Cardiol, I-27100 Pavia, Italy; [Gnecchi, Massimiliano] Univ Cape Town, Dept Med, ZA-7925 Cape Town, South Africa; [Vanoli, Emilio] IRCCS Multimedia, Dept Cardiol, Milan, Italy; [Spazzolini, Carla] IRCCS Ist Auxol Italiano, Ctr Cardiac Arrhythmias Genet Base, Milan, Italy; [Roughan, John] Univ Newcastle, Comparat Biol Ctr, Inst Neurosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Calvillo, Laura] IRCCS Ist Auxol Italiano, Lab Cardiac Arrhythmias Genet Base, Milan, Italy	IRCCS Fondazione Casimiro Mondino; IRCCS Fondazione San Matteo; IRCCS Fondazione Casimiro Mondino; IRCCS Fondazione San Matteo; IRCCS Fondazione San Matteo; IRCCS Istituto Auxologico Italiano; University of Pavia; University of Cape Town; IRCCS Multimedica; IRCCS Istituto Auxologico Italiano; Newcastle University - UK; IRCCS Istituto Auxologico Italiano	Calvillo, L (corresponding author), IRCCS Ist Auxol Italiano, Lab Cardiac Arrhythmias Genet Base, Milan, Italy.	l.calvillo@auxologico.it	Tolva, Valerio/AAG-9168-2021; tolva, valerio stefano/FHS-3400-2022; tolva, valerio/AAY-1802-2020; Spazzolini, Carla/AAA-5023-2020; Roughan, John Vincent/AAF-3586-2021; calvillo, laura/K-1901-2019; Gnecchi, Massimiliano/J-8609-2018; Casana, Renato/AAA-2364-2020; Gnecchi, Massimiliano/X-7095-2019	tolva, valerio/0000-0002-4642-0727; Spazzolini, Carla/0000-0003-1209-0157; Roughan, John Vincent/0000-0002-0031-3918; calvillo, laura/0000-0002-5151-8243; Gnecchi, Massimiliano/0000-0001-7435-4328; Casana, Renato/0000-0002-1049-9656; Gnecchi, Massimiliano/0000-0001-7435-4328; Ciuffreda, Maria Chiara/0000-0003-1673-313X; VANOLI, EMILIO/0000-0001-9068-9099	UK NC3Rs; Ministero Italiano della Sanita [GR-2008-1142871, GR-2010-2320533]; Fondazione Cariplo [2007-5984]; Ministero Italiano degli Affari Esteri [ZA11GR2]; National Centre for the Replacement [G0900763/1] Funding Source: researchfish	UK NC3Rs(UK Research & Innovation (UKRI)National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs)); Ministero Italiano della Sanita(Ministry of Health, Italy); Fondazione Cariplo(Fondazione Cariplo); Ministero Italiano degli Affari Esteri; National Centre for the Replacement	Dr. Roughan is funded by the UK NC3Rs (http://www.nc3rs.org.uk/). This work was supported by the Ministero Italiano della Sanita (GR-2008-1142871; GR-2010-2320533)(http://www.salute.gov.it/), the Fondazione Cariplo (2007-5984)(http://www.fondazionecariplo.it/it/index.html) and the Ministero Italiano degli Affari Esteri (ZA11GR2)(http://www.esteri. it/MAE/IT). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Calvillo L, 2003, CARDIOVASC DRUG THER, V17, P199, DOI 10.1023/A:1026182404805; Calvillo L, 2011, J CARDIOVASC PHARM, V58, P500, DOI 10.1097/FJC.0b013e31822b7204; Cannon CZ, 2011, LAB ANIMAL, V40, P85, DOI 10.1038/laban0311-85; Cannon CZ, 2010, LAB ANIMAL, V39, P342, DOI 10.1038/laban1110-342; Ceyhan A, 2005, J VET MED A, V52, P249, DOI 10.1111/j.1439-0442.2005.00719.x; Gaspani L, 2002, J NEUROIMMUNOL, V129, P18, DOI 10.1016/S0165-5728(02)00165-0; Hazir T, 2008, LANCET, V371, P49, DOI 10.1016/S0140-6736(08)60071-9; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kongara K, 2012, NEW ZEAL VET J, V60, P129, DOI 10.1080/00480169.2011.641156; Liu YM, 2008, J ZHEJIANG UNIV-SC B, V9, P895, DOI 10.1631/jzus.B0820039; McIntyre AR, 2007, J AM ASSOC LAB ANIM, V46, P65; Michael LH, 1999, AM J PHYSIOL-HEART C, V277, pH660, DOI 10.1152/ajpheart.1999.277.2.H660; Roughan JV, 2004, LAB ANIM-UK, V38, P286, DOI 10.1258/002367704323133673; Roughan JV, 2001, PAIN, V90, P65, DOI 10.1016/S0304-3959(00)00387-0; SELYE H., 1960, ANGIOLOGY, V11, P398, DOI 10.1177/000331976001100505; Valtchanova-Matchouganska A, 2004, LIFE SCI, V75, P901, DOI 10.1016/j.lfs.2003.12.029; Wright-Williams S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075948; Zhang LZ, 2009, EUR J ANAESTH, V26, P1048, DOI 10.1097/EJA.0b013e32832c785d	18	11	11	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2014	9	4							e5913	10.1371/journal.pone.0095913	http://dx.doi.org/10.1371/journal.pone.0095913			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG2IS	24756074	Green Published, gold, Green Submitted			2023-01-03	WOS:000335240300118
J	Pfeil, J; Borrmann, S; Tozan, Y				Pfeil, Johannes; Borrmann, Steffen; Tozan, Yesim			Dihydroartemisinin-Piperaquine vs. Artemether-Lumefantrine for First-Line Treatment of Uncomplicated Malaria in African Children: A Cost-Effectiveness Analysis	PLOS ONE			English	Article							PLASMODIUM-FALCIPARUM; COMBINATION THERAPY; NON-INFERIORITY; ARTESUNATE; EFFICACY; BURDEN	Background: Recent multi-centre trials showed that dihydroartemisinin-piperaquine (DP) was as efficacious and safe as artemether-lumefantrine (AL) for treatment of young children with uncomplicated P. falciparum malaria across diverse transmission settings in Africa. Longitudinal follow-up of patients in these trials supported previous findings that DP had a longer post-treatment prophylactic effect than AL, reducing the risk of reinfection and conferring additional health benefits to patients, particularly in areas with moderate to high malaria transmission. Methods: We developed a Markov model to assess the cost-effectiveness of DP versus AL for first-line treatment of uncomplicated malaria in young children from the provider perspective, taking into consideration the post-treatment prophylactic effects of the drugs as reported by a recent multi-centre trial in Africa and using the maximum manufacturer drug prices for artemisinin-based combination therapies set by the Global Fund in 2013. We estimated the price per course of treatment threshold above which DP would cease to be a cost-saving alternative to AL as a first-line antimalarial drug. Results: First-line treatment with DP compared to AL averted 0.03 DALYs (95% CI: 0.006-0.07) and 0.001 deaths (95% CI: 0.00-0.002) and saved $0.96 (95% CI: 0.33-2.46) per child over one year. The results of the threshold analysis showed that DP remained cost-saving over AL for any DP cost below $1.23 per course of treatment. Conclusions: DP is superior to AL from both the clinical and economic perspectives for treatment of uncomplicated P. falciparum malaria in young children. A paediatric dispersible formulation of DP is under development and should facilitate a targeted deployment of this antimalarial drug. The use of DP as first-line antimalarial drug in paediatric malaria patients in moderate to high transmission areas of Africa merits serious consideration by health policymakers.	[Pfeil, Johannes] Univ Hosp, Ctr Childhood & Adolescent Med, Heidelberg, Germany; [Pfeil, Johannes] Univ Hosp, Dept Infect Dis, Heidelberg, Germany; [Pfeil, Johannes] German Ctr Infect Res DZIF, Heidelberg, Germany; [Borrmann, Steffen] Kenyan Med Res Inst KEMRI, Kilifi, Kenya; [Borrmann, Steffen] Univ Tubingen, Inst Trop Med, Tubingen, Germany; [Tozan, Yesim] NYU, Steinhardt Sch Culture Educ & Human Dev, New York, NY USA; [Tozan, Yesim] Heidelberg Univ, Inst Publ Hlth, Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; German Center for Infection Research; Kenya Medical Research Institute; Eberhard Karls University of Tubingen; New York University; Ruprecht Karls University Heidelberg	Tozan, Y (corresponding author), NYU, Steinhardt Sch Culture Educ & Human Dev, New York, NY USA.	tozan@nyu.edu	; Borrmann, Steffen/G-1838-2013	Pfeil, Johannes/0000-0003-0104-8375; Borrmann, Steffen/0000-0001-9189-4393	Deutsche Forschungsgemeinschaft; Ruprecht-Karls-Universitat Heidelberg	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Ruprecht-Karls-Universitat Heidelberg	The authors acknowledge the financial support of the Deutsche Forschungsgemeinschaft and Ruprecht-Karls-Universitat Heidelberg within the funding programme Open Access Publishing. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2010, GUID TREATM MAL; Arinaitwe E, 2009, CLIN INFECT DIS, V49, P1629, DOI 10.1086/647946; Awab GR, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-105; Ayieko Philip, 2009, Cost Eff Resour Alloc, V7, P3, DOI 10.1186/1478-7547-7-3; Bassat Q, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007871; Bhattarai A, 2007, PLOS MED, V4, P1784, DOI 10.1371/journal.pmed.0040309; Briggs A, 1998, PHARMACOECONOMICS, V13, P397, DOI 10.2165/00019053-199813040-00003; Creek DJ, 2013, J INFECT DIS, V207, P1646, DOI 10.1093/infdis/jit078; Davis WA, 2011, B WORLD HEALTH ORGAN, V89, P211, DOI 10.2471/BLT.10.084103; Dondorp AM, 2010, LANCET, V376, P1647, DOI 10.1016/S0140-6736(10)61924-1; Goodman C, 2000, EC ANAL MALARIA CONT; Hasugian AR, 2007, CLIN INFECT DIS, V44, P1067, DOI 10.1086/512677; Lopez ADAO, 2001, 40 GPE WHO; Lubell Y, 2011, B WORLD HEALTH ORGAN, V89, P504, DOI 10.2471/BLT.11.085878; Malmberg M, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-103; Moon S, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000106; Mulligan JA, 2006, TROP MED INT HEALTH, V11, P452, DOI 10.1111/j.1365-3156.2006.01590.x; Murray C, 1993, WORLD DEV REP INV HL, P19; Nambozi M, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-50; Roca-Feltrer A, 2008, TROP MED INT HEALTH, V13, P771, DOI 10.1111/j.1365-3156.2008.02076.x; Shaukat Ayesha M, 2012, Malar J, V11, P207, DOI 10.1186/1475-2875-11-207; Shillcutt S, 2008, B WORLD HEALTH ORGAN, V86, P101, DOI 10.2471/BLT.07.042259; Stepniewska K, 2008, ANTIMICROB AGENTS CH, V52, P1589, DOI 10.1128/AAC.00903-07; The Four Artemisinin-Based Combinations Study Group, 2011, PLOS MED, V8; The Global Fund website, ACT PRIC AFF MED FAC; Ubben D, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-211; US Department of Labor Bureau of Labor Statistics, CPI INFL CALC; White L, 2012, MAL C 2012; White NJ, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-9; World Bank, 1993, WORLD DEV REP INV HL	30	14	16	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2014	9	4							e95681	10.1371/journal.pone.0095681	http://dx.doi.org/10.1371/journal.pone.0095681			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG2DP	24748395	Green Published, Green Submitted, gold			2023-01-03	WOS:000335226500137
J	Cox, JF				Cox, John F.			Review: Exercise reduces mortality compared with drugs in stroke but not in CHD, HF, or prediabetes	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Rochester, Sch Med, Rochester, NY USA	University of Rochester	Cox, JF (corresponding author), Univ Rochester, Sch Med, Rochester, NY USA.							Lian XQ, 2014, PREV MED, V58, P64, DOI 10.1016/j.ypmed.2013.10.020	1	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 16	2014	160	8							JC3	10.7326/0003-4819-160-8-201404150-02003	http://dx.doi.org/10.7326/0003-4819-160-8-201404150-02003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CW3QU	24733220				2023-01-03	WOS:000364907600002
J	Kaw, R				Kaw, Roop			In patients with obstructive sleep apnea and resistant hypertension, CPAP reduced 24-hour blood pressure	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Cleveland Clin, Cleveland, OH 44106 USA	Cleveland Clinic Foundation	Kaw, R (corresponding author), Cleveland Clin, Cleveland, OH 44106 USA.		Kaw, Roop/A-7877-2009	Kaw, Roop/0000-0001-7712-7729				Fagard RH, 2008, HYPERTENSION, V51, P55, DOI 10.1161/HYPERTENSIONAHA.107.100727; Logan AG, 2003, EUR RESPIR J, V21, P241, DOI 10.1183/09031936.03.00035402; Lozano L, 2010, J HYPERTENS, V28, P2161, DOI 10.1097/HJH.0b013e32833b9c63; Seif F, 2014, J HYPERTENS, V32, P267, DOI 10.1097/HJH.0000000000000011; Weaver Terri E, 2008, Proc Am Thorac Soc, V5, P173, DOI 10.1513/pats.200708-119MG	5	0	0	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 16	2014	160	8							JC10	10.7326/0003-4819-160-8-201404150-02010	http://dx.doi.org/10.7326/0003-4819-160-8-201404150-02010			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CW3QU	24733215				2023-01-03	WOS:000364907600009
J	Gao, DQ; Li, CY; Xie, XH; Zhao, P; Wei, XF; Sun, WH; Liu, HC; Alexandrou, AT; Jones, J; Zhao, RH; Li, JJ				Gao, Daiqing; Li, Changyou; Xie, Xihe; Zhao, Peng; Wei, Xiaofang; Sun, Weihong; Liu, Hsin-Chen; Alexandrou, Aris T.; Jones, Jennifer; Zhao, Ronghua; Li, Jian Jian			Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy with Cytokine-Induced Killer Cells Improves Survival in Gastric and Colorectal Cancer Patients	PLOS ONE			English	Article							SIPULEUCEL-T; ACTIVE IMMUNOTHERAPY; IMMUNE-RESPONSE; PHASE-I; VACCINATION; PEPTIDE; ANTIGEN; CHEMOTHERAPY; LYMPHOMA; ENHANCE	Gastric and colorectal cancers (GC and CRC) have poor prognosis and are resistant to chemo- and/or radiotherapy. In the present study, the prophylactic effects of dendritic cell (DC) vaccination are evaluated on disease progression and clinical benefits in a group of 54 GC and CRC patients treated with DC immunotherapy combined with cytokine-induced killer (CIK) cells after surgery with or without chemo-radiotherapy. DCs were prepared from the mononuclear cells isolated from patients using IL-2/GM-CSF and loaded with tumor antigens; CIK cells were prepared by incubating peripheral blood lymphocytes with IL-2, IFN-gamma, and CD3 antibodies. The DC/CIK therapy started 3 days after low-dose chemotherapy and was repeated 3-5 times in 2 weeks as one cycle with a total of 188.3 +/- 79.8x10(6) DCs and 58.8 +/- 22.3x10(8) CIK cells. Cytokine levels in patients' sera before and after treatments were measured and the follow-up was conducted for 98 months to determine disease-free survival (DFS) and overall survival (OS). The results demonstrate that all cytokines tested were elevated with significantly higher levels of IFN-gamma and IL-12 in both GC and CRC cohorts of DC/CIK treated patients. By Cox regression analysis, DC/CIK therapy reduced the risk of post-operative disease progression (p<0.01) with an increased OS (<0.01). These results demonstrate that in addition to chemo- and/or radiotherapy, DC/CIK immunotherapy is a potential effective approach in the control of tumor growth for post-operative GC and CRC patients.	[Gao, Daiqing; Li, Changyou; Xie, Xihe; Zhao, Peng; Wei, Xiaofang; Sun, Weihong] Qingdao Univ, Coll Med, Affiliated Hosp 2, Qingdao Ctr Hosp,Biotherapy Ctr, Qingdao 266071, Peoples R China; [Liu, Hsin-Chen; Alexandrou, Aris T.; Li, Jian Jian] Univ Calif Davis, NCI Designated Comprehens Canc Ctr, Dept Radiat Oncol, Sacramento, CA 95817 USA; [Jones, Jennifer; Zhao, Ronghua] Univ Saskatchewan, Dept Med, Saskatoon, SK S7N 0W0, Canada	Qingdao University; University of California System; University of California Davis; University of Saskatchewan	Gao, DQ (corresponding author), Qingdao Univ, Coll Med, Affiliated Hosp 2, Qingdao Ctr Hosp,Biotherapy Ctr, Qingdao 266071, Peoples R China.	gaodaiqing@126.com; jian-jian.li@ucdmc.ucdavis.edu	Zhao, Peng/AAQ-2494-2020	Li, Jian Jian/0000-0003-3694-9675				Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Beutler N, 2013, EUR J IMMUNOL, V43, P1459, DOI 10.1002/eji.201242725; Boulikas T, 2004, ONCOL REP, V11, P559; Chan JK, 2006, CLIN CANCER RES, V12, P1859, DOI 10.1158/1078-0432.CCR-05-2019; Duru N, 2012, CLIN CANCER RES, V18, P6634, DOI 10.1158/1078-0432.CCR-12-1436; Fong L, 2001, P NATL ACAD SCI USA, V98, P8809, DOI 10.1073/pnas.141226398; Frankenberger B, 2012, EUR J CELL BIOL, V91, P53, DOI 10.1016/j.ejcb.2011.01.012; Frohlich MW, 2012, SEMIN ONCOL, V39, P245, DOI 10.1053/j.seminoncol.2012.02.004; Gonzalez-Carmona MA, 2006, LIVER INT, V26, P369, DOI 10.1111/j.1478-3231.2005.01235.x; Gutgemann Stefan, 2007, Ger Med Sci, V5, pDoc07; Higano CS, 2010, NAT REV DRUG DISCOV, V9, P513, DOI 10.1038/nrd3220; Higano CS, 2009, CANCER-AM CANCER SOC, V115, P3670, DOI 10.1002/cncr.24429; Hontscha C, 2011, J CANCER RES CLIN, V137, P305, DOI 10.1007/s00432-010-0887-7; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; Huber ML, 2012, J NATL CANCER I, V104, P273, DOI 10.1093/jnci/djr514; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Leemhuis T, 2005, BIOL BLOOD MARROW TR, V11, P181, DOI 10.1016/j.bbmt.2004.11.019; Li CD, 2005, CELL RES, V15, P539, DOI 10.1038/sj.cr.7290323; Li H, 2009, CYTOTHERAPY, V11, P1076, DOI 10.3109/14653240903121252; Linn YC, 2003, LEUKEMIA LYMPHOMA, V44, P1457, DOI 10.1080/1042819031000083082; LU PH, 1994, J IMMUNOL, V153, P1687; Madan RA, 2012, J NATL COMPR CANC NE, V10, P1505, DOI 10.6004/jnccn.2012.0156; Margolin KA, 1997, IMMUNOL REV, V157, P231, DOI 10.1111/j.1600-065X.1997.tb00986.x; Marten A, 2001, J IMMUNOTHER, V24, P502, DOI 10.1097/00002371-200111000-00007; Marten A, 2002, CANCER IMMUNOL IMMUN, V51, P25, DOI 10.1007/s00262-001-0251-5; Marten A, 2001, CANCER GENE THER, V8, P211, DOI 10.1038/sj.cgt.7700292; Melief CJM, 2007, NATURE, V450, P803, DOI 10.1038/nature06363; Mesiano G, 2012, EXPERT OPIN BIOL TH, V12, P673, DOI 10.1517/14712598.2012.675323; Moiseyenko V, 2007, ADV EXP MED BIOL, V601, P387; Morse MA, 1999, CLIN CANCER RES, V5, P1331; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; O'Neill D, 2005, METH MOLEC MED, V109, P1; O'Neill DW, 2007, MOL BIOTECHNOL, V36, P131, DOI 10.1007/s12033-007-0020-6; OTTOMAN RE, 1963, RADIOLOGY, V81, P1014, DOI 10.1148/81.6.1014; Palesty JA, 2004, J CLIN ONCOL, V22, P2507, DOI 10.1200/jco.2004.09.168; Pan YB, 2005, J MED CHEM, V48, P875, DOI 10.1021/jm0494422; Pan Y, 2006, BIOCHEM BIOPH RES CO, V347, P551, DOI 10.1016/j.bbrc.2006.05.214; Schadendorf D, 2009, ANN ONCOL, V20, P41, DOI 10.1093/annonc/mdp253; Schlom J, 2012, CANCER BIOTHER RADIO, V27, P2, DOI 10.1089/cbr.2012.1200; Sharma A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028217; Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175; Su XS, 2010, J CLIN IMMUNOL, V30, P766, DOI 10.1007/s10875-010-9434-1; Sun Yi, 2010, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V18, P219; Thanendrarajan S, 2011, LEUKEMIA RES, V35, P1136, DOI 10.1016/j.leukres.2011.05.005; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; Timmerman JM, 2002, BLOOD, V99, P1517, DOI 10.1182/blood.V99.5.1517; van Broekhoven CL, 2004, CANCER RES, V64, P4357, DOI 10.1158/0008-5472.CAN-04-0138; Wongkajornsilp A, 2005, J ORTHOP RES, V23, P1460, DOI 10.1016/j.orthres.2005.03.009	49	72	89	0	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 3	2014	9	4							e93886	10.1371/journal.pone.0093886	http://dx.doi.org/10.1371/journal.pone.0093886			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE6LR	24699863	Green Submitted, Green Published, gold			2023-01-03	WOS:000334105000118
J	Lyu, XD; Xin, YP; Mi, RH; Ding, J; Wang, XW; Hu, JY; Fan, RH; Wei, XD; Song, YP; Zhao, RY				Lyu, Xiaodong; Xin, Yaping; Mi, Ruihua; Ding, Jing; Wang, Xianwei; Hu, Jieying; Fan, Ruihua; Wei, Xudong; Song, Yongping; Zhao, Richard Y.			Overexpression of Wilms Tumor 1 Gene as a Negative Prognostic Indicator in Acute Myeloid Leukemia	PLOS ONE			English	Article							WT1 PROTEIN; EXPRESSION; DIAGNOSIS; RECOMMENDATIONS; PROLIFERATION; SUPPRESSOR; INHIBIT; LEVEL; CELLS	Chromosomal aberrations are useful in assessing treatment options and clinical outcomes of acute myeloid leukemia (AML) patients. However, 40 similar to 50% of the AML patients showed no chromosomal abnormalities, i.e., with normal cytogenetics aka the CN-AML patients. Testing of molecular aberrations such as FLT3 or NPM1 can help to define clinical outcomes in the CN-AML patients but with various successes. Goal of this study was to test the possibility of Wilms' tumor 1 (WT1) gene overexpression as an additional molecular biomarker. A total of 103 CN-AML patients, among which 28% had overexpressed WT1, were studied over a period of 38 months. Patient's response to induction chemotherapy as measured by the complete remission (CR) rate, disease-free survival (DFS) and overall survival (OS) were measured. Our data suggested that WT1 overexpression correlated negatively with the CR rate, DFS and OS. Consistent with previous reports, CN-AML patients can be divided into three different risk subgroups based on the status of known molecular abnormalities, i.e., the favorable (NPM1(mt)/no FLT3(ITD)), the unfavorable (FLT3(ITD)) and the intermediate risk subgroups. The WT1 overexpression significantly reduced the CR, DFS and OS in both the favorable and unfavorable groups. As the results, patients with normal WT1 gene expression in the favorable risk group showed the best clinical outcomes and all survived with complete remission and disease-free survival over the 37 month study period; in contrast, patients with WT1 overexpression in the unfavorable risk group displayed the worst clinical outcomes. WT1 overexpression by itself is an independent and negative indicator for predicting CR rate, DFS and OS of the CN-AML patients; moreover, it increases the statistical power of predicting the same clinical outcomes when it is combined with the NPM1 mt or the FLT3(ITD) genotypes that are the good or poor prognostic markers of CN-AML.	[Lyu, Xiaodong; Mi, Ruihua; Ding, Jing; Wang, Xianwei; Hu, Jieying; Fan, Ruihua; Wei, Xudong; Song, Yongping] Zhengzhou Univ, Henan Inst Hematol, Affiliated Tumor Hosp, Zhengzhou 450052, Henan, Peoples R China; [Xin, Yaping] Zhengzhou Univ, Dept Endocrinol & Metab Dis, Affiliated Hosp 2, Zhengzhou 450052, Henan, Peoples R China; [Lyu, Xiaodong; Zhao, Richard Y.] Univ Maryland Sch Med, Div Mol Pathol, Dept Pathol, Baltimore, MD USA	Zhengzhou University; Zhengzhou University; University System of Maryland; University of Maryland Baltimore	Lyu, XD (corresponding author), Zhengzhou Univ, Henan Inst Hematol, Affiliated Tumor Hosp, Zhengzhou 450052, Henan, Peoples R China.	xiaodonglv2007@sina.com; RZhao@som.uamryland.edu		Zhao, Richard Y./0000-0003-3424-2852	Social Public Service Foundation of Henan Technology Department [072103810503]	Social Public Service Foundation of Henan Technology Department	This work was supported by the Social Public Service Foundation of Henan Technology Department [072103810503] to Xiaodong Lyu who was a visiting physician scientist in the RZ's laboratory at the University of Maryland School of Medicine when this manuscript was written. The authors would like to thank Ge Li for helpful discussions and revision. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adachi Y, 1996, ONCOGENE, V13, P2197; Barragan E, 2004, HAEMATOLOGICA, V89, P926; Bergmann L, 1997, LEUKEMIA LYMPHOMA, V25, P435, DOI 10.3109/10428199709039030; Cheson BD, 2003, J CLIN ONCOL, V21, P4642, DOI 10.1200/JCO.2003.04.036; Cilloni D, 2009, J CLIN ONCOL, V27, P5195, DOI 10.1200/JCO.2009.22.4865; Damm F, 2011, BLOOD, V117, P4561, DOI 10.1182/blood-2010-08-303479; Dohner H, 2010, BLOOD, V115, P453, DOI 10.1182/blood-2009-07-235358; Gao SM, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-110; Garg M, 2003, BRIT J HAEMATOL, V123, P49, DOI 10.1046/j.1365-2141.2003.04552.x; Jono Hirofumi, 2010, Cancers (Basel), V2, P624, DOI 10.3390/cancers2020624; Lyu XD, 2013, J CLIN EXP PATHO, V3, P143; Ma ZH, 2013, J CANCER RES CLIN, V139, P557, DOI 10.1007/s00432-012-1357-1; Marcucci G, 2011, J CLIN ONCOL, V29, P475, DOI 10.1200/JCO.2010.30.2554; Miglino M, 2011, LEUKEMIA LYMPHOMA, V52, P1961, DOI 10.3109/10428194.2011.585673; Miyawaki S, 2010, LEUKEMIA LYMPHOMA, V51, P1855, DOI 10.3109/10428194.2010.507829; Mrozek K, 2007, BLOOD, V109, P431, DOI 10.1182/blood-2006-06-001149; Oka Y, 2004, P NATL ACAD SCI USA, V101, P13885, DOI 10.1073/pnas.0405884101; Rau R, 2009, HEMATOL ONCOL, V27, P171, DOI 10.1002/hon.904; Spassov BV, 2011, HEMATOLOGY, V16, P37, DOI 10.1179/102453311X12902908411913; Tuna M, 2005, ONCOGENE, V24, P1648, DOI 10.1038/sj.onc.1208345; Werner H, 1996, J MOL NEUROSCI, V7, P111, DOI 10.1007/BF02736791; Yang L, 2007, LEUKEMIA, V21, P868, DOI 10.1038/sj.leu.2404624	22	28	34	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2014	9	3							e92470	10.1371/journal.pone.0092470	http://dx.doi.org/10.1371/journal.pone.0092470			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE0SD	24667279	gold, Green Published, Green Submitted			2023-01-03	WOS:000333675600042
J	Horowitz, E; Bergman, LC; Ashkenazy, C; Moscona-Hurvitz, I; Grinvald-Fogel, H; Magnezi, R				Horowitz, Einav; Bergman, Lisa Carroll; Ashkenazy, Charna; Moscona-Hurvitz, Irit; Grinvald-Fogel, Haya; Magnezi, Racheli			Off-Label Use of Sodium Valproate for Schizophrenia	PLOS ONE			English	Article							MOOD STABILIZERS; SCHIZOAFFECTIVE DISORDER; ACUTE EXACERBATIONS; BIPOLAR DISORDER; DIVALPROEX; OLANZAPINE; ANTIPSYCHOTICS; PRESCRIPTION; RISPERIDONE; GUIDELINES	Background: Off-label use of a drug not according to its regulatory labeling has become common in medicine, especially in the field of psychiatry. Mood stabilizers are intended to be used to attenuate mood fluctuations in bipolar disorder, but their use has spread to patients with schizophrenia, as it provides greater control of impulsivity and aggressiveness. Sodium valproate is one of the most frequently used mood stabilizers in psychiatry. This study determined the prevalence of off-label use of sodium valproate for schizophrenia and schizoaffective disorder in Abarbanel Psychiatric Hospital and the demographic and clinical characteristics associated with its use. Methods: Retrospective study of patients hospitalized in 2011-2012 with a diagnosis of schizophrenia or schizoaffective disorder in one of three general psychiatric wards. Results: Valproate use was significantly lower in the geriatric group (11.6% vs. 20.1%, chi square = 4.7, p = .03), in patients with schizophrenia (14.1% vs. schizoaffective disorder (35.2%), chi square = 29, p<.001) and in patients receiving both atypical and typical antipsychotics (23.3% vs. 16.4%, p = .04). In multivariate logistic regression analysis, diagnosis and the combination of atypical and typical antipsychotics predicted the use of sodium valproate. The number of other medications prescribed did not predict sodium valproate use. Conclusions: Off-label use of sodium valproate in psychiatric patients with schizophrenia or schizoaffective disorder is extensive, especially in younger patients and those with schizoaffective disorder. More research is needed to determine whether it is being prescribed appropriately.	[Horowitz, Einav] Haim Sheba Med Ctr, Gertner Inst, Israeli Ctr Technol Assessment Hlth Care, Ramat Gan, Israel; [Bergman, Lisa Carroll; Grinvald-Fogel, Haya; Magnezi, Racheli] Bar Ilan Univ, Publ Hlth & Hlth Syst Management Program, Ramat Gan, Israel; [Ashkenazy, Charna] Abarbanel Mental Hlth Ctr, Bat Yam, Israel; [Moscona-Hurvitz, Irit] Teva Pharmaceut Ind Ltd, Petah Tiqwa, Israel	Chaim Sheba Medical Center; Bar Ilan University; Teva Pharmaceutical Industries	Horowitz, E (corresponding author), Haim Sheba Med Ctr, Gertner Inst, Israeli Ctr Technol Assessment Hlth Care, Ramat Gan, Israel.	EinavH@gertner.health.gov.il						Abou-Setta AM, 2012, AHRQ COMP EFFECTIVEN; Benabarre A, 2001, EUR PSYCHIAT, V16, P167, DOI 10.1016/S0924-9338(01)00559-4; Buchanan RW, 2010, SCHIZOPHRENIA BULL, V36, P71, DOI 10.1093/schbul/sbp116; Casey DE, 2009, NEUROPSYCHOPHARMACOL, V34, P1330, DOI 10.1038/npp.2008.209; Chen DT, 2009, PHARMACOEPIDEM DR S, V18, P1094, DOI 10.1002/pds.1825; Chen H, 2007, CURR MED RES OPIN, V23, P1351, DOI 10.1185/030079907X187883; Citrome L, 2004, PSYCHIAT SERV, V55, P290, DOI 10.1176/appi.ps.55.3.290; Citrome L, 2002, PSYCHIATR SERV, V53, P1212, DOI 10.1176/appi.ps.53.10.1212; Citrome L, 2000, PSYCHIATR SERV, V51, P634, DOI 10.1176/appi.ps.51.5.634; Citrome L., 2004, CURR PSYCHIAT, V3, P23; Citrome L, 2009, EXPERT REV NEUROTHER, V9, P55, DOI 10.1586/14737175.9.1.55; Conley RR, 2001, BIOL PSYCHIAT, V50, P898, DOI 10.1016/S0006-3223(01)01271-9; Davids E, 2006, PROG NEURO-PSYCHOPH, V30, P1109, DOI 10.1016/j.pnpbp.2006.04.015; European Medicines Agency, 2013, VALPR; Falkai P, 2005, WORLD J BIOL PSYCHIA, V6, P132, DOI 10.1080/15622970510030090; Gallego JA, 2012, SCHIZOPHR RES, V138, P18, DOI 10.1016/j.schres.2012.03.018; Hartling L, 2012, ANN INTERN MED, V157, P498, DOI 10.7326/0003-4819-157-7-201210020-00525; Haw C, 2005, J PSYCHOPHARMACOL, V19, P402, DOI 10.1177/0269881105053307; Healy D, 1998, PSYCHIAT B, V22, P680; Kelly DL, 2006, PSYCHIAT QUART, V77, P81, DOI 10.1007/s11126-006-7963-9; Lehman AF, 2004, AM J PSYCHIAT, V161, P1; Leslie DL, 2009, PSYCHIAT SERV, V60, P1174, DOI 10.1176/ps.2009.60.9.1175; Levinson DF, 1999, AM J PSYCHIAT, V156, P1138; Lonergan E, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003945.pub3; McGorry P, 2005, AUST NZ J PSYCHIAT, V39, P1; Meltzer HY, 2011, J CLIN PSYCHIAT, V72, P1602, DOI 10.4088/JCP.10m05997; Moore TA, 2007, J CLIN PSYCHIAT, V68, P1751, DOI 10.4088/JCP.v68n1115; Murru A, 2011, EUR NEUROPSYCHOPHARM, V21, P680, DOI 10.1016/j.euroneuro.2011.03.001; National Institute for Clinical Excellence, 2003, SCHIZ FULL NAT GUID; Olfson M, 2009, PSYCHIAT SERV, V60, P210, DOI 10.1176/appi.ps.60.2.210; Pickar D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003150; Qian K, 2012, ADV EXP MED BIOL, V736, P563, DOI 10.1007/978-1-4419-7210-1_33; Radley DC, 2006, ARCH INTERN MED, V166, P1021, DOI 10.1001/archinte.166.9.1021; Schwarz C, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004028.pub3; Sim K, 2011, INT J NEUROPSYCHOPH, V14, P1157, DOI 10.1017/S1461145711000563; Suzuki T, 2009, HUM PSYCHOPHARM CLIN, V24, P628, DOI 10.1002/hup.1073; Wassef AA, 2000, J CLIN PSYCHOPHARM, V20, P357, DOI 10.1097/00004714-200006000-00011; Wessels T, 2007, PSYCHIAT QUART, V78, P91, DOI 10.1007/s11126-006-9030-y; Wittich CM, 2012, MAYO CLIN PROC, V87, P982, DOI 10.1016/j.mayocp.2012.04.017	39	25	26	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 24	2014	9	3							e92573	10.1371/journal.pone.0092573	http://dx.doi.org/10.1371/journal.pone.0092573			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AD7QO	24664210	Green Published, Green Submitted, gold			2023-01-03	WOS:000333459900078
J	Boerleider, AW; Francke, AL; van de Reep, M; Mannien, J; Wiegers, TA; Deville, WLJM				Boerleider, Agatha W.; Francke, Anneke L.; van de Reep, Merle; Mannien, Judith; Wiegers, Therese A.; Deville, Walter L. J. M.			"Being Flexible and Creative'': A Qualitative Study on Maternity Care Assistants' Experiences with Non-Western Immigrant Women	PLOS ONE			English	Article							HEALTH-CARE; PROFESSIONALS; MORTALITY	Background: Several studies conducted in developed countries have explored postnatal care professionals' experiences with non-western women. These studies reported different cultural practices, lack of knowledge of the maternity care system, communication difficulties, and the important role of the baby's grandmother as care-giver in the postnatal period. However, not much attention has been paid in existing literature to postnatal care professionals' approaches to these issues. Our main objective was to gain insight into how Dutch postnatal care providers - 'maternity care assistants' (MCA) - address issues encountered when providing care for non-western women. Methods: A generic qualitative research approach was used. Two researchers interviewed fifteen MCAs individually, analysing the interview material separately and then comparing and discussing their results. Analytical codes were organised into main themes and subthemes. Results: MCAs perceive caring for non-western women as interesting and challenging, but sometimes difficult too. To guarantee the health and safety of mother and baby, they have adopted flexible and creative approaches to address issues concerning traditional practices, socioeconomic status and communication. Furthermore, they employ several other strategies to establish relationships with non-western clients and their families, improve women's knowledge of the maternity care system and give health education. Conclusion: Provision of postnatal care to non-western clients may require special skills and measures. The quality of care for non-western clients might be improved by including these skills in education and retraining programmes for postnatal care providers on top of factual knowledge about traditional practices.	[Boerleider, Agatha W.; Francke, Anneke L.; van de Reep, Merle; Wiegers, Therese A.; Deville, Walter L. J. M.] Netherlands Inst Hlth Serv Res NIVEL, Utrecht, Netherlands; [Francke, Anneke L.] Vrije Univ Amsterdam, Med Ctr, Dept Publ & Occupat Hlth, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands; [Mannien, Judith] Vrije Univ Amsterdam, Med Ctr, Dept Midwifery Sci, AVAG, Amsterdam, Netherlands; [Mannien, Judith] Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands; [Deville, Walter L. J. M.] Univ Amsterdam, Fac Social & Behav Sci, Amsterdam, Netherlands; [Deville, Walter L. J. M.] Natl Knowledge & Advisory Ctr Migrants Refugees &, Utrecht, Netherlands	Netherlands Institute for Health Services Research; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam	Boerleider, AW (corresponding author), Netherlands Inst Hlth Serv Res NIVEL, Utrecht, Netherlands.	agathawb75@yahoo.com		Mannien, Judith/0000-0003-1698-9979	Academy of Midwifery Amsterdam-Groningen (AVAG); Dutch Ministry of Education, Culture and Science	Academy of Midwifery Amsterdam-Groningen (AVAG); Dutch Ministry of Education, Culture and Science	This study was funded by the Academy of Midwifery Amsterdam-Groningen (AVAG) and the Dutch Ministry of Education, Culture and Science. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Caelli K., 2003, INT J QUAL METHODS, V2, P1, DOI [10.1177/160940690300200201, DOI 10.1177/160940690300200201]; Cioffi J, 2004, J MIDWIFERY WOM HEAL, V49, P437, DOI 10.1016/j.jmwh.2004.01.019; El Fakiri F, 1999, KRAAMZORG ALLOCHTONE; Foets M, 2008, GEZONDHEIDS ZORG OND, P29; Fort A.L., 2006, POSTPARTUM CARE LEVE; Green J, 2009, QUALITATIVE METHODS, P198; Jirwe M, 2010, SCAND J CARING SCI, V24, P436, DOI 10.1111/j.1471-6712.2009.00733.x; Lyons SM, 2008, ETHNIC HEALTH, V13, P261, DOI 10.1080/13557850801903020; Mathai M, 2010, WHO TECHNICAL CONSUL; McAree T., 2010, EVIDENCE BASED MIDWI, V8, P91; Ockleford E. M., 2004, BRIT J MIDWIFERY, V12, P166, DOI DOI 10.12968/BJOM.2004.12.3.15363; Priebe S, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-187; Puthussery S, 2008, J HEALTH SERV RES PO, V13, P195, DOI 10.1258/jhsrp.2008.007153; Ravelli ACJ, 2011, J EPIDEMIOL COMMUN H, V65, P696, DOI 10.1136/jech.2009.095406; Rice PL, 1999, MIDWIFERY, V15, P47, DOI 10.1016/S0266-6138(99)90037-2; Schutte JM, 2010, BJOG-INT J OBSTET GY, V117, P399, DOI 10.1111/j.1471-0528.2009.02382.x; Statistics Netherlands StatLine, 2012, GEB HERK LEEFT MOED; Tran M, 2001, J Qual Clin Pract, V21, P135, DOI 10.1046/j.1440-1762.2001.00431.x; Tucker CM, 2011, HEALTH PSYCHOL, V30, P342, DOI 10.1037/a0022967; Wiegers TA, 2006, J NEONATAL NURS, V12, P163, DOI [10.1016/j.jnn.2006.07.003, DOI 10.1016/J.JNN.2006.07.003]; Wiklund H, 2000, MIDWIFERY, V16, P105, DOI 10.1054/midw.1999.0197; Yelland J, 1998, MIDWIFERY, V14, P144, DOI 10.1016/S0266-6138(98)90029-8	22	8	8	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2014	9	3							e91843	10.1371/journal.pone.0091843	http://dx.doi.org/10.1371/journal.pone.0091843			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AC9HN	24622576	Green Published, gold, Green Submitted			2023-01-03	WOS:000332845300134
J	Edmondson, D; Green, P; Ye, SQ; Halazun, HJ; Davidson, KW				Edmondson, Donald; Green, Philip; Ye, Siqin; Halazun, Hadi J.; Davidson, Karina W.			Psychological Stress and 30-Day All-Cause Hospital Readmission in Acute Coronary Syndrome Patients: An Observational Cohort Study	PLOS ONE			English	Article							ACUTE MYOCARDIAL-INFARCTION; SYMPTOMS; METAANALYSIS; ASSOCIATION; DEPRESSION; SURGERY; RISK	Background: Many acute coronary syndrome (ACS; myocardial infarction and unstable angina) patients are rehospitalized within 30 days of discharge, and recent US health policy initiatives have tied hospital Medicare reimbursement to 30-day readmission rates. Patient-perceived psychological stress is thought to impact prognosis after ACS. A recently offered "posthospital syndrome" model of 30-day readmissions posits that the stress level at the time of the index hospitalization itself may increase 30-day risk for readmission in ACS patients. We tested whether self-reported stress in the days surrounding the ACS hospitalization was associated with increased risk for readmission within 30 days. Methods: A mean of 8.5 days after discharge, 342 consecutively hospitalized ACS patients reported on how often they felt stress during the past two weeks. Readmission within 30 days of hospital discharge for any cause was determined by follow-up telephone calls to patients and confirmed by hospital records. Results: Overall, 40 (11.7%) participants were readmitted within 30 days, and 22 (6.4%) reported high stress. Readmission within 30 days was more common in patients with high stress (5 admissions, 23%) than in patients with low stress (35 admissions, 11%). After adjustment for demographic and clinical factors, as well as depression, high stress was associated with a 3-fold increased risk of 30-day readmission (HR = 3.21, 95% CI = 1.13, 9.10). Conclusions: Previous research has shown that stress in the days surrounding a hospitalization can mark long-term cardiovascular risk, but this is the first study to test a hypothesis of the posthospital syndrome model of early readmission. Further research is needed to confirm the association between stress and readmission risk, and to identify the processes of hospitalization that could be modified to both reduce the stress experienced and that would also be effective for reducing readmissions.	[Edmondson, Donald; Green, Philip; Ye, Siqin; Halazun, Hadi J.; Davidson, Karina W.] Columbia Univ, Med Ctr, Ctr Behav Cardiovasc Hlth, Dept Med, New York, NY 10027 USA	Columbia University	Edmondson, D (corresponding author), Columbia Univ, Med Ctr, Ctr Behav Cardiovasc Hlth, Dept Med, New York, NY 10027 USA.	dee2109@columbia.edu	Edmondson, Donald/G-7486-2016; Davidson, Karina/GWC-0996-2022; Davidson, Karina/AAG-2388-2019	Davidson, Karina/0000-0002-9162-477X; Davidson, Karina/0000-0002-9162-477X; Edmondson, Donald/0000-0002-4518-8196	New York State Department of Health ECRIP research program;  [HL088117];  [HL117832]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL088117, R01HL117832] Funding Source: NIH RePORTER	New York State Department of Health ECRIP research program; ; ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by grants HL088117 and HL117832, and in part by New York State Department of Health ECRIP research program. The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official view of any of the sponsors. All authors had full access to the data and approved the manuscript. Dr. Edmondson is responsible for analyses. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5; Dharmarajan K, 2013, JAMA-J AM MED ASSOC, V309, P355, DOI 10.1001/jama.2012.216476; Edmondson D, 2013, JAMA INTERN MED, V173, P472, DOI 10.1001/jamainternmed.2013.2536; Edmondson D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038915; Fontanarosa PB, 2013, JAMA-J AM MED ASSOC, V309, P398, DOI 10.1001/jama.2013.42; Fox KAA, 2006, BMJ-BRIT MED J, V333, P1091, DOI 10.1136/bmj.38985.646481.55; FRASURESMITH N, 1991, AM J CARDIOL, V67, P121, DOI 10.1016/0002-9149(91)90432-K; Fredrikson M, 1990, ANN BEHAV MED; Krumholz HM, 2013, NEW ENGL J MED, V368, P100, DOI 10.1056/NEJMp1212324; Linden W, 2007, EUR HEART J, V28, P2972, DOI 10.1093/eurheartj/ehm504; Oxlad M, 2006, J PSYCHOSOM RES, V61, P775, DOI 10.1016/j.jpsychores.2006.09.008; Raikkonen K, 1996, METABOLISM, V45, P1533, DOI 10.1016/S0026-0495(96)90184-5; Richardson S, 2012, AM J CARDIOL, V110, P1711, DOI 10.1016/j.amjcard.2012.08.004; Shah SJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047420; Tsigos C, 2002, J PSYCHOSOM RES, V53, P865, DOI 10.1016/S0022-3999(02)00429-4; Tully PJ, 2008, J BEHAV MED, V31, P281, DOI 10.1007/s10865-008-9153-8; Weiss D, 1997, CROSS CULTURAL ASSES, P219	18	33	34	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2014	9	3							e91477	10.1371/journal.pone.0091477	http://dx.doi.org/10.1371/journal.pone.0091477			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AC9HN	24621575	Green Published, gold, Green Submitted			2023-01-03	WOS:000332845300092
J	Walkowski, S; Singh, M; Puertas, J; Pate, M; Goodrum, K; Benencia, F				Walkowski, Stevan; Singh, Manindra; Puertas, Juan; Pate, Michelle; Goodrum, Kenneth; Benencia, Fabian			Osteopathic Manipulative Therapy Induces Early Plasma Cytokine Release and Mobilization of a Population of Blood Dendritic Cells	PLOS ONE			English	Article							ACUTE MENTAL STRESS; NITRIC-OXIDE; MONOCYTES	It has been claimed that osteopathic manipulative treatment (OMT) is able to enhance the immune response of individuals. In particular, it has been reported that OMT has the capability to increase antibody titers, enhance the efficacy of vaccination, and upregulate the numbers of circulating leukocytes. Recently, it has been shown in human patients suffering chronic low back pain, that OMT is able to modify the levels of cytokines such as IL-6 and TNF-alpha in blood upon repeated treatment. Further, experimental animal models show that lymphatic pump techniques can induce a transient increase of cytokines in the lymphatic circulation. Taking into account all these data, we decided to investigate in healthy individuals the capacity of OMT to induce a rapid modification of the levels of cytokines and leukocytes in circulation. Human volunteers were subjected to a mixture of lymphatic and thoracic OMT, and shortly after the levels of several cytokines were evaluated by protein array technology and ELISA multiplex analysis, while the profile and activation status of circulating leukocytes was extensively evaluated by multicolor flow cytometry. In addition, the levels of nitric oxide and C-reactive protein (CRP) in plasma were determined. In this study, our results show that OMT was not able to induce a rapid modification in the levels of plasma nitrites or CRP or in the proportion or activation status of central memory, effector memory or naive CD4 and CD8 T cells. A significant decrease in the proportion of a subpopulation of blood dendritic cells was detected in OMT patients. Significant differences were also detected in the levels of immune molecules such as IL-8, MCP-1, MIP-1 alpha and most notably, G-CSF. Thus, OMT is able to induce a rapid change in the immunological profile of particular circulating cytokines and leukocytes.	[Walkowski, Stevan] Ohio Univ, Heritage Coll Osteopath Med, Osteopath Manipulat Med Dept, Athens, OH 45701 USA; [Singh, Manindra; Benencia, Fabian] Ohio Univ, Mol & Cellular Biol Program, Athens, OH 45701 USA; [Puertas, Juan; Pate, Michelle; Goodrum, Kenneth; Benencia, Fabian] Ohio Univ, Heritage Coll Osteopath Med, Dept Biomed Sci, Athens, OH 45701 USA; [Benencia, Fabian] Ohio Univ, Biomed Engn Program, Russ Coll Engn & Technol, Athens, OH 45701 USA; [Benencia, Fabian] Ohio Univ, Inst Diabet, Athens, OH 45701 USA	University System of Ohio; Ohio University; University System of Ohio; Ohio University; University System of Ohio; Ohio University; University System of Ohio; Ohio University; University System of Ohio; Ohio University	Benencia, F (corresponding author), Ohio Univ, Mol & Cellular Biol Program, Athens, OH 45701 USA.	benencia@ohio.edu	Benencia, Fabian/AAH-1613-2020	Benencia, Fabian/0000-0003-3049-6150	Research & Scholarly Affairs Committee grant from Heritage College of Osteopathic Medicine, Ohio University; American Osteopathic Association [10-08-606]	Research & Scholarly Affairs Committee grant from Heritage College of Osteopathic Medicine, Ohio University; American Osteopathic Association	This work was funded by a Research & Scholarly Affairs Committee grant from the Heritage College of Osteopathic Medicine, Ohio University (http://www.oucom.ohiou.edu/) and a research grant (10-08-606) from the American Osteopathic Association (www.osteopathic.org). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Bockenhauer Susan E., 2002, Journal of the American Osteopathic Association, V102, P371; Bonasio R, 2006, CURR OPIN IMMUNOL, V18, P503, DOI 10.1016/j.coi.2006.05.011; Breithaupt Thomas, 2001, Journal of the American Osteopathic Association, V101, P21; Calo L, 1998, ANGIOLOGY, V49, P419, DOI 10.1177/000331979804900601; Castlio Y, 1934, COLL J KANSAS CITY, V18, P196; Castlio Y, 1932, COLL J KANSAS CITY, V16, P111; Chikly BJ, 2005, J AM OSTEOPATH ASSOC, V105, P457; Creasy C, 2013, LYMPHAT RES BIOL, V11, P183, DOI 10.1089/lrb.2013.0007; Dugan EP, 2001, J AM OSTEOPATH ASSOC, V101, P472; Guiney PA, 2005, J AM OSTEOPATH ASSOC, V105, P7; Hodge LM, 2012, INT J OSTEOPATH MED, V15, P13, DOI 10.1016/j.ijosm.2011.11.004; Hodge LM, 2010, LYMPHAT RES BIOL, V8, P103, DOI 10.1089/lrb.2009.0011; Hodge Lisa M., 2007, Lymphatic Research and Biology, V5, P127, DOI 10.1089/lrb.2007.1001; Hruby Raymond J, 2007, Osteopath Med Prim Care, V1, P10, DOI 10.1186/1750-4732-1-10; Jackson Kelly M., 1998, Journal of the American Osteopathic Association, V98, P155; Knott EM, 2005, J AM OSTEOPATH ASSOC, V105, P447; Kop WJ, 2008, AM J CARDIOL, V101, P767, DOI 10.1016/j.amjcard.2007.11.006; Lanzavecchia A, 2001, CURR OPIN IMMUNOL, V13, P291, DOI 10.1016/S0952-7915(00)00218-1; Licciardone JC, 2013, J AM OSTEOPATH ASSOC, V113, P468; Licciardone JC, 2012, J AM OSTEOPATH ASSOC, V112, P596, DOI 10.7556/jaoa.2012.112.9.596; MEASEL JW, 1982, J AM OSTEOPATH ASSOC, V82, P59; Mesina Julian, 1998, Journal of the American Osteopathic Association, V98, P91; Noll D, 2005, INT J OSTEOPATH MED, V8, P124; Noll Donald R., 2000, Journal of the American Osteopathic Association, V100, P776; Noll DR, 2008, J AM OSTEOPATH ASSOC, V108, P69; Noll DR, 2013, J AM OSTEOPATH ASSOC, V113, P520, DOI 10.7556/jaoa.2013.003; Noll Donald R., 2004, Journal of the American Osteopathic Association, V104, P107; Noll Donald R., 1999, Journal of the American Osteopathic Association, V99, P143; Noll DR, 2004, ALTERN THER HEALTH M, V10, P74; Palucka K, 2013, IMMUNITY, V39, P38, DOI 10.1016/j.immuni.2013.07.004; Palucka K, 2013, CURR OPIN IMMUNOL, V25, P396, DOI 10.1016/j.coi.2013.05.001; Patterson MM, 2005, J AM OSTEOPATH ASSOC, V105, P498; PAUL RT, 1986, J AM OSTEOPATH ASSOC, V86, P92; Ridgway D, 2003, CANCER INVEST, V21, P873, DOI 10.1081/CNV-120025091; Rivers WE, 2008, J AM OSTEOPATH ASSOC, V108, P646; Salamon E, 2004, INT J MOL MED, V14, P443; Schander A, 2012, EXP BIOL MED, V237, P58, DOI 10.1258/ebm.2011.011220; Skrzeczynska-Moncznik J, 2008, SCAND J IMMUNOL, V67, P152, DOI 10.1111/j.1365-3083.2007.02051.x; Ward RC, 1997, FDN OSTEOPATHIC MED; Weinstein AA, 2010, BIOL PSYCHOL, V84, P228, DOI 10.1016/j.biopsycho.2010.01.016; Ziegler-Heitbrock L, 2007, J LEUKOCYTE BIOL, V81, P584, DOI 10.1189/jlb.0806510	42	20	20	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 10	2014	9	3							e90132	10.1371/journal.pone.0090132	http://dx.doi.org/10.1371/journal.pone.0090132			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC9FH	24614605	gold, Green Published, Green Submitted			2023-01-03	WOS:000332839300019
J	Scharnowski, F; Rosa, MJ; Golestani, N; Hutton, C; Josephs, O; Weiskopf, N; Rees, G				Scharnowski, Frank; Rosa, Maria Joao; Golestani, Narly; Hutton, Chloe; Josephs, Oliver; Weiskopf, Nikolaus; Rees, Geraint			Connectivity Changes Underlying Neurofeedback Training of Visual Cortex Activity	PLOS ONE			English	Article							DYNAMIC CAUSAL-MODELS; NEURAL ACTIVITY; ACTIVITY FLUCTUATIONS; FMRI NEUROFEEDBACK; DIRECTED ATTENTION; SPATIAL ATTENTION; PARIETAL CORTEX; MECHANISMS; PERCEPTION; ACTIVATION	Neurofeedback based on real-time functional magnetic resonance imaging (fMRI) is a new approach that allows training of voluntary control over regionally specific brain activity. However, the neural basis of successful neurofeedback learning remains poorly understood. Here, we assessed changes in effective brain connectivity associated with neurofeedback training of visual cortex activity. Using dynamic causal modeling (DCM), we found that training participants to increase visual cortex activity was associated with increased effective connectivity between the visual cortex and the superior parietal lobe. Specifically, participants who learned to control activity in their visual cortex showed increased top-down control of the superior parietal lobe over the visual cortex, and at the same time reduced bottom-up processing. These results are consistent with efficient employment of top-down visual attention and imagery, which were the cognitive strategies used by participants to increase their visual cortex activity.	[Scharnowski, Frank; Hutton, Chloe; Josephs, Oliver; Weiskopf, Nikolaus; Rees, Geraint] UCL, Wellcome Trust Ctr Neuroimaging, UCL Inst Neurol, London, England; [Scharnowski, Frank; Golestani, Narly; Rees, Geraint] UCL, UCL Inst Cognit Neurosci, London, England; [Scharnowski, Frank] Ecole Polytech Fed Lausanne, Swiss Inst Technol Lausanne, Inst Bioengn, CH-1015 Lausanne, Switzerland; [Scharnowski, Frank] Univ Geneva, CIBM, Dept Radiol & Med Informat, Geneva, Switzerland; [Rosa, Maria Joao] Kings Coll London, Inst Psychiat, Dept Neurosci, London WC2R 2LS, England; [Golestani, Narly] Univ Geneva, Univ Med Sch, Geneva, Switzerland	University of London; University College London; University of London; University College London; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Geneva; University of London; King's College London; University of Geneva	Scharnowski, F (corresponding author), UCL, Wellcome Trust Ctr Neuroimaging, UCL Inst Neurol, London, England.	frank.scharnowski@epfl.ch	Weiskopf, Nikolaus/B-9357-2008; Rees, Geraint/C-1493-2008; Rosa, Maria J./K-3185-2015; Golestani, Narly/C-4879-2009	Weiskopf, Nikolaus/0000-0001-5239-1881; Rees, Geraint/0000-0002-9623-7007; Rosa, Maria J./0000-0001-9822-3752; Golestani, Narly/0000-0001-7388-4714; Scharnowski, Frank/0000-0002-9973-2521	Swiss National Science Foundation; European Union; Wellcome Trust [091593/Z10/Z]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); European Union(European Commission); Wellcome Trust(Wellcome TrustEuropean Commission)	This work was supported by the Swiss National Science Foundation, the European Union, and the Wellcome Trust (GR). The Wellcome Trust Centre for Neuroimaging is supported by core funding from the Wellcome Trust 091593/Z10/Z. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arieli A, 1996, SCIENCE, V273, P1868, DOI 10.1126/science.273.5283.1868; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Birbaumer N, 2013, TRENDS COGN SCI, V17, P295, DOI 10.1016/j.tics.2013.04.009; Boly M, 2007, P NATL ACAD SCI USA, V104, P12187, DOI 10.1073/pnas.0611404104; Brefczynski JA, 1999, NAT NEUROSCI, V2, P370, DOI 10.1038/7280; Chiu YC, 2009, J NEUROSCI, V29, P3930, DOI 10.1523/JNEUROSCI.5737-08.2009; Decharms RC, 2007, TRENDS COGN SCI, V11, P473, DOI 10.1016/j.tics.2007.08.014; Deichmann R, 2004, NEUROIMAGE, V21, P757, DOI 10.1016/j.neuroimage.2003.09.062; Desseilles M, 2011, NEUROIMAGE, V54, P1662, DOI 10.1016/j.neuroimage.2010.08.061; Disner SG, 2011, NAT REV NEUROSCI, V12, P467, DOI 10.1038/nrn3027; Drevets WC, 2001, CURR OPIN NEUROBIOL, V11, P240, DOI 10.1016/S0959-4388(00)00203-8; Driver J, 2001, COGNITION, V79, P39, DOI 10.1016/S0010-0277(00)00124-4; Fox MD, 2007, NEURON, V56, P171, DOI 10.1016/j.neuron.2007.08.023; Friston KJ, 2007, NEUROIMAGE, V34, P220, DOI 10.1016/j.neuroimage.2006.08.035; Friston KJ, 1997, NEUROIMAGE, V6, P218, DOI 10.1006/nimg.1997.0291; Friston KJ, 2003, NEUROIMAGE, V19, P1273, DOI 10.1016/S1053-8119(03)00202-7; Gitelman DR, 2003, NEUROIMAGE, V19, P200, DOI 10.1016/S1053-8119(03)00058-2; Greenberg AS, 2010, J NEUROSCI, V30, P14330, DOI 10.1523/JNEUROSCI.4248-09.2010; Hayes JP, 2012, BIOL MOOD ANXIETY DI, V2, DOI 10.1186/2045-5380-2-9; Hesselmann G, 2008, P NATL ACAD SCI USA, V105, P10984, DOI 10.1073/pnas.0712043105; Hesselmann G, 2008, J NEUROSCI, V28, P14481, DOI 10.1523/JNEUROSCI.4398-08.2008; Hoeting JA, 1999, STAT SCI, V14, P382, DOI 10.1214/ss/1009212519; Hopfinger JB, 2000, NAT NEUROSCI, V3, P284, DOI 10.1038/72999; Hutton C, 2011, NEUROIMAGE, V57, P101, DOI 10.1016/j.neuroimage.2011.04.018; Hutton C, 2002, NEUROIMAGE, V16, P217, DOI 10.1006/nimg.2001.1054; James W, 1890, PRINCIPLES PSYCHOL; Kastner S, 1998, SCIENCE, V282, P108, DOI 10.1126/science.282.5386.108; Kastner S, 1999, NEURON, V22, P751, DOI 10.1016/S0896-6273(00)80734-5; Kelley TA, 2008, CEREB CORTEX, V18, P114, DOI 10.1093/cercor/bhm036; Kiebel SJ, 2007, NEUROIMAGE, V34, P1487, DOI 10.1016/j.neuroimage.2006.10.026; Koenigs M, 2009, J NEUROSCI, V29, P14980, DOI 10.1523/JNEUROSCI.3706-09.2009; Kosslyn SM, 2001, NAT REV NEUROSCI, V2, P635, DOI 10.1038/35090055; Koush Y, 2013, NEUROIMAGE, V81, P422, DOI 10.1016/j.neuroimage.2013.05.010; Kriegeskorte N, 2009, NAT NEUROSCI, V12, P535, DOI 10.1038/nn.2303; Lee JH, 2012, NEUROSCI RES, V72, P347, DOI 10.1016/j.neures.2012.01.002; Lee S, 2011, NEUROREHAB NEURAL RE, V25, P259, DOI 10.1177/1545968310385128; Li X, 2008, P NATL ACAD SCI USA, V105, P6202, DOI 10.1073/pnas.0801390105; Mechelli A, 2004, CEREB CORTEX, V14, P1256, DOI 10.1093/cercor/bhh087; Patel R, 2012, NEUROSCI BIOBEHAV R, V36, P2130, DOI 10.1016/j.neubiorev.2012.06.003; Penny WD, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000709; Rota G, 2011, BRAIN LANG, V117, P123, DOI 10.1016/j.bandl.2010.07.008; Scharnowski F, 2012, J NEUROSCI, V32, P17830, DOI 10.1523/JNEUROSCI.6334-11.2012; Shibata K, 2011, SCIENCE, V334, P1413, DOI 10.1126/science.1212003; Slotnick SD, 2005, CEREB CORTEX, V15, P1570, DOI 10.1093/cercor/bhi035; Stephan KE, 2010, NEUROIMAGE, V49, P3099, DOI 10.1016/j.neuroimage.2009.11.015; Stephan KE, 2007, J BIOSCIENCES, V32, P129, DOI 10.1007/s12038-007-0012-5; Stephan KE, 2008, NEUROIMAGE, V42, P649, DOI 10.1016/j.neuroimage.2008.04.262; Stephan KE, 2009, NEUROIMAGE, V46, P1004, DOI 10.1016/j.neuroimage.2009.03.025; Stokes M, 2009, J NEUROSCI, V29, P1565, DOI 10.1523/JNEUROSCI.4657-08.2009; Sulzer J, 2013, NEUROIMAGE, V76, P386, DOI 10.1016/j.neuroimage.2013.03.033; Vossel S, 2012, J NEUROSCI, V32, P10637, DOI 10.1523/JNEUROSCI.0414-12.2012; Vuilleumier P, 2008, CURR BIOL, V18, P1525, DOI 10.1016/j.cub.2008.08.072; Weiskopf N, 2004, J PHYSIOL-PARIS, V98, P357, DOI 10.1016/j.jphysparis.2005.09.019; Weiskopf N, 2004, IEEE T BIO-MED ENG, V51, P966, DOI 10.1109/TBME.2004.827063; Wundt W, 1882, PHILOS STUDIEN, V1, P251; Yantis S, 2002, NAT NEUROSCI, V5, P995, DOI 10.1038/nn921; Zotev V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024522	57	20	21	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2014	9	3							e91090	10.1371/journal.pone.0091090	http://dx.doi.org/10.1371/journal.pone.0091090			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC4IY	24609065	gold, Green Published, Green Submitted, Green Accepted			2023-01-03	WOS:000332485800099
J	Li, J; Li, X; Wang, Q; Hu, S; Wang, YF; Masoudi, FA; Spertus, JA; Krumholz, HM; Jiang, LX				Li, Jing; Li, Xi; Wang, Qing; Hu, Shuang; Wang, Yongfei; Masoudi, Frederick A.; Spertus, John A.; Krumholz, Harlan M.; Jiang, Lixin		China PEACE Collaborative Grp	RETRACTED: ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data (Retracted article. See vol. 385, pg. 402, 2015)	LANCET			English	Article; Retracted Publication							ACUTE CORONARY SYNDROMES; STANDARDIZED MORTALITY-RATES; QUALITY-OF-CARE; REPERFUSION THERAPY; PRACTICE PATTERNS; IMPROVEMENT; TRANSITION; TRENDS; REFORM	Background Despite the importance of ST-segment elevation myocardial infarction (STEMI) in China, no nationally representative studies have characterised the clinical profiles, management, and outcomes of this cardiac event during the past decade. We aimed to assess trends in characteristics, treatment, and outcomes for patients with STEMI in China between 2001 and 2011. Methods In a retrospective analysis of hospital records, we used a two-stage random sampling design to create a nationally representative sample of patients in China admitted to hospital for STEMI in 3 years (2001, 2006, and 2011). In the first stage, we used a simple random-sampling procedure stratified by economic-geographical region to generate a list of participating hospitals. In the second stage we obtained case data for rates of STEMI, treatments, and baseline characteristics from patients attending each sampled hospital with a systematic sampling approach. We weighted our findings to estimate nationally representative rates and assess changes from 2001 to 2011. This study is registered with ClinicalTrials.gov, number NCT01624883. Findings We sampled 175 hospitals (162 participated in the study) and 18 631 acute myocardial infarction admissions, of which 13 815 were STEMI admissions. 12 264 patients were included in analysis of treatments, procedures, and tests, and 11 986 were included in analysis of in-hospital outcomes. Between 2001 and 2011, estimated national rates of hospital admission for STEMI per 100 000 people increased (from 3.5 in 2001, to 7.9 in 2006, to 15.4 in 2011; p(trend)<0.0001) and the prevalence of risk factors-including smoking, hypertension, diabetes, and dyslipidaemia-increased. We noted significant increases in use of aspirin within 24 h (79.7% [95% CI 77.9-81.5] in 2001 vs 91.2% [90.5-91.8] in 2011, p(trend)<0.0001) and clopidogrel (1.5% [95% CI 1.0-2.1] in 2001 vs 82.1% [81.1-83.0] in 2011, p(trend)<0.0001) in patients without documented contraindications. Despite an increase in the use of primary percutaneous coronary intervention (10.6% [95% CI 8.6-12.6] in 2001 vs 28.1% [26.6-29.7] in 2011, p(trend)<0.0001), the proportion of patients who did not receive reperfusion did not significantly change (45.3% [95% CI 42.1-48.5] in 2001 vs 44.8% [43.1-46.5] in 2011, p(trend)=0.69). The median length of hospital stay decreased from 12 days (IQR 7-18) in 2001 to 10 days (6-14) in 2011 (p(trend)<0.0001). Adjusted in-hospital mortality did not significantly change between 2001 and 2011 (odds ratio 0.82, 95% CI 0.62-1.10, p(trend)=0.07). Interpretation During the past decade in China, hospital admissions for STEMI have risen; in these patients, comorbidities and the intensity of testing and treatment have increased. Quality of care has improved for some treatments, but important gaps persist and in-hospital mortality has not decreased. National efforts are needed to improve the care and outcomes for patients with STEMI in China.	[Li, Jing; Li, Xi; Wang, Qing; Hu, Shuang; Jiang, Lixin] Chinese Acad Med Sci, Natl Ctr Cardiovasc Dis, State Key Lab Cardiovasc Dis, Natl Clin Res Ctr Cardiovasc Dis,Fuwai Hosp, Beijing 100730, Peoples R China; [Li, Jing; Li, Xi; Wang, Qing; Hu, Shuang; Jiang, Lixin] Peking Union Med Coll, Beijing 100021, Peoples R China; [Wang, Yongfei; Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA; [Wang, Yongfei; Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT 06510 USA; [Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Internal Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06510 USA; [Krumholz, Harlan M.] Yale Univ, Dept Hlth Policy & Management, Sch Publ Hlth, New Haven, CT USA; [Masoudi, Frederick A.] Univ Colorado, Div Cardiol, Aurora, CO USA; [Spertus, John A.] Univ Missouri, St Lukes Mid Amer Heart Inst, Kansas City, MO 64110 USA	Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Yale University; Yale University; Yale University; Yale University; University of Colorado System; University of Colorado Anschutz Medical Campus; Saint Luke's Mid America Heart Institute; University of Missouri System; University of Missouri Kansas City	Jiang, LX (corresponding author), Fuwai Hosp, Natl Ctr Cardiovasc Dis, State Key Lab Cardiovasc Dis, Natl Clin Res Ctr Cardiovasc Dis, Beijing 100037, Peoples R China.	jiangl@fwoxford.org	, Harlan/AAI-2875-2020; Masoudi, Frederick/Q-7467-2019; Spertus, John/ABD-3075-2021	Li, Xi/0000-0003-2249-688X; Normand, Sharon-Lise/0000-0001-7027-4769	National Health and Family Planning Commission of China; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL105270] Funding Source: NIH RePORTER	National Health and Family Planning Commission of China; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	National Health and Family Planning Commission of China.	[Anonymous], 2010, LANCET, V376, P657, DOI 10.1016/S0140-6736(10)61315-3; [Anonymous], 2007, CHIN STAT YB; [Anonymous], 2012, CHIN STAT YB; [Anonymous], 2000, 5 CENSUS DATA COUNTY; Antman EM, 2008, CIRCULATION, V117, P296, DOI 10.1161/CIRCULATIONAHA.107.188209; Bradley EH, 2005, MED CARE, V43, P282, DOI 10.1097/00005650-200503000-00011; Chen J, 2010, CIRCULATION, V121, P1322, DOI 10.1161/CIRCULATIONAHA.109.862094; Chen Z, 2009, LANCET, V373, P1322, DOI 10.1016/S0140-6736(09)60753-4; Chen ZM, 2005, LANCET, V366, P1607, DOI 10.1016/s0140-6736(05)67660-x; China Society of Cardiology of Chinese Medical Association, 2010, Zhonghua Xin Xue Guan Bing Za Zhi, V38, P675; Chung SC, 2014, LANCET, V383, P1305, DOI 10.1016/S0140-6736(13)62070-X; COLLINS R, 1995, LANCET, V345, P669; Dharmarajan K, 2013, CIRC-CARDIOVASC QUAL, V6, P732, DOI 10.1161/CIRCOUTCOMES.113.000441; Drye EE, 2012, ANN INTERN MED, V156, P19, DOI 10.7326/0003-4819-156-1-201201030-00004; Du X, 2014, CIRC-CARDIOVASC QUAL, V7, P217, DOI 10.1161/CIRCOUTCOMES.113.000526; [Editorial Board of Chinese Journal of Circulation Editorial Board of Chinese Journal of Cardiology China Society of Cardiology of Chinese Medical Association], 2001, CHIN J CIRC, V16, P407; Gale CP, 2012, EUR HEART J, V33, P630, DOI 10.1093/eurheartj/ehr381; Gao R, 2008, HEART, V94, P554, DOI 10.1136/hrt.2007.119750; Gershlick AH, 2013, LANCET, V382, P624, DOI 10.1016/S0140-6736(13)61454-3; Gibson CM, 2008, AM HEART J, V156, P1035, DOI 10.1016/j.ahj.2008.07.029; Krumholz HM, 2009, JAMA-J AM MED ASSOC, V302, P767, DOI 10.1001/jama.2009.1178; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; Li J, 2007, Cochrane Database Syst Rev, pCD002755; Liu Qun, 2009, Zhonghua Xinxueguanbing Zazhi, V37, P213, DOI 10.3760/cma.j.issn.0253-3758.2009.03.004; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; Masoudi FA, 2013, J AM COLL CARDIOL, V62, P1931, DOI 10.1016/j.jacc.2013.05.099; Mehta RH, 2004, J AM COLL CARDIOL, V43, P2166, DOI 10.1016/j.jacc.2003.08.067; Ministry of Health of the People's Republic of China, QUAL STAND TERT GEN; Ministry of Health of the People's Republic of China, 2012, CHIN PUBL HLTH STAT; OMRAN AR, 1971, MILBANK MEML FUND Q, V49, P509, DOI 10.2307/3349375; Ranasinghe I, 2014, CIRC-CARDIOVASC QUAL, V7, P209, DOI 10.1161/CIRCOUTCOMES.113.000527; Roe MT, 2010, J AM COLL CARDIOL, V56, P254, DOI 10.1016/j.jacc.2010.05.008; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; *SAS I, MI PROC; Simms AD, 2013, HEART, V99, P35, DOI 10.1136/heartjnl-2012-302632; Tang SL, 2008, LANCET, V372, P1493, DOI 10.1016/S0140-6736(08)61364-1; The World Bank, HLTH HARM LIF CHIN S; Thygesen K, 2007, EUR HEART J, V28, P2525; Widimsky P, 2010, EUR HEART J, V31, P943, DOI 10.1093/eurheartj/ehp492; Wu TX, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004465.pub2; Yang GH, 2013, LANCET, V381, P1987, DOI 10.1016/S0140-6736(13)61097-1	41	273	367	4	98	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 31	2015	385	9966					441	451		10.1016/S0140-6736(14)60921-1	http://dx.doi.org/10.1016/S0140-6736(14)60921-1			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AZ9CT	24969506	Green Accepted			2023-01-03	WOS:000348509900031
J	McLellan, AT				McLellan, A. Thomas			Should at-risk patients be paid to receive interventions?	LANCET			English	Editorial Material							PERCEPTION; CARE		Treatment Res Inst, Philadelphia, PA 19106 USA		McLellan, AT (corresponding author), Treatment Res Inst, Philadelphia, PA 19106 USA.	TMcLellan@tresearch.org						Aspinall EJ, 2011, OCCUP MED-OXFORD, V61, P531, DOI 10.1093/occmed/kqr136; Black N, 2010, NEW ENGL J MED, V363, P1103, DOI 10.1056/NEJMp1009188; Boden-Albala B, 2011, NEUROEPIDEMIOLOGY, V37, P83, DOI 10.1159/000329522; Hogarth RM, 2011, J BEHAV DECIS MAKING, V24, P202, DOI 10.1002/bdm.689; Ott JJ, 2012, VACCINE, V30, P2212, DOI 10.1016/j.vaccine.2011.12.116; Pozgar, 2014, LEGAL ETHICAL ISSUES; Weaver T., 2014, LANCET	7	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 12	2014	384	9938					113	114		10.1016/S0140-6736(14)60490-6	http://dx.doi.org/10.1016/S0140-6736(14)60490-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AL1YC	24725466	hybrid			2023-01-03	WOS:000338921500012
J	Gao, XY; Guo, MX; Li, Q; Peng, L; Liu, HY; Zhang, L; Bai, X; Wang, YX; Li, J; Cai, CK				Gao, Xiaoyan; Guo, Mingxing; Li, Qiang; Peng, Long; Liu, Haiyu; Zhang, Li; Bai, Xu; Wang, Yingxin; Li, Jian; Cai, Chengke			Plasma Metabolomic Profiling to Reveal Antipyretic Mechanism of Shuang-Huang-Lian Injection on Yeast-Induced Pyrexia Rats	PLOS ONE			English	Article							BETA-HYDROXYBUTYRIC ACID; DISEASE DIAGNOSIS; MASS-SPECTROMETRY; BAKERS-YEAST; METABONOMICS; FEVER; FAD; FMN; IDENTIFICATION; EXPRESSION	Shuang-huang-lian injection (SHLI) is a famous Chinese patent medicine, which has been wildly used in clinic for the treatment of acute respiratory tract infection, pneumonia, influenza, etc. The existing randomized controlled trial (RCT) studies suggested that SHLI could afford a certain anti-febrile action. However, seldom does research concern the pharmacological mechanisms of SHLI. In the current study, we explored plasma metabolomic profiling technique and selected potential metabolic markers to reveal the antipyretic mechanism of SHLI on yeast-induced pyrexia rat model using UPLC-Q-TOF/MS coupled with multivariate statistical analysis and pattern recognition techniques. We discovered a significant perturbance of metabolic profile in the plasma of fever rats and obvious reversion in SHLI-administered rats. Eight potential biomarkers, i.e. 1) 3-hydeoxybutyric acid, 2) leucine, 3) 16:0 LPC, 4) allocholic acid, 5) vitamin B2, 6) Cys-Lys-His, 7) 18:2 LPC, and 8) 3-hydroxychola-7, 22-dien-24-oic acid, were screened out by OPLS-DA approach. Five potential perturbed metabolic pathways, i.e. 1) valine, leucine, and isoleucine biosynthesis, 2) glycerophospholipid metabolism, 3) ketone bodies synthesis and degradation, 4) bile acid biosynthesis, and 5) riboflavin metabolism, were revealed to relate to the antipyretic mechanisms of SHLI. Overall, we investigated antipyretic mechanisms of SHLI at metabolomic level for the first time, and the obtained results highlights the necessity of adopting metabolomics as a reliable tool for understanding the holism and synergism of Chinese patent drug.	[Gao, Xiaoyan; Guo, Mingxing; Peng, Long; Liu, Haiyu; Zhang, Li] Beijing Univ Chinese Med, Sci Expt Ctr TCM, Beijing, Peoples R China; [Li, Qiang; Cai, Chengke] Beijing Univ Chinese Med, Sch Chinese Mat Med, Beijing, Peoples R China; [Bai, Xu] Waters Technol Shanghai Ltd, Shanghai, Peoples R China; [Wang, Yingxin] 2nd Tradit Chinese Med Factory Harbin Pharm Grp C, Harbin, Peoples R China; [Li, Jian] Beijing Univ Chinese Med, Sch Basic Med Sci, Beijing, Peoples R China	Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine	Li, J (corresponding author), Beijing Univ Chinese Med, Sch Basic Med Sci, Beijing, Peoples R China.	lijiancn922@126.com; cck98@126.com			National Science and Technology Major Projects for "Major new drugs innovation and development" [2011ZX09201-201-15]; National Science Foundation of China [81173562]	National Science and Technology Major Projects for "Major new drugs innovation and development"; National Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported in part by National Science and Technology Major Projects for "Major new drugs innovation and development" (Grant No. 2011ZX09201-201-15), and National Science Foundation of China (Grant No. 81173562). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1987, PFLUGERS ARCH, V410, P567; Bai Yun-ping WZ-w, 2011, CJTCMP, V26, P5; Biermann M, 2013, AMINO ACIDS, V44, P1225, DOI 10.1007/s00726-013-1459-3; Bjerrum JT, 2010, J PROTEOME RES, V9, P954, DOI 10.1021/pr9008223; Blough ER, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00072; Brkic L, 2012, ATHEROSCLEROSIS, V224, P348, DOI 10.1016/j.atherosclerosis.2012.07.038; Cabezas A, 2005, BIOCHEM BIOPH RES CO, V338, P1682, DOI 10.1016/j.bbrc.2005.10.142; Chen X, 2002, LIFE SCI, V70, P2897, DOI 10.1016/S0024-3205(02)01541-2; Duncker DJ, 1996, AM J PHYSIOL-HEART C, V270, pH1189, DOI 10.1152/ajpheart.1996.270.4.H1189; Fan Y P, 2001, Zhongguo Zhong Xi Yi Jie He Za Zhi, V21, P406; Fraunberger P, 2002, CLIN CHEM LAB MED, V40, P304, DOI 10.1515/CCLM.2002.048; Gao XY, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/864747; Gao XY, 2013, CHEM-BIOL INTERACT, V204, P39, DOI 10.1016/j.cbi.2013.04.001; Han R, 2011, J ETHNOPHARMACOL, V135, P522, DOI 10.1016/j.jep.2011.03.060; Haque MM, 2012, J BIOL CHEM, V287, P30105, DOI 10.1074/jbc.M112.339697; Hasegawa S, 1968, Nihon Jibiinkoka Gakkai Kaiho, V71, P1726; Jiang Hong-li, 2009, Zhong Xi Yi Jie He Xue Bao, V7, P9, DOI 10.3736/jcim20090102; Kaufmann TB, 2010, BMC VET RES, V6, DOI 10.1186/1746-6148-6-47; KONG XT, 1993, ARCH DIS CHILD, V68, P468, DOI 10.1136/adc.68.4.468; Laeger T, 2012, J ENDOCRINOL, V213, P193, DOI 10.1530/JOE-11-0457; Laeger T, 2010, APPETITE, V54, P450, DOI 10.1016/j.appet.2010.04.005; Launey Y, 2011, CRIT CARE, V15, DOI 10.1186/cc10097; Li Dong, 2005, Zhong Yao Cai, V28, P796; Lindon JC, 2004, BIOMARKERS, V9, P1, DOI 10.1080/13547500410001668379; Lindon JC, 2007, FEBS J, V274, P1140, DOI 10.1111/j.1742-4658.2007.05673.x; Liu F, 2012, MOL CELL BIOCHEM, V363, P147, DOI 10.1007/s11010-011-1167-9; Lu AP, 2012, CHIN J INTEGR MED, V18, P883, DOI 10.1007/s11655-012-1290-6; LYCHIK GZ, 1987, UKR BIOKHIM ZH+, V59, P55; Pasin JSM, 2010, INFLAMM RES, V59, P189, DOI 10.1007/s00011-009-0085-8; Meng JR, 2012, ANAL CHIM ACTA, V710, P125, DOI 10.1016/j.aca.2011.09.033; MoHot P.R.C, 2009, DIAGNOSIS TREATMENT; Nicholson JK, 1999, XENOBIOTICA, V29, P1181, DOI 10.1080/004982599238047; Panousis N, 2012, RES VET SCI, V93, P435, DOI 10.1016/j.rvsc.2011.06.019; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; Rao SP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065155; Rawat A, 2013, J BIOSCIENCES, V38, P63, DOI 10.1007/s12038-012-9288-1; Rice P, 2005, J IMMUNOL, V174, P3676, DOI 10.4049/jimmunol.174.6.3676; Schober C, 2009, BIOORG CHEM, V37, P202, DOI 10.1016/j.bioorg.2009.09.002; Shevaga V N, 1976, Vrach Delo, P124; SOBRADO J, 1983, INFECT IMMUN, V42, P997, DOI 10.1128/IAI.42.3.997-1005.1983; Song Z. J., 2000, Chinese Medical Sciences Journal, V15, P83; Tsuge H, 2006, SEIKAGAKU, V78, P41; Wang Y, 2011, J ETHNOPHARMACOL, V134, P165, DOI 10.1016/j.jep.2010.11.066; Xia JG, 2010, BIOINFORMATICS, V26, P2342, DOI 10.1093/bioinformatics/btq418; Yan GY, 2010, EXP BIOL MED, V235, P1356, DOI 10.1258/ebm.2010.009390; Ye J, 2012, J CHROMATOGR B, V898, P130, DOI 10.1016/j.jchromb.2012.04.036; Zhang FS, 2013, J PHARMACEUT BIOMED, V81-82, P168, DOI 10.1016/j.jpba.2013.04.005; Zhang Hai-ying RX-l, 2010, CHINA PHARM, V21, P4; Zhao YY, 2012, BIOMARKERS, V17, P721, DOI 10.3109/1354750X.2012.724450	49	24	27	2	47	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 18	2014	9	6							e100017	10.1371/journal.pone.0100017	http://dx.doi.org/10.1371/journal.pone.0100017			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK6AC	24940599	Green Submitted, Green Published, gold			2023-01-03	WOS:000338508200065
J	Liu, M; Wu, QS; Chen, P; Buechele, B; Bian, MH; Dong, SJ; Huang, DK; Ren, CP; Zhang, YX; Hou, X; Simmet, T; Shen, JJ				Liu, Miao; Wu, Qingsi; Chen, Peng; Buechele, Berthold; Bian, Maohong; Dong, Shengjian; Huang, Dake; Ren, Cuiping; Zhang, Yuxia; Hou, Xin; Simmet, Thomas; Shen, Jijia			A Boswellic Acid-Containing Extract Ameliorates Schistosomiasis Liver Granuloma and Fibrosis through Regulating NF-kappa B Signaling in Mice	PLOS ONE			English	Article							HEPATIC STELLATE CELLS; ACETYL-11-KETO-BETA-BOSWELLIC ACID; GROWTH-FACTOR; IN-VITRO; INHIBITION; INFECTION; SERRATA; ACTIVATION; PREVENTION; MORTALITY	Boswellic acid (BA)-containing extracts such as BSE have anti-inflammatory and immunomodulatory activity. In chronic schistosomiasis, the hepatic granuloma and fibrosis induced by egg deposition in the liver is the most serious pathological manifestations. However, little is known regarding the role of BAs in Schistosoma japonicum (S. japonicum) egg-induced liver granuloma and fibrosis. In order to investigate the effect of a water-soluble complex preparation of BSE, BSE-CD, on S. japonicum egg-induced liver pathology, liver granuloma and fibrosis were induced by infecting C57BL/6 mice with 18-22 cercariae of S. japonicum. S. japonicum cercariae infected mice were injected with BSE-CD at the onset of egg granuloma formation (early phase BSE-CD treatment after 4 weeks infection) or after the formation of liver fibrosis (late phase BSE-CD treatment after 7 weeks infection). Our data show that treatment of infected mice with BSE-CD significantly reduced both the extent of hepatic granuloma and fibrosis. Consistent with an inhibition of NF-kappa B signaling as evidenced by reduced I kappa B kinase (IKK) activation, the mRNA expression of VEGF (vascular endothelial growth factor, VEGF), TNF-alpha (tumor necrosis factor-alpha TNF-alpha) and MCP-1 (monocyte chemotactic protein 1, MCP-1) was decreased. Moreover, immunohistochemical analysis (IHC) revealed that the content of alpha-SMA in liver tissue of BSE-CD treated mice was dramatically decreased. Our findings suggest that BSE-CD treatment attenuates S. japonicum egg-induced hepatic granulomas and fibrosis, at least partly due to reduced NF-kappa B signaling and the subsequently decreased expression of VEGF, TNF-alpha, and MCP-1. Suppression of the activation of hepatic stellate cells (HSC) may also be involved in the therapeutic efficacy of BSE-CD.	[Liu, Miao; Wu, Qingsi; Huang, Dake; Ren, Cuiping; Zhang, Yuxia; Hou, Xin; Shen, Jijia] Anhui Med Univ, Dept Microbiol & Parasitol, Hefei, Anhui, Peoples R China; [Liu, Miao; Wu, Qingsi; Huang, Dake; Ren, Cuiping; Hou, Xin; Shen, Jijia] Anhui Med Univ, Anhui Prov Lab Microbiol & Parasitol, Hefei, Anhui, Peoples R China; [Chen, Peng] Anhui Med Univ, Coll Clin Med Sci, Hefei, Anhui, Peoples R China; [Buechele, Berthold; Simmet, Thomas] Univ Ulm, Inst Pharmacol Nat Prod & Clin Pharmacol, D-89069 Ulm, Germany; [Bian, Maohong] Anhui Med Univ, Affiliated Hosp 1, Dept Blood Transfus, Hefei, Anhui, Peoples R China; [Dong, Shengjian] Hefei Second Peoples Hosp, Dept Clin Lab, Hefei, Anhui, Peoples R China	Anhui Medical University; Anhui Medical University; Anhui Medical University; Ulm University	Simmet, T (corresponding author), Univ Ulm, Inst Pharmacol Nat Prod & Clin Pharmacol, D-89069 Ulm, Germany.	thomas.simmet@uni-ulm.de; shenjijia@hotmail.com		Syrovets, Tatiana/0000-0002-6751-2233	Natural Science Foundation of China [30901251, 30972569]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by Natural Science Foundation of China (http://www.nsfc.gov.cn) (grant numbers 30901251 and 30972569). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdel-Tawab M, 2011, CLIN PHARMACOKINET, V50, P349, DOI 10.2165/11586800-000000000-00000; Ali EN, 2011, CHIN MED-UK, V6, DOI 10.1186/1749-8546-6-36; Ammon HPT, 2010, PHYTOMEDICINE, V17, P862, DOI 10.1016/j.phymed.2010.03.003; Anan A, 2006, HEPATOLOGY, V43, P335, DOI 10.1002/hep.21036; Andrade ZA, 2008, ACTA TROP, V108, P79, DOI 10.1016/j.actatropica.2008.04.003; Bartley PB, 2006, INT J PARASITOL, V36, P993, DOI 10.1016/j.ijpara.2006.04.015; Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; Caldas IR, 2008, ACTA TROP, V108, P109, DOI 10.1016/j.actatropica.2008.05.027; Cuaz-Perolin C, 2008, ARTERIOSCL THROM VAS, V28, P272, DOI 10.1161/ATVBAHA.107.155606; Fallon PG, 1999, J IMMUNOL, V162, P4122; Fattah NSA, 2012, EXP PARASITOL, V130, P58, DOI 10.1016/j.exppara.2011.09.014; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Friedman SL, 2008, PHYSIOL REV, V88, P125, DOI 10.1152/physrev.00013.2007; Friedman SL, 2007, HEPATOLOGY, V45, P242, DOI 10.1002/hep.21459; Friedman SL, 2004, NAT CLIN PRACT GASTR, V1, P98, DOI 10.1038/ncpgasthep0055; Giatromanolaki A, 2007, MEDIAT INFLAMM, V2007, DOI 10.1155/2007/67187; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Herbert DR, 2008, J IMMUNOL, V181, P7214, DOI 10.4049/jimmunol.181.10.7214; Hou X, 2009, HEPATOLOGY, V49, P940, DOI 10.1002/hep.22725; Kiela PR, 2005, AM J PHYSIOL-GASTR L, V288, pG798, DOI 10.1152/ajpgi.00433.2004; Kumar A, 2012, BIOORG MED CHEM LETT, V22, P431, DOI 10.1016/j.bmcl.2011.10.112; Latella G, 2008, EUR J CLIN INVEST, V38, P410, DOI 10.1111/j.1365-2362.2008.01955.x; Li Shi-Zhu, 2013, Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi, V25, P557; Liu M, 2013, PARASITOL RES, V112, P1105, DOI 10.1007/s00436-012-3237-7; Luedde T, 2011, NAT REV GASTRO HEPAT, V8, P108, DOI 10.1038/nrgastro.2010.213; Makhlouf Madiha M., 2002, Journal of the Egyptian Society of Parasitology, V32, P907; Mann DA, 2002, GUT, V50, P891, DOI 10.1136/gut.50.6.891; Mohamed-Ali Q, 1999, J INFECT DIS, V180, P1298, DOI 10.1086/314999; Molyneux DH, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-234; Park B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026943; SAFAYHI H, 1995, MOL PHARMACOL, V47, P1212; Sailer ER, 1996, BRIT J PHARMACOL, V117, P615, DOI 10.1111/j.1476-5381.1996.tb15235.x; Saraswati S, 2011, MICROVASC RES, V82, P263, DOI 10.1016/j.mvr.2011.08.002; Shariati F, 2011, EXP PARASITOL, V128, P44, DOI 10.1016/j.exppara.2011.01.016; Shehata AM, 2011, PHYTOMEDICINE, V18, P1037, DOI 10.1016/j.phymed.2011.06.035; Siemoneit U, 2011, BRIT J PHARMACOL, V162, P147, DOI 10.1111/j.1476-5381.2010.01020.x; Silveira-Lemos D, 2008, ACTA TROP, V108, P150, DOI 10.1016/j.actatropica.2008.04.006; Souza PRS, 2008, ACTA TROP, V108, P135, DOI 10.1016/j.actatropica.2008.04.016; Steinmann P, 2006, LANCET INFECT DIS, V6, P411, DOI 10.1016/S1473-3099(06)70521-7; Syrovets T, 2005, J BIOL CHEM, V280, P6170, DOI 10.1074/jbc.M409477200; Syrovets T, 2005, J IMMUNOL, V174, P498, DOI 10.4049/jimmunol.174.1.498; Wang H, 2006, J IMMUNOL, V183, P4755; Wang XH, 2008, ZHONGGUO XUE XI CHON, V28, P314; Weng HL, 2009, HEPATOLOGY, V50, P230, DOI 10.1002/hep.22934; Yu Xin-Ling, 2013, Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi, V31, P307	45	13	16	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 18	2014	9	6							e100129	10.1371/journal.pone.0100129	http://dx.doi.org/10.1371/journal.pone.0100129			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK6AC	24941000	gold, Green Submitted, Green Published			2023-01-03	WOS:000338508200075
J	Hayashi, H; Terao, A; Kunimatsu, R; Kawata, T				Hayashi, Hidetaka; Terao, Akiko; Kunimatsu, Ryo; Kawata, Toshitsugu			Effects of a Low Level Laser on Periodontal Tissue in Hypofunctional Teeth	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; OCCLUSAL STIMULI; ROOT RESORPTION; THERAPY; IRRADIATION; FIBROBLASTS; PROLIFERATION; GINGIVECTOMY; LIGAMENT	Malocclusions, such as an open bite and high canines, are often encountered in orthodontic practice. Teeth without occlusal stimuli are known as hypofunctional teeth, and numerous atrophic changes have been reported in the periodontal tissue, including reductions in blood vessels in the periodontal ligament (PDL), heavy root resorption, and reduced bone mineral density (BMD) in the alveolar bone. Low Level Laser (LLL) has been shown to have a positive effect on bone formation and the vasculature. Although the recovery of hypofunctional teeth remains unclear, LLL is expected to have a positive influence on periodontal tissue in occlusal hypofunction. The aim of the present study was to elucidate the relationship between LLL and periodontal tissue in occlusal hypofunction. Twenty-four male rats aged 5 weeks were randomly divided into control and hypofunctional groups. An anterior metal cap and bite plate were attached to the maxillary and mandibular incisors in the hypofunctional group to simulate occlusal hypofunction in the molars. LLL irradiation was applied to the maxillary first molar through the gingival sulcus in half of the rats. Rats were divided into four groups; control, control+LLL, hypofunctional, and hypofunctional+LLL. Exposure to LLL irradiation was performed for 3 minutes every other day for 2 weeks. Animals were examined by Micro-CT at 5 and 7 weeks and were subsequently sacrificed. Heads were resected and examined histologically and immunohistologically. The hypofunctional group had obvious stricture of the PDL. However, no significant differences were observed in the PDL and alveolar bone between the hypofunctional+LLL and the control groups. In addition, the expression of basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF)positive cells were higher in the hypofunctional + LLL group than in the hypofunctional group. These results indicated that LLL enhanced the production of bFGF and VEGF in the periodontal tissue of hypofunctional teeth.	[Hayashi, Hidetaka] Hiroshima Shuccho Dent Clin, Hiroshima, Japan; [Terao, Akiko; Kunimatsu, Ryo] Hiroshima Univ, Dept Orthodont & Craniofacial Dev Biol, Grad Sch Biomed Sci, Hiroshima, Japan; [Kawata, Toshitsugu] Kanagawa Dent Univ, Dept Orthodont, Yokosuka, Kanagawa, Japan	Hiroshima University; Kanagawa Dental College	Hayashi, H (corresponding author), Hiroshima Shuccho Dent Clin, Hiroshima, Japan.	hidetaka423@yahoo.co.jp			ministry of Education, Culture, Sports, Science and Technology of Japan [24890141]	ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This study was funded by a Grant-in-Aid for Scientific Research from the ministry of Education, Culture, Sports, Science and Technology of Japan (24890141). Hidetaka Hayashi provided support in the form of salaries for author HH, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The Ministry of Education, Culture, Sports, Science and Technology of Japan had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aldridge SE, 2005, BIOCHEM BIOPH RES CO, V335, P793, DOI 10.1016/j.bbrc.2005.07.145; Barolet D, 2008, SEMIN CUTAN MED SURG, V27, P227, DOI 10.1016/j.sder.2008.08.003; Boonpratham Supatchai, 2007, Journal of Medical and Dental Sciences, V54, P71; Faitova J, 2004, Cesk Fysiol, V53, P92; Amorim JCF, 2006, PHOTOMED LASER SURG, V24, P588; GOSPODAROWICZ D, 1990, CLIN ORTHOP RELAT R, P231; HARRIS EF, 1992, AM J ORTHOD DENTOFAC, V101, P112, DOI 10.1016/0889-5406(92)70002-R; Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin; Khadra M, 2005, J BIOMED MATER RES A, V73A, P55, DOI 10.1002/jbm.a.30270; Kilkenny C, 2012, OSTEOARTHR CARTILAGE, V20, P256, DOI 10.1016/j.joca.2012.02.010; Kreisler M, 2003, J CLIN PERIODONTOL, V30, P353, DOI 10.1034/j.1600-051X.2003.00001.x; Kronfeld R, 1931, J AM DENT ASSOC, V18, P1242; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Motokawa M, 2013, ANGLE ORTHOD, V83, P597, DOI 10.2319/081812-661.1; Niida S, 1999, J EXP MED, V190, P293, DOI 10.1084/jem.190.2.293; Ozcelik O, 2008, J CLIN PERIODONTOL, V35, P250, DOI 10.1111/j.1600-051X.2007.01194.x; Saygun I, 2008, LASER MED SCI, V23, P211, DOI 10.1007/s10103-007-0477-3; Seifi M, 2010, LASER MED SCI, V25, P61, DOI 10.1007/s10103-009-0651-x; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Shakouri SK, 2010, LASER MED SCI, V25, P73, DOI 10.1007/s10103-009-0670-7; Shimomoto Y, 2007, J DENT RES, V86, P47, DOI 10.1177/154405910708600107; Sringkarnboriboon S, 2003, J DENT RES, V82, P486, DOI 10.1177/154405910308200616; Tajali SB, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749-799X-5-1; Tanaka A, 1998, ORTHOD WAVES, V57, P180; Tuby H, 2006, LASER SURG MED, V38, P682, DOI 10.1002/lsm.20377	25	6	8	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2014	9	6							e100066	10.1371/journal.pone.0100066	http://dx.doi.org/10.1371/journal.pone.0100066			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK2VQ	24927024	Green Published, Green Submitted, gold			2023-01-03	WOS:000338278100115
J	Gottlieb, DJ; Punjabi, NM; Mehra, R; Patel, SR; Quan, SF; Babineau, DC; Tracy, RP; Rueschman, M; Blumenthal, RS; Lewis, EF; Bhatt, DL; Redline, S				Gottlieb, Daniel J.; Punjabi, Naresh M.; Mehra, Reena; Patel, Sanjay R.; Quan, Stuart F.; Babineau, Denise C.; Tracy, Russell P.; Rueschman, Michael; Blumenthal, Roger S.; Lewis, Eldrin F.; Bhatt, Deepak L.; Redline, Susan			CPAP versus Oxygen in Obstructive Sleep Apnea	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITIVE AIRWAY PRESSURE; CORONARY-ARTERY-DISEASE; BLOOD-PRESSURE; INTERMITTENT HYPOXIA; CARDIOVASCULAR OUTCOMES; SYSTEMIC HYPERTENSION; SYMPATHETIC ACTIVITY; SUPPLEMENTAL OXYGEN; ASSOCIATION; STROKE	BACKGROUND Obstructive sleep apnea is associated with hypertension, inflammation, and increased cardiovascular risk. Continuous positive airway pressure (CPAP) reduces blood pressure, but adherence is often suboptimal, and the benefit beyond management of conventional risk factors is uncertain. Since intermittent hypoxemia may underlie cardiovascular sequelae of sleep apnea, we evaluated the effects of nocturnal supplemental oxygen and CPAP on markers of cardiovascular risk. METHODS We conducted a randomized, controlled trial in which patients with cardiovascular disease or multiple cardiovascular risk factors were recruited from cardiology practices. Patients were screened for obstructive sleep apnea with the use of the Berlin questionnaire, and home sleep testing was used to establish the diagnosis. Participants with an apnea-hypopnea index of 15 to 50 events per hour were randomly assigned to receive education on sleep hygiene and healthy lifestyle alone (the control group) or, in addition to education, either CPAP or nocturnal supplemental oxygen. Cardiovascular risk was assessed at baseline and after 12 weeks of the study treatment. The primary outcome was 24-hour mean arterial pressure. RESULTS Of 318 patients who underwent randomization, 281 (88%) could be evaluated for ambulatory blood pressure at both baseline and follow-up. On average, the 24-hour mean arterial pressure at 12 weeks was lower in the group receiving CPAP than in the control group (-2.4 mm Hg; 95% confidence interval [CI], -4.7 to -0.1; P = 0.04) or the group receiving supplemental oxygen (-2.8 mm Hg; 95% CI, -5.1 to -0.5; P = 0.02). There was no significant difference in the 24-hour mean arterial pressure between the control group and the group receiving oxygen. A sensitivity analysis performed with the use of multiple imputation approaches to assess the effect of missing data did not change the results of the primary analysis. CONCLUSIONS In patients with cardiovascular disease or multiple cardiovascular risk factors, the treatment of obstructive sleep apnea with CPAP, but not nocturnal supplemental oxygen, resulted in a significant reduction in blood pressure.	[Gottlieb, Daniel J.; Babineau, Denise C.] Vet Affairs Boston Healthcare Syst, Boston, MA USA; [Gottlieb, Daniel J.; Patel, Sanjay R.; Quan, Stuart F.; Rueschman, Michael; Lewis, Eldrin F.; Bhatt, Deepak L.; Redline, Susan] Brigham & Womens Hosp, Boston, MA 02115 USA; [Gottlieb, Daniel J.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Patel, Sanjay R.; Redline, Susan] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Punjabi, Naresh M.; Blumenthal, Roger S.] Johns Hopkins Univ, Baltimore, MD USA; [Mehra, Reena] Cleveland Clin, Cleveland, OH USA; [Mehra, Reena; Babineau, Denise C.] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Tracy, Russell P.] Univ Vermont, Colchester, Essex, England	US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Harvard University; Brigham & Women's Hospital; Boston University; Harvard University; Beth Israel Deaconess Medical Center; Johns Hopkins University; Cleveland Clinic Foundation; Case Western Reserve University	Gottlieb, DJ (corresponding author), Brigham & Womens Hosp, Div Sleep Med, 221 Longwood Ave,BLI 225E, Boston, MA 02115 USA.	djgottlieb@partners.org	Mehra, Reena/ABA-5710-2021; Blumenthal, Roger S/H-3223-2018; Quan, Stuart/J-5026-2019; Punjabi, Naresh/EMH-1007-2022	Blumenthal, Roger S/0000-0003-1910-3168; Quan, Stuart/0000-0002-9474-7679; Mehra, Reena/0000-0002-6222-2675; Patel, Sanjay/0000-0002-9142-5172	National Heart, Lung, and Blood Institute [RC2 HL101417, 1R01HL109493, R21HL108226]; National Center for Research Resources [UL1 RR024989]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000439, UL1TR001079] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024989] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL109493, RC2HL101417, R21HL108226] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by grants from the National Heart, Lung, and Blood Institute (RC2 HL101417, 1R01HL109493, and R21HL108226) and by a grant from the National Center for Research Resources (UL1 RR024989).	Barbe F, 2012, JAMA-J AM MED ASSOC, V307, P2161, DOI 10.1001/jama.2012.4366; Barbe F, 2010, AM J RESP CRIT CARE, V181, P718, DOI 10.1164/rccm.200901-0050OC; Bazzano LA, 2007, HYPERTENSION, V50, P417, DOI 10.1161/HYPERTENSIONAHA.106.085175; Brooks D, 1997, J CLIN INVEST, V99, P106, DOI 10.1172/JCI119120; Chesson A., 2007, AASM MANUAL SCORING; Doherty LS, 2005, CHEST, V127, P2076, DOI 10.1378/chest.127.6.2076; Duran-Cantolla J, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5991; Friedman O, 2009, INTEGR BLOOD PRESS C, V2, P25; Gottlieb DJ, 2010, CIRCULATION, V122, P352, DOI 10.1161/CIRCULATIONAHA.109.901801; Greenberg H, 2006, BIOCHEM BIOPH RES CO, V343, P591, DOI 10.1016/j.bbrc.2006.03.015; Jelic S, 2008, TRENDS CARDIOVAS MED, V18, P253, DOI 10.1016/j.tcm.2008.11.008; Kapur VK, 2005, SLEEP, V28, P472, DOI 10.1093/sleep/28.4.472; Kohler M, 2009, THORAX, V64, P67, DOI 10.1136/thx.2008.097931; Law MR, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1665; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; Loredo JS, 2006, SLEEP, V29, P564, DOI 10.1093/sleep/29.4.564; Lozano L, 2010, J HYPERTENS, V28, P2161, DOI 10.1097/HJH.0b013e32833b9c63; Marin JM, 2005, LANCET, V365, P1046, DOI 10.1016/S0140-6736(05)71141-7; Marin JM, 2012, JAMA-J AM MED ASSOC, V307, P2169, DOI 10.1001/jama.2012.3418; Maronna RA, 2000, J STAT PLAN INFER, V89, P197, DOI 10.1016/S0378-3758(99)00208-6; McArdle N, 1999, AM J RESP CRIT CARE, V159, P1108, DOI 10.1164/ajrccm.159.4.9807111; Milleron O, 2004, EUR HEART J, V25, P728, DOI 10.1016/j.ehj.2004.02.008; Mooe T, 2001, AM J RESP CRIT CARE, V164, P1910, DOI 10.1164/ajrccm.164.10.2101072; Netzer NC, 1999, ANN INTERN MED, V131, P485, DOI 10.7326/0003-4819-131-7-199910050-00002; Nieto FJ, 2000, JAMA-J AM MED ASSOC, V283, P1829, DOI 10.1001/jama.283.14.1829; Nieto FJ, 2002, JAMA-J AM MED ASSOC, V288, P1985; Norman D, 2006, HYPERTENSION, V47, P840, DOI 10.1161/01.HYP.0000217128.41284.78; Peker Y, 2002, AM J RESP CRIT CARE, V166, P159, DOI 10.1164/rccm.2105124; Pepin JL, 2010, AM J RESP CRIT CARE, V182, P954, DOI 10.1164/rccm.200912-1803OC; Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901; PHILLIPS BA, 1990, CHEST, V98, P325, DOI 10.1378/chest.98.2.325; Punjabi NM, 2009, DRUGS, V69, P13, DOI 10.2165/11531150-000000000-00000; Redline S, 2010, AM J RESP CRIT CARE, V182, P269, DOI 10.1164/rccm.200911-1746OC; Ryan Silke, 2008, Archives of Physiology and Biochemistry, V114, P261, DOI [10.1080/13813450802307337, 10.1080/13813450802307337 ]; Schneider H, 2000, J APPL PHYSIOL, V88, P1093, DOI 10.1152/jappl.2000.88.3.1093; Somers VK, 2008, CIRCULATION, V118, P1080, DOI 10.1161/CIRCULATIONAHA.107.189375; SOMERS VK, 1989, J APPL PHYSIOL, V67, P2101, DOI 10.1152/jappl.1989.67.5.2101; Somers VK, 2009, NY TIMES        1026, V119, pe380; Tamisier R, 2011, EUR RESPIR J, V37, P119, DOI 10.1183/09031936.00204209; Yaggi HK, 2005, NEW ENGL J MED, V353, P2034, DOI 10.1056/NEJMoa043104; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	42	233	234	2	45	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 12	2014	370	24					2276	2285		10.1056/NEJMoa1306766	http://dx.doi.org/10.1056/NEJMoa1306766			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AI7BB	24918372	Green Accepted			2023-01-03	WOS:000337033700007
J	Park, JD; Kang, HJ; Kim, YA; Jo, M; Lee, ES; Shin, HY; Yun, YH				Park, June Dong; Kang, Hyoung Jin; Kim, Young Ae; Jo, MinKyoung; Lee, Eun Sook; Shin, Hee Young; Yun, Young Ho			Trends in the Aggressiveness of End-of-Life Care for Korean Pediatric Cancer Patients Who Died in 2007-2010	PLOS ONE			English	Article							CHILDREN; QUALITY; PERSPECTIVES; INDICATORS; SYMPTOMS	Background: In light of the Korean Supreme Court's 2009 ruling favoring a patient's right to die with dignity, we evaluated trends in aggressive care in a cohort of pediatric cancer patients. Methods We conducted a population-based retrospective study that used administrative data for patients who died in 2007-2010 among the 5,203 pediatric cancer patients registered at the Korean Cancer Central Registry (KCCR) during 2007-2009. Results: In the time period covered, 696 patients died. The proportion who had received chemotherapy in the last 30 days of life decreased from 58.1% to 28.9% (P<0.001), those who received new chemotherapy in the same time period decreased from 55.2% to 15.1% (P<0.001), and those who received treatment in the last 2 weeks of life decreased from 51.4% to 21.7% (P<0.001). In the last 30 days of life, the proportion of patients whose hospital admission period was over 14 days increased from 70.5% to 82.5% (P = 0.03), the proportion who received cardiopulmonary resuscitation decreased from 28.6% to 9.6% (P<0.001), and we found no statistically significant trends in the proportion of emergency department visits, intensive care unit admissions, or mechanical ventilation. Conclusions: In this study, in contrast with earlier ones, the aggressiveness of end-of-life care of Korean pediatric cancer patients decreased dramatically.	[Park, June Dong; Kang, Hyoung Jin; Shin, Hee Young] Seoul Natl Univ, Coll Med, Dept Pediat, Seoul, South Korea; [Kang, Hyoung Jin; Shin, Hee Young; Yun, Young Ho] Seoul Natl Univ, Coll Med, Inst Canc, Seoul, South Korea; [Kim, Young Ae; Jo, MinKyoung; Lee, Eun Sook] Natl Canc Ctr, Hosp & Res Inst, Goyang, South Korea; [Yun, Young Ho] Seoul Natl Univ Hosp, Dept Biomed Sci, Seoul 110744, South Korea; [Yun, Young Ho] Coll Med, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); National Cancer Center - Korea (NCC); Seoul National University (SNU); Seoul National University Hospital	Yun, YH (corresponding author), Seoul Natl Univ, Coll Med, Inst Canc, Seoul, South Korea.	lawyun@snu.ac.kr		Park, June Dong/0000-0001-8113-1384	National Cancer Center [1010081];  [1310250-1]	National Cancer Center; 	This study was supported by National Cancer Center 1010081 grants and 1310250-1. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beretta S, 2010, PEDIATR BLOOD CANCER, V54, P88, DOI 10.1002/pbc.22284; Bradshaw Glenna, 2005, J Palliat Med, V8, P86, DOI 10.1089/jpm.2005.8.86; Earle CC, 2005, INT J QUAL HEALTH C, V17, P505, DOI 10.1093/intqhc/mzi061; Earle CC, 2003, J CLIN ONCOL, V21, P1133, DOI 10.1200/JCO.2003.03.059; Earle CC, 2004, J CLIN ONCOL, V22, P315, DOI 10.1200/JCO.2004.08.136; Earle CC, 2008, J CLIN ONCOL, V26, P3860, DOI 10.1200/JCO.2007.15.8253; Fujii Y, 2003, PEDIATR INT, V45, P54, DOI 10.1046/j.1442-200X.2003.01664.x; Ho TH, 2011, J CLIN ONCOL, V29, P1587, DOI 10.1200/JCO.2010.31.9897; Mack JW, 2005, J CLIN ONCOL, V23, P9155, DOI 10.1200/JCO.2005.04.010; Meert KL, 2009, PEDIATR CRIT CARE ME, V10, P544, DOI 10.1097/PCC.0b013e3181a7045c; Pui CH, 2011, NAT REV CLIN ONCOL, V8, P540, DOI 10.1038/nrclinonc.2011.95; Sato K, 2008, SUPPORT CARE CANCER, V16, P113, DOI 10.1007/s00520-007-0332-x; Ser MJ, 2009, JOONGANG DAILY  0522; Shin Hai-Rim, 2005, Cancer Res Treat, V37, P325, DOI 10.4143/crt.2005.37.6.325; Tang ST, 2011, J CLIN ONCOL, V29, P890, DOI 10.1200/JCO.2010.32.5639; Tang ST, 2009, J CLIN ONCOL, V27, P4613, DOI 10.1200/JCO.2008.20.5096; von Lutzau P, 2012, J PALLIAT CARE, V28, P274, DOI 10.1177/082585971202800406; Wolfe J, 2000, NEW ENGL J MED, V342, P326, DOI 10.1056/NEJM200002033420506; Wolfe J, 2008, J CLIN ONCOL, V26, P1717, DOI 10.1200/JCO.2007.14.0277; Yun YH, 2007, ONCOLOGY-BASEL, V72, P164, DOI 10.1159/000112802; Yun YH, 2011, CAN MED ASSOC J, V183, pE673, DOI 10.1503/cmaj.110020	21	14	14	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2014	9	6							e99888	10.1371/journal.pone.0099888	http://dx.doi.org/10.1371/journal.pone.0099888			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK8TP	24923320	Green Submitted, gold, Green Published			2023-01-03	WOS:000338701300104
J	Tsai, WL; Lai, KH; Liang, HL; Hsu, PI; Chan, HH; Chen, WC; Yu, HC; Tsay, FW; Wang, HM; Tsai, HC; Cheng, JS				Tsai, Wei-Lun; Lai, Kwok-Hung; Liang, Huei-Lung; Hsu, Ping-I; Chan, Hoi-Hung; Chen, Wen-Chi; Yu, Hsien-Chung; Tsay, Feng-Woei; Wang, Huay-Min; Tsai, Hung-Chih; Cheng, Jin-Shiung			Hepatic Arterial Infusion Chemotherapy for Patients with Huge Unresectable Hepatocellular Carcinoma	PLOS ONE			English	Article							VEIN TUMOR THROMBOSIS; 10 CM; TRANSARTERIAL CHEMOEMBOLIZATION; RESECTION; LARGER; EMBOLIZATION; MANAGEMENT; NATIONWIDE; CISPLATIN; CANCER	Background and Aim: The optimal treatment for huge unresectable hepatocellular carcinoma (HCC) remains controversial. The outcome of transcatheter arterial chemoembolization (TACE) for patients huge unresectable HCC is generally poor and the survival benefit of TACE in these patients is unclear. The aim of the study is to compare the effect of hepatic arterial infusion chemotherapy (HAIC) versus symptomatic treatment in patients with huge unresectable HCC. Methods: Since 2000 to 2005, patients with huge (size >8cm) unresectable HCC were enrolled. Fifty-eight patients received HAIC and 44 patients received symptomatic treatment. In the HAIC group, each patient received 2.4+1.4 (range: 1-6) courses of HAIC. Baseline characteristics and survival were compared between the HAIC and symptomatic treatment groups. Results: The HAIC group and the symptomatic treatment group were similar in baseline characteristics and tumor stages. The overall survival rates at one and two years were 29% and 14% in the HAIC group and 7% and 5% in the symptomatic treatment group, respectively. The patients in the HAIC group had significantly better overall survival than the symptomatic treatment group (P<0.001). Multivariate analysis revealed that HAIC was the significant factor associated with the overall survival (relative risk: 0.321, 95% confidence interval: 0.200-0.515, P<0.001). None of the patients died due to immediate complications of HAIC. Conclusions: HAIC is a safe procedure and provides better survival than symptomatic treatment in patients with huge unresectable HCC.	[Tsai, Wei-Lun; Lai, Kwok-Hung; Hsu, Ping-I; Chan, Hoi-Hung; Chen, Wen-Chi; Yu, Hsien-Chung; Tsay, Feng-Woei; Wang, Huay-Min; Cheng, Jin-Shiung] Kaohsiung Vet Gen Hosp, Div Gastroenterol, Dept Internal Med, Kaohsiung, Taiwan; [Tsai, Wei-Lun; Lai, Kwok-Hung; Liang, Huei-Lung; Hsu, Ping-I; Chan, Hoi-Hung; Chen, Wen-Chi; Yu, Hsien-Chung; Tsay, Feng-Woei; Wang, Huay-Min; Cheng, Jin-Shiung] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan; [Liang, Huei-Lung] Kaohsiung Vet Gen Hosp, Dept Radiol, Kaohsiung, Taiwan; [Tsai, Hung-Chih] Kun Shan Univ, Dept Finance & Banking, Coll Business & Management, Tainan, Taiwan	Kaohsiung Veterans General Hospital; National Yang Ming Chiao Tung University; Kaohsiung Veterans General Hospital; Kun Shan University	Cheng, JS (corresponding author), Kaohsiung Vet Gen Hosp, Div Gastroenterol, Dept Internal Med, Kaohsiung, Taiwan.	rcheng@ms2.hinet.net						Adachi E, 1996, CANCER, V77, P2022, DOI 10.1002/(SICI)1097-0142(19960515)77:10<2022::AID-CNCR9>3.0.CO;2-S; Ando E, 2002, CANCER-AM CANCER SOC, V95, P588, DOI 10.1002/cncr.10694; Bruix J, 2001, J HEPATOL, V35, P421, DOI 10.1016/S0168-8278(01)00130-1; Bruix J, 2001, HEPATOLOGY, V53, P1020; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Chung YH, 2000, CANCER, V88, P1986, DOI 10.1002/(SICI)1097-0142(20000501)88:9<1986::AID-CNCR2>3.0.CO;2-I; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; FURUTA T, 1992, J SURG ONCOL, V51, P114, DOI 10.1002/jso.2930510210; HSU HC, 1985, CANCER-AM CANCER SOC, V56, P672, DOI 10.1002/1097-0142(19850801)56:3<672::AID-CNCR2820560340>3.0.CO;2-V; Huang YH, 2006, ALIMENT PHARM THER, V23, P129, DOI 10.1111/j.1365-2036.2006.02704.x; Huang YH, 2005, ALIMENT PHARM THER, V21, P687, DOI 10.1111/j.1365-2036.2005.02404.x; JWO SC, 1992, HEPATOLOGY, V16, P1367, DOI 10.1002/hep.1840160611; Kao JH, 2005, LIVER INT, V25, P696, DOI 10.1111/j.1478-3231.2005.01139.x; Lau WY, 2013, ONCOLOGY-BASEL, V84, P311, DOI 10.1159/000348325; Lee NH, 1998, BRIT J SURG, V85, P1654; Liang HL, 2007, ACTA RADIOL, V48, P734, DOI 10.1080/02841850701408210; Lin Chi-Pin, 2004, J Chin Med Assoc, V67, P602; Llovet JM, 2005, SEMIN LIVER DIS, V25, P181, DOI 10.1055/s-2005-871198; Manghisi G, 1998, HEPATOLOGY, V28, P751; Mok KT, 2003, J AM COLL SURGEONS, V197, P730, DOI 10.1016/j.jamcollsurg.2003.07.013; Noguchi T, 1997, SEMIN ONCOL, V24, P7; Nouso K, 2013, BRIT J CANCER, V109, P1904, DOI 10.1038/bjc.2013.542; Poon RTP, 2002, J AM COLL SURGEONS, V194, P592, DOI 10.1016/S1072-7515(02)01163-8; Poon RTP, 2000, J SURG ONCOL, V73, P109, DOI 10.1002/(SICI)1096-9098(200002)73:2<109::AID-JSO10>3.3.CO;2-A; SHELL JC, 1985, CANCER, V56, P660, DOI 10.1002/1097-0142(19850801)56:3<660::AID-CNCR2820560338>3.0.CO;2-F; Song DS, 2013, WORLD J GASTROENTERO, V19, P4679, DOI 10.3748/wjg.v19.i29.4679; Takayasu K, 2006, GASTROENTEROLOGY, V131, P461, DOI 10.1053/j.gastro.2006.05.021; Tsai WL, 2008, ALIMENT PHARM THER, V28, P304, DOI 10.1111/j.1365-2036.2008.03702.x; Urbe T, 1998, ONCOLOGY, V55, P39; Yamasaki T, 2005, J GASTROENTEROL, V40, P70, DOI 10.1007/s00535-004-1494-7; Yoshioka H, 1997, SEMIN ONCOL, V24, P29	32	22	26	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2014	9	5							e92784	10.1371/journal.pone.0092784	http://dx.doi.org/10.1371/journal.pone.0092784			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AH8EY	24824520	Green Published, Green Submitted, gold			2023-01-03	WOS:000336369200002
J	Katsimpardi, L; Litterman, NK; Schein, PA; Miller, CM; Loffredo, FS; Wojtkiewicz, GR; Chen, JW; Lee, RT; Wagers, AJ; Rubin, LL				Katsimpardi, Lida; Litterman, Nadia K.; Schein, Pamela A.; Miller, Christine M.; Loffredo, Francesco S.; Wojtkiewicz, Gregory R.; Chen, John W.; Lee, Richard T.; Wagers, Amy J.; Rubin, Lee L.			Vascular and Neurogenic Rejuvenation of the Aging Mouse Brain by Young Systemic Factors	SCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; NEURAL STEM-CELLS; SUBVENTRICULAR ZONE; DENTATE GYRUS; ADULT; PROLIFERATION; DIFFERENTIATION; EXPRESSION; HIPPOCAMPUS; MICE	In the adult central nervous system, the vasculature of the neurogenic niche regulates neural stem cell behavior by providing circulating and secreted factors. Age-related decline of neurogenesis and cognitive function is associated with reduced blood flow and decreased numbers of neural stem cells. Therefore, restoring the functionality of the niche should counteract some of the negative effects of aging. We show that factors found in young blood induce vascular remodeling, culminating in increased neurogenesis and improved olfactory discrimination in aging mice. Further, we show that GDF11 alone can improve the cerebral vasculature and enhance neurogenesis. The identification of factors that slow the age-dependent deterioration of the neurogenic niche in mice may constitute the basis for new methods of treating age-related neurodegenerative and neurovascular diseases.	[Katsimpardi, Lida; Litterman, Nadia K.; Schein, Pamela A.; Miller, Christine M.; Loffredo, Francesco S.; Lee, Richard T.; Wagers, Amy J.; Rubin, Lee L.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA; [Katsimpardi, Lida; Litterman, Nadia K.; Schein, Pamela A.; Miller, Christine M.; Loffredo, Francesco S.; Lee, Richard T.; Wagers, Amy J.; Rubin, Lee L.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA; [Miller, Christine M.; Wagers, Amy J.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Joslin Diabet Ctr, Boston, MA 02115 USA; [Miller, Christine M.; Wagers, Amy J.] Harvard Univ, Sch Med, Paul F Glenn Labs Biol Mech Aging, Boston, MA 02115 USA; [Loffredo, Francesco S.; Lee, Richard T.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA; [Wojtkiewicz, Gregory R.; Chen, John W.] Harvard Univ, Sch Med, Ctr Syst Biol, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Wojtkiewicz, Gregory R.; Chen, John W.] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA	Harvard University; Harvard University; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Katsimpardi, L (corresponding author), Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.	lida_katsimpardi@harvard.edu; lee_rubin@harvard.edu	Loffredo, Francesco S/F-6638-2014; Loffredo, Francesco/P-1389-2019; Wojtkiewicz, Gregory/L-3660-2018	Loffredo, Francesco S/0000-0001-5911-780X; Loffredo, Francesco/0000-0001-5911-780X; Lee, Richard/0000-0003-4687-1381; Rubin, Lee/0000-0002-8658-841X; Wojtkiewicz, Gregory/0000-0002-3148-8411	Ellison Medical Foundation; GlaxoSmithKline; Harvard Stem Cell Institute; NIH [R01 AG032977 1R01 AG040019, 1R01 AG033053, 1DP2 OD004345, 5U01 HL100402, R01NS070835, R01NS072167]; Paul F. Glenn Foundation for Medical Research; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL100402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS070835, R01NS072167] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG032977, R01AG040019, R01AG033053] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD004345] Funding Source: NIH RePORTER	Ellison Medical Foundation(Lawrence Ellison Foundation); GlaxoSmithKline(GlaxoSmithKline); Harvard Stem Cell Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Paul F. Glenn Foundation for Medical Research; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank C. McGillivray and D. Faria at the HSCRB Histology Core for providing help with sectioning and D. Smith and B. Gotze at the HCBI for providing microscope facilities. We also thank W. Stallcup for providing the anti-NG2 antibody, C. Bonal for technical help and J. LaLonde for editorial assistance. This work was supported by a Senior Scholar in Aging Award from The Ellison Medical Foundation to L. L. R.; awards from GlaxoSmithKline and the Harvard Stem Cell Institute to L. L. R.; NIH (R01 AG032977 1R01 AG040019) to R. T. L.; and the Paul F. Glenn Foundation for Medical Research, NIH (1R01 AG033053, 1DP2 OD004345, and 5U01 HL100402), and Harvard Stem Cell Institute to A. J. W. Additional data are in the Supplement. J. C. was funded by NIH R01NS070835 and R01NS072167. L. L. R., A. J. W., R. T. L., and L. K. are inventors on a U.S. patent application filed by Harvard University and Brigham and Women's Hospital entitled "Methods and Compositions for Increasing Neurogenesis and Angiogenesis" (61/833, 813).	Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Balabanov R, 1998, J NEUROSCI RES, V53, P637, DOI 10.1002/(SICI)1097-4547(19980915)53:6<637::AID-JNR1>3.0.CO;2-6; Brines M, 2005, NAT REV NEUROSCI, V6, P484, DOI 10.1038/nrn1687; Carleton A, 2003, NAT NEUROSCI, V6, P507, DOI 10.1038/nn1048; Carmeliet P, 2003, NAT REV GENET, V4, P710, DOI 10.1038/nrg1158; Farkas E, 2001, PROG NEUROBIOL, V64, P575, DOI 10.1016/S0301-0082(00)00068-X; Garcia A, 2004, AGING CELL, V3, P363, DOI 10.1111/j.1474-9728.2004.00130.x; Grady CL, 1998, NEUROIMAGE, V8, P409, DOI 10.1006/nimg.1998.0376; Katsimpardi L, 2008, STEM CELLS, V26, P1796, DOI 10.1634/stemcells.2007-0921; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Loffredo FS, 2013, CELL, V153, P828, DOI 10.1016/j.cell.2013.04.015; Luo J, 2006, AGING CELL, V5, P139, DOI 10.1111/j.1474-9726.2006.00197.x; Matarredona ER, 2005, BRAIN RES REV, V49, P355, DOI 10.1016/j.brainresrev.2005.01.001; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; Reed May J, 2004, Sci Aging Knowledge Environ, V2004, ppe7, DOI 10.1126/sageke.2004.7.pe7; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Riddle DR, 2003, AGEING RES REV, V2, P149, DOI 10.1016/S1568-1637(02)00064-8; Rivard A, 1999, CIRCULATION, V99, P111, DOI 10.1161/01.CIR.99.1.111; Ruckh JM, 2012, CELL STEM CELL, V10, P96, DOI 10.1016/j.stem.2011.11.019; Seki T, 1995, NEUROREPORT, V6, P2479, DOI 10.1097/00001756-199512150-00010; Seki T, 2002, J NEUROSCI RES, V70, P327, DOI 10.1002/jnr.10387; Shen Q, 2004, SCIENCE, V304, P1338, DOI 10.1126/science.1095505; Shingo T, 2003, SCIENCE, V299, P117, DOI 10.1126/science.1076647; Sinha M, 2014, SCIENCE, V344, P649, DOI 10.1126/science.1251152; Snyder JS, 2011, NATURE, V476, P458, DOI 10.1038/nature10287; Tavazoie M, 2008, CELL STEM CELL, V3, P279, DOI 10.1016/j.stem.2008.07.025; Tropepe V, 1997, J NEUROSCI, V17, P7850; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357; Witt R. M., 2009, JOVE-J VIS EXP, V28, P949; Wright DE, 2001, SCIENCE, V294, P1933, DOI 10.1126/science.1064081; Wu P, 2008, NEUROBIOL AGING, V29, P1502, DOI 10.1016/j.neurobiolaging.2007.03.028	32	630	677	4	205	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 9	2014	344	6184					630	634		10.1126/science.1251141	http://dx.doi.org/10.1126/science.1251141			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG6OD	24797482	Green Accepted			2023-01-03	WOS:000335537400043
J	Medina-Echeverz, J; Fioravanti, J; Diaz-Valdes, N; Frank, K; Aranda, F; Gomar, C; Ardaiz, N; Dotor, J; Umansky, V; Prieto, J; Berraondo, P				Medina-Echeverz, Jose; Fioravanti, Jessica; Diaz-Valdes, Nancy; Frank, Kathrin; Aranda, Fernando; Gomar, Celia; Ardaiz, Nuria; Dotor, Javier; Umansky, Viktor; Prieto, Jesus; Berraondo, Pedro			Harnessing High Density Lipoproteins to Block Transforming Growth Factor Beta and to Inhibit the Growth of Liver Tumor Metastases	PLOS ONE			English	Article							TRANSGENIC MOUSE MODEL; TGF-BETA; T-CELLS; ADENOASSOCIATED VIRUS; SYNTHETIC PEPTIDE; IMMUNE CELLS; GENE-THERAPY; CANCER; PROGRESSION; MELANOMA	Transforming growth factor beta (TGF-beta) is a powerful promoter of cancer progression and a key target for antitumor therapy. As cancer cells exhibit active cholesterol metabolism, high density lipoproteins (HDLs) appear as an attractive delivery system for anticancer TGF beta-inhibitory molecules. We constructed a plasmid encoding a potent TGF-beta-blocking peptide (P144) linked to apolipoprotein A-I (ApoA-I) through a flexible linker (pApoLinkerP144). The ApoLinkerP144 sequence was then incorporated into a hepatotropic adeno-associated vector (AAVApoLinkerP144). The aim was to induce hepatocytes to produce HDLs containing a modified ApoA-I capable of blocking TGF-b. We observed that transduction of the murine liver with pApoLinkerP144 led to the appearance of a fraction of circulating HDL containing the fusion protein. These HDLs were able to attenuate TGF-b signaling in the liver and to enhance IL-12 -mediated IFN-gamma production. Treatment of liver metastasis of MC38 colorectal cancer with AAVApoLinkerP144 resulted in a significant reduction of tumor growth and enhanced expression of IFN-c and GM-CSF in cancerous tissue. ApoLinkerP144 also delayed MC38 liver metastasis in Rag2(-/) (-)IL2r gamma (-/)-immunodeficient mice. This effect was associated with downregulation of TGF-beta target genes essential for metastatic niche conditioning. Finally, in a subset of ret transgenic mice, a model of aggressive spontaneous metastatic melanoma, AAVApoLinkerP144 delayed tumor growth in association with increased CD8(+) T cell numbers in regional lymph nodes. In conclusion, modification of HDLs to transport TGF-b-blocking molecules is a novel and promising approach to inhibit the growth of liver metastases by immunological and non-immunological mechanisms.	[Medina-Echeverz, Jose; Fioravanti, Jessica; Diaz-Valdes, Nancy; Aranda, Fernando; Gomar, Celia; Ardaiz, Nuria; Prieto, Jesus; Berraondo, Pedro] Univ Navarra, Ctr Appl Med Res, Div Hepatol & Gene Therapy, E-31080 Pamplona, Spain; [Diaz-Valdes, Nancy; Frank, Kathrin; Umansky, Viktor] German Canc Res Ctr, Skin Canc Unit, Heidelberg, Germany; [Diaz-Valdes, Nancy; Frank, Kathrin; Umansky, Viktor] Heidelberg Univ, Univ Med Ctr Mannheim, Dept Dermatol Venereol & Allergol, Heidelberg, Germany; [Dotor, Javier] DIGNA Biotech, Madrid, Spain; [Prieto, Jesus] Univ Navarra Clin, Networked Biomed Res Ctr Hepat & Digest Dis, Liver Unit, Pamplona, Spain	University of Navarra; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; University of Navarra	Prieto, J (corresponding author), Univ Navarra, Ctr Appl Med Res, Div Hepatol & Gene Therapy, E-31080 Pamplona, Spain.	jprieto@unav.es; pberraondol@unav.es	Fioravanti, Jessica/AAS-1245-2020; Aranda, Fernando/N-9649-2019; Aranda, Fernando/N-2112-2014; Berraondo, Pedro/J-3154-2012	Fioravanti, Jessica/0000-0001-6263-4306; Aranda, Fernando/0000-0002-9364-474X; Aranda, Fernando/0000-0002-9364-474X; Berraondo, Pedro/0000-0001-7410-1865; Prieto, Jesus/0000-0002-1091-9593	FIMA; UTE project CIMA [IMMUNONET-SOE1/P1/E014]; Instituto de Salud Carlos III, Fondo de Investigacion Sanitaria [FIS PI10/00264]; Foundation for Cancer Research [108992]; Initiative and Networking Fund of the Helmholtz Association within the Helmholtz Alliance on Immunotherapy of Cancer; fellowship of Spanish Fondo de Investigacion Sanitaria; Martin Escudero fellowship; Miguel Servet contract from Spanish Fondo de Investigacion Sanitaria	FIMA; UTE project CIMA; Instituto de Salud Carlos III, Fondo de Investigacion Sanitaria(Instituto de Salud Carlos III); Foundation for Cancer Research; Initiative and Networking Fund of the Helmholtz Association within the Helmholtz Alliance on Immunotherapy of Cancer; fellowship of Spanish Fondo de Investigacion Sanitaria; Martin Escudero fellowship; Miguel Servet contract from Spanish Fondo de Investigacion Sanitaria	This work was supported by the agreement between FIMA and the "UTE project CIMA'', Red de Inmunoterapia IMMUNONET-SOE1/P1/E014, Instituto de Salud Carlos III, Fondo de Investigacion Sanitaria (FIS PI10/00264), Fundacion Mutua Madrilena, Dr. Mildred Scheel Foundation for Cancer Research (grant 108992, to V.U.) and by the Initiative and Networking Fund of the Helmholtz Association within the Helmholtz Alliance on Immunotherapy of Cancer (to V.U.). J. F. and J.M-E. were supported by a fellowship of Spanish Fondo de Investigacion Sanitaria. N.D-V. was supported by a Martin Escudero fellowship. P. B. was supported by a Miguel Servet contract from Spanish Fondo de Investigacion Sanitaria. J.D. was employee of Digna Biotech until June 2013. He has neither rights nor benefits from the data presented in this manuscript. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abschuetz Oliver, 2012, Cancers (Basel), V4, P490, DOI 10.3390/cancers4020490; Akhurst RJ, 2012, NAT REV DRUG DISCOV, V11, P790, DOI 10.1038/nrd3810; Cao WM, 2004, CANCER RES, V64, P1515, DOI 10.1158/0008-5472.CAN-03-0675; Chou YT, 2006, ONCOGENE, V25, P5547, DOI 10.1038/sj.onc.1209552; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Ezquerro IJ, 2003, CYTOKINE, V22, P12, DOI 10.1016/S1043-4666(03)00101-7; Fioravanti J, 2011, HEPATOLOGY, V53, P1864, DOI 10.1002/hep.24306; Flavell RA, 2010, NAT REV IMMUNOL, V10, P554, DOI 10.1038/nri2808; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; Grieger JC, 2005, ADV BIOCHEM ENG BIOT, V99, P119, DOI 10.1007/10_005; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; Hermida N, 2009, CARDIOVASC RES, V81, P601, DOI 10.1093/cvr/cvn315; Kato M, 1998, ONCOGENE, V17, P1885, DOI 10.1038/sj.onc.1202077; Lacko AG, 2006, CHEMOTHERAPY, V52, P171, DOI 10.1159/000093268; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Melero I, 1999, GENE THER, V6, P1779, DOI 10.1038/sj.gt.3301010; Nakai H, 2005, J VIROL, V79, P214, DOI 10.1128/JVI.79.1.214-224.2005; Nam JS, 2008, CANCER RES, V68, P3835, DOI 10.1158/0008-5472.CAN-08-0215; Neil JR, 2008, CARCINOGENESIS, V29, P2227, DOI 10.1093/carcin/bgn202; Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; Pickup M, 2013, NAT REV CANCER, V13, P788, DOI 10.1038/nrc3603; Pussinen PJ, 2000, BIOCHEM J, V349, P559, DOI 10.1042/0264-6021:3490559; Santiago B, 2005, J INVEST DERMATOL, V125, P450, DOI 10.1111/j.0022-202X.2005.23859.x; Schlingensiepen KH, 2006, CYTOKINE GROWTH F R, V17, P129, DOI 10.1016/j.cytogfr.2005.09.002; Sevko A, 2013, J INVEST DERMATOL, V133, P1610, DOI 10.1038/jid.2012.444; Shahzad MMK, 2011, NEOPLASIA, V13, P309, DOI 10.1593/neo.101372; Shirakihara T, 2011, EMBO J, V30, P783, DOI 10.1038/emboj.2010.351; Takaku S, 2010, INT J CANCER, V126, P1666, DOI 10.1002/ijc.24961; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Umansky V, 2008, CANCER RES, V68, P9451, DOI 10.1158/0008-5472.CAN-08-1464; Yang L, 2010, TRENDS IMMUNOL, V31, P220, DOI 10.1016/j.it.2010.04.002; Zabala M, 2007, J HEPATOL, V47, P807, DOI 10.1016/j.jhep.2007.07.025	34	10	10	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 5	2014	9	5							e96799	10.1371/journal.pone.0096799	http://dx.doi.org/10.1371/journal.pone.0096799			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI1ZV	24797128	Green Published, gold			2023-01-03	WOS:000336656000128
J	Hick, JL; Hanfling, D; Courtney, B; Lurie, N				Hick, John L.; Hanfling, Dan; Courtney, Brooke; Lurie, Nicole			Rationing Salt Water - Disaster Planning and Daily Care Delivery	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Hick, John L.] Univ Minnesota, Dept Emergency Med, Minneapolis, MN 55455 USA; [Hick, John L.] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA; [Hanfling, Dan] George Washington Univ, Dept Emergency Med, Washington, DC USA; [Lurie, Nicole] Dept Hlth & Human Serv, Off Assistant Secretary Preparedness & Response, Washington, DC USA; [Hanfling, Dan] Inova Hlth Syst, Falls Church, VA USA; [Courtney, Brooke] US FDA, Off Counterterrorism & Emerging Threats, Silver Spring, MD USA	University of Minnesota System; University of Minnesota Twin Cities; Hennepin County Medical Center; George Washington University; Inova Health System; US Food & Drug Administration (FDA)	Hick, JL (corresponding author), Univ Minnesota, Dept Emergency Med, Minneapolis, MN 55455 USA.							[Anonymous], 2014, DRUG SHORT PUBL HLTH; [Anonymous], 2012, COP MIT EFF SHORT EM, DOI [10.1056/NEJMp1401833, DOI 10.1056/NEJMP1401833]; Hanfling D., 2012, CRISIS STANDARDS CAR; Lee J., MODERN HEALTHCARE	4	5	5	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 24	2014	370	17					1573	1576		10.1056/NEJMp1401833	http://dx.doi.org/10.1056/NEJMp1401833			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AH4TG	24645847				2023-01-03	WOS:000336120500002
J	Shaw, JE				Shaw, Jane E.			Alejandro Zaffaroni (1923-2014) OBITUARY	NATURE			English	Biographical-Item												janeeshaw@comcast.net						ZAFFARONI A, PUBLICATION LIST	1	1	1	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 10	2014	508	7495					187	187		10.1038/508187a	http://dx.doi.org/10.1038/508187a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE4UK	24717508	Bronze			2023-01-03	WOS:000333979900029
J	Muller, PA; Dhamne, SC; Vahabzadeh-Hagh, AM; Pascual-Leone, A; Jensen, FE; Rotenberg, A				Muller, Paul A.; Dhamne, Sameer C.; Vahabzadeh-Hagh, Andrew M.; Pascual-Leone, Alvaro; Jensen, Frances E.; Rotenberg, Alexander			Suppression of Motor Cortical Excitability in Anesthetized Rats by Low Frequency Repetitive Transcranial Magnetic Stimulation	PLOS ONE			English	Article							LONG-TERM DEPRESSION; VALERIC ACID APV; CORTICOSPINAL EXCITABILITY; CORTEX EXCITABILITY; STATUS EPILEPTICUS; NMDA RECEPTORS; ELECTRIC-FIELD; MODULATION; INHIBITION; RTMS	Repetitive transcranial magnetic stimulation (rTMS) is a widely-used method for modulating cortical excitability in humans, by mechanisms thought to involve use-dependent synaptic plasticity. For example, when low frequency rTMS (LF rTMS) is applied over the motor cortex, in humans, it predictably leads to a suppression of the motor evoked potential (MEP), presumably reflecting long-term depression (LTD) - like mechanisms. Yet how closely such rTMS effects actually match LTD is unknown. We therefore sought to (1) reproduce cortico-spinal depression by LF rTMS in rats, (2) establish a reliable animal model for rTMS effects that may enable mechanistic studies, and (3) test whether LTD-like properties are evident in the rat LF rTMS setup. Lateralized MEPs were obtained from anesthetized Long-Evans rats. To test frequency-dependence of LF rTMS, rats underwent rTMS at one of three frequencies, 0.25, 0.5, or 1 Hz. We next tested the dependence of rTMS effects on N-methyl-D-aspartate glutamate receptor (NMDAR), by application of two NMDAR antagonists. We find that 1 Hz rTMS preferentially depresses unilateral MEP in rats, and that this LTD-like effect is blocked by NMDAR antagonists. These are the first electrophysiological data showing depression of cortical excitability following LF rTMS in rats, and the first to demonstrate dependence of this form of cortical plasticity on the NMDAR. We also note that our report is the first to show that the capacity for LTD-type cortical suppression by rTMS is present under barbiturate anesthesia, suggesting that future neuromodulatory rTMS applications under anesthesia may be considered.	[Muller, Paul A.; Dhamne, Sameer C.; Vahabzadeh-Hagh, Andrew M.; Rotenberg, Alexander] Harvard Univ, Sch Med, Dept Neurol, Boston Childrens Hosp, Boston, MA 02115 USA; [Vahabzadeh-Hagh, Andrew M.; Pascual-Leone, Alvaro; Rotenberg, Alexander] Harvard Univ, Sch Med, Berenson Allen Ctr Noninvas Brain Stimulat, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; [Pascual-Leone, Alvaro] Univ Autonoma Barcelona, Inst Univ Neurorehabilitacio Guttmann, Badalona, Spain; [Jensen, Frances E.] Univ Penn Hlth Syst, Perelman Sch Med, Dept Neurol, Philadelphia, PA USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Autonomous University of Barcelona; University of Pennsylvania; Pennsylvania Medicine	Rotenberg, A (corresponding author), Harvard Univ, Sch Med, Dept Neurol, Boston Childrens Hosp, Boston, MA 02115 USA.	alexander.rotenberg@childrens.harvard.edu	Pascual-Leone, Alvaro/AAC-5101-2019	Pascual-Leone, Alvaro/0000-0001-8975-0382; Muller, Paul/0000-0002-1957-4763	Boston Children's Hospital Translational Research Program; NIH [K08 NS055895, 5R01NS031718]; IDDRC [P30-HD18655]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS055895, R01NS031718] Funding Source: NIH RePORTER	Boston Children's Hospital Translational Research Program; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); IDDRC; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by the Boston Children's Hospital Translational Research Program (AR), NIH K08 NS055895 (AR), NIH 5R01NS031718 (FEJ), IDDRC P30-HD18655 (AR, FEJ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aydin-Abidin S, 2008, EXP BRAIN RES, V188, P249, DOI 10.1007/s00221-008-1356-2; Benali A, 2011, J NEUROSCI, V31, P1193, DOI 10.1523/JNEUROSCI.1379-10.2011; Bouras R, 2003, HIPPOCAMPUS, V13, P780, DOI 10.1002/hipo.10124; Brasil-Neto JP, 2004, ARQ NEURO-PSIQUIAT, V62, P21, DOI 10.1590/S0004-282X2004000100004; Chen R, 1997, NEUROLOGY, V48, P1398, DOI 10.1212/WNL.48.5.1398; Cincotta M, 2003, CLIN NEUROPHYSIOL, V114, P1827, DOI 10.1016/S1388-2457(03)00181-0; de Olmos S, 2009, NEUROSCIENCE, V164, P1347, DOI 10.1016/j.neuroscience.2009.09.022; Dragasevic N, 2002, MOVEMENT DISORD, V17, P528, DOI 10.1002/mds.10109; Esser SK, 2006, BRAIN RES BULL, V69, P86, DOI 10.1016/j.brainresbull.2005.11.003; Fitzgerald PB, 2006, CLIN NEUROPHYSIOL, V117, P2584, DOI 10.1016/j.clinph.2006.06.712; Fitzgerald PB, 2005, NEUROREPORT, V16, P1525, DOI 10.1097/01.wnr.0000177005.14108.f1; Fregni Felipe, 2005, Curr Psychiatry Rep, V7, P381, DOI 10.1007/s11920-005-0041-4; Funke K, 2011, J PHYSIOL-LONDON, V589, P4423, DOI 10.1113/jphysiol.2011.206573; Gersner R, 2011, J NEUROSCI, V31, P7521, DOI 10.1523/JNEUROSCI.6751-10.2011; Ghiglieri V, 2012, EXP NEUROL, V236, P395, DOI 10.1016/j.expneurol.2012.04.020; Guerrini L, 1997, J NEUROSCI, V17, P6057; Hallett M, 2007, NEURON, V55, P187, DOI 10.1016/j.neuron.2007.06.026; Han RZ, 2009, NEUROSCI BULL, V25, P367, DOI 10.1007/s12264-009-0608-x; Hoogendam JM, 2010, BRAIN STIMUL, V3, P95, DOI 10.1016/j.brs.2009.10.005; Kent S, 1996, DEV BRAIN RES, V94, P1, DOI 10.1016/0165-3806(96)00023-5; Khedr EM, 2007, CLIN NEUROPHYSIOL, V118, P140, DOI 10.1016/j.clinph.2006.09.006; Kobayashi M, 2003, LANCET NEUROL, V2, P145, DOI 10.1016/S1474-4422(03)00321-1; Kobayashi M, 2010, RESTOR NEUROL NEUROS, V28, P437, DOI 10.3233/RNN-2010-0562; Kourrich S., 2008, NEURAL PLAST, V2008; Lai MC, 2009, PEDIATR RES, V66, P441, DOI 10.1203/PDR.0b013e3181b337d2; Lee SL, 2008, OTOLARYNG HEAD NECK, V138, P398, DOI 10.1016/j.otohns.2007.11.035; Liu AL, 2013, SEIZURE-EUR J EPILEP, V22, P893, DOI 10.1016/j.seizure.2013.06.014; LOEB C, 1990, EPILEPSY RES, V6, P249, DOI 10.1016/0920-1211(90)90080-F; Loeb C, 1993, Seizure, V2, P309, DOI 10.1016/S1059-1311(05)80146-3; Maeda F, 2000, CLIN NEUROPHYSIOL, V111, P800, DOI 10.1016/S1388-2457(99)00323-5; ManahanVaughan D, 1997, J NEUROSCI, V17, P3303; McGuire M, 2008, J APPL PHYSIOL, V105, P942, DOI 10.1152/japplphysiol.01274.2006; Muellbacher W, 2000, CLIN NEUROPHYSIOL, V111, P1002, DOI 10.1016/S1388-2457(00)00284-4; Muller PA, 2012, BRAIN STIMUL, V5, P320, DOI 10.1016/j.brs.2011.05.003; Nakano M, 2004, EUR J NEUROSCI, V19, P2881, DOI 10.1111/j.0953-816X.2004.03390.x; Padberg F, 2009, EXP NEUROL, V219, P2, DOI 10.1016/j.expneurol.2009.04.020; Patrizi F, 2006, THESCIENTIFICWORLDJO, V6, P472, DOI 10.1100/tsw.2006.98; Peinemann A, 2004, CLIN NEUROPHYSIOL, V115, P1519, DOI 10.1016/j.clinph.2004.02.005; Pell GS, 2011, PROG NEUROBIOL, V93, P59, DOI 10.1016/j.pneurobio.2010.10.003; Rizzo V, 2004, J PHYSIOL-LONDON, V554, P483, DOI 10.1113/jphysiol.2003.048777; Rodriguez-Moreno A, 2008, NAT NEUROSCI, V11, P744, DOI 10.1038/nn.2125; Rogan SC, 2011, PHARMACOL REV, V63, P291, DOI 10.1124/pr.110.003020; Rosen AC, 2009, CURR PAIN HEADACHE R, V13, P12, DOI 10.1007/s11916-009-0004-2; Rotenberg A, 2010, CLIN NEUROPHYSIOL, V121, P104, DOI 10.1016/j.clinph.2009.09.008; Rotenberg A, 2010, BRAIN TOPOGR, V22, P257, DOI 10.1007/s10548-009-0116-3; Rotenberg A, 2009, EPILEPSY BEHAV, V14, P253, DOI 10.1016/j.yebeh.2008.09.007; Rotenberg A, 2008, CLIN NEUROPHYSIOL, V119, P2697, DOI 10.1016/j.clinph.2008.09.003; Siegelbaum S A, 1991, Curr Opin Neurobiol, V1, P113, DOI 10.1016/0959-4388(91)90018-3; Sokhadze EM, 2009, J AUTISM DEV DISORD, V39, P619, DOI 10.1007/s10803-008-0662-7; Stefan K, 2002, J PHYSIOL-LONDON, V543, P699, DOI 10.1113/jphysiol.2002.023317; Sun W, 2012, EPILEPSIA, V53, P1782, DOI 10.1111/j.1528-1167.2012.03626.x; Thordstein M, 2012, EPILEPSY BEHAV, V25, P468, DOI 10.1016/j.yebeh.2012.07.026; Ting JT, 2013, BEHAV BRAIN RES, V255, P3, DOI 10.1016/j.bbr.2013.02.037; TOFTS PS, 1991, ELECTROEN CLIN NEURO, V81, P238, DOI 10.1016/0168-5597(91)90077-B; Tostes JG, 2013, NEUROSCIENCE, V255, P212, DOI 10.1016/j.neuroscience.2013.09.064; Vahabzadeh-Hagh AM, 2012, NEUROMODULATION, V15, P296, DOI 10.1111/j.1525-1403.2012.00482.x; Vahabzadeh-Hagh AM, 2011, J NEUROPHYSIOL, V105, P615, DOI 10.1152/jn.00660.2010; Wang F, 2010, J MOL NEUROSCI, V41, P145, DOI 10.1007/s12031-009-9311-7; Wankerl K, 2010, J NEUROSCI, V30, P6197, DOI 10.1523/JNEUROSCI.4673-09.2010; Watanabe K, 2007, BRAIN RES, V1166, P20, DOI 10.1016/j.brainres.2007.06.049; WHISHAW IQ, 1977, PHYSIOL BEHAV, V19, P719, DOI 10.1016/0031-9384(77)90304-3; Wohrl R, 2007, EUR J NEUROSCI, V25, P251, DOI 10.1111/j.1460-9568.2006.05274.x; Zheng JB, 2005, P ANN INT IEEE EMBS, P1529	63	48	54	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2014	9	3							e91065	10.1371/journal.pone.0091065	http://dx.doi.org/10.1371/journal.pone.0091065			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AD6ER	24646791	Green Published, gold, Green Submitted			2023-01-03	WOS:000333348500021
J	Jiao, SP; Wu, MQ; Ye, F; Tang, HL; Xie, XH; Xie, XM				Jiao, Shiping; Wu, Minqing; Ye, Feng; Tang, Hailin; Xie, Xinhua; Xie, Xiaoming			BikDDA, a Mutant of Bik with Longer Half-Life Expression Protein, Can Be a Novel Therapeutic Gene for Triple-Negative Breast Cancer	PLOS ONE			English	Article							NONINVASIVE IMAGING MODELS; MALIGNANT-TRANSFORMATION; TARGETED EXPRESSION; DRUG-RESISTANCE; POOR-PROGNOSIS; CELL-DEATH; BCL-2; APOPTOSIS; PROMOTES; PATHWAY	Our previous studies showed that BikDD, a constitutively active mutant form of Bik, exhibited powerful antitumor effects in preclinical pancreatic, lung and breast cancer models. Howerver, the antitumor activity of BikDD in triple-negative breast cancer (TNBC) is unknown. Here we show that aberrant expression of p-ERK1/2 was a meaningful molecular phenotype in TNBC patients, and can be an obstacle for treatment because of the converse correlation with Bik. A novel mutant, BikDDA, in which Ser(124) was changed to Alanine to block BikDD phosphorylation by p-ERK1/2 prevented subsequent ubiquitin-proteasome degradation. BikDDA showed a prolonged half-life and enhanced pro-apoptotic ability in TNBC cells compared with BikDD. Moreover, aberrant expression of p-ERK1/2 was associated with 5-fluorouracil resistance in breast cancer patients and BikDDA enhanced the therapeutic effects of 5-fluorouracil in vitro.	[Jiao, Shiping; Wu, Minqing; Ye, Feng; Tang, Hailin; Xie, Xinhua; Xie, Xiaoming] Sun Yat Sen Univ, Ctr Canc, Dept Breast Oncol, Guangzhou 510275, Guangdong, Peoples R China; [Jiao, Shiping; Ye, Feng; Tang, Hailin; Xie, Xinhua; Xie, Xiaoming] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China; [Wu, Minqing] Sun Yat Sen Univ, Ctr Canc, Dept Canc Prevent Ctr, Guangzhou 510275, Guangdong, Peoples R China; [Jiao, Shiping] Sun Yat Sen Univ, Zhongshan Sch Med, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Xie, XM (corresponding author), Sun Yat Sen Univ, Ctr Canc, Dept Breast Oncol, Guangzhou 510275, Guangdong, Peoples R China.	xiexm@sysucc.org.cn		Jiao, Shiping/0000-0001-6546-9369	National Natural Science Foundation of China [81272514, 31100935, 81302318, 31030061]; China Postdoctoral Science Foundation [2012M520075]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by funds from the National Natural Science Foundation of China (81272514, 31100935, 81302318), the Key Programme of the National Natural Science Foundation of China (31030061), and the China Postdoctoral Science Foundation (2012M520075). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albeck JG, 2011, CELL, V144, P638, DOI 10.1016/j.cell.2011.02.030; Bartholomeusz C, 2012, ONCOLOGIST, V17, P766, DOI 10.1634/theoncologist.2011-0377; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Cleator S, 2007, LANCET ONCOL, V8, P235, DOI 10.1016/S1470-2045(07)70074-8; Corkery B, 2009, ANN ONCOL, V20, P862, DOI 10.1093/annonc/mdn710; Ding QQ, 2007, CANCER RES, V67, P4564, DOI 10.1158/0008-5472.CAN-06-1788; Elangovan B, 1997, J BIOL CHEM, V272, P24494, DOI 10.1074/jbc.272.39.24494; Eralp Y, 2008, ANN ONCOL, V19, P669, DOI 10.1093/annonc/mdm522; Ewings KE, 2007, EMBO J, V26, P2856, DOI 10.1038/sj.emboj.7601723; Gao J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065138; Hamilton A, 2000, ANN ONCOL, V11, P647, DOI 10.1023/A:1008390429428; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Lang JY, 2011, CANCER CELL, V20, P341, DOI 10.1016/j.ccr.2011.07.017; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li YM, 2003, CANCER RES, V63, P7630; Lopez J, 2012, CELL DEATH DIFFER, V19, P1459, DOI 10.1038/cdd.2012.21; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001; McCubrey JA, 2006, ADV ENZYME REGUL, V46, P249, DOI 10.1016/j.advenzreg.2006.01.004; Mebratu YA, 2008, J CELL BIOL, V183, P429, DOI 10.1083/jcb.200801186; Sher YP, 2011, MOL CANCER THER, V10, P637, DOI 10.1158/1535-7163.MCT-10-0827; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Wu MQ, 2012, MED ONCOL, V29, P3240, DOI 10.1007/s12032-012-0260-6; Xie XM, 2007, CANCER CELL, V12, P52, DOI 10.1016/j.ccr.2007.05.009; Xie XH, 2012, MOL CANCER THER, V11, P1915, DOI 10.1158/1535-7163.MCT-12-0191; Yoon H, 2011, BIOCHEM BIOPH RES CO, V405, P333, DOI 10.1016/j.bbrc.2010.11.130; Zou YY, 2002, CANCER RES, V62, P8	30	5	5	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 17	2014	9	3							e92172	10.1371/journal.pone.0092172	http://dx.doi.org/10.1371/journal.pone.0092172			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AD4XD	24637719	gold, Green Published, Green Submitted			2023-01-03	WOS:000333254100123
J	Eriksen, KT; Halkjaer, J; Sorensen, M; Meliker, JR; McElroy, JA; Tjonneland, A; Raaschou-Nielsen, O				Eriksen, Kirsten T.; Halkjaer, Jytte; Sorensen, Mette; Meliker, Jaymie R.; McElroy, Jane A.; Tjonneland, Anne; Raaschou-Nielsen, Ole			Dietary Cadmium Intake and Risk of Breast, Endometrial and Ovarian Cancer in Danish Postmenopausal Women: A Prospective Cohort Study	PLOS ONE			English	Article							EXPOSURE; ESTROGEN; ACTIVATION; HEALTH; ALPHA; CELL	Purpose: Cadmium is a human lung carcinogen and possesses estrogen-like activity. This combination of carcinogenic and estrogenic activity makes cadmium a contaminant of high concern for hormone-related cancers. Diet and smoking are the main sources of cadmium exposure. The aim of this study was to investigate the association between dietary cadmium intake and risk of breast, endometrial and ovarian cancer in Danish postmenopausal woman. Methods: We estimated dietary cadmium intake in the Diet, Cancer and Health cohort at enrolment 1993-97. The estimates were based on food frequency questionnaires and cadmium contents in all foods. Among 23,815 postmenopausal women we identified 1390 breast, 192 endometrial, and 146 ovarian cancer cases from enrolment through December 31, 2010 using the Danish Cancer Registry. Cox regression was used to analyse the association between dietary cadmium intake and cancer risk. Results: Mean dietary cadmium intake was 14 mu g/day. Cadmium was not associated with breast cancer, incidence rate ratio (IRR) = 0.99, 95% confidence interval (CI): 0.87-1.13 per 10 mu g higher dietary cadmium intake/day; endometrial cancer, IRR = 1.08, 95% CI: 0.76-1.53; or ovarian cancer, IRR = 1.15, 95% CI: 0.78-1.70. We found a positive association between cadmium and endometrial cancer for the women with BMI<25 (IRR = 1.50, 95% CI: 0.94-2.39), whereas an inverse association was seen for the women with BMI >= 25 (IRR = 0.69, 95% CI: 0.42-1.12); p value for interaction = 0.02. Conclusions: Our study does not indicate that our estimated dietary cadmium intake is associated with hormone-related cancers in women.	[Eriksen, Kirsten T.; Halkjaer, Jytte; Sorensen, Mette; Tjonneland, Anne; Raaschou-Nielsen, Ole] Danish Canc Soc, Res Ctr, Copenhagen, Denmark; [Meliker, Jaymie R.] SUNY Stony Brook, Dept Prevent Med, Stony Brook, NY 11794 USA; [Meliker, Jaymie R.] SUNY Stony Brook, Grad Program Publ Hlth, Stony Brook, NY 11794 USA; [McElroy, Jane A.] Univ Missouri, Columbia, MT USA	Danish Cancer Society; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Missouri System; University of Missouri Columbia	Eriksen, KT (corresponding author), Danish Canc Soc, Res Ctr, Copenhagen, Denmark.	kirsthor@cancer.dk	Raaschou-Nielsen, Ole/GOK-0338-2022	Raaschou-Nielsen, Ole/0000-0002-1223-0909; McElroy, Jane/0000-0001-7518-747X; Tjonneland, Anne/0000-0003-4385-2097; Meliker, Jaymie/0000-0002-6408-8596; Sorensen, Mette/0000-0002-7302-4789	National Institutes of Health (NIH) [R01ES019209]; Danish Cancer Society [R20A93010S2]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES019209] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Danish Cancer Society(Danish Cancer Society); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by research grants from the National Institutes of Health (NIH) (grant no.: R01ES019209) and from the Danish Cancer Society (grant no: R20A93010S2). The funders had no role in the design of the study, data collection, interpretation of results, or writing of the manuscript.	Abshire MK, 1996, J TOXICOL ENV HEALTH, V48, P359, DOI 10.1080/009841096161258; Adams SV, 2012, CANCER CAUSE CONTROL, V23, P845, DOI 10.1007/s10552-012-9953-6; Akesson A, 2008, CANCER RES, V68, P6435, DOI 10.1158/0008-5472.CAN-08-0329; Althuis MD, 2004, CANCER EPIDEM BIOMAR, V13, P1558; Barlow WE, 1999, J CLIN EPIDEMIOL, V52, P1165, DOI 10.1016/S0895-4356(99)00102-X; BARON JA, 1990, AM J OBSTET GYNECOL, V162, P502, DOI 10.1016/0002-9378(90)90420-C; Brama M, 2007, MOL CELL ENDOCRINOL, V264, P102, DOI 10.1016/j.mce.2006.10.013; Coyle YM, 2004, BREAST CANCER RES TR, V84, P273, DOI 10.1023/B:BREA.0000019964.33963.09; FISCHERMAN K, 1988, ACTA ONCOL, V27, P593, DOI 10.3109/02841868809091756; FLANAGAN PR, 1978, GASTROENTEROLOGY, V74, P841; Gallagher CM, 2010, AGING-US, V2, P804, DOI 10.18632/aging.100226; GARCIAMORALES P, 1994, J BIOL CHEM, V269, P16896; International Agency for Research on Cancer, IARC MONOGRAPHS EVAL; Itoh H, 2014, INT J HYG ENVIR HEAL, V217, P70, DOI 10.1016/j.ijheh.2013.03.010; Jarup L, 2009, TOXICOL APPL PHARM, V238, P201, DOI 10.1016/j.taap.2009.04.020; Jarup Lars, 1998, Scandinavian Journal of Work Environment and Health, V24, P1; Johnson MD, 2003, NAT MED, V9, P1081, DOI 10.1038/nm902; Joseph P, 2009, TOXICOL APPL PHARM, V238, P272, DOI 10.1016/j.taap.2009.01.011; Julin B, 2011, BRIT J CANCER, V105, P441, DOI 10.1038/bjc.2011.238; Julin B, 2012, CANCER RES, V72, P1459, DOI 10.1158/0008-5472.CAN-11-0735; KAJI T, 1992, TOXICOLOGY, V76, P257, DOI 10.1016/0300-483X(92)90194-J; Larsen EH, 2002, FOOD ADDIT CONTAM, V19, P33, DOI 10.1080/02652030110087447; Lauritsen J., 1998, FOODCALC 1 3; Liu ZW, 2008, TOXICOL APPL PHARM, V228, P286, DOI 10.1016/j.taap.2007.12.017; MADIGAN MP, 1995, J NATL CANCER I, V87, P1681, DOI 10.1093/jnci/87.22.1681; Martinez-Campa C, 2006, J PINEAL RES, V40, P291, DOI 10.1111/j.1600-079X.2006.00315.x; McElroy JA, 2006, JNCI-J NATL CANCER I, V98, P869, DOI 10.1093/jnci/djj233; Sartor F, 1992, IARC Sci Publ, P101; Sawada N, 2012, EPIDEMIOLOGY, V23, P368, DOI 10.1097/EDE.0b013e31824d063c; Schottenfeld D, 2006, CANC EPIDEMIOLOGY PR; Stoica A, 2000, MOL ENDOCRINOL, V14, P545, DOI 10.1210/me.14.4.545; Strumylaite L, 2010, MEDICINA-LITHUANIA, V46, P867, DOI 10.3390/medicina46120121; Tjonneland A, 2007, SCAND J PUBLIC HEALT, V35, P432, DOI 10.1080/14034940601047986; van Wijngaarden E, 2008, PROSTATE, V68, P122, DOI 10.1002/pros.20668; Waalkes MP, 2003, MUTAT RES-FUND MOL M, V533, P107, DOI 10.1016/j.mrfmmm.2003.07.011; Wilson VS, 2004, TOXICOL SCI, V81, P69, DOI 10.1093/toxsci/kfh180; Yu XY, 2010, TOXICOL APPL PHARM, V245, P83, DOI 10.1016/j.taap.2010.02.005	37	43	45	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2014	9	6							e100815	10.1371/journal.pone.0100815	http://dx.doi.org/10.1371/journal.pone.0100815			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK8WO	24963789	gold, Green Published, Green Submitted			2023-01-03	WOS:000338709500084
J	Jin, J; Hu, C; Yu, MX; Chen, FF; Ye, L; Yin, XF; Zhuang, ZP; Tong, HY				Jin, Jie; Hu, Chao; Yu, Mengxia; Chen, Feifei; Ye, Li; Yin, Xiufeng; Zhuang, Zhengping; Tong, Hongyan			Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis	PLOS ONE			English	Article							ACUTE MYELOID-LEUKEMIA; WORLD-HEALTH-ORGANIZATION; SCORING SYSTEM; IDH2 MUTATIONS; CLASSIFICATION; GENES; TET2; 2-HYDROXYGLUTARATE; PATHOGENESIS; CANCER	Background: Recent genomic sequencing efforts have identified a number of recurrent mutations in myelodysplastic syndromes (MDS) that may contribute to disease progression and overall survival, including mutations in isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2). Methods: Pretreatment bone marrow (BM) samples were acquired from mononuclear cells in 146 adult patients with de novo MDS from January 2006 to June 2013. Polymerase chain reaction (PCR) and direct sequencing were performed on exon 4 of IDH1/2 genes and mutation status was correlated with overall survival (OS) and leukemia-free survival (LFS). We then performed a meta-analysis combining previously published and current studies to explore the effect of IDH mutations on OS and LFS in MDS. Results: In our study, somatic mutations of either IDH gene were discovered in 11 MDS patients (7.53%) and were significantly correlated with poorer OS (P = 0.007). IDH mutations were specifically associated with a poorer OS in the intermediate-1 risk group by the International Prognostic Scoring System (IPSS) (P = 0.039). In addition, we discovered decitabine achieved a better therapeutic effect compared to other treatments in IDH mutation-positive patients (P = 0.023). We identified six previous studies of IDH mutations in MDS. A meta-analysis of these studies included 111 MDS patients IDH mutations and 1671 MDS patients with wild-type IDH1/2. The hazard ratios (HRs) of OS and LFS for patients with IDH mutations were 1.62 (95% CI, 1.27-2.09) and 2.21 (95% CI, 1.48-3.30), respectively. Conclusion: The results from our study and the meta-analysis provide firm evidence that IDH mutations are significantly associated with poorer clinical outcomes in MDS. Identification of IDH mutations may be pivotal for better risk stratification in MDS patients and improving IPSS score. Additionally, hypomethylating agents may be an effective treatment option for MDS patients with IDH mutations.	[Jin, Jie; Hu, Chao; Yu, Mengxia; Chen, Feifei; Ye, Li; Yin, Xiufeng; Tong, Hongyan] Zhejiang Univ, Dept Hematol, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China; [Jin, Jie; Hu, Chao; Yu, Mengxia; Chen, Feifei; Ye, Li; Yin, Xiufeng; Tong, Hongyan] Zhejiang Univ, Sch Med, Inst Hematol, Hangzhou 310003, Zhejiang, Peoples R China; [Zhuang, Zhengping] NINDS, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA	Zhejiang University; Zhejiang University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Tong, HY (corresponding author), Zhejiang Univ, Dept Hematol, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China.	zjuhongyantong@163.com			Zhejiang Province Fund for Distinguished Young Scholars [LR12H08001]; Foundation of Key Innovation Team of Zhejiang Province [2011R50015]; National Public Health Grand Research Foundation [201202017]; Science Technology Department of Zhejiang Province [2013c03043-2]; National Natural Science Foundation of China [30870914, 81270582]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS003052] Funding Source: NIH RePORTER	Zhejiang Province Fund for Distinguished Young Scholars; Foundation of Key Innovation Team of Zhejiang Province; National Public Health Grand Research Foundation; Science Technology Department of Zhejiang Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This study was supported by grants from Zhejiang Province Fund for Distinguished Young Scholars (LR12H08001), the Foundation of Key Innovation Team of Zhejiang Province (2011R50015), National Public Health Grand Research Foundation (201202017), major program of Science Technology Department of Zhejiang Province fund (2013c03043-2) and the National Natural Science Foundation of China (No. 30870914, No. 81270582). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbas S, 2010, BLOOD, V116, P2122, DOI 10.1182/blood-2009-11-250878; Abdel-Wahab O, 2012, CANCER CELL, V22, P180, DOI 10.1016/j.ccr.2012.06.032; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Bejar R, 2011, NEW ENGL J MED, V364, P2496, DOI 10.1056/NEJMoa1013343; Bejar R, 2011, J CLIN ONCOL, V29, P504, DOI 10.1200/JCO.2010.31.1175; Bennett JM, 2000, INT J HEMATOL, V72, P131; BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb02771.x; Caramazza D, 2010, LEUKEMIA, V24, P2120, DOI 10.1038/leu.2010.213; Chou WC, 2011, LEUKEMIA, V25, P246, DOI 10.1038/leu.2010.267; Chou WC, 2010, BLOOD, V115, P2749, DOI 10.1182/blood-2009-11-253070; Chung YR, 2012, INT J HEMATOL, V96, P413, DOI 10.1007/s12185-012-1181-z; Corey SJ, 2007, NAT REV CANCER, V7, P118, DOI 10.1038/nrc2047; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; DiNardo CD, 2013, BLOOD, V121, P4917, DOI 10.1182/blood-2013-03-493197; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fathi AT, 2012, BLOOD, V120, P4649, DOI 10.1182/blood-2012-06-438267; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Garcia-Manero G, 2008, LEUKEMIA, V22, P538, DOI 10.1038/sj.leu.2405070; Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079; Greenberg PL, 2012, BLOOD, V120, P2454, DOI 10.1182/blood-2012-03-420489; Grimes DA, 2002, LANCET, V359, P341, DOI 10.1016/S0140-6736(02)07500-1; Head DR, 2011, BONE MARROW RES, DOI 10.1155/2011/950934; Jin GL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016812; Kaelin WG, 2011, COLD SH Q B, V76, P335, DOI 10.1101/sqb.2011.76.010975; Khan H, 2013, SEMIN HEMATOL, V50, P16, DOI 10.1053/j.seminhematol.2013.01.001; Kosmider O, 2010, LEUKEMIA, V24, P1094, DOI 10.1038/leu.2010.52; Krell D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019868; Lin CC, 2013, AM J HEMATOL; Lin J, 2012, ANN HEMATOL, V91, P519, DOI 10.1007/s00277-011-1352-7; Lin TL, 2013, HAEMATOLOGICA; Malcovati L, 2007, J CLIN ONCOL, V25, P3503, DOI 10.1200/JCO.2006.08.5696; Muto T, 2013, J EXP MED, V210, P2627, DOI 10.1084/jem.20131144; Nimer SD, 2008, BLOOD, V111, P4841, DOI 10.1182/blood-2007-08-078139; Pardanani A, 2010, LEUKEMIA, V24, P1146, DOI 10.1038/leu.2010.77; Patnaik MM, 2012, LEUKEMIA, V26, P101, DOI 10.1038/leu.2011.298; Reitman ZJ, 2010, JNCI-J NATL CANCER I, V102, P932, DOI 10.1093/jnci/djq187; Rocquain J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-401; Shih AH, 2011, SEMIN ONCOL, V38, P613, DOI 10.1053/j.seminoncol.2011.04.013; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Steensma DP, 2006, LEUKEMIA RES, V30, P1227, DOI 10.1016/j.leukres.2005.12.001; Tefferi A, 2012, LEUKEMIA, V26, P475, DOI 10.1038/leu.2011.253; Thol F, 2010, HAEMATOL-HEMATOL J, V95, P1668, DOI 10.3324/haematol.2010.025494; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; Tong HY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067537; Tong HY, 2012, LEUKEMIA LYMPHOMA, V53, P2412, DOI 10.3109/10428194.2012.696637; Tothova Z, 2013, CLIN CANCER RES, V19, P1637, DOI 10.1158/1078-0432.CCR-12-1251; Vardiman JW, 2002, BLOOD, V100, P2292, DOI 10.1182/blood-2002-04-1199; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Yoshida K, 2011, LEUKEMIA, V25, P184, DOI 10.1038/leu.2010.241; Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944	50	73	76	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2014	9	6							e100206	10.1371/journal.pone.0100206	http://dx.doi.org/10.1371/journal.pone.0100206			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK5YM	24936872	Green Published, gold, Green Submitted			2023-01-03	WOS:000338503400092
J	Fu, Y; Qiao, LP; Cao, YM; Zhou, XZ; Liu, Y; Ye, XQ				Fu, Yu; Qiao, Liping; Cao, Yuming; Zhou, Xiaozhou; Liu, Yu; Ye, Xingqian			Structural Elucidation and Antioxidant Activities of Proanthocyanidins from Chinese Bayberry (Myrica rubra Sieb. et Zucc.) Leaves	PLOS ONE			English	Article							TANDEM MASS-SPECTROMETRY; PHENOLIC-COMPOUNDS; PEANUT SKINS; IDENTIFICATION; CHROMATOGRAPHY; PROCYANIDINS; OLIGOMERS; POLYMERIZATION; FLAVONOIDS; PLASMA	Proanthocyanidins in Chinese bayberry leaves (PCBLs) were qualitatively analyzed. NMR data suggest that PCBLs are mostly composed of (epi) gallocatechin gallate units. Matrix-assisted laser desorption time-of-flight MS data indicate 95 possible prodelphinidin structures, ranging from dimers to tridecamers. Preparative normal-phase HPLC and further analysis by reverse-phase HPLC together with electrospray ionization MS enabled detection of 20 compounds, including seven newly identified compounds in Chinese bayberry leaves. The antioxidant capacity of PCBLs was evaluated by (1,1-diphenyl-2-picryl-hydrazyl), ferric-reducing antioxidant power, and oxygen radical absorption capacity assays. The EC50 of DPPH radical scavenging activities (as 50% decrease in the initial DPPH concentration) were 7.60 mu g. The FRAP and ORAC values were 8859.336 +/- 978.39 and 12991.61 +/- 1553.34 mu mol Trolox equivalents per gram, respectively. The results indicate the high antioxidant potency of PCBLs.	[Fu, Yu; Qiao, Liping; Cao, Yuming; Zhou, Xiaozhou; Ye, Xingqian] Zhejiang Univ, Zhejiang R&D Ctr Food Technol & Equipment, Zhejiang Key Lab Agrofood Proc,Fuli Inst Food Sci, Dept Food Sci & Nutr,Coll Biosyst Engn & Food Sci, Hangzhou 310003, Zhejiang, Peoples R China; [Liu, Yu] Zhejiang Univ, Coll Life Sci, Hangzhou 310003, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University	Ye, XQ (corresponding author), Zhejiang Univ, Zhejiang R&D Ctr Food Technol & Equipment, Zhejiang Key Lab Agrofood Proc,Fuli Inst Food Sci, Dept Food Sci & Nutr,Coll Biosyst Engn & Food Sci, Hangzhou 310003, Zhejiang, Peoples R China.	psu@zju.edu.cn			Chinese National Key Technologies R&D Program of 12th Five-year Plan [2012BAD31B06]; Province Key Science and Technology Innovation Team Project [2010R50032, 2012T2T123]	Chinese National Key Technologies R&D Program of 12th Five-year Plan; Province Key Science and Technology Innovation Team Project	This project was supported by the Chinese National Key Technologies R&D Program of 12th Five-year Plan (2012BAD31B06) and the Province Key Science and Technology Innovation Team Project (2010R50032, 2012T2T123). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arora A, 1998, FREE RADICAL BIO MED, V24, P1355, DOI 10.1016/S0891-5849(97)00458-9; Bao JS, 2005, J AGR FOOD CHEM, V53, P2327, DOI 10.1021/jf048312z; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; Cespedes CL, 2010, FOOD CHEM, V119, P886, DOI 10.1016/j.foodchem.2009.07.045; Chen KunSong, 2004, Horticultural Reviews, V30, P83, DOI 10.1002/9780470650837.ch3; CZOCHANSKA Z, 1980, J CHEM SOC PERK T 1, P2278, DOI 10.1039/p19800002278; Davis AL, 1996, MAGN RESON CHEM, V34, P887, DOI 10.1002/(SICI)1097-458X(199611)34:11<887::AID-OMR995>3.0.CO;2-U; Dinelli G, 2011, J CHROMATOGR A, V1218, P7670, DOI 10.1016/j.chroma.2011.05.065; Feghali K, 2012, J AGR FOOD CHEM, V60, P5728, DOI 10.1021/jf203304v; Fu C, 2007, J AGR FOOD CHEM, V55, P7689, DOI 10.1021/jf071166n; Gu HF, 2008, FOOD RES INT, V41, P208, DOI 10.1016/j.foodres.2007.11.011; Gu LW, 2003, J MASS SPECTROM, V38, P1272, DOI 10.1002/jms.541; Hammerstone JF, 1999, J AGR FOOD CHEM, V47, P490, DOI 10.1021/jf980760h; Hellstrom J, 2007, J AGR FOOD CHEM, V55, P157, DOI 10.1021/jf062441t; Jaiswal R, 2012, J MASS SPECTROM, V47, P502, DOI 10.1002/jms.2954; Karioti A, 2011, J AGR FOOD CHEM, V59, P6412, DOI 10.1021/jf2011535; Khanal RC, 2009, J FOOD SCI, V74, pH52, DOI 10.1111/j.1750-3841.2009.01063.x; Kim KK, 2012, INT J ONCOL, V40, P227, DOI 10.3892/ijo.2011.1198; Kimura H, 2011, J CHROMATOGR A, V1218, P7704, DOI 10.1016/j.chroma.2011.07.024; Koga K, 2013, J FOOD SCI, V78, pH105, DOI 10.1111/1750-3841.12001; Li CM, 2010, J AGR FOOD CHEM, V58, P9033, DOI 10.1021/jf102552b; Li HJ, 2007, ANAL CHEM, V79, P1739, DOI 10.1021/ac061823v; Liu YX, 2010, MOLECULES, V15, P7763, DOI 10.3390/molecules15117763; Masuda T, 2010, BIOSCI BIOTECH BIOCH, V74, P212, DOI 10.1271/bbb.90697; Monagas M, 2007, J AGR FOOD CHEM, V55, P8498, DOI 10.1021/jf071780z; Monagas M, 2009, J AGR FOOD CHEM, V57, P10590, DOI 10.1021/jf901391a; Monagas M, 2010, J PHARMACEUT BIOMED, V51, P358, DOI 10.1016/j.jpba.2009.03.035; Prior RL, 2005, PHYTOCHEMISTRY, V66, P2264, DOI 10.1016/j.phytochem.2005.03.025; Prior RL, 2003, J AGR FOOD CHEM, V51, P3273, DOI 10.1021/jf0262256; Gonzalez-Centeno MR, 2012, J AGR FOOD CHEM, V60, P11850, DOI 10.1021/jf303047k; Rosales-Castro M, 2012, HOLZFORSCHUNG, V66, P577, DOI 10.1515/hf-2011-0157; Ruiz-Valdiviezo VM, 2009, GAYANA BOT, V66, P206; Sarnoski PJ, 2012, J FOOD SCI, V77, pM242, DOI 10.1111/j.1750-3841.2012.02652.x; Sarnoski PJ, 2012, FOOD CHEM, V131, P927, DOI 10.1016/j.foodchem.2011.09.081; SEIFTER S, 1950, ARCH BIOCHEM, V25, P191; Shoji T, 2006, J CHROMATOGR A, V1102, P206, DOI 10.1016/j.chroma.2005.10.065; Song XY, 2010, MOL CARCINOGEN, V49, P450, DOI 10.1002/mc.20616; Spranger I, 2008, FOOD CHEM, V108, P519, DOI 10.1016/j.foodchem.2007.11.004; Sun BS, 1998, J AGR FOOD CHEM, V46, P4267, DOI 10.1021/jf980366j; Sun WX, 2003, J MASS SPECTROM, V38, P438, DOI 10.1002/jms.456; Tatsuno T, 2012, BIOL PHARM BULL, V35, P909, DOI 10.1248/bpb.35.909; Tong Y, 2009, ARCH PHARM RES, V32, P527, DOI 10.1007/s12272-009-1408-6; Valls J, 2009, J CHROMATOGR A, V1216, P7143, DOI 10.1016/j.chroma.2009.07.030; Wang SJ, 2010, PLANTA MED, V76, P1492, DOI 10.1055/s-0030-1249780; Yang HH, 2011, FOOD CHEM, V128, P1128, DOI 10.1016/j.foodchem.2011.03.118; Yang HH, 2011, J AGR FOOD CHEM, V59, P1622, DOI 10.1021/jf103918v; Yao WR, 2011, J AGR FOOD CHEM, V59, P5312, DOI 10.1021/jf200211m; Yokozawa T., 2012, EVIDENCE BASED COMPL; Zhang SM, 2009, HORTSCIENCE, V44, P487, DOI 10.21273/HORTSCI.44.2.487	49	39	44	4	67	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2014	9	5							e96162	10.1371/journal.pone.0096162	http://dx.doi.org/10.1371/journal.pone.0096162			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG9HB	24805126	Green Submitted, Green Published, gold			2023-01-03	WOS:000335728900037
J	Rawlins, MD				Rawlins, Michael D.			MEDICAL LEGISLATION The "Saatchi bill" will allow responsible innovation in treatment	BMJ-BRITISH MEDICAL JOURNAL			English	News Item									Royal Soc Med, London W1G 0AE, England		Rawlins, MD (corresponding author), Royal Soc Med, London W1G 0AE, England.	m.d.rawlins@ncl.ac.uk						Department of Health, 1959, LEG ENC MED INN; Fialova J, 2014, DERMATOL THER, V27, P105, DOI 10.1111/dth.12065	2	9	10	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 15	2014	348								g2771	10.1136/bmj.g2771	http://dx.doi.org/10.1136/bmj.g2771			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AF5GN	24735990				2023-01-03	WOS:000334742100018
J	O'Shea, JJ; Kanno, Y; Chan, AC				O'Shea, John J.; Kanno, Yuka; Chan, Andrew C.			In Search of Magic Bullets: The Golden Age of Immunotherapeutics	CELL			English	Review							B-CELL DEPLETION; SYSTEMIC-LUPUS-ERYTHEMATOSUS; MONOCLONAL-ANTIBODY THERAPY; JANUS KINASE INHIBITOR; TUMOR-NECROSIS-FACTOR; TARGETING BTK; AUTOIMMUNE; TNF; EFFICACY; SAFETY	Once upon a time, immunology was a black box, inflammatory and autoimmune diseases were a mystery, and relatively blunt tools were used to treat these diseases. In the last 40 years, advances in molecular biology, DNA recombination technology, and genome sequencing allowed immunologists to open the box. As the complexity and diversity of the immune response are unveiled, targeted cellular and molecular therapies now offer rational approaches to treat immune-mediated diseases. Here, we discuss how the tried and true bench-to-bedside strategies resulted in some spectacular successes, along with some puzzling failures. Conversely, the advent of targeted therapies in the clinic has led to a wealth of information that changes how we think about the pathogenesis of immune-mediated diseases and how we categorize disease. In turn, these insights can inform next-generation drug discovery and refine targeted therapies for the appropriate patient subsets.	[O'Shea, John J.; Kanno, Yuka] NIAMSD, Mol Immunol & Inflammat Branch, NIH, Bethesda, MD 20892 USA; [Chan, Andrew C.] Genentech Inc, San Francisco, CA 94080 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Roche Holding; Genentech	O'Shea, JJ (corresponding author), NIAMSD, Mol Immunol & Inflammat Branch, NIH, 10 Ctr Dr, Bethesda, MD 20892 USA.	osheajo@mail.nih.gov; acc@gene.com	Kanno, Yuka/B-5802-2013	Kanno, Yuka/0000-0001-5668-9319	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041159, ZIAAR041106] Funding Source: NIH RePORTER; Intramural NIH HHS [ZIA AR041106-19] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Aggarwal BB, 2012, BLOOD, V119, P651, DOI 10.1182/blood-2011-04-325225; Angulo I, 2013, SCIENCE, V342, P866, DOI 10.1126/science.1243292; [Anonymous], 1999, Neurology, V53, P457; Arnett HA, 2001, NAT NEUROSCI, V4, P1116, DOI 10.1038/nn738; Arron JR, 2013, ADV PHARMACOL, V66, P1, DOI 10.1016/B978-0-12-404717-4.00001-9; Bandala-Sanchez E, 2013, NAT IMMUNOL, V14, P741, DOI 10.1038/ni.2610; Banham-Hall Edward, 2012, Open Rheumatol J, V6, P245, DOI 10.2174/1874312901206010245; Barr TA, 2012, J EXP MED, V209, P1001, DOI 10.1084/jem.20111675; Belkina AC, 2013, J IMMUNOL, V190, P3670, DOI 10.4049/jimmunol.1202838; Bielekova B, 2013, NEUROTHERAPEUTICS, V10, P55, DOI 10.1007/s13311-012-0147-4; Boyman O, 2012, NAT REV IMMUNOL, V12, P180, DOI 10.1038/nri3156; Byrd JC, 2013, NEW ENGL J MED, V369, P32, DOI 10.1056/NEJMoa1215637; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.immunol.12.1.555; Changelian PS, 2003, SCIENCE, V302, P875, DOI 10.1126/science.1087061; Daien CI, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/386148; de Weerd NA, 2013, NAT IMMUNOL, V14, P901, DOI 10.1038/ni.2667; Dennis G, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4555; Derer S, 2013, GUT, V62, P376, DOI 10.1136/gutjnl-2011-300384; Dhib-Jalbut S, 2010, NEUROLOGY, V74, pS17, DOI 10.1212/WNL.0b013e3181c97d99; Dinarello CA, 2010, CELL, V140, P935, DOI 10.1016/j.cell.2010.02.043; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Federici S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00351; Feldmann M, 2002, NAT REV IMMUNOL, V2, P364, DOI 10.1038/nri802; Gabay C, 2010, NAT REV RHEUMATOL, V6, P232, DOI 10.1038/nrrheum.2010.4; Ge DL, 2009, NATURE, V461, P399, DOI 10.1038/nature08309; Genovese MC, 2009, ARTHRITIS RHEUM, V60, P317, DOI 10.1002/art.24264; Goldbach-Mansky R, 2009, J ALLERGY CLIN IMMUN, V124, P1141, DOI 10.1016/j.jaci.2009.11.016; Gran B, 2004, J NEUROIMMUNOL, V156, P123, DOI 10.1016/j.jneuroim.2004.07.019; Hauser SL, 2008, NEW ENGL J MED, V358, P676, DOI 10.1056/NEJMoa0706383; Huh JR, 2011, NATURE, V472, P486, DOI 10.1038/nature09978; Ingram JL, 2012, J ALLERGY CLIN IMMUN, V130, P829, DOI 10.1016/j.jaci.2012.06.034; Isaacs JD, 1997, CLIN EXP IMMUNOL, V110, P158; Jacobi AM, 2010, CURR OPIN PHARMACOL, V10, P316, DOI 10.1016/j.coph.2010.02.002; Keating GM, 2013, DRUGS, V73, P1095, DOI 10.1007/s40265-013-0080-9; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Levin AM, 2012, NATURE, V484, P529, DOI 10.1038/nature10975; Lichtman EI, 2012, CLIN IMMUNOL, V143, P210, DOI 10.1016/j.clim.2012.03.005; Malek TR, 2010, IMMUNITY, V33, P153, DOI 10.1016/j.immuni.2010.08.004; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Martin R, 2012, CLIN IMMUNOL, V142, P9, DOI 10.1016/j.clim.2011.10.008; Mauri C, 2012, ANNU REV IMMUNOL, V30, P221, DOI 10.1146/annurev-immunol-020711-074934; Meffre E, 2011, ANN NY ACAD SCI, V1246, P1, DOI 10.1111/j.1749-6632.2011.06347.x; Mele DA, 2013, J EXP MED, V210, P2181, DOI 10.1084/jem.20130376; Merrill JT, 2010, ARTHRITIS RHEUM-US, V62, P222, DOI 10.1002/art.27233; Miossec P, 2012, NAT REV DRUG DISCOV, V11, P763, DOI 10.1038/nrd3794; Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589; Nielsen OH, 2013, NEW ENGL J MED, V369, P754, DOI 10.1056/NEJMct1209614; Nishimoto N, 2006, NAT CLIN PRACT RHEUM, V2, P619, DOI 10.1038/ncprheum0338; O'Shea JJ, 2013, NAT REV RHEUMATOL, V9, P173, DOI 10.1038/nrrheum.2013.7; OPPENHEIM JJ, 1993, IMMUNOL TODAY, V14, P232, DOI 10.1016/0167-5699(93)90169-L; Palucka AK, 2005, P NATL ACAD SCI USA, V102, P3372, DOI 10.1073/pnas.0408506102; Patton DT, 2006, J IMMUNOL, V177, P6598, DOI 10.4049/jimmunol.177.10.6598; Pestka S, 2007, J BIOL CHEM, V282, P20047, DOI 10.1074/jbc.R700004200; Pillai S, 2011, CURR OPIN IMMUNOL, V23, P721, DOI 10.1016/j.coi.2011.10.007; Roll P, 2006, ARTHRITIS RHEUM-US, V54, P2377, DOI 10.1002/art.22019; Rommel C, 2007, NAT REV IMMUNOL, V7, P191, DOI 10.1038/nri2036; Rovin BH, 2012, ARTHRITIS RHEUM-US, V64, P1215, DOI 10.1002/art.34359; Ruuls SR, 2001, IMMUNITY, V15, P533, DOI 10.1016/S1074-7613(01)00215-1; Sadler AJ, 2008, NAT REV IMMUNOL, V8, P559, DOI 10.1038/nri2314; Sandborn WJ, 2012, NEW ENGL J MED, V367, P616, DOI 10.1056/NEJMoa1112168; Schmidt J, 2013, EMERG MICROBES INFEC, V2, DOI 10.1038/emi.2013.14; Stohl W, 2012, ARTHRITIS RHEUM-US, V64, P2328, DOI 10.1002/art.34400; Strober B, 2013, BRIT J DERMATOL, V169, P992, DOI 10.1111/bjd.12517; Tanaka T, 2012, ANNU REV PHARMACOL, V52, P199, DOI 10.1146/annurev-pharmtox-010611-134715; Thakker P, 2007, J IMMUNOL, V178, P2589, DOI 10.4049/jimmunol.178.4.2589; Uno JK, 2010, GASTROENTEROLOGY, V139, P1642, DOI 10.1053/j.gastro.2010.07.008; Urbani S, 2006, J VIROL, V80, P11398, DOI 10.1128/JVI.01177-06; Van Dyken SJ, 2013, ANNU REV IMMUNOL, V31, P317, DOI 10.1146/annurev-immunol-032712-095906; Verstovsek S, 2010, NEW ENGL J MED, V363, P1117, DOI 10.1056/NEJMoa1002028; Vojinovic J, 2011, MOL MED, V17, P397, DOI 10.2119/molmed.2011.00030; Waldmann H, 2005, PHILOS T ROY SOC B, V360, P1707, DOI 10.1098/rstb.2005.1702; Wang ML, 2013, NEW ENGL J MED, V369, P507, DOI 10.1056/NEJMoa1306220; Winkler DG, 2013, CHEM BIOL, V20, P1364, DOI 10.1016/j.chembiol.2013.09.017	74	29	31	1	28	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 27	2014	157	1					227	240		10.1016/j.cell.2014.03.010	http://dx.doi.org/10.1016/j.cell.2014.03.010			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	AE4QW	24679538	Green Accepted, Bronze			2023-01-03	WOS:000333968900019
J	Durairajan, SSK; Huang, YY; Yuen, PY; Chen, LL; Kwok, KY; Liu, LF; Song, JX; Han, QB; Xue, L; Chung, SK; Huang, JD; Baum, L; Senapati, S; Li, M				Durairajan, Siva Sundara Kumar; Huang, Ying-Yu; Yuen, Pui-Yee; Chen, Lei-Lei; Kwok, Ka-Yan; Liu, Liang-Feng; Song, Ju-Xian; Han, Quan-Bin; Xue, Lei; Chung, Sookja K.; Huang, Jian-Dong; Baum, Larry; Senapati, Sanjib; Li, Min			Effects of Huanglian-Jie-Du-Tang and Its Modified Formula on the Modulation of Amyloid-beta Precursor Protein Processing in Alzheimer's Disease Models	PLOS ONE			English	Article							OREN-GEDOKU-TO; SCUTELLARIA-BAICALENSIS GEORGI; TRANSIENT CEREBRAL-ISCHEMIA; TRANSGENIC MOUSE MODEL; PHOSPHORYLATION; EXTRACT; GENERATION; IMPAIRMENT; CELLS; MICE	Huanglian-Jie-Du-Tang (HLJDT) is a famous traditional Chinese herbal formula that has been widely used clinically to treat cerebral ischemia. Recently, we found that berberine, a major alkaloid compound in HLJDT, reduced amyloid-beta (A beta) accumulation in an Alzheimer's disease (AD) mouse model. In this study, we compared the effects of HLJDT, four single component herbs of HLJDT (Rhizoma coptidis (RC), Radix scutellariae (RS), Cortex phellodendri (CP) and Fructus gardenia (FG)) and the modified formula of HLJDT (HLJDT-M, which is free of RS) on the regulatory processing of amyloid-beta precursor protein (APP) in an in vitro model of AD. Here we show that treatment with HLJDT-M and its components RC, CP, and the main compound berberine on N2a mouse neuroblastoma cells stably expressing human APP with the Swedish mutation (N2a-SwedAPP) significantly decreased the levels of full-length APP, phosphorylated APP at threonine 668, C-terminal fragments of APP, soluble APP (sAPP)-alpha and sAPP beta-Swedish and reduced the generation of A beta peptide in the cell lysates of N2a-SwedAPP. HLJDT-M showed more significant APP- and A beta-reducing effects than berberine, RC or CP treatment alone. In contrast, HLJDT, its component RS and the main active compound of RS, baicalein, strongly increased the levels of all the metabolic products of APP in the cell lysates. The extract from FG, however, did not influence APP modulation. Interestingly, regular treatment of TgCRND8 APP transgenic mice with baicalein exacerbated the amyloid plaque burden, APP metabolism and A beta production. Taken together, these data provide convincing evidence that HLJDT and baicalein treatment can increase the amyloidogenic metabolism of APP which is at least partly responsible for the baicalein-mediated A beta plaque increase in the brains of TgCRND8 mice. On the other hand, HLJDT-M significantly decreased all the APP metabolic products including A beta. Further study of HLJDT-M for therapeutic use in treating AD is warranted.	[Durairajan, Siva Sundara Kumar; Huang, Ying-Yu; Yuen, Pui-Yee; Chen, Lei-Lei; Liu, Liang-Feng; Song, Ju-Xian; Li, Min] Hong Kong Baptist Univ, Sch Chinese Med, Neurosci Res Lab, Kowloon Tong, Hong Kong, Peoples R China; [Kwok, Ka-Yan; Han, Quan-Bin] Hong Kong Baptist Univ, Sch Chinese Med, Nat Prod Chem & Anal Lab, Kowloon Tong, Hong Kong, Peoples R China; [Xue, Lei] Tongji Univ, Sch Life Sci & Technol, Shanghai Key Lab Signaling & Dis Res, Shanghai 200092, Peoples R China; [Chung, Sookja K.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, Pokfulam, Hong Kong, Peoples R China; [Huang, Jian-Dong] Univ Hong Kong, Li Ka Shing Fac Med, Dept Biochem, Pokfulam, Hong Kong, Peoples R China; [Baum, Larry] Chinese Univ Hong Kong, Sch Pharm, Shatin, Hong Kong, Peoples R China; [Senapati, Sanjib] Indian Inst Technol, Dept Biotechnol, Madras 600036, Tamil Nadu, India	Hong Kong Baptist University; Hong Kong Baptist University; Tongji University; University of Hong Kong; University of Hong Kong; Chinese University of Hong Kong; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Madras	Durairajan, SSK (corresponding author), Hong Kong Baptist Univ, Sch Chinese Med, Neurosci Res Lab, Kowloon Tong, Hong Kong, Peoples R China.	dsskumar@hkbu.edu.hk; limin@hkbu.edu.hk	Durairajan, Siva Sundara Kumar/AAW-4617-2020; Baum, Lawrence/B-1005-2013; /C-4277-2009	Durairajan, Siva Sundara Kumar/0000-0001-7376-7163; Baum, Lawrence/0000-0002-5345-9355; /0000-0001-7531-2816; Li, Min/0000-0002-7113-2700; Song, Ju-Xian/0000-0001-7266-2060; Han, Quanbin/0000-0001-9051-1485	NSFC-RGC from the Hong Kong Government [RGC-N_HKBU 213/11, SCM/10-11/03, IRMS/12-13/1A, FRG1/11-12/045, FRG II/12-13/038, FRG1/12-13/037, HMRF/1112251]; Hong Kong Baptist University [38-40-115]	NSFC-RGC from the Hong Kong Government; Hong Kong Baptist University	This study was partly supported by NSFC-RGC joint research grant (RGC-N_HKBU 213/11) from the Hong Kong Government, research grants SCM/10-11/03, IRMS/12-13/1A, FRG1/11-12/045, FRG II/12-13/038, FRG1/12-13/037, and HMRF/1112251, and RC Start up grant for new academics for Dr. Durairajan Siva Sundara Kumar (38-40-115) from Hong Kong Baptist University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Badiola N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058837; Benilova I, 2012, NAT NEUROSCI, V15, P349, DOI 10.1038/nn.3028; Boyd M.R., 1997, ANTICANCER DRUG DEV, P23, DOI [DOI 10.1007/978-1-4615-8152-9_2, 10.1007/978-1-4615-8152-9_2]; Chen GH, 2007, J EMERG TCM, V16, P386; Chen JH, 2008, ANAL CHIM ACTA, V613, P184, DOI 10.1016/j.aca.2008.02.060; Chishti MA, 2001, J BIOL CHEM, V276, P21562, DOI 10.1074/jbc.M100710200; Colombo A, 2009, NEUROBIOL DIS, V33, P518, DOI 10.1016/j.nbd.2008.12.014; De Strooper B, 2000, J CELL SCI, V113, P1857; Durairajan SSK, 2008, NEUROCHEM INT, V52, P741, DOI 10.1016/j.neuint.2007.09.006; Durairajan SSK, 2012, NEUROBIOL AGING, V33, P2903, DOI 10.1016/j.neurobiolaging.2012.02.016; Durairajan SSK, 2011, J ALZHEIMERS DIS, V25, P245, DOI 10.3233/JAD-2011-102085; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hayes CD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045841; Hu YH, 2012, J ETHNOPHARMACOL, V141, P728, DOI 10.1016/j.jep.2011.08.011; Iijima K, 2000, J NEUROCHEM, V75, P1085, DOI 10.1046/j.1471-4159.2000.0751085.x; Ito E, 1991, GERIATR MED, V29, P303; Khoddami A, 2013, MOLECULES, V18, P2328, DOI 10.3390/molecules18022328; Kondo Y, 2000, NEUROCHEM RES, V25, P205, DOI 10.1023/A:1007515318434; LaFerla FM, 2007, NAT REV NEUROSCI, V8, P499, DOI 10.1038/nrn2168; Lazarov O, 2005, J NEUROSCI, V25, P2386, DOI 10.1523/JNEUROSCI.3089-04.2005; Lee MS, 2003, J CELL BIOL, V163, P83, DOI 10.1083/jcb.200301115; Lewczuk P, 2010, MOL PSYCHIATR, V15, P138, DOI 10.1038/mp.2008.84; Li Y, 2006, FASEB J, V20, P285, DOI 10.1096/fj.05-4986com; Lleo A, 2006, ANNU REV MED, V57, P513, DOI 10.1146/annurev.med.57.121304.131442; Lu JH, 2011, CHEMBIOCHEM, V12, P615, DOI 10.1002/cbic.201000604; Luo JL, 2012, J FOOD DRUG ANAL, V20, P887, DOI 10.6227/jfda.2012200419; Nam Y, 2013, J TRADIT CHIN MED, V33, P223, DOI 10.1016/S0254-6272(13)60129-6; Okamoto H, 2013, NEUROPSYCH DIS TREAT, V9, P151, DOI 10.2147/NDT.S38318; Otomo E, 1991, GERIAT MED, V29, P121; Paris D, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-17; Peng Y, 2007, NEUROSCIENCE, V150, P386, DOI 10.1016/j.neuroscience.2007.09.022; Pham TQ, 2000, J AGR FOOD CHEM, V48, P1455, DOI 10.1021/jf991263j; Qiu Xin, 2011, Zhongguo Zhong Xi Yi Jie He Za Zhi, V31, P1379; Quan QK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059155; Rockenstein E, 2007, J NEUROSCI, V27, P1981, DOI 10.1523/JNEUROSCI.4321-06.2007; Sekiya N, 2005, BIOL PHARM BULL, V28, P294, DOI 10.1248/bpb.28.294; Selkoe DJ, 2004, NAT CELL BIOL, V6, P1054, DOI 10.1038/ncb1104-1054; Shang YZ, 2006, PHYTOTHER RES, V20, P53, DOI 10.1002/ptr.1802; Shao ZH, 1999, J MOL CELL CARDIOL, V31, P1885, DOI 10.1006/jmcc.1999.1021; Silva EFDE, 2003, NEUROCHEM RES, V28, P1553, DOI 10.1023/A:1025630627319; Suzuki T, 2006, J BIOCHEM, V139, P949, DOI 10.1093/jb/mvj121; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Tsai TH, 2002, BRIT J PHARMACOL, V137, P1314, DOI 10.1038/sj.bjp.0704959; Wang GX, 2010, VET PARASITOL, V171, P305, DOI 10.1016/j.vetpar.2010.03.032; Wang L, 2012, MOL NEURODEGENER, V7, pS4; Wang Shan, 2007, Zhongguo Zhong Yao Za Zhi, V32, P2289; Wang XL, 2005, LIFE SCI, V77, P3058, DOI 10.1016/j.lfs.2005.02.033; Xu JH, 2000, J ETHNOPHARMACOL, V73, P405, DOI 10.1016/S0378-8741(00)00303-2; Ye YL, 2012, BIOL PHARM BULL, V35, P355, DOI 10.1248/bpb.35.355; Youmans KL, 2011, J NEUROSCI METH, V196, P51, DOI 10.1016/j.jneumeth.2010.12.025; Yun SM, 2013, NEUROBIOL AGING, V34, P650, DOI 10.1016/j.neurobiolaging.2012.08.005; Zeng HW, 2011, J ETHNOPHARMACOL, V135, P561, DOI 10.1016/j.jep.2011.03.055; Zhang SQ, 2013, J NEUROSCI RES, V91, P1239, DOI 10.1002/jnr.23244; Zhu HX, 2013, PHYTOMEDICINE, V20, P767, DOI 10.1016/j.phymed.2012.11.012	54	31	35	1	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2014	9	3							e92954	10.1371/journal.pone.0092954	http://dx.doi.org/10.1371/journal.pone.0092954			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE0SR	24671102	Green Published, Green Submitted, gold			2023-01-03	WOS:000333677000094
J	Ocan, M; Bwanga, F; Bbosa, GS; Bagenda, D; Waako, P; Ogwal-Okeng, J; Obua, C				Ocan, Moses; Bwanga, Freddie; Bbosa, Godfrey S.; Bagenda, Danstan; Waako, Paul; Ogwal-Okeng, Jasper; Obua, Celestino			Patterns and Predictors of Self-Medication in Northern Uganda	PLOS ONE			English	Article							ANTIMICROBIAL DRUGS; RESISTANCE; ANTIBIOTICS; PHARMACIES; COMMUNITY; CHILDREN; INDIA; CARE	Self-medication with antimicrobial agents is a common form of self-care among patients globally with the prevalence and nature differing from country to country. Here we assessed the prevalence and predictors of antimicrobial self-medication in post-conflict northern Uganda. A cross-sectional study was carried out using structured interviews on 892 adult (>= 18 years) participants. Information on drug name, prescriber, source, cost, quantity of drug obtained, and drug use was collected. Households were randomly selected using multistage cluster sampling method. One respondent who reported having an illness within three months in each household was recruited. In each household, information was obtained from only one adult individual. Data was analyzed using STATA at 95% level of significance. The study found that a high proportion (75.7%) of the respondents practiced antimicrobial self-medication. Fever, headache, lack of appetite and body weakness were the disease symptoms most treated through self-medication (30.3%). The commonly self-medicated antimicrobials were coartem (27.3%), amoxicillin (21.7%), metronidazole (12.3%), and cotrimoxazole (11.6%). Drug use among respondents was mainly initiated by self-prescription (46.5%) and drug shop attendants (57.6%). On average, participants obtained 13.9 +/- 8.8 (95% CI: 12.6-13.8) tablets/capsules of antimicrobial drugs from drug shops and drugs were used for an average of 3.7 +/- 2.8 days (95% CI: 3.3-3.5). Over half (68.2%) of the respondents would recommend self-medication to another sick person. A high proportion (76%) of respondents reported that antimicrobial self-medication had associated risks such as wastage of money (42.1%), drug resistance (33.2%), and masking symptoms of underlying disease (15.5%). Predictors of self-medication with antimicrobial agents included gender, drug knowledge, drug leaflets, advice from friends, previous experience, long waiting time, and distance to the health facility. Despite knowledge of associated risks, use of self-medication with antimicrobial drugs in management of disease symptoms is a common practice in post-conflict northern Uganda.	[Ocan, Moses; Bbosa, Godfrey S.; Waako, Paul; Obua, Celestino] Makerere Univ, Coll Hlth Sci, Dept Pharmacol & Therapeut, Kampala, Uganda; [Bwanga, Freddie] Makerere Univ, Coll Hlth Sci, Dept Microbiol, Kampala, Uganda; [Bagenda, Danstan] Makerere Univ, Coll Hlth Sci, Dept Biostat, Kampala, Uganda; [Ogwal-Okeng, Jasper] Gulu Univ, Fac Med, Gulu, Uganda	Makerere University; Makerere University; Makerere University	Ocan, M (corresponding author), Makerere Univ, Coll Hlth Sci, Dept Pharmacol & Therapeut, Kampala, Uganda.	mocan@chs.mak.ac.ug	Kawooya, Ismael/O-4541-2016	Kawooya, Ismael/0000-0002-7159-7153; Obua, Celestino/0000-0001-6949-3059; Ocan, Moses/0000-0002-8852-820X	OGAC; NIH; HRSA;  [5R24TW008886]; FOGARTY INTERNATIONAL CENTER [R24TW008886] Funding Source: NIH RePORTER	OGAC; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); HRSA(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); ; FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	This study was funded by grant number 5R24TW008886 supported by OGAC, NIH and HRSA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akello Grace, 2010, WARTIME CHILDRENS SU; Asiimwe D, 2000, TRANSFORMATIONS PROG; Awad A, 2005, J PHARM PHARM SCI, V8, P326; Bennet S, 1993, B INT STAT I, V55, P21; Brass EP, 2011, CLIN PHARMACOL THER, V90, P791, DOI 10.1038/clpt.2011.231; Brass EP, 2001, NEW ENGL J MED, V345, P810, DOI 10.1056/NEJMra011080; Calva J, 1996, SOC SCI MED, V42, P1121, DOI 10.1016/0277-9536(95)00385-1; Cars O., 2005, International Journal of Risk & Safety in Medicine, V17, P103; DUA V, 1994, SOC SCI MED, V38, P717, DOI 10.1016/0277-9536(94)90462-6; ETKIN NL, 1990, SOC SCI MED, V30, P919, DOI 10.1016/0277-9536(90)90220-M; Figueiras A, 2000, EUR J EPIDEMIOL, V16, P19, DOI 10.1023/A:1007608702063; Gallup JL, 2001, AM J TROP MED HYG, V64, P85, DOI 10.4269/ajtmh.2001.64.85; Hussain S, 2010, S MED REV, V3, P32; Kamat VR, 1998, SOC SCI MED, V47, P779, DOI 10.1016/S0277-9536(98)00134-8; KHALLAF N, 1991, LANCET, V338, P248, DOI 10.1016/0140-6736(91)90380-8; Kiwanuka SN, 2008, T ROY SOC TROP MED H, V102, P1067, DOI 10.1016/j.trstmh.2008.04.023; KUNIN CM, 1993, ANN INTERN MED, V118, P557, DOI 10.7326/0003-4819-118-7-199304010-00011; Ministry of Health, 2002, UG NAT DRUG POL; Ministry of Health, 2010, INT COMM CAS MAN IMP; Naila K, 2009, WOMENS EC EMPOWERMEN; NICHTER M, 1994, SOC SCI MED, V39, P1509, DOI 10.1016/0277-9536(94)90003-5; RICHARDS L, 1993, PEDIATR INFECT DIS J, V12, P5, DOI 10.1097/00006454-199301000-00003; Sharma R., 2005, INDIAN J PHARM, V3, P37; Skliros E, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471-2296-11-58; STOLLER EP, 1993, MED CARE, V31, P24, DOI 10.1097/00005650-199301000-00002; Uganda Bureau of Statistics, 2002, 2002 UG POP HOUS CEN; UNICEF, 2007, UG UNICEF HUM SIT RE; Vialle-Valentin CE, 2012, TROP MED INT HEALTH, V17, P211, DOI 10.1111/j.1365-3156.2011.02895.x; WERNSDORFER WH, 1991, PHARMACOL THERAPEUT, V50, P95, DOI 10.1016/0163-7258(91)90074-V; WHO, 2001, WHOCDSCSRDRS20012; Whyte SR, 2000, P WORKSH PEOPL MED E, P127; World Health Organization, 1986, GUID ASS DRUGS US SE; World Health Organization, 2000, GUID REG ASS MED PRO	33	79	84	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2014	9	3							e92323	10.1371/journal.pone.0092323	http://dx.doi.org/10.1371/journal.pone.0092323			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AD6GL	24658124	Green Published, gold, Green Submitted			2023-01-03	WOS:000333355300073
J	Qiao, Y; Zhao, YL; Wu, QL; Sun, LM; Ruan, QL; Chen, YY; Wang, M; Duan, JN; Wang, DY				Qiao, Yan; Zhao, Yunli; Wu, Qiuli; Sun, Lingmei; Ruan, Qinli; Chen, Yanyan; Wang, Meng; Duan, Jinao; Wang, Dayong			Full Toxicity Assessment of Genkwa Flos and the Underlying Mechanism in Nematode Caenorhabditis elegans	PLOS ONE			English	Article							ENVIRONMENTAL RELEVANT CONCENTRATIONS; POTENT INHIBITORY-ACTIVITY; MICROCYSTIN-LR EXPOSURE; WALLED CARBON NANOTUBES; LUNG-CANCER CELLS; DAPHNE-GENKWA; OXIDATIVE STRESS; DITERPENE ESTERS; FLOWER BUDS; REPRODUCTIVE TOXICITY	Genkwa Flos (GF), the dried flower bud from Daphne genkwa Sieb. et Zucc. (Thymelaeaceae), is a well-known and widely used traditional Chinese medicine. However, we know little about the in vivo mechanism of GF toxicity. Nematode Caenorhabditis elegans has been considered as a useful toxicity assay system by offering a system best suited for asking the in vivo questions. In the present study, we employed the prolonged exposure assay system of C. elegans to perform the full in vivo toxicity assessment of raw-processed GF. Our data show that GF exposure could induce the toxicity on lifespan, development, reproduction, and locomotion behavior. GF exposure not only decreased body length but also induced the formation of abnormal vulva. The decrease in brood size in GF exposed nematodes appeared mainly at day-1 during the development of adult nematodes. The decrease of locomotion behavior in GF exposed nematodes might be due to the damage on development of D-type GABAergic motor neurons. Moreover, we observed the induction of intestinal reactive oxygen species (ROS) production and alteration of expression patterns of genes required for development of apical domain, microvilli, and apical junction of intestine in GF exposed nematodes, implying the possible dysfunction of the primary targeted organ. In addition, GF exposure induced increase in defecation cycle length and deficits in development of AVL and DVB neurons controlling the defecation behavior. Therefore, our study implies the usefulness of C. elegans assay system for toxicity assessment from a certain Chinese medicine or plant extract. The observed toxicity of GF might be the combinational effects of oxidative stress, dysfunction of intestine, and altered defecation behavior in nematodes.	[Qiao, Yan; Ruan, Qinli; Chen, Yanyan; Wang, Meng; Duan, Jinao] Nanjing Univ Chinese Med, Jiangsu Key Lab High Technol Res TCM Formulae, Nanjing, Jiangsu, Peoples R China; [Qiao, Yan; Zhao, Yunli; Wu, Qiuli; Sun, Lingmei; Wang, Dayong] Southeast Univ, Sch Med, Minist Educ, Key Lab Dev Genes & Human Dis, Nanjing, Jiangsu, Peoples R China	Nanjing University of Chinese Medicine; Southeast University - China	Wang, M (corresponding author), Nanjing Univ Chinese Med, Jiangsu Key Lab High Technol Res TCM Formulae, Nanjing, Jiangsu, Peoples R China.	mengwang.drug@hotmail.com; dja@njutcm.edu.cn; dayongw@seu.edu.cn	Cote, Rick H/G-3363-2013	Cote, Rick H/0000-0002-1573-6526	National Basic Research Program of China (973 Program) [2011CB505303]; National Natural Science Foundation of China [81172698, 81202233, 81302814]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from National Basic Research Program of China (973 Program) (No. 2011CB505303), and National Natural Science Foundation of China (No. 81172698, 81202233, 81302814). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allard P, 2010, P NATL ACAD SCI USA, V107, P20405, DOI 10.1073/pnas.1010386107; Bang KK, 2013, BIOORG MED CHEM LETT, V23, P3334, DOI 10.1016/j.bmcl.2013.03.096; Boyd WA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007024; BRENNER S, 1974, GENETICS, V77, P71; Chang CW, 2012, VIRUSES-BASEL, V4, P539, DOI 10.3390/v4040539; Chen YY, 2013, PHYTOMEDICINE, V21, P82, DOI 10.1016/j.phymed.2013.06.012; Dharmalingam K, 2012, J ETHNOPHARMACOL, V139, P657, DOI 10.1016/j.jep.2011.12.016; DONKIN SG, 1995, ENVIRON TOXICOL CHEM, V14, P2139, DOI 10.1002/etc.5620141218; Dostal V, 2010, GENETICS, V186, P857, DOI 10.1534/genetics.110.120436; Du M, 2009, ENVIRON TOXICOL PHAR, V27, P314, DOI 10.1016/j.etap.2008.11.011; Fan D, 2011, FOOD CHEM, V124, P195, DOI 10.1016/j.foodchem.2010.06.008; Geng LL, 2013, PHYTOTHER RES, V27, P521, DOI 10.1002/ptr.4748; Goh GY, 2013, AGING CELL, DOI [10.1111/acel.12, DOI 10.1111/ACEL.12]; Helmcke KJ, 2009, TOXICOL APPL PHARM, V240, P265, DOI 10.1016/j.taap.2009.03.013; Hong JY, 2011, J NAT PROD, V74, P2102, DOI 10.1021/np2003512; Hong JY, 2010, CHEM PHARM BULL, V58, P234, DOI 10.1248/cpb.58.234; Hu YO, 2008, BIOMED ENVIRON SCI, V21, P467, DOI 10.1016/S0895-3988(09)60004-0; Jiang B, 2011, J BIOL INORG CHEM, V16, P267, DOI 10.1007/s00775-010-0723-1; Jiangsu New Medical College, 1985, ENC TRAD CHIN MED; Ju JJ, 2013, ENVIRON SCI POLLUT R, V20, P1823, DOI 10.1007/s11356-012-1151-2; Kandasamy S, 2012, MAR DRUGS, V10, P84, DOI 10.3390/md10010084; Kumar S, 2010, REPROD TOXICOL, V29, P415, DOI 10.1016/j.reprotox.2010.02.006; Lapierre LR, 2012, TRENDS ENDOCRIN MET, V23, P637, DOI 10.1016/j.tem.2012.07.007; Lee MY, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/728196; Leung MCK, 2008, TOXICOL SCI, V106, P5, DOI 10.1093/toxsci/kfn121; Li FF, 2013, BIOORG MED CHEM LETT, V23, P2500, DOI 10.1016/j.bmcl.2013.03.025; Li YX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044688; Li YX, 2013, NANOTOXICOLOGY, V7, P1004, DOI 10.3109/17435390.2012.689884; Li YX, 2012, J HAZARD MATER, V219, P221, DOI 10.1016/j.jhazmat.2012.03.083; Li YP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071180; Li YH, 2009, J ENVIRON SCI, V21, P971, DOI 10.1016/S1001-0742(08)62370-0; Li ZJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067451; Liu PD, 2012, ECOTOX ENVIRON SAFE, V79, P90, DOI 10.1016/j.ecoenv.2011.12.007; Lublin A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027762; Ma HB, 2009, ENVIRON TOXICOL CHEM, V28, P1324, DOI 10.1897/08-262.1; MCGHEE JD, 2007, C ELEGANS INTESTINE, DOI DOI 10.1895/W0RMB00K.1.133.1; MCINTIRE SL, 1993, NATURE, V364, P337, DOI 10.1038/364337a0; Mohan N, 2010, NANO LETT, V10, P3692, DOI 10.1021/nl1021909; Mukai D, 2008, J NAT MED, V62, P155, DOI 10.1007/s11418-007-0201-4; Nouara A, 2013, NANOSCALE, V5, P6088, DOI 10.1039/c3nr00847a; Onken B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008758; Park BY, 2008, INT IMMUNOPHARMACOL, V8, P967, DOI 10.1016/j.intimp.2008.02.012; Park BY, 2006, PHYTOTHER RES, V20, P610, DOI 10.1002/ptr.1915; Pluskota A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006622; Qu Y, 2011, NANO LETT, V11, P3174, DOI 10.1021/nl201391e; Ruan QL, 2012, J APPL TOXICOL, V32, P527, DOI 10.1002/jat.1783; Ruan QL, 2009, J TOXICOL ENV HEAL A, V72, P746, DOI 10.1080/15287390902841532; Rui Q, 2009, FRONT MED-PRC, V3, P76; Rui Q, 2013, CHEMOSPHERE, V93, P2289, DOI 10.1016/j.chemosphere.2013.08.007; Sangha JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043990; Tullet JM, 2008, CELL, V132; Wang DY, 2008, ARCH ENVIRON CON TOX, V54, P447, DOI 10.1007/s00244-007-9050-0; Wang DY, 2010, ECOTOX ENVIRON SAFE, V73, P1221, DOI 10.1016/j.ecoenv.2010.05.002; Wang DY, 2010, ECOTOX ENVIRON SAFE, V73, P423, DOI 10.1016/j.ecoenv.2009.12.014; Wang DY, 2009, ENVIRON TOXICOL PHAR, V28, P459, DOI 10.1016/j.etap.2009.07.008; Wang R, 2013, J ASIAN NAT PROD RES, V15, P502, DOI 10.1080/10286020.2013.786703; Wang SC, 2009, CHEM-BIOL INTERACT, V180, P151, DOI 10.1016/j.cbi.2009.03.012; WILLIAMS PL, 1990, ENVIRON TOXICOL CHEM, V9, P1285, DOI [10.1897/1552-8618(1990)9[1285:ATTUTN]2.0.CO;2, 10.1002/etc.5620091007]; Wu QL, 2013, NANOSCALE, V5, P11166, DOI 10.1039/c3nr03917j; Wu QL, 2013, NANOSCALE, V5, P9934, DOI 10.1039/c3nr02084c; Wu QL, 2012, J HAZARD MATER, V243, P161, DOI 10.1016/j.jhazmat.2012.10.013; Wu QL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043729; Wu QL, 2011, ENVIRON TOXICOL PHAR, V32, P175, DOI 10.1016/j.etap.2011.04.009; Wu QL, 2012, CHEMOSPHERE, V87, P1281, DOI 10.1016/j.chemosphere.2012.01.035; Wu S, 2011, ENVIRON TOXICOL PHAR, V31, P179, DOI 10.1016/j.etap.2010.10.005; Xie HC, 2011, J LIQ CHROMATOGR R T, V34, P2360, DOI 10.1080/10826076.2011.589094; Xing X, 2009, B ENVIRON CONTAM TOX, V83, P530, DOI 10.1007/s00128-009-9816-3; Xing XJ, 2009, J ENVIRON SCI, V21, P1684, DOI 10.1016/S1001-0742(08)62474-2; Yang CL, 1993, TOXIC HERBAL MED; Yang XY, 2012, ENVIRON SCI TECHNOL, V46, P1119, DOI 10.1021/es202417t; Ye HY, 2008, NEUROBIOL LEARN MEM, V90, P10, DOI 10.1016/j.nlm.2007.12.001; Yu SH, 2011, ENVIRON TOXICOL PHAR, V32, P233, DOI 10.1016/j.etap.2011.05.008; Zeitoun-Ghandour S, 2010, FEBS J, V277, P2531, DOI 10.1111/j.1742-4658.2010.07667.x; Zhan ZJ, 2005, BIOORGAN MED CHEM, V13, P645, DOI 10.1016/j.bmc.2004.10.054; Zhang HF, 2010, METALLOMICS, V2, P806, DOI 10.1039/c0mt00059k; Zhang SX, 2006, BIOORGAN MED CHEM, V14, P3888, DOI 10.1016/j.bmc.2006.01.055; Zhang WM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074553; Zhao YL, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/564093; Zhao YL, 2014, NANOMED-NANOTECHNOL, V10, P89, DOI 10.1016/j.nano.2013.07.004; Zhao YL, 2013, RSC ADV, V3, P5741, DOI 10.1039/c2ra22798c; Zheng WF, 2007, INT IMMUNOPHARMACOL, V7, P117, DOI 10.1016/j.intimp.2006.07.010; Zheng WF, 2007, INT IMMUNOPHARMACOL, V7, P128, DOI 10.1016/j.intimp.2006.07.011	82	33	36	1	49	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 13	2014	9	3							e91825	10.1371/journal.pone.0091825	http://dx.doi.org/10.1371/journal.pone.0091825			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC9JS	24626436	Green Published, Green Submitted, gold			2023-01-03	WOS:000332851300139
J	Cohen, M; Hamilton, J; Narang, I				Cohen, Michal; Hamilton, Jill; Narang, Indra			Clinically Important Age-Related Differences in Sleep Related Disordered Breathing in Infants and Children with Prader-Willi Syndrome	PLOS ONE			English	Article							GROWTH-HORMONE THERAPY; POLYSOMNOGRAPHIC VALUES; BODY-COMPOSITION; APNEA; MANAGEMENT; CHILDHOOD; ADOLESCENTS; DIAGNOSIS; TODDLERS; OBESITY	Background: Sleep related disordered breathing (SDB) in pediatric Prader-Willi Syndrome is gaining increased attention due to the possible association of growth hormone therapy, SDB and sudden death. However data on the patterns of SDB and their management, particularly in infants in this population, is lacking. Objective: The aim of this study was to 1) describe patterns of SDB in growth hormone naive infants with PWS and the management of these disorders in our institution 2) Compare the patterns of sleep disorders between infants and children with PWS. Methods and Design: Polysomnograms of infants and children (0-18 years of age) with Prader-Willi Syndrome were reviewed. Age, sex, anthropometrics, sleep architecture, obstructive and central apnea indices and oxygen saturations were recorded. Data of infants with central sleep apnea treated with oxygen were analyzed to evaluate the efficacy of this treatment. The main outcome measures were obstructive and central apnea indices on a polysomnogram. Results: Data of 44 patients, 23 under 2 years of age and 21 older children were included. Infants when compared with older children were more likely to experience central sleep apnea (43% vs. 5%; p = 0.003). In older children obstructive was significantly more prevalent than central sleep apnea. Supplemental oxygen was used to treat 9/23 infants with central sleep apnea. Oxygen therapy resulted in a significant decrease in the median central apnea index from 14 (5,68) to 1 (0,6; p = 0.008) events/hour and an improvement in the oxygen saturation nadir from 70% (52, 92) to 81% (64, 95; p = 0.080). Conclusions: Central sleep apnea with associated oxygen desaturations is more prevalent in infants compared with older children with Prader-Willi Syndrome. Supplemental oxygen was efficacious in treating central sleep apnea in infants. Routine sleep surveillance for all children with Prader-Willi Syndrome and treatment with oxygen for central sleep apnea should be considered.	[Cohen, Michal; Hamilton, Jill] Hosp Sick Children, Div Endocrinol, Toronto, ON M5G 1X8, Canada; [Cohen, Michal; Hamilton, Jill; Narang, Indra] Univ Toronto, Toronto, ON, Canada; [Narang, Indra] Hosp Sick Children, Div Resp Med, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Cohen, M (corresponding author), Hosp Sick Children, Div Endocrinol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	indra.narang@sickkids.ca						ARENS R, 1994, J APPL PHYSIOL, V77, P2224, DOI 10.1152/jappl.1994.77.5.2224; Barbera Joseph VI, 2010, SLEEP MENTAL ILLNESS; Bass JL, 2004, PEDIATRICS, V114, P805, DOI 10.1542/peds.2004-0227; Beck SE, 2009, SLEEP MED CLIN, V4, P393, DOI 10.1016/j.jsmc.2009.04.007; Bekx MT, 2003, J PEDIATR-US, V143, P372, DOI 10.1067/S0022-3476(03)00386-X; Bruni O, 2010, CURR OPIN PULM MED, V16, P568, DOI 10.1097/MCP.0b013e32833ef547; Capdevila Oscar Sans, 2008, Proc Am Thorac Soc, V5, P274, DOI 10.1513/pats.200708-138MG; Carrel AL, 2004, J PEDIATR-US, V145, P744, DOI 10.1016/j.jpeds.2004.08.002; Cassidy SB, 2012, GENET MED, V14, P10, DOI 10.1038/gim.0b013e31822bead0; Chesson A., 2007, AASM MANUAL SCORING; Eiholzer U, 1999, J PEDIATR-US, V134, P222, DOI 10.1016/S0022-3476(99)70419-1; Festen DAM, 2008, CLIN ENDOCRINOL, V68, P919, DOI 10.1111/j.1365-2265.2007.03126.x; Festen DAM, 2006, J CLIN ENDOCR METAB, V91, P4911, DOI 10.1210/jc.2006-0765; Festen DAM, 2007, PEDIATR RES, V62, P221, DOI 10.1203/PDR.0b013e31809871dd; Goldstone AP, 2008, J CLIN ENDOCR METAB, V93, P4183, DOI 10.1210/jc.2008-0649; Gozal D, 1998, PEDIATRICS, V102, P616, DOI 10.1542/peds.102.3.616; HELBINGZWANENBURG B, 1993, J INTELL DISABIL RES, V37, P533; HERTZ G, 1995, AM J MED GENET, V56, P188, DOI 10.1002/ajmg.1320560215; Lin HY, 2007, PEDIATR PULM, V42, P881, DOI 10.1002/ppul.20673; Marcus CL, 2012, PEDIATRICS, V130, pE714, DOI 10.1542/peds.2012-1672; MARCUS CL, 1992, AM REV RESPIR DIS, V146, P1235, DOI 10.1164/ajrccm/146.5_Pt_1.1235; Mary Cataletto GH, 2010, ROMANIAN J RARE DIS; McCandless SE, 2011, PEDIATRICS, V127, P195, DOI 10.1542/peds.2010-2820; Miller JL, 2012, J CLIN ENDOCR METAB, V97, P3837, DOI 10.1210/jc.2012-2543; Miller JL, 2011, AM J MED GENET A, V155A, P1040, DOI 10.1002/ajmg.a.33951; Miller JL, 2009, J CLIN SLEEP MED, V5, P448; Montgomery-Downs HE, 2006, PEDIATRICS, V117, P741, DOI 10.1542/peds.2005-1067; Nixon GM, 2002, PEDIATR PULM, V34, P209, DOI 10.1002/ppul.10152; O'Donoghue FJ, 2005, J PEDIATR-US, V147, P823, DOI 10.1016/j.jpeds.2005.07.021; RICHARDS A, 1994, CLIN OTOLARYNGOL, V19, P193, DOI 10.1111/j.1365-2273.1994.tb01213.x; Sacco M, 2005, HORM RES, V63, P29, DOI 10.1159/000082525; Scholle S, 2011, SLEEP MED, V12, P988, DOI 10.1016/j.sleep.2011.05.006; Tapia IE, 2008, SLEEP, V31, P1737, DOI 10.1093/sleep/31.12.1737; Tauber M, 2008, AM J MED GENET A, V146A, P881, DOI 10.1002/ajmg.a.32131; Traeger N, 2005, PEDIATR PULM, V40, P22, DOI 10.1002/ppul.20236; Urquhart DS, 2013, ARCH DIS CHILD, V98, P592, DOI 10.1136/archdischild-2012-303441; Vandeleur M, 2013, J PAEDIATR CHILD H, V49, P238, DOI 10.1111/jpc.12109; Williams K, 2008, J CLIN SLEEP MED, V4, P111	38	63	63	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 30	2014	9	6							e101012	10.1371/journal.pone.0101012	http://dx.doi.org/10.1371/journal.pone.0101012			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK5ZO	24979549	gold, Green Submitted, Green Published			2023-01-03	WOS:000338506400062
J	Richard, AJ; Fuller, S; Fedorcenco, V; Beyl, R; Burris, TP; Mynatt, R; Ribnicky, DM; Stephens, JM				Richard, Allison J.; Fuller, Scott; Fedorcenco, Veaceslav; Beyl, Robbie; Burris, Thomas P.; Mynatt, Randall; Ribnicky, David M.; Stephens, Jacqueline M.			Artemisia scoparia Enhances Adipocyte Development and Endocrine Function In Vitro and Enhances Insulin Action In Vivo	PLOS ONE			English	Article							ACTIVATED PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA; ADIPOSE-TISSUE; SKELETAL-MUSCLE; PPAR-GAMMA; METABOLIC SYNDROME; DIABETES-MELLITUS; 3T3-L1 ADIPOCYTES; HEPATIC INSULIN; GENE-EXPRESSION	Background: Failure of adipocytes to expand during periods of energy excess can result in undesirable metabolic consequences such as ectopic fat accumulation and insulin resistance. Blinded screening studies have indicated that Artemisia scoparia (SCO) extracts can enhance adipocyte differentiation and lipid accumulation in cultured adipocytes. The present study tested the hypothesis that SCO treatment modulates fat cell development and function in vitro and insulin sensitivity in adipose tissue in vivo. Methods: In vitro experiments utilized a Gal4-PPAR gamma ligand binding domain (LBD) fusion protein-luciferase reporter assay to examine PPAR gamma activation. To investigate the ability of SCO to modulate adipogenesis and mature fat cell function in 3T3-L1 cells, neutral lipid accumulation, gene expression, and protein secretion were measured by Oil Red O staining, qRT-PCR, and immunoblotting, respectively. For the in vivo experiments, diet-induced obese (DIO) C57BL/6J mice were fed a high-fat diet (HFD) or HFD containing 1% w/w SCO for four weeks. Body weight and composition, food intake, and fasting glucose and insulin levels were measured. Phospho-activation and expression of insulin-sensitizing proteins in epididymal adipose tissue (eWAT) were measured by immunoblotting. Results: Ethanolic extracts of A. scoparia significantly activated the PPAR gamma LBD and enhanced lipid accumulation in differentiating 3T3-L1 cells. SCO increased the transcription of several PPAR gamma target genes in differentiating 3T3-L1 cells and rescued the negative effects of tumor necrosis factor alpha on production and secretion of adiponectin and monocyte chemoattractant protein-1 in fully differentiated fat cells. DIO mice treated with SCO had elevated adiponectin levels and increased phosphorylation of AMPK alpha in eWAT when compared to control mice. In SCO-treated mice, these changes were also associated with decreased fasting insulin and glucose levels. Conclusion: SCO has metabolically beneficial effects on adipocytes in vitro and adipose tissue in vivo, highlighting its potential as a metabolically favorable botanical supplement.	[Richard, Allison J.; Fuller, Scott; Fedorcenco, Veaceslav; Beyl, Robbie; Mynatt, Randall; Stephens, Jacqueline M.] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA; [Burris, Thomas P.] St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA; [Ribnicky, David M.] Rutgers State Univ, Dept Plant Biol & Pathol, New Brunswick, NJ 08903 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Saint Louis University; Rutgers State University New Brunswick	Stephens, JM (corresponding author), Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA.	jsteph1@lsu.edu	Burris, Thomas P/B-3886-2016; Richard, Allison/N-1987-2017; Mynatt, Randall L/N-1980-2017; Stephens, Jacqueline M/R-5217-2018; Fuller, Scott/GWM-5641-2022; Beyl, Robbie Albert/N-1951-2017	Burris, Thomas P/0000-0003-2922-4449; Mynatt, Randall L/0000-0003-4399-0019; Fuller, Scott/0000-0002-2677-1677	NCAAM; ODS - NIH [2P50AT002776-06]; NIH [T32 AT004094]; COBRE [NIH 8 P20 GM103528]; NORC from the National Institutes of Health [NIH 2P30DK072476]; National Institute of General Medical Sciences of the National Institutes of Health [1 U54 GM104940]; National Center for Complementary & Integrative Health [P50AT002776] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM104940, P20GM103528] Funding Source: NIH RePORTER	NCAAM; ODS - NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); COBRE; NORC from the National Institutes of Health; National Institute of General Medical Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This research project was supported by an NCAAM and ODS funded NIH grant (2P50AT002776-06) awarded to the PBRC Botanical Research Center. AJR and SF were supported by an NIH T-32 postdoctoral training fellowship in botanicals granted to PBRC (T32 AT004094). This research project used PBRC Genomics Core facilities that are supported in part by COBRE (NIH 8 P20 GM103528) and NORC (NIH 2P30DK072476) center grants from the National Institutes of Health. Statistical analysis for this project was supported by 1 U54 GM104940 from the National Institute of General Medical Sciences of the National Institutes of Health, which funds the Louisiana Clinical and Translational Science Center. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Bijland S, 2013, CLIN SCI, V124, P491, DOI 10.1042/CS20120536; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Bruun JM, 2003, AM J PHYSIOL-ENDOC M, V285, pE527, DOI 10.1152/ajpendo.00110.2003; Busby SA, 2011, ACS CHEM BIOL, V6, P618, DOI 10.1021/cb100396s; Choi JH, 2011, NATURE, V477, P477, DOI 10.1038/nature10383; Choi JH, 2010, NATURE, V466, P451, DOI 10.1038/nature09291; Chopra I, 2012, DIABETOLOGIA, V55, P783, DOI 10.1007/s00125-011-2407-y; Cinti S, 2005, J LIPID RES, V46, P2347, DOI 10.1194/jlr.M500294-JLR200; Danforth E, 2000, NAT GENET, V26, P13, DOI 10.1038/79111; Daval M, 2006, J PHYSIOL-LONDON, V574, P55, DOI 10.1113/jphysiol.2006.111484; DeFronzo RA, 2011, NEW ENGL J MED, V364, P1104, DOI 10.1056/NEJMoa1010949; Donath MY, 2011, NAT REV IMMUNOL, V11, P98, DOI 10.1038/nri2925; Fasshauer M, 2003, BIOCHEM BIOPH RES CO, V301, P1045, DOI 10.1016/S0006-291X(03)00090-1; Frosig C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062338; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Hamza N, 2010, J ETHNOPHARMACOL, V128, P513, DOI 10.1016/j.jep.2010.01.004; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Huang JV, 2012, J LIPID RES, V53, P1738, DOI 10.1194/jlr.R024505; Kim JY, 2007, J CLIN INVEST, V117, P2621, DOI 10.1172/JCI31021; Kumar N, 2010, MOL PHARMACOL, V77, P228, DOI 10.1124/mol.109.060905; KURIHARCUCH W, 1978, P NATL ACAD SCI USA, V75, P6107, DOI 10.1073/pnas.75.12.6107; Lim DW, 2013, MOLECULES, V18, P9241, DOI 10.3390/molecules18089241; Mantzoros CS, 1999, ANN INTERN MED, V130, P671, DOI 10.7326/0003-4819-130-8-199904200-00014; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Nissen SE, 2007, NEW ENGL J MED, V356, P2457, DOI 10.1056/NEJMoa072761; Obanda DN, 2012, DIABETES, V61, P597, DOI 10.2337/db11-0396; Ribnicky DM, 2006, PHYTOMEDICINE, V13, P550, DOI 10.1016/j.phymed.2005.09.007; Richard AJ, 2012, BBA-MOL BASIS DIS, V1822, P557, DOI 10.1016/j.bbadis.2011.12.005; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rotter V, 2003, J BIOL CHEM, V278, P45777, DOI 10.1074/jbc.M301977200; Rubenstrunk A, 2007, BBA-MOL CELL BIOL L, V1771, P1065, DOI 10.1016/j.bbalip.2007.02.003; Ruderman NB, 2013, J CLIN INVEST, V123, P2764, DOI 10.1172/JCI67227; Sartipy P, 2003, P NATL ACAD SCI USA, V100, P7265, DOI 10.1073/pnas.1133870100; Shibata T, 2013, J PHARMACOL SCI, V122, P93, DOI 10.1254/jphs.12270FP; Solt LA, 2012, NATURE, V485, P62, DOI 10.1038/nature11030; Sun K, 2011, J CLIN INVEST, V121, P2094, DOI 10.1172/JCI45887; Tripathy D, 2013, DIABETOLOGIA, V56, P2153, DOI 10.1007/s00125-013-2976-z; Wang ZQ, 2008, METABOLISM, V57, pS58, DOI 10.1016/j.metabol.2008.04.003; Wang ZQ, 2013, METABOLISM, V62, P1239, DOI 10.1016/j.metabol.2013.03.004; Wang ZQ, 2011, J NUTR BIOCHEM, V22, P71, DOI 10.1016/j.jnutbio.2009.11.015; Whitehead JP, 2006, DIABETES OBES METAB, V8, P264, DOI 10.1111/j.1463-1326.2005.00510.x; Xing XH, 2009, J ETHNOPHARMACOL, V125, P410, DOI 10.1016/j.jep.2009.07.021; Yamamoto N, 2011, FOOD FUNCT, V2, P45, DOI 10.1039/c0fo00129e; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788	47	22	22	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 10	2014	9	6							e98897	10.1371/journal.pone.0098897	http://dx.doi.org/10.1371/journal.pone.0098897			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AN9SD	24915004	Green Published, gold			2023-01-03	WOS:000340947700042
J	Bhattacharya, D; Dwivedi, VP; Maiga, M; Maiga, M; Van Kaer, L; Bishai, WR; Das, G				Bhattacharya, Debapriya; Dwivedi, Ved Prakash; Maiga, Mamoudou; Maiga, Mariama; Van Kaer, Luc; Bishai, William R.; Das, Gobardhan			Small Molecule-directed Immunotherapy against Recurrent Infection by Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY T-CELLS; SUPLATAST TOSILATE IPD-1151T; TUMOR-NECROSIS-FACTOR; TGF-BETA; IN-VIVO; TRANSCRIPTION FACTOR; LINEAGE COMMITMENT; IMMUNE-RESPONSES; TH1; GAMMA	Tuberculosis remains the biggest infectious threat to humanity with one-third of the population infected and 1.4 million deaths and 8.7 million new cases annually. Current tuberculosis therapy is lengthy and consists of multiple antimicrobials, which causes poor compliance and high treatment dropout, resulting in the development of drug-resistant variants of tuberculosis. Therefore, alternate methods to treat tuberculosis are urgently needed. Mycobacterium tuberculosis evades host immune responses by inducing T helper (Th)2 and regulatory T (Treg) cell responses, which diminish protective Th1 responses. Here, we show that animals (Stat-6(-/-)CD4-TGF beta RIIDN mice) that are unable to generate both Th2 cells and Tregs are highly resistant to M. tuberculosis infection. Furthermore, simultaneous inhibition of these two subsets of Th cells by therapeutic compounds dramatically reduced bacterial burden in different organs. This treatment was associated with the generation of protective Th1 immune responses. As these therapeutic agents are not directed to the harbored organisms, they should avoid the risk of promoting the development of drug-resistant M. tuberculosis variants.	[Bhattacharya, Debapriya; Dwivedi, Ved Prakash; Das, Gobardhan] Univ Kwazulu Natal, Coll Hlth Sci, Lab Med & Med Sci, ZA-4001 Durban, South Africa; [Maiga, Mamoudou; Maiga, Mariama; Bishai, William R.] Johns Hopkins Univ, Dept Med, Ctr TB Res, Baltimore, MD 21231 USA; [Van Kaer, Luc] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA	University of Kwazulu Natal; Johns Hopkins University; Vanderbilt University	Das, G (corresponding author), Jawaharlal Neheru Univ, Special Ctr Mol Med, New Delhi 110067, India.	gobardhan.das07@gmail.com	Van Kaer, Luc/H-1033-2015	Van Kaer, Luc/0000-0001-5275-2309; Dwivedi, Ved Prakash/0000-0003-4321-2567	Wellcome Trust; Department of Biotechnology India Alliance; Department of Biotechnology; Council for Scientific and Industrial research-Open Source Drug Discovery (CSIR-OSDD) program Government of India; College of Health Sciences, University of KwaZulu Natal (Durban, South Africa)	Wellcome Trust(Wellcome TrustEuropean Commission); Department of Biotechnology India Alliance(Wellcome Trust DBT India Alliance); Department of Biotechnology; Council for Scientific and Industrial research-Open Source Drug Discovery (CSIR-OSDD) program Government of India; College of Health Sciences, University of KwaZulu Natal (Durban, South Africa)	This work was supported by grants from The Wellcome Trust, Department of Biotechnology India Alliance, Department of Biotechnology, Council for Scientific and Industrial research-Open Source Drug Discovery (CSIR-OSDD) program Government of India, and College of Health Sciences, University of KwaZulu Natal (Durban, South Africa).	Agger EM, 2001, VACCINE, V19, P2298, DOI 10.1016/S0264-410X(00)00519-3; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; Boussiotis VA, 2000, J CLIN INVEST, V105, P1317, DOI 10.1172/JCI9918; Callahan JF, 2002, J MED CHEM, V45, P999, DOI 10.1021/jm010493y; Chen WJ, 2010, J MOL CELL BIOL, V2, P30, DOI 10.1093/jmcb/mjp004; CHENSUE SW, 1994, AM J PATHOL, V145, P1105; Demissie A, 2004, J IMMUNOL, V172, P6938, DOI 10.4049/jimmunol.172.11.6938; Dlugovitzky D, 1999, RESP MED, V93, P557, DOI 10.1016/S0954-6111(99)90155-5; Elo LL, 2010, IMMUNITY, V32, P852, DOI 10.1016/j.immuni.2010.06.011; Fenhalls G, 2000, INFECT IMMUN, V68, P2827, DOI 10.1128/IAI.68.5.2827-2836.2000; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Gorelik L, 2000, IMMUNITY, V12, P171, DOI 10.1016/S1074-7613(00)80170-3; Henneekes H., 2002, CURR MED CHEM ANTIIN, P41; Hernandez-Pando R, 2004, EUR J IMMUNOL, V34, P174, DOI 10.1002/eji.200324253; Jayaswal S, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000839; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Kurokawa M, 2001, MEDIAT INFLAMM, V10, P333, DOI 10.1080/09629350120102352; Lienhardt C, 2002, EUR J IMMUNOL, V32, P1605, DOI 10.1002/1521-4141(200206)32:6<1605::AID-IMMU1605>3.0.CO;2-6; Marie JC, 2005, J EXP MED, V201, P1061, DOI 10.1084/jem.20042276; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; Oda N, 1999, LIFE SCI, V65, P763, DOI 10.1016/S0024-3205(99)00303-3; Oertelt S, 2006, J IMMUNOL, V177, P1655, DOI 10.4049/jimmunol.177.3.1655; Ordway Diane J, 2005, Acta Med Port, V18, P27; Peng YF, 2004, P NATL ACAD SCI USA, V101, P4572, DOI 10.1073/pnas.0400810101; Raghuvanshi S, 2010, P NATL ACAD SCI USA, V107, P21653, DOI 10.1073/pnas.1007967107; Randolph DA, 2006, ANNU REV MED, V57, P381, DOI 10.1146/annurev.med.57.121304.131337; Rook GAW, 2005, NAT REV IMMUNOL, V5, P661, DOI 10.1038/nri1666; Rook GAW, 2004, TRENDS IMMUNOL, V25, P483, DOI 10.1016/j.it.2004.06.005; Rook GAW, 1996, ANNU REV MICROBIOL, V50, P259, DOI 10.1146/annurev.micro.50.1.259; Roy E, 2008, TUBERCULOSIS, V88, P197, DOI [10.1016/j.tube.2007.11.005, 10.1016/S1472-9792(08)70011-8]; Scott-Browne JP, 2007, J EXP MED, V204, P2159, DOI 10.1084/jem.20062105; Seah GT, 2000, J INFECT DIS, V181, P385, DOI 10.1086/315200; Shafiani S, 2013, IMMUNITY, V38, P1261, DOI 10.1016/j.immuni.2013.06.003; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; Sweeney KA, 2011, NAT MED, V17, P1261, DOI 10.1038/nm.2420; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Szabo SJ, 2002, SCIENCE, V295, P338, DOI 10.1126/science.1065543; Toossi Z, 1998, CLIN IMMUNOL IMMUNOP, V87, P107, DOI 10.1006/clin.1998.4528; van der Werf N, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003215; Walzl G, 2011, NAT REV IMMUNOL, V11, P343, DOI 10.1038/nri2960; WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1	41	33	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2014	289	23					16508	16515		10.1074/jbc.M114.558098	http://dx.doi.org/10.1074/jbc.M114.558098			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	AJ8ON	24711459	Green Published, hybrid			2023-01-03	WOS:000337965700052
J	Damasceno, MV; Duarte, M; Pasqua, LA; Lima-Silva, AE; MacIntosh, BR; Bertuzzi, R				Damasceno, Mayara V.; Duarte, Marcos; Pasqua, Leonardo A.; Lima-Silva, Adriano E.; MacIntosh, Brian R.; Bertuzzi, Romulo			Static Stretching Alters Neuromuscular Function and Pacing Strategy, but Not Performance during a 3-Km Running Time-Trial	PLOS ONE			English	Article							VERTICAL JUMP PERFORMANCE; OXYGEN-UPTAKE; PERCEIVED EXERTION; SPRINT PERFORMANCE; HAMSTRING MUSCLES; FORCE PRODUCTION; BODY-COMPOSITION; ECONOMY; RUNNERS; STIFFNESS	Purpose: Previous studies report that static stretching (SS) impairs running economy. Assuming that pacing strategy relies on rate of energy use, this study aimed to determine whether SS would modify pacing strategy and performance in a 3-km running time-trial. Methods: Eleven recreational distance runners performed a) a constant-speed running test without previous SS and a maximal incremental treadmill test; b) an anthropometric assessment and a constant-speed running test with previous SS; c) a 3-km time-trial familiarization on an outdoor 400-m track; d and e) two 3-km time-trials, one with SS (experimental situation) and another without (control situation) previous static stretching. The order of the sessions d and e were randomized in a counterbalanced fashion. Sit-and-reach and drop jump tests were performed before the 3-km running time-trial in the control situation and before and after stretching exercises in the SS. Running economy, stride parameters, and electromyographic activity (EMG) of vastus medialis (VM), biceps femoris (BF) and gastrocnemius medialis (GA) were measured during the constant-speed tests. Results: The overall running time did not change with condition (SS 11:35 +/- 00:31 s; control 11:28 +/- 00:41 s, p=0.304), but the first 100 m was completed at a significantly lower velocity after SS. Surprisingly, SS did not modify the running economy, but the iEMG for the BF (+22.6%, p=0.031), stride duration (+2.1%, p=0.053) and range of motion (+11.1%, p = 0.0001) were significantly modified. Drop jump height decreased following SS (-9.2%, p=0.001). Conclusion: Static stretch impaired neuromuscular function, resulting in a slow start during a 3-km running time-trial, thus demonstrating the fundamental role of the neuromuscular system in the self-selected speed during the initial phase of the race.	[Damasceno, Mayara V.; Pasqua, Leonardo A.; Bertuzzi, Romulo] Univ Sao Paulo, Sch Phys Educ & Sport, Endurance Performance Res Grp, Sao Paulo, Brazil; [Duarte, Marcos] Fed Univ ABC, Sao Paulo, Brazil; [Lima-Silva, Adriano E.] Univ Fed Pernambuco, Dept Phys Educ & Sports Sci, Sports Sci Res Grp, Vitoria De Santo Antao, PE, Brazil; [MacIntosh, Brian R.] Univ Calgary, Fac Kinesiol, Human Performance Lab, Calgary, AB, Canada	Universidade de Sao Paulo; Universidade Federal do ABC (UFABC); Universidade Federal de Pernambuco; University of Calgary	Bertuzzi, R (corresponding author), Univ Sao Paulo, Sch Phys Educ & Sport, Endurance Performance Res Grp, Sao Paulo, Brazil.	bertuzzi@usp.br	Damasceno, Mayara/P-3468-2015; Lima-Silva, Adriano/Y-2404-2019; Lima-Silva, Adriano Eduardo/C-2800-2013; Duarte, Marcos/D-1854-2011; Bertuzzi, Romulo/E-7048-2012	Lima-Silva, Adriano/0000-0002-0613-5104; Lima-Silva, Adriano Eduardo/0000-0002-0613-5104; Duarte, Marcos/0000-0002-0344-7460; 	Sao Paulo Research Foundation [FAPESP: 2011/10742-9, FAPESP: 2011/02769-4, 2010/13913-6]	Sao Paulo Research Foundation(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This study was supported by Sao Paulo Research Foundation (FAPESP: 2011/10742-9). Mayara Vieira Damasceno and Leonardo Alves Pasqua were supported by a master scholarship from Sao Paulo Research Foundation (FAPESP: 2011/02769-4 and 2010/13913-6), www.fapesp.br. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbiss CR, 2008, SPORTS MED, V38, P239, DOI 10.2165/00007256-200838030-00004; Allison SJ, 2008, J SPORT SCI, V26, P1489, DOI 10.1080/02640410802392715; Avela J, 1999, J APPL PHYSIOL, V86, P1283, DOI 10.1152/jappl.1999.86.4.1283; Baltaci G, 2003, BRIT J SPORT MED, V37, P59, DOI 10.1136/bjsm.37.1.59; Baron B, 2009, EUR J APPL PHYSIOL, V105, P749, DOI 10.1007/s00421-008-0957-6; Batterham AM, 2006, INT J SPORT PHYSIOL, V1, P50, DOI 10.1123/ijspp.1.1.50; Behm DG, 2007, EUR J APPL PHYSIOL, V101, P587, DOI 10.1007/s00421-007-0533-5; Bertuzzi R, 2013, J STRENGTH COND RES; Billat VL, 2001, MED SCI SPORT EXER, V33, P2089, DOI 10.1097/00005768-200112000-00018; Bishop D, 2002, MED SCI SPORT EXER, V34, P1041, DOI 10.1097/00005768-200206000-00022; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Bradley PS, 2007, J STRENGTH COND RES, V21, P223, DOI 10.1519/00124278-200702000-00040; BROZEK J, 1963, ANN NY ACAD SCI, V110, P113, DOI 10.1111/j.1749-6632.1963.tb17079.x; Cornwell A, 2001, J HUM MOVEMENT STUD, V40, P307; de Morree HM, 2012, PSYCHOPHYSIOLOGY, V49, P1242, DOI 10.1111/j.1469-8986.2012.01399.x; Faulkner J, 2008, PSYCHOPHYSIOLOGY, V45, P977, DOI 10.1111/j.1469-8986.2008.00712.x; Fletcher JR, 2009, J APPL PHYSIOL, V107, P1918, DOI 10.1152/japplphysiol.00307.2009; HAKKINEN K, 1983, MED SCI SPORT EXER, V15, P455; Hayes PR, 2007, J STRENGTH COND RES, V21, P1227; Higashihara A, 2010, J SPORT SCI, V28, P1085, DOI 10.1080/02640414.2010.494308; HOWLEY ET, 1995, MED SCI SPORT EXER, V27, P1292; JACKSON AS, 1985, PHYSICIAN SPORTSMED, V13, P76, DOI 10.1080/00913847.1985.11708790; Jones AM, 2008, SCAND J MED SCI SPOR, V18, P615, DOI 10.1111/j.1600-0838.2007.00725.x; Jones AM, 2002, INT J SPORTS MED, V23, P40, DOI 10.1055/s-2002-19271; Kyrolainen H, 2001, MED SCI SPORT EXER, V33, P1330; Lima-Silva AE, 2010, EUR J APPL PHYSIOL, V108, P1045, DOI 10.1007/s00421-009-1300-6; LOHMAN TG, 1981, HUM BIOL, V53, P181; Lusk G, 1928, SCI NUTR, P177; Marcora SM, 2009, J APPL PHYSIOL, V106, P857, DOI 10.1152/japplphysiol.91324.2008; Mikkola J, 2011, J SPORT SCI, V29, P1359, DOI 10.1080/02640414.2011.589467; Mizuno T, 2013, INT J SPORTS MED, V34, P484, DOI 10.1055/s-0032-1327655; Nelson AG, 2005, J SPORT SCI, V23, P449, DOI 10.1080/02640410410001730205; Nummela AT, 2008, INT J SPORTS MED, V29, P738, DOI 10.1055/s-2007-989404; Nummela AT, 2006, EUR J APPL PHYSIOL, V97, P1, DOI 10.1007/s00421-006-0147-3; Ogura Y, 2007, J STRENGTH COND RES, V21, P788; Paavolainen L, 1999, J APPL PHYSIOL, V86, P1527; Ryan ED, 2009, J SPORT SCI, V27, P957, DOI 10.1080/02640410902998254; Lopes FAS, 2010, J STRENGTH COND RES, V24, P1650, DOI 10.1519/JSC.0b013e3181d32f7b; Sandals LE, 2006, INT J SPORTS MED, V27, P37, DOI 10.1055/s-2005-837468; Sayers AL, 2008, J STRENGTH COND RES, V22, P1416, DOI 10.1519/JSC.0b013e318181a450; Tucker R, 2006, INT J SPORT PHYSIOL, V1, P233, DOI 10.1123/ijspp.1.3.233; Ulmer HV, 1996, EXPERIENTIA, V52, P416, DOI 10.1007/BF01919309; Young W, 2001, RES Q EXERCISE SPORT, V72, P273, DOI 10.1080/02701367.2001.10608960; Young WB., 1995, J STRENGTH CONDITION, V9, P232, DOI DOI 10.1519/00124278-199511000-06005	44	17	17	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2014	9	6							e99238	10.1371/journal.pone.0099238	http://dx.doi.org/10.1371/journal.pone.0099238			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AP1YS	24905918	Green Submitted, Green Published, gold			2023-01-03	WOS:000341869000113
J	Suzuki, Y; Kitahara, T; Soma, K; Konno, S; Sato, K; Suzuki, S; Oka, H; Yamada, M; Fujii, K; Kitahara, Y; Yamamoto, Y; Otsuka, T; Sugiura, Y; Kanoh, Y; Tamai, Y; Ohto, H				Suzuki, Yuhko; Kitahara, Takao; Soma, Kazui; Konno, Shingo; Sato, Kimitoshi; Suzuki, Sachio; Oka, Hidehiro; Yamada, Masaru; Fujii, Kiyotaka; Kitahara, Yukio; Yamamoto, Yuji; Otsuka, Takashi; Sugiura, Yoshihiro; Kanoh, Yuhsaku; Tamai, Yoshiko; Ohto, Hitoshi			Impact of Platelet Transfusion on Survival of Patients with Intracerebral Hemorrhage after Administration of Anti-Platelet Agents at a Tertiary Emergency Center	PLOS ONE			English	Article							PERCUTANEOUS CORONARY INTERVENTION; CARDIOVASCULAR-DISEASE; HEMATOMA EXPANSION; CONTROLLED-TRIAL; HIGH-RISK; THERAPY; ASPIRIN; CLOPIDOGREL; STROKE; EVENTS	This study examined the impact of platelet transfusion (PLT) on the survival of intracerebral hemorrhage (ICH) patients who had been administered anti-platelet agents (APA). This retrospective cohort analysis investigated 432 patients (259 men, 60%) who were newly diagnosed with ICH between January 2006 and June 2011 at the tertiary emergency center of Kitasato University Hospital. Median age on arrival was 67.0 years (range, 40-95 years). ICH was subcortical in 72 patients (16.7%), supratentorial in 233 (53.9%), and infratentorial in 133 (30.8%). PLT was performed in 16 patients (3.7%). Within 90 days after admission to the center, 178 patients (41.2%) had died due to ICH. Before the onset of ICH, 66 patients had been prescribed APA because of atherosclerotic diseases. Multivariate regression analysis indicated APA administration was an independent risk factor for death within 7 days (odds ratio, 5.12; P = 0.006) and within 90 days (hazard ratio, 1.87; P = 0.006) after arrival. Regarding the effect of a PLT in ICH patients with APA, no patient with PLT died. PLT had a survival benefit on patients with ICH, according to our analysis. Further prospective analysis is necessary to confirm the effects of PLT on survival in ICH with APA.	[Suzuki, Yuhko; Ohto, Hitoshi] Fukushima Med Univ, Dept Blood Transfus, Fukushima, Japan; [Suzuki, Yuhko; Ohto, Hitoshi] Fukushima Med Univ, Dept Transplantat Immunol, Fukushima, Japan; [Kitahara, Takao; Soma, Kazui; Konno, Shingo] Kitasato Univ, Sch Med, Dept Emergency Med, Sagamihara, Kanagawa 228, Japan; [Kitahara, Takao; Soma, Kazui; Konno, Shingo] Kitasato Univ, Sch Med, Dept Crit Care Med, Sagamihara, Kanagawa 228, Japan; [Sato, Kimitoshi; Suzuki, Sachio; Oka, Hidehiro; Yamada, Masaru; Fujii, Kiyotaka] Kitasato Univ, Sch Med, Dept Neurosurg, Sagamihara, Kanagawa 228, Japan; [Kitahara, Yukio] Fuchinobe Gen Hosp, Dept Neurosurg, Sagamihara, Kanagawa, Japan; [Yamamoto, Yuji] Ashigarakami Hosp, Dept Neurosurg, Ashigarakami, Kanagawa, Japan; [Otsuka, Takashi] Sagamihara Chuo Hosp, Dept Neurosurg, Sagamihara, Kanagawa, Japan; [Sugiura, Yoshihiro] Fukushima Med Univ, Dept Neurol, Fukushima, Japan; [Kanoh, Yuhsaku] Kitasato Univ, Sch Med, Dept Clin Lab Med, Sagamihara, Kanagawa 228, Japan; [Tamai, Yoshiko] Hirosaki Univ, Sch Med, Dept Transfus, Hirosaki, Aomori 036, Japan	Fukushima Medical University; Fukushima Medical University; Kitasato University; Kitasato University; Kitasato University; Fukushima Medical University; Kitasato University; Hirosaki University	Suzuki, Y (corresponding author), Fukushima Med Univ, Dept Blood Transfus, Fukushima, Japan.	ysuzuki-hki@umin.ac.jp						Balami JS, 2012, LANCET NEUROL, V11, P101, DOI 10.1016/S1474-4422(11)70264-2; Batchelor JS, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000588; Butler AC, 1998, BLOOD REV, V12, P35, DOI 10.1016/S0268-960X(98)90028-5; Creutzfeldt CJ, 2009, J STROKE CEREBROVASC, V18, P221, DOI 10.1016/j.jstrokecerebrovasdis.2008.10.007; De Schryver EL, 2010, COCHRANE DB SYST REV; Dearden NM, 1998, CLIN NEUROPATHOL, V17, P221; Dewilde WJM, 2013, LANCET, V381, P1107, DOI 10.1016/S0140-6736(12)62177-1; Ducruet AF, 2010, NEUROL RES, V32, P706, DOI 10.1179/174313209X459129; Eikelboom JW, 2002, CIRCULATION, V105, P1650, DOI 10.1161/01.CIR.0000013777.21160.07; FitzGerald R, 2011, PHARMACOL THERAPEUT, V130, P213, DOI 10.1016/j.pharmthera.2011.01.011; Flaherty ML, 2010, SEMIN NEUROL, V30, P565, DOI 10.1055/s-0030-1268866; Flibotte JJ, 2004, NEUROLOGY, V63, P1059, DOI 10.1212/01.WNL.0000138428.40673.83; Florczak-Rzepka M, 2012, CEREBROVASC DIS, V34, P249, DOI 10.1159/000341686; FLORESRUNK P, 1993, ANN PHARMACOTHER, V27, P1090, DOI 10.1177/106002809302700915; Garg RK, 2012, STROKE, V43, P67, DOI 10.1161/STROKEAHA.111.629493; Hankey GJ, 2000, STROKE, V31, P1779, DOI 10.1161/01.STR.31.7.1779; Hennekens C, 2013, NONRESPONSE RESISTAN; Hennekens CH, 2013, SECONDARY PREVENTION; Hermosillo AJ, 2008, ANN PHARMACOTHER, V42, P790, DOI 10.1345/aph.1K591; Hoshino K, 2009, CIRC J, V73, P336, DOI 10.1253/circj.CJ-08-0559; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jinnai T, 2009, CIRC J, V73, P1498, DOI 10.1253/circj.CJ-09-0019; Kiyohara Y, 2003, STROKE, V34, P2343, DOI 10.1161/01.STR.0000091845.14833.43; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Lee KR, 1997, J NEUROSURG, V86, P272, DOI 10.3171/jns.1997.86.2.0272; Menon RS, 2012, ANN NEUROL, V71, P199, DOI 10.1002/ana.22668; Miyata Shigeki, 2008, Brain and Nerve (Tokyo), V60, P1357; Naidech AM, 2012, NEUROCRIT CARE, V16, P82, DOI 10.1007/s12028-011-9619-3; Naidech AM, 2009, STROKE, V40, P2398, DOI 10.1161/STROKEAHA.109.550939; Rincon F, 2013, NEUROCRIT CARE, V19, P95, DOI 10.1007/s12028-012-9793-y; Roquer J, 2005, J NEUROL, V252, P412, DOI 10.1007/s00415-005-0659-5; Sacco S, 2009, STROKE, V40, P394, DOI 10.1161/STROKEAHA.108.523209; Samama CM, 2005, CAN J ANAESTH, V52, P30, DOI 10.1007/BF03018577; Sarafoff N, 2012, CURR PHARM DESIGN, V18, P5224, DOI 10.2174/138161212803251853; Seizer P, 2013, THROMB HAEMOST, V110; Shinohara Y, 2008, STROKE, V39, P1827, DOI 10.1161/STROKEAHA.107.505131; Shinohara Y, 2010, LANCET NEUROL, V9, P959, DOI 10.1016/S1474-4422(10)70198-8; Steinhubl SR, 2009, ANN INTERN MED, V150, P379, DOI 10.7326/0003-4819-150-6-200903170-00006; TANAKA H, 1981, STROKE, V12, P460, DOI 10.1161/01.STR.12.4.460; Thompson BB, 2010, NEUROLOGY, V75, P1333, DOI 10.1212/WNL.0b013e3181f735e5; Toyoda K, 2005, NEUROLOGY, V65, P1000, DOI 10.1212/01.wnl.0000179178.37713.69; Toyoda K, 2008, STROKE, V39, P1740, DOI 10.1161/STROKEAHA.107.504993; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Washington CW, 2011, J TRAUMA, V71, P358, DOI 10.1097/TA.0b013e318220ad7e; Wijeyeratne YD, 2011, BRIT J CLIN PHARMACO, V72, P647, DOI 10.1111/j.1365-2125.2011.03999.x	45	19	24	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2014	9	5							e97328	10.1371/journal.pone.0097328	http://dx.doi.org/10.1371/journal.pone.0097328			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI4TS	24869669	Green Published, Green Submitted, gold			2023-01-03	WOS:000336858300008
J	Bennell, KL; Egerton, T; Martin, J; Abbott, JH; Metcalf, B; McManus, F; Sims, K; Pua, YH; Wrigley, TV; Forbes, A; Smith, C; Harris, A; Buchbinder, R				Bennell, Kim L.; Egerton, Thorlene; Martin, Joel; Abbott, J. Haxby; Metcalf, Ben; McManus, Fiona; Sims, Kevin; Pua, Yong-Hao; Wrigley, Tim V.; Forbes, Andrew; Smith, Catherine; Harris, Anthony; Buchbinder, Rachelle			Effect of Physical Therapy on Pain and Function in Patients With Hip Osteoarthritis A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; PHYSIOTHERAPY MANAGEMENT; MANUAL THERAPY; EXERCISE THERAPY; MUSCLE STRENGTH; WESTERN-ONTARIO; KNEE; INTERVENTION; PERFORMANCE; DISABILITY	IMPORTANCE There is limited evidence supporting use of physical therapy for hip osteoarthritis. OBJECTIVE To determine efficacy of physical therapy on pain and physical function in patients with hip osteoarthritis. DESIGN, SETTING, AND PARTICIPANTS Randomized, placebo-controlled, participant-and assessor-blinded trial involving 102 community volunteers with hip pain levels of 40 or higher on a visual analog scale of 100 mm(range, 0-100 mm; 100 indicates worst pain possible) and hip osteoarthritis confirmed by radiograph. Forty-nine patients in the active group and 53 in the sham group underwent 12 weeks of intervention and 24 weeks of follow-up (May 2010-February 2013) INTERVENTIONS Participants attended 10 treatment sessions over 12 weeks. Active treatment included education and advice, manual therapy, home exercise, and gait aid if appropriate. Sham treatment included inactive ultrasound and inert gel. For 24 weeks after treatment, the active group continued unsupervised home exercise while the sham group self-applied gel 3 times weekly. MAIN OUTCOMES AND MEASURES Primary outcomes were average pain (0 mm, no pain; 100 mm, worst pain possible) and physical function (Western Ontario and McMaster Universities Osteoarthritis Index, 0 no difficulty to 68 extreme difficulty) at week 13. Secondary outcomes were these measures at week 36 and impairments, physical performance, global change, psychological status, and quality of life at weeks 13 and 36. RESULTS Ninety-six patients (94%) completed week 13 measurements and 83 (81%) completed week 36 measurements. The between-group differences for improvements in pain were not significant. For the active group, the baseline mean (SD) visual analog scale score was 58.8 mm(13.3) and the week-13 score was 40.1 mm(24.6); for the sham group, the baseline score was 58.0 mm (11.6) and the week-13 score was 35.2 mm(21.4). The mean difference was 6.9 mm favoring sham treatment (95% CI, -3.9 to 17.7). The function scores were not significantly different between groups. The baseline mean (SD) physical function score for the active group was 32.3 (9.2) and the week-13 score was 27.5 (12.9) units, whereas the baseline score for the sham treatment group was 32.4 (8.4) units and the week-13 score was 26.4 (11.3) units, for a mean difference of 1.4 units favoring sham (95% CI, -3.8 to 6.5) at week 13. There were no between-group differences in secondary outcomes (except greater week-13 improvement in the balance step test in the active group). Nineteen of 46 patients (41%) in the active group reported 26 mild adverse effects and 7 of 49 (14%) in the sham group reported 9 mild adverse events (P = .003). CONCLUSIONS AND RELEVANCE Among adults with painful hip osteoarthritis, physical therapy did not result in greater improvement in pain or function compared with sham treatment, raising questions about its value for these patients.	[Bennell, Kim L.; Egerton, Thorlene; Martin, Joel; Metcalf, Ben; McManus, Fiona; Wrigley, Tim V.] Univ Melbourne, Sch Hlth Sci, Ctr Hlth Exercise & Sports Med, Melbourne, Vic 3010, Australia; [Abbott, J. Haxby] Univ Otago, Dept Surg Sci, Dunedin Sch Med, Ctr Musculoskeletal Outcomes Res, Dunedin, New Zealand; [Sims, Kevin] Cricket Australia Ctr Excellence, Brisbane, Qld, Australia; [Pua, Yong-Hao] Singapore Gen Hosp, Dept Physiotherapy, Singapore, Singapore; [Forbes, Andrew; Smith, Catherine; Buchbinder, Rachelle] Monash Univ, Dept Epidemiol & Prevent Med, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia; [Harris, Anthony] Monash Univ, Ctr Hlth Econ, Melbourne, Vic, Australia; [Buchbinder, Rachelle] Cabrini Hlth, Dept Clin Epidemiol, Melbourne, Vic, Australia	University of Melbourne; University of Otago; Singapore General Hospital; Monash University; Monash University; Cabrini Health	Bennell, KL (corresponding author), Univ Melbourne, Sch Hlth Sci, Ctr Hlth Exercise & Sports Med, Melbourne, Vic 3010, Australia.	k.bennell@unimelb.edu.au	Abbott, J. Haxby/AAK-4346-2020; Egerton, Thorlene/AAN-5810-2020; Buchbinder, Rachelle/G-2952-2011; ABBOTT, J. Haxby/AAH-3262-2019; Bennell, Kim/C-7022-2014	Abbott, J. Haxby/0000-0001-6468-7284; Egerton, Thorlene/0000-0003-4751-7624; Buchbinder, Rachelle/0000-0002-0597-0933; Smith, Catherine/0000-0001-9327-0154; McManus, Fiona/0000-0002-1001-8146; Harris, Anthony/0000-0003-1641-3320; Pua, Yong-Hao/0000-0003-2313-9665; WRIGLEY, TIM/0000-0003-3222-4706; Bennell, Kim/0000-0003-4982-5639; Metcalf, Ben/0000-0002-4945-3217; Forbes, Andrew/0000-0003-4269-914X	National Health and Medical Research Council [628556]; Australian Research Council Future Fellowship; Australian National Health and Medical Research Council Practitioner Fellowship	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council Future Fellowship(Australian Research Council); Australian National Health and Medical Research Council Practitioner Fellowship(National Health and Medical Research Council (NHMRC) of Australia)	This study was funded by project 628556 from the National Health and Medical Research Council. Dr Bennell is funded in part by an Australian Research Council Future Fellowship. Dr Buchbinder is funded in part by an Australian National Health and Medical Research Council Practitioner Fellowship.	Abbott JH, 2013, OSTEOARTHR CARTILAGE, V21, P525, DOI 10.1016/j.joca.2012.12.014; Abhishek A, 2013, OSTEOARTHR CARTILAGE, V21, P1229, DOI 10.1016/j.joca.2013.04.018; ALTMAN R, 1991, ARTHRITIS RHEUM, V34, P505, DOI 10.1002/art.1780340502; Angst F, 2001, ARTHRIT RHEUM-ARTHR, V45, P384, DOI 10.1002/1529-0131(200108)45:4<384::AID-ART352>3.0.CO;2-0; Bellamy N, 1997, J RHEUMATOL, V24, P768; BELLAMY N, 1992, J RHEUMATOL, V19, P451; Bennell K, 2013, J PHYSIOTHER, V59, P145, DOI 10.1016/S1836-9553(13)70179-6; Bennell K, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2756; Bennell KL, 2011, PHYS THER, V91, P1525, DOI 10.2522/ptj.20100430; Bennell KL, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-238; BORKOVEC TD, 1972, J BEHAV THER EXP PSY, V3, P257, DOI 10.1016/0005-7916(72)90045-6; Cibulka Michael T, 2009, J Orthop Sports Phys Ther, V39, pA1, DOI 10.2519/jospt.2009.0301; Cowan SM, 2010, PHYSIOTHERAPY, V96, P289, DOI 10.1016/j.physio.2010.02.004; Fransen M, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007912; Fransen M, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004376.pub2; French HP, 2007, PHYSIOTHERAPY, V93, P253, DOI 10.1016/j.physio.2006.12.008; French HP, 2013, ARCH PHYS MED REHAB, V94, P302, DOI 10.1016/j.apmr.2012.09.030; Hall AM, 2010, PHYS THER, V90, P1099, DOI 10.2522/ptj.20090245; Hawthorne G, 2005, AUST NZ J PUBL HEAL, V29, P136, DOI 10.1111/j.1467-842X.2005.tb00063.x; Hernandez-Molina G, 2008, ARTHRIT RHEUM-ARTHR, V59, P1221, DOI 10.1002/art.24010; Hoeksma HL, 2004, ARTHRIT RHEUM-ARTHR, V51, P722, DOI 10.1002/art.20685; James KE, 1996, STAT MED, V15, P1421; Juhl C, 2014, ARTHRITIS RHEUMATOL, V66, P622, DOI 10.1002/art.38290; Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25; Klassbo M, 2003, SCAND J RHEUMATOL, V32, P46, DOI 10.1080/03009740310000409; Little R.J.A., 2002, STAT ANAL MISSING DA, Vsecond; LORIG K, 1989, ARTHRITIS RHEUM, V32, P37, DOI 10.1002/anr.1780320107; McConnell S, 2001, ARTHRIT RHEUM-ARTHR, V45, P453, DOI 10.1002/1529-0131(200110)45:5<453::AID-ART365>3.0.CO;2-W; Osman A, 2000, J BEHAV MED, V23, P351, DOI 10.1023/A:1005548801037; Pinto RZ, 2012, J PHYSIOTHER, V58, P77, DOI 10.1016/S1836-9553(12)70087-5; Pua YH, 2008, ARCH PHYS MED REHAB, V89, P1146, DOI 10.1016/j.apmr.2007.10.028; Pua YH, 2009, ARTHRIT RHEUM-ARTHR, V61, P442, DOI 10.1002/art.24344; REJESKI WJ, 1995, OSTEOARTHR CARTILAGE, V3, P157, DOI 10.1016/S1063-4584(05)80050-0; Stuart E, 2008, PREV SCI, V9, P288, DOI 10.1007/s11121-008-0104-y; WASHBURN RA, 1993, J CLIN EPIDEMIOL, V46, P153, DOI 10.1016/0895-4356(93)90053-4; White IR, 2012, CLIN TRIALS, V9, P396, DOI 10.1177/1740774512450098; Whitfield K, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-19; Wood L, 2008, BMJ-BRIT MED J, V336, P601, DOI 10.1136/bmj.39465.451748.AD; Wright AA, 2011, J ORTHOP SPORT PHYS, V41, P319, DOI 10.2519/jospt.2011.3515; Zhang W, 2008, ANN RHEUM DIS, V67, P1716, DOI 10.1136/ard.2008.092015; Zhang W, 2010, OSTEOARTHR CARTILAGE, V18, P476, DOI 10.1016/j.joca.2010.01.013	41	98	100	0	72	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	2014	311	19					1987	1997		10.1001/jama.2014.4591	http://dx.doi.org/10.1001/jama.2014.4591			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AH4UA	24846036				2023-01-03	WOS:000336122800021
J	Siegel, AM; Sisti, DA; Caplan, AL				Siegel, Andrew M.; Sisti, Dominic A.; Caplan, Arthur L.			Pediatric Euthanasia in Belgium Disturbing Developments	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Siegel, Andrew M.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Sisti, Dominic A.] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA; [Caplan, Arthur L.] NYU, Div Med Eth, Langone Med Ctr, New York, NY USA	University of Pennsylvania; University of Pennsylvania; New York University; NYU Langone Medical Center	Siegel, AM (corresponding author), Univ Penn, Dept Psychiat, Perelman Sch Med, 3535 Market St,Second Floor, Philadelphia, PA 19104 USA.	andrew.siegel@uphs.upenn.edu		Siegel, Andrew/0000-0002-8605-2519; Sisti, Dominic/0000-0002-2282-9253				Casell, 2004, NATURE SUFFERING GOA; Dan B, 2014, LANCET, V383, P671, DOI 10.1016/S0140-6736(14)60110-0; Jennings B, 2013, HASTINGS CTR GUIDELI; Orentlicher D, 2014, JAMA-J AM MED ASSOC, V311, P1961, DOI 10.1001/jama.2014.4117; Pousset G, 2011, ARCH DIS CHILD, V96, P948, DOI 10.1136/adc.2009.182139; Quill TE, 1997, JAMA-J AM MED ASSOC, V278, P2099, DOI 10.1001/jama.278.23.2099; Verhagen E, 2005, NEW ENGL J MED, V352, P959, DOI 10.1056/NEJMp058026	7	30	32	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	2014	311	19					1963	1964		10.1001/jama.2014.4257	http://dx.doi.org/10.1001/jama.2014.4257			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AH4UA	24743867				2023-01-03	WOS:000336122800012
J	Sinha, M; Jang, YC; Oh, J; Khong, D; Wu, EY; Manohar, R; Miller, C; Regalado, SG; Loffredo, FS; Pancoast, JR; Hirshman, MF; Lebowitz, J; Shadrach, JL; Cerletti, M; Kim, MJ; Serwold, T; Goodyear, LJ; Rosner, B; Lee, RT; Wagers, AJ				Sinha, Manisha; Jang, Young C.; Oh, Juhyun; Khong, Danika; Wu, Elizabeth Y.; Manohar, Rohan; Miller, Christine; Regalado, Samuel G.; Loffredo, Francesco S.; Pancoast, James R.; Hirshman, Michael F.; Lebowitz, Jessica; Shadrach, Jennifer L.; Cerletti, Massimiliano; Kim, Mi-Jeong; Serwold, Thomas; Goodyear, Laurie J.; Rosner, Bernard; Lee, Richard T.; Wagers, Amy J.			Restoring Systemic GDF11 Levels Reverses Age-Related Dysfunction in Mouse Skeletal Muscle	SCIENCE			English	Article							DIFFERENTIATION FACTOR 11; DNA-DAMAGE; STEM-CELLS; MYOSTATIN; REJUVENATION; HYPERTROPHY; REPAIR	Parabiosis experiments indicate that impaired regeneration in aged mice is reversible by exposure to a young circulation, suggesting that young blood contains humoral "rejuvenating" factors that can restore regenerative function. Here, we demonstrate that the circulating protein growth differentiation factor 11 (GDF11) is a rejuvenating factor for skeletal muscle. Supplementation of systemic GDF11 levels, which normally decline with age, by heterochronic parabiosis or systemic delivery of recombinant protein, reversed functional impairments and restored genomic integrity in aged muscle stem cells (satellite cells). Increased GDF11 levels in aged mice also improved muscle structural and functional features and increased strength and endurance exercise capacity. These data indicate that GDF11 systemically regulates muscle aging and may be therapeutically useful for reversing age-related skeletal muscle and stem cell dysfunction.	[Sinha, Manisha; Jang, Young C.; Oh, Juhyun; Khong, Danika; Wu, Elizabeth Y.; Manohar, Rohan; Miller, Christine; Regalado, Samuel G.; Loffredo, Francesco S.; Pancoast, James R.; Lebowitz, Jessica; Shadrach, Jennifer L.; Cerletti, Massimiliano; Lee, Richard T.; Wagers, Amy J.] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA; [Sinha, Manisha; Jang, Young C.; Oh, Juhyun; Khong, Danika; Wu, Elizabeth Y.; Manohar, Rohan; Miller, Christine; Regalado, Samuel G.; Loffredo, Francesco S.; Pancoast, James R.; Lebowitz, Jessica; Shadrach, Jennifer L.; Cerletti, Massimiliano; Lee, Richard T.; Wagers, Amy J.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA; [Sinha, Manisha; Jang, Young C.; Oh, Juhyun; Khong, Danika; Wu, Elizabeth Y.; Manohar, Rohan; Miller, Christine; Hirshman, Michael F.; Lebowitz, Jessica; Shadrach, Jennifer L.; Cerletti, Massimiliano; Kim, Mi-Jeong; Serwold, Thomas; Goodyear, Laurie J.; Wagers, Amy J.] Joslin Diabet Ctr, Boston, MA 02215 USA; [Sinha, Manisha; Shadrach, Jennifer L.; Wagers, Amy J.] Howard Hughes Med Inst, Cambridge, MA USA; [Sinha, Manisha; Jang, Young C.; Oh, Juhyun; Khong, Danika; Wu, Elizabeth Y.; Manohar, Rohan; Miller, Christine; Lebowitz, Jessica; Wagers, Amy J.] Harvard Univ, Sch Med, Paul F Glenn Labs Biol Mech Aging, Boston, MA USA; [Regalado, Samuel G.] Univ Calif Berkeley, Berkeley, CA 94720 USA; [Loffredo, Francesco S.; Pancoast, James R.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA; [Loffredo, Francesco S.; Pancoast, James R.] Brigham Regenerat Med Ctr, Boston, MA USA; [Goodyear, Laurie J.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Goodyear, Laurie J.] Harvard Univ, Sch Med, Boston, MA USA; [Rosner, Bernard] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA	Harvard University; Harvard University; Harvard University; Joslin Diabetes Center, Inc.; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; University of California System; University of California Berkeley; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Wagers, AJ (corresponding author), Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA.	amy_wagers@harvard.edu	Loffredo, Francesco S/F-6638-2014; Loffredo, Francesco/P-1389-2019	Loffredo, Francesco S/0000-0001-5911-780X; Loffredo, Francesco/0000-0001-5911-780X; Wu, Elizabeth/0000-0002-6537-9790; Oh, Juhyun/0000-0002-4492-6978; Khong, Danika/0000-0002-2128-8619; Lee, Richard/0000-0003-4687-1381	American Heart Association; NIH [R01 AR42238, 1R01 AG033053, 1DP2 OD004345, 5U01 HL100402, R01 AG032977 1R01 AG040019]; Glenn Foundation for Medical Research; Harvard Stem Cell Institute; Project Ascelegen; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL100402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042238] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [T32DE007057] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG040019, R01AG032977, R01AG033053] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD004345] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Glenn Foundation for Medical Research; Harvard Stem Cell Institute; Project Ascelegen; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank the Harvard Stem Cell Institute/Department of Stem Cell and Regenerative Biology's Flow Cytometry Core, Harvard's Center for Biological Imaging, and C. Dall'Osso and B. Hunter for technical assistance. This work was funded in part by grants from the American Heart Association to F. S. L. (postdoctoral fellowship); NIH (R01 AR42238) to L. J. G.; Glenn Foundation for Medical Research, Harvard Stem Cell Institute, and NIH (1R01 AG033053, 1DP2 OD004345, and 5U01 HL100402) to A. J. W.; NIH (R01 AG032977 1R01 AG040019) to R. T. L.; and Project Ascelegen to A. J. W. and R. T. L. A. J. W. is an Early Career Scientist of the Howard Hughes Medical Institute. M. F. H. owns shares in Abbott Laboratories, Amgen Inc., Colgate Palmolive Co., Eli Lilly and Co., Medtronic Inc., and Abbvie Inc. A. J. W. and R. T. L. are inventors on patent applications filed by Harvard University and Brigham and Women's Hospital entitled 'Methods and Compositions for Rejuvenating Skeletal Muscle Stem Cells' and 'Methods and Compositions for Rejuvenating Neuromuscular Junctions.'	Amthor H, 2009, P NATL ACAD SCI USA, V106, P7479, DOI 10.1073/pnas.0811129106; Brack AS, 2007, SCIENCE, V317, P807, DOI 10.1126/science.1144090; Cerletti M, 2008, CELL, V134, P37, DOI 10.1016/j.cell.2008.05.049; Cerletti M, 2012, CELL STEM CELL, V10, P515, DOI 10.1016/j.stem.2012.04.002; Chakkalakal JV, 2012, NATURE, V490, P355, DOI 10.1038/nature11438; Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260; Cosgrove BD, 2014, NAT MED, V20, P255, DOI 10.1038/nm.3464; De Santis C, 2011, J EXP BIOL, V214, P2671, DOI 10.1242/jeb.056374; Hakim CH, 2011, METHODS MOL BIOL, V709, P75, DOI 10.1007/978-1-61737-982-6_5; Jang YC, 2011, COLD SH Q B, V76, P101, DOI 10.1101/sqb.2011.76.010652; Katsimpardi L, 2014, SCIENCE, V344, P630, DOI 10.1126/science.1251141; Kim J, 2005, SCIENCE, V308, P1927, DOI 10.1126/science.1110175; Larsen BD, 2010, P NATL ACAD SCI USA, V107, P4230, DOI 10.1073/pnas.0913089107; Lee YJ, 2010, DEV BIOL, V347, P195, DOI 10.1016/j.ydbio.2010.08.022; Loffredo FS, 2013, CELL, V153, P828, DOI 10.1016/j.cell.2013.04.015; Mah LJ, 2010, LEUKEMIA, V24, P679, DOI 10.1038/leu.2010.6; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; McPherron AC, 1999, NAT GENET, V22, P260, DOI 10.1038/10320; McPherron AC, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471-213X-9-24; Nickel J, 2009, CYTOKINE GROWTH F R, V20, P367, DOI 10.1016/j.cytogfr.2009.10.022; Rossi DJ, 2007, NATURE, V447, P725, DOI 10.1038/nature05862; Shefer G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013307; Sherwood RI, 2004, CELL, V119, P543, DOI 10.1016/j.cell.2004.10.021	23	544	587	9	268	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 9	2014	344	6184					649	652		10.1126/science.1251152	http://dx.doi.org/10.1126/science.1251152			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG6OD	24797481	Green Accepted			2023-01-03	WOS:000335537400048
J	Shanahan, M; Ritter, A				Shanahan, Marian; Ritter, Alison			Cost Benefit Analysis of Two Policy Options for Cannabis: Status Quo and Legalisation	PLOS ONE			English	Article							WILLINGNESS-TO-PAY; MARIJUANA USE; CONTINGENT VALUATION; ADDICTION TREATMENT; DRUG-USE; PROHIBITION; PREVALENCE; CIGARETTES; AUSTRALIA; OUTCOMES	Aims: To date there has been limited analysis of the economic costs and benefits associated with cannabis legalisation. This study redresses this gap. A cost benefit analysis of two cannabis policy options the status quo (where cannabis use is illegal) and a legalised-regulated option was conducted. Method: A cost benefit analysis was used to value the costs and benefits of the two policies in monetary terms. Costs and benefits of each policy option were classified into five categories (direct intervention costs, costs or cost savings to other agencies, benefits or lost benefits to the individual or the family, other impacts on third parties, and adverse or spill over events). The results are expressed as a net social benefit (NSB). Findings: The mean NSB per annum from Monte Carlo simulations (with the 5 and 95 percentiles) for the status quo was $294.6 million AUD ($201.1 to $392.7 million) not substantially different from the $234.2 million AUD ($136.4 to $331.1 million) for the legalised-regulated model which excludes government revenue as a benefit. When government revenue is included, the NSB for legalised-regulated is higher than for status quo. Sensitivity analyses demonstrate the significant impact of educational attainment and wellbeing as drivers for the NSB result. Conclusion: Examining the percentiles around the two policy options, there appears to be no difference between the NSB for these two policy options. Economic analyses are essential for good public policy, providing information about the extent to which one policy is substantially economically favourable over another. In cannabis policy, for these two options this does not appear to be the case.	[Shanahan, Marian; Ritter, Alison] UNSW Australia, Natl Drug & Alcohol Res Ctr, Sydney, NSW, Australia	University of New South Wales Sydney	Shanahan, M (corresponding author), UNSW Australia, Natl Drug & Alcohol Res Ctr, Sydney, NSW, Australia.	M.Shanahan@unsw.edu.au		Ritter, Alison/0000-0001-9540-1920; Shanahan, Marian/0000-0001-9873-3576	Australian Research Council [DP0880066]; Colonial Foundation Trust; National Drug and Alcohol Research Centre; Commonwealth Government of Australia; NHMRC Senior Research Fellowship	Australian Research Council(Australian Research Council); Colonial Foundation Trust; National Drug and Alcohol Research Centre; Commonwealth Government of Australia(Australian Government); NHMRC Senior Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by grant from the Australian Research Council [DP0880066]. This work forms part of the Drug Policy Modelling Program, a program funded by the Colonial Foundation Trust and auspiced by the National Drug and Alcohol Research Centre, which receives core funding from the Commonwealth Government of Australia. Professor Ritter is funded through an NHMRC Senior Research Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ableson P, 2000, PUBLIC EC PRINCIPLES; Access Economics, 2008, HLTH NAT VAL STAT LI; Australian Bureau of Statistics, 2020, AV WEEKL EARN AUSTR; Australian Competition and Consumer Commission, 2008, REP ACCC INQ COMP RE; Australian Government Productivity Commission, 2007, REP GOV SERV 2006 CO; Australian Institute of Health and Welfare, 2008, 2007 NAT DRUG STRAT; Australian Institute of Health and Welfare (AIHW), 2008, 2007 NAT DRUG STRAT; Babor TF, 2003, ALCOHOL NO ORDINARY; Boys A, 2001, HEALTH EDUC RES, V16, P457, DOI 10.1093/her/16.4.457; Bureau of Crime Statistics and Research, 2006, COURT STAT; Burns L, 2006, ADDICTION, V101, P873, DOI 10.1111/j.1360-0443.2006.01444.x; California Department of Public Health, 2010, MED MAR PROGR FEES; Callard C, 2005, TOB CONTROL, V14, P278, DOI 10.1136/tc.2005.011353; Cameron L, 2001, ECON REC, V77, P19, DOI 10.1111/1475-4932.00002; Cancer Council Victoria, 2010, TOB AUSTR FACTS ISS; Carr VJ, 2003, AUST NZ J PSYCHIAT, V37, P31, DOI 10.1046/j.1440-1614.2003.01092.x; Caulkins JP, 2011, ADDICTION, V106, P1886, DOI 10.1111/j.1360-0443.2011.03461.x; Communities Office of Liquor Gaming and Racing, 2010, UND DRINK OFF; Crancer A, 2010, INVOLVEMENT MARIJUAN; Department of Justice, 2009, BEC POPP GROW; Donnelly N., 1999, EFFECTS CANNABIS EXP; Drummer OH, 2004, ACCIDENT ANAL PREV, V36, P239, DOI 10.1016/S0001-4575(02)00153-7; Drummond MF., 2005, METHODS EC EVALUATIO, P55; Englesman E, 2003, INT J DRUG POLICY, V14, P217; English DR, 1997, ADDICTION, V92, P1553; European Legal Database on Drugs, 2007, ADDICTION; Fergusson DM, 2002, BJOG-INT J OBSTET GY, V109, P21, DOI 10.1111/j.1471-0528.2002.01020.x; Fergusson DM, 2001, ACCIDENT ANAL PREV, V33, P703, DOI 10.1016/S0001-4575(00)00082-8; Freeman B, 2008, ADDICTION, V103, P580, DOI 10.1111/j.1360-0443.2008.02145.x; French MT, 2002, HEALTH SERV RES, V37, P433, DOI 10.1111/1475-6773.031; Geis G, 2005, CHOP CHOP ILLEGAL CI; Godfrey C, 2006, ECONOMIST-NETHERLAND, V154, P563, DOI 10.1007/s10645-006-9030-1; Haden M., 2004, International Journal of Drug Policy, V15, P225, DOI 10.1016/j.drugpo.2004.03.006; Hall W, 2003, CANNABIS USE DEPENDE; Hall W, 2009, CURR OPIN PSYCHIATR, V22, P258, DOI 10.1097/YCO.0b013e3283298f36; Hickman M, 2009, ADDICTION, V104, P1856, DOI 10.1111/j.1360-0443.2009.02736.x; Horwood LJ, 2010, DRUG ALCOHOL DEPEN, V110, P247, DOI 10.1016/j.drugalcdep.2010.03.008; Hughes C., 2007, EFFECTS DECRIMINALIZ; Kilmer B., 2010, ALTERED STATE ASSESS, DOI DOI 10.1089/jpm.2015.0051; King County Bar Association, 2005, EFF DRUG CONTR NEW L; Laumon B, 2005, BRIT MED J, V331, P1371, DOI 10.1136/bmj.38648.617986.1F; Leigh A, 2008, ECON EDUC REV, V27, P149, DOI 10.1016/j.econedurev.2006.09.004; Limb M, 2012, BMJ-BRIT MED J, V344, DOI [10.1136/:bmj.e3936, DOI 10.1136/:BMJ.E3936]; MacCoun R, 2001, DRUG WAR HERISIES LE; MacCoun R.J., 2010, ESTIMATING NONPRICE; Mann RE, 2008, CANNABIS USE DRIVING; Mann RE, 2007, J SAFETY RES, V38, P669, DOI 10.1016/j.jsr.2007.09.004; Martire K, 2009, PRINCIPAL DRUG ANAL; May T, 2002, TIMES THEY ARE CHANG; May T., 2007, POLICING CANNABIS CL; McCaffrey DF, 2010, HEALTH ECON, V19, P1281, DOI 10.1002/hec.1561; McDonald D, 1994, CANBERRA COMMONWEALT; McIntosh E, 2010, APPL METHODS COST BE; McLaren J, 2006, CANNABIS AUSTR USE S; Ministerial Council on Drug Strategy, 2005, AUSTR NAT TOB STRAT; Miron J, 2005, BUDGETARY IMPLICATIO; Mishan EJQE, 2007, COST BENEFIT ANAL; Moore THM, 2007, LANCET, V370, P319, DOI 10.1016/S0140-6736(07)61162-3; NADELMANN EA, 1989, SCIENCE, V245, P939, DOI 10.1126/science.2772647; Ngui R, 2010, CANNABIS USE DISORDE; NSW Industrial Relations, 2008, NSW PUBL SECT AW AGR; NSW Police Force, 2009, THIN BLUE LIN INF SE; NSW Police Force, 2007, CANN CAUT SCHEM; Pacula R.L., 2010, EXAMINING IMPACT MAR; Passey M, 2003, EVALUATION LISMORE M; Phillips B, 2008, NSW DRUG TRENDS 2008; Pudney S., 2006, MEASURING DIFFERENT; Pudney S, 2010, ECON POLICY, P165; Rhodes W, 1997, WHAT AM USERS SPEND; Roads and Traffic Authority, 2010, LIC; Rolles Stephen, 2009, WAR DRUGS BLUEPRINT; Room R., 2008, CANNABIS POLICY MOVI; Shanahan M., 2011, ASSESSING EC CONSEQU; Shanahan M, 2014, J EXP CRIMINOL, V10, P59, DOI 10.1007/s11292-013-9176-1; Sindelar JL, 2004, DRUG ALCOHOL DEPEN, V73, P41, DOI 10.1016/j.drugalcdep.2003.09.002; Teesson M, 2012, AUST NZ J PSYCHIAT, V46, P1182, DOI 10.1177/0004867412460591; Tolkien II Team, 2006, TOLK 2 NEEDS BAS COS; TRUMBULL WN, 1990, J POLICY ANAL MANAG, V9, P201, DOI 10.2307/3325412; Tsuchiya A, 2001, EC EVALUATION HLTH C; UNODC United Nations Office on Drugs and Crime Vienna, 2010, WORLD DRUG REP 2010; van Ours JC, 2009, J HEALTH ECON, V28, P132, DOI 10.1016/j.jhealeco.2008.09.001; Vining A, 2010, J BENEFIT-COST ANAL, V1, DOI 10.2202/2152-2812.1013; Weatherburn D, 2003, AUST NZ J CRIMINOL, V36, P77, DOI 10.1375/000486503764805473; Weimer DL, 2009, HEALTH ECON, V18, P181, DOI 10.1002/hec.1365; WHITTINGTON D, 1986, J POLICY ANAL MANAG, V5, P665, DOI 10.2307/3324877; Williams J, 2004, HEALTH ECON, V13, P825, DOI 10.1002/hec.859; Williams J, 2004, HEALTH ECON, V13, P123, DOI 10.1002/hec.796; Wilson J, 1991, CRIME JUSTICE, V13; WILSON JQ, 1990, COMMENTARY, V89, P21; Wodak A, 2002, BRIT MED J, V324, P105, DOI 10.1136/bmj.324.7329.105; Wood E, 2010, TOOLS DEBATE US FEDE; World Health Organization, 2005, WHO FRAM CONV TOB CO; Zarkin GA, 2000, J SUBST ABUSE TREAT, V18, P149, DOI 10.1016/S0740-5472(99)00030-6	93	19	19	3	70	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2014	9	4							095569	10.1371/journal.pone.0095569	http://dx.doi.org/10.1371/journal.pone.0095569			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AG2IS	24755942	Green Published, gold, Green Submitted			2023-01-03	WOS:000335240300055
J	Ford, ES; Mannino, DM; Wheaton, AG; Presley-Cantrell, L; Liu, Y; Giles, WH; Croft, JB				Ford, Earl S.; Mannino, David M.; Wheaton, Anne G.; Presley-Cantrell, Letitia; Liu, Yong; Giles, Wayne H.; Croft, Janet B.			Trends in the Use, Sociodemographic Correlates, and Undertreatment of Prescription Medications for Chronic Obstructive Pulmonary Disease among Adults with Chronic Obstructive Pulmonary Disease in the United States from 1999 to 2010	PLOS ONE			English	Article							CLINICAL-PRACTICE GUIDELINE; AMERICAN-COLLEGE; COPD; CARE; MANAGEMENT; PHYSICIANS; ADHERENCE; DIAGNOSIS; BARRIERS; AWARENESS	Background: The extent to which patients with COPD are receiving indicated treatment with medications to improve lung function and recent trends in the use of these medications is not well documented in the United States. The objective of this study was to examine trends in prescription medications for COPD among adults in the United States from 1999 to 2010. Methods: We performed a trend analysis using data from up to 1426 participants aged >= 20 years with self-reported COPD from six national surveys (National Health and Nutrition Examination Survey 1999-2010). Results: During 2009-2010, the age-adjusted percentage of participants who used any kind of medication was 44.2%. Also during 2009-2010, the most commonly used medications were short-acting agents (36.0%), inhaled corticosteroids (ICS) (18.3%), and LABAs (16.7%). The use of long-acting beta-2 agonists (LABAs) (p for trend <0.001), ICS (p for trend = 0.013) increased significantly over the 12-year period. Furthermore, the use of tiotropium increased rapidly during this period (p for trend <0.001). For the years 2005-2010, the use of LABAs, ICS and tiotropium increased with age. Compared with whites, Mexican Americans were less likely to use short-acting agents, LABAs, ICS, tiotropium, and any kind of COPD medication. Among participants aged 20-79 years with spirometry measurements during 2007-2010, the use of any medication was reported by 19.0% of those with a moderate/severe obstructive impairment and by 72.6% of those with self-reported COPD and any obstructive impairment. Conclusion: The percentages of adults with COPD who reported having various classes of prescription medications that improve airflow limitations changed markedly from 1999-2000 to 2009-2010. However, many adults with COPD did not report having recommended prescription medications.	[Ford, Earl S.; Wheaton, Anne G.; Presley-Cantrell, Letitia; Liu, Yong; Giles, Wayne H.; Croft, Janet B.] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA; [Mannino, David M.] Univ Kentucky, Coll Publ Hlth, Dept Prevent Med & Environm Hlth, Lexington, KY USA	Centers for Disease Control & Prevention - USA; University of Kentucky	Ford, ES (corresponding author), Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.	eford@cdc.gov		Wheaton, Anne/0000-0002-3181-9612; Mannino, David/0000-0003-3646-7828				Barr R Graham, 2005, Am J Med, V118, P1415; Brehm JM, 2008, AM J RESP CRIT CARE, V177, P473, DOI 10.1164/rccm.200708-1274PP; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; CDC National Centre for Chronic Disease Prevention & Health Promotion; Division of adult and community health, 2011, PUBL HLTH STRAT FRAM; Centers for Disease Control and Prevention, 2011, SPIR 1 TEST 2 TEST B; Centers for Disease Control and Prevention, 2009, NAT HLTH NUTR EX SUR; Colorado COPD Coalition American Lung Association of Colorado, 2007, STRAT PLAN ADDR CHRO; Decramer M, 2013, ACTA CLIN BELG, V68, P325, DOI 10.2143/ACB.3403; Foster Jill A, 2007, MedGenMed, V9, P24; Fromer L, 2011, INT J CHRONIC OBSTR, V6, P605, DOI 10.2147/COPD.S24692; Global Initiative for Chronic Obstructive Lung Disease, 2011, GLOB STRAT DIAGN MAN; Halbert RJ, 2006, EUR RESPIR J, V28, P523, DOI 10.1183/09031936.06.00124605; Halpin DMG, 2007, RESP MED, V101, P2378, DOI 10.1016/j.rmed.2007.06.010; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Ingebrigtsen TS, 2013, CHEST, V144, P1811, DOI 10.1378/chest.13-0453; Jones R, 2011, PRIM CARE RESP J, V20, P33, DOI 10.4104/pcrj.2010.00069; Make B, 2012, INT J CHRONIC OBSTR, V7, P1, DOI 10.2147/COPD.S27032; Nair KV, 2011, PATIENT PREFER ADHER, V5, P195, DOI 10.2147/PPA.S18481; National Heart Lung and Blood Institute, 2012, COPD LEARN MOR BREAT; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Perez X, 2012, RESP MED, V106, P374, DOI 10.1016/j.rmed.2011.09.010; Qaseem A, 2007, ANN INTERN MED, V147, P633, DOI 10.7326/0003-4819-147-9-200711060-00008; Qaseem A, 2011, ANN INTERN MED, V155, P179, DOI 10.7326/0003-4819-155-3-201108020-00008; Rabe KF, 2011, LANCET, V378, P1038, DOI 10.1016/S0140-6736(11)61295-6; Salinas GD, 2011, INT J CHRONIC OBSTR, V6, P171, DOI 10.2147/COPD.S16396; Sarc I, 2011, J EVAL CLIN PRACT, V17, P737, DOI 10.1111/j.1365-2753.2010.01617.x; Suh DC, 2008, RESP CARE, V53, P1461; Takahashi TU, 2003, RESPIROLOGY, V8, P504, DOI 10.1046/j.1440-1843.2003.00501.x; Toy EL, 2011, RESP MED, V105, P435, DOI 10.1016/j.rmed.2010.09.006; U.S. Department of Health and Human Services Public Health Service Centers for Disease Control and Prevention National Center for Health Statistics, 1994, VITAL HLTH STAT, V1; Voelkel NF, 2000, CHEST, V117, p372S, DOI 10.1378/chest.117.5_suppl_2.372S; Zielinski J, 2006, EUR RESPIR J, V27, P833, DOI 10.1183/09031936.06.00025905	32	10	10	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 21	2014	9	4							e95305	10.1371/journal.pone.0095305	http://dx.doi.org/10.1371/journal.pone.0095305			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG2DX	24751857	Green Published, gold			2023-01-03	WOS:000335227400050
J	Chang, CB; Lai, HY; Yang, SY; Wu, RS; Liu, HC; Hsu, HY; Hwang, SJ; Chan, DC				Chang, Chirn-Bin; Lai, Hsiu-Yun; Yang, Shu-Yu; Wu, Ru-Shu; Liu, Hsing-Cheng; Hsu, Hsiu-Ying; Hwang, Shinn-Jang; Chan, Ding-Cheng			Patient- and Clinic Visit-Related Factors Associated with Potentially Inappropriate Medication Use among Older Home Healthcare Service Recipients	PLOS ONE			English	Article							DRUG; OUTCOMES; OUTPATIENTS; PREVALENCE; RESIDENTS; CRITERIA; GERMANY	Objectives: Taiwanese National Health Insurance (TNHI) provides home healthcare services to patients with skilled nursing needs who were homebound or lived in nursing homes. Studies on potentially inappropriate medications (PIMs) for older home healthcare service recipients (HHSRs) are growing, but comparisons among newer criteria of PIMs have not been applied. The aim of this study was to explore the prevalence and correlates of PIMs based on three different instruments published after 2010 among older HHSRs. Materials and Methods: We performed cross-sectional analysis of the TNHI Research Database. A total of 25,187 HHSRs aged more than 65 years in 2009 were included. Medication lists independent of chronic conditions from the 2012 Beers criteria, PIM-Taiwan criteria, and the PRISCUS (Latin for "old and venerable') criteria were used. Analysis was performed separately at patient and clinic-visit level. T-tests, chi-square analysis, and multivariate logistic regressions were used where appropriate. Results: The prevalence of having at least one PIM at patient and clinic-visit level was highest with the Beers (82.67%, 36.14% respectively), followed by the PRISCUS (68.49%, 25.13%) and PIM-Taiwan (63.04%, 19.21%) criteria. At patient level, polypharmacy (odds ratio (OR) 2.53 to 4.90), higher number of clinic (OR 1.15 to 1.41), hospital (OR 1.24 to 1.64), and physician (OR 1.15 to 1.41) visits were associated with PIM use for all 3 sets of criteria. At clinic-visit level, internist/family physicians (OR 1.26 to 1.72) and neurologists/psychiatrists (OR 1.73 to 5.87) were more likely to prescribe PIMs than others. Psychotropic drugs and first generation antihistamines accounted for most of the top ten PIMs. Conclusion: The prevalence of PIMs was high among older Taiwanese HHSRs. Polypharmacy and certain medical specialties were associated with a higher likelihood of PIM prescriptions. Provider education and medication review and reconciliation should be considered.	[Chang, Chirn-Bin] Changhua Christian Hosp, Dept Internal Med, Changhua, Taiwan; [Chang, Chirn-Bin] Kaohsiung Med Univ, Sch Med, Kaohsiung, Taiwan; [Chang, Chirn-Bin] Chung Shan Med Univ, Sch Med, Taichung, Taiwan; [Lai, Hsiu-Yun] Natl Taiwan Univ Hosp, Dept Family Med, Hsinchu, Taiwan; [Yang, Shu-Yu; Wu, Ru-Shu; Hsu, Hsiu-Ying] Taipei City Hosp, Dept Pharm, Taipei, Taiwan; [Liu, Hsing-Cheng] Taipei City Hosp, Taipei City Psychiat Ctr, Taipei, Taiwan; [Hwang, Shinn-Jang] Taipei Vet Gen Hosp, Dept Family Med, Taipei, Taiwan; [Chan, Ding-Cheng] Natl Taiwan Univ Hosp, Dept Geriatr & Gerontol, Taipei, Taiwan; [Chan, Ding-Cheng] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan	Changhua Christian Hospital; Kaohsiung Medical University; Chung Shan Medical University; National Taiwan University; National Taiwan University Hospital; Taipei City Hospital; Taipei City Hospital; Taipei Veterans General Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Hwang, SJ (corresponding author), Taipei Vet Gen Hosp, Dept Family Med, Taipei, Taiwan.	sjhwang@vghtpe.gov.tw; doctord6226@yahoo.com	Bin Chang, Chirn/E-8605-2010	Chang, Chirn-Bin/0000-0001-9423-7655; CHAN, DING-CHENG/0000-0003-2215-2243				Baldoni AD, 2013, INT J CLIN PHARM; Bao YH, 2012, J GEN INTERN MED, V27, P304, DOI 10.1007/s11606-011-1905-4; Cannon Katrina T, 2006, Am J Geriatr Pharmacother, V4, P134, DOI 10.1016/j.amjopharm.2006.06.010; CHANG C, 2011, FILM COMMENT, V47, P72; Chang CB, 2012, PHARMACOEPIDEM DR S, V21, P1269, DOI 10.1002/pds.3274; Chang HT, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-274; Chen LL, 2012, INT J CLIN PHARM-NET, V34, P596, DOI 10.1007/s11096-012-9651-1; Chiatti C, 2012, DRUG SAFETY, V35, P73, DOI 10.1007/BF03319105; Chu HY, 2012, MED CARE, V50, P1002, DOI 10.1097/MLR.0b013e31826c870f; Fialova D, 2005, JAMA-J AM MED ASSOC, V293, P1348, DOI 10.1001/jama.293.11.1348; Fick D, 2012, J AM GERIATR SOC, V60, P616, DOI 10.1111/j.1532-5415.2012.03923.x; Garcia-Gollarte F, 2012, J AM MED DIR ASSOC, V13, DOI 10.1016/j.jamda.2011.02.009; Hakkarainen KM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033236; Holt S, 2010, DTSCH ARZTEBL INT, V107, P543, DOI 10.3238/arztebl.2010.0543; Jano E, 2007, ANN PHARMACOTHER, V41, P438, DOI 10.1345/aph.1H473; Kolzsch M, 2011, PHARMACOEPIDEM DR S, V20, P12, DOI 10.1002/pds.2005; Lai HY, 2009, CLIN THER, V31, P1859, DOI 10.1016/j.clinthera.2009.08.023; Lau DT, 2005, ARCH INTERN MED, V165, P68, DOI 10.1001/archinte.165.1.68; Maio V, 2010, J CLIN PHARM THER, V35, P219, DOI 10.1111/j.1365-2710.2009.01094.x; Maio V, 2006, DRUG AGING, V23, P915, DOI 10.2165/00002512-200623110-00006; Murtaugh Christopher, 2009, J Healthc Qual, V31, P34; O'Sullivan DP, 2013, DRUG AGING, V30, P39, DOI 10.1007/s40266-012-0039-7; Onder G, 2002, J AM GERIATR SOC, V50, P1962, DOI 10.1046/j.1532-5415.2002.50607.x; Perri M, 2005, ANN PHARMACOTHER, V39, P405, DOI 10.1345/aph.1E230; Pugh MJV, 2005, J AM GERIATR SOC, V53, P1282, DOI 10.1111/j.1532-5415.2005.53402.x; Pugh MJV, 2008, MED CARE, V46, P167, DOI 10.1097/MLR.0b013e318158aec2; Raivio MM, 2006, DRUG AGING, V23, P333, DOI 10.2165/00002512-200623040-00006; Riker GI, 2012, HOME HEALTHC NURSE, V30, P486; Riker Gretchen I, 2013, Home Healthc Nurse, V31, P65, DOI 10.1097/NHH.0b013e31827f43b2; Riker Gretchen I, 2012, Home Healthc Nurse, V30, P474, DOI 10.1097/NHH.0b013e31826502dd; Schubert I, 2013, PHARMACOEPIDEM DR S, V22, P719, DOI 10.1002/pds.3429; de Lima TJV, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-52; Weng MC, 2013, QJM-INT J MED, V106, P1009, DOI 10.1093/qjmed/hct141	33	23	24	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 10	2014	9	4							e94350	10.1371/journal.pone.0094350	http://dx.doi.org/10.1371/journal.pone.0094350			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AI5LS	24722537	gold, Green Submitted, Green Published			2023-01-03	WOS:000336909100057
J	Garcia-Alvarez, A; Egan, B; de Klein, S; Dima, L; Maggi, FM; Isoniemi, M; Ribas-Barba, L; Raats, MM; Meissner, EM; Badea, M; Bruno, F; Salmenhaara, M; Mila-Villarroel, R; Knaze, V; Hodgkins, C; Marculescu, A; Uusitalo, L; Restani, P; Serra-Majem, L				Garcia-Alvarez, Alicia; Egan, Bernadette; de Klein, Simone; Dima, Lorena; Maggi, Franco M.; Isoniemi, Merja; Ribas-Barba, Lourdes; Raats, Monique M.; Meissner, Eva Melanie; Badea, Mihaela; Bruno, Flavia; Salmenhaara, Maija; Mila-Villarroel, Raimon; Knaze, Viktoria; Hodgkins, Charo; Marculescu, Angela; Uusitalo, Liisa; Restani, Patrizia; Serra-Majem, Lluis			Usage of Plant Food Supplements across Six European Countries: Findings from the PlantLIBRA Consumer Survey	PLOS ONE			English	Article							NATIONAL-HEALTH; ALTERNATIVE MEDICINE; DIETARY-SUPPLEMENTS; UNITED-STATES; HERBAL SUPPLEMENTS; ADULT-POPULATION; US ADULTS; COMPLEMENTARY; PATTERNS; PREVALENCE	Background: The popularity of botanical products is on the rise in Europe, with consumers using them to complement their diets or to maintain health, and products are taken in many different forms (e. g. teas, juices, herbal medicinal products, plant food supplements (PFS)). However there is a scarcity of data on the usage of such products at European level. Objective: To provide an overview of the characteristics and usage patterns of PFS consumers in six European countries. Design: Data on PFS usage were collected in a cross-sectional, retrospective survey of PFS consumers using a bespoke frequency of PFS usage questionnaire. Subjects/setting: A total sample of 2359 adult PFS consumers from Finland, Germany, Italy, Romania, Spain and the United Kingdom. Data analyses: Descriptive analyses were conducted, with all data stratified by gender, age, and country. Absolute frequencies, percentages and 95% confidence intervals are reported. Results: Overall, an estimated 18.8% of screened survey respondents used at least one PFS. Characteristics of PFS consumers included being older, well-educated, never having smoked and self-reporting health status as "good or very good". Across countries, 491 different botanicals were identified in the PFS products used, with Ginkgo biloba (Ginkgo), Oenothera biennis (Evening primrose) and Cynara scolymus (Artichoke) being most frequently reported; the most popular dose forms were capsules and pills/tablets. Most consumers used one product and half of all users took single-botanical products. Some results varied across countries. Conclusions: The PlantLIBRA consumer survey is unique in reporting on usage patterns of PFS consumers in six European countries. The survey highlights the complexity of measuring the intake of such products, particularly at pan-European level. Incorporating measures of the intake of botanicals in national dietary surveys would provide much-needed data for comprehensive risk and benefit assessments at the European level.	[Garcia-Alvarez, Alicia; Ribas-Barba, Lourdes; Mila-Villarroel, Raimon; Knaze, Viktoria; Serra-Majem, Lluis] Univ Barcelona, Fdn Invest Nutr, Barcelona, Spain; [Egan, Bernadette; Raats, Monique M.; Hodgkins, Charo] Univ Surrey, Food Consumer Behav & Hlth Res Ctr, Guildford GU2 5XH, Surrey, England; [de Klein, Simone; Meissner, Eva Melanie] PhytoLab GmbH & Co KG, Vestenbergsgreuth, Germany; [Dima, Lorena; Badea, Mihaela; Marculescu, Angela] Transilvania Univ Brasov, Brasov, Romania; [Maggi, Franco M.; Bruno, Flavia; Restani, Patrizia] Univ Milan, Dipartimento Sci Farmacol & Biomol, Milan, Italy; [Isoniemi, Merja; Salmenhaara, Maija; Uusitalo, Liisa] Finnish Food Safety Author Evira, Helsinki, Finland; [Ribas-Barba, Lourdes; Serra-Majem, Lluis] Inst Salud Carlos III, Ciber Obn Fisiopatol Obesidad & Nutr, Madrid, Spain; [Serra-Majem, Lluis] Univ Las Palmas Gran Canaria, Inst Biomed & Hlth Res Las Palmas, Las Palmas Gran Canaria, Spain	University of Barcelona; University of Surrey; Transylvania University of Brasov; University of Milan; Finnish Food Authority; CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; Instituto de Salud Carlos III; Universidad de Las Palmas de Gran Canaria	Serra-Majem, L (corresponding author), Univ Barcelona, Fdn Invest Nutr, Barcelona Sci Pk, Barcelona, Spain.	lserra@dcc.ulpgc.es	Milà Villarroel, Raimon/AGR-2823-2022; Serra-Majem, Lluis/I-6708-2019; Garcia-Alvarez, Alicia/AAV-9762-2020; Raats, Monique/G-5348-2012; Badea, Mihaela/Z-1490-2018; Badea, Mihaela/B-8240-2012	Serra-Majem, Lluis/0000-0002-9658-9061; Raats, Monique/0000-0002-8057-2783; Badea, Mihaela/0000-0003-4824-2175; Egan, Bernadette/0000-0002-5767-0457; Dima, Lorena/0000-0002-4406-9304; Hodgkins, Charo/0000-0003-4775-0338	European Community [245199]; European Commission	European Community(European Commission); European Commission(European CommissionEuropean Commission Joint Research Centre)	The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement no 245199. It has been carried out within the PlantLIBRA project (www.plantlibra.eu). This report does not necessarily reflect the Commission's views or its future policy on this area. The European Commission had no direct say in the project methods or outcome beyond providing funding for materials and personnel, and did not directly contribute to the writing of this manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams J, 2009, BIRTH-ISS PERINAT C, V36, P237, DOI 10.1111/j.1523-536X.2009.00328.x; [Anonymous], 2002, OFF J EUR COMMUNIT L, VL183, P51; Bailey RL, 2013, JAMA INTERN MED, V173, P355, DOI 10.1001/jamainternmed.2013.2299; Bardia A, 2007, MAYO CLIN PROC, V82, P561, DOI 10.4065/82.5.561; Bishop FL, 2010, EVID-BASED COMPL ALT, V7, P11, DOI 10.1093/ecam/nen023; Block G, 2007, NUTR J, V6, DOI 10.1186/1475-2891-6-30; Bundesinstitut fur Risikobewertung, 2013, TARG GROUP OR RISK C; Centro de Investigacion sobre Fitoterapia, 2007, EST INFITO CONS PLAN; Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB; Dwyer J, 2013, AM J CLIN NUTR, V97, P1331, DOI 10.3945/ajcn.112.052373; EFSA, 2009, EFSA J, V7, DOI 10.2903/j.efsa.2009.225r; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; European Advisory Services (EAS), 2007, US SUBST NUTR PHYS E; European Food Safety Authority, 2012, EFSA J, V10, DOI 10.2903/j.efsa.2012.2663; Federal Office of Consumer Protection and Food Safety (BVL), 2010, SUBST LIST DRAFT LIS; Finger JD, 2013, BUNDESGESUNDHEITSBLA, V56, P607; Foote JA, 2003, AM J EPIDEMIOL, V157, P888, DOI 10.1093/aje/kwg072; Harrison RA, 2004, INT J VITAM NUTR RES, V74, P183, DOI 10.1024/0300-9831.74.3.183; Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337; Kelly JP, 2005, ARCH INTERN MED, V165, P281, DOI 10.1001/archinte.165.3.281; Larranaga-Guetaria A, 2012, AGRO FOOD IND HI TEC, V23, P20; Max Rubner Institut, 2008, GERM NAT NUTR SURV N; Menniti-Ippolito F, 2002, EUR J CLIN PHARMACOL, V58, P61, DOI 10.1007/s00228-002-0435-8; Messerer M, 2001, J INTERN MED, V250, P160, DOI 10.1046/j.1365-2796.2001.00872.x; National Center for Health Statistics, 2009, NAT HLTH NUTR EX SUR; National Center for Health Statistics, 2003, 2002 NAT HLTH INT SU; Nielsen MW, 2005, ANN PHARMACOTHER, V39, P1534, DOI 10.1345/aph.1G119; Nilsson M, 2001, J INTERN MED, V250, P225, DOI 10.1046/j.1365-2796.2001.00882.x; Picciano MF, 2007, ARCH PEDIAT ADOL MED, V161, P978, DOI 10.1001/archpedi.161.10.978; Radimer K, 2004, AM J EPIDEMIOL, V160, P339, DOI 10.1093/aje/kwh207; Ritchie MR, 2007, P NUTR SOC, V66, P479, DOI 10.1017/S0029665107005794; Rock CL, 2007, AM J CLIN NUTR, V85, p277S, DOI 10.1093/ajcn/85.1.277S; Rovira MA, 2013, J NUTR EDUC BEHAV, V45, P386, DOI 10.1016/j.jneb.2012.03.007; Schaffer DM, 2003, J AM DIET ASSOC, V103, P1500, DOI 10.1016/j.jada.2003.08.026; Silano V, 2011, FOOD FUNCT, V2, P710, DOI 10.1039/c1fo10105f; Skeie G, 2009, EUR J CLIN NUTR, V63, pS226, DOI 10.1038/ejcn.2009.83; Thomas KJ, 2001, COMPLEMENT THER MED, V9, P2, DOI 10.1054/ctim.2000.0407; Timbo BB, 2006, J AM DIET ASSOC, V106, P1966, DOI 10.1016/j.jada.2006.09.002; Touvier M, 2009, EUR J CLIN NUTR, V63, P39, DOI 10.1038/sj.ejcn.1602907; Vargas-Murga L, 2011, FOOD FUNCT, V2, P731, DOI 10.1039/c1fo10075k; World Health Organization (WHO), 2013, BMI CLASS; Wu CH, 2011, CLIN THER, V33, P1749, DOI 10.1016/j.clinthera.2011.09.024	42	81	81	0	46	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2014	9	3							e92265	10.1371/journal.pone.0092265	http://dx.doi.org/10.1371/journal.pone.0092265			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AD4ZE	24642692	gold, Green Submitted, Green Published			2023-01-03	WOS:000333259900115
J	Cillo, AR; Krishnan, S; McMahon, DK; Mitsuyasu, RT; Para, MF; Mellors, JW				Cillo, Anthony R.; Krishnan, Supriya; McMahon, Deborah K.; Mitsuyasu, Ronald T.; Para, Michael F.; Mellors, John W.			Impact of Chemotherapy for HIV-1 Related Lymphoma on Residual Viremia and Cellular HIV-1 DNA in Patients on Suppressive Antiretroviral Therapy	PLOS ONE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; LATENT RESERVOIR; PCR ASSAY; TRANSPLANTATION; BLOOD; CELLS; QUANTIFICATION; RESISTANCE; COFACTOR; DEFENSE	The first cure of HIV-1 infection was achieved through complex, multimodal therapy including myeloablative chemotherapy, total body irradiation, anti-thymocyte globulin, and allogeneic stem cell transplantation with a CCR5 delta32 homozygous donor. The contributions of each component of this therapy to HIV-1 eradication are unclear. To assess the impact of cytotoxic chemotherapy alone on HIV-1 persistence, we longitudinally evaluated low-level plasma viremia and HIV-1 DNA in PBMC from patients in the ACTG A5001/ALLRT cohort on suppressive antiretroviral therapy (ART) who underwent chemotherapy for HIV-1 related lymphoma without interrupting ART. Plasma HIV-1 RNA, total HIV-1 DNA and 2-LTR circles (2-LTRs) in PBMC were measured using sensitive qPCR assays. In the 9 patients who received moderately intensive chemotherapy for HIV-1 related lymphoma with uninterrupted ART, low-level plasma HIV-1 RNA did not change significantly with chemotherapy: median HIV-1 RNA was 1 copy/mL (interquartile range: 1.0 to 20) pre-chemotherapy versus 4 copies/mL (interquartile range: 1.0 to 7.0) post-chemotherapy. HIV-1 DNA levels also did not change significantly, with median pre-chemotherapy HIV-1 DNA of 355 copies/10(6) CD4+ cells versus 228 copies/10(6) CD4+ cells post-chemotherapy. 2-LTRs were detectable in 2 of 9 patients pre-chemotherapy and in 3 of 9 patients post-chemotherapy. In summary, moderately intensive chemotherapy for HIV-1 related lymphoma in the context of continuous ART did not have a prolonged impact on HIV-1 persistence.	[Cillo, Anthony R.; McMahon, Deborah K.; Mellors, John W.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA; [Krishnan, Supriya] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Mitsuyasu, Ronald T.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA; [Para, Michael F.] Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Harvard T.H. Chan School of Public Health; University of California System; University of California Los Angeles; University System of Ohio; Ohio State University	Cillo, AR (corresponding author), Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA.	arc85@pitt.edu; jwm1@pitt.edu			National Institute of Allergy and Infectious Diseases [U01AI068636]; National Institute of Mental Health (NIMH); National Institute of Dental and Craniofacial Research (NIDCR); AIDS Clinical Trials Group to the Pittsburgh Virology Specialty Laboratory [AI068636]; Statistical and Data Management Center [UM1 AI068634]; Clinical Trials Units at the University of Pittsburgh [AI069494]; Ohio State University [AI069474]; University of California Los Angeles Clinical Research Core [AI28697]; Pitt AIDS Research Training Grant [5 T32 AI065380-08]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI069494, UM1AI106701, U01AI069474, T32AI065380, UM1AI069494, P30AI028697, UM1AI068636, UM1AI069474, UM1AI069424, U01AI068636, UM1AI068634] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Mental Health (NIMH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Institute of Dental and Craniofacial Research (NIDCR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); AIDS Clinical Trials Group to the Pittsburgh Virology Specialty Laboratory; Statistical and Data Management Center; Clinical Trials Units at the University of Pittsburgh; Ohio State University(Ohio State University); University of California Los Angeles Clinical Research Core; Pitt AIDS Research Training Grant; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The project described was supported by award number U01AI068636 from the National Institute of Allergy and Infectious Diseases and supported by National Institute of Mental Health (NIMH) and the National Institute of Dental and Craniofacial Research (NIDCR). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health. This work was also supported by grants from the AIDS Clinical Trials Group to the Pittsburgh Virology Specialty Laboratory (AI068636), the Statistical and Data Management Center (UM1 AI068634), the Clinical Trials Units at the University of Pittsburgh (AI069494), Ohio State University (AI069474), and the University of California Los Angeles Clinical Research Core (AI28697). ARC also received support from the Pitt AIDS Research Training Grant (#5 T32 AI065380-08). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agrawal L, 2004, J VIROL, V78, P2277, DOI 10.1128/JVI.78.5.2277-2287.2004; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Bolotin E, 1999, BONE MARROW TRANSPL, V23, P783, DOI 10.1038/sj.bmt.1701655; Casorati G, 2005, EXP HEMATOL, V33, P212, DOI 10.1016/j.exphem.2004.10.008; Chomont N, 2009, NAT MED, V15, P893, DOI 10.1038/nm.1972; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Cillo AR, 2013, JAIDS-J ACQ IMM DEF, V63, P438, DOI 10.1097/QAI.0b013e31828e6163; DiGiusto DL, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000931; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Henrich TJ, 2013, J INFECT DIS, V207, P1694, DOI 10.1093/infdis/jit086; Henrich TJ, 6 INT WORKSH HIV PER; Ho YC, 2013, CELL, V155, P540, DOI 10.1016/j.cell.2013.09.020; Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905; Lehrnbecher T, 1997, J PEDIAT HEMATOL ONC, V19, P399, DOI 10.1097/00043426-199709000-00001; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; MACKALL CL, 1994, BLOOD, V84, P2221; Maldarelli F, 2007, PLOS PATHOG, V3, P484, DOI 10.1371/journal.ppat.0030046; Malnati MS, 2008, NAT PROTOC, V3, P1240, DOI 10.1038/nprot.2008.108; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Martinson JJ, 1997, NAT GENET, V16, P100, DOI 10.1038/ng0597-100; Mitsuyasu RT, 2009, NAT MED, V15, P285, DOI 10.1038/nm.1932; Palmer S, 2003, J CLIN MICROBIOL, V41, P4531, DOI 10.1128/JCM.41.10.4531-4536.2003; Palmer S, 2008, P NATL ACAD SCI USA, V105, P3879, DOI 10.1073/pnas.0800050105; Petz LD, 2013, BIOL BLOOD MARROW TR, V19, P393, DOI 10.1016/j.bbmt.2012.10.017; Sanchez G, 1997, J VIROL, V71, P2233, DOI 10.1128/JVI.71.3.2233-2240.1997; Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880; Smurzynski M, 2008, HIV CLIN TRIALS, V9, P269, DOI 10.1310/hct0904-269; Tebas P, 2013, BLOOD, V121, P1524, DOI 10.1182/blood-2012-07-447250; Turtle CJ, 2009, IMMUNITY, V31, P834, DOI 10.1016/j.immuni.2009.09.015; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Zou SM, 2013, BLOOD, V122, P3111, DOI 10.1182/blood-2013-07-518316	32	15	16	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 17	2014	9	3							e92118	10.1371/journal.pone.0092118	http://dx.doi.org/10.1371/journal.pone.0092118			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AD4XD	24638072	Green Published, Green Accepted, gold			2023-01-03	WOS:000333254100114
J	Solem, CT; Snedecor, SJ; Khachatryan, A; Nedrow, K; Tawadrous, M; Chambers, R; Haider, S; Simpson, K				Solem, Caitlyn T.; Snedecor, Sonya J.; Khachatryan, Alexandra; Nedrow, Katherine; Tawadrous, Margaret; Chambers, Richard; Haider, Seema; Simpson, Kit			Cost of Treatment in a US Commercially Insured, HIV-1-Infected Population	PLOS ONE			English	Article							COMBINATION ANTIRETROVIRAL THERAPY; VIROLOGICAL FAILURE; HEALTH-CARE; HIV; ADHERENCE; OUTCOMES	Objective: Recent treatment patterns and cost data associated with HIV in the United States are limited. This study assessed first-line persistence and healthcare costs of HIV-1 in patients by treatment line and CD4 cell count. Methods: MarketScan Commercial Claims and Encounters Database (2007-2011) and Lab Database (2007-2010) were used to construct two HIV-1 cohorts: 1) newly treated HIV-1-infected patients with >= 6 months' continuous enrollment prior to first third-agent drug claim (Newly Treated Cohort) and 2) CD4 cell count test results (CD4 Measurements Cohort). All patients were >= 18 years old and without hepatitis co-infection. The Kaplan-Meier method was used to measure treatment switch rates. Generalized linear models (gamma distribution, log link) were used to compare healthcare costs by treatment line and CD4 cell count controlling for potential confounders. Results: Newly treated patients (n = 8,617) had mean age of 41, 82% were male, and 20% had experienced AIDS-defining events at baseline. Over 20% of newly treated patients switched initial treatment regimen within 2 years. Average unadjusted (and covariate-adjusted) total healthcare cost/year was $33,674 ($28,861) for first-line, $39,191 ($35,805) for second-line, and $39,882 ($40,804) for third-line treatment. Covariate-adjusted costs of care on second-and third-line treatments were significantly more expensive than first-line treatment (24% [p<0.001] and 41% [p=0.006] higher, respectively). The CD4 Measurements Cohort included 803 CD4 measurements (mean age 49, 76% male, 8% experienced an AIDS-defining event). Costs associated with CD4 measurements <100 cells/mu L were 92% higher than those with >350 cells/mu L (p<0.001). For higher CD4 cell counts, the majority of expenditures were for antiretrovirals (64% of total for CD4 > 350 cells/mu L). Conclusions: Despite modern advances in antiretroviral therapy and medical care, direct medical costs of HIV-1-infected patients increase after treatment switch and with lower CD4 counts, consistent with previous costing studies.	[Solem, Caitlyn T.; Snedecor, Sonya J.; Khachatryan, Alexandra] Pharmerit Int, Bethesda, MD 20814 USA; [Nedrow, Katherine; Tawadrous, Margaret; Haider, Seema] Pfizer Inc, Groton, CT 06340 USA; [Chambers, Richard] Pfizer Inc, Philadelphia, PA USA; [Simpson, Kit] Med Univ S Carolina, Charleston, SC 29425 USA	Pfizer; Pfizer; Medical University of South Carolina	Snedecor, SJ (corresponding author), Pharmerit Int, Bethesda, MD 20814 USA.	ssnedecor@pharmerit.com	Tawadrous, Margaret/AAY-3551-2020	Solem, Caitlyn/0000-0002-4914-8052	ViiV Healthcare	ViiV Healthcare	The study was sponsored by ViiV Healthcare, who also funded editorial assistance during the development of this manuscript. All authors participated in study design, data collection and analysis, decision to publish, and preparation and review of manuscript.	Centers for Disease Control and Prevention, 2014, CTR DIS CONTR PREV H; Centers for Disease Control and Prevention, 2008, MMWR-MORBID MORTAL W, V57, pRR; Chen RY, 2006, CLIN INFECT DIS, V42, P1003, DOI 10.1086/500453; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Fong R, 2013, SEX HEALTH, V10, P442, DOI 10.1071/SH13043; Freedberg KA, 2001, NEW ENGL J MED, V344, P824, DOI 10.1056/NEJM200103153441108; Gebo KA, 2010, AIDS, V24, P2705, DOI 10.1097/QAD.0b013e32833f3c14; Hall HI, 2008, JAMA-J AM MED ASSOC, V300, P520, DOI 10.1001/jama.300.5.520; Hogg R, 2013, 7 IAS C HIV PATH TRE; Mannheimer S, 2002, CLIN INFECT DIS, V34, P1115, DOI 10.1086/339074; Martin S, 2007, 4 IAS C HIV PATH TRE; Meenan RT, 2010, CLIN MED RES, V8, P52, DOI [DOI 10.3121/CMR.8.1.52-A, 10.3121/cmr.8.1.52-a]; National Center forHealth Statistics, 2011, HLTH US 2010 SPEC FE; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Rodger AJ, 2013, AIDS, V27, P973, DOI 10.1097/QAD.0b013e32835cae9c; Rosenblum M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007196; Schackman BR, 2006, MED CARE, V44, P990, DOI 10.1097/01.mlr.0000228021.89490.2a; Snedecor SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072784; Stansell J, 2000, 7 C RETR OPP INF SAN	19	19	20	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2014	9	5							e98152	10.1371/journal.pone.0098152	http://dx.doi.org/10.1371/journal.pone.0098152			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI5NG	24866200	gold, Green Submitted, Green Published			2023-01-03	WOS:000336914100036
J	Chin, Y; Lim, SH; Zorlu, Y; Ahsen, V; Kiew, LV; Chung, LY; Dumoulin, F; Lee, HB				Chin, Yunni; Lim, Siang Hui; Zorlu, Yunus; Ahsen, Vefa; Kiew, Lik Voon; Chung, Lip Yong; Dumoulin, Fabienne; Lee, Hong Boon			Improved Photodynamic Efficacy of Zn(II) Phthalocyanines via Glycerol Substitution	PLOS ONE			English	Article							IN-VITRO; PHOTOPHYSICAL PROPERTIES; THERAPY; CANCER; DERIVATIVES; PHOTOSENSITIZERS; BACTERIOCHLORIN; PLATINUM(II); COMPLEXES; MG(II)	Phthalocyanines are excellent photosensitizers for photodynamic therapy as they have strong absorbance in the near infrared region which is most relevant for in vivo activation in deeper tissular regions. However, most phthalocyanines present two major challenges, ie, a strong tendency to aggregate and low water-solubility, limiting their effective usage clinically. In the present study, we evaluated the potential enhancement capability of glycerol substitution on the photodynamic properties of zinc (II) phthalocyanines (ZnPc). Three glycerol substituted ZnPc, 1-3, (tetra peripherally, tetra non-peripherally and mono iodinated tri non-peripherally respectively) were evaluated in terms of their spectroscopic properties, rate of singlet oxygen generation, partition coefficient (log P), intracellular uptake, photo-induced cytotoxicity and vascular occlusion efficiency. Tetrasulfonated ZnPc (ZnPcS4) was included as a reference compound. Here, we showed that 1-3 exhibited 10-100 nm red-shifted absorption peaks with higher molar absorptivity, and at least two-fold greater singlet oxygen generation rates compared to ZnPcS4. Meanwhile, phthalocyanines 1 and 2 showed more hydrophilic log P values than 3 consistent with the number of glycerol attachments but 3 was most readily taken up by cells compared to the rest. Both phthalocyanines 2 and 3 exhibited potent phototoxicity against MCF-7, HCT-116 and HSC-2 cancer cell-lines with IC50 ranging 2.8-3.2 mM and 0.04-0.06 mu M respectively, while 1 and ZnPcS4 (up to 100 mu M) failed to yield determinable IC50 values. In terms of vascular occlusion efficiency, phthalocyanine 3 showed better effects than 2 by causing total occlusion of vessels with diameter similar to 70 mu m of the chorioallantoic membrane. Meanwhile, no detectable vascular occlusion was observed for ZnPcS4 with treatment under similar experimental conditions. These findings provide evidence that glycerol substitution, in particular in structures 2 and 3, is able to improve the photodynamic properties of ZnPc.	[Chin, Yunni; Kiew, Lik Voon] Univ Malaya, Fac Med, Dept Pharmacol, Kuala Lumpur 50603, Malaysia; [Lim, Siang Hui; Chung, Lip Yong] Univ Malaya, Fac Med, Dept Pharm, Kuala Lumpur, Malaysia; [Chin, Yunni; Lim, Siang Hui; Lee, Hong Boon] Canc Res Initiat Fdn CARIF, Drug Discovery Lab, Subang Jaya, Selangor, Malaysia; [Zorlu, Yunus; Ahsen, Vefa; Dumoulin, Fabienne] Gebze Inst Technol, Dept Chem, TR-41400 Gebze, Kocaeli, Turkey	Universiti Malaya; Universiti Malaya; Gebze Technical University	Lim, SH (corresponding author), Univ Malaya, Fac Med, Dept Pharm, Kuala Lumpur, Malaysia.	sianghui.lim@carif.com.my; fdumoulin@gyte.edu.tr	Dumoulin, Fabienne/AAA-9838-2019; Zorlu, Yunus/AAA-9320-2020; CHUNG, LIP YONG/B-7764-2010; KIEW, LIK VOON/B-8789-2010	Dumoulin, Fabienne/0000-0002-0388-8338; Zorlu, Yunus/0000-0003-2811-1872; CHUNG, LIP YONG/0000-0002-3596-768X; KIEW, LIK VOON/0000-0002-6855-9631; , LEE/0000-0002-0768-2222	Ministry of Higher Education of Malaysia (HIR/MoHE) [UM.C/625/1/HIR/MOHE/MED/17, UM.C/625/1/HIR/MOHE/MED/33]; Scientific and Technological Research Council of Turkey TUBITAK [106T376, 111T031]; University of Malaya [PG042-2012B]	Ministry of Higher Education of Malaysia (HIR/MoHE); Scientific and Technological Research Council of Turkey TUBITAK(Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)); University of Malaya(Universiti Malaya)	These works were supported by the Ministry of Higher Education of Malaysia (HIR/MoHE grants, UM.C/625/1/HIR/MOHE/MED/17 and UM.C/625/1/HIR/MOHE/MED/33), the Scientific and Technological Research Council of Turkey TUBITAK (projects 106T376 and 111T031) and the Postgraduate Research Grant (PPP) from University of Malaya (PG042-2012B). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ackroyd R, 2001, PHOTOCHEM PHOTOBIOL, V74, P656, DOI 10.1562/0031-8655(2001)074<0656:THOPAP>2.0.CO;2; Allen CM, 2002, PHOTOCHEM PHOTOBIOL, V76, P208, DOI 10.1562/0031-8655(2002)076<0208:PPOADO>2.0.CO;2; Allison RR, 2010, PHOTODIAGN PHOTODYN, V7, P61, DOI 10.1016/j.pdpdt.2010.02.001; Allison RR, 2004, PHOTODIAGN PHOTODYN, V1, P27, DOI 10.1016/S1572-1000(04)00007-9; Arslanoglu Y, 2012, SPECTROCHIM ACTA A, V95, P407, DOI 10.1016/j.saa.2012.04.004; AYE KT, 1995, INORG CHIM ACTA, V235, P307, DOI 10.1016/0020-1693(95)90072-E; Azenha EG, 2002, CHEM PHYS, V280, P177, DOI 10.1016/S0301-0104(02)00485-8; Biyiklioglu Z, 2012, SYNTHETIC MET, V162, P1156, DOI 10.1016/j.synthmet.2012.04.032; Brown, 1999, Expert Opin Investig Drugs, V8, P1967, DOI 10.1517/13543784.8.12.1967; Canlica M, 2012, POLYHEDRON, V31, P704, DOI 10.1016/j.poly.2011.10.024; Dumoulin F, 2011, TETRAHEDRON LETT, V52, P4395, DOI 10.1016/j.tetlet.2011.06.010; Dumoulin F, 2010, COORDIN CHEM REV, V254, P2792, DOI 10.1016/j.ccr.2010.05.002; Erdogmus A, 2010, J MOL STRUCT, V977, P26, DOI 10.1016/j.molstruc.2010.04.048; Gorman A, 2004, J AM CHEM SOC, V126, P10619, DOI 10.1021/ja047649e; Hajri A, 2002, PHOTOCHEM PHOTOBIOL, V75, P140, DOI 10.1562/0031-8655(2002)075<0140:IVAIVE>2.0.CO;2; Huang YY, 2010, J MED CHEM, V53, P4018, DOI 10.1021/jm901908s; Konan YN, 2002, J PHOTOCH PHOTOBIO B, V66, P89, DOI 10.1016/S1011-1344(01)00267-6; Kozhevnikov DN, 2009, INORG CHEM, V48, P4179, DOI 10.1021/ic802401j; Lange N, 2001, INVEST OPHTH VIS SCI, V42, P38; Lim SH, 2011, PHOTOCHEM PHOTOBIOL, V87, P1152, DOI 10.1111/j.1751-1097.2011.00939.x; Lim SH, 2010, J MED CHEM, V53, P2865, DOI 10.1021/jm901823u; Lim SH, 2010, PHOTOCHEM PHOTOBIOL, V86, P397, DOI 10.1111/j.1751-1097.2009.00684.x; Lo PC, 2003, TETRAHEDRON LETT, V44, P1967, DOI 10.1016/S0040-4039(03)00061-3; Maduray K, 2011, J PHOTOCH PHOTOBIO B, V103, P98, DOI 10.1016/j.jphotobiol.2011.01.020; Margaron P, 1996, PHOTOCHEM PHOTOBIOL, V63, P217, DOI 10.1111/j.1751-1097.1996.tb03017.x; Miller JN, 2005, ENCY ANAL SCI, P163; Nyokong T, 2004, J PORPHYR PHTHALOCYA, V8, P1083, DOI 10.1142/S1088424604000453; Nyokong T, 2007, COORDIN CHEM REV, V251, P1707, DOI 10.1016/j.ccr.2006.11.011; Obata M, 2009, J MED CHEM, V52, P2747, DOI 10.1021/jm8015427; Ogunbayo TB, 2009, POLYHEDRON, V28, P2710, DOI 10.1016/j.poly.2009.05.026; Sekkat N, 2012, MOLECULES, V17, P98, DOI 10.3390/molecules17010098; Serra AC, 2008, J PHOTOCH PHOTOBIO B, V92, P59, DOI 10.1016/j.jphotobiol.2008.04.006; Sharman WM, 1999, DRUG DISCOV TODAY, V4, P507, DOI 10.1016/S1359-6446(99)01412-9; SIBILLE A, 1995, GASTROENTEROLOGY, V108, P337, DOI 10.1016/0016-5085(95)90058-6; Tuncel S, 2011, DALTON T, V40, P4067, DOI 10.1039/c0dt01260b; Wang AJ, 2011, J INCL PHENOM MACRO, V71, P1, DOI 10.1007/s10847-010-9918-x; Wieder ME, 2006, PHOTOCH PHOTOBIO SCI, V5, P727, DOI 10.1039/b602830f; Zorlu Y, 2009, PHOTOCH PHOTOBIO SCI, V8, P312, DOI 10.1039/b817348f; Zorlu Y, 2010, TETRAHEDRON, V66, P3248, DOI 10.1016/j.tet.2010.02.079	39	41	41	0	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2014	9	5							e97894	10.1371/journal.pone.0097894	http://dx.doi.org/10.1371/journal.pone.0097894			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AN9SK	24840576	Green Published, gold, Green Submitted			2023-01-03	WOS:000340948600088
J	Patnode, CD; O'Connor, E; Rowland, M; Burda, BU; Perdue, LA; Whitlock, EP				Patnode, Carrie D.; O'Connor, Elizabeth; Rowland, Maya; Burda, Brittany U.; Perdue, Leslie A.; Whitlock, Evelyn P.			Primary Care Behavioral Interventions to Prevent or Reduce Illicit Drug Use and Nonmedical Pharmaceutical Use in Children and Adolescents: A Systematic Evidence Review for the US Preventive Services Task Force	ANNALS OF INTERNAL MEDICINE			English	Review							SUBSTANCE USE; YOUNG-PEOPLE; COMPUTER; OUTCOMES; SCHOOL; TEENS	Background: Drug use among youths is associated with negative health and social consequences. Even infrequent use increases the risk for serious adverse events by increasing risk-taking behaviors in intoxicated or impaired persons. Purpose: To systematically review the benefits and harms of primary care-relevant interventions designed to prevent or reduce illicit drug use or the nonmedical use of prescription drugs among youths. Data Sources: PubMed, PsycINFO, and the Cochrane Central Register of Controlled Trials through 4 June 2013; MEDLINE through 31 August 2013; and manual searches of reference lists and gray literature. Study Selection: Two investigators independently reviewed 2253 abstracts and 144 full-text articles. English-language trials of primary care-relevant behavioral interventions that reported drug use, health outcomes, or harms were included. Data Extraction: One investigator abstracted data from good- and fair-quality trials into prespecified evidence tables, and a second investigator checked these data. Data Synthesis: Six trials were included, 4 of which examined the effect of the intervention on a health or social outcome. One trial found no effect of the intervention on marijuana-related consequences or driving under the influence of marijuana; 3 trials generally found no reduction in depressed mood at 12 or 24 months. Four of the 5 trials assessing self-reported marijuana use found statistically significant differences favoring the intervention group participants (such as a between-group difference of 0.10 to 0.17 use occasions in the past month). Three trials also reported positive outcomes in nonmedical prescription drug use occasions. Limitations: The body of evidence was small, and there were heterogeneous measures of outcomes of limited clinical applicability. Trials primarily included adolescents with little or no substance use. Conclusion: Evidence is inadequate on the benefits of primary care-relevant behavioral interventions in reducing self-reported illicit and pharmaceutical drug use among adolescents.	[Patnode, Carrie D.; O'Connor, Elizabeth; Rowland, Maya; Burda, Brittany U.; Perdue, Leslie A.; Whitlock, Evelyn P.] Kaiser Permanente Northwest, Portland, OR USA	Kaiser Permanente	Patnode, CD (corresponding author), Kaiser Permanente Ctr Hlth Res, 3800 North Interstate Ave, Portland, OR 97227 USA.				Agency for Healthcare Research and Quality	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Agency for Healthcare Research and Quality.	[Anonymous], 2008, US PREV SERV TASK FO; Barnett E, 2012, ADDICT BEHAV, V37, P1325, DOI 10.1016/j.addbeh.2012.07.001; Becker SJ, 2008, J CONSULT CLIN PSYCH, V76, P531, DOI 10.1037/0022-006X.76.4.531; Belani Hrishikesh, 2012, Morbidity and Mortality Weekly Report, V61, P1; Carney T, 2012, SUBST ABUSE TREAT PR, V7, DOI 10.1186/1747-597X-7-25; Committee on Substance Abuse, 2011, SUBST US SCREEN BRIE; Eaton Danice K., 2012, Morbidity and Mortality Weekly Report, V61, P1; Fang L, 2013, PSYCHOL ADDICT BEHAV, V27, P788, DOI 10.1037/a0030925; Fang L, 2010, J ADOLESCENT HEALTH, V47, P529, DOI 10.1016/j.jadohealth.2010.03.011; Gates S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005030.pub2; Harris SK, 2012, PEDIATRICS, V129, P1072, DOI 10.1542/peds.2011-1624; Hays S. P., 2003, J PRIM PREV, V24, P125, DOI [10.1023/A:1025940311556, DOI 10.1023/A:1025940311556]; Ioannidis JPA, 2012, J PSYCHOSOM RES, V73, P408, DOI 10.1016/j.jpsychores.2012.09.014; Jackson C, 2012, ADDICTION, V107, P733, DOI 10.1111/j.1360-0443.2011.03751.x; Jensen CD, 2011, J CONSULT CLIN PSYCH, V79, P433, DOI 10.1037/a0023992; Knight JR, 1999, ARCH PEDIAT ADOL MED, V153, P591; Mayberry ML, 2009, J YOUTH ADOLESCENCE, V38, P1038, DOI 10.1007/s10964-009-9425-9; Mitchell SG, 2013, J SUBST ABUSE TREAT, V44, P463, DOI 10.1016/j.jsat.2012.11.005; Polen MR, 2008, SCREENING PRIMARY CA; Rhee Hyekyun, 2008, J Pediatr Nurs, V23, P439, DOI 10.1016/j.pedn.2008.01.079; Schinke SP, 2009, PREV MED, V49, P429, DOI 10.1016/j.ypmed.2009.08.001; Schinke SP, 2009, ADDICT BEHAV, V34, P1060, DOI 10.1016/j.addbeh.2009.06.007; Substance Abuse and Mental Health Services Administration, 2013, RES 2012 NAT SURV DR; Substance Abuse and Mental Health Services Administration, 2012, SCREEN BRIEF INT REF; U. S. Preventive Services Task Force, 2008, SCREEN ILL DRUG US U; Vuckovic N, 2003, PREV MED, V37, P209, DOI 10.1016/S0091-7435(03)00115-4; Walton MA, 2013, DRUG ALCOHOL DEPEN, V132, P646, DOI 10.1016/j.drugalcdep.2013.04.020	27	23	23	0	22	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 6	2014	160	9					612	U161		10.7326/M13-2064	http://dx.doi.org/10.7326/M13-2064			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AI0GO	24615613				2023-01-03	WOS:000336524400004
J	Lazo, MD; Bernabe-Ortiz, A; Pinto, ME; Ticse, R; Malaga, G; Sacksteder, K; Miranda, JJ; Gilman, RH				de los Angeles Lazo, Maria; Bernabe-Ortiz, Antonio; Pinto, Miguel E.; Ticse, Ray; Malaga, German; Sacksteder, Katherine; Jaime Miranda, J.; Gilman, Robert H.			Diabetic Peripheral Neuropathy in Ambulatory Patients with Type 2 Diabetes in a General Hospital in a Middle Income Country: A Cross-Sectional Study	PLOS ONE			English	Article							PREVALENCE; MELLITUS; POLYNEUROPATHY; MORTALITY	Aim: We aimed to estimate the morbidity rate and associated factors for diabetic peripheral neuropathy (DPN) in a low-middle income country setting. Methods: Cross-sectional study, data was gathered at Peru's Ministry of Health national specialized hospital for endocrinological conditions through standardized interviews, anthropometric measurements and blood tests for glycated haemoglobin (HbA1c). DPN was evaluated using two techniques: the Semmes-Weinstein monofilament test and the diabetic neuropathy symptom score. Overall prevalence and 95% confidence intervals (95% CI) were calculated. Potential factors related to DPN explored included body mass index, years with disease (<10 vs. >= 10 years), glycaemic control (HbA1c <7% vs. >= 7%), microalbuminuria, retinopathy, and current pharmacological treatment. Multivariable analysis was performed using Poisson analysis to calculate prevalence ratios. Results: DPN was observed in 73/129 (56.6%) patients. In multivariable analysis adjusted by age and sex, the prevalence ratio of neuropathy was 1.4 times higher (95% CI 1.07-1.88) in patients who took insulin plus metformin compared to patients who used one treatment alone, and 1.4 higher (95% CI 1.02-1.93) in patients with >= 10 years of disease compared to those with a shorter duration of disease. Also we found some characteristics in foot evaluation associated to neuropathy such as deformities (p<0.001), onychomycosis (p = 0.012), abnormal Achilles reflex (p<0.001), pain perception (p<0.001) and vibration perception (p<0.001). Conclusion: DPN is highly frequent among patients with diabetes in a national specialized facility from Peru. Associated factors to DPN included being a diabetic patient for over ten years, and receiving insulin plus metformin	[de los Angeles Lazo, Maria; Bernabe-Ortiz, Antonio; Malaga, German; Jaime Miranda, J.; Gilman, Robert H.] Univ Peruana Cayetano Heredia, CRON Ctr Excellence Chron Dis, Lima, Peru; [de los Angeles Lazo, Maria; Malaga, German] Univ Peruana Cayetano Heredia, Unidad Conocimiento & Evidencia, Lima, Peru; [Pinto, Miguel E.; Ticse, Ray; Malaga, German; Jaime Miranda, J.] Univ Peruana Cayetano Heredia, Fac Med Alberto Hurtado, Lima, Peru; [Pinto, Miguel E.; Ticse, Ray] Hosp Nacl Cayetano Heredia, Serv Endocrinol, Lima, Peru; [Sacksteder, Katherine; Gilman, Robert H.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA	Universidad Peruana Cayetano Heredia; Universidad Peruana Cayetano Heredia; Universidad Peruana Cayetano Heredia; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Miranda, JJ (corresponding author), Univ Peruana Cayetano Heredia, CRON Ctr Excellence Chron Dis, Lima, Peru.	Jaime.Miranda@upch.pe		Miranda, J. Jaime/0000-0002-4738-5468; Malaga, German/0000-0002-7828-300X; Bernabe-Ortiz, Antonio/0000-0002-6834-1376; TICSE, RAY/0000-0002-4568-5723	National Heart, Lung, and Blood Institute Global Health Initiative [268200900033C]; Medical Research Council [MR/K007467/1] Funding Source: researchfish; MRC [MR/K007467/1] Funding Source: UKRI	National Heart, Lung, and Blood Institute Global Health Initiative; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	ML, ABO, KS, GM, JJM, RHG are affiliated with the CRONICAS Centre of Excellence in Chronic Diseases at Universidad Peruana Cayetano Heredia supported by the National Heart, Lung, and Blood Institute Global Health Initiative under the contract Global Health Activities in Developing Countries to Combat Non-Communicable Chronic Diseases (Project Number 268200900033C). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS11, DOI 10.2337/dc13-S011; Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS62, DOI 10.2337/dc10-s062; Bos M, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-387; Boulton AJM, 2008, DIABETES CARE, V31, P1679, DOI 10.2337/dc08-9021; Chan JCN, 2009, DIABETES CARE, V32, P227, DOI 10.2337/dc08-0435; Chuang LM, 2002, DIABETIC MED, V19, P978, DOI 10.1046/j.1464-5491.2002.00833.x; Chung JO, 2011, DIABETES METAB J, V35, P390, DOI 10.4093/dmj.2011.35.4.390; Currie CJ, 2013, J CLIN ENDOCR METAB, V98, P668, DOI 10.1210/jc.2012-3042; Janghorbani M, 2006, ACTA NEUROL SCAND, V114, P384, DOI 10.1111/j.1600-0404.2006.00716.x; Karvestedt L, 2011, J DIABETES COMPLICAT, V25, P97, DOI 10.1016/j.jdiacomp.2010.04.001; Kiani J, 2013, ARCH IRAN MED, V16, P17, DOI 013161/AIM.006; Ko SH, 2012, DIABETES METAB J, V36, P6, DOI 10.4093/dmj.2012.36.1.6; MCNEELY MJ, 1995, DIABETES CARE, V18, P216, DOI 10.2337/diacare.18.2.216; Meijer JWG, 2002, DIABETIC MED, V19, P962, DOI 10.1046/j.1464-5491.2002.00819.x; Menchaca-Diaz R, 2012, GAC MED MEX, V148, P34; *MIN SAL PER, 2007, RES MIN; Mold JW, 2004, J AM BOARD FAM PRACT, V17, P309, DOI 10.3122/jabfm.17.5.309; Ollendorf DA, 1998, DIABETES CARE, V21, P1240, DOI 10.2337/diacare.21.8.1240; Palumbo P.J, 1985, DIABETES AM DIABETES; Singh N, 2005, JAMA-J AM MED ASSOC, V293, P217, DOI 10.1001/jama.293.2.217; Tentolouris N, 2004, DIABETES CARE, V27, P1598, DOI 10.2337/diacare.27.7.1598; Ibarra RCT, 2012, REV MED CHILE, V140, P1126, DOI 10.4067/S0034-98872012000900004; Tres GS, 2007, ARQ BRAS ENDOCRINOL, V51, P987, DOI 10.1590/S0004-27302007000600014	23	16	19	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2014	9	5							e95403	10.1371/journal.pone.0095403	http://dx.doi.org/10.1371/journal.pone.0095403			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG6EE	24789071	Green Published, gold, Green Submitted			2023-01-03	WOS:000335510600036
J	Woodard, D; Bell, D; Tipton, D; Durrance, S; Cole, L; Li, B; Xu, SH				Woodard, Daniel; Bell, Dylan; Tipton, David; Durrance, Samuel; Cole, Lisa; Li, Bin; Xu, Shaohua			Gel Formation in Protein Amyloid Aggregation: A Physical Mechanism for Cytotoxicity	PLOS ONE			English	Article							DIFFUSION; CONVECTION; VULNERABILITY; TRANSPORT; DEMENTIA; WATER	Amyloid fibers are associated with disease but have little chemical reactivity. We investigated the formation and structure of amyloids to identify potential mechanisms for their pathogenic effects. We incubated lysozyme 20 mg/ml at 55C and pH 2.5 in a glycine-HCl buffer and prepared slides on mica substrates for examination by atomic force microscopy. Structures observed early in the aggregation process included monomers, small colloidal aggregates, and amyloid fibers. Amyloid fibers were observed to further self-assemble by two mechanisms. Two or more fibers may merge together laterally to form a single fiber bundle, usually in the form of a helix. Alternatively, fibers may become bound at points where they cross, ultimately forming an apparently irreversible macromolecular network. As the fibers assemble into a continuous network, the colloidal suspension undergoes a transition from a Newtonian fluid into a viscoelastic gel. Addition of salt did not affect fiber formation but inhibits transition of fibers from linear to helical conformation, and accelerates gel formation. Based on our observations, we considered the effects of gel formation on biological transport. Analysis of network geometry indicates that amyloid gels will have negligible effects on diffusion of small molecules, but they prevent movement of colloidal-sized structures. Consequently gel formation within neurons could completely block movement of transport vesicles in neuronal processes. Forced convection of extracellular fluid is essential for the transport of nutrients and metabolic wastes in the brain. Amyloid gel in the extracellular space can essentially halt this convection because of its low permeability. These effects may provide a physical mechanism for the cytotoxicity of chemically inactive amyloid fibers in neurodegenerative disease.	[Woodard, Daniel] InnoMed Hlth Applicat Inc, Kennedy Space Ctr, FL 32899 USA; [Bell, Dylan; Durrance, Samuel] Florida Inst Technol, Dept Phys & Space Sci, Melbourne, FL 32901 USA; [Tipton, David] Aerosp Med & Occupat Hlth Branch, Kennedy Space Ctr, FL USA; [Li, Bin; Xu, Shaohua] Florida Inst Technol, Dept Biol Sci, Melbourne, FL 32901 USA; [Cole, Lisa] Columbia Univ, Inst Human Nutr, New York, NY 10032 USA	Florida Institute of Technology; Florida Institute of Technology; Columbia University	Woodard, D (corresponding author), InnoMed Hlth Applicat Inc, Kennedy Space Ctr, FL 32899 USA.	daniel.woodard-1@nasa.gov		Xu, Shaohua/0000-0003-1221-6354	NASA Kennedy Space Center; Florida Institute of Technology; Community Foundation of Brevard; Space Florida	NASA Kennedy Space Center(National Aeronautics & Space Administration (NASA)); Florida Institute of Technology; Community Foundation of Brevard; Space Florida	This work was supported by grants from: NASA Kennedy Space Center (http://www.ksc.nasa.gov), Florida Institute of Technology (http://www.fit.edu), The Community Foundation of Brevard (http://www.cfbrevard.org/), and Space Florida (http://www.spaceflorida.gov/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adalbert R, 2013, NEUROPATH APPL NEURO, V39, P90, DOI 10.1111/j.1365-2990.2012.01308.x; Aggeli A, 2006, MOL GELS MAT SELFASS, P721; Arnsdorf MF, 1996, J CARDIOVASC ELECTR, V7, P639, DOI 10.1111/j.1540-8167.1996.tb00572.x; ASTBURY WT, 1959, BIOCHIM BIOPHYS ACTA, V35, P17, DOI 10.1016/0006-3002(59)90330-0; Bolisetty S, 2012, BIOMACROMOLECULES, V13, P3241, DOI 10.1021/bm301005w; Bostrom M, 2006, J PHYS CHEM B, V110, P7563, DOI 10.1021/jp051025t; Budzinski KL, 2009, BIOPHYS J, V97, P2577, DOI 10.1016/j.bpj.2009.08.032; CHARY SR, 1989, P NATL ACAD SCI USA, V86, P5385, DOI 10.1073/pnas.86.14.5385; Chatterjee AP, 2012, J PHYS-CONDENS MAT, V24, DOI 10.1088/0953-8984/24/37/375106; Cole L, 2010, APPL PROTEIN AGGREGA; Conforti L, 2007, TRENDS NEUROSCI, V30, P159, DOI 10.1016/j.tins.2007.02.004; Cserr H F, 1988, Ann N Y Acad Sci, V529, P9, DOI 10.1111/j.1749-6632.1988.tb51415.x; Estroff LA, 2006, MOLECULAR GELS: MATERIALS WITH SELF-ASSEMBLED FIBRILLAR NETWORKS, P721, DOI 10.1007/1-4020-3689-2_21; Fujiwara S, 2003, J MOL BIOL, V331, P21, DOI 10.1016/S0022-2836(03)00722-8; Galvin JE, 2006, ACTA NEUROPATHOL, V112, P115, DOI 10.1007/s00401-006-0096-2; Gosal WS, 2004, BIOMACROMOLECULES, V5, P2408, DOI 10.1021/bm049659d; Hauser CAE, 2011, P NATL ACAD SCI USA, V108, P1361, DOI 10.1073/pnas.1014796108; Head D, 2004, CEREB CORTEX, V14, P410, DOI 10.1093/cercor/bhh003; Herculano-Houzel S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017514; Hill SE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018171; Israelachvili JN, 2011, INTERMOLECULAR AND SURFACE FORCES, 3RD EDITION, P1; Johnston ST, 1999, J MEMBRANE SCI, V153, P271, DOI 10.1016/S0376-7388(98)00260-9; LAUFFER MA, 1961, BIOPHYS J, V1, P205, DOI 10.1016/S0006-3495(61)86884-7; LEVICK JR, 1987, Q J EXP PHYSIOL CMS, V72, P409, DOI 10.1113/expphysiol.1987.sp003085; Manno M, 2010, LANGMUIR, V26, P1424, DOI 10.1021/la903340v; Martin M, 1999, MOL BIOL CELL, V10, P3717, DOI 10.1091/mbc.10.11.3717; Masaro L, 1999, PROG POLYM SCI, V24, P731, DOI 10.1016/S0079-6700(99)00016-7; MILLERO FJ, 1976, J BIOL CHEM, V251, P4001; Moores B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025954; Nicholson C, 2001, REP PROG PHYS, V64, P815, DOI 10.1088/0034-4885/64/7/202; Nield DA, 2006, CONVECTION POROUS ME; Ow SY, 2013, SOFT MATTER, V9, P9692, DOI 10.1039/c3sm51671g; Perutz MF, 2002, P NATL ACAD SCI USA, V99, P5591, DOI 10.1073/pnas.042681399; Raghavan SR, 2006, MOLECULAR GELS: MATERIALS WITH SELF-ASSEMBLED FIBRILLAR NETWORKS, P241, DOI 10.1007/1-4020-3689-2_9; Ramanujan S, 2002, BIOPHYS J, V83, P1650, DOI 10.1016/S0006-3495(02)73933-7; Ruben G, 1997, MICROSC MICROANAL, V3, P47; Silverberg GD, 2001, NEUROLOGY, V57, P1763, DOI 10.1212/WNL.57.10.1763; Tamagawa H, 2000, POLYMER, V41, P7201, DOI 10.1016/S0032-3861(00)00047-1; Terech P, 2006, ENCY SURFACE COLLOID, V4, P2678; Terech P, 2012, J PHYS CHEM B, V116, P11344, DOI 10.1021/jp305365m; Verkman AS, 2002, TRENDS BIOCHEM SCI, V27, P27, DOI 10.1016/S0968-0004(01)02003-5; Wang F, 1996, ACTA CRYSTALLOGR D, V52, P901, DOI 10.1107/S0907444996005227; Ward SM, 2012, BIOCHEM SOC T, V40, P667, DOI 10.1042/BST20120134; Xu SH, 2007, AMYLOID, V14, P119, DOI 10.1080/13506120701260059; Xu SH, 2009, J PHYS CHEM B, V113, P12447, DOI 10.1021/jp903106x; Zhang B, 1998, NEURON, V21, P1465, DOI 10.1016/S0896-6273(00)80664-9	46	26	27	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2014	9	4							e94789	10.1371/journal.pone.0094789	http://dx.doi.org/10.1371/journal.pone.0094789			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI4VW	24740416	gold, Green Published, Green Submitted			2023-01-03	WOS:000336863900066
J	Bosmans, JE; Beerepoot, MAJ; Prins, JM; ter Riet, G; Geerlings, SE				Bosmans, Judith E.; Beerepoot, Marielle A. J.; Prins, Jan M.; ter Riet, Gerben; Geerlings, Suzanne E.			Cost-Effectiveness of Cranberries vs Antibiotics to Prevent Urinary Tract Infections in Premenopausal Women: A Randomized Clinical Trial	PLOS ONE			English	Article							ESCHERICHIA-COLI; RESISTANCE; TRIMETHOPRIM; CONSUMPTION; VALIDATION; IMPUTATION; HEALTH; JUICE	Background: Urinary tract infections (UTIs) are common and result in an enormous economic burden. The increasing prevalence of antibiotic-resistant microorganisms has stimulated interest in non-antibiotic agents to prevent UTIs. Objective: To evaluate the cost-effectiveness of cranberry prophylaxis compared to antibiotic prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX) over a 12 month period in premenopausal women with recurrent UTIs. Materials and Methods: An economic evaluation was performed alongside a randomized trial. Primary outcome was the number of UTIs during 12 months. Secondary outcomes included satisfaction and quality of life. Healthcare utilization was measured using questionnaires. Missing data were imputed using multiple imputation. Bootstrapping was used to evaluate the cost-effectiveness of the treatments. Results: Cranberry prophylaxis was less effective than TMP-SMX prophylaxis, but the differences in clinical outcomes were not statistically significant. Costs after 12 months in the cranberry group were statistically significantly higher than in the TMP-SMX group (mean difference (sic)249, 95% confidence interval 70 to 516). Cost-effectiveness planes and cost-effectiveness acceptability curves showed that cranberry prophylaxis to prevent UTIs is less effective and more expensive than (dominated by) TMP-SMX prophylaxis. Conclusion: In premenopausal women with recurrent UTIs, cranberry prophylaxis is not cost-effective compared to TMP-SMX prophylaxis. However, it was not possible to take into account costs attributed to increased antibiotic resistance within the framework of this randomized trial; modeling studies are recommended to investigate these costs. Moreover, although we based the dosage of cranberry extract on available evidence, this may not be the optimal dosage. Results may change when this optimal dosage is identified.	[Bosmans, Judith E.] Vrije Univ Amsterdam, Fac Earth & Life Sci, Dept Hlth Sci, Amsterdam, Netherlands; [Bosmans, Judith E.] Vrije Univ Amsterdam, Fac Earth & Life Sci, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands; [Beerepoot, Marielle A. J.; Prins, Jan M.; Geerlings, Suzanne E.] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, Div Infect Dis, NL-1105 AZ Amsterdam, Netherlands; [ter Riet, Gerben] Univ Amsterdam, Acad Med Ctr, Dept Gen Practice, NL-1105 AZ Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Bosmans, JE (corresponding author), Vrije Univ Amsterdam, Fac Earth & Life Sci, Dept Hlth Sci, Amsterdam, Netherlands.	j.e.bosmans@vu.nl	Riet, Gerben ter/A-6943-2011; Prins, Jan M./AAF-4945-2020	Riet, Gerben ter/0000-0002-2231-7637; Prins, Jan/0000-0002-5415-8933; Bosmans, Judith/0000-0002-1443-1026	ZonMw [62000017]	ZonMw(Netherlands Organization for Health Research and Development)	This study was financially supported by ZonMw, grant number 62000017. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; Aston JL, 2006, PHARMACOTHERAPY, V26, P1314, DOI 10.1592/phco.26.9.1314; Beerepoot MAJ, 2011, ARCH INTERN MED, V171, P1270, DOI 10.1001/archinternmed.2011.306; BLACK WC, 1990, MED DECIS MAKING, V10, P212, DOI 10.1177/0272989X9001000308; Brazier J, 2002, J HEALTH ECON, V21, P271, DOI 10.1016/S0167-6296(01)00130-8; Briggs A, 2003, HEALTH ECON, V12, P377, DOI 10.1002/hec.766; Burton A, 2007, CLIN TRIALS, V4, P154, DOI 10.1177/1740774507076914; Clayson D, 2005, BJU INT, V96, P350, DOI 10.1111/j.1464-410X.2005.05630.x; Colgan R, 2004, CLIN DRUG INVEST, V24, P55, DOI 10.2165/00044011-200424010-00007; ECDC and EMEA Joint Working Group, 2009, ECDC EMEA JOINT TECH; EFRON B, 1994, J AM STAT ASSOC, V89, P463, DOI 10.2307/2290846; Ellis A K, 2000, J Am Board Fam Pract, V13, P392; Fenwick E, 2004, HEALTH ECON, V13, P405, DOI 10.1002/hec.903; Foxman B, 2002, AM J MED, V113, p5S; Foxman B, 2010, NAT REV UROL, V7, P653, DOI 10.1038/nrurol.2010.190; Guay DRP, 2009, DRUGS, V69, P775, DOI 10.2165/00003495-200969070-00002; Gupta K, 2003, INFECT DIS CLIN N AM, V17, P243, DOI 10.1016/S0891-5520(03)00006-0; Hakkaart-van Roijen L, 2011, HANDLEIDING KOSTENON; Hooton TM, 2001, INT J ANTIMICROB AG, V17, P259, DOI 10.1016/S0924-8579(00)00350-2; Howard D, 2001, CLIN INFECT DIS, V33, P1573, DOI 10.1086/323758; Howell AB, 2002, JAMA-J AM MED ASSOC, V287, P3082, DOI 10.1001/jama.287.23.3082; Howell AB, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-94; Jepson RG, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001321.pub5; Malterud K, 1999, SCAND J PRIM HEALTH, V17, P49; McMurdo MET, 2009, J ANTIMICROB CHEMOTH, V63, P389, DOI 10.1093/jac/dkn489; MURRAY BE, 1982, NEW ENGL J MED, V306, P130, DOI 10.1056/NEJM198201213060302; Neal DE, 2008, UROL CLIN N AM, V35, P13, DOI 10.1016/j.ucl.2007.09.010; Oostenbrink JB, 2005, HEALTH ECON, V14, P763, DOI 10.1002/hed.966; Raz R, 2004, CLIN INFECT DIS, V38, P1413, DOI 10.1086/386328; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Stothers Lynn, 2002, Can J Urol, V9, P1558; Terris MK, 2001, UROLOGY, V57, P26, DOI 10.1016/S0090-4295(00)00884-0; Vasileiou I, 2013, NUTR RES, V33, P595, DOI 10.1016/j.nutres.2013.05.018; Willan AR, 2004, HEALTH ECON, V13, P461, DOI 10.1002/hec.843	34	13	13	0	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2014	9	4							e91939	10.1371/journal.pone.0091939	http://dx.doi.org/10.1371/journal.pone.0091939			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE6MJ	24705418	Green Submitted, Green Published, gold			2023-01-03	WOS:000334107500010
J	Page, L				Page, Leigh			FEATURE The end of life	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							OF-LIFE				Page, L (corresponding author), 2525 North Talman Ave, Chicago, IL USA.	leighpage@comcast.net						American Association of Neurological Surgeons (AANS), INF CONS; American Medical Association (AMA) Council on Ethical and Judicial Affairs, 2008, 5A08 CEJA AMA; Astrow AB, 2011, NEW ENGL J MED, V364, P1885, DOI 10.1056/NEJMp1102392; Bergman J, 2013, JAMA SURG, V148, P215, DOI 10.1001/jamasurg.2013.1568; Davison SN, 2010, CLIN J AM SOC NEPHRO, V5, P195, DOI 10.2215/CJN.05960809; Mack JW, 2012, J CLIN ONCOL, V30, P4387, DOI 10.1200/JCO.2012.43.6055; National Hospice and Palliative Care Organization (NHPCO), 2006, TALK TREATM OPT PALL	7	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 26	2014	348								g2261	10.1136/bmj.g2261	http://dx.doi.org/10.1136/bmj.g2261			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AD9LN	24671982				2023-01-03	WOS:000333586700003
J	Li, YH; Yu, B; Duan, ZZ; Akinyi, OM; Yu, JH; Zhou, K; Zhang, Y; Gao, XM				Li, Yu Hong; Yu, Bin; Duan, Zhen Zhen; Akinyi, Olunga Mary; Yu, Jia Hui; Zhou, Kun; Zhang, Yue; Gao, Xiu Mei			The Coronary Dilation Effect of Shen Fu Injection Was Mediated through NO	PLOS ONE			English	Article							NITRIC-OXIDE SYNTHASE; ISCHEMIA/REPERFUSION INJURY; CARDIOVASCULAR-SYSTEM; ISCHEMIA-REPERFUSION; PERFUSION PRESSURE; ENDOTHELIAL-CELLS; CARDIAC-FUNCTION; GINSENOSIDE RB1; RAT-HEART; IN-VIVO	Objectives: Shen Fu Injection (SF), which consisted of Red ginseng extraction injection (RG) and prepared aconite extraction injection (RA), is a traditional Chinese medicine mainly used for various cardiac diseases. This study is to analyse SF's effects on cardiac performance and coronary circulation. And the coronary dilating effect and mechanism of the above three injections were also explored. Methods: Mature male guinea pigs were used as our animal model. We employed two types of perfusion methods (constant pressure and constant flow) in vitro, using Langendorff heart preparations to observe the cardiac function and coronary response to SF (1/200). The coronary dilation effects of the above three injections (1/800, 1/400 and 1/200) were recorded at basal coronary resting tone and when coronary vessels were pre-contracted with a thromboxane A2 analogue (U46619), in the presence or the absence of the inhibitor of nitric oxide synthesis (L-NAME, 10(-4) M), the blocker of Ca2+-activated potassium channel(TEA, 10(-3) M), or the blocker of adenosine triphosphate (ATP)-sensitive potassium channel (glybenclamide) (10(-5) M). Results: When perfused with constant pressure, SF significantly increased coronary flow, left ventricular developed pressure (LVDP) and the rate-pressure product (RPP). When perfused with constant flow, SF produced a significant reduction in the coronary perfusion pressure (CPP), LVDP and RPP. The coronary vasodilatation response of the above three injections can be reduced by L-NAME but was unaffected by TEA or glybenclamide when coronary vessels were pre-contracted with U46619 but not at resting tone. SF, RG and RA can all up-regulate eNOS expression in the human umbilical vein cells (EA.hy926). Conclusion: We demonstrated that SF does not contribute to the inotropic change of myocardium whose improvement is due to alternation of coronary flow. The coronary dilation effect of SF was mediated through RG and RA, via promoting NO release.	[Li, Yu Hong; Yu, Bin; Duan, Zhen Zhen; Akinyi, Olunga Mary; Yu, Jia Hui; Zhou, Kun; Zhang, Yue; Gao, Xiu Mei] Tianjin Univ Tradit Chinese Med, State Key Lab Modern Chinese Med, Tianjin, Peoples R China; [Li, Yu Hong; Yu, Bin; Duan, Zhen Zhen; Akinyi, Olunga Mary; Yu, Jia Hui; Zhou, Kun; Zhang, Yue; Gao, Xiu Mei] Tianjin Univ Tradit Chinese Med, Minist Educ, Key Lab Pharmacol Tradit Chinese Med Formulae, Tianjin, Peoples R China; [Li, Yu Hong; Yu, Bin; Duan, Zhen Zhen; Akinyi, Olunga Mary; Yu, Jia Hui; Zhou, Kun; Zhang, Yue; Gao, Xiu Mei] Tianjin Univ Tradit Chinese Med, Inst Tradit Chinese Med Res, Tianjin, Peoples R China; [Gao, Xiu Mei] Tianjin Univ Tradit Chinese Med, State Key Lab Modern Chinese Med, Minist Educ, Key Lab Pharmacol Tradit Chinese Med Formulae, Tianjin, Peoples R China	Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine	Gao, XM (corresponding author), Tianjin Univ Tradit Chinese Med, State Key Lab Modern Chinese Med, Tianjin, Peoples R China.	gaoxiumei@tjutcm.edu.cn			National Basic Research Program of China [2012CB518400, 2012CB518404]; National Natural Science Foundation of China [81202779]; Tianjin Science and Technology Developmeng Fund for Colleges and Universities [2011ZD01]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tianjin Science and Technology Developmeng Fund for Colleges and Universities	This work was supported by the financial support from the National Basic Research Program of China(2012CB518400) to (2012CB518404) http://www.973.gov.cn/AreaAppl.aspx; The National Natural Science Foundation of China (81202779); http://www.nsfc.gov.cn/Portal0/default166.htm. Tianjin Science and Technology Developmeng Fund for Colleges and Universities (2011ZD01). http://www.tstc.gov.cn/english. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ARNOLD G, 1968, PFLUG ARCH EUR J PHY, V299, P339, DOI 10.1007/BF00602910; Bak MJ, 2012, MOLECULES, V17, P13769, DOI 10.3390/molecules171213769; Cao J, 2005, CHINESE MED J-PEKING, V118, P505; Chen IJ, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/595271; Chen X, 1996, CLIN EXP PHARMACOL P, V23, P728, DOI 10.1111/j.1440-1681.1996.tb01767.x; Choi KT, 2008, ACTA PHARMACOL SIN, V29, P1109, DOI 10.1111/j.1745-7254.2008.00869.x; Chong Won-Seog, 1998, Korean Journal of Physiology and Pharmacology, V2, P323; Deng J, 2010, BIOL PHARM BULL, V33, P631, DOI 10.1248/bpb.33.631; DUBE GP, 1995, J PHARMACOL EXP THER, V272, P799; Favaloro JL, 2007, CARDIOVASC RES, V73, P587, DOI 10.1016/j.cardiores.2006.11.018; GREGG DE, 1963, CIRC RES, V13, P497, DOI 10.1161/01.RES.13.6.497; Guo Liang, 2009, Journal of Pharmacological and Toxicological Methods, V60, P130, DOI 10.1016/j.vascn.2009.07.002; Hambrecht R, 2003, CIRCULATION, V107, P3152, DOI 10.1161/01.CIR.0000074229.93804.5C; Han JY, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/479016; Ji XF, 2011, SHOCK, V35, P530, DOI 10.1097/SHK.0b013e31820e2058; Montoya JJ, 2011, J CARDIOVASC PHARM, V58, P392, DOI 10.1097/FJC.0b013e318226bcf7; Li HX, 2012, PHYTOMEDICINE, V19, P477, DOI 10.1016/j.phymed.2012.01.002; Liao RL, 2012, AM J PHYSIOL-HEART C, V303, pH156, DOI 10.1152/ajpheart.00333.2012; Liu CH, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/408187; Garcia-Villalon AL, 2011, EUR J PHARMACOL, V660, P394, DOI 10.1016/j.ejphar.2011.04.006; Luo X.Y., 2009, CHINESE J INTEGRATED, V8, P685; MANTELLI L, 1992, EUR J PHARMACOL, V213, P79, DOI 10.1016/0014-2999(92)90235-V; McLean PG, 2002, CIRC RES, V90, P465, DOI 10.1161/hh0402.105372; Meng XZ, 1997, SHOCK, V7, P111, DOI 10.1097/00024382-199702000-00007; Mishra RC, 2013, CARDIOVASC RES, V97, P339, DOI 10.1093/cvr/cvs326; Morrison RR, 2006, AM J PHYSIOL-HEART C, V291, pH1875, DOI 10.1152/ajpheart.00158.2005; NISHIDA M, 1993, AM J PHYSIOL, V264, pH639, DOI 10.1152/ajpheart.1993.264.2.H639; Niu C., 2004, ZHONG YAO YAO LI YU, V20, P23; Peng L, 2012, CARDIOVASC THER, V30, pe183, DOI 10.1111/j.1755-5922.2011.00271.x; Ponto LLB, 2004, J CLIN PHARMACOL, V44, P751, DOI 10.1177/0091270004265699; Popovich DG, 2011, INT J BIOMEDICAL PHA, V6, P56; SAKUMA I, 1989, CAN J PHYSIOL PHARM, V67, P943, DOI 10.1139/y89-148; SHIBATA S, 1963, CHEM PHARM BULL, V11, P762; Shouyuan T, 2009, CHINESE J INTEGRATIV, V7, P1317; Skrzypiec-Spring Monika, 2007, Journal of Pharmacological and Toxicological Methods, V55, P113, DOI 10.1016/j.vascn.2006.05.006; Stowe DF, 1996, AM J PHYSIOL-HEART C, V271, pH1884, DOI 10.1152/ajpheart.1996.271.5.H1884; Wen-Ting S, 2012, EVID-BASED COMPL ALT, V2012; Yang Fang-ju, 2003, Zhongguo Zhongyao Zazhi, V28, P259; Yi XQ, 2010, PHYTOMEDICINE, V17, P1006, DOI 10.1016/j.phymed.2010.06.012; Yoshimura M, 1998, HUM GENET, V103, P65, DOI 10.1007/s004390050785; Yoshizaki K, 2012, CHEM PHARM BULL, V60, P354, DOI 10.1248/cpb.60.354; Yu J, 2007, BIOCHEM BIOPH RES CO, V353, P764, DOI 10.1016/j.bbrc.2006.12.119; ZeLong H, 2001, CHINESE J INTEGRATIV, V21, P386; Zhao DD, 2012, J TRADIT CHIN MED, V32, P308, DOI 10.1016/S0254-6272(13)60030-8; Zheng CD, 2008, CHIN J INTEGR MED, V14, P10, DOI 10.1007/s11655-008-0010-y; Zhou Su-juan, 2003, Zhongguo Zhongyao Zazhi, V28, P910; Zhou W, 2005, J VASC SURG, V41, P861, DOI 10.1016/j.jvs.2005.01.054; Zhu J, 2013, PLOS ONE, V30, P8	48	14	17	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 24	2014	9	3							e92415	10.1371/journal.pone.0092415	http://dx.doi.org/10.1371/journal.pone.0092415			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AD7QO	24662941	gold, Green Published, Green Submitted			2023-01-03	WOS:000333459900061
J	Liu, XL; Ward, BD; Binder, JR; Li, SJ; Hudetz, AG				Liu, Xiaolin; Ward, B. Douglas; Binder, Jeffrey R.; Li, Shi-Jiang; Hudetz, Anthony G.			Scale-Free Functional Connectivity of the Brain Is Maintained in Anesthetized Healthy Participants but Not in Patients with Unresponsive Wakefulness Syndrome	PLOS ONE			English	Article							PROPOFOL-INDUCED LOSS; PERSISTENT VEGETATIVE STATE; SMALL-WORLD; THALAMOCORTICAL CONNECTIVITY; ADAPTIVE-RECONFIGURATION; INDUCED UNCONSCIOUSNESS; NEURONAL AVALANCHES; CEREBRAL METABOLISM; GENERAL-ANESTHESIA; FREE ORGANIZATION	Loss of consciousness in anesthetized healthy participants and in patients with unresponsive wakefulness syndrome (UWS) is associated with substantial alterations of functional connectivity across large-scale brain networks. Yet, a prominent distinction between the two cases is that after anesthesia, brain connectivity and consciousness are spontaneously restored, whereas in patients with UWS this restoration fails to occur, but why? A possible explanation is that the self-organizing capability of the brain is compromised in patients with UWS but not in healthy participants undergoing anesthesia. According to the theory of self-organized criticality, many natural complex systems, including the brain, evolve spontaneously to a critical state wherein system behaviors display spatial and/or temporal scale-invariant characteristics. Here we tested the hypothesis that the scale-free property of brain network organization is in fact fundamentally different between anesthetized healthy participants and UWS patients. We introduced a novel, computationally efficient approach to determine anatomical-functional parcellation of the whole-brain network at increasingly finer spatial scales. We found that in healthy participants, scale-free distributions of node size and node degree were present across wakefulness, propofol sedation, and recovery, despite significant propofol-induced functional connectivity changes. In patients with UWS, the scale-free distribution of node degree was absent, reflecting a fundamental difference between the two groups in adaptive reconfiguration of functional interaction between network components. The maintenance of scale-invariance across propofol sedation in healthy participants suggests the presence of persistent, on-going self-organizing processes to a critical state - a capacity that is compromised in patients with UWS.	[Liu, Xiaolin; Ward, B. Douglas; Li, Shi-Jiang] Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA; [Binder, Jeffrey R.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Hudetz, Anthony G.] Med Coll Wisconsin, Dept Anesthesiol, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin	Hudetz, AG (corresponding author), Med Coll Wisconsin, Dept Anesthesiol, Milwaukee, WI 53226 USA.	ahudetz@mcw.edu	Li, Shi-Jiang/M-2534-2017; Binder, Jeff/CAJ-3303-2022	Binder, Jeffrey/0000-0002-2233-5640	National Institute of General Medical Sciences of the National Institutes of Health [R01-GM103894]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM103894] Funding Source: NIH RePORTER	National Institute of General Medical Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R01-GM103894. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Achard S, 2006, J NEUROSCI, V26, P63, DOI 10.1523/JNEUROSCI.3874-05.2006; Achard S, 2007, PLOS COMPUT BIOL, V3, P174, DOI 10.1371/journal.pcbi.0030017; Achard S, 2012, P NATL ACAD SCI USA, V109, P20608, DOI 10.1073/pnas.1208933109; Agnati LF, 2004, LECT NOTES COMPUT SC, V3146, P24; Alkire MT, 2008, SCIENCE, V322, P876, DOI 10.1126/science.1149213; Alkire MT, 2005, PROG BRAIN RES, V150, P229, DOI 10.1016/S0079-6123(05)50017-7; Alkire MT, 1997, ANESTHESIOLOGY, V86, P549, DOI 10.1097/00000542-199703000-00006; Baars BJ, 2005, PROG BRAIN RES, V150, P45, DOI 10.1016/S0079-6123(05)50004-9; BAK P, 1987, PHYS REV LETT, V59, P381, DOI 10.1103/PhysRevLett.59.381; BAK P, 1995, P NATL ACAD SCI USA, V92, P6689, DOI 10.1073/pnas.92.15.6689; Bassettt DS, 2006, P NATL ACAD SCI USA, V103, P19518, DOI 10.1073/pnas.0606005103; Beggs JM, 2003, J NEUROSCI, V23, P11167; Beggs JM, 2008, PHILOS T R SOC A, V366, P329, DOI 10.1098/rsta.2007.2092; Boonstra TW, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00079; Boubela RN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00168; Boveroux P, 2010, ANESTHESIOLOGY, V113, P1038, DOI 10.1097/ALN.0b013e3181f697f5; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Chialvo DR, 2004, PHYSICA A, V340, P756, DOI 10.1016/j.physa.2004.05.064; Clauset A, 2009, SIAM REV, V51, P661, DOI 10.1137/070710111; Davis MH, 2007, P NATL ACAD SCI USA, V104, P16032, DOI 10.1073/pnas.0701309104; de Reus MA, 2013, NEUROIMAGE, V80, P397, DOI 10.1016/j.neuroimage.2013.03.053; Eguiluz VM, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.018102; Fiset P, 1999, J NEUROSCI, V19, P5506; Fraiman D, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00307; Gisiger T, 2001, BIOL REV, V76, P161, DOI 10.1017/S1464793101005607; Hudetz AG, 2012, BRAIN CONNECT, V2, P291, DOI 10.1089/brain.2012.0107; Isono M, 2002, BRAIN INJURY, V16, P705, DOI 10.1080/02699050210127303; Kaiser M, 2007, PHILOS T R SOC A, V365, P3033, DOI 10.1098/rsta.2007.0007; Kello CT, 2010, TRENDS COGN SCI, V14, P223, DOI 10.1016/j.tics.2010.02.005; Kitzbichler MG, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000314; Klaus A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019779; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 2009, NEUROLOGY OF CONSCIOUSNESS: COGNITIVE NEUROSCIENCE AND NEUROPATHOLOGY, P1; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Laureys S, 1999, J NEUROL NEUROSUR PS, V67, P121, DOI 10.1136/jnnp.67.1.121; Laureys S, 2002, NEUROIMAGE, V17, P732, DOI 10.1006/nimg.2002.1236; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Lee H, 2013, ANESTHESIOLOGY, V119, P1347, DOI 10.1097/ALN.0b013e3182a8ec8c; Lee U, 2010, ANESTHESIOLOGY, V113, P1081, DOI 10.1097/ALN.0b013e3181f229b5; Liang ZF, 2012, J NEUROSCI, V32, P10183, DOI 10.1523/JNEUROSCI.1020-12.2012; Liu XL, 2013, ANESTHESIOLOGY, V118, P59, DOI 10.1097/ALN.0b013e318277a801; Liu XL, 2012, HUM BRAIN MAPP, V33, P2487, DOI 10.1002/hbm.21385; Logothetis NK, 2008, NATURE, V453, P869, DOI 10.1038/nature06976; Meunier D., 2009, FRONT NEUROINFORM, V3, DOI [10.3389/neuro.11.037.2009, 37, 10.3389/neuro.11.037.2009.eCollection2009]; Niazy RK, 2011, PROG BRAIN RES, V193, P259, DOI 10.1016/B978-0-444-53839-0.00017-X; Perlin K, 2002, ACM T GRAPHIC, V21, P681, DOI 10.1145/566570.566636; Plourde G, 2006, ANESTHESIOLOGY, V104, P448, DOI 10.1097/00000542-200603000-00011; Ribeiro TL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014129; Sanz-Arigita EJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013788; Schroter MS, 2012, J NEUROSCI, V32, P12832, DOI 10.1523/JNEUROSCI.6046-11.2012; Sporns O, 2004, TRENDS COGN SCI, V8, P418, DOI 10.1016/j.tics.2004.07.008; Sporns O, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001049; Stam CJ, 2007, CEREB CORTEX, V17, P92, DOI 10.1093/cercor/bhj127; Stam CJ, 2012, CLIN NEUROPHYSIOL, V123, P1067, DOI 10.1016/j.clinph.2012.01.011; Stam CJ, 2004, HUM BRAIN MAPP, V22, P97, DOI 10.1002/hbm.20016; Steyn-Ross ML, 2004, PROG BIOPHYS MOL BIO, V85, P369, DOI 10.1016/j.pbiomolbio.2004.02.001; SteynRoss DA, 2010, SPR SER COMPUT NEURO, V4, P1; Tagliazucchi E, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00015; Tononi Giulio, 2004, BMC Neurosci, V5, P42, DOI 10.1186/1471-2202-5-42; Touboul J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008982; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; van den Heuvel MP, 2008, NEUROIMAGE, V43, P528, DOI 10.1016/j.neuroimage.2008.08.010; Werner G, 2007, J PHYSIOL-PARIS, V101, P273, DOI 10.1016/j.jphysparis.2007.12.001; Werner G, 2007, BIOSYSTEMS, V90, P496, DOI 10.1016/j.biosystems.2006.12.001; Werner G, 2010, FRONT PHYSIOL, V1, DOI 10.3389/fphys.2010.00015; White NS, 2003, NEUROIMAGE, V19, P402, DOI 10.1016/S1053-8119(03)00103-4; ZEKI SM, 1978, NATURE, V274, P423, DOI 10.1038/274423a0; Zhou JS, 2011, CONSCIOUS COGN, V20, P257, DOI 10.1016/j.concog.2010.08.003	68	28	28	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2014	9	3							e92182	10.1371/journal.pone.0092182	http://dx.doi.org/10.1371/journal.pone.0092182			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AD6ER	24647227	gold, Green Published			2023-01-03	WOS:000333348500095
J	Nugraha, C; Bora, M; Venkatraman, SS				Nugraha, Chandra; Bora, Meghali; Venkatraman, Subbu S.			Release Retardation of Model Protein on Polyelectrolyte-Coated PLGA Nano- and Microparticles	PLOS ONE			English	Article							BOVINE SERUM-ALBUMIN; POLYMERIC MICROSPHERES; MULTILAYERED LIPOSOMES; ORAL DELIVERY; NANOPARTICLES; NANOCAPSULES; CELLS; FILMS; FUNCTIONALIZATION; PARTICLES	PEM capsules have been proposed for vehicles of drug microencapsulation, with the release triggered by pH, salt, magnetic field, or light. When built on another carrier encapsulating drugs, such as nanoparticles, it could provide additional release barrier to the releasing drug, providing further control to drug release. Although liposomes have received considerable attention with PEM coating for sustained drug release, similar results employing PEM built on poly(lactic-co-lycolic acid) (PLGA) particles is scant. In this work, we demonstrate that the build-up pH and polyelectrolyte pairs of PEM affect the release retardation of BSA from PLGA particles. PAH/PSS pair, the most commonly used polyelectrolyte pair, was used in comparison with PLL/DES. In addition, we also demonstrate that the release retardation effect of PEM-coated PLGA particles diminishes as the particle size increases. We attribute this to the diminishing relative thickness of the PEM coating with respect to the size of the particle as the particle size increases, reducing the diffusional resistance of the PEM.	[Nugraha, Chandra; Bora, Meghali; Venkatraman, Subbu S.] Nanyang Technol Univ, Sch Mat Sci & Engn, Singapore 639798, Singapore	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Venkatraman, SS (corresponding author), Nanyang Technol Univ, Sch Mat Sci & Engn, Singapore 639798, Singapore.	assubbu@ntu.edu.sg	Venkatraman, Subramanian/A-2228-2011	Venkatraman, Subramanian/0000-0002-8693-1070; Bora, Meghali/0000-0002-8676-6810	National Research Foundation	National Research Foundation	This study was supported by the grant from National Research Foundation (http://www.nrf.gov.sg/) under the Competitive Research Programme Funding Scheme. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbas AO, 2008, J PHARM SCI-US, V97, P2448, DOI 10.1002/jps.21215; Acharya S, 2011, ADV DRUG DELIVER REV, V63, P170, DOI 10.1016/j.addr.2010.10.008; Anandhakumar S, 2010, COLLOID SURFACE B, V78, P266, DOI 10.1016/j.colsurfb.2010.03.016; Antipov AA, 2001, J PHYS CHEM B, V105, P2281, DOI 10.1021/jp002184+; Antipov AA, 2004, ADV COLLOID INTERFAC, V111, P49, DOI 10.1016/j.cis.2004.07.006; Ball V, 2002, J PHYS CHEM B, V106, P2357, DOI 10.1021/jp012522m; Bordi F, 2009, J PHYS-CONDENS MAT, V21, DOI 10.1088/0953-8984/21/20/203102; Crouzier T, 2009, BIOMACROMOLECULES, V10, P433, DOI 10.1021/bm8012378; Cuomo F, 2012, SOFT MATTER, V8, P4415, DOI 10.1039/c2sm07388a; De Geest BG, 2007, CHEM SOC REV, V36, P636, DOI 10.1039/b600460c; Dejeu J, 2006, COLLOID SURFACE A, V288, P26, DOI 10.1016/j.colsurfa.2006.03.050; Fischer S, 2006, J CONTROL RELEASE, V111, P135, DOI 10.1016/j.jconrel.2005.11.015; Fischer S, 2007, BIOMATERIALS, V28, P994, DOI 10.1016/j.biomaterials.2006.10.034; Fujimoto K, 2007, MACROMOLECULES, V40, P5122, DOI 10.1021/ma070477w; Gebhart B., 1993, HEAT CONDUCTION MASS; Gillies G, 2007, J PHYS CHEM B, V111, P8626, DOI 10.1021/jp069009z; Girod S, 2004, CARBOHYD POLYM, V55, P37, DOI 10.1016/j.carbpol.2003.07.006; Gupta GK, 2011, AAPS PHARMSCITECH, V12, P344, DOI 10.1208/s12249-011-9593-2; Haidar ZS, 2008, BIOMATERIALS, V29, P1207, DOI 10.1016/j.biomaterials.2007.11.012; Huang XB, 2013, CARBOHYD POLYM, V92, P1064, DOI 10.1016/j.carbpol.2012.10.063; Jain P, 2009, MOL PHARMACEUT, V6, P593, DOI 10.1021/mp8002539; Jain S, 2012, MOL PHARMACEUT, V9, P2626, DOI 10.1021/mp300202c; Jain S, 2012, BIOMATERIALS, V33, P6758, DOI 10.1016/j.biomaterials.2012.05.026; Kakade S, 2009, INT J PHARMACEUT, V365, P44, DOI 10.1016/j.ijpharm.2008.08.019; Kato N, 2002, MACROMOLECULES, V35, P9780, DOI 10.1021/ma0209388; Keren K, 2002, PHYS REV LETT, V89, P4; Kittitheeranun P, 2010, LANGMUIR, V26, P6869, DOI 10.1021/la1003676; Luo RC, 2012, SMALL, V8, P2585, DOI 10.1002/smll.201200398; Monge C, 2012, TISSUE ENG PT A, V18, P1664, DOI [10.1089/ten.tea.2012.0079, 10.1089/ten.TEA.2012.0079]; Na K, 2007, J AM CHEM SOC, V129, P5788, DOI 10.1021/ja067707r; Palama IE, 2013, BIOTECHNOL BIOENG, V110, P586, DOI 10.1002/bit.24626; Pechenkin MA, 2012, SOFT MATTER, V8, P8659, DOI 10.1039/c2sm25971k; SACCO D, 1986, FEBS LETT, V199, P254, DOI 10.1016/0014-5793(86)80490-2; Salis A, 2011, LANGMUIR, V27, P11597, DOI 10.1021/la2024605; Sato K, 2012, POLYM BULL, V68, P891, DOI 10.1007/s00289-011-0670-1; Sennato S, 2009, COLLOID SURFACE A, V343, P34, DOI 10.1016/j.colsurfa.2009.01.026; Shu SJ, 2010, BIOMATERIALS, V31, P6039, DOI 10.1016/j.biomaterials.2010.04.016; Shu SJ, 2010, ACTA BIOMATER, V6, P210, DOI 10.1016/j.actbio.2009.06.020; Sukhorukov GB, 1998, COLLOID SURFACE A, V137, P253, DOI 10.1016/S0927-7757(98)00213-1; Tripathy J, 2013, COLLOID SURFACE B, V101, P487, DOI 10.1016/j.colsurfb.2012.07.025; van der Walle CF, 2009, EXPERT OPIN DRUG DEL, V6, P177, DOI [10.1517/17425240802680169, 10.1517/17425240802680169 ]; Volodkin D, 2007, J CONTROL RELEASE, V117, P111, DOI 10.1016/j.jconrel.2006.10.021; Wang ZJ, 2009, COLLOID SURFACE A, V348, P137, DOI 10.1016/j.colsurfa.2009.07.008; Yang YW, 2008, BIOMATERIALS, V29, P2516, DOI 10.1016/j.biomaterials.2008.02.015; Yang YY, 2001, BIOMATERIALS, V22, P231, DOI 10.1016/S0142-9612(00)00178-2; Zhang JX, 2004, J MICROENCAPSUL, V21, P775, DOI 10.1080/02652040400008465; Zhao QH, 2008, NANOMED-NANOTECHNOL, V4, P302, DOI 10.1016/j.nano.2008.06.004; Zhou J, 2010, J COLLOID INTERF SCI, V345, P241, DOI 10.1016/j.jcis.2010.02.004; Zhou J, 2009, MACROMOL BIOSCI, V9, P326, DOI 10.1002/mabi.200800188	49	6	6	3	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2014	9	3							e92393	10.1371/journal.pone.0092393	http://dx.doi.org/10.1371/journal.pone.0092393			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AD6ER	24647768	Green Published, gold			2023-01-03	WOS:000333348500125
J	Sartorius, T; Peter, A; Schulz, N; Drescher, A; Bergheim, I; Machann, J; Schick, F; Siegel-Axel, D; Schurmann, A; Weigert, C; Haring, HU; Hennige, AM				Sartorius, Tina; Peter, Andreas; Schulz, Nadja; Drescher, Andrea; Bergheim, Ina; Machann, Juergen; Schick, Fritz; Siegel-Axel, Dorothea; Schuermann, Annette; Weigert, Cora; Haering, Hans-Ulrich; Hennige, Anita M.			Cinnamon Extract Improves Insulin Sensitivity in the Brain and Lowers Liver Fat in Mouse Models of Obesity	PLOS ONE			English	Article							FASTING BLOOD-GLUCOSE; IN-VITRO; ANTIOXIDANT ACTIVITY; ESSENTIAL OILS; GLYCOGEN; EUGENOL; CINNAMALDEHYDE; INFLAMMATION; INHIBITION; OVERWEIGHT	Objectives: Treatment of diabetic subjects with cinnamon demonstrated an improvement in blood glucose concentrations and insulin sensitivity but the underlying mechanisms remained unclear. This work intends to elucidate the impact of cinnamon effects on the brain by using isolated astrocytes, and an obese and diabetic mouse model. Methods: Cinnamon components (eugenol, cinnamaldehyde) were added to astrocytes and liver cells to measure insulin signaling and glycogen synthesis. Ob/ob mice were supplemented with extract from cinnamomum zeylanicum for 6 weeks and cortical brain activity, locomotion and energy expenditure were evaluated. Insulin action was determined in brain and liver tissues. Results: Treatment of primary astrocytes with eugenol promoted glycogen synthesis, whereas the effect of cinnamaldehyde was attenuated. In terms of brain function in vivo, cinnamon extract improved insulin sensitivity and brain activity in ob/ob mice, and the insulin-stimulated locomotor activity was improved. In addition, fasting blood glucose levels and glucose tolerance were greatly improved in ob/ob mice due to cinnamon extracts, while insulin secretion was unaltered. This corresponded with lower triglyceride and increased liver glycogen content and improved insulin action in liver tissues. In vitro, Fao cells exposed to cinnamon exhibited no change in insulin action. Conclusions: Together, cinnamon extract improved insulin action in the brain as well as brain activity and locomotion. This specific effect may represent an important central feature of cinnamon in improving insulin action in the brain, and mediates metabolic alterations in the periphery to decrease liver fat and improve glucose homeostasis.	[Sartorius, Tina; Peter, Andreas; Drescher, Andrea; Siegel-Axel, Dorothea; Weigert, Cora; Haering, Hans-Ulrich] Univ Tubingen, Dept Internal Med, Div Endocrinol Diabetol Vasc Dis Nephrol & Clin C, Tubingen, Germany; [Sartorius, Tina; Schulz, Nadja; Machann, Juergen; Schuermann, Annette; Weigert, Cora; Haering, Hans-Ulrich; Hennige, Anita M.] German Ctr Diabet Res DZD, Tubingen, Germany; [Sartorius, Tina; Machann, Juergen; Weigert, Cora; Haering, Hans-Ulrich; Hennige, Anita M.] Univ Tuebingen IDM, Inst Diabet Res & Metab Dis, Helmholtz Ctr Munich, Tubingen, Germany; [Schulz, Nadja; Schuermann, Annette] German Inst Human Nutr, Dept Expt Diabetol, Potsdam, Germany; [Bergheim, Ina] Univ Jena, Dept Nutr Sci, SD Model Syst Mol Nutr, Jena, Germany; [Machann, Juergen; Schick, Fritz] Univ Tubingen, Dept Diagnost & Intervent Radiol, Sect Expt Radiol, Tubingen, Germany	Eberhard Karls University of Tubingen; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE); Friedrich Schiller University of Jena; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Sartorius, T (corresponding author), Univ Tubingen, Dept Internal Med, Div Endocrinol Diabetol Vasc Dis Nephrol & Clin C, Tubingen, Germany.	tina.sartorius@med.uni-tuebingen.de		Schick, Fritz/0000-0002-4231-3406; Schurmann, Annette/0000-0002-4113-4377	German Federal Ministry of Education and Research (BMBF) [01GI0925]; University of Tuebingen	German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); University of Tuebingen	The project was supported in part by grants from the German Federal Ministry of Education and Research (BMBF) to the German Center for Diabetes Research (DZD e.V.; 01GI0925). Additional parts of the funding are internal department funds of the University of Tuebingen (employment of people at the University of Tuebingen). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altschuler JA, 2007, DIABETES CARE, V30, P813, DOI 10.2337/dc06-1871; Anand P, 2010, CHEM-BIOL INTERACT, V186, P72, DOI 10.1016/j.cbi.2010.03.044; Brown AM, 2003, J PHYSIOL-LONDON, V549, P501, DOI 10.1113/jphysiol.2003.042416; Cai YZ, 2004, LIFE SCI, V74, P2157, DOI 10.1016/j.lfs.2003.09.047; CHAN TM, 1976, ANAL BIOCHEM, V71, P96, DOI 10.1016/0003-2697(76)90014-2; Chericoni S, 2005, J AGR FOOD CHEM, V53, P4762, DOI 10.1021/jf050183e; Choi IY, 2003, J NEUROSCI RES, V72, P25, DOI 10.1002/jnr.10574; Couturier K, 2011, METABOLISM, V60, P1590, DOI 10.1016/j.metabol.2011.03.016; Davis PA, 2011, J MED FOOD, V14, P884, DOI 10.1089/jmf.2010.0180; Deepa B, 2013, TOXICOL MECH METHOD, V23, P223, DOI 10.3109/15376516.2012.743638; Frydman-Marom A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016564; Gruenwald J, 2010, CRIT REV FOOD SCI, V50, P822, DOI 10.1080/10408390902773052; Heni M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021594; Hennige AM, 2009, DIABETOLOGIA, V52, P2416, DOI 10.1007/s00125-009-1522-5; Hennige AM, 2006, DIABETOLOGIA, V49, P1274, DOI 10.1007/s00125-006-0192-9; Hennige AM, 2005, DIABETES, V54, P361, DOI 10.2337/diabetes.54.2.361; Hennige AM, 2003, J CLIN INVEST, V112, P1521, DOI 10.1172/JCI200318581; Ho YS, 2010, AGEING RES REV, V9, P354, DOI 10.1016/j.arr.2009.10.001; Inoue H, 2006, CELL METAB, V3, P267, DOI 10.1016/j.cmet.2006.02.009; Kantartzis K, 2010, DIABETOLOGIA, V53, P882, DOI 10.1007/s00125-010-1663-6; Khan A, 2003, DIABETES CARE, V26, P3215, DOI 10.2337/diacare.26.12.3215; Kleinridders A, 2009, CURR OPIN PHARMACOL, V9, P794, DOI 10.1016/j.coph.2009.10.006; Lu T, 2012, NUTR RES, V32, P408, DOI 10.1016/j.nutres.2012.05.003; Lungarini S, 2008, FOOD ADDIT CONTAM A, V25, P1297, DOI 10.1080/02652030802105274; Machann J, 2005, J MAGN RESON IMAGING, V21, P455, DOI 10.1002/jmri.20292; Milanski M, 2012, DIABETES, V61, P1455, DOI 10.2337/db11-0390; Nagababu E, 2010, METHODS MOL BIOL, V610, P165, DOI 10.1007/978-1-60327-029-8_10; Obici S, 2002, NAT MED, V8, P1376, DOI 10.1038/nm798; Peterson DW, 2009, J ALZHEIMERS DIS, V17, P585, DOI 10.3233/JAD-2009-1083; Pfeiffer-Guglielmi B, 2003, J NEUROCHEM, V85, P73, DOI 10.1046/j.1471-4159.2003.01644.x; Plum L, 2006, J CLIN INVEST, V116, P1761, DOI 10.1172/JCI29063; Rafehi H, 2012, DIABETES OBES METAB, V14, P493, DOI 10.1111/j.1463-1326.2011.01538.x; Ranasinghe P, 2012, DIABETIC MED, V29, P1480, DOI 10.1111/j.1464-5491.2012.03718.x; Roussel AM, 2009, J AM COLL NUTR, V28, P16, DOI 10.1080/07315724.2009.10719756; Sartorius T, 2012, CELL PHYSIOL BIOCHEM, V30, P238, DOI 10.1159/000339060; Sartorius T, 2012, DIABETES, V61, P1669, DOI 10.2337/db11-1521; Sartorius T, 2012, FASEB J, V26, P1799, DOI 10.1096/fj.11-191023; Saur L, 2014, BRAIN STRUCT FUNCT, V219, P293, DOI 10.1007/s00429-012-0500-8; Sebai H, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-189; Shimada Y, 2000, PHYTOTHER RES, V14, P466, DOI 10.1002/1099-1573(200009)14:6&lt;466::AID-PTR614&gt;3.0.CO;2-Z; Simic A, 2004, PHYTOTHER RES, V18, P713, DOI 10.1002/ptr.1516; Singh G, 2007, FOOD CHEM TOXICOL, V45, P1650, DOI 10.1016/j.fct.2007.02.031; Stefan N, 2008, ENDOCR REV, V29, P939, DOI 10.1210/er.2008-0009; Suppapitiporn Suchat, 2006, J Med Assoc Thai, V89 Suppl 3, pS200; Tschritter O, 2006, P NATL ACAD SCI USA, V103, P12103, DOI 10.1073/pnas.0604404103; Tschritter O, 2009, J CLIN ENDOCR METAB, V94, P4600, DOI 10.1210/jc.2009-0469; Tsou RC, 2013, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00192; Usta J, 2003, HUM EXP TOXICOL, V22, P355, DOI 10.1191/0960327103ht379oa; Usta J, 2002, FOOD CHEM TOXICOL, V40, P935, DOI 10.1016/S0278-6915(02)00071-6; Vuksan V, 2005, NUTR METAB CARDIOVAS, V15, P149, DOI 10.1016/j.numecd.2005.05.001; Wickenbere J, 2012, BRIT J NUTR, V107, P1845, DOI 10.1017/S0007114511005113; Wie MB, 1997, NEUROSCI LETT, V225, P93, DOI 10.1016/S0304-3940(97)00195-X; Yu IC, 2013, DIABETES, V62, P411, DOI 10.2337/db12-0135; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003	54	61	64	4	39	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2014	9	3							e92358	10.1371/journal.pone.0092358	http://dx.doi.org/10.1371/journal.pone.0092358			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AD4ZE	24643026	Green Published, gold			2023-01-03	WOS:000333259900125
J	Cheng, CY; Lin, JG; Tang, NY; Kao, ST; Hsieh, CL				Cheng, Chin-Yi; Lin, Jaung-Geng; Tang, Nou-Ying; Kao, Shung-Te; Hsieh, Ching-Liang			Electroacupuncture-Like Stimulation at the Baihui (GV20) and Dazhui (GV14) Acupoints Protects Rats against Subacute-Phase Cerebral Ischemia-Reperfusion Injuries by Reducing S100B-Mediated Neurotoxicity	PLOS ONE			English	Article							PERMANENT FOCAL ISCHEMIA; APOPTOTIC CELL-DEATH; BRAIN-DAMAGE; ASTROCYTIC ACTIVATION; ARTERY OCCLUSION; NEONATAL-RAT; EXPRESSION; STROKE; S100B; INFARCTION	Objectives: The purpose of this study was to evaluate the effects of electroacupuncture-like stimulation at the Baihui (GV20) and Dazhui (GV14) acupoints (EA at acupoints) during the subacute phase of cerebral ischemia-reperfusion (I/R) injury and to establish the neuroprotective mechanisms involved in the modulation of the S100B-mediated signaling pathway. Methods: The experimental rats were subjected to middle cerebral artery occlusion (MCAo) for 15 min followed by 1 d or 7 d of reperfusion. EA at acupoints was applied 1 d postreperfusion then once daily for 6 consecutive days. Results: We observed that 15 min of MCAo caused delayed infarct expansion 7 d after reperfusion. EA at acupoints significantly reduced the cerebral infarct and neurological deficit scores. EA at acupoints also downregulated the expression of the glial fibrillary acidic protein (GFAP), S100B, nuclear factor-kappa B (NF-kappa B; p50), and tumor necrosis factor-alpha (TNF-alpha), and reduced the level of inducible nitric oxide synthase (iNOS) and apoptosis in the ischemic cortical penumbra 7 d after reperfusion. Western blot analysis showed that EA at acupoints significantly downregulated the cytosolic expression of phospho-p38 MAP kinase (p-p38 MAP kinase), tumor necrosis factor receptor type 1-associated death domain (TRADD), Fas-associated death domain (FADD), cleaved caspase-8, and cleaved caspase-3 in the ischemic cortical penumbra 7 d after reperfusion. EA at acupoints significantly reduced the numbers of GFAP/S100B and S100B/nitrotyrosine double-labeled cells. Conclusion: Our study results indicate that EA at acupoints initiated 1 d postreperfusion effectively downregulates astrocytic S100B expression to provide neuroprotection against delayed infarct expansion by modulating p38 MAP kinase-mediated NF-kappa B expression. These effects subsequently reduce oxidative/nitrative stress and inhibit the TNF-alpha/TRADD/ FADD/cleaved caspase-8/cleaved caspase-3 apoptotic pathway in the ischemic cortical penumbra 7 d after reperfusion.	[Cheng, Chin-Yi; Lin, Jaung-Geng; Tang, Nou-Ying; Kao, Shung-Te] China Med Univ, Sch Chinese Med, Coll Chinese Med, Taichung, Taiwan; [Cheng, Chin-Yi] Hui Sheng Hosp, Dept Chinese Med, Taichung, Taiwan; [Hsieh, Ching-Liang] China Med Univ, Acupuncture Res Ctr, Taichung, Taiwan; [Hsieh, Ching-Liang] China Med Univ Hosp, Dept Chinese Med, Taichung, Taiwan; [Hsieh, Ching-Liang] China Med Univ, Grad Inst Integrated Med, Coll Chinese Med, Taichung, Taiwan	China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan	Hsieh, CL (corresponding author), China Med Univ, Acupuncture Res Ctr, Taichung, Taiwan.	clhsieh@mail.cmuh.org.tw			China Medical University [CMU101-S-07]; Taiwanese Department of Health, Clinical Trials and Research Center of Excellence [DOH102-TD-B-111-004]	China Medical University(China Medical University); Taiwanese Department of Health, Clinical Trials and Research Center of Excellence	This study was supported by grants from China Medical University (CMU101-S-07), and the Taiwanese Department of Health, Clinical Trials and Research Center of Excellence (DOH102-TD-B-111-004). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asano T, 2005, CNS NEUROL DISORD-DR, V4, P127, DOI 10.2174/1568007053544084; Bianchi R, 2007, J LEUKOCYTE BIOL, V81, P108, DOI 10.1189/jlb.0306198; Buyukuysal RL, 2005, NEUROCHEM INT, V47, P580, DOI 10.1016/j.neuint.2005.06.009; Chao XD, EXP NEUROL, V239, P163; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Cheng CY, 2010, ACTA PHARMACOL SIN, V31, P889, DOI 10.1038/aps.2010.66; Clemens JA, 1997, MOL BRAIN RES, V48, P187, DOI 10.1016/S0169-328X(97)00092-2; Coeroli L, 1998, J NEUROCHEM, V70, P2516; Collino M, 2008, SHOCK, V30, P299, DOI 10.1097/SHK.0b013e318164e762; Collino M, 2006, FREE RADICAL BIO MED, V41, P1619, DOI 10.1016/j.freeradbiomed.2006.09.013; Donato R, 2009, BBA-MOL CELL RES, V1793, P1008, DOI 10.1016/j.bbamcr.2008.11.009; Figiel I, 2008, ACTA NEUROBIOL EXP, V68, P526; Gow AJ, 1996, FEBS LETT, V385, P63, DOI 10.1016/0014-5793(96)00347-X; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Hu JR, 1996, BBA-MOL CELL RES, V1313, P239, DOI 10.1016/0167-4889(96)00095-X; Iadecola C, 1997, J NEUROSCI, V17, P9157; Johansson BB, 2001, STROKE, V32, P707, DOI 10.1161/01.STR.32.3.707; Jung DH, 2009, J ETHNOPHARMACOL, V125, P374, DOI 10.1016/j.jep.2009.08.002; Lee JM, 2002, NEUROSCIENCE, V115, P871, DOI 10.1016/S0306-4522(02)00513-4; Lee SH, 2002, BRAIN RES, V956, P14, DOI 10.1016/S0006-8993(02)03197-9; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Luo Y, 2011, CHIN J INTEGR MED, V17, P750, DOI 10.1007/s11655-011-0754-7; Matsui T, 2002, J CEREBR BLOOD F MET, V22, P711, DOI 10.1097/00004647-200206000-00010; Mori T, 2005, J CEREBR BLOOD F MET, V25, P748, DOI 10.1038/sj.jcbfm.9600063; Mori T., 2010, CARDIOVASC PSYCHIAT; Mori T, 2008, STROKE, V39, P2114, DOI 10.1161/STROKEAHA.107.503821; Park J, 2001, J NEUROL, V248, P558, DOI 10.1007/s004150170132; Pizzi M, 2009, FEBS J, V276, P27, DOI 10.1111/j.1742-4658.2008.06767.x; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Sallstrom S, 1995, Tidsskr Nor Laegeforen, V115, P2884; Tanaka Y, 2007, BRAIN RES, V1137, P140, DOI 10.1016/j.brainres.2006.12.025; Tateishi N, 1998, Nihon Yakurigaku Zasshi, V112 Suppl 1, p103P; Wang Q, 2005, NEUROSCI LETT, V381, P158, DOI 10.1016/j.neulet.2005.02.019; Wang YH, 2006, J BIOMED SCI, V13, P127, DOI 10.1007/s11373-005-9031-0; Xiong L, 2003, CHINESE MED J-PEKING, V116, P108; Yang J, 2011, BRAIN RES, V1398, P94, DOI 10.1016/j.brainres.2011.05.007; Yasuda Y, 2004, BRAIN RES, V1021, P20, DOI 10.1016/j.brainres.2004.06.015; Ye YL, 2007, EUR J PHARMACOL, V557, P23, DOI 10.1016/j.ejphar.2006.11.003; Yu LY, 2006, NEUROCHEM RES, V31, P21, DOI 10.1007/s11064-005-9004-8; Zhai DX, 2008, NEUROSCI LETT, V445, P117, DOI 10.1016/j.neulet.2008.08.077; Zhang F, 2011, BRAIN INJURY, V25, P895, DOI 10.3109/02699052.2011.581639; Zhou Hai-peng, 2011, Zhonghua Yi Xue Za Zhi, V91, P1203; Zhu CL, 2004, J NEUROCHEM, V90, P462, DOI 10.1111/j.1471-4159.2004.02500.x; Zong H, J BIOL CHEM, V285, P23137	44	37	41	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 13	2014	9	3							e91426	10.1371/journal.pone.0091426	http://dx.doi.org/10.1371/journal.pone.0091426			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC9JS	24626220	Green Published, Green Submitted, gold			2023-01-03	WOS:000332851300084
J	Heaf, JG; Wehberg, S				Heaf, James G.; Wehberg, Sonja			Relative Survival of Peritoneal Dialysis and Haemodialysis Patients: Effect of Cohort and Mode of Dialysis Initiation	PLOS ONE			English	Article							RESIDUAL RENAL-FUNCTION; MORTALITY-RATES; COMPARING MORTALITY; MEMBRANE-TRANSPORT; HOME HEMODIALYSIS; TECHNIQUE FAILURE; SIMILAR OUTCOMES; ESRD PATIENTS; RISK-FACTORS; MODALITY	Introduction: Epidemiological studies consistently show an initial survival advantage for PD patients compared to HD. It has recently been suggested that this is due to the fact that many HD patients are referred late, and start dialysis on an acute, inpatient basis. The present study was performed to investigate (1) whether, and if so, how, PD and HD prognosis had changed in recent years, (2) whether a potential survival advantage of PD versus HD is constant over dialysis duration, and (3) whether differences in prognosis could be explained by patient age, renal diagnosis of diabetic nephropathy, or mode of dialysis initiation. Patients and Methods: 12095 patients starting dialysis therapy between 1990 and 2010 in Denmark were studied. Prognosis was assessed according to initial dialysis modality on an intention-to-treat basis, censored for transplantation. Results were adjusted for age, sex, renal diagnosis, Charlson Comorbidity Index (CCI), and mode of dialysis initiation. Results: Overall adjusted prognosis improved by 34% (HD 30%, PD 42%). PD prognosis relative to HD improved, and was 16% better at the end of the period. Final PD prognosis improved consistently from 1990-99 to 2000-10 in all subgroups. PD was associated with a significant initial survival advantage, both overall and for all subgroups For the latter cohort, overall PD prognosis was better than HD for the first 4 years, after which it was insignificantly worse. The initial survival advantage was also present in a subgroup analysis of patients with early & routine ESRD initiation. Conclusions: Dialysis survival has increased during the past 20 years. PD survival since 2000 has been better than HD, overall and for all subgroups. The difference in survival is not explained by mode of dialysis initiation.	[Heaf, James G.] Copenhagen Univ Hosp Herlev, Dept Nephrol B, Herlev, Denmark; [Wehberg, Sonja] Odense Univ Hosp, Dept Epidemiol, DK-5000 Odense, Denmark	University of Copenhagen; University of Southern Denmark; Odense University Hospital	Heaf, JG (corresponding author), Copenhagen Univ Hosp Herlev, Dept Nephrol B, Herlev, Denmark.	heaf@dadlnet.dk		Wehberg, Sonja/0000-0003-1503-2649	Baxter; Fresenius	Baxter; Fresenius	The authors have read the journal's policy and have the following conflicts. James Heaf has received travel funding and lecture fees from Baxter and Fresenius, and a research grant from Fresenius. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.	Andersen TF, 1999, DAN MED BULL, V46, P263; Brimble KS, 2006, J AM SOC NEPHROL, V17, P2591, DOI 10.1681/ASN.2006030194; Burton JO, 2009, CLIN J AM SOC NEPHRO, V4, P914, DOI 10.2215/CJN.03900808; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Churchill DN, 1998, J AM SOC NEPHROL, V9, P1285; Collins AJ, 2002, SEMIN DIALYSIS, V15, P98, DOI 10.1046/j.1525-139X.2002.00032.x; Collins AJ, 2012, AM J KIDNEY DIS, V59, pEVII, DOI 10.1053/j.ajkd.2011.11.015; Davies SJ, 2006, KIDNEY INT, V70, pS76, DOI 10.1038/sj.ki.5001920; Eknoyan G, 2002, NEW ENGL J MED, V347, P2010, DOI 10.1056/NEJMoa021583; Fenton SSA, 1997, AM J KIDNEY DIS, V30, P334, DOI 10.1016/S0272-6386(97)90276-6; Foley RN, 2011, NEW ENGL J MED, V365, P1099, DOI 10.1056/NEJMoa1103313; Frimat L, 2006, PERITON DIALYSIS INT, V26, P231; Ganesh SK, 2003, J AM SOC NEPHROL, V14, P415, DOI 10.1097/01.ASN.0000043140.23422.4F; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Grooteman MPC, 2012, J AM SOC NEPHROL, V23, P1087, DOI 10.1681/ASN.2011121140; Heaf JG, 2002, NEPHROL DIAL TRANSPL, V17, P112, DOI 10.1093/ndt/17.1.112; Heaf JG, 2011, DANISH NEPHROLOGY RE, P1; Huang CC, 2008, PERITON DIALYSIS INT, V28, pS15; Jaar BG, 2005, ANN INTERN MED, V143, P174, DOI 10.7326/0003-4819-143-3-200508020-00003; Jansen MAM, 2002, KIDNEY INT, V62, P1046, DOI 10.1046/j.1523-1755.2002.00505.x; Johnson DW, 2012, NEPHROL DIAL TRANSPL, V27, P4445, DOI 10.1093/ndt/gfs314; Johnson DW, 2012, J AM SOC NEPHROL, V23, P1097, DOI 10.1681/ASN.2011121201; Johnson DW, 2010, NEPHROL DIAL TRANSPL, V25, P1973, DOI 10.1093/ndt/gfp780; Lang SM, 2001, PERITON DIALYSIS INT, V21, P52; Lee CC, 2009, PERITON DIALYSIS INT, V29, P182; Liem YS, 2007, KIDNEY INT, V71, P153, DOI 10.1038/sj.ki.5002014; Locatelli F, 2001, J AM SOC NEPHROL, V12, P2411, DOI 10.1681/ASN.V12112411; Lynge E, 2011, SCAND J PUBLIC HEALT, V39, P30, DOI 10.1177/1403494811401482; Marshall MR, 2011, AM J KIDNEY DIS, V58, P782, DOI 10.1053/j.ajkd.2011.04.027; McDonald SP, 2009, J AM SOC NEPHROL, V20, P155, DOI 10.1681/ASN.2007111188; Mehrotra R, 2011, ARCH INTERN MED, V171, P110, DOI 10.1001/archinternmed.2010.352; Mircescu G, 2006, PERITON DIALYSIS INT, V26, P266; Moist LM, 2000, J AM SOC NEPHROL, V11, P556, DOI 10.1681/ASN.V113556; Paniagua R, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1351307; Pauly RP, 2009, NEPHROL DIAL TRANSPL, V24, P2915, DOI 10.1093/ndt/gfp295; Pedersen CB, 2006, DAN MED BULL, V53, P441; Port FK, 2006, CLIN J AM SOC NEPHRO, V1, P246, DOI 10.2215/CJN.01050905; Quinn RR, 2011, J AM SOC NEPHROL, V22, P1534, DOI 10.1681/ASN.2010121232; Sanabria M, 2008, KIDNEY INT, V73, pS165, DOI 10.1038/sj.ki.5002619; Schaubel DE, 1998, PERITON DIALYSIS INT, V18, P478; Sens F, 2011, KIDNEY INT, V80, P970, DOI 10.1038/ki.2011.233; Stack AG, 2003, KIDNEY INT, V64, P1071, DOI 10.1046/j.1523-1755.2003.00165.x; Termorshuizen F, 2003, J AM SOC NEPHROL, V14, P2851, DOI 10.1097/01.ASN.0000091585.45723.9E; van de Luijtgaarden MWM, 2011, NEPHROL DIAL TRANSPL, V26, P2940, DOI 10.1093/ndt/gfq845; Vilar E, 2009, NEPHROL DIAL TRANSPL, V24, P2502, DOI 10.1093/ndt/gfp071; Vonesh EF, 2004, KIDNEY INT, V66, P2389, DOI 10.1111/j.1523-1755.2004.66028.x; Vonesh EF, 1999, J AM SOC NEPHROL, V10, P354; Wehberg S, 2010, DATAGRUNDLAG ANALYSE, P14; Weinhandl ED, 2010, J AM SOC NEPHROL, V21, P499, DOI 10.1681/ASN.2009060635; Winkelmayer WC, 2002, J AM SOC NEPHROL, V13, P2353, DOI 10.1097/01.ASN.0000025785.41314.76; Yang X, 2008, PERITON DIALYSIS INT, V28, P82; Yeates K, 2012, NEPHROL DIAL TRANSPL, V27, P3568, DOI 10.1093/ndt/gfr674	52	61	67	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 10	2014	9	3							e90119	10.1371/journal.pone.0090119	http://dx.doi.org/10.1371/journal.pone.0090119			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC9FH	24614569	Green Submitted, Green Published, gold			2023-01-03	WOS:000332839300018
J	Liu, CY; Huang, CJ; Huang, LH; Chen, IJ; Chiu, JP; Hsu, CH				Liu, Chia-Yu; Huang, Chien-Jung; Huang, Lin-Huang; Chen, I-Ju; Chiu, Jung-Peng; Hsu, Chung-Hua			Effects of Green Tea Extract on Insulin Resistance and Glucagon-Like Peptide 1 in Patients with Type 2 Diabetes and Lipid Abnormalities: A Randomized, Double-Blinded, and Placebo-Controlled Trial	PLOS ONE			English	Article							WEIGHT-LOSS; GLUCOSE; IMMUNOASSAYS; INTERVENTION; CHOLESTEROL; MANAGEMENT; HORMONE; DIETARY; SYSTEM; RISK	The aim of this study is to investigate the effect of green tea extract on patients with type 2 diabetes mellitus and lipid abnormalities on glycemic and lipid profiles, and hormone peptides by a double-blinded, randomized and placebo controlled clinical trial. This trial enrolled 92 subjects with type 2 diabetes mellitus and lipid abnormalities randomized into 2 arms, each arm comprising 46 participants. Of the participants, 39 in therapeutic arm took 500 mg green tea extract, three times a day, while 38 in control arm took cellulose with the same dose and frequency to complete the 16-week study. Anthropometrics measurements, glycemic and lipid profiles, safety parameters, and obesity-related hormone peptides were analyzed at screening and after 16-week course. Within-group comparisons showed that green tea extract caused a significant decrease in triglyceride and homeostasis model assessment of insulin resistance index after 16 weeks. Green tea extract also increased significantly high density lipoprotein cholesterol. The HOMA-IR index decreased from 5.4+/-3.9 to 3.5+/-2.0 in therapeutic arm only. Adiponectin, apolipoprotein A1, and apolipoprotein B100 increased significantly in both arms, but only glucagon-like peptide 1 increased in the therapeutic arm. However, only decreasing trend in triglyceride was found in between-group comparison. Our study suggested that green tea extract significantly improved insulin resistance and increased glucagon-like peptide 1 only in within-group comparison. The potential effects of green tea extract on insulin resistance and glucagon-like peptide 1 warrant further investigation.	[Liu, Chia-Yu; Huang, Lin-Huang; Chen, I-Ju; Chiu, Jung-Peng; Hsu, Chung-Hua] Natl Yang Ming Univ, Inst Tradit Med, Sch Med, Taipei 112, Taiwan; [Liu, Chia-Yu; Chen, I-Ju; Chiu, Jung-Peng; Hsu, Chung-Hua] Taipei City Hosp, Dept Chinese Med, Branch Linsen & Chinese Med, Taipei, Taiwan; [Huang, Chien-Jung] Taipei City Hosp, Branch Linsen & Chinese Med, Dept Metab, Taipei, Taiwan	National Yang Ming Chiao Tung University; Taipei City Hospital; Taipei City Hospital	Hsu, CH (corresponding author), Natl Yang Ming Univ, Inst Tradit Med, Sch Med, Taipei 112, Taiwan.	owlherbs@yahoo.com.tw		Huang, Chien-Jung/0000-0003-4233-4677	National Science Council, Taiwan [101-2320-B-010-075]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	This study was supported financially by the National Science Council, Taiwan, under Grant No. 101-2320-B-010-075. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agin A, 2006, CLIN CHEM LAB MED, V44, P1379, DOI 10.1515/CCLM.2006.257; Badulescu O, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/169420; Baggio LL, 2007, GASTROENTEROLOGY, V132, P2131, DOI 10.1053/j.gastro.2007.03.054; Brown AS, 2005, AM J CARDIOL, V96, p26E, DOI 10.1016/j.amjcard.2005.07.001; Cernea Simona, 2011, Rev Diabet Stud, V8, P323, DOI 10.1900/RDS.2011.8.323; Davidson M, 2008, AM J CARDIOL, V102, p19L, DOI 10.1016/j.amjcard.2008.09.071; Deacon CF, 2009, BEST PRACT RES CL EN, V23, P425, DOI 10.1016/j.beem.2009.03.006; Drucker DJ, 2006, LANCET, V368, P1696, DOI 10.1016/S0140-6736(06)69705-5; Goto T, 2012, BRIT J NUTR, V107, P769, DOI 10.1017/S0007114511003758; Guyton JR, 1998, AM J CARDIOL, V82, p85U, DOI 10.1016/S0002-9149(98)00956-4; Heijboer AC, 2011, CLIN CHIM ACTA, V412, P1191, DOI 10.1016/j.cca.2011.03.010; Hsu CH, 2008, CLIN NUTR, V27, P363, DOI 10.1016/j.clnu.2008.03.007; Hsu Chung-Hua, 2011, Altern Med Rev, V16, P157; Hursel R, 2011, OBES REV, V12, pE573, DOI 10.1111/j.1467-789X.2011.00862.x; Hursel R, 2009, INT J OBESITY, V33, P956, DOI 10.1038/ijo.2009.135; Ikeda I, 2005, BIOSCI BIOTECH BIOCH, V69, P1049, DOI 10.1271/bbb.69.1049; Imatoh T, 2011, EUR J NUTR, V50, P279, DOI 10.1007/s00394-010-0136-5; Jing YL, 2009, J GEN INTERN MED, V24, P557, DOI 10.1007/s11606-009-0929-5; Kappe C, 2012, J GASTROENTEROL; Khan N, 2007, LIFE SCI, V81, P519, DOI 10.1016/j.lfs.2007.06.011; Kishimoto M, 2011, CARDIOVASC DIABETOL, V10, DOI 10.1186/1475-2840-10-115; Kreisberg RA, 1998, AM J CARDIOL, V82, p67U, DOI 10.1016/S0002-9149(98)00848-0; Li L, 2006, J LIPID RES, V47, P67, DOI 10.1194/jlr.M500424-JLR200; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Mazzanti G, 2009, EUR J CLIN PHARMACOL, V65, P331, DOI 10.1007/s00228-008-0610-7; Olofsson SO, 2007, VASC HEALTH RISK MAN, V3, P491; Ortsater H, 2012, NUTR METAB, V9, DOI 10.1186/1743-7075-9-11; Pan HJ, 2011, J CHIN MED ASSOC, V74, P169, DOI 10.1016/j.jcma.2011.01.038; Phung OJ, 2010, AM J CLIN NUTR, V91, P73, DOI 10.3945/ajcn.2009.28157; Polonsky KS, 2012, NEW ENGL J MED, V367, P1332, DOI 10.1056/NEJMra1110560; Rask E, 2001, DIABETES CARE, V24, P1640, DOI 10.2337/diacare.24.9.1640; Sone T, 2011, FOOD NUTR RES, V55, DOI 10.3402/fnr.v55i0.8326; STARR JI, 1978, J LAB CLIN MED, V91, P683; Thondam SK, 2012, DIABETIC MED, V29, pE205, DOI 10.1111/j.1464-5491.2012.03675.x; Tian C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053796; van Woudenbergh GJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036910; Vilsboll T, 2001, DIABETES, V50, P609, DOI 10.2337/diabetes.50.3.609; Wu AH, 2012, CANCER PREV RES, V5, P393, DOI 10.1158/1940-6207.CAPR-11-0407; Wu AH, 2011, NUTR CANCER, V63, P549, DOI 10.1080/01635581.2011.551986; Yamaoka-Tojo M, 2010, CARDIOVASC DIABETOL, V9, DOI 10.1186/1475-2840-9-17; Yao G, 2002, J FORMOS MED ASSOC, V101, P342	41	66	67	1	39	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 10	2014	9	3							e91163	10.1371/journal.pone.0091163	http://dx.doi.org/10.1371/journal.pone.0091163			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC9FH	24614112	Green Published, Green Submitted, gold			2023-01-03	WOS:000332839300087
J	Shet, A; Antony, J; Arumugam, K; Dodderi, SK; Rodrigues, R; DeCosta, A				Shet, Anita; Antony, Jimmy; Arumugam, Karthika; Dodderi, Sunil Kumar; Rodrigues, Rashmi; DeCosta, Ayesha			Influence of Adverse Drug Reactions on Treatment Success: Prospective Cohort Analysis of HIV-Infected Individuals Initiating First-Line Antiretroviral Therapy in India	PLOS ONE			English	Article							VIRUS POSITIVE PATIENTS; HAART REGIMEN; SEX-DIFFERENCES; RISK-FACTORS; DISCONTINUATION; ANEMIA; COMBINATION; EVENTS; PREDICTORS; TOXICITIES	Introduction: Adverse drug reactions related to antiretroviral therapy (ART) remain a challenge in resource-limited settings, often causing significant morbidity and impaired adherence leading to treatment failure. This 2-year prospective study aimed to describe patterns and predictors of adverse reactions to first-line ART and assess the impact of these events on treatment success. Methods: Between 2010-2013, 321 ART-naive eligible adults were enrolled at two clinics in southern India. ART regimens included zidovudine or stavudine plus lamivudine, plus nevirapine or efavirenz. Pill count adherence, immunological and virological monitoring, and laboratory-based adverse drug reactions were measured prospectively and analyzed. Results: Among 321 patients in the study, 289 (90.0%) patients experienced at least 1 adverse reaction, and 85 (26.5%) experienced at least 1 severe reaction. The incidence rate was 52 and 15 per 100 person-years for all reactions and severe reactions respectively. The cumulative incidence of zidovudine-induced anemia was 37.1% over 2 years. At 12 and 24 months, the proportion of patients with optimal adherence, undetectable viral load and CD4 counts >350 cells/mm(3) were similar between patients who experienced or did not experience severe adverse drug reactions. Conclusions: Our results highlight the high frequency of ART-related adverse drug reactions among individuals initiating first-line ART in India, underscoring the importance of detailed counseling and monitoring for maintaining ART durability. Severe drug-induced anemia needs to be addressed urgently with alternative first-line agents, and close laboratory surveillance. High treatment efficacy despite decreased drug safety seen here may be because patients have limited treatment options. Our results support the use of currently recommended safer first-line ART regimens that minimize the risk of severe life-threatening toxicities and provide for a better quality of life.	[Shet, Anita] St Johns Med Coll Hosp, Dept Pediat, Bangalore, Karnataka, India; [Antony, Jimmy] St Johns Res Inst, Div Publ Hlth & Infect, Bangalore, Karnataka, India; [Arumugam, Karthika] St Johns Res Inst, Div Biostat, Bangalore, Karnataka, India; [Dodderi, Sunil Kumar] Govt India, Natl AIDS Control Org, Minist Hlth & Family Welf, New Delhi, India; [Rodrigues, Rashmi] St Johns Med Coll Hosp, Dept Community Med, Bangalore, Karnataka, India; [Shet, Anita; DeCosta, Ayesha] Karolinska Inst, Div Global Hlth, Stockholm, Sweden	St. John's National Academy of Health Sciences; St. John's Medical College; St. John's National Academy of Health Sciences; St. John's Research Institute; St. John's National Academy of Health Sciences; St. John's Research Institute; St. John's National Academy of Health Sciences; St. John's Medical College; Karolinska Institutet	Shet, A (corresponding author), St Johns Med Coll Hosp, Dept Pediat, Bangalore, Karnataka, India.	anitashet@stjohns.in	Rodrigues, Rashmi J/H-1901-2012	Rodrigues, Rashmi J/0000-0002-0656-0178; Shet, Anita/0000-0002-7204-8164	European Union [222946]	European Union(European Commission)	The study was financially supported by a grant under the European Union Framework Program 7 (project no: 222946). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agu Kenneth A, 2013, Perspect Clin Res, V4, P117, DOI 10.4103/2229-3485.111784; [Anonymous], 2007, ANT THER GUID HIV IN; [Anonymous], 2012, NAT AIDS CONTR ORG A; Antinori A, 2001, AIDS, V15, P1579, DOI 10.1097/00002030-200108170-00018; Anuradha S, 2013, J Int Assoc Provid AIDS Care, V12, P195, DOI 10.1177/1545109711431344; Bersoff-Matcha SJ, 2001, CLIN INFECT DIS, V32, P124, DOI 10.1086/317536; Blake M, 2000, CLIN INFECT DIS, V30, pS96, DOI 10.1086/313859; Campbell TB, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001290; Cicconi P, 2010, HIV MED, V11, P104, DOI 10.1111/j.1468-1293.2009.00750.x; De Costa A, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-25; Division of AIDS (DAIDS), 2004, TABL GRAD SEV AD PED; Edwards IR, 2000, LANCET, V356, P1255, DOI 10.1016/S0140-6736(00)02799-9; Eluwa George I, 2012, BMC Clin Pharmacol, V12, P7, DOI 10.1186/1472-6904-12-7; Elzi L, 2010, ARCH INTERN MED, V170, P57, DOI 10.1001/archinternmed.2009.432; International Diabetes Federation, 2013, IDF DIABETES ATLAS, V6th ed.; Keiser O, 2007, ANTIVIR THER, V12, P1157; Kesselring AM, 2009, AIDS, V23, P1689, DOI 10.1097/QAD.0b013e32832d3b54; Khalili H, 2009, PHARMACOEPIDEM DR S, V18, P848, DOI 10.1002/pds.1793; Kumarasamy N, 2008, AIDS PATIENT CARE ST, V22, P337, DOI 10.1089/apc.2007.0093; Lichtenstein KA, 2008, JAIDS-J ACQ IMM DEF, V47, P27, DOI 10.1097/QAI.0b013e31815acacc; Lodwick RK, 2008, AIDS, V22, P1039, DOI 10.1097/QAD.0b013e3282fec415; Luma HN, 2012, PAN AFR MED J, V12; Mihanovic MP, 2013, MED SCI MONITOR, V19, P483, DOI 10.12659/MSM.889283; Modayil RR, 2010, PHARMACOEPIDEM DR S, V19, P247, DOI 10.1002/pds.1907; Moh R, 2005, ANTIVIR THER, V10, P615; Monforte AD, 2000, AIDS, V14, P499, DOI 10.1097/00002030-200003310-00005; Murphy RA, 2007, J INFECT DIS, V196, pS449, DOI 10.1086/521112; O'Brien ME, 2003, JAIDS-J ACQ IMM DEF, V34, P407, DOI 10.1097/00126334-200312010-00008; Ofotokun I, 2007, GENDER MED, V4, P106, DOI 10.1016/S1550-8579(07)80025-8; Phe T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060206; Prosperi MCF, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-296; Rajesh Radhakrishnan, 2011, Int J Risk Saf Med, V23, P171, DOI 10.3233/JRS-2011-0531; Robison LS, 2008, AIDS RES HUM RETROV, V24, P1347, DOI 10.1089/aid.2008.0083; Ruud KW, 2012, EUR J CLIN PHARMACOL, V68, P1321, DOI 10.1007/s00228-012-1254-1; Severe P, 2005, NEW ENGL J MED, V353, P2325, DOI 10.1056/NEJMoa051908; Sivadasan Ajith, 2009, J Assoc Physicians India, V57, P384; Srikanth BA, 2012, J ADV PHARM TECHNOL, V3, P62, DOI 10.4103/2231-4040.93557; Ssali F, 2006, ANTIVIR THER, V11, P741; WHO, 2001, IRON DEFICIENCY ANAE; World Health Organization, 1972, WHO TECHN REP SER, V498; Yuan Y, 2006, HIV MED, V7, P156, DOI 10.1111/j.1468-1293.2006.00355.x; Zhou JL, 2012, J INT AIDS SOC, V15, DOI 10.1186/1758-2652-15-5	42	30	31	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 10	2014	9	3							e91028	10.1371/journal.pone.0091028	http://dx.doi.org/10.1371/journal.pone.0091028			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC9FH	24614165	Green Submitted, gold, Green Published			2023-01-03	WOS:000332839300068
J	Rothman, DJ				Rothman, David J.			Where We Die	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Columbia Univ Coll Phys & Surg, Ctr Study Soc & Med, New York, NY 10032 USA	Columbia University	Rothman, DJ (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Study Soc & Med, 630 W 168th St, New York, NY 10032 USA.							Faust Drew Gilpin, 2009, THIS REPUBLIC SUFFER; National Center for Health Statistics, HLTH US 2010 SPEC FE; Rothman S., 1994, INT J HIST SPORT; Teno JM, 2013, JAMA-J AM MED ASSOC, V309, P470, DOI 10.1001/jama.2012.207624	4	15	17	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 26	2014	370	26					2457	2460		10.1056/NEJMp1404427	http://dx.doi.org/10.1056/NEJMp1404427			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AJ6KY	24963563				2023-01-03	WOS:000337804400001
J	Zhang, ZY; Xu, J; Ren, Y; Li, KKW; Ng, HK; Mao, Y; Zhong, P; Yao, Y; Zhou, LF				Zhang, Zhen-Yu; Xu, Jian; Ren, Yong; Li, Kay Ka-Wai; Ng, Ho-Keung; Mao, Ying; Zhong, Ping; Yao, Yu; Zhou, Liang-Fu			Medulloblastoma in China: Clinicopathologic Analyses of SHH, WNT, and Non-SHH/WNT Molecular Subgroups Reveal Different Therapeutic Responses to Adjuvant Chemotherapy	PLOS ONE			English	Article							PROGNOSTIC-FACTORS; ADULT MEDULLOBLASTOMA; CHILDREN; RADIATION; SERIES; TUMORS	Medulloblastoma (MB) is one of the most common primary central nervous system tumors in children. Data is lacking of a large cohort of medulloblastoma patients in China. Also, our knowledge on the sensitivity of different molecular subgroups of MB to adjuvant radiation therapy (RT) or chemotherapy (CHT) is still limited. The authors performed a retrospective study of 173 medulloblastoma patients treated at two institutions from 2002 to 2011. Formalin-fixed paraffin embedded (FFPE) tissues were available in all the cases and sections were stained to classify histological and molecular subgroups. Univariate and multivariate analyses were used to investigate prognostic factors. Of 173 patients, there were 118 children and 55 adults, 112 males and 61 females. Estimated 5-year overall survival (OS) rates for all patients, children and adults were 52%, 48% and 63%, respectively. After multivariate analysis, postoperative primary radiation therapy (RT) and chemotherapy (CHT) were revealed as favorable prognostic factors influencing OS and EFS. Postoperative primary chemotherapy (CHT) was found significantly improving the survival of children (p<0.001) while it was not a significant prognostic factor for adult patients. Moreover, patients in WNT subtype had better OS (p=0.028) than others (SHH and Non-SHH/WNT subtypes) given postoperative adjuvant therapies. Postoperative primary RT was found to be a strong prognostic factor influencing the survival in all histological and molecular subgroups (p<0.001). Postoperative primary CHT was found significantly to influence the survival of classic medulloblastoma (CMB) (OS p<0.001, EFS p<0.001), SHH subgroup (OS p=0.020, EFS p=0.049) and WNT subgroup (OS p=0.003, EFS p=0.016) but not in desmoplastic/nodular medulloblastoma (DMB) (OS p=0.361, EFS p=0.834) and Non-SHH/WNT subgroup (OS p=0.127, EFS p=0.055). Our study showed postoperative primary CHT significantly influence the survival of CMB, SHH subgroup and WNT subgroup but not in DMB and Non-SHH/WNT subgroup of MB.	[Zhang, Zhen-Yu; Xu, Jian; Mao, Ying; Zhong, Ping; Yao, Yu; Zhou, Liang-Fu] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai 200433, Peoples R China; [Ren, Yong] Wuhan Gen Hosp Guangzhou Command, Dept Pathol, Peoples Liberat Army, Wuhan, Peoples R China; [Li, Kay Ka-Wai; Ng, Ho-Keung] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Hong Kong, Peoples R China	Fudan University; Chinese University of Hong Kong; Prince of Wales Hospital	Zhong, P; Yao, Y (corresponding author), Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai 200433, Peoples R China.	zhp2288991@126.com; yu_yao03@126.com	Ng, Ho Keung/I-3952-2015	Mao, Ying/0000-0001-8055-115X	Shanghai Talents Development Funds [2011063]	Shanghai Talents Development Funds	This study was supported by Shanghai Talents Development Funds (No. 2011063 to YY). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albright AL, 1996, NEUROSURGERY, V38, P265, DOI 10.1097/00006123-199602000-00007; Brandes AA, 2007, CANCER-AM CANCER SOC, V110, P2035, DOI 10.1002/cncr.23003; CARRIE C, 1994, CANCER-AM CANCER SOC, V74, P2352, DOI 10.1002/1097-0142(19941015)74:8<2352::AID-CNCR2820740821>3.0.CO;2-H; Chan AW, 2000, NEUROSURGERY, V47, P623, DOI 10.1097/00006123-200009000-00018; Choux M, 1983, Clin Neurosurg, V30, P246; Curran EK, 2009, J NEURO-ONCOL, V95, P81, DOI 10.1007/s11060-009-9894-4; del Charco JO, 1998, INT J RADIAT ONCOL, V42, P147, DOI 10.1016/S0360-3016(98)00197-7; Ellison DW, 2011, ACTA NEUROPATHOL, V121, P381, DOI 10.1007/s00401-011-0800-8; FROST PJ, 1995, INT J RADIAT ONCOL, V32, P951, DOI 10.1016/0360-3016(94)00612-O; Gajjar A, 2006, LANCET ONCOL, V7, P813, DOI 10.1016/S1470-2045(06)70867-1; Herrlinger U, 2005, J NEUROL, V252, P291, DOI 10.1007/s00415-005-0560-2; Johnston DL, 2009, J NEURO-ONCOL, V94, P51, DOI 10.1007/s11060-009-9799-2; Johnstone PAS, 2002, CURR PROB CANCER, V26, P317, DOI 10.1067/mcn.2002.130267; Kool M, 2012, ACTA NEUROPATHOL, V123, P473, DOI 10.1007/s00401-012-0958-8; Liu YP, 2005, JPN J CLIN ONCOL, V35, P111, DOI 10.1093/jjco/hyi038; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Malheiros SMF, 2002, J NEURO-ONCOL, V60, P247, DOI 10.1023/A:1021178518361; Menon G, 2008, J CLIN NEUROSCI, V15, P122, DOI 10.1016/j.jocn.2007.06.007; Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324; Packer R J, 1999, Neuro Oncol, V1, P232, DOI 10.1093/neuonc/1.3.232; PACKER RJ, 1994, J NEUROSURG, V81, P690, DOI 10.3171/jns.1994.81.5.0690; PACKER RJ, 1991, J NEUROSURG, V74, P433, DOI 10.3171/jns.1991.74.3.0433; Packer RJ, 2008, ARCH NEUROL-CHICAGO, V65, P1419, DOI 10.1001/archneur.65.11.1419; Padovani L, 2007, INT J RADIAT ONCOL, V68, P433, DOI 10.1016/j.ijrobp.2006.12.030; Rieken S, 2011, INT J RADIAT ONCOL, V81, pE7, DOI 10.1016/j.ijrobp.2010.12.042; Rieken S, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-450; Riffaud L, 2009, J NEUROSURG, V111, P478, DOI 10.3171/2009.1.JNS081004; Roldan G, 2008, CAN J NEUROL SCI, V35, P210, DOI 10.1017/S0317167100008659; Sarkar C, 2002, J NEURO-ONCOL, V59, P49, DOI 10.1023/A:1016357731363; Sun LM, 2002, J NEURO-ONCOL, V58, P77, DOI 10.1023/A:1015865614640; Taylor MD, 2012, ACTA NEUROPATHOL, V123, P465, DOI 10.1007/s00401-011-0922-z; von Hoff K, 2009, EUR J CANCER, V45, P1209, DOI 10.1016/j.ejca.2009.01.015; Weil MD, 1998, JAMA-J AM MED ASSOC, V279, P1474, DOI 10.1001/jama.279.18.1474; Whelan HT, 1998, PEDIATR NEUROL, V18, P103, DOI 10.1016/S0887-8994(97)00221-X; Wolff JEA, 1998, KLIN PADIATR, V210, P234, DOI 10.1055/s-2008-1043884; Wrensch M, 2002, NEURO-ONCOLOGY, V4, P278, DOI 10.1093/neuonc/4.4.278; Zeltzer PM, 1999, J CLIN ONCOL, V17, P832, DOI 10.1200/JCO.1999.17.3.832	37	15	21	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 16	2014	9	6							e99490	10.1371/journal.pone.0099490	http://dx.doi.org/10.1371/journal.pone.0099490			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AJ5PV	24932704	Green Published, gold			2023-01-03	WOS:000337738600036
J	Briguori, C; Condorelli, G				Briguori, Carlo; Condorelli, Gerolama			Hydration in contrast-induced acute kidney injury	LANCET			English	Editorial Material							INDUCED NEPHROPATHY; PREVENTION; PREDICTION; FUROSEMIDE; SYSTEM		[Briguori, Carlo] Clin Mediterranea, Lab Intervent Cardiol, I-80121 Naples, Italy; [Briguori, Carlo] Clin Mediterranea, Dept Cardiol, I-80121 Naples, Italy; [Condorelli, Gerolama] Univ Naples Federico II, Dept Mol Med & Med Biotechnol, Naples, Italy; [Condorelli, Gerolama] Univ Naples Federico II, Inst Expt Endocrinol & Oncol G Salvatore, Naples, Italy	Mediterranean Clinic; Mediterranean Clinic; University of Naples Federico II; University of Naples Federico II	Briguori, C (corresponding author), Clin Mediterranea, Lab Intervent Cardiol, I-80121 Naples, Italy.	carlobriguori@clinicamediterranea.it	Condorelli, Gerolama/AAC-3472-2022	Condorelli, Gerolama/0000-0003-0177-8829				Brar SS, 2014, LANCET, V383, P1814, DOI 10.1016/S0140-6736(14)60689-9; Brar SS, 2009, CLIN J AM SOC NEPHRO, V4, P1584, DOI 10.2215/CJN.03120509; Briguori C, 2011, CIRCULATION, V124, P1260, DOI 10.1161/CIRCULATIONAHA.111.030759; Chertow GM, 2005, J AM SOC NEPHROL, V16, P3365, DOI 10.1681/ASN.2004090740; Clavijo LC, 2006, AM J CARDIOL, V97, P981, DOI 10.1016/j.amjcard.2005.10.033; Dorval JF, 2013, INT J CARDIOL, V166, P482, DOI 10.1016/j.ijcard.2011.11.035; Gurm HS, 2013, J AM COLL CARDIOL, V61, P2242, DOI 10.1016/j.jacc.2013.03.026; Marenzi G, 2012, JACC-CARDIOVASC INTE, V5, P90, DOI 10.1016/j.jcin.2011.08.017; Mehran R, 2004, J AM COLL CARDIOL, V44, P1393, DOI 10.1016/j.jacc.2004.06.068; NOSSEN JO, 1995, SCAND J CLIN LAB INV, V55, P341, DOI 10.3109/00365519509104972; Romano G, 2008, EUR HEART J, V29, P2569, DOI 10.1093/eurheartj/ehn197; SOLOMON R, 1994, NEW ENGL J MED, V331, P1416, DOI 10.1056/NEJM199411243312104; Stevens NA, 1999, J AM COLL CARDIOL, V33, P403	13	14	17	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 24	2014	383	9931					1786	1788		10.1016/S0140-6736(14)60753-4	http://dx.doi.org/10.1016/S0140-6736(14)60753-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AH6US	24856014				2023-01-03	WOS:000336267800006
J	Bynum, W				Bynum, William			When kidneys fail	LANCET			English	Editorial Material												w.bynum@ucl.ac.uk						Cameron JS, 2002, HIST TREATMENT RENAL; Chasis H, 1965, HW SMITH HIS LITERAR; Fox R., 1974, COURAGE FAIL SOCIAL; Peitzman SJ, 2007, DROPSY DIALYSSI TRAN; Schlich T., 2010, ORIGINS ORGAN TRANPL	5	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 24	2014	383	9931					1798	1799		10.1016/S0140-6736(14)60870-9	http://dx.doi.org/10.1016/S0140-6736(14)60870-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AH6US	24868570				2023-01-03	WOS:000336267800013
J	Minniear, TD; Girde, S; Angira, F; Mills, LA; Zeh, C; Peters, PJ; Masaba, R; Lando, R; Thomas, TK; Taylor, AW				Minniear, Timothy D.; Girde, Sonali; Angira, Frank; Mills, Lisa A.; Zeh, Clement; Peters, Philip J.; Masaba, Rose; Lando, Richard; Thomas, Timothy K.; Taylor, Allan W.		Kisumu Breastfeeding Study Team	Outcomes in a Cohort of Women Who Discontinued Maternal Triple-Antiretroviral Regimens Initially Used to Prevent Mother-to-Child Transmission during Pregnancy and Breastfeeding-Kenya, 2003-2009	PLOS ONE			English	Article							HIV-1 INFECTION; SURVIVAL	Background: In 2012, the World Health Organization (WHO) amended their 2010 guidelines for women receiving limited duration, triple-antiretroviral drug regimens during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV (tARV-PMTCT) (Option B) to include the option to continue lifelong combination antiretroviral therapy (cART) (Option B+). We evaluated clinical and CD4 outcomes in women who had received antiretrovirals for prevention of mother-to-child transmission and then discontinued antiretrovirals 6-months postpartum. Methods and Findings: The Kisumu Breastfeeding Study, 2003-2009, was a prospective, non-randomized, open-label clinical trial of tARV-PMTCT in ARV-naive, Kenyan women. Women received tARV-PMTCT from 34 weeks' gestation until 6-months postpartum when women were instructed to discontinue breastfeeding. Women with CD4 count (CD4) <250cells/mm3 or WHO stage III/IV prior to 6-months postpartum continued cART indefinitely. We estimated the change in CD4 after discontinuing tARV-PMTCT and the adjusted relative risk [aRR] for factors associated with declines in maternal CD4. We compared maternal and infant outcomes following weaning-when tARV-PMTCT discontinued-by maternal ARV status through 24-months postpartum. Compared with women who continued cART, discontinuing antiretrovirals was associated with infant HIV transmission and death (10.1% vs. 2.4%; P = 0.03). Among women who discontinued antiretrovirals, CD4,500 cells/mm3 at either initiation (21.8% vs. 1.5%; P = 0.002; aRR: 9.8; 95%-confidence interval [CI]: 2.4-40.6) or discontinuation (36.9% vs. 8.3%; P<0.0001; aRR: 4.4; 95%-CI: 1.9-5.0) were each associated with increased risk of women requiring cART for their own health within 6 months after discontinuing. Conclusions: Considering the serious health risks to the woman's infant and the brief reprieve from cART gained by stopping, every country should evaluate the need for and feasibility to implement WHO Option B+ for PMTCT. Evaluating CD4 at antiretroviral initiation or 6-months postpartum can identify pregnant women who would most benefit from continuing cART in settings unable to implement WHO Option B+.	[Minniear, Timothy D.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA; [Minniear, Timothy D.; Mills, Lisa A.; Zeh, Clement; Peters, Philip J.; Thomas, Timothy K.; Taylor, Allan W.] CDC, Div HIV AIDS Prevent, Atlanta, GA 30333 USA; [Minniear, Timothy D.] St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA; [Girde, Sonali] ICF Int, CDC Informat Management Serv, Atlanta, GA USA; [Angira, Frank; Mills, Lisa A.; Zeh, Clement; Masaba, Rose; Lando, Richard] CDC Res & Publ Hlth Collaborat, Kenya Med Res Inst, Kisumu, Kenya	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; St Jude Children's Research Hospital; Kenya Medical Research Institute	Taylor, AW (corresponding author), CDC, Div HIV AIDS Prevent, Atlanta, GA 30333 USA.	avt0@cdc.gov		Taylor, Allan/0000-0001-7496-8768	Kenya Medical Research Institute (KEMRI) through US Centers for Disease Control and Prevention (CDC)	Kenya Medical Research Institute (KEMRI) through US Centers for Disease Control and Prevention (CDC)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	Funding for the study was provided by the Kenya Medical Research Institute (KEMRI) through a cooperative agreement with the US Centers for Disease Control and Prevention (CDC). The study design, data collection instruments, data collection, data analysis, decision to publish, and preparation of the manuscript were led by CDC and KEMRI staff based in Atlanta and at the KEMRI/CDC Research and Public Health Collaboration in Kisumu, Kenya. This publication has been approved by the Director of the Kenya Medical Research Institute.	Cames C, 2010, MATERN CHILD NUTR, V6, P253, DOI 10.1111/j.1740-8709.2009.00201.x; Ciaranello AL, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001156; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Coovadia HM, 2012, LANCET, V379, P221, DOI 10.1016/S0140-6736(11)61653-X; Emery S, 2008, J INFECT DIS, V197, P1133, DOI 10.1086/586713; Fao P, 2012, CLIN INFECT DIS, V55, P449, DOI 10.1093/cid/cis461; Johansson KA, 2010, AIDS RES THER, V7, DOI 10.1186/1742-6405-7-3; Mermin J, 2008, LANCET, V371, P752, DOI 10.1016/S0140-6736(08)60345-1; Shah M, 2011, AIDS, V25, P1093, DOI 10.1097/QAD.0b013e32834670b9; Thomas TK, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001015; WHO, 2010, ANT THER HIV INF AD; WHO, 2012, US ANT DRUGS TREAT P; WHO, 2010, T PRIC ANT MED HIV D	13	5	5	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 14	2014	9	4							e93556	10.1371/journal.pone.0093556	http://dx.doi.org/10.1371/journal.pone.0093556			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI6GP	24733021	Green Submitted, gold, Green Published			2023-01-03	WOS:000336970400008
J	Gao, QL; Chen, CH; Ji, T; Wu, P; Han, ZQ; Fang, HY; Li, F; Liu, Y; Hu, WC; Gong, DN; Zhang, ZY; Wang, SX; Zhou, JF; Ma, D				Gao, Qinglei; Chen, Caihong; Ji, Teng; Wu, Peng; Han, Zhiqiang; Fang, Haiyan; Li, Fei; Liu, Yi; Hu, Wencheng; Gong, Danni; Zhang, Zeyu; Wang, Shixuan; Zhou, Jianfeng; Ma, Ding			A Systematic Comparison of the Anti-Tumoural Activity and Toxicity of the Three Adv-TKs	PLOS ONE			English	Article							SELECTIVE ONCOLYTIC ADENOVIRUS; VIRUS-THYMIDINE KINASE/GANCICLOVIR; GENE-TRANSFER VECTORS; PHASE-I TRIAL; REPLICATION-COMPETENT; CLINICAL-TRIAL; HEPATOCELLULAR-CARCINOMA; RADIATION-THERAPY; IMMUNE-RESPONSES; PROSTATE-CANCER	Adenovirus 5 vectors, known respectively as, the first generation, second generation and oncolytic adenovirus, have been studied extensively in preclinical and clinical trials. However, hitherto few systemic evaluations of the efficacy and toxicity of these adenoviral vectors that have reflected the vertical history of adenovirus based cancer gene therapy strategies have been undertaken. This study has chosen Adv-TK, the well-established adjuvant treatment in cancer, and compared its efficacy and safety with those of the two newly synthesized oncolytic adenovirus vectors encoding the HSV-TK gene, namely M7 and M8. The results obtained showed that systemic administration of 1x10(8) pfu M7 had an anti-tumour efficacy similar to that of 3x10(10) pfu Adv-TK whilst M8 performed even better. Furthermore, compared to Adv-TK, M7 and M8 reduced the incidence of metastases and substantially prolonged the survival time of the mice xenografted with human orthotopic gastric carcinomas with disseminated metastasis. Even more exciting, however, were the similar toxic and immune safety results obtained from the administration of high doses of M7 or M8 in comparison with Adv-TK in immunocompetent and permissive syrian hamster. The data here exhibit a comprehensive display of the efficacy and safety of the three mutants and provide evidence for the future preclinical use of the M7 and M8 viruses.	[Gao, Qinglei; Ji, Teng; Wu, Peng; Han, Zhiqiang; Fang, Haiyan; Li, Fei; Liu, Yi; Hu, Wencheng; Gong, Danni; Wang, Shixuan; Zhou, Jianfeng; Ma, Ding] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Canc Biol Res Ctr, Wuhan 430074, Hubei, Peoples R China; [Chen, Caihong] Zhengzhou Univ, Affiliated Hosp 1, Ctr Reprod Med, Zhengzhou 450052, Peoples R China	Huazhong University of Science & Technology; Zhengzhou University	Zhou, JF (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Canc Biol Res Ctr, Wuhan 430074, Hubei, Peoples R China.	jfzhou@tjh.tjmu.edu.cn; dma@tjh.tjmu.edu.cn	Hu, Wencheng/K-2380-2014; Gao, Qinglei/B-1141-2019; wu, peng/M-1812-2019	wu, peng/0000-0002-4016-6641; gao, qinglei/0000-0002-9448-3423	National Science Foundation of China [81072135, 81372801, 81230038, 81272426, 81270770, 81230052, 81071663, 31130031, 30901587, 81101963, 81025011, 81090414, 81001151, 81172467]; Chinese Postdoctoral Science Foundation [2013M541999]; "973" Program of China [2009CB521808]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese Postdoctoral Science Foundation(China Postdoctoral Science Foundation); "973" Program of China(National Basic Research Program of China)	Grant Support: National Science Foundation of China (81072135, 81372801,81230038, 81272426, 81270770, 81230052, 81071663, 31130031, 30901587, 81101963, 81025011, 81090414, 81001151, 81172467), Chinese Postdoctoral Science Foundation (2013M541999) and the "973" Program of China (No. 2009CB521808). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Benedict CA, 2001, J BIOL CHEM, V276, P3270, DOI 10.1074/jbc.M008218200; Chen G, 2006, CANCER GENE THER, V13, P930, DOI 10.1038/sj.cgt.7700967; Crystal RG, 1997, HUM GENE THER, V8, P985, DOI 10.1089/hum.1997.8.8-985; DeWeese TL, 2001, CANCER RES, V61, P7464; Freytag SO, 2003, CANCER RES, V63, P7497; Galanis E, 2005, GENE THER, V12, P437, DOI 10.1038/sj.gt.3302436; Ganly I, 2000, CLIN CANCER RES, V6, P798; Gao QL, 2006, MOL THER, V13, P928, DOI 10.1016/j.ymthe.2005.12.009; Habib N, 2002, CANCER GENE THER, V9, P254, DOI 10.1038/sj.cgt.7700431; Habib NA, 2001, HUM GENE THER, V12, P219, DOI 10.1089/10430340150218369; Han ZQ, 2009, CARCINOGENESIS, V30, P2014, DOI 10.1093/carcin/bgp249; Harvey BG, 1999, J VIROL, V73, P6729, DOI 10.1128/JVI.73.8.6729-6742.1999; Harvey BG, 2002, MOL THER, V6, P287, DOI 10.1006/mthe.2002.0658; Harvey BG, 2002, HUM GENE THER, V13, P15, DOI 10.1089/10430340152712638; Hawkins LK, 2001, GENE THER, V8, P1123, DOI 10.1038/sj.gt.3301507; Huang XY, 2008, MOL CANCER THER, V7, P1624, DOI 10.1158/1535-7163.MCT-07-2134; Ketner Gary, 2007, Methods Mol Med, V130, P19; Kirn D, 2000, ONCOGENE, V19, P6660, DOI 10.1038/sj.onc.1204094; Kurbacher CM, 2011, METHODS MOL BIOL, V731, P161, DOI 10.1007/978-1-61779-080-5_15; Li N, 2007, CLIN CANCER RES, V13, P5847, DOI 10.1158/1078-0432.CCR-07-0499; Lichtenstein DL, 2009, CANCER GENE THER, V16, P644, DOI 10.1038/cgt.2009.5; Ma D, 1997, BLOOD, V90, P2738, DOI 10.1182/blood.V90.7.2738.2738_2738_2746; Makower D, 2003, CLIN CANCER RES, V9, P693; Mesnil M, 2000, CANCER RES, V60, P3989; Page JG, 2007, AM J OBSTET GYNECOL, V196, DOI 10.1016/j.ajog.2006.12.016; Reid T, 2001, GENE THER, V8, P1618, DOI 10.1038/sj.gt.3301512; Reid T, 2002, CANCER RES, V62, P6070; Su CQ, 2008, TOXICOL SCI, V106, P242, DOI 10.1093/toxsci/kfn168; Sung MW, 2001, MOL THER, V4, P182, DOI 10.1006/mthe.2001.0444; Thomas MA, 2008, MOL THER, V16, P1665, DOI 10.1038/mt.2008.162; TOLLEFSON AE, 1992, J VIROL, V66, P3633, DOI 10.1128/JVI.66.6.3633-3642.1992; Tollefson AE, 1996, J VIROL, V70, P2296, DOI 10.1128/JVI.70.4.2296-2306.1996; Tollefson AE, 1996, VIROLOGY, V220, P152, DOI 10.1006/viro.1996.0295; Tollefson AE, 2003, J VIROL, V77, P7764, DOI 10.1128/JVI.77.14.7764-7778.2003; Wang YH, 2003, NAT BIOTECHNOL, V21, P1328, DOI 10.1038/nbt887; Wold WSM, 1999, CURR OPIN IMMUNOL, V11, P380, DOI 10.1016/S0952-7915(99)80064-8; Wu P, 2005, BIOCHEM BIOPH RES CO, V335, P36, DOI 10.1016/j.bbrc.2005.07.039; Yazawa K, 2002, WORLD J SURG, V26, P783, DOI 10.1007/s00268-002-4053-5; Zheng FQ, 2009, ACTA PHARMACOL SIN, V30, P617, DOI 10.1038/aps.2009.33; Zhou JF, 2005, CLIN CANCER RES, V11, P8431, DOI 10.1158/1078-0432.CCR-05-1085	40	10	12	2	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 10	2014	9	4							e94050	10.1371/journal.pone.0094050	http://dx.doi.org/10.1371/journal.pone.0094050			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI5LS	24722669	gold, Green Published, Green Submitted			2023-01-03	WOS:000336909100036
J	Hofstede, SN; van Bodegom-Vos, L; Wentink, MM; Vleggeert-Lankamp, CLA; Vlieland, TPMV; Marang-van de Mheen, PJ				Hofstede, Stefanie N.; van Bodegom-Vos, Leti; Wentink, Manon M.; Vleggeert-Lankamp, Carmen L. A.; Vlieland, Thea P. M. Vliet; Marang-van de Mheen, Perla J.		DISC Study Grp	Most Important Factors for the Implementation of Shared Decision Making in Sciatica Care: Ranking among Professionals and Patients	PLOS ONE			English	Article							SURGERY; DISC; FACILITATORS; MANAGEMENT; BARRIERS	Introduction: Due to the increasing specialization of medical professionals, patients are treated by multiple disciplines. To ensure that delivered care is patient-centered, it is crucial that professionals and the patient together decide on treatment (shared decision making (SDM)). However, it is not known how SDM should be integrated in multidisciplinary practice. This study determines the most important factors for SDM implementation in sciatica care, as it is known that a prior inventory of factors is crucial to develop a successful implementation strategy. Methods: 246 professionals (general practitioners, physical therapists, neurologists, neurosurgeons, orthopedic surgeons) (30% response) and 155 patients (96% response) responded to an internet-based survey. Respondents ranked barriers and facilitators identified in previous interviews, on their importance using Maximum Difference Scaling. Feeding back the personal top 5 most important factors, each respondent indicated whether these factors were barriers or facilitators. Hierarchical Bayes estimation was used to estimate the relative importance (RI) of each factor. Results: Professionals assigned the highest importance to: quality of professional-patient relationship (RI 4.87; CI 4.75-4.99); importance of quick recovery of patient (RI 4.83; CI 4.69-4.97); and knowledge about treatment options (RI 6.64; CI 4.534.74), which were reported as barrier and facilitator. Professionals working in primary care had a different ranking than those working in hospital care. Patients assigned the highest importance to: correct diagnosis by professionals (barrier, RI 8.19; CI 7.99-8.38); information provision about treatment options and potential harm and benefits (RI 7.87; CI 7.65-8.08); and explanation of the professional about the care trajectory (RI 7.16; CI 6.94-7.38), which were reported as barrier and facilitator. Conclusions: Knowledge, information provision and a good relationship are the most important conditions for SDM perceived by both patients and professionals. These conditions are not restricted to one specific disease or health care system, because they are mostly professional or patient dependent and require healthcare professional training.	[Hofstede, Stefanie N.; van Bodegom-Vos, Leti; Wentink, Manon M.; Marang-van de Mheen, Perla J.] Leiden Univ, Med Ctr, Dept Med Decis Making, Leiden, Netherlands; [Vleggeert-Lankamp, Carmen L. A.] Leiden Univ, Med Ctr, Dept Neurosurg, Leiden, Netherlands; [Vlieland, Thea P. M. Vliet] Leiden Univ, Med Ctr, Dept Orthopaed, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Marang-van de Mheen, PJ (corresponding author), Leiden Univ, Med Ctr, Dept Med Decis Making, Leiden, Netherlands.	p.j.marang@lumc.nl	de Mheen, Perla J. Marang-van/I-2783-2015; Vlieland, Thea Vliet/AAJ-8119-2020; van Bodegom-Vos, Leti/J-8087-2015; Vleggeert-Lankamp, Carmen/AGX-9660-2022; assendelft, willem/AAW-1854-2021; Assendelft, W.J.J./H-8008-2014	de Mheen, Perla J. Marang-van/0000-0003-1439-0989; Vlieland, Thea Vliet/0000-0001-6322-3859; van Bodegom-Vos, Leti/0000-0002-8486-6404; Vleggeert-Lankamp, Carmen/0000-0001-9597-7225; assendelft, willem/0000-0002-2966-3778; Assendelft, W.J.J./0000-0002-2966-3778; Hofstede, Stefanie/0000-0002-7181-9959	Netherlands Organization for Health Research and Development [171203003]; Netherlands Organization for Scientific Research (NWO) Incentive Fund Open Access Publications	Netherlands Organization for Health Research and Development(Netherlands Organization for Health Research and Development); Netherlands Organization for Scientific Research (NWO) Incentive Fund Open Access Publications	This research project is supported by a grant from the Netherlands Organization for Health Research and Development (grant number 171203003). Funding was obtained from the Netherlands Organization for Scientific Research (NWO) Incentive Fund Open Access Publications. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	CHERKIN DC, 1994, SPINE, V19, P1201, DOI 10.1097/00007632-199405310-00001; Cohen S, 2004, MARK RES, V16, P32; Cohen Steven H., 2002, C P AMST NETH; DEGNER LF, 1992, J CLIN EPIDEMIOL, V45, P941, DOI 10.1016/0895-4356(92)90110-9; Dobrow MJ, 2008, J MED INTERNET RES, V10, DOI 10.2196/jmir.1090; Elwyn G, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5146; Flynn TN, 2007, J HEALTH ECON, V26, P171, DOI 10.1016/j.jhealeco.2006.04.002; Gravel K, 2006, IMPLEMENT SCI, V1, DOI 10.1186/1748-5908-1-16; Hofstede SN, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-95; Jacobs WCH, 2011, EUR SPINE J, V20, P513, DOI 10.1007/s00586-010-1603-7; Jessup RL, 2007, AUST HEALTH REV, V31, P330, DOI 10.1071/AH070330; Konstantinou K, 2008, SPINE, V33, P2464, DOI 10.1097/BRS.0b013e318183a4a2; Legare F, 2011, J EVAL CLIN PRACT, V17, P554, DOI 10.1111/j.1365-2753.2010.01515.x; Legare F, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006732.pub2; Legare F, 2008, PATIENT EDUC COUNS, V73, P526, DOI 10.1016/j.pec.2008.07.018; Lurie JD, 2008, SPINE, V33, P2663, DOI 10.1097/BRS.0b013e31818cb0db; McIntosh E, 2002, HLTH EC STUD GROUP M; OCONNOR A, 2009, COCHRANE DB SYST REV, V10; Peul WC, 2008, BRIT MED J, V336, P1355, DOI 10.1136/bmj.a143; Quality Institute for Health Care CBO, 2008, GUID LUMB RAD SYNDR; Rajakumar R., 2014, PRIM HLTH CARE RES D, P1; Sawtooth Software, 2009, CBC HB SYSTEM HIERAR; Sawtooth Software I, 2013, MAXDIFF SYST VERS 8; Sawtooth Software I, 2012, SSI WEB V8 1 SOFTW W; Van Beek E, 2010, REDUCTION VARIATION; Veroff D, 2013, HEALTH AFFAIR, V32, P285, DOI 10.1377/hlthaff.2011.0941; Vroomen PCAJ, 2002, BRIT J GEN PRACT, V52, P119; Webster BS, 2005, J GEN INTERN MED, V20, P1132, DOI 10.1111/j.1525-1497.2005.0230.x; Wiebe ER, 2012, CAN FAM PHYSICIAN, V58, pE225; Wirth R, 2011, USING MAXDIFF EVALUA	30	25	25	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 7	2014	9	4							e94176	10.1371/journal.pone.0094176	http://dx.doi.org/10.1371/journal.pone.0094176			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AE7EP	24710328	Green Published, Green Submitted, gold			2023-01-03	WOS:000334159800112
J	Nowak, A; Friedrich, B; Artunc, F; Serra, AL; Breidthardt, T; Twerenbold, R; Peter, M; Mueller, C				Nowak, Albina; Friedrich, Bjoern; Artunc, Ferruh; Serra, Andreas L.; Breidthardt, Tobias; Twerenbold, Raphael; Peter, Myriam; Mueller, Christian			Prognostic Value and Link to Atrial Fibrillation of Soluble Klotho and FGF23 in Hemodialysis Patients	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; GROWTH-FACTOR 23; STAGE RENAL-DISEASE; SECRETED KLOTHO; MYOCARDIAL-INFARCTION; ARTERY CALCIFICATION; MEDIA CALCIFICATION; RISK-FACTORS; MORTALITY; DIALYSIS	Deranged calcium-phosphate metabolism contributes to the burden of morbidity and mortality in dialysis patients. This study aimed to assess the association of the phosphaturic hormone fibroblast growth factor 23 (FGF23) and soluble Klotho with all-cause mortality. We measured soluble Klotho and FGF23 levels at enrolment and two weeks later in 239 prevalent hemodialysis patients. The primary hypothesis was that low Klotho and high FGF23 are associated with increased mortality. The association between Klotho and atrial fibrillation (AF) at baseline was explored as secondary outcome. AF was defined as presence of paroxysmal, persistent or permanent AF. During a median follow-up of 924 days, 59 (25%) patients died from any cause. Lower Klotho levels were not associated with mortality in a multivariable adjusted analysis when examined either on a continuous scale (HR 1.25 per SD increase, 95% CI 0.84-1.86) or in tertiles, with tertile 1 as the reference category (HR for tertile two 0.65, 95% CI 0.26-1.64; HR for tertile three 2.18, 95% CI 0.91-2.23). Higher Klotho levels were associated with the absence of AF in a multivariable logistic regression analysis (OR 0.66 per SD increase, 95% CI 0.41-1.00). Higher FGF23 levels were associated with mortality risk in a multivariable adjusted analysis when examined either on a continuous scale (HR 1.45 per SD increase, 95% CI 1.05-1.99) or in tertiles, with the tertile 1 as the reference category (HR for tertile two 1.63, 95% CI 0.64-4.14; HR for tertile three 3.91, 95% CI 1.28-12.20). FGF23 but not Klotho levels are associated with mortality in hemodialysis patients. Klotho may be protective against AF.	[Nowak, Albina] Univ Zurich Hosp, Div Internal Med, CH-8091 Zurich, Switzerland; [Friedrich, Bjoern; Artunc, Ferruh] Univ Tubingen, Dept Internal Med, Div Endocrinol Diabetol Vasc Dis Nephrol & Clin C, Tubingen, Germany; [Friedrich, Bjoern] Dialysis Ctr Leonberg, Leonberg, Germany; [Serra, Andreas L.] Univ Zurich Hosp, Div Nephrol, CH-8091 Zurich, Switzerland; [Breidthardt, Tobias] Univ Basel Hosp, Div Nephrol, CH-4031 Basel, Switzerland; [Twerenbold, Raphael; Peter, Myriam; Mueller, Christian] Univ Basel Hosp, Div Cardiol, CH-4031 Basel, Switzerland	University of Zurich; University Zurich Hospital; Eberhard Karls University of Tubingen; University of Zurich; University Zurich Hospital; University of Basel; University of Basel	Nowak, A (corresponding author), Univ Zurich Hosp, Div Internal Med, CH-8091 Zurich, Switzerland.	albina.nowak@usz.ch	Müller, Christian/AAB-4783-2022; Twerenbold, Raphael/H-3533-2018	Müller, Christian/0000-0002-1120-6405; Twerenbold, Raphael/0000-0003-3814-6542; Breidthardt, Tobias/0000-0003-2671-6456				Akimoto T, 2012, CLIN EXP NEPHROL, V16, P442, DOI 10.1007/s10157-011-0582-2; Alexander RT, 2009, J AM SOC NEPHROL, V20, P2371, DOI 10.1681/ASN.2008121273; Anour R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031376; Artunc F, 2012, KIDNEY BLOOD PRESS R, V36, P172, DOI 10.1159/000343406; Artunc F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047610; Drueke TB, 2010, KIDNEY INT, V78, P1057, DOI 10.1038/ki.2010.339; Etter C, 2010, EUR HEART J, V31, P354, DOI 10.1093/eurheartj/ehp429; Gutierrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130; Gutierrez OM, 2011, CLIN J AM SOC NEPHRO, V6, P2871, DOI 10.2215/CJN.02740311; Heijboer AC, 2013, NEPHROL DIAL TRANSPL; Huang CL, 2010, KIDNEY INT, V77, P855, DOI 10.1038/ki.2010.73; Imura A, 2004, FEBS LETT, V565, P143, DOI 10.1016/j.febslet.2004.03.090; Isakova T, 2011, JAMA-J AM MED ASSOC, V305, P2432, DOI 10.1001/jama.2011.826; Kendrick J, 2011, J AM SOC NEPHROL, V22, P1913, DOI 10.1681/ASN.2010121224; Kitagawa M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056695; Komaba H, 2012, NEPHROL DIAL TRANSPL, V27, P1967, DOI 10.1093/ndt/gfr645; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Kuwahara K, 2006, J CLIN INVEST, V116, P3114, DOI 10.1172/JCI27702; Lim K, 2012, CIRCULATION, V125, P2243, DOI 10.1161/CIRCULATIONAHA.111.053405; London GM, 2003, NEPHROL DIAL TRANSPL, V18, P1731, DOI 10.1093/ndt/gfg414; Maekawa Y, 2009, ENDOCRINE, V35, P341, DOI 10.1007/s12020-009-9181-3; Moe SM, 2011, J BONE MINER RES, V26, P2672, DOI 10.1002/jbmr.485; Pavik I, 2012, NEPHROL DIAL TRANSPL; Pavik I, 2013, NEPHROL DIAL TRANSPL, V28, P352, DOI 10.1093/ndt/gfs460; Quarles LD, 2008, J CLIN INVEST, V118, P3820, DOI 10.1172/JCI36479; Seiler C, 2011, EUR HEART J, V32, P261, DOI [10.1093/eurheartj/ehq314, 10.1093/eurheartj/ehr215]; Seiler S, 2013, KIDNEY INT, V83, P121, DOI 10.1038/ki.2012.288; Shroff GR, 2012, AM HEART J, V163, P399, DOI 10.1016/j.ahj.2011.12.002; Six I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093423; Smith ER, 2013, CLIN CHEM LAB MED, V51, P1971, DOI 10.1515/cclm-2013-0208; Takeshita K, 2004, CIRCULATION, V109, P1776, DOI 10.1161/01.CIR.0000124224.48962.32; Tandon T, 2013, NEPHROL DIAL TRANSPL, V28, P1562, DOI 10.1093/ndt/gfs597; Tangri N, 2011, NEPHROL DIAL TRANSPL, V26, P3998, DOI 10.1093/ndt/gfr188; Tong LL, 2008, HEMODIAL INT, V12, P16, DOI 10.1111/j.1542-4758.2008.00234.x; Trivedi H, 2009, NEPHROL DIAL TRANSPL, V24, P258, DOI 10.1093/ndt/gfn426; Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315; Winn MP, 2005, SCIENCE, V308, P1801, DOI 10.1126/science.1106215; Xie J, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2240; Yamazaki Y, 2010, BIOCHEM BIOPH RES CO, V398, P513, DOI 10.1016/j.bbrc.2010.06.110; Yoshida H, 2011, CLIN NEPHROL, V75, P1, DOI 10.2379/CN106401; Zaritsky J, 2013, NEPHROL DIAL TRANSPL	41	49	51	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 3	2014	9	7							e100688	10.1371/journal.pone.0100688	http://dx.doi.org/10.1371/journal.pone.0100688			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO3RT	24991914	Green Published, gold, Green Submitted			2023-01-03	WOS:000341253400026
J	Hung, SF; Hsieh, CM; Chen, YC; Wang, YC; Ho, HO; Sheu, MT				Hung, Sheng-Feng; Hsieh, Chien-Ming; Chen, Ying-Chen; Wang, Yu-Chun; Ho, Hsiu-O; Sheu, Ming-Thau			Characterizations of Plasticized Polymeric Film Coatings for Preparing Multiple-Unit Floating Drug Delivery Systems (muFDDSs) with Controlled-Release Characteristics	PLOS ONE			English	Article							GASTRORETENTIVE DOSAGE FORMS; IN-VITRO EVALUATION; HELICOBACTER-PYLORI; GASTROINTESTINAL-TRACT; MECHANICAL-PROPERTIES; MICROSPHERES; DESIGN; MICROBALLOONS; DENSITY; INVITRO	Effervescent multiple-unit floating drug delivery systems (muFDDSs) consisting of drug (lorsartan)- and effervescent (sodium bicarbonate)-containing pellets were characterized in this study. The mechanical properties (stress and strain at rupture, Young's modulus, and toughness) of these plasticized polymeric films of acrylic (Eudragit RS, RL, and NE) and cellulosic materials (ethyl cellulose (EC), and Surelease) were examined by a dynamic mechanical analyzer. Results demonstrated that polymeric films prepared from Surelease and EC were brittle with less elongation compared to acrylic films. Eudragit NE films were very flexible in both the dry and wet states. Because plasticizer leached from polymeric films during exposure to the aqueous medium, plasticization of wet Eudragit RS and RL films with 15% triethyl citrate (TEC) or diethyl phthalate (DEP) resulted in less elongation. DEP might be the plasticizer of choice among the plasticizers examined in this study for Eudragit RL to provide muFDDSs with a short time for all pellets to float (TPF) and a longer period of floating. Eudragit RL and RS at a 1:1 ratio plasticized with 15% DEP were optimally selected as the coating membrane for the floating system. Although the release of losartan from the pellets was still too fast as a result of losartan being freely soluble in water, muFDDSs coated with Eudragit RL and RS at a 1:1 ratio might have potential use for the sustained release of water-insoluble or the un-ionized form of drugs from gastroretentive drug delivery systems.	[Hung, Sheng-Feng; Hsieh, Chien-Ming; Chen, Ying-Chen; Wang, Yu-Chun; Ho, Hsiu-O; Sheu, Ming-Thau] Taipei Med Univ, Coll Pharm, Sch Pharm, Taipei, Taiwan; [Sheu, Ming-Thau] Taipei Med Univ Hosp, Clin Res Ctr, Taipei, Taiwan; [Sheu, Ming-Thau] Taipei Med Univ Hosp, Tradit Herbal Med Res Ctr, Taipei, Taiwan; [Hsieh, Chien-Ming] Providence Univ, Dept Cosmet Sci, Taichung, Taiwan	Taipei Medical University; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Medical University Hospital; Providence University - Taiwan	Ho, HO (corresponding author), Taipei Med Univ, Coll Pharm, Sch Pharm, Taipei, Taiwan.	hsiuoho@tmu.edu.tw; mingsheu@tmu.edu.tw		Hsieh, Chien-Ming/0000-0002-7204-4681				Bardonnet PL, 2006, J CONTROL RELEASE, V111, P1, DOI 10.1016/j.jconrel.2005.10.031; BECHGAARD H, 1978, J PHARM PHARMACOL, V30, P690, DOI 10.1111/j.2042-7158.1978.tb13366.x; Bi YX, 1996, CHEM PHARM BULL, V44, P2121; BODMEIER R, 1994, PHARMACEUT RES, V11, P882, DOI 10.1023/A:1018942127524; Chen YC, 2012, J PHARM SCI-US, V101, P3811, DOI 10.1002/jps.23279; Dixit N, 2011, J CURR PHARM RES, V7, P6; Hamdani J, 2006, INT J PHARM, V322, P96, DOI 10.1016/j.ijpharm.2006.05.052; Iannuccelli V, 1998, INT J PHARM, V174, P47, DOI 10.1016/S0378-5173(98)00229-4; ICHIKAWA M, 1991, J PHARM SCI, V80, P1062, DOI 10.1002/jps.2600801113; Jain SK, 2005, J CONTROL RELEASE, V107, P300, DOI 10.1016/j.jconrel.2005.06.007; Kawano Yoshio, 2002, Polímeros, V12, P96, DOI 10.1590/S0104-14282002000200008; KAWASHIMA Y, 1991, J CONTROL RELEASE, V16, P279, DOI 10.1016/0168-3659(91)90004-W; Krogel I, 1999, INT J PHARM, V187, P175, DOI 10.1016/S0378-5173(99)00189-1; Munday DL, 2003, DRUG DEV IND PHARM, V29, P575, DOI 10.1081/DDC-120018646; Pawar VK, 2011, DRUG DELIV, V18, P97, DOI 10.3109/10717544.2010.520354; Prajapati VD, 2013, J CONTROL RELEASE, V168, P151, DOI 10.1016/j.jconrel.2013.02.028; Rouge N, 1996, INT J PHARMACEUT, V136, P117, DOI 10.1016/0378-5173(96)85200-8; Sato Y, 2004, INT J PHARM, V275, P97, DOI 10.1016/j.ijpharm.2004.01.036; SETA Y, 1988, INT J PHARM, V41, P245, DOI 10.1016/0378-5173(88)90201-3; Sica DA, 2005, CLIN PHARMACOKINET, V44, P797, DOI 10.2165/00003088-200544080-00003; Singh BN, 2000, J CONTROL RELEASE, V63, P235, DOI 10.1016/S0168-3659(99)00204-7; Streubel A, 2003, J MICROENCAPSUL, V20, P329, DOI 10.1080/0265204021000058384; Sungthonjeen S, 2008, EUR J PHARM BIOPHARM, V69, P255, DOI 10.1016/j.ejpb.2007.09.013; Talukder R, 2004, DRUG DEV IND PHARM, V30, P405, DOI 10.1081/DDC-120030935; Umamaheshwari RB, 2003, J PHARM PHARMACOL, V55, P1607, DOI 10.1211/0022357022223; Waterman KC, 2007, PHARM DEV TECHNOL, V12, P1, DOI 10.1080/10837450601168680; Wu JS, 2001, EUR J PHARM SCI, V12, P417, DOI 10.1016/S0928-0987(00)00196-2; Wurster DE, 2003, J PHARM SCI-US, V92, P2008, DOI 10.1002/jps.10454; Yang LB, 1999, J CONTROL RELEASE, V57, P215, DOI 10.1016/S0168-3659(98)00066-2	29	12	12	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 26	2014	9	6							e100321	10.1371/journal.pone.0100321	http://dx.doi.org/10.1371/journal.pone.0100321			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK2WP	24967594	Green Published, Green Submitted, gold			2023-01-03	WOS:000338280800034
J	Yang, FY; Lin, YL; Chou, FI; Lin, YC; Liu, YWH; Chang, LW; Hsieh, YL				Yang, Feng-Yi; Lin, Yi-Li; Chou, Fong-In; Lin, Yu-Chuan; Liu, Yen-Wan Hsueh; Chang, Lun-Wei; Hsieh, Yu-Ling			Pharmacokinetics of BPA in Gliomas with Ultrasound Induced Blood-Brain Barrier Disruption as Measured by Microdialysis	PLOS ONE			English	Article							NEUTRON-CAPTURE THERAPY; NEWLY-DIAGNOSED GLIOBLASTOMA; FOCUSED ULTRASOUND; ENHANCED SURVIVAL; DRUG-DELIVERY; INTRACAROTID INJECTION; LIPOSOMAL DOXORUBICIN; SODIUM BOROCAPTATE; TUMORS; BORONOPHENYLALANINE	The blood-brain barrier (BBB) can be transiently disrupted by focused ultrasound (FUS) in the presence of microbubbles for targeted drug delivery. Previous studies have illustrated the pharmacokinetics of drug delivery across the BBB after sonication using indirect visualization techniques. In this study, we investigated the in vivo extracellular kinetics of boronophenylalanine-fructose (BPA-f) in glioma-bearing rats with FUS-induced BBB disruption by microdialysis. After simultaneous intravenous administration of BPA and FUS exposure, the boron concentration in the treated brains was quantified by inductively coupled plasma mass spectroscopy. With FUS, the mean peak concentration of BPA-f in the glioma dialysate was 3.6 times greater than without FUS, and the area under the concentration-time curve was 2.1 times greater. This study demonstrates that intracerebral microdialysis can be used to assess local BBB transport profiles of drugs in a sonicated site. Applying microdialysis to the study of metabolism and pharmacokinetics is useful for obtaining selective information within a specific brain site after FUS-induced BBB disruption.	[Yang, Feng-Yi; Lin, Yi-Li; Chang, Lun-Wei; Hsieh, Yu-Ling] Natl Yang Ming Univ, Dept Biomed Imaging & Radiol Sci, Taipei 112, Taiwan; [Yang, Feng-Yi] Natl Yang Ming Univ, Biophoton & Mol Imaging Res Ctr, Taipei 112, Taiwan; [Chou, Fong-In] Natl Tsing Hua Univ, Nucl Sci & Technol Dev Ctr, Hsinchu, Taiwan; [Chou, Fong-In; Lin, Yu-Chuan; Liu, Yen-Wan Hsueh] Natl Tsing Hua Univ, Inst Nucl Engn & Sci, Hsinchu, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Tsing Hua University; National Tsing Hua University	Yang, FY (corresponding author), Natl Yang Ming Univ, Dept Biomed Imaging & Radiol Sci, Taipei 112, Taiwan.	fyyang@ym.edu.tw			National Science Council of Taiwan [NSC 102-2221-E-010-005-MY3, NSC 101-2320-B-010-036-MY3]; Cheng Hsin General Hospital Foundation [102F218C11, 103F003C17]; Biophotonics & Molecular Imaging Research Center; Ministry of Education, Aim for the Top University Plan	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); Cheng Hsin General Hospital Foundation; Biophotonics & Molecular Imaging Research Center; Ministry of Education, Aim for the Top University Plan(Ministry of Education, Taiwan)	This study was supported by grants from the National Science Council of Taiwan (no. NSC 102-2221-E-010-005-MY3 and NSC 101-2320-B-010-036-MY3), Cheng Hsin General Hospital Foundation (no. 102F218C11 and 103F003C17), Biophotonics & Molecular Imaging Research Center, and the Ministry of Education, Aim for the Top University Plan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alkins RD, 2013, NEURO-ONCOLOGY, V15, P1225, DOI 10.1093/neuonc/not052; Barth RF, 2000, INT J RADIAT ONCOL, V47, P209, DOI 10.1016/S0360-3016(00)00421-1; Barth RF, 1996, CANCER INVEST, V14, P534, DOI 10.3109/07357909609076899; Barth RF, 2005, CLIN CANCER RES, V11, P3987, DOI 10.1158/1078-0432.CCR-05-0035; Barth RF, 1998, J NEURO-ONCOL, V36, P91, DOI 10.1023/A:1005805203044; Barth RF, 2002, INT J RADIAT ONCOL, V52, P858, DOI 10.1016/S0360-3016(01)02734-1; Barth RF, 1997, CANCER RES, V57, P1129; BENVENISTE H, 1990, PROG NEUROBIOL, V35, P195, DOI 10.1016/0301-0082(90)90027-E; Bergenheim AT, 2005, J NEURO-ONCOL, V71, P287, DOI 10.1007/s11060-004-1724-0; Evrard PA, 1996, PHARMACEUT RES, V13, P12, DOI 10.1023/A:1016056628685; Hynynen K, 2001, RADIOLOGY, V220, P640, DOI 10.1148/radiol.2202001804; Johansen MJ, 1997, PHARMACOTHERAPY, V17, P464; Kabalka GW, 2003, J NEURO-ONCOL, V62, P187, DOI 10.1007/BF02699944; Kawabata S, 2009, J RADIAT RES, V50, P51, DOI 10.1269/jrr.08043; KEHR J, 1993, J NEUROSCI METH, V48, P251, DOI 10.1016/0165-0270(93)90096-A; Kroll RA, 1998, NEUROSURGERY, V42, P1083, DOI 10.1097/00006123-199805000-00082; Miyatake SI, 2009, J NEURO-ONCOL, V91, P199, DOI 10.1007/s11060-008-9699-x; Park J, 2012, J CONTROL RELEASE, V162, P134, DOI 10.1016/j.jconrel.2012.06.012; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; Skold K, 2010, BRIT J RADIOL, V83, P596, DOI 10.1259/bjr/56953620; Smith DR, 2001, CANCER RES, V61, P8179; Vlachos F, 2010, PHYS MED BIOL, V55, P5451, DOI 10.1088/0031-9155/55/18/012; Vlachos F, 2011, MAGN RESON MED, V66, P821, DOI 10.1002/mrm.22848; Wang HE, 2004, J NUCL MED, V45, P302; WESTERINK BHC, 1987, LIFE SCI, V41, P1763, DOI 10.1016/0024-3205(87)90695-3; Yang FY, 2012, FUTURE ONCOL, V8, P1361, DOI [10.2217/fon.12.118, 10.2217/FON.12.118]; Yang FY, 2012, J CONTROL RELEASE, V160, P652, DOI 10.1016/j.jconrel.2012.02.023; Yang FY, 2012, INT J NANOMED, V7, P965, DOI 10.2147/IJN.S29229; Yang FY, 2011, J NUCL MED, V52, P478, DOI 10.2967/jnumed.110.083071; Yang FY, 2011, J CONTROL RELEASE, V150, P111, DOI 10.1016/j.jconrel.2010.10.038; YOSHINO K, 1989, STRAHLENTHER ONKOL, V165, P127	31	13	13	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2014	9	6							e100104	10.1371/journal.pone.0100104	http://dx.doi.org/10.1371/journal.pone.0100104			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK5YM	24936788	Green Submitted, Green Published, gold			2023-01-03	WOS:000338503400075
J	Powell, TY; Boonstra, TW; Martin, DM; Loo, CK; Breakspear, M				Powell, Tamara Y.; Boonstra, Tjeerd W.; Martin, Donel M.; Loo, Colleen K.; Breakspear, Michael			Modulation of Cortical Activity by Transcranial Direct Current Stimulation in Patients with Affective Disorder	PLOS ONE			English	Article							DORSOLATERAL PREFRONTAL CORTEX; NONINVASIVE BRAIN-STIMULATION; WORKING-MEMORY IMPROVEMENT; ANTERIOR CINGULATE; THETA-OSCILLATIONS; MAJOR DEPRESSION; EEG ALPHA; TDCS; EXCITABILITY; INHIBITION	Transcranial direct current stimulation (tDCS) has been shown to have antidepressant efficacy in patients experiencing a major depressive episode, but little is known about the underlying neurophysiology. The purpose of our study was to investigate the acute effects of tDCS on cortical activity using electroencephalography (EEG) in patients with an affective disorder. Eighteen patients diagnosed with an affective disorder and experiencing a depressive episode participated in a sham-controlled study of tDCS, each receiving a session of active (2 mA for 20 minutes) and sham tDCS to the left dorsolateral prefrontal cortex (DLPFC). The effects of tDCS on EEG activity were assessed after each session using event-related potentials (ERP) and measurement of spectral activity during a visual working memory (VWM) task. We observed task and intervention dependent effects on both ERPs and task-related alpha and theta activity, where active compared to sham stimulation resulted in a significant reduction in the N2 amplitude and reduced theta activity over frontal areas during memory retrieval. In summary a single session of anodal tDCS stimulation to the left DLPFC during a major depressive episode resulted in modulated brain activity evident in task-related EEG. Effects on the N2 and frontal theta activity likely reflect modulated activity in the medial frontal cortex and hence indicate that the after-effects of tDCS extend beyond the direct focal effects to the left DLPFC.	[Powell, Tamara Y.; Boonstra, Tjeerd W.; Martin, Donel M.; Loo, Colleen K.; Breakspear, Michael] Univ New S Wales, Sch Psychiat, Sydney, NSW, Australia; [Powell, Tamara Y.; Boonstra, Tjeerd W.; Martin, Donel M.; Loo, Colleen K.; Breakspear, Michael] Black Dog Inst, Sydney, NSW, Australia; [Boonstra, Tjeerd W.] Vrije Univ Amsterdam, MOVE Res Inst, Amsterdam, Netherlands; [Loo, Colleen K.] St George Hosp, Kogarah, NSW, Australia; [Breakspear, Michael] Queensland Inst Med Res, Brisbane, Qld 4006, Australia; [Breakspear, Michael] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia	University of New South Wales Sydney; Black Dog Institute; Vrije Universiteit Amsterdam; St George Hospital; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital	Powell, TY (corresponding author), Univ New S Wales, Sch Psychiat, Sydney, NSW, Australia.	tamara.powell@qimrberghofer.edu.au	Boonstra, Tjeerd/C-5433-2011; Breakspear, Michael/M-5859-2014; Breakspear, Michael/ABF-6302-2020	Boonstra, Tjeerd/0000-0002-6969-7243; Breakspear, Michael/0000-0003-4943-3969; Martin, Donel/0000-0002-8452-0390; powell, tamara/0000-0003-2859-3103; Loo, Colleen/0000-0003-3267-0554	ARC Thinking Systems grant [TS0669860]; National Health and Medical Research Council (NHMRC) [510142]; BrainNRG collaborative award [JSMF22002082]; Netherlands Organisation for Scientific Research (NWO) [45110-030]	ARC Thinking Systems grant(Australian Research Council); National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); BrainNRG collaborative award; Netherlands Organisation for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO))	This research was supported by the ARC Thinking Systems grant (TS0669860); the National Health and Medical Research Council (NHMRC #510142); BrainNRG collaborative award (JSMF22002082), and the Netherlands Organisation for Scientific Research (NWO #45110-030). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antal A, 2008, BRAIN STIMUL, V1, P97, DOI 10.1016/j.brs.2007.10.001; Arul-Anandam AP, 2009, J AFFECT DISORDERS, V117, P137, DOI 10.1016/j.jad.2009.01.016; Asada H, 1999, NEUROSCI LETT, V274, P29, DOI 10.1016/S0304-3940(99)00679-5; Awh E, 2008, NAT NEUROSCI, V11, P5, DOI 10.1038/nn0108-5; Baskaran A, 2012, NEUROPHARMACOLOGY; Boonstra TW, 2013, INT J PSYCHOPHYSIOL, V89, P409, DOI 10.1016/j.ijpsycho.2013.04.001; Brunoni AR, 2013, JAMA PSYCHIAT, V70, P383, DOI 10.1001/2013.jamapsychiatry.32; Brunoni AR, 2014, BRAIN COGNITION, V86, P1, DOI 10.1016/j.bandc.2014.01.008; Brunoni AR, 2012, BRAIN STIMUL, V5, P175, DOI 10.1016/j.brs.2011.03.002; Chi RP, 2010, BRAIN RES, V1353, P168, DOI 10.1016/j.brainres.2010.07.062; da Silva MC, 2013, J PHYSIOL-PARIS, V107, P493, DOI 10.1016/j.jphysparis.2013.07.003; Dell'Osso B, 2012, EUR PSYCHIAT, V27, P513, DOI 10.1016/j.eurpsy.2011.02.008; Faria P, 2012, EPILEPSY BEHAV, V25, P417, DOI 10.1016/j.yebeh.2012.06.027; Folstein JR, 2008, PSYCHOPHYSIOLOGY, V45, P152, DOI 10.1111/j.1469-8986.2007.00602.x; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Fregni F, 2007, NAT CLIN PRACT NEURO, V3, P383, DOI 10.1038/ncpneuro0530; Fukuda K, 2010, CURR OPIN NEUROBIOL, V20, P177, DOI 10.1016/j.conb.2010.03.005; Heimrath K, 2012, Front Psychiatry, V3, P56, DOI 10.3389/fpsyt.2012.00056; Hoy KE, 2013, NEUROPSYCHOLOGIA, V51, P1777, DOI 10.1016/j.neuropsychologia.2013.05.018; Jacobson L, 2012, CLIN NEUROPHYSIOL, V123, P979, DOI 10.1016/j.clinph.2011.09.016; Jensen MP, 2013, CLIN NEUROPHYSIOL, V124, P2016, DOI 10.1016/j.clinph.2013.04.009; Jensen O, 2002, EUR J NEUROSCI, V15, P1395, DOI 10.1046/j.1460-9568.2002.01975.x; Kalska H, 1999, Appl Neuropsychol, V6, P96, DOI 10.1207/s15324826an0602_5; Kalu UG, 2012, PSYCHOL MED, V42, P1791, DOI 10.1017/S0033291711003059; Kasashima Y, 2012, EXP BRAIN RES, V221, P263, DOI 10.1007/s00221-012-3166-9; Keeser D, 2011, NEUROIMAGE, V55, P644, DOI 10.1016/j.neuroimage.2010.12.004; Keeser D, 2011, J NEUROSCI, V31, P15284, DOI 10.1523/JNEUROSCI.0542-11.2011; Klimesch W, 1999, BRAIN RES REV, V29, P169, DOI 10.1016/S0165-0173(98)00056-3; Klimesch W, 2007, BRAIN RES REV, V53, P63, DOI 10.1016/j.brainresrev.2006.06.003; Kochan NA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023960; Krause CM, 2000, CLIN NEUROPHYSIOL, V111, P2071, DOI 10.1016/S1388-2457(00)00429-6; Kuo MF, 2014, NEUROIMAGE, V85, P948, DOI 10.1016/j.neuroimage.2013.05.117; Linkenkaer-Hansen K, 2005, J NEUROSCI, V25, P10131, DOI 10.1523/JNEUROSCI.3244-05.2005; Liu ZX, 2014, NEUROIMAGE, V85, P873, DOI 10.1016/j.neuroimage.2013.08.054; Loo CK, 2012, BRIT J PSYCHIAT, V200, P52, DOI 10.1192/bjp.bp.111.097634; Maeoka H, 2012, NEUROSCI LETT, V512, P12, DOI 10.1016/j.neulet.2012.01.037; Mayberg HS, 2005, NEURON, V45, P651, DOI 10.1016/j.neuron.2005.02.014; Moran RJ, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00200; Nieuwenhuis S, 2003, COGN AFFECT BEHAV NE, V3, P17, DOI 10.3758/CABN.3.1.17; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2009, BIOL PSYCHIAT, V66, P503, DOI 10.1016/j.biopsych.2009.03.022; Ohn SH, 2008, NEUROREPORT, V19, P43, DOI 10.1097/WNR.0b013e3282f2adfd; Oliveira JF, 2013, NEUROSCI LETT, V537, P60, DOI 10.1016/j.neulet.2013.01.023; Onton J, 2005, NEUROIMAGE, V27, P341, DOI 10.1016/j.neuroimage.2005.04.014; Palm U, 2009, WORLD J BIOL PSYCHIA, V10, P632, DOI 10.1080/15622970802480905; Palva S, 2011, J NEUROSCI, V31, P5013, DOI 10.1523/JNEUROSCI.5592-10.2011; Pfurtscheller G, 1999, CLIN NEUROPHYSIOL, V110, P1842, DOI 10.1016/S1388-2457(99)00141-8; Ridderinkhof KR, 2004, SCIENCE, V306, P443, DOI 10.1126/science.1100301; Rosa MA, 2012, NEUROPSYCHOPHARMACOL, V37, P102, DOI 10.1038/npp.2011.225; Rose EJ, 2006, J AFFECT DISORDERS, V90, P149, DOI 10.1016/j.jad.2005.11.003; Ruffini G, 2014, NEUROIMAGE, V89, P216, DOI 10.1016/j.neuroimage.2013.12.002; Sankoh AJ, 1997, STAT MED, V16, P2529, DOI 10.1002/(SICI)1097-0258(19971130)16:22<2529::AID-SIM692>3.0.CO;2-J; Schestatsky P, 2013, JOVE-J VIS EXP, DOI 10.3791/50426; Segrave RA, 2010, J AFFECT DISORDERS, V127, P191, DOI 10.1016/j.jad.2010.05.022; Seminowicz DA, 2004, NEUROIMAGE, V22, P409, DOI 10.1016/j.neuroimage.2004.01.015; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Stagg CJ, 2011, NEUROSCIENTIST, V17, P37, DOI 10.1177/1073858410386614; Terney D, 2008, J NEUROSCI, V28, P14147, DOI 10.1523/JNEUROSCI.4248-08.2008; Tseng P, 2012, J NEUROSCI, V32, P10554, DOI 10.1523/JNEUROSCI.0362-12.2012; Tsoneva Tsvetomira, 2011, Annu Int Conf IEEE Eng Med Biol Soc, V2011, P3828, DOI 10.1109/IEMBS.2011.6090952; van Schie HT, 2004, NAT NEUROSCI, V7, P549, DOI 10.1038/nn1239; van Veen V, 2002, PHYSIOL BEHAV, V77, P477, DOI 10.1016/S0031-9384(02)00930-7; Vanderhasselt MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062219; Weiland-Fiedler P, 2004, J AFFECT DISORDERS, V82, P253, DOI 10.1016/j.jad.2003.10.009; Zaehle T, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-2	65	27	28	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 10	2014	9	6							e98503	10.1371/journal.pone.0098503	http://dx.doi.org/10.1371/journal.pone.0098503			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AN9SD	24914953	Green Submitted, Green Published, gold			2023-01-03	WOS:000340947700023
J	Bergmann, N; Ballegaard, S; Bech, P; Hjalmarson, A; Krogh, J; Gyntelberg, F; Faber, J				Bergmann, Natasha; Ballegaard, Soren; Bech, Per; Hjalmarson, Ake; Krogh, Jesper; Gyntelberg, Finn; Faber, Jens			The Effect of Daily Self-Measurement of Pressure Pain Sensitivity Followed by Acupressure on Depression and Quality of Life versus Treatment as Usual in Ischemic Heart Disease: A Randomized Clinical Trial	PLOS ONE			English	Article							INTEGRATED REHABILITATION; CARDIOVASCULAR EVENTS; MYOCARDIAL-INFARCTION; PSYCHOLOGICAL STRESS; ANGINA-PECTORIS; ASSOCIATION; MORTALITY; THERAPY; RISK	Background: Depressive symptoms and reduced quality of life (QOL) are parts of the chronic stress syndrome and predictive of adverse outcome in patients with ischemic heart disease (IHD). Chronic stress is associated with increased sensitivity for pain, which can be measured by algometry as Pressure Pain Sensitivity (PPS) on the sternum. Aim: To evaluate if stress focus by self-measurement of PPS, followed by stress reducing actions including acupressure, can decrease depressive symptoms and increase psychological well-being in people with stable IHD. Design: Observer blinded randomized clinical trial over 3 months of either intervention or treatment as usual (TAU). Statistical analysis: Intention to treat. Methods: Two hundred and thirteen participants with IHD were included: 106 to active treatment and 107 to TAU. Dropout: 20 and 12, respectively. The active intervention included self-measurement of PPS twice daily followed by acupressure as mandatory action, aiming at a reduction in PPS. Primary endpoint: change in depressive symptoms as measured by Major depression inventory (MDI). Other endpoints: changes in PPS, Well-being (WHO-5) and mental and physical QOL (SF-36). Results: At 3 months PPS decreased 28%, to 58, in active and 11%, to 72, in TAU, p<0.001. MDI decreased 22%, to 6.5, in active group vs. 12%, to 8.3 in TAU, p = 0.040. WHO-5 increased to 71.0 and 64.8, active group and TAU, p = 0.015. SF-36 mental score sum increased to 55.3 and 53.3, active and TAU, p = 0.08. Conclusions: PPS measurements followed by acupressure reduce PPS, depressive symptoms and increase QOL in patients with stable IHD.	[Bergmann, Natasha; Krogh, Jesper; Faber, Jens] Herlev Univ Hosp, Dept Endocrinol, DK-2730 Herlev, Denmark; [Ballegaard, Soren] Ull Care AS, Hellerup, Denmark; [Bech, Per] Psychiat Ctr North Zealand, Psychiat Res Unit, Hillerod, Denmark; [Hjalmarson, Ake] Sahlgrens Univ Hosp, Dept Cardiol, Gothenburg, Sweden; [Gyntelberg, Finn] Natl Res Ctr Working Environm, Copenhagen, Denmark; [Faber, Jens] Univ Copenhagen, Fac Hlth Sci, Copenhagen, Denmark	University of Copenhagen; Herlev & Gentofte Hospital; Sahlgrenska University Hospital; National Research Centre for the Working Environment; University of Copenhagen	Bergmann, N (corresponding author), Herlev Univ Hosp, Dept Endocrinol, DK-2730 Herlev, Denmark.	n.c.bergmann@hotmail.com		Bergmann, Natasha Chidekel/0000-0002-6797-8041; Ballegaard, soeren/0000-0002-4253-6909; Krogh, Jesper/0000-0003-4834-6724; Bech, Per/0000-0002-4948-6115	Johan Schroder's Family and Business Foundation; Lundbeck Foundation; Else and Mogens Wedell-Wedellsborg's Foundation	Johan Schroder's Family and Business Foundation; Lundbeck Foundation(Lundbeckfonden); Else and Mogens Wedell-Wedellsborg's Foundation	This work was supported by the Johan Schroder's Family and Business Foundation. Natasha Bergmann held a pre-graduate scholarship sponsored by the Lundbeck Foundation. Grants from Else and Mogens Wedell-Wedellsborg's Foundation, and Carpenter Sophus Jacobsen and Wife Astrid Jacobsen's Foundation were used to cover travel expenses. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraha I, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2697; [Anonymous], 2012, CLIN PSYCHOMETRICS; Arendt-Nielsen L, 2010, PAIN, V149, P573, DOI 10.1016/j.pain.2010.04.003; Arendt-Nielsen L, 2009, J PAIN, V10, P556, DOI 10.1016/j.jpain.2009.02.002; Ballegaard S, 2004, J ALTERN COMPLEM MED, V10, P777; Ballegaard S, 2013, PSYCHOTHER PSYCHOSOM, V82, P9; Ballegaard S, 1999, J ALTERN COMPLEM MED, V5, P405, DOI 10.1089/acm.1999.5.405; Ballegaard S, 2009, SCAND J CLIN LAB INV, V69, P713, DOI 10.1080/00365510903042734; Ballegaard S, 2012, SCAND J CLIN LAB INV, V72, P459, DOI 10.3109/00365513.2012.695023; Barth J, 2004, PSYCHOSOM MED, V66, P802, DOI 10.1097/01.psy.0000146332.53619.b2; Bayer L, 2010, HDB CLIN RATING SCAL; Bech P, 2007, PHARMACOPSYCHIATRY, V40, P163, DOI 10.1055/s-2007-984400; Bech P, 2011, DEPRESS RES TREAT, V2011; Bergmann N, 2013, SCAND J CLIN LAB INV, V73, P373, DOI 10.3109/00365513.2013.785588; Egede LE, 2007, GEN HOSP PSYCHIAT, V29, P409, DOI 10.1016/j.genhosppsych.2007.06.002; Grippo AJ, 2009, STRESS, V12, P1, DOI 10.1080/10253890802046281; Gulliksson M, 2011, ARCH INTERN MED, V171, P134, DOI 10.1001/archinternmed.2010.510; Hedges L.V., 2014, STAT METHODS META AN; Herring MP, 2012, ARCH INTERN MED, V172, P101, DOI 10.1001/archinternmed.2011.696; Hsieh LLC, 2006, BMJ-BRIT MED J, V332, P696, DOI 10.1136/bmj.38744.672616.AE; Lichtman JH, 2009, PROG CARDIOVASC NURS, V24, P19; Magnusson G, 2010, J ALTERN COMPLEM MED, V16, P369, DOI 10.1089/acm.2009.0097; Matsubara T, 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1155/2011/543291; Meijer A, 2011, GEN HOSP PSYCHIAT, V33, P203, DOI 10.1016/j.genhosppsych.2011.02.007; Netterstrom B, 2002, STRESS; Reidler JS, 2012, J PAIN, V13, P450, DOI 10.1016/j.jpain.2012.01.005; Richebe P, 2011, ANESTHESIOLOGY, V114, P1280, DOI 10.1097/ALN.0b013e31821c112b; ROSENGREN A, 1991, AM J CARDIOL, V68, P1171, DOI 10.1016/0002-9149(91)90189-R; Rosengren A, 2004, LANCET, V364, P953, DOI 10.1016/S0140-6736(04)17019-0; Rugulies R, 2002, AM J PREV MED, V23, P51, DOI 10.1016/S0749-3797(02)00439-7; Adachi LNS, 2012, BRAIN RES, V1489, P17, DOI 10.1016/j.brainres.2012.10.009; Sterne JAC, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2393; Van DT, 2011, HLTH ED BEHAV; Whalley B, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD002902, 10.1002/14651858.CD002902.pub3]	34	17	17	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2014	9	5							e97553	10.1371/journal.pone.0097553	http://dx.doi.org/10.1371/journal.pone.0097553			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AI3AL	24849077	gold, Green Submitted, Green Published			2023-01-03	WOS:000336730600035
J	Dubljevic, V; Saigle, V; Racine, E				Dubljevic, Veljko; Saigle, Victoria; Racine, Eric			The Rising Tide of tDCS in the Media and Academic Literature	NEURON			English	Editorial Material							NONINVASIVE BRAIN-STIMULATION; ENHANCEMENT; ETHICS	Academic and public interest in tDCS has been fueled by strong claims of therapeutic and enhancement effects. We report a rising tide of tDCS coverage in the media, while regulatory action is lacking and ethical issues need to be addressed.	[Dubljevic, Veljko; Saigle, Victoria; Racine, Eric] Inst Rech Clin Montreal, Neuroeth Res Unit, Montreal, PQ H2W 1R7, Canada; [Dubljevic, Veljko; Racine, Eric] McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; [Racine, Eric] McGill Univ, Expt Med & Biomed Eth Unit, Montreal, PQ H3A 1A3, Canada; [Racine, Eric] Univ Montreal, Dept Med, Montreal, PQ H3T 1J4, Canada; [Racine, Eric] Univ Montreal, Dept Social & Prevent Med, Montreal, PQ H3T 1J4, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; McGill University; McGill University; Universite de Montreal; Universite de Montreal	Dubljevic, V (corresponding author), Inst Rech Clin Montreal, Neuroeth Res Unit, 110 Ave Pins Ouest, Montreal, PQ H2W 1R7, Canada.	veljko.dubljevic@ircm.qc.ca; eric.racine@ircm.qc.ca	Saigle, Victoria/AAT-2846-2020	Saigle, Victoria/0000-0002-6797-6732; Dubljevic, Veljko/0000-0003-3606-587X				Bell E, 2010, J CLIN ETHIC, V21, P112; Bikson M, 2013, NATURE, V501, P167, DOI 10.1038/501167b; Brunoni AR, 2012, BRAIN STIMUL, V5, P175, DOI 10.1016/j.brs.2011.03.002; Dubljevic V., 2012, AM J BIOETHICS NEURO, V3, P29, DOI [DOI 10.1080/21507740.2012.700681, 10.1080/21507740.2012.700681]; Finger S., 1994, ORIGINS NEUROSCIENCE; Fitz Nicholas S., 2013, J MED ETHICS; Food and Drug Administration, 2014, DEV APPR DEN CLEAR M; Graf WD, 2013, NEUROLOGY, V80, P1251, DOI 10.1212/WNL.0b013e318289703b; Guleyupoglu B, 2013, J NEUROSCI METH, V219, P297, DOI 10.1016/j.jneumeth.2013.07.016; Hamilton R, 2011, NEUROLOGY, V76, P187, DOI 10.1212/WNL.0b013e318205d50d; Iuculano T, 2013, J NEUROSCI, V33, P4482, DOI 10.1523/JNEUROSCI.4927-12.2013; Kadosh RC, 2012, CURR BIOL, V22, pR108, DOI 10.1016/j.cub.2012.01.013; Larriviere D, 2009, NEUROLOGY, V73, P1406, DOI 10.1212/WNL.0b013e3181beecfe; Lauber C, 2005, PSYCHIAT RES, V134, P205, DOI 10.1016/j.psychres.2004.07.010; Maslen H, 2014, J LAW BIOSCI, V1, P68, DOI 10.1093/jlb/lst003; Priori A, 2003, CLIN NEUROPHYSIOL, V114, P589, DOI 10.1016/S1388-2457(02)00437-6; Racine E., 2007, ETHICS, V16, P314; Racine E, 2010, SOC SCI MED, V71, P725, DOI 10.1016/j.socscimed.2010.05.017; Stagg CJ, 2011, NEUROSCIENTIST, V17, P37, DOI 10.1177/1073858410386614	19	65	65	0	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	MAY 21	2014	82	4					731	736		10.1016/j.neuron.2014.05.003	http://dx.doi.org/10.1016/j.neuron.2014.05.003			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	AH8IA	24853934	Bronze			2023-01-03	WOS:000336379800005
J	Zhu, W; Gao, YF; Chang, CF; Wan, JR; Zhu, SS; Wang, J				Zhu, Wei; Gao, Yufeng; Chang, Che-Feng; Wan, Jie-ru; Zhu, Shan-shan; Wang, Jian			Mouse Models of Intracerebral Hemorrhage in Ventricle, Cortex, and Hippocampus by Injections of Autologous Blood or Collagenase	PLOS ONE			English	Article							TUFTSIN FRAGMENT 1-3; TAIL SUSPENSION TEST; BRAIN-INJURY; RECOGNITION MEMORY; RAT MODEL; MICE; STROKE; EDEMA; INFLAMMATION; MECHANISMS	Intracerebral hemorrhage (ICH) is a devastating condition. Existing preclinical ICH models focus largely on striatum but neglect other brain areas such as ventricle, cortex, and hippocampus. Clinically, however, hemorrhagic strokes do occur in these other brain regions. In this study, we established mouse hemorrhagic models that utilize stereotactic injections of autologous whole blood or collagenase to produce ventricular, cortical, and hippocampal injury. We validated and characterized these models by histology, immunohistochemistry, and neurobehavioral tests. In the intraventricular hemorrhage (IVH) model, C57BL/6 mice that received unilateral ventricular injections of whole blood demonstrated bilateral ventricular hematomas, ventricular enlargement, and brain edema in the ipsilateral cortex and basal ganglia at 72 h. Unilateral injections of collagenase (150 U/ml) caused reproducible hematomas and brain edema in the frontal cortex in the cortical ICH (c-ICH) model and in the hippocampus in the hippocampal ICH (h-ICH) model. Immunostaining revealed cellular inflammation and neuronal death in the periventricular regions in the IVH brain and in the perihematomal regions in the c-ICH and h-ICH brains. Locomotor abnormalities measured with a 24-point scoring system were present in all three models, especially on days 1, 3, and 7 post-ICH. Locomotor deficits measured by the wire-hanging test were present in models of IVH and c-ICH, but not h-ICH. Interestingly, mice in the c-ICH model demonstrated emotional abnormality, as measured by the tail suspension test and forced swim test, whereas h-ICH mice exhibited memory abnormality, as measured by the novel object recognition test. All three ICH models generated reproducible brain damage, brain edema, inflammation, and consistent locomotor deficits. Additionally, the c-ICH model produced emotional deficits and the h-ICH model produced cognitive deficits. These three models closely mimic human ICH and should be useful for investigating the pathophysiology of ICH in ventricle, cortex, and hippocampus and for evaluating potential therapeutic strategies.	[Zhu, Wei] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Emergency Med, Wuhan 430074, Hubei, Peoples R China; [Zhu, Wei; Gao, Yufeng; Chang, Che-Feng; Wang, Jian] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA; [Wan, Jie-ru] IIT, Coll Sci, Dept Biol Sci, Chicago, IL 60616 USA; [Zhu, Shan-shan] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA	Huazhong University of Science & Technology; Johns Hopkins University; Illinois Institute of Technology; Johns Hopkins University	Wang, J (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA.	jwang79@jhmi.edu	Wang, Jian/I-4874-2019	Wang, Jian/0000-0003-2291-640X; Chang, Che-Feng/0000-0002-3211-1739	AHA [13GRNT15730001]; NIH [K01AG031926, R01NS078026, R01AT007317]; National Center for Complementary & Integrative Health [R01AT007317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS078026] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K01AG031926] Funding Source: NIH RePORTER	AHA(American Heart Association); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by AHA 13GRNT15730001, NIH K01AG031926, R01NS078026, and R01AT007317. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aronowski J, 2011, STROKE, V42, P1781, DOI 10.1161/STROKEAHA.110.596718; Bai F, 2001, PHARMACOL BIOCHEM BE, V70, P187, DOI 10.1016/S0091-3057(01)00599-8; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Broadbent NJ, 2004, P NATL ACAD SCI USA, V101, P14515, DOI 10.1073/pnas.0406344101; Can A, 2012, JOVE-J VIS EXP, DOI 10.3791/3769; Can A, 2012, JOVE-J VIS EXP, DOI 10.3791/3638; Cervo L, 2005, J NEUROSCI, V25, P8165, DOI 10.1523/JNEUROSCI.1816-05.2005; Chen Z, 2011, STROKE, V42, P465, DOI 10.1161/STROKEAHA.110.602755; Chu K, 2004, J CEREBR BLOOD F MET, V24, P926, DOI 10.1097/01.WCB.0000130866.25040.7D; Cohen SJ, 2013, CURR BIOL, V23, P1685, DOI 10.1016/j.cub.2013.07.002; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Feron F, 2005, BRAIN RES BULL, V65, P141, DOI 10.1016/j.brainresbull.2004.12.007; Gertz K, 2006, CIRC RES, V99, P1132, DOI 10.1161/01.RES.0000250175.14861.77; Hattori K, 2000, STROKE, V31, P1939, DOI 10.1161/01.STR.31.8.1939; Keep RF, 2012, LANCET NEUROL, V11, P720, DOI 10.1016/S1474-4422(12)70104-7; Kirkman MA, 2011, J CEREBR BLOOD F MET, V31, P2135, DOI 10.1038/jcbfm.2011.124; Kleinig TJ, 2009, BRAIN RES, V1287, P164, DOI 10.1016/j.brainres.2009.06.077; Krafft PR, 2012, INT J STROKE, V7, P398, DOI 10.1111/j.1747-4949.2012.00838.x; Lan X, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-98; Liesz Arthur, 2011, Exp Transl Stroke Med, V3, P11, DOI 10.1186/2040-7378-3-11; Lockridge A, 2013, BEHAV BRAIN RES, V246, P168, DOI 10.1016/j.bbr.2013.02.032; Lodhia KR, 2006, ACTA NEUROCHIR SUPPL, V96, P207; MacLellan CL, 2012, J CEREBR BLOOD F MET, V32, P612, DOI 10.1038/jcbfm.2012.8; Masuda T, 2010, BRAIN RES, V1355, P228, DOI 10.1016/j.brainres.2010.07.101; Matsushita K, 2000, J CEREBR BLOOD F MET, V20, P396, DOI 10.1097/00004647-200002000-00022; Moxon-Emre I, 2011, J NEUROPATH EXP NEUR, V70, P218, DOI 10.1097/NEN.0b013e31820d94a5; Renard CE, 2004, PROG NEURO-PSYCHOPH, V28, P1255, DOI 10.1016/j.pnpbp.2004.06.010; Rogove AD, 2002, CELL DEATH DIFFER, V9, P801, DOI 10.1038/sj.cdd.4401041; ROSENBERG GA, 1990, STROKE, V21, P801, DOI 10.1161/01.STR.21.5.801; Rynkowski MA, 2008, NAT PROTOC, V3, P122, DOI 10.1038/nprot.2007.513; Song S, 2008, ACTA NEUROCHIR SUPPL, V105, P13; van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0; van Rossum D, 2004, METAB BRAIN DIS, V19, P393, DOI 10.1023/B:MEBR.0000043984.73063.d8; Wang J, 2005, BRAIN, V128, P1622, DOI 10.1093/brain/awh489; Wang J, 2005, STROKE, V36, P613, DOI 10.1161/01.STR.0000155729.12931.8f; Wang J, 2003, ANN NEUROL, V54, P655, DOI 10.1002/ana.10750; Wang J, 2008, BRAIN RES, V1222, P214, DOI 10.1016/j.brainres.2008.05.058; Wang JA, 2007, BRAIN, V130, P1643, DOI 10.1093/brain/awm095; Wang JA, 2007, FREE RADICAL BIO MED, V43, P408, DOI 10.1016/j.freeradbiomed.2007.04.020; Wang J, 2007, J CEREBR BLOOD F MET, V27, P894, DOI 10.1038/sj.jcbfm.9600403; Wang J, 2006, NEUROBIOL DIS, V22, P473, DOI 10.1016/j.nbd.2005.12.009; Wang JA, 2010, PROG NEUROBIOL, V92, P463, DOI 10.1016/j.pneurobio.2010.08.001; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Wu H, 2012, NEUROBIOL DIS, V45, P388, DOI 10.1016/j.nbd.2011.08.028; Wu H, 2011, J CEREBR BLOOD F MET, V31, P1243, DOI 10.1038/jcbfm.2010.209; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Xi GH, 2001, STROKE, V32, P162, DOI 10.1161/01.STR.32.1.162; Xi GH, 1998, STROKE, V29, P2580, DOI 10.1161/01.STR.29.12.2580	48	66	69	1	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2014	9	5							e97423	10.1371/journal.pone.0097423	http://dx.doi.org/10.1371/journal.pone.0097423			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI3UI	24831292	Green Published, gold, Green Submitted			2023-01-03	WOS:000336789500056
J	De Buyser, SL; Petrovic, M; Taes, YE; Vetrano, DL; Corsonello, A; Volpato, S; Onder, G				De Buyser, Stefanie L.; Petrovic, Mirko; Taes, Youri E.; Vetrano, Davide L.; Corsonello, Andrea; Volpato, Stefano; Onder, Graziano			Functional Changes during Hospital Stay in Older Patients Admitted to an Acute Care Ward: A Multicenter Observational Study	PLOS ONE			English	Article							LOWER-EXTREMITY FUNCTION; PHYSICAL PERFORMANCE-MEASURES; APPROPRIATE MEDICATION USE; SELF-REPORT; MORTALITY; MOBILITY; HEALTH; CRITERIA; OUTCOMES; DECLINE	Objectives: Changes in physical performance during hospital stay have rarely been evaluated. In this study, we examined functional changes during hospital stay by assessing both physical performance and activities of daily living. Additionally, we investigated characteristics of older patients associated with meaningful in-hospital improvement in physical performance. Methods: The CRiteria to assess appropriate Medication use among Elderly complex patients project recruited 1123 patients aged >= 65 years, consecutively admitted to geriatric or internal medicine acute care wards of seven Italian hospitals. We analyzed data from 639 participating participants with a Mini Mental State Examination score >= 18/30. Physical performance was assessed by walking speed and grip strength, and functional status by activities of daily living at hospital admission and at discharge. Meaningful improvement was defined as a measured change of at least 1 standard deviation. Multivariable logistic regression models predicting meaningful improvement, included age, gender, type of admission (through emergency room or elective), and physical performance at admission. Results: Mean age of the study participants was 79 years (range 65-98), 52% were female. Overall, mean walking speed and grip strength performance improved during hospital stay (walking speed improvement: 0.04 +/- 0.20 m/s, p<0.001; grip strength improvement: 0.43 +/- 5.66 kg, p = 0.001), no significant change was observed in activities of daily living. Patients with poor physical performance at admission had higher odds for in-hospital improvement. Conclusion: Overall, physical performance measurements show an improvement during hospital stay. The margin for meaningful functional improvement is larger in patients with poor physical function at admission. Nevertheless, most of these patients continue to have poor performance at discharge.	[De Buyser, Stefanie L.; Petrovic, Mirko] Ghent Univ Hosp, Dept Geriatr, Ghent, Belgium; [Taes, Youri E.] Ghent Univ Hosp, Dept Endocrinol, Ghent, Belgium; [Taes, Youri E.] Ghent Univ Hosp, Unit Osteoporosis & Metab Bone Dis, Ghent, Belgium; [Vetrano, Davide L.; Onder, Graziano] Univ Cattolica Sacro Cuore, Ctr Med Invecchiamento, Rome, Italy; [Corsonello, Andrea] IRCCS, INRCA, Unit Geriatr Pharmaco Epidemiol, Cosenza, Italy; [Volpato, Stefano] Univ Ferrara, Dept Med Sci, I-44100 Ferrara, Italy	Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS INRCA; University of Ferrara	De Buyser, SL (corresponding author), Ghent Univ Hosp, Dept Geriatr, Ghent, Belgium.	stefanie.debuyser@UGent.be	Andrea, Corsonello/AAC-1845-2022; VOLPATO, STEFANO/H-2977-2014; Vetrano, Davide Liborio/K-7417-2016	VOLPATO, STEFANO/0000-0003-4335-6034; De Buyser, Stefanie/0000-0002-9584-5529; Vetrano, Davide Liborio/0000-0002-3099-4830	Italian Ministry of Labour, Health and Social Policy; Postdoctoral Fellow - 'Fonds voor Wetenschappelijk Onderzoek - Vlaanderen' (FWO; Research Foundation)	Italian Ministry of Labour, Health and Social Policy(Ministry of Health, Italy); Postdoctoral Fellow - 'Fonds voor Wetenschappelijk Onderzoek - Vlaanderen' (FWO; Research Foundation)(FWO)	This work was supported by the Italian Ministry of Labour, Health and Social Policy who funded the CRIME project (Bando Giovani Ricercatori 2007, convenzione no 4). Youri Taes is a Postdoctoral Fellow with the 'Fonds voor Wetenschappelijk Onderzoek - Vlaanderen' (FWO; Research Foundation - Flanders; http://www. fwo. be/Postdoctoraal-onderzoeker.aspx). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alley DE, 2011, J AM GERIATR SOC, V59, P1650, DOI 10.1111/j.1532-5415.2011.03560.x; Bautmans I, 2005, J GERONTOL A-BIOL, V60, P361, DOI 10.1093/gerona/60.3.361; Bean JF, 2011, PHYS THER, V91, P1804, DOI 10.2522/ptj.20100417; Ble A, 2003, J AM GERIATR SOC, V51, P1814, DOI 10.1046/j.1532-5415.2003.51572_1.x; Bodilsen AC, 2013, AM J PHYS MED REHAB, V92, P789, DOI 10.1097/PHM.0b013e31828cd2b6; Brown CJ, 2004, J AM GERIATR SOC, V52, P1263, DOI 10.1111/j.1532-5415.2004.52354.x; Corsonello A, 2009, J AM GERIATR SOC, V57, P1007, DOI 10.1111/j.1532-5415.2009.02266.x; Covinsky KE, 2003, J AM GERIATR SOC, V51, P451, DOI 10.1046/j.1532-5415.2003.51152.x; Covinsky KE, 1997, J GEN INTERN MED, V12, P203, DOI 10.1007/s11606-006-5041-5; CREDITOR MC, 1993, ANN INTERN MED, V118, P219, DOI 10.7326/0003-4819-118-3-199302010-00011; De Buyser SL, 2013, EUR J CLIN INVEST, V43, P379, DOI 10.1111/eci.12056; Diehr PH, 2013, J GERONTOL A-BIOL, V68, P1059, DOI 10.1093/gerona/glt038; FOLSTEIN MF, 1983, ARCH GEN PSYCHIAT, V40, P812; Fortinsky RH, 1999, J GERONTOL A-BIOL, V54, pM521, DOI 10.1093/gerona/54.10.M521; Fusco D, 2009, DRUG AGING, V26, P3, DOI 10.2165/11534620-000000000-00000; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; HOENIG HM, 1991, J AM GERIATR SOC, V39, P220, DOI 10.1111/j.1532-5415.1991.tb01632.x; Inouye SK, 1998, JAMA-J AM MED ASSOC, V279, P1187, DOI 10.1001/jama.279.15.1187; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; LANDEFELD CS, 1995, NEW ENGL J MED, V332, P1338, DOI 10.1056/NEJM199505183322006; Lauretani F, 2003, J APPL PHYSIOL, V95, P1851, DOI 10.1152/japplphysiol.00246.2003; MAHONEY F I, 1965, Md State Med J, V14, P61; Nitschke J E, 1999, J Hand Ther, V12, P25; Onder G, 2002, J GERONTOL A-BIOL, V57, pM289, DOI 10.1093/gerona/57.5.M289; Ostir GV, 2012, ARCH INTERN MED, V172, P353, DOI 10.1001/archinternmed.2011.1615; Palleschi L, 2011, J AM GERIATR SOC, V59, P193, DOI 10.1111/j.1532-5415.2010.03239.x; Perera S, 2006, J AM GERIATR SOC, V54, P743, DOI 10.1111/j.1532-5415.2006.00701.x; Purser JL, 2005, J REHABIL RES DEV, V42, P535, DOI 10.1682/JRRD.2004.07.0087; SAGER MA, 1992, J AM GERIATR SOC, V40, P457, DOI 10.1111/j.1532-5415.1992.tb02011.x; Sallinen J, 2010, J AM GERIATR SOC, V58, P1721, DOI 10.1111/j.1532-5415.2010.03035.x; Sleiman I, 2009, J GERONTOL A-BIOL, V64, P659, DOI 10.1093/gerona/glp015; Studenski S, 2003, J AM GERIATR SOC, V51, P314, DOI 10.1046/j.1532-5415.2003.51104.x; Tosato M, 2013, CURR DRUG SAF, V8, P98, DOI 10.2174/1574886311308020002; Vetrano DL, 2014, EUR J INTERN MED, V25, P56, DOI 10.1016/j.ejim.2013.08.709; Volpato S, 2011, J GERONTOL A-BIOL, V66, P89, DOI 10.1093/gerona/glq167; Volpato S, 2008, J GERONTOL A-BIOL, V63, P1393, DOI 10.1093/gerona/63.12.1393; Wittink H, 2003, SPINE, V28, P2407, DOI 10.1097/01.BRS.0000085304.01483.17	38	24	24	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2014	9	5							e96398	10.1371/journal.pone.0096398	http://dx.doi.org/10.1371/journal.pone.0096398			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI1ZC	24820733	Green Published, Green Submitted, gold			2023-01-03	WOS:000336653300016
J	Subramani, R; Lopez-Valdez, R; Arumugam, A; Nandy, S; Boopalan, T; Lakshmanaswamy, R				Subramani, Ramadevi; Lopez-Valdez, Rebecca; Arumugam, Arunkumar; Nandy, Sushmita; Boopalan, Thiyagarajan; Lakshmanaswamy, Rajkumar			Targeting Insulin-Like Growth Factor 1 Receptor Inhibits Pancreatic Cancer Growth and Metastasis	PLOS ONE			English	Article							FACTOR-I RECEPTOR; CELL LUNG-CANCER; METABOLIC SYNDROME; SIGNALING PATHWAY; IGF-1 RECEPTOR; MESSENGER-RNA; EXPRESSION; AKT; PROLIFERATION; PROGRESSION	Pancreatic cancer is one of the most lethal cancers. Increasing incidence and mortality indicates that there is still much lacking in detection and management of the disease. This is partly due to a lack of specific symptoms during early stages of the disease. Several growth factor receptors have been associated with pancreatic cancer. Here, we have investigated if an RNA interference approach targeted to IGF-IR could be effective and efficient against pancreatic cancer growth and metastasis. For that, we evaluated the effects of IGF-1R inhibition using small interfering RNA (siRNAs) on tumor growth and metastasis in HPAC and PANC-1 pancreatic cancer cell lines. We found that silencing IGF-1R inhibits pancreatic cancer growth and metastasis by blocking key signaling pathways such AKT/PI3K, MAPK, JAK/STAT and EMT. Silencing IGF-1R resulted in an anti-proliferative effect in PANC-1 and HPAC pancreatic cancer cell lines. Matrigel invasion, transwell migration and wound healing assays also revealed a role for IGF-1R in metastatic properties of pancreatic cancer. These results were further confirmed using Western blotting analysis of key intermediates involved in proliferation, epithelial mesenchymal transition, migration, and invasion. In addition, soft agar assays showed that silencing IGF-1R also blocks the colony forming capabilities of pancreatic cancer cells in vitro. Western blots, as well as, flow cytometric analysis revealed the induction of apoptosis in IGF-1R silenced cells. Interestingly, silencing IGF-1R also suppressed the expression of insulin receptor beta. All these effects together significantly control pancreatic cancer cell growth and metastasis. To conclude, our results demonstrate the significance of IGF-1R in pancreatic cancer.	[Subramani, Ramadevi; Lopez-Valdez, Rebecca; Arumugam, Arunkumar; Nandy, Sushmita; Boopalan, Thiyagarajan; Lakshmanaswamy, Rajkumar] Texas Tech Univ, Hlth Sci Ctr, Paul L Foster Sch Med, Ctr Excellence Canc Res,Dept Biomed Sci MSB1, El Paso, TX 79905 USA	Texas Tech University System; Texas Tech University	Lakshmanaswamy, R (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Paul L Foster Sch Med, Ctr Excellence Canc Res,Dept Biomed Sci MSB1, El Paso, TX 79905 USA.	rajkumar.lakshmanaswamy@ttuhsc.edu			Texas Tech University Health Sciences Center Paul L. Foster School of Medicine funds	Texas Tech University Health Sciences Center Paul L. Foster School of Medicine funds	The study was supported by Texas Tech University Health Sciences Center Paul L. Foster School of Medicine funds. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	All-Ericsson C, 2002, INVEST OPHTH VIS SCI, V43, P1; Ashour AA, 2013, APOPTOSIS INT J PROG; Bahr C, 2005, GROWTH FACTORS, V23, P1, DOI 10.1080/08977190400020229; Braun S, 2011, INT J BIOL SCI, V7, P1003, DOI 10.7150/ijbs.7.1003; Cardillo TM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-170; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chan JM, 2002, J NATL CANCER I, V94, P1099; Chaves J, 2011, ANTI-CANCER DRUG, V22, P206, DOI 10.1097/CAD.0b013e32834258a1; Chen HX, 2013, CHIN J CANCER, V32, P242, DOI 10.5732/cjc.012.10263; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Cheng H, 2012, EXP THER MED, V4, P181, DOI 10.3892/etm.2012.585; Costello L.C., 2013, PANCREATIC DISORD S4, V4; Delafontaine P, 2004, ARTERIOSCL THROM VAS, V24, P435, DOI 10.1161/01.ATV.0000105902.89459.09; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Fang YT, 2013, MED SCI MONITOR, V19, P916, DOI 10.12659/MSM.889636; Galet C, 2013, INT J MOL SCI, V14, P13782, DOI 10.3390/ijms140713782; Garcia-Carracedo D, 2013, CLIN CANC RES OFFICI; Cao H, 2013, ANTICANCER RES, V33, P1785; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kamrava M, 2011, AGEING RES REV, V10, P62, DOI 10.1016/j.arr.2009.10.007; Kandasamy K, 2002, CANCER RES, V62, P4929; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khan S, 2013, CYTOKINE GROWTH FACT; Kim WY, 2012, CANCER-AM CANCER SOC, V118, P3993, DOI 10.1002/cncr.26656; Leiphrakpam PD, 2013, ONCOLOGY REPORTS; Longati P, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-95; Ma J, 1999, J NATL CANCER I, V91, P620, DOI 10.1093/jnci/91.7.620; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Morrione A, 1997, P NATL ACAD SCI USA, V94, P3777, DOI 10.1073/pnas.94.8.3777; Mughal TI, 2013, LEUKEMIA LYMPHOMA; Nair PN, 2001, ONCOGENE, V20, P8203, DOI 10.1038/sj.onc.1205044; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Philip B, 2013, GASTROENTEROLOGY, V145, P1449, DOI 10.1053/j.gastro.2013.08.018; Pothiwala P, 2009, METAB SYNDR RELAT D, V7, P279, DOI 10.1089/met.2008.0065; Qin B, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2644; Roy SK, 2010, J MOL SIGNALING, V5; Scagliotti GV, 2012, CANCER TREAT REV, V38, P292, DOI 10.1016/j.ctrv.2011.07.008; Silvestris N, 2013, CURRENT MED CHEM; St-Germain ME, 2004, INT J ONCOL, V24, P1311; Subbaramaiah K, 2011, CANCER PREV RES, V4, P329, DOI 10.1158/1940-6207.CAPR-10-0381; Tamburrino A, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00056; Tang J, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-71; Tomizawa M, 2010, WORLD J GASTROENTERO, V16, P1854, DOI 10.3748/wjg.v16.i15.1854; Vazquez-Martin A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02560; Yamada S, 2013, SURGERY, V154, P946, DOI 10.1016/j.surg.2013.05.004; Yao Z, 2002, PANCREAS, V24, P42, DOI 10.1097/00006676-200201000-00006; Zumsteg A, 2012, MOL CANCER RES, V10, P800, DOI 10.1158/1541-7786.MCR-11-0522	48	68	72	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 8	2014	9	5							e97016	10.1371/journal.pone.0097016	http://dx.doi.org/10.1371/journal.pone.0097016			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK1XT	24809702	Green Published, Green Submitted, gold			2023-01-03	WOS:000338213300106
J	Wang, MJ; Li, HM; You, L; Yu, XL; Zhang, M; Zhu, RJ; Hao, CM; Zhang, ZJ; Chen, J				Wang, Mengjing; Li, Haiming; You, Li; Yu, Xiaoling; Zhang, Min; Zhu, Ruijiang; Hao, Chuanming; Zhang, Zhijie; Chen, Jing			Association of Serum Phosphorus Variability with Coronary Artery Calcification among Hemodialysis Patients	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; FIBROBLAST GROWTH FACTOR-23; STAGE RENAL-DISEASE; BEAM COMPUTED-TOMOGRAPHY; SMOOTH-MUSCLE-CELLS; VASCULAR CALCIFICATION; RISK-FACTORS; CARDIOVASCULAR-DISEASE; PARATHYROID-HORMONE; OSTEOBLASTIC DIFFERENTIATION	Coronary artery calcification (CAC) is associated with increased mortality in patients on maintenance hemodialysis (MHD), but the pathogenesis of this condition is not well understood. We evaluated the relationship of CAC score (CACs) and variability in serum phosphorus in MHD patients. Seventy-seven adults on MHD at Huashan Hospital (Shanghai) were enrolled in July, 2010. CAC of all the patients were measured by computed tomography and CACs was calculated by the Agatston method at the entry of enrollment. Patients were divided into three categories according to their CACs (0 similar to 10, 11 similar to 400, and >400). Blood chemistry was recorded every 3 months from January 2008 to July 2010. Phosphorus variation was defined by the standard deviation (SD) or coefficient of variation (CV) and it was calculated from the past records. The ordinal multivariate logistic regression analysis was used to analyze the predictors of CAC. The mean patient age (+/- SD) was 61.7 years (+/- 11.3) and 51% of patients were men. The mean CACs was 609.6 (+/- 1062.9), the median CACs was 168.5, and 78% of patients had CACs more than 0. Multivariate analysis indicated that female gender (OR = 0.20, 95% CI = 0.07-0.55), age (OR = 2.31, 95% CI = 1.32-4.04), serum fibroblast growth factor 23 (OR = 2.25, 95% CI = 1.31-3.85), SD-phosphorus calculated from the most recent 6 measurements (OR = 2.12; 95% CI = 1.23-3.63), and CV-phosphorus calculated from the most recent 6 measurements (OR = 1.90, 95% CI = 1.16-3.11) were significantly and independently associated with CACs. These associations persisted for phosphorus variation calculated from past 7, 8, 9, 10, and 11 follow-up values. Variability of serum phosphorus may contribute significantly to CAC and keeping serum phosphorus stable may decrease coronary calcification and associated morbidity and mortality in MHD patients.	[Wang, Mengjing; Li, Haiming; You, Li; Yu, Xiaoling; Zhang, Min; Hao, Chuanming; Chen, Jing] Fudan Univ, Div Nephrol, Huashan Hosp, Shanghai Med Coll, Shanghai 200433, Peoples R China; [Zhu, Ruijiang] Fudan Univ, Div Radiol, Huashan Hosp, Shanghai Med Coll, Shanghai 200433, Peoples R China; [Zhang, Zhijie] Fudan Univ, Dept Epidemiol & Biostatist, Sch Publ Hlth, Shanghai 200433, Peoples R China; [Zhang, Zhijie] Fudan Univ, Biomed Stat Ctr, Shanghai 200433, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University	Chen, J (corresponding author), Fudan Univ, Div Nephrol, Huashan Hosp, Shanghai Med Coll, Shanghai 200433, Peoples R China.	chenjing1998@fudan.edu.cn	Chen, Jing/AAM-2184-2021	zhang, zhijie/0000-0002-1276-787X	Major State Basic Research Development Program of China (973 program) [374 2012CB517700]; China Natural Science Foundation [81170684/30971373]	Major State Basic Research Development Program of China (973 program)(National Basic Research Program of China); China Natural Science Foundation(National Natural Science Foundation of China (NSFC))	This work was supported in part by the Major State Basic Research Development Program of China (973 program, No. 374 2012CB517700), and the China Natural Science Foundation (81170684/30971373) to Jing Chen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AGATSTON AS, 1990, J AM COLL CARDIOL, V15, P827, DOI 10.1016/0735-1097(90)90282-T; Allison MA, 2005, INT J CARDIOL, V98, P325, DOI 10.1016/j.ijcard.2004.03.015; Arad Y, 2005, J AM COLL CARDIOL, V46, P158, DOI 10.1016/j.jacc.2005.02.088; Atkinson J, 2008, J APPL PHYSIOL, V105, P1643, DOI 10.1152/japplphysiol.90476.2008; Barreto DV, 2008, AM J KIDNEY DIS, V52, P1139, DOI 10.1053/j.ajkd.2008.06.024; Barreto DV, 2005, KIDNEY INT, V67, P1576, DOI 10.1111/j.1523-1755.2005.00239.x; Barreto FC, 2008, KIDNEY INT, V73, P771, DOI 10.1038/sj.ki.5002769; Bas A, 2006, J BONE MINER RES, V21, P484, DOI 10.1359/JBMR.051211; Bhan I, 2009, CLIN J AM SOC NEPHRO, V4, pS102, DOI 10.2215/CJN.04800709; Bild DE, 2005, CIRCULATION, V111, P1313, DOI 10.1161/01.CIR.0000157730.94423.4B; Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176; Braun J, 1996, AM J KIDNEY DIS, V27, P394, DOI 10.1016/S0272-6386(96)90363-7; Cannata-Andia JB, 2011, NEPHROL DIAL TRANSPL, V26, P3429, DOI 10.1093/ndt/gfr591; Chen NX, 2006, NEPHROL DIAL TRANSPL, V21, P3435, DOI 10.1093/ndt/gfl429; Cheung AK, 2004, KIDNEY INT, V65, P2380, DOI 10.1111/j.1523-1755.2004.00657.x; Civilibal M, 2009, PEDIATR NEPHROL, V24, P555, DOI 10.1007/s00467-008-1038-0; Coen G, 2010, BMC NEPHROL, V11, DOI 10.1186/1471-2369-11-10; DAUGIRDAS JT, 1993, J AM SOC NEPHROL, V4, P1205; de Jager DJ, 2009, JAMA-J AM MED ASSOC, V302, P1782, DOI 10.1001/jama.2009.1488; Dellegrottaglie S, 2006, AM J CARDIOL, V98, P571, DOI 10.1016/j.amjcard.2006.03.030; Desjardins L, 2012, OSTEOPOROSIS INT, V23, P2017, DOI 10.1007/s00198-011-1838-0; Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272-6386(03)00111-2; Foley RN, 1998, J AM SOC NEPHROL, V9, P267; Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470; Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003; Harris DCH, 1995, J AM SOC NEPHROL, V6, P1607; Haydar AA, 2004, NEPHROL DIAL TRANSPL, V19, P2307, DOI 10.1093/ndt/gfh120; Hruska KA, 2005, CIRC RES, V97, P105, DOI 10.1161/01.RES.00000175571.53833.6c; Hruska KA, 2008, KIDNEY INT, V74, P148, DOI 10.1038/ki.2008.130; Hu MC, 2011, J AM SOC NEPHROL, V22, P124, DOI 10.1681/ASN.2009121311; Hujairi NMA, 2004, AM J KIDNEY DIS, V43, P234, DOI 10.1053/j.ajkd.2003.10.014; Inaba M, 2006, OSTEOPOROSIS INT, V17, P1506, DOI 10.1007/s00198-006-0154-6; Jean G, 2012, NEPHRON CLIN PRACT, V120, pC132, DOI 10.1159/000334424; Jono S, 2000, CIRC RES, V87, pE10, DOI 10.1161/01.RES.87.7.e10; Jung HH, 2006, NEPHROL DIAL TRANSPL, V21, P1915, DOI 10.1093/ndt/gfl118; Kakuta T, 2011, AM J KIDNEY DIS, V57, P422, DOI 10.1053/j.ajkd.2010.10.055; Kendrick J, 2011, AM J KIDNEY DIS, V58, P826, DOI 10.1053/j.ajkd.2011.07.020; Kestenbaum B, 2005, J AM SOC NEPHROL, V16, P520, DOI 10.1681/ASN.2004070602; Kestenbaum B, 2007, SEMIN DIALYSIS, V20, P286, DOI 10.1111/j.1525-139X.2007.00303.x; Khan AM, 2012, CLIN J AM SOC NEPHRO, V7, P2017, DOI 10.2215/CJN.02160212; Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188; Kolovou GD, 2008, ANGIOLOGY, V59, p54S, DOI 10.1177/0003319708319645; Kondos GT, 2003, CIRCULATION, V107, P2571, DOI 10.1161/01.CIR.0000068341.61180.55; Lim K, 2012, CIRCULATION, V125, P2243, DOI 10.1161/CIRCULATIONAHA.111.053405; London GM, 2004, J AM SOC NEPHROL, V15, P1943, DOI 10.1097/01.asn.0000129337.50739.48; Masai H, 2013, ATHEROSCLEROSIS, V226, P228, DOI 10.1016/j.atherosclerosis.2012.10.045; Mathew S, 2008, J AM SOC NEPHROL, V19, P1092, DOI 10.1681/ASN.2007070760; McCullough PA, 2004, J NEPHROL, V17, P205; Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891-5849(01)00610-4; Nasrallah MM, 2010, NEPHROL DIAL TRANSPL, V25, P2679, DOI 10.1093/ndt/gfq089; Neves KR, 2007, KIDNEY INT, V71, P1262, DOI 10.1038/sj.ki.5002241; Nitta K, 2004, HYPERTENS RES, V27, P47, DOI 10.1291/hypres.27.47; Nitta K, 2011, THER APHER DIAL, V15, P513, DOI 10.1111/j.1744-9987.2011.00979.x; Noordzij M, 2011, NEPHROL DIAL TRANSPL, V26, P1662, DOI 10.1093/ndt/gfq582; Ohtake T, 2010, HEMODIAL INT, V14, P218, DOI 10.1111/j.1542-4758.2009.00423.x; Olesen P, 2007, AM J PHYSIOL-HEART C, V292, pH1058, DOI 10.1152/ajpheart.00047.2006; Ozkok A, 2012, CLIN J AM SOC NEPHRO, V7, P965, DOI 10.2215/CJN.11191111; Palmer SC, 2011, JAMA-J AM MED ASSOC, V305, P1119, DOI 10.1001/jama.2011.308; Pencak P, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-10; PORTALE AA, 1987, J CLIN INVEST, V80, P1147, DOI 10.1172/JCI113172; Raggi P, 2002, J AM COLL CARDIOL, V39, P695, DOI 10.1016/S0735-1097(01)01781-8; Rothwell PM, 2010, LANCET, V375, P895, DOI 10.1016/S0140-6736(10)60308-X; Rumberger JA, 1999, MAYO CLIN PROC, V74, P243, DOI 10.4065/74.3.243; Shanahan CM, 2011, CIRC RES, V109, P697, DOI 10.1161/CIRCRESAHA.110.234914; Shantouf R, 2009, CLIN J AM SOC NEPHRO, V4, P1106, DOI 10.2215/CJN.06091108; Shimada T, 2004, J BONE MINER RES, V19, P429, DOI 10.1359/JBMR.0301264; Son BK, 2006, CIRC RES, V98, P1024, DOI 10.1161/01.RES.0000218859.90970.8d; Srivaths PR, 2011, PEDIATR NEPHROL, V26, P945, DOI 10.1007/s00467-011-1822-0; Taki K, 2006, KIDNEY INT, V70, P218, DOI 10.1038/sj.ki.5000330; Terauchi Masakazu, 2011, Clin Calcium, V21, P1353, DOI CliCa110913531359; Termorshuizen F, 2004, J AM SOC NEPHROL, V15, P1061, DOI 10.1097/01.ASN.0000117976.29592.93; Tomson C, 2003, NEPHRON CLIN PRACT, V93, pC124, DOI 10.1159/000070231; Vliegenthart R, 2004, ARCH INTERN MED, V164, P2355, DOI 10.1001/archinte.164.21.2355; Wadwa RP, 2006, INT J BIOCHEM CELL B, V38, P996, DOI 10.1016/j.biocel.2005.09.015; Wang MJ, 2013, CLIN J AM SOC NEPHRO, V8, P116, DOI 10.2215/CJN.00230112; WATSON PE, 1980, AM J CLIN NUTR, V33, P27, DOI 10.1093/ajcn/33.1.27; Wexler L, 1996, CIRCULATION, V94, P1175, DOI 10.1161/01.CIR.94.5.1175; Wong ND, 2000, AM J CARDIOL, V86, P495, DOI 10.1016/S0002-9149(00)01000-6; Zarjou A, 2009, J AM SOC NEPHROL, V20, P1254, DOI 10.1681/ASN.2008070788; Zoppellaro G, 2012, AM J KIDNEY DIS, V59, P135, DOI 10.1053/j.ajkd.2011.07.027	80	8	12	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2014	9	4							e93360	10.1371/journal.pone.0093360	http://dx.doi.org/10.1371/journal.pone.0093360			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG2DP	24747427	gold, Green Published, Green Submitted			2023-01-03	WOS:000335226500005
J	Dzierma, Y; Nuesken, FG; Fleckenstein, J; Melchior, P; Licht, NP; Rube, C				Dzierma, Yvonne; Nuesken, Frank G.; Fleckenstein, Jochen; Melchior, Patrick; Licht, Norbert P.; Ruebe, Christian			Comparative Planning of Flattening-Filter-Free and Flat Beam IMRT for Hypopharynx Cancer as a Function of Beam and Segment Number	PLOS ONE			English	Article							VOLUMETRIC MODULATED ARC; PHOTON BEAMS; THERAPY; CONFORMITY; DELIVERY; INDEX	Although highly conformal dose distributions can be achieved by IMRT planning, this often requires a large number of segments or beams, resulting in increased treatment times. While flattening-filter-free beams offer a higher dose rate, even more segments may be required to create homogeneous target coverage. Therefore, it is worthwhile to systematically investigate the dependence of plan quality on gantry angles and number of segments for flat vs. FFF beams in IMRT planning. For the practical example of hypopharynx cancer, we present a planning study of flat vs. FFF beams using three different configurations of gantry angles and different segment numbers. The two beams are very similar in physical properties, and are hence well-suited for comparative planning. Starting with a set of plans of equal quality for flat and FFF beams, we assess how far the number of segments can be reduced before the plan quality is markedly compromised, and compare monitor units and treatment times for the resulting plans. As long as a sufficiently large number of segments is permitted, all planning scenarios give good results, independently of gantry angles and flat or FFF beams. For smaller numbers of segments, plan quality decreases both for flat and FFF energies; this effect is stronger for fewer gantry angles and for FFF beams. For low segment numbers, FFF plans are generally worse than the corresponding flat beam plans, but they are less sensitive to a decrease in segment number if many gantry angles are used ( 18 beams); in this case the quality of flat and FFF plans remains comparable even for few segments.	[Dzierma, Yvonne; Nuesken, Frank G.; Fleckenstein, Jochen; Melchior, Patrick; Licht, Norbert P.; Ruebe, Christian] Univ Saarland, Med Ctr, Dept Radiat Oncol, Homburg, Germany	Saarland University	Dzierma, Y (corresponding author), Univ Saarland, Med Ctr, Dept Radiat Oncol, Homburg, Germany.	yvonne.dzierma@uks.eu						Bratengeier K, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-170; Chan OSH, 2011, RADIOTHER ONCOL, V101, P298, DOI 10.1016/j.radonc.2011.08.015; Deasy JO, 2010, INT J RADIAT ONCOL, V76, pS58, DOI 10.1016/j.ijrobp.2009.06.090; Dempsey JF, 2005, MED PHYS, V32, P380, DOI 10.1118/1.1843354; Dzierma Y, 2014, PRACT RADIAT ONCOL, V4, pE109, DOI 10.1016/j.prro.2013.04.004; Dzierma Y, 2012, MED PHYS, V39, P2595, DOI 10.1118/1.3703835; Fu WH, 2004, PHYS MED BIOL, V49, P1535, DOI 10.1088/0031-9155/49/8/011; Guckenberger M, 2009, RADIOTHER ONCOL, V93, P259, DOI 10.1016/j.radonc.2009.08.015; Hoogeman MS, 2008, INT J RADIAT ONCOL, V70, P609, DOI 10.1016/j.ijrobp.2007.08.066; Kirkpatrick JP, 2010, INT J RADIAT ONCOL, V76, pS42, DOI 10.1016/j.ijrobp.2009.04.095; Kretschmer M, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-133; Otto K, 2008, MED PHYS, V35, P310, DOI 10.1118/1.2818738; Paddick I, 2000, J NEUROSURG, V93, P219, DOI 10.3171/jns.2000.93.supplement_3.0219; Paddick I, 2006, J NEUROSURG, V105, P194, DOI 10.3171/sup.2006.105.7.194; Rancati T, 2010, INT J RADIAT ONCOL, V76, pS64, DOI 10.1016/j.ijrobp.2009.03.079; SHAW E, 1993, INT J RADIAT ONCOL, V27, P1231, DOI 10.1016/0360-3016(93)90548-A; Spruijt KH, 2013, INT J RADIAT ONCOL, V85, P506, DOI 10.1016/j.ijrobp.2012.03.040; Stathakis S, 2009, APPL RADIAT ISOTOPES, V67, P1629, DOI 10.1016/j.apradiso.2009.03.014; Teoh M, 2011, BRIT J RADIOL, V84, P967, DOI 10.1259/bjr/22373346; Zwahlen DR, 2012, INT J RADIAT ONCOL, V83, P1655, DOI 10.1016/j.ijrobp.2011.10.019	20	8	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 10	2014	9	4							e94371	10.1371/journal.pone.0094371	http://dx.doi.org/10.1371/journal.pone.0094371			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI5LS	24722621	Green Submitted, gold, Green Published			2023-01-03	WOS:000336909100059
J	Gaiad, TP; Araujo, KPC; Serrao, JC; Miglino, MA; Ambrosio, CE				Gaiad, Thais P.; Araujo, Karla P. C.; Serrao, Julio C.; Miglino, Maria A.; Ambrosio, Carlos Eduardo			Motor Physical Therapy Affects Muscle Collagen Type I and Decreases Gait Speed in Dystrophin-Deficient Dogs	PLOS ONE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; FIBROSIS; MODELS; RANGE; GENE	Golden Retriever Muscular Dystrophy (GRMD) is a dystrophin-deficient canine model genetically homologous to Duchenne Muscular Dystrophy (DMD) in humans. Muscular fibrosis secondary to cycles of degeneration/regeneration of dystrophic muscle tissue and muscular weakness leads to biomechanical adaptation that impairs the quality of gait. Physical therapy (PT) is one of the supportive therapies available for DMD, however, motor PT approaches have controversial recommendations and there is no consensus regarding the type and intensity of physical therapy. In this study we investigated the effect of physical therapy on gait biomechanics and muscular collagen deposition types I and III in dystrophin-deficient dogs. Two dystrophic dogs (treated dogs-TD) underwent a PT protocol of active walking exercise, 3 x/week, 40 minutes/day, 12 weeks. Two dystrophic control dogs (CD) maintained their routine of activities of daily living. At t0 (pre) and t1 (post-physical therapy), collagen type I and III were assessed by immunohistochemistry and gait biomechanics were analyzed. Angular displacement of shoulder, elbow, carpal, hip, stifle and tarsal joint and vertical (Fy), mediolateral (Fz) and craniocaudal (Fx) ground reaction forces (GRF) were assessed. Wilcoxon test was used to verify the difference of biomechanical variables between t0 and t1, considering p<.05. Type I collagen of endomysium suffered the influence of PT, as well as gait speed that had decreased from t0 to t1 (p<.000). The PT protocol employed accelerates morphological alterations on dystrophic muscle and promotes a slower velocity of gait. Control dogs which maintained their routine of activities of daily living seem to have found a better balance between movement and preservation of motor function.	[Gaiad, Thais P.] Univ Jequitinhonha & Mucuri Valley UFVJM, Fac Biol Sci & Hlth, Dept Phys Therapy, Diamantina, MG, Brazil; [Araujo, Karla P. C.; Miglino, Maria A.] Univ Sao Paulo, Sch Vet Med & Anim Sci, Dept Surg, BR-09500900 Sao Paulo, Brazil; [Serrao, Julio C.] Univ Sao Paulo, Sch Phys Educ & Sports, Dept Biodynam, BR-09500900 Sao Paulo, Brazil; [Ambrosio, Carlos Eduardo] Univ Sao Paulo, Sch Anim Sci & Food Engn, Dept Vet Med, Pirassununga, SP, Brazil	Universidade Federal dos Vales do Jequitinhonha e Mucuri (UFVJM); Universidade de Sao Paulo	Ambrosio, CE (corresponding author), Univ Sao Paulo, Sch Anim Sci & Food Engn, Dept Vet Med, Pirassununga, SP, Brazil.	ceambrosio@usp.br	SERRÃO, JULIO CERCA/G-8499-2015; Ambrosio, Carlos Eduardo/F-3402-2010; Miglino, Maria Angelica/B-9519-2012	SERRÃO, JULIO CERCA/0000-0002-3646-3387; Ambrosio, Carlos Eduardo/0000-0002-8224-5022; Miglino, Maria Angelica/0000-0003-4979-115X	FAPESP (Fundacao de Amparo a pesquisa do Estado de Sao Paulo) [06/61561-6]	FAPESP (Fundacao de Amparo a pesquisa do Estado de Sao Paulo)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This research was supported by FAPESP (Fundacao de Amparo a pesquisa do Estado de Sao Paulo) process no 06/61561-6. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdelhadi J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052202; Alexakis C, 2007, AM J PHYSIOL-CELL PH, V293, pC661, DOI 10.1152/ajpcell.00061.2007; Ambrosio CE, 2009, GENET MOL RES, V8, P389, DOI 10.4238/vol8-2gmr581; Ansved T, 2003, CURR OPIN CLIN NUTR, V6, P435, DOI 10.1097/00075197-200307000-00013; Araujo KPC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061367; Barthelemy I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048478; Barthelemy I, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-75; Barthelemy I, 2009, NEUROMUSCULAR DISORD, V19, P788, DOI 10.1016/j.nmd.2009.07.014; Besancon MF, 2004, AM J VET RES, V65, P1497, DOI 10.2460/ajvr.2004.65.1497; Bushby K, 2010, LANCET NEUROL, V9, P177, DOI 10.1016/S1474-4422(09)70272-8; Carter GT, 2008, AM J PHYS MED RE S11, V81, P151; Collins CA, 2003, INT J EXP PATHOL, V84, P165, DOI 10.1046/j.1365-2613.2003.00354.x; Cozzi F, 2001, ACTA NEUROPATHOL, V101, P469; Cup EH, 2007, ARCH PHYS MED REHAB, V88, P1452, DOI 10.1016/j.apmr.2007.07.024; Desguerre I, 2009, J NEUROPATH EXP NEUR, V68, P762, DOI 10.1097/NEN.0b013e3181aa31c2; Doglio L, 2011, EUR J PHYS REHAB MED, V47, P587; Eagle M, 2002, NEUROMUSCULAR DISORD, V12, P926, DOI 10.1016/S0960-8966(02)00140-2; Gaiad TP, 2009, BRAZ J PHYS THER, V13, P244, DOI 10.1590/S1413-35552009005000032; Gaiad TP, 2011, RES VET SCI, V91, P188, DOI 10.1016/j.rvsc.2011.01.007; Gaiad TP, 2012, MUSCULAR DYSTROPHY, P535, DOI [10.5772/30329, DOI 10.5772/30329]; Ganea R, 2012, J CHILD NEUROL, V27, P30, DOI 10.1177/0883073811413581; Gillette RL, 2008, VET J, V178, P165, DOI 10.1016/j.tvjl.2008.01.009; Howell JM, 1997, NEUROMUSCULAR DISORD, V7, P325; Huang P, 2009, FASEB J, V23, P2539, DOI 10.1096/fj.09-129833; Huebner KD, 2008, AM J PHYSIOL-HEART C, V294, pH1550, DOI 10.1152/ajpheart.01253.2007; Kerkis I, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-35; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; Kornegay JN, 2012, MAMM GENOME, V23, P85, DOI 10.1007/s00335-011-9382-y; Lee DV, 2004, J EXP BIOL, V207, P1715, DOI 10.1242/jeb.00947; Marsh AP, 2010, NEUROMUSCULAR DISORD, V20, P16, DOI 10.1016/j.nmd.2009.10.007; McLoon LK, 2008, AM J PHYSIOL-HEART C, V294, pH1505, DOI 10.1152/ajpheart.00176.2008; Meij BP, 2006, VET SURG, V35, P168, DOI 10.1111/j.1532-950X.2006.00128.x; Nguyen F, 2002, J COMP PATHOL, V126, P100, DOI 10.1053/jcpa.2001.0526; Passerini L, 2002, NEUROMUSCULAR DISORD, V12, P828, DOI 10.1016/S0960-8966(02)00071-8; Shin JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059875; Shin JH, 2013, MOL THER, V21, P750, DOI 10.1038/mt.2012.283; Strober Jonathan B, 2006, NeuroRx, V3, P225; Thibaud JL, 2007, NEUROMUSCULAR DISORD, V17, P575, DOI 10.1016/j.nmd.2007.03.013; VALENTINE BA, 1990, J NEUROL SCI, V97, P1, DOI 10.1016/0022-510X(90)90095-5; van der Walt AM, 2008, J S AFR VET ASSOC, V79, P175; Zhou L, 2010, J NEUROPATH EXP NEUR, V69, P771, DOI 10.1097/NEN.0b013e3181e9a34b	41	10	13	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 8	2014	9	4							e93500	10.1371/journal.pone.0093500	http://dx.doi.org/10.1371/journal.pone.0093500			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE7FA	24713872	Green Published, gold, Green Submitted			2023-01-03	WOS:000334160900029
J	Gupta, AK; David, W				Gupta, Ashwani K.; David, Waseem			Does Erythropoietin Cause Hemoglobin Variability- Is It 'Normal'?	PLOS ONE			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; SERUM-ALBUMIN; LEVEL VARIABILITY; HEMODIALYSIS-PATIENTS; ANEMIA MANAGEMENT; DIALYSIS PATIENTS; INFLAMMATION; MORTALITY; ASSOCIATION; CYTOKINES	Hemoglobin variability (Hb-var) in patients with chronic kidney disease has been stipulated to be a result of exogenous treatment with erythropoiesis stimulating agents (ESA) and has been related to mortality in dialysis patients. We hypothesized the existence of Hb-var independent of ESA administration and compared it to that in healthy adults using data from the Scripps-Kaiser and NHANES III databases. We studied the Hb-var in 1571 peritoneal dialysis patients which included 116 patients not requiring treatment with erythropoietin. We systematically studied the differences between the groups that needed ESA therapy and those who did not. White race and male sex were significant predictors of need for erythropoietin therapy. We found peritoneal dialysis patients to exhibit significantly increased Hb-var independent of treatment with exogenous erythropoietin (0.99 gm/dL vs. 1.17 gm/dL, p-value<0.001). We found age to be a significant determinant of Hb-var in the ESA treated group. Hb-var in younger patients (<30 years) was increased by 50% compared to young healthy adults. The Hb-var in elderly (>60 years) peritoneal dialysis patients was similar to that seen in healthy elders, suggesting similarity with anemia of aging. We conclude that exogenous ESA administration does not explain Hb-var entirely but may enhance it. Intrinsic factors affecting erythropoiesis including age may be the major determinants of Hb-var.	[Gupta, Ashwani K.; David, Waseem] Univ Florida, Dept Nephrol, Jacksonville, FL USA	State University System of Florida; University of Florida	Gupta, AK (corresponding author), Univ Florida, Dept Nephrol, Jacksonville, FL USA.	akgupta@ufl.edu						AHMAD R, 1987, NEW ENGL J MED, V317, P169; Arneson TJ, 2009, NEPHROL DIAL TRANSPL, V24, P1378, DOI 10.1093/ndt/gfp018; Ashby DR, 2010, HAEMATOL-HEMATOL J, V95, P505, DOI 10.3324/haematol.2009.013136; Ashby DR, 2009, KIDNEY INT, V75, P976, DOI 10.1038/ki.2009.21; Berns JS, 2003, KIDNEY INT, V64, P1514, DOI 10.1046/j.1523-1755.2003.00229.x; Beutler E, 2006, BLOOD, V107, P1747, DOI 10.1182/blood-2005-07-3046; Bian XX, 2010, NEUROL MED-CHIR, V50, P361, DOI 10.2176/nmc.50.361; Brunelli SM, 2008, CLIN J AM SOC NEPHRO, V3, P1733, DOI 10.2215/CJN.02390508; Canavese C, 2002, CLIN NEPHROL, V58, P438; Canavesi Elena, 2012, World J Nephrol, V1, P166, DOI 10.5527/wjn.v1.i6.166; Chen Ho-Ching, 2012, Chang Gung Med J, V35, P79; Cooper AC, 2003, J AM SOC NEPHROL, V14, P1776, DOI 10.1097/01.ASN.0000071514.36428.61; Ebben JP, 2006, CLIN J AM SOC NEPHRO, V1, P1205, DOI 10.2215/CJN.01110306; Eckardt KU, 2010, J AM SOC NEPHROL, V21, P1765, DOI 10.1681/ASN.2009101017; Eschbach J W, 1988, Contrib Nephrol, V66, P63; FAQUIN WC, 1992, BLOOD, V79, P1987; Ferrucci L, 2008, SEMIN HEMATOL, V45, P242, DOI 10.1053/j.seminhematol.2008.06.001; Fishbane S, 2005, KIDNEY INT, V68, P1337, DOI 10.1111/j.1523-1755.2005.00532.x; Gilbertson DT, 2008, CLIN J AM SOC NEPHRO, V3, P133, DOI 10.2215/CJN.01610407; Gilbertson DT, 2009, AM J NEPHROL, V30, P491, DOI 10.1159/000243565; Ishani A, 2008, NEPHROL DIAL TRANSPL, V23, P1682, DOI 10.1093/ndt/gfm845; Johansen KL, 2010, AM J KIDNEY DIS, V55, P535, DOI 10.1053/j.ajkd.2009.12.018; Kainz A, 2012, TRANSPL INT, V25, P323, DOI 10.1111/j.1432-2277.2012.01428.x; Kainz A, 2010, NEPHROL DIAL TRANSPL, V25, P3701, DOI 10.1093/ndt/gfq287; Kaufman JS, 2008, AM J KIDNEY DIS, V52, P1035, DOI 10.1053/j.ajkd.2008.10.002; Kausz AT, 2005, AM J KIDNEY DIS, V45, P136, DOI 10.1053/j.ajkd.2004.08.042; Kaysen GA, 2000, KIDNEY INT, V58, P346, DOI 10.1046/j.1523-1755.2000.00172.x; Kaysen GA, 2004, KIDNEY INT, V65, P1408, DOI 10.1111/j.1523-1755.2004.00520.x; Kaysen GA, 2002, KIDNEY INT, V61, P2240, DOI 10.1046/j.1523-1755.2002.00076.x; Kaysen GA, 2001, KIDNEY INT, V60, P333, DOI 10.1046/j.1523-1755.2001.00804.x; Lacson E, 2008, AM J KIDNEY DIS, V52, P1104, DOI 10.1053/j.ajkd.2008.07.026; Lau JH, 2010, NEPHROL DIAL TRANSPL, V25, P4002, DOI 10.1093/ndt/gfq330; Massimetti C, 1998, BLOOD PURIFICAT, V16, P317, DOI 10.1159/000014351; McCranor BJ, 2013, HAEMATOLOGICA, V98, P1633, DOI 10.3324/haematol.2013.087114; Selby NM, 2012, PERITON DIALYSIS INT, V32, P177, DOI 10.3747/pdi.2010.00299; Shen Y, 2010, TRANSPL P, V42, P1595, DOI 10.1016/j.transproceed.2009.11.050; Singh AK, 2008, KIDNEY INT, V74, P679, DOI 10.1038/ki.2008.59; van der Putten K, 2009, INT J ARTIF ORGANS, V32, P787, DOI 10.1177/039139880903201104; Walker R, 2009, NEPHROLOGY, V14, P689, DOI 10.1111/j.1440-1797.2009.01166.x; Weinhandl ED, 2011, AM J KIDNEY DIS, V57, P255, DOI 10.1053/j.ajkd.2010.06.013; Yang W, 2007, J AM SOC NEPHROL, V18, P3164, DOI 10.1681/ASN.2007010058; Yeun J Y, 1998, Am J Kidney Dis, V32, pS118, DOI 10.1016/S0272-6386(98)70174-X; Yeun JY, 1997, AM J KIDNEY DIS, V30, P923, DOI 10.1016/S0272-6386(97)90105-0; Yilmaz MI, 2011, BLOOD PURIFICAT, V32, P220, DOI 10.1159/000328037	44	5	5	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 7	2014	9	4							e92890	10.1371/journal.pone.0092890	http://dx.doi.org/10.1371/journal.pone.0092890			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE7EP	24709756	Green Published, Green Submitted, gold			2023-01-03	WOS:000334159800020
J	Zhang, CL; Xu, YJ; Zhong, QN; Li, XP; Gao, P; Feng, CY; Chu, Q; Chen, Y; Liu, D				Zhang, Chengliang; Xu, Yanjiao; Zhong, Qiaoni; Li, Xiping; Gao, Ping; Feng, Chengyang; Chu, Qian; Chen, Yuan; Liu, Dong			In Vitro Evaluation of the Inhibitory Potential of Pharmaceutical Excipients on Human Carboxylesterase 1A and 2	PLOS ONE			English	Article							P-GLYCOPROTEIN FUNCTION; CREMOPHOR EL; TRANSCRIPTIONAL REGULATION; INTESTINAL TRANSPORT; SITU ABSORPTION; COA REDUCTASE; POLOXAMER 407; C57BL/6 MICE; RAT; METABOLISM	Two major forms of human carboxylesterase (CES), CES1A and CES2, dominate the pharmacokinetics of most prodrugs such as imidapril and irinotecan (CPT-11). Excipients, largely used as insert vehicles in formulation, have been recently reported to affect drug enzyme activity. The influence of excipients on the activity of CES remains undefined. In this study, the inhibitory effects of 25 excipients on the activities of CES1A1 and CES2 were evaluated. Imidapril and CPT-11 were used as substrates and cultured with liver microsomes in vitro. Imidapril hydrolase activities of recombinant CES1A1 and human liver microsomes (HLM) were strongly inhibited by sodium lauryl sulphate (SLS) and polyoxyl 40 hydrogenated castor oil (RH40) [Inhibition constant (K-i) = 0.04 +/- 0.01 mu g/ml and 0.20 +/- 0.09 mu g/ml for CES1A1, and 0.12 +/- 0.03 mu g/ml and 0.76 +/- 0.33 mu g/ml, respectively, for HLM]. The enzyme hydrolase activity of recombinant CES2 was substantially inhibited by Tween 20 and polyoxyl 35 castor oil (EL35) (K-i = 0.93 +/- 0.36 mu g/ml and 4.4 +/- 1.24 mu g/ml, respectively). Thus, these results demonstrate that surfactants such as SLS, RH40, Tween 20 and EL35 may attenuate the CES activity; such inhibition should be taken into consideration during drug administration.	[Zhang, Chengliang; Xu, Yanjiao; Li, Xiping; Feng, Chengyang; Liu, Dong] Huazhong Univ Sci & Technol, Tongji Med Sch, Tongji Hosp, Dept Pharm, Wuhan 430074, Hubei, Peoples R China; [Zhong, Qiaoni] Hubei Pharmaceut Ind Res Inst Co Ltd, Wuhan, Hubei, Peoples R China; [Gao, Ping] Wuhan Childrens Hosp, Dept Pharm, Wuhan, Hubei, Peoples R China; [Chu, Qian; Chen, Yuan] Huazhong Univ Sci & Technol, Tongji Med Sch, Tongji Hosp, Dept Oncol, Wuhan 430074, Hubei, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology	Liu, D (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Sch, Tongji Hosp, Dept Pharm, Wuhan 430074, Hubei, Peoples R China.	ld2069@outlook.com	Zhang, Cheng/GRS-8698-2022; Chu, Qian/K-2996-2017	Chu, Qian/0000-0001-8192-7630	National Natural Science Foundation of China [81301953]; Fundamental Research Funds for the Central Universities [HUST: 2013ZHYX013]; Hubei Pharmaceutical Industry Research Institute Co. Ltd.	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Hubei Pharmaceutical Industry Research Institute Co. Ltd.	This work is supported by the National Natural Science Foundation of China (No: 81301953) and the Fundamental Research Funds for the Central Universities (HUST: 2013ZHYX013). Hubei Pharmaceutical Industry Research Institute Co. Ltd. only provided support in the form of a salary for author QZ, and did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Ahuja N, 2007, EUR J PHARM BIOPHARM, V65, P26, DOI 10.1016/j.ejpb.2006.07.007; Blonder JM, 1999, LIFE SCI, V65, pPL261, DOI 10.1016/S0024-3205(99)00495-6; Buggins TR, 2007, ADV DRUG DELIVER REV, V59, P1482, DOI 10.1016/j.addr.2007.08.017; Cornaire G, 2004, INT J PHARMACEUT, V278, P119, DOI 10.1016/j.ijpharm.2004.03.001; EMA, 2005, EMACHMPPEG1948102005; Engel A, 2012, MOL PHARMACEUT, V9, P2577, DOI 10.1021/mp3001815; Fukami T, 2010, DRUG METAB DISPOS, V38, P2173, DOI 10.1124/dmd.110.034454; Godin SJ, 2007, DRUG METAB DISPOS, V35, P1664, DOI 10.1124/dmd.107.015388; GOLIGHTLY LK, 1988, MED TOXICOL ADV DRUG, V3, P128, DOI 10.1007/BF03259937; Gonzalez RCB, 2004, BIOPHARM DRUG DISPOS, V25, P37, DOI 10.1002/bdd.383; Hamid KA, 2009, INT J PHARMACEUT, V379, P100, DOI 10.1016/j.ijpharm.2009.06.018; Hatfield MJ, 2011, EXPERT OPIN THER PAT, V21, P1159, DOI 10.1517/13543776.2011.586339; Hirama S, 2004, TOXICOLOGY, V199, P137, DOI 10.1016/j.tox.2004.02.017; Hosokawa M, 2007, DRUG METAB REV, V39, P1, DOI 10.1080/03602530600952164; Humerickhouse R, 2000, CANCER RES, V60, P1189; Imai T, 2006, DRUG METAB PHARMACOK, V21, P173, DOI 10.2133/dmpk.21.173; Iwase K, 2004, TOXICOL LETT, V154, P143, DOI 10.1016/j.toxlet.2004.08.003; Johnston TP, 1999, J CARDIOVASC PHARM, V34, P831, DOI 10.1097/00005344-199912000-00010; JOHNSTON TP, 1993, BIOCHEM PHARMACOL, V46, P1037, DOI 10.1016/0006-2952(93)90668-M; Johnston TP, 1997, J CARDIOVASC PHARM, V29, P580, DOI 10.1097/00005344-199705000-00003; Johnston TP, 2000, ATHEROSCLEROSIS, V149, P303, DOI 10.1016/S0021-9150(99)00339-1; Lin YL, 2007, BIOL PHARM BULL, V30, P1301, DOI 10.1248/bpb.30.1301; Maruichi T, 2010, BIOCHEM PHARMACOL, V79, P288, DOI 10.1016/j.bcp.2009.08.019; Maxwell DM, 2001, J APPL TOXICOL, V21, pS103, DOI 10.1002/jat.833; Nahata MC, 2009, ARCH DIS CHILD-FETAL, V94, pF392, DOI 10.1136/adc.2009.160192; Rege BD, 2002, EUR J PHARM SCI, V16, P237, DOI 10.1016/S0928-0987(02)00055-6; Ren XH, 2009, EUR J PHARM SCI, V36, P401, DOI 10.1016/j.ejps.2008.11.002; Ross MK, 2007, J BIOCHEM MOL TOXIC, V21, P187, DOI 10.1002/jbt.20178; Sachs-Barrable K, 2007, J PHARM PHARM SCI, V10, P319; Satoh T, 2002, DRUG METAB DISPOS, V30, P488, DOI 10.1124/dmd.30.5.488; Schwer H, 1997, BIOCHEM BIOPH RES CO, V233, P117, DOI 10.1006/bbrc.1997.6413; Shen Q, 2006, INT J PHARMACEUT, V313, P49, DOI 10.1016/j.ijpharm.2006.01.020; Shen Q, 2008, J PHARM PHARMACOL, V60, P1633, DOI 10.1211/jpp/60.12.0009; Shono Y, 2004, J PHARM SCI-US, V93, P877, DOI 10.1002/jps.20017; Sintov AC, 2004, J CONTROL RELEASE, V95, P173, DOI 10.1016/j.jconrel.2003.11.004; Takahashi S, 2009, DRUG METAB DISPOS, V37, P956, DOI 10.1124/dmd.108.024331; Takahashi S, 2008, J PHARM SCI-US, V97, P5434, DOI 10.1002/jps.21376; Thackaberry EA, 2010, TOXICOL SCI, V117, P485, DOI 10.1093/toxsci/kfq207; Tompkins L, 2010, PHARM RES-DORDR, V27, P1703, DOI 10.1007/s11095-010-0170-2; Ursino MG, 2011, REGUL TOXICOL PHARM, V60, P93, DOI 10.1016/j.yrtph.2011.02.010; Vandecruys R, 2007, INT J PHARMACEUT, V342, P168, DOI 10.1016/j.ijpharm.2007.05.006; Wasan KM, 2003, J PHARM PHARM SCI, V6, P189; Watanabe A, 2009, DRUG METAB DISPOS, V37, P1513, DOI 10.1124/dmd.109.026567; Xu YJ, 2013, DRUG METAB PHARMACOK; Zhang CL, 2012, J HUAZHONG U SCI-MED, V32, P798, DOI 10.1007/s11596-012-1037-z; Zhu SJ, 2009, EUR J PHARM SCI, V37, P573, DOI 10.1016/j.ejps.2009.05.001	46	19	20	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 3	2014	9	4							e93819	10.1371/journal.pone.0093819	http://dx.doi.org/10.1371/journal.pone.0093819			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE6LR	24699684	Green Submitted, gold, Green Published			2023-01-03	WOS:000334105000112
J	ten Hoope-Bender, P; de Bernis, L; Campbell, J; Downe, S; Fauveau, V; Fogstad, H; Homer, CSE; Kennedy, HP; Matthews, Z; McFadden, A; Renfrew, MJ; Van Lerberghe, W				ten Hoope-Bender, Petra; de Bernis, Luc; Campbell, James; Downe, Soo; Fauveau, Vincent; Fogstad, Helga; Homer, Caroline S. E.; Kennedy, Holly Powell; Matthews, Zoe; McFadden, Alison; Renfrew, Mary J.; Van Lerberghe, Wim			Improvement of maternal and newborn health through midwifery	LANCET			English	Article							EFFECTIVE COVERAGE; GLOBAL HEALTH; CARE; INTERVENTIONS; AFGHANISTAN; STRENGTHEN; RETENTION; FRAMEWORK; POST-2015; MORTALITY	In the concluding paper of this Series about midwifery, we look at the policy implications from the framework for quality maternal and newborn care, the potential effect of life-saving interventions that fall within the scope of practice of midwives, and the historic sequence of health system changes that made a reduction in maternal mortality possible in countries that have expanded their midwifery workforce. Achievement of better health outcomes for women and newborn infants is possible, but needs improvements in the quality of reproductive, maternal, and newborn care, alongside necessary increases in universal coverage. In this report, we propose three priority research areas and outline how national investment in midwives and in their work environment, education, regulation, and management can improve quality of care. Midwifery and midwives are crucial to the achievement of national and international goals and targets in reproductive, maternal, newborn, and child health; now and beyond 2015.	[ten Hoope-Bender, Petra; Campbell, James] Inst Cooperac Social Integrare, Barcelona 08007, Spain; [de Bernis, Luc] UN Populat Fund, Geneva, Switzerland; [Downe, Soo] Univ Cent Lancashire, Sch Hlth, Preston PR1 2HE, Lancs, England; [Fauveau, Vincent] Holist Sante, Montpellier, France; [Fogstad, Helga] Norwegian Agcy Dev Cooperat, Oslo, Norway; [Homer, Caroline S. E.] Univ Technol, Fac Hlth, Sydney, NSW, Australia; [Kennedy, Holly Powell] Yale Univ, Sch Nursing, New Haven, CT 06536 USA; [Matthews, Zoe] Univ Southampton, Southampton, Hants, England; [McFadden, Alison; Renfrew, Mary J.] Univ Dundee, Coll Med Dent & Nursing, Sch Nursing & Midwifery, Mother & Infant Res Unit, Dundee, Scotland; [Van Lerberghe, Wim] WHO, Reg Off Europe, DK-2100 Copenhagen, Denmark	United Nations Population Fund; University of Central Lancashire; University of Technology Sydney; Yale University; University of Southampton; University of Dundee; World Health Organization	ten Hoope-Bender, P (corresponding author), Inst Cooperac Social Integrare, Barcelona 08007, Spain.	petra.tenhoope@integrare.es	Matthews, Zoe/HGD-0506-2022; Homer, Caroline/J-2101-2014	McFadden, Alison/0000-0002-5164-2025; Matthews, Zoe/0000-0003-1533-6618; Renfrew, Mary/0000-0003-2905-403X; Homer, Caroline/0000-0002-7454-3011	Bill & Melinda Gates Foundation [OPP1042500]; University of Dundee; Instituto de Cooperacion Social Integrare	Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation); University of Dundee; Instituto de Cooperacion Social Integrare	The work on this paper was supported partly through a grant from the Bill & Melinda Gates Foundation (grant number OPP1042500). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of their employers or the Bill & Melinda Gates Foundation. MJR's work was supported by the University of Dundee. PtH-B's work was supported by the Instituto de Cooperacion Social Integrare. Maria Guerra Arias managed and checked all the references. Thomson Prentice edited sections of the first draft. Joanne McManus edited the second draft. Administrative support was provided by Jenny Brown and Tracy Sparey, and Natalie Muir provided project support. We thank all series co-authors, dose readers, and the reviewers from ICM, FIGO, WHO, and the Bill & Melinda Gates Foundation for their contributions and support.	Abe Eghe, 2008, Afr J Reprod Health, V12, P17; [Anonymous], 1986, WHO CHRON, V40, P175; [Anonymous], 2012, UNICEF PROGR REPORT; [Anonymous], 2011, GLOB REV KEY INT REL; [Anonymous], 2008, PRIM HLTH CAR NOW MO; Bailey PE, 2011, INT J GYNECOL OBSTET, V115, P300, DOI 10.1016/j.ijgo.2011.09.004; Bhutta Z, 2010, LANCET, V376, P1375; Bowser D, 2010, EXPLORING EVIDENCE D; Bustreo F, 2013, LANCET GLOB HEALTH, V1, pE176, DOI 10.1016/S2214-109X(13)70059-7; Campbell, 2013, UNIVERSAL TRUTH NO H; Campbell J, 2013, B WORLD HEALTH ORGAN, V91, P853, DOI 10.2471/BLT.13.118729; Campbell J, 2013, LANCET, V381, P725, DOI 10.1016/S0140-6736(13)60579-6; Colston J., 2011, USE EFFECTIVE COVERA; Ebener S, 2013, 5 INT C HLTH BANGK T; Evans T., 2013, VAL MON ASS COMM BAS; Family Planning 2020, 2012, LOND SUMM FAM PLANN; Gibbons L, 2010, GLOBAL NUMBERS COSTS; Global Alliance for Vaccine and Immunization (GAVI), IMM IS ON MOST COST; Hassan-Bitar S, 2011, MIDWIFERY, V27, P154, DOI 10.1016/j.midw.2009.05.007; High-Level Panel of Eminent Persons on the Post-2015 Development Agenda, 2013, NEW GLOB PARTN ER PO; Homer CSE, 2014, LANCET; Horton R, 2013, LANCET, V382, P382, DOI 10.1016/S0140-6736(13)61641-4; ICM, 2011, ICM INT DEF MIDW; ILO, 2012, INT STAND CLASS OCC, V1; Independent Expert Review Group (iERG), 2013, EV WOM EV CHILD STRE; Info MME, 2013, MAL MAT MORT EST 201; International Confederation of midwives (ICM), 2013, ESS COMP BAS MIDW PR; Jaffre Y, 2003, B AMADES, V56, P639; Jamison DT, 2013, LANCET, V382, P1898, DOI 10.1016/S0140-6736(13)62105-4; Kruk ME, 2014, B WORLD HEALTH ORGAN, V92, P246, DOI 10.2471/BLT.13.126417; Kruk ME, 2014, BUSTING MYTHS DO HLT; Kyei NNA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046475; Langer A, 2013, LANCET, V381, P601, DOI 10.1016/S0140-6736(13)60259-7; Lawn JE, 2011, LANCET; Leap N., 2009, BRIT J MIDWIFERY, V17, P12, DOI [10.12968/bjom.2009.17.1.37646, DOI 10.12968/BJOM.2009.17.1.37646]; Lemiere C, 2011, WOR BANK WORK PAPER, P1, DOI 10.1596/978-0-8213-8599-9; Lemiere C, 2014, PRINC MAH AW C 2014; Mansoor GF, 2013, MIDWIFERY, V29, P1088, DOI 10.1016/j.midw.2013.07.021; Montenegro H, 2012, INT J PERS CENT MED, V2, P93; Ngwenya BN, 2011, HEALTH CARE WOMEN IN, V32, P917, DOI 10.1080/07399332.2011.603860; Rath AD, 2007, REPROD HEALTH MATTER, V15, P72, DOI 10.1016/S0968-8080(07)30329-7; Renfrew MJ, 2014, LANCET; Sandall J, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004667.pub5, 10.1002/14651858.CD004667.pub3]; Schaaf M, 2013, HLTH POLICY PLAN, DOI [10.1093/heapol/czt09, DOI 10.1093/HEAPOL/CZT09]; Scheffler R., 2012, LABOUR MARKET HUMAN; Shaban I, 2012, MIDWIFERY, V28, P106, DOI 10.1016/j.midw.2010.11.012; Shengelia B, 2005, SOC SCI MED, V61, P97, DOI 10.1016/j.socscimed.2004.11.055; Soucat A, 2013, DIR DEV, P1, DOI 10.1596/978-0-8213-9555-4; Sousa A, 2013, B WORLD HEALTH ORGAN, V91, P892, DOI 10.2471/BLT.13.118927; Souza JP, 2013, LANCET, V381, P1747, DOI 10.1016/S0140-6736(13)60686-8; Stenberg K, 2014, LANCET, V383, P1333, DOI 10.1016/S0140-6736(13)62231-X; Tatem AJ, 2014, INT J HEALTH GEOGR, V13, DOI 10.1186/1476-072X-13-2; ten Hoope-Bender P, 2011, INT J GYNECOL OBSTET, V114, P211, DOI 10.1016/j.ijgo.2011.06.002; UNAIDS, 2011, COUNTD ZER GLOB PLAN; UNFPA, 2011, STAT WORLDS MIDW 201; UNFPA, 2014, STAT WORLDS MIDW 201; United Nations Fund for Population Activities (UNFPA), 2014, FRAM ACT FOLL UP PRO; United Nations Human Rights Council, 2011, PRACT AD HUM RIGHTS; United Nations - Department of Economic and Social Affairs - Population Division, 2012, WORLD POP PROSP 2012; Van Lerberghe W, 2014, LANCET; van Teijlingen E, 2014, MIDWIFERY, V30, P1, DOI 10.1016/j.midw.2013.10.022; Vega J, 2013, LANCET, V381, P179, DOI 10.1016/S0140-6736(13)60062-8; Vujicic M, 2009, MEASURING HLTH WORKF; Walker N, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-S3-S1; WHO, 2010, INCREASING ACCESS TO HEALTH WORKERS IN REMOTE AND RURAL AREAS THROUGH IMPROVED RETENTION: GLOBAL POLICY RECOMMENDATIONS, P1; WHO, 2014, EV NEWB DRAFT ACT PL; WHO, 2010, TRENDS MAT MORT 1990; WHO, 2005, MAK EV MOTH CHILD CO; Wood ME, 2013, MIDWIFERY, V29, P1137, DOI 10.1016/j.midw.2013.07.004; World Health Organisation, 2000, WORLD HLTH REPORT 20; World Health Organization, 2011, WHO GUID PREV EARL P; World Health Organization, 2010, FRAMEWORK ACTION INT; World Health Organization, 2001, BACKGR PAP TECHN CON; World Health Organization, 2010, WORKL IND STAFF NEED; World Health Organization, 2013, WHO GUID 2013; World Health Organization, 2007, EVERYBODYS BUSINESS; World Health Organization (WHO), 2014, MAK FAIR CHOIC PATH; World Health Organization & World Bank, 2013, MON PROGR UN HLTH CO	78	250	251	5	43	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 27	2014	384	9949					1226	1235		10.1016/S0140-6736(14)60930-2	http://dx.doi.org/10.1016/S0140-6736(14)60930-2			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AQ7MT	24965818				2023-01-03	WOS:000343002600029
J	Maskey, M; Lowry, J; Rodgers, J; McConachie, H; Parr, JR				Maskey, Morag; Lowry, Jessica; Rodgers, Jacqui; McConachie, Helen; Parr, Jeremy R.			Reducing Specific Phobia/Fear in Young People with Autism Spectrum Disorders (ASDs) through a Virtual Reality Environment Intervention	PLOS ONE			English	Article							HIGH-FUNCTIONING AUTISM; COMORBID PSYCHIATRIC-DISORDERS; ANXIETY DISORDERS; CHILDREN; ADOLESCENTS; SYMPTOMS; YOUTH; RESPONSES; EMOTIONS; SKILLS	Anxiety is common in children with autism spectrum disorders (ASD), with specific fears and phobias one of the most frequent subtypes. Specific fears and phobias can have a serious impact on young people with ASD and their families. In this study we developed and evaluated a unique treatment combining cognitive behaviour therapy (CBT) with graduated exposure in a virtual reality environment (VRE). Nine verbally fluent boys with an ASD diagnosis and no reported learning disability, aged 7 to 13 years old, were recruited. Each had anxiety around a specific situation (e. g. crowded buses) or stimulus (e. g. pigeons). An individualised scene was recreated in our 'wrap-around' VRE. In the VRE participants were coached by a psychologist in cognitive and behavioural techniques (e.g. relaxation and breathing exercises) while the exposure to the phobia/fear stimulus was gradually increased as the child felt ready. Each child received four 20-30 minute sessions. After participating in the study, eight of the nine children were able to tackle their phobia situation. Four of the participants completely overcame their phobia. Treatment effects were maintained at 12 months. These results provide evidence that CBT with VRE can be a highly effective treatment for specific phobia/fear for some young people with ASD.	[Maskey, Morag; Rodgers, Jacqui; Parr, Jeremy R.] Newcastle Univ, Inst Neurosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Lowry, Jessica; McConachie, Helen] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK	Maskey, M (corresponding author), Newcastle Univ, Inst Neurosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	morag.maskey@ncl.ac.uk; Jeremy.parr@ncl.ac.uk		Rodgers, Jacqui/0000-0002-1759-316X	Newcastle University	Newcastle University	Dr Morag Maskey has a Daphne Jackson Fellowship sponsored by Newcastle University (http://www.daphnejackson.org/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agostinis A., 2008, LEEDS RELIABLE CHANG; [Anonymous], 2005, EMOTIONAL DEV RECENT; Arnold LE, 2003, J AM ACAD CHILD PSY, V42, P1443, DOI 10.1097/00004583-200312000-00011; Ashburner J, 2010, RES AUTISM SPECT DIS, V4, P18, DOI 10.1016/j.rasd.2009.07.002; Berument SK, 1999, BRIT J PSYCHIAT, V175, P444, DOI 10.1192/bjp.175.5.444; Chalfant AM, 2007, J AUTISM DEV DISORD, V37, P1842, DOI 10.1007/s10803-006-0318-4; de Bruin EI, 2007, J AUTISM DEV DISORD, V37, P877, DOI 10.1007/s10803-006-0215-x; Drahota A, 2011, J AUTISM DEV DISORD, V41, P257, DOI 10.1007/s10803-010-1037-4; Eaves LC, 2006, AUTISM, V10, P229, DOI 10.1177/1362361306063288; Fabri M, 2007, LECT NOTES COMPUT SC, V4552, P275; Gjevik E, 2011, J AUTISM DEV DISORD, V41, P761, DOI 10.1007/s10803-010-1095-7; Hill E, 2004, J AUTISM DEV DISORD, V34, P229, DOI 10.1023/B:JADD.0000022613.41399.14; Hirstein W, 2001, P ROY SOC B-BIOL SCI, V268, P1883, DOI 10.1098/rspb.2001.1724; IALONGO N, 1995, J CHILD PSYCHOL PSYC, V36, P427, DOI 10.1111/j.1469-7610.1995.tb01300.x; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Joshi G, 2010, J AUTISM DEV DISORD, V40, P1361, DOI 10.1007/s10803-010-0996-9; Josman N, 2008, INT J DISABIL HUM DE, V7, P49; Leyfer OT, 2006, J AUTISM DEV DISORD, V36, P849, DOI 10.1007/s10803-006-0123-0; Lind SE, 2014, NEUROPSYCHOLOGY, V28, P55, DOI 10.1037/neu0000005; Low J, 2009, BRIT J DEV PSYCHOL, V27, P425, DOI 10.1348/026151008X334728; Maskey M, 2013, J AUTISM DEV DISORD, V43, P851, DOI 10.1007/s10803-012-1622-9; Mattila ML, 2010, J AUTISM DEV DISORD, V40, P1080, DOI 10.1007/s10803-010-0958-2; Mayes SD, 2013, RES AUTISM SPECT DIS, V7, P151, DOI 10.1016/j.rasd.2012.08.002; McConachie H, 2009, ARCH DIS CHILD, V94, P38, DOI 10.1136/adc.2007.126326; McConachie H, 2013, AUTISM; McPheeters ML, 2011, J AUTISM DEV DISORD, V41, P646, DOI 10.1007/s10803-010-1085-9; Mitchell P, 2007, J AUTISM DEV DISORD, V37, P589, DOI 10.1007/s10803-006-0189-8; Moore M, 2000, J AUTISM DEV DISORD, V30, P359, DOI 10.1023/A:1005535602064; Moree BN, 2010, RES AUTISM SPECT DIS, V4, P346, DOI 10.1016/j.rasd.2009.10.015; National Institute for Health and Care Excellence (NICE), 2011, REC REF DIAGN CHILDR, V128; Nauta MH, 2004, BEHAV RES THER, V42, P813, DOI 10.1016/S0005-7967(03)00200-6; O'Riordan MA, 2001, J EXP PSYCHOL HUMAN, V27, P719, DOI 10.1037//0096-1523.27.3.719; Ollendick TH, 2006, HDB INTERVENTIONS WO, P3; Ozsivadjian Ann, 2011, Clin Child Psychol Psychiatry, V16, P203, DOI 10.1177/1359104511404749; Pine DS, 1998, ARCH GEN PSYCHIAT, V55, P56, DOI 10.1001/archpsyc.55.1.56; Puleo CM, 2011, J AUTISM DEV DISORD, V41, P275, DOI 10.1007/s10803-010-1047-2; Rieffe C, 2007, J AUTISM DEV DISORD, V37, P455, DOI 10.1007/s10803-006-0171-5; Rothbaum BO, 1999, BEHAV MODIF, V23, P507, DOI 10.1177/0145445599234001; Samson AC, 2012, EMOTION, V12, P659, DOI 10.1037/a0027975; Silverman W. K., 1996, ANXIETY DISORDERS IN; Simonoff E, 2008, J AM ACAD CHILD PSY, V47, P921, DOI 10.1097/CHI.0b013e318179964f; Slater M, 2006, CYBERPSYCHOL BEHAV, V9, P627, DOI 10.1089/cpb.2006.9.627; Sofronoff K, 2005, J CHILD PSYCHOL PSYC, V46, P1152, DOI 10.1111/j.1469-7610.2005.00411.x; Spence SH, 1998, BEHAV RES THER, V36, P545, DOI 10.1016/S0005-7967(98)00034-5; Strickland DC, 2007, TOP LANG DISORD, V27, P226, DOI 10.1097/01.TLD.0000285357.95426.72; van Steensel FJA, 2013, J AUTISM DEV DISORD, P1; Wallace S, 2010, AUTISM, V14, P199, DOI 10.1177/1362361310363283; Witwer AN, 2010, J DEV PHYS DISABIL, V22, P367, DOI 10.1007/s10882-010-9194-0; Wood JJ, 2010, CLIN PSYCHOL-SCI PR, V17, P281, DOI 10.1111/j.1468-2850.2010.01220.x	49	84	89	3	85	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 2	2014	9	7							e100374	10.1371/journal.pone.0100374	http://dx.doi.org/10.1371/journal.pone.0100374			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AO5BA	24987957	Green Submitted, Green Published, gold			2023-01-03	WOS:000341354100029
J	Wells, C; Kolt, GS; Marshall, P; Hill, B; Bialocerkowski, A				Wells, Cherie; Kolt, Gregory S.; Marshall, Paul; Hill, Bridget; Bialocerkowski, Andrea			The Effectiveness of Pilates Exercise in People with Chronic Low Back Pain: A Systematic Review	PLOS ONE			English	Review							FUNCTIONAL DISABILITY; GENERAL EXERCISE; DELPHI SURVEY; PERSISTENT; OUTCOMES; THERAPY; TRIALS; MANAGEMENT; BURDEN	Objective: To evaluate the effectiveness of Pilates exercise in people with chronic low back pain (CLBP) through a systematic review of randomised controlled trials (RCTs). Data Sources: A search for RCTs was undertaken using Medical Search Terms and synonyms for "Pilates" and "low back pain" within the maximal date range of 10 databases. Databases included the Cumulative Index to Nursing and Allied Health Literature; Cochrane Library; Medline; Physiotherapy Evidence Database; ProQuest: Health and Medical Complete, Nursing and Allied Health Source, Dissertation and Theses; Scopus; Sport Discus; Web of Science. Study Selection: Two independent reviewers were involved in the selection of evidence. To be included, relevant RCTs needed to be published in the English language. From 152 studies, 14 RCTs were included. Data Extraction: Two independent reviewers appraised the methodological quality of RCTs using the McMaster Critical Review Form for Quantitative Studies. The author(s), year of publication, and details regarding participants, Pilates exercise, comparison treatments, and outcome measures, and findings, were then extracted. Data Synthesis: The methodological quality of RCTs ranged from "poor" to "excellent". A meta-analysis of RCTs was not undertaken due to the heterogeneity of RCTs. Pilates exercise provided statistically significant improvements in pain and functional ability compared to usual care and physical activity between 4 and 15 weeks, but not at 24 weeks. There were no consistent statistically significant differences in improvements in pain and functional ability with Pilates exercise, massage therapy, or other forms of exercise at any time period. Conclusions: Pilates exercise offers greater improvements in pain and functional ability compared to usual care and physical activity in the short term. Pilates exercise offers equivalent improvements to massage therapy and other forms of exercise. Future research should explore optimal Pilates exercise designs, and whether some people with CLBP may benefit from Pilates exercise more than others.	[Wells, Cherie] Univ Canberra, Fac Hlth, Bruce, ACT, Australia; [Wells, Cherie; Kolt, Gregory S.; Marshall, Paul] Univ Western Sydney, Sch Sci & Hlth, Campbelltown, NSW, Australia; [Hill, Bridget] Epworth HealthCare, Richmond, Vic, Australia; [Bialocerkowski, Andrea] Griffith Univ, Griffith Hlth Inst, Gold Coast, Qld, Australia	University of Canberra; Western Sydney University; Griffith University; Menzies Health Institute Queensland	Wells, C (corresponding author), Univ Canberra, Fac Hlth, Bruce, ACT, Australia.	Cherie.Wells@canberra.edu.au	Kolt, Gregory/W-1342-2019	Kolt, Gregory/0000-0002-9223-3324; Hill, Bridget/0000-0002-8632-094X; Wells, Cherie/0000-0002-4424-1207				Aladro-Gonzalvo AR, 2013, J BODYW MOV THER, V17, P125, DOI 10.1016/j.jbmt.2012.08.003; Anderson B, 2005, THESIS U MIAMI MIAMI; Australian Government: National Health Medical Research Council (NHMRC), 2009, NHMRC ADD LEV EV GRA; Borges J, 2014, J BODYW MOV THER, V18, P68, DOI 10.1016/j.jbmt.2013.05.010; Brennan S, 2008, PHYS THER REV, V13, P212; Brooks C, 2012, SPINE, V37, pE1543, DOI 10.1097/BRS.0b013e31826feac0; Chapman JR, 2011, SPINE, V36, pS54, DOI 10.1097/BRS.0b013e31822ef74d; Colle F, 2002, ARCH PHYS MED REHAB, V83, P1745, DOI 10.1053/apmr.2002.35657; Collins J, HUM REPROD UPDATE, V11, P103; Cook DJ, 1997, ANN INTERN MED, V126, P376, DOI 10.7326/0003-4819-126-5-199703010-00006; Costa LOP, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD010265, DOI 10.1002/14651858.CD010265]; da Fonseca JL, 2009, J SPORT REHABIL, V18, P269, DOI 10.1123/jsr.18.2.269; Da Luz MA, 2014, PHYS THER, V94, P623, DOI 10.2522/ptj.20130277; Dagenais S, 2008, SPINE J, V8, P8, DOI 10.1016/j.spinee.2007.10.005; Daly AE, 2009, EUR J PAIN, V13, P339, DOI 10.1016/j.ejpain.2008.05.003; Dworkin RH, 2005, PAIN, V113, P9, DOI 10.1016/j.pain.2004.09.012; Edmond-Charlton, 2005, CHAPTER 12 SEX GENDE; Fletcher J, 2007, BMJ-BRIT MED J, V334, P94, DOI 10.1136/bmj.39057.406644.68; Gagnon LH, 2005, EFFICACY PILATES EXE; Gladwell V, 2006, J SPORT REHABIL, V15, P338, DOI 10.1123/jsr.15.4.338; Hayden JA, 2005, ANN INTERN MED, V142, P776, DOI 10.7326/0003-4819-142-9-200505030-00014; Herbert R., 2013, CONFIDENCE INTERVAL; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hopewell S, 2008, LANCET, V371, P281, DOI 10.1016/S0140-6736(07)61835-2; Hoy D, 2010, BEST PRACT RES CL RH, V24, P155, DOI 10.1016/j.berh.2009.11.002; Kamper SJ, 2014, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000335.PUB2; Katrak Persis, 2004, BMC Med Res Methodol, V4, P22, DOI 10.1186/1471-2288-4-22; Kawanishi CY, 2011, REV TERAPIA MANUAL, V9, P410; Kunz R, 2007, COCHRANE DB SYST REV, V2; La Touche R, 2008, J BODYW MOV THER, V12, P364, DOI 10.1016/j.jbmt.2007.11.004; Latey P., 2001, J BODYW MOV THER, V5, P275, DOI [10.1054/jbmt.2001.0237, DOI 10.1054/JBMT.2001.0237]; Law M, 1998, EVIDENCE BASED REHAB; Lekkas P, 2007, AUST J PHYSIOTHER, V53, P19, DOI 10.1016/S0004-9514(07)70058-2; Lim ECW, 2011, J ORTHOP SPORT PHYS, V41, P70, DOI 10.2519/jospt.2011.3393; Macedo LG, 2009, PHYS THER, V89, P9, DOI 10.2522/ptj.20080103; MacIntyre L, 2006, THESIS U WITWATERSRA; Marshall PWM, 2013, SPINE, V38, pE952, DOI 10.1097/BRS.0b013e318297c1e5; Miyamoto GC, 2013, BRAZ J PHYS THER, V17, P517, DOI 10.1590/S1413-35552012005000127; Miyamoto GC, 2013, PHYS THER, V93, P310, DOI 10.2522/ptj.20120190; Montero-Camara J., 2013, FISIOTERAPIA, V35, P206, DOI [10.1016/j.ft.2012.10.004, DOI 10.1016/J.FT.2012.10.004]; Noordzij M, 2010, NEPHROL DIAL TRANSPL, V25, P1388, DOI 10.1093/ndt/gfp732; Ostelo RWJG, 2008, SPINE, V33, P90, DOI 10.1097/BRS.0b013e31815e3a10; Ostelo RWJG, 2005, BEST PRACT RES CL RH, V19, P593, DOI 10.1016/j.berh.2005.03.003; Pereira LM, 2012, CLIN REHABIL, V26, P10, DOI 10.1177/0269215511411113; Pillastrini P, 2012, JOINT BONE SPINE, V79, P176, DOI 10.1016/j.jbspin.2011.03.019; Posadzki Paul, 2011, Complement Ther Clin Pract, V17, P85, DOI 10.1016/j.ctcp.2010.09.005; Quinn J, 2005, THESIS FLORIDA ATLAN; Quinn K, 2011, PHYSIOTHERAPY IRELAN, V32, P5; Rajpal N, 2008, PHYSIOTHERAPY OCCUPA, V1, P33; Riley RD, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d549; Rydeard RA, 2001, THESIS QUEENS U KING; Rydeard R, 2006, J ORTHOP SPORT PHYS, V36, P472, DOI 10.2519/jospt.2006.2144; Schabrun SM, 2009, CLIN REHABIL, V23, P27, DOI 10.1177/0269215508098897; Stolze LR, 2012, J ORTHOP SPORT PHYS, V42, P425, DOI 10.2519/jospt.2012.3826; The Cochrane Collaboration, 2012, REV MAN REVMAN VERS; van Tulder M, 2007, SPINE, V32, P1785, DOI 10.1097/BRS.0b013e3180b9ef49; Viera AJ, 2005, FAM MED, V37, P360; Wajswelner H, 2012, MED SCI SPORT EXER, V44, P1197, DOI 10.1249/MSS.0b013e318248f665; Wells C, 2014, PHYS THER, V94, P806, DOI 10.2522/ptj.20130568; Wells C, 2014, PHYS THER, V94, P792, DOI 10.2522/ptj.20130030; Wells C, 2012, COMPLEMENT THER MED, V20, P253, DOI 10.1016/j.ctim.2012.02.005; Welss C, 2013, BMC MED RES METHODOL, V19, P13, DOI DOI 10.1186/1471-2288-13-7; Woolf AD, 2003, B WORLD HEALTH ORGAN, V81, P646; Zeada MA, 2011, OVIDIUS U ANN SERIES, V12, P41	64	65	67	2	96	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 1	2014	9	7							e100402	10.1371/journal.pone.0100402	http://dx.doi.org/10.1371/journal.pone.0100402			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM1UX	24984069	Green Published, gold			2023-01-03	WOS:000339635000022
J	Feng, DJ; Ji, LQ; Xu, LZ				Feng, Danjun; Ji, Linqin; Xu, Lingzhong			Mediating Effect of Social Support on the Association between Functional Disability and Psychological Distress in Older Adults in Rural China: Does Age Make a Difference?	PLOS ONE			English	Article							DEPRESSIVE SYMPTOMS; AFRICAN-AMERICAN; MENTAL-ILLNESS; LIFE; PREVALENCE; ANXIETY; STRESS	This study aimed to determine the prevalence of psychological distress among elderly people in rural China. Moreover, the mediating effect of social support on the association between functional disability and psychological distress and whether this effect varies with age would be examined. A total of 741 elderly people aged 60-89 years from a rural area of Shandong Province, China participated in a cross-sectional survey. Their psychological distress, perceived social support, enacted social support, and functional disability were assessed through questionnaires. A total of 217 (29.3%) rural elderly people had psychological distress. The functional disability of people >= 75 years old had smaller total effects (0.18) on their psychological distress than in people <75 years old (0.30). Moreover, most of the effects of functional disability on psychological distress among the people >= 75 years old were indirect (0.12; 66.67% of total effects) through the mediating effect of social support especially perceived support, while the direct effect of functional disability was insignificant. In contrast, most of the effects of functional disability on psychological distress among the people <75 years old were direct (0.29; 96.67% of total effects), while the mediating effect of social support was insignificant. In conclusion, the total effect of functional disability, especially the direct effect, on psychological distress decreases sharply with age. The mediating effect of social support on the association between functional disability and psychological distress varies with age and is only found in people >= 75 years.	[Feng, Danjun] Shandong Univ, Sch Nursing, Jinan 250100, Peoples R China; [Ji, Linqin] Shandong Normal Univ, Sch Psychol, Jinan, Peoples R China; [Xu, Lingzhong] Shandong Univ, Dept Hlth Serv Management & Maternal & Child Heal, Jinan 250100, Peoples R China	Shandong University; Shandong Normal University; Shandong University	Xu, LZ (corresponding author), Shandong Univ, Dept Hlth Serv Management & Maternal & Child Heal, Jinan 250100, Peoples R China.	lzxu@sdu.edu.cn			Ministry of Education in China [10YJCXLX007]; Project of Humanities and Social Sciences	Ministry of Education in China(Ministry of Education, China); Project of Humanities and Social Sciences	This study was supported by the Ministry of Education in China, Project of Humanities and Social Sciences (grant No. 10YJCXLX007). The URL of its website is http://www.sinoss.net/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BARRERA M, 1986, AM J COMMUN PSYCHOL, V14, P413, DOI 10.1007/BF00922627; Bierman A, 2010, J GERONTOL B-PSYCHOL, V65, P631, DOI 10.1093/geronb/gbp128; Briere J, 2010, J TRAUMA STRESS, V23, P767, DOI 10.1002/jts.20578; Chen RL, 2005, ARCH INTERN MED, V165, P2019, DOI 10.1001/archinte.165.17.2019; Department of Human Services, 2008, VICT POP HLTH SURV 2; Elder GH, 2003, HDB LIFE COURSE, P3, DOI DOI 10.1007/978-0-306-48247-2_1; ENSEL WM, 1991, J HEALTH SOC BEHAV, V32, P321, DOI 10.2307/2137101; Hamano T, 2011, STRESS HEALTH, V27, P163, DOI 10.1002/smi.1324; He W.-M., 2007, INT J OPHTHALMOL-CHI, V7, P854; Hooper D., 2008, ELECT J BUSINESS RES, V6, P53, DOI 10.21427/D7CF7R; Huang JP, 2009, AUST NZ J PSYCHIAT, V43, P674, DOI 10.1080/00048670902970817; Hudson CG, 2005, AM J ORTHOPSYCHIAT, V75, P3, DOI 10.1037/0002-9432.75.1.3; Jang Y, 2005, J GERONTOL B-PSYCHOL, V60, pP313, DOI 10.1093/geronb/60.6.P313; Jang YR, 2004, INT J AGING HUM DEV, V59, P125, DOI 10.2190/RT1W-2HD7-KG5X-K1FB; Kessler RC, 2003, ARCH GEN PSYCHIAT, V60, P184, DOI 10.1001/archpsyc.60.2.184; Kuriyama S, 2009, J EPIDEMIOL, V19, P294, DOI 10.2188/jea.JE20080076; Liu JF, 2009, GERIATR GERONTOL INT, V9, P253, DOI 10.1111/j.1447-0594.2009.00529.x; Miller NB, 1998, J FAM ISSUES, V19, P181, DOI 10.1177/019251398019002004; Prelow HM, 2006, J BLACK PSYCHOL, V32, P442, DOI 10.1177/0095798406292677; Prina AM, 2011, BRIT J PSYCHIAT, V199, P485, DOI 10.1192/bjp.bp.110.083915; Ross CE, 2008, J AGING HEALTH, V20, P273, DOI 10.1177/0898264308315428; Schieman S, 1998, J HEALTH SOC BEHAV, V39, P169, DOI 10.2307/2676310; Schnittker J, 2005, SOC SCI MED, V60, P13, DOI 10.1016/j.socscimed.2004.04.020; Sicular T, 2007, REV INCOME WEALTH, V53, P93, DOI 10.1111/j.1475-4991.2007.00219.x; Suttajit S, 2010, PSYCHOL MED, V40, P1711, DOI 10.1017/S003329170999208X; Vaeroy H, 2005, NORD J PSYCHIAT, V59, P109, DOI 10.1080/08039480510022945; Yang Y, 2006, J HEALTH SOC BEHAV, V47, P355, DOI 10.1177/002214650604700404; [周成超 ZHOU Chengchao], 2008, [中国临床心理学杂志, Chinese Journal of Clinical Psychology], V16, P627	28	12	13	3	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2014	9	6							e100945	10.1371/journal.pone.0100945	http://dx.doi.org/10.1371/journal.pone.0100945			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AK8WO	24963867	Green Published, Green Submitted, gold			2023-01-03	WOS:000338709500103
J	Shibuya, KC; Goel, VK; Xiong, W; Sham, JG; Pollack, SM; Leahy, AM; Whiting, SH; Yeh, MM; Yee, C; Riddell, SR; Pillarisetty, VG				Shibuya, Kendall C.; Goel, Vikas K.; Xiong, Wei; Sham, Jonathan G.; Pollack, Seth M.; Leahy, Allison M.; Whiting, Samuel H.; Yeh, Matthew M.; Yee, Cassian; Riddell, Stanley R.; Pillarisetty, Venu G.			Pancreatic Ductal Adenocarcinoma Contains an Effector and Regulatory Immune Cell Infiltrate that Is Altered by Multimodal Neoadjuvant Treatment	PLOS ONE			English	Article							T-CELLS; TUMOR MICROENVIRONMENT; CLINICAL-SIGNIFICANCE; PERIPHERAL-BLOOD; SUPPRESSOR-CELLS; BONE-MARROW; TH17 CELLS; CANCER; CARCINOMA; GEMCITABINE	Objective: The immune response to pancreatic ductal adenocarcinoma (PDA) may play a role in defining its uniquely aggressive biology; therefore, we sought to clearly define the adaptive immune infiltrate in PDA. Design: We used immunohistochemistry and flow cytometry to characterize the immune infiltrate in human PDA and compared our findings to the patients' peripheral blood. Results: In contrast to the myeloid cell predominant infiltrate seen in murine models, T cells comprised the majority of the hematopoietic cell component of the tumor stroma in human PDA. Most intratumoral CD8(+) T cells exhibited an antigen-experienced effector memory cell phenotype and were capable of producing IFN-gamma. CD4(+) regulatory T cells (Treg) and IL-17 producing T helper cells were significantly more prevalent in tumor than in blood. Consistent with the association with reduced survival in previous studies, we observed higher frequencies of both myeloid cells and Treg in poorly differentiated tumors. The majority of intratumoral T cells expressed the co-inhibitory receptor programmed death-1 (PD-1), suggesting one potential mechanism through which PDA may evade antitumor immunity. Successful multimodal neoadjuvant therapy altered the immunoregulatory balance and was associated with reduced infiltration of both myeloid cells and Treg. Conclusion: Our data show that human PDA contains a complex mixture of inflammatory and regulatory immune cells, and that neoadjuvant therapy attenuates the infiltration of intratumoral cells associated with immunosuppression and worsened survival.	[Shibuya, Kendall C.; Pollack, Seth M.; Yee, Cassian; Riddell, Stanley R.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA; [Pollack, Seth M.; Whiting, Samuel H.; Yeh, Matthew M.; Yee, Cassian; Riddell, Stanley R.] Univ Washington, Dept Med, Seattle, WA USA; [Xiong, Wei; Yeh, Matthew M.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA; [Goel, Vikas K.; Sham, Jonathan G.; Pillarisetty, Venu G.] Univ Washington, Dept Surg, Seattle, WA 98195 USA; [Leahy, Allison M.] Seattle Canc Care Alliance, Seattle, WA USA; [Xiong, Wei] Univ Calgary, Dept Pathol & Lab Med, Calgary, AB, Canada	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Seattle Cancer Care Alliance; University of Calgary	Pillarisetty, VG (corresponding author), Univ Washington, Dept Surg, Seattle, WA 98195 USA.	vgp@uw.edu	Pillarisetty, Venu/AAF-4425-2020; Pollack, Seth/ABI-1013-2020	Pillarisetty, Venu/0000-0002-1162-9643; 	NIH Cancer Center Support Grant [NIH R01 CA114536]; Fred Hutchinson/University of Washington Cancer Consortium; University of Washington Department of Surgery Research Reinvestment Fund; NATIONAL CANCER INSTITUTE [K23CA175167, R01CA114536] Funding Source: NIH RePORTER	NIH Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fred Hutchinson/University of Washington Cancer Consortium; University of Washington Department of Surgery Research Reinvestment Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NIH Cancer Center Support Grant, NIH R01 CA114536 (SRR), Fred Hutchinson/University of Washington Cancer Consortium Startup Funding (VGP), and the University of Washington Department of Surgery Research Reinvestment Fund (VGP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bayne LJ, 2012, CANCER CELL, V21, P822, DOI 10.1016/j.ccr.2012.04.025; Beatty GL, 2011, SCIENCE, V331, P1612, DOI 10.1126/science.1198443; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Clark CE, 2007, CANCER RES, V67, P9518, DOI 10.1158/0008-5472.CAN-07-0175; Crippa S, 2012, SURGERY, V152, pS112, DOI 10.1016/j.surg.2012.05.017; Fine RL, 2008, CANCER CHEMOTH PHARM, V61, P167, DOI 10.1007/s00280-007-0473-0; Fukunaga A, 2004, PANCREAS, V28, pE26, DOI 10.1097/00006676-200401000-00023; Gabitass RF, 2011, CANCER IMMUNOL IMMUN, V60, P1419, DOI 10.1007/s00262-011-1028-0; Garnett CT, 2008, CLIN CANCER RES, V14, P3536, DOI 10.1158/1078-0432.CCR-07-4025; Geng L, 2008, J CANCER RES CLIN, V134, P1021, DOI 10.1007/s00432-008-0364-8; Gillen S, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000267; Gnerlich JL, 2010, J IMMUNOL, V185, P4063, DOI 10.4049/jimmunol.0902609; Haeno H, 2012, CELL, V148, P362, DOI 10.1016/j.cell.2011.11.060; He DG, 2010, J IMMUNOL, V184, P2281, DOI 10.4049/jimmunol.0902574; He SB, 2011, INT J MOL SCI, V12, P7424, DOI 10.3390/ijms12117424; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hinz S, 2007, CANCER RES, V67, P8344, DOI 10.1158/0008-5472.CAN-06-3304; Hiraoka N, 2006, CLIN CANCER RES, V12, P5423, DOI 10.1158/1078-0432.CCR-06-0369; Homma Y, 2014, CLIN TRANSL ONCOL, V16, P330, DOI 10.1007/s12094-013-1079-0; Ikemoto T, 2006, PANCREAS, V33, P386, DOI 10.1097/01.mpa.0000240275.68279.13; Ino Y, 2013, BRIT J CANCER, V108, P914, DOI 10.1038/bjc.2013.32; Katz SC, 2013, ANN SURG ONCOL, V20, P946, DOI 10.1245/s10434-012-2668-9; Kryczek I, 2007, J IMMUNOL, V178, P6730, DOI 10.4049/jimmunol.178.11.6730; Kryczek I, 2009, BLOOD, V114, P357, DOI 10.1182/blood-2008-09-177360; Kurahara H, 2011, J SURG RES, V167, pE211, DOI 10.1016/j.jss.2009.05.026; Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499; Liyanage UK, 2006, J IMMUNOTHER, V29, P416, DOI 10.1097/01.cji.0000205644.43735.4e; Lyford-Pike S, 2013, CANCER RES, V73, P1733, DOI 10.1158/0008-5472.CAN-12-2384; Milne K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006412; Nomi T, 2007, CLIN CANCER RES, V13, P2151, DOI 10.1158/1078-0432.CCR-06-2746; Plate JMD, 2005, CANCER IMMUNOL IMMUN, V54, P915, DOI 10.1007/s00262-004-0638-1; Porembka MR, 2012, CANCER IMMUNOL IMMUN, V61, P1373, DOI 10.1007/s00262-011-1178-0; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Ryschich E, 2005, CLIN CANCER RES, V11, P498; Sakuishi K, 2010, J EXP MED, V207, P2187, DOI 10.1084/jem.20100643; Schmitz-Winnenthal FH, 2005, CANCER RES, V65, P10079, DOI 10.1158/0008-5472.CAN-05-1098; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Vincent J, 2010, CANCER RES, P3052; Vonderheide RH, 2013, CURR OPIN IMMUNOL, V25, P200, DOI 10.1016/j.coi.2013.01.006; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yoon HH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042274	43	92	97	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2014	9	5							e96565	10.1371/journal.pone.0096565	http://dx.doi.org/10.1371/journal.pone.0096565			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI1ZS	24794217	gold, Green Published, Green Submitted			2023-01-03	WOS:000336655700114
J	Olsen, CM; Knight, LL; Green, AC				Olsen, Catherine M.; Knight, Lani L.; Green, Adele C.			Risk of Melanoma in People with HIV/AIDS in the Pre- and Post-HAART Eras: A Systematic Review and Meta-Analysis of Cohort Studies	PLOS ONE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; AIDS-DEFINING CANCERS; HIV-INFECTION; UNITED-STATES; TRANSPLANT RECIPIENTS; IMMUNOSUPPRESSION; RECOMMENDATIONS; HETEROGENEITY; EPIDEMIOLOGY	Objective: Following the introduction of highly active antiretroviral therapy (HAART) the risk of AIDS-defining cancers decreased but incidence of many non-AIDS-defining cancers has reportedly increased in those with HIV/AIDS. Whether melanoma risk has also changed in HIV/AIDS patients post-HAART is unknown and therefore we evaluated this in comparison with the risk before HAART. Design: Systematic review and meta-analysis. Methods: We searched Medline, Embase and ISI science citation index databases to April 2013. All cohort studies of patients diagnosed with HIV/AIDS that permitted quantitative assessment of the association with melanoma were eligible. Detailed quality assessment of eligible studies was conducted, focussing particularly on adjustment for ethnicity, a priori considered essential for an unbiased assessment of melanoma risk. Data were pooled using a random effects model. Results: From 288 articles, we identified 21 that met the inclusion criteria, 13 presenting data for the post-HAART era and 8 for the pre-HAART era. Post-HAART the pooled relative risk (pRR) for the association between HIV/AIDS and melanoma was 1.26 (95% CI, 0.97-1.64) and 1.50 (95% CI 1.12-2.01) among studies that accounted for ethnicity, with evidence of significant heterogeneity (P = 0.004, I-2 = 55.5). Pre-HAART pRRs were 1.26 (95% CI 1.11-1.43; P-het = 0.82) and 1.28 (95% CI 1.10-1.49) among studies adjusted for ethnicity. Conclusions: People with HIV/AIDS remain at a significantly increased risk of developing melanoma in the post-HAART era. White skinned people with HIV/AIDS should be screened regularly and counselled against excessive sun exposure.	[Olsen, Catherine M.; Knight, Lani L.; Green, Adele C.] QIMR Berghofer Med Res Inst, Dept Populat Hlth, Brisbane, Qld, Australia; [Green, Adele C.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Inst Inflammat & Repair, Manchester, Lancs, England	QIMR Berghofer Medical Research Institute; University of Manchester	Olsen, CM (corresponding author), QIMR Berghofer Med Res Inst, Dept Populat Hlth, Brisbane, Qld, Australia.	Catherine.Olsen@qimr.edu.au	Green, Adele C/B-5324-2011; Green, Adele C/P-2736-2014; Olsen, Catherine/C-8785-2009	Green, Adele C/0000-0002-2753-4841; Olsen, Catherine/0000-0003-4483-1888				Bedimo RJ, 2009, JAIDS-J ACQ IMM DEF, V52, P203, DOI 10.1097/QAI.0b013e3181b033ab; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Calabresi A, 2013, HIV MED; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; Cebon Jonathan, 2007, Clin Adv Hematol Oncol, V5, P994; Cooksley CD, 1999, INT J STD AIDS, V10, P795, DOI 10.1258/0956462991913574; Cress RD, 1997, CANCER CAUSE CONTROL, V8, P246, DOI 10.1023/A:1018432632528; Dal Maso L, 2009, BRIT J CANCER, V100, P840, DOI 10.1038/sj.bjc.6604923; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dubrow R, 2012, CURR OPIN ONCOL, V24, P506, DOI 10.1097/CCO.0b013e328355e131; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Engels EA, 2008, INT J CANCER, V123, P187, DOI 10.1002/ijc.23487; Engels EA, 2006, AIDS, V20, P1645, DOI 10.1097/01.aids.0000238411.75324.59; Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027; Flegg P J, 1990, Int J STD AIDS, V1, P46; Franceschi S, 2010, BRIT J CANCER, V103, P416, DOI 10.1038/sj.bjc.6605756; Frisch M, 2001, JAMA-J AM MED ASSOC, V285, P1736, DOI 10.1001/jama.285.13.1736; Gallagher B, 2001, AM J EPIDEMIOL, V154, P544, DOI 10.1093/aje/154.6.544; Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2; Hardy RJ, 1998, STAT MED, V17, P841, DOI 10.1002/(SICI)1097-0258(19980430)17:8<841::AID-SIM781>3.0.CO;2-D; Herida M, 2003, J CLIN ONCOL, V21, P3447, DOI 10.1200/JCO.2003.01.096; Hessol NA, 2004, JAIDS-J ACQ IMM DEF, V36, P978, DOI 10.1097/00126334-200408010-00013; Hessol NA, 2007, AM J EPIDEMIOL, V165, P1143, DOI 10.1093/aje/kwm017; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Houghton AN, 2001, CURR OPIN IMMUNOL, V13, P134, DOI 10.1016/S0952-7915(00)00195-3; Kalialis LV, 2009, MELANOMA RES, V19, P275, DOI 10.1097/CMR.0b013e32832eabd5; Le Gal FA, 2001, J INVEST DERMATOL, V117, P1464, DOI 10.1046/j.0022-202x.2001.01605.x; Long JL, 2008, AIDS, V22, P489, DOI 10.1097/QAD.0b013e3282f47082; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Moore RD, 2011, CLIN INFECT DIS, V52, pS208, DOI 10.1093/cid/ciq044; Newnham A, 2005, BRIT J CANCER, V92, P194, DOI 10.1038/sj.bjc.6602273; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Patel P, 2008, ANN INTERN MED, V148, P728, DOI 10.7326/0003-4819-148-10-200805200-00005; Powles T, 2009, J CLIN ONCOL, V27, P884, DOI 10.1200/JCO.2008.19.6626; Seaberg EC, 2010, CANCER-AM CANCER SOC, V116, P5507, DOI 10.1002/cncr.25530; Serraino D, 2007, EUR J CANCER, V43, P2117, DOI 10.1016/j.ejca.2007.07.015; Shiels MS, 2009, JAIDS-J ACQ IMM DEF, V52, P611, DOI 10.1097/QAI.0b013e3181b327ca; Silverberg MJ, 2013, JNCI-J NATL CANCER I, V105, P350, DOI 10.1093/jnci/djs529; Silverberg MJ, 2011, CANCER EPIDEM BIOMAR, V20, P2551, DOI 10.1158/1055-9965.EPI-11-0777; Simard EP, 2010, ARCH INTERN MED, V170, P1337, DOI 10.1001/archinternmed.2010.253; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; van Leeuwen MT, 2009, AIDS, V23, P2183, DOI 10.1097/QAD.0b013e328331d384; Vandenbroucke JP, 2007, ANN INTERN MED, V147, pW163, DOI 10.7326/0003-4819-147-8-200710160-00010-w1; Vella S, 2012, AIDS, V26, P1231, DOI 10.1097/QAD.0b013e32835521a3; Vogel M, 2011, EUR J MED RES, V16, P101, DOI 10.1186/2047-783X-16-3-101; Wong WCW, 2008, EMERG THEMES EPIDEMI, V5, DOI 10.1186/1742-7622-5-23; World Health Organization, 2006, WHO CAS DEF HIV SURV; Yeni PG, 2002, JAMA-J AM MED ASSOC, V288, P222, DOI 10.1001/jama.288.2.222	50	38	38	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2014	9	4							e95096	10.1371/journal.pone.0095096	http://dx.doi.org/10.1371/journal.pone.0095096			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI4VW	24740329	Green Published, gold, Green Submitted			2023-01-03	WOS:000336863900101
J	Stevenson, DG; Huskamp, HA				Stevenson, David G.; Huskamp, Haiden A.			Integrating Care at the End of Life Should Medicare Advantage Include Hospice?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PALLIATIVE CARE		[Stevenson, David G.] Vanderbilt Univ, Sch Med, Dept Hlth Policy, Nashville, TN 37215 USA; [Huskamp, Haiden A.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA	Vanderbilt University; Harvard University; Harvard Medical School	Stevenson, DG (corresponding author), Vanderbilt Univ, Sch Med, Dept Hlth Policy, 2525 W End Ave,Ste 1200, Nashville, TN 37215 USA.	david.stevenson@vanderbilt.edu			NIA NIH HHS [K01 AG038481] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K01AG038481] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Dahlin CM, 2010, INT J PALLIAT NURS, V16, P420, DOI 10.12968/ijpn.2010.16.9.78633; Harrison S, 2013, PRESENTED AT MEDICAR; Spettell CM, 2009, J PALLIAT MED, V12, P827, DOI 10.1089/jpm.2009.0089; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Teno JM, 2013, JAMA-J AM MED ASSOC, V309, P470, DOI 10.1001/jama.2012.207624	5	11	11	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	2014	311	15					1493	1494		10.1001/jama.2014.1018	http://dx.doi.org/10.1001/jama.2014.1018			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AE9DX	24633593	Green Accepted			2023-01-03	WOS:000334306000013
J	Courtois, A; Berthou, C; Guezennec, J; Boisset, C; Bordron, A				Courtois, Anthony; Berthou, Christian; Guezennec, Jean; Boisset, Claire; Bordron, Anne			Exopolysaccharides Isolated from Hydrothermal Vent Bacteria Can Modulate the Complement System	PLOS ONE			English	Article							SURFACE-PLASMON RESONANCE; POLYSACCHARIDES; PATHWAY; C1Q; ACTIVATION; EXPRESSION; ANTITUMOR; CLEAVAGE; BINDING; C3B	The complement system is involved in the defence against bacterial infection, or in the elimination of tumour cells. However, disturbances in this system contributes to the pathogenesis of various inflammatory diseases. The efficiency of therapeutic anti-tumour antibodies is enhanced when the complement system is stimulated. In contrast, cancer cells are able to inhibit the complement system and thus proliferate. Some marine molecules are currently being developed as new drugs for use in humans. Among them, known exopolyssacharides (EPSs) generally originate from fungi, but few studies have been performed on bacterial EPSs and even fewer on EPSs extracted from deep-sea hydrothermal vent microbes. For use in humans, these high molecular weight EPSs must be depolymerised. Furthermore, the over-sulphation of EPSs can modify their biological activity. The aim of this study was to investigate the immunodulation of the complement system by either native or over-sulphated low molecular weight EPSs isolated from vent bacteria in order to find pro or anti-activators of complement.	[Courtois, Anthony; Guezennec, Jean; Boisset, Claire] IFREMER, Biotechnol & Marine Mol Lab, Brest, France; [Courtois, Anthony; Berthou, Christian; Bordron, Anne] Univ Hosp Brest, Cellular Therapy & Immunobiol Canc Lab, Brest, France	Ifremer; CHU Brest; Universite de Bretagne Occidentale	Bordron, A (corresponding author), Univ Hosp Brest, Cellular Therapy & Immunobiol Canc Lab, Brest, France.	anne.bordron@univ-brest.fr	Bordron, Anne/Y-1615-2019	Bordron, Anne/0000-0002-7886-2546	Brest Metropole Oceane; "Celine et Stephane" association; Canceropole Grand Ouest	Brest Metropole Oceane(Region Bretagne); "Celine et Stephane" association; Canceropole Grand Ouest	This work was supported by Brest Metropole Oceane, the "Celine et Stephane" association and Canceropole Grand Ouest. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alberto MF, 2008, THROMB RES, V122, P109, DOI 10.1016/j.thromres.2007.09.001; Arena A, 2006, INT IMMUNOPHARMACOL, V6, P8, DOI 10.1016/j.intimp.2005.07.004; Blondin C, 1996, BIOMATERIALS, V17, P597, DOI 10.1016/0142-9612(96)88710-2; Caldwell EEO, 1999, ARCH BIOCHEM BIOPHYS, V361, P215, DOI 10.1006/abbi.1998.0996; Cheng SC, 2012, EUR J IMMUNOL, V42, P993, DOI 10.1002/eji.201142057; Courtois A, 2008, MAR DRUGS, V6, P407, DOI [10.3390/md20080019, 10.3390/md6030407]; Courtois A, 2012, ELECTRON J BIOTECHN, V15, DOI 10.2225/vol15-issue5-fulltext-3; Gadjeva M, 2001, CURR OPIN IMMUNOL, V13, P74, DOI 10.1016/S0952-7915(00)00185-0; Galili U, 2001, BIOCHIMIE, V83, P557, DOI 10.1016/S0300-9084(01)01294-9; GOOD AH, 1992, TRANSPL P, V24, P559; Hodoniczky J, 2005, BIOTECHNOL PROGR, V21, P1644, DOI 10.1021/bp050228w; Hosszu KK, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00038; Hu WG, 2011, CANCER RES, V71, P2298, DOI 10.1158/0008-5472.CAN-10-3016; Jokiranta TS, 2001, INT IMMUNOPHARMACOL, V1, P495, DOI 10.1016/S1567-5769(00)00042-4; Jouault SC, 2001, BBA-GEN SUBJECTS, V1528, P141, DOI 10.1016/S0304-4165(01)00185-4; Kazatchkine M, 1985, DOSAGES HEMOLYTIQUES, P15; Khalikova T. A., 2006, Experimental Oncology, V28, P308; Kirschfink M, 1997, J IMMUNOL, V158, P1324; Kwang-Soon S, 2007, FOOD TECHNOL BIOTECH, V45, P319; LIJOUR Y, 1994, ANAL BIOCHEM, V220, P244, DOI 10.1006/abio.1994.1334; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lutz HU, 1996, BLOOD, V88, P184; MaigaRevel O, 1997, CARBOHYD POLYM, V32, P89, DOI 10.1016/S0144-8617(96)00171-3; Makino S, 2006, J DAIRY SCI, V89, P2873, DOI 10.3168/jds.S0022-0302(06)72560-7; Makrides SC, 1998, PHARMACOL REV, V50, P59; Markiewski MM, 2007, AM J PATHOL, V171, P715, DOI 10.2353/ajpath.2007.070166; McDonnell JM, 2001, CURR OPIN CHEM BIOL, V5, P572, DOI 10.1016/S1367-5931(00)00251-9; MULLEREB.HJ, 1969, ANNU REV BIOCHEM, V38, P389, DOI 10.1146/annurev.bi.38.070169.002133; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; Mulloy B, 2000, J BIOTECHNOL, V77, P123, DOI 10.1016/S0168-1656(99)00211-4; Nardella A, CARBOHYDR RES, V289, P201; Nwodo UU, 2012, INT J MOL SCI, V13, P14002, DOI 10.3390/ijms131114002; OKUTANI K, 1984, B JPN SOC SCI FISH, V50, P1035; Raguenes G, 1997, INT J SYST BACTERIOL, V47, P989, DOI 10.1099/00207713-47-4-989; Raguenes GHC, 1997, J APPL MICROBIOL, V82, P422, DOI 10.1046/j.1365-2672.1997.00125.x; Rougeaux H, 1999, CARBOHYD RES, V322, P40, DOI 10.1016/S0008-6215(99)00214-1; Roumenina LT, 2011, J IMMUNOL, V187, P4369, DOI 10.4049/jimmunol.1101749; Rudd PM, 2004, TRENDS BIOTECHNOL, V22, P524, DOI 10.1016/j.tibtech.2004.07.012; TALMONT F, 1991, FEBS LETT, V281, P55, DOI 10.1016/0014-5793(91)80357-9; Tissot B, 2005, BIOCHEMISTRY-US, V44, P2602, DOI 10.1021/bi047802h; Tissot B, 2003, GLYCOBIOLOGY, V13, p29G, DOI 10.1093/glycob/cwg126; Triolo G, 2003, CLIN EXP RHEUMATOL, V21, P225; Tzianabos AO, 2000, CLIN MICROBIOL REV, V13, P523, DOI 10.1128/CMR.13.4.523-533.2000; VUKAJLOVICH SW, 1986, INFECT IMMUN, V53, P480, DOI 10.1128/IAI.53.3.480-485.1986; Yamamoto F, 2004, Immunohematology, V20, P3; Zanchetta P, 2003, CALCIFIED TISSUE INT, V73, P232, DOI 10.1007/s00223-002-2081-7; Zanchetta P, 2003, CALCIFIED TISSUE INT, V72, P74, DOI 10.1007/s00223-001-2091-x	47	13	17	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2014	9	4							e94965	10.1371/journal.pone.0094965	http://dx.doi.org/10.1371/journal.pone.0094965			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI5PW	24736648	gold, Green Published			2023-01-03	WOS:000336922600113
J	Southwell, DG; Nicholas, CR; Basbaum, AI; Stryker, MP; Kriegstein, AR; Rubenstein, JL; Alvarez-Buylla, A				Southwell, Derek G.; Nicholas, Cory R.; Basbaum, Allan I.; Stryker, Michael P.; Kriegstein, Arnold R.; Rubenstein, John L.; Alvarez-Buylla, Arturo			Interneurons from Embryonic Development to Cell-Based Therapy	SCIENCE			English	Review							MEDIAL GANGLIONIC EMINENCE; EXPERIENCE-DEPENDENT PLASTICITY; STEM-CELLS; VISUAL-CORTEX; CORTICAL INTERNEURONS; GABAERGIC INTERNEURONS; DIRECTED DIFFERENTIATION; FUNCTIONAL MATURATION; NEURAL PRECURSORS; MIGRATORY STREAM		[Southwell, Derek G.; Alvarez-Buylla, Arturo] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Nicholas, Cory R.; Kriegstein, Arnold R.; Rubenstein, John L.; Alvarez-Buylla, Arturo] Univ Calif San Francisco, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco, CA 94143 USA; [Nicholas, Cory R.; Kriegstein, Arnold R.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Basbaum, Allan I.] Univ Calif San Francisco, Dept Anat, San Francisco, CA 94158 USA; [Stryker, Michael P.] Univ Calif San Francisco, Ctr Integrat Neurosci, San Francisco, CA 94143 USA; [Stryker, Michael P.] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; [Rubenstein, John L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Alvarez-Buylla, A (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.	abuylla@stemcell.ucsf.edu		Southwell, Derek/0000-0001-6465-3869; Alvarez-Buylla, Arturo/0000-0003-4426-8925; Stryker, Michael/0000-0003-1546-5831	NIH [R01-EY02874, HD032116, NS28478, MH049428, NS78326, NS14627]; California Institute of Regenerative Medicine [RC1-00346, TR3-05606, RB2-01602, TR2-01749]; JG Bowes Foundation; M.S. Scientific Advisory Board of the Allen Institute for Brain Science; National Institutes of Health; National Institute of Mental Health; California Institute for Regenerative Medicine; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD032116] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032116] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY002874, P30EY002162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH049428, R01MH049428] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028478, R01NS014627, R01NS078326, R37NS014627, R29NS028478, R37NS028478] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); California Institute of Regenerative Medicine(California Institute for Regenerative Medicine); JG Bowes Foundation; M.S. Scientific Advisory Board of the Allen Institute for Brain Science; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); California Institute for Regenerative Medicine(California Institute for Regenerative Medicine); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank S. Baraban for comments on the manuscript. We apologize to colleagues whose work we could not include because of space limitations. This work was supported by the NIH (R01-EY02874 to M.P.S., HD032116, NS28478 to A.A.-B., MH049428 to J.L.R., NS78326 and NS14627 to A.I.B.), by the California Institute of Regenerative Medicine (RC1-00346 and TR3-05606 to A.R.K., RB2-01602 to J.L.R., and TR2-01749 to A.A.-B.) and by the JG Bowes Foundation. A.A.-B., A.R.K., J.L.R., C.R.N.; Founders and shareholders, Neurona Therapeutics; M.S. Scientific Advisory Board of the Allen Institute for Brain Science. Related research in the authors' laboratories is funded by the National Institutes of Health (A.I.B., M.P.S., A.R.K., J.L.R., A.A.-B.), National Institute of Mental Health (J.L.R.), and California Institute for Regenerative Medicine (C.R.N., A.I.B., M.P.S., A.R.K., J.L.R., A.A.-B.). Patents related to this work: 20020151066 (UC Regents, issued 2000, Production of GABAergic Cells)-J.L.R., M. Mione, S. Anderson, T. Stuehmer, K. Yun; 20090311222 (UC Regents, 2006-pending, Transplantation of Neural Cells)-S. Baraban, J.L.R., A.A.-B.; 20130202568 (UC Regents, 2008-pending, Ameliorating Nervous System Disorders)-A.R.K., J.L.R., S. Baraban, A.A.-B.; 2013155222 A2 (UC Regents, 2012-pending, Brain-Specific Enhancers for Cell-Based Therapy)-V. Axel, J.L.R., Y.-J. Chen, L. Pennacchio, D. Vogt, A.R.K.; 61783594 (UC Regents, 2013-pending, In Vitro Production of Medial Ganglionic Eminence Precursor Cells)-C.R.N., J.L.R., A.R.K.	ALTMAN J, 1963, ANAT REC, V145, P573, DOI 10.1002/ar.1091450409; Alvarez-Dolado M, 2006, J NEUROSCI, V26, P7380, DOI 10.1523/JNEUROSCI.1540-06.2006; Anderson SA, 1997, SCIENCE, V278, P474, DOI 10.1126/science.278.5337.474; Au E, 2013, NEURON, V80, P1145, DOI 10.1016/j.neuron.2013.09.022; Baraban SC, 2009, P NATL ACAD SCI USA, V106, P15472, DOI 10.1073/pnas.0900141106; Bartolini G, 2013, NEURON, V79, P849, DOI 10.1016/j.neuron.2013.08.014; Ben-Ari Y, 2008, TRENDS NEUROSCI, V31, P626, DOI 10.1016/j.tins.2008.09.002; Braz JM, 2012, NEURON, V74, P663, DOI 10.1016/j.neuron.2012.02.033; Buss RR, 2006, ANNU REV NEUROSCI, V29, P1, DOI 10.1146/annurev.neuro.29.051605.112800; Butt SJB, 2005, NEURON, V48, P591, DOI 10.1016/j.neuron.2005.09.034; Calcagnotto ME, 2010, EPILEPSIA, V51, P71, DOI 10.1111/j.1528-1167.2010.02614.x; Cambray S, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1817; Chambers SM, 2009, NAT BIOTECHNOL, V27, P275, DOI 10.1038/nbt.1529; Chao HT, 2010, NATURE, V468, P263, DOI 10.1038/nature09582; Chen YJJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061956; Danjo T, 2011, J NEUROSCI, V31, P1919, DOI 10.1523/JNEUROSCI.5128-10.2011; De la Cruz E, 2011, NEUROTHERAPEUTICS, V8, P763, DOI 10.1007/s13311-011-0058-9; Dekkers MPJ, 2013, SCIENCE, V340, P39, DOI 10.1126/science.1236152; Du TG, 2008, DEVELOPMENT, V135, P1559, DOI 10.1242/dev.015123; Dunnett SB, 2012, PROG BRAIN RES, V201, P3, DOI 10.1016/B978-0-444-59544-7.00017-2; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fagiolini M, 2004, SCIENCE, V303, P1681, DOI 10.1126/science.1091032; Failor S, 2010, J NEUROSCI, V30, P81, DOI 10.1523/JNEUROSCI.5656-08.2010; Fogarty M, 2007, J NEUROSCI, V27, P10935, DOI 10.1523/JNEUROSCI.1629-07.2007; Gage FH, 2012, PROG BRAIN RES, V200, P7, DOI 10.1016/B978-0-444-59575-1.00001-6; GOLDMAN SA, 1983, P NATL ACAD SCI-BIOL, V80, P2390, DOI 10.1073/pnas.80.8.2390; Gonchar Yuri, 2007, Front Neuroanat, V1, P3, DOI 10.3389/neuro.05.003.2007; Gordon JA, 1996, J NEUROSCI, V16, P3274; Goulburn AL, 2012, STEM CELL RES, V8, P416, DOI 10.1016/j.scr.2011.12.002; Goulburn AL, 2011, STEM CELLS, V29, P462, DOI 10.1002/stem.587; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; GRAYBIEL AM, 1989, J NEUROSCI, V9, P3250; HAMBURGER V, 1949, J EXP ZOOL, V111, P457, DOI 10.1002/jez.1401110308; Hanover JL, 1999, J NEUROSCI, V19, part. no.; Hansen DV, 2013, NAT NEUROSCI, V16, P1576, DOI 10.1038/nn.3541; Hebert JM, 2008, NAT REV NEUROSCI, V9, P678, DOI 10.1038/nrn2463; Hensch TK, 2005, NAT REV NEUROSCI, V6, P877, DOI 10.1038/nrn1787; Hensch TK, 1998, SCIENCE, V282, P1504, DOI 10.1126/science.282.5393.1504; Hoch RV, 2009, SEMIN CELL DEV BIOL, V20, P378, DOI 10.1016/j.semcdb.2009.02.005; Hunt RF, 2013, NAT NEUROSCI, V16, P692, DOI 10.1038/nn.3392; Inan M, 2012, CEREB CORTEX, V22, P820, DOI 10.1093/cercor/bhr148; ISACSON O, 1987, NEUROSCIENCE, V22, P481, DOI 10.1016/0306-4522(87)90348-4; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; Kato M, 2005, J CHILD NEUROL, V20, P392, DOI 10.1177/08830738050200042001; Kawaguchi Y, 1997, CEREB CORTEX, V7, P476, DOI 10.1093/cercor/7.6.476; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; Kornack DR, 2001, P NATL ACAD SCI USA, V98, P4752, DOI 10.1073/pnas.081074998; Letinic K, 2002, NATURE, V417, P645, DOI 10.1038/nature00779; LEVIMONTALCINI R, 1949, J COMP NEUROL, V91, P209, DOI 10.1002/cne.900910204; Lewis DA, 2005, NAT REV NEUROSCI, V6, P312, DOI 10.1038/nrn1648; Li XJ, 2009, DEVELOPMENT, V136, P4055, DOI 10.1242/dev.036624; LINDVALL O, 1990, SCIENCE, V247, P574, DOI 10.1126/science.2105529; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; Ma T, 2013, NAT NEUROSCI, V16, P1588, DOI 10.1038/nn.3536; Maisano X, 2012, J NEUROSCI, V32, P46, DOI 10.1523/JNEUROSCI.2683-11.2012; Marin O, 2003, ANNU REV NEUROSCI, V26, P441, DOI 10.1146/annurev.neuro.26.041002.131058; Marin O, 2012, NAT REV NEUROSCI, V13, P107, DOI 10.1038/nrn3155; Markram H, 2004, NAT REV NEUROSCI, V5, P793, DOI 10.1038/nrn1519; Maroof AM, 2013, CELL STEM CELL, V12, P559, DOI 10.1016/j.stem.2013.04.008; Maroof AM, 2010, J NEUROSCI, V30, P4667, DOI 10.1523/JNEUROSCI.4255-09.2010; Martinez-Cerdeno V, 2010, CELL STEM CELL, V6, P238, DOI 10.1016/j.stem.2010.01.004; Nery S, 2002, NAT NEUROSCI, V5, P1279, DOI 10.1038/nn971; Nicholas CR, 2013, CELL STEM CELL, V12, P573, DOI 10.1016/j.stem.2013.04.005; Nikoletopoulou V, 2010, NATURE, V467, P59, DOI 10.1038/nature09336; Olsson M, 1997, NEUROSCIENCE, V79, P57, DOI 10.1016/S0306-4522(96)00606-9; OLSSON M, 1995, NEUROSCIENCE, V69, P1169, DOI 10.1016/0306-4522(95)00325-D; PAKZABAN P, 1993, EXP BRAIN RES, V97, P13; Palop JJ, 2010, NAT NEUROSCI, V13, P812, DOI 10.1038/nn.2583; Pencea V, 2001, EXP NEUROL, V172, P1, DOI 10.1006/exnr.2001.7768; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Pleasure SJ, 2000, NEURON, V28, P727, DOI 10.1016/S0896-6273(00)00149-5; Richardson RM, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E16; Rossignol E, 2011, NEURAL PLAST, V2011, DOI 10.1155/2011/649325; Rubenstein JLR, 2003, GENES BRAIN BEHAV, V2, P255, DOI 10.1034/j.1601-183X.2003.00037.x; Southwell DG, 2012, NATURE, V491, P109, DOI 10.1038/nature11523; Southwell DG, 2010, SCIENCE, V327, P1145, DOI 10.1126/science.1183962; Sugiyama S, 2008, CELL, V134, P508, DOI 10.1016/j.cell.2008.05.054; Tanaka DH, 2011, J NEUROSCI, V31, P14116, DOI 10.1523/JNEUROSCI.2786-11.2011; Taniguchi H, 2013, SCIENCE, V339, P70, DOI 10.1126/science.1227622; Valente MF, 2013, CELL TRANSPLANT, V22, P1237, DOI 10.3727/096368912X657422; Verret L, 2012, CELL, V149, P708, DOI 10.1016/j.cell.2012.02.046; Watanabe K, 2005, NAT NEUROSCI, V8, P288, DOI 10.1038/nn1402; Watanabe K, 2007, NAT BIOTECHNOL, V25, P681, DOI 10.1038/nbt1310; Wichterle H, 2001, DEVELOPMENT, V128, P3759; Wichterle H, 1999, NAT NEUROSCI, V2, P461, DOI 10.1038/8131; Wonders C, 2005, NEUROSCIENTIST, V11, P199, DOI 10.1177/1073858404270968; Wonders CP, 2008, DEV BIOL, V314, P127, DOI 10.1016/j.ydbio.2007.11.018; Xu Q, 2004, J NEUROSCI, V24, P2612, DOI 10.1523/JNEUROSCI.5667-03.2004; Xu Q, 2010, NEURON, V65, P328, DOI 10.1016/j.neuron.2010.01.004; Ying QL, 2003, METHOD ENZYMOL, V365, P327; Yozu M, 2005, J NEUROSCI, V25, P7268, DOI 10.1523/JNEUROSCI.2072-05.2005; Zipancic I, 2010, CELL TRANSPLANT, V19, P549, DOI 10.3727/096368910X491383	93	133	136	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 11	2014	344	6180					167	+	1240622	10.1126/science.1240622	http://dx.doi.org/10.1126/science.1240622			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CB7VN	24723614	Green Accepted			2023-01-03	WOS:000349836700001
J	Voigtsberger, S; Urner, M; Hasler, M; Z'Graggen, BR; Booy, C; Spahn, DR; Beck-Schimmer, B				Voigtsberger, Stefanie; Urner, Martin; Hasler, Melanie; Z'Graggen, Birgit Roth; Booy, Christa; Spahn, Donat R.; Beck-Schimmer, Beatrice			Modulation of Early Inflammatory Response by Different Balanced and Non-Balanced Colloids and Crystalloids in a Rodent Model of Endotoxemia	PLOS ONE			English	Article							ACUTE-RENAL-FAILURE; ACUTE KIDNEY INJURY; GELATINASE-ASSOCIATED LIPOCALIN; SEVERE SEPSIS; HYDROXYETHYLSTARCH; MICROCIRCULATION; PATHOPHYSIOLOGY; RESUSCITATION; EXPRESSION; BIOMARKERS	The use of hydroxyethyl starch (HES) in sepsis has been shown to increase mortality and acute kidney injury. However, the knowledge of the exact mechanism by which several fluids, especially starch preparations may impair end-organ function particularly in the kidney, is still missing. The aim of this study was to measure the influence of different crystalloid and colloid fluid compositions on the inflammatory response in the kidney, the liver and the lung using a rodent model of acute endotoxemia. Rats were anesthetized and mechanically ventilated. Lipopolysaccharide (5 mg/kg) was administered intravenously. After one hour crystalloids [lactate- buffered (RLac) or acetate-buffered (RAc)] were infused i.v. (30 ml/kg) in all groups. At 2 hours rats either received different crystalloids (75 ml/kg of RLac or RAc) or colloids (25 ml/kg of HES in saline or HES in RAc or gelatin in saline). Expression of messenger RNA for cytokine-induced neutrophil chemoattractant-1 (CINC-1), monocyte chemotactic protein-1 (MCP-1), necrosis factor a (TNFa) and intercellular adhesion molecule 1 (ICAM-1) was assessed in kidney, liver and lung tissue by real-time PCR after 4 hours. The use of acetate-buffered solutions was associated with a significantly higher expression of CINC-1 and TNFa mRNA in the liver, in the kidney and in the lung. Only marginal effects of gelatin and hydroxyethyl starch on mRNA expression of inflammatory mediators were observed. The study provides evidence that the type of buffering agent of different colloidal and crystalloid solutions might be a crucial factor determining the extent of early end-organ inflammatory response in sepsis.	[Voigtsberger, Stefanie; Urner, Martin; Hasler, Melanie; Spahn, Donat R.; Beck-Schimmer, Beatrice] Univ Zurich Hosp, Inst Anesthesiol, CH-8091 Zurich, Switzerland; [Urner, Martin; Z'Graggen, Birgit Roth; Booy, Christa; Beck-Schimmer, Beatrice] Univ Zurich, Inst Physiol, Zurich, Switzerland; [Urner, Martin; Z'Graggen, Birgit Roth; Booy, Christa; Beck-Schimmer, Beatrice] Univ Zurich, Zurich Ctr Integrat Human Physiol, Zurich, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP)	Beck-Schimmer, B (corresponding author), Univ Zurich Hosp, Inst Anesthesiol, CH-8091 Zurich, Switzerland.	beatrice.beckschimmer@uzh.ch	Urner, Martin/AAK-5701-2020	Urner, Martin/0000-0003-1133-4885	Swiss National Science Foundation Grant [3200B0-122305]; B. Braun, Melsungen, Germany; University of Zurich	Swiss National Science Foundation Grant(Swiss National Science Foundation (SNSF)); B. Braun, Melsungen, Germany; University of Zurich	This work was supported by the Swiss National Science Foundation Grant Nr. 3200B0-122305 and B. Braun, Melsungen, Germany. The project was supported by the University of Zurich with a grant for "protected research time'' for the first author. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aksu U, 2012, SHOCK, V37, P205, DOI 10.1097/SHK.0b013e31823ca89c; Bienholz A, 2012, AM J PHYSIOL-RENAL, V303, pF56, DOI 10.1152/ajprenal.00070.2012; BINGEL M, 1987, LANCET, V1, P14; Bonventre JV, 2011, J CLIN INVEST, V121, P4210, DOI 10.1172/JCI45161; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Campbell SJ, 2003, FASEB J, V17, P1168, DOI 10.1096/fj.02-0757fje; DASILVA AMT, 1993, NEW ENGL J MED, V328, P1457, DOI 10.1056/NEJM199305203282005; Davies PG, 2011, CRIT CARE, V15, DOI 10.1186/cc9966; Dejager L, 2011, TRENDS MICROBIOL, V19, P198, DOI 10.1016/j.tim.2011.01.001; Dellinger R. P., 2013, INTENS CARE MED, V41, P580, DOI [DOI 10.1007/s00134-012-2769-8, 10.1007/s00134-012-2769-8]; Dellinger RP, 2008, INTENS CARE MED, V34, P17, DOI 10.1007/s00134-007-0934-2; Doi K, 2009, J CLIN INVEST, V119, P2868, DOI 10.1172/JCI39421; Ernandez T, 2009, KIDNEY INT, V76, P262, DOI 10.1038/ki.2009.142; Ertmer C, 2011, CRIT CARE MED, V39, P783, DOI 10.1097/CCM.0b013e318206d403; Feldkamp T, 2004, AM J PHYSIOL-RENAL, V286, pF749, DOI 10.1152/ajprenal.00276.2003; Flower DR, 2000, BBA-PROTEIN STRUCT M, V1482, P9, DOI 10.1016/S0167-4838(00)00148-5; Godet G, 2001, LANCET, V358, P581, DOI 10.1016/S0140-6736(01)05719-1; Goldstein SL, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-135; Guidet B, 2012, CRIT CARE, V16, DOI 10.1186/cc11358; Guidet B, 2010, CRIT CARE, V14, DOI 10.1186/cc9230; Haase M, 2009, AM J KIDNEY DIS, V54, P1012, DOI 10.1053/j.ajkd.2009.07.020; Han M, 2012, BMC NEPHROL, V13, DOI 10.1186/1471-2369-13-25; Handa O, 2006, J CLIN BIOCHEM NUTR, V38, P51, DOI 10.3164/jcbn.38.51; Hoffmann JN, 2002, ANESTHESIOLOGY, V97, P460, DOI 10.1097/00000542-200208000-00025; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mishra J, 2003, J AM SOC NEPHROL, V14, P2534, DOI 10.1097/01.ASN.0000088027.54400.C6; Neveu H, 1996, NEPHROL DIAL TRANSPL, V11, P293, DOI 10.1093/oxfordjournals.ndt.a027256; Rabelink TJ, 2010, NAT REV NEPHROL, V6, P404, DOI 10.1038/nrneph.2010.65; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Schick MA, 2010, INTENS CARE MED, V36, P541, DOI 10.1007/s00134-009-1704-0; Schortgen F, 2001, LANCET, V357, P911, DOI 10.1016/S0140-6736(00)04211-2; Selby NM, 2006, ASAIO J, V52, P62, DOI 10.1097/01.mat.0000189725.93808.58; Simon TP, 2012, CRIT CARE, V16, DOI 10.1186/cc11161; Soni N, 2012, CRIT CARE, V16, DOI 10.1186/cc11155; Thaha M, 2005, Acta Med Indones, V37, P145; Uchino S, 2005, JAMA-J AM MED ASSOC, V294, P813, DOI 10.1001/jama.294.7.813; Urbschat A, 2011, BIOMARKERS, V16, pS22, DOI 10.3109/1354750X.2011.587129; VEECH RL, 1988, ADV ENZYME REGUL, V27, P313, DOI 10.1016/0065-2571(88)90024-6; Wan L, 2008, CRIT CARE MED, V36, pS198, DOI 10.1097/CCM.0b013e318168ccd5; WATANABE K, 1992, EXP MOL PATHOL, V56, P60, DOI 10.1016/0014-4800(92)90023-5; Wittlinger M, 2010, ANESTH ANALG, V110, P531, DOI 10.1213/ANE.0b013e3181c03c97; [No title captured]	42	12	13	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 7	2014	9	4							e93863	10.1371/journal.pone.0093863	http://dx.doi.org/10.1371/journal.pone.0093863			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE7EP	24709833	gold, Green Accepted, Green Submitted, Green Published			2023-01-03	WOS:000334159800060
J	Pinna, G; Pascale, C; Fornengo, P; Arras, S; Piras, C; Panzarasa, P; Carmosino, G; Franza, O; Semeraro, V; Lenti, S; Pietrelli, S; Panzone, S; Bracco, C; Fiorini, R; Rastelli, G; Bergandi, D; Zampaglione, B; Musso, R; Marengo, C; Santoro, G; Zamboni, S; Traversa, B; Barattini, M; Bruno, G				Pinna, Giuliano; Pascale, Claudio; Fornengo, Paolo; Arras, Sebastiana; Piras, Carmela; Panzarasa, Pietro; Carmosino, Gianpaolo; Franza, Orietta; Semeraro, Vincenzo; Lenti, Salvatore; Pietrelli, Susanna; Panzone, Sergio; Bracco, Christian; Fiorini, Roberto; Rastelli, Giovanni; Bergandi, Daniela; Zampaglione, Bruno; Musso, Roberto; Marengo, Claudio; Santoro, Giancarlo; Zamboni, Sergio; Traversa, Barbara; Barattini, Maddalena; Bruno, Graziella			Hospital Admissions for Hypertensive Crisis in the Emergency Departments: A Large Multicenter Italian Study	PLOS ONE			English	Article							URGENCIES; PREVALENCE; MANAGEMENT; PATTERNS	Epidemiological data on the impact of hypertensive crises (emergencies and urgencies) on referral to the Emergency Departments (EDs) are lacking, in spite of the evidence that they may be life-threatening conditions. We performed a multicenter study to identify all patients aged 18 years and over who were admitted to 10 Italian EDs during 2009 for hypertensive crises (systolic blood pressure >= 220 mmHg and/or diastolic blood pressure >= 120 mmHg). We classified patients as affected by either hypertensive emergencies or hypertensive urgencies depending on the presence or the absence of progressive target organ damage, respectively. Logistic regression analysis was then performed to assess variables independently associated with hypertensive emergencies with respect to hypertensive urgencies. Of 333,407 patients admitted to the EDs over the one-year period, 1,546 had hypertensive crises (4.6/1,000, 95% CI 4.4-4.9), and 23% of them had unknown hypertension. Hypertensive emergencies (n = 391, 25.3% of hypertensive crises) were acute pulmonary edema (30.9%), stroke (22.0%,), myocardial infarction (17.9%), acute aortic dissection (7.9%), acute renal failure (5.9%) and hypertensive encephalopathy (4.9%). Men had higher frequency than women of unknown hypertension (27.9% vs 18.5%, p<0.001). Even among known hypertensive patients, a larger proportion of men than women reported not taking antihypertensive drug (12.6% among men and 9.4% among women (p<0.001). Compared to women of similar age, men had higher likelihood of having hypertensive emergencies than urgencies (OR = 1.34, 95% CI 1.06-1.70), independently of presenting symptoms, creatinine, smoking habit and known hypertension. This study shows that hypertensive crises involved almost 5 out of 1,000 patients-year admitted to EDs. Sex differences in frequencies of unknown hypertension, compliance to treatment and risk of hypertensive emergencies might have implications for public health programs.	[Pinna, Giuliano; Pascale, Claudio] Osped Cottolengo, Dept Internal Med, Turin, Italy; [Arras, Sebastiana; Piras, Carmela] Osped Civile, Emergency Dept, Sassari, Italy; [Panzarasa, Pietro; Carmosino, Gianpaolo] Osped Umberto Parini, Emergency Dept, Aosta, Italy; [Franza, Orietta; Semeraro, Vincenzo] Osped Cardinal Massaia, Emergency Dept, Aosta, Italy; [Lenti, Salvatore; Pietrelli, Susanna] Osped San Donato, Emergency Dept, Arezzo, Italy; [Panzone, Sergio; Bracco, Christian] Azienda Osped Santa Croce & Carle, Emergency Dept, Cuneo, Italy; [Fiorini, Roberto; Rastelli, Giovanni] Presidio Osped, Emergency Dept, Parma, Italy; [Bergandi, Daniela; Zampaglione, Bruno] Presidio Osped Martini, Emergency Dept, Turin, Italy; [Musso, Roberto; Marengo, Claudio] Osped Santa Croce, Emergency Dept, Turin, Italy; [Santoro, Giancarlo; Zamboni, Sergio] Osped Civile, Emergency Dept, Rovigo, Italy; [Traversa, Barbara; Barattini, Maddalena] Osped SS Antonio & Margherita, Emergency Dept, Tortona, Italy; [Bruno, Graziella] Univ Turin, Dept Med Sci, Turin, Italy	Azienda USL della Valle d'Aosta; IRCCS Policlinico San Donato; University of Parma; University Hospital of Parma; University of Turin	Fornengo, P (corresponding author), Univ Turin, Dept Med Sci, Turin, Italy.	paolo.fornengo@unito.it		BRUNO, Graziella/0000-0002-3011-8304	Societa Italiana dell'Ipertensione Arteriosa	Societa Italiana dell'Ipertensione Arteriosa	The funder is the Societa Italiana dell'Ipertensione Arteriosa. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Cerrillo MR, 2002, REV CLIN ESP, V202, P255, DOI 10.1016/S0014-2565(02)71046-1; Cherney D, 2002, J GEN INTERN MED, V17, P937, DOI 10.1046/j.1525-1497.2002.20389.x; CHOBANIAN AV, 2003, HYPERTENSION, V42, P1206, DOI [DOI 10.1161/01.HYP.0000107251.49515.c2, DOI 10.1161/01.HYP.0000107251.49515.C2]; Elijovich F, 2010, HYPERTENSION, V56, P808, DOI 10.1161/HYPERTENSIONAHA.110.159038; Hu D, 2010, NUTR METAB CARDIOVAS, V20, P394, DOI 10.1016/j.numecd.2010.02.016; Katz JN, 2009, AM HEART J, V158, P599, DOI 10.1016/j.ahj.2009.07.020; Levey AS, 2006, ANN INTERN MED, V145, P247, DOI 10.7326/0003-4819-145-4-200608150-00004; Liu LS, 2006, INT J STROKE, V1, P150, DOI 10.1111/j.1747-4949.2006.00041.x; Mancia G, 2007, J HYPERTENS, V25, P1751, DOI 10.1097/HJH.0b013e3282f0580f; Marik PE, 2007, CHEST, V131, P1949, DOI 10.1378/chest.06-2490; Martin Jose Fernando Vilela, 2004, Arq Bras Cardiol, V83, P131; National High Blood Pressure Education Program, 2004, NIH PUBLICATION, V04-5230; Perez MI, 2008, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003653.pub3; Saguner AM, 2010, AM J HYPERTENS, V23, P775, DOI 10.1038/ajh.2010.71; Slama M, 2006, CURR OPIN CARDIOL, V21, P279, DOI 10.1097/01.hco.0000231396.56738.d8; Vilela Martin JF, 2010, HYPERTENS RES, V1, P1; Vlcek M, 2008, J HYPERTENS, V26, P657, DOI 10.1097/HJH.0b013e3282f4e8b6; WEBSTER J, 1993, Q J MED, V86, P485, DOI 10.1093/qjmed/86.8.485; World Health Organization Statistical Information System (WHOSIS), 2004, EST WHO REG; Zampaglione B, 1996, HYPERTENSION, V27, P144, DOI 10.1161/01.HYP.27.1.144	20	62	70	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2014	9	4							e93542	10.1371/journal.pone.0093542	http://dx.doi.org/10.1371/journal.pone.0093542			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE6LC	24695800	Green Submitted, gold, Green Published			2023-01-03	WOS:000334103000086
J	Corvaglia, L; Fantini, MP; Aceti, A; Gibertoni, D; Rucci, P; Baronciani, D; Faldella, G				Corvaglia, Luigi; Fantini, Maria Pia; Aceti, Arianna; Gibertoni, Dino; Rucci, Paola; Baronciani, Dante; Faldella, Giacomo		Emilia Romagna Perinatal Network	Predictors of Full Enteral Feeding Achievement in Very Low Birth Weight Infants	PLOS ONE			English	Article							INTRAUTERINE GROWTH-RETARDATION; PATENT DUCTUS-ARTERIOSUS; CLINICAL RISK INDEX; PRETERM INFANTS; ANTENATAL CORTICOSTEROIDS; PREMATURE-INFANTS; MORTALITY; AGE; TERM; MORBIDITY	Background: To elucidate the role of prenatal, neonatal and early postnatal variables in influencing the achievement of full enteral feeding (FEF) in very low birth weight (VLBW) infants and to determine whether neonatal intensive care units (NICUs) differ in this outcome. Methods: Population-based retrospective cohort study using data on 1,864 VLBW infants drawn from the "Emilia-Romagna Perinatal Network'' Registry from 2004 to 2009. The outcome of interest was time to FEF achievement. Eleven prenatal, neonatal and early postnatal variables and the study NICUs were selected as potential predictors of time to FEF. Parametric survival analysis was used to model time to FEF as a function of the predictors. Marginal effects were used to obtain adjusted estimates of median time to FEF for specific subgroups of infants. Results: Lower gestational age, exclusive formula feeding, higher CRIB II score, maternal hypertension, cesarean delivery, SGA and PDA predicted delayed FEF. NICUs proved to be heterogeneous in terms of FEF achievement. Newborns with PDA had a 4.2 days longer predicted median time to FEF compared to those without PDA; newborns exclusively formula-fed had a 1.4 days longer time to FEF compared to those fed human milk. Conclusions: The results of our study suggest that time to FEF is influenced by clinical variables and NICU-specific practices. Knowledge of the variables associated with delayed/earlier FEF achievement could help in improving specific aspects of routine clinical management of VLBW infants and to reduce practice variability.	[Corvaglia, Luigi; Aceti, Arianna; Faldella, Giacomo] Univ Bologna, S Orsola Malpighi Hosp, Neonatol & Neonatal Intens Care Unit, Bologna, Italy; [Fantini, Maria Pia; Gibertoni, Dino; Rucci, Paola] Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy; [Baronciani, Dante] Direz Gen Sanita & Polit Sociali, Serv Presidi Osped, Bologna, Italy	IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; University of Bologna	Aceti, A (corresponding author), Univ Bologna, S Orsola Malpighi Hosp, Neonatol & Neonatal Intens Care Unit, Bologna, Italy.	arianna.aceti2@unibo.it	Gibertoni, Dino/H-4443-2017; Aceti, Arianna/AAB-4007-2019	Gibertoni, Dino/0000-0002-1722-3724; Aceti, Arianna/0000-0001-9274-985X; Rucci, Paola/0000-0002-7704-0831; Garani, Giampaolo/0000-0002-3514-2717				Abitbol CL, 2012, NAT REV NEPHROL, V8, P265, DOI 10.1038/nrneph.2012.38; Bakker R, 2011, AM J EPIDEMIOL, V174, P797, DOI 10.1093/aje/kwr151; Bartels DB, 2005, ARCH DIS CHILD-FETAL, V90, pF53, DOI 10.1136/adc.2004.053892; Baud O, 2000, BRIT J OBSTET GYNAEC, V107, P877, DOI 10.1111/j.1471-0528.2000.tb11086.x; Been JV, 2013, J PEDIATR-US, V162, P236, DOI 10.1016/j.jpeds.2012.07.012; Been JV, 2009, AM J OBSTET GYNECOL, V201, DOI 10.1016/j.ajog.2009.06.025; Bernstein IM, 2000, AM J OBSTET GYNECOL, V182, P198, DOI 10.1016/S0002-9378(00)70513-8; Berrington JE, 2013, ARCH DIS CHILD-FETAL, V98, pF286, DOI 10.1136/archdischild-2012-302134; BERSETH CL, 1990, J PEDIATR-US, V117, P777, DOI 10.1016/S0022-3476(05)83343-8; Blennow M, 2009, JAMA-J AM MED ASSOC, V301, P2225, DOI 10.1001/jama.2009.771; Bozzetti V, 2013, J MATERN-FETAL NEO M, V26, P1610, DOI 10.3109/14767058.2012.746303; Burrin DG, 2002, CLIN PERINATOL, V29, P65, DOI 10.1016/S0095-5108(03)00065-4; Carlisle EM, 2013, CURR OPIN PEDIATR, V25, P382, DOI 10.1097/MOP.0b013e3283600e91; Cleves M., 2010, INTRO SURVIVAL ANAL; COOMBS RC, 1990, ARCH DIS CHILD-FETAL, V65, P1067, DOI 10.1136/adc.65.10_Spec_No.1067; Corpeleijn WE, 2012, NEONATOLOGY, V102, P276, DOI 10.1159/000341335; Costalos C, 2003, EARLY HUM DEV, V74, P83, DOI 10.1016/S0378-3782(03)00087-2; Database VON, 2012, DAT VON MAN OP 2; Dorling J, 2005, ARCH DIS CHILD-FETAL, V90, pF359, DOI 10.1136/adc.2004.060350; Ehrenkranz RA, 2011, PEDIATR RES, V69, P522, DOI 10.1203/PDR.0b013e318217f4f1; Ersch J, 2008, J PAEDIATR CHILD H, V44, P651, DOI 10.1111/j.1440-1754.2008.01375.x; Faldella G, 2011, EARLY HUM DEV, V87, pS5, DOI 10.1016/j.earlhumdev.2011.01.001; Fang S, 2001, ARCH DIS CHILD-FETAL, V85, pF42, DOI 10.1136/fn.85.1.F42; Greenwood S, 2012, J PAEDIATR CHILD H, V48, P588, DOI 10.1111/j.1440-1754.2012.02430.x; Hofman PL, 2004, NEW ENGL J MED, V351, P2179, DOI 10.1056/NEJMoa042275; Horbar J D, 1999, Pediatrics, V103, P350; Horbar JD, 1997, PEDIATRICS, V99, P149, DOI 10.1542/peds.99.2.149; Horbar JD, 2010, CLIN PERINATOL, V37, P29, DOI 10.1016/j.clp.2010.01.003; Hovi P, 2007, NEW ENGL J MED, V357, P617; Hyde MJ, 2012, BIOL REV, V87, P229, DOI 10.1111/j.1469-185X.2011.00195.x; ISTAT, 2011, VOL POP LEG 15 CENS; Kandasamy Y, 2009, ARCH DIS CHILD-FETAL, V94, pF78, DOI 10.1136/adc.2008.145284; Kent AL, 2012, PEDIATRICS, V129, P124, DOI 10.1542/peds.2011-1578; Lanigan J, 2009, P NUTR SOC, V68, P422, DOI 10.1017/S002966510999019X; Leaf A, 2012, PEDIATRICS, V129, pE1260, DOI 10.1542/peds.2011-2379; Lodha A, 2009, DEV MED CHILD NEUROL, V51, P895, DOI 10.1111/j.1469-8749.2009.03284.x; Mihatsch WA, 2002, J PEDIATR GASTR NUTR, V35, P144, DOI 10.1097/00005176-200208000-00008; Morgan J, 2011, COCHRANE DB SYST REV, V3; Mosalli R, 2010, COCHRANE DB SYST REV, V1; Neu J, 2011, NEW ENGL J MED, V364, P255, DOI 10.1056/NEJMra1005408; Parry G, 2003, LANCET, V361, P1789, DOI 10.1016/S0140-6736(03)13397-1; Patole SK, 2007, ARCH DIS CHILD-FETAL, V92, pF53, DOI 10.1136/adc.2006.093708; Regev RH, 2004, CLIN PERINATOL, V31, P453, DOI 10.1016/j.clp.2004.04.017; Regev RH, 2003, J PEDIATR-US, V143, P186, DOI 10.1067/S0022-3476(03)00181-1; Ronnestad A, 2005, PEDIATRICS, V115, pE269, DOI 10.1542/peds.2004-1833; SAIGAL S, 1991, J PEDIATR-US, V118, P751, DOI 10.1016/S0022-3476(05)80043-5; Shulman RJ, 1998, PEDIATR RES, V44, P519, DOI 10.1203/00006450-199810000-00009; Smith PB, 2012, PEDIATRICS, V129, pE1508, DOI 10.1542/peds.2011-2216; Surbek D, 2012, ARCH GYNECOL OBSTET, V286, P277, DOI 10.1007/s00404-012-2339-x; Tyson JE, 2008, NEW ENGL J MED, V358, P1672, DOI 10.1056/NEJMoa073059; Williams R, 2012, STATA J, V12, P308, DOI 10.1177/1536867X1201200209; Wold SHW, 2009, ARCH DIS CHILD-FETAL, V94, pF363, DOI 10.1136/adc.2009.157800; Wolfs TGAM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005837	54	21	22	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2014	9	3							e92235	10.1371/journal.pone.0092235	http://dx.doi.org/10.1371/journal.pone.0092235			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AD6ER	24647523	gold, Green Published, Green Submitted			2023-01-03	WOS:000333348500102
J	Anderson, DJ; Moehring, RW; Sloane, R; Schmader, KE; Weber, DJ; Fowler, VG; Smathers, E; Sexton, DJ				Anderson, Deverick J.; Moehring, Rebekah W.; Sloane, Richard; Schmader, Kenneth E.; Weber, David J.; Fowler, Vance G., Jr.; Smathers, Emily; Sexton, Daniel J.			Bloodstream Infections in Community Hospitals in the 21st Century: A Multicenter Cohort Study	PLOS ONE			English	Article							STAPHYLOCOCCUS-AUREUS BACTEREMIA; METHICILLIN-RESISTANT; ANTIMICROBIAL TREATMENT; MORTALITY; EPIDEMIOLOGY; ENDOCARDITIS; METAANALYSIS; VALIDATION; PREVENTION; SEVERITY	Background: While the majority of healthcare in the US is provided in community hospitals, the epidemiology and treatment of bloodstream infections in this setting is unknown. Methods and Findings: We undertook this multicenter, retrospective cohort study to 1) describe the epidemiology of bloodstream infections (BSI) in a network of community hospitals and 2) determine risk factors for inappropriate therapy for bloodstream infections in community hospitals. 1,470 patients were identified as having a BSI in 9 community hospitals in the southeastern US from 2003 through 2006. The majority of BSIs were community-onset, healthcare associated (n = 823, 56%); 432 (29%) patients had community-acquired BSI, and 215 (15%) had hospital-onset, healthcare-associated BSI. BSIs due to multidrug-resistant pathogens occurred in 340 patients (23%). Overall, the three most common pathogens were S. aureus (n = 428, 28%), E. coli (n = 359, 24%), coagulase-negative Staphylococci (n = 148, 10%), though type of infecting organism varied by location of acquisition (e. g., community-acquired). Inappropriate empiric antimicrobial therapy was given to 542 (38%) patients. Proportions of inappropriate therapy varied by hospital (median = 33%, range 21-71%). Multivariate logistic regression identified the following factors independently associated with failure to receive appropriate empiric antimicrobial therapy: hospital where the patient received care (p<0.001), assistance with >= 3 ADLs (p = 0.005), Charlson score (p = 0.05), community-onset, healthcare-associated infection (p = 0.01), and hospital-onset, healthcare-associated infection (p = 0.02). Important interaction was observed between Charlson score and location of acquisition. Conclusions: Our large, multicenter study provides the most complete picture of BSIs in community hospitals in the US to date. The epidemiology of BSIs in community hospitals has changed: community-onset, healthcare-associated BSI is most common, S. aureus is the most common cause, and 1 of 3 patients with a BSI receives inappropriate empiric antimicrobial therapy. Our data suggest that appropriateness of empiric antimicrobial therapy is an important and needed performance metric for physicians and hospital stewardship programs in community hospitals.	[Anderson, Deverick J.; Moehring, Rebekah W.; Fowler, Vance G., Jr.; Sexton, Daniel J.] Duke Univ, Med Ctr, Duke Univ Div Infect Dis, Durham, NC 27708 USA; [Anderson, Deverick J.; Moehring, Rebekah W.; Smathers, Emily; Sexton, Daniel J.] Duke Infect Control Outreach Network, Durham, NC USA; [Sloane, Richard] Duke Univ, Med Ctr, Ctr Study Aging & Human Dev, Durham, NC 27710 USA; [Schmader, Kenneth E.] Duke Univ, Med Ctr, Dept Geriatr Med, Durham, NC USA; [Schmader, Kenneth E.] Durham VA Med Ctr, GRECC, Durham, NC USA; [Weber, David J.] Univ North Carolina Hlth Syst, Dept Hosp Epidemiol, Chapel Hill, NC USA	Duke University; Duke University; Duke University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; University North Carolina Hospital	Anderson, DJ (corresponding author), Duke Univ, Med Ctr, Duke Univ Div Infect Dis, Durham, NC 27708 USA.	deverick.anderson@duke.edu	Fowler, Vance/AAW-2017-2021	Anderson, Deverick/0000-0001-6882-5496; Sexton, Daniel J/0000-0001-9604-5948	Robert Wood Johnson Foundation [66327]; National Institute of Health/National Institute of Allergy and Infectious Diseases [K23 AIO95357, K24 AI093969]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI095357, K24AI093969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG028716] Funding Source: NIH RePORTER	Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); National Institute of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by the Robert Wood Johnson Foundation [#66327 to DJA] and the National Institute of Health/National Institute of Allergy and Infectious Diseases [K23 AIO95357 to DJA; K24 AI093969 to VGF]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agency for Healthcare Research and Quality, 2013, HEALTHC COST UT PROJ; Ammerlaan HSM, 2013, CLIN INFECT DIS, V56, P798, DOI 10.1093/cid/cis1006; Anderson DJ, 2007, INFECT CONT HOSP EP, V28, P767, DOI 10.1086/518518; Anderson DJ, 2011, INFECT CONT HOSP EP, V32, P315, DOI 10.1086/658940; BION JF, 1985, BRIT MED J, V291, P432, DOI 10.1136/bmj.291.6493.432; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cosgrove SE, 2003, CLIN INFECT DIS, V36, P53, DOI 10.1086/345476; ELHANAN G, 1995, J ANTIMICROB CHEMOTH, V36, P681, DOI 10.1093/jac/36.4.681; Fishman N, 2012, INFECT CONT HOSP EP, V33, P322, DOI 10.1086/665010; Fowler VG, 2005, JAMA-J AM MED ASSOC, V293, P3012, DOI 10.1001/jama.293.24.3012; Fowler VG, 2003, ARCH INTERN MED, V163, P2066, DOI 10.1001/archinte.163.17.2066; Haddy RI, 1996, J FAM PRACTICE, V42, P273; HADDY RI, 1987, J FAM PRACTICE, V24, P253; HADDY RI, 1991, J FAM PRACTICE, V32, P601; Ibrahim EH, 2000, CHEST, V118, P146, DOI 10.1378/chest.118.1.146; Jarvis WR, 1998, AM J INFECT CONTROL, V26, P522; Javaloyas M, 2002, SCAND J INFECT DIS, V34, P436, DOI 10.1080/00365540110080629; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Kaye KS, 2008, CLIN INFECT DIS, V46, P1568, DOI 10.1086/587673; Klevens RM, 2007, JAMA-J AM MED ASSOC, V298, P1763, DOI 10.1001/jama.298.15.1763; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kollef MH, 2011, J INFECTION, V62, P130, DOI 10.1016/j.jinf.2010.12.009; Landerman LR, 1997, SOCIOL METHOD RES, V26, P3, DOI 10.1177/0049124197026001001; Magiorakos AP, 2011, CLIN MICROBIOLOGY IN; Micek ST, 2006, CRIT CARE MED, V34, P2707, DOI 10.1097/01.CCM.0000241151.25426.D7; Murdoch DR, 2009, ARCH INTERN MED, V169, P463, DOI 10.1001/archinternmed.2008.603; Mylotte JM, 2001, AM J INFECT CONTROL, V29, P13, DOI 10.1067/mic.2001.110567; National Center for Health Statistics, 2012, HLTH US 2011 SPEC FE; Paul M, 2010, ANTIMICROB AGENTS CH, V54, P4851, DOI 10.1128/AAC.00627-10; Pittet D, 1997, CLIN INFECT DIS, V24, P1068, DOI 10.1086/513640; Scheckler WE, 2003, INFECT CONT HOSP EP, V24, P936, DOI 10.1086/502162; Schramm GE, 2006, CRIT CARE MED, V34, P2069, DOI 10.1097/01.CCM.0000227655.41566.3E; SETIA U, 1977, ARCH INTERN MED, V137, P1698, DOI 10.1001/archinte.137.12.1698; Shorr AF, 2006, CRIT CARE MED, V34, P2588, DOI 10.1097/01.CCM.0000239121.09533.09; Warren DK, 2001, CLIN INFECT DIS, V33, P1329, DOI 10.1086/322483	35	59	67	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2014	9	3							e91713	10.1371/journal.pone.0091713	http://dx.doi.org/10.1371/journal.pone.0091713			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AD4ZE	24643200	Green Published, gold, Green Submitted			2023-01-03	WOS:000333259900031
J	Shimizu, E; Glaspy, K; Witt, MD; Poon, K; Black, S; Schwartz, S; Bholat, T; Diaz, N; Kuo, A; Spellberg, B				Shimizu, Eri; Glaspy, Kathleen; Witt, Mallory D.; Poon, Kimble; Black, Susan; Schwartz, Shelley; Bholat, Tasneem; Diaz, Norma; Kuo, Allen; Spellberg, Brad			Readmissions at a Public Safety Net Hospital	PLOS ONE			English	Article							POTENTIALLY PREVENTABLE READMISSIONS; HEALTH LITERACY; MEDICARE BENEFICIARIES; INPATIENT CARE; DISCHARGE; QUALITY; PROGRAM; REHOSPITALIZATION; ASSOCIATION; EVENTS	Objective: We aimed to determine factors related to avoidability of 30-day readmissions at our public, safety net hospital in the United States (US). Methods: We prospectively reviewed medical records of adult internal medicine patients with scheduled and unscheduled 30-day readmissions. We also interviewed patients if they were available. An independent panel used pre-specified, objective criteria to adjudicate potential avoidability. Results: Of 153 readmissions evaluated, 68% were unscheduled. Among these, 67% were unavoidable, primarily due to disease progression and development of new diagnoses. Scheduled readmissions accounted for 32% of readmissions and most (69%) were clinically appropriate and unavoidable. The scheduled but avoidable readmissions (31%) were attributed largely to limited resources in our healthcare system. Conclusions: Most readmissions at our public, safety net hospital were unavoidable, even among our unscheduled readmissions. Surprisingly, one-third of our overall readmissions were scheduled, the majority reflecting appropriate management strategies designed to reduce unnecessary hospital days. The scheduled but avoidable readmissions were due to constrained access to non-emergent, expensive procedures that are typically not reimbursed given our system's payor mix, a problem which likely plague other safety net systems. These findings suggest that readmissions do not necessarily reflect inadequate medical care, may reflect resource constraints that are unlikely to be addressable in systems caring for a large burden of uninsured patients, and merit individualized review.	[Shimizu, Eri; Glaspy, Kathleen; Schwartz, Shelley; Bholat, Tasneem; Kuo, Allen; Spellberg, Brad] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Div Gen Internal Med, Torrance, CA 90509 USA; [Shimizu, Eri] Hawaii Permanente Med Grp, Dept Med, Wailuku, HI USA; [Shimizu, Eri; Poon, Kimble] Maui Mem Med Ctr, Dept Med, Wailuku, HI USA; [Glaspy, Kathleen; Witt, Mallory D.; Spellberg, Brad] Univ Calif Los Angeles, David Geffen Sch Med, Torrance, CA USA; [Witt, Mallory D.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Div HIV Med, Torrance, CA 90509 USA; [Black, Susan; Diaz, Norma] Harbor UCLA Med Ctr, Dept Qual, Torrance, CA 90509 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Lundquist Institute; Permanente Medical Groups; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Lundquist Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Shimizu, E (corresponding author), Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Div Gen Internal Med, Torrance, CA 90509 USA.	eshimizu37@gmail.com						[Anonymous], 2007, MED PAYM ADV COMM RE, P107; Arbaje AI, 2008, GERONTOLOGIST, V48, P495, DOI 10.1093/geront/48.4.495; ASHTON CM, 1995, ANN INTERN MED, V122, P415, DOI 10.7326/0003-4819-122-6-199503150-00003; ASHTON CM, 1994, MED CARE, V32, P755, DOI 10.1097/00005650-199408000-00001; Ashton CM, 1997, MED CARE, V35, P1044, DOI 10.1097/00005650-199710000-00006; Berenson Julia, 2012, Issue Brief (Commonw Fund), V34, P1; Calvillo-King L, 2013, J GEN INTERN MED, V28, P269, DOI 10.1007/s11606-012-2235-x; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chew LD, 2004, FAM MED, V36, P588; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Dudas V, 2001, AM J MED, V111, P26, DOI 10.1016/S0002-9343(01)00966-4; Forster AJ, 2005, J GEN INTERN MED, V20, P317, DOI 10.1111/j.1525-1497.2005.30390.x; Forster AJ, 2004, CAN MED ASSOC J, V170, P345; Goldfield NI, 2008, HEALTH CARE FINANC R, V30, P75; Horwitz LI, 2013, JAMA INTERN MED, V173, P1715, DOI 10.1001/jamainternmed.2013.9318; Hughes M R, 2000, Top Health Inf Manage, V20, P65; Jack BW, 2009, ANN INTERN MED, V150, P178, DOI 10.7326/0003-4819-150-3-200902030-00007; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Jiang HJ, 2005, AM J PUBLIC HEALTH, V95, P1561, DOI 10.2105/AJPH.2004.044222; Joynt KE, 2013, JAMA-J AM MED ASSOC, V309, P342, DOI 10.1001/jama.2012.94856; Joynt KE, 2012, NEW ENGL J MED, V366, P1366, DOI 10.1056/NEJMp1201598; Joynt KE, 2011, JAMA-J AM MED ASSOC, V305, P675, DOI 10.1001/jama.2011.123; Makaryus AN, 2005, MAYO CLIN PROC, V80, P991, DOI 10.4065/80.8.991; Maniaci MJ, 2008, MAYO CLIN PROC, V83, P554, DOI 10.4065/83.5.554; Mitchell SE, 2012, J HEALTH COMMUN, V17, P325, DOI 10.1080/10810730.2012.715233; Oddone EZ, 1996, J GEN INTERN MED, V11, P597, DOI 10.1007/BF02599027; Rodriguez F, 2011, AM HEART J, V162, P254, DOI 10.1016/j.ahj.2011.05.009; Strunin L, 2007, J HOSP MED, V2, P297, DOI 10.1002/jhm.206; van Walraven C, 2011, CAN MED ASSOC J, V183, pE391, DOI 10.1503/cmaj.101860; Weissman JS, 1999, MED CARE, V37, P490, DOI 10.1097/00005650-199905000-00008; WEISSMAN JS, 1994, INQUIRY-J HEALTH CAR, V31, P163	31	7	8	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 11	2014	9	3							e91244	10.1371/journal.pone.0091244	http://dx.doi.org/10.1371/journal.pone.0091244			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC9GM	24618829	gold, Green Submitted, Green Published			2023-01-03	WOS:000332842400064
J	Tsai, JR; Liu, PL; Chen, YH; Chou, SH; Yang, MC; Cheng, YJ; Hwang, JJ; Yin, WH; Chong, IW				Tsai, Jong-Rung; Liu, Po-Len; Chen, Yung-Hsiang; Chou, Shah-Hwa; Yang, Ming-Chan; Cheng, Yu-Jen; Hwang, Jhi-Jhu; Yin, Wei-Hsian; Chong, Inn-Wen			Ginkgo biloba Extract Decreases Non-Small Cell Lung Cancer Cell Migration by Downregulating Metastasis-Associated Factor Heat-Shock Protein 27	PLOS ONE			English	Article							HEPATOCELLULAR-CARCINOMA; ESTROGEN-RECEPTOR; STRESS-PROTEINS; EXPRESSION; HSP27; ACTIVATION; CHEMOTHERAPY; APOPTOSIS; SURVIVAL; ADENOCARCINOMA	Heat-shock proteins (HSPs) are molecular chaperones that protect proteins from damage. HSP27 expression is associated with cancer transformation and invasion. Ginkgo biloba extract (EGb761), the most widely sold herbal supplement, has antiangiogenic effects and induces tumor apoptosis. Data regarding the effect of EGb761 on HSP expression is limited, particularly in cancer. HSP27 expression in paired tumors and normal lung tissues of 64 patients with non-small cell lung cancer (NSCLC) were detected by real-time PCR, western blotting, and immunohistochemistry. NSCLC cell lines (A549/H441) were used to examine the migratory abilities in vitro. NSCLC tissue showed higher HSP27 expression than normal lung tissue. Kaplan-Meier survival analysis showed that NSCLC patients with low HSP27 expression ratio (<1) had significantly longer survival time than those with a high expression ratio (>1) (p = 0.04). EGb761 inhibited HSP27 expression and migratory ability of A549/H441 cells, which is the same as HSP27-siRNA transfection effect. Moreover, EGb761 treatment activated the AKT and p38 pathways and did not affect the expression of PI3K, ERK, and JNK pathways. HSP27 is a poor prognostic indicator of NSCLC. EGb761 can decrease the migration ability of A549/H441 by inhibiting HSP27 expression most likely through AKT and p38 MAPK pathways activation.	[Tsai, Jong-Rung; Liu, Po-Len; Chou, Shah-Hwa; Hwang, Jhi-Jhu; Chong, Inn-Wen] Kaohsiung Med Univ, Coll Med, Dept Resp Therapy, Kaohsiung, Taiwan; [Tsai, Jong-Rung; Hwang, Jhi-Jhu; Chong, Inn-Wen] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Kaohsiung, Taiwan; [Chen, Yung-Hsiang] China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan; [Chou, Shah-Hwa] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Div Chest Surg, Dept Surg, Kaohsiung, Taiwan; [Yang, Ming-Chan] Yuans Gen Hosp, Dept Surg, Kaohsiung, Taiwan; [Cheng, Yu-Jen] I Shou Univ, E Da Hosp, Dept Surg, Dept Hlth Management,Div Thorac Surg, Kaohsiung, Taiwan; [Yin, Wei-Hsian] Natl Yang Ming Univ, Fac Med, Cheng Hsin Gen Hosp, Div Cardiol, Taipei 112, Taiwan; [Yin, Wei-Hsian] Natl Yang Ming Univ, Sch Med, Cardiovasc Res Ctr, Taipei 112, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; China Medical University Taiwan; Kaohsiung Medical University; Kaohsiung Medical University Hospital; E-Da Hospital; I Shou University; Cheng Hsin General Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Chong, IW (corresponding author), Kaohsiung Med Univ, Coll Med, Dept Resp Therapy, Kaohsiung, Taiwan.	chong@kmu.edu.tw	Chen, Yung-Hsiang/K-6766-2015	Chen, Yung-Hsiang/0000-0002-8756-5113; Tsai, Jong rung/0000-0002-3222-0409	Kaohsiung Medical University [KMU-Q098022]; National Science Council, Taiwan [NSC102-2314-B-037-067]	Kaohsiung Medical University; National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported in part by grant KMU-Q098022 from the Kaohsiung Medical University, and grant NSC102-2314-B-037-067 from National Science Council, Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aldrian S, 2002, CELL STRESS CHAPERON, V7, P177, DOI 10.1379/1466-1268(2002)007<0177:OOHATM>2.0.CO;2; Arts HJG, 1999, INT J CANCER, V84, P234, DOI 10.1002/(SICI)1097-0215(19990621)84:3<234::AID-IJC6>3.0.CO;2-9; Atkins D, 2005, CONTRIB NEPHROL, V148, P35, DOI 10.1159/000086042; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bausero MA, 2004, TUMOR BIOL, V25, P243, DOI 10.1159/000081387; Berrieman HK, 2006, ONCOL REP, V15, P283; Bubendorf L, 1999, J NATL CANCER I, V91, P1758, DOI 10.1093/jnci/91.20.1758; Chao JCJ, 2004, WORLD J GASTROENTERO, V10, P37; Chen XF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059314; Chen XH, 2011, CELL PHYSIOL BIOCHEM, V27, P227, DOI 10.1159/000327948; CHRETIEN P, 1988, J CELL PHYSIOL, V137, P157, DOI 10.1002/jcp.1041370119; CIOCCA DR, 1989, CANCER RES, V49, P4298; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Conroy SE, 1998, BRIT J CANCER, V77, P1875, DOI 10.1038/bjc.1998.312; Cornford PA, 2000, CANCER RES, V60, P7099; DeFeudis FV, 2003, FUND CLIN PHARMACOL, V17, P405, DOI 10.1046/j.1472-8206.2003.00156.x; Dorion S, 2002, CELL STRESS CHAPERON, V7, P200, DOI 10.1379/1466-1268(2002)007<0200:AOTMAP>2.0.CO;2; Erkizan O, 2004, UROLOGY, V64, P474, DOI 10.1016/j.urology.2004.04.017; Eskenazi AE, 1998, CLIN EXP METASTAS, V16, P283, DOI 10.1023/A:1006553127695; Fukaya H, 1999, Nihon Jibiinkoka Gakkai Kaiho, V102, P907; Gandour-Edwards R, 1998, OTOLARYNG HEAD NECK, V118, P610, DOI 10.1177/019459989811800508; Ghosh A, 2013, EXP MOL PATHOL, V94, P103, DOI 10.1016/j.yexmp.2012.09.001; Grabinski N, 2011, CELL SIGNAL; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; Hadchity E, 2009, MOL THER, V17, P1387, DOI 10.1038/mt.2009.90; Hauns B, 1999, ARZNEIMITTEL-FORSCH, V49, P1030; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; Hsu HS, 2011, CANCER; KANITAKIS J, 1989, J CUTAN PATHOL, V16, P272, DOI 10.1111/j.1600-0560.1989.tb00051.x; Kapranos N, 2002, J CANCER RES CLIN, V128, P426, DOI 10.1007/s00432-002-0357-y; Kim KS, 2005, ORAL ONCOL, V41, P383, DOI 10.1016/j.oraloncology.2004.09.013; King KL, 2000, CANCER, V88, P2464, DOI 10.1002/1097-0142(20000601)88:11<2464::AID-CNCR6>3.0.CO;2-W; Lemieux P., 1997, BIOL DELAY SYSTEMS L, V17, P113; Malusecka E, 2008, ANTICANCER RES, V28, P501; Mansi L, 2011, B CANC; Moon A, 2010, PATHOLOGY, V42, P421, DOI 10.3109/00313025.2010.493866; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; Nano M, 2000, Chir Ital, V52, P313; Oken BS, 1998, ARCH NEUROL-CHICAGO, V55, P1409, DOI 10.1001/archneur.55.11.1409; Onen A, 1999, ACTA GASTRO-ENT BELG, V62, P386; Pietri S, 1997, CARDIOVASC DRUG THER, V11, P121, DOI 10.1023/A:1007728729844; PUY LA, 1989, CANCER, V64, P1067, DOI 10.1002/1097-0142(19890901)64:5<1067::AID-CNCR2820640518>3.0.CO;2-H; Rozsas A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077459; Sarhadi V, 2006, J PATHOL, V209, P206, DOI 10.1002/path.1960; Soldes OS, 1999, BRIT J CANCER, V79, P595, DOI 10.1038/sj.bjc.6690094; Storm FK, 1996, ANN SURG ONCOL, V3, P570, DOI 10.1007/BF02306091; Takeno S, 2001, DIS ESOPHAGUS, V14, P149, DOI 10.1046/j.1442-2050.2001.00174.x; Takeno S, 2001, ANN SURG ONCOL, V8, P215, DOI 10.1245/aso.2001.8.3.215; Tang SQ, 1997, J BIOL CHEM, V272, P28704, DOI 10.1074/jbc.272.45.28704; Tian T, 2007, CANCER SCI, V98, P1265, DOI 10.1111/j.1349-7006.2007.00514.x; Tsuruta M, 2008, ONCOL REP, V20, P1165, DOI 10.3892/or_00000125; Wang GD, 2004, ONCOL REP, V12, P955; Wang W, 2011, TUMOR BIOL, V32, P1199, DOI 10.1007/s13277-011-0223-0; WEISS A, 1984, J IMMUNOL, V133, P123; Wikman H, 2002, ONCOGENE, V21, P5804, DOI 10.1038/sj.onc.1205726; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yao HX, 2009, LUNG CANCER, V65, P41, DOI 10.1016/j.lungcan.2008.10.024; Zhang Y, 2007, CLIN CANCER RES, V13, P2855, DOI 10.1158/1078-0432.CCR-06-2090; Zimmermann M, 2012, CLIN CHIM ACTA, V413, P1115, DOI 10.1016/j.cca.2012.03.008	59	24	31	0	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 11	2014	9	3							e91331	10.1371/journal.pone.0091331	http://dx.doi.org/10.1371/journal.pone.0091331			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC9GM	24618684	Green Published, gold, Green Submitted			2023-01-03	WOS:000332842400078
J	Berridge, V				Berridge, Virginia			Electronic cigarettes and history	LANCET			English	Editorial Material							TOBACCO; SMOKING		London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, Ctr Hist Publ Hlth, London WC1H 9SH, England	University of London; London School of Hygiene & Tropical Medicine	Berridge, V (corresponding author), London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, Ctr Hist Publ Hlth, London WC1H 9SH, England.	Virginia.Berridge@lshtm.ac.uk		berridge, virginia/0000-0001-8011-8348				Anderson S, 2007, ADDICTION, V102, P704, DOI 10.1111/j.1360-0443.2007.01790.x; Berridge V., 2007, MARKETING HLTH SMOKI; Berridge Virginia, 2013, DEMONS OUR CHANGING; Houses of Parliament Parliamentary Office of Science and Technology, 2014, POSTNOTE, V455, P1; Parascandola M, 2005, NICOTINE TOB RES, V7, P779, DOI 10.1080/14622200500262584; Williams -Alvarez J., 2014, WHAT YOU NEED KNOW L	6	14	14	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 28	2014	383	9936					2204	2205		10.1016/S0140-6736(14)61074-6	http://dx.doi.org/10.1016/S0140-6736(14)61074-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AK8DO	24983089				2023-01-03	WOS:000338657600013
J	Costandi, M				Costandi, Moheb			REHABILITATION Machine recovery	NATURE			English	Editorial Material							ROBOT-ASSISTED THERAPY; UPPER-LIMB IMPAIRMENT; STROKE											Burgar CG, 2011, J REHABIL RES DEV, V48, P445, DOI 10.1682/JRRD.2010.04.0062; Jarrasse N., 2013, IEEE INT C REH ROB; Kleim JA, 1998, J NEUROPHYSIOL, V80, P3321, DOI 10.1152/jn.1998.80.6.3321; Lambercy O, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-63; Lo AC, 2010, NEW ENGL J MED, V362, P1772, DOI 10.1056/NEJMoa0911341; Maciejasz P, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-3; Taheri H, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-10; Volpe BT, 2000, NEUROLOGY, V54, P1938, DOI 10.1212/WNL.54.10.1938; Wagner TH, 2011, STROKE, V42, P2630, DOI 10.1161/STROKEAHA.110.606442	9	8	8	1	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 26	2014	510	7506					S8	S9		10.1038/510S8a	http://dx.doi.org/10.1038/510S8a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AJ6LK	24964027				2023-01-03	WOS:000337806300006
J	Fukushima, FB; Bezerra, DM; Boas, PJFV; Valle, AP; Vidal, EIO				Fukushima, Fernanda B.; Bezerra, Dailson M.; Villas Boas, Paulo J. F.; Valle, Adriana P.; Vidal, Edison I. O.			Complex regional pain syndrome	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Fukushima, Fernanda B.; Bezerra, Dailson M.] Univ Estadual Paulista UNESP, Dept Anesthesiol, BR-18618970 Botucatu, SP, Brazil; [Villas Boas, Paulo J. F.; Valle, Adriana P.; Vidal, Edison I. O.] Univ Estadual Paulista UNESP, Dept Internal Med, BR-18618970 Botucatu, SP, Brazil	Universidade Estadual Paulista; Universidade Estadual Paulista	Fukushima, FB (corresponding author), Univ Estadual Paulista UNESP, Dept Anesthesiol, BR-18618970 Botucatu, SP, Brazil.	ffukushima@fmb.unesp.br	Fukushima, Fernanda Bono/E-3196-2012; Vidal, Edison Iglesias de Oliveira/G-1882-2012; Boas, Paulo J F Villas/I-4656-2014; Valle, Adriana/ABI-5894-2020; Valle, Adriana P/F-9897-2014; Fukushima, Fernanda Bono/AAR-2740-2021	Fukushima, Fernanda Bono/0000-0001-8055-5425; Vidal, Edison Iglesias de Oliveira/0000-0002-1573-4678; Boas, Paulo J F Villas/0000-0001-9876-3222; Valle, Adriana P/0000-0002-0090-8524; 				Albazaz R, 2008, ANN VASC SURG, V22, P297, DOI 10.1016/j.avsg.2007.10.006; Allen G, 1999, PAIN, V80, P539, DOI 10.1016/S0304-3959(98)00246-2; Beerthuizen A, 2012, PAIN, V153, P1187, DOI 10.1016/j.pain.2012.01.026; Centre for Clinical Practice at NICE (UK)-National Institute for Health and Care Excellence: Clinical Guidelines, 2010, NEUR PAIN PHARM MAN; de Mos M, 2007, PAIN, V129, P12, DOI 10.1016/j.pain.2006.09.008; de Mos M, 2009, CLIN J PAIN, V25, P590, DOI 10.1097/AJP.0b013e3181a11623; Dworkin RH, 2010, MAYO CLIN PROC, V85, pS3, DOI 10.4065/mcp.2009.0649; Goebel A, 2012, COMPLEX REGIONAL PAI; Harden RN, 2013, PAIN MED, V14, P180, DOI 10.1111/pme.12033; Harden RN, 2010, PAIN, V150, P268, DOI 10.1016/j.pain.2010.04.030; International Association for the Study of Pain, CLASSIFICATION CHRON; Marinus Johan, 2011, Lancet Neurol, V10, P637, DOI 10.1016/S1474-4422(11)70106-5; Moseley GL, 2014, J PAIN, V15, P16, DOI 10.1016/j.jpain.2013.08.009; O'Connell NE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009416.pub2; Sandroni P, 2003, PAIN, V103, P199, DOI 10.1016/S0304-3959(03)00065-4	15	8	9	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 25	2014	348								g3683	10.1136/bmj.g3683	http://dx.doi.org/10.1136/bmj.g3683			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AK1UK	24965221	Green Published			2023-01-03	WOS:000338202200001
J	Wilkinson, ST; D'Souza, DC				Wilkinson, Samuel T.; D'Souza, Deepak Cyril			Problems With the Medicalization of Marijuana	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RISK		[Wilkinson, Samuel T.; D'Souza, Deepak Cyril] Yale Univ, Sch Med, Dept Psychiat, West Haven, CT 06516 USA; [D'Souza, Deepak Cyril] Connecticut Mental Hlth Ctr, Abraham Ribicoff Res Facil, New Haven, CT 06519 USA; [D'Souza, Deepak Cyril] VA Connecticut Healthcare Syst, Schizophrenia & Neuropharmacol Res Grp, West Haven, CT USA	Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	D'Souza, DC (corresponding author), Yale Univ, Sch Med, Dept Psychiat, Psychiat Serv 116A,VA Connecticut Healthcare Syst, 950 Campbell Ave, West Haven, CT 06516 USA.	deepak.dsouza@yale.edu	Wilkinson, Samuel/GQP-1952-2022		NATIONAL INSTITUTE OF MENTAL HEALTH [R25MH071584] Funding Source: NIH RePORTER; NIMH NIH HHS [R25 MH071584, L30 MH111000] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bhattacharyya S, 2010, NEUROPSYCHOPHARMACOL, V35, P764, DOI 10.1038/npp.2009.184; Budney AJ, 2006, CURR OPIN PSYCHIATR, V19, P233, DOI 10.1097/01.yco.0000218592.00689.e5; Callaghan RC, 2013, CANCER CAUSE CONTROL, V24, P1811, DOI 10.1007/s10552-013-0259-0; Castle D, 2012, MARIJUANA MADNESS; Cooper ZD, 2013, NEUROPSYCHOPHARMACOL, V38, P1984, DOI 10.1038/npp.2013.97; Kleber HD, 2012, AM J PSYCHIAT, V169, P564, DOI 10.1176/appi.ajp.2012.12030373; Leweke FM, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.15; Meier MH, 2012, P NATL ACAD SCI USA, V109, pE2657, DOI 10.1073/pnas.1206820109; Moore THM, 2007, LANCET, V370, P319, DOI 10.1016/S0140-6736(07)61162-3; Verweij PE, 2000, JAMA-J AM MED ASSOC, V284, P2875, DOI 10.1001/jama.284.22.2875	10	33	36	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	2014	311	23					2377	2378		10.1001/jama.2014.6175	http://dx.doi.org/10.1001/jama.2014.6175			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AI9XV	24845238	Green Accepted			2023-01-03	WOS:000337301500014
J	Tang, QC; Wang, YH; Huang, R; You, Q; Wang, GY; Chen, YG; Jiang, Z; Liu, Z; Yu, L; Muhammad, S; Wang, XS				Tang, Qingchao; Wang, Yihui; Huang, Rui; You, Qi; Wang, Guiyu; Chen, Yinggang; Jiang, Zheng; Liu, Zheng; Yu, Lei; Muhammad, Shan; Wang, Xishan			Preparation of Anti-Tumor Nanoparticle and Its Inhibition to Peritoneal Dissemination of Colon Cancer	PLOS ONE			English	Article							COLORECTAL-CANCER; TARGETED DELIVERY; GASTRIC-CANCER; CARCINOMATOSIS; 5-FU; SENSITIVITY; THERAPY; GROWTH; CELLS	Background: 5-Fluorouracil (5-FU) is one of the most classic chemotherapy drugs. Nanoparticle drug delivery vehicles offer superiority over target effect enhancement and abatement of side effects. Little is known however as to the specific effect of nanoparticle on peritoneal dissemination of colon cancer. The aim of this study is to prepare one NPs (nanoparticles) loaded with 5-FU and investigate the characteristic of NPs and the role of it in peritoneal metastasis nodules formation of human colon cancer. Methodology/Principal Findings: Prepared the NPs (nanoparticles) loaded with 5-FU (5-Fluorouracil) by PEG-PLGA with the method of double emulsion. Then evaluate the characteristics of the NPs by scanning electron microscopy, analyzing the particle diameter distribution and determining the loading efficiency. Detect the release features of NPs in vitro and in vivo. Nude mice with peritoneal metastases were treated with 5-FU solution or 5-FU-NPs through peritoneal cavity. Count the nodules on peritoneum and mesenterium and survey the size of them. We got NPs with average-diameter of 310 nm. In vitro release test shows NPs can release equably for 5 days with release rate of 99.2%. In vivo, NPs group can keep higher plasma concentration of 5-FU longer than it in solution group. The number of peritoneal dissemination nodule below 1 mm in 5-FU-sol group(17.3 +/- 3.5) and 5-FU-NP group(15.2 +/- 3.2) is less than control group(27.2 +/- 4.7)(P<0.05). The total number of nodules in 5-FU-NP group(28.7 +/- 4.2) is significantly smaller than in 5-FU-sol group(37.7 +/- 6.3) (P<0.05). Conclusions/Significance: The novel anti-tumor nanoparticles loaded with 5-FU by PEG-PLGA can release maintain 5 days and have inhibitory action to peritoneal dissemination of colon cancer in mice.	[Tang, Qingchao; Huang, Rui; Wang, Guiyu; Chen, Yinggang; Jiang, Zheng; Liu, Zheng; Yu, Lei; Muhammad, Shan; Wang, Xishan] Harbin Med Univ, Affiliated Hosp 2, Dept Colorectal Canc Surg, Ctr Canc, Harbin, Peoples R China; [Wang, Yihui; You, Qi] Harbin Med Univ, Affiliated Hosp 3, Dept Colorectal Surg, Harbin, Peoples R China	Harbin Medical University; Harbin Medical University	Wang, XS (corresponding author), Harbin Med Univ, Affiliated Hosp 2, Dept Colorectal Canc Surg, Ctr Canc, Harbin, Peoples R China.	wxshan1208@126.com			"Wu Jie-ping'' Medicine Foundation of China [04102303]; Special Foundation of Harbin Technical Innovation [2006RFQXS075]; Heilongjiang Province of China [JC04-02]	"Wu Jie-ping'' Medicine Foundation of China; Special Foundation of Harbin Technical Innovation; Heilongjiang Province of China	This work was supported by the "Wu Jie-ping'' Medicine Foundation of China, (No. 04102303) and the Special Foundation of Harbin Technical Innovation for Talented Person (No. 2006RFQXS075) and the Science Fund for Distinguished Young Scholars of Heilongjiang Province of China under Grant No. JC04-02. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Botella P, 2011, J CONTROL RELEASE, V156, P246, DOI 10.1016/j.jconrel.2011.06.039; Brigger I, 2002, ADV DRUG DELIVER REV, V54, P631, DOI 10.1016/S0169-409X(02)00044-3; Burke AR, 2012, BIOMATERIALS, V33, P2961, DOI 10.1016/j.biomaterials.2011.12.052; Cai JC, 2013, J CLIN INVEST, V123, P566, DOI 10.1172/JCI65871; Chaturvedi K, 2013, J CONTROL RELEASE, V165, P129, DOI 10.1016/j.jconrel.2012.11.005; Chester JD, 2000, ANN ONCOL, V11, P235, DOI 10.1023/A:1008356017611; Couvreur P, 2013, ADV DRUG DELIVER REV, V65, P21, DOI 10.1016/j.addr.2012.04.010; de Cuba EMV, 2012, VIRCHOWS ARCH, V461, P231, DOI 10.1007/s00428-012-1287-y; Drecoll E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005715; Emoto S, 2012, CANCER SCI, V103, P1304, DOI 10.1111/j.1349-7006.2012.02274.x; Gomez-Portilla Alberto, 2005, Cir Esp, V77, P6; Hasegawa S, 2006, ONCOL REP, V15, P1185; Jayne DG, 2002, BRIT J SURG, V89, P1545, DOI 10.1046/j.1365-2168.2002.02274.x; Koppe MJ, 2006, ANN SURG, V243, P212, DOI 10.1097/01.sla.0000197702.46394.16; Lamppa JW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017042; Li Q, 2013, CANCER LETT, V335, P168, DOI 10.1016/j.canlet.2013.02.029; Li S, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-103; Lin H, 2008, CHEM RES CHINESE U, V24, P805; Lu HX, 2007, CANCER CHEMOTH PHARM, V59, P175, DOI 10.1007/s00280-006-0256-z; Pera M, 2012, ANN ONCOL, V23, P664, DOI 10.1093/annonc/mdr291; Smith MH, 2012, ACCOUNTS CHEM RES, V45, P985, DOI 10.1021/ar200216f; Soma D, 2009, CANCER SCI, V100, P1979, DOI 10.1111/j.1349-7006.2009.01265.x; Wang AZ, 2012, ANNU REV MED, V63, P185, DOI 10.1146/annurev-med-040210-162544; Wang YS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-402; Wohlfart S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019121; Yang SH, 2004, J SURG ONCOL, V87, P167, DOI 10.1002/jso.20109	26	19	20	0	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2014	9	6							e98455	10.1371/journal.pone.0098455	http://dx.doi.org/10.1371/journal.pone.0098455			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK4YO	24896096	Green Published, Green Submitted, gold			2023-01-03	WOS:000338430700043
J	Lee, CC; Lee, MTG; Chang, SS; Lee, SH; Huang, YC; Yo, CH; Lee, SH; Chen, SC				Lee, Chien-Chang; Lee, Meng-Tse Gabriel; Chang, Shy-Shin; Lee, Si-Huei; Huang, Yu-Chi; Yo, Chia-Hung; Lee, Shih-Hao; Chen, Shyr-Chyr			A Comparison of Vasopressin, Terlipressin, and Lactated Ringers for Resuscitation of Uncontrolled Hemorrhagic Shock in an Animal Model	PLOS ONE			English	Article							RESPIRATORY-DISTRESS-SYNDROME; DELAYED FLUID RESUSCITATION; MASSIVE SPLENIC INJURY; CYTOKINE RESPONSE; LIVER TRAUMA; SEPSIS; RATS; INFLAMMATION; EPINEPHRINE; MECHANISMS	Aim: The aim of this study is to compare the effect of lactated ringer (LR), vasopressin (Vaso) or terlipressin (Terli) on uncontrolled hemorrhagic shock (UHS) in rats. Methods: 48 rats were divided into four treatment groups for UHS study. Vaso group was given bolus vasopressin (0.8 U/kg); the Terli group was given bolus terlipressin (15 mcg/ kg); LR group was given LR and the sham group was not given anything. Mean arterial pressure (MAP), serum lactate level, plasma cytokine levels, lung injury and mortality are investigated for these different treatment groups. Results: Compared with LR group, vasopressin and terlipressin-treated groups were associated with higher MAP, lowered mortality rates, less lung injury, lowered serum lactate level, less proinflammatory and more anti-inflammatory cytokine production at certain time points. Comparing between vasopressin and terlipressin treated groups, there is no statistical difference in mortality rates, lung injury, serum lactate level and cytokine level. However, there is a difference in the length of time in maintaining a restored level of MAP (80 to 110 mmHg). The terlipressin treated rats can maintain this restored level of MAP for 45 minutes, but the vasopressin treated rats can only maintain this restored level of MAP for 5 minutes before decreasing gradually to the MAP observed in LR group (40 mmHg). Conclusion: Early optimization of hemodynamics with terlipressin or vasopressin in an animal model of UHS was associated with improved hemodynamics and inflammatory cytokine profile than the LR control. Compared with vasopressin, terlipressin has the advantage of ease of use and sustained effects.	[Lee, Chien-Chang; Lee, Meng-Tse Gabriel; Huang, Yu-Chi; Lee, Shih-Hao; Chen, Shyr-Chyr] Natl Taiwan Univ Hosp, Dept Emergency Med, Taipei, Taiwan; [Chang, Shy-Shin] Chang Gung Univ, Grad Inst Clin Med Sci, Taoyuan, Taiwan; [Chang, Shy-Shin] Chang Gung Mem Hosp, Dept Family Med & Emergency Med, Taoyuan, Taiwan; [Lee, Si-Huei] Natl Yang Ming Univ, Dept Phys Med & Rehabil, Taipei 112, Taiwan; [Lee, Si-Huei] Natl Yang Ming Univ, Taipei Vet Gen Hosp, Taipei 112, Taiwan; [Lee, Si-Huei] Natl Yang Ming Univ, Taipei Vet Gen Hosp, Ctr Geriatr & Gerontol, Taipei 112, Taiwan; [Yo, Chia-Hung] Far Eastern Mem Hosp, Dept Emergency Med, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; Chang Gung University; Chang Gung Memorial Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; Far Eastern Memorial Hospital	Chen, SC (corresponding author), Natl Taiwan Univ Hosp, Dept Emergency Med, Taipei, Taiwan.	scchen@ntu.edu.tw	Lee, Chien-Chang/HHM-5986-2022	LEE, CHIEN-CHANG/0000-0002-1243-2463; CHEN, SHYR-CHYR/0000-0002-5858-3013	National Science Council [NSC 96-2314-B-002-042]; National Taiwan University Hospital Grant [NTUH96N01]	National Science Council(Ministry of Science and Technology, Taiwan); National Taiwan University Hospital Grant(National Taiwan University)	This study was supported by the National Science Council Grant NSC 96-2314-B-002-042 and National Taiwan University Hospital Grant NTUH96N01. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asfar P, 2003, CRIT CARE MED, V31, P215, DOI 10.1097/00003246-200301000-00033; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Boyd JH, 2008, RESUSCITATION, V79, P325, DOI 10.1016/j.resuscitation.2008.07.006; Burris D, 1999, J TRAUMA, V46, P216, DOI 10.1097/00005373-199902000-00003; CAPONE A, 1995, RESUSCITATION, V29, P143, DOI 10.1016/0300-9572(95)00829-I; Dib N, 2006, CAN MED ASSOC J, V174, P1433, DOI 10.1503/cmaj.051700; Fink MP, 2002, CURR OPIN CLIN NUTR, V5, P167, DOI 10.1097/00075197-200203000-00009; Haas T, 2004, J TRAUMA, V57, P177, DOI 10.1097/01.TA.0000044357.25191.1B; Ioannou G, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002147]; Jarrar D, 1999, INT J MOL MED, V4, P575; Kalkan E, 2006, TURKISH J TRAUMA EME, V12, P263; Kaszaki J, 2006, TRANSPLANT P, V38, P826, DOI 10.1016/j.transproceed.2006.02.152; Kolarova J, 2005, CHEST, V127, P1327, DOI 10.1378/chest.127.4.1327; Krausz MM, 2001, SHOCK, V16, P383, DOI 10.1097/00024382-200116050-00011; Krismer AC, 2005, ANAESTHESIST, V54, P220, DOI 10.1007/s00101-004-0793-y; Lee CC, 2005, SHOCK, V24, P177, DOI 10.1097/01.shk.0000171870.42900.15; Lee CC, 2007, ANN EMERG MED, V49, P37, DOI 10.1016/j.annemergmed.2006.05.031; Leppaniemi A, 1996, J SURG RES, V63, P413, DOI 10.1006/jsre.1996.0285; Lienhart HG, 2008, CURR OPIN CRIT CARE, V14, P247, DOI 10.1097/MCC.0b013e3282fce62a; Meybohm P, 2007, J TRAUMA, V62, P640, DOI 10.1097/01.ta.0000240962.62319.c8; Morales D, 1999, CIRCULATION, V100, P226, DOI 10.1161/01.CIR.100.3.226; Mzezewa S, 2004, BURNS, V30, P236, DOI 10.1016/j.burns.2003.11.004; Perl M, 2005, AM J PATHOL, V167, P1545, DOI 10.1016/S0002-9440(10)61240-0; Raedler C, 2004, ANESTH ANALG, V98, P1759, DOI 10.1213/01.ANE.0000117150.29361.5A; REDL H, 1993, BRIT MED BULL, V49, P556, DOI 10.1093/oxfordjournals.bmb.a072630; Rocha JA, 2009, CLINICS, V64, P591, DOI 10.1590/S1807-59322009000600016; Rostron AJ, 2008, TRANSPLANTATION, V85, P597, DOI 10.1097/TP.0b013e31816398dd; ROUMEN RMH, 1993, ANN SURG, V218, P769, DOI 10.1097/00000658-199312000-00011; Rozenfeld V, 2000, ANN PHARMACOTHER, V34, P250; Schummer W, 2005, ANAESTHESIST, V54, P707, DOI 10.1007/s00101-005-0854-x; Sharma RM, 2005, ANESTH ANALG, V101, P833, DOI 10.1213/01.ANE.0000175209.61051.7F; Shires GT, 2005, AM J SURG, V189, P85, DOI 10.1016/j.amjsurg.2004.06.040; Solomonov E, 2000, CRIT CARE MED, V28, P749, DOI 10.1097/00003246-200003000-00024; Stadlbauer KH, 2003, ANESTHESIOLOGY, V98, P699, DOI 10.1097/00000542-200303000-00018; Tamion F, 1997, AM J PHYSIOL-GASTR L, V273, pG314, DOI 10.1152/ajpgi.1997.273.2.G314; Tsuneyoshi Isao, 2005, J Anesth, V19, P170, DOI 10.1007/s00540-004-0299-4; Watters JM, 2006, J TRAUMA, V61, P300, DOI 10.1097/01.ta.0000224211.36154.44; Wenzel V, 2004, NEW ENGL J MED, V350, P105, DOI 10.1056/NEJMoa025431; Yang GM, 2010, EUR J PHARMACOL, V628, P148, DOI 10.1016/j.ejphar.2009.11.040	39	9	10	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2014	9	4							e95821	10.1371/journal.pone.0095821	http://dx.doi.org/10.1371/journal.pone.0095821			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG3EI	24759799	gold, Green Published, Green Submitted			2023-01-03	WOS:000335298200093
J	Yoo, DS; Chang, J; Kim, JT; Choi, MJ; Choi, J; Choi, KH; Park, MS; Cho, KH				Yoo, Deok-Sang; Chang, Jane; Kim, Joon-Tae; Choi, Min-Ji; Choi, Jina; Choi, Kang-Ho; Park, Man-Seok; Cho, Ki-Hyun			Various Blood Glucose Parameters that Indicate Hyperglycemia after Intravenous Thrombolysis in Acute Ischemic Stroke Could Predict Worse Outcome	PLOS ONE			English	Article							POSTSTROKE HYPERGLYCEMIA; OXIDATIVE STRESS; CONTROLLED-TRIAL; INFARCT SIZE; MEAN GLUCOSE; ADMISSION; VARIABILITY; PRESSURE; TOPOGRAPHY; MORTALITY	Background: Hyperglycemia is common after stroke, and it is well known to worsen its outcome. However, it is important to consider that blood glucose (BG) levels can undergo dynamic changes during the acute stage of ischemic stroke. We sought to investigate the clinical significance of various glucose parameters within first 24 hours in acute ischemic stroke (AIS). The study focused on hyperacute stage patients who underwent IVT and investigated which parameters of glucose demonstrated to be helpful for predicting outcome. Methods: This was a retrospective study of consecutive patients with AIS at a single stroke center. Patients were consecutively enrolled if they were treated with IV-tPA within 3 hours of symptom onset. BG was measured immediately upon arrival in ER, after IVT and every 6-8 hours during the first 24 hours after IVT. The various parameters of BG were the following: BG before IVT, BG after IVT, mean BG (mBG), maximal BG (max BG), standard deviation of BG (sdBG), and standard deviation of mean BG (sdmBG). Results: 207 patients (127 men and 80 women) were included in this study. Seventy seven of 207 patients had favorable outcomes at 3 months. High BG after IVT, mBG and max BG were independently associated with mRS>2 at 3 months (adjusted by age, NIHSS, and atrial fibrillation). Several parameters of BG were also independently associated with early mortality within 3 months (BG after IVT, mBG, and max BG). BG after IVT and mBG over 180 mg/dL were independently associated with early mortality within 3 months. Conclusion: Serial measurements of BG might be a better predictor of clinical outcome in patients with AIS treated with IVT than single BG measurements before IVT. Therefore, these results suggest that variable parameters of BG could be important for the prediction of clinical outcome in AIS treated with IVT.	[Yoo, Deok-Sang; Chang, Jane; Kim, Joon-Tae; Choi, Min-Ji; Choi, Jina; Choi, Kang-Ho; Park, Man-Seok; Cho, Ki-Hyun] Chonnam Natl Univ Hosp, Dept Neurol, Cerebrovasc Ctr, Kwangju, South Korea	Chonnam National University; Chonnam National University Hospital	Kim, JT (corresponding author), Chonnam Natl Univ Hosp, Dept Neurol, Cerebrovasc Ctr, Kwangju, South Korea.	alldelight2@hanmail.net			Chonnam National University Hospital Biomedical Research Institute [CRI13041-21]; Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea [HI10C2020]	Chonnam National University Hospital Biomedical Research Institute; Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea	This study was supported by a grant (CRI13041-21) Chonnam National University Hospital Biomedical Research Institute. This study was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (HI10C2020). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; Ahmed N, 2010, ARCH NEUROL-CHICAGO, V67, P1123, DOI 10.1001/archneurol.2010.210; Ali NA, 2008, CRIT CARE MED, V36, P2316, DOI 10.1097/CCM.0b013e3181810378; Baird TA, 2003, STROKE, V34, P2208, DOI 10.1161/01.STR.0000085087.41330.FF; Bellolio MF, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005346.pub4; Bruno A, 1999, NEUROLOGY, V52, P280, DOI 10.1212/WNL.52.2.280; Bruno A, 2002, NEUROLOGY, V59, P669, DOI 10.1212/WNL.59.5.669; Ceriello A, 2008, DIABETES, V57, P1349, DOI 10.2337/db08-0063; Christensen H, 2002, EUR J NEUROL, V9, P297, DOI 10.1046/j.1468-1331.2002.00409.x; Darby DG, 1999, STROKE, V30, P2043, DOI 10.1161/01.STR.30.10.2043; Fuentes B, 2009, STROKE, V40, P562, DOI 10.1161/STROKEAHA.108.519926; Gray CS, 2007, LANCET NEUROL, V6, P397, DOI 10.1016/S1474-4422(07)70080-7; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; HELGASON CM, 1988, STROKE, V19, P1049, DOI 10.1161/01.STR.19.8.1049; Johnston KC, 2009, STROKE, V40, P3804, DOI 10.1161/STROKEAHA.109.561498; Kang J, 2012, NEUROLOGY, V79, P2018, DOI 10.1212/WNL.0b013e3182749eb8; KIERS L, 1992, J NEUROL NEUROSUR PS, V55, P263, DOI 10.1136/jnnp.55.4.263; Kim JT, 2011, EUR J NEUROL, V18, P988, DOI 10.1111/j.1468-1331.2011.03351.x; Kruyt ND, 2010, NAT REV NEUROL, V6, P145, DOI 10.1038/nrneurol.2009.231; Luitse MJA, 2012, LANCET NEUROL, V11, P261, DOI 10.1016/S1474-4422(12)70005-4; MacDougall NJJ, 2011, J CEREBR BLOOD F MET, V31, P807, DOI 10.1038/jcbfm.2010.210; McCormick M, 2010, ANN NEUROL, V67, P570, DOI 10.1002/ana.21983; Monnier L, 2006, JAMA-J AM MED ASSOC, V295, P1681, DOI 10.1001/jama.295.14.1681; Parsons MW, 2002, ANN NEUROL, V52, P20, DOI 10.1002/ana.10241; Pisarchik AN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046582; PRADO R, 1988, J CEREBR BLOOD F MET, V8, P186, DOI 10.1038/jcbfm.1988.48; Putaala J, 2011, CEREBROVASC DIS, V31, P83, DOI 10.1159/000321332; Rothwell PM, 2010, LANCET, V375, P938, DOI 10.1016/S0140-6736(10)60309-1; Rothwell PM, 2010, LANCET, V375, P895, DOI 10.1016/S0140-6736(10)60308-X; Scott JF, 1999, LANCET, V353, P376, DOI 10.1016/S0140-6736(05)74948-5; Siegelaar SE, 2010, CRIT CARE, V14, DOI 10.1186/cc9369; TONI D, 1994, J NEUROL SCI, V123, P129, DOI 10.1016/0022-510X(94)90214-3	32	22	22	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2014	9	4							e94364	10.1371/journal.pone.0094364	http://dx.doi.org/10.1371/journal.pone.0094364			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG2DP	24747428	Green Published, gold, Green Submitted			2023-01-03	WOS:000335226500027
J	Krauss, BS; Krauss, BA; Green, SM				Krauss, Baruch S.; Krauss, Benjamin A.; Green, Steven M.			Procedural Sedation and Analgesia in Children	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EMERGENCY-DEPARTMENT; ADVERSE EVENTS	This video shows the technique of procedural sedation and analgesia in children, reviewing indications, patient assessment, the use of sedative and analgesic drugs, potential adverse events, recovery, and discharge from the hospital.	[Krauss, Baruch S.] Brigham & Womens Hosp, Div Emergency Med, Boston, MA 02115 USA; [Krauss, Benjamin A.] Univ Massachusetts, Boston, MA 02125 USA; [Green, Steven M.] Loma Linda Univ, Med Ctr, Dept Emergency Med, Loma Linda, CA USA	Harvard University; Brigham & Women's Hospital; University of Massachusetts System; University of Massachusetts Boston; Loma Linda University	Krauss, BS (corresponding author), Brigham & Womens Hosp, Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA.	baruch.krauss@childrens.harvard.edu			Oridion Medical	Oridion Medical	Dr. Krauss reports receiving consulting fees from Oridion Medical and being named in four patents held by Boston Children's Hospital - one patent related to respiratory analysis with capnography (U.S. patent 6,648,833), two patents related to a waveform interpreter for respiratory analysis (U.S. patents 6,997,880 and 6,428,483), and one patent related to an automated interpretive medical care system and methodology (U.S. patent 8,147,419). No other potential conflict of interest relevant to this article was reported.	Agrawal D, 2003, ANN EMERG MED, V42, P636, DOI 10.1016/S0196-0644(03)00516-X; Bhatt M, 2009, ANN EMERG MED, V53, P426, DOI 10.1016/j.annemergmed.2008.09.030; Green SM, 2002, ACAD EMERG MED, V9, P35, DOI 10.1197/aemj.9.1.35; Green SM, 2007, ANN EMERG MED, V49, P454, DOI 10.1016/j.annemergmed.2006.08.017; Green SM, 2011, ANN EMERG MED, V57, P449, DOI 10.1016/j.annemergmed.2010.11.030; Krauss B, 2006, LANCET, V367, P766, DOI 10.1016/S0140-6736(06)68230-5; Krauss B, 2000, NEW ENGL J MED, V342, P938, DOI 10.1056/NEJM200003303421306; Krauss B, 2007, ANN EMERG MED, V50, P172, DOI 10.1016/j.annemergmed.2006.10.016	8	17	18	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 10	2014	370	15							e23	10.1056/NEJMvcm1108559	http://dx.doi.org/10.1056/NEJMvcm1108559			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AE6IW	24716701				2023-01-03	WOS:000334095200002
J	Jespersen, L; Abildstrom, SZ; Hvelplund, A; Madsen, JK; Galatius, S; Pedersen, F; Hojberg, S; Prescott, E				Jespersen, Lasse; Abildstrom, Steen Z.; Hvelplund, Anders; Madsen, Jan K.; Galatius, Soren; Pedersen, Frants; Hojberg, Soren; Prescott, Eva			Burden of Hospital Admission and Repeat Angiography in Angina Pectoris Patients with and without Coronary Artery Disease: A Registry-Based Cohort Study	PLOS ONE			English	Article							ISCHEMIA-SYNDROME-EVALUATION; STABLE ANGINA; CHEST-PAIN; WOMEN; HEART	Aims: To evaluate risk of hospitalization due to cardiovascular disease (CVD) and repeat coronary angiography (CAG) in stable angina pectoris (SAP) with no obstructive coronary artery disease (CAD) versus obstructive CAD, and asymptomatic reference individuals. Methods and Results: We followed 11,223 patients with no prior CVD having a first-time CAG in 1998-2009 due to SAP symptoms and 5,695 asymptomatic reference individuals from the Copenhagen City Heart Study through registry linkage for 7.8 years (median). In recurrent event survival analysis, patients with SAP had 3-4-fold higher risk of hospitalization for CVD irrespective of CAG findings and cardiovascular comorbidity. Multivariable adjusted hazard ratios(95%CI) for patients with angiographically normal coronary arteries was 3.0(2.5-3.5), for angiographically diffuse non-obstructive CAD 3.9(3.3-4.6) and for 1-3-vessel disease 3.6-4.1(range)(all P<0.001). Mean accumulated hospitalization time was 3.5(3.0-4.0)(days/10 years follow-up) in reference individuals and 4.5(3.8-5.2)/7.0(5.4-8.6)/6.7(5.2-8.1)/6.1(5.2-7.4)/8.6(6.6-10.7) in patients with angiographically normal coronary arteries/angiographically diffuse non-obstructive CAD/1-, 2-, and 3-vessel disease, respectively (all P<0.05, age-adjusted). SAP symptoms predicted repeat CAG with multivariable adjusted hazard ratios for patients with angiographically normal coronary arteries being 2.3(1.9-2.9), for angiographically diffuse non-obstructive CAD 5.5(4.4-6.8) and for obstructive CAD 6.6-9.4(range)(all P<0.001). Conclusions: Patients with SAP symptoms and angiographically normal coronary arteries or angiographically diffuse non-obstructive CAD suffer from considerably greater CVD burdens in terms of hospitalization for CVD and repeat CAG compared with asymptomatic reference individuals even after adjustment for cardiac risk factors and exclusion of cardiovascular comorbidity as cause. Contrary to common perception, excluding obstructive CAD by CAG in such patients does not ensure a benign cardiovascular prognosis.	[Jespersen, Lasse; Abildstrom, Steen Z.; Hojberg, Soren; Prescott, Eva] Bispebjerg Hosp, Dept Cardiol, Copenhagen, Denmark; [Hvelplund, Anders] Univ Southern Denmark, Natl Inst Publ Hlth, Copenhagen, Denmark; [Hvelplund, Anders; Madsen, Jan K.; Galatius, Soren] Gentofte Univ Hosp, Dept Cardiol, Hellerup, Denmark; [Pedersen, Frants] Copenhagen Univ Hosp, Rigshosp, Dept Cardiol, Copenhagen, Denmark; [Prescott, Eva] Bispebjerg Hosp, Copenhagen City Heart Study, Copenhagen, Denmark	University of Copenhagen; Bispebjerg Hospital; University of Southern Denmark; University of Copenhagen; Herlev & Gentofte Hospital; Rigshospitalet; University of Copenhagen; University of Copenhagen; Bispebjerg Hospital	Jespersen, L (corresponding author), Bispebjerg Hosp, Dept Cardiol, Copenhagen, Denmark.	lasjes@gmail.com	Prescott, Eva/AAJ-7441-2020	Hoejberg, Soeren/0000-0001-8385-587X; Prescott, Eva/0000-0002-4134-0349	Research Unit of the Department of Cardiology, Bispebjerg University Hospital	Research Unit of the Department of Cardiology, Bispebjerg University Hospital	The work was funded by the Research Unit of the Department of Cardiology, Bispebjerg University Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al Suwaidi J, 2000, CIRCULATION, V101, P948, DOI 10.1161/01.CIR.101.9.948; Buchthal SD, 2000, NEW ENGL J MED, V342, P829, DOI 10.1056/NEJM200003233421201; Bugiardini R, 2004, CIRCULATION, V109, P2518, DOI 10.1161/01.CIR.0000128208.22378.E3; CANNON RO, 1988, AM J CARDIOL, V61, P1338, DOI 10.1016/0002-9149(88)91180-0; CHAMBERS J, 1990, PROG CARDIOVASC DIS, V33, P161, DOI 10.1016/0033-0620(90)90007-O; Fox K, 2006, EUR HEART J, V27, P1341, DOI 10.1093/eurheartj/ehl001; Gulati M, 2009, ARCH INTERN MED, V169, P843, DOI 10.1001/archinternmed.2009.50; Halcox JPJ, 2002, CIRCULATION, V106, P653, DOI 10.1161/01.CIR.0000025404.78001.D8; Hemingway H, 2007, EUR J CARDIOV PREV R, V14, P373, DOI 10.1097/01.hjr.0000230106.01396.a2; Jespersen L, 2013, CLIN RES CARDIOL, V102, P571, DOI 10.1007/s00392-013-0568-z; Jespersen L, 2012, EUR HEART J, V33, P734, DOI 10.1093/eurheartj/ehr331; Kleinbaum D.G., 2005, SURVIVAL ANAL SELF L; Ong P, 2012, J AM COLL CARDIOL, V59, P655, DOI 10.1016/j.jacc.2011.11.015; PAPANICOLAOU MN, 1986, AM J CARDIOL, V58, P1181, DOI 10.1016/0002-9149(86)90378-4; Pepine CJ, 2010, J AM COLL CARDIOL, V55, P2825, DOI 10.1016/j.jacc.2010.01.054; PROUDFIT WL, 1980, CIRCULATION, V62, P712, DOI 10.1161/01.CIR.62.4.712; Schnohr P, 2001, EUR HEART J SUPPL, V3, pH1; Shaw LJ, 2006, CIRCULATION, V114, P894, DOI 10.1161/CIRCULATIONAHA.105.609990	18	51	51	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2014	9	4							e93170	10.1371/journal.pone.0093170	http://dx.doi.org/10.1371/journal.pone.0093170			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE6MJ	24705387	gold, Green Published, Green Submitted			2023-01-03	WOS:000334107500028
J	Ubel, PA; Jagsi, R				Ubel, Peter A.; Jagsi, Reshma			Promoting Population Health through Financial Stewardship	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								Health care costs are straining budgets throughout the developed world, threatening the fiscal solvency of governments, employers, and individuals. Many countries are trying to restrain health care spending through top-down approaches, such as price regulation and even refusal to reimburse for interventions that are not cost-effective. Still controversial is the role that physicians should play in controlling health care costs. For instance, the Choosing Wisely campaign of the American Board of Internal Medicine Foundation encourages physicians to avoid interventions that "may be unnecessary, and in some instances can cause harm," but it does not ask physicians to contemplate trading off . . . Financial stewardship of health care resources promotes population health by increasing access to affordable care, reducing pressure on health care institutions to cut back on important services, and freeing up resources for other activities that improve health.	[Ubel, Peter A.] Duke Univ, Fuqua Sch Business, Durham, NC 27706 USA; [Ubel, Peter A.] Duke Univ, Sanford Sch Publ Policy, Durham, NC USA; [Ubel, Peter A.] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA; [Jagsi, Reshma] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; [Jagsi, Reshma] Univ Michigan, Ctr Bioeth & Social Sci Med, Ann Arbor, MI 48109 USA	Duke University; Duke University; Duke University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Ubel, PA (corresponding author), Duke Univ, Fuqua Sch Business, Durham, NC 27706 USA.			Jagsi, Reshma/0000-0001-6562-1228				Briesacher BA, 2007, J GEN INTERN MED, V22, P864, DOI 10.1007/s11606-007-0180-x; Cassel CK, 2012, JAMA-J AM MED ASSOC, V307, P1801, DOI 10.1001/jama.2012.476; Finkelstein A, 2012, Q J ECON, V127, P1057, DOI 10.1093/qje/qjs020; Muennig P, 2011, AM J PUBLIC HEALTH, V101, P512, DOI 10.2105/AJPH.2010.200063; Needleman J, 2011, NEW ENGL J MED, V364, P1037, DOI 10.1056/NEJMsa1001025	5	24	23	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 3	2014	370	14					1280	1281		10.1056/NEJMp1401335	http://dx.doi.org/10.1056/NEJMp1401335			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AE2VA	24693887				2023-01-03	WOS:000333830000004
J	Rohde, JM; Dimcheff, DE; Blumberg, N; Saint, S; Langa, KM; Kuhn, L; Hickner, A; Rogers, MAM				Rohde, Jeffrey M.; Dimcheff, Derek E.; Blumberg, Neil; Saint, Sanjay; Langa, Kenneth M.; Kuhn, Latoya; Hickner, Andrew; Rogers, Mary A. M.			Health Care-Associated Infection After Red Blood Cell Transfusion A Systematic Review and Meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							RESTRICTIVE TRANSFUSION; CARDIAC-SURGERY; CONTROLLED-TRIAL; STRATEGIES; RISK; REQUIREMENTS; MULTICENTER; THRESHOLDS	IMPORTANCE The association between red blood cell (RBC) transfusion strategies and health care-associated infection is not fully understood. OBJECTIVE To evaluate whether RBC transfusion thresholds are associated with the risk of infection and whether risk is independent of leukocyte reduction. DATA SOURCES MEDLINE, EMBASE, Web of Science Core Collection, Cochrane Central Register of Controlled Trials, Cochrane Database of Sytematic Reviews, ClinicalTrials.gov, International Clinical Trials Registry, and the International Standard Randomized Controlled Trial Number register were searched through January 22, 2014. STUDY SELECTION Randomized clinical trials with restrictive vs liberal RBC transfusion strategies. DATA EXTRACTION AND SYNTHESIS Twenty-one randomized trials with 8735 patients met eligibility criteria, of which 18 trials (n = 7593 patients) contained sufficient information for meta-analyses. DerSimonian and Laird random-effects models were used to report pooled risk ratios. Absolute risks of infection were calculated using the profile likelihood random-effects method. MAIN OUTCOMES AND MEASURES Incidence of health care-associated infection such as pneumonia, mediastinitis, wound infection, and sepsis. RESULTS The pooled risk of all serious infections was 11.8% (95% CI, 7.0%-16.7%) in the restrictive group and 16.9% (95% CI, 8.9%-25.4%) in the liberal group. The risk ratio (RR) for the association between transfusion strategies and serious infection was 0.82 (95% CI, 0.72-0.95) with little heterogeneity (I-2 = 0%; t(2) <. 0001). The number needed to treat (NNT) with restrictive strategies to prevent serious infection was 38 (95% CI, 24-122). The risk of infection remained reduced with a restrictive strategy, even with leukocyte reduction (RR, 0.80 [95% CI, 0.67-0.95]). For trials with a restrictive hemoglobin threshold of < 7.0 g/dL, the RR was 0.82 (95% CI, 0.70-0.97) with NNT of 20 (95% CI, 12-133). With stratification by patient type, the RR was 0.70 (95% CI, 0.54-0.91) in patients undergoing orthopedic surgery and 0.51 (95% CI, 0.28-0.95) in patients presenting with sepsis. There were no significant differences in the incidence of infection by RBC threshold for patients with cardiac disease, the critically ill, those with acute upper gastrointestinal bleeding, or for infants with low birth weight. CONCLUSIONS AND RELEVANCE Among hospitalized patients, a restrictive RBC transfusion strategy was associated with a reduced risk of health care-associated infection compared with a liberal transfusion strategy. Implementing restrictive strategies may have the potential to lower the incidence of health care-associated infection.	[Rohde, Jeffrey M.; Dimcheff, Derek E.; Saint, Sanjay; Langa, Kenneth M.; Hickner, Andrew; Rogers, Mary A. M.] Univ Michigan, Div Gen Med, Dept Internal Med, Ann Arbor, MI 48109 USA; [Blumberg, Neil] Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA; [Saint, Sanjay; Langa, Kenneth M.; Kuhn, Latoya; Hickner, Andrew; Rogers, Mary A. M.] Univ Michigan, Patient Safety Enhancement Program, VA Ann Arbor Med Ctr, Ann Arbor, MI 48109 USA; [Saint, Sanjay; Langa, Kenneth M.; Kuhn, Latoya] VA Ann Arbor Hlth Serv, Res & Dev Ctr Excellence, Ann Arbor, MI USA; [Saint, Sanjay; Langa, Kenneth M.; Rogers, Mary A. M.] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Rochester; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan	Rogers, MAM (corresponding author), Univ Michigan, Patient Safety Enhancement Program, Dept Internal Med, 016-422W NCRC, Ann Arbor, MI 48109 USA.	maryroge@umich.edu	Callahan, Charles D/L-1641-2013; Girelli, Domenico/B-1183-2008; Saint, Sanjay/AAF-5126-2019	Girelli, Domenico/0000-0001-9684-1899; Langa, Kenneth/0000-0002-2798-1836; Hickner, Andy/0000-0003-1922-3813; Rogers, Mary/0000-0001-5519-3223	National Heart, Lung, and Blood Institute [5R21HL093129-02]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL093129] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was funded by grant 5R21HL093129-02 from National Heart, Lung, and Blood Institute.	Boyce JM, 2002, AM J INFECT CONTROL, V30, pS1, DOI 10.1067/mic.2002.130391; Bracey AW, 1999, TRANSFUSION, V39, P1070, DOI 10.1046/j.1537-2995.1999.39101070.x; Buddeberg F, 2008, BEST PRACT RES-CLIN, V22, P503, DOI 10.1016/j.bpa.2008.05.003; Carson Jeffrey L, 2012, Cochrane Database Syst Rev, pCD002042, DOI 10.1002/14651858.CD002042.pub3; Carson JL, 2013, AM HEART J, V165, P964, DOI 10.1016/j.ahj.2013.03.001; Carson JL, 2012, ANN INTERN MED, V157, P49, DOI 10.7326/0003-4819-157-1-201206190-00429; Carson JL, 2011, NEW ENGL J MED, V365, P2453, DOI 10.1056/NEJMoa1012452; Carson JL, 1998, TRANSFUSION, V38, P522, DOI 10.1046/j.1537-2995.1998.38698326331.x; Centers for Disease Control and Prevention, CDC NHSN SURVEILLANC; Cholette JM, 2011, PEDIATR CRIT CARE ME, V12, P39, DOI 10.1097/PCC.0b013e3181e329db; Cooper HA, 2011, AM J CARDIOL, V108, P1108, DOI 10.1016/j.amjcard.2011.06.014; de Gast-Bakker DH, 2013, INTENS CARE MED, V39, P2011, DOI 10.1007/s00134-013-3085-7; Department of Health and Human Services, NATIONAL ACTION PLAN; Fergusson D, 2004, CAN J ANAESTH, V51, P417, DOI 10.1007/BF03018302; Foss NB, 2009, TRANSFUSION, V49, P227, DOI 10.1111/j.1537-2995.2008.01967.x; FREEMAN MF, 1950, ANN MATH STAT, V21, P607, DOI 10.1214/aoms/1177729756; Gregersen M, 2012, EUR GERIATR MED SUPP, V3, pS74, DOI [10.1016/j.eurger.2012.07.139, DOI 10.1016/J.EURGER.2012.07.139]; Grover M, 2006, VOX SANG, V90, P105, DOI 10.1111/j.1423-0410.2006.00730.x; Hajjar LA, 2010, JAMA-J AM MED ASSOC, V304, P1559, DOI 10.1001/jama.2010.1446; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hill GE, 2003, J TRAUMA, V54, P908, DOI 10.1097/01.TA.0000022460.21283.53; Horvath KA, 2013, ANN THORAC SURG, V95, P2194, DOI 10.1016/j.athoracsur.2012.11.078; Howard J, 2013, LANCET, V381, P930, DOI 10.1016/S0140-6736(12)61726-7; Karam O, 2011, PEDIATR CRIT CARE ME, V12, P512, DOI 10.1097/PCC.0b013e3181fe344b; Kirpalani H, 2006, J PEDIATR-US, V149, P301, DOI 10.1016/j.jpeds.2006.05.011; Kuhnert R, 2007, STAT MED, V26, P2277, DOI 10.1002/sim.2710; Lacroix J, 2007, NEW ENGL J MED, V356, P1609, DOI 10.1056/NEJMoa066240; Lannan KL, 2013, BLOOD CELL MOL DIS, V50, P61, DOI 10.1016/j.bcmd.2012.08.009; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Prick BW, 2014, BJOG-INT J OBSTET GY, V121, P1005, DOI 10.1111/1471-0528.12531; Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115; Rogers MAM, 2006, AM HEART J, V152, P1028, DOI 10.1016/j.ahj.2006.07.009; Rogers MAM, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-37; Saint S, 2013, JAMA INTERN MED, V173, P874, DOI 10.1001/jamainternmed.2013.101; Scott RD, THE DIRECT MEDICAL C; Shehata N, 2012, TRANSFUSION, V52, P91, DOI 10.1111/j.1537-2995.2011.03236.x; So-Osman C, 2010, VOX SANG, V98, P56, DOI 10.1111/j.1423-0410.2009.01225.x; So-Osman C, 2013, BLOOD TRANSFUS-ITALY, V11, P289, DOI 10.2450/2013.0172-12; VICHINSKY EP, 1995, NEW ENGL J MED, V333, P206, DOI 10.1056/NEJM199507273330402; Villanueva C, 2013, NEW ENGL J MED, V368, P11, DOI 10.1056/NEJMoa1211801; Wacker C, 2013, LANCET INFECT DIS, V13, P426, DOI 10.1016/S1473-3099(12)70323-7; Whitaker BI, THE 2011 NATIONAL BL	42	402	422	3	36	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	2014	311	13					1317	1326		10.1001/jama.2014.2726	http://dx.doi.org/10.1001/jama.2014.2726			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AE0HU	24691607	Green Accepted			2023-01-03	WOS:000333645400015
J	Eisenberg, MS; Bobrow, BJ; Rea, T				Eisenberg, Mickey S.; Bobrow, Bentley J.; Rea, Tom			Fulfilling the Promise of "Anyone, Anywhere" to Perform CPR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ASSISTED CARDIOPULMONARY-RESUSCITATION; HOSPITAL CARDIAC-ARREST; SURVIVAL; INSTRUCTIONS		[Eisenberg, Mickey S.; Rea, Tom] Univ Washington, Dept Med, Seattle, WA USA; [Eisenberg, Mickey S.; Rea, Tom] King Cty Emergency Med Serv, Seattle, WA USA; [Bobrow, Bentley J.] Univ Arizona, Coll Med, Dept Emergency Med, Maricopa Med Ctr, Phoenix, AZ USA; [Bobrow, Bentley J.] Arizona Dept Hlth Serv, Bur Emergency Med Serv & Trauma Syst, Phoenix, AZ 85007 USA	University of Washington; University of Washington Seattle; University of Arizona; Arizona Department of Health Services	Bobrow, BJ (corresponding author), Arizona Dept Hlth Serv, Bur Emergency Med Serv & Trauma Syst, 150 N 18th Ave,Ste 540, Phoenix, AZ 85007 USA.	bentley.bobrow@azdhs.gov						Bobrow BJ, 2008, CIRCULATION, V118, P2550, DOI 10.1161/CIRCULATIONAHA.108.799940; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; Lerner EB, 2012, CIRCULATION, V125, P648, DOI 10.1161/CIR.0b013e31823ee5fc; Lewis M, 2013, CIRCULATION, V128, P1522, DOI 10.1161/CIRCULATIONAHA.113.002627; Rea TD, 2001, CIRCULATION, V104, P2513, DOI 10.1161/hc4601.099468; Rea TD, 2006, CIRCULATION, V114, P2760, DOI 10.1161/CIRCULATIONAHA.106.654715; Resuscitation Academy, RESOURCES; Sasson C, 2010, CIRC-CARDIOVASC QUAL, V3, P63, DOI 10.1161/CIRCOUTCOMES.109.889576; Song KJ, 2014, RESUSCITATION, V85, P34, DOI 10.1016/j.resuscitation.2013.06.004; Valenzuela TD, 1997, CIRCULATION, V96, P3308	10	2	3	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	2014	311	12					1197	1198		10.1001/jama.2014.1485	http://dx.doi.org/10.1001/jama.2014.1485			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AD6CE	24668098				2023-01-03	WOS:000333340500018
J	Gallace, A; Soravia, G; Cattaneo, Z; Moseley, GL; Vallar, G				Gallace, Alberto; Soravia, Giovanna; Cattaneo, Zaira; Moseley, G. Lorimer; Vallar, Giuseppe			Temporary Interference over the Posterior Parietal Cortices Disrupts Thermoregulatory Control in Humans	PLOS ONE			English	Article							REGIONAL PAIN SYNDROME; TRANSCRANIAL MAGNETIC STIMULATION; POSITRON-EMISSION-TOMOGRAPHY; SOMATOSENSORY CORTEX; SKIN TEMPERATURE; BODY-OWNERSHIP; INTRAPARIETAL SULCUS; RUBBER HAND; STROKE; BRAIN	The suggestion has recently been made that certain higher-order cortical areas involved in supporting multisensory representations of the body, and of the space around it, might also play a role in controlling thermoregulatory functions. Here we demonstrate that temporary interference with the function of one of these areas, the posterior parietal cortex, by repetitive transcranial magnetic stimulation, results in a decrease in limb temperature. By contrast, interference with the activity of a sensory-specific area (the primary somatosensory cortex) had no effect on temperature. The results of this experiment suggest that associative multisensory brain areas might exert a top-down modulation over basic physiological control. Such a function might be part of a larger neural circuit responsible for maintaining the integrity of the body at both a homeostatic and a psychological level.	[Gallace, Alberto; Soravia, Giovanna; Cattaneo, Zaira; Vallar, Giuseppe] Univ Milano Bicocca, Dept Psychol, Milan, Italy; [Moseley, G. Lorimer] Univ S Australia, Sansom Inst Hlth Res, Adelaide, SA 5001, Australia; [Moseley, G. Lorimer] Neurosci Res Australia, Sydney, NSW, Australia; [Vallar, Giuseppe] IRCCS Ist Auxol Italiano, Milan, Italy	University of Milano-Bicocca; University of South Australia; Neuroscience Research Australia; IRCCS Istituto Auxologico Italiano	Gallace, A (corresponding author), Univ Milano Bicocca, Dept Psychol, Milan, Italy.	alberto.gallace1@unimib.it	Gallace, Alberto/L-7276-2015; Moseley, Lorimer/A-7095-2009	Moseley, Lorimer/0000-0002-3750-4945; GALLACE, ALBERTO/0000-0002-4561-8926	National Health & Medical Research Council of Australia [571090]; Ricerca Corrente Grant from the IRCCS Istituto Auxologico Italiano; Futuro in Ricerca grant [RBFR12F0BD_003]	National Health & Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Ricerca Corrente Grant from the IRCCS Istituto Auxologico Italiano; Futuro in Ricerca grant	GLM was supported by the National Health & Medical Research Council of Australia ID 571090. G. V. was supported by a Ricerca Corrente Grant from the IRCCS Istituto Auxologico Italiano. A. G. and Z. C. were supported by a Futuro in Ricerca 2012 grant (RBFR12F0BD_003). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acerra NE, 2007, J REHABIL MED, V39, P109, DOI 10.2340/16501977-0027; Barnsley N, 2011, CURR BIOL, V21, pR945, DOI 10.1016/j.cub.2011.10.039; BASSETTI C, 1993, NEUROLOGY, V43, P1942, DOI 10.1212/WNL.43.10.1942; Blankenburg F, 2010, CEREB CORTEX, V20, P2702, DOI 10.1093/cercor/bhq015; Blatow M, 2007, NEUROIMAGE, V37, P927, DOI 10.1016/j.neuroimage.2007.05.038; Bottini G, 2005, NEUROLOGY, V65, P1278, DOI 10.1212/01.wnl.0000182398.14088.e8; Botvinick M, 1998, NATURE, V391, P756, DOI 10.1038/35784; Cappelletti M, 2007, EXP BRAIN RES, V179, P631, DOI 10.1007/s00221-006-0820-0; DELUCA B, 1989, BRAIN RES BULL, V22, P1003, DOI 10.1016/0361-9230(89)90012-9; Dijkerman HC, 2007, BEHAV BRAIN SCI, V30, P189, DOI 10.1017/S0140525X07001392; Egan GF, 2005, P NATL ACAD SCI USA, V102, P5262, DOI 10.1073/pnas.0409753102; Ehrsson HH, 2005, J NEUROSCI, V25, P10564, DOI 10.1523/JNEUROSCI.0800-05.2005; Ellis LB, 1936, ARCH NEURO PSYCHIATR, V36, P362, DOI 10.1001/archneurpsyc.1936.02260080134008; Ferretti A, 2003, NEUROIMAGE, V20, P1625, DOI 10.1016/j.neuroimage.2003.07.004; Fiorio M, 2005, EUR J NEUROSCI, V22, P773, DOI 10.1111/j.1460-9568.2005.04267.x; Fregni F, 2007, NAT CLIN PRACT NEURO, V3, P383, DOI 10.1038/ncpneuro0530; Freund Hans-Joachim, 2003, Adv Neurol, V93, P179; Gallace A., 2010, PSYCHE INTERDISCIPLI, V16, P30; Gallace A, 2008, CONSCIOUS COGN, V17, P370, DOI 10.1016/j.concog.2007.01.005; Giummarra MJ, 2008, NEUROSCI BIOBEHAV R, V32, P143, DOI 10.1016/j.neubiorev.2007.07.001; Grefkes C, 2005, J ANAT, V207, P3, DOI 10.1111/j.1469-7580.2005.00426.x; Hallett M, 2007, NEURON, V55, P187, DOI 10.1016/j.neuron.2007.06.026; Hasselberg MJ, SLEEP MED IN PRESS; Herwig U, 2003, BRAIN TOPOGR, V16, P95, DOI 10.1023/B:BRAT.0000006333.93597.9d; Hung J, 2005, J NEUROSCI, V25, P9602, DOI 10.1523/JNEUROSCI.0879-05.2005; Ishii K, 1996, CLIN NEUROLOGY, V36, P951; Iwamura Y, 2000, PHILOS T R SOC B, V355, P267, DOI 10.1098/rstb.2000.0563; Kammers MPM, 2011, NEUROPSYCHOLOGIA, V49, P1316, DOI 10.1016/j.neuropsychologia.2011.02.039; Kim JS, 2007, NEUROLOGY, V68, P174, DOI 10.1212/01.wnl.0000251298.12763.9b; Kitazawa S, 2002, CONSCIOUS COGN, V11, P475, DOI 10.1016/S1053-8100(02)00031-4; Longo MR, 2008, COGNITION, V107, P978, DOI 10.1016/j.cognition.2007.12.004; Makin TR, 2008, BEHAV BRAIN RES, V191, P1, DOI 10.1016/j.bbr.2008.02.041; Marinus J, 2011, LANCET NEUROL, V10, P637, DOI 10.1016/S1474-4422(11)70106-5; MELZACK R, 1990, TRENDS NEUROSCI, V13, P88, DOI 10.1016/0166-2236(90)90179-E; Miniussi C, 2010, CORTEX, V46, P128, DOI 10.1016/j.cortex.2009.03.004; Moseley GL, 2008, P NATL ACAD SCI USA, V105, P13169, DOI 10.1073/pnas.0803768105; Moseley GL, 2013, PAIN, V154, P2463, DOI 10.1016/j.pain.2013.07.026; Moseley GL, 2012, BRAIN, V135, P3676, DOI 10.1093/brain/aws297; Moseley GL, 2012, NEUROLOGY, V79, P327, DOI 10.1212/WNL.0b013e318260cba2; Moseley GL, 2012, NEUROSCI BIOBEHAV R, V36, P34, DOI 10.1016/j.neubiorev.2011.03.013; Moseley GL, 2009, BRAIN, V132, P3142, DOI 10.1093/brain/awp224; NAVER H, 1995, STROKE, V26, P1379, DOI 10.1161/01.STR.26.8.1379; Okamoto M, 2004, NEUROIMAGE, V21, P99, DOI 10.1016/j.neuroimage.2003.08.026; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Oliveira FTP, 2010, P NATL ACAD SCI USA, V107, P17751, DOI 10.1073/pnas.1006223107; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; Petchkrua W, 2000, NEUROREHAB NEURAL RE, V14, P59, DOI 10.1177/154596830001400107; Reed CL, 1996, BRAIN, V119, P875, DOI 10.1093/brain/119.3.875; Riedl B, 2001, ACTA NEUROL SCAND, V103, P27, DOI 10.1034/j.1600-0404.2001.00139.x; Robertson EM, 2003, J COGNITIVE NEUROSCI, V15, P948, DOI 10.1162/089892903770007344; Rohde M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021659; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Salomon R, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00065; Satoh M, 2002, J NEUROL, V249, P1404, DOI 10.1007/S00415-002-0853-7; Smith ADH, 2010, PHYSIOL MEAS, V31, P95, DOI 10.1088/0967-3334/31/1/007; STERZI R, 1993, J NEUROL NEUROSUR PS, V56, P308, DOI 10.1136/jnnp.56.3.308; Tsakiris M, 2008, NEUROPSYCHOLOGIA, V46, P3014, DOI 10.1016/j.neuropsychologia.2008.06.004; Tsakiris M, 2011, P ROY SOC B-BIOL SCI, V278, P2470, DOI 10.1098/rspb.2010.2547; Tsakiris M, 2010, NEUROPSYCHOLOGIA, V48, P2740, DOI 10.1016/j.neuropsychologia.2010.05.021; Tsakiris M, 2010, NEUROPSYCHOLOGIA, V48, P703, DOI 10.1016/j.neuropsychologia.2009.09.034; Vallar G, 1997, HIPPOCAMPAL PARIETAL, P33; Vallar G, 2007, BEHAV BRAIN SCI, V30, P223, DOI 10.1017/S0140525X0700163X; Vallar G, 2009, EXP BRAIN RES, V192, P533, DOI 10.1007/s00221-008-1562-y; Lichtenbelt WDV, 2006, PHYSIOL BEHAV, V88, P489, DOI 10.1016/j.physbeh.2006.04.026; Walsh V, 2000, NAT REV NEUROSCI, V1, P73, DOI 10.1038/35036239; WANKLYN P, 1994, STROKE, V25, P1765, DOI 10.1161/01.STR.25.9.1765; Wolpert DM, 1998, NAT NEUROSCI, V1, P529, DOI 10.1038/2245	67	18	18	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2014	9	3							e88209	10.1371/journal.pone.0088209	http://dx.doi.org/10.1371/journal.pone.0088209			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC9HN	24622382	Green Submitted, gold, Green Accepted, Green Published			2023-01-03	WOS:000332845300004
J	Sadhu, S; Manukonda, AR; Yeruva, AR; Patel, SK; Saggurti, N				Sadhu, Santhosh; Manukonda, Archana Rao; Yeruva, Anthony Reddy; Patel, Sangram Kishor; Saggurti, Niranjan			Role of a Community-to-Community Learning Strategy in the Institutionalization of Community Mobilization among Female Sex Workers in India	PLOS ONE			English	Article							ANDHRA-PRADESH; CONDOM USE; HEALTH	Introduction: The institutionalization of community mobilization is not well understood in literature. This paper aims to understand the role of the community-to-community learning strategy in the institutionalization of community mobilization among sex workers communities across eight districts of Andhra Pradesh, India. Materials and Methods: Data collected during baseline (March, 2010) and endline (June, 2012) under an HIV prevention project (SAKSHAM project) was used to investigate the strength (as score) of community mobilization based on two learning strategies: non-government organization (NGO)-to-community-based organization (CBO) strategy, and community-to-CBO strategy. The strength of community mobilization was assessed based on different parameters. The change in scores were computed as a percentage of the improvement to the total potential improvement from baseline to endline on specific indicators and overall. Results: Most of the CBOs considered in the pre-post assessment had been registered during 2004-2008. At baseline, the community ownership and preparedness index scores for the eight CBOs under the community-to-CBO strategy ranged between 21.5 and 27.7 while the scores for the three CBOs under the NGO-to-CBO strategy ranged between 16.3 and 21.5. By endline, the strength of community mobilization among CBOs under the community-to-CBO strategy increased 18 points (equivalent to 23% potential improvement) whereas the strength of community mobilization among CBOs under the NGO-to-CBO strategy increased only 10 points (equivalent to 13% potential improvement). The average percentage difference in improvement between the strategies was 10% (p = 0.102). Further analyses indicate that a greater improvement in community-to-CBO learning strategy was noted around managerial capacities and engagement with stakeholders than other parameters. Conclusion: The community -to- CBO learning strategy presents promising results for HIV prevention with regard to institutionalization of community mobilization among sex workers communities. Findings support the scaling-up of community mobilization initiatives within HIV prevention interventions using well trained community members in India and elsewhere.	[Sadhu, Santhosh; Manukonda, Archana Rao; Yeruva, Anthony Reddy] CARE India, Hyderabad, Andhra Pradesh, India; [Patel, Sangram Kishor; Saggurti, Niranjan] Populat Council, HIV & AIDS Program, New Delhi, India		Sadhu, S (corresponding author), CARE India, Hyderabad, Andhra Pradesh, India.	santhoshsadhu@gmail.com		Saggurti, Niranjan/0000-0002-5267-8425	Bill & Melinda Gates Foundation	Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation)	The study was funded by Bill & Melinda Gates Foundation to CARE-India as part of Avahan, its India AIDS Initiative. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This paper was written as part of a mentorship program to the first author, under the Knowledge Network Project of the Population Council, which is a grantee of the Bill & Melinda Gates Foundation through Avahan, its India AIDS Initiative. The views expressed herein are those of the authors and do not necessarily reflect the official policy or position of the Bill & Melinda Gates Foundation and Avahan.	Blankenship KA, 2008, AIDS, V22, pS109, DOI 10.1097/01.aids.0000343769.92949.dd; BRACHT N, 1994, HEALTH EDUC RES, V9, P243, DOI 10.1093/her/9.2.243; CARE India, 2010, LEARN SIT ASS TARG I; CARE India, 2012, COMM COMM LEARN NEW; Chambers R., 1997, WHOSE REALITY COUNTS; Chattopadhyay A, 2004, AIDS PATIENT CARE ST, V18, P159, DOI 10.1089/108729104322994847; Gaikwad SS, 2012, J EPIDEMIOL COMMUN H, V66, pII69, DOI 10.1136/jech-2011-200514; Galavotti C, 2012, J EPIDEMIOL COMMUN H, V66, pII9, DOI 10.1136/jech-2011-200465; Jana S, 2004, AIDS EDUC PREV, V16, P405, DOI 10.1521/aeap.16.5.405.48734; Kothari Cooke, 2001, PARTICIPATION NEW TY; Michau, 2007, GENDER DEV, V15, P95; Mintrom M, 1997, AM J POLIT SCI, V41, P738, DOI 10.2307/2111674; Narayanan P, 2012, J EPIDEMIOL COMMUN H, V66, pII34, DOI 10.1136/jech-2012-201065; Nyonator FK, 2005, HEALTH POLICY PLANN, V20, P25, DOI 10.1093/heapol/czi003; Pinto RM, 2008, WOMEN HEALTH, V47, P83, DOI 10.1300/J013v47n01_05; Praxis, 2009, MEAS COMM MOB PROC M; Saggurti N, 2013, AIDS CARE, V25, pS55, DOI 10.1080/09540121.2012.749334; Sarkar S, 2010, SEX TRANSM INFECT, V86, pI2, DOI 10.1136/sti.2009.039289; Thomas T, 2012, J EPIDEMIOL COMMUN H, V66, pII26, DOI 10.1136/jech-2011-200590; Tripathy P, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-182; UNFPA UNAIDS APNSW, 2012, HIV SEX WORK COLL IN; World Bank, 2012, IND COMM EMP KEY TUR; World Bank, 2007, COMM LED TOT SAN RUR	23	6	6	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2014	9	3							e90592	10.1371/journal.pone.0090592	http://dx.doi.org/10.1371/journal.pone.0090592			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AC4IY	24608680	Green Published, gold, Green Submitted			2023-01-03	WOS:000332485800035
J	Blivet, S; Cobarzan, D; Beauchet, A; El Hajjam, M; Lacombe, P; Chinet, T				Blivet, Sandra; Cobarzan, Daniel; Beauchet, Alain; El Hajjam, Mostafa; Lacombe, Pascal; Chinet, Thierry			Impact of Pulmonary Arteriovenous Malformations on Respiratory-Related Quality of Life in Patients with Hereditary Haemorrhagic Telangiectasia	PLOS ONE			English	Article							HEALTH-STATUS; QUESTIONNAIRE; EMBOLIZATION; EPISTAXIS; DISEASE; HHT	Fifteen to fifty percent of patients with hereditary haemorrhagic telangiectasia have pulmonary arteriovenous malformations. The objective of this study was to measure the effect of the presence of pulmonary arteriovenous malformations and of their embolisation on respiratory-related quality of life (QoL). We prospectively recruited patients with a diagnosis of hereditary haemorrhagic telangiectasia based on the Curacao criteria and/or the identification of a pathogenic mutation. Respiratory-related quality of life was measured using the Saint George's Respiratory Questionnaire (SGRQ). Patients who underwent embolisation of pulmonary arteriovenous malformations completed the questionnaire before and 6-12 mo after the procedure. The 56 participants were divided into three groups: no pulmonary arteriovenous malformation (group A, n = 10), small pulmonary arteriovenous malformations not accessible to embolotherapy (group B, n = 19), and large pulmonary arteriovenous malformations accessible to embolotherapy (group C, n = 27). The SGRQ score was significantly higher in group C compared to the other groups, indicating a worse respiratory-specific QoL. There was no significant difference between groups A and B. Among the 17 patients who underwent an embolisation, the SGRQ score decreased significantly after the procedure, to a value similar to that in patients without pulmonary arteriovenous malformation. Our results indicate that the presence of large but not small pulmonary arteriovenous malformations negatively affects the respiratory-related quality of life and that embolisation of pulmonary arteriovenous malformations normalizes the respiratory-related quality of life.	[Blivet, Sandra; Cobarzan, Daniel; El Hajjam, Mostafa; Lacombe, Pascal; Chinet, Thierry] Univ Versailles St Quentin En Yvelines, Hop Ambroise Pare, AP HP, Boulogne, France; [Beauchet, Alain] Univ Versailles St Quentin En Yvelines, Hop Ambroise Pare, AP HP, Dept Sante Publ, Boulogne, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Saclay	Chinet, T (corresponding author), Univ Versailles St Quentin En Yvelines, Hop Ambroise Pare, AP HP, Boulogne, France.	Thierry.Chinet@Apr.Aphp.Fr			French HHT patient association, AMRO-France HHT (Association Maladie Rendu-Osler)	French HHT patient association, AMRO-France HHT (Association Maladie Rendu-Osler)	This work received financial support from the French HHT patient association, AMRO-France HHT (Association Maladie Rendu-Osler). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Abdalla SA, 2006, J MED GENET, V43, P97, DOI 10.1136/jmg.2005.030833; Al-Shair K, 2013, CHEST, V144, P623, DOI 10.1378/chest.12-0014; Bouchet C, 1996, REV MAL RESPIR, V13, P43; de Gussem EM, 2009, RHINOLOGY, V47, P85; Faughnan ME, 2011, J MED GENET, V48, P73, DOI 10.1136/jmg.2009.069013; Faughnan ME, 2009, EUR RESPIR J, V33, P1186, DOI 10.1183/09031936.00061308; Geirdal AO, 2012, AM J MED GENET A, V158A, P1269, DOI 10.1002/ajmg.a.35309; Geisthoff UW, 2007, OTOLARYNG HEAD NECK, V136, P726, DOI 10.1016/j.otohns.2006.12.019; Gossage JR, 1998, AM J RESP CRIT CARE, V158, P643, DOI 10.1164/ajrccm.158.2.9711041; Gupta S, 2009, CHEST, V136, P849, DOI 10.1378/chest.09-0334; GUTTMACHER AE, 1995, NEW ENGL J MED, V333, P918, DOI 10.1056/NEJM199510053331407; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; Jones PW, 2002, EUR RESPIR J, V19, P398, DOI 10.1183/09031936.02.00063702; Karapantzos I, 2005, EUR ARCH OTO-RHINO-L, V262, P830, DOI 10.1007/s00405-004-0911-0; Lacombe P, 2009, CHEST, V135, P1031, DOI 10.1378/chest.08-1794; Lennox PA, 2005, AM J RHINOL, V19, P71, DOI 10.1177/194589240501900112; Moussouttas M, 2000, NEUROLOGY, V55, P959, DOI 10.1212/WNL.55.7.959; Nishiyama O, 2005, RESP MED, V99, P408, DOI 10.1016/j.rmed.2004.09.005; Pasculli G, 2004, QUAL LIFE RES, V13, P1715, DOI 10.1007/s11136-004-7865-y; Pfister M, 2009, ACTA OTO-LARYNGOL, V129, P862, DOI 10.1080/00016480802468138; Rubenfire M, 2009, CHEST, V136, P597, DOI 10.1378/chest.08-1260; Shovlin CL, 2000, AM J MED GENET, V91, P66, DOI 10.1002/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P; Trerotola SO, 2010, AM J ROENTGENOL, V195, P837, DOI 10.2214/AJR.10.5230; Velthuis S, 2013, CHEST, V144, P542, DOI 10.1378/chest.12-1599	24	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 6	2014	9	3							e90937	10.1371/journal.pone.0090937	http://dx.doi.org/10.1371/journal.pone.0090937			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC4ID	24603803	Green Submitted, Green Published, gold			2023-01-03	WOS:000332483600110
J	Pagani, O; Regan, MM; Walley, BA; Fleming, GF; Colleoni, M; Lang, I; Gomez, HL; Tondini, C; Burstein, HJ; Perez, EA; Ciruelos, E; Stearns, V; Bonnefoi, HR; Martino, S; Geyer, CE; Pinotti, G; Puglisi, F; Crivellari, D; Ruhstaller, T; Winer, EP; Rabaglio-Poretti, M; Maibach, R; Ruepp, B; Giobbie-Hurder, A; Price, KN; Bernhard, J; Luo, WX; Ribi, K; Viale, G; Coates, AS; Gelber, RD; Goldhirsch, A; Francis, PA				Pagani, Olivia; Regan, Meredith M.; Walley, Barbara A.; Fleming, Gini F.; Colleoni, Marco; Lang, Istvan; Gomez, Henry L.; Tondini, Carlo; Burstein, Harold J.; Perez, Edith A.; Ciruelos, Eva; Stearns, Vered; Bonnefoi, Herve R.; Martino, Silvana; Geyer, Charles E., Jr.; Pinotti, Graziella; Puglisi, Fabio; Crivellari, Diana; Ruhstaller, Thomas; Winer, Eric P.; Rabaglio-Poretti, Manuela; Maibach, Rudolf; Ruepp, Barbara; Giobbie-Hurder, Anita; Price, Karen N.; Bernhard, Juerg; Luo, Weixiu; Ribi, Karin; Viale, Giuseppe; Coates, Alan S.; Gelber, Richard D.; Goldhirsch, Aron; Francis, Prudence A.		TEXT SOFT Investigators Int Breast	Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSTMENOPAUSAL WOMEN; ENDOCRINE THERAPY; AMERICAN-SOCIETY; FOLLOW-UP; TAMOXIFEN; TRIAL; METAANALYSIS; LETROZOLE; SEQUENCE	BACKGROUND Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared with tamoxifen, in postmenopausal women with hormone-receptor-positive breast cancer. METHODS In two phase 3 trials, we randomly assigned premenopausal women with hormone-receptor-positive early breast cancer to the aromatase inhibitor exemestane plus ovarian suppression or tamoxifen plus ovarian suppression for a period of 5 years. Suppression of ovarian estrogen production was achieved with the use of the gonadotropin-releasing-hormone agonist triptorelin, oophorectomy, or ovarian irradiation. The primary analysis combined data from 4690 patients in the two trials. RESULTS After a median follow-up of 68 months, disease-free survival at 5 years was 91.1% in the exemestane-ovarian suppression group and 87.3% in the tamoxifen-ovarian suppression group (hazard ratio for disease recurrence, second invasive cancer, or death, 0.72; 95% confidence interval [CI], 0.60 to 0.85; P<0.001). The rate of freedom from breast cancer at 5 years was 92.8% in the exemestane-ovarian suppression group, as compared with 88.8% in the tamoxifen-ovarian suppression group (hazard ratio for recurrence, 0.66; 95% CI, 0.55 to 0.80; P<0.001). With 194 deaths (4.1% of the patients), overall survival did not differ significantly between the two groups (hazard ratio for death in the exemestane-ovarian suppression group, 1.14; 95% CI, 0.86 to 1.51; P = 0.37). Selected adverse events of grade 3 or 4 were reported for 30.6% of the patients in the exemestane-ovarian suppression group and 29.4% of those in the tamoxifen-ovarian suppression group, with profiles similar to those for postmenopausal women. CONCLUSIONS In premenopausal women with hormone-receptor-positive early breast cancer, adjuvant treatment with exemestane plus ovarian suppression, as compared with tamoxifen plus ovarian suppression, significantly reduced recurrence. (Funded by Pfizer and others; TEXT and SOFT ClinicalTrials.gov numbers, NCT00066703 and NCT00066690, respectively.)	[Pagani, Olivia] Kantonsspital St Gallen, Breast Ctr, Inst Oncol Southern Switzerland, St Gallen, Switzerland; [Regan, Meredith M.; Bernhard, Juerg] Univ Hosp Inselspital, Bern, Switzerland; [Regan, Meredith M.; Maibach, Rudolf; Ruepp, Barbara; Bernhard, Juerg; Ribi, Karin] Coordinating Ctr, Int Breast Canc Study Grp IBCSG, Bern, Switzerland; [Regan, Meredith M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, IBCSG Stat Ctr, Boston, MA 02115 USA; [Burstein, Harold J.; Winer, Eric P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Susan F Smith Ctr Womens Canc, Boston, MA 02115 USA; [Giobbie-Hurder, Anita; Luo, Weixiu] Harvard Univ, Sch Med, Dana Farber Canc Inst, IBCSG Stat Ctr, Boston, MA 02115 USA; [Price, Karen N.] Harvard Univ, Sch Med, Dana Farber Canc Inst, IBCSG Stat Ctr,Frontier Sci & Technol Res Fdn, Boston, MA 02115 USA; [Gelber, Richard D.] Harvard Univ, Sch Publ Hlth, Sch Med, IBCSG Stat Ctr,Dana Farber Canc Inst,Frontier Sci, Boston, MA 02115 USA; [Walley, Barbara A.] Tom Baker Canc Clin, Calgary, AB, Canada; [Fleming, Gini F.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA; [Colleoni, Marco] Univ Milan, European Inst Oncol, IBCSG Cent Pathol Ctr, Div Med Senol, Milan, Italy; [Goldhirsch, Aron] European Inst Oncol, Milan, Italy; [Tondini, Carlo] Osped Papa Giovanni XXIII, Bergamo, Italy; [Pinotti, Graziella] Osped Circolo Varese, Varese, Italy; [Pinotti, Graziella] Fdn Macchi, Varese, Italy; [Puglisi, Fabio] Univ Udine, Dept Oncol, Univ Hosp Udine, I-33100 Udine, Italy; [Crivellari, Diana] Ctr Riferimento Oncol, Aviano, Italy; [Lang, Istvan] Natl Inst Oncol, Budapest, Hungary; [Gomez, Henry L.] Inst Nacl Enfermedades Neoplas, Lima, Peru; [Perez, Edith A.] Mayo Clin, Jacksonville, FL 32224 USA; [Ciruelos, Eva] Hosp Univ 12 Octubre, Madrid, Spain; [Stearns, Vered] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA; [Bonnefoi, Herve R.] Univ Bordeaux, Inst Bergonie Comprehens Canc Ctr, INSERM, U916, Bordeaux, France; [Martino, Silvana] Angeles Clin & Res Inst, Santa Monica, CA USA; [Geyer, Charles E., Jr.] Virginia Commonwealth Univ, Sch Med, Massey Canc Ctr, Richmond, VA 23284 USA; [Coates, Alan S.] Univ Sydney, Sydney, NSW 2006, Australia; [Francis, Prudence A.] Univ Melbourne, St Vincents Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia	Kantonsspital St. Gallen; University of Bern; University Hospital of Bern; International Breast Cancer Study Group; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Frontier Science Foundation; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard T.H. Chan School of Public Health; Tom Baker Cancer Clinic; University of Calgary; University of Chicago; University of Chicago Medical Center; IRCCS European Institute of Oncology (IEO); University of Milan; IRCCS European Institute of Oncology (IEO); ASST Papa Giovanni XXIII; Ospedale Circolo & Fondazione Macchi; Hospital Santa Maria della Misericordia; University of Udine; University Hospital of Udine; IRCCS Aviano (CRO); National Institute of Oncology Hungary; Instituto Nacional de Enfermedades Neoplasicas; Mayo Clinic; Hospital Universitario 12 de Octubre; Johns Hopkins University; Johns Hopkins Medicine; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Angeles Clinic & Research Institute; Virginia Commonwealth University; University of Sydney; Peter Maccallum Cancer Center; St Vincent's Hospital Melbourne; University of Melbourne	Pagani, O (corresponding author), Osped San Giovanni Bellinzona, Inst Oncol Southern Switzerland, CH-6500 Bellinzona, Switzerland.	ibcsgcc@ibcsg.org	Viale, Giuseppe/AAE-8921-2019; TONDINI, CARLO ALBERTO/AAB-7786-2019; Geyer, Charles/AGY-0119-2022; Saini, Kamal S./ABD-5499-2021; Giobbie-Hurder, Anita/AAU-6193-2021; Puglisi, Fabio/N-3863-2017; Lluch, Ana/R-5493-2019; Pagani, Olivia/ABF-3164-2020; Colleoni, Marco/AAN-8647-2020; Francis, Prudence A/J-4003-2012; Perren, Timothy/D-5387-2013	TONDINI, CARLO ALBERTO/0000-0003-0635-8954; Geyer, Charles/0000-0002-2379-5702; Saini, Kamal S./0000-0001-6301-3309; Puglisi, Fabio/0000-0003-0573-4938; Lluch, Ana/0000-0003-2766-407X; Colleoni, Marco/0000-0002-5743-3013; Francis, Prudence A/0000-0002-7207-9286; Rabaglio, Manuela/0000-0002-6764-1844; Di Leo, Angelo/0000-0002-3665-9056; Villanova Biazus, Jorge/0000-0002-3821-5264; Earl, Helena/0000-0003-1549-8094; Gomez, Henry/0000-0003-2660-1843; Bliss, Judith/0000-0001-7957-7424; Llombart Cussac, Antonio/0000-0003-4515-8293; Kroep, Judith/0000-0003-2671-1903; Perren, Timothy/0000-0001-8472-8856; Haba Rodriguez, Juan Rafael de la/0000-0001-5111-1702; Ciruelos, Eva/0000-0002-2796-1042	Pfizer; Ipsen; International Breast Cancer Study Group; National Cancer Institute; Boehringer Ingelheim; Taiho Pharmaceutical; AbbVie; AstraZeneca; Novartis; Roche; Eli Lilly; NATIONAL CANCER INSTITUTE [U10CA180888, U24CA075362, U10CA180867] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001079] Funding Source: NIH RePORTER	Pfizer(Pfizer); Ipsen(Ipsen); International Breast Cancer Study Group; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Boehringer Ingelheim(Boehringer Ingelheim); Taiho Pharmaceutical; AbbVie(AbbVie); AstraZeneca(AstraZeneca); Novartis(Novartis); Roche(Roche Holding); Eli Lilly(Eli Lilly); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Supported by Pfizer, Ipsen, the International Breast Cancer Study Group, and the National Cancer Institute.; Dr. Fleming reports receiving a study drug for investigation in a clinical trial from Corcept Therapeutics; Dr. Colleoni, receiving fees for serving on advisory boards from Boehringer Ingelheim, Taiho Pharmaceutical, AbbVie, and AstraZeneca and consulting and lecture fees from Novartis; Dr. Stearns, receiving grant support from Pfizer and Novartis; Dr. Ruhstaller, receiving travel support and fees for serving on an advisory board from Novartis; and Dr. Viale, receiving fees for serving on advisory boards from Novartis, Roche, and Eli Lilly. No other potential conflict of interest relevant to this article was reported.	Bernhard J, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.557; Burstein HJ, 2010, J CLIN ONCOL, V28, P3784, DOI [10.1200/JCO.2009.26.3756, 10.1200/JOP.000082]; Carlson RW, 2009, J NATL COMPR CANC NE, V7, P122, DOI 10.6004/jnccn.2009.0012; Colleoni M, 2011, J CLIN ONCOL, V29, P1117, DOI 10.1200/JCO.2010.31.6455; Coombes RC, 2007, LANCET, V369, P559, DOI 10.1016/S0140-6736(07)60200-1; Cuzick J, 2007, LANCET, V369, P1711; Davies C, 2011, LANCET, V378, P771, DOI 10.1016/S0140-6736(11)60993-8; Gnant M, 2011, LANCET ONCOL, V12, P631, DOI 10.1016/S1470-2045(11)70122-X; Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303; Goss PE, 2013, J CLIN ONCOL, V31, P1398, DOI 10.1200/JCO.2012.44.7805; Howell A, 2005, LANCET, V365, P60, DOI 10.1016/s0140-6736(04)17666-6; Mouridsen H, 2009, NEW ENGL J MED, V361, P766, DOI 10.1056/NEJMoa0810818; Regan MM, 2013, BREAST, V22, P1094, DOI 10.1016/j.breast.2013.08.009; Regan MM, 2011, LANCET ONCOL, V12, P1101, DOI 10.1016/S1470-2045(11)70270-4; van de Velde CJH, 2011, LANCET, V377, P321, DOI 10.1016/S0140-6736(10)62312-4; Winer EP, 2005, J CLIN ONCOL, V23, P619, DOI 10.1200/JCO.2005.09.121	16	478	512	2	69	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 10	2014	371	2					107	118		10.1056/NEJMoa1404037	http://dx.doi.org/10.1056/NEJMoa1404037			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AK7YZ	24881463	Green Accepted, Green Published, Bronze			2023-01-03	WOS:000338645500007
J	Ge, XY; Yang, LQ; Jiang, Y; Yang, WW; Fu, J; Li, SL				Ge, Xi-Yuan; Yang, Lin-Qian; Jiang, Yang; Yang, Wen-Wen; Fu, Jia; Li, Sheng-Lin			Reactive Oxygen Species and Autophagy Associated Apoptosis and Limitation of Clonogenic Survival Induced by Zoledronic Acid in Salivary Adenoid Cystic Carcinoma Cell Line SACC-83	PLOS ONE			English	Article							HUMAN FIBROSARCOMA CELLS; S-PHASE ARREST; IN-VITRO; POSTMENOPAUSAL OSTEOPOROSIS; PANCREATIC-CANCER; MULTIPLE-MYELOMA; PROSTATE-CANCER; BISPHOSPHONATES; METASTASES; GROWTH	Salivary adenoid cystic carcinoma is an epithelial tumor in the head and neck region. Despite its slow growth, patients with salivary adenoid cystic carcinoma exhibit poor long term survival because of a high rate of distant metastasis. Lung and bone are common distant metastasis sites. Zoledronic acid, a third generation bisphosphonate, has been used for tumor-induced osteolysis due to bone metastasis and has direct antitumor activity in several human neoplasms. Here, we observed that zoledronic acid inhibited salivary adenoid cystic carcinoma cell line SACC-83 xenograft tumor growth in nude mice. In vitro, zoledronic acid induced apoptosis and reduced clonogenic survival in SACC-83. Flow cytometry and western blotting indicated that the cell cycle was arrested at G0/G1. Zoledronic acid treatment upregulated reactive oxygen species as well as the autophagy marker protein LC-3B. Reactive oxygen species scavenger N-acetylcysteine and autophagy antagonist 3-methyladenine decreased zoledronic acid-induced apoptosis and increased clonogenic survival. Silencing of the autophagy related gene Beclin-1 also decreased zoledronic acid-induced apoptosis and inhibition of clonogenic formation. In addition, isobolographic analysis revealed synergistic effects on apoptosis when zoledronic acid and paclitaxel/cisplatin were combined. Taken together, our results suggest that zoledronic acid induced apoptosis and reduced clonogenic survival via upregulation of reactive oxygen species and autophagy in the SACC-83 cell line. Thus, zoledronic acid should be considered a promising drug for the treatment of salivary adenoid cystic carcinoma.	[Ge, Xi-Yuan; Fu, Jia; Li, Sheng-Lin] Peking Univ, Cent Lab, Sch & Hosp Stomatol, Beijing 100871, Peoples R China; [Yang, Lin-Qian; Jiang, Yang; Yang, Wen-Wen; Li, Sheng-Lin] Peking Univ, Dept Oral & Maxillofacial Surg, Sch & Hosp Stomatol, Beijing 100871, Peoples R China	Peking University; Peking University	Li, SL (corresponding author), Peking Univ, Cent Lab, Sch & Hosp Stomatol, Beijing 100871, Peoples R China.	kqshlli@bjmu.edu.cn			National Natural Science Foundation of China [81272966, 81272967]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Natural Science Foundation of China (Nos. 81272966 and 81272967). URL: http://www.nsfc.gov.cn. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almubarak Hussain, 2011, J Carcinog, V10, P2, DOI 10.4103/1477-3163.75723; [Anonymous], ZHONGHUA KOU QIANG Y; BERENBAUM MC, 1989, PHARMACOL REV, V41, P93; Berenson JR, 2005, ONCOLOGIST, V10, P52, DOI 10.1634/theoncologist.10-1-52; Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312; Bruzzese F, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.406; Budman DR, 2006, ONCOLOGY-BASEL, V70, P147, DOI 10.1159/000093006; Chang J, 2012, ONCOL LETT, V4, P299, DOI 10.3892/ol.2012.723; Coleman RE, 2004, ONCOLOGIST, V9, P14, DOI 10.1634/theoncologist.9-90004-14; Corey E, 2003, CLIN CANCER RES, V9, P295; Di Salvatore M, 2011, CELL PROLIFERAT, V44, P139, DOI 10.1111/j.1365-2184.2011.00745.x; Dong L, 2011, J DENT RES, V90, P804, DOI 10.1177/0022034511401407; Dong L, 2013, ORAL ONCOL, V49, P1051, DOI 10.1016/j.oraloncology.2013.07.012; Fordice J, 1999, ARCH OTOLARYNGOL, V125, P149, DOI 10.1001/archotol.125.2.149; GRECO WR, 1995, PHARMACOL REV, V47, P331; Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128; Grimm M, 2012, INT ENDOD J, V45, P1156, DOI 10.1111/j.1365-2591.2012.02079.x; Han NL, 2000, PAIN, V85, P465, DOI 10.1016/S0304-3959(99)00294-8; Heymann D, 2004, TRENDS MOL MED, V10, P337, DOI 10.1016/j.molmed.2004.05.007; Hiraga T, 2004, CLIN CANCER RES, V10, P4559, DOI 10.1158/1078-0432.CCR-03-0325; Hitre E, 2013, BR J CANC; Ibrahim T, 2013, INT J ONCOL, V42, P1263, DOI 10.3892/ijo.2013.1809; Ibrahim T, 2012, CANCER CELL INT, V12, DOI 10.1186/1475-2867-12-48; Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727; Jaso J, 2011, ARCH PATHOL LAB MED, V135, P511, DOI 10.1043/2009-0527-RS.1; Koto K, 2013, INT J ONCOL, V42, P525, DOI 10.3892/ijo.2012.1735; Koto K, 2010, ONCOL REP, V24, P233, DOI 10.3892/or_00000851; Li YY, 2008, LUNG CANCER, V59, P180, DOI 10.1016/j.lungcan.2007.08.026; Lin JF, 2011, J UROLOGY, V185, P1490, DOI 10.1016/j.juro.2010.11.045; Liu Q, 2013, CHINESE MED J-PEKING, V126, P1486, DOI 10.3760/cma.j.issn.0366-6999.20122385; MATSUBA HM, 1986, CANCER, V57, P519, DOI 10.1002/1097-0142(19860201)57:3<519::AID-CNCR2820570319>3.0.CO;2-V; Ohnuki H, 2012, ARCH ORAL BIOL, V57, P906, DOI 10.1016/j.archoralbio.2011.11.015; Ozturk OH, 2007, CELL BIOL INT, V31, P1069, DOI 10.1016/j.cellbi.2007.02.004; Polascik Thomas J, 2008, Ther Clin Risk Manag, V4, P261; Recknor C, 2011, EXPERT OPIN PHARMACO, V12, P807, DOI 10.1517/14656566.2011.562201; Richhariya Akshara, 2012, Cancer Manag Res, V4, P55, DOI 10.2147/CMAR.S27693; Romani AA, 2009, BIOCHEM PHARMACOL, V78, P133, DOI 10.1016/j.bcp.2009.04.004; Sewing L, 2008, APOPTOSIS, V13, P782, DOI 10.1007/s10495-008-0211-z; Sieber P, 2013, CLIN DRUG INVEST, V33, P117, DOI 10.1007/s40261-012-0041-1; Silverman SL, 2008, JCR-J CLIN RHEUMATOL, V14, P299, DOI 10.1097/RHU.0b013e318188b1f3; Sung MW, 2003, ARCH OTOLARYNGOL, V129, P1193, DOI 10.1001/archotol.129.11.1193; Tallarida RJ, 2001, J PHARMACOL EXP THER, V298, P865; TALLARIDA RJ, 1992, PAIN, V49, P93, DOI 10.1016/0304-3959(92)90193-F; TALLARIDA RJ, 1992, PAIN, V51, P382, DOI 10.1016/0304-3959(92)90225-Z; Tallarida Ronald J, 2011, Genes Cancer, V2, P1003, DOI 10.1177/1947601912440575; Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986; van der Wal JE, 2002, HEAD NECK-J SCI SPEC, V24, P779, DOI 10.1002/hed.10126; van Weert S, 2013, ORAL ONCOL, V49, P824, DOI 10.1016/j.oraloncology.2013.05.004; Wang J, 2008, CANCER BIOL THER, V7, P1875, DOI 10.4161/cbt.7.12.7067; XY Li, 2012, MED ONCOL; Zhao M, 2012, CANCER SCI, V103, P58, DOI 10.1111/j.1349-7006.2011.02113.x; Zwolak P, 2010, J BONE JOINT SURG AM, V92A, P162, DOI 10.2106/JBJS.H.01679	52	23	26	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2014	9	6							e101207	10.1371/journal.pone.0101207	http://dx.doi.org/10.1371/journal.pone.0101207			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK8WO	24963720	Green Published, Green Submitted			2023-01-03	WOS:000338709500119
J	Svensson, B; Hansson, L				Svensson, Bengt; Hansson, Lars			Effectiveness of Mental Health First Aid Training in Sweden. A Randomized Controlled Trial with a Six-Month and Two-Year Follow-Up	PLOS ONE			English	Article							STIGMATIZING ATTITUDES; DISORDERS; KNOWLEDGE; ILLNESS; PEOPLE; EXPERIENCES; DEPRESSION; AUSTRALIA; LITERACY; BEHAVIOR	Background: According to a recent report from the European Brain Council and the European Colleague of Neuropsychopharmacology the one year prevalence of some kind of mental disorder is around 27% among the adult population in Europe. Research has shown a lack of mental health literacy in the population in general and it is thus important to find ways to improve the public's knowledge and skills to provide first hand support to people with mental disorders. Mental Health First Aid (MHFA) is a training program that has shown positive changes in knowledge and helping behavior. This study investigates if MHFA training in a Swedish context provides a sustained improvement in knowledge about mental disorders, a better ability to be helpful in contacts with people who are ill and if it changes attitudes in a positive direction. Methods and Findings: The introduction of the training program was made in accordance with the constructor's instructions. Participants were mainly public sector employees from a county in the west of Sweden. The study was a randomized controlled trial with an experiment group (n = 199) and a control group (n = 207) placed on a waiting list during a 6-month follow-up. A two-year follow-up was conducted for participants (n = 155) from both the intervention and waiting list group who had completed the training and during the follow-up been in contact with persons with mental disorders. The intervention group improved in knowledge as well as in confidence in providing help for someone in need. The two-year follow-up showed that the improvements were to a great extent maintained. Conclusions: Mental Health First Aid might raise the level of awareness of mental disorders and have an influence on the number of people who can receive professional treatment for their problems.	[Svensson, Bengt; Hansson, Lars] Lund Univ, Dept Hlth Sci, Lund, Sweden	Lund University	Svensson, B (corresponding author), Lund Univ, Dept Hlth Sci, Lund, Sweden.	Bengt.svensson@med.lu.se			Swedish Board of Health and Welfare	Swedish Board of Health and Welfare	The study was funded by the Swedish Board of Health and Welfare, (www.socialstyrelsen.se). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Angermeyer MC, 2013, BRIT J PSYCHIAT, V203, P146, DOI 10.1192/bjp.bp.112.122978; Eekhout I, 2013, J CLIN EPIDEMIOL; Griffiths KM, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-25; Griffiths KM, 2004, BRIT J PSYCHIAT, V185, P342, DOI 10.1192/bjp.185.4.342; Hossain D, 2010, RURAL REMOTE HEALTH, V10; Hossain D., 2009, AUSTRALAS PSYCHIATRY, V17, P116, DOI [DOI 10.1080/10398560902948365, 10.1080/10398560902948365]; Jorm AF, 2005, BMC PSYCHIATRY, V5, DOI 10.1186/1471-244X-5-43; Jorm AF, 2007, INT J CLIN HLTH PSYC, V7, P141; Jorm AF, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-33; Jorm AF, 2010, AUST NZ J PSYCHIAT, V44, P1072, DOI 10.3109/00048674.2010.516426; Jorm AF, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-51; Kanowski Len G, 2009, Int J Ment Health Syst, V3, P10, DOI 10.1186/1752-4458-3-10; Kelly CM, 2011, INT J MENT HEALTH SY, V5, DOI 10.1186/1752-4458-5-4; Kitchener BA, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-23; Kitchener BA, 2002, BMC PSYCHIATRY, V2, DOI 10.1186/1471-244X-2-10; Lam AYK, 2010, INT J MENT HEALTH SY, V4, DOI 10.1186/1752-4458-4-18; Link BG, 1999, AM J PUBLIC HEALTH, V89, P1328, DOI 10.2105/AJPH.89.9.1328; Minas Harry, 2009, Int J Ment Health Syst, V3, P19, DOI 10.1186/1752-4458-3-19; O'Reilly CL, 2011, AUST NZ J PSYCHIAT, V45, P549, DOI 10.3109/00048674.2011.585454; Pierce D, 2010, INT J MENT HEALTH SY, V4, DOI 10.1186/1752-4458-4-10; Reavley NJ, 2012, BRIT J PSYCHIAT, V200, P419, DOI 10.1192/bjp.bp.111.104208; Reavley NJ, 2011, AUST NZ J PSYCHIAT, V45, P1086, DOI 10.3109/00048674.2011.621061; Sartore GM, 2008, AUST J RURAL HEALTH, V16, P313, DOI 10.1111/j.1440-1584.2008.01005.x; Schomerus G, 2012, ACTA PSYCHIAT SCAND, V125, P440, DOI 10.1111/j.1600-0447.2012.01826.x; Terry J, 2010, J PSYCHIATR MENT HLT, V17, P594, DOI 10.1111/j.1365-2850.2010.01557.x; Wang PS, 2007, WORLD PSYCHIATRY, V6, P177; Wittchen HU, 2011, EUR NEUROPSYCHOPHARM, V21, P655, DOI 10.1016/j.euroneuro.2011.07.018; Wittchen HU, 2005, EUR NEUROPSYCHOPHARM, V15, P357, DOI 10.1016/j.euroneuro.2005.04.012	28	47	47	2	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2014	9	6							e100911	10.1371/journal.pone.0100911	http://dx.doi.org/10.1371/journal.pone.0100911			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AK8WO	24964164	gold, Green Published			2023-01-03	WOS:000338709500097
J	Determan, C; Anderson, R; Becker, A; Witowski, N; Lusczek, E; Mulier, K; Beilman, GJ				Determan, Charles, Jr.; Anderson, Rebecca; Becker, Aaron; Witowski, Nancy; Lusczek, Elizabeth; Mulier, Kristine; Beilman, Greg J.			Fed State Prior to Hemorrhagic Shock and Polytrauma in a Porcine Model Results in Altered Liver Transcriptomic Response	PLOS ONE			English	Article							CELL-VOLUME REGULATION; NO-REFLOW PHENOMENON; ISCHEMIA-REPERFUSION INJURY; COMBAT CASUALTY CARE; HYPERTONIC SALINE; MYOCARDIAL-ISCHEMIA; GENE-EXPRESSION; HYDRATION STATE; TISSUE-DAMAGE; RESUSCITATION	Hemorrhagic shock is a leading cause of trauma-related mortality in both civilian and military settings. Resuscitation often results in reperfusion injury and survivors are susceptible to developing multiple organ failure (MOF). The impact of fed state on the overall response to shock and resuscitation has been explored in some murine models but few clinically relevant large animal models. We have previously used metabolomics to establish that the fed state results in a different metabolic response in the porcine liver following hemorrhagic shock and resuscitation. In this study, we used our clinically relevant model of hemorrhagic shock and polytrauma and the Illumina HiSeq platform to determine if the liver transcriptomic response is also altered with respect to fed state. Functional analysis of the response to shock and resuscitation confirmed several typical responses including carbohydrate metabolism, cytokine inflammation, decreased cholesterol synthesis, and apoptosis. Our findings also suggest that the fasting state, relative to a carbohydrate prefed state, displays decreased carbohydrate metabolism, increased cytoskeleton reorganization and decreased inflammation in response to hemorrhagic shock and reperfusion. Evidence suggests that this is a consequence of a shrunken, catabolic state of the liver cells which provides an anti-inflammatory condition that partially mitigates hepatocellar damage.	[Determan, Charles, Jr.; Anderson, Rebecca; Becker, Aaron; Witowski, Nancy; Lusczek, Elizabeth; Mulier, Kristine; Beilman, Greg J.] Univ Minnesota, Dept Surg, Div Crit Care & Acute Care Surg, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Determan, C (corresponding author), Univ Minnesota, Dept Surg, Div Crit Care & Acute Care Surg, Box 242 UMHC, Minneapolis, MN 55455 USA.	deter088@umn.edu		Lusczek, Elizabeth/0000-0003-4680-965X; Beilman, Gregory/0000-0001-5036-3027	University of Minnesota Department of Surgery Grant; Office of Naval Research [N00014-09-1-0323 P00005]	University of Minnesota Department of Surgery Grant; Office of Naval Research(Office of Naval Research)	This work was funding by the University of Minnesota Department of Surgery Grant and the Office of Naval Research (N00014-09-1-0323 P00005). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Angele MK, 2008, CRIT CARE, V12, DOI 10.1186/cc6919; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bahrami S, 2006, SHOCK, V25, P283, DOI 10.1097/01.shk.0000208808.03148.ea; Benkhart EM, 2000, J IMMUNOL, V165, P1612, DOI 10.4049/jimmunol.165.3.1612; Benkoel L, 2001, DIGEST DIS SCI, V46, P1663, DOI 10.1023/A:1010693218680; Cinel I, 2009, CRIT CARE MED, V37, P291, DOI 10.1097/CCM.0b013e31819267fb; Coimbra R, 1997, J TRAUMA, V42, P602, DOI 10.1097/00005373-199704000-00004; Determan CE, 2014, METABOLOMICS, V10, P950, DOI 10.1007/s11306-014-0621-6; Dubick Michael A, 2011, US Army Med Dep J, P18; Durinck S, 2005, BIOINFORMATICS, V21, P3439, DOI 10.1093/bioinformatics/bti525; Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; FLORES J, 1972, J MEMBRANE BIOL, V10, P331, DOI 10.1007/BF01867864; Gatsios P, 1998, J BIOL CHEM, V273, P22962, DOI 10.1074/jbc.273.36.22962; GAUSSIN V, 1992, BIOCHEM J, V287, P17, DOI 10.1042/bj2870017; GAVIN JB, 1983, VIRCHOWS ARCH A, V399, P325, DOI 10.1007/BF00612950; HAUSSINGER D, 1994, AM J PHYSIOL, V267, pE343, DOI 10.1152/ajpendo.1994.267.3.E343; HAUSSINGER D, 1993, LANCET, V341, P1330, DOI 10.1016/0140-6736(93)90828-5; Haussinger D, 1996, BIOCHEM J, V313, P697; Hoffmann EK, 2009, PHYSIOL REV, V89, P193, DOI 10.1152/physrev.00037.2007; Holcomb JB, 2006, J TRAUMA, V60, P397, DOI 10.1097/01.ta.0000203581.75241.f1; Holcomb JB, 1999, J TRAUMA, V46, P49, DOI 10.1097/00005373-199901000-00009; Holcomb John, 2007, US Army Med Dep J, P24; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Iyegha UP, 2012, J AM COLL SURGEONS, V215, pS52, DOI 10.1016/j.jamcollsurg.2012.06.152; Ke QH, 2006, DIGEST DIS SCI, V51, P2257, DOI 10.1007/s10620-006-9135-6; Kol A, 2000, J IMMUNOL, V164, P13, DOI 10.4049/jimmunol.164.1.13; LEAF A, 1973, CIRCULATION, V48, P455, DOI 10.1161/01.CIR.48.3.455; Lexcen DR, 2012, J TRAUMA ACUTE CARE, V73, pS147, DOI 10.1097/TA.0b013e3182609821; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Lusczek ER, 2013, METABOLOMICS, V9, P223, DOI 10.1007/s11306-012-0441-5; MANCIET LH, 1994, AM J PHYSIOL, V266, pH1541, DOI 10.1152/ajpheart.1994.266.4.H1541; Molitoris BA, 1997, AM J PHYSIOL-RENAL, V272, pF430, DOI 10.1152/ajprenal.1997.272.4.F430; Murao Y, 2003, SHOCK, V20, P23, DOI 10.1097/01.shk.0000078832.57685.6c; Oreopoulos GD, 2004, HEPATOLOGY, V40, P211, DOI 10.1002/hep.20281; Oshlack A, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-12-220; Pedersen SF, 2001, COMP BIOCHEM PHYS A, V130, P385, DOI 10.1016/S1095-6433(01)00429-9; Peitzman A B, 1995, Curr Probl Surg, V32, P925, DOI 10.1016/S0011-3840(05)80008-5; Rezkalla SH, 2002, CIRCULATION, V105, P656, DOI 10.1161/hc0502.102867; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Scribner DM, 2010, J SURG RES, V164, pE131, DOI 10.1016/j.jss.2010.07.046; Smedley D, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-22; Spinella PC, 2009, BLOOD REV, V23, P231, DOI 10.1016/j.blre.2009.07.003; THEODOROPOULOS PA, 1992, FEBS LETT, V311, P241, DOI 10.1016/0014-5793(92)81111-X; TRANUMJENSEN J, 1981, CIRC RES, V49, P364, DOI 10.1161/01.RES.49.2.364; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Tsan MF, 2004, AM J PHYSIOL-CELL PH, V286, pC739, DOI 10.1152/ajpcell.00364.2003; Yoshidome H, 1999, HEPATOLOGY, V30, P203, DOI 10.1002/hep.510300120	50	7	7	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2014	9	6							e100088	10.1371/journal.pone.0100088	http://dx.doi.org/10.1371/journal.pone.0100088			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK5YM	24937255	Green Published, Green Submitted, gold			2023-01-03	WOS:000338503400071
J	van Riet-Nales, DA; Romkens, EGAW; Saint-Raymond, A; Kozarewicz, P; Schobben, AFAM; Egberts, TCG; Rademaker, CMA				van Riet-Nales, Diana A.; Romkens, Erwin G. A. W.; Saint-Raymond, Agnes; Kozarewicz, Piotr; Schobben, Alfred F. A. M.; Egberts, Toine C. G.; Rademaker, Carin M. A.			Oral Medicines for Children in the European Paediatric Investigation Plans	PLOS ONE			English	Article							MINI-TABLETS; FORMULATIONS; ACCEPTANCE; INFANTS	Introduction: Pharmaceutical industry is no longer allowed to develop new medicines for use in adults only, as the 2007 Paediatric Regulation requires children to be considered also. The plans for such paediatric development called Paediatric Investigation Plans (PIPs) are subject to agreement by the European Medicines Agency (EMA) and its Paediatric Committee (PDCO). The aim of this study was to evaluate the key characteristics of oral paediatric medicines in the PIPs and the changes implemented as a result of the EMA/PDCO review. Methods: All PIPs agreed by 31 December 2011 were identified through a proprietary EMA-database. PIPs were included if they contained an agreed proposal to develop an oral medicine for children 0 to 11 years. Information on the therapeutic area (EMA classification system); target age range (as defined by industry) and pharmaceutical characteristics (active substance, dosage form(s) as listed in the PIP, strength of each dosage form, excipients in each strength of each dosage form) was extracted from the EMA website or the EMA/PDCO assessment reports. Results: A hundred and fifty PIPs were included corresponding to 16 therapeutic areas and 220 oral dosage forms in 431 strengths/compositions. Eighty-two PIPs (37%) included tablets, 44 (20%) liquids and 35 (16%) dosage forms with a specific composition/strength that were stored as a solid but swallowed as a liquid e. g. dispersible tablets. The EMA/PDCO review resulted in an increase of 13 (207 to 220) oral paediatric dosage forms and 44 (387 to 431) dosage forms with a specific composition/strength. For many PIPs, the target age range was widened and the excipient composition and usability aspects modified. Conclusion: The EMA/PDCO review realized an increase in the number of requirements for the development of oral dosage forms and a larger increase in the number of dosage forms with a specific composition/strength, both targeting younger children. Changes to their pharmaceutical design were less profound.	[van Riet-Nales, Diana A.; Schobben, Alfred F. A. M.] Med Evaluat Board Netherlands MEB, Dept Chem Pharmaceut Assessment, Utrecht, Netherlands; [van Riet-Nales, Diana A.; Romkens, Erwin G. A. W.; Schobben, Alfred F. A. M.; Egberts, Toine C. G.] Univ Utrecht, Fac Sci, UIPS, Dept Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands; [Saint-Raymond, Agnes] European Med Agcy, Human Med Special Areas, London, England; [Kozarewicz, Piotr] European Med Agcy, Qual Med, London, England; [Egberts, Toine C. G.; Rademaker, Carin M. A.] Univ Med Ctr Utrecht, Dept Clin Pharm, Utrecht, Netherlands	Utrecht University; Utrecht University; Utrecht University Medical Center	van Riet-Nales, DA (corresponding author), Med Evaluat Board Netherlands MEB, Dept Chem Pharmaceut Assessment, Utrecht, Netherlands.	da.v.riet@cbg-meb.nl	Egberts, Toine/A-6625-2012; Egberts, Toine/K-4579-2019	Egberts, Toine/0000-0003-1758-7779; Egberts, Toine/0000-0003-1758-7779	Medicines Evaluation Board in the Netherlands (MEB); National Institute for Public Health and the Environment (RIVM)	Medicines Evaluation Board in the Netherlands (MEB); National Institute for Public Health and the Environment (RIVM)	This study was supported by a grant from the Medicines Evaluation Board in the Netherlands (MEB) and the National Institute for Public Health and the Environment (RIVM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allegaert K, 2010, ARCH DIS CHILD, V95, P1054, DOI 10.1136/adc.2010.190330; [Anonymous], 2008, EFSA J, V6, DOI 10.2903/j.efsa.2008.660; Breitkreutz J, 2008, CLIN THER, V30, P2146, DOI 10.1016/j.clinthera.2008.11.016; European Medicines Agency Committee for Medicinal Products for Human use, 2011, GUID PHARM IN PRESS; European Medicines Agency Committee for Medicinal Products for Human Use, 2013, GUID PHARM DEV MED P; Fabiano V, 2011, PHARMACOL RES, V63, P362, DOI 10.1016/j.phrs.2011.01.006; Fowles JR, 2013, CRIT REV TOXICOL, V43, P363, DOI 10.3109/10408444.2013.792328; Klingmann V, 2013, J PEDIATR-US, V163, P1728, DOI 10.1016/j.jpeds.2013.07.014; McCann D, 2007, LANCET, V370, P1542; Mentzer D, 2014, INT J PHARMACEUT, V469, P240, DOI 10.1016/j.ijpharm.2014.03.019; Michele TM, 2002, J ASTHMA, V39, P391, DOI 10.1081/JAS-120004032; Ruiz BQ, 2014, EXPERT REV CLIN PHAR, V7, P25, DOI 10.1586/17512433.2014.857600; Saint Raymond Agnes, 2005, Paediatr Respir Rev, V6, P45; Sam T, 2012, INT J PHARMACEUT, V435, P115, DOI 10.1016/j.ijpharm.2012.05.024; Spomer N, 2012, ARCH DIS CHILD, V97, P283, DOI 10.1136/archdischild-2011-300958; Sundh UB, 2013, EFSA J, V11, DOI 10.2903/j.efsa.2013.3155; Thomson SA, 2009, PEDIATRICS, V123, pE235, DOI 10.1542/peds.2008-2059; van Riet-Nales DA, 2014, INT J PHARMACEUT, V466, P44, DOI 10.1016/j.ijpharm.2014.02.031; van Riet-Nales DA, 2013, ARCH DIS CHILD, V98, P725, DOI 10.1136/archdischild-2012-303303; van Riet-Nales DA, 2012, INT J PHARMACEUT, V435, P132, DOI 10.1016/j.ijpharm.2012.05.053; van Riet-Nales DA, 2011, BRIT J CLIN PHARMACO, V72, P465, DOI 10.1111/j.1365-2125.2011.03982.x; Van Vooren L, 2002, J PHARM PHARM SCI, V5, P190; Walsh J, 2011, INT J PHARMACEUT, V415, P221, DOI 10.1016/j.ijpharm.2011.05.048	23	16	16	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2014	9	6							e98348	10.1371/journal.pone.0098348	http://dx.doi.org/10.1371/journal.pone.0098348			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK4YO	24897509	Green Published, gold			2023-01-03	WOS:000338430700035
J	Zimmerman, DL; Ruzicka, M; Hebert, P; Fergusson, D; Touyz, RM; Burns, KD				Zimmerman, Deborah L.; Ruzicka, Marcel; Hebert, Paul; Fergusson, Dean; Touyz, Rhian M.; Burns, Kevin D.			Short Daily versus Conventional Hemodialysis for Hypertensive Patients: A Randomized Cross-Over Study	PLOS ONE			English	Article							BLOOD-PRESSURE CONTROL; LEFT-VENTRICULAR HYPERTROPHY; OXIDATIVE STRESS; NITRIC-OXIDE; DRY-WEIGHT; DYSFUNCTION; MANAGEMENT; REDUCTION; TIME	Background: Treatment of end stage renal disease patients with short daily hemodialysis has been associated with an improvement in blood pressure. It is unclear from these studies if anti-hypertensive management had been optimized prior to starting short daily hemodialysis. Also, the potential mechanism(s) of blood pressure improvement remain to be fully elucidated. Study Design, Setting and Participants: We undertook a randomized cross-over trial in adult hypertensive patients with ESRD treated with conventional hemodialysis to determine: 1) if short-daily hemodialysis is associated with a reduction in systolic blood pressure after a 3-month blood pressure optimization period and; 2) the potential mechanism(s) of blood pressure reduction. Blood pressure was measured using Canadian Hypertension Education Program guidelines. Extracellular fluid volume (ECFV) was assessed with bioimpedance. Serum catecholamines were used to assess the sympathetic nervous system. Interleukin-6 (IL-6) and thiobarbituric acid reactive substances (T-BARS) were used as markers of inflammation and oxidative stress respectively. Results: After a 3-month run-in phase in which systolic blood pressure improved, there was no significant difference in pre-dialysis systolic pressure between short-daily and conventional hemodialysis (p = 0.39). However, similar blood pressures were achieved on fewer anti-hypertensive medications with short daily hemodialysis compared to conventional hemodialysis (p = 0.01). Short daily hemodialysis, compared to conventional hemodialysis, was not associated with a difference in dry weight or ECFV (p = 0.77). Sympathetic nervous system activity as assessed by plasma epinephrine (p = 1.0) and norepinephrine (p = 0.52) was also not different. Markers of inflammation (p = 0.42) and oxidative stress (p = 0.83) were also similar between the two treatment arms. Conclusions: Patients treated with short daily, compared to conventional hemodialysis, have similar blood pressure control on fewer anti-hypertensive medications. The mechanism(s) by which short daily hemodialysis allows for decreased antihypertensive medication use remains unclear but effects on sodium balance and changes in peripheral vascular resistance require further study.	[Zimmerman, Deborah L.; Ruzicka, Marcel] Univ Ottawa, Ottawa Hosp, Res Inst, Div Nephrol,Kidney Res Ctr, Ottawa, ON, Canada; [Hebert, Paul] Univ Ottawa, Ottawa, ON, Canada; [Hebert, Paul] Ottawa Hosp, Res Inst, Ottawa, ON, Canada; [Fergusson, Dean] Ottawa Hosp, Res Inst, Dept Med, Ottawa, ON, Canada; [Fergusson, Dean] Ottawa Hosp, Res Inst, Dept Surg, Ottawa, ON, Canada; [Fergusson, Dean] Ottawa Hosp, Res Inst, Dept Epidemiol, Ottawa, ON, Canada; [Fergusson, Dean] Ottawa Hosp, Res Inst, Dept Community Med, Ottawa, ON, Canada; [Fergusson, Dean] Ottawa Hosp, Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada; [Touyz, Rhian M.] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland; [Burns, Kevin D.] Univ Ottawa, Div Nephrol, Ottawa, ON, Canada; [Burns, Kevin D.] Univ Ottawa, Ottawa Hosp, Res Inst, Kidney Res Ctr, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Glasgow; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute	Zimmerman, DL (corresponding author), Univ Ottawa, Ottawa Hosp, Res Inst, Div Nephrol,Kidney Res Ctr, Ottawa, ON, Canada.	dzimmerman@toh.on.ca	Touyz, Rhian/AAM-3564-2020	Touyz, Rhian/0000-0003-0670-0887; Fergusson, Dean/0000-0002-3389-2485	Ontario Heart and Stroke Foundation; Ottawa Hospital Department of Medicine	Ontario Heart and Stroke Foundation(Heart & Stroke Foundation of Ontario); Ottawa Hospital Department of Medicine	This study was funded by the Ontario Heart and Stroke Foundation and the Ottawa Hospital Department of Medicine. The funders had no role in study design, data collection and analysis, decison to publish, or preparation of the manuscript.	Agarwal R, 2003, AM J MED, V115, P291, DOI 10.1016/S0002-9343(03)00366-8; Agarwal R, 2009, HYPERTENSION, V53, P500, DOI 10.1161/HYPERTENSIONAHA.108.125674; Ayus JC, 2005, J AM SOC NEPHROL, V16, P2778, DOI 10.1681/ASN.2005040392; Chan CT, 2003, HYPERTENSION, V42, P925, DOI 10.1161/01.HYP.0000097605.35343.64; Chan CT, 2002, KIDNEY INT, V61, P2235, DOI 10.1046/j.1523-1755.2002.00362.x; Chertow GM, 2010, NEW ENGL J MED, V363, P2287, DOI 10.1056/NEJMoa1001593; Cox-Reijven PL, 2001, AM J KIDNEY DIS, V38, P832, DOI 10.1053/ajkd.2001.27703; de Paula FM, 2004, KIDNEY INT, V66, P1232, DOI 10.1111/j.1523-1755.2004.00876.x; Di Marco GS, 2008, AM J PHYSIOL-RENAL, V294, pF1381, DOI 10.1152/ajprenal.00003.2008; Fagugli RM, 2001, AM J KIDNEY DIS, V38, P371, DOI 10.1053/ajkd.2001.26103; FOLEY RN, 1995, J AM SOC NEPHROL, V5, P2024; Hirooka Y, 2011, AM J PHYSIOL-REG I, V300, pR818, DOI 10.1152/ajpregu.00426.2010; Horl MP, 2002, AM J KIDNEY DIS, V39, P227, DOI 10.1053/ajkd.2002.30542; Jefferies HJ, 2011, CLIN J AM SOC NEPHRO, V6, P1326, DOI 10.2215/CJN.05200610; Katzarski KS, 1999, NEPHROL DIAL TRANSPL, V14, P369, DOI 10.1093/ndt/14.2.369; Laupacis A, 1996, KIDNEY INT, V50, P235, DOI 10.1038/ki.1996.307; Luik AJ, 2001, AM J NEPHROL, V21, P471, DOI 10.1159/000046651; Montezano AC, 2012, CAN J CARDIOL, V28, P288, DOI 10.1016/j.cjca.2012.01.017; Nesrallah G, 2003, AM J KIDNEY DIS, V42, pS13, DOI 10.1016/S0272-6386(03)00532-8; Oberleithner H, 2007, P NATL ACAD SCI USA, V104, P16281, DOI 10.1073/pnas.0707791104; Penne EL, 2010, BLOOD PURIFICAT, V30, P71, DOI 10.1159/000317124; Ponnuchamy B, 2009, AM J PHYSIOL-REG I, V296, pR1001, DOI 10.1152/ajpregu.90960.2008; Rocco MV, 2011, KIDNEY INT, V80, P1080, DOI 10.1038/ki.2011.213; Schulz E, 2011, HYPERTENS RES, V34, P665, DOI 10.1038/hr.2011.39; Song JH, 2002, AM J KIDNEY DIS, V40, P291, DOI 10.1053/ajkd.2002.34507; Thein H, 2007, NEPHROL DIAL TRANSPL, V22, P2630, DOI 10.1093/ndt/gfm220; Virdis A, 2002, HYPERTENSION, V40, P504, DOI 10.1161/01.HYP.0000034738.79310.06; White M, 2006, CLIN SCI, V110, P483, DOI 10.1042/CS20050317; Yoon JW, 2007, KIDNEY INT, V71, P167, DOI 10.1038/sj.ki.5002019; Yuen D, 2005, CLIN NEPHROL, V64, P364; Zilch O, 2007, J HYPERTENS, V25, P1285, DOI 10.1097/HJH.0b013e3280f9df85; Zimmerman DL, 2003, ASAIO J, V49, P426, DOI 10.1097/01.MAT.0000073969.50918.59; Zoccali C, 1991, J HYPERTENS, V17, P355	33	7	8	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2014	9	5							e97135	10.1371/journal.pone.0097135	http://dx.doi.org/10.1371/journal.pone.0097135			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI3UR	24875804	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000336790800004
J	Rohlmann, A; Pohl, D; Bender, A; Graichen, F; Dymke, J; Schmidt, H; Bergmann, G				Rohlmann, Antonius; Pohl, David; Bender, Alwina; Graichen, Friedmar; Dymke, Joern; Schmidt, Hendrik; Bergmann, Georg			Activities of Everyday Life with High Spinal Loads	PLOS ONE			English	Article							VERTEBRAL BODY REPLACEMENT; MEASURED IN-VIVO; INTRADISCAL PRESSURE; LUMBAR SPINE; DISK PRESSURE; IMPLANT; ELEMENT; WALKING; WEIGHT; HEIGHT	Activities with high spinal loads should be avoided by patients with back problems. Awareness about these activities and knowledge of the associated loads are important for the proper design and pre-clinical testing of spinal implants. The loads on an instrumented vertebral body replacement have been telemetrically measured for approximately 1000 combinations of activities and parameters in 5 patients over a period up to 65 months postoperatively. A database containing, among others, extreme values for load components in more than 13,500 datasets was searched for 10 activities that cause the highest resultant force, bending moment, torsional moment, or shear force in an anatomical direction. The following activities caused high resultant forces: lifting a weight from the ground, forward elevation of straight arms with a weight in hands, moving a weight laterally in front of the body with hanging arms, changing the body position, staircase walking, tying shoes, and upper body flexion. All activities have in common that the center of mass of the upper body was moved anteriorly. Forces up to 1650 N were measured for these activities of daily life. However, there was a large intra-and inter-individual variation in the implant loads for the various activities depending on how exercises were performed. Measured shear forces were usually higher in the posterior direction than in the anterior direction. Activities with high resultant forces usually caused high values of other load components.	[Rohlmann, Antonius; Pohl, David; Bender, Alwina; Graichen, Friedmar; Dymke, Joern; Schmidt, Hendrik; Bergmann, Georg] Charite, Julius Wolff Inst, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Rohlmann, A (corresponding author), Charite, Julius Wolff Inst, D-13353 Berlin, Germany.	antonius.rohlmann@charite.de	Rohlmann, Antonius/E-4778-2011	Rohlmann, Antonius/0000-0002-0083-2793; Schmidt, Hendrik/0000-0003-3300-8685; Bender, Alwina/0000-0002-4444-6309	Deutsche Forschungsgemeinschaft [Ro 581/18-1, Ro 581/20-1, Schm 2572/3-1]; Deutsche Arthrose-Hilfe, Frankfurt	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Arthrose-Hilfe, Frankfurt	Funding for this study was obtained from the Deutsche Forschungsgemeinschaft [Ro 581/18-1, Ro 581/20-1 and Schm 2572/3-1] and the Deutsche Arthrose-Hilfe, Frankfurt. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANDERSSON GBJ, 1977, CLIN ORTHOP RELAT R, P156; BRINCKMANN P, 1991, SPINE, V16, P641, DOI 10.1097/00007632-199106000-00008; CHOLEWICKI J, 1994, J BIOMECH, V27, P1287, DOI 10.1016/0021-9290(94)90282-8; Dreischarf M, 2013, MED ENG PHYS, V35, P1385, DOI 10.1016/j.medengphy.2013.03.007; Graichen F, 2007, IEEE T BIO-MED ENG, V54, P253, DOI 10.1109/TBME.2006.886857; Han KS, 2013, MED ENG PHYS, V35, P969, DOI 10.1016/j.medengphy.2012.09.009; Magerl F, 1994, Eur Spine J, V3, P184, DOI 10.1007/BF02221591; Marras WS, 2009, ERGONOMICS, V52, P384, DOI 10.1080/00140130802376075; McGill SM, 2013, ERGONOMICS, V56, P293, DOI 10.1080/00140139.2012.752528; NACHEMSON A., 1966, CLIN ORTHO RELAT RES, V45, P107; NACHEMSON AL, 1981, SPINE, V6, P93, DOI 10.1097/00007632-198101000-00020; Rohlmann A, 1997, J BIOMECH, V30, P41, DOI 10.1016/S0021-9290(96)00103-0; Rohlmann A, 2014, GAIT POSTURE, V39, P750, DOI 10.1016/j.gaitpost.2013.10.010; Rohlmann A, 2013, EUR SPINE J, V22, P2575, DOI 10.1007/s00586-013-3057-1; Rohlmann A, 2012, CLIN BIOMECH, V27, P754, DOI 10.1016/j.clinbiomech.2012.04.006; Rohlmann A, 2001, ERGONOMICS, V44, P781, DOI 10.1080/00140130120943; Rohlmann A, 2000, J BIOMECH, V33, P1099, DOI 10.1016/S0021-9290(00)00075-0; Rohlmann A, 2007, MED ENG PHYS, V29, P580, DOI 10.1016/j.medengphy.2006.06.012; Rohlmann A, 2013, J BIOMECH, V46, P511, DOI 10.1016/j.jbiomech.2012.10.022; Rohlmann A, 2011, SPINE J, V11, P870, DOI 10.1016/j.spinee.2011.06.017; Rohlmann A, 2010, EUR SPINE J, V19, P1129, DOI 10.1007/s00586-010-1346-5; Sato K, 1999, SPINE, V24, P2468, DOI 10.1097/00007632-199912010-00008; SCHULTZ AB, 1981, SPINE, V6, P76, DOI 10.1097/00007632-198101000-00017; Shirazi-Adl A, 2006, J BIOMECH, V39, P267, DOI 10.1016/j.jbiomech.2004.11.022; Wilke HJ, 1999, SPINE, V24, P755, DOI 10.1097/00007632-199904150-00005; Wilke HJ, 2001, CLIN BIOMECH, V16, pS111, DOI 10.1016/S0268-0033(00)00103-0	26	50	51	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2014	9	5							e98510	10.1371/journal.pone.0098510	http://dx.doi.org/10.1371/journal.pone.0098510			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI5NG	24866883	Green Published, Green Submitted, gold			2023-01-03	WOS:000336914100062
J	Jiang, M; Han, YQ; Zhou, MG; Zhao, HZ; Xiao, X; Hou, YY; Gao, J; Bai, G; Luo, GA				Jiang, Min; Han, Yan-qi; Zhou, Meng-ge; Zhao, Hong-zhi; Xiao, Xue; Hou, Yuan-yuan; Gao, Jie; Bai, Gang; Luo, Guo-an			The Screening Research of Anti-Inflammatory Bioactive Markers from Different Flowering Phases of Flos Lonicerae Japonicae	PLOS ONE			English	Article							IDENTIFICATION; INFLAMMATION; INJECTION; MS	Flos Lonicerae Japonicae (FLJ) is an important cash crop in eastern Asia, and it is an anti-inflammatory Traditional Chinese Medicine. There are large variations in the quality of the marketed FLJ products. To find marker ingredients useful for quality control, a tandem technology integrating ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-Q/TOF), principal component analysis (PCA), heat map analysis and hierarchical cluster analysis coupled with a NF-kappa B luciferase reporter gene assay were used to identify the different ingredients from the green bud, white bud, flowering stage and leaf stages, as well as to screen the anti-inflammatory activity of FLJ compositions. As flowering progressed, the anti-inflammatory effects of FLJ gradually decreased; however, chlorogenic acid, swertiamarin and sweroside should be used to evaluate the quality of FLJ products.	[Jiang, Min; Han, Yan-qi; Zhou, Meng-ge; Zhao, Hong-zhi; Xiao, Xue; Hou, Yuan-yuan; Gao, Jie; Bai, Gang; Luo, Guo-an] Nankai Univ, State Key Lab Med Chem Biol, Tianjin 300071, Peoples R China; [Jiang, Min; Han, Yan-qi; Zhou, Meng-ge; Zhao, Hong-zhi; Xiao, Xue; Hou, Yuan-yuan; Gao, Jie; Bai, Gang; Luo, Guo-an] Nankai Univ, Coll Pharm, Tianjin 300071, Peoples R China; [Jiang, Min; Han, Yan-qi; Zhou, Meng-ge; Zhao, Hong-zhi; Hou, Yuan-yuan; Gao, Jie; Bai, Gang] Nankai Univ, Tianjin Key Lab Mol Drug Res, Tianjin 300071, Peoples R China; [Luo, Guo-an] Tsinghua Univ, Dept Chem, Beijing 100084, Peoples R China	Nankai University; Nankai University; Nankai University; Tsinghua University	Bai, G (corresponding author), Nankai Univ, State Key Lab Med Chem Biol, Tianjin 300071, Peoples R China.	gangbai@nankai.edu.cn	赵, 洪芝/AAB-4771-2022; Jiang, Min/HGT-8781-2022		National Natural Science Foundation of China [81373506]; Key Program of Natural Science of Foundation of Tianjin, China [13JCZDJC31400]; Specialized Research Fund for the Doctor Program of Higher Education of China [20120031110042]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Program of Natural Science of Foundation of Tianjin, China; Specialized Research Fund for the Doctor Program of Higher Education of China(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP))	This work was supported by a Grant from the National Natural Science Foundation of China (No. 81373506), the Key Program of Natural Science of Foundation of Tianjin, China (Nos. 13JCZDJC31400) and the Specialized Research Fund for the Doctor Program of Higher Education of China (Nos. 20120031110042). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Calder PC, 2006, AM J CLIN NUTR, V83, p1505S, DOI 10.1093/ajcn/83.6.1505S; Ciarcia R, 2012, J CELL PHYSIOL, V227, P2798, DOI 10.1002/jcp.23029; Commission C.P., 2010, PHARM PEOPL REP CHIN; Fraige K, 2014, FOOD CHEM, V145, P395, DOI 10.1016/j.foodchem.2013.08.066; Jiang M, 2013, J ETHNOPHARMACOL, V147, P426, DOI 10.1016/j.jep.2013.03.032; Kim HR, 2010, INT IMMUNOPHARMACOL, V10, P1242, DOI 10.1016/j.intimp.2010.07.005; Krishnamoorthy S, 2006, CANCER METAST REV, V25, P481, DOI 10.1007/s10555-006-9016-0; Li MZ, 2010, MODERN BUSINESS, V9, P278; Li YJ, 2012, BIOMED CHROMATOGR, V26, P449, DOI 10.1002/bmc.1685; Oeckinghaus A, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000034; Panaro MA, 2012, BR J NUTR, V17, P1; Park KI, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/828521; Peng LY, 2000, FITOTERAPIA, V71, P713, DOI 10.1016/S0367-326X(00)00212-4; Ryu KH, 2010, BIOSCI BIOTECH BIOCH, V74, P2022, DOI 10.1271/bbb.100279; Shang XF, 2011, J ETHNOPHARMACOL, V138, P1, DOI 10.1016/j.jep.2011.08.016; Shen WJ, 2012, BRAIN RES BULL, V88, P487, DOI 10.1016/j.brainresbull.2012.04.010; Tang D, 2008, J SEP SCI, V31, P3519, DOI 10.1002/jssc.200800173; Vaijanathappa J, 2009, PLANTA MED, V75, P12, DOI 10.1055/s-0028-1088333; Xing L, 2013, J ETHNOPHARMACOL, V148, P239, DOI 10.1016/j.jep.2013.04.019; Xu KJ, 2011, J PHARMACEUT BIOMED, V56, P1089, DOI 10.1016/j.jpba.2011.07.034; Xu YB, 2007, J ETHNOPHARMACOL, V111, P667, DOI 10.1016/j.jep.2007.01.017; Xu YX, 2010, INFLAMM RES, V59, P871, DOI 10.1007/s00011-010-0199-z; Yoo HJ, 2008, J PHARM PHARMACOL, V60, P779, DOI 10.1211/jpp.60.6.0014; Yue GGL, 2012, PHYTOTHER RES, V26, P915, DOI 10.1002/ptr.3659	24	24	29	2	46	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 8	2014	9	5							e96214	10.1371/journal.pone.0096214	http://dx.doi.org/10.1371/journal.pone.0096214			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK1XT	24809338	Green Published, gold, Green Submitted			2023-01-03	WOS:000338213300021
J	Galicia-Connolly, E; Adams, D; Bateman, J; Dagenais, S; Clifford, T; Baydala, L; King, WJ; Vohra, S				Galicia-Connolly, Elaine; Adams, Denise; Bateman, Justin; Dagenais, Simon; Clifford, Tammy; Baydala, Lola; King, W. James; Vohra, Sunita			CAM Use in Pediatric Neurology: An Exploration of Concurrent Use with Conventional Medicine	PLOS ONE			English	Article							DEFICIT HYPERACTIVITY DISORDER; ALTERNATIVE MEDICINE; SPECTRUM DISORDER; THERAPY USE; COMPLEMENTARY; CHILDREN; EPILEPSY; CANCER; ILLNESS; AUTISM	Background: Previous studies have found that up to 60% of children with neurologic conditions have tried complementary and alternative medicine (CAM). Objective: To assess the use of CAM among patients presenting to neurology clinics at two academic centers in Canada. Methods: A survey instrument was developed to inquire about use of CAM products and therapies, including reasons for use, perceived helpfulness, and concurrent use with conventional medicine, and administered to patients or their parents/guardians at the Stollery Children's Hospital in Edmonton and the Children's Hospital of Eastern Ontario (CHEO) in Ottawa. Results: Overall CAM use at the Stollery was 78%, compared to 48% at CHEO. The most common CAM products used were multi-vitamins (84%), vitamin C (37%), homeopathic remedies (24%), and fish oil/omega 3 s (22%). The most common CAM practices used were massage (47%), chiropractic (37%), faith healing (18%), aromatherapy (16%), homeopathy (16%), and relaxation (16%). Many patients used CAM products at the same time as conventional medicine but just over half (57%) discussed this concurrent use with their physician. Conclusion: CAM use is common in pediatric neurology patients and most respondents felt that it was helpful, with few or no harms associated. However, this use is often undisclosed, increasing possibility of interactions with conventional drugs. We urge clinicians to inquire about CAM use during routine history taking at every patient visit. Parents would clearly like more information about CAM from their specialty clinics; such information would be easier to share if more primary data were available about the safety and effectiveness of commonly used therapies.	[Galicia-Connolly, Elaine; Adams, Denise] Univ Alberta, Dept Pediat, CARE Program, Edmonton, AB, Canada; [Bateman, Justin] Univ Alberta, Fac Med & Dent, Edmonton, AB, Canada; [Dagenais, Simon] Palladian Hlth, West Seneca, NY USA; [Clifford, Tammy] Univ Ottawa, Dept Pediat, Ottawa, ON K1N 6N5, Canada; [Clifford, Tammy] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada; [Clifford, Tammy] Canadian Agcy Drugs & Technol Hlth, Ottawa, ON, Canada; [Clifford, Tammy; Baydala, Lola] Univ Alberta, Dept Pediat, Fac Med & Dent, Edmonton, AB, Canada; [King, W. James] Univ Ottawa, Dept Pediat, Div Pediat Med, Ottawa, ON K1N 6N5, Canada; [King, W. James] Childrens Hosp Eastern Ontario, Ottawa, ON K1H 8L1, Canada; [Vohra, Sunita] Univ Alberta, Dept Pediat, PedCAM Network, Fac Med & Dent,CARE Program, Edmonton, AB, Canada; [Vohra, Sunita] Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada	University of Alberta; University of Alberta; University of Ottawa; University of Ottawa; University of Alberta; University of Ottawa; University of Ottawa; Children's Hospital of Eastern Ontario; University of Alberta; University of Alberta	Vohra, S (corresponding author), Univ Alberta, Dept Pediat, PedCAM Network, Fac Med & Dent,CARE Program, Edmonton, AB, Canada.	svohra@ualberta.ca	; Vohra, Sunita/F-5755-2016	Dagenais, Simon/0000-0003-3062-9312; Vohra, Sunita/0000-0002-6210-7933	SickKids Foundation; Alberta Innovates-Health Solutions	SickKids Foundation; Alberta Innovates-Health Solutions	This project was supported by a grant from the SickKids Foundation. Sunita Vohra receives salary support from Alberta Innovates-Health Solutions (formerly Alberta Heritage Foundation for Medical Research), which is a government agency that supports research in Alberta. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams D, 2013, PEDIATRICS, V131, P225, DOI 10.1542/peds.2012-1220; Armishaw J, 1999, ARCH DIS CHILD, V81, P133, DOI 10.1136/adc.81.2.133; Ball SD, 2005, J AM DIET ASSOC, V105, P78, DOI 10.1016/j.jada.2004.10.008; Barnes Patricia M., 2008, NATL HLTH STAT REPOR, V12, P1, DOI DOI 10.1037/E623942009-001; Birdee GS, 2010, PEDIATRICS, V125, P249, DOI 10.1542/peds.2009-1406; Cheuk DKL, 2008, COCHRANE DB SYST REV, V4; Christon LM, 2010, RES AUTISM SPECT DIS, V4, P249, DOI 10.1016/j.rasd.2009.09.013; Cvijovic K, 2009, CAN PHARM J, V142, P224, DOI 10.3821/1913-701X-142.5.224; Devinsky O, 2005, COMPLEMENTARY ALTERN, pe129; Fernandez CV, 1998, J CLIN ONCOL, V16, P1279, DOI 10.1200/JCO.1998.16.4.1279; Friedman T, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.6.e1; Golomb MR, 2003, J CHILD NEUROL, V18, P714, DOI 10.1177/08830738030180100201; Gross-Tsur V, 2003, PEDIATR NEUROL, V29, P53, DOI 10.1016/s0887-8994(03)00027-4; Hagen LEM, 2003, ARTHRIT RHEUM-ARTHR, V49, P3, DOI 10.1002/art.10931; Hanson E, 2007, J AUTISM DEV DISORD, V37, P628, DOI 10.1007/s10803-006-0192-0; Harrington JW, 2006, J DEV BEHAV PEDIATR, V27, pS156, DOI 10.1097/00004703-200604002-00014; Hurvitz EA, 2003, DEV MED CHILD NEUROL, V45, P364, DOI 10.1017/S0012162203000707; Johnston GA, 2004, BRIT J DERMATOL, V150, P1186, DOI 10.1111/j.1365-2133.2004.05888.x; Kemper KJ, 2010, PEDIATR REV, V31, pE17, DOI 10.1542/pir.31-2-e17; Kemper KJ, 2008, PEDIATRICS, V122, P1374, DOI 10.1542/peds.2008-2173; Levy R, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001903; Levy SE, 2003, J DEV BEHAV PEDIATR, V24, P418, DOI 10.1097/00004703-200312000-00003; Lim J Y F, 2004, Ann Acad Med Singap, V33, pS76; Maha Nita, 2007, BMC Complement Altern Med, V7, P17, DOI 10.1186/1472-6882-7-17; Mazur L J, 2001, Tex Med, V97, P64; Murphy SP, 2002, AM J EPIDEMIOL, V156, P669, DOI 10.1093/aje/kwf097; Neuhouser ML, 2001, PREV MED, V33, P347, DOI 10.1006/pmed.2001.0911; PENDERGRASS TW, 1981, AM J PEDIAT HEMATOL, V3, P339; Ramaratnam S, 2009, COCHRANE DB SYST REV, V3; Ranganathan LN, 2005, COCHRANE DB SYST REV, V2; Ricotti V, 2006, CURR NEUROL NEUROSCI, V6, P347, DOI 10.1007/s11910-006-0029-4; Rogovik AL, 2010, ANN PHARMACOTHER, V44, P311, DOI 10.1345/aph.1M238; Samuels N, 2008, EPILEPSIA, V49, P373, DOI 10.1111/j.1528-1167.2007.01379.x; Sinha D, 2005, J PAEDIATR CHILD H, V41, P23, DOI 10.1111/j.1440-1754.2005.00530.x; Sirven JI, 2007, SEMIN NEUROL, V27, P325, DOI 10.1055/s-2007-985334; Soo I, 2005, CAN J NEUROL SCI, V32, P524, DOI 10.1017/S0317167100004558; Weber W, 2007, PEDIATR CLIN N AM, V54, P983, DOI 10.1016/j.pcl.2007.09.006	37	20	20	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2014	9	4							e94078	10.1371/journal.pone.0094078	http://dx.doi.org/10.1371/journal.pone.0094078			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI5PW	24736474	gold, Green Submitted, Green Published			2023-01-03	WOS:000336922600043
J	Handley, AJ				Handley, Anthony J.			Basic Life Support	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Colchester Hosp Univ, NHS Fdn Trust, Colchester, Essex, England	Oxford University Hospitals NHS Foundation Trust	Handley, AJ (corresponding author), Colchester Hosp Univ, NHS Fdn Trust, Colchester, Essex, England.	digitalrightsuk@wiley.com						[Anonymous], 2011, CARD RES AUT EXT DEF; Handley AJ, 2010, ADULT BLS GUIDELINES; Koster RW, 2010, RESUSCITATION, V81, P1277, DOI 10.1016/j.resuscitation.2010.08.009	3	1	1	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 2	2014	348								g1730	10.1136/bmj.g1730	http://dx.doi.org/10.1136/bmj.g1730			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AE4TP	24696230				2023-01-03	WOS:000333977000018
J	Nakagawa, Y; Nishikimi, T; Kuwahara, K; Yasuno, S; Kinoshita, H; Kuwabara, Y; Nakao, K; Minami, T; Yamada, C; Ueshima, K; Ikeda, Y; Okamoto, H; Horii, K; Nagata, K; Kangawa, K; Minamino, N; Nakao, K				Nakagawa, Yasuaki; Nishikimi, Toshio; Kuwahara, Koichiro; Yasuno, Shinji; Kinoshita, Hideyuki; Kuwabara, Yoshihiro; Nakao, Kazuhiro; Minami, Takeya; Yamada, Chinatsu; Ueshima, Kenji; Ikeda, Yoshihiro; Okamoto, Hiroyuki; Horii, Kazukiyo; Nagata, Kiyoshi; Kangawa, Kenji; Minamino, Naoto; Nakao, Kazuwa			The Effects of Super-Flux (High Performance) Dialyzer on Plasma Glycosylated Pro-B-Type Natriuretic Peptide (proBNP) and Glycosylated N-Terminal proBNP in End-Stage Renal Disease Patients on Dialysis	PLOS ONE			English	Article							HEART-FAILURE; MORTALITY; ATRIAL; MARKER; FORMS; BNP	Background: Plasma BNP levels are predictive of prognosis in hemodialysis patients. However, recent studies showed that the current BNP immunoassay cross-reacts with glycosylated proBNP, and the NT-proBNP assay underestimates glycosylated NT-proBNP. In addition, the recently developed high performance dialyzer removes medium-sized molecular solutes such as beta 2-microgloburin. We therefore investigated the effects of high performance dialysis on measured levels of glycosylated proBNP, glycosylated NT-proBNP and other BNP-related peptides in end-stage renal disease (ESRD) patients on hemodialysis. Method: The relationships between clinical parameters and BNP-related molecule were also investigated. We used our newly developed immunoassay to measure plasma total BNP and proBNP in 105 normal subjects and 36 ESRD patients before and after hemodialysis. Plasma NT-proBNP was measured using Elecsys II after treatment with or without deglycosylating enzymes. We also measured plasma ANP and cGMP using radioimmunoassays. Results: All the measured BNP-related peptides were significantly higher in ESRD patients than healthy subjects. Total BNP (-38.9%), proBNP (-29.7%), glycoNT-proBNP (-45.5%), nonglycoNT-proBNP (-53.4%), ANP (-50.4%) and cGMP (-72.1%) were all significantly reduced after hemodialysis, and the magnitude of the reduction appeared molecular weight-dependent. Both the proBNP/total BNP and glycoNT-proBNP/nonglycoNT-proBNP ratios were increased after hemodialysis. The former correlated positively with hemodialysis vintage and negatively with systolic blood pressure, while the latter correlated positively with parathyroid hormone levels. Conclusion: These results suggest that hemodialysis using super-flux dialyzer removes BNP-related peptides in a nearly molecular weight-dependent manner. The ProBNP/total BNP and glycoNT-proBNP/nonglycoNT-proBNP ratios appear to be influenced by hemodialysis-related parameters in ESRD patients on hemodialysis.	[Nakagawa, Yasuaki; Nishikimi, Toshio; Kuwahara, Koichiro; Kinoshita, Hideyuki; Kuwabara, Yoshihiro; Nakao, Kazuhiro; Minami, Takeya; Yamada, Chinatsu; Nakao, Kazuwa] Kyoto Univ Grad Sch Med, Dept Med & Clin Sci, Kyoto, Japan; [Yasuno, Shinji; Ueshima, Kenji] Kyoto Univ Hosp, Dept EBM Res, Inst Adv Clin & Translat Sci, Kyoto 606, Japan; [Ikeda, Yoshihiro] Med Corp, Ikeda Clin, Kyoto, Japan; [Okamoto, Hiroyuki; Horii, Kazukiyo; Nagata, Kiyoshi] Shionogi & Co Ltd, Div Diagnost, Oska, Japan; [Kangawa, Kenji] Natl Cerebral & Cardiovasc Ctr Res Inst, Dept Biochem, Suita, Osaka, Japan; [Minamino, Naoto] Natl Cerebral & Cardiovasc Ctr Res Inst, Dept Mol Pharmacol, Suita, Osaka, Japan	Kyoto University; Kyoto University; Shionogi & Company Limited; National Cerebral & Cardiovascular Center - Japan; National Cerebral & Cardiovascular Center - Japan	Nishikimi, T (corresponding author), Kyoto Univ Grad Sch Med, Dept Med & Clin Sci, Kyoto, Japan.	nishikim@kuhp.kyoto-u.ac.jp	Kuwahara, Koichiro/AFK-1723-2022	Kuwahara, Koichiro/0000-0003-2670-7170; Kuwabara, Yoshihiro/0000-0003-4161-2970	Ministry of Education, Culture, Sports, Science and Technology of Japan [20590837, 23591041]; Japan Science and Technology Agency [AS 232Z01302F]; Suzuken Memorial Foundation; Grants-in-Aid for Scientific Research [24591095] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Science and Technology Agency(Japan Science & Technology Agency (JST)); Suzuken Memorial Foundation; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported in part by Scientific Research Grants-in-Aid 20590837 and 23591041 from the Ministry of Education, Culture, Sports, Science and Technology of Japan (to T. Nishikimi); a grant (AS 232Z01302F) from the Japan Science and Technology Agency (to T. Nishikimi); and a grant from the Suzuken Memorial Foundation (to T. Nishikimi). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Cataliotti A, 2001, MAYO CLIN PROC, V76, P1111, DOI 10.4065/76.11.1111; Cowie MR, 1997, LANCET, V350, P1349, DOI 10.1016/S0140-6736(97)06031-5; Daniels LB, 2007, J AM COLL CARDIOL, V50, P2357, DOI 10.1016/j.jacc.2007.09.021; DAVIS M, 1994, LANCET, V343, P440, DOI 10.1016/S0140-6736(94)92690-5; Hammerer-Lercher A, 2008, CLIN CHEM, V54, P858, DOI 10.1373/clinchem.2007.090266; Hunt PJ, 1997, CLIN ENDOCRINOL, V47, P287, DOI 10.1046/j.1365-2265.1997.2361058.x; Jackson S, 1985, NURSES AIDS SERIES; Januzzi JL, 2005, AM J CARDIOL, V95, P948, DOI 10.1016/j.amjcard.2004.12.032; Jourdain P, 2003, EUR J HEART FAIL, V5, P155, DOI 10.1016/S1388-9842(02)00247-7; Liang FQ, 2007, J AM COLL CARDIOL, V49, P1071, DOI 10.1016/j.jacc.2006.10.063; Luckenbill KN, 2008, CLIN CHEM, V54, P619, DOI 10.1373/clinchem.2007.097998; Madsen LH, 2007, KIDNEY INT, V71, P548, DOI 10.1038/sj.ki.5002087; Maisel AS, 2002, NEW ENGL J MED, V347, P161, DOI 10.1056/NEJMoa020233; Mallamaci F, 2001, KIDNEY INT, V59, P1559, DOI 10.1046/j.1523-1755.2001.0590041559.x; Niizuma S, 2009, CLIN CHEM, V55, P1347, DOI 10.1373/clinchem.2008.121236; Niizuma S, 2009, NEPHROL DIAL TRANSPL, V24, P597, DOI 10.1093/ndt/gfn491; Nishikimi T, 1996, HYPERTENSION, V28, P22, DOI 10.1161/01.HYP.28.1.22; Nishikimi T, 2006, CARDIOVASC RES, V69, P318, DOI 10.1016/j.cardiores.2005.10.001; Nishikimi T, 2010, HEART, V96, P432, DOI 10.1136/hrt.2009.178392; Nishikimi T, 2001, AM J KIDNEY DIS, V37, P1201; Nishikimi T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053233; Nishikimi T, 2012, HEART, V98, P152, DOI 10.1136/heartjnl-2011-300102; Nishikimi T, 2011, J CARDIOL, V57, P131, DOI 10.1016/j.jjcc.2011.01.002; Satyan S, 2007, AM J KIDNEY DIS, V50, P1009, DOI 10.1053/j.ajkd.2007.08.017; Schellenberger U, 2006, ARCH BIOCHEM BIOPHYS, V451, P160, DOI 10.1016/j.abb.2006.03.028; Schluter KD, 1998, CARDIOVASC RES, V37, P34, DOI 10.1016/S0008-6363(97)00194-6; Seferian KR, 2008, CLIN CHEM, V54, P866, DOI 10.1373/clinchem.2007.100040; Sheen V, 2007, AM HEART J, V153, DOI 10.1016/j.ahj.2006.10.041; Sivalingam M, 2011, HEMODIAL INT, V15, P359, DOI 10.1111/j.1542-4758.2011.00557.x; Troughton RW, 2004, J AM COLL CARDIOL, V43, P416, DOI 10.1016/j.jacc.2003.08.046; Wang AYM, 2007, J AM SOC NEPHROL, V18, P321, DOI 10.1681/ASN.2005121299; Weber M, 2006, HEART, V92, P671, DOI 10.1136/hrt.2005.065607; Yamamoto K, 1996, HYPERTENSION, V28, P988, DOI 10.1161/01.HYP.28.6.988; YASUE H, 1994, CIRCULATION, V90, P195, DOI 10.1161/01.CIR.90.1.195	34	8	8	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2014	9	3							e92314	10.1371/journal.pone.0092314	http://dx.doi.org/10.1371/journal.pone.0092314			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE0SD	24667631	Green Published, gold			2023-01-03	WOS:000333675600032
J	Peeters, F; Oehlen, M; Ronner, J; van Os, J; Lousberg, R				Peeters, Frenk; Oehlen, Mare; Ronner, Jacco; van Os, Jim; Lousberg, Richel			Neurofeedback As a Treatment for Major Depressive Disorder - A Pilot Study	PLOS ONE			English	Article							FRONTAL EEG ASYMMETRY; ALPHA ASYMMETRY; ELECTROENCEPHALOGRAPHIC ASYMMETRY; BRAIN ASYMMETRY; ANXIETY; ANTIDEPRESSANT; ENDOPHENOTYPE; SEVERITY; EMOTION	Background: There is growing interest in neurofeedback as a treatment for major depressive disorder. Reduction of asymmetry of alpha-activity between left and right prefrontal areas with neurofeedback has been postulated as effective in earlier studies. Unfortunately, methodological shortcomings limit conclusions that can be drawn from these studies. In a pilot-study, we investigated the effectiveness of reduction of asymmetry of alpha-activity with neurofeedback in depressed participants with the use of a stringent methodological approach. Methods: Nine participants meeting DSM-IV criteria for major depressive disorder were treated with a maximum of 30 neurofeedback-sessions, aimed at reducing asymmetry of alpha-activity, over a 10-week period. No changes in the use of antidepressants were allowed 6 weeks before and during the intervention. Changes in depressive symptomatology were assessed with the Quick Inventory of Depressive Symptoms, self-report version. Results: We observed response in 1 and remission in 4 out of a total of 9 participants. The effectiveness appeared largest in female participants. The mean asymmetry of alpha-activity decreased significantly over sessions in a quadratic fashion. This decrease was associated with clinical response. Conclusions: This pilot study suggests that neurofeedback aimed at a reduction of frontal asymmetry of alpha-activity may be effective as a treatment for depression. However, this was an open label pilot study. Non-specific effects of the procedure and/or a beneficial natural course may have confounded the results. Randomized controlled trials will have to establish the efficacy of neurofeedback for depression.	[Peeters, Frenk; Oehlen, Mare; van Os, Jim; Lousberg, Richel] Maastricht Univ, EURON, Dept Psychiat & Psychol, South Limburg Mental Hlth Res & Teaching Network, Maastricht, Netherlands; [Ronner, Jacco] Maastricht Univ, Fac Psychol & Neurosci, Dept Instrumentat, Maastricht, Netherlands; [van Os, Jim] Kings Coll London, Kings Hlth Partners, Dept Psychosis Studies, Inst Psychiat, London WC2R 2LS, England	Maastricht University; Maastricht University; University of London; King's College London	Peeters, F (corresponding author), Maastricht Univ, EURON, Dept Psychiat & Psychol, South Limburg Mental Hlth Res & Teaching Network, Maastricht, Netherlands.	f.peeters@maastrichtuniversity.nl	van Os, Jim/V-8884-2019; Vasconcelos, Ana Carolina Souza de/GXW-3453-2022; van Os, Jim/C-2113-2014	van Os, Jim/0000-0002-7245-1586; Peeters, F/0000-0002-6167-8582				Allen JJB, 2004, PSYCHOPHYSIOLOGY, V41, P269, DOI 10.1111/j.1469-8986.2003.00149.x; Allen JJB, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00232; Baehr E., 1997, J NEUROTHERAPY, V2, P10, DOI DOI 10.1300/J184V02N03_02; Baehr E., 2001, J NEUROTHER, V4, P11, DOI [10.1300/J184v04n04_03, DOI 10.1300/J184V04N04_03]; BIRBAUMER N, 1988, INT J NEUROSCI, V39, P101, DOI 10.3109/00207458808985696; Blom MBJ, 2007, J AFFECT DISORDERS, V104, P119, DOI 10.1016/j.jad.2007.03.010; Bruder GE, 2001, BIOL PSYCHIAT, V49, P416, DOI 10.1016/S0006-3223(00)01016-7; Bruder GE, 1997, BIOL PSYCHIAT, V41, P939, DOI 10.1016/S0006-3223(96)00260-0; Bruder GE, 2004, NEUROPSYCHOPHARMACOL, V29, P1752, DOI 10.1038/sj.npp.1300519; Bruder GE, 2008, BIOL PSYCHIAT, V63, P1171, DOI 10.1016/j.biopsych.2007.10.009; Choi SW, 2011, NEUROPSYCHOBIOLOGY, V63, P43, DOI 10.1159/000322290; Coan JA, 2004, BIOL PSYCHOL, V67, P7, DOI 10.1016/j.biopsycho.2004.03.002; Davidson RJ, 2002, ANNU REV PSYCHOL, V53, P545, DOI 10.1146/annurev.psych.53.100901.135148; Debener S, 2000, NEUROPSYCHOBIOLOGY, V41, P31, DOI 10.1159/000026630; Evans JR, 1999, INTRO QUANTITATIVE E; Hammond DC, 2005, J ADULT DEV, V12, P131, DOI 10.1007/s10804-005-7029-5; Hardman E, 1997, NEUROSCI LETT, V221, P117, DOI 10.1016/S0304-3940(96)13303-6; Herrington JD, 2010, PSYCHOPHYSIOLOGY, V47, P442, DOI 10.1111/j.1469-8986.2009.00958.x; Lofthouse N, 2012, CURR PSYCHIAT REP, V14, P536, DOI 10.1007/s11920-012-0301-z; Niedermeyer E., 2004, ELECTROENCEPHALOGRAP; Peeters F, INT J PSYCH IN PRESS; Pizzagalli DA, 2002, BIOL PSYCHIAT, V52, P73, DOI 10.1016/S0006-3223(02)01313-6; Reid SA, 1998, PSYCHOPHYSIOLOGY, V35, P389, DOI 10.1111/1469-8986.3540389; Rosenfeld JP, 1996, INT J PSYCHOPHYSIOL, V23, P137, DOI 10.1016/0167-8760(96)00037-2; Rush AJ, 2003, BIOL PSYCHIAT, V54, P573, DOI 10.1016/S0006-3223(02)01866-8; Snijders T. A., 2012, MULTILEVEL ANAL INTR; Stewart JL, 2011, J AFFECT DISORDERS, V129, P167, DOI 10.1016/j.jad.2010.08.029; Stewart JL, 2010, J ABNORM PSYCHOL, V119, P502, DOI 10.1037/a0019196; Thibodeau R, 2006, J ABNORM PSYCHOL, V115, P715, DOI 10.1037/0021-843X.115.4.715	29	27	29	2	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2014	9	3							e91837	10.1371/journal.pone.0091837	http://dx.doi.org/10.1371/journal.pone.0091837			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AD4ZE	24642756	Green Published, gold, Green Submitted			2023-01-03	WOS:000333259900039
J	Wielders, CCH; Wuister, AMH; de Visser, VL; de Jager-Leclercq, MG; Groot, CAR; Dijkstra, F; van Gageldonk-Lafeber, AB; van Leuken, JPG; Wever, PC; van der Hoek, W; Schneeberger, PM				Wielders, Cornelia C. H.; Wuister, Annemarie M. H.; de Visser, Veerle L.; de Jager-Leclercq, Monique G.; Groot, Cornelis A. R.; Dijkstra, Frederika; van Gageldonk-Lafeber, Arianne B.; van Leuken, Jeroen P. G.; Wever, Peter C.; van der Hoek, Wim; Schneeberger, Peter M.			Characteristics of Hospitalized Acute Q Fever Patients during a Large Epidemic, The Netherlands	PLOS ONE			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; OUTBREAK; MORTALITY; HYPONATREMIA; ASSOCIATION; MANAGEMENT; IDENTIFY; FEATURES	Background: From 2007 to 2009, the Netherlands experienced a major Q fever epidemic, with higher hospitalization rates than the 2-5% reported in the literature for acute Q fever pneumonia and hepatitis. We describe epidemiological and clinical features of hospitalized acute Q fever patients and compared patients presenting with Q fever pneumonia with patients admitted for other forms of community-acquired pneumonia (CAP). We also examined whether proximity to infected ruminant farms was a risk factor for hospitalization. Methods: A retrospective cohort study was conducted for all patients diagnosed and hospitalized with acute Q fever between 2007 and 2009 in one general hospital situated in the high incidence area in the south of the Netherlands. Pneumonia severity scores (PSI and CURB-65) of acute Q fever pneumonia patients (defined as infiltrate on a chest x-ray) were compared with data from CAP patients. Hepatitis was defined as a. twofold the reference value for alanine aminotransferase and for bilirubin. Results: Among the 183 hospitalized acute Q fever patients, 86.0% had pneumonia. Elevated liver enzymes (alanine aminotransferase) were found in 32.3% of patients, although hepatitis was not observed in any of them. The most frequent clinical signs upon presentation were fever, cough and dyspnoea. The median duration of admission was five days. Acute Q fever pneumonia patients were younger, had less co-morbidity, and lower PSI and CURB-65 scores than other CAP patients. Anecdotal information from attending physicians suggests that some patients were admitted because of severe subjective dyspnoea, which was not included in the scoring systems. Proximity to an infected ruminant farm was not associated with hospitalization. Conclusion: Hospitalized Dutch acute Q fever patients mostly presented with fever and pneumonia. Patients with acute Q fever pneumonia were hospitalized despite low PSI and CURB-65 scores, presumably because subjective dyspnoea was not included in the scoring systems.	[Wielders, Cornelia C. H.; Wever, Peter C.; Schneeberger, Peter M.] Jeroen Bosch Hosp, Dept Med Microbiol & Infect Control, Shertogenbosch, Netherlands; [Wielders, Cornelia C. H.; Wuister, Annemarie M. H.; Dijkstra, Frederika; van Gageldonk-Lafeber, Arianne B.; van Leuken, Jeroen P. G.; van der Hoek, Wim; Schneeberger, Peter M.] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, Bilthoven, Netherlands; [Wuister, Annemarie M. H.; de Jager-Leclercq, Monique G.] Bernhoven Hosp, Dept Internal Med, Uden, Netherlands; [de Visser, Veerle L.] Jeroen Bosch Hosp, Dept Pulm Dis, Shertogenbosch, Netherlands; [Groot, Cornelis A. R.] Bernhoven Hosp, Dept Pulm Dis, Uden, Netherlands; [van Leuken, Jeroen P. G.] Univ Utrecht, Fac Vet Sci, Inst Risk Assessment Sci, Utrecht, Netherlands	Jeroen Bosch Ziekenhuis; Netherlands National Institute for Public Health & the Environment; Jeroen Bosch Ziekenhuis; Utrecht University	Wielders, CCH (corresponding author), Jeroen Bosch Hosp, Dept Med Microbiol & Infect Control, Shertogenbosch, Netherlands.	l.wielders@jbz.nl	Wielders, Cornelia CH/I-1970-2019; Dijkstra, Frederika/ABF-3865-2021	Wielders, Cornelia CH/0000-0002-2413-9088; Dijkstra, Frederika/0000-0003-0012-740X	Netherlands Organisation for Health Research and Development (ZonMw) [205520006]	Netherlands Organisation for Health Research and Development (ZonMw)(Netherlands Organization for Health Research and Development)	This work was supported by the Netherlands Organisation for Health Research and Development (ZonMw)(http://www.zonmw.nl/), grant number 205520006. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Angelakis E, 2010, VET MICROBIOL, V140, P297, DOI 10.1016/j.vetmic.2009.07.016; BERNARD E, 1994, EUR J CLIN MICROBIOL, V13, P658, DOI 10.1007/BF01973993; Bernit E, 2002, ARCH INTERN MED, V162, P693, DOI 10.1001/archinte.162.6.693; Caron F, 1998, CHEST, V114, P808, DOI 10.1378/chest.114.3.808; Comprehensive Cancer Centre the Netherlands, 2011, NETH CANC REG COMPR; Cunha BA, 2000, CLIN MICROBIOL INFEC, V6, P633, DOI 10.1046/j.1469-0691.2000.0194f.x; de Alarcon A, 2003, J INFECTION, V47, P110, DOI 10.1016/S0163-4453(03)00013-6; de Wit NCJ, 2009, CLIN CHEM LAB MED, V47, P1407, DOI 10.1515/CCLM.2009.307; Dijkstra F, 2011, EPIDEMIOL INFECT, V139, P1332, DOI 10.1017/S0950268810002621; Dijkstra F, 2012, FEMS IMMUNOL MED MIC, V64, P3, DOI 10.1111/j.1574-695X.2011.00876.x; DUPONT HT, 1992, AM J MED, V93, P427, DOI 10.1016/0002-9343(92)90173-9; Ergas D, 2006, ISR MED ASSOC J, V8, P337; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Fournier PE, 1998, J CLIN MICROBIOL, V36, P1823, DOI 10.1128/JCM.36.7.1823-1834.1998; Gilsdorf A, 2008, EPIDEMIOL INFECT, V136, P1084, DOI 10.1017/S0950268807009533; Gommer AM, 2011, BETTER HLTH DUTCH 20; Kampschreur LM, 2010, NETH J MED, V68, P408; Kampschreur LM, 2012, EMERG INFECT DIS, V18, P563, DOI 10.3201/eid1804.111478; Karagiannis I, 2009, EPIDEMIOL INFECT, V137, P1283, DOI 10.1017/S0950268808001908; Lai CH, 2008, SCAND J INFECT DIS, V40, P105, DOI 10.1080/00365540701558722; Lim WS, 2003, THORAX, V58, P377, DOI 10.1136/thorax.58.5.377; Marrie TJ, 1996, J INFECT DIS, V173, P484, DOI 10.1093/infdis/173.2.484; MARRIE TJ, 1990, CAN VET J, V31, P555; Maurin M, 1999, CLIN MICROBIOL REV, V12, P518, DOI 10.1128/CMR.12.4.518; Medic S, 2012, EUROSURVEILLANCE, V17, P2; Nair V, 2007, AM J NEPHROL, V27, P184, DOI 10.1159/000100866; Oyston PCF, 2011, J MED MICROBIOL, V60, P9, DOI 10.1099/jmm.0.024778-0; Parker NR, 2006, LANCET, V367, P679, DOI 10.1016/S0140-6736(06)68266-4; Porten K, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-147; Raoult D, 2005, LANCET INFECT DIS, V5, P219, DOI 10.1016/S1473-3099(05)70052-9; Raoult D, 2000, MEDICINE, V79, P109, DOI 10.1097/00005792-200003000-00005; Schimmer B, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-69; SMITH DL, 1993, RESP MED, V87, P509, DOI 10.1016/0954-6111(93)90006-L; Snijders BEP, 2013, PRIM CARE RESP J, V22, P400, DOI 10.4104/pcrj.2013.00085; SOBRADILLO V, 1989, EUR RESPIR J, V2, P263; Statistics Netherlands, 2013, HLTH LIF MED CONT RE; TIGERTT WD, 1961, BACTERIOL REV, V25, P285, DOI 10.1128/MMBR.25.3.285-293.1961; Van den Brom R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054021; van der Hoek W, 2010, EURO SURVEILL, P15; van der Hoek W, 2012, ADV EXP MED BIOL, V984, P329, DOI 10.1007/978-94-007-4315-1_17; van Gageldonk-Lafeber AB, 2013, NETH J MED, V71, P418; Vardi M, 2011, EUR J CLIN MICROBIOL, V30, P1527, DOI 10.1007/s10096-011-1255-5; Waikar SS, 2009, AM J MED, V122, P857, DOI 10.1016/j.amjmed.2009.01.027; Wald R, 2010, ARCH INTERN MED, V170, P294, DOI 10.1001/archinternmed.2009.513; Wegdam-Blans MCA, 2012, J INFECTION, V64, P247, DOI 10.1016/j.jinf.2011.12.014; Wielders CCH, 2013, J CLIN MICROBIOL, V51, P3192, DOI 10.1128/JCM.00993-13; Wielders CCH, 2013, EUR J CLIN INVEST, V43, P616, DOI 10.1111/eci.12073; Wiersinga WJ, 2012, NETH J MED, V70, P90; Zilberberg Marya D, 2008, BMC Pulm Med, V8, P16, DOI 10.1186/1471-2466-8-16	49	24	25	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 10	2014	9	3							e91764	10.1371/journal.pone.0091764	http://dx.doi.org/10.1371/journal.pone.0091764			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC9FH	24614585	gold, Green Published, Green Submitted			2023-01-03	WOS:000332839300155
J	Hoermann, G; Blatt, K; Greiner, G; Putz, EM; Berger, A; Herrmann, H; Cerny-Reiterer, S; Gleixner, KV; Walz, C; Hoetzenecker, K; Mullauer, L; Reiter, A; Sotlar, K; Sexl, V; Valent, P; Mayerhofer, M				Hoermann, Gregor; Blatt, Katharina; Greiner, Georg; Putz, Eva Maria; Berger, Angelika; Herrmann, Harald; Cerny-Reiterer, Sabine; Gleixner, Karoline V.; Walz, Christoph; Hoetzenecker, Konrad; Muellauer, Leonhard; Reiter, Andreas; Sotlar, Karl; Sexl, Veronika; Valent, Peter; Mayerhofer, Matthias			CD52 is a molecular target in advanced systemic mastocytosis	FASEB JOURNAL			English	Article						CAMPATH-1; RAS G12V; alemtuzumab; mast cell leukemia	CHRONIC LYMPHOCYTIC-LEUKEMIA; MONOCLONAL-ANTIBODY CAMPATH-1H; NEOPLASTIC MAST-CELLS; C-KIT; THERAPEUTIC TARGET; CATALYTIC DOMAIN; ACTIVATING MUTATIONS; GENE-EXPRESSION; RAS ACTIVATION; ONCOSTATIN M	Advanced systemic mastocytosis (SM) is an aggressive hematopoietic neoplasm with poor prognosis and short survival times. So far, no curative therapy is available for affected patients. We have identified the cell surface antigen CD52 (CAMPATH-1) as a molecular target expressed abundantly on the surface of primary neoplastic mast cells (MCs) in patients with advanced SM. In contrast, neoplastic MCs of patients with indolent SM and normal MCs expressed only low levels or did not express CD52. To study the mechanisms of CD52 expression and the value of this antigen as a potential therapeutic target, we generated a human MC cell line, designated MCPV-1, by lentiviral immortalization of cord blood-derived MC progenitor cells. Functional studies revealed that activated RAS profoundly promotes surface expression of CD52. The CD52-targeting antibody alemtuzumab induced cell death in CD52(+) primary neoplastic MCs obtained from patients with SM as well as in MCPV-1 cells. NSG mice xenotransplanted with MCPV-1 cells survived significantly longer after treatment with alemtuzumab (median survival: 31 d untreated vs. 46 d treated; P = 0.0012). We conclude that CD52 is a novel marker and potential therapeutic target in neoplastic MCs in patients with advanced SM.	[Hoermann, Gregor; Greiner, Georg] Med Univ Vienna, Dept Lab Med, Vienna, Austria; [Blatt, Katharina; Cerny-Reiterer, Sabine; Gleixner, Karoline V.; Valent, Peter] Med Univ Vienna, Div Hematol & Hemostaseol, Dept Internal Med 1, Vienna, Austria; [Hoetzenecker, Konrad] Med Univ Vienna, Div Thorac Surg, Dept Surg, Vienna, Austria; [Muellauer, Leonhard] Med Univ Vienna, Dept Pathol, Vienna, Austria; [Putz, Eva Maria; Berger, Angelika; Sexl, Veronika] Univ Vet Med Vienna, Inst Pharmacol & Toxicol, Vienna, Austria; [Herrmann, Harald; Cerny-Reiterer, Sabine; Valent, Peter] Ludwig Boltzmann Cluster Oncol, Vienna, Austria; [Walz, Christoph; Sotlar, Karl] Univ Munich, Inst Pathol, D-80539 Munich, Germany; [Reiter, Andreas] Univ Med Mannheim, Med Univ Klin, Mannheim, Germany; [Mayerhofer, Matthias] Hanusch Hosp, Ludwig Boltzmann Inst Osteol, A-1140 Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; University of Veterinary Medicine Vienna; Ludwig Boltzmann Institute; University of Munich; Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ludwig Boltzmann Institute; WGKK - Hanusch Hospital	Mayerhofer, M (corresponding author), Hanusch Hosp, Ludwig Boltzmann Inst Osteol, Heinrich Collin Str 30, A-1140 Vienna, Austria.	matthias.mayerhofer@meduniwien.ac.at	Gamperl, Susi/V-2715-2019; Hoermann, Gregor/B-8832-2016; Test, PV/U-9451-2019; König, Eva Maria/AAF-4041-2019; Test, Test/Y-7921-2019; Hermann, Harald/E-7073-2018; Valent, Peter/B-8533-2016; Müllauer, Leonhard/GSN-9884-2022; Sexl, Veronika/B-8657-2016	Gamperl, Susi/0000-0003-0456-5095; Hoermann, Gregor/0000-0002-7374-4380; König, Eva Maria/0000-0002-9990-4477; Hermann, Harald/0000-0002-5095-4641; Valent, Peter/0000-0003-0456-5095; Müllauer, Leonhard/0000-0002-3399-078X; Berger, Angelika/0000-0001-8775-2405; Sexl, Veronika/0000-0001-9363-0412; Putz, Eva Maria/0000-0002-5309-4114; Greiner, Georg/0000-0002-0917-4117; Gleixner, Karoline/0000-0001-5753-0203; Hoetzenecker, Konrad/0000-0001-6775-7460	Fonds zur Forderung der Wissenschaftlichen Forschung in Osterreich (FWF) grant [P26079-B13, SFB F4704-B20]; Austrian Science Fund (FWF) [P 26079] Funding Source: researchfish	Fonds zur Forderung der Wissenschaftlichen Forschung in Osterreich (FWF) grant; Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	The authors thank Elisabeth Wieser and Lukas Kenner (Department of Pathology, Medical University of Vienna, Vienna, Austria) for help with electron microscopy, Andrea Alvarez Hernandez and Ingrid Simonitsch-Klupp (Department of Pathology, Medical University of Vienna) for help with immunochemistry double staining, Hans-Peter Horny (Institute of Pathology, Ludwig Maximilians University, Munich, Germany) for reviewing immunohistochemistry data, Andreas Jung (Institute of Pathology, Ludwig Maximilians University) for help with RAS mutational analysis, and Katharina Worda (Department of Gynecology, Medical University of Vienna) for providing CB samples. The authors also thank Gunther Hofbauer and Andreas Spittler (Cell Sorting Core Unit, Medical University of Vienna) for technical support. This study was supported by the Fonds zur Forderung der Wissenschaftlichen Forschung in Osterreich (FWF) grant P26079-B13 and SFB F4704-B20. The authors declare no conflicts of interest.	Akin C, 2004, ANNU REV MED, V55, P419, DOI 10.1146/annurev.med.55.091902.103822; Akin C, 2003, EXP HEMATOL, V31, P686, DOI 10.1016/S0301-472X(03)00112-7; Arock M, 2010, EXPERT REV HEMATOL, V3, P497, DOI [10.1586/ehm.10.42, 10.1586/EHM.10.42]; Beillard E, 2003, LEUKEMIA, V17, P2474, DOI 10.1038/sj.leu.2403136; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; Coles AJ, 2008, NEW ENGL J MED, V359, P1786, DOI 10.1056/NEJMoa0802670; Elad-Sfadia G, 2002, J BIOL CHEM, V277, P37169, DOI 10.1074/jbc.M205698200; Feger F, 2002, INT ARCH ALLERGY IMM, V127, P110, DOI 10.1159/000048179; Fiordalisi JJ, 2001, METHOD ENZYMOL, V332, P3; Fritsche-Polanz R, 2001, BRIT J HAEMATOL, V113, P357, DOI 10.1046/j.1365-2141.2001.02783.x; Gao JS, 2011, FEBS LETT, V585, P693, DOI 10.1016/j.febslet.2011.01.033; Georgin-Lavialle S, 2013, BLOOD, V121, P1285, DOI 10.1182/blood-2012-07-442400; Golay J, 2004, HAEMATOLOGICA, V89, P1476; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hale C, 1996, IMMUNOLOGY, V88, P183, DOI 10.1111/j.1365-2567.1996.tb00003.x; Hale G, 2001, J BIOL REG HOMEOS AG, V15, P386; Hanssens K, 2014, HAEMATOLOGICA, V99, P830, DOI 10.3324/haematol.2013.095133; Hoermann G, 2012, FASEB J, V26, P894, DOI 10.1096/fj.11-193078; Hoermann G, 2011, AM J PATHOL, V178, P2344, DOI 10.1016/j.ajpath.2011.01.020; Horny HP AC, 2008, WHO CLASSIFICATION T, P54; Hu YP, 2009, IMMUNOLOGY, V128, P260, DOI 10.1111/j.1365-2567.2009.03115.x; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Kondo R, 2007, BLOOD, V110, P661, DOI 10.1182/blood-2006-10-054411; Longley BJ, 1999, P NATL ACAD SCI USA, V96, P1609, DOI 10.1073/pnas.96.4.1609; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Malbec O, 2007, J IMMUNOL, V178, P6465, DOI 10.4049/jimmunol.178.10.6465; MATTESON EL, 1995, ARTHRITIS RHEUM, V38, P1187, DOI 10.1002/art.1780380903; Mayerhofer M, 2008, J IMMUNOL, V180, P5466, DOI 10.4049/jimmunol.180.8.5466; Mone AP, 2006, LEUKEMIA, V20, P272, DOI 10.1038/sj.leu.2404014; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Osterborg A, 1996, BRIT J HAEMATOL, V93, P151, DOI 10.1046/j.1365-2141.1996.450989.x; Osterborg A, 1997, J CLIN ONCOL, V15, P1567, DOI 10.1200/JCO.1997.15.4.1567; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Rao SP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039416; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Saito Y, 2011, LEUKEMIA, V25, P921, DOI 10.1038/leu.2011.36; Salmon P, 2000, MOL THER, V2, P404, DOI 10.1006/mthe.2000.0141; Santos DD, 2006, CLIN LYMPHOMA MYELOM, V6, P478, DOI 10.3816/CLM.2006.n.029; Schwaab J, 2013, BLOOD, V122, P2460, DOI 10.1182/blood-2013-04-496448; Siders WM, 2010, LEUKEMIA LYMPHOMA, V51, P1293, DOI 10.3109/10428191003777963; Sobering AK, 2004, CELL, V117, P637, DOI 10.1016/j.cell.2004.05.003; Stanglmaier M, 2004, ANN HEMATOL, V83, P634, DOI 10.1007/s00277-004-0917-0; Szulc J, 2006, NAT METHODS, V3, P109, DOI 10.1038/NMETH846; Teodosio C, 2013, J ALLERGY CLIN IMMUN, V131, P1213, DOI 10.1016/j.jaci.2012.12.674; Tsujimura T, 1999, BLOOD, V93, P1319, DOI 10.1182/blood.V93.4.1319.404k11_1319_1329; Valent P, 2004, EUR J CLIN INVEST, V34, P41, DOI 10.1111/j.0960-135X.2004.01369.x; Valent P, 2003, LEUKEMIA RES, V27, P635, DOI 10.1016/S0145-2126(02)00168-6; VALENT P, 1989, BLOOD, V73, P1778; Wilson TM, 2011, HAEMATOL-HEMATOL J, V96, P459, DOI 10.3324/haematol.2010.031690; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Zappulla JP, 2005, J EXP MED, V202, P1635, DOI 10.1084/jem.20050807; Zent CS, 2008, LEUKEMIA RES, V32, P1849, DOI 10.1016/j.leukres.2008.05.014; Zhang PL, 2007, ANN CLIN LAB SCI, V37, P148	55	20	22	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3540	3551		10.1096/fj.14-250894	http://dx.doi.org/10.1096/fj.14-250894			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24760752				2023-01-03	WOS:000340265400023
J	Weaver, T; Metrebian, N; Hellier, J; Pilling, S; Charles, V; Little, N; Poovendran, D; Mitcheson, L; Ryan, F; Bowden-Jones, O; Dunn, J; Glasper, A; Finch, E; Strang, J				Weaver, Tim; Metrebian, Nicola; Hellier, Jennifer; Pilling, Stephen; Charles, Vikki; Little, Nicholas; Poovendran, Dilkushi; Mitcheson, Luke; Ryan, Frank; Bowden-Jones, Owen; Dunn, John; Glasper, Anthony; Finch, Emily; Strang, John			Use of contingency management incentives to improve completion of hepatitis B vaccination in people undergoing treatment for heroin dependence: a cluster randomised trial	LANCET			English	Article							INJECTING DRUG-USERS; USE DISORDERS; TUBERCULOSIS; ADHERENCE; INTERVENTIONS; PREVENTION; OUTREACH; THERAPY; ENGLAND	Background Poor adherence to treatment diminishes its individual and public health benefit. Financial incentives, provided on the condition of treatment attendance, could address this problem. Injecting drug users are a high-risk group for hepatitis B virus (HBV) infection and transmission, but adherence to vaccination programmes is poor. We aimed to assess whether contingency management delivered in routine clinical practice increased the completion of HBV vaccination in individuals receiving opioid substitution therapy. Methods In our cluster randomised controlled trial, we enrolled participants at 12 National Health Service drug treatment services in the UK that provided opioid substitution therapy and nurse-led HBV vaccination with a super-accelerated schedule (vaccination days 0, 7, and 21). Clusters were randomly allocated 1:1:1 to provide vaccination without incentive (treatment as usual), with fixed value contingency management (three 10 pound vouchers), or escalating value contingency management (5 pound, 10 pound, and 15 pound vouchers). Both contingency management schedules rewarded on-time attendance at appointments. The primary outcome was completion of clinically appropriate HBV vaccination within 28 days. We also did sensitivity analyses that examined vaccination completion with full adherence to appointment times and within a 3 month window. The trial is registered with Current Controlled Trials, number ISRCTN72794493. Findings Between March 16, 2011, and April 26, 2012, we enrolled 210 eligible participants. Compared with six (9%) of 67 participants treated as usual, 35 (45%) of 78 participants in the fixed value contingency management group met the primary outcome measure (odds ratio 12.1, 95% CI 3.7-39.9; p<0.0001), as did 32 (49%) of 65 participants in the escalating value contingency management group (14.0,4.2-46.2; p<0.0001). These differences remained significant with sensitivity analyses. Interpretation Modest financial incentives delivered in routine clinical practice significantly improve adherence to, and completion of, HBV vaccination programmes in patients receiving opioid substitution therapy. Achievement of this improvement in routine clinical practice should now prompt actual implementation. Drug treatment providers should employ contingency management to promote adherence to vaccination programmes. The effectiveness of routine use of contingency management to achieve long-term behaviour change remains unknown. Funding National Institute for Health Research (RP-PG-0707-10149).	[Weaver, Tim; Poovendran, Dilkushi] Univ London Imperial Coll Sci Technol & Med, Ctr Mental Hlth, London, England; [Metrebian, Nicola; Charles, Vikki; Strang, John] Kings Coll London, Inst Psychiat, Natl Addict Ctr, London SE5 8BB, England; [Hellier, Jennifer] Kings Coll London, Inst Psychiat, Dept Biostat, Kings Clin Trials Unit, London SE5 8BB, England; [Pilling, Stephen; Little, Nicholas] UCL, Res Dept Clin Educ & Hlth Psychol, London, England; [Mitcheson, Luke; Finch, Emily; Strang, John] South London & Maudsley NHS Fdn Trust, London, England; [Ryan, Frank; Dunn, John] Camden & Islington NHS Fdn Trust, London, England; [Bowden-Jones, Owen] Cent & North West London NHS Fdn Trust, London, England; [Glasper, Anthony] Sussex NHS Fdn Trust, Worthing, England	Imperial College London; University of London; King's College London; University of London; King's College London; University of London; University College London; South London & Maudsley NHS Trust	Strang, J (corresponding author), Kings Coll London, Natl Addict Ctr, Addict Sci Bldg,4 Windsor Walk,Denmark Hill, London SE5 8BB, England.	john.strang@kcl.ac.uk	Strang, John/H-5460-2011	Strang, John/0000-0002-5413-2725; Weaver, Tim/0000-0002-3437-3556; Hellier, Jennifer/0000-0003-1760-3708; Little, Nicholas/0000-0001-5419-0100; Poovendran, Dilkushi/0000-0002-9919-2932	National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme [RP-PG-0707-10149]; NIHR Biomedical Research Centre for Mental Health at South London; Maudsley NHS Foundation Trust; Mental Health Research Network; King's College London; National Institute for Health Research [RP-PG-0707-10149] Funding Source: researchfish	National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme(National Institute for Health Research (NIHR)); NIHR Biomedical Research Centre for Mental Health at South London; Maudsley NHS Foundation Trust; Mental Health Research Network; King's College London; National Institute for Health Research(National Institute for Health Research (NIHR))	This paper presents independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme (grant reference number RP-PG-0707-10149). The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health. JS and JH are in part supported by the NIHR Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and King's College London. JH is a member of the King's Clinical Trials Unit. The trial was supported by the Mental Health Research Network and we are extremely grateful for the sterling efforts of all the Clinical Studies Offices from the North and South London Hubs who worked on the trial and helped us achieve our recruitment targets. We also gratefully acknowledge the support and guidance of members of our Trial Steering Committee (Simon Coulton [Chair], Christopher Whiteley, and Soraya Mayet) and our Data Management and Ethics Committee (Louise Sell [Chair], Anne R Lingford-Hughes, and Zoe Hoare). Finally, we thank the patients who took part in the study and all the staff in the participating services who gave their time so generously to recruit patients to the study and of course deliver the intervention.	[Anonymous], 2003, ADHERENCE LONG TERM; Banatvala J, 2000, LANCET, V355, P561, DOI 10.1016/S0140-6736(99)07239-6; Batki SL, 2002, DRUG ALCOHOL DEPEN, V66, P283, DOI 10.1016/S0376-8716(01)00208-3; Brim N, 2007, EXPERT OPIN BIOL TH, V7, P379, DOI 10.1517/14712598.7.3.379; Campbell MK, 2000, FAM PRACT, V17, P192, DOI 10.1093/fampra/17.2.192; Chaisson RE, 2001, AM J MED, V110, P610, DOI 10.1016/S0002-9343(01)00695-7; DARKE S, 1992, BRIT J ADDICT, V87, P733; Department of Health Scottish Government Welsh Assembly Government Northern Ireland Executive, 2007, DRUG MIS DEP UK GUID; Des Jarlais DC, 2001, AM J PUBLIC HEALTH, V91, P1791, DOI 10.2105/AJPH.91.11.1791; Eldridge SM, 2006, INT J EPIDEMIOL, V35, P1292, DOI 10.1093/ije/dyl129; Gossop M, 2001, DRUG ALCOHOL DEPEN, V62, P255, DOI 10.1016/S0376-8716(00)00211-8; Higgins S.T., 2008, CONTINGENCY MANAGEME; Hope VD, 2007, J VIRAL HEPATITIS, V14, P653, DOI 10.1111/j.1365-2893.2007.00856.x; Judd A, 2007, J VIRAL HEPATITIS, V14, P584, DOI 10.1111/j.1365-2893.2007.00844.x; KAZDIN AE, 2000, BEHAV MODIFICATION A; Lamagni T L, 2001, Commun Dis Public Health, V4, P71; Lussier JP, 2006, ADDICTION, V101, P192, DOI 10.1111/j.1360-0443.2006.01311.x; Malotte CK, 2001, AM J PREV MED, V20, P103, DOI 10.1016/S0749-3797(00)00283-X; Marsden J, 2009, LANCET, V374, P1262, DOI 10.1016/S0140-6736(09)61420-3; Nelson PK, 2011, LANCET, V378, P571, DOI 10.1016/S0140-6736(11)61097-0; NICE, 2007, DRUG MIS PSYCH INT C; Norton EC, 1996, J CONSULT CLIN PSYCH, V64, P919, DOI 10.1037/0022-006X.64.5.919; Petry NM, 2006, BRIT J PSYCHIAT, V189, P97, DOI 10.1192/bjp.bp.106.022293; Pilling S, 2007, BRIT MED J, V335, P203, DOI 10.1136/bmj.39265.639641.AD; Prendergast M, 2006, ADDICTION, V101, P1546, DOI 10.1111/j.1360-0443.2006.01581.x; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Seal KH, 2003, DRUG ALCOHOL DEPEN, V71, P127, DOI 10.1016/S0376-8716(03)00074-7; Sorensen JL, 2007, DRUG ALCOHOL DEPEN, V88, P54, DOI 10.1016/j.drugalcdep.2006.09.019; Stitzer ML, 2010, DRUG ALCOHOL DEPEN, V107, P76, DOI 10.1016/j.drugalcdep.2009.09.006; Strang J, 2012, LANCET, V379, P71, DOI 10.1016/S0140-6736(11)61674-7; Topp L, 2013, PREV MED, V57, P297, DOI 10.1016/j.ypmed.2013.04.013; Trubatch BN, 2000, AM J PUBLIC HEALTH, V90, P447, DOI 10.2105/AJPH.90.3.447; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; World Health Organization, 2012, PREV CONTR VIR HEP I; World Health Organization, 2012, POL BRIEF GUID PREV	36	59	59	0	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 12	2014	384	9938					153	163		10.1016/S0140-6736(14)60196-3	http://dx.doi.org/10.1016/S0140-6736(14)60196-3			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AL1YC	24725468	Green Published, hybrid, Green Accepted			2023-01-03	WOS:000338921500034
J	Morgan, N; Irwin, MR; Chung, M; Wang, CC				Morgan, Nani; Irwin, Michael R.; Chung, Mei; Wang, Chenchen			The Effects of Mind-Body Therapies on the Immune System: Meta-Analysis	PLOS ONE			English	Article							QUALITY-OF-LIFE; INFLAMMATORY GENE-EXPRESSION; RANDOMIZED CONTROLLED-TRIAL; ACUTE PSYCHOLOGICAL STRESS; BREAST-CANCER SURVIVORS; VARICELLA-ZOSTER-VIRUS; NECROSIS-FACTOR-ALPHA; TAI CHI CHUAN; NF-KAPPA-B; OLDER-ADULTS	Importance: Psychological and health-restorative benefits of mind-body therapies have been investigated, but their impact on the immune system remain less defined. Objective: To conduct the first comprehensive review of available controlled trial evidence to evaluate the effects of mind-body therapies on the immune system, focusing on markers of inflammation and anti-viral related immune responses. Methods: Data sources included MEDLINE, CINAHL, SPORTDiscus, and PsycINFO through September 1, 2013. Randomized controlled trials published in English evaluating at least four weeks of Tai Chi, Qi Gong, meditation, or Yoga that reported immune outcome measures were selected. Studies were synthesized separately by inflammatory (n = 18), anti-viral related immunity (n = 7), and enumerative (n = 14) outcomes measures. We performed random-effects meta-analyses using standardized mean difference when appropriate. Results: Thirty-four studies published in 39 articles (total 2, 219 participants) met inclusion criteria. For inflammatory measures, after 7 to 16 weeks of mind-body intervention, there was a moderate effect on reduction of C-reactive protein (effect size [ES], 0.58; 95% confidence interval [CI], 0.04 to 1.12), a small but not statistically significant reduction of interleukin-6 (ES, 0.35; 95% CI, -0.04 to 0.75), and negligible effect on tumor necrosis factor-alpha (ES, 0.21; 95% CI, -0.15 to 0.58). For anti-viral related immune and enumerative measures, there were negligible effects on CD4 counts (ES, 0.15; 95% CI, -0.04 to 0.34) and natural killer cell counts (ES, 0.12, 95% CI -0.21 to 0.45). Some evidence indicated mind-body therapies increase immune responses to vaccination. Conclusions: Mind-body therapies reduce markers of inflammation and influence virus-specific immune responses to vaccination despite minimal evidence suggesting effects on resting anti-viral or enumerative measures. These immunomodulatory effects, albeit incomplete, warrant further methodologically rigorous studies to determine the clinical implications of these findings for inflammatory and infectious disease outcomes.	[Morgan, Nani; Wang, Chenchen] Tufts Univ Sch Med, Div Rheumatol, Ctr Integrat Med, Tufts Med Ctr, Boston, MA 02111 USA; [Irwin, Michael R.] Univ Calif Los Angeles, Cousins Ctr Psychoneuroimmunol, UCLA Semel Inst Neurosci, Los Angeles, CA USA; [Chung, Mei] Tufts Univ Sch Med, Dept Publ Hlth & Community Med, Nutr Infect Unit, Boston, MA USA	Tufts Medical Center; Tufts University; University of California System; University of California Los Angeles; Massachusetts Department of Public Health; Tufts University	Wang, CC (corresponding author), Tufts Univ Sch Med, Div Rheumatol, Ctr Integrat Med, Tufts Med Ctr, Boston, MA 02111 USA.	cwang2@tuftsmedicalcenter.org	Irwin, Michael/H-4870-2013	Irwin, Michael/0000-0002-1502-8431	National Center for Complementary and Alternative Medicine [K24 AT007323, R01 AT006367, R01 AT005521, R01 AT006367-01A1]; Cousins Center for Psychoneuroimmunology at the Semel Institute for Neuroscience; National Institutes of Health [R01-AG034588, R01-AG026364, R01 CA160245-01, R01-CA119159, R01 HL095799, R01 DA032922-01, P30-AG028748]; National Institutes of Health (UCLA CTSI) [UL1TR000124]; NATIONAL CANCER INSTITUTE [R01CA160245, R01CA119159] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000124] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [R01AT006367, R01AT005521] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [K24AT007323] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL095799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG028748, R01AG026364, R01AG034588] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA032922] Funding Source: NIH RePORTER	National Center for Complementary and Alternative Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); Cousins Center for Psychoneuroimmunology at the Semel Institute for Neuroscience; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health (UCLA CTSI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	Dr. Wang is supported by the National Center for Complementary and Alternative Medicine (K24 AT007323, R01 AT006367, R01 AT005521, R01 AT006367-01A1). Dr. Irwin is supported by the Cousins Center for Psychoneuroimmunology at the Semel Institute for Neuroscience, and by the National Institutes of Health (R01-AG034588; R01-AG026364; R01 CA160245-01; R01-CA119159; R01 HL095799; R01 DA032922-01; P30-AG028748; and UCLA CTSI UL1TR000124). The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official views of the NCCAM. The investigators are solely responsible for the content of the manuscript and the decision to submit for publication. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antoni MH, 2007, PSYCHONEUROIMMUNOLOGY, VOLS I AND II, 4TH EDITION, P675; Antoni MH, 2012, BIOL PSYCHIAT, V71, P366, DOI 10.1016/j.biopsych.2011.10.007; Arias AJ, 2006, J ALTERN COMPLEM MED, V12, P817, DOI 10.1089/acm.2006.12.817; Barnes Patricia M, 2008, Natl Health Stat Report, P1; Barrett B, 2012, ANN FAM MED, V10, P337, DOI 10.1370/afm.1376; Bierhaus A, 2003, P NATL ACAD SCI USA, V100, P1920, DOI 10.1073/pnas.0438019100; Black DS, 2013, PSYCHONEUROENDOCRINO, V38, P348, DOI 10.1016/j.psyneuen.2012.06.011; Bower JE, 2007, BRAIN BEHAV IMMUN, V21, P251, DOI 10.1016/j.bbi.2006.08.001; Bussing A, 2012, J PAIN, V13, P1, DOI 10.1016/j.jpain.2011.10.001; Cade WT, 2010, HIV MED, V11, P379, DOI 10.1111/j.1468-1293.2009.00801.x; Chen E, 2009, THORAX, V64, P38, DOI 10.1136/thx.2007.095091; Chen HH, 2006, AM J CHINESE MED, V34, P741, DOI 10.1142/S0192415X06004259; Chen SC, 2010, J ALTERN COMPLEM MED, V16, P1153, DOI 10.1089/acm.2009.0560; Chiesa A, 2011, J ALTERN COMPLEM MED, V17, P83, DOI 10.1089/acm.2009.0546; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cohen J., 2013, STAT POWER ANAL BEHA; Cole SW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r189; Cole SW, 2011, P NATL ACAD SCI USA, V108, P3080, DOI 10.1073/pnas.1014218108; Cole SW, 2010, P NATL ACAD SCI USA, V107, P5681, DOI 10.1073/pnas.0911515107; Cole SW, 1998, J IMMUNOL, V161, P610; Creswell JD, 2012, BRAIN BEHAV IMMUN, V26, P1095, DOI 10.1016/j.bbi.2012.07.006; Creswell JD, 2009, BRAIN BEHAV IMMUN, V23, P184, DOI 10.1016/j.bbi.2008.07.004; Davidson RJ, 2003, PSYCHOSOM MED, V65, P564, DOI 10.1097/01.PSY.0000077505.67574.E3; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Elsenbruch S, 2005, PSYCHOTHER PSYCHOSOM, V74, P277, DOI 10.1159/000086318; Esposito K, 2003, JAMA-J AM MED ASSOC, V289, P1799, DOI 10.1001/jama.289.14.1799; Fan YX, 2010, J ALTERN COMPLEM MED, V16, P151, DOI 10.1089/acm.2009.0234; Glaser R, 2005, NAT REV IMMUNOL, V5, P243, DOI 10.1038/nri1571; Goebel MU, 2000, PSYCHOSOM MED, V62, P591, DOI 10.1097/00006842-200007000-00019; Gopal Aravind, 2011, Int J Yoga, V4, P26, DOI 10.4103/0973-6131.78178; Grebe KM, 2010, J IMMUNOL, V184, P540, DOI 10.4049/jimmunol.0903395; Grossman P, 2004, J PSYCHOSOM RES, V57, P35, DOI 10.1016/S0022-3999(03)00573-7; Haaland DA, 2008, CLIN J SPORT MED, V18, P539, DOI 10.1097/JSM.0b013e3181865eec; Haaz S, 2011, RHEUM DIS CLIN N AM, V37, P33, DOI 10.1016/j.rdc.2010.11.001; Hamer M, 2007, PSYCHOSOM MED, V69, P660, DOI 10.1097/PSY.0b013e318148c4c0; HERBERT TB, 1993, PSYCHOL BULL, V113, P472, DOI 10.1037/0033-2909.113.3.472; HERBERT TB, 1993, PSYCHOSOM MED, V55, P364, DOI 10.1097/00006842-199307000-00004; Hidderley Margaret, 2004, Eur J Oncol Nurs, V8, P61, DOI 10.1016/j.ejon.2003.09.003; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Irwin M, 2014, J NATL CANC IN PRESS; Irwin MR, 2007, J AM GERIATR SOC, V55, P511, DOI 10.1111/j.1532-5415.2007.01109.x; Irwin MR, 2012, AM J GERIAT PSYCHIAT, V20, P764, DOI 10.1097/JGP.0b013e3182330fd3; Irwin MR, 2011, NAT REV IMMUNOL, V11, P625, DOI 10.1038/nri3042; Irwin MR, 2003, PSYCHOSOM MED, V65, P824, DOI 10.1097/01.PSY.0000088591.86103.8F; Jahnke Roger, 2010, Am J Health Promot, V24, pe1, DOI 10.4278/ajhp.081013-LIT-248; Janelsins MC, 2011, CLIN BREAST CANCER, V11, P161, DOI 10.1016/j.clbc.2011.03.013; Keng SL, 2011, CLIN PSYCHOL REV, V31, P1041, DOI 10.1016/j.cpr.2011.04.006; Kiecolt-Glaser JK, 2002, J CONSULT CLIN PSYCH, V70, P537, DOI 10.1037//0022-006X.70.3.537; Lavretsky H, 2011, AM J GERIAT PSYCHIAT, V19, P839, DOI 10.1097/JGP.0b013e31820ee9ef; Lee HJ, 2000, J EXP MED, V192, P105, DOI 10.1084/jem.192.1.105; Lengacher CA, 2013, BIOL RES NURS, V15, P37, DOI 10.1177/1099800411419245; Li AW, 2012, ALTERN MED REV, V17, P21; Malarkey WB, 2013, BRAIN BEHAV IMMUN, V27, P145, DOI 10.1016/j.bbi.2012.10.009; Manzaneque JM, 2004, MED SCI MONITOR, V10, pCR264; Manzaneque JM, 2009, J HEALTH PSYCHOL, V14, P60, DOI 10.1177/1359105308097946; Mars TS, 2010, INT J OSTEOPATH MED, V13, P56, DOI 10.1016/j.ijosm.2009.07.005; McCain NL, 2008, J CONSULT CLIN PSYCH, V76, P431, DOI 10.1037/0022-006X.76.3.431; Medicine TNCfCaA, 2011, EXPL SCI COMPL ALT M; Miller GE, 2001, HEALTH PSYCHOL, V20, P47, DOI 10.1037/0278-6133.20.1.47; Miller G, 2009, ANNU REV PSYCHOL, V60, P501, DOI 10.1146/annurev.psych.60.110707.163551; Miller GE, 2008, BIOL PSYCHIAT, V64, P266, DOI 10.1016/j.biopsych.2008.03.017; Miller GE, 2009, PSYCHOSOM MED, V71, P57, DOI 10.1097/PSY.0b013e318190d7de; Motivala S, 2005, PSYCHOSOMATIC MED; Nance DM, 2007, BRAIN BEHAV IMMUN, V21, P736, DOI 10.1016/j.bbi.2007.03.008; Oh B, 2010, ANN ONCOL, V21, P608, DOI 10.1093/annonc/mdp479; Oh B, 2008, AM J CHINESE MED, V36, P459, DOI 10.1142/S0192415X08005904; Oh B, 2012, SUPPORT CARE CANCER, V20, P1235, DOI 10.1007/s00520-011-1209-6; Oken BS, 2010, J ALTERN COMPLEM MED, V16, P1031, DOI 10.1089/acm.2009.0733; Pace TWW, 2006, AM J PSYCHIAT, V163, P1630, DOI 10.1176/appi.ajp.163.9.1630; Pace TWW, 2009, PSYCHONEUROENDOCRINO, V34, P87, DOI 10.1016/j.psyneuen.2008.08.011; PaninaBordignon P, 1997, J CLIN INVEST, V100, P1513, DOI 10.1172/JCI119674; Posadzki P, 2011, CLIN RHEUMATOL, V30, P1257, DOI 10.1007/s10067-011-1764-8; Powell ND, 2013, P NATL ACAD SCI USA, V110, P16574, DOI 10.1073/pnas.1310655110; Powell ND, 2011, BRAIN BEHAV IMMUN, V25, P46, DOI 10.1016/j.bbi.2010.07.243; Pullen PR, 2008, J CARD FAIL, V14, P407, DOI 10.1016/j.cardfail.2007.12.007; Pullen PR, 2010, MED SCI SPORT EXER, V42, P651, DOI 10.1249/MSS.0b013e3181bf24c4; Raman Gowri, 2013, J Sleep Disord Ther, V2, DOI 10.4172/2167-0277.1000141; Rao Raghavendra M, 2008, Int J Yoga, V1, P11, DOI [10.4103/0973-6131.36795, 10.4103/0973-6131.36789]; Roland KP, 2011, J AGING PHYS ACTIV, V19, P62, DOI 10.1123/japa.19.1.62; Rosenkranz MA, 2013, BRAIN BEHAV IMMUN, V27, P174, DOI 10.1016/j.bbi.2012.10.013; SEVERN A, 1992, J IMMUNOL, V148, P3441; SeyedAlinaghi S, 2012, PSYCHOSOM MED, V74, P620, DOI 10.1097/PSY.0b013e31825abfaa; Solberg EE, 1995, BRIT J SPORT MED, V29, P255, DOI 10.1136/bjsm.29.4.255; Sprod LK, 2012, J CANCER SURVIV, V6, P146, DOI 10.1007/s11764-011-0205-7; Steensberg A, 2003, AM J PHYSIOL-ENDOC M, V285, pE433, DOI 10.1152/ajpendo.00074.2003; Steptoe A, 2007, BRAIN BEHAV IMMUN, V21, P901, DOI 10.1016/j.bbi.2007.03.011; Subramanian Swapna, 2012, Int J Yoga, V5, P21, DOI 10.4103/0973-6131.91702; TAYLOR DN, 1995, PSYCHOL REP, V76, P451, DOI 10.2466/pr0.1995.76.2.451; van Westerloo DJ, 2011, MOL MED, V17, P180, DOI 10.2119/molmed.2010.00204; vanderPoll T, 1996, J CLIN INVEST, V97, P713, DOI 10.1172/JCI118469; Vogler Juliane, 2011, Int J Yoga Therap, P61; Wang C, 2005, RHEUMATOLOGY, V44, P685, DOI 10.1093/rheumatology/keh572; Wang CC, 2004, ARCH INTERN MED, V164, P493, DOI 10.1001/archinte.164.5.493; Wang Chenchen, 2010, BMC Complement Altern Med, V10, P23, DOI 10.1186/1472-6882-10-23; Wang CC, 2012, CURR RHEUMATOL REP, V14, P598, DOI 10.1007/s11926-012-0294-y; Wang CC, 2011, RHEUM DIS CLIN N AM, V37, P19, DOI 10.1016/j.rdc.2010.11.002; Wang CC, 2010, NEW ENGL J MED, V363, P743, DOI 10.1056/NEJMoa0912611; Wang CC, 2009, ARTHRIT RHEUM-ARTHR, V61, P1545, DOI 10.1002/art.24832; Wang Chenchen, 2008, V52, P218, DOI 10.1159/000134302; Wang MY, 2011, BIOL SPORT, V28, P45, DOI 10.5604/935875; Zautra AJ, 2008, J CONSULT CLIN PSYCH, V76, P408, DOI 10.1037/0022-006X.76.3.408; Zorrilla EP, 2001, BRAIN BEHAV IMMUN, V15, P199, DOI 10.1006/brbi.2000.0597	103	136	143	4	86	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 2	2014	9	7							e100903	10.1371/journal.pone.0100903	http://dx.doi.org/10.1371/journal.pone.0100903			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AO5BA	24988414	Green Published, Green Submitted, gold			2023-01-03	WOS:000341354100049
J	Silver, J				Silver, Jonathan			Drugs for Macular Degeneration, Price Discrimination, and Medicare's Responsibility Not to Overpay	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									George Washington Univ, Washington, DC 20052 USA	George Washington University	Silver, J (corresponding author), George Washington Univ, 801 22nd St NW,Ste 739, Washington, DC 20052 USA.	jesilver@gwu.edu		Silver, Jonathan/0000-0001-9231-6368				[Anonymous], 2012, MED PAYM DRUGS US TE; [Anonymous], REV MED PART B AV LU; Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053; Rodwin Marc, 2013, MANAGING OFF LABEL D	4	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	2014	312	1					23	24		10.1001/jama.2014.6672	http://dx.doi.org/10.1001/jama.2014.6672			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AK0UK	24860863				2023-01-03	WOS:000338131100012
J	Moniz, MH; Davis, MM; Chang, T				Moniz, Michelle H.; Davis, Matthew M.; Chang, Tammy			Attitudes About Mandated Coverage of Birth Control Medication and Other Health Benefits in a US National Sample	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Moniz, Michelle H.] Univ Michigan, Robert Wood Johnson Fdn, Clin Scholars Program, Ann Arbor, MI 48109 USA; [Davis, Matthew M.] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA; [Chang, Tammy] Univ Michigan, Dept Family Med, Ann Arbor, MI 48109 USA	Robert Wood Johnson Foundation (RWJF); University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Moniz, MH (corresponding author), Univ Michigan, Robert Wood Johnson Fdn, Clin Scholars Program, 2800 Plymouth Rd,Bldg 10 G016, Ann Arbor, MI 48109 USA.	mmoniz@med.umich.edu		Chang, Tammy/0000-0002-3580-9438				Butler AS, 2009, REVIEW OF THE HHS FAMILY PLANNING PROGRAM: MISSION, MANAGEMENT, AND MEASUREMENT OF RESULTS, P1; Eckholm E., 2014, NEW YORK TIMES; Eilperin J., 2014, WASHINGTON POST; Gossett DR, 2013, JAMA-J AM MED ASSOC, V309, P1997, DOI 10.1001/jama.2013.4262; Public Religion Research Institute, 2012, SURV MAJ CATH THINK; Zimmer EA, 2013, JAMA-J AM MED ASSOC, V309, P1999, DOI 10.1001/jama.2013.3730	6	7	7	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	2014	311	24					2539	2541		10.1001/jama.2014.4766	http://dx.doi.org/10.1001/jama.2014.4766			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AJ5VE	24756439	Bronze			2023-01-03	WOS:000337757000029
J	Chatterjee, S; Chakraborty, A; Weinberg, I; Kadakia, M; Wilensky, RL; Sardar, P; Kumbhani, DJ; Mukherjee, D; Jaff, MR; Giri, J				Chatterjee, Saurav; Chakraborty, Anasua; Weinberg, Ido; Kadakia, Mitul; Wilensky, Robert L.; Sardar, Partha; Kumbhani, Dharam J.; Mukherjee, Debabrata; Jaff, Michael R.; Giri, Jay			Thrombolysis for Pulmonary Embolism and Risk of All-Cause Mortality, Major Bleeding, and Intracranial Hemorrhage A Meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTROLLED CLINICAL-TRIAL; VENOUS THROMBOEMBOLISM; PLASMINOGEN-ACTIVATOR; SEQUENTIAL-ANALYSIS; INFORMATION SIZE; RANDOMIZED-TRIAL; PROGNOSTIC VALUE; HEPARIN; THERAPY; ALTEPLASE	IMPORTANCE Thrombolytic therapy may be beneficial in the treatment of some patients with pulmonary embolism. To date, no analysis has had adequate statistical power to determine whether thrombolytic therapy is associated with improved survival, compared with conventional anticoagulation. OBJECTIVE To determine mortality benefits and bleeding risks associated with thrombolytic therapy compared with anticoagulation in acute pulmonary embolism, including the subset of hemodynamically stable patients with right ventricular dysfunction (intermediate-risk pulmonary embolism). DATA SOURCES PubMed, the Cochrane Library, EMBASE, EBSCO, Web of Science, and CINAHL databases from inception through April 10, 2014. STUDY SELECTION Eligible studies were randomized clinical trials comparing thrombolytic therapy vs anticoagulant therapy in pulmonary embolism patients. Sixteen trials comprising 2115 individuals were identified. Eight trials comprising 1775 patients specified inclusion of patients with intermediate-risk pulmonary embolism. DATA EXTRACTION AND SYNTHESIS Two reviewers independently extracted trial-level data including number of patients, patient characteristics, duration of follow-up, and outcomes. MAIN OUTCOMES AND MEASURES The primary outcomes were all-cause mortality and major bleeding. Secondary outcomes were risk of recurrent embolism and intracranial hemorrhage (ICH). Peto odds ratio (OR) estimates and associated 95% CIs were calculated using a fixed-effects model. RESULTS Use of thrombolytics was associated with lower all-cause mortality (OR, 0.53; 95% CI, 0.32-0.88; 2.17%[23/1061] vs 3.89% [41/1054] with anticoagulants; number needed to treat [NNT] = 59) and greater risks of major bleeding (OR, 2.73; 95% CI, 1.91-3.91; 9.24% [98/1061] vs 3.42%[36/1054]; number needed to harm [NNH] = 18) and ICH (OR, 4.63; 95% CI, 1.78-12.04; 1.46%[15/1024] vs 0.19% [2/1019]; NNH = 78). Major bleeding was not significantly increased in patients 65 years and younger (OR, 1.25; 95% CI, 0.50-3.14). Thrombolysis was associated with a lower risk of recurrent pulmonary embolism (OR, 0.40; 95% CI, 0.22-0.74; 1.17%[12/1024] vs 3.04%[31/1019]; NNT = 54). In intermediate-risk pulmonary embolism trials, thrombolysis was associated with lower mortality (OR, 0.48; 95% CI, 0.25-0.92) and more major bleeding events (OR, 3.19; 95% CI, 2.07-4.92). CONCLUSIONS AND RELEVANCE Among patients with pulmonary embolism, including those who were hemodynamically stable with right ventricular dysfunction, thrombolytic therapy was associated with lower rates of all-cause mortality and increased risks of major bleeding and ICH. However, findings may not apply to patients with pulmonary embolism who are hemodynamically stable without right ventricular dysfunction.	[Chatterjee, Saurav] Mt Sinai Hlth Syst, Div Cardiol, St Lukes Roosevelt Hosp Ctr, New York, NY USA; [Chakraborty, Anasua] Thomas Jefferson Univ Hosp, Div Pulmonol & Crit Care, Philadelphia, PA 19107 USA; [Weinberg, Ido; Jaff, Michael R.] Massachusetts Gen Hosp, Inst Heart Vasc & Stroke Care, Boston, MA 02114 USA; [Kadakia, Mitul; Wilensky, Robert L.; Giri, Jay] Univ Penn, Div Cardiovasc Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Sardar, Partha; Mukherjee, Debabrata] Texas Tech Univ, Div Cardiol, El Paso, TX USA; [Kumbhani, Dharam J.] Univ Texas SW Med Ctr Dallas, Div Cardiol, Dallas, TX 75390 USA	Icahn School of Medicine at Mount Sinai; Mount Sinai St. Luke's; Mount Sinai West; Jefferson University; Harvard University; Massachusetts General Hospital; University of Pennsylvania; Pennsylvania Medicine; Texas Tech University System; Texas Tech University; University of Texas System; University of Texas Southwestern Medical Center Dallas	Giri, J (corresponding author), Hosp Univ Penn, Div Cardiovasc Med, Gates Pavil,Ninth Floor,3400 Spruce St, Philadelphia, PA 19104 USA.	giri.jay@gmail.com	Mukherjee, Debabrata/AAG-1486-2019	Mukherjee, Debabrata/0000-0002-5131-3694	EKOS Corporation; Embolitech; Boston Scientific; Cordis Corporation	EKOS Corporation; Embolitech; Boston Scientific(Boston Scientific); Cordis Corporation	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Jaff reported having served as a consultant to AstraZeneca; having received support from EKOS Corporation, Embolitech, Boston Scientific, and Cordis Corporation; and being a board member for VIVA Physicians, a 501(c)(3) not-for profit education and research organization. Dr Wilensky reported being a member of the scientific advisor boards of Cardiostem, GenWay, Soteria, and Vascular Magnetics and having equity interest in Johnson & Johnson. No other disclosures were reported.	[Anonymous], 1970, J AMER MED ASSOC, V214, P2163; [Anonymous], 1990, Chest, V97, P528; [Anonymous], VEN THROMB DIS MAN V; Becattini C, 2007, CIRCULATION, V116, P427, DOI 10.1161/CIRCULATIONAHA.106.680421; Becattini C, 2010, THROMB RES, V125, pE82, DOI 10.1016/j.thromres.2009.09.017; Beckman MG, 2010, AM J PREV MED, V38, pS495, DOI 10.1016/j.amepre.2009.12.017; Brok J, 2008, J CLIN EPIDEMIOL, V61, P763, DOI 10.1016/j.jclinepi.2007.10.007; Buller HR, 2012, NEW ENGL J MED, V366, P1287, DOI 10.1056/NEJMoa1113572; DALLAVOLTA S, 1992, J AM COLL CARDIOL, V20, P520, DOI 10.1016/0735-1097(92)90002-5; Dong BR, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004437.pub3; Fang MC, 2007, AM J MED, V120, P700, DOI 10.1016/j.amjmed.2006.07.034; Fasullo S, 2011, AM J MED SCI, V341, P33, DOI 10.1097/MAJ.0b013e3181f1fc3e; GOLDHABER SZ, 1993, LANCET, V341, P507, DOI 10.1016/0140-6736(93)90274-K; Goldhaber SZ, 2001, CIRCULATION, V104, P2876, DOI 10.1161/circ.104.24.2876; Hamel E, 2001, CHEST, V120, P120, DOI 10.1378/chest.120.1.120; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2011, STAT MED, V30, P903, DOI 10.1002/sim.4088; Jaff MR, 2011, CIRCULATION, V123, P1788, DOI 10.1161/CIR.0b013e318214914f; Jerjes-Sanchez, 1995, J Thromb Thrombolysis, V2, P227; Kearon Clive, 2012, Chest, V141, pe419S, DOI 10.1378/chest.11-2301; Kline JA, 2014, J THROMB HAEMOST, V12, P459, DOI 10.1111/jth.12521; Konstantinides S, 2002, NEW ENGL J MED, V347, P1143, DOI 10.1056/NEJMoa021274; Kucher N, 2014, CIRCULATION, V129, P479, DOI 10.1161/CIRCULATIONAHA.113.005544; LEVINE M, 1990, CHEST, V98, P1473, DOI 10.1378/chest.98.6.1473; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; LY B, 1978, ACTA MED SCAND, V203, P465; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; MARINI C, 1988, RESPIRATION, V54, P162, DOI 10.1159/000195517; MENEVEAU N, 1993, J AM COLL CARDIOL, V22, P1075, DOI 10.1016/0735-1097(93)90418-Z; Meyer G, 2014, NEW ENGL J MED, V370, P1402, DOI 10.1056/NEJMoa1302097; Ruiz-Gimenez N, 2008, THROMB HAEMOSTASIS, V100, P26, DOI 10.1160/TH08-03-0193; Sanchez O, 2008, EUR HEART J, V29, P1569, DOI 10.1093/eurheartj/ehn208; Sharifi M, 2013, AM J CARDIOL, V111, P273, DOI 10.1016/j.amjcard.2012.09.027; Stein PD, 2012, AM J MED, V125, P465, DOI 10.1016/j.amjmed.2011.10.015; Thabut G, 2002, J AM COLL CARDIOL, V40, P1660, DOI 10.1016/S0735-1097(02)02381-1; Thorlund K, 2011, USER MANUAL TRIAL SE, V1, P1115, DOI DOI 10.1158/1055-9965.EPI-08-0169; TIBBUTT DA, 1974, BRIT MED J, V1, P343, DOI 10.1136/bmj.1.5904.343; Wan S, 2004, CIRCULATION, V110, P744, DOI 10.1161/01.CIR.0000137826.09715.9C; Weinberg I, 2014, CIRCULATION, V129, P420, DOI 10.1161/CIRCULATIONAHA.113.007132; Wetterslev J, 2008, J CLIN EPIDEMIOL, V61, P64, DOI 10.1016/j.jclinepi.2007.03.013; Wetterslev J, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-86; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	42	447	460	2	29	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	2014	311	23					2414	2421		10.1001/jama.2014.5990	http://dx.doi.org/10.1001/jama.2014.5990			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AI9XV	24938564	Bronze			2023-01-03	WOS:000337301500022
J	Mazur, G; Butrym, A; Kryczek, I; Dlubek, D; Jaskula, E; Lange, A; Kuliczkowski, K; Jelen, M				Mazur, Grzegorz; Butrym, Aleksandra; Kryczek, Ilona; Dlubek, Dorota; Jaskula, Emilia; Lange, Andrzej; Kuliczkowski, Kazimierz; Jelen, Michal			Decreased Expression of CXCR4 Chemokine Receptor in Bone Marrow after Chemotherapy in Patients with Non-Hodgkin Lymphomas Is a Good Prognostic Factor	PLOS ONE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; NODE METASTASIS; TUMOR-GROWTH; CANCER; MICROENVIRONMENT; PROGRESSION; MIGRATION; CELLS	Background: CXCR4 chemokine receptor is constitutively expressed on normal and malignant B lymphocytes derived from patients with B-cell lymphoproliferative disorders and has a significant role in cell migration to lymph nodes and bone marrow. Non-Hodgkin's lymphomas (NHL) constitute a heterogeneous group of lymphoproliferative diseases, which can localize not only to lymph nodes, but also can migrate to peripheral blood and metastase to other organs, including bone marrow. Aim: The purpose of this study was to determine CXCR4 gene expression in peripheral blood and bone marrow of NHL patients before and after treatment. Methods: Samples of lymphoma lymph nodes, peripheral blood and bone marrow aspirates of patients with B-cell NHL were taken at diagnosis and after chemotherapy. Gene expression was determined by the reverse transcription (RT)polymerase chain reaction method. Expression was estimated from 0 AU (no amplificate signal) to 3 AU (maximal amplificate signal). Results: No significant difference in the level of CXCR4 expression was found in reactive lymph nodes compared to lymphoma samples We observed high level of CXCR4 expression in most patients before treatment: in bone marrow: 3 AU-10 pts, 2 AU-8 pts, 1 AU-2 pts. In peripheral blood: 3 AU-14 pts, 2 AU-4 pts, 1 AU-1 pts, 0 AU-1 pts. After chemotherapy, significant decrease in CXCR4 expression was observed. Bone marrow: 3 AU-5 pts, 2 AU-7 pts, 1 AU-5 pts, 0 AU-3 pts (p = 0.03). Peripheral blood: 3 AU-2 pts, 2 AU-6 pts, 1 AU-10 pts, 0 AU-2 pts (p = 0.0002). There was a good response to treatment in patients with significant decrease of CXCR4 expression in the bone marrow after treatment with 10-fold lower risk of death (p = 0.03). Conclusions: Decrease in CXCR4 expression in the bone marrow of NHL patients after chemotherapy may be a good prognostic factor.	[Mazur, Grzegorz] Wroclaw Med Univ, Dept Internal & Occupat Dis & Hypertens, Wroclaw, Poland; [Butrym, Aleksandra; Kuliczkowski, Kazimierz] Wroclaw Med Univ, Dept Haematol Blood Neoplasms & Bone Marrow Trans, Wroclaw, Poland; [Butrym, Aleksandra] Wroclaw Med Univ, Dept Physiol, Wroclaw, Poland; [Kryczek, Ilona; Dlubek, Dorota; Jaskula, Emilia; Lange, Andrzej] Polish Acad Sci, L Hirszfeld Inst Immunol & Expt Therapy, Dept Clin Immunol, Wroclaw, Poland; [Jelen, Michal] Wroclaw Med Univ, Div Pathomorphol & Oncol Cytol, Div Pathomorphol & Oncol Cytol, Wroclaw, Poland	Wroclaw Medical University; Wroclaw Medical University; Wroclaw Medical University; Polish Academy of Sciences; Hirszfeld Institute of Immunology & Experimental Therapy of the Polish Academy of Sciences; Wroclaw Medical University	Butrym, A (corresponding author), Wroclaw Med Univ, Dept Haematol Blood Neoplasms & Bone Marrow Trans, Wroclaw, Poland.	aleksandra.butrym@gmail.com	Lange, Andrzej/AAR-3247-2021; Jaskuła, Emilia/AAA-4515-2020; Butrym, Aleksandra/T-6582-2018	Lange, Andrzej/0000-0003-3544-1853; Jaskuła, Emilia/0000-0002-4894-7522; Butrym, Aleksandra/0000-0002-8199-2018; Mazur, Grzegorz/0000-0001-6610-2008; Kuliczkowski, Kazimierz/0000-0001-6812-1421	Wroclaw Medical University [ST-338]	Wroclaw Medical University	The study was supported by Wroclaw Medical University grant No: ST-338, www.umed.wroc.pl. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alsayed Y, 2007, BLOOD, V109, P2708, DOI 10.1182/blood-2006-07-035857; Arya Manit, 2004, J Exp Ther Oncol, V4, P291; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Beider K, 2013, CLIN CANCER RES, V19, P3495, DOI 10.1158/1078-0432.CCR-12-3015; Berghuis D, 2012, CLIN SARCOMA RES, V2, DOI 10.1186/2045-3329-2-24; Burger JA, 2014, SEMIN CANCER BIOL, V24, P71, DOI 10.1016/j.semcancer.2013.08.011; Busillo JM, 2007, BBA-BIOMEMBRANES, V1768, P952, DOI 10.1016/j.bbamem.2006.11.002; Caligaris-Cappio F, 2003, BRIT J HAEMATOL, V123, P380, DOI 10.1046/j.1365-2141.2003.04679.x; Corcione A, 2004, CLIN CANCER RES, V10, P964, DOI 10.1158/1078-0432.CCR-1182-3; Corcione A, 2000, J NATL CANCER I, V92, P628, DOI 10.1093/jnci/92.8.628; Darash-Yahana M, 2004, FASEB J, V18, P1240, DOI 10.1096/fj.03-0935fje; Deutsch AJA, 2013, MODERN PATHOL, V26, P182, DOI 10.1038/modpathol.2012.134; Durig J, 2001, LEUKEMIA, V15, P752, DOI 10.1038/sj.leu.2402107; Ghobrial IM, 2004, MAYO CLIN PROC, V79, P318, DOI 10.4065/79.3.318; Guo MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090518; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Juarez JG, 2009, BRIT J HAEMATOL, V145, P491, DOI 10.1111/j.1365-2141.2009.07648.x; Kato M, 2003, BREAST CANCER RES, V5, pR144, DOI 10.1186/bcr627; Lopez-Giral S, 2004, J LEUKOCYTE BIOL, V76, P462, DOI 10.1189/jlb.1203652; Mancuso P, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-644; Mazur G, 2013, CYTOKINE, V64, P422, DOI 10.1016/j.cyto.2013.05.004; Mazur Grzegorz, 2005, Acta Haematologica Polonica, V36, P113; Moser B, 2003, IMMUNOL LETT, V85, P105, DOI 10.1016/S0165-2478(02)00233-X; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Ngo HT, 2008, BLOOD, V112, P150, DOI 10.1182/blood-2007-12-129395; Peled A, 2013, THERANOSTICS, V3, P34, DOI 10.7150/thno.5150; Ratajczak MZ, 2012, SCI WORLD J, DOI 10.1100/2012/758512; Rombouts EJC, 2004, BLOOD, V104, P550, DOI 10.1182/blood-2004-02-0566; Tesfai Y, 2012, LEUKEMIA RES, V36, P299, DOI 10.1016/j.leukres.2011.08.001; Wong SWJ, 2004, LEUKEMIA LYMPHOMA, V45, P2491, DOI 10.1080/10428190410001723449; Yasuoka H, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-340	31	15	16	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2014	9	5							e98194	10.1371/journal.pone.0098194	http://dx.doi.org/10.1371/journal.pone.0098194			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI4ML	24859274	Green Published, Green Submitted, gold			2023-01-03	WOS:000336839400053
J	Lorch, JA; Pollak, VE				Lorch, Jonathan A.; Pollak, Victor E.			Continuous Quality Improvement in Daily Clinical Practice: A Proof of Concept Study	PLOS ONE			English	Article							ERYTHROPOIESIS-STIMULATING AGENT; CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; HEMODIALYSIS-PATIENTS; HEMOGLOBIN LEVELS; EPOETIN-ALPHA; MORTALITY; ANEMIA; LEVEL; IRON	Continuous Quality Improvement (CQI) is an iterative process of: planning to improve a product or process, plan implementation, analyzing and comparing results against those expected, and corrective action on differences between actual and expected results. It is little used in clinical medicine. Anemia, a complex problem in End Stage Renal Disease patients, served to test the ability of an unique electronic medical record (EMR) optimized for daily care to empower CQI in practice. We used data collected during daily care, stored in the EMR, and organized to display temporal relationships between clinical, laboratory, and therapeutic events. Our aims were optimal hemoglobin with minimum epoetin, and maintaining stable hemoglobin and epoetin. The study was done on 250 patients treated by maintenance hemodialysis (HD), receiving epoetin prior to February 1, 2010 and followed to July 31, 2011. Repleting iron, ensuring iron sufficiency, slow epoetin reduction, and decision support tools enabling data display over long periods in patient-centered reports were key elements. Epoetin dose, adjusted 6-8 weekly, was based on current clinical conditions and past responses. Hemoglobin increased by months 1-2; epoetin decreased from month 4. By months 16-18, epoetin had decreased 42% to 9,720 units/week while hemoglobin increased 8% to 123.6 g/L. Hemoglobin and epoetin were stable from month 7 onward. New epoetin orders decreased 83%. Transferrin saturation increased after the study start. Individual patient hemoglobin variation decreased by 23%, range by 27%. Mortality, 11.78 per 100 patient years, was 42% less than United States dialysis patient mortality. Allowable epoetin charges decreased by $15.33 per treatment and were $22.88 less than current Medicare allowance. The study validates the hypothesis that an EMR optimized for daily patient care can empower CQI in clinical medicine and serve to monitor medical care quality and cost.	[Lorch, Jonathan A.] Weill Cornell Med Coll, Dept Med, New York, NY USA; [Pollak, Victor E.] Univ Colorado, Hlth Sci Ctr, Dept Med, Aurora, CO 80045 USA; [Lorch, Jonathan A.] Rogosin Inst, New York, NY USA; [Pollak, Victor E.] MIQS Inc, Boulder, CO USA	Cornell University; University of Colorado System; University of Colorado Anschutz Medical Campus	Pollak, VE (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Aurora, CO 80045 USA.	vpollak@miqs.com			MIQS, Inc.	MIQS, Inc.	VEP received salary support from MIQS, Inc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agarwal R, 2010, CLIN J AM SOC NEPHRO, V5, P1340, DOI 10.2215/CJN.02830310; Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; Besarab A, 2009, ADV CHRONIC KIDNEY D, V16, P131, DOI 10.1053/j.ackd.2008.12.007; Buntin MB, 2011, HEALTH AFFAIR, V30, P464, DOI 10.1377/hlthaff.2011.0178; Deming W, 1982, OUT CRISIS; Drueke TB, 2006, NEW ENGL J MED, V355, P2071, DOI 10.1056/NEJMoa062276; ESCHBACH JW, 1967, NEW ENGL J MED, V276, P653, DOI 10.1056/NEJM196703232761202; ESCHBACH JW, 1991, AM J KIDNEY DIS, V18, P3; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; Feinstein AR, 1997, AM J MED, V103, P529, DOI 10.1016/S0002-9343(97)00244-1; Fort J, 2010, NEPHROL DIAL TRANSPL, V25, P2702, DOI 10.1093/ndt/gfq073; FRIES JF, 1972, J AMER MED ASSOC, V222, P1536, DOI 10.1001/jama.222.12.1536; Fuller DS, 2013, AM J KIDNEY DIS, V61, P342, DOI 10.1053/j.ajkd.2012.10.002; Goodkin DA, 2003, J AM SOC NEPHROL, V14, P3270, DOI 10.1097/01.ASN.0000100127.54107.57; Hampl H, 2005, AM J NEPHROL, V25, P211, DOI 10.1159/000085881; Heffler S, 2005, HLTH AFF MILLWOOD S; Hsu CY, 2002, J AM SOC NEPHROL, V13, P2783, DOI 10.1097/01.ASN.0000034200.82278.DC; Levin A, 2006, AM J KIDNEY DIS, V47, pS9, DOI 10.1053/j.ajkd.2006.04.023; McFarlane PA, 2010, KIDNEY INT, V78, P215, DOI 10.1038/ki.2010.108; National Research Council, 2012, BEST CAR LOW COST PA; Ofsthun N, 2003, KIDNEY INT, V63, P1908, DOI 10.1046/j.1523-1755.2003.00937.x; POLLAK VE, 1977, ARCH INTERN MED, V137, P446, DOI 10.1001/archinte.137.4.446; Pollak VE, 2001, J INVEST MED, V49, P173, DOI 10.2310/6650.2001.34044; POLLAK VE, 1985, JAMA-J AM MED ASSOC, V253, P62; Pollak VE, 2009, BMC NEPHROL, V10, DOI 10.1186/1471-2369-10-6; Pollak VE, 2007, BMC MED INFORM DECIS, V7, DOI 10.1186/1472-6947-7-38; Portoles J, 2007, NEPHROL DIAL TRANSPL, V22, P500, DOI 10.1093/ndt/gfl558; Rawlins M, 2008, LANCET, V372, P2152, DOI 10.1016/S0140-6736(08)61930-3; Regidor DL, 2006, J AM SOC NEPHROL, V17, P1181, DOI 10.1681/ASN.2005090997; Servilla KS, 2009, AM J KIDNEY DIS, V54, P498, DOI 10.1053/j.ajkd.2009.05.007; Shewhart W. A., 1986, STAT METHOD VIEWPOIN; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; U S Renal Data System, 2011, ANN DAT REP ATL CHRO; Weinhandl ED, 2011, AM J NEPHROL, V34, P298, DOI 10.1159/000330693	34	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2014	9	5							e97066	10.1371/journal.pone.0097066	http://dx.doi.org/10.1371/journal.pone.0097066			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM0UW	24844323	Green Submitted, gold, Green Published			2023-01-03	WOS:000339563400013
J	Talekar, SJ; Chochua, S; Nelson, K; Klugman, KP; Quave, CL; Vidal, JE				Talekar, Sharmila J.; Chochua, Sopio; Nelson, Katie; Klugman, Keith P.; Quave, Cassandra L.; Vidal, Jorge E.			220D-F2 from Rubus ulmifolius Kills Streptococcus pneumoniae Planktonic Cells and Pneumococcal Biofilms	PLOS ONE			English	Article							IN-VITRO; BACTERIAL BIOFILMS; ANTIBIOTIC SUSCEPTIBILITIES; STAPHYLOCOCCUS-AUREUS; VIRULENCE FACTORS; GENOME SEQUENCE; COLONIZATION; DISEASE; EPIDEMIOLOGY; RESISTANCE	Streptococcus pneumoniae (pneumococcus) forms organized biofilms to persist in the human nasopharynx. This persistence allows the pneumococcus to produce severe diseases such as pneumonia, otitis media, bacteremia and meningitis that kill nearly a million children every year. While bacteremia and meningitis are mediated by planktonic pneumococci, biofilm structures are present during pneumonia and otitis media. The global emergence of S. pneumoniae strains resistant to most commonly prescribed antibiotics warrants further discovery of alternative therapeutics. The present study assessed the antimicrobial potential of a plant extract, 220D-F2, rich in ellagic acid, and ellagic acid derivatives, against S. pneumoniae planktonic cells and biofilm structures. Our studies first demonstrate that, when inoculated together with planktonic cultures, 220D-F2 inhibited the formation of pneumococcal biofilms in a dose-dependent manner. As measured by bacterial counts and a LIVE/DEAD bacterial viability assay, 100 and 200 mu g/ml of 220D-F2 had significant bactericidal activity against pneumococcal planktonic cultures as early as 3 h post-inoculation. Quantitative MIC's, whether quantified by qPCR or dilution and plating, showed that 80 mu g/ml of 220D-F2 completely eradicated overnight cultures of planktonic pneumococci, including antibiotic resistant strains. When preformed pneumococcal biofilms were challenged with 220D-F2, it significantly reduced the population of biofilms 3 h post-inoculation. Minimum biofilm inhibitory concentration (MBIC)(50) was obtained incubating biofilms with 100 mu g/ml of 220D-F2 for 3 h and 6 h of incubation. 220D-F2 also significantly reduced the population of pneumococcal biofilms formed on human pharyngeal cells. Our results demonstrate potential therapeutic applications of 220D-F2 to both kill planktonic pneumococcal cells and disrupt pneumococcal biofilms.	[Talekar, Sharmila J.; Chochua, Sopio; Klugman, Keith P.; Vidal, Jorge E.] Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30332 USA; [Nelson, Katie; Quave, Cassandra L.] Emory Coll Arts & Sci, Ctr Study Human Hlth, Atlanta, GA USA; [Quave, Cassandra L.] Emory Univ, Sch Med, Dept Dermatol, Atlanta, GA 30322 USA	Emory University; Rollins School Public Health; Emory University	Vidal, JE (corresponding author), Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30332 USA.	jvidalg@emory.edu	Quave, Cassandra/AAD-2066-2020	Quave, Cassandra/0000-0001-9615-7886				Aaron SD, 2002, J CLIN MICROBIOL, V40, P4172, DOI 10.1128/JCM.40.11.4172-4179.2002; Ash SY, 2013, MED CLIN N AM, V97, P647, DOI 10.1016/j.mcna.2013.03.005; Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; Baselski V, 2013, J CLIN MICROBIOL, V51, P740, DOI 10.1128/JCM.03383-12; Bogaert D, 2004, LANCET, V363, P1871, DOI 10.1016/S0140-6736(04)16357-5; Carvalho MDS, 2007, J CLIN MICROBIOL, V45, P2460, DOI 10.1128/JCM.02498-06; Cerca N, 2005, J ANTIMICROB CHEMOTH, V56, P331, DOI 10.1093/jac/dki217; Ceri H, 1999, J CLIN MICROBIOL, V37, P1771, DOI 10.1128/JCM.37.6.1771-1776.1999; Clinical and Laboratory Standards Institute (CLSI), 2009, METHODS DILUTION ANT, V8th ed.; Costerton JW, 2011, PLAST RECONSTR SURG, V127, p36S, DOI 10.1097/PRS.0b013e3182001845; Costerton JW, 1999, INT J ANTIMICROB AG, V11, P217, DOI 10.1016/S0924-8579(99)00018-7; Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318; David MZ, 2010, CLIN MICROBIOL REV, V23, P616, DOI 10.1128/CMR.00081-09; Davis SC, 2008, WOUND REPAIR REGEN, V16, P23, DOI 10.1111/j.1524-475X.2007.00303.x; del Prado G, 2010, DIAGN MICR INFEC DIS, V67, P311, DOI 10.1016/j.diagmicrobio.2010.03.016; Domenech M, 2011, ANTIMICROB AGENTS CH, V55, P4144, DOI 10.1128/AAC.00492-11; Dong W, 2014, ANTIMICROB AGENTS CH, V58, P2459, DOI 10.1128/AAC.02630-13; Donlan RM, 2002, CLIN MICROBIOL REV, V15, P167, DOI 10.1128/CMR.15.2.167-193.2002; Donlan RM, 2001, CLIN INFECT DIS, V33, P1387, DOI 10.1086/322972; Elaissi A, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-81; Garcia-Castillo M, 2007, J ANTIMICROB CHEMOTH, V59, P301, DOI 10.1093/jac/dkl482; Hall-Stoodley L, 2006, JAMA-J AM MED ASSOC, V296, P202, DOI 10.1001/jama.296.2.202; Henriques-Normark B, 2013, COLD SPRING HARB PER, V3; Imamura Y, 2008, ANTIMICROB AGENTS CH, V52, P171, DOI 10.1128/AAC.00387-07; Jedrzejas MJ, 2001, MICROBIOL MOL BIOL R, V65, P187, DOI 10.1128/MMBR.65.2.187-207.2001; Kadioglu A, 2008, NAT REV MICROBIOL, V6, P288, DOI 10.1038/nrmicro1871; Lanie JA, 2007, J BACTERIOL, V189, P38, DOI 10.1128/JB.01148-06; Levine OS, 2009, AM J EPIDEMIOL, V170, P1067, DOI 10.1093/aje/kwp316; Lynch JP, 2010, CURR OPIN PULM MED, V16, P217, DOI 10.1097/MCP.0b013e3283385653; Marcinkiewicz J, 2013, POL ARCH MED WEWN, V123, P309, DOI 10.20452/pamw.1780; Marks LR, 2012, INFECT IMMUN, V80, P2744, DOI 10.1128/IAI.00488-12; Moscoso M, 2009, INT MICROBIOL, V12, P77, DOI 10.2436/20.1501.01.84; Nieto C, 2003, PLASMID, V49, P281, DOI 10.1016/S0147-619X(03)00020-9; O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6; Parsek MR, 2003, ANNU REV MICROBIOL, V57, P677, DOI 10.1146/annurev.micro.57.030502.090720; Pichichero ME, 2013, PEDIATR CLIN N AM, V60, P391, DOI 10.1016/j.pcl.2012.12.007; Quave CL, 2008, J ETHNOPHARMACOL, V118, P418, DOI 10.1016/j.jep.2008.05.005; Quave CL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028737; Ramage G, 2006, FEMS YEAST RES, V6, P979, DOI 10.1111/j.1567-1364.2006.00117.x; Sanchez CJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028738; Sanchez CJ, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001044; Shak JR, 2013, MBIO, V4, DOI 10.1128/mBio.00655-13; Shakl JR, 2013, TRENDS MICROBIOL, V21, P129, DOI 10.1016/j.tim.2012.11.005; Shiu WK, 2013, INT J ANTIMICROB AGE; Simell B, 2012, EXPERT REV VACCINES, V11, P841, DOI [10.1586/erv.12.53, 10.1586/ERV.12.53]; Song JH, 2013, EXPERT REV RESP MED, V7, P491, DOI 10.1586/17476348.2013.816572; Song JH, 2012, VACCINE, V30, P2728, DOI 10.1016/j.vaccine.2012.01.091; Stamm WE, 1999, INT J ANTIMICROB AG, V11, P237; Tettelin H, 2001, SCIENCE, V293, P498, DOI 10.1126/science.1061217; Thomas JG, 2005, BIOFILMS, INFECTION, AND ANTIMICROBIAL THERAPY, P21; Trappetti C, 2009, J INFECT DIS, V199, P1497, DOI 10.1086/598483; van der Poll T, 2009, LANCET, V374, P1543, DOI 10.1016/S0140-6736(09)61114-4; Vidal JE, 2013, INFECT IMMUN, V81, P1341, DOI 10.1128/IAI.01096-12; Vidal JE, 2011, INFECT IMMUN, V79, P4050, DOI 10.1128/IAI.05186-11; Weimer KED, 2010, J INFECT DIS, V202, P1068, DOI 10.1086/656046; Weycker D, 2010, VACCINE, V28, P4955, DOI 10.1016/j.vaccine.2010.05.030; Wolcott RD, 2010, J WOUND CARE, V19, P45, DOI 10.12968/jowc.2010.19.2.46966; Wolcott R, 2011, PLAST RECONSTR SURG, V127, p28S, DOI 10.1097/PRS.0b013e3181fca244; Wolter N, 2005, ANTIMICROB AGENTS CH, V49, P3554, DOI 10.1128/AAC.49.8.3554-3557.2005; Yadav MK, 2012, MICROB PATHOGENESIS, V53, P219, DOI 10.1016/j.micpath.2012.08.003; Yang F, 2008, INT J ANTIMICROB AG, V32, P386, DOI 10.1016/j.ijantimicag.2008.05.004; Zampini IC, 2012, J ETHNOPHARMACOL, V140, P287, DOI 10.1016/j.jep.2012.01.019	62	17	17	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2014	9	5							e97314	10.1371/journal.pone.0097314	http://dx.doi.org/10.1371/journal.pone.0097314			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AH8EY	24823499	Green Submitted, Green Published, gold			2023-01-03	WOS:000336369200094
J	Yang, SC; Chen, JC; Tai, WC; Wu, CK; Lee, CH; Wu, KL; Chiu, YC; Wang, JH; Lu, SN; Chuah, SK				Yang, Shih-Cheng; Chen, Jen-Chieh; Tai, Wei-Chen; Wu, Cheng-Kun; Lee, Chen-Hsiang; Wu, Keng-Liang; Chiu, Yi-Chun; Wang, Jing-Houng; Lu, Sheng-Nan; Chuah, Seng-Kee			The Influential Roles of Antibiotics Prophylaxis in Cirrhotic Patients with Peptic Ulcer Bleeding after Initial Endoscopic Treatments	PLOS ONE			English	Article							PREVENTS BACTERIAL-INFECTION; GASTROINTESTINAL HEMORRHAGE; MORTALITY; RISK; NORFLOXACIN; FAILURE	The influential roles of antibiotic prophylaxis on cirrhotic patients with peptic ulcer bleeding are still not well documented. The purpose of this study is to clarify these influential roles and to identify the risk factors associated with rebleeding, bacterial infection and in-hospital mortality. A cross-sectional, chart review study was conducted on 210 cirrhotic patients with acute peptic ulcer hemorrhage who underwent therapeutic endoscopic procedures. Patients were divided into group A (with prophylactic intravenous ceftriaxone, n = 74) and group B (without antibiotics, n = 136). The outcomes were length of hospital days, prevention of infection, rebleeding rate and in-hospital mortality. Our results showed that more patients suffered from rebleeding and infection in group B than group A (31.6% vs. 5.4%; p<0.001 and 25% vs. 10.8%; p = 0.014 respectively). The risk factors for rebleeding were active alcoholism, unit of blood transfusion, Rockall score, model for end-stage liver disease score and antibiotic prophylaxis. The risk factors for infection were active alcoholism, Child-Pugh C, Rockall score and antibiotic prophylaxis. Rockall score was the predictive factor for in-hospital mortality. In conclusions, antibiotic prophylaxis in cirrhotic patients after endoscopic interventions for acute peptic ulcer hemorrhage reduced infections and rebleeding rate but not in-hospital mortality. Rockall score was the predictive factor of in-hospital mortality.	[Yang, Shih-Cheng; Chen, Jen-Chieh; Tai, Wei-Chen; Wu, Cheng-Kun; Wu, Keng-Liang; Chiu, Yi-Chun; Wang, Jing-Houng; Lu, Sheng-Nan; Chuah, Seng-Kee] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Hepatogastroenterol, Kaohsiung, Taiwan; [Yang, Shih-Cheng; Chen, Jen-Chieh; Tai, Wei-Chen; Wu, Cheng-Kun; Lee, Chen-Hsiang; Wu, Keng-Liang; Chiu, Yi-Chun; Wang, Jing-Houng; Lu, Sheng-Nan; Chuah, Seng-Kee] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan; [Lee, Chen-Hsiang] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Infect Dis, Kaohsiung, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital	Chuah, SK (corresponding author), Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Hepatogastroenterol, Kaohsiung, Taiwan.	chuahsk@seed.net.tw						[Anonymous], 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002907; BERNARD B, 1995, GASTROENTEROLOGY, V108, P1828, DOI 10.1016/0016-5085(95)90146-9; BLAISE M, 1994, HEPATOLOGY, V20, P34, DOI 10.1016/0270-9139(94)90131-7; Burroughs AK, 2009, NAT CLIN PRACT GASTR, V6, P72, DOI 10.1038/ncpgasthep1336; CHRISTENSEN E, 1981, GASTROENTEROLOGY, V81, P944; Fernandez J, 2006, GASTROENTEROLOGY, V131, P1049, DOI 10.1053/j.gastro.2006.07.010; FORREST JAH, 1974, LANCET, V2, P394; Goulis J, 1998, HEPATOLOGY, V27, P1207, DOI 10.1002/hep.510270504; Hung CH, 2003, J GASTROENTEROL, V38, P153, DOI 10.1007/s005350300025; Kamath PS, 2001, HEPATOLOGY, V33, P464, DOI 10.1053/jhep.2001.22172; Koulaouzidis A, 2009, WORLD J GASTROENTERO, V15, P1042, DOI 10.3748/wjg.15.1042; Lodato F, 2008, WORLD J GASTROENTERO, V14, P2980, DOI 10.3748/wjg.14.2980; Marmo R, 2008, AM J GASTROENTEROL, V103, P1639, DOI 10.1111/j.1572-0241.2008.01865.x; Mathurin P, 2012, J HEPATOL, V57, P399, DOI 10.1016/j.jhep.2012.04.004; O'Shea RS, 2010, HEPATOLOGY, V51, P307, DOI 10.1002/hep.23258; Pauwels A, 1996, HEPATOLOGY, V24, P802; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; Rockall TA, 1996, GUT, V38, P316, DOI 10.1136/gut.38.3.316; Rosa H, 2000, AM J GASTROENTEROL, V95, P1290, DOI 10.1111/j.1572-0241.2000.02026.x; Sanders DS, 2002, AM J GASTROENTEROL, V97, P630; Sarwar S, 2007, JCPSP-J COLL PHYSICI, V17, P253; SORIANO G, 1992, GASTROENTEROLOGY, V103, P1267, DOI 10.1016/0016-5085(92)91514-5; Vivas S, 2001, DIGEST DIS SCI, V46, P2752, DOI 10.1023/A:1012739815892; Wang H, 2011, ALCOHOL ALCOHOLISM, V46, P26, DOI 10.1093/alcalc/agq076; Wong F, 2005, GUT, V54, P718, DOI 10.1136/gut.2004.038679; Wu CK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061666; WYKE RJ, 1987, GUT, V28, P623, DOI 10.1136/gut.28.5.623; Xu HW, 2011, SURG ENDOSC, V25, P2911, DOI 10.1007/s00464-011-1642-0	28	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2014	9	5							e96394	10.1371/journal.pone.0096394	http://dx.doi.org/10.1371/journal.pone.0096394			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI1ZS	24788341	Green Published, Green Submitted, gold			2023-01-03	WOS:000336655700085
J	Farrell, M; Buchbinder, R; Hall, W				Farrell, Michael; Buchbinder, Rachelle; Hall, Wayne			Should doctors prescribe cannabinoids?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CHEMOTHERAPY-INDUCED NAUSEA; RANDOMIZED CONTROLLED-TRIAL; CENTRAL NEUROPATHIC PAIN; MULTIPLE-SCLEROSIS; DOUBLE-BLIND; CANCER-PATIENTS; SPASTICITY; NABILONE; METAANALYSIS; NABIXIMOLS		[Farrell, Michael] Univ New S Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2031, Australia; [Buchbinder, Rachelle] Cabrini Hosp, Monash Dept Clin Epidemiol, Melbourne, Vic, Australia; [Buchbinder, Rachelle] Monash Univ, Sch Publ Hlth & Prevent Med, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; [Hall, Wayne] Univ Queensland, Clin Res Ctr, Herston, Qld, Australia	University of New South Wales Sydney; Cabrini Health; Monash University; Monash University; University of Queensland	Farrell, M (corresponding author), Univ New S Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2031, Australia.	michael.farrell@unsw.edu.au	Farrell, Michael P/A-4769-2012; Hall, Wayne D/A-3283-2008; Buchbinder, Rachelle/G-2952-2011	Farrell, Michael P/0000-0001-7008-8130; Hall, Wayne D/0000-0003-1984-0096; Buchbinder, Rachelle/0000-0002-0597-0933				Amar MB, 2006, J ETHNOPHARMACOL, V105, P1, DOI 10.1016/j.jep.2006.02.001; Christie MJ, 2006, BRIT J PHARMACOL, V148, P385, DOI 10.1038/sj.bjp.0706756; Collin C, 2007, EUR J NEUROL, V14, P290, DOI 10.1111/j.1468-1331.2006.01639.x; Collin C, 2010, NEUROL RES, V32, P451, DOI 10.1179/016164109X12590518685660; Corey-Bloom J, 2012, CAN MED ASSOC J, V184, P1143, DOI 10.1503/cmaj.110837; Dyer O, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4755; Eddy, 2010, 75700 C RES SERV; Guindon J, 2008, BRIT J PHARMACOL, V153, P319, DOI 10.1038/sj.bjp.0707531; Hall W, 2009, LANCET, V374, P1383, DOI 10.1016/S0140-6736(09)61037-0; Institute of Medicine (US). Division of Neuroscience and Behavioral Health, 1999, MARIJUANA MED ASSESS; Johnson JR, 2010, J PAIN SYMPTOM MANAG, V39, P167, DOI 10.1016/j.jpainsymman.2009.06.008; Kalant H, 2001, Pain Res Manag, V6, P80; Langford RM, 2013, J NEUROL, V260, P984, DOI 10.1007/s00415-012-6739-4; Lutge EE, 2013, COCHRANE DB SYST REV, V4; Lynch ME, 2011, BRIT J CLIN PHARMACO, V72, P735, DOI 10.1111/j.1365-2125.2011.03970.x; Martin-Sanchez E, 2009, PAIN MED, V10, P1353, DOI 10.1111/j.1526-4637.2009.00703.x; Nascimento SD, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/149468; Navari RM, 2009, DRUGS, V69, P515, DOI 10.2165/00003495-200969050-00002; Phillips TJC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014433; Pini LA, 2012, J HEADACHE PAIN, V13, P677, DOI 10.1007/s10194-012-0490-1; Podda G, 2012, EXPERT OPIN BIOL TH, V12, P1517, DOI 10.1517/14712598.2012.721765; Portenoy RK, 2012, J PAIN, V13, P438, DOI 10.1016/j.jpain.2012.01.003; Richards BL, 2011, COCHRANE DB SYST REV, V1; Rintala DH, 2010, AM J PHYS MED REHAB, V89, P840, DOI 10.1097/PHM.0b013e3181f1c4ec; Rocha FCM, 2008, EUR J CANCER CARE, V17, P431, DOI 10.1111/j.1365-2354.2008.00917.x; Rog DJ, 2005, NEUROLOGY, V65, P812, DOI 10.1212/01.wnl.0000176753.45410.8b; Russo E, 2006, MED HYPOTHESES, V66, P234, DOI 10.1016/j.mehy.2005.08.026; Selvarajah D, 2010, DIABETES CARE, V33, P128, DOI 10.2337/dc09-1029; Skrabek RQ, 2008, J PAIN, V9, P164, DOI 10.1016/j.jpain.2007.09.002; Snedecor SJ, 2013, J PAIN RES, V6, P539, DOI 10.2147/JPR.S45966; Svendsen KB, 2004, BMJ-BRIT MED J, V329, P31; Toth C, 2012, PAIN, V153, P2073, DOI 10.1016/j.pain.2012.06.024; Tramer MR, 2001, BMJ-BRIT MED J, V323, P16, DOI 10.1136/bmj.323.7303.16; Wade DT, 2010, MULT SCLER J, V16, P707, DOI 10.1177/1352458510367462; Wade DT, 2004, MULT SCLER, V10, P434, DOI 10.1191/1352458504ms1082oa; Wade DT, 2003, CLIN REHABIL, V17, P21, DOI 10.1191/0269215503cr581oa; Ware MA, 2010, ANESTH ANALG, V110, P604, DOI 10.1213/ANE.0b013e3181c76f70	37	9	10	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 23	2014	348								g2737	10.1136/bmj.g2737	http://dx.doi.org/10.1136/bmj.g2737			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AG1DH	24760158				2023-01-03	WOS:000335154800003
J	Havers, FP; Detrick, B; Cardoso, SW; Berendes, S; Lama, JR; Sugandhavesa, P; Mwelase, NH; Campbell, TB; Gupta, A				Havers, Fiona P.; Detrick, Barbara; Cardoso, Sandra W.; Berendes, Sima; Lama, Javier R.; Sugandhavesa, Patcharaphan; Mwelase, Noluthando H.; Campbell, Thomas B.; Gupta, Amita		ACTG A5175 PEARLS Team; NCWS319 Team	Change in Vitamin D Levels Occurs Early after Antiretroviral Therapy Initiation and Depends on Treatment Regimen in Resource-Limited Settings	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; D DEFICIENCY; 25-HYDROXYVITAMIN D; DISEASE PROGRESSION; HIV-INFECTION; T-CELLS; ASSOCIATION; RECEPTOR; ADULTS; INSUFFICIENCY	Study Background: Vitamin D has wide-ranging effects on the immune system, and studies suggest that low serum vitamin D levels are associated with worse clinical outcomes in HIV. Recent studies have identified an interaction between antiretrovirals used to treat HIV and reduced serum vitamin D levels, but these studies have been done in North American and European populations. Methods: Using a prospective cohort study design nested in a multinational clinical trial, we examined the effect of three combination antiretroviral (cART) regimens on serum vitamin D levels in 270 cART-naive, HIV-infected adults in nine diverse countries, (Brazil, Haiti, Peru, Thailand, India, Malawi, South Africa, Zimbabwe and the United States). We evaluated the change between baseline serum vitamin D levels and vitamin D levels 24 and 48 weeks after cART initiation. Results: Serum vitamin D levels decreased significantly from baseline to 24 weeks among those randomized to efavirenz/lamivudine/zidovudine (mean change: -7.94 [95% Confidence Interval (CI) -10.42, -5.54] ng/ml) and efavirenz/emtricitabine/tenofovir-DF (mean change: -6.66 [95% CI -9.40, -3.92] ng/ml) when compared to those randomized to atazanavir/emtricitabine/didanosine-EC (mean change: -2.29 [95% CI -4.83, 0.25] ng/ml). Vitamin D levels did not change significantly between week 24 and 48. Other factors that significantly affected serum vitamin D change included country (p < 0.001), season (p < 0.001) and baseline vitamin D level (p < 0.001). Conclusion: Efavirenz-containing cART regimens adversely affected vitamin D levels in patients from economically, geographically and racially diverse resource-limited settings. This effect was most pronounced early after cART initiation. Research is needed to define the role of Vitamin D supplementation in HIV care.	[Havers, Fiona P.; Detrick, Barbara; Gupta, Amita] Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA; [Havers, Fiona P.; Gupta, Amita] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Cardoso, Sandra W.] Fiocruz MS, Evandro Chagas Clin Res Inst IPEC, BR-21045900 Rio De Janeiro, Brazil; [Berendes, Sima] Johns Hopkins Univ, Coll Med, Res Project, Blantyre, Malawi; [Berendes, Sima] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; [Lama, Javier R.] Asociac Civil Impacta Salud & Educ, Lima, Peru; [Sugandhavesa, Patcharaphan] Chiang Mai Univ, Chiang Mai 50000, Thailand; [Mwelase, Noluthando H.] Univ Witwatersrand, Johannesburg, South Africa; [Campbell, Thomas B.] Univ Colorado Denver, Aurora, CO USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Fundacao Oswaldo Cruz; University of Malawi; Liverpool School of Tropical Medicine; University of Liverpool; Chiang Mai University; University of Witwatersrand; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Havers, FP (corresponding author), Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA.	fhavers@cdc.gov; agupta25@jhmi.edu	Cardoso, Sandra W/D-7965-2015; Berendes, Sima/AAH-9616-2019	Cardoso, Sandra W/0000-0001-5230-0003; Berendes, Sima/0000-0001-7000-868X; Gupta, Amita/0000-0001-7036-2718	AIDS Clinical Trials Group; US National Institute of Allergy and Infectious Diseases [AI68636, AI069450]; US National Institutes of Health [R01 AI45462, T32 AI007291]; Boehringer-Ingelheim; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI069399, UM1AI069450, R01AI045462, UM1AI068636, U01AI069450, UM1AI069432, T32AI007291, UM1AI069463, U01AI068636] Funding Source: NIH RePORTER	AIDS Clinical Trials Group; US National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Boehringer-Ingelheim(Boehringer Ingelheim); Bristol-Myers Squibb(Bristol-Myers Squibb); Gilead Sciences(Gilead Sciences); GlaxoSmithKline(GlaxoSmithKline); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the AIDS Clinical Trials Group and was funded by the US National Institute of Allergy and Infectious Diseases [AI68636, AI069450] and by additional grants from the US National Institutes of Health [R01 AI45462 to AG and T32 AI007291 to FH]. This research was also supported in part by Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, and GlaxoSmithKline. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adeyemi OM, 2011, JAIDS-J ACQ IMM DEF, V57, P197, DOI 10.1097/QAI.0b013e31821ae418; Al Anouti F, 2011, DERM-ENDOCRINOL, V3, P235, DOI 10.4161/derm.3.4.16881; Allavena C, 2012, J ANTIMICROB CHEMOTH, V67, P2222, DOI 10.1093/jac/dks176; Bang UC, 2010, SCAND J INFECT DIS, V42, P306, DOI 10.3109/00365540903463981; Brown TT, 2010, ANTIVIR THER, V15, P425, DOI [10.3851/IMP1502, 10.3851/IMP15021]; Campbell T SL, 2011, EFFICACY SAFETY EFV; Cheng JB, 2004, P NATL ACAD SCI USA, V101, P7711, DOI 10.1073/pnas.0402490101; Childs K, 2011, AIDS; Dao CN, 2011, CLIN INFECT DIS, V52, P396, DOI 10.1093/cid/ciq158; Ferreira GB, 2011, DIABETES-METAB RES, V27, P933, DOI 10.1002/dmrr.1275; Fox J, 2011, AIDS RES HUM RETROV, V27, P29, DOI 10.1089/aid.2010.0081; Greene-Finestone LS, 2011, OSTEOPOROSIS INT, V22, P1389, DOI 10.1007/s00198-010-1362-7; HAUG C, 1994, J INFECT DIS, V169, P889, DOI 10.1093/infdis/169.4.889; Havers F SL, 2012, INSUFFICIENCY INDEPE; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Hollis BW, 2008, CURR OPIN ENDOCRINOL, V15, P489, DOI 10.1097/MED.0b013e328317ca6c; Khoo AL, 2011, IMMUNOLOGY, V134, P459, DOI 10.1111/j.1365-2567.2011.03507.x; Lai H, 2012, J INVEST MED, V60, P801, DOI 10.2310/JIM.0b013e318250bf99; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Mehta S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008770; Mehta S, 2009, J INFECT DIS, V200, P1022, DOI 10.1086/605699; Mueller NJ, 2010, AIDS, V24, P1127, DOI 10.1097/QAD.0b013e328337b161; Nansera D, 2011, INT J TUBERC LUNG D, V15, P1522, DOI 10.5588/ijtld.10.0701; Powe CE, 2013, NEW ENGL J MED, V369, P1991, DOI 10.1056/NEJMoa1306357; Van Den Bout-Van Den Beukel CJP, 2008, AIDS RES HUM RETROV, V24, P1375, DOI 10.1089/aid.2008.0058; Viard JP, 2011, AIDS, V25, P1305, DOI 10.1097/QAD.0b013e328347f6f7; von Essen MR, 2010, NAT IMMUNOL, V11, P344, DOI 10.1038/ni.1851; Wang TJ, 2010, LANCET, V376, P180, DOI 10.1016/S0140-6736(10)60588-0; Wasserman P, 2010, AIDS PATIENT CARE ST, V24, P223, DOI 10.1089/apc.2009.0241; Welz T, 2010, AIDS, V24, P1923, DOI 10.1097/QAD.0b013e32833c3281; Wiboonchutikul S, 2012, J INT ASS PHYS AIDS; Zhou CC, 2006, J CLIN INVEST, V116, P1703, DOI 10.1172/JCI27793; Zhu Y, 2005, EUR J IMMUNOL, V35, P217, DOI 10.1002/eji.200425491	33	20	22	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 21	2014	9	4							e95164	10.1371/journal.pone.0095164	http://dx.doi.org/10.1371/journal.pone.0095164			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG2DX	24752177	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000335227400038
J	Huysentruyt, K; Alliet, P; Raes, M; Willekens, J; De Schutter, I; De Wachter, E; Malfroot, A; Devreker, T; Goyens, P; Vandenplas, Y; De Schepper, J				Huysentruyt, Koen; Alliet, Philippe; Raes, Marc; Willekens, Julie; De Schutter, Iris; De Wachter, Elke; Malfroot, Anne; Devreker, Thierry; Goyens, Philippe; Vandenplas, Yvan; De Schepper, Jean			Nutritional Status of Children Hospitalized for Parapneumonic Effusion	PLOS ONE			English	Article							RISK-FACTORS; EMPYEMA; PNEUMONIA; MALNUTRITION; ADMISSIONS; MANAGEMENT; BACTERIAL; OUTCOMES	Background & Aims: Among children hospitalized for pneumonia, those with parapneumonic effusion (PPE) are at particular risk for nutritional deterioration. This study aimed to 1) investigate the evolution of the nutritional status during hospitalization and at outpatient follow-up; 2) determine clinical risk factors for weight loss during hospitalization; 3) describe the nutritional interventions for these children. Methods: Retrospective chart review (January `07 - September `12) of 56 children with pneumonia, complicated by PPE in two Belgian hospitals for data on body weight and height at admission (t(0)) and discharge (t(1)), and two weeks (t(2)) and one month (t(3)) after discharge. Length of hospitalization (LoS), length of stay in paediatric intensive care (LoS(PICU)) and maximal in-hospital weight loss (t(max)) were calculated and nutritional interventions were recorded. Results: The median (range) age was 3.5 (1.0-14.8) years. Weight or height was lacking in five (8.9%) children at t(0) and in 28 (50%) at t(1); 21.4% was weighed only once during hospitalization. At t(max), respectively 17/44 and 5/44 children lost >= 5% and >= 10% of their weight. Median (range) LoS and LoS(PICU) were 18.0 (10-41) and 4.0 (0-23) days. One-fourth received a nutritional intervention. Weight for height at admission (WFH(t(0))) significantly predicted maximal weight loss (beta (95% CI) = -0.34 (-2.0--0.1); p = 0.03). At t(2) and t(3), 13/32 and 5/22 of the children with available follow-up data did not reach WFH(t(0)), whilst in 4/35 and 5/26 body weight remained >= 5% under the weight(t(0)). Conclusions: One-third of children with pneumonia complicated by PPE and monitored for weight and height, lost >= 5% of their body weight during hospitalization. One-fourth did not reach initial WFH one month after discharge. Those with a higher WFH at admission were at higher risk of weight loss. More attention for monitoring of weight loss and the nutritional policy during and after hospitalization is warranted.	[Huysentruyt, Koen] VUB, Univ Ziekenhuis Brussel, Dept Paediat, Brussels, Belgium; [Alliet, Philippe; Raes, Marc] Jessa Hosp, Dept Paediat, Hasselt, Belgium; [Willekens, Julie; De Schutter, Iris; De Wachter, Elke; Malfroot, Anne] VUB, Univ Ziekenhuis Brussel, Cyst Fibrosis Clin & Paediat Infect Dis, Dept Paediat Pulmonol, Brussels, Belgium; [Devreker, Thierry; Vandenplas, Yvan] VUB, Univ Ziekenhuis Brussel, Dept Paediat Gastroenterol, Brussels, Belgium; [Goyens, Philippe] Univ Childrens Hosp Queen Fabiola, Dept Paediat, Nutr & Metab Unit, Brussels, Belgium; [De Schepper, Jean] VUB, Univ Ziekenhuis Brussel, Dept Paediat Endocrinol, Brussels, Belgium	University Hospital Brussels; Vrije Universiteit Brussel; University Hospital Brussels; Vrije Universiteit Brussel; University Hospital Brussels; Vrije Universiteit Brussel; University Hospital Brussels; Vrije Universiteit Brussel	De Schepper, J (corresponding author), VUB, Univ Ziekenhuis Brussel, Dept Paediat Endocrinol, Brussels, Belgium.	Jean.Deschepper@uzbrussel.be						Byington CL, 2002, CLIN INFECT DIS, V34, P434, DOI 10.1086/338460; Caksen H, 2003, J EMERG MED, V24, P474, DOI 10.1016/S0736-4679(03)00051-9; Chalmers JD, 2009, THORAX, V64, P592, DOI 10.1136/thx.2008.105080; Cirino Luís Marcelo Inaco, 2004, Sao Paulo Med. J., V122, P269, DOI 10.1590/S1516-31802004000600008; Clark JE, 2007, ARCH DIS CHILD, V92, P394, DOI 10.1136/adc.2006.097402; Cohen E, 2012, ARCH PEDIAT ADOL MED, V166, P999, DOI 10.1001/archpediatrics.2012.1055; Flood RG, 2008, PEDIATR INFECT DIS J, V27, P95, DOI 10.1097/INF.0b013e318157aced; Griffin MR, 2013, NEW ENGL J MED, V369, P155, DOI 10.1056/NEJMoa1209165; Grijalva CG, 2010, CLIN INFECT DIS, V50, P805, DOI 10.1086/650573; HARTMAN C, 2012, CLIN NUTR S, V7, P191; Huysentruyt K, 2013, ACTA PAEDIATR, V102, pE460, DOI 10.1111/apa.12344; Islam S, 2012, J PEDIATR SURG, V47, P2101, DOI 10.1016/j.jpedsurg.2012.07.047; Joosten KFM, 2008, CURR OPIN PEDIATR, V20, P590, DOI 10.1097/MOP.0b013e32830c6ede; Koshy E, 2010, THORAX, V65, P770, DOI 10.1136/thx.2010.137802; Nair H, 2013, LANCET, V381, P1380, DOI 10.1016/S0140-6736(12)61901-1; NWILOH J, 1989, J NATL MED ASSOC, V81, P525; O'Connor J, 2004, J PAEDIATR CHILD H, V40, P295, DOI 10.1111/j.1440-1754.2004.00367.x; Paraskakis E, 2012, CURR MED RES OPIN, V28, P1179, DOI 10.1185/03007995.2012.684674; Proesmans M, 2009, EUR J PEDIATR, V168, P639, DOI 10.1007/s00431-009-0929-9; Rocha Geila A., 2006, J. Pediatr. (Rio J.), V82, P70, DOI 10.2223/JPED.1440; Roelants M, 2009, ANN HUM BIOL, V36, P680, DOI 10.3109/03014460903049074; Sermet-Gaudelus I, 2000, AM J CLIN NUTR, V72, P64; Shouman B, 2012, EUR J PEDIATR, V171, P811, DOI 10.1007/s00431-011-1619-y; TAN TQ, 2002, PEDIATRICS, V110, pNIL81; van Wayenburg CAM, 2010, J PRIM HEALTH CARE, V2, P16, DOI 10.1071/HC10016; World Health Organization, 1999, MAN SEV MALN MAN PHY	26	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2014	9	4							e94242	10.1371/journal.pone.0094242	http://dx.doi.org/10.1371/journal.pone.0094242			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE6MJ	24705414	Green Published, Green Submitted, gold			2023-01-03	WOS:000334107500136
J	Tran, B; Falster, MO; Douglas, K; Blyth, F; Jorm, LR				Bich Tran; Falster, Michael O.; Douglas, Kirsty; Blyth, Fiona; Jorm, Louisa R.			Health Behaviours and Potentially Preventable Hospitalisation: A Prospective Study of Older Australian Adults	PLOS ONE			English	Article							ALL-CAUSE MORTALITY; CARE SENSITIVE CONDITIONS; LIFE-STYLE FACTORS; MEDITERRANEAN DIET; RISK-FACTORS; AVOIDABLE HOSPITALIZATION; ALCOHOL-CONSUMPTION; PROSPECTIVE COHORT; PHYSICAL-ACTIVITY; COMBINED IMPACT	Objective : Several Studies have demonstrated the effetcs of health behaviors on risk of chronic diseases and mortality , but none have investigated their contribution to potentially preventable hospitalisation (PPH). We aimed to quantify the effects on risk of PPH of six health behaviours: smoking; alcohol consumption; physical activity; fruit and vegetables consumption; sitting time; and sleeping time. Design/ Setting: Prospective observational study in New South Wales, Australia. Subjects: 267,006 men and women aged 45 years and over. Outcome Measures: PPH admissions and mortality during follow- up according to individual positive health behaviours ( non- smoking < 14 alcoholic drinks per week, >= 2.5 hours of physical activity per week, >= 2 servings of fruit and 5 servings of vegetables per day < 8 hours sitting and >= 7 hours sleeping per day) and the total number of these behaviours. Results: During an average of 3 years follow- up, 20971 ( 8%) participants had at least one PPH admission. After adjusting for potential confounders, participants who reported all six positive health behaviours at baseline had 46% lower risk of PPH admission ( 95% CI 0.48-0.61), compared to those who reported having only one of these behaviours. Based on these risk estimates, approximately 29% of PPH admissions in Australians aged 45 years and over were attributable to not adhering to the six health behaviours. Estimates were similar for acute, chronic and vaccine- preventable categories of PPH admissions. Conclusions: Individual and combined positive health behaviours were associated with lower risk of PPH admission. These findings suggest that there is a significant opportunity to reduce PPH by promoting healthy behaviours.	[Bich Tran; Falster, Michael O.; Jorm, Louisa R.] Univ Western Sydney, Sch Med, Ctr Hlth Res, Campbelltown, NSW, Australia; [Douglas, Kirsty] Australian Natl Univ, Canberra, ACT, Australia; [Blyth, Fiona] Sax Inst, Haymarket, NSW, Australia; [Blyth, Fiona] Univ Sydney, Concord Clin Sch, Sydney, NSW, Australia	Western Sydney University; Australian National University; University of Sydney; University of Sydney	Tran, B (corresponding author), Univ Western Sydney, Sch Med, Ctr Hlth Res, Campbelltown, NSW, Australia.	b.tran@uws.edu.au	Douglas, Kirsty/E-3083-2017; Jorm, Louisa/AAN-6874-2020; Falster, Michael/X-7118-2019	Douglas, Kirsty/0000-0003-0174-782X; Jorm, Louisa/0000-0003-0390-661X; Falster, Michael/0000-0001-6444-7272; Blyth, Fiona/0000-0003-1128-6756	National Health and Medical Research Council [1036858]; Australian Commission on Safety and Quality in Health Care; Agency for Clinical Innovation; NSW Bureau of Health Information	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian Commission on Safety and Quality in Health Care; Agency for Clinical Innovation; NSW Bureau of Health Information	The study was funded by a National Health and Medical Research Council Partnership Project Grant (#1036858) and by partner agencies the Australian Commission on Safety and Quality in Health Care, the Agency for Clinical Innovation and the NSW Bureau of Health Information. The funders play no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2012, NATIONAL HEALTHCARE; Ansari Z, 2007, AUST J PRIM HEALTH, V13, P91, DOI 10.1071/PY07043; Australian Government, 2005, PHYSICAL ACTIVITY GU; Australian Health Survey, 2011, AUSTRALIAN HEALTH SU; Australian Institute of Health and Welfare, 2004, RURAL REGIONAL AND R; Australian Institute of Health and Welfare, 2003, THE ACTIVE AUSTRALIA; Babitsch B, 2012, RE REVISITING ANDERS, V9, pDoc11; Banks E, 2008, INT J EPIDEMIOL, V37, P941, DOI 10.1093/ije/dym184; BINDMAN AB, 1995, JAMA-J AM MED ASSOC, V274, P305, DOI 10.1001/jama.274.4.305; Buckland G, 2008, OBES REV, V9, P582, DOI 10.1111/j.1467-789X.2008.00503.x; Calderon-Larranaga A, 2011, THORAX, V66, P191, DOI 10.1136/thx.2010.147058; Callaway LK, 2006, MED J AUSTRALIA, V184, P56, DOI 10.5694/j.1326-5377.2006.tb00115.x; Chiuve SE, 2008, CIRCULATION, V118, P947, DOI 10.1161/CIRCULATIONAHA.108.781062; Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB; Daly LE, 1998, AM J EPIDEMIOL, V147, P783; Ezzati M, 2003, LANCET, V362, P847, DOI 10.1016/S0140-6736(03)14338-3; Feldman C, 2013, J INFECTION, V67, P169, DOI 10.1016/j.jinf.2013.05.004; Ford ES, 2011, AM J PUBLIC HEALTH, V101, P1922, DOI [10.2105/AJPH.2011.300167, 10.2105//AJPH.2011.300167]; Forey BA, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-36; George ES, 2013, INT J BEHAV NUTR PHY, V10, DOI 10.1186/1479-5868-10-20; Hanley JA, 2001, J EPIDEMIOL COMMUN H, V55, P508, DOI 10.1136/jech.55.7.508; Hu FB, 2001, NEW ENGL J MED, V345, P790, DOI 10.1056/NEJMoa010492; Jackson G, 2001, AUST NZ J PUBL HEAL, V25, P212, DOI 10.1111/j.1467-842X.2001.tb00565.x; Jorm LR, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-002344; Katteri R, 2013, PHC RIS POLICY ISSUE; Khaw KT, 2008, PLOS MED, V5, P39, DOI 10.1371/journal.pmed.0050012; Knoops KTB, 2004, JAMA-J AM MED ASSOC, V292, P1433, DOI 10.1001/jama.292.12.1433; Korda RJ, 2013, INT J OBESITY, V37, P790, DOI 10.1038/ijo.2012.155; Kornum JB, 2010, EUR RESPIR J, V36, P1330, DOI 10.1183/09031936.00184209; Kubo A, 2009, GASTROENTEROLOGY, V136, P806, DOI 10.1053/j.gastro.2008.11.042; Kvaavik E, 2010, ARCH INTERN MED, V170, P711, DOI 10.1001/archinternmed.2010.76; Magee CA, 2013, SLEEP MED, V14, P591, DOI 10.1016/j.sleep.2013.02.002; Mealing NM, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-26; Muenchberger H, 2010, J PUBLIC HEALTH POL, V31, P150, DOI 10.1057/jphp.2010.3; National Health and Medical Research Council, 2013, AUSTRALIAN DIETARY G; National Health and Medical Research Council (NHMRC), 2009, AUSTRALIAN GUIDELINE; Niti M, 2003, J EPIDEMIOL COMMUN H, V57, P17, DOI 10.1136/jech.57.1.17; Northcote J, 2011, ALCOHOL ALCOHOLISM, V46, P709, DOI 10.1093/alcalc/agr138; Pavey TG, 2012, BRIT J SPORT MED, V0, P1, DOI DOI 10.1136/BJSP0RTS-2012-091676; Pelegrino NRG, 2013, AM J MED SCI, V345, P440, DOI 10.1097/MAJ.0b013e31825f32a7; POIKOLAINEN K, 1985, BRIT J ADDICT, V80, P215; Ponsonby AL, 1996, AUST NZ J PUBL HEAL, V20, P54, DOI 10.1111/j.1467-842X.1996.tb01336.x; Reid MC, 2003, AM J ADDICTION, V12, P211, DOI 10.1111/j.1521-0391.2003.tb00649.x; Roos LL, 2005, HEALTH SERV RES, V40, P1167, DOI 10.1111/j.1475-6773.2005.00407.x; Rosano A, 2013, EUR J PUBLIC HEALTH, V23, P356, DOI 10.1093/eurpub/cks053; Strasser B, 2013, ANN NY ACAD SCI, V1281, P141, DOI 10.1111/j.1749-6632.2012.06785.x; Thiebaut ACM, 2004, STAT MED, V23, P3803, DOI 10.1002/sim.2098; Thrift AP, 2011, AM J GASTROENTEROL, V106, P1220, DOI 10.1038/ajg.2011.89; Tomlin AM, 2008, DIABETES RES CLIN PR, V80, P244, DOI 10.1016/j.diabres.2007.12.017; van Dam RM, 2008, BRIT MED J, V337, pa1440, DOI [DOI 10.1136/BMJ.A1440, 10.1136/bmj.a1440]; van den Brandt PA, 2011, AM J CLIN NUTR, V94, P913, DOI 10.3945/ajcn.110.008250; van der Ploeg HP, 2012, ARCH INTERN MED, V172, P494, DOI 10.1001/archinternmed.2011.2174; Veugelers PJ, 2006, DIS ESOPHAGUS, V19, P321, DOI 10.1111/j.1442-2050.2006.00602.x; Vgontzas AN, 2010, SLEEP, V33, P1159, DOI 10.1093/sleep/33.9.1159; Zheng XY, 2012, CURR MED RES OPIN, V28, P1791, DOI 10.1185/03007995.2012.722991	55	16	17	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2014	9	4							e93111	10.1371/journal.pone.0093111	http://dx.doi.org/10.1371/journal.pone.0093111			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AE6KM	24691471	Green Published, Green Submitted, gold			2023-01-03	WOS:000334101100046
J	Catto, G; Cork, N; Williams, G				Catto, Graeme; Cork, Nick; Williams, Gareth			Should medical students be taught alternative medicine?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							COMPLEMENTARY; CAM		[Catto, Graeme] Guys Hosp, Coll Med, London SE1 9RT, England; [Cork, Nick] Univ Cambridge, Sch Clin Med, Cambridge CB2 0SP, England; [Williams, Gareth] Univ Bristol, Bristol BS8 1TH, Avon, England	Guy's & St Thomas' NHS Foundation Trust; University of Cambridge; University of Bristol	Catto, G (corresponding author), Guys Hosp, Coll Med, London SE1 9RT, England.	president@collegeofmedicine.org.uk; nicholascork@gmail.com						[Anonymous], 1989, HOM PHARM US MON; Chalmers I, 2003, ANN AM ACAD POLIT SS, V589, P22, DOI 10.1177/0002716203254762; College of Medicine, 2013, CONST COLL MED; Epel E, 2009, ANN NY ACAD SCI, V1172, P34, DOI 10.1111/j.1749-6632.2009.04414.x; Ernst E., 2011, EVID-BASED COMPL ALT, V2011, P3; Ernst E, 2011, BRIT J GEN PRACT, V61, P404, DOI 10.3399/bjgp11X578070; Flexner A., 1910, MEDICAL ED US CANADA; General Medical Council, 2009, TOM DOCT OUTC STAND; General Medical Council, 2009, TOMORROWS DOCTORS; Ho D., 2013, FOCUS ALTERNAT COMPL, V18, P176; Leggatt J, 2008, TELEGRAPH; Moses GM, 2010, AUST PRESCR, V33, P177; National Cancer Institute, 2013, COMPL ALT MED CANC T; National Institute for Clinical Excellence, 2006, PARK DIS DIAGN MAN P; National Institute for Health and Care Excellence (NICE, 2009, LOW BACK PAIN EARL M; NICE, 2008, ANT CAR NICE CLIN GU; Ornish D, 2013, LANCET ONCOL, V14, P1112, DOI 10.1016/S1470-2045(13)70366-8; Posadzki P, 2012, INT J CLIN PRACT, V66, P1178, DOI 10.1111/ijcp.12026; Posadzki P, 2013, CLIN MED, V13, P126, DOI 10.7861/clinmedicine.13-2-126; Posadzki P, 2013, BRIT J CLIN PHARMACO, V75, P603, DOI 10.1111/j.1365-2125.2012.04350.x; Roberts I, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3879; *SEL COMM SCI TECH, 2000, 6 SEL COMM SCI TECHN; Smith KR, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000074; The Royal London Hospital for Integrated Medicine, 2013, INT COMPL MED EV PRA	24	3	4	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 28	2014	348								g2417	10.1136/bmj.g2417	http://dx.doi.org/10.1136/bmj.g2417			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AD9MF	24682533				2023-01-03	WOS:000333588500005
J	Lohse, KR; Hilderman, CGE; Cheung, KL; Tatla, S; Van der Loos, HFM				Lohse, Keith R.; Hilderman, Courtney G. E.; Cheung, Katharine L.; Tatla, Sandy; Van der Loos, H. F. Machiel			Virtual Reality Therapy for Adults Post-Stroke: A Systematic Review and Meta-Analysis Exploring Virtual Environments and Commercial Games in Therapy	PLOS ONE			English	Review							RANDOMIZED CLINICAL-TRIAL; CHRONIC STROKE; MOTOR RECOVERY; MOVEMENT REPRESENTATIONS; UPPER EXTREMITIES; IMPROVE BALANCE; DOUBLE-BLIND; UPPER-LIMB; REHABILITATION; INDIVIDUALS	Background: The objective of this analysis was to systematically review the evidence for virtual reality (VR) therapy in an adult post-stroke population in both custom built virtual environments (VE) and commercially available gaming systems (CG). Methods: MEDLINE, CINAHL, EMBASE, ERIC, PSYCInfo, DARE, PEDro, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews were systematically searched from the earliest available date until April 4, 2013. Controlled trials that compared VR to conventional therapy were included. Population criteria included adults (>18) post-stroke, excluding children, cerebral palsy, and other neurological disorders. Included studies were reported in English. Quality of studies was assessed with the Physiotherapy Evidence Database Scale (PEDro). Results: Twenty-six studies met the inclusion criteria. For body function outcomes, there was a significant benefit of VR therapy compared to conventional therapy controls, G = 0.48, 95% CI = [ 0.27, 0.70], and no significant difference between VE and CG interventions (P = 0.38). For activity outcomes, there was a significant benefit of VR therapy, G = 0.58, 95% CI = [ 0.32, 0.85], and no significant difference between VE and CG interventions (P = 0.66). For participation outcomes, the overall effect size was G = 0.56, 95% CI = [ 0.02, 1.10]. All participation outcomes came from VE studies. Discussion: VR rehabilitation moderately improves outcomes compared to conventional therapy in adults post-stroke. Current CG interventions have been too few and too small to assess potential benefits of CG. Future research in this area should aim to clearly define conventional therapy, report on participation measures, consider motivational components of therapy, and investigate commercially available systems in larger RCTs.	[Lohse, Keith R.] Auburn Univ, Sch Kinesiol, Auburn, AL 36849 USA; [Lohse, Keith R.] Univ British Columbia, Sch Kinesiol, Vancouver, BC V5Z 1M9, Canada; [Hilderman, Courtney G. E.; Cheung, Katharine L.] Univ British Columbia, Dept Phys Therapy, Vancouver, BC V5Z 1M9, Canada; [Tatla, Sandy] Univ British Columbia, Dept Occupat Sci & Occupat Therapy, Vancouver, BC V5Z 1M9, Canada; [Van der Loos, H. F. Machiel] Univ British Columbia, Dept Mech Engn, Vancouver, BC V6T 1W5, Canada	Auburn University System; Auburn University; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia	Lohse, KR (corresponding author), Auburn Univ, Sch Kinesiol, Auburn, AL 36849 USA.	kelopelli@gmail.com	Tatla, Sandy/V-6805-2019	Lohse, Keith/0000-0002-7643-3887; Tatla, Sandy/0000-0001-5708-2666; Van der Loos, H.F. Machiel/0000-0003-1355-980X; Hilderman, Courtney G E/0000-0003-0209-4939	Peter Wall Solutions Initiative at the University of British Columbia [11-079]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007357, K24DK085446] Funding Source: NIH RePORTER	Peter Wall Solutions Initiative at the University of British Columbia; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This research was funded by #11-079 from the Peter Wall Solutions Initiative at the University of British Columbia awarded to H. F. M. Van der Loos. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adamovich SV, 2009, NEUROREHABILITATION, V25, P29, DOI 10.3233/NRE-2009-0497; Agmon M, 2011, J GERIATR PHYS THER, V34, P161, DOI 10.1519/JPT.0b013e3182191d98; Bailey BW, 2001, ARCH PEDIAT ADOLESC, V165, P597; Borenstein M., 2011, INTRO METAANALYSIS, P450; Broeren J, 2008, CEREBROVASC DIS, V26, P289, DOI 10.1159/000149576; Burke JW, 2009, VISUAL COMPUT, V25, P1085, DOI 10.1007/s00371-009-0387-4; Cho KH, 2013, AM J PHYS MED REHAB, V92, P371, DOI 10.1097/PHM.0b013e31828cd5d3; Cikajlo I, 2012, DISABIL REHABIL, V34, P13, DOI 10.3109/09638288.2011.583308; Crosbie JH, 2012, CLIN REHABIL, V26, P798, DOI 10.1177/0269215511434575; Crosbie J.H., 2008, SCREEN, V229, P235; Cameirao MDS, 2011, RESTOR NEUROL NEUROS, V29, P287, DOI 10.3233/RNN-2011-0599; Deutsch JE, 2004, RESTOR NEUROL NEUROS, V22, P371; Deutsch JE, 2011, TOP STROKE REHABIL, V18, P701, DOI 10.1310/tsr1806-701; Flaghouse. ca, GEST TEK IREX SYST; Foley Norine C, 2003, Top Stroke Rehabil, V10, P1; Gil-Gomez JA, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-30; Harding J, 2009, CAN J OCCUP THER, V76, P133, DOI 10.1177/000841740907600302; Henderson A, 2007, TOP STROKE REHABIL, V14, P52, DOI 10.1310/tsr1402-52; Housman SJ, 2009, NEUROREHAB NEURAL RE, V23, P505, DOI 10.1177/1545968308331148; In TS, 2012, J PHYS THER SCI, V24, P339, DOI 10.1589/jpts.24.339; Jo K, 2012, J PHYS THER SCI, V24, P1205; Jung J, 2012, J PHYS THER SCI, V24, P1133, DOI 10.1589/jpts.24.1133; Katz N, 2005, DISABIL REHABIL, V27, P1235, DOI 10.1080/09638280500076079; Kim EK, 2012, J PHYS THER SCI, V24, P901, DOI 10.1589/jpts.24.901; Kim JH, 2009, AM J PHYS MED REHAB, V88, P693, DOI 10.1097/PHM.0b013e3181b33350; Kiper P, 2011, NEUROL NEUROCHIR POL, V45, P436; Kwakkel G, 2006, DISABIL REHABIL, V28, P823, DOI 10.1080/09638280500534861; Kwon JS, 2012, NEUROREHABILITATION, V31, P379, DOI 10.3233/NRE-2012-00807; Lam YS, 2006, NEUROREHABILITATION, V21, P245; Lang CE, 2009, ARCH PHYS MED REHAB, V90, P1692, DOI 10.1016/j.apmr.2009.04.005; Langhorne P, 2009, LANCET NEUROL, V8, P741, DOI 10.1016/S1474-4422(09)70150-4; Laver KE, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008349.pub2, 10.1002/14651858.CD008349.pub3, 10.1002/14651858.CD008349.pub4]; Lohse K, 2013, J NEUROL PHYS THER, V37, P166, DOI 10.1097/NPT.0000000000000017; Majnemer A, 2008, DEV MED CHILD NEUROL, V50, P751, DOI 10.1111/j.1469-8749.2008.03068.x; Mang CS, 2013, PHYS THER; Mirelman A, 2010, GAIT POSTURE, V31, P433, DOI 10.1016/j.gaitpost.2010.01.016; Mirelman A, 2009, STROKE, V40, P169, DOI 10.1161/STROKEAHA.108.516328; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Nichols-Larsen DS, 2005, STROKE, V36, P1480, DOI 10.1161/01.STR.0000170706.13595.4f; Nintendo Co. Ltd, CONS SAL TRANS REG; Nudo RJ, 1996, J NEUROPHYSIOL, V75, P2144, DOI 10.1152/jn.1996.75.5.2144; Patton J, 2006, ASSIST TECHNOL, V18, P181, DOI 10.1080/10400435.2006.10131917; Piron L, 2007, VIRTUAL REHABILITATI, P121; Piron L, 2010, NEUROREHAB NEURAL RE, V24, P501, DOI 10.1177/1545968310362672; Piron L, 2009, J REHABIL MED, V41, P1016, DOI 10.2340/16501977-0459; Plautz EJ, 2000, NEUROBIOL LEARN MEM, V74, P27, DOI 10.1006/nlme.1999.3934; Saposnik G, 2011, STROKE, V42, P1380, DOI 10.1161/STROKEAHA.110.605451; Saposnik G, 2010, STROKE, V41, P1477, DOI 10.1161/STROKEAHA.110.584979; Shirzad N, 2012, P ANN INT C IEEE ENG; Subramanian SK, 2013, NEUROREHAB NEURAL RE, V27, P13, DOI 10.1177/1545968312449695; Sullivan KJ, 2011, PHYS THER, V91, P1892, DOI 10.2522/ptj.20110003; Taylor MJD, 2011, J REHABIL RES DEV, V48, P1171, DOI 10.1682/JRRD.2010.09.0171; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; World Health Organization, 2002, COMM LANG FUNCT DIS; Yang SW, 2011, AM J PHYS MED REHAB, V90, P969, DOI 10.1097/PHM.0b013e3182389fae; Yang YR, 2008, GAIT POSTURE, V28, P201, DOI 10.1016/j.gaitpost.2007.11.007; Yavuzer G, 2008, EUR J PHYS REHAB MED, V44, P237; You SH, 2005, STROKE, V36, P1166, DOI 10.1161/01.STR.0000162715.43417.91	58	250	258	4	101	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2014	9	3							e93318	10.1371/journal.pone.0093318	http://dx.doi.org/10.1371/journal.pone.0093318			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AE0TC	24681826	Green Published, gold, Green Submitted			2023-01-03	WOS:000333678100041
J	Zhang, JB; An, M; Wu, HW; Liu, DL; Stanton, R				Zhang, Jinbiao; An, Min; Wu, Hanwen; Liu, De Li; Stanton, Rex			Phytotoxic Activity and Chemical Composition of Aqueous Volatile Fractions from Eucalyptus Species	PLOS ONE			English	Article							ESSENTIAL OIL; MONOTERPENES	The essential oils from four Eucalyptus species (E. spathulata, E. salubris, E. brockwayii and E. dundasii) have been previously confirmed to have stronger inhibitory effects on germination and seedling growth of silverleaf nightshade (Solanum elaeagnifolium Cav.). The aqueous volatile fractions (AVFs) were the water soluble volatile fractions produced together with the essential oils (water insoluble fractions) during the steam distillation process. The aim of this study was to further assess the phytotoxicity of AVFs from the four Eucalyptus species and their chemical composition. The fresh leaves of the four Eucalyptus species were used for the extraction of AVFs. The AVFs were tested for their phytotoxic effects on the perennial weed, silverleaf nightshade under laboratory conditions. The chemical compositions of the AVFs were determined by gas chromatograph-mass spectrometry (GC-MS). Our results showed that the AVFs had strong inhibition on the germination and seedling growth of silverleaf nightshade. The inhibition index increased with the increasing concentrations of AVFs. The inhibitory effects of the AVFs varied between different Eucalyptus species. The AVF from E. salubris demonstrated the highest inhibitory activity on the weed tested, with complete inhibition on germination and seedling growth at a concentration of 75%. The GC-MS analysis revealed that 1,8-cineole, isopentyl isovalerate, isomenthol, pinocarvone, trans-pinocarveol, alpha-terpineol and globulol were the main compounds in the AVFs. These results indicated that all AVFs tested had differential inhibition on the germination and seedling growth of silverleaf nightshade, which could be due to the joint effects of compounds present in the AVFs as these compounds were present in different quantities and ratio between Eucalyptus species.	[Zhang, Jinbiao] Fujian Agr & Forestry Univ, Minist Educ, Key Lab Biopesticide & Chem Biol, Fuzhou, Peoples R China; [Zhang, Jinbiao] Fujian Agr & Forestry Univ, Sch Life Sci, Fuzhou, Peoples R China; [An, Min] Charles Sturt Univ, Fac Sci, Environm & Analyt Labs, Wagga Wagga, NSW, Australia; [Wu, Hanwen; Liu, De Li; Stanton, Rex] Wagga Wagga Agr Inst, EH Graham Ctr Agr Innovat, Wagga Wagga, NSW, Australia	Fujian Agriculture & Forestry University; Fujian Agriculture & Forestry University; Charles Sturt University	Zhang, JB (corresponding author), Fujian Agr & Forestry Univ, Minist Educ, Key Lab Biopesticide & Chem Biol, Fuzhou, Peoples R China.	jbzhangfj@yahoo.com	, De Li Liu/Y-4656-2019; Wu, Hanwen/B-7901-2010	Wu, Hanwen/0000-0001-5157-4977; Liu, De Li/0000-0003-2574-1908	Meat and Livestock of Australia	Meat and Livestock of Australia	This work was supported by Meat and Livestock of Australia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams R. P, 1995, IDENTIFICATION ESSEN; An Min, 2005, Nonlinearity in Biology Toxicology and Medicine, V3, P245, DOI 10.2201/nonlin.003.02.006; Anonymous, 2007, Bulletin OEPP, V37, P236, DOI 10.1111/j.1365-2338.2007.01112.x; AWC (Australian Weeds Committee), 2012, WEEDS NAT SIGN; Babu RC, 1997, J AGRON CROP SCI, V179, P123, DOI 10.1111/j.1439-037X.1997.tb00507.x; Batish DR, 2006, Z NATURFORSCH C, V61, P52; Baum SF, 1998, J PLANT GROWTH REGUL, V17, P107, DOI 10.1007/PL00007015; Cuevas-Glory LF, 2007, FOOD CHEM, V103, P1032, DOI 10.1016/j.foodchem.2006.07.068; DELMORAL R, 1978, AUST J BOT, V26, P203; Deng CH, 2004, J CHROMATOGR A, V1059, P149, DOI 10.1016/j.chroma.2004.10.005; Kaur S, 2011, J PLANT INTERACT, V6, P297, DOI 10.1080/17429145.2010.539709; Khan M. A., 2008, Pakistan Journal of Weed Science Research, V14, P201; Li XF, 2011, PLANT SOIL, V341, P383, DOI 10.1007/s11104-010-0652-3; Liu DL, 2007, ALLELOPATHY J, V19, P203; Martins C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061233; Romagni JG, 2000, J CHEM ECOL, V26, P303, DOI 10.1023/A:1005414216848; Setia N, 2007, J ENVIRON BIOL, V28, P63; Singh HP, 2005, ANN APPL BIOL, V146, P89, DOI 10.1111/j.1744-7348.2005.04018.x; Singh HP, 2002, CROP PROT, V21, P347, DOI 10.1016/S0261-2194(01)00096-5; Stanton R, 2008, P 16 AUSTR WEEDS C C, P330; Stanton R, 2012, WEED SCI, V60, P42, DOI 10.1614/WS-D-11-00105.1; USDA-NRCS, 2005, PLANTS DAT VERS 35; Van Vuuren SF, 2007, FLAVOUR FRAG J, V22, P540, DOI 10.1002/ffj.1843; VAUGHN SF, 1993, WEED SCI, V41, P114, DOI 10.1017/S0043174500057672; Wu H, 1999, WEED RES, V39, P171, DOI 10.1046/j.1365-3180.1999.00136.x; Wu HW, 2011, ALLELOPATHY J, V28, P87; Zhang JB, 2012, PLANT GROWTH REGUL, V68, P231, DOI 10.1007/s10725-012-9711-5; Zhang JB, 2010, ALLELOPATHY J, V25, P313	28	30	32	1	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2014	9	3							e93189	10.1371/journal.pone.0093189	http://dx.doi.org/10.1371/journal.pone.0093189			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE0TC	24681490	Green Submitted, Green Published, gold			2023-01-03	WOS:000333678100031
J	Plischke, M; Kohl, M; Bankir, L; Shayganfar, S; Handisurya, A; Heinze, G; Haas, M				Plischke, Max; Kohl, Maria; Bankir, Lise; Shayganfar, Sascha; Handisurya, Ammon; Heinze, Georg; Haas, Martin			Urine Osmolarity and Risk of Dialysis Initiation in a Chronic Kidney Disease Cohort - a Possible Titration Target?	PLOS ONE			English	Article							CHRONIC-RENAL-FAILURE; WATER-INTAKE; RECEPTOR ANTAGONISM; ANTIDIURETIC ACTION; COMPETING RISK; VASOPRESSIN; RATS; PROGRESSION; VOLUME; PROTEIN	Background: Increasing evidence is linking fluid intake, vasopressin suppression and osmotic control with chronic kidney disease progression. Interestingly, the association between urine volume, urine osmolarity and risk of dialysis initiation has not been studied in chronic kidney disease patients before. Objective: To study the relationship between urine volume, urine osmolarity and the risk of initiating dialysis in chronic kidney disease. Design: In a retrospective cohort analysis of 273 patients with chronic kidney disease stage 1-4 we assessed the association between urine volume, urine osmolarity and the risk of dialysis by a multivariate proportional sub-distribution hazards model for competing risk data according to Fine and Gray. Co-variables were selected via the purposeful selection algorithm. Results: Dialysis was reached in 105 patients over a median follow-up period of 92 months. After adjustment for age, baseline creatinine clearance, other risk factors and diuretics, a higher risk for initiation of dialysis was found in patients with higher urine osmolarity. The adjusted sub-distribution hazard ratio for initiation of dialysis was 2.04 ( 95% confidence interval, 1.06 to 3.92) for each doubling of urine osmolarity. After 72 months, the estimated adjusted cumulative incidence probabilities of dialysis were 15%, 24%, and 34% in patients with a baseline urine osmolarity of 315, 510, and 775 mosm/ L, respectively. Conclusions: We conclude that higher urine osmolarity is associated with a higher risk of initiating dialysis. As urine osmolarity is a potentially modifiable risk factor, it thus deserves further, prospective research as a potential target in chronic kidney disease progression.	[Plischke, Max; Handisurya, Ammon; Haas, Martin] Med Univ Vienna, Dept Internal Med 3, Div Nephrol & Dialysis, Vienna, Austria; [Kohl, Maria; Heinze, Georg] Med Univ Vienna, Sect Clin Biometr, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria; [Bankir, Lise] Ctr Rech Cordeliers, INSERM UMRS 1138, Equipe 2, Paris, France; [Shayganfar, Sascha] Univ Hosp Dusseldorf, Fac Med, Div Cardiol Pulmonol & Vasc Med, Dusseldorf, Germany	Medical University of Vienna; Medical University of Vienna; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital	Haas, M (corresponding author), Med Univ Vienna, Dept Internal Med 3, Div Nephrol & Dialysis, Vienna, Austria.	martin.haas@meduniwien.ac.at	BANKIR, Lise/AAK-2733-2020	BANKIR, Lise/0000-0002-3321-0819; Heinze, Georg/0000-0003-1147-8491; Plischke, Max/0000-0002-7410-2611	European Community [241544]	European Community(European Commission)	Maria Kohl (statistician) was supported by the European Community's Seventh Framework Programme, grant number 241544. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Maria Kohl was involved in study design, analysis, and preparation of the manuscript. Mortality data, obtained via Statistics Austria, was payed for using the authors' departments (Department of Internal Med. III, Division of Nephrology and Dialysis, Medical University Vienna) research budget, which is not tied to any external funding institution. As this was a retrospective study, other expenses (laboratory, etc) were fully covered by routine patient care at the authors' outpatient department.	Anastasio P, 2001, KIDNEY INT, V60, P748, DOI 10.1046/j.1523-1755.2001.060002748.x; Bankir L, 2001, CARDIOVASC RES, V51, P372, DOI 10.1016/S0008-6363(01)00328-5; BANKIR L, 1991, AM J KIDNEY DIS, V17, P661, DOI 10.1016/S0272-6386(12)80346-5; Bankir L, 2013, NAT REV NEPHROL, V9, P223, DOI 10.1038/nrneph.2013.22; Bardoux P, 2003, NEPHROL DIAL TRANSPL, V18, P1755, DOI 10.1093/ndt/gfg277; Bouby N, 1996, J AM SOC NEPHROL, V7, P842; Bouby N, 2003, EUR J CLIN NUTR, V57, pS39, DOI 10.1038/sj.ejcn.1601900; BOUBY N, 1990, AM J PHYSIOL, V258, pF973, DOI 10.1152/ajprenal.1990.258.4.F973; Clark WF, 2011, CLIN J AM SOC NEPHRO, V6, P2634, DOI 10.2215/CJN.01990211; FEINFELD DA, 1987, AM J KIDNEY DIS, V10, P231, DOI 10.1016/S0272-6386(87)80179-8; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; GELLAI M, 1984, AM J PHYSIOL, V246, pF819, DOI 10.1152/ajprenal.1984.246.6.F819; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Hebert LA, 2003, AM J KIDNEY DIS, V41, P962, DOI 10.1016/S0272-6386(03)00193-8; Hosmer D. W., 2008, APPL SURVIVAL ANAL R; LUFT FC, 1983, J LAB CLIN MED, V101, P605; Meijer E, 2010, KIDNEY INT, V77, P29, DOI 10.1038/ki.2009.397; Meijer E, 2009, TRANSPLANTATION, V88, P561, DOI 10.1097/TP.0b013e3181b11ae4; Nagao S, 2006, J AM SOC NEPHROL, V17, P2220, DOI 10.1681/ASN.2006030251; Perico N, 2009, KIDNEY INT, V76, P960, DOI 10.1038/ki.2009.267; Perucca J, 2007, AM J PHYSIOL-REG I, V292, pR700, DOI 10.1152/ajpregu.00500.2006; ROYSTON P, 1994, J R STAT SOC C-APPL, V43, P429, DOI 10.2307/2986270; Strippoli GFM, 2011, NEPHROLOGY, V16, P326, DOI 10.1111/j.1440-1797.2010.01415.x; Sugiura T, 1999, KIDNEY INT, V55, P1800, DOI 10.1046/j.1523-1755.1999.00443.x; Thomas MC, 2011, DIABETES CARE, V34, P861, DOI 10.2337/dc10-1722; Torres VE, 2011, CLIN J AM SOC NEPHRO, V6, P640, DOI 10.2215/CJN.03250410; Wang CJ, 2013, KIDNEY INT, V84, P45, DOI 10.1038/ki.2013.23; Wang CJ, 2011, CLIN J AM SOC NEPHRO, V6, P192, DOI 10.2215/CJN.03950510; Wang XL, 2006, J AM SOC NEPHROL, V17, P2900, DOI 10.1681/ASN.2005101106	29	23	24	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 27	2014	9	3							e93226	10.1371/journal.pone.0093226	http://dx.doi.org/10.1371/journal.pone.0093226			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE0SW	24675963	Green Published, Green Submitted, gold			2023-01-03	WOS:000333677500094
J	Marcus, JL; Glidden, DV; McMahan, V; Lama, JR; Mayer, KH; Liu, AY; Montoya-Herrera, O; Casapia, M; Hoagland, B; Grant, RM				Marcus, Julia L.; Glidden, David V.; McMahan, Vanessa; Lama, Javier R.; Mayer, Kenneth H.; Liu, Albert Y.; Montoya-Herrera, Orlando; Casapia, Martin; Hoagland, Brenda; Grant, Robert M.			Daily Oral Emtricitabine/Tenofovir Preexposure Prophylaxis and Herpes Simplex Virus Type 2 among Men Who Have Sex with Men	PLOS ONE			English	Article							HIGH-RISK; HIV; INFECTION; PREVALENCE; TENOFOVIR; WOMEN; ACQUISITION; ACYCLOVIR	Background: In addition to protecting against HIV acquisition, antiretroviral preexposure prophylaxis (PrEP) using topical 1% tenofovir gel reduced Herpes simplex virus type 2 (HSV-2) acquisition by 51% among women in the CAPRISA 004 study. We examined the effect of daily oral emtricitabine/tenofovir (FTC/TDF) PrEP on HSV-2 seroincidence and ulcer occurrence among men who have sex with men (MSM) in the iPrEx trial. Methods: HSV-2 serum testing was performed at screening and every six months. Among HSV-2-seronegative individuals, we used Cox regression models to estimate hazard ratios (HRs) of HSV-2 seroincidence associated with randomization to FTC/TDF. We used multiple imputation and Cox regression to estimate HRs for HSV-2 seroincidence accounting for drug exposure. We assessed ulcer occurrence among participants with prevalent or incident HSV-2 infection. Results: Of the 2,499 participants, 1383 (55.3%) tested HSV-2-seronegative at baseline, 892 (35.7%) tested positive, 223 (8.9%) had indeterminate tests, and one test was not done. Of the 1,347 HSV-2-seronegative participants with follow-up, 125 (9.3%) had incident HSV-2 infection (5.9 per 100 person-years). Compared with participants receiving placebo, there was no difference in HSV-2 seroincidence among participants receiving FTC/TDF (HR 1.1, 95% CI: 0.8-1.5; P = 0.64) or among participants receiving FTC/TDF with a concentration of tenofovir diphosphate >16 per million viable cells (HR 1.0, 95% CI: 0.3-3.5; P = 0.95). Among participants with HSV-2 infection, the proportion with >= 1 moderate or severe ulcer adverse event was twice as high in the placebo vs. active arm (5.9% vs. 2.9%, P = 0.02), but there were no differences in the proportions with >= 1 clinical examination during which perianal or groin ulcers were identified. Conclusions: Tenofovir in daily oral FTC/TDF PrEP may reduce the occurrence of ulcers in individuals with HSV-2 infection but does not protect against HSV-2 incidence among MSM.	[Marcus, Julia L.; McMahan, Vanessa; Grant, Robert M.] Gladstone Inst Virol & Immunol, San Francisco, CA USA; [Marcus, Julia L.] Univ Calif Berkeley, Berkeley, CA 94720 USA; [Glidden, David V.; Grant, Robert M.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Lama, Javier R.] Asociac Civil Impacta Salud & Educ, Lima, Peru; [Mayer, Kenneth H.] Fenway Hlth, Fenway Inst, Boston, MA USA; [Mayer, Kenneth H.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Liu, Albert Y.] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA; [Montoya-Herrera, Orlando] Fdn Ecuatoriana Equidad, Guayaquil, Guayas, Ecuador; [Casapia, Martin] Asociac Civil Selva Amazon, Iquitos, Peru; [Hoagland, Brenda] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California Berkeley; University of California System; University of California San Francisco; Fenway Health; Harvard University; Beth Israel Deaconess Medical Center; San Francisco Department of Public Health; Fundacao Oswaldo Cruz	Grant, RM (corresponding author), Gladstone Inst Virol & Immunol, San Francisco, CA USA.	robert.grant@ucsf.edu	Glidden, David/AAD-4730-2020	Casapia Morales, Wilfredo Martin/0000-0002-5972-0948; Glidden, David/0000-0001-5888-1419; Grant, Robert/0000-0002-0851-7085	Division of Acquired Immunodeficiency Syndrome, National Institute of Allergy and Infectious Diseases, National Institutes of Health [UO1 AI64002]; Bill and Melinda Gates Foundation; Gladstone Institutes; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI064002, P30AI027763] Funding Source: NIH RePORTER	Division of Acquired Immunodeficiency Syndrome, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Gladstone Institutes(University of California System); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by the Division of Acquired Immunodeficiency Syndrome, National Institute of Allergy and Infectious Diseases, National Institutes of Health, as a cooperative agreement (UO1 AI64002, to Dr. Grant), by the Bill and Melinda Gates Foundation, and by the Gladstone Institutes. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006; Andrei G, 2011, CELL HOST MICROBE, V10, P379, DOI 10.1016/j.chom.2011.08.015; Boily MC, 2011, 18 C RETR OPP INF BO; Celum C, 2010, NEW ENGL J MED, V362, P427, DOI 10.1056/NEJMoa0904849; Celum C, 2013, 20 C RETR OPP INF AT; Celum C, 2008, LANCET, V371, P2109, DOI 10.1016/S0140-6736(08)60920-4; Freeman EE, 2006, AIDS, V20, P73, DOI 10.1097/01.aids.0000198081.09337.a7; Golden MR, 2005, SEX TRANSM DIS, V32, P771, DOI 10.1097/01.olq.0000175377.88358.f3; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Gupta R, 2007, LANCET, V370, P2127, DOI 10.1016/S0140-6736(07)61908-4; Hendrix CW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055013; Hendrix CW, 2012, CURR OPIN HIV AIDS, V7, P498, DOI 10.1097/COH.0b013e32835847ae; Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748; LeGoff J, 2008, J CLIN MICROBIOL, V46, P1914, DOI 10.1128/JCM.02332-07; Looker KJ, 2008, B WORLD HEALTH ORGAN, V86, P805, DOI 10.2471/BLT.07.046128; Lupi O, 2011, INT J DERMATOL, V50, P709, DOI 10.1111/j.1365-4632.2010.04863.x; Okuku HS, 2011, SEX TRANSM DIS, V38, P837, DOI 10.1097/OLQ.0b013e31821a6225; Patterson KB, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003174; Paz-Bailey G, 2007, SEX TRANSM INFECT, V83, P16, DOI 10.1136/sti.2006.020966; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Tan DHS, 2012, INT J WOMENS HEALTH, V4, P341, DOI 10.2147/IJWH.S27601; Tan DHS, 2011, AIDS, V25, P207, DOI 10.1097/QAD.0b013e328341ddf7; van de Laar MJW, 1998, INT J EPIDEMIOL, V27, P127, DOI 10.1093/ije/27.1.127; Wald A, 2002, J INFECT DIS, V185, P45, DOI 10.1086/338231; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; Xu F., 2010, Morbidity and Mortality Weekly Report, V59, P456	26	23	23	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 17	2014	9	3							e91513	10.1371/journal.pone.0091513	http://dx.doi.org/10.1371/journal.pone.0091513			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AD4XD	24637511	gold, Green Published, Green Submitted			2023-01-03	WOS:000333254100039
J	Pierobon, M; Wulfkuhle, J; Liotta, L; Petricoin, E				Pierobon, M.; Wulfkuhle, J.; Liotta, L.; Petricoin, E.			Application of molecular technologies for phosphoproteomic analysis of clinical samples	ONCOGENE			English	Review							PHASE PROTEIN MICROARRAYS; HUMAN BREAST-CANCER; LASER CAPTURE MICRODISSECTION; FLOW-CYTOMETRY; TISSUE; TRIAL; PHOSPHORYLATION; PROTEOMICS; INHIBITOR; PATHWAY	The integration of small kinase inhibitors and monoclonal antibodies into oncological practice has opened a new paradigm for treating cancer patients. As proteins are the direct targets of the new generations of targeted therapeutics, many of which are kinase/enzymatic inhibitors, there is an increasing interest in developing technologies capable of monitoring post-translational changes of the human proteome for the identification of new predictive, prognostic and therapeutic biomarkers. It is well known that the vast majority of the activation/deactivation of these drug targets is driven by phosphorylation. This review provides a description of the main proteomic platforms (planar and bead array, reverse phase protein microarray, phosphoflow, AQUA and mass spectrometry) that have successfully been used for measuring changes in phosphorylation level of drug targets and downstream substrates using clinical specimens. Major emphasis was given to the strengths and weaknesses of the different platforms and to the major barriers that are associated with the analysis of the phosphoproteome. Finally, a number of examples of application of the above-mentioned technologies in the clinical setting are reported.	[Pierobon, M.; Wulfkuhle, J.; Liotta, L.; Petricoin, E.] George Mason Univ, Ctr Appl Prote & Mol Med, Manassas, VA 20110 USA	George Mason University	Petricoin, E (corresponding author), George Mason Univ, Ctr Appl Prote & Mol Med, 10900 Univ Blvd,Bull Run Hall,Room 324, Manassas, VA 20110 USA.	epetrico@gmu.edu	Pierobon, Mariaelena/GXA-0544-2022					Angevin E, 2013, CLIN CANCER RES, V19, P1257, DOI 10.1158/1078-0432.CCR-12-2885; Arends JW, 2000, J PATHOL, V190, P412; Balboni I, 2006, ANNU REV IMMUNOL, V24, P391, DOI 10.1146/annurev.immunol.24.021605.090709; Bantscheff M, 2007, NAT BIOTECHNOL, V25, P1035, DOI 10.1038/nbt1328; Barker AD, 2009, CLIN PHARMACOL THER, V86, P97, DOI 10.1038/clpt.2009.68; Baselga J, 2010, CLIN CANCER RES, V16, P4876, DOI 10.1158/1078-0432.CCR-10-0748; Braeckmans K, 2002, NAT REV DRUG DISCOV, V1, P447, DOI 10.1038/nrd817; Breen EC, 2011, CLIN VACCINE IMMUNOL, V18, P1229, DOI 10.1128/CVI.05032-11; Brennan DJ, 2010, NAT REV CANCER, V10, P605, DOI 10.1038/nrc2902; Camp RL, 2002, NAT MED, V8, P1323, DOI 10.1038/nm791; Camp RL, 2008, J CLIN ONCOL, V26, P5630, DOI 10.1200/JCO.2008.17.3567; Carbone M, 2004, SEMIN CANCER BIOL, V14, P399, DOI 10.1016/j.semcancer.2004.06.002; Chen L, 2011, ELECTROPHORESIS, V32, P1984, DOI 10.1002/elps.201100101; Chowdhury F, 2009, J IMMUNOL METHODS, V340, P55, DOI 10.1016/j.jim.2008.10.002; Dabitao D, 2011, J IMMUNOL METHODS, V372, P71, DOI 10.1016/j.jim.2011.06.033; Dahut WL, 2008, CLIN CANCER RES, V14, P209, DOI 10.1158/1078-0432.CCR-07-1355; Daub H, 2008, MOL CELL, V31, P438, DOI 10.1016/j.molcel.2008.07.007; Drobin Kimi, 2013, Methods Mol Biol, V1023, P137, DOI 10.1007/978-1-4614-7209-4_8; Du JY, 2009, NAT BIOTECHNOL, V27, P77, DOI 10.1038/nbt.1513; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Espina V, 2008, MOL CELL PROTEOMICS, V7, P1998, DOI 10.1074/mcp.M700596-MCP200; Espina V, 2011, METHODS MOL BIOL, V785, P23, DOI 10.1007/978-1-61779-286-1_3; Espina V, 2009, CLIN LAB MED, V29, P1, DOI 10.1016/j.cll.2009.03.001; Esserman LJ, 2012, J CLIN ONCOL, V30, P3242, DOI 10.1200/JCO.2011.39.2779; Faratian D, 2011, EUR J CANCER, V47, P1420, DOI 10.1016/j.ejca.2011.01.014; Fu Q, 2010, CLIN CHEM, V56, P314, DOI 10.1373/clinchem.2009.135087; Gamez-Pozo A, 2011, MOL BIOSYST, V7, P2368, DOI 10.1039/c1mb05113j; Geiger T, 2010, NAT METHODS, V7, P383, DOI 10.1038/nmeth.1446; Haura EB, 2010, J CLIN ONCOL, V28, P1387, DOI 10.1200/JCO.2009.25.4029; Institute of Cancer Research (United Kingdom), 2000, AN PHARM CHANG AUY92; Irish JM, 2004, CELL, V118, P217, DOI 10.1016/j.cell.2004.06.028; Irwin ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070608; Jameson GS, 2012, J CLIN ONCOL, V30; Kornblau SM, 2010, CLIN CANCER RES, V16, P3721, DOI 10.1158/1078-0432.CCR-10-0093; Krutzik Peter O, 2011, Curr Protoc Cytom, VChapter 6, DOI 10.1002/0471142956.cy0631s55; Krutzik PO, 2011, METHODS MOL BIOL, V699, P179, DOI 10.1007/978-1-61737-950-5_9; Kummar S, 2011, EUR J CANCER, V47, P997, DOI 10.1016/j.ejca.2010.12.016; Leng SX, 2008, J GERONTOL A-BIOL, V63, P879, DOI 10.1093/gerona/63.8.879; Lineberger Comprehensive Cancer Center, 2000, DEF TRIPL NEG BREAST; Liu Angen, 2010, J Biomol Tech, V21, P120; Mascaux C, 2011, CLIN CANCER RES, V17, P7796, DOI 10.1158/1078-0432.CCR-11-0209; Mueller C, 2010, MOL ONCOL, V4, P461, DOI 10.1016/j.molonc.2010.09.003; Narumi R, 2012, J PROTEOME RES, V11, P5311, DOI 10.1021/pr3005474; Oberprieler NG, 2011, CELL SIGNAL, V23, P14, DOI 10.1016/j.cellsig.2010.07.009; Osborne CK, 2011, CLIN CANCER RES, V17, P1147, DOI 10.1158/1078-0432.CCR-10-1869; Paweletz CP, 2001, ONCOGENE, V20, P1981, DOI 10.1038/sj.onc.1204265; Peck AR, 2011, J CLIN ONCOL, V29, P2448, DOI 10.1200/JCO.2010.30.3552; Pectasides E, 2011, CLIN CANCER RES, V17, P2947, DOI 10.1158/1078-0432.CCR-10-2040; Perkins G, 2010, INT J CANCER, V127, P1321, DOI 10.1002/ijc.25152; Perl AE, 2012, CLIN CANCER RES, V18, P1716, DOI 10.1158/1078-0432.CCR-11-2346; Petricoin EF, 2007, CANCER RES, V67, P3431, DOI 10.1158/0008-5472.CAN-06-1344; Pierobon M, 2012, METHODS MOL BIOL, V823, P215, DOI 10.1007/978-1-60327-216-2_14; Pierobon M, 2011, METHODS MOL BIOL, V785, P3, DOI 10.1007/978-1-61779-286-1_1; Rimm D, 2012, CANCER RES, V72, DOI 10.1158/0008-5472.SABCS12-S5-4; Rimm DL, 2011, J CLIN ONCOL, V29, P2282, DOI 10.1200/JCO.2010.33.2023; Roth BJ, 2013, J CLIN ONCOL, V31, P131, DOI 10.1200/JCO.2012.47.1938; Sato T, 2011, AM J CANCER RES, V1, P347; Schwenk JM, 2011, METHODS MOL BIOL, V723, P29, DOI 10.1007/978-1-61779-043-0_3; Shah MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054014; Shi TJ, 2012, P NATL ACAD SCI USA, V109, P15395, DOI 10.1073/pnas.1204366109; Silvestri A, 2010, LAB INVEST, V90, P787, DOI 10.1038/labinvest.2010.47; Sourial S, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/187426; Speer R, 2006, P AM ASS CANC RES, V47; Sprung RW, 2012, J PROTEOME RES, V11, P3498, DOI 10.1021/pr300130t; Stasyk T, 2012, TRENDS MOL MED, V18, P43, DOI 10.1016/j.molmed.2011.11.001; Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535-7163.MCT-06-0334; Tong FK, 2006, CYTOM PART B-CLIN CY, V70B, P107, DOI 10.1002/cyto.b.20092; University of Michigan University Hospital, 2000, CET BEV TREAT PAT RE; VanMeter A, 2007, EXPERT REV MOL DIAGN, V7, P625, DOI 10.1586/14737159.7.5.625; VanMeter AJ, 2008, MOL CELL PROTEOMICS, V7, P1902, DOI 10.1074/mcp.M800204-MCP200; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wulfkuhle JD, 2008, J PROTEOME RES, V7, P1508, DOI 10.1021/pr7008127; Wulfkuhle JD, 2012, CLIN CANCER RES, V18, P6426, DOI 10.1158/1078-0432.CCR-12-0452; Xu BJ, 2010, PROTEOM CLIN APPL, V4, P116, DOI 10.1002/prca.200900138; Yap TA, 2011, J CLIN ONCOL, V29, P4688, DOI 10.1200/JCO.2011.35.5263	75	59	59	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2015	34	7					805	814		10.1038/onc.2014.16	http://dx.doi.org/10.1038/onc.2014.16			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB2QF	24608425				2023-01-03	WOS:000349472000001
J	Manchini, MT; Serra, AJ; Feliciano, RDS; Santana, ET; Antonio, EL; de Carvalho, PDC; Montemor, J; Crajoinas, RO; Girardi, ACC; Tucci, PJF; Silva, JA				Manchini, Martha Trindade; Serra, Andrey Jorge; Feliciano, Regiane dos Santos; Santana, Eduardo Tadeu; Antonio, Ednei Luis; Camillo de Carvalho, Paulo de Tarso; Montemor, Jairo; Crajoinas, Renato Oliveira; Costa Girardi, Adriana Castello; Ferreira Tucci, Paulo Jose; Silva, Jose Antonio, Jr.			Amelioration of Cardiac Function and Activation of Anti-Inflammatory Vasoactive Peptides Expression in the Rat Myocardium by Low Level Laser Therapy	PLOS ONE			English	Article							ANGIOTENSIN-CONVERTING ENZYME; NITRIC-OXIDE SYNTHASE; ENDOTHELIAL-CELL PROLIFERATION; HEART-FAILURE; INFARCT SIZE; MESSENGER-RNA; GROWTH-FACTOR; B2 RECEPTORS; KININ B1; IRRADIATION	Low-level laser therapy (LLLT) has been used as an anti-inflammatory treatment in several disease conditions, even when inflammation is a secondary consequence, such as in myocardial infarction (MI). However, the mechanism by which LLLT is able to protect the remaining myocardium remains unclear. The present study tested the hypothesis that LLLT reduces inflammation after acute MI in female rats and ameliorates cardiac function. The potential participation of the Renin-Angiotensin System (RAS) and Kallikrein-Kinin System (KKS) vasoactive peptides was also evaluated. LLLT treatment effectively reduced MI size, attenuated the systolic dysfunction after MI, and decreased the myocardial mRNA expression of interleukin-1 beta and interleukin-6 in comparison to the non-irradiated rat tissue. In addition, LLLT treatment increased protein and mRNA levels of the Mas receptor, the mRNA expression of kinin B2 receptors and the circulating levels of plasma kallikrein compared to non-treated post-MI rats. On the other hand, the kinin B1 receptor mRNA expression decreased after LLLT. No significant changes were found in the expression of vascular endothelial growth factor (VEGF) in the myocardial remote area between laser-irradiated and non-irradiated post-MI rats. Capillaries density also remained similar between these two experimental groups. The mRNA expression of the inducible nitric oxide synthase (iNOS) was increased three days after MI, however, this effect was blunted by LLLT. Moreover, endothelial NOS mRNA content increased after LLLT. Plasma nitric oxide metabolites (NOx) concentration was increased three days after MI in non-treated rats and increased even further by LLLT treatment. Our data suggest that LLLT diminishes the acute inflammation in the myocardium, reduces infarct size and attenuates left ventricle dysfunction post-MI and increases vasoactive peptides expression and nitric oxide (NO) generation.	[Manchini, Martha Trindade; Serra, Andrey Jorge; Feliciano, Regiane dos Santos; Santana, Eduardo Tadeu; Camillo de Carvalho, Paulo de Tarso; Silva, Jose Antonio, Jr.] Univ Nove Julho, UNINOVE, Sao Paulo, Brazil; [Antonio, Ednei Luis; Montemor, Jairo; Ferreira Tucci, Paulo Jose] Univ Fed Sao Paulo, UNIFESP, Sao Paulo, Brazil; [Crajoinas, Renato Oliveira; Costa Girardi, Adriana Castello] Univ Sao Paulo, Heart Inst InCor, Sao Paulo, Brazil	Universidade Nove de Julho; Universidade Federal de Sao Paulo (UNIFESP); Universidade de Sao Paulo	Silva, JA (corresponding author), Univ Nove Julho, UNINOVE, Sao Paulo, Brazil.	josejr@uninove.br	Silva, Jose Antonio/AAA-8100-2019; de Tarso C de Carvalho, Paulo/G-5333-2011; Serra, Andrey Jorge/E-7460-2015; Girardi, Adriana C. C./B-4334-2014; Girardi, Adriana/C-4827-2012; Antonio, Ednei/AGG-9987-2022; Tucci, Paulo/D-1441-2015	Silva, Jose Antonio/0000-0001-6904-9185; de Tarso C de Carvalho, Paulo/0000-0001-9624-4103; Serra, Andrey Jorge/0000-0002-5407-8183; Girardi, Adriana C. C./0000-0003-3715-6917; Girardi, Adriana/0000-0003-3715-6917; Antonio, Ednei/0000-0002-8254-5762; Tucci, Paulo/0000-0001-9793-670X; Manchini, Martha/0000-0001-5785-0899	Sao Paulo Research Foundation (FAPESP); CNPq [477458/2009-2, 309715/2011-3, 479395/2012-8];  [2009/54225-8]	Sao Paulo Research Foundation (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); 	This work was supported by the grant #2009/54225-8, Sao Paulo Research Foundation (FAPESP), and the CNPq #477458/2009-2, #309715/2011-3 and #479395/2012-8 grants. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ad N, 2001, INT J CARDIOL, V80, P109, DOI 10.1016/S0167-5273(01)00503-4; Al-Maghrebi M, 2009, PHARMACOL RES, V59, P263, DOI 10.1016/j.phrs.2008.12.008; Araujo RC, 2006, BIOL CHEM, V387, P431, DOI 10.1515/BC.2006.057; Bader M, 2013, PFLUG ARCH EUR J PHY, V465, P79, DOI 10.1007/s00424-012-1120-0; Bortone F, 2008, INT IMMUNOPHARMACOL, V8, P206, DOI 10.1016/j.intimp.2007.09.004; Brovkovych V, 2011, J CELL MOL MED, V15, P258, DOI 10.1111/j.1582-4934.2009.00992.x; Burrell LM, 2005, EUR HEART J, V26, P369, DOI 10.1093/eurheartj/ehi114; Chen CH, 2008, LASER SURG MED, V40, P46, DOI 10.1002/lsm.20589; Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786; Cury V, 2013, J PHOTOCH PHOTOBIO B, V125, P164, DOI 10.1016/j.jphotobiol.2013.06.004; de Almeida P, 2012, LASER MED SCI, V27, P453, DOI 10.1007/s10103-011-0957-3; De Mello W, 2003, REGUL PEPTIDES, V114, P87, DOI 10.1016/S0167-0115(03)00121-6; Dimmeler S, 2000, REGUL PEPTIDES, V90, P19, DOI 10.1016/S0167-0115(00)00105-1; Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1; dos Santos AA, 2013, INT J CARDIOL, V167, P357, DOI 10.1016/j.ijcard.2011.12.097; Dourado DM, 2011, PHOTOCHEM PHOTOBIOL, V87, P418, DOI 10.1111/j.1751-1097.2010.00878.x; Feng J, 2012, CELL SIGNAL, V24, P1116, DOI 10.1016/j.cellsig.2012.01.013; Frangogiannis NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5; Gross ER, 2006, CARDIOVASC RES, V70, P212, DOI 10.1016/j.cardiores.2005.12.019; Hamblin MR, 2010, LASER SURG MED, V42, P447, DOI 10.1002/lsm.20959; Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin; JOHNSTON CI, 1994, HYPERTENSION, V23, P258, DOI 10.1161/01.HYP.23.2.258; Kanashiro RM, 2006, J CARD FAIL, V12, P163, DOI 10.1016/j.cardfail.2005.09.007; Keidar S, 2007, CARDIOVASC RES, V73, P463, DOI 10.1016/j.cardiores.2006.09.006; KOIDE A, 1993, J PHYSIOL-LONDON, V467, pP125; Kompa AR, 2008, J PHARMACOL EXP THER, V325, P741, DOI 10.1124/jpet.107.133546; Kuhr F, 2010, NEUROPEPTIDES, V44, P145, DOI 10.1016/j.npep.2009.12.004; LAFOLLETTE L, 1987, J LAB CLIN MED, V110, P318; LINZ W, 1993, J HYPERTENS, V11, pS96; Loot AE, 2002, CIRCULATION, V105, P1548, DOI 10.1161/01.CIR.0000013847.07035.B9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu J, 2013, NEUROPEPTIDES, V47, P289, DOI 10.1016/j.npep.2013.09.002; Marchesi C, 2008, TRENDS PHARMACOL SCI, V29, P367, DOI 10.1016/j.tips.2008.05.003; Marcondes S., 2005, Current Medicinal Chemistry - Cardiovascular & Hematological Agents, V3, P33, DOI 10.2174/1568016052773351; Marketou M, 2010, AM J HYPERTENS, V23, P562, DOI 10.1038/ajh.2010.20; Oliveira FAM, 2012, PHOTOMED LASER SURG, V30, P705, DOI 10.1089/pho.2012.3272; Meng CB, 2013, J NEUROSCI, V33, P13505, DOI 10.1523/JNEUROSCI.0918-13.2013; Meotti FC, 2012, BRIT J PHARMACOL, V166, P1127, DOI 10.1111/j.1476-5381.2012.01830.x; Mercure C, 2008, CIRC RES, V103, P1319, DOI 10.1161/CIRCRESAHA.108.184911; MESTER E, 1971, AM J SURG, V122, P532, DOI 10.1016/0002-9610(71)90482-X; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; Nadu AP, 2008, J AM SOC HYPERTENS, V2, P341, DOI 10.1016/j.jash.2008.04.012; Nozawa E, 2006, BRAZ J MED BIOL RES, V39, P687, DOI 10.1590/S0100-879X2006000500016; Oron U, 2001, LASER SURG MED, V28, P204, DOI 10.1002/lsm.1039; Oron U, 2001, CIRCULATION, V103, P296; Pereira MG, 2009, EUR J APPL PHYSIOL, V105, P843, DOI 10.1007/s00421-008-0967-4; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PFEFFER MA, 1990, CIRCULATION, V81, P1161, DOI 10.1161/01.CIR.81.4.1161; Pontes FL, 2008, INT IMMUNOPHARMACOL, V8, P261, DOI 10.1016/j.intimp.2007.09.001; Potier L, 2013, J PHARMACOL EXP THER, V346, P23, DOI 10.1124/jpet.113.203927; Sampaio WO, 2007, HYPERTENSION, V49, P185, DOI 10.1161/01.HYP.0000251865.35728.2f; Santos AA, 2009, J CARD FAIL, V15, P163, DOI 10.1016/j.cardfail.2008.10.017; Santos RAS, 2003, P NATL ACAD SCI USA, V100, P8258, DOI 10.1073/pnas.1432869100; Santos RAS, 2006, HYPERTENSION, V47, P996, DOI 10.1161/01.HYP.0000215289.51180.5c; Scholkens BA, 1996, IMMUNOPHARMACOLOGY, V33, P209, DOI 10.1016/0162-3109(96)00061-6; Sharma JN, 2008, THESCIENTIFICWORLDJO, V8, DOI 10.1100/tsw.2008.53; Silva MP, 2011, REV BRAS FISIOTER, V15, P1; Silveira KD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066082; Souza APS, 2013, CLIN SCI, V125, P449, DOI 10.1042/CS20120519; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; Szymanska J, 2013, J PHYSIOL PHARMACOL, V64, P387; Tsai WC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038235; van Nieuwenhoven FA, 2013, VASC PHARMACOL, V58, P182, DOI 10.1016/j.vph.2012.07.003; Venema RC, 2002, INT IMMUNOPHARMACOL, V2, P1755, DOI 10.1016/S1567-5769(02)00185-6; Westermann D, 2009, DIABETES, V58, P1373, DOI 10.2337/db08-0329; Whittaker P, 2000, LASER SURG MED, V27, P29, DOI 10.1002/1096-9101(2000)27:1<29::AID-LSM4>3.0.CO;2-8; Xu XH, 2008, J MOL CELL CARDIOL, V44, P114, DOI 10.1016/j.yjmcc.2007.10.004; Yang ZK, 2011, PHOTOMED LASER SURG, V29, P391, DOI 10.1089/pho.2010.2866; Yin H, 2007, PEPTIDES, V28, P1383, DOI 10.1016/j.peptides.2007.05.010; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; Zhang YK, 2007, J BIOL CHEM, V282, P32453, DOI 10.1074/jbc.M706242200; Zisman LS, 2003, CIRCULATION, V108, P1707, DOI 10.1161/01.CIR.0000094734.67990.99	72	24	25	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 3	2014	9	7							e101270	10.1371/journal.pone.0101270	http://dx.doi.org/10.1371/journal.pone.0101270			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO3RT	24991808	Green Published, Green Submitted, gold			2023-01-03	WOS:000341253400057
J	McCartney, M				McCartney, Margaret			NO HOLDS BARRED Overprescribing antidepressants: where's the evidence?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				Coupland C, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4551; Gotzsche P., 2014, GUARDIAN; Health and Social Care Information Centre, 2012, PRESCR DISP COMM STA; Health Foundation Nuffield Trust; QualityWatch, 2014, FOC ANT PRESCR; Moberly T., 2011, GP              0705; Moore M, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3999; Siddique H., 2014, GUARDIAN; Thompson S., 2014, DAILY TELEGRAPH	8	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 30	2014	348								g4218	10.1136/bmj.g4218	http://dx.doi.org/10.1136/bmj.g4218			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AK7YU	24982509	Bronze, Green Published			2023-01-03	WOS:000338644600002
J	Sugisaki, N; Kurokawa, S; Okada, J; Kanehisa, H				Sugisaki, Norihide; Kurokawa, Sadao; Okada, Junichi; Kanehisa, Hiroaki			Difference in the Recruitment of Hip and Knee Muscles between Back Squat and Plyometric Squat Jump	PLOS ONE			English	Article							KINETIC CHAIN EXERCISES; MUSCULAR ENDURANCE; ELECTROMYOGRAPHIC ACTIVITY; POWER OUTPUT; FIBER-TYPE; PROTON T2; MR-IMAGES; INTENSITY; LOAD; BIOMECHANICS	Athletes who aim to improve both muscular endurance and power often perform exercises that involve similar joint actions under different lifting conditions, such as changes in the load or speed, which are implemented at different times during a periodized exercise program or simultaneously. The prescribed exercises are considered to recruit the same muscles even if the lifting conditions differ to each other. The present study aimed to clarify this by examining whether the recruitment of individual hip and knee muscles during the squat exercise differs between lifting conditions adopted for muscular endurance and power training regimens. Moderately trained men performed back squats (BS), with a load of approximately 60% of one repetition maximum, as a muscular endurance training exercise, and they performed plyometric squat jumping (PSJ) for power training. During each exercise, the lower limb joint torques and the recruitment of five hip and knee muscles were determined with inverse-dynamics and T2-weighted magnetic resonance imaging, respectively. While the maximal and mean knee joint torques were greater during PSJ than during BS (p<0.01), the T2 values for the quadriceps femoris muscle did not differ between the exercises. In contrast, the T2 values of the gluteus maximus and hip adductor muscles were higher during PSJ (p<0.05) than during BS, although there was no significant difference in the mean hip extension torque between the two exercises. The current results indicate that the individual use of the agonist muscles differs between BS and PSJ, and it does not always correspond with the joint kinetics during the exercises. Therefore, in addition to the exercise type, the lifting condition should also be taken into consideration as a determinant of the major muscles trained during a resistance exercise.	[Sugisaki, Norihide] Chiba Univ, Ctr Environm Hlth & Field Sci, Kashiwa, Chiba, Japan; [Sugisaki, Norihide] Waseda Univ, Waseda Inst Sport Sci, Tokorozawa, Saitama, Japan; [Kurokawa, Sadao] Meiji Gakuin Univ, Ctr Liberal Arts, Yokohama, Kanagawa, Japan; [Okada, Junichi] Waseda Univ, Fac Sport Sci, Tokorozawa, Saitama, Japan; [Kanehisa, Hiroaki] Natl Inst Fitness & Sports Kanoya, Kanoya, Kagoshima, Japan	Chiba University; Waseda University; Waseda University; National Institute Fitness & Sports Kanoya	Sugisaki, N (corresponding author), Chiba Univ, Ctr Environm Hlth & Field Sci, Kashiwa, Chiba, Japan.	sugisaki@chiba-u.jp			JSPS [24700667]	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This study was supported by JSPS Grant-in-Aid for Scientific Research (24700667), (http://www.jsps.go.jp/j-grantsinaid/index.html). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADAMS GR, 1992, J APPL PHYSIOL, V73, P1578, DOI 10.1152/jappl.1992.73.4.1578; ADAMS GR, 1993, J APPL PHYSIOL, V74, P532, DOI 10.1152/jappl.1993.74.2.532; Baechle T. R., 2008, ESSENTIALS STRENGTH, P414; Baker D, 2001, J STRENGTH COND RES, V15, P92; Ball N, 2011, EUR J SPORT SCI, V11, P447, DOI 10.1080/17461391.2010.536583; CAVAGNA GA, 1968, J APPL PHYSIOL, V24, P21, DOI 10.1152/jappl.1968.24.1.21; DOSTAL WF, 1986, PHYS THER, V66, P351, DOI 10.1093/ptj/66.3.351; Earle R. W., 2008, ESSENTIALS STRENGTH, V3th, P325; EDMAN KAP, 1979, J PHYSIOL-LONDON, V291, P143, DOI 10.1113/jphysiol.1979.sp012804; ELDER GCB, 1982, J APPL PHYSIOL, V53, P1473, DOI 10.1152/jappl.1982.53.6.1473; Enocson AG, 2005, EUR J APPL PHYSIOL, V94, P357, DOI 10.1007/s00421-005-1339-y; Escamilla RF, 1998, MED SCI SPORT EXER, V30, P556, DOI 10.1097/00005768-199804000-00014; Escamilla RF, 2001, MED SCI SPORT EXER, V33, P1552, DOI 10.1097/00005768-200109000-00020; Farina D, 2004, J APPL PHYSIOL, V96, P1486, DOI 10.1152/japplphysiol.01070.2003; Farina D, 2006, EXERC SPORT SCI REV, V34, P121, DOI 10.1249/00003677-200607000-00006; FISHER MJ, 1990, INVEST RADIOL, V25, P480, DOI 10.1097/00004424-199005000-00003; FLECKENSTEIN JL, 1993, J APPL PHYSIOL, V74, P2855, DOI 10.1152/jappl.1993.74.6.2855; Ishikawa M, 2003, ACTA PHYSIOL SCAND, V178, P205, DOI 10.1046/j.1365-201X.2003.01149.x; JOHNSON MA, 1973, J NEUROL SCI, V18, P111, DOI 10.1016/0022-510X(73)90023-3; Kawakami Y, 2006, AM J HUM BIOL, V18, P845, DOI 10.1002/ajhb.20561; Newton RU, 1997, EUR J APPL PHYSIOL O, V75, P333, DOI 10.1007/s004210050169; PLOUTZSNYDER LL, 1995, AM J PHYSIOL-REG I, V269, pR536, DOI 10.1152/ajpregu.1995.269.3.R536; Potach DH., 2008, ESSENTIALS STRENGTH, P413; Price TB, 1998, MED SCI SPORT EXER, V30, P1374, DOI 10.1097/00005768-199809000-00006; Prior BM, 2001, J APPL PHYSIOL, V90, P615, DOI 10.1152/jappl.2001.90.2.615; Ratamess A, 2011, ACSMS FDN STRENGTH T, P192; Ratamess A, 2011, ACSMS FDN STRENGTH T, P331; Rhea MR, 2003, J STRENGTH COND RES, V17, P82; Sedano S, 2013, J STRENGTH COND RES, V27, P2433, DOI 10.1519/JSC.0b013e318280cc26; Smilios I, 2010, J STRENGTH COND RES, V24, P2122, DOI 10.1519/JSC.0b013e3181a5bc44; Taipale RS, 2013, EUR J APPL PHYSIOL, V113, P325, DOI 10.1007/s00421-012-2440-7; Voigt M, 1998, ACTA PHYSIOL SCAND, V163, P181; Wakahara T, 2012, EUR J APPL PHYSIOL, V112, P1569, DOI 10.1007/s00421-011-2121-y; Wathen D., 2008, ESSENTIALS STRENGTH, V3rd, P507; Weiss LW, 2000, J ORTHOP SPORT PHYS, V30, P143, DOI 10.2519/jospt.2000.30.3.143; Wilk KE, 1996, AM J SPORT MED, V24, P518, DOI 10.1177/036354659602400418; Willardson JM, 2006, J STRENGTH COND RES, V20, P400; Winter D.A., 2009, BIOMECHANICS MOTOR C, V4, P176; Yamaguchi GT., 1990, MULTIPLE MUSCLE SYST, P717; [No title captured]	40	9	9	1	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 30	2014	9	6							e101203	10.1371/journal.pone.0101203	http://dx.doi.org/10.1371/journal.pone.0101203			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK5ZO	24979707	Green Published, Green Submitted, gold			2023-01-03	WOS:000338506400099
J	Sode, J; Vogel, U; Bank, S; Andersen, PS; Thomsen, MK; Hetland, ML; Locht, H; Heegaard, NHH; Andersen, V				Sode, Jacob; Vogel, Ulla; Bank, Steffen; Andersen, Paal Skytt; Thomsen, Marianne Kragh; Hetland, Merete Lund; Locht, Henning; Heegaard, Niels H. H.; Andersen, Vibeke			Anti-TNF Treatment Response in Rheumatoid Arthritis Patients Is Associated with Genetic Variation in the NLRP3-Inflammasome	PLOS ONE			English	Article							SINGLE-NUCLEOTIDE POLYMORPHISMS; DANISH DANBIO REGISTRY; THERAPY; ADHERENCE; PATHWAYS; DISEASE; RISK	Objective: Many patients with rheumatoid arthritis (RA) benefit from tumor necrosis factor-alpha blocking treatment (anti-TNF), but about one third do not respond. The objective of this study was to replicate and extend previously found associations between anti-TNF treatment response and genetic variation in the TNF-, NF-kappa B-and pattern recognition receptor signalling pathways. Methods: Forty-one single nucleotide polymorphisms (SNPs), including 34 functional, in 28 genes involved in inflammatory pathways were assessed in 538 anti-TNF naive Danish RA patients with clinical data. Multivariable logistic regression analyses were performed to test associations between genotypes and treatment response at 3-6 months using the European League Against Rheumatism (EULAR) response criterion. American College of Rheumatology treatment response (ACR50) and relative change in 28-joint disease activity score (relDAS28) were used as secondary outcomes. Subgroup analyses were stratified according to smoking status, type of anti-TNF drug and IgM-Rheumatoid Factor (IgM-RF) status. False discovery rate (FDR) controlling was used to adjust for multiple testing. Results: Statistically significant associations with EULAR response were found for two SNPs in NLRP3(rs4612666) (OR (odds ratio) for good/moderate response = 0.64 (95% confidence interval: 0.44-0.95), p = 0.025, q = 0.95) and INFG(rs2430561) (OR = 0.40 (0.21-0.76), p = 0.005, q = 0.18) and among IgM-RF positive patients for TNFRS1A(rs4149570) (0.59 (0.36-0.98), p = 0.040, q = 0.76). Current smokers who carried the NLRP3(rs4612666) variant allele were less likely to benefit from anti-TNF treatment (OR = 0.24 (0.10-0.56), p = 0.001, q = 0.04). Conclusions: In a population of Danish RA patients, we confirm the NLRP3 gene as associated with EULAR anti-TNF response as previously reported. The NLRP3 variant (T) allele is associated with lower treatment response, in particular among current smokers. Furthermore, we find that a functional polymorphism in the interferon-gamma gene is associated with anti-TNF response. All findings should be tested by replication in independent validation cohorts and augmented by assessing cytokine levels and activities of the relevant gene products.	[Sode, Jacob; Heegaard, Niels H. H.] Statens Serum Inst, DK-2300 Copenhagen, Denmark; [Sode, Jacob; Locht, Henning] Frederiksberg Univ Hosp, Dept Rheumatol, Frederiksberg, Denmark; [Sode, Jacob; Andersen, Vibeke] Univ Southern Denmark, Inst Reg Hlth Res, Odense, Denmark; [Vogel, Ulla] Natl Res Ctr Working Environm, Copenhagen, Denmark; [Bank, Steffen; Andersen, Vibeke] Viborg Reg Hosp, Dept Med, Viborg, Denmark; [Bank, Steffen] Univ Aarhus, Aarhus, Denmark; [Andersen, Paal Skytt] Statens Serum Inst, Dept Microbiol & Infect Control, DK-2300 Copenhagen, Denmark; [Thomsen, Marianne Kragh] Aarhus Univ Hosp, Dept Clin Microbiol, DK-8000 Aarhus, Denmark; [Hetland, Merete Lund] Glostrup Cty Hosp, Ctr Rheumatol & Spine Dis, Copenhagen Ctr Arthrit Res, DANBIO Registry, Glostrup, Denmark; [Hetland, Merete Lund] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark; [Hetland, Merete Lund] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark; [Andersen, Vibeke] Hosp Southern Jutland, Organ Ctr, Aabenraa, Denmark; [Andersen, Vibeke] Odense Univ Hosp, OPEN, DK-5000 Odense, Denmark	Statens Serum Institut; University of Southern Denmark; National Research Centre for the Working Environment; Aarhus University; Aarhus University; Statens Serum Institut; Aarhus University; University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Southern Denmark; Odense University Hospital	Sode, J (corresponding author), Statens Serum Inst, DK-2300 Copenhagen, Denmark.	jaso@ssi.dk	Hetland, Merete L/AAE-5297-2019; Vogel, Ulla B/I-5048-2012; Thomsen, Marianne Kragh/AAJ-5115-2020; Andersen, Paal S/H-2087-2015; Sode, Jacob/AAD-9615-2020; Andersen, Vibeke/I-7932-2012; Vogel, Ulla/ABC-2212-2020	Hetland, Merete L/0000-0003-4229-6818; Vogel, Ulla B/0000-0001-6807-1524; Andersen, Paal S/0000-0001-5656-0427; Sode, Jacob/0000-0002-2718-9320; Andersen, Vibeke/0000-0002-0127-2863; Vogel, Ulla/0000-0001-6807-1524; Thomsen, Marianne Kragh/0000-0002-3645-6689	Danish Rheumatism Association; Region of Southern Denmark's PhD Fund; Department of Rheumatology, Frederiksberg Hospital	Danish Rheumatism Association; Region of Southern Denmark's PhD Fund; Department of Rheumatology, Frederiksberg Hospital	This study was supported by the Danish Rheumatism Association (www.gigtforeningen.dk), Region of Southern Denmark's PhD Fund (www.regionsyddanmark.dk) and the Department of Rheumatology, Frederiksberg Hospital (www.frederiksberghospital.dk). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bank S, 2014, PHARMACOGENOMICS J, V14, P526, DOI 10.1038/tpj.2014.19; Bank S, 2014, PLOS ONE IN PRESS; Bank S, 2013, GENET TEST MOL BIOMA, V17, P501, DOI 10.1089/gtmb.2012.0429; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blomgran R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031326; Chen HM, 2006, HUM MOL GENET, V15, P519, DOI 10.1093/hmg/ddi469; Coenen MJH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014326; Cui J, 2010, ARTHRITIS RHEUM-US, V62, P1849, DOI 10.1002/art.27457; Emery P, 2011, ANN RHEUM DIS, V70, P2063, DOI 10.1136/ard.2010.148015; Espinoza JL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026229; Fransen J, 2005, CLIN EXP RHEUMATOL, V23, pS93; Goh FG, 2012, RHEUMATOLOGY, V51, P7, DOI 10.1093/rheumatology/ker257; Gu W, 2007, ANN SURG, V246, P151, DOI 10.1097/01.sla.0000262788.67171.3f; Hetland ML, 2008, ANN RHEUM DIS, V67, P1023, DOI 10.1136/ard.2007.087262; Hetland ML, 2011, RHEUMATOLOGY, V50, P69, DOI 10.1093/rheumatology/keq309; Hetland ML, 2010, ARTHRITIS RHEUM-US, V62, P22, DOI 10.1002/art.27227; Hitomi Y, 2009, J ALLERGY CLIN IMMUN, V124, P779, DOI 10.1016/j.jaci.2009.07.044; Johnson AD, 2008, BIOINFORMATICS, V24, P2938, DOI 10.1093/bioinformatics/btn564; Klareskog L, 2009, LANCET, V373, P659, DOI 10.1016/S0140-6736(09)60008-8; Krintel SB, 2012, PHARMACOGENET GENOM, V22, P577, DOI 10.1097/FPC.0b013e3283544043; Mathews RJ, 2014, ANN RHEUM DIS, V73, P1202, DOI 10.1136/annrheumdis-2013-203276; Mirkov MU, 2013, ANN RHEUM DIS, V72, P1375, DOI 10.1136/annrheumdis-2012-202405; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; Plant D, 2012, ARTHRITIS RHEUM-US, V64, P665, DOI 10.1002/art.33381; Plenge RM, 2011, ARTHRITIS RHEUM-US, V63, P2839, DOI 10.1002/art.30509; Potter C, 2010, ANN RHEUM DIS, V69, P1315, DOI 10.1136/ard.2009.117309; Pravica V, 2000, HUM IMMUNOL, V61, P863, DOI 10.1016/S0198-8859(00)00167-1; Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149; Rosenblum H, 2011, AUTOIMMUN REV, V10, P563, DOI 10.1016/j.autrev.2011.04.010; Rosengren S, 2005, ANN RHEUM DIS, V64, P708, DOI 10.1136/ard.2004.025577; Simard JC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072138; Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759; Toonen EJM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033199; Valavanidis A, 2009, INT J ENV RES PUB HE, V6, P445, DOI 10.3390/ijerph6020445; van Loo G, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3324; Wang GB, 2011, HUM IMMUNOL, V72, P451, DOI 10.1016/j.humimm.2011.02.004	36	47	52	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 26	2014	9	6							e100361	10.1371/journal.pone.0100361	http://dx.doi.org/10.1371/journal.pone.0100361			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK2WP	24967817	Green Published, gold, Green Submitted			2023-01-03	WOS:000338280800037
J	Kim, HW; Kim, SH; Kim, YO; Jin, DC; Song, HC; Choi, EJ; Kim, YL; Kim, YS; Kang, SW; Kim, NH; Yang, CW; Kim, YK				Kim, Hyung Wook; Kim, Su-Hyun; Kim, Young Ok; Jin, Dong Chan; Song, Ho Chul; Choi, Euy Jin; Kim, Yong-Lim; Kim, Yon-Su; Kang, Shin-Wook; Kim, Nam-Ho; Yang, Chul Woo; Kim, Yong Kyun			Comparison of the Impact of High-Flux Dialysis on Mortality in Hemodialysis Patients with and without Residual Renal Function	PLOS ONE			English	Article							DIALYZER MEMBRANE-CHARACTERISTICS; MAINTENANCE HEMODIALYSIS; CLINICAL-OUTCOMES; PERMEABILITY; REUSE; BETA(2)-MICROGLOBULIN; SURVIVAL; HEMO; RISK	Background: The effect of flux membranes on mortality in hemodialysis (HD) patients is controversial. Residual renal function (RRF) has shown to not only be as a predictor of mortality but also a contributor to beta 2-microglobulin clearance in HD patients. Our study aimed to determine the interaction of residual renal function with dialyzer membrane flux on mortality in HD patients. Methods: HD Patients were included from the Clinical Research Center registry for End Stage Renal Disease, a prospective observational cohort study in Korea. Cox proportional hazards regression models were used to study the association between use of high-flux dialysis membranes and all-cause mortality with RRF and without RRF. The primary outcome was all-cause mortality. Results: This study included 893 patients with 24 h-residual urine volume >= 100 ml (569 and 324 dialyzed using low-flux and high-flux dialysis membranes, respectively) and 913 patients with 24 h-residual urine volume < 100 ml (570 and 343 dialyzed using low-flux and high-flux dialysis membranes, respectively). After a median follow-up period of 31 months, mortality was not significantly different between the high and low-flux groups in patients with 24 h-residual urine volume >= 100 ml (HR 0.86, 95% CI, 0.38-1.95, P = 0.723). In patients with 24 h-residual urine volume < 100 ml, HD using high-flux dialysis membrane was associated with decreased mortality compared to HD using low-flux dialysis membrane in multivariate analysis (HR 0.40, 95% CI, 0.21-0.78, P = 0.007). Conclusions: Our data showed that HD using high-flux dialysis membranes had a survival benefit in patients with 24 h-residual urine volume < 100 ml, but not in patients with 24 h-residual urine volume >= 100 ml. These findings suggest that high-flux dialysis rather than low-flux dialysis might be considered in HD patients without RRF.	[Kim, Hyung Wook; Kim, Young Ok; Jin, Dong Chan; Song, Ho Chul; Choi, Euy Jin; Yang, Chul Woo; Kim, Yong Kyun] Catholic Univ Korea, Dept Internal Med, Coll Med, Seoul, South Korea; [Kim, Su-Hyun] Chung Ang Univ, Coll Med, Dept Internal Med, Seoul 156756, South Korea; [Kim, Yong-Lim] Kyungpook Natl Univ, Sch Med, Dept Internal Med, Taegu, South Korea; [Kim, Yon-Su] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea; [Kang, Shin-Wook] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea; [Kim, Nam-Ho] Chonnam Natl Univ, Sch Med, Dept Internal Med, Kwangju, South Korea; [Kim, Hyung Wook] St Vincents Hosp, Suwon, South Korea; [Kim, Yong Kyun] Catholic Univ Korea, MRC Cell Death Dis Res Ctr, Seoul, South Korea	Catholic University of Korea; Chung Ang University; Chung Ang University Hospital; Kyungpook National University; Seoul National University (SNU); Yonsei University; Yonsei University Health System; Chonnam National University; Catholic University of Korea	Kim, YK (corresponding author), Catholic Univ Korea, Dept Internal Med, Coll Med, Seoul, South Korea.	drkimyk@catholic.ac.kr			Korea Healthcare Technology R & D Project, Ministry of Health and Welfare, Republic of Korea [HI10C2020]	Korea Healthcare Technology R & D Project, Ministry of Health and Welfare, Republic of Korea	This work was supported by a grant of the Korea Healthcare Technology R & D Project, Ministry of Health and Welfare, Republic of Korea (HI10C2020). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chauveau P, 2005, AM J KIDNEY DIS, V45, P565, DOI 10.1053/j.ajkd.2004.11.014; Cheung AK, 1999, J AM SOC NEPHROL, V10, P117; Cheung AK, 2003, J AM SOC NEPHROL, V14, P3251, DOI 10.1097/01.ASN.0000096373.13406.94; Cheung AK, 2006, J AM SOC NEPHROL, V17, P546, DOI 10.1681/ASN.2005020132; DIRAIMONDO CR, 1989, AM J KIDNEY DIS, V13, P390, DOI 10.1016/S0272-6386(89)80022-8; Eknoyan G, 2002, NEW ENGL J MED, V347, P2010, DOI 10.1056/NEJMoa021583; HORNBERGER JC, 1992, J AM SOC NEPHROL, V3, P1227; Krane V, 2007, AM J KIDNEY DIS, V49, P267, DOI 10.1053/j.ajkd.2006.11.026; Locatelli F, 2009, J AM SOC NEPHROL, V20, P645, DOI 10.1681/ASN.2008060590; Matos JPS, 2000, AM J KIDNEY DIS, V35, P839, DOI 10.1016/S0272-6386(00)70253-8; MCCARTHY JT, 1994, J LAB CLIN MED, V123, P495; Peritoneal Dialysis Adequacy 2006 Work Group, 2006, AM J KIDNEY DIS S, V48, pS91, DOI DOI 10.1053/J.AJKD.2006.05.016; Port FK, 2001, AM J KIDNEY DIS, V37, P276, DOI 10.1053/ajkd.2001.21290; Shemin D, 2001, AM J KIDNEY DIS, V38, P85, DOI 10.1053/ajkd.2001.25198; Tattersall J, 2010, NEPHROL DIAL TRANSPL, V25, P1230, DOI 10.1093/ndt/gfp626; van der Wal WM, 2011, NEPHROL DIAL TRANSPL, V26, P2978, DOI 10.1093/ndt/gfq856; Vilar E, 2009, NEPHROL DIAL TRANSPL, V24, P2502, DOI 10.1093/ndt/gfp071; Ward RA, 2004, SEMIN DIALYSIS, V17, P489, DOI 10.1111/j.0894-0959.2004.17617.x; Ward RA, 2011, SEMIN DIALYSIS, V24, P65, DOI 10.1111/j.1525-139X.2010.00807.x; Yoshino M, 2006, J AM SOC NEPHROL, V17, P3510, DOI 10.1681/ASN.2006020156	20	6	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2014	9	6							e97184	10.1371/journal.pone.0097184	http://dx.doi.org/10.1371/journal.pone.0097184			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AP1YS	24906205	Green Published, Green Submitted, gold			2023-01-03	WOS:000341869000005
J	Koren, I; Dagan, G; Altaratz, O				Koren, Ilan; Dagan, Guy; Altaratz, Orit			From aerosol-limited to invigoration of warm convective clouds	SCIENCE			English	Article							CONDENSATION NUCLEI; CCN CONCENTRATIONS; PRECIPITATION; MODEL; UNCERTAINTY; ALGORITHM; PRODUCTS; RAIN	Among all cloud-aerosol interactions, the invigoration effect is the most elusive. Most of the studies that do suggest this effect link it to deep convective clouds with a warm base and cold top. Here, we provide evidence from observations and numerical modeling of a dramatic aerosol effect on warm clouds. We propose that convective-cloud invigoration by aerosols can be viewed as an extension of the concept of aerosol-limited clouds, where cloud development is limited by the availability of cloud-condensation nuclei. A transition from pristine to slightly polluted atmosphere yields estimated negative forcing of similar to 15 watts per square meter (cooling), suggesting that a substantial part of this anthropogenic forcing over the oceans occurred at the beginning of the industrial era, when the marine atmosphere experienced such transformation.	[Koren, Ilan; Dagan, Guy; Altaratz, Orit] Weizmann Inst Sci, Dept Earth & Planetary Sci, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Koren, I (corresponding author), Weizmann Inst Sci, Dept Earth & Planetary Sci, IL-76100 Rehovot, Israel.	ilan.koren@weizmann.ac.il	Keyes, Dennis/AAZ-9285-2021; Dagan, Guy/ABH-4574-2020; Koren, Ilan/K-1417-2012	Dagan, Guy/0000-0002-8391-6334; Koren, Ilan/0000-0001-6759-6265	European Research Council (ERC) under the European Union's Seventh Framework Programme (FP7)/ERC [306965]	European Research Council (ERC) under the European Union's Seventh Framework Programme (FP7)/ERC(European Research Council (ERC))	The research leading to these results received funding from the European Research Council (ERC) under the European Union's Seventh Framework Programme (FP7/2007-2013)/ERC Grant agreement no. 306965 (CAPRI).	Altaratz O, 2013, ENVIRON RES LETT, V8, DOI 10.1088/1748-9326/8/3/034025; Andreae MO, 2008, EARTH-SCI REV, V89, P13, DOI 10.1016/j.earscirev.2008.03.001; Andreae MO, 2009, ATMOS CHEM PHYS, V9, P543, DOI 10.5194/acp-9-543-2009; Andreae MO, 2007, SCIENCE, V315, P50, DOI 10.1126/science.1136529; Andreae MO, 2004, SCIENCE, V303, P1337, DOI 10.1126/science.1092779; BAKER MB, 1990, NATURE, V345, P142, DOI 10.1038/345142a0; Carslaw KS, 2013, NATURE, V503, P67, DOI 10.1038/nature12674; Forster P, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P129; HEGG DA, 1991, J GEOPHYS RES-ATMOS, V96, P18727, DOI 10.1029/91JD01870; HINDMAN EE, 1994, ATMOS ENVIRON, V28, P3393, DOI 10.1016/1352-2310(94)00171-G; Huffman GJ, 2007, J HYDROMETEOROL, V8, P38, DOI 10.1175/JHM560.1; Jiang HL, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2005JD006138; Kaufman YJ, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023125; Kaufman YJ, 2005, P NATL ACAD SCI USA, V102, P11207, DOI 10.1073/pnas.0505191102; Koren I, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023187; Koren I, 2010, ATMOS CHEM PHYS, V10, P8855, DOI 10.5194/acp-10-8855-2010; Koren I, 2010, ATMOS CHEM PHYS, V10, P5001, DOI 10.5194/acp-10-5001-2010; Koren I, 2009, ATMOS CHEM PHYS, V9, P155, DOI 10.5194/acp-9-155-2009; Koren I, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL029253; Koren I, 2012, NAT GEOSCI, V5, P118, DOI [10.1038/NGEO1364, 10.1038/ngeo1364]; Lohmann U, 2005, ATMOS CHEM PHYS, V5, P715, DOI 10.5194/acp-5-715-2005; PARRISH DF, 1992, MON WEATHER REV, V120, P1747, DOI 10.1175/1520-0493(1992)120<1747:TNMCSS>2.0.CO;2; Pierce JR, 2009, ATMOS CHEM PHYS, V9, P1339, DOI 10.5194/acp-9-1339-2009; Platnick S, 2003, IEEE T GEOSCI REMOTE, V41, P459, DOI 10.1109/TGRS.2002.808301; Reisin T, 1996, J APPL METEOROL, V35, P1416, DOI 10.1175/1520-0450(1996)035<1416:SCCWIN>2.0.CO;2; Remer LA, 2005, J ATMOS SCI, V62, P947, DOI 10.1175/JAS3385.1; Reutter P, 2009, ATMOS CHEM PHYS, V9, P7067, DOI 10.5194/acp-9-7067-2009; Rosenfeld D., 2013, CLIMATE SCI SERVING, P105, DOI [DOI 10.1007/978-94-007-6692-1_5, 10.1007/978-94-007-6692-1_5]; Rosenfeld D, 2008, SCIENCE, V321, P1309, DOI 10.1126/science.1160606; Rosenfeld D, 2014, SCIENCE, V343, P379, DOI 10.1126/science.1247490; Tao WK, 2012, REV GEOPHYS, V50, DOI 10.1029/2011RG000369; TRIPOLI GJ, 1980, J APPL METEOROL, V19, P1037, DOI 10.1175/1520-0450(1980)019<1037:ANIOSF>2.0.CO;2; TWOMEY S, 1959, TELLUS, V11, P408; TZIVION S, 1994, J APPL METEOROL, V33, P252, DOI 10.1175/1520-0450(1994)033<0252:NSOHSI>2.0.CO;2; Wang M, 2009, ATMOS CHEM PHYS, V9, P239, DOI 10.5194/acp-9-239-2009; Wen GY, 2007, J GEOPHYS RES-ATMOS, V112, DOI 10.1029/2006JD008267; Wielicki BA, 1998, IEEE T GEOSCI REMOTE, V36, P1127, DOI 10.1109/36.701020; Xue HW, 2008, J ATMOS SCI, V65, P392, DOI 10.1175/2007JAS2428.1; Yu HB, 2009, J GEOPHYS RES-ATMOS, V114, DOI 10.1029/2008JD010648; Yuan T, 2011, ATMOS CHEM PHYS, V11, P7119, DOI 10.5194/acp-11-7119-2011; Yum SS, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD003864	41	154	156	5	112	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 6	2014	344	6188					1143	1146		10.1126/science.1252595	http://dx.doi.org/10.1126/science.1252595			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI3UU	24904161				2023-01-03	WOS:000336791200043
J	OlaOlorun, FM; Hindin, MJ				OlaOlorun, Funmilola M.; Hindin, Michelle J.			Having a Say Matters: Influence of Decision-Making Power on Contraceptive Use among Nigerian Women Ages 35-49 Years	PLOS ONE			English	Article							AUTONOMY; EMPOWERMENT; BEHAVIOR; YORUBA; INDIA	Background: Research suggests that women of reproductive age who are involved in household decision-making are more likely than those who are not involved to be able to control their fertility. Little is known, however, about this relationship among women at the upper end of the reproductive spectrum. The aim of this study was to determine the association between household decision-making power and modern contraceptive use among Nigerian women ages 35-49 years. Methods: A descriptive, cross-sectional study involving a secondary analysis of data from the Nigerian 2008 Demographic and Health Survey was conducted among women ages 35-49 years who were considered to be in need of contraception. The outcome was modern contraceptive use while the main independent variable was a woman's household decision-making power score, constructed using principal component analysis. Multivariate logistic regression was performed to determine whether the women's household decision-making power score, categorized into tertiles, was independently associated with modern contraceptive use. Data were weighted and adjusted for the complex survey design. Results: Prevalence of modern contraceptive use among Nigerian women deemed to be in need of contraception in this study was 18.7%. Multivariate logistic regression showed that women's decision-making power remained statistically significantly associated with modern contraceptive use, even after adjusting for age, education, religion, polygyny, parity, wealth and domicile. Women who were in the highest decision-making power tertile had more than one and a half times the odds of using modern contraception compared with women in the lowest tertile [Adjusted Odds Ratio = 1.70; 95% Confidence Interval = 1.31-2.21, p<0.001]. Significance: Older Nigerian women who are involved in making household decisions are also able to make decisions related to their fertility. Programs in Nigeria focused on increasing modern contraceptive use should include strategies to increase women's status through encouraging more visible involvement in decision-making across different spheres of their lives.	[OlaOlorun, Funmilola M.] Univ Ibadan, Dept Prevent Med & Primary Care, Coll Med, Ibadan, Nigeria; [Hindin, Michelle J.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Populat Family & Reprod Hlth, Baltimore, MD USA	University of Ibadan; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	OlaOlorun, FM (corresponding author), Univ Ibadan, Dept Prevent Med & Primary Care, Coll Med, Ibadan, Nigeria.	fmolaolorun@gmail.com	OlaOlorun, Funmilola/ABN-6506-2022	OlaOlorun, Funmilola/0000-0001-5544-2875; Hindin, Michelle/0000-0001-9941-7639				Acharya DR, 2010, REPROD HEALTH, V7, DOI 10.1186/1742-4755-7-15; [Anonymous], 2002, WORLD BANK WORKSH PO; Barak B., 1981, COGNITIVE AGE NONCHR; Beasley A, 2010, SEMIN REPROD MED, V28, P147, DOI 10.1055/s-0030-1248140; Clark-Kazak CR, 2009, J DEV STUD, V45, P1307, DOI 10.1080/00220380902862952; Dimka Ritgak A, 2013, Afr J Reprod Health, V17, P102; Do M, 2012, INT PERSPECT SEX R H, V38, P23, DOI 10.1363/3802312; Federal Ministry of Women Affairs & Social Development, 2006, NIG NAT GEND POL; Feyisetan BJ, 2000, POPUL RES POLICY REV, V19, P29, DOI 10.1023/A:1006388011947; GAGE AJ, 1995, STUD FAMILY PLANN, V26, P264, DOI 10.2307/2138012; Hindin MJ, 2000, SOC SCI MED, V51, P1517, DOI 10.1016/S0277-9536(00)00051-4; Hogan DP, 1999, STUD FAMILY PLANN, V30, P302, DOI 10.1111/j.1728-4465.1999.t01-2-.x; Jacobsson B, 2004, OBSTET GYNECOL, V104, P727, DOI 10.1097/01.AOG.0000140682.63746.be; Jarrett M E, 1990, Nurse Pract, V15, P34; Jejeebhoy SJ, 2002, STUD FAMILY PLANN, V33, P299, DOI 10.1111/j.1728-4465.2002.00299.x; Jejeebhoy SJ, 2001, POPUL DEV REV, V27, P687, DOI 10.1111/j.1728-4457.2001.00687.x; Joliffe I T, 1992, Stat Methods Med Res, V1, P69, DOI 10.1177/096228029200100105; Koster W, 2010, SOC SCI MED, V71, P1788, DOI 10.1016/j.socscimed.2010.06.033; Lawrence PG, 2003, EVOLUTION HOUSEHOLD; Musalia JM, 2005, SEX ROLES, V53, P835, DOI 10.1007/s11199-005-8296-0; NPC and ICF Macro, 2009, NIG DEM HLTH SURV 20; ODDENS BJ, 1994, CONTRACEPTION, V49, P73, DOI 10.1016/0010-7824(94)90110-4; SCHULER SR, 1994, STUD FAMILY PLANN, V25, P65, DOI 10.2307/2138085; Senarath U, 2009, ASIA-PAC J PUBLIC HE, V21, P137, DOI 10.1177/1010539509331590; Sherman CA, 2005, J SOC ISSUES, V61, P139, DOI 10.1111/j.0022-4537.2005.00398.x; Stephenson R, 2008, HEALTH PLACE, V14, P841, DOI 10.1016/j.healthplace.2008.01.005; UNDESA (United Nations Department of Economic & Social Affairs), 2011, WORLD POP PROSP 2010; Woldemicael G, 2009, J BIOSOC SCI, V41, P161, DOI 10.1017/S0021932008003040	28	51	52	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2014	9	6							e98702	10.1371/journal.pone.0098702	http://dx.doi.org/10.1371/journal.pone.0098702			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AK4YO	24897300	gold, Green Published, Green Submitted			2023-01-03	WOS:000338430700068
J	Oduwole, OO; Vydra, N; Wood, NEM; Samanta, L; Owen, L; Keevil, B; Donaldson, M; Naresh, K; Huhtaniemi, IT				Oduwole, Olayiwola O.; Vydra, Natalia; Wood, Nicholas E. M.; Samanta, Luna; Owen, Laura; Keevil, Brian; Donaldson, Mandy; Naresh, Kikkeri; Huhtaniemi, Ilpo T.			Overlapping dose responses of spermatogenic and extragonadal testosterone actions jeopardize the principle of hormonal male contraception	FASEB JOURNAL			English	Article						azoospermia; oligozoospermia; hypothalamic-pituitary-testicular axis	FOLLICLE-STIMULATING-HORMONE; LUTEINIZING-HORMONE; ENANTHATE; AZOOSPERMIA; INDUCTION; PLASMA; TESTIS	Testosterone (T), alone or in combination with progestin, provides a promising approach to hormonal male contraception. Its principle relies on enhanced negative feedback of exogenous T to suppress gonadotropins, thereby blocking the testicular T production needed for spermatogenesis, while simultaneously maintaining the extragonadal androgen actions, such as potency and libido, to avoid hypogonadism. A serious drawback of the treatment is that a significant proportion of men do not reach azoospermia or severe oligozoospermia, commensurate with contraceptive efficacy. We tested here, using hypogonadal luteinizing hormone/choriongonadotropin receptor (LHCGR) knockout (LHR-/-) mice, the basic principle of the T-based male contraceptive method, that a specific T dose could maintain extragonadal androgen actions without simultaneously activating spermatogenesis. LHR-/- mice were treated with increasing T doses, and the responses of their spermatogenesis and extragonadal androgen actions (including gonadotropin suppression and sexual behavior) were assessed. Conspicuously, all dose responses to T were practically superimposable, and no dose of T could be defined that would maintain sexual function and suppress gonadotropins without simultaneously activating spermatogenesis. This finding, never addressed in clinical contraceptive trials, is not unexpected in light of the same androgen receptor mediating androgen actions in all organs. When extrapolated to humans, our findings may jeopardize the current approach to hormonal male contraception and call for more effective means of inhibiting intratesticular T production or action, to achieve consistent spermatogenic suppression.	[Oduwole, Olayiwola O.; Vydra, Natalia; Wood, Nicholas E. M.; Samanta, Luna; Huhtaniemi, Ilpo T.] Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, Dept Surg & Canc, London W12 0NN, England; [Naresh, Kikkeri] Univ London Imperial Coll Sci Technol & Med, Imperial Coll Healthcare, Natl Hlth Serv Trust, Dept Histopathol, London W12 0NN, England; [Vydra, Natalia] Marie Curie Sklodowska Univ, Mem Canc Ctr, Gliwice, Poland; [Vydra, Natalia] Inst Oncol, Gliwice, Poland; [Samanta, Luna] Ravenshaw Univ, Sch Life Sci, Dept Zool, Biochem Lab, Cuttack, Orissa, India; [Owen, Laura; Keevil, Brian] Univ S Manchester Hosp, Dept Biochem, Manchester M20 8LR, Lancs, England; [Donaldson, Mandy] Charing Cross Hosp, Imperial Coll Healthcare, Natl Hlth Serv Trust, Dept Clin Biochem, London, England	Imperial College London; Imperial College London; Maria Curie-Sklodowska University; Maria Sklodowska-Curie National Research Institute of Oncology; Ravenshaw University; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Imperial College London	Huhtaniemi, IT (corresponding author), Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, Dept Surg & Canc, Hammersmith Campus,Cane Rd, London W12 0NN, England.	ilpo.huhtaniemi@imperial.ac.uk	Samanta, Luna/H-4206-2019; keevil, brian/AAP-6147-2020	Samanta, Luna/0000-0002-2969-0071; Oduwole, Olayiwola/0000-0003-3840-7335; Vydra, Natalia/0000-0001-7749-7770; Naresh, Kikkeri N/0000-0003-3807-3638	Wellcome Trust [082101/Z/07/Z]; MRC [0600002]	Wellcome Trust(Wellcome TrustEuropean Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The authors thank Prof. Jimmy Bell [Metabolic and Molecular Imaging Group, Medical Research Council (MRC) Clinical Sciences Centre, Imperial College London] for his valuable advice on the body composition analysis. The authors also thank Jennifer H. Steel (Institute of Reproductive and Developmental Biology, Imperial College London) for advice on histology, and Tuula Hamalainen, Taina Kirjonen, and Anu Salminen (Department of Physiology, University of Turku, Turku, Finland) for the gonadotropin assay. This work was supported by the Wellcome Trust Programme, grant 082101/Z/07/Z, and the MRC, grant 0600002 to I.T.H.	ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; AMANN RP, 1962, AM J ANAT, V110, P69, DOI 10.1002/aja.1001100107; Anderson RA, 2002, ENDOCR REV, V23, P735, DOI 10.1210/er.2002-0002; [Anonymous], 1990, Lancet, V336, P955; Aribarg A, 1996, FERTIL STERIL, V65, P821; CUNNINGHAM GR, 1979, ENDOCRINOLOGY, V105, P177, DOI 10.1210/endo-105-1-177; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GEISSLER WM, 1994, NAT GENET, V7, P34, DOI 10.1038/ng0594-34; Gu XQ, 2003, J CLIN ENDOCR METAB, V88, P562, DOI 10.1210/jc.2002-020447; Gu YQ, 2009, J CLIN ENDOCR METAB, V94, P1910, DOI 10.1210/jc.2008-1846; Guerif F, 2002, INT J ANDROL, V25, P358, DOI 10.1046/j.1365-2605.2002.00382.x; HAAVISTO AM, 1993, ENDOCRINOLOGY, V132, P1687, DOI 10.1210/en.132.4.1687; HANDELSMAN DJ, 1995, FERTIL STERIL, V63, P125, DOI 10.1016/S0015-0282(16)57307-5; Handelsman DJ, 1999, ENDOCRINOLOGY, V140, P3938, DOI 10.1210/en.140.9.3938; HUHTANIEMI I, 1985, J CLIN ENDOCR METAB, V61, P698, DOI 10.1210/jcem-61-4-698; Huhtaniemi I, 2010, PROG BRAIN RES, V181, P273, DOI 10.1016/S0079-6123(08)81015-1; Ilani N, 2011, ASIAN J ANDROL, V13, P579, DOI 10.1038/aja.2010.133; KORENBROT CC, 1977, BIOL REPROD, V17, P298, DOI 10.1095/biolreprod17.2.298; Matthiesson KL, 2005, J CLIN ENDOCR METAB, V90, P5647, DOI 10.1210/jc.2005-0639; MCLACHLAN RI, 1995, TRENDS ENDOCRIN MET, V6, P95, DOI 10.1016/1043-2760(94)00215-P; McLachlan RI, 2002, J ANDROL, V23, P149; Meriggiola MC, 1996, J CLIN ENDOCR METAB, V81, P3018, DOI 10.1210/jc.81.8.3018; Mustonen MVJ, 1997, BIOCHEM J, V325, P199, DOI 10.1042/bj3250199; Narula A, 2002, J CLIN ENDOCR METAB, V87, P3399, DOI 10.1210/jc.87.7.3399; Nieschlag E, 2010, Handb Exp Pharmacol, P197, DOI 10.1007/978-3-642-02062-9_11; Nixon JP, 2010, OBESITY, V18, P1652, DOI 10.1038/oby.2009.471; O'Donnell L., 2012, TESTOSTERONE ACTION; Ogawa S, 1999, P NATL ACAD SCI USA, V96, P12887, DOI 10.1073/pnas.96.22.12887; Owen LJ, 2012, ANN CLIN BIOCHEM, V49, P600, DOI 10.1258/acb.2012.012037; ROBERTS KP, 1991, ANN NY ACAD SCI, V637, P90, DOI 10.1111/j.1749-6632.1991.tb27303.x; RUSSELL LD, 1977, ANAT RECORD, V187, P347, DOI 10.1002/ar.1091870307; SANTULLI R, 1990, ENDOCRINOLOGY, V126, P95, DOI 10.1210/endo-126-1-95; Segatelli TM, 2004, J ANDROL, V25, P872; Sharpe Richard M., 1994, P1363; Shetty G, 2000, ENDOCRINOLOGY, V141, P1735, DOI 10.1210/en.141.5.1735; SINGH J, 1995, ENDOCRINOLOGY, V136, P5311, DOI 10.1210/en.136.12.5311; STEINBERGER E, 1971, PHYSIOL REV, V51, P1, DOI 10.1152/physrev.1971.51.1.1; SUN YT, 1989, ENDOCRINOLOGY, V125, P1000, DOI 10.1210/endo-125-2-1000; TURNER TT, 1984, ENDOCRINOLOGY, V115, P1925, DOI 10.1210/endo-115-5-1925; van Casteren JIJ, 2000, BIOL REPROD, V62, P886, DOI 10.1095/biolreprod62.4.886; WALLACE EM, 1993, J CLIN ENDOCR METAB, V77, P290, DOI 10.1210/jc.77.1.290; Weiss J, 1999, LAB ANIM, V33, P192, DOI 10.1258/002367799780578417; WING TY, 1982, AM J ANAT, V165, P13, DOI 10.1002/aja.1001650103; Zhang FP, 2003, P NATL ACAD SCI USA, V100, P13692, DOI 10.1073/pnas.2232815100; Zhang FP, 2001, MOL ENDOCRINOL, V15, P172, DOI 10.1210/me.15.1.172	45	17	17	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2566	2576		10.1096/fj.13-249219	http://dx.doi.org/10.1096/fj.13-249219			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24599970	Green Published, hybrid			2023-01-03	WOS:000339883600016
J	Eticha, T; Mesfin, K				Eticha, Tadele Y.; Mesfin, Kalkidan			Self-Medication Practices in Mekelle, Ethiopia	PLOS ONE			English	Article								Background: Self-medication makes consumers more health conscious, reduces treatment burden on healthcare facilities and curtails the cost and time of obtaining access to treatment. However, it increases risks such as drug resistance, adverse drug reactions, incorrect diagnosis, drug interactions and polypharmacy. The purpose of this study was to assess the practices and factors associated with self-medication in Mekelle, Tigray region, Ethiopia. Methods: A cross-sectional study was undertaken in Mekelle from February to March 2013. A structured and pre-tested questionnaire was used for data collection to assess self-medication practices. Data were analyzed using of Statistical Package for Social Sciences (SPSS) version 20.0. Results: Among self-medicated study participants, 199(73.7%) were males and 71(26.3%) were females with mean age of 28.65 years. The most frequently reported illnesses or symptoms of illnesses that prompted self-medication of study participants were headache/fever (20.7%), gastrointestinal diseases (17.3%) and respiratory tract infections (15.9%) with the main reasons being mildness of the disease, prior experience and less expensive. The majority of drug consumers made their requests by telling their symptoms, by mentioning specific names of the drugs and by showing old samples. Analgesics/antipyretics, gastrointestinal drugs, respiratory drugs and oral rehydration salt were the most frequently requested categories of drugs. Pharmacists followed by other healthcare providers were the most frequently reported source of drug information for self-medication. Conclusions: The results of this study demonstrated that self-medication practices were common for a wide range of illnesses. Health professionals, especially community pharmacists need to educate people on the benefits and risks of selfmedication to encourage responsible self-medication.	[Eticha, Tadele Y.; Mesfin, Kalkidan] Mekelle Univ, Coll Hlth Sci, Dept Pharm, Mekelle, Ethiopia	Mekelle University	Eticha, T (corresponding author), Mekelle Univ, Coll Hlth Sci, Dept Pharm, Mekelle, Ethiopia.	td.eticha@gmail.com						Almasdy D, 2011, ARCH PHARM PRACT, V2, P95; Andualem T., 2004, ETHIOP J HEALTH SCI, V14, P1; Auta A, 2012, N AM J MED SCI, V4, P24, DOI 10.4103/1947-2714.92899; Belachew G., 2011, J APPL PHARM SCI, V1, P183; da Silva MGC, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-339; Covington TR, 2006, AM J PHARM EDUC, V70, DOI 10.5688/aj7006137; Gaddam D, 2012, IJHP, V49, P79; Hughes CM, 2001, DRUG SAFETY, V24, P1027, DOI 10.2165/00002018-200124140-00002; Hussain A., 2008, S MED REV, V1, P14; Jain P, 2012, INDO GLOBAL J PHARM, V2, P21; Khade AM, 2012, INT J BASIC APP MED, V2, P254; Kumar N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072247; Patil A, 2013, INT J BASIC CLIN PHA, V2, P498, DOI [10.5455/2319-2003.ijbcp20130829, DOI 10.5455/2319-2003.IJBCP20130829]; Sapkota AR, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-610; Solomon Worku, 2003, Ethiopian Journal of Health Development, V17, P111; Sweileh WM, 2004, J AL AQSA U, V8, P1; Tamuno I., 2011, J BASIC APPL SCI RES, V1, P1319; World Health Organization, ROL PHARM SELF CAR S	18	45	45	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2014	9	5							e97464	10.1371/journal.pone.0097464	http://dx.doi.org/10.1371/journal.pone.0097464			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI1ZC	24820769	Green Submitted, Green Published, gold			2023-01-03	WOS:000336653300116
J	McCartney, M				McCartney, Margaret			NO HOLDS BARRED How the UK drug regulator became the herbalists' marketeer	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				Cameron M, 2013, COCHRANE DATABASE SY, V5; Ernst E, 1998, ARCH SURG-CHICAGO, V133, P1187, DOI 10.1001/archsurg.133.11.1187; Gagnier JJ, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004504; Medicines and Healthcare Products Regulatory Agency, 2011, REG YOUR PROD TRAD H; Medicines and Healthcare Products Regulatory Agency, 2013, LIST PROD GRANT TRAD; Medicines and Healthcare Products Regulatory Agency, 2011, HERB MED REG LIC HER; PITTLER MH, 2004, COCHRANE DB SYST REV, V1; Tacklind J, 2012, COCHRANE DB SYST REV, V12	8	4	4	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 9	2014	348								g3194	10.1136/bmj.g3194	http://dx.doi.org/10.1136/bmj.g3194			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AH0OT	24816732				2023-01-03	WOS:000335820400005
J	Ocak, G; Drechsler, C; Vossen, CY; Vos, HL; Rosendaal, FR; Reitsma, PH; Hoffmann, MM; Marz, W; Ouwehand, WH; Krediet, RT; Boeschoten, EW; Dekker, FW; Wanner, C; Verduijn, M				Ocak, Gurbey; Drechsler, Christiane; Vossen, Carla Y.; Vos, Hans L.; Rosendaal, Frits R.; Reitsma, Pieter H.; Hoffmann, Michael M.; Maerz, Winfried; Ouwehand, Willem H.; Krediet, Raymond T.; Boeschoten, Elisabeth W.; Dekker, Friedo W.; Wanner, Christoph; Verduijn, Marion			Single Nucleotide Variants in the Protein C Pathway and Mortality in Dialysis Patients	PLOS ONE			English	Article							HUMAN BRAIN ENDOTHELIUM; FACTOR-V-LEIDEN; VENOUS THROMBOSIS; ACTIVATED RECEPTOR-1; VASCULAR ACCESS; SEVERE SEPSIS; GENE POLYMORPHISM; ORGAN DYSFUNCTION; ISCHEMIC-STROKE; RENAL-DISEASE	Background: The protein C pathway plays an important role in the maintenance of endothelial barrier function and in the inflammatory and coagulant processes that are characteristic of patients on dialysis. We investigated whether common single nucleotide variants (SNV) in genes encoding protein C pathway components were associated with all-cause 5 years mortality risk in dialysis patients. Methods: Single nucleotides variants in the factor V gene (F5 rs6025; factor V Leiden), the thrombomodulin gene (THBD rs1042580), the protein C gene (PROC rs1799808 and 1799809) and the endothelial protein C receptor gene (PROCR rs867186, rs2069951, and rs2069952) were genotyped in 1070 dialysis patients from the NEtherlands COoperative Study on the Adequacy of Dialysis (NECOSAD) cohort) and in 1243 dialysis patients from the German 4D cohort. Results: Factor V Leiden was associated with a 1.5-fold (95% CI 1.1-1.9) increased 5-year all-cause mortality risk and carriers of the AG/GG genotypes of the PROC rs1799809 had a 1.2-fold (95% CI 1.0-1.4) increased 5-year all-cause mortality risk. The other SNVs in THBD, PROC, and PROCR were not associated with 5-years mortality. Conclusion: Our study suggests that factor V Leiden and PROC rs1799809 contributes to an increased mortality risk in dialysis patients.	[Ocak, Gurbey; Vossen, Carla Y.; Rosendaal, Frits R.; Dekker, Friedo W.; Verduijn, Marion] Leiden Univ Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands; [Drechsler, Christiane; Wanner, Christoph] Univ Hosp, Dept Med, Div Nephrol, Wurzburg, Germany; [Drechsler, Christiane; Wanner, Christoph] Univ Wurzburg, Comprehens Heart Failure Ctr, Wurzburg, Germany; [Drechsler, Christiane] Univ Wurzburg, Inst Clin Epidemiol & Biometry, Wurzburg, Germany; [Vos, Hans L.; Rosendaal, Frits R.; Reitsma, Pieter H.] Leiden Univ Med Ctr, Dept Thrombosis & Haemostasis, Leiden, Netherlands; [Vos, Hans L.; Rosendaal, Frits R.; Reitsma, Pieter H.] Leiden Univ Med Ctr, Einthoven Lab Expt Vasc Med, Leiden, Netherlands; [Hoffmann, Michael M.] Univ Med Ctr, Inst Clin Chem & Lab Med, Freiburg, Germany; [Maerz, Winfried] Heidelberg Univ, Dept Publ Hlth Social & Prevent Med, Mannheim, Germany; [Ouwehand, Willem H.] Univ Cambridge, Dept Hematol, Cambridge, England; [Ouwehand, Willem H.] Natl Hlth Serv Blood & Transplant, Cambridge, England; [Ouwehand, Willem H.] Wellcome Trust Sanger Inst, Dept Human Genet, Cambridge, England; [Krediet, Raymond T.] Univ Amsterdam, Acad Med Ctr, Dept Nephrol, NL-1105 AZ Amsterdam, Netherlands; [Boeschoten, Elisabeth W.] Hans Mak Inst, Naarden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); University of Wurzburg; University of Wurzburg; University of Wurzburg; Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); University of Freiburg; Ruprecht Karls University Heidelberg; University of Cambridge; NHS Blood & Transplant (NHSBT); Wellcome Trust Sanger Institute; University of Amsterdam; Academic Medical Center Amsterdam	Ocak, G (corresponding author), Leiden Univ Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands.	g.ocak@lumc.nl	Hoffmann, Michael M/D-4074-2015; Krediet, Raymond/GLT-2390-2022; Krediet, Raymond/AAP-3291-2021; Dekker, Friedo W/B-6452-2011; Rosendaal, Frits/Q-3842-2017	Hoffmann, Michael M/0000-0001-8459-6080; Krediet, Raymond/0000-0002-9851-8507; Dekker, Friedo W/0000-0002-2433-2494; Rosendaal, Frits/0000-0003-2558-7496; Ouwehand, Willem/0000-0002-7744-1790	Dutch Kidney Foundation; British Heart Foundation [RG/09/012/28096] Funding Source: researchfish; National Institute for Health Research [NF-SI-0510-10214, RP-PG-0310-1002, NF-SI-0513-10151] Funding Source: researchfish	Dutch Kidney Foundation; British Heart Foundation(British Heart Foundation); National Institute for Health Research(National Institute for Health Research (NIHR))	The NECOSAD was supported in part by unrestricted grants from the Dutch Kidney Foundation. No additional funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALLAART CF, 1993, LANCET, V341, P134, DOI 10.1016/0140-6736(93)90003-Y; Allon M, 2012, AM J KIDNEY DIS, V59, P682, DOI 10.1053/j.ajkd.2011.11.036; Auro K, 2007, PLOS GENET, V3, P1244, DOI 10.1371/journal.pgen.0030120; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; Bezemer ID, 2008, JAMA-J AM MED ASSOC, V299, P1306, DOI 10.1001/jama.299.11.1306; BRANSON HE, 1983, LANCET, V2, P1165; Casserly LF, 2000, AM J KIDNEY DIS, V36, P405, DOI 10.1053/ajkd.2000.8983; Chen QX, 2008, HUM GENET, V123, P281, DOI 10.1007/s00439-008-0476-x; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; de Jager DJ, 2009, JAMA-J AM MED ASSOC, V302, P1782, DOI 10.1001/jama.2009.1488; De Willige SU, 2004, J THROMB HAEMOST, V2, P1305, DOI 10.1046/j.1538-7836.2004.00855.x; Domotor E, 2003, BLOOD, V101, P4797, DOI 10.1182/blood-2002-12-3680; Feldman HI, 1996, J AM SOC NEPHROL, V7, P523; Folsom AR, 1999, CIRCULATION, V100, P736, DOI 10.1161/01.CIR.100.7.736; Girndt M, 2007, SEMIN DIALYSIS, V20, P63, DOI 10.1111/j.1525-139X.2007.00243.x; Heijmans BT, 1998, THROMB HAEMOSTASIS, V80, P607; Ireland H, 2005, ATHEROSCLEROSIS, V183, P283, DOI 10.1016/j.atherosclerosis.2005.02.028; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Kenet G, 2000, STROKE, V31, P1283, DOI 10.1161/01.STR.31.6.1283; Knoll GA, 2005, J AM SOC NEPHROL, V16, P1108, DOI 10.1681/ASN.2004110999; Mosnier LO, 2007, BLOOD, V109, P3161, DOI 10.1182/blood-2006-09-003004; Mosnier LO, 2003, BIOCHEM J, V373, P65, DOI 10.1042/BJ20030341; Pabinger I, 2012, J THROMB HAEMOST, V10, P217, DOI 10.1111/j.1538-7836.2011.04573.x; Pomp ER, 2009, THROMB HAEMOSTASIS, V101, P62, DOI 10.1160/TH08-08-0502; Reiner AP, 2008, J THROMB HAEMOST, V6, P1625, DOI 10.1111/j.1538-7836.2008.03118.x; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Saposnik B, 2004, BLOOD, V103, P1311, DOI 10.1182/blood-2003-07-2520; Smith NL, 2007, JAMA-J AM MED ASSOC, V297, P489, DOI 10.1001/jama.297.5.489; Tveit DP, 2002, AM J KIDNEY DIS, V39, P1011, DOI 10.1053/ajkd.2002.32774; van Dijk PCW, 2001, NEPHROL DIAL TRANSPL, V16, P1120, DOI 10.1093/ndt/16.6.1120; Verduijn M, 2011, NEPHRON CLIN PRACT, V119, pC236, DOI 10.1159/000326685; Walley KR, 2007, CRIT CARE MED, V35, P12, DOI 10.1097/01.CCM.0000249823.44726.4E; Wanner C, 2005, NEW ENGL J MED, V353, P238, DOI 10.1056/NEJMoa043545; Ye Z, 2006, LANCET, V367, P651, DOI 10.1016/S0140-6736(06)68263-9	35	5	7	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2014	9	5							e97251	10.1371/journal.pone.0097251	http://dx.doi.org/10.1371/journal.pone.0097251			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI4LX	24816905	Green Submitted, Green Published, gold			2023-01-03	WOS:000336838000123
J	Ginsburg, G				Ginsburg, Geoffrey			Gather and use genetic data in health care	NATURE			English	Editorial Material							GENOMIC MEDICINE; WARFARIN		Duke Univ, Durham, NC 27706 USA	Duke University	Ginsburg, G (corresponding author), Duke Univ, Durham, NC 27706 USA.	geoffrey.ginsburg@duke.edu						Gilfillan RJ, 2010, AM J MANAG CARE, V16, P607; Green ED, 2011, NATURE, V470, P204, DOI 10.1038/nature09764; Green RC, 2013, GENET MED, V15, P565, DOI 10.1038/gim.2013.73; Kimmel SE, 2013, NEW ENGL J MED, V369, P2283, DOI 10.1056/NEJMoa1310669; Lynch JA, 2013, GENET MED, V15, P630, DOI 10.1038/gim.2013.5; Mallal S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMoa0706135; Manolio TA, 2013, GENET MED, V15, P258, DOI 10.1038/gim.2012.157; Pirmohamed M, 2013, NEW ENGL J MED, V369, P2294, DOI 10.1056/NEJMoa1311386; Van Driest SL, 2014, CLIN PHARMACOL THER, V95, P423, DOI 10.1038/clpt.2013.229; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122	10	35	36	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 24	2014	508	7497					451	453		10.1038/508451a	http://dx.doi.org/10.1038/508451a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AF5GI	24765668	Bronze			2023-01-03	WOS:000334741600011
J	Azzopardi, EA; Azzopardi, E; Camilleri, L; Villapalos, J; Boyce, DE; Dziewulski, P; Dickson, WA; Whitaker, IS				Azzopardi, Ernest A.; Azzopardi, Elayne; Camilleri, Liberato; Villapalos, Jorge; Boyce, Dean E.; Dziewulski, Peter; Dickson, William A.; Whitaker, Iain S.			Gram Negative Wound Infection in Hospitalised Adult Burn Patients-Systematic Review and Metanalysis-	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; ANTIMICROBIAL RESISTANCE; ACINETOBACTER-BAUMANNII; RISK-FACTORS; BACTERIOLOGY; EPIDEMIOLOGY; SURVEILLANCE; ACQUISITION; PATHOGENS; INJURIES	Background: Gram negative infection is a major determinant of morbidity and survival. Traditional teaching suggests that burn wound infections in different centres are caused by differing sets of causative organisms. This study established whether Gram-negative burn wound isolates associated to clinical wound infection differ between burn centres. Methods: Studies investigating adult hospitalised patients (2000-2010) were critically appraised and qualified to a levels of evidence hierarchy. The contribution of bacterial pathogen type, and burn centre to the variance in standardised incidence of Gram-negative burn wound infection was analysed using two-way analysis of variance. Primary Findings: Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumanni, Enterobacter spp., Proteus spp. and Escherichia coli emerged as the commonest Gram-negative burn wound pathogens. Individual pathogens' incidence did not differ significantly between burn centres (F (4, 20) = 1.1, p = 0.3797; r2 = 9.84). Interpretation: Gram-negative infections predominate in burn surgery. This study is the first to establish that burn wound infections do not differ significantly between burn centres. It is the first study to report the pathogens responsible for the majority of Gram-negative infections in these patients. Whilst burn wound infection is not exclusive to these bacteria, it is hoped that reporting the presence of this group of common Gram-negative "target organisms'' facilitate clinical practice and target research towards a defined clinical demand.	[Azzopardi, Ernest A.; Whitaker, Iain S.] Swansea Univ, Coll Med, Inst Life Sci, Swansea, W Glam, Wales; [Azzopardi, Ernest A.; Boyce, Dean E.; Dickson, William A.; Whitaker, Iain S.] Morriston Hosp, Welsh Ctr Burns & Plast Surg, Swansea, W Glam, Wales; [Azzopardi, Elayne] Manchester Metropolitan Univ, Res Inst Hlth & Social Change, Fac Hlth Psychol & Social Care, Manchester M15 6BH, Lancs, England; [Camilleri, Liberato] Univ Malta, Dept Stat & Operat, Msida, Malta; [Villapalos, Jorge] Chelsea & Westminster Hosp NHS Trust, Dept Burns & Plast Surg, London, England; [Dziewulski, Peter] St Andrews Ctr Burns & Plast Surg, Chelmsford, England	Swansea University; Morriston Hospital; Manchester Metropolitan University; University of Malta; Imperial College London	Azzopardi, EA (corresponding author), Swansea Univ, Coll Med, Inst Life Sci, Singleton Pk, Swansea, W Glam, Wales.	ernest_azzopardi@yahoo.co.uk	Azzopardi, Elayne/AAE-2342-2021; Whitaker, Iain/O-5896-2019	Whitaker, Iain/0000-0002-3922-2079; Azzopardi, Ernest/0000-0002-4511-0954	Strategic Educational Pathways Scholarship Malta; European Union - European Social Fund	Strategic Educational Pathways Scholarship Malta; European Union - European Social Fund(European Social Fund (ESF))	EA and EAA are funded by the Strategic Educational Pathways Scholarship Malta, co-financed by by the European Union - European Social Fund under Operational Programme II. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Individuals employed or contracted by the funders (other than the named authors) played no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agnihotri N, 2004, BURNS, V30, P241, DOI 10.1016/j.burns.2003.11.010; Appelgren P, 2002, BURNS, V28, P39, DOI 10.1016/S0305-4179(01)00070-5; Azzopardi E, 2009, CHARACTERISING AETIO; Azzopardi EA, 2013, BIORESPONSIVE DEXTRI; Azzopardi E, 2014, LANCET, V383, P9; Azzopardi EA, 2013, J CARBOHYD CHEM, V32, P438, DOI 10.1080/07328303.2013.831434; Azzopardi EA, 2013, J ANTIMICROB CHEMOTH, V68, P257, DOI 10.1093/jac/dks379; Azzopardi EA, 2009, BURNS, V35, P911, DOI 10.1016/j.burns.2009.03.001; Boucher HW, 2009, CLIN INFECT DIS, V48, P1, DOI 10.1086/595011; British Association of Antimicrobial Chemotherapy, 2009, BURN WOUND INF; Calum H, 2009, CLIN EXP IMMUNOL, V156, P102, DOI 10.1111/j.1365-2249.2008.03861.x; Chim H, 2007, BURNS, V33, P1008, DOI 10.1016/j.burns.2007.03.003; Chim H, 2007, BURNS, V33, P756, DOI 10.1016/j.burns.2006.10.389; Church D, 2006, CLIN MICROBIOL REV, V19, P403, DOI 10.1128/CMR.19.2.403-434.2006; Cochrane A., 1972, PUBLIC HEALTH, DOI DOI 10.1016/S0033-3506(73)80082-4; D'Avignon LC, 2010, BURNS, V36, P773, DOI 10.1016/j.burns.2009.11.007; DATUBOBROWN DD, 1989, BURNS, V15, P152, DOI 10.1016/0305-4179(89)90170-8; Dawes Martin, 2005, BMC Med Educ, V5, P1; Gales AC, 2011, J ANTIMICROB CHEMOTH, V66, P2070, DOI 10.1093/jac/dkr239; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Gomez R, 2009, J AM COLL SURGEONS, V208, P348, DOI 10.1016/j.jamcollsurg.2008.11.012; Greenhalgh DG, 2007, J BURN CARE RES, V28, P776, DOI 10.1097/BCR.0b013e3181599bc9; Guo S, 2010, J DENT RES, V89, P219, DOI 10.1177/0022034509359125; Herndon D.N., 2007, TOTAL BURN CARE; Herruzo R, 2004, BURNS, V30, P419, DOI 10.1016/j.burns.2004.01.008; Ipaktchi K, 2006, J IMMUNOL, V177, P8065, DOI 10.4049/jimmunol.177.11.8065; Kaushik R, 2001, BURNS, V27, P595, DOI 10.1016/S0305-4179(01)00023-7; Keen EF, 2010, BURNS, V36, P819, DOI 10.1016/j.burns.2009.10.013; Keen EF, 2010, BURNS, V36, P461, DOI 10.1016/j.burns.2009.10.012; Khorasani G, 2008, BURNS, V34, P947, DOI 10.1016/j.burns.2007.12.008; Komolafe OO, 2003, BURNS, V29, P235, DOI 10.1016/S0305-4179(02)00273-5; Lari AR, 2000, BURNS, V26, P737, DOI 10.1016/S0305-4179(00)00048-6; Lindholm LH, 2002, LANCET, V359, P1004, DOI 10.1016/S0140-6736(02)08090-X; Mayer D, 2004, EVIDENCE BASED MED; Mayhall CG, 2003, CLIN INFECT DIS, V37, P543, DOI 10.1086/376993; Muir-Gray J., 1997, EVIDENCE BASED HEALT, V2; Murray CK, 2008, J TRAUMA, V64, pS232, DOI 10.1097/TA.0b013e318163c3f5; National Library of Medicine, 2009, MESH BROWS; Newman M, 2002, EVIDENCE BASED PRACT, P86; Ozkurt Z, 2005, BURNS, V31, P870, DOI 10.1016/j.burns.2005.04.015; Ozumba UC, 2000, BURNS, V26, P178, DOI 10.1016/S0305-4179(99)00075-3; Peck MD, 1998, J BURN CARE REHABIL, V19, P386, DOI 10.1097/00004630-199809000-00005; Phillips P, 2001, OXFORD CTR EVIDENCE; Polavarapu N, 2008, J CRANIOFAC SURG, V19, P899, DOI 10.1097/SCS.0b013e318175b4f0; Polit D, 2006, ESSENTIALS NURSING R, V2, P11; PORZSOLT F, 2003, EV BASED MED, V8, P165, DOI DOI 10.1136/EBM.8.6.165; Pruitt BA, 1998, WORLD J SURG, V22, P135; Rice LB, 2008, J INFECT DIS, V197, P1079, DOI 10.1086/533452; ROSENBERG W, 1995, BMJ-BRIT MED J, V310, P1122, DOI 10.1136/bmj.310.6987.1122; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; Silla RC, 2006, BURNS, V32, P139, DOI 10.1016/j.burns.2005.09.002; Simor AE, 2002, INFECT CONT HOSP EP, V23, P261, DOI 10.1086/502046; Singh NP, 2003, BURNS, V29, P129, DOI 10.1016/S0305-4179(02)00249-8; Straus S., 2005, EVIDENCE BASED MED P; Tredget EE, 2004, BURNS, V30, P3, DOI 10.1016/j.burns.2003.08.007; Valerie EJ, 2003, BURNS, V29, P15, DOI 10.1016/S0305-4179(02)00203-6; Wibbenmeyer L, 2006, J BURN CARE RES, V27, P152, DOI 10.1097/01.BCR.0000203359.32756.F7	57	105	109	3	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 21	2014	9	4							e95042	10.1371/journal.pone.0095042	http://dx.doi.org/10.1371/journal.pone.0095042			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG2DX	24751699	Green Published, Green Submitted, gold			2023-01-03	WOS:000335227400026
J	Smodis, NC; Silar, M; Erzen, R; Rijavec, M; Kosnik, M; Korosec, P				Smodis, Nina Celesnik; Silar, Mira; Erzen, Renato; Rijavec, Matija; Kosnik, Mitja; Korosec, Peter			Down-Regulation of Fc epsilon RI-Mediated CD63 Basophil Response during Short-Term VIT Determined Venom-Nonspecific Desensitization	PLOS ONE			English	Article							ALLERGEN-SPECIFIC IMMUNOTHERAPY; LEUKOCYTE SENSITIVITY; THRESHOLD-SENSITIVITY; INJECTION THERAPY; IGE-SENSITIZATION; HISTAMINE; RELEASE; ACTIVATION; MECHANISMS; CHALLENGE	Background: We recently showed a desensitization of Fc epsilon RI-mediated basophil response after short-term VIT. Our aim was to evaluate the allergen specificity of this desensitization. Methods: In 11 Hymenoptera-venom double positive subjects, basophil threshold sensitivity (CD-sens) to anti-Fc epsilon RI, honeybee, and Vespula venom was assessed at the beginning and just before the first maintenance dose (MD) of single ultra-rush VIT. In some patients we also monitored CD-sens to rApi m 1 and/or rVes v 5 or other co-sensitizations (i.e., grass pollen). In additional 7 patients, basophils were stripped and sensitized with house dust mite (HDM) IgEs at the same time points. Results: We demonstrated a marked reduction of CD-sens to anti-FceRI and VIT-specific venom before the first MD in all 18 subjects included. Furthermore, in 10 out of 11 double positive subjects, a significant and comparable decrease before the first MD was also evident for non-VIT venom; this nonspecific decrease was further supported by the opposite recombinant species-specific major allergen. In one subject with additional grass pollen allergy, a decrease of CD-sens to grass allergen was also demonstrated. Similarly, in 7 cases of patients with passively HDM-sensitized basophils, a significant reduction of CD-sens was also evident to de novo sensitized HDM allergen. Conclusions: Short-term VIT induced basophil desensitization to VIT-specific as well as to VIT-nonspecific venom. As opposed to long-term VIT, which induces venom-specific changes, the effect of short-term VIT seems to be venom-nonspecific.	[Smodis, Nina Celesnik; Silar, Mira; Erzen, Renato; Rijavec, Matija; Kosnik, Mitja; Korosec, Peter] Univ Clin Resp & Allerg Dis Golnik, Golnik, Slovenia	University Clinic Golnik	Smodis, NC (corresponding author), Univ Clin Resp & Allerg Dis Golnik, Golnik, Slovenia.	nina.celesnik@klinika-golnik.si	Košnik, Mitja/AAI-2295-2019	Košnik, Mitja/0000-0002-4701-7374; Korosec, Peter/0000-0002-0835-1599; Rijavec, Matija/0000-0002-2596-4952	Slovenian Research Agency	Slovenian Research Agency(Slovenian Research Agency - Slovenia)	The study was supported by the Slovenian Research Agency. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Bieber T, 2011, ALLERGY, V66, P709, DOI 10.1111/j.1398-9995.2011.02595.x; Bilo BM, 2011, IMMUNOTHERAPY-UK, V3, P229, DOI 10.2217/IMT.10.88; Bilo MB, 2011, ALLERGY, V66, P35, DOI 10.1111/j.1398-9995.2011.02630.x; Bonifazi F, 2005, ALLERGY, V60, P1459, DOI 10.1111/j.1398-9995.2005.00960.x; Bussmann C, 2010, ALLERGY, V65, P1558, DOI 10.1111/j.1398-9995.2010.02430.x; Celesnik N, 2012, ALLERGY, V67, P1594, DOI 10.1111/all.12044; Eckman JA, 2010, J ALLERGY CLIN IMMUN, V125, P889, DOI 10.1016/j.jaci.2009.09.012; Erzen R, 2012, ALLERGY, V67, P822, DOI 10.1111/j.1398-9995.2012.02817.x; FORCK G, 1986, ALLERGOLOGIE, V9, pS18; Glaumann S, 2012, ALLERGY, V67, P242, DOI 10.1111/j.1398-9995.2011.02754.x; Goldberg A, 2010, ALLERGY, V65, P391, DOI 10.1111/j.1398-9995.2009.02198.x; Johansson SGO, 2009, ALLERGY, V64, P1472, DOI 10.1111/j.1398-9995.2009.02051.x; Johansson SGO, 2005, ALLERGY, V60, P1192, DOI 10.1111/j.1398-9995.2005.00870.x; Jutel M, 1996, CLIN EXP ALLERGY, V26, P1112, DOI 10.1111/j.1365-2222.1996.tb00496.x; Jutel M, 2011, ALLERGY, V66, P725, DOI 10.1111/j.1398-9995.2011.02589.x; Karasuyama H, 2011, ALLERGY, V66, P1133, DOI 10.1111/j.1398-9995.2011.02613.x; Korosec P, 2013, INT ARCH ALLERGY IMM, V161, P363, DOI 10.1159/000348500; Korosec P, 2011, J ALLERGY CLIN IMMUN, V128, P671, DOI 10.1016/j.jaci.2011.03.012; Kosnik M, 2003, ALLERGY HYPERSENSITI, V1, P33; Lalek N, 2010, CLIN EXP ALLERGY, V40, P1186, DOI 10.1111/j.1365-2222.2010.03524.x; MACGLASHAN DW, 1981, J IMMUNOL, V127, P2410; MAY C D, 1973, Clinical Allergy, V3, P319, DOI 10.1111/j.1365-2222.1973.tb01340.x; MAY CD, 1972, J ALLERGY CLIN IMMUN, V50, P99, DOI 10.1016/0091-6749(72)90005-X; MAY CD, 1971, J ALLERGY CLIN IMMUN, V48, P313, DOI 10.1016/0091-6749(71)90033-9; Mikkelsen Susan, 2010, Clin Mol Allergy, V8, P2, DOI 10.1186/1476-7961-8-2; Mittermann I, 2010, J ALLERGY CLIN IMMUN, V125, P1300, DOI 10.1016/j.jaci.2010.03.017; Nopp A, 2009, ALLERGY, V64, P811, DOI 10.1111/j.1398-9995.2008.01900.x; Novak N, 2012, J ALLERGY CLIN IMMUN, V130, P1153, DOI 10.1016/j.jaci.2012.04.039; Nullens S, 2013, CYTOM PART B-CLIN CY, V84B, P173, DOI 10.1002/cyto.b.21084; Pierkes M, 1999, J ALLERGY CLIN IMMUN, V103, P326, DOI 10.1016/S0091-6749(99)70509-9; Plewako H, 2006, INT ARCH ALLERGY IMM, V141, P346, DOI 10.1159/000095461; Savage JH, 2012, J ALLERGY CLIN IMMUN, V130, P1123, DOI 10.1016/j.jaci.2012.05.039; SOBOTKA AK, 1979, J IMMUNOL, V122, P511; Varga EM, 2009, CLIN EXP ALLERGY, V39, P1353, DOI 10.1111/j.1365-2222.2009.03303.x; Zitnik SEK, 2012, PEDIAT ALLERG IMM-UK, V23, P167, DOI 10.1111/j.1399-3038.2011.01233.x	36	8	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 14	2014	9	4							e94762	10.1371/journal.pone.0094762	http://dx.doi.org/10.1371/journal.pone.0094762			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI6GP	24733549	Green Published, gold, Green Submitted			2023-01-03	WOS:000336970400093
J	Caironi, P; Tognoni, G; Masson, S; Fumagalli, R; Pesenti, A; Romero, M; Fanizza, C; Caspani, L; Faenza, S; Grasselli, G; Iapichino, G; Antonelli, M; Parrini, V; Fiore, G; Latini, R; Gattinoni, L				Caironi, Pietro; Tognoni, Gianni; Masson, Serge; Fumagalli, Roberto; Pesenti, Antonio; Romero, Marilena; Fanizza, Caterina; Caspani, Luisa; Faenza, Stefano; Grasselli, Giacomo; Iapichino, Gaetano; Antonelli, Massimo; Parrini, Vieri; Fiore, Gilberto; Latini, Roberto; Gattinoni, Luciano		ALBIOS Study Investigators	Albumin Replacement in Patients with Severe Sepsis or Septic Shock	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-SERUM-ALBUMIN; ORGAN DYSFUNCTION/FAILURE; INTENSIVE-CARE; NITRIC-OXIDE; CONTROLLED-TRIALS; SOFA SCORE; METAANALYSIS; MULTICENTER; FLUID; RESUSCITATION	BackgroundAlthough previous studies have suggested the potential advantages of albumin administration in patients with severe sepsis, its efficacy has not been fully established. MethodsIn this multicenter, open-label trial, we randomly assigned 1818 patients with severe sepsis, in 100 intensive care units (ICUs), to receive either 20% albumin and crystalloid solution or crystalloid solution alone. In the albumin group, the target serum albumin concentration was 30 g per liter or more until discharge from the ICU or 28 days after randomization. The primary outcome was death from any cause at 28 days. Secondary outcomes were death from any cause at 90 days, the number of patients with organ dysfunction and the degree of dysfunction, and length of stay in the ICU and the hospital. ResultsDuring the first 7 days, patients in the albumin group, as compared with those in the crystalloid group, had a higher mean arterial pressure (P=0.03) and lower net fluid balance (P<0.001). The total daily amount of administered fluid did not differ significantly between the two groups (P=0.10). At 28 days, 285 of 895 patients (31.8%) in the albumin group and 288 of 900 (32.0%) in the crystalloid group had died (relative risk in the albumin group, 1.00; 95% confidence interval [CI], 0.87 to 1.14; P=0.94). At 90 days, 365 of 888 patients (41.1%) in the albumin group and 389 of 893 (43.6%) in the crystalloid group had died (relative risk, 0.94; 95% CI, 0.85 to 1.05; P=0.29). No significant differences in other secondary outcomes were observed between the two groups. ConclusionsIn patients with severe sepsis, albumin replacement in addition to crystalloids, as compared with crystalloids alone, did not improve the rate of survival at 28 and 90 days. (Funded by the Italian Medicines Agency; ALBIOS ClinicalTrials.gov number, NCT00707122.) In patients with severe sepsis, albumin replacement in addition to crystalloid administration conferred no benefit, as compared with crystalloids alone, with respect to mortality at 28 or 90 days. Post hoc analysis suggested a possible benefit in patients with septic shock. For decades, human albumin has been administered to patients to provide adequate oncotic pressure and intravascular volume.(1) In 1998, however, a report from the Cochrane Injuries Group Albumin Reviewers indicated that the administration of albumin may be potentially harmful in critically ill patients, as compared with the administration of crystalloid solutions.(2) Subsequent meta-analyses reported contradictory findings.(3),(4) To clarify this issue, a large, double-blind, randomized trial (the Saline versus Albumin Fluid Evaluation [SAFE] study)(5) was conducted, in which 4% albumin solution was compared with normal saline as fluid replacement in critically ill patients, with results indicating that albumin administration was ...	[Caironi, Pietro; Tognoni, Gianni; Gattinoni, Luciano] Univ Milan, Dipartimento Fisiopatol Medico Chirurg & Trapiant, Fdn IRCCS Granda, Osped Maggiore Policlinico, I-20122 Milan, Italy; [Caironi, Pietro; Caspani, Luisa; Gattinoni, Luciano] Univ Milan, Dipartimento Anestesia, Rianimazione Terapia Dolore, Fdn IRCCS Granda,Osped Maggiore Policlin, Milan, Italy; [Masson, Serge; Latini, Roberto] IRCCS, Ist Ric Farmacolo Mario Negri, Milan, Italy; [Fumagalli, Roberto; Pesenti, Antonio] Univ Milano Bicocca, Dipartimento Sci Salute, Milan, Italy; [Iapichino, Gaetano] Polo Univ, Dipartimento Emergenza Urgenza, Azienda Osped S Paolo, Milan, Italy; [Faenza, Stefano] Policlinico Univ S Orsola Malpighi, Anestesiol Rianimazione, Dipartimento Emergenza Urgenza, Bologna, Italy; [Grasselli, Giacomo] Azienda Ospedaliera S Gerardo, Dipartimento Emergenza Urgenza, Monza, Italy; [Antonelli, Massimo] Univ Cattol, Policlinico Univ Gemelli, Rome, Italy; [Parrini, Vieri] Osped Mugello Azienda Sanitaria Firenze, Florence, Italy; [Fiore, Gilberto] Osped S Croce, Moncalieri, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of Milano-Bicocca; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Catholic University of the Sacred Heart; Azienda Sanitaria di Firenze	Gattinoni, L (corresponding author), Univ Milan, Dipartimento Fisiopatol Medico Chirurg & Trapiant, Fdn IRCCS Granda, Osped Maggiore Policlinico, Via F Sforza 35, I-20122 Milan, Italy.	gattinon@policlinico.mi.it	Fumagalli, Roberto/AAB-9746-2019; Pesenti, Antonio/H-7483-2012; Latini, Roberto/AAB-1410-2020; Rocco, Monica/B-8407-2013; Colombo, Riccardo/AAK-9081-2020; Cortegiani, Andrea/H-4902-2016; Antonelli, Massimo/K-9915-2016; Casadio, Rita/K-3747-2017; Volta, Carlo A/G-5981-2012; Iacobone, Emanuele/AAJ-8335-2020; Chelazzi, Cosimo/E-5611-2017; Panigada, Mauro/K-4650-2014	Fumagalli, Roberto/0000-0003-0398-1329; Pesenti, Antonio/0000-0003-2593-729X; Latini, Roberto/0000-0002-3729-4650; Rocco, Monica/0000-0001-8380-3607; Colombo, Riccardo/0000-0002-9616-803X; Cortegiani, Andrea/0000-0003-1416-9993; Antonelli, Massimo/0000-0003-3007-1670; Volta, Carlo A/0000-0003-3533-6121; Gattinoni, Luciano/0000-0001-5380-2494; Chelazzi, Cosimo/0000-0002-5156-8638; Panigada, Mauro/0000-0003-4841-9794; Caironi, Pietro/0000-0003-0490-0818; Raineri, Santi Maurizio/0000-0002-0675-2399; Bottazzi, Andrea/0000-0002-5531-298X; GIARRATANO, Antonino/0000-0001-9344-8311; Grasselli, Giacomo/0000-0002-1735-1400; Vincent, Jean-Louis/0000-0001-6011-6951; martini, alvise/0000-0002-7280-5356	Italian Medicines Agency	Italian Medicines Agency	Supported by the Italian Medicines Agency.	BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Delaney AP, 2011, CRIT CARE MED, V39, P386, DOI 10.1097/CCM.0b013e3181ffe217; Dubois MJ, 2006, CRIT CARE MED, V34, P2536, DOI 10.1097/01.CCM.0000239119.57544.0C; ERSTAD BL, 1991, ARCH INTERN MED, V151, P901, DOI 10.1001/archinte.151.5.901; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Finfer S, 2011, INTENS CARE MED, V37, P86, DOI 10.1007/s00134-010-2039-6; Hollenberg SM, 1997, AM J PHYSIOL-REG I, V272, pR969, DOI 10.1152/ajpregu.1997.272.3.R969; Kellum JA, 2007, CONTRIB NEPHROL, V156, P10; KING TP, 1961, J BIOL CHEM, V236, pPC5; LEGALL JR, 1994, JAMA-J AM MED ASSOC, V271, P1321; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; McCann KB, 2009, BIOLOGICALS, V37, P32, DOI 10.1016/j.biologicals.2008.08.004; Moreno R, 1999, INTENS CARE MED, V25, P686, DOI 10.1007/s001340050931; Quinlan GJ, 1998, CLIN SCI, V95, P459, DOI 10.1042/CS19980191; Quinlan GJ, 2005, HEPATOLOGY, V41, P1211, DOI 10.1002/hep.20720; REEVES RB, 1976, J APPL PHYSIOL, V40, P762, DOI 10.1152/jappl.1976.40.5.762; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Roberts I, 1998, BMJ-BRIT MED J, V317, P235; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; SUDLOW G, 1975, MOL PHARMACOL, V11, P824; Titheradge MA, 1999, BBA-BIOENERGETICS, V1411, P437, DOI 10.1016/S0005-2728(99)00031-6; Vincent JL, 2011, MINERVA ANESTESIOL, V77, P1190; Vincent JL, 2009, BEST PRACT RES-CLIN, V23, P183, DOI 10.1016/j.bpa.2008.11.004; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Vincent JL, 2003, ANN SURG, V237, P319, DOI 10.1097/00000658-200303000-00005; WEIL MH, 1979, CRIT CARE MED, V7, P113, DOI 10.1097/00003246-197903000-00006; Wilkes MM, 2001, ANN INTERN MED, V135, P149, DOI 10.7326/0003-4819-135-3-200108070-00007	28	616	658	2	79	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 10	2014	370	15					1412	1421		10.1056/NEJMoa1305727	http://dx.doi.org/10.1056/NEJMoa1305727			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AE6IW	24635772	Green Published			2023-01-03	WOS:000334095200009
J	Kaczocha, M; Rebecchi, MJ; Ralph, BP; Teng, YHG; Berger, WT; Galbavy, W; Elmes, MW; Glaser, ST; Wang, LQ; Rizzo, RC; Deutsch, DG; Ojima, I				Kaczocha, Martin; Rebecchi, Mario J.; Ralph, Brian P.; Teng, Yu-Han Gary; Berger, William T.; Galbavy, William; Elmes, Matthew W.; Glaser, Sherrye T.; Wang, Liqun; Rizzo, Robert C.; Deutsch, Dale G.; Ojima, Iwao			Inhibition of Fatty Acid Binding Proteins Elevates Brain Anandamide Levels and Produces Analgesia	PLOS ONE			English	Article							ACTIVATED-RECEPTOR-ALPHA; CANNABINOID RECEPTOR; AMIDE HYDROLASE; MULTIPLE-SCLEROSIS; COST-EFFECTIVENESS; INFLAMMATORY PAIN; NUCLEAR RECEPTORS; MOUSE-BRAIN; MICE; ATHEROSCLEROSIS	The endocannabinoid anandamide (AEA) is an antinociceptive lipid that is inactivated through cellular uptake and subsequent catabolism by fatty acid amide hydrolase (FAAH). Fatty acid binding proteins (FABPs) are intracellular carriers that deliver AEA and related N-acylethanolamines (NAEs) to FAAH for hydrolysis. The mammalian brain expresses three FABP subtypes: FABP3, FABP5, and FABP7. Recent work from our group has revealed that pharmacological inhibition of FABPs reduces inflammatory pain in mice. The goal of the current work was to explore the effects of FABP inhibition upon nociception in diverse models of pain. We developed inhibitors with differential affinities for FABPs to elucidate the subtype(s) that contributes to the antinociceptive effects of FABP inhibitors. Inhibition of FABPs reduced nociception associated with inflammatory, visceral, and neuropathic pain. The antinociceptive effects of FABP inhibitors mirrored their affinities for FABP5, while binding to FABP3 and FABP7 was not a predictor of in vivo efficacy. The antinociceptive effects of FABP inhibitors were mediated by cannabinoid receptor 1 (CB1) and peroxisome proliferator-activated receptor alpha (PPAR(proportional to)) and FABP inhibition elevated brain levels of AEA, providing the first direct evidence that FABPs regulate brain endocannabinoid tone. These results highlight FABPs as novel targets for the development of analgesic and antiinflammatory therapeutics.	[Kaczocha, Martin; Rebecchi, Mario J.; Galbavy, William] SUNY Stony Brook, Dept Anesthesiol, Stony Brook, NY 11794 USA; [Ralph, Brian P.; Elmes, Matthew W.; Wang, Liqun; Deutsch, Dale G.] SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; [Teng, Yu-Han Gary; Berger, William T.; Ojima, Iwao] SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA; [Teng, Yu-Han Gary; Berger, William T.; Ojima, Iwao] SUNY Stony Brook, Inst Chem Biol & Drug Discovery, Stony Brook, NY 11794 USA; [Glaser, Sherrye T.] Kingsborough Community Coll, Dept Biol Sci, Brooklyn, NY USA; [Rizzo, Robert C.] SUNY Stony Brook, Dept Appl Math & Stat, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; City University of New York (CUNY) System; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kaczocha, M (corresponding author), SUNY Stony Brook, Dept Anesthesiol, Stony Brook, NY 11794 USA.	Martin.Kaczocha@Stonybrook.edu		Galbavy, William/0000-0003-0948-9538; Kaczocha, Martin/0000-0002-2527-1398; Ojima, Iwao/0000-0002-3628-1161	National Institutes of Health [DA035923, DA032232, DA016419]; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA035923, R01DA016419, R21DA032232] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by National Institutes of Health grants DA035923, DA032232, and DA016419. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrahamsen B, 2008, SCIENCE, V321, P702, DOI 10.1126/science.1156916; Ahn K, 2009, CHEM BIOL, V16, P411, DOI 10.1016/j.chembiol.2009.02.013; Babaev VR, 2011, ARTERIOSCL THROM VAS, V31, P1283, DOI 10.1161/ATVBAHA.111.225839; Balius TE, 2013, J COMPUT CHEM, V34, P1226, DOI 10.1002/jcc.23245; BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6; Berger WT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050968; Bestard JA, 2010, PAIN PRACT; Binas B, 1999, FASEB J, V13, P805, DOI 10.1096/fasebj.13.8.805; Boneva NB, 2010, NEUROSCI RES, V68, P94, DOI 10.1016/j.neures.2010.07.2028; Boneva NB, 2011, HIPPOCAMPUS, V21, P162, DOI 10.1002/hipo.20732; Booker L, 2012, BRIT J PHARMACOL, V165, P2485, DOI 10.1111/j.1476-5381.2011.01445.x; Cao HM, 2008, CELL, V134, P933, DOI 10.1016/j.cell.2008.07.048; Cavanaugh DJ, 2009, P NATL ACAD SCI USA, V106, P9075, DOI 10.1073/pnas.0901507106; Clapper JR, 2010, NAT NEUROSCI, V13, P1265, DOI 10.1038/nn.2632; Cravatt BF, 2004, J NEUROBIOL, V61, P149, DOI 10.1002/neu.20080; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; DeLeon M, 1996, J NEUROSCI RES, V44, P283; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Dinh TP, 2004, MOL PHARMACOL, V66, P1260, DOI 10.1124/mol.104.002071; Egertova M, 2003, NEUROSCIENCE, V119, P481, DOI 10.1016/S0306-4522(03)00145-3; Erbay E, 2009, NAT MED, V15, P1383, DOI 10.1038/nm.2067; Flachenecker P, 2013, EXPERT REV NEUROTHER, V13, P15, DOI [10.1586/ern.13.1, 10.1586/ERN.13.1]; Furuhashi M, 2008, NAT REV DRUG DISCOV, V7, P489, DOI 10.1038/nrd2589; Furuhashi M, 2008, J CLIN INVEST, V118, P2640, DOI 10.1172/JCI34750; Furuhashi M, 2007, NATURE, V447, P959, DOI 10.1038/nature05844; Gaskin DJ, 2012, J PAIN, V13, P715, DOI 10.1016/j.jpain.2012.03.009; Gerstner JR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015890; Hanhoff T, 2002, MOL CELL BIOCHEM, V239, P45, DOI 10.1023/A:1020502624234; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Hawrylycz MJ, 2012, NATURE, V489, P391, DOI 10.1038/nature11405; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; Hui XY, 2010, J BIOL CHEM, V285, P10273, DOI 10.1074/jbc.M109.097907; Kaczocha M, 2012, J BIOL CHEM, V287, P3415, DOI 10.1074/jbc.M111.304907; Kaczocha M, 2009, P NATL ACAD SCI USA, V106, P6375, DOI 10.1073/pnas.0901515106; Kinsey SG, 2011, NEUROPHARMACOLOGY, V60, P244, DOI 10.1016/j.neuropharm.2010.09.004; Lichtman AH, 2004, PAIN, V109, P319, DOI 10.1016/j.pain.2004.01.022; Liu JW, 2008, J NEUROCHEM, V106, P2015, DOI 10.1111/j.1471-4159.2008.05507.x; Lo Verme J, 2005, MOL PHARMACOL, V67, P15, DOI 10.1124/mol.104.006353; Long JZ, 2009, NAT CHEM BIOL, V5, P37, DOI 10.1038/nchembio.129; LoVerme J, 2006, J PHARMACOL EXP THER, V319, P1051, DOI 10.1124/jpet.106.111385; Maeda K, 2005, CELL METAB, V1, P107, DOI 10.1016/j.cmet.2004.12.008; Mishra SK, 2011, EMBO J, V30, P582, DOI 10.1038/emboj.2010.325; Mukherjee S, 2010, J CHEM INF MODEL, V50, P1986, DOI 10.1021/ci1001982; Notcutt W, 2012, MULT SCLER J, V18, P219, DOI 10.1177/1352458511419700; Owada Y, 1996, J CHEM NEUROANAT, V12, P113, DOI 10.1016/S0891-0618(96)00192-5; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Reynolds JM, 2007, J IMMUNOL, V179, P313, DOI 10.4049/jimmunol.179.1.313; Schug TT, 2007, CELL, V129, P723, DOI 10.1016/j.cell.2007.02.050; Shioda N, 2010, J NEUROSCI, V30, P3146, DOI 10.1523/JNEUROSCI.4140-09.2010; SMITH PB, 1994, J PHARMACOL EXP THER, V270, P219; Sulsky R, 2007, BIOORG MED CHEM LETT, V17, P3511, DOI 10.1016/j.bmcl.2006.12.044; Turk DC, 2002, CLIN J PAIN, V18, P355, DOI 10.1097/00002508-200211000-00003; Yamamoto T, 2009, BIOTECHNOL LETT, V31, P1695, DOI 10.1007/s10529-009-0065-7	53	89	94	2	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2014	9	4							e94200	10.1371/journal.pone.0094200	http://dx.doi.org/10.1371/journal.pone.0094200			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE6MJ	24705380	gold, Green Published			2023-01-03	WOS:000334107500132
J	Morgan, HM; Davis, NJ; Bracewell, RM				Morgan, Helen M.; Davis, Nick J.; Bracewell, R. Martyn			Does Transcranial Direct Current Stimulation to Prefrontal Cortex Affect Mood and Emotional Memory Retrieval in Healthy Individuals?	PLOS ONE			English	Article							MAGNETIC STIMULATION; DOUBLE-BLIND; MAJOR DEPRESSION; COGNITIVE CONTROL; BRAIN-STIMULATION; NEGATIVE AFFECT; CLINICAL-TRIAL; RISK-TAKING; TDCS; EFFICACY	Studies using transcranial direct current stimulation (tDCS) of prefrontal cortex to improve symptoms of depression have had mixed results. We examined whether using tDCS to change the balance of activity between left and right dorsolateral prefrontal cortex (DLPFC) can alter mood and memory retrieval of emotional material in healthy volunteers. Participants memorised emotional images, then tDCS was applied bilaterally to DLPFC while they performed a stimulus-response compatibility task. Participants were then presented with a set of images for memory retrieval. Questionnaires to examine mood and motivational state were administered at the beginning and end of each session. Exploratory data analyses showed that the polarity of tDCS to DLPFC influenced performance on a stimulus-response compatibility task and this effect was dependent on participants' prior motivational state. However, tDCS polarity had no effect on the speed or accuracy of memory retrieval of emotional images and did not influence positive or negative affect. These findings suggest that the balance of activity between left and right DLPFC does not play a critical role in the mood state of healthy individuals. We suggest that the efficacy of prefrontal tDCS depends on the initial activation state of neurons and future work should take this into account.	[Morgan, Helen M.] Liverpool John Moores Univ, Sch Nat Sci & Psychol, Liverpool L3 5UX, Merseyside, England; [Davis, Nick J.] Swansea Univ, Dept Psychol, Swansea, W Glam, Wales; [Bracewell, R. Martyn] Bangor Univ, Sch Psychol, Bangor, Gwynedd, Wales; [Bracewell, R. Martyn] Bangor Univ, Sch Med Sci, Bangor, Gwynedd, Wales	Liverpool John Moores University; Swansea University; Bangor University; Bangor University	Morgan, HM (corresponding author), Liverpool John Moores Univ, Sch Nat Sci & Psychol, Liverpool L3 5UX, Merseyside, England.	H.M.Morgan@ljmu.ac.uk		Davis, Nick/0000-0001-7630-2097	Future and Emerging Technologies (FET) program within the Seventh Framework Programme for Research of the European Commission (FET-Open grant) [222079]	Future and Emerging Technologies (FET) program within the Seventh Framework Programme for Research of the European Commission (FET-Open grant)	This work was supported by the Future and Emerging Technologies (FET) program within the Seventh Framework Programme for Research of the European Commission (FET-Open grant no. 222079). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adolphs R, 2001, NEUROPSYCHOLOGY, V15, P516, DOI 10.1037//0894-4105.15.4.516; AHERN GL, 1985, NEUROPSYCHOLOGIA, V23, P745, DOI 10.1016/0028-3932(85)90081-8; American Electroencephalographic Society, J CLIN NEUROPHYSIOL, V8, P200; B4U-ACT, 2011, YOUTH SUIC SEEK CAR; Baeken C, 2006, J AFFECT DISORDERS, V90, P63, DOI 10.1016/j.jad.2005.09.013; Berlim MT, 2013, NEUROPSYCHOPHARMACOL, V38, P543, DOI 10.1038/npp.2012.237; Berlim MT, 2013, J PSYCHIATR RES, V47, P1, DOI 10.1016/j.jpsychires.2012.09.025; Berman RM, 2000, BIOL PSYCHIAT, V47, P332, DOI 10.1016/S0006-3223(99)00243-7; BLANEY PH, 1986, PSYCHOL BULL, V99, P229, DOI 10.1037/0033-2909.99.2.229; Blumberger Daniel M, 2012, Front Psychiatry, V3, P74, DOI 10.3389/fpsyt.2012.00074; Boggio PS, 2008, INT J NEUROPSYCHOPH, V11, P249, DOI 10.1017/S1461145707007833; Boggio PS, 2010, DRUG ALCOHOL DEPEN, V112, P220, DOI 10.1016/j.drugalcdep.2010.06.019; Boggio PS, 2009, NEUROPSYCHOLOGIA, V47, P212, DOI 10.1016/j.neuropsychologia.2008.07.022; Brunoni AR, 2013, PSYCHONEUROENDOCRINO, V38, P58, DOI 10.1016/j.psyneuen.2012.04.020; Campbell S., 2001, P HUMAN FACTORS ERGO, V45, P906, DOI [10.1177/154193120104501302, DOI 10.1177/154193120104501302]; Clore GL, 2007, TRENDS COGN SCI, V11, P393, DOI 10.1016/j.tics.2007.08.005; Crawford JR, 2004, BRIT J CLIN PSYCHOL, V43, P245, DOI 10.1348/0144665031752934; Davidson RJ, 1998, COGNITION EMOTION, V12, P307, DOI 10.1080/026999398379628; Davidson RJ, 1999, TRENDS COGN SCI, V3, P11, DOI 10.1016/S1364-6613(98)01265-0; Dienes Z, 2011, PERSPECT PSYCHOL SCI, V6, P274, DOI 10.1177/1745691611406920; DONALDSON W, 1993, B PSYCHONOMIC SOC, V31, P271; Egner T, 2009, NAT NEUROSCI, V12, P821, DOI 10.1038/nn0709-821; Fecteau S, 2007, J NEUROSCI, V27, P12500, DOI 10.1523/JNEUROSCI.3283-07.2007; Figiel GS, 1998, J NEUROPSYCH CLIN N, V10, P20, DOI 10.1176/jnp.10.1.20; FITTS PM, 1954, J EXP PSYCHOL, V48, P483, DOI 10.1037/h0054967; Fregni F, 2006, BIPOLAR DISORD, V8, P203, DOI 10.1111/j.1399-5618.2006.00291.x; Fregni F, 2006, DEPRESS ANXIETY, V23, P482, DOI 10.1002/da.20201; Gainotti G, 1972, Cortex, V8, P41; George MS, 1997, AM J PSYCHIAT, V154, P1752, DOI 10.1176/ajp.154.12.1752; GRIER JB, 1971, PSYCHOL BULL, V75, P424, DOI 10.1037/h0031246; Grisaru N, 2001, J ECT, V17, P184, DOI 10.1097/00124509-200109000-00007; Hagler DJ, 2006, NEUROIMAGE, V29, P567, DOI 10.1016/j.neuroimage.2005.08.058; Heller W, 1997, COGNITION EMOTION, V11, P637, DOI 10.1080/026999397379845a; Jacobson L, 2012, EXP BRAIN RES, V216, P1, DOI 10.1007/s00221-011-2891-9; Jenkins J, 2002, BMC PSYCHIATRY, V2, DOI 10.1186/1471-244X-2-1; Kalu UG, 2012, PSYCHOL MED, V42, P1791, DOI 10.1017/S0033291711003059; Kessler SK, 2012, BRAIN STIMUL, V5, P155, DOI 10.1016/j.brs.2011.02.007; Kirov R, 2009, P NATL ACAD SCI USA, V106, P15460, DOI 10.1073/pnas.0904438106; Klein E, 1999, ARCH GEN PSYCHIAT, V56, P315, DOI 10.1001/archpsyc.56.4.315; Koenigs M, 2009, CLIN NEUROPHYSIOL, V120, P80, DOI 10.1016/j.clinph.2008.10.010; Koessler L, 2009, NEUROIMAGE, V46, P64, DOI 10.1016/j.neuroimage.2009.02.006; Kouneiher F, 2009, NAT NEUROSCI, V12, P939, DOI 10.1038/nn.2321; Lang N, 2004, EXP BRAIN RES, V156, P439, DOI 10.1007/s00221-003-1800-2; Lang P. J., 2005, A6 U FLOR, DOI DOI 10.1027/0269-8803/A000147; Lenth RV., 2006, JAVA APPLETS POWER S; Loo CK, 2012, BRIT J PSYCHIAT, V200, P52, DOI 10.1192/bjp.bp.111.097634; Loo CK, 2010, INT J NEUROPSYCHOPH, V13, P61, DOI 10.1017/S1461145709990411; Maeoka H, 2012, NEUROSCI LETT, V512, P12, DOI 10.1016/j.neulet.2012.01.037; Marshall L, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-23; Marshall L, 2004, J NEUROSCI, V24, P9985, DOI 10.1523/JNEUROSCI.2725-04.2004; Marshall L, 2006, NATURE, V444, P610, DOI 10.1038/nature05278; Metuki N, 2012, BRAIN STIMUL, V5, P110, DOI 10.1016/j.brs.2012.03.002; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Miranda PC, 2009, CLIN NEUROPHYSIOL, V120, P1183, DOI 10.1016/j.clinph.2009.03.023; Morey RD, 2011, PSYCHOL METHODS, V16, P406, DOI 10.1037/a0024377; Mosimann UP, 2000, PSYCHIAT RES, V94, P251, DOI 10.1016/S0165-1781(00)00146-3; Nitsche MA, 2007, J NEUROPHYSIOL, V97, P3109, DOI 10.1152/jn.01312.2006; Nitsche M A, 2012, Front Psychiatry, V3, P58, DOI 10.3389/fpsyt.2012.00058; Nitsche MA, 2009, EXP NEUROL, V219, P14, DOI 10.1016/j.expneurol.2009.03.038; O'Connell NE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047514; Palm U, 2012, BRAIN STIMUL, V5, P242, DOI 10.1016/j.brs.2011.08.005; PascualLeone A, 1996, LANCET, V348, P233, DOI 10.1016/S0140-6736(96)01219-6; Pena-Gomez C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022812; Penolazzi B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010623; Plazier M, 2012, BRAIN STIMUL, V5, P454, DOI 10.1016/j.brs.2011.07.005; Reis J, 2009, P NATL ACAD SCI USA, V106, P1590, DOI 10.1073/pnas.0805413106; ROBINSON RG, 1984, BRAIN, V107, P81, DOI 10.1093/brain/107.1.81; Rouder JN, 2012, J MATH PSYCHOL, V56, P356, DOI 10.1016/j.jmp.2012.08.001; Russo R, 2013, BRAIN STIMUL, V6, P946, DOI 10.1016/j.brs.2013.05.009; SACKEIM HA, 1982, ARCH NEUROL-CHICAGO, V39, P210, DOI 10.1001/archneur.1982.00510160016003; Schacter DL, 1999, HIPPOCAMPUS, V9, P7, DOI 10.1002/(SICI)1098-1063(1999)9:1<7::AID-HIPO2>3.0.CO;2-K; Schaller G, 2011, J PSYCHIATR RES, V45, P1178, DOI 10.1016/j.jpsychires.2011.02.006; Sela T, 2012, NEUROPSYCHOLOGIA, V50, P2271, DOI 10.1016/j.neuropsychologia.2012.05.031; Silvanto J, 2008, TRENDS COGN SCI, V12, P447, DOI 10.1016/j.tics.2008.09.004; Slotema CW, 2010, J CLIN PSYCHIAT, V71, P873, DOI 10.4088/JCP.08m04872gre; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Wise EA, 2012, J PSYCHIATR RES, V46, P412, DOI 10.1016/j.jpsychires.2011.11.005	77	21	22	1	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2014	9	3							e92162	10.1371/journal.pone.0092162	http://dx.doi.org/10.1371/journal.pone.0092162			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AD6FV	24651375	Green Accepted, Green Submitted, Green Published, gold			2023-01-03	WOS:000333352800075
J	Gomes, B; Calanzani, N; Higginson, IJ				Gomes, Barbara; Calanzani, Natalia; Higginson, Irene J.			Benefits and Costs of Home Palliative Care Compared With Usual Care for Patients With Advanced Illness and Their Family Caregivers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								CLINICAL QUESTION Are home palliative care services associated with benefits to patients with advanced illness and family caregivers, and are they cost-effective? BOTTOM LINE Compared with usual care, home palliative care is associated with increased odds of dying at home and fewer symptoms for patients with advanced illness. It is not associated with changes in caregiver grief. Cost-effectiveness is inconclusive.	[Gomes, Barbara; Calanzani, Natalia; Higginson, Irene J.] Kings Coll London, Cicely Saunders Inst, Dept Palliat Care Policy & Rehabil, London SE5 9PJ, England	University of London; King's College London	Gomes, B (corresponding author), Kings Coll London, Cicely Saunders Inst, Dept Palliat Care Policy & Rehabil, Bessemer Rd, London SE5 9PJ, England.	barbara.gomes@kcl.ac.uk	Calanzani, Natalia/AAK-2007-2020; Higginson, Irene Julie/C-7309-2012	Calanzani, Natalia/0000-0002-5068-2543; Gomes, Barbara/0000-0001-8149-1806; Higginson, Irene Julie/0000-0002-3687-1313	Cicely Saunders International; Calouste Gulbenkian Foundation; Medical Research Council [G0802654] Funding Source: researchfish; National Institute for Health Research [NF-SI-0611-10209] Funding Source: researchfish; MRC [G0802654] Funding Source: UKRI	Cicely Saunders International; Calouste Gulbenkian Foundation; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was funded by Cicely Saunders International and the Calouste Gulbenkian Foundation.	Abernethy AP, 2013, J PAIN SYMPTOM MANAG, V45, P488, DOI 10.1016/j.jpainsymman.2012.02.024; Cohen J, 2010, J CLIN ONCOL, V28, P2267, DOI 10.1200/JCO.2009.23.2850; Gomes B., 2011, LIVING AGEING DYING, P3; Gomes B, 2013, BMC PALLIAT CARE, V12, DOI 10.1186/1472-684X-12-7; Gomes B, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD007760.pub2, 10.1590/1516-3180.20161341T2]; National Institute for Health and Care Excellence, 2004, IMPR SUPP PALL CAR A	6	37	37	1	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 12	2014	311	10					1060	1061		10.1001/jama.2014.553	http://dx.doi.org/10.1001/jama.2014.553			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AC5QO	24618968				2023-01-03	WOS:000332575800024
J	Behar, SM; Sassetti, CM				Behar, Samuel M.; Sassetti, Christopher M.			Fixing the odds against tuberculosis	NATURE			English	Editorial Material							MYCOBACTERIUM-TUBERCULOSIS; IMMUNITY		[Behar, Samuel M.; Sassetti, Christopher M.] Univ Massachusetts, Sch Med, Dept Microbiol & Physiol Syst, Worcester, MA 01655 USA; [Sassetti, Christopher M.] Howard Hughes Med Inst, Chevy Chase, MD USA	University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute	Behar, SM (corresponding author), Univ Massachusetts, Sch Med, Dept Microbiol & Physiol Syst, Worcester, MA 01655 USA.	samuel.behar@umassmed.edu; christopher.sassetti@umassmed.edu		Behar, Samuel/0000-0002-3374-6699				Antonelli LRV, 2010, J CLIN INVEST, V120, P1674, DOI 10.1172/JCI40817; Berry MPR, 2010, NATURE, V466, P973, DOI 10.1038/nature09247; Divangahi M, 2010, NAT IMMUNOL, V11, P751, DOI 10.1038/ni.1904; Divangahi M, 2009, NAT IMMUNOL, V10, P899, DOI 10.1038/ni.1758; Lin PL, 2014, NAT MED, V20, P75, DOI 10.1038/nm.3412; Manca C, 2001, P NATL ACAD SCI USA, V98, P5752, DOI 10.1073/pnas.091096998; Mayer-Barber KD, 2014, NATURE, V511, P99, DOI 10.1038/nature13489; Mayer-Barber KD, 2010, J IMMUNOL, V184, P3326, DOI 10.4049/jimmunol.0904189; Mishra BB, 2013, NAT IMMUNOL, V14, P52, DOI 10.1038/ni.2474; Ordway D, 2007, J IMMUNOL, V179, P522, DOI 10.4049/jimmunol.179.1.522; Redford PS, 2014, J INFECT DIS, V209, P270, DOI 10.1093/infdis/jit424; Tobin DM, 2010, CELL, V140, P717, DOI 10.1016/j.cell.2010.02.013; Zhao MW, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001249	13	5	7	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 3	2014	511	7507					39	40		10.1038/nature13512	http://dx.doi.org/10.1038/nature13512			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK1TN	24990740				2023-01-03	WOS:000338199400028
J	Jha, AK; Jackson, WM; Healy, KE				Jha, Amit K.; Jackson, Wesley M.; Healy, Kevin E.			Controlling Osteogenic Stem Cell Differentiation via Soft Bioinspired Hydrogels	PLOS ONE			English	Article							SEMIINTERPENETRATING POLYMER NETWORKS; TISSUE ENGINEERING APPLICATIONS; POLY(ACRYLIC ACID) CHAINS; OSTEOBLASTIC DIFFERENTIATION; LIGAND DENSITY; BONE-FORMATION; EXPRESSION; STIFFNESS; ADHESION; MECHANOTRANSDUCTION	Osteogenic differentiation of human mesenchymal stem cells (hMSCs) is guided by various physical and biochemical factors. Among these factors, modulus (i.e., rigidiy) of the ECM has gained significant attention as a physical osteoinductive signal that can contribute to endochondral ossification of a cartilaginous skeletal template. However, MSCs also participate in intramembranous bone formation, which occurs de novo from within or on a more compliant tissue environment. To further understand the role of the matrix interactions in this process, we evaluated osteogenic differentiation of hMSCs cultured on low moduli (102, 390 or 970 Pa) poly(N-isopropylacrylamide) (p(NIPAAm)) based semi-interpenetrating networks (sIPN) modified with the integrin engaging peptide bsp-RGD(15) (0, 105 or 210 mu M). Cell adhesion, proliferation, and osteogenic differentiation of hMSCs, as measured by alkaline phosphatase (ALP), runt-related transcription factor 2 (RUNX2), bone sialoprotein-2 (iBSP), and osteocalcien (OCN) protein expression, was highest on substrates with the highest modulus and peptide concentrations. However, within this range of substrate stiffness, many osteogenic cellular functions were enhanced by increasing either the modulus or the peptide density. These findings suggest that within a compliant and low modulus substrate, a high affinity adhesive ligand serves as a substitute for a rigid matrix to foster osteogenic differentiation.	[Jha, Amit K.; Jackson, Wesley M.; Healy, Kevin E.] Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA; [Healy, Kevin E.] Univ Calif Berkeley, Dept Mat Sci & Engn, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Healy, KE (corresponding author), Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA.	kehealy@berkeley.edu			National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health [R01AR043187, R01AR047304]; National Heart, Lung and Blood Institute of the National Institutes of Health [R01HL096525]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL096525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043187, R01AR047304] Funding Source: NIH RePORTER	National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); National Heart, Lung and Blood Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Numbers R01AR043187 and R01AR047304 and the National Heart, Lung and Blood Institute of the National Institutes of Health under award number R01HL096525. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alsberg E, 2003, J DENT RES, V82, P903, DOI 10.1177/154405910308201111; Barber TA, 2005, BIOMATERIALS, V26, P6897, DOI 10.1016/j.biomaterials.2005.04.043; Barber TA, 2007, J BIOMED MATER RES A, V80A, P306, DOI 10.1002/jbm.a.30927; Barber TA, 2006, J ORTHOP RES, V24, P1366, DOI 10.1002/jor.20165; Bearinger JP, 1998, J BIOMAT SCI-POLYM E, V9, P629, DOI 10.1163/156856298X00064; BIANCO P, 1991, CALCIFIED TISSUE INT, V49, P421, DOI 10.1007/BF02555854; Bidarra SJ, 2010, BIOMACROMOLECULES, V11, P1956, DOI 10.1021/bm100264a; Born AK, 2009, EUR CELLS MATER, V18, P49; Chu C, 2009, TISSUE ENG PT A, V15, P255, DOI 10.1089/ten.tea.2008.0100; Chung EH, 2006, J BIOMED MATER RES A, V79A, P815, DOI 10.1002/jbm.a.30809; Collins JM, 2010, SMALL, V6, P355, DOI 10.1002/smll.200901757; Coquelin L, 2012, TISSUE ENG PT A, V18, P1921, DOI [10.1089/ten.TEA.2011.0645, 10.1089/ten.tea.2011.0645]; Docheva D, 2008, J CELL MOL MED, V12, P537, DOI 10.1111/j.1582-4934.2007.00138.x; Engler A, 2004, BIOPHYS J, V86, P617, DOI 10.1016/S0006-3495(04)74140-5; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Forgacs G, 1998, BIOPHYS J, V74, P2227, DOI 10.1016/S0006-3495(98)77932-9; Fu JP, 2010, NAT METHODS, V7, P733, DOI 10.1038/nmeth.1487; Gronthos S, 1999, J BONE MINER RES, V14, P47, DOI 10.1359/jbmr.1999.14.1.47; Han SJ, 2012, BIOPHYS J, V103, P640, DOI 10.1016/j.bpj.2012.07.023; Harbers GM, 2005, J BIOMED MATER RES A, V75A, P855, DOI 10.1002/jbm.a.30482; Harbers GM, 2005, LANGMUIR, V21, P8374, DOI 10.1021/la050396y; Ho JE, 2007, J BIOMED MATER RES A, V83A, P1200, DOI 10.1002/jbm.a.31355; Hsiong SX, 2008, J BIOMED MATER RES A, V85A, P145, DOI 10.1002/jbm.a.31521; Huebsch N, 2010, NAT MATER, V9, P518, DOI [10.1038/nmat2732, 10.1038/NMAT2732]; Kasza KE, 2011, CURR OPIN CELL BIOL, V23, P30, DOI 10.1016/j.ceb.2010.10.014; Khanna R, 2011, J NANOTECHNOLOGY ENG, V2; Khatiwala CB, 2007, J CELL PHYSIOL, V211, P661, DOI 10.1002/jcp.20974; Khatiwala CB, 2009, J BONE MINER RES, V24, P886, DOI [10.1359/jbmr.081240, 10.1359/JBMR.081240]; Khetan S, 2013, NAT MATER, V12, P458, DOI [10.1038/NMAT3586, 10.1038/nmat3586]; Kim HJ, 2005, BIOMATERIALS, V26, P4442, DOI 10.1016/j.biomaterials.2004.11.013; Kim S, 2005, J BIOMED MATER RES A, V75A, P73, DOI 10.1002/jbm.a.30375; Kim S, 2003, BIOMACROMOLECULES, V4, P1214, DOI 10.1021/bm0340467; Kimura Y, 2010, TISSUE ENG PT A, V16, P1263, DOI [10.1089/ten.tea.2009.0322, 10.1089/ten.TEA.2009.0322]; Kisiel M, 2013, BIOMATERIALS, V34, P704, DOI 10.1016/j.biomaterials.2012.10.015; Mari-Buye N, 2013, TISSUE ENG PT A, V19, P870, DOI [10.1089/ten.tea.2012.0077, 10.1089/ten.TEA.2012.0077]; McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534-5807(04)00075-9; McMurray RJ, 2011, NAT MATER, V10, P637, DOI [10.1038/NMAT3058, 10.1038/nmat3058]; Morimoto D, 2009, RHEUMATOLOGY, V48, P643, DOI 10.1093/rheumatology/kep044; Oliveira SM, 2010, J BIOMED MATER RES A, V94A, P371, DOI 10.1002/jbm.a.32694; Petrie TA, 2008, BIOMATERIALS, V29, P2849, DOI 10.1016/j.biomaterials.2008.03.036; Rezania A, 1999, BIOTECHNOL PROGR, V15, P19, DOI 10.1021/bp980083b; Rezania A, 2000, J BIOMED MATER RES, V52, P595, DOI 10.1002/1097-4636(20001215)52:4<595::AID-JBM3>3.0.CO;2-3; Rowlands AS, 2008, AM J PHYSIOL-CELL PH, V295, pC1037, DOI 10.1152/ajpcell.67.2008; Saha K, 2007, J BIOMED MATER RES A, V81A, P240, DOI 10.1002/jbm.a.30986; Shapiro F, 2008, EUR CELLS MATER, V15, P53, DOI 10.22203/eCM.v015a05; Shih YRV, 2011, J BONE MINER RES, V26, P730, DOI 10.1002/jbmr.278; Shui CX, 2003, J BONE MINER RES, V18, P213, DOI 10.1359/jbmr.2003.18.2.213; Stile RA, 2004, J BIOMAT SCI-POLYM E, V15, P865, DOI 10.1163/1568562041271129; Stile RA, 2001, BIOMACROMOLECULES, V2, P185, DOI 10.1021/bm0000945; Stile RA, 2002, BIOMACROMOLECULES, V3, P591, DOI 10.1021/bm0101466; Sun J, 2012, SOFT MATTER, V8, P2398, DOI 10.1039/c2sm06869a; Thomas CH, 2002, P NATL ACAD SCI USA, V99, P1972, DOI 10.1073/pnas.032668799; Trappmann B, 2012, NAT MATER, V11, P642, DOI [10.1038/NMAT3339, 10.1038/nmat3339]; Wall ST, 2010, J BIOMED MATER RES A, V95A, P1055, DOI 10.1002/jbm.a.32904; Wang LS, 2010, BIOMATERIALS, V31, P8608, DOI 10.1016/j.biomaterials.2010.07.075; Wise JK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012987; Wozniak MA, 2009, NAT REV MOL CELL BIO, V10, P34, DOI 10.1038/nrm2592; Wu LC, 2011, BIOMATERIALS, V32, P5341, DOI 10.1016/j.biomaterials.2011.04.014	58	30	32	2	45	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2014	9	6							e98640	10.1371/journal.pone.0098640	http://dx.doi.org/10.1371/journal.pone.0098640			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK5YM	24937602	Green Published, Green Submitted, gold			2023-01-03	WOS:000338503400008
J	Casas, R; Sacanella, E; Urpi-Sarda, M; Chiva-Blanch, G; Ros, E; Martinez-Gonzalez, MA; Covas, MI; Lamuela-Raventos, RM; Salas-Salvado, J; Fiol, M; Aros, F; Estruch, R				Casas, Rosa; Sacanella, Emilio; Urpi-Sarda, Mireia; Chiva-Blanch, Gemma; Ros, Emilio; Martinez-Gonzalez, Miguel-Angel; Covas, Maria-Isabel; Ma Lamuela-Raventos, Rosa; Salas-Salvado, Jordi; Fiol, Miquel; Aros, Fernando; Estruch, Ramon			The Effects of the Mediterranean Diet on Biomarkers of Vascular Wall Inflammation and Plaque Vulnerability in Subjects with High Risk for Cardiovascular Disease. A Randomized Trial	PLOS ONE			English	Article							BLOOD-PRESSURE; PROFILE; ADULTS; NUTS	Background: Adherence to the Mediterranean diet (MD) is associated with reduced morbidity and mortality due to cardiovascular disease. However, how the MD exerts its effects is not fully known. Aim: To assess the 12-month effects of two enhanced MDs compared to a low-fat diet on inflammatory biomarkers related to atherosclerosis and plaque vulnerability in a subcohort of the PREDIMED (Prevencion con Dieta Mediterranea) study. Methods: A total of 164 participants at high risk for cardiovascular disease were randomized into three diet groups: MD supplemented with 50 mL/d of extra virgin olive oil (MD+EVOO) or 30 g/d of nuts (MD+Nuts) and a low-fat diet. Changes in classical cardiovascular risk factors, inflammatory biomarkers of atherosclerosis and plaque vulnerability were measured after 12 months of intervention. Results: Compared to participants in the low-fat diet group, those receiving MD+EVOO and MD+Nuts showed a higher decrease in systolic (6 mmHg)and diastolic (3 mmHg) blood pressure (P = 0.02; both), as well as a reduction of 10% and 8% in LDL-cholesterol (P = 0.04), respectively. Patients in the MD+Nuts group showed a significant reduction of 34% in CD40 expression on monocyte surface compared to low-fat diet patients (P = 0.03). In addition, inflammatory biomarkers related to plaque instability such as C-reactive protein and interleukin-6 were reduced by 45% and 35% and 95% and 90% in the MD+EVOO and MD+Nuts groups, respectively (P<0.05; all) compared to the low-fat diet group. Likewise, sICAM and Pselectin were also reduced by 50% and 27%, respectively in the MD+ EVOO group (P = 0.04) and P-selectin by 19% in MD+Nuts group (P = 0.04) compared to the low-fat diet group. Conclusions: Adherence to the MD is associated with an increase in serum markers of atheroma plaque stability which may explain, at least in part, the protective role of MD against ischemic heart disease.	[Casas, Rosa; Sacanella, Emilio; Urpi-Sarda, Mireia; Chiva-Blanch, Gemma; Estruch, Ramon] Univ Barcelona, IDIBAPS, Hosp Clin, Dept Internal Med, Barcelona, Spain; [Casas, Rosa; Sacanella, Emilio; Chiva-Blanch, Gemma; Ros, Emilio; Martinez-Gonzalez, Miguel-Angel; Covas, Maria-Isabel; Ma Lamuela-Raventos, Rosa; Salas-Salvado, Jordi; Fiol, Miquel; Aros, Fernando; Estruch, Ramon] Inst Salud Carlos III, CIBER Fisiopatol Obesidad & Nutr 06 03, Madrid, Spain; [Urpi-Sarda, Mireia; Ma Lamuela-Raventos, Rosa] Univ Barcelona, Fac Pharm, Nutr & Food Sci Dept, Barcelona, Spain; [Ros, Emilio] IDIBAPS, Hosp Clin, Lipid Clin, Serv Endocrinol & Nutr, Barcelona, Spain; [Martinez-Gonzalez, Miguel-Angel] Univ Navarra, Sch Med, Dept Prevent Med & Publ Hlth, E-31080 Pamplona, Spain; [Covas, Maria-Isabel] Municipal Inst Med Res IMIM, Cardiovasc Epidemiol Unit, Barcelona, Spain; [Salas-Salvado, Jordi] Univ Rovira & Virgili, IISPV, Hosp Univ Sant Joan de Reus, Human Nutr Unit, E-43201 Reus, Spain; [Fiol, Miquel] Univ Inst Hlth Sci Invest, Palma De Mallorca, Spain; [Aros, Fernando] Hosp Alava, Dept Cardiol, Vitoria, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Instituto de Salud Carlos III; University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Navarra; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Universitat Rovira i Virgili; Institut d'Investigacio Sanitaria Pere Virgili (IISPV)	Sacanella, E (corresponding author), Univ Barcelona, IDIBAPS, Hosp Clin, Dept Internal Med, Barcelona, Spain.	esacane@clinic.ub.es	Martinez-Gonzalez, Miguel A./AAE-7669-2019; Salas-Salvado, Jordi/C-7229-2017; Chiva-Blanch, Gemma/O-8072-2018; Urpi-Sarda, Mireia/D-5937-2013; Estruch, Ramon/AAZ-3723-2020; Fiol, Miguel/F-6793-2016; Casas, Rosa/ABD-1915-2020; Lamuela-Raventos, Rosa M/F-3986-2016	Salas-Salvado, Jordi/0000-0003-2700-7459; Chiva-Blanch, Gemma/0000-0001-6093-0160; Urpi-Sarda, Mireia/0000-0002-4064-5175; Fiol, Miguel/0000-0002-5370-1391; Casas, Rosa/0000-0002-0211-9166; Lamuela-Raventos, Rosa M/0000-0002-1287-4560; Martinez-Gonzalez, Miguel A./0000-0002-3917-9808; Ros, Emilio/0000-0002-2573-1294	CIBEROBN; RETICS [RD06/0045]; Spanish Ministry of Economy and Competitiveness (MEC) [AGL2009-13906-C02-02, AGL2010-22319-C03-02]; Instituto de Salud Carlos III [PI10/01407, G03/140]; European Union (FEDER)	CIBEROBN; RETICS; Spanish Ministry of Economy and Competitiveness (MEC)(Spanish Government); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); European Union (FEDER)(European Commission)	This work has been supported by grants from CIBEROBN, RETICS RD06/0045, Spanish Ministry of Economy and Competitiveness (MEC) (AGL2009-13906-C02-02 and AGL2010-22319-C03-02); Instituto de Salud Carlos III (PI10/01407, G03/140), CIBEROBN, and European Union (FEDER). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Martinez-Gonzalez MA, 2012, INT J EPIDEMIOL, V41, P377, DOI 10.1093/ije/dyq250; Babio N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058354; Barbaresko J, 2013, NUTR REV, V71, P511, DOI 10.1111/nure.12035; Bendinelli B, 2011, AM J CLIN NUTR, V93, P275, DOI 10.3945/ajcn.110.000521; Bjorck L, 2007, VASC HEALTH RISK MAN, V3, P1045; Castaner O, 2013, AM J CLIN NUTR, V98, P845, DOI 10.3945/ajcn.113.060582; Chiva-Blanch G, 2013, ALCOHOL ALCOHOLISM, V48, P270, DOI 10.1093/alcalc/agt007; Estruch R, 2013, NEW ENGL J MED, V368, P1279, DOI 10.1056/NEJMoa1200303; Estruch R, 2006, ANN INTERN MED, V145, P1, DOI 10.7326/0003-4819-145-1-200607040-00004; Finn AV, 2010, ARTERIOSCL THROM VAS, V30, P1282, DOI 10.1161/ATVBAHA.108.179739; Hansson GK, 2011, NAT IMMUNOL, V12, P204, DOI 10.1038/ni.2001; Hansson J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016185; Hermus L, 2010, ATHEROSCLEROSIS, V213, P21, DOI 10.1016/j.atherosclerosis.2010.05.013; Hu EA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060166; Hu Y, 2009, DIABETES VASC DIS RE, V6, P262, DOI 10.1177/1479164109339966; Juanola-Falgarona M, 2013, CARDIOVASC DIABETOL, V12, DOI 10.1186/1475-2840-12-7; Khan DA, 2011, J INTERF CYTOK RES, V31, P561, DOI 10.1089/jir.2010.0157; Koenig W, 2007, ARTERIOSCL THROM VAS, V27, P15, DOI 10.1161/01.ATV.0000251503.35795.4f; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; Llorente-Cortes V, 2010, ATHEROSCLEROSIS, V208, P442, DOI 10.1016/j.atherosclerosis.2009.08.004; Lohse B, 2010, J NUTR, V140, P1322, DOI 10.3945/jn.109.120188; Lopez-Miranda J, 2010, NUTR METAB CARDIOVAS, V20, P284, DOI 10.1016/j.numecd.2009.12.007; Marin C, 2011, AM J CLIN NUTR, V93, P267, DOI 10.3945/ajcn.110.006866; Mena MP, 2009, AM J CLIN NUTR, V89, P248, DOI 10.3945/ajcn.2008.26094; Mente A, 2009, ARCH INTERN MED, V169, P659, DOI 10.1001/archinternmed.2009.38; Ros E, 2009, AM J CLIN NUTR, V89, pS1649, DOI 10.3945/ajcn.2009.26736R; Salas-Salvado J, 2011, DIABETES CARE, V34, P14, DOI 10.2337/dc10-1288; Sofi F, 2010, AM J CLIN NUTR, V92, P1189, DOI 10.3945/ajcn.2010.29673; Tanindi A, 2011, CORONARY ARTERY DIS, V22, P253, DOI 10.1097/MCA.0b013e328343fc18; Mitjavila MT, 2013, CLIN NUTR, V32, P172, DOI 10.1016/j.clnu.2012.08.002; Toledo E, 2009, BRIT J NUTR, V101, P59, DOI 10.1017/S0007114508981496; Troseid M, 2010, CARDIOVASC DIABETOL, V9, DOI 10.1186/1475-2840-9-11; Urpi-Sarda M, 2012, PHARMACOL RES, V65, P577, DOI 10.1016/j.phrs.2012.03.006	33	157	160	2	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2014	9	6							e100084	10.1371/journal.pone.0100084	http://dx.doi.org/10.1371/journal.pone.0100084			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK8TP	24925270	Green Published, Green Submitted, gold			2023-01-03	WOS:000338701300120
J	Hutchens, MP; Kosaka, Y; Zhang, W; Fujiyoshi, T; Murphy, S; Alkayed, N; Anderson, S				Hutchens, Michael P.; Kosaka, Yasuharu; Zhang, Wenri; Fujiyoshi, Tetsuhiro; Murphy, Stephanie; Alkayed, Nabil; Anderson, Sharon			Estrogen-Mediated Renoprotection following Cardiac Arrest and Cardiopulmonary Resuscitation Is Robust to GPR30 Gene Deletion	PLOS ONE			English	Article							ACUTE-RENAL-FAILURE; ACUTE KIDNEY INJURY; PERFORMANCE LIQUID-CHROMATOGRAPHY; G-PROTEIN; IN-VIVO; EXPERIMENTAL STROKE; RECEPTOR; 17-BETA-ESTRADIOL; MICE; ISCHEMIA	Introduction: Acute kidney injury is a serious, sexually dimorphic perioperative complication, primarily attributed to hypoperfusion. We previously found that estradiol is renoprotective after cardiac arrest and cardiopulmonary resuscitation in ovariectomized female mice. Additionally, we found that neither estrogen receptor alpha nor beta mediated this effect. We hypothesized that the G protein estrogen receptor (GPR30) mediates the renoprotective effect of estrogen. Methods: Ovariectomized female and gonadally intact male wild-type and GPR30 gene-deleted mice were treated with either vehicle or 17 beta-estradiol for 7 days, then subjected to cardiac arrest and cardiopulmonary resuscitation. Twenty four hours later, serum creatinine and urea nitrogen were measured, and histologic renal injury was evaluated by unbiased stereology. Results: In both males and females, GPR30 gene deletion was associated with reduced serum creatinine regardless of treatment. Estrogen treatment of GPR30 gene-deleted males and females was associated with increased preprocedural weight. In ovariectomized female mice, estrogen treatment did not alter resuscitation, but was renoprotective regardless of GPR30 gene deletion. In males, estrogen reduced the time-to-resuscitate and epinephrine required. In wild-type male mice, serum creatinine was reduced, but neither serum urea nitrogen nor histologic outcomes were affected by estrogen treatment. In GPR30 gene-deleted males, estrogen did not alter renal outcomes. Similarly, renal injury was not affected by G1 therapy of ovariectomized female wild-type mice. Conclusion: Treatment with 17 beta-estradiol is renoprotective after whole-body ischemia-reperfusion in ovariectomized female mice irrespective of GPR30 gene deletion. Treatment with the GPR30 agonist G1 did not alter renal outcome in females. We conclude GPR30 does not mediate the renoprotective effect of estrogen in ovariectomized female mice. In males, estrogen therapy was not renoprotective. Estrogen treatment of GPR30 gene-deleted mice was associated with increased preprocedural weight in both sexes. Of significance to further investigation, GPR30 gene deletion was associated with reduced serum creatinine, regardless of treatment.	[Hutchens, Michael P.; Kosaka, Yasuharu; Zhang, Wenri; Fujiyoshi, Tetsuhiro; Murphy, Stephanie; Alkayed, Nabil] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA; [Anderson, Sharon] Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Hutchens, MP (corresponding author), Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA.	hutchenm@ohsu.edu		Hutchens, Michael/0000-0001-8583-1812	National Institute of Diabetes and Digestive and Kidney Disease [DK90754]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK090754] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Disease(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Funded by a grant from the National Institute of Diabetes and Digestive and Kidney Disease (http://www2.niddk.nih.gov), #DK90754 to MPH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aigouy B, 2013, NAT METHODS, V10, P1048, DOI 10.1038/nmeth.2692; Ardelt AA, 2005, STROKE, V36, P337, DOI 10.1161/01.STR.0000153795.38388.72; Bologa CG, 2006, NAT CHEM BIOL, V2, P207, DOI 10.1038/nchembio775; Bove T, 2004, J CARDIOTHOR VASC AN, V18, P442, DOI 10.1053/j.jvca.2004.05.021; Deschamps AM, 2009, AM J PHYSIOL-HEART C, V297, pH1806, DOI 10.1152/ajpheart.00283.2009; Dhandapani KM, 2002, BIOL REPROD, V67, P1379, DOI 10.1095/biolreprod.102.003848; Dietrich W, 2008, ANESTHESIOLOGY, V108, P189, DOI 10.1097/01.anes.0000299428.55062.67; Doddakula Kishore, 2007, Interact Cardiovasc Thorac Surg, V6, P314, DOI 10.1510/icvts.2006.148874; Duff GL, 1941, AM J MED SCI, V201, P429; Filardo EJ, 2002, MOL ENDOCRINOL, V16, P70, DOI 10.1210/me.16.1.70; Ford J, 2011, J BONE MINER RES, V26, P298, DOI 10.1002/jbmr.209; Foryst-Ludwig A, 2010, J STEROID BIOCHEM, V122, P74, DOI 10.1016/j.jsbmb.2010.06.012; Gruber CJ, 2002, NEW ENGL J MED, V346, P340, DOI 10.1056/NEJMra000471; Haas E, 2009, CIRC RES, V104, P288, DOI 10.1161/CIRCRESAHA.108.190892; Hofmeister MV, 2012, AM J PHYSIOL-RENAL, V302, pF358, DOI 10.1152/ajprenal.00343.2011; HOU SH, 1983, AM J MED, V74, P243, DOI 10.1016/0002-9343(83)90618-6; Hutchens MP, 2008, ANESTH ANALG, V107, P239, DOI 10.1213/ane.0b013e318178ca42; Hutchens MP, 2008, RESUSCITATION, V76, P89, DOI 10.1016/j.resuscitation.2007.06.031; Hutchens MP, 2012, AM J PHYSIOL-RENAL, V303, pF377, DOI 10.1152/ajprenal.00354.2011; Hutchens MP, 2010, ANESTHESIOLOGY, V112, P395, DOI 10.1097/ALN.0b013e3181c98da9; Keppler A, 2007, KIDNEY INT, V71, P74, DOI 10.1038/sj.ki.5001988; Kheterpal S, 2009, ANESTHESIOLOGY, V110, P505, DOI 10.1097/ALN.0b013e3181979440; Kim J, 2006, J BIOL CHEM, V281, P20349, DOI 10.1074/jbc.M512740200; Kosaka Y, 2012, TRANSL STROKE RES, V3, P500, DOI 10.1007/s12975-012-0211-8; Kowdley Gopal C, 2005, Curr Surg, V62, P64, DOI 10.1016/j.cursur.2004.06.007; Li X, 2012, AM J PHYSIOL-RENAL, V302, pF519, DOI 10.1152/ajprenal.00011.2011; Liang Y, 2001, BRAIN RES BULL, V54, P661, DOI 10.1016/S0361-9230(01)00483-X; Lindsey SH, 2011, HYPERTENSION, V58, P665, DOI 10.1161/HYPERTENSIONAHA.111.175174; Lindsey SH, 2011, J CARDIOVASC PHARM; Liu SB, 2013, BRAIN RES BULL, V93, P27, DOI 10.1016/j.brainresbull.2012.10.004; Meyer MR, 2010, PHARMACOLOGY, V86, P58, DOI 10.1159/000315497; MEYER MH, 1985, ANAL BIOCHEM, V144, P285, DOI 10.1016/0003-2697(85)90118-6; Micevych PE, 2012, NEUROENDOCRINOLOGY, V96, P103, DOI 10.1159/000338400; Muller V, 2002, KIDNEY INT, V62, P1364, DOI 10.1111/j.1523-1755.2002.kid590.x; Noppens RR, 2005, CRIT CARE MED, V33, P1595, DOI 10.1097/01.CCM.0000169884.81769.F7; Park KM, 2004, J BIOL CHEM, V279, P52282, DOI 10.1074/jbc.M407629200; Park KM, 2005, BIOCHEM BIOPH RES CO, V328, P312, DOI 10.1016/j.bbrc.2004.12.177; Perez E, 2005, BRAIN RES, V1038, P216, DOI 10.1016/j.brainres.2005.01.026; Qiu J, 2003, J NEUROSCI, V23, P9529; Raz L, 2008, NEUROSIGNALS, V16, P140, DOI 10.1159/000111559; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Satake A, 2008, KIDNEY INT, V73, P308, DOI 10.1038/sj.ki.5002690; Sharma G., 2013, ENDOCRINOLOGY; Shibata Y, 2004, J CARDIOVASC PHARM, V44, pS459, DOI 10.1097/01.fjc.0000166315.38258.e1; Simpkins JW, 2012, NEUROENDOCRINOLOGY, V96, P119, DOI 10.1159/000338409; Song HK, 2008, ANN THORAC SURG, V85, P2040, DOI 10.1016/j.athoracsur.2008.02.082; Tanaka R, 2013, EUR J PHARMACOL, V714, P397, DOI 10.1016/j.ejphar.2013.07.008; Thakar CV, 2003, AM J KIDNEY DIS, V41, P742, DOI 10.1016/S0272-6386(03)00021-0; Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064; Toran-Allerand CD, 2005, ANN NY ACAD SCI, V1052, P136, DOI 10.1196/annals.1347.009; Wang C, 2008, MOL ENDOCRINOL, V22, P636, DOI 10.1210/me.2007-0359; Wang C, 2009, J IMMUNOL, V182, P3294, DOI 10.4049/jimmunol.0803205; Weil BR, 2010, SURGERY, V148, P436, DOI 10.1016/j.surg.2010.03.011; Yue W, 2010, INT J CANCER, V127, P1748, DOI 10.1002/ijc.25207; Zhang B, 2010, J IMMUNOL, V184, P4087, DOI 10.4049/jimmunol.0902339	55	14	14	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2014	9	6							e99910	10.1371/journal.pone.0099910	http://dx.doi.org/10.1371/journal.pone.0099910			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK8TP	24923556	Green Published, gold, Green Submitted			2023-01-03	WOS:000338701300106
J	Vanholder, R; Van Biesen, W; Lameire, N				Vanholder, Raymond; Van Biesen, Wim; Lameire, Norbert			Renal replacement therapy: how can we contain the costs?	LANCET			English	Editorial Material							DIALYSIS; DISEASE		[Vanholder, Raymond; Van Biesen, Wim] Ghent Univ Hosp, Sect Internal Med, Div Renal, B-9000 Ghent, Belgium; [Lameire, Norbert] Ghent Univ Hosp, B-9000 Ghent, Belgium	Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital	Vanholder, R (corresponding author), Ghent Univ Hosp, Sect Internal Med, Div Renal, B-9000 Ghent, Belgium.	raymond.vanholder@ugent.be						Couchoud C, 2009, NEPHROL DIAL TRANSPL, V24, P1553, DOI 10.1093/ndt/gfn698; Desai AA, 2009, CLIN J AM SOC NEPHRO, V4, P772, DOI 10.2215/CJN.05661108; Icks A, 2010, NEPHROL DIAL TRANSPL, V25, P1647, DOI 10.1093/ndt/gfp672; Jassal SV, 2002, NEPHROL DIAL TRANSPL, V17, P474, DOI 10.1093/ndt/17.3.474; Kleophas Werner, 2007, Int J Health Care Finance Econ, V7, P185, DOI 10.1007/s10754-007-9020-0; Lameire N, 2010, NEW ENGL J MED, V363, P678, DOI 10.1056/NEJMe1006669; Laupacis A, 1996, KIDNEY INT, V50, P235, DOI 10.1038/ki.1996.307; Murtagh FEM, 2007, NEPHROL DIAL TRANSPL, V22, P1955, DOI 10.1093/ndt/gfm153; Ponce P, 2012, BLOOD PURIF; Robinson BM, 2014, KIDNEY INT, V85, P158, DOI 10.1038/ki.2013.252; Rubin HR, 2004, JAMA-J AM MED ASSOC, V291, P697, DOI 10.1001/jama.291.6.697; Swanepoel CR, 2013, NAT REV NEPHROL, V9, P610, DOI 10.1038/nrneph.2013.168; Vanholder R, 2012, J AM SOC NEPHROL, V23, P1291, DOI 10.1681/ASN.2011111094	13	15	15	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 24	2014	383	9931					1783	1785		10.1016/S0140-6736(14)60721-2	http://dx.doi.org/10.1016/S0140-6736(14)60721-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AH6US	24856012				2023-01-03	WOS:000336267800004
J	Jung, IL				Jung, Il Lae			Soluble Extract from Moringa oleifera Leaves with a New Anticancer Activity	PLOS ONE			English	Article							MEDICINAL-PLANT EXTRACTS; BREAST-CANCER CELLS; PHARMACOLOGICAL PROPERTIES; ANTIOXIDANT PROPERTIES; LAM. LEAVES; IN-VITRO; VIRUS; VIVO; CARCINOGENESIS; THIOCARBAMATE	Moringa oleifera has been regarded as a food substance since ancient times and has also been used as a treatment for many diseases. Recently, various therapeutic effects of M. oleifera such as antimicrobial, anticancer, anti-inflammatory, antidiabetic, and antioxidant effects have been investigated; however, most of these studies described only simple biological phenomena and their chemical compositions. Due to the increasing attention on natural products, such as those from plants, and the advantages of oral administration of anticancer drugs, soluble extracts from M. oleifera leaves (MOL) have been prepared and their potential as new anticancer drug candidates has been assessed in this study. Here, the soluble cold Distilled Water extract (4 degrees C; concentration, 300 mu g/mL) from MOL greatly induced apoptosis, inhibited tumor cell growth, and lowered the level of internal reactive oxygen species (ROS) in human lung cancer cells as well as other several types of cancer cells, suggesting that the treatment of cancer cells with MOL significantly reduced cancer cell proliferation and invasion. Moreover, over 90% of the genes tested were unexpectedly downregulated more than 2-fold, while just below 1% of the genes were upregulated more than 2-fold in MOL extract-treated cells, when compared with nontreated cells. Since severe dose-dependent rRNA degradation was observed, the abnormal downregulation of numerous genes was considered to be attributable to abnormal RNA formation caused by treatment with MOL extracts. Additionally, the MOL extract showed greater cytotoxicity for tumor cells than for normal cells, strongly suggesting that it could potentially be an ideal anticancer therapeutic candidate specific to cancer cells. These results suggest the potential therapeutic implications of the soluble extract from MOL in the treatment of various types of cancers.	Korea Atom Energy Res Inst, Dept Radiat Biol, Environm Radiat Res Grp, Taejon, South Korea	Korea Atomic Energy Research Institute (KAERI)	Jung, IL (corresponding author), Korea Atom Energy Res Inst, Dept Radiat Biol, Environm Radiat Res Grp, Taejon, South Korea.	ex-jil7147@kaeri.re.kr			Korea Atomic Energy Research Institute [527240-14]	Korea Atomic Energy Research Institute	Funding for this study was provided by the Korea Atomic Energy Research Institute (grant number 527240-14). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anwar F, 2007, PHYTOTHER RES, V21, P17, DOI 10.1002/ptr.2023; Bharali Rupjyoti, 2003, Asian Pac J Cancer Prev, V4, P131; Brunelli D, 2010, BIOCHEM PHARMACOL, V79, P1141, DOI 10.1016/j.bcp.2009.12.008; Budda S, 2011, ASIAN PAC J CANCER P, V12, P3221; CACERES A, 1992, J ETHNOPHARMACOL, V36, P233, DOI 10.1016/0378-8741(92)90049-W; CACERES A, 1991, J ETHNOPHARMACOL, V33, P213, DOI 10.1016/0378-8741(91)90078-R; Chen SS, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0036784, 10.1371/journal.pone.0045763, 10.1371/journal.pone.0049275, 10.1371/journal.pone.0050456]; Chumark P, 2008, J ETHNOPHARMACOL, V116, P439, DOI 10.1016/j.jep.2007.12.010; D'Souza B, 2008, ONCOGENE, V27, P5148, DOI 10.1038/onc.2008.229; Dahiru D, 2006, AFR J TRADIT COMPLEM, V3, P70; Dahot MU, 1985, J PHARM, V3, P75; Fahey J., 2005, TREES LIFE J; FAIZI S, 1994, J NAT PROD, V57, P1256, DOI 10.1021/np50111a011; FAIZI S, 1995, PHYTOCHEMISTRY, V38, P957, DOI 10.1016/0031-9422(94)00729-D; Fakurazi S, 2008, FOOD CHEM TOXICOL, V46, P2611, DOI 10.1016/j.fct.2008.04.018; Fuglie LJ, 1999, MIRACLE TREE MORINGA, V68, P172; Ghasi S, 2000, J ETHNOPHARMACOL, V69, P21, DOI 10.1016/S0378-8741(99)00106-3; Guevara AP, 1999, MUTAT RES-GEN TOX EN, V440, P181, DOI 10.1016/S1383-5718(99)00025-X; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Iqbal S, 2006, J FOOD COMPOS ANAL, V19, P544, DOI 10.1016/j.jfca.2005.05.001; Kampa M, 2004, BREAST CANCER RES, V6, pR63, DOI 10.1186/bcr752; Katoh M, 2007, INT J ONCOL, V30, P247; Khalafalla MM, 2010, AFR J BIOTECHNOL, V9, P8467; Khan HA, 2011, J APPL TOXICOL, V31, P707, DOI 10.1002/jat.1716; Kumar Gupta S, 2012, J OCUL PHAR IN PRESS; Kumar N. Ashok, 2003, Journal of Medicinal Food, V6, P255; Kumar V., 2012, INT J PHARMA SCI REV, V12, P89; Lai EC, 2004, DEVELOPMENT, V131, P965, DOI 10.1242/dev.01074; Li HT, 2010, BRIT J PHARMACOL, V160, P1352, DOI 10.1111/j.1476-5381.2010.00785.x; Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0; Lipinski CA, 2000, J PHARMACOL TOX MET, V44, P235, DOI 10.1016/S1056-8719(00)00107-6; Lipipun V, 2003, ANTIVIR RES, V60, P175, DOI 10.1016/S0166-3542(03)00152-9; Lotito SB, 2000, P SOC EXP BIOL MED, V225, P32, DOI 10.1046/j.1525-1373.2000.22504.x; Mahajan SG, 2007, J IMMUNOTOXICOL, V4, P39, DOI 10.1080/15476910601115184; Mahmood K.T., 2010, J PHARM SCI RES, V2, P775, DOI DOI 10.1371/JOURNAL.PONE.0095492; Miele L, 2006, CLIN CANCER RES, V12, P1074, DOI 10.1158/1078-0432.CCR-05-2570; Miyoshi N, 2004, CARCINOGENESIS, V25, P567, DOI 10.1093/carcin/bgh051; Mukunzi D., 2011, Pakistan Journal of Nutrition, V10, P602; Murakami A, 1998, PLANTA MED, V64, P319, DOI 10.1055/s-2006-957442; Oliveira JTA, 1999, J SCI FOOD AGR, V79, P815, DOI [10.1002/(SICI)1097-0010(19990501)79:6&lt;815::AID-JSFA290&gt;3.0.CO;2-P, 10.1002/(SICI)1097-0010(19990501)79:6<815::AID-JSFA290>3.0.CO;2-P]; Pari L., 2002, Journal of Medicinal Food, V5, P171, DOI 10.1089/10966200260398206; Peschel W, 2006, FOOD CHEM, V97, P137, DOI 10.1016/j.foodchem.2005.03.033; Sanchez-Gonzalez PD, 2011, CRIT REV TOXICOL, V41, P803, DOI 10.3109/10408444.2011.602662; Siddhuraju P, 2003, J AGR FOOD CHEM, V51, P2144, DOI 10.1021/jf020444+; Sultana B, 2009, MOLECULES, V14, P2167, DOI 10.3390/molecules14062167; Tani TH, 2002, P NATL ACAD SCI USA, V99, P13471, DOI 10.1073/pnas.212510999; Teicher B.A., 2004, ANTICANCER DRUG DEV; Thangapazham RL, 2007, CANCER BIOL THER, V6, P1938, DOI 10.4161/cbt.6.12.4974; Tiloke C, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-226; Tsaknis J, 1999, J AGR FOOD CHEM, V47, P4495, DOI 10.1021/jf9904214; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659; Velayutham P, 2008, CURR MED CHEM, V15, P1840; Waiyaput W, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-246; Welstead G Grant, 2008, J Vis Exp, DOI 10.3791/734; WOOD M, 1997, BOOK HERBAL WISDOM U, P374	55	117	126	0	60	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2014	9	4							e95492	10.1371/journal.pone.0095492	http://dx.doi.org/10.1371/journal.pone.0095492			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG2DP	24748376	Green Submitted, gold, Green Published			2023-01-03	WOS:000335226500114
J	Yuan, G; Yan, SF; Xue, H; Zhang, P; Sun, JT; Li, G				Yuan, Guang; Yan, Shao-Feng; Xue, Hao; Zhang, Ping; Sun, Jin-Tang; Li, Gang			Cucurbitacin I Induces Protective Autophagy in Glioblastoma in Vitro and in Vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						Apoptosis; Autophagy; Glioblastoma; Hypoxia-inducible Factor (HIF); Signal Transduction; Chloroquine; Cucurbitacin I	CELL-CYCLE ARREST; SIGNAL TRANSDUCER; MEDIATED APOPTOSIS; CANCER-CELLS; STAT3; INHIBITION; ACTIVATION; INDUCTION; TARGET; DEATH	Background: Targeting disruption of STAT3 results in inhibition of tumor growth and survival in malignant glioma. Results: Cucurbitacin I triggers protective autophagy through the AMPK/mTOR/p70S6K pathway and down-regulates HIF-1. Conclusion: Autophagy blockade sensitizes glioblastoma to cucurbitacin I treatment. Significance: This study provides new insights into the biological and antiproliferative activities of cucurbitacin I against glioblastoma. There is an urgent need for new therapeutic avenues to improve the outcome of patients with glioblastoma multiforme (GBM). Current studies have suggested that cucurbitacin I, a natural selective inhibitor of JAK2/STAT3, has a potent anticancer effect on a variety of cancer cell types. This study showed that autophagy and apoptosis were induced by cucurbitacin I. Exposure of GBM cells to cucurbitacin I resulted in pronounced apoptotic cell death through activating bcl-2 family proteins. Cells treatment with cucurbitacin I up-regulated Beclin 1 and triggered autophagosome formation and accumulation as well as conversion of LC3I to LC3II. Activation of the AMP-activated protein kinase/mammalian target of rapamycin/p70S6K pathway, but not the PI3K/AKT pathway, occurred in autophagy induced by cucurbitacin I, which was accompanied by decreased hypoxia-inducible factor 1. Stable overexpression of hypoxia-inducible factor 1 induced by FG-4497 prevented cucurbitacin I-induced autophagy and down-regulation of bcl-2. Knockdown of beclin 1 or treatment with the autophagy inhibitor 3-methyladenine also inhibited autophagy induced by cucurbitacin I. A coimmunoprecipitation assay showed that the interaction of Bcl-2 and Beclin 1/hVps34 decreased markedly in cells treated with cucurbitacin I. Furthermore, knockdown of beclin 1 or treatment with the lysosome inhibitor chloroquine sensitized cancer cells to cucurbitacin I-induced apoptosis. Finally, a xenograft model provided additional evidence for the occurrence of cucurbitacin I-induced apoptosis and autophagy in vitro. Our findings provide new insights into the molecular mechanisms underlying cucurbitacin I-mediated GBM cell death and may provide an efficacious therapy for patients harboring GBM.	[Yuan, Guang; Yan, Shao-Feng; Xue, Hao; Zhang, Ping; Li, Gang] Shandong Univ, Dept Neurosurg, Qilu Hosp, Jinan 250012, Shandong, Peoples R China; [Yuan, Guang; Li, Gang] Shandong Univ, Brain Sci Res Inst, Jinan 250012, Shandong, Peoples R China; [Sun, Jin-Tang] Shandong Univ, Inst Basic Med Sci, Qilu Hosp, Jinan 250012, Shandong, Peoples R China; [Sun, Jin-Tang] Shandong Univ, Key Lab Cardiovasc Prote Shandong Prov, Qilu Hosp, Jinan 250012, Shandong, Peoples R China	Shandong University; Shandong University; Shandong University; Shandong University	Li, G (corresponding author), Shandong Univ, Dept Neurosurg, Qilu Hosp, 107 Wenhua Western Rd, Jinan 250012, Shandong, Peoples R China.	doctorligang@126.com	Xue, Hao/GXV-4717-2022		Natural Science Foundation of China [81172403]; Independent Innovation Foundation of Shandong University [IIFSDU2009TS067]; Promotive Research Fund for Excellent Young and Middle-aged Scientists of Shandong Province [BS2010YY022]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Independent Innovation Foundation of Shandong University; Promotive Research Fund for Excellent Young and Middle-aged Scientists of Shandong Province	This work was supported by Natural Science Foundation of China Grant 81172403, by Independent Innovation Foundation of Shandong University Grant IIFSDU2009TS067, and by Promotive Research Fund for Excellent Young and Middle-aged Scientists of Shandong Province Grant BS2010YY022.	Anglesio MS, 2011, CLIN CANCER RES, V17, P2538, DOI 10.1158/1078-0432.CCR-10-3314; Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562; Banerjee S, 2010, CANCER RES, V70, P1356, DOI 10.1158/0008-5472.CAN-09-2178; Blaskovich MA, 2003, CANCER RES, V63, P1270; Bommareddy A, 2009, CANCER RES, V69, P3704, DOI 10.1158/0008-5472.CAN-08-4344; Cao Yiting, 2010, Genes Cancer, V1, P50; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Chan KS, 2008, ONCOGENE, V27, P1087, DOI 10.1038/sj.onc.1210726; Chen JC, 2005, NAT PROD REP, V22, P386, DOI 10.1039/b418841c; Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Garner JM, 2013, J BIOL CHEM, V288, P26167, DOI 10.1074/jbc.M113.477950; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Horiguchi A, 2010, BRIT J CANCER, V102, P1592, DOI 10.1038/sj.bjc.6605691; Hoyer-Hansen M, 2008, AUTOPHAGY, V4, P574, DOI 10.4161/auto.5921; Huang SB, 2011, J BIOL CHEM, V286, P40002, DOI 10.1074/jbc.M111.297432; Jing N, 2005, ANTI-CANCER DRUG, V16, P601, DOI 10.1097/00001813-200507000-00002; Kandala PK, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-9; Kim DJ, 2007, MOL CARCINOGEN, V46, P725, DOI 10.1002/mc.20342; Kim KW, 2006, J BIOL CHEM, V281, P36883, DOI 10.1074/jbc.M607094200; Kim RH, 2009, CANCER RES, V69, P700, DOI 10.1158/0008-5472.CAN-08-3157; Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0; Li Y, 2007, CANCER RES, V67, P8494, DOI 10.1158/0008-5472.CAN-07-0647; Ling XY, 2005, CANCER RES, V65, P2532, DOI 10.1158/0008-5472.CAN-04-2425; Livesey KM, 2009, CURR OPIN INVEST DR, V10, P1269; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Marino ML, 2012, J BIOL CHEM, V287, P30664, DOI 10.1074/jbc.M112.339127; Maycotte P, 2011, CANCER BIOL THER, V11, P127, DOI 10.4161/cbt.11.2.14627; Meijer AJ, 2009, CRIT REV CL LAB SCI, V46, P210, DOI 10.1080/10408360903044068; Meley D, 2006, J BIOL CHEM, V281, P34870, DOI 10.1074/jbc.M605488200; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Molavi O, 2008, IMMUNOL CELL BIOL, V86, P506, DOI 10.1038/icb.2008.27; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Park JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040531; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Penuelas S, 2009, CANCER CELL, V15, P315, DOI 10.1016/j.ccr.2009.02.011; Qadir MA, 2008, BREAST CANCER RES TR, V112, P389, DOI 10.1007/s10549-007-9873-4; Redell MS, 2011, BLOOD, V117, P5701, DOI 10.1182/blood-2010-04-280123; Reischl S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084767; Robinson A, 2008, GASTROENTEROLOGY, V134, P145, DOI 10.1053/j.gastro.2007.09.033; Roca H, 2008, J BIOL CHEM, V283, P25057, DOI 10.1074/jbc.M801073200; Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Sotelo J, 2006, ANN INTERN MED, V144, P337, DOI 10.7326/0003-4819-144-5-200603070-00008; Stechishin OD, 2013, NEURO-ONCOLOGY, V15, P198, DOI 10.1093/neuonc/nos302; Su YH, 2008, CANCER BIOL THER, V7, P1243, DOI 10.4161/cbt.7.8.6263; Sy LK, 2008, CANCER RES, V68, P10229, DOI 10.1158/0008-5472.CAN-08-1983; Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640; Turkson J, 2005, J BIOL CHEM, V280, P32979, DOI 10.1074/jbc.M502694200; Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069; Wang H, 2009, STEM CELLS, V27, P2393, DOI 10.1002/stem.188; Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814; Yang ZF, 2009, CURR TOP MICROBIOL, V335, P1, DOI 10.1007/978-3-642-00302-8_1; Yu HC, 2013, J BIOL CHEM, V288, P18249, DOI 10.1074/jbc.M112.446385; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200; Zhao W, 2010, J BIOL CHEM, V285, P35855, DOI 10.1074/jbc.M110.154088	62	66	68	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2014	289	15					10607	10619		10.1074/jbc.M113.528760	http://dx.doi.org/10.1074/jbc.M113.528760			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	AE8CI	24599950	Green Published, hybrid			2023-01-03	WOS:000334226400032
J	de Vrij, EL; Vogelaar, PC; Goris, M; Houwertjes, MC; Herwig, A; Dugbartey, GJ; Boerema, AS; Strijkstra, AM; Bouma, HR; Henning, RH				de Vrij, Edwin L.; Vogelaar, Pieter C.; Goris, Maaike; Houwertjes, Martin C.; Herwig, Annika; Dugbartey, George J.; Boerema, Ate S.; Strijkstra, Arjen M.; Bouma, Hjalmar R.; Henning, Robert H.			Platelet Dynamics during Natural and Pharmacologically Induced Torpor and Forced Hypothermia	PLOS ONE			English	Article							HIBERNATING GROUND-SQUIRRELS; ISCHEMIA-REPERFUSION INJURY; LOW-TEMPERATURE; SYRIAN-HAMSTER; COLD-STORAGE; BLOOD-FLOW; ACTIVATION; MECHANISM; AGGREGATION; COAGULATION	Hibernation is an energy-conserving behavior in winter characterized by two phases: torpor and arousal. During torpor, markedly reduced metabolic activity results in inactivity and decreased body temperature. Arousal periods intersperse the torpor bouts and feature increased metabolism and euthermic body temperature. Alterations in physiological parameters, such as suppression of hemostasis, are thought to allow hibernators to survive periods of torpor and arousal without organ injury. While the state of torpor is potentially procoagulant, due to low blood flow, increased viscosity, immobility, hypoxia, and low body temperature, organ injury due to thromboembolism is absent. To investigate platelet dynamics during hibernation, we measured platelet count and function during and after natural torpor, pharmacologically induced torpor and forced hypothermia. Splenectomies were performed to unravel potential storage sites of platelets during torpor. Here we show that decreasing body temperature drives thrombocytopenia during torpor in hamster with maintained functionality of circulating platelets. Interestingly, hamster platelets during torpor do not express P-selectin, but expression is induced by treatment with ADP. Platelet count rapidly restores during arousal and rewarming. Platelet dynamics in hibernation are not affected by splenectomy before or during torpor. Reversible thrombocytopenia was also induced by forced hypothermia in both hibernating (hamster) and non-hibernating (rat and mouse) species without changing platelet function. Pharmacological torpor induced by injection of 5'-AMP in mice did not induce thrombocytopenia, possibly because 5'-AMP inhibits platelet function. The rapidness of changes in the numbers of circulating platelets, as well as marginal changes in immature platelet fractions upon arousal, strongly suggest that storage-and-release underlies the reversible thrombocytopenia during natural torpor. Possibly, margination of platelets, dependent on intrinsic platelet functionality, governs clearance of circulating platelets during torpor.	[de Vrij, Edwin L.; Goris, Maaike; Dugbartey, George J.; Strijkstra, Arjen M.; Bouma, Hjalmar R.; Henning, Robert H.] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands; [Vogelaar, Pieter C.] Sulfateq BV, Groningen, Netherlands; [Houwertjes, Martin C.] Univ Groningen, Univ Med Ctr Groningen, Dept Anesthesiol, Groningen, Netherlands; [Herwig, Annika] Univ Hamburg, Inst Zool, Hamburg, Germany; [Boerema, Ate S.; Strijkstra, Arjen M.] Univ Groningen, Dept Chronobiol, Ctr Behav & Neurosci, Groningen, Netherlands; [Boerema, Ate S.] Univ Groningen, Dept Mol Neurobiol, Ctr Behav & Neurosci, Groningen, Netherlands; [Boerema, Ate S.] Univ Groningen, Univ Med Ctr Groningen, Dept Nucl Med & Mol Imaging, Groningen, Netherlands; [Bouma, Hjalmar R.] Univ Groningen, Univ Med Ctr Groningen, Dept Rheumatol & Clin Immunol, Groningen, Netherlands	University of Groningen; University of Groningen; University of Hamburg; University of Groningen; University of Groningen; University of Groningen; University of Groningen	de Vrij, EL (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands.	E.L.de.Vrij@umcg.nl	Bouma, Hjalmar/F-9737-2015; Boerema, A.S./W-9810-2018; Henning, Robert H/AAY-5222-2020	Bouma, Hjalmar/0000-0003-1032-321X; Boerema, A.S./0000-0002-4771-5156; Herwig, Annika/0000-0003-3048-0618; Henning, Robert/0000-0002-5135-4621; Vogelaar, Pieter/0000-0001-8271-3204; Dugbartey, George/0000-0001-8161-7202	University Medical Center Groningen	University Medical Center Groningen	An MD/PhD grant was provided by the University Medical Center Groningen on behalf of Hjalmar Bouma. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bombeli T, 1998, J EXP MED, V187, P329, DOI 10.1084/jem.187.3.329; Bouma HR, 2010, VET IMMUNOL IMMUNOP, V136, P319, DOI 10.1016/j.vetimm.2010.03.016; Bouma HR, 2013, J LEUKOCYTE BIOL, V94, P89, DOI 10.1189/jlb.1212613; Bouma HR, 2011, P NATL ACAD SCI USA, V108, P2052, DOI 10.1073/pnas.1008823108; Bouma HR, 2010, J LEUKOCYTE BIOL, V88, P619, DOI 10.1189/jlb.0310174; BULLARD RW, 1962, AM J PHYSIOL, V203, P266, DOI 10.1152/ajplegacy.1962.203.2.266; Carey HV, 2012, CIRC RES, V110, P915, DOI 10.1161/CIRCRESAHA.111.255398; Carey HV, 2003, PHYSIOL REV, V83, P1153, DOI 10.1152/physrev.00008.2003; Cooper ST, 2012, AM J PHYSIOL-REG I, V302, pR1202, DOI 10.1152/ajpregu.00018.2012; Deutsch VR, 2006, BRIT J HAEMATOL, V134, P453, DOI 10.1111/j.1365-2141.2006.06215.x; Egidi MG, 2010, BLOOD TRANSFUS-ITALY, V8, pS73, DOI 10.2450/2010.012S; Fuentes E, 2014, THROMB HAEMOSTASIS, V111, P491, DOI 10.1160/TH13-05-0386; Geiser F, 2004, ANNU REV PHYSIOL, V66, P239, DOI 10.1146/annurev.physiol.66.032102.115105; Ghasemzadeh M, 2013, THROMB RES, V131, P191, DOI 10.1016/j.thromres.2012.11.028; Hampton M, 2010, AM J PHYSIOL-REG I, V299, pR1478, DOI 10.1152/ajpregu.00273.2010; Heldmaier G, 2004, RESP PHYSIOL NEUROBI, V141, P317, DOI 10.1016/j.resp.2004.03.014; Henning RH, 2002, LIFE SCI, V70, P2071, DOI 10.1016/S0024-3205(02)01505-9; HEYNS ADP, 1980, BRIT J HAEMATOL, V44, P269, DOI 10.1111/j.1365-2141.1980.tb01209.x; Hoffmeister KM, 2003, CELL, V112, P87, DOI 10.1016/S0092-8674(02)01253-9; Hoffmeister KM, 2001, J BIOL CHEM, V276, P24751, DOI 10.1074/jbc.M011642200; Hut RA, 2002, J COMP PHYSIOL B, V172, P47; Ishikawa M, 2004, J CEREBR BLOOD F MET, V24, P907, DOI 10.1097/01.WCB.0000132690.96836.7F; Jinka TR, 2011, J NEUROSCI, V31, P10752, DOI 10.1523/JNEUROSCI.1240-11.2011; KLONIZAKIS I, 1981, J CLIN PATHOL, V34, P377, DOI 10.1136/jcp.34.4.377; Kortner G, 2000, CHRONOBIOL INT, V17, P103, DOI 10.1081/CBI-100101036; Krause S, 2001, PLATELETS, V12, P423, DOI 10.1080/09537100120071040; Kurtz CC, 2006, AM J PHYSIOL-GASTR L, V291, pG895, DOI 10.1152/ajpgi.00155.2006; LECHLER E, 1963, AM J PHYSIOL, V205, P985, DOI 10.1152/ajplegacy.1963.205.5.985; Leng XH, 2004, ARTERIOSCL THROM VAS, V24, P376, DOI 10.1161/01.ATV.0000110445.95304.91; Lindell SL, 2005, AM J PHYSIOL-GASTR L, V288, pG473, DOI 10.1152/ajpgi.00223.2004; Miglis M, 2002, PLATELETS, V13, P5, DOI 10.1080/09537100120112558; Milsom WK, 1999, COMP BIOCHEM PHYS A, V124, P383, DOI 10.1016/S1095-6433(99)00130-0; Miyazawa S, 2008, AM J PHYSIOL-REG I, V295, pR991, DOI 10.1152/ajpregu.00142.2008; Moran N, 2006, ANAL BIOCHEM, V357, P77, DOI 10.1016/j.ab.2006.06.037; Pinsky DJ, 1996, J CLIN INVEST, V97, P493, DOI 10.1172/JCI118440; PIVORUN EB, 1981, CRYOBIOLOGY, V18, P515, DOI 10.1016/0011-2240(81)90212-1; Reasor D., 2012, ANN BIOMED ENG; REDDICK RL, 1973, LAB INVEST, V28, P270; Rittiner JE, 2012, J BIOL CHEM, V287, P5301, DOI 10.1074/jbc.M111.291666; Russell J, 2003, AM J PHYSIOL-GASTR L, V284, pG123, DOI 10.1152/ajpgi.00303.2002; Ruzicka K, 2001, ARCH PATHOL LAB MED, V125, P391; Sandovici M, 2004, NITRIC OXIDE-BIOL CH, V11, P194, DOI 10.1016/j.niox.2004.08.002; Saunders DK, 2000, J EXP ZOOL, V287, P459, DOI 10.1002/1097-010X(20001201)287:7<459::AID-JEZ1>3.3.CO;2-Y; SCHAFFNER A, 1985, ARCH INTERN MED, V145, P651, DOI 10.1001/archinte.145.4.651; Scharbert G, 2010, PLATELETS, V21, P44, DOI 10.3109/09537100903420269; Stephens G, 1998, J BIOL CHEM, V273, P20317, DOI 10.1074/jbc.273.32.20317; Straub A, 2011, ARTERIOSCL THROM VAS, V31, P1607, DOI 10.1161/ATVBAHA.111.226373; Tailor A, 2005, MICROCIRCULATION, V12, P275, DOI 10.1080/10739680590925691; Talaei F, 2012, J EXP BIOL, V215, P2912, DOI 10.1242/jeb.067363; Thon JN, 2008, TRANSFUS MED REV, V22, P268, DOI 10.1016/j.tmrv.2008.05.004; TILLES AW, 1987, MICROVASC RES, V33, P211, DOI 10.1016/0026-2862(87)90018-5; Tupone D, 2013, J NEUROSCI, V33, P14512, DOI 10.1523/JNEUROSCI.1980-13.2013; Vostal JG, 1997, TRANSFUS MED REV, V11, P286, DOI 10.1016/S0887-7963(97)80094-6; Wandall HH, 2008, BLOOD, V111, P3249, DOI 10.1182/blood-2007-06-097295; Yasuma Yoshihide, 1997, American Journal of Physiology, V273, pR1861; ZUCKER MB, 1954, BLOOD, V9, P602, DOI 10.1182/blood.V9.6.602.602	56	26	26	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 10	2014	9	4							e93218	10.1371/journal.pone.0093218	http://dx.doi.org/10.1371/journal.pone.0093218			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI5LS	24722364	gold, Green Published, Green Submitted			2023-01-03	WOS:000336909100014
J	De Roo, ML; Miccinesi, G; Onwuteaka-Philipsen, BD; Van Den Noortgate, N; Van den Block, L; Bonacchi, A; Donker, GA; Alonso, JEL; Moreels, S; Deliens, L; Francke, AL				De Roo, Maaike L.; Miccinesi, Guido; Onwuteaka-Philipsen, Bregje D.; Van Den Noortgate, Nele; Van den Block, Lieve; Bonacchi, Andrea; Donker, Ge A.; Alonso, Jose E. Lozano; Moreels, Sarah; Deliens, Luc; Francke, Anneke L.		EURO IMPACT	Actual and Preferred Place of Death of Home-Dwelling Patients in Four European Countries: Making Sense of Quality Indicators	PLOS ONE			English	Article							OF-LIFE CARE; PALLIATIVE-CARE; CANCER-PATIENTS; GENERAL-PRACTITIONERS; PATIENTS PREFERENCES; HEALTH-CARE; PEOPLE DIE; NETHERLANDS; CONGRUENCE; AWARENESS	Background: Dying at home and dying at the preferred place of death are advocated to be desirable outcomes of palliative care. More insight is needed in their usefulness as quality indicators. Our objective is to describe whether " the percentage of patients dying at home'' and "the percentage of patients who died in their place of preference'' are feasible and informative quality indicators. Methods and Findings: A mortality follow-back study was conducted, based on data recorded by representative GP networks regarding home-dwelling patients who died non-suddenly in Belgium (n = 1036), the Netherlands (n = 512), Italy (n = 1639) or Spain (n = 565). "The percentage of patients dying at home'' ranged between 35.3% (Belgium) and 50.6% (the Netherlands) in the four countries, while "the percentage of patients dying at their preferred place of death'' ranged between 67.8% (Italy) and 86.0% (Spain). Both indicators were strongly associated with palliative care provision by the GP (odds ratios of 1.55-13.23 and 2.30-6.63, respectively). The quality indicator concerning the preferred place of death offers a broader view than the indicator concerning home deaths, as it takes into account all preferences met in all locations. However, GPs did not know the preferences for place of death in 39.6% (the Netherlands) to 70.3% (Italy), whereas the actual place of death was known in almost all cases. Conclusion: GPs know their patients' actual place of death, making the percentage of home deaths a feasible indicator for collection by GPs. However, patients' preferred place of death was often unknown to the GP. We therefore recommend using information from relatives as long as information from GPs on the preferred place of death is lacking. Timely communication about the place where patients want to be cared for at the end of life remains a challenge for GPs.	[De Roo, Maaike L.; Onwuteaka-Philipsen, Bregje D.; Deliens, Luc; Francke, Anneke L.] Vrije Univ Amsterdam, Med Ctr, Expertise Ctr Palliat Care, EMGO Inst Hlth & Care Res,Dept Publ & Occupat Hlt, Amsterdam, Netherlands; [Miccinesi, Guido; Bonacchi, Andrea] Canc Prevent & Res Inst, ISPO, Clin & Descript Epidemiol Unit, Florence, Italy; [Van Den Noortgate, Nele] Ghent Univ Hosp, Dept Geriatr, Ghent, Belgium; [Van den Block, Lieve; Deliens, Luc] Vrije Univ Brussel, End Of Life Care Res Grp, Brussels, Belgium; [Van den Block, Lieve; Deliens, Luc] Univ Ghent, Vrije Univ Brussel, Brussels, Belgium; [Donker, Ge A.; Francke, Anneke L.] Netherlands Inst Hlth Serv Res, NIVEL, Utrecht, Netherlands; [Alonso, Jose E. Lozano] Govt Castilla & Leon, Reg Minist Hlth, Publ Hlth Directorate Gen, Valladolid, Spain; [Moreels, Sarah] WIV ISP, Sci Inst Publ Hlth Publ Hlth & Surveillance, Hlth Serv Res, Brussels, Belgium	Vrije Universiteit Amsterdam; Ghent University; Ghent University Hospital; Vrije Universiteit Brussel; Ghent University; Vrije Universiteit Brussel; Netherlands Institute for Health Services Research	De Roo, ML (corresponding author), Vrije Univ Amsterdam, Med Ctr, Expertise Ctr Palliat Care, EMGO Inst Hlth & Care Res,Dept Publ & Occupat Hlt, Amsterdam, Netherlands.	eol@vumc.nl	Caraceni, Augusto/C-1012-2017; Donker, Gé/AAX-8564-2021; Van den Block, Lieve/D-1247-2011; miccinesi, guido/AAB-5476-2022	Caraceni, Augusto/0000-0002-0375-6204; Van den Block, Lieve/0000-0002-7770-348X; miccinesi, guido/0000-0002-7452-9594; Harding, Richard/0000-0001-9653-8689; Lozano Alonso, Jose Eugenio/0000-0003-2589-0671; Bonacchi, Andrea/0000-0003-4703-4067; Moreels, Sarah/0000-0002-4020-9533; Donker, Ge/0000-0001-6314-9249; Deliens, Luc/0000-0002-8158-2422; Onwuteaka-Philipsen, Bregje/0000-0002-9440-1248; De Roo, Maaike/0000-0002-2972-0867	Institute for the Promotion of Innovation by Science and Technology in Flanders as a Strategic Basic Research project [SBO IWT 050158]; Vrije Universiteit Brussel; Ghent University; Antwerp University; Scientific Institute for Public Health, Belgium; VU University Medical Centre Amsterdam, the Netherlands; Italian Ministry of Health; Massimo Costantini (IRCCS AOU San Martino-IST, Genoa); Autonomous Community of Castilla y Leon; Comunitat Valenciana; EUROIMPACT: European Intersectorial; Multidisciplinary Palliative Care Research Training; European Union [264697]	Institute for the Promotion of Innovation by Science and Technology in Flanders as a Strategic Basic Research project; Vrije Universiteit Brussel; Ghent University(Ghent University); Antwerp University; Scientific Institute for Public Health, Belgium; VU University Medical Centre Amsterdam, the Netherlands(Netherlands Government); Italian Ministry of Health(Ministry of Health, Italy); Massimo Costantini (IRCCS AOU San Martino-IST, Genoa); Autonomous Community of Castilla y Leon; Comunitat Valenciana; EUROIMPACT: European Intersectorial; Multidisciplinary Palliative Care Research Training; European Union(European Commission)	Funding for the study came from the Institute for the Promotion of Innovation by Science and Technology in Flanders as a Strategic Basic Research project (SBO) (contract SBO IWT 050158) (2006-2010), as part of the "Monitoring Quality of End-of-Life Care (MELC) Study'', a collaboration between the Vrije Universiteit Brussel, Ghent University, Antwerp University, the Scientific Institute for Public Health, Belgium, and VU University Medical Centre Amsterdam, the Netherlands. Funding also came from the Italian Ministry of Health through the "Evaluation, testing and implementation of supportive care, care interventions, integrated programs and improving the quality of care for cancer patients'' program ("Integrated Oncology Project no6, years 2008-2011''), led by Massimo Costantini (IRCCS AOU San Martino-IST, Genoa), from the annual budgets of the Autonomous Community of Castilla y Leon and Comunitat Valenciana and from EUROIMPACT: European Intersectorial and Multidisciplinary Palliative Care Research Training, funded by the European Union Seventh Framework Programme (FP7/2007-2013, under grant agreement no [264697]). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aabom B, 2005, BRIT J GEN PRACT, V55, P684; Abarshi E, 2011, J PALLIAT MED, V14, P323, DOI 10.1089/jpm.2010.0312; Abarshi E, 2009, J PAIN SYMPTOM MANAG, V38, P568, DOI 10.1016/j.jpainsymman.2008.12.007; Abel J, 2013, BMJ SUPPORT PALLIAT, V3, P168, DOI 10.1136/bmjspcare-2012-000327; Agar M, 2008, PALLIATIVE MED, V22, P787, DOI 10.1177/0269216308092287; Barbera L, 2005, PALLIATIVE MED, V19, P435, DOI 10.1177/026921630501900515; Barclay S, 2009, BRIT J GEN PRACT, V59, P642, DOI 10.3399/bjgp09X454052; Beccaro M, 2006, J EPIDEMIOL COMMUN H, V60, P412, DOI 10.1136/jech.2005.043646; Bell CL, 2009, PALLIATIVE MED, V23, P482, DOI 10.1177/0269216309106318; Bell CL, 2010, J PAIN SYMPTOM MANAG, V39, P591, DOI 10.1016/j.jpainsymman.2009.07.007; Billingham MJ, 2013, BMJ SUPPORT PALLIAT, V3, P144, DOI 10.1136/bmjspcare-2012-000292; Brazil K, 2005, PALLIATIVE MED, V19, P492, DOI 10.1191/0269216305pm1050oa; Brogaard T, 2013, PALLIATIVE MED, V27, P155, DOI 10.1177/0269216312438468; Campbell SM, 2003, BRIT MED J, V326, P816, DOI 10.1136/bmj.326.7393.816; Claessen SJJ, 2011, J PAIN SYMPTOM MANAG, V42, P169, DOI 10.1016/j.jpainsymman.2010.10.267; Cohen J, 2008, PALLIATIVE MED, V22, P702, DOI 10.1177/0269216308092285; Cohen J, 2006, HEALTH POLICY, V78, P319, DOI 10.1016/j.healthpol.2005.11.003; Cohen J, 2010, J CLIN ONCOL, V28, P2267, DOI 10.1200/JCO.2009.23.2850; Costantini M, 1999, J PAIN SYMPTOM MANAG, V18, P243, DOI 10.1016/S0885-3924(99)00084-6; Currow DC, 2008, J PALLIAT CARE, V24, P144, DOI 10.1177/082585970802400303; Davies E, 2004, SOLID FACTS PALLIATI; De Roo ML, 2013, J PAIN SYMPTOM MANAG, V46, P556, DOI 10.1016/j.jpainsymman.2012.09.013; Deckers JGM, 2006, FAM PRACT, V23, P151, DOI 10.1093/fampra/cmi118; Department of Health, 2009, END LIF CAR STRAT QU; Desmedt M, 2002, SUPPORT CARE CANCER, V10, P343, DOI 10.1007/s00520-002-0345-4; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; Earle CC, 2003, J CLIN ONCOL, V21, P1133, DOI 10.1200/JCO.2003.03.059; Fukui S, 2003, PALLIATIVE MED, V17, P445, DOI 10.1191/0269216303pm782oa; Gomes B, 2006, BMJ-BRIT MED J, V332, P515, DOI 10.1136/bmj.38740.614954.55; Gomes B, 2012, ANN ONCOL, V23, P2006, DOI 10.1093/annonc/mdr602; Gomes B, 2008, PALLIATIVE MED, V22, P33, DOI 10.1177/0269216307084606; Gomes B, 2013, BMC PALLIAT CARE, V12, DOI 10.1186/1472-684X-12-7; Gott M, 2008, SOC SCI MED, V67, P1113, DOI 10.1016/j.socscimed.2008.05.024; Gruneir A, 2007, MED CARE RES REV, V64, P351, DOI 10.1177/1077558707301810; Hannon KL, 2012, PALLIATIVE MED, V26, P336, DOI 10.1177/0269216311406990; Higginson IJ, 2013, PALLIATIVE MED, V27, P918, DOI 10.1177/0269216313487940; Hoek JF, 2003, INT J GERIATR PSYCH, V18, P244, DOI 10.1002/gps.816; Holdsworth L, 2010, INT J PALLIAT NURS, V16, P424, DOI 10.12968/ijpn.2010.16.9.78634; Houttekier D, 2010, J PALLIAT MED, V13, P1461, DOI 10.1089/jpm.2010.0279; Howat A, 2007, PALLIATIVE MED, V21, P41, DOI 10.1177/0269216306072383; IIS, 2009, AT CUID PAL ORG COM; Jordhoy MS, 2000, LANCET, V356, P888, DOI 10.1016/S0140-6736(00)02678-7; Ko W, 2013, EUR J CANCER, V49, P1967, DOI 10.1016/j.ejca.2013.01.006; Macleod U, 2011, BRIT J HOSP MED, V72, P441, DOI 10.12968/hmed.2011.72.8.441; Meeussen K, 2011, J CLIN ONCOL, V29, P4327, DOI 10.1200/JCO.2011.34.9498; Meeussen K, 2009, BRIT J GEN PRACT, V59, P665, DOI 10.3399/bjgp09X454124; Ministerie van Volksgezondheid WeS, 2011, VER PALL ZORG PRAKT; Mitchell SL, 2005, J AM GERIATR SOC, V53, P299, DOI 10.1111/j.1532-5415.2005.53118.x; Paddy Miranda, 2011, Nurs Stand, V26, P33; Pasman HRW, 2009, J PAIN SYMPTOM MANAG, V38, P145, DOI 10.1016/j.jpainsymman.2008.07.008; Peruselli C, 1997, J PALLIAT CARE, V13, P34, DOI 10.1177/082585979701300306; Petkova H., 2012, UNDERSTANDING PLACE; Saugo M, 2008, TUMORI J, V94, P87; Sbanotto A, 1998, SUPPORT CARE CANCER, V6, P426, DOI 10.1007/s005200050189; Seale C, 1997, SOC SCI MED, V45, P477, DOI 10.1016/S0277-9536(96)00379-6; Tang ST, 2010, J PAIN SYMPTOM MANAG, V40, P566, DOI 10.1016/j.jpainsymman.2010.01.020; Teno JM, 2013, JAMA-J AM MED ASSOC, V309, P470, DOI 10.1001/jama.2012.207624; Thomas C, 2004, SOC SCI MED, V58, P2431, DOI 10.1016/j.socscimed.2003.09.005; Van den Block Lieve, 2007, BMC Palliat Care, V6, P6; Van den Block L, 2013, BMC FAM PRACT, V14, DOI 10.1186/1471-2296-14-73; van Gestel YRBM, 2012, MED CARE, V50, P662, DOI 10.1097/MLR.0b013e31824ebd9f; Vega Alonso Agustin Tomas, 2006, Gac Sanit, V20 Suppl 3, P52, DOI 10.1157/13101090	62	97	97	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 8	2014	9	4							e93762	10.1371/journal.pone.0093762	http://dx.doi.org/10.1371/journal.pone.0093762			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AE7FA	24714736	Green Published, Green Submitted, gold			2023-01-03	WOS:000334160900046
J	El Emam, K; Arbuckle, L; Essex, A; Samet, S; Eze, B; Middleton, G; Buckeridge, D; Jonker, E; Moher, E; Earle, C				El Emam, Khaled; Arbuckle, Luk; Essex, Aleksander; Samet, Saeed; Eze, Benjamin; Middleton, Grant; Buckeridge, David; Jonker, Elizabeth; Moher, Ester; Earle, Craig			Secure Surveillance of Antimicrobial Resistant Organism Colonization or Infection in Ontario Long Term Care Homes	PLOS ONE			English	Article							STAPHYLOCOCCUS-AUREUS; RESIDENTS; FACILITIES; PREVALENCE; STAFF; MRSA	long term care homes, yet there is a need to collect data about their prevalence for public health surveillance and intervention purposes. Objective: We conducted a point prevalence study to assess ARO rates in long term care homes in Ontario using a secure data collection system. Methods: All long term care homes in the province were asked to provide colonization or infection counts for methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and extended-spectrum beta-lactamase (ESBL) as recorded in their electronic medical records, and the number of current residents. Data was collected online during the October-November 2011 period using a Paillier cryptosystem that allows computation on encrypted data. Results: A provably secure data collection system was implemented. Overall, 82% of the homes in the province responded. MRSA was the most frequent ARO identified at 3 cases per 100 residents, followed by ESBL at 0.83 per 100 residents, and VRE at 0.56 per 100 residents. The microbiological findings and their distribution were consistent with available provincial laboratory data reporting test results for AROs in hospitals. Conclusions: We describe an ARO point prevalence study which demonstrated the feasibility of collecting data from long term care homes securely across the province and providing strong privacy and confidentiality assurances, while obtaining high response rates.	[El Emam, Khaled; Arbuckle, Luk; Jonker, Elizabeth; Moher, Ester] Childrens Hosp, Eastern Ontario Res Inst, Elect Hlth Informat Lab, Ottawa, ON, Canada; [El Emam, Khaled] Univ Ottawa, Ottawa, ON, Canada; [Essex, Aleksander] Western Univ, London, ON, Canada; [Samet, Saeed] Mem Univ Newfoundland, St John, NF, Canada; [Eze, Benjamin; Middleton, Grant] Privacy Analyt Inc, Ottawa, ON, Canada; [Buckeridge, David] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada; [Earle, Craig] Inst Clin Evaluat Sci, Canc Res Program, Toronto, ON, Canada	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; Western University (University of Western Ontario); Memorial University Newfoundland; McGill University; University of Toronto	El Emam, K (corresponding author), Childrens Hosp, Eastern Ontario Res Inst, Elect Hlth Informat Lab, Ottawa, ON, Canada.	kelemam@uottawa.ca		Samet, Saeed/0000-0002-5116-5484	Canada Research Chairs program; Ontario Institute for Cancer Research	Canada Research Chairs program(Canada Research Chairs); Ontario Institute for Cancer Research	The funders for this project were: (1) The Canada Research Chairs program through a research grant. (2) The Ontario Institute for Cancer Research through a research grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acquisti A, 2012, J MARKETING RES, V49, P160, DOI 10.1509/jmr.09.0215; Bryce EA, 2000, INFECT CONT HOSP EP, V21, P270, DOI 10.1086/501757; Canadian Healthcare Technology, 2013, CBC CLAIMS PROV BLOC; Conchie SM, 2008, RISK ANAL, V28, P141, DOI 10.1111/j.1539-6924.2008.01006.x; Denis O, 2009, J ANTIMICROB CHEMOTH, V64, P1299, DOI 10.1093/jac/dkp345; El Emam K, 2013, J LAW MED ETHICS; El Emam K., 2013, GUIDE DE IDENTIFICAT; El Emam K, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-454; El Emam K, 2011, J AM MED INFORM ASSN, V18, P212, DOI 10.1136/amiajnl-2011-000100; Gravely Steve D, 2009, J Healthc Inf Manag, V23, P33; Jackson Virginia, 2008, Biotechnol Healthc, V5, P57; Jarvis WR, 2007, AM J INFECT CONTROL, V35, P631, DOI 10.1016/j.ajic.2007.10.009; Kellerman SE, 2001, AM J PREV MED, V20, P61, DOI 10.1016/S0749-3797(00)00258-0; Koch AM, 2009, J HOSP INFECT, V71, P269, DOI 10.1016/j.jhin.2008.10.032; Kreman T, 2005, INFECT CONT HOSP EP, V26, P811, DOI 10.1086/502498; Kress A, 2004, MORB MORTAL WKLY R S, V53, P247; Lindner J.R., 2001, J AGR ED, V42, P43, DOI [DOI 10.5032/JAE.2001.04043, https://doi.org/10.5032/jae.2001.04043]; Lober William B, 2004, MMWR Suppl, V53, P203; Ludbrook J, 1998, AM STAT, V52, P127, DOI 10.2307/2685470; Manly B.F.J., 1997, RANDOMIZATION BOOTST, V2; Manzur A, 2008, CLIN MICROBIOL INFEC, V14, P867, DOI 10.1111/j.1469-0691.2008.02060.x; March A, 2010, CLIN MICROBIOL INFEC, V16, P934, DOI 10.1111/j.1469-0691.2009.03024.x; McGeer A, 2011, ANTIMICROBIAL RESIST; Muller M, 2002, Can Commun Dis Rep, V28, P113; MYLOTTE JM, 1992, INFECT CONT HOSP EP, V13, P711; O'Fallon E, 2009, INFECT CONT HOSP EP, V30, P1172, DOI 10.1086/648453; Paillier P, 1999, LECT NOTES COMPUT SC, V1592, P223; Public Health Ontario Provincial Infectious Diseases Advisory Committee, 2011, ANN A SCREEN TEST SU; Schwaber MJ, 2011, CLIN INFECT DIS, V53, P910, DOI 10.1093/cid/cir607; Standing Committee on Public Accounts, 2011, INF PREV CONTR LONG; Stone ND, 2008, INFECT CONT HOSP EP, V29, P143, DOI 10.1086/526437; THURN JR, 1991, J AM GERIATR SOC, V39, P1105, DOI 10.1111/j.1532-5415.1991.tb02877.x; Trick WE, 2001, J AM GERIATR SOC, V49, P270, DOI 10.1046/j.1532-5415.2001.4930270.x; Tsai J, 2009, THESIS CARNEGIE MELL; Wojcik R, 2007, OBTAINING DATA DIS S	35	8	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 8	2014	9	4							e93285	10.1371/journal.pone.0093285	http://dx.doi.org/10.1371/journal.pone.0093285			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE7FA	24714643	Green Submitted, Green Published, gold			2023-01-03	WOS:000334160900022
J	Yang, YL; Luo, XP; Xian, L				Yang, Yan-Long; Luo, Xiu-Ping; Xian, Lei			The Prognostic Role of the Class III beta-Tubulin in Non-Small Cell Lung Cancer (NSCLC) Patients Receiving the Taxane/Vinorebine-Based Chemotherapy: A Meta-Analysis	PLOS ONE			English	Article							ADJUVANT CHEMOTHERAPY; CLINICAL-SIGNIFICANCE; RANDOMIZED-TRIAL; EXPRESSION; TAXANE; SURVIVAL; ERCC1; RESISTANCE; BENEFIT; STATISTICS	Background: A number of studies have examined the relationship between the expression of the class III beta-tubulin (TUBB3) and the treatment responses to the taxane/vinorebine-based chemotherapy in patients with non-small cell lung cancer (NSCLC). However, the results of these studies were inconsistent and inconclusive. Therefore, we conducted an up-to-date meta-analysis to evaluate the prognostic role of TUBB3 in the taxane/vinorebine-based chemotherapy. Methods: A literature search for relevant studies was conducted in PubMed, Embase, and CNKI. The inclusion criteria were the taxane/vinorebine-based chemotherapy in patients with NSCLC and the evaluation of the clinical outcomes in relation to the expression of TUBB3. The clinical outcomes analyzed in this study included the overall response rate (ORR), overall survival (OS), and event-free survival (EFS). Odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) were calculated to assess the risk associated with the TUBB3 expression in the taxane/vinorebine-based chemotherapy. Results: A total of 28 studies with 2401 NSCLC patients were qualified for this meta-analysis. We found that the positive or high level of TUBB3 expression was associated with a poorer ORR (OR = 0.24, 95% CI = 0.16-0.36, p<0.001), an unfavorable OS (HR = 1.52, 95% CI = 1.27-1.82, p<0.001), and a worse EFS (HR = 1.47, 95% CI = 1.24-1.74, p<0.001) compared to the negative or low level of TUBB3 expression. The statistically significant associations between TUBB3 and chemotherapy responses were also observed in the stratified subgroup analysis, which included the analysis by ethnic subgroup (Asian and Caucasian), chemotherapy regimen (taxane-based and vinorebine-based), TUBB3 detection method (IHC and PCR), and treatment strategy (surgery plus adjuvant chemotherapy and palliative chemotherapy). Conclusions: The expression level of TUBB3 may be a useful biomarker to predict the clinical outcomes of the taxane/vinorebine-based chemotherapy in patients with NSCLC.	[Yang, Yan-Long; Xian, Lei] Guangxi Med Univ, Affiliated Hosp 1, Dept Cardiothorac Surg, Nanning, Guangxi Zhuang, Peoples R China; [Luo, Xiu-Ping] Guangxi Med Univ, Clin Fac, Nanning, Guangxi Zhuang, Peoples R China	Guangxi Medical University; Guangxi Medical University	Xian, L (corresponding author), Guangxi Med Univ, Affiliated Hosp 1, Dept Cardiothorac Surg, Nanning, Guangxi Zhuang, Peoples R China.	xianlei59@163.com			Guangxi Scientific Research and Technology Development projects [10124001A-592 44]	Guangxi Scientific Research and Technology Development projects	This work was supported by the Guangxi Scientific Research and Technology Development projects (grant no. 10124001A-592 44). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Azuma K, 2009, LUNG CANCER, V64, P326, DOI 10.1016/j.lungcan.2008.09.002; Azuma K, 2009, CANCER CHEMOTH PHARM, V64, P565, DOI 10.1007/s00280-008-0907-3; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Custodio AB, 2009, J THORAC ONCOL, V4, P891, DOI 10.1097/JTO.0b013e3181a4b8fb; Chiou JF, 2003, LUNG, V181, P267, DOI 10.1007/s00408-003-1029-7; Christoph DC, 2012, BRIT J CANCER, V107, P823, DOI 10.1038/bjc.2012.324; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dumontet C, 1999, J CLIN ONCOL, V17, P1061, DOI 10.1200/JCO.1999.17.3.1061; Dumontet Charles, 2005, Bull Cancer, V92, pE25; Dumontet C, 2009, MOL CANCER THER, V8, P17, DOI 10.1158/1535-7163.MCT-08-0986; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Felip E, 2011, ANN ONCOL, V22, P1507, DOI 10.1093/annonc/mdr150; Ferrandina G, 2006, CLIN CANCER RES, V12, P2774, DOI 10.1158/1078-0432.CCR-05-2715; Galano G, 2011, CURR DRUG SAF, V6, P185, DOI 10.2174/157488611797579302; Gao LH, 2012, J NANTONG U MED SCI, V32, P188; [龚健 GONG Jian], 2009, [中国新药杂志, Chinese Journal New Drugs], V18, P815; Guilbert J J, 2003, Educ Health (Abingdon), V16, P230; Guo HQ, 2011, ONCOLOGY PROGR, V9, P420; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Huang CL, 2010, EXP THER MED, V1, P445, DOI 10.3892/etm_00000069; Ikeda N, 2009, ANN THORAC CARDIOVAS, V15, P144; Ikeda S, 2009, PATHOL INT, V59, P863, DOI 10.1111/j.1440-1827.2009.02463.x; *INT AG RES CANC, 2010, GLOBOCAN PROJ; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jiang H, 2013, EXP THER MED, V5, P1506, DOI 10.3892/etm.2013.1007; Kaira K, 2013, INT J CLIN ONCOL, V18, P371, DOI 10.1007/s10147-012-0386-8; Kang CH, 2010, LUNG CANCER, V68, P478, DOI 10.1016/j.lungcan.2009.07.004; Krawczyk P, 2012, CHEMOTHERAPY, V58, P60, DOI 10.1159/000336143; Liu P, 2013, J CLIN MED PRACTICE, V17, P12; MANTEL N, 1959, J NATL CANCER I, V22, P719; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; Non-small Cell Lung Cancer Collaborative Group, 2000, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD002139; Okuda K, 2008, LUNG CANCER, V62, P105, DOI 10.1016/j.lungcan.2008.02.021; OYE RK, 1984, JAMA-J AM MED ASSOC, V252, P2722, DOI 10.1001/jama.252.19.2722; Pu Xiaolin, 2009, Zhongguo Fei Ai Za Zhi, V12, P49, DOI 10.3779/j.issn.1009-3419.2009.01.008; Reiman T, 2012, ANN ONCOL, V23, P86, DOI 10.1093/annonc/mdr033; Rosell R, 2003, ONCOGENE, V22, P3548, DOI 10.1038/sj.onc.1206419; Seve P, 2005, MOL CANCER THER, V4, P2001, DOI 10.1158/1535-7163.MCT-05-0244; Seve P, 2005, CLIN CANCER RES, V11, P5481, DOI 10.1158/1078-0432.CCR-05-0285; Seve P, 2008, LANCET ONCOL, V9, P168, DOI 10.1016/S1470-2045(08)70029-9; Seve P, 2007, CLIN CANCER RES, V13, P994, DOI 10.1158/1078-0432.CCR-06-1503; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Stewart DJ, 2010, CRIT REV ONCOL HEMAT, V75, P173, DOI 10.1016/j.critrevonc.2009.11.006; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; Tommasi S, 2007, INT J CANCER, V120, P2078, DOI 10.1002/ijc.22557; Urano N, 2006, INT J ONCOL, V28, P375; Vilmar AC, 2011, CLIN CANCER RES, V17, P5205, DOI 10.1158/1078-0432.CCR-11-0658; [万一元 WAN Yiyuan], 2011, [中华内科杂志, Chinese Journal of Internal Medicine], V50, P469; Wells GA., 2003, NEWCASTLE OTTAWA SCA; Xiao YY, 2009, CHIN J LUNG CANC, V12, P14; Yang JQ, 2009, CHIN CLIN ONCOL, V14, P884; Yared JA, 2012, DRUG DES DEV THER, V6, P371, DOI 10.2147/DDDT.S28997; Zhang HL, 2012, LUNG CANCER, V77, P9, DOI 10.1016/j.lungcan.2012.01.005; Zhang JP, 2012, MED RECAPITULATE, V18, P2637; Zhang YL, 2013, ONCOL LETT, V6, P220, DOI 10.3892/ol.2013.1323; Zheng QH, 2012, J CHIN ONCOL, V18, P806	57	26	28	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2014	9	4							e93997	10.1371/journal.pone.0093997	http://dx.doi.org/10.1371/journal.pone.0093997			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE6MJ	24705847	gold, Green Published, Green Submitted			2023-01-03	WOS:000334107500107
J	de Goeij, MCM; Rotmans, JI; Eijgenraam, JW; Dekker, FW; Halbesma, N				de Goeij, Moniek C. M.; Rotmans, Joris I.; Eijgenraam, Jan-Willem; Dekker, Friedo W.; Halbesma, Nynke			Course of Symptoms and Health-Related Quality of Life during Specialized Pre-Dialysis Care	PLOS ONE			English	Article							STAGE RENAL-DISEASE; ILLNESS PERCEPTION QUESTIONNAIRE; CHRONIC KIDNEY-DISEASE; DIALYSIS INITIATION; START; HEMODIALYSIS; MORTALITY; SURVIVAL; REPRESENTATIONS; COMORBIDITY	Background:Concerns are present on the limited value of renal function alone in defining the optimal moment to start dialysis. Disease-related symptoms and health-related quality of life (HRQOL) may have additional clinical value in defining this moment, but little is known about how these parameters change during pre-dialysis care. The aims of our study were to describe the course of symptoms and HRQOL during pre-dialysis care and to investigate their association with poor health outcomes. Methods: In the prospective PREPARE-2 cohort, incident patients starting specialized pre-dialysis care were included when referred to one of the 25 participating Dutch outpatient clinics (2004-2011). In the present analysis, 436 patients with data available on symptoms and HRQOL were included. Clinical data, symptoms (revised illness perception questionnaire), and HRQOL (short form-36 questionnaire; physical and mental summary score) were collected every 6-month interval. A time-dependent Cox proportional hazard model was used to associate symptoms and HRQOL with the combined poor health outcome (i.e. starting dialysis, receiving a kidney transplant, and death). Results: All symptoms increased, especially fatigue and loss of strength, and both the physical and mental summary score decreased over time, with the most pronounced change during the last 6-12 months of follow-up. Furthermore, each additional symptom (adjusted HR 1.04 (95% CI, 1.00-1.09)) and each 3-point lower physical and mental summary score (adjusted HR 1.04 (1.02-1.06) and 1.04 (1.02-1.06) respectively) were associated with a higher risk of reaching the combined poor health outcome within the subsequent 6 months. Conclusions: The number of symptoms increased and both the physical and mental HRQOL score decreased during pre-dialysis care and these changes were associated with starting dialysis, receiving a kidney transplant, and death. These results may indicate that symptoms and HRQOL are good markers for the medical condition and disease stage of pre-dialysis patients.	[de Goeij, Moniek C. M.; Rotmans, Joris I.; Dekker, Friedo W.; Halbesma, Nynke] Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands; [Rotmans, Joris I.] Leiden Univ, Med Ctr, Dept Nephrol, Leiden, Netherlands; [Eijgenraam, Jan-Willem] Groene Hart Hosp, Dept Internal Med, Gouda, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	de Goeij, MCM (corresponding author), Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands.	M.C.M.de_Goeij@lumc.nl	Rotmans, Joris I./G-8866-2014; Dekker, Friedo W/B-6452-2011	Rotmans, Joris I./0000-0001-9682-6234; Dekker, Friedo W/0000-0002-2433-2494	Dutch Kidney Foundation [SB 110]; Amgen; Baxter	Dutch Kidney Foundation; Amgen(Amgen); Baxter	This study was supported by a grant from the Dutch Kidney Foundation (SB 110, www.nierstichting.nl), and unrestricted grants from Amgen (www.amgen.nl) and Baxter (www.baxter.nl). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; Abdel-Kader K, 2009, CLIN J AM SOC NEPHRO, V4, P1057, DOI 10.2215/CJN.00430109; [Anonymous], 2011, ERA EDTA REG ANN REP; Beddhu S, 2003, J AM SOC NEPHROL, V14, P2305, DOI 10.1097/01.ASN.0000080184.67406.11; Chilcot J, 2013, ANN BEHAV MED, V45, P78, DOI 10.1007/s12160-012-9410-5; Chilcot J, 2012, PSYCHOL HEALTH MED, V17, P578, DOI 10.1080/13548506.2011.647702; Chin HJ, 2008, NEPHROL DIAL TRANSPL, V23, P2810, DOI 10.1093/ndt/gfn132; Clark WF, 2011, CAN MED ASSOC J, V183, P47, DOI 10.1503/cmaj.100349; Cooper BA, 2010, NEW ENGL J MED, V363, P609, DOI 10.1056/NEJMoa1000552; Covic A, 2004, NEPHROL DIAL TRANSPL, V19, P2078, DOI 10.1093/ndt/gfh254; Donders ART, 2006, J CLIN EPIDEMIOL, V59, P1087, DOI 10.1016/j.jclinepi.2006.01.014; DUBOIS D, 1989, NUTRITION, V5, P303; Dutch Federation of Nephrology, 2011, MULT GUID PRED; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; European Best Practice Guidelines Expert Group on Hemodialysis European Renal Association, 2002, Nephrol Dial Transplant, V17 Suppl 7, P7; Hwang SJ, 2010, NEPHROL DIAL TRANSPL, V25, P2616, DOI 10.1093/ndt/gfq308; Jager KJ, 2012, NEPHROL DIAL TRANSPL, V27, P27, DOI 10.1093/ndt/gfs277; Kazmi WH, 2005, AM J KIDNEY DIS, V46, P887, DOI 10.1053/j.ajkd.2005.08.005; Kidney Disease: Improving Global Outcomes (KDIGO), 2011, CLIN PRACT GUID; Korevaar JC, 2001, LANCET, V358, P1046, DOI 10.1016/S0140-6736(01)06180-3; Krediet RT, 2010, NAT REV NEPHROL, V6, P563, DOI 10.1038/nrneph.2010.109; Kusek JW, 2002, AM J KIDNEY DIS, V39, P513, DOI 10.1053/ajkd.2002.31401; Lameire N, 2010, NEW ENGL J MED, V363, P678, DOI 10.1056/NEJMe1006669; Lassalle M, 2010, KIDNEY INT, V77, P700, DOI 10.1038/ki.2010.14; Leaf DE, 2009, KIDNEY INT, V75, P15, DOI 10.1038/ki.2008.414; Ledebo Ingrid, 2001, Nephrology Dialysis Transplantation, V16, P1132, DOI 10.1093/ndt/16.6.1132; Levey AS, 2000, J AM SOC NEPHROL, V11, p155A; Meyer TW, 2007, NEW ENGL J MED, V357, P1316, DOI 10.1056/NEJMra071313; Moss-Morris R, 2002, PSYCHOL HEALTH, V17, P1, DOI 10.1080/08870440290001494; Pagels A, 2012, SCAND J CARING SCI, V26, P474, DOI 10.1111/j.1471-6712.2011.00952.x; Perlman RL, 2005, AM J KIDNEY DIS, V45, P658, DOI 10.1053/j.ajkd.2004.12.021; Rosansky SJ, 2011, ARCH INTERN MED, V171, P396, DOI 10.1001/archinternmed.2010.415; Rosansky SJ, 2009, KIDNEY INT, V76, P257, DOI 10.1038/ki.2009.161; Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147; Stel VS, 2011, CAN MED ASSOC J, V183, P24, DOI 10.1503/cmaj.101636; Stel VS, 2010, NEPHROL DIAL TRANSPL, V25, P3315, DOI 10.1093/ndt/gfq209; Stel VS, 2009, NEPHROL DIAL TRANSPL, V24, P3175, DOI 10.1093/ndt/gfp264; Tattersall J, 2011, NEPHROL DIAL TRANSPL, V26, P2082, DOI 10.1093/ndt/gfr168; Termorshuizen F, 2003, NEPHROL DIAL TRANSPL, V18, P552, DOI 10.1093/ndt/18.3.552; Traynor JP, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000025294.40179.E8; Tsai YC, 2010, NEPHROL DIAL TRANSPL, V25, P1621, DOI 10.1093/ndt/gfp671; Van Biesen W, 2010, NEPHROL DIAL TRANSPL, V25, P2405, DOI 10.1093/ndt/gfq391; Van Buuren S, 1999, STAT MED, V18, P681, DOI 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.3.CO;2-I; van Dijk S, 2009, NEPHROL DIAL TRANSPL, V24, P3183, DOI 10.1093/ndt/gfp184; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weinman J, 1996, PSYCHOL HEALTH, V11, P431, DOI 10.1080/08870449608400270; Weisbord SD, 2005, J AM SOC NEPHROL, V16, P2487, DOI 10.1681/ASN.2005020157; Wright S, 2010, CLIN J AM SOC NEPHRO, V5, P1828, DOI 10.2215/CJN.06230909	48	25	25	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 3	2014	9	4							e93069	10.1371/journal.pone.0093069	http://dx.doi.org/10.1371/journal.pone.0093069			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AE6LR	24699666	Green Published, Green Submitted, gold			2023-01-03	WOS:000334105000042
J	Doron, R; Lotan, D; Versano, Z; Benatav, L; Franko, M; Armoza, S; Kately, N; Rehavi, M				Doron, Ravid; Lotan, Dafna; Versano, Ziv; Benatav, Layla; Franko, Motty; Armoza, Shir; Kately, Nadav; Rehavi, Moshe			Escitalopram or Novel Herbal Mixture Treatments during or following Exposure to Stress Reduce Anxiety-Like Behavior through Corticosterone and BDNF Modifications	PLOS ONE			English	Article							NEUROTROPHIC FACTOR EXPRESSION; NEONATAL MATERNAL SEPARATION; LONG-LASTING CHANGES; MOOD DISORDERS; ANIMAL-MODELS; MILD STRESS; DEPRESSION; BRAIN; MICE; MOUSE	Anxiety disorders are a major public health concern worldwide. Studies indicate that repeated exposure to adverse experiences early in life can lead to anxiety disorders in adulthood. Current treatments for anxiety disorders are characterized by a low success rate and are associated with a wide variety of side effects. The aim of the present study was to evaluate the anxiolytic effects of a novel herbal treatment, in comparison to treatment with the selective serotonin reuptake inhibitor escitalopram. We recently demonstrated the anxiolytic effects of these treatments in BALB mice previously exposed to one week of stress. In the present study, ICR mice were exposed to post natal maternal separation and to 4 weeks of unpredictable chronic mild stress in adolescence, and treated during or following exposure to stress with the novel herbal treatment or with escitalopram. Anxiety-like behavior was evaluated in the elevated plus maze. Blood corticosterone levels were evaluated using radioimmunoassay. Brain derived neurotrophic factor levels in the hippocampus were evaluated using enzyme-linked immunosorbent assay. We found that (1) exposure to stress in childhood and adolescence increased anxiety-like behavior in adulthood; (2) the herbal treatment reduced anxiety-like behavior, both when treated during or following exposure to stress; (3) blood corticosterone levels were reduced following treatment with the herbal treatment or escitalopram, when treated during or following exposure to stress; (4) brain derived neurotrophic factor levels in the hippocampus of mice treated with the herbal treatment or escitalopram were increased, when treated either during or following exposure to stress. This study expands our previous findings and further points to the proposed herbal compound's potential to be highly efficacious in treating anxiety disorders in humans.	[Doron, Ravid; Versano, Ziv; Benatav, Layla; Franko, Motty; Armoza, Shir] Acad Coll Tel Aviv Yaffo, Sch Behav Sci, Tel Aviv, Israel; [Doron, Ravid; Lotan, Dafna] Open Univ Israel, Dept Educ & Psychol, Raanana, Israel; [Doron, Ravid] Hadassah Acad Coll, Sch Hlth & Life Sci, Jerusalem, Israel; [Lotan, Dafna] Sch Psychol Sci, Tel Aviv, Israel; [Lotan, Dafna] Sagol Sch Neurosci, Tel Aviv, Israel; [Kately, Nadav] Tel Aviv Univ, IL-69978 Tel Aviv, Israel; [Versano, Ziv; Armoza, Shir; Rehavi, Moshe] Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel; [Rehavi, Moshe] Tel Aviv Univ, Sackler Fac Med, Dr Miriam & Sheldon G Adelson Chair Biol Addict D, IL-69978 Tel Aviv, Israel	Open University Israel; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	Doron, R (corresponding author), Acad Coll Tel Aviv Yaffo, Sch Behav Sci, Tel Aviv, Israel.	raviddor@mta.ac.il			Israel Science Foundation [ISF 738/11]; National Institute for Psychobiology in Israel [NIPI-7-2011-12]; Open University foundation	Israel Science Foundation(Israel Science Foundation); National Institute for Psychobiology in Israel; Open University foundation	This work was funded by the Israel Science Foundation (http://www.isf.org.il/english/ [ISF 738/11]), by the National Institute for Psychobiology in Israel (http://www.psychobiology.org.il/ [NIPI-7-2011-12]), and by the Open University foundation. No individuals employed or contracted by the funders (other than the named authors) played any role in: study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Avital A, 2005, INT J NEUROPSYCHOPH, V8, P163, DOI 10.1017/S1461145704004808; Avitsur R, 2006, BRAIN BEHAV IMMUN, V20, P339, DOI 10.1016/j.bbi.2005.09.006; Baker-Herman TL, 2004, NAT NEUROSCI, V7, P48, DOI 10.1038/nn1166; Baldwin DS, 2011, INT J NEUROPSYCHOPH, V14, P697, DOI 10.1017/S1461145710001434; Barbui C, 2009, EVID-BASED MENT HEAL, V12, P79, DOI 10.1136/ebmh.12.3.79; Buhl ES, 2010, AM J PHYSIOL-ENDOC M, V298, pE920, DOI 10.1152/ajpendo.00606.2009; Carobrez AP, 2005, NEUROSCI BIOBEHAV R, V29, P1193, DOI 10.1016/j.neubiorev.2005.04.017; Cryan JF, 2005, NAT REV DRUG DISCOV, V4, P775, DOI 10.1038/nrd1825; Culpepper L, 2002, J CLIN PSYCHIAT, V63, P35; De Bellis MD, 2005, CHILD ADOL PSYCH CL, V14, P745, DOI 10.1016/j.chc.2005.05.006; Dording Christina M, 2002, Ann Clin Psychiatry, V14, P143, DOI 10.1023/A:1021137118956; Doron R, 2014, LIFE SCI, V94, P151, DOI 10.1016/j.lfs.2013.10.025; Doron R, 2012, LIFE SCI, V90, P995, DOI 10.1016/j.lfs.2012.05.014; Ducottet C, 2004, PHYSIOL BEHAV, V81, P417, DOI 10.1016/j.physbeh.2004.01.013; Dulawa SC, 2004, NEUROPSYCHOPHARMACOL, V29, P1321, DOI 10.1038/sj.npp.1300433; Duman RS, 2006, BIOL PSYCHIAT, V59, P1116, DOI 10.1016/j.biopsych.2006.02.013; Dwivedi Y, 2006, NEUROSCIENCE, V139, P1017, DOI 10.1016/j.neuroscience.2005.12.058; File SE, 2001, BEHAV BRAIN RES, V125, P151, DOI 10.1016/S0166-4328(01)00292-3; Frielingsdorf H, 2010, ANN NY ACAD SCI, V1208, P150, DOI 10.1111/j.1749-6632.2010.05722.x; Hashimoto K, 2004, BRAIN RES REV, V45, P104, DOI 10.1016/j.brainresrev.2004.02.003; Heim C, 2001, BIOL PSYCHIAT, V49, P1023, DOI 10.1016/S0006-3223(01)01157-X; Heim C, 1997, ANN NY ACAD SCI, V821, P194, DOI 10.1111/j.1749-6632.1997.tb48279.x; Ihne JL, 2012, NEUROPHARMACOLOGY, V62, P464, DOI 10.1016/j.neuropharm.2011.08.045; Kalinichev M, 2002, PHARMACOL BIOCHEM BE, V73, P131, DOI 10.1016/S0091-3057(02)00781-5; Katzman MA, 2009, CNS DRUGS, V23, P103, DOI 10.2165/00023210-200923020-00002; Lang UE, 2005, PSYCHOPHARMACOLOGY, V180, P95, DOI 10.1007/s00213-004-2137-7; Larsen MH, 2010, J PSYCHIATR RES, V44, P808, DOI 10.1016/j.jpsychires.2010.01.005; Lee TTY, 2012, NEUROSCIENCE, V204, P17, DOI 10.1016/j.neuroscience.2011.10.006; Lenze EJ, 2011, AM J GERIAT PSYCHIAT, V19, P482, DOI 10.1097/JGP.0b013e3181ec806c; Linde K, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000448.pub3; Liu D, 1997, SCIENCE, V277, P1659, DOI 10.1126/science.277.5332.1659; Maayan R, 2006, EUR NEUROPSYCHOPHARM, V16, P329, DOI 10.1016/j.euroneuro.2005.10.002; Mantella RC, 2008, PSYCHONEUROENDOCRINO, V33, P773, DOI 10.1016/j.psyneuen.2008.03.002; Marco EM, 2012, NEUROPHARMACOLOGY; Middeldorp CM, 2010, GENES BRAIN BEHAV, V9, P808, DOI 10.1111/j.1601-183X.2010.00619.x; Millstein RA, 2007, NEUROSCI BIOBEHAV R, V31, P3, DOI 10.1016/j.neubiorev.2006.05.003; Muller WE, 1997, PHARMACOPSYCHIATRY, V30, P102, DOI 10.1055/s-2007-979528; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Panossian A, 1999, PHYTOMEDICINE, V6, P147, DOI 10.1016/S0944-7113(99)80002-6; Reinhold JA, 2011, EXPERT OPIN PHARMACO, V12, P2457, DOI 10.1517/14656566.2011.618496; Roceri M, 2004, BIOL PSYCHIAT, V55, P708, DOI 10.1016/j.biopsych.2003.12.011; Romeo RD, 2003, HORM BEHAV, V43, P561, DOI 10.1016/S0018-506X(03)00063-1; Sanchez C, 2003, PSYCHOPHARMACOLOGY, V167, P353, DOI 10.1007/s00213-002-1364-z; Sanchez MM, 2001, DEV PSYCHOPATHOL, V13, P419, DOI 10.1017/S0954579401003029; Sarris J, 2009, J ALTERN COMPLEM MED, V15, P827, DOI 10.1089/acm.2009.0066; Scheid Volker, 2009, CHINESE HERBAL MED F, V2nd; Schmidt MV, 2007, PSYCHONEUROENDOCRINO, V32, P417, DOI 10.1016/j.psyneuen.2007.02.011; Simmen U, 1999, J RECEPT SIGNAL TR R, V19, P59, DOI 10.3109/10799899909036637; Slotten HA, 2006, BRAIN RES, V1097, P123, DOI 10.1016/j.brainres.2006.04.066; Tamaji A, 2012, HUM PSYCHOPHARM CLIN, V27, P329, DOI 10.1002/hup.2220; Thase ME, 2006, EXPERT OPIN PHARMACO, V7, P429, DOI 10.1517/14656566.7.4.429; Tsoory M, 2007, EUR NEUROPSYCHOPHARM, V17, P245, DOI 10.1016/j.euroneuro.2006.06.007; Vermetten E, 2006, ANN NY ACAD SCI, V1071, P184, DOI 10.1196/annals.1364.014; Vreeburg SA, 2010, PSYCHOSOM MED, V72, P340, DOI 10.1097/PSY.0b013e3181d2f0c8; WILLNER P, 1992, NEUROSCI BIOBEHAV R, V16, P525, DOI 10.1016/S0149-7634(05)80194-0; Witte S, 2005, PHYTOTHER RES, V19, P183, DOI 10.1002/ptr.1609	56	29	29	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2014	9	4							e91455	10.1371/journal.pone.0091455	http://dx.doi.org/10.1371/journal.pone.0091455			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE6KM	24690945	Green Submitted, Green Published, gold			2023-01-03	WOS:000334101100015
J	Gavi, MBRO; Vassalo, DV; Amaral, FT; Macedo, DCF; Gava, PL; Dantas, EM; Valim, V				Renoldi Oliveira Gavi, Maria Bernadete; Vassalo, Dalton Valentin; Amaral, Fabian Tadeu; Felicio Macedo, Danielle Constancia; Gava, Pablo Lucio; Dantas, Eduardo Miranda; Valim, Valeria			Strengthening Exercises Improve Symptoms and Quality of Life but Do Not Change Autonomic Modulation in Fibromyalgia: A Randomized Clinical Trial	PLOS ONE			English	Article							HEART-RATE-VARIABILITY; ACUTE RESISTANCE EXERCISE; AEROBIC EXERCISE; PREMENOPAUSAL WOMEN; SPECTRAL-ANALYSIS; QUESTIONNAIRE; ADAPTATIONS; DYSFUNCTION; SEVERITY; THERAPY	Objective: Autonomic dysfunction is an important mechanism that could explain many symptoms observed in fibromyalgia (FM). Exercise is an effective treatment, with benefits potentially mediated through changes in autonomic modulation. Strengthening is one of the less studied exercises in FM, and the acute and chronic effects of strengthening on the autonomic system remain unknown. The objective of this study was to assess the chronic effects of strengthening exercises (STRE) on autonomic modulation, pain perception and the quality of life (QOL) of FM patients. Methods: Eighty sedentary women with FM (ACR 1990) were randomly selected to participate in STRE or flexibility (FLEX) exercises in a blinded controlled trial. The intensity of STRE was set at 45% of the estimated load of 1 Repetition Maximum (RM) in 12 different exercises. Outcomes were Visual Analog Scale (VAS) for pain, Heart Rate Variability (HRV) analysis, treadmill test, the sit and reach test (Wells and Dillon's Bench), maximal repetitions test and handgrip dynamometry; and quality of life by the Fibromyalgia Impact Questionnaire (FIQ), the Beck and Idate Trait-State Inventory (IDATE), a short-form health survey (SF-36). Results: The STRE group was more effective to strength gain for all muscles and pain control after 4 and 16 weeks (p<0.05). The FLEX group showed higher improvements in anxiety (p<0.05). Both groups showed improvements in the QOL, and there was no significant difference observed between the groups. There was no change in the HRV of the STRE and FLEX groups. Conclusions: Strengthening exercises show greater and more rapid improvements in pain and strength than flexibility exercises. Despite the benefits in fitness, pain, depression, anxiety and quality of life, no effect was observed on the autonomic modulation in both groups. This observation suggests that changes in autonomic modulation are not a target tobe clinically achieved in fibromyalgia.	[Renoldi Oliveira Gavi, Maria Bernadete] Univ Fed Espirito Santo, Univ Hosp, Div Rheumatol, Vitoria, ES, Brazil; [Vassalo, Dalton Valentin] Univ Fed Espirito Santo, Post Grad Program Physiol Sci, Vitoria, ES, Brazil; [Amaral, Fabian Tadeu] Univ Fed Espirito Santo, Vitoria, ES, Brazil; [Felicio Macedo, Danielle Constancia; Gava, Pablo Lucio] Univ Fed Espirito Santo, Ctr Hlth Sci, Vitoria, ES, Brazil; [Dantas, Eduardo Miranda] Fed Univ Vale do Sao Francisco, Coll Biol Sci, Petrolina, MG, Brazil; [Valim, Valeria] Univ Fed Espirito Santo, Dept Med, Univ Hosp, Div Rheumatol, Vitoria, ES, Brazil	Universidade Federal do Espirito Santo; Universidade Federal do Espirito Santo; Universidade Federal do Espirito Santo; Universidade Federal do Espirito Santo; Universidade Federal do Espirito Santo	Valim, V (corresponding author), Univ Fed Espirito Santo, Dept Med, Univ Hosp, Div Rheumatol, Vitoria, ES, Brazil.	val.valim@gmail.com	Dantas, Eduardo M/F-9290-2013; Dantas, Estélio Henrique Martin/F-6962-2012	Dantas, Eduardo M/0000-0002-6589-5592; Dantas, Estélio Henrique Martin/0000-0003-0981-8020				Aubert AE, 2003, SPORTS MED, V33, P889, DOI 10.2165/00007256-200333120-00003; Bircan C, 2008, RHEUMATOL INT, V28, P527, DOI 10.1007/s00296-007-0484-5; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Brosseau L, 2008, PHYS THER, V88, P873, DOI 10.2522/ptj.20070115; BURCKHARDT CS, 1991, J RHEUMATOL, V18, P728; Busch AJ, 2011, CURR PAIN HEADACHE R, V15, P358, DOI 10.1007/s11916-011-0214-2; Clauw Daniel J, 2009, Am J Med, V122, pS3, DOI 10.1016/j.amjmed.2009.09.006; Cooke WH, 2005, EUR J APPL PHYSIOL, V93, P719, DOI 10.1007/s00421-004-1243-x; Cuatrecasas G, 2014, PITUITARY, V17, P277, DOI 10.1007/s11102-013-0486-0; Dantas EM, 2012, COMPUT BIOL MED, V42, P164, DOI 10.1016/j.compbiomed.2011.11.004; Faria TD, 2010, EUR J APPL PHYSIOL, V110, P359, DOI 10.1007/s00421-010-1508-5; Figueroa A, 2008, CLIN PHYSIOL FUNCT I, V28, P49, DOI 10.1111/j.1475-097X.2007.00776.x; Gamelin FX, 2007, INT J SPORTS MED, V28, P564, DOI 10.1055/s-2007-964861; Gorenstein C, 1996, BRAZ J MED BIOL RES, V29, P453; Grant CC, 2012, ANN NONINVAS ELECTRO, V17, P219, DOI 10.1111/j.1542-474X.2012.00511.x; Hakkinen A, 2001, ANN RHEUM DIS, V60, P21, DOI 10.1136/ard.60.1.21; Hakkinen K, 2002, J RHEUMATOL, V29, P1287; Heffernan KS, 2007, AM J PHYSIOL-HEART C, V293, pH3180, DOI 10.1152/ajpheart.00648.2007; Hooten WM, 2012, PAIN, V153, P915, DOI 10.1016/j.pain.2012.01.020; Innes E, 1999, AUST OCCUP THER J, V46, P120, DOI DOI 10.1046/J.1440-1630.1999.00182.X; Jones KD, 2002, J RHEUMATOL, V29, P1041; Kingsley JD, 2010, ARCH PHYS MED REHAB, V91, P1551, DOI 10.1016/j.apmr.2010.07.003; Kingsley JD, 2009, ARCH PHYS MED REHAB, V90, P1628, DOI 10.1016/j.apmr.2009.02.023; Koziris LP, 1999, J APPL PHYSIOL, V86, P1436, DOI 10.1152/jappl.1999.86.4.1436; Kulshreshtha P, 2013, CLIN PHYSIOL FUNCT I, V33, P83, DOI 10.1111/cpf.12000; Martinez-Lavin M, 2000, SEMIN ARTHRITIS RHEU, V29, P197, DOI 10.1016/S0049-0172(00)80008-6; Martinez-Lavin M, 1998, ARTHRITIS RHEUM-US, V41, P1966, DOI 10.1002/1529-0131(199811)41:11<1966::AID-ART11>3.0.CO;2-O; Martinez-Lavin M, 2012, PAIN RES TREAT, V2012, DOI 10.1155/2012/981565; Penrod JR, 2004, J RHEUMATOL, V31, P1391; Pereira AM, 2009, CLIN EXP RHEUMATOL, V27, P42; Ratamess NA, 2009, MED SCI SPORT EXER, V41, P687, DOI 10.1249/MSS.0b013e3181915670; Routledge FS, 2010, CAN J CARDIOL, V26, P303, DOI 10.1016/S0828-282X(10)70395-0; Sanudo B, 2010, ARCH PHYS MED REHAB, V91, P1838, DOI 10.1016/j.apmr.2010.09.006; Shin K, 1995, JPN J PHYSIOL, V45, P1053, DOI 10.2170/jjphysiol.45.1053; Solano C, 2009, JCR-J CLIN RHEUMATOL, V15, P172, DOI 10.1097/RHU.0b013e3181a1083d; Srikuea R, 2013, ARTHRITIS RHEUM-US, V65, P519, DOI 10.1002/art.37763; Takahashi ACM, 2009, EUR J APPL PHYSIOL, V105, P315, DOI 10.1007/s00421-008-0905-5; Valim V, 2003, J RHEUMATOL, V30, P1060; Valim V, 2013, REV BRAS REUMATOL, V53, P538, DOI [10.1016/j.rbr.2013.02.001, 10.1016/j.rbre.2013.02.001]; Valkeinen H, 2006, ARTHRITIS RHEUM, V54, P1334, DOI 10.1002/art.21751; Valkeinen H, 2004, RHEUMATOLOGY, V43, P225, DOI 10.1093/rheumatology/keh027; Valkeinen H, 2008, ARCH PHYS MED REHAB, V89, P1660, DOI 10.1016/j.apmr.2008.01.022; Wells KF, 1952, RES QUART, V23, P115, DOI 10.1080/10671188.1952.10761965; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203	44	55	55	0	48	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2014	9	3							e90767	10.1371/journal.pone.0090767	http://dx.doi.org/10.1371/journal.pone.0090767			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AD6FV	24651512	gold, Green Published			2023-01-03	WOS:000333352800023
J	Zhao, TT; Zhang, HJ; Lu, XG; Huang, XR; Zhang, WK; Wang, H; Lan, HY; Li, P				Zhao, Ting Ting; Zhang, Hao Jun; Lu, Xiao Guang; Huang, Xiao Ru; Zhang, Wei Ku; Wang, Hua; Lan, Hui Yao; Li, Ping			Chaihuang-Yishen Granule Inhibits Diabetic Kidney Disease in Rats through Blocking TGF-beta/Smad3 Signaling	PLOS ONE			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; RENAL FIBROSIS; DIVERSE ROLES; NEPHROPATHY; RECEPTOR; MICRORNA; SMAD3; INFLAMMATION; ACTIVATION	Objective: Increasing evidence shows that TGF-beta 1 is a key mediator in diabetic nephropathy (DN) and induces renal fibrosis positively by Smad3 but negatively by Smad7. However, treatment of DN by blocking the TGF-beta/Smad pathway remains limited. The present study investigated the anti-fibrotic effect of a traditional Chinese medicine, Chaihuang-Yishen granule (CHYS), on DN. Research Design and Methods: Protective role of CHYS in DN was examined in an accelerated type 1 DN induced by streptozotocin in uninephrectomized Wistar rats. CHYS, at a dose of 0.56 g/kg body weight, was administered by a daily gastric gavage for 20 weeks and the therapeutic effect and potential mechanisms of CHYS on diabetic kidney injury were examined. Results: Treatment with CHYS attenuated diabetic kidney injury by significantly inhibiting 24-h proteinuria and progressive renal fibrosis including glomerulosclerotic index, tubulointerstitial fibrosis index, and upregulation of extracellular matrix (collagen I, IV, and fibronectin), despite the same levels of blood glucose. Further studies revealed that inhibition of renal fibrosis in CHYS-treated diabetic rats was associated with inhibition of TGF-beta 1/Smad3 signaling as demonstrated by upregulation of Smad7 but downregulation of TGF-beta 1, TGF-beta receptors, activation of Smad3, and expression of miRNA-21. Conclusions: CHYS may be a therapeutic agent for DN. CHYS attenuates DN by blocking TGF-beta/Smad3-mediated renal fibrosis.	[Zhao, Ting Ting; Zhang, Hao Jun; Lu, Xiao Guang; Zhang, Wei Ku; Wang, Hua; Li, Ping] China Japan Friendship Hosp, Inst Clin Med Sci, Dept Pharmacol, Beijing, Peoples R China; [Huang, Xiao Ru; Lan, Hui Yao] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; [Huang, Xiao Ru; Lan, Hui Yao] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; [Huang, Xiao Ru; Lan, Hui Yao] CUHK Shenzhen Res Inst, Shenzhen, Peoples R China	China-Japan Friendship Hospital; Chinese University of Hong Kong; Chinese University of Hong Kong	Lan, HY (corresponding author), Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China.	hylan@cuhk.edu.hk; lp8675@163.com	Lan, Hui Yao/C-9734-2015	Lan, Hui Yao/0000-0003-4283-9755	National Natural Scientific Foundation of China [30973911, 81173422]; International S&T Cooperation Program of China [2011DFA31860]; Municipal Science and Technology R & D funding of basic research, Shenzhen [JC201104220290A]; Research Grant Council of Hong Kong [CUHK5/CRF/09, CUHK3/CRF/12R]; Focused Investment Scheme A and B from the Chinese University of Hong Kong	National Natural Scientific Foundation of China(National Natural Science Foundation of China (NSFC)); International S&T Cooperation Program of China; Municipal Science and Technology R & D funding of basic research, Shenzhen; Research Grant Council of Hong Kong(Hong Kong Research Grants Council); Focused Investment Scheme A and B from the Chinese University of Hong Kong	This work was supported by the National Natural Scientific Foundation of China [grant number: 30973911, 81173422 to PL]; International S&T Cooperation Program of China [grant number: 2011DFA31860 to PL]; Municipal Science and Technology R & D funding of basic research, Shenzhen (Major Program JC201104220290A to HYL); the Research Grant Council of Hong Kong (CUHK5/CRF/09 and CUHK3/CRF/12R to HYL); and the Focused Investment Scheme A and B from the Chinese University of Hong Kong. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Belghith M, 2003, NAT MED, V9, P1202, DOI 10.1038/nm924; Chen HY, 2011, DIABETES, V60, P590, DOI 10.2337/db10-0403; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chung ACK, 2013, INT J NEPHROL RENOV, V6, P169, DOI 10.2147/IJNRD.S37885; Critchley JAJH, 2002, CHINESE MED J-PEKING, V115, P129; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Fujimoto M, 2003, BIOCHEM BIOPH RES CO, V305, P1002, DOI 10.1016/S0006-291X(03)00885-4; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hong SW, 2001, AM J PATHOL, V158, P1653; Hou CC, 2005, AM J PATHOL, V166, P761, DOI 10.1016/S0002-9440(10)62297-3; Huang CM, 2002, DIABETES, V51, P3577, DOI 10.2337/diabetes.51.12.3577; Huang XR, 2008, J AM SOC NEPHROL, V19, P233, DOI 10.1681/ASN.2007040484; International Diabetes Federation, 2013, COMPL DIAB; Kantharidis P, 2011, DIABETES, V60, P1832, DOI 10.2337/db11-0082; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Lan HY, 2011, INT J BIOL SCI, V7, P1056, DOI 10.7150/ijbs.7.1056; LAN HY, 1995, J HISTOCHEM CYTOCHEM, V43, P97, DOI 10.1177/43.1.7822770; Li JH, 2004, FASEB J, V18, P176, DOI 10.1096/fj.02-1117fje; Li P, 2007, NEPHROLOGY, V12, P466, DOI 10.1111/j.1440-1797.2007.00828.x; Mason RM, 2003, J AM SOC NEPHROL, V14, P1358, DOI 10.1097/01.ASN.0000065640.77499.D7; MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; Meng XM, 2012, J PATHOL, V227, P175, DOI 10.1002/path.3976; Patel V, 2012, CURR OPIN NEPHROL HY, V21, P410, DOI 10.1097/MNH.0b013e328354e559; Reeves WB, 2000, P NATL ACAD SCI USA, V97, P7667, DOI 10.1073/pnas.97.14.7667; Tervaert TWC, 2010, J AM SOC NEPHROL, V21, P556, DOI 10.1681/ASN.2010010010; Verrecchia F, 2001, ONCOGENE, V20, P3332, DOI 10.1038/sj.onc.1204448; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Wang A, 2007, AM J PHYSIOL-RENAL, V293, pF1657, DOI 10.1152/ajprenal.00274.2007; Wang WS, 2005, J AM SOC NEPHROL, V16, P1371, DOI 10.1681/ASN.2004121070; Wang WS, 2006, CIRC RES, V98, P1032, DOI 10.1161/01.RES.0000218782.52610.dc; Wang WS, 2005, NEPHROLOGY, V10, P48, DOI 10.1111/j.1440-1797.2005.00334.x; Wen XY, 2012, J ETHNOPHARMACOL, V142, P144, DOI 10.1016/j.jep.2012.04.028; Yang FY, 2010, J PATHOL, V221, P390, DOI 10.1002/path.2721; Zarjou A, 2011, AM J PHYSIOL-RENAL, V301, pF793, DOI 10.1152/ajprenal.00273.2011; Zhang HT, 2011, EURASIP J WIREL COMM, P1, DOI 10.1186/1687-1499-2011-69; Zhao T, 2012, J PHARMACEUT BIOMED, V60, P32, DOI 10.1016/j.jpba.2011.11.010; Zhong X, 2013, DIABETOLOGIA, V56, P663, DOI 10.1007/s00125-012-2804-x; Zhong X, 2011, J AM SOC NEPHROL, V22, P1668, DOI 10.1681/ASN.2010111168	38	51	60	2	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2014	9	3							e90807	10.1371/journal.pone.0090807	http://dx.doi.org/10.1371/journal.pone.0090807			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AD6ER	24646636	Green Submitted, gold, Green Published			2023-01-03	WOS:000333348500017
J	Zhao, X; Cui, HX; Chen, WJ; Wang, Y; Cui, B; Sun, CJ; Meng, ZG; Liu, GQ				Zhao, Xiang; Cui, Haixin; Chen, Wenjie; Wang, Yan; Cui, Bo; Sun, Changjiao; Meng, Zhigang; Liu, Guoqiang			Morphology, Structure and Function Characterization of PEI Modified Magnetic Nanoparticles Gene Delivery System	PLOS ONE			English	Article							DNA NANOPARTICLES; MAGNETOFECTION; THERAPEUTICS	Modified magnetic nanoparticles are used as non-viral gene carriers in biological applications. To achieve successful gene delivery, it is critical that nanoparticles effectually assemble with nucleic acids. However, relatively little work has been conducted on the assemble mechanisms between nanoparticles and DNA, and its effects on transfection efficiency. Using biophysical and biochemical characterization, along with Atomic force microscopy (AFM) and Transmission electron microscopy (TEM), we investigate the morphologies, assembling structures and gene delivering abilities of the PEI modified magnetic nanoparticles (MNPs) gene delivery system. In this gene delivery system, MNP/DNA complexes are formed via binding of DNA onto the surface of MNPs. MNPs are favorable to not only increase DNA concentration but also prevent DNA degradation. Magnetofection experiments showed that MNPs has low cytotoxicity and introduces highly stable transfection in mammalian somatic cells. In addition, different binding ratios between MNPs and DNA result in various morphologies of MNP/DNA complexes and have an influence on transfection efficiency. Dose-response profile indicated that transfection efficiency positively correlate with MNP/DNA ratio. Furthermore, intracellular tracking demonstrate that MNPs move though the cell membranes, deliver and release exogenous DNA into the nucleus.	[Zhao, Xiang; Cui, Haixin; Chen, Wenjie; Wang, Yan; Cui, Bo; Sun, Changjiao; Liu, Guoqiang] Chinese Acad Agr Sci, Inst Environm & Sustainable Dev Agr, Beijing 100193, Peoples R China; [Zhao, Xiang; Cui, Haixin] Chinese Acad Agr Sci, Nano Biol Res Ctr, Beijing 100193, Peoples R China; [Meng, Zhigang] Chinese Acad Agr Sci, Biotechnol Res Inst, Beijing 100193, Peoples R China	Chinese Academy of Agricultural Sciences; Institute of Environment & Sustainable Development in Agriculture, CAAS; Chinese Academy of Agricultural Sciences; Chinese Academy of Agricultural Sciences; Biotechnology Research Institute, CAAS	Cui, HX (corresponding author), Chinese Acad Agr Sci, Inst Environm & Sustainable Dev Agr, Beijing 100193, Peoples R China.	cuihaixin@caas.cn		CHEN, WenJie/0000-0001-9512-9664; Meng, ZhiGang/0000-0001-8959-5685	Genetically Modified Organisms Breeding Major Projects [2009ZX08010-006B]	Genetically Modified Organisms Breeding Major Projects	The authors thank the Genetically Modified Organisms Breeding Major Projects (No. 2009ZX08010-006B) for the financial support of this work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akinc A, 2010, MOL THER, V18, P1357, DOI 10.1038/mt.2010.85; Arvizo RR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024374; Barreto JA, 2011, ADV MATER, V23, pH18, DOI 10.1002/adma.201100140; Choi HS, 2010, NAT NANOTECHNOL, V5, P42, DOI [10.1038/NNANO.2009.314, 10.1038/nnano.2009.314]; Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614; De Jong WH, 2008, INT J NANOMED, V3, P133, DOI 10.2147/ijn.s596; Fallini C, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-17; Gu JL, 2011, SCI CHINA LIFE SCI, V54, P793, DOI 10.1007/s11427-011-4215-5; Gu W, 2010, EUR CELLS MAT S, V20, P294; Hamidi M, 2008, ADV DRUG DELIVER REV, V60, P1638, DOI 10.1016/j.addr.2008.08.002; Harush-Frenkel O, 2007, BIOCHEM BIOPH RES CO, V353, P26, DOI 10.1016/j.bbrc.2006.11.135; Honig D, 2010, BIOMACROMOLECULES, V11, P1802, DOI 10.1021/bm1002569; Krotz F, 2003, MOL THER, V7, P700, DOI 10.1016/S1525-0016(03)00065-0; Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001; Lee H, 2012, NAT NANOTECHNOL, V7, P389, DOI [10.1038/NNANO.2012.73, 10.1038/nnano.2012.73]; MacDonald C, 2010, NANOMEDICINE-UK, V5, P65, DOI 10.2217/NNM.09.97; Mykhaylyk O, 2007, NAT PROTOC, V2, P2391, DOI 10.1038/nprot.2007.352; Namgung R, 2010, BIOMATERIALS, V31, P4204, DOI 10.1016/j.biomaterials.2010.01.123; Park IK, 2008, BIOMATERIALS, V29, P724, DOI 10.1016/j.biomaterials.2007.10.018; Petros RA, 2010, NAT REV DRUG DISCOV, V9, P615, DOI 10.1038/nrd2591; Plank C, 2011, ADV DRUG DELIVER REV, V63, P1300, DOI 10.1016/j.addr.2011.08.002; Prijic S, 2010, J MEMBRANE BIOL, V236, P167, DOI 10.1007/s00232-010-9271-4; Qi LF, 2012, BIOMACROMOLECULES, V13, P2723, DOI 10.1021/bm3006903; Rackstraw BJ, 2001, LANGMUIR, V17, P3185, DOI 10.1021/la001456x; Roy I, 2005, P NATL ACAD SCI USA, V102, P279, DOI 10.1073/pnas.0408039101; Schillinger U, 2005, J MAGN MAGN MATER, V293, P501, DOI 10.1016/j.jmmm.2005.01.032; Singh R, 2009, TRENDS BIOTECHNOL, V27, P220, DOI 10.1016/j.tibtech.2009.01.003; Thanh NTK, 2010, NANO TODAY, V5, P213, DOI 10.1016/j.nantod.2010.05.003; Thurn KT, 2011, NANOMED-NANOTECHNOL, V7, P123, DOI 10.1016/j.nano.2010.09.004; Vijayanathan V, 2004, NUCLEIC ACIDS RES, V32, P127, DOI 10.1093/nar/gkg936; Vijayanathan V, 2002, BIOCHEMISTRY-US, V41, P14085, DOI 10.1021/bi0203987; Volcke C, 2006, J BIOTECHNOL, V125, P11, DOI 10.1016/j.jbiotec.2006.02.010; Weissleder R, 2005, NAT BIOTECHNOL, V23, P1418, DOI 10.1038/nbt1159	33	16	17	0	74	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 9	2014	9	6							e98919	10.1371/journal.pone.0098919	http://dx.doi.org/10.1371/journal.pone.0098919			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI8LF	24911360	Green Published, gold, Green Submitted			2023-01-03	WOS:000337165600024
J	Detsky, AS; Krumholz, HM				Detsky, Allan S.; Krumholz, Harlan M.			Reducing the Trauma of Hospitalization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Detsky, Allan S.] Univ Toronto, Mt Sinai Hosp, Inst Hlth Policy Management & Evaluat, Dept Med, Toronto, ON M5G 1X5, Canada; [Detsky, Allan S.] Univ Hlth Network, Toronto, ON, Canada; [Krumholz, Harlan M.] Yale Univ, Yale New Haven Hosp, Sect Cardiovasc Med, Sch Med,Ctr Outcomes Res & Evaluat, New Haven, CT USA; [Krumholz, Harlan M.] Yale Univ, Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Yale University; Yale University	Detsky, AS (corresponding author), Mt Sinai Hosp, Dept Med, 600 Univ Ave,Room 429, Toronto, ON M5N 2N8, Canada.	adetsky@mtsinai.on.ca	, Harlan/AAI-2875-2020					Chen C, 2014, JAMA-J AM MED ASSOC, V311, P673, DOI 10.1001/jama.2014.11; Detsky ME, 2008, JAMA-J AM MED ASSOC, V300, P954, DOI 10.1001/jama.300.8.954; Dharmarajan K, 2013, JAMA-J AM MED ASSOC, V309, P355, DOI 10.1001/jama.2012.216476; Krumholz HM, 2013, NEW ENGL J MED, V368, P100, DOI 10.1056/NEJMp1212324; Sinha SK, 2012, JAMA-J AM MED ASSOC, V308, P2573, DOI 10.1001/jama.2012.68313	5	65	65	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	2014	311	21					2169	2170		10.1001/jama.2014.3695	http://dx.doi.org/10.1001/jama.2014.3695			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AI2DU	24788549				2023-01-03	WOS:000336668400013
J	Qiu, YW; Lv, XF; Su, HH; Jiang, GH; Li, C; Tian, JZ				Qiu, Yingwei; Lv, Xiaofei; Su, Huanhuan; Jiang, Guihua; Li, Cheng; Tian, Junzhang			Structural and Functional Brain Alterations in End Stage Renal Disease Patients on Routine Hemodialysis: A Voxel-Based Morphometry and Resting State Functional Connectivity Study	PLOS ONE			English	Article							GRAY-MATTER VOLUME; CHRONIC KIDNEY-DISEASE; COGNITIVE IMPAIRMENT; FAILURE; CORTEX; ABNORMALITIES; METABOLISM; SYMPTOMS; ATROPHY	Background and Purpose: Cognitive impairment is a well-described phenomenon in end-stage renal disease (ESRD) patients. However, its pathogenesis remains poorly understood. The primary focus of this study was to examine structural and functional brain deficits in ESRD patients. Materials and Methods: Thirty ESRD patients on hemodialysis (without clinical neurological disease) and 30 age- and gender-matched control individuals (without renal or neurological problems) were recruited in a prospective, single-center study. High-resolution structural magnetic resonance imaging (MRI) and resting state functional MRI were performed on both groups to detect the subtle cerebral deficits in ESRD patients. Voxel-based morphometry was used to characterize gray matter deficits in ESRD patients. The impact of abnormal morphometry on the cerebral functional integrity was investigated by evaluating the alterations in resting state functional connectivity when brain regions with gray matter volume reduction were used as seed areas. Results: A significant decrease in gray matter volume was observed in ESRD patients in the bilateral medial orbito-prefrontal cortices, bilateral dorsal lateral prefrontal cortices, and the left middle temporal cortex. When brain regions with gray matter volume reduction were used as seed areas, the integration was found to be significantly decreased in ESRD patients in the fronto-cerebellum circuits and within prefrontal circuits. In addition, significantly enhanced functional connectivity was found between the prefrontal cortex and the left temporal cortex and within the prefrontal circuits. Conclusions: Our study revealed that both the structural and functional cerebral cortices were impaired in ESRD patients on routine hemodialysis.	[Qiu, Yingwei; Su, Huanhuan; Jiang, Guihua; Tian, Junzhang] Guangdong 2 Prov Peoples Hosp, Dept Med Imaging, Guangzhou, Guangdong, Peoples R China; [Qiu, Yingwei] Gannan Med Univ, Affiliated Hosp 1, Dept Med Imaging, Ganzhou, Peoples R China; [Lv, Xiaofei] Sun Yat Sen Univ, Ctr Canc, Dept Med Imaging, Guangzhou, Guangdong, Peoples R China; [Lv, Xiaofei] Sun Yat Sen Univ, Ctr Canc, Dept Intervent Radiol, Guangzhou, Guangdong, Peoples R China; [Li, Cheng] Guangdong 2 Prov Peoples Hosp, Dept Renal Transplantat, Guangzhou, Guangdong, Peoples R China	Gannan Medical University; Sun Yat Sen University; Sun Yat Sen University	Qiu, YW (corresponding author), Guangdong 2 Prov Peoples Hosp, Dept Med Imaging, Guangzhou, Guangdong, Peoples R China.	qiuyw1201@gmail.com		Qiu, Yingwei/0000-0003-1298-8506; Tian, Junzhang/0000-0002-6212-1882	Natural Scientific Foundation of China [81201084]; Planned Science and Technology Project of Guangdong Province, China [2011B031800044]	Natural Scientific Foundation of China(National Natural Science Foundation of China (NSFC)); Planned Science and Technology Project of Guangdong Province, China	This work was supported by the grants from the Natural Scientific Foundation of China [Grant No. 81201084 for YQ], and the Planned Science and Technology Project of Guangdong Province, China [Grant No. 2011B031800044 for GJ]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alosco ML, 2013, BRAIN BEHAV, V3, P626, DOI 10.1002/brb3.171; Bremer BA, 1997, ANN BEHAV MED, V19, P348, DOI 10.1007/BF02895153; Burruss JW, 2000, RADIOLOGY, V214, P227, DOI 10.1148/radiology.214.1.r00ja43227; Chetelat G, 2008, BRAIN, V131, P60, DOI 10.1093/brain/awm288; Chiu ML, 2010, EUR RADIOL, V20, P1502, DOI 10.1007/s00330-009-1673-2; Denier Niklaus, 2013, Front Psychiatry, V4, P135, DOI 10.3389/fpsyt.2013.00135; Drew DA, 2013, AM J KIDNEY DIS, V61, P271, DOI 10.1053/j.ajkd.2012.08.035; Etgen T, 2012, AM J NEPHROL, V35, P474, DOI 10.1159/000338135; FAZEKAS G, 1995, J NEUROL SCI, V134, P83, DOI 10.1016/0022-510X(95)00226-7; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Gili T, 2011, J NEUROL NEUROSUR PS, V82, P58, DOI 10.1136/jnnp.2009.199935; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; Grieve SM, 2013, NEUROIMAGE-CLIN, V3, P332, DOI 10.1016/j.nicl.2013.08.016; Herting MM, 2011, NEUROIMAGE, V54, P2582, DOI 10.1016/j.neuroimage.2010.10.030; Hoekzema E, 2010, HUM BRAIN MAPP, V31, P1942, DOI 10.1002/hbm.20988; Horwitz B, 1998, P NATL ACAD SCI USA, V95, P8939, DOI 10.1073/pnas.95.15.8939; Ikram MA, 2008, STROKE, V39, P55, DOI 10.1161/STROKEAHA.107.493494; Jenkins G.M., 1968, SPECTRAL ANAL ITS AP; John John P, 2009, Indian J Psychiatry, V51, P180, DOI 10.4103/0019-5545.55084; Kamata T, 2000, AM J NEPHROL, V20, P27, DOI 10.1159/000013551; Kanai H, 2001, AM J KIDNEY DIS, V38, pS129, DOI 10.1053/ajkd.2001.27421; Kimmel PL, 2007, ADV CHRONIC KIDNEY D, V14, P328, DOI 10.1053/j.ackd.2007.07.007; Kringelbach ML, 2005, NAT REV NEUROSCI, V6, P691, DOI 10.1038/nrn1747; KUPERMAN S, 1990, J AM ACAD CHILD PSY, V29, P159, DOI 10.1097/00004583-199003000-00001; Kurella M, 2004, J AM GERIATR SOC, V52, P1863, DOI 10.1111/j.1532-5415.2004.52508.x; Liang X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071507; Lui S, 2009, AM J PSYCHIAT, V166, P196, DOI 10.1176/appi.ajp.2008.08020183; Maudsley AA, 2010, EPILEPSY RES, V88, P127, DOI 10.1016/j.eplepsyres.2009.10.009; Miglior M, 2009, ROLE BRAIN DERIVED N; Nasser ME, 2012, SAUDI J KIDNEY DIS T, V23, P1208, DOI 10.4103/1319-2442.103561; Pomarol-Clotet E, 2010, MOL PSYCHIATR, V15, P823, DOI 10.1038/mp.2009.146; Prohovnik I, 2007, J CEREBR BLOOD F MET, V27, P1861, DOI 10.1038/sj.jcbfm.9600478; Qiu YW, 2014, DRUG ALCOHOL DEPEN, V134, P314, DOI 10.1016/j.drugalcdep.2013.10.023; Qiu YW, 2013, NEUROSCI LETT, V538, P43, DOI 10.1016/j.neulet.2013.01.019; Rauch A, 2008, P NATL ACAD SCI USA, V105, P6759, DOI 10.1073/pnas.0800312105; Regolisti G, 2013, NEPHROL DIAL TRANSPL, V28, P79, DOI 10.1093/ndt/gfs182; Rogers BP, 2012, ALCOHOL CLIN EXP RES, V36, P294, DOI 10.1111/j.1530-0277.2011.01614.x; Savazzi GM, 2001, NEPHRON, V89, P31, DOI 10.1159/000046040; Sehgal AR, 1997, AM J KIDNEY DIS, V30, P41, DOI 10.1016/S0272-6386(97)90563-1; Skinner H, 2005, BRIT J ANAESTH, V94, P203, DOI 10.1093/bja/aei016; Song SH, 2008, PSYCHIAT CLIN NEUROS, V62, P554, DOI 10.1111/j.1440-1819.2008.01849.x; Stefanidis I, 2005, CLIN NEPHROL, V64, P129; Tamura MK, 2013, AM J KIDNEY DIS, V61, P228, DOI 10.1053/j.ajkd.2012.09.009; Tamura MK, 2011, KIDNEY INT, V79, P14, DOI 10.1038/ki.2010.336; Tryc AB, 2011, NEPHROL DIAL TRANSPL, V26, P2635, DOI 10.1093/ndt/gfq729; Whitwell JL, 2009, J NEUROSCI, V29, P9661, DOI 10.1523/JNEUROSCI.2160-09.2009; Yan CG, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00013; Zelazo P. D., 2010, WILEY BLACKWELL HDB, P574, DOI DOI 10.1002/9781444325485.CH22; Zhang LJ, 2013, METAB BRAIN DIS, V28, P647, DOI 10.1007/s11011-013-9438-7; Zhang LJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042824	50	44	52	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2014	9	5							e98346	10.1371/journal.pone.0098346	http://dx.doi.org/10.1371/journal.pone.0098346			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK3KS	24854737	gold, Green Published, Green Submitted			2023-01-03	WOS:000338323200064
J	du Toit, E; van Schalkwyk, C; Dunbar, R; Jennings, K; Yang, B; Coetzee, D; Beyers, N				du Toit, Elizabeth; van Schalkwyk, Cari; Dunbar, Rory; Jennings, Karen; Yang, Blia; Coetzee, David; Beyers, Nulda			Missed Opportunities for Retention in Pre-ART Care in Cape Town, South Africa	PLOS ONE			English	Article							ANTIRETROVIRAL THERAPY; HIV DIAGNOSIS; FOLLOW-UP; MORTALITY; OUTCOMES; SERVICE; TB	Background: Few studies have evaluated access to and retention in pre-ART care. Objectives: To evaluate the proportion of People Living With HIV (PLWH) in pre-ART and ART care and factors associated with retention in pre-ART and ART care from a community cohort. Methods: A cross sectional survey was conducted from February - April 2011. Self reported HIV positive, negative or participants of unknown status completed a questionnaire on their HIV testing history, access to pre-ART and retention in pre-ART and ART care. Results: 872 randomly selected adults who reported being HIV positive in the ZAMSTAR 2010 prevalence survey were included and revisited. 579 (66%) reconfirmed their positive status and were included in this analysis. 380 (66%) had initiated ART with 357 of these (94%) retained in ART care. 199 (34%) had never initiated ART of whom 186 (93%) accessed pre-ART care, and 86 (43%) were retained in pre-ART care. In a univariable analysis none of the factors analysed were significantly associated with retention in care in the pre-ART group. Due to the high retention in ART care, factors associated with retention in ART care, were not analysed further. Conclusion: Retention in ART care was high; however it was low in pre-ART care. The opportunity exists, if care is better integrated, to engage with clients in primary health care facilities to bring them back to, and retain them in, pre-ART care.	[du Toit, Elizabeth; Dunbar, Rory; Yang, Blia; Beyers, Nulda] Univ Stellenbosch, Dept Paediat & Child Hlth, Desmond Tutu TB Ctr, Parow, South Africa; [van Schalkwyk, Cari] Univ Stellenbosch, Natl Res Fdn, Ctr Excellence Epidemiol Modelling & Anal SACEMA, South African Dept Sci & Technol, ZA-7600 Stellenbosch, South Africa; [Jennings, Karen] City Cape Town Hlth Directorate, Cape Town, South Africa; [Coetzee, David] Univ Cape Town, Sch Publ Hlth & Family Med, ZA-7925 Cape Town, South Africa	Stellenbosch University; National Research Foundation - South Africa; Stellenbosch University; University of Cape Town	du Toit, E (corresponding author), Univ Stellenbosch, Dept Paediat & Child Hlth, Desmond Tutu TB Ctr, Parow, South Africa.	elizabethd@sun.ac.za		van Schalkwyk, Cari/0000-0001-5154-1390	United States Agency for International Development (USAID) Cooperative Agreement [GHN-A-00-08-00004-00]	United States Agency for International Development (USAID) Cooperative Agreement(United States Agency for International Development (USAID))	This research was supported by a United States Agency for International Development (USAID) Cooperative Agreement (TREAT TB - Agreement No. GHN-A-00-08-00004-00). The contents are the responsibility of the author(s) and do not necessarily reflect the views of USAID. Funders URL:www.usaid.gov/south-africa. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Actuarial Society of South Africa, 2011, ASSA 2008 AIDS DEM M; Amuron B, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-290; Ayles H, 2013, LANCET; Ayles HM, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-63; Brinkhof MW, B WHO; Coetzee D, 2004, AIDS, V18, P887, DOI 10.1097/00002030-200404090-00006; FORD N, 2006, SOUTH AFR J HIV  DEC, P17; Fried J, 2012, SEX TRANSM INFECT, V88, P147, DOI 10.1136/sextrans-2011-050140; IeDEA and ART Cohort Collaborations, 2014, J Acquir Immune Defic Syndr, V65, pe8, DOI 10.1097/QAI.0b013e3182a39979; Ingle SM, 2010, SAMJ S AFR MED J, V100, P675, DOI 10.7196/SAMJ.3952; Jarvis JN, 2010, AIDS, V24, P1233, DOI 10.1097/QAD.0b013e3283383aeb; Kranzer K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013801; Larson BA, 2010, TROP MED INT HEALTH, V15, P43, DOI 10.1111/j.1365-3156.2010.02511.x; Lawn SD, 2008, AIDS, V22, P1897, DOI 10.1097/QAD.0b013e32830007cd; Lessells RJ, 2011, J ACQ IMMUN DEF SYND, V56, P1, DOI 10.1097/QAI.0b013e3182075ae2; Losina E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009538; Loveday M, 2011, TROP MED INT HEALTH, V16, P431, DOI 10.1111/j.1365-3156.2010.02721.x; Marston Barbara J, 2007, J Int Assoc Physicians AIDS Care (Chic), V6, P106, DOI 10.1177/1545109707300688; Pepper DJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019484; Rosen S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001056; Scott V, 2011, TROP MED INT HEALTH, V16, P1384, DOI 10.1111/j.1365-3156.2011.02842.x; South Africa National Department of Health, 2010, CLIN GUID MAN HIV AI; South African National Department of Health, 2013, NAT STRAT PLAN HIV S; South African National Department of Health, 2013, S AFR ANT TREATM GUI	24	6	6	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2014	9	5							e96867	10.1371/journal.pone.0096867	http://dx.doi.org/10.1371/journal.pone.0096867			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG9HB	24806474	Green Published, gold			2023-01-03	WOS:000335728900108
J	Rhee, C; Gohil, S; Klompas, M				Rhee, Chanu; Gohil, Shruti; Klompas, Michael			Regulatory Mandates for Sepsis Care - Reasons for Caution	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								Sepsis, the syndrome of dysregulated inflammation that occurs with severe infection, affects millions of people worldwide each year. Multiple studies suggest that the incidence of sepsis is dramatically increasing. According to the Centers for Disease Control and Prevention (CDC), for example, sepsis rates doubled between 2000 and 2008.(1) In 2010, sepsis was the 11th leading cause of death in the United States,(2) and in 2011, it was the single most expensive condition treated in hospitals.(3) This apparent explosion in sepsis is spurring high-profile initiatives to promote earlier recognition and better treatment. Standardized screening protocols, bundled order sets, and algorithms for . . . The attention and resources being dedicated to improving sepsis care are welcome. The policy response to this apparent epidemic, however, ought to be tempered by recognition that we do not yet have reliable tools for measuring sepsis incidence.	[Rhee, Chanu; Klompas, Michael] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA 02115 USA; [Rhee, Chanu; Klompas, Michael] Harvard Pilgrim Hlth Care Inst, Boston, MA USA; [Rhee, Chanu; Klompas, Michael] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Gohil, Shruti] Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Harvard University; Brigham & Women's Hospital; University of California System; University of California Irvine	Rhee, C (corresponding author), Harvard Univ, Sch Med, Dept Populat Med, Boston, MA 02115 USA.		Rhee, Chanu/AAO-8368-2020; Klompas, Michael/Z-2415-2019		NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000147] Funding Source: NIH RePORTER; NCATS NIH HHS [KL2 TR000147] Funding Source: Medline	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))		Hall Margaret Jean, 2011, NCHS Data Brief, P1; Lagu T, 2012, CRIT CARE MED, V40, P2932; Lagu T, 2012, CRIT CARE MED, V40, P754, DOI 10.1097/CCM.0b013e318232db65; Murphy SL, 2012, NATL VITAL STAT REP, V60, P1; Wachter RM, 2008, ANN INTERN MED, V149, P29, DOI 10.7326/0003-4819-149-1-200807010-00007	5	148	157	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 1	2014	370	18					1673	1676		10.1056/NEJMp1400276	http://dx.doi.org/10.1056/NEJMp1400276			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AG4QM	24738642	Green Accepted, Green Submitted			2023-01-03	WOS:000335405200003
J	Chiong, W; Kim, AS; Huang, IA; Farahany, NA; Josephson, SA				Chiong, Winston; Kim, Anthony S.; Huang, Ivy A.; Farahany, Nita A.; Josephson, S. Andrew			Testing the Presumption of Consent to Emergency Treatment for Acute Ischemic Stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Chiong, Winston; Kim, Anthony S.; Huang, Ivy A.; Josephson, S. Andrew] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94158 USA; [Farahany, Nita A.] Duke Univ, Sch Law, Durham, NC 27706 USA	University of California System; University of California San Francisco; Duke University	Chiong, W (corresponding author), Univ Calif San Francisco, 675 Nelson Rising Ln,Ste 190, San Francisco, CA 94158 USA.	winston.chiong@ucsf.edu	Farahany, Nita/AGH-5500-2022	Farahany, Nita/0000-0003-4808-6256	NCATS NIH HHS [KL2 TR000143] Funding Source: Medline; NIA NIH HHS [K23 AG043553] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K23AG043553] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		American Academy of Neurology, AM AC NEUR POL CONS; Callegaro M, 2008, PUBLIC OPIN QUART, V72, P1008, DOI 10.1093/poq/nfn065; Gadhia J, 2010, STROKE, V41, P300, DOI 10.1161/STROKEAHA.109.566935; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; McNally Bryan, 2011, Morbidity and Mortality Weekly Report, V60, P1; Rubin EB, 2010, NEUROL CLIN, V28, P459, DOI 10.1016/j.ncl.2009.11.007	6	19	19	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	2014	311	16					1689	1691		10.1001/jama.2014.3302	http://dx.doi.org/10.1001/jama.2014.3302			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AF4OU	24756520	Green Accepted			2023-01-03	WOS:000334693900030
J	Zebis, MK; Andersen, CH; Sundstrup, E; Pedersen, MT; Sjogaard, G; Andersen, LL				Zebis, Mette K.; Andersen, Christoffer H.; Sundstrup, Emil; Pedersen, Mogens T.; Sjogaard, Gisela; Andersen, Lars L.			Time-Wise Change in Neck Pain in Response to Rehabilitation with Specific Resistance Training: Implications for Exercise Prescription	PLOS ONE			English	Article							PHYSICAL-EXERCISE; INDUSTRIAL-WORKERS; UPPER EXTREMITY; FORCE CAPACITY; SHOULDER PAIN; SYMPTOMS; PROGRAMS; WOMEN; TRIAL; INTERVENTION	Purpose: To determine the time-wise effect of specific resistance training on neck pain among industrial technicians with frequent neck pain symptoms. Methods: Secondary analysis of a parallel-group cluster randomized controlled trial of 20 weeks performed at two large industrial production units in Copenhagen, Denmark. Women with neck pain > 30 mm VAS (N = 131) were included in the present analysis. The training group ( N = 77) performed specific resistance training for the neck/shoulder muscles three times a week, and the control group ( N = 54) received advice to stay active. Participants of both groups registered neck pain intensity (0-100 mm VAS) once a week. Results: Neck pain intensity was 55 mm (SD 23) at baseline. There was a significant group by time interaction for neck pain (F-value 2.61,P < 0.001, DF = 19). Between-group differences in neck pain reached significance after 4 weeks (11 mm, 95% Cl 2 to 20). The time-wise change in pain showed three phases; a rapid decrease in the training group compared with the control group during the initial 7 weeks, a slower decrease in pain during the following weeks (week 8-15), and a plateau during the last weeks (week 16-20). Adherence to training followed a two-phase pattern, i.e. weekly participation rate was between 70-86% during the initial 7 weeks, dropping towards 55-63% during the latter half of the training period. Conclusion: Four weeks of specific resistance training reduced neck pain significantly, but 15 weeks is required to achieve maximal pain reduction. The time-wise change in pain followed a three-phase pattern with a rapid effect during the initial 7 weeks followed by a slower but still positive effect, and finally a plateau from week 15 and onwards. Decreased participation rate may explain the decreased efficacy during the latter phase of the intervention.	[Zebis, Mette K.] Copenhagen Univ Hosp, Arthroscop Ctr Amager, Copenhagen S, Denmark; [Zebis, Mette K.] Copenhagen Univ Hosp, Gait Anal Lab, Hvidovre, Denmark; [Andersen, Christoffer H.; Sundstrup, Emil; Andersen, Lars L.] Natl Res Ctr Working Environm, Copenhagen O, Denmark; [Pedersen, Mogens T.] Univ Copenhagen, Dept Nutr Exercise & Sports, Copenhagen N, Denmark; [Sundstrup, Emil; Sjogaard, Gisela] Univ Southern Denmark, Inst Sports Sci & Clin Biomech, Odense, Denmark	University of Copenhagen; University of Copenhagen; National Research Centre for the Working Environment; University of Copenhagen; University of Southern Denmark	Zebis, MK (corresponding author), Copenhagen Univ Hosp, Arthroscop Ctr Amager, Copenhagen S, Denmark.	mettezebis@hotmail.com	Andersen, Lars Louis/AAQ-4802-2020; Pedersen, Mogens Theisen/C-6991-2015	Pedersen, Mogens Theisen/0000-0002-3178-6320; Sjogaard, Gisela/0000-0002-2961-7800; Sundstrup, Emil/0000-0001-7408-222X; Andersen, Lars L./0000-0003-2777-8085; Hojnicke Andersen, Christoffer/0000-0001-9568-4043	Danish Working Environment Research Fund [8-2007-3]	Danish Working Environment Research Fund	This study was financially supported by funding from the Danish Working Environment Research Fund (Grant 8-2007-3). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahlgren C, 2001, J REHABIL MED, V33, P162, DOI 10.1080/165019701750300627; Andersen LL, 2008, J BIOMECH, V41, P2029, DOI 10.1016/j.jbiomech.2008.03.016; Andersen LL, 2008, MED SCI SPORT EXER, V40, P983, DOI 10.1249/MSS.0b013e3181676640; Andersen LL, 2008, ARTHRIT RHEUM-ARTHR, V59, P84, DOI 10.1002/art.23256; Andersen LL, 2012, INT ARCH OCC ENV HEA, V85, P615, DOI 10.1007/s00420-011-0709-5; Andersen LL, 2011, PAIN, V152, P440, DOI 10.1016/j.pain.2010.11.016; Andersen LL, 2009, J APPL PHYSIOL, V107, P1413, DOI 10.1152/japplphysiol.00555.2009; Andersen LL, 2008, CLIN BIOMECH, V23, P1237, DOI 10.1016/j.clinbiomech.2008.08.002; Andersen LL, 2008, J APPL PHYSIOL, V105, P1796, DOI 10.1152/japplphysiol.91057.2008; Andersen LL, 2011, OCCUP ENVIRON MED, V68, P590, DOI 10.1136/oem.2010.056259; Blangsted AK, 2008, SCAND J WORK ENV HEA, V34, P55, DOI 10.5271/sjweh.1192; Bot SDM, 2005, ANN RHEUM DIS, V64, P118, DOI 10.1136/ard.2003.019349; Dworkin RH, 2009, PAIN, V146, P238, DOI 10.1016/j.pain.2009.08.019; GRONNINGSAETER H, 1992, PSYCHOL HEALTH, V7, P147, DOI 10.1080/08870449208520016; Hagberg M, 2000, ARCH PHYS MED REHAB, V81, P1051, DOI 10.1053/apmr.2000.7582; Kamaleri Y, 2009, EUR J PAIN, V13, P426, DOI 10.1016/j.ejpain.2008.05.009; Kovacs FM, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-43; Kraemer WJ, 2004, MED SCI SPORT EXER, V36, P674, DOI 10.1249/01.MSS.0000121945.36635.61; Kraemer WJ, 2002, MED SCI SPORT EXER, V34, P364, DOI 10.1097/00005768-200202000-00027; Larsson B, 2007, BEST PRACT RES CL RH, V21, P447, DOI 10.1016/j.berh.2007.02.015; Morken T, 2003, BMC MUSCULOSKEL DIS, V4, DOI 10.1186/1471-2474-4-21; Pedersen MT, 2013, J STRENGTH COND RES, V27, P229, DOI 10.1519/JSC.0b013e3182541ceb; Rhea MR, 2002, J STRENGTH COND RES, V16, P250, DOI 10.1519/00124278-200205000-00013; Sjogren T, 2005, PAIN, V116, P119, DOI 10.1016/j.pain.2005.03.031; TAKALA EP, 1992, SCAND J WORK ENV HEA, V18, P257, DOI 10.5271/sjweh.1580; Trost SG, 2002, MED SCI SPORT EXER, V34, P1996, DOI 10.1097/00005768-200212000-00020; van Dongen JM, 2012, SCAND J WORK ENV HLT; Viljanen M, 2003, BRIT MED J, V327, P475, DOI 10.1136/bmj.327.7413.475; Ylinen J, 2007, Eura Medicophys, V43, P119; Ylinen J, 2003, JAMA-J AM MED ASSOC, V289, P2509, DOI 10.1001/jama.289.19.2509; Zebis MK, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-205	31	10	11	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 7	2014	9	4							e93867	10.1371/journal.pone.0093867	http://dx.doi.org/10.1371/journal.pone.0093867			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE7EP	24709874	Green Published, gold, Green Submitted			2023-01-03	WOS:000334159800061
J	Nordgreen, J; Tahamtani, FM; Janczak, AM; Horsberg, TE				Nordgreen, Janicke; Tahamtani, Fernanda M.; Janczak, Andrew M.; Horsberg, Tor Einar			Behavioural Effects of the Commonly Used Fish Anaesthetic Tricaine Methanesulfonate (MS-222) on Zebrafish (Danio rerio) and Its Relevance for the Acetic Acid Pain Test	PLOS ONE			English	Article							MORPHINE; NOCICEPTION; RESPONSES; SALMON; EUGENOL; STRESS	The pros and cons of using anaesthesia when handling fish in connection with experiments are debated. A widely adopted practice is to wait thirty minutes after anaesthesia before behavioural observations are initiated, but information about immediate effects of a treatment is then lost. This is pertinent for responses to acute stressors, such as acid injection in the acetic acid pain test. However, omission of anaesthetics in order to obtain data on immediate responses will compromise the welfare of fish and contribute to experimental noise due to stress. We therefore tested the effect of tricaine methanesulfonate on the behaviour of zebrafish. We predicted that tricaine (MS 222) would decrease swimming velocity and that the control fish would show an increased level of anxiety-and stress-related behaviours compared to the tricaine group. Following acclimatization to the test tank, baseline behaviour was recorded before immersion in either tricaine (168 mgl(-1), treatment group, N = 8) or tank water (control group, N = 7). Latencies to lose equilibrium and to lose response to touch were registered. The fish was then returned to the test tank, and the latency to regain equilibrium was registered in anaesthetized fish. When equilibrium was regained, and at five, thirty and sixty minutes after the fish had been returned to the test tank, behaviour was recorded. The tricaine fish showed the following responses (mean +/- sd): latency to lose equilibrium 22.6 s +/- 3.9; latency to lose response to touch 101.9 s +/- 26.8; latency to regain equilibrium 92.0 s +/- 54.4. Contrary to our predictions, neither treatment caused a change in any of the behaviours registered. This indicates that tricaine has no effect on several commonly used behavioural parameters, and that it may be unnecessary to postpone behavioural observations to 30 min after anaesthesia.	[Nordgreen, Janicke; Horsberg, Tor Einar] NMBU, Sch Vet Sci, Dept Food Safety & Infect Biol, Oslo, Norway; [Tahamtani, Fernanda M.; Janczak, Andrew M.] NMBU, Sch Vet Sci, Dept Prod Anim Clin Sci, Anim Welf Res Grp, Oslo, Norway	Norwegian University of Life Sciences; Norwegian University of Life Sciences	Nordgreen, J (corresponding author), NMBU, Sch Vet Sci, Dept Food Safety & Infect Biol, Oslo, Norway.	janicke.nordgreen@nmbu.no	Nordgreen, Janicke/H-9442-2017; Tahamtani, Fernanda/J-6339-2019; Janczak, Andrew M/B-4113-2013	Tahamtani, Fernanda/0000-0002-4439-9733; Janczak, Andrew M/0000-0002-1141-8272	Norwegian School of Veterinary Science	Norwegian School of Veterinary Science	This study was funded by the Norwegian School of Veterinary Science. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arnolds DEW, 2002, BIOL BULL, V203, P188, DOI 10.2307/1543388; Ashley PJ, 2007, BRAIN RES, V1166, P47, DOI 10.1016/j.brainres.2007.07.011; Bakke MJ, 2010, AQUAT TOXICOL, V99, P1, DOI 10.1016/j.aquatox.2010.03.013; Brydges NM, 2009, APPL ANIM BEHAV SCI, V116, P295, DOI 10.1016/j.applanim.2008.09.003; Cachat J, 2010, NAT PROTOC, V5, P1786, DOI 10.1038/nprot.2010.140; Correia AD, 2011, PHARMACEUTICALS, V4, P665, DOI 10.3390/ph4040665; Egan RJ, 2009, BEHAV BRAIN RES, V205, P38, DOI 10.1016/j.bbr.2009.06.022; FRAZIER DT, 1975, EUR J PHARMACOL, V33, P313, DOI 10.1016/0014-2999(75)90175-2; Godwin J., 2012, ZEBRAFISH PROTOCOLS, P181, DOI 10.1007/978-1-61779-597-8_13; HIKASA Y, 1986, JPN J VET SCI, V48, P341; Kalueff AV, 2013, ZEBRAFISH, V10, P70, DOI 10.1089/zeb.2012.0861; Lopez-Olmeda JF, 2012, FISH PHYSIOL BIOCHEM, V38, P143, DOI 10.1007/s10695-011-9523-y; Maximino C, 2010, BEHAV BRAIN RES, V214, P157, DOI 10.1016/j.bbr.2010.05.031; Newby NC, 2009, CAN J ZOOL, V87, P388, DOI 10.1139/Z09-023; Newby NC, 2007, T AM FISH SOC, V136, P341, DOI 10.1577/T06-110.1; Newby NC, 2009, APPL ANIMAL BEHAV SC, V116, P96; Nordgreen J, 2013, APPL ANIM BEHAV SCI, V145, P129, DOI 10.1016/j.applanim.2013.03.002; Nordgreen J, 2009, APPL ANIM BEHAV SCI, V119, P101, DOI 10.1016/j.applanim.2009.03.015; Palmer LM, 2004, J NEUROPHYSIOL, V92, P1034, DOI 10.1152/jn.01151.2003; Popovic NT, 2012, J APPL ICHTHYOL, V28, P553, DOI 10.1111/j.1439-0426.2012.01950.x; Raymond J, 2012, ZEBRAFISH PROTOCOLS, P273; Readman GD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073773; Reilly SC, 2008, APPL ANIM BEHAV SCI, V114, P248, DOI 10.1016/j.applanim.2008.01.016; Sanchez-Vazquez FJ, 2011, CHRONOBIOL INT, V28, P109, DOI 10.3109/07420528.2010.538105; Sneddon LU, 2003, J PAIN, V4, P431, DOI 10.1067/S1526-5900(03)00717-X; Sneddon LU, 2003, APPL ANIM BEHAV SCI, V83, P153, DOI 10.1016/S0168-1591(03)00113-8; Sneddon LU, 2012, J EXOT PET MED, V21, P32, DOI 10.1053/j.jepm.2011.11.009; Sneddon LU, 2009, APPL ANIM BEHAV SCI, V116, P96, DOI 10.1016/j.applanim.2008.07.006; Summerfelt R.C., 1990, P213; TAYLOR PB, 1988, J FISH BIOL, V32, P161, DOI 10.1111/j.1095-8649.1988.tb05349.x; Vindas MA, 2012, ANIM COGN, V15, P903, DOI 10.1007/s10071-012-0517-7; Zahl IH, 2012, FISH PHYSIOL BIOCHEM, V38, P201, DOI 10.1007/s10695-011-9565-1; Zahl IH, 2009, AQUACULTURE, V295, P52, DOI 10.1016/j.aquaculture.2009.06.019	33	34	34	0	62	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2014	9	3							e92116	10.1371/journal.pone.0092116	http://dx.doi.org/10.1371/journal.pone.0092116			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AD6GL	24658262	gold, Green Submitted, Green Published			2023-01-03	WOS:000333355300055
J	Peng, TM; Qian, ZH; Liu, AH; Li, YX; Jiang, CH; Wu, ZX				Peng, Tangming; Qian, Zenghui; Liu, Aihua; Li, Youxiang; Jiang, Chuhan; Wu, Zhongxue			Progressive Occlusion of Enterprise Stent-Assisted Coiling of Ruptured Wide-Necked Intracranial Aneurysms and Related Factors on Angiographic Follow-Up: A Single-Center Experience with 468 Patients	PLOS ONE			English	Article							ENDOVASCULAR TREATMENT; EMBOLIZATION; NEUROFORM	This study was designed to assess the effect of the Enterprise stent on progressive occlusion of wide-necked aneurysms and to evaluate the association between dubious factors and progressive occlusion, which is a consecutive, retrospective, single-center study. Data from 468 patients with 495 wide-necked aneurysms, who had undergone Enterprise stent-assisted coiling (SAC) were reviewed, and the clinical outcomes and the angiographic results were analyzed. A 14-month clinical follow-up was achieved in 421 of the 468 patients (90.0%), showing modified Rankin Scale (mRS) 0-1 in 364 (86.4%), mRS 2 in 17 (4.1%), mRS 3 in 17 (4.1%), mRS 4-5 in 9 (2.1%), and mRS 6 in 14 (3.3%) patients. Overall, the morbidity and mortality were 10.2% and 3.3%, respectively. Initial angiographic results showed Raymond scale (RS) 1 in 273 (55.2%), RS2 in 194 (39.2%), and RS3 in 28 (5.6%) patients. Eight-month angiographic follow-up was available in 394 of 495 patients (79.6%), and RS1 was seen in 315 (79.9%), RS2 in 65 (16.5%) and RS3 in 14 (3.6%) cases. At the end of the follow-up, 115 of the 165 (69.7%) patients with initial RS2 and RS3 showed progressive occlusion. Statistical analysis showed no significant difference between progressive occlusion and age (p = 0.654), sex (p = 0.016), aneurysm diameter (p = 0.010), neck size (p = 0.124), dome-to neck ratio (DNR) (p = 0.018) and location (p = 0.001) at the time of follow-up. SAC using Enterprise stent is not only feasible for wide-necked aneurysms, but can achieve a high rate of progressive occlusion with good clinical outcomes at medium-term follow-up. Patient age and aneurysm neck size showed no associated with progressive occlusion at follow-up, while sex, aneurysm diameter, DNR and location were significantly associated with progressive occlusion.	[Peng, Tangming; Qian, Zenghui; Liu, Aihua; Li, Youxiang; Jiang, Chuhan; Wu, Zhongxue] Capital Med Univ, Beijing Tiantan Hosp, Beijing Neurosurg Inst, Dept Intervent Neuroradiol, Beijing, Peoples R China	Beijing Neurosurgical Institute; Capital Medical University	Liu, AH (corresponding author), Capital Med Univ, Beijing Tiantan Hosp, Beijing Neurosurg Inst, Dept Intervent Neuroradiol, Beijing, Peoples R China.	liuaihua_ttyy@126.com			National Natural Science Foundation of China [30901557]; High Level Health Technique Talent Training Plan of Beijing Health System [2011-3-036]; Nova Plan of Beijing Municipal Science and Technology [2007A043]; Disciplines Backbone of Beijing Tiantan Hospital [DLB2011-09]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); High Level Health Technique Talent Training Plan of Beijing Health System; Nova Plan of Beijing Municipal Science and Technology; Disciplines Backbone of Beijing Tiantan Hospital	This article was supported by the National Natural Science Foundation of China (No. 30901557), The High Level Health Technique Talent Training Plan of Beijing Health System (No. 2011-3-036), and the Nova Plan of Beijing Municipal Science and Technology (2007A043), Disciplines Backbone of Beijing Tiantan Hospital (No. DLB2011-09). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Fargen KM, 2012, NEUROSURGERY, V71, P239, DOI 10.1227/NEU.0b013e3182571953; Gentric JC, 2013, AM J NEURORADIOL, V34, P1203, DOI 10.3174/ajnr.A3379; Golshani Kiarash, 2012, Surg Neurol Int, V3, P84, DOI 10.4103/2152-7806.99174; Gu DQ, 2013, J CLIN NEUROSCI, V20, P238, DOI 10.1016/j.jocn.2012.01.053; Heller RS, 2011, AM J NEURORADIOL, V32, P1714, DOI 10.3174/ajnr.A2584; Huang QH, 2013, J CLIN NEUROSCI, V20, P261, DOI 10.1016/j.jocn.2012.02.027; Jeon P, 2012, AM J NEURORADIOL, V33, P965, DOI 10.3174/ajnr.A2857; Jia J, 2012, INTERV NEURORADIOL, V18, P426, DOI 10.1177/159101991201800408; Kadkhodayan Y, 2013, AM J ROENTGENOL, V200, P872, DOI 10.2214/AJR.12.8954; Kim DJ, 2010, ACTA NEUROCHIR, V152, P423, DOI 10.1007/s00701-009-0522-z; Lazzaro Marc A, 2011, Front Neurol, V2, P52, DOI 10.3389/fneur.2011.00052; Lee JI, 2012, J KOREAN NEUROSURG S, V51, P370, DOI 10.3340/jkns.2012.51.6.370; Lodi YM, 2012, J NEUROINTERV SURG, V4, P281, DOI 10.1136/neurintsurg-2011-010035; Lopes D, 2005, NEUROSURGERY, V56, P416, DOI 10.1227/01.NEU.0000145867.25167.CF; Lubicz B, 2008, NEUROSURGERY, V62, P1063, DOI 10.1227/01.neu.0000325868.06764.de; Lv XL, 2012, EUR J RADIOL, V81, P1179, DOI 10.1016/j.ejrad.2011.03.052; Maldonado IL, 2011, AM J NEURORADIOL, V32, P131, DOI 10.3174/ajnr.A2245; Shima H, 2009, J CLIN NEUROSCI, V16, P560, DOI 10.1016/j.jocn.2008.05.031; Spiotta AM, 2013, J NEUROINTERV SURG, V5, P582, DOI 10.1136/neurintsurg-2012-010552; Tahtinen OI, 2009, RADIOLOGY, V253, P199, DOI 10.1148/radiol.2531081923; Wanke I, 2008, NEURORADIOLOGY, V50, P991, DOI 10.1007/s00234-008-0460-0; Weber W, 2007, NEURORADIOLOGY, V49, P555, DOI 10.1007/s00234-007-0232-2; Xu XA, 2011, CHINESE MED J-PEKING, V124, P611, DOI 10.3760/cma.j.issn.0366-6999.2011.04.023	23	17	19	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2014	9	3							e92407	10.1371/journal.pone.0092407	http://dx.doi.org/10.1371/journal.pone.0092407			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AD6GL	24658387	Green Published, gold, Green Submitted			2023-01-03	WOS:000333355300080
J	Barnieh, L; Clement, F; Harris, A; Blom, M; Donaldson, C; Klarenbach, S; Husereau, D; Lorenzetti, D; Manns, B				Barnieh, Lianne; Clement, Fiona; Harris, Anthony; Blom, Marja; Donaldson, Cam; Klarenbach, Scott; Husereau, Don; Lorenzetti, Diane; Manns, Braden			A Systematic Review of Cost-Sharing Strategies Used within Publicly-Funded Drug Plans in Member Countries of the Organisation for Economic Co-Operation and Development	PLOS ONE			English	Review							HEALTH TECHNOLOGY-ASSESSMENT; POSITIVE LIST SYSTEM; DECISION-MAKING; SOUTH-KOREA; PRACTICE GUIDELINES; MANDATORY PRACTICE; CARE-SYSTEMS; REIMBURSEMENT; IMPACT; THAILAND	Background: Publicly-funded drug plans vary in strategies used and policies employed to reduce continually increasing pharmaceutical expenditures. We systematically reviewed the utilization of cost-sharing strategies and physician-directed prescribing regulations in publicly-funded formularies within member nations of the Organization of Economic Cooperation and Development (OECD). Methods & Findings: Using the OECD nations as the sampling frame, a search for cost-sharing strategies and physician-directed prescribing regulations was done using published and grey literature. Collected data was verified by a system expert within the prescription drug insurance plan in each country, to ensure the accuracy of key data elements across plans. Significant variation in the use of cost-sharing mechanisms was seen. Copayments were the most commonly used cost-containment measure, though their use and amount varied for those with certain conditions, most often chronic diseases (in 17 countries), and by socio-economic status (either income or employment status), or with age (in 15 countries). Caps and deductibles were only used by five systems. Drug cost-containment strategies targeting physicians were also identified in 24 countries, including guideline-based prescribing, prescription monitoring and incentive structures. Conclusions: There was variable use of cost-containment strategies to limit pharmaceutical expenditures in publicly funded formularies within OECD countries. Further research is needed to determine the best approach to constrain costs while maintaining access to pharmaceutical drugs.	[Barnieh, Lianne; Manns, Braden] Univ Calgary, Dept Med, Calgary, AB, Canada; [Clement, Fiona; Lorenzetti, Diane] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; [Harris, Anthony] Monash Univ, Ctr Hlth Econ, Melbourne, Vic 3004, Australia; [Blom, Marja] Univ Helsinki, Fac Pharm, Helsinki, Finland; [Donaldson, Cam] Glasgow Caledonian Univ, Yunus Ctr Social Business & Hlth, Glasgow G4 0BA, Lanark, Scotland; [Klarenbach, Scott] Univ Alberta, Dept Med, Edmonton, AB, Canada; [Husereau, Don] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada	University of Calgary; University of Calgary; Monash University; University of Helsinki; Glasgow Caledonian University; University of Alberta; University of Ottawa	Manns, B (corresponding author), Univ Calgary, Dept Med, Calgary, AB, Canada.	Braden.manns@albertahealthservices.ca	Husereau, Don/AAJ-7722-2021	Husereau, Don/0000-0002-4416-6876; Donaldson, Cam/0000-0003-4670-5340; Harris, Anthony/0000-0003-1641-3320; Lorenzetti, Diane L./0000-0001-8423-3458				Anell A, 2005, EUR J HEALTH ECON, V50, P274; Austvoll-Dahlgren A, 2009, COCHRANE DB SYST REV; Bae EY, 2009, VALUE HEALTH, V12, pS36, DOI 10.1111/j.1524-4733.2009.00625.x; Balfour DC, 2009, J MANAGE CARE PHARM, V15, pS3, DOI 10.18553/jmcp.2009.15.s1.3; Barrett P., 2007, HLTH SYSTEMS TRANSIT, P1; Barry M, 2008, EC DRUG USAGE IRISH; Barry M, 2010, EXPERT REV PHARM OUT, V10, P239, DOI [10.1586/erp.10.23, 10.1586/ERP.10.23]; Barry Michael, 2007, Expert Rev Pharmacoecon Outcomes Res, V7, P605, DOI 10.1586/14737167.7.6.605; Bekkering GE, 2008, EUR J HEALTH ECON, V9, pS5, DOI 10.1007/s10198-008-0122-5; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; Bryndova L, 2009, HLTH SYSTEMS TRANSIT, V11, P1; Caisse Nationale de la Sante, 2011, FORM INSCR LIST POS; Canadian Agency for Drugs and Technologies in Health, 2010, PROC COMM DRUG REV; Canadian Institute for Health Information, 2007, CAN I HLTH INF DRUG; Canadian Treatment Action Council, 2007, GEN DRUGS CAN POL PA; Chalkidou Kalipso, 2009, Issue Brief (Commonw Fund), V59, P1; Choudhry NK, 2011, NEW ENGL J MED, V365, P2088, DOI 10.1056/NEJMsa1107913; Chun C.B., 2009, HLTH SYSTEMS TRANSIT, V11, P1; Cleemput I, 2006, GUIDELINES PHARMACOE; Cleemput I, 2009, VALUE HEALTH, V12, P441, DOI 10.1111/j.1524-4733.2008.00469.x; Cumming Jacqueline, 2010, BMJ, V340, pc2441, DOI 10.1136/bmj.c2441; Dasbach Erik J, 2010, J Med Econ, V13, P110, DOI 10.3111/13696990903546013; Davidova J, 2008, PHARM WORLD SCI, V30, P57, DOI 10.1007/s11096-007-9141-z; Daw JR, 2012, HEALTH POLICY, V104, P19, DOI 10.1016/j.healthpol.2011.08.015; Decollogny A, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-17; Demers V, 2008, CAN MED ASSOC J, V178, P405, DOI 10.1503/cmaj.070587; Department of Health and Aged Care, 2000, AUSTR HLTH CAR SYST; Department of Health and Ageing, 2008, GUID PREP SUBM PHARM; DeSwaef A., 2008, PHARM PRICING REIMBU; Dormuth CR, 2006, CLIN THER, V28, P964, DOI 10.1016/j.clinthera.2006.06.007; Dormuth CR, 2009, MED CARE, V47, P508, DOI 10.1097/MLR.0b013e318190d482; Doshi JA, 2009, CIRCULATION, V119, P390, DOI 10.1161/CIRCULATIONAHA.108.783944; Drummond M, 2012, EUR J HEALTH ECON, V13, P1, DOI 10.1007/s10198-011-0353-8; Duerden Martin, 2004, J Ambul Care Manage, V27, P132; Duran A, 2006, HLTH SYSTEMS TRANSIT, V8, P1; DurandZaleski I, 1997, BRIT MED J, V315, P943; Durieux P, 2000, INT J TECHNOL ASSESS, V16, P969, DOI 10.1017/S0266462300103046; Elliott D, 2007, PHARM PRICING REIMBU; Ess SM, 2003, PHARMACOECONOMICS, V21, P89, DOI 10.2165/00019053-200321020-00002; Festoy H, 2008, PHARM PRICING REIMBU; Finnish Medicines Agency and Social Insurance Institution, 2011, FINN STAT MED 2010; Folino-Gallo P, 2008, EUR J HEALTH ECON, V9, P305, DOI 10.1007/s10198-008-0114-5; Fretheim A, 2007, PLOS MED, V4, P1178, DOI 10.1371/journal.pmed.0040232; Fricke FU, 2009, VALUE HEALTH, V12, pS20, DOI 10.1111/j.1524-4733.2009.00555.x; Garattini L, 2007, HEALTH POLICY, V82, P330, DOI 10.1016/j.healthpol.2006.11.004; Gerkens S, 2010, HEALT SYST TRANSIT, V12, P1; Gibson TB, 2006, AM J MANAG CARE, V12, pSP11; Glenngard AH., 2005, HLTH SYSTEMS TRANSIT; Godman Brian, 2008, Expert Rev Pharmacoecon Outcomes Res, V8, P357, DOI 10.1586/14737167.8.4.357; Goldman DP, 2007, JAMA-J AM MED ASSOC, V298, P61, DOI 10.1001/jama.298.1.61; Goldman DP, 2006, AM J MANAG CARE, V12, P21; Greenberg D, 2009, INT J TECHNOL ASSESS, V25, P255, DOI 10.1017/S026646230999016X; Habl C, 2006, SURVEYING ASSESSING; Halldorsson M, 2003, HLTH CARE SYSTEMS TR; Hynd A, 2008, PHARMACOEPIDEM DR S, V17, P1091, DOI 10.1002/pds.1670; Iizuka T, 2008, EC PHARM PRICING PHY; Janiszewski R, 2007, PHARM PRICING REIMBU; Jirawattanapisal T, 2009, VALUE HEALTH, V12, pS4, DOI 10.1111/j.1524-4733.2009.00620.x; Joyce GF, 2007, HEALTH AFFAIR, V26, P1333, DOI 10.1377/hlthaff.26.5.1333; Joyce GF, 2002, JAMA-J AM MED ASSOC, V288, P1733, DOI 10.1001/jama.288.14.1733; Kalo Z, 2008, PHARM PRICING REIMBU; Kamae I, 2010, PHARMACOECONOMICS, V28, P831, DOI 10.2165/11538360-000000000-00000; Kanavos P, 2009, REV ESTONIAN PHARM S; Kaypa hoito, 2012, CURR CAR GUID; Kazakov R, 2007, J GEN MED, V4, P249, DOI DOI 10.1057/PALGRAVE.JGM.4950068; Kovacs T, 2007, PHARM PRICING REIMBU; Kuszewski K, 2005, HLTH SYSTEMS TRANSIT; Lee KM, 2017, GUID EC EV HLTH TECH, V4th; Leopold C, 2008, PHARM PRICING REIMBU; Liu GG, 2009, VALUE HEALTH, V12, pS12, DOI 10.1111/j.1524-4733.2009.00621.x; Liu SZ, 2004, HEALTH POLICY, V68, P277, DOI 10.1016/j.healthpol.2003.12.013; Lopert Ruth, 2009, Issue Brief (Commonw Fund), V60, P1; Lu M, 2008, FINANCING HLTH CARE; Martini N, 2007, PHARM PRICING REIMBU; Mazag J, 2007, PHARM PRICING REIMBU; McDaid D, 2009, HEALT SYST TRANSIT, V11, P1; Mencin D, 2009, VALUE HEALTH, V12, pS14, DOI 10.1111/j.1524-4733.2009.00554.x; Moise P., 2007, OECD HLTH WORKING PA, V28, DOI [10.2139/ssrn.1329310, DOI 10.2139/SSRN.1329310]; Nakao S, 2010, YAKUGAKU ZASSHI, V130, P1347, DOI 10.1248/yakushi.130.1347; Nasser Mona, 2009, Issue Brief (Commonw Fund), V57, P1; National Institute for Health and Clinical Excellence, 2008, GUID METH TECHN APPR; Ngorsuraches S, 2012, VALUE HEALTH, V15, pS120, DOI 10.1016/j.jval.2011.11.002; Oortwijn W, 2010, HEALTH POLICY, V95, P174, DOI 10.1016/j.healthpol.2009.12.008; Organisation of Economic Cooperation and Development, 2012, OECD HLTH DAT 2012 F; Palnoch D., 2007, PHARM PRICING REIMBU; Paris V, 2006, PHARM PRICING REIMBU; Paris V, 2007, PHARM PRICING REIMBU; Park SE, 2012, HEALTH POLICY, V104, P32, DOI 10.1016/j.healthpol.2011.09.006; Peura S., 2007, PHARM PRICING REIMBU; Pharmaceutical Benefits Board L, 2007, SWED PHARM REIMB SYS; PPRI secretariat, 2007, PHARM PRIC REIMB INF; Profili S., 2009, HLTH SYST TRANSIT, V11, P1; Pudersell K, 2007, PHARM PRICING REIMBU; Raftery JP, 2008, MED J AUSTRALIA, V188, P26, DOI 10.5694/j.1326-5377.2008.tb01500.x; Rapoport J, 2009, COST CONTAINMENT EFF; Rawlins M, 2010, BRIT J CLIN PHARMACO, V70, P346, DOI 10.1111/j.1365-2125.2009.03589.x; Redman T, 2007, PHARM PRICING REIMBU; Rochaix Lise, 2009, Issue Brief (Commonw Fund), V58, P1; Sch?fer, 2009, HLTH SYST TRANSIT, V11, P1; Schafer Willemijn, 2010, Health Syst Transit, V12, pv; Sermet C, 2010, APPL HEALTH ECON HEA, V8, P7, DOI 10.2165/11313900-000000000-00000; Shani S, 2000, HEALTH POLICY, V54, P169, DOI 10.1016/S0168-8510(00)00109-3; Solomon MD, 2009, ARCH INTERN MED, V169, P740, DOI 10.1001/archinternmed.2009.62; Stargardt T., 2008, PHARM PRICING REIMBU; Strandberg-Larsen M., 2007, HLTH SYST TRANSIT, V9, P1; Streat S, 2012, CRIT CARE CLIN, V28, P125, DOI 10.1016/j.ccc.2011.10.008; Sundakov A, 2005, NZ PHARM POLICIES TI; Sweeny K, 2009, AUST HEALTH REV, V33, P215, DOI 10.1071/AH090215; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421; Tatar M, 2007, PHARM PRICING REIMBU; Tatara K, 2009, HEALT SYST TRANSIT, V11, P1; Teixeira I, 2008, PHARM PRICING REIMBU; Thomsen E., 2008, PHARM PRICING REIMBU; Tilson L, 2010, EXPERT REV PHARM OUT, V10, P221, DOI [10.1586/erp.10.33, 10.1586/ERP.10.33]; Van Ganse E, 2008, PHARM PRICING REIMBU; Vardica A, 2007, PHARM PRICING REIMBU; Vogler Sabine, 2009, Pharmaceuticals Policy and Law, V11, P213, DOI 10.3233/PPL-2009-0222; Vogler Sabine, 2011, South Med Rev, V4, P69, DOI 10.5655/smr.v4i2.1004; von der Schulenburg JM, 2010, EUR J HEALTH ECON, V10, P21, DOI 10.1007/s10198-009-0194-x; Vuorenkoski L, 2008, FINLAND HLTH SYSTEM, V10, P1; Walter E, 2006, GUIDELINES HLTH EC E; Wild C, 2009, INT J TECHNOL ASSESS, V25, P74, DOI 10.1017/S026646230909045X; Yang BM, 2008, HEALTH AFFAIR, V27, P179, DOI 10.1377/hlthaff.27.1.179; Yfantopoulos J, 2008, EUR J HEALTH ECON, V9, P87, DOI 10.1007/s10198-007-0061-6; Yoongthong W, 2012, VALUE HEALTH, V15, pS126, DOI 10.1016/j.jval.2011.11.003	125	20	20	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 11	2014	9	3							e90434	10.1371/journal.pone.0090434	http://dx.doi.org/10.1371/journal.pone.0090434			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AC9GM	24618721	Green Submitted, gold, Green Published			2023-01-03	WOS:000332842400019
J	Hayat, T; Ashraf, MB; Alsulami, HH; Alhuthali, MS				Hayat, Tasawar; Ashraf, Muhammad Bilal; Alsulami, Hamed H.; Alhuthali, Muhammad Shahab			Three-Dimensional Mixed Convection Flow of Viscoelastic Fluid with Thermal Radiation and Convective Conditions	PLOS ONE			English	Article							BOUNDARY-LAYER-FLOW; MASS-TRANSFER; HEAT-TRANSFER; STAGNATION-POINT; CHEMICAL-REACTION; STRETCHING SHEET; MAXWELL FLUID; SLIP-FLOW; MHD FLOW; NANOFLUID	The objective of present research is to examine the thermal radiation effect in three-dimensional mixed convection flow of viscoelastic fluid. The boundary layer analysis has been discussed for flow by an exponentially stretching surface with convective conditions. The resulting partial differential equations are reduced into a system of nonlinear ordinary differential equations using appropriate transformations. The series solutions are developed through a modern technique known as the homotopy analysis method. The convergent expressions of velocity components and temperature are derived. The solutions obtained are dependent on seven sundry parameters including the viscoelastic parameter, mixed convection parameter, ratio parameter, temperature exponent, Prandtl number, Biot number and radiation parameter. A systematic study is performed to analyze the impacts of these influential parameters on the velocity and temperature, the skin friction coefficients and the local Nusselt number. It is observed that mixed convection parameter in momentum and thermal boundary layers has opposite role. Thermal boundary layer is found to decrease when ratio parameter, Prandtl number and temperature exponent are increased. Local Nusselt number is increasing function of viscoelastic parameter and Biot number. Radiation parameter on the Nusselt number has opposite effects when compared with viscoelastic parameter.	[Hayat, Tasawar; Ashraf, Muhammad Bilal] Quaid I Azam Univ, Dept Math, Islamabad, Pakistan; [Hayat, Tasawar; Alsulami, Hamed H.; Alhuthali, Muhammad Shahab] King Abdulaziz Univ, Fac Sci, Nonlinear Anal & Appl Math NAAM Res Grp, Jeddah 21413, Saudi Arabia	Quaid I Azam University; King Abdulaziz University	Ashraf, MB (corresponding author), Quaid I Azam Univ, Dept Math, Islamabad, Pakistan.	bilalashraf_qau@yahoo.com	Hayat, Tasawar/Y-2524-2019; Hayat, Tasawar/E-9449-2015; Hayat, Tasawar/A-3853-2013		Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah [26-130-35 Hi Ci]; DSR	Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah; DSR	This paper was funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, under grant number 26-130-35 Hi Ci. The authors, therefore, acknowledge with thanks DSR technical and financial support. The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbasbandy S, 2013, QUAEST MATH, V36, P93, DOI 10.2989/16073606.2013.780336; Abbasbandy S, 2012, UPB SCI B, V74; Al-Odat M. Q., 2006, International Journal of Applied Mechanics and Engineering, V11, P289; Aziz MAE, 2012, MATH PROBL ENG, V2012; Bhattacharyya K., 2010, J MATH MATH SCI, V25, P41; Bhattacharyya K, 2012, INT J HEAT MASS TRAN, V55, P2945, DOI 10.1016/j.ijheatmasstransfer.2012.01.051; Bhattacharyya K, 2011, CHINESE PHYS LETT, V28, DOI 10.1088/0256-307X/28/8/084702; Bhattacharyya K, 2011, INT COMMUN HEAT MASS, V38, P917, DOI 10.1016/j.icheatmasstransfer.2011.04.020; Cortell R, 2007, APPL MATH COMPUT, V184, P864, DOI 10.1016/j.amc.2006.06.077; Deger G, 2011, Z NATURFORSCH A, V66, P321, DOI 10.1515/zna-2011-0508; Elbashbeshy E. M. A., 2001, Archives of Mechanics, V53, P643; Ellahi R, 2013, APPL MATH MODEL, V37, P1451, DOI 10.1016/j.apm.2012.04.004; GUPTA PS, 1977, CAN J CHEM ENG, V55, P744, DOI 10.1002/cjce.5450550619; Hayat T, 2013, J THERMOPHYS HEAT TR, V27, P733, DOI 10.2514/1.T4039; Hayat T, 2013, APPL MATH MECH-ENGL, V34, P823, DOI 10.1007/s10483-013-1710-7; Hayat T, 2013, APPL MATH MECH-ENGL, V34, P153, DOI 10.1007/s10483-013-1660-8; Hayat T, 2011, APPL MATH MECH-ENGL, V32, P1119, DOI 10.1007/s10483-011-1486-6; Hayat T, 2010, INT J HEAT MASS TRAN, V53, P466, DOI 10.1016/j.ijheatmasstransfer.2009.09.010; Hayat T, 2009, NONLINEAR ANAL-REAL, V10, P1514, DOI 10.1016/j.nonrwa.2008.01.019; Jamil M, 2011, COMMUN NONLINEAR SCI, V16, P1378, DOI 10.1016/j.cnsns.2010.07.004; Jamil M, 2010, NONLINEAR ANAL-REAL, V11, P4302, DOI 10.1016/j.nonrwa.2010.05.016; Kandasamy R, 2011, NUCL ENG DES, V241, P2155, DOI 10.1016/j.nucengdes.2011.03.002; Keimanesh M, 2011, COMPUT MATH APPL, V62, P2871, DOI 10.1016/j.camwa.2011.07.054; Liao S.J., 2003, PERTURBATION INTRO H, DOI 10.1201/9780203491164; Liao S.J., 2012, HOMOTOPY ANAL METHOD; Liu IC, 2013, CHEM ENG COMMUN, V200, P253, DOI 10.1080/00986445.2012.703148; Liu JG, 2010, NONLINEAR ANAL-REAL, V11, P3066, DOI 10.1016/j.nonrwa.2009.10.026; Liu YP, 2013, J SYMB COMPUT, V55, P72, DOI 10.1016/j.jsc.2013.03.006; Magyari E, 1999, J PHYS D APPL PHYS, V32, P577, DOI 10.1088/0022-3727/32/5/012; Makinde OD, 2005, INT COMMUN HEAT MASS, V32, P1411, DOI 10.1016/j.icheatmasstransfer.2005.07.005; Mukhopadhyay S, 2013, CHINESE PHYS B, V22, DOI 10.1088/1674-1056/22/7/074701; Mukhopadhyay S, 2013, J APPL MECH-T ASME, V80, DOI 10.1115/1.4023618; Mustafaa M, 2013, INT J NUMER METHOD H, V23, P945, DOI 10.1108/HFF-09-2011-0179; Nadeem S, 2012, NANOSCALE RES LETT, V7, P1, DOI 10.1186/1556-276X-7-94; Nazar R., 2009, EUR J SCI RES, V29, P509; Pal D, 2010, APPL MATH COMPUT, V217, P2356, DOI 10.1016/j.amc.2010.07.035; Rashidi MM, 2014, INT J HEAT MASS TRAN, V70, P892, DOI 10.1016/j.ijheatmasstransfer.2013.11.058; Sajid M, 2008, INT COMMUN HEAT MASS, V35, P347, DOI 10.1016/j.icheatmasstransfer.2007.08.006; SAKIADIS BC, 1961, AICHE J, V7, P26, DOI 10.1002/aic.690070108; Sanjayanand E, 2006, INT J THERM SCI, V45, P819, DOI 10.1016/j.ijthermalsci.2005.11.002; Schlichting H, 1964, BOUNDARY LAYER THEOR; Turkyilmazoglu M, 2013, INT J HEAT MASS TRAN, V57, P82, DOI 10.1016/j.ijheatmasstransfer.2012.10.006; Turkyilmazoglu M, 2012, COMMUN NONLINEAR SCI, V17, P4097, DOI 10.1016/j.cnsns.2012.01.030; Turkyilmazoglu M, 2011, INT J THERM SCI, V50, P2264, DOI 10.1016/j.ijthermalsci.2011.05.014; Zheng LC, 2012, MATH COMPUT MODEL, V56, P133, DOI 10.1016/j.mcm.2011.11.080	45	28	28	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2014	9	3							e90038	10.1371/journal.pone.0090038	http://dx.doi.org/10.1371/journal.pone.0090038			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC4IY	24608594	Green Published, gold, Green Submitted			2023-01-03	WOS:000332485800013
J	Gruener, AM; Jeffries, MAR; El Housseini, Z; Whitefield, L				Gruener, Anna M.; Jeffries, Megan A. R.; El Housseini, Zine; Whitefield, Laurence			Poppers maculopathy	LANCET			English	Editorial Material									[Gruener, Anna M.; Jeffries, Megan A. R.; El Housseini, Zine] Guys & St Thomas NHS Fdn Trust, Dept Ophthalmol, London SE1 7EH, England; [Gruener, Anna M.; Jeffries, Megan A. R.; Whitefield, Laurence] Queen Marys Hosp, Dept Ophthalmol, Sidcup, Kent, England	Guy's & St Thomas' NHS Foundation Trust	Gruener, AM (corresponding author), Guys & St Thomas NHS Fdn Trust, Dept Ophthalmol, Westminster Bridge Rd, London SE1 7EH, England.	anna.gruener@nhs.net							0	12	13	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 1	2014	384	9954					1606	1606		10.1016/S0140-6736(14)60887-4	http://dx.doi.org/10.1016/S0140-6736(14)60887-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AR9NK	24954683				2023-01-03	WOS:000343901700029
J	Shamian, J				Shamian, Judith			Interprofessional collaboration, the only way to Save Every Woman and Every Child	LANCET			English	Editorial Material									Int Council Nurses, CH-1201 Geneva, Switzerland		Shamian, J (corresponding author), Int Council Nurses, Pl Jean Marteau, CH-1201 Geneva, Switzerland.	shamianjudith@gmail.com							0	14	15	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 20	2014	384	9948					E41	E42		10.1016/S0140-6736(14)60858-8	http://dx.doi.org/10.1016/S0140-6736(14)60858-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AQ2PU	24965821				2023-01-03	WOS:000342630600002
J	Frederick, DT; Fragomeni, RAS; Schalck, A; Ferreiro-Neira, I; Hoff, T; Cooper, ZA; Haq, R; Panka, DJ; Kwong, LN; Davies, MA; Cusack, JC; Flaherty, KT; Fisher, DE; Mier, JW; Wargo, JA; Sullivan, RJ				Frederick, Dennie T.; Fragomeni, Roberto A. Salas; Schalck, Aislyn; Ferreiro-Neira, Isabel; Hoff, Taylor; Cooper, Zachary A.; Haq, Rizwan; Panka, David J.; Kwong, Lawrence N.; Davies, Michael A.; Cusack, James C.; Flaherty, Keith T.; Fisher, David E.; Mier, James W.; Wargo, Jennifer A.; Sullivan, Ryan J.			Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance sing BH3 Mimetics	PLOS ONE			English	Article							ACQUIRED-RESISTANCE; METASTATIC MELANOMA; SOLID TUMORS; PHASE-I; POTENTIAL MECHANISM; DOWN-REGULATION; BIM EXPRESSION; V600E MUTATION; HUMAN CANCERS; SURVIVAL	While response rates to BRAF inhibitiors (BRAFi) are high, disease progression emerges quickly. One strategy to delay the onset of resistance is to target anti-apoptotic proteins such as BCL-2, known to be associated with a poor prognosis. We analyzed BCL-2 family member expression levels of 34 samples from 17 patients collected before and 10 to 14 days after treatment initiation with either vemurafenib or dabrafenib/trametinib combination. The observed changes in mRNA and protein levels with BRAFi treatment led us to hypothesize that combining BRAFi with a BCL-2 inhibitor (the BH3-mimetic navitoclax) would improve outcome. We tested this hypothesis in cell lines and in mice. Pretreatment mRNA levels of BCL-2 negatively correlated with maximal tumor regression. Early increases in mRNA levels were seen in BIM, BCL-XL, BID and BCL2-W, as were decreases in MCL-1 and BCL2A. No significant changes were observed with BCL-2. Using reverse phase protein array (RPPA), significant increases in protein levels were found in BIM and BID. No changes in mRNA or protein correlated with response. Concurrent BRAF (PLX4720) and BCL2 (navitoclax) inhibition synergistically reduced viability in BRAF mutant cell lines and correlated with down-modulation of MCL-1 and BIM induction after PLX4720 treatment. In xenograft models, navitoclax enhanced the efficacy of PLX4720. The combination of a selective BRAF inhibitor with a BH3-mimetic promises to be an important therapeutic strategy capable of enhancing the clinical efficacy of BRAF inhibition in many patients that might otherwise succumb quickly to de novo resistance.	[Frederick, Dennie T.; Fragomeni, Roberto A. Salas; Ferreiro-Neira, Isabel; Hoff, Taylor; Cusack, James C.] Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA; [Fragomeni, Roberto A. Salas; Haq, Rizwan; Panka, David J.; Cusack, James C.; Flaherty, Keith T.; Fisher, David E.; Mier, James W.; Sullivan, Ryan J.] Harvard Univ, Sch Med, Boston, MA 02138 USA; [Schalck, Aislyn; Haq, Rizwan; Flaherty, Keith T.; Sullivan, Ryan J.] Massachusetts Gen Hosp, Ctr Canc, Div Med Oncol, Boston, MA USA; [Cooper, Zachary A.; Kwong, Lawrence N.; Davies, Michael A.; Wargo, Jennifer A.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol & Genom Med, Houston, TX 77030 USA; [Panka, David J.; Mier, James W.] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA; [Fisher, David E.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital	Sullivan, RJ (corresponding author), Harvard Univ, Sch Med, Boston, MA 02138 USA.	rsullivan7@partners.org	Fisher, David/AAH-2878-2019; Davies, Michael/GWV-2527-2022; Akbar, Noreen Sher/ABA-2946-2021; Nadeem, Sohail/I-5248-2013	Akbar, Noreen Sher/0000-0003-4530-5978; Nadeem, Sohail/0000-0002-1052-011X; Cooper, Zachary/0000-0003-1059-0940; Schalck, Aislyn/0000-0002-4020-1822	MGH; Eugene Michael Egan Translational Research Fund at BIDMC; NATIONAL CANCER INSTITUTE [R01CA166480, P01CA163222, UM1CA186709, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043369] Funding Source: NIH RePORTER	MGH; Eugene Michael Egan Translational Research Fund at BIDMC; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Funding Sources for this work include: 1. Internal sundry funds at MGH. 2. The Eugene Michael Egan Translational Research Fund at BIDMC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Boisvert-Adamo K, 2008, ONCOGENE, V27, P3301, DOI 10.1038/sj.onc.1211003; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Cartlidge RA, 2008, PIGM CELL MELANOMA R, V21, P534, DOI 10.1111/j.1755-148X.2008.00491.x; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chen S, 2007, CANCER RES, V67, P782, DOI 10.1158/0008-5472.CAN-06-3964; Chetoui N, 2008, MOL CANCER RES, V6, P42, DOI 10.1158/1541-7786.MCR-07-0080; Chiappori AA, 2012, BRIT J CANCER, V106, P839, DOI 10.1038/bjc.2012.21; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Cragg MS, 2008, J CLIN INVEST, V118, P3651, DOI 10.1172/JCI35437; Falchook GS, 2012, LANCET, V379, P1893, DOI 10.1016/S0140-6736(12)60398-5; Gradilone A, 2003, J CLIN ONCOL, V21, P306, DOI 10.1200/JCO.2003.08.066; Haq R, 2013, P NATL ACAD SCI USA, V110, P4321, DOI 10.1073/pnas.1205575110; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Hughes R, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-69; Hwang JJ, 2010, CLIN CANCER RES, V16, P4038, DOI 10.1158/1078-0432.CCR-10-0822; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Lee JT, 2010, PIGM CELL MELANOMA R, V23, P820, DOI 10.1111/j.1755-148X.2010.00763.x; Long GV, 2013, PIGM CELL MELANOMA R, V26, DOI 10.1111/pcmr.12098; Montagut C, 2008, CANCER RES, V68, P4853, DOI 10.1158/0008-5472.CAN-07-6787; Nathanson KL, 2011, CHICAGO J CLIN ONC S; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Paik PK, 2010, CANCER CHEMOTH PHARM, V66, P1079, DOI 10.1007/s00280-010-1265-5; Paraiso KHT, 2011, CANCER RES, V71, P2750, DOI 10.1158/0008-5472.CAN-10-2954; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; SAENZSANTAMARIA MC, 1994, J CUTAN PATHOL, V21, P393; Salas Fragomeni RA, 2013, MOL CANC THERAPEUTIC; Sheridan C, 2008, J BIOL CHEM, V283, P22128, DOI 10.1074/jbc.M800271200; Shi HB, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1727; Smalley KSM, 2008, MOL CANCER THER, V7, P2876, DOI 10.1158/1535-7163.MCT-08-0431; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Tahir SK, 2010, MOL CANCER THER, V9, P545, DOI 10.1158/1535-7163.MCT-09-0651; Tap WD, 2010, NEOPLASIA, V12, P637, DOI 10.1593/neo.10414; Trunzer K, 2013, J CLIN ONCOL, V31, P1767, DOI 10.1200/JCO.2012.44.7888; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Vlaykova T, 2002, ONCOLOGY-BASEL, V62, P259, DOI 10.1159/000059574; Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312; Wang HS, 2011, CANCER RES, V71, P5535, DOI 10.1158/0008-5472.CAN-10-4351; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Wroblewski D, 2013, CARCINOGENESIS, V34, P237, DOI 10.1093/carcin/bgs330; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308	44	33	33	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 1	2014	9	7							e101286	10.1371/journal.pone.0101286	http://dx.doi.org/10.1371/journal.pone.0101286			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM1UX	24983357	Green Published, gold, Green Submitted			2023-01-03	WOS:000339635000084
J	Kaldenbach, M; Cubero, FJ; Erschfeld, S; Liedtke, C; Trautwein, C; Streetz, K				Kaldenbach, Michaela; Cubero, Francisco Javier; Erschfeld, Stephanie; Liedtke, Christian; Trautwein, Christian; Streetz, Konrad			Hepatic Tissue Environment in NEMO-Deficient Mice Critically Regulates Positive Selection of Donor Cells after Hepatocyte Transplantation	PLOS ONE			English	Article							NF-KAPPA-B; LIVER-INJURY; HEPATOCELLULAR-CARCINOMA; IN-VIVO; CIRRHOSIS; RATS; REGENERATION; REPOPULATION; REPLACEMENT; PROGRESSION	Background: Hepatocyte transplantation (HT) is a promising alternative treatment strategy for end-stage liver diseases compared with orthotopic liver transplantation. A limitation for this approach is the low engraftment of donor cells. The deletion of the I-kappa B kinase-regulatory subunit IKK gamma/NEMO in hepatocytes prevents nuclear factor (NF)-kB activation and triggers spontaneous liver apoptosis, chronic hepatitis and the development of liver fibrosis and hepatocellular carcinoma. We hypothesized that NEMO Delta hepa mice may therefore serve as an experimental model to study HT. Methods: Pre-conditioned NEMO Delta hepa mice were transplanted with donor-hepatocytes from wildtype (WT) and mice deficient for the pro-apoptotic mediator Caspase-8 (CaspehePa). Results: Transplantation of isolated WT-hepatocytes into pre-conditioned NEMO Delta hepa mice resulted in a 6-7 fold increase of donor cells 12 weeks after HT, while WT-recipients showed no liver repopulation. The use of apoptosis-resistant Casp8(Delta hepa)-derived donor cells further enhanced the selection 3-fold after 12-weeks and up to 10-fold increase after 52 weeks compared with WT donors. While analysis of NEMO Delta hepa mice revealed strong liver injury, HT-recipient NEMO Delta hepa mice showed improved liver morphology and decrease in serum transaminases. Concomitant with these findings, the histological examination elicited an improved liver tissue architecture associated with significantly lower levels of apoptosis, decreased proliferation and a lesser amount of liver fibrogenesis. Altogether, our data clearly support the therapeutic benefit of the HT procedure into NEMO Delta hepa mice. Conclusion: This study demonstrates the feasibility of the NEMO Delta hepa mouse as an in vivo tool to study liver repopulation after HT. The improvement of the characteristic phenotype of chronic liver injury in NEMO Delta hepa ice after HT suggests the therapeutic potential of HT in liver diseases with a chronic inflammatory phenotype and opens a new door for the applicability of this technique to combat liver disease in the human clinic.	[Kaldenbach, Michaela; Cubero, Francisco Javier; Erschfeld, Stephanie; Liedtke, Christian; Trautwein, Christian; Streetz, Konrad] Rhein Westfal TH Aachen, Univ Hosp, Dept Internal Med 3, D-52062 Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital	Streetz, K (corresponding author), Rhein Westfal TH Aachen, Univ Hosp, Dept Internal Med 3, D-52062 Aachen, Germany.	kstreetz@ukaachen.de	Liedtke, Christian/DTV-1874-2022	Liedtke, Christian/0000-0003-4681-7887; Cubero, Francisco Javier/0000-0003-1499-650X	Deutsche Forschungsgemeinschaft (DFG) [5TR661/4-2]; DFG SFB/TRR [57]; faculty of medicine [691405]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); DFG SFB/TRR(German Research Foundation (DFG)); faculty of medicine	KS, MK, SE were supported by a grant of the Deutsche Forschungsgemeinschaft (DFG) grant nr. 5TR661/4-2. CL and CT were supported by a grant of the DFG SFB/TRR 57, and FJC was supported by the faculty of medicine grant nr. 691405. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201; Beraza N, 2009, J EXP MED, V206, P1727, DOI 10.1084/jem.20082152; Chaudhary K, 2013, J HEPATOL, V59, P1292, DOI 10.1016/j.jhep.2013.07.026; Christ B, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00168; Cubero FJ, 2013, CELL DEATH DIFFER, V20, P1580, DOI 10.1038/cdd.2013.112; FITZGERALD MJ, 1995, CELL GROWTH DIFFER, V6, P417; Fox IJ, 1998, NEW ENGL J MED, V338, P1422, DOI 10.1056/NEJM199805143382004; Freimuth J, 2013, HEPATOLOGY; Grompe M, 2001, J INHERIT METAB DIS, V24, P231, DOI 10.1023/A:1010375203539; Guha C, 2001, ARTIF ORGANS, V25, P522, DOI 10.1046/j.1525-1594.2001.025007522.x; Kaldenbach M, 2012, GUT, V61, P1209, DOI 10.1136/gutjnl-2011-301345; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kobayashi N, 2000, HEPATOLOGY, V31, P851, DOI 10.1053/he.2000.5636; Krampera M, 2007, STEM CELLS DEV, V16, P797, DOI 10.1089/scd.2007.0024; Laconi S, 2001, AM J PATHOL, V158, P771, DOI 10.1016/S0002-9440(10)64019-9; Liedtke C, 2011, GASTROENTEROLOGY, V141, P2176, DOI 10.1053/j.gastro.2011.08.037; Luedde T, 2007, CANCER CELL, V11, P119, DOI 10.1016/j.ccr.2006.12.016; Luedde T, 2011, NAT REV GASTRO HEPAT, V8, P108, DOI 10.1038/nrgastro.2010.213; Nagata H, 2003, GASTROENTEROLOGY, V124, P422, DOI 10.1053/gast.2003.50065; Overturf K, 1996, NAT GENET, V12, P266, DOI 10.1038/ng0396-266; Pareja E, 2013, EUR SURG RES, V50, P273, DOI 10.1159/000351332; PONDER KP, 1991, P NATL ACAD SCI USA, V88, P1217, DOI 10.1073/pnas.88.4.1217; QUINN PS, 1965, AM J PATHOL, V47, P353; Quintanilha LF, 2008, CELL TRANSPLANT, V17, P943, DOI 10.3727/096368908786576453; Sakaida I, 2004, HEPATOLOGY, V40, P1304, DOI 10.1002/hep.20452; SHEN RF, 1987, NUCLEIC ACIDS RES, V15, P8399, DOI 10.1093/nar/15.20.8399; Streetz KL, 2008, HEPATOLOGY, V47, P706, DOI 10.1002/hep.22012; Tschaharganeh DF, 2010, LIVER TRANSPLANT, V16, P23, DOI 10.1002/lt.21962; van Poll D, 2008, HEPATOLOGY, V47, P1634, DOI 10.1002/hep.22236; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	32	1	1	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 30	2014	9	6							e100786	10.1371/journal.pone.0100786	http://dx.doi.org/10.1371/journal.pone.0100786			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK5ZO	24979756	gold, Green Published, Green Submitted			2023-01-03	WOS:000338506400040
J	Xu, KN; Zhang, YF; Wang, Y; Ling, P; Xie, X; Jiang, CY; Zhang, ZZ; Lian, XY				Xu, Kangning; Zhang, Yufen; Wang, Yan; Ling, Peng; Xie, Xin; Jiang, Chenyao; Zhang, Zhizhen; Lian, Xiao-Yuan			Ginseng Rb Fraction Protects Glia, Neurons and Cognitive Function in a Rat Model of Neurodegeneration	PLOS ONE			English	Article							GABAERGIC NEURONS; CORTICAL ASTROCYTES; STATUS EPILEPTICUS; CELL-DEATH; HIPPOCAMPAL; INTERNEURONS; PARVALBUMIN; ACTIVATION; MEMORY; OSCILLATIONS	The loss and injury of neurons play an important role in the onset of various neurodegenerative diseases, while both microgliosis and astrocyte loss or dysfunction are significant causes of neuronal degeneration. Previous studies have suggested that an extract enriched panaxadiol saponins from ginseng has more neuroprotective potential than the total saponins of ginseng. The present study investigated whether a fraction of highly purified panaxadiol saponins (termed as Rb fraction) was protective for both glia and neurons, especially GABAergic interneurons, against kainic acid (KA)-induced excitotoxicity in rats. Rats received Rb fraction at 30 mg/kg (ip), 40 mg/kg (ip or saline followed 40 min later by an intracerebroventricular injection of KA. Acute hippocampal injury was determined at 48 h after KA, and impairment of hippocampus-dependent learning and memory as well as delayed neuronal injury was determined 16 to 21 days later. KA injection produced significant acute hippocampal injuries, including GAD67-positive GABAergic interneuron loss in CA1, paralbumin (PV)-positive GABAergic interneuron loss, pyramidal neuron degeneration and astrocyte damage accompanied with reactive microglia in both CA1 and CA3 regions of the hippocampus. There was also a delayed loss of GAD67-positive interneurons in CA1, CA3, hilus and dentate gyrus. Microgliosis also became more severe 21 days later. Accordingly, KA injection resulted in hippocampus-dependent spatial memory impairment. Interestingly, the pretreatment with Rb fraction at 30 or 40 mg/kg significantly protected the pyramidal neurons and GABAergic interneurons against KA-induced acute excitotoxicity and delayed injury. Rb fraction also prevented memory impairments and protected astrocytes from KA-induced acute excitotoxicity. Additionally, microglial activation, especially the delayed microgliosis, was inhibited by Rb fraction. Overall, this study demonstrated that Rb fraction protected both astrocytes and neurons, especially GABAergic interneurons, and maintained microglial homeostasis against KA-induced excitotoxicity. Therefore, Rb fraction has the potential to prevent and treat neurodegenerative diseases.	[Xu, Kangning; Wang, Yan; Xie, Xin; Jiang, Chenyao; Lian, Xiao-Yuan] Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou 310003, Zhejiang, Peoples R China; [Zhang, Zhizhen] Zhejiang Univ, Ocean Coll, Hangzhou 310003, Zhejiang, Peoples R China; [Zhang, Yufen; Ling, Peng] Anhui Univ Chinese Med, Hefei, Peoples R China	Zhejiang University; Zhejiang University; Anhui University of Chinese Medicine	Zhang, ZZ (corresponding author), Zhejiang Univ, Ocean Coll, Hangzhou 310003, Zhejiang, Peoples R China.	zzhang88@zju.edu.cn; xylian@zju.edu.cn	ZHANG, ZHIZHEN/GYA-3230-2022		National Basic Research Program of China (973 program) [2011CB504403]; Major Project of the Modernization of Traditional Chines Medicine, the Science and Technology Commission of Shanghai Municipality [08DZ1972000]	National Basic Research Program of China (973 program)(National Basic Research Program of China); Major Project of the Modernization of Traditional Chines Medicine, the Science and Technology Commission of Shanghai Municipality	This study was financially supported by grants from the National Basic Research Program of China (973 program, No 2011CB504403) and the Major Project of the Modernization of Traditional Chines Medicine, the Science and Technology Commission of Shanghai Municipality (No. 08DZ1972000). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andrews-Zwilling Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040555; Andrews-Zwilling Y, 2010, J NEUROSCI, V30, P13707, DOI 10.1523/JNEUROSCI.4040-10.2010; Attele AS, 1999, BIOCHEM PHARMACOL, V58, P1685, DOI 10.1016/S0006-2952(99)00212-9; Bechstein M, 2012, EXP NEUROL, V236, P141, DOI 10.1016/j.expneurol.2012.04.009; BENARI Y, 1980, BRAIN RES, V191, P79, DOI 10.1016/0006-8993(80)90316-9; BENARI Y, 1979, BRAIN RES, V163, P176, DOI 10.1016/0006-8993(79)90163-X; Bissonette GB, 2014, BEHAV BRAIN RES, V259, P143, DOI 10.1016/j.bbr.2013.10.051; Budd SL, 1998, NAT NEUROSCI, V1, P431, DOI 10.1038/2147; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Cho IH, 2008, BRAIN, V131, P3019, DOI 10.1093/brain/awn230; Cho IH, 2006, J NEUROSCI RES, V84, P1505, DOI 10.1002/jnr.21052; COBB SR, 1995, NATURE, V378, P75, DOI 10.1038/378075a0; Colangelo AM, 2012, BIOTECHNOL ADV, V30, P261, DOI 10.1016/j.biotechadv.2011.06.016; Cui YJ, 2008, CELL, V135, P549, DOI 10.1016/j.cell.2008.09.060; Doble A, 1999, PHARMACOL THERAPEUT, V81, P163, DOI 10.1016/S0163-7258(98)00042-4; Fuchs EC, 2007, NEURON, V53, P591, DOI 10.1016/j.neuron.2007.01.031; Gouder N, 2004, J NEUROSCI, V24, P692, DOI 10.1523/JNEUROSCI.4781-03.2004; Goutagny R, 2013, EUR J NEUROSCI, V37, P1896, DOI 10.1111/ejn.12233; Gulyas AI, 2010, J NEUROSCI, V30, P15134, DOI 10.1523/JNEUROSCI.4104-10.2010; Hong J, 2010, J BIOL CHEM, V285, P39447, DOI 10.1074/jbc.M110.132522; Klausberger T, 2003, NATURE, V421, P844, DOI 10.1038/nature01374; Klausberger T, 2005, J NEUROSCI, V25, P9782, DOI 10.1523/JNEUROSCI.3269-05.2005; Klausberger T, 2004, NAT NEUROSCI, V7, P41, DOI 10.1038/nn1159; Klausberger T, 2008, SCIENCE, V321, P53, DOI 10.1126/science.1149381; Kullmann DM, 2011, CURR OPIN NEUROBIOL, V21, P709, DOI 10.1016/j.conb.2011.05.006; Kuruba R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024493; Lazarus MS, 2013, CEREB CORTEX, DOI [10.1093/cercor/bht1322, DOI 10.1093/CERCOR/BHT1322]; Lee JK, 2008, NEUROSCI LETT, V440, P260, DOI 10.1016/j.neulet.2008.05.112; Leung L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053569; Li TF, 2012, GLIA, V60, P83, DOI 10.1002/glia.21250; Lian XY, 2006, EPILEPSY RES, V70, P244, DOI 10.1016/j.eplepsyres.2006.05.010; Lian XY, 2005, ANN NEUROL, V57, P642, DOI 10.1002/ana.20450; Lian XY, 2005, EPILEPSIA, V46, P15, DOI 10.1111/j.0013-9580.2005.40904.x; Liu B, 2013, NEUROSCI RES, V75, P160, DOI 10.1016/j.neures.2012.12.002; Liu Z, 2013, NEUROL SCI, V34, P1189, DOI 10.1007/s10072-012-1220-9; Miles R, 1996, NEURON, V16, P815, DOI 10.1016/S0896-6273(00)80101-4; MITCHELL J, 1993, EXP NEUROL, V121, P224, DOI 10.1006/exnr.1993.1089; Montgomery SM, 2007, P NATL ACAD SCI USA, V104, P14495, DOI 10.1073/pnas.0701826104; Murray AJ, 2011, NAT NEUROSCI, V14, P297, DOI 10.1038/nn.2751; Nakazawa K, 2012, NEUROPHARMACOLOGY, V62, P1574, DOI 10.1016/j.neuropharm.2011.01.022; Palop JJ, 2010, NAT NEUROSCI, V13, P812, DOI 10.1038/nn.2583; Park D, 2012, CELL TRANSPLANT, V21, P365, DOI 10.3727/096368911X586765; Ratte Stephanie, 2006, Adv Neurol, V97, P69; Rizzi M, 2003, NEUROBIOL DIS, V14, P494, DOI 10.1016/j.nbd.2003.08.001; Shetty AK, 2001, EXP NEUROL, V169, P276, DOI 10.1006/exnr.2001.7668; Shetty AK, 2009, J CELL MOL MED, V13, P2408, DOI 10.1111/j.1582-4934.2009.00675.x; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.physiol.55.1.349; SPERK G, 1985, BRAIN RES, V338, P289, DOI 10.1016/0006-8993(85)90159-3; StubleyWeatherly L, 1996, BRAIN RES, V716, P29, DOI 10.1016/0006-8993(95)01589-2; Verkhratsky A, 2012, ASN NEURO, V4, DOI 10.1042/AN20120010; Verret L, 2012, CELL, V149, P708, DOI 10.1016/j.cell.2012.02.046; Volman V, 2011, J NEUROSCI, V31, P18137, DOI 10.1523/JNEUROSCI.3041-11.2011; Wang Q, 2005, MOL NEUROBIOL, V31, P3, DOI 10.1385/MN:31:1-3:003; Watson C, 2006, RAT BRAIN STEREOTAXI; Wenk G.L., 2004, CURRENT PROTOCOLS NE; WILLIAMS SM, 1992, J COMP NEUROL, V320, P353, DOI 10.1002/cne.903200307; Zhang Z, 2011, PHARM CROPS, V2, P65; Zheng HH, 2010, NEUROIMMUNOMODULAT, V17, P31, DOI 10.1159/000243083; Zheng XY, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/457079	59	10	10	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2014	9	6							e101077	10.1371/journal.pone.0101077	http://dx.doi.org/10.1371/journal.pone.0101077			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK6BK	24971630	Green Published, Green Submitted, gold			2023-01-03	WOS:000338512200088
J	Schou, JV; Rossi, S; Jensen, BV; Nielsen, DL; Pfeiffer, P; Hogdall, E; Yilmaz, M; Tejpar, S; Delorenzi, M; Kruhoffer, M; Johansen, JS				Schou, Jakob V.; Rossi, Simona; Jensen, Benny V.; Nielsen, Dorte L.; Pfeiffer, Per; Hogdall, Estrid; Yilmaz, Mette; Tejpar, Sabine; Delorenzi, Mauro; Kruhoffer, Mogens; Johansen, Julia S.			miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3rd Line Cetuximab and Irinotecan	PLOS ONE			English	Article							1ST-LINE TREATMENT; LIVER METASTASES; EXPRESSION DATA; BREAST-CANCER; MICRORNA; PLASMA; SERUM; MIR-143; MIR-21; BLOOD	Introduction: MicroRNAs (miRNAs) have important regulatory functions in cellular processes and have shown promising potential as prognostic markers for disease outcome in patients with cancer. The aim of the present study was to find miRNA expression profiles in whole blood that were prognostic for overall survival (OS) in patients with metastatic colorectal cancer (mCRC) treated with cetuximab and irinotecan. Methods: From 138 patients with mCRC in 3rd line therapy with cetuximab and irinotecan in a prospective phase II study, 738 pretreatment miRNAs were isolated and profiled from whole blood using the TaqMan MicroRNA Array v2.0. Mutation status of KRAS, BRAF, and PI3KCA was known. Results: After Bonferroni adjustment, 6 miRNAs: (miR-345, miR-143, miR-34a*, miR-628-5p, miR-886-3p and miR-324-3p), were found associated with short OS. miR-345 was the strongest prognostic miRNA, significant in the full cohort and in the non-KRAS mutant population. miR-345, as a continuous variable in the full cohort, resulted in a hazard ratio (HR) of 2.38 per IQR (CI 95%: 1.8-3.1, P-value = 2.86e-07, Bonferroni adjusted, univariable analysis) and a HR = 1.75 per IQR (CI 95%: 1.24-2.48, P-Wald = 1.45e-03) in the multivariable analysis adjusted for gender, age, KRAS, PI3KCA and performance status. miR-345 was prognostic in progression-free survival (PFS) with a HR = 1.63 per IQR (CI 95%: 1.25-2.114, P-Wald = 2.92e-4) in the multivariable analysis. In addition, high miR-345 expression was associated with lack of response to treatment with cetuximab and irinotecan. Conclusion: We identified miR-345 in whole blood as a potential biomarker for clinical outcome. MiR-345 was a single prognostic biomarker for both OS and PFS in all patients and also in the non-KRAS mutant population.	[Schou, Jakob V.; Jensen, Benny V.; Nielsen, Dorte L.; Johansen, Julia S.] Herlev Univ Hosp, Dept Oncol, DK-2730 Herlev, Denmark; [Rossi, Simona; Delorenzi, Mauro] Swiss Inst Bioinformat, Bioinformat Core Facil, Lausanne, Switzerland; [Pfeiffer, Per] Odense Univ Hosp, Dept Oncol, DK-5000 Odense, Denmark; [Tejpar, Sabine] Univ Hosp Gasthuisberg, Digest Oncol Unit, Leuven, Belgium; [Hogdall, Estrid] Herlev Univ Hosp, Dept Pathol, DK-2730 Herlev, Denmark; [Yilmaz, Mette] Aalborg Univ Hosp, Dept Oncol, Aalborg, Denmark; [Kruhoffer, Mogens] AROS Appl Biotechnol, Aarhus, Denmark; [Delorenzi, Mauro] Univ Lausanne, Dept Oncol, Lausanne, Switzerland; [Delorenzi, Mauro] Univ Lausanne, Ludwig Ctr Canc Res, Lausanne, Switzerland	University of Copenhagen; Herlev & Gentofte Hospital; Swiss Institute of Bioinformatics; University of Southern Denmark; Odense University Hospital; KU Leuven; University Hospital Leuven; University of Copenhagen; Herlev & Gentofte Hospital; Aalborg University; Aalborg University Hospital; University of Lausanne; University of Lausanne	Schou, JV (corresponding author), Herlev Univ Hosp, Dept Oncol, DK-2730 Herlev, Denmark.	j.schou@dadlnet.dk		Pfeiffer, Per/0000-0002-2925-0586; Hogdall, Estrid/0000-0003-4689-5658; Nielsen, Dorte Lisbet/0000-0002-8766-8729	Research Council at Herlev Hospital; Danish Ministry of the Interior and Health, Merck-Serono Denmark/Sweden; European Union [222916]; Belgian National Cancer Plan; Foundation Fournier-Majoie, FFMI, Belgium; Swiss National Science Foundation (SNF) [320030_135421]; Krebsforschung Schweiz (KFS) [02697-08-2010]; Fondation Medic	Research Council at Herlev Hospital; Danish Ministry of the Interior and Health, Merck-Serono Denmark/Sweden; European Union(European Commission); Belgian National Cancer Plan; Foundation Fournier-Majoie, FFMI, Belgium; Swiss National Science Foundation (SNF)(Swiss National Science Foundation (SNSF)); Krebsforschung Schweiz (KFS); Fondation Medic	This work was supported by grants from The Research Council at Herlev Hospital, the Danish Ministry of the Interior and Health, Merck-Serono Denmark/Sweden, and the European Union Seventh Framework Programme [FP7/2007-2013] under grant agreement no 222916 (given to MK). ST is a senior clinical investigator of the Fund for Scientific Research Flanders and is supported by Belgian National Cancer Plan. ST and SR is also supported by the Foundation Fournier-Majoie, FFMI, Belgium. MD is supported in part by the Swiss National Science Foundation (SNF; http://www.snf.ch/E/; Grant No. 320030_135421); Krebsforschung Schweiz (KFS; http://www.krebsforschung.ch/; Grant No. 02697-08-2010); and by the Fondation Medic. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arndt GM, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-374; Boeri M, 2011, P NATL ACAD SCI USA, V108, P3713, DOI 10.1073/pnas.1100048108; Bokemeyer C, 2009, J CLIN ONCOL, V27, P663, DOI 10.1200/JCO.2008.20.8397; Chen X, 2009, ONCOGENE, V28, P1385, DOI 10.1038/onc.2008.474; Chen X, 2008, CELL RES, V18, P997, DOI 10.1038/cr.2008.282; Cheng HY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017745; Cheng HH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064795; Cross J, 2008, PHARMACOGENOMICS, V9, P463, DOI 10.2217/14622416.9.4.463; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; D'haene Barbara, 2012, Methods Mol Biol, V822, P261, DOI 10.1007/978-1-61779-427-8_18; Dvinge H, 2013, NATURE, V497, P378, DOI 10.1038/nature12108; Heneghan HM, 2010, J CLIN ONCOL, V28, pE573, DOI 10.1200/JCO.2010.29.8901; Hofsli E, 2013, BRIT J CANCER, V108, P1712, DOI 10.1038/bjc.2013.121; Hu ZB, 2012, CARCINOGENESIS, V33, P828, DOI 10.1093/carcin/bgs030; Huang ZH, 2010, INT J CANCER, V127, P118, DOI 10.1002/ijc.25007; Jensen Bv, 2010, J CLIN ONCOL, V28; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821; Kotoula V, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007746; Kruhoffer M, 2007, J MOL DIAGN, V9, P452, DOI 10.2353/jmoldx.2007.060175; Kulda V, 2010, CANCER GENET CYTOGEN, V200, P154, DOI 10.1016/j.cancergencyto.2010.04.015; Luo XY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062880; Madi A, 2012, BRIT J CANCER, V107, P1037, DOI 10.1038/bjc.2012.384; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Ng EKO, 2009, GUT, V58, P1375, DOI 10.1136/gut.2008.167817; Nugent M, 2012, J SURG ONCOL, V106, P947, DOI 10.1002/jso.23174; Papadopoulos GL, 2009, BIOINFORMATICS, V25, P1991, DOI 10.1093/bioinformatics/btp299; Patnaik SK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046045; Pichler M, 2012, BRIT J CANCER, V106, P1826, DOI 10.1038/bjc.2012.175; Pu XX, 2010, J GASTROEN HEPATOL, V25, P1674, DOI 10.1111/j.1440-1746.2010.06417.x; Richman SD, 2009, J CLIN ONCOL, V27, P5931, DOI 10.1200/JCO.2009.22.4295; Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182; Schultz NA, 2014, JAMA-J AM MED ASSOC, V311, P392, DOI 10.1001/jama.2013.284664; Shen J, 2013, NATURE, V497, P383, DOI 10.1038/nature12080; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Slaby O, 2007, ONCOLOGY-BASEL, V72, P397, DOI 10.1159/000113489; Tang JT, 2011, CARCINOGENESIS, V32, P1207, DOI 10.1093/carcin/bgr114; Toiyama Y, 2013, JNCI-J NATL CANCER I, V105, P849, DOI 10.1093/jnci/djt101; Turchinovich A, 2011, NUCLEIC ACIDS RES, V39, P7223, DOI 10.1093/nar/gkr254; Tveit KM, 2012, J CLIN ONCOL, V30, P1755, DOI 10.1200/JCO.2011.38.0915; Van Cutsem E, 2006, EUR J CANCER, V42, P2212, DOI 10.1016/j.ejca.2006.04.012; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; Vickers KC, 2011, NAT CELL BIOL, V13, P423, DOI 10.1038/ncb2210; Willems E, 2008, ANAL BIOCHEM, V379, P127, DOI 10.1016/j.ab.2008.04.036; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103	46	57	60	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 18	2014	9	6							e99886	10.1371/journal.pone.0099886	http://dx.doi.org/10.1371/journal.pone.0099886			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK6AC	24940606	Green Published, Green Submitted, gold			2023-01-03	WOS:000338508200051
J	Jensen, A; Sherman, S				Jensen, Ashley; Sherman, Scott			In patients at high CV risk, a Mediterranean diet plus olive oil reduced diabetes more than advising a low-fat diet	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Jensen, Ashley] VA New York Harbor Healthcare Syst, New York, NY 11209 USA; NYU, Sch Med, New York, NY USA	New York University	Jensen, A (corresponding author), VA New York Harbor Healthcare Syst, New York, NY 11209 USA.		Jensen, Ashley E/B-6452-2015	Jensen, Ashley E/0000-0002-5702-2978; Sherman, Scott/0000-0003-1752-7303				DPP Res Grp, 2002, DIABETES CARE, V25, P2165; Esposito K, 2010, DIABETES RES CLIN PR, V89, P97, DOI 10.1016/j.diabres.2010.04.019	2	2	2	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 17	2014	160	12							JC2	10.7326/0003-4819-160-12-201406170-02002	http://dx.doi.org/10.7326/0003-4819-160-12-201406170-02002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AJ0VR	24935508				2023-01-03	WOS:000337374900002
J	Williams, DL; Mann, BK				Williams, David L.; Mann, Brenda K.			Efficacy of a Crosslinked Hyaluronic Acid-Based Hydrogel as a Tear Film Supplement: A Masked Controlled Study	PLOS ONE			English	Article							CANINE KERATOCONJUNCTIVITIS SICCA; OPHTHALMIC APPLICATIONS; EYE DROPS; GEL; MODEL	Keratoconjunctivitis sicca (KCS), or dry eye, is a significant medical problem in both humans and dogs. Treating KCS often requires the daily application of more than one type of eye drop in order to both stimulate tear prodcution and provide a tear supplement to increase hydration and lubrication. A previous study demonstrated the potential for a crosslinked hyaluronic acid-based hydrogel (xCMHA-S) to reduce the clinical signs associated with KCS in dogs while using a reduced dosing regimen of only twice-daily administration. The present study extended those results by comparing the use of the xCMHA-S to a standard HA-containing tear supplement in a masked, randomized clinical study in dogs with a clinical diagnosis of KCS. The xCMHA-S was found to significantly improve ocular surface health (conjunctival hyperaemia, ocular irritation, and ocular discharge) to a greater degree than the alternative tear supplement (P = 0.0003). Further, owners reported the xCMHA-S treatment as being more highly effective than the alternative tear supplement (P = 0.0024). These results further demonstrate the efficacy of the xCMHA-S in reducing the clinical signs associated with KCS, thereby improving patient health and owner happiness.	[Williams, David L.] Univ Cambridge, Dept Vet Med, Cambridge, England; [Mann, Brenda K.] SentrX Anim Care Inc, Salt Lake City, UT USA; [Mann, Brenda K.] Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA	University of Cambridge; Utah System of Higher Education; University of Utah	Williams, DL (corresponding author), Univ Cambridge, Dept Vet Med, Cambridge, England.	dlw33@cam.ac.uk						Barbucci R, 2002, BIOMATERIALS, V23, P4503, DOI 10.1016/S0142-9612(02)00194-1; Bron AJ, 1998, EUR J OPHTHALMOL, V8, P81, DOI 10.1177/112067219800800206; Festing Michael F W, 2002, ILAR J, V43, P244; GIBBS DA, 1968, BIOPOLYMERS, V6, P777, DOI 10.1002/bip.1968.360060603; Guillaumie F, 2010, J BIOMED MATER RES A, V92A, P1421, DOI 10.1002/jbm.a.32481; Hamano T, 1996, JPN J OPHTHALMOL, V40, P62; Higashide T, 2008, CLIN OPHTHALMOL, V2, P21; KASWAN RL, 1989, ARCH OPHTHALMOL-CHIC, V107, P1210, DOI 10.1001/archopht.1989.01070020276038; KOBAYASHI Y, 1994, BIORHEOLOGY, V31, P235; Nakamura S, 2004, CORNEA, V23, P390, DOI 10.1097/00003226-200405000-00015; NEWCOMBE RG, 1987, BRIT J OPHTHALMOL, V71, P645, DOI 10.1136/bjo.71.9.645; Rah MJ, 2011, OPTOMETRY, V82, P38, DOI 10.1016/j.optm.2010.08.003; Smith JA, 2007, OCUL SURF, V5, P93; Stonecipher K, 2005, CURR MED RES OPIN, V21, P1057, DOI 10.1185/030079905X50615; Williams David, 2012, Vet Res Forum, V3, P229; Williams DL, 2008, VET CLIN N AM-SMALL, V38, P251, DOI 10.1016/j.cvsm.2007.12.002; Williams DL, 2013, INT J BIOMATER, V2013, DOI 10.1155/2013/460437; Yang GH, 2010, VET OPHTHALMOL, V13, P144, DOI 10.1111/j.1463-5224.2010.00771.x; Yang GF, 2011, INT J GYNECOL CANCER, V21, P486, DOI 10.1097/IGC.0b013e31820fa168	19	27	27	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 10	2014	9	6							e99766	10.1371/journal.pone.0099766	http://dx.doi.org/10.1371/journal.pone.0099766			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AN9SD	24914681	Green Published, gold, Green Submitted			2023-01-03	WOS:000340947700129
J	Hansen, ML; Fallentin, E; Lauridsen, C; Law, I; Federspiel, B; Bksgaard, L; Svendsen, LB; Nielsen, MB				Hansen, Martin Lundsgaard; Fallentin, Eva; Lauridsen, Carsten; Law, Ian; Federspiel, Birgitte; Bksgaard, Lene; Svendsen, Lars Bo; Nielsen, Michael Bachmann			Computed Tomography (CT) Perfusion as an Early Predictive Marker for Treatment Response to Neoadjuvant Chemotherapy in Gastroesophageal Junction Cancer and Gastric Cancer - A Prospective Study	PLOS ONE			English	Article							SQUAMOUS-CELL CARCINOMA; TUMOR BLOOD-FLOW; GROWTH-FACTOR EXPRESSION; ESOPHAGOGASTRIC JUNCTION; QUANTITATIVE ASSESSMENT; PREOPERATIVE CHEMORADIOTHERAPY; PERIOPERATIVE CHEMOTHERAPY; ESOPHAGEAL-CARCINOMA; MONITORING RESPONSE; 1ST-PASS PERFUSION	Objectives: To evaluate whether early reductions in CT perfusion parameters predict response to pre-operative chemotherapy prior to surgery for gastroesophageal junction (GEJ) and gastric cancer. Materials and Methods: Twenty-eight patients with adenocarcinoma of the gastro-esophageal junction (GEJ) and stomach were included. Patients received three series of chemotherapy before surgery, each consisting of a 3-week cycle of intravenous epirubicin, cisplatin or oxaliplatin, concomitant with capecitabine peroral. The patients were evaluated with a CT perfusion scan prior to, after the first series of, and after three series of chemotherapy. The CT perfusion scans were performed using a 320-detector row scanner. Tumour volume and perfusion parameters (arterial flow, blood volume and permeability) were computed on a dedicated workstation with a consensus between two radiologists. Response to chemotherapy was evaluated by two measures. Clinical response was defined as a tumour size reduction of more than 50%. Histological response was evaluated based on residual tumour cells in the surgical specimen using the standardized Mandard Score 1 to 5, in which values of 1 and 2 were classified as responders, and 3 to 5 were classified as nonresponders. Results: A decrease in tumour permeability after one series of chemotherapy was positively correlated with clinical response after three series of chemotherapy. Significant changes in permeability and tumour volume were apparent after three series of chemotherapy in both clinical and histological responders. A cut-off value of more than 25% reduction in tumour permeability yielded a sensitivity of 69% and a specificity of 58% for predicting clinical response. Conclusion: Early decrease in permeability is correlated with the likelihood of clinical response to pre-operative chemotherapy in GEJ and gastric cancer. As a single diagnostic test, CT Perfusion only has moderate sensitivity and specificity in response assessment of pre-operative chemotherapy making it insufficient for clinical decision purposes.	[Hansen, Martin Lundsgaard; Fallentin, Eva; Lauridsen, Carsten; Nielsen, Michael Bachmann] Rigshosp, Dept Radiol, DK-2100 Copenhagen, Denmark; [Lauridsen, Carsten] Metropolitan Univ Coll, Dept Technol, Bachelors Degree Programme Radiog, Copenhagen, Denmark; [Law, Ian] Rigshosp, Dept Clin Physiol Nucl Med & PET, DK-2100 Copenhagen, Denmark; [Federspiel, Birgitte] Rigshosp, Dept Pathol, DK-2100 Copenhagen, Denmark; [Bksgaard, Lene] Rigshosp, Dept Oncol, DK-2100 Copenhagen, Denmark; [Svendsen, Lars Bo] Rigshosp, Dept Surg Gastroenterol, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	Hansen, ML (corresponding author), Rigshosp, Dept Radiol, DK-2100 Copenhagen, Denmark.	mlundsgaard@dadlnet.dk	Nielsen, Michael Bachmann/U-2749-2018	Nielsen, Michael Bachmann/0000-0002-9380-1688; Law, Ian/0000-0001-9644-7496; Svendsen, Lars Bo/0000-0002-3216-9121	Poul Lundbeck and wife Fund; Civil engineer Johs. E. Ormstrup and wife Grete Ormstrup Fund	Poul Lundbeck and wife Fund; Civil engineer Johs. E. Ormstrup and wife Grete Ormstrup Fund	The authors acknowledge financial support from Poul Lundbeck and wife Fund and Civil engineer Johs. E. Ormstrup and wife Grete Ormstrup Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bellomi M, 2007, RADIOLOGY, V244, P486, DOI 10.1148/radiol.2442061189; Chen TW, 2012, CLIN RADIOL, V67, P746, DOI 10.1016/j.crad.2011.07.053; Chen TW, 2009, CLIN RADIOL, V64, P38, DOI 10.1016/j.crad.2008.06.005; Chen YM, 2011, NUCL MED COMMUN, V32, P1005, DOI 10.1097/MNM.0b013e32834a8366; Cunningham D, 2008, NEW ENGL J MED, V358, P36, DOI 10.1056/NEJMoa073149; Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531; d'Assignies G, 2009, RADIOLOGY, V250, P407, DOI 10.1148/radiol.2501080291; Duyndam MCA, 2007, BIOCHEM PHARMACOL, V74, P191, DOI 10.1016/j.bcp.2007.04.003; Fournier LS, 2010, RADIOLOGY, V256, P511, DOI 10.1148/radiol.10091362; Fraioli F, 2013, BRIT J RADIOL, V86, DOI 10.1259/bjr.20120174; Goh V, 2008, AM J ROENTGENOL, V191, pW288, DOI 10.2214/AJR.07.3985; Hansen ML, 2013, DIAGNOSTICS, V3, P261, DOI 10.3390/diagnostics3020261; Hayano K, 2007, ONCOL REP, V18, P901; Jiang T, 2012, INVEST RADIOL, V47, P11, DOI 10.1097/RLI.0b013e3182199bb5; Kim DH, 2012, EUR J RADIOL, V81, P3542, DOI 10.1016/j.ejrad.2012.02.012; Koyasu S, 2012, EUR J RADIOL, V81, P43, DOI 10.1016/j.ejrad.2010.11.013; Lee TY, 2003, Q J NUCL MED, V47, P171; Li ZP, 2005, WORLD J GASTROENTERO, V11, P1287, DOI 10.3748/wjg.v11.i9.1287; Lordick F, 2007, LANCET ONCOL, V8, P797, DOI 10.1016/S1470-2045(07)70244-9; Ma GL, 2012, HEPATOB PANCREAT DIS, V11, P407, DOI 10.1016/S1499-3872(12)60199-4; Makari Y, 2007, J SURG ONCOL, V96, P220, DOI 10.1002/jso.20820; MANDARD AM, 1994, CANCER, V73, P2680, DOI 10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C; McShane LM, 2005, BRIT J CANCER, V93, P387, DOI 10.1038/sj.bjc.6602678; Motosugi U, 2012, EUR J RADIOL, V81, P2533, DOI 10.1016/j.ejrad.2011.11.054; Mukai Kota, 2006, Gastric Cancer, V9, P192, DOI 10.1007/s10120-006-0374-7; Ng QS, 2006, AM J ROENTGENOL, V187, P1079, DOI 10.2214/AJR.05.0889; Ott K, 2011, ANN SURG ONCOL, V18, P3316, DOI 10.1245/s10434-011-1743-y; Sahani DV, 2005, RADIOLOGY, V234, P785, DOI 10.1148/radiol.2343040286; Satoh A, 2010, DIGEST SURG, V27, P253, DOI 10.1159/000288703; SIU KF, 1986, ANN SURG, V203, P173, DOI 10.1097/00000658-198602000-00011; Sjoquist KM, 2011, LANCET ONCOL, V12, P681, DOI 10.1016/S1470-2045(11)70142-5; Song T, 2012, DIGEST DIS SCI, V57, P2195, DOI 10.1007/s10620-012-2149-9; Stewart EE, 2012, RADIOLOGY, V264, P68, DOI 10.1148/radiol.12110674; Tacelli N, 2013, EUR RADIOL, V23, P2127, DOI 10.1007/s00330-013-2821-2; van Hagen P, 2012, NEW ENGL J MED, V366, P2074, DOI 10.1056/NEJMoa1112088; Weber WA, 2001, J CLIN ONCOL, V19, P3058, DOI 10.1200/JCO.2001.19.12.3058; Wieder HA, 2007, EUR J NUCL MED MOL I, V34, P1925, DOI 10.1007/s00259-007-0521-3; Yao J, 2011, ABDOM IMAGING, V36, P15, DOI 10.1007/s00261-010-9609-5; Ychou M, 2011, J CLIN ONCOL, V29, P1715, DOI 10.1200/JCO.2010.33.0597; Zhong XS, 2007, BIOCHEM BIOPH RES CO, V358, P92, DOI 10.1016/j.bbrc.2007.04.083; Zum Buschenfelde CM, 2011, J NUCL MED, V52, P1189, DOI 10.2967/jnumed.110.085803	41	29	32	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2014	9	5							e97605	10.1371/journal.pone.0097605	http://dx.doi.org/10.1371/journal.pone.0097605			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM0UW	24845062	gold, Green Published, Green Submitted			2023-01-03	WOS:000339563400038
J	Gerard, C; Baudson, N; Ory, T; Louahed, J				Gerard, Catherine; Baudson, Nathalie; Ory, Thierry; Louahed, Jamila			Tumor Mouse Model Confirms MAGE-A3 Cancer Immunotherapeutic As an Efficient Inducer of Long-Lasting Anti-Tumoral Responses	PLOS ONE			English	Article							T-CELL RESPONSES; INTERFERON-GAMMA; NECROSIS-FACTOR; PHASE-II; IN-VIVO; EXPRESSION; ADJUVANT; PROTEIN; MELANOMA; GROWTH	Purpose: MAGE-A3 is a potential target for immunotherapy due to its tumor-specific nature and expression in several tumor types. Clinical data on MAGE-A3 immunotherapy have raised many questions that can only be addressed by using animal models. In the present study, different aspects of the murine anti-tumor immune responses induced by a recombinant MAGE-A3 protein (recMAGE-A3) in combination with different immunostimulants (AS01, AS02, CpG7909 or AS15) were investigated. Experimental Design and Results: Based on cytokine profile analyses and protection against challenge with MAGE-A3-expressing tumor, the combination recMAGE-A3+AS15 was selected for further experimental work, in particular to study the mechanisms of anti-tumor responses. By using MHC class I-, MHC class II-, perforin-, B-cell- and IFN-gamma- knock-out mice and CD4(+) T cell-, CD8(+) T cell- and NK cell- depleted mice, we demonstrated that CD4(+) T cells and NK cells are the main antitumor effectors, and that IFN-gamma is a major effector molecule. This mouse tumor model also established the need to repeat recMAGE-A3+AS15 injections to sustain efficient anti-tumor responses. Furthermore, our results indicated that the efficacy of tumor rejection by the elicited anti-MAGE-A3 responses depends on the proportion of tumor cells expressing MAGE-A3. Conclusions: The recMAGE-A3+AS15 cancer immunotherapy efficiently induced an antigen-specific, functional and long-lasting immune response able to recognize and eliminate MAGE-A3-expressing tumor cells up to several months after the last immunization in mice. The data highlighted the importance of the immunostimulant to induce a Th1-type immune response, as well as the key role played by IFN-gamma, CD4(+) T cells and NK cells in the anti-tumoral effect.	[Gerard, Catherine; Baudson, Nathalie; Ory, Thierry; Louahed, Jamila] GlaxoSmithKline Vaccines, Rixensart, Belgium	GlaxoSmithKline	Gerard, C (corresponding author), GlaxoSmithKline Vaccines, Rixensart, Belgium.	catherine.gerard@gsk.com			GlaxoSmithKline Biologicals SA	GlaxoSmithKline Biologicals SA(GlaxoSmithKline)	The funders had role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. GlaxoSmithKline Biologicals SA was the funding source and was involved in all stages of the study conduct and analysis. GlaxoSmithKline Biologicals SA also funded all costs associated with the development and publishing of the present manuscript. JL was involved in study supervision at all stages. All authors were involved in study design, review of study reports, data analysis and interpretation. NB and TO conducted the study and were involved in data generation. All authors were involved in drafting and approval of the manuscript.	Atanackovic D, 2004, J IMMUNOL, V172, P3289, DOI 10.4049/jimmunol.172.5.3289; Atanackovic D, 2008, P NATL ACAD SCI USA, V105, P1650, DOI 10.1073/pnas.0707140104; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chu RS, 1997, J EXP MED, V186, P1623, DOI 10.1084/jem.186.10.1623; Corbiere V, 2011, CANCER RES, V71, P1253, DOI 10.1158/0008-5472.CAN-10-2693; Corthay A, 2005, IMMUNITY, V22, P371, DOI 10.1016/j.immuni.2005.02.003; Coughlin CM, 1998, IMMUNITY, V9, P25, DOI 10.1016/S1074-7613(00)80585-3; den Brok MHMGM, 2006, CANCER RES, V66, P7285, DOI 10.1158/0008-5472.CAN-06-0206; DEPLAEN E, 1994, IMMUNOGENETICS, V40, P360, DOI 10.1007/BF01246677; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; FRANSEN L, 1986, EUR J CANCER CLIN ON, V22, P419, DOI 10.1016/0277-5379(86)90107-0; Garcon N, 2007, EXPERT REV VACCINES, V6, P723, DOI 10.1586/14760584.6.5.723; Garcon Nathalie, 2003, Expert Rev Vaccines, V2, P231, DOI 10.1586/14760584.2.2.231; Garcon N, 2011, EXPERT REV VACCINES, V10, P471, DOI [10.1586/erv.11.29, 10.1586/ERV.11.29]; GAUGLER B, 1994, J EXP MED, V179, P921, DOI 10.1084/jem.179.3.921; GREENBERG PD, 1991, ADV IMMUNOL, V49, P281; HOCK H, 1991, J EXP MED, V174, P1291, DOI 10.1084/jem.174.6.1291; Hudolin T, 2009, ACTA DERMATOVENER CR, V17, P103; Hunder NN, 2008, NEW ENGL J MED, V358, P2698, DOI 10.1056/NEJMoa0800251; Hung K, 1998, J EXP MED, V188, P2357, DOI 10.1084/jem.188.12.2357; Jungbluth AA, 2000, INT J CANCER, V85, P460, DOI 10.1002/(SICI)1097-0215(20000215)85:4<460::AID-IJC3>3.0.CO;2-N; Jungbluth Achim A, 2007, Cancer Immun, V7, P15; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Kruit WHJ, 2013, J CLIN ONCOL, V31, P2413, DOI 10.1200/JCO.2012.43.7111; Lally KM, 2001, INT J CANCER, V93, P841, DOI 10.1002/ijc.1420; LAURITZSEN GF, 1994, P NATL ACAD SCI USA, V91, P5700, DOI 10.1073/pnas.91.12.5700; Lin KY, 1996, CANCER RES, V56, P21; Marchand M, 2003, EUR J CANCER, V39, P70, DOI 10.1016/S0959-8049(02)00479-3; Marturano J, 2008, CANCER RES, V68, P1555, DOI 10.1158/0008-5472.CAN-07-5233; Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731; Nierkens S, 2011, CANCER RES, V71, P6428, DOI 10.1158/0008-5472.CAN-11-2154; Perez-Diez A, 2007, BLOOD, V109, P5346, DOI 10.1182/blood-2006-10-051318; Qin ZH, 2000, IMMUNITY, V12, P677, DOI 10.1016/S1074-7613(00)80218-6; Rakhra K, 2010, CANCER CELL, V18, P485, DOI 10.1016/j.ccr.2010.10.002; Rosenberg SA, 2008, NAT REV CANCER, V8, P299, DOI 10.1038/nrc2355; Seliger B, 2008, ADV CANCER RES, V101, P249, DOI 10.1016/S0065-230X(08)00407-7; Street SEA, 2001, BLOOD, V97, P192, DOI 10.1182/blood.V97.1.192; Street SEA, 2002, J EXP MED, V196, P129, DOI 10.1084/jem.20020063; Tatsumi T, 2002, J EXP MED, V196, P619, DOI 10.1084/jem.20012142; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; VANPEL A, 1995, IMMUNOL REV, V145, P229, DOI 10.1111/j.1600-065X.1995.tb00084.x; VANPEL A, 1982, P NATL ACAD SCI-BIOL, V79, P4718; Vansteenkiste J, 2013, J CLIN ONCOL, V31, P2396, DOI 10.1200/JCO.2012.43.7103; Vantomme V, 2004, J IMMUNOTHER, V27, P124, DOI 10.1097/00002371-200403000-00006; WILLIAMSON BD, 1983, P NATL ACAD SCI-BIOL, V80, P5397, DOI 10.1073/pnas.80.17.5397; Xu XL, 1998, CANCER RES, V58, P2832	49	22	24	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2014	9	5							e94883	10.1371/journal.pone.0094883	http://dx.doi.org/10.1371/journal.pone.0094883			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI3UI	24830315	Green Submitted, gold, Green Published			2023-01-03	WOS:000336789500006
J	Guery, B; Alberti, C; Servais, A; Harrami, E; Bererhi, L; Zins, B; Touam, M; Joly, D				Guery, Bruno; Alberti, Corinne; Servais, Aude; Harrami, Elarbi; Bererhi, Lynda; Zins, Brigitte; Touam, Malik; Joly, Dominique			Hemodialysis without Systemic Anticoagulation: A Prospective Randomized Trial to Evaluate 3 Strategies in Patients at Risk of Bleeding	PLOS ONE			English	Article							HEPARIN-FREE DIALYSIS; CITRATE ANTICOAGULATION; COAGULATION; MEMBRANE; PROSTACYCLIN; ACTIVATION; BINDING	Objective: In this clinical trial, we aimed to compare three means of performing chronic hemodialysis in patients with contra-indication to systemic heparinization. Methods: This open-label monocentric randomized << n-of-one >> trial, conducted in a single tertiary care center, recruited chronic hemodialysis patients with a contra-indication to systemic heparinization for at least 3 consecutive sessions. All patients underwent hemodialysis with an AN69ST dialyzer, and were administered three alternative dialysis procedures in a random sequence: intermittent saline flushes, constant saline infusion, or pre-dialysis heparin coating of the membrane. The primary outcome was the need to interrupt the dialysis session because of clotting events due to either (i) a complete coagulation of the circuit; (ii) a partial coagulation of the circuit; (iii) a>50% rise over baseline in the venous pressure. Results: At the end of the inclusion period (May, 2007 to December, 2008), the number of patients to include (n = 75) was not reached: only 46 patients were included and underwent randomization. The study was terminated, and statistical analysis took into account 224 hemodialysis sessions performed in 44 patients with analyzable data. Heparin adsorption was associated with a significant reduction of the need to interrupt the dialysis session because of clotting events: odds ratio 0.3 (CI 95% 0.2 to 0.6; p<0.001, versus intermittent saline flushes). Heparin adsorption was also associated with higher odds for performing>3 h dialysis sessions and for having complete blood restitution. There were no significant effects of the dialysis procedure on weight loss, online ionic dialysance, and adverse events. Conclusion: Heparin-coated AN69ST dialysis membrane is a safe and effective method to avoid or delay per-dialytic clotting events in patients with contra-indication to systemic anticoagulation. However, results are not generalizable safely to patients with active bleeding, since weak heparinemia, not assessed in this study, may occur.	[Guery, Bruno; Servais, Aude; Harrami, Elarbi; Bererhi, Lynda; Zins, Brigitte; Touam, Malik; Joly, Dominique] Univ Paris 05, Hop Necker Enfants Malad, AP HP, Serv Nephrol, Paris, France; [Alberti, Corinne] Univ Paris 07, Hop Robert Debre, AP HP, Unite Epidemiol Clin, Paris, France; [Alberti, Corinne] Inst Natl Sante & Rech Med CIE 5, Paris, France; [Joly, Dominique] Hop Necker Enfants Malad, INSERM, U845, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Joly, D (corresponding author), Univ Paris 05, Hop Necker Enfants Malad, AP HP, Serv Nephrol, Paris, France.	doume.joly@gmail.com		Servais, Aude/0000-0002-8165-8212	Departement a la Recherche Clinique et au Developpement, Assistance Publique-Hopitaux de Paris [CRC 05 032]; AURA (Association pour l'Utilisation du Rein Artificiel)	Departement a la Recherche Clinique et au Developpement, Assistance Publique-Hopitaux de Paris; AURA (Association pour l'Utilisation du Rein Artificiel)	This work was supported by a research grant from the Departement a la Recherche Clinique et au Developpement, Assistance Publique-Hopitaux de Paris, which was also the sponsor of the study (CRC 05 032), and AURA (Association pour l'Utilisation du Rein Artificiel). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Apsner R, 2001, AM J KIDNEY DIS, V38, P979, DOI 10.1053/ajkd.2001.28584; Bartels PCM, 2000, SCAND J CLIN LAB INV, V60, P283, DOI 10.1080/003655100750046440; Camici M, 1997, INT J ARTIF ORGANS, V20, P163, DOI 10.1177/039139889702000307; CARUANA RJ, 1991, BLOOD PURIFICAT, V9, P296, DOI 10.1159/000170027; CARUANA RJ, 1987, KIDNEY INT, V31, P1351, DOI 10.1038/ki.1987.149; Chanard J, 2005, ASAIO J, V51, P342, DOI 10.1097/01.mat.0000169119.06419.ed; Evenepoel P, 2007, AM J KIDNEY DIS, V49, P642, DOI 10.1053/j.ajkd.2007.02.001; FLANIGAN MJ, 1987, AM J KIDNEY DIS, V9, P147, DOI 10.1016/S0272-6386(87)80092-6; Frank RD, 2006, NEPHROL DIAL TRANSPL, V21, P1013, DOI 10.1093/ndt/gfi293; JANSSEN MJFM, 1993, NEPHROL DIAL TRANSPL, V8, P1228; KELLEHER SP, 1987, AM J KIDNEY DIS, V9, P235, DOI 10.1016/S0272-6386(87)80061-6; Kodras K, 2008, BLOOD PURIFICAT, V26, P226, DOI 10.1159/000118846; Lavaud S, 2005, ASAIO J, V51, P348, DOI 10.1097/01.mat.0000169121.09075.53; Lavaud S, 2003, NEPHROL DIAL TRANSPL, V18, P2097, DOI 10.1093/ndt/gfg272; Lim W, 2004, J AM SOC NEPHROL, V15, P3192, DOI 10.1097/01.ASN.0000145014.80714.35; MARTINMALO A, 1993, KIDNEY INT, V43, pS213; Nurmohamed M T, 1991, ASAIO Trans, V37, pM459; PINNICK RV, 1983, NEW ENGL J MED, V308, P258, DOI 10.1056/NEJM198302033080506; PREUSCHOF L, 1988, INT J ARTIF ORGANS, V11, P255, DOI 10.1177/039139888801100408; Richtrova P, 2007, NEPHROL DIAL TRANSPL, V22, P2978, DOI 10.1093/ndt/gfm137; Romao JE, 1997, NEPHROL DIAL TRANSPL, V12, P106, DOI 10.1093/ndt/12.1.106; Sagedal S, 2006, NEPHROL DIAL TRANSPL, V21, P444, DOI 10.1093/ndt/gfi203; SCHWAB SJ, 1987, AM J MED, V83, P405, DOI 10.1016/0002-9343(87)90748-0; SWARTZ RD, 1988, J CLIN PHARMACOL, V28, P818, DOI 10.1002/j.1552-4604.1988.tb03222.x; SWARTZ RD, 1981, NEPHRON, V28, P65, DOI 10.1159/000182111; Weitz JI, 1997, NEW ENGL J MED, V337, P688, DOI 10.1056/NEJM199709043371007; Zucker DR, 2010, AM J KIDNEY DIS, V55, P635, DOI 10.1053/j.ajkd.2009.11.010	27	22	23	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2014	9	5							e97187	10.1371/journal.pone.0097187	http://dx.doi.org/10.1371/journal.pone.0097187			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AH8EY	24825343	gold, Green Submitted, Green Published			2023-01-03	WOS:000336369200071
J	Rothgerber, H				Rothgerber, Hank			Horizontal Hostility among Non-Meat Eaters	PLOS ONE			English	Article							VEGETARIAN; MEAT; ATTITUDES; MINORITY; DIETS	The present study examined intergroup judgments made between four groups of non-meat eaters: health vegetarians; ethical vegetarians; health vegans, and ethical vegans. Consistent with hypotheses based on horizontal hostility and the need to maintain ingroup distinctiveness, ethical vegetarians gave unfavorable evaluations to health vegetarians relative to vegans, especially when the mainstream omnivore group was made salient. Contrary to expectations, vegans gave relatively more favorable evaluations to ethical vegetarians than health vegetarians when mainstream salience was low. This was especially true for vegans who were motivated primarily by ethical concerns. When mainstream salience was high, vegans did not distinguish between the vegetarian subgroups. Results suggest that one's motives for abstaining from meat often play a larger role in this type of intergroup perceptions than one's dietary practices.	Bellarmine Univ, Dept Psychol, Louisville, KY 40205 USA	Bellarmine University	Rothgerber, H (corresponding author), Bellarmine Univ, Dept Psychol, Louisville, KY 40205 USA.	hrothgerber@bellarmine.edu						[Anonymous], 2007, VEG J; Caro Mark, 2009, FOIE GRAS WARS; Corliss Richard, 2002, Time, V160, P48; Cunningham J., 2009, VEGETARIAN J, V29; Fox N, 2008, APPETITE, V50, P422, DOI 10.1016/j.appet.2007.09.007; Hamilton M., 2006, Food, Culture & Society, V9, P155, DOI 10.2752/155280106778606053; Herzog J.H., 1991, ANTHROZOOS, V4, P184, DOI DOI 10.2752/089279391787057170; Jabs J, 1998, J NUTR EDUC, V30, P196, DOI 10.1016/S0022-3182(98)70319-X; Jetten J, 2004, J PERS SOC PSYCHOL, V86, P862, DOI 10.1037/0022-3514.86.6.862; Lindeman M, 2001, APPETITE, V37, P175, DOI 10.1006/appe.2001.0437; Maurer Donna, 2010, VEGETARIANISM MOVEME; MOSCOVICI S, 1969, SOCIOMETRY, V32, P365, DOI 10.2307/2786541; Potts A, 2010, FEM PSYCHOL, V20, P53, DOI 10.1177/0959353509351181; Povey R, 2001, APPETITE, V37, P15, DOI 10.1006/appe.2001.0406; Rothgerber H, 1997, J PERS SOC PSYCHOL, V73, P1191, DOI 10.1037/0022-3514.73.6.1191; Rothgerber H, 2014, APPETITE, V72, P98, DOI 10.1016/j.appet.2013.10.002; Rothgerber H, 2013, APPETITE, V68, P76, DOI 10.1016/j.appet.2013.04.012; Rozin P, 1997, PSYCHOL SCI, V8, P67, DOI 10.1111/j.1467-9280.1997.tb00685.x; Ruby MB, 2012, APPETITE, V58, P141, DOI 10.1016/j.appet.2011.09.019; Ruby Matthew Byron, 2008, THESIS; Tajfel H., 1986, PSYCHOL INTERGROUP R, P7, DOI [DOI 10.4324/9780203505984-16, 10.4324/9780203505984-16]; White JB, 1999, J SOC ISSUES, V55, P537, DOI 10.1111/0022-4537.00132; White JB, 2006, GROUP PROCESS INTERG, V9, P339, DOI 10.1177/1368430206064638; WILDER DA, 1988, J PERS SOC PSYCHOL, V54, P62, DOI 10.1037/0022-3514.54.1.62	24	18	18	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 8	2014	9	5							e96457	10.1371/journal.pone.0096457	http://dx.doi.org/10.1371/journal.pone.0096457			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AK1XT	24809342	gold, Green Submitted, Green Published			2023-01-03	WOS:000338213300041
J	Chen, LY; Qu, C; Chen, H; Xu, LT; Qi, Q; Luo, JM; Wang, K; Meng, ZQ; Chen, Z; Wang, P; Liu, LM				Chen, Lianyu; Qu, Chao; Chen, Hao; Xu, Litao; Qi, Qi; Luo, Jianmin; Wang, Kun; Meng, Zhiqiang; Chen, Zhen; Wang, Peng; Liu, Luming			Chinese Herbal Medicine Suppresses Invasion-Promoting Capacity of Cancer-Associated Fibroblasts in Pancreatic Cancer	PLOS ONE			English	Article							INFLAMMATORY CYTOKINES CXCL1; TUMOR STROMA; CLINICAL-SIGNIFICANCE; ALTERNATIVE MEDICINE; QINGYIHUAJI FORMULA; LIVER METASTASES; BREAST-CANCER; IN-VIVO; CELLS; EXPRESSION	Pancreatic cancer remains one of the leading causes of cancer-related deaths, due to aggressive growth, high metastatic rates during the early stage and the lack of an effective therapeutic approach. We previously showed that Qingyihuaji (QYHJ), a seven-herb Chinese medicine formula, exhibited significant anti-cancer effects in pancreatic cancer, associated with modifications in the tumor microenvironment, particularly the inhibition of cancer-associated fibroblast (CAF) activation. In the present study, we generated CAF and paired normal fibroblast (NF) cultures from resected human pancreatic cancer tissues. We observed that CAFs exhibited an enhanced capacity for inducing pancreatic cancer cell migration and invasion compared with NFs, while QYHJ-treated CAFs exhibited decreased migration and invasion-promoting capacities in vitro. The results of further analyses indicated that compared with NFs, CAFs exhibit increased CXCL1, 2 and 8 expression, contributing to the enhanced invasion-promoting capacities of these cells, while QYHJ treatment significantly suppressed CAF proliferation activities and the production of CAF-derived CXCL1, 2 and 8. These in vitro observations were confirmed in mice models of human pancreatic cancer. Taken together, these results suggested that suppressing the tumor-promoting capacity of CAFs through Chinese herbal medicine attenuates pancreatic cancer cell invasion.	[Chen, Lianyu; Qu, Chao; Chen, Hao; Xu, Litao; Qi, Qi; Wang, Kun; Meng, Zhiqiang; Chen, Zhen; Wang, Peng; Liu, Luming] Fudan Univ, Shanghai Canc Ctr, Dept Integrat Oncol, Shanghai 200433, Peoples R China; [Chen, Lianyu; Qu, Chao; Chen, Hao; Xu, Litao; Qi, Qi; Luo, Jianmin; Wang, Kun; Meng, Zhiqiang; Chen, Zhen; Wang, Peng; Liu, Luming] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200433, Peoples R China	Fudan University; Fudan University	Chen, Z (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Integrat Oncol, Shanghai 200433, Peoples R China.	cz.chenzhen@gmail.com; wangp413@163.com; llm1010@yahoo.com.cn	Meng, Zhiqiang/ABE-7747-2021; Luo, jian/HGE-7331-2022	Chen, Zhen/0000-0002-4502-0801	National Science Fundation of China [81001061, 81370068, 81273953, 81173461]; Shanghai Nature Science Fund, Shanghai, China [09ZR1406800]; Doctoral Programs Foundation of Ministry of Education of China [20090071120076]; Shanghai Science and Technology Committee Rising-Star Program [11QA1401300]; Medical Talents Training Program of Health Bureau of Shanghai [XYQ2011008]; Fudan University Zhuo-Xue program	National Science Fundation of China; Shanghai Nature Science Fund, Shanghai, China; Doctoral Programs Foundation of Ministry of Education of China(Ministry of Education, China); Shanghai Science and Technology Committee Rising-Star Program; Medical Talents Training Program of Health Bureau of Shanghai; Fudan University Zhuo-Xue program	This study was supported by National Science Fundation of China (81001061, 81370068, 81273953, 81173461); Shanghai Nature Science Fund, Shanghai, China (09ZR1406800); Doctoral Programs Foundation of Ministry of Education of China (20090071120076); Shanghai Science and Technology Committee Rising-Star Program (11QA1401300); Medical Talents Training Program of Health Bureau of Shanghai (XYQ2011008); and Fudan University Zhuo-Xue program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bandapalli OR, 2012, CYTOKINE, V57, P46, DOI 10.1016/j.cyto.2011.10.019; Benelli R, 2013, PROSTATE, V73, P941, DOI 10.1002/pros.22640; Chang KH, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-196; Chen Z, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/635702; Chen Z, 2008, J ALTERN COMPLEM MED, V14, P1049, DOI 10.1089/acm.2008.0039; Dong QM, 2011, WORLD J GASTROENTERO, V17, P2658, DOI 10.3748/wjg.v17.i21.2658; Feng Q, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/184358; Frick VO, 2008, PANCREATOLOGY, V8, P488, DOI 10.1159/000151776; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hwang RF, 2008, CANCER RES, V68, P918, DOI 10.1158/0008-5472.CAN-07-5714; Ino Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055146; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kavandi L, 2012, J CELL BIOCHEM, V113, P3143, DOI 10.1002/jcb.24191; Killian PH, 2012, CARCINOGENESIS, V33, P2507, DOI 10.1093/carcin/bgs312; Kinoshita T, 2013, CANCER SCI, V104, P409, DOI 10.1111/cas.12099; Langley RR, 2011, INT J CANCER, V128, P2527, DOI 10.1002/ijc.26031; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Martinez-Outschoorn UE, 2011, CELL CYCLE, V10, P2521, DOI 10.4161/cc.10.15.16584; Merika EE, 2012, GASTROENT RES PRACT, V2012, DOI 10.1155/2012/781765; Muerkoster S, 2004, CANCER RES, V64, P1331, DOI 10.1158/0008-5472.CAN-03-1860; Nishikawa R, 2012, EUR J GYNAECOL ONCOL, V33, P138; Ouyang HQ, 2011, PANCREAS, V40, P120, DOI 10.1097/MPA.0b013e3181e6e398; Pietras K, 2010, EXP CELL RES, V316, P1324, DOI 10.1016/j.yexcr.2010.02.045; Quiros RM, 2008, GYNECOL ONCOL, V110, P99, DOI 10.1016/j.ygyno.2008.03.006; Sato N, 2004, CANCER RES, V64, P6950, DOI 10.1158/0008-5472.CAN-04-0677; Schoppmann SF, 2013, CLIN EXP METASTAS, V30, P441, DOI 10.1007/s10585-012-9549-2; Tchou J, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-39; Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224; Walter K, 2008, CANCER BIOL THER, V7, P882, DOI 10.4161/cbt.7.6.5869; Wang P, 2013, ONCOGENE; Wang P, 2010, INTEGR CANCER THER, V9, P50, DOI 10.1177/1534735409359179; Wang P, 2009, CARCINOGENESIS, V30, P1497, DOI 10.1093/carcin/bgp154; Yin JH, 2012, INTEGR CANCER THER, V11, P37, DOI 10.1177/1534735411400315; Zhang J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070334; Zhu QC, 2012, J MOL HISTOL, V43, P699, DOI 10.1007/s10735-012-9435-x	36	23	25	2	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2014	9	4							e96177	10.1371/journal.pone.0096177	http://dx.doi.org/10.1371/journal.pone.0096177			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG6CA	24781445	Green Published, Green Submitted, gold			2023-01-03	WOS:000335504900021
J	Pelletier, EB; Emond, M; Lauzier, F; Savard, M; Turgeon, AF				Pelletier, Elyse Berger; Emond, Marcel; Lauzier, Francois; Savard, Martin; Turgeon, Alexis F.			Hyperosmolar Therapy in Severe Traumatic Brain Injury: A Survey of Emergency Physicians from a Large Canadian Province	PLOS ONE			English	Article							INCREASED INTRACRANIAL-PRESSURE; HYPERTONIC SALINE; HEAD-INJURY; MANAGEMENT; MANNITOL; HYPOTENSION; INFUSION; CARE	Introduction: Worldwide, severe traumatic brain injury is a frequent pathology and is associated with high morbidity and mortality. Mannitol and hypertonic saline are therapeutic options for intracranial hypertension occurring in the acute phase of care. However, current practices of emergency physicians are unknown. Methods: We conducted a self-administered survey of emergency physicians in the province of Quebec, Canada, to understand their attitudes surrounding the use of hyperosmolar solutions in patients with severe traumatic brain injury. Using information from a systematic review of hypertonic saline solutions and experts' opinion, we developed a questionnaire following a systematic approach (items generation and reduction). We tested the questionnaire for face and content validity, and test-retest reliability. Physicians were identified through the department head of each eligible level I and II trauma centers. We administered the survey using a web-based interface and planned email reminders. Results: We received 210 questionnaires out of 429 potentials respondents (response rate 49%). Most respondents worked in level II trauma centers (69%). Fifty-three percent (53%) of emergency physicians stated using hypertonic saline to treat severe traumatic brain injury. Most reported using hyperosmolar therapy in the presence of severe traumatic brain injury and unilateral reactive mydriasis, midline shift or cistern compression on brain computed tomography. Conclusion: Hyperosmolar therapy is believed being broadly used by emergency physicians in Quebec following severe traumatic brain injury. Despite the absence of clinical practice guidelines promoting the use of hypertonic saline, a majority of them said to use these solutions in specific clinical situations.	[Pelletier, Elyse Berger; Emond, Marcel; Lauzier, Francois; Savard, Martin; Turgeon, Alexis F.] Univ Laval, Hop Enfant Jesus, Ctr Hosp Univ Quebec,Res Ctr, Populat Hlth & Optimal Hlth Practices Res Unit, Quebec City, PQ, Canada; [Pelletier, Elyse Berger; Emond, Marcel] Univ Laval, Dept Family & Emergency Med, Quebec City, PQ, Canada; [Lauzier, Francois; Turgeon, Alexis F.] Univ Laval, Dept Anesthesiol, Div Crit Care, Quebec City, PQ, Canada; [Lauzier, Francois] Univ Laval, Dept Med, Quebec City, PQ G1K 7P4, Canada; [Savard, Martin] Univ Laval, Dept Neurol Sci, Quebec City, PQ, Canada	Laval University; Laval University; Laval University; Laval University; Laval University	Turgeon, AF (corresponding author), Univ Laval, Hop Enfant Jesus, Ctr Hosp Univ Quebec,Res Ctr, Populat Hlth & Optimal Hlth Practices Res Unit, Quebec City, PQ, Canada.	alexis.turgeon@fmed.ulaval.ca	Savard, Martin/O-2549-2019; Lauzier, Francois/B-9237-2015; Emond, Marcel/G-5804-2014	Lauzier, Francois/0000-0002-6530-5513; Emond, Marcel/0000-0001-7158-8110	Association des medecins d'urgence du Quebec (AMUQ)	Association des medecins d'urgence du Quebec (AMUQ)	The Association des medecins d'urgence du Quebec (AMUQ) partly funded this project. The AMUQ had no influence on the design, conduct, analysis, or decision to submit the manuscript for publication. No additional external funding was received for this study.	AAPOR, 2016, STAND DEF FIN DISP C; [American College of Surgeons committee on trauma American College of Surgeons], 2008, ADV TRAUM LIF SUPP, P131; Asch DA, 1997, J CLIN EPIDEMIOL, V50, P1129, DOI 10.1016/S0895-4356(97)00126-1; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Behnia R, 1996, ANESTH ANALG, V82, P902, DOI 10.1097/00000539-199605000-00002; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; BROWN FD, 1979, J NEUROSURG, V50, P423, DOI 10.3171/jns.1979.50.4.0423; Burns KEA, 2008, CAN MED ASSOC J, V179, P245, DOI 10.1503/cmaj.080372; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; COTE CJ, 1979, ANESTHESIOLOGY, V50, P30, DOI 10.1097/00000542-197901000-00007; Cote N, 2013, NEUROCRIT CARE, V18, P154, DOI 10.1007/s12028-012-9787-9; Dillman Don, 2014, INTERNET PHONE MAIL; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Jacka MJ, 2007, CAN J NEUROL SCI, V34, P307, DOI 10.1017/S0317167100006727; JAMES HE, 1980, ACTA NEUROCHIR, V51, P161, DOI 10.1007/BF01406742; Marko NF, 2012, CRIT CARE, V16, DOI 10.1186/cc11182; MATTOX KL, 1991, ANN SURG, V213, P482, DOI 10.1097/00000658-199105000-00014; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Papangelou A, 2009, CURR TREAT OPTION NE, V11, P64, DOI 10.1007/s11940-009-0009-5; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Turgeon A, 2009, CRIT CARE MED, V37, pA435; Turgeon AF, 2013, CRIT CARE MED, V41, P1086, DOI 10.1097/CCM.0b013e318275d046; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; Vincent JL, 2005, CRIT CARE MED, V33, P1392, DOI 10.1097/01.CCM.0000166890.93559.2D; Wenham TN, 2008, ANAESTHESIA, V63, P558, DOI 10.1111/j.1365-2044.2008.05532.x	29	8	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2014	9	4							e95778	10.1371/journal.pone.0095778	http://dx.doi.org/10.1371/journal.pone.0095778			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG2IS	24755863	Green Submitted, gold, Green Published			2023-01-03	WOS:000335240300091
J	Tricotel, A; Raguideau, F; Collin, C; Zureik, M				Tricotel, Aurore; Raguideau, Fanny; Collin, Cedric; Zureik, Mahmoud			Estimate of Venous Thromboembolism and Related-Deaths Attributable to the Use of Combined Oral Contraceptives in France	PLOS ONE			English	Article							DEEP-VEIN THROMBOSIS; HORMONAL CONTRACEPTION; PULMONARY-EMBOLISM; RISK	Purpose: To estimate the number of venous thromboembolic events and related-premature mortality (including immediate in-hospital lethality) attributable to the use of combined oral contraceptives in women aged 15 to 49 years-old between 2000 and 2011 in France. Methods: French data on sales of combined oral contraceptives and on contraception behaviours from two national surveys conducted in 2000 and 2010 were combined to estimate the number of exposed women according to contraceptives generation and age. Absolute risk of first time venous thromboembolism in non-users of hormonal contraception and increased risk of thromboembolism in users vs. non-users of hormonal contraception were estimated on the basis of literature data. Finally, immediate in-hospital lethality due to pulmonary embolism and premature mortality due to recurrent venous thromboembolism were estimated from the French national database of hospitalisation and literature data. Results: In France, more than four million women are daily exposed to combined oral contraceptives. The mean annual number of venous thromboembolic events attributable to their use was 2,529 (778 associated to the use of first- and second-generation contraceptives and 1,751 to the use of third-and fourth-generation contraceptives), corresponding to 20 premature deaths (six with first-and second-generation contraceptives and fourteen with third-and fourth-generation contraceptives), of which there were eight to nine immediate in-hospital deaths. As compared to the use of first-and second-generation contraceptives, exposure to third- and fourth-generation contraceptives led to a mean annual excess of 1,167 venous thromboembolic events and nine premature deaths (including three immediate in-hospital deaths). Conclusions: Corrective actions should be considered to limit exposure to third-and fourth-generation contraceptives, and thus optimise the benefit-risk ratio of combined oral contraception.	[Tricotel, Aurore; Raguideau, Fanny; Collin, Cedric; Zureik, Mahmoud] French Natl Agcy Med & Hlth Prod Safety ANSM, Dept Epidemiol Hlth Prod, St Denis, France		Zureik, M (corresponding author), French Natl Agcy Med & Hlth Prod Safety ANSM, Dept Epidemiol Hlth Prod, St Denis, France.	mahmoud.zureik@ansm.sante.fr	Zureik, Mahmoud/F-7855-2018	Zureik, Mahmoud/0000-0002-8393-4217				ANAND JK, 1961, LANCET, V2, P1146; Baglin T, 2003, LANCET, V362, P523, DOI 10.1016/S0140-6736(03)14111-6; Baillargeon JP, 2005, J CLIN ENDOCR METAB, V90, P3863, DOI 10.1210/jc.2004-1958; Bajos N, 2003, HUM REPROD, V18, P994, DOI 10.1093/humrep/deg215; Bajos N, 2012, POPUL SOC; BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; BOYCE J, 1963, LANCET, V1, P111, DOI 10.1016/S0140-6736(63)91117-6; Dinger JC, 2007, CONTRACEPTION, V75, P344, DOI 10.1016/j.contraception.2006.12.019; FARLEY TMM, 1995, LANCET, V346, P1582; Goldhaber SZ, 1999, LANCET, V353, P1386, DOI 10.1016/S0140-6736(98)07534-5; Helmerhorst FM, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1464; Hoffmann B, 2010, THROMB RES, V125, P303, DOI 10.1016/j.thromres.2009.06.015; IMS-Health, MS MIDAS MARK SEGM; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; Jick SS, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2151; Laporte S, 2008, CIRCULATION, V117, P1711, DOI 10.1161/CIRCULATIONAHA.107.726232; Lidegaard O, 2012, NEW ENGL J MED, V366, P2257, DOI 10.1056/NEJMoa1111840; Lidegaard O, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2990; Lidegaard O, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d6423; Lidegaard O, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2890; Naess IA, 2007, J THROMB HAEMOST, V5, P692, DOI 10.1111/j.1538-7836.2007.02450.x; National Institute of Statistics and Economic Studies (Insee), POP SEX 5 YEAR AG GR; Oger E, 2000, THROMB HAEMOSTASIS, V83, P657; Parkin L, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2139; Silverstein MD, 1998, ARCH INTERN MED, V158, P585, DOI 10.1001/archinte.158.6.585; Spitzer WO, 1996, BRIT MED J, V312, P83; Vlieg AV, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2921; White RH, 2008, THROMB HAEMOSTASIS, V99, P683, DOI 10.1160/TH07-09-0557	28	11	12	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 21	2014	9	4							e93792	10.1371/journal.pone.0093792	http://dx.doi.org/10.1371/journal.pone.0093792			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG2DX	24751717	Green Published, Green Submitted, gold			2023-01-03	WOS:000335227400007
J	Fu, SP; He, SY; Xu, B; Hu, CJ; Lu, SF; Shen, WX; Huang, Y; Hong, H; Li, Q; Wang, N; Liu, XL; Liang, FR; Zhu, BM				Fu, Shu-Ping; He, Su-Yun; Xu, Bin; Hu, Chen-Jun; Lu, Sheng-Feng; Shen, Wei-Xing; Huang, Yan; Hong, Hao; Li, Qian; Wang, Ning; Liu, Xuan-Liang; Liang, Fanrong; Zhu, Bing-Mei			Acupuncture Promotes Angiogenesis after Myocardial Ischemia through H3K9 Acetylation Regulation at VEGF Gene	PLOS ONE			English	Article							RNA-SEQ; ELECTROACUPUNCTURE; RATS; PRETREATMENT; REPERFUSION; INJURY; HEART; INVOLVEMENT; HYPOXIA; KINASE	Background: Acupuncture exerts cardioprotective effects on several types of cardiac injuries, especially myocardial ischemia (MI), but the mechanisms have not yet been well elucidated. Angiogenesis mediated by VEGF gene expression and its modification through histone acetylation has been considered a target in treating myocardial ischemia. This study aims to exam whether modulation of angiogenesis through H3K9 acetylation regulation at VEGF gene is one possible cardioprotective mechanism of acupuncture. Results: We generated rat MI models by ligating the left anterior descending coronary artery and applied electroacupuncture (EA) treatment at the Neiguan (PC6) acupoint. Our results showed that acupuncture reversed the S-T segment change, reduced Q-wave area, decreased CK, CK-MB, LDH levels, mitigated myocardial remodeling, and promoted microvessel formation in the MI heart. RNA-seq analysis showed that VEGF-induced angiogenesis signaling was involved in the modulation of EA. Western blot results verified that the protein expressions of VEGF, Ras, phospho-p44/42 MAPK, phospho-p38 MAPK, phospho-SAPK/JNK and Akt, were all elevated significantly by EA treatment in the MI heart. Furthermore, increased H3K9 acetylation was also observed according with the VEGF. ChIP assay confirmed that EA treatment could notably stimulate the recruitment of H3K9ace at the VEGF promoter. Conclusions: Our study demonstrates for the first time that acupuncture can effectively up-regulate VEGF expression through H3K9 acetylation modification directly at the VEGF promoter and hence activate VEGF-induced angiogenesis in rat MI models. We employed high throughput sequencing in this study and, for the first time, generated genome-wide gene expression profiles both in the rat MI model and in acupuncture treatment.	[Fu, Shu-Ping; He, Su-Yun; Xu, Bin; Lu, Sheng-Feng; Shen, Wei-Xing; Huang, Yan; Hong, Hao; Li, Qian; Wang, Ning; Liu, Xuan-Liang; Zhu, Bing-Mei] Nanjing Univ Chinese Med, Minist Educ, Key Lab Acupuncture & Med Res, Nanjing, Jiangsu, Peoples R China; [Liang, Fanrong] Chengdu Univ Tradit Chinese Med, Sch Acupuncture & Tuina, Chengdu, Sichuan, Peoples R China; [Hu, Chen-Jun] Nanjing Univ Chinese Med, Sch Informat Technol, Nanjing, Jiangsu, Peoples R China	Nanjing University of Chinese Medicine; Chengdu University of Traditional Chinese Medicine; Nanjing University of Chinese Medicine	Liang, FR (corresponding author), Chengdu Univ Tradit Chinese Med, Sch Acupuncture & Tuina, Chengdu, Sichuan, Peoples R China.	0001170@cdutcm.edu.cn; zhubm64@hotmail.com		huang, yan/0000-0002-5588-0274; Liang, Fanrong/0000-0003-2210-2027	national basic research program of China (973 program) [2012CB518501]; National Natural Science Foundation of China [81273838]; Natural Science Foundation of the Jiangsu Hager Education Institutions of China [12KJB360005]; Natural Science Foundation of the Jiangsu Province of China [BK20130956]; Scientific and Technological Innovation Group of "Qinglan-Project" of Jiangsu Province	national basic research program of China (973 program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of the Jiangsu Hager Education Institutions of China; Natural Science Foundation of the Jiangsu Province of China(Natural Science Foundation of Jiangsu Province); Scientific and Technological Innovation Group of "Qinglan-Project" of Jiangsu Province	This work was supported by grants from the national basic research program of China (973 program, No. 2012CB518501), the National Natural Science Foundation of China (No. 81273838), the Natural Science Foundation of the Jiangsu Hager Education Institutions of China (No. 12KJB360005), the Natural Science Foundation of the Jiangsu Province of China (No. BK20130956) and the Scientific and Technological Innovation Group of "Qinglan-Project" of Jiangsu Province. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Cao YH, 2010, BLOOD, V115, P2336, DOI 10.1182/blood-2009-12-256933; Cheng K, 2010, CIRC RES, V106, P1570, DOI 10.1161/CIRCRESAHA.109.212589; Dasgupta Piyali, 2007, V383, P135, DOI 10.1007/978-1-59745-335-6_9; Du YH, 2011, NEUROL RES, V33, P101, DOI 10.1179/016164110X12714125204317; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; Gao JH, 2006, J PHYSIOL SCI, V56, P275, DOI 10.2170/physiolsci.RP006606; Gao JH, 2008, J PHYSIOL SCI, V58, P389, DOI 10.2170/physiolsci.RP007108; Henry TD, 2003, CIRCULATION, V107, P1359, DOI 10.1161/01.CIR.0000061911.47710.8A; Hu Jinsheng, 2008, J Tradit Chin Med, V28, P228; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Zhang J, 2010, MOL MED, V16, P307, DOI 10.2119/molmed.2009.00121; Lorier G, 2011, ARQ BRAS CARDIOL, V97, pE140, DOI 10.1590/S0066-782X2011001500019; Lu YH, 2011, MOL CELL BIOL, V31, P3339, DOI 10.1128/MCB.01121-10; Lujan HL, 2007, AM J PHYSIOL-HEART C, V292, pH2550, DOI 10.1152/ajpheart.00979.2006; Meng Jingbi, 2004, J Tradit Chin Med, V24, P16; Ni XL, 2012, PEDIATR ANESTH, V22, P805, DOI 10.1111/j.1460-9592.2012.03822.x; Park SI, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/464586; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Sun XC, 2010, EXP NEUROL, V224, P347, DOI 10.1016/j.expneurol.2010.04.009; Tjen-A-Looi SC, 2003, AUTON NEUROSCI-BASIC, V106, P119, DOI 10.1016/S1566-0702(03)00076-6; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Tseng A, 2010, CARDIOVASC RES, V87, P704, DOI 10.1093/cvr/cvq110; Tsou MT, 2004, AM J CHINESE MED, V32, P951, DOI 10.1142/S0192415X04002557; Wang SB, 2008, WORLD J GASTROENTERO, V14, P6496, DOI 10.3748/wjg.14.6496; Xu Feng-hua, 2005, Zhongguo Zhen Jiu, V25, P89; Yang LF, 2010, ANN THORAC SURG, V89, P781, DOI 10.1016/j.athoracsur.2009.12.003; Zhang F, 2011, BRAIN INJURY, V25, P895, DOI 10.3109/02699052.2011.581639; Zhang HX, 2009, CAN J CARDIOL, V25, P359, DOI 10.1016/S0828-282X(09)70095-9; Zhao L, 2013, BRAIN RES, V1503, P78, DOI 10.1016/j.brainres.2013.01.051	33	51	68	3	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 10	2014	9	4							e94604	10.1371/journal.pone.0094604	http://dx.doi.org/10.1371/journal.pone.0094604			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI5LS	24722278	Green Published, gold, Green Submitted			2023-01-03	WOS:000336909100106
J	Lasser, KE; Hanchate, AD; McCormick, D; Manze, MG; Chu, C; Kressin, NR				Lasser, Karen E.; Hanchate, Amresh D.; McCormick, Danny; Manze, Meredith G.; Chu, Chieh; Kressin, Nancy R.			The effect of Massachusetts health reform on 30 day hospital readmissions: retrospective analysis of hospital episode statistics	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MEDICARE BENEFICIARIES; 30-DAY READMISSION; HEART-FAILURE; CARE; INSURANCE; ADULTS; ACCESS; OUTCOMES; DISPARITIES; MORTALITY	Objectives To analyse changes in overall readmission rates and disparities in such rates, among patients aged 18-64 (those most likely to have been affected by reform), using all payer inpatient discharge databases (hospital episode statistics) from Massachusetts and two control states (New York and New Jersey). Design Difference in differences analysis to identify the post-reform change, adjusted for secular changes unrelated to reform. Setting US hospitals in Massachusetts, New York, and New Jersey. Participants Adults aged 18-64 admitted for any cause, excluding obstetrical. Main outcome measure Readmissions at 30 days after an index admission. Results After adjustment for known confounders, including age, sex, comorbidity, hospital ownership, teaching hospital status, and nurse to census ratio, the odds of all cause readmission in Massachusetts was slightly increased compared with control states post-reform (odds ratio 1.02, 95% confidence interval 1.01 to 1.04, P<0.05). Racial and ethnic disparities in all cause readmission rates did not change in Massachusetts compared with control states. In analyses limited to Massachusetts only, there were minimal overall differences in changes in readmission rates between counties with differing baseline uninsurance rates, but black people in counties with the highest uninsurance rates had decreased odds of readmission (0.91, 0.84 to 1.00) compared with black people in counties with lower uninsurance rates. Similarly, white people in counties with the highest uninsurance rates had decreased odds of readmission (0.96, 0.94 to 0.99) compared with white people in counties with lower uninsurance rates. Conclusions In the United States, and in Massachusetts in particular, extending health insurance coverage alone seems insufficient to improve readmission rates. Additional efforts are needed to reduce hospital readmissions and disparities in this outcome.	[Lasser, Karen E.; Hanchate, Amresh D.; Chu, Chieh; Kressin, Nancy R.] Boston Univ, Sch Med, Gen Internal Med Sect, Boston, MA 02118 USA; [Hanchate, Amresh D.; Kressin, Nancy R.] Vet Affairs Boston Healthcare Syst, Boston, MA USA; [McCormick, Danny] Harvard Univ, Sch Med, Dept Med, Cambridge Hlth Alliance, Cambridge, MA 02138 USA; [Manze, Meredith G.] CUNY, Sch Publ Hlth, New York, NY 10021 USA	Boston University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Harvard University; Cambridge Health Alliance; City University of New York (CUNY) System	Lasser, KE (corresponding author), Boston Univ, Sch Med, Gen Internal Med Sect, Boston, MA 02118 USA.	karen.lasser@bmc.org		Hanchate, Amresh/0000-0002-7038-4463; Kressin, Nancy/0000-0003-2767-4286	US National Institutes of Health [1R21NS062677, 1U01HL105342-01]; Rx foundation; Department of Veterans Affairs, Health Services Research and Development Service [RCS 02-066-1]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL105342] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS062677] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [R01MD007705] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rx foundation; Department of Veterans Affairs, Health Services Research and Development Service(US Department of Veterans Affairs); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	This research has been funded by US National Institutes of Health grants (1R21NS062677, ADH, principal investigator, and 1U01HL105342-01, NRK, principal investigator) and a grant from the Rx foundation. NRK is supported in part by a senior research career scientist award from the Department of Veterans Affairs, Health Services Research and Development Service (RCS 02-066-1). The views expressed in this article are those of the authors and do not necessarily represent the views of the National Institutes of Health, the Rx foundation, Boston University, or the Department of Veterans Affairs.	Abadie A, 2005, REV ECON STUD, V72, P1, DOI 10.1111/0034-6527.00321; Andrulis DP, 1998, ANN INTERN MED, V129, P412, DOI 10.7326/0003-4819-129-5-199809010-00012; Ayanian JZ, 2000, JAMA-J AM MED ASSOC, V284, P2061, DOI 10.1001/jama.284.16.2061; AYANIAN JZ, 1993, NEW ENGL J MED, V329, P326, DOI 10.1056/NEJM199307293290507; Baker DW, 2002, MED CARE, V40, P1126, DOI 10.1097/00005650-200211000-00013; Baker DW, 2001, NEW ENGL J MED, V345, P1106, DOI 10.1056/NEJMsa002887; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; Burke RE, 2013, J HOSP MED, V8, P102, DOI 10.1002/jhm.1990; Centers for Disease Control and Prevention (CDC), 2011, BEH RISK FACT SURV S; Centers for Disease Control and Prevention (CDC), 2007, BEH RISK FACT SURV S; CMS.gov, READM RED PROGR 2013; *COMM CONS UN BOAR, 2002, CAR COV TOO LITTL TO; Cook A, 2007, HLTH INSURANCE COVER; DeVoe JE, 2003, AM J PUBLIC HEALTH, V93, P786, DOI 10.2105/AJPH.93.5.786; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Epstein AM, 2011, NEW ENGL J MED, V365, P2287, DOI 10.1056/NEJMsa1101942; FRANKS P, 1993, AM J PUBLIC HEALTH, V83, P1295, DOI 10.2105/AJPH.83.9.1295; FRANKS P, 1993, JAMA-J AM MED ASSOC, V270, P737, DOI 10.1001/jama.270.6.737; Freeman JD, 2008, MED CARE, V46, P1023, DOI 10.1097/MLR.0b013e318185c913; Galbraith AA, 2013, HEALTH AFFAIR, V32, P974, DOI 10.1377/hlthaff.2012.0864; Hanchate AD, 2012, MED CARE, V50, P569, DOI 10.1097/MLR.0b013e31824e319f; Hasan O, 2010, J GEN INTERN MED, V25, P211, DOI 10.1007/s11606-009-1196-1; Healthcare Cost and Utilization Project, CLIN CLASS SOFTW CCS; HealthCare.gov, ESS HLTH BEN; Hernandez AF, 2010, JAMA-J AM MED ASSOC, V303, P1716, DOI 10.1001/jama.2010.533; Hersh AM, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000116; Hyams T, MASSACHUSETTS HLTH R; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Joynt KE, 2013, NEW ENGL J MED, V368, P1175, DOI 10.1056/NEJMp1300122; Joynt KE, 2012, JAMA-J AM MED ASSOC, V308, P1460, DOI 10.1001/jama.2012.12922; Joynt KE, 2011, JAMA-J AM MED ASSOC, V305, P675, DOI 10.1001/jama.2011.123; Joynt KE, 2011, ANN INTERN MED, V154, P94, DOI 10.7326/0003-4819-154-2-201101180-00008; KFF, SUMM AFF CAR ACT; kff.org, MASS HLTH CAR REF 6; kff.org, STAT MARK PROF MASS; Long SK, 2011, HEALTH SERV RES, V46, P365, DOI 10.1111/j.1475-6773.2010.01211.x; Long SK, 2009, HEALTH AFFAIR, V28, pW578, DOI 10.1377/hlthaff.28.4.w578; MA Division of Health Care Finance and Policy, 2009, FY2007 INP HOSP DISC; Mass.gov, MIN CRED COV; Mass.gov, HLTH CAR REF GEN INF; Massachusetts Medical Society. Massachusetts Medical Society's, 2013, MASS MED SOC 2013 PH; McCormick D, 2012, J GEN INTERN MED, V27, P1548, DOI 10.1007/s11606-012-2173-7; McDonough JE, 2008, HEALTH AFFAIR, V27, pW285, DOI 10.1377/hlthaff.27.4.w285; Medicare.gov, 30 DAY DEATH READM M; National Conference of State Legislatures, HLTH REF STAT EX; QualityNet, 2012, READM MEAS OV PUBL R; Sommers BD, 2012, NEW ENGL J MED, V367, P1025, DOI 10.1056/NEJMsa1202099; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206; Werner RM, 2008, JAMA-J AM MED ASSOC, V299, P2180, DOI 10.1001/jama.299.18.2180; Williams MV, 2013, JAMA-J AM MED ASSOC, V309, P394, DOI 10.1001/jama.2012.233964; Wilper AP, 2009, AM J PUBLIC HEALTH, V99, P2289, DOI 10.2105/AJPH.2008.157685; Zhu J, 2010, J GEN INTERN MED, V25, P1356, DOI 10.1007/s11606-010-1482-y	53	20	20	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 31	2014	348								g2329	10.1136/bmj.g2329	http://dx.doi.org/10.1136/bmj.g2329			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AE4TK	24687184	Green Published, hybrid			2023-01-03	WOS:000333976100005
J	Browne, S; Macdonald, S; May, CR; Macleod, U; Mair, FS				Browne, Susan; Macdonald, Sara; May, Carl R.; Macleod, Una; Mair, Frances S.			Patient, Carer and Professional Perspectives on Barriers and Facilitators to Quality Care in Advanced Heart Failure	PLOS ONE			English	Article							NORMALIZATION PROCESS THEORY; PALLIATIVE CARE; EUROPEAN-SOCIETY; COMMUNITY; PEOPLE; CANCER; ASSOCIATION; PREVALENCE; DIAGNOSIS; SURVIVAL	Background: Those with advanced heart failure (HF) experience high levels of morbidity and mortality, similar to common cancers. However, there remains evidence of inequity of access to palliative care services compared to people with cancer. This study examines patient, carer, and professional perspectives on current management of advanced HF and barriers and facilitators to improved care. Methods: Qualitative study involving semi-structured interviews and focus groups with advanced HF patients (n = 30), carers (n = 20), and professionals (n = 65). Data analysed using Normalisation Process Theory (NPT) as the underpinning conceptual framework. Findings: Uncertainty is ubiquitous in accounts from advanced HF patients and their caregivers. This uncertainty relates to understanding of the implications of their diagnosis, appropriate treatments, and when and how to seek effective help. Health professionals agree this is a major problem but feel they lack knowledge, opportunities, or adequate support to improve the situation. Fragmented care with lack of coordination and poor communication makes life difficult. Poor understanding of the condition extends to the wider circle of carers and means that requests for help may not be perceived as legitimate, and those with advanced HF are not prioritised for social and financial supports. Patient and caregiver accounts of emergency care are uniformly poor. Managing polypharmacy and enduring concomitant side effects is a major burden, and the potential for rationalisation exists. This study has potential limitations because it was undertaken within a single geographical location within the United Kingdom. Conclusions: Little progress is being made to improve care experiences for those with advanced HF. Even in the terminal stages, patients and caregivers are heavily and unnecessarily burdened by health care services that are poorly coordinated and offer fragmented care. There is evidence that these poor experiences could be improved to a large extent by simple organisational rather than complex clinical mechanisms.	[Browne, Susan; Macdonald, Sara; Mair, Frances S.] Univ Glasgow, Inst Hlth & Wellbeing MVLS, Gen Practice & Primary Care, Glasgow, Lanark, Scotland; [May, Carl R.] Univ Southampton, Fac Hlth Sci, Southampton, Hants, England; [Macleod, Una] Univ Hull, Hull York Med Sch, Kingston Upon Hull HU6 7RX, N Humberside, England	University of Glasgow; University of Southampton; University of Hull; University of York - UK	Mair, FS (corresponding author), Univ Glasgow, Inst Hlth & Wellbeing MVLS, Gen Practice & Primary Care, Glasgow, Lanark, Scotland.	Frances.Mair@glasgow.ac.uk	Macdonald, Sara/D-3340-2018; Morris, Josephine D./F-3366-2018	Macdonald, Sara/0000-0002-5380-6943; Morris, Josephine D./0000-0001-9404-5602; Browne, Susan/0000-0003-1785-1429; Mair, Frances/0000-0001-9780-1135; May, Carl/0000-0002-0451-2690	Marie Curie Cancer Care; British Heart Foundation; NHS Greater Glasgow and Clyde	Marie Curie Cancer Care; British Heart Foundation(British Heart Foundation); NHS Greater Glasgow and Clyde	This work was funded by the Caring Together programme (http://www.mariecurie.org.uk/caring), a partnership between Marie Curie Cancer Care, British Heart Foundation, and NHS Greater Glasgow and Clyde. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adler ED, 2009, CIRCULATION, V120, P2597, DOI 10.1161/CIRCULATIONAHA.109.869123; Allen LA, 2012, CIRCULATION, V125, P1928, DOI 10.1161/CIR.0b013e31824f2173; Barclay S., 2011, BRITISH JOURNAL OF G, V61, P582; Barnes S, 2006, J PAIN SYMPTOM MANAG, V32, P208, DOI 10.1016/j.jpainsymman.2006.04.005; Beattie JM, 2007, IMPLANTABLE CARDIOVE; Dev S, 2012, AM HEART J, V164, P313, DOI 10.1016/j.ahj.2012.05.023; Gadoud A, 2013, PALLIATIVE MED, V27, P822, DOI 10.1177/0269216313494960; Gallacher K, 2011, ANN FAM MED, V9, P235, DOI 10.1370/afm.1249; Haga K, 2012, HEART, V98, P579, DOI 10.1136/heartjnl-2011-301021; Hogg KJ, 2012, HEART, V98, P523, DOI 10.1136/heartjnl-2012-301753; Hunt SA, 2005, CIRCULATION, V112, pE154, DOI 10.1161/CIRCULATIONAHA.105.167586; Jaarsma T, 2009, EUR J HEART FAIL, V11, P433, DOI 10.1093/eurjhf/hfp041; Jhund PS, 2009, CIRCULATION, V119, P515, DOI 10.1161/CIRCULATIONAHA.108.812172; LeMond L, 2011, PROG CARDIOVASC DIS, V54, P168, DOI 10.1016/j.pcad.2011.03.012; Low J, 2011, J CARD FAIL, V17, P231, DOI 10.1016/j.cardfail.2010.10.003; May C, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2803; May C, 2009, SOCIOLOGY, V43, P535, DOI 10.1177/0038038509103208; May CR, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-29; McMurray JJV, 2012, EUR HEART J, V33, P1787, DOI 10.1093/eurheartj/ehs104; Metzger M, 2013, HEART LUNG, V42, P112, DOI 10.1016/j.hrtlng.2012.11.002; Momen Natalie C, 2011, Curr Opin Support Palliat Care, V5, P312, DOI 10.1097/SPC.0b013e32834b8c4d; Murray SA, 2002, BRIT MED J, V325, P929, DOI 10.1136/bmj.325.7370.929; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; Nordgren Lena, 2003, Eur J Cardiovasc Nurs, V2, P213; Ritchie J., 2003, GUIDE SOCIAL SCI STU, V1, P77; Rogers AE, 2000, BMJ-BRIT MED J, V321, P605, DOI 10.1136/bmj.321.7261.605; Shah AB, 2013, REV CARDIOVASC MED, V14, P41, DOI 10.3909/ricm0635; SIGN, 2007, GUID 95 MAN CHRON HE; Solano JP, 2006, J PAIN SYMPTOM MANAG, V31, P58, DOI 10.1016/j.jpainsymman.2005.06.007; Stewart S, 2001, EUR J HEART FAIL, V3, P315, DOI 10.1016/S1388-9842(00)00141-0; Stuart B, 2007, J PALLIAT MED, V10, P210, DOI 10.1089/jpm.2006.9988; Walke LM, 2006, J PAIN SYMPTOM MANAG, V31, P31, DOI 10.1016/j.jpainsymman.2005.05.014	32	64	66	2	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 27	2014	9	3							e93288	10.1371/journal.pone.0093288	http://dx.doi.org/10.1371/journal.pone.0093288			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE0SW	24676421	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000333677500104
J	Wonkam, A; Bitoungui, VJN; Vorster, AA; Ramesar, R; Cooper, RS; Tayo, B; Lettre, G; Ngogang, J				Wonkam, Ambroise; Bitoungui, Valentina J. Ngo; Vorster, Anna A.; Ramesar, Raj; Cooper, Richard S.; Tayo, Bamidele; Lettre, Guillaume; Ngogang, Jeanne			Association of Variants at BCL11A and HBS1L-MYB with Hemoglobin F and Hospitalization Rates among Sickle Cell Patients in Cameroon	PLOS ONE			English	Article							GENOME-WIDE ASSOCIATION; ACUTE CHEST SYNDROME; FETAL-HEMOGLOBIN; GENETIC-VARIATION; BETA-THALASSEMIA; ANEMIA PATIENTS; RISK-FACTORS; DISEASE; POPULATION; HAPLOTYPES	Background: Genetic variation at loci influencing adult levels of HbF have been shown to modify the clinical course of sickle cell disease (SCD). Data on this important aspect of SCD have not yet been reported from West Africa. We investigated the relationship between HbF levels and the relevant genetic loci in 610 patients with SCD (98% HbSS homozygotes) from Cameroon, and compared the results to a well-characterized African-American cohort. Methods and Findings: Socio-demographic and clinical features were collected and medical records reviewed. Only patients >5 years old, who had not received a blood transfusion or treatment with hydroxyurea were included. Hemoglobin electrophoresis and a full blood count were conducted upon arrival at the hospital. RFLP-PCR was used to describe the HBB gene haplotypes. SNaPshot PCR, Capillary electrophoresis and cycle sequencing were used for the genotyping of 10 selected SNPs. Genetic analysis was performed with PLINK software and statistical models in the statistical package R. Allele frequencies of relevant variants at BCL11A were similar to those detected in African Americans; although the relationships with Hb F were significant (p < .001), they explained substantially less of the variance in HbF than was observed among African Americans (similar to 2% vs 10%). SNPs in HBS1L-MYB region (HMIP) likewise had a significant impact on HbF, however, we did not find an association between HbF and the variations in HBB cluster and OR51B5/6 locus on chromosome 11p, due in part to the virtual absence of the Senegal and Indian Arab haplotypes. We also found evidence that selected SNPs in HBS1L-MYB region (HMIP) and BCL11A affect both other hematological indices and rates of hospitalization. Conclusions: This study has confirmed the associations of SNPs in BCL11A and HBS1L-MYB and fetal haemoglobin in Cameroonian SCA patients; hematological indices and hospitalization rates were also associated with specific allelic variants.	[Wonkam, Ambroise; Vorster, Anna A.; Ramesar, Raj] Univ Cape Town, Div Human Genet, Inst Infect Dis & Mol Med, Fac Hlth Sci, ZA-7925 Cape Town, South Africa; [Bitoungui, Valentina J. Ngo; Ngogang, Jeanne] Univ Yaounde I, Fac Med & Biomed Sci, Dept Microbiol Parasitol & Haematol, Yaounde, Cameroon; [Ramesar, Raj] Univ Cape Town, Fac Hlth Sci, Inst Infect Dis & Mol Med, UCT MRC Human Genet Res Unit,Div Human Genet, ZA-7925 Cape Town, South Africa; [Cooper, Richard S.; Tayo, Bamidele] Loyola Univ Chicago, Stritch Sch Med, Dept Publ Hlth Sci, Maywood, IL USA; [Lettre, Guillaume] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada; [Lettre, Guillaume] Univ Montreal, Montreal, PQ, Canada	University of Cape Town; University of Yaounde I; University of Cape Town; Loyola University Chicago; Universite de Montreal; Universite de Montreal	Wonkam, A (corresponding author), Univ Cape Town, Div Human Genet, Inst Infect Dis & Mol Med, Fac Hlth Sci, ZA-7925 Cape Town, South Africa.	ambroise.wonkam@uct.ac.za	Wonkam, Ambroise/AFU-6901-2022; Ramesar, Raj S/I-6941-2015	Ramesar, Raj S/0000-0001-5688-1634	National Health Laboratory Services (NHLS), South Africa; University of Cape Town (UCT) Research Committee; Carnegie Research Development Grant, South Africa; Third World Academy of Sciences (TWAS)	National Health Laboratory Services (NHLS), South Africa; University of Cape Town (UCT) Research Committee; Carnegie Research Development Grant, South Africa; Third World Academy of Sciences (TWAS)	The molecular experiments of the study were funded by the National Health Laboratory Services (NHLS), South Africa; the University of Cape Town (UCT) Research Committee and Carnegie Research Development Grant, South Africa. The students' bursaries were supported by the Third World Academy of Sciences (TWAS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bae HT, 2012, BLOOD, V120, P1961, DOI 10.1182/blood-2012-06-432849; Bartolucci P, 2012, CURR OPIN HEMATOL, V19, P149, DOI 10.1097/MOH.0b013e328351c35f; Bauer DE, 2013, SCIENCE, V342, P253, DOI 10.1126/science.1242088; Bean CJ, 2013, BRIT J HAEMATOL, V163, P268, DOI 10.1111/bjh.12507; Creary LE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004218; Elderdery AY, 2012, INT J LAB HEMATOL, V34, P262, DOI 10.1111/j.1751-553X.2011.01388.x; Farrell JJ, 2011, BLOOD, V117, P4935, DOI 10.1182/blood-2010-11-317081; Galarneau G, 2013, BLOOD, V122, P434, DOI 10.1182/blood-2013-01-478776; Garner C, 2000, BLOOD, V95, P342; Grosse SD, 2011, AM J PREV MED, V41, pS398, DOI 10.1016/j.amepre.2011.09.013; Hanchard N, 2007, BMC GENET, V8, DOI 10.1186/1471-2156-8-52; LABIE D, 1985, P NATL ACAD SCI USA, V82, P2111, DOI 10.1073/pnas.82.7.2111; Lettre G, 2008, P NATL ACAD SCI USA, V105, P11869, DOI 10.1073/pnas.0804799105; Makani J, 2011, BLOOD, V117, P1390, DOI 10.1182/blood-2010-08-302703; Menzel S, 2007, BLOOD, V110, P3624, DOI 10.1182/blood-2007-05-093419; Njamnshi AK, 2006, J NEUROL SCI, V250, P79, DOI 10.1016/j.jns.2006.07.003; Ondei LS, 2007, GENET MOL RES, V6, P453; Pati N, 2004, J BIOCHEM BIOPH METH, V60, P1, DOI 10.1016/j.jbbm.2003.11.005; Piel FB, 2013, LANCET, V381, P142, DOI 10.1016/S0140-6736(12)61229-X; Platt OS, 2008, NEW ENGL J MED, V358, P1362, DOI 10.1056/NEJMct0708272; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Ruffieux N, 2013, CHILD NEUROPSYCHOL, V19, P143, DOI 10.1080/09297049.2011.640932; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Solovieff N, 2010, BLOOD, V115, P1815, DOI 10.1182/blood-2009-08-239517; STEINBERG MH, 1984, BLOOD, V63, P1353; Steinberg MH, 1998, AM J HEMATOL, V59, P121, DOI 10.1002/(SICI)1096-8652(199810)59:2<121::AID-AJH4>3.0.CO;2-#; Thein SL, 2007, P NATL ACAD SCI USA, V104, P11346, DOI 10.1073/pnas.0611393104; Thein SL, 2009, BRIT J HAEMATOL, V145, P455, DOI 10.1111/j.1365-2141.2009.07650.x; Uda M, 2008, P NATL ACAD SCI USA, V105, P1620, DOI 10.1073/pnas.0711566105; Weatherall DJ, 2001, B WORLD HEALTH ORGAN, V79, P704; Wonkam A, 2013, J GENETIC COUNSELING; World Bank, 2010, 48373CM WORLD BANK, P1; Xu J, 2011, SCIENCE, V334, P993, DOI 10.1126/science.1211053	35	67	69	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2014	9	3							e92506	10.1371/journal.pone.0092506	http://dx.doi.org/10.1371/journal.pone.0092506			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE0SD	24667352	Green Published, Green Submitted, gold			2023-01-03	WOS:000333675600044
J	Gyllensten, H; Hakkarainen, KM; Hagg, S; Carlsten, A; Petzold, M; Rehnberg, C; Jonsson, AK				Gyllensten, Hanna; Hakkarainen, Katja M.; Hagg, Staffan; Carlsten, Anders; Petzold, Max; Rehnberg, Clas; Jonsson, Anna K.			Economic Impact of Adverse Drug Events - A Retrospective Population-Based Cohort Study of 4970 Adults	PLOS ONE			English	Article							COSTS; ADMISSIONS	Background: The aim was to estimate the direct costs caused by ADEs, including costs for dispensed drugs, primary care, other outpatient care, and inpatient care, and to relate the direct costs caused by ADEs to the societal COI (direct and indirect costs), for patients with ADEs and for the entire study population. Methods: We conducted a population-based observational retrospective cohort study of ADEs identified from medical records. From a random sample of 5025 adults in a Swedish county council, 4970 were included in the analyses. During a three-month study period in 2008, direct and indirect costs were estimated from resource use identified in the medical records and from register data on costs for resource use. Results: Among 596 patients with ADEs, the average direct costs per patient caused by ADEs were USD 444.9 [95% CI: 264.4 to 625.3], corresponding to USD 21 million per 100 000 adult inhabitants per year. Inpatient care accounted for 53.9% of all direct costs caused by ADEs. For patients with ADEs, the average societal cost of illness was USD 6235.0 [5442.8 to 7027.2], of which direct costs were USD 2830.1 [2260.7 to 3399.4] (45%), and indirect costs USD 3404.9 [2899.3 to 3910.4] (55%). The societal cost of illness was higher for patients with ADEs compared to other patients. ADEs caused 9.5% of all direct healthcare costs in the study population. Conclusions: Healthcare costs for patients with ADEs are substantial across different settings; in primary care, other outpatient care and inpatient care. Hence the economic impact of ADEs will be underestimated in studies focusing on inpatient ADEs alone. Moreover, the high proportion of indirect costs in the societal COI for patients with ADEs suggests that the observed costs caused by ADEs would be even higher if including indirect costs. Additional studies are needed to identify interventions to prevent and manage ADEs.	[Gyllensten, Hanna; Hakkarainen, Katja M.; Carlsten, Anders] Nord Sch Publ Hlth NHV, Gothenburg, Sweden; [Gyllensten, Hanna; Hakkarainen, Katja M.] Univ Gothenburg, Sahlgrenska Acad, Dept Publ Hlth & Community Med, Sect Social Med, Gothenburg, Sweden; [Hagg, Staffan; Jonsson, Anna K.] Linkoping Univ, Fac Hlth Sci, Dept Drug Res Clin Pharmacol, Linkoping, Sweden; [Hagg, Staffan] Jonkoping Cty Council, Futurum Acad Hlth & Care, Jonkoping, Sweden; [Carlsten, Anders] Med Prod Agcy, Uppsala, Sweden; [Petzold, Max] Univ Gothenburg, Sahlgrenska Acad, Ctr Appl Biostat Occupat & Environm Med, Akad Stat, Gothenburg, Sweden; [Rehnberg, Clas] Karolinska Inst, Dept Learning Informat Management & Eth LIME, Stockholm, Sweden; [Jonsson, Anna K.] Cty Council Ostergotland, Dept Clin Pharmacol, Linkoping, Sweden	University of Gothenburg; Linkoping University; Futurum; Medical Products Agency; University of Gothenburg; Karolinska Institutet; City Council Ostergotland	Gyllensten, H (corresponding author), Nord Sch Publ Hlth NHV, Gothenburg, Sweden.	hanna.gyllensten@nhv.se	Hägg, Staffan/G-5612-2013; Gyllensten, Hanna/H-7378-2016	Hägg, Staffan/0000-0002-5137-8420; Gyllensten, Hanna/0000-0001-6890-5162; Rehnberg, Clas/0000-0001-5326-450X	National Corporation of Swedish Pharmacies (Apoteket AB); Region Vastra Gotaland; Ostergotland County Council	National Corporation of Swedish Pharmacies (Apoteket AB); Region Vastra Gotaland; Ostergotland County Council	The research was funded by an unrestricted grant from the National Corporation of Swedish Pharmacies (Apoteket AB). Additional funding was received from Region Vastra Gotaland and Ostergotland County Council. The study sponsor had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The research was conducted independently from the sponsor.	Anell Anders, 2012, Health Syst Transit, V14, P1; BATES DW, 1995, J GEN INTERN MED, V10, P199, DOI 10.1007/BF02600255; EINARSON TR, 1993, ANN PHARMACOTHER, V27, P832, DOI 10.1177/106002809302700702; Gyllensten H, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002574; Gyllensten H, 2012, DRUG SAFETY, V35, P207, DOI 10.2165/11597090-000000000-00000; Hakkarainen KM, 2013, BR J CLIN P IN PRESS, DOI [10.1111/bcp.12314, DOI 10.1111/BCP.12314:IN]; HALLAS J, 1990, J INTERN MED, V228, P83, DOI 10.1111/j.1365-2796.1990.tb00199.x; Hohl CM, 2011, ANN EMERG MED, V58, P270, DOI 10.1016/j.annemergmed.2011.01.003; Hoonhout LHF, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-27; Howard RL, 2003, QUAL SAF HEALTH CARE, V12, P280, DOI 10.1136/qhc.12.4.280; Hug BL, 2012, JT COMM J QUAL PATIE, V38, P120, DOI 10.1016/S1553-7250(12)38016-1; Krahenbuhl-Melcher A, 2007, DRUG SAFETY, V30, P379; Nordic Centre for Classifications in Health Care, NORD CTR CLASS HLTH; RICE DP, 1967, AM J PUBLIC HEALTH N, V57, P424, DOI 10.2105/AJPH.57.3.424; Rodriguez-Monguio R, 2003, PHARMACOECONOMICS, V21, P623, DOI 10.2165/00019053-200321090-00002; Segel J. E., 2006, RTI UNC CTR EXCELLEN, P1; Statistics Sweden, STAT FOLKM EFT REG C; Statistics Sweden, 2013, STAT GEN GRUND MAN S; Sveriges Riksbank, SVER RIKSB ARSG VAL; Swedish Tax Agency, 2007, SKATT SVER SKATT ARS; Tafreshi MJ, 1999, ANN PHARMACOTHER, V33, P1252, DOI 10.1345/aph.19062	21	35	35	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 17	2014	9	3							e92061	10.1371/journal.pone.0092061	http://dx.doi.org/10.1371/journal.pone.0092061			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AD4XD	24637879	gold, Green Submitted, Green Published			2023-01-03	WOS:000333254100109
J	Di Marco, F; Di Paolo, M; Romeo, S; Colecchi, L; Fiorani, L; Spana, S; Stone, J; Bisti, S				Di Marco, Fabiana; Di Paolo, Mattia; Romeo, Stefania; Colecchi, Linda; Fiorani, Lavinia; Spana, Sharon; Stone, Jonathan; Bisti, Silvia			Combining Neuroprotectants in a Model of Retinal Degeneration: No Additive Benefit	PLOS ONE			English	Article							SAFFRON SUPPLEMENTATION; LIGHT; PHOTOBIOMODULATION; DEATH; MECHANISMS; SURVIVAL; OXYGEN	The central nervous system undergoing degeneration can be stabilized, and in some models can be restored to function, by neuroprotective treatments. Photobiomodulation (PBM) and dietary saffron are distinctive as neuroprotectants in that they upregulate protective mechanisms, without causing measurable tissue damage. This study reports a first attempt to combine the actions of PBM and saffron. Our working hypothesis was that the actions of PBM and saffron in protecting retinal photoreceptors, in a rat light damage model, would be additive. Results confirmed the neuroprotective potential of each used separately, but gave no evidence that their effects are additive. Detailed analysis suggests that there is actually a negative interaction between PBM and saffron when given simultaneously, with a consequent reduction of the neuroprotection. Specific testing will be required to understand the mechanisms involved and to establish whether there is clinical potential in combining neuroprotectants, to improve the quality of life of people affected by retinal pathology, such as age-related macular degeneration, the major cause of blindness and visual impairment in older adults.	[Di Marco, Fabiana; Di Paolo, Mattia; Romeo, Stefania; Colecchi, Linda; Fiorani, Lavinia; Bisti, Silvia] Univ Aquila, Dept Biotechnol & Appl Clin Sci, I-67100 Laquila, Italy; [Spana, Sharon; Stone, Jonathan] Univ Sydney, Discipline Physiol, Sydney, NSW 2006, Australia; [Spana, Sharon; Stone, Jonathan] Univ Sydney, Bosch Inst, Sydney, NSW 2006, Australia; [Stone, Jonathan; Bisti, Silvia] Australian Natl Univ, ARC Ctr Excellence Vis Sci, Canberra, ACT, Australia	University of L'Aquila; University of Sydney; University of Sydney; Australian National University	Di Marco, F (corresponding author), Univ Aquila, Dept Biotechnol & Appl Clin Sci, I-67100 Laquila, Italy.	dm.fabiana@hotmail.it			Australian Research Council Centre of Excellence in Vision Science; Sir Zelman Cowen Universities Fund; Lord Mayor's Charitable Foundation; Australian Travel Awards for L'Aquila Researchers (ARIA); Ministero dell'Istruzione, dell'Universita e della Ricerca dedicato ai PRIN, Progetti di Ricerca di Interesse Nazionale (MIUR-PRIN)	Australian Research Council Centre of Excellence in Vision Science(Australian Research Council); Sir Zelman Cowen Universities Fund; Lord Mayor's Charitable Foundation; Australian Travel Awards for L'Aquila Researchers (ARIA); Ministero dell'Istruzione, dell'Universita e della Ricerca dedicato ai PRIN, Progetti di Ricerca di Interesse Nazionale (MIUR-PRIN)	This work was supported by the Australian Research Council Centre of Excellence in Vision Science, by the Sir Zelman Cowen Universities Fund and the Lord Mayor's Charitable Foundation, by Australian Travel Awards for L'Aquila Researchers (ARIA) to FDM and SR and by a Ministero dell'Istruzione, dell'Universita e della Ricerca dedicato ai PRIN, Progetti di Ricerca di Interesse Nazionale (MIUR-PRIN) (2010-2011) research grant to SB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albarracin R, 2011, INVEST OPHTH VIS SCI, V52, P3582, DOI 10.1167/iovs.10-6664; Begum R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057828; Bisti S, 2014, VISUAL NEUROSCI, V12, P1; Bowers F, 2001, INVEST OPHTH VIS SCI, V42, P804; Di Marco F, 2013, AM J NEURODEGENER DI, V2, P208; Eells JT, 2008, LECT NOTES ELECTR EN, V12, P39; Falsini B, 2010, INVEST OPHTH VIS SCI, V51, P6118, DOI 10.1167/iovs.09-4995; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Giaccio M, 2004, CRIT REV FOOD SCI, V44, P155, DOI 10.1080/10408690490441433; Maccarone R, 2008, INVEST OPHTH VIS SCI, V49, P1254, DOI 10.1167/iovs.07-0438; Marangoni D, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-228; Maslim J, 1997, INVEST OPHTH VIS SCI, V38, P1667; Natoli R, 2010, MOL VIS, V16, P1801; Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004; Purushothuman S, 2013, BRAIN RES, V1535, P61, DOI 10.1016/j.brainres.2013.08.047; Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-257; Stone J, 1999, PROG RETIN EYE RES, V18, P689, DOI 10.1016/S1350-9462(98)00032-9	17	12	13	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 23	2014	9	6							e100389	10.1371/journal.pone.0100389	http://dx.doi.org/10.1371/journal.pone.0100389			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AL1WV	24955576	Green Submitted, Green Published, gold			2023-01-03	WOS:000338917900046
J	Cohen, RL; Settleman, J				Cohen, Robert L.; Settleman, Jeff			From Cancer Genomics to Precision Oncology-Tissue's Still an Issue	CELL			English	Article							ABL TYROSINE KINASE; CELL LUNG-CANCER; TARGETED THERAPY; INHIBITION; MULTICENTER; SORAFENIB; MELANOMA; SURVIVAL; LABEL	Rapidly evolving genome technology has enabled extensive molecular analysis of limited tumor biopsy material, thereby facilitating the broader implementation of personalized cancer medicine. However, genomics-based patient stratification across diverse tumor types is unlikely to supplant tissue-of-origin considerations in addressing clinical needs, including the development and application of novel "rationally targeted" cancer therapies.	[Cohen, Robert L.] Calico Life Sci, San Francisco, CA 94080 USA; [Settleman, Jeff] Genentech Inc, San Francisco, CA 94080 USA	Roche Holding; Genentech	Settleman, J (corresponding author), Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.	settleman.jeffrey@gene.com						AACR Cancer Progress Report Writing Committee, 2013, Clin Cancer Res, V19, pS4, DOI 10.1158/1078-0432.CCR-13-2107; Bauml J, 2013, CLIN LUNG CANCER, V14, P581, DOI 10.1016/j.cllc.2013.05.002; Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Crowther M, 2013, HEMATOL-AM SOC HEMAT, P15, DOI 10.1182/asheducation-2013.1.15; Custodio A, 2013, CRIT REV ONCOL HEMAT, V85, P45, DOI 10.1016/j.critrevonc.2012.05.001; Dancey JE, 2012, CELL, V148, P409, DOI 10.1016/j.cell.2012.01.014; Dietrich S, 2012, NEW ENGL J MED, V366, P2038, DOI 10.1056/NEJMc1202124; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Eifert C, 2012, NAT REV CANCER, V12, P572, DOI 10.1038/nrc3299; Eisen T, 2006, BRIT J CANCER, V95, P581, DOI 10.1038/sj.bjc.6603291; Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655; Figueroa-Magalhaes MC, 2014, BREAST, V23, P128, DOI 10.1016/j.breast.2013.11.011; Garraway LA, 2013, J CLIN ONCOL, V31, P1803, DOI 10.1200/JCO.2013.49.4799; Heng DYC, 2008, CURR CANCER DRUG TAR, V8, P676, DOI 10.2174/156800908786733450; Horning SJ, 2013, CLIN CANCER RES, V19, P4297, DOI 10.1158/1078-0432.CCR-13-0523; Iyer R, 2010, EXPERT OPIN PHARMACO, V11, P1943, DOI 10.1517/14656566.2010.496453; Minuti G, 2013, EXPERT OPIN BIOL TH, V13, P1401, DOI 10.1517/14712598.2013.827657; Monzon FA, 2009, J CLIN ONCOL, V27, P2503, DOI 10.1200/JCO.2008.17.9762; Mullighan CG, 2012, J CLIN INVEST, V122, P3407, DOI 10.1172/JCI61203; Mullins CD, 2012, J CLIN ONCOL, V30, P661, DOI 10.1200/JCO.2011.35.5198; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Sauter G, 2009, J CLIN ONCOL, V27, P1323, DOI 10.1200/JCO.2007.14.8197; Tiacci E, 2011, NEW ENGL J MED, V364, P2305, DOI 10.1056/NEJMoa1014209; Willyard C, 2013, NAT MED, V19, P655, DOI 10.1038/nm0613-655	28	21	26	1	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 19	2014	157	7					1509	1514		10.1016/j.cell.2014.05.027	http://dx.doi.org/10.1016/j.cell.2014.05.027			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	AN9QG	24949964	Bronze			2023-01-03	WOS:000340941900007
J	Pahor, M; Guralnik, JM; Ambrosius, WT; Blair, S; Bonds, DE; Church, TS; Espeland, MA; Fielding, RA; Gill, TM; Groessl, EJ; King, AC; Kritchevsky, SB; Manini, TM; McDermott, MM; Miller, ME; Newman, AB; Rejeski, WJ; Sink, KM; Williamson, JD				Pahor, Marco; Guralnik, Jack M.; Ambrosius, Walter T.; Blair, Steven; Bonds, Denise E.; Church, Timothy S.; Espeland, Mark A.; Fielding, Roger A.; Gill, Thomas M.; Groessl, Erik J.; King, Abby C.; Kritchevsky, Stephen B.; Manini, Todd M.; McDermott, Mary M.; Miller, Michael E.; Newman, Anne B.; Rejeski, W. Jack; Sink, Kaycee M.; Williamson, Jeff D.		LIFE Study Investigators	Effect of Structured Physical Activity on Prevention of Major Mobility Disability in Older Adults The LIFE Study Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOWER-EXTREMITY FUNCTION; STYLE INTERVENTIONS; KNEE OSTEOARTHRITIS; GAIT SPEED; INDEPENDENCE; PERFORMANCE; ELDERS; PREDICTORS; MORTALITY; LIMITATION	IMPORTANCE In older adults reduced mobility is common and is an independent risk factor for morbidity, hospitalization, disability, and mortality. Limited evidence suggests that physical activity may help prevent mobility disability; however, there are no definitive clinical trials examining whether physical activity prevents or delays mobility disability. OBJECTIVE To test the hypothesis that a long-term structured physical activity program is more effective than a health education program (also referred to as a successful aging program) in reducing the risk of major mobility disability. DESIGN, SETTING, AND PARTICIPANTS The Lifestyle Interventions and Independence for Elders (LIFE) study was a multicenter, randomized trial that enrolled participants between February 2010 and December 2011, who participated for an average of 2.6 years. Follow-up ended in December 2013. Outcome assessors were blinded to the intervention assignment. Participants were recruited from urban, suburban, and rural communities at 8 centers throughout the United States. We randomized a volunteer sample of 1635 sedentary men and women aged 70 to 89 years who had physical limitations, defined as a score on the Short Physical Performance Battery of 9 or below, but were able to walk 400 m. INTERVENTIONS Participants were randomized to a structured, moderate-intensity physical activity program (n = 818) conducted in a center (twice/wk) and at home (3-4 times/wk) that included aerobic, resistance, and flexibility training activities or to a health education program (n = 817) consisting of workshops on topics relevant to older adults and upper extremity stretching exercises. MAIN OUTCOMES AND MEASURES The primary outcome was major mobility disability objectively defined by loss of ability to walk 400 m. RESULTS Incident major mobility disability occurred in 30.1%(246 participants) of the physical activity group and 35.5%(290 participants) of the health education group (hazard ratio [HR], 0.82 [95% CI, 0.69-0.98], P = .03). Persistent mobility disability was experienced by 120 participants (14.7%) in the physical activity group and 162 participants (19.8%) in the health education group (HR, 0.72 [95% CI, 0.57-0.91]; P = .006). Serious adverse events were reported by 404 participants (49.4%) in the physical activity group and 373 participants (45.7%) in the health education group (risk ratio, 1.08 [95% CI, 0.98-1.20]). CONCLUSIONS AND RELEVANCE A structured, moderate-intensity physical activity program compared with a health education program reduced major mobility disability over 2.6 years among older adults at risk for disability. These findings suggest mobility benefit from such a program in vulnerable older adults.	[Pahor, Marco; Guralnik, Jack M.; Manini, Todd M.] Univ Florida, Dept Aging & Geriatr Res, Gainesville, FL 32610 USA; [Guralnik, Jack M.] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA; [Ambrosius, Walter T.; Espeland, Mark A.; Kritchevsky, Stephen B.; Miller, Michael E.; Rejeski, W. Jack; Sink, Kaycee M.; Williamson, Jeff D.] Wake Forest Univ, Dept Internal Med, Winston Salem, NC 27109 USA; [Ambrosius, Walter T.; Espeland, Mark A.; Kritchevsky, Stephen B.; Miller, Michael E.; Rejeski, W. Jack; Sink, Kaycee M.; Williamson, Jeff D.] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA; [Blair, Steven] Univ S Carolina, Dept Exercise Sci, Arnold Sch Publ Hlth, Columbia, SC 29208 USA; [Bonds, Denise E.] NHLBI, Div Cardiac Sci, Bethesda, MD 20892 USA; [Church, Timothy S.] Pennington Biomed Res Ctr, Dept Preventat Med, Baton Rouge, LA USA; [Fielding, Roger A.] Tufts Univ, Jean Mayer US Dept, Agr Human Nutr Res Ctr Aging, Boston, MA 02111 USA; [Gill, Thomas M.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; [Groessl, Erik J.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA; [Groessl, Erik J.] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA; [King, Abby C.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA; [King, Abby C.] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA; [McDermott, Mary M.] Northwestern Univ, Dept Med & Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA; [Newman, Anne B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA	State University System of Florida; University of Florida; University System of Maryland; University of Maryland Baltimore; Wake Forest University; Wake Forest University; Wake Forest Baptist Medical Center; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Tufts University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of California System; University of California San Diego; Stanford University; Stanford University; Northwestern University; Feinberg School of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Pahor, M (corresponding author), Univ Florida, Dept Aging & Geriatr Res, POB 100107, Gainesville, FL 32610 USA.	mpahor@ufl.edu	Sink, Kaycee/AAY-5920-2020; Beavers, Daniel P/G-5338-2016; Buford, Thomas W/B-1111-2011; Gill, Thomas M./H-7043-2019; Newman, Anne B./C-6408-2013; King, Abby/AAD-5257-2021	Buford, Thomas W/0000-0002-9541-4358; Gill, Thomas M./0000-0002-6450-0368; Newman, Anne B./0000-0002-0106-1150; Kaplan, Robert/0000-0003-4837-5330; King, Abby/0000-0002-7949-8811; Marsiske, Michael/0000-0001-5973-2116; Handberg, Eileen/0000-0002-7805-9577	National Institutes of Health (NIH) [UO1AG22376]; National Institute on Aging; National Heart, Lung, and Blood Institute [3U01AG022376-05A2S]; Intramural Research Program; Claude D. Pepper Older Americans Independence Centers at the University of Florida [1 P30 AG028740]; Wake Forest University [1 P30 AG21332]; Tufts University [1P30AG031679]; University of Pittsburgh [P30 AG024827]; Yale University [P30AG021342]; NIH/NCRR CTSA at Stanford University [UL1 RR025744]; NIH/NCRR CTSA at University of Florida [U54RR025208]; NIH/NCRR CTSA at Yale University [UL1 TR000142]; Boston Rehabilitation Outcomes Center [1R24HD065688-01A1]; National Institute on Aging [K07AG3587]; Department of Veterans Affairs; US Department of Agriculture [58-1950-0-014]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R24HD065688] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000064, UL1TR000142] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025744, UL1RR029890] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL121023] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG021332, P30AG024827, U01AG022376, P30AG021342, P30AG031679, P30AG028740] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Intramural Research Program; Claude D. Pepper Older Americans Independence Centers at the University of Florida; Wake Forest University; Tufts University; University of Pittsburgh(University of Pittsburgh); Yale University; NIH/NCRR CTSA at Stanford University; NIH/NCRR CTSA at University of Florida; NIH/NCRR CTSA at Yale University; Boston Rehabilitation Outcomes Center; National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Department of Veterans Affairs(US Department of Veterans Affairs); US Department of Agriculture(United States Department of Agriculture (USDA)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The Lifestyle Interventions and Independence for Elders Study is funded by cooperative agreement UO1AG22376 from the National Institutes of Health (NIH) and National Institute on Aging; supplement 3U01AG022376-05A2S from the National Heart, Lung, and Blood Institute; and was sponsored in part by the Intramural Research Program. The research is partially supported by the Claude D. Pepper Older Americans Independence Centers at the University of Florida (1 P30 AG028740), Wake Forest University (1 P30 AG21332), Tufts University (1P30AG031679), University of Pittsburgh (P30 AG024827), and Yale University (P30AG021342) and the NIH/NCRR CTSA at Stanford University (UL1 RR025744), at University of Florida (U54RR025208) and at Yale University (UL1 TR000142). Tufts University is also supported by the Boston Rehabilitation Outcomes Center (1R24HD065688-01A1). LIFE investigators are also partially supported by the following: Dr Thomas Gill (Yale University) is the recipient of an Academic Leadership Award (K07AG3587) from the National Institute on Aging. Dr Carlos Fragoso (Spirometry Reading Center, Yale University) is the recipient of a Career Development Award from the Department of Veterans Affairs. Dr Roger Fielding (Tufts University) is partially supported by the US Department of Agriculture, under agreement 58-1950-0-014.	Andresen EM, 1998, MED CARE, V36, P1349, DOI 10.1097/00005650-199809000-00007; Berry Michael J, 2003, J Cardiopulm Rehabil, V23, P60, DOI 10.1097/00008483-200301000-00011; Borg G., 1988, PERCEIVED EXERTION P; BRANCH LG, 1982, AM J PUBLIC HEALTH, V72, P1373, DOI 10.2105/AJPH.72.12.1373; BRANCH LG, 1991, J GERONTOL, V46, pM145, DOI 10.1093/geronj/46.4.M145; CORTI MC, 1994, JAMA-J AM MED ASSOC, V272, P1036, DOI 10.1001/jama.272.13.1036; Ettinger WH, 1997, JAMA-J AM MED ASSOC, V277, P25, DOI 10.1001/jama.277.1.25; Fielding RA, 2011, J GERONTOL A-BIOL, V66, P1226, DOI 10.1093/gerona/glr123; Guralnik JM, 2000, J GERONTOL A-BIOL, V55, pM221, DOI 10.1093/gerona/55.4.M221; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; GURALNIK JM, 1993, AM J EPIDEMIOL, V137, P845, DOI 10.1093/oxfordjournals.aje.a116746; Hirvensalo M, 2000, J AM GERIATR SOC, V48, P493, DOI 10.1111/j.1532-5415.2000.tb04994.x; KATZ S, 1983, NEW ENGL J MED, V309, P1218, DOI 10.1056/NEJM198311173092005; Khokhar SR, 2001, J AM GERIATR SOC, V49, P1539, DOI 10.1046/j.1532-5415.2001.4911251.x; Lampinen P, 2003, AGING CLIN EXP RES, V15, P205; LONERGAN ET, 1991, NEW ENGL J MED, V324, P1825, DOI 10.1056/NEJM199106203242527; Marsh AP, 2013, J GERONTOL A-BIOL, V68, P1549, DOI 10.1093/gerona/glt064; Matthews CE, 2005, MED SCI SPORT EXER, V37, pS512, DOI 10.1249/01.mss.0000185659.11982.3d; Messier SP, 2004, ARTHRITIS RHEUM-US, V50, P1501, DOI 10.1002/art.20256; Newman AB, 2006, JAMA-J AM MED ASSOC, V295, P2018, DOI 10.1001/jama.295.17.2018; Pahor M, 2006, J GERONTOL A-BIOL, V61, P1157; Physical Activity Guidelines Advisory Committee, 2008, PHYS ACT GUID ADV CO; Rejeski WJ, 2013, CLIN INTERV AGING, V8, P657, DOI 10.2147/CIA.S44797; Rolland YM, 2004, J AM GERIATR SOC, V52, P972, DOI 10.1111/j.1532-5415.2004.52267.x; Shumway-Cook A, 2003, J AM GERIATR SOC, V51, P393, DOI 10.1046/j.1532-5415.2003.51114.x; Shumway-Cook A, 2002, PHYS THER, V82, P670, DOI 10.1093/ptj/82.7.670; Stewart AL, 2001, J GERONTOL A-BIOL, V56, pM465, DOI 10.1093/gerona/56.8.M465; Studenski S, 2011, JAMA-J AM MED ASSOC, V305, P50, DOI 10.1001/jama.2010.1923; Szanton SL, 2009, BIOL RES NURS, V10, P248, DOI 10.1177/1099800408323452; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; Therneau T.M., 2000, STAT BIOL HEALTH, DOI 10.1007/978-1-4757-3294-8; van der Wal WM, 2011, J STAT SOFTW, V43, P1; Werner CA, OLDER POPULATION	33	845	855	16	208	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	2014	311	23					2387	2396		10.1001/jama.2014.5616	http://dx.doi.org/10.1001/jama.2014.5616			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AI9XV	24866862	Green Accepted			2023-01-03	WOS:000337301500019
J	Liang, Y; Zhou, YY; Zhang, JW; Rao, T; Zhou, LJ; Xing, R; Wang, Q; Fu, HX; Hao, K; Xie, L; Wang, GJ				Liang, Yan; Zhou, Yuanyuan; Zhang, Jingwei; Rao, Tai; Zhou, Lijun; Xing, Rong; Wang, Qian; Fu, Hanxu; Hao, Kun; Xie, Lin; Wang, Guangji			Pharmacokinetic Compatibility of Ginsenosides and Schisandra Lignans in Shengmai-san: From the Perspective of P-Glycoprotein	PLOS ONE			English	Article							TRADITIONAL CHINESE MEDICINE; INTESTINAL CACO-2 CELLS; IN-VITRO; CYCLOSPORINE-A; RATS; ABSORPTION; TRANSPORT; EXTRACT; EFFLUX; INJURY	Background: Phytochemical-mediated alterations in P-glycoprotein (P-gp) activity may result in herb-drug interactions by altering drug pharmacokinetics. Shengmai-san, a traditional Chinese herbal medicine composed by Panax Ginseng, Ophiopogon Japonicus, and Schisandra Chinensis, is routinely being used for treating various coronary heart diseases. In our previous studies, Schisandra Lignans Extract (SLE) was proved as a strong P-gp inhibitor, and herein, the compatibility of Shengmai-san was studied by investigating the influence of SLE on the pharmacokinetics of the ginsenosides from the perspective of P-gp. Methodology: Pharmacokinetic experiments were firstly performed based on in vitro uptake, efflux and transport experiments in Caco-2, LLC-PK1 wild-type and MDR1-overexpressing L-MDR1 cells. During the whole experiment, digoxin, a classical P-gp substrate, was used as a positive control drug to verify the cells used are the valid models. Meanwhile, the effects of SLE on the pharmacokinetics of ginsenosides were further investigated in rats after single-dose and multi-dose of SLE. Results and Conclusions: The efflux ratios of ginsenoside Rb2, Rc, Rg2, Rg3, Rd and Rb1 were found more than 3.5 in L-MDR1 cells and can be decreased significantly by verapamil (a classical P-gp inhibitor). Contrarily, the efflux ratios of other ginsenosides (Rh1, F1, Re, and Rg1) were lower than 2.0 and not affected by verapamil. Then, the effects of SLE on the uptake and transport of ginsenosides were investigated, and SLE was found can significantly enhance the uptake and inhibit the efflux ratio of ginsenoside Rb2, Rc, Rg2, Rg3, Rd and Rb1 in Caco-2 and L-MDR1 cells. Besides, In vivo experiments showed that single-dose and multi-dose of SLE at 500 mg/kg could increase the area under the plasma concentration time curve of Rb2, Rc and Rd significantly without affecting terminal elimination half-time. In conclusion, SLE could enhance the exposure of ginsenosides Rb2, Rc, Rg2, Rg3, Rd and Rb1 significantly.	[Liang, Yan; Zhou, Yuanyuan; Zhang, Jingwei; Rao, Tai; Zhou, Lijun; Xing, Rong; Wang, Qian; Fu, Hanxu; Hao, Kun; Xie, Lin; Wang, Guangji] China Pharmaceut Univ, Key Lab Drug Metab & Pharmacokinet, Nanjing, Jiangsu, Peoples R China	China Pharmaceutical University	Xie, L (corresponding author), China Pharmaceut Univ, Key Lab Drug Metab & Pharmacokinet, Nanjing, Jiangsu, Peoples R China.	jsxielin@sina.com.cn; guangjiwang@hotmail.com	Zhou, Li/GSE-4531-2022		National Nature Science Foundation [81102881, 81273589, 81374054]; Natural Science Foundation of Jiangsu Province [BK20131311]	National Nature Science Foundation(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province)	This study was supported by the National Nature Science Foundation (81102881, 81273589, 81374054), Natural Science Foundation of Jiangsu Province (Grants BK20131311). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Angela PA, 2000, J NUTR, V130, P1329; Bao Hong, 2010, Chin J Cancer, V29, P937; Cao HJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081650; Chen CY, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/703815; Fan L, 2009, XENOBIOTICA, V39, P249, DOI 10.1080/00498250802687657; Feng Y, 2006, ARTIF INTELL MED, V38, P219, DOI 10.1016/j.artmed.2006.07.005; Gnoth MJ, 2011, J PHARMACOL EXP THER, V338, P372, DOI 10.1124/jpet.111.180240; Han M, 2006, PLANTA MED, V72, P398, DOI 10.1055/s-2005-916211; Hashiguchi Y, 2013, BIOCHEM BIOPH RES CO, V439, P221, DOI 10.1016/j.bbrc.2013.08.054; Hoenders H J R, 2006, Tijdschr Psychiatr, V48, P733; Kim SW, 2003, BIOCHEM PHARMACOL, V65, P75, DOI 10.1016/S0006-2952(02)01446-6; Li LH, 2013, CHIN J NAT MEDICINES, V11, P222, DOI [10.1016/S1875-5364(13)60020-5, 10.3724/SP.J.1009.2013.00222]; Liang Y, 2013, PHYTOMEDICINE, V20, P1030, DOI 10.1016/j.phymed.2013.04.005; Lin TX, 2009, DTSCH Z AKUPUNKT, V52, P27, DOI 10.1016/J.DZA.2009.05.008; Liu HF, 2009, DRUG METAB DISPOS, V37, P2290, DOI 10.1124/dmd.109.029819; Meng Z, 2007, BIOMED CHROMATOGR, V21, P635, DOI 10.1002/bmc.799; Mills E, 2005, THER DRUG MONIT, V27, P549, DOI 10.1097/01.ftd.0000170880.95267.90; SCHINKEL AH, 1995, J CLIN INVEST, V96, P1698, DOI 10.1172/JCI118214; Seo TB, 2009, J PHARMACOL SCI, V110, P483, DOI 10.1254/jphs.09044FP; Wang J, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/896467; Wang L, 2008, P NATL ACAD SCI USA, V105, P4826, DOI 10.1073/pnas.0712365105; Wang SP, 2012, J ETHNOPHARMACOL, V143, P412, DOI 10.1016/j.jep.2012.07.033; Wang XJ, 2013, MOL CELL PROTEOMICS, V12, P1226, DOI 10.1074/mcp.M112.021683; Yang Z, 2012, DRUG METAB DISPOS, V40, P1538, DOI 10.1124/dmd.111.044008; Yao HT, 2008, J ETHNOPHARMACOL, V116, P49, DOI 10.1016/j.jep.2007.10.043; Yoo HH, 2007, PLANTA MED, V73, P444, DOI 10.1055/s-2007-967178; Yu CP, 2013, PHYTOMEDICINE, V20, P648, DOI 10.1016/j.phymed.2013.01.008; Zhang JM, 2013, J ETHNOPHARMACOL, V147, P128, DOI 10.1016/j.jep.2013.02.019; Zhang JW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035768; Zhang JZ, 2012, J ETHNOPHARMACOL, V144, P277, DOI 10.1016/j.jep.2012.09.009; Zhou SF, 2005, EUR J PHARM SCI, V24, P513, DOI 10.1016/j.ejps.2005.01.006	32	23	29	2	86	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2014	9	6							e98717	10.1371/journal.pone.0098717	http://dx.doi.org/10.1371/journal.pone.0098717			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK8TP	24922060	Green Published, gold, Green Submitted			2023-01-03	WOS:000338701300014
J	Clemens, A; Noack, H; Brueckmann, M; Lip, GYH				Clemens, Andreas; Noack, Herbert; Brueckmann, Martina; Lip, Gregory Y. H.			Twice- or Once-Daily Dosing of Novel Oral Anticoagulants for Stroke Prevention: A Fixed-Effects Meta-Analysis with Predefined Heterogeneity Quality Criteria	PLOS ONE			English	Article							FACTOR XA INHIBITOR; ATRIAL-FIBRILLATION; WARFARIN; PHARMACODYNAMICS; PHARMACOKINETICS; DABIGATRAN; APIXABAN; EDOXABAN; SAFETY; EFFICACY	Background: A number of novel oral anticoagulants (direct thrombin inhibitors or factor Xa inhibitors) are in clinical use for various indications. The dosing regimens differ between twice-daily and once-daily dosing for the prevention of stroke in patients with atrial fibrillation. With the availability of the results from four phase 3 studies (> 70,000 patients), we explored whether twice-daily or once-daily dosing provides better risk-benefit balance among novel oral anticoagulants. Methods: We conducted a strict, stepwise, fixed-effects meta-analysis with predefined heterogeneity quality criteria to generate the most appropriate common estimates for twice-daily (BID) or once-daily (QD) dosing regimens. An indirect comparison of these dosing regimens with fixed-effects meta-analysis common estimates (where available), or individual compound results, was done respectively. Results: Comparing indirectly BID vs QD dosing regimens resulted in hazard ratios (HR [95% confidence interval]) for stroke and systemic embolism of 0.75 (0.58-0.96) for dabigatran 150 mg BID, and 0.91 (0.73-1.13) for apixaban BID vs the QD dosing regimen. For ischemic stroke, the HR of BID vs QD was 0.85 (0.69-1.05). For intracranial hemorrhage, BID vs rivaroxaban QD was 0.57 (0.37-0.88) and, vs edoxaban QD, 0.81 (0.54-1.22). Due to heterogeneity, common estimates for major bleeding QD or BID were not justified, therefore indirect comparison of regimens were not possible. All non-vitamin K antagonist oral anticoagulants reduced all-cause mortality vs warfarin with a HR of 0.90 (0.86-0.96) without differences between regimen. Conclusions: Based on the available phase 3 study evidence, the twice-daily dosing regimen of non-vitamin K antagonist oral anticoagulants appears to offer a more balanced risk-benefit profile with respect to stroke prevention and intracranial hemorrhage.	[Clemens, Andreas] Univ Med Ctr Mainz, Ctr Thrombosis & Hemostasis, Mainz, Germany; [Clemens, Andreas] Boehringer Ingelheim Pharma GmbH & Co KG, Global Biostat & Data Management, Ingelheim, Germany; [Noack, Herbert; Brueckmann, Martina] Boehringer Ingelheim Pharma GmbH & Co KG, Corp Div Med, Global Therapeut Area Cardiovasc, Ingelheim, Germany; [Brueckmann, Martina] Heidelberg Univ, Fac Med Mannheim, Mannheim, Germany; [Lip, Gregory Y. H.] Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Birmingham, W Midlands, England	Johannes Gutenberg University of Mainz; Boehringer Ingelheim; Boehringer Ingelheim; Ruprecht Karls University Heidelberg; University of Birmingham	Clemens, A (corresponding author), Univ Med Ctr Mainz, Ctr Thrombosis & Hemostasis, Mainz, Germany.	andreas.clemens66@gmail.com		Noack, Herbert/0000-0002-3194-2039	Federal Ministry of Education and Research [BMBF 01EO1003]	Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF))	The Center for Thrombosis and Hemostasis, University Medical Center Mainz, Germany is supported by the Federal Ministry of Education and Research (BMBF 01EO1003). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8; Claxton AJ, 2001, CLIN THER, V23, P1296, DOI 10.1016/S0149-2918(01)80109-0; Clemens A, 2012, CURR MED RES OPIN, V28, P195, DOI 10.1185/03007995.2011.654109; Connolly SJ, 2010, NEW ENGL J MED, V363, P1875, DOI 10.1056/NEJMc1007378; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Francis KM, 2012, BLOOD, V120, DOI 10.1182/blood.V120.21.365.365; Frost C, 2013, BRIT J CLIN PHARMACO, V76, P776, DOI 10.1111/bcp.12106; Giugliano RP, 2013, NEW ENGL J MED, V369, P2093, DOI 10.1056/NEJMoa1310907; Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039; Hardy RJ, 1998, STAT MED, V17, P841, DOI 10.1002/(SICI)1097-0258(19980430)17:8<841::AID-SIM781>3.0.CO;2-D; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Jackson D, 2006, STAT MED, V25, P2688, DOI 10.1002/sim.2481; Lopes RD, 2010, AM HEART J, V159, P331, DOI 10.1016/j.ahj.2009.07.035; Mueck W, 2008, THROMB HAEMOSTASIS, V100, P453, DOI 10.1160/07-12-0714; Mueck W, 2014, CLIN PHARMACOKINET, V53, P1, DOI 10.1007/s40262-013-0100-7; Ogata K, 2010, J CLIN PHARMACOL, V50, P743, DOI 10.1177/0091270009351883; Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638; RD Lopes, 2010, AM HEART J, V159, P1162; Ruff CT, 2014, LANCET, V383, P955, DOI 10.1016/S0140-6736(13)62343-0; Ruff CT, 2010, AM HEART J, V160, P635, DOI 10.1016/j.ahj.2010.06.042; Siegfried N, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003362.pub2; Song F, 2003, BMJ-BRIT MED J, V326, P472, DOI 10.1136/bmj.326.7387.472; Song X, 2012, AM J CARDIOVASC DRUG, V12, P245, DOI 10.2165/11632540-000000000-00000; van Ryn J, 2010, THROMB HAEMOSTASIS, V103, P1116, DOI 10.1160/TH09-11-0758	25	32	32	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 9	2014	9	6							e99276	10.1371/journal.pone.0099276	http://dx.doi.org/10.1371/journal.pone.0099276			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI8LF	24911432	Green Published, gold			2023-01-03	WOS:000337165600065
J	Herath, SC; Poole, P				Herath, Samantha C.; Poole, Phillippa			Prophylactic Antibiotic Therapy in Chronic Obstructive Pulmonary Disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							EXACERBATIONS; ERYTHROMYCIN; AZITHROMYCIN; PREVENTION; SPUTUM		[Herath, Samantha C.] Montreal Chest Inst, Dept Resp Med, Day Unit, 3650,Rue St Urbain,Level 4, Montreal, PQ H2X 2P4, Canada; [Poole, Phillippa] Univ Auckland, Dept Med, Auckland 1, New Zealand	McGill University; University of Auckland	Herath, SC (corresponding author), Montreal Chest Inst, Dept Resp Med, Day Unit, 3650,Rue St Urbain,Level 4, Montreal, PQ H2X 2P4, Canada.	scherath@yahoo.com						Albert RK, 2011, NEW ENGL J MED, V365, P689, DOI 10.1056/NEJMoa1104623; Banerjee D, 2005, RESP MED, V99, P208, DOI 10.1016/j.rmed.2004.06.009; He ZY, 2010, RESPIRATION, V80, P445, DOI 10.1159/000321374; Herath SC, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009764.pub2; Mygind LH, 2010, PRESENTED AT EUROPEA; Seemungal TAR, 2008, AM J RESP CRIT CARE, V178, P1139, DOI 10.1164/rccm.200801-145OC; Sethi S, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-10; Staykova T., 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004105; Suzuki T, 2001, CHEST, V120, P730, DOI 10.1378/chest.120.3.730; Uzun S, 2014, LANCET RESP MED, V2, P361, DOI 10.1016/S2213-2600(14)70019-0	10	4	9	1	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	2014	311	21					2225	2226		10.1001/jama.2014.4929	http://dx.doi.org/10.1001/jama.2014.4929			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AI2DU	24893090				2023-01-03	WOS:000336668400024
J	Gravitz, L				Gravitz, Lauren			THERAPY This time it's personal	NATURE			English	Editorial Material							CANCER; IMMUNOTHERAPY											Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956; Fan XZ, 2014, J EXP MED, V211, P715, DOI 10.1084/jem.20130590; Murtaza M, 2013, NATURE, V497, P108, DOI 10.1038/nature12065; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Vanneman M, 2012, NAT REV CANCER, V12, P237, DOI 10.1038/nrc3237; Welch JS, 2011, JAMA-J AM MED ASSOC, V305, P1577, DOI 10.1001/jama.2011.497	6	8	9	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	2014	509	7502					S52	S54		10.1038/509S52a	http://dx.doi.org/10.1038/509S52a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AH9JC	24870820	Bronze			2023-01-03	WOS:000336457100003
J	Kleijn, A; Kloezeman, J; Treffers-Westerlaken, E; Fulci, G; Leenstra, S; Dirven, C; Debets, R; Lamfers, M				Kleijn, Anne; Kloezeman, Jenneke; Treffers-Westerlaken, Elike; Fulci, Giulia; Leenstra, Sieger; Dirven, Clemens; Debets, Reno; Lamfers, Martine			The In Vivo Therapeutic Efficacy of the Oncolytic Adenovirus Delta24-RGD Is Mediated by Tumor-Specific Immunity	PLOS ONE			English	Article							CONDITIONALLY REPLICATIVE ADENOVIRUS; VESICULAR STOMATITIS-VIRUS; PHASE I/II TRIAL; INFLAMMATORY RESPONSE; ANTITUMOR IMMUNITY; MALIGNANT GLIOMAS; CANCER-PATIENTS; CELL-DEATH; GLIOBLASTOMA; VECTORS	The oncolytic adenovirus Delta24-RGD represents a new promising therapeutic agent for patients with a malignant glioma and is currently under investigation in clinical phase I/II trials. Earlier preclinical studies showed that Delta24-RGD is able to effectively lyse tumor cells, yielding promising results in various immune-deficient glioma models. However, the role of the immune response in oncolytic adenovirus therapy for glioma has never been explored. To this end, we assessed Delta24-RGD treatment in an immune-competent orthotopic mouse model for glioma and evaluated immune responses against tumor and virus. Delta24-RGD treatment led to long-term survival in 50% of mice and this effect was completely lost upon administration of the immunosuppressive agent dexamethasone. Delta24-RGD enhanced intra-tumoral infiltration of F4/80+ macrophages, CD4+ and CD8+ T-cells, and increased the local production of pro-inflammatory cytokines and chemokines. In treated mice, T cell responses were directed to the virus as well as to the tumor cells, which was reflected in the presence of protective immunological memory in mice that underwent tumor rechallenge. Together, these data provide evidence that the immune system plays a vital role in the therapeutic efficacy of oncolytic adenovirus therapy of glioma, and may provide angles to future improvements on Delta24-RGD therapy.	[Kleijn, Anne; Kloezeman, Jenneke; Leenstra, Sieger; Dirven, Clemens; Lamfers, Martine] ErasmusMC, Dept Neurosurg, Brain Tumor Ctr, Rotterdam, Netherlands; [Treffers-Westerlaken, Elike; Debets, Reno] ErasmusMC, Dept Med Oncol, Lab Expt Tumor Immunol, Rotterdam, Netherlands; [Fulci, Giulia] Massachusetts Gen Hosp, Dept Neurosurg, Mol Neurosurg Lab, Brain Tumor Res Ctr, Boston, MA 02114 USA	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Harvard University; Massachusetts General Hospital	Lamfers, M (corresponding author), ErasmusMC, Dept Neurosurg, Brain Tumor Ctr, Rotterdam, Netherlands.	m.lamfers@erasmusmc.nl	Lamfers, Martine/C-6246-2016	Lamfers, Martine/0000-0001-7745-9029				Allen C, 2012, GENE THER; Alonso MM, 2008, MOL THER, V16, P487, DOI 10.1038/sj.mt.6300400; Alonso MM, 2007, CANCER RES, V67, P11499, DOI 10.1158/0008-5472.CAN-07-5312; Altomonte J, 2008, MOL THER, V16, P146, DOI 10.1038/sj.mt.6300343; Alvarez-Breckenridge CA, 2012, NAT MED, V18, P1827, DOI 10.1038/nm.3013; Appledorn DM, 2008, J IMMUNOL, V181, P2134, DOI 10.4049/jimmunol.181.3.2134; Badie B, 2000, J NEUROSURG, V93, P634, DOI 10.3171/jns.2000.93.4.0634; Badruddoja MA, 2003, NEURO-ONCOLOGY, V5, P235, DOI 10.1215/S1152851703000073; Bauerschmitz GJ, 2002, CANCER RES, V62, P1266; Bauerschmitz GJ, 2004, INT J CANCER, V111, P303, DOI 10.1002/ijc.20217; Blackham AU, 2012, SURGERY; Cartmell T, 1999, J NEUROSCI, V19, P1517; Chiocca EA, 2004, MOL THER, V10, P958, DOI 10.1016/j.ymthe.2004.07.021; Datta SC, 2008, J NEUROSCI METH, V175, P119, DOI 10.1016/j.jneumeth.2008.08.007; Diaz RM, 2007, CANCER RES, V67, P2840, DOI 10.1158/0008-5472.CAN-06-3974; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; Freeman AI, 2006, MOL THER, V13, P221, DOI 10.1016/j.ymthe.2005.08.016; Fueyo J, 2003, J NATL CANCER I, V95, P652, DOI 10.1093/jnci/95.9.652; Fulci G, 2006, P NATL ACAD SCI USA, V103, P12873, DOI 10.1073/pnas.0605496103; Galanis E, 2005, GENE THER, V12, P437, DOI 10.1038/sj.gt.3302436; GOODWIN JS, 1986, J CLIN INVEST, V77, P1244, DOI 10.1172/JCI112427; Grauer OM, 2007, INT J CANCER, V121, P95, DOI 10.1002/ijc.22607; Grote D, 2003, CANCER RES, V63, P6463; Gujar SA, 2010, MOL CANCER THER, V9, P2924, DOI 10.1158/1535-7163.MCT-10-0590; Huang PY, 2012, MOL THER, V20, P298, DOI 10.1038/mt.2011.245; Idema S, 2007, J GENE MED, V9, P1046, DOI 10.1002/jgm.1113; Jiang H, 2007, J NATL CANCER I, V99, P1410, DOI 10.1093/jnci/djm102; Kanerva A, 2013, CLIN CANCER RES, V19, P2734, DOI 10.1158/1078-0432.CCR-12-2546; Karapanagiotou EM, 2012, CLIN CANCER RES, V18, P2080, DOI 10.1158/1078-0432.CCR-11-2181; Kiang A, 2006, MOL THER, V14, P588, DOI 10.1016/j.ymthe.2006.03.024; Kimball KJ, 2010, CLIN CANCER RES, V16, P5277, DOI 10.1158/1078-0432.CCR-10-0791; Kleijn A, 2011, CLIN CANCER RES, V17, P4484, DOI 10.1158/1078-0432.CCR-11-0575; Lamfers MLM, 2007, CLIN CANCER RES, V13, P7451, DOI 10.1158/1078-0432.CCR-07-1265; Lamfers MLM, 2006, MOL THER, V14, P779, DOI 10.1016/j.ymthe.2006.08.008; Lamfers MLM, 2002, CANCER RES, V62, P5736; Lesniak MS, 2004, J NEURO-ONCOL, V70, P23, DOI 10.1023/B:NEON.0000040821.50347.c5; Liikanen I, 2013, MOL THER, V21, P1212, DOI 10.1038/mt.2013.51; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; Muruve DA, 2004, HUM GENE THER, V15, P1157, DOI 10.1089/hum.2004.15.1157; Pouw N, 2010, CANCER IMMUNOL IMMUN, V59, P921, DOI 10.1007/s00262-010-0818-0; Reid TR, 2005, CANCER GENE THER, V12, P673, DOI 10.1038/sj.cgt.7700819; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Robbins PF, 2011, J CLIN ONCOL, V29, P917, DOI 10.1200/JCO.2010.32.2537; Rolle CE, 2012, ADV EXP MED BIOL, V746, P53, DOI 10.1007/978-1-4614-3146-6_5; Sebestyen Z, 2007, CANCER RES, V67, P11309, DOI 10.1158/0008-5472.CAN-07-0739; Sengupta S, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/831090; Sprangers MC, 2003, J CLIN MICROBIOL, V41, P5046, DOI 10.1128/JCM.41.11.5046-5052.2003; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Suzuki K, 2001, CLIN CANCER RES, V7, P120; Szatmari T, 2006, CANCER SCI, V97, P546, DOI 10.1111/j.1349-7006.2006.00208.x; Thomas MA, 2008, MOL THER, V16, P1665, DOI 10.1038/mt.2008.162; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Witlox AM, 2004, CLIN CANCER RES, V10, P61, DOI 10.1158/1078-0432.CCR-0609-03; Young AM, 2012, MOL THER, V20, P1676, DOI 10.1038/mt.2012.116	54	47	48	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2014	9	5							e97495	10.1371/journal.pone.0097495	http://dx.doi.org/10.1371/journal.pone.0097495			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI5NG	24866126	Green Published, gold, Green Submitted			2023-01-03	WOS:000336914100014
J	Martin, JW; Chilton-MacNeill, S; Koti, M; van Wijnen, AJ; Squire, JA; Zielenska, M				Martin, Jeffrey W.; Chilton-MacNeill, Susan; Koti, Madhuri; van Wijnen, Andre J.; Squire, Jeremy A.; Zielenska, Maria			Digital Expression Profiling Identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as Potential Predictive Biomarkers for Neo-Adjuvant Chemotherapy Response in Paediatric Osteosarcoma	PLOS ONE			English	Article							TRANSCRIPTION FACTOR RUNX2; HIGH-GRADE OSTEOSARCOMA; CELL-CYCLE KINASES; GENE-EXPRESSION; OSTEOBLAST DIFFERENTIATION; CHROMOSOMAL INSTABILITY; PROTEIN EXPRESSION; PROGNOSTIC-FACTORS; TUMOR-SUPPRESSOR; COPY NUMBER	Osteosarcoma is the most common malignancy of bone, and occurs most frequently in children and adolescents. Currently, the most reliable technique for determining a patients' prognosis is measurement of histopathologic tumor necrosis following pre-operative neo-adjuvant chemotherapy. Unfavourable prognosis is indicated by less than 90% estimated necrosis of the tumor. Neither genetic testing nor molecular biomarkers for diagnosis and prognosis have been described for osteosarcomas. We used the novel nanoString mRNA digital expression analysis system to analyse gene expression in 32 patients with sporadic paediatric osteosarcoma. This system used specific molecular barcodes to quantify expression of a set of 17 genes associated with osteosarcoma tumorigenesis. Five genes, from this panel, which encoded the bone differentiation regulator RUNX2, the cell cycle regulator CDC5L, the TP53 transcriptional inactivator MDM2, the DNA helicase RECQL4, and the cyclin-dependent kinase gene CDK4, were differentially expressed in tumors that responded poorly to neo-adjuvant chemotherapy. Analysis of the signalling relationships of these genes, as well as other expression markers of osteosarcoma, indicated that gene networks linked to RB1, TP53, PI3K, PTEN/Akt, myc and RECQL4 are associated with osteosarcoma. The discovery of these networks provides a basis for further experimental studies of role of the five genes (RUNX2, CDC5L, MDM2, RECQL4, and CDK4) in differential response to chemotherapy.	[Martin, Jeffrey W.; Chilton-MacNeill, Susan; Zielenska, Maria] Hosp Sick Children, Dept Paediat Lab Med, Toronto, ON M5G 1X8, Canada; [van Wijnen, Andre J.] Mayo Clin, Dept Orthoped Surg, Rochester, MN USA; [van Wijnen, Andre J.] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN USA; [Squire, Jeremy A.] Queens Univ, Dept Pathol & Mol Med, Kingston, ON, Canada; [Koti, Madhuri] Queens Univ, Dept Biomed & Mol Sci, Kingston, ON, Canada; [Squire, Jeremy A.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Genet, Ribeirao Preto, SP, Brazil; [Squire, Jeremy A.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pathol, Ribeirao Preto, SP, Brazil	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Mayo Clinic; Mayo Clinic; McMaster University; Queens University - Canada; Queens University - Canada; Universidade de Sao Paulo; Universidade de Sao Paulo	Squire, JA (corresponding author), Queens Univ, Dept Pathol & Mol Med, Kingston, ON, Canada.	jsquireinsp@gmail.com	Squire, Jeremy A/A-9352-2012; van Wijnen, Andre J./AAG-3578-2019	Squire, Jeremy A/0000-0002-9863-468X; van Wijnen, Andre J./0000-0002-4458-0946	Canadian Cancer Society [CCRI-020247]; National Institutes of Health [AR049069]	Canadian Cancer Society(Canadian Cancer Society (CCS)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was funded by the Canadian Cancer Society through grant CCRI-020247. Additional support was provided by National Institutes of Health grant AR049069 (to AvW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bernstein HS, 1998, J BIOL CHEM, V273, P4666, DOI 10.1074/jbc.273.8.4666; Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776; Broadhead Matthew L., 2011, Sarcoma, V2011, P959248, DOI 10.1155/2011/959248; Brunelle JK, 2009, J CELL SCI, V122, P437, DOI 10.1242/jcs.031682; Chibon F, 2010, NAT MED, V16, P781, DOI 10.1038/nm.2174; Clark JCM, 2008, J CANCER RES CLIN, V134, P281, DOI 10.1007/s00432-007-0330-x; Cleton-Jansen AM, 2009, BRIT J CANCER, V101, P1909, DOI 10.1038/sj.bjc.6605405; Dalla-Torre CA, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-237; Dujardin F, 2011, MODERN PATHOL, V24, P624, DOI 10.1038/modpathol.2010.229; Feugeas O, 1996, J CLIN ONCOL, V14, P467, DOI 10.1200/JCO.1996.14.2.467; Freeman SS, 2008, CANCER-AM CANCER SOC, V113, P1453, DOI 10.1002/cncr.23782; Gallaher B, 2000, CELL MOL BIOL, V46, P79; Gamberi G, 1998, ONCOLOGY-BASEL, V55, P556, DOI 10.1159/000011912; Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Helman LJ, 2003, NAT REV CANCER, V3, P685, DOI 10.1038/nrc1168; Janssens Nico, 2004, Mol Diagn, V8, P107, DOI 10.2165/00066982-200408020-00005; Kang MI, 2007, J CELL BIOCHEM, V102, P224, DOI 10.1002/jcb.21291; Kelly AD, 2013, GENOME MED, V5, DOI 10.1186/gm406; Kuijjer ML, 2012, GENE CHROMOSOME CANC, V51, P696, DOI 10.1002/gcc.21956; Kurek KC, 2010, CANCER RES, V70, P5577, DOI 10.1158/0008-5472.CAN-09-4602; Kyriazoglou AI, 2012, CANCER GENET-NY, V205, P332, DOI 10.1016/j.cancergen.2012.04.011; Lapenna S, 2009, NAT REV DRUG DISCOV, V8, P547, DOI 10.1038/nrd2907; Lee JS, 2006, J BONE MINER RES, V21, P921, DOI 10.1359/JBMR.060303; Lengner CJ, 2006, J CELL BIOL, V172, P909, DOI 10.1083/jcb.200508130; Liu JC, 2011, J BIOL CHEM, V286, P30057, DOI 10.1074/jbc.M111.241505; Lu XY, 2008, MOL CANCER RES, V6, P937, DOI 10.1158/1541-7786.MCR-07-2115; Lucero CMJ, 2013, J CELL PHYSIOL, V228, P714, DOI 10.1002/jcp.24218; Maire G, 2009, NEOPLASIA, V11, P260, DOI 10.1593/neo.81384; Malkov Vladislav A, 2009, BMC Res Notes, V2, P80, DOI 10.1186/1756-0500-2-80; Malumbres M, 2007, CURR OPIN GENET DEV, V17, P60, DOI 10.1016/j.gde.2006.12.008; Martin J. W., 2011, Sarcoma, V2011, P282745, DOI 10.1155/2011/282745; Martin Jeff W., 2012, Sarcoma, V2012, P627254, DOI 10.1155/2012/627254; Mauro M, 2012, NUCLEIC ACIDS RES, V40, P8348, DOI 10.1093/nar/gks612; Mohseny AB, 2010, GENE CHROMOSOME CANC, V49, P1095, DOI 10.1002/gcc.20817; Namlos Heidi M., 2012, Sarcoma, V2012, P639038, DOI 10.1155/2012/639038; Nathan SS, 2009, MOL BIOL REP, V36, P153, DOI 10.1007/s11033-008-9378-1; Northcott PA, 2012, ACTA NEUROPATHOL, V123, P615, DOI 10.1007/s00401-011-0899-7; Sadikovic B, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-202; Sadikovic B, 2009, HUM MOL GENET, V18, P1962, DOI 10.1093/hmg/ddp117; Sato N, 2000, ANTICANCER RES, V20, P837; Scott MC, 2011, BONE, V49, P356, DOI 10.1016/j.bone.2011.05.008; Selvarajah S, 2008, CYTOGENET GENOME RES, V122, P5, DOI 10.1159/000151310; Shimizu T, 2010, ONCOGENE, V29, P5687, DOI 10.1038/onc.2010.312; Smida J, 2010, CLIN CANCER RES, V16, P4256, DOI 10.1158/1078-0432.CCR-10-0284; Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676; Teplyuk NM, 2008, J BIOL CHEM, V283, P27585, DOI 10.1074/jbc.M802453200; Terry A, 2004, GENE, V336, P115, DOI 10.1016/j.gene.2004.04.015; Thangavel S, 2010, MOL CELL BIOL, V30, P1382, DOI 10.1128/MCB.01290-09; Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187; Tsuchiya T, 2000, CANCER GENET CYTOGEN, V120, P91, DOI 10.1016/S0165-4608(99)00255-1; Turner NC, 2012, LANCET ONCOL, V13, pE178, DOI 10.1016/S1470-2045(11)70335-7; van der Deen M, 2013, J BIOL CHEM, V288, P21307, DOI 10.1074/jbc.M112.445890; Wang LL, 2003, J NATL CANCER I, V95, P669, DOI 10.1093/jnci/95.9.669; Wang ZX, 2010, BONE, V47, P445, DOI 10.1016/j.bone.2010.05.027; Won KY, 2009, TUMORI J, V95, P311; Wunder JS, 2005, J CLIN ONCOL, V23, P1483, DOI 10.1200/JCO.2005.04.074; Xiao ZS, 1998, GENE, V214, P187, DOI 10.1016/S0378-1119(98)00227-3; Yoshida A, 2012, AM J SURG PATHOL, V36, P423, DOI 10.1097/PAS.0b013e31824230d0; Zhang NX, 2009, EMBO REP, V10, P1029, DOI 10.1038/embor.2009.122	60	65	67	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2014	9	5							e95843	10.1371/journal.pone.0095843	http://dx.doi.org/10.1371/journal.pone.0095843			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM1NZ	24835790	Green Submitted, Green Published, gold			2023-01-03	WOS:000339614800010
J	Tavares, LDC; Zanon, G; Weber, AD; Neto, AT; Mostardeiro, CP; Da Cruz, IBM; Oliveira, RM; Ilha, V; Dalcol, II; Morel, AF				Tavares, Luciana de C.; Zanon, Graciane; Weber, Andreia D.; Neto, Alexandre T.; Mostardeiro, Clarice P.; Da Cruz, Ivana B. M.; Oliveira, Raul M.; Ilha, Vinicius; Dalcol, Ionara I.; Morel, Ademir F.			Structure-Activity Relationship of Benzophenanthridine Alkaloids from Zanthoxylum rhoifolium Having Antimicrobial Activity	PLOS ONE			English	Article							OXIDATIVE STRESS; CHELERYTHRINE; FUROQUINOLINE; SANGUINARINE; ANTIMALARIAL; CHELIDONINE; FAGARONINE; GENERATION	Zanthoxylum rhoifolium (Rutaceae) is a plant alkaloid that grows in South America and has been used in Brazilian traditional medicine for the treatment of different health problems. The present study was designed to evaluate the antimicrobial activity of the steam bark crude methanol extract, fractions, and pure alkaloids of Z. rhoifolium. Its stem bark extracts exhibited a broad spectrum of antimicrobial activity, ranging from 12.5 to 100 mu g/mL using bioautography method, and from 125 to 500 mu g/mL in the microdilution bioassay. From the dichloromethane basic fraction, three furoquinoline alkaloids (1-3), and nine benzophenanthridine alkaloids (4-12) were isolated and the antimicrobial activity of the benzophenanthridine alkaloids is discussed in terms of structure-activity relationships. The alkaloid with the widest spectrum of activity was chelerythrine (10), followed by avicine (12) and dihydrochelerythrine (4). The minimal inhibitory concentrations of chelerythrine, of 1.50 mu g/mL for all bacteria tested, and between 3.12 and 6.25 mu g/mL for the yeast tested, show this compound to be a more powerful antimicrobial agent when compared with the other active alkaloids isolated from Z. rhoifolium. To verify the potential importance of the methylenedioxy group (ring A) of these alkaloids, chelerythrine was selected to represent the remainder of the benzophenanthridine alkaloids isolated in this work and was subjected to a demethylation reaction giving derivative 14. Compared to chelerythrine, the derivative (14) was less active against the tested bacteria and fungi. Kinetic measurements of the bacteriolytic activities of chelerythrine against the bacteria Bacillus subtilis (Gram-positive) and Escherichia coli (Gram-negative) were determined by optical density based on real time assay, suggesting that its mechanism of action is not bacteriolytic. The present study did not detect hemolytic effects of chelerythrine on erythrocytes and found a protective effect considering the decrease in TBARS and AOPP (advanced oxidized protein products) levels when compared to the control group.	[Tavares, Luciana de C.; Zanon, Graciane; Weber, Andreia D.; Neto, Alexandre T.; Ilha, Vinicius; Dalcol, Ionara I.; Morel, Ademir F.] Univ Fed Santa Maria, Ctr Res Nat Prod NPPN, BR-97119900 Santa Maria, RS, Brazil; [Mostardeiro, Clarice P.; Da Cruz, Ivana B. M.; Oliveira, Raul M.; Dalcol, Ionara I.] Univ Fed Santa Maria, Hlth Sci Ctr, Grad Program Pharmacol, BR-97119900 Santa Maria, RS, Brazil; [Da Cruz, Ivana B. M.] Univ Fed Santa Maria, Grad Program Toxicol Biochem, BR-97119900 Santa Maria, RS, Brazil	Universidade Federal de Santa Maria (UFSM); Universidade Federal de Santa Maria (UFSM); Universidade Federal de Santa Maria (UFSM)	Morel, AF (corresponding author), Univ Fed Santa Maria, Ctr Res Nat Prod NPPN, BR-97119900 Santa Maria, RS, Brazil.	afmorel@base.ufsm.br	da Cruz, Ivana BM/G-4329-2012; Dalcol, Ionara/AAN-4140-2020; Ilha, Vinicius/E-1690-2013	da Cruz, Ivana BM/0000-0003-3008-6899; Ilha, Vinicius/0000-0003-2555-4731	CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico); FAPERGS (Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul)-PRONEX	CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); FAPERGS (Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul)-PRONEX	The authors thank CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico) and FAPERGS (Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul)-PRONEX for financial support for this work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALSHAMMA A, 1979, PHYTOCHEMISTRY, V18, P1417, DOI 10.1016/0031-9422(79)83044-7; BARRET Y, 1992, PHYTOTHER RES, V6, P59, DOI 10.1002/ptr.2650060202; BASCO LK, 1994, ANTIMICROB AGENTS CH, V38, P1169, DOI 10.1128/AAC.38.5.1169; FANG SD, 1993, J ORG CHEM, V58, P5025, DOI 10.1021/jo00071a001; Fernandes CC, 2009, J BRAZIL CHEM SOC, V20, P379, DOI 10.1590/S0103-50532009000200025; Freitas FFBP, 2011, J ETHNOPHARMACOL, V137, P700, DOI 10.1016/j.jep.2011.06.026; Gehrke ITS, 2013, J ETHNOPHARMACOL, V148, P486, DOI 10.1016/j.jep.2013.04.043; Gonzaga WDA, 2003, PLANTA MED, V69, P371, DOI 10.1055/s-2003-38882; HAMBURGER MO, 1987, J NAT PROD, V50, P19, DOI 10.1021/np50049a003; Jentzsch AM, 1996, FREE RADICAL BIO MED, V20, P251, DOI 10.1016/0891-5849(95)02043-8; Jullian V, 2006, J ETHNOPHARMACOL, V106, P348, DOI 10.1016/j.jep.2006.01.011; Kemeny-Beke A, 2006, CANCER LETT, V237, P67, DOI 10.1016/j.canlet.2005.05.037; KHALID SA, 1982, J NAT PROD, V45, P343, DOI 10.1021/np50021a017; Kim J, 2005, J CELL BIOCHEM, V94, P39, DOI 10.1002/jcb.20276; Lehtinen J, 2006, J MICROBIOL METH, V66, P381, DOI 10.1016/j.mimet.2006.01.002; LENFELD J, 1981, PLANTA MED, V43, P161, DOI 10.1055/s-2007-971493; Mazzanti G, 2009, J ETHNOPHARMACOL, V126, P518, DOI 10.1016/j.jep.2009.09.004; MESSMER WM, 1972, J PHARM SCI-US, V61, P1858, DOI 10.1002/jps.2600611145; Miao F, 2011, NAT PROD RES, V25, P863, DOI 10.1080/14786419.2010.482055; Moura NF, 1998, FITOTERAPIA, V69, P271; Moura NF, 1997, PHYTOCHEMISTRY, V46, P443; Navarro V, 1999, J ETHNOPHARMACOL, V66, P223, DOI 10.1016/S0378-8741(98)00182-2; NCCLS: National Committee for Clinical Laboratory Standards, 2002, M27A2 NCCLS CLSI; NCCLS: National Committee for Clinical Laboratory Standards, 2002, M7A5 NCCLS CLSI; Nissanka APK, 2001, PHYTOCHEMISTRY, V56, P857, DOI 10.1016/S0031-9422(00)00402-7; Nyangulu JM, 2005, BIOORG MED CHEM LETT, V15, P2007, DOI 10.1016/j.bmcl.2005.02.074; ODEBIYI OO, 1979, PLANTA MED, V36, P204, DOI 10.1055/s-0028-1097271; de Oliveira S, 2008, CLIN HEMORHEOL MICRO, V39, P363, DOI 10.3233/CH-2008-1101; Panzer A, 2001, EUR J CELL BIOL, V80, P111, DOI 10.1078/0171-9335-00135; Parlakpinar H, 2006, CELL BIOCHEM FUNCT, V24, P41, DOI 10.1002/cbf.1182; Pereira SS, 2010, J ETHNOPHARMACOL, V129, P227, DOI 10.1016/j.jep.2010.03.009; RAHALISON L, 1991, PHYTOCHEM ANALYSIS, V2, P199, DOI 10.1002/pca.2800020503; Schiar VPP, 2009, CHEM-BIOL INTERACT, V177, P28, DOI 10.1016/j.cbi.2008.10.007; Selmeci L, 2005, CLIN CHEM LAB MED, V43, P294, DOI 10.1515/CCLM.2005.050; Taylor PW, 2013, INT J ANTIMICROB AG, V42, P195, DOI 10.1016/j.ijantimicag.2013.05.004; Tillequin Francois, 2007, Phytochemistry Reviews, V6, P65, DOI 10.1007/s11101-006-9010-8; TINWA M, 1974, J PHARM SCI-US, V63, P1476, DOI 10.1002/jps.2600630935; Wansi JD, 2010, PHYTOTHER RES, V24, P775, DOI 10.1002/ptr.2894; Weber AD, 2009, PLANTA MED, V75, P979; Yamamoto S, 2001, J MOL CELL CARDIOL, V33, P1829, DOI 10.1006/jmcc.2001.1446; Yang XJ, 2012, MOLECULES, V17, P13026, DOI 10.3390/molecules171113026	41	27	33	3	43	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2014	9	5							e97000	10.1371/journal.pone.0097000	http://dx.doi.org/10.1371/journal.pone.0097000			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AH8EY	24824737	Green Published, gold, Green Submitted			2023-01-03	WOS:000336369200047
J	Goldenberg, I; Kutyifa, V; Klein, HU; Cannom, DS; Brown, MW; Dan, A; Daubert, JP; Estes, NAM; Foster, E; Greenberg, H; Kautzner, J; Klempfner, R; Kuniss, M; Merkely, B; Pfeffer, MA; Quesada, A; Viskin, S; McNitt, S; Polonsky, B; Ghanem, A; Solomon, SD; Wilber, D; Zareba, W; Moss, AJ				Goldenberg, Ilan; Kutyifa, Valentina; Klein, Helmut U.; Cannom, David S.; Brown, Mary W.; Dan, Ariela; Daubert, James P.; Estes, N. A. Mark, III; Foster, Elyse; Greenberg, Henry; Kautzner, Josef; Klempfner, Robert; Kuniss, Malte; Merkely, Bela; Pfeffer, Marc A.; Quesada, Aurelio; Viskin, Sami; McNitt, Scott; Polonsky, Bronislava; Ghanem, Ali; Solomon, Scott D.; Wilber, David; Zareba, Wojciech; Moss, Arthur J.			Survival with Cardiac-Resynchronization Therapy in Mild Heart Failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEFIBRILLATOR IMPLANTATION TRIAL; LEFT-VENTRICULAR ACTIVATION; BUNDLE-BRANCH BLOCK; MADIT-CRT; EVENTS; MORTALITY; RISK	BackgroundThe Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) showed that early intervention with cardiac-resynchronization therapy with a defibrillator (CRT-D) in patients with an electrocardiographic pattern showing left bundle-branch block was associated with a significant reduction in heart-failure events over a median follow-up of 2.4 years, as compared with defibrillator therapy alone. MethodsWe evaluated the effect of CRT-D on long-term survival in the MADIT-CRT population. Post-trial follow-up over a median period of 5.6 years was assessed among all 1691 surviving patients (phase 1) and subsequently among 854 patients who were enrolled in post-trial registries (phase 2). All reported analyses were performed on an intention-to-treat basis. ResultsAt 7 years of follow-up after initial enrollment, the cumulative rate of death from any cause among patients with left bundle-branch block was 18% among patients randomly assigned to CRT-D, as compared with 29% among those randomly assigned to defibrillator therapy alone (adjusted hazard ratio in the CRT-D group, 0.59; 95% confidence interval [CI], 0.43 to 0.80; P<0.001). The long-term survival benefit of CRT-D in patients with left bundle-branch block did not differ significantly according to sex, cause of cardiomyopathy, or QRS duration. In contrast, CRT-D was not associated with any clinical benefit and possibly with harm in patients without left bundle-branch block (adjusted hazard ratio for death from any cause, 1.57; 95% CI, 1.03 to 2.39; P=0.04; P<0.001 for interaction of treatment with QRS morphologic findings). ConclusionsOur findings indicate that in patients with mild heart-failure symptoms, left ventricular dysfunction, and left bundle-branch block, early intervention with CRT-D was associated with a significant long-term survival benefit. (Funded by Boston Scientific; ClinicalTrials.gov numbers, NCT00180271, NCT01294449, and NCT02060110.)	[Goldenberg, Ilan; Kutyifa, Valentina; Klein, Helmut U.; Brown, Mary W.; McNitt, Scott; Polonsky, Bronislava; Zareba, Wojciech; Moss, Arthur J.] Univ Rochester, Med Ctr, Dept Med, Heart Res Follow Up Program,Div Cardiol, Rochester, NY 14642 USA; [Goldenberg, Ilan; Dan, Ariela; Klempfner, Robert] Chaim Sheba Med Ctr, Leviev Heart Ctr, Israeli Assoc Cardiovasc Trials, IL-5265601 Tel Hashomer, Israel; [Goldenberg, Ilan; Viskin, Sami] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; [Viskin, Sami] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel; [Cannom, David S.] Cedars Sinai Heart Inst, Los Angeles, CA USA; [Cannom, David S.] Hosp Good Samaritan, Los Angeles, CA 90017 USA; [Daubert, James P.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Estes, N. A. Mark, III] Tufts Med Ctr, New England Cardiac Arrhythmia Ctr, Boston, MA USA; [Pfeffer, Marc A.; Solomon, Scott D.] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; [Pfeffer, Marc A.; Solomon, Scott D.] Harvard Univ, Sch Med, Boston, MA USA; [Foster, Elyse] Univ Calif San Francisco, Cardiol Unit, San Francisco, CA 94143 USA; [Greenberg, Henry] St Lukes Roosevelt Hosp, Cardiol Unit, New York, NY 10025 USA; [Kautzner, Josef] Inst Clin & Expt Med, Dept Cardiol, Prague, Czech Republic; [Kuniss, Malte] Max Planck Inst Physiol & Clin Res, Kerckhoff Klin, Bad Nauheim, Germany; [Ghanem, Ali] Univ Bonn, Dept Med Cardiol, Bonn, Germany; [Merkely, Bela] Semmelweis Univ, Ctr Heart, H-1085 Budapest, Hungary; [Quesada, Aurelio] Hosp Gen Valencia, Valencia, Spain; [Wilber, David] Loyola Univ, Med Ctr, Cardiovasc Inst, Chicago, IL 60611 USA	University of Rochester; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Cedars Sinai Medical Center; Duke University; Tufts Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of California System; University of California San Francisco; Mount Sinai St. Luke's; Mount Sinai West; Institute for Clinical & Experimental Medicine (IKEM); Kerckhoff Clinic; Max Planck Society; University of Bonn; Semmelweis University; Loyola University Chicago	Goldenberg, I (corresponding author), Chaim Sheba Med Ctr, Leviev Heart Ctr, IL-5265601 Tel Hashomer, Israel.	ilan.goldenberg@sheba.health.gov.il; heartajm@heart.rochester.edu	QUESADA, AURELIO/K-4925-2017; Daubert, James P./ABC-1476-2021; Klempfner, Robert/M-4989-2016	QUESADA, AURELIO/0000-0003-4709-1993; Merkely, Bela/0000-0001-6514-0723	Boston Scientific	Boston Scientific(Boston Scientific)	Supported by unrestricted research grants from Boston Scientific to the University of Rochester School of Medicine and Dentistry and to the Israeli Association for Cardiovascular Trials.	Auricchio A, 2004, CIRCULATION, V109, P1133, DOI 10.1161/01.CIR.0000118502.91105.F6; Bradley DJ, 2003, JAMA-J AM MED ASSOC, V289, P730, DOI 10.1001/jama.289.6.730; Bristow MR, 2004, NEW ENGL J MED, V350, P2140, DOI 10.1056/NEJMoa032423; Cleland JGF, 2005, NEW ENGL J MED, V352, P1539, DOI 10.1056/NEJMoa050496; Cleland JGF, 2006, EUR HEART J, V27, P1928, DOI 10.1093/eurheartj/ehl099; Fantoni C, 2005, J CARDIOVASC ELECTR, V16, P112, DOI 10.1046/j.1540-8167.2005.40777.x; Goldenberg I, 2011, J AM COLL CARDIOL, V58, P729, DOI 10.1016/j.jacc.2011.04.024; Linde C, 2008, J AM COLL CARDIOL, V52, P1834, DOI 10.1016/j.jacc.2008.08.027; Moss AJ, 2005, ANN NONINVAS ELECTRO, V10, P34, DOI 10.1111/j.1542-474X.2005.00073.x; Moss AJ, 2009, NEW ENGL J MED, V361, P1329, DOI 10.1056/NEJMoa0906431; Ouellet G, 2012, J AM COLL CARDIOL, V60, P1809, DOI 10.1016/j.jacc.2012.05.057; Tang ASL, 2010, NEW ENGL J MED, V363, P2385, DOI 10.1056/NEJMoa1009540; Ypenburg C, 2008, J AM COLL CARDIOL, V52, P1402, DOI 10.1016/j.jacc.2008.06.046; Zareba W, 2011, CIRCULATION, V123, P1061, DOI 10.1161/CIRCULATIONAHA.110.960898	14	219	230	1	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 1	2014	370	18					1694	1701		10.1056/NEJMoa1401426	http://dx.doi.org/10.1056/NEJMoa1401426			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AG4QM	24678999	Bronze, Green Submitted, Green Published			2023-01-03	WOS:000335405200007
J	Wall, M; McDermott, MP; Kieburtz, KD; Corbett, JJ; Feldon, SE; Friedman, DI; Katz, DM; Keltner, JL; Schron, EB; Kupersmith, MJ				Wall, Michael; McDermott, Michael P.; Kieburtz, Karl D.; Corbett, James J.; Feldon, Steven E.; Friedman, Deborah I.; Katz, David M.; Keltner, John L.; Schron, Eleanor B.; Kupersmith, Mark J.		NORDIC Idiopathic Intracranial	Effect of Acetazolamide on Visual Function in Patients With Idiopathic Intracranial Hypertension and Mild Visual Loss The Idiopathic Intracranial Hypertension Treatment Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PSEUDOTUMOR CEREBRI; PRESSURE; VALIDATION; DIAGNOSIS	IMPORTANCE Acetazolamide is commonly used to treat idiopathic intracranial hypertension (IIH), but there is insufficient information to establish an evidence base for its use. OBJECTIVE To determine whether acetazolamide is beneficial in improving vision when added to a low-sodium weight reduction diet in patients with IIH and mild visual loss. DESIGN, SETTING, AND PARTICIPANTS Multicenter, randomized, double-masked, placebo-controlled study of acetazolamide in 165 participants with IIH and mild visual loss who received a low-sodium weight-reduction diet. Participants were enrolled at 38 academic and private practice sites in North America from March 2010 to November 2012 and followed up for 6 months (last visit in June 2013). All participants met the modified Dandy criteria for IIH and had a perimetric mean deviation (PMD) between -2 dB and -7 dB. The mean age was 29 years and all but 4 participants were women. INTERVENTIONS Low-sodium weight-reduction diet plus the maximally tolerated dosage of acetazolamide (up to 4 g/d) or matching placebo for 6 months. MAIN OUTCOMES AND MEASURES The planned primary outcome variable was the change in PMD from baseline to month 6 in the most affected eye, as measured by Humphrey Field Analyzer. Perimetric mean deviation is a measure of global visual field loss (mean deviation from age-corrected normal values), with a range of 2 to -32 dB; larger negative values indicate greater vision loss. Secondary outcome variables included changes in papilledema grade, quality of life (Visual Function Questionnaire 25 [VFQ-25] and 36-Item Short Form Health Survey), headache disability, and weight at month 6. RESULTS The mean improvement in PMD was greater with acetazolamide (1.43 dB, from -3.53 dB at baseline to -2.10dB at month 6; n = 86) than with placebo (0.71 dB, from -3.53 dB to -2.82 dB; n = 79); the difference was 0.71 dB (95% CI, 0to 1.43 dB; P = .050). Mean improvements in papilledema grade (acetazolamide: -1.31, from 2.76 to 1.45; placebo: -0.61, from 2.76 to 2.15; treatment effect, -0.70; 95% CI, -0.99 to -0.41; P < .001) and vision-related quality of life as measured by the National Eye Institute VFQ-25 (acetazolamide: 8.33, from 82.97 to 91.30; placebo: 1.98, from 82.97 to 84.95; treatment effect, 6.35; 95% CI, 2.22 to 10.47; P = .003) and its 10-item neuro-ophthalmic supplement (acetazolamide: 9.82, from 75.45 to 85.27; placebo: 1.59, from 75.45 to 77.04; treatment effect, 8.23; 95% CI, 3.89 to 12.56; P < .001) were also observed with acetazolamide. Participants assigned to acetazolamide also experienced a reduction in weight (acetazolamide: -7.50 kg, from 107.72 kg to 100.22 kg; placebo: -3.45 kg, from 107.72 kg to 104.27 kg; treatment effect, -4.05 kg, 95% CI, -6.27 to -1.83 kg; P < .001). CONCLUSIONS AND RELEVANCE In patients with IIH and mild visual loss, the use of acetazolamide with a low-sodium weight-reduction diet compared with diet alone resulted in modest improvement in visual field function. The clinical importance of this improvement remains to be determined.	[Wall, Michael] Univ Iowa, Iowa City, IA USA; [McDermott, Michael P.; Kieburtz, Karl D.] Univ Rochester, Sch Med & Dent, Rochester, NY USA; [Corbett, James J.] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; [Feldon, Steven E.] Univ Rochester, Inst Eye, Rochester, NY USA; [Friedman, Deborah I.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Katz, David M.] Bethesda Neurol LLC, Bethesda, MD USA; [Keltner, John L.] Univ Calif Davis, Med Ctr, Davis, CA USA; [Schron, Eleanor B.] NEI, Bethesda, MD 20892 USA; [Kupersmith, Mark J.] St Lukes Roosevelt Hosp, New York, NY 10025 USA	University of Iowa; University of Rochester; University of Mississippi; University of Mississippi Medical Center; University of Rochester; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of California System; University of California Davis; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Mount Sinai St. Luke's; Mount Sinai West	Wall, M (corresponding author), Univ Iowa Hosp & Clin, Dept Neurol, 200 Hawkins Dr, Iowa City, IA 52242 USA.	michael-wall@uiowa.edu	Friedman, Deborah I/HCG-8707-2022; McDermott, Michael Francis/GZM-5330-2022	Friedman, Deborah I/0000-0002-6652-6158; Feldon, Steven/0000-0003-0603-9312; Subramanian, Prem/0000-0001-5824-8322; Bruce, Beau/0000-0003-3003-2962; Wall, Michael/0000-0002-9802-4806; Kardon, Randy/0000-0002-3173-7123	National Eye Institute (NEI) [1U10EY017281-01A1, 1U10EY017387-01A1, 3U10EY017281-01A1S1, 1U10EY017387-01A1S1]; NATIONAL EYE INSTITUTE [U10EY017281, U10EY017387] Funding Source: NIH RePORTER	National Eye Institute (NEI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported by National Eye Institute (NEI) grants 1U10EY017281-01A1, DCBC 1U10EY017387-01A1, ARRA for NORDIC 3U10EY017281-01A1S1, and DCBC 1U10EY017387-01A1S1, and supplements for NORDIC 3U10EY017281-01A1S2.	Banta JT, 2000, OPHTHALMOLOGY, V107, P1907, DOI 10.1016/S0161-6420(00)00340-7; Dandy WE, 1937, ANN SURG, V106, P492, DOI 10.1097/00000658-193710000-00002; De Wecker L, 1872, INT OPHTHALMOL CONG, V4, P11; EPSTEIN DL, 1977, ARCH OPHTHALMOL-CHIC, V95, P1378, DOI 10.1001/archopht.1977.04450080088009; Friedman DI, 2014, J NEURO-OPHTHALMOL, V34, P107, DOI 10.1097/WNO.0000000000000114; FRISEN L, 1982, J NEUROL NEUROSUR PS, V45, P13, DOI 10.1136/jnnp.45.1.13; GUCER G, 1978, J NEUROSURG, V49, P256, DOI 10.3171/jns.1978.49.2.0256; JEFFERSON A, 1976, J NEUROL NEUROSUR PS, V39, P627, DOI 10.1136/jnnp.39.7.627; Johnson LN, 1998, OPHTHALMOLOGY, V105, P2313, DOI 10.1016/S0161-6420(98)91234-9; Kosinski M, 2003, QUAL LIFE RES, V12, P963, DOI 10.1023/A:1026119331193; Lubow M., 1976, NEURO-OPHTHALMOLOGY, V9, P199; Lueck C, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003434.pub2; Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496; Molenberghs G, 2004, BIOSTATISTICS, V5, P445, DOI 10.1093/biostatistics/kxh001; NEWBORG B, 1974, ARCH INTERN MED, V133, P802, DOI 10.1001/archinte.133.5.802; PATERSON R, 1961, MEDICINE, V40, P85, DOI 10.1097/00005792-196102000-00003; Raphael BA, 2006, AM J OPHTHALMOL, V142, P1026, DOI 10.1016/j.ajo.2006.06.060; RUBIN RC, 1966, J NEUROSURG, V25, P430, DOI 10.3171/jns.1966.25.4.0430; Scott CJ, 2010, ARCH OPHTHALMOL-CHIC, V128, P705, DOI 10.1001/archophthalmol.2010.94; SMITH JL, 1985, J CLIN NEURO-OPHTHAL, V5, P55; Suner IJ, 2009, INVEST OPHTH VIS SCI, V50, P3629, DOI 10.1167/iovs.08-3225; VANDERAR.GD, 1971, J AMER MED ASSOC, V217, P1832, DOI 10.1001/jama.217.13.1832; Wall M, 2014, JAMA NEUROL, V71, P693, DOI 10.1001/jamaneurol.2014.133; Ware JE, 2001, SF 36 PHYSICAL AND M; Woodworth GF, 2005, STEREOT FUNCT NEUROS, V83, P12, DOI 10.1159/000084059	25	271	273	1	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	2014	311	16					1641	1651		10.1001/jama.2014.3312	http://dx.doi.org/10.1001/jama.2014.3312			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AF4OU	24756514	Green Accepted, Bronze			2023-01-03	WOS:000334693900024
J	Marx, V				Marx, Vivien			SHARP SHOOTERS	NATURE			English	Editorial Material																		Deye JA, 2012, HEALTH PHYS, V103, P662, DOI 10.1097/HP.0b013e3182609bb7; Durante M, 2010, NAT REV CLIN ONCOL, V7, P37, DOI 10.1038/nrclinonc.2009.183; PEGGS S, 2002, P EPAC PAR FRANC, P2754; Suit H, 2003, ACTA ONCOL, V42, P800, DOI 10.1080/02841860310017676; Tsujii H, 2012, JPN J CLIN ONCOL, V42, P670, DOI 10.1093/jjco/hys104	5	22	22	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 3	2014	508	7494					133	138		10.1038/508133a	http://dx.doi.org/10.1038/508133a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AD9UL	24695279	Bronze			2023-01-03	WOS:000333609900057
J	Casaer, MP; Van den Berghe, G				Casaer, Michael P.; Van den Berghe, Greet			Nutrition in the Acute Phase of Critical Illness	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INTENSIVE-CARE-UNIT; SUPPLEMENTAL PARENTERAL-NUTRITION; RANDOMIZED CLINICAL-TRIAL; ENTERAL NUTRITION; ILL PATIENTS; ICU PATIENTS; MULTICENTER; METAANALYSIS; MORTALITY; GLUTAMINE	This review covers current knowledge related to the initiation of enteral or parenteral feeding among critically ill patients in the ICU. Critically ill patients requiring vital organ support in the intensive care unit (ICU) commonly have anorexia and may be unable to feed volitionally by mouth for periods ranging from days to months. Unless such patients are provided with macronutrients in the form of enteral or parenteral nutrition, they accumulate an energy deficit that rapidly reaches proportions that contribute to lean-tissue wasting and that are associated with adverse outcomes.(1) The catabolic response to acute critical illness is much more pronounced than that evoked by fasting in healthy persons, since the energy deficit in acutely ill patients is often superimposed on immobilization ...	[Van den Berghe, Greet] Katholieke Univ Leuven, Clin Dept, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Lab Intens Care Med, Div Cellular & Mol Med, B-3000 Louvain, Belgium	KU Leuven; KU Leuven	Van den Berghe, G (corresponding author), Katholieke Univ Leuven, Clin Dept, Herestr 49, B-3000 Louvain, Belgium.	greet.vandenberghe@med.kuleuven.be	Casaer, Michael/Y-7131-2019; Van den Berghe, Greet/J-6788-2018	Casaer, Michael/0000-0002-7087-0795; Van den Berghe, Greet/0000-0002-5320-1362				Acosta-Escribano J, 2010, INTENS CARE MED, V36, P1532, DOI 10.1007/s00134-010-1908-3; Alberda C, 2009, INTENS CARE MED, V35, P1728, DOI 10.1007/s00134-009-1567-4; Alhazzani W, 2013, CRIT CARE MED, V41, P1555, DOI 10.1097/CCM.0b013e31828a24c6; Allingstrup MJ, 2012, CLIN NUTR, V31, P462, DOI 10.1016/j.clnu.2011.12.006; Andrews PJD, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1542; Arabi YM, 2011, AM J CLIN NUTR, V93, P569, DOI 10.3945/ajcn.110.005074; Artinian V, 2006, CHEST, V129, P960, DOI 10.1378/chest.129.4.960; Braunschweig CL, 2001, AM J CLIN NUTR, V74, P534; Casaer MP, 2013, AM J RESP CRIT CARE, V187, P247, DOI 10.1164/rccm.201206-0999OC; Casaer MP, 2011, NEW ENGL J MED, V365, P506, DOI 10.1056/NEJMoa1102662; Davies AR, 2012, CRIT CARE MED, V40, P2342, DOI 10.1097/CCM.0b013e318255d87e; De Jonghe B, 2007, CRIT CARE MED, V35, P2007, DOI 10.1097/01.ccm.0000281450.01881.d8; Dissanaike S, 2007, CRIT CARE, V11, DOI 10.1186/cc6167; Doig GS, 2013, JAMA-J AM MED ASSOC, V309, P2130, DOI 10.1001/jama.2013.5124; Doig GS, 2009, INTENS CARE MED, V35, P2018, DOI 10.1007/s00134-009-1664-4; Doig GS, 2008, JAMA-J AM MED ASSOC, V300, P2731, DOI 10.1001/jama.2008.826; Frankenfield DC, 2011, JPEN-PARENTER ENTER, V35, P563, DOI 10.1177/0148607111415859; Grau T, 2007, CRIT CARE, V11, DOI 10.1186/cc5670; Heidegger CP, 2013, LANCET, V381, P1716, DOI 10.1016/S0140-6736(13)61072-7; Heidegger CP, 2013, LANCET, V381, P385, DOI 10.1016/S0140-6736(12)61351-8; Hermans G, 2013, LANCET RESP MED, V1, P621, DOI 10.1016/S2213-2600(13)70183-8; Heyland D, 2013, NEW ENGL J MED, V368, P1489, DOI 10.1056/NEJMoa1212722; Koretz RL, 2009, NUTR CLIN PRACT, V24, P316, DOI 10.1177/0884533609335378; Kutsogiannis J, 2011, CRIT CARE MED, V39, P2691, DOI 10.1097/CCM.0b013e3182282a83; MacLaren R, 2008, JPEN-PARENTER ENTER, V32, P412, DOI 10.1177/0148607108319803; Manzanares W, 2013, JPEN J PARENTER ENTE; Manzanares W, 2012, CRIT CARE, V16, DOI 10.1186/cc11316; Marik PE, 2008, INTENS CARE MED, V34, P1980, DOI 10.1007/s00134-008-1213-6; Marik PE, 1996, ARCH SURG-CHICAGO, V131, P1043, DOI 10.1001/archsurg.1996.01430220037007; Martin CM, 2004, CAN MED ASSOC J, V170, P197, DOI 10.1503/cmaj.1040621; Martindale RG, 2009, CRIT CARE MED, V37, P1757, DOI 10.1097/CCM.0b013e3181a40116; Montejo JC, 2010, INTENS CARE MED, V36, P1386, DOI 10.1007/s00134-010-1856-y; Needham DM, 2013, AM J RESP CRIT CARE; Nguyen NQ, 2007, CRIT CARE MED, V35, P483, DOI 10.1097/01.CCM.0000253410.36492.E9; Novak F, 2002, CRIT CARE MED, V30, P2022, DOI 10.1097/00003246-200209000-00011; Peter JV, 2005, CRIT CARE MED, V33, P213, DOI 10.1097/01.CCM.0000150960.36228.C0; Pontes-Arruda A, 2008, JPEN-PARENTER ENTER, V32, P596, DOI 10.1177/0148607108324203; Pontes-Arruda A, 2011, CRIT CARE, V15, DOI 10.1186/cc10267; Reignier J, 2013, JAMA-J AM MED ASSOC, V309, P249, DOI 10.1001/jama.2012.196377; Rice TW, 2012, JAMA-J AM MED ASSOC, V307, P795, DOI 10.1001/jama.2012.137; Rice TW, 2012, JAMA-J AM MED ASSOC, V307, P563, DOI 10.1001/jama.2012.114; Scheinkestel CD, 2003, NUTRITION, V19, P909, DOI 10.1016/S0899-9007(03)00175-8; Singer P, 2011, INTENS CARE MED, V37, P601, DOI 10.1007/s00134-011-2146-z; Singer P, 2009, CLIN NUTR, V28, P387, DOI 10.1016/j.clnu.2009.04.024; Takala J, 1999, NEW ENGL J MED, V341, P785, DOI 10.1056/NEJM199909093411102; Taylor SJ, 1999, CRIT CARE MED, V27, P2525, DOI 10.1097/00003246-199911000-00033; Umpierrez GE, 2012, CRIT CARE MED, V40, P1792, DOI 10.1097/CCM.0b013e3182474bf9; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vanderheyden S, 2012, CRIT CARE, V16, DOI 10.1186/cc11361; Wanten GJA, 2007, AM J CLIN NUTR, V85, P1171; Wernerman J, 2011, ACTA ANAESTH SCAND, V55, P812, DOI 10.1111/j.1399-6576.2011.02453.x	51	172	188	0	44	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 27	2014	370	13					1227	1236		10.1056/NEJMra1304623	http://dx.doi.org/10.1056/NEJMra1304623			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AD7EW	24670169				2023-01-03	WOS:000333426000010
J	Huber, A; Lui, F; Duzzi, D; Pagnoni, G; Porro, CA				Huber, Alexa; Lui, Fausta; Duzzi, Davide; Pagnoni, Giuseppe; Porro, Carlo Adolfo			Structural and Functional Cerebral Correlates of Hypnotic Suggestibility	PLOS ONE			English	Article							RESTING-STATE FMRI; HUMAN BRAIN; COGNITIVE CONTROL; HYPNOTIZABILITY; HYPNOSIS; SUSCEPTIBILITY; CONFLICT; PAIN; INTEGRATION; ABSORPTION	Little is known about the neural bases of hypnotic suggestibility, a cognitive trait referring to the tendency to respond to hypnotic suggestions. In the present magnetic resonance imaging study, we performed regression analyses to assess hypnotic suggestibility-related differences in local gray matter volume, using voxel-based morphometry, and in waking resting state functional connectivity of 10 resting state networks, in 37 healthy women. Hypnotic suggestibility was positively correlated with gray matter volume in portions of the left superior and medial frontal gyri, roughly overlapping with the supplementary and pre-supplementary motor area, and negatively correlated with gray matter volume in the left superior temporal gyrus and insula. In the functional connectivity analysis, hypnotic suggestibility was positively correlated with functional connectivity between medial posterior areas, including bilateral posterior cingulate cortex and precuneus, and both the lateral visual network and the left fronto-parietal network; a positive correlation was also found with functional connectivity between the executive-control network and a right postcentral/parietal area. In contrast, hypnotic suggestibility was negatively correlated with functional connectivity between the right fronto-parietal network and the right lateral thalamus. These findings demonstrate for the first time a correlation between hypnotic suggestibility, the structural features of specific cortical regions, and the functional connectivity during the normal resting state of brain structures involved in imagery and self-monitoring activity.	[Huber, Alexa; Lui, Fausta; Duzzi, Davide; Pagnoni, Giuseppe; Porro, Carlo Adolfo] Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, Modena, Italy	Universita di Modena e Reggio Emilia	Porro, CA (corresponding author), Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, Modena, Italy.	carlo.porro@unimore.it	Porro, Carlo Adolfo/N-2580-2015; Lui, Fausta/P-3816-2015; Pagnoni, Giuseppe/F-3398-2015	Porro, Carlo Adolfo/0000-0003-2345-5852; Lui, Fausta/0000-0001-6577-059X; Pagnoni, Giuseppe/0000-0002-8272-8091; Mullner-Huber, Alexa/0000-0003-2372-7942	Fondazione Cassa di Risparmio di Modena (FCRM); FCRM International grant [A0FF-0AAB-9711-FA30]	Fondazione Cassa di Risparmio di Modena (FCRM); FCRM International grant	The authors thank the Fondazione Cassa di Risparmio di Modena (FCRM) for its financial support to the Modena MR center. A. H. is supported by a FCRM International grant 2010 (code: A0FF-0AAB-9711-FA30) to C. A. P. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Carli G., 2008, CONT HYPNOSIS, V25, P65, DOI [DOI 10.1002/CH.356, 10.1002/ch.v25:210.1002/ch.356, DOI 10.1002/CH.V25:210.1002/CH.356]; Carli G, 2008, COGN NEUROPSYCHOL, V25, P1065, DOI 10.1080/02643290801913712; Castellani E, 2011, INT J CLIN EXP HYP, V59, P250, DOI 10.1080/00207144.2011.546269; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Corbetta M, 2008, NEURON, V58, P306, DOI 10.1016/j.neuron.2008.04.017; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Craig AD, 2010, BRAIN STRUCT FUNCT, V214, P563, DOI 10.1007/s00429-010-0248-y; De Pascalis V, 2000, INT J CLIN EXP HYP, V48, P315, DOI 10.1080/00207140008415249; De Pascalis V, 2008, PAIN, V134, P197, DOI 10.1016/j.pain.2007.09.005; Dienes Z, 2013, CORTEX, V49, P386, DOI 10.1016/j.cortex.2012.07.009; Draganski B, 2008, BEHAV BRAIN RES, V192, P137, DOI 10.1016/j.bbr.2008.02.015; Egner T, 2005, NEUROIMAGE, V27, P969, DOI 10.1016/j.neuroimage.2005.05.002; Filippini N, 2009, P NATL ACAD SCI USA, V106, P7209, DOI 10.1073/pnas.0811879106; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; Garcia-Larrea L, 2012, NEUROPHYSIOL CLIN, V42, P299, DOI 10.1016/j.neucli.2012.06.001; GLISKY ML, 1995, INT J CLIN EXP HYP, V43, P34, DOI 10.1080/00207149508409374; Glover GH, 2000, MAGNET RESON MED, V44, P162, DOI 10.1002/1522-2594(200007)44:1<162::AID-MRM23>3.0.CO;2-E; Gotts SJ, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00356; Green JP, 2011, INT J CLIN EXP HYP, V59, P103, DOI 10.1080/00207144.2011.522914; Gruzelier J, 2010, CONT HYPNOSIS, V28, P116; Hoeft F, 2012, ARCH GEN PSYCHIAT, V69, P1064, DOI 10.1001/archgenpsychiatry.2011.2190; Horton JE, 2004, BRAIN, V127, P1741, DOI 10.1093/brain/awh196; Huber A, 2013, PAIN, V154, P1509, DOI 10.1016/j.pain.2013.03.031; Aguilar EJ, 2008, EUR J RADIOL, V67, P434, DOI 10.1016/j.ejrad.2008.02.046; Jo HJ, 2010, NEUROIMAGE, V52, P571, DOI 10.1016/j.neuroimage.2010.04.246; Kirsch I, 2001, CURR DIR PSYCHOL SCI, V10, P57, DOI 10.1111/1467-8721.00115; LYNN SJ, 1986, J PERS SOC PSYCHOL, V51, P404, DOI 10.1037/0022-3514.51.2.404; Maquet P, 1999, BIOL PSYCHIAT, V45, P327, DOI 10.1016/S0006-3223(97)00546-5; McGeown WJ, 2012, CONSCIOUS COGN, V21, P100, DOI 10.1016/j.concog.2011.10.015; McGeown WJ, 2009, CONSCIOUS COGN, V18, P848, DOI 10.1016/j.concog.2009.09.001; Menzocchi M, 2010, INT J CLIN EXP HYP, V58, P122, DOI 10.1080/00207140903316169; Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228; Molinari E, 2013, CEREB CORTEX, V23, P178, DOI 10.1093/cercor/bhr393; Nachev P, 2008, NAT REV NEUROSCI, V9, P856, DOI 10.1038/nrn2478; Oakley DA, 2013, NAT REV NEUROSCI, V14, P565, DOI 10.1038/nrn3538; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Pedrabissi L, 1989, INVENTARIO ANSIA STA; PICCIONE C, 1989, J PERS SOC PSYCHOL, V56, P289, DOI 10.1037/0022-3514.56.2.289; Pochon JB, 2008, J NEUROSCI, V28, P3468, DOI 10.1523/JNEUROSCI.4195-07.2008; Preacher KJ, 2005, PSYCHOL METHODS, V10, P178, DOI 10.1037/1082-989X.10.2.178; Pyka M, 2011, NEUROIMAGE, V56, P2173, DOI 10.1016/j.neuroimage.2011.03.078; Raz A, 2005, P NATL ACAD SCI USA, V102, P9978, DOI 10.1073/pnas.0503064102; Raz A, 2008, INT J CLIN EXP HYP, V56, P99, DOI 10.1080/00207140701506482; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; TELLEGEN A, 1974, J ABNORM PSYCHOL, V83, P268, DOI 10.1037/h0036681; Terhune DB, 2011, PSYCHOPHYSIOLOGY, V48, P1444, DOI 10.1111/j.1469-8986.2011.01211.x; Vincent JL, 2008, J NEUROPHYSIOL, V100, P3328, DOI 10.1152/jn.90355.2008; Weitzenhoffer A., 1959, STANFORD HYPNOTIC SU; Whittingstall K, 2013, STRUCTURAL NETWORK U; Woody EZ, 2005, PSYCHOL ASSESSMENT, V17, P200, DOI 10.1037/1040-3590.17.2.200; Wylie KP, 2010, SCHIZOPHR RES, V123, P93, DOI 10.1016/j.schres.2010.08.027	52	17	17	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2014	9	3							e93187	10.1371/journal.pone.0093187	http://dx.doi.org/10.1371/journal.pone.0093187			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE0SR	24671130	gold, Green Published, Green Submitted			2023-01-03	WOS:000333677000126
J	Cai, H; Xie, ZY; Liu, GH; Sun, XM; Peng, GT; Lin, BQ; Liao, QF				Cai, Hao; Xie, Zhiyong; Liu, Guanghui; Sun, Xiuman; Peng, Guangtian; Lin, Baoqin; Liao, Qiongfeng			Isolation, Identification and Activities of Natural Antioxidants from Callicarpa kwangtungensis Chun	PLOS ONE			English	Article							PHENOLIC CONTENTS; PEPTIDES; CAPACITY; TRANSITION; ACTEOSIDE; RADICALS; TANNINS; BARLEY; FRUITS; L.	Reactive oxygen species leads to some diseases associated with oxidative stress. Callicarpa kwangtungensis Chun (CK) is a common remedy in traditional Chinese medicine and possesses diverse biological activities involving antioxidant properties; its main compounds phenylethanoid glycosides (PG) and flavonoids are always reported as antioxidants. In order to develop CK as a safe and activated antioxidant, our investigation was performed to validate antioxidant properties and assess which types of compounds (similar polarity or similar structure), even which compounds, played the role of antioxidants. The extracted compounds of CK were analyzed qualitatively and quantitatively by HPLC-DAD-ESI-Trap MS and UV for their contents and antioxidant activities. The correlations between antioxidant activities and known contents were respectively counted and a semi-quantitative experiment was designed to screen antioxidant compounds of CK with HPLC-UV. The n-butanol fraction (BF) showed the highest total phenolic and flavonoid contents (TPC, TFC), and three PG (forsythiaside B, poliumoside and acteoside) contents. BF showed the significantly best (P<0.05) activities in most assays. There were significant correlations (P<0.05) between DPPH center dot, ABTS(+)center dot, center dot O-2(-) scavenging, Cu2+-chelating, anti-lipidperoxidation activities and TPC. BF also has significant antioxidant activities on CCl4-induced acute liver injury Mice and TBHP-reduced HepG2 cells. Nine PG (forsythiaside B, poliumoside, acteoside, alyssonoside, brandioside and their derivatives) and one flavone (rhamnazin) were screened out as antioxidants. BF in CK contained abundant polyphenolic, which reflected some definite antioxidant properties. The antioxidant compounds consisted at the least of nine PG and one flavone.	[Cai, Hao; Liu, Guanghui; Sun, Xiuman; Peng, Guangtian; Lin, Baoqin; Liao, Qiongfeng] Guangzhou Univ Chinese Med, Sch Chinese Mat Med, Guangzhou, Guangdong, Peoples R China; [Cai, Hao; Xie, Zhiyong] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510275, Guangdong, Peoples R China	Guangzhou University of Chinese Medicine; Sun Yat Sen University	Xie, ZY (corresponding author), Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510275, Guangdong, Peoples R China.	xiezy2074@yahoo.com; liaoqf2075@yahoo.com		Xie, Zhi/0000-0002-5589-4836	National Natural Science Foundation of China [81173564, 81274028]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (Grant Nos. 81173564 and 81274028). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amarowicz R, 2004, FOOD CHEM, V84, P551, DOI 10.1016/S0308-8146(03)00278-4; Bourgou S, 2008, CR BIOL, V331, P48, DOI 10.1016/j.crvi.2007.11.001; Cai H, 2013, CHIN J EXP TRADIT ME, V19, P63; Celep E, 2012, FOOD CHEM TOXICOL, V50, P3329, DOI 10.1016/j.fct.2012.06.010; Chao J, 2013, INT J MOL SCI, V14, P2928, DOI 10.3390/ijms14022928; Chen DJ, 2012, FOOD CHEM, V134, P2126, DOI 10.1016/j.foodchem.2012.04.011; Chung KT, 1998, CRIT REV FOOD SCI, V38, P421, DOI 10.1080/10408699891274273; Eder K, 2002, J NUTR, V132, P3400, DOI 10.1093/jn/132.11.3400; Hagerman AE, 1998, J AGR FOOD CHEM, V46, P1887, DOI 10.1021/jf970975b; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HALLIWELL B, 1990, FREE RADICAL RES COM, V9, P1, DOI 10.3109/10715769009148569; Huang MH, 2011, J ETHNOPHARMACOL, V133, P743, DOI 10.1016/j.jep.2010.11.005; Huang X, 1998, CHINESE TRADITIONAL, V29, P246; Iturbe-Ormaetxe I, 1998, PLANT PHYSIOL, V116, P173, DOI 10.1104/pp.116.1.173; Jiang H, 1999, CHINESE TRADITIONAL, V22, P139; Koo KA, 2006, LIFE SCI, V79, P709, DOI 10.1016/j.lfs.2006.02.019; Kumar NSS, 2012, AMINO ACIDS, V42, P1641, DOI 10.1007/s00726-011-0858-6; Lee KY, 2006, BIOL PHARM BULL, V29, P71, DOI 10.1248/bpb.29.71; Lee YR, 2007, FOOD SCI BIOTECHNOLO, V16; Li XC, 2012, CHEM CENT J, V6, DOI 10.1186/1752-153X-6-140; Li XC, 2012, MOLECULES, V17, P13457, DOI 10.3390/molecules171113457; Li XC, 2009, MOLECULES, V14, P5349, DOI 10.3390/molecules14125349; [林朝展 LIN Chao-zhan], 2009, [热带亚热带植物学报, Journal of Tropical and Subtropical Botany], V17, P401; Liu LX, 2009, FOOD CHEM, V112, P35, DOI 10.1016/j.foodchem.2008.05.038; Morkunaite-Haimi S, 2003, BIOCHEM PHARMACOL, V65, P43, DOI 10.1016/S0006-2952(02)01450-8; Nie W., 2011, MODERN CHINESE MED, V13, P37; Ning D, 2012, GUIHAIA, V32, P845; Ozsoy N, 2009, FOOD CHEM, V116, P867, DOI 10.1016/j.foodchem.2009.03.036; Prior RL, 2005, J AGR FOOD CHEM, V53, P4290, DOI 10.1021/jf0502698; Prochazkova D, 2011, FITOTERAPIA, V82, P513, DOI 10.1016/j.fitote.2011.01.018; Re R, 1999, FREE RADICAL BIO MED, V26, P1231, DOI 10.1016/S0891-5849(98)00315-3; RiceEvans CA, 1997, TRENDS PLANT SCI, V2, P152, DOI 10.1016/S1360-1385(97)01018-2; Saiga A, 2003, J AGR FOOD CHEM, V51, P3661, DOI 10.1021/jf021156g; Sharma P, 2012, FOOD CHEM, V131, P1406, DOI 10.1016/j.foodchem.2011.10.009; Singh A, 2012, INT RES J PHARM, V3, P452; Tu YH, 2013, J ETHNOPHARMACOL, V146, P465, DOI 10.1016/j.jep.2012.12.051; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Wiriyaphan C, 2012, FOOD CHEM, V132, P104, DOI 10.1016/j.foodchem.2011.10.040; Xie ZJ, 2008, FOOD CHEM, V111, P370, DOI 10.1016/j.foodchem.2008.03.078; Yamasaki T, 2007, J NAT MED, V61, P318, DOI 10.1007/s11418-007-0135-x; Yan H., 2006, CHINA PHARM, V15, P3; Yesilada E, 2000, J ETHNOPHARMACOL, V73, P471, DOI 10.1016/S0378-8741(00)00327-5; Zhao HF, 2008, FOOD CHEM, V107, P296, DOI 10.1016/j.foodchem.2007.08.018; Zheng Q, 2012, STUDIES MED MAT QUAL, P1; Zhu XW, 2004, BRAIN RES, V1000, P32, DOI 10.1016/j.brainres.2004.01.012; Zou YP, 2011, J AGR FOOD CHEM, V59, P2268, DOI 10.1021/jf104640k	46	42	49	1	78	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2014	9	3							e93000	10.1371/journal.pone.0093000	http://dx.doi.org/10.1371/journal.pone.0093000			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE0SD	24667350	Green Published, gold, Green Submitted			2023-01-03	WOS:000333675600122
J	Ruchlewska, A; Wierdsma, AI; Kamperman, AM; van der Gaag, M; Smulders, R; Roosenschoon, BJ; Mulder, CL				Ruchlewska, Asia; Wierdsma, Andre I.; Kamperman, Astrid M.; van der Gaag, Mark; Smulders, Renee; Roosenschoon, Bert-Jan; Mulder, Cornelis L.			Effect of Crisis Plans on Admissions and Emergency Visits: A Randomized Controlled Trial	PLOS ONE			English	Article							ADVANCE DIRECTIVES; COMPULSORY TREATMENT; SELF-REPORT; HEALTH; PEOPLE; PSYCHIATRY; PSYCHOSIS	Objective: To establish whether patients with a crisis plan had fewer voluntary or involuntary admissions, or fewer outpatient emergency visits, than patients without such a plan. Design: Multicenter randomized controlled trial with two intervention conditions and one control condition. Participants: Adult outpatients diagnosed with psychotic or bipolar disorder who had experienced at least one psychiatric crisis in the previous two years. Intervention: Two types of advance statement were used: (1) a crisis plan formulated by the patient with the help of a patient advocate (Patient Advocate Crisis Plan: PACP); and (2) a crisis plan developed together with the clinician (Clinician-facilitated Crisis Plan: CCP). Outcome: The percentages of patients admitted voluntarily or involuntarily (on an emergency basis or by court order), and the percentage who made outpatient emergency visits over an 18-month follow-up period. Results: A total of 212 patients were included: 69 in the PACP condition, 70 in the CCP condition, and 73 in the control condition. No effects of the two interventions were found on the numbers of voluntary admissions, involuntary admissions and emergency visits. Regarding involuntary admissions, there was no significant effect on emergency admissions, which were 17% (12/69) in the PACP condition, 10% (7/70) in the CCP condition, and 19% (14/73) in the control condition. There was a significant effect on planned court-ordered admissions, with 16% (11/69) in the PACP condition, 10% (7/70) in the CCP condition, and 26% (19/73) in the control condition. Finally, the interventions had no effect on outpatient emergency visits, with 32% (22/69) in the PACP group, 31% (22/70) in the CCP group, and 34% (25/73) in the control group. Conclusions: Crisis plans may be an effective intervention for reducing court-ordered admissions in patients with psychotic and bipolar disorders.	[Ruchlewska, Asia; Wierdsma, Andre I.; Kamperman, Astrid M.; Roosenschoon, Bert-Jan; Mulder, Cornelis L.] Erasmus MC, Epidemiol & Social Psychiat Res Inst, Rotterdam, Netherlands; [Roosenschoon, Bert-Jan; Mulder, Cornelis L.] BavoEuropoort, Ctr Mental Hlth Care, Rotterdam, Netherlands; [van der Gaag, Mark] Parnassia Psychiat Inst, The Hague, Netherlands; [van der Gaag, Mark] Vrije Univ Amsterdam, Amsterdam, Netherlands; [van der Gaag, Mark] EMGO Inst Hlth & Care Res, Amsterdam, Netherlands; [Smulders, Renee] Landelijk Crisiskaart O GGZ Informatie Ondersteun, Utrecht, Netherlands	Erasmus University Rotterdam; Erasmus MC; Parnassia Psychiatric Institute; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	Ruchlewska, A (corresponding author), Erasmus MC, Epidemiol & Social Psychiat Res Inst, Rotterdam, Netherlands.	j.ruchlewska@erasmusmc.nl	Mulder, Cornelis Lambert/HGU-3446-2022; Kamperman, Astrid/J-8046-2015; van der Gaag, Mark/A-6840-2008	Kamperman, Astrid/0000-0003-4455-6492; van der Gaag, Mark/0000-0002-3525-6415; Wierdsma, Andre/0000-0002-0734-4776	Dutch organization for health research and development (ZonMw); BavoEuropoort	Dutch organization for health research and development (ZonMw)(Netherlands Organization for Health Research and Development); BavoEuropoort	The trial was funded by the Dutch organization for health research and development (ZonMw) and BavoEuropoort. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BIRCHWOOD M, 1994, ACTA PSYCHIAT SCAND, V89, P62, DOI 10.1111/j.1600-0447.1994.tb01487.x; Campbell LA, 2009, COCHRANE DB SYST REV, V21; Cohen J., 2013, STAT POWER ANAL BEHA; Gaag M. van der, 2002, DTH, V22, P15; Henderson C, 2004, BRIT MED J, V329, P136, DOI 10.1136/bmj.38155.585046.63; Henderson C, 2008, PSYCHIAT SERV, V59, P63, DOI 10.1176/ps.2008.59.1.63; HORVATH AO, 1989, J COUNS PSYCHOL, V36, P223, DOI 10.1037/0022-0167.36.2.223; Mulder C., 2004, TIJDSCHR PSYCHIAT, V46, P273; Mulder CL, 2008, INT J LAW PSYCHIAT, V31, P331, DOI 10.1016/j.ijlp.2008.06.007; Mulder C L, 2008, Tijdschr Psychiatr, V50, P229; Mulder CL, 2002, TIJD PSYCHIAT, V44, P523; Papageorgiou A, 2002, BRIT J PSYCHIAT, V181, P513, DOI 10.1192/bjp.181.6.513; Ruchlewska A, 2009, BMC PSYCHIATRY, V9, DOI 10.1186/1471-244X-9-41; Salize HJ, 2004, BRIT J PSYCHIAT, V184, P163, DOI 10.1192/bjp.184.2.163; Srebnik DS, 1999, PSYCHIAT SERV, V50, P919, DOI 10.1176/ps.50.7.919; Sutherby K, 1999, ACTA PSYCHIAT SCAND, V100, P56, DOI 10.1111/j.1600-0447.1999.tb10914.x; Swanson JW, 2006, AM J PSYCHIAT, V163, P1943, DOI 10.1176/appi.ajp.163.11.1943; Swartz MS, 2003, BEHAV SCI LAW, V21, P459, DOI 10.1002/bsl.539; Tait Lynda, 2002, J Ment Health, V11, P191, DOI 10.1080/09638230020023570-2; Thornicroft G, 2013, LANCET, V381, P1634, DOI 10.1016/S0140-6736(13)60105-1; Vervaeke GAC, 1996, GEDRAGSTEHRAPIE, V2, P139; Wierdsma AI, 2008, CURR OPIN PSYCHIATR, V21, P379, DOI 10.1097/YCO.0b013e328304d99b; Wing JK, 1998, BRIT J PSYCHIAT, V172, P11, DOI 10.1192/bjp.172.1.11; WIZNITZER M, 1992, ACTA PSYCHIAT SCAND, V86, P32, DOI 10.1111/j.1600-0447.1992.tb03221.x	24	28	28	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2014	9	3							e91882	10.1371/journal.pone.0091882	http://dx.doi.org/10.1371/journal.pone.0091882			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AD6ER	24647274	Green Published, Green Submitted, gold			2023-01-03	WOS:000333348500057
J	Lisnevskaia, L; Murphy, G; Isenberg, D				Lisnevskaia, Larissa; Murphy, Grainne; Isenberg, David			Systemic lupus erythematosus	LANCET			English	Article							ANTIPHOSPHOLIPID SYNDROME; MYCOPHENOLATE-MOFETIL; MONOCLONAL-ANTIBODY; DOUBLE-BLIND; ACCELERATED ATHEROSCLEROSIS; CLASSIFICATION CRITERIA; RHEUMATOID-ARTHRITIS; ANTIMALARIAL-DRUGS; DISEASE-ACTIVITY; RISK-FACTORS	Systemic lupus erythematosus is a remarkable and challenging disorder. Its diversity of clinical features is matched by the complexity of the factors (genetic, hormonal, and environmental) that cause it, and the array of autoantibodies with which it is associated. In this Seminar we reflect on changes in its classification criteria; consider aspects of its more serious clinical expression; and provide a brief review of its aetiopathogenesis, major complications, coping strategies, and conventional treatment. Increased understanding of the cells and molecules involved in the development of the diseases has encouraged the identification of new, better targeted biological approaches to its treatment. The precise role of these newer therapies remains to be established.	[Lisnevskaia, Larissa] Oshawa Clin, Oshawa, ON, Canada; [Murphy, Grainne; Isenberg, David] Univ Coll London Hosp, Dept Med, Ctr Rheumatol, London WC1E 6JF, England	University College London Hospitals NHS Foundation Trust; University of London; University College London	Isenberg, D (corresponding author), Univ Coll London Hosp, Dept Med, Ctr Rheumatol, Rayne Bldg,Room 424,5 Univ St, London WC1E 6JF, England.	d.isenberg@ucl.ac.uk	绾柚, 苏/ABG-4442-2021	Isenberg, David/0000-0001-9514-2455				Abu-Shakra M, 2001, LUPUS, V10, P152, DOI 10.1191/096120301676669495; Adler M, 2006, RHEUMATOLOGY, V45, P1144, DOI 10.1093/rheumatology/kel039; Alessandri C, 2011, AUTOIMMUN REV, V10, P609, DOI 10.1016/j.autrev.2011.04.011; Ames PRJ, 2009, J THROMB HAEMOST, V7, P537, DOI 10.1111/j.1538-7836.2009.03308.x; Bernatsky S, 2006, ARTHRITIS RHEUM-US, V54, P2550, DOI 10.1002/art.21955; Bertsias GK, 2012, ANN RHEUM DIS, V71, P1771, DOI 10.1136/annrheumdis-2012-201940; Blair PA, 2010, IMMUNITY, V32, P129, DOI 10.1016/j.immuni.2009.11.009; Bracewell C, 2009, EXPERT OPIN BIOL TH, V9, P909, DOI 10.1517/14712590903033919; Broder A, 2013, J RHEUMATOL, V40, P30, DOI 10.3899/jrheum.120157; Brucato A, 2011, CLIN REV ALLERG IMMU, V40, P27, DOI 10.1007/s12016-009-8190-6; Burness CB, 2011, DRUGS, V71, P2435, DOI 10.2165/11208440-000000000-00000; Buyon JP, 2005, ANN INTERN MED, V142, P953, DOI 10.7326/0003-4819-142-12_Part_1-200506210-00004; Caricchio R, 2003, J IMMUNOL, V171, P5778, DOI 10.4049/jimmunol.171.11.5778; Cervera R, 2009, LUPUS, V18, P869, DOI 10.1177/0961203309106831; Cervera R, 2010, REUMATOL CLIN, V6, P37, DOI 10.1016/j.reuma.2008.11.020; Clowse MEB, 2007, RHEUM DIS CLIN N AM, V33, P237, DOI 10.1016/j.rdc.2007.01.002; Condon MB, 2013, ANN RHEUM DIS, V72, P1280, DOI 10.1136/annrheumdis-2012-202844; Costenbader KH, 2007, ARTHRITIS RHEUM-US, V56, P1251, DOI 10.1002/art.22510; D'Cruz DP, 2007, LANCET, V369, P587, DOI 10.1016/S0140-6736(07)60279-7; David KM, 2005, CLIN TRANSPLANT, V19, P279, DOI 10.1111/j.1399-0012.2005.00338.x; Day CJ, 2009, NEPHROL DIAL TRANSPL, V24, P344, DOI 10.1093/ndt/gfn651; de Carvalho MRP, 2005, ARTHRIT RHEUM-ARTHR, V53, P838, DOI 10.1002/art.21605; Dobkin PL, 2001, J RHEUMATOL, V28, P2442; Dorner T, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1942; Dorner T, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3433; Dolff S, 2010, EXPERT REV CLIN IMMU, V6, P901, DOI 10.1586/ECI.10.79; Dooley MA, 2011, NEW ENGL J MED, V365, P1886, DOI 10.1056/NEJMoa1014460; dos Reis-Neto ET, 2013, RHEUMATOLOGY, V52, P2187, DOI 10.1093/rheumatology/ket283; El-Magadmi M, 2004, CIRCULATION, V110, P399, DOI 10.1161/01.CIR.0000136807.78534.50; Emer Jason J, 2009, J Clin Aesthet Dermatol, V2, P29; Escarcega RO, 2009, LUPUS, V18, P383, DOI 10.1177/0961203308101435; Ezeonyeji AN, 2012, RHEUMATOLOGY, V51, P476, DOI 10.1093/rheumatology/ker337; Furie R, 2011, ARTHRITIS RHEUM-US, V63, P3918, DOI 10.1002/art.30613; Giles I, 2012, LUPUS, V21, P1263, DOI 10.1177/0961203312458843; Ginzler EM, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3738; Guerra SG, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3844; Gustafsson JT, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3759; Ioannou Y, 2008, ANN RHEUM DIS, V67, P425, DOI 10.1136/ard.2007.078402; Isenberg D, 2013, ANN RHEUM DIS, V72, P258; Jacob N, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3349; Jajoria P, 2009, ANN NY ACAD SCI, V1173, P736, DOI 10.1111/j.1749-6632.2009.04815.x; Jung HJ, 2010, ARTHRITIS RHEUM-US, V62, P863, DOI 10.1002/art.27289; Kamen D, 2008, CURR OPIN RHEUMATOL, V20, P532, DOI 10.1097/BOR.0b013e32830a991b; Kiani AN, 2012, RHEUMATOL INT, V32, P2701, DOI 10.1007/s00296-011-2048-y; Kirou KA, 2013, CLIN IMMUNOL, V148, P303, DOI 10.1016/j.clim.2013.02.013; Kumar Deepak, 2010, Curr Rheumatol Rep, V12, P40, DOI 10.1007/s11926-009-0074-5; Lee YH, 2011, LUPUS, V20, P636, DOI 10.1177/0961203310389486; Lopez-Pedrera C, 2012, CURR RHEUMATOL REP, V14, P87, DOI 10.1007/s11926-011-0222-6; Manzi S, 1997, AM J EPIDEMIOL, V145, P408; Manzi S, 1999, ARTHRITIS RHEUM-US, V42, P51, DOI 10.1002/1529-0131(199901)42:1<51::AID-ANR7>3.0.CO;2-D; Mazzoni D, 2011, LUPUS, V20, P1117, DOI 10.1177/0961203311412994; Merrill JT, 2010, ARTHRITIS RHEUM-US, V62, P3077, DOI 10.1002/art.27601; Merrill JT, 2011, ANN RHEUM DIS, V70, P1905, DOI 10.1136/ard.2010.144485; Merrill JT, 2010, ARTHRITIS RHEUM-US, V62, P222, DOI 10.1002/art.27233; Miyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111/j.1538-7836.2006.01753.x; Moroni G, 2009, NEPHROL DIAL TRANSPL, V24, P15, DOI 10.1093/ndt/gfn565; Moulton VR, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3251; Navarra SV, 2011, LANCET, V377, P721, DOI 10.1016/S0140-6736(10)61354-2; Nikpour M, 2012, ARTHRITIS RHEUM-US, V64, P3052, DOI 10.1002/art.34541; Ntali S, 2011, CLIN REV ALLERG IMMU, V40, P181, DOI 10.1007/s12016-009-8196-0; Pepper R, 2009, NEPHROL DIAL TRANSPL, V24, P3717, DOI 10.1093/ndt/gfp336; Petri M, 2013, ARTHRITIS RHEUM-US, V65, P1011, DOI 10.1002/art.37824; Petri M, 2012, ARTHRITIS RHEUM-US, V64, P2677, DOI 10.1002/art.34473; Philip Errol J, 2009, J Allied Health, V38, P106; Pierangeli SS, 2010, LUPUS, V19, P475, DOI 10.1177/0961203310361489; Popescu A, 2011, CURR NEUROPHARMACOL, V9, P449, DOI 10.2174/157015911796557984; Rahman P, 1999, J RHEUMATOL, V26, P325; Renau AI, 2012, LUPUS, V21, P1041, DOI 10.1177/0961203312444771; Roman MJ, 2003, NEW ENGL J MED, V349, P2399, DOI 10.1056/NEJMoa035471; Rovin BH, 2012, ARTHRITIS RHEUM-US, V64, P1215, DOI 10.1002/art.34359; Ruiz-Irastorza G, 2008, LUPUS, V17, P271, DOI 10.1177/0961203307086643; Ruiz-Irastorza G, 2009, BEST PRACT RES CL RH, V23, P575, DOI 10.1016/j.berh.2009.04.004; Sardy M, 2009, ARCH DERMATOL RES, V301, P93, DOI 10.1007/s00403-008-0894-6; Shao WH, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3206; Somers EC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037000; Stohl W, 2012, NAT BIOTECHNOL, V30, P69, DOI 10.1038/nbt.2076; Symmons DPM, 2011, NAT REV RHEUMATOL, V7, P399, DOI 10.1038/nrrheum.2011.75; Teschner S, 2010, IMMUNOTHERAPY-UK, V2, P637, DOI [10.2217/imt.10.52, 10.2217/IMT.10.52]; Thompson A, 2010, TARASCON POCKET RHEU; Todd DJ, 2007, INT J CLIN PRACT, V61, P494, DOI 10.1111/j.1742-1241.2007.01289.x; Traczewski P, 2011, BRIT J CLIN PHARMACO, V71, P175, DOI 10.1111/j.1365-2125.2010.03767.x; Urowitz MB, 2008, J RHEUMATOL, V35, P2152, DOI 10.3899/jrheum.080214; Vasudevan A, 2010, RHEUM DIS CLIN N AM, V36, P1, DOI 10.1016/j.rdc.2009.12.005; Wahren-Herlenius M, 2013, LANCET, V382, P819, DOI 10.1016/S0140-6736(13)60954-X; Wallace DJ, 2014, ANN RHEUM DIS, V73, P183, DOI 10.1136/annrheumdis-2012-202760; Williams EL, 2009, RHEUMATOLOGY, V48, P716, DOI 10.1093/rheumatology/kep080; Wong J. M., 2005, Lupus, V14, P101, DOI 10.1191/0961203305lu2043rr; Yamaguchi H, 2008, J LEUKOCYTE BIOL, V83, P1300, DOI 10.1189/jlb.1107730; Yee CS, 2012, RHEUMATOLOGY, V51, P1877, DOI 10.1093/rheumatology/kes158; Zandman-Goddard G, 2012, LUPUS, V21, P241, DOI 10.1177/0961203311426568; Zandman-Goddard G, 2009, LUPUS, V18, P884, DOI 10.1177/0961203309106921; Zandman-Goddard G, 2007, SEMIN ARTHRITIS RHEU, V36, P297, DOI 10.1016/j.semarthrit.2006.11.003	92	457	495	19	139	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	2014	384	9957					1878	1888		10.1016/S0140-6736(14)60128-8	http://dx.doi.org/10.1016/S0140-6736(14)60128-8			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AT7LA	24881804				2023-01-03	WOS:000345116800028
J	Pepin, J; Abou Chakra, CN; Pepin, E; Nault, V; Valiquette, L				Pepin, Jacques; Abou Chakra, Claire Nour; Pepin, Eric; Nault, Vincent; Valiquette, Louis			Evolution of the Global Burden of Viral Infections from Unsafe Medical Injections, 2000-2010	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEALTH-CARE WORKERS; OCCUPATIONAL-EXPOSURE; HIV-INFECTION; RISK-FACTORS; HUMAN-PAPILLOMAVIRUS; UGANDAN ADULTS; DRUG-USERS; E-ANTIGEN; TRANSMISSION	Background: In 2000, the World Health Organization estimated that, in developing and transitional countries, unsafe injections accounted for respectively 5%, 32% and 40% of new infections with HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV). Safe injection campaigns were organized worldwide. The present study sought to measure the progress in reducing the transmission of these viruses through unsafe injections over the subsequent decade. Methods: A mass action model was updated, to recalculate the number of injection-related HIV, HCV and HBV infections acquired in 2000 and provide estimates for 2010. Data about the annual number of unsafe injections were updated. HIV prevalence in various regions in 2000 and 2010 were calculated from UNAIDS data. The ratio of HIV prevalence in healthcare settings compared to the general population was estimated from a literature review. Improved regional estimates of the prevalence of HCV seropositivity, HBsAg and HBeAg antigenemia were used for 2000 and 2010. For HIV and HCV, revised estimates of the probability of transmission per episode of unsafe injection were used, with low and high values allowing sensitivity analyses. Results: Despite a 13% population growth, there was a reduction of respectively 87% and 83% in the absolute numbers of HIV and HCV infections transmitted through injections. For HBV, the reduction was more marked (91%) due to the additional impact of vaccination. While injections-related cases had accounted for 4.6%-9.1% of newly acquired HIV infections in 2000, this proportion decreased to 0.7%-1.3% in 2010, when unsafe injections caused between 16,939 and 33,877 HIV infections, between 157,592 and 315,120 HCV infections, and 1,679,745 HBV infections. Conslusion: From 2000 to 2010, substantial progress was made in reducing the burden of HIV, HCV and HBV infections transmitted through injections. In some regions, their elimination might become a reasonable public health goal.	[Pepin, Jacques; Abou Chakra, Claire Nour; Pepin, Eric; Nault, Vincent; Valiquette, Louis] Univ Sherbrooke, Dept Microbiol & Infect Dis, Sherbrooke, PQ J1K 2R1, Canada	University of Sherbrooke	Pepin, J (corresponding author), Univ Sherbrooke, Dept Microbiol & Infect Dis, Sherbrooke, PQ J1K 2R1, Canada.	jacques.pepin@usherbrooke.ca			Safe Injection Global Network	Safe Injection Global Network	This work was supported by the Safe Injection Global Network which had no role in study design, data collection and analysis, preparation of the manuscript and decision to publish. The views expressed in this article are those of the authors only.	[Anonymous], DEM HLTH SURV; Avert, S AFR HIV AIDS STAT; Baggaley RF, 2006, AIDS, V20, P805, DOI 10.1097/01.aids.0000218543.46963.6d; Banura C, 2008, J INFECT DIS, V197, P555, DOI 10.1086/526792; Bebell LM, 2010, AIDS, V24, P1945, DOI 10.1097/QAD.0b013e32833bb732; Bell David M., 1997, American Journal of Medicine, V102, P9, DOI 10.1016/S0002-9343(97)89441-7; Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101; U.S. Public Health Service, 2001, MMWR Recomm Rep, V50, P1; Chang LW, 2002, J ACQ IMMUN DEF SYND, V29, P511, DOI 10.1097/00042560-200204150-00012; Croce F, 2007, TROP MED INT HEALTH, V12, P1011, DOI 10.1111/j.1365-3156.2007.01880.x; Francesconi P, 2001, AIDS, V15, P2445, DOI 10.1097/00002030-200112070-00013; Gerberding JL, 2003, NEW ENGL J MED, V348, P826, DOI 10.1056/NEJMcp020892; GERBERDING JL, 1995, NEW ENGL J MED, V332, P444, DOI 10.1056/NEJM199502163320707; Gisselquist D, 2006, INFECT CONT HOSP EP, V27, P944, DOI 10.1086/506408; Hanafiah KM, 2013, HEPATOLOGY, V57, P1333, DOI 10.1002/hep.26141; Hauri AM, 2004, INT J STD AIDS, V15, P7, DOI 10.1258/095646204322637182; Hauri AM., 2004, COMP QUANTIFICATION; Horwood C, 2011, TROP MED INT HEALTH, V16, P42, DOI 10.1111/j.1365-3156.2010.02672.x; Hudgens MG, 2002, AM J EPIDEMIOL, V155, P159, DOI 10.1093/aje/155.2.159; Hudgens MG, 2001, J ROY STAT SOC C-APP, V50, P1, DOI 10.1111/1467-9876.00216; Hutin YJF, 2003, BMJ-BRIT MED J, V327, P1075, DOI 10.1136/bmj.327.7423.1075; IPPOLITO G, 1993, ARCH INTERN MED, V153, P1451, DOI 10.1001/archinte.153.12.1451; Ivers Louise C, 2007, AIDS Res Ther, V4, P28, DOI 10.1186/1742-6405-4-28; Jagger J, 2002, JAMA-J AM MED ASSOC, V288, P1469, DOI 10.1001/jama.288.12.1469; Kamya MR, 2006, J INFECT DIS, V193, P9, DOI 10.1086/498577; KAPLAN EH, 1992, J ACQ IMMUN DEF SYND, V5, P1116; La Ruche G, 1998, INT J CANCER, V76, P480, DOI 10.1002/(SICI)1097-0215(19980518)76:4&lt;480::AID-IJC6&gt;3.0.CO;2-N; Njobvu P, 1998, J RHEUMATOL, V25, P1553; Ott JJ, 2012, VACCINE, V30, P2212, DOI 10.1016/j.vaccine.2011.12.116; Ott JJ, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-131; Pepin J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080948; Pilcher CD, 2004, AIDS, V18, P517, DOI 10.1097/00002030-200402200-00019; Reid S, 2009, INT J STD AIDS, V20, P295, DOI 10.1258/ijsa.2008.008441; Schmid GP, 2004, LANCET, V363, P482, DOI 10.1016/S0140-6736(04)15497-4; Shisana O, 2008, AIDS CARE, V20, P755, DOI 10.1080/09540120701771705; Solomon SS, 2004, INT J STD AIDS, V15, P658, DOI 10.1258/0956462041944402; Tharyan P, 2003, AIDS CARE, V15, P197, DOI 10.1080/0954012031000068344; TOKARS JI, 1993, ANN INTERN MED, V118, P913, DOI 10.7326/0003-4819-118-12-199306150-00001; UNAIDS, 2010, UNAIDS REP GLOB AIDS; United Nations Department of Economic and Social Affairs, WORLD POP PROSP 2010; Van Geertruyden JP, 2006, J INFECT DIS, V194, P917, DOI 10.1086/507310; Wanyenze RK, 2008, B WORLD HEALTH ORGAN, V86, P302, DOI 10.2471/BLT.07.042580; WERNER BG, 1982, ANN INTERN MED, V97, P367, DOI 10.7326/0003-4819-97-3-367; World Health Organization, IMM SURV ASS MON; Yazdanpanah Y, 2005, CLIN INFECT DIS, V41, P1423, DOI 10.1086/497131	45	73	77	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 9	2014	9	6							e99677	10.1371/journal.pone.0099677	http://dx.doi.org/10.1371/journal.pone.0099677			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI8LF	24911341	Green Published, gold, Green Submitted			2023-01-03	WOS:000337165600114
J	Periyakoil, VS; Neri, E; Fong, A; Kraemer, H				Periyakoil, Vyjeyanthi S.; Neri, Eric; Fong, Ann; Kraemer, Helena			Do Unto Others: Doctors' Personal End-of-Life Resuscitation Preferences and Their Attitudes toward Advance Directives	PLOS ONE			English	Article							CANCER-PATIENTS; PHYSICIANS ATTITUDES; CARE; SIZE	Objective: High-intensity interventions are provided to seriously-ill patients in the last months of life by medical sub-specialists. This study was undertaken to determine if doctors' age, ethnicity, medical sub-specialty and personal resuscitation and organ donation preferences influenced their attitudes toward Advance Directives (AD) and to compare a cohort of 2013 doctors to a 1989 (one year before the Patient Self Determination Act in 1990) cohort to determine any changes in attitudes towards AD in the past 23 years. Design: Doctors in two academic medical centers participated in an AD simulation and attitudes survey in 2013 and their responses were compared to a cohort of doctors in 1989. Outcomes: Resuscitation and organ donation preferences (2013 cohort) and attitudes toward AD (1989 and 2013 cohorts). Results: In 2013, 1081 (94.2%) doctors of the 1147 approached participated. Compared to 1989, 2013 cohort did not feel that widespread acceptance of AD would result in less aggressive treatment even of patients who do not have an AD (p<0.001, AUC = 0.77); had greater confidence in their treatment decisions if guided by an AD (p<.001, AUC = 0.58) and were less worried about legal consequences of limiting treatment when following an AD (p<.001, AUC = 0.57). The gender (p = 0.00172), ethnicity (chi(2) 14.68, DF = 3, p = .0021) and sub-specialty (chi(2) 28.92, p = .004, DF = 12) influenced their attitudes towards AD. 88.3% doctors chose do-not-resuscitate status and wanted to become organ donors. Those less supportive of AD were more likely to opt for "full code'' even if terminally ill and were less supportive of organ donation. Conclusions: Doctors' attitudes towards AD has not changed significantly in the past 23 years. Doctors' gender, ethnicity and sub-specialty influence their attitudes towards AD. Our study raises questions about why doctors continue to provide high-intensity care for terminally ill patients but personally forego such care for themselves at the end of life.	[Periyakoil, Vyjeyanthi S.; Neri, Eric; Kraemer, Helena] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; [Periyakoil, Vyjeyanthi S.] Vet Affairs VA Palo Alto Hlth Care Syst, Palo Alto, CA USA; [Fong, Ann] Stanford Hosp & Clin, Palo Alto, CA USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Periyakoil, VS (corresponding author), Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.	periyakoil@stanford.edu			National Institutes of Health Grants [1R25MD006857]; Stanford University School of Medicine and the Department of Veterans Affairs; NATIONAL CANCER INSTITUTE [R25CA115562] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [R25MD006857] Funding Source: NIH RePORTER	National Institutes of Health Grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Stanford University School of Medicine and the Department of Veterans Affairs; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	Dr. Periyakoil's work is supported by National Institutes of Health Grants 1R25MD006857, Stanford University School of Medicine and the Department of Veterans Affairs. Project site http://aging.stanford.edu. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barnato AE, 2007, MED CARE, V45, P386, DOI 10.1097/01.mlr.0000255248.79308.41; Blechman JA, 2013, J PALLIAT MED, V16, P1285, DOI 10.1089/jpm.2013.0257; Blondeau D, 1998, J MED ETHICS, V24, P328, DOI 10.1136/jme.24.5.328; Bond CJ, 2011, AGE AGEING, V40, P450, DOI 10.1093/ageing/afr025; Bradley CT, 2010, SURGERY, V148, P209, DOI 10.1016/j.surg.2010.05.020; Brotherton Sarah E, 2013, JAMA, V310, P2328, DOI 10.1001/jama.2013.278364; Cassell J, 2003, CRIT CARE MED, V31, P1551, DOI 10.1097/00003246-200305000-00039; Chow E, 2001, CLIN ONCOL-UK, V13, P209, DOI 10.1007/s001740170078; Christakis NA, 2000, BRIT MED J, V320, P469, DOI 10.1136/bmj.320.7233.469; Cutler D.M., 2013, NBER WORKING PAPER S; DAVIDSON KW, 1989, JAMA-J AM MED ASSOC, V262, P2415, DOI 10.1001/jama.262.17.2415; Gallo JJ, 2003, J AM GERIATR SOC, V51, P961, DOI 10.1046/j.1365-2389.2003.51309.x; Gallup GH, 1997, SPIRITUAL BELIEFS DY; Hsu LA, 2004, PSYCHOL METHODS, V9, P183, DOI 10.1037/1082-989X.9.2.183; HUGHES DL, 1992, CAN MED ASSOC J, V146, P1937; Kraemer H. C, 2008, WILEY ENCY CLIN TRIA, P1; Kraemer HC, 2006, BIOL PSYCHIAT, V59, P990, DOI 10.1016/j.biopsych.2005.09.014; KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441; Kung HC, 2008, NATL VITAL STAT REPO; Maltoni M, 2005, J CLIN ONCOL, V23, P6240, DOI 10.1200/JCO.2005.06.866; MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491; Periyakoil VS, 2010, J PALLIAT MED, V13, P495, DOI 10.1089/jpm.2009.0279; Periyakoil VS, 2009, J PALLIAT MED, V12, P1125, DOI 10.1089/jpm.2009.0123; Redmann AJ, 2012, ANN SURG, V255, P418, DOI 10.1097/SLA.0b013e31823b6782; Schuklenk U, 2011, BIOETHICS, V25, P1, DOI 10.1111/j.1467-8519.2011.01939.x; Schwarze ML, 2010, CRIT CARE MED, V38, P843, DOI 10.1097/CCM.0b013e3181cc466b; Smits HL, 2002, PALLIATIVE CARE OPPO; Straton JB, 2004, J AM GERIATR SOC, V52, P577, DOI 10.1111/j.1532-5415.2004.52165.x; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Toller CAS, 2006, J PALLIATIVE CARE, V22, P141, DOI 10.1177/082585970602200303; WILCOXON F, 1946, J ECON ENTOMOL, V39, P269, DOI 10.1093/jee/39.2.269; Wittink MN, 2008, ARCH INTERN MED, V168, P2125, DOI 10.1001/archinte.168.19.2125; Wu S. Y., 2000, PROJECTION CHRONIC I	33	59	62	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2014	9	5							e98246	10.1371/journal.pone.0098246	http://dx.doi.org/10.1371/journal.pone.0098246			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AI4TS	24869673	Green Submitted, Green Published, gold			2023-01-03	WOS:000336858300028
J	Huang, JC; Chen, SC; Lin, MY; Chang, JM; Hwang, SJ; Tsai, JC; Chen, HC				Huang, Jiun-Chi; Chen, Szu-Chia; Lin, Ming-Yen; Chang, Jer-Ming; Hwang, Shang-Jyh; Tsai, Jer-Chia; Chen, Hung-Chun			Association of Relatives of Hemodialysis Patients with Metabolic Syndrome, Albuminuria and Framingham Risk Score	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; CORONARY-HEART-DISEASE; STAGE RENAL-DISEASE; FAMILY-HISTORY; CARDIOVASCULAR-DISEASE; ENDOTHELIAL DYSFUNCTION; INSULIN-RESISTANCE; PUBLIC-HEALTH; POPULATION; ARECA	Background and Aim: Metabolic syndrome (MetS), albuminuria, and the Framingham Risk Score (FRS) are significant predictors for cardiovascular disease (CVD). However, the relationship and clinical significance of these CVD predictors in individuals with a family history of end-stage renal disease (ESRD) are unclear. We investigated the association of relatives of hemodialysis (HD) patients with MetS, albuminuria, and the FRS. Methods: One hundred and sixty-six relatives of HD patients and 374 age- and sex-matched community controls were enrolled. MetS was defined using the Adult Treatment Panel III for Asians. Albuminuria was defined as urine albumin-to-creatinine ratio >= 30 mg/g. CVD risk was evaluated by the FRS. Results: A significantly higher prevalence of MetS (19.9% vs. 12.5%, P=0.026), albuminuria (12.7% vs. 5.1%, P=0.002) and high FRS risk >= 10% of 10-year risk (15.7% vs. 8.5%, P=0.013) was found in relatives of HD patients compared to their counterpart controls. In multivariate analysis, being relatives of HD patients (vs. controls) was an independent determinant for MetS (odds ratio [OR], 1.785; 95% confidence interval [CI], 1.045 to 3.050), albuminuria (OR, 2.891; 95% CI, 1.431 to 5.841), and high FRS risk (OR, 1.863; 95% CI, 1.015 to 3.418). Higher low-density lipoprotein cholesterol (OR, 1.034; 95% CI, 1.017 to 1.052) and betel nut chewing (OR, 13.994; 95% CI, 3.384 to 57.871) were independent determinants for having a high FRS risk in relatives of HD patients. Conclusions: Being relatives of HD patients was independently associated with MetS, albuminuria and high FRS risk, suggesting family members of ESRD patients may have higher CVD risks through the interactions of renal risk factors. Proactive surveillance of these CVD predictors and preventive strategies should be targeted to this high-risk population.	[Huang, Jiun-Chi; Chen, Szu-Chia; Lin, Ming-Yen; Chang, Jer-Ming; Hwang, Shang-Jyh; Tsai, Jer-Chia; Chen, Hung-Chun] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Div Nephrol, Kaohsiung, Taiwan; [Huang, Jiun-Chi; Chen, Szu-Chia; Chang, Jer-Ming] Kaohsiung Med Univ, Kaohsiung Municipal Hsiao Kang Hosp, Dept Internal Med, Kaohsiung, Taiwan; [Chen, Szu-Chia] Kaohsiung Med Univ, Fac Med, Kaohsiung, Taiwan; [Chang, Jer-Ming; Hwang, Shang-Jyh; Tsai, Jer-Chia; Chen, Hung-Chun] Kaohsiung Med Univ, Coll Med, Fac Renal Care, Kaohsiung, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Municipal Siao-Gang Hospital; Kaohsiung Medical University; Kaohsiung Medical University	Tsai, JC (corresponding author), Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Div Nephrol, Kaohsiung, Taiwan.	jerchia@kmu.edu.tw	Lin, Ming Yen/A-8637-2010; 蘇, 河名/AAE-9843-2019; Huang, Jiun-Chi/AAI-2494-2021	Lin, Ming Yen/0000-0002-8194-4833; Huang, Jiun-Chi/0000-0002-5897-2860				Alexander MP, 2009, AM J KIDNEY DIS, V53, P751, DOI 10.1053/j.ajkd.2009.01.255; Bello AK, 2008, AM J KIDNEY DIS, V52, P434, DOI 10.1053/j.ajkd.2007.12.034; Cersosimo E, 2006, DIABETES-METAB RES, V22, P423, DOI 10.1002/dmrr.634; Chawla V, 2010, CLIN J AM SOC NEPHRO, V5, P1582, DOI 10.2215/CJN.01450210; Chen J, 2004, ANN INTERN MED, V140, P167, DOI 10.7326/0003-4819-140-3-200402030-00007; Chu NS, 2002, ADDICT BIOL, V7, P111, DOI 10.1080/13556210120091473; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Davignon J, 2004, CIRCULATION, V109, P27, DOI 10.1161/01.CIR.0000131515.03336.f8; de Zeeuw D, 2006, J AM SOC NEPHROL, V17, P2100, DOI 10.1681/ASN.2006050517; Deanfield JE, 2007, CIRCULATION, V115, P1285, DOI 10.1161/CIRCULATIONAHA.106.652859; FERGUSON R, 1988, J CLIN EPIDEMIOL, V41, P1189, DOI 10.1016/0895-4356(88)90023-6; Greenland P, 2010, J AM COLL CARDIOL, V56, pE50, DOI 10.1016/j.jacc.2010.09.001; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Guh JY, 2006, AM J CLIN NUTR, V83, P1313, DOI 10.1093/ajcn/83.6.1313; Gupta PC, 2002, ADDICT BIOL, V7, P77, DOI 10.1080/13556210020091437; Hillege HL, 2002, CIRCULATION, V106, P1777, DOI 10.1161/01.CIR.0000031732.78052.81; Hong YL, 1997, AM J HUM GENET, V60, P143; Jurkovitz C, 2005, AM J KIDNEY DIS, V46, P11, DOI 10.1053/j.ajkd.2005.04.012; Jurkovitz C, 2002, AM J KIDNEY DIS, V40, P1173, DOI 10.1053/ajkd.2002.36866; Kong XL, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-19; Lai KC, 2006, MUTAT RES-FUND MOL M, V599, P66, DOI 10.1016/j.mrfmmm.2006.01.005; Laslett LJ, 2012, J AM COLL CARDIOL, V60, pS1, DOI 10.1016/j.jacc.2012.11.002; Lei HH, 1998, J AM SOC NEPHROL, V9, P1270; Levey AS, 2007, KIDNEY INT, V72, P247, DOI 10.1038/sj.ki.5002343; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Malik S, 2004, CIRCULATION, V110, P1245, DOI 10.1161/01.CIR.0000140677.20606.0E; Massy ZA, 2013, KIDNEY INT, V84, P451, DOI 10.1038/ki.2013.181; McClellan W, 2007, J AM SOC NEPHROL, V18, P1344, DOI 10.1681/ASN.2006090952; McClellan WM, 2012, AM J KIDNEY DIS, V59, P25, DOI 10.1053/j.ajkd.2011.09.018; McClellan WM, 2009, AM J KIDNEY DIS, V53, pS100, DOI 10.1053/j.ajkd.2008.07.059; McCullough PA, 2007, ARCH INTERN MED, V167, P1122, DOI 10.1001/archinte.167.11.1122; Mottillo S, 2010, J AM COLL CARDIOL, V56, P1113, DOI 10.1016/j.jacc.2010.05.034; O'Dea DF, 1998, AM J KIDNEY DIS, V32, P794, DOI 10.1016/S0272-6386(98)70135-0; Palaniappan L, 2003, AM J HYPERTENS, V16, P952, DOI 10.1016/S0895-7061(03)01009-4; Sarnak MJ, 2000, AM J KIDNEY DIS, V35, pS117, DOI 10.1016/S0272-6386(00)70239-3; Satko SG, 2007, SEMIN DIALYSIS, V20, P229, DOI 10.1111/j.1525-139X.2007.00282.x; Shafique K, 2012, J INFLAMM-LOND, V9, DOI 10.1186/1476-9255-9-22; Singh AK, 2013, CURR OPIN NEPHROL HY, V22, P198, DOI 10.1097/MNH.0b013e32835dda78; Speckman RA, 2006, AM J KIDNEY DIS, V48, P50, DOI 10.1053/j.ajkd.2006.03.086; Tan CE, 2004, DIABETES CARE, V27, P1182, DOI 10.2337/diacare.27.5.1182; Tsai JC, 2010, AM J KIDNEY DIS, V55, P856, DOI 10.1053/j.ajkd.2009.12.021; Wannamethee SG, 2005, ARCH INTERN MED, V165, P2644, DOI 10.1001/archinte.165.22.2644; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; Xiang AH, 2001, CIRCULATION, V103, P78; Yamada T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070679; Yoon PW, 2002, GENET MED, V4, P304, DOI 10.1097/00125817-200207000-00009	46	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2014	9	5							e96362	10.1371/journal.pone.0096362	http://dx.doi.org/10.1371/journal.pone.0096362			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG9HB	24804770	Green Published, gold, Green Submitted			2023-01-03	WOS:000335728900052
J	Reekie, J; Donovan, B; Guy, R; Hocking, JS; Jorm, L; Kaldor, JM; Mak, DB; Preen, D; Pearson, S; Roberts, CL; Stewart, L; Wand, H; Ward, J; Liu, B				Reekie, Joanne; Donovan, Basil; Guy, Rebecca; Hocking, Jane S.; Jorm, Louisa; Kaldor, John M.; Mak, Donna B.; Preen, David; Pearson, Sallie; Roberts, Christine L.; Stewart, Louise; Wand, Handan; Ward, James; Liu, Bette			Hospitalisations for Pelvic Inflammatory Disease Temporally Related to a Diagnosis of Chlamydia or Gonorrhoea: A Retrospective Cohort Study	PLOS ONE			English	Article							CLINICAL HEALTH PEACH; INFECTION; WOMEN; TRACHOMATIS; AUSTRALIA; ADOLESCENTS; POPULATION; PREVENTION; SEQUELAE; TRIAL	Objectives: The presence and severity of pelvic inflammatory disease (PID) symptoms are thought to vary by microbiological etiology but there is limited empirical evidence. We sought to estimate and compare the rates of hospitalisation for PID temporally related to diagnoses of gonorrhoea and chlamydia. Methods: All women, aged 15-45 years in the Australian state of New South Wales (NSW), with a diagnosis of chlamydia or gonorrhoea between 01/07/2000 and 31/12/2008 were followed by record linkage for up to one year after their chlamydia or gonorrhoea diagnosis for hospitalisations for PID. Standardised incidence ratios compared the incidence of PID hospitalisations to the age-equivalent NSW population. Results: A total of 38,193 women had a chlamydia diagnosis, of which 483 were hospitalised for PID; incidence rate (IR) 13.9 per 1000 person-years of follow-up (PYFU) (95% CI 12.6-15.1). In contrast, 1015 had a gonorrhoea diagnosis, of which 45 were hospitalised for PID (IR 50.8 per 1000 PYFU, 95% CI 36.0-65.6). The annual incidence of PID hospitalisation temporally related to a chlamydia or gonorrhoea diagnosis was 27.0 (95% CI 24.4-29.8) and 96.6 (95% CI 64.7-138.8) times greater, respectively, than the age-equivalent NSW female population. Younger age, socio-economic disadvantage, having a diagnosis prior to 2005 and having a prior birth were also associated with being hospitalised for PID. Conclusions: Chlamydia and gonorrhoea are both associated with large increases in the risk of PID hospitalisation. Our data suggest the risk of PID hospitalisation is much higher for gonorrhoea than chlamydia; however, further research is needed to confirm this finding.	[Reekie, Joanne; Donovan, Basil; Guy, Rebecca; Kaldor, John M.; Wand, Handan; Ward, James] UNSW Australia, Kirby Inst, Sydney, NSW, Australia; [Donovan, Basil] Sydney Hosp, Sydney Sexual Hlth Ctr, Sydney, NSW, Australia; [Hocking, Jane S.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia; [Jorm, Louisa] Univ Western Sydney, Ctr Hlth Res, Sydney, NSW, Australia; [Mak, Donna B.] Univ Notre Dame, Sch Med, Fremantle, WA, Australia; [Preen, David] Univ Western Australia, Ctr Hlth Serv & Res, Crawley, WA, Australia; [Pearson, Sallie] Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia; [Pearson, Sallie] Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia; [Roberts, Christine L.] Univ Sydney, Kolling Inst Med Res, Sydney, NSW 2006, Australia; [Stewart, Louise] Curtin Univ, Ctr Populat Hlth Res, Perth, WA 6845, Australia; [Ward, James] Baker IDI, Alice Springs, NT, Australia; [Liu, Bette] UNSW Australia, Sch Publ Hlth & Community Med, Sydney, NSW, Australia; [Liu, Bette] Sax Inst, Sydney, NSW, Australia	University of New South Wales Sydney; Kirby Institute; University of Melbourne; Western Sydney University; University of Notre Dame Australia; University of Western Australia; University of Sydney; University of Sydney; University of Sydney; Kolling Institute of Medical Research; Curtin University; Baker Heart and Diabetes Institute; University of New South Wales Sydney; University of Sydney	Reekie, J (corresponding author), UNSW Australia, Kirby Inst, Sydney, NSW, Australia.	jreekie@kirby.unsw.edu.au	Stewart, Louise M/I-3753-2013; Donovan, Basil J/K-1246-2012; Hocking, Jane/AAD-5203-2021; Jorm, Louisa/AAN-6874-2020; Ward, James/ABD-1439-2020; Preen, David B/H-5663-2014	Stewart, Louise M/0000-0003-2015-6320; Donovan, Basil J/0000-0001-8851-4126; Hocking, Jane/0000-0001-9329-8501; Jorm, Louisa/0000-0003-0390-661X; Ward, James/0000-0002-2892-4542; Preen, David B/0000-0002-2982-2169; Mak, Donna/0000-0003-3215-4330; Guy, Rebecca/0000-0002-2929-4634	National Health and Medical Research Council (NHMRC) [1020628]; NHMRC	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	The study was funded by the National Health and Medical Research Council (NHMRC) grant #1020628. BD, RG, JH, JK, CR, and BL are all supported by NHMRC Fellowships. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali H, 2012, SEX HEALTH, V9, P399, DOI 10.1071/SH11183; Ansari Z, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-475; Australian Bureau of Statistics, 2012, AUSTR SOC TRENDS SEX; Australian Bureau of Statistics, 2011, 2011 CENS POP HOUS A; Bakken IJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-130; Centers for Disease Control and Prevention, 2012, SEX TRANSM DIS SURV; Chen MY, 2004, INT J STD AIDS, V15, P762, DOI 10.1258/0956462042395113; Davies B, 2013, SEX TRANSM DIS, V40, P230, DOI 10.1097/OLQ.0b013e31827b9d75; Department of Health and Aged Care & National Key Centre for Social Applications of Geographical Information Systems (GISCA), 2001, MEAS REM ACC REM IND; European Centre for Disease Prevention and Control, 2012, SEX TRANSM INF EUR 1; Gray-Swain MR, 2006, CURR OPIN OBSTET GYN, V18, P503, DOI 10.1097/01.gco.0000242952.87125.69; Guy R, 2012, SEX HEALTH, V9, P205, DOI 10.1071/SH11074; Herzog SA, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-187; Kong FYS, 2011, MED J AUSTRALIA, V194, P249, DOI 10.5694/j.1326-5377.2011.tb02957.x; Liu B, 2013, SEX TRANSM INFECT, V89, P45, DOI 10.1136/sextrans-2011-050252; Low N, 2006, SEX TRANSM INFECT, V82, P212, DOI 10.1136/sti.2005.017186; McKinley S, 2000, HEART LUNG, V29, P237, DOI 10.1067/mhl.2000.106940; Ness RB, 2006, SEX TRANSM DIS, V33, P137, DOI 10.1097/01.olq.0000187205.67390.d1; Ness RB, 2002, AM J OBSTET GYNECOL, V186, P929, DOI 10.1067/mob.2002.121625; Ness RB, 2008, SEX TRANSM DIS, V35, P129, DOI 10.1097/OLQ.0b013e3181557c25; Oakeshott P., 2010, BRIT MED J, V340, pc1642, DOI [10.1136/bmj.c1642, DOI 10.1136/BMJ.C1642]; Risser WL, 2012, INT J STD AIDS, V23, P457, DOI 10.1258/ijsa.2011.011362; Scholes D, 2012, SEX TRANSM DIS, V39, P81, DOI 10.1097/OLQ.0b013e31823e3009; Short VL, 2009, CLIN INFECT DIS, V48, P41, DOI 10.1086/594123; SOPER DE, 1994, AM J OBSTET GYNECOL, V170, P1008, DOI 10.1016/S0002-9378(94)70094-X; Statistics ABo, 2006, CENS POP HOUS SOC IN; The Kirby Institute, 2012, BLOODB VIR SEX TRANS; The Kirby Institute, 2012, HIV VIR HEP SEX TRAN; WASHINGTON AE, 1991, JAMA-J AM MED ASSOC, V266, P2581, DOI 10.1001/jama.266.18.2581; WASSERHEIT JN, 1986, ANN INTERN MED, V104, P187, DOI 10.7326/0003-4819-104-2-187; WESTROM L, 1992, SEX TRANSM DIS, V19, P185, DOI 10.1097/00007435-199207000-00001; WHO. World Health Organization, 1992, INT STAT CLASS DIS R	32	22	25	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2014	9	4							e94361	10.1371/journal.pone.0094361	http://dx.doi.org/10.1371/journal.pone.0094361			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG3IK	24743388	gold, Green Published			2023-01-03	WOS:000335309100030
J	Haagensen, AMJ; Sorensen, DB; Sandoe, P; Matthews, LR; Birck, MM; Fels, JJ; Astrup, A				Haagensen, Annika Maria Juul; Sorensen, Dorte Bratbo; Sandoe, Peter; Matthews, Lindsay R.; Birck, Malene Muusfeldt; Fels, Johannes Josef; Astrup, Arne			High Fat, Low Carbohydrate Diet Limit Fear and Aggression in Gottingen Minipigs	PLOS ONE			English	Article							ANXIETY-LIKE BEHAVIOR; SOCIAL-BEHAVIOR; GUT MICROBIOTA; YOUNG-ADULTS; CHOLESTEROL; BRAIN; PIGS; ASSOCIATION; HOSTILITY; DISEASE	High fat, low carbohydrate diets have become popular, as short-term studies show that such diets are effective for reducing body weight, and lowering the risk of diabetes and cardiovascular disease. There is growing evidence from both humans and other animals that diet affects behaviour and intake of fat has been linked, positively and negatively, with traits such as exploration, social interaction, anxiety and fear. Animal models with high translational value can help provide relevant and important information in elucidating potential effects of high fat, low carbohydrate diets on human behaviour. Twenty four young, male Gottingen minipigs were fed either a high fat/cholesterol, low carbohydrate diet or a low fat, high carbohydrate/sucrose diet in contrast to a standard low fat, high carbohydrate minipig diet. Spontaneous behaviour was observed through video recordings of home pens and test-related behaviours were recorded during tests involving animal-human contact and reaction towards a novel object. We showed that the minipigs fed a high fat/cholesterol, low carbohydrate diet were less aggressive, showed more non-agonistic social contact and had fewer and less severe skin lesions and were less fearful of a novel object than minipigs fed low fat, high carbohydrate diets. These results found in a porcine model could have important implications for general health and wellbeing of humans and show the potential for using dietary manipulations to reduce aggression in human society.	[Haagensen, Annika Maria Juul; Sorensen, Dorte Bratbo] Univ Copenhagen, Fac Hlth & Med Sci, Sect Expt Anim Models, Dept Vet Dis Biol, Frederiksberg, Denmark; [Sandoe, Peter] Univ Copenhagen, Dept Food & Resource Econ, Frederiksberg, Denmark; [Sandoe, Peter] Univ Copenhagen, Dept Large Anim Sci, Frederiksberg, Denmark; [Matthews, Lindsay R.] Lindsay R Matthews & Associates Res Int, Scerne Di Pineto, Italy; [Matthews, Lindsay R.] Univ Auckland, Dept Psychol, Auckland, New Zealand; [Birck, Malene Muusfeldt; Astrup, Arne] Univ Copenhagen, Fac Sci, Dept Nutr Exercise & Sports, Frederiksberg, Denmark; [Fels, Johannes Josef] Novo Nordisk AS, Malov, Denmark	University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Auckland; University of Copenhagen; Novo Nordisk	Sorensen, DB (corresponding author), Univ Copenhagen, Fac Hlth & Med Sci, Sect Expt Anim Models, Dept Vet Dis Biol, Frederiksberg, Denmark.	brat@sund.ku.dk	Sandøe, Peter/E-8758-2015; Astrup, Arne/B-1407-2015	Sandøe, Peter/0000-0003-0397-3273; Sorensen, Dorte Bratbo/0000-0002-6144-1710; Astrup, Arne/0000-0001-8968-8996	Centre for Applied Laboratory Animal Research; Danish Council for Strategic Research [2101-06-0034]	Centre for Applied Laboratory Animal Research; Danish Council for Strategic Research(Danske Strategiske Forskningsrad (DSF))	This study was supported by the Centre for Applied Laboratory Animal Research and the Danish Council for Strategic Research (Grant Number: 2101-06-0034). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Astrup A, 2011, AM J CLIN NUTR, V93, P684, DOI 10.3945/ajcn.110.004622; Bercik P, 2011, GASTROENTEROLOGY, V141, P599, DOI 10.1053/j.gastro.2011.04.052; Birck MM, 2011, AM J PHYSIOL-HEART C, V300, pH1595, DOI 10.1152/ajpheart.01253.2010; Bollen P, 1998, SCAND J LAB ANIM SCI, V25, P23; Bollen PJA, 2002, 32 SCAND LAS S GARD; BRAMBLETT C A, 1981, Primates, V22, P96, DOI 10.1007/BF02382560; Bravo JA, 2011, P NATL ACAD SCI USA, V108, P16050, DOI 10.1073/pnas.1102999108; Broom DM, 2009, ANIM BEHAV, V78, P1037, DOI 10.1016/j.anbehav.2009.07.027; Coccaro E, 2012, BRAIN BEHAV IMMUN S1, V26, pS28; Cryan JF, 2012, NAT REV NEUROSCI, V13, P701, DOI 10.1038/nrn3346; D'Eath RB, 2002, BEHAVIOUR, V139, P1175, DOI 10.1163/15685390260437326; Dalmau A, 2009, APPL ANIM BEHAV SCI, V117, P173, DOI 10.1016/j.applanim.2008.12.014; DeWall CN, 2011, AGGRESSIVE BEHAV, V37, P73, DOI 10.1002/ab.20366; Golomb BA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032175; Greenwood CE, 2001, J PSYCHIATR NEUROSCI, V26, P182; Grover CD, 2007, P ROY SOC B-BIOL SCI, V274, P2951, DOI 10.1098/rspb.2007.1065; Gunnarsson S, 2009, LIVEST SCI, V123, P306, DOI 10.1016/j.livsci.2008.12.002; Haagensen AMJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079429; Heijtza RD, 2011, P NATL ACAD SCI USA, V108, P3047, DOI 10.1073/pnas.1010529108; Held S, 2001, ANIM WELFARE, V10, pS209; HilakiviClarke L, 1996, LIFE SCI, V58, P1653, DOI 10.1016/0024-3205(96)00140-3; Hooper L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002137.pub3; Hu T, 2012, AM J EPIDEMIOL, V176, pS44, DOI 10.1093/aje/kws264; Iribarren C, 2000, JAMA-J AM MED ASSOC, V283, P2546, DOI 10.1001/jama.283.19.2546; Iribarren C, 2004, EUR J CLIN NUTR, V58, P24, DOI 10.1038/sj.ejcn.1601739; Janczak AM, 2003, APPL ANIM BEHAV SCI, V81, P13, DOI 10.1016/S0168-1591(02)00252-6; Johansen T, 2001, COMPARATIVE MED, V51, P150; Kanter MM, 2012, ADV NUTR, V3, P711, DOI 10.3945/an.111.001321; KAPLAN JR, 1991, PSYCHOSOM MED, V53, P634, DOI 10.1097/00006842-199111000-00005; KAPLAN JR, 1994, PSYCHOSOM MED, V56, P479, DOI 10.1097/00006842-199411000-00001; Larsen MO, 2006, AM J PHYSIOL-ENDOC M, V290, pE670, DOI 10.1152/ajpendo.00251.2005; Lewis CRG, 2008, LIVEST SCI, V116, P338, DOI 10.1016/j.livsci.2008.02.014; Lieberman HR, 2005, BRAIN RES BULL, V66, P149, DOI 10.1016/j.brainresbull.2005.04.011; LORE R, 1986, AGGRESSIVE BEHAV, V12, P409, DOI 10.1002/1098-2337(1986)12:6<409::AID-AB2480120603>3.0.CO;2-6; Neufeld KM, 2011, NEUROGASTROENT MOTIL, V23, DOI 10.1111/j.1365-2982.2010.01620.x; Pond WG, 2008, J NUTR, V138, P282, DOI 10.1093/jn/138.2.282; Ramsden CE, 2013, J BRIT MED, P346; Re S, 2008, VET RES COMMUN, V32, P225, DOI 10.1007/s11259-007-9021-y; Rodriguez-Estevez V, 2010, APPL ANIM BEHAV SCI, V127, P28, DOI 10.1016/j.applanim.2010.08.010; Rosado B, 2010, APPL ANIM BEHAV SCI, V123, P124, DOI 10.1016/j.applanim.2010.01.009; Schook L, 2005, ANIM BIOTECHNOL, V16, P183, DOI 10.1080/10495390500265034; Smulders D, 2006, PHYSIOL BEHAV, V89, P438, DOI 10.1016/j.physbeh.2006.07.002; Solnick SJ, 2012, INJURY PREV, V18, P259, DOI 10.1136/injuryprev-2011-040117; Sondergaard LV, 2007, SCAND J LAB ANIM SCI, V34, P91; Sparks DL, 2008, J ALZHEIMERS DIS, V15, P641; Spensley JC, 1995, APPL ANIM BEHAV SCI, V44, P257; Stewart CL, 2010, ANIM WELFARE, V19, P349; STOLBA A, 1989, ANIM PROD, V48, P419, DOI 10.1017/S0003356100040411; Sullivan EL, 2010, J NEUROSCI, V30, P3826, DOI 10.1523/JNEUROSCI.5560-09.2010; Swindle MM, 1998, SCAND J LAB ANIM SCI, V25, P11; Tsutsumi H, 2001, LAB ANIM-UK, V35, P236, DOI 10.1258/0023677011911688	51	29	30	1	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2014	9	4							e93821	10.1371/journal.pone.0093821	http://dx.doi.org/10.1371/journal.pone.0093821			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI4VW	24740321	Green Submitted, Green Published, gold			2023-01-03	WOS:000336863900027
J	Zhang, LL; Shao, XM; Zhou, CL; Guo, XQ; Jin, L; Lian, LL; Yu, XJ; Dong, ZH; Mo, YD; Fang, JQ				Zhang, Lele; Shao, Xiaomei; Zhou, Chuanlong; Guo, Xiaoqing; Jin, Ling; Lian, Linli; Yu, Xiaojing; Dong, Zhenhua; Mo, Yadi; Fang, Jianqiao			Transcutaneous Electrical Nerve Stimulation Regulates Organ Blood Flow and Apoptosis during Controlled Hypotension in Dogs	PLOS ONE			English	Article							CEREBRAL-ISCHEMIA; OPIOID RECEPTORS; ELECTROACUPUNCTURE; ACUPUNCTURE; HIPPOCAMPAL; MOXIBUSTION; ANESTHESIA; PREVENTS; ACUPOINT; BLOCKADE	Transcutaneous electrical nerve stimulation (TENS) is commonly used in clinical practice for alleviating pains and physiological disorders. It has been reported that TENS could counteract the ischemic injury happened in some vital organs. To determine the protective effect of TENS on internal organs during CH in dogs, target hypotension was maintained for 60 min at 50% of the baseline mean arterial pressure (MAP). The perfusion to the brain, liver, stomach, and kidney was recorded and apoptosis within these organs was observed. Results showed that when arriving at the target MAP, and during the maintaining stage for 10 min, perfusion to the stomach and liver in the CH+TENS group was much higher than in the CH group (P<0.05). Perfusion to the cerebral cortex greatly declined in both the controlled pressure groups when compared with the general anesthesia (GA) group (P<0.05). After withdrawing CH, the hepatic blood flow in both the CH and CH+TENS groups, and the gastric and cerebral cortical blood flow in the CH+TENS group, were rapidly increased. By the end of MAP restoration, gastric blood flow in the CH group was still low. At 72 h after applying CH, terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL)-positive cells in stomach and kidney tissue from the CH group were significantly increased compared with those in the GA group (P<0.05). There was no significant difference in TUNEL-positive cells in the liver and hippocampus among the three groups. Our results demonstrated that CH with a 50% MAP level could cause lower perfusion to the liver, stomach, cerebral cortex, and kidney, with apoptosis subsequently occurring in the stomach and kidney. TENS combined GA is able to improve the blood flow to the liver, stomach, and reduce the apoptosis in the stomach and kidney.	[Zhang, Lele; Shao, Xiaomei; Zhou, Chuanlong; Guo, Xiaoqing; Jin, Ling; Lian, Linli; Yu, Xiaojing; Dong, Zhenhua; Mo, Yadi; Fang, Jianqiao] Zhejiang Chinese Med Univ, Clin Med Coll 3, Dept Neurobiol & Acupuncture Res, Hangzhou, Zhejiang, Peoples R China	Zhejiang Chinese Medical University	Fang, JQ (corresponding author), Zhejiang Chinese Med Univ, Clin Med Coll 3, Dept Neurobiol & Acupuncture Res, Hangzhou, Zhejiang, Peoples R China.	fangjianqiao7532@163.com		Fang, Jianqiao/0000-0002-5155-8544	National Basic Research Program of China [2007CB512506]; First-foremost Key Subject of Acupuncture and Moxibustion Foundation of Zhejiang [[2008] 255]	National Basic Research Program of China(National Basic Research Program of China); First-foremost Key Subject of Acupuncture and Moxibustion Foundation of Zhejiang	This study was supported by the National Basic Research Program of China (2007CB512506) and the First-foremost Key Subject of Acupuncture and Moxibustion Foundation of Zhejiang ([2008] 255). The funders had no role in study design, date collection and analysis, decision to publish, or preparation of the manuscript.	Arai YCP, 2008, BRIT J ANAESTH, V100, P78, DOI 10.1093/bja/aem306; Arai YCP, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/727121; Chen AZ, 2012, INT J MOL MED, V30, P791, DOI 10.3892/ijmm.2012.1074; Chen L, 1998, ANESTH ANALG, V87, P1129, DOI 10.1097/00000539-199811000-00028; Dolman RM, 2000, J ORAL MAXIL SURG, V58, P834, DOI 10.1053/joms.2000.8194; Fang Jian-Qiao, 2011, Zhongguo Zhen Jiu, V31, P625; Fang JQ, 1999, J ZHEJIANG COLL TRAD, V23, P52; Haker E, 2000, J AUTONOM NERV SYST, V79, P52, DOI 10.1016/S0165-1838(99)00090-9; Hallen K, 2010, J PAIN SYMPTOM MANAG, V40, P95, DOI 10.1016/j.jpainsymman.2009.12.009; Jang MH, 2003, NEUROSCI LETT, V347, P5, DOI 10.1016/S0304-3940(03)00512-3; Jessurun G, 2003, EUR J PAIN, V7, P507, DOI 10.1016/S1090-3801(03)00022-3; Kalra A, 2001, J PHARMACOL EXP THER, V298, P257; Kawahara N, 2004, J CEREBR BLOOD F MET, V24, P212, DOI 10.1097/01.WCB.0000106012.33322.A2; Khalil Z, 2000, J GERONTOL A-BIOL, V55, pB257, DOI 10.1093/gerona/55.6.B257; Kurt F, 2005, ADV THER, V22, P234, DOI 10.1007/BF02849932; LESSARD MR, 1989, ANESTH ANALG, V69, P379; Li P, 2004, CLIN AUTON RES, V14, P182, DOI 10.1007/s10286-004-0175-1; Li ZY, 2005, EUR J APPL PHYSIOL, V94, P633, DOI 10.1007/s00421-005-1362-z; Liebano RE, 2013, EUR J PAIN; MCDOWALL DG, 1985, BRIT J ANAESTH, V57, P110, DOI 10.1093/bja/57.1.110; Schneider MP, 2013, BJU INT; [邵晓梅 Shao Xiaomei], 2012, [临床麻醉学杂志, The Journal of Clinical Anesthestology], V28, P599; Shi X, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/750620; Sluka KA, 1999, J PHARMACOL EXP THER, V289, P840; Stener-Victorin E, 2005, REPROD BIOL ENDOCRIN, V3, DOI 10.1186/1477-7827-3-44; Syuu Y, 2003, AM J PHYSIOL-REG I, V285, pR1446, DOI 10.1152/ajpregu.00243.2003; Syuu Y, 2001, JPN J PHYSIOL, V51, P231, DOI 10.2170/jjphysiol.51.231; Takeda S, 2004, CAN J ANAESTH, V51, P348, DOI 10.1007/BF03018238; Tellenbach M, 2012, WORLD J UROL; Vassal F, 2013, CLIN NEUROPHYSIOL; Wang B, 2007, ANESTH ANALG, V85, P406; Wang HM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019790; WANG JQ, 1992, INT J NEUROSCI, V65, P117, DOI 10.3109/00207459209003283; Wiessner C, 2000, CELL MOL BIOL, V46, P53; Wu HG, 2007, DIGEST DIS SCI, V52, P379, DOI 10.1007/s10620-006-9561-y; Wu HG, 2004, WORLD J GASTROENTERO, V10, P682, DOI 10.3748/wjg.v10.i5.682; Xie HS, 2007, XIES VET ACUPUNCTURE, P129; Zhang D., 2011, EVID-BASED COMPL ALT, V2011; Zhang HX, 2009, CAN J CARDIOL, V25, P359, DOI 10.1016/S0828-282X(09)70095-9; Zhang LL, 2012, CHINESE ARCH TRADITI, V30, P2167; Zhao JX, 2011, J TRADIT CHIN MED, V31, P349, DOI 10.1016/S0254-6272(12)60017-X; Zhong SB, 2009, EVID-BASED COMPL ALT, V6, P51, DOI 10.1093/ecam/nem062; Zhou Hai-peng, 2011, Zhonghua Yi Xue Za Zhi, V91, P1203	43	5	6	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 14	2014	9	4							e94368	10.1371/journal.pone.0094368	http://dx.doi.org/10.1371/journal.pone.0094368			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI6GP	24732970	Green Published, gold, Green Submitted			2023-01-03	WOS:000336970400033
J	Liao, DL; Huang, CY; Hu, SE; Fang, SC; Wu, CS; Chen, WT; Lee, TSH; Chen, PC; Li, CSR				Liao, Ding-Lieh; Huang, Cheng-Yi; Hu, Sien; Fang, Su-Chen; Wu, Chi-Shin; Chen, Wei-Ti; Lee, Tony Szu-Hsien; Chen, Pau-Chung; Li, Chiang-shan R.			Cognitive Control in Opioid Dependence and Methadone Maintenance Treatment	PLOS ONE			English	Article							STOP SIGNAL TASK; RESPONSE-INHIBITION; GENDER-DIFFERENCES; NEURAL PROCESSES; INDIRECT ANALOG; WORKING-MEMORY; RISK-TAKING; HEROIN; PERFORMANCE; DEFICITS	Background: Substance misuse is associated with cognitive dysfunction. We used a stop signal task to examine deficits in cognitive control in individuals with opioid dependence (OD). We examined how response inhibition and post-error slowing are compromised and whether methadone maintenance treatment (MMT), abstinence duration, and psychiatric comorbidity are related to these measures in individuals with OD. Methods: Two-hundred-and-sixty-four men with OD who were incarcerated at a detention center and abstinent for up to 2 months (n = 108) or at a correctional facility and abstinent for approximately 6 months (n = 156), 65 OD men under MMT at a psychiatric clinic, and 64 age and education matched healthy control (HC) participants were assessed. We computed the stop signal reaction time (SSRT) to index the capacity of response inhibition and post-error slowing (PES) to represent error-related behavioral adjustment, as in our previous work. We examined group effects with analyses of variance and covariance analyses, followed by planned comparisons. Specifically, we compared OD and HC participants to examine the effects of opioid dependence and MMT and compared OD sub-groups to examine the effects of abstinence duration and psychiatric comorbidity. Results: The SSRT was significantly prolonged in OD but not MMT individuals, as compared to HC. The extent of post-error slowing diminished in OD and MMT, as compared to HC (trend; p = 0.061), and there was no difference between the OD and MMT groups. Individuals in longer abstinence were no less impaired in these measures. Furthermore, these results remained when psychiatric comorbidities including misuse of other substances were accounted for. Conclusions: Methadone treatment appears to be associated with relatively intact cognitive control in opioid dependent individuals. MMT may facilitate public health by augmenting cognitive control and thereby mitigating risky behaviors in heroin addicts.	[Liao, Ding-Lieh; Huang, Cheng-Yi] Bali Psychiat Ctr, Dept Addict Psychiat, Dept Hlth, New Taipei City, Taiwan; [Liao, Ding-Lieh; Chen, Pau-Chung] Natl Taiwan Univ, Inst Occupat Med & Ind Hyg, Coll Publ Hlth, Taipei 10764, Taiwan; [Hu, Sien; Li, Chiang-shan R.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA; [Fang, Su-Chen] Oriental Inst Technol, Dept Nursing, New Taipei City, Taiwan; [Wu, Chi-Shin] Far Eastern Mem Hosp, Dept Psychiat, New Taipei City, Taiwan; [Chen, Wei-Ti] Yale Univ, Sch Nursing, New Haven, CT 06536 USA; [Lee, Tony Szu-Hsien] Natl Taiwan Normal Univ, Dept Hlth Promot & Hlth Educ, Taipei, Taiwan	National Taiwan University; Yale University; Asia Eastern University of Science & Technology; Far Eastern Memorial Hospital; Yale University; National Taiwan Normal University	Liao, DL (corresponding author), Bali Psychiat Ctr, Dept Addict Psychiat, Dept Hlth, New Taipei City, Taiwan.	dlliao@balipc.gov.tw; chiang-shan.li@yale.edu	Chen, Weiti/L-6222-2019; Li, Chiang-Shan Ray/J-2813-2016; Chen, Pau-Chung/H-5686-2011; Chen, Wei-Ti/L-3935-2019; Fang, Su-Chen/GOP-0356-2022; Wu, Chi-Shin/GQP-4970-2022	Li, Chiang-Shan Ray/0000-0002-9393-1212; Chen, Pau-Chung/0000-0002-6242-5974; Chen, Wei-Ti/0000-0002-2342-045X; Fang, Su-Chen/0000-0001-6916-4511; Lee, Tony Szu-Hsien/0000-0003-2574-3372; WU, CHI-SHIN/0000-0003-2762-7295	National Health Research Institute (NHRI) [PH-099-PP-40]; Department of Health (DOH), Taiwan [DOH99-TD-PH-27]; National Institutes of Health (NIH), U.S.A. [K02DA026990]; NATIONAL INSTITUTE OF NURSING RESEARCH [K23NR014107] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K02DA026990] Funding Source: NIH RePORTER	National Health Research Institute (NHRI)(National Health Research Institutes - Taiwan); Department of Health (DOH), Taiwan; National Institutes of Health (NIH), U.S.A.(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This study was supported by grants PH-099-PP-40 (Liao) from the National Health Research Institute (NHRI) and DOH99-TD-PH-27 (Liao) from the Department of Health (DOH), Taiwan; and a grant K02DA026990 (Li) from the National Institutes of Health (NIH), U.S.A. The NHRI, DOH, and NIH have no further role in data collection and analysis or the decision in publishing these results.	Bach P, 2012, CLIN NEUROPHARMACOL, V35, P153, DOI 10.1097/WNF.0b013e31825c38f5; Bednarski SR, 2012, ALCOHOL CLIN EXP RES, V36, P768, DOI 10.1111/j.1530-0277.2011.01672.x; Bracken BK, 2012, DRUG ALCOHOL DEPEN, V125, P132, DOI 10.1016/j.drugalcdep.2012.04.004; Brooks DJ, 2006, J ADDICT DIS, V25, P15, DOI 10.1300/J069v25n04_02; Brown TG, 2009, DRUG ALCOHOL REV, V28, P406, DOI 10.1111/j.1465-3362.2009.00053.x; Byrd DA, 2013, J INT NEUROPSYCH SOC, V19, P463, DOI 10.1017/S1355617712001634; Cheng JQ, 2012, EXP CLIN PSYCHOPHARM, V20, P400, DOI 10.1037/a0029657; Chou YC, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-190; Connock M, 2007, HEALTH TECHNOL ASSES, V11, P1; Connolly CG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059645; Connolly CG, 2012, DRUG ALCOHOL DEPEN, V121, P45, DOI 10.1016/j.drugalcdep.2011.08.007; Corsenac P, 2012, DRUG ALCOHOL DEPEN, V123, P91, DOI 10.1016/j.drugalcdep.2011.10.022; Darke S, 2000, ADDICTION, V95, P687, DOI 10.1046/j.1360-0443.2000.9556874.x; Darke S, 2012, DRUG ALCOHOL DEPEN, V126, P309, DOI 10.1016/j.drugalcdep.2012.05.032; Davis PE, 2002, DRUG ALCOHOL DEPEN, V67, P105, DOI 10.1016/S0376-8716(02)00012-1; Farr OM, 2012, NEUROIMAGE, V63, P1070, DOI 10.1016/j.neuroimage.2012.07.049; Fillmore MT, 2002, DRUG ALCOHOL DEPEN, V66, P265, DOI 10.1016/S0376-8716(01)00206-X; Garavan H, 2007, NEUROPSYCHOL REV, V17, P337, DOI 10.1007/s11065-007-9034-x; Gruber SA, 2006, EXP CLIN PSYCHOPHARM, V14, P157, DOI 10.1037/1064-1297.14.2.157; Hakansson A, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-111; Hendrick OM, 2012, OBESITY, V20, P1796, DOI 10.1038/oby.2011.180; Henry PK, 2012, DRUG ALCOHOL DEPEN, V124, P167, DOI 10.1016/j.drugalcdep.2011.12.009; Hu S, 2013, BRAIN STRUCT FUNCT; Hu S, 2012, HUM BRAIN MAPP, V33, P2785, DOI 10.1002/hbm.21399; Hu S, 2012, FRONT AGING NEUROSCI, V4, DOI 10.3389/fnagi.2012.00004; Ide JS, 2013, J NEUROSCI, V33, P2039, DOI 10.1523/JNEUROSCI.2201-12.2013; Jiang GH, 2011, NEUROIMAGE, V57, P149, DOI 10.1016/j.neuroimage.2011.04.004; Kaufman MJ, 1999, PSYCHIAT RES-NEUROIM, V90, P143, DOI 10.1016/S0925-4927(99)00017-7; Levitt H, 1971, J ACOUST SOC AM S2, V49, P467; Li CSR, 2010, DRUG ALCOHOL DEPEN, V109, P181, DOI 10.1016/j.drugalcdep.2010.01.008; Li CSR, 2008, J COGNITIVE NEUROSCI, V20, P1021, DOI 10.1162/jocn.2008.20071; Li CSR, 2008, NEUROSCI BIOBEHAV R, V32, P581, DOI 10.1016/j.neubiorev.2007.10.003; Li CSR, 2006, DRUG ALCOHOL DEPEN, V85, P205, DOI 10.1016/j.drugalcdep.2006.04.008; Li CSR, 2006, NEUROIMAGE, V32, P1918, DOI 10.1016/j.neuroimage.2006.05.017; Li CSR, 2009, BRAIN IMAGING BEHAV, V3, P262, DOI 10.1007/s11682-009-9068-1; Li CSR, 2009, CEREB CORTEX, V19, P839, DOI 10.1093/cercor/bhn132; Li CSR, 2005, EXP BRAIN RES, V167, P305, DOI 10.1007/s00221-005-0110-2; Lin WC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033809; Lin WC, 2012, PSYCHIAT RES-NEUROIM, V201, P89, DOI 10.1016/j.pscychresns.2011.05.009; LOGAN GD, 1984, J EXP PSYCHOL HUMAN, V10, P276, DOI 10.1037/0096-1523.10.2.276; Luo X, 2013, BRAIN, V136, P1231, DOI 10.1093/brain/awt040; Ma N, 2010, NEUROIMAGE, V49, P738, DOI 10.1016/j.neuroimage.2009.08.037; Marvel CL, 2012, CEREBELLUM, V11, P300, DOI 10.1007/s12311-011-0311-0; McDonald S, 2013, ADDICTION, V108, P566, DOI 10.1111/add.12040; Messinis L, 2009, HUM PSYCHOPHARM CLIN, V24, P524, DOI 10.1002/hup.1050; Mintzer MZ, 2005, DRUG ALCOHOL DEPEN, V78, P225, DOI 10.1016/j.drugalcdep.2004.10.008; Mintzer MZ, 2002, DRUG ALCOHOL DEPEN, V67, P41, DOI 10.1016/S0376-8716(02)00013-3; Monterosso JR, 2005, DRUG ALCOHOL DEPEN, V79, P273, DOI 10.1016/j.drugalcdep.2005.02.002; Nestor LJ, 2011, PSYCHIAT RES-NEUROIM, V194, P287, DOI 10.1016/j.pscychresns.2011.04.010; Pirastu R, 2006, DRUG ALCOHOL DEPEN, V83, P163, DOI 10.1016/j.drugalcdep.2005.11.008; Pluck G, 2012, DRUG ALCOHOL DEPEN, V124, P181, DOI 10.1016/j.drugalcdep.2012.01.001; Prosser J, 2006, DRUG ALCOHOL DEPEN, V84, P240, DOI 10.1016/j.drugalcdep.2006.02.006; Qiu YW, 2011, RADIOLOGY, V261, P551, DOI 10.1148/radiol.11102466; RABBITT PMA, 1966, J EXP PSYCHOL, V71, P264, DOI 10.1037/h0022853; Rapeli Pekka, 2007, BMC Clin Pharmacol, V7, P5, DOI 10.1186/1472-6904-7-5; Rapeli Pekka, 2011, BMC Clin Pharmacol, V11, P13, DOI 10.1186/1472-6904-11-13; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Soyka M, 2008, J CLIN PSYCHOPHARM, V28, P699, DOI 10.1097/JCP.0b013e31818a6d38; Soyka M, 2011, AM J DRUG ALCOHOL AB, V37, P497, DOI 10.3109/00952990.2011.600381; Soyka M, 2010, WORLD J BIOL PSYCHIA, V11, P400, DOI [10.1080/15622970902995604, 10.3109/15622970902995604]; Streel Emmanuel, 2005, J Opioid Manag, V1, P49; van Holst Ruth Janke, 2011, Curr Drug Abuse Rev, V4, P42; Verdejo A, 2005, DRUG ALCOHOL DEPEN, V78, P283, DOI 10.1016/j.drugalcdep.2004.11.006; Walters GD, 2012, LAW HUMAN BEHAV, V36, P506, DOI 10.1037/h0093936; Wang GY, 2013, CURR DRUG ABUSE REV; Wang YR, 2011, NEUROSCI LETT, V494, P49, DOI 10.1016/j.neulet.2011.02.053; WETHERIL.GB, 1966, BIOMETRIKA, V53, P439, DOI 10.2307/2333650; Wilson SJ, 2013, SOC COGN AFFECT NEUR; Yucel M, 2007, MOL PSYCHIATR, V12, P691, DOI 10.1038/sj.mp.4001955	69	29	29	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 11	2014	9	4							e94589	10.1371/journal.pone.0094589	http://dx.doi.org/10.1371/journal.pone.0094589			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI3CI	24727743	Green Published, Green Submitted, gold			2023-01-03	WOS:000336736200100
J	Morris, RG; TenEyck, M; Barnes, JC; Kovandzic, TV				Morris, Robert G.; TenEyck, Michael; Barnes, J. C.; Kovandzic, Tomislav V.			The Effect of Medical Marijuana Laws on Crime: Evidence from State Panel Data, 1990-2006	PLOS ONE			English	Article							JUVENILE DETENTION CENTER; VIOLENT BEHAVIOR; DRUG-USE; USE LEAD; ALCOHOL; ASSOCIATION; AGGRESSION; CANNABIS; INVOLVEMENT; AMERICAN	Background: Debate has surrounded the legalization of marijuana for medical purposes for decades. Some have argued medical marijuana legalization (MML) poses a threat to public health and safety, perhaps also affecting crime rates. In recent years, some U.S. states have legalized marijuana for medical purposes, reigniting political and public interest in the impact of marijuana legalization on a range of outcomes. Methods: Relying on U.S. state panel data, we analyzed the association between state MML and state crime rates for all Part I offenses collected by the FBI. Findings: Results did not indicate a crime exacerbating effect of MML on any of the Part I offenses. Alternatively, state MML may be correlated with a reduction in homicide and assault rates, net of other covariates. Conclusions: These findings run counter to arguments suggesting the legalization of marijuana for medical purposes poses a danger to public health in terms of exposure to violent crime and property crimes.	[Morris, Robert G.; TenEyck, Michael; Barnes, J. C.; Kovandzic, Tomislav V.] Univ Texas Dallas, Program Criminol, Richardson, TX 75083 USA	University of Texas System; University of Texas Dallas	Morris, RG (corresponding author), Univ Texas Dallas, Program Criminol, Richardson, TX 75083 USA.	morris@utdallas.edu		Barnes, J.C./0000-0001-6932-5397				Allison Paul D., 2009, FIXED EFFECT REGRESS; Anderson DM, 2013, J LAW ECON, V56, P333, DOI 10.1086/668812; Arseneault L, 2000, ARCH GEN PSYCHIAT, V57, P979, DOI 10.1001/archpsyc.57.10.979; Bertrand M, 2004, Q J ECON, V119, P249, DOI 10.1162/003355304772839588; Boden JM, 2012, DRUG ALCOHOL DEPEN, V122, P135, DOI 10.1016/j.drugalcdep.2011.09.023; Brady SS, 2008, J ADOLESCENT HEALTH, V43, P285, DOI 10.1016/j.jadohealth.2008.02.007; Bureau of Justice Statistics, 2008, DEATHS CUST REP PROG; Cleveland HH, 2008, DEV PSYCHOPATHOL, V20, P615, DOI 10.1017/S0954579408000308; DEMBO R, 1987, J PSYCHOACTIVE DRUGS, V19, P47, DOI 10.1080/02791072.1987.10472379; DEMBO R, 1987, J PSYCHOACTIVE DRUGS, V19, P361, DOI 10.1080/02791072.1987.10472424; DESIMONE J, 1998, E EC J, V0024; DiNardo J, 2001, J HEALTH ECON, V20, P991, DOI 10.1016/S0167-6296(01)00102-3; Freisthler B, 2013, AM J COMMUN PSYCHOL, V51, P278, DOI 10.1007/s10464-012-9542-6; Green KM, 2010, DRUG ALCOHOL DEPEN, V112, P117, DOI 10.1016/j.drugalcdep.2010.05.018; Harris AWF, 2010, AUST NZ J PSYCHIAT, V44, P85, DOI 10.3109/00048670903270423; Jacobs EA, 2004, PEDIATRICS, V113, P1825; Johnson Kevin, 2013, US TODAY; Kepple NJ, 2012, J STUD ALCOHOL DRUGS, V73, P523, DOI 10.15288/jsad.2012.73.523; Keyes KM, 2011, ADDICTION, V106, P1790, DOI 10.1111/j.1360-0443.2011.03485.x; KOVANDZIC TV, 2009, CRIMINOLOGY PUBLIC P, V0008; Levinthal C.F., 2008, DRUGS SOC CRIMINAL J; Monshouwer K, 2006, BRIT J PSYCHIAT, V188, P148, DOI 10.1192/bjp.188.2.148; Moore TM, 2005, AGGRESS VIOLENT BEH, V10, P171, DOI 10.1016/j.avb.2003.10.002; Niveau G, 2003, MED SCI LAW, V43, P115, DOI 10.1258/rsmmsl.43.2.115; O'Brien PK, 2013, DEVIANT BEHAV, V34, P423, DOI 10.1080/01639625.2012.735608; Ostrowsky MK, 2011, J DRUG EDUC, V41, P369, DOI 10.2190/DE.41.4.c; Pedersen W, 2010, ADDICTION, V105, P109, DOI 10.1111/j.1360-0443.2009.02719.x; Reingle JM, 2012, J INTERPERS VIOLENCE, V27, P1562, DOI 10.1177/0886260511425787; Scribner R, 1999, J STUD ALCOHOL, V60, P310, DOI 10.15288/jsa.1999.60.310; Swartout KM, 2010, J INTERPERS VIOLENCE, V25, P1716, DOI 10.1177/0886260509354586; Wooldridge J.M., 2009, INTRO ECONOMETRICS M	31	64	64	1	54	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2014	9	3							e92816	10.1371/journal.pone.0092816	http://dx.doi.org/10.1371/journal.pone.0092816			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AE0SR	24671103	gold, Green Submitted, Green Published			2023-01-03	WOS:000333677000080
J	Li, CW; Lu, HG; Chen, DH; Lin, ZB; Wang, DY; Li, TY				Li, Chun Wei; Lu, Han Gui; Chen, De Hua; Lin, Zhi Bin; Wang, De Yun; Li, Tian Ying			In Vivo and In Vitro Studies of Th17 Response to Specific Immunotherapy in House Dust Mite-Induced Allergic Rhinitis Patients	PLOS ONE			English	Article							T(H)17 CELLS; HEALTH; DIFFERENTIATION; IL-10	T helper (Th)17 cells have been implicated in the development of allergic rhinitis (AR), but their response to specific immunotherapy (SIT) remains unclear. We investigated the impact of SIT on Th17 response and Th1/Th2 changes in AR patients. Blood samples from AR patients (n = 20) who were monosensitized to house dust mite (HDM) were collected before the initiation of SIT (SIT-untreated) and after the end of 2-year SIT (SIT-treated) treatment. Twenty healthy volunteers were recruited as controls. In vitro HDM stimulation in peripheral blood mononuclear cells (PBMCs) was also performed. Expression levels of Th17 associated genes were determined in both PBMCs and plasma by PCR and ELISA, while Th17/Th1/Th2/IL10 producing cell proportions were evaluated in PBMCs by flow cytometry. The SIT effect was evaluated by assessing clinical symptoms. mRNA levels of Th17 specific genes (IL17 and RORC) were increased in SIT-untreated AR versus controls, and decreased following SIT treatment. SIT can change the production of Th17 associated genes (reduction of IL17, IL6, and IL23, but increase of IL27) in plasma from AR patients. Th2/Th1 ratio and proportions of Th17 cells were suppressed while IL10 producing CD4(+) T cells were elevated after SIT. In vitro HDM challenge presents concordant patterns with in vivo findings: 1) increase of Th2 and Th17 response in AR patients; 2) suppression of IL10 producing CD4(+) T cells in SIT-untreated AR but elevation in SIT-treated AR patients. Most importantly, a positive correlation between IL17 mRNA/protein levels and clinical symptom scores was observed. SIT significantly inhibits Th17 mediated inflammation in AR and IL17 may be a useful biomarker for both AR severity and SIT therapeutic effect.	[Li, Chun Wei; Wang, De Yun] Natl Univ Singapore, Natl Univ Hlth Syst, Dept Otolaryngol, Singapore 117548, Singapore; [Lu, Han Gui; Chen, De Hua; Lin, Zhi Bin; Li, Tian Ying] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Otorhinolaryngol, Guangzhou 510275, Guangdong, Peoples R China; [Lu, Han Gui] Sun Yat Sen Univ, Shantou Cent Hosp, Dept Otolaryngol Head & Neck Surg, Shantou, Peoples R China; [Chen, De Hua; Lin, Zhi Bin; Li, Tian Ying] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Allergy, Guangzhou 510275, Guangdong, Peoples R China	National University of Singapore; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Wang, DY (corresponding author), Natl Univ Singapore, Natl Univ Hlth Syst, Dept Otolaryngol, Singapore 117548, Singapore.	entwdy@nus.edu.sg; litianying@yeah.net			Science and Technology Planning Project of Guangdong Province, China [99M04901G]	Science and Technology Planning Project of Guangdong Province, China	This study was supported by grant from Science and Technology Planning Project of Guangdong Province, China (No. 99M04901G). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; [Anonymous], CELL, V126, P1121; Borish L, 2003, J ALLERGY CLIN IMMUN, V112, P1021, DOI 10.1016/j.jaci.2003.09.015; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Ciprandi G, 2009, ALLERGY, V64, P1375, DOI 10.1111/j.1398-9995.2009.02010.x; Ciprandi G, 2010, INT IMMUNOPHARMACOL, V10, P226, DOI 10.1016/j.intimp.2009.11.004; Ciprandi G, 2009, INT IMMUNOPHARMACOL, V9, P1247, DOI 10.1016/j.intimp.2009.07.004; Crome SQ, 2010, CLIN EXP IMMUNOL, V159, P109, DOI 10.1111/j.1365-2249.2009.04037.x; Dong C, 2008, NAT REV IMMUNOL, V8, P337, DOI 10.1038/nri2295; Hansen I, 2004, CURR OPIN ALLERGY CL, V4, P159, DOI 10.1097/01.all.0000129444.81350.23; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; JUTEL M, 1995, J IMMUNOL, V154, P4187; Littman DR, 2010, CELL, V140, P845, DOI 10.1016/j.cell.2010.02.021; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Louten J, 2009, J ALLERGY CLIN IMMUN, V123, P1004, DOI 10.1016/j.jaci.2009.04.003; Murugaiyan G, 2009, J IMMUNOL, V183, P2435, DOI 10.4049/jimmunol.0900568; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; Park SJ, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-78; Pipe A, 2009, RESP MED, V103, P800, DOI 10.1016/j.rmed.2009.01.008; Qu Shen-hong, 2005, Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V40, P908; Schmidt-Weber CB, 2007, J ALLERGY CLIN IMMUN, V120, P247, DOI 10.1016/j.jaci.2007.06.039; Wilson RH, 2009, AM J RESP CRIT CARE, V180, P720, DOI 10.1164/rccm.200904-0573OC; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488; Zhou L, 2009, CURR OPIN IMMUNOL, V21, P146, DOI 10.1016/j.coi.2009.03.001; Zuberbier T, 2010, ALLERGY, V65, P1525, DOI 10.1111/j.1398-9995.2010.02474.x	25	15	15	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2014	9	3							e91950	10.1371/journal.pone.0091950	http://dx.doi.org/10.1371/journal.pone.0091950			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AD6ER	24647473	Green Published, Green Submitted, gold			2023-01-03	WOS:000333348500063
J	Nijs, J; Ickmans, K				Nijs, Jo; Ickmans, Kelly			Chronic whiplash-associated disorders: to exercise or not?	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; PAIN; EDUCATION; PEOPLE		[Nijs, Jo; Ickmans, Kelly] Vrije Univ Brussel, Fac Phys Educ & Physiotherapy, Dept Human Physiol, Pain Mot Res Grp, BE-1090 Brussels, Belgium; [Nijs, Jo; Ickmans, Kelly] Vrije Univ Brussel, Fac Phys Educ & Physiotherapy, Dept Physiotherapy, BE-1090 Brussels, Belgium; [Nijs, Jo] Univ Hosp Brussels, Dept Phys Med & Physiotherapy, Pain Mot Res Grp, Brussels, Belgium	Pain in Motion; Vrije Universiteit Brussel; Vrije Universiteit Brussel; Pain in Motion; University Hospital Brussels	Nijs, J (corresponding author), Vrije Univ Brussel, Fac Phys Educ & Physiotherapy, Dept Human Physiol, Pain Mot Res Grp, BE-1090 Brussels, Belgium.	Jo.Nijs@vub.ac.be	Nijs, Jo/B-3336-2011	Nijs, Jo/0000-0002-4976-6563; Ickmans, Kelly/0000-0003-0751-6504				Brunner E, 2013, DISABIL REHABIL, V35, P1, DOI 10.3109/09638288.2012.683848; Daenen L, 2013, J REHABIL MED, V45, P113, DOI 10.2340/16501977-1091; Dunne RL, 2012, CLIN J PAIN, V28, P755, DOI 10.1097/AJP.0b013e318243e16b; Gaab J, 2005, PAIN, V119, P219, DOI 10.1016/j.pain.2005.10.001; Hodges PW, 2011, PAIN S3, V152, P18; Huijnen IPJ, 2011, EUR J PAIN, V15, P748, DOI 10.1016/j.ejpain.2010.11.015; Lamb SE, 2013, LANCET, V381, P546, DOI 10.1016/S0140-6736(12)61304-X; Meeus M, 2012, PAIN PHYSICIAN, V15, P351; Michaleff ZA, 2014, LANCET; Tucker K, 2012, PAIN, V153, P636, DOI 10.1016/j.pain.2011.11.024; Van Oosterwijck J, 2013, EUR J PAIN, V17, P299, DOI 10.1002/j.1532-2149.2012.00193.x; Van Oosterwijck J, 2012, J PAIN, V13, P242, DOI 10.1016/j.jpain.2011.11.006; Van Oosterwijck J, 2011, J REHABIL RES DEV, V48, P43, DOI 10.1682/JRRD.2009.12.0206	13	12	12	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 12	2014	384	9938					109	111		10.1016/S0140-6736(14)60130-6	http://dx.doi.org/10.1016/S0140-6736(14)60130-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AL1YC	24703833				2023-01-03	WOS:000338921500010
J	Fang, Y				Fang, Yu			PERSONAL VIEW China should curb non-prescription use of antibiotics in the community	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							ATTITUDES; KNOWLEDGE		Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharm Adm, Xian, Shaanxi, Peoples R China	Xi'an Jiaotong University	Fang, Y (corresponding author), Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharm Adm, Xian, Shaanxi, Peoples R China.	yufang@mail.xjtu.edu.cn						China Food and Drug Administration, PROV SUP DRUG DISTR; China Food and Drug Administration, 2013, 2013 ANN REP NAT ADV; Hvistendahl M, 2012, SCIENCE, V336, P795, DOI 10.1126/science.336.6083.795; Jiang MH, 2013, CHINESE J HLTH POLIC, V1, P40; Li YF, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-995; Liu ZJ, 2011, EVALUATION ANAL DRUG, V11, P853; Lv B, 2014, TROP MED INT HEALTH, V19, P769, DOI 10.1111/tmi.12322; Morgan DJ, 2011, LANCET INFECT DIS, V11, P692, DOI 10.1016/S1473-3099(11)70054-8; Reynolds L, 2009, HEALTH POLICY, V90, P32, DOI 10.1016/j.healthpol.2008.09.002; The State Council, 12 5 YEAR PLAN DRUG; Xiao Y., 2010, CHINESE HLTH EC, V29, P94, DOI [10.3969/j.issn.1003-0743.2010.05.034, DOI 10.3969/J.ISSN.1003-0743.2010.05.034]; Xiao YH, 2011, DRUG RESIST UPDATE, V14, P236, DOI 10.1016/j.drup.2011.07.001; Xiao YH, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001556; Xiao YH, 2013, LANCET INFECT DIS, V13, P189, DOI 10.1016/S1473-3099(13)70011-2; Yip WCM, 2010, LANCET, V375, P1120, DOI 10.1016/S0140-6736(10)60063-3; Yu M, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-112; SHANGHAI DAILY	17	30	30	0	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 30	2014	348								g4233	10.1136/bmj.g4233	http://dx.doi.org/10.1136/bmj.g4233			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AK7YU	24982508				2023-01-03	WOS:000338644600003
J	Pearl, RG				Pearl, Ronald G.			Review: Noninvasive vs invasive weaning from mechanical ventilation reduces mortality in respiratory failure	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							METAANALYSIS		Stanford Univ, Stanford, CA 94305 USA	Stanford University	Pearl, RG (corresponding author), Stanford Univ, Stanford, CA 94305 USA.							Burns KEA, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1574; Glossop AJ, 2012, BRIT J ANAESTH, V109, P305, DOI 10.1093/bja/aes270; Keenan SP, 2011, CAN MED ASSOC J, V183, pE195, DOI 10.1503/cmaj.100071	3	0	0	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 17	2014	160	12							JC8	10.7326/0003-4819-160-12-201406170-02008	http://dx.doi.org/10.7326/0003-4819-160-12-201406170-02008			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AJ0VR	24935514				2023-01-03	WOS:000337374900008
J	Ohnishi, N; Tahara, Y; Kuriki, D; Haraguchi, A; Shibata, S				Ohnishi, Nobuaki; Tahara, Yu; Kuriki, Daisuke; Haraguchi, Atsushi; Shibata, Shigenobu			Warm Water Bath Stimulates Phase-Shifts of the Peripheral Circadian Clocks in PER2::LUCIFERASE Mouse	PLOS ONE			English	Article							AMBIENT-TEMPERATURE CYCLES; REV-ERB-ALPHA; BODY-TEMPERATURE; ACTIVITY RHYTHMS; LIVER CLOCK; ENTRAINMENT; OSCILLATIONS; PROTEIN; LOOP	Circadian clocks in the peripheral tissues of mice are known to be entrained by pulse stimuli such as restricted feeding, novel wheel running, and several other agents. However, there are no reports on high temperature pulse-mediated entrainment on the phase-shift of peripheral clocks in vivo. Here we show that temperature treatment of mice for two days at 41 degrees C, instead of 37 degrees C, for 1-2 h during the inactive period, using a temperature controlled water bath stimulated phase-advance of peripheral clocks in the kidney, liver, and submandibular gland of PER2::LUCIFERASE mice. On the other hand, treatment for 2 days at 35 degrees C ambient room temperature for 2 h did not cause a phase-advance. Maintenance of mice at 41 degrees C in a water bath, sustained the core body temperature at 40-41 degrees C. However, the use of 37 degrees C water bath or the 35 degrees C ambient room temperature elevated the core body temperature to 38.5 degrees C, suggesting that at least a core body temperature of 40-41 degrees C is necessary to cause phase-advance under light-dark cycle conditions. The temperature pulse stimulation at 41 degrees C, instead of 37 degrees C water bath for 2 h led to the elevated expression of Per1 and Hsp70 in the peripheral tissue of mice. In summary, the present study demonstrates that transient high temperature pulse using water bath during daytime causes phase-advance in mouse peripheral clocks in vivo. The present results suggest that hot water bath may affect the phase of peripheral clocks.	[Ohnishi, Nobuaki; Tahara, Yu; Kuriki, Daisuke; Haraguchi, Atsushi; Shibata, Shigenobu] Waseda Univ, Sch Adv Sci & Engn, Lab Physiol & Pharmacol, Tokyo, Japan	Waseda University	Shibata, S (corresponding author), Waseda Univ, Sch Adv Sci & Engn, Lab Physiol & Pharmacol, Tokyo, Japan.	shibatas@waseda.jp	Haraguchi, Atsushi/ABC-6337-2020; Tahara, Yu/Q-4324-2018	Haraguchi, Atsushi/0000-0003-4162-2474; Tahara, Yu/0000-0002-3015-8883	Ministry of Education, Culture, Sports, Science and Technology of Japan [23300278]	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This study was supported by a Grant-in-Aid for Scientific Research (B) (23300278) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (S. S.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; Brown SA, 2002, CURR BIOL, V12, P1574, DOI 10.1016/S0960-9822(02)01145-4; Buhr Ethan D, 2013, Handb Exp Pharmacol, P3, DOI 10.1007/978-3-642-25950-0_1; Buhr ED, 2010, SCIENCE, V330, P379, DOI 10.1126/science.1195262; Chappuis S, 2013, MOL METAB, V2, P184, DOI 10.1016/j.molmet.2013.05.002; FRANCIS AJP, 1988, PHYSIOL BEHAV, V43, P471, DOI 10.1016/0031-9384(88)90121-7; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Gerhart-Hines Z, 2013, NATURE, V503, P410, DOI 10.1038/nature12642; Goldman BD, 1997, J BIOL RHYTHM, V12, P348, DOI 10.1177/074873049701200407; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; Hara R, 2001, GENES CELLS, V6, P269, DOI 10.1046/j.1365-2443.2001.00419.x; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Itokawa M, 2013, NUTR RES, V33, P109, DOI 10.1016/j.nutres.2012.12.004; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; LINDBERG RG, 1974, CHRONOBIOLOGIA, V1, P356; Lowrey PL, 2011, ADV GENET, V74, P175, DOI 10.1016/B978-0-12-387690-4.00006-4; Marchant EG, 1996, PHYSIOL BEHAV, V60, P657, DOI 10.1016/S0031-9384(96)80045-X; Morf J, 2012, SCIENCE, V338, P379, DOI 10.1126/science.1217726; Pohl H, 1998, BIOL RHYTHM RES, V29, P311, DOI 10.1076/brhm.29.3.311.1436; Rajaratnam SMW, 1998, PHYSIOL BEHAV, V63, P271, DOI 10.1016/S0031-9384(97)00440-X; REEBS SG, 1989, J BIOL RHYTHM, V4, P39, DOI 10.1177/074873048900400103; Refinetti R, 2007, BIOL RHYTHM RES, V38, P275, DOI 10.1080/09291010600903692; Refinetti R, 2010, J BIOL RHYTHM, V25, P247, DOI 10.1177/0748730410372074; Roenneberg T, 2010, J BIOL RHYTHM, V25, P329, DOI 10.1177/0748730410379082; Saini C, 2012, GENE DEV, V26, P567, DOI 10.1101/gad.183251.111; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; Sato TK, 2006, NAT GENET, V38, P312, DOI 10.1038/ng1745; Sujino M, 2012, ENDOCRINOLOGY, V153, P2277, DOI 10.1210/en.2011-1794; Tahara Y, 2012, CURR BIOL, V22, P1029, DOI 10.1016/j.cub.2012.04.009; Tahara Y, 2011, J BIOL RHYTHM, V26, P230, DOI 10.1177/0748730411405958; Tamaru T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024521; Yoo SH, 2005, P NATL ACAD SCI USA, V102, P2608, DOI 10.1073/pnas.0409763102; Yoo SH, 2004, P NATL ACAD SCI USA, V101, P5339, DOI 10.1073/pnas.0308709101	33	14	14	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 16	2014	9	6							e100272	10.1371/journal.pone.0100272	http://dx.doi.org/10.1371/journal.pone.0100272			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AJ5PV	24933288	Green Published, Green Submitted, gold			2023-01-03	WOS:000337738600105
J	Wahl, AS; Omlor, W; Rubio, JC; Chen, JL; Zheng, H; Schroter, A; Gullo, M; Weinmann, O; Kobayashi, K; Helmchen, F; Ommer, B; Schwab, ME				Wahl, A. S.; Omlor, W.; Rubio, J. C.; Chen, J. L.; Zheng, H.; Schroeter, A.; Gullo, M.; Weinmann, O.; Kobayashi, K.; Helmchen, F.; Ommer, B.; Schwab, M. E.			NEURONAL REPAIR Asynchronous therapy restores motor control by rewiring of the rat corticospinal tract after stroke	SCIENCE			English	Article							ADULT RATS; REHABILITATION; PLASTICITY; RECOVERY; PATHWAYS; CIRCUIT	The brain exhibits limited capacity for spontaneous restoration of lost motor functions after stroke. Rehabilitation is the prevailing clinical approach to augment functional recovery, but the scientific basis is poorly understood. Here, we show nearly full recovery of skilled forelimb functions in rats with large strokes when a growth-promoting immunotherapy against a neurite growth-inhibitory protein was applied to boost the sprouting of new fibers, before stabilizing the newly formed circuits by intensive training. In contrast, early high-intensity training during the growth phase destroyed the effect and led to aberrant fiber patterns. Pharmacogenetic experiments identified a subset of corticospinal fibers originating in the intact half of the forebrain, side-switching in the spinal cord to newly innervate the impaired limb and restore skilled motor function.	[Wahl, A. S.; Gullo, M.; Weinmann, O.; Schwab, M. E.] Swiss Fed Inst Technol, Dept Hlth Sci & Technol, Zurich, Switzerland; [Wahl, A. S.; Omlor, W.; Chen, J. L.; Gullo, M.; Weinmann, O.; Helmchen, F.; Schwab, M. E.] Univ Zurich, Brain Res Inst, Zurich, Switzerland; [Rubio, J. C.; Zheng, H.; Ommer, B.] Heidelberg Univ, Comp Vis Grp, Heidelberg Collaboratory Image Proc, Heidelberg, Germany; [Rubio, J. C.; Zheng, H.; Ommer, B.] Heidelberg Univ, Interdisciplinary Ctr Sci Comp IWR, Heidelberg, Germany; [Schroeter, A.] Swiss Fed Inst Technol, Inst Biomed Engn, Zurich, Switzerland; [Kobayashi, K.] Natl Inst Nat Sci Myodaiji, Natl Inst Physiol Sci, Okazaki, Aichi, Japan	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Swiss Federal Institutes of Technology Domain; ETH Zurich; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)	Wahl, AS (corresponding author), Swiss Fed Inst Technol, Dept Hlth Sci & Technol, Zurich, Switzerland.	wahl@hifo.uzh.ch; schwab@hifo.uzh.ch	Omlor, Wolfgang/AAS-3163-2020; Schwab, Martin E/B-6818-2016; Omlor, Wolfgang/AAJ-8288-2021; Helmchen, Fritjof/A-6255-2008	Chen, Jerry/0000-0002-7409-7859; Wahl, Anna-Sophia/0000-0001-9498-4263; Omlor, Wolfgang/0000-0003-1979-7147; Helmchen, Fritjof/0000-0002-8867-9569	European Union [201024, 223524]; advanced European Research Council grant NOGORISE; Swiss National Science Foundation [31-138676, 3100A0_12252711, 31003A_149858]; Christopher and Dana Reeve Foundation; Dr. Wilhelm Hurka Foundation; German Excellence Initiative, Deutsche Forschungsgemeinschaft project [49/2]	European Union(European Commission); advanced European Research Council grant NOGORISE; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Christopher and Dana Reeve Foundation; Dr. Wilhelm Hurka Foundation; German Excellence Initiative, Deutsche Forschungsgemeinschaft project	We thank T. Isa from the National Institute for Physiological Sciences, Okazaki, Japan, as well as K. Kobayashi, Fukushima Medical University, and D. Watanabe, Kyoto University, for kindly providing plasmids for viral vector production. We thank H. Kasper, C. Bleul, and N. Lindau for technical advice and fruitful discussions, as well as B. Seifert for statistical assistance. This work is supported by the European Union grants FP7 Collaborative Projects ARISE (201024) and PLASTICISE (223524), the advanced European Research Council grant NOGORISE (to M. E. S.), the Swiss National Science Foundation grants Nr. 31-138676 and 3100A0_12252711 (to M. E. S.) and Nr. 31003A_149858 (to F. H.), the Christopher and Dana Reeve Foundation (to M. E. S.), and the Dr. Wilhelm Hurka Foundation (F.H. and W.O.). The work by J.C.R and B.O. was supported by the German Excellence Initiative, Deutsche Forschungsgemeinschaft project number 49/2. A. S. W. and M. E. S. designed the study; A. S. W. and M. G. carried out experiments; A.S.W., W.O., B.O., and F.H. performed data analysis; J.C.R., H.Z., and B.O. developed computer and machine learning algorithm tools for data analysis; J. L. C. and K. K. provided virus vectors; A. S. performed magnetic resonance imaging; O.W. carried out histological analysis; and A.S.W, B.O., F.H., and M.E.S. prepared figures and wrote the manuscript. The University of Zurich holds joint patents with Novartis Pharma for antibodies against Nogo-A and their use in neurological diseases. Otherwise, we have no patents pending or financial conflicts to disclose. Materials and methods are available as supplementary materials on Science Online. Plasmids for lentiviral and AAV vectors for the TeNT experiment were obtained under material transfer agreements (MTAs) with Kyoto University, Japan (pLenti-TRE-EGFP-eTeNT-PEST-WPRE, pLenti-TRE-EGFP-WPRE, pRSV-Rev, pMDLg/pRRE, pAAV2-RC, pAAV2-CMV-rtTAV16), and Fukushima Medical University, Japan (pCAGGS-FuG-B2), respectively. Viral vectors for the DREADD experiment were obtained under a MTA with the University of Pennsylvania, Philadelphia, PA (AAV2.9-CamKII alpha.-Cre vector). The anti-Nogo-A antibody (11C7) was a gift from Novartis Pharma. The supplementary materials contain additional data.	Adkins DL, 2005, NEUROSCI LETT, V380, P214, DOI 10.1016/j.neulet.2005.01.036; Alaverdashvili M, 2008, BEHAV BRAIN RES, V188, P281, DOI 10.1016/j.bbr.2007.11.007; Alexander GM, 2009, NEURON, V63, P27, DOI 10.1016/j.neuron.2009.06.014; Asante CO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074454; Azim E, 2014, NATURE, V508, P357, DOI 10.1038/nature13021; Carmichael ST, 2006, ANN NEUROL, V59, P735, DOI 10.1002/ana.20845; Conklin BR, 2008, NAT METHODS, V5, P673, DOI 10.1038/nmeth.1232; Dimyan MA, 2011, NAT REV NEUROL, V7, P76, DOI 10.1038/nrneurol.2010.200; Ferguson SM, 2011, NAT NEUROSCI, V14, P22, DOI 10.1038/nn.2703; Garcia-Alias G, 2009, NAT NEUROSCI, V12, P1145, DOI 10.1038/nn.2377; Kinoshita M, 2012, NATURE, V487, P235, DOI 10.1038/nature11206; Krakauer JW, 2012, NEUROREHAB NEURAL RE, V26, P923, DOI 10.1177/1545968312440745; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Lindau NT, 2014, BRAIN, V137, P739, DOI 10.1093/brain/awt336; Maier IC, 2008, J NEUROSCI, V28, P9386, DOI 10.1523/JNEUROSCI.1697-08.2008; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; Oertle T, 2003, J NEUROSCI, V23, P5393; Ommer B, 2009, INT J COMPUT VISION, V83, P57, DOI 10.1007/s11263-009-0211-7; Petruska JC, 2007, J NEUROSCI, V27, P4460, DOI 10.1523/JNEUROSCI.2302-06.2007; Starkey ML, 2011, EXP NEUROL, V232, P81, DOI 10.1016/j.expneurol.2011.08.006; Tsai SY, 2007, EXP BRAIN RES, V182, P261, DOI 10.1007/s00221-007-1067-0; Wiessner C, 2003, J CEREBR BLOOD F MET, V23, P154, DOI 10.1097/01.WCB.0000040400.30600.AF; Zeiler SR, 2013, CURR OPIN NEUROL, V26, P609, DOI 10.1097/WCO.0000000000000025	23	226	237	5	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2014	344	6189					1250	1255		10.1126/science.1253050	http://dx.doi.org/10.1126/science.1253050			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI7ND	24926013				2023-01-03	WOS:000337077500032
J	Villeda, SA; Plambeck, KE; Middeldorp, J; Castellano, JM; Mosher, KI; Luo, J; Smith, LK; Bieri, G; Lin, K; Berdnik, D; Wabl, R; Udeochu, J; Wheatley, EG; Zou, BD; Simmons, DA; Xie, XMS; Longo, FM; Wyss-Coray, T				Villeda, Saul A.; Plambeck, Kristopher E.; Middeldorp, Jinte; Castellano, Joseph M.; Mosher, Kira I.; Luo, Jian; Smith, Lucas K.; Bieri, Gregor; Lin, Karin; Berdnik, Daniela; Wabl, Rafael; Udeochu, Joe; Wheatley, Elizabeth G.; Zou, Bende; Simmons, Danielle A.; Xie, Xinmin S.; Longo, Frank M.; Wyss-Coray, Tony			Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice	NATURE MEDICINE			English	Article							LONG-TERM POTENTIATION; ALZHEIMER-DISEASE; DENTATE GYRUS; MEMORY; RATS; DECLINE; NEUROGENESIS; REJUVENATION; SYNAPSES; SYSTEMS	As human lifespan increases, a greater fraction of the population is suffering from age-related cognitive impairments, making it important to elucidate a means to combat the effects of aging(1,2). Here we report that exposure of an aged animal to young blood can counteract and reverse pre-existing effects of brain aging at the molecular, structural, functional and cognitive level. Genome-wide microarray analysis of heterochronic parabionts-in which circulatory systems of young and aged animals are connected identified synaptic plasticity-related transcriptional changes in the hippocampus of aged mice. Dendritic spine density of mature neurons increased and synaptic plasticity improved in the hippocampus of aged heterochronic parabionts. At the cognitive level, systemic administration of young blood plasma into aged mice improved age-related cognitive impairments in both contextual fear conditioning and spatial learning and memory. Structural and cognitive enhancements elicited by exposure to young blood are mediated, in part, by activation of the cyclic AMP response element binding protein (Creb) in the aged hippocampus. Our data indicate that exposure of aged mice to young blood late in life is capable of rejuvenating synaptic plasticity and improving cognitive function.	[Villeda, Saul A.; Plambeck, Kristopher E.; Smith, Lucas K.; Bieri, Gregor; Lin, Karin; Udeochu, Joe; Wheatley, Elizabeth G.] Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; [Villeda, Saul A.; Plambeck, Kristopher E.; Smith, Lucas K.; Bieri, Gregor; Lin, Karin; Udeochu, Joe; Wheatley, Elizabeth G.] Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco, CA USA; [Villeda, Saul A.; Lin, Karin] Univ Calif San Francisco, Neurosci Grad Program, San Francisco, CA 94143 USA; [Villeda, Saul A.; Udeochu, Joe] Univ Calif San Francisco, Biomed Sci Grad Program, San Francisco, CA 94143 USA; [Villeda, Saul A.; Wheatley, Elizabeth G.] Univ Calif San Francisco, Dev & Stem Cell Biol Grad Program, San Francisco, CA 94143 USA; [Villeda, Saul A.; Middeldorp, Jinte; Castellano, Joseph M.; Mosher, Kira I.; Luo, Jian; Bieri, Gregor; Berdnik, Daniela; Wabl, Rafael; Simmons, Danielle A.; Longo, Frank M.; Wyss-Coray, Tony] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; [Mosher, Kira I.; Bieri, Gregor; Wyss-Coray, Tony] Stanford Univ, Sch Med, Neurosci Grad Program, Stanford, CA 94305 USA; [Zou, Bende; Xie, Xinmin S.] AfaSci Res Lab, Redwood City, CA USA; [Wyss-Coray, Tony] VA Palo Alto Hlth Care Syst, Ctr Tissue Regenerat Repair & Restorat, Palo Alto, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Villeda, SA (corresponding author), Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.	saul.villeda@ucsf.edu; twc@stanford.edu	Middeldorp, Jinte/M-2352-2016; , Jinte/AHA-6575-2022; Castellano, Joseph M/ABD-7639-2021; Wyss-Coray, Tony/AAF-3380-2019; Luo, Jian/B-8449-2014	Middeldorp, Jinte/0000-0002-9198-8020; , Jinte/0000-0002-9198-8020; Wyss-Coray, Tony/0000-0001-5893-0831; Luo, Jian/0000-0002-2064-8467; Castellano, Joseph/0000-0002-8026-6292; Xie, Xinmin Simon/0000-0002-4049-6499; Mosher, Kira/0000-0002-3041-3186; Wabl, Rafael/0000-0002-3701-7848	California Institute for Regenerative Medicine (CIRM); Netherlands Organization for Scientific Research (NWO); Child Health Research Institute fellowship (Stanford National Institutes of Health (NIH)/National Center for Research Resources) [CTSA-UL1-RR025744]; Jane Coffin Childs fellowship; National Science Foundation; National Research Service Award fellowship [1F31-AG034045-01]; Veterans Affairs; National Institute on Aging [AG03144, AG045034]; CIRM; University of California San Francisco (UCSF); Sandler Foundation; UCSF Clinical and Translational Science Institute [UL1-TR000004]; NIH [DP5-OD12178]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007470] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000004, UL1TR001085] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH020016] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [F31AG034045, R01AG045034] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP5OD012178] Funding Source: NIH RePORTER	California Institute for Regenerative Medicine (CIRM)(California Institute for Regenerative Medicine); Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); Child Health Research Institute fellowship (Stanford National Institutes of Health (NIH)/National Center for Research Resources); Jane Coffin Childs fellowship; National Science Foundation(National Science Foundation (NSF)); National Research Service Award fellowship(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veterans Affairs(US Department of Veterans Affairs); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); CIRM(California Institute for Regenerative Medicine); University of California San Francisco (UCSF)(University of California System); Sandler Foundation; UCSF Clinical and Translational Science Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank A. Eggel, K. Lucin and N. Woodling for critical review and advice, and D. Jing and F. Lee (Cornell University) for Golgi stain reagents. This work was funded by California Institute for Regenerative Medicine (CIRM) fellowships (K.E.P. and K.L.), a Netherlands Organization for Scientific Research (NWO) Rubicon fellowship (J.M.), a Child Health Research Institute fellowship (Stanford National Institutes of Health (NIH)/National Center for Research Resources CTSA-UL1-RR025744, J.M.C.), a Jane Coffin Childs fellowship (J.M.C.), National Science Foundation fellowships (K.I.M. and J.U.), a National Research Service Award fellowship (1F31-AG034045-01, S.A.V.), anonymous (T.W.-C.), Veterans Affairs (T.W.-C.), the National Institute on Aging (AG045034, AG03144, T.W.-C.), CIRM (T.W.-C.), the University of California San Francisco (UCSF) Program for Breakthrough Biomedical Research, the Sandler Foundation (S.A.V.), the UCSF Clinical and Translational Science Institute (UL1-TR000004, S.A.V.) and an NIH Director's Independence Award (DP5-OD12178, S.A.V.).	Alberini CM, 2009, PHYSIOL REV, V89, P121, DOI 10.1152/physrev.00017.2008; Andrews-Hanna JR, 2007, NEURON, V56, P924, DOI 10.1016/j.neuron.2007.10.038; Bishop NA, 2010, NATURE, V464, P529, DOI 10.1038/nature08983; Bizon JL, 2003, EUR J NEUROSCI, V18, P215, DOI 10.1046/j.1460-9568.2003.02733.x; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Brack AS, 2007, SCIENCE, V317, P807, DOI 10.1126/science.1144090; Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260; Drapeau E, 2003, P NATL ACAD SCI USA, V100, P14385, DOI 10.1073/pnas.2334169100; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; GEINISMAN Y, 1986, P NATL ACAD SCI USA, V83, P3027, DOI 10.1073/pnas.83.9.3027; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Hedden T, 2004, NAT REV NEUROSCI, V5, P87, DOI 10.1038/nrn1323; Jeong H, 2012, NAT MED, V18, P159, DOI 10.1038/nm.2559; Loffredo FS, 2013, CELL, V153, P828, DOI 10.1016/j.cell.2013.04.015; Mattson MP, 2006, NAT REV NEUROSCI, V7, P278, DOI 10.1038/nrn1886; Merrill DA, 2003, J COMP NEUROL, V459, P201, DOI 10.1002/cne.10616; Morrison JH, 2012, NAT REV NEUROSCI, V13, P240, DOI 10.1038/nrn3200; Nicholson DA, 2004, J NEUROSCI, V24, P7648, DOI 10.1523/JNEUROSCI.1725-04.2004; Pavlopoulos E, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006373; RAPP PR, 1994, CURR OPIN NEUROL, V7, P294, DOI 10.1097/00019052-199408000-00003; Raz N, 1998, NEUROPSYCHOLOGY, V12, P95, DOI 10.1037/0894-4105.12.1.95; Rosenzweig ES, 2003, PROG NEUROBIOL, V69, P143, DOI 10.1016/S0301-0082(02)00126-0; Ruckh JM, 2012, CELL STEM CELL, V10, P96, DOI 10.1016/j.stem.2011.11.019; Scheff SW, 2007, NEUROLOGY, V68, P1501, DOI 10.1212/01.wnl.0000260698.46517.8f; Small SA, 2011, NAT REV NEUROSCI, V12, P585, DOI 10.1038/nrn3085; Smith TD, 2000, J NEUROSCI, V20, P6587, DOI 10.1523/JNEUROSCI.20-17-06587.2000; Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357	27	592	633	15	243	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2014	20	6					659	663		10.1038/nm.3569	http://dx.doi.org/10.1038/nm.3569			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	AI7LB	24793238	Green Accepted			2023-01-03	WOS:000337071000029
J	Feikin, DR; Bigogo, G; Audi, A; Pals, SL; Aol, G; Mbakaya, C; Williamson, J; Breiman, RF; Larson, CP				Feikin, Daniel R.; Bigogo, Godfrey; Audi, Allan; Pals, Sherri L.; Aol, George; Mbakaya, Charles; Williamson, John; Breiman, Robert F.; Larson, Charles P.			Village-Randomized Clinical Trial of Home Distribution of Zinc for Treatment of Childhood Diarrhea in Rural Western Kenya	PLOS ONE			English	Article							COMMUNITY CASE-MANAGEMENT; DEVELOPING-COUNTRIES; MORBIDITY SURVEILLANCE; POOLED ANALYSIS; CHILDREN; SUPPLEMENTATION; INFANTS; DISEASE; PNEUMONIA; MORTALITY	Background: Zinc treatment shortens diarrhea episodes and can prevent future episodes. In rural Africa, most children with diarrhea are not brought to health facilities. In a village-randomized trial in rural Kenya, we assessed if zinc treatment might have a community-level preventive effect on diarrhea incidence if available at home versus only at health facilities. Methods: We randomized 16 Kenyan villages (1,903 eligible children) to receive a 10-day course of zinc and two oral rehydration solution (ORS) sachets every two months at home and 17 villages (2,241 eligible children) to receive ORS at home, but zinc at the health-facility only. Children's caretakers were educated in zinc/ORS use by village workers, both unblinded to intervention arm. We evaluated whether incidence of diarrhea and acute lower respiratory illness (ALRI) reported at biweekly home visits and presenting to clinic were lower in zinc villages, using poisson regression adjusting for baseline disease rates, distance to clinic, and children's age. Results: There were no differences between village groups in diarrhea incidence either reported at the home or presenting to clinic. In zinc villages (1,440 children analyzed), 61.2% of diarrheal episodes were treated with zinc, compared to 5.4% in comparison villages (1,584 children analyzed, p<0.0001). There were no differences in ORS use between zinc (59.6%) and comparison villages (58.8%). Among children with fever or cough without diarrhea, zinc use was low (<0.5%). There was a lower incidence of reported ALRI in zinc villages (adjusted RR 0.68, 95% CI 0.46-0.99), but not presenting at clinic. Conclusions: In this study, home zinc use to treat diarrhea did not decrease disease rates in the community. However, with proper training, availability of zinc at home could lead to more episodes of pediatric diarrhea being treated with zinc in parts of rural Africa where healthcare utilization is low.	[Feikin, Daniel R.; Bigogo, Godfrey; Audi, Allan; Aol, George; Breiman, Robert F.] Ctr Dis Control & Prevent Kisumu, Int Emerging Infect Program, Kisumu, Kenya; [Pals, Sherri L.] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA; [Williamson, John] US Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA; [Bigogo, Godfrey; Audi, Allan; Aol, George; Mbakaya, Charles] Kenya Govt Med Res Ctr, Nairobi, Kenya; [Larson, Charles P.] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh; [Larson, Charles P.] Univ British Columbia, Dept Pediat, Vancouver, BC V6T 1W5, Canada	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Kenya Medical Research Institute; International Centre for Diarrhoeal Disease Research (ICDDR); University of British Columbia	Feikin, DR (corresponding author), Ctr Dis Control & Prevent Kisumu, Int Emerging Infect Program, Kisumu, Kenya.	dfeikin@jhsph.edu	Bigogo, Godfrey/W-3591-2019	Audi, Allan/0000-0003-1683-554X	The Bill and Melinda Gates Foundation; Centers for Disease Control and Prevention	The Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	Support was provided by The Bill and Melinda Gates Foundation and Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baqui AH, 2002, BRIT MED J, V325, P1059, DOI 10.1136/bmj.325.7372.1059; Bhandari N, 2008, PEDIATRICS, V121, pE1279, DOI 10.1542/peds.2007-1939; Bhutta ZA, 1999, J PEDIATR-US, V135, P689, DOI 10.1016/S0022-3476(99)70086-7; Bhutta ZA, 2000, AM J CLIN NUTR, V72, P1516; Bigogo G, 2010, INT J INFECT DIS, V14, pE967, DOI 10.1016/j.ijid.2010.05.016; Brooks WA, 2005, AM J CLIN NUTR, V82, P605, DOI 10.1093/ajcn/82.3.605; Burton DC, 2011, J HEALTH POPUL NUTR, V29, P61, DOI 10.3329/jhpn.v29i1.7567; Deutscher M, 2012, J EPIDEMIOL IN PRESS; Feikin DR, 2013, PEDIATR INFECT DIS J, V32, pE14, DOI 10.1097/INF.0b013e31826fd39b; Feikin DR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016085; Feikin DR, 2010, INT J EPIDEMIOL, V39, P450, DOI 10.1093/ije/dyp374; George A, 2012, AM J TROP MED HYG, V87, P85, DOI 10.4269/ajtmh.2012.11-0757; Gibson RS, 2008, BRIT J NUTR, V99, pS14, DOI 10.1017/S0007114508006818; Gill CJ, 2013, LANCET, V381, P1487, DOI 10.1016/S0140-6736(13)60314-1; Hamel MJ, 2011, AM J TROP MED HYG, V85, P597, DOI 10.4269/ajtmh.2011.10-0678; Hotz C., 2004, FOOD NUTR BULL, V25, pS91; Kenya National Bureau of Statistics (KNBS) ICF Macro, 2010, KEN DEM HLTH SURV 20; Kotloff KL, 2013, LANCET, V382, P209, DOI 10.1016/S0140-6736(13)60844-2; Larson CP, 2012, HEALTH POLICY PLANN, V27, P102, DOI 10.1093/heapol/czr015; Lazzerini M, 2012, COCHRANE DB SYST REV, V6; Marsh DR, 2012, AM J TROP MED HYG, V87, P2, DOI 10.4269/ajtmh.2012.12-0504; Phillips-Howard PA, 2003, AM J TROP MED HYG, V68, P38; Rochon J, 1998, STAT MED, V17, P1643, DOI 10.1002/(SICI)1097-0258(19980730)17:14<1643::AID-SIM869>3.0.CO;2-3; Tougher S, 2012, LANCET, V380, P1916, DOI 10.1016/S0140-6736(12)61732-2; Walker CLF, 2007, AM J CLIN NUTR, V85, P887, DOI 10.1093/ajcn/85.3.887; Walker CLF, 2006, J PEDIATR GASTR NUTR, V43, P357, DOI 10.1097/01.mpg.0000232018.40907.00; Walker CLF, 2013, LANCET, V381, P1405, DOI 10.1016/S0140-6736(13)60222-6; WHO, 2010, GUID TREATM MAL, V2nd; WHO, 2008, INT MAN CHILDH ILLN; WHO/UNICEF, 2004, CLIN MAN AC DIARRH; WHO/UNICEF, 2013, INT GLOB ACT PLAN PR; Wilson SE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033273; Winch PJ, 2008, J HEALTH POPUL NUTR, V26, P151; Winch PJ, 2006, AM J TROP MED HYG, V74, P880, DOI 10.4269/ajtmh.2006.74.880	34	3	3	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2014	9	5							e94436	10.1371/journal.pone.0094436	http://dx.doi.org/10.1371/journal.pone.0094436			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM1NZ	24835009	Green Submitted, Green Published, gold			2023-01-03	WOS:000339614800004
J	Chiu, SS; Lo, JYC; Chan, KH; Chan, ELY; So, LY; Wu, P; Cowling, BJ; Chen, R; Peiris, JSM				Chiu, Susan S.; Lo, Janice Y. C.; Chan, Kwok-Hung; Chan, Eunice L. Y.; So, Lok-Yee; Wu, Peng; Cowling, Benjamin J.; Chen, Robin; Peiris, J. S. Malik			Population-Based Hospitalization Burden of Influenza A Virus Subtypes and Antigenic Drift Variants in Children in Hong Kong (2004-2011)	PLOS ONE			English	Article							RESPIRATORY VIRUSES; SEASONAL INFLUENZA; RAPID DIAGNOSIS; H1N1 INFLUENZA; YOUNG-CHILDREN; B-VIRUS; INFECTION; MORTALITY; INFANTS; EPIDEMIOLOGY	Objectives: We aim to document and analyze influenza hospitalization burden in light of antigenic changes in circulating influenza viruses in Hong Kong. Methods: The pediatric age-specific rates of influenza A hospitalization in Hong Kong for 2004-2011 which encompassed the emergence of H1N1pdm09 were extrapolated from admissions to 2 hospitals that together catered for 72.5% of all pediatric admissions on Hong Kong Island. Influenza A was detected by immunofluorescence, culture and/or PCR on nasopharyngeal aspirates. Results: Influenza A caused high rates of hospitalization in children with year to year fluctuations. The highest hospitalization burden was seen with H1N1pdm09 in 2009. Additional factors affecting hospitalization were the proportion of viral circulation among different subtypes, and antigenic drifts. Taking these into effect, an H3N2 dominated year was not always associated with more hospitalizations than a 'seasonal' H1N1 year. Hospitalization burden was higher in seasons when drifted viruses of H1N1 or H3N2 dominated. No hospitalization was documented in infants <6 months of age during years when an undrifted virus circulated (2006 for H1N1 and 2008 for H3N2) but significant hospitalization was observed with a drifted or shifted virus (2004, 2005, 2007 and 2010 for H3N2, and 2009 for H1N1pdm09). Conclusions: We documented a consistently high pediatric hospitalization burden of influenza A. Knowledge of antigenic changes and their proportion of circulation aids in the interpretation of impact of the subtypes. Year-to-year variation in hospitalization rates in young infants appeared to correlate with antigenic variation, lending support to the role of protection from maternal antibodies.	[Chiu, Susan S.; Chan, Eunice L. Y.; Chen, Robin] Univ Hong Kong, Dept Pediat & Adolescent Med, Pokfulam, Hong Kong, Peoples R China; [Lo, Janice Y. C.] Ctr Hlth Protect, Dept Hlth, Publ Hlth Lab, Serv Branch, Kowloon, Hong Kong, Peoples R China; [Chan, Kwok-Hung] Univ Hong Kong, Dept Microbiol, Pokfulam, Hong Kong, Peoples R China; [So, Lok-Yee] Pamela Youde Nethersole Eastern Hosp, Dept Pediat & Adolescent Med, Chaiwan, Hong Kong, Peoples R China; [Wu, Peng; Cowling, Benjamin J.] Univ Hong Kong, Sch Publ Hlth, Div Epidemiol & Biostat, Pokfulam, Hong Kong, Peoples R China; [Peiris, J. S. Malik] Univ Hong Kong, Sch Publ Hlth, Influenza Res Ctr, Pokfulam, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; Pamela Youde Nethersole Eastern Hospital; University of Hong Kong; University of Hong Kong	Peiris, JSM (corresponding author), Univ Hong Kong, Sch Publ Hlth, Influenza Res Ctr, Pokfulam, Hong Kong, Peoples R China.	malik@hkucc.hku.hk	Chan, Kwok Hung/ABD-5399-2021; Cowling, Benjamin John/C-4263-2009; Chiu, Susan Shui Seng/C-4247-2009	Cowling, Benjamin John/0000-0002-6297-7154; Wu, Peng/0000-0003-1157-9401; Chiu, Susan Shui Seng/0000-0002-3908-1974	Area of Excellence Scheme of the University Grants Committee of Hong Kong [AoE/M-12/06]	Area of Excellence Scheme of the University Grants Committee of Hong Kong	This work was supported by Area of Excellence Scheme of the University Grants Committee of Hong Kong (grant no. AoE/M-12/06). The authors also want to clarify that no funding from MedImmune Inc. was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 30 GOV HONG KONG SPE; Campbell CNJ, 2011, EPIDEMIOL INFECT, V139, P1560, DOI 10.1017/S0950268810002657; Centers for Disease Control and Prevention (CDC), 2007, 100705 CDC; Chan KH, 2008, J CLIN VIROL, V42, P65, DOI 10.1016/j.jcv.2007.12.003; Chan KH, 2002, J CLIN MICROBIOL, V40, P1675, DOI 10.1128/JCM.40.5.1675-1680.2002; Chan KH, 2008, J CLIN MICROBIOL, V46, P2195, DOI 10.1128/JCM.00315-08; CHIN TDY, 1960, PUBLIC HEALTH REP, V75, P149, DOI 10.2307/4590751; Chiu SS, 2002, NEW ENGL J MED, V347, P2097, DOI 10.1056/NEJMoa020546; Chiu SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021837; Chiu SS, 2009, CLIN INFECT DIS, V49, P1016, DOI 10.1086/605570; Cowling BJ, 2010, EPIDEMIOLOGY, V21, P842, DOI 10.1097/EDE.0b013e3181f20977; Dawood FS, 2010, J PEDIATR-US, V157, P808, DOI 10.1016/j.jpeds.2010.05.012; Eick AA, 2011, ARCH PEDIAT ADOL MED, V165, P104, DOI 10.1001/archpediatrics.2010.192; Jules A, 2012, INFLUENZA OTHER RESP, V6, pe63, DOI 10.1111/j.1750-2659.2012.00343.x; KIM HW, 1979, AM J EPIDEMIOL, V109, P464, DOI 10.1093/oxfordjournals.aje.a112704; Kumar S, 2010, VIRUSES-BASEL, V2, P782, DOI 10.3390/v2040782; Lau JTF, 2010, VACCINE, V28, P5389, DOI 10.1016/j.vaccine.2010.05.071; Libster R, 2010, NEW ENGL J MED, V362, P45, DOI 10.1056/NEJMoa0907673; Lo JYC, 2005, EMERG INFECT DIS, V11, P1738, DOI 10.3201/eid1111.050729; LUI KJ, 1987, AM J PUBLIC HEALTH, V77, P712, DOI 10.2105/AJPH.77.6.712; Monto AS, 2008, VACCINE, V26, pD45, DOI 10.1016/j.vaccine.2008.07.066; MONTO AS, 1975, AM J EPIDEMIOL, V102, P553, DOI 10.1093/oxfordjournals.aje.a112193; MONTO AS, 1985, AM J EPIDEMIOL, V121, P811, DOI 10.1093/oxfordjournals.aje.a114052; Moral L, 2011, ENFERM INFEC MICR CL, V29, P497, DOI 10.1016/j.eimc.2011.01.015; Neuzil KM, 2002, J INFECT DIS, V185, P147, DOI 10.1086/338363; Poehling KA, 2013, PEDIATRICS, V131, P207, DOI 10.1542/peds.2012-1255; Proff R, 2009, EMERG INFECT DIS, V15, P892, DOI 10.3201/eid1506.081645; Riley S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000442; Sebastian R, 2008, VACCINE, V26, P1397, DOI 10.1016/j.vaccine.2007.11.090; Silvennoinen H, 2011, PEDIATR INFECT DIS J, V30, pE24, DOI 10.1097/INF.0b013e3181fe37c8; Simmerman JM, 2009, PLOS ONE, V4, pA107, DOI 10.1371/journal.pone.0007776; Tarrant M, 2012, MATERN CHILD HLTH J, DOI [10.1007/s10995.011-0943-1, DOI 10.1007/S10995.011-0943-1]; To KKW, 2010, POSTGRAD MED J, V86, P515, DOI 10.1136/pgmj.2009.096206; van Gageldonk-Lafeber AB, 2011, INFLUENZA OTHER RESP, V5, pR513, DOI 10.1111/j.1750-2659.2011.00260.x; Wu JT, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001103; Wu JT, 2010, CLIN INFECT DIS, V51, P1184, DOI 10.1086/656740; Wu P, 2012, J INFECT DIS, V206, P1862, DOI 10.1093/infdis/jis628; Zaman K, 2008, NEW ENGL J MED, V359, P1555, DOI 10.1056/NEJMoa0708630	38	20	20	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2014	9	4							e92914	10.1371/journal.pone.0092914	http://dx.doi.org/10.1371/journal.pone.0092914			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AL1WP	24786780	Green Published, Green Submitted, gold			2023-01-03	WOS:000338917300002
J	Monge, ME; Dwivedi, P; Zhou, MS; Payne, M; Harris, C; House, B; Juggins, Y; Cizmarik, P; Newton, PN; Fernandez, FM; Jenkins, D				Monge, Maria Eugenia; Dwivedi, Prabha; Zhou, Manshui; Payne, Michael; Harris, Chris; House, Blaine; Juggins, Yvonne; Cizmarik, Peter; Newton, Paul N.; Fernandez, Facundo M.; Jenkins, David			A Tiered Analytical Approach for Investigating Poor Quality Emergency Contraceptives	PLOS ONE			English	Article							SUBSTANDARD MEDICINES; LEVONORGESTREL; PRIORITY; DRUGS	Reproductive health has been deleteriously affected by poor quality medicines. Emergency contraceptive pills (ECPs) are an important birth control method that women can use after unprotected coitus for reducing the risk of pregnancy. In response to the detection of poor quality ECPs commercially available in the Peruvian market we developed a tiered multi-platform analytical strategy. In a survey to assess ECP medicine quality in Peru, 7 out of 25 different batches showed inadequate release of levonorgestrel by dissolution testing or improper amounts of active ingredient. One batch was found to contain a wrong active ingredient, with no detectable levonorgestrel. By combining ultrahigh performance liquid chromatography-ion mobility spectrometry-mass spectrometry (UHPLC-IMS-MS) and direct analysis in real time MS (DART-MS) the unknown compound was identified as the antibiotic sulfamethoxazole. Quantitation by UHPLC-triple quadrupole tandem MS (QqQ-MS/MS) indicated that the wrong ingredient was present in the ECP sample at levels which could have significant physiological effects. Further chemical characterization of the poor quality ECP samples included the identification of the excipients by 2D Diffusion-Ordered Nuclear Magnetic Resonance Spectroscopy (DOSY H-1 NMR) indicating the presence of lactose and magnesium stearate.	[Monge, Maria Eugenia; Dwivedi, Prabha; Zhou, Manshui; Fernandez, Facundo M.] Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA; [Payne, Michael; Harris, Chris; House, Blaine; Juggins, Yvonne; Cizmarik, Peter; Jenkins, David] FHI 360, Prod Qual & Compliance, Durham, NC USA; [Newton, Paul N.] Mahosot Hosp, Lao Oxford Mahosot Hosp Wellcome Trust Res Unit, Microbiol Lab, Viangchan, Laos; [Newton, Paul N.] Univ Oxford, Churchill Hosp, Ctr Trop Med, Oxford, England; [Newton, Paul N.] Univ Oxford, Churchill Hosp, WorldWide Antimalarial Resistance Network, Oxford, England	University System of Georgia; Georgia Institute of Technology; FHI 360; University of Oxford; University of Oxford; Worldwide Antimalarial Resistance Network (WWARN)	Fernandez, FM (corresponding author), Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA.	facundo.fernandez@chemistry.gatech.edu; djenkins@fhi360.org	Jenkins, David/K-8021-2019; Fernandez, Facundo Martin/B-7015-2008	Jenkins, David/0000-0001-6698-272X; Fernandez, Facundo Martin/0000-0002-0302-2534; Dwivedi, Prabha/0000-0002-6435-2166; Newton, Paul/0000-0002-4608-6431; Monge, Maria/0000-0001-6517-5301	Prosalud Inter Americana [FHI 360]; ACT Consortium; Bill & Melinda Gates Foundation; Wellcome Trust of Great Britain; Division Of Chemistry [1004570] Funding Source: National Science Foundation	Prosalud Inter Americana; ACT Consortium; Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation); Wellcome Trust of Great Britain(Wellcome Trust); Division Of Chemistry(National Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS))	Sample collection, HPLC analysis, dissolution testing and TLC screening were funded through a contract between Prosalud Inter Americana (http://prosaludinteramericana.org/) to FHI 360. All drug purchasing was handled in-country by an independent organization subcontracted by FHI 360. PD was partially supported by the ACT Consortium (www.actconsortium.org), which is funded through a grant from the Bill & Melinda Gates Foundation to the London School of Hygiene & Tropical Medicine. The authors are also thankful for access to MS instrumentation acquired through the ACT Consortium and the NSF/NASA Center for Chemical Evolution. Paul Newton is supported by the Wellcome Trust of Great Britain (http://www.wellcome.ac.uk/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2013, COUNT PROBL FALS SUB; [Anonymous], 2011, CONTRACEPTIVE TECHNO; Attaran A, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e7381; Caudron JM, 2008, TROP MED INT HEALTH, V13, P1062, DOI 10.1111/j.1365-3156.2008.02106.x; CDC, 2013, US EM CONTR WOM AG 1; Cody RB, 2005, ANAL CHEM, V77, P2297, DOI 10.1021/ac050162j; Csillag C, 1998, LANCET, V352, P553, DOI 10.1016/S0140-6736(05)79267-9; Dorlo TPC, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e7518; FDA, 2004, FDA JOHNS JOHNS WARN; FDA, 2011, UN EM BIRTH CONTR ME; Fernandez FM, 2011, ANALYST, V136, P3073, DOI 10.1039/c0an00627k; Holzgrabe U, 2008, NMR SPECTROSCOPY IN PHARMACEUTICAL ANALYSIS, P1; Kuczynski PP, 2006, CONSTITUYEN GRUPO TE; Ministerio de salud, 2006, EV SIT MED PER; Newton P, 2009, DEV COUNTRIES; Newton PN, 2008, PLOS MED, V5, P209, DOI 10.1371/journal.pmed.0050032; Newton PN, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001139; Newton PN, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-352; Newton PN, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000052; Nishtar S, 2012, LANCET, V379, P1084, DOI 10.1016/S0140-6736(12)60277-3; Noe G, 2010, CONTRACEPTION, V81, P414, DOI 10.1016/j.contraception.2009.12.015; Novikova N, 2007, CONTRACEPTION, V75, P112, DOI 10.1016/j.contraception.2006.08.015; Nyadong L, 2009, ANAL CHEM, V81, P4803, DOI 10.1021/ac900384j; Smith CA, 2005, THER DRUG MONIT, V27, P747, DOI 10.1097/01.ftd.0000179845.53213.39; Smith RM, 2012, NEW ENGL J MED; Trussell J, 2012, EMERGENCY CONTRACEPTION: THE STORY OF A GLOBAL REPRODUCTIVE HEALTH TECHNOLOGY, P19; von Hertzen H, 2002, LANCET, V360, P1803, DOI 10.1016/S0140-6736(02)11767-3; Wanja J, 2009, DAILY NATION KENYA; WHO, 2015, PREQ PROGR; WHO, 2011, LEV TABL; World Health Organization IES, 2013, FALS BATCH POST 2 RE	31	10	11	2	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2014	9	4							e95353	10.1371/journal.pone.0095353	http://dx.doi.org/10.1371/journal.pone.0095353			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG2DP	24748219	Green Published, Green Submitted, gold			2023-01-03	WOS:000335226500091
J	Dong, JF; Zhang, SM; Ma, J; Liu, HM; Du, YY; Liu, YH				Dong, JunFeng; Zhang, ShengMin; Ma, Jun; Liu, HaoMing; Du, YingYing; Liu, YongHui			Preparation, Characterization, and In Vitro Cytotoxicity Evaluation of a Novel Anti-Tuberculosis Reconstruction Implant	PLOS ONE			English	Article							HYDROXYAPATITE COMPOSITE SCAFFOLDS; SPINAL TUBERCULOSIS; MECHANICAL-PROPERTIES; LACTIDE COMPOSITE; VIVO EVALUATION; BONE; FABRICATION; DEGRADATION; BIOACTIVITY; RIFAMPICIN	Background: Reconstruction materials currently used in clinical for osteoarticular tuberculosis (TB) are unsatisfactory due to a variety of reasons. Rifampicin (RFP) is a well-known and highly effective first-line anti-tuberculosis (anti-TB) drug. Poly-DL-lactide (PDLLA) and nano-hydroxyapatite (nHA) are two promising materials that have been used both for orthopedic reconstruction and as carriers for drug release. In this study we report the development of a novel anti-TB implant for osteoarticular TB reconstruction using a combination of RFP, PDLLA and nHA. Methods: RFP, PDLLA and nHA were used as starting materials to produce a novel anti-TB activity implant by the solvent evaporation method. After manufacture, the implant was characterized and its biodegradation and drug release profile were tested. The in vitro cytotoxicity of the implant was also evaluated in pre-osteoblast MC3T3-E1 cells using multiple methodologies. Results: A RFP/PDLLA/nHA composite was successfully synthesized using the solvent evaporation method. The composite has a loose and porous structure with evenly distributed pores. The production process was steady and no chemical reaction occurred as proved by Fourier Transform Infrared Spectroscopy (FTIR) and X-Ray Diffraction (XRD). Meanwhile, the composite blocks degraded and released drug for at least 12 weeks. Evaluation of in vitro cytotoxicity in MC3T3-E1 cells verified that the synthesized composite blocks did not affect cell growth and proliferation. Conclusion: It is feasible to manufacture a novel bioactive anti-TB RFP/PDLLA/nHA composite by the solvent evaporation method. The composite blocks showed appropriate properties such as degradation, drug release and biosafety to MC3T3-E1 cells. In conclusion, the novel composite blocks may have great potential for clinical applications in repairing bone defects caused by osteoarticular TB.	[Dong, JunFeng; Zhang, ShengMin; Ma, Jun; Liu, HaoMing; Du, YingYing; Liu, YongHui] Huazhong Univ Sci & Technol, Adv Biomat & Tissue Engn Ctr, Wuhan 430074, Peoples R China; [Dong, JunFeng; Zhang, ShengMin; Ma, Jun] Huazhong Univ Sci & Technol, Dept Biomed Engn, Wuhan 430074, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology	Zhang, SM (corresponding author), Huazhong Univ Sci & Technol, Adv Biomat & Tissue Engn Ctr, Wuhan 430074, Peoples R China.	smzhang@mail.hust.edu.cn	Ma, Jun/K-2084-2012; Liu, Yong/GWQ-6163-2022	Ma, Jun/0000-0001-5167-1750; 	National Basic Research Program of China (973 Program) [2012CB933601]	National Basic Research Program of China (973 Program)(National Basic Research Program of China)	This project was supported in part by the National Basic Research Program of China (973 Program, 2012CB933601). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad Z, 2011, ANTIMICROB AGENTS CH, V55, P1527, DOI 10.1128/AAC.01524-10; Aydin E, 2011, J MATER SCI-MATER M, V22, P2413, DOI 10.1007/s10856-011-4435-z; Bahna P, 2007, INT J ANTIMICROB AG, V29, P593, DOI 10.1016/j.ijantimicag.2006.12.013; Barbosa MC, 2013, MAT SCI ENG C-MATER, V33, P2620, DOI 10.1016/j.msec.2013.02.027; Bemer-Melchior P, 2000, J ANTIMICROB CHEMOTH, V46, P571, DOI 10.1093/jac/46.4.571; Chen L, 2011, COMPOS SCI TECHNOL, V71, P1842, DOI 10.1016/j.compscitech.2011.08.015; Chen L, 2013, J MECH BEHAV BIOMED, V22, P41, DOI 10.1016/j.jmbbm.2013.03.008; Chlopek J, 2009, POLYM DEGRAD STABIL, V94, P1479, DOI 10.1016/j.polymdegradstab.2009.05.010; Dong JF, 2014, EXPERT OPIN DRUG DEL, V11, P299, DOI 10.1517/17425247.2014.872625; Furukawa T, 2000, BIOMATERIALS, V21, P889, DOI 10.1016/S0142-9612(99)00232-X; Garg RK, 2011, J SPINAL CORD MED, V34, P440, DOI 10.1179/2045772311Y.0000000023; Gauthier O, 1999, J MATER SCI-MATER M, V10, P199, DOI 10.1023/A:1008949910440; Ge ZH, 2008, EUR SPINE J, V17, P1482, DOI 10.1007/s00586-008-0778-7; Guillaume M, 2012, MED MALADIES INFECT, V42, P414, DOI 10.1016/j.medmal.2012.07.018; Guillaume O, 2012, J CONTROL RELEASE, V162, P492, DOI 10.1016/j.jconrel.2012.08.003; Hasegawa S, 2005, J BIOMED MATER RES A, V75A, P567, DOI 10.1002/jbm.a.30460; Hasegawa S, 2007, J BIOMED MATER RES A, V81A, P930, DOI 10.1002/jbm.a.31109; Jain AK, 2007, CLIN ORTHOP RELAT R, P39, DOI 10.1097/BLO.0b013e318065b7c3; Jain AK, 2012, INT ORTHOP, V36, P285, DOI 10.1007/s00264-011-1296-5; Javerliat I, 2007, ANN VASC SURG, V21, P603, DOI 10.1016/j.avsg.2007.06.005; Jing Z, 2003, J CONTROL RELEASE, V92, P227, DOI 10.1016/S0168-3659(03)00372-9; Jones WL, 2011, BIOFOULING, V27, P207, DOI 10.1080/08927014.2011.554977; Khoo Larry T, 2003, Spine J, V3, P130, DOI 10.1016/S1529-9430(02)00410-2; Nazhat SN, 2001, J BIOMED MATER RES, V58, P335, DOI 10.1002/jbm.1026; Norowski PA, 2009, J BIOMED MATER RES B, V88B, P530, DOI 10.1002/jbm.b.31152; Onyebujoh P, 2005, B WORLD HEALTH ORGAN, V83, P857; Ravelingien M, 2010, EUR J PHARM BIOPHARM, V76, P366, DOI 10.1016/j.ejpb.2010.08.010; Ren J, 2008, J MATER SCI-MATER M, V19, P1075, DOI 10.1007/s10856-007-3181-8; Russias J, 2006, MAT SCI ENG C-BIO S, V26, P1289, DOI 10.1016/j.msec.2005.08.004; Sun F, 2011, ACTA BIOMATER, V7, P3813, DOI 10.1016/j.actbio.2011.07.002; Tan QG, 2011, INT J MOL SCI, V12, P890, DOI 10.3390/ijms12020890; Teng XR, 2007, J BIOMED MATER RES B, V81B, P185, DOI 10.1002/jbm.b.30652; Vagaska B, 2010, PHYSIOL RES, V59, P309, DOI 10.33549/physiolres.931776; van Ingen J, 2011, CLIN INFECT DIS, V52, pE194, DOI 10.1093/cid/cir184; Wan T, 2005, BIO-MED MATER ENG, V15, P333; Wang RG, 2012, MACROMOLECULES, V45, P6830, DOI 10.1021/ma301183k; World Health Organization, 2004, WORLD HLTH REP 2004; Zhang SM, 2005, CURR APPL PHYS, V5, P516, DOI 10.1016/j.cap.2005.01.023	38	5	6	0	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2014	9	4							e94937	10.1371/journal.pone.0094937	http://dx.doi.org/10.1371/journal.pone.0094937			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI4VW	24740373	Green Published, gold, Green Submitted			2023-01-03	WOS:000336863900083
J	Xu, HY; Xu, WL; Wang, LQ; Chen, MB; Shen, HL				Xu, Hai-Yuan; Xu, Wen-Lin; Wang, Li-Qiang; Chen, Min-Bin; Shen, Hui-Ling			Relationship between P53 Status and Response to Chemotherapy in Patients with Gastric Cancer: A Meta-Analysis	PLOS ONE			English	Article							BIOLOGICAL MARKERS; NEOADJUVANT CHEMOTHERAPY; GASTROESOPHAGEAL CANCER; PREDICTIVE MARKERS; EXPRESSION; PROTEIN; CARCINOMA; CISPLATIN; PROGNOSIS; THERAPY	Background: Previous studies have yielded conflicting results regarding the relationship between p53 status and response to chemotherapy in patients with gastric cancer. We therefore performed a meta-analysis to expound the relationship between p53 status and response to chemotherapy. Methods/Findings: Thirteen previously published eligible studies, including 564 cases, were identified and included in this meta-analysis. p53 positive status (high expression of p53 protein and/or a mutant p53 gene) was associated with improved response in gastric cancer patients who received chemotherapy (good response: risk ratio [RR] = 0.704; 95% confidence intervals [CI] = 0.550-0.903; P = 0.006). In further stratified analyses, association with a good response remained in the East Asian population (RR = 0.657; 95% CI = 0.488-0.884; P = 0.005), while in the European subgroup, patients with p53 positive status tended to have a good response to chemotherapy, although this did not reach statistical significance (RR = 0.828, 95% CI = 0.525-1.305; P = 0.417). As five studies used neoadjuvant chemotherapy (NCT) and one used neoadjuvant chemoradiotherapy (NCRT), we also analyzed these data, and found that p53 positive status was associated with a good response in gastric cancer patients who received chemotherapy-based neoadjuvant treatment (RR = 0.675, 95% CI = 0.463-0.985; P = 0.042). Conclusion: This meta-analysis indicated that p53 status may be a useful predictive biomarker for response to chemotherapy in gastric cancer. Further prospective studies with larger sample sizes and better study designs are required to confirm our findings.	[Xu, Hai-Yuan; Wang, Li-Qiang; Chen, Min-Bin] Jiangsu Univ, Kunshan Peoples Hosp 1, Dept Med Oncol, Kunshan, Peoples R China; [Xu, Wen-Lin] Jiangsu Univ, Zhenjiang Peoples Hosp 4, Dept Cent Lab, Zhenjiang, Peoples R China; [Shen, Hui-Ling] Jiangsu Univ, Zhenjiang Peoples Hosp 1, Dept Med Oncol, Zhenjiang, Peoples R China	Jiangsu University; Jiangsu University; Jiangsu University	Shen, HL (corresponding author), Jiangsu Univ, Zhenjiang Peoples Hosp 1, Dept Med Oncol, Zhenjiang, Peoples R China.	shenhuiling0826@163.com			National Natural Science Foundation [81101677, 81070423]	National Natural Science Foundation(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation (No. 81101677,81070423). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bataille F, 2003, J CLIN PATHOL-MOL PA, V56, P286; Boku N, 1998, CLIN CANCER RES, V4, P1469; Boku N, 2007, JPN J CLIN ONCOL, V37, P275, DOI 10.1093/jjco/hym015; Cascinu S, 1998, CANCER-AM CANCER SOC, V83, P1917, DOI 10.1002/(SICI)1097-0142(19981101)83:9<1917::AID-CNCR6>3.0.CO;2-1; Chen MB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039655; Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531; Fareed KR, 2010, BRIT J CANCER, V102, P1600, DOI 10.1038/sj.bjc.6605686; Fareed KR, 2009, GUT, V58, P127, DOI 10.1136/gut.2008.155861; Giatromanolaki A, 2001, AM J CLIN ONCOL-CANC, V24, P222, DOI 10.1097/00000421-200106000-00002; Japanese Gastric Cancer Association, 1998, GASTRIC CANCER, V1, P10, DOI DOI 10.1007/S101209800016; Japanese Research Society for Gastric Cancer, 1995, JAP CLASS GASTR CARC; Japanese Research Society of Gastric Cancer, 1999, JAP CLASS GASTR CARC, P101; Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308; Kamoshida S, 2007, BRIT J CANCER, V96, P277, DOI 10.1038/sj.bjc.6603546; Kikuyama S, 2001, ANTICANCER RES, V21, P2149; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Mezhir JJ, 2010, J SURG ONCOL, V101, P305, DOI 10.1002/jso.21483; Nagashima F, 2005, JPN J CLIN ONCOL, V35, P714, DOI 10.1093/jjco/hyi194; Nakata B, 1998, SURG TODAY, V28, P595, DOI 10.1007/s005950050190; Nashimoto Atsushi, 1999, Gastric Cancer, V2, P57, DOI 10.1007/s101200050022; Ott K, 2003, CLIN CANCER RES, V9, P2307; Ott Katja, 2003, Gastric Cancer, V6, P159, DOI 10.1007/s10120-003-0245-4; Pakos EE, 2004, CLIN CANCER RES, V10, P6208, DOI 10.1158/1078-0432.CCR-04-0246; Qu Jian-jun, 2013, Zhonghua Wei Chang Wai Ke Za Zhi, V16, P276; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sirak I, 2009, HEPATO-GASTROENTEROL, V56, P1213; Tewari M, 2008, SURG ONCOL, V17, P301, DOI 10.1016/j.suronc.2008.03.003; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Weller M, 1998, CELL TISSUE RES, V292, P435, DOI 10.1007/s004410051072; World Health Organization, 1979, WHO OFFS PUBL; Yeh KH, 1999, HEPATO-GASTROENTEROL, V46, P610	34	19	20	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2014	9	4							e95371	10.1371/journal.pone.0095371	http://dx.doi.org/10.1371/journal.pone.0095371			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI4VW	24740294	Green Published, Green Submitted, gold			2023-01-03	WOS:000336863900134
J	Couch, FJ; Nathanson, KL; Offit, K				Couch, Fergus J.; Nathanson, Katherine L.; Offit, Kenneth			Two Decades After BRCA: Setting Paradigms in Personalized Cancer Care and Prevention	SCIENCE			English	Editorial Material							GENOME-WIDE ASSOCIATION; EARLY-ONSET BREAST; HIGH FAMILIAL RISK; MUTATION CARRIERS; OVARIAN-CANCER; UNCERTAIN SIGNIFICANCE; GENETIC SUSCEPTIBILITY; SALPINGO-OOPHORECTOMY; CLINICAL-SIGNIFICANCE; ORAL-CONTRACEPTIVES	The cloning of the breast cancer susceptibility genes BRCA1 and BRCA2 nearly two decades ago helped set in motion an avalanche of research exploring how genomic information can be optimally applied to identify and clinically care for individuals with a high risk of developing cancer. Genetic testing for mutations in BRCA1, BRCA2, and other breast cancer susceptibility genes has since proved to be a valuable tool for determining eligibility for enhanced screening and prevention strategies, as well as for identifying patients most likely to benefit from a targeted therapy. Here, we discuss the landscape of inherited mutations and sequence variants in BRCA1 and BRCA2, the complexities of determining disease risk when the pathogenicity of sequence variants is uncertain, and current strategies for clinical management of women who carry BRCA1/2 mutations.	[Couch, Fergus J.] Mayo Clin, Dept Lab Med & Pathol, Div Expt Pathol & Lab Med, Rochester, MN 55905 USA; [Nathanson, Katherine L.] Univ Penn, Div Translat Med & Human Genet, Dept Med, Abramson Canc Ctr,Perelman Sch Med, Philadelphia, PA 19104 USA; [Offit, Kenneth] Mem Sloan Kettering Canc Ctr, Clin Genet Serv, Canc Biol & Genet Program, Dept Med,Sloan Kettering Inst, New York, NY 10065 USA; [Offit, Kenneth] Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA; [Offit, Kenneth] Weill Cornell Med Coll, Dept Publ Hlth, New York, NY 10065 USA	Mayo Clinic; University of Pennsylvania; Pennsylvania Medicine; Memorial Sloan Kettering Cancer Center; Cornell University; Cornell University	Couch, FJ (corresponding author), Mayo Clin, Dept Lab Med & Pathol, Div Expt Pathol & Lab Med, Rochester, MN 55905 USA.	couch.fergus@mayo.edu			NATIONAL CANCER INSTITUTE [U01CA164947, U01CA116167, P30CA016520, R01CA128978, P50CA116201, R01CA135509, P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA116167, P50 CA116201, CA016520, R01 CA135509, U01CA164947, P30 CA016520, CA116201, CA135509, U01 CA164947, 3P30CA008748-47, R01 CA128978, CA116167, P30 CA008748, CA128978, U01 CA116167] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antoniou AC, 2008, BRIT J CANCER, V98, P1457, DOI 10.1038/sj.bjc.6604305; Antoniou AC, 2011, HUM MOL GENET, V20, P3304, DOI 10.1093/hmg/ddr226; Antoniou AC, 2010, CANCER RES, V70, P9742, DOI 10.1158/0008-5472.CAN-10-1907; Bahcall OG, 2013, NAT GENET, V45, P343, DOI 10.1038/ng.2592; Beral V, 2001, LANCET, V358, P1389, DOI 10.1016/S0140-6736(01)06524-2; Biswas K, 2012, HUM MOL GENET, V21, P3993, DOI 10.1093/hmg/dds222; Bombard Y, 2013, JAMA-J AM MED ASSOC, V310, P795, DOI 10.1001/jama.2013.276573; Bouwman P, 2013, CANCER DISCOV, V3, P1142, DOI 10.1158/2159-8290.CD-13-0094; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Bubien V, 2013, J MED GENET, V50, P255, DOI 10.1136/jmedgenet-2012-101339; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Chang SH, 2011, NAT MED, V17, P1275, DOI 10.1038/nm.2459; Chen SN, 2007, J CLIN ONCOL, V25, P1329, DOI 10.1200/JCO.2006.09.1066; Collett K, 2005, CANCER EPIDEM BIOMAR, V14, P1108, DOI 10.1158/1055-9965.EPI-04-0394; Couch FJ, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003212; Curtin N, 2014, BIOCHEM SOC T, V42, P82, DOI 10.1042/BST20130187; De Lorenzo SB, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00228; Domchek SM, 2013, J CLIN ONCOL, V31, P1267, DOI 10.1200/JCO.2012.46.9403; Domchek SM, 2010, JAMA-J AM MED ASSOC, V304, P967, DOI 10.1001/jama.2010.1237; Drost R, 2011, CANCER CELL, V20, P797, DOI 10.1016/j.ccr.2011.11.014; Edwards SL, 2008, NATURE, V451, P1111, DOI 10.1038/nature06548; Eisen A, 2005, J CLIN ONCOL, V23, P7491, DOI 10.1200/JCO.2004.00.7138; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Finch A, 2006, JAMA-J AM MED ASSOC, V296, P185, DOI 10.1001/jama.296.2.185; French JD, 2013, AM J HUM GENET, V92, P489, DOI 10.1016/j.ajhg.2013.01.002; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Garcia-Closas M, 2013, NAT GENET, V45, P392, DOI 10.1038/ng.2561; Gaudet MM, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003173; Gaudet MM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001183; Gayther SA, 1997, AM J HUM GENET, V60, P1239; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; Goldgar DE, 2004, AM J HUM GENET, V75, P535, DOI 10.1086/424388; Gronwald J, 2006, INT J CANCER, V118, P2281, DOI 10.1002/ijc.21536; Guidugli L, 2014, HUM MUTAT, V35, P151, DOI 10.1002/humu.22478; Guidugli L, 2013, CANCER RES, V73, P265, DOI 10.1158/0008-5472.CAN-12-2081; Haile RW, 2006, CANCER EPIDEM BIOMAR, V15, P1863, DOI 10.1158/1055-9965.EPI-06-0258; Haiman CA, 2011, NAT GENET, V43, P1210, DOI 10.1038/ng.985; Hall A. E., 2013, J PUBLIC HLTH, V2013; Hearle N, 2006, CLIN CANCER RES, V12, P3209, DOI 10.1158/1078-0432.CCR-06-0083; Hermsen BBJ, 2007, BRIT J CANCER, V96, P1335, DOI 10.1038/sj.bjc.6603725; Iversen ES, 2011, CANCER EPIDEM BIOMAR, V20, P1078, DOI 10.1158/1055-9965.EPI-10-1214; Judkins T, 2012, CANCER-AM CANCER SOC, V118, P5210, DOI 10.1002/cncr.27556; Kauff ND, 2002, NEW ENGL J MED, V346, P1609, DOI 10.1056/NEJMoa020119; King MC, 2014, SCIENCE, V343, P1462, DOI 10.1126/science.1251900; King MC, 2001, JAMA-J AM MED ASSOC, V286, P2251, DOI 10.1001/jama.286.18.2251; Kriege M, 2004, NEW ENGL J MED, V351, P427, DOI 10.1056/NEJMoa031759; Kuhl CK, 2005, J CLIN ONCOL, V23, P8469, DOI 10.1200/JCO.2004.00.4960; Leach MO, 2005, LANCET, V365, P1769, DOI 10.1016/S0140-6736(05)66481-1; Lee MS, 2010, CANCER RES, V70, P4880, DOI 10.1158/0008-5472.CAN-09-4563; Lehman CD, 2005, CANCER, V103, P1898, DOI 10.1002/cncr.20971; Lindor NM, 2012, HUM MUTAT, V33, P8, DOI 10.1002/humu.21627; Lord CJ, 2013, NAT MED, V19, P1381, DOI 10.1038/nm.3369; Loveday C, 2012, NAT GENET, V44, P475, DOI 10.1038/ng.2224; Mavaddat N, 2010, MOL ONCOL, V4, P174, DOI 10.1016/j.molonc.2010.04.011; Maxwell KN, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3591; McLaughlin JR, 2007, LANCET ONCOL, V8, P26, DOI 10.1016/S1470-2045(06)70983-4; Metcalfe KA, 2008, INT J CANCER, V122, P2017, DOI 10.1002/ijc.23340; Meyer KB, 2013, AM J HUM GENET, V93, P1046, DOI 10.1016/j.ajhg.2013.10.026; Michailidou K, 2013, NAT GENET, V45, P353, DOI 10.1038/ng.2563; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Narod SA, 2002, JNCI-J NATL CANCER I, V94, P1773, DOI 10.1093/jnci/94.23.1773; Narod SA, 1998, NEW ENGL J MED, V339, P424, DOI 10.1056/NEJM199808133390702; Oddoux C, 1996, NAT GENET, V14, P188, DOI 10.1038/ng1096-188; Offit K, 2006, J NATL CANCER I, V98, P1675, DOI 10.1093/jnci/djj500; Offit K, 2011, HUM GENET, V130, P3, DOI 10.1007/s00439-011-1028-3; Offit K, 2010, J CLIN ONCOL, V28, P4665, DOI 10.1200/JCO.2010.31.2926; Olivier RI, 2006, GYNECOL ONCOL, V100, P20, DOI 10.1016/j.ygyno.2005.08.038; Pashayan N, 2013, J INTERN MED, V274, P451, DOI 10.1111/joim.12094; Pennington KP, 2014, CLIN CANCER RES, V20, P764, DOI 10.1158/1078-0432.CCR-13-2287; Peto J, 1999, J NATL CANCER I, V91, P943, DOI 10.1093/jnci/91.11.943; PetrijBosch A, 1997, NAT GENET, V17, P341, DOI 10.1038/ng1197-341; Purrington KS, 2014, CARCINOGENESIS, V35, P1012, DOI 10.1093/carcin/bgt404; Rahman N, 2007, NAT GENET, V39, P165, DOI 10.1038/ng1959; Rebbeck TR, 2011, CANCER RES, V71, P5792, DOI 10.1158/0008-5472.CAN-11-0773; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; Rebbeck TR, 2004, J CLIN ONCOL, V22, P1055, DOI 10.1200/JCO.2004.04.188; Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185; Robson M, 2007, NEW ENGL J MED, V357, P154, DOI 10.1056/NEJMcp071286; Robson ME, 2011, J CLIN ONCOL, V29, P3724, DOI 10.1200/JCO.2011.37.2540; Rosen EM, 2014, CURR DRUG TARGETS, V15, P17, DOI 10.2174/1389450114666140106095432; Sardanelli F, 2007, RADIOLOGY, V242, P698, DOI 10.1148/radiol.2423051965; Sawyer S, 2012, J CLIN ONCOL, V30, P4330, DOI 10.1200/JCO.2012.41.7469; Spurdle AB, 2012, J MED GENET, V49, P525, DOI 10.1136/jmedgenet-2012-101037; Stadler ZK, 2014, J CLIN ONCOL, V32, P687, DOI 10.1200/JCO.2013.49.7271; Stadler ZK, 2010, HEMATOL ONCOL CLIN N, V24, P973, DOI 10.1016/j.hoc.2010.06.009; Stevens KN, 2012, CANCER RES, V72, P1795, DOI 10.1158/0008-5472.CAN-11-3364; Tavtigian SV, 2008, HUM MUTAT, V29, P1342, DOI 10.1002/humu.20896; Thompson D, 2001, AM J HUM GENET, V68, P410, DOI 10.1086/318181; Wacholder S, 2010, NEW ENGL J MED, V362, P986, DOI 10.1056/NEJMoa0907727; Wang XS, 2010, HUM MOL GENET, V19, P2886, DOI 10.1093/hmg/ddq174; Warner E, 2004, JAMA-J AM MED ASSOC, V292, P1317, DOI 10.1001/jama.292.11.1317; Weitzel JN, 2013, J CLIN ONCOL, V31, P210, DOI 10.1200/JCO.2011.41.0027; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Wu CC, 2006, CANCER RES, V66, P8287, DOI 10.1158/0008-5472.CAN-05-4247	94	230	237	2	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	2014	343	6178					1466	1470		10.1126/science.1251827	http://dx.doi.org/10.1126/science.1251827			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AD7TZ	24675953	Green Accepted			2023-01-03	WOS:000333471000036
J	Kovacs, S; Hawes, SE; Maley, SN; Mosites, E; Wong, L; Stergachis, A				Kovacs, Stephanie; Hawes, Stephen E.; Maley, Stephen N.; Mosites, Emily; Wong, Ling; Stergachis, Andy			Technologies for Detecting Falsified and Substandard Drugs in Low and Middle-Income Countries	PLOS ONE			English	Article							COUNTERFEIT DRUGS; QUALITY; IDENTIFICATION; SPECTROMETRY; SPECTROSCOPY; ARTESUNATE; PRODUCTS; TABLETS	Falsified and substandard drugs are a global health problem, particularly in low-and middle-income countries (LMIC) that have weak pharmacovigilance and drug regulatory systems. Poor quality medicines have important health consequences, including the potential for treatment failure, development of antimicrobial resistance, and serious adverse drug reactions, increasing healthcare costs and undermining the public's confidence in healthcare systems. This article presents a review of the methods employed for the analysis of pharmaceutical formulations. Technologies for detecting substandard and falsified drugs were identified primarily through literature reviews. Key-informant interviews with experts augmented our methods when warranted. In order to aid comparisons, technologies were assigned a suitability score for use in LMIC ranging from 0-8. Scores measured the need for electricity, need for sample preparation, need for reagents, portability, level of training required, and speed of analysis. Technologies with higher scores were deemed the most feasible in LMICs. We categorized technologies that cost $10,000 USD or less as low cost, $10,000-100,000 USD as medium cost and those greater than $100,000 USD as high cost technologies (all prices are 2013 USD). This search strategy yielded information on 42 unique technologies. Five technologies were deemed both low cost and had feasibility scores between 6-8, and an additional four technologies had medium cost and high feasibility. Twelve technologies were deemed portable and therefore could be used in the field. Many technologies can aid in the detection of substandard and falsified drugs that vary from the simplest of checklists for packaging to the most complex mass spectrometry analyses. Although there is no single technology that can serve all the requirements of detecting falsified and substandard drugs, there is an opportunity to bifurcate the technologies into specific niches to address specific sections within the workflow process of detecting products.	[Kovacs, Stephanie; Hawes, Stephen E.; Maley, Stephen N.; Mosites, Emily; Stergachis, Andy] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Wong, Ling] Bill & Melinda Gates Fdn, Seattle, WA USA; [Stergachis, Andy] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [Stergachis, Andy] Univ Washington, Global Med Program, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; Bill & Melinda Gates Foundation; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Kovacs, S (corresponding author), Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.	kovacs2@uw.edu		Mosites, Emily/0000-0002-2968-9564	Strategic Analysis and Research Training Program (START); Bill and Melinda Gates Foundation	Strategic Analysis and Research Training Program (START); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation)	This work was funded by the Strategic Analysis and Research Training Program (START) funded by the Bill and Melinda Gates Foundation. The funders role was limited to the design of the original project. The funders had no role in decision to publish or preparation of the manuscript.	Almuzaini T, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002923; [Anonymous], QUALITY ANTIMALARIAL; [Anonymous], 2013, COUNT PROBL FALS SUB; Bate R, 2012, RES REP TROP MED, V3, P57, DOI 10.2147/RRTM.S33108; Bate R, 2009, AFR J PHARM PHARMACO, V3, P165; Davison Mark, 2011, PHARM ANTICOUNTERFEI; Deconinck E, 2013, J CHROMATOGR SCI, V51, P791, DOI 10.1093/chromsci/bmt006; Felton LA, 2011, DRUG DEV IND PHARM, V37, P88, DOI 10.3109/03639045.2010.492397; Fernandes RD, 2012, J PHARMACEUT BIOMED, V66, P85, DOI 10.1016/j.jpba.2012.03.004; Fernandez FM, 2011, ANALYST, V136, P3073, DOI 10.1039/c0an00627k; Food and Drug Administration, 1995, GUID IND IMM REL SOL; GPHF, GPHF MIN PROT COUNT; Green MD, 2001, TROP MED INT HEALTH, V6, P980, DOI 10.1046/j.1365-3156.2001.00793.x; Green MD, 2007, J PHARMACEUT BIOMED, V43, P105, DOI 10.1016/j.jpba.2006.06.047; Harris GA, 2012, ANALYST, V137, P3039, DOI 10.1039/c2an35431d; Harris GA, 2011, ANAL CHEM, V83, P1908, DOI 10.1021/ac102246h; Holzgrabe U, 2011, J PHARMACEUT BIOMED, V55, P679, DOI 10.1016/j.jpba.2010.12.017; Hostetler DM, 2012, ANAL METHODS-UK, V4, P3392, DOI 10.1039/c2ay25443c; Hu CQ, 2006, J PHARMACEUT BIOMED, V40, P68, DOI 10.1016/j.jpba.2005.06.026; KAINE LA, 1994, J CHROMATOGR A, V674, P255, DOI 10.1016/0021-9673(94)85231-6; Kaur H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003403; KENYON AS, 1995, J AOAC INT, V78, P41; Lal R, 2010, AAPS J, V12, P716, DOI 10.1208/s12248-010-9232-y; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Marini RD, 2010, J PHARMACEUT BIOMED, V53, P1278, DOI 10.1016/j.jpba.2010.07.026; Martino R, 2010, ANAL BIOANAL CHEM, V398, P77, DOI 10.1007/s00216-010-3748-y; Maurin JK, 2007, J PHARMACEUT BIOMED, V43, P1514, DOI 10.1016/j.jpba.2006.10.033; Nayyar GML, 2012, LANCET INFECT DIS, V12, P488, DOI 10.1016/S1473-3099(12)70064-6; Newton PN, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001139; Poole C.F., 2021, GAS CHROMATOGRAPHY; Roll Back Malaria, 2012, GLOB MAL ACT PLAN; Santamaria-Fernandez R, 2009, SCI JUSTICE, V49, P102, DOI 10.1016/j.scijus.2008.12.003; Sherma J, 2007, ACTA CHROMATOGR, V19, P5; Stanton C, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000431; Stein MJ, 2012, ANAL CHEM, V84, P1572, DOI 10.1021/ac2028134; Storme-Paris I, 2010, ANAL CHIM ACTA, V658, P163, DOI 10.1016/j.aca.2009.11.005; Twohig M, 2010, DRUG TEST ANAL, V2, P45, DOI 10.1002/dta.115; USP, 2013, PQM PROM QUAL MED DE; Weaver AA, 2013, ANAL CHEM, V85, P6453, DOI 10.1021/ac400989p; WHO, 2011, SURV QUAL SEL ANT ME; Wilkinson N, 2012, BRIEFCASE ENCOUNTER; World Health Organization, TOOL VIS INSP; World Health Organization, 2012, SPUR FALS LAB FALS C	43	82	84	0	42	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2014	9	3							e90601	10.1371/journal.pone.0090601	http://dx.doi.org/10.1371/journal.pone.0090601			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE0SR	24671033	Green Published, Green Submitted, gold			2023-01-03	WOS:000333677000009
J	Li, X; Wu, LH; Liu, W; Jin, YC; Chen, Q; Wang, LL; Fan, XH; Li, Z; Cheng, YY				Li, Xiang; Wu, Leihong; Liu, Wei; Jin, Yecheng; Chen, Qian; Wang, Linli; Fan, Xiaohui; Li, Zheng; Cheng, Yiyu			A Network Pharmacology Study of Chinese Medicine QiShenYiQi to Reveal Its Underlying Multi-Compound, Multi-Target, Multi-Pathway Mode of Action	PLOS ONE			English	Article							PPAR-GAMMA AGONISTS; SIGNALING PATHWAYS; HEME OXYGENASE-1; RAW264.7; EXPRESSION; MECHANISMS; PROTEIN; LIPOPOLYSACCHARIDE; INFLAMMATION; THERAPEUTICS	Chinese medicine is a complex system guided by traditional Chinese medicine (TCM) theories, which has proven to be especially effective in treating chronic and complex diseases. However, the underlying modes of action (MOA) are not always systematically investigated. Herein, a systematic study was designed to elucidate the multi-compound, multi-target and multi-pathway MOA of a Chinese medicine, QiShenYiQi (QSYQ), on myocardial infarction. QSYQ is composed of Astragalus membranaceus (Huangqi), Salvia miltiorrhiza (Danshen), Panax notoginseng (Sanqi), and Dalbergia odorifera (Jiangxiang). Male Sprague Dawley rat model of myocardial infarction were administered QSYQ intragastrically for 7 days while the control group was not treated. The differentially expressed genes (DEGs) were identified from myocardial infarction rat model treated with QSYQ, followed by constructing a cardiovascular disease (CVD)-related multilevel compound-target-pathway network connecting main compounds to those DEGs supported by literature evidences and the pathways that are functionally enriched in ArrayTrack. 55 potential targets of QSYQ were identified, of which 14 were confirmed in CVD-related literatures with experimental supporting evidences. Furthermore, three sesquiterpene components of QSYQ, Trans-nerolidol, (3S, 6S, 7R)-3,7,11-trimethyl-3,6-epoxy-1,10-dodecadien-7-ol and (3S, 6R, 7R)-3,7,11-trimethyl- 3,6-epoxy-1,10-dodecadien-7-ol from Dalbergia odorifera T. Chen, were validated experimentally in this study. Their anti-inflammatory effects and potential targets including extracellular signal-regulated kinase-1/2, peroxisome proliferator-activated receptor-gamma and heme oxygenase-1 were identified. Finally, through a three-level compound-target-pathway network with experimental analysis, our study depicts a complex MOA of QSYQ on myocardial infarction.	[Li, Xiang; Wu, Leihong; Liu, Wei; Jin, Yecheng; Chen, Qian; Wang, Linli; Fan, Xiaohui; Cheng, Yiyu] Zhejiang Univ, Coll Pharmaceut Sci, Pharmaceut Informat Inst, Hangzhou 310003, Zhejiang, Peoples R China; [Li, Zheng] Tianjin Univ Tradit Chinese Med, State Key Lab Modern Chinese Med, Tianjin, Peoples R China	Zhejiang University; Tianjin University of Traditional Chinese Medicine	Fan, XH (corresponding author), Zhejiang Univ, Coll Pharmaceut Sci, Pharmaceut Informat Inst, Hangzhou 310003, Zhejiang, Peoples R China.	fanxh@zju.edu.cn; lizheng1@gmail.com	Wu, Leihong/AAM-9483-2020; FAN, Xiaohui/F-6458-2010; Bligh, S W Annie/AAI-9786-2020	Wu, Leihong/0000-0002-4093-3708; FAN, Xiaohui/0000-0002-6336-3007; LI, Xiaojun/0000-0003-0336-8081; Bligh, S W Annie/0000-0002-4757-2159	National Basic Research Program of China [2012CB518405]; National Natural Science Foundation of China [81373893]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was financially supported by the National Basic Research Program of China (no. 2012CB518405) and the National Natural Science Foundation of China (no. 81373893). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The Microarray test was performed by National Engineering Center for Biochip at Shanghai by Dr. Huasheng Xiao's team.	Abraham NG, 2008, PHARMACOL REV, V60, P79, DOI 10.1124/pr.107.07104; Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Amara U, 2008, ADV EXP MED BIOL, V632, P71, DOI 10.1007/978-0-387-78952-1_6; Aramoto H, 2004, AM J PHYSIOL-HEART C, V287, pH1590, DOI 10.1152/ajpheart.00767.2003; Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Barber GN, 2011, CURR OPIN IMMUNOL, V23, P10, DOI 10.1016/j.coi.2010.12.015; Berger SI, 2009, BIOINFORMATICS, V25, P2466, DOI 10.1093/bioinformatics/btp465; Burns KA, 2007, BBA-MOL CELL BIOL L, V1771, P952, DOI 10.1016/j.bbalip.2007.04.018; Campbell IW, 2005, CURR MOL MED, V5, P349, DOI 10.2174/1566524053766068; Chao W, 2009, AM J PHYSIOL-HEART C, V296, pH1, DOI 10.1152/ajpheart.00995.2008; Chen G, 2009, ANNU REV PATHOL-MECH, V4, P365, DOI 10.1146/annurev.pathol.4.110807.092239; Chen T, 2011, JIANGXI MED J, V46, P3; Cheung F, 2011, NATURE, V480, pS82, DOI 10.1038/480S82a; Cline MS, 2007, NAT PROTOC, V2, P2366, DOI 10.1038/nprot.2007.324; Crow MT, 2004, CIRC RES, V95, P957, DOI 10.1161/01.RES.0000148632.35500.d9; di Bernardo D, 2005, NAT BIOTECHNOL, V23, P377, DOI 10.1038/nbt1075; Diez D, 2010, MOL BIOSYST, V6, P289, DOI 10.1039/b912078e; Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283; Finck BN, 2007, CARDIOVASC RES, V73, P269, DOI 10.1016/j.cardiores.2006.08.023; Fritz JH, 2006, NAT IMMUNOL, V7, P1250, DOI 10.1038/ni1412; Gardner TS, 2003, SCIENCE, V301, P102, DOI 10.1126/science.1081900; Goh KI, 2007, P NATL ACAD SCI USA, V104, P8685, DOI 10.1073/pnas.0701361104; Hirota SA, 2009, RECENT PATENTS INFLA, V3, P1, DOI 10.2174/187221309787158434; Hong SeChul, 2012, Journal of Medicinal Plants Research, V6, P4494; Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118; Hopkins AL, 2007, NAT BIOTECHNOL, V25, P1110, DOI 10.1038/nbt1007-1110; Humar R, 2002, FASEB J, V16, DOI 10.1096/fj.01-0658com; Jeong JB, 2013, FOOD CHEM TOXICOL, V55, P229, DOI 10.1016/j.fct.2012.12.062; Ji HY, 2010, INFLAMM RES, V59, P921, DOI 10.1007/s00011-010-0203-7; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Jiang WY, 2005, TRENDS PHARMACOL SCI, V26, P558, DOI 10.1016/j.tips.2005.09.006; Kaminska B, 2005, BBA-PROTEINS PROTEOM, V1754, P253, DOI 10.1016/j.bbapap.2005.08.017; Kim BC, 2006, J ETHNOPHARMACOL, V106, P364, DOI 10.1016/j.jep.2006.01.009; Kitano H, 2002, SCIENCE, V295, P1662, DOI 10.1126/science.1069492; Kronke G, 2007, ARTERIOSCL THROM VAS, V27, P1276, DOI 10.1161/ATVBAHA.107.142638; Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011; Lee M, 2012, STRAD, V123, P7; Li YF, 2008, J PHARMACEUT BIOMED, V47, P407, DOI 10.1016/j.jpba.2007.12.037; Li YF, 2008, CHROMATOGRAPHIA, V67, P293, DOI 10.1365/s10337-007-0479-0; Lin HY, 2003, BIOCHEM PHARMACOL, V66, P1821, DOI 10.1016/S0006-2952(03)00422-2; Markiewski MM, 2007, TRENDS IMMUNOL, V28, P184, DOI 10.1016/j.it.2007.02.006; Martin H, 2009, MUTAT RES-FUND MOL M, V669, P1, DOI 10.1016/j.mrfmmm.2009.06.009; Miksa M, 2007, J IMMUNOL, V179, P6263, DOI 10.4049/jimmunol.179.9.6263; Murphy GJ, 2000, TRENDS PHARMACOL SCI, V21, P469, DOI 10.1016/S0165-6147(00)01559-5; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Palojoki E, 2001, AM J PHYSIOL-HEART C, V280, pH2726, DOI 10.1152/ajpheart.2001.280.6.H2726; Petit V, 2000, BIOL CELL, V92, P477, DOI 10.1016/S0248-4900(00)01101-1; PFEFFER MA, 1979, CIRC RES, V44, P503, DOI 10.1161/01.RES.44.4.503; Robinson ES, 2010, SEMIN NEPHROL, V30, P591, DOI 10.1016/j.semnephrol.2010.09.007; Sawle P, 2005, BRIT J PHARMACOL, V145, P800, DOI 10.1038/sj.bjp.0706241; Suefuji H, 1997, AM HEART J, V134, P253, DOI 10.1016/S0002-8703(97)70132-7; Suh SJ, 2006, ARCH BIOCHEM BIOPHYS, V447, P136, DOI 10.1016/j.abb.2006.01.016; Tang S, 2011, INFLAMMATION, V34, P111, DOI 10.1007/s10753-010-9214-3; Tao Y, 2010, FITOTERAPIA, V81, P393, DOI 10.1016/j.fitote.2009.11.012; Terzic A, 2011, CTS-CLIN TRANSL SCI, V4, P225, DOI 10.1111/j.1752-8062.2011.00295.x; Timmers L, 2008, CIRC RES, V102, P257, DOI 10.1161/CIRCRESAHA.107.158220; Tong WD, 2003, ENVIRON HEALTH PERSP, V111, P1819, DOI 10.1289/ehp.6497; von Knethen A, 2011, FREE RADICAL BIO MED, V51, P396, DOI 10.1016/j.freeradbiomed.2011.04.033; Wahli W, 2012, TRENDS ENDOCRIN MET, V23, P351, DOI 10.1016/j.tem.2012.05.001; Waldman SA, 2011, CLIN PHARMACOL THER, V90, P483, DOI 10.1038/clpt.2011.213; Wang Linli, 2013, Evid Based Complement Alternat Med, V2013, P652373, DOI 10.1155/2013/652373; [魏万林 WEI Wan-lin], 2009, [中国循环杂志, Chinese Circulation Journal], V24, P182; Wozniak MA, 2004, BBA-MOL CELL RES, V1692, P103, DOI 10.1016/j.bbamcr.2004.04.007; Wu GY, 2004, J NUTR, V134, P489, DOI 10.1093/jn/134.3.489; Wu Leihong, 2013, Database (Oxford), V2013, pbat047, DOI 10.1093/database/bat047; Xing B, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-4; Yamaguchi F, 1997, J MOL CELL CARDIOL, V29, P753, DOI 10.1006/jmcc.1996.0319; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yan F. F., 2007, SHANGHAI J TRADITION, V41, P59; Yaoita H, 2000, CARDIOVASC RES, V45, P630, DOI 10.1016/S0008-6363(99)00349-1; Zaytseva YY, 2011, ANTICANCER RES, V31, P813; Zhang L, 2010, INT J CARDIOL, V143, P105, DOI 10.1016/j.ijcard.2008.11.210; Zhang YF, 2012, CURR DRUG METAB, V13, P510, DOI 10.2174/1389200211209050510; Zhao S, 2012, ANNU REV PHARMACOL, V52, P505, DOI 10.1146/annurev-pharmtox-010611-134520; Zheng XH, 2007, AM J CHINESE MED, V35, P831, DOI 10.1142/S0192415X07005302; Zimmermann GR, 2007, DRUG DISCOV TODAY, V12, P34, DOI 10.1016/j.drudis.2006.11.008; 朱明丹, 2013, [时珍国医国药, Lishizhen Medicine and Materia Medica Research], V24, P22; 刘梅, 2009, [时珍国医国药, Lishizhen Medicine and Materia Medica Research], V20, P829	80	220	236	12	55	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2014	9	5							e95004	10.1371/journal.pone.0095004	http://dx.doi.org/10.1371/journal.pone.0095004			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI4LX	24587076	gold, Green Submitted, Green Published			2023-01-03	WOS:000336838000010
J	Zhang, ZL; Wang, J; Chen, SF; Wei, ZY; Li, ZT; Zhao, SW; Lu, WJ				Zhang, Zili; Wang, Jian; Chen, Sifan; Wei, Zhaoyu; Li, Zhengtu; Zhao, Siwen; Lu, Wenju			Comparison of Vegetarian Diets and Omnivorous Diets on Plasma Level of HDL-c: A Meta-Analysis	PLOS ONE			English	Article							HIGH-DENSITY-LIPOPROTEIN; CORONARY-HEART-DISEASE; CARDIOVASCULAR-DISEASE; SERUM-LIPIDS; RISK-FACTORS; METABOLIC SYNDROME; CHOLESTEROL; ASSOCIATION; CONSUMPTION; PREVENTION	Low plasma level of high density lipoprotein cholesterol (HDL-c) was an independent risk factor for cardio vascular disorder, and associated with poor outcomes in pulmonary arterial hypertension. To compare the effects of vegetarian diets and omnivorous diets on HDL-c in plasma, we identified cross-sectional and cohort studies related to HDL-c listed on PubMed and ISI Web of Knowledge as well as the corresponding references (until Nov, 2013). Twelve studies with a total of 4177 individuals were selected for meta-analysis. This meta-analysis indicates that vegetarian diets did not alter plasma HDL-c concentrations, as it wasn't initially expected by the authors [Standardized Mean Difference (SMD) = 0.02 mmol/l; 95% confidence interval (CI): -0.19 to 0.22 mmol/l]. In Asia and Latin America countries, no significant differences in HDL-c levels between vegetarians and omnivores were found (SMD = -0.09 mmol/l; 95% CI: -0.43 to 0.25 mmol/l). In Europe and North America countries, the plasma level of HDL-c was also not different between the two diets (SMD = 0.09 mmol/l; 95% CI: 2 0.19 to 0.36 mmol/l). In light of this meta-analysis, we conclude that there is no evidence that plasma HDL-c levels differs in vegetarians and omnivores, even after adjusting for cultural circumstances.	[Zhang, Zili; Wang, Jian; Li, Zhengtu; Lu, Wenju] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Dis, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China; [Chen, Sifan] Sun Yat Sen Univ, Sch Publ Hlth, Dept Nutr, Guangzhou 510275, Guangdong, Peoples R China; [Wei, Zhaoyu] Guangzhou Med Univ, Dept Student Affairs, Guangzhou, Guangdong, Peoples R China; [Zhao, Siwen] Guangzhou Med Univ, Affiliated Hosp 2, Guangzhou, Guangdong, Peoples R China	Guangzhou Medical University; State Key Laboratory of Respiratory Disease; Sun Yat Sen University; Guangzhou Medical University; Guangzhou Medical University	Lu, WJ (corresponding author), Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Dis, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China.	wlu92@yahoo.com	Zhao, Qiongyi/B-4106-2014; Zhang, Zong Hong/N-9126-2013; Bauer, Denis/C-3903-2009; Wray, Naomi/C-8639-2015	Zhao, Qiongyi/0000-0002-6341-0416; Zhang, Zong Hong/0000-0002-8056-891X; Bauer, Denis/0000-0001-8033-9810; Edson, Janette/0000-0002-1864-0095; Wray, Naomi/0000-0001-7421-3357; Narayanan, Ramesh/0000-0001-8171-474X; Jhaveri, Dhanisha/0000-0002-5615-3546	NIH [R01-HL093020]; National Natural Science Foundation of China [81070043, 81173112, 81170052, 81220108001]; Guangdong Natural Science Foundation Team Grant [1035101200300000]; Guangzhou Department of Education Yangcheng Scholarship [10A058S, 12A001S]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL093020] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Foundation Team Grant; Guangzhou Department of Education Yangcheng Scholarship; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by NIH (R01-HL093020), National Natural Science Foundation of China (81070043, 81173112, 81170052, 81220108001), Guangdong Natural Science Foundation Team Grant (1035101200300000), and Guangzhou Department of Education Yangcheng Scholarship (10A058S, 12A001S). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexander H, 1999, J AM COLL NUTR, V18, P127, DOI 10.1080/07315724.1999.10718840; Grundy Scott M, 2005, Crit Pathw Cardiol, V4, P198; Assmann G, 1999, ARTERIOSCL THROM VAS, V19, P1819, DOI 10.1161/01.ATV.19.8.1819; Baer DJ, 2002, AM J CLIN NUTR, V75, P593, DOI 10.1093/ajcn/75.3.593; Barnard ND, 2000, AM J CARDIOL, V85, P969, DOI 10.1016/S0002-9149(99)00911-X; CASTELLI WP, 1977, CIRCULATION, V55, P767, DOI 10.1161/01.CIR.55.5.767; Chen CW, 2011, YONSEI MED J, V52, P13, DOI 10.3349/ymj.2011.52.1.13; CHOI SSY, 1994, J LIPID RES, V35, P848; Clarke R, 1997, BRIT MED J, V314, P112, DOI 10.1136/bmj.314.7074.112; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Craig WJ, 2009, J AM DIET ASSOC, V109, P1266, DOI 10.1016/j.jada.2009.05.027; De Biase SG, 2007, ARQ BRAS CARDIOL, V88, P35, DOI 10.1590/S0066-782X2007000100006; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Famodu AA, 1998, CLIN BIOCHEM, V31, P545, DOI 10.1016/S0009-9120(98)00067-8; Dourado KF, 2011, NUTR HOSP, V26, P959, DOI [10.3305/nh.2011.26.5.5108, 10.1590/S0212-16112011000500006]; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; HAMSTEN A, 1986, ATHEROSCLEROSIS, V60, P199, DOI 10.1016/0021-9150(86)90166-8; Harper CR, 1999, ARCH INTERN MED, V159, P1049, DOI 10.1001/archinte.159.10.1049; HELLER DA, 1993, NEW ENGL J MED, V328, P1150, DOI 10.1056/NEJM199304223281603; Heresi GA, 2010, AM J RESP CRIT CARE, V182, P661, DOI 10.1164/rccm.201001-0007OC; Hoffmann I, 2001, EUR J CLIN NUTR, V55, P887, DOI 10.1038/sj.ejcn.1601243; Kelley GA, 2012, CLIN NUTR, V31, P156, DOI 10.1016/j.clnu.2011.11.011; Krajcovicova-Kudlackova M, 2000, SCAND J CLIN LAB INV, V60, P657, DOI 10.1080/00365510050216385; Li D, 1999, EUR J CLIN NUTR, V53, P612, DOI 10.1038/sj.ejcn.1600817; Li D, 2001, CLIN SCI, V100, P25, DOI 10.1042/CS20000109; Matsuzawa Y, 2004, ARTERIOSCL THROM VAS, V24, P29, DOI 10.1161/01.ATV.0000099786.99623.EF; McCoy MG, 2002, J LIPID RES, V43, P921; Mensink RP, 2003, AM J CLIN NUTR, V77, P1146, DOI 10.1093/ajcn/77.5.1146; Teixeira RDMD, 2007, ARQ BRAS CARDIOL, V89, P237, DOI 10.1590/S0066-782X2007001600005; Papadaki A, 2008, PUBLIC HEALTH NUTR, V11, P1022, DOI 10.1017/S1368980007001498; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; Qin SC, 2000, J LIPID RES, V41, P269; Rader DJ, 1996, CURR OPIN LIPIDOL, V7, P117, DOI 10.1097/00041433-199606000-00002; Robinson F, 2002, J HUM NUTR DIET, V15, P323, DOI 10.1046/j.1365-277X.2002.00383.x; Rosamond W, 2008, CIRCULATION, V117, pE25, DOI 10.1161/CIRCULATIONAHA.107.187998; Rosengren A, 1997, EUR HEART J, V18, P754; SCOTT LW, 1994, ARCH INTERN MED, V154, P1261, DOI 10.1001/archinte.154.11.1261; SINCLAIR AJ, 1987, LIPIDS, V22, P523, DOI 10.1007/BF02540369; THOROGOOD M, 1987, BMJ-BRIT MED J, V295, P351, DOI 10.1136/bmj.295.6594.351; van der Gaag MS, 2001, J LIPID RES, V42, P2077; Vinagre JC, 2013, NUTR METAB CARDIOVAS, V23, P61, DOI 10.1016/j.numecd.2011.02.011; Vinagre JC, 2013, EUR J NUTR; WATTS GF, 1988, BMJ-BRIT MED J, V296, P235, DOI 10.1136/bmj.296.6617.235; Yoshikawa H, 1976, Rinsho Ketsueki, V17, P553; Zimmet P, 2005, J ATHEROSCLER THROMB, V12, P295, DOI 10.5551/jat.12.295	46	35	39	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2014	9	3							e92609	10.1371/journal.pone.0092609	http://dx.doi.org/10.1371/journal.pone.0092609			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE0SR	25119138	Green Published, Green Submitted, gold			2023-01-03	WOS:000333677000058
J	Zhao, YL; Wang, HM; Chen, W; Li, YH				Zhao, Yunlei; Wang, Hongmei; Chen, Wei; Li, Yunhai			Genetic Structure, Linkage Disequilibrium and Association Mapping of Verticillium Wilt Resistance in Elite Cotton (Gossypium hirsutum L.) Germplasm Population	PLOS ONE			English	Article							SIMPLE SEQUENCE REPEAT; QUANTITATIVE TRAIT LOCI; FIBER QUALITY; NUCLEOTIDE DIVERSITY; COMPUTER-PROGRAM; GENOME STRUCTURE; UPLAND COTTON; YIELD; QTL; SSR	Understanding the population structure and linkage disequilibrium in an association panel can effectively avoid spurious associations and improve the accuracy in association mapping. In this study, one hundred and fifty eight elite cotton (Gossypium hirsutum L.) germplasm from all over the world, which were genotyped with 212 whole genome-wide marker loci and phenotyped with an disease nursery and greenhouse screening method, were assayed for population structure, linkage disequilibrium, and association mapping of Verticillium wilt resistance. A total of 480 alleles ranging from 2 to 4 per locus were identified from all collections. Model-based analysis identified two groups (G1 and G2) and seven subgroups (G1a-c, G2a-d), and differentiation analysis showed that subgroup having a single origin or pedigree was apt to differentiate with those having a mixed origin. Only 8.12% linked marker pairs showed significant LD (P<0.001) in this association panel. The LD level for linked markers is significantly higher than that for unlinked markers, suggesting that physical linkage strongly influences LD in this panel, and LD level was elevated when the panel was classified into groups and subgroups. The LD decay analysis for several chromosomes showed that different chromosomes showed a notable change in LD decay distances for the same gene pool. Based on the disease nursery and greenhouse environment, 42 marker loci associated with Verticillium wilt resistance were identified through association mapping, which widely were distributed among 15 chromosomes. Among which 10 marker loci were found to be consistent with previously identified QTLs and 32 were new unreported marker loci, and QTL clusters for Verticillium wilt resistanc on Chr.16 were also proved in our study, which was consistent with the strong linkage in this chromosome. Our results would contribute to association mapping and supply the marker candidates for marker-assisted selection of Verticillium wilt resistance in cotton.	[Zhao, Yunlei; Wang, Hongmei; Chen, Wei; Li, Yunhai] Chinese Acad Agr Sci, Inst Cotton Res, State Key Lab Cotton Biol, Anyang, Peoples R China	Chinese Academy of Agricultural Sciences; Institute of Cotton Research, CAAS	Wang, HM (corresponding author), Chinese Acad Agr Sci, Inst Cotton Res, State Key Lab Cotton Biol, Anyang, Peoples R China.	wanghm@cricaas.com.cn		Liang, Peng/0000-0001-8485-1694; Liu, Jin/0000-0002-2026-2513	National Natural Science Foundation of China [31000733]; National Hi-Tech Research and Development Program of China [2012AA101108-02-02]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Hi-Tech Research and Development Program of China(National High Technology Research and Development Program of China)	This research was supported by the National Natural Science Foundation of China (Grant No. 31000733) and by the National Hi-Tech Research and Development Program of China (Grant No. 2012AA101108-02-02). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdurakhmonov IY, 2009, GENETICA, V136, P401, DOI 10.1007/s10709-008-9337-8; Abdurakhmonov IY, 2008, MOL DIVERSITY ASS MA; [Anonymous], GENOMICS, V92, P478; Bolek Y, 2005, PLANT SCI, V168, P1581, DOI 10.1016/j.plantsci.2005.02.008; Bradbury PJ, 2007, BIOINFORMATICS, V23, P2633, DOI 10.1093/bioinformatics/btm308; Caldwell KS, 2006, GENETICS, V172, P557, DOI 10.1534/genetics.104.038489; Chen Guang, 2006, Acta Genetica Sinica, V33, P733, DOI 10.1016/S0379-4172(06)60106-6; Chen ZJ, 2007, PLANT PHYSIOL, V145, P1303, DOI 10.1104/pp.107.107672; Bertini CHCD, 2006, GENET MOL BIOL, V29, P321, DOI 10.1590/S1415-47572006000200021; Ersoz E.S., 2007, GENOMICS ASSISTED CR, P97, DOI DOI 10.1007/978-1-4020-6295-7_5; Esbroeck G. van., 1998, Journal of Cotton Science, V2, P121; Evanno G, 2005, MOL ECOL, V14, P2611, DOI 10.1111/j.1365-294X.2005.02553.x; Falush D, 2003, GENETICS, V164, P1567; Flint-Garcia SA, 2003, ANNU REV PLANT BIOL, V54, P357, DOI 10.1146/annurev.arplant.54.031902.134907; Guo WZ, 2007, GENETICS, V176, P527, DOI 10.1534/genetics.107.070375; Ha C, 2011, PLOS ONE, V6; Hardy OJ, 2002, MOL ECOL NOTES, V2, P618, DOI 10.1046/j.1471-8286.2002.00305.x; Hartl D.L., 1997, PRINCIPLES POPULATIO, V3rd; He DH, 2005, EUPHYTICA, V144, P141, DOI 10.1007/s10681-005-5297-6; Huang XH, 2010, NAT GENET, V42, P961, DOI 10.1038/ng.695; Iqbal MJ, 2001, THEOR APPL GENET, V103, P547, DOI 10.1007/PL00002908; Jiang F, 2009, SCI CHINA SER C, V52, P872, DOI 10.1007/s11427-009-0110-8; Kalinowski ST, 2005, MOL ECOL NOTES, V5, P187, DOI 10.1111/j.1471-8286.2004.00845.x; Lacape JM, 2007, MOL BREEDING, V19, P45, DOI 10.1007/s11032-006-9042-1; Lacape JM, 2010, BMC PLANT BIOL, V10, DOI 10.1186/1471-2229-10-132; Lacape JM, 2009, THEOR APPL GENET, V119, P281, DOI 10.1007/s00122-009-1037-y; Lam HM, 2010, NAT GENET, V42, P1053, DOI 10.1038/ng.715; Lijavetzky D, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-424; Liu AZ, 2006, GENETICS, V173, P321, DOI 10.1534/genetics.105.051110; Liu KJ, 2005, BIOINFORMATICS, V21, P2128, DOI 10.1093/bioinformatics/bti282; Liu S, 2000, CROP SCI, V40, P1459, DOI 10.2135/cropsci2000.4051459x; Ma XX, 2008, J INTEGR PLANT BIOL, V50, P491, DOI 10.1111/j.1744-7909.2008.00636.x; McNally KL, 2009, P NATL ACAD SCI USA, V106, P12273, DOI 10.1073/pnas.0900992106; Moiana L. D., 2012, African Journal of Biotechnology, V11, P11640; Morrell PL, 2005, P NATL ACAD SCI USA, V102, P2442, DOI 10.1073/pnas.0409804102; Nordborg M, 2002, NAT GENET, V30, P190, DOI 10.1038/ng813; Paterson A. H., 1993, Plant Molecular Biology Reporter, V11, P122, DOI 10.1007/BF02670470; Pritchard JK, 2000, GENETICS, V155, P945; Qin HD, 2008, THEOR APPL GENET, V117, P883, DOI 10.1007/s00122-008-0828-x; Rungis D, 2005, AUST J AGR RES, V56, P301, DOI 10.1071/AR04190; Schneider S., 2000, ARLEQUIN SOFTWARE PO; Shen XL, 2007, EUPHYTICA, V155, P371, DOI 10.1007/s10681-006-9338-6; Song BH, 2009, GENETICS, V181, P1021, DOI 10.1534/genetics.108.095364; Stich B, 2005, THEOR APPL GENET, V111, P723, DOI 10.1007/s00122-005-2057-x; Wang Baohua, 2007, Journal of Genetics and Genomics, V34, P35, DOI 10.1016/S1673-8527(07)60005-8; WANG HM, 2007, J INTE PL BIO, V50, P174; Wang HM, 2008, J INTEGR PLANT BIOL, V50, P174, DOI 10.1111/j.1744-7909.2007.00612.x; Whitt Sr, 2003, METH MOL B, V236, P123; Yan JB, 2010, NAT GENET, V42, P322, DOI 10.1038/ng.551; Yan JB, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008451; Yang C, 2008, PLANT SCI, V174, P290, DOI 10.1016/j.plantsci.2007.11.016; Yu JW, 2007, J INTEGR PLANT BIOL, V49, P716, DOI 10.1111/j.1744-7909.2007.00459.x; Yu JW, 2013, THEOR APPL GENET, V126, P275, DOI 10.1007/s00122-012-1980-x; Yu JM, 2006, NAT GENET, V38, P203, DOI 10.1038/ng1702; Yu JZ, 2012, G3-GENES GENOM GENET, V2, P43, DOI 10.1534/g3.111.001552; Yu Y, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-15; Zhang J, 2007, WORLD COTT RES C 4 L, P1014; Zhang TZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057220; Zhang TZ, 2003, THEOR APPL GENET, V106, P262, DOI 10.1007/s00122-002-1101-3; Zhang XueYong, 2007, Agricultural Sciences in China, V6, P255, DOI 10.1016/S1671-2927(07)60043-1; Zhu CS, 2008, PLANT GENOME-US, V1, P5, DOI 10.3835/plantgenome2008.02.0089	61	101	119	0	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2014	9	1							e86308	10.1371/journal.pone.0086308	http://dx.doi.org/10.1371/journal.pone.0086308			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297XI	24466016	Green Submitted, Green Published, gold			2023-01-03	WOS:000330288000082
J	Tang, Y; He, H; Cheng, N; Song, YL; Ding, WJ; Zhang, YF; Zhang, WH; Zhang, J; Peng, H; Jiang, H				Tang, Yi; He, Hua; Cheng, Ning; Song, Yanling; Ding, Weijin; Zhang, Yingfan; Zhang, Wenhao; Zhang, Jie; Peng, Heng; Jiang, Hua			PDGF, NT-3 and IGF-2 in Combination Induced Transdifferentiation of Muscle-Derived Stem Cells into Schwann Cell-Like Cells	PLOS ONE			English	Article							DIFFERENTIATION; REGENERATION	Muscle-derived stem cells (MDSCs) are multipotent stem cells with a remarkable long-term self-renewal and regeneration capacity. Here, we show that postnatal MDSCs could be transdifferentiated into Schwann cell-like cells upon the combined treatment of three neurotrophic factors (PDGF, NT-3 and IGF-2). The transdifferentiation of MDSCs was initially induced by Schwann cell (SC) conditioned medium. MDSCs adopted a spindle-like morphology similar to SCs after the transdifferentiation. Immunocytochemistry and immunoblot showed clearly that the SC markers S100, GFAP and p75 were expressed highly only after the transdifferentiation. Flow cytometry assay showed that the portion of S100 expressed cells was more than 60 percent and over one fourth of the transdifferentiated cells expressed all the three SC markers, indicating an efficient transdifferentiation. We then tested neurotrophic factors in the conditioned medium and found it was PDGF, NT-3 and IGF-2 in combination that conducted the transdifferentiation. Our findings demonstrate that it is possible to use specific neurotrophic factors to transdifferentiate MDSCs into Schwann cell-like cells, which might be therapeutically useful for clinical applications.	[Tang, Yi; Song, Yanling; Ding, Weijin; Zhang, Yingfan; Zhang, Jie; Jiang, Hua] Second Mil Med Univ, Changzheng Hosp, Dept Plast Surg, Shanghai, Peoples R China; [Tang, Yi] 411 Hosp CPLA, Dept Plast Surg, Shanghai, Peoples R China; [He, Hua] Second Mil Med Univ, Changzheng Hosp, Dept Neurosurg, Shanghai, Peoples R China; [Cheng, Ning] Second Mil Med Univ, Changhai Hosp, Dept Transfus, Shanghai, Peoples R China; [Zhang, Wenhao] Shanghai Jiao Tong Univ, XinHua Hosp, Dept Hematol, Sch Med, Shanghai 200030, Peoples R China; [Peng, Heng] Hong Kong Baptist Univ, Dept Math, Kowloon, Hong Kong, Peoples R China	Naval Medical University; Naval Medical University; Naval Medical University; Shanghai Jiao Tong University; Hong Kong Baptist University	Jiang, H (corresponding author), Second Mil Med Univ, Changzheng Hosp, Dept Plast Surg, Shanghai, Peoples R China.	lmiao.simm@gmail.com	Peng, Heng/B-7152-2009; Johnson, William/N-1972-2017	Peng, Heng/0000-0001-7807-8527; Johnson, William/0000-0002-3823-4094	National Natural Science Foundation of China [81100950]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by National Natural Science Foundation of China (Grant No. 81100950. Website http://www.nsfc.gov.cn no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; BUNGE RP, 1994, J NEUROL, V242, pS19, DOI 10.1007/BF00939235; Cheng HL, 1999, ENDOCRINOLOGY, V140, P4478, DOI 10.1210/en.140.10.4478; Cohen RI, 1999, J EXP BIOL, V202, P461; Deasy BM, 2001, BLOOD CELL MOL DIS, V27, P924, DOI 10.1006/bcmd.2001.0463; Deasy BM, 2005, MOL BIOL CELL, V16, P3323, DOI 10.1091/mbc.E05-02-0169; Frostick SP, 1998, MICROSURG, V18, P397, DOI 10.1002/(SICI)1098-2752(1998)18:7<397::AID-MICR2>3.0.CO;2-F; Gharaibeh B, 2008, NAT PROTOC, V3, P1501, DOI 10.1038/nprot.2008.142; Grompe M, 2012, CELL STEM CELL, V10, P685, DOI 10.1016/j.stem.2012.04.006; GUENARD V, 1992, J NEUROSCI, V12, P3310; Ide C, 1996, NEUROSCI RES, V25, P101; Keilhoff G, 2006, EUR J CELL BIOL, V85, P11, DOI 10.1016/j.ejcb.2005.09.021; Keilhoff G, 2000, NEUROREPORT, V11, P3805, DOI 10.1097/00001756-200011270-00042; Keilhoff G, 1999, J NEUROSCI METH, V89, P17, DOI 10.1016/S0165-0270(99)00034-5; Kingham PJ, 2007, EXP NEUROL, V207, P267, DOI 10.1016/j.expneurol.2007.06.029; Lee JY, 2000, J CELL BIOL, V150, P1085, DOI 10.1083/jcb.150.5.1085; Li QF, 2006, MICROSURG, V26, P116, DOI 10.1002/micr.20192; Mosahebi A, 2001, GLIA, V34, P8, DOI 10.1002/glia.1035; Qu-Petersen ZQ, 2002, J CELL BIOL, V157, P851, DOI 10.1083/jcb.200108150; Schuldiner M, 2000, P NATL ACAD SCI USA, V97, P11307, DOI 10.1073/pnas.97.21.11307; Usas A, 2007, BIOMATERIALS, V28, P5401, DOI 10.1016/j.biomaterials.2007.09.008; Zhao JL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041506	22	62	66	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 14	2014	9	1							e73402	10.1371/journal.pone.0073402	http://dx.doi.org/10.1371/journal.pone.0073402			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292TQ	24637790	Green Submitted, Green Published, gold			2023-01-03	WOS:000329925800001
J	Kim, H; Choi, K; Kang, H; Lee, SY; Chi, SW; Lee, MS; Song, J; Im, D; Choi, Y; Cho, SC				Kim, Hyeongki; Choi, Kwangman; Kang, Hyunju; Lee, So-Young; Chi, Seung-Wook; Lee, Min-Sung; Song, Jaehyoung; Im, Donghwa; Choi, Yura; Cho, Sungchan			Identification of a Novel Function of CX-4945 as a Splicing Regulator	PLOS ONE			English	Article							PROTEIN-KINASE CK2; PRE-MESSENGER-RNA; SERINE-RICH; SR PROTEINS; IN-VIVO; DISEASE; PHOSPHORYLATION; INHIBITOR; FAMILY; PURIFICATION	Alternative splicing is a nearly ubiquitous versatile process that controls gene expression and creates numerous protein isoforms with different functions from a single gene. The significance of alternative splicing has been confirmed by the increasing number of human diseases that are caused by misregulation of splicing events. Very few compounds, however, have been reported to act as inhibitors of alternative splicing, and their potential clinical use needs to be evaluated. Here, we report that CX-4945, a previously well-characterized inhibitor of casein kinase 2 (CK2) and a molecule currently in clinical trials (Phase II) for cancer treatment, regulates splicing in mammalian cells in a CK2-independent manner. Transcriptome-wide analysis using exon array also showed a widespread alteration in alternative splicing of numerous genes. We found that CX-4945 potently inhibits the Cdc2-like kinases (Clks) in vitro and in turn, leads to suppression of the phosphorylation of serine/arginine-rich (SR) proteins in mammalian cells. Surprisingly, the overall efficacy of CX-4945 on Clks (IC50 = 3-90 nM) was stronger than that of TG-003, the strongest inhibitor reported to date. Of the Clks, Clk2 was most strongly inhibited by CX-4945 in an ATP-competitive manner. Our research revealed an unexpected activity of the drug candidate CX-4945 as a potent splicing modulator and also suggested a potential application for therapy of diseases caused by abnormal splicing.	[Kim, Hyeongki; Choi, Kwangman; Kang, Hyunju; Song, Jaehyoung; Im, Donghwa; Choi, Yura; Cho, Sungchan] Korea Res Inst Biosci & Biotechnol, Targeted Med Res Ctr, Cheongwon, Chungbuk, South Korea; [Kim, Hyeongki; Cho, Sungchan] Univ Sci & Technol, Dept Biomol Sci, Taejon, South Korea; [Lee, So-Young] Minist Food & Drug Safety, Int Cooperat Off, Cheongwon, Chungbuk, South Korea; [Chi, Seung-Wook; Lee, Min-Sung] Korea Res Inst Biosci & Biotechnol, BioMed Prote Res Ctr, Cheongwon, Chungbuk, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Ministry of Food & Drug Safety (MFDS), Republic of Korea; Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Cho, SC (corresponding author), Korea Res Inst Biosci & Biotechnol, Targeted Med Res Ctr, Cheongwon, Chungbuk, South Korea.	sungchan@kribb.re.kr		Shin, Ju-Young/0000-0003-1010-7525	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [2012R1A1A2003182]; KRIBB Research Initiative Program	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology; KRIBB Research Initiative Program	This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2012R1A1A2003182) and KRIBB Research Initiative Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad KA, 2008, ADV ENZYME REGUL, V48, P179, DOI 10.1016/j.advenzreg.2008.04.002; Bardella C, 2004, CANCER RES, V64, P5154, DOI 10.1158/0008-5472.CAN-04-0600; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Blencowe BJ, 2006, CELL, V126, P37, DOI 10.1016/j.cell.2006.06.023; Cabrejos ME, 2004, J CELL BIOCHEM, V93, P2, DOI 10.1002/jcb.20209; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Chabot B, 1996, TRENDS GENET, V12, P472, DOI 10.1016/0168-9525(96)10037-8; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; Coombs TC, 2013, BIOORG MED CHEM LETT, V23, P3654, DOI 10.1016/j.bmcl.2013.02.096; DAHMUS ME, 1981, J BIOL CHEM, V256, P3319; Dalma-Weiszhausz DD, 2006, METHOD ENZYMOL, V410, P3, DOI 10.1016/S0076-6879(06)10001-4; Di Maira G, 2005, CELL DEATH DIFFER, V12, P668, DOI 10.1038/sj.cdd.4401604; Dredge BK, 2001, NAT REV NEUROSCI, V2, P43, DOI 10.1038/35049061; Duncan PI, 1997, MOL CELL BIOL, V17, P5996, DOI 10.1128/MCB.17.10.5996; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; Ferguson AD, 2011, FEBS LETT, V585, P104, DOI 10.1016/j.febslet.2010.11.019; FU XD, 1995, RNA, V1, P663; Guerra B, 2008, CURR MED CHEM, V15, P1870, DOI 10.2174/092986708785132933; GUI JF, 1994, P NATL ACAD SCI USA, V91, P10824, DOI 10.1073/pnas.91.23.10824; Hertel KJ, 2005, TRENDS BIOCHEM SCI, V30, P115, DOI 10.1016/j.tibs.2005.01.002; Kaida D, 2007, NAT CHEM BIOL, V3, P576, DOI 10.1038/nchembio.2007.18; Kim E, 2008, RNA BIOL, V5, P17, DOI 10.4161/rna.5.1.5944; Kotake Y, 2007, NAT CHEM BIOL, V3, P570, DOI 10.1038/nchembio.2007.16; Kuroyanagi N, 1998, BIOCHEM BIOPH RES CO, V242, P357, DOI 10.1006/bbrc.1997.7913; Levinson N, 2006, RNA, V12, P925, DOI 10.1261/rna.8306; Licatalosi DD, 2006, NEURON, V52, P93, DOI 10.1016/j.neuron.2006.09.017; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Lukong KE, 2008, TRENDS GENET, V24, P416, DOI 10.1016/j.tig.2008.05.004; Martinez-Contreras R, 2007, ADV EXP MED BIOL, V623, P123, DOI 10.1007/978-0-387-77374-2_8; Matlin AJ, 2005, NAT REV MOL CELL BIO, V6, P386, DOI 10.1038/nrm1645; Misteli T, 1998, J CELL BIOL, V143, P297, DOI 10.1083/jcb.143.2.297; Muraki M, 2004, J BIOL CHEM, V279, P24246, DOI 10.1074/jbc.M314298200; Nayler O, 1997, BIOCHEM J, V326, P693, DOI 10.1042/bj3260693; Ng B, 2004, J ALLERGY CLIN IMMUN, V114, P1463, DOI 10.1016/j.jaci.2004.09.006; Pagano MA, 2007, CHEMBIOCHEM, V8, P129, DOI 10.1002/cbic.200600293; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Pilch B, 2001, CANCER RES, V61, P6876; Rodgers JT, 2010, CELL METAB, V11, P23, DOI 10.1016/j.cmet.2009.11.006; Sanford J R, 2003, Prog Mol Subcell Biol, V31, P33; Sarno S, 2001, FEBS LETT, V496, P44, DOI 10.1016/S0014-5793(01)02404-8; Siddiqui-Jain A, 2010, CANCER RES, V70, P10288, DOI 10.1158/0008-5472.CAN-10-1893; Soret J, 2005, P NATL ACAD SCI USA, V102, P8764, DOI 10.1073/pnas.0409829102; Stoilov P, 2008, P NATL ACAD SCI USA, V105, P11218, DOI 10.1073/pnas.0801661105; Sumanasekera C, 2008, BIOCHEM SOC T, V36, P483, DOI 10.1042/BST0360483; Takehara T, 2001, HEPATOLOGY, V34, P55, DOI 10.1053/jhep.2001.25387; Tawfic S, 2001, HISTOL HISTOPATHOL, V16, P573, DOI 10.14670/HH-16.573; Trembley JH, 2009, CELL MOL LIFE SCI, V66, P1858, DOI 10.1007/s00018-009-9154-y; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; Venkatachalam CM, 2003, J MOL GRAPH MODEL, V21, P289, DOI 10.1016/S1093-3263(02)00164-X; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; Younis I, 2010, MOL CELL BIOL, V30, P1718, DOI 10.1128/MCB.01301-09; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837	53	78	81	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2014	9	4							e94978	10.1371/journal.pone.0094978	http://dx.doi.org/10.1371/journal.pone.0094978			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG3IK	24743259	Green Published, gold, Green Submitted			2023-01-03	WOS:000335309100056
J	Kim, MC; Lee, SW; Ryu, DY; Cui, FJ; Bhak, J; Kim, Y				Kim, Myung-Chul; Lee, Seung-Woo; Ryu, Doug-Young; Cui, Feng-Ji; Bhak, Jong; Kim, Yongbaek			Identification and Characterization of MicroRNAs in Normal Equine Tissues by Next Generation Sequencing	PLOS ONE			English	Article							ADIPOSE-TISSUE; EXPRESSION; HORSE; RNA; PRINCIPLES; DISORDERS; MIR-17-92; CARTILAGE; GENOMICS; PLANT	The role of microRNAs (miRNAs) as a post-transcriptional gene regulator has been elucidated in a broad range of organisms including domestic animals. Characterization of miRNAs in normal tissues is an important step to investigate the functions of miRNAs in various physiological and pathological conditions. Using Illumina Next Generation Sequencing (NGS) technology, we identified a total of 292 known and 329 novel miRNAs in normal horse tissues including skeletal muscle, colon and liver. Distinct sets of miRNAs were differentially expressed in a tissue-specific manner. The miRNA genes were distributed across all the chromosomes except chromosomes 29 and 31 in the horse reference genome. In some chromosomes, multiple miRNAs were clustered and considered to be polycistronic transcript. A base composition analysis showed that equine miRNAs had a higher frequency of A+U than G+C. Furthermore, U tended to be more frequent at the 59 end of miRNA sequences. This is the first experimental study that identifies and characterizes the global miRNA expression profile in normal horse tissues. The present study enriches the horse miRNA database and provides useful information for further research dissecting biological functions of miRNAs in horse.	[Kim, Myung-Chul; Cui, Feng-Ji; Kim, Yongbaek] Seoul Natl Univ, Coll Vet Med, Clin Pathol Lab, Seoul, South Korea; [Lee, Seung-Woo; Ryu, Doug-Young] Seoul Natl Univ, Coll Vet Med, Lab Environm Hlth, Seoul, South Korea; [Ryu, Doug-Young; Kim, Yongbaek] Seoul Natl Univ, Coll Vet Med, Res Inst Vet Sci, Seoul, South Korea; [Bhak, Jong] Theragen Bio Inst, Suwon, Gyeonggi Do, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Kim, Y (corresponding author), Seoul Natl Univ, Coll Vet Med, Clin Pathol Lab, Seoul, South Korea.	yongbaek@snu.ac.kr			Bio-industry Technology Development Program of iPET (Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries), Ministry of Agriculture, Food and Rural Affairs, Republic of Korea [1111594]; Brain Korea 21 Plus Program for Creative Veterinary Science Research, College of Veterinary Medicine, Seoul National University	Bio-industry Technology Development Program of iPET (Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries), Ministry of Agriculture, Food and Rural Affairs, Republic of Korea; Brain Korea 21 Plus Program for Creative Veterinary Science Research, College of Veterinary Medicine, Seoul National University	This study was supported by Bio-industry Technology Development Program (Grant no. 1111594) of iPET (Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries), Ministry of Agriculture, Food and Rural Affairs, Republic of Korea. Myung-Chul Kim and Seung-Woo Lee were additionally supported by the Brain Korea 21 Plus Program for Creative Veterinary Science Research, College of Veterinary Medicine, Seoul National University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ai L, 2012, PARASITOL RES, V110, P2373, DOI 10.1007/s00436-011-2773-x; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Barrey E, 2010, EQUINE VET J, V42, P561, DOI 10.1111/j.2042-3306.2010.00267.x; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Boggs RM, 2008, MAMM GENOME, V19, P561, DOI 10.1007/s00335-008-9128-7; Boggs RM, 2007, GENE, V404, P25, DOI 10.1016/j.gene.2007.08.015; Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242; Chi XY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027530; Chowdhary BP, 2008, ANIM REPROD SCI, V107, P208, DOI 10.1016/j.anireprosci.2008.04.010; Creighton CJ, 2009, BRIEF BIOINFORM, V10, P490, DOI 10.1093/bib/bbp019; Das PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056535; Dunn W, 2009, ARTHRITIS RHEUM-US, V60, P2333, DOI 10.1002/art.24678; Engels BM, 2006, ONCOGENE, V25, P6163, DOI 10.1038/sj.onc.1209909; Fleischhacker SN, 2013, VET J, V197, P688, DOI 10.1016/j.tvjl.2013.03.027; Flynt AS, 2008, NAT REV GENET, V9, P831, DOI 10.1038/nrg2455; Frank F, 2010, NATURE, V465, P818, DOI 10.1038/nature09039; FREESTONE JF, 1991, EQUINE VET J, V23, P86, DOI 10.1111/j.2042-3306.1991.tb02726.x; GALUPPO LD, 1995, AM J VET RES, V56, P518; Gu ZL, 2007, FEBS LETT, V581, P981, DOI 10.1016/j.febslet.2007.01.081; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023; Ji ZB, 2012, MOL BIOL REP, V39, P9361, DOI 10.1007/s11033-012-1779-5; Jin WW, 2009, BMC MOL BIOL, V10, DOI 10.1186/1471-2199-10-90; Kozomara A, 2011, NUCLEIC ACIDS RES, V39, pD152, DOI 10.1093/nar/gkq1027; Lacourt M, 2012, OSTEOARTHR CARTILAGE, V20, P572, DOI 10.1016/j.joca.2012.02.004; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; Li GX, 2011, J CELL BIOCHEM, V112, P1318, DOI 10.1002/jcb.23045; Li HL, 2012, MOL MED REP, V5, P1457, DOI 10.3892/mmr.2012.831; Liang Y, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-166; Mair T., 2002, MANUAL EQUINE GASTRO; Mair TS, 2005, EQUINE VET J, V37, P296, DOI 10.2746/0425164054529409; McKenzie E, 2011, EQUINE VET J, V43, P637, DOI 10.1111/j.2042-3306.2011.00468.x; Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001; Nicholas FW, 2003, NUCLEIC ACIDS RES, V31, P275, DOI 10.1093/nar/gkg074; Rajewsky N, 2006, NAT GENET, V38, pS8, DOI 10.1038/ng1798; Shendure J, 2008, NAT BIOTECHNOL, V26, P1135, DOI 10.1038/nbt1486; Song GS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007829; Thatcher EJ, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-253; Vila C, 2001, SCIENCE, V291, P474, DOI 10.1126/science.291.5503.474; Voelkerding KV, 2009, CLIN CHEM, V55, P641, DOI 10.1373/clinchem.2008.112789; Wade CM, 2009, SCIENCE, V326, P865, DOI 10.1126/science.1178158; Wang LW, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-154; Wei LQ, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r53; West HJ, 1996, EQUINE VET J, V28, P146, DOI 10.1111/j.2042-3306.1996.tb01607.x; Yang Hong, 2010, Yichuan, V32, P211, DOI 10.3724/SP.J.1005.2010.00211; Zhang BH, 2006, PLANT J, V46, P243, DOI 10.1111/j.1365-313X.2006.02697.X; Zhou M, 2009, GENOMICS, V94, P125, DOI 10.1016/j.ygeno.2009.04.006	48	28	30	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2014	9	4							e93662	10.1371/journal.pone.0093662	http://dx.doi.org/10.1371/journal.pone.0093662			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE6LC	24988450	Green Published, Green Submitted, gold			2023-01-03	WOS:000334103000099
J	Zhang, XY; Zhang, T; Young, AA; Li, XS				Zhang, Xingyu; Zhang, Tao; Young, Alistair A.; Li, Xiaosong			Applications and Comparisons of Four Time Series Models in Epidemiological Surveillance Data	PLOS ONE			English	Article							SUPPORT VECTOR MACHINES; NEURAL-NETWORK; HYBRID ARIMA; PREDICTION; FORECAST; FEVER	Public health surveillance systems provide valuable data for reliable predication of future epidemic events. This paper describes a study that used nine types of infectious disease data collected through a national public health surveillance system in mainland China to evaluate and compare the performances of four time series methods, namely, two decomposition methods (regression and exponential smoothing), autoregressive integrated moving average (ARIMA) and support vector machine (SVM). The data obtained from 2005 to 2011 and in 2012 were used as modeling and forecasting samples, respectively. The performances were evaluated based on three metrics: mean absolute error (MAE), mean absolute percentage error (MAPE), and mean square error (MSE). The accuracy of the statistical models in forecasting future epidemic disease proved their effectiveness in epidemiological surveillance. Although the comparisons found that no single method is completely superior to the others, the present study indeed highlighted that the SVMs outperforms the ARIMA model and decomposition methods in most cases.	[Zhang, Xingyu; Zhang, Tao; Li, Xiaosong] Sichuan Univ, West China Sch Publ Hlth, Dept Med Stat, Chengdu 610064, Sichuan, Peoples R China; [Zhang, Xingyu; Young, Alistair A.] Univ Auckland, Dept Anat Radiol, Auckland 1, New Zealand	Sichuan University; University of Auckland	Li, XS (corresponding author), Sichuan Univ, West China Sch Publ Hlth, Dept Med Stat, Chengdu 610064, Sichuan, Peoples R China.	lixiaosong1101@126.com		Zhang, Xingyu/0000-0001-8108-1997; Young, Alistair/0000-0001-5702-4220	National Special Foundation for Health Research of China [200802133]	National Special Foundation for Health Research of China	The entire study and the paper were financially supported by the National Special Foundation for Health Research of China (grant no. 200802133). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bowerman B. L., 1993, FORECASTING TIME SER; Chadwick D, 2006, J CLIN VIROL, V35, P147, DOI 10.1016/j.jcv.2005.06.002; Chang CC, 2011, ACM T INTEL SYST TEC, V2, DOI 10.1145/1961189.1961199; Christodoulos C, 2011, TECHNOL FORECAST SOC, V78, P163, DOI 10.1016/j.techfore.2010.08.007; Davision AC, 1997, BOOTSTRAP METHODS TH, P23; Farrington C, 2003, MONITORING HLTH POPU, V2003, P203; Galbraith JW, 1999, J ECONOMETRICS, V93, P25, DOI 10.1016/S0304-4076(98)00097-9; Gonzalez-Parra G, 2009, COMMUN NONLINEAR SCI, V14, P3967, DOI 10.1016/j.cnsns.2009.02.023; Grahn T., 1995, J TIMES SERIES ANAL, V16, P509, DOI [DOI 10.1111/J.1467-9892.1995.TB00251.X, 10.1111/j.1467-9892.1995.tb00251.x]; Hamilton J., 1994, TIME SERIES ANAL; Ho SL, 2002, COMPUT IND ENG, V42, P371, DOI 10.1016/S0360-8352(02)00036-0; Hong WC, 2006, INT J ADV MANUF TECH, V28, P154, DOI 10.1007/s00170-004-2340-z; KOEHLER AB, 1988, J R STAT SOC C-APPL, V37, P187; Li Q, 2012, AM J TROP MED HYG, V87, P364, DOI 10.4269/ajtmh.2012.11-0472; Liu Q, 2011, BMC INFECT DIS, V11; Luz PM, 2008, AM J TROP MED HYG, V79, P933, DOI 10.4269/ajtmh.2008.79.933; MOGHRAM I, 1989, IEEE T POWER SYST, V4, P1484, DOI 10.1109/59.41700; Muller K.-R., 1997, Artificial Neural Networks - ICANN '97. 7th International Conference Proceedings, P999, DOI 10.1007/BFb0020283; Nobre FF, 2001, STAT MED, V20, P3051, DOI 10.1002/sim.963; Pai PF, 2005, INT J ADV MANUF TECH, V27, P205, DOI 10.1007/s00170-004-2139-y; Pai PF, 2005, OMEGA-INT J MANAGE S, V33, P497, DOI 10.1016/j.omega.2004.07.024; Rios M, 2000, EUR J EPIDEMIOL, V16, P483, DOI 10.1023/A:1007653329972; Smola AJ, 2004, STAT COMPUT, V14, P199, DOI 10.1023/B:STCO.0000035301.49549.88; Spaeder MC, 2012, EPIDEMIOL INFECT, V140, P602, DOI 10.1017/S0950268811001026; Tay FEH, 2002, NEUROCOMPUTING, V48, P847, DOI 10.1016/S0925-2312(01)00676-2; Tay FEH, 2001, OMEGA-INT J MANAGE S, V29, P309, DOI 10.1016/S0305-0483(01)00026-3; Thiessen U, 2003, CHEMOMETR INTELL LAB, V69, P35, DOI 10.1016/S0169-7439(03)00111-4; Thomason M., 1999, J COMPUT FINANC, V7, P36; TSAY RS, 1988, J FORECASTING, V7, P1, DOI 10.1002/for.3980070102; Ture M, 2006, EXPERT SYST APPL, V31, P41, DOI 10.1016/j.eswa.2005.09.002; Wei W. W.-S., 1994, TIME SERIES ANAL; Wongkoon S, 2012, ASIAN PAC J TROP MED, V5, P249, DOI 10.1016/S1995-7645(12)60034-0; Wu CH, 2003, 2003 IEEE INTELLIGENT TRANSPORTATION SYSTEMS PROCEEDINGS, VOLS. 1 & 2, P1438; Yan WR, 2010, JPN J INFECT DIS, V63, P264; Zhang GP, 2003, NEUROCOMPUTING, V50, P159, DOI 10.1016/S0925-2312(01)00702-0; Zhang XG., 2000, ACTA AUTOMATICA SIN, V1, P36, DOI [10.16383/j.aas.2000.01.005, DOI 10.1007/S11431-011-4595-6]; Zhang XY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063116	37	121	128	4	45	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2014	9	2							e88075	10.1371/journal.pone.0088075	http://dx.doi.org/10.1371/journal.pone.0088075			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AA1AT	24505382	Green Published, gold, Green Submitted			2023-01-03	WOS:000330829200110
J	Xu, XY; Li, F; Zhang, X; Li, PC; Zhang, X; Wu, ZX; Li, DP				Xu, Xiaoyan; Li, Feng; Zhang, Xin; Li, Pengcheng; Zhang, Xing; Wu, Zhaoxi; Li, Dapeng			In Vitro Synergistic Antioxidant Activity and Identification of Antioxidant Components from Astragalus membranaceus and Paeonia lactiflora	PLOS ONE			English	Article							RADIX-ASTRAGALI; HPLC; MECHANISMS; CONSTITUENTS; PERSPECTIVE; ANTICANCER; FLAVONOIDS; APOPTOSIS; EXTRACT; ASSAY	Many traditionally used herbs demonstrate significantly better pharmacological effects when used in combination than when used alone. However, the mechanism underlying this synergism is still poorly understood. This study aimed to investigate the synergistic antioxidant activity of Astragalus membranaceus (AME) and Paeonia Lactiflora (PL), and identify the potential antioxidant components by 1,1-diphenyl-2-picrylhydrazine (DPPH) radical spiking test followed by a high performance liquid chromatography separation combined with diode array detection and tandem mass spectrometry analysis (DPPH-HPLC-DAD-MS/MS). Eight AME-PL combined extracts (E-1-E-8) were prepared based on bioactivity-guided fractionation. Among them, E-1 exhibited the strongest synergistic effect in scavenging DPPH radicals and reducing ferric ions (P<0.05). Moreover, E-1 presented strong cytoprotection against H2O2-induced oxidative damage in MRC-5 cells by suppressing the decrease of the superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and catalase (CAT) activities. A strong correlation between the increment of total phenolic/flavonoid and synergistic antioxidant activity, especially between the increment of total flavonoid and the increase in ferric reducing power was observed. Finally, seven antioxidant substances were identified in E-1 as oxypaeoniflora, catechin, calycosin-7-O-beta-D-glucopyranoside, fomononetin-7-O-beta-D-glucopyranoside, 9,10-dimethoxy-pterocarpan-3-O-beta-D-glucopyranoside, quercetin and 2'-dihydroxy-3',4'-dimethyl-isoflavan- 7-O-beta-D-glucopyranoside.	[Xu, Xiaoyan; Li, Feng; Zhang, Xin; Zhang, Xing; Wu, Zhaoxi; Li, Dapeng] Shandong Agr Univ, Dept Food Sci, Tai An, Shandong, Peoples R China; [Li, Pengcheng] Shandong Agr Univ, Coll Life Sci, Tai An, Shandong, Peoples R China; [Li, Dapeng] Natl Res Ctr Apple Engn & Technol, Tai An, Shandong, Peoples R China	Shandong Agricultural University; Shandong Agricultural University	Li, DP (corresponding author), Shandong Agr Univ, Dept Food Sci, Tai An, Shandong, Peoples R China.	dpli73@sdau.edu.cn	DaPeng, Li/G-4164-2010; li, dapeng/G-4166-2010	DaPeng, Li/0000-0002-1816-3217; li, dapeng/0000-0002-1816-3217; Xu, Xiaomeng/0000-0003-3695-4845; Demos, Kathryn/0000-0002-8578-4312; Ross, Kathryn/0000-0002-3628-766X	National Key Technology R&D Program of China [2012BAK17B05]; Shandong Provincial Natural Science Foundation of China [ZR2009DM046]; Foundation of National Natural Science Foundation of China [31201417]	National Key Technology R&D Program of China(National Key Technology R&D Program); Shandong Provincial Natural Science Foundation of China(Natural Science Foundation of Shandong Province); Foundation of National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Key Technology R&D Program of China (2012BAK17B05), Shandong Provincial Natural Science Foundation of China (ZR2009DM046), and the Foundation of National Natural Science Foundation of China (31201417). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Atangwho IJ, 2012, J ETHNOPHARMACOL, V141, P878, DOI 10.1016/j.jep.2012.03.041; Bandoniene D, 2002, J BIOCHEM BIOPH METH, V53, P45, DOI 10.1016/S0165-022X(02)00091-X; Barbouti A, 2002, FREE RADICAL BIO MED, V33, P691, DOI 10.1016/S0891-5849(02)00967-X; Bendaoud H, 2010, J FOOD SCI, V75, pC466, DOI 10.1111/j.1750-3841.2010.01711.x; Benzie IFF, 1999, METHOD ENZYMOL, V299, P15; Cai YZ, 2004, LIFE SCI, V74, P2157, DOI 10.1016/j.lfs.2003.09.047; CHOU TC, 1994, JNCI-J NATL CANCER I, V86, P1517, DOI 10.1093/jnci/86.20.1517; Chu C, 2010, J SEP SCI, V33, P570, DOI 10.1002/jssc.200900687; Fattahi M, 2013, FOOD CHEM, V141, P139, DOI 10.1016/j.foodchem.2013.03.019; GRECO WR, 1995, PHARMACOL REV, V47, P331; Huang DJ, 2005, J AGR FOOD CHEM, V53, P1841, DOI 10.1021/jf030723c; Jia Z, 1999, FOOD CHEM, V64, P555, DOI 10.1016/S0308-8146(98)00102-2; Kim SH, 2009, J ENZYM INHIB MED CH, V24, P1138, DOI 10.1080/14756360802667977; Leung HWC, 2006, EUR J PHARMACOL, V534, P12, DOI 10.1016/j.ejphar.2006.01.021; Ma XH, 2009, DRUG DISCOV TODAY, V14, P579, DOI 10.1016/j.drudis.2009.03.012; MAK IT, 1983, J BIOL CHEM, V258, P3733; Misbah H, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-118; Nagata Hidetaka, 1999, Tokai Journal of Experimental and Clinical Medicine, V24, P1; Nijveldt RJ, 2001, AM J CLIN NUTR, V74, P418; Rathee JS, 2006, J AGR FOOD CHEM, V54, P9046, DOI 10.1021/jf061679e; Rodea-Palomares I, 2010, WATER RES, V44, P427, DOI 10.1016/j.watres.2009.07.026; SIMIC MG, 1988, MUTAT RES, V202, P377, DOI 10.1016/0027-5107(88)90199-6; SINGLETON V. L., 1965, AMER J ENOL VITICULT, V16, P144; Stermitz FR, 2000, P NATL ACAD SCI USA, V97, P1433, DOI 10.1073/pnas.030540597; Tang D, 2008, J SEP SCI, V31, P3519, DOI 10.1002/jssc.200800173; Verma AR, 2010, FOOD CHEM TOXICOL, V48, P704, DOI 10.1016/j.fct.2009.11.052; Wang L.S., 2012, NUTR WELL BEING HLTH, V7, P201, DOI DOI 10.5772/25862; Wang PC, 2003, MECH AGEING DEV, V124, P1025, DOI 10.1016/j.mad.2003.08.005; Wijesekara I, 2011, FOOD RES INT, V44, P703, DOI 10.1016/j.foodres.2010.12.022; Xiao HB, 2004, J CHROMATOGR A, V1032, P117, DOI 10.1016/j.chroma.2003.09.032; Yang WJ, 2009, BIOL PHARM BULL, V32, P1021, DOI 10.1248/bpb.32.1021; Yao H, 2012, FOOD CHEM, V135, P2802, DOI 10.1016/j.foodchem.2012.07.076; Zhu YZ, 2004, NAT PROD REP, V21, P478, DOI 10.1039/b304821g	33	85	91	0	64	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2014	9	5							e96780	10.1371/journal.pone.0096780	http://dx.doi.org/10.1371/journal.pone.0096780			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI4LX	24816851	gold, Green Published, Green Submitted			2023-01-03	WOS:000336838000064
J	Wang, YP; Nie, JX; Yap, PT; Li, G; Shi, F; Geng, XJ; Guo, L; Shen, DG				Wang, Yaping; Nie, Jingxin; Yap, Pew-Thian; Li, Gang; Shi, Feng; Geng, Xiujuan; Guo, Lei; Shen, Dinggang		Alzheimers Dis Neuroimaging Initia	Knowledge-Guided Robust MRI Brain Extraction for Diverse Large-Scale Neuroimaging Studies on Humans and Non-Human Primates	PLOS ONE			English	Article							SKULL STRIPPING PROBLEM; ALZHEIMERS-DISEASE; AUTOMATIC SEGMENTATION; GRAY-MATTER; IMAGES; CLASSIFICATION; REGISTRATION; ALGORITHM; VOLUMES; CORTEX	Accurate and robust brain extraction is a critical step in most neuroimaging analysis pipelines. In particular, for the large-scale multi-site neuroimaging studies involving a significant number of subjects with diverse age and diagnostic groups, accurate and robust extraction of the brain automatically and consistently is highly desirable. In this paper, we introduce population-specific probability maps to guide the brain extraction of diverse subject groups, including both healthy and diseased adult human populations, both developing and aging human populations, as well as non-human primates. Specifically, the proposed method combines an atlas-based approach, for coarse skull-stripping, with a deformable-surface-based approach that is guided by local intensity information and population-specific prior information learned from a set of real brain images for more localized refinement. Comprehensive quantitative evaluations were performed on the diverse large-scale populations of ADNI dataset with over 800 subjects (55 similar to 90 years of age, multi-site, various diagnosis groups), OASIS dataset with over 400 subjects (18 similar to 96 years of age, wide age range, various diagnosis groups), and NIH pediatrics dataset with 150 subjects (5 similar to 18 years of age, multi-site, wide age range as a complementary age group to the adult dataset). The results demonstrate that our method consistently yields the best overall results across almost the entire human life span, with only a single set of parameters. To demonstrate its capability to work on non-human primates, the proposed method is further evaluated using a rhesus macaque dataset with 20 subjects. Quantitative comparisons with popularly used state-of-the-art methods, including BET, Two-pass BET, BET-B, BSE, HWA, ROBEX and AFNI, demonstrate that the proposed method performs favorably with superior performance on all testing datasets, indicating its robustness and effectiveness.	[Wang, Yaping; Guo, Lei] Northwestern Polytech Univ, Sch Automat, Xian 710072, Shaanxi Provinc, Peoples R China; [Wang, Yaping; Nie, Jingxin; Yap, Pew-Thian; Li, Gang; Shi, Feng; Shen, Dinggang] Univ N Carolina, Dept Radiol, Chapel Hill, NC 27515 USA; [Wang, Yaping; Nie, Jingxin; Yap, Pew-Thian; Li, Gang; Shi, Feng; Shen, Dinggang] Univ N Carolina, BRIC, Chapel Hill, NC USA; [Geng, Xiujuan] NIDA, Neuroimaging Res Branch, Baltimore, MD USA; [Shen, Dinggang] Korea Univ, Dept Brain & Cognit Engn, Seoul, South Korea	Northwestern Polytechnical University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); Korea University	Shen, DG (corresponding author), Univ N Carolina, Dept Radiol, Chapel Hill, NC 27515 USA.	dgshen@med.unc.edu	Shen, Dinggang/ABF-6812-2020; Li, Gang/D-3324-2013; Geng, Xiujuan/AAR-4306-2020	Shen, Dinggang/0000-0002-7934-5698; Li, Gang/0000-0001-9585-1382; Geng, Xiujuan/0000-0003-4953-0208	NIH [EB008374, EB006733, EB009634, AG041721, MH100217, AG042599]; National Natural Science Foundation of China [61273362, 61333017]; National Research Foundation grant of Korea [2012-005741]; Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant) [U01 AG024904]; NATIONAL CENTER FOR RESEARCH RESOURCES [U24RR021382] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB009634, R01EB006733, R01EB008374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH100217, P50MH071616, R01MH056584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021910, K01AG030514, P50AG005681, R01AG041721, P01AG003991, P30AG010129, R01AG042599, U01AG024904] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Research Foundation grant of Korea(National Research Foundation of Korea); Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported in part by NIH grants EB008374, EB006733, EB009634, AG041721, MH100217, AG042599, National Natural Science Foundation of China (No. 61273362, No. 61333017), and National Research Foundation grant of Korea (No. 2012-005741). The University of North Carolina at Chapel Hill's Libraries provided support for open access publication. ADNI data collection and sharing for this project was supported by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904), P30 AG010129, K01 AG030514, the Dana Foundation. OASIS data collection and sharing for this project was supported by P50 AG05681, P01 AG03991, R01 AG021910, P50 MH071616, U24 RR021382, R01 MH56584. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Atkins MS, 1998, IEEE T MED IMAGING, V17, P98, DOI 10.1109/42.668699; BOMANS M, 1990, IEEE T MED IMAGING, V9, P177, DOI 10.1109/42.56342; BRUMMER ME, 1993, IEEE T MED IMAGING, V12, P153, DOI 10.1109/42.232244; Carass A, 2011, NEUROIMAGE, V56, P1982, DOI 10.1016/j.neuroimage.2011.03.045; Chiverton J, 2007, COMPUT BIOL MED, V37, P342, DOI 10.1016/j.compbiomed.2006.04.001; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; DANIELSSON PE, 1980, COMPUT VISION GRAPH, V14, P227, DOI 10.1016/0146-664X(80)90054-4; Evans AC, 2006, NEUROIMAGE, V30, P184, DOI 10.1016/j.neuroimage.2005.09.068; Fennema-Notestine C, 2006, HUM BRAIN MAPP, V27, P99, DOI 10.1002/hbm.20161; Germond L, 2000, ARTIF INTELL MED, V20, P77, DOI 10.1016/S0933-3657(00)00054-3; Hahn HK, 2000, LECT NOTES COMPUT SC, V1935, P134; HOHNE KH, 1992, J COMPUT ASSIST TOMO, V16, P285, DOI 10.1097/00004728-199203000-00019; Holmes CJ, 1998, J COMPUT ASSIST TOMO, V22, P324, DOI 10.1097/00004728-199803000-00032; Huh S, 2002, COMPUT BIOL MED, V32, P311, DOI 10.1016/S0010-4825(02)00023-9; Iglesias JE, 2011, IEEE T MED IMAGING; Jack CR, 2008, J MAGN RESON IMAGING, V27, P685, DOI 10.1002/jmri.21049; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Kapur T, 1996, Med Image Anal, V1, P109, DOI 10.1016/S1361-8415(96)80008-9; Klein S, 2010, IEEE T MED IMAGING, V29, P196, DOI 10.1109/TMI.2009.2035616; Lee C, 1998, COMPUT BIOL MED, V28, P309, DOI 10.1016/S0010-4825(98)00013-4; Lemieux L, 1999, MAGN RESON MED, V42, P127, DOI 10.1002/(SICI)1522-2594(199907)42:1<127::AID-MRM17>3.0.CO;2-O; Leung KK, 2011, NEUROIMAGE, V55, P1091, DOI 10.1016/j.neuroimage.2010.12.067; Marcus DS, 2007, J COGNITIVE NEUROSCI, V19, P1498, DOI 10.1162/jocn.2007.19.9.1498; Miura N, 2002, J COMPUT ASSIST TOMO, V26, P927, DOI 10.1097/00004728-200211000-00012; Mueller SG, 2005, NEUROIMAG CLIN N AM, V15, P869, DOI 10.1016/j.nic.2005.09.008; Popescu V, 2012, NEUROIMAGE, V61, P1484, DOI 10.1016/j.neuroimage.2012.03.074; Raz N, 1997, CEREB CORTEX, V7, P268, DOI 10.1093/cercor/7.3.268; Rehm K, 2004, NEUROIMAGE, V22, P1262, DOI 10.1016/j.neuroimage.2004.03.011; Rex DE, 2004, NEUROIMAGE, V23, P625, DOI 10.1016/j.neuroimage.2004.06.019; Rodrigue KM, 2004, J NEUROSCI, V24, P956, DOI 10.1523/JNEUROSCI.4166-03.2004; Sadananthan SA, 2010, NEUROIMAGE, V49, P225, DOI 10.1016/j.neuroimage.2009.08.050; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; Shan ZY, 2002, NEUROIMAGE, V17, P1587, DOI 10.1006/nimg.2002.1287; Shannon C, 1998, AM J PRIMATOL, V46, P311, DOI 10.1002/(SICI)1098-2345(1998)46:4<311::AID-AJP3>3.0.CO;2-L; Shattuck DW, 2009, NEUROIMAGE, V45, P431, DOI 10.1016/j.neuroimage.2008.10.066; Shattuck DW, 2001, NEUROIMAGE, V13, P856, DOI 10.1006/nimg.2000.0730; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Sowell ER, 1999, NEUROIMAGE, V9, P587, DOI 10.1006/nimg.1999.0436; Stokking R, 2000, NEUROIMAGE, V12, P726, DOI 10.1006/nimg.2000.0661; Styner M, 2000, IEEE T MED IMAGING, V19, P153, DOI 10.1109/42.845174; Tisserand DJ, 2004, CEREB CORTEX, V14, P966, DOI 10.1093/cercor/bhh057; Vercauteren T., 2007, LNCS, V10, P319, DOI DOI 10.1016/J.NEUR0IMAGE.2008.10.040; Wang Y, 2012, GROUPWISE SEGMENTATI, P185; Wang YP, 2013, I S BIOMED IMAGING, P1364; Wang YP, 2011, LECT NOTES COMPUT SC, V6893, P635, DOI 10.1007/978-3-642-23626-6_78; Yushkevich PA, 2006, NEUROIMAGE, V31, P1116, DOI 10.1016/j.neuroimage.2006.01.015; Zhuang AH, 2006, NEUROIMAGE, V32, P79, DOI 10.1016/j.neuroimage.2006.03.019	49	298	308	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 29	2014	9	1							e77810	10.1371/journal.pone.0077810	http://dx.doi.org/10.1371/journal.pone.0077810			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301ZC	24489639	Green Submitted, Green Published, gold			2023-01-03	WOS:000330570000002
J	Harvey, AE; Lashinger, LM; Hays, D; Harrison, LM; Lewis, K; Fischer, SM; Hursting, SD				Harvey, Alison E.; Lashinger, Laura M.; Hays, Drew; Harrison, Lauren M.; Lewis, Kimberly; Fischer, Susan M.; Hursting, Stephen D.			Calorie Restriction Decreases Murine and Human Pancreatic Tumor Cell Growth, Nuclear Factor-kB Activation, and Inflammation-Related Gene Expression in an Insulin-like Growth Factor-1-Dependent Manner	PLOS ONE			English	Article							FACTOR-KAPPA-B; ENERGY-BALANCE; FACTOR-I; DIETARY MODULATION; CANCER; OBESITY; CARCINOGENESIS; PROGRESSION; SERUM; INDUCTION	Calorie restriction (CR) prevents obesity and has potent anticancer effects that may be mediated through its ability to reduce serum growth and inflammatory factors, particularly insulin-like growth factor (IGF)-1 and protumorigenic cytokines. IGF-1 is a nutrient-responsive growth factor that activates the inflammatory regulator nuclear factor (NF)-kB, which is linked to many types of cancers, including pancreatic cancer. We hypothesized that CR would inhibit pancreatic tumor growth through modulation of IGF-1-stimulated NF-kB activation and protumorigenic gene expression. To test this, 30 male C57BL/ 6 mice were randomized to either a control diet consumed ad libitum or a 30% CR diet administered in daily aliquots for 21 weeks, then were subcutaneously injected with syngeneic mouse pancreatic cancer cells (Panc02) and tumor growth was monitored for 5 weeks. Relative to controls, CR mice weighed less and had decreased serum IGF-1 levels and smaller tumors. Also, CR tumors demonstrated a 70% decrease in the expression of genes encoding the pro-inflammatory factors S100a9 and F4/80, and a 56% decrease in the macrophage chemoattractant, Ccl2. Similar CR effects on tumor growth and NF-kB-related gene expression were observed in a separate study of transplanted MiaPaCa-2 human pancreatic tumor cell growth in nude mice. In vitro analyses in Panc02 cells showed that IGF-1 treatment promoted NF-kB nuclear localization, increased DNA-binding of p65 and transcriptional activation, and increased expression of NF-kB downstream genes. Finally, the IGF-1-induced increase in expression of genes downstream of NF-kB (Ccdn1, Vegf, Birc5, and Ptgs2) was decreased significantly in the context of silenced p65. These findings suggest that the inhibitory effects of CR on Panc02 pancreatic tumor growth are associated with reduced IGF-1-dependent NF-kB activation.	[Harvey, Alison E.; Lashinger, Laura M.; Hays, Drew; Harrison, Lauren M.; Lewis, Kimberly; Hursting, Stephen D.] Univ Texas Austin, Dept Nutr Sci, Austin, TX 78712 USA; [Fischer, Susan M.; Hursting, Stephen D.] Univ Texas MD Anderson Canc Ctr, Dept Mol Carcinogenesis, Smithville, TX USA	University of Texas System; University of Texas Austin; University of Texas System; UTMD Anderson Cancer Center	Hursting, SD (corresponding author), Univ Texas Austin, Dept Nutr Sci, Austin, TX 78712 USA.	shursting@austin.utexas.edu		Callan, Mitchell/0000-0002-6737-8281; Lewis, Kimberly/0000-0002-2590-8627	National Institutes of Health (NIH) [R01 CA135386]; NIH-sponsored postdoctoral fellowship [R25T CA57730, T32 CA135386]; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA135386, R25CA057730] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH-sponsored postdoctoral fellowship(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by National Institutes of Health (NIH) grant, R01 CA135386, awarded to S. D. Hursting and S. M. Fischer and NIH-sponsored postdoctoral fellowship grants, R25T CA57730 and T32 CA135386, awarded to L. M. Lashinger. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adachi Y, 2010, WORLD J GASTROENTERO, V16, P5779, DOI 10.3748/wjg.v16.i46.5779; Balkwill F, 2004, NATURE, V431, P405, DOI 10.1038/431405a; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Bellone G, 2006, CANCER IMMUNOL IMMUN, V55, P684, DOI 10.1007/s00262-005-0047-0; Bhattacharya A, 2006, BIOCHEM BIOPH RES CO, V349, P925, DOI 10.1016/j.bbrc.2006.08.093; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; CORBETT TH, 1984, CANCER RES, V44, P717; CRAVENGILES T, 1994, CANCER RES, V54, pS1964; Dolcet X, 2005, VIRCHOWS ARCH, V446, P475, DOI 10.1007/s00428-005-1264-9; Fenton JI, 2009, DIABETES OBES METAB, V11, P343, DOI 10.1111/j.1463-1326.2008.00974.x; Ford NA, 2013, ENDOCR-RELAT CANCER, V20, P39, DOI 10.1530/ERC-12-0329; Goecke H, 2000, SURGERY, V128, P806, DOI 10.1067/msy.2000.108613; Govannucci E, 2007, GASTROENTEROLOGY, V132, P2208, DOI 10.1053/j.gastro.2007.03.050; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Harvey AE, 2012, MOL CARCINOGENESIS; Harvey AE, 2011, ANN NY ACAD SCI, V1229, P45, DOI 10.1111/j.1749-6632.2011.06096.x; Hursting SD, 2012, ANN NY ACAD SCI, V1271, P82, DOI 10.1111/j.1749-6632.2012.06737.x; Hursting SD, 2010, J CLIN ONCOL, V28, P4058, DOI 10.1200/JCO.2010.27.9935; Karin M, 2005, NAT MED, V11, P20, DOI 10.1038/nm0105-20; Karna E, 2002, INT J EXP PATHOL, V83, P239, DOI 10.1046/j.1365-2613.2002.00237.x; Kim DH, 2008, BIOGERONTOLOGY, V9, P33, DOI 10.1007/s10522-007-9114-6; Kim HJ, 2002, FREE RADICAL BIO MED, V32, P991, DOI 10.1016/S0891-5849(02)00798-0; Kokawa A, 2001, CANCER, V91, P333, DOI 10.1002/1097-0142(20010115)91:2<333::AID-CNCR1006>3.0.CO;2-N; Lashinger LM, 2014, J NUTR, V144, P109, DOI 10.3945/jn.113.178533; Lashinger LM, 2013, CANCER PREV RES, V6, P1046, DOI 10.1158/1940-6207.CAPR-13-0185; Lashinger LM, 2011, CANCER PREV RES, V4, P1041, DOI 10.1158/1940-6207.CAPR-11-0023; Lashinger LM, 2011, CANCER PREV RES, V4, P1030, DOI 10.1158/1940-6207.CAPR-11-0027; Lin YS, 2004, INT J CANCER, V110, P584, DOI 10.1002/ijc.20147; LOWENFELS AB, 1993, NEW ENGL J MED, V328, P1433, DOI 10.1056/NEJM199305203282001; Luedde T, 2006, J GASTROEN HEPATOL, V21, pS43, DOI 10.1111/j.1440-1746.2006.04588.x; Ma JC, 2010, J SURG RES, V160, P90, DOI 10.1016/j.jss.2008.08.016; Maier HJ, 2010, CANCER LETT, V295, P214, DOI 10.1016/j.canlet.2010.03.003; Mancino A, 2010, CLIN CANCER RES, V16, P784, DOI 10.1158/1078-0432.CCR-09-1015; Monti P, 2003, CANCER RES, V63, P7451; Moore T, 2008, CANCER PREV RES, V1, P65, DOI 10.1158/1940-6207.CAPR-08-0022; Nunez NP, 2008, NUTR CANCER, V60, P534, DOI 10.1080/01635580801966195; Olivo-Marston SE, 2009, MOL CARCINOGEN, V48, P1071, DOI 10.1002/mc.20577; ROEBUCK BD, 1993, CANCER RES, V53, P46; ROEBUCK BD, 1981, CANCER RES, V41, P888; Rouet-Benzineb R, 2004, J BIOL CHEM, V279, P16495, DOI 10.1074/jbc.M312999200; Shaib YH, 2006, ALIMENT PHARM THER, V24, P87, DOI 10.1111/j.1365-2036.2006.02961.x; Sica A, 2008, CANCER LETT, V267, P204, DOI 10.1016/j.canlet.2008.03.028; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Wang WX, 1999, CLIN CANCER RES, V5, P119; Wheatley KE, 2008, NUTR CANCER, V60, P61, DOI 10.1080/01635580701510150; Xiong Henry Q, 2004, Surg Oncol Clin N Am, V13, P737, DOI 10.1016/j.soc.2004.06.010; YEBRA M, 1995, MOL BIOL CELL, V6, P841, DOI 10.1091/mbc.6.7.841	47	54	54	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2014	9	5							e94151	10.1371/journal.pone.0094151	http://dx.doi.org/10.1371/journal.pone.0094151			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG9HB	25036011	Green Submitted, Green Published, gold			2023-01-03	WOS:000335728900009
J	Peng, Z; Wang, CX; Fang, EH; Lu, XM; Wang, GB; Tong, Q				Peng, Zhao; Wang, Chenxiao; Fang, Erhu; Lu, Xiaoming; Wang, Guobin; Tong, Qiang			Co-Delivery of Doxorubicin and SATB1 shRNA by Thermosensitive Magnetic Cationic Liposomes for Gastric Cancer Therapy	PLOS ONE			English	Article							OVERCOME DRUG-RESISTANCE; IN-VITRO; TEMPERATURE; GENE; RNA; ADENOCARCINOMA; NANOPARTICLES; EXPRESSION; RELEASE; CELLS	In previous a study, we had developed a novel thermosensitive magnetic delivery system based on liposomes. This study aimed to evaluate the efficiency of this system for the co-delivery of both drugs and genes to the same cell and its antitumor effects on gastric cancer. Doxorubicin (DOX) and SATB1 shRNA vector were loaded into the co-delivery system, and in vitro DOX thermosensitive release activity, targeted gene silencing efficiency, targeted cellular uptake, in vitro cytotoxicity, as well as in vivo anti-tumor activity were determined. The results showed that this co-delivery system had desirable targeted delivery efficacy, DOX thermosensitive release and SATB1 gene silencing. Moreover, the co-delivery of DOX and SATB1 shRNA exhibited enhanced activity to inhibit gastric cancer cell growth in vitro and in vivo, compared to single delivery. In conclusion, the novel thermosensitive magnetic drug and gene co-delivery system has promising application in combined chemotherapy and gene therapy for gastric cancer.	[Peng, Zhao; Wang, Chenxiao; Fang, Erhu; Lu, Xiaoming; Wang, Guobin; Tong, Qiang] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan 430074, Hubei, Peoples R China	Huazhong University of Science & Technology	Wang, GB (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan 430074, Hubei, Peoples R China.	guobinwang1954@gmail.com; qiangtong@hust.edu.cn	Li, Yilin/AAW-9533-2021		National Natural Science Foundation of China [81172186]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Natural Science Foundation of China (No. 81172186). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agrelo R, 2009, DEV CELL, V16, P507, DOI 10.1016/j.devcel.2009.03.006; Alberts SR, 2003, ANN ONCOL, V14, P31, DOI 10.1093/annonc/mdg726; Alexiou C, 2000, CANCER RES, V60, P6641; Chen J, 2013, DRUG DEV IND PHARM, V39, P197, DOI 10.3109/03639045.2012.668912; Chen YC, 2010, J BIOL CHEM, V285, P22639, DOI 10.1074/jbc.M110.125906; Cheng C, 2010, APMIS, V118, P855, DOI 10.1111/j.1600-0463.2010.02673.x; Dicken BJ, 2005, ANN SURG, V241, P27, DOI 10.1097/01.sla.0000149300.28588.23; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; GABER MH, 1995, PHARMACEUT RES, V12, P1407, DOI 10.1023/A:1016206631006; Heger Z, 2013, INT J MOL SCI, V14, P21629, DOI 10.3390/ijms141121629; Huang B, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-8; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Juergen S, 2012, FUNDAMENTALS APPL CO, P291; Kohwi-Shigematsu T, 2013, SEMIN CANCER BIOL, V23, P72, DOI 10.1016/j.semcancer.2012.06.009; Kono K, 2004, METHODS ENZYMOL, V387, P73; Li Wei, 2011, Zhonghua Wei Chang Wai Ke Za Zhi, V14, P432; Liu CX, 2013, BIOMATERIALS, V34, P2547, DOI 10.1016/j.biomaterials.2012.12.038; Lu XM, 2010, ONCOL REP, V24, P981, DOI 10.3892/or_00000945; Mir R, 2012, CURR DRUG TARGETS, V13, P1603, DOI 10.2174/138945012803530008; Mykhaylyk O, 2010, METHODS MOL BIOL, V605, P487, DOI 10.1007/978-1-60327-360-2_34; Park SC, 2013, GUT LIVER, V7, P385, DOI 10.5009/gnl.2013.7.4.385; Patani N, 2009, CANCER CELL INT, V9, DOI 10.1186/1475-2867-9-18; Pradhan P, 2010, J CONTROL RELEASE, V142, P108, DOI 10.1016/j.jconrel.2009.10.002; Pradhan P, 2010, METHODS MOL BIOL, V605, P279, DOI 10.1007/978-1-60327-360-2_19; Shen JA, 2012, BIOMATERIALS, V33, P8613, DOI 10.1016/j.biomaterials.2012.08.007; Shim G, 2011, J CONTROL RELEASE, V155, P60, DOI 10.1016/j.jconrel.2010.10.017; Skeel R, 2011, HDB CANC CHEMOTHERAP; Stebbing J, 2002, CANCER TREAT REV, V28, P121, DOI 10.1053/ctrv.2002.0262; Ta T, 2013, J CONTROL RELEASE, V169, P112, DOI 10.1016/j.jconrel.2013.03.036; Takahashi Tsunehiro, 2013, Cancers (Basel), V5, P48, DOI 10.3390/cancers5010048; Torchilin Vladimir P, 2010, Handb Exp Pharmacol, P3, DOI 10.1007/978-3-642-00477-3_1; Wang CM, 2011, BIOCHEM BIOPH RES CO, V410, P537, DOI 10.1016/j.bbrc.2011.06.019; Xiao YL, 2012, NANOSCALE, V4, P7185, DOI 10.1039/c2nr31853a; Yang L, 2006, WORLD J GASTROENTERO, V12, P17, DOI 10.3748/wjg.v12.i1.17; Zhang J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0047902; Zhao F, 2014, BIOMATERIALS, V35, P1050, DOI 10.1016/j.biomaterials.2013.10.044; Zheng XL, 2009, INT J PHARMACEUT, V366, P211, DOI 10.1016/j.ijpharm.2008.09.019; Zhou Lai-Yong, 2009, Nan Fang Yi Ke Da Xue Xue Bao, V29, P534; Zhu XD, 2010, ONCOL LETT, V1, P407, DOI 10.3892/ol_00000071	39	137	147	2	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 27	2014	9	3							e92924	10.1371/journal.pone.0092924	http://dx.doi.org/10.1371/journal.pone.0092924			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE0SW	24416238	gold, Green Submitted, Green Published			2023-01-03	WOS:000333677500056
J	Peng, Z; Zhu, Y; Wang, QQ; Gao, J; Li, YL; Li, YY; Ge, S; Shen, L				Peng, Zhi; Zhu, Yan; Wang, Qianqian; Gao, Jing; Li, Yilin; Li, Yanyan; Ge, Sai; Shen, Lin			Prognostic Significance of MET Amplification and Expression in Gastric Cancer: A Systematic Review with Meta-Analysis	PLOS ONE			English	Review							HEPATOCYTE GROWTH-FACTOR; C-MET; FACTOR-RECEPTOR; POOR-PROGNOSIS; E-CADHERIN; GENE; OVEREXPRESSION; MARKER; CARCINOMA; P53	Background and Aims: MET, the hepatocyte growth factor receptor, is a receptor tyrosine kinase overexpressed and activated in a subset of gastric cancer. Several studies investigated the relationship between MET amplification and expression with the clinical outcome in patients with gastric cancer, but yielded conflicting results. We performed a systematic review and meta-analysis to determine the influence of MET amplification and expression on prognosis in gastric cancer. Methods: MEDLINE and EMBASE were searched for studies that explored the association between MET amplification and expression with survival in patients with gastric cancer up to 1 April, 2013. Data of individual hazard ratios (HRs) and 95% confidence intervals (CIs) for meta-analyses were extracted from the publications and combined in pooled HRs. Results: Fourteen studies involving 2,258 patients with gastric cancer were included. It was suggested that MET overexpression had an unfavorable impact on survival of patients with gastric cancer, with HRs (95% CIs) of 2.57 (95% CI: 1.97-3.35) overall, 2.82 (95% CI: 1.86-4.27) among studies using amplification for measure scale of MET and 2.42 (95% CI: 1.66-3.54) for expression. The magnitude of association was reduced whereas remained statistically significant in high quality studies or in larger sample size studies and corresponding HRs were 2.18(1.76, 2.70) and 2.35(1.93, 2.87), respectively, without significant heterogeneity. Conclusion: The findings from present study indicated that higher MET gene amplification and expression in gastric cancer was an indicator of poor prognosis.	[Peng, Zhi; Zhu, Yan; Gao, Jing; Li, Yilin; Li, Yanyan; Ge, Sai; Shen, Lin] Peking Univ, Canc Hosp & Inst, Minist Educ, Dept Gastrointestinal Oncol,Key Lab Carcinogenesi, Beijing 100871, Peoples R China; [Wang, Qianqian] Peking Univ, Clin Med Coll 4, Beijing Jishuitan Hosp, Dept Epidemiol, Beijing 100871, Peoples R China	Peking University; Peking University	Shen, L (corresponding author), Peking Univ, Canc Hosp & Inst, Minist Educ, Dept Gastrointestinal Oncol,Key Lab Carcinogenesi, Beijing 100871, Peoples R China.	lin100@medmail.com.cn	Li, Yilin/AAW-9533-2021		National Natural Science Foundation of China [81172110]; National High Technology Research and Development Program [2006AA 02A 402-B02, 2012AA 02A 504]; China Postdoctoral Scientific Fund [2013M530494]; Beijing Municipal Science & Technology Commission Program "Exploring the utilization of molecular markers in the individual treatment of gastric cancer based on the clinical research cohort''	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High Technology Research and Development Program(National High Technology Research and Development Program of China); China Postdoctoral Scientific Fund; Beijing Municipal Science & Technology Commission Program "Exploring the utilization of molecular markers in the individual treatment of gastric cancer based on the clinical research cohort''	This work was supported by National Natural Science Foundation of China (No. 81172110), National High Technology Research and Development Program (No. 2006AA 02A 402-B02, 2012AA 02A 504), China Postdoctoral Scientific Fund (2013M530494) and Beijing Municipal Science & Technology Commission Program "Exploring the utilization of molecular markers in the individual treatment of gastric cancer based on the clinical research cohort''. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amemiya H, 2010, INVEST CLIN, V51, P369; Asaoka Y, 2011, EXPERT OPIN INV DRUG, V20, P595, DOI 10.1517/13543784.2011.566863; Bamias A, 2010, CANCER CHEMOTH PHARM, V65, P1009, DOI 10.1007/s00280-010-1256-6; Bang YJ, 2010, LANCET, V376, P1302; Bertuccio P, 2009, INT J CANCER, V125, P666, DOI 10.1002/ijc.24290; Catenacci DVT, 2011, CANCER BIOL THER, V12, P9, DOI 10.4161/cbt.12.1.15747; de Graeff P, 2009, BRIT J CANCER, V101, P149, DOI 10.1038/sj.bjc.6605112; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Drebber U, 2008, ONCOL REP, V19, P1477; Egger M, 1998, BMJ-BRIT MED J, V316, P61, DOI 10.1136/bmj.316.7124.61; Ge SH, 2011, CHINESE J CANCER RES, V23, P153, DOI 10.1007/s11670-011-0153-9; Gooden MJM, 2011, BRIT J CANCER, V105, P93, DOI 10.1038/bjc.2011.189; Graziano F, 2011, J CLIN ONCOL, V29, P4789, DOI 10.1200/JCO.2011.36.7706; Hayes DF, 1996, JNCI-J NATL CANCER I, V88, P1456, DOI 10.1093/jnci/88.20.1456; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Huang TJ, 2001, ACTA ONCOL, V40, P638; Janjigian YY, 2011, CANCER EPIDEM BIOMAR, V20, P1021, DOI 10.1158/1055-9965.EPI-10-1080; Jatoi Ismail, 2010, Curr Probl Surg, V47, P750, DOI 10.1067/j.cpsurg.2010.06.002; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kubicka S, 2002, DIGEST DIS SCI, V47, P114, DOI 10.1023/A:1013275706401; KUNIYASU H, 1992, BIOCHEM BIOPH RES CO, V189, P227, DOI 10.1016/0006-291X(92)91548-5; Lee HE, 2012, BRIT J CANCER, V107, P325, DOI 10.1038/bjc.2012.237; Lee J, 2011, ONCOL REP, V25, P1517, DOI 10.3892/or.2011.1219; Lennerz JK, 2011, J CLIN ONCOL, V29, P4803, DOI 10.1200/JCO.2011.35.4928; Li Y, 2012, J SURG ONCOL, V106, P304, DOI 10.1002/jso.23008; McShane LM, 2005, J CLIN ONCOL, V23, P9067, DOI 10.1200/JCO.2004.01.0454; Meert AP, 2002, EUR RESPIR J, V20, P975, DOI 10.1183/09031936.02.00296502; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Nakajima M, 1999, CANCER, V85, P1894; Oldenhuis CNAM, 2008, EUR J CANCER, V44, P946, DOI 10.1016/j.ejca.2008.03.006; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; Peters S, 2012, NAT REV CLIN ONCOL, V9, P314, DOI 10.1038/nrclinonc.2012.71; Shi J, 2012, INT J MOL SCI, V13, P4714, DOI 10.3390/ijms13044714; Sierra J Rafael, 2011, Ther Adv Med Oncol, V3, pS21, DOI 10.1177/1758834011422557; Smith RA, 2011, BRIT J CANCER, V104, P1440, DOI 10.1038/bjc.2011.110; Taniguchi K, 1998, CANCER, V82, P2112, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2112::AID-CNCR5>3.3.CO;2-U; Toiyama Y, 2012, INT J CANCER, V130, P2912, DOI 10.1002/ijc.26330; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Tsugawa K, 1998, ONCOLOGY-BASEL, V55, P475, DOI 10.1159/000011898; Wu H, 2009, CONSERV GENET RESOUR, V1, P1, DOI 10.1007/s12686-009-9000-4; Yonemura Y, 1996, INT J ONCOL, V8, P555; Yonemura Y, 1997, ONCOL REP, V4, P743; Zhao J, 2011, HISTOL HISTOPATHOL, V26, P1111, DOI 10.14670/HH-26.1111; Zhuang X, 2000, Zhonghua Bing Li Xue Za Zhi, V29, P409	44	137	147	2	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 8	2014	9	1							e84502	10.1371/journal.pone.0084502	http://dx.doi.org/10.1371/journal.pone.0084502			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	291WL	24416238	Green Submitted, gold, Green Published			2023-01-03	WOS:000329862500132
J	Chen, YP; Chiao, CC				Chen, Yin-Peng; Chiao, Chuan-Chin			Spatial Distribution of Excitatory Synapses on the Dendrites of Ganglion Cells in the Mouse Retina	PLOS ONE			English	Article							PRIMATE RETINA; CAT RETINA; POSTSYNAPTIC DENSITIES; DIRECTION-SELECTIVITY; QUANTITATIVE-ANALYSIS; RECEPTOR SUBUNITS; MACAQUE RETINA; RABBIT RETINA; BIPOLAR CELLS; TOTAL NUMBER	Excitatory glutamatergic inputs from bipolar cells affect the physiological properties of ganglion cells in the mammalian retina. The spatial distribution of these excitatory synapses on the dendrites of retinal ganglion cells thus may shape their distinct functions. To visualize the spatial pattern of excitatory glutamatergic input into the ganglion cells in the mouse retina, particle-mediated gene transfer of plasmids expressing postsynaptic density 95-green fluorescent fusion protein (PSD95-GFP) was used to label the excitatory synapses. Despite wide variation in the size and morphology of the retinal ganglion cells, the expression of PSD95 puncta was found to follow two general rules. Firstly, the PSD95 puncta are regularly spaced, at 1-2 mu m intervals, along the dendrites, whereby the presence of an excitatory synapse creates an exclusion zone that rules out the presence of other glutamatergic synaptic inputs. Secondly, the spatial distribution of PSD95 puncta on the dendrites of diverse retinal ganglion cells are similar in that the number of excitatory synapses appears to be less on primary dendrites and to increase to a plateau on higher branch order dendrites. These observations suggest that synaptogenesis is spatially regulated along the dendritic segments and that the number of synaptic contacts is relatively constant beyond the primary dendrites. Interestingly, we also found that the linear puncta density is slightly higher in large cells than in small cells. This may suggest that retinal ganglion cells with a large dendritic field tend to show an increased connectivity of excitatory synapses that makes up for their reduced dendrite density. Mapping the spatial distribution pattern of the excitatory synapses on retinal ganglion cells thus provides explicit structural information that is essential for our understanding of how excitatory glutamatergic inputs shape neuronal responses.	[Chen, Yin-Peng; Chiao, Chuan-Chin] Natl Tsing Hua Univ, Inst Syst Neurosci, Hsinchu, Taiwan; [Chiao, Chuan-Chin] Natl Tsing Hua Univ, Dept Life Sci, Hsinchu, Taiwan	National Tsing Hua University; National Tsing Hua University	Chiao, CC (corresponding author), Natl Tsing Hua Univ, Inst Syst Neurosci, Hsinchu, Taiwan.	ccchiao@life.nthu.edu.tw	Chiao, Chuan-Chin/L-7708-2019; Chen, Yeng/A-6873-2011	Chen, Yeng/0000-0002-0064-7678	National Science Council of Taiwan [NSC-98-2311-B-007-004-MY3, NSC-101-2628-B-007-001-MY3]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan)	This study was supported by the National Science Council of Taiwan NSC-98-2311-B-007-004-MY3 and NSC-101-2628-B-007-001-MY3 (to CCC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arnold DB, 1999, NEURON, V23, P149, DOI 10.1016/S0896-6273(00)80761-8; Badea TC, 2004, J COMP NEUROL, V480, P331, DOI 10.1002/cne.20304; Briggman KL, 2011, NATURE, V471, P183, DOI 10.1038/nature09818; Calkins DJ, 1998, J NEUROSCI, V18, P3373; Calkins DJ, 1996, NATURE, V381, P613, DOI 10.1038/381613a0; Chen YP, 2012, BRAIN RES, V1427, P10, DOI 10.1016/j.brainres.2011.10.019; COHEN E, 1991, J NEUROPHYSIOL, V65, P352, DOI 10.1152/jn.1991.65.2.352; Coombs J, 2006, NEUROSCIENCE, V140, P123, DOI 10.1016/j.neuroscience.2006.02.079; De la Huerta I, 2012, P NATL ACAD SCI USA, V109, P17663, DOI 10.1073/pnas.1215806109; Ebihara T, 2003, J NEUROSCI, V23, P2170; FREED MA, 1988, J NEUROSCI, V8, P2303; Garcia-Lopez P, 2006, J NEUROSCI, V26, P11249, DOI 10.1523/JNEUROSCI.3543-06.2006; Gartland AJ, 2011, J NEUROSCI, V31, P18353, DOI 10.1523/JNEUROSCI.4212-11.2011; Gulyas AI, 1999, J NEUROSCI, V19, P10082; Huberman AD, 2009, NEURON, V62, P327, DOI 10.1016/j.neuron.2009.04.014; Jacoby R, 1996, J NEUROSCI, V16, P8041; Jakobs TC, 2008, J COMP NEUROL, V510, P221, DOI 10.1002/cne.21795; Jeon CJ, 2002, J COMP NEUROL, V449, P195, DOI 10.1002/cne.10288; Jusuf PR, 2006, J COMP NEUROL, V494, P260, DOI 10.1002/cne.20804; Kay JN, 2011, J NEUROSCI, V31, P7753, DOI 10.1523/JNEUROSCI.0907-11.2011; Kim IJ, 2008, NATURE, V452, P478, DOI 10.1038/nature06739; Klug K, 2003, J NEUROSCI, V23, P9881; Koizumi A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000221; Koizumi A, 2011, J COMP NEUROL, V519, P341, DOI 10.1002/cne.22522; Kong JH, 2005, J COMP NEUROL, V489, P293, DOI 10.1002/cne.20631; Lin B, 2002, VISUAL NEUROSCI, V19, P453, DOI 10.1017/S0952523802194077; Lin B, 2000, EUR J NEUROSCI, V12, P4155, DOI 10.1111/j.1460-9568.2000.01311.x; Lye Ming H, 2007, J Vis Exp, P190, DOI 10.3791/190; MacNeil MA, 2004, J COMP NEUROL, V472, P73, DOI 10.1002/cne.20063; Macri J, 2000, VISUAL NEUROSCI, V17, P437, DOI 10.1017/S0952523800173109; Marshak DW, 2002, VISUAL NEUROSCI, V19, P299, DOI 10.1017/S0952523802192078; Masland RH, 2012, NEURON, V76, P266, DOI 10.1016/j.neuron.2012.10.002; MCGUIRE BA, 1986, J NEUROSCI, V6, P907; Megias M, 2001, NEUROSCIENCE, V102, P527, DOI 10.1016/S0306-4522(00)00496-6; Morgan JL, 2008, NEURAL DEV, V3, DOI 10.1186/1749-8104-3-8; Moritoh S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054667; Moritoh S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012917; Oesch N, 2005, NEURON, V47, P739, DOI 10.1016/j.neuron.2005.06.036; Qin LX, 2001, J COMP NEUROL, V440, P284, DOI 10.1002/cne.1386; Sanchez AL, 2006, DEVELOPMENT, V133, P2477, DOI 10.1242/dev.02409; Schubert T, 2005, J COMP NEUROL, V490, P29, DOI 10.1002/cne.20621; Schubert T, 2005, J COMP NEUROL, V485, P191, DOI 10.1002/cne.20510; Soto F, 2011, NEURAL DEV, V6, DOI 10.1186/1749-8104-6-31; STERLING P, 1983, ANNU REV NEUROSCI, V6, P149, DOI 10.1146/annurev.ne.06.030183.001053; Sun WZ, 2002, J COMP NEUROL, V451, P115, DOI 10.1002/cne.10323; Taylor W, 2011, CURR OPIN NEUROBIOL; Taylor WR, 2000, SCIENCE, V289, P2347, DOI 10.1126/science.289.5488.2347; Volgyi B, 2009, J COMP NEUROL, V512, P664, DOI 10.1002/cne.21912; Volgyi B, 2005, J COMP NEUROL, V492, P66, DOI 10.1002/cne.20700; Wassle H, 2009, J NEUROSCI, V29, P106, DOI 10.1523/JNEUROSCI.4442-08.2009; Weng SJ, 2005, J PHYSIOL-LONDON, V562, P915, DOI 10.1113/jphysiol.2004.076695; Xu Y, 2008, J COMP NEUROL, V507, P1871, DOI 10.1002/cne.21644; Zhang J, 2006, J COMP NEUROL, V498, P810, DOI 10.1002/cne.21089	53	84	87	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2014	9	1							e86159	10.1371/journal.pone.0086159	http://dx.doi.org/10.1371/journal.pone.0086159			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297EA	24465934	Green Published, gold, Green Submitted			2023-01-03	WOS:000330237000088
J	Chen, XX; Shi, Y; Chai, WM; Feng, HL; Zhuang, JX; Chen, QX				Chen, Xiao-Xin; Shi, Yan; Chai, Wei-Ming; Feng, Hui-Ling; Zhuang, Jiang-Xing; Chen, Qing-Xi			Condensed Tannins from Ficus virens as Tyrosinase Inhibitors: Structure, Inhibitory Activity and Molecular Mechanism	PLOS ONE			English	Article							TOF MS ANALYSIS; MUSHROOM TYROSINASE; SKIN; PIGMENTATION; DOPAMINE; KINETICS; LEAVES; IONS; HPLC; NMR	Condensed tannins from Ficus virens leaves, fruit, and stem bark were isolated and their structures characterized by C-13 nuclear magnetic resonance spectrometry, high performance liquid chromatography electrospray ionization mass spectrometry, and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. The results showed that the leaves, fruit, and stem bark condensed tannins were complex mixtures of homo-and heteropolymers of B-type procyanidins and prodelphinidins with degrees of polymerization up to hexamer, dodecamer, and pentadecamer, respectively. Antityrosinase activities of the condensed tannins were studied. The results indicated that the condensed tannins were potent tyrosinase inhibitors. The concentrations for the leaves, fruit, and stem bark condensed tannins leading to 50% enzyme activity were determined to be 131.67, 99.89, and 106.22 mu g/ml on monophenolase activity, and 128.42, 43.07, and 74.27 mu g/ml on diphenolase activity. The inhibition mechanism, type, and constants of the condensed tannins on the diphenolase activity were further investigated. The results indicated that the condensed tannins were reversible and mixed type inhibitors. Fluorescence quenching, copper interacting, and molecular docking techniques were utilized to unravel the molecular mechanisms of the inhibition. The results showed that the hydroxyl group on the B ring of the condensed tannins could chelate the dicopper irons of the enzyme. Moreover, the condensed tannins could reduce the enzyme product o-quinones into colourless compounds. These results would contribute to the development and design of antityrosinase agents.	[Chen, Xiao-Xin; Shi, Yan; Chai, Wei-Ming; Feng, Hui-Ling; Chen, Qing-Xi] Xiamen Univ, Sch Life Sci, Key Lab, Minist Educ Coastal & Wetland Ecosyst, Xiamen, Peoples R China; [Zhuang, Jiang-Xing] Xiamen Univ, Coll Med, Fujian Prov Key Lab Neurodegenerat Dis & Aging Re, Xiamen, Peoples R China	Xiamen University; Xiamen University	Zhuang, JX (corresponding author), Xiamen Univ, Coll Med, Fujian Prov Key Lab Neurodegenerat Dis & Aging Re, Xiamen, Peoples R China.	jiangxingzhuang@xmu.edu.cn; chenqx@xmu.edu.cn	Zhang, Anthony Lin/AAR-6673-2021; Yang, Kun/A-4293-2010; Chen, Xin-Zu/G-6579-2014; Xue, Charlie C/F-1244-2014; Chen, Xin-Zu/K-2988-2019	Zhang, Anthony Lin/0000-0002-0968-9380; Xue, Charlie/0000-0001-6937-9088; May, Brian/0000-0002-5864-3020; Chen, Xiankun/0000-0002-0353-4185; , Zongguang/0000-0002-7616-1199; Chen, Xin-lin/0000-0002-2650-8051	Natural Science Foundation of China [31071611, 31070522]; National Science Foundation for Fostering Talents in Basic Research of the National Natural Science Foundation of China [J1310027/J0106]; Science and Technology Foundation of Fujian Province [2010N5013]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038329, R21HD061763, R01HD018269] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [R01MD007828] Funding Source: NIH RePORTER	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science Foundation for Fostering Talents in Basic Research of the National Natural Science Foundation of China; Science and Technology Foundation of Fujian Province(Natural Science Foundation of Fujian Province); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	The present investigation was supported by the Natural Science Foundation of China (No. 31071611; No. 31070522), the National Science Foundation for Fostering Talents in Basic Research of the National Natural Science Foundation of China (Grant No. J1310027/J0106) and by the Science and Technology Foundation of Fujian Province (No. 2010N5013). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdel-Hameed ESS, 2009, FOOD CHEM, V114, P1271, DOI 10.1016/j.foodchem.2008.11.005; Anandjiwala S, 2008, INDIAN J PHARM SCI, V70, P31, DOI 10.4103/0250-474X.40328; Asanuma M, 2003, NEUROTOX RES, V5, P165, DOI 10.1007/BF03033137; Baby Joseph, 2010, International Journal of Pharma and Bio Sciences, V1, pP; Bawadi HA, 2005, CANCER LETT, V218, P153, DOI 10.1016/j.canlet.2004.06.021; Chai WM, 2012, J AGR FOOD CHEM, V60, P5013, DOI 10.1021/jf300740d; Chauhan S, 2013, J MED PLANTS STUD, V1, P3846; Chen QX, 2005, FOOD CHEM, V91, P269, DOI 10.1016/j.foodchem.2004.01.078; Chen XX, 2014, FOOD CHEM, V155, P1, DOI 10.1016/j.foodchem.2014.01.011; Chen XX, 2013, INT J BIOL MACROMOL, V62, P726, DOI 10.1016/j.ijbiomac.2013.09.052; Chen XX, 2013, J ZHEJIANG UNIV-SC B, V14, P903, DOI 10.1631/jzus.B1200365; Choi H, 2005, PIGM CELL RES, V18, P439, DOI 10.1111/j.1600-0749.2005.00266.x; Espin JC, 2001, BBA-PROTEIN STRUCT M, V1544, P289, DOI 10.1016/S0167-4838(00)00230-2; Chiari ME, 2011, BIOORGAN MED CHEM, V19, P3474, DOI 10.1016/j.bmc.2011.04.025; Haslam E., 1989, Plant polyphenols: vegetable tannins revisited.; Hummer W, 2008, MOL NUTR FOOD RES, V52, P1381, DOI 10.1002/mnfr.200700463; Jimenez M, 2001, J AGR FOOD CHEM, V49, P4060, DOI 10.1021/jf010194h; Khatib S, 2007, J MED CHEM, V50, P2676, DOI 10.1021/jm061361d; Kim D, 2006, J AGR FOOD CHEM, V54, P935, DOI 10.1021/jf0521855; Kim YJ, 2005, CELL MOL LIFE SCI, V62, P1707, DOI 10.1007/s00018-005-5054-y; Kubo I, 1999, J AGR FOOD CHEM, V47, P4121, DOI 10.1021/jf990201q; Lee N, 2012, ACS CHEM BIOL, V7, P1687, DOI 10.1021/cb300222b; Lim YY, 2007, LWT-FOOD SCI TECHNOL, V40, P1664, DOI 10.1016/j.lwt.2006.12.013; Lin JY, 2007, NATURE, V445, P843, DOI 10.1038/nature05660; Matoba Y, 2006, J BIOL CHEM, V281, P8981, DOI 10.1074/jbc.M509785200; McDonald M, 1996, J AGR FOOD CHEM, V44, P599, DOI 10.1021/jf950459q; Niranjan S, 2012, GLOBAL J PHARM RES, V1, P318; Sanjust E, 2003, ARCH BIOCHEM BIOPHYS, V412, P272, DOI 10.1016/S0003-9861(03)00053-5; Santos-Buelga C, 2000, J SCI FOOD AGR, V80, P1094, DOI [10.1002/(SICI)1097-0010(20000515)80:7<1094::AID-JSFA569>3.3.CO;2-T, 10.1002/(SICI)1097-0010(20000515)80:7&lt;1094::AID-JSFA569&gt;3.0.CO;2-1]; Sisti M, 2008, LWT-FOOD SCI TECHNOL, V41, P946, DOI 10.1016/j.lwt.2007.05.012; Slominski A, 2004, PHYSIOL REV, V84, P1155, DOI 10.1152/physrev.00044.2003; Slominski A, 2012, PIGM CELL MELANOMA R, V25, P14, DOI 10.1111/j.1755-148X.2011.00898.x; Takahashi S, 2010, BIOORGAN MED CHEM, V18, P8112, DOI 10.1016/j.bmc.2010.08.056; Tanner GJ, 2003, J BIOL CHEM, V278, P31647, DOI 10.1074/jbc.M302783200; Xiang P, 2006, CHINESE J ANAL CHEM, V34, P1019, DOI 10.1016/S1872-2040(06)60047-9; Xu YM, 1998, J NEUROSCI RES, V54, P691, DOI 10.1002/(SICI)1097-4547(19981201)54:5<691::AID-JNR14>3.0.CO;2-F; Zhang LL, 2008, MOLECULES, V13, P2986, DOI 10.3390/molecules13122986; Zhuang JX, 2010, J AGR FOOD CHEM, V58, P12993, DOI 10.1021/jf103723k	38	337	358	33	74	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 17	2014	9	3							e91809	10.1371/journal.pone.0091809	http://dx.doi.org/10.1371/journal.pone.0091809			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AD4XD	24622390	gold, Green Published, Green Submitted			2023-01-03	WOS:000333254100063
J	Chen, XH; Scholl, TO				Chen, Xinhua; Scholl, Theresa O.			Maternal Biomarkers of Endothelial Dysfunction and Preterm Delivery	PLOS ONE			English	Article							CARDIOVASCULAR-DISEASE; ADHESION MOLECULE-1; RETROSPECTIVE COHORT; HEART-DISEASE; UNITED-STATES; SE-SELECTIN; PREECLAMPSIA; RISK; WOMEN; INFLAMMATION	Background: Endothelial dysfunction is key to the development of atherosclerosis. Preterm delivery foreshadows later maternal cardiovascular disease (CVD), but it is not known if endothelial dysfunction also occurs. We prospectively measured circulating biomarkers of endothelial dysfunction in pregnant women with preterm or term delivery. Methods: We conducted a case-control study nested within a large prospective epidemiological study of young, generally healthy pregnant women. Women who delivered preterm (, 37 completed weeks gestation, n = 240) and controls who delivered at term (n = 439) were included. Pregnancies complicated by preeclampsia were analyzed separately. Circulating endothelial dysfunction biomarkers included soluble intercellular adhesion molecule-1 (sICAM-1), vascular cell adhesion molecule-1 (sVCAM-1) and soluble E-selectin (sE-selectin). Results: Elevated levels of sICAM-1 and sVCAM-1 were positively associated with preterm delivery independent of usual risk factors. At entry (similar to 16 wks), the adjusted odds ratio (AOR) was 1.73 (95% confidence interval (CI) 1.09-2.74) for the highest quartile of sICAM-1 versus the lowest quartile and for sVCAM-1 the AOR was 2.17 (95% CI 1.36-3.46). When analysis was limited to cases with a spontaneous preterm delivery, the results were unchanged. Similar results were obtained for the 3rd trimester (similar to 30 wks). Elevated sE-selectin was increased only in preterm delivery complicated by preeclampsia; risk was increased at entry (AOR 2.32, 95% CI 1.22-4.40) and in the 3rd trimester (AOR 3.37, 95% CI 1.78-6.39). Conclusions: Impaired endothelial function as indicated by increased levels of soluble molecules commonly secreted by endothelial cells is a pathogenic precursor to CVD that is also present in women with preterm delivery. Our findings underscore the need for follow-up studies to determine if improving endothelial function prevents later CVD risk in women.	[Chen, Xinhua; Scholl, Theresa O.] Rowan Univ, Sch Osteopath Med, Dept Obstet & Gynecol, Stratford, NJ 08084 USA	Rowan University; Rowan University School of Osteopathic Medicine	Chen, XH (corresponding author), Rowan Univ, Sch Osteopath Med, Dept Obstet & Gynecol, Stratford, NJ 08084 USA.	chenx1@rowan.edu	Zhang, Anthony Lin/AAR-6673-2021; Yang, Kun/A-4293-2010; Chen, Xin-Zu/G-6579-2014; Xue, Charlie C/F-1244-2014; Chen, Xin-Zu/K-2988-2019	Zhang, Anthony Lin/0000-0002-0968-9380; Xue, Charlie/0000-0001-6937-9088; May, Brian/0000-0002-5864-3020; Chen, Xiankun/0000-0002-0353-4185; , Zongguang/0000-0002-7616-1199; Chen, Xin-lin/0000-0002-2650-8051	National Institute of Child Health and Human Development [HD061763, HD18269, HD38329]; National Institute on Minority Health and Health Disparities [1R01MD007828]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038329, R21HD061763, R01HD018269] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [R01MD007828] Funding Source: NIH RePORTER	National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	This work was supported by research grants from the National Institute of Child Health and Human Development (HD061763 to Chen; HD18269 and HD38329 to Scholl) and the National Institute on Minority Health and Health Disparities (1R01MD007828 to Chen). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agatisa PK, 2004, AM J PHYSIOL-HEART C, V286, pH1389, DOI 10.1152/ajpheart.00298.2003; [Anonymous], 2006, INCOME EARNINGS POVE; Bartha JL, 2012, J WOMENS HEALTH, V21, P643, DOI 10.1089/jwh.2011.3013; Blankenberg S, 2003, ATHEROSCLEROSIS, V170, P191, DOI 10.1016/S0021-9150(03)00097-2; Bonamy AKE, 2011, CIRCULATION, V124, P2839, DOI 10.1161/CIRCULATIONAHA.111.034884; Caughey AB, 2005, OBSTET GYNECOL, V106, P156, DOI 10.1097/01.AOG.0000164478.91731.06; Chaiworapongsa T, 2002, J Matern Fetal Neonatal Med, V12, P19; Chambers JC, 2001, JAMA-J AM MED ASSOC, V285, P1607, DOI 10.1001/jama.285.12.1607; Clapp BR, 2004, CARDIOVASC RES, V64, P172, DOI 10.1016/j.cardiores.2004.06.020; Frieden Thomas R, 2011, MMWR Suppl, V60, P1; Glowinska B, 2005, METABOLISM, V54, P1020, DOI 10.1016/j.metabol.2005.03.004; Goldenberg RL, 2008, LANCET, V371, P75, DOI 10.1016/S0140-6736(08)60074-4; Gong J, 2012, PAEDIATR PERINAT EP, V26, P45, DOI 10.1111/j.1365-3016.2011.01222.x; Hamilton SJ, 2009, DIABETES CARE, V32, P810, DOI 10.2337/dc08-1736; Hastie CE, 2011, INT J EPIDEMIOL, V40, P914, DOI 10.1093/ije/dyq270; Hediger ML, 1997, ANN EPIDEMIOL, V7, P400, DOI 10.1016/S1047-2797(97)00046-X; Jenny NS, 2006, J THROMB HAEMOST, V4, P107, DOI 10.1111/j.1538-7836.2005.01678.x; Kim C, 2002, DIABETES CARE, V25, P1862, DOI 10.2337/diacare.25.10.1862; Kim SY, 2004, J KOREAN MED SCI, V19, P688, DOI 10.3346/jkms.2004.19.5.688; Magnussen EB, 2007, BRIT MED J, V335, P978, DOI 10.1136/bmj.39366.416817.BE; Martin Joyce A., 2011, Morbidity and Mortality Weekly Report, V60, P78; Marvin KW, 2000, AM J REPROD IMMUNOL, V43, P264, DOI 10.1111/j.8755-8920.2000.430504.x; Meigs JB, 2004, JAMA-J AM MED ASSOC, V291, P1978, DOI 10.1001/jama.291.16.1978; Pell JP, 2004, AM J EPIDEMIOL, V159, P336, DOI 10.1093/aje/kwh064; Pina IL, 2011, CARDIOL REV, V19, P71, DOI 10.1097/CRD.0b013e318209c233; Roberts JM, 2003, HYPERTENSION, V41, P437, DOI 10.1161/01.HYP.0000054981.03589.E9; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Steinborn A, 2000, OBSTET GYNECOL, V95, P671, DOI 10.1016/S0029-7844(99)00604-3; Stewart FM, 2007, J CLIN ENDOCR METAB, V92, P969, DOI 10.1210/jc.2006-2083; Veas CJ, 2011, J MATERN-FETAL NEO M, V24, P1371, DOI 10.3109/14767058.2011.556204; Velez DR, 2009, AJOG, V200; Wei SQ, 2010, OBSTET GYNECOL, V116, P393, DOI 10.1097/AOG.0b013e3181e6dbc0; Wolf M, 2004, J CLIN ENDOCR METAB, V89, P6239, DOI 10.1210/jc.2004-0548	33	337	358	33	74	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 22	2014	9	1							e85716	10.1371/journal.pone.0085716	http://dx.doi.org/10.1371/journal.pone.0085716			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297VL	24622390	Green Submitted, gold, Green Published			2023-01-03	WOS:000330283100065
J	Chen, XK; May, B; Di, YM; Zhang, AL; Lu, CJ; Xue, CC; Lin, L				Chen, Xiankun; May, Brian; Di, Yuan Ming; Zhang, Anthony Lin; Lu, Chuanjian; Xue, Charlie Changli; Lin, Lin			Oral Chinese Herbal Medicine Combined with Pharmacotherapy for Stable COPD: A Systematic Review of Effect on BODE Index and Six Minute Walk Test	PLOS ONE			English	Review							OBSTRUCTIVE PULMONARY-DISEASE; QUALITY-OF-LIFE; CORDYCEPS-SINENSIS; ASTRAGALUS-MEMBRANACEUS; DISTANCE; COMPLEMENTARY; MANAGEMENT; PREDICTOR; CAPACITY; OUTCOMES	This systematic review evaluated the effects of Chinese herbal medicine (CHM) plus routine pharmacotherapy (RP) on the objective outcome measures BODE index, 6-minute walk test (6MWT), and 6-minute walk distance (6MWD) in individuals with stable chronic obstructive pulmonary disease (COPD). Searches were conducted of six English and Chinese databases (PubMed, EMBASE, CENTRAL, CINAHL, CNKI and CQVIP) from their inceptions until 18th November 2013 for randomized controlled trials involving oral administration of CHM plus RP compared to the same RP, with BODE Index and/or 6MWT/D as outcomes. Twenty-five studies were identified. BODE Index was used in nine studies and 6MWT/D was used in 22 studies. Methodological quality was assessed using the Cochrane Risk of Bias tool. Weaknesses were identified in most studies. Six studies were judged as 'low' risk of bias for randomisation sequence generation. Twenty-two studies involving 1,834 participants were included in the meta-analyses. The main meta-analysis results showed relative benefits for BODE Index in nine studies (mean difference [MD] -0.71, 95% confidence interval [CI] -0.94, -0.47) and 6MWT/D in 17 studies (MD 54.61 meters, 95% CI 33.30, 75.92) in favour of the CHM plus RP groups. The principal plants used were Astragalus membranaceus, Panax ginseng and Cordyceps sinensis. A. membranaceus was used in combination with other herbs in 18 formulae in 16 studies. Detailed sub-group and sensitivity analyses were conducted. Clinically meaningful benefits for BODE Index and 6MWT were found in multiple studies. These therapeutic effects were promising but need to be interpreted with caution due to variations in the CHMs and RPs used and methodological weakness in the studies. These issues should be addressed in future trials.	[Chen, Xiankun] Guangdong Prov Acad Chinese Med Sci, Evidence Based Med & Clin Res Serv Grp, Guangzhou, Guangdong, Peoples R China; [Chen, Xiankun; Lu, Chuanjian; Xue, Charlie Changli] Guangdong Prov Hosp Chinese Med, Guangzhou, Guangdong, Peoples R China; [May, Brian; Di, Yuan Ming; Zhang, Anthony Lin; Xue, Charlie Changli] RMIT Univ, Sch Hlth Sci, Hlth Innovat Res Inst, Tradit & Complementary Med Res Program, Melbourne, Vic, Australia; [Lu, Chuanjian; Xue, Charlie Changli] Guangdong Prov Acad Chinese Med Sci, Guangzhou, Guangdong, Peoples R China; [Lin, Lin] Guangdong Prov Hosp Chinese Med, Dept Resp Med, Guangzhou, Guangdong, Peoples R China	Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Royal Melbourne Institute of Technology (RMIT); Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine	Lin, L (corresponding author), Guangdong Prov Hosp Chinese Med, Dept Resp Med, Guangzhou, Guangdong, Peoples R China.	drlinlin620@163.com	Zhang, Anthony Lin/AAR-6673-2021; Yang, Kun/A-4293-2010; Chen, Xin-Zu/G-6579-2014; Xue, Charlie C/F-1244-2014; Chen, Xin-Zu/K-2988-2019	Zhang, Anthony Lin/0000-0002-0968-9380; Xue, Charlie/0000-0001-6937-9088; May, Brian/0000-0002-5864-3020; Chen, Xiankun/0000-0002-0353-4185; , Zongguang/0000-0002-7616-1199; Chen, Xin-lin/0000-0002-2650-8051	International Science & Technology Cooperation Project of the Ministry of Science and Technology of China [2012DFA31760]; China-Australia International Research Centre for Chinese Medicine; Guangdong Provincial Academy of Chinese Medical Sciences & Guangdong Provincial Hospital of Chinese Medicine (GPACMS GPHCM); Guangdong China; RMIT University, Australia; GPHCM; School of Health Sciences, RMIT University; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038329, R21HD061763, R01HD018269] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [R01MD007828] Funding Source: NIH RePORTER	International Science & Technology Cooperation Project of the Ministry of Science and Technology of China; China-Australia International Research Centre for Chinese Medicine; Guangdong Provincial Academy of Chinese Medical Sciences & Guangdong Provincial Hospital of Chinese Medicine (GPACMS GPHCM); Guangdong China; RMIT University, Australia; GPHCM; School of Health Sciences, RMIT University; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	This study is funded by a project grant from the International Science & Technology Cooperation Project of the Ministry of Science and Technology of China (Project Grant Number: 2012DFA31760, Project Title: Evaluation of Traditional and Scientific Evidence of Chinese Medicine). The project is partially supported by the China-Australia International Research Centre for Chinese Medicine, funded by Guangdong Provincial Academy of Chinese Medical Sciences & Guangdong Provincial Hospital of Chinese Medicine (GPACMS & GPHCM), Guangdong China, and RMIT University, Australia. The authors also acknowledge the support provided by the GPHCM and the School of Health Sciences, RMIT University to the first author (XKC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Thoracic Society, 1999, AM J RESP CRIT CARE, V159, P1666; An XD, 2012, J ALTERN COMPLEM MED, V18, P731, DOI 10.1089/acm.2011.0389; An XD, 2011, RESP MED, V105, P165, DOI 10.1016/j.rmed.2010.11.007; Brown Cynthia D, 2007, COPD, V4, P217; Celli BR, 2004, NEW ENGL J MED, V350, P1005, DOI 10.1056/NEJMoa021322; Chan E, 2010, CURR OPIN DRUG DISC, V13, P50; Chen GC, 2012, SHANGHAI J TRADITION, V46, P42; Chen Ning, 2009, Zhong Xi Yi Jie He Xue Bao, V7, P105, DOI 10.3736/jcim20090202; Chen Q, 2009, J FUJIAN U TRAD CHIN, V19, P12; Cote CG, 2008, EUR RESPIR J, V31, P571, DOI 10.1183/09031936.00104507; Cote CG, 2005, EUR RESPIR J, V26, P630, DOI 10.1183/09031936.05.00045505; CSRD, 2007, CHIN J INRERN MED, V46, P254; Cui Peng, 2012, Zhongguo Zhong Yao Za Zhi, V37, P3451; Cui Zhao-bo, 2004, Zhongguo Zhong Xi Yi Jie He Za Zhi, V24, P885; Denzler KL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012561; Faganello MM, 2010, AM J MED SCI, V339, P10, DOI 10.1097/MAJ.0b013e3181bb8111; Fan BD, 2012, J SICHUAN TRADITIONA, P83; George J, 2004, MED J AUSTRALIA, V181, P248, DOI 10.5694/j.1326-5377.2004.tb06262.x; Glaab T, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-79; Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2011, GLOB STRAT DIAGN MAN; Guo WX, 2008, HEBEI J TRADITIONAL, V30, P121; Holland AE, 2010, ARCH PHYS MED REHAB, V91, P221, DOI 10.1016/j.apmr.2009.10.017; Hu J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028696; Hu QG, 2012, J GUIYANG COLLAGE TR, V34, P135; [黄东晖 Huang Donghui], 2005, [第四军医大学学报, Journal of the Fourth Military Medical University], V26, P1611; Imfeld S, 2006, CHEST, V129, P873, DOI 10.1378/chest.129.4.873; Jian XY, 2012, J BEIJING U TRADITIO, V19, P32; Jones PW, 2001, THORAX, V56, P880, DOI 10.1136/thorax.56.11.880; Kim HG, 2006, EUR J PHARMACOL, V545, P192, DOI 10.1016/j.ejphar.2006.06.047; Koh JH, 2002, BIOSCI BIOTECH BIOCH, V66, P407, DOI 10.1271/bbb.66.407; Kumar R, 2011, J ETHNOPHARMACOL, V136, P260, DOI 10.1016/j.jep.2011.04.040; Kuo YH, 2009, J ETHNOPHARMACOL, V122, P28, DOI 10.1016/j.jep.2008.11.025; Kuo YC, 1996, AM J CHINESE MED, V24, P111, DOI 10.1142/S0192415X96000165; Kuo YC, 2001, LIFE SCI, V68, P1067, DOI 10.1016/S0024-3205(00)01011-0; Li CY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040824; Li SY, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-197; Liang AW, 2013, J EMERGENCY TRADITIO, P1125; Liao Y.L., 2011, HERALD MED, V30, P63; Lin YZ, 2013, CHINESE MANIPULATION, P103; Liu CS, 2009, GUIDING J TRADITIONA, V11, P10; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Mansori F, 2010, CLIN RESPIR J, V4, P241, DOI 10.1111/j.1752-699X.2010.00185.x; Marin JM, 2011, RESP MED, V105, P916, DOI 10.1016/j.rmed.2011.01.007; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Ong KC, 2005, CHEST, V128, P3810, DOI 10.1378/chest.128.6.3810; Peng ZQ, 2013, THESIS FUJIAN U TRAD; Pinto-Plata V, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-71; Pinto-Plata VM, 2004, EUR RESPIR J, V23, P28, DOI 10.1183/09031936.03.00034603; Qaseem A, 2011, ANN INTERN MED, V155, P179, DOI 10.7326/0003-4819-155-3-201108020-00008; Rao YK, 2007, J ETHNOPHARMACOL, V114, P78, DOI 10.1016/j.jep.2007.07.028; Shahed AR, 2001, TRANSPL P, V33, P2986, DOI 10.1016/S0041-1345(01)02282-5; Shan LN, 2011, J GUANGZHOU U TRADIT, V28, P590; Shang QH, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/716459; Shao BM, 2004, BIOCHEM BIOPH RES CO, V320, P1103, DOI 10.1016/j.bbrc.2004.06.065; Shergis JL, 2013, PHYTOTHER RES, V27, P949, DOI 10.1002/ptr.4832; Shin IS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045734; Spruit MA, 2012, J AM MED DIR ASSOC, V13, P291, DOI 10.1016/j.jamda.2011.06.009; Vickers A, 1999, BRIT MED J, V319, P1050, DOI 10.1136/bmj.319.7216.1050; Wise Robert A, 2005, COPD, V2, P125; Wu L, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/705315; Xu JZ, 2012, YUNNAN J TRADITIONAL, V33, P31; Xu TingZhen, 2012, Chinese Archives of Traditional Chinese Medicine, V30, P570; Yang CM, 2013, MODERN J INTEGRATED, P729; Yu JY, 2011, J MED INFORM, P4019; Zeng JQ, 2013, J NEW CHINESE MED, P32; Zhang FY, 2007, SHANXI ZHONGYI J, V28, P1594; Zhang FY, 2007, J EMERGENCY TRADITIO, V19, P198; Zhang R.Z., 2011, CHINA PRACTICAL MED, V6, P118; Zhao YL, 2012, J TRADIT CHIN MED, V32, P203, DOI 10.1016/S0254-6272(13)60012-6; 茅蓉, 2009, [中国中西医结合杂志, Chinese Journal of Integrated Traditional and Western Medicine], V29, P362	70	337	358	33	74	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2014	9	3							e91830	10.1371/journal.pone.0091830	http://dx.doi.org/10.1371/journal.pone.0091830			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC9HN	24622390	gold, Green Submitted, Green Published			2023-01-03	WOS:000332845300132
J	Chen, XF; Li, LZ; Zhou, T; Li, ZZ				Chen, Xiaofang; Li, Lezhi; Zhou, Tao; Li, Zhanzhan			Prevalence of Hypertension in Rural Areas of China: A Meta-Analysis of Published Studies	PLOS ONE			English	Article							STAGE RENAL-DISEASE; BLOOD-PRESSURE; RISK-FACTORS; MEN; AWARENESS; MORTALITY	Background: Hypertension is one of the leading causes of disease burden across the world. In China, the latest nationwide survey of prevalence of hypertension was ten year ago, and data in rural areas is little known. More information about hypertension prevalence could help to improve overall antihypertensive health care. We aimed to estimate the pooled prevalence of hypertension in rural areas of China. Methods: Comprehensive electronic searches of PubMed, Web of Knowledge, Chinese Web of Knowledge, Wangfang, Weipu and SinoMed databases were conducted to identify any study in each database published from January 1, 2004 to December 31, 2013, reporting the prevalence of hypertension in Chinese rural areas. Prevalence estimates were stratified by age, area, sex, publication year, and sample size. All statistical calculations were made using the Stata Version 11.0 (College Station, Texas) and Statsdirect Version 2.7.9. Results: We identified 124 studies with a total population of 3,735,534 in the present meta-analysis. Among people aged 18 years old in Chinese rural areas, the summarized prevalence is 22.81% (19.41%-26.41%). Subgroup analysis shows the following results: for male 24.46% (21.19%-27.89%, for female 22.17% (18.25%-26.35%). For 2004-2006: 18.94% (14.41%-23.94%), for 2007-2009, 21.24% (15.98%-27.01%) for 2010-2013: 26.68%, (20.79%-33.02%). For Northern region 25.76% (22.36%-29.32%), for Southern region 19.30%, (15.48%-24.08%). Conclusions: The last decade witnessed the growth in prevalence of hypertension in rural areas of China compared with the fourth national investigation, which has climbed the same level as the urban area. Guidelines for screening and treatment of hypertension in rural areas need to be given enough attention.	[Chen, Xiaofang] Cent South Univ, Xiangya Nursing Sch, Changsha, Hunan, Peoples R China; [Chen, Xiaofang] Southern Med Univ, Affiliated Hostipal 3, Dept Nursing, Guangzhou, Guangdong, Peoples R China; [Li, Lezhi] Cent South Univ, Dept Nursing, Xiangya Hosp 2, Changsha, Hunan, Peoples R China; [Zhou, Tao] Southern Med Univ, Dept Cardiol, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China; [Li, Zhanzhan] Cent South Univ, Dept Epidemiol & Hlth Stat, Sch Publ Hlth, Changsha, Hunan, Peoples R China	Central South University; Southern Medical University - China; Central South University; Southern Medical University - China; Central South University	Li, LZ (corresponding author), Cent South Univ, Dept Nursing, Xiangya Hosp 2, Changsha, Hunan, Peoples R China.	lilz1988@126.com	Zhang, Anthony Lin/AAR-6673-2021; Yang, Kun/A-4293-2010; Chen, Xin-Zu/G-6579-2014; Xue, Charlie C/F-1244-2014; Chen, Xin-Zu/K-2988-2019	Zhang, Anthony Lin/0000-0002-0968-9380; Xue, Charlie/0000-0001-6937-9088; May, Brian/0000-0002-5864-3020; Chen, Xiankun/0000-0002-0353-4185; , Zongguang/0000-0002-7616-1199; Chen, Xin-lin/0000-0002-2650-8051	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038329, R21HD061763, R01HD018269] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [R01MD007828] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))		Chen B, 2008, MOEDERN PREV MED, V35, P2823; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Department of Disease Control and Prevention Ministry of Health, 2006, REP CHRON DIS CHIN; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Diaz AA, 2014, RURAL REMOTE HEALTH, V14; Dong CX, 2013, J INT MED RES, V41, P1291, DOI 10.1177/0300060513488498; Firmann M, 2008, BMC CARDIOVASC DISOR, V8, DOI 10.1186/1471-2261-8-6; FLACK JM, 1995, CIRCULATION, V92, P2437, DOI 10.1161/01.CIR.92.9.2437; Gong Jie, 2011, Chinese Preventive Medicine, V12, P227; Han B, 2009, J ZHENGZHOU U MED SC, V44, P337; He F, 2012, CHIN J DIS CONTROL P, V16, P560; He J, 2005, NEW ENGL J MED, V353, P1124, DOI 10.1056/NEJMsa050467; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hu HH, 2008, PREV TREATMENT CARDI, V8, P195; Hu XJ, 2013, CHIN HLTH SERVICE MA, V5, P391; Hu Y, 2000, Zhonghua Liu Xing Bing Xue Za Zhi, V21, P177; Huang JP, 2011, KIDNEY BLOOD PRESS R, V34, P69, DOI 10.1159/000323164; Kannel WB, 1996, JAMA-J AM MED ASSOC, V276, P1269, DOI 10.1001/jama.276.15.1269; Klag MJ, 1996, NEW ENGL J MED, V334, P13, DOI 10.1056/NEJM199601043340103; Kokiwar Prashant R, 2012, J Assoc Physicians India, V60, P26; Levy D, 1996, JAMA-J AM MED ASSOC, V275, P1557, DOI 10.1001/jama.275.20.1557; Li LM, 2008, CHINESE REDIDENTS NU; Li Y, 2011, J SHENYANG MED COLL, V13, P228; Lin Kang, 2014, Wuhan Daxue Xuebao (Yixue Ban), V35, P114; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; Ma YQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058302; Ministry of Health of the People's Republic of China, 2005, CHIN PREV CONTR HYP; Mittal BV, 2010, AM J KIDNEY DIS, V55, P590, DOI 10.1053/j.ajkd.2009.06.044; Ni GH, 2013, FOOD NUTR CHIN, V19, P70; O'Brien E, 2000, BMJ-BRIT MED J, V320, P1128, DOI 10.1136/bmj.320.7242.1128; O'Brien E, 2013, J HYPERTENS, V31, P1731, DOI 10.1097/HJH.0b013e328363e964; PRC National Blood Pressure Survey Cooperative Group, 1995, CHIN J HYPERTENS, V3, P1; Reynolds K, 2003, J HYPERTENS, V21, P1273, DOI 10.1097/00004872-200307000-00014; Rostom A, 2004, Evid Rep Technol Assess (Summ), P1; Stuart A, 1996, KENDALLS ADV THEORY; Tozawa M, 2003, HYPERTENSION, V41, P1341, DOI 10.1161/01.HYP.0000069699.92349.8C; van den Hoogen PCW, 2000, NEW ENGL J MED, V342, P1, DOI 10.1056/NEJM200001063420101; [王克伟 Wang Kewei], 2011, [中国公共卫生, China Public Health], V27, P1291; Wang YM., 2013, J BENBU MED COLL, V38, P321; Wolf-Maier K, 2003, JAMA-J AM MED ASSOC, V289, P2363, DOI 10.1001/jama.289.18.2363; Wu XG, 1995, INT J CARDIOL, V52, P39, DOI 10.1016/0167-5273(95)02443-Z; Xia YiYin, 2013, Journal of Tropical Medicine (Guangzhou), V13, P350; Xin RB, 2011, GUANGXI MED, V33, P963; Yang HJ, 2010, CHIN J GEN PRAC, V8, P896; Ye HaoFeng, 2005, China Tropical Medicine, V5, P1114; Ye ZW, 2011, ANHUI J PREV MED, V17, P190; Yin CG, 2009, PREV TREATMENT CARDI, V9, P137; Yu QH, 2011, WORLD HLTH DIG MED P, V8, P13; Yu YX, 2009, MED J CHIN PEOPLE HL, V21, P2364; Zhang AH, 2009, PREV MED TRIB, V15, P720; Zhang G, 2009, GONG GONG WEI SHENG, V20, P24; Zhang LJ, 2010, OCCUP HLTH, V26, P1872; Zhang Y., 2011, NINGXIA MED J, V33, P1222; Zhao JiQing, 2013, Bulletin of Disease Control and Prevention, V28, P27; Zheng YT, 2011, CHIN MED J METALL IN, V28, P573; Zheng ZH, 2010, CHINA CHLIN PRAC MED, V4, P219; Zhong DC, 2009, SICHUAN MED J, V30, P1056; Zhou YX, 2011, PRE MED TRIB, V17, P909	59	337	358	33	74	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 18	2014	9	12							e115462	10.1371/journal.pone.0115462	http://dx.doi.org/10.1371/journal.pone.0115462			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA4AC	24622390	Green Published, Green Submitted, gold			2023-01-03	WOS:000348845600050
J	Chen, XL; Chen, XZ; Lu, ZH; Wang, L; Yang, K; Hu, JK; Zhang, B; Chen, ZX; Chen, JP; Zhou, ZG				Chen, Xiao-Long; Chen, Xin-Zu; Lu, Zheng-Hao; Wang, Li; Yang, Kun; Hu, Jian-Kun; Zhang, Bo; Chen, Zhi-Xin; Chen, Jia-Ping; Zhou, Zong-Guang			Comparison of Ultrasonic Scalpel versus Conventional Techniques in Open Gastrectomy for Gastric Carcinoma Patients: A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							ACTIVATED SHEARS; CANCER; LYMPHADENECTOMY	Objectives: To compare surgical efficacy and postoperative recovery of ultrasonic scalpel (USS) with conventional techniques for the resection of gastric carcinoma. Methods: A systematic search of major medical databases (PubMed, Embase, CCRT and CNKI) was conducted. Both randomized and non-randomized controlled trials (RCTs and nRCTs) were considered eligible. Operation time (OT), intraoperative blood loss (BL) and postoperative complications (POC) rates as well as postoperative hospitalization days, number of dissected lymph nodes, abdominal drainage volume and time for recovery of gastrointestinal functions were synthesized and compared. Results: Nineteen studies were included (7 RCTs and 12 nRCTs), in which 1930 patients were enrolled totally (946 in the USS group and 984 in the conventional group). Monopolar electrocautery and ligation were used as the conventional methods. Comparative meta-analysis showed perioperative outcomes were significantly improved using USS compared with conventional surgical instrumentation. OT was reduced from a weighted mean of 185.3 min in the conventional group to 151.0 min in the USS group (MD = -33.30, 95% CI [-41.75, -24.86], p<0.001) and intraoperative BL was decreased from a weighted mean of 217.9 ml in the conventional group to 111.6 ml in the USS group (MD = -113.42, 95% CI [-142.05, -84.79], p<0.001). Results from RCTs subgroup were consistent with those from nRCTs subgroup. The weighted cumulative risk of POC accounted for 8.9% (0%-25%) and 12.9% (5.5%-45%) in the USS and conventional groups, respectively. Pooled estimated results from nRCTs (OR = 0.54, 95% CI [0.27, 1.06], p = 0.07) and RCTs (RR = 0.75, 95% CI [0.44, 1.26], p = 0.27) showed no significant difference between the USS and control groups. Analysis of secondary outcomes showed the improvements of the USS group over control group regarding the number of dissected lymph nodes, postoperative hospitalization days, abdominal drainage volume and time for recovery of gastrointestinal functions. Conclusion: Compared with conventional electrosurgery, the USS is a safe and effective technique with more short-term advantages in open surgery for gastric cancer.	[Chen, Xiao-Long; Chen, Xin-Zu; Lu, Zheng-Hao; Yang, Kun; Hu, Jian-Kun; Zhang, Bo; Chen, Zhi-Xin; Chen, Jia-Ping; Zhou, Zong-Guang] Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, Chengdu 610064, Sichuan Provinc, Peoples R China; [Wang, Li] Sichuan Univ, West China Hosp, Chinese Cochrane Ctr, Chengdu 610064, Sichuan Provinc, Peoples R China	Sichuan University; Sichuan University	Hu, JK (corresponding author), Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, Chengdu 610064, Sichuan Provinc, Peoples R China.	hujkwch@126.com	Zhang, Anthony Lin/AAR-6673-2021; Yang, Kun/A-4293-2010; Chen, Xin-Zu/G-6579-2014; Xue, Charlie C/F-1244-2014; Chen, Xin-Zu/K-2988-2019	Zhang, Anthony Lin/0000-0002-0968-9380; Xue, Charlie/0000-0001-6937-9088; May, Brian/0000-0002-5864-3020; Chen, Xiankun/0000-0002-0353-4185; , Zongguang/0000-0002-7616-1199; Chen, Xin-lin/0000-0002-2650-8051	Outstanding Young Scientific Scholarship Foundation of Sichuan University; Fundamental Research Funds for the Central Universities of China [2011SCU04B19]; Ministry of Education of China [2012SCU-NCET-11-0343]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038329, R21HD061763, R01HD018269] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [R01MD007828] Funding Source: NIH RePORTER	Outstanding Young Scientific Scholarship Foundation of Sichuan University; Fundamental Research Funds for the Central Universities of China(Fundamental Research Funds for the Central Universities); Ministry of Education of China(Ministry of Education, China); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	Domestic support from (1) Outstanding Young Scientific Scholarship Foundation of Sichuan University, from the Fundamental Research Funds for the Central Universities of China (No. 2011SCU04B19); and (2) New Century Excellent Talents in University support program, Ministry of Education of China (2012SCU-NCET-11-0343). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ajani JA, 1998, ONCOLOGY-NY, V12, P44; Ajani JA, 2010, J NATL COMPR CANC NE, V8, P378, DOI 10.6004/jnccn.2010.0030; Chen CP, 2012, GUID CHIN MED, V10, P345; Chen XZ, 2010, J AM COLL SURGEONS, V210, P100, DOI 10.1016/j.jamcollsurg.2009.09.033; Chen Z, 2009, CHIN J MOD OPER SURG, V13, P257; Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Fu YM, 2011, CONT MED, V17, P104; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hu JK, 2009, SURG TODAY, V39, P207, DOI 10.1007/s00595-008-3856-x; Hu JK, 2008, CHIN J BASES CLIN GE, V15, P718; Inoue K, 2012, J GASTROINTEST SURG, V16, P1840, DOI 10.1007/s11605-012-1970-y; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Japanese Gastric Canc Assoc, 2011, GASTRIC CANCER, V14, P101, DOI 10.1007/s10120-011-0041-5; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Li G, 2010, J MED POSTGRA, V23, P1050; Li P, 2011, CHIN MED HERALD, V8, P177; Li ZR, 2009, CHIN ARCH GEN SURG E, V3, P510; Lin YH, 2011, CHIN J CLIN ELECT ED, V5, P975; [陆维祺 LU Weiqi], 2008, [中国实用外科杂志, Chinese Journal of Practical Surgery], V28, P203; Mahabaleshwar V, 2012, CAN J SURG, V55, P307, DOI 10.1503/cjs.000411; McCarus SD, 1996, J AM ASSOC GYN LAP, V3, P601, DOI 10.1016/S1074-3804(05)80174-4; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Mohri Y, 2007, SURG TODAY, V37, P1060, DOI 10.1007/s00595-007-3551-3; Pons Y, 2009, HEAD NECK ONCOL, V24, P1; Shi YF, 2012, GUID CHIN MED, V10, P154; Songun I, 2010, LANCET ONCOL, V11, P439, DOI 10.1016/S1470-2045(10)70070-X; Tou S, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007886.pub2; Tsimoyiannis EC, 2002, WORLD J SURG, V26, P158; Tu JC, 2010, MED J COMMUN, V24, P60; Tu XH, 2009, CHIN J MOD OPER SURG, V13, P407; Van Cutsem E, 2008, EUR J CANCER, V44, P182, DOI 10.1016/j.ejca.2007.11.001; Wei ZM, 2010, J MINI INVA MED, V5, P445; Wells G, 2009, OTTAWA HOSP RES I NE; Xu L, 2010, PEOPLES MIL SURG, V53, P490; Yang K, 2009, WORLD J GASTROENTERO, V15, P5352, DOI 10.3748/wjg.15.5352; Yang L, 2006, WORLD J GASTROENTERO, V12, P17, DOI 10.3748/wjg.v12.i1.17; Zhang ZY, 2012, CHIN J MOD DRUG APPL, V6, P3; Zhong L, 2012, ANN ACAD MED SINGAP, V41, P161; 尹蓓, 2011, [江苏医药, Jiangsu Medical Journal], V37, P2877; 宋小平, 2011, [南京医科大学学报. 自然科学版, Acta Universitatis Medicinalis Nanjing], V31, P590; 刘磊, 2010, [中国癌症杂志, China Oncology], V20, P799	41	337	358	33	74	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2014	9	7							e103330	10.1371/journal.pone.0103330	http://dx.doi.org/10.1371/journal.pone.0103330			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM6EF	24622390	Green Published, Green Submitted, gold			2023-01-03	WOS:000339954800038
J	Liu, N; Lin, ZF; Guan, LL; Gaughan, G; Lin, GZ				Liu, Nan; Lin, Zhifang; Guan, Lanlan; Gaughan, Gerald; Lin, Guizhu			Antioxidant Enzymes Regulate Reactive Oxygen Species during Pod Elongation in Pisum sativum and Brassica chinensis	PLOS ONE			English	Article							HYDROXYL RADICALS; HYDROGEN-PEROXIDE; CELL-WALL; ROOT; SUPEROXIDE; GROWTH; LEAVES; H2O2	Previous research has focused on the involvement of reactive oxygen species (ROS) in cell wall loosening and cell extension in plant vegetative growth, but few studies have investigated ROS functions specifically in plant reproductive organs. In this study, ROS levels and antioxidant enzyme activities were assessed in Pisum sativum and Brassica chinensis pods at five developmental stages. In juvenile pods, the high levels of O-2(-) and OH indicates that they had functions in cell wall loosening and cell elongation. In later developmental stages, high levels of. OH were also related to increases in cell wall thickness in lignified tissues. Throughout pod development, most of the O-2(-) was detected on plasma membranes of parenchyma cells and outer epidermis cells of the mesocarp, while most of the H2O2 was detected on plasma membranes of most cells throughout the mesocarp. This suggests that these sites are presumably the locations of ROS generation. The antioxidant enzymes superoxide dismutase (SOD), peroxidase (POD), and catalase (CAT) apparently contributed to ROS accumulation in pod wall tissues. Furthermore, specifically SOD and POD were found to be associated with pod growth through the regulation of ROS generation and transformation. Throughout pod development, O-2(-) decreases were associated with increased SOD activity, while changes in H2O2 accumulation were associated with changes in CAT and POD activities. Additionally, high POD activity may contribute to the generation of. OH in the early development of pods. It is concluded that the ROS are produced in different sites of plasma membranes with the regulation of antioxidant enzymes, and that substantial ROS generation and accumulation are evident in cell elongation and cell wall loosening in pod wall cells.	[Liu, Nan; Lin, Zhifang; Guan, Lanlan; Lin, Guizhu] Chinese Acad Sci, South China Bot Garden, Key Lab Vegetat Restorat & Management Degraded Ec, Guangzhou, Guangdong, Peoples R China; [Gaughan, Gerald] Univ Illinois, Dept Biol Sci, Chicago, IL 60680 USA	Chinese Academy of Sciences; South China Botanical Garden, CAS; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lin, ZF (corresponding author), Chinese Acad Sci, South China Bot Garden, Key Lab Vegetat Restorat & Management Degraded Ec, Guangzhou, Guangdong, Peoples R China.	linzhif@scbg.ac.cn	León, Rafael I/N-6510-2014; Malausa, Thibaut/X-1614-2018; Strugnell, Jan M/P-9921-2016; Moltschaniwskyj, Natalie/AAB-7236-2019; Pecl, Gretta/D-7267-2011; 刘, 芳延/AAO-8535-2021; van den Bosch, Frank C./ABH-3801-2020; Botton, Marcos/I-1731-2016; Bertin, Aline/T-5005-2017; Persinoti, Gabriela/C-5933-2016; Leimar, Olof/L-3781-2014; Apparecida Desiderio, Janete/F-5848-2012; Deary, Ian/C-6297-2009; Inskip, Hazel/L-5467-2018; Dodds, Richard/D-7772-2016; Guazzaroni, Maria-Eugenia/E-2599-2013; Sujii, Edison/H-7715-2015; Silva-Rocha, Rafael/H-4929-2012; Sujii, Edison Ryoiti/H-7715-2015; Aidar, Marcos Pereira Marinho/B-2212-2013; Benzeval, Michaela/J-3163-2015	León, Rafael I/0000-0003-3197-4185; Malausa, Thibaut/0000-0003-1681-7958; Pecl, Gretta/0000-0003-0192-4339; 刘, 芳延/0000-0002-5155-1916; van den Bosch, Frank C./0000-0003-3236-2068; Botton, Marcos/0000-0002-0554-3157; Bertin, Aline/0000-0003-4232-4241; Lye, David/0000-0003-0324-0205; Cooper, Cyrus/0000-0003-3510-0709; Persinoti, Gabriela/0000-0002-0975-7283; Jagger, Carol/0000-0002-6377-9926; Robinson, Sian/0000-0003-1766-7269; Gale, Catharine/0000-0002-3361-8638; Favati, Anna/0000-0002-6435-011X; Wong, Jason/0000-0002-8167-540X; timbo, renata/0000-0003-1989-7412; Cooper, Rachel/0000-0003-3370-5720; Leimar, Olof/0000-0001-8621-6977; Aihie Sayer, Avan/0000-0003-1283-6457; Moltschaniwskyj, Natalie/0000-0001-9709-9876; De Vivo, Immaculata/0000-0002-7185-7402; Souza, Silvia/0000-0001-6293-7665; Apparecida Desiderio, Janete/0000-0001-7723-3070; Teixeira da Silva, Jaime A./0000-0003-3299-2772; Deary, Ian/0000-0002-1733-263X; Semmens, Jayson/0000-0003-1742-6692; Dennison, Elaine/0000-0002-3048-4961; Germain, Jean-Francois/0000-0001-7927-6031; Inskip, Hazel/0000-0001-8897-1749; Dodds, Richard/0000-0003-4968-7678; Der, Geoff/0000-0002-8677-073X; Strugnell, Jan/0000-0003-2994-637X; Guazzaroni, Maria-Eugenia/0000-0002-4657-3731; Sujii, Edison/0000-0002-0702-0181; R. Silva, Rogerio/0000-0002-0599-2155; Pacheco da Silva, Vitor/0000-0002-8420-1779; Silva-Rocha, Rafael/0000-0001-6319-631X; Vucicevic, Katarina/0000-0001-9676-5785; Gan, Victor/0000-0002-6966-2729; Lawlor, Debbie A/0000-0002-6793-2262; Choo, Robin/0000-0002-3240-3029; Fernandes, Odair/0000-0003-3489-4754; Sujii, Edison Ryoiti/0000-0001-7602-8999; Aidar, Marcos Pereira Marinho/0000-0001-5728-6749; Ramos, Jorge E/0000-0002-8690-761X; Tilling, Kate/0000-0002-1010-8926; N. Silva, Roberto/0000-0002-8992-7130; Wong, Joshua/0000-0001-8268-5610; Paveley, Neil/0000-0002-1709-4563; Benzeval, Michaela/0000-0002-0372-2098	China Scholarship Council [201204910138]; Biotechnology and Biological Sciences Research Council [BBS/E/C/00005198] Funding Source: researchfish	China Scholarship Council(China Scholarship Council); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	The current study was supported by China Scholarship Council (No. 201204910138, http://www.csc.edu.cn/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alscher RG, 1997, PHYSIOL PLANTARUM, V100, P224, DOI 10.1034/j.1399-3054.1997.1000203.x; BARRETO JC, 1994, LIFE SCI, V56, pPL89, DOI 10.1016/0024-3205(94)00925-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carol RJ, 2006, J EXP BOT, V57, P1829, DOI 10.1093/jxb/erj201; Derbyshire P, 2007, J EXP BOT, V58, P2079, DOI 10.1093/jxb/erm074; Dunand C, 2007, NEW PHYTOL, V174, P332, DOI 10.1111/j.1469-8137.2007.01995.x; Foreman J, 2003, NATURE, V422, P442, DOI 10.1038/nature01485; Fry SC, 2001, BIOCHEM J, V357, P729, DOI 10.1042/0264-6021:3570729; Gapper C, 2006, PLANT PHYSIOL, V141, P341, DOI 10.1104/pp.106.079079; GIANNOPOLITIS CN, 1977, PLANT PHYSIOL, V59, P315, DOI [10.1104/pp.59.2.315, 10.1104/pp.59.2.309]; GILBERT DL, 1981, OXYGEN LIVING PROCES; Hernandez JA, 2001, PLANT PHYSIOL, V127, P817, DOI 10.1104/pp.010188; Ivakov A, 2013, FRONT PLANT SCI, V4, DOI 10.3389/fpls.2013.00439; Ivanchenko MG, 2013, ANN BOT, DOI [10.1093/aob/mct181, DOI 10.1093/A0B/MCT181]; Johnansen DA, 1940, PLANT MICROTECHNIQUE; Kranner I, 2010, J PLANT PHYSIOL, V167, P805, DOI 10.1016/j.jplph.2010.01.019; Kukavica B, 2009, PLANT CELL PHYSIOL, V50, P304, DOI 10.1093/pcp/pcn199; Li SW, 2009, ENVIRON EXP BOT, V65, P63, DOI 10.1016/j.envexpbot.2008.06.004; Liszkay A, 2004, PLANT PHYSIOL, V136, P3114, DOI 10.1104/pp.104.044784; Liu N, 2013, J PLANT GROWTH REGUL, V32, P83, DOI 10.1007/s00344-012-9278-4; Liu N, 2010, ECOTOX ENVIRON SAFE, V73, P1238, DOI 10.1016/j.ecoenv.2010.06.017; Muller K, 2009, PLANT PHYSIOL, V150, P1855, DOI 10.1104/pp.109.139204; Perl RT., 2002, OXIDATIVE STRESS PLA, P1; Romero-Puertas MC, 2004, PLANT CELL ENVIRON, V27, P1122, DOI 10.1111/j.1365-3040.2004.01217.x; Barcelo AR, 2009, SIGNAL COMMUN PLANTS, P73, DOI 10.1007/978-3-642-00390-5_5; Schopfer P, 2006, BIOFACTORS, V28, P73, DOI 10.1002/biof.5520280202; Schopfer P, 2002, PLANTA, V214, P821, DOI 10.1007/s00425-001-0699-8; Schopfer P, 2001, PLANT PHYSIOL, V125, P1591, DOI 10.1104/pp.125.4.1591; Sugimoto-Shirasu K, 2003, CURR OPIN PLANT BIOL, V6, P544, DOI 10.1016/j.pbi.2003.09.009; Yang XF, 2001, ANALYST, V126, P928, DOI 10.1039/b100085n; ZENG S-X, 1991, Acta Phytophysiologica Sinica, V17, P177; [张玲玲 ZHANG LingLing], 2006, [生态学报, Acta Ecologica Sinica], V26, P1330, DOI 10.1016/S1872-2032(06)60025-5	32	449	501	61	152	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 4	2014	9	2							e87588	10.1371/journal.pone.0087588	http://dx.doi.org/10.1371/journal.pone.0087588			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302VA	25072296	Green Published, gold, Green Submitted			2023-01-03	WOS:000330631800048
J	Hobbelen, PHF; Paveley, ND; van den Bosch, F				Hobbelen, Peter H. F.; Paveley, Neil D.; van den Bosch, Frank			The Emergence of Resistance to Fungicides	PLOS ONE			English	Article							STRESS-INDUCED MUTAGENESIS; MYCOSPHAERELLA-GRAMINICOLA; PESTICIDE RESISTANCE; SPRAY HETEROGENEITY; SEPTORIA-TRITICI; SELECTION; MIXTURES; PATHOGEN; MODEL; POPULATIONS	Many studies exist about the selection phase of fungicide resistance evolution, where a resistant strain is present in a pathogen population and is differentially selected for by the application of fungicides. The emergence phase of the evolution of fungicide resistance - where the resistant strain is not present in the population and has to arise through mutation and subsequently invade the population - has not been studied to date. Here, we derive a model which describes the emergence of resistance in pathogen populations of crops. There are several important examples where a single mutation, affecting binding of a fungicide with the target protein, shifts the sensitivity phenotype of the resistant strain to such an extent that it cannot be controlled effectively('qualitative' or 'single-step' resistance). The model was parameterized for this scenario for Mycosphaerella graminicola on winter wheat and used to evaluate the effect of fungicide dose rate on the time to emergence of resistance for a range of mutation probabilities, fitness costs of resistance and sensitivity levels of the resistant strain. We also evaluated the usefulness of mixing two fungicides of differing modes of action for delaying the emergence of resistance. The results suggest that it is unlikely that a resistant strain will already have emerged when a fungicide with a new mode of action is introduced. Hence, 'anti-emergence' strategies should be identified and implemented. For all simulated scenarios, the median emergence time of a resistant strain was affected little by changing the dose rate applied, within the range of doses typically used on commercial crops. Mixing a single-site acting fungicide with a multi-site acting fungicide delayed the emergence of resistance to the single-site component. Combining the findings with previous work on the selection phase will enable us to develop more efficient anti-resistance strategies.	[Hobbelen, Peter H. F.; van den Bosch, Frank] Rothamsted Res, Harpenden, Herts, England; [Paveley, Neil D.] ADAS UK Ltd, Malton, N Yorkshire, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	van den Bosch, F (corresponding author), Rothamsted Res, Harpenden, Herts, England.	frank.vandenbosch@rothamsted.ac.uk	León, Rafael I/N-6510-2014; Malausa, Thibaut/X-1614-2018; Strugnell, Jan M/P-9921-2016; Moltschaniwskyj, Natalie/AAB-7236-2019; Pecl, Gretta/D-7267-2011; 刘, 芳延/AAO-8535-2021; van den Bosch, Frank C./ABH-3801-2020; Botton, Marcos/I-1731-2016; Bertin, Aline/T-5005-2017; Persinoti, Gabriela/C-5933-2016; Leimar, Olof/L-3781-2014; Apparecida Desiderio, Janete/F-5848-2012; Deary, Ian/C-6297-2009; Inskip, Hazel/L-5467-2018; Dodds, Richard/D-7772-2016; Guazzaroni, Maria-Eugenia/E-2599-2013; Sujii, Edison/H-7715-2015; Silva-Rocha, Rafael/H-4929-2012; Sujii, Edison Ryoiti/H-7715-2015; Aidar, Marcos Pereira Marinho/B-2212-2013; Benzeval, Michaela/J-3163-2015	León, Rafael I/0000-0003-3197-4185; Malausa, Thibaut/0000-0003-1681-7958; Pecl, Gretta/0000-0003-0192-4339; 刘, 芳延/0000-0002-5155-1916; van den Bosch, Frank C./0000-0003-3236-2068; Botton, Marcos/0000-0002-0554-3157; Bertin, Aline/0000-0003-4232-4241; Lye, David/0000-0003-0324-0205; Cooper, Cyrus/0000-0003-3510-0709; Persinoti, Gabriela/0000-0002-0975-7283; Jagger, Carol/0000-0002-6377-9926; Robinson, Sian/0000-0003-1766-7269; Gale, Catharine/0000-0002-3361-8638; Favati, Anna/0000-0002-6435-011X; Wong, Jason/0000-0002-8167-540X; timbo, renata/0000-0003-1989-7412; Cooper, Rachel/0000-0003-3370-5720; Leimar, Olof/0000-0001-8621-6977; Aihie Sayer, Avan/0000-0003-1283-6457; Moltschaniwskyj, Natalie/0000-0001-9709-9876; De Vivo, Immaculata/0000-0002-7185-7402; Souza, Silvia/0000-0001-6293-7665; Apparecida Desiderio, Janete/0000-0001-7723-3070; Teixeira da Silva, Jaime A./0000-0003-3299-2772; Deary, Ian/0000-0002-1733-263X; Semmens, Jayson/0000-0003-1742-6692; Dennison, Elaine/0000-0002-3048-4961; Germain, Jean-Francois/0000-0001-7927-6031; Inskip, Hazel/0000-0001-8897-1749; Dodds, Richard/0000-0003-4968-7678; Der, Geoff/0000-0002-8677-073X; Strugnell, Jan/0000-0003-2994-637X; Guazzaroni, Maria-Eugenia/0000-0002-4657-3731; Sujii, Edison/0000-0002-0702-0181; R. Silva, Rogerio/0000-0002-0599-2155; Pacheco da Silva, Vitor/0000-0002-8420-1779; Silva-Rocha, Rafael/0000-0001-6319-631X; Vucicevic, Katarina/0000-0001-9676-5785; Gan, Victor/0000-0002-6966-2729; Lawlor, Debbie A/0000-0002-6793-2262; Choo, Robin/0000-0002-3240-3029; Fernandes, Odair/0000-0003-3489-4754; Sujii, Edison Ryoiti/0000-0001-7602-8999; Aidar, Marcos Pereira Marinho/0000-0001-5728-6749; Ramos, Jorge E/0000-0002-8690-761X; Tilling, Kate/0000-0002-1010-8926; N. Silva, Roberto/0000-0002-8992-7130; Wong, Joshua/0000-0001-8268-5610; Paveley, Neil/0000-0002-1709-4563; Benzeval, Michaela/0000-0002-0372-2098	Biological and Biotechnological Research Council of the United Kingdom; Department for Environment, Food and Rural Affairs of the United Kingdom [PS2712]; Biotechnology and Biological Sciences Research Council [BBS/E/C/00005198] Funding Source: researchfish	Biological and Biotechnological Research Council of the United Kingdom(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Department for Environment, Food and Rural Affairs of the United Kingdom(Department for Environment, Food & Rural Affairs (DEFRA)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	Rothamsted Research receives support from the Biological and Biotechnological Research Council of the United Kingdom. Part of this research was funded by the Department for Environment, Food and Rural Affairs of the United Kingdom (project number PS2712). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Birch CPD, 1997, J APPL ECOL, V34, P1032, DOI 10.2307/2405292; Bjedov I, 2003, SCIENCE, V300, P1404, DOI 10.1126/science.1082240; Cao Y, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2159468; Carnegie SF, 2008, POTATO RES, V51, P113, DOI 10.1007/s11540-008-9094-1; DOSTER MA, 1990, PHYTOPATHOLOGY, V80, P1190, DOI 10.1094/Phyto-80-1190; Eyal Z, 1999, EUR J PLANT PATHOL, V105, P629, DOI 10.1023/A:1008716812259; Fraaije BA, 2005, PHYTOPATHOLOGY, V95, P933, DOI 10.1094/PHYTO-95-0933; Fraaije BA, 2012, MOL PLANT PATHOL, V13, P263, DOI 10.1111/j.1364-3703.2011.00746.x; Galhardo RS, 2007, CRIT REV BIOCHEM MOL, V42, P399, DOI 10.1080/10409230701648502; Genet JL, 2006, PEST MANAG SCI, V62, P188, DOI 10.1002/ps.1146; Grabski C., 1985, BRIT CROP PROT C MON, V31, P315; Grimmer M, 2011, RESISTANCE 2011, P94; Gubbins S, 1999, P ROY SOC B-BIOL SCI, V266, P2539, DOI 10.1098/rspb.1999.0957; Hall RJ, 2007, B MATH BIOL, V69, P525, DOI 10.1007/s11538-006-9139-z; Hall RJ, 2004, B MATH BIOL, V66, P825, DOI 10.1016/j.bulm.2003.11.006; HOARE FA, 1986, PLANT PATHOL, V35, P506, DOI 10.1111/j.1365-3059.1986.tb02048.x; Hobbelen PHF, 2013, PHYTOPATHOLOGY, V103, P690, DOI 10.1094/PHYTO-06-12-0142-R; Hobbelen PHF, 2011, PHYTOPATHOLOGY, V101, P1224, DOI 10.1094/PHYTO-10-10-0290; Hobbelen PHF, 2011, PLANT PATHOL, V60, P304, DOI 10.1111/j.1365-3059.2010.02380.x; Horsten JAHM, 1979, THESIS WAGENINGEN U; HUNTER T, 1987, ANN APPL BIOL, V110, P515, DOI 10.1111/j.1744-7348.1987.tb04169.x; Iwasa Y, 2004, J THEOR BIOL, V226, P205, DOI 10.1016/j.jtbi.2003.08.014; JOSEPOVITS G, 1989, CROP PROT, V8, P106, DOI 10.1016/0261-2194(89)90084-7; Kang JM, 2006, FASEB J, V20, P2476, DOI 10.1096/fj.06-6209com; LaMondia J. A., 2001, Journal of Environmental Horticulture, V19, P51; Mavroeidi VI, 2006, PLANT PATHOL, V55, P715, DOI 10.1111/j.1365-3059.2006.01441.x; McCartney C, 2007, CROP PROT, V26, P1272, DOI 10.1016/j.cropro.2006.10.027; Metcalfe RJ, 2000, PLANT PATHOL, V49, P546, DOI 10.1046/j.1365-3059.2000.00486.x; MILGROOM MG, 1990, PHYTOPATHOLOGY, V80, P410, DOI 10.1094/Phyto-80-410; Parnell S, 2006, PHYTOPATHOLOGY, V96, P549, DOI 10.1094/PHYTO-96-0549; Parnell S, 2005, PHYTOPATHOLOGY, V95, P632, DOI 10.1094/PHYTO-95-0632; Paveley ND, 2011, HGCA WHEAT DIS MANAG; Robert C, 2008, FUNCT PLANT BIOL, V35, P997, DOI 10.1071/FP08066; SANDERS PL, 1985, PLANT DIS, V69, P939; SANOAMUANG N, 1995, MYCOL RES, V99, P677, DOI 10.1016/S0953-7562(09)80527-3; Serra MC, 2007, THEOR POPUL BIOL, V72, P167, DOI 10.1016/j.tpb.2007.01.005; Serra MC, 2006, J APPL PROBAB, V43, P296, DOI 10.1239/jap/1143936262; Shaw MW, 2000, PHYTOPATHOLOGY, V90, P333, DOI 10.1094/PHYTO.2000.90.4.333; SHAW MW, 1993, CROP PROT, V12, P120, DOI 10.1016/0261-2194(93)90138-9; Tenaillon O, 2004, TRENDS MICROBIOL, V12, P264, DOI 10.1016/j.tim.2004.04.002; Thornley JHM., 1990, PLANT CROP MODELLING; Thygesen K, 2009, EUR J PLANT PATHOL, V123, P435, DOI 10.1007/s10658-008-9381-3; Turechek WW, 2004, PLANT HLTH PROG; VALI RJ, 1992, PLANT DIS, V76, P919, DOI 10.1094/PD-76-0919; van den Bosch F, 2011, PLANT PATHOL, V60, P597, DOI 10.1111/j.1365-3059.2011.02439.x; van den Bosch F, 2008, ANNU REV PHYTOPATHOL, V46, P123, DOI 10.1146/annurev.phyto.011108.135838; WAGGONER PE, 1987, PHYTOPATHOLOGY, V77, P393; Zhang CQ, 2008, ANN APPL BIOL, V153, P205, DOI 10.1111/j.1744-7348.2008.00248.x	48	449	501	61	152	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2014	9	3							e91910	10.1371/journal.pone.0091910	http://dx.doi.org/10.1371/journal.pone.0091910			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AD6GL	25072296	Green Published, Green Submitted, gold			2023-01-03	WOS:000333355300044
J	da Silva, VCP; Bertin, A; Blin, A; Germain, JF; Bernardi, D; Rignol, G; Botton, M; Malausa, T				Pacheco da Silva, Vitor C.; Bertin, Aline; Blin, Aurelie; Germain, Jean-Francois; Bernardi, Daniel; Rignol, Guylene; Botton, Marcos; Malausa, Thibaut			Molecular and Morphological Identification of Mealybug Species (Hemiptera: Pseudococcidae) in Brazilian Vineyards	PLOS ONE			English	Article							FERRISIA FULLAWAY HEMIPTERA; SCALE INSECTS HEMIPTERA; EXPORT GRAPE PRODUCTION; MULTIPLEX PCR; PEST; PHYLOGENY; MARKERS	Mealybugs (Hemiptera: Pseudococcidae) are pests constraining the international trade of Brazilian table grapes. They damage grapes by transmitting viruses and toxins, causing defoliation, chlorosis, and vigor losses and favoring the development of sooty mold. Difficulties in mealybug identification remain an obstacle to the adequate management of these pests. In this study, our primary aim was to identify the principal mealybug species infesting the major table grape-producing regions in Brazil, by morphological and molecular characterization. Our secondary aim was to develop a rapid identification kit based on species-specific Polymerase Chain Reactions, to facilitate the routine identification of the most common pest species. We surveyed 40 sites infested with mealybugs and identified 17 species: Dysmicoccus brevipes (Cockerell), Dysmicoccus sylvarum Williams and Granara de Willink, Dysmicoccus texensis (Tinsley), Ferrisia cristinae Kaydan and Gullan, Ferrisia meridionalis Williams, Ferrisia terani Williams and Granara de Willink, Phenacoccus baccharidis Williams, Phenacoccus parvus Morrison, Phenacoccus solenopsis Tinsley, Planococcus citri (Risso), Pseudococcus viburni (Signoret), Pseudococcus cryptus Hempel, four taxa closely related each of to Pseudococcus viburni, Pseudococcus sociabilis Hambleton, Pseudococcus maritimus (Ehrhorn) and Pseudococcus meridionalis Prado, and one specimen from the genus Pseudococcus Westwood. The PCR method developed effectively identified five mealybug species of economic interest on grape in Brazil: D. brevipes, Pl. citri, Ps. viburni, Ph. solenopsis and Planococcus ficus (Signoret). Nevertheless, it is not possible to assure that this procedure is reliable for taxa that have not been sampled already and might be very closely related to the target species.	[Pacheco da Silva, Vitor C.; Botton, Marcos] Embrapa Uva & Vinho, Bento Goncalves, Brazil; [Bertin, Aline; Bernardi, Daniel] Univ Sao Paulo, Escola Super Agr Luiz de Queiroz, Piracicaba, Brazil; [Blin, Aurelie; Rignol, Guylene; Malausa, Thibaut] INRA, Inst Sophia Agrobiotech, UMR INRA UNSA CNRS, F-06903 Sophia Antipolis, France; [Germain, Jean-Francois] ANSES, Lab Sante Vegetaux, Unite Entomol & Plantes Invas, Montferrier Sur Lez, France	Empresa Brasileira de Pesquisa Agropecuaria (EMBRAPA); Universidade de Sao Paulo; INRAE; UDICE-French Research Universities; Universite Cote d'Azur; Agence Nationale de Securite Sanitaire de l'Alimentation, de l'Environnement du Travail (ANSES); Laboratoire de la Sante des Vegetaux	Malausa, T (corresponding author), INRA, Inst Sophia Agrobiotech, UMR INRA UNSA CNRS, BP 167, F-06903 Sophia Antipolis, France.	tmalausa@sophia.inra.fr	León, Rafael I/N-6510-2014; Malausa, Thibaut/X-1614-2018; Strugnell, Jan M/P-9921-2016; Moltschaniwskyj, Natalie/AAB-7236-2019; Pecl, Gretta/D-7267-2011; 刘, 芳延/AAO-8535-2021; van den Bosch, Frank C./ABH-3801-2020; Botton, Marcos/I-1731-2016; Bertin, Aline/T-5005-2017; Persinoti, Gabriela/C-5933-2016; Leimar, Olof/L-3781-2014; Apparecida Desiderio, Janete/F-5848-2012; Deary, Ian/C-6297-2009; Inskip, Hazel/L-5467-2018; Dodds, Richard/D-7772-2016; Guazzaroni, Maria-Eugenia/E-2599-2013; Sujii, Edison/H-7715-2015; Silva-Rocha, Rafael/H-4929-2012; Sujii, Edison Ryoiti/H-7715-2015; Aidar, Marcos Pereira Marinho/B-2212-2013; Benzeval, Michaela/J-3163-2015	León, Rafael I/0000-0003-3197-4185; Malausa, Thibaut/0000-0003-1681-7958; Pecl, Gretta/0000-0003-0192-4339; 刘, 芳延/0000-0002-5155-1916; van den Bosch, Frank C./0000-0003-3236-2068; Botton, Marcos/0000-0002-0554-3157; Bertin, Aline/0000-0003-4232-4241; Lye, David/0000-0003-0324-0205; Cooper, Cyrus/0000-0003-3510-0709; Persinoti, Gabriela/0000-0002-0975-7283; Jagger, Carol/0000-0002-6377-9926; Robinson, Sian/0000-0003-1766-7269; Gale, Catharine/0000-0002-3361-8638; Favati, Anna/0000-0002-6435-011X; Wong, Jason/0000-0002-8167-540X; timbo, renata/0000-0003-1989-7412; Cooper, Rachel/0000-0003-3370-5720; Leimar, Olof/0000-0001-8621-6977; Aihie Sayer, Avan/0000-0003-1283-6457; Moltschaniwskyj, Natalie/0000-0001-9709-9876; De Vivo, Immaculata/0000-0002-7185-7402; Souza, Silvia/0000-0001-6293-7665; Apparecida Desiderio, Janete/0000-0001-7723-3070; Teixeira da Silva, Jaime A./0000-0003-3299-2772; Deary, Ian/0000-0002-1733-263X; Semmens, Jayson/0000-0003-1742-6692; Dennison, Elaine/0000-0002-3048-4961; Germain, Jean-Francois/0000-0001-7927-6031; Inskip, Hazel/0000-0001-8897-1749; Dodds, Richard/0000-0003-4968-7678; Der, Geoff/0000-0002-8677-073X; Strugnell, Jan/0000-0003-2994-637X; Guazzaroni, Maria-Eugenia/0000-0002-4657-3731; Sujii, Edison/0000-0002-0702-0181; R. Silva, Rogerio/0000-0002-0599-2155; Pacheco da Silva, Vitor/0000-0002-8420-1779; Silva-Rocha, Rafael/0000-0001-6319-631X; Vucicevic, Katarina/0000-0001-9676-5785; Gan, Victor/0000-0002-6966-2729; Lawlor, Debbie A/0000-0002-6793-2262; Choo, Robin/0000-0002-3240-3029; Fernandes, Odair/0000-0003-3489-4754; Sujii, Edison Ryoiti/0000-0001-7602-8999; Aidar, Marcos Pereira Marinho/0000-0001-5728-6749; Ramos, Jorge E/0000-0002-8690-761X; Tilling, Kate/0000-0002-1010-8926; N. Silva, Roberto/0000-0002-8992-7130; Wong, Joshua/0000-0001-8268-5610; Paveley, Neil/0000-0002-1709-4563; Benzeval, Michaela/0000-0002-0372-2098	European Union [265865, 269196, 324475]; French grants Agropolis Fondation (RTRA - Montpellier, BIOFIS) [1001001]; Bibliotheque du Vivant; Biotechnology and Biological Sciences Research Council [BBS/E/C/00005198] Funding Source: researchfish	European Union(European Commission); French grants Agropolis Fondation (RTRA - Montpellier, BIOFIS); Bibliotheque du Vivant; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was supported by the European Union Seventh Framework Programme FP7-KBBE #265865 "PURE'', FP7-IRSES #269196 "IPRABIO'' and FP7-IAPP #324475 "COLBICS'' and by the French grants Agropolis Fondation (http://www.agropolis-fondation.fr/) (RTRA - Montpellier, BIOFIS project number 1001001) and 'Bibliotheque du Vivant'. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abd-Rabou S, 2012, B ENTOMOL RES, V102, P515, DOI 10.1017/S0007485312000041; Beltra A, 2012, B ENTOMOL RES, V102, P165, DOI 10.1017/S0007485311000514; Ben-Dov Y, 2012, SCALENET DATABASE SC; Bertin S, 2010, PHYTOPARASITICA, V38, P401, DOI 10.1007/s12600-010-0109-5; Beuning LL, 1999, J ECON ENTOMOL, V92, P463, DOI 10.1093/jee/92.2.463; Camargo UA, 2011, REV BRAS FRUTIC, V33, P144, DOI 10.1590/S0100-29452011000500017; Cavalieri V, 2008, ZOOTAXA, P65, DOI 10.11646/zootaxa.1816.1.6; Charles J. G., 2006, New Zealand Plant Protection, V59, P330; Charles JG, 2011, BIOCONTROL, V56, P155, DOI 10.1007/s10526-010-9322-x; Correa L. R. B., 2005, Laranja, V26, P265; Correa MCG, 2012, B ENTOMOL RES, V102, P524, DOI 10.1017/S0007485312000053; Correa M, 2011, ZOOTAXA, P46, DOI 10.11646/zootaxa.2926.1.2; Santa-Cecilia LVC, 2009, ACTA SCI-AGRON, V31, P13, DOI 10.4025/actasciagron.v31i1.6603; Culik Mark Paul, 2007, Biota Neotrop., V7, P61, DOI 10.1590/S1676-06032007000300006; Culik MP, 2005, ZOOTAXA, P1; Daane KM, 2008, CALIF AGR, V62, P167, DOI 10.3733/ca.v062n04p167; Daane Kent M., 2012, P271; Daane KM, 2011, ENVIRON ENTOMOL, V40, P1595, DOI 10.1603/EN11075; Granara De Willink María Cristina, 2007, Rev. Soc. Entomol. Argent., V66, P29; Demontis MA, 2007, J APPL ENTOMOL, V131, P59, DOI 10.1111/j.1439-0418.2006.01126.x; Foldi Imre, 2005, Nouvelle Revue d'Entomologie, V22, P305; GARAU R, 1995, VITIS, V34, P67; Gimpel William F. Jr, 1996, Contributions on Entomology International, V2, P1; Golino D. A., 2002, California Agriculture, V56, P196, DOI 10.3733/ca.v056n06p196; Gonzalez R. H., 2004, Revista Fruticola, V25, P41; Gullan PJ, 2010, SYST ENTOMOL, V35, P329, DOI 10.1111/j.1365-3113.2009.00513.x; Gullan PJ, 2003, ANN ENTOMOL SOC AM, V96, P723, DOI 10.1603/0013-8746(2003)096[0723:ANPSOT]2.0.CO;2; Hall T.A., 1999, NUCL ACIDS S SER, V41, P95; Hebert PDN, 2003, P ROY SOC B-BIOL SCI, V270, pS96, DOI 10.1098/rsbl.2003.0025; Kaydan MB, 2012, ZOOTAXA, P1; Kuniyuki Hugo, 2006, Summa phytopathol., V32, P151, DOI 10.1590/S0100-54052006000200009; Malausa T, 2011, J APPL ENTOMOL, V135, P142, DOI 10.1111/j.1439-0418.2009.01495.x; Martelli G P, 2002, Arch Virol, V147, P2039, DOI 10.1007/s007050200048; Mello LMR, 2013, VITICULTURA BRASILEI; Miller DR, 2002, P ENTOMOL SOC WASH, V104, P825; Morandi Filho WJ, 2008, ARQ I BIOL-SAO PAULO, V76, P427; Morse GE, 2006, SYST ENTOMOL, V31, P338, DOI 10.1111/j.1365-3113.2005.00316.x; Park DS, 2011, B ENTOMOL RES, V101, P429, DOI 10.1017/S0007485310000714; Puillandre N, 2012, MOL ECOL, V21, P1864, DOI 10.1111/j.1365-294X.2011.05239.x; Saccaggi DL, 2008, B ENTOMOL RES, V98, P27, DOI 10.1017/S000748530700538X; SANTA-CECÍLIA LENIRA V.C., 2002, Neotrop. entomol., V31, P333, DOI 10.1590/S1519-566X2002000200024; Selwyn B, 2007, J AGRAR CHANGE, V7, P526, DOI 10.1111/j.1471-0366.2007.00155.x; Selwyn B, 2010, J AGRAR CHANGE, V10, P537, DOI 10.1111/j.1471-0366.2009.00245.x; Souza B., 2008, Coffee Science, V3, P104; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; Villard P, 2013, MOL ECOL RESOUR, V13, P755, DOI 10.1111/1755-0998.12116; Walton V. M., 2004, South African Journal of Enology and Viticulture, V25, P54; Walton VM, 2009, J INSECT SCI, V9, DOI 10.1673/031.009.4701; Willians DJ, 1992, MEALYBUGS CENTRAL S; Yokogawa T, 2009, GENES GENET SYST, V84, P57, DOI 10.1266/ggs.84.57	50	449	501	61	152	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2014	9	7							e103267	10.1371/journal.pone.0103267	http://dx.doi.org/10.1371/journal.pone.0103267			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM6RP	25072296	Green Published, Green Submitted, gold			2023-01-03	WOS:000339992600050
J	Ramos, JE; Pecl, GT; Moltschaniwskyj, NA; Strugnell, JM; Leon, RI; Semmens, JM				Ramos, Jorge E.; Pecl, Gretta T.; Moltschaniwskyj, Natalie A.; Strugnell, Jan M.; Leon, Rafael I.; Semmens, Jayson M.			Body Size, Growth and Life Span: Implications for the Polewards Range Shift of Octopus tetricus in South-Eastern Australia	PLOS ONE			English	Article							CLIMATE-CHANGE; COMMON OCTOPUS; REPRODUCTIVE-CYCLE; UPWELLING SYSTEM; VULGARIS; SQUID; EVOLUTIONARY; ECOLOGY; AGE; TEMPERATURE	Understanding the response of any species to climate change can be challenging. However, in short-lived species the faster turnover of generations may facilitate the examination of responses associated with longer-term environmental change. Octopus tetricus, a commercially important species, has undergone a recent polewards range shift in the coastal waters of south-eastern Australia, thought to be associated with the southerly extension of the warm East Australian Current. At the cooler temperatures of a polewards distribution limit, growth of a species could be slower, potentially leading to a bigger body size and resulting in a slower population turnover, affecting population viability at the extreme of the distribution. Growth rates, body size, and life span of O. tetricus were examined at the leading edge of a polewards range shift in Tasmanian waters (40 degrees S and 147 degrees E) throughout 2011. Octopus tetricus had a relatively small body size and short lifespan of approximately 11 months that, despite cooler temperatures, would allow a high rate of population turnover and may facilitate the population increase necessary for successful establishment in the new extended area of the range. Temperature, food availability and gender appear to influence growth rate. Individuals that hatched during cooler and more productive conditions, but grew during warming conditions, exhibited faster growth rates and reached smaller body sizes than individuals that hatched into warmer waters but grew during cooling conditions. This study suggests that fast growth, small body size and associated rapid population turnover may facilitate the range shift of O. tetricus into Tasmanian waters.	[Ramos, Jorge E.; Pecl, Gretta T.; Leon, Rafael I.; Semmens, Jayson M.] Univ Tasmania, Inst Marine & Antarctic Studies, Hobart, Tas, Australia; [Moltschaniwskyj, Natalie A.] Univ Newcastle, Sch Environm & Life Sci, Ourimbah, NSW, Australia; [Strugnell, Jan M.] La Trobe Univ, Dept Genet, La Trobe Inst Mol Sci, Bundoora, Vic, Australia	University of Tasmania; University of Newcastle; La Trobe University	Ramos, JE (corresponding author), Univ Tasmania, Inst Marine & Antarctic Studies, Hobart, Tas, Australia.	jeramos@utas.edu.au	León, Rafael I/N-6510-2014; Malausa, Thibaut/X-1614-2018; Strugnell, Jan M/P-9921-2016; Moltschaniwskyj, Natalie/AAB-7236-2019; Pecl, Gretta/D-7267-2011; 刘, 芳延/AAO-8535-2021; van den Bosch, Frank C./ABH-3801-2020; Botton, Marcos/I-1731-2016; Bertin, Aline/T-5005-2017; Persinoti, Gabriela/C-5933-2016; Leimar, Olof/L-3781-2014; Apparecida Desiderio, Janete/F-5848-2012; Deary, Ian/C-6297-2009; Inskip, Hazel/L-5467-2018; Dodds, Richard/D-7772-2016; Guazzaroni, Maria-Eugenia/E-2599-2013; Sujii, Edison/H-7715-2015; Silva-Rocha, Rafael/H-4929-2012; Sujii, Edison Ryoiti/H-7715-2015; Aidar, Marcos Pereira Marinho/B-2212-2013; Benzeval, Michaela/J-3163-2015	León, Rafael I/0000-0003-3197-4185; Malausa, Thibaut/0000-0003-1681-7958; Pecl, Gretta/0000-0003-0192-4339; 刘, 芳延/0000-0002-5155-1916; van den Bosch, Frank C./0000-0003-3236-2068; Botton, Marcos/0000-0002-0554-3157; Bertin, Aline/0000-0003-4232-4241; Lye, David/0000-0003-0324-0205; Cooper, Cyrus/0000-0003-3510-0709; Persinoti, Gabriela/0000-0002-0975-7283; Jagger, Carol/0000-0002-6377-9926; Robinson, Sian/0000-0003-1766-7269; Gale, Catharine/0000-0002-3361-8638; Favati, Anna/0000-0002-6435-011X; Wong, Jason/0000-0002-8167-540X; timbo, renata/0000-0003-1989-7412; Cooper, Rachel/0000-0003-3370-5720; Leimar, Olof/0000-0001-8621-6977; Aihie Sayer, Avan/0000-0003-1283-6457; Moltschaniwskyj, Natalie/0000-0001-9709-9876; De Vivo, Immaculata/0000-0002-7185-7402; Souza, Silvia/0000-0001-6293-7665; Apparecida Desiderio, Janete/0000-0001-7723-3070; Teixeira da Silva, Jaime A./0000-0003-3299-2772; Deary, Ian/0000-0002-1733-263X; Semmens, Jayson/0000-0003-1742-6692; Dennison, Elaine/0000-0002-3048-4961; Germain, Jean-Francois/0000-0001-7927-6031; Inskip, Hazel/0000-0001-8897-1749; Dodds, Richard/0000-0003-4968-7678; Der, Geoff/0000-0002-8677-073X; Strugnell, Jan/0000-0003-2994-637X; Guazzaroni, Maria-Eugenia/0000-0002-4657-3731; Sujii, Edison/0000-0002-0702-0181; R. Silva, Rogerio/0000-0002-0599-2155; Pacheco da Silva, Vitor/0000-0002-8420-1779; Silva-Rocha, Rafael/0000-0001-6319-631X; Vucicevic, Katarina/0000-0001-9676-5785; Gan, Victor/0000-0002-6966-2729; Lawlor, Debbie A/0000-0002-6793-2262; Choo, Robin/0000-0002-3240-3029; Fernandes, Odair/0000-0003-3489-4754; Sujii, Edison Ryoiti/0000-0001-7602-8999; Aidar, Marcos Pereira Marinho/0000-0001-5728-6749; Ramos, Jorge E/0000-0002-8690-761X; Tilling, Kate/0000-0002-1010-8926; N. Silva, Roberto/0000-0002-8992-7130; Wong, Joshua/0000-0001-8268-5610; Paveley, Neil/0000-0002-1709-4563; Benzeval, Michaela/0000-0002-0372-2098	Consejo Nacional de Ciencia y Tecnologia of Mexico [308672]; University of Tasmania; Biotechnology and Biological Sciences Research Council [BBS/E/C/00005198] Funding Source: researchfish	Consejo Nacional de Ciencia y Tecnologia of Mexico(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); University of Tasmania; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	J. Ramos was awarded the scholarship 308672 by Consejo Nacional de Ciencia y Tecnologia of Mexico, a Tasmania Graduate Research scholarship from the University of Tasmania and a Bookend Lynchpin Ocean Scholarship 2012. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Amundsen PA, 2012, BIOL INVASIONS, V14, P1501, DOI 10.1007/s10530-012-0175-3; Anderson RC, 2008, MAR ECOL PROG SER, V371, P199, DOI 10.3354/meps07649; [Anonymous], CEPHALOPOD BEHAV; Arenas M, 2012, MOL BIOL EVOL, V29, P207, DOI 10.1093/molbev/msr187; Arkhipkin AI, 2005, MAR FRESHWATER RES, V56, P371, DOI 10.1071/MF04274; Barratt IM, 2010, ICES J MAR SCI, V67, P1452, DOI 10.1093/icesjms/fsq047; Berteaux D, 2004, INTEGR COMP BIOL, V44, P140, DOI 10.1093/icb/44.2.140; Blois JL, 2013, SCIENCE, V341, P499, DOI 10.1126/science.1237184; Calosi P, 2013, INTEGR COMP BIOL, V53, P660, DOI 10.1093/icb/ict041; Calosi P, 2010, J ANIM ECOL, V79, P194, DOI 10.1111/j.1365-2656.2009.01611.x; Canali E, 2011, MAR ECOL PROG SER, V441, P141, DOI 10.3354/meps09399; Carrasco JF, 2006, AQUAC RES, V37, P1601, DOI 10.1111/j.1365-2109.2006.01594.x; CHEN Y, 1992, CAN J FISH AQUAT SCI, V49, P1228, DOI 10.1139/f92-138; Clarke MR, 1996, PHILOS T ROY SOC B, V351, P1105, DOI 10.1098/rstb.1996.0096; Colautti RI, 2006, BIOL INVASIONS, V8, P1023, DOI 10.1007/s10530-005-3735-y; Cowen RK, 2009, ANNU REV MAR SCI, V1, P443, DOI 10.1146/annurev.marine.010908.163757; Dia M.A., 1988, THESIS U W BRITTANY THESIS U W BRITTANY; Domain F, 2000, J MAR BIOL ASSOC UK, V80, P699, DOI 10.1017/S0025315400002526; Doubleday Z, 2006, J EXP MAR BIOL ECOL, V338, P35, DOI 10.1016/j.jembe.2006.06.027; Edgar G. J., 2000, AUSTR MARINE LIFE PL; Engel Katharina, 2011, Communicative & Integrative Biology, V4, P247, DOI 10.4161/cib.4.3.14885; Forsythe J.W., 1987, P135; FORSYTHE JW, 1988, MAR BIOL, V98, P369, DOI 10.1007/BF00391113; Forsythe JW, 2004, MAR FRESHWATER RES, V55, P331, DOI 10.1071/MF03146; Fox J, 2019, R COMPANION APPL REG, Vthird; Fulton EA, 2011, ICES J MAR SCI, V68, P1329, DOI 10.1093/icesjms/fsr032; Guzik MT, 2005, MOL PHYLOGENET EVOL, V37, P235, DOI 10.1016/j.ympev.2005.05.009; Harrington JJ, 2006, FISH RES, V77, P10, DOI 10.1016/j.fishres.2005.09.003; Hermosilla CA, 2010, ICES J MAR SCI, V67, P1458, DOI 10.1093/icesjms/fsq054; Herwig JN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043679; Hill KL, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2007GL032912; Hoffmann AA, 2008, NAT REV GENET, V9, P421, DOI 10.1038/nrg2339; Holt RD, 2003, EVOL ECOL RES, V5, P159; Hoving HJT, 2013, GLOBAL CHANGE BIOL, V19, P2089, DOI 10.1111/gcb.12198; Jackson GD, 2004, MAR FRESHWATER RES, V55, P357, DOI 10.1071/MF03152; Jackson GD, 2003, MAR BIOL, V142, P925, DOI 10.1007/s00227-002-1005-4; Jackson GD, 2001, MAR ECOL PROG SER, V218, P167, DOI 10.3354/meps218167; Johnson CR, 2011, J EXP MAR BIOL ECOL, V400, P17, DOI 10.1016/j.jembe.2011.02.032; Katsanevakis S, 2006, ICES J MAR SCI, V63, P151, DOI 10.1016/j.icesjms.2005.07.004; Last PR, 2011, GLOBAL ECOL BIOGEOGR, V20, P58, DOI 10.1111/j.1466-8238.2010.00575.x; Lee CE, 2002, TRENDS ECOL EVOL, V17, P386, DOI 10.1016/S0169-5347(02)02554-5; Leporati SC, 2008, MAR ECOL PROG SER, V367, P213, DOI 10.3354/meps07558; Leporati SC, 2008, MAR BIOL, V155, P375, DOI 10.1007/s00227-008-1033-9; Leporati SC, 2007, MAR BIOL, V151, P1375, DOI 10.1007/s00227-006-0575-y; Lourenco S, 2012, FISH RES, V127, P116, DOI 10.1016/j.fishres.2012.04.006; Mangold K., 1983, P335; Mangold K., 1987, P157; Mather JA, 2012, CURR ZOOL, V58, P597, DOI 10.1093/czoolo/58.4.597; McMahon RF, 2002, CAN J FISH AQUAT SCI, V59, P1235, DOI 10.1139/F02-105; Moreno A, 2012, J MAR BIOL ASSOC UK, V92, P1619, DOI 10.1017/S0025315411002141; Norman M.D., 2000, GUIDE SQUID CUTTLEFI; Okei N, 1999, STOCK ENHANCEMENT AND SEA RANCHING, P468; Oosthuizen A, 2003, J MAR BIOL ASSOC UK, V83, P535, DOI 10.1017/S0025315403007458h; Otero J, 2008, MAR ECOL PROG SER, V362, P181, DOI 10.3354/meps07437; Otero J, 2007, FISH RES, V85, P122, DOI 10.1016/j.fishres.2007.01.007; Parmesan C, 2003, NATURE, V421, P37, DOI 10.1038/nature01286; Parmesan C, 2006, ANNU REV ECOL EVOL S, V37, P637, DOI 10.1146/annurev.ecolsys.37.091305.110100; Pecl GT, 2008, REV FISH BIOL FISHER, V18, P373, DOI 10.1007/s11160-007-9077-3; Pecl GT, 2004, MAR FRESHWATER RES, V55, P387, DOI 10.1071/MF03153; Pinsky ML, 2013, SCIENCE, V341, P1239, DOI 10.1126/science.1239352; Portner HO, 2008, SCIENCE, V322, P690, DOI 10.1126/science.1163156; Poloczanska ES, 2007, OCEANOGR MAR BIOL, V45, P407; Poloczanska ES, 2013, NAT CLIM CHANGE, V3, P919, DOI [10.1038/NCLIMATE1958, 10.1038/nclimate1958]; R Core Team, 2021, R LANG ENV STAT COMP; Ridgway KR, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL030392; Ridgway KR, 2003, PROG OCEANOGR, V56, P189, DOI 10.1016/S0079-6611(03)00004-1; Rosa R, 2008, P NATL ACAD SCI USA, V105, P20776, DOI 10.1073/pnas.0806886105; Rosas C, 2008, AQUACULTURE, V275, P291, DOI 10.1016/j.aquaculture.2008.01.015; Sandery PA, 2007, ESTUAR COAST SHELF S, V74, P684, DOI 10.1016/j.ecss.2007.05.011; Scandol J, 2008, STATUS FISHERIES RES, P193; Schwarz R, 2010, FISH RES, V106, P177, DOI 10.1016/j.fishres.2010.06.008; Semmens J, 2011, J EXP BIOL, V214, P2799, DOI 10.1242/jeb.051631; Semmens JM, 2004, MAR FRESHWATER RES, V55, P367, DOI 10.1071/MF03155; Shea K, 2002, TRENDS ECOL EVOL, V17, P170, DOI 10.1016/S0169-5347(02)02495-3; Spiess A, 2013, QPCR MODELLING ANAL; Sunday JM, 2012, NAT CLIM CHANGE, V2, P686, DOI 10.1038/NCLIMATE1539; Tasmania Wild Fisheries Management Branch Tasmania Department of Primary Industries and Water, 2009, SACL FISH MAN PLAN R; Travis JMJ, 2013, OIKOS, V122, P1532, DOI 10.1111/j.1600-0706.2013.00399.x; Villanueva R, 1995, CAN J FISH AQUAT SCI, V52, P2639, DOI 10.1139/f95-853; VILLANUEVA R, 1992, J EXP MAR BIOL ECOL, V159, P157, DOI 10.1016/0022-0981(92)90034-8; Villanueva R, 2008, OCEANOGR MAR BIOL, V46, P105; Wagenmakers EJ, 2004, PSYCHON B REV, V11, P192, DOI 10.3758/BF03206482; Ware DM, 2005, SCIENCE, V308, P1280, DOI 10.1126/science.1109049; Wolf BM, 1997, J SHELLFISH RES, V16, P533	85	449	501	61	152	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 4	2014	9	8							e103480	10.1371/journal.pone.0103480	http://dx.doi.org/10.1371/journal.pone.0103480			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM4GX	25072296	Green Published, Green Accepted, gold			2023-01-03	WOS:000339812700029
J	Wu, KL; Zeng, SJ; Lin, DI; da Silva, JAT; Bu, ZY; Zhang, JX; Duan, J				Wu, Kunlin; Zeng, Songjun; Lin, Danni; da Silva, Jaime A. Teixeira; Bu, Zhaoyang; Zhang, Jianxia; Duan, Ju			In Vitro Propagation and Reintroduction of the Endangered Renanthera imschootiana Rolfe	PLOS ONE			English	Article							ASYMBIOTIC SEED-GERMINATION; CALCIUM HYPOCHLORITE; ESTABLISHMENT; REGENERATION; GROWTH; ORCHID	Renanthera imschootiana Rolfe is an endangered tropical epiphytic orchid that is threatened with extinction due to over-collection and the loss of suitable habitats. In vitro propagation is a useful way to mass produce plants for re-establishment in the wild and for commercial propagation. Seeds collected 150 days after pollination (DAP) were the optimum stage for in vitro culture. Seed germination reached 93.1% on quarter-strength MS (i.e., MS containing a quarter of macro-and micronutrients) medium containing 0.5 mg l(-1) a-naphthaleneacetic acid (NAA), 20% coconut water (CW), 1.0 g l(-1) peptone, 10 g l(-1) sucrose and 1.0 g l(-1) activated charcoal (AC). Quarter-strength MS medium supplemented with 1.0 mg l(-1) BA, 0.5 mg l(-1) NAA, 1.0 g l(-1) peptone, 10 g l(-1) sucrose and 20% CW was suitable for the sub-culture of protocorm-like bodies (PLBs) in which the PLB proliferation ratio was 2.88. Quarter-strength MS medium containing 1.0 mg l(-1) NAA, 1.0 g l(-1) peptone, 100 g l(-1) banana homogenate (BH), and 1.0 g l(-1) AC was suitable for plantlet formation and 95.67% of plantlets developed from PLBs within 60 days of culture. Hyponex N016 medium supplemented with 0.5 mg l(-1) NAA, 1.0 g l(-1) peptone, 20 g l(-1) sucrose, 150 g l(-1) BH, and 1.0 g l(-1) AC was suitable for the in vitro growth of plantlets about 2-cm in height. Plantlets 3-cm in height or taller were transplanted to Chilean sphagnum moss, and 95% of plantlets survived after 60 days in a greenhouse. Three hundred transplanted of seedlings 360-days old were reintroduced into three natural habitats. Highest percentage survival (79.67%) was observed in Yuanjiang Nature Reserve two years after reintroduction, followed by Huolu Mountain forest park (71.33%). This protocol is an efficient means for the large-scale propagation and in vitro and in vivo germplasm conservation of R. imschootiana.	[Wu, Kunlin; Zeng, Songjun; Lin, Danni; Zhang, Jianxia] Chinese Acad Sci, South China Bot Garden, Key Lab Plant Resources Conservat & Sustainable U, Guangzhou, Guangdong, Peoples R China; [Duan, Ju] Chinese Acad Sci, South China Bot Garden, Key Lab S China Agr Plant Mol Anal & Gene Improve, Guangzhou, Guangdong, Peoples R China; [da Silva, Jaime A. Teixeira] Kagawa Ken, Takamatsu, Kagawa, Japan; [Bu, Zhaoyang] Guangxi Acad Agr Sci, Flower Res Inst, Nanning 150931, Peoples R China	Chinese Academy of Sciences; South China Botanical Garden, CAS; Chinese Academy of Sciences; South China Botanical Garden, CAS; Guangxi Academy of Agricultural Sciences	Zeng, SJ (corresponding author), Chinese Acad Sci, South China Bot Garden, Key Lab Plant Resources Conservat & Sustainable U, Guangzhou, Guangdong, Peoples R China.	zengsongjun@scib.ac.cn; yangnv@126.com	León, Rafael I/N-6510-2014; Malausa, Thibaut/X-1614-2018; Strugnell, Jan M/P-9921-2016; Moltschaniwskyj, Natalie/AAB-7236-2019; Pecl, Gretta/D-7267-2011; 刘, 芳延/AAO-8535-2021; van den Bosch, Frank C./ABH-3801-2020; Botton, Marcos/I-1731-2016; Bertin, Aline/T-5005-2017; Persinoti, Gabriela/C-5933-2016; Leimar, Olof/L-3781-2014; Apparecida Desiderio, Janete/F-5848-2012; Deary, Ian/C-6297-2009; Inskip, Hazel/L-5467-2018; Dodds, Richard/D-7772-2016; Guazzaroni, Maria-Eugenia/E-2599-2013; Sujii, Edison/H-7715-2015; Silva-Rocha, Rafael/H-4929-2012; Sujii, Edison Ryoiti/H-7715-2015; Aidar, Marcos Pereira Marinho/B-2212-2013; Benzeval, Michaela/J-3163-2015	León, Rafael I/0000-0003-3197-4185; Malausa, Thibaut/0000-0003-1681-7958; Pecl, Gretta/0000-0003-0192-4339; 刘, 芳延/0000-0002-5155-1916; van den Bosch, Frank C./0000-0003-3236-2068; Botton, Marcos/0000-0002-0554-3157; Bertin, Aline/0000-0003-4232-4241; Lye, David/0000-0003-0324-0205; Cooper, Cyrus/0000-0003-3510-0709; Persinoti, Gabriela/0000-0002-0975-7283; Jagger, Carol/0000-0002-6377-9926; Robinson, Sian/0000-0003-1766-7269; Gale, Catharine/0000-0002-3361-8638; Favati, Anna/0000-0002-6435-011X; Wong, Jason/0000-0002-8167-540X; timbo, renata/0000-0003-1989-7412; Cooper, Rachel/0000-0003-3370-5720; Leimar, Olof/0000-0001-8621-6977; Aihie Sayer, Avan/0000-0003-1283-6457; Moltschaniwskyj, Natalie/0000-0001-9709-9876; De Vivo, Immaculata/0000-0002-7185-7402; Souza, Silvia/0000-0001-6293-7665; Apparecida Desiderio, Janete/0000-0001-7723-3070; Teixeira da Silva, Jaime A./0000-0003-3299-2772; Deary, Ian/0000-0002-1733-263X; Semmens, Jayson/0000-0003-1742-6692; Dennison, Elaine/0000-0002-3048-4961; Germain, Jean-Francois/0000-0001-7927-6031; Inskip, Hazel/0000-0001-8897-1749; Dodds, Richard/0000-0003-4968-7678; Der, Geoff/0000-0002-8677-073X; Strugnell, Jan/0000-0003-2994-637X; Guazzaroni, Maria-Eugenia/0000-0002-4657-3731; Sujii, Edison/0000-0002-0702-0181; R. Silva, Rogerio/0000-0002-0599-2155; Pacheco da Silva, Vitor/0000-0002-8420-1779; Silva-Rocha, Rafael/0000-0001-6319-631X; Vucicevic, Katarina/0000-0001-9676-5785; Gan, Victor/0000-0002-6966-2729; Lawlor, Debbie A/0000-0002-6793-2262; Choo, Robin/0000-0002-3240-3029; Fernandes, Odair/0000-0003-3489-4754; Sujii, Edison Ryoiti/0000-0001-7602-8999; Aidar, Marcos Pereira Marinho/0000-0001-5728-6749; Ramos, Jorge E/0000-0002-8690-761X; Tilling, Kate/0000-0002-1010-8926; N. Silva, Roberto/0000-0002-8992-7130; Wong, Joshua/0000-0001-8268-5610; Paveley, Neil/0000-0002-1709-4563; Benzeval, Michaela/0000-0002-0372-2098	Key Laboratory of Plant Resources Conservation and Sustainable Utilization, South China Botanical Garden, Chinese Academy of Sciences [211026]; Guangzhou Key Technology Research and Development Program [Y233051001]; Biotechnology and Biological Sciences Research Council [BBS/E/C/00005198] Funding Source: researchfish	Key Laboratory of Plant Resources Conservation and Sustainable Utilization, South China Botanical Garden, Chinese Academy of Sciences; Guangzhou Key Technology Research and Development Program; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This study was supported by a fund of the Key Laboratory of Plant Resources Conservation and Sustainable Utilization, South China Botanical Garden, Chinese Academy of Sciences (No. 211026), and the Guangzhou Key Technology Research and Development Program (Y233051001). Songjun Zeng received the funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akeroyd J., 1995, HDB BOT GARDENS REIN; [Anonymous], 2014, WORLD CHECKLIST SELE; Arditti J., 1993, MICROPROPAGATION ORC; Arditti J, 1982, ORCHID BIOL REV PERS, P352; Chu Chin-Chang, 1994, Lindleyana, V9, P153; Chugh S, 2009, SCI HORTIC-AMSTERDAM, V122, P507, DOI 10.1016/j.scienta.2009.07.016; da Silva JAT, 2006, PLANT CELL TISS ORG, V84, P135, DOI 10.1007/s11240-005-9003-0; da Silva JAT, 2005, PROPAG ORNAM PLANTS, V5, P129; DASILVA JAT, 2012, ASIAN AUSTRALASIAN J, V6, P121; DeMarie E., 1991, HORTSCIENCE, V26, P272; Dix L., 1982, PLANT CELL TISSUE OR, V12, P39; Ernst R., 1975, American Orchid Society Bulletin, V44, P12; Ernst R., 1974, American Orchid Society Bulletin, V43, P35; Goh C. J., 1982, Orchid Review, V90, P295; GOH CJ, 1990, SCI HORTIC-AMSTERDAM, V44, P315, DOI 10.1016/0304-4238(90)90132-X; HARVAIS G, 1973, CAN J BOT, V51, P327, DOI 10.1139/b73-040; Hossain MM, 2013, CRIT REV PLANT SCI, V32, P69, DOI 10.1080/07352689.2012.715984; Kauth P.J., 2008, FLORICULTURE ORNAMEN, P375; Kishor R, 2009, EUPHYTICA, V165, P247, DOI 10.1007/s10681-008-9755-9; Knudson Lewis, 1946, AMER ORCHID SOC BULL, V15, P214; Lee YI, 2006, ANN BOT-LONDON, V98, P1311, DOI 10.1093/aob/mcl222; Lin DL, 2008, J FOOD DRUG ANAL, V16, P1; Lo SF, 2004, IN VITRO CELL DEV-PL, V40, P528, DOI 10.1079/IVP2004571; McNaughton S.J., 1989, P109; Miyoshi K, 1998, PHYSIOL PLANTARUM, V102, P481, DOI 10.1034/j.1399-3054.1998.1020401.x; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Mweetwa AM, 2008, SCI HORTIC-AMSTERDAM, V117, P257, DOI 10.1016/j.scienta.2008.03.035; NAGASHIMA T, 1982, J JPN SOC HORTIC SCI, V51, P94, DOI 10.2503/jjshs.51.94; PIERIK RLM, 1988, SCI HORTIC-AMSTERDAM, V34, P139, DOI 10.1016/0304-4238(88)90084-2; Raghavan V., 1977, CRC HDB SERIES NUTR, P361; Ren H, 2012, ORYX, V46, P391, DOI 10.1017/S0030605311000615; Rout TM, 2009, ECOL APPL, V19, P515, DOI 10.1890/07-1989.1; SEENI S, 1992, PLANT CELL TISS ORG, V29, P167, DOI 10.1007/BF00034349; Seeni S, 2000, PLANT CELL TISS ORG, V61, P1, DOI 10.1023/A:1006444614657; Teixeira da Silva J., 2013, FLORIC ORNAM BIOTECH, V7, P1, DOI DOI 10.1016/0168-1656(90)90117-T; Thomale H., 1954, ORCHIDEEN, P62; Thomas TD, 2008, BIOTECHNOL ADV, V26, P618, DOI 10.1016/j.biotechadv.2008.08.003; Tsi Z. H., 1999, FLORA REIPUBLICAE PO, V19, P291; VACIN EF, 1949, BOT GAZ, V110, P605, DOI 10.1086/335561; van der Kinderen G., 1987, LINDLEYANA, V2, P84; VANWAES JM, 1986, PHYSIOL PLANTARUM, V66, P435, DOI 10.1111/j.1399-3054.1986.tb05947.x; Vyas S, 2009, SCI HORTIC-AMSTERDAM, V121, P32, DOI 10.1016/j.scienta.2009.01.012; Wu KL, 2012, SCI HORTIC-AMSTERDAM, V135, P194, DOI 10.1016/j.scienta.2011.11.028; Wu KunLin, 2010, Acta Horticulturae Sinica, V37, P685; Wu Z.Y., 2009, FLORA CHINA, V25; YAM T W, 1990, Lindleyana, V5, P256; Yong JWH, 2009, MOLECULES, V14, P5144, DOI 10.3390/molecules14125144; Zeng SJ, 2015, CRIT REV BIOTECHNOL, V35, P279; Zeng SJ, 2011, HORTSCIENCE, V46, P460, DOI 10.21273/HORTSCI.46.3.460; Zeng SJ, 2012, SCI HORTIC-AMSTERDAM, V138, P198, DOI 10.1016/j.scienta.2012.02.026	51	449	501	61	152	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 28	2014	9	10							e110033	10.1371/journal.pone.0110033	http://dx.doi.org/10.1371/journal.pone.0110033			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS0BH	25072296	Green Submitted, gold, Green Published			2023-01-03	WOS:000343943100017
